Selegiline B-Chemical 0 0.9993018
- O 0 0.014003717
induced O 0 0.0062381243
postural B-Disease 0 0.9920533
hypotension I-Disease 2 0.99974304
in O 0 0.0041615386
Parkinson B-Disease 0 0.99891233
' I-Disease 0 0.0015267055
s I-Disease 0 0.0012846476
disease I-Disease 0 0.3290683
: O 0 0.0010943026
a O 0 0.0005991191
longitudinal O 0 0.001135176
study O 0 0.0008225473
on O 0 0.0004303523
the O 0 0.0008021261
effects O 0 0.0022161934
of O 0 0.0033060624
drug O 0 0.76807165
withdrawal O 0 0.93168145
. O 0 0.008228039

OBJECTIVES O 0 0.030879678
: O 0 0.0046900753
The O 0 0.0020699818
United O 0 0.0032093239
Kingdom O 0 0.008081547
Parkinson B-Disease 0 0.9960068
' I-Disease 0 0.0015962094
s I-Disease 0 0.0015032921
Disease I-Disease 0 0.24224003
Research O 0 0.032171674
Group O 0 0.022431312
( O 0 0.00095833006
UKPDRG O 0 0.062534176
) O 0 0.00083051017
trial O 0 0.00077513093
found O 0 0.0003006238
an O 0 0.00039280645
increased O 0 0.00064622425
mortality O 0 0.10112741
in O 0 0.0003317891
patients O 0 0.0016331233
with O 0 0.0008684224
Parkinson B-Disease 0 0.99937195
' I-Disease 0 0.00059077854
s I-Disease 0 0.000631371
disease I-Disease 0 0.592626
( O 0 0.0014292212
PD B-Disease 0 0.9898461
) O 0 0.00060647755
randomized O 0 0.00040131478
to O 0 0.00019172118
receive O 0 0.00029913313
10 O 0 0.0003201221
mg O 0 0.33893386
selegiline B-Chemical 1 0.9998355
per O 0 0.0002451221
day O 0 0.00037982408
and O 0 0.0006161674
L B-Chemical 1 0.86387235
- I-Chemical 1 0.004013033
dopa I-Chemical 1 0.99934524
compared O 0 0.0004586617
with O 0 0.0009073656
those O 0 0.001577788
taking O 0 0.009578054
L B-Chemical 1 0.9292962
- I-Chemical 1 0.031230206
dopa I-Chemical 1 0.99822515
alone O 0 0.012466654
. O 0 0.007798108

Recently O 0 0.0074874344
, O 0 0.0030863364
we O 0 0.0010666044
found O 0 0.0011307844
that O 0 0.0008769042
therapy O 0 0.01171315
with O 0 0.0024515977
selegiline B-Chemical 1 0.9998691
and O 0 0.008156619
L B-Chemical 1 0.98243064
- I-Chemical 1 0.015731417
dopa I-Chemical 1 0.99960333
was O 0 0.0008897857
associated O 0 0.00087398285
with O 0 0.0008647557
selective O 0 0.04135864
systolic B-Disease 0 0.9935899
orthostatic I-Disease 2 0.9997243
hypotension I-Disease 2 0.99991775
which O 0 0.0036156008
was O 0 0.0010800913
abolished O 0 0.002361773
by O 0 0.0019233137
withdrawal O 0 0.80230063
of O 0 0.01621042
selegiline B-Chemical 1 0.99939585
. O 0 0.011144066

This O 0 0.0061186827
unwanted O 0 0.011060305
effect O 0 0.002882703
on O 0 0.0015418498
postural O 0 0.5083386
blood O 0 0.015215376
pressure O 0 0.040378332
was O 0 0.0012191636
not O 0 0.0009227901
the O 0 0.00097424287
result O 0 0.0011658353
of O 0 0.0024562634
underlying O 0 0.0111168595
autonomic O 0 0.95936984
failure O 0 0.8581702
. O 0 0.010136672

The O 0 0.0025647394
aims O 0 0.0025529028
of O 0 0.0015097004
this O 0 0.00099605
study O 0 0.0011231235
were O 0 0.0005660469
to O 0 0.00039645538
confirm O 0 0.00024927862
our O 0 0.00027416518
previous O 0 0.0003378486
findings O 0 0.0007727076
in O 0 0.0002552088
a O 0 0.0002632338
separate O 0 0.00017765482
cohort O 0 0.0006223503
of O 0 0.00033196053
patients O 0 0.0009504695
and O 0 0.0002474718
to O 0 0.00016824446
determine O 0 8.482785e-05
the O 0 0.00013856647
time O 0 0.00013830578
course O 0 0.00031514507
of O 0 0.00031248113
the O 0 0.00030583754
cardiovascular O 0 0.92616284
consequences O 0 0.0018141726
of O 0 0.00051479903
stopping O 0 0.053042095
selegiline B-Chemical 1 0.999926
in O 0 0.0003785022
the O 0 0.00025140002
expectation O 0 0.00037626372
that O 0 0.00019284121
this O 0 0.00022394954
might O 0 0.00019036794
shed O 0 0.0005054433
light O 0 0.0005888548
on O 0 0.00020786168
the O 0 0.00035349838
mechanisms O 0 0.0008695546
by O 0 0.00062295055
which O 0 0.0010066978
the O 0 0.0011451474
drug O 0 0.57546306
causes O 0 0.12869245
orthostatic B-Disease 2 0.99924743
hypotension I-Disease 2 0.9995664
. O 0 0.013792023

METHODS O 0 0.0066340226
: O 0 0.0034568398
The O 0 0.0016657922
cardiovascular O 0 0.6096746
responses O 0 0.0024634497
to O 0 0.00085542246
standing O 0 0.0020731676
and O 0 0.00089328643
head O 0 0.015562907
- O 0 0.0010960109
up O 0 0.00047054084
tilt O 0 0.013736087
were O 0 0.00041423377
studied O 0 0.00054067053
repeatedly O 0 0.0007072975
in O 0 0.0005736535
PD B-Disease 0 0.9846847
patients O 0 0.005244976
receiving O 0 0.023932608
selegiline B-Chemical 1 0.9998228
and O 0 0.0014393895
as O 0 0.0009250706
the O 0 0.0014173425
drug O 0 0.28750637
was O 0 0.0036896125
withdrawn O 0 0.02876637
. O 0 0.006072092

RESULTS O 0 0.044222727
: O 0 0.006794699
Head O 0 0.026947292
- O 0 0.003167305
up O 0 0.0015604085
tilt O 0 0.031572305
caused O 0 0.0025015024
systolic B-Disease 0 0.9821132
orthostatic I-Disease 2 0.99956614
hypotension I-Disease 2 0.9999027
which O 0 0.002759006
was O 0 0.0005555289
marked O 0 0.00069948373
in O 0 0.00026187205
six O 0 0.000193085
of O 0 0.00042311224
20 O 0 0.0006555717
PD B-Disease 0 0.97440946
patients O 0 0.0022319125
on O 0 0.00038983274
selegiline B-Chemical 1 0.9998419
, O 0 0.00093133503
one O 0 0.0003660367
of O 0 0.0006814678
whom O 0 0.0022428627
lost O 0 0.0015317542
consciousness O 0 0.816588
with O 0 0.003105025
unrecordable O 0 0.7882431
blood O 0 0.05439262
pressures O 0 0.04835373
. O 0 0.006339516

A O 0 0.025481883
lesser O 0 0.013104697
degree O 0 0.007990507
of O 0 0.011303822
orthostatic B-Disease 2 0.99774194
hypotension I-Disease 2 0.9992405
occurred O 0 0.018672938
with O 0 0.0113526285
standing O 0 0.029456196
. O 0 0.012828054

Orthostatic B-Disease 0 0.9933234
hypotension I-Disease 2 0.9991615
was O 0 0.003867825
ameliorated O 0 0.2067104
4 O 0 0.0010145212
days O 0 0.0006611354
after O 0 0.00042215598
withdrawal O 0 0.25941816
of O 0 0.0014902735
selegiline B-Chemical 1 0.9998379
and O 0 0.0012837626
totally O 0 0.0019048522
abolished O 0 0.001387635
7 O 0 0.00051763555
days O 0 0.00051653216
after O 0 0.00052176835
discontinuation O 0 0.32585394
of O 0 0.0022856307
the O 0 0.0032737833
drug O 0 0.49111968
. O 0 0.006964148

Stopping O 0 0.6296598
selegiline B-Chemical 1 0.9991534
also O 0 0.0037635036
significantly O 0 0.0020403129
reduced B-Disease 0 0.0012581546
the I-Disease 0 0.0009453398
supine I-Disease 0 0.0049996697
systolic I-Disease 0 0.5328546
and I-Disease 0 0.0010298776
diastolic I-Disease 0 0.8823783
blood I-Disease 0 0.0045876494
pressures I-Disease 0 0.0031360372
consistent O 0 0.00063436874
with O 0 0.00079619524
a O 0 0.0009932673
previously O 0 0.0012004325
undescribed O 0 0.0027500952
supine O 0 0.024933144
pressor O 0 0.9821784
action O 0 0.05546913
. O 0 0.0073270397

CONCLUSION O 0 0.79045177
: O 0 0.004191317
This O 0 0.0020894073
study O 0 0.0014092051
confirms O 0 0.00072290725
our O 0 0.0005756425
previous O 0 0.0006604827
finding O 0 0.001122969
that O 0 0.0007980695
selegiline B-Chemical 1 0.9998056
in O 0 0.0009839643
combination O 0 0.00491024
with O 0 0.0029814336
L B-Chemical 1 0.97044295
- I-Chemical 1 0.01898153
dopa I-Chemical 1 0.99940383
is O 0 0.00174284
associated O 0 0.0023286296
with O 0 0.003513805
selective O 0 0.3369141
orthostatic B-Disease 2 0.9991216
hypotension I-Disease 2 0.999514
. O 0 0.014616013

The O 0 0.0027663405
possibilities O 0 0.0025117814
that O 0 0.0014303051
these O 0 0.0020611766
cardiovascular O 0 0.90496945
findings O 0 0.0036354943
might O 0 0.00064682344
be O 0 0.00059300044
the O 0 0.00040947224
result O 0 0.0003874039
of O 0 0.00067766133
non O 0 0.0019970112
- O 0 0.0013179315
selective O 0 0.0085890815
inhibition O 0 0.0065947874
of O 0 0.0023059347
monoamine O 0 0.9997143
oxidase O 0 0.9962818
or O 0 0.0016420103
of O 0 0.0063979584
amphetamine B-Chemical 1 0.9997893
and O 0 0.011207637
metamphetamine B-Chemical 0 0.9980526
are O 0 0.0052131624
discussed O 0 0.0054029906
. O 0 0.006412258

Further O 0 0.0064459615
studies O 0 0.0046068444
on O 0 0.002338231
effects O 0 0.0040874328
of O 0 0.0039816895
irrigation O 0 0.026398882
solutions O 0 0.02566131
on O 0 0.0046280376
rat O 0 0.04898297
bladders O 0 0.5217426
. O 0 0.013383401

Further O 0 0.004318127
studies O 0 0.0028173965
on O 0 0.0011147085
the O 0 0.0011241768
effects O 0 0.0015949269
of O 0 0.0011650453
certain O 0 0.001804303
irrigating O 0 0.10488736
fluids O 0 0.024731716
on O 0 0.00056340947
the O 0 0.00082985085
rat O 0 0.0076382477
bladder O 0 0.4836479
for O 0 0.0012054167
18 O 0 0.0015925128
hours O 0 0.0016713222
are O 0 0.0026170136
reported O 0 0.0058340635
. O 0 0.0059208362

The O 0 0.0027435066
results O 0 0.0019506046
have O 0 0.0016994211
shown O 0 0.0009900084
that O 0 0.0007844103
the O 0 0.0008575799
degradation O 0 0.003803793
product O 0 0.0022515217
p B-Chemical 0 0.0030047512
- I-Chemical 0 0.0013967847
choloroaniline I-Chemical 0 0.031446315
is O 0 0.0005562585
not O 0 0.0004280605
a O 0 0.0005486816
significant O 0 0.0007963936
factor O 0 0.0034341488
in O 0 0.0011418588
chlorhexidine B-Chemical 0 0.98991334
- I-Chemical 0 0.012978703
digluconate I-Chemical 0 0.9908832
associated O 0 0.044960268
erosive O 0 0.99790996
cystitis B-Disease 0 0.9994066
. O 0 0.020819912

A O 0 0.012351541
high O 0 0.0030071635
percentage O 0 0.0013633382
of O 0 0.0025524087
kanamycin B-Chemical 1 0.9830904
- O 0 0.006962038
colistin B-Chemical 0 0.99862254
and O 0 0.0024588068
povidone B-Chemical 0 0.9945992
- I-Chemical 0 0.0061319866
iodine I-Chemical 0 0.9974058
irrigations O 0 0.4744885
were O 0 0.00072669215
associated O 0 0.000904486
with O 0 0.0014996642
erosive O 0 0.99845123
cystitis B-Disease 0 0.99983525
and O 0 0.0019297841
suggested O 0 0.0010279813
a O 0 0.0010072883
possible O 0 0.0013886258
complication O 0 0.27076727
with O 0 0.0028996288
human O 0 0.006175196
usage O 0 0.0067939083
. O 0 0.0063637057

Picloxydine B-Chemical 0 0.6536946
irrigations O 0 0.13008438
appeared O 0 0.0027036886
to O 0 0.0013227293
have O 0 0.0010785223
a O 0 0.0009506267
lower O 0 0.00078608945
incidence O 0 0.0036925373
of O 0 0.0016949904
erosive O 0 0.998357
cystitis B-Disease 0 0.9998555
but O 0 0.00112256
further O 0 0.000582887
studies O 0 0.0006472974
would O 0 0.0002496799
have O 0 0.00029902993
to O 0 0.00026895167
be O 0 0.00027648802
performed O 0 0.00023105153
before O 0 0.0001865147
it O 0 0.00036292826
could O 0 0.0002832629
be O 0 0.00042943374
recommended O 0 0.00060923636
for O 0 0.0005817739
use O 0 0.0012683626
in O 0 0.0015569564
urological O 0 0.11631287
procedures O 0 0.006818902
. O 0 0.006033811

Effects O 0 0.015623329
of O 0 0.00622177
tetrandrine B-Chemical 0 0.9985083
and O 0 0.0068213367
fangchinoline B-Chemical 0 0.9949242
on O 0 0.0017173353
experimental O 0 0.005356501
thrombosis B-Disease 2 0.99751854
in O 0 0.002208641
mice O 0 0.0015034633
and O 0 0.00291212
human O 0 0.009829323
platelet B-Disease 2 0.9859087
aggregation I-Disease 2 0.84115523
. O 0 0.012038072

Tetrandrine B-Chemical 0 0.9979505
( O 0 0.017726973
TET B-Chemical 1 0.9842067
) O 0 0.0059078047
and O 0 0.002913595
fangchinoline B-Chemical 0 0.99616337
( O 0 0.0071109775
FAN B-Chemical 1 0.9870674
) O 0 0.002631744
are O 0 0.00092382205
two O 0 0.0007002672
naturally O 0 0.0032965352
occurring O 0 0.0037196458
analogues O 0 0.3719324
with O 0 0.0032220262
a O 0 0.0052757477
bisbenzylisoquinoline B-Chemical 0 0.9918751
structure O 0 0.02552959
. O 0 0.008940997

The O 0 0.0024025135
present O 0 0.0014632791
study O 0 0.0018068394
was O 0 0.0009630385
undertaken O 0 0.00067777437
to O 0 0.000540753
investigate O 0 0.00036338062
the O 0 0.0004514096
effects O 0 0.000992491
of O 0 0.0010352801
TET B-Chemical 1 0.9911289
and O 0 0.001279012
FAN B-Chemical 1 0.98071426
on O 0 0.00030780144
the O 0 0.00038826928
experimental O 0 0.0015249692
thrombosis B-Disease 2 0.9991948
induced O 0 0.0021350007
by O 0 0.00084382034
collagen O 0 0.32530326
plus O 0 0.0016093978
epinephrine B-Chemical 0 0.9994055
( O 0 0.0038114092
EP B-Chemical 0 0.95887065
) O 0 0.0012132162
in O 0 0.00036316187
mice O 0 0.00030452298
, O 0 0.0006823096
and O 0 0.00083739794
platelet B-Disease 2 0.9726423
aggregation I-Disease 2 0.52795
and O 0 0.0026263748
blood B-Disease 2 0.3502372
coagulation I-Disease 2 0.9706316
in O 0 0.0039779563
vitro O 0 0.010678608
. O 0 0.0064562736

In O 0 0.0029740736
the O 0 0.0019731112
in O 0 0.0014144562
vivo O 0 0.0020127716
study O 0 0.001673968
, O 0 0.0011328446
the O 0 0.0007314483
administration O 0 0.07748711
( O 0 0.0010110727
50 O 0 0.0008937683
mg O 0 0.28131515
/ O 0 0.0012523327
kg O 0 0.004424106
, O 0 0.00050117593
i O 0 0.00085091544
. O 0 0.00021004546
p O 0 0.00042846383
. O 0 0.00019312992
) O 0 0.00044124006
of O 0 0.000463818
TET B-Chemical 1 0.9797507
and O 0 0.00074765953
FAN B-Chemical 1 0.9795109
in O 0 0.00033010554
mice O 0 0.00018432738
showed O 0 0.00025439032
the O 0 0.00026397296
inhibition O 0 0.0018996197
of O 0 0.0008364692
thrombosis B-Disease 2 0.9992405
by O 0 0.00059100887
55 O 0 0.00054154714
% O 0 0.00029686734
and O 0 0.00023274739
35 O 0 0.0003042386
% O 0 0.00028614252
, O 0 0.0003185907
respectively O 0 0.0006715558
, O 0 0.00043339553
while O 0 0.00050039386
acetylsalicylic B-Chemical 0 0.99992394
acid I-Chemical 0 0.9976082
( O 0 0.004592159
ASA B-Chemical 1 0.9841038
, O 0 0.0007186066
50 O 0 0.0007057781
mg O 0 0.2769466
/ O 0 0.0009822194
kg O 0 0.0038295444
, O 0 0.0004084029
i O 0 0.000763301
. O 0 0.00019787379
p O 0 0.00044010754
. O 0 0.00021493343
) O 0 0.0005282017
, O 0 0.00038515142
a O 0 0.00034668762
positive O 0 0.000360417
control O 0 0.00047390285
, O 0 0.0008042775
showed O 0 0.0007590179
only O 0 0.0011560075
30 O 0 0.0015975396
% O 0 0.002717592
inhibition O 0 0.008224651
. O 0 0.0055395444

In O 0 0.0033518213
the O 0 0.0023882943
vitro O 0 0.0035837793
human O 0 0.0040664454
platelet B-Disease 0 0.96294314
aggregations I-Disease 0 0.08648947
induced O 0 0.0021185526
by O 0 0.0010272837
the O 0 0.00084222044
agonists O 0 0.75846326
used O 0 0.0007146594
in O 0 0.0005637256
tests O 0 0.0017659426
, O 0 0.0015806345
TET B-Chemical 1 0.97705895
and O 0 0.0019986872
FAN B-Chemical 1 0.976967
showed O 0 0.0019519103
the O 0 0.0025486927
inhibitions O 0 0.80378175
dose O 0 0.42890066
dependently O 0 0.9870006
. O 0 0.01125415

In O 0 0.0031182484
addition O 0 0.0018633789
, O 0 0.002263624
neither O 0 0.0018559033
TET B-Chemical 1 0.9650657
nor O 0 0.0017074667
FAN B-Chemical 1 0.97751105
showed O 0 0.00093315064
any O 0 0.0005734445
anticoagulation O 0 0.599453
activities O 0 0.0009733824
in O 0 0.00031285436
the O 0 0.0002577232
measurement O 0 0.00023258723
of O 0 0.00037658314
the O 0 0.0003152406
activated O 0 0.0005695766
partial O 0 0.0011457534
thromboplastin O 0 0.8527446
time O 0 0.00048484307
( O 0 0.0011400338
APTT O 0 0.9812184
) O 0 0.0012941868
, O 0 0.0006560777
prothrombin O 0 0.7400393
time O 0 0.0004643345
( O 0 0.0008254734
PT O 0 0.032942563
) O 0 0.0008461108
and O 0 0.0005139599
thrombin O 0 0.3661877
time O 0 0.0005968297
( O 0 0.0011353338
TT O 0 0.09736944
) O 0 0.0015306845
using O 0 0.000915605
human O 0 0.0030127587
- O 0 0.0045738034
citrated O 0 0.1797921
plasma O 0 0.12357778
. O 0 0.006604628

These O 0 0.004137717
results O 0 0.002085873
suggest O 0 0.0014322337
that O 0 0.0013758366
antithrombosis O 0 0.20081587
of O 0 0.0027146575
TET B-Chemical 1 0.9911402
and O 0 0.0023950804
FAN B-Chemical 1 0.98246026
in O 0 0.0008803906
mice O 0 0.0004916244
may O 0 0.0006604182
be O 0 0.0006563872
mainly O 0 0.0010619222
related O 0 0.00065867894
to O 0 0.0009596002
the O 0 0.0016573739
antiplatelet O 0 0.9681341
aggregation O 0 0.28992468
activities O 0 0.015079341
. O 0 0.007725911

Angioedema B-Disease 0 0.99348444
due O 0 0.006120901
to O 0 0.006316472
ACE B-Chemical 0 0.99482685
inhibitors I-Chemical 0 0.6955767
: O 0 0.008680909
common O 0 0.0066141607
and O 0 0.0066434504
inadequately O 0 0.24748674
diagnosed O 0 0.1900593
. O 0 0.012712529

The O 0 0.002922378
estimated O 0 0.0023463145
incidence O 0 0.0066611366
of O 0 0.0037712243
angioedema B-Disease 2 0.99937254
during O 0 0.0035006045
angiotensin B-Chemical 1 0.9995882
- I-Chemical 0 0.025087954
converting I-Chemical 0 0.3315618
enzyme I-Chemical 0 0.48001444
( I-Chemical 0 0.0047152666
ACE I-Chemical 0 0.9985966
) I-Chemical 0 0.0045997654
inhibitor I-Chemical 0 0.12244541
treatment O 0 0.0027159604
is O 0 0.0006458727
between O 0 0.0003715745
1 O 0 0.00065030437
and O 0 0.0007083086
7 O 0 0.00073415367
per O 0 0.0007686521
thousand O 0 0.0025695942
patients O 0 0.0072386344
. O 0 0.0054190066

This O 0 0.005729008
potentially O 0 0.005582879
serious O 0 0.08231579
adverse O 0 0.5990548
effect O 0 0.0020558203
is O 0 0.001139714
often O 0 0.0014373098
preceded O 0 0.0013009432
by O 0 0.0010175606
minor O 0 0.0027278168
manifestations O 0 0.51995414
that O 0 0.0011120335
may O 0 0.0014331798
serve O 0 0.0024145013
as O 0 0.0020678777
a O 0 0.004593506
warning O 0 0.05537499
. O 0 0.007595639

Cocaine B-Chemical 0 0.99849117
- O 0 0.01109791
induced O 0 0.0052509527
mood B-Disease 0 0.97690773
disorder I-Disease 0 0.9481442
: O 0 0.0027886238
prevalence O 0 0.0019888377
rates O 0 0.0010348986
and O 0 0.0015065351
psychiatric B-Disease 2 0.99560106
symptoms O 0 0.90916973
in O 0 0.0011324077
an O 0 0.0016931293
outpatient O 0 0.011692392
cocaine B-Chemical 1 0.99870455
- O 0 0.005689431
dependent O 0 0.0029399486
sample O 0 0.0050205165
. O 0 0.0062610107

This O 0 0.0043331124
paper O 0 0.003127794
attempts O 0 0.0021980572
to O 0 0.0010278181
examine O 0 0.000565252
and O 0 0.00069461815
compare O 0 0.0003435352
prevalence O 0 0.0009639472
rates O 0 0.0006168522
and O 0 0.00072731945
symptom O 0 0.02213617
patterns O 0 0.0006631788
of O 0 0.0012891219
DSM O 0 0.2759958
substance O 0 0.9746149
- O 0 0.002935976
induced O 0 0.0018104713
and O 0 0.0018646847
other O 0 0.0033813815
mood B-Disease 0 0.98177296
disorders I-Disease 0 0.91906273
. O 0 0.008451835

243 O 0 0.0621236
cocaine B-Chemical 1 0.9971405
- O 0 0.0053280867
dependent O 0 0.0017075838
outpatients O 0 0.017333632
with O 0 0.0023967172
cocaine B-Chemical 1 0.9993154
- O 0 0.0049505876
induced O 0 0.0024273607
mood B-Disease 0 0.9916019
disorder I-Disease 0 0.9826371
( O 0 0.0038617125
CIMD B-Disease 0 0.9580876
) O 0 0.0014961476
, O 0 0.00057571696
other O 0 0.0005180689
mood B-Disease 0 0.9666323
disorders I-Disease 0 0.78785527
, O 0 0.00072553195
or O 0 0.00033089824
no O 0 0.0004015754
mood B-Disease 0 0.94100606
disorder I-Disease 0 0.8022657
were O 0 0.00057659444
compared O 0 0.0003468086
on O 0 0.00042698768
measures O 0 0.0011279098
of O 0 0.003329269
psychiatric B-Disease 2 0.99452835
symptoms O 0 0.96760297
. O 0 0.00809525

The O 0 0.0047038477
prevalence O 0 0.005673108
rate O 0 0.0035258804
for O 0 0.003653939
CIMD B-Disease 0 0.66506165
was O 0 0.0038788053
12 O 0 0.0030626743
% O 0 0.0040179933
at O 0 0.0033692357
baseline O 0 0.0081571285
. O 0 0.009091251

Introduction O 0 0.0076109096
of O 0 0.0037650093
the O 0 0.0031144961
DSM O 0 0.105277285
- O 0 0.0040778224
IV O 0 0.06991192
diagnosis O 0 0.009409811
of O 0 0.0019660438
CIMD B-Disease 0 0.8853244
did O 0 0.0009311191
not O 0 0.0006241984
substantially O 0 0.00080782914
affect O 0 0.0005341363
rates O 0 0.00085644063
of O 0 0.0013987755
the O 0 0.0017576988
other O 0 0.00447916
depressive B-Disease 2 0.9980361
disorders I-Disease 0 0.95957273
. O 0 0.009739627

Patients O 0 0.010802641
with O 0 0.0039406945
CIMD B-Disease 0 0.66820914
had O 0 0.0023735873
symptom O 0 0.06622811
severity O 0 0.016622405
levels O 0 0.0009012226
between O 0 0.00043765636
those O 0 0.00079367694
of O 0 0.0008489184
patients O 0 0.002067867
with O 0 0.001163745
and O 0 0.001323357
without O 0 0.001897982
a O 0 0.003977361
mood B-Disease 0 0.97845465
disorder I-Disease 0 0.9577923
. O 0 0.008787914

These O 0 0.0041867127
findings O 0 0.0034118756
suggest O 0 0.0012892834
some O 0 0.0013802974
validity O 0 0.0017268526
for O 0 0.0006871992
the O 0 0.0007122837
new O 0 0.0014467936
DSM O 0 0.12912701
- O 0 0.0019430483
IV O 0 0.07263506
diagnosis O 0 0.009305408
of O 0 0.0012882027
CIMD B-Disease 0 0.9446638
, O 0 0.0009983764
but O 0 0.00046709445
also O 0 0.0004393566
suggest O 0 0.00035244465
that O 0 0.00044932292
it O 0 0.00069993123
requires O 0 0.00063696044
further O 0 0.0015806119
specification O 0 0.015979242
and O 0 0.0035575444
replication O 0 0.037714213
. O 0 0.0064480077

Effect O 0 0.010530169
of O 0 0.006763866
fucoidan B-Chemical 0 0.9871585
treatment O 0 0.012478025
on O 0 0.0028838958
collagenase O 0 0.85195404
- O 0 0.0100206155
induced O 0 0.010952043
intracerebral B-Disease 0 0.9963529
hemorrhage I-Disease 2 0.99839395
in O 0 0.009088146
rats O 0 0.049187202
. O 0 0.009392054

Inflammatory O 0 0.5294812
cells O 0 0.006462268
are O 0 0.0027586136
postulated O 0 0.003813472
to O 0 0.0015592714
mediate O 0 0.0014830246
some O 0 0.0015712514
of O 0 0.001957287
the O 0 0.0023781236
brain B-Disease 2 0.6690486
damage I-Disease 2 0.9750534
following O 0 0.03392879
ischemic B-Disease 2 0.9991689
stroke I-Disease 2 0.99829775
. O 0 0.01608349

Intracerebral B-Disease 0 0.9858348
hemorrhage I-Disease 2 0.9971859
is O 0 0.006426666
associated O 0 0.0050559836
with O 0 0.004567644
more O 0 0.0072044646
inflammation B-Disease 2 0.98551995
than O 0 0.010495977
ischemic B-Disease 2 0.9986908
stroke I-Disease 2 0.9977574
. O 0 0.019315107

We O 0 0.0033638652
tested O 0 0.0021821205
the O 0 0.0022720764
sulfated O 0 0.8259228
polysaccharide O 0 0.6006227
fucoidan B-Chemical 0 0.99754864
, O 0 0.0032500732
which O 0 0.0013855286
has O 0 0.00075897586
been O 0 0.0007733123
reported O 0 0.0007712793
to O 0 0.0004329479
reduce O 0 0.0005106888
inflammatory O 0 0.90455484
brain B-Disease 2 0.8920676
damage I-Disease 2 0.977394
, O 0 0.0010924164
in O 0 0.00031709374
a O 0 0.00039879087
rat O 0 0.0031226126
model O 0 0.0005457394
of O 0 0.0009337728
intracerebral B-Disease 0 0.99814403
hemorrhage I-Disease 2 0.999582
induced O 0 0.0021117267
by O 0 0.00068458024
injection O 0 0.002858614
of O 0 0.00096829643
bacterial O 0 0.024866667
collagenase O 0 0.6947587
into O 0 0.0011213094
the O 0 0.0023226829
caudate O 0 0.81424266
nucleus O 0 0.013416478
. O 0 0.0054955645

Rats O 0 0.035964254
were O 0 0.0025905124
treated O 0 0.0024393618
with O 0 0.0013960294
seven O 0 0.00095760124
day O 0 0.0009849219
intravenous O 0 0.24217866
infusion O 0 0.04883775
of O 0 0.001894
fucoidan B-Chemical 0 0.99665487
( O 0 0.0021284847
30 O 0 0.00092191703
micrograms O 0 0.1029149
h O 0 0.00137024
- O 0 0.0019777291
1 O 0 0.0015408619
) O 0 0.0025703276
or O 0 0.0024470633
vehicle O 0 0.02958675
. O 0 0.0063340967

The O 0 0.0078069824
hematoma B-Disease 0 0.96331125
was O 0 0.0046578944
assessed O 0 0.0030635623
in O 0 0.00313801
vivo O 0 0.0056486167
by O 0 0.005511578
magnetic O 0 0.19630821
resonance O 0 0.736117
imaging O 0 0.07279197
. O 0 0.015175701

Motor O 0 0.5164879
behavior O 0 0.008425066
, O 0 0.0033944435
passive O 0 0.0043568886
avoidance O 0 0.0062004426
, O 0 0.0019932275
and O 0 0.001264888
skilled O 0 0.0029101353
forelimb O 0 0.09224634
function O 0 0.0013300304
were O 0 0.0009169045
tested O 0 0.00087037106
repeatedly O 0 0.0019232426
for O 0 0.0016046788
six O 0 0.0022471114
weeks O 0 0.0047408645
. O 0 0.006117949

Fucoidan B-Chemical 0 0.9904614
- O 0 0.00710783
treated O 0 0.0034322613
rats O 0 0.004233742
exhibited O 0 0.001114082
evidence O 0 0.00091356854
of O 0 0.0009855519
impaired B-Disease 0 0.002848853
blood I-Disease 0 0.019854391
clotting I-Disease 0 0.68825185
and O 0 0.0011169002
hemodilution B-Disease 0 0.99519557
, O 0 0.0008883837
had O 0 0.0004869481
larger O 0 0.0005725902
hematomas B-Disease 0 0.9981098
, O 0 0.0006962804
and O 0 0.0003685847
tended O 0 0.00031953608
to O 0 0.00024316515
have O 0 0.000333897
less O 0 0.0005217452
inflammation B-Disease 2 0.93640876
in O 0 0.00048497596
the O 0 0.00045631893
vicinity O 0 0.00066046254
of O 0 0.0009146229
the O 0 0.0012756876
hematoma B-Disease 0 0.9929133
after O 0 0.0011400154
three O 0 0.0014460965
days O 0 0.0035237246
. O 0 0.004748976

They O 0 0.0062017296
showed O 0 0.0022193876
significantly O 0 0.001839551
more O 0 0.0014087872
rapid O 0 0.0019505817
improvement O 0 0.0012606226
of O 0 0.00097220717
motor O 0 0.046101417
function O 0 0.0007968244
in O 0 0.0003599426
the O 0 0.00029992615
first O 0 0.00025060572
week O 0 0.00033365452
following O 0 0.00056555244
hemorrhage B-Disease 2 0.99810445
and O 0 0.00067337847
better O 0 0.000857247
memory O 0 0.11816194
retention O 0 0.0027563558
in O 0 0.0008426218
the O 0 0.0011591736
passive O 0 0.0051315282
avoidance O 0 0.011785992
test O 0 0.005593276
. O 0 0.006193665

Acute O 0 0.96482044
white B-Disease 0 0.02718909
matter I-Disease 0 0.035299204
edema I-Disease 0 0.99768794
and O 0 0.0032890488
eventual O 0 0.056644272
neuronal B-Disease 0 0.92430985
loss I-Disease 0 0.023427945
in O 0 0.0008157631
the O 0 0.0008129052
striatum O 0 0.5019617
adjacent O 0 0.00089110836
to O 0 0.0005270507
the O 0 0.0007465489
hematoma B-Disease 0 0.99500847
did O 0 0.00071692315
not O 0 0.00059319113
differ O 0 0.0008665881
between O 0 0.00068772136
the O 0 0.001385916
two O 0 0.002032369
groups O 0 0.0048917825
. O 0 0.0060118707

Investigation O 0 0.015275603
of O 0 0.0037922298
more O 0 0.003023498
specific O 0 0.0022025597
anti O 0 0.009822553
- O 0 0.0044890596
inflammatory O 0 0.74718386
agents O 0 0.31456456
and O 0 0.0020530636
hemodiluting O 0 0.3193366
agents O 0 0.17791244
are O 0 0.0019303564
warranted O 0 0.002404569
in O 0 0.0041059204
intracerebral B-Disease 0 0.99537045
hemorrhage I-Disease 2 0.9980342
. O 0 0.012293564

Recurarization O 0 0.07246177
in O 0 0.012846748
the O 0 0.013035799
recovery O 0 0.02307932
room O 0 0.016913652
. O 0 0.023396172

A O 0 0.017926475
case O 0 0.0046289577
of O 0 0.0046593235
recurarization O 0 0.3443532
in O 0 0.0029868092
the O 0 0.0028272388
recovery O 0 0.0059990897
room O 0 0.0033894305
is O 0 0.0056841383
reported O 0 0.010951233
. O 0 0.010228052

Accumulation O 0 0.017468492
of O 0 0.0043018134
atracurium B-Chemical 0 0.99319905
in O 0 0.0018908198
the O 0 0.0013104728
intravenous O 0 0.30813175
line O 0 0.0019114363
led O 0 0.0012553055
to O 0 0.000856459
recurarization O 0 0.37490895
after O 0 0.00066563097
flushing O 0 0.5521145
the O 0 0.0010109078
line O 0 0.0017825383
in O 0 0.0012102352
the O 0 0.0017725182
recovery O 0 0.005487986
room O 0 0.0036357762
. O 0 0.0060657123

A O 0 0.077614866
respiratory B-Disease 0 0.8414535
arrest I-Disease 0 0.79891056
with O 0 0.009714287
severe O 0 0.6521602
desaturation B-Disease 0 0.9932719
and O 0 0.01781096
bradycardia B-Disease 0 0.9958188
occurred O 0 0.021075027
. O 0 0.01233703

Circumstances O 0 0.1677196
leading O 0 0.0050398563
to O 0 0.00181835
this O 0 0.0013141838
event O 0 0.0024649303
and O 0 0.0008841984
the O 0 0.0006201052
mechanisms O 0 0.001090657
enabling O 0 0.0009807766
a O 0 0.0008940996
neuromuscular B-Disease 0 0.9492525
blockade I-Disease 0 0.790791
to O 0 0.0005838703
occur O 0 0.0006008753
, O 0 0.00047630176
following O 0 0.00032600938
the O 0 0.00033025254
administration O 0 0.022825556
of O 0 0.00058639527
a O 0 0.00060906576
small O 0 0.0008317437
dose O 0 0.011609021
of O 0 0.002261581
relaxant O 0 0.9911361
, O 0 0.0038173688
are O 0 0.003143229
discussed O 0 0.004368548
. O 0 0.005806891

The O 0 0.0035229411
haemodynamic O 0 0.4150412
effects O 0 0.0038443494
of O 0 0.002548922
propofol B-Chemical 1 0.9967728
in O 0 0.0013040768
combination O 0 0.0029604714
with O 0 0.0019271399
ephedrine B-Chemical 1 0.99940646
in O 0 0.0014808308
elderly O 0 0.4460351
patients O 0 0.008310535
( O 0 0.0021056
ASA O 1 0.9027386
groups O 0 0.0016994261
3 O 0 0.001349165
and O 0 0.0019056221
4 O 0 0.0025560705
) O 0 0.005612822
. O 0 0.0051709334

The O 0 0.0038365691
marked O 0 0.0054504094
vasodilator O 0 0.98597413
and O 0 0.0026107458
negative O 0 0.0019365399
inotropic O 0 0.98014885
effects O 0 0.0040178364
of O 0 0.0024602623
propofol B-Chemical 1 0.9970836
are O 0 0.0017016036
disadvantages O 0 0.0011956521
in O 0 0.0019221011
frail O 0 0.23670256
elderly O 0 0.41213998
patients O 0 0.01786416
. O 0 0.0074296985

We O 0 0.0029303588
investigated O 0 0.0019662534
the O 0 0.0014268251
safety O 0 0.0026461012
and O 0 0.0010710122
efficacy O 0 0.0021477737
of O 0 0.00086670654
adding O 0 0.0009767425
different O 0 0.0006980287
doses O 0 0.029305011
of O 0 0.0016789647
ephedrine B-Chemical 1 0.99948776
to O 0 0.00145807
propofol B-Chemical 1 0.99791795
in O 0 0.00088885025
order O 0 0.00065829983
to O 0 0.0011524356
obtund O 0 0.12297236
the O 0 0.0031241875
hypotensive B-Disease 2 0.99499965
response O 0 0.015985105
. O 0 0.0074987854

The O 0 0.0032680535
haemodynamic O 0 0.3541975
effects O 0 0.0030412683
of O 0 0.001578586
adding O 0 0.0015731773
15 O 0 0.00074379786
, O 0 0.00069392245
20 O 0 0.00048083774
or O 0 0.00031470248
25 O 0 0.00060263724
mg O 0 0.100037366
of O 0 0.00067435787
ephedrine B-Chemical 1 0.999376
to O 0 0.00046576082
200 O 0 0.0013372308
mg O 0 0.21355067
of O 0 0.00057569525
propofol B-Chemical 1 0.9980603
were O 0 0.00033588364
compared O 0 0.00014538948
to O 0 0.00018666522
control O 0 0.00019664073
in O 0 0.00022570453
40 O 0 0.00041604662
ASA O 1 0.7860904
3 O 0 0.00030758115
/ O 0 0.000544026
4 O 0 0.00020659792
patients O 0 0.0004401669
over O 0 0.00015659901
60 O 0 0.00038040912
years O 0 0.00070467324
presenting O 0 0.0028763204
for O 0 0.00089226296
genito O 0 0.07216358
- O 0 0.005264964
urinary O 0 0.8176001
surgery O 0 0.0663298
. O 0 0.00691797

The O 0 0.0028066894
addition O 0 0.0017759062
of O 0 0.0027580995
ephedrine B-Chemical 1 0.9984824
to O 0 0.002475059
propofol B-Chemical 1 0.9979296
appears O 0 0.0012214989
to O 0 0.0006005862
be O 0 0.0005132298
an O 0 0.0005192554
effective O 0 0.00063899916
method O 0 0.00072360836
of O 0 0.0007106988
obtunding O 0 0.7380117
the O 0 0.0007653791
hypotensive B-Disease 2 0.99794215
response O 0 0.0018784256
to O 0 0.0006968145
propofol B-Chemical 1 0.99738806
at O 0 0.00046701677
all O 0 0.0006126708
doses O 0 0.0134579465
used O 0 0.0010395963
in O 0 0.001281264
this O 0 0.0022042831
study O 0 0.005330114
. O 0 0.0054051876

However O 0 0.0046663783
, O 0 0.0034821068
marked O 0 0.0038873982
tachycardia B-Disease 2 0.995861
associated O 0 0.0022438457
with O 0 0.0011058794
the O 0 0.0006471024
use O 0 0.00076492154
of O 0 0.0009834226
ephedrine B-Chemical 1 0.9994703
in O 0 0.00062843715
combination O 0 0.0019384061
with O 0 0.00095432386
propofol B-Chemical 1 0.99863523
occurred O 0 0.000783637
in O 0 0.00028175671
the O 0 0.00025137726
majority O 0 0.00033142552
of O 0 0.00048217198
patients O 0 0.002020394
, O 0 0.0006667277
occasionally O 0 0.0014890649
reaching O 0 0.0012037071
high O 0 0.0009994308
levels O 0 0.0009815355
in O 0 0.0012067811
individual O 0 0.0020384185
patients O 0 0.010054831
. O 0 0.0055079884

Due O 0 0.0042250045
to O 0 0.002212563
the O 0 0.0017427846
risk O 0 0.0075159078
of O 0 0.0017164366
this O 0 0.0015675806
tachycardia B-Disease 2 0.9986382
inducing O 0 0.038457006
myocardial B-Disease 0 0.9993643
ischemia I-Disease 2 0.99979
, O 0 0.0016508609
we O 0 0.00021750541
would O 0 0.00022663242
not O 0 0.00021934939
recommend O 0 0.0002488068
the O 0 0.00023993106
use O 0 0.00037080343
in O 0 0.000311106
elderly O 0 0.098139994
patients O 0 0.0011470688
of O 0 0.00047469838
any O 0 0.00036218175
of O 0 0.00068814354
the O 0 0.0010610806
ephedrine B-Chemical 1 0.9993666
/ O 0 0.031931885
propofol B-Chemical 1 0.99783343
/ O 0 0.011459739
mixtures O 0 0.028524509
studied O 0 0.007725323
. O 0 0.0062756427

Gemcitabine B-Chemical 0 0.9953263
plus O 0 0.006359969
vinorelbine B-Chemical 1 0.99661
in O 0 0.0033220297
nonsmall B-Disease 0 0.9965809
cell I-Disease 0 0.11795535
lung I-Disease 0 0.86540014
carcinoma I-Disease 2 0.99926215
patients O 0 0.017046452
age O 0 0.0018220015
70 O 0 0.0007164733
years O 0 0.0008765552
or O 0 0.00047307895
older O 0 0.0014571568
or O 0 0.00068351993
patients O 0 0.0024230713
who O 0 0.0033848512
cannot O 0 0.008417713
receive O 0 0.006632156
cisplatin B-Chemical 1 0.99495256
. O 0 0.0097688

Oncopaz O 0 0.30424994
Cooperative O 0 0.24040581
Group O 0 0.11773658
. O 0 0.047504235

BACKGROUND O 0 0.7215864
: O 0 0.004656676
Although O 0 0.0017347957
the O 0 0.0012409234
prevalence O 0 0.0020087652
of O 0 0.0020373845
nonsmall B-Disease 0 0.9969078
cell I-Disease 0 0.16392228
lung I-Disease 0 0.942524
carcinoma I-Disease 2 0.99969614
( O 0 0.026965726
NSCLC B-Disease 2 0.9986255
) O 0 0.0020140882
is O 0 0.0003778727
high O 0 0.0004587266
among O 0 0.00046920052
elderly O 0 0.1411108
patients O 0 0.0015348559
, O 0 0.00034263526
few O 0 0.0001636147
data O 0 0.00027062802
are O 0 0.00023259343
available O 0 0.00021340392
regarding O 0 0.00019833884
the O 0 0.00026652898
efficacy O 0 0.0017099865
and O 0 0.00064661755
toxicity B-Disease 2 0.98181057
of O 0 0.0013318335
chemotherapy O 0 0.7633825
in O 0 0.00084001914
this O 0 0.0009923772
group O 0 0.0017748262
of O 0 0.0030489233
patients O 0 0.01324909
. O 0 0.0057875896

Recent O 0 0.0051875473
reports O 0 0.0032221612
indicate O 0 0.0013306024
that O 0 0.001072643
single O 0 0.0012279055
agent O 0 0.058921177
therapy O 0 0.04038667
with O 0 0.0025265333
vinorelbine B-Chemical 1 0.99915373
( O 0 0.0067959256
VNB B-Chemical 1 0.9959596
) O 0 0.0018816342
or O 0 0.0005659342
gemcitabine B-Chemical 1 0.99855214
( O 0 0.0026957032
GEM B-Chemical 0 0.9945879
) O 0 0.001085888
may O 0 0.00027759076
obtain O 0 0.00016688844
a O 0 0.00024979108
response O 0 0.00035309847
rate O 0 0.0002234579
of O 0 0.00034963668
20 O 0 0.00041060048
- O 0 0.00041946673
30 O 0 0.00019588137
% O 0 0.00021896364
in O 0 0.00018487973
elderly O 0 0.05099125
patients O 0 0.0011605971
, O 0 0.0003911585
with O 0 0.0003802215
acceptable O 0 0.00071915187
toxicity B-Disease 2 0.9727275
and O 0 0.0005939147
improvement O 0 0.00095983746
in O 0 0.00063735276
symptoms O 0 0.14977333
and O 0 0.0011596822
quality O 0 0.0013884967
of O 0 0.0031730959
life O 0 0.009555657
. O 0 0.005630521

In O 0 0.0026380129
the O 0 0.0016754695
current O 0 0.0019649945
study O 0 0.0015523178
the O 0 0.0008834893
efficacy O 0 0.003013658
and O 0 0.0011187978
toxicity B-Disease 2 0.97825897
of O 0 0.0009249097
the O 0 0.00049875595
combination O 0 0.0014573747
of O 0 0.0011180914
GEM B-Chemical 0 0.99531317
and O 0 0.0014097382
VNB B-Chemical 1 0.99425125
in O 0 0.0005408661
elderly O 0 0.25650474
patients O 0 0.0021909508
with O 0 0.00064853823
advanced O 0 0.18285729
NSCLC B-Disease 2 0.9977208
or O 0 0.0005194247
those O 0 0.0006344799
with O 0 0.0005179702
some O 0 0.00060100155
contraindication O 0 0.0012634179
to O 0 0.00085756887
receiving O 0 0.014009303
cisplatin B-Chemical 1 0.99695134
were O 0 0.0035831784
assessed O 0 0.003874007
. O 0 0.0055619306

METHODS O 0 0.00672119
: O 0 0.0036574618
Forty O 0 0.0052792025
- O 0 0.0019603942
nine O 0 0.0010034681
patients O 0 0.0017826407
with O 0 0.0010556757
advanced O 0 0.09171021
NSCLC B-Disease 2 0.9961254
were O 0 0.0007550504
included O 0 0.00046016288
, O 0 0.00048943004
38 O 0 0.00050885836
of O 0 0.00037526505
whom O 0 0.0010715348
were O 0 0.00035016309
age O 0 0.0009010264
> O 0 0.00082645717
/ O 0 0.0006715226
= O 0 0.00037223913
70 O 0 0.00024416717
years O 0 0.00034380372
and O 0 0.00022695724
11 O 0 0.0002615731
were O 0 0.00021140145
age O 0 0.00046284046
< O 0 0.0003015671
70 O 0 0.00029990982
years O 0 0.0004944719
but O 0 0.0003375988
who O 0 0.00082153536
had O 0 0.0005807343
some O 0 0.00091092836
contraindication O 0 0.002155619
to O 0 0.0018749724
receiving O 0 0.042541105
cisplatin B-Chemical 1 0.99633694
. O 0 0.009195349

All O 0 0.007219094
patients O 0 0.0086247
were O 0 0.0050170016
evaluable O 0 0.013400457
for O 0 0.0047707083
response O 0 0.009358392
and O 0 0.012571293
toxicity B-Disease 2 0.9791286
. O 0 0.01780334

Treatment O 0 0.028569939
was O 0 0.0027957933
comprised O 0 0.0021120203
of O 0 0.002527887
VNB B-Chemical 1 0.9806159
, O 0 0.002105056
25 O 0 0.0018047823
mg O 0 0.41363135
/ O 0 0.0023693463
m O 0 0.0033568607
( O 0 0.0007910558
2 O 0 0.00046406835
) O 0 0.0006308246
, O 0 0.0004383275
plus O 0 0.00045580688
GEM B-Chemical 0 0.97815806
, O 0 0.0007413176
1000 O 0 0.0012290231
mg O 0 0.41980687
/ O 0 0.0015806599
m O 0 0.0025873797
( O 0 0.0005337933
2 O 0 0.0003429961
) O 0 0.0004930567
, O 0 0.00034301373
both O 0 0.000264192
on O 0 0.00023856352
Days O 0 0.044162508
1 O 0 0.00048465683
, O 0 0.00054818526
8 O 0 0.0004517292
, O 0 0.00058384193
and O 0 0.00060419523
15 O 0 0.00065781974
every O 0 0.00064823456
28 O 0 0.001972914
days O 0 0.002585457
. O 0 0.0040276125

Patients O 0 0.008988707
received O 0 0.0033203003
a O 0 0.0021780832
minimum O 0 0.0013535898
of O 0 0.001641804
three O 0 0.0010632788
courses O 0 0.003607404
unless O 0 0.0029554581
progressive O 0 0.3797567
disease O 0 0.77837944
was O 0 0.00573073
detected O 0 0.0049434397
. O 0 0.008145108

RESULTS O 0 0.023410255
: O 0 0.004758839
One O 0 0.0027678576
hundred O 0 0.0024172016
sixty O 0 0.0029748231
- O 0 0.0019664182
five O 0 0.0007836183
courses O 0 0.001998385
were O 0 0.0011638667
administered O 0 0.002713888
, O 0 0.0015903079
with O 0 0.0015232184
a O 0 0.001913732
median O 0 0.0022121114
of O 0 0.0038151175
3 O 0 0.004916306
. O 0 0.00613246

6 O 0 0.015825015
courses O 0 0.022219554
per O 0 0.014428378
patient O 0 0.029038139
. O 0 0.027242146

The O 0 0.0030493406
overall O 0 0.0024954719
response O 0 0.0023990166
rate O 0 0.0014371489
was O 0 0.0012805095
26 O 0 0.0015843019
% O 0 0.0011062177
( O 0 0.00096188526
95 O 0 0.0012315847
% O 0 0.00069913093
confidence O 0 0.0013752156
interval O 0 0.0012894786
, O 0 0.0013431059
15 O 0 0.0012306148
- O 0 0.0025386855
41 O 0 0.003916553
% O 0 0.0036540593
) O 0 0.006154972
. O 0 0.005803013

Two O 0 0.004636493
patients O 0 0.004506084
attained O 0 0.0032320207
a O 0 0.0016154498
complete O 0 0.0012050419
response O 0 0.0017469515
( O 0 0.0013041726
4 O 0 0.0006361827
% O 0 0.0007112202
) O 0 0.00076304935
and O 0 0.00051981595
11 O 0 0.0006447361
patients O 0 0.0013837557
( O 0 0.0009401306
22 O 0 0.0010227174
% O 0 0.0009249287
) O 0 0.0012667038
achieved O 0 0.0013685641
a O 0 0.0019856677
partial O 0 0.0050408468
response O 0 0.0071194433
. O 0 0.0064632357

Eastern O 0 0.034541655
Cooperative O 0 0.044982146
Oncology O 0 0.022642605
Group O 0 0.00680543
performance O 0 0.0014208141
status O 0 0.0010215265
improved O 0 0.0012538823
in O 0 0.000508087
35 O 0 0.00055021135
% O 0 0.00038329908
of O 0 0.00035694172
those O 0 0.00044880086
patients O 0 0.0008499743
with O 0 0.00036884146
an O 0 0.00037206354
initial O 0 0.00030560145
value O 0 0.0003445088
> O 0 0.0006125946
0 O 0 0.0002637362
, O 0 0.00023745297
whereas O 0 0.00018833735
relief O 0 0.01015641
of O 0 0.00027764236
at O 0 0.00013787676
least O 0 0.0001428584
1 O 0 0.00024006743
symptom O 0 0.0072470075
without O 0 0.00028236126
worsening O 0 0.2500323
of O 0 0.00047392797
other O 0 0.0004998825
symptoms O 0 0.28299144
was O 0 0.0004765749
noted O 0 0.00046762638
in O 0 0.00047988308
27 O 0 0.0012195655
patients O 0 0.0022207366
( O 0 0.0017666657
55 O 0 0.0022543084
% O 0 0.002779307
) O 0 0.0049049123
. O 0 0.004694135

The O 0 0.0026997058
median O 0 0.0018469627
time O 0 0.0013343316
to O 0 0.0013702372
progression O 0 0.053007454
was O 0 0.0010032146
16 O 0 0.0007724207
weeks O 0 0.0005772838
and O 0 0.00061027
the O 0 0.00061644375
1 O 0 0.00080124673
- O 0 0.0010947098
year O 0 0.00095930987
survival O 0 0.008053016
rate O 0 0.0015789708
was O 0 0.0023285607
33 O 0 0.0050171684
% O 0 0.0051025725
. O 0 0.0053717243

Toxicity B-Disease 0 0.9361835
was O 0 0.046655882
mild O 0 0.5631503
. O 0 0.04740571

Six O 0 0.0063055954
patients O 0 0.00590936
( O 0 0.002786255
12 O 0 0.0011807904
% O 0 0.0012630394
) O 0 0.0011825439
had O 0 0.0007493311
World O 0 0.0015504838
Health O 0 0.001366253
Organization O 0 0.0013277655
Grade O 0 0.2534116
3 O 0 0.00051259785
- O 0 0.00071231625
4 O 0 0.00041324852
neutropenia B-Disease 2 0.9966017
, O 0 0.00060542906
2 O 0 0.00033271778
patients O 0 0.0008757943
( O 0 0.00041439154
4 O 0 0.00022996713
% O 0 0.0002949138
) O 0 0.00037307575
had O 0 0.00033637986
Grade O 0 0.2911946
3 O 0 0.00035163565
- O 0 0.0005834992
4 O 0 0.00037452485
thrombocytopenia B-Disease 0 0.9986179
, O 0 0.0006038406
and O 0 0.00040478894
2 O 0 0.0004108458
patients O 0 0.0011153563
( O 0 0.0007004327
4 O 0 0.0005022357
% O 0 0.0007927303
) O 0 0.0012711987
had O 0 0.0016861558
Grade O 0 0.56951725
3 O 0 0.00458317
neurotoxicity B-Disease 2 0.9966408
. O 0 0.0077947406

Three O 0 0.007027949
patients O 0 0.0074040582
with O 0 0.004936142
severe O 0 0.41498923
neutropenia B-Disease 2 0.9974154
( O 0 0.005762038
6 O 0 0.0021485023
% O 0 0.0027928436
) O 0 0.0039332956
died O 0 0.013785585
of O 0 0.008840366
sepsis B-Disease 2 0.9917502
. O 0 0.013750265

The O 0 0.0026250624
median O 0 0.0019025998
age O 0 0.0023361046
of O 0 0.0014570048
those O 0 0.0014463401
patients O 0 0.002578217
developing O 0 0.006086665
Grade O 0 0.638173
3 O 0 0.000661149
- O 0 0.00081014796
4 O 0 0.00039982898
neutropenia B-Disease 2 0.99635553
was O 0 0.0003510515
significantly O 0 0.00032595036
higher O 0 0.00022368428
than O 0 0.00013625184
that O 0 0.00014940626
of O 0 0.0002580261
the O 0 0.00021791935
remaining O 0 0.00028207118
patients O 0 0.001299686
( O 0 0.00044979452
75 O 0 0.00044685535
years O 0 0.0005092783
vs O 0 0.00058106123
. O 0 0.00022231966
72 O 0 0.00046866547
years O 0 0.0009559614
; O 0 0.0012702993
P O 0 0.015470205
= O 0 0.0017506907
0 O 0 0.0015082649
. O 0 0.0014993566
047 O 0 0.12538153
) O 0 0.0060849255
. O 0 0.005276221

CONCLUSIONS O 0 0.66267484
: O 0 0.0046736924
The O 0 0.001615549
combination O 0 0.0025727798
of O 0 0.0022076608
GEM B-Chemical 0 0.988144
and O 0 0.0026352932
VNB B-Chemical 1 0.9928791
is O 0 0.0010551941
moderately O 0 0.0074480907
active O 0 0.001070026
and O 0 0.0005266377
well O 0 0.0003974902
tolerated O 0 0.006327909
except O 0 0.00040189666
in O 0 0.0005299723
patients O 0 0.0021757714
age O 0 0.0025723896
> O 0 0.0026547571
/ O 0 0.0029988007
= O 0 0.0026866896
75 O 0 0.0032334311
years O 0 0.005215861
. O 0 0.0048026433

This O 0 0.007913343
age O 0 0.006842756
group O 0 0.0044335797
had O 0 0.0037280011
an O 0 0.0047848173
increased O 0 0.0072505823
risk O 0 0.09545955
of O 0 0.024472374
myelosuppression B-Disease 0 0.9979235
. O 0 0.019913092

Therefore O 0 0.003323718
the O 0 0.0023111494
prophylactic O 0 0.008287584
use O 0 0.0024855447
of O 0 0.0026190183
granulocyte O 0 0.87621653
- O 0 0.0044150385
colony O 0 0.012774435
stimulating O 0 0.0030348413
factor O 0 0.005348705
should O 0 0.0007653991
be O 0 0.0010628323
considered O 0 0.0010760676
with O 0 0.001897496
this O 0 0.0028063224
treatment O 0 0.009666143
. O 0 0.0067948056

New O 0 0.0073900674
chemotherapy O 0 0.26965442
combinations O 0 0.0023639752
with O 0 0.0017187535
higher O 0 0.0011923176
activity O 0 0.001303631
and O 0 0.0009411161
lower O 0 0.0010832539
toxicity B-Disease 2 0.9720989
are O 0 0.00090617634
needed O 0 0.0005476575
for O 0 0.0008385357
elderly O 0 0.17846751
patients O 0 0.005510272
with O 0 0.0040567107
advanced O 0 0.49351287
NSCLC B-Disease 2 0.993636
. O 0 0.010864061

A O 0 0.043306336
selective O 0 0.10053138
dopamine B-Chemical 1 0.99759406
D4 O 0 0.99380773
receptor O 0 0.7957799
antagonist O 0 0.9910817
, O 0 0.012865684
NRA0160 B-Chemical 1 0.9839315
: O 0 0.005669193
a O 0 0.0038882198
preclinical O 0 0.11623406
neuropharmacological O 0 0.97771
profile O 0 0.014540266
. O 0 0.010048569

NRA0160 B-Chemical 1 0.9348061
, O 0 0.0063722483
5 B-Chemical 0 0.0027669822
- I-Chemical 0 0.0032839533
[ I-Chemical 0 0.0027912639
2 I-Chemical 0 0.0011798774
- I-Chemical 0 0.0014554745
( I-Chemical 0 0.00094129355
4 I-Chemical 0 0.00054248946
- I-Chemical 0 0.000864441
( I-Chemical 0 0.000603382
3 I-Chemical 0 0.00036962237
- I-Chemical 0 0.0006467874
fluorobenzylidene I-Chemical 0 0.006344015
) I-Chemical 0 0.0011357156
piperidin I-Chemical 0 0.26258385
- I-Chemical 0 0.0013213677
1 I-Chemical 0 0.00060252036
- I-Chemical 0 0.0012857921
yl I-Chemical 0 0.7355071
) I-Chemical 0 0.002263663
ethyl I-Chemical 0 0.99616146
] I-Chemical 0 0.004830352
- I-Chemical 0 0.00086874556
4 I-Chemical 0 0.00032963505
- I-Chemical 0 0.0005931222
( I-Chemical 0 0.0004255585
4 I-Chemical 0 0.00029182906
- I-Chemical 0 0.0007392925
fluorophenyl I-Chemical 0 0.9215376
) I-Chemical 0 0.0015915941
thiazole I-Chemical 0 0.9751873
- I-Chemical 0 0.0013157813
2 I-Chemical 0 0.00041907103
- I-Chemical 0 0.000723355
carboxamide I-Chemical 0 0.96220917
, O 0 0.00047722773
has O 0 0.00024806688
a O 0 0.00026508974
high O 0 0.0003582873
affinity O 0 0.00089139724
for O 0 0.00025950986
human O 0 0.001101525
cloned O 0 0.002029512
dopamine B-Chemical 1 0.999587
D4 O 0 0.9958288
. O 0 0.0003075838
2 O 0 0.0003742777
, O 0 0.00052663294
D4 O 0 0.93226117
. O 0 0.00019675813
4 O 0 0.00021728716
and O 0 0.00032739353
D4 O 0 0.92902964
. O 0 0.0002048959
7 O 0 0.00024171743
receptors O 0 0.01821561
, O 0 0.00042034092
with O 0 0.0004429798
Ki O 0 0.75046736
values O 0 0.00028979426
of O 0 0.00038509854
0 O 0 0.00038618542
. O 0 0.00017424584
5 O 0 0.0002305876
, O 0 0.0003277055
0 O 0 0.00032510248
. O 0 0.00019655787
9 O 0 0.00032407665
and O 0 0.00041315221
2 O 0 0.00056733214
. O 0 0.00049666327
7 O 0 0.000980691
nM O 0 0.0064437264
, O 0 0.002857618
respectively O 0 0.005997546
. O 0 0.004916227

NRA0160 B-Chemical 1 0.87568253
is O 0 0.0032867999
over O 0 0.0013428368
20 O 0 0.0017381576
, O 0 0.0015476614
000fold O 0 0.0040063183
more O 0 0.001235914
potent O 0 0.008275491
at O 0 0.0005583155
the O 0 0.0009851416
dopamine B-Chemical 1 0.9991048
D4 O 0 0.9940428
. O 0 0.0005712283
2 O 0 0.0006141739
receptor O 0 0.012817171
compared O 0 0.00038659322
with O 0 0.000747636
the O 0 0.00089378835
human O 0 0.002921264
cloned O 0 0.00784249
dopamine B-Chemical 1 0.99866223
D2L O 0 0.99701476
receptor O 0 0.7284754
. O 0 0.010387157

NRA0160 B-Chemical 1 0.88304716
has O 0 0.0033079456
negligible O 0 0.0027693124
affinity O 0 0.0031717943
for O 0 0.0010263319
the O 0 0.0009819425
human O 0 0.0021528392
cloned O 0 0.0036804702
dopamine B-Chemical 1 0.99943584
D3 O 0 0.99939716
receptor O 0 0.7260239
( O 0 0.0051044556
Ki O 0 0.95573896
= O 0 0.0012777438
39 O 0 0.0010754311
nM O 0 0.016619949
) O 0 0.0008385641
, O 0 0.0006108674
rat O 0 0.017023696
serotonin B-Chemical 1 0.99879885
( O 0 0.0012591544
5 B-Chemical 0 0.00045029176
- I-Chemical 0 0.001107464
HT I-Chemical 0 0.9730075
) O 0 0.0014036268
2A O 0 0.0011343964
receptors O 0 0.11148221
( O 0 0.0013835732
Ki O 0 0.8900762
= O 0 0.0008546501
180 O 0 0.0012886395
nM O 0 0.007999728
) O 0 0.0007174901
and O 0 0.00056165917
rat O 0 0.017106486
alpha1 O 0 0.96744406
adrenoceptor O 0 0.9995555
( O 0 0.018526215
Ki O 0 0.9662733
= O 0 0.004574092
237 O 0 0.01501558
nM O 0 0.03826796
) O 0 0.007046102
. O 0 0.005649741

NRA0160 B-Chemical 1 0.9582315
and O 0 0.011706462
clozapine B-Chemical 1 0.9993222
antagonized O 0 0.9896563
locomotor O 0 0.9943803
hyperactivity B-Disease 2 0.99941385
induced O 0 0.017837089
by O 0 0.0075598024
methamphetamine B-Chemical 1 0.9995096
( O 0 0.016426358
MAP B-Chemical 0 0.82926506
) O 0 0.0062487456
in O 0 0.0034711869
mice O 0 0.004041646
. O 0 0.006953808

NRA0160 B-Chemical 1 0.960909
and O 0 0.009276905
clozapine B-Chemical 1 0.99948007
antagonized O 0 0.98836386
MAP B-Chemical 0 0.97118247
- O 0 0.005600718
induced O 0 0.0020895167
stereotyped O 0 0.68198603
behavior O 0 0.0028211235
in O 0 0.000425076
mice O 0 0.0002772525
, O 0 0.00043708726
although O 0 0.00027836303
their O 0 0.00030929464
effects O 0 0.0006141446
did O 0 0.00028453476
not O 0 0.00025063657
exceed O 0 0.00031536596
50 O 0 0.0005662317
% O 0 0.0004405525
inhibition O 0 0.0012189855
, O 0 0.00061263697
even O 0 0.00052273425
at O 0 0.00044160555
the O 0 0.000837407
highest O 0 0.001753347
dose O 0 0.015944667
given O 0 0.0034302326
. O 0 0.00547367

NRA0160 B-Chemical 1 0.9527939
and O 0 0.0072159036
clozapine B-Chemical 1 0.9992174
significantly O 0 0.0062283953
induced O 0 0.0089145005
catalepsy B-Disease 2 0.999803
in O 0 0.001451766
rats O 0 0.008286334
, O 0 0.0007746336
although O 0 0.00040052613
their O 0 0.00040297915
effects O 0 0.0007382171
did O 0 0.00033810752
not O 0 0.00029004662
exceed O 0 0.0003534472
50 O 0 0.000595089
% O 0 0.00044026808
induction O 0 0.00054625724
even O 0 0.00051465706
at O 0 0.00044447358
the O 0 0.0008470603
highest O 0 0.0017737976
dose O 0 0.015898408
given O 0 0.0034747398
. O 0 0.0055336244

NRA0160 B-Chemical 1 0.9466254
and O 0 0.006864369
clozapine B-Chemical 1 0.99904805
significantly O 0 0.003960611
reversed O 0 0.0037618342
the O 0 0.0010997951
disruption O 0 0.0015250505
of O 0 0.0016524248
prepulse O 0 0.95616144
inhibition O 0 0.024734193
( O 0 0.0024504913
PPI O 0 0.17433664
) O 0 0.0021942162
in O 0 0.0012203279
rats O 0 0.0048025157
produced O 0 0.0029045825
by O 0 0.007141602
apomorphine B-Chemical 1 0.9987979
. O 0 0.011495864

NRA0160 B-Chemical 1 0.9435778
and O 0 0.006825665
clozapine B-Chemical 1 0.99900144
significantly O 0 0.004000358
shortened O 0 0.004840811
the O 0 0.0026196586
phencyclidine B-Chemical 0 0.9999263
( O 0 0.031877395
PCP B-Chemical 0 0.99763334
) O 0 0.0063768416
- O 0 0.0014936122
induced O 0 0.0008794981
prolonged O 0 0.01180067
swimming O 0 0.10474334
latency O 0 0.0064670453
in O 0 0.000734605
rats O 0 0.0027199786
in O 0 0.0009505461
a O 0 0.0018353463
water O 0 0.020817807
maze O 0 0.16851181
task O 0 0.011508936
. O 0 0.007016996

These O 0 0.004533359
findings O 0 0.0038881944
suggest O 0 0.0015681561
that O 0 0.0015790805
NRA0160 B-Chemical 1 0.90210056
may O 0 0.0012713918
have O 0 0.0009707923
unique O 0 0.0015234599
antipsychotic O 0 0.9981183
activities O 0 0.0015490266
without O 0 0.0006354685
the O 0 0.00056007947
liability O 0 0.075669155
of O 0 0.0010879703
motor O 0 0.12600428
side O 0 0.021099245
effects O 0 0.0022802048
typical O 0 0.002115476
of O 0 0.0030285404
classical O 0 0.04731341
antipsychotics O 0 0.99697745
. O 0 0.009213975

Warfarin B-Chemical 0 0.9960276
- O 0 0.014815298
induced O 0 0.008900113
artery B-Disease 2 0.9489149
calcification I-Disease 2 0.9964489
is O 0 0.003821685
accelerated O 0 0.007531324
by O 0 0.003614196
growth O 0 0.021159554
and O 0 0.009504019
vitamin B-Chemical 0 0.9979728
D I-Chemical 0 0.9655286
. O 0 0.014572818

The O 0 0.0024744794
present O 0 0.0014961873
studies O 0 0.0018417132
demonstrate O 0 0.00093224546
that O 0 0.0009394645
growth O 0 0.0053212424
and O 0 0.001688113
vitamin B-Chemical 0 0.99951684
D I-Chemical 0 0.9531762
treatment O 0 0.004070611
enhance O 0 0.00045057622
the O 0 0.00039589868
extent O 0 0.0003058524
of O 0 0.00091705605
artery B-Disease 2 0.9587984
calcification I-Disease 2 0.999153
in O 0 0.00050745177
rats O 0 0.0023071
given O 0 0.00018565344
sufficient O 0 0.00020133524
doses O 0 0.014165492
of O 0 0.000931478
Warfarin B-Chemical 0 0.9996512
to O 0 0.0005451774
inhibit O 0 0.0012731433
gamma O 0 0.60656416
- O 0 0.0054431814
carboxylation O 0 0.96296006
of O 0 0.0012250815
matrix O 0 0.11094737
Gla O 0 0.9933484
protein O 0 0.006440207
, O 0 0.0008698894
a O 0 0.0008457119
calcification B-Disease 2 0.99634945
inhibitor O 0 0.21365526
known O 0 0.0008280902
to O 0 0.00033677186
be O 0 0.0003247781
expressed O 0 0.00024092522
by O 0 0.00043515407
smooth O 0 0.036979843
muscle O 0 0.058307886
cells O 0 0.0014966832
and O 0 0.00092483225
macrophages O 0 0.004128795
in O 0 0.001246388
the O 0 0.0022672885
artery O 0 0.4099045
wall O 0 0.15655835
. O 0 0.0067694276

The O 0 0.002325064
first O 0 0.0014053127
series O 0 0.0018255465
of O 0 0.0011520808
experiments O 0 0.0007489181
examined O 0 0.00057311385
the O 0 0.000547923
influence O 0 0.0005061703
of O 0 0.0007859067
age O 0 0.001598999
and O 0 0.0007882456
growth O 0 0.0035582425
status O 0 0.0011959882
on O 0 0.0007485963
artery B-Disease 2 0.942174
calcification I-Disease 2 0.9985429
in O 0 0.0045577185
Warfarin B-Chemical 0 0.9991861
- O 0 0.01046093
treated O 0 0.007895607
rats O 0 0.022257615
. O 0 0.0064609637

Treatment O 0 0.021655826
for O 0 0.00229603
2 O 0 0.0016284791
weeks O 0 0.0012087327
with O 0 0.0016695228
Warfarin B-Chemical 0 0.99845433
caused O 0 0.002239489
massive O 0 0.08703899
focal O 0 0.3781842
calcification B-Disease 2 0.99681395
of I-Disease 0 0.0013472467
the I-Disease 0 0.0006954332
artery I-Disease 0 0.2970725
media O 0 0.0028665385
in O 0 0.00036402012
20 O 0 0.0004628164
- O 0 0.00048283752
day O 0 0.0002888707
- O 0 0.0004450427
old O 0 0.00031991862
rats O 0 0.00076502876
and O 0 0.00028542918
less O 0 0.00032272897
extensive O 0 0.0006540801
focal O 0 0.10858984
calcification B-Disease 2 0.9945133
in O 0 0.0008980369
42 O 0 0.0016295151
- O 0 0.0015259221
day O 0 0.0012487272
- O 0 0.0025616453
old O 0 0.003008805
rats O 0 0.008710614
. O 0 0.005161261

In O 0 0.0035023717
contrast O 0 0.002930044
, O 0 0.0027696495
no O 0 0.0017319658
artery B-Disease 2 0.8562883
calcification I-Disease 2 0.9972512
could O 0 0.00095261633
be O 0 0.0006919021
detected O 0 0.00033007213
in O 0 0.00040775383
10 O 0 0.0005151017
- O 0 0.00060782937
month O 0 0.0003986043
- O 0 0.00061362126
old O 0 0.0004431868
adult O 0 0.00056834024
rats O 0 0.0010629953
even O 0 0.00043168827
after O 0 0.00033219892
4 O 0 0.00054688944
weeks O 0 0.00085739477
of O 0 0.0024519828
Warfarin B-Chemical 0 0.99766636
treatment O 0 0.0282576
. O 0 0.007053626

To O 0 0.0025504294
directly O 0 0.0017277383
examine O 0 0.0008682614
the O 0 0.00093174074
importance O 0 0.00081872393
of O 0 0.0011917572
growth O 0 0.007962545
to O 0 0.0012945894
Warfarin B-Chemical 0 0.9995735
- O 0 0.0061359485
induced O 0 0.0028277445
artery B-Disease 2 0.9640711
calcification I-Disease 2 0.9989448
in O 0 0.00042777535
animals O 0 0.00025602986
of O 0 0.0003000208
the O 0 0.0002131449
same O 0 0.00014558288
age O 0 0.00068336586
, O 0 0.0003697817
20 O 0 0.0003317549
- O 0 0.0003687522
day O 0 0.00022390833
- O 0 0.00034369295
old O 0 0.00023681107
rats O 0 0.00056502933
were O 0 0.00017238244
fed O 0 0.00031332477
for O 0 0.00015441843
2 O 0 0.00018083281
weeks O 0 0.000160396
either O 0 0.00017228107
an O 0 0.00028916393
ad O 0 0.0009372553
libitum O 0 0.011144991
diet O 0 0.011874783
or O 0 0.00029248977
a O 0 0.0003764665
6 O 0 0.00028051916
- O 0 0.000515745
g O 0 0.00081116415
/ O 0 0.000667868
d O 0 0.0004458444
restricted O 0 0.0003658731
diet O 0 0.008231589
that O 0 0.0005566805
maintains O 0 0.0013459931
weight O 0 0.0077842767
but O 0 0.0020243514
prevents O 0 0.005706351
growth O 0 0.033677008
. O 0 0.006887518

Concurrent O 0 0.021509917
treatment O 0 0.004523488
of O 0 0.0022822437
both O 0 0.0015794188
dietary O 0 0.35312778
groups O 0 0.0016277442
with O 0 0.0016946411
Warfarin B-Chemical 0 0.9991041
produced O 0 0.0012972263
massive O 0 0.08189833
focal O 0 0.36411068
calcification B-Disease 2 0.99708444
of I-Disease 0 0.0012157079
the I-Disease 0 0.0006157622
artery I-Disease 0 0.29747424
media O 0 0.0025741102
in O 0 0.00030545198
the O 0 0.0002989444
ad O 0 0.0017574579
libitum O 0 0.03538796
- O 0 0.0006708375
fed O 0 0.0006654371
rats O 0 0.0013691278
but O 0 0.00032138015
no O 0 0.00026981492
detectable O 0 0.0004031563
artery B-Disease 2 0.8744472
calcification I-Disease 2 0.99846834
in O 0 0.00057685527
the O 0 0.00048586016
restricted O 0 0.00060185883
- O 0 0.0014620397
diet O 0 0.05857082
, O 0 0.0017667236
growth O 0 0.009293582
- O 0 0.0036322866
inhibited O 0 0.0053892145
group O 0 0.0060169846
. O 0 0.005972671

Although O 0 0.002962995
the O 0 0.0017186906
explanation O 0 0.0011076112
for O 0 0.0008555256
the O 0 0.0007881678
association O 0 0.0007016112
between O 0 0.00063511165
artery B-Disease 2 0.8752607
calcification I-Disease 2 0.998412
and O 0 0.0011188361
growth O 0 0.004713423
status O 0 0.0006774582
cannot O 0 0.002277143
be O 0 0.0003076647
determined O 0 0.000177407
from O 0 0.00019821974
the O 0 0.00017930267
present O 0 0.0001599575
study O 0 0.00040078702
, O 0 0.0002807552
there O 0 0.00013102192
was O 0 0.00019256999
a O 0 0.00020000164
relationship O 0 0.00014321397
between O 0 0.00011947525
higher O 0 0.0002804066
serum O 0 0.08198184
phosphate B-Chemical 1 0.98380107
and O 0 0.0006803841
susceptibility O 0 0.009360784
to O 0 0.0006125873
artery B-Disease 2 0.95764583
calcification I-Disease 2 0.9992716
, O 0 0.00083159865
with O 0 0.00036686202
30 O 0 0.000218338
% O 0 0.00019863993
higher O 0 0.00015803291
levels O 0 0.00019534586
of O 0 0.00038908146
serum O 0 0.14794375
phosphate B-Chemical 1 0.98787373
in O 0 0.00046287855
young O 0 0.0096785305
, O 0 0.00045102768
ad O 0 0.0016345365
libitum O 0 0.03158405
- O 0 0.0005038477
fed O 0 0.00046196327
rats O 0 0.00076050253
compared O 0 0.00012412814
with O 0 0.00022106219
either O 0 0.00019560511
of O 0 0.0002753825
the O 0 0.000221237
groups O 0 0.00029063702
that O 0 0.00020297244
was O 0 0.00027764819
resistant O 0 0.0009443095
to O 0 0.00051309523
Warfarin B-Chemical 0 0.99971336
- O 0 0.0037562717
induced O 0 0.0024603677
artery B-Disease 2 0.97542137
calcification I-Disease 2 0.9993895
, O 0 0.0011885228
ie O 0 0.0012330661
, O 0 0.00041369034
the O 0 0.00023846234
10 O 0 0.00031034707
- O 0 0.00037098682
month O 0 0.00025072714
- O 0 0.0004039509
old O 0 0.00029959177
rats O 0 0.00075906346
and O 0 0.00029257286
the O 0 0.0003057509
restricted O 0 0.0004397377
- O 0 0.0011328165
diet O 0 0.0505116
, O 0 0.001430805
growth O 0 0.008648584
- O 0 0.002964012
inhibited O 0 0.004879354
young O 0 0.03149587
rats O 0 0.01834058
. O 0 0.0059764762

This O 0 0.004258273
observation O 0 0.0021761048
suggests O 0 0.0011579252
that O 0 0.0010250029
increased O 0 0.0018607855
susceptibility O 0 0.008981918
to O 0 0.0018078028
Warfarin B-Chemical 0 0.99950695
- O 0 0.007858826
induced O 0 0.0039018476
artery B-Disease 2 0.9727729
calcification I-Disease 2 0.99867046
could O 0 0.00083493267
be O 0 0.0007482147
related O 0 0.0005690582
to O 0 0.00086341036
higher O 0 0.0015734537
serum O 0 0.18115133
phosphate B-Chemical 1 0.9820296
levels O 0 0.008255264
. O 0 0.007662559

The O 0 0.0026053342
second O 0 0.0017729696
set O 0 0.0012917152
of O 0 0.0013159647
experiments O 0 0.00092645845
examined O 0 0.00076957047
the O 0 0.00083267625
possible O 0 0.0011680617
synergy O 0 0.009872368
between O 0 0.0013446816
vitamin B-Chemical 0 0.9992255
D I-Chemical 0 0.968838
and O 0 0.008457444
Warfarin B-Chemical 0 0.9988803
in O 0 0.008910137
artery B-Disease 2 0.98297274
calcification I-Disease 2 0.9963021
. O 0 0.012909439

High O 0 0.023684474
doses O 0 0.05009398
of O 0 0.005830575
vitamin B-Chemical 0 0.99889827
D I-Chemical 0 0.945948
are O 0 0.0018920997
known O 0 0.001604039
to O 0 0.000954603
cause O 0 0.0062344573
calcification B-Disease 2 0.99161726
of I-Disease 0 0.0013109884
the I-Disease 0 0.00089171535
artery I-Disease 0 0.27217877
media O 0 0.0028493146
in O 0 0.0005705699
as O 0 0.0004997482
little O 0 0.0007087823
as O 0 0.00072535954
3 O 0 0.0009533809
to O 0 0.0012349449
4 O 0 0.0017973977
days O 0 0.0030062632
. O 0 0.004435936

High O 0 0.02092868
doses O 0 0.031524498
of O 0 0.0034967542
the O 0 0.0032522161
vitamin B-Chemical 0 0.9993561
K I-Chemical 1 0.99879646
antagonist O 0 0.9977076
Warfarin B-Chemical 0 0.99971
are O 0 0.0015973146
also O 0 0.000805662
known O 0 0.00078715984
to O 0 0.00049347983
cause O 0 0.0055797403
calcification B-Disease 2 0.9934581
of I-Disease 0 0.0008840182
the I-Disease 0 0.00055743835
artery I-Disease 0 0.34530017
media O 0 0.004447911
, O 0 0.00050907495
but O 0 0.00024490556
at O 0 0.00014868869
treatment O 0 0.0004252292
times O 0 0.00017197627
of O 0 0.00035203615
2 O 0 0.00031676862
weeks O 0 0.00029296614
or O 0 0.00029231608
longer O 0 0.0003597862
yet O 0 0.0008510152
not O 0 0.00076322135
at O 0 0.000911589
1 O 0 0.0020153008
week O 0 0.0029485838
. O 0 0.0042735613

In O 0 0.0026462458
the O 0 0.0016979107
current O 0 0.0020491711
study O 0 0.0016872886
, O 0 0.0010371163
we O 0 0.0003760676
investigated O 0 0.0005230792
the O 0 0.00045490026
synergy O 0 0.0026284219
between O 0 0.0002465669
these O 0 0.0004977918
2 O 0 0.00035482866
treatments O 0 0.000940197
and O 0 0.00033461238
found O 0 0.00025564033
that O 0 0.00022104576
concurrent O 0 0.0054117744
Warfarin B-Chemical 0 0.99972075
administration O 0 0.36612284
dramatically O 0 0.0012100858
increased O 0 0.0008898362
the O 0 0.000284798
extent O 0 0.00021985649
of O 0 0.0006984094
calcification B-Disease 2 0.9942802
in O 0 0.0003919254
the O 0 0.0003741189
media O 0 0.0027473478
of O 0 0.0017160778
vitamin B-Chemical 0 0.9997627
D I-Chemical 0 0.9797332
- O 0 0.003002481
treated O 0 0.0015282175
rats O 0 0.0025603531
at O 0 0.0005596557
3 O 0 0.0008533307
and O 0 0.0012537725
4 O 0 0.0016556666
days O 0 0.0027769844
. O 0 0.0041319826

There O 0 0.0050535332
was O 0 0.002184493
a O 0 0.0015856873
close O 0 0.0009741598
parallel O 0 0.0010379031
between O 0 0.00048629622
the O 0 0.00060731685
effect O 0 0.00083074643
of O 0 0.0015496963
vitamin B-Chemical 0 0.9996406
D I-Chemical 0 0.97761714
dose O 0 0.14758947
on O 0 0.00059997744
artery B-Disease 2 0.951446
calcification I-Disease 2 0.998931
and O 0 0.00069343724
the O 0 0.00035063663
effect O 0 0.00047348972
of O 0 0.0010499415
vitamin B-Chemical 0 0.9997756
D I-Chemical 0 0.96817577
dose O 0 0.063340835
on O 0 0.00024219588
the O 0 0.00036433138
elevation O 0 0.20223768
of O 0 0.00095141813
serum O 0 0.41590625
calcium B-Chemical 1 0.9983724
, O 0 0.0011556201
which O 0 0.0005759381
suggests O 0 0.00028803083
that O 0 0.00055603374
vitamin B-Chemical 0 0.99967957
D I-Chemical 0 0.95568246
may O 0 0.0010547373
induce O 0 0.0012664937
artery B-Disease 2 0.9594982
calcification I-Disease 2 0.99841976
through O 0 0.0011356102
its O 0 0.0023490486
effect O 0 0.001791385
on O 0 0.0017007143
serum O 0 0.4440601
calcium B-Chemical 1 0.99266374
. O 0 0.009993604

Because O 0 0.004451992
Warfarin B-Chemical 0 0.995391
treatment O 0 0.005130944
had O 0 0.0014425615
no O 0 0.0007669583
effect O 0 0.0008792693
on O 0 0.00042896467
the O 0 0.00066091365
elevation O 0 0.20086968
in O 0 0.00073434185
serum O 0 0.22974202
calcium B-Chemical 1 0.9970663
produced O 0 0.0011953809
by O 0 0.0014414972
vitamin B-Chemical 0 0.9997551
D I-Chemical 0 0.9714386
, O 0 0.0009968798
the O 0 0.00037984108
synergy O 0 0.0090881325
between O 0 0.00033093832
Warfarin B-Chemical 0 0.9995926
and O 0 0.0021998
vitamin B-Chemical 0 0.9998115
D I-Chemical 0 0.9613863
is O 0 0.0004831884
probably O 0 0.0005293478
best O 0 0.00029653215
explained O 0 0.00023834892
by O 0 0.00025486763
the O 0 0.00024115852
hypothesis O 0 0.0004879483
that O 0 0.00043166336
Warfarin B-Chemical 0 0.9995421
inhibits O 0 0.0016659668
the O 0 0.0005151419
activity O 0 0.0008209692
of O 0 0.0010610023
matrix O 0 0.083595045
Gla O 0 0.98429734
protein O 0 0.005267419
as O 0 0.0016668853
a O 0 0.0046105087
calcification B-Disease 2 0.9934476
inhibitor O 0 0.60541743
. O 0 0.009059942

High O 0 0.015701778
levels O 0 0.0027905311
of O 0 0.002864082
matrix O 0 0.04183783
Gla O 0 0.97196925
protein O 0 0.0038043258
are O 0 0.0009053602
found O 0 0.0005653228
at O 0 0.00033471928
sites O 0 0.0004616195
of O 0 0.0009325098
artery B-Disease 2 0.93957394
calcification I-Disease 2 0.99894935
in O 0 0.00066414464
rats O 0 0.0054100137
treated O 0 0.0011345639
with O 0 0.0012085643
vitamin B-Chemical 0 0.9997603
D I-Chemical 0 0.96781665
plus O 0 0.0019924424
Warfarin B-Chemical 0 0.9997087
, O 0 0.0008952906
and O 0 0.00037515615
chemical O 0 0.012265705
analysis O 0 0.0005647048
showed O 0 0.00030407764
that O 0 0.00024597778
the O 0 0.0003097092
protein O 0 0.0008077534
that O 0 0.00035719192
accumulated O 0 0.0006232641
was O 0 0.00071373297
indeed O 0 0.0010724814
not O 0 0.0017265017
gamma B-Chemical 0 0.77731013
- I-Chemical 0 0.026318317
carboxylated I-Chemical 0 0.9531981
. O 0 0.008034127

These O 0 0.004012669
observations O 0 0.0026139761
indicate O 0 0.0012318826
that O 0 0.0010492128
although O 0 0.0010434997
the O 0 0.0010787443
gamma B-Chemical 0 0.67915565
- I-Chemical 0 0.003795844
carboxyglutamate I-Chemical 0 0.24975094
residues O 0 0.016834745
of O 0 0.0010091801
matrix O 0 0.05880682
Gla O 0 0.98576444
protein O 0 0.0023114579
are O 0 0.0003996489
apparently O 0 0.00088934245
required O 0 0.00015055908
for O 0 0.00020802466
its O 0 0.0005787323
function O 0 0.0004579644
as O 0 0.00029019656
a O 0 0.0007209582
calcification B-Disease 2 0.9963605
inhibitor O 0 0.28024006
, O 0 0.0007564948
they O 0 0.00032313625
are O 0 0.0003212325
not O 0 0.0002851678
required O 0 0.00022900268
for O 0 0.0004473069
its O 0 0.0015816415
accumulation O 0 0.0036579883
at O 0 0.0018941144
calcification B-Disease 2 0.9882885
sites O 0 0.00611062
. O 0 0.0061577293

Test O 0 0.022542285
conditions O 0 0.0045028683
influence O 0 0.0027467126
the O 0 0.0025238649
response O 0 0.0033444355
to O 0 0.0024899407
a O 0 0.0034820554
drug O 0 0.1968017
challenge O 0 0.0062076813
in O 0 0.0054372065
rodents O 0 0.020880373
. O 0 0.009334392

These O 0 0.0038373051
studies O 0 0.0027341063
were O 0 0.0013841426
conducted O 0 0.0009651207
to O 0 0.00072039914
examine O 0 0.0004205876
the O 0 0.00051104964
differential O 0 0.0010654913
response O 0 0.0008602983
to O 0 0.0004172175
a O 0 0.00047133
drug O 0 0.088937245
challenge O 0 0.0004618138
under O 0 0.00017844052
varied O 0 0.00035053116
experimental O 0 0.0004065142
test O 0 0.00031460257
conditions O 0 0.00036401788
routinely O 0 0.00032646875
employed O 0 0.00039981928
to O 0 0.00031235843
study O 0 0.0007626067
drug O 0 0.25163436
- O 0 0.0012708717
induced O 0 0.0009713299
behavioral O 0 0.02392898
and O 0 0.0012071416
neurophysiological O 0 0.117065065
responses O 0 0.0039528906
in O 0 0.0026415898
rodents O 0 0.014587951
. O 0 0.005492943

Apomorphine B-Chemical 0 0.9989385
, O 0 0.007912965
a O 0 0.004024538
nonselective O 0 0.9767423
dopamine B-Chemical 1 0.9991769
agonist I-Chemical 0 0.9916032
, O 0 0.002009356
was O 0 0.0006100522
selected O 0 0.00040267734
due O 0 0.00028389826
to O 0 0.00033076326
its O 0 0.00075660396
biphasic O 0 0.06448783
behavioral O 0 0.04578371
effects O 0 0.0015610565
, O 0 0.00051546266
its O 0 0.0006562865
ability O 0 0.00033552886
to O 0 0.00030196758
induce O 0 0.00050424563
hypothermia B-Disease 2 0.99799734
, O 0 0.0007122977
and O 0 0.00036399477
to O 0 0.0002831662
produce O 0 0.00030937218
distinct O 0 0.00050805457
changes O 0 0.00085062196
to O 0 0.00081062905
dopamine B-Chemical 1 0.9981035
turnover O 0 0.0062097204
in O 0 0.0013314207
the O 0 0.0019852878
rodent O 0 0.013032002
brain O 0 0.15843688
. O 0 0.006533156

From O 0 0.0037908957
such O 0 0.0018305446
experiments O 0 0.0012853618
there O 0 0.0008372655
is O 0 0.0008326508
evidence O 0 0.00073927554
that O 0 0.0004987564
characterization O 0 0.0010318924
and O 0 0.0006673335
detection O 0 0.000814298
of O 0 0.0018654284
apomorphine B-Chemical 1 0.9998919
- O 0 0.0055199484
induced O 0 0.001126868
activity O 0 0.00084053644
in O 0 0.0004543254
rodents O 0 0.0021330237
critically O 0 0.0019702213
depends O 0 0.0005555882
upon O 0 0.00070873764
the O 0 0.0010004963
test O 0 0.0017704387
conditions O 0 0.0034136793
employed O 0 0.0061451737
. O 0 0.0062414957

In O 0 0.0037759137
rats O 0 0.0066382405
, O 0 0.0027364083
detection O 0 0.0020027403
of O 0 0.0030701726
apomorphine B-Chemical 1 0.9997527
- O 0 0.012613513
induced O 0 0.004573439
hyperactivity B-Disease 2 0.9988644
was O 0 0.0009635115
facilitated O 0 0.0008987512
by O 0 0.0005973379
a O 0 0.0006014437
period O 0 0.00058498915
of O 0 0.00093623373
acclimatization O 0 0.034623794
to O 0 0.0011824201
the O 0 0.0015432258
test O 0 0.0028903077
conditions O 0 0.005825198
. O 0 0.006400512

Moreover O 0 0.0053896136
, O 0 0.0031028427
test O 0 0.0019610857
conditions O 0 0.0016808352
can O 0 0.0009717746
impact O 0 0.0007586722
upon O 0 0.0006678578
other O 0 0.00082118635
physiological O 0 0.0034464772
responses O 0 0.002338413
to O 0 0.0013757462
apomorphine B-Chemical 1 0.999634
such O 0 0.0020442274
as O 0 0.0018098078
drug O 0 0.6330659
- O 0 0.008464984
induced O 0 0.012232773
hypothermia B-Disease 2 0.99547887
. O 0 0.009800202

In O 0 0.0034407265
mice O 0 0.0020695957
, O 0 0.00332182
apomorphine B-Chemical 1 0.99909675
produced O 0 0.0016496275
qualitatively O 0 0.0012712387
different O 0 0.00066779123
responses O 0 0.001083486
under O 0 0.0003343216
novel O 0 0.00080486824
conditions O 0 0.0005915567
when O 0 0.00028401494
compared O 0 0.0002533157
to O 0 0.0004022875
those O 0 0.00076529116
behaviors O 0 0.0058327643
elicited O 0 0.0010921775
in O 0 0.00078056677
the O 0 0.0010526268
home O 0 0.002094554
test O 0 0.0031374549
cage O 0 0.009175474
. O 0 0.006376395

Drug O 0 0.9449361
- O 0 0.006260032
induced O 0 0.002764543
gross O 0 0.0037795561
activity O 0 0.001477169
counts O 0 0.0008242362
were O 0 0.0005915697
increased O 0 0.0007736071
in O 0 0.00039654403
the O 0 0.00036298658
novel O 0 0.00076110713
exploratory O 0 0.003307029
box O 0 0.0007492461
only O 0 0.00046430327
, O 0 0.00054206944
while O 0 0.00035415584
measures O 0 0.00047285983
of O 0 0.00090665306
stereotypic O 0 0.7230788
behavior O 0 0.0030388793
were O 0 0.0010907213
similar O 0 0.0011423037
in O 0 0.0020116274
both O 0 0.0038891362
. O 0 0.0054872264

By O 0 0.006958943
contrast O 0 0.0045854095
, O 0 0.0064454577
apomorphine B-Chemical 1 0.9994223
- O 0 0.007750079
induced O 0 0.0029089374
locomotion O 0 0.12044233
was O 0 0.0013352112
more O 0 0.0015365406
prominent O 0 0.0037752825
in O 0 0.0013157435
the O 0 0.001706144
novel O 0 0.004477791
exploratory O 0 0.015989862
box O 0 0.00940515
. O 0 0.007904958

Dopamine B-Chemical 1 0.9953054
turnover O 0 0.023560451
ratios O 0 0.006408838
( O 0 0.013096645
DOPAC B-Chemical 1 0.9996642
: O 0 0.019880353
DA B-Chemical 0 0.99755895
and O 0 0.005775193
HVA B-Chemical 0 0.9997377
: O 0 0.014662896
DA B-Chemical 0 0.9981816
) O 0 0.0017622311
were O 0 0.0004519635
found O 0 0.00033163032
to O 0 0.0002939465
be O 0 0.00030402458
lower O 0 0.0002740507
in O 0 0.00023600302
those O 0 0.00035142116
animals O 0 0.00024584206
exposed O 0 0.00033457507
to O 0 0.00025410965
the O 0 0.00029742456
exploratory O 0 0.0019682928
box O 0 0.00065510947
when O 0 0.00032859587
compared O 0 0.00035434915
to O 0 0.0006429324
their O 0 0.0011091812
home O 0 0.00215433
cage O 0 0.005462605
counterparts O 0 0.005164633
. O 0 0.0056343866

However O 0 0.0062423125
, O 0 0.0070053306
apomorphine B-Chemical 1 0.99930763
- O 0 0.0071937195
induced O 0 0.0023524805
reductions O 0 0.002106787
in O 0 0.0012332833
striatal O 0 0.9864022
dopamine B-Chemical 1 0.9990503
turnover O 0 0.008166705
were O 0 0.0007225994
detected O 0 0.00041174915
in O 0 0.00055334455
both O 0 0.0007472813
novel O 0 0.0017466537
and O 0 0.0015786595
home O 0 0.0028031506
cage O 0 0.006764018
environments O 0 0.008587689
. O 0 0.0066490066

The O 0 0.0029061434
implications O 0 0.0027099585
of O 0 0.00196988
these O 0 0.0019074867
findings O 0 0.0024524946
are O 0 0.0010595361
discussed O 0 0.00080179976
with O 0 0.0008861062
particular O 0 0.0007508876
emphasis O 0 0.0017293048
upon O 0 0.0007691306
conducting O 0 0.0014884453
psychopharmacological O 0 0.6336204
challenge O 0 0.0028700174
tests O 0 0.0046649748
in O 0 0.0034698
rodents O 0 0.016424324
. O 0 0.0068005905

Hemolysis B-Disease 0 0.97881466
of O 0 0.005369272
human O 0 0.0055675614
erythrocytes O 0 0.097443886
induced O 0 0.003306598
by O 0 0.0025765246
tamoxifen B-Chemical 1 0.99630785
is O 0 0.0019419963
related O 0 0.001140683
to O 0 0.0013747253
disruption O 0 0.0027092611
of O 0 0.0037856319
membrane O 0 0.04814645
structure O 0 0.012806051
. O 0 0.008018226

Tamoxifen B-Chemical 0 0.997511
( O 0 0.01887631
TAM B-Chemical 1 0.9971468
) O 0 0.006248672
, O 0 0.0018984157
the O 0 0.00109674
antiestrogenic O 0 0.9920346
drug O 0 0.5226136
most O 0 0.0017918744
widely O 0 0.0015572476
prescribed O 0 0.030589374
in O 0 0.00038224377
the O 0 0.00040162404
chemotherapy O 0 0.6132472
of O 0 0.0018401702
breast B-Disease 2 0.99818546
cancer I-Disease 2 0.99942786
, O 0 0.0032258343
induces O 0 0.0010748063
changes O 0 0.0009756116
in O 0 0.000438325
normal O 0 0.0014973874
discoid O 0 0.2562273
shape O 0 0.001925168
of O 0 0.0020460687
erythrocytes O 0 0.35327357
and O 0 0.014806635
hemolytic B-Disease 2 0.9995179
anemia I-Disease 2 0.9994361
. O 0 0.02064353

This O 0 0.004127707
work O 0 0.0025256982
evaluates O 0 0.0016573612
the O 0 0.0011395941
effects O 0 0.0017953338
of O 0 0.0016749565
TAM B-Chemical 1 0.9978873
on O 0 0.0005809416
isolated O 0 0.0007750106
human O 0 0.0014053843
erythrocytes O 0 0.087702386
, O 0 0.00064724893
attempting O 0 0.00080330286
to O 0 0.0002589782
identify O 0 0.0002319229
the O 0 0.00024992783
underlying O 0 0.0008371904
mechanisms O 0 0.0010431807
on O 0 0.00038947226
TAM B-Chemical 1 0.99938345
- O 0 0.007740396
induced O 0 0.011035412
hemolytic B-Disease 2 0.99991286
anemia I-Disease 2 0.99990976
and O 0 0.0018989778
the O 0 0.0006579853
involvement O 0 0.0021372582
of O 0 0.0013642741
biomembranes O 0 0.94467443
in O 0 0.0013091777
its O 0 0.0048651677
cytostatic O 0 0.94871134
action O 0 0.07810598
mechanisms O 0 0.0155398175
. O 0 0.006668792

TAM B-Chemical 1 0.9924043
induces O 0 0.01790192
hemolysis B-Disease 0 0.9949679
of O 0 0.007949041
erythrocytes O 0 0.16191465
as O 0 0.0032730121
a O 0 0.004092217
function O 0 0.005289607
of O 0 0.0075438092
concentration O 0 0.02553115
. O 0 0.0113190785

The O 0 0.0031593917
extension O 0 0.0033765193
of O 0 0.003251493
hemolysis B-Disease 0 0.9959603
is O 0 0.0015923467
variable O 0 0.0010845058
with O 0 0.001146089
erythrocyte O 0 0.15575492
samples O 0 0.0008435155
, O 0 0.00087305193
but O 0 0.00049936346
12 O 0 0.00037962408
. O 0 0.00030214756
5 O 0 0.0005099669
microM O 0 0.45602384
TAM B-Chemical 1 0.9979601
induces O 0 0.0018014318
total O 0 0.0014953939
hemolysis B-Disease 0 0.99742895
of O 0 0.0025198394
all O 0 0.0020222727
tested O 0 0.0028409085
suspensions O 0 0.057574153
. O 0 0.0068972306

Despite O 0 0.005471352
inducing O 0 0.0053247446
extensive O 0 0.0042465045
erythrocyte O 0 0.3475784
lysis O 0 0.29012978
, O 0 0.0046805646
TAM B-Chemical 1 0.9970475
does O 0 0.0013810917
not O 0 0.0010253105
shift O 0 0.0019162692
the O 0 0.0014223963
osmotic O 0 0.42804596
fragility O 0 0.56207997
curves O 0 0.006237463
of O 0 0.007356898
erythrocytes O 0 0.3889361
. O 0 0.009165292

The O 0 0.0050814836
hemolytic B-Disease 0 0.9942484
effect O 0 0.0036560132
of O 0 0.0035830694
TAM B-Chemical 1 0.9982534
is O 0 0.0018190962
prevented O 0 0.0033115335
by O 0 0.0007962699
low O 0 0.00092067017
concentrations O 0 0.0037660436
of O 0 0.0014570887
alpha B-Chemical 0 0.89115703
- I-Chemical 0 0.025286278
tocopherol I-Chemical 0 0.9998889
( O 0 0.013586999
alpha B-Chemical 0 0.89699334
- I-Chemical 0 0.009599873
T I-Chemical 0 0.91505444
) O 0 0.0016251425
and O 0 0.00067331496
alpha B-Chemical 0 0.77921885
- I-Chemical 0 0.01689518
tocopherol I-Chemical 0 0.9999145
acetate I-Chemical 0 0.9990721
( O 0 0.0081965495
alpha B-Chemical 0 0.8694829
- I-Chemical 0 0.008166839
TAc I-Chemical 0 0.9661547
) O 0 0.0015924514
( O 0 0.00056605804
inactivated O 0 0.0005686504
functional O 0 0.0013062435
hydroxyl B-Chemical 0 0.99409086
) O 0 0.0016229332
indicating O 0 0.0003773734
that O 0 0.0005753929
TAM B-Chemical 1 0.99929845
- O 0 0.0051950626
induced O 0 0.0035503863
hemolysis B-Disease 0 0.999022
is O 0 0.001043811
not O 0 0.00076731504
related O 0 0.000832683
to O 0 0.0017505301
oxidative O 0 0.9756958
membrane O 0 0.31819263
damage O 0 0.9127424
. O 0 0.008992114

This O 0 0.004541011
was O 0 0.002037594
further O 0 0.0016129507
evidenced O 0 0.001606788
by O 0 0.0009976246
absence O 0 0.000569483
of O 0 0.0012441475
oxygen B-Chemical 1 0.9680293
consumption O 0 0.26283878
and O 0 0.0014903423
hemoglobin O 0 0.9457043
oxidation O 0 0.9169479
both O 0 0.0007860321
determined O 0 0.0005478277
in O 0 0.0006642086
parallel O 0 0.0013661698
with O 0 0.0032444024
TAM B-Chemical 1 0.99823713
- O 0 0.02086502
induced O 0 0.023703244
hemolysis B-Disease 0 0.9970902
. O 0 0.01101236

Furthermore O 0 0.005734182
, O 0 0.0035278506
it O 0 0.0020407692
was O 0 0.001306167
observed O 0 0.0008763983
that O 0 0.0010536767
TAM B-Chemical 1 0.99782217
inhibits O 0 0.0032007056
the O 0 0.0013943929
peroxidation O 0 0.9996786
of O 0 0.0028474035
human O 0 0.0049522347
erythrocytes O 0 0.23952293
induced O 0 0.0020437778
by O 0 0.002157892
AAPH B-Chemical 0 0.9998661
, O 0 0.0025207768
thus O 0 0.0014354691
ruling O 0 0.008620864
out O 0 0.0012268183
TAM B-Chemical 1 0.9984875
- O 0 0.006306199
induced O 0 0.0040501347
cell O 0 0.08898144
oxidative O 0 0.989542
stress O 0 0.87968946
. O 0 0.01025176

Hemolysis B-Disease 0 0.9848593
caused O 0 0.005469101
by O 0 0.0035528871
TAM B-Chemical 1 0.99631774
was O 0 0.0016613724
not O 0 0.00083300075
preceded O 0 0.0010427302
by O 0 0.0007069299
the O 0 0.0006630951
leakage O 0 0.27361727
of O 0 0.0022661898
K B-Chemical 1 0.99649566
( O 0 0.0021776306
+ O 0 0.00074800156
) O 0 0.0005698949
from O 0 0.00024185322
the O 0 0.00023977303
cells O 0 0.0006090062
, O 0 0.0003468205
also O 0 0.00026357535
excluding O 0 0.00045630586
a O 0 0.00043755458
colloid O 0 0.606745
- O 0 0.0012866461
osmotic O 0 0.20512836
type O 0 0.00048719652
mechanism O 0 0.00071775203
of O 0 0.0011895654
hemolysis B-Disease 0 0.9991278
, O 0 0.0011449313
according O 0 0.00047209737
to O 0 0.00044666327
the O 0 0.00057139795
effects O 0 0.0015142369
on O 0 0.0010112104
osmotic O 0 0.5124739
fragility O 0 0.705548
curves O 0 0.012572713
. O 0 0.007305644

However O 0 0.005718273
, O 0 0.0055467812
TAM B-Chemical 1 0.994972
induces O 0 0.0040602493
release O 0 0.049805757
of O 0 0.0017088976
peripheral O 0 0.053138375
proteins O 0 0.0018365695
of O 0 0.0012385854
membrane O 0 0.036016006
- O 0 0.0022527024
cytoskeleton O 0 0.05269956
and O 0 0.001007676
cytosol O 0 0.013403571
proteins O 0 0.0015779173
essentially O 0 0.0010861527
bound O 0 0.0010348542
to O 0 0.0018323315
band O 0 0.006043599
3 O 0 0.0043325243
. O 0 0.0053444346

Either O 0 0.064757206
alpha B-Chemical 0 0.69634795
- I-Chemical 0 0.010487606
T I-Chemical 0 0.74271643
or O 0 0.0023306923
alpha B-Chemical 0 0.6765704
- I-Chemical 0 0.0056345137
TAc I-Chemical 0 0.8411707
increases O 0 0.0015155582
membrane O 0 0.015723638
packing O 0 0.038813863
and O 0 0.0015213715
prevents O 0 0.004231085
TAM B-Chemical 1 0.9976743
partition O 0 0.008972708
into O 0 0.0020381003
model O 0 0.005249695
membranes O 0 0.10046358
. O 0 0.007835779

These O 0 0.004159205
effects O 0 0.0032698028
suggest O 0 0.0013200646
that O 0 0.0010805019
the O 0 0.0010655626
protection O 0 0.004376546
from O 0 0.0014134686
hemolysis B-Disease 0 0.99863106
by O 0 0.002544386
tocopherols B-Chemical 0 0.99959666
is O 0 0.0010013283
related O 0 0.0003786711
to O 0 0.00035048436
a O 0 0.0004538242
decreased O 0 0.0023222896
TAM B-Chemical 1 0.9991541
incorporation O 0 0.008525051
in O 0 0.0004238508
condensed O 0 0.02344418
membranes O 0 0.022962233
and O 0 0.00048174433
the O 0 0.00042340354
structural O 0 0.0034671156
damage O 0 0.3308786
of O 0 0.0011101951
the O 0 0.0010755305
erythrocyte O 0 0.42284846
membrane O 0 0.036343347
is O 0 0.0026896258
consequently O 0 0.006528067
avoided O 0 0.006437014
. O 0 0.0061906544

Therefore O 0 0.0048225787
, O 0 0.0059072985
TAM B-Chemical 1 0.99660456
- O 0 0.0066388166
induced O 0 0.0035852033
hemolysis B-Disease 0 0.99796766
results O 0 0.0010319704
from O 0 0.0006214509
a O 0 0.00057314086
structural O 0 0.0015627557
perturbation O 0 0.0011370974
of O 0 0.00063969387
red O 0 0.0016194731
cell O 0 0.009786056
membrane O 0 0.019568246
, O 0 0.0006336895
leading O 0 0.00077269686
to O 0 0.00027166825
changes O 0 0.00041434218
in O 0 0.00019119217
the O 0 0.00019536784
framework O 0 0.00031500868
of O 0 0.00033548268
the O 0 0.00033472278
erythrocyte O 0 0.22515418
membrane O 0 0.011928649
and O 0 0.0005266405
its O 0 0.0012966044
cytoskeleton O 0 0.049073633
caused O 0 0.000794942
by O 0 0.0006384428
its O 0 0.0012558869
high O 0 0.0012683613
partition O 0 0.0028415164
in O 0 0.0016693948
the O 0 0.0028447553
membrane O 0 0.03672943
. O 0 0.006582371

These O 0 0.004802019
defects O 0 0.003336244
explain O 0 0.0017975973
the O 0 0.0014886665
abnormal O 0 0.010824691
erythrocyte O 0 0.20454456
shape O 0 0.002270768
and O 0 0.001047762
decreased O 0 0.0018412365
mechanical O 0 0.0415122
stability O 0 0.0019167829
promoted O 0 0.003487126
by O 0 0.0022467554
TAM B-Chemical 1 0.9982576
, O 0 0.0036527137
resulting O 0 0.0034868966
in O 0 0.0076853996
hemolytic B-Disease 2 0.99944395
anemia I-Disease 2 0.9993868
. O 0 0.021684073

Additionally O 0 0.005085166
, O 0 0.0031427224
since O 0 0.0014829342
membrane O 0 0.008381231
leakage O 0 0.23261909
is O 0 0.0011031812
a O 0 0.0008173636
final O 0 0.0010714363
stage O 0 0.0014602342
of O 0 0.0011096388
cytotoxicity O 0 0.98248994
, O 0 0.00083919626
the O 0 0.00033974618
disruption O 0 0.00048016856
of O 0 0.00039304356
the O 0 0.00029648523
structural O 0 0.0011968154
characteristics O 0 0.00041825126
of O 0 0.00061277655
biomembranes O 0 0.95406705
by O 0 0.0011342019
TAM B-Chemical 1 0.99896765
may O 0 0.00067278993
contribute O 0 0.00051848905
to O 0 0.00039559667
the O 0 0.0004324325
multiple O 0 0.0010469003
mechanisms O 0 0.0015625099
of O 0 0.0017419618
its O 0 0.0067785415
anticancer O 0 0.9708737
action O 0 0.13557108
. O 0 0.007405187

Changes O 0 0.007093795
of O 0 0.0048775263
sodium B-Chemical 0 0.9910206
and O 0 0.0044367807
ATP B-Chemical 1 0.9749658
affinities O 0 0.008878187
of O 0 0.0015850301
the O 0 0.0012382978
cardiac O 0 0.5712942
( O 0 0.0062372824
Na B-Chemical 1 0.99909294
, O 0 0.0057797916
K B-Chemical 1 0.99413437
) O 0 0.0040999856
- O 0 0.0019853048
ATPase O 0 0.07298902
during O 0 0.0006467803
and O 0 0.0010799463
after O 0 0.0012356668
nitric B-Chemical 0 0.9975298
oxide I-Chemical 0 0.9968919
deficient O 0 0.036708903
hypertension B-Disease 2 0.99857545
. O 0 0.014015213

In O 0 0.0039529544
the O 0 0.0034018217
cardiovascular O 0 0.84576887
system O 0 0.0049967747
, O 0 0.003535441
NO B-Chemical 0 0.9906341
is O 0 0.0017525002
involved O 0 0.0011520446
in O 0 0.00088675617
the O 0 0.0009024363
regulation O 0 0.0009800598
of O 0 0.0016212296
a O 0 0.0022302035
variety O 0 0.0062423423
of O 0 0.005077102
functions O 0 0.009778611
. O 0 0.0078214565

Inhibition O 0 0.039816324
of O 0 0.017192002
NO B-Chemical 0 0.9850424
synthesis O 0 0.49949124
induces O 0 0.028954396
sustained O 0 0.55858815
hypertension B-Disease 2 0.9966344
. O 0 0.02868048

In O 0 0.0030934073
several O 0 0.0024691797
models O 0 0.0030769843
of O 0 0.0035490238
hypertension B-Disease 2 0.9989303
, O 0 0.004676688
elevation O 0 0.30025303
of O 0 0.0022635856
intracellular O 0 0.04881693
sodium B-Chemical 0 0.9970138
level O 0 0.0014881322
was O 0 0.0016328015
documented O 0 0.003073369
in O 0 0.0025715258
cardiac O 0 0.42602414
tissue O 0 0.068013
. O 0 0.0077833314

To O 0 0.0023162276
assess O 0 0.0010625115
the O 0 0.0012148728
molecular O 0 0.0038000653
basis O 0 0.0013482921
of O 0 0.0013755923
disturbances O 0 0.45495275
in O 0 0.0009154141
transmembraneous O 0 0.15847029
transport O 0 0.024301631
of O 0 0.00239462
Na B-Chemical 1 0.9994456
+ O 0 0.0014033667
, O 0 0.00051182887
we O 0 0.0001580409
studied O 0 0.000394858
the O 0 0.00026802786
response O 0 0.0005530495
of O 0 0.00064170506
cardiac O 0 0.6467582
( O 0 0.0052543315
Na B-Chemical 1 0.99955434
, O 0 0.0048500886
K B-Chemical 1 0.9964664
) O 0 0.004272571
- O 0 0.0015653045
ATPase O 0 0.19537087
to O 0 0.0005433563
NO B-Chemical 0 0.99847966
- O 0 0.0031468768
deficient O 0 0.00077010575
hypertension B-Disease 2 0.99969685
induced O 0 0.0018748268
in O 0 0.0004196631
rats O 0 0.005101657
by O 0 0.0006279755
NO B-Chemical 0 0.9984602
- O 0 0.003996157
synthase O 0 0.8962887
inhibition O 0 0.009388957
with O 0 0.00060877204
40 O 0 0.0006329036
mg O 0 0.36076817
/ O 0 0.0011589791
kg O 0 0.00491583
/ O 0 0.00076071237
day O 0 0.0004326661
N B-Chemical 0 0.72803724
( I-Chemical 0 0.0013863562
G I-Chemical 0 0.5366526
) I-Chemical 0 0.0025840604
- I-Chemical 0 0.0024120328
nitro I-Chemical 0 0.99594814
- I-Chemical 0 0.010308704
L I-Chemical 1 0.9516385
- I-Chemical 1 0.009649128
arginine I-Chemical 1 0.9914227
methyl I-Chemical 0 0.9949891
ester I-Chemical 0 0.99423295
( O 0 0.010456907
L B-Chemical 1 0.9605347
- I-Chemical 1 0.017783431
NAME I-Chemical 1 0.99878854
) O 0 0.0026454858
for O 0 0.0010904346
4 O 0 0.0013101958
four O 0 0.0015298671
weeks O 0 0.0035133257
. O 0 0.0048290296

After O 0 0.0028999199
4 O 0 0.00236448
- O 0 0.00231406
week O 0 0.0012596991
administration O 0 0.034105025
of O 0 0.0026121642
L B-Chemical 1 0.9438682
- I-Chemical 1 0.01480071
NAME I-Chemical 1 0.99889237
, O 0 0.0017856386
the O 0 0.000952886
systolic O 0 0.67614806
blood O 0 0.014648669
pressure O 0 0.09028205
( O 0 0.0021731227
SBP O 0 0.4518415
) O 0 0.0021396542
increased O 0 0.0022879567
by O 0 0.0024917745
36 O 0 0.0039130724
% O 0 0.004972875
. O 0 0.0053298157

Two O 0 0.0049045566
weeks O 0 0.002700173
after O 0 0.0016441669
terminating O 0 0.0063847895
the O 0 0.0019534922
treatment O 0 0.0038136172
, O 0 0.0025728522
the O 0 0.0020186102
SBP O 0 0.24957313
recovered O 0 0.0019954692
to O 0 0.0023852522
control O 0 0.0032844623
value O 0 0.0057574944
. O 0 0.00773687

When O 0 0.004059351
activating O 0 0.005252211
the O 0 0.0030687398
( O 0 0.0053855786
Na B-Chemical 1 0.99776435
, O 0 0.0071247
K B-Chemical 1 0.99314344
) O 0 0.0053763003
- O 0 0.002160985
ATPase O 0 0.119808026
with O 0 0.0007739861
its O 0 0.0016168947
substrate O 0 0.009300865
ATP B-Chemical 1 0.9866654
, O 0 0.0009011445
no O 0 0.00034039526
changes O 0 0.0006497991
in O 0 0.00043274031
Km O 0 0.18437304
and O 0 0.0006287181
Vmax O 0 0.5435046
values O 0 0.0005483632
were O 0 0.0005951894
observed O 0 0.0006556207
in O 0 0.0013640162
NO B-Chemical 0 0.99375486
- O 0 0.006034275
deficient O 0 0.0036289042
rats O 0 0.019519933
. O 0 0.0064393654

During O 0 0.003603245
activation O 0 0.0055728597
with O 0 0.004096148
Na B-Chemical 1 0.9973629
+ O 0 0.0029578758
, O 0 0.0013743935
the O 0 0.00078482745
Vmax O 0 0.51029867
remained O 0 0.0009739074
unchanged O 0 0.00082569645
, O 0 0.0007159847
however O 0 0.00071973185
the O 0 0.0006474339
K B-Chemical 1 0.99352443
( O 0 0.0042018355
Na B-Chemical 1 0.9993419
) O 0 0.0014865401
increased O 0 0.0007293719
by O 0 0.00038272564
50 O 0 0.0005636917
% O 0 0.00032398335
, O 0 0.0002731419
indicating O 0 0.00017953894
a O 0 0.0002785149
profound O 0 0.0043070945
decrease O 0 0.00041083992
in O 0 0.00024222961
the O 0 0.00027457194
affinity O 0 0.0010139197
of O 0 0.00063508557
the O 0 0.000896489
Na B-Chemical 1 0.99934524
+ O 0 0.0020360358
- O 0 0.0013401922
binding O 0 0.00082137994
site O 0 0.00094900146
in O 0 0.0014152679
NO B-Chemical 0 0.9946631
- O 0 0.005933437
deficient O 0 0.003450903
rats O 0 0.019169504
. O 0 0.0061618187

After O 0 0.0026552128
recovery O 0 0.004419561
from O 0 0.0026715978
hypertension B-Disease 2 0.99797887
, O 0 0.0024795602
the O 0 0.0010124615
activity O 0 0.0012081631
of O 0 0.0013560065
( O 0 0.0030990208
Na B-Chemical 1 0.9991487
, O 0 0.0052691605
K B-Chemical 1 0.9957397
) O 0 0.0045388835
- O 0 0.0016106041
ATPase O 0 0.1514113
increased O 0 0.0009574408
, O 0 0.00048635574
due O 0 0.0001852669
to O 0 0.00021993408
higher O 0 0.00026725567
affinity O 0 0.00083524303
of O 0 0.00049239746
the O 0 0.0005609455
ATP B-Chemical 1 0.9899407
- O 0 0.0014426103
binding O 0 0.0005105056
site O 0 0.0004219317
, O 0 0.00047276652
as O 0 0.00027410846
revealed O 0 0.00044993023
from O 0 0.0005067057
the O 0 0.00070301077
lowered O 0 0.007407668
Km O 0 0.21776295
value O 0 0.0021670558
for O 0 0.0034553716
ATP B-Chemical 1 0.9703231
. O 0 0.00831055

The O 0 0.0077690263
K B-Chemical 1 0.96708965
( O 0 0.012471347
Na B-Chemical 1 0.995181
) O 0 0.005626062
value O 0 0.0023935563
for O 0 0.002595638
Na B-Chemical 1 0.99577016
+ O 0 0.0038242799
returned O 0 0.0025244362
to O 0 0.0024106277
control O 0 0.0032975695
value O 0 0.005767611
. O 0 0.007744529

Inhibition O 0 0.0234115
of O 0 0.006399775
NO B-Chemical 0 0.99403507
- O 0 0.012643079
synthase O 0 0.87615204
induced O 0 0.0037539797
a O 0 0.0021899242
reversible O 0 0.74969524
hypertension B-Disease 2 0.9996494
accompanied O 0 0.034359623
by O 0 0.0023941898
depressed B-Disease 2 0.96392995
Na B-Chemical 1 0.99964523
+ O 0 0.0035567954
- O 0 0.0015910297
extrusion O 0 0.14709502
from O 0 0.00041211062
cardiac O 0 0.18378153
cells O 0 0.0008481482
as O 0 0.00022128742
a O 0 0.00028871157
consequence O 0 0.00023233988
of O 0 0.0005545085
deteriorated O 0 0.4845721
Na B-Chemical 1 0.9996055
+ O 0 0.0019279841
- O 0 0.00095480174
binding O 0 0.00049184705
properties O 0 0.00084033905
of O 0 0.00073656364
the O 0 0.00093152147
( O 0 0.0031858813
Na B-Chemical 1 0.9985561
, O 0 0.0074757994
K B-Chemical 1 0.99017465
) O 0 0.010476146
- O 0 0.009381421
ATPase O 0 0.3148911
. O 0 0.007094514

After O 0 0.0024038146
recovery O 0 0.0034505806
of O 0 0.0020868876
blood O 0 0.005485114
pressure O 0 0.016846841
to O 0 0.0008273354
control O 0 0.00057533704
values O 0 0.00059381285
, O 0 0.00067959214
the O 0 0.00049866876
extrusion O 0 0.12648591
of O 0 0.0018126881
Na B-Chemical 1 0.9993968
+ O 0 0.0011095776
from O 0 0.0004255512
cardiac O 0 0.17963314
cells O 0 0.0009520384
was O 0 0.0002811192
normalized O 0 0.00019192422
, O 0 0.00034287805
as O 0 0.00019780852
revealed O 0 0.00031810172
by O 0 0.00035640973
restoration O 0 0.0007541062
of O 0 0.00067991577
the O 0 0.00083265157
( O 0 0.0028964418
Na B-Chemical 1 0.99881786
, O 0 0.0063170614
K B-Chemical 1 0.99147815
) O 0 0.0077342354
- O 0 0.0063518435
ATPase O 0 0.26059872
activity O 0 0.0071782097
. O 0 0.0064413673

Effects O 0 0.011799508
of O 0 0.0037157657
long O 0 0.0033012237
- O 0 0.0030351677
term O 0 0.0019506179
pretreatment O 0 0.16952002
with O 0 0.0034087542
isoproterenol B-Chemical 1 0.9989403
on O 0 0.0022661488
bromocriptine B-Chemical 1 0.9997173
- O 0 0.016677924
induced O 0 0.007386417
tachycardia B-Disease 2 0.9982412
in O 0 0.004503792
conscious O 0 0.2597724
rats O 0 0.024391377
. O 0 0.0071431203

It O 0 0.0059196064
has O 0 0.0026083628
been O 0 0.002222765
shown O 0 0.0012169756
that O 0 0.0013842256
bromocriptine B-Chemical 1 0.9995803
- O 0 0.0072544417
induced O 0 0.0029328032
tachycardia B-Disease 2 0.99917763
, O 0 0.0013019001
which O 0 0.0006288598
persisted O 0 0.0005955307
after O 0 0.00025061076
adrenalectomy O 0 0.73026854
, O 0 0.00071438495
is O 0 0.00043189508
( O 0 0.0005512996
i O 0 0.0011630456
) O 0 0.00062460866
mediated O 0 0.00030221496
by O 0 0.0004008674
central O 0 0.0060941936
dopamine B-Chemical 1 0.999624
D2 O 0 0.9975458
receptor O 0 0.44050574
activation O 0 0.0072932816
and O 0 0.0005846995
( O 0 0.0006140223
ii O 0 0.00084532116
) O 0 0.0005314035
reduced O 0 0.00029686055
by O 0 0.00030175285
5 O 0 0.00026349144
- O 0 0.00039232557
day O 0 0.0002843262
isoproterenol B-Chemical 1 0.9990625
pretreatment O 0 0.3507306
, O 0 0.00049464736
supporting O 0 0.00032468088
therefore O 0 0.00033513183
the O 0 0.0002117771
hypothesis O 0 0.0003550439
that O 0 0.00022419779
this O 0 0.00030864278
effect O 0 0.0004914979
is O 0 0.0004868212
dependent O 0 0.00055883516
on O 0 0.0006510839
sympathetic O 0 0.8765255
outflow O 0 0.96034545
to O 0 0.002510833
the O 0 0.0036830292
heart O 0 0.5531928
. O 0 0.006903537

This O 0 0.004306119
study O 0 0.002730685
was O 0 0.001372957
conducted O 0 0.0009678054
to O 0 0.0007501331
examine O 0 0.00044943986
whether O 0 0.0003755988
prolonged O 0 0.0042262585
pretreatment O 0 0.23121089
with O 0 0.0024111094
isoproterenol B-Chemical 1 0.9993249
could O 0 0.0012287502
abolish O 0 0.009186123
bromocriptine B-Chemical 1 0.9998074
- O 0 0.0149971135
induced O 0 0.007131841
tachycardia B-Disease 2 0.9985885
in O 0 0.0037897574
conscious O 0 0.26520947
rats O 0 0.023235315
. O 0 0.006336982

Isoproterenol B-Chemical 0 0.998323
pretreatment O 0 0.33583415
for O 0 0.002130763
15 O 0 0.001307198
days O 0 0.0011199719
caused O 0 0.0016723329
cardiac B-Disease 2 0.88559186
hypertrophy I-Disease 2 0.9982869
without O 0 0.0017892835
affecting O 0 0.0018641461
baseline O 0 0.0018767847
blood O 0 0.009413559
pressure O 0 0.053350247
and O 0 0.0030128863
heart O 0 0.31829572
rate O 0 0.0055014472
. O 0 0.0066644377

In O 0 0.0033652254
control O 0 0.0023476197
rats O 0 0.0060159666
, O 0 0.002929991
intravenous O 0 0.7246216
bromocriptine B-Chemical 1 0.99957615
( O 0 0.0035489933
150 O 0 0.0024529276
microg O 0 0.0028379974
/ O 0 0.0023769313
kg O 0 0.007342593
) O 0 0.0018032532
induced O 0 0.0019026289
significant O 0 0.0044193305
hypotension B-Disease 2 0.99890494
and O 0 0.013313153
tachycardia B-Disease 2 0.9971789
. O 0 0.010673916

Bromocriptine B-Chemical 0 0.9983028
- O 0 0.012751417
induced O 0 0.0065275407
hypotension B-Disease 2 0.99913836
was O 0 0.0018792786
unaffected O 0 0.0013102844
by O 0 0.0012980067
isoproterenol B-Chemical 1 0.9993092
pretreatment O 0 0.7621404
, O 0 0.0016389723
while O 0 0.0007204857
tachycardia B-Disease 2 0.9991301
was O 0 0.00063773076
reversed O 0 0.0013668921
to O 0 0.0003532656
significant O 0 0.00090908975
bradycardia B-Disease 0 0.99909055
, O 0 0.0005973635
an O 0 0.00038022836
effect O 0 0.00031040443
that O 0 0.00020799055
was O 0 0.00026087847
partly O 0 0.00045679958
reduced O 0 0.00037676244
by O 0 0.00042215924
i O 0 0.0016824307
. O 0 0.00032451074
v O 0 0.008782227
. O 0 0.00051949226
domperidone B-Chemical 0 0.99983335
( O 0 0.001442453
0 O 0 0.0007700906
. O 0 0.00044602063
5 O 0 0.0008103685
mg O 0 0.132125
/ O 0 0.004266162
kg O 0 0.013301389
) O 0 0.0059439647
. O 0 0.005048879

Neither O 0 0.009254822
cardiac O 0 0.24314672
vagal O 0 0.9112983
nor O 0 0.005408713
sympathetic O 0 0.8753057
tone O 0 0.4995669
was O 0 0.0041251397
altered O 0 0.0062147896
by O 0 0.007938504
isoproterenol B-Chemical 1 0.99669206
pretreatment O 0 0.87004966
. O 0 0.014795982

In O 0 0.003101868
isolated O 0 0.0025775896
perfused O 0 0.07954394
heart O 0 0.31036612
preparations O 0 0.0054134782
from O 0 0.0015865149
isoproterenol B-Chemical 1 0.9991997
- O 0 0.006370639
pretreated O 0 0.06956242
rats O 0 0.0109207565
, O 0 0.00082249177
the O 0 0.00059095345
isoproterenol B-Chemical 1 0.99950325
- O 0 0.0024460987
induced O 0 0.000625615
maximal O 0 0.00053130277
increase O 0 0.00031848348
in O 0 0.00026986326
left O 0 0.0015367138
ventricular O 0 0.96476275
systolic O 0 0.84235024
pressure O 0 0.04673611
was O 0 0.000261145
significantly O 0 0.00030476172
reduced O 0 0.00029512396
, O 0 0.00031337314
compared O 0 0.00013418718
with O 0 0.00034347104
saline O 0 0.17780617
- O 0 0.0010536852
pretreated O 0 0.027337523
rats O 0 0.005980012
( O 0 0.0004915068
the O 0 0.0002962829
EC50 O 0 0.6951257
of O 0 0.00054098625
the O 0 0.0005705873
isoproterenol B-Chemical 1 0.99963987
- O 0 0.0028084568
induced O 0 0.00067680713
increase O 0 0.0003877681
in O 0 0.0003371525
left O 0 0.0020123252
ventricular O 0 0.9660168
systolic O 0 0.8360785
pressure O 0 0.040892407
was O 0 0.00054839713
enhanced O 0 0.00081938773
approximately O 0 0.0011210265
22 O 0 0.002087251
- O 0 0.002874256
fold O 0 0.004766067
) O 0 0.006082017
. O 0 0.0050817

These O 0 0.004055104
results O 0 0.0020449192
show O 0 0.0013796982
that O 0 0.0011024121
15 O 0 0.0010124713
- O 0 0.0012694412
day O 0 0.000822585
isoproterenol B-Chemical 1 0.99861085
pretreatment O 0 0.4230007
not O 0 0.00061880366
only O 0 0.0005394159
abolished O 0 0.0017882652
but O 0 0.0005771503
reversed O 0 0.012689055
bromocriptine B-Chemical 1 0.99990666
- O 0 0.008855078
induced O 0 0.002956591
tachycardia B-Disease 2 0.9995493
to O 0 0.0011469038
bradycardia B-Disease 0 0.9994997
, O 0 0.0006671103
an O 0 0.00037324833
effect O 0 0.000294457
that O 0 0.00019019158
is O 0 0.00022643026
mainly O 0 0.00040859604
related O 0 0.0001804943
to O 0 0.00021084807
further O 0 0.00037854278
cardiac O 0 0.41030642
beta O 0 0.7350942
- O 0 0.0056747627
adrenoceptor O 0 0.99963665
desensitization O 0 0.74847424
rather O 0 0.00041939953
than O 0 0.00026611148
to O 0 0.00042105737
impairment O 0 0.09340085
of O 0 0.001203233
autonomic O 0 0.7558303
regulation O 0 0.0011709593
of O 0 0.0021659043
the O 0 0.003236829
heart O 0 0.5421748
. O 0 0.0065261615

They O 0 0.005932008
suggest O 0 0.0018888282
that O 0 0.001563315
, O 0 0.0017089042
in O 0 0.00088679284
normal O 0 0.0016364354
conscious O 0 0.03443802
rats O 0 0.0036966777
, O 0 0.0007677104
the O 0 0.0004597238
central O 0 0.0021098081
tachycardia B-Disease 2 0.9987338
of O 0 0.0024363073
bromocriptine B-Chemical 1 0.9998342
appears O 0 0.0008232452
to O 0 0.00040872578
predominate O 0 0.0041223946
and O 0 0.00043904068
to O 0 0.0003628932
mask O 0 0.0010110349
the O 0 0.0006099174
bradycardia B-Disease 0 0.99798405
of O 0 0.0010143685
this O 0 0.0010212754
agonist O 0 0.8829521
at O 0 0.0012682998
peripheral O 0 0.42284858
dopamine B-Chemical 1 0.9988691
D2 O 0 0.9933948
receptors O 0 0.6337914
. O 0 0.008552697

A O 0 0.014747481
developmental O 0 0.0056316378
analysis O 0 0.0031405706
of O 0 0.0030640168
clonidine B-Chemical 1 0.99923575
' O 0 0.00245487
s O 0 0.0014959779
effects O 0 0.0014431585
on O 0 0.00059061416
cardiac O 0 0.07490127
rate O 0 0.0010628484
and O 0 0.0013792239
ultrasound O 0 0.02629884
production O 0 0.004446936
in O 0 0.0028261985
infant O 0 0.030775378
rats O 0 0.025660682
. O 0 0.0072583235

Under O 0 0.007102835
controlled O 0 0.0026764134
conditions O 0 0.0025082377
, O 0 0.0020379575
infant O 0 0.0045777783
rats O 0 0.0035348327
emit O 0 0.0023684844
ultrasonic O 0 0.0215567
vocalizations O 0 0.046406303
during O 0 0.0004322664
extreme O 0 0.0012667188
cold O 0 0.0098385615
exposure O 0 0.0027451902
and O 0 0.00047178875
after O 0 0.00026526948
administration O 0 0.023387097
of O 0 0.00068553345
the O 0 0.00071265514
alpha O 0 0.17467016
( O 0 0.0017321717
2 O 0 0.0012712494
) O 0 0.003507476
adrenoceptor O 0 0.9988776
agonist O 0 0.99100375
, O 0 0.038430247
clonidine B-Chemical 1 0.99902713
. O 0 0.010232213

Previous O 0 0.0042486526
investigations O 0 0.0043049157
have O 0 0.0018948268
determined O 0 0.0011144399
that O 0 0.0010014757
, O 0 0.0012315494
in O 0 0.00067737815
response O 0 0.0011464374
to O 0 0.0009183366
clonidine B-Chemical 1 0.9997125
, O 0 0.0017008227
ultrasound O 0 0.03521666
production O 0 0.0016166985
increases O 0 0.00071344536
through O 0 0.00051638455
the O 0 0.00061916496
2nd O 0 0.003128472
- O 0 0.0012011777
week O 0 0.00082712807
postpartum O 0 0.006343272
and O 0 0.0017237967
decreases O 0 0.0035278995
thereafter O 0 0.0061312863
. O 0 0.0055428846

Given O 0 0.0031068912
that O 0 0.0023157275
sympathetic O 0 0.5730686
neural O 0 0.018304056
dominance O 0 0.004638155
exhibits O 0 0.0019234958
a O 0 0.0007883737
similar O 0 0.00044474084
developmental O 0 0.0013145016
pattern O 0 0.00051416276
, O 0 0.0005424908
and O 0 0.00036152249
given O 0 0.0002536466
that O 0 0.000411358
clonidine B-Chemical 1 0.9997944
induces O 0 0.0030478016
sympathetic O 0 0.9761698
withdrawal O 0 0.9006083
and O 0 0.0011709856
bradycardia B-Disease 0 0.99932635
, O 0 0.0005040527
we O 0 0.00013000009
hypothesized O 0 0.00032167445
that O 0 0.00032095335
clonidine B-Chemical 1 0.99977976
' O 0 0.0005843636
s O 0 0.0004380765
developmental O 0 0.0008042844
effects O 0 0.00060039846
on O 0 0.0002180665
cardiac O 0 0.07821842
rate O 0 0.0004814808
and O 0 0.00064583356
ultrasound O 0 0.017493846
production O 0 0.001996896
would O 0 0.0010199633
mirror O 0 0.004255439
each O 0 0.0015033996
other O 0 0.00410695
. O 0 0.0056451675

Therefore O 0 0.003408197
, O 0 0.002641537
in O 0 0.0011860862
the O 0 0.0008625226
present O 0 0.00058107224
experiment O 0 0.0005685035
, O 0 0.0007422999
the O 0 0.00044828633
effects O 0 0.00097363564
of O 0 0.0011764113
clonidine B-Chemical 1 0.99985087
administration O 0 0.6658374
( O 0 0.0011297405
0 O 0 0.0004130961
. O 0 0.00015957393
5 O 0 0.00021357779
mg O 0 0.09173958
/ O 0 0.0006845624
kg O 0 0.0028904136
) O 0 0.0003755159
on O 0 0.00012908822
cardiac O 0 0.034581076
rate O 0 0.00025293804
and O 0 0.00028790755
ultrasound O 0 0.010067384
production O 0 0.0007374026
were O 0 0.00026334627
examined O 0 0.00020632979
in O 0 0.00026487172
2 O 0 0.00036829474
- O 0 0.0005637525
, O 0 0.00039823624
8 O 0 0.00032633496
- O 0 0.00050742296
, O 0 0.00039261117
15 O 0 0.00031166474
- O 0 0.0005730044
, O 0 0.0004814599
and O 0 0.0004994834
20 O 0 0.00077165355
- O 0 0.0011760903
day O 0 0.001090833
- O 0 0.0023410178
old O 0 0.002859725
rats O 0 0.008319028
. O 0 0.005059276

Age O 0 0.190584
- O 0 0.0047065425
related O 0 0.0014998562
changes O 0 0.001654042
in O 0 0.0008908631
ultrasound O 0 0.00877243
production O 0 0.0015787054
corresponded O 0 0.000567379
with O 0 0.00062994106
changes O 0 0.00080051133
in O 0 0.00047987417
cardiovascular O 0 0.8943838
variables O 0 0.001234509
, O 0 0.0006152387
including O 0 0.00043825211
baseline O 0 0.00079951773
cardiac O 0 0.09875999
rate O 0 0.00094726286
and O 0 0.0021932705
clonidine B-Chemical 1 0.9995516
- O 0 0.015414099
induced O 0 0.01742908
bradycardia B-Disease 0 0.99736965
. O 0 0.00819422

This O 0 0.0039112903
experiment O 0 0.0016505207
is O 0 0.001341784
discussed O 0 0.00092295284
with O 0 0.0008697481
regard O 0 0.000603439
to O 0 0.0004824681
the O 0 0.00042478475
hypothesis O 0 0.00061512965
that O 0 0.00037954247
ultrasound O 0 0.017215448
production O 0 0.0014859472
is O 0 0.0004349034
the O 0 0.00035670854
acoustic O 0 0.027784402
by O 0 0.00052283413
- O 0 0.0006650194
product O 0 0.0005461146
of O 0 0.00037026586
a O 0 0.00036762774
physiological O 0 0.0022531182
maneuver O 0 0.115694314
that O 0 0.00027274893
compensates O 0 0.0003956433
for O 0 0.0005518984
clonidine B-Chemical 1 0.9996556
' O 0 0.0011628524
s O 0 0.0010701045
detrimental O 0 0.0021692757
effects O 0 0.002348748
on O 0 0.0015151731
cardiovascular O 0 0.9548131
function O 0 0.009428801
. O 0 0.006443769

Recurrent O 0 0.1963566
use O 0 0.004948364
of O 0 0.0040358286
newer O 0 0.0695334
oral B-Chemical 1 0.89808595
contraceptives I-Chemical 1 0.99715734
and O 0 0.0045232004
the O 0 0.0034116665
risk O 0 0.041357674
of O 0 0.009625171
venous B-Disease 0 0.9640445
thromboembolism I-Disease 0 0.9985135
. O 0 0.01917045

The O 0 0.0027224699
epidemiological O 0 0.0042289225
studies O 0 0.002134827
that O 0 0.0009904994
assessed O 0 0.0007863524
the O 0 0.000827538
risk O 0 0.00905197
of O 0 0.0015960771
venous B-Disease 0 0.9292138
thromboembolism I-Disease 0 0.9998621
( O 0 0.028504763
VTE B-Disease 2 0.99954176
) O 0 0.0023876522
associated O 0 0.0007200615
with O 0 0.00063448603
newer O 0 0.095048316
oral B-Chemical 1 0.95397985
contraceptives I-Chemical 1 0.99967337
( O 0 0.008121727
OC B-Chemical 1 0.9977639
) O 0 0.0013686976
did O 0 0.0002806112
not O 0 0.00020261337
distinguish O 0 0.00023341164
between O 0 0.00014004223
patterns O 0 0.00026060626
of O 0 0.0005728132
OC B-Chemical 1 0.99268675
use O 0 0.0009267486
, O 0 0.00066047645
namely O 0 0.00079659093
first O 0 0.00047671216
- O 0 0.0009131673
time O 0 0.0005918914
users O 0 0.0034035183
, O 0 0.0018522077
repeaters O 0 0.038323484
and O 0 0.0032786902
switchers O 0 0.041261178
. O 0 0.006197605

Data O 0 0.0052590487
from O 0 0.002313019
a O 0 0.0020994202
Transnational O 0 0.0046023796
case O 0 0.0012675341
- O 0 0.0011923903
control O 0 0.00048504435
study O 0 0.000694743
were O 0 0.00039094978
used O 0 0.00031048438
to O 0 0.00026836077
assess O 0 0.00016094848
the O 0 0.00030580955
risk O 0 0.007419774
of O 0 0.0010275411
VTE B-Disease 2 0.9991003
for O 0 0.00042045076
the O 0 0.00035624616
latter O 0 0.0008380916
patterns O 0 0.00034257665
of O 0 0.0005016255
use O 0 0.00064198027
, O 0 0.00063107867
while O 0 0.00047341324
accounting O 0 0.0011608221
for O 0 0.00078820135
duration O 0 0.001987814
of O 0 0.003062418
use O 0 0.0055202604
. O 0 0.005737706

Over O 0 0.0050962823
the O 0 0.0025975334
period O 0 0.0024347361
1993 O 0 0.00904289
- O 0 0.0028255465
1996 O 0 0.0039962353
, O 0 0.0013106675
551 O 0 0.0090960795
cases O 0 0.0012881941
of O 0 0.0013031543
VTE B-Disease 2 0.9984565
were O 0 0.0008548174
identified O 0 0.0005970289
in O 0 0.0006467945
Germany O 0 0.004144303
and O 0 0.00083345745
the O 0 0.00098626
UK O 0 0.0057605356
along O 0 0.0016447376
with O 0 0.0030495974
2066 O 0 0.029868655
controls O 0 0.007093526
. O 0 0.0064277616

Totals O 0 0.55582726
of O 0 0.0034373277
128 O 0 0.004892184
cases O 0 0.0022706361
and O 0 0.0011741958
650 O 0 0.0022173272
controls O 0 0.00086156774
were O 0 0.0004802922
analysed O 0 0.0004525209
for O 0 0.00038279718
repeat O 0 0.0007334355
use O 0 0.00066837645
and O 0 0.0006262001
135 O 0 0.0018593179
cases O 0 0.0011308823
and O 0 0.00093209953
622 O 0 0.0074172397
controls O 0 0.0015963833
for O 0 0.0013743632
switching O 0 0.0039053261
patterns O 0 0.0044820313
. O 0 0.0059668636

The O 0 0.0025893888
adjusted O 0 0.0023193264
rate O 0 0.0014252041
ratio O 0 0.0014949227
of O 0 0.0017999113
VTE B-Disease 2 0.9976115
for O 0 0.0008560156
repeat O 0 0.001192864
users O 0 0.00248078
of O 0 0.0005974154
third O 0 0.0005883061
generation O 0 0.0010791364
OC B-Chemical 1 0.99353844
was O 0 0.0005912663
0 O 0 0.0004436475
. O 0 0.0001775808
6 O 0 0.00019352586
( O 0 0.00030070695
95 O 0 0.0005437907
% O 0 0.0003120923
CI O 0 0.041169703
: O 0 0.0003864867
0 O 0 0.00026175598
. O 0 0.00013582403
3 O 0 0.00019254998
- O 0 0.00032972178
1 O 0 0.00019855265
. O 0 0.000112001566
2 O 0 0.00016953859
) O 0 0.00022445126
relative O 0 0.000105381725
to O 0 0.00014264877
repeat O 0 0.00031178482
users O 0 0.0009423928
of O 0 0.00026225433
second O 0 0.0002357145
generation O 0 0.0005974458
pills O 0 0.6681146
, O 0 0.00051793066
whereas O 0 0.0002660532
it O 0 0.00028645995
was O 0 0.00024226979
1 O 0 0.00023917686
. O 0 0.00012627587
3 O 0 0.0001729308
( O 0 0.00025874545
95 O 0 0.00048811806
% O 0 0.0002739718
CI O 0 0.039482754
: O 0 0.0003528183
0 O 0 0.00024413178
. O 0 0.00012884276
7 O 0 0.00018323165
- O 0 0.00030113728
2 O 0 0.00018289841
. O 0 0.00010832397
4 O 0 0.00014477911
) O 0 0.00023195098
for O 0 0.00012862867
switchers O 0 0.0013752718
from O 0 0.00017973162
second O 0 0.0001805012
to O 0 0.00018708734
third O 0 0.0002832035
generation O 0 0.0004979885
pills O 0 0.27137023
relative O 0 0.00030251566
to O 0 0.00039158223
switchers O 0 0.0041070576
from O 0 0.00055834616
third O 0 0.00081359147
to O 0 0.0008825688
second O 0 0.0015390181
generation O 0 0.0046440233
pills O 0 0.76365125
. O 0 0.007139888

We O 0 0.0027674288
conclude O 0 0.0018936512
that O 0 0.0011458937
second O 0 0.000984862
and O 0 0.00089610217
third O 0 0.0008145432
generation O 0 0.0010655696
agents O 0 0.07366994
are O 0 0.0005609385
associated O 0 0.00060006406
with O 0 0.00047219364
equivalent O 0 0.0004829563
risks O 0 0.010314709
of O 0 0.0011430896
VTE B-Disease 2 0.9993493
when O 0 0.00027519488
the O 0 0.0002500656
same O 0 0.0001642235
agent O 0 0.03025614
is O 0 0.00027418762
used O 0 0.00019700461
repeatedly O 0 0.00031397183
after O 0 0.00013338261
interruption O 0 0.0010127724
periods O 0 0.0003746813
or O 0 0.00022068481
when O 0 0.0002055138
users O 0 0.0011718957
are O 0 0.00035324288
switched O 0 0.0007270576
between O 0 0.00028860892
the O 0 0.0005388932
two O 0 0.0007117473
generations O 0 0.0017920858
of O 0 0.004081362
pills O 0 0.8031467
. O 0 0.0072996295

These O 0 0.0037083135
analyses O 0 0.0027131008
suggest O 0 0.0012018604
that O 0 0.0009405195
the O 0 0.00081534544
higher O 0 0.00079576817
risk O 0 0.0069995876
observed O 0 0.00047401217
for O 0 0.00039622965
the O 0 0.0004514679
newer O 0 0.044175044
OC B-Chemical 1 0.9943415
in O 0 0.00048592806
other O 0 0.00040544258
studies O 0 0.00063561724
may O 0 0.00033871955
be O 0 0.00028033898
the O 0 0.00020819965
result O 0 0.00020282772
of O 0 0.00032939002
inadequate O 0 0.0006743104
comparisons O 0 0.00032634803
of O 0 0.00060922065
pill O 0 0.400942
users O 0 0.0040142643
with O 0 0.0008042519
different O 0 0.00086237845
patterns O 0 0.0012426504
of O 0 0.0028378868
pill O 0 0.5935242
use O 0 0.007350222
. O 0 0.006478429

Differential O 0 0.014151702
effects O 0 0.0045107966
of O 0 0.0028889521
systemically O 0 0.18828996
administered O 0 0.03362266
ketamine B-Chemical 1 0.9992755
and O 0 0.0026140944
lidocaine B-Chemical 0 0.9989021
on O 0 0.00063429866
dynamic O 0 0.0017176787
and O 0 0.0010061782
static O 0 0.009514205
hyperalgesia B-Disease 2 0.9988136
induced O 0 0.003716641
by O 0 0.0024851733
intradermal O 0 0.4797983
capsaicin B-Chemical 0 0.99821067
in O 0 0.0056743966
humans O 0 0.037490364
. O 0 0.007013083

We O 0 0.002942345
have O 0 0.002023556
examined O 0 0.0011794559
the O 0 0.0010501298
effect O 0 0.0010882402
of O 0 0.0012749182
systemic O 0 0.8133204
administration O 0 0.37408394
of O 0 0.0030260463
ketamine B-Chemical 1 0.9996822
and O 0 0.0022258211
lidocaine B-Chemical 0 0.99950945
on O 0 0.0004974932
brush O 0 0.13970698
- O 0 0.0016739434
evoked O 0 0.09158962
( O 0 0.0007201047
dynamic O 0 0.0012729038
) O 0 0.0012998929
pain B-Disease 0 0.9180643
and O 0 0.0007285737
punctate O 0 0.0019247605
- O 0 0.0015859493
evoked O 0 0.07234783
( O 0 0.0013608049
static O 0 0.004476979
) O 0 0.005031569
hyperalgesia B-Disease 2 0.99812764
induced O 0 0.00826415
by O 0 0.008530982
capsaicin B-Chemical 0 0.9971064
. O 0 0.0100763785

In O 0 0.002956522
a O 0 0.0023133403
randomized O 0 0.0025287743
, O 0 0.0017299601
double O 0 0.0010901683
- O 0 0.0016959719
blind O 0 0.004303687
, O 0 0.0011880838
placebo O 0 0.12611203
- O 0 0.00096218137
controlled O 0 0.00048673793
, O 0 0.0005471159
crossover O 0 0.0018165194
study O 0 0.00076082576
, O 0 0.00057651696
we O 0 0.00028308795
studied O 0 0.00077113375
12 O 0 0.0006109818
volunteers O 0 0.00199838
in O 0 0.0010208695
three O 0 0.0012313013
experiments O 0 0.003122703
. O 0 0.0055316645

Capsaicin B-Chemical 1 0.99723274
100 O 0 0.009987361
micrograms O 0 0.22226737
was O 0 0.0015601559
injected O 0 0.0009991042
intradermally O 0 0.0016283721
on O 0 0.0003708098
the O 0 0.00048356666
volar O 0 0.006086388
forearm O 0 0.04820582
followed O 0 0.0003672029
by O 0 0.00042121738
an O 0 0.0005586165
i O 0 0.0012515115
. O 0 0.00026022492
v O 0 0.0029575622
. O 0 0.00020295638
infusion O 0 0.008270523
of O 0 0.00070964533
ketamine B-Chemical 1 0.9996859
( O 0 0.0010318515
bolus O 0 0.055161946
0 O 0 0.00033901204
. O 0 0.00012946321
1 O 0 0.00020987667
mg O 0 0.0808806
kg O 0 0.003252674
- O 0 0.00033378878
1 O 0 0.00014656245
over O 0 7.399957e-05
10 O 0 0.00014472418
min O 0 0.00019048068
followed O 0 0.00010318316
by O 0 0.00017151478
infusion O 0 0.0030768379
of O 0 0.00029876546
7 O 0 0.00024760276
micrograms O 0 0.07900851
kg O 0 0.0068050753
- O 0 0.00048712688
1 O 0 0.00025707827
min O 0 0.0004361481
- O 0 0.00042490344
1 O 0 0.00028828828
) O 0 0.00047031685
, O 0 0.00047543354
lidocaine B-Chemical 0 0.99831605
5 O 0 0.0004662459
mg O 0 0.22200559
kg O 0 0.006353625
- O 0 0.0008649328
1 O 0 0.00053929276
or O 0 0.0005706942
saline O 0 0.013142187
for O 0 0.0012330485
50 O 0 0.0032258003
min O 0 0.0046861903
. O 0 0.004525997

Infusion O 0 0.3017156
started O 0 0.008180373
15 O 0 0.004661544
min O 0 0.005619357
after O 0 0.0035829435
injection O 0 0.011916487
of O 0 0.013857423
capsaicin B-Chemical 0 0.9927771
. O 0 0.019808846

The O 0 0.0028973622
following O 0 0.0021601738
were O 0 0.0016409234
measured O 0 0.0011778662
: O 0 0.0019709358
spontaneous O 0 0.018720694
pain B-Disease 0 0.9742634
, O 0 0.002801533
pain B-Disease 0 0.9684751
evoked O 0 0.16096126
by O 0 0.000704552
punctate O 0 0.0011586181
and O 0 0.00061810313
brush O 0 0.033610627
stimuli O 0 0.00836435
( O 0 0.0011816003
VAS O 0 0.38434562
) O 0 0.0008965676
, O 0 0.0005008006
and O 0 0.00040926342
areas O 0 0.00090811704
of O 0 0.0008361891
brush O 0 0.07819989
- O 0 0.0023102676
evoked O 0 0.07089183
and O 0 0.0016369701
punctate O 0 0.0051907543
- O 0 0.0074769882
evoked O 0 0.56659216
hyperalgesia B-Disease 2 0.9973997
. O 0 0.009831425

Ketamine B-Chemical 1 0.99612844
reduced O 0 0.00373779
both O 0 0.0017766975
the O 0 0.0012533929
area O 0 0.0015737624
of O 0 0.0014738572
brush O 0 0.09711023
- O 0 0.0023852251
evoked O 0 0.07031242
and O 0 0.0009017182
punctate O 0 0.0023158377
- O 0 0.001918536
evoked O 0 0.28077203
hyperalgesia B-Disease 2 0.9993262
significantly O 0 0.0015253861
and O 0 0.0007339833
it O 0 0.0007090417
tended O 0 0.0006776468
to O 0 0.0006883351
reduce O 0 0.0011505883
brush O 0 0.09972686
- O 0 0.0074638575
evoked O 0 0.43213215
pain B-Disease 0 0.98207736
. O 0 0.008556975

Lidocaine B-Chemical 0 0.99553657
reduced O 0 0.0063032354
the O 0 0.0037347616
area O 0 0.0045979866
of O 0 0.004548417
punctate O 0 0.009933539
- O 0 0.011912564
evoked O 0 0.57598126
hyperalgesia B-Disease 2 0.99696845
significantly O 0 0.021868309
. O 0 0.012064334

It O 0 0.0062466054
tended O 0 0.002807263
to O 0 0.0018715578
reduce O 0 0.0016257634
VAS O 0 0.11619615
scores O 0 0.0013551661
of O 0 0.0015552442
spontaneous O 0 0.04305436
pain B-Disease 0 0.9670156
but O 0 0.0014923908
had O 0 0.0013156264
no O 0 0.0011904916
effect O 0 0.002098159
on O 0 0.0022802611
evoked O 0 0.39060763
pain B-Disease 0 0.98259777
. O 0 0.010203679

The O 0 0.0028319373
differential O 0 0.0035360523
effects O 0 0.0030828114
of O 0 0.0026778572
ketamine B-Chemical 1 0.9990408
and O 0 0.00273349
lidocaine B-Chemical 0 0.9989937
on O 0 0.0005444345
static O 0 0.0019841413
and O 0 0.00061452726
dynamic O 0 0.0021655282
hyperalgesia B-Disease 2 0.99888796
suggest O 0 0.00039775326
that O 0 0.00029484354
the O 0 0.00027526208
two O 0 0.00023086545
types O 0 0.00040549514
of O 0 0.0009185156
hyperalgesia B-Disease 2 0.9992786
are O 0 0.00069205946
mediated O 0 0.00046698915
by O 0 0.00046105857
separate O 0 0.00041516792
mechanisms O 0 0.0011752432
and O 0 0.00091435714
have O 0 0.0012298122
a O 0 0.0020838473
distinct O 0 0.0040107165
pharmacology O 0 0.42604363
. O 0 0.0066745277

Development O 0 0.024416188
of O 0 0.007596302
apomorphine B-Chemical 1 0.99935275
- O 0 0.010507686
induced O 0 0.0036790646
aggressive B-Disease 2 0.60286325
behavior I-Disease 2 0.042794902
: O 0 0.0018709137
comparison O 0 0.0008164421
of O 0 0.0013136769
adult O 0 0.002261199
male O 0 0.0042639174
and O 0 0.0024576283
female O 0 0.010930149
Wistar O 0 0.36691967
rats O 0 0.01608341
. O 0 0.007523983

The O 0 0.0034695626
development O 0 0.0048485533
of O 0 0.0044190134
apomorphine B-Chemical 1 0.9996172
- O 0 0.0094929375
induced O 0 0.0024341783
( O 0 0.0014468307
1 O 0 0.00062488735
. O 0 0.00028717835
0 O 0 0.00043723377
mg O 0 0.09786761
/ O 0 0.00082639774
kg O 0 0.0020500412
s O 0 0.00039367593
. O 0 0.00017354346
c O 0 0.00093403383
. O 0 0.00015933096
once O 0 0.00022853259
daily O 0 0.00094076816
) O 0 0.00062140555
aggressive B-Disease 2 0.22294113
behavior I-Disease 2 0.008073493
of O 0 0.000452437
adult O 0 0.00068731245
male O 0 0.0012465745
and O 0 0.00031851899
female O 0 0.001405642
Wistar O 0 0.10812584
rats O 0 0.0009223778
obtained O 0 0.00025888512
from O 0 0.0002626562
the O 0 0.00026771115
same O 0 0.00024427962
breeder O 0 0.0017228469
was O 0 0.00064231653
studied O 0 0.001048303
in O 0 0.00090099935
two O 0 0.0011999466
consecutive O 0 0.0030088397
sets O 0 0.00398986
. O 0 0.0058165393

In O 0 0.003194139
male O 0 0.0043210387
animals O 0 0.001608739
, O 0 0.0015555405
repeated O 0 0.0013513537
apomorphine B-Chemical 1 0.99963343
treatment O 0 0.008810984
induced O 0 0.0012646302
a O 0 0.0006498657
gradual O 0 0.0009560352
development O 0 0.0011695091
of O 0 0.0006804998
aggressive B-Disease 2 0.5571904
behavior I-Disease 2 0.019462211
as O 0 0.00027167966
evidenced O 0 0.0004701519
by O 0 0.00028636822
the O 0 0.0002326755
increased O 0 0.00044604912
intensity O 0 0.000266638
of O 0 0.00065297796
aggressiveness B-Disease 2 0.928914
and O 0 0.00060322334
shortened O 0 0.0012776381
latency O 0 0.002195206
before O 0 0.0003223031
the O 0 0.0005743629
first O 0 0.00085350545
attack O 0 0.08406447
toward O 0 0.0024402367
the O 0 0.0036216406
opponent O 0 0.16889043
. O 0 0.0070769675

In O 0 0.0045434237
female O 0 0.006991208
rats O 0 0.0073978994
, O 0 0.0030178027
only O 0 0.0018760221
a O 0 0.0020985922
weak O 0 0.0040148785
tendency O 0 0.0041840314
toward O 0 0.0041277576
aggressiveness B-Disease 2 0.91946214
was O 0 0.0063182674
found O 0 0.0070751654
. O 0 0.008452163

In O 0 0.0026880084
conclusion O 0 0.0019126165
, O 0 0.0016422059
the O 0 0.0008141812
present O 0 0.00054290844
study O 0 0.00083682593
demonstrates O 0 0.00042139672
gender O 0 0.0018249628
differences O 0 0.0002989444
in O 0 0.0002941876
the O 0 0.0003105655
development O 0 0.0007865907
of O 0 0.00056826085
the O 0 0.000733244
apomorphine B-Chemical 1 0.9999168
- O 0 0.004514488
induced O 0 0.0011545983
aggressive B-Disease 2 0.65186673
behavior I-Disease 2 0.025859179
and O 0 0.00034692432
indicates O 0 0.00019965715
that O 0 0.00018723028
the O 0 0.00023833322
female O 0 0.001043633
rats O 0 0.0010287205
do O 0 0.00021989549
not O 0 0.00021500085
fill O 0 0.00022175969
the O 0 0.0002517152
validation O 0 0.00047193898
criteria O 0 0.00085875613
for O 0 0.0005839585
use O 0 0.0011996507
in O 0 0.0012769591
this O 0 0.0022579299
method O 0 0.0059174974
. O 0 0.0056618326

Intracranial B-Disease 0 0.9753043
aneurysms I-Disease 2 0.9907516
and O 0 0.01490824
cocaine B-Disease 0 0.99891376
abuse I-Disease 2 0.9948165
: O 0 0.00885537
analysis O 0 0.0054531754
of O 0 0.0059888507
prognostic O 0 0.02118318
indicators O 0 0.011881308
. O 0 0.011347539

OBJECTIVE O 0 0.53740895
: O 0 0.0056724595
The O 0 0.002269841
outcome O 0 0.0038155266
of O 0 0.0038914718
subarachnoid B-Disease 0 0.9970168
hemorrhage I-Disease 2 0.9987643
associated O 0 0.009711814
with O 0 0.013215805
cocaine B-Disease 0 0.9996126
abuse I-Disease 2 0.9974953
is O 0 0.00832975
reportedly O 0 0.1610395
poor O 0 0.030260287
. O 0 0.008831384

However O 0 0.004169137
, O 0 0.002731533
no O 0 0.001201799
study O 0 0.001531267
in O 0 0.00077927846
the O 0 0.0006846866
literature O 0 0.0012775547
has O 0 0.0006310401
reported O 0 0.0007822195
the O 0 0.00042765873
use O 0 0.00052012474
of O 0 0.0005214757
a O 0 0.0005279311
statistical O 0 0.0016387486
model O 0 0.0006797807
to O 0 0.00047347412
analyze O 0 0.0004251684
the O 0 0.0006871744
variables O 0 0.0014841753
that O 0 0.0013516368
influence O 0 0.0025127062
outcome O 0 0.01010886
. O 0 0.0064600767

METHODS O 0 0.0070352997
: O 0 0.003933008
A O 0 0.0055177137
review O 0 0.0026299711
of O 0 0.0014150091
admissions O 0 0.0045824125
during O 0 0.00064440194
a O 0 0.0008021326
6 O 0 0.0005041718
- O 0 0.00066553196
year O 0 0.0004143742
period O 0 0.00040997192
revealed O 0 0.0005470935
14 O 0 0.0007664768
patients O 0 0.0018819744
with O 0 0.0023422407
cocaine B-Chemical 1 0.9986815
- O 0 0.008312625
related O 0 0.0042007393
aneurysms B-Disease 2 0.9860621
. O 0 0.008192392

This O 0 0.004491283
group O 0 0.0025468243
was O 0 0.0013909168
compared O 0 0.0007051878
with O 0 0.0009019279
a O 0 0.0007848896
control O 0 0.00053975586
group O 0 0.00069971115
of O 0 0.00074230443
135 O 0 0.0026453752
patients O 0 0.0019872938
with O 0 0.0013621917
ruptured B-Disease 0 0.9522494
aneurysms I-Disease 2 0.99753237
and O 0 0.0016774685
no O 0 0.0012487427
history O 0 0.028959194
of O 0 0.011124599
cocaine B-Disease 0 0.99939907
abuse I-Disease 2 0.9963576
. O 0 0.012428706

Age O 0 0.04999676
at O 0 0.0023538868
presentation O 0 0.005280179
, O 0 0.0019028861
time O 0 0.0009693562
of O 0 0.0014318437
ictus O 0 0.36478594
after O 0 0.00078281533
intoxication O 0 0.99755967
, O 0 0.0018517263
Hunt O 0 0.11781869
and O 0 0.00076531194
Hess O 0 0.5059652
grade O 0 0.15561517
of O 0 0.0018597852
subarachnoid B-Disease 0 0.9991295
hemorrhage I-Disease 2 0.9996314
, O 0 0.0012916316
size O 0 0.0005617619
of O 0 0.00051254407
the O 0 0.00051628065
aneurysm B-Disease 2 0.9810301
, O 0 0.00065688626
location O 0 0.0003511769
of O 0 0.0004835097
the O 0 0.00054716965
aneurysm B-Disease 2 0.97912395
, O 0 0.00084622006
and O 0 0.00054302125
the O 0 0.00060533534
Glasgow O 0 0.24153742
Outcome O 0 0.0145011805
Scale O 0 0.28554344
score O 0 0.00092346204
were O 0 0.0008915318
assessed O 0 0.0010902928
and O 0 0.0021518776
compared O 0 0.0025491123
. O 0 0.004978324

RESULTS O 0 0.023202172
: O 0 0.0036893352
The O 0 0.0013809693
patients O 0 0.0021357182
in O 0 0.0007976544
the O 0 0.0006526296
study O 0 0.00089874223
group O 0 0.00067996467
were O 0 0.00048080433
significantly O 0 0.0006158943
younger O 0 0.0028788075
than O 0 0.00026162202
the O 0 0.000338073
patients O 0 0.00099097
in O 0 0.0003592604
the O 0 0.00040150248
control O 0 0.0004985568
group O 0 0.0010644161
( O 0 0.0014814599
P O 0 0.023773389
< O 0 0.0016829178
0 O 0 0.0017039152
. O 0 0.0016871169
002 O 0 0.0802052
) O 0 0.006694452
. O 0 0.0057431166

In O 0 0.0034222454
patients O 0 0.0042118025
in O 0 0.0016348804
the O 0 0.0013557752
study O 0 0.0018523133
group O 0 0.0016404367
, O 0 0.0015908593
all O 0 0.0012657726
aneurysms B-Disease 2 0.9532669
were O 0 0.0015938053
located O 0 0.0015668673
in O 0 0.0016216418
the O 0 0.0026811108
anterior O 0 0.03640529
circulation O 0 0.03556042
. O 0 0.0075372504

The O 0 0.0027000448
majority O 0 0.0021341627
of O 0 0.0019522059
these O 0 0.002289342
aneurysms B-Disease 2 0.9531138
were O 0 0.00096901355
smaller O 0 0.0005996462
than O 0 0.00034719994
those O 0 0.0004922865
of O 0 0.000454361
the O 0 0.00035187742
control O 0 0.00034195877
group O 0 0.0006038346
( O 0 0.0006143437
8 O 0 0.0003818576
+ O 0 0.00048711876
/ O 0 0.0008660981
- O 0 0.000523043
6 O 0 0.00020829019
. O 0 0.0001693195
08 O 0 0.0021498809
mm O 0 0.000946313
versus O 0 0.00025652442
11 O 0 0.00039384
+ O 0 0.00047379266
/ O 0 0.0008967471
- O 0 0.0006195398
5 O 0 0.000308518
. O 0 0.00023987636
4 O 0 0.0004069339
mm O 0 0.0020721504
; O 0 0.001236598
P O 0 0.012401806
= O 0 0.0017704369
0 O 0 0.0015610387
. O 0 0.0015544669
05 O 0 0.027659187
) O 0 0.006212378
. O 0 0.0055748373

The O 0 0.0033172367
differences O 0 0.002094273
in O 0 0.0021628973
mortality O 0 0.040185545
and O 0 0.002452658
morbidity O 0 0.114469945
between O 0 0.0010142665
the O 0 0.0012556955
two O 0 0.0012663731
groups O 0 0.0022115388
were O 0 0.0024798466
not O 0 0.0033401914
significant O 0 0.0068571987
. O 0 0.0076710926

Hunt O 0 0.058158923
and O 0 0.0051191854
Hess O 0 0.32569554
grade O 0 0.15442836
( O 0 0.0035450375
P O 0 0.021750389
< O 0 0.0013708129
0 O 0 0.0008810511
. O 0 0.0004940223
005 O 0 0.017584346
) O 0 0.0008725184
and O 0 0.0005254714
age O 0 0.0011887505
( O 0 0.0007974679
P O 0 0.012772458
< O 0 0.0005136543
0 O 0 0.00037588607
. O 0 0.00021868282
007 O 0 0.01409665
) O 0 0.0004757992
were O 0 0.0002285934
significant O 0 0.0002892251
predictors O 0 0.0002567226
of O 0 0.00038657885
outcome O 0 0.00083725865
for O 0 0.00036314962
the O 0 0.00054493884
patients O 0 0.002558218
with O 0 0.0026949802
cocaine B-Chemical 1 0.9989735
- O 0 0.009182404
related O 0 0.0040440215
aneurysms B-Disease 2 0.9871836
. O 0 0.007832121

CONCLUSION O 0 0.9329494
: O 0 0.014791736
Cocaine B-Chemical 0 0.9987779
use O 0 0.007436192
predisposed O 0 0.62019295
aneurysmal B-Disease 0 0.9990243
rupture I-Disease 0 0.9956856
at O 0 0.0011192774
a O 0 0.0011582187
significantly O 0 0.0011312239
earlier O 0 0.0011077927
age O 0 0.00210329
and O 0 0.0013196799
in O 0 0.0013602633
much O 0 0.0017255142
smaller O 0 0.004315227
aneurysms B-Disease 2 0.9799242
. O 0 0.009067219

Contrary O 0 0.004092827
to O 0 0.0023805979
the O 0 0.0018319302
published O 0 0.0019101975
literature O 0 0.0026763028
, O 0 0.0016352136
this O 0 0.0010423372
group O 0 0.0013555326
did O 0 0.0010886944
reasonably O 0 0.0020281232
well O 0 0.0015801032
with O 0 0.0034412155
aggressive O 0 0.16294365
management O 0 0.022866042
. O 0 0.008992059

Effect O 0 0.009825763
of O 0 0.0060746884
intravenous O 0 0.8420112
nimodipine B-Chemical 0 0.9994203
on O 0 0.00315155
blood O 0 0.020736163
pressure O 0 0.06828252
and O 0 0.0032373695
outcome O 0 0.006537933
after O 0 0.0040925588
acute B-Disease 0 0.9916203
stroke I-Disease 2 0.9973719
. O 0 0.016127856

BACKGROUND O 0 0.77330023
AND O 0 0.009040001
PURPOSE O 0 0.035817724
: O 0 0.0036925285
The O 0 0.0019895115
Intravenous O 0 0.97686964
Nimodipine B-Chemical 0 0.99980336
West O 0 0.058543246
European O 0 0.012500968
Stroke B-Disease 0 0.99530977
Trial O 0 0.3374547
( O 0 0.0013613084
INWEST O 0 0.23962577
) O 0 0.00086123653
found O 0 0.00031913357
a O 0 0.00032898766
correlation O 0 0.00024277571
between O 0 0.0003258394
nimodipine B-Chemical 0 0.99989736
- O 0 0.0037281695
induced O 0 0.00091089326
reduction B-Disease 0 0.0012473084
in I-Disease 0 0.0004209356
blood I-Disease 0 0.010016228
pressure I-Disease 0 0.097924404
( O 0 0.0012461013
BP O 0 0.6550996
) O 0 0.001015975
and O 0 0.00061309815
an O 0 0.0009850411
unfavorable O 0 0.023642888
outcome O 0 0.005526061
in O 0 0.003457379
acute B-Disease 0 0.9951024
stroke I-Disease 2 0.99833554
. O 0 0.01245103

We O 0 0.0029006368
sought O 0 0.0026376655
to O 0 0.0011632463
confirm O 0 0.0006483852
this O 0 0.00064410927
correlation O 0 0.00043590183
with O 0 0.0006054874
and O 0 0.00049226236
without O 0 0.00040119045
adjustment O 0 0.0005011334
for O 0 0.00027139284
prognostic O 0 0.0018177867
variables O 0 0.0005646925
and O 0 0.00033949685
to O 0 0.00025979502
investigate O 0 0.00021569095
outcome O 0 0.0008063837
in O 0 0.00039115216
subgroups O 0 0.001069272
with O 0 0.0008263855
increasing O 0 0.0015441676
levels O 0 0.0017346077
of O 0 0.0046131555
BP B-Disease 0 0.9799586
reduction I-Disease 0 0.075540185
. O 0 0.0073932516

METHODS O 0 0.0064385296
: O 0 0.0035032171
Patients O 0 0.0036627026
with O 0 0.001361066
a O 0 0.00117993
clinical O 0 0.0050164643
diagnosis O 0 0.0105352225
of O 0 0.0027165688
ischemic B-Disease 2 0.9997124
stroke I-Disease 2 0.99960214
( O 0 0.0015968926
within O 0 0.0002008218
24 O 0 0.0002526852
hours O 0 0.00022164894
) O 0 0.00031996038
were O 0 0.000170686
consecutively O 0 0.00028679552
allocated O 0 0.00018907074
to O 0 0.00018836341
receive O 0 0.0003584963
placebo O 0 0.09432793
( O 0 0.00044198986
n O 0 0.0002414332
= O 0 0.00038837962
100 O 0 0.000507187
) O 0 0.0004173271
, O 0 0.00030322597
1 O 0 0.00026715148
mg O 0 0.13149256
/ O 0 0.0006478936
h O 0 0.00029710832
( O 0 0.00032709277
low O 0 0.00039453254
- O 0 0.0006721584
dose O 0 0.020321371
) O 0 0.002698307
nimodipine B-Chemical 0 0.9999132
( O 0 0.0012883695
n O 0 0.00035117217
= O 0 0.0005299556
101 O 0 0.0018293774
) O 0 0.00048597966
, O 0 0.0003118086
or O 0 0.00021167171
2 O 0 0.00031209824
mg O 0 0.15613334
/ O 0 0.00079988426
h O 0 0.00038876338
( O 0 0.000454033
high O 0 0.0006002062
- O 0 0.00108377
dose O 0 0.024993487
) O 0 0.0049624545
nimodipine B-Chemical 0 0.99977356
( O 0 0.0031945764
n O 0 0.0016910037
= O 0 0.002965577
94 O 0 0.0036036302
) O 0 0.0053594457
. O 0 0.004946997

The O 0 0.0025129574
correlation O 0 0.0014655418
between O 0 0.00096587284
average O 0 0.0009072004
BP O 0 0.20240264
change O 0 0.0009578135
during O 0 0.0004808485
the O 0 0.00049386127
first O 0 0.00041895578
2 O 0 0.0004598919
days O 0 0.00040554733
and O 0 0.0004687222
the O 0 0.0005013291
outcome O 0 0.0012403433
at O 0 0.00058159226
day O 0 0.0011135909
21 O 0 0.0018566531
was O 0 0.001904798
analyzed O 0 0.0031417399
. O 0 0.0054381764

RESULTS O 0 0.020785261
: O 0 0.0038469194
Two O 0 0.0020544776
hundred O 0 0.0019190438
sixty O 0 0.0023288147
- O 0 0.0014481539
five O 0 0.000508361
patients O 0 0.0012348684
were O 0 0.00047693984
included O 0 0.00036475746
in O 0 0.00030930142
this O 0 0.00033729608
analysis O 0 0.0006724637
( O 0 0.0005768701
n O 0 0.00032585525
= O 0 0.00047539664
92 O 0 0.0005430593
, O 0 0.00032883498
93 O 0 0.00052187627
, O 0 0.00029358856
and O 0 0.00022838774
80 O 0 0.00035388817
for O 0 0.00023283083
placebo O 0 0.046351306
, O 0 0.00046819885
low O 0 0.00055605127
dose O 0 0.008846912
, O 0 0.00079625286
and O 0 0.00069752074
high O 0 0.0013903269
dose O 0 0.025003593
, O 0 0.0031072856
respectively O 0 0.0063316333
) O 0 0.00668267
. O 0 0.00526972

Nimodipine B-Chemical 0 0.99898607
treatment O 0 0.011134134
resulted O 0 0.0021545824
in O 0 0.0012345079
a O 0 0.0011406336
statistically O 0 0.00092654186
significant O 0 0.00094419124
reduction B-Disease 0 0.0012990765
in I-Disease 0 0.0007464511
systolic I-Disease 0 0.8506445
BP I-Disease 0 0.88342154
( O 0 0.0014676256
SBP O 0 0.5249599
) O 0 0.0009659473
and O 0 0.0006118296
diastolic O 0 0.96166646
BP O 0 0.8360687
( O 0 0.0010361539
DBP O 0 0.3804828
) O 0 0.00058387313
from O 0 0.0002592675
baseline O 0 0.00037007136
compared O 0 0.00020764301
with O 0 0.00050596724
placebo O 0 0.028014166
during O 0 0.00052615674
the O 0 0.000782517
first O 0 0.0010179873
few O 0 0.0015914713
days O 0 0.0033040927
. O 0 0.0047431146

In O 0 0.0026001318
multivariate O 0 0.0055088303
analysis O 0 0.0026922517
, O 0 0.0017084895
a O 0 0.0010150523
significant O 0 0.00087554654
correlation O 0 0.0004717898
between O 0 0.0004380462
DBP B-Disease 0 0.75899744
reduction I-Disease 0 0.0034982068
and O 0 0.0005832915
worsening O 0 0.32991678
of O 0 0.00059377943
the O 0 0.00043454432
neurological O 0 0.90864533
score O 0 0.0004964448
was O 0 0.00027795095
found O 0 0.00021362076
for O 0 0.00017951839
the O 0 0.00022889393
high O 0 0.00050653744
- O 0 0.00071103853
dose O 0 0.008441723
group O 0 0.0007026323
( O 0 0.0008233974
beta O 0 0.21580125
= O 0 0.0010009486
0 O 0 0.0004922319
. O 0 0.00028912915
49 O 0 0.0008705519
, O 0 0.0009029654
P O 0 0.015396537
= O 0 0.0016770316
0 O 0 0.0014440742
. O 0 0.0014251214
048 O 0 0.07417529
) O 0 0.005855956
. O 0 0.0051354896

Patients O 0 0.010175054
with O 0 0.003292186
a O 0 0.0029729933
DBP B-Disease 0 0.77766806
reduction I-Disease 0 0.0054131136
of O 0 0.0015390263
> O 0 0.0018163631
or O 0 0.00056035875
= O 0 0.00075401936
20 O 0 0.00041250777
% O 0 0.00033117124
in O 0 0.00020530637
the O 0 0.00022953843
high O 0 0.00045879156
- O 0 0.000580472
dose O 0 0.0042624283
group O 0 0.00035528024
had O 0 0.00026331065
a O 0 0.00027499767
significantly O 0 0.000323018
increased O 0 0.00047696554
adjusted O 0 0.00055454334
OR O 0 0.027946264
for O 0 0.00020756599
the O 0 0.0002480205
compound O 0 0.026297051
outcome O 0 0.0012377818
variable O 0 0.0006196812
death B-Disease 2 0.9862509
or O 0 0.00037334973
dependency O 0 0.0025273087
( O 0 0.0006754552
Barthel O 0 0.005747764
Index O 0 0.0015386055
< O 0 0.0002950865
60 O 0 0.00029027511
) O 0 0.00042552623
( O 0 0.00033967433
n O 0 0.00025065616
/ O 0 0.0007936641
N O 0 0.4498346
= O 0 0.00059534406
25 O 0 0.0004429939
/ O 0 0.0005428016
26 O 0 0.00038928367
, O 0 0.00032897512
OR O 0 0.0073170024
10 O 0 0.00026984038
. O 0 0.00013810309
16 O 0 0.00022920515
, O 0 0.00026362762
95 O 0 0.0005294833
% O 0 0.00029479124
CI O 0 0.024509605
1 O 0 0.00024652062
. O 0 0.00015394048
02 O 0 0.0019563222
to O 0 0.00022175188
101 O 0 0.0012478555
. O 0 0.00017101606
74 O 0 0.0005059419
) O 0 0.0004837003
and O 0 0.00042448705
death B-Disease 2 0.97218704
alone O 0 0.0008287355
( O 0 0.000635888
n O 0 0.00033937747
/ O 0 0.0011754329
N O 0 0.61778635
= O 0 0.0006838711
9 O 0 0.00028850438
/ O 0 0.00052417355
26 O 0 0.0003871575
, O 0 0.00033193082
OR O 0 0.007913886
4 O 0 0.00022800895
. O 0 0.00015526917
336 O 0 0.0015898598
, O 0 0.0003083022
95 O 0 0.0005718294
% O 0 0.00029554177
CI O 0 0.023215638
1 O 0 0.00022820359
. O 0 0.00013283786
131 O 0 0.0006188712
16 O 0 0.00023835688
. O 0 0.0001449681
619 O 0 0.007473917
) O 0 0.00033879347
compared O 0 0.000114576105
with O 0 0.00022888064
all O 0 0.00022746848
placebo O 0 0.0699688
patients O 0 0.0018048384
( O 0 0.0005553965
n O 0 0.00036141288
/ O 0 0.0011825986
N O 0 0.5189388
= O 0 0.00086710067
62 O 0 0.0008552892
/ O 0 0.0008611812
92 O 0 0.0008903777
and O 0 0.00058813236
14 O 0 0.0008899095
/ O 0 0.0017624309
92 O 0 0.0023550997
, O 0 0.0022192388
respectively O 0 0.0047352677
) O 0 0.0061581237
. O 0 0.0052712983

There O 0 0.008863778
was O 0 0.0044752476
no O 0 0.003168731
correlation O 0 0.0028607368
between O 0 0.003349481
SBP O 0 0.20832685
change O 0 0.0062606186
and O 0 0.007560592
outcome O 0 0.01680601
. O 0 0.012242797

CONCLUSIONS O 0 0.8243694
: O 0 0.008233081
DBP O 0 0.3659296
, O 0 0.0027353857
but O 0 0.0013333998
not O 0 0.0010445163
SBP O 0 0.31952468
, O 0 0.0010731821
reduction O 0 0.0010180537
was O 0 0.00049176806
associated O 0 0.00063766685
with O 0 0.00077074475
neurological O 0 0.9575677
worsening O 0 0.6809236
after O 0 0.00029478592
the O 0 0.00040937308
intravenous O 0 0.4157169
administration O 0 0.109903194
of O 0 0.0009375044
high O 0 0.0016971786
- O 0 0.002995311
dose O 0 0.18118905
nimodipine B-Chemical 0 0.99977106
after O 0 0.0051037245
acute B-Disease 0 0.99692565
stroke I-Disease 2 0.9986387
. O 0 0.012815053

For O 0 0.0046251346
low O 0 0.005465385
- O 0 0.006908822
dose O 0 0.111779265
nimodipine B-Chemical 0 0.99940836
, O 0 0.0060985335
the O 0 0.0027032604
results O 0 0.002845984
were O 0 0.0036553892
not O 0 0.0047993353
conclusive O 0 0.017450534
. O 0 0.00983238

These O 0 0.00549192
results O 0 0.002983535
do O 0 0.0022487831
not O 0 0.0016421371
confirm O 0 0.0012495696
or O 0 0.001521939
exclude O 0 0.001619443
a O 0 0.0032978063
neuroprotective O 0 0.91231143
property O 0 0.051202092
of O 0 0.02561038
nimodipine B-Chemical 0 0.99921703
. O 0 0.019835306

Neonatal O 0 0.5698489
pyridoxine B-Chemical 1 0.9982008
responsive O 0 0.05429306
convulsions B-Disease 0 0.99799734
due O 0 0.008040106
to O 0 0.011242552
isoniazid B-Chemical 1 0.9975005
therapy O 0 0.4779344
. O 0 0.01733766

A O 1 0.05853725
17 O 1 0.0069197123
- O 0 0.0034407529
day O 0 0.0016618732
- O 0 0.001848895
old O 0 0.0011120209
infant O 0 0.002698167
on O 0 0.00056217593
isoniazid B-Chemical 1 0.9993531
therapy O 0 0.055199526
13 O 0 0.001000554
mg O 0 0.37061062
/ O 0 0.0010366975
kg O 0 0.0021614537
daily O 0 0.00065996265
from O 0 0.0002576129
birth O 0 0.00070475176
because O 0 0.00022043161
of O 0 0.00045595522
maternal O 0 0.003023744
tuberculosis B-Disease 2 0.6175952
was O 0 0.0007735456
admitted O 0 0.0034510659
after O 0 0.00043433413
4 O 0 0.0006762503
days O 0 0.0010272161
of O 0 0.0032123483
clonic B-Disease 0 0.99889237
fits I-Disease 0 0.3154704
. O 0 0.008206542

No O 0 0.01029683
underlying O 0 0.009122046
infective O 0 0.055213284
or O 0 0.0049051214
biochemical O 0 0.03703972
cause O 0 0.012072544
could O 0 0.0048600226
be O 0 0.0069726743
found O 0 0.00834376
. O 0 0.010780509

The O 0 0.0031155208
fits B-Disease 0 0.004608472
ceased O 0 0.0032604514
within O 0 0.00081421726
4 O 0 0.0007289237
hours O 0 0.0005830403
of O 0 0.0007670453
administering O 0 0.012016291
intramuscular O 0 0.80937546
pyridoxine B-Chemical 1 0.99987113
, O 0 0.0021451837
suggesting O 0 0.0006513502
an O 0 0.0010477802
aetiology O 0 0.23344165
of O 0 0.005041495
pyridoxine B-Chemical 1 0.9998596
deficiency O 0 0.9363312
secondary O 0 0.04998616
to O 0 0.006176361
isoniazid B-Chemical 1 0.9992417
medication O 0 0.83238107
. O 0 0.00851317

Ketamine B-Chemical 1 0.996367
sedation O 0 0.6771682
for O 0 0.002237176
the O 0 0.0016268905
reduction O 0 0.002175522
of O 0 0.001779506
children O 0 0.0033167389
' O 0 0.0020126156
s O 0 0.0026811946
fractures B-Disease 2 0.76022494
in O 0 0.0022551506
the O 0 0.002989801
emergency O 0 0.026710076
department O 0 0.044763315
. O 0 0.00956434

BACKGROUND O 0 0.7492878
: O 0 0.0052847774
There O 0 0.0029093162
recently O 0 0.001994443
has O 0 0.0012684597
been O 0 0.0011873964
a O 0 0.00095897773
resurgence O 0 0.0037447782
in O 0 0.00061754545
the O 0 0.0005565476
utilization O 0 0.0013100334
of O 0 0.0012224511
ketamine B-Chemical 1 0.99946135
, O 0 0.0011254562
a O 0 0.0005977705
unique O 0 0.0008172753
anesthetic O 0 0.33333376
, O 0 0.00088602136
for O 0 0.0005456598
emergency O 0 0.0022999714
- O 0 0.0015601759
department O 0 0.0020533956
procedures O 0 0.002407428
requiring O 0 0.005019687
sedation O 0 0.7150116
. O 0 0.0065386016

The O 0 0.0024805558
purpose O 0 0.0018884185
of O 0 0.0014103927
the O 0 0.0009211794
present O 0 0.00062499964
study O 0 0.0009640845
was O 0 0.00050349196
to O 0 0.00036486247
examine O 0 0.00022754312
the O 0 0.000315742
safety O 0 0.0010276248
and O 0 0.00039078825
efficacy O 0 0.0016304951
of O 0 0.0007492443
ketamine B-Chemical 1 0.9994929
for O 0 0.0004924973
sedation O 0 0.5522487
in O 0 0.0003011844
the O 0 0.00028846943
treatment O 0 0.000760455
of O 0 0.00060362305
children O 0 0.0016283495
' O 0 0.0008573617
s O 0 0.0013213457
fractures B-Disease 2 0.77633727
in O 0 0.001308197
the O 0 0.00191797
emergency O 0 0.026091045
department O 0 0.0432637
. O 0 0.007226107

METHODS O 0 0.0063486965
: O 0 0.0031348967
One O 0 0.0019208109
hundred O 0 0.0016413906
and O 0 0.0011392279
fourteen O 0 0.0017380904
children O 0 0.002070419
( O 0 0.0008976703
average O 0 0.00033733348
age O 0 0.0010554721
, O 0 0.00060449354
5 O 0 0.000317208
. O 0 0.00018622381
3 O 0 0.00021174256
years O 0 0.00044857225
; O 0 0.00038548105
range O 0 0.00033279392
, O 0 0.0002531069
twelve O 0 0.0002003171
months O 0 0.00019679921
to O 0 0.00014278732
ten O 0 0.00013070097
years O 0 0.00031839206
and O 0 0.00017793861
ten O 0 0.00014157878
months O 0 0.00025123399
) O 0 0.000341774
who O 0 0.00041664258
underwent O 0 0.000323168
closed O 0 0.0002890724
reduction O 0 0.00045170725
of O 0 0.00034951972
an O 0 0.00045310837
isolated O 0 0.00049635425
fracture B-Disease 0 0.81967145
or O 0 0.00045348707
dislocation B-Disease 0 0.82620615
in O 0 0.00036008403
the O 0 0.00034381094
emergency O 0 0.005594051
department O 0 0.003858566
at O 0 0.0003196092
a O 0 0.0005715608
level O 0 0.0005472698
- O 0 0.0015523975
I O 0 0.0038526796
trauma B-Disease 0 0.5193378
center O 0 0.0015710657
were O 0 0.0016430957
prospectively O 0 0.004125015
evaluated O 0 0.0036811677
. O 0 0.005478721

Ketamine B-Chemical 1 0.99867827
hydrochloride I-Chemical 0 0.9973954
was O 0 0.003262043
administered O 0 0.006107488
intravenously O 0 0.019287685
( O 0 0.0010151196
at O 0 0.00032048736
a O 0 0.00042464669
dose O 0 0.0021846178
of O 0 0.00039491412
two O 0 0.00021049756
milligrams O 0 0.0013410685
per O 0 0.00016182793
kilogram O 0 0.0010840652
of O 0 0.00038220244
body O 0 0.0020544925
weight O 0 0.0040318724
) O 0 0.0005084077
in O 0 0.00020953776
ninety O 0 0.001109972
- O 0 0.00040829548
nine O 0 0.00021269175
of O 0 0.0002675897
the O 0 0.00023105637
patients O 0 0.0009946565
and O 0 0.0003423778
intramuscularly O 0 0.040709473
( O 0 0.00035273423
at O 0 0.00012368601
a O 0 0.00021446137
dose O 0 0.001461778
of O 0 0.00025465412
four O 0 0.00015440902
milligrams O 0 0.0013212722
per O 0 0.00017818429
kilogram O 0 0.0013387983
of O 0 0.0005971316
body O 0 0.0031639317
weight O 0 0.0051037585
) O 0 0.0014070582
in O 0 0.00087791396
the O 0 0.0013520799
other O 0 0.0024622162
fifteen O 0 0.0060470924
. O 0 0.0057927477

A O 0 0.018165965
board O 0 0.0054355254
- O 0 0.0033444134
certified O 0 0.0020814352
emergency O 0 0.0026021432
physician O 0 0.002782189
skilled O 0 0.0020769194
in O 0 0.00065668067
airway O 0 0.019117208
management O 0 0.0016799467
supervised O 0 0.0019924925
administration O 0 0.05640782
of O 0 0.00068344566
the O 0 0.0005282656
anesthetic O 0 0.39896128
, O 0 0.00073823123
and O 0 0.0004639116
the O 0 0.00043426795
patients O 0 0.0012595016
were O 0 0.000605393
monitored O 0 0.00054168986
by O 0 0.0011301814
a O 0 0.001954273
registered O 0 0.00370233
nurse O 0 0.007339511
. O 0 0.0060941586

Any O 0 0.009550744
pain B-Disease 0 0.76277804
during O 0 0.0016214648
the O 0 0.0012818908
reduction O 0 0.0016402979
was O 0 0.0007840034
rated O 0 0.00092026894
by O 0 0.0005276979
the O 0 0.00041917487
orthopaedic O 0 0.0013423989
surgeon O 0 0.0010625164
treating O 0 0.0013996608
the O 0 0.0003558821
patient O 0 0.00061464385
according O 0 0.00030990152
to O 0 0.00028863727
the O 0 0.00036253736
Children O 0 0.0020350912
' O 0 0.00053413917
s O 0 0.00071659347
Hospital O 0 0.0023970592
of O 0 0.0011243573
Eastern O 0 0.06879497
Ontario O 0 0.10953813
Pain B-Disease 2 0.9906585
Scale O 0 0.84548825
( O 0 0.0055614165
CHEOPS O 0 0.7358827
) O 0 0.0089340955
. O 0 0.0063440027

RESULTS O 0 0.022280326
: O 0 0.0034112062
The O 0 0.0011275944
average O 0 0.0006453644
time O 0 0.0006954485
from O 0 0.00076139
intravenous O 0 0.25100118
administration O 0 0.124107435
of O 0 0.0014951063
ketamine B-Chemical 1 0.9994554
to O 0 0.0005349424
manipulation O 0 0.0006374572
of O 0 0.0005057845
the O 0 0.00044952167
fracture B-Disease 0 0.82697475
or O 0 0.00045309475
dislocation B-Disease 0 0.8005581
was O 0 0.00031318262
one O 0 0.00016018799
minute O 0 0.00020089015
and O 0 0.00021379802
thirty O 0 0.0003179256
- O 0 0.00032728087
six O 0 0.00011976862
seconds O 0 0.00023315298
( O 0 0.00024137313
range O 0 0.0002648929
, O 0 0.0002008601
twenty O 0 0.00014772463
seconds O 0 0.00016718244
to O 0 0.00012560097
five O 0 0.00010963093
minutes O 0 0.0002130112
) O 0 0.00035052016
, O 0 0.00022926262
and O 0 0.00016864215
the O 0 0.0001313617
average O 0 9.002249e-05
time O 0 0.0001364177
from O 0 0.00019963089
intramuscular O 0 0.1259911
administration O 0 0.04308741
to O 0 0.00020941533
manipulation O 0 0.0003354571
was O 0 0.00018029424
four O 0 0.000120209115
minutes O 0 0.00019342329
and O 0 0.00022073321
forty O 0 0.0005279825
- O 0 0.00043317414
two O 0 0.00020101681
seconds O 0 0.00037560757
( O 0 0.00043993414
range O 0 0.00055365846
, O 0 0.0005650664
sixty O 0 0.0010289357
seconds O 0 0.00077295356
to O 0 0.0008474648
fifteen O 0 0.001982499
minutes O 0 0.002621299
) O 0 0.0056809643
. O 0 0.0052159154

The O 0 0.00241137
average O 0 0.0012855858
score O 0 0.001525442
according O 0 0.0009861857
to O 0 0.0007871047
the O 0 0.0007547796
Children O 0 0.0027425976
' O 0 0.00073580066
s O 0 0.0007718903
Hospital O 0 0.0020149625
of O 0 0.0007063211
Eastern O 0 0.041160997
Ontario O 0 0.044498086
Pain B-Disease 2 0.98765355
Scale O 0 0.5801572
was O 0 0.0003708459
6 O 0 0.00021966605
. O 0 0.00014174872
4 O 0 0.00016968574
points O 0 0.00027427683
( O 0 0.00031674237
range O 0 0.00036251263
, O 0 0.0003088438
5 O 0 0.00018209728
to O 0 0.00018175572
10 O 0 0.00024599492
points O 0 0.00035103227
) O 0 0.00053541036
, O 0 0.0003979154
reflecting O 0 0.00043885346
minimal O 0 0.00058611337
or O 0 0.0005546126
no O 0 0.0009080241
pain B-Disease 0 0.92582715
during O 0 0.002282383
fracture B-Disease 0 0.9222924
reduction O 0 0.015645552
. O 0 0.0066159125

Adequate O 0 0.017761247
fracture B-Disease 0 0.5555064
reduction O 0 0.006831301
was O 0 0.003326444
obtained O 0 0.0029295704
in O 0 0.003017865
111 O 0 0.008295528
of O 0 0.0047776387
the O 0 0.0059764534
children O 0 0.015825957
. O 0 0.010889762

Ninety O 0 0.011311535
- O 0 0.003971412
nine O 0 0.0017198757
percent O 0 0.0012689431
( O 0 0.0014395082
sixty O 0 0.0017264547
- O 0 0.0011777126
eight O 0 0.00050470885
) O 0 0.0007428762
of O 0 0.0004732368
the O 0 0.00037526523
sixty O 0 0.0009651681
- O 0 0.00059823645
nine O 0 0.0003018893
parents O 0 0.0004812789
present O 0 0.0001771558
during O 0 0.00016985604
the O 0 0.00022510554
reduction O 0 0.0004857766
were O 0 0.00027116522
pleased O 0 0.002093956
with O 0 0.0003582286
the O 0 0.00032934162
sedation O 0 0.35513067
and O 0 0.00036509908
would O 0 0.00023179225
allow O 0 0.00023055683
it O 0 0.00036450804
to O 0 0.00034608165
be O 0 0.0004554815
used O 0 0.0004632026
again O 0 0.000760172
in O 0 0.00084870966
a O 0 0.0015721597
similar O 0 0.0018453792
situation O 0 0.0054463036
. O 0 0.005352844

Patency O 0 0.014249581
of O 0 0.0034187213
the O 0 0.002309193
airway O 0 0.018212717
and O 0 0.0017624376
independent O 0 0.0011139112
respiration O 0 0.051651523
were O 0 0.001261577
maintained O 0 0.0012530705
in O 0 0.0011330647
all O 0 0.0013675959
of O 0 0.0026411605
the O 0 0.00364599
patients O 0 0.012854171
. O 0 0.007753391

Blood O 0 0.062009785
pressure O 0 0.039052267
and O 0 0.009648891
heart O 0 0.14255753
rate O 0 0.008156198
remained O 0 0.01219245
stable O 0 0.016254235
. O 0 0.015951425

Minor O 0 0.169613
side O 0 0.015479133
effects O 0 0.0044228667
included O 0 0.0026526367
nausea B-Disease 2 0.999496
( O 0 0.0026050948
thirteen O 0 0.0016809527
patients O 0 0.0038465192
) O 0 0.0016940531
, O 0 0.0013423739
emesis B-Disease 0 0.99955064
( O 0 0.00081070716
eight O 0 0.0002574683
of O 0 0.00035801317
the O 0 0.00028720984
thirteen O 0 0.0006227072
patients O 0 0.0017638995
with O 0 0.0013835982
nausea B-Disease 2 0.9999014
) O 0 0.006179312
, O 0 0.0013655695
clumsiness B-Disease 0 0.99821657
( O 0 0.0007835146
evident O 0 0.00036072018
as O 0 0.00035767985
ataxic B-Disease 0 0.999268
movements I-Disease 0 0.03746355
in O 0 0.00030557346
ten O 0 0.0002774299
patients O 0 0.0017298755
) O 0 0.00096782006
, O 0 0.0007346296
and O 0 0.0010328888
dysphoric B-Disease 0 0.998547
reaction I-Disease 0 0.14113717
( O 0 0.0023360883
one O 0 0.0015110803
patient O 0 0.004586565
) O 0 0.0066906
. O 0 0.0052722828

No O 0 0.006937462
long O 0 0.0040022433
- O 0 0.0036152813
term O 0 0.0024840033
sequelae O 0 0.24237216
were O 0 0.0016573177
noted O 0 0.0013946579
, O 0 0.0014675885
and O 0 0.001146303
no O 0 0.0010850561
patients O 0 0.003912052
had O 0 0.004373815
hallucinations B-Disease 2 0.9988856
or O 0 0.008282177
nightmares O 0 0.9856652
. O 0 0.0098656295

CONCLUSIONS O 0 0.8477288
: O 0 0.0097910585
Ketamine B-Chemical 1 0.9974159
reliably O 0 0.0037623206
, O 0 0.0018719301
safely O 0 0.0038951074
, O 0 0.0009615756
and O 0 0.0005679707
quickly O 0 0.00075858546
provided O 0 0.00043638347
adequate O 0 0.00056625117
sedation O 0 0.24313284
to O 0 0.00033153864
effectively O 0 0.00044918907
facilitate O 0 0.00023252804
the O 0 0.00027448268
reduction O 0 0.00058336696
of O 0 0.00049871794
children O 0 0.0013628424
' O 0 0.000590416
s O 0 0.00082100707
fractures B-Disease 2 0.758254
in O 0 0.0005780165
the O 0 0.0006936229
emergency O 0 0.006068731
department O 0 0.0053391666
at O 0 0.001202481
our O 0 0.0021699737
institution O 0 0.0066132625
. O 0 0.0057305666

Ketamine B-Chemical 1 0.9963331
should O 0 0.0022733589
only O 0 0.0016382228
be O 0 0.0012249372
used O 0 0.00079231296
in O 0 0.0005986425
an O 0 0.0007516293
environment O 0 0.00093831134
such O 0 0.0004611109
as O 0 0.0003567299
the O 0 0.00039769962
emergency O 0 0.00585788
department O 0 0.0072058095
, O 0 0.00057026296
where O 0 0.00026007288
proper O 0 0.00030994578
one O 0 0.0002689509
- O 0 0.0005273457
on O 0 0.00016699954
- O 0 0.00038746023
one O 0 0.0001493953
monitoring O 0 0.00032560094
is O 0 0.00022409693
used O 0 0.00019814113
and O 0 0.00025366328
board O 0 0.0005413136
- O 0 0.00044044774
certified O 0 0.00037118365
physicians O 0 0.00055391446
skilled O 0 0.0007658088
in O 0 0.0002691192
airway O 0 0.026827276
management O 0 0.0016050639
are O 0 0.00043917377
directly O 0 0.0004197131
involved O 0 0.0004535068
in O 0 0.0004948407
the O 0 0.0006695438
care O 0 0.0015018344
of O 0 0.0018119377
the O 0 0.0024570345
patient O 0 0.0066775316
. O 0 0.005665079

Cyclosporine B-Chemical 0 0.99671966
and O 0 0.029273752
tacrolimus B-Chemical 0 0.9980038
- O 0 0.07082351
associated O 0 0.079548486
thrombotic B-Disease 2 0.9980672
microangiopathy I-Disease 2 0.99911565
. O 0 0.03987353

The O 0 0.004023036
development O 0 0.006026101
of O 0 0.0064002513
thrombotic B-Disease 2 0.9990621
microangiopathy I-Disease 2 0.99985576
( O 0 0.046950214
TMA B-Disease 2 0.99142104
) O 0 0.0030157736
associated O 0 0.0012013464
with O 0 0.0009223296
the O 0 0.00073159044
use O 0 0.0011367514
of O 0 0.002184784
cyclosporine B-Chemical 1 0.9996094
has O 0 0.0034365226
been O 0 0.0035969163
well O 0 0.003155675
documented O 0 0.00921313
. O 0 0.006743047

Treatments O 0 0.1550685
have O 0 0.0029387078
included O 0 0.0018403034
discontinuation O 0 0.449365
or O 0 0.0010162571
reduction O 0 0.0014621975
of O 0 0.0013391299
cyclosporine B-Chemical 1 0.9998042
dose O 0 0.1569666
with O 0 0.00089117384
or O 0 0.00037972556
without O 0 0.0004186342
concurrent O 0 0.002541377
plasma O 0 0.051440235
exchange O 0 0.0016096232
, O 0 0.00079586374
plasma O 0 0.034118798
infusion O 0 0.054399908
, O 0 0.0010715363
anticoagulation O 0 0.6988845
, O 0 0.0013371914
and O 0 0.0014296043
intravenous O 0 0.746367
immunoglobulin O 0 0.89706534
G O 0 0.85964054
infusion O 0 0.4266574
. O 0 0.0072614085

However O 0 0.0041811266
, O 0 0.0027781862
for O 0 0.0013728432
recipients O 0 0.0026176483
of O 0 0.0013966105
organ O 0 0.03616518
transplantation O 0 0.16841419
, O 0 0.0010826245
removing O 0 0.0008549339
the O 0 0.0006736731
inciting O 0 0.3090047
agent O 0 0.15262038
is O 0 0.0005817145
not O 0 0.00038129315
without O 0 0.00042619364
the O 0 0.0004315058
attendant O 0 0.002036841
risk O 0 0.030013384
of O 0 0.0019446365
precipitating O 0 0.9029245
acute O 0 0.9929472
rejection O 0 0.99319685
and O 0 0.0059989644
graft O 0 0.21306497
loss O 0 0.019434744
. O 0 0.0069040176

The O 0 0.002676634
last O 0 0.0017003095
decade O 0 0.0034475485
has O 0 0.0014064079
seen O 0 0.0009898484
the O 0 0.00075830723
emergence O 0 0.0014642423
of O 0 0.0013696032
tacrolimus B-Chemical 0 0.999608
as O 0 0.00079746294
a O 0 0.0008291467
potent O 0 0.039112378
immunosuppressive O 0 0.979917
agent O 0 0.23813772
with O 0 0.00084786303
mechanisms O 0 0.0011696407
of O 0 0.0007700921
action O 0 0.004882384
virtually O 0 0.00086310593
identical O 0 0.00060615136
to O 0 0.0010998306
those O 0 0.0024780745
of O 0 0.006434007
cyclosporine B-Chemical 1 0.9990897
. O 0 0.011051987

As O 0 0.0024614516
a O 0 0.0023759017
result O 0 0.0015786949
, O 0 0.001700447
switching O 0 0.0016049477
to O 0 0.0011884487
tacrolimus B-Chemical 0 0.99940753
has O 0 0.0012461701
been O 0 0.0009443568
reported O 0 0.00081763207
to O 0 0.00043396853
be O 0 0.00041901076
a O 0 0.00040185958
viable O 0 0.00045562413
therapeutic O 0 0.004464133
option O 0 0.0008848373
in O 0 0.00049794174
the O 0 0.0006199455
setting O 0 0.0013419387
of O 0 0.003598677
cyclosporine B-Chemical 1 0.99966764
- O 0 0.038328476
induced O 0 0.02055958
TMA B-Disease 2 0.985607
. O 0 0.009766691

With O 0 0.005274697
the O 0 0.0023433564
more O 0 0.0021934926
widespread O 0 0.0031833048
application O 0 0.0027495236
of O 0 0.0022519447
tacrolimus B-Chemical 0 0.99940884
in O 0 0.0015982791
organ O 0 0.13050762
transplantation O 0 0.48291847
, O 0 0.004024794
tacrolimus B-Chemical 0 0.99965763
- O 0 0.006809453
associated O 0 0.003441296
TMA B-Disease 2 0.97463053
has O 0 0.002414107
also O 0 0.003022902
been O 0 0.0043789055
recognized O 0 0.007091984
. O 0 0.0068236054

However O 0 0.0042690816
, O 0 0.0029419984
literature O 0 0.002400802
regarding O 0 0.0010639274
the O 0 0.0009755331
incidence O 0 0.002759267
of O 0 0.0010485572
the O 0 0.0008649534
recurrence O 0 0.47160468
of O 0 0.0016865933
TMA B-Disease 2 0.97511554
in O 0 0.0008275877
patients O 0 0.002328306
exposed O 0 0.0008799676
sequentially O 0 0.0011868327
to O 0 0.0013303047
cyclosporine B-Chemical 1 0.99962735
and O 0 0.008849279
tacrolimus B-Chemical 0 0.99930215
is O 0 0.0055922903
limited O 0 0.0059034578
. O 0 0.0065284623

We O 0 0.003238539
report O 0 0.0042213686
a O 0 0.0018713457
case O 0 0.0013269185
of O 0 0.0012511696
a O 0 0.0011170013
living O 0 0.0032654328
donor O 0 0.0017137155
renal O 0 0.9786202
transplant O 0 0.72655076
recipient O 0 0.004711531
who O 0 0.002621421
developed O 0 0.003456416
cyclosporine B-Chemical 1 0.9998871
- O 0 0.006958657
induced O 0 0.001709954
TMA B-Disease 2 0.9772562
that O 0 0.0003858537
responded O 0 0.00087358773
to O 0 0.00028102915
the O 0 0.0003192812
withdrawal O 0 0.43832773
of O 0 0.001012861
cyclosporine B-Chemical 1 0.9998635
in O 0 0.0005964933
conjunction O 0 0.0009251565
with O 0 0.0007288272
plasmapheresis O 0 0.6161832
and O 0 0.0009300028
fresh O 0 0.0022639914
frozen O 0 0.0034756237
plasma O 0 0.05178001
replacement O 0 0.025070766
therapy O 0 0.13732505
. O 0 0.0070031523

Introduction O 0 0.007727274
of O 0 0.0044823075
tacrolimus B-Chemical 0 0.998156
as O 0 0.0018490454
an O 0 0.0016207295
alternative O 0 0.0013594971
immunosuppressive O 0 0.966098
agent O 0 0.24464342
resulted O 0 0.00087024015
in O 0 0.0005567101
the O 0 0.00059843855
recurrence O 0 0.4743624
of O 0 0.0014855029
TMA B-Disease 2 0.97135496
and O 0 0.0009487306
the O 0 0.0006866886
subsequent O 0 0.0010892277
loss O 0 0.0022516064
of O 0 0.002145156
the O 0 0.0034498458
renal O 0 0.99136096
allograft O 0 0.98511535
. O 0 0.010876504

Patients O 0 0.010508529
who O 0 0.00462724
are O 0 0.0019048252
switched O 0 0.0026868412
from O 0 0.0015896902
cyclosporine B-Chemical 1 0.9994723
to O 0 0.0021320262
tacrolimus B-Chemical 0 0.9995944
or O 0 0.0010138797
vice O 0 0.011105269
versa O 0 0.001038036
should O 0 0.00034002034
be O 0 0.0004058658
closely O 0 0.00038529685
monitored O 0 0.00025980666
for O 0 0.000375866
the O 0 0.0006309418
signs O 0 0.047238715
and O 0 0.0016165108
symptoms O 0 0.35600317
of O 0 0.0053192945
recurrent O 0 0.9244714
TMA B-Disease 2 0.9884389
. O 0 0.010313039

Analgesic O 0 0.9923639
effect O 0 0.004272069
of O 0 0.0032248013
intravenous O 0 0.8439561
ketamine B-Chemical 1 0.9994128
in O 0 0.0024347547
cancer B-Disease 2 0.99069256
patients O 0 0.011108495
on O 0 0.0005722621
morphine B-Chemical 1 0.99951756
therapy O 0 0.13287823
: O 0 0.001054576
a O 0 0.0004362508
randomized O 0 0.000674372
, O 0 0.00043717766
controlled O 0 0.00038161775
, O 0 0.0004775654
double O 0 0.00039575965
- O 0 0.00087529875
blind O 0 0.0027755836
, O 0 0.0008459565
crossover O 0 0.0036068163
, O 0 0.0012434236
double O 0 0.0012316925
- O 0 0.003284211
dose O 0 0.020254204
study O 0 0.006579447
. O 0 0.0057421443

Pain B-Disease 2 0.86593443
not O 0 0.0073301336
responsive O 0 0.0077129407
to O 0 0.0075622424
morphine B-Chemical 1 0.995501
is O 0 0.010553841
often O 0 0.013910494
problematic O 0 0.017925328
. O 0 0.013471076

Animal O 0 0.013207649
and O 0 0.0029220767
clinical O 0 0.005144521
studies O 0 0.002138138
have O 0 0.0013415432
suggested O 0 0.0013199276
that O 0 0.0012940624
N B-Chemical 0 0.927694
- I-Chemical 0 0.0106633715
methyl I-Chemical 0 0.9843621
- I-Chemical 0 0.011199941
D I-Chemical 0 0.8480486
- I-Chemical 0 0.0133218
aspartate I-Chemical 1 0.99949086
( O 0 0.01635594
NMDA B-Chemical 1 0.999881
) O 0 0.010064789
antagonists O 0 0.9699857
, O 0 0.0008443881
such O 0 0.00040820907
as O 0 0.00046127706
ketamine B-Chemical 1 0.99960715
, O 0 0.0008048594
may O 0 0.00034571066
be O 0 0.0002910594
effective O 0 0.00042505618
in O 0 0.00026825818
improving O 0 0.0006461164
opioid O 0 0.99826473
analgesia O 0 0.995675
in O 0 0.0007020356
difficult O 0 0.001233395
pain B-Disease 0 0.9856749
syndromes O 0 0.8504385
, O 0 0.0018972118
such O 0 0.0017938269
as O 0 0.0036859487
neuropathic B-Disease 0 0.99940515
pain I-Disease 0 0.99655545
. O 0 0.011641637

A O 0 0.014009514
slow O 0 0.0067960704
bolus O 0 0.053031433
of O 0 0.002954555
subhypnotic O 0 0.99726665
doses O 0 0.22994271
of O 0 0.004067326
ketamine B-Chemical 1 0.9995999
( O 0 0.0021181363
0 O 0 0.00062823866
. O 0 0.00023634237
25 O 0 0.0005282185
mg O 0 0.12016118
/ O 0 0.00077964505
kg O 0 0.0017386995
or O 0 0.00022167555
0 O 0 0.00027779993
. O 0 0.00013311223
50 O 0 0.00034792777
mg O 0 0.10130526
/ O 0 0.00068621786
kg O 0 0.002824542
) O 0 0.00037585362
was O 0 0.00017522955
given O 0 0.00013035609
to O 0 0.00019665234
10 O 0 0.00031961958
cancer B-Disease 2 0.9155929
patients O 0 0.0024634781
whose O 0 0.0013265173
pain B-Disease 0 0.9655924
was O 0 0.0005538513
unrelieved O 0 0.86878616
by O 0 0.0007591651
morphine B-Chemical 1 0.9996061
in O 0 0.00038726453
a O 0 0.00037996983
randomized O 0 0.0006550636
, O 0 0.0004159604
double O 0 0.00034470853
- O 0 0.00078677514
blind O 0 0.002698386
, O 0 0.00077058433
crossover O 0 0.0034981237
, O 0 0.0011606164
double O 0 0.0011624874
- O 0 0.0031452274
dose O 0 0.019977415
study O 0 0.006376183
. O 0 0.0055676512

Pain B-Disease 2 0.8278559
intensity O 0 0.0027461327
on O 0 0.0013244294
a O 0 0.0014655321
0 O 0 0.0010794717
to O 0 0.00068081927
10 O 0 0.00067420915
numerical O 0 0.00343847
scale O 0 0.0013983033
; O 0 0.002442436
nausea B-Disease 2 0.9997491
and O 0 0.0029154366
vomiting B-Disease 0 0.9997111
, O 0 0.0073868437
drowsiness O 0 0.99968827
, O 0 0.0020284054
confusion B-Disease 0 0.7393437
, O 0 0.0006455655
and O 0 0.0004160151
dry B-Disease 2 0.16082956
mouth I-Disease 2 0.36094174
, O 0 0.00048543082
using O 0 0.00021107316
a O 0 0.0002715243
scale O 0 0.00035182547
from O 0 0.00021245622
0 O 0 0.0002380344
to O 0 0.00017226413
3 O 0 0.00018561735
( O 0 0.00023688152
not O 0 0.00014639164
at O 0 0.000121122364
all O 0 0.00018794124
, O 0 0.00032705974
slight O 0 0.0005519768
, O 0 0.00037363675
a O 0 0.0003312334
lot O 0 0.0006253971
, O 0 0.00062721403
awful O 0 0.053927686
) O 0 0.0012402453
; O 0 0.0009151707
Mini O 0 0.0037530528
- O 0 0.00069954345
Mental O 0 0.01134331
State O 0 0.00160135
Examination O 0 0.0008073786
( O 0 0.0006633912
MMSE O 0 0.84328306
) O 0 0.00069960376
( O 0 0.00042154797
0 O 0 0.0003237135
- O 0 0.00037180205
30 O 0 0.0002143896
) O 0 0.00039407436
; O 0 0.00037094278
and O 0 0.00025038933
arterial O 0 0.19507346
pressure O 0 0.014702978
were O 0 0.00021050397
recorded O 0 0.00021976762
before O 0 0.00012163639
administration O 0 0.012859763
of O 0 0.00045958292
drugs O 0 0.6455399
( O 0 0.00069291994
T0 O 0 0.007408268
) O 0 0.0004964711
and O 0 0.00020978104
after O 0 0.000118163574
30 O 0 0.00017269797
minutes O 0 0.00021826495
( O 0 0.0003811814
T30 O 0 0.06695833
) O 0 0.00047116226
, O 0 0.0002869249
60 O 0 0.0002538544
minutes O 0 0.000249412
( O 0 0.00040976485
T60 O 0 0.019734878
) O 0 0.0005437881
, O 0 0.00036243457
120 O 0 0.00043807292
minutes O 0 0.00035982972
( O 0 0.0006331043
T120 O 0 0.045381565
) O 0 0.00091738947
, O 0 0.00071846717
and O 0 0.00073705026
180 O 0 0.001957425
minutes O 0 0.0014801287
( O 0 0.002976951
T180 O 0 0.0757934
) O 0 0.0071670823
. O 0 0.0058259163

Ketamine B-Chemical 1 0.9970536
, O 0 0.005735644
but O 0 0.0021198431
not O 0 0.0013530253
saline O 0 0.0697304
solution O 0 0.015572246
, O 0 0.0012191567
significantly O 0 0.0008362839
reduced O 0 0.00069666037
the O 0 0.0007002629
pain B-Disease 0 0.89282614
intensity O 0 0.0005946517
in O 0 0.00048602856
almost O 0 0.00046852656
all O 0 0.00054747175
the O 0 0.00077588245
patients O 0 0.0024345948
at O 0 0.0011771236
both O 0 0.0028206513
doses O 0 0.085707545
. O 0 0.0066090403

This O 0 0.005835862
effect O 0 0.0034056455
was O 0 0.0022971248
more O 0 0.0022953684
relevant O 0 0.0019758604
in O 0 0.0016300287
patients O 0 0.004043263
treated O 0 0.0037724355
with O 0 0.003819429
higher O 0 0.005233544
doses O 0 0.13456218
. O 0 0.009961236

Hallucinations B-Disease 2 0.98966277
occurred O 0 0.003927363
in O 0 0.0017265445
4 O 0 0.0011709615
patients O 0 0.0021134305
, O 0 0.0011257817
and O 0 0.0007978289
an O 0 0.0010969783
unpleasant O 0 0.3387164
sensation O 0 0.83040947
( O 0 0.0012997795
" O 0 0.0007751989
empty O 0 0.00074923504
head O 0 0.010783708
" O 0 0.0011172609
) O 0 0.0012136503
was O 0 0.0007319235
also O 0 0.0010240474
reported O 0 0.0018601764
by O 0 0.001973807
2 O 0 0.0029219629
patients O 0 0.007915263
. O 0 0.0056182723

These O 0 0.006986264
episodes O 0 0.050919317
reversed O 0 0.005938425
after O 0 0.001793155
the O 0 0.0023498074
administration O 0 0.08803579
of O 0 0.0071506794
diazepam B-Chemical 1 0.9993925
1 O 0 0.009695213
mg O 0 0.7783071
intravenously O 0 0.09415114
. O 0 0.008897859

Significant O 0 0.006820646
increases O 0 0.0030296347
in O 0 0.0023485436
drowsiness O 0 0.99754167
were O 0 0.0014113366
reported O 0 0.0012500855
in O 0 0.00059044076
patients O 0 0.0016053
treated O 0 0.0011205456
with O 0 0.0010213028
ketamine B-Chemical 1 0.9994469
in O 0 0.0005055023
both O 0 0.0003806371
groups O 0 0.0004369327
and O 0 0.00037574652
were O 0 0.00035014405
more O 0 0.0004962433
marked O 0 0.0009622551
with O 0 0.0011877404
ketamine B-Chemical 1 0.99903834
0 O 0 0.0013486427
. O 0 0.00067409954
50 O 0 0.0019961863
mg O 0 0.23350604
/ O 0 0.006386278
kg O 0 0.017289737
. O 0 0.0052250084

A O 0 0.013666883
significant O 0 0.0031859935
difference O 0 0.0014538441
in O 0 0.0015548475
MMSE O 0 0.6398319
was O 0 0.0009634987
observed O 0 0.00057528
at O 0 0.00051183277
T30 O 0 0.049019173
in O 0 0.00053323875
patients O 0 0.0013669006
who O 0 0.0012440502
received O 0 0.00083313615
0 O 0 0.00075427734
. O 0 0.00044150348
50 O 0 0.001231482
mg O 0 0.14733827
/ O 0 0.0033469666
kg O 0 0.009811374
of O 0 0.005449272
ketamine B-Chemical 1 0.99689794
. O 0 0.008717048

Ketamine B-Chemical 1 0.9953792
can O 0 0.004343021
improve O 0 0.0036352351
morphine B-Chemical 1 0.9984376
analgesia O 0 0.9937942
in O 0 0.0026031036
difficult O 0 0.003154086
pain B-Disease 0 0.9829654
syndromes O 0 0.8512708
, O 0 0.003484121
such O 0 0.0030324936
as O 0 0.005490556
neuropathic B-Disease 0 0.9991811
pain I-Disease 0 0.9958477
. O 0 0.0150836045

However O 0 0.004376187
, O 0 0.0029658896
the O 0 0.0015602116
occurrence O 0 0.0022638838
of O 0 0.0015016255
central O 0 0.0030812614
adverse O 0 0.5252122
effects O 0 0.0019523507
should O 0 0.0004507936
be O 0 0.0005242337
taken O 0 0.00037049004
into O 0 0.0003429825
account O 0 0.00064837234
, O 0 0.0008456187
especially O 0 0.0010561313
when O 0 0.0007812935
using O 0 0.0013696488
higher O 0 0.002903794
doses O 0 0.0801574
. O 0 0.0069509004

This O 0 0.005779767
observation O 0 0.0032059604
should O 0 0.0017789875
be O 0 0.0019135834
tested O 0 0.0014302935
in O 0 0.0016332344
studies O 0 0.002860209
of O 0 0.003982718
prolonged O 0 0.21132758
ketamine B-Chemical 1 0.99848783
administration O 0 0.8456873
. O 0 0.012347388

Paclitaxel B-Chemical 0 0.9967924
, O 0 0.010695615
cisplatin B-Chemical 1 0.99665606
, O 0 0.0036213154
and O 0 0.0019299226
gemcitabine B-Chemical 1 0.99520135
combination O 0 0.0071045067
chemotherapy O 0 0.72170204
within O 0 0.00046429
a O 0 0.00069178967
multidisciplinary O 0 0.001839391
therapeutic O 0 0.008119392
approach O 0 0.0015732793
in O 0 0.0014221787
metastatic O 0 0.98195
nonsmall B-Disease 0 0.99795437
cell I-Disease 0 0.46358305
lung I-Disease 0 0.9736702
carcinoma I-Disease 2 0.9982981
. O 0 0.01504862

BACKGROUND O 0 0.89478564
: O 0 0.011627885
Cisplatin B-Chemical 1 0.9981546
- O 0 0.0037531278
based O 0 0.0015120007
chemotherapy O 0 0.28991398
combinations O 0 0.0009026199
improve O 0 0.0005425551
quality O 0 0.0004948716
of O 0 0.00068802224
life O 0 0.0014110463
and O 0 0.00071664713
survival O 0 0.022463534
in O 0 0.000802831
advanced O 0 0.2045295
nonsmall B-Disease 0 0.9983374
cell I-Disease 0 0.31131205
lung I-Disease 0 0.9707375
carcinoma I-Disease 2 0.9993575
( O 0 0.08745008
NSCLC B-Disease 2 0.99552673
) O 0 0.01961725
. O 0 0.0074967807

The O 0 0.003011328
emergence O 0 0.003417461
of O 0 0.0020832263
new O 0 0.0022024466
active O 0 0.002649282
drugs O 0 0.41090345
might O 0 0.00081634003
translate O 0 0.00088002486
into O 0 0.00038597287
more O 0 0.0006587539
effective O 0 0.00092356326
regimens O 0 0.005395342
for O 0 0.00066708645
the O 0 0.0009026126
treatment O 0 0.0024618441
of O 0 0.002574027
this O 0 0.003911467
disease O 0 0.75651634
. O 0 0.00819867

METHODS O 0 0.0057045734
: O 0 0.0026884212
The O 0 0.0010724539
objective O 0 0.0014486132
of O 0 0.00087488437
this O 0 0.0006381746
study O 0 0.0008385425
was O 0 0.0004390363
to O 0 0.00032104543
determine O 0 0.00017229894
the O 0 0.0002852075
feasibility O 0 0.00042219102
, O 0 0.00047177234
response O 0 0.000547811
rate O 0 0.0003790731
, O 0 0.00054580806
and O 0 0.000542828
toxicity B-Disease 2 0.9821838
of O 0 0.00093654246
a O 0 0.0012556089
paclitaxel B-Chemical 1 0.99886847
, O 0 0.003773812
cisplatin B-Chemical 1 0.99913234
, O 0 0.001521405
and O 0 0.0011012198
gemcitabine B-Chemical 1 0.9968719
combination O 0 0.0062550385
to O 0 0.0019335863
treat O 0 0.10132216
metastatic O 0 0.9919138
NSCLC B-Disease 2 0.9956939
. O 0 0.010634765

Thirty O 0 0.010100169
- O 0 0.00362141
five O 0 0.0012152947
consecutive O 0 0.0018924959
chemotherapy O 0 0.54440075
- O 0 0.0021885722
naive O 0 0.0021258288
patients O 0 0.001870781
with O 0 0.0009858495
Stage O 0 0.44017833
IV O 0 0.36950225
NSCLC B-Disease 2 0.99677175
and O 0 0.0008007121
an O 0 0.00082564796
Eastern O 0 0.040112924
Cooperative O 0 0.095097765
Oncology O 0 0.031455968
Group O 0 0.004677239
performance O 0 0.00041100994
status O 0 0.00037444636
of O 0 0.00037693084
0 O 0 0.0004083912
- O 0 0.000399885
2 O 0 0.00019099464
were O 0 0.00016417106
treated O 0 0.000307349
with O 0 0.00025372178
a O 0 0.00026936975
combination O 0 0.0007418433
of O 0 0.0007591278
paclitaxel B-Chemical 1 0.9989084
( O 0 0.0011194759
135 O 0 0.0055995653
mg O 0 0.4651469
/ O 0 0.0014298978
m O 0 0.002463321
( O 0 0.00039313198
2 O 0 0.00022873076
) O 0 0.00028965203
given O 0 0.00012929196
intravenously O 0 0.0012435858
in O 0 0.00017004854
3 O 0 0.00016150606
hours O 0 0.00019082117
) O 0 0.00030272338
on O 0 0.000124555
Day O 0 0.0012364202
1 O 0 0.00027405852
, O 0 0.00042708553
cisplatin B-Chemical 1 0.99793917
( O 0 0.00058255455
120 O 0 0.000573042
mg O 0 0.25078756
/ O 0 0.0010464257
m O 0 0.0018724513
( O 0 0.00037372383
2 O 0 0.00022352418
) O 0 0.00028490965
given O 0 0.00012805837
intravenously O 0 0.0011784906
in O 0 0.00016587356
6 O 0 0.00013832923
hours O 0 0.00017877873
) O 0 0.00028968928
on O 0 0.00011949257
Day O 0 0.0010971595
1 O 0 0.0002368488
, O 0 0.00027830785
and O 0 0.0003178389
gemcitabine B-Chemical 1 0.9967235
( O 0 0.00071070995
800 O 0 0.0038220698
mg O 0 0.40605822
/ O 0 0.001306974
m O 0 0.002186499
( O 0 0.00040319064
2 O 0 0.00024111668
) O 0 0.00030688228
given O 0 0.00014185905
intravenously O 0 0.0011322475
in O 0 0.00019309751
30 O 0 0.00020630244
minutes O 0 0.00025040345
) O 0 0.00041870362
on O 0 0.00022603033
Days O 0 0.021126198
1 O 0 0.0004968674
and O 0 0.0005602145
8 O 0 0.0006699398
, O 0 0.0009103699
every O 0 0.00067684316
4 O 0 0.0014362495
weeks O 0 0.0025922041
. O 0 0.0039009177

Although O 0 0.003273261
responding O 0 0.0044103335
patients O 0 0.002950638
were O 0 0.001004291
scheduled O 0 0.00065146503
to O 0 0.0005719352
receive O 0 0.00077950646
consolidation O 0 0.036065985
radiotherapy O 0 0.47518557
and O 0 0.0005714606
24 O 0 0.00034854276
patients O 0 0.0006021862
received O 0 0.00037020087
preplanned O 0 0.0048068706
second O 0 0.00034367444
- O 0 0.0005286822
line O 0 0.0005180857
chemotherapy O 0 0.38343433
after O 0 0.00025408203
disease O 0 0.704157
progression O 0 0.5063947
, O 0 0.00061846134
the O 0 0.00029047197
response O 0 0.00067097816
and O 0 0.0005708449
toxicity B-Disease 2 0.9869113
rates O 0 0.0006408084
reported O 0 0.000951464
refer O 0 0.0008861738
only O 0 0.0005526917
to O 0 0.00066637003
the O 0 0.0011305689
chemotherapy O 0 0.6798649
regimen O 0 0.036261518
given O 0 0.0037007877
. O 0 0.0055913827

RESULTS O 0 0.023185644
: O 0 0.0043803086
All O 0 0.0020925147
the O 0 0.0015327565
patients O 0 0.002499318
were O 0 0.0011793952
examined O 0 0.00097616523
for O 0 0.0014367293
toxicity B-Disease 2 0.982947
; O 0 0.0034752537
34 O 0 0.002220354
were O 0 0.0016635993
examinable O 0 0.00580759
for O 0 0.0029903399
response O 0 0.007936459
. O 0 0.0075011966

An O 0 0.0056722094
objective O 0 0.0038818724
response O 0 0.0023164572
was O 0 0.0011891281
observed O 0 0.00072218565
in O 0 0.0006504614
73 O 0 0.0012164371
. O 0 0.00035109805
5 O 0 0.00032133822
% O 0 0.0003167683
of O 0 0.0003109747
the O 0 0.000302627
patients O 0 0.0010673078
( O 0 0.0004815035
95 O 0 0.0006513036
% O 0 0.00026652898
confidence O 0 0.0006422489
interval O 0 0.0005985438
[ O 0 0.0010432245
CI O 0 0.16578996
] O 0 0.00078178436
, O 0 0.00036917496
55 O 0 0.00035490227
. O 0 0.00016523537
6 O 0 0.00020252222
- O 0 0.00037545717
87 O 0 0.000465376
. O 0 0.00016988665
1 O 0 0.0002736512
% O 0 0.00032598546
) O 0 0.00043112488
, O 0 0.0003445392
including O 0 0.00031311545
4 O 0 0.0003123042
complete O 0 0.00040693235
responses O 0 0.0011250597
( O 0 0.0010180377
11 O 0 0.0010152047
. O 0 0.0007520932
7 O 0 0.0013771541
% O 0 0.0024995152
) O 0 0.0046551875
. O 0 0.00462596

According O 0 0.005051227
to O 0 0.0026643581
intention O 0 0.008344635
- O 0 0.0027005738
to O 0 0.0012618342
- O 0 0.0016813651
treat O 0 0.0033484336
, O 0 0.0008650119
the O 0 0.0004390803
overall O 0 0.0004946412
response O 0 0.0006571856
rate O 0 0.00040589366
was O 0 0.00041231103
71 O 0 0.0009272401
. O 0 0.0002277037
4 O 0 0.00027399635
% O 0 0.00036774937
( O 0 0.000399539
95 O 0 0.0007285807
% O 0 0.0004665111
CI O 0 0.028825978
, O 0 0.0005535954
53 O 0 0.00082082645
. O 0 0.00036207782
7 O 0 0.0005526417
- O 0 0.0010277653
85 O 0 0.0012157154
. O 0 0.00078717043
4 O 0 0.0013968899
% O 0 0.0026390334
) O 0 0.004865521
. O 0 0.0048565418

After O 0 0.002493845
154 O 0 0.0052740816
courses O 0 0.0027669994
of O 0 0.0016609998
therapy O 0 0.01079947
, O 0 0.0011539641
the O 0 0.0005376918
median O 0 0.0004990853
dose O 0 0.0027808112
intensity O 0 0.00040734804
was O 0 0.0004664399
131 O 0 0.0029355101
mg O 0 0.39755842
/ O 0 0.001658958
m O 0 0.0025969513
( O 0 0.00052444986
2 O 0 0.0003117845
) O 0 0.00042952053
for O 0 0.00027503067
paclitaxel B-Chemical 1 0.9961498
( O 0 0.00065550045
97 O 0 0.00058570685
. O 0 0.00016505222
3 O 0 0.00020980687
% O 0 0.0002852736
) O 0 0.0003773281
, O 0 0.00031343143
117 O 0 0.0013756846
mg O 0 0.24769932
/ O 0 0.0011315667
m O 0 0.0019577062
( O 0 0.00042657857
2 O 0 0.00026808868
) O 0 0.00038691636
for O 0 0.00025805022
cisplatin B-Chemical 1 0.99816614
( O 0 0.0006565824
97 O 0 0.00058514497
. O 0 0.0001639586
3 O 0 0.00021255715
% O 0 0.00029424258
) O 0 0.00039553523
, O 0 0.00032574066
and O 0 0.00035615003
1378 O 0 0.04640177
mg O 0 0.35035282
/ O 0 0.0014669667
m O 0 0.0023043796
( O 0 0.0005894186
2 O 0 0.00041414765
) O 0 0.0006423771
for O 0 0.0005228048
gemcitabine B-Chemical 1 0.99443865
( O 0 0.0017089978
86 O 0 0.0019447412
. O 0 0.0008950048
2 O 0 0.0017352155
% O 0 0.0027899076
) O 0 0.0049684388
. O 0 0.0048387097

World O 0 0.009025875
Health O 0 0.005565814
Organization O 0 0.004378818
Grade O 0 0.18335886
3 O 0 0.0015279009
- O 0 0.0017577123
4 O 0 0.0009640588
neutropenia B-Disease 2 0.99632806
and O 0 0.0015953372
thrombocytopenia B-Disease 0 0.99908054
occurred O 0 0.0011666835
in O 0 0.00047365428
39 O 0 0.00080790534
. O 0 0.00026312162
9 O 0 0.0003539034
% O 0 0.00036948567
and O 0 0.00036011697
11 O 0 0.00048609966
. O 0 0.00030160186
4 O 0 0.0004470172
% O 0 0.00068082934
of O 0 0.0010721065
patients O 0 0.003771165
, O 0 0.003583892
respectively O 0 0.0073380563
. O 0 0.005391188

There O 0 0.012373204
was O 0 0.0072047007
one O 0 0.0062777093
treatment O 0 0.014141328
- O 0 0.01582405
related O 0 0.012477596
death B-Disease 2 0.9710652
. O 0 0.020286486

Nonhematologic O 0 0.9845449
toxicities B-Disease 2 0.98543555
were O 0 0.034060396
mild O 0 0.60928464
. O 0 0.032892607

After O 0 0.0023827609
a O 0 0.002137713
median O 0 0.0014156199
follow O 0 0.001292472
- O 0 0.0014435261
up O 0 0.0006751489
of O 0 0.00070347387
22 O 0 0.0007504012
months O 0 0.00048997626
, O 0 0.00044556975
the O 0 0.0002844103
median O 0 0.00036445993
progression O 0 0.05758184
free O 0 0.00084810785
survival O 0 0.017294731
rate O 0 0.0003903102
was O 0 0.00035466888
7 O 0 0.00027270525
months O 0 0.0003295342
, O 0 0.00038073256
and O 0 0.00034387337
the O 0 0.0003726638
median O 0 0.000583269
survival O 0 0.004408562
time O 0 0.00094888976
was O 0 0.0015742324
16 O 0 0.0024790082
months O 0 0.0036582001
. O 0 0.004557853

CONCLUSIONS O 0 0.6714223
: O 0 0.0047570015
The O 0 0.0016552954
combination O 0 0.0027514372
of O 0 0.0025221007
paclitaxel B-Chemical 1 0.99772483
, O 0 0.006321624
cisplatin B-Chemical 1 0.9989466
, O 0 0.0022486337
and O 0 0.0011441135
gemcitabine B-Chemical 1 0.9976948
is O 0 0.0007797424
well O 0 0.00049774844
tolerated O 0 0.008834285
and O 0 0.00064148934
shows O 0 0.00043358185
high O 0 0.0012800058
activity O 0 0.0020004173
in O 0 0.00261729
metastatic O 0 0.98387396
NSCLC B-Disease 2 0.99457175
. O 0 0.010270643

This O 0 0.0055690957
treatment O 0 0.0041964334
merits O 0 0.002500703
further O 0 0.0021095304
comparison O 0 0.0017049083
with O 0 0.0024953769
other O 0 0.00395241
cisplatin B-Chemical 1 0.9968483
- O 0 0.011222247
based O 0 0.0068585034
regimens O 0 0.09504725
. O 0 0.0097917

Serotonergic B-Chemical 0 0.98392093
antidepressants I-Chemical 1 0.9952187
and O 0 0.038277872
urinary B-Disease 0 0.95546675
incontinence I-Disease 2 0.9805228
. O 0 0.041116778

Many O 0 0.009330063
new O 0 0.008207255
serotonergic B-Chemical 0 0.99048984
antidepressants I-Chemical 1 0.9984824
have O 0 0.004942962
been O 0 0.0033961006
introduced O 0 0.00208913
over O 0 0.0018289568
the O 0 0.0032998302
past O 0 0.008355762
decade O 0 0.021707509
. O 0 0.010972911

Although O 0 0.004708009
urinary B-Disease 0 0.7070688
incontinence I-Disease 2 0.98578334
is O 0 0.0021333944
listed O 0 0.0007283862
as O 0 0.00061175413
one O 0 0.000503137
side O 0 0.0031374223
effect O 0 0.0006091592
of O 0 0.0006129085
these O 0 0.000825158
drugs O 0 0.47353405
in O 0 0.00045665883
their O 0 0.0005212136
package O 0 0.0012951202
inserts O 0 0.0009599522
there O 0 0.0003610873
is O 0 0.0005625812
only O 0 0.0006335817
one O 0 0.0007159263
report O 0 0.0028584334
in O 0 0.0015877102
the O 0 0.0026671775
literature O 0 0.008697318
. O 0 0.0061113155

This O 0 0.006365199
concerns O 0 0.0055893897
2 O 0 0.0026768502
male O 0 0.0043674842
patients O 0 0.004111247
who O 0 0.004372266
experienced O 0 0.005692613
incontinence B-Disease 2 0.9805479
while O 0 0.00564619
taking O 0 0.04877079
venlafaxine B-Chemical 0 0.99815613
. O 0 0.013596403

In O 0 0.002610695
the O 0 0.0016094506
present O 0 0.0010267877
paper O 0 0.0015285296
the O 0 0.0007492758
authors O 0 0.00086150947
describe O 0 0.00074553746
2 O 0 0.0005903384
female O 0 0.0012136705
patients O 0 0.0012498107
who O 0 0.0012585866
developed O 0 0.0014999305
incontinence B-Disease 2 0.989553
secondary O 0 0.0038458288
to O 0 0.00049249653
the O 0 0.0005188104
selective O 0 0.08862005
serotonin B-Chemical 1 0.99980265
reuptake O 0 0.99975675
inhibitors O 0 0.9752837
paroxetine B-Chemical 1 0.99996614
and O 0 0.009195384
sertraline B-Chemical 0 0.99993706
, O 0 0.0010148577
as O 0 0.0002627338
well O 0 0.00023459391
as O 0 0.00023465163
a O 0 0.00036190197
third O 0 0.00045594736
who O 0 0.001029817
developed O 0 0.0010226803
this O 0 0.0008579604
side O 0 0.012370098
effect O 0 0.0023677093
on O 0 0.002842472
venlafaxine B-Chemical 0 0.9986852
. O 0 0.008414959

In O 0 0.003015338
2 O 0 0.0018775157
of O 0 0.0015093869
the O 0 0.0010337427
3 O 0 0.0007306938
cases O 0 0.0009851829
the O 0 0.0005444519
patients O 0 0.0012779752
were O 0 0.0004956573
also O 0 0.00057740207
taking O 0 0.0030860926
lithium B-Chemical 1 0.99937195
carbonate I-Chemical 0 0.99817574
and O 0 0.0025153055
beta O 0 0.82673687
- O 0 0.008196821
blockers O 0 0.99758744
, O 0 0.0011018314
both O 0 0.00046273303
of O 0 0.00065919576
which O 0 0.0008165894
could O 0 0.00052657037
have O 0 0.0009136799
contributed O 0 0.0026947751
to O 0 0.0019302573
the O 0 0.0037226882
incontinence B-Disease 2 0.9871787
. O 0 0.00855416

Animal O 0 0.012720541
studies O 0 0.003488791
suggest O 0 0.0016564345
that O 0 0.0017498086
incontinence B-Disease 2 0.9708651
secondary O 0 0.006584704
to O 0 0.0018590781
serotonergic B-Chemical 0 0.9974456
antidepressants I-Chemical 1 0.9996513
could O 0 0.001031882
be O 0 0.000809061
mediated O 0 0.0006691996
by O 0 0.00083474134
the O 0 0.0011817646
5HT4 O 0 0.9961046
receptors O 0 0.25769556
found O 0 0.0018304556
on O 0 0.0014502323
the O 0 0.0036099243
bladder O 0 0.83380055
. O 0 0.008481793

Further O 0 0.0043641077
research O 0 0.0031529597
is O 0 0.0014921068
needed O 0 0.00080268306
to O 0 0.0007616175
delineate O 0 0.00066741183
the O 0 0.0005571176
frequency O 0 0.0006802142
of O 0 0.0007658683
this O 0 0.000711865
troubling O 0 0.010569551
side O 0 0.009791945
effect O 0 0.000996718
and O 0 0.00091624295
how O 0 0.00078675157
best O 0 0.0014381852
to O 0 0.0019173002
treat O 0 0.012156844
it O 0 0.0062533193
. O 0 0.0063132606

Acute O 0 0.9857721
cocaine B-Chemical 1 0.9981267
- O 0 0.016469706
induced O 0 0.008965553
seizures B-Disease 2 0.9992507
: O 0 0.0046949997
differential O 0 0.0033339362
sensitivity O 0 0.0034612122
of O 0 0.0021563617
six O 0 0.0016669196
inbred O 0 0.004602124
mouse O 0 0.005661468
strains O 0 0.00768605
. O 0 0.008160856

Mature O 0 0.030662725
male O 0 0.0064203623
and O 0 0.0022048107
female O 0 0.0027322033
mice O 0 0.00070764194
from O 0 0.0006347867
six O 0 0.0004149491
inbred O 0 0.0009853677
stains O 0 0.0022807014
were O 0 0.00049396313
tested O 0 0.00036786948
for O 0 0.0004167554
susceptibility O 0 0.0021923506
to O 0 0.00069108064
behavioral O 0 0.16810991
seizures B-Disease 2 0.99970645
induced O 0 0.0021585587
by O 0 0.0010342124
a O 0 0.0011729214
single O 0 0.0015283595
injection O 0 0.007874159
of O 0 0.0070885075
cocaine B-Chemical 1 0.997577
. O 0 0.008896186

Cocaine B-Chemical 0 0.9980399
was O 0 0.0042332155
injected O 0 0.0023654103
ip O 0 0.2682807
over O 0 0.00068510533
a O 0 0.00083414547
range O 0 0.0009556773
of O 0 0.0008834606
doses O 0 0.043184567
( O 0 0.0010987358
50 O 0 0.00092926103
- O 0 0.00079000794
100 O 0 0.0009703041
mg O 0 0.21063197
/ O 0 0.0012535313
kg O 0 0.0039801844
) O 0 0.0007607439
and O 0 0.0005273105
behavior O 0 0.0012237459
was O 0 0.0006526731
monitored O 0 0.000605059
for O 0 0.0010739905
20 O 0 0.0023388937
minutes O 0 0.003195708
. O 0 0.0044562547

Seizure B-Disease 2 0.9866607
end O 0 0.002204385
points O 0 0.0021907443
included O 0 0.001267522
latency O 0 0.0030821816
to O 0 0.0010335733
forelimb O 0 0.09899219
or O 0 0.00093883404
hindlimb O 0 0.4051888
clonus O 0 0.99752694
, O 0 0.0013736848
latency O 0 0.0038594748
to O 0 0.00089570484
clonic O 0 0.99907553
running O 0 0.025025358
seizure B-Disease 2 0.9985262
and O 0 0.0019871811
latency O 0 0.008951587
to O 0 0.0021892115
jumping O 0 0.22017193
bouncing O 0 0.40728435
seizure B-Disease 2 0.9965564
. O 0 0.010833952

A O 0 0.01273426
range O 0 0.0033603865
of O 0 0.0020738188
strain O 0 0.0012851469
specific O 0 0.0010477015
sensitivities O 0 0.0018991025
was O 0 0.000922167
documented O 0 0.0014171711
with O 0 0.0012464854
A O 0 0.028691642
/ O 0 0.003875218
J O 0 0.4394855
and O 0 0.000945247
SJL O 0 0.08805298
mice O 0 0.00044139745
being O 0 0.00087219506
most O 0 0.0011239627
sensitive O 0 0.0011165272
and O 0 0.0015808181
C57BL O 0 0.732752
/ O 0 0.0072203763
6J O 0 0.060864665
most O 0 0.0052903066
resistant O 0 0.00915087
. O 0 0.006585683

DBA O 0 0.9029564
/ O 0 0.020523421
2J O 0 0.5719484
, O 0 0.006029786
BALB O 0 0.13298365
/ O 0 0.0056107654
cByJ O 0 0.007900647
and O 0 0.0025276283
NZW O 0 0.10589085
/ O 0 0.0050947787
LacJ O 0 0.018417846
strains O 0 0.002709545
exhibited O 0 0.0032001964
intermediate O 0 0.008619475
sensitivity O 0 0.014999395
. O 0 0.009021489

EEG O 0 0.7132819
recordings O 0 0.00988077
were O 0 0.0024027214
made O 0 0.0019600147
in O 0 0.0016483777
SJL O 0 0.15005478
, O 0 0.0025802134
A O 0 0.02229211
/ O 0 0.0043639815
J O 0 0.47738388
and O 0 0.0014707308
C57BL O 0 0.7367384
/ O 0 0.002871011
6J O 0 0.017177096
mice O 0 0.0003674695
revealing O 0 0.00089437823
a O 0 0.0006276422
close O 0 0.00054774
correspondence O 0 0.0014664988
between O 0 0.0007463546
electrical O 0 0.17575394
activity O 0 0.0031040218
and O 0 0.0036324542
behavior O 0 0.011154833
. O 0 0.006346519

Additionally O 0 0.0052597597
, O 0 0.0032398521
levels O 0 0.0017130182
of O 0 0.0022761228
cocaine B-Chemical 1 0.99827313
determined O 0 0.0012882812
in O 0 0.0011215488
hippocampus O 0 0.35471055
and O 0 0.0010998939
cortex O 0 0.10571198
were O 0 0.0005608596
not O 0 0.00047557591
different O 0 0.000606277
between O 0 0.00054715585
sensitive O 0 0.001360078
and O 0 0.0019338505
resistant O 0 0.005017211
strains O 0 0.0060045174
. O 0 0.006326553

Additional O 0 0.0023819536
studies O 0 0.002401459
of O 0 0.0017505649
these O 0 0.0017950697
murine O 0 0.004755004
strains O 0 0.0013497266
may O 0 0.00084609794
be O 0 0.0006807888
useful O 0 0.0007221963
for O 0 0.0004624548
investigating O 0 0.0007097299
genetic O 0 0.0018187488
influences O 0 0.0014679674
on O 0 0.0015677252
cocaine B-Chemical 1 0.99883395
- O 0 0.019596526
induced O 0 0.029304888
seizures B-Disease 2 0.99896324
. O 0 0.010902296

Hypotension B-Disease 2 0.9933356
following O 0 0.0030752849
the O 0 0.0017512703
initiation O 0 0.0018240138
of O 0 0.0020881135
tizanidine B-Chemical 0 0.9996661
in O 0 0.0012393158
a O 0 0.00097082986
patient O 0 0.0013061352
treated O 0 0.0013572933
with O 0 0.0011065134
an O 0 0.0022405474
angiotensin B-Chemical 1 0.99926597
converting O 0 0.62708783
enzyme O 0 0.5383506
inhibitor O 0 0.47429737
for O 0 0.005417521
chronic O 0 0.99407
hypertension B-Disease 2 0.99904233
. O 0 0.01563041

Centrally O 0 0.92256624
acting O 0 0.022930343
alpha O 0 0.3797733
- O 0 0.0046562767
2 O 0 0.0017777862
adrenergic O 0 0.99278295
agonists O 0 0.91571754
are O 0 0.0007587901
one O 0 0.00033983996
of O 0 0.00047193127
several O 0 0.0004884935
pharmacologic O 0 0.23301004
agents O 0 0.139367
used O 0 0.00042896956
in O 0 0.0003035531
the O 0 0.00032258037
treatment O 0 0.001024954
of O 0 0.0010939342
spasticity B-Disease 0 0.9991394
related O 0 0.0006693622
to O 0 0.00080655277
disorders B-Disease 0 0.4388814
of I-Disease 0 0.0016130437
the I-Disease 0 0.0017723374
central I-Disease 0 0.00996316
nervous I-Disease 0 0.8499123
system I-Disease 0 0.009766503
. O 0 0.006587777

In O 0 0.0032070638
addition O 0 0.0017903262
to O 0 0.0016736207
their O 0 0.0016319498
effects O 0 0.0023906173
on O 0 0.0012486415
spasticity B-Disease 0 0.9981431
, O 0 0.0025493866
certain O 0 0.0031539088
adverse O 0 0.7688972
cardiorespiratory O 0 0.7506634
effects O 0 0.0046605086
have O 0 0.0028927152
been O 0 0.0047374633
reported O 0 0.007878935
. O 0 0.0069694854

Adults O 0 0.023795087
chronically O 0 0.030821126
treated O 0 0.0043709422
with O 0 0.0033768401
angiotensin B-Chemical 1 0.9989047
converting O 0 0.5932806
enzyme O 0 0.41643146
inhibitors O 0 0.19063543
may O 0 0.00085910887
have O 0 0.00059023994
a O 0 0.0005226307
limited O 0 0.00044432931
ability O 0 0.00044502894
to O 0 0.0003964034
respond O 0 0.00062688714
to O 0 0.00075083895
hypotension B-Disease 2 0.9992317
when O 0 0.00065566757
the O 0 0.0010043809
sympathetic O 0 0.7525048
response O 0 0.0026018186
is O 0 0.0020308278
simultaneously O 0 0.0034918578
blocked O 0 0.009503436
. O 0 0.0065507023

The O 0 0.0026609546
authors O 0 0.002408065
present O 0 0.0012915755
a O 0 0.0014709543
10 O 0 0.0012419157
- O 0 0.0012723004
year O 0 0.0008042906
- O 0 0.00096973893
old O 0 0.0006406628
boy O 0 0.0025884665
chronically O 0 0.022764824
treated O 0 0.0014630284
with O 0 0.0016426842
lisinopril B-Chemical 0 0.99989164
, O 0 0.002827789
an O 0 0.0020858957
angiotensin B-Chemical 1 0.9996799
converting O 0 0.6033402
enzyme O 0 0.5232133
inhibitor O 0 0.3750624
, O 0 0.00082827045
to O 0 0.00032524165
control O 0 0.00042723806
hypertension B-Disease 2 0.99959344
who O 0 0.007090487
developed O 0 0.0039996095
hypotension B-Disease 2 0.9997074
following O 0 0.0004930877
the O 0 0.00027063832
addition O 0 0.00021157366
of O 0 0.0008451053
tizanidine B-Chemical 0 0.9999025
, O 0 0.0014652676
an O 0 0.0010393031
alpha O 0 0.25559053
- O 0 0.0016874414
2 O 0 0.00069599185
agonist O 0 0.7408019
, O 0 0.000890158
for O 0 0.0005939973
the O 0 0.0010032477
treatment O 0 0.0040089353
of O 0 0.0072822906
spasticity B-Disease 0 0.99778086
. O 0 0.008846697

The O 0 0.0027467597
possible O 0 0.0023653372
interaction O 0 0.0020431955
of O 0 0.0023633174
tizanidine B-Chemical 0 0.99959797
and O 0 0.0020111497
other O 0 0.0012467928
antihypertensive O 0 0.993769
agents O 0 0.23681782
should O 0 0.00037010104
be O 0 0.0003593243
kept O 0 0.00026940825
in O 0 0.00027315022
mind O 0 0.00075949647
when O 0 0.00027030308
prescribing O 0 0.009874763
therapy O 0 0.007806561
to O 0 0.00050587277
treat O 0 0.0056267395
either O 0 0.0013106726
hypertension B-Disease 2 0.9993734
or O 0 0.0026772318
spasticity B-Disease 0 0.9987828
in O 0 0.0022806504
such O 0 0.0034015598
patients O 0 0.015250813
. O 0 0.006034048

Two O 0 0.0042260094
mouse O 0 0.0030036003
lines O 0 0.0034421922
selected O 0 0.0011236746
for O 0 0.00085612497
differential O 0 0.0017192863
sensitivities O 0 0.0021856823
to O 0 0.0011371549
beta B-Chemical 0 0.9099505
- I-Chemical 0 0.012736312
carboline I-Chemical 0 0.99844104
- O 0 0.004358567
induced O 0 0.00244982
seizures B-Disease 2 0.9998084
are O 0 0.0006025665
also O 0 0.00039065434
differentially O 0 0.0004736091
sensitive O 0 0.00036703455
to O 0 0.00027848195
various O 0 0.0006904618
pharmacological O 0 0.21633492
effects O 0 0.0018341518
of O 0 0.0012937665
other O 0 0.0028343794
GABA B-Chemical 1 0.99957114
( O 0 0.0069368873
A O 0 0.06674685
) O 0 0.005903833
receptor O 0 0.22361352
ligands O 0 0.29062098
. O 0 0.00831839

Two O 0 0.004396421
mouse O 0 0.0032477472
lines O 0 0.0041288044
were O 0 0.0013662387
selectively O 0 0.0020612807
bred O 0 0.0018102343
according O 0 0.0006753938
to O 0 0.00052827795
their O 0 0.00061888824
sensitivity O 0 0.002119119
( O 0 0.0011458566
BS O 0 0.6904347
line O 0 0.001656078
) O 0 0.0009474304
or O 0 0.0003781628
resistance O 0 0.010609624
( O 0 0.0008999105
BR O 0 0.32769248
line O 0 0.0013438597
) O 0 0.0008776184
to O 0 0.00046681002
seizures B-Disease 2 0.9997743
induced O 0 0.001090165
by O 0 0.00038754876
a O 0 0.00034325419
single O 0 0.00032729807
i O 0 0.0010918322
. O 0 0.00017979743
p O 0 0.00037155472
. O 0 0.00015520879
injection O 0 0.0009121908
of O 0 0.00068782683
methyl B-Chemical 0 0.9818148
beta I-Chemical 0 0.969114
- I-Chemical 0 0.016253306
carboline I-Chemical 0 0.9989222
- I-Chemical 0 0.003279563
3 I-Chemical 0 0.00045558793
- I-Chemical 0 0.0011316043
carboxylate I-Chemical 0 0.94080806
( O 0 0.0016589217
beta B-Chemical 0 0.8567808
- I-Chemical 0 0.0041240393
CCM I-Chemical 0 0.9465504
) O 0 0.0014932681
, O 0 0.0005491337
an O 0 0.0005164426
inverse O 0 0.00091849105
agonist O 0 0.8513563
of O 0 0.0013558632
the O 0 0.0018408509
GABA B-Chemical 1 0.99961495
( O 0 0.005564569
A O 0 0.065655485
) O 0 0.0055540926
receptor O 0 0.53336936
benzodiazepine B-Chemical 1 0.9990245
site O 0 0.010050366
. O 0 0.007690405

Our O 0 0.0033415982
aim O 0 0.0023746677
was O 0 0.001377402
to O 0 0.000986698
characterize O 0 0.00070435856
both O 0 0.0007707737
lines O 0 0.0022519566
' O 0 0.00081048
sensitivities O 0 0.001060007
to O 0 0.00046779355
various O 0 0.0008515805
physiological O 0 0.0022362054
effects O 0 0.0010938456
of O 0 0.00077181496
other O 0 0.000826794
ligands O 0 0.043247286
of O 0 0.0019097942
the O 0 0.0028587163
GABA B-Chemical 1 0.9993544
( O 0 0.008651119
A O 0 0.0739892
) O 0 0.008371978
receptor O 0 0.20529372
. O 0 0.008198954

We O 0 0.003800049
measured O 0 0.0029589888
diazepam B-Chemical 1 0.9993185
- O 0 0.0071348534
induced O 0 0.003172146
anxiolysis O 0 0.9973991
with O 0 0.0014558141
the O 0 0.00070615823
elevated O 0 0.0049138293
plus O 0 0.0007835123
- O 0 0.0012037744
maze O 0 0.04730766
test O 0 0.00072759954
, O 0 0.00132044
diazepam B-Chemical 1 0.99988854
- O 0 0.002233342
induced O 0 0.0007761887
sedation O 0 0.51326585
by O 0 0.0003205955
recording O 0 0.00063868146
the O 0 0.00028658725
vigilance O 0 0.05839735
states O 0 0.0011673911
, O 0 0.0006799287
and O 0 0.0009327773
picrotoxin B-Chemical 0 0.9999143
- O 0 0.0058808452
and O 0 0.0019041706
pentylenetetrazol B-Chemical 0 0.99994683
- O 0 0.007411737
induced O 0 0.004062792
seizures B-Disease 2 0.99969673
after O 0 0.000777389
i O 0 0.0032978817
. O 0 0.0008936661
p O 0 0.0021511845
. O 0 0.0016390511
injections O 0 0.012457224
. O 0 0.0050852573

Results O 0 0.004219181
presented O 0 0.0023549024
here O 0 0.0012782272
show O 0 0.0009123651
that O 0 0.0007237652
the O 0 0.0006880931
differential O 0 0.001346222
sensitivities O 0 0.0015966112
of O 0 0.0012024323
BS O 0 0.83412117
and O 0 0.0011321715
BR O 0 0.5089706
lines O 0 0.009003254
to O 0 0.00078675075
beta B-Chemical 0 0.89471817
- I-Chemical 0 0.004219992
CCM I-Chemical 0 0.89399517
can O 0 0.0004144919
be O 0 0.00036076765
extended O 0 0.00033982133
to O 0 0.0005337631
diazepam B-Chemical 1 0.9999068
, O 0 0.008698127
picrotoxin B-Chemical 0 0.9999354
, O 0 0.0020366083
and O 0 0.0011448462
pentylenetetrazol B-Chemical 0 0.99995184
, O 0 0.0009209833
suggesting O 0 0.00025734262
a O 0 0.0002753114
genetic O 0 0.00057464436
selection O 0 0.00030486664
of O 0 0.0003224826
a O 0 0.00030373113
general O 0 0.00030254218
sensitivity O 0 0.00087866886
and O 0 0.00039267278
resistance O 0 0.0026253536
to O 0 0.00037050826
several O 0 0.0005834528
ligands O 0 0.022552686
of O 0 0.0014136947
the O 0 0.0022691123
GABA B-Chemical 1 0.99937683
( O 0 0.0073143467
A O 0 0.06824928
) O 0 0.007730536
receptor O 0 0.19909918
. O 0 0.0076993103

Propylthiouracil B-Chemical 0 0.9962314
- O 0 0.01032343
induced O 0 0.004181068
perinuclear O 0 0.0098963445
- O 0 0.0032123209
staining O 0 0.0023345826
antineutrophil O 0 0.89189965
cytoplasmic O 0 0.0099393185
autoantibody O 0 0.8931008
- O 0 0.0051726806
positive O 0 0.002553017
vasculitis B-Disease 2 0.9983322
in O 0 0.0029747635
conjunction O 0 0.0062959134
with O 0 0.010244917
pericarditis B-Disease 0 0.9952991
. O 0 0.01144188

OBJECTIVE O 0 0.4671452
: O 0 0.0050638574
To O 0 0.0018180808
describe O 0 0.0018783655
a O 0 0.0018710528
case O 0 0.001881517
of O 0 0.0035197153
propylthiouracil B-Chemical 0 0.99913365
- O 0 0.027169533
induced O 0 0.02207103
vasculitis B-Disease 2 0.9990533
manifesting O 0 0.9654568
with O 0 0.054775715
pericarditis B-Disease 0 0.9965178
. O 0 0.013835755

METHODS O 0 0.0058297375
: O 0 0.0027872145
We O 0 0.0011242455
present O 0 0.0006991592
the O 0 0.0006618718
first O 0 0.0005048853
case O 0 0.0005958198
report O 0 0.001297691
of O 0 0.00069438986
a O 0 0.00073303713
woman O 0 0.020770779
with O 0 0.0013861094
hyperthyroidism B-Disease 0 0.99963164
treated O 0 0.0066871787
with O 0 0.0019998148
propylthiouracil B-Chemical 0 0.9996754
in O 0 0.00093037635
whom O 0 0.0060524396
a O 0 0.001080875
syndrome O 0 0.84659195
of O 0 0.004007879
pericarditis B-Disease 0 0.9990872
, O 0 0.021823712
fever B-Disease 0 0.99871254
, O 0 0.0060126283
and O 0 0.0064903414
glomerulonephritis B-Disease 2 0.99922717
developed O 0 0.06301646
. O 0 0.008407828

Serologic O 0 0.22678137
testing O 0 0.003929892
and O 0 0.0030525255
immunologic O 0 0.035734046
studies O 0 0.0027484295
were O 0 0.0015613411
done O 0 0.0012770169
, O 0 0.0017614982
and O 0 0.001565098
a O 0 0.0022013811
pericardial O 0 0.08096612
biopsy O 0 0.011648535
was O 0 0.0039564045
performed O 0 0.0053331084
. O 0 0.0075774277

RESULTS O 0 0.035505857
: O 0 0.00589688
A O 0 0.00880466
25 O 0 0.0029331467
- O 0 0.0020316916
year O 0 0.0011560263
- O 0 0.0012754628
old O 0 0.0008308929
woman O 0 0.0037611553
with O 0 0.0009901479
Graves B-Disease 2 0.9535736
' I-Disease 2 0.0012764278
disease I-Disease 2 0.71643627
had O 0 0.0009030504
a O 0 0.0012015341
febrile B-Disease 0 0.9983871
illness I-Disease 0 0.99274933
and O 0 0.0009162076
evidence O 0 0.0008645983
of O 0 0.0017547698
pericarditis B-Disease 0 0.9983199
, O 0 0.0020438225
which O 0 0.0015467317
was O 0 0.0012888758
confirmed O 0 0.0019451447
by O 0 0.0032535042
biopsy O 0 0.025405947
. O 0 0.0065324414

Serologic O 0 0.26819825
evaluation O 0 0.003960056
revealed O 0 0.002183077
the O 0 0.0014586978
presence O 0 0.0012752028
of O 0 0.0016439902
perinuclear O 0 0.0071549593
- O 0 0.0022484486
staining O 0 0.0017418151
antineutrophil O 0 0.9122682
cytoplasmic O 0 0.009241823
autoantibodies O 0 0.6756755
( O 0 0.004588927
pANCA O 0 0.2706874
) O 0 0.00420882
against O 0 0.0031254992
myeloperoxidase O 0 0.9913946
( O 0 0.019274112
MPO O 0 0.9789665
) O 0 0.017359715
. O 0 0.008495446

Propylthiouracil B-Chemical 0 0.9947784
therapy O 0 0.06681485
was O 0 0.0025252504
withdrawn O 0 0.006783806
, O 0 0.0015246163
and O 0 0.0008528068
she O 0 0.0007887637
was O 0 0.00061322056
treated O 0 0.0009337887
with O 0 0.0006847193
a O 0 0.0006879206
1 O 0 0.00058480375
- O 0 0.0006392061
month O 0 0.00039405687
course O 0 0.00078490906
of O 0 0.0013428316
prednisone B-Chemical 1 0.9988876
, O 0 0.0026976548
which O 0 0.0026944804
alleviated O 0 0.11848047
her O 0 0.0111854635
symptoms O 0 0.6832633
. O 0 0.0074047376

A O 0 0.013964374
literature O 0 0.0044367
review O 0 0.0035606711
revealed O 0 0.0014554814
no O 0 0.00083622494
prior O 0 0.00064756826
reports O 0 0.0013760724
of O 0 0.0017670996
pericarditis B-Disease 0 0.99785477
in O 0 0.0014056829
anti O 0 0.029984646
- O 0 0.006631047
MPO O 0 0.98838145
pANCA O 0 0.5516663
- O 0 0.0028541717
positive O 0 0.0013867412
vasculitis B-Disease 2 0.99893814
associated O 0 0.0041910266
with O 0 0.0038003507
propylthio B-Chemical 0 0.8374637
- I-Chemical 0 0.010538788
uracil I-Chemical 0 0.79448205
therapy O 0 0.19525836
. O 0 0.00785583

CONCLUSION O 0 0.9278829
: O 0 0.011401842
Pericarditis B-Disease 0 0.99307173
may O 0 0.0023218067
be O 0 0.0013418468
the O 0 0.00085349526
initial O 0 0.001028937
manifestation O 0 0.05917788
of O 0 0.0016129813
drug O 0 0.6928875
- O 0 0.004013357
induced O 0 0.003975284
vasculitis B-Disease 2 0.9991322
attributable O 0 0.0020317074
to O 0 0.0021147435
propylthio B-Chemical 0 0.7675615
- I-Chemical 0 0.009044146
uracil I-Chemical 0 0.7795367
therapy O 0 0.18875892
. O 0 0.0078077875

Repeated O 0 0.044904917
transient O 0 0.14450544
anuria B-Disease 2 0.9957111
following O 0 0.006104082
losartan B-Chemical 1 0.99918514
administration O 0 0.4841414
in O 0 0.0017940557
a O 0 0.0018875828
patient O 0 0.0028146394
with O 0 0.0027852694
a O 0 0.004417799
solitary O 0 0.14144926
kidney O 0 0.8692921
. O 0 0.010783901

We O 0 0.00316056
report O 0 0.0040145977
the O 0 0.0015652627
case O 0 0.0013163772
of O 0 0.0012650688
a O 0 0.0011022247
70 O 0 0.0011551287
- O 0 0.0011528691
year O 0 0.0007537822
- O 0 0.0010213028
old O 0 0.0008667082
hypertensive B-Disease 2 0.9974595
man O 0 0.16948704
with O 0 0.0006822616
a O 0 0.000620871
solitary O 0 0.034996133
kidney O 0 0.76000065
and O 0 0.0010035143
chronic B-Disease 0 0.9923419
renal I-Disease 0 0.99860376
insufficiency I-Disease 0 0.9994025
who O 0 0.01132378
developed O 0 0.0012721834
two O 0 0.00045995743
episodes O 0 0.08468886
of O 0 0.0015027297
transient O 0 0.31752092
anuria B-Disease 2 0.99861586
after O 0 0.0035502343
losartan B-Chemical 1 0.9993236
administration O 0 0.8360106
. O 0 0.008383704

He O 0 0.009625913
was O 0 0.0034429152
hospitalized O 0 0.03522429
for O 0 0.0018631286
a O 0 0.002919298
myocardial B-Disease 0 0.9979267
infarction I-Disease 2 0.9997539
with O 0 0.016530076
pulmonary B-Disease 0 0.99210256
edema I-Disease 0 0.99943334
, O 0 0.0037860724
treated O 0 0.0025776997
with O 0 0.0017987449
high O 0 0.0032050342
- O 0 0.006040051
dose O 0 0.19768646
diuretics O 0 0.9976737
. O 0 0.0112864245

Due O 0 0.009743781
to O 0 0.007312027
severe O 0 0.24429116
systolic B-Disease 0 0.9856765
dysfunction I-Disease 0 0.9945515
losartan B-Chemical 1 0.9987469
was O 0 0.02051665
prescribed O 0 0.3420773
. O 0 0.01515986

Surprisingly O 0 0.0040894253
, O 0 0.002653521
the O 0 0.0012860671
first O 0 0.000915769
dose O 0 0.0046479814
of O 0 0.0010946003
50 O 0 0.0013622234
mg O 0 0.32574496
of O 0 0.0013467842
losartan B-Chemical 1 0.99964416
resulted O 0 0.0009056986
in O 0 0.00052190357
a O 0 0.00082516705
sudden O 0 0.987097
anuria B-Disease 2 0.9993218
, O 0 0.0009395208
which O 0 0.00045858664
lasted O 0 0.00032793736
eight O 0 0.00022932776
hours O 0 0.00029684298
despite O 0 0.0003750669
high O 0 0.00092858647
- O 0 0.0018555808
dose O 0 0.09137254
furosemide B-Chemical 1 0.9995536
and O 0 0.009196562
amine B-Chemical 0 0.99235326
infusion O 0 0.50558484
. O 0 0.0077272966

One O 0 0.004376528
week O 0 0.0020892941
later O 0 0.0017326007
, O 0 0.0017866766
by O 0 0.0012727635
mistake O 0 0.010945398
, O 0 0.0018692333
losartan B-Chemical 1 0.99944
was O 0 0.0010601403
prescribed O 0 0.029280202
again O 0 0.00048849045
and O 0 0.00032748032
after O 0 0.00016184166
the O 0 0.00021217424
second O 0 0.000241608
dose O 0 0.0026928703
of O 0 0.00041505633
50 O 0 0.00066789857
mg O 0 0.23087978
, O 0 0.00038745845
the O 0 0.00023498185
patient O 0 0.0004901075
developed O 0 0.00058112765
a O 0 0.00040106615
second O 0 0.0004075327
episode O 0 0.0032524047
of O 0 0.0011896894
transient O 0 0.20071447
anuria B-Disease 2 0.99800354
lasting O 0 0.01971818
10 O 0 0.003017021
hours O 0 0.0035029906
. O 0 0.004496006

During O 0 0.003103039
these O 0 0.0030930424
two O 0 0.0019955793
episodes O 0 0.04792224
, O 0 0.0024568639
his O 0 0.002572661
blood O 0 0.0068191085
pressure O 0 0.036711752
diminished O 0 0.0027751613
but O 0 0.0016360756
no O 0 0.001861977
severe O 0 0.56845486
hypotension B-Disease 2 0.99903464
was O 0 0.006765632
noted O 0 0.0069822758
. O 0 0.0072566294

Ultimately O 0 0.014973704
, O 0 0.0055116205
an O 0 0.0041542505
arteriography O 0 0.14109111
showed O 0 0.0024814312
a O 0 0.0025324465
70 O 0 0.0028812233
- O 0 0.003501882
80 O 0 0.003757455
% O 0 0.004849426
renal B-Disease 0 0.9828448
artery I-Disease 0 0.8949482
stenosis I-Disease 0 0.99174434
. O 0 0.014344087

In O 0 0.0030676196
this O 0 0.0022035115
patient O 0 0.003119116
, O 0 0.0029389313
renal B-Disease 0 0.99039876
artery I-Disease 0 0.80493665
stenosis I-Disease 0 0.99653864
combined O 0 0.0029112617
with O 0 0.0012877182
heart B-Disease 0 0.57601523
failure I-Disease 0 0.64525354
and O 0 0.0010756453
diuretic O 0 0.99956733
therapy O 0 0.093492985
certainly O 0 0.00095179444
resulted O 0 0.00040857095
in O 0 0.00032543737
a O 0 0.00041444608
strong O 0 0.00059199776
activation O 0 0.0012731999
of O 0 0.00081952516
the O 0 0.0010919321
renin O 0 0.9954882
- O 0 0.016649216
angiotensin B-Chemical 1 0.9990299
system O 0 0.014538331
( O 0 0.007847527
RAS O 0 0.9356277
) O 0 0.012986915
. O 0 0.0071681207

Under O 0 0.008682628
such O 0 0.0032781123
conditions O 0 0.0038941682
, O 0 0.004809873
angiotensin B-Chemical 1 0.9991725
II I-Chemical 1 0.5795953
receptor O 0 0.51038074
blockade O 0 0.6439625
by O 0 0.0030280293
losartan B-Chemical 1 0.9996427
probably O 0 0.004861524
induced O 0 0.0015881079
a O 0 0.0010953868
critical O 0 0.0011696278
fall O 0 0.0039377664
in O 0 0.0019378121
glomerular O 0 0.86098486
filtration O 0 0.12039919
pressure O 0 0.2962567
. O 0 0.007960534

This O 0 0.004301365
case O 0 0.0022091442
report O 0 0.002984798
highlights O 0 0.0013595639
the O 0 0.0008876526
fact O 0 0.00071511656
that O 0 0.0007053148
the O 0 0.0011478667
angiotensin B-Chemical 1 0.99967253
II I-Chemical 1 0.7438993
receptor O 0 0.799306
antagonist O 0 0.9977696
losartan B-Chemical 1 0.9998833
can O 0 0.0011089351
cause O 0 0.0068234825
serious O 0 0.15534744
unexpected O 0 0.0028644498
complications O 0 0.5628238
in O 0 0.00039661417
patients O 0 0.0024718351
with O 0 0.0010592642
renovascular B-Disease 0 0.9998276
disease I-Disease 0 0.989419
and O 0 0.0008111847
should O 0 0.00029914852
be O 0 0.0003938862
used O 0 0.00036556297
with O 0 0.0006414295
extreme O 0 0.0017570965
caution O 0 0.0018193275
in O 0 0.0013472453
this O 0 0.0022623546
setting O 0 0.005159642
. O 0 0.005625251

Calcineurin O 0 0.98127145
- O 0 0.011543395
inhibitor O 0 0.15776144
induced O 0 0.008091602
pain B-Disease 0 0.9933171
syndrome O 0 0.98600566
( O 0 0.0123292925
CIPS B-Disease 0 0.9952602
) O 0 0.004062576
: O 0 0.0019814868
a O 0 0.001544302
severe O 0 0.18498524
disabling O 0 0.94924134
complication O 0 0.56520796
after O 0 0.002507508
organ O 0 0.17707664
transplantation O 0 0.4937825
. O 0 0.008142308

Bone O 0 0.17399324
pain B-Disease 0 0.8212676
after O 0 0.0022633162
transplantation O 0 0.046997126
is O 0 0.001677275
a O 0 0.001525721
frequent O 0 0.0038424397
complication O 0 0.14436209
that O 0 0.0012087178
can O 0 0.0012325147
be O 0 0.0015606337
caused O 0 0.002211763
by O 0 0.002882876
several O 0 0.005573581
diseases O 0 0.73441386
. O 0 0.009829178

Treatment O 0 0.026876338
strategies O 0 0.0056627723
depend O 0 0.0035922572
on O 0 0.0021494546
the O 0 0.0026877166
correct O 0 0.003653252
diagnosis O 0 0.011906861
of O 0 0.006785476
the O 0 0.009326458
pain B-Disease 0 0.9702562
. O 0 0.01496119

Nine O 0 0.009663004
patients O 0 0.005845625
with O 0 0.0031923268
severe O 0 0.18807274
pain B-Disease 0 0.9569943
in O 0 0.0014417361
their O 0 0.0013531669
feet O 0 0.019932231
, O 0 0.001362444
which O 0 0.0011328403
was O 0 0.00085881096
registered O 0 0.0012441716
after O 0 0.00089385087
transplantation O 0 0.06542066
, O 0 0.0029315727
were O 0 0.0027724905
investigated O 0 0.0046119667
. O 0 0.006442127

Bone O 0 0.053953186
scans O 0 0.009042933
showed O 0 0.0035159744
an O 0 0.0036425483
increased O 0 0.004322065
tracer O 0 0.025860338
uptake O 0 0.0145325065
of O 0 0.004989755
the O 0 0.005632884
foot O 0 0.13173597
bones O 0 0.11558034
. O 0 0.012264475

Magnetic O 0 0.7511743
resonance O 0 0.3298041
imaging O 0 0.017240353
demonstrated O 0 0.006358197
bone B-Disease 0 0.102745585
marrow I-Disease 0 0.71120274
oedema I-Disease 0 0.9960083
in O 0 0.0062640794
the O 0 0.0073799584
painful O 0 0.94940215
bones O 0 0.19938838
. O 0 0.013348389

Pain B-Disease 2 0.88994205
was O 0 0.0030253774
not O 0 0.0015872522
explained O 0 0.0012312351
by O 0 0.0010865885
other O 0 0.0011752269
diseases O 0 0.49013954
causing O 0 0.01672671
foot O 0 0.28852078
pain B-Disease 0 0.99011946
, O 0 0.0014640172
like O 0 0.00082535384
reflex B-Disease 0 0.8642616
sympathetic I-Disease 0 0.9708466
dystrophy I-Disease 0 0.9959824
, O 0 0.005559077
polyneuropathy B-Disease 2 0.99968874
, O 0 0.0030087908
Morton B-Disease 0 0.4426906
' I-Disease 0 0.0007809157
s I-Disease 0 0.0014551197
neuralgia I-Disease 0 0.99973875
, O 0 0.0063021663
gout B-Disease 0 0.999795
, O 0 0.012635559
osteoporosis B-Disease 2 0.999616
, O 0 0.0074925176
avascular B-Disease 0 0.996467
necrosis I-Disease 2 0.99949825
, O 0 0.0032497086
intermittent B-Disease 0 0.4129077
claudication I-Disease 0 0.9946384
, O 0 0.0012019152
orthopaedic O 0 0.0065321033
foot B-Disease 0 0.096819274
deformities I-Disease 0 0.63162357
, O 0 0.0029678433
stress B-Disease 0 0.91956043
fractures I-Disease 2 0.9962507
, O 0 0.007356554
and O 0 0.008363875
hyperparathyroidism B-Disease 0 0.99872005
. O 0 0.010530398

The O 0 0.0033308007
reduction O 0 0.0038614701
of O 0 0.003739312
cyclosporine B-Chemical 1 0.9995509
- O 0 0.008477568
or O 0 0.0015343386
tacrolimus B-Chemical 0 0.9995726
trough O 0 0.31802562
levels O 0 0.0007978205
and O 0 0.00062709657
the O 0 0.00055106
administration O 0 0.08125756
of O 0 0.0019788395
calcium B-Chemical 1 0.99805593
channel O 0 0.5883732
blockers O 0 0.9975364
led O 0 0.004309635
to O 0 0.002195024
relief O 0 0.28653488
of O 0 0.008800363
pain B-Disease 0 0.9853629
. O 0 0.009035091

The O 0 0.0064664697
Calcineurin O 0 0.9754169
- O 0 0.00902601
inhibitor O 0 0.26029995
Induced O 0 0.8050084
Pain B-Disease 2 0.9960443
Syndrome O 0 0.98493123
( O 0 0.0059600635
CIPS B-Disease 0 0.99512357
) O 0 0.00214429
is O 0 0.0005710949
a O 0 0.000559431
rare O 0 0.00395776
but O 0 0.0005240923
severe O 0 0.08767699
side O 0 0.01645907
effect O 0 0.0005894809
of O 0 0.0010413239
cyclosporine B-Chemical 1 0.999897
or O 0 0.00144472
tacrolimus B-Chemical 0 0.9998472
and O 0 0.00088005804
is O 0 0.0003908555
accurately O 0 0.00038621618
diagnosed O 0 0.006791733
by O 0 0.00037962152
its O 0 0.000765309
typical O 0 0.0008096472
presentation O 0 0.005514875
, O 0 0.0012618124
magnetic O 0 0.10235771
resonance O 0 0.5277543
imaging O 0 0.013482082
and O 0 0.0030359467
bone O 0 0.08010848
scans O 0 0.018965852
. O 0 0.007200872

Incorrect O 0 0.046150155
diagnosis O 0 0.0090999575
of O 0 0.0028121262
the O 0 0.0020885048
syndrome O 0 0.52360505
will O 0 0.0010217767
lead O 0 0.0049358327
to O 0 0.0007520449
a O 0 0.0007616611
significant O 0 0.00082830637
reduction O 0 0.0010648724
of O 0 0.00090624316
life O 0 0.0017653493
quality O 0 0.0009034339
in O 0 0.0011722394
patients O 0 0.0065364465
suffering O 0 0.8032588
from O 0 0.007905762
CIPS B-Disease 0 0.98967767
. O 0 0.008878238

Brain O 0 0.529134
natriuretic O 0 0.9672802
peptide O 0 0.015857963
is O 0 0.0035394544
a O 0 0.0030211173
predictor O 0 0.0024297475
of O 0 0.006037392
anthracycline B-Chemical 1 0.9978116
- O 0 0.047640212
induced O 0 0.06325389
cardiotoxicity B-Disease 0 0.99903715
. O 0 0.019601464

Anthracyclines B-Chemical 0 0.99067545
are O 0 0.0047134277
effective O 0 0.0052676806
antineoplastic O 0 0.97760415
drugs O 0 0.88173676
, O 0 0.0031251544
but O 0 0.0014200588
they O 0 0.0011933242
frequently O 0 0.0026207976
cause O 0 0.006325504
dose O 0 0.09682987
- O 0 0.007755559
related O 0 0.0060665514
cardiotoxicity B-Disease 0 0.99892646
. O 0 0.012368317

The O 0 0.0048713037
cardiotoxicity B-Disease 0 0.9982023
of O 0 0.0034472565
conventional O 0 0.0034852223
anthracycline B-Chemical 1 0.99837387
therapy O 0 0.071617514
highlights O 0 0.0011141219
a O 0 0.00071001
need O 0 0.00040132436
to O 0 0.00034338867
search O 0 0.00047094296
for O 0 0.0003070046
methods O 0 0.0004933975
that O 0 0.00034395157
are O 0 0.00045550492
highly O 0 0.0007106846
sensitive O 0 0.00066745916
and O 0 0.0007300225
capable O 0 0.0012076193
of O 0 0.0017588658
predicting O 0 0.0037393812
cardiac B-Disease 0 0.9669653
dysfunction I-Disease 0 0.99389076
. O 0 0.010161185

We O 0 0.0029641474
measured O 0 0.0016280743
the O 0 0.0015722255
plasma O 0 0.0063093584
level O 0 0.00091824745
of O 0 0.0013959575
brain O 0 0.10297407
natriuretic O 0 0.99341327
peptide O 0 0.045298953
( O 0 0.0024072633
BNP O 0 0.98412687
) O 0 0.0010127153
to O 0 0.00029359641
determine O 0 0.00015098289
whether O 0 0.00018514224
BNP O 0 0.9001731
might O 0 0.00026149407
serve O 0 0.00040500506
as O 0 0.00020624798
a O 0 0.00027867293
simple O 0 0.0005107129
diagnostic O 0 0.0005516117
indicator O 0 0.00028116044
of O 0 0.0009790877
anthracycline B-Chemical 1 0.99968064
- O 0 0.009151181
induced O 0 0.005694972
cardiotoxicity B-Disease 0 0.99992836
in O 0 0.0008424585
patients O 0 0.0099770585
with O 0 0.0024790645
acute B-Disease 0 0.9988951
leukemia I-Disease 0 0.9999286
treated O 0 0.025977943
with O 0 0.0020373631
a O 0 0.003334266
daunorubicin B-Chemical 1 0.9996172
( O 0 0.017101765
DNR B-Chemical 0 0.99715745
) O 0 0.004951084
- O 0 0.0032775388
containing O 0 0.0026860547
regimen O 0 0.026486559
. O 0 0.005804326

Thirteen O 0 0.01614357
patients O 0 0.008651405
with O 0 0.006063715
acute B-Disease 0 0.9936365
leukemia I-Disease 0 0.99948055
were O 0 0.004154782
treated O 0 0.004274629
with O 0 0.0029642347
a O 0 0.004545967
DNR B-Chemical 0 0.99258786
- O 0 0.0073320004
containing O 0 0.004832472
regimen O 0 0.040230893
. O 0 0.0085070785

Cardiac O 0 0.36673707
functions O 0 0.0068150545
were O 0 0.0036804914
evaluated O 0 0.0033681185
with O 0 0.0047172946
radionuclide O 0 0.10870758
angiography O 0 0.28924742
before O 0 0.00670193
chemotherapies O 0 0.70176065
. O 0 0.013918841

The O 0 0.0034925565
plasma O 0 0.010153792
levels O 0 0.0020815607
of O 0 0.0025663597
atrial O 0 0.973605
natriuretic O 0 0.9947174
peptide O 0 0.06785224
( O 0 0.0041807247
ANP O 1 0.99769825
) O 0 0.0028385483
and O 0 0.0011584067
BNP O 0 0.93942726
were O 0 0.00074558763
measured O 0 0.0004988891
at O 0 0.00050084124
the O 0 0.00078282465
time O 0 0.0011018331
of O 0 0.002925801
radionuclide O 0 0.25722945
angiography O 0 0.57939297
. O 0 0.008504497

Three O 0 0.007074777
patients O 0 0.007858323
developed O 0 0.008210513
congestive B-Disease 0 0.9981026
heart I-Disease 0 0.8347141
failure I-Disease 0 0.54040384
after O 0 0.0019886487
the O 0 0.00242094
completion O 0 0.002908637
of O 0 0.0068104337
chemotherapy O 0 0.841795
. O 0 0.011559512

Five O 0 0.0068989336
patients O 0 0.005367385
were O 0 0.002319302
diagnosed O 0 0.006646972
as O 0 0.0013705563
having O 0 0.0021610158
subclinical O 0 0.8176819
heart B-Disease 0 0.66205704
failure I-Disease 0 0.47128803
after O 0 0.0012110192
the O 0 0.0016104899
completion O 0 0.0020472198
of O 0 0.0051738485
chemotherapy O 0 0.83734226
. O 0 0.009345311

The O 0 0.00318301
plasma O 0 0.009468391
levels O 0 0.001793451
of O 0 0.0020155646
BNP O 0 0.9478051
in O 0 0.000856866
all O 0 0.0005138933
the O 0 0.00045914418
patients O 0 0.0011197175
with O 0 0.0005360643
clinical O 0 0.0058426494
and O 0 0.0006027383
subclinical O 0 0.8787047
heart B-Disease 0 0.70926744
failure I-Disease 0 0.61455595
increased O 0 0.0009534536
above O 0 0.00021507691
the O 0 0.00023987156
normal O 0 0.0005760427
limit O 0 0.000592575
( O 0 0.00045605414
40 O 0 0.00036281446
pg O 0 0.004546837
/ O 0 0.0008143437
ml O 0 0.001281339
) O 0 0.00038756317
before O 0 0.00012822638
the O 0 0.00020251043
detection O 0 0.00033490377
of O 0 0.00048913836
clinical O 0 0.0052707437
or O 0 0.00074545725
subclinical O 0 0.8810755
heart B-Disease 0 0.7270438
failure I-Disease 0 0.69373775
by O 0 0.0036572341
radionuclide O 0 0.45892483
angiography O 0 0.66839445
. O 0 0.0074919043

On O 0 0.0038580308
the O 0 0.0021106517
other O 0 0.0018154003
hand O 0 0.0023392655
, O 0 0.0022254451
BNP O 0 0.9535194
did O 0 0.0008562171
not O 0 0.0004958012
increase O 0 0.0004404469
in O 0 0.00034531506
the O 0 0.0003486426
patients O 0 0.0010794644
without O 0 0.00052514113
heart B-Disease 0 0.41356233
failure I-Disease 0 0.5583822
given O 0 0.0006186489
DNR B-Chemical 0 0.99709284
, O 0 0.00072258495
even O 0 0.0003871756
at O 0 0.00024444854
more O 0 0.00049101043
than O 0 0.00035052883
700 O 0 0.0022503114
mg O 0 0.31848314
/ O 0 0.0033138047
m O 0 0.0054804855
( O 0 0.0027177962
2 O 0 0.0028076142
) O 0 0.0054358603
. O 0 0.0049529374

The O 0 0.0033454737
plasma O 0 0.009331667
level O 0 0.001664837
of O 0 0.0024230324
ANP O 1 0.9951988
did O 0 0.001381285
not O 0 0.0007436482
always O 0 0.00070373307
increase O 0 0.000541684
in O 0 0.00044491442
all O 0 0.00042101264
the O 0 0.0005080514
patients O 0 0.0015305848
with O 0 0.0010531022
clinical O 0 0.010414789
and O 0 0.0024521772
subclinical O 0 0.94369066
heart B-Disease 0 0.8816881
failure I-Disease 0 0.8800084
. O 0 0.008785522

These O 0 0.003914154
preliminary O 0 0.0033053143
results O 0 0.0016081732
suggest O 0 0.001194578
that O 0 0.0013190806
BNP O 0 0.9466175
may O 0 0.0012011226
be O 0 0.0008198853
useful O 0 0.00083526684
as O 0 0.00047933398
an O 0 0.0007503122
early O 0 0.0011813527
and O 0 0.00075279013
sensitive O 0 0.00089479337
indicator O 0 0.00086947763
of O 0 0.0031868175
anthracycline B-Chemical 1 0.99901617
- O 0 0.0448722
induced O 0 0.061105542
cardiotoxicity B-Disease 0 0.99939466
. O 0 0.0139322905

Nephrotoxicity B-Disease 2 0.9911816
of O 0 0.012815602
combined O 0 0.024393953
cephalothin B-Chemical 1 0.9957211
- O 0 0.06698431
gentamicin B-Chemical 1 0.9926984
regimen O 0 0.26131478
. O 0 0.017084302

Two O 0 0.0053360607
patients O 0 0.006579014
developed O 0 0.0065298113
acute B-Disease 2 0.9867813
tubular I-Disease 2 0.9958864
necrosis I-Disease 2 0.9994474
, O 0 0.0069570546
characterized O 0 0.0036889303
clinically O 0 0.13917126
by O 0 0.0013033393
acute O 0 0.9892313
oliguric B-Disease 0 0.9998354
renal I-Disease 0 0.9989568
failure I-Disease 0 0.953137
, O 0 0.0012004657
while O 0 0.00035124665
they O 0 0.0002755619
were O 0 0.0002961205
receiving O 0 0.00095692324
a O 0 0.00047068263
combination O 0 0.0013066963
of O 0 0.0022405174
cephalothin B-Chemical 1 0.99964
sodium I-Chemical 0 0.9992519
and O 0 0.022690115
gentamicin B-Chemical 1 0.9992926
sulfate I-Chemical 0 0.99791735
therapy O 0 0.6157914
. O 0 0.009511658

Patients O 0 0.009978241
who O 0 0.004295324
are O 0 0.001667552
given O 0 0.00095665245
this O 0 0.0010212492
drug O 0 0.10930192
regimen O 0 0.008696368
should O 0 0.000594536
be O 0 0.0006826235
observed O 0 0.0004908067
very O 0 0.0008349124
carefully O 0 0.0007134856
for O 0 0.0009623881
early O 0 0.0038504475
signs O 0 0.27916947
of O 0 0.020590805
nephrotoxicity B-Disease 0 0.9994025
. O 0 0.014495689

High O 0 0.01814582
doses O 0 0.017923396
of O 0 0.0029327981
this O 0 0.0019788293
antibiotic O 0 0.07733723
combination O 0 0.0039031154
should O 0 0.0011694168
be O 0 0.0014894848
avoided O 0 0.0019069085
especially O 0 0.0028489842
in O 0 0.0029331103
elderly O 0 0.37883967
patients O 0 0.019874629
. O 0 0.007983092

Patients O 0 0.0142081985
with O 0 0.0063957768
renal B-Disease 0 0.9797146
insufficiency I-Disease 0 0.99163884
should O 0 0.002817792
not O 0 0.0025850465
be O 0 0.0027356094
given O 0 0.0024271403
this O 0 0.0045401705
regimen O 0 0.027133737
. O 0 0.009705685

In O 0 0.0035777243
vivo O 0 0.004169942
protection O 0 0.0052826013
of O 0 0.0025577873
dna O 0 0.19383939
damage O 0 0.73284817
associated O 0 0.0051390333
apoptotic O 0 0.8187771
and O 0 0.002174666
necrotic B-Disease 2 0.88845694
cell O 0 0.06625657
deaths O 0 0.7757485
during O 0 0.0010354568
acetaminophen B-Chemical 0 0.99993384
- O 0 0.016438399
induced O 0 0.011328442
nephrotoxicity B-Disease 0 0.9999591
, O 0 0.026771717
amiodarone B-Chemical 1 0.99992704
- O 0 0.009535672
induced O 0 0.0029112783
lung B-Disease 0 0.97326535
toxicity I-Disease 2 0.9995783
and O 0 0.0068935216
doxorubicin B-Chemical 1 0.9996669
- O 0 0.00968334
induced O 0 0.005995526
cardiotoxicity B-Disease 0 0.9998541
by O 0 0.0014524885
a O 0 0.0014304522
novel O 0 0.0047351103
IH636 B-Chemical 1 0.98020977
grape I-Chemical 1 0.9390119
seed I-Chemical 1 0.088021934
proanthocyanidin I-Chemical 1 0.9974184
extract I-Chemical 1 0.61157835
. O 0 0.011494216

Grape B-Chemical 0 0.9411813
seed I-Chemical 0 0.009242907
extract I-Chemical 0 0.085916854
, O 0 0.002936568
primarily O 0 0.0020639894
a O 0 0.0012455515
mixture O 0 0.0026829892
of O 0 0.0017462741
proanthocyanidins B-Chemical 0 0.99898213
, O 0 0.0021194397
has O 0 0.0006898268
been O 0 0.0006347489
shown O 0 0.0002956948
to O 0 0.00029141674
modulate O 0 0.00029246046
a O 0 0.0003926402
wide O 0 0.0010894611
- O 0 0.00060116744
range O 0 0.00045526706
of O 0 0.00042700046
biological O 0 0.0011073158
, O 0 0.00068866287
pharmacological O 0 0.14633934
and O 0 0.0009087199
toxicological O 0 0.56863874
effects O 0 0.0030523532
which O 0 0.00215051
are O 0 0.0023302177
mainly O 0 0.008152038
cytoprotective O 0 0.9771896
. O 0 0.009254459

This O 0 0.0045108846
study O 0 0.0028286262
assessed O 0 0.0013592195
the O 0 0.001225823
ability O 0 0.0012124815
of O 0 0.0017986413
IH636 B-Chemical 1 0.9681414
grape I-Chemical 1 0.914713
seed I-Chemical 1 0.029481823
proanthocyanidin I-Chemical 1 0.99907184
extract I-Chemical 1 0.60589945
( O 0 0.028928675
GSPE B-Chemical 0 0.9999342
) O 0 0.008614314
to O 0 0.0007343348
prevent O 0 0.0020182005
acetaminophen B-Chemical 0 0.99992454
( O 0 0.013947885
AAP B-Chemical 1 0.9959558
) O 0 0.0060522705
- O 0 0.0018806582
induced O 0 0.0035173746
nephrotoxicity B-Disease 0 0.99994755
, O 0 0.02173512
amiodarone B-Chemical 1 0.999926
( O 0 0.021433758
AMI B-Chemical 1 0.9996803
) O 0 0.006071298
- O 0 0.0013777902
induced O 0 0.0012651832
lung B-Disease 0 0.95422435
toxicity I-Disease 2 0.9994548
, O 0 0.0027112977
and O 0 0.0015079166
doxorubicin B-Chemical 1 0.9994173
( O 0 0.011718505
DOX B-Chemical 1 0.99918586
) O 0 0.007638934
- O 0 0.0034029053
induced O 0 0.0060202996
cardiotoxicity B-Disease 0 0.99953735
in O 0 0.004067514
mice O 0 0.0036137172
. O 0 0.005714487

Experimental O 0 0.009679491
design O 0 0.004812161
consisted O 0 0.0017098946
of O 0 0.0015387032
four O 0 0.0008881298
groups O 0 0.0013178292
: O 0 0.0013906101
control O 0 0.0007586628
( O 0 0.0011632678
vehicle O 0 0.009811578
alone O 0 0.0013428126
) O 0 0.002143504
, O 0 0.002155566
GSPE B-Chemical 0 0.999838
alone O 0 0.0034865504
, O 0 0.0021641424
drug O 0 0.3983241
alone O 0 0.0029558938
and O 0 0.006067141
GSPE B-Chemical 0 0.9996793
+ O 0 0.03085172
drug O 0 0.8050906
. O 0 0.008777449

For O 0 0.0031114551
the O 0 0.0027628632
cytoprotection O 0 0.9568768
study O 0 0.0032372696
, O 0 0.0015559389
animals O 0 0.00078521605
were O 0 0.0007421226
orally O 0 0.029747503
gavaged O 0 0.20920442
100 O 0 0.0020967268
mg O 0 0.45530045
/ O 0 0.0023407436
Kg O 0 0.22062801
GSPE B-Chemical 0 0.9998585
for O 0 0.0005675934
7 O 0 0.00038881632
- O 0 0.00043054394
10 O 0 0.00020249035
days O 0 0.00015417201
followed O 0 0.00013653639
by O 0 0.0002233874
i O 0 0.00067211705
. O 0 0.00015493228
p O 0 0.00031224528
. O 0 0.00012652631
injections O 0 0.00077652454
of O 0 0.0002946676
organ O 0 0.009459383
specific O 0 0.00026608765
three O 0 0.00018813078
drugs O 0 0.57675904
( O 0 0.0011249578
AAP B-Chemical 1 0.9720876
: O 0 0.0008966437
500 O 0 0.002030903
mg O 0 0.2769348
/ O 0 0.0008627282
Kg O 0 0.012729921
for O 0 0.000181845
24 O 0 0.00024338713
h O 0 0.00032384993
; O 0 0.00078490423
AMI B-Chemical 1 0.9986192
: O 0 0.00078732445
50 O 0 0.00061768555
mg O 0 0.22204868
/ O 0 0.0009790312
Kg O 0 0.02336414
/ O 0 0.0004602835
day O 0 0.00018930019
for O 0 0.00015954426
four O 0 0.00017721036
days O 0 0.00037694589
; O 0 0.0010605449
DOX B-Chemical 1 0.99736977
: O 0 0.0011770878
20 O 0 0.0008038691
mg O 0 0.19528916
/ O 0 0.0019846945
Kg O 0 0.015797056
for O 0 0.0008777701
48 O 0 0.0016229431
h O 0 0.0025146168
) O 0 0.0053208447
. O 0 0.0049952026

Parameters O 0 0.016985022
of O 0 0.0027924746
study O 0 0.0023185937
included O 0 0.0011547155
analysis O 0 0.0014889898
of O 0 0.0014743037
serum O 0 0.10445731
chemistry O 0 0.3082687
( O 0 0.0042987037
ALT O 0 0.9980756
, O 0 0.0055128075
BUN O 0 0.999567
and O 0 0.0027625058
CPK O 0 0.99912363
) O 0 0.0028789009
, O 0 0.00068602624
and O 0 0.0004391035
orderly O 0 0.00476108
fragmentation O 0 0.010599863
of O 0 0.00059479056
genomic O 0 0.0011754676
DNA O 0 0.056893457
( O 0 0.00069351913
both O 0 0.0003498921
endonuclease O 0 0.050396603
- O 0 0.00066729926
dependent O 0 0.00024170637
and O 0 0.00025884513
independent O 0 0.00019953003
) O 0 0.0004861808
in O 0 0.00017952078
addition O 0 0.00014701848
to O 0 0.0002070108
microscopic O 0 0.0018025159
evaluation O 0 0.0005684808
of O 0 0.000693857
damage O 0 0.48021474
and O 0 0.0008445466
/ O 0 0.0015941984
or O 0 0.00055727904
protection O 0 0.002505946
in O 0 0.00089433097
corresponding O 0 0.0013349327
PAS O 0 0.22374949
stained O 0 0.004469178
tissues O 0 0.012067704
. O 0 0.006287301

Results O 0 0.0051568826
indicate O 0 0.0024439432
that O 0 0.002866946
GSPE B-Chemical 0 0.99954176
preexposure O 0 0.37343743
prior O 0 0.001252746
to O 0 0.0014068627
AAP B-Chemical 1 0.9824004
, O 0 0.0037880116
AMI B-Chemical 1 0.9990471
and O 0 0.0022150676
DOX B-Chemical 1 0.9990054
, O 0 0.0010534645
provided O 0 0.00045598063
near O 0 0.00041011893
complete O 0 0.00033544796
protection O 0 0.0012591508
in O 0 0.00027701547
terms O 0 0.0002547505
of O 0 0.0005253079
serum O 0 0.0809878
chemistry O 0 0.14472802
changes O 0 0.0024809476
( O 0 0.0021683904
ALT O 0 0.99841344
, O 0 0.004536295
BUN O 0 0.9995906
and O 0 0.0029087544
CPK O 0 0.9988871
) O 0 0.0032886888
, O 0 0.0012810823
and O 0 0.0010941552
significantly O 0 0.0017698717
reduced O 0 0.0027635423
DNA O 0 0.09449859
fragmentation O 0 0.1651383
. O 0 0.008224741

Histopathological O 0 0.5407303
examination O 0 0.0050863745
of O 0 0.0033160497
kidney O 0 0.7241171
, O 0 0.0027881612
heart O 0 0.28249803
and O 0 0.0011425125
lung O 0 0.093759164
sections O 0 0.0011199047
revealed O 0 0.0005953412
moderate O 0 0.003979092
to O 0 0.00046591027
massive O 0 0.03002104
tissue B-Disease 0 0.19870923
damage I-Disease 0 0.9128136
with O 0 0.00072592206
a O 0 0.00044071797
variety O 0 0.0012996539
of O 0 0.00051970524
morphological O 0 0.016798384
aberrations O 0 0.37133956
by O 0 0.000365735
all O 0 0.00023457914
the O 0 0.0002289293
three O 0 0.00018109732
drugs O 0 0.21434279
in O 0 0.0003359767
the O 0 0.00034332045
absence O 0 0.00033648268
of O 0 0.0019152911
GSPE B-Chemical 0 0.99987733
preexposure O 0 0.56005013
than O 0 0.0011996038
in O 0 0.0016639474
its O 0 0.0046027205
presence O 0 0.0047465023
. O 0 0.006124168

GSPE B-Chemical 0 0.9988921
+ O 0 0.00967885
drug O 0 0.36207592
exposed O 0 0.0033418692
tissues O 0 0.0039923848
exhibited O 0 0.0017789445
minor O 0 0.0030676213
residual O 0 0.0028274353
damage O 0 0.38231617
or O 0 0.0023182386
near O 0 0.0032790222
total O 0 0.0038370574
recovery O 0 0.012532251
. O 0 0.007866607

Additionally O 0 0.0063798036
, O 0 0.004604678
histopathological O 0 0.21599178
alterations O 0 0.009543493
mirrored O 0 0.0025471468
both O 0 0.0015390358
serum O 0 0.044593778
chemistry O 0 0.060516622
changes O 0 0.002189446
and O 0 0.0014185888
the O 0 0.0013700891
pattern O 0 0.0019770795
of O 0 0.003973823
DNA O 0 0.111212045
fragmentation O 0 0.17940392
. O 0 0.009942307

Interestingly O 0 0.0042328755
, O 0 0.0029807636
all O 0 0.001474633
the O 0 0.0014404791
drugs O 0 0.40645152
, O 0 0.0015947068
such O 0 0.0008721311
as O 0 0.0007715575
, O 0 0.0015110536
AAP B-Chemical 1 0.982333
, O 0 0.003408317
AMI B-Chemical 1 0.99928844
and O 0 0.0025631252
DOX B-Chemical 1 0.99935347
induced O 0 0.009426454
apoptotic O 0 0.9544554
death O 2 0.9972633
in O 0 0.0005328588
addition O 0 0.00031084128
to O 0 0.0005052853
necrosis B-Disease 2 0.9921433
in O 0 0.00042946055
the O 0 0.00035319658
respective O 0 0.00037005908
organs O 0 0.0054315594
which O 0 0.00085969316
was O 0 0.00072884705
very O 0 0.0012287355
effectively O 0 0.0024195807
blocked O 0 0.0066335383
by O 0 0.009508904
GSPE B-Chemical 0 0.99932206
. O 0 0.013926888

Since O 0 0.0053560007
AAP B-Chemical 1 0.9241568
, O 0 0.0073282053
AMI B-Chemical 1 0.9968925
and O 0 0.003900369
DOX B-Chemical 1 0.997773
undergo O 0 0.0027069498
biotransformation O 0 0.9904157
and O 0 0.0010902014
are O 0 0.0006369465
known O 0 0.0006778082
to O 0 0.00040137334
produce O 0 0.00048312644
damaging O 0 0.09964048
radicals O 0 0.99481106
in O 0 0.00067778083
vivo O 0 0.0015699002
, O 0 0.00059482513
the O 0 0.00036285596
protection O 0 0.0041666958
by O 0 0.0010316465
GSPE B-Chemical 0 0.9999285
may O 0 0.0010489458
be O 0 0.0004946334
linked O 0 0.00037137003
to O 0 0.0003247394
both O 0 0.0003772673
inhibition O 0 0.0021555973
of O 0 0.0009438931
metabolism O 0 0.41297302
and O 0 0.0011345549
/ O 0 0.0024622667
or O 0 0.001134697
detoxification O 0 0.660369
of O 0 0.006681758
cytotoxic O 0 0.96002597
radicals O 0 0.9933436
. O 0 0.012152195

In O 0 0.0030720094
addition O 0 0.0018171794
, O 0 0.0021399183
its O 0 0.0021146466
' O 0 0.0013026553
presumed O 0 0.0022917718
contribution O 0 0.0006043498
to O 0 0.00065106066
DNA O 0 0.011771972
repair O 0 0.0011459384
may O 0 0.0005475208
be O 0 0.00045336154
another O 0 0.00045928796
important O 0 0.0004073317
attribute O 0 0.0007673754
, O 0 0.00072998105
which O 0 0.0007629556
played O 0 0.0017241348
a O 0 0.00091067544
role O 0 0.0007188202
in O 0 0.0011757409
the O 0 0.0021547722
chemoprevention O 0 0.8587872
process O 0 0.008664125
. O 0 0.0071588797

Additionally O 0 0.0051727933
, O 0 0.003140039
this O 0 0.0016262634
may O 0 0.0013333585
have O 0 0.0011623048
been O 0 0.0010779647
the O 0 0.0007203281
first O 0 0.0006698099
report O 0 0.002475565
on O 0 0.00093759026
AMI B-Chemical 1 0.99877065
- O 0 0.0055068578
induced O 0 0.0037264237
apoptotic O 0 0.8961867
death O 2 0.99375725
in O 0 0.0024567842
the O 0 0.0031764472
lung O 0 0.47605646
tissue O 0 0.13204788
. O 0 0.008097241

Taken O 0 0.0060049673
together O 0 0.0028233267
, O 0 0.0024956358
these O 0 0.0018556205
events O 0 0.0035596834
undoubtedly O 0 0.002374161
establish O 0 0.0014347497
GSPE B-Chemical 0 0.9998246
' O 0 0.0018110953
s O 0 0.0010113396
abundant O 0 0.00082183286
bioavailability O 0 0.9642544
, O 0 0.0007516848
and O 0 0.0003789974
the O 0 0.00028685023
power O 0 0.0013380591
to O 0 0.00032409452
defend O 0 0.0011394975
multiple O 0 0.0005786421
target O 0 0.0003886959
organs O 0 0.0055760927
from O 0 0.0005000443
toxic O 0 0.78617656
assaults O 0 0.63684726
induced O 0 0.0010713134
by O 0 0.00062383944
structurally O 0 0.004981275
diverse O 0 0.0014432252
and O 0 0.0007979669
functionally O 0 0.0013601545
different O 0 0.0012202517
entities O 0 0.00767595
in O 0 0.002587136
vivo O 0 0.0075546983
. O 0 0.005839986

Antidepressant B-Chemical 0 0.997242
- O 0 0.013778475
induced O 0 0.007794198
mania B-Disease 0 0.9971329
in O 0 0.004093233
bipolar B-Disease 2 0.97631764
patients O 0 0.011507737
: O 0 0.0038405217
identification O 0 0.0034487788
of O 0 0.004552813
risk O 0 0.075785525
factors O 0 0.028195694
. O 0 0.009833847

BACKGROUND O 0 0.73537606
: O 0 0.0052429163
Concerns O 0 0.007708967
about O 0 0.0012884866
possible O 0 0.0012016715
risks O 0 0.0037248821
of O 0 0.0010545257
switching O 0 0.0013488522
to O 0 0.0008967812
mania B-Disease 0 0.9988526
associated O 0 0.0017370483
with O 0 0.0014374672
antidepressants B-Chemical 1 0.9995153
continue O 0 0.00086085586
to O 0 0.00034422745
interfere O 0 0.0004011071
with O 0 0.00041735792
the O 0 0.00033425723
establishment O 0 0.0006499648
of O 0 0.00056403276
an O 0 0.00065214705
optimal O 0 0.00046039015
treatment O 0 0.0019216081
paradigm O 0 0.0030871285
for O 0 0.0025464487
bipolar B-Disease 2 0.9918572
depression I-Disease 0 0.9915987
. O 0 0.008693366

METHOD O 0 0.035951562
: O 0 0.0038821336
The O 0 0.0014220963
response O 0 0.0015985302
of O 0 0.0012377995
44 O 0 0.0014358843
patients O 0 0.0018465335
meeting O 0 0.0014563175
DSM O 0 0.08512775
- O 0 0.0013487784
IV O 0 0.03210963
criteria O 0 0.0008514548
for O 0 0.00042769936
bipolar B-Disease 2 0.9693564
disorder I-Disease 0 0.8345635
to O 0 0.0003938507
naturalistic O 0 0.016824314
treatment O 0 0.0008360058
was O 0 0.00023760875
assessed O 0 0.00016197025
for O 0 0.00015878346
at O 0 0.00012924217
least O 0 0.00013473416
6 O 0 0.00015380992
weeks O 0 0.000193113
using O 0 0.0002212963
the O 0 0.00041836372
Montgomery O 0 0.0459926
- O 0 0.0018566279
Asberg O 0 0.5404463
Depression O 2 0.98569864
Rating O 0 0.15030096
Scale O 0 0.3187177
and O 0 0.00094792654
the O 0 0.0013207952
Bech O 0 0.19662347
- O 0 0.0045743203
Rafaelson O 0 0.13641934
Mania O 2 0.96540445
Rating O 0 0.34914452
Scale O 0 0.61749077
. O 0 0.007241719

Patients O 0 0.009744033
who O 0 0.0046462477
experienced O 0 0.0033805026
a O 0 0.0026068052
manic B-Disease 0 0.9983693
or O 0 0.0018342801
hypomanic B-Disease 0 0.9983418
switch O 0 0.0015772111
were O 0 0.0004968634
compared O 0 0.00023920742
with O 0 0.00040332347
those O 0 0.00049500697
who O 0 0.0007295241
did O 0 0.00024686943
not O 0 0.00018780188
on O 0 0.00012201695
several O 0 0.00023066392
variables O 0 0.0003978934
including O 0 0.0003079811
age O 0 0.0010033088
, O 0 0.00048221226
sex O 0 0.00685192
, O 0 0.00057874917
diagnosis O 0 0.012485595
( O 0 0.0011635952
DSM B-Disease 0 0.14024948
- I-Disease 0 0.0015955893
IV I-Disease 0 0.28318107
bipolar I-Disease 2 0.9980324
I I-Disease 0 0.08163283
vs O 0 0.0027431021
. O 0 0.00033442775
bipolar B-Disease 2 0.99602723
II I-Disease 0 0.21055311
) O 0 0.0009317132
, O 0 0.00032028026
number O 0 0.000167192
of O 0 0.00028999383
previous O 0 0.0005006057
manic B-Disease 0 0.99966836
episodes O 0 0.41978687
, O 0 0.0006044097
type O 0 0.0003209111
of O 0 0.0005700005
antidepressant B-Chemical 1 0.99954623
therapy O 0 0.074086174
used O 0 0.00045327947
( O 0 0.00062709156
electroconvulsive O 0 0.9958839
therapy O 0 0.05665179
vs O 0 0.0027820729
. O 0 0.00024389262
antidepressant B-Chemical 1 0.99936944
drugs O 0 0.7639979
and O 0 0.000550594
, O 0 0.00046384675
more O 0 0.0004167649
particularly O 0 0.0009007033
, O 0 0.0006937816
selective O 0 0.06901317
serotonin B-Chemical 1 0.99982125
reuptake I-Chemical 0 0.9997546
inhibitors I-Chemical 0 0.94823027
[ O 0 0.069824524
SSRIs B-Chemical 0 0.9997142
] O 0 0.005845287
) O 0 0.00073935656
, O 0 0.0003304777
use O 0 0.00027773104
and O 0 0.00024634838
type O 0 0.00028925575
of O 0 0.00061962334
mood O 0 0.98415565
stabilizers O 0 0.94669056
( O 0 0.0028076821
lithium B-Chemical 1 0.99935263
vs O 0 0.005230655
. O 0 0.00030752717
anticonvulsants O 0 0.99932396
) O 0 0.0011191708
, O 0 0.00036684022
and O 0 0.00026820984
temperament O 0 0.0913511
of O 0 0.0003040069
the O 0 0.00022705355
patient O 0 0.00048289503
, O 0 0.00028500528
assessed O 0 0.00015683394
during O 0 0.00015589746
a O 0 0.000327878
normothymic O 0 0.80892026
period O 0 0.00032106842
using O 0 0.00027039123
the O 0 0.00040862488
hyperthymia O 0 0.2329368
component O 0 0.0007004103
of O 0 0.00093497604
the O 0 0.0011418075
Semi O 0 0.08575309
- O 0 0.0025742303
structured O 0 0.0024182287
Affective O 0 0.21411844
Temperament O 0 0.50986904
Interview O 0 0.040519472
. O 0 0.006593119

RESULTS O 0 0.034187667
: O 0 0.0058952617
Switches O 0 0.020731667
to O 0 0.002584454
hypomania B-Disease 0 0.99589276
or O 0 0.0020360232
mania B-Disease 0 0.99786913
occurred O 0 0.0014778072
in O 0 0.0006042361
27 O 0 0.00085543265
% O 0 0.00042564407
of O 0 0.0003813737
all O 0 0.0003363369
patients O 0 0.0017673386
( O 0 0.0008750569
N O 0 0.6424828
= O 0 0.0007128545
12 O 0 0.00024333026
) O 0 0.0004499311
( O 0 0.00029970775
and O 0 0.00020398964
in O 0 0.00016826627
24 O 0 0.00018940005
% O 0 0.00017486385
of O 0 0.00018343145
the O 0 0.00017700554
subgroup O 0 0.00086482574
of O 0 0.00035867386
patients O 0 0.0018256614
treated O 0 0.0010528133
with O 0 0.0011815148
SSRIs B-Chemical 0 0.9995968
[ O 0 0.0030363768
8 O 0 0.00036410152
/ O 0 0.0007085428
33 O 0 0.00061843864
] O 0 0.0008079804
) O 0 0.00055834884
; O 0 0.00048828236
16 O 0 0.00031130185
% O 0 0.00034637062
( O 0 0.00046648862
N O 0 0.37292796
= O 0 0.0006119291
7 O 0 0.00026346254
) O 0 0.00046303746
experienced O 0 0.0010680386
manic B-Disease 0 0.99941826
episodes O 0 0.2762282
, O 0 0.0007505177
and O 0 0.00049959455
11 O 0 0.000607158
% O 0 0.00063351134
( O 0 0.0008759387
N O 0 0.37653047
= O 0 0.0014135009
5 O 0 0.0008093208
) O 0 0.0018053717
experienced O 0 0.0051001133
hypomanic B-Disease 0 0.99695957
episodes O 0 0.56231725
. O 0 0.0072887465

Sex O 0 0.27052763
, O 0 0.005389468
age O 0 0.0049535106
, O 0 0.0030841304
diagnosis O 0 0.015733343
( O 0 0.0037156104
bipolar B-Disease 2 0.9941949
I I-Disease 0 0.07974656
vs O 0 0.0037434406
. O 0 0.00077030825
bipolar B-Disease 2 0.9949709
II I-Disease 0 0.2644115
) O 0 0.0016175738
, O 0 0.0006507923
and O 0 0.00043116536
additional O 0 0.00029612024
treatment O 0 0.0010555201
did O 0 0.000528808
not O 0 0.0005337839
affect O 0 0.0005828806
the O 0 0.0011902653
risk O 0 0.01932176
of O 0 0.0042207954
switching O 0 0.009460536
. O 0 0.0065608355

The O 0 0.003272813
incidence O 0 0.0063426318
of O 0 0.0030858037
mood O 0 0.8993593
switches O 0 0.005645976
seemed O 0 0.0014820194
not O 0 0.0006303483
to O 0 0.0005166319
differ O 0 0.00058280054
between O 0 0.00033580186
patients O 0 0.0014345769
receiving O 0 0.0026605797
an O 0 0.001468928
anticonvulsant O 0 0.99876595
and O 0 0.0013332836
those O 0 0.0017381401
receiving O 0 0.00585697
no O 0 0.002716574
mood O 0 0.97158706
stabilizer O 0 0.7826638
. O 0 0.008470785

In O 0 0.003200373
contrast O 0 0.0027146987
, O 0 0.0028456617
mood O 0 0.76521957
switches O 0 0.003290065
were O 0 0.0008094415
less O 0 0.00063922914
frequent O 0 0.0014479408
in O 0 0.00045155053
patients O 0 0.0017126732
receiving O 0 0.009383671
lithium B-Chemical 1 0.99920136
( O 0 0.0011566012
15 O 0 0.00034208348
% O 0 0.0003459035
, O 0 0.00032082116
4 O 0 0.00022108771
/ O 0 0.0004903479
26 O 0 0.0003727185
) O 0 0.00032367214
than O 0 0.00012596403
in O 0 0.00017147324
patients O 0 0.0005877018
not O 0 0.00023926739
treated O 0 0.0006332301
with O 0 0.0007982684
lithium B-Chemical 1 0.99921465
( O 0 0.0012038837
44 O 0 0.0008539391
% O 0 0.0005064015
, O 0 0.0005127496
8 O 0 0.00045558097
/ O 0 0.0009862572
18 O 0 0.00072563917
; O 0 0.0011771892
p O 0 0.0014498373
= O 0 0.002074023
. O 0 0.001514061
04 O 0 0.025147866
) O 0 0.0064455797
. O 0 0.0055326167

The O 0 0.002585199
number O 0 0.0017180124
of O 0 0.0018352797
previous O 0 0.0019952063
manic B-Disease 0 0.99879944
episodes O 0 0.353803
did O 0 0.000813772
not O 0 0.00042913973
affect O 0 0.00027202722
the O 0 0.00029291143
probability O 0 0.0003556081
of O 0 0.00045595935
switching O 0 0.00080724934
, O 0 0.00046506495
whereas O 0 0.0002615611
a O 0 0.00026647278
high O 0 0.00031867027
score O 0 0.0002763839
on O 0 0.0001404437
the O 0 0.00025646522
hyperthymia O 0 0.18061222
component O 0 0.0003126647
of O 0 0.00032479974
the O 0 0.00028715478
Semistructured O 0 0.0013166636
Affective O 0 0.064778745
Temperament O 0 0.28613922
Interview O 0 0.0053192046
was O 0 0.00027507372
associated O 0 0.0003793945
with O 0 0.00038493192
a O 0 0.00039680646
greater O 0 0.00043112302
risk O 0 0.0072305556
of O 0 0.00090969796
switching O 0 0.0018661496
( O 0 0.0015799259
p O 0 0.0019002324
= O 0 0.0023451087
. O 0 0.0015210479
008 O 0 0.016283907
) O 0 0.005982411
. O 0 0.0052497573

CONCLUSION O 0 0.77668214
: O 0 0.0044036675
The O 0 0.0015005491
frequency O 0 0.0015484631
of O 0 0.0018422252
mood O 0 0.8763834
switching O 0 0.0022765344
associated O 0 0.0016392362
with O 0 0.0019141821
acute O 0 0.98367727
antidepressant B-Chemical 1 0.9995425
therapy O 0 0.19458923
may O 0 0.001571244
be O 0 0.0013710792
reduced O 0 0.001846901
by O 0 0.0035923715
lithium B-Chemical 1 0.9971318
treatment O 0 0.052590556
. O 0 0.008483213

Particular O 0 0.005663264
attention O 0 0.005226545
should O 0 0.0013265047
be O 0 0.001305713
paid O 0 0.0017078551
to O 0 0.0008191207
patients O 0 0.0017437072
with O 0 0.00095403515
a O 0 0.001281563
hyperthymic O 0 0.9966097
temperament O 0 0.5819412
, O 0 0.0012349273
who O 0 0.0014606202
have O 0 0.0007427997
a O 0 0.00096658204
greater O 0 0.0012410465
risk O 0 0.020433288
of O 0 0.004920434
mood O 0 0.9711618
switches O 0 0.03496204
. O 0 0.007665867

Peritubular O 0 0.40209797
capillary O 0 0.12274734
basement O 0 0.20492363
membrane O 0 0.02720188
reduplication O 0 0.089387976
in O 0 0.001476667
allografts O 0 0.110886335
and O 0 0.0012071731
native O 0 0.001893307
kidney B-Disease 0 0.8148324
disease I-Disease 0 0.7858498
: O 0 0.0019031831
a O 0 0.001041317
clinicopathologic O 0 0.09095162
study O 0 0.0017326452
of O 0 0.0018603712
278 O 0 0.032089643
consecutive O 0 0.004258698
renal O 0 0.9581121
specimens O 0 0.009630126
. O 0 0.0075683896

BACKGROUND O 0 0.74785656
: O 0 0.0050280774
An O 0 0.003005837
association O 0 0.0012552387
has O 0 0.0012255231
been O 0 0.0012285558
found O 0 0.00084155187
between O 0 0.00065970264
transplant B-Disease 0 0.9703775
glomerulopathy I-Disease 0 0.9998031
( O 0 0.017348379
TG B-Disease 2 0.9855489
) O 0 0.0019461653
and O 0 0.00079734746
reduplication O 0 0.049354363
of O 0 0.0015535672
peritubular O 0 0.7413723
capillary O 0 0.47274292
basement O 0 0.6087019
membranes O 0 0.25953576
( O 0 0.007910913
PTCR O 0 0.827954
) O 0 0.012035598
. O 0 0.007280488

Although O 0 0.0032507745
such O 0 0.002052122
an O 0 0.001894329
association O 0 0.0010552956
is O 0 0.0009029494
of O 0 0.00087966316
practical O 0 0.0012143267
and O 0 0.00070726674
theoretical O 0 0.0023288014
importance O 0 0.0006155469
, O 0 0.0007220745
only O 0 0.0004758965
one O 0 0.0004264814
prospective O 0 0.0018145258
study O 0 0.0011365912
has O 0 0.0010385114
tried O 0 0.0023527313
to O 0 0.001649713
confirm O 0 0.0021131963
it O 0 0.005420898
. O 0 0.006140094

METHODS O 0 0.006721569
: O 0 0.0032628607
We O 0 0.001411715
examined O 0 0.0010448168
278 O 0 0.004438573
consecutive O 0 0.001509218
renal O 0 0.888658
specimens O 0 0.0016085483
( O 0 0.0010233949
from O 0 0.00053986156
135 O 0 0.0017159831
transplants O 0 0.023621075
and O 0 0.0006697135
143 O 0 0.0019814896
native O 0 0.0011358785
kidneys O 0 0.017369486
) O 0 0.0015585969
for O 0 0.0009723892
ultrastructural O 0 0.050945062
evidence O 0 0.0031647768
of O 0 0.005992327
PTCR O 0 0.8445113
. O 0 0.008915095

In O 0 0.0029854863
addition O 0 0.0017093029
to O 0 0.0019217326
renal O 0 0.94923294
allografts O 0 0.4770981
with O 0 0.0026856125
TG B-Disease 2 0.9541031
, O 0 0.0010483719
we O 0 0.00027724536
also O 0 0.00041719622
examined O 0 0.00032152788
grafts O 0 0.002508295
with O 0 0.0008061693
acute O 0 0.95779544
rejection O 0 0.9943334
, O 0 0.0049303067
recurrent O 0 0.9420779
glomerulonephritis B-Disease 2 0.9999094
, O 0 0.014499435
chronic B-Disease 0 0.99711406
allograft I-Disease 0 0.9983077
nephropathy I-Disease 2 0.9999417
and O 0 0.0022563247
stable O 0 0.0018635615
grafts O 0 0.012714469
( O 0 0.0013229569
" O 0 0.0012616863
protocol O 0 0.0019460467
biopsies O 0 0.006087568
" O 0 0.0044262363
) O 0 0.0070024827
. O 0 0.005713368

Native O 0 0.02396527
kidney O 0 0.32324508
specimens O 0 0.0024751658
included O 0 0.0011223728
a O 0 0.0009883869
wide O 0 0.0015236621
range O 0 0.0011266286
of O 0 0.0012143956
glomerulopathies B-Disease 0 0.9979382
as O 0 0.0006470454
well O 0 0.00043759734
as O 0 0.00038817103
cases O 0 0.0012455236
of O 0 0.0026268922
thrombotic B-Disease 2 0.9998054
microangiopathy I-Disease 2 0.9999659
, O 0 0.077005595
malignant B-Disease 0 0.99942625
hypertension I-Disease 2 0.9999323
, O 0 0.037623577
acute O 0 0.9964057
interstitial B-Disease 2 0.9977857
nephritis I-Disease 2 0.9999175
, O 0 0.030445896
and O 0 0.008297497
acute B-Disease 2 0.9961747
tubular I-Disease 2 0.9968008
necrosis I-Disease 2 0.9989166
. O 0 0.020055434

RESULTS O 0 0.026501257
: O 0 0.0044509103
We O 0 0.0018264594
found O 0 0.0015089959
PTCR O 0 0.1185893
in O 0 0.00096449425
14 O 0 0.0007963315
of O 0 0.00066360564
15 O 0 0.00046327518
cases O 0 0.00079057156
of O 0 0.00087101245
TG B-Disease 2 0.9262687
, O 0 0.0007772508
in O 0 0.00035295187
7 O 0 0.0003322835
transplant O 0 0.06650683
biopsy O 0 0.002204538
specimens O 0 0.0006262962
without O 0 0.0006647725
TG B-Disease 2 0.9133247
, O 0 0.00075927115
and O 0 0.0005026387
in O 0 0.00043336535
13 O 0 0.00065440126
of O 0 0.0008099975
143 O 0 0.0033543936
native O 0 0.002418643
kidney O 0 0.6107926
biopsy O 0 0.025943544
specimens O 0 0.007060909
. O 0 0.0063516987

These O 0 0.0046424544
13 O 0 0.0029423186
included O 0 0.0016268054
cases O 0 0.0025242104
of O 0 0.0029738024
malignant B-Disease 0 0.9975751
hypertension I-Disease 2 0.9998565
, O 0 0.10578354
thrombotic B-Disease 2 0.9997731
microangiopathy I-Disease 2 0.99995553
, O 0 0.11683455
lupus B-Disease 0 0.99974495
nephritis I-Disease 0 0.99991
, O 0 0.07195583
Henoch B-Disease 0 0.99930465
- I-Disease 0 0.061171263
Schonlein I-Disease 0 0.9995043
nephritis I-Disease 0 0.999884
, O 0 0.034486085
crescentic O 0 0.9992107
glomerulonephritis B-Disease 2 0.99989915
, O 0 0.00924474
and O 0 0.0029711453
cocaine B-Chemical 1 0.9994116
- O 0 0.0055294433
related O 0 0.0019431073
acute B-Disease 0 0.985313
renal I-Disease 0 0.9958768
failure I-Disease 0 0.9638121
. O 0 0.010070844

Mild O 0 0.9713262
PTCR O 0 0.6233556
in O 0 0.0028763507
allografts O 0 0.15265168
without O 0 0.0022386243
TG B-Disease 2 0.8860502
did O 0 0.0009310291
not O 0 0.0005739289
predict O 0 0.0006504544
renal B-Disease 0 0.97562534
failure I-Disease 0 0.6732992
or O 0 0.000666553
significant O 0 0.0014556741
proteinuria B-Disease 2 0.9996265
after O 0 0.00039226684
follow O 0 0.00051303435
- O 0 0.00066476874
up O 0 0.00033007024
periods O 0 0.0004725223
of O 0 0.00053090585
between O 0 0.00037128804
3 O 0 0.0006223147
months O 0 0.0009437999
and O 0 0.0013161979
1 O 0 0.0020900667
year O 0 0.0035373012
. O 0 0.004624285

CONCLUSIONS O 0 0.6464454
: O 0 0.004422714
We O 0 0.0015404014
conclude O 0 0.0012174166
that O 0 0.00084461505
in O 0 0.00080482033
transplants O 0 0.069984436
, O 0 0.00089718075
there O 0 0.00032794895
is O 0 0.00038319622
a O 0 0.00035761832
strong O 0 0.00039810146
association O 0 0.00026571067
between O 0 0.00018865727
well O 0 0.00031017905
- O 0 0.00069026375
developed O 0 0.00088630174
PTCR O 0 0.6462199
and O 0 0.00078334473
TG B-Disease 2 0.95457774
, O 0 0.00052417157
while O 0 0.000233846
the O 0 0.0002170538
significance O 0 0.00048047997
of O 0 0.00048473908
mild O 0 0.38552007
PTCR O 0 0.7013277
and O 0 0.0005076837
its O 0 0.0007661376
predictive O 0 0.00079021684
value O 0 0.00046818322
in O 0 0.00042661087
the O 0 0.0005426032
absence O 0 0.00061996625
of O 0 0.0024209656
TG B-Disease 2 0.95572746
is O 0 0.003884239
unclear O 0 0.006581321
. O 0 0.0065499884

PTCR O 0 0.35367197
also O 0 0.003383296
occurs O 0 0.0018826562
in O 0 0.0012064277
certain O 0 0.0018284695
native O 0 0.0021957576
kidney B-Disease 0 0.8327967
diseases I-Disease 0 0.7532421
, O 0 0.0014307124
though O 0 0.000605115
the O 0 0.00046416325
association O 0 0.00047377168
is O 0 0.0005838959
not O 0 0.0005462104
as O 0 0.0005717103
strong O 0 0.0011727281
as O 0 0.0010791128
that O 0 0.001671373
for O 0 0.0034059032
TG B-Disease 2 0.9462744
. O 0 0.007926512

We O 0 0.003053315
suggest O 0 0.0017727999
that O 0 0.001493416
repeated O 0 0.0020464386
endothelial B-Disease 0 0.9903865
injury I-Disease 0 0.99220943
, O 0 0.0025739071
including O 0 0.0013063349
immunologic B-Disease 0 0.91639453
injury I-Disease 0 0.99465865
, O 0 0.0015677349
may O 0 0.0005705231
be O 0 0.00044921285
the O 0 0.00037557964
cause O 0 0.0010842428
of O 0 0.00064771174
this O 0 0.0006406292
lesion O 0 0.027241342
both O 0 0.0008128234
in O 0 0.001000432
allografts O 0 0.15258195
and O 0 0.0023055794
native O 0 0.0051302467
kidneys O 0 0.10370121
. O 0 0.006494124

Caffeine B-Chemical 0 0.9979722
- O 0 0.016273888
induced O 0 0.00847881
cardiac B-Disease 0 0.9593105
arrhythmia I-Disease 2 0.99895716
: O 0 0.008310629
an O 0 0.0039888117
unrecognised O 0 0.026000883
danger O 0 0.0125143705
of O 0 0.0059872502
healthfood O 0 0.0775804
products O 0 0.01816246
. O 0 0.01013165

We O 0 0.003068187
describe O 0 0.0024114982
a O 0 0.0020720414
25 O 0 0.0023319002
- O 0 0.0017358128
year O 0 0.0010105381
- O 0 0.0011314113
old O 0 0.00071992155
woman O 0 0.0034996602
with O 0 0.0006496273
pre O 0 0.0024654733
- O 0 0.00084483076
existing O 0 0.0006933017
mitral B-Disease 0 0.70265925
valve I-Disease 0 0.23456848
prolapse I-Disease 0 0.9634986
who O 0 0.0024629051
developed O 0 0.001437233
intractable O 0 0.9552391
ventricular B-Disease 0 0.99610305
fibrillation I-Disease 0 0.99972445
after O 0 0.0003418346
consuming O 0 0.0041239453
a O 0 0.00043435505
" O 0 0.00043366873
natural O 0 0.0013677634
energy O 0 0.005330675
" O 0 0.0009954666
guarana O 0 0.98935807
health O 0 0.012269352
drink O 0 0.28924206
containing O 0 0.000820819
a O 0 0.0010450642
high O 0 0.0017629408
concentration O 0 0.0059196237
of O 0 0.0067260843
caffeine B-Chemical 1 0.9967849
. O 0 0.009869621

This O 0 0.0049359826
case O 0 0.0025715942
highlights O 0 0.0020320448
the O 0 0.0014347347
need O 0 0.0011785799
for O 0 0.0009952338
adequate O 0 0.0015631411
labelling O 0 0.00309872
and O 0 0.0018701062
regulation O 0 0.0018706048
of O 0 0.003272645
such O 0 0.0047730245
products O 0 0.014267039
. O 0 0.00888545

Conformationally O 0 0.91921073
restricted O 0 0.0037402695
analogs O 0 0.09862606
of O 0 0.003344591
BD1008 B-Chemical 0 0.9838626
and O 0 0.0018548082
an O 0 0.0016542232
antisense O 0 0.03621974
oligodeoxynucleotide B-Chemical 0 0.8783952
targeting O 0 0.0014809535
sigma1 O 0 0.9129324
receptors O 0 0.28948024
produce O 0 0.0015629254
anti O 0 0.028601157
- O 0 0.010349151
cocaine B-Chemical 1 0.9985386
effects O 0 0.008198259
in O 0 0.0030249602
mice O 0 0.0033673581
. O 0 0.0057648476

Cocaine B-Chemical 0 0.997903
' O 0 0.0047948183
s O 0 0.002634088
ability O 0 0.0013212324
to O 0 0.00092077145
interact O 0 0.0007197219
with O 0 0.0009394954
sigma O 0 0.0052436423
receptors O 0 0.049613133
suggests O 0 0.00049226027
that O 0 0.00046653446
these O 0 0.00082072004
proteins O 0 0.0013160025
mediate O 0 0.00088836934
some O 0 0.0011544989
of O 0 0.0017253696
its O 0 0.0044619367
behavioral O 0 0.10195889
effects O 0 0.011846482
. O 0 0.006526632

Therefore O 0 0.003336407
, O 0 0.0024827549
three O 0 0.00096981844
novel O 0 0.0021944856
sigma O 0 0.008721
receptor O 0 0.14425766
ligands O 0 0.13946618
with O 0 0.0019638548
antagonist O 0 0.96495193
activity O 0 0.0012417253
were O 0 0.00045529028
evaluated O 0 0.00040752883
in O 0 0.00040572806
Swiss O 0 0.011383755
Webster O 0 0.10876084
mice O 0 0.00032617134
: O 0 0.0010735466
BD1018 B-Chemical 0 0.8186748
( O 0 0.0015152567
3S B-Chemical 0 0.6058874
- I-Chemical 0 0.0012073932
1 I-Chemical 0 0.00049293315
- I-Chemical 0 0.0007303502
[ I-Chemical 0 0.0008098678
2 I-Chemical 0 0.00034258462
- I-Chemical 0 0.0005180931
( I-Chemical 0 0.0003607384
3 I-Chemical 0 0.00022232837
, I-Chemical 0 0.000326056
4 I-Chemical 0 0.0002791005
- I-Chemical 0 0.0007472296
dichlorophenyl I-Chemical 0 0.9763365
) I-Chemical 0 0.0027346006
ethyl I-Chemical 0 0.99660885
] I-Chemical 0 0.0047763376
- I-Chemical 0 0.00079062016
1 I-Chemical 0 0.00032518923
, I-Chemical 0 0.00034608957
4 I-Chemical 0 0.0002547758
- I-Chemical 0 0.0005333506
diazabicyclo I-Chemical 0 0.13467513
[ I-Chemical 0 0.0007846518
4 I-Chemical 0 0.00021407728
. I-Chemical 0 0.00013503514
3 I-Chemical 0 0.00018227518
. I-Chemical 0 0.00014138845
0 I-Chemical 0 0.0003176668
] I-Chemical 0 0.0007988366
nonane I-Chemical 0 0.9099655
) O 0 0.0013277465
, O 0 0.0010928994
BD1063 B-Chemical 0 0.9994355
( O 0 0.0010971716
1 B-Chemical 0 0.0004790175
- I-Chemical 0 0.0007066625
[ I-Chemical 0 0.0007826393
2 I-Chemical 0 0.0003225936
- I-Chemical 0 0.00049465767
( I-Chemical 0 0.00034496497
3 I-Chemical 0 0.00021395527
, I-Chemical 0 0.00031656877
4 I-Chemical 0 0.0002731247
- I-Chemical 0 0.00074266386
dichlorophenyl I-Chemical 0 0.9768986
) I-Chemical 0 0.0028394526
ethyl I-Chemical 0 0.99677175
] I-Chemical 0 0.0054139355
- I-Chemical 0 0.0009030504
4 I-Chemical 0 0.00034792427
- I-Chemical 0 0.000795678
methylpiperazine I-Chemical 0 0.7487104
) O 0 0.00095110317
, O 0 0.0004976528
and O 0 0.0005156506
LR132 B-Chemical 0 0.9083433
( O 0 0.0020147583
1R O 0 0.95600235
, O 0 0.0015615805
2S O 0 0.8726845
- O 0 0.0019367897
( O 0 0.000792122
+ O 0 0.0006307888
) O 0 0.00086511136
- O 0 0.00079282507
cis O 0 0.008700068
- O 0 0.0017281479
N O 0 0.86203444
- O 0 0.0016572167
[ O 0 0.0012437364
2 O 0 0.00038156062
- O 0 0.0005624555
( O 0 0.00037972847
3 O 0 0.00023568013
, O 0 0.00035091967
4 O 0 0.0003088276
- O 0 0.0008420215
dichlorophenyl O 0 0.9735561
) O 0 0.002964046
ethyl O 0 0.9957497
] O 0 0.0052896445
- O 0 0.0012506143
2 O 0 0.0006792574
- O 0 0.001137215
( O 0 0.0010020498
1 O 0 0.0010264541
- O 0 0.0022913336
pyrrolidinyl O 0 0.7572259
) O 0 0.008543098
cyclohexylamine O 0 0.99634403
) O 0 0.013836886
. O 0 0.006912638

Competition O 0 0.0110759875
binding O 0 0.0033465244
assays O 0 0.002477014
demonstrated O 0 0.0016792518
that O 0 0.0010787273
all O 0 0.00097501965
three O 0 0.0008179944
compounds O 0 0.13900124
have O 0 0.0016921083
high O 0 0.0025899822
affinities O 0 0.0073871054
for O 0 0.0037006927
sigma1 O 0 0.8624254
receptors O 0 0.4853469
. O 0 0.010422468

The O 0 0.0026849355
three O 0 0.0015469363
compounds O 0 0.087035686
vary O 0 0.0020253775
in O 0 0.00091509137
their O 0 0.00087133
affinities O 0 0.0020747397
for O 0 0.0006129173
sigma2 O 0 0.029896088
receptors O 0 0.08261488
and O 0 0.000669835
exhibit O 0 0.00063801464
negligible O 0 0.0008319022
affinities O 0 0.003942106
for O 0 0.000859124
dopamine B-Chemical 1 0.9991602
, O 0 0.0044748033
opioid O 0 0.9983789
, O 0 0.013358234
GABA B-Chemical 1 0.9995634
( O 0 0.0054408535
A O 0 0.04612281
) O 0 0.0045629824
and O 0 0.0054786983
NMDA B-Chemical 1 0.99894375
receptors O 0 0.72293586
. O 0 0.009885698

In O 0 0.003347024
behavioral O 0 0.010620174
studies O 0 0.003033177
, O 0 0.0021144312
pre O 0 0.0037957628
- O 0 0.0017479646
treatment O 0 0.0014081037
of O 0 0.0008617246
mice O 0 0.00050205423
with O 0 0.0011672482
BD1018 B-Chemical 0 0.9079451
, O 0 0.0035277503
BD1063 B-Chemical 0 0.9993356
, O 0 0.0015407086
or O 0 0.00076126197
LR132 B-Chemical 0 0.8500065
significantly O 0 0.0018050075
attenuated O 0 0.030896999
cocaine B-Chemical 1 0.99950504
- O 0 0.015696768
induced O 0 0.015619127
convulsions B-Disease 0 0.9994387
and O 0 0.010780779
lethality O 0 0.6688014
. O 0 0.007901185

Moreover O 0 0.0063739964
, O 0 0.004061657
post O 0 0.0032163635
- O 0 0.002925765
treatment O 0 0.0027459136
with O 0 0.0021238928
LR132 B-Chemical 0 0.9208863
prevented O 0 0.048535444
cocaine B-Chemical 1 0.9995585
- O 0 0.007610013
induced O 0 0.0022165426
lethality O 0 0.16908935
in O 0 0.00094527856
a O 0 0.0011885014
significant O 0 0.0015162526
proportion O 0 0.0013741172
of O 0 0.003188954
animals O 0 0.004427136
. O 0 0.006084615

In O 0 0.002911861
contrast O 0 0.002099898
to O 0 0.0014194975
the O 0 0.0011411373
protection O 0 0.002667293
provided O 0 0.0009779474
by O 0 0.000751505
the O 0 0.000602533
putative O 0 0.0010325325
antagonists O 0 0.9406206
, O 0 0.0009715066
the O 0 0.00041050932
well O 0 0.0003852015
- O 0 0.000799085
characterized O 0 0.0008805244
sigma O 0 0.016734593
receptor O 0 0.35702068
agonist O 0 0.9874917
di B-Chemical 0 0.055005237
- I-Chemical 0 0.0023292399
o I-Chemical 0 0.007418286
- I-Chemical 0 0.0012589445
tolylguanidine I-Chemical 0 0.027926335
( O 0 0.0012891992
DTG B-Chemical 0 0.99831676
) O 0 0.0009840886
and O 0 0.00030260131
the O 0 0.0002447671
novel O 0 0.0007104289
sigma O 0 0.013163796
receptor O 0 0.38095853
agonist O 0 0.99356633
BD1031 B-Chemical 0 0.9929207
( O 0 0.0040057153
3R B-Chemical 0 0.83445984
- I-Chemical 0 0.0015551834
1 I-Chemical 0 0.00048239194
- I-Chemical 0 0.0007159232
[ I-Chemical 0 0.00078381854
2 I-Chemical 0 0.00032066857
- I-Chemical 0 0.000491739
( I-Chemical 0 0.0003423747
3 I-Chemical 0 0.00021250485
, I-Chemical 0 0.00031442
4 I-Chemical 0 0.00027114374
- I-Chemical 0 0.00073424174
dichlorophenyl I-Chemical 0 0.9761331
) I-Chemical 0 0.0027023773
ethyl I-Chemical 0 0.9965706
] I-Chemical 0 0.0047155465
- I-Chemical 0 0.00079146324
1 I-Chemical 0 0.00032918912
, I-Chemical 0 0.0003526152
4 I-Chemical 0 0.0002623504
- I-Chemical 0 0.00055314915
diazabicyclo I-Chemical 0 0.13066226
[ I-Chemical 0 0.00081280683
4 I-Chemical 0 0.00023177214
. I-Chemical 0 0.00015086388
3 I-Chemical 0 0.00020703765
. I-Chemical 0 0.00016757187
0 I-Chemical 0 0.00037342196
] I-Chemical 0 0.0008750878
nonane I-Chemical 0 0.7711374
) O 0 0.0008011452
each O 0 0.0003083116
worsened O 0 0.047156315
the O 0 0.0011510749
behavioral O 0 0.15251818
toxicity B-Disease 2 0.99269485
of O 0 0.022177396
cocaine B-Chemical 1 0.9982114
. O 0 0.009624707

At O 0 0.0027669219
doses O 0 0.012122814
where O 0 0.0018146305
alone O 0 0.0017850905
, O 0 0.0013570193
they O 0 0.00067098875
produced O 0 0.0006227535
no O 0 0.00044606157
significant O 0 0.00067555305
effects O 0 0.0010328759
on O 0 0.0003950133
locomotion O 0 0.13291939
, O 0 0.0015036165
BD1018 B-Chemical 0 0.89064723
, O 0 0.0024740454
BD1063 B-Chemical 0 0.9992799
and O 0 0.001382266
LR132 B-Chemical 0 0.88386846
significantly O 0 0.0012364757
attenuated O 0 0.0027406435
the O 0 0.0011139074
locomotor O 0 0.46055937
stimulatory O 0 0.052355085
effects O 0 0.009235259
of O 0 0.013458761
cocaine B-Chemical 1 0.99813676
. O 0 0.010157119

To O 0 0.0023726104
further O 0 0.0018216859
validate O 0 0.0010549105
the O 0 0.00097186136
hypothesis O 0 0.0011518088
that O 0 0.000671248
the O 0 0.0007583899
anti O 0 0.0075494945
- O 0 0.0027770635
cocaine B-Chemical 1 0.99909437
effects O 0 0.0019617407
of O 0 0.0005857562
the O 0 0.00036078083
novel O 0 0.00087284023
ligands O 0 0.04272485
involved O 0 0.00053651846
antagonism O 0 0.55008537
of O 0 0.00091851386
sigma O 0 0.029846998
receptors O 0 0.250378
, O 0 0.0007073989
an O 0 0.00053790945
antisense O 0 0.030605868
oligodeoxynucleotide B-Chemical 0 0.89433366
against O 0 0.00090354757
sigma1 O 0 0.93372416
receptors O 0 0.29475996
was O 0 0.0004554472
also O 0 0.0003740066
shown O 0 0.00023200958
to O 0 0.00028327532
significantly O 0 0.00054147816
attenuate O 0 0.005603951
the O 0 0.0009888451
convulsive B-Disease 2 0.99972934
and O 0 0.002106592
locomotor O 0 0.62458867
stimulatory O 0 0.059891894
effects O 0 0.009011283
of O 0 0.012625775
cocaine B-Chemical 1 0.9981877
. O 0 0.009500051

Together O 0 0.008726361
, O 0 0.003449531
the O 0 0.0015911364
data O 0 0.0014228141
suggests O 0 0.00074871903
that O 0 0.0006868351
functional O 0 0.0013581009
antagonism O 0 0.35881898
of O 0 0.0012688929
sigma O 0 0.022310428
receptors O 0 0.16427495
is O 0 0.0006968012
capable O 0 0.0007472442
of O 0 0.0007914196
attenuating O 0 0.017694082
a O 0 0.0010356285
number O 0 0.0008726112
of O 0 0.002987062
cocaine B-Chemical 1 0.9990777
- O 0 0.010934784
induced O 0 0.007008018
behaviors O 0 0.14373104
. O 0 0.0066173263

Ranitidine B-Chemical 0 0.99843746
- O 0 0.017968312
induced O 0 0.009952248
acute O 0 0.98230386
interstitial B-Disease 2 0.9921812
nephritis I-Disease 2 0.9996043
in O 0 0.0066256877
a O 0 0.0067387763
cadaveric O 0 0.47701237
renal O 0 0.98986137
allograft O 0 0.98060703
. O 0 0.015169944

Ranitidine B-Chemical 0 0.9978309
frequently O 0 0.009252229
is O 0 0.003399404
used O 0 0.0025155763
for O 0 0.0024733946
preventing O 0 0.010801586
peptic O 0 0.9975777
ulceration O 0 0.99786156
after O 0 0.008185812
renal O 0 0.99068224
transplantation O 0 0.84345686
. O 0 0.01322029

This O 0 0.0067501604
drug O 0 0.1540695
occasionally O 0 0.006707541
has O 0 0.0024066255
been O 0 0.0023886824
associated O 0 0.0026662338
with O 0 0.0038059906
acute O 0 0.9881572
interstitial B-Disease 2 0.9949633
nephritis I-Disease 2 0.9997298
in O 0 0.008815483
native O 0 0.013314137
kidneys O 0 0.2251979
. O 0 0.0089181205

There O 0 0.010103633
are O 0 0.0054468075
no O 0 0.0038687545
similar O 0 0.0037853317
reports O 0 0.0076698074
with O 0 0.010763766
renal O 0 0.9790867
transplantation O 0 0.768797
. O 0 0.018634306

We O 0 0.0033735298
report O 0 0.004557403
a O 0 0.0021073641
case O 0 0.0017171549
of O 0 0.0027437247
ranitidine B-Chemical 1 0.99975747
- O 0 0.013880047
induced O 0 0.004454707
acute O 0 0.99181366
interstitial B-Disease 2 0.99683976
nephritis I-Disease 2 0.99993825
in O 0 0.0012372237
a O 0 0.00062247965
recipient O 0 0.00094438327
of O 0 0.00043120232
a O 0 0.0004804094
cadaveric O 0 0.07551203
renal O 0 0.98986185
allograft O 0 0.9796361
presenting O 0 0.12943119
with O 0 0.0016298348
acute O 0 0.9762591
allograft O 0 0.9912765
dysfunction O 0 0.97173315
within O 0 0.00037689236
48 O 0 0.0005247984
hours O 0 0.00047102774
of O 0 0.00084431
exposure O 0 0.0028948914
to O 0 0.001551932
the O 0 0.002761496
drug O 0 0.40642643
. O 0 0.006540268

The O 0 0.0037090268
biopsy O 0 0.006445329
specimen O 0 0.0032073976
showed O 0 0.0022619383
pathognomonic O 0 0.01923111
features O 0 0.0051575014
, O 0 0.0025854988
including O 0 0.0025738655
eosinophilic O 0 0.99292177
infiltration O 0 0.8521906
of O 0 0.0044707437
the O 0 0.004059906
interstitial O 0 0.6845394
compartment O 0 0.02184686
. O 0 0.008415993

Allograft O 0 0.19446906
function O 0 0.00452456
improved O 0 0.0044409544
rapidly O 0 0.0038457136
and O 0 0.0019516698
returned O 0 0.0016732693
to O 0 0.0014224085
baseline O 0 0.0020044814
after O 0 0.0014983324
stopping O 0 0.008967206
the O 0 0.004964181
drug O 0 0.44103193
. O 0 0.009907695

Liver B-Disease 0 0.97603136
disease I-Disease 0 0.94187754
caused O 0 0.03215594
by O 0 0.0341065
propylthiouracil B-Chemical 0 0.99293655
. O 0 0.042129654

This O 0 0.004671674
report O 0 0.0045243003
presents O 0 0.0023090919
the O 0 0.0013041898
clinical O 0 0.0050183544
, O 0 0.0012704488
laboratory O 0 0.0014381078
, O 0 0.0008057262
and O 0 0.00051257975
light O 0 0.0008305169
and O 0 0.0004628272
electron O 0 0.01124962
microscopic O 0 0.005454608
observations O 0 0.00068308425
on O 0 0.00021474989
a O 0 0.00038737437
patient O 0 0.0006764978
with O 0 0.0006868224
chronic B-Disease 0 0.9397701
active I-Disease 0 0.0055008833
( I-Disease 0 0.0016377777
aggressive I-Disease 0 0.2426509
) I-Disease 0 0.0079577705
hepatitis I-Disease 2 0.99967146
caused O 0 0.00292002
by O 0 0.001483692
the O 0 0.0016630855
administration O 0 0.27321115
of O 0 0.012072328
propylthiouracil B-Chemical 0 0.9985808
. O 0 0.0122083975

This O 0 0.0051870476
is O 0 0.0023140844
an O 0 0.0017767568
addition O 0 0.00086418935
to O 0 0.0008209484
the O 0 0.00066885905
list O 0 0.00063043594
of O 0 0.0008938058
drugs O 0 0.32738325
that O 0 0.0005681813
must O 0 0.00041840383
be O 0 0.00053149875
considered O 0 0.00046468785
in O 0 0.00048032997
the O 0 0.0006559007
evaluation O 0 0.0015395663
of O 0 0.0031011545
chronic O 0 0.9935893
liver B-Disease 2 0.99556065
disease I-Disease 2 0.99378246
. O 0 0.013201025

Withdrawal B-Disease 0 0.92341465
- I-Disease 0 0.00989604
emergent I-Disease 0 0.010434367
rabbit I-Disease 0 0.041597076
syndrome I-Disease 0 0.91881037
during O 0 0.0033826868
dose O 0 0.046296638
reduction O 0 0.01023869
of O 0 0.016673293
risperidone B-Chemical 0 0.9988238
. O 0 0.016081357

Rabbit B-Disease 0 0.34785667
syndrome I-Disease 0 0.96996474
( O 0 0.009571936
RS B-Disease 0 0.88249934
) O 0 0.0041510467
is O 0 0.0015020086
a O 0 0.0016205645
rare O 0 0.032695763
extrapyramidal O 0 0.99953604
side O 0 0.11592841
effect O 0 0.0021708854
caused O 0 0.002327441
by O 0 0.0027782246
prolonged O 0 0.3791363
neuroleptic O 0 0.9997019
medication O 0 0.90459216
. O 0 0.009877528

Here O 0 0.0045915875
we O 0 0.0013908778
present O 0 0.0012125798
a O 0 0.0013759256
case O 0 0.0011747534
of O 0 0.001571882
withdrawal B-Disease 0 0.7770158
- I-Disease 0 0.0027732342
emergent I-Disease 0 0.007941528
RS I-Disease 0 0.9073718
, O 0 0.0011586999
which O 0 0.0007930188
is O 0 0.00050126074
the O 0 0.00043100037
first O 0 0.00044975936
of O 0 0.000897705
its O 0 0.0019271519
kind O 0 0.002573831
to O 0 0.002013516
be O 0 0.0032102922
reported O 0 0.0065068924
. O 0 0.0061195754

The O 0 0.0052976846
patient O 0 0.0069355667
developed O 0 0.008402518
RS B-Disease 0 0.61169475
during O 0 0.004067092
dose O 0 0.03864351
reduction O 0 0.011350226
of O 0 0.017990556
risperidone B-Chemical 0 0.99862397
. O 0 0.01815419

The O 0 0.0052726264
symptom O 0 0.019456906
was O 0 0.0037093863
treated O 0 0.0047997455
successfully O 0 0.006270078
with O 0 0.011359739
trihexyphenidyl B-Chemical 1 0.9997247
anticholinergic O 0 0.9988323
therapy O 0 0.73178
. O 0 0.015739445

The O 0 0.002859752
underlying O 0 0.0036723695
mechanism O 0 0.0023666145
of O 0 0.0021981157
withdrawal B-Disease 0 0.7853693
- I-Disease 0 0.0028575177
emergent I-Disease 0 0.005551281
RS I-Disease 0 0.8186236
in O 0 0.0004858199
the O 0 0.00033771063
present O 0 0.00024607845
case O 0 0.00034715014
may O 0 0.0003111695
have O 0 0.00032165082
been O 0 0.0003516796
related O 0 0.00019914552
to O 0 0.00021823957
the O 0 0.00023198241
pharmacological O 0 0.14291635
profile O 0 0.00075659575
of O 0 0.0014772197
risperidone B-Chemical 0 0.9999318
, O 0 0.001944905
a O 0 0.0013576229
serotonin B-Chemical 1 0.99942076
- O 0 0.01362391
dopamine B-Chemical 1 0.9996001
antagonist O 0 0.98734206
, O 0 0.00077684544
suggesting O 0 0.0002768895
the O 0 0.00028851014
pathophysiologic O 0 0.038176514
influence O 0 0.0003821888
of O 0 0.0006870957
the O 0 0.00082795677
serotonin B-Chemical 1 0.99761593
system O 0 0.0018180272
in O 0 0.0009484857
the O 0 0.0013358688
development O 0 0.0046474338
of O 0 0.0062455665
RS B-Disease 0 0.93273365
. O 0 0.008101471

Pharmacokinetic O 0 0.9434088
/ O 0 0.0069242753
pharmacodynamic O 0 0.55010986
assessment O 0 0.0016366341
of O 0 0.0012833836
the O 0 0.00090553757
effects O 0 0.0018096657
of O 0 0.0023743198
E4031 B-Chemical 0 0.99979705
, O 0 0.011977345
cisapride B-Chemical 1 0.9998165
, O 0 0.012760568
terfenadine B-Chemical 1 0.9998994
and O 0 0.003406058
terodiline B-Chemical 1 0.9993648
on O 0 0.00069400773
monophasic O 0 0.57335997
action O 0 0.008366129
potential O 0 0.0020785627
duration O 0 0.002945601
in O 0 0.0028946854
dog O 0 0.010600953
. O 0 0.0061728493

1 O 0 0.08232081
. O 0 0.074582

Torsades B-Disease 0 0.9960639
de I-Disease 0 0.48367804
pointes I-Disease 0 0.9997744
( O 0 0.032258008
TDP B-Disease 0 0.99456245
) O 0 0.004111813
is O 0 0.0010066705
a O 0 0.0009320692
potentially O 0 0.0035754626
fatal O 0 0.98966414
ventricular B-Disease 2 0.9990491
tachycardia I-Disease 2 0.99979585
associated O 0 0.0027905114
with O 0 0.0007779248
increases O 0 0.0006544982
in O 0 0.0005153428
QT O 0 0.9816522
interval O 0 0.0009537639
and O 0 0.0006087988
monophasic O 0 0.3340535
action O 0 0.005436804
potential O 0 0.0017508316
duration O 0 0.0030819762
( O 0 0.004552698
MAPD O 0 0.74016225
) O 0 0.008533592
. O 0 0.0061325594

TDP B-Disease 0 0.9742619
is O 0 0.0041505224
a O 0 0.0028958167
side O 0 0.020394925
- O 0 0.0021502562
effect O 0 0.0009760872
that O 0 0.00056495087
has O 0 0.0005956724
led O 0 0.00077465764
to O 0 0.0005296423
withdrawal O 0 0.35351497
of O 0 0.0006516432
several O 0 0.0006397979
drugs O 0 0.38075304
from O 0 0.00047961832
the O 0 0.00045411196
market O 0 0.0019375631
( O 0 0.00079744577
e O 0 0.0011389994
. O 0 0.0004377335
g O 0 0.0018689876
. O 0 0.0009752073
terfenadine B-Chemical 1 0.99952686
and O 0 0.0075848326
terodiline B-Chemical 1 0.9985545
) O 0 0.016504189
. O 0 0.006837865

2 O 0 0.0815455
. O 0 0.074968144

The O 0 0.0031695191
potential O 0 0.003195527
of O 0 0.0028760785
compounds O 0 0.3110049
to O 0 0.0020109862
cause O 0 0.008517015
TDP B-Disease 0 0.9904822
was O 0 0.0012928161
evaluated O 0 0.0009062172
by O 0 0.00089606293
monitoring O 0 0.0013100521
their O 0 0.0012227386
effects O 0 0.002361663
on O 0 0.0015029915
MAPD O 0 0.5601053
in O 0 0.0037669956
dog O 0 0.012382572
. O 0 0.0073298463

Four O 0 0.00722347
compounds O 0 0.20129739
known O 0 0.003161176
to O 0 0.0016128179
increase O 0 0.0015625712
QT O 0 0.9760094
interval O 0 0.0021390938
and O 0 0.0012039057
cause O 0 0.0049554175
TDP B-Disease 0 0.99037594
were O 0 0.0012147346
investigated O 0 0.0013547395
: O 0 0.0044416776
terfenadine B-Chemical 1 0.9997942
, O 0 0.014756055
terodiline B-Chemical 1 0.999303
, O 0 0.018958958
cisapride B-Chemical 1 0.99931896
and O 0 0.033649188
E4031 B-Chemical 0 0.9987872
. O 0 0.0117768105

On O 0 0.0034233218
the O 0 0.0017917873
basis O 0 0.0016877715
that O 0 0.00096454524
only O 0 0.000933184
free O 0 0.0014303718
drug O 0 0.18427296
in O 0 0.00063349504
the O 0 0.0005839313
systemic O 0 0.6931839
circulation O 0 0.018053677
will O 0 0.00029468277
elicit O 0 0.00030508236
a O 0 0.0003590981
pharmacological O 0 0.16625203
response O 0 0.0008208398
target O 0 0.000383772
, O 0 0.00045886173
free O 0 0.00059298147
concentrations O 0 0.0016975583
in O 0 0.0003164607
plasma O 0 0.009593247
were O 0 0.0003168668
selected O 0 0.00030227433
to O 0 0.0003802262
mimic O 0 0.00081351656
the O 0 0.0006662002
free O 0 0.0019763494
drug O 0 0.35717276
exposures O 0 0.09010066
in O 0 0.004146996
man O 0 0.36893973
. O 0 0.0068947156

Infusion O 0 0.40067515
regimens O 0 0.014745009
were O 0 0.0016030784
designed O 0 0.0011956994
that O 0 0.00068130123
rapidly O 0 0.0012197096
achieved O 0 0.00076817547
and O 0 0.00053889246
maintained O 0 0.0005027971
target O 0 0.00049698155
- O 0 0.0007298315
free O 0 0.0005996802
concentrations O 0 0.0012550922
of O 0 0.00043246328
these O 0 0.0005984
drugs O 0 0.5456002
in O 0 0.00036688882
plasma O 0 0.021133672
and O 0 0.00030843742
data O 0 0.0002899034
on O 0 0.0001331064
the O 0 0.0001872467
relationship O 0 0.00017481565
between O 0 0.00015516291
free O 0 0.0005660518
concentration O 0 0.0013638993
and O 0 0.00048373447
changes O 0 0.00077346194
in O 0 0.000567259
MAPD O 0 0.35490406
were O 0 0.0007851028
obtained O 0 0.0009879745
for O 0 0.0013964217
these O 0 0.004108495
compounds O 0 0.60517347
. O 0 0.007393118

3 O 0 0.07487772
. O 0 0.072802074

These O 0 0.004185037
data O 0 0.002552524
indicate O 0 0.0012960654
that O 0 0.0010958534
the O 0 0.00108932
free O 0 0.0021930344
ED50 O 0 0.97548985
in O 0 0.00095533225
plasma O 0 0.037898373
for O 0 0.0009958732
terfenadine B-Chemical 1 0.9998939
( O 0 0.002264098
1 O 0 0.00056158844
. O 0 0.00025338435
9 O 0 0.0003965644
nM O 0 0.006826534
) O 0 0.00071286265
, O 0 0.00070649706
terodiline B-Chemical 1 0.99942565
( O 0 0.0009914227
76 O 0 0.0011742981
nM O 0 0.017877651
) O 0 0.00079267315
, O 0 0.0007436472
cisapride B-Chemical 1 0.99975353
( O 0 0.0012220797
11 O 0 0.0006116296
nM O 0 0.015926462
) O 0 0.0006737977
and O 0 0.0005742619
E4031 B-Chemical 0 0.9998099
( O 0 0.0010185367
1 O 0 0.00035994826
. O 0 0.00017323747
9 O 0 0.00028944743
nM O 0 0.0034722956
) O 0 0.00040178464
closely O 0 0.00025786302
correlate O 0 0.00028166999
with O 0 0.00039950147
the O 0 0.00041518573
free O 0 0.0010715582
concentration O 0 0.002791066
in O 0 0.0011780558
man O 0 0.26077577
causing O 0 0.03921276
QT O 0 0.9933264
effects O 0 0.02025694
. O 0 0.0072944416

For O 0 0.0034668152
compounds O 0 0.12187079
that O 0 0.0017954431
have O 0 0.001701005
shown O 0 0.0013018057
TDP B-Disease 0 0.97803795
in O 0 0.00096285535
the O 0 0.00076550385
clinic O 0 0.0018654746
( O 0 0.002507013
terfenadine B-Chemical 1 0.9998894
, O 0 0.007734082
terodiline B-Chemical 1 0.99972945
, O 0 0.0054092337
cisapride B-Chemical 1 0.99984133
) O 0 0.0017492515
there O 0 0.0002171776
is O 0 0.00026982315
little O 0 0.00028685245
differentiation O 0 0.020819187
between O 0 0.00014817747
the O 0 0.00024592178
dog O 0 0.0016460464
ED50 O 0 0.9656101
and O 0 0.000376721
the O 0 0.00029473
efficacious O 0 0.013603183
free O 0 0.0009004373
plasma O 0 0.04314819
concentrations O 0 0.003960767
in O 0 0.00044812998
man O 0 0.17379019
( O 0 0.00076104404
< O 0 0.000526837
10 O 0 0.0004413909
- O 0 0.0006962121
fold O 0 0.0009261382
) O 0 0.00085350056
reflecting O 0 0.00077956996
their O 0 0.0009812093
limited O 0 0.0015966493
safety O 0 0.006608245
margins O 0 0.0120203225
. O 0 0.005564732

These O 0 0.0038960068
data O 0 0.0023464654
underline O 0 0.0018106384
the O 0 0.0011072177
need O 0 0.00077587616
to O 0 0.00057780335
maximize O 0 0.0003580978
the O 0 0.00048097665
therapeutic O 0 0.004413854
ratio O 0 0.0007473981
with O 0 0.00055210775
respect O 0 0.00039795786
to O 0 0.00047178473
TDP B-Disease 0 0.98065954
in O 0 0.00035782275
potential O 0 0.0005184557
development O 0 0.000726039
candidates O 0 0.0003142042
and O 0 0.00028035315
the O 0 0.00022632969
importance O 0 0.00024076934
of O 0 0.0004119195
using O 0 0.00036810836
free O 0 0.0010297672
drug O 0 0.24957356
concentrations O 0 0.0049652127
in O 0 0.0011862625
pharmacokinetic O 0 0.82808524
/ O 0 0.008910323
pharmacodynamic O 0 0.86644465
studies O 0 0.008204097
. O 0 0.0061581237

Bladder O 0 0.65614116
retention B-Disease 0 0.009720794
of I-Disease 0 0.0031681226
urine I-Disease 0 0.22029887
as O 0 0.0012429884
a O 0 0.0010809356
result O 0 0.00067105226
of O 0 0.00087229145
continuous O 0 0.0011115919
intravenous O 0 0.46154058
infusion O 0 0.0889228
of O 0 0.0033736967
fentanyl B-Chemical 1 0.99915206
: O 0 0.0050126812
2 O 0 0.0023504337
case O 0 0.0029746084
reports O 0 0.0071099102
. O 0 0.006273076

Sedation O 0 0.2774305
has O 0 0.0028090456
been O 0 0.0020455848
commonly O 0 0.002444454
used O 0 0.0009708687
in O 0 0.00068078685
the O 0 0.00063986523
neonate O 0 0.0075967684
to O 0 0.00051103474
decrease O 0 0.00060961104
the O 0 0.00045705686
stress O 0 0.11972521
and O 0 0.00083354156
pain B-Disease 0 0.94475585
from O 0 0.00041365845
the O 0 0.00033911646
noxious O 0 0.6117072
stimuli O 0 0.0029881555
and O 0 0.0003360502
invasive O 0 0.00272463
procedures O 0 0.0004609046
in O 0 0.00022677984
the O 0 0.00023673997
neonatal O 0 0.004661197
intensive O 0 0.0005505762
care O 0 0.0005932612
unit O 0 0.00032472613
, O 0 0.00036998585
as O 0 0.00019908174
well O 0 0.00021264999
as O 0 0.00022648189
to O 0 0.0002934652
facilitate O 0 0.00035770817
synchrony O 0 0.002408087
between O 0 0.0005305935
ventilator O 0 0.022159228
and O 0 0.0022378159
spontaneous O 0 0.047385238
breaths O 0 0.10588232
. O 0 0.006108889

Fentanyl B-Chemical 0 0.99798393
, O 0 0.006465679
an O 0 0.0040696566
opioid O 0 0.9956519
analgesic O 0 0.99474066
, O 0 0.0025131844
is O 0 0.0008971214
frequently O 0 0.0011440902
used O 0 0.00052659324
in O 0 0.0004439817
the O 0 0.0004930713
neonatal O 0 0.0043570623
intensive O 0 0.0010388014
care O 0 0.0011448856
unit O 0 0.00077388476
setting O 0 0.0011912686
for O 0 0.0010187819
these O 0 0.0022645937
very O 0 0.0036858504
purposes O 0 0.0059630666
. O 0 0.0062158504

Various O 0 0.012704638
reported O 0 0.0045949235
side O 0 0.009498957
effects O 0 0.0031362176
of O 0 0.0026655367
fentanyl B-Chemical 1 0.9992681
administration O 0 0.5410425
include O 0 0.0028300176
chest B-Disease 0 0.71491444
wall I-Disease 0 0.31684214
rigidity I-Disease 2 0.9947883
, O 0 0.009420422
hypotension B-Disease 2 0.9995777
, O 0 0.005798506
respiratory B-Disease 0 0.80702984
depression I-Disease 0 0.994826
, O 0 0.0058300938
and O 0 0.0067183613
bradycardia B-Disease 0 0.99620926
. O 0 0.008156569

Here O 0 0.0062624817
, O 0 0.0033633292
2 O 0 0.0016493135
cases O 0 0.0018284443
of O 0 0.0016149292
urinary B-Disease 0 0.89204913
bladder I-Disease 0 0.9194728
retention I-Disease 0 0.037424777
leading O 0 0.003392784
to O 0 0.0009698619
renal O 0 0.9932816
pelvocalyceal O 0 0.8260422
dilatation O 0 0.9854414
mimicking O 0 0.1328584
hydronephrosis B-Disease 0 0.99894243
as O 0 0.0005963515
a O 0 0.00055516127
result O 0 0.00037077573
of O 0 0.0006036363
continuous O 0 0.0008919894
infusion O 0 0.036491744
of O 0 0.0031269528
fentanyl B-Chemical 1 0.9988617
are O 0 0.004926595
reported O 0 0.00830205
. O 0 0.00597906

Fatal O 0 0.8846573
myeloencephalopathy B-Disease 0 0.97424364
due O 0 0.003397153
to O 0 0.0030583532
accidental O 0 0.5875105
intrathecal O 0 0.9902998
vincristin B-Chemical 0 0.99911183
administration O 0 0.7661823
: O 0 0.004224637
a O 0 0.0022198842
report O 0 0.0045993635
of O 0 0.0031630162
two O 0 0.0034216503
cases O 0 0.010259985
. O 0 0.00826737

We O 0 0.0034001847
report O 0 0.004361017
on O 0 0.0012977348
two O 0 0.0013648283
fatal O 0 0.78261614
cases O 0 0.0026891194
of O 0 0.0017595205
accidental O 0 0.76546866
intrathecal O 0 0.9938247
vincristine B-Chemical 1 0.9998053
instillation O 0 0.6241901
in O 0 0.00068365707
a O 0 0.00058987265
5 O 0 0.00035472587
- O 0 0.00044752564
year O 0 0.00029551273
old O 0 0.00039059887
girl O 0 0.0017917327
with O 0 0.0006684331
recurrent O 0 0.78630733
acute B-Disease 0 0.9983676
lymphoblastic I-Disease 0 0.9998894
leucemia I-Disease 0 0.9981737
and O 0 0.0019052178
a O 0 0.0010525055
57 O 0 0.0015671962
- O 0 0.0010880828
year O 0 0.00091013673
old O 0 0.0016658889
man O 0 0.17364927
with O 0 0.013831876
lymphoblastic B-Disease 0 0.99949384
lymphoma I-Disease 0 0.99857414
. O 0 0.01960725

The O 0 0.0038540158
girl O 0 0.0077574155
died O 0 0.0069846166
seven O 0 0.0017569436
days O 0 0.0014945897
, O 0 0.0015281307
the O 0 0.0010658578
man O 0 0.012460234
four O 0 0.0008025633
weeks O 0 0.0011342051
after O 0 0.0010790598
intrathecal O 0 0.79046476
injection O 0 0.022475967
of O 0 0.011413211
vincristine B-Chemical 1 0.99813735
. O 0 0.013091389

Clinically O 0 0.14521527
, O 0 0.0038121354
the O 0 0.0018517034
onset O 0 0.0040681125
was O 0 0.0012928875
characterized O 0 0.0015993249
by O 0 0.0009570586
the O 0 0.0008396479
signs O 0 0.038132653
of O 0 0.0013389245
opistothonus B-Disease 0 0.023315419
, I-Disease 0 0.0016934306
sensory I-Disease 0 0.062273957
and I-Disease 0 0.0016962368
motor I-Disease 0 0.22422458
dysfunction I-Disease 0 0.9506234
and O 0 0.005130437
ascending O 0 0.5989054
paralysis B-Disease 2 0.99634427
. O 0 0.009914799

Histological O 0 0.19004668
and O 0 0.0038595556
immunohistochemical O 0 0.012337064
investigations O 0 0.0071741985
( O 0 0.0041590766
HE O 0 0.9544229
- O 0 0.0072791884
LFB O 0 0.9877686
, O 0 0.0028046826
CD O 0 0.87616366
- O 0 0.001972926
68 O 0 0.0014152485
, O 0 0.0010428746
Neurofilament O 0 0.8808076
) O 0 0.001156457
revealed O 0 0.0006772404
degeneration B-Disease 0 0.9649589
of I-Disease 0 0.0010038567
myelin I-Disease 0 0.33848998
and I-Disease 0 0.0006130794
axons I-Disease 0 0.013957705
as O 0 0.00022784225
well O 0 0.00022532434
as O 0 0.00027909275
pseudocystic B-Disease 0 0.5666434
transformation I-Disease 0 0.19736771
in O 0 0.00039893613
areas O 0 0.001275597
exposed O 0 0.0005717771
to O 0 0.0005641148
vincristine B-Chemical 1 0.99957436
, O 0 0.001390732
accompanied O 0 0.002030789
by O 0 0.0007354863
secondary O 0 0.002283179
changes O 0 0.0016286728
with O 0 0.0016920996
numerous O 0 0.0060844645
prominent O 0 0.033259265
macrophages O 0 0.05014059
. O 0 0.0065814015

The O 0 0.0037153454
clinical O 0 0.006680436
course O 0 0.003627587
and O 0 0.002556458
histopathological O 0 0.12852022
results O 0 0.0017756864
of O 0 0.0021362302
the O 0 0.001847331
two O 0 0.0019618147
cases O 0 0.0050048865
are O 0 0.004650007
presented O 0 0.0075156866
. O 0 0.008379304

A O 0 0.016463742
review O 0 0.006689637
of O 0 0.0034388697
all O 0 0.0024394246
reported O 0 0.0032655431
cases O 0 0.0037786805
in O 0 0.0022909432
the O 0 0.0027642448
literature O 0 0.006465122
is O 0 0.0048485007
given O 0 0.005503435
. O 0 0.0087085925

A O 0 0.01287402
better O 0 0.0035808007
controlled O 0 0.0025279135
regimen O 0 0.0062628677
for O 0 0.0019955179
administering O 0 0.047379833
vincristine B-Chemical 1 0.9988356
and O 0 0.007073139
intrathecal O 0 0.986566
chemotherapy O 0 0.9613375
is O 0 0.007196656
recommended O 0 0.009420125
. O 0 0.008070485

Palpebral B-Disease 0 0.93533206
twitching I-Disease 0 0.91701084
in O 0 0.008482788
a O 0 0.009814784
depressed B-Disease 2 0.64709705
adolescent O 0 0.17206834
on O 0 0.011874501
citalopram B-Chemical 1 0.9976562
. O 0 0.021999309

Current O 0 0.0138171585
estimates O 0 0.0023435517
suggest O 0 0.0013117278
that O 0 0.0010406259
between O 0 0.00065787655
0 O 0 0.0008983856
. O 0 0.00043009088
4 O 0 0.00041452545
% O 0 0.00044700917
and O 0 0.0003787446
8 O 0 0.00035602684
. O 0 0.00021564223
3 O 0 0.00025999968
% O 0 0.0003177129
of O 0 0.00039457623
children O 0 0.0009940639
and O 0 0.00068260403
adolescents O 0 0.0045803995
are O 0 0.00091820664
affected O 0 0.001138949
by O 0 0.0022938945
major B-Disease 2 0.02120807
depression I-Disease 2 0.9942879
. O 0 0.008838695

We O 0 0.003197335
report O 0 0.0042329817
a O 0 0.0019538791
favorable O 0 0.0049339193
response O 0 0.0017301126
to O 0 0.00087963097
treatment O 0 0.0020320853
with O 0 0.0017023894
citalopram B-Chemical 1 0.9998215
by O 0 0.00095419335
a O 0 0.00066186045
15 O 0 0.00041122272
- O 0 0.00055486267
year O 0 0.00039399212
- O 0 0.0005326038
old O 0 0.00037657164
boy O 0 0.0014126174
with O 0 0.0004829494
major B-Disease 2 0.003960242
depression I-Disease 2 0.9980046
who O 0 0.0041124597
exhibited O 0 0.0009433954
palpebral B-Disease 0 0.8400541
twitching I-Disease 0 0.9396332
during O 0 0.00050632714
his O 0 0.0010589104
first O 0 0.00057793444
2 O 0 0.0008352632
weeks O 0 0.0010533701
of O 0 0.0022339988
treatment O 0 0.0074705505
. O 0 0.005547118

This O 0 0.005395455
may O 0 0.0026815059
have O 0 0.0021139835
been O 0 0.001897068
a O 0 0.001615872
side O 0 0.0065941024
effect O 0 0.0015214724
of O 0 0.0025279252
citalopram B-Chemical 1 0.999713
as O 0 0.0016390161
it O 0 0.002258087
remitted O 0 0.89537096
with O 0 0.002710063
redistribution O 0 0.0093703745
of O 0 0.0059437
doses O 0 0.23799548
. O 0 0.008384599

The O 0 0.007557677
3 O 0 0.006469534
- O 0 0.008327095
week O 0 0.007792779
sulphasalazine B-Chemical 1 0.99781454
syndrome O 0 0.9668933
strikes O 0 0.3401247
again O 0 0.016569493
. O 0 0.014393683

A O 0 0.018791206
34 O 0 0.004882009
- O 0 0.003309241
year O 0 0.0017892928
- O 0 0.0018529515
old O 0 0.0011409807
lady O 0 0.0026644103
developed O 0 0.0013374997
a O 0 0.0009139146
constellation O 0 0.021514878
of O 0 0.0020621517
dermatitis B-Disease 2 0.99928695
, O 0 0.016429696
fever B-Disease 0 0.9993754
, O 0 0.007942839
lymphadenopathy B-Disease 2 0.99811375
and O 0 0.0032081371
hepatitis B-Disease 2 0.9998461
, O 0 0.0013300489
beginning O 0 0.00029906185
on O 0 0.0001802709
the O 0 0.0002760279
17th O 0 0.001435295
day O 0 0.00027702627
of O 0 0.0003501966
a O 0 0.00037366163
course O 0 0.0006187975
of O 0 0.0008266719
oral O 0 0.6899999
sulphasalazine B-Chemical 1 0.9997607
for O 0 0.0017206707
sero O 0 0.21462333
- O 0 0.005092111
negative O 0 0.0050387857
rheumatoid B-Disease 2 0.99766374
arthritis I-Disease 2 0.9987091
. O 0 0.01763644

Cervical O 0 0.23350751
and O 0 0.0038642518
inguinal O 0 0.0053915307
lymph O 0 0.021677563
node O 0 0.0025440566
biopsies O 0 0.0024876571
showed O 0 0.0008020897
the O 0 0.0006352612
features O 0 0.0016487428
of O 0 0.0011616505
severe O 0 0.6831735
necrotising O 0 0.99947697
lymphadenitis B-Disease 0 0.99932814
, O 0 0.0024635717
associated O 0 0.0010987519
with O 0 0.0010376697
erythrophagocytosis O 0 0.9567719
and O 0 0.00084106764
prominent O 0 0.04725403
eosinophilic O 0 0.9983552
infiltrates O 0 0.98827064
, O 0 0.0010214312
without O 0 0.0003929312
viral O 0 0.016606037
inclusion O 0 0.00039032783
bodies O 0 0.003020184
, O 0 0.00039792547
suggestive O 0 0.00079770345
of O 0 0.00039362966
an O 0 0.0006075739
adverse B-Disease 0 0.87283874
drug I-Disease 0 0.5982763
reaction I-Disease 0 0.051346544
. O 0 0.00024188732
A O 0 0.003283994
week O 0 0.0002338855
later O 0 0.00026930115
, O 0 0.00062397105
fulminant O 0 0.9995515
drug B-Disease 0 0.8973762
- I-Disease 0 0.004543234
induced I-Disease 0 0.0039305463
hepatitis I-Disease 2 0.9998996
, O 0 0.0022013853
associated O 0 0.00076397695
with O 0 0.00043548044
the O 0 0.00026065693
presence O 0 0.0002862558
of O 0 0.0005157364
anti O 0 0.011945497
- O 0 0.0014152626
nuclear O 0 0.010500187
autoantibodies O 0 0.4721281
( O 0 0.0007806494
but O 0 0.0002452011
not O 0 0.00019297493
with O 0 0.00026770605
other O 0 0.0002609158
markers O 0 0.00090067496
of O 0 0.0010946862
autoimmunity B-Disease 0 0.99717534
) O 0 0.003098608
, O 0 0.00061186723
and O 0 0.00042353277
accompanied O 0 0.0011222552
by O 0 0.00063185435
multi B-Disease 0 0.052753158
- I-Disease 0 0.0022343816
organ I-Disease 0 0.0928815
failure I-Disease 0 0.7019967
and O 0 0.0044768136
sepsis B-Disease 2 0.9970722
, O 0 0.017445117
supervened O 0 0.95716625
. O 0 0.008021694

She O 0 0.0059995386
subsequently O 0 0.0036941234
died O 0 0.006022879
some O 0 0.001433014
5 O 0 0.0007163897
weeks O 0 0.0005050573
after O 0 0.00028444553
the O 0 0.00034394124
commencement O 0 0.0006051873
of O 0 0.0004860487
her O 0 0.0007599932
drug O 0 0.22379301
therapy O 0 0.029062394
. O 0 0.00034570176
Post O 0 0.013465564
- O 0 0.0007223075
mortem O 0 0.06401101
examination O 0 0.00065579003
showed O 0 0.00030648577
evidence O 0 0.00042143886
of O 0 0.00076277135
massive B-Disease 0 0.5977558
hepatocellular I-Disease 0 0.9999565
necrosis I-Disease 2 0.9999094
, O 0 0.10434799
acute O 0 0.9986557
hypersensitivity O 2 0.9995096
myocarditis B-Disease 0 0.9999769
, O 0 0.021414315
focal O 0 0.6100183
acute O 0 0.9958973
tubulo O 0 0.9757707
- O 0 0.021084191
interstitial O 2 0.98980635
nephritis B-Disease 2 0.99993324
and O 0 0.0021096969
extensive O 0 0.0027659985
bone B-Disease 0 0.43721497
marrow I-Disease 0 0.8216688
necrosis I-Disease 2 0.9985495
, O 0 0.002121164
with O 0 0.0012784755
no O 0 0.0010986333
evidence O 0 0.0022893136
of O 0 0.00621673
malignancy B-Disease 2 0.9951159
. O 0 0.0098645585

It O 0 0.0060763992
is O 0 0.0024980095
thought O 0 0.0022525694
that O 0 0.0010535688
the O 0 0.0011040537
clinico O 0 0.17193455
- O 0 0.002002219
pathological O 0 0.10821463
features O 0 0.0021401127
and O 0 0.00055376533
chronology O 0 0.004359693
of O 0 0.0004788209
this O 0 0.00033969368
case O 0 0.00037448827
bore O 0 0.0023039982
the O 0 0.00031383923
hallmarks O 0 0.0018398805
of O 0 0.0005077244
the O 0 0.0003539334
so O 0 0.00039091086
- O 0 0.0007078734
called O 0 0.00048480145
" O 0 0.00045220897
3 O 0 0.00029514224
- O 0 0.00047317977
week O 0 0.0004050503
sulphasalazine B-Chemical 1 0.99980086
syndrome O 0 0.94770765
" O 0 0.00093185966
, O 0 0.00062021916
a O 0 0.00054075016
rare O 0 0.006160242
, O 0 0.00084011647
but O 0 0.0006488668
often O 0 0.0020540846
fatal O 0 0.9744547
, O 0 0.0046873232
immunoallergic O 0 0.9962962
reaction O 0 0.14594541
to O 0 0.008686967
sulphasalazine B-Chemical 1 0.9989814
. O 0 0.011115664

Intravenous O 0 0.91089267
administration O 0 0.17479399
of O 0 0.0041464525
prochlorperazine B-Chemical 1 0.99945754
by O 0 0.0019081179
15 O 0 0.00084670325
- O 0 0.0008220521
minute O 0 0.00041944708
infusion O 0 0.00609452
versus O 0 0.00037404353
2 O 0 0.00035427822
- O 0 0.00039837768
minute O 0 0.00023959
bolus O 0 0.009765348
does O 0 0.00021593973
not O 0 0.00020210419
affect O 0 0.00017743559
the O 0 0.0002897807
incidence O 0 0.0039079017
of O 0 0.001837014
akathisia B-Disease 0 0.99988294
: O 0 0.0017321042
a O 0 0.0007690881
prospective O 0 0.0028425136
, O 0 0.0010485803
randomized O 0 0.001617111
, O 0 0.0017988561
controlled O 0 0.0023812812
trial O 0 0.006577388
. O 0 0.0053188754

STUDY O 0 0.036811236
OBJECTIVE O 0 0.3800133
: O 0 0.003360524
We O 0 0.0012947428
sought O 0 0.0014363225
to O 0 0.00071190845
compare O 0 0.00035684032
the O 0 0.00048690243
rate O 0 0.0005358365
of O 0 0.0011561024
akathisia B-Disease 0 0.9998037
after O 0 0.0004536222
administration O 0 0.094362885
of O 0 0.00097450975
intravenous O 0 0.8860494
prochlorperazine B-Chemical 1 0.9998715
as O 0 0.00059621315
a O 0 0.0006155789
2 O 0 0.00047917958
- O 0 0.0005864573
minute O 0 0.00042380087
bolus O 0 0.010516341
or O 0 0.000650195
15 O 0 0.00088191987
- O 0 0.0017651794
minute O 0 0.002030846
infusion O 0 0.031636287
. O 0 0.004900439

METHODS O 0 0.0061031734
: O 0 0.0029300216
We O 0 0.0012426819
conducted O 0 0.0009958708
a O 0 0.0010376411
prospective O 0 0.0023373207
, O 0 0.0009737761
randomized O 0 0.0010810117
, O 0 0.00073404174
double O 0 0.0004997382
- O 0 0.00085913925
blind O 0 0.001883057
study O 0 0.0006895205
in O 0 0.00037527367
the O 0 0.00044683297
emergency O 0 0.003684536
department O 0 0.0035928278
of O 0 0.0011114998
a O 0 0.0013119495
central O 0 0.0034531623
- O 0 0.0028471667
city O 0 0.0044189235
teaching O 0 0.006409652
hospital O 0 0.015353119
. O 0 0.0064202747

Patients O 0 0.009630741
aged O 0 0.004163877
18 O 0 0.0018162539
years O 0 0.0018637574
or O 0 0.00095441245
older O 0 0.0021800604
treated O 0 0.0015363276
with O 0 0.0016304278
prochlorperazine B-Chemical 1 0.9996699
for O 0 0.002619295
headache B-Disease 2 0.9993949
, O 0 0.010929495
nausea B-Disease 2 0.9997893
, O 0 0.0025590444
or O 0 0.0013812082
vomiting B-Disease 0 0.99861646
were O 0 0.0016813033
eligible O 0 0.0022627304
for O 0 0.0019431073
inclusion O 0 0.0040691015
. O 0 0.0056392443

Study O 0 0.010288034
participants O 0 0.0021480476
were O 0 0.0012682852
randomized O 0 0.001362422
to O 0 0.0007577964
receive O 0 0.0008665473
10 O 0 0.00070412166
mg O 0 0.13305208
of O 0 0.0010624577
prochlorperazine B-Chemical 1 0.999782
administered O 0 0.013089725
intravenously O 0 0.011735527
by O 0 0.00032733046
means O 0 0.00028107176
of O 0 0.00037936194
2 O 0 0.000336894
- O 0 0.00037325989
minute O 0 0.0002185417
push O 0 0.0013051591
( O 0 0.00040261762
bolus O 0 0.019482583
group O 0 0.0004069013
) O 0 0.00042041228
or O 0 0.00017691137
10 O 0 0.00025766276
mg O 0 0.10836948
diluted O 0 0.0007157728
in O 0 0.00018190622
50 O 0 0.00034402078
mL O 0 0.00082486286
of O 0 0.00022994215
normal O 0 0.0005451654
saline O 0 0.050582457
solution O 0 0.0060105114
administered O 0 0.0009413312
by O 0 0.0002168058
means O 0 0.00021704387
of O 0 0.00034875816
intravenous O 0 0.35085768
infusion O 0 0.02674032
during O 0 0.00024859697
a O 0 0.00039611256
15 O 0 0.00032948202
- O 0 0.00051669247
minute O 0 0.0004051802
period O 0 0.0006732681
( O 0 0.0013400945
infusion O 0 0.016469138
group O 0 0.0032580176
) O 0 0.006024359
. O 0 0.004932283

The O 0 0.002961771
main O 0 0.002955138
outcome O 0 0.0030916962
was O 0 0.0013025599
the O 0 0.0009047639
number O 0 0.0007238504
of O 0 0.000949768
study O 0 0.0012716928
participants O 0 0.0011813719
experiencing O 0 0.07116247
akathisia B-Disease 0 0.9996051
within O 0 0.00090625527
60 O 0 0.0015383799
minutes O 0 0.0015581867
of O 0 0.003259062
administration O 0 0.16844267
. O 0 0.006828484

Akathisia O 0 0.99621
was O 0 0.0030186411
defined O 0 0.0014944216
as O 0 0.00094724976
either O 0 0.0008353361
a O 0 0.00084587466
spontaneous O 0 0.004523198
report O 0 0.002219867
of O 0 0.0011650681
restlessness O 0 0.99726427
or O 0 0.00077689573
agitation B-Disease 2 0.96194446
or O 0 0.00038686785
a O 0 0.00036947243
change O 0 0.0003015438
of O 0 0.00033687538
2 O 0 0.00025492063
or O 0 0.00016992698
more O 0 0.00025771288
in O 0 0.00017376205
the O 0 0.00020747795
patient O 0 0.00064341084
- O 0 0.0006610277
reported O 0 0.0010535422
akathisia B-Disease 0 0.999879
rating O 0 0.002087714
scale O 0 0.000471997
and O 0 0.00025149976
a O 0 0.00024774089
change O 0 0.00023045111
of O 0 0.00026848412
at O 0 0.00016210545
least O 0 0.00018479602
1 O 0 0.00030586228
in O 0 0.00026579382
the O 0 0.0004093409
investigator O 0 0.0022839534
- O 0 0.0016700616
observed O 0 0.001537434
akathisia B-Disease 0 0.9994929
rating O 0 0.014421531
scale O 0 0.006858322
. O 0 0.005552773

The O 0 0.0033189019
intensity O 0 0.0026208875
of O 0 0.0040675486
headache B-Disease 2 0.99702114
and O 0 0.005330731
nausea B-Disease 2 0.99950874
was O 0 0.0017571067
measured O 0 0.0008313431
with O 0 0.0012263375
a O 0 0.001467736
100 O 0 0.0029457689
- O 0 0.0028980854
mm O 0 0.0073399977
visual O 0 0.08330161
analog O 0 0.034643978
scale O 0 0.008130186
. O 0 0.006983576

RESULTS O 0 0.044248078
: O 0 0.013196268
One O 0 0.009627862
hundred O 0 0.010429337
patients O 0 0.014447608
were O 0 0.011478715
enrolled O 0 0.022048796
. O 0 0.017881518

One O 0 0.007819965
study O 0 0.005618571
participant O 0 0.0036441444
was O 0 0.0038386213
excluded O 0 0.004663708
after O 0 0.0039502126
protocol O 0 0.010348902
violation O 0 0.037455264
. O 0 0.013262744

Seventy O 0 0.014198892
- O 0 0.004006575
three O 0 0.0011604816
percent O 0 0.0013180055
( O 0 0.0015600304
73 O 0 0.0017003947
/ O 0 0.0014449648
99 O 0 0.0013225727
) O 0 0.00070802274
of O 0 0.00043938804
the O 0 0.00034090478
study O 0 0.00053144514
participants O 0 0.00038564886
were O 0 0.0003413507
treated O 0 0.0006715929
for O 0 0.0005486542
headache B-Disease 2 0.9983071
and O 0 0.00080219674
70 O 0 0.00084875576
% O 0 0.00076171843
( O 0 0.0008089615
70 O 0 0.0009262105
/ O 0 0.0018710295
99 O 0 0.0027004145
) O 0 0.002840884
for O 0 0.0035254161
nausea B-Disease 2 0.9983398
. O 0 0.009137779

In O 0 0.003012472
the O 0 0.0021944009
bolus O 0 0.023454089
group O 0 0.0021719742
, O 0 0.0015948314
26 O 0 0.0013016218
. O 0 0.0004851988
0 O 0 0.000614178
% O 0 0.0005591204
( O 0 0.000527753
13 O 0 0.0004545238
/ O 0 0.0006712534
50 O 0 0.0005334767
) O 0 0.0005305725
had O 0 0.00049429503
akathisia B-Disease 0 0.99979156
compared O 0 0.00023838777
with O 0 0.0003855788
32 O 0 0.0005308034
. O 0 0.00016896838
7 O 0 0.00020831224
% O 0 0.0002641036
( O 0 0.0002782447
16 O 0 0.00024176444
/ O 0 0.00044163817
49 O 0 0.00040938845
) O 0 0.0003212956
in O 0 0.00015678475
the O 0 0.00019736653
infusion O 0 0.009735093
group O 0 0.00048664908
( O 0 0.0005457435
Delta O 0 0.017225683
= O 0 0.0006436614
- O 0 0.00041216952
6 O 0 0.00016472646
. O 0 0.000121562625
7 O 0 0.00016600934
% O 0 0.00022770283
; O 0 0.00029329874
95 O 0 0.00041042475
% O 0 0.0002076319
confidence O 0 0.0005430575
interval O 0 0.0005669905
[ O 0 0.0010757707
CI O 0 0.16684851
] O 0 0.0010115384
- O 0 0.000602504
24 O 0 0.00034586893
. O 0 0.00023413848
6 O 0 0.00030846684
% O 0 0.00047068956
to O 0 0.00049938704
11 O 0 0.0009163215
. O 0 0.000751316
2 O 0 0.0015739227
% O 0 0.0026504437
) O 0 0.0048389207
. O 0 0.004787307

The O 0 0.002355639
difference O 0 0.0012656449
between O 0 0.00082126533
the O 0 0.00096452696
bolus O 0 0.019015376
and O 0 0.0009499346
infusion O 0 0.013359013
groups O 0 0.00062424265
in O 0 0.00032138935
the O 0 0.00025924772
percentage O 0 0.00016773782
of O 0 0.0003425342
participants O 0 0.00037358952
who O 0 0.00067899853
saw O 0 0.0004908144
a O 0 0.00034040146
50 O 0 0.00045399513
% O 0 0.00027530195
reduction O 0 0.00036782317
in O 0 0.00020254095
their O 0 0.0003673634
headache B-Disease 2 0.99813265
intensity O 0 0.0002391315
within O 0 0.00012354081
30 O 0 0.00016616183
minutes O 0 0.00017043586
was O 0 0.00018304096
11 O 0 0.00024118679
. O 0 0.00013355023
8 O 0 0.00021018049
% O 0 0.00026774508
( O 0 0.00030931467
95 O 0 0.00060888875
% O 0 0.00039484465
CI O 0 0.047506716
- O 0 0.00059430546
9 O 0 0.0003542323
. O 0 0.00023434509
6 O 0 0.00030639436
% O 0 0.00047106846
to O 0 0.00050667196
33 O 0 0.0012349983
. O 0 0.0007745071
3 O 0 0.0014233359
% O 0 0.002655165
) O 0 0.004873942
. O 0 0.0048389114

The O 0 0.0024993252
difference O 0 0.0013747247
in O 0 0.0011203015
the O 0 0.0008461544
percentage O 0 0.0005072155
of O 0 0.0008481062
patients O 0 0.0017357317
with O 0 0.00074282027
a O 0 0.00062873366
50 O 0 0.0007431697
% O 0 0.00044514347
reduction O 0 0.00054839085
in O 0 0.00030822962
their O 0 0.0005985181
nausea B-Disease 2 0.9997614
was O 0 0.0005028831
12 O 0 0.00025987852
. O 0 0.00016605272
6 O 0 0.00019223851
% O 0 0.0002911557
( O 0 0.0003300253
95 O 0 0.00063112157
% O 0 0.00040582707
CI O 0 0.04285213
- O 0 0.0005766953
4 O 0 0.00030151877
. O 0 0.00023615899
6 O 0 0.0003074598
% O 0 0.00047509852
to O 0 0.0005207086
29 O 0 0.0014134094
. O 0 0.00078778
8 O 0 0.0015490444
% O 0 0.0026309043
) O 0 0.0048702178
. O 0 0.004831888

CONCLUSION O 0 0.85829186
: O 0 0.006403831
A O 0 0.008851232
50 O 0 0.002415303
% O 0 0.0013605612
reduction O 0 0.0012025635
in O 0 0.00058076746
the O 0 0.000561619
incidence O 0 0.0035678735
of O 0 0.0017404981
akathisia B-Disease 0 0.9998789
when O 0 0.00082445535
prochlorperazine B-Chemical 1 0.9998561
was O 0 0.00072949915
administered O 0 0.0015714323
by O 0 0.00027711238
means O 0 0.00025019632
of O 0 0.00033091212
15 O 0 0.00025828503
- O 0 0.00034877728
minute O 0 0.0002310978
intravenous O 0 0.13530073
infusion O 0 0.014931807
versus O 0 0.0003280775
a O 0 0.0004213035
2 O 0 0.00043499935
- O 0 0.00063004484
minute O 0 0.00054740184
intravenous O 0 0.15383334
push O 0 0.0045195865
was O 0 0.001484562
not O 0 0.0019252286
detected O 0 0.0025431893
. O 0 0.0050119725

The O 0 0.0030282843
efficacy O 0 0.005431333
of O 0 0.0031951226
prochlorperazine B-Chemical 1 0.99928385
in O 0 0.0014942801
the O 0 0.0009173515
treatment O 0 0.002065422
of O 0 0.0019457224
headache B-Disease 2 0.9993506
and O 0 0.0038626478
nausea B-Disease 2 0.9998838
likewise O 0 0.07402725
did O 0 0.00046446887
not O 0 0.00029331047
appear O 0 0.00031298233
to O 0 0.00023255464
be O 0 0.00025537453
affected O 0 0.00021592181
by O 0 0.0002609128
the O 0 0.00023856512
rate O 0 0.0002850982
of O 0 0.0005366699
administration O 0 0.096890636
, O 0 0.0007161197
although O 0 0.0004532572
no O 0 0.00043073113
formal O 0 0.0011103568
statistical O 0 0.0028641145
comparisons O 0 0.0014228027
were O 0 0.0022999141
made O 0 0.0040417747
. O 0 0.0055143763

Combined O 0 0.038136095
antiretroviral O 0 0.39730644
therapy O 0 0.08784846
causes O 0 0.033989355
cardiomyopathy B-Disease 2 0.9993333
and O 0 0.0066169244
elevates O 0 0.41687024
plasma O 0 0.39514542
lactate B-Chemical 0 0.96593285
in O 0 0.003672701
transgenic O 0 0.0074011153
AIDS B-Disease 2 0.9890331
mice O 0 0.0062859994
. O 0 0.008527776

Highly O 0 0.048532713
active O 0 0.005776688
antiretroviral O 0 0.299406
therapy O 0 0.076296575
( O 0 0.0038500817
HAART O 0 0.92017215
) O 0 0.0021823978
is O 0 0.0007622493
implicated O 0 0.0009510415
in O 0 0.0009950295
cardiomyopathy B-Disease 2 0.9997569
( O 0 0.0058029275
CM B-Disease 2 0.897496
) O 0 0.001488369
and O 0 0.0005088002
in O 0 0.00041775996
elevated O 0 0.006855049
plasma O 0 0.1491051
lactate B-Chemical 0 0.97859156
( O 0 0.0028571617
LA B-Chemical 0 0.9820734
) O 0 0.0021375318
in O 0 0.0010508262
AIDS B-Disease 2 0.9877465
through O 0 0.0012163057
mechanisms O 0 0.0031099059
of O 0 0.004467186
mitochondrial B-Disease 2 0.9698155
dysfunction I-Disease 2 0.9948932
. O 0 0.011342571

To O 0 0.0027054632
determine O 0 0.0014073076
mitochondrial O 0 0.060651526
events O 0 0.0063091796
from O 0 0.001420261
HAART O 0 0.8114849
in O 0 0.000799629
vivo O 0 0.0015257637
, O 0 0.00085358595
8 O 0 0.0005019012
- O 0 0.00057214533
week O 0 0.0003273732
- O 0 0.00051394233
old O 0 0.00036446148
hemizygous O 0 0.0014158841
transgenic O 0 0.0008397943
AIDS B-Disease 2 0.99599034
mice O 0 0.0004376357
( O 0 0.0012547898
NL4 O 0 0.7410373
- O 0 0.0013688749
3Delta O 0 0.0773719
gag O 0 0.02834936
/ O 0 0.0021553298
pol O 0 0.011724533
; O 0 0.0026388576
TG O 2 0.96559316
) O 0 0.00090203097
and O 0 0.00032086857
wild O 0 0.0002579051
- O 0 0.0005368172
type O 0 0.00033926585
FVB O 0 0.0077939034
/ O 0 0.0006091267
n O 0 0.00016578138
littermates O 0 7.39839e-05
were O 0 0.00016048229
treated O 0 0.00032830777
with O 0 0.00028964068
the O 0 0.00029994643
HAART O 0 0.7890775
combination O 0 0.001523647
of O 0 0.000961178
zidovudine B-Chemical 1 0.9937075
, O 0 0.0035231924
lamivudine B-Chemical 1 0.99978215
, O 0 0.0016167393
and O 0 0.0008243863
indinavir B-Chemical 1 0.99830306
or O 0 0.0005042977
vehicle O 0 0.00876793
control O 0 0.00041037588
for O 0 0.00042860192
10 O 0 0.0006498945
days O 0 0.0006948864
or O 0 0.0009559846
35 O 0 0.0020163674
days O 0 0.0026802027
. O 0 0.0040333513

At O 0 0.0023530873
termination O 0 0.0029465558
of O 0 0.0016840604
the O 0 0.0010582715
experiments O 0 0.00086215284
, O 0 0.00094945775
mice O 0 0.00040275927
underwent O 0 0.0007848398
echocardiography O 0 0.1033704
, O 0 0.0006735464
quantitation O 0 0.0012664999
of O 0 0.0004592234
abundance O 0 0.00038606528
of O 0 0.00044186407
molecular O 0 0.009445369
markers O 0 0.0014384517
of O 0 0.0010761209
CM B-Disease 2 0.9148074
( O 0 0.0015571453
ventricular O 0 0.96918786
mRNA O 0 0.0017501017
encoding O 0 0.0013132347
atrial O 0 0.98932844
natriuretic O 0 0.9974988
factor O 0 0.1198382
[ O 0 0.020273421
ANF O 1 0.9990133
] O 0 0.0062267906
and O 0 0.00097399746
sarcoplasmic O 0 0.98059744
calcium B-Chemical 1 0.9987224
ATPase O 0 0.8711854
[ O 0 0.022361668
SERCA2 O 0 0.99099624
] O 0 0.005750246
) O 0 0.0014710341
, O 0 0.000988651
and O 0 0.0009918342
determination O 0 0.0033892645
of O 0 0.0035937459
plasma O 0 0.34465152
LA B-Chemical 0 0.98175067
. O 0 0.00887341

Myocardial O 0 0.710083
histologic O 0 0.19865286
features O 0 0.004940571
were O 0 0.0016321478
analyzed O 0 0.0012614958
semiquantitatively O 0 0.0039444584
and O 0 0.0013395367
results O 0 0.0011147519
were O 0 0.0012414207
confirmed O 0 0.0016195293
by O 0 0.0023563895
transmission O 0 0.0069612497
electron O 0 0.0764637
microscopy O 0 0.01193436
. O 0 0.009025865

After O 0 0.0026334154
35 O 0 0.002501942
days O 0 0.0016037349
in O 0 0.001287216
the O 0 0.0015283774
TG O 2 0.88802207
+ O 0 0.002460707
HAART O 0 0.83605635
cohort O 0 0.0039105737
, O 0 0.0013694897
left O 0 0.0024954006
ventricular O 0 0.90477407
mass O 0 0.0056209057
increased O 0 0.002484123
160 O 0 0.006762313
% O 0 0.0025557505
by O 0 0.0032002954
echocardiography O 0 0.27239573
. O 0 0.007324817

Molecularly O 0 0.3876406
, O 0 0.009912921
ANF O 1 0.98992014
mRNA O 0 0.008171786
increased O 0 0.004355408
250 O 0 0.0046325973
% O 0 0.0025339753
and O 0 0.002774854
SERCA2 O 0 0.92435354
mRNA O 0 0.007538763
decreased O 0 0.008221489
57 O 0 0.009628067
% O 0 0.0076748542
. O 0 0.0073493007

Biochemically O 0 0.41861293
, O 0 0.007399549
LA B-Chemical 0 0.9110852
was O 0 0.0029295145
elevated O 0 0.006828073
( O 0 0.0023142037
8 O 0 0.0011784176
. O 0 0.0007181793
5 O 0 0.0008607669
+ O 0 0.0013353854
/ O 0 0.0023994753
- O 0 0.0020409215
2 O 0 0.0014145552
. O 0 0.0012374435
0 O 0 0.0028882101
mM O 0 0.07272907
) O 0 0.007126083
. O 0 0.006029117

Pathologically O 0 0.6308435
, O 0 0.005157861
granular O 0 0.023328127
cytoplasmic O 0 0.0031351445
changes O 0 0.0020643095
were O 0 0.0010999506
found O 0 0.0009114853
in O 0 0.0008978269
cardiac O 0 0.18813704
myocytes O 0 0.11634564
, O 0 0.0019105759
indicating O 0 0.0013790885
enlarged O 0 0.016343655
, O 0 0.004096471
damaged O 0 0.030971527
mitochondria O 0 0.3223847
. O 0 0.008453169

Findings O 0 0.041312307
were O 0 0.020926272
confirmed O 0 0.02514455
ultrastructurally O 0 0.13506176
. O 0 0.035104025

No O 0 0.012919475
changes O 0 0.008237388
were O 0 0.0059401034
found O 0 0.005686478
in O 0 0.0061458405
other O 0 0.008658242
cohorts O 0 0.01647808
. O 0 0.0152207995

After O 0 0.0027116279
10 O 0 0.0024021456
days O 0 0.0017351006
, O 0 0.0018782218
only O 0 0.0015547113
ANF O 1 0.9936743
was O 0 0.0017152391
elevated O 0 0.005557907
, O 0 0.0014373473
and O 0 0.0009987408
only O 0 0.0009947522
in O 0 0.001101693
the O 0 0.0019525943
TG O 2 0.95052665
+ O 0 0.0066687954
HAART O 0 0.9109504
cohort O 0 0.019274008
. O 0 0.0076284115

Results O 0 0.005258662
show O 0 0.002447726
that O 0 0.0019515174
cumulative O 0 0.0062308516
HAART O 0 0.9045207
caused O 0 0.004067104
mitochondrial O 0 0.6616702
CM B-Disease 2 0.9194457
with O 0 0.0041863285
elevated O 0 0.072244726
LA B-Chemical 0 0.9879814
in O 0 0.005304705
AIDS B-Disease 2 0.991322
transgenic O 0 0.0063862447
mice O 0 0.0049425825
. O 0 0.007533684

A O 0 0.021040007
Phase O 0 0.012613131
II O 0 0.009502461
trial O 0 0.0036131914
of O 0 0.002731141
cisplatin B-Chemical 1 0.99758494
plus O 0 0.004263875
WR B-Chemical 0 0.9679557
- I-Chemical 0 0.00813151
2721 I-Chemical 0 0.9899837
( O 0 0.002946856
amifostine B-Chemical 0 0.9992168
) O 0 0.0023119894
for O 0 0.00080498256
metastatic O 0 0.98741376
breast B-Disease 2 0.99840003
carcinoma I-Disease 2 0.999775
: O 0 0.010008666
an O 0 0.00234873
Eastern O 0 0.114842944
Cooperative O 0 0.24247652
Oncology O 0 0.11834527
Group O 0 0.046209186
Study O 0 0.045928393
( O 0 0.0045420155
E8188 O 0 0.05237319
) O 0 0.009344058
. O 0 0.0071243285

BACKGROUND O 0 0.88967097
: O 0 0.010541035
Cisplatin B-Chemical 1 0.9977568
has O 0 0.0023398686
minimal O 0 0.0020099478
antitumor O 0 0.71743214
activity O 0 0.0013687555
when O 0 0.00046848968
used O 0 0.0004947031
as O 0 0.00040596814
second O 0 0.00056059
- O 0 0.00090517954
or O 0 0.00043229092
third O 0 0.00075006124
- O 0 0.0011023963
line O 0 0.001193043
treatment O 0 0.0023624294
of O 0 0.0035913151
metastatic O 0 0.99289376
breast B-Disease 2 0.9973677
carcinoma I-Disease 2 0.9991768
. O 0 0.019456415

Older O 0 0.02700013
reports O 0 0.003249132
suggest O 0 0.0013632469
an O 0 0.0015952132
objective O 0 0.001742019
response O 0 0.0011002634
rate O 0 0.0006068835
of O 0 0.000754589
8 O 0 0.00054444955
% O 0 0.00043261785
when O 0 0.00022925825
60 O 0 0.00043181912
- O 0 0.0005248126
120 O 0 0.00056318427
mg O 0 0.12398653
/ O 0 0.0010311292
m2 O 0 0.012693214
of O 0 0.0008405681
cisplatin B-Chemical 1 0.99813795
is O 0 0.0009099243
administered O 0 0.0019554854
every O 0 0.0005059225
3 O 0 0.000953654
- O 0 0.001876389
4 O 0 0.0015206047
weeks O 0 0.0026572517
. O 0 0.0039007561

Although O 0 0.0035587025
a O 0 0.0027659617
dose O 0 0.020166595
- O 0 0.002461482
response O 0 0.0014527299
effect O 0 0.00096656545
has O 0 0.000701401
been O 0 0.0007219968
observed O 0 0.00041681182
with O 0 0.00089490676
cisplatin B-Chemical 1 0.99893194
, O 0 0.0010759926
the O 0 0.0004413623
dose O 0 0.029358584
- O 0 0.0010242576
limiting O 0 0.0010191533
toxicities B-Disease 2 0.9988919
associated O 0 0.0015423314
with O 0 0.0016110445
cisplatin B-Chemical 1 0.9994536
( O 0 0.0013575229
e O 0 0.0012727664
. O 0 0.00021248905
g O 0 0.0010089854
. O 0 0.00022529022
, O 0 0.00084817485
nephrotoxicity B-Disease 0 0.99991286
, O 0 0.0080226315
ototoxicity B-Disease 0 0.9998221
, O 0 0.0018673883
and O 0 0.001228965
neurotoxicity B-Disease 2 0.99969876
) O 0 0.0013002
have O 0 0.00036297084
limited O 0 0.00037887174
its O 0 0.00083157606
use O 0 0.000643157
as O 0 0.0005023418
a O 0 0.0009672044
treatment O 0 0.0029337923
for O 0 0.0026745573
breast B-Disease 2 0.9948755
carcinoma I-Disease 2 0.99898
. O 0 0.015424293

WR B-Chemical 0 0.8298053
- I-Chemical 0 0.011174679
2721 I-Chemical 0 0.9202292
or O 0 0.0028978428
amifostine B-Chemical 0 0.9977215
initially O 0 0.003952155
was O 0 0.0013068856
developed O 0 0.0017247159
to O 0 0.00097317284
protect O 0 0.0026894775
military O 0 0.0068469024
personnel O 0 0.0027178766
in O 0 0.0010275744
the O 0 0.001282107
event O 0 0.004767268
of O 0 0.0036985732
nuclear O 0 0.032504477
war O 0 0.073017165
. O 0 0.008589045

Amifostine B-Chemical 0 0.9967153
subsequently O 0 0.006034529
was O 0 0.0020193309
shown O 0 0.0010117795
to O 0 0.00089643087
protect O 0 0.0018690983
normal O 0 0.001429388
tissues O 0 0.0016156312
from O 0 0.00050586456
the O 0 0.000503159
toxic O 0 0.5325762
effects O 0 0.0019252405
of O 0 0.0012643822
alkylating B-Chemical 0 0.9978035
agents I-Chemical 0 0.5937653
and O 0 0.0018290926
cisplatin B-Chemical 1 0.9989176
without O 0 0.0009689485
decreasing O 0 0.0014338277
the O 0 0.0009585251
antitumor O 0 0.69799286
effect O 0 0.0018082218
of O 0 0.0026522344
the O 0 0.0038502098
chemotherapy O 0 0.89021605
. O 0 0.0075731473

Early O 0 0.020916749
trials O 0 0.004380444
of O 0 0.003346146
cisplatin B-Chemical 1 0.99700135
and O 0 0.003226244
amifostine B-Chemical 0 0.9990094
also O 0 0.001409189
suggested O 0 0.0007561128
that O 0 0.00043913053
the O 0 0.00048199142
incidence O 0 0.004656142
and O 0 0.00071538414
severity O 0 0.025350891
of O 0 0.0022554263
cisplatin B-Chemical 1 0.9994605
- O 0 0.011420001
induced O 0 0.013194784
nephrotoxicity B-Disease 0 0.9999261
, O 0 0.040501233
ototoxicity B-Disease 0 0.99968505
, O 0 0.0049572065
and O 0 0.0039502815
neuropathy B-Disease 0 0.9988404
were O 0 0.0040643625
reduced O 0 0.0056254966
. O 0 0.006255417

METHODS O 0 0.0072933575
: O 0 0.0042467923
A O 0 0.0070115593
Phase O 0 0.0055422983
II O 0 0.0044403663
study O 0 0.0012821704
of O 0 0.00085883425
the O 0 0.00060766103
combination O 0 0.001467247
of O 0 0.0012884296
cisplatin B-Chemical 1 0.9990387
plus O 0 0.0019678825
amifostine B-Chemical 0 0.999619
was O 0 0.00060447486
conducted O 0 0.0003193713
in O 0 0.00025213504
patients O 0 0.000979603
with O 0 0.000495471
progressive O 0 0.51358056
metastatic O 0 0.9957768
breast B-Disease 2 0.99914
carcinoma I-Disease 2 0.99989414
who O 0 0.019428726
had O 0 0.00048418372
received O 0 0.00050447776
one O 0 0.00025782152
, O 0 0.00040340426
but O 0 0.0002556508
not O 0 0.00023763435
more O 0 0.00036264348
than O 0 0.00022423586
one O 0 0.0003350906
, O 0 0.00081299007
chemotherapy O 0 0.46706632
regimen O 0 0.017200915
for O 0 0.002103517
metastatic O 0 0.97496945
disease O 0 0.92192274
. O 0 0.008269513

Patients O 0 0.013256609
received O 0 0.0071396916
amifostine B-Chemical 0 0.99605966
, O 0 0.005990648
910 O 0 0.026156638
mg O 0 0.5401534
/ O 0 0.005617053
m2 O 0 0.024702031
intravenously O 0 0.007254981
over O 0 0.001788187
15 O 0 0.0029268805
minutes O 0 0.004575011
. O 0 0.0063322517

After O 0 0.0023581905
completion O 0 0.0017716492
of O 0 0.0021001468
the O 0 0.0020240126
amifostine B-Chemical 0 0.99820256
infusion O 0 0.32073775
, O 0 0.0032356463
cisplatin B-Chemical 1 0.99789244
120 O 0 0.0034184938
mg O 0 0.5096319
/ O 0 0.0025456436
m2 O 0 0.017179914
was O 0 0.0009897023
administered O 0 0.0020661713
over O 0 0.0009899796
30 O 0 0.0019994178
minutes O 0 0.0032752685
. O 0 0.0047155605

Intravenous O 0 0.92269623
hydration O 0 0.42796892
and O 0 0.006756513
mannitol B-Chemical 1 0.98567235
was O 0 0.0042446353
administered O 0 0.0061113383
before O 0 0.002218165
and O 0 0.003957474
after O 0 0.0049047936
cisplatin B-Chemical 1 0.99151105
. O 0 0.013296678

Treatment O 0 0.034841675
was O 0 0.0046356157
administered O 0 0.005844938
every O 0 0.0019772453
3 O 0 0.0023040003
weeks O 0 0.0026305327
until O 0 0.003167272
disease O 0 0.44928864
progression O 0 0.610586
. O 0 0.013047947

RESULTS O 0 0.026833732
: O 0 0.0048518563
Forty O 0 0.006285201
- O 0 0.002139534
four O 0 0.00078241073
patients O 0 0.0016930512
were O 0 0.0007581942
enrolled O 0 0.0011415107
in O 0 0.00049195794
the O 0 0.0005058809
study O 0 0.0008475317
of O 0 0.0008649407
which O 0 0.001204922
7 O 0 0.0009206008
( O 0 0.0012795139
16 O 0 0.0012560353
% O 0 0.0015941262
) O 0 0.0024876238
were O 0 0.0026593176
ineligible O 0 0.010707503
. O 0 0.006156436

A O 0 0.0122829955
median O 0 0.0025995614
of O 0 0.0022644685
2 O 0 0.0014863038
cycles O 0 0.001030055
of O 0 0.0013362468
therapy O 0 0.007457191
was O 0 0.001334526
administered O 0 0.0025663646
to O 0 0.0012381462
the O 0 0.0015247442
37 O 0 0.0031382337
eligible O 0 0.004138539
patients O 0 0.0096555045
. O 0 0.007044073

Six O 0 0.006094147
partial O 0 0.004533374
responses O 0 0.0036973485
were O 0 0.0017191233
observed O 0 0.0011553741
for O 0 0.0011412052
an O 0 0.0016725964
overall O 0 0.0016298735
response O 0 0.002489905
rate O 0 0.0021673373
of O 0 0.0039050274
16 O 0 0.0053863223
% O 0 0.0066428874
. O 0 0.0066601457

Most O 0 0.011205397
patients O 0 0.008588558
( O 0 0.004493296
57 O 0 0.003893439
% O 0 0.0025238625
) O 0 0.0024692852
stopped O 0 0.0029310514
treatment O 0 0.003268114
because O 0 0.0019829709
of O 0 0.005082689
disease O 0 0.86501837
progression O 0 0.83369786
. O 0 0.0119659165

Neurologic B-Disease 0 0.98920524
toxicity I-Disease 2 0.993159
was O 0 0.006785907
reported O 0 0.0059500844
in O 0 0.0038024164
52 O 0 0.0060625337
% O 0 0.0050065634
of O 0 0.0063694622
patients O 0 0.016617082
. O 0 0.011397506

Seven O 0 0.009276686
different O 0 0.0035648558
life O 0 0.006274191
- O 0 0.0046523907
threatening O 0 0.1111275
toxicities B-Disease 2 0.9961467
were O 0 0.0017544139
observed O 0 0.0010443451
in O 0 0.0012305687
patients O 0 0.0035218033
while O 0 0.0022953956
receiving O 0 0.010530998
treatment O 0 0.013986229
. O 0 0.007978621

CONCLUSIONS O 0 0.6752702
: O 0 0.004698566
The O 0 0.0016236285
combination O 0 0.002639115
of O 0 0.002309284
cisplatin B-Chemical 1 0.9979651
and O 0 0.0028744966
amifostine B-Chemical 0 0.9991757
in O 0 0.0008939539
this O 0 0.0006220123
study O 0 0.00089446816
resulted O 0 0.00057402684
in O 0 0.0005500079
an O 0 0.0008473453
overall O 0 0.0008898578
response O 0 0.0015057693
rate O 0 0.001374934
of O 0 0.0026889455
16 O 0 0.003919274
% O 0 0.004979245
. O 0 0.0051084096

Neither O 0 0.005458257
a O 0 0.00402111
tumor B-Disease 2 0.6066557
- O 0 0.0034759075
protective O 0 0.008107281
effect O 0 0.001258015
nor O 0 0.00082567753
reduced O 0 0.0011799211
toxicity B-Disease 2 0.99044573
to O 0 0.00061826565
normal O 0 0.0012671466
tissues O 0 0.0015940723
was O 0 0.0003652211
observed O 0 0.00025219683
with O 0 0.00039749
the O 0 0.00034489643
addition O 0 0.0003392544
of O 0 0.0011871511
amifostine B-Chemical 0 0.9991297
to O 0 0.0023468316
cisplatin B-Chemical 1 0.9980909
in O 0 0.0022864572
this O 0 0.0029430531
trial O 0 0.008425749
. O 0 0.0056018652

Oral B-Chemical 0 0.96886694
contraceptives I-Chemical 0 0.99147123
and O 0 0.009874083
the O 0 0.007528125
risk O 0 0.062336817
of O 0 0.022732457
myocardial B-Disease 0 0.9965454
infarction I-Disease 2 0.99878913
. O 0 0.032621317

BACKGROUND O 0 0.737053
: O 0 0.0046335384
An O 0 0.0026564908
association O 0 0.0010186078
between O 0 0.0006127175
the O 0 0.0007153009
use O 0 0.00087533763
of O 0 0.0010721724
oral B-Chemical 1 0.80570537
contraceptives I-Chemical 1 0.99901307
and O 0 0.0010993803
the O 0 0.00063700357
risk O 0 0.030773813
of O 0 0.0021261869
myocardial B-Disease 0 0.9994716
infarction I-Disease 2 0.9999145
has O 0 0.0019480686
been O 0 0.0010273727
found O 0 0.0005241874
in O 0 0.00047433784
some O 0 0.0007715767
, O 0 0.0009828602
but O 0 0.0007991407
not O 0 0.0009874316
all O 0 0.0014635517
, O 0 0.0031553095
studies O 0 0.0055850768
. O 0 0.005569553

We O 0 0.0027735056
investigated O 0 0.0018424969
this O 0 0.0012857439
association O 0 0.0009995888
, O 0 0.0011957262
according O 0 0.0006288733
to O 0 0.00048806274
the O 0 0.00043644878
type O 0 0.00050389126
of O 0 0.0008040181
progestagen B-Chemical 0 0.9990865
included O 0 0.0006481949
in O 0 0.00039774188
third O 0 0.0005711055
- O 0 0.00074195606
generation O 0 0.00065561384
( O 0 0.0005949014
i O 0 0.0009848581
. O 0 0.00020332109
e O 0 0.0006898442
. O 0 0.00020691332
, O 0 0.0005568277
desogestrel B-Chemical 1 0.9996618
or O 0 0.0006348986
gestodene B-Chemical 0 0.9998524
) O 0 0.0013177439
and O 0 0.00034174937
second O 0 0.00032759615
- O 0 0.0005787359
generation O 0 0.00054111134
( O 0 0.0005163245
i O 0 0.0009223006
. O 0 0.00018790166
e O 0 0.00068650366
. O 0 0.00020317419
, O 0 0.000580781
levonorgestrel B-Chemical 0 0.99920136
) O 0 0.0019605332
oral B-Chemical 1 0.8323538
contraceptives I-Chemical 1 0.9994388
, O 0 0.00079222576
the O 0 0.00029288375
dose O 0 0.010728793
of O 0 0.00084045803
estrogen B-Chemical 1 0.9993536
, O 0 0.0008642894
and O 0 0.00031459748
the O 0 0.00021725464
presence O 0 0.00022922679
or O 0 0.0001794075
absence O 0 0.00014127592
of O 0 0.0004127359
prothrombotic O 0 0.8788708
mutations O 0 0.019365767
METHODS O 0 0.002706525
: O 0 0.00040083152
In O 0 0.00017332501
a O 0 0.00021815198
nationwide O 0 0.00056202925
, O 0 0.00035748095
population O 0 0.0005107375
- O 0 0.00046058156
based O 0 0.00028174758
, O 0 0.00032895696
case O 0 0.00028575675
- O 0 0.00036889454
control O 0 0.00016095999
study O 0 0.00033544988
, O 0 0.00022586339
we O 0 8.8612745e-05
identified O 0 0.00015700527
and O 0 0.0002220682
enrolled O 0 0.0005486243
248 O 0 0.005230769
women O 0 0.002688012
18 O 0 0.00020819489
through O 0 0.00014226517
49 O 0 0.0002936748
years O 0 0.00028252872
of O 0 0.00022185993
age O 0 0.0005075178
who O 0 0.00051871745
had O 0 0.00023879086
had O 0 0.00026687578
a O 0 0.00031570555
first O 0 0.00033430505
myocardial B-Disease 0 0.9990501
infarction I-Disease 2 0.9999
between O 0 0.00035783843
1990 O 0 0.006000492
and O 0 0.00036197493
1995 O 0 0.0039080577
and O 0 0.00028770507
925 O 0 0.009730029
control O 0 0.00021908601
women O 0 0.004254179
who O 0 0.00057486206
had O 0 0.00024924678
not O 0 0.00021648212
had O 0 0.00031046127
a O 0 0.0005862916
myocardial B-Disease 0 0.99922466
infarction I-Disease 2 0.9999167
and O 0 0.0010375086
who O 0 0.0013095487
were O 0 0.00022416958
matched O 0 0.00019969066
for O 0 0.00019479421
age O 0 0.0006019822
, O 0 0.00033238018
calendar O 0 0.00039421604
year O 0 0.00031849407
of O 0 0.00041185634
the O 0 0.00041600087
index O 0 0.0009978351
event O 0 0.0028881908
, O 0 0.0012197979
and O 0 0.0012130053
area O 0 0.0024822091
of O 0 0.0035078574
residence O 0 0.04068184
. O 0 0.006588673

Subjects O 0 0.008002729
supplied O 0 0.005735131
information O 0 0.0033640584
on O 0 0.0018048458
oral B-Chemical 0 0.5153952
- I-Chemical 0 0.005524516
contraceptive I-Chemical 0 0.8963734
use O 0 0.0030531876
and O 0 0.0025404296
major O 0 0.004786371
cardiovascular O 0 0.9727738
risk O 0 0.26039106
factors O 0 0.043957617
. O 0 0.009590112

An O 0 0.0056520775
analysis O 0 0.0034635272
for O 0 0.0020780328
factor O 1 0.04248232
V O 1 0.48260742
Leiden O 1 0.9319458
and O 0 0.0015200668
the O 0 0.0012371164
G20210A O 0 0.99823797
mutation O 0 0.010065859
in O 0 0.0005794866
the O 0 0.00051353977
prothrombin O 0 0.79244787
gene O 0 0.00077354006
was O 0 0.00034475967
conducted O 0 0.00026999222
in O 0 0.00025659314
217 O 0 0.0028165716
patients O 0 0.0008783939
and O 0 0.00037590202
763 O 0 0.039957248
controls O 0 0.00070602255
RESULTS O 0 0.04127449
: O 0 0.0004100378
The O 0 0.00018426517
odds O 0 0.0010059179
ratio O 0 0.00039805882
for O 0 0.00036306065
myocardial B-Disease 0 0.99914956
infarction I-Disease 2 0.99992096
among O 0 0.0027985172
women O 0 0.04413518
who O 0 0.0010923528
used O 0 0.00021292936
any O 0 0.00016739797
type O 0 0.00021812307
of O 0 0.0003014699
combined O 0 0.0010510124
oral B-Chemical 0 0.8399225
contraceptive I-Chemical 0 0.98770744
, O 0 0.0007025185
as O 0 0.00020102428
compared O 0 0.0001450649
with O 0 0.00036723263
nonusers O 0 0.5236605
, O 0 0.0004582976
was O 0 0.00026196992
2 O 0 0.00023922295
. O 0 0.00013192481
0 O 0 0.00022630228
( O 0 0.00022832525
95 O 0 0.00033686685
percent O 0 0.000153802
confidence O 0 0.0005924439
interval O 0 0.000534692
, O 0 0.00050459796
1 O 0 0.00044148453
. O 0 0.00030472685
5 O 0 0.0004373661
to O 0 0.0006012514
2 O 0 0.0010024294
. O 0 0.0009978665
8 O 0 0.0021056922
) O 0 0.004565823
. O 0 0.004515525

The O 0 0.0026656394
adjusted O 0 0.0026411728
odds O 0 0.0038240259
ratio O 0 0.001602018
was O 0 0.0010204985
2 O 0 0.00076431717
. O 0 0.0003930136
5 O 0 0.00037313535
( O 0 0.00041282136
95 O 0 0.00047979114
percent O 0 0.00020054892
confidence O 0 0.0006428819
interval O 0 0.00048789431
, O 0 0.0003909841
1 O 0 0.000275037
. O 0 0.00014289137
5 O 0 0.00015755912
to O 0 0.00016239012
4 O 0 0.00017685404
. O 0 0.00012513212
1 O 0 0.00020513927
) O 0 0.00029797098
among O 0 0.0002400054
women O 0 0.0027197225
who O 0 0.00055316126
used O 0 0.00020641596
second O 0 0.0002612025
- O 0 0.00049543864
generation O 0 0.0005377193
oral B-Chemical 1 0.7871101
contraceptives I-Chemical 1 0.99938226
and O 0 0.00067225413
1 O 0 0.00035140556
. O 0 0.00013681687
3 O 0 0.00016103336
( O 0 0.00020479824
95 O 0 0.0002869405
percent O 0 0.00011522
confidence O 0 0.00045090835
interval O 0 0.00035847796
, O 0 0.00029097643
0 O 0 0.00024816007
. O 0 0.00012387795
7 O 0 0.0001528874
to O 0 0.00016707998
2 O 0 0.00022211096
. O 0 0.00014405944
5 O 0 0.00020771388
) O 0 0.0003694006
among O 0 0.00031922487
those O 0 0.00047941552
who O 0 0.0009371628
used O 0 0.0005563441
third O 0 0.0011226016
- O 0 0.0021622847
generation O 0 0.0036480017
oral B-Chemical 1 0.9428316
contraceptives I-Chemical 1 0.9975726
. O 0 0.010182048

Among O 0 0.008710339
women O 0 0.012298892
who O 0 0.0040255683
used O 0 0.0018393884
oral B-Chemical 1 0.67164737
contraceptives I-Chemical 1 0.9983546
, O 0 0.0018350738
the O 0 0.0006833916
odds O 0 0.0026534202
ratio O 0 0.00073586276
was O 0 0.00046398188
2 O 0 0.00038179546
. O 0 0.00019932962
1 O 0 0.00026181887
( O 0 0.00026792564
95 O 0 0.00034367904
percent O 0 0.00013853742
confidence O 0 0.00050132454
interval O 0 0.00039224364
, O 0 0.00031915796
1 O 0 0.00023342633
. O 0 0.00012210333
5 O 0 0.00013975622
to O 0 0.00014522142
3 O 0 0.00016001794
. O 0 0.0001106367
0 O 0 0.00019844211
) O 0 0.00023832776
for O 0 0.00012657847
those O 0 0.00023109737
without O 0 0.00020920279
a O 0 0.00030138687
prothrombotic O 0 0.6942319
mutation O 0 0.0029442005
and O 0 0.00036917566
1 O 0 0.0002847462
. O 0 0.00012664341
9 O 0 0.0001778689
( O 0 0.00019134773
95 O 0 0.00027307574
percent O 0 0.00010823425
confidence O 0 0.0004293615
interval O 0 0.00033689418
, O 0 0.00026759427
0 O 0 0.00022286702
. O 0 0.000105434585
6 O 0 0.000113171445
to O 0 0.00013359849
5 O 0 0.00014856625
. O 0 0.00010257022
5 O 0 0.00014320265
) O 0 0.00023120269
for O 0 0.00012969512
those O 0 0.0002508388
with O 0 0.00026994717
a O 0 0.00035249285
mutation O 0 0.0029885506
CONCLUSIONS O 0 0.9537099
: O 0 0.00064394943
The O 0 0.00025423834
risk O 0 0.009830454
of O 0 0.0011748653
myocardial B-Disease 0 0.999482
infarction I-Disease 2 0.9999254
was O 0 0.0011663196
increased O 0 0.00135525
among O 0 0.0007813267
women O 0 0.015915029
who O 0 0.0013943885
used O 0 0.0006082692
second O 0 0.0009530821
- O 0 0.00223351
generation O 0 0.0037331865
oral B-Chemical 1 0.94530743
contraceptives I-Chemical 1 0.9975908
. O 0 0.01021801

The O 0 0.0025908141
results O 0 0.0017816647
with O 0 0.0015486623
respect O 0 0.00096247013
to O 0 0.00076179614
the O 0 0.00062471017
use O 0 0.0007253312
of O 0 0.0007256834
third O 0 0.00082184415
- O 0 0.0009834985
generation O 0 0.00087977754
oral B-Chemical 1 0.8117995
contraceptives I-Chemical 1 0.99927324
were O 0 0.0006578636
inconclusive O 0 0.009128116
but O 0 0.00035262125
suggested O 0 0.0003121914
that O 0 0.00022128827
the O 0 0.00028003522
risk O 0 0.01026847
was O 0 0.00033094813
lower O 0 0.00029233086
than O 0 0.00019834016
the O 0 0.0003278702
risk O 0 0.009061184
associated O 0 0.00093878567
with O 0 0.000990172
second O 0 0.0011618569
- O 0 0.0025466986
generation O 0 0.0040917755
oral B-Chemical 1 0.9547334
contraceptives I-Chemical 1 0.99773574
. O 0 0.010127494

The O 0 0.0037038059
risk O 0 0.0132055115
of O 0 0.0043909084
myocardial B-Disease 0 0.9977762
infarction I-Disease 2 0.99969935
was O 0 0.0019434976
similar O 0 0.000700095
among O 0 0.00090645254
women O 0 0.008758982
who O 0 0.0014939011
used O 0 0.00066822895
oral B-Chemical 1 0.6804922
contraceptives I-Chemical 1 0.9984193
whether O 0 0.00047317456
or O 0 0.0005829956
not O 0 0.00065935566
they O 0 0.00077689544
had O 0 0.0013621146
a O 0 0.0027567043
prothrombotic O 0 0.8692755
mutation O 0 0.03134246
. O 0 0.0074757435

End B-Disease 0 0.031208817
- I-Disease 0 0.0068282923
stage I-Disease 0 0.008166283
renal I-Disease 0 0.9956175
disease I-Disease 0 0.9914954
( O 0 0.020630097
ESRD B-Disease 2 0.9992124
) O 0 0.0026495655
after O 0 0.0005739885
orthotopic O 0 0.96286404
liver O 0 0.903652
transplantation O 0 0.5043414
( O 0 0.001763599
OLTX O 0 0.9155427
) O 0 0.0012138913
using O 0 0.00053760526
calcineurin O 0 0.8485899
- O 0 0.0014369839
based O 0 0.00082838215
immunotherapy O 0 0.064305305
: O 0 0.0019375713
risk O 0 0.0153324865
of O 0 0.0020048479
development O 0 0.0050055296
and O 0 0.0034614196
treatment O 0 0.011451515
. O 0 0.00645564

BACKGROUND O 0 0.77585113
: O 0 0.006970037
The O 0 0.0031021659
calcineurin O 0 0.8121715
inhibitors O 0 0.4682255
cyclosporine B-Chemical 1 0.9996321
and O 0 0.013062238
tacrolimus B-Chemical 0 0.9994137
are O 0 0.0032998477
both O 0 0.00228562
known O 0 0.003436983
to O 0 0.0033273008
be O 0 0.0069552273
nephrotoxic B-Disease 2 0.99583423
. O 0 0.012028202

Their O 0 0.01424012
use O 0 0.004428973
in O 0 0.0030477652
orthotopic O 0 0.9289302
liver O 0 0.8942308
transplantation O 0 0.5181039
( O 0 0.004709099
OLTX O 0 0.90181625
) O 0 0.0033207638
has O 0 0.0017731449
dramatically O 0 0.0031796393
improved O 0 0.0058811745
success O 0 0.0076130605
rates O 0 0.0071651964
. O 0 0.008513548

Recently O 0 0.008171114
, O 0 0.0036486138
however O 0 0.0024443376
, O 0 0.0015420553
we O 0 0.0005583285
have O 0 0.00075193454
had O 0 0.00070075283
an O 0 0.0007501942
increase O 0 0.00049625704
of O 0 0.00066879415
patients O 0 0.0020792473
who O 0 0.001330501
are O 0 0.00047140798
presenting O 0 0.004680862
after O 0 0.00035491565
OLTX O 0 0.7884472
with O 0 0.00077849755
end B-Disease 0 0.00052185735
- I-Disease 0 0.0016262525
stage I-Disease 0 0.0053912704
renal I-Disease 0 0.9977324
disease I-Disease 0 0.99443495
( O 0 0.06789169
ESRD B-Disease 2 0.99849844
) O 0 0.022938544
. O 0 0.0074853445

This O 0 0.004320255
retrospective O 0 0.008091697
study O 0 0.0024503702
examines O 0 0.00202783
the O 0 0.0011723287
incidence O 0 0.004313179
and O 0 0.0011713321
treatment O 0 0.0024549223
of O 0 0.0026090986
ESRD B-Disease 2 0.9994179
and O 0 0.0037700133
chronic B-Disease 2 0.99620134
renal I-Disease 2 0.9984333
failure I-Disease 2 0.99192446
( O 0 0.029232074
CRF B-Disease 0 0.9984713
) O 0 0.0057578413
in O 0 0.0029545971
OLTX O 0 0.91499496
patients O 0 0.019202346
. O 0 0.0073291897

METHODS O 0 0.0067316047
: O 0 0.0036643876
Patients O 0 0.0040028417
receiving O 0 0.0028760415
an O 0 0.0016533297
OLTX O 0 0.6710357
only O 0 0.0008789858
from O 0 0.0006780673
June O 0 0.00075156626
1985 O 0 0.0015969937
through O 0 0.0003923489
December O 0 0.00054551574
of O 0 0.00050308404
1994 O 0 0.0022908973
who O 0 0.0008689922
survived O 0 0.0006570557
6 O 0 0.00029828702
months O 0 0.00039835603
postoperatively O 0 0.00085957476
were O 0 0.00056371675
studied O 0 0.0011474676
( O 0 0.001511345
n O 0 0.0015222745
= O 0 0.0034703047
834 O 0 0.01880734
) O 0 0.0064506694
. O 0 0.005489397

Our O 0 0.0057985773
prospectively O 0 0.0066056037
collected O 0 0.003356355
database O 0 0.004514475
was O 0 0.003408745
the O 0 0.0036475584
source O 0 0.004941229
of O 0 0.008156696
information O 0 0.013661345
. O 0 0.012765719

Patients O 0 0.008042518
were O 0 0.0021134815
divided O 0 0.0012005497
into O 0 0.00073759543
three O 0 0.00058098807
groups O 0 0.0010942355
: O 0 0.0014522596
Controls O 0 0.020237856
, O 0 0.001052406
no O 0 0.0007494264
CRF B-Disease 0 0.99828583
or O 0 0.0015060639
ESRD B-Disease 2 0.99952984
, O 0 0.0015232923
n O 0 0.00056129956
= O 0 0.0008605414
748 O 0 0.0134795895
; O 0 0.0014701217
CRF B-Disease 0 0.99844897
, O 0 0.0008815327
sustained O 0 0.012667675
serum O 0 0.21761586
creatinine B-Chemical 1 0.99777454
> O 0 0.0018790067
2 O 0 0.0003458643
. O 0 0.00017648612
5 O 0 0.00025343843
mg O 0 0.09207901
/ O 0 0.0009607111
dl O 0 0.0060011884
, O 0 0.000544753
n O 0 0.00040816978
= O 0 0.0007391773
41 O 0 0.0010649851
; O 0 0.0011223066
and O 0 0.0013546821
ESRD B-Disease 2 0.99830186
, O 0 0.0027716388
n O 0 0.0020993394
= O 0 0.003747907
45 O 0 0.0035435609
. O 0 0.004470255

Groups O 0 0.010857488
were O 0 0.0019476654
compared O 0 0.00088737026
for O 0 0.0008047743
preoperative O 0 0.0037976257
laboratory O 0 0.0014840735
variables O 0 0.0012420611
, O 0 0.00093934854
diagnosis O 0 0.0039746496
, O 0 0.00074912794
postoperative O 0 0.017503176
variables O 0 0.0009588347
, O 0 0.00072854036
survival O 0 0.021604419
, O 0 0.00064519036
type O 0 0.0005292809
of O 0 0.0012933551
ESRD B-Disease 2 0.9995041
therapy O 0 0.12207483
, O 0 0.0014140339
and O 0 0.0010497312
survival O 0 0.027640227
from O 0 0.001629633
onset O 0 0.018103229
of O 0 0.009729322
ESRD B-Disease 2 0.99779654
. O 0 0.010458346

RESULTS O 0 0.022819115
: O 0 0.0039542355
At O 0 0.0012780749
13 O 0 0.0013720539
years O 0 0.0013805979
after O 0 0.0006301519
OLTX O 0 0.57716984
, O 0 0.0010032683
the O 0 0.000554179
incidence O 0 0.0027056488
of O 0 0.0010026088
severe O 0 0.47500086
renal B-Disease 2 0.99913174
dysfunction I-Disease 2 0.9981894
was O 0 0.0010055595
18 O 0 0.00057857134
. O 0 0.00024950216
1 O 0 0.00038048238
% O 0 0.00046342894
( O 0 0.00068321906
CRF B-Disease 0 0.9958066
8 O 0 0.00051327544
. O 0 0.0002719956
6 O 0 0.00033453427
% O 0 0.0005644614
and O 0 0.0009158397
ESRD B-Disease 2 0.9976617
9 O 0 0.0014735754
. O 0 0.00093960186
5 O 0 0.0015089378
% O 0 0.002684185
) O 0 0.0049003456
. O 0 0.004844387

Compared O 0 0.0031943012
with O 0 0.0023065163
control O 0 0.001584652
patients O 0 0.00413442
, O 0 0.0026753827
CRF B-Disease 0 0.99789846
and O 0 0.0028062714
ESRD B-Disease 2 0.9993395
patients O 0 0.0066104652
had O 0 0.00057275454
higher O 0 0.0004435473
preoperative O 0 0.027801706
serum O 0 0.18248254
creatinine B-Chemical 1 0.99709773
levels O 0 0.0005884253
, O 0 0.00043554648
a O 0 0.00024677435
greater O 0 0.00018808253
percentage O 0 0.00011461815
of O 0 0.00028640428
patients O 0 0.001443177
with O 0 0.00092136953
hepatorenal B-Disease 0 0.9998197
syndrome I-Disease 0 0.9706461
, O 0 0.00057833595
higher O 0 0.00021748386
percentage O 0 0.00011281105
requirement O 0 0.0001632541
for O 0 0.00017903702
dialysis O 0 0.016835881
in O 0 0.0002086432
the O 0 0.00019168739
first O 0 0.00017407846
3 O 0 0.0001851417
months O 0 0.00023803416
postoperatively O 0 0.0005616286
, O 0 0.0003690518
and O 0 0.0003466805
a O 0 0.00047794476
higher O 0 0.00059670745
1 O 0 0.0009247939
- O 0 0.0016307615
year O 0 0.0020375727
serum O 0 0.20683962
creatinine B-Chemical 1 0.9908098
. O 0 0.0077779004

Multivariate O 0 0.014453062
stepwise O 0 0.005716148
logistic O 0 0.0036154173
regression O 0 0.0043794643
analysis O 0 0.001528208
using O 0 0.0007002742
preoperative O 0 0.005196206
and O 0 0.00067954784
postoperative O 0 0.013244503
variables O 0 0.00070817734
identified O 0 0.00031495639
that O 0 0.00025074315
an O 0 0.00038854268
increase O 0 0.00029402386
of O 0 0.0005036485
serum O 0 0.152973
creatinine B-Chemical 1 0.9963509
compared O 0 0.00020375251
with O 0 0.00026771115
average O 0 0.00013011889
at O 0 0.00013983648
1 O 0 0.00019929996
year O 0 0.00021249917
, O 0 0.0002359841
3 O 0 0.00014029659
months O 0 0.0001725416
, O 0 0.00018462006
and O 0 0.00014759817
4 O 0 0.00011153262
weeks O 0 0.00011304472
postoperatively O 0 0.00025837123
were O 0 0.0001162951
independent O 0 0.000109035514
risk O 0 0.0035027708
factors O 0 0.00088395964
for O 0 0.00018976284
the O 0 0.00022603896
development O 0 0.0008110517
of O 0 0.00083517336
CRF B-Disease 0 0.9993568
or O 0 0.0008308447
ESRD B-Disease 2 0.999653
with O 0 0.0008349032
odds O 0 0.005582424
ratios O 0 0.00042377526
of O 0 0.0004451921
2 O 0 0.00035635894
. O 0 0.00018194957
6 O 0 0.00021203955
, O 0 0.00033811526
2 O 0 0.00030263164
. O 0 0.00021346642
2 O 0 0.00037125958
, O 0 0.0005290893
and O 0 0.00059333653
1 O 0 0.00078800647
. O 0 0.0006453601
6 O 0 0.0010656223
, O 0 0.0023462032
respectively O 0 0.005263643
. O 0 0.0046647238

Overall O 0 0.005705553
survival O 0 0.010510968
from O 0 0.0014489333
the O 0 0.0009274123
time O 0 0.0006977467
of O 0 0.001090515
OLTX O 0 0.8348513
was O 0 0.00066867296
not O 0 0.00039777905
significantly O 0 0.0004579609
different O 0 0.00035854653
among O 0 0.0004524075
groups O 0 0.0004740486
, O 0 0.00044937863
but O 0 0.00026539294
by O 0 0.0002542313
year O 0 0.00030524415
13 O 0 0.0003266512
, O 0 0.0002691679
the O 0 0.00019610747
survival O 0 0.0049895984
of O 0 0.00032358052
the O 0 0.00026193372
patients O 0 0.0012632182
who O 0 0.0011537409
had O 0 0.00065841497
ESRD B-Disease 2 0.9995521
was O 0 0.0004512726
only O 0 0.00032017857
28 O 0 0.00039970016
. O 0 0.00015873137
2 O 0 0.00022859471
% O 0 0.00023312874
compared O 0 0.00013734194
with O 0 0.00033866125
54 O 0 0.0007161962
. O 0 0.0002857034
6 O 0 0.0003790142
% O 0 0.0005907608
in O 0 0.0005882221
the O 0 0.0010089157
control O 0 0.0017990138
group O 0 0.004435304
. O 0 0.005260408

Patients O 0 0.014846664
developing O 0 0.01986932
ESRD B-Disease 2 0.99753225
had O 0 0.0024018073
a O 0 0.0015205656
6 O 0 0.0007930116
- O 0 0.00093966315
year O 0 0.00056116685
survival O 0 0.0048347046
after O 0 0.00027773104
onset O 0 0.0019324244
of O 0 0.00097347697
ESRD B-Disease 2 0.9994148
of O 0 0.0009136669
27 O 0 0.0008406046
% O 0 0.00029539192
for O 0 0.00016134736
the O 0 0.00020196954
patients O 0 0.00072276744
receiving O 0 0.0017456174
hemodialysis O 0 0.65660274
versus O 0 0.0003723701
71 O 0 0.0008786584
. O 0 0.00016471263
4 O 0 0.00019429947
% O 0 0.00022777753
for O 0 0.00017348208
the O 0 0.00029509043
patients O 0 0.0014979023
developing O 0 0.014777792
ESRD B-Disease 2 0.9992391
who O 0 0.0067172027
subsequently O 0 0.0027519083
received O 0 0.004005934
kidney O 0 0.8896407
transplants O 0 0.62490976
. O 0 0.007403105

CONCLUSIONS O 0 0.7088614
: O 0 0.005960323
Patients O 0 0.0060353787
who O 0 0.002902284
are O 0 0.0012291587
more O 0 0.0011223075
than O 0 0.0005796808
10 O 0 0.00070176594
years O 0 0.0010420197
post O 0 0.0009988005
- O 0 0.0015382306
OLTX O 0 0.7673699
have O 0 0.0017956876
CRF B-Disease 0 0.9980552
and O 0 0.0039642784
ESRD B-Disease 2 0.9985216
at O 0 0.0016438484
a O 0 0.0026669581
high O 0 0.004034681
rate O 0 0.00508198
. O 0 0.006865198

The O 0 0.0036373292
development O 0 0.0050632423
of O 0 0.004533247
ESRD B-Disease 2 0.99820435
decreases O 0 0.005283341
survival O 0 0.12492239
, O 0 0.0019580582
particularly O 0 0.0017245614
in O 0 0.0008691612
those O 0 0.0013584391
patients O 0 0.0028185118
treated O 0 0.0026382538
with O 0 0.0030525883
dialysis O 0 0.15897964
only O 0 0.006343693
. O 0 0.007091095

Patients O 0 0.010799697
who O 0 0.005502845
develop O 0 0.0046517397
ESRD B-Disease 2 0.99754983
have O 0 0.0018116263
a O 0 0.001133853
higher O 0 0.00077734306
preoperative O 0 0.01010822
and O 0 0.0008732324
1 O 0 0.00072096445
- O 0 0.0008140199
year O 0 0.00060435705
serum O 0 0.05090392
creatinine B-Chemical 1 0.99201816
and O 0 0.00089485047
are O 0 0.00071740535
more O 0 0.00090208254
likely O 0 0.00079474057
to O 0 0.0012231984
have O 0 0.0035732347
hepatorenal B-Disease 0 0.9987509
syndrome I-Disease 0 0.9805891
. O 0 0.01016061

However O 0 0.004517073
, O 0 0.003129632
an O 0 0.0020201497
increase O 0 0.0012400681
of O 0 0.0015247923
serum O 0 0.09657226
creatinine B-Chemical 1 0.99151456
at O 0 0.00055068557
various O 0 0.0008590671
times O 0 0.0003636963
postoperatively O 0 0.0010886826
is O 0 0.0004457945
more O 0 0.000553958
predictive O 0 0.0008747776
of O 0 0.00084371
the O 0 0.0009527171
development O 0 0.0031943242
of O 0 0.00475135
CRF B-Disease 0 0.997696
or O 0 0.011145043
ESRD B-Disease 2 0.99774384
. O 0 0.011643644

New O 0 0.0072324346
strategies O 0 0.0038472665
for O 0 0.0020645494
long O 0 0.0025520627
- O 0 0.0027200277
term O 0 0.0021490313
immunosuppression O 0 0.93205595
may O 0 0.0019478331
be O 0 0.0014358172
needed O 0 0.0009903522
to O 0 0.0015612259
decrease O 0 0.002907141
this O 0 0.004283705
complication O 0 0.46064478
. O 0 0.008838261

Epileptic B-Disease 0 0.9982666
seizures I-Disease 2 0.99925536
following O 0 0.005946306
cortical O 0 0.09171427
application O 0 0.0046919254
of O 0 0.0031871959
fibrin O 0 0.39972204
sealants O 0 0.24789542
containing O 0 0.0049774596
tranexamic B-Chemical 0 0.99691236
acid I-Chemical 0 0.9745734
in O 0 0.007043126
rats O 0 0.03528349
. O 0 0.008834469

BACKGROUND O 0 0.8344701
: O 0 0.009877421
Fibrin O 0 0.26895285
sealants O 0 0.09635956
( O 0 0.004143571
FS O 0 0.11895372
) O 0 0.0024145918
derived O 0 0.0010951436
from O 0 0.0011153101
human O 0 0.0021943664
plasma O 0 0.017734263
are O 0 0.0017413682
frequently O 0 0.0029488797
used O 0 0.0022896205
in O 0 0.0034870212
neurosurgery O 0 0.038529646
. O 0 0.0077017527

In O 0 0.0033052047
order O 0 0.0019623477
to O 0 0.0018261506
increase O 0 0.0017380376
clot O 0 0.053302206
stability O 0 0.0027355186
, O 0 0.0022365928
FS O 0 0.11177853
typically O 0 0.0024884653
contain O 0 0.0017214696
aprotinin O 0 0.98705494
, O 0 0.0032800324
a O 0 0.003075572
natural O 0 0.031325165
fibrinolysis O 0 0.98963344
inhibitor O 0 0.6299763
. O 0 0.011263386

Recently O 0 0.009704708
, O 0 0.0048572975
synthetic O 0 0.007765667
fibrinolysis O 0 0.9776813
inhibitors O 0 0.16492514
such O 0 0.0019847748
as O 0 0.0017768863
tranexamic B-Chemical 0 0.9983341
acid I-Chemical 0 0.99133354
( O 0 0.008034354
tAMCA B-Chemical 1 0.9433322
) O 0 0.002062669
have O 0 0.0009921906
been O 0 0.001197291
considered O 0 0.0010171682
as O 0 0.0012652127
substitutes O 0 0.006813331
for O 0 0.003932393
aprotinin O 0 0.9846147
. O 0 0.008938285

However O 0 0.008759234
, O 0 0.008773376
tAMCA B-Chemical 1 0.6251338
has O 0 0.0049600815
been O 0 0.0048845527
shown O 0 0.0034560054
to O 0 0.005351544
cause O 0 0.11397703
epileptic B-Disease 2 0.9990845
seizures I-Disease 0 0.9993333
. O 0 0.02550379

We O 0 0.003855468
wanted O 0 0.0034417
to O 0 0.0020902466
study O 0 0.0024717413
whether O 0 0.0012209511
tAMCA B-Chemical 1 0.5394869
retains O 0 0.0033062089
its O 0 0.0066337087
convulsive B-Disease 2 0.99941313
action O 0 0.040196173
if O 0 0.0015276857
incorporated O 0 0.0022201512
into O 0 0.0020524373
a O 0 0.005178617
FS O 0 0.28067052
. O 0 0.0086391205

METHOD O 0 0.06406782
: O 0 0.0058167237
FS O 0 0.065163
containing O 0 0.002452916
aprotinin O 0 0.96288294
or O 0 0.0011531711
different O 0 0.0009517292
concentrations O 0 0.003090509
of O 0 0.0015591403
tAMCA B-Chemical 1 0.94085145
( O 0 0.0012536211
0 O 0 0.00056269806
. O 0 0.00023478635
5 O 0 0.00028062108
- O 0 0.00043258426
47 O 0 0.00047952504
. O 0 0.00016324833
5 O 0 0.00023094207
mg O 0 0.077801116
/ O 0 0.00077862444
ml O 0 0.001288737
) O 0 0.00046655932
were O 0 0.00024337343
applied O 0 0.0002791082
to O 0 0.00032438294
the O 0 0.0005133948
pial O 0 0.88895494
surface O 0 0.0023793026
of O 0 0.0012082147
the O 0 0.0014386488
cortex O 0 0.22583227
of O 0 0.0033831813
anaesthetized O 0 0.518459
rats O 0 0.019102355
. O 0 0.006208999

The O 0 0.002745433
response O 0 0.0025917557
of O 0 0.0016906679
the O 0 0.0010596628
animals O 0 0.00081023335
was O 0 0.00064941775
evaluated O 0 0.0005689104
using O 0 0.0005443577
electroencephalography O 0 0.42598113
and O 0 0.0006193922
by O 0 0.0004787778
monitoring O 0 0.00064114406
the O 0 0.0004595895
clinical O 0 0.0033159822
behaviour O 0 0.0015514325
during O 0 0.00051420054
and O 0 0.0008243937
after O 0 0.0007423348
recovery O 0 0.0032102892
from O 0 0.002950574
anaesthesia O 0 0.20924668
. O 0 0.0059753377

FINDINGS O 0 0.13181406
: O 0 0.007221231
FS O 0 0.0885638
containing O 0 0.0034594445
tAMCA B-Chemical 1 0.7849369
caused O 0 0.0042379936
paroxysmal O 0 0.9984841
brain O 0 0.27012983
activity O 0 0.0022889748
which O 0 0.0016798434
was O 0 0.0012643526
associated O 0 0.002001999
with O 0 0.002856108
distinct O 0 0.007738463
convulsive B-Disease 2 0.9990809
behaviours O 0 0.39038628
. O 0 0.00938607

The O 0 0.003985617
degree O 0 0.004070089
of O 0 0.003655455
these O 0 0.0056046974
seizures B-Disease 2 0.99876463
increased O 0 0.0071585746
with O 0 0.0041315993
increasing O 0 0.0061074444
concentration O 0 0.020887975
of O 0 0.01295
tAMCA B-Chemical 1 0.9620016
. O 0 0.012601498

Thus O 0 0.0047615566
, O 0 0.003969997
FS O 0 0.04789479
containing O 0 0.0017942846
47 O 0 0.0022329076
. O 0 0.00069253606
5 O 0 0.00068973535
mg O 0 0.16605033
/ O 0 0.0018175615
ml O 0 0.0047471635
tAMCA B-Chemical 1 0.8529984
evoked O 0 0.2727043
generalized B-Disease 0 0.87090296
seizures I-Disease 2 0.999926
in O 0 0.00058912876
all O 0 0.00030765298
tested O 0 0.00028152822
rats O 0 0.0029186695
( O 0 0.00047247735
n O 0 0.00025087112
= O 0 0.00037193266
6 O 0 0.00015662576
) O 0 0.00027300286
while O 0 0.00014926927
the O 0 0.00016713288
lowest O 0 0.00028701822
concentration O 0 0.0010877289
of O 0 0.000692408
tAMCA B-Chemical 1 0.93608034
( O 0 0.00068419386
0 O 0 0.00032810314
. O 0 0.00013783063
5 O 0 0.00019929728
mg O 0 0.08913551
/ O 0 0.0007022798
ml O 0 0.0012459982
) O 0 0.00041124076
only O 0 0.00023623962
evoked O 0 0.0076405755
brief O 0 0.00048175786
episodes O 0 0.05364973
of O 0 0.0008480173
jerk O 0 0.89982396
- O 0 0.001641962
correlated O 0 0.0008608161
convulsive B-Disease 2 0.99963915
potentials O 0 0.22144414
in O 0 0.001073807
1 O 0 0.0012734163
of O 0 0.0018084396
6 O 0 0.0021160739
rats O 0 0.007773618
. O 0 0.004873408

In O 0 0.004665426
contrast O 0 0.004173273
, O 0 0.004676244
FS O 0 0.09666577
containing O 0 0.003712043
aprotinin O 0 0.9788765
did O 0 0.0028861703
not O 0 0.0024644274
evoke O 0 0.009372075
any O 0 0.004821936
paroxysmal O 0 0.9956038
activity O 0 0.015139051
. O 0 0.010250942

INTERPRETATION O 0 0.30118197
: O 0 0.019788573
Tranexamic B-Chemical 0 0.99163276
acid I-Chemical 0 0.9670834
retains O 0 0.012588307
its O 0 0.023387216
convulsive B-Disease 2 0.99865204
action O 0 0.14326392
within O 0 0.007124406
FS O 0 0.43498152
. O 0 0.013718009

Thus O 0 0.0042709527
, O 0 0.0031385408
use O 0 0.0020874874
of O 0 0.001960007
FS O 0 0.12997907
containing O 0 0.0015743575
tAMCA B-Chemical 1 0.6730085
for O 0 0.0007024789
surgery O 0 0.0018588383
within O 0 0.00029460413
or O 0 0.00035656503
close O 0 0.00035751352
to O 0 0.0004095825
the O 0 0.00056859
CNS O 0 0.35878867
may O 0 0.00075048563
pose O 0 0.0013970176
a O 0 0.000987154
substantial O 0 0.0016734081
risk O 0 0.01560177
to O 0 0.001933026
the O 0 0.002755657
patient O 0 0.007238765
. O 0 0.0061518224

Sequential O 0 0.010516852
observations O 0 0.0037014454
of O 0 0.003258493
exencephaly B-Disease 2 0.96480423
and O 0 0.001600585
subsequent O 0 0.0012686258
morphological O 0 0.007927749
changes O 0 0.0011958064
by O 0 0.0006606332
mouse O 0 0.0009276948
exo O 0 0.042018026
utero O 0 0.030077793
development O 0 0.0019082214
system O 0 0.00095398654
: O 0 0.0006898636
analysis O 0 0.0005682227
of O 0 0.0005462775
the O 0 0.00049958244
mechanism O 0 0.00093047245
of O 0 0.001241969
transformation O 0 0.047500636
from O 0 0.0028688768
exencephaly B-Disease 2 0.9903554
to O 0 0.00649964
anencephaly B-Disease 2 0.98812765
. O 0 0.008879317

Anencephaly B-Disease 0 0.72238666
has O 0 0.0032536618
been O 0 0.0022619232
suggested O 0 0.001474975
to O 0 0.0010896792
develop O 0 0.0015119575
from O 0 0.0012110609
exencephaly B-Disease 2 0.990644
; O 0 0.002055805
however O 0 0.0008641667
, O 0 0.00054320507
there O 0 0.0002219683
is O 0 0.00027289876
little O 0 0.00023761897
direct O 0 0.00024375871
experimental O 0 0.0004467808
evidence O 0 0.00038177165
to O 0 0.00029657056
support O 0 0.00038102377
this O 0 0.00041551294
, O 0 0.00057735114
and O 0 0.0004910916
the O 0 0.000530829
mechanism O 0 0.0010902232
of O 0 0.001613135
transformation O 0 0.041547842
remains O 0 0.0036167745
unclear O 0 0.0068113557
. O 0 0.006622779

We O 0 0.0027979263
examined O 0 0.0015492812
this O 0 0.0013713262
theory O 0 0.0026552684
using O 0 0.0009789544
the O 0 0.0009194109
exo O 0 0.02712236
utero O 0 0.02525801
development O 0 0.0019112143
system O 0 0.0008569868
that O 0 0.00033975704
allows O 0 0.00033221857
direct O 0 0.00034475425
and O 0 0.0003901478
sequential O 0 0.0008199649
observations O 0 0.00073312595
of O 0 0.00080423226
mid O 0 0.0028656854
- O 0 0.001387222
to O 0 0.0008220271
late O 0 0.004382135
- O 0 0.002770983
gestation O 0 0.010318015
mouse O 0 0.0036669527
embryos O 0 0.0051421863
. O 0 0.0055343695

We O 0 0.0035546196
observed O 0 0.0021351927
the O 0 0.0022713179
exencephaly B-Disease 2 0.9593171
induced O 0 0.0026218623
by O 0 0.0013670737
5 B-Chemical 0 0.00093788496
- I-Chemical 0 0.0014919889
azacytidine I-Chemical 0 0.97978836
at O 0 0.0004223635
embryonic O 0 0.022027362
day O 0 0.00040573426
13 O 0 0.0004341365
. O 0 0.00019364659
5 O 0 0.00026111712
( O 0 0.00044621003
E13 O 0 0.17470554
. O 0 0.00019215146
5 O 0 0.00023542882
) O 0 0.00039617292
, O 0 0.00029517853
let O 0 0.00041427047
the O 0 0.00022489211
embryos O 0 0.00035491463
develop O 0 0.0004708195
exo O 0 0.027778681
utero O 0 0.016739624
until O 0 0.000281775
E18 O 0 0.13086279
. O 0 0.00020732546
5 O 0 0.0002463947
, O 0 0.000340877
and O 0 0.00036394395
re O 0 0.0061096996
- O 0 0.00067207887
observed O 0 0.00029296812
the O 0 0.000389133
same O 0 0.00038399638
embryos O 0 0.0010770962
at O 0 0.0010349246
E18 O 0 0.07987661
. O 0 0.0018138507
5 O 0 0.003150271
. O 0 0.004331545

We O 0 0.004531358
confirmed O 0 0.0035561332
several O 0 0.003416485
cases O 0 0.0047563645
of O 0 0.0045116213
transformation O 0 0.038742978
from O 0 0.006926583
exencephaly B-Disease 2 0.98367715
to O 0 0.012455617
anencephaly B-Disease 2 0.9817129
. O 0 0.015269666

However O 0 0.004592235
, O 0 0.00319539
in O 0 0.0015220244
many O 0 0.0015217721
cases O 0 0.0021984763
, O 0 0.0014018407
the O 0 0.0009248472
exencephalic B-Disease 2 0.47771466
brain O 0 0.05592008
tissue O 0 0.0067468425
was O 0 0.0005927628
preserved O 0 0.00093521073
with O 0 0.0006350692
more O 0 0.0007423518
or O 0 0.00054252817
less O 0 0.00078873057
reduction O 0 0.00151843
during O 0 0.001069599
this O 0 0.0020230184
period O 0 0.0038776593
. O 0 0.0051309

To O 0 0.0025431106
analyze O 0 0.0015205367
the O 0 0.0015519534
transformation O 0 0.0058860555
patterns O 0 0.0011461077
, O 0 0.001046621
we O 0 0.0003886703
classified O 0 0.0007636342
the O 0 0.0006747732
exencephaly B-Disease 2 0.9754254
by O 0 0.0006492624
size O 0 0.0006365132
and O 0 0.00044446954
shape O 0 0.0006605925
of O 0 0.0005116898
the O 0 0.000484792
exencephalic B-Disease 2 0.4087082
tissue O 0 0.0038661554
into O 0 0.0002757154
several O 0 0.00044728958
types O 0 0.0005572965
at O 0 0.00052096724
E13 O 0 0.29283556
. O 0 0.00058055745
5 O 0 0.0008231841
and O 0 0.0014457651
E18 O 0 0.06007787
. O 0 0.0018379835
5 O 0 0.0031885812
. O 0 0.0044297255

It O 0 0.005446053
was O 0 0.0021884474
found O 0 0.0013997748
that O 0 0.0009356924
the O 0 0.0009363617
transformation O 0 0.007386871
of O 0 0.0013671947
exencephalic B-Disease 2 0.65726113
tissue O 0 0.012403273
was O 0 0.0005234466
not O 0 0.00033647544
simply O 0 0.0004339263
size O 0 0.00058961014
- O 0 0.0006517323
dependent O 0 0.0003115946
, O 0 0.00040257254
and O 0 0.0002689263
all O 0 0.00021333357
cases O 0 0.0005766002
of O 0 0.00063200947
anencephaly B-Disease 2 0.98112476
at O 0 0.00032870617
E18 O 0 0.2164955
. O 0 0.00017533868
5 O 0 0.00017595348
resulted O 0 0.000180192
from O 0 0.00021079097
embryos O 0 0.00031034026
with O 0 0.00030947605
a O 0 0.0003483767
large O 0 0.00043065456
amount O 0 0.00031300884
of O 0 0.0010297874
exencephalic B-Disease 2 0.5469835
tissue O 0 0.013674846
at O 0 0.0015217373
E13 O 0 0.4792387
. O 0 0.0020412684
5 O 0 0.0033367486
. O 0 0.004461631

Microscopic O 0 0.12314301
observation O 0 0.0030506032
showed O 0 0.0017427555
the O 0 0.0012754798
configuration O 0 0.0019010874
of O 0 0.0018207636
exencephaly B-Disease 2 0.9842859
at O 0 0.00087436347
E13 O 0 0.61635137
. O 0 0.00041680963
5 O 0 0.00038464027
, O 0 0.0004906815
frequent O 0 0.0021039695
hemorrhaging B-Disease 0 0.9910035
and O 0 0.00072800147
detachment O 0 0.9030304
of O 0 0.00060724973
the O 0 0.00037672982
neural O 0 0.010954936
plate O 0 0.0009956746
from O 0 0.0003339769
surface O 0 0.0023111294
ectoderm O 0 0.2482667
in O 0 0.00029856217
the O 0 0.00034340014
exencephalic B-Disease 2 0.43997666
head O 0 0.014924516
at O 0 0.00031181338
E15 O 0 0.6736512
. O 0 0.00019733963
5 O 0 0.00020836788
, O 0 0.00024844933
and O 0 0.00020853104
multiple O 0 0.00038104662
modes O 0 0.00044027416
of O 0 0.00051905797
reduction O 0 0.0010219958
in O 0 0.00051725865
the O 0 0.0007770612
exencephalic B-Disease 2 0.45394024
tissue O 0 0.010628767
at O 0 0.0013867444
E18 O 0 0.15131912
. O 0 0.0019173219
5 O 0 0.0032243857
. O 0 0.0043740436

From O 0 0.0044890177
observations O 0 0.0028200692
of O 0 0.0021804462
the O 0 0.0017274042
vasculature O 0 0.16430563
, O 0 0.0016219537
altered O 0 0.001233352
distribution O 0 0.00059631804
patterns O 0 0.0007174884
of O 0 0.0011168119
vessels O 0 0.022340223
were O 0 0.0010419135
identified O 0 0.001086113
in O 0 0.0014825268
the O 0 0.0027794363
exencephalic B-Disease 2 0.63037527
head O 0 0.12169749
. O 0 0.008179782

These O 0 0.004329043
findings O 0 0.003687606
suggest O 0 0.001408329
that O 0 0.0012975142
overgrowth O 0 0.052572165
of O 0 0.0013481632
the O 0 0.0009938614
exencephalic B-Disease 2 0.56042844
neural O 0 0.024755817
tissue O 0 0.008453929
causes O 0 0.0012788421
the O 0 0.00035388142
altered O 0 0.0005156015
distribution O 0 0.00023035907
patterns O 0 0.00028535383
of O 0 0.00047191465
vessels O 0 0.042689946
, O 0 0.00044749727
subsequent O 0 0.00042686373
peripheral O 0 0.06547207
circulatory B-Disease 0 0.96862674
failure I-Disease 0 0.961287
and O 0 0.0008390281
/ O 0 0.0016884137
or O 0 0.00034390274
hemorrhaging B-Disease 0 0.9904874
in O 0 0.00028073802
various O 0 0.0005694241
parts O 0 0.000335798
of O 0 0.00037256756
the O 0 0.00036350414
exencephalic B-Disease 2 0.5888805
head O 0 0.026818832
, O 0 0.0005145163
leading O 0 0.0006178728
to O 0 0.00023620584
the O 0 0.0002182325
multiple O 0 0.00045408166
modes O 0 0.00048486667
of O 0 0.0005775837
tissue O 0 0.0065566823
reduction O 0 0.001374629
during O 0 0.00067285507
transformation O 0 0.02951009
from O 0 0.0023442763
exencephaly B-Disease 2 0.98893833
to O 0 0.0057355273
anencephaly B-Disease 2 0.98789495
. O 0 0.008283273

99mTc B-Chemical 0 0.8153631
- I-Chemical 0 0.011753801
glucarate I-Chemical 0 0.9509426
for O 0 0.0029001087
detection O 0 0.0032165851
of O 0 0.0048051784
isoproterenol B-Chemical 1 0.9985108
- O 0 0.021823237
induced O 0 0.018409517
myocardial B-Disease 0 0.99858826
infarction I-Disease 2 0.99955624
in O 0 0.012665164
rats O 0 0.07321924
. O 0 0.009389648

Infarct B-Disease 0 0.9912573
- O 0 0.009185114
avid O 0 0.013817595
radiopharmaceuticals O 0 0.16345143
are O 0 0.0017635939
necessary O 0 0.00095349544
for O 0 0.0009627554
rapid O 0 0.0025342251
and O 0 0.0015239023
timely O 0 0.0033184222
diagnosis O 0 0.021112408
of O 0 0.0072457925
acute O 2 0.9954645
myocardial B-Disease 2 0.9990632
infarction I-Disease 2 0.9996184
. O 0 0.027505657

The O 0 0.0029458527
animal O 0 0.003627637
model O 0 0.0025580903
used O 0 0.0015702688
to O 0 0.0013907963
produce O 0 0.0019709882
infarction B-Disease 2 0.9994399
implies O 0 0.0023814929
artery O 0 0.41353703
ligation O 0 0.0059882635
but O 0 0.0009872329
chemical O 0 0.01776415
induction O 0 0.0016105275
can O 0 0.00092403986
be O 0 0.0011619864
easily O 0 0.0017510301
obtained O 0 0.0019794125
with O 0 0.00565913
isoproterenol B-Chemical 1 0.9960627
. O 0 0.010178421

A O 0 0.022437736
new O 0 0.0077976724
infarct B-Disease 0 0.9928438
- O 0 0.006155707
avid O 0 0.016896147
radiopharmaceutical O 0 0.2979427
based O 0 0.0017878046
on O 0 0.001025489
glucaric B-Chemical 0 0.9967219
acid I-Chemical 0 0.9395187
was O 0 0.0012521931
prepared O 0 0.0012479423
in O 0 0.0007705479
the O 0 0.0009261359
hospital O 0 0.0033966608
radiopharmacy O 0 0.0034401857
of O 0 0.0033691109
the O 0 0.004888416
INCMNSZ O 0 0.651155
. O 0 0.008172845

99mTc B-Chemical 0 0.8421845
- I-Chemical 0 0.009924291
glucarate I-Chemical 0 0.9668464
was O 0 0.0021023853
easy O 0 0.0020216028
to O 0 0.00091213686
prepare O 0 0.00107007
, O 0 0.00075733516
stable O 0 0.0006357696
for O 0 0.00037694446
96 O 0 0.0006870011
h O 0 0.00037768888
and O 0 0.0003335464
was O 0 0.00029360957
used O 0 0.00025337588
to O 0 0.000266058
study O 0 0.0005092497
its O 0 0.00083751767
biodistribution O 0 0.13059685
in O 0 0.00057481026
rats O 0 0.0043707676
with O 0 0.0019076894
isoproterenol B-Chemical 1 0.9992095
- O 0 0.013240596
induced O 0 0.014457824
acute O 2 0.9968521
myocardial B-Disease 2 0.9993211
infarction I-Disease 2 0.9997156
. O 0 0.024980208

Histological O 0 0.20496458
studies O 0 0.004586998
demonstrated O 0 0.0024135618
that O 0 0.0014861681
the O 0 0.0015060955
rats O 0 0.004426409
developed O 0 0.0029719002
an O 0 0.0030931807
infarct B-Disease 0 0.99277496
18 O 0 0.0023593889
h O 0 0.0020599018
after O 0 0.0022050939
isoproterenol B-Chemical 1 0.99623483
administration O 0 0.6511559
. O 0 0.009481441

The O 0 0.0043527894
rat O 0 0.01000594
biodistribution O 0 0.07588616
studies O 0 0.0035757055
showed O 0 0.0021813167
a O 0 0.0024381343
rapid O 0 0.0051113786
blood O 0 0.015450498
clearance O 0 0.074985765
via O 0 0.0040250965
the O 0 0.0054126033
kidneys O 0 0.097156405
. O 0 0.009722874

Thirty O 0 0.007824983
minutes O 0 0.0026926398
after O 0 0.0016099925
99mTc B-Chemical 0 0.63652045
- I-Chemical 0 0.0040933113
glucarate I-Chemical 0 0.9827723
administration O 0 0.14208098
the O 0 0.0007662387
standardised O 0 0.0010655365
heart O 0 0.3991884
uptake O 0 0.020943426
value O 0 0.0009278936
S O 0 0.60816824
( O 0 0.0009033551
h O 0 0.00056232815
) O 0 0.00083885016
UV O 0 0.42671996
was O 0 0.00042496502
4 O 0 0.00028392614
. O 0 0.00016604416
7 O 0 0.00019944787
in O 0 0.00021572839
infarcted O 0 0.06676525
rat O 0 0.005480574
heart O 0 0.1844139
which O 0 0.00056353083
is O 0 0.00034165996
six O 0 0.00024482617
times O 0 0.00033064155
more O 0 0.0007702385
than O 0 0.00062589283
in O 0 0.001232
normal O 0 0.004386664
rats O 0 0.011170638
. O 0 0.0054541533

ROIs O 0 0.009372522
drawn O 0 0.0037624456
over O 0 0.0015630578
the O 0 0.002021302
gamma O 0 0.05108921
camera O 0 0.005235804
images O 0 0.0026113992
showed O 0 0.001558809
a O 0 0.0018614873
ratio O 0 0.002320867
of O 0 0.0029030323
4 O 0 0.0027695484
. O 0 0.0025876022
4 O 0 0.0042870436
. O 0 0.005851292

The O 0 0.0024670006
high O 0 0.0022149086
image O 0 0.002063919
quality O 0 0.0010282409
suggests O 0 0.0006121035
that O 0 0.0005127823
high O 0 0.000714545
contrast O 0 0.0006036665
images O 0 0.0008195633
can O 0 0.00035529712
be O 0 0.00034585604
obtained O 0 0.00028782772
in O 0 0.00027398227
humans O 0 0.0010090306
and O 0 0.00029949637
the O 0 0.00024212683
96 O 0 0.00045668727
h O 0 0.00025652858
stability O 0 0.00034755172
makes O 0 0.0003031667
it O 0 0.00032182533
an O 0 0.00038341657
ideal O 0 0.0003974826
agent O 0 0.020601125
to O 0 0.0004298312
detect O 0 0.00038927436
, O 0 0.0007921118
in O 0 0.00067434565
patients O 0 0.0030529175
, O 0 0.0022064256
early O 0 0.012146764
cardiac B-Disease 0 0.98825943
infarction I-Disease 2 0.9996189
. O 0 0.0147293685

Bupropion B-Chemical 0 0.9947237
( O 0 0.07160795
Zyban B-Chemical 0 0.9887029
) O 0 0.060898952
toxicity B-Disease 2 0.97250915
. O 0 0.02952233

Bupropion B-Chemical 0 0.9965933
is O 0 0.008488597
a O 0 0.008433946
monocyclic O 0 0.9890435
antidepressant B-Chemical 1 0.9976737
structurally O 0 0.09632191
related O 0 0.006292144
to O 0 0.011426045
amphetamine B-Chemical 1 0.99816436
. O 0 0.018020403

Zyban B-Chemical 0 0.992249
, O 0 0.005270338
a O 0 0.0027346327
sustained O 0 0.013898699
- O 0 0.0031640746
release O 0 0.03812805
formulation O 0 0.17324756
of O 0 0.0035543796
bupropion B-Chemical 0 0.9999101
hydrochloride I-Chemical 0 0.9995559
, O 0 0.0023454465
was O 0 0.00068615895
recently O 0 0.0008668792
released O 0 0.0014146832
in O 0 0.00076321955
Ireland O 0 0.043442905
, O 0 0.0011233772
as O 0 0.00084473257
a O 0 0.0019179992
smoking O 1 0.72695106
cessation O 0 0.055960573
aid O 0 0.009652851
. O 0 0.006684822

In O 0 0.0028756477
the O 0 0.0018383624
initial O 0 0.0014898152
6 O 0 0.00090249773
months O 0 0.0007976525
since O 0 0.00050982425
it O 0 0.0006623539
' O 0 0.0006594527
s O 0 0.0006623514
introduction O 0 0.00055845943
, O 0 0.00069900503
12 O 0 0.0005328841
overdose B-Disease 2 0.99812466
cases O 0 0.001565921
have O 0 0.00075005944
been O 0 0.0009175815
reported O 0 0.001132094
to O 0 0.00091746385
The O 0 0.0012707991
National O 0 0.0063008135
Poisons O 0 0.8144982
Information O 0 0.011600729
Centre O 0 0.0211203
. O 0 0.0066298232

8 O 0 0.011278754
patients O 0 0.015212054
developed O 0 0.01636611
symptoms O 0 0.35154316
of O 0 0.025136404
toxicity B-Disease 2 0.98102164
. O 0 0.025324937

Common O 0 0.021981413
features O 0 0.010038324
included O 0 0.006199068
tachycardia B-Disease 2 0.99503016
, O 0 0.019655844
drowsiness O 0 0.9979479
, O 0 0.036659848
hallucinations B-Disease 2 0.99875474
and O 0 0.037984565
convulsions B-Disease 0 0.9981323
. O 0 0.0175252

Two O 0 0.0051221903
patients O 0 0.005740408
developed O 0 0.0046330113
severe O 0 0.24671334
cardiac B-Disease 2 0.9691897
arrhythmias I-Disease 2 0.9997327
, O 0 0.0030125438
including O 0 0.00096397393
one O 0 0.0006218872
patient O 0 0.0013483557
who O 0 0.001953615
was O 0 0.0010990149
resuscitated O 0 0.030627348
following O 0 0.0018935725
a O 0 0.0037869937
cardiac B-Disease 2 0.9145101
arrest I-Disease 2 0.9433021
. O 0 0.008515103

All O 0 0.015101133
patients O 0 0.01925548
recovered O 0 0.013632556
without O 0 0.019699344
sequelae O 0 0.655109
. O 0 0.026688911

We O 0 0.0031696232
report O 0 0.004115285
a O 0 0.0018085799
case O 0 0.0012681446
of O 0 0.0011720497
a O 0 0.0009826163
31 O 0 0.000948301
year O 0 0.00055972004
old O 0 0.00058697513
female O 0 0.001009621
who O 0 0.00075329683
required O 0 0.00021282645
admission O 0 0.0027488377
to O 0 0.00031582962
the O 0 0.0003693119
Intensive O 0 0.11662128
Care O 0 0.01073851
Unit O 0 0.0021481947
for O 0 0.00025097805
ventilation O 0 0.011091124
and O 0 0.0003534814
full O 0 0.00030832484
supportive O 0 0.0016248379
therapy O 0 0.014442674
, O 0 0.0008369411
following O 0 0.00078986556
ingestion O 0 0.3583698
of O 0 0.0016243375
13 O 0 0.0020944362
. O 0 0.0014944073
5g O 0 0.057956293
bupropion B-Chemical 0 0.99830425
. O 0 0.008287404

Recurrent O 0 0.7425712
seizures B-Disease 2 0.9983473
were O 0 0.0037031076
treated O 0 0.0037081973
with O 0 0.0030358457
diazepam B-Chemical 1 0.99956566
and O 0 0.0022203287
broad O 0 0.002596865
complex O 0 0.0021874718
tachycardia B-Disease 2 0.9975594
was O 0 0.0021469032
successfully O 0 0.0035961473
treated O 0 0.0050523104
with O 0 0.0075655393
adenosine B-Chemical 1 0.9899587
. O 0 0.011268034

Zyban B-Chemical 0 0.9865584
caused O 0 0.009199412
significant O 0 0.008502727
neurological B-Disease 0 0.95083416
and I-Disease 0 0.01164752
cardiovascular I-Disease 0 0.9951225
toxicity I-Disease 2 0.99735045
in O 0 0.033354405
overdose B-Disease 2 0.99724054
. O 0 0.017889878

The O 0 0.0032688177
potential O 0 0.0038044616
toxic O 0 0.4230894
effects O 0 0.0036632628
should O 0 0.0010285656
be O 0 0.0010856179
considered O 0 0.0008221431
when O 0 0.0007144939
prescribing O 0 0.007742645
it O 0 0.0013209368
as O 0 0.0011325232
a O 0 0.0024510254
smoking O 1 0.7249825
cessation O 0 0.059999943
aid O 0 0.011081101
. O 0 0.0076281372

GLEPP1 O 0 0.73661363
receptor O 0 0.54090905
tyrosine B-Chemical 1 0.9755037
phosphatase O 0 0.88646233
( O 0 0.013879002
Ptpro O 0 0.489383
) O 0 0.0091812285
in O 0 0.005891116
rat O 0 0.20146959
PAN B-Chemical 1 0.9956905
nephrosis B-Disease 2 0.9983278
. O 0 0.025407609

A O 0 0.039711203
marker O 0 0.017648548
of O 0 0.022775428
acute O 0 0.9711888
podocyte O 0 0.9804125
injury O 0 0.9746957
. O 0 0.033241257

Glomerular O 0 0.751971
epithelial O 0 0.21967497
protein O 0 0.0070722853
1 O 0 0.002412532
( O 0 0.0023969791
GLEPP1 O 0 0.46836343
) O 0 0.0020179786
is O 0 0.00074634544
a O 0 0.0009074373
podocyte O 0 0.8835391
receptor O 0 0.38815948
membrane O 0 0.06960852
protein O 0 0.012426277
tyrosine B-Chemical 1 0.9790678
phosphatase O 0 0.7665666
located O 0 0.00064412464
on O 0 0.00024999122
the O 0 0.00038248417
apical O 0 0.0010603949
cell O 0 0.0037196195
membrane O 0 0.007469837
of O 0 0.0012009152
visceral O 0 0.55581194
glomerular O 0 0.9519817
epithelial O 0 0.4322516
cell O 0 0.028975312
and O 0 0.003177479
foot O 0 0.11162071
processes O 0 0.014735687
. O 0 0.006419657

This O 0 0.0067263846
receptor O 0 0.04289257
plays O 0 0.003013648
a O 0 0.0019946878
role O 0 0.0011037892
in O 0 0.0010127414
regulating O 0 0.000831504
the O 0 0.0010464506
structure O 0 0.001967774
and O 0 0.0014132384
function O 0 0.0021599547
of O 0 0.0036969325
podocyte O 0 0.9452185
foot O 0 0.3173986
process O 0 0.010373687
. O 0 0.008407327

To O 0 0.0025107597
better O 0 0.0020884352
understand O 0 0.0010712362
the O 0 0.00096749415
utility O 0 0.0010185617
of O 0 0.0012122678
GLEPP1 O 0 0.38137504
as O 0 0.0006309836
a O 0 0.0006585879
marker O 0 0.0008233672
of O 0 0.001169488
glomerular B-Disease 0 0.99423534
injury I-Disease 0 0.99563783
, O 0 0.0010427203
the O 0 0.00028880106
amount O 0 0.00016473778
and O 0 0.00025178143
distribution O 0 0.00018915656
of O 0 0.0004594984
GLEPP1 O 0 0.5269546
protein O 0 0.0014521657
and O 0 0.00039273492
mRNA O 0 0.00059461704
were O 0 0.00021952386
examined O 0 0.00017396062
by O 0 0.00026374654
immunohistochemistry O 0 0.0051987357
, O 0 0.000490036
Western O 0 0.0048095975
blot O 0 0.0071192505
and O 0 0.0008243725
RNase O 0 0.93119097
protection O 0 0.008972479
assay O 0 0.0012095718
in O 0 0.00043922933
a O 0 0.000618332
model O 0 0.0009321305
of O 0 0.0017796691
podocyte O 0 0.9681525
injury O 0 0.96279097
in O 0 0.0027154966
the O 0 0.0036116005
rat O 0 0.044226173
. O 0 0.0065868823

Puromycin B-Chemical 0 0.9978157
aminonucleoside I-Chemical 0 0.99971837
nephrosis B-Disease 2 0.99951696
was O 0 0.00403839
induced O 0 0.002199027
by O 0 0.0010886114
single O 0 0.0009997311
intraperitoneal O 0 0.1421486
injection O 0 0.007334972
of O 0 0.00216303
puromycin B-Chemical 0 0.99171406
aminonucleoside I-Chemical 0 0.9998553
( O 0 0.016283922
PAN B-Chemical 1 0.99792516
, O 0 0.0024227719
20 O 0 0.0019685398
mg O 0 0.46925423
/ O 0 0.007074147
100g O 0 0.4731415
BW O 0 0.48670042
) O 0 0.0088468585
. O 0 0.0063642794

Tissues O 0 0.012415925
were O 0 0.0023432772
analyzed O 0 0.0015282982
at O 0 0.0010469132
0 O 0 0.0012503683
, O 0 0.0010790151
5 O 0 0.0006223008
, O 0 0.0006931134
7 O 0 0.0004344557
, O 0 0.0005081437
11 O 0 0.0004396878
, O 0 0.00042091095
21 O 0 0.0003985672
, O 0 0.00032942768
45 O 0 0.00025133078
, O 0 0.0002608929
80 O 0 0.00030891006
and O 0 0.00022400038
126 O 0 0.00080491806
days O 0 0.00019395
after O 0 0.00016635937
PAN B-Chemical 1 0.9919052
injection O 0 0.0025138943
so O 0 0.00023841803
as O 0 0.0001748038
to O 0 0.0001927447
include O 0 0.00028294334
both O 0 0.0002346391
the O 0 0.00029351524
acute O 0 0.84619355
phase O 0 0.0027672774
of O 0 0.0014947143
proteinuria B-Disease 2 0.9998703
associated O 0 0.0024782137
with O 0 0.0008598218
foot O 0 0.059641887
process O 0 0.0008243808
effacement O 0 0.31993133
( O 0 0.0005031358
days O 0 0.0002540929
5 O 0 0.00022931292
- O 0 0.00036880633
11 O 0 0.00026637805
) O 0 0.0003253862
and O 0 0.00021597947
the O 0 0.00025924426
chronic O 0 0.78023326
phase O 0 0.0024296227
of O 0 0.0017520272
proteinuria B-Disease 2 0.9998271
associated O 0 0.005705548
with O 0 0.0062121483
glomerulosclerosis B-Disease 2 0.9997707
( O 0 0.004356676
days O 0 0.0014049165
45 O 0 0.0016933485
- O 0 0.0031342471
126 O 0 0.010179906
) O 0 0.0056765117
. O 0 0.004895284

At O 0 0.0024776903
day O 0 0.0021921862
5 O 0 0.0016029159
, O 0 0.0018046879
GLEPP1 O 0 0.18717265
protein O 0 0.0021736266
and O 0 0.0009309993
mRNA O 0 0.0011810067
were O 0 0.00044561626
reduced O 0 0.0004203387
from O 0 0.00032916054
the O 0 0.00030108273
normal O 0 0.00069037825
range O 0 0.0006882374
( O 0 0.00059048925
265 O 0 0.007996002
. O 0 0.00021725359
2 O 0 0.00031554908
+ O 0 0.00041020126
/ O 0 0.00072709005
- O 0 0.0004504072
79 O 0 0.00041265943
. O 0 0.00012982443
6 O 0 0.00014820686
x O 0 0.0004944887
10 O 0 0.00024249533
( O 0 0.0002727297
6 O 0 0.00016551951
) O 0 0.00036076194
moles O 0 0.024618378
/ O 0 0.0009537416
glomerulus O 0 0.04583786
and O 0 0.00033438887
100 O 0 0.0006963136
% O 0 0.0002944525
) O 0 0.00030059344
to O 0 0.00016126016
15 O 0 0.00016100587
% O 0 0.00018324108
of O 0 0.0002174225
normal O 0 0.0005819502
( O 0 0.0003943466
41 O 0 0.0005350275
. O 0 0.00015711655
8 O 0 0.00024765066
+ O 0 0.00035018142
/ O 0 0.0006718202
- O 0 0.0004256088
4 O 0 0.00019161117
. O 0 0.00012751711
8 O 0 0.00019639413
x O 0 0.00054688577
10 O 0 0.00028486183
( O 0 0.00034315616
6 O 0 0.00023339051
) O 0 0.00055074465
moles O 0 0.031070866
/ O 0 0.0018126147
glomerulus O 0 0.07768822
, O 0 0.0011609287
p O 0 0.0013242161
< O 0 0.0013049328
0 O 0 0.001408812
. O 0 0.0014177766
005 O 0 0.037134893
) O 0 0.006007467
. O 0 0.005374581

This O 0 0.0044548763
occurred O 0 0.0023161045
in O 0 0.001221713
association O 0 0.0008911497
with O 0 0.0010365607
an O 0 0.0010006446
increase O 0 0.0006701138
in O 0 0.000601062
urinary O 0 0.6386801
protein O 0 0.002304123
content O 0 0.00076496706
from O 0 0.00047834418
1 O 0 0.00043426442
. O 0 0.00021376071
8 O 0 0.00031112085
+ O 0 0.00041941772
/ O 0 0.0007735051
- O 0 0.00048610198
1 O 0 0.00024020529
to O 0 0.00020450515
99 O 0 0.0005900799
. O 0 0.00017649202
0 O 0 0.00034016286
+ O 0 0.0004170276
/ O 0 0.00080943725
- O 0 0.0006134058
61 O 0 0.00080208323
mg O 0 0.15264343
/ O 0 0.0011062291
day O 0 0.00058926636
( O 0 0.00087091164
p O 0 0.0010750648
< O 0 0.0012138741
0 O 0 0.0014150011
. O 0 0.0015096716
001 O 0 0.118305646
) O 0 0.0066262125
. O 0 0.005689855

In O 0 0.004346668
contrast O 0 0.0038383845
, O 0 0.0041639917
podocalyxin O 0 0.074161075
did O 0 0.0022400795
not O 0 0.0017651896
change O 0 0.0021133411
significantly O 0 0.0025493526
at O 0 0.001961909
this O 0 0.0033957167
time O 0 0.0052448763
. O 0 0.007961034

By O 0 0.0061999317
day O 0 0.003417003
11 O 0 0.0031596227
, O 0 0.0030530915
GLEPP1 O 0 0.2078245
protein O 0 0.003747259
and O 0 0.0019747305
mRNA O 0 0.0027108544
had O 0 0.0017115435
begun O 0 0.0029285424
to O 0 0.001917428
return O 0 0.0036956577
towards O 0 0.0037824952
baseline O 0 0.0074647684
. O 0 0.007201597

By O 0 0.0049094255
day O 0 0.0025228926
45 O 0 0.0021002747
- O 0 0.0020854757
126 O 0 0.003097327
, O 0 0.0009455857
at O 0 0.00039026685
a O 0 0.0004765386
time O 0 0.00036093927
when O 0 0.00036800082
glomerular O 0 0.78172165
scarring O 0 0.983422
was O 0 0.00064008933
present O 0 0.00034568345
, O 0 0.00067422516
GLEPP1 O 0 0.39008918
was O 0 0.00037503688
absent O 0 0.0002928673
from O 0 0.0003343713
glomerulosclerotic O 0 0.86225647
areas O 0 0.001218813
although O 0 0.0003108093
the O 0 0.00026954466
total O 0 0.00037518528
glomerular O 0 0.61170965
content O 0 0.00090635236
of O 0 0.0012528157
GLEPP1 O 0 0.5734484
was O 0 0.0010192678
not O 0 0.0009502944
different O 0 0.0014494541
from O 0 0.0023972301
normal O 0 0.0071143857
. O 0 0.0055115134

We O 0 0.003770327
conclude O 0 0.0029438534
that O 0 0.0024250087
GLEPP1 O 0 0.3569447
expression O 0 0.004058599
, O 0 0.0024177777
unlike O 0 0.001667379
podocalyxin O 0 0.23630348
, O 0 0.0028613096
reflects O 0 0.0023792838
podocyte O 0 0.9664151
injury O 0 0.9779244
induced O 0 0.014883379
by O 0 0.012548276
PAN B-Chemical 1 0.9939136
. O 0 0.012429754

GLEPP1 O 0 0.3675329
expression O 0 0.008429677
may O 0 0.0044308277
be O 0 0.0036037243
a O 0 0.0034640688
useful O 0 0.004366962
marker O 0 0.0057729697
of O 0 0.0104433615
podocyte O 0 0.9768444
injury O 0 0.9781718
. O 0 0.017704353

Antithymocyte B-Chemical 0 0.92887664
globulin I-Chemical 0 0.9840391
in O 0 0.003658814
the O 0 0.0026020315
treatment O 0 0.00498682
of O 0 0.005190722
D B-Chemical 0 0.95584744
- I-Chemical 0 0.05841376
penicillamine I-Chemical 1 0.99964035
- O 0 0.100512885
induced O 0 0.120672405
aplastic B-Disease 2 0.9994129
anemia I-Disease 2 0.9992669
. O 0 0.027424777

A O 0 0.015601653
patient O 0 0.0047757505
who O 0 0.0043248157
received O 0 0.0031770165
antithymocyte B-Chemical 0 0.99337584
globulin I-Chemical 0 0.9971008
therapy O 0 0.2748818
for O 0 0.0040258532
aplastic B-Disease 2 0.9997712
anemia I-Disease 2 0.9997973
due O 0 0.002142456
to O 0 0.002499829
D B-Chemical 0 0.9485308
- I-Chemical 0 0.027248569
penicillamine I-Chemical 1 0.99967206
therapy O 0 0.42281175
is O 0 0.005636336
described O 0 0.0054263873
. O 0 0.0069419215

Bone O 0 0.08576
marrow O 0 0.09455699
recovery O 0 0.004382886
and O 0 0.0017675638
peripheral O 0 0.011089331
blood O 0 0.004463121
recovery O 0 0.0015764214
were O 0 0.00051449717
complete O 0 0.00040729524
1 O 0 0.00033644435
month O 0 0.00027424516
and O 0 0.00028789137
3 O 0 0.00022051572
months O 0 0.0002717688
, O 0 0.00031804136
respectively O 0 0.00052679057
, O 0 0.0002763702
after O 0 0.00013262838
treatment O 0 0.0006142817
, O 0 0.00034824767
and O 0 0.00026810475
blood O 0 0.0026417093
transfusion O 0 0.03241157
or O 0 0.00021315749
other O 0 0.00025497118
therapies O 0 0.0061084144
were O 0 0.00025341669
not O 0 0.0001963524
necessary O 0 0.00016351332
in O 0 0.00022189718
a O 0 0.0003259096
follow O 0 0.0003683599
- O 0 0.00060702144
up O 0 0.00035976217
period O 0 0.0004477444
of O 0 0.00076224486
more O 0 0.0012043965
than O 0 0.0009969164
2 O 0 0.0021494504
years O 0 0.0050123744
. O 0 0.0044613048

Use O 0 0.011845847
of O 0 0.004971318
antithymocyte B-Chemical 0 0.9909786
globulin I-Chemical 0 0.9948061
may O 0 0.0027054248
be O 0 0.001373919
the O 0 0.000857093
optimal O 0 0.00074792275
treatment O 0 0.0025910297
of O 0 0.0030737517
D B-Chemical 0 0.95983297
- I-Chemical 0 0.048242267
penicillamine I-Chemical 1 0.9997577
- O 0 0.086100414
induced O 0 0.11022906
aplastic B-Disease 2 0.9995271
anemia I-Disease 2 0.9993886
. O 0 0.024262479

Metamizol B-Chemical 0 0.993236
potentiates O 0 0.72032416
morphine B-Chemical 1 0.9991345
antinociception O 0 0.99918526
but O 0 0.007009067
not O 0 0.005328092
constipation B-Disease 2 0.9971781
after O 0 0.0052941903
chronic O 0 0.96890914
treatment O 0 0.06650663
. O 0 0.011965291

This O 0 0.0043236287
work O 0 0.0027113468
evaluates O 0 0.0018958839
the O 0 0.0015961415
antinociceptive O 0 0.9936684
and O 0 0.0019733722
constipating B-Disease 0 0.9971469
effects O 0 0.0027144663
of O 0 0.0007662431
the O 0 0.00043242035
combination O 0 0.0010640054
of O 0 0.00058478536
3 O 0 0.0003463548
. O 0 0.00018667144
2 O 0 0.000283345
mg O 0 0.11904842
/ O 0 0.0006921699
kg O 0 0.0019315234
s O 0 0.00034079398
. O 0 0.0001588513
c O 0 0.0011433624
. O 0 0.00023309694
morphine B-Chemical 1 0.9990797
with O 0 0.00064352667
177 O 0 0.01013905
. O 0 0.00017867105
8 O 0 0.00025214176
mg O 0 0.11185372
/ O 0 0.0006488303
kg O 0 0.001988605
s O 0 0.0003339877
. O 0 0.00016085779
c O 0 0.0014026554
. O 0 0.00027827627
metamizol B-Chemical 0 0.9998716
in O 0 0.00054131134
acutely O 0 0.09363471
and O 0 0.00049989513
chronically O 0 0.034749255
treated O 0 0.0011317601
( O 0 0.0005741806
once O 0 0.00037596808
a O 0 0.00045000314
day O 0 0.00046728615
for O 0 0.0005100037
12 O 0 0.0007462003
days O 0 0.001307277
) O 0 0.0033289678
rats O 0 0.008143953
. O 0 0.0049222675

On O 0 0.0043016807
the O 0 0.002522986
13th O 0 0.005076291
day O 0 0.0017618026
, O 0 0.002004079
antinociceptive O 0 0.9888242
effects O 0 0.0020354115
were O 0 0.0005882154
assessed O 0 0.0003746404
using O 0 0.0003493818
a O 0 0.00044528142
model O 0 0.0005641411
of O 0 0.00081661786
inflammatory O 0 0.9278155
nociception O 0 0.9971642
, O 0 0.0046383883
pain B-Disease 0 0.9907088
- O 0 0.0014679618
induced O 0 0.0005533126
functional O 0 0.00086005445
impairment O 0 0.20005195
model O 0 0.00064383284
, O 0 0.00047480944
and O 0 0.0003357028
the O 0 0.000363714
charcoal B-Chemical 0 0.7940786
meal O 0 0.020005297
test O 0 0.0006122882
was O 0 0.00051677844
used O 0 0.000514241
to O 0 0.0006453878
evaluate O 0 0.00071383617
the O 0 0.0019557283
intestinal O 0 0.35375544
transit O 0 0.19448353
. O 0 0.00799385

Simultaneous O 0 0.022556152
administration O 0 0.105703324
of O 0 0.0042622737
morphine B-Chemical 1 0.99909484
with O 0 0.011030646
metamizol B-Chemical 0 0.9998714
resulted O 0 0.0021872493
in O 0 0.00078811945
a O 0 0.0008354997
markedly O 0 0.011439447
antinociceptive O 0 0.999008
potentiation O 0 0.965776
and O 0 0.00061416836
an O 0 0.0004458712
increasing O 0 0.00041920366
of O 0 0.00034806796
the O 0 0.00022232518
duration O 0 0.00035371145
of O 0 0.00034637126
action O 0 0.002394381
after O 0 0.0001620509
a O 0 0.0003008764
single O 0 0.0003667965
( O 0 0.000633317
298 O 0 0.14008728
+ O 0 0.0005798504
/ O 0 0.0009857913
- O 0 0.0004914864
7 O 0 0.00020333155
vs O 0 0.00042914625
. O 0 0.0001514976
139 O 0 0.0009508033
+ O 0 0.0003918363
/ O 0 0.00070049113
- O 0 0.0004186885
36 O 0 0.00024820238
units O 0 0.00025314672
area O 0 0.0005494138
( O 0 0.00066750014
ua O 0 0.53650624
) O 0 0.0012322231
; O 0 0.00086406944
P O 0 0.018718075
< O 0 0.00038799897
0 O 0 0.00029418198
. O 0 0.00017693316
001 O 0 0.06246193
) O 0 0.00040095954
and O 0 0.00021847982
repeated O 0 0.0002720503
administration O 0 0.058809116
( O 0 0.0006682073
280 O 0 0.012070252
+ O 0 0.00060337194
/ O 0 0.001035695
- O 0 0.0005880334
17 O 0 0.00044774948
vs O 0 0.00060311594
. O 0 0.00022766768
131 O 0 0.0015531722
+ O 0 0.00065381057
/ O 0 0.001289601
- O 0 0.0010562404
22 O 0 0.0012002965
ua O 0 0.40011567
; O 0 0.0022012775
P O 0 0.026993688
< O 0 0.0016918876
0 O 0 0.0016851038
. O 0 0.0016934185
001 O 0 0.13221753
) O 0 0.0070887418
. O 0 0.006017002

Antinociceptive O 0 0.9926158
effect O 0 0.004554245
of O 0 0.0038644795
morphine B-Chemical 1 0.99890673
was O 0 0.0019550659
reduced O 0 0.0011799933
in O 0 0.00072859804
chronically O 0 0.030309854
treated O 0 0.0017000206
rats O 0 0.0067938752
( O 0 0.0008320655
39 O 0 0.0008856977
+ O 0 0.00059682573
/ O 0 0.0009925814
- O 0 0.0005374454
10 O 0 0.00027495335
vs O 0 0.0004571762
. O 0 0.00015070818
18 O 0 0.00026854762
+ O 0 0.0003392448
/ O 0 0.00064477726
- O 0 0.00041156763
5 O 0 0.0001987703
au O 0 0.0048768963
) O 0 0.0004125831
while O 0 0.00018639649
the O 0 0.00021170785
combination O 0 0.0013907559
- O 0 0.0009775549
induced O 0 0.0011699777
antinociception O 0 0.9997218
was O 0 0.0004015149
remained O 0 0.0004399297
similar O 0 0.0001932832
as O 0 0.0002152942
an O 0 0.00054519245
acute O 0 0.88860583
treatment O 0 0.008840003
( O 0 0.0013698029
298 O 0 0.26962858
+ O 0 0.0008061927
/ O 0 0.001300558
- O 0 0.0007056758
7 O 0 0.00034091974
vs O 0 0.0007517035
. O 0 0.00035480942
280 O 0 0.0041961586
+ O 0 0.0012457501
/ O 0 0.0025074913
- O 0 0.0024226522
17 O 0 0.0030068106
au O 0 0.023358896
) O 0 0.0070899534
. O 0 0.0055642566

Acute O 0 0.97375077
antinociceptive O 0 0.99354434
effects O 0 0.005284745
of O 0 0.0019330224
the O 0 0.001114873
combination O 0 0.0021096217
were O 0 0.00088423176
partially O 0 0.0009577404
prevented O 0 0.001896196
by O 0 0.00080207974
3 O 0 0.0005984112
. O 0 0.00039482603
2 O 0 0.00068183313
mg O 0 0.15948969
/ O 0 0.0026190681
kg O 0 0.030168526
naloxone B-Chemical 1 0.9991021
s O 0 0.004245124
. O 0 0.0024342893
c O 0 0.012274263
. O 0 0.006689288

( O 0 0.008563069
P O 0 0.022155467
< O 0 0.0030954885
0 O 0 0.0019421127
. O 0 0.0011099577
05 O 0 0.01650415
) O 0 0.0015759073
, O 0 0.0009087797
suggesting O 0 0.0005226573
the O 0 0.00052499457
partial O 0 0.0011702682
involvement O 0 0.0014904963
of O 0 0.0010434347
the O 0 0.0011984291
opioidergic O 0 0.9763163
system O 0 0.0024902688
in O 0 0.0014900323
the O 0 0.002261323
synergism O 0 0.17754388
observed O 0 0.0047882083
. O 0 0.0068816585

In O 0 0.0027965833
independent O 0 0.0017029241
groups O 0 0.0023893418
, O 0 0.002819576
morphine B-Chemical 1 0.9986093
inhibited O 0 0.0057397843
the O 0 0.0010822198
intestinal O 0 0.29954144
transit O 0 0.04147948
in O 0 0.0005953835
48 O 0 0.0006217734
+ O 0 0.0006525963
/ O 0 0.0010872424
- O 0 0.0006004227
4 O 0 0.00024235665
% O 0 0.00026599632
and O 0 0.00024334675
38 O 0 0.0005364436
+ O 0 0.00043289652
/ O 0 0.0008002826
- O 0 0.0004665584
4 O 0 0.0001941215
% O 0 0.00021258408
after O 0 0.00013353533
acute O 0 0.5824234
and O 0 0.0005530437
chronic O 0 0.941667
treatment O 0 0.008805144
, O 0 0.00079861004
respectively O 0 0.0013621573
, O 0 0.00041813368
suggesting O 0 0.00026568107
that O 0 0.00030835837
tolerance O 0 0.021867657
did O 0 0.00048765092
not O 0 0.00049892004
develop O 0 0.0010086203
to O 0 0.0010186877
the O 0 0.0020626562
constipating B-Disease 0 0.99488103
effects O 0 0.023221344
. O 0 0.0067742574

The O 0 0.0030450206
combination O 0 0.0045386814
inhibited O 0 0.0046303705
intestinal O 0 0.26880622
transit O 0 0.029156668
similar O 0 0.0006989534
to O 0 0.0005566913
that O 0 0.00040493772
produced O 0 0.0005104038
by O 0 0.00064505194
morphine B-Chemical 1 0.99918205
regardless O 0 0.00029603983
of O 0 0.0004548077
the O 0 0.00028182467
time O 0 0.00024726798
of O 0 0.00046131003
treatment O 0 0.0016600696
, O 0 0.0006170086
suggesting O 0 0.00040024138
that O 0 0.0006309496
metamizol B-Chemical 0 0.99986136
did O 0 0.0011967449
not O 0 0.0011398547
potentiate O 0 0.1757923
morphine B-Chemical 1 0.99949276
- O 0 0.032092337
induced O 0 0.031296603
constipation B-Disease 2 0.9983903
. O 0 0.010383619

These O 0 0.004347132
findings O 0 0.0037145054
show O 0 0.0014292138
a O 0 0.0013632864
significant O 0 0.0012720113
interaction O 0 0.001094877
between O 0 0.00061778625
morphine B-Chemical 1 0.9992397
and O 0 0.0030267718
metamizol B-Chemical 0 0.99991107
in O 0 0.0011418201
chronically O 0 0.093589924
treated O 0 0.0016820462
rats O 0 0.0050992044
, O 0 0.00048164284
suggesting O 0 0.00024687438
that O 0 0.0002134243
this O 0 0.0002683495
combination O 0 0.00077532756
could O 0 0.00030511146
be O 0 0.0003942083
useful O 0 0.0005509008
for O 0 0.0004382761
the O 0 0.0007335893
treatment O 0 0.0027008574
of O 0 0.0041175582
chronic B-Disease 0 0.9898649
pain I-Disease 0 0.9928335
. O 0 0.010075428

Ifosfamide B-Chemical 1 0.9960718
encephalopathy B-Disease 2 0.99709034
presenting O 0 0.67609453
with O 0 0.08315211
asterixis B-Disease 0 0.9965274
. O 0 0.03779402

CNS O 0 0.67051595
toxic O 0 0.6488838
effects O 0 0.00445937
of O 0 0.0021838476
the O 0 0.0016518215
antineoplastic O 0 0.98613745
agent O 0 0.7474183
ifosfamide B-Chemical 1 0.9996898
( O 0 0.014853328
IFX B-Chemical 0 0.99879456
) O 0 0.0019717454
are O 0 0.00048253036
frequent O 0 0.0013114269
and O 0 0.00042309306
include O 0 0.00048328072
a O 0 0.0004937414
variety O 0 0.0016249925
of O 0 0.0013013453
neurological O 0 0.99663323
symptoms O 0 0.8995001
that O 0 0.0010111785
can O 0 0.0011382141
limit O 0 0.0031973894
drug O 0 0.4105739
use O 0 0.0067963926
. O 0 0.0061868774

We O 0 0.0032466364
report O 0 0.0042354874
a O 0 0.0018902717
case O 0 0.0013559129
of O 0 0.001307327
a O 0 0.0011891542
51 O 0 0.0016778822
- O 0 0.0011468852
year O 0 0.00069712097
- O 0 0.0008442827
old O 0 0.0005878819
man O 0 0.02997047
who O 0 0.0012209367
developed O 0 0.0011039623
severe O 0 0.13834393
, O 0 0.0010420479
disabling O 0 0.86193955
negative O 0 0.0012047663
myoclonus B-Disease 2 0.9998437
of O 0 0.0008933762
the O 0 0.0004127806
upper O 0 0.00069455034
and O 0 0.00040075625
lower O 0 0.00045427284
extremities O 0 0.04636688
after O 0 0.00033231583
the O 0 0.0006143454
infusion O 0 0.0220933
of O 0 0.0028113988
ifosfamide B-Chemical 1 0.9987025
for O 0 0.006820549
plasmacytoma B-Disease 0 0.99450463
. O 0 0.008877185

He O 0 0.009123504
was O 0 0.0030735563
awake O 0 0.008381381
, O 0 0.001994985
revealed O 0 0.001174997
no O 0 0.00076440856
changes O 0 0.0010885192
of O 0 0.0010254399
mental O 0 0.03994772
status O 0 0.0010346413
and O 0 0.000639223
at O 0 0.0003965304
rest O 0 0.00084504206
there O 0 0.0004967497
were O 0 0.00085140776
no O 0 0.0010418737
further O 0 0.0024828825
motor O 0 0.18664268
symptoms O 0 0.56940866
. O 0 0.0072583095

Cranial O 0 0.6372461
magnetic O 0 0.086467266
resonance O 0 0.258314
imaging O 0 0.0073072105
and O 0 0.001658107
extensive O 0 0.0014570521
laboratory O 0 0.0016411016
studies O 0 0.001261495
failed O 0 0.0010294439
to O 0 0.0006797457
reveal O 0 0.00093147706
structural B-Disease 0 0.003133586
lesions I-Disease 0 0.08628614
of I-Disease 0 0.0015753394
the I-Disease 0 0.0016200305
brain I-Disease 0 0.07674493
and O 0 0.0038907197
metabolic B-Disease 0 0.8683397
abnormalities I-Disease 0 0.887083
. O 0 0.008634205

An O 0 0.007427286
electroencephalogram O 0 0.555934
showed O 0 0.0021809859
continuous O 0 0.0019457085
, O 0 0.0019997319
generalized O 0 0.030582432
irregular O 0 0.006825319
slowing O 0 0.049705
with O 0 0.0018154986
admixed O 0 0.04086836
periodic O 0 0.04861558
triphasic O 0 0.95980674
waves O 0 0.16718058
indicating O 0 0.004312531
symptomatic O 0 0.8727551
encephalopathy B-Disease 2 0.99884534
. O 0 0.014144206

The O 0 0.0036432766
administration O 0 0.029496122
of O 0 0.0038208119
ifosfamide B-Chemical 1 0.9978543
was O 0 0.0024513833
discontinued O 0 0.034011018
and O 0 0.0013000118
within O 0 0.0006690766
12 O 0 0.00090421713
h O 0 0.0014204315
the O 0 0.0024581428
asterixis B-Disease 0 0.99877065
resolved O 0 0.011287797
completely O 0 0.0076384353
. O 0 0.007509351

In O 0 0.0027898068
the O 0 0.0018993302
patient O 0 0.0023030601
described O 0 0.0011335004
, O 0 0.0012195527
the O 0 0.00067649723
presence O 0 0.0006858436
of O 0 0.0012970206
asterixis B-Disease 0 0.9997148
during O 0 0.0005746734
infusion O 0 0.046981256
of O 0 0.0010746957
ifosfamide B-Chemical 1 0.9995871
, O 0 0.00085147505
normal O 0 0.00072978705
laboratory O 0 0.00062167126
findings O 0 0.0007002091
and O 0 0.0002712464
imaging O 0 0.001740851
studies O 0 0.0004245844
and O 0 0.0002482265
the O 0 0.00021250345
resolution O 0 0.0035584506
of O 0 0.0004490842
symptoms O 0 0.19075708
following O 0 0.00030730912
the O 0 0.00026480507
discontinuation O 0 0.47560686
of O 0 0.00038754262
the O 0 0.00029305834
drug O 0 0.1135603
suggest O 0 0.00026736606
that O 0 0.00031610072
negative O 0 0.00086849474
myoclonus B-Disease 2 0.9998165
is O 0 0.0009401355
associated O 0 0.0011471364
with O 0 0.0011484628
the O 0 0.0012066598
use O 0 0.002423482
of O 0 0.0059082448
IFX B-Chemical 0 0.99483854
. O 0 0.008664784

Antagonism O 0 0.79833597
between O 0 0.0032550339
interleukin O 0 0.6849781
3 O 0 0.0018282823
and O 0 0.0016286116
erythropoietin O 0 0.9599835
in O 0 0.001034653
mice O 0 0.0006480374
with O 0 0.0015676499
azidothymidine B-Chemical 1 0.9983188
- O 0 0.0070337085
induced O 0 0.0052233012
anemia B-Disease 0 0.99927014
and O 0 0.0024947238
in O 0 0.0019028643
bone O 0 0.1904598
marrow O 0 0.7062423
endothelial O 0 0.9689672
cells O 0 0.018920036
. O 0 0.0075697727

Azidothymidine B-Chemical 0 0.9921956
( O 0 0.015366214
AZT B-Chemical 1 0.9966446
) O 0 0.009986389
- O 0 0.003389247
induced O 0 0.002926175
anemia B-Disease 0 0.99915123
in O 0 0.00095642137
mice O 0 0.00043151283
can O 0 0.00041380947
be O 0 0.00043447598
reversed O 0 0.0009171147
by O 0 0.00040136185
the O 0 0.00039126058
administration O 0 0.08627178
of O 0 0.001718087
IGF O 0 0.9976472
- O 0 0.010010017
IL O 0 0.89889944
- O 0 0.0011619373
3 O 0 0.0003157002
( O 0 0.00038659616
fusion O 0 0.0004137996
protein O 0 0.0006949472
of O 0 0.00067089725
insulin O 0 0.97138387
- O 0 0.001375991
like O 0 0.0005578061
growth O 0 0.0076791733
factor O 0 0.016847614
II O 0 0.061406985
( O 0 0.0030495434
IGF O 0 0.9900484
II O 0 0.059237134
) O 0 0.003269178
and O 0 0.002668807
interleukin O 0 0.8168312
3 O 0 0.0037739626
) O 0 0.0069239475
. O 0 0.0055919024

Although O 0 0.0064958595
interleukin O 0 0.69266903
3 O 0 0.0031672388
( O 0 0.0036675835
IL O 0 0.64606607
- O 0 0.0024248036
3 O 0 0.00085362303
) O 0 0.001132178
and O 0 0.0008170748
erythropoietin O 0 0.9905614
( O 0 0.003098626
EPO O 0 0.9982158
) O 0 0.0018248603
are O 0 0.0004459373
known O 0 0.0005182427
to O 0 0.00032471062
act O 0 0.0006664581
synergistically O 0 0.007958651
on O 0 0.000291247
hematopoietic O 0 0.8193053
cell O 0 0.03164531
proliferation O 0 0.7159667
in O 0 0.00037228543
vitro O 0 0.0011196913
, O 0 0.0005254701
injection O 0 0.0021348237
of O 0 0.0010292816
IGF O 0 0.997127
- O 0 0.007503354
IL O 0 0.8877961
- O 0 0.0010191954
3 O 0 0.00027754813
and O 0 0.0003971459
EPO O 0 0.99716395
in O 0 0.00064464303
AZT B-Chemical 1 0.999042
- O 0 0.0015344768
treated O 0 0.00066893053
mice O 0 0.00015798169
resulted O 0 0.00022354505
in O 0 0.00019796153
a O 0 0.0002629293
reduction O 0 0.00047805544
of O 0 0.00035809987
red O 0 0.0008998369
cells O 0 0.0007068187
and O 0 0.00027853987
an O 0 0.0003305413
increase O 0 0.00025337562
of O 0 0.0005073246
plasma O 0 0.1391979
EPO O 0 0.9985208
levels O 0 0.00047339516
as O 0 0.00024097462
compared O 0 0.0001648256
to O 0 0.00024092341
animals O 0 0.0003128123
treated O 0 0.00094151066
with O 0 0.0014759569
IGF O 0 0.99521166
- O 0 0.010928804
IL O 0 0.8353947
- O 0 0.0027108649
3 O 0 0.0013653837
or O 0 0.0021541528
EPO O 0 0.9888093
alone O 0 0.007969592
. O 0 0.006995128

We O 0 0.002967485
tested O 0 0.0017566978
the O 0 0.0014649543
hypothesis O 0 0.0015741707
that O 0 0.0008929051
the O 0 0.0008939837
antagonistic O 0 0.0039662314
effect O 0 0.0012620954
of O 0 0.001987608
IL O 0 0.92239714
- O 0 0.002192995
3 O 0 0.00060040154
and O 0 0.0008151357
EPO O 0 0.99501073
on O 0 0.0006694962
erythroid O 0 0.918893
cells O 0 0.0022598603
may O 0 0.0010246641
be O 0 0.0011260279
mediated O 0 0.0014248114
by O 0 0.0028892842
endothelial O 0 0.9163902
cells O 0 0.014687084
. O 0 0.0070827575

Bovine O 0 0.30980554
liver O 0 0.86136794
erythroid O 0 0.95273167
cells O 0 0.00454617
were O 0 0.0013445356
cultured O 0 0.0015625576
on O 0 0.0004899138
monolayers O 0 0.0054271873
of O 0 0.0009561318
human O 0 0.0018800917
bone O 0 0.099021904
marrow O 0 0.5319543
endothelial O 0 0.9506255
cells O 0 0.0026802744
previously O 0 0.0008201923
treated O 0 0.0015706395
with O 0 0.0019788125
EPO O 0 0.9974069
and O 0 0.0055227135
IGF O 0 0.99456453
- O 0 0.025290761
IL O 0 0.8430741
- O 0 0.0077056885
3 O 0 0.004715643
. O 0 0.0056836433

There O 0 0.0053325314
was O 0 0.0023969791
a O 0 0.0018746182
significant O 0 0.0017043193
reduction O 0 0.0018804858
of O 0 0.0016798801
thymidine B-Chemical 0 0.8159984
incorporation O 0 0.0050210455
into O 0 0.00046153174
both O 0 0.0006777543
erythroid O 0 0.93106437
and O 0 0.0010062557
endothelial O 0 0.9068282
cells O 0 0.0018319573
in O 0 0.00044470286
cultures O 0 0.0009021754
pre O 0 0.0034114993
- O 0 0.0012204836
treated O 0 0.0013728858
with O 0 0.0019507775
IGF O 0 0.99400675
- O 0 0.012254238
IL O 0 0.8181278
- O 0 0.0039327075
3 O 0 0.0022477908
and O 0 0.004411296
EPO O 0 0.9871952
. O 0 0.008451379

Endothelial O 0 0.9820404
cell O 0 0.014336013
culture O 0 0.0042853137
supernatants O 0 0.0017184942
separated O 0 0.0011539734
by O 0 0.0008818544
ultrafiltration O 0 0.07384099
and O 0 0.0007508218
ultracentrifugation O 0 0.0063842116
from O 0 0.0005213994
cells O 0 0.0009525266
treated O 0 0.00096721307
with O 0 0.00095718127
EPO O 0 0.99840266
and O 0 0.0017812414
IL O 0 0.9275037
- O 0 0.0012063874
3 O 0 0.00026981827
significantly O 0 0.0003523378
reduced O 0 0.00045554838
thymidine B-Chemical 0 0.8026652
incorporation O 0 0.004111403
into O 0 0.00025712236
erythroid O 0 0.9143832
cells O 0 0.00091136637
as O 0 0.00018085953
compared O 0 0.0001187044
to O 0 0.0001526469
identical O 0 0.00012797829
fractions O 0 0.00034312397
obtained O 0 0.00026600648
from O 0 0.00029803545
the O 0 0.0003593029
media O 0 0.0014463635
of O 0 0.00089419587
cells O 0 0.0021125597
cultured O 0 0.002958181
with O 0 0.003925989
EPO O 0 0.9944214
alone O 0 0.009895549
. O 0 0.0070601436

These O 0 0.004066378
results O 0 0.0020516256
suggest O 0 0.00142438
that O 0 0.0014310709
endothelial O 0 0.7701793
cells O 0 0.0029696205
treated O 0 0.0017811804
simultaneously O 0 0.0011302099
with O 0 0.0016470936
EPO O 0 0.9978125
and O 0 0.0024682237
IL O 0 0.89016074
- O 0 0.0015375073
3 O 0 0.0004770394
have O 0 0.00049402483
a O 0 0.00064747164
negative O 0 0.0007871475
effect O 0 0.0013305751
on O 0 0.0013611418
erythroid O 0 0.92678285
cell O 0 0.051364094
production O 0 0.020451816
. O 0 0.007829498

The O 0 0.0029060123
relationship O 0 0.001966538
between O 0 0.0015968038
hippocampal O 0 0.8777549
acetylcholine B-Chemical 1 0.9985612
release O 0 0.32588378
and O 0 0.00265779
cholinergic O 0 0.9938992
convulsant O 0 0.99956626
sensitivity O 0 0.02040432
in O 0 0.0009875002
withdrawal O 0 0.94769377
seizure B-Disease 2 0.9995103
- O 0 0.0033125326
prone O 0 0.0010520162
and O 0 0.0009197784
withdrawal O 0 0.9091049
seizure B-Disease 2 0.9991296
- O 0 0.0035351757
resistant O 0 0.0026158516
selected O 0 0.001691626
mouse O 0 0.0039981357
lines O 0 0.015916277
. O 0 0.0061813383

BACKGROUND O 0 0.77180296
: O 0 0.00549187
The O 0 0.0022160935
septo O 0 0.10723263
- O 0 0.0038178186
hippocampal O 0 0.84927535
cholinergic O 0 0.9775532
pathway O 0 0.0022776283
has O 0 0.0007582422
been O 0 0.00076317665
implicated O 0 0.00074861443
in O 0 0.0006465655
epileptogenesis O 0 0.9977335
, O 0 0.0007392286
and O 0 0.00036091157
genetic O 0 0.00079086365
factors O 0 0.0011050713
influence O 0 0.00027145338
the O 0 0.00027824682
response O 0 0.0005903874
to O 0 0.00039956032
cholinergic O 0 0.96861064
agents O 0 0.20787859
, O 0 0.0005891389
but O 0 0.00027611025
limited O 0 0.00029239108
data O 0 0.00041336162
are O 0 0.00039701493
available O 0 0.00044057245
on O 0 0.00043061865
cholinergic O 0 0.91231036
involvement O 0 0.0046461592
in O 0 0.0020404865
alcohol B-Chemical 0 0.9963707
withdrawal O 0 0.96373516
severity O 0 0.30794945
. O 0 0.0074228724

Thus O 0 0.0039311405
, O 0 0.002699508
the O 0 0.0013297228
relationship O 0 0.0009293407
between O 0 0.00073404796
cholinergic O 0 0.86759037
activity O 0 0.0013444006
and O 0 0.0007371854
responsiveness O 0 0.0014749109
and O 0 0.0008104561
alcohol B-Chemical 0 0.99652845
withdrawal O 0 0.8274373
was O 0 0.0005339407
investigated O 0 0.00042685497
in O 0 0.00034372968
a O 0 0.00048191263
genetic O 0 0.0010634151
animal O 0 0.0013542965
model O 0 0.0014182512
of O 0 0.0027547404
ethanol B-Chemical 1 0.9946418
withdrawal O 0 0.9680073
severity O 0 0.34810096
. O 0 0.007858904

METHODS O 0 0.009180013
: O 0 0.006679758
Cholinergic O 0 0.9773163
convulsant O 0 0.9978078
sensitivity O 0 0.007090064
was O 0 0.0013002334
examined O 0 0.00086282025
in O 0 0.0012087835
alcohol B-Chemical 0 0.99653095
- O 0 0.01709569
na O 0 0.995434
ve O 0 0.5496775
Withdrawal O 0 0.99692863
Seizure B-Disease 2 0.99948263
- O 0 0.012573191
Prone O 0 0.9256536
( O 0 0.002396797
WSP O 0 0.80552727
) O 0 0.0022994012
and O 0 0.0015549975
- O 0 0.0032184082
Resistant O 0 0.18126352
( O 0 0.004304092
WSR O 0 0.84142524
) O 0 0.005744767
mice O 0 0.0036368936
. O 0 0.006333206

Animals O 0 0.009513576
were O 0 0.0029628766
administered O 0 0.007319081
nicotine B-Chemical 1 0.99493164
, O 0 0.005629587
carbachol B-Chemical 1 0.99837446
, O 0 0.0021136217
or O 0 0.00087613735
neostigmine B-Chemical 0 0.99945146
via O 0 0.00070537464
timed O 0 0.0013757991
tail O 0 0.00085802696
vein O 0 0.034838997
infusion O 0 0.028980535
, O 0 0.0005082888
and O 0 0.00031335527
the O 0 0.00026882195
latencies O 0 0.003467044
to O 0 0.00030450584
onset O 0 0.00195477
of O 0 0.0009385791
tremor B-Disease 0 0.9993606
and O 0 0.00132676
clonus O 0 0.99752194
were O 0 0.000707323
recorded O 0 0.00081884954
and O 0 0.0008540708
converted O 0 0.0014711132
to O 0 0.0013692805
threshold O 0 0.0028574714
dose O 0 0.03673827
. O 0 0.006201735

We O 0 0.003172689
also O 0 0.00229276
used O 0 0.0016840294
microdialysis O 0 0.095098734
to O 0 0.0011425095
measure O 0 0.0006654181
basal O 0 0.0025978521
and O 0 0.0016440079
potassium B-Chemical 0 0.9989513
- O 0 0.007559992
stimulated O 0 0.0022414664
acetylcholine B-Chemical 1 0.9992118
( O 0 0.011586424
ACh B-Chemical 1 0.99929583
) O 0 0.0035793805
release O 0 0.03425046
in O 0 0.00086244824
the O 0 0.0013791833
CA1 O 0 0.9744446
region O 0 0.0018805839
of O 0 0.0026333393
the O 0 0.00397314
hippocampus O 0 0.5716379
. O 0 0.006863274

Potassium B-Chemical 0 0.99348927
was O 0 0.005253028
applied O 0 0.0033873934
by O 0 0.0028948754
reverse O 0 0.010446999
dialysis O 0 0.05500397
twice O 0 0.002996019
, O 0 0.00294731
separated O 0 0.0027627964
by O 0 0.0033322966
75 O 0 0.0062424922
min O 0 0.007946151
. O 0 0.007440625

Hippocampal O 0 0.9796611
ACh B-Chemical 1 0.99512213
also O 0 0.0041248812
was O 0 0.0020306518
measured O 0 0.001223637
during O 0 0.0011444319
testing O 0 0.001763389
for O 0 0.0020329838
handling O 0 0.012122641
- O 0 0.009296824
induced O 0 0.017182345
convulsions B-Disease 0 0.9982502
. O 0 0.01460651

RESULTS O 0 0.033497177
: O 0 0.0057160715
Sensitivity O 0 0.016070377
to O 0 0.0018648391
several O 0 0.002181398
convulsion B-Disease 2 0.99843377
endpoints O 0 0.016625982
induced O 0 0.002074928
by O 0 0.0015719217
nicotine B-Chemical 1 0.99819726
, O 0 0.0056239334
carbachol B-Chemical 1 0.99903524
, O 0 0.0017438934
and O 0 0.0011205833
neostigmine B-Chemical 0 0.9994881
were O 0 0.00096466247
significantly O 0 0.001002172
greater O 0 0.0010181561
in O 0 0.0014428219
WSR O 0 0.84471434
versus O 0 0.0032250586
WSP O 0 0.6947236
mice O 0 0.0042107585
. O 0 0.0066603986

In O 0 0.0030571464
microdialysis O 0 0.070795774
experiments O 0 0.0017660308
, O 0 0.0016856486
the O 0 0.00093576027
lines O 0 0.0024501
did O 0 0.0006802032
not O 0 0.0004980958
differ O 0 0.00062900514
in O 0 0.00050921575
basal O 0 0.0022340384
release O 0 0.03181836
of O 0 0.0017692896
ACh B-Chemical 1 0.999348
, O 0 0.0013773482
and O 0 0.0007508948
50 O 0 0.0016284109
mM O 0 0.39711514
KCl B-Chemical 0 0.99587315
increased O 0 0.0037424308
ACh B-Chemical 1 0.9986979
output O 0 0.0019690872
in O 0 0.00091047323
both O 0 0.0012648676
lines O 0 0.005000913
of O 0 0.0034435536
mice O 0 0.0034273977
. O 0 0.0058062575

However O 0 0.0044662952
, O 0 0.0030828433
the O 0 0.0015977928
increase O 0 0.0013422914
in O 0 0.0011301446
release O 0 0.021269904
of O 0 0.001929381
ACh B-Chemical 1 0.99878067
produced O 0 0.00097193953
by O 0 0.0005904991
the O 0 0.00040269995
first O 0 0.0003502586
application O 0 0.0010587147
of O 0 0.0010610628
KCl B-Chemical 0 0.99667966
was O 0 0.0007562425
2 O 0 0.00068557105
- O 0 0.0009557839
fold O 0 0.001072222
higher O 0 0.00079456903
in O 0 0.0012455444
WSP O 0 0.6467973
versus O 0 0.0033336196
WSR O 0 0.82090443
mice O 0 0.003817804
. O 0 0.006265959

When O 0 0.0045729196
hippocampal O 0 0.8264984
ACh B-Chemical 1 0.99695206
was O 0 0.0017104668
measured O 0 0.000670632
during O 0 0.00047267915
testing O 0 0.0006123357
for O 0 0.00053487153
handling O 0 0.005773577
- O 0 0.0018720751
induced O 0 0.0023844992
convulsions B-Disease 0 0.9998241
, O 0 0.0050408705
extracellular O 0 0.2522826
ACh B-Chemical 1 0.99956495
was O 0 0.0006746973
significantly O 0 0.0007037742
elevated O 0 0.007322418
( O 0 0.0007476734
192 O 0 0.00786497
% O 0 0.00044345463
) O 0 0.000492218
in O 0 0.00030160588
WSP O 0 0.4834834
mice O 0 0.00028670646
, O 0 0.000521226
but O 0 0.00038407877
was O 0 0.0005013205
nonsignificantly O 0 0.26515895
elevated O 0 0.010293302
( O 0 0.0014845358
59 O 0 0.0019117484
% O 0 0.0013780876
) O 0 0.0020271789
in O 0 0.0020252618
WSR O 0 0.6518274
mice O 0 0.0033589366
. O 0 0.0058053136

CONCLUSIONS O 0 0.6456792
: O 0 0.004387879
These O 0 0.0020516473
results O 0 0.0010950664
suggest O 0 0.00076235743
that O 0 0.00066306884
differences O 0 0.00053378165
in O 0 0.0006820713
cholinergic O 0 0.9226776
activity O 0 0.0011840916
and O 0 0.0007847329
postsynaptic O 0 0.90454173
sensitivity O 0 0.0041980837
to O 0 0.00075271813
cholinergic O 0 0.99433774
convulsants B-Disease 0 0.99982566
may O 0 0.0008503902
be O 0 0.0004602252
associated O 0 0.00059223815
with O 0 0.00081592833
ethanol B-Chemical 1 0.9957384
withdrawal O 0 0.90808594
severity O 0 0.058523692
and O 0 0.00090406503
implicate O 0 0.0015404491
cholinergic O 0 0.96108663
mechanisms O 0 0.0050593955
in O 0 0.0029318475
alcohol B-Chemical 0 0.9957098
withdrawal O 0 0.9550033
. O 0 0.0077591343

Specifically O 0 0.0058783814
, O 0 0.004376989
WSP O 0 0.3955018
mice O 0 0.0013248085
may O 0 0.0011676564
have O 0 0.00093894947
lower O 0 0.00082866877
sensitivity O 0 0.00195557
to O 0 0.0009771623
cholinergic O 0 0.9909671
convulsants B-Disease 0 0.99974006
compared O 0 0.00050277164
with O 0 0.0007965982
WSR O 0 0.8536906
because O 0 0.00036756654
of O 0 0.0008227497
postsynaptic O 0 0.9585244
receptor O 0 0.30365098
desensitization O 0 0.6463397
brought O 0 0.0014403749
on O 0 0.00041650678
by O 0 0.000747455
higher O 0 0.00096590957
activity O 0 0.0018553751
of O 0 0.0036023036
cholinergic O 0 0.98134434
neurons O 0 0.17200245
. O 0 0.006619542

Capsaicin B-Chemical 1 0.9978788
- O 0 0.012448821
induced O 0 0.005786237
muscle B-Disease 0 0.6570663
pain I-Disease 0 0.9926964
alters O 0 0.0028346127
the O 0 0.0019521473
excitability O 0 0.8343302
of O 0 0.002098776
the O 0 0.0018449102
human O 0 0.004865445
jaw O 0 0.39400944
- O 0 0.009048977
stretch O 0 0.07946213
reflex O 0 0.871039
. O 0 0.009394316

The O 0 0.0037111822
pathophysiology O 0 0.06326796
of O 0 0.004309013
painful O 0 0.9767482
temporomandibular B-Disease 0 0.99707544
disorders I-Disease 0 0.9913932
is O 0 0.0014070944
not O 0 0.00064728415
fully O 0 0.0005573045
understood O 0 0.00094428874
, O 0 0.00058672763
but O 0 0.00035337813
evidence O 0 0.00041180843
suggests O 0 0.00031083685
that O 0 0.0005161151
muscle B-Disease 0 0.57482636
pain I-Disease 0 0.9961099
modulates O 0 0.0017159781
motor O 0 0.13840094
function O 0 0.002003461
in O 0 0.0017060529
characteristic O 0 0.0048190164
ways O 0 0.0073629464
. O 0 0.005979024

This O 0 0.004143624
study O 0 0.0025556486
tested O 0 0.0011927299
the O 0 0.0010462562
hypothesis O 0 0.0012542749
that O 0 0.00075399806
activation O 0 0.0018779079
of O 0 0.0013881245
nociceptive B-Disease 0 0.9906159
muscle I-Disease 0 0.7588645
afferent O 0 0.6931942
fibers O 0 0.024164543
would O 0 0.00034250235
be O 0 0.00033241027
linked O 0 0.00028483034
to O 0 0.00025737623
an O 0 0.0003966601
increased O 0 0.0007763806
excitability O 0 0.8495713
of O 0 0.00049018644
the O 0 0.00034661475
human O 0 0.0011764073
jaw O 0 0.30348843
- O 0 0.001090248
stretch O 0 0.008783143
reflex O 0 0.60006416
and O 0 0.0003217247
whether O 0 0.00013056857
this O 0 0.00022648988
process O 0 0.00033975346
would O 0 0.00024923537
be O 0 0.00033081687
sensitive O 0 0.00041098366
to O 0 0.0003934302
length O 0 0.00056637375
and O 0 0.0008714428
velocity O 0 0.0032365078
of O 0 0.0022099488
the O 0 0.0031068735
stretch O 0 0.0394037
. O 0 0.0066067176

Capsaicin B-Chemical 1 0.997497
( O 0 0.0066942554
10 O 0 0.0025122794
micro O 0 0.005706113
g O 0 0.0036721933
) O 0 0.0017353129
was O 0 0.0007824827
injected O 0 0.00064696674
into O 0 0.00043046227
the O 0 0.00066098874
masseter O 0 0.13171478
muscle O 0 0.032552842
to O 0 0.0010023381
induce O 0 0.001465992
pain B-Disease 0 0.92475563
in O 0 0.0018393191
11 O 0 0.0028225817
healthy O 0 0.009828992
volunteers O 0 0.011230303
. O 0 0.0056725624

Short O 0 0.0132863335
- O 0 0.0055311113
latency O 0 0.0072206873
reflex O 0 0.47060227
responses O 0 0.0029667572
were O 0 0.0011212754
evoked O 0 0.019473352
in O 0 0.0006200082
the O 0 0.0005809615
masseter O 0 0.09735918
and O 0 0.0006275937
temporalis O 0 0.01179022
muscles O 0 0.0031179877
by O 0 0.00037249952
a O 0 0.00037733416
stretch O 0 0.0019555003
device O 0 0.00079562905
with O 0 0.00037224233
different O 0 0.00034407817
velocities O 0 0.0018630243
and O 0 0.00050036685
displacements O 0 0.008337753
before O 0 0.00035260443
, O 0 0.0007010374
during O 0 0.0005086938
, O 0 0.0010313482
and O 0 0.0010608223
after O 0 0.0011064048
the O 0 0.003074101
pain B-Disease 0 0.94929224
. O 0 0.0072854003

The O 0 0.0027914671
normalized O 0 0.0018508151
reflex O 0 0.36667484
amplitude O 0 0.008717349
increased O 0 0.0018346075
with O 0 0.0010887795
an O 0 0.000921015
increase O 0 0.0005507512
in O 0 0.00040447342
velocity O 0 0.0014159345
at O 0 0.0002542541
a O 0 0.0003675454
given O 0 0.0002559874
displacement O 0 0.0018326436
, O 0 0.0005176616
but O 0 0.00030545666
remained O 0 0.0004526305
constant O 0 0.00043185457
with O 0 0.00057130674
different O 0 0.00072575157
displacements O 0 0.0107358005
at O 0 0.00085355307
a O 0 0.0017902442
given O 0 0.0020378209
velocity O 0 0.011805693
. O 0 0.0059990506

The O 0 0.002944947
normalized O 0 0.0019848628
reflex O 0 0.35264552
amplitude O 0 0.0085352715
was O 0 0.0012225477
significantly O 0 0.001057954
higher O 0 0.0007636076
during O 0 0.0007281864
pain B-Disease 0 0.9452973
, O 0 0.0012389843
but O 0 0.0005977289
only O 0 0.0005311042
at O 0 0.0004177528
faster O 0 0.00079678994
stretches O 0 0.0035165811
in O 0 0.0014684943
the O 0 0.0029147754
painful B-Disease 0 0.9874248
muscle I-Disease 0 0.8167421
. O 0 0.008840721

Increased O 0 0.007628257
sensitivity O 0 0.0048108553
of O 0 0.002539957
the O 0 0.0018431592
fusimotor O 0 0.3261638
system O 0 0.0022196516
during O 0 0.0010821364
acute O 0 0.9446854
muscle B-Disease 0 0.89216477
pain I-Disease 0 0.9969387
could O 0 0.00087428605
be O 0 0.0007178097
one O 0 0.00049180014
likely O 0 0.0006474398
mechanism O 0 0.0011581361
to O 0 0.0011233827
explain O 0 0.0016156036
the O 0 0.002785961
findings O 0 0.0100425035
. O 0 0.0066633644

Effects O 0 0.012527294
of O 0 0.0041447086
5 O 0 0.0026399672
- O 0 0.0034175192
HT1B O 0 0.28357533
receptor O 0 0.13368663
ligands O 0 0.117948994
microinjected O 0 0.0059680063
into O 0 0.000545548
the O 0 0.0008678867
accumbal O 0 0.9970722
shell O 0 0.021373931
or O 0 0.00053854694
core O 0 0.00066768756
on O 0 0.00043403674
the O 0 0.0011010194
cocaine B-Chemical 1 0.99912983
- O 0 0.0061561214
induced O 0 0.0058190385
locomotor B-Disease 0 0.98654187
hyperactivity I-Disease 2 0.999037
in O 0 0.005510964
rats O 0 0.038220912
. O 0 0.006566812

The O 0 0.002375661
present O 0 0.0014480175
study O 0 0.0018048245
was O 0 0.0009829989
designed O 0 0.0008459335
to O 0 0.0005590167
examine O 0 0.0003325897
the O 0 0.0004261315
effect O 0 0.0005551039
of O 0 0.00069877424
5 O 0 0.00056298246
- O 0 0.0010277046
HT1B O 0 0.32529262
receptor O 0 0.12069509
ligands O 0 0.1085655
microinjected O 0 0.0035945072
into O 0 0.00020091335
the O 0 0.00026656553
subregions O 0 0.0026123903
of O 0 0.0004109935
the O 0 0.00040528295
nucleus O 0 0.006073019
accumbens O 0 0.9750748
( O 0 0.0004743976
the O 0 0.00027135608
shell O 0 0.0033339984
and O 0 0.00034535228
the O 0 0.00032347164
core O 0 0.00052433164
) O 0 0.0007475206
on O 0 0.00030118093
the O 0 0.0007644438
locomotor B-Disease 0 0.9565663
hyperactivity I-Disease 2 0.9994516
induced O 0 0.0058682472
by O 0 0.0042479117
cocaine B-Chemical 1 0.9986363
in O 0 0.004525125
rats O 0 0.029887948
. O 0 0.0061028874

Male O 0 0.035347477
Wistar O 0 0.14845592
rats O 0 0.0054179477
were O 0 0.0015517451
implanted O 0 0.003290823
bilaterally O 0 0.009129476
with O 0 0.0010129256
cannulae O 0 0.006734842
into O 0 0.0004286475
the O 0 0.0006707991
accumbens O 0 0.95096856
shell O 0 0.00817808
or O 0 0.00035316945
core O 0 0.0004495063
, O 0 0.00044302456
and O 0 0.0003014817
then O 0 0.00023865934
were O 0 0.0002742951
locally O 0 0.003740042
injected O 0 0.00039440073
with O 0 0.0007368778
GR B-Chemical 0 0.9913578
55562 I-Chemical 0 0.9967867
( O 0 0.0011660857
an O 0 0.0006979104
antagonist O 0 0.88032424
of O 0 0.000816048
5 O 0 0.0004924393
- O 0 0.0010270028
HT1B O 0 0.37797606
receptors O 0 0.16134857
) O 0 0.0014094422
or O 0 0.0006204468
CP B-Chemical 0 0.99405223
93129 I-Chemical 0 0.99916327
( O 0 0.0016725042
an O 0 0.001219159
agonist O 0 0.8152104
of O 0 0.0016794427
5 O 0 0.0014841809
- O 0 0.0035659925
HT1B O 0 0.4499146
receptors O 0 0.2643135
) O 0 0.01029002
. O 0 0.0061987774

Given O 0 0.0033055155
alone O 0 0.002927226
to O 0 0.0019906417
any O 0 0.0019495032
accumbal O 0 0.99589044
subregion O 0 0.09253517
, O 0 0.0026552458
GR B-Chemical 0 0.98643506
55562 I-Chemical 0 0.99449533
( O 0 0.0015585204
0 O 0 0.000619665
. O 0 0.0002611405
1 O 0 0.00036630552
- O 0 0.00047263317
10 O 0 0.0003098687
microg O 0 0.00082550675
/ O 0 0.00094303326
side O 0 0.009134856
) O 0 0.00079081726
or O 0 0.0004270373
CP B-Chemical 0 0.99159336
93129 I-Chemical 0 0.99927765
( O 0 0.0010778066
0 O 0 0.0004236151
. O 0 0.00018381998
1 O 0 0.00029968977
- O 0 0.00042209667
10 O 0 0.00030776186
microg O 0 0.00086769817
/ O 0 0.0010894259
side O 0 0.0073742117
) O 0 0.0009674632
did O 0 0.00053394935
not O 0 0.0006742705
change O 0 0.0013566109
basal O 0 0.005942412
locomotor O 0 0.37627152
activity O 0 0.006072308
. O 0 0.0055770157

Systemic O 0 0.96297866
cocaine B-Chemical 1 0.9976398
( O 0 0.006390113
10 O 0 0.002641375
mg O 0 0.31402576
/ O 0 0.0034929577
kg O 0 0.007570224
) O 0 0.0018372132
significantly O 0 0.0012922087
increased O 0 0.0018863577
the O 0 0.0018626108
locomotor O 0 0.2916819
activity O 0 0.0036797605
of O 0 0.0050743045
rats O 0 0.02333286
. O 0 0.007531168

GR B-Chemical 0 0.974095
55562 I-Chemical 0 0.9842486
( O 0 0.0047973725
0 O 0 0.0019090009
. O 0 0.00082503265
1 O 0 0.00086680235
- O 0 0.00096579536
10 O 0 0.0005688212
microg O 0 0.001289736
/ O 0 0.0013321742
side O 0 0.012030662
) O 0 0.0010214009
, O 0 0.0005893105
administered O 0 0.001793697
intra O 0 0.016033031
- O 0 0.00234043
accumbens O 0 0.9714972
shell O 0 0.00693943
prior O 0 0.0002531892
to O 0 0.00047508607
cocaine B-Chemical 1 0.9993162
, O 0 0.0014292235
dose O 0 0.06224438
- O 0 0.0028796182
dependently O 0 0.96605766
attenuated O 0 0.011037551
the O 0 0.0020380497
psychostimulant O 0 0.99886787
- O 0 0.012302508
induced O 0 0.013763056
locomotor B-Disease 0 0.98880184
hyperactivity I-Disease 2 0.9986482
. O 0 0.010282995

Such O 0 0.0077196
attenuation O 0 0.005420405
was O 0 0.0019149801
not O 0 0.0012244513
found O 0 0.00096273614
in O 0 0.0007097989
animals O 0 0.0006640409
which O 0 0.0009009392
had O 0 0.0008158692
been O 0 0.0009943618
injected O 0 0.0009265653
with O 0 0.0018319268
GR B-Chemical 0 0.983718
55562 I-Chemical 0 0.9878802
into O 0 0.0018497152
the O 0 0.0034990131
accumbens O 0 0.96193254
core O 0 0.0067828097
. O 0 0.006878651

When O 0 0.0033610524
injected O 0 0.0023759976
into O 0 0.00132341
the O 0 0.0017930707
accumbens O 0 0.96258855
shell O 0 0.032692265
( O 0 0.0013162631
but O 0 0.00057011325
not O 0 0.00041763668
the O 0 0.0004191813
core O 0 0.00061037793
) O 0 0.0008509823
before O 0 0.0003600288
cocaine B-Chemical 1 0.99926513
, O 0 0.0026082725
CP B-Chemical 0 0.99579597
93129 I-Chemical 0 0.99937123
( O 0 0.0012364085
0 O 0 0.00042841627
. O 0 0.0001735362
1 O 0 0.00026774764
- O 0 0.00035674882
10 O 0 0.00023889724
microg O 0 0.0006856445
/ O 0 0.0007725717
side O 0 0.007572058
) O 0 0.0005326985
enhanced O 0 0.00035826498
the O 0 0.0002886414
locomotor O 0 0.22518046
response O 0 0.0007030257
to O 0 0.00042397648
cocaine B-Chemical 1 0.99954164
; O 0 0.0009744987
the O 0 0.00022987132
maximum O 0 0.00028244578
effect O 0 0.0003411197
being O 0 0.00042641003
observed O 0 0.00025189933
after O 0 0.00024622297
10 O 0 0.0005410482
microg O 0 0.0015812598
/ O 0 0.002003682
side O 0 0.007180056
of O 0 0.002286499
the O 0 0.0035682926
agonist O 0 0.92962205
. O 0 0.0072236345

The O 0 0.0031115054
later O 0 0.0024623207
enhancement O 0 0.004102572
was O 0 0.0016200168
attenuated O 0 0.0025527815
after O 0 0.00084411335
intra O 0 0.018289858
- O 0 0.0047160718
accumbens O 0 0.97979856
shell O 0 0.02200723
treatment O 0 0.002494248
with O 0 0.0020398295
GR B-Chemical 0 0.99076205
55562 I-Chemical 0 0.99395084
( O 0 0.0027735848
1 O 0 0.0016370073
microg O 0 0.0045276927
/ O 0 0.0059311423
side O 0 0.034282498
) O 0 0.008513387
. O 0 0.0061898385

Our O 0 0.0036975227
findings O 0 0.0039048125
indicate O 0 0.0015708265
that O 0 0.0018226831
cocaine B-Chemical 1 0.99874336
induced O 0 0.024822768
hyperlocomotion B-Disease 0 0.9998293
is O 0 0.0014998063
modified O 0 0.0012439697
by O 0 0.0006548426
5 O 0 0.0005264607
- O 0 0.00094905705
HT1B O 0 0.29233167
receptor O 0 0.11527569
ligands O 0 0.11662314
microinjected O 0 0.0050138934
into O 0 0.0002510465
the O 0 0.00046177596
accumbens O 0 0.97970575
shell O 0 0.020157253
, O 0 0.00043865188
but O 0 0.00023242431
not O 0 0.00019799193
core O 0 0.00027918137
, O 0 0.00030385912
this O 0 0.0002083192
modification O 0 0.00063014316
consisting O 0 0.0002605101
in O 0 0.00024708794
inhibitory O 0 0.009055654
and O 0 0.00040883216
facilitatory O 0 0.6556814
effects O 0 0.0010819688
of O 0 0.0004897313
the O 0 0.00037856895
5 O 0 0.00040400965
- O 0 0.00094248884
HT1B O 0 0.43535632
receptor O 0 0.33337176
antagonist O 0 0.9922396
( O 0 0.0066772536
GR B-Chemical 0 0.99509615
55562 I-Chemical 0 0.9968935
) O 0 0.0030488812
and O 0 0.0013215931
agonist O 0 0.9622607
( O 0 0.006577297
CP B-Chemical 0 0.9949063
93129 I-Chemical 0 0.9984646
) O 0 0.008735333
, O 0 0.0047547305
respectively O 0 0.008728482
. O 0 0.005791943

In O 0 0.0029751882
other O 0 0.0021399464
words O 0 0.002565337
, O 0 0.0015117258
the O 0 0.0007501345
present O 0 0.00049927924
results O 0 0.00051216315
suggest O 0 0.00043476513
that O 0 0.00049191806
the O 0 0.00079125364
accumbal O 0 0.99798334
shell O 0 0.050446745
5 O 0 0.000598588
- O 0 0.000996828
HT1B O 0 0.22999373
receptors O 0 0.051368576
play O 0 0.0007194781
a O 0 0.00053747615
permissive O 0 0.0006865269
role O 0 0.0003674056
in O 0 0.0004964172
the O 0 0.0006808183
behavioural O 0 0.0085975
response O 0 0.0020163492
to O 0 0.0018366326
the O 0 0.0038670374
psychostimulant O 0 0.99520254
. O 0 0.008012373

Cocaine B-Chemical 0 0.99725217
related O 0 0.006721652
chest B-Disease 0 0.39891902
pain I-Disease 0 0.9680798
: O 0 0.0047309217
are O 0 0.00198926
we O 0 0.0012592821
seeing O 0 0.004629591
the O 0 0.0025818222
tip O 0 0.0058802487
of O 0 0.005695458
an O 0 0.009853136
iceberg O 0 0.06541649
? O 0 0.022816008

The O 0 0.0059803925
recreational O 0 0.042800542
use O 0 0.006173987
of O 0 0.0074203783
cocaine B-Chemical 1 0.995827
is O 0 0.0062663145
on O 0 0.0037583977
the O 0 0.0059838854
increase O 0 0.009114778
. O 0 0.011818021

The O 0 0.003893158
emergency O 0 0.0054877647
nurse O 0 0.0041863904
ought O 0 0.0033078885
to O 0 0.0015007991
be O 0 0.0013521139
familiar O 0 0.0024713415
with O 0 0.0012180331
some O 0 0.0011990555
of O 0 0.0014539713
the O 0 0.0017010317
cardiovascular O 0 0.93646026
consequences O 0 0.010858625
of O 0 0.00776666
cocaine B-Chemical 1 0.9979547
use O 0 0.013448858
. O 0 0.008513722

In O 0 0.0029780637
particular O 0 0.002051587
, O 0 0.0020685154
the O 0 0.0011656854
tendency O 0 0.0017594701
of O 0 0.001550455
cocaine B-Chemical 1 0.9987243
to O 0 0.0009884556
produce O 0 0.0008344102
chest B-Disease 0 0.36105183
pain I-Disease 0 0.97423106
ought O 0 0.0014829639
to O 0 0.00035563894
be O 0 0.00032216427
in O 0 0.00021706498
the O 0 0.00023486986
mind O 0 0.0005976053
of O 0 0.000358908
the O 0 0.00029175647
emergency O 0 0.0009616169
nurse O 0 0.00060453394
when O 0 0.00021560561
faced O 0 0.00070324086
with O 0 0.00044531882
a O 0 0.00048405383
young O 0 0.0031153862
victim O 0 0.005027696
of O 0 0.0008498916
chest B-Disease 0 0.45713994
pain I-Disease 0 0.98064524
who O 0 0.0041877446
is O 0 0.001014269
otherwise O 0 0.0017979847
at O 0 0.0010441531
low O 0 0.0034234684
risk O 0 0.067581505
. O 0 0.0066708233

The O 0 0.0033190441
mechanism O 0 0.0033150192
of O 0 0.0030185361
chest B-Disease 0 0.267178
pain I-Disease 0 0.95327103
related O 0 0.0014403693
to O 0 0.0014639072
cocaine B-Chemical 1 0.99840146
use O 0 0.0018942371
is O 0 0.0010640521
discussed O 0 0.0009834663
and O 0 0.0013852279
treatment O 0 0.0035643952
dilemmas O 0 0.007962661
are O 0 0.0036329785
discussed O 0 0.004992189
. O 0 0.006564535

Finally O 0 0.0051873447
, O 0 0.0039592828
moral O 0 0.008991383
issues O 0 0.002658776
relating O 0 0.0011582822
to O 0 0.00094005855
the O 0 0.0008173083
testing O 0 0.00097559625
of O 0 0.0014581062
potential O 0 0.0034558119
cocaine B-Chemical 1 0.9984484
users O 0 0.020749362
will O 0 0.0022683786
be O 0 0.0033667628
addressed O 0 0.0037064743
. O 0 0.006268073

Crossover O 0 0.03237115
comparison O 0 0.0024193123
of O 0 0.0022569934
efficacy O 0 0.004019447
and O 0 0.0014443621
preference O 0 0.0015289023
for O 0 0.001317326
rizatriptan B-Chemical 1 0.9995641
10 O 0 0.0020465085
mg O 0 0.46842435
versus O 0 0.0026581795
ergotamine B-Chemical 1 0.99968386
/ O 0 0.063401
caffeine B-Chemical 1 0.99809164
in O 0 0.012759531
migraine B-Disease 2 0.9985481
. O 0 0.011827307

Rizatriptan B-Chemical 0 0.9980684
is O 0 0.0041004606
a O 0 0.00262693
selective O 0 0.008581607
5 B-Chemical 0 0.0016724906
- I-Chemical 0 0.002904222
HT I-Chemical 0 0.9705208
( O 0 0.001899172
1B O 0 0.0011818558
/ O 0 0.0017282902
1D O 0 0.0034761587
) O 0 0.0012870462
receptor O 0 0.09663298
agonist O 0 0.926272
with O 0 0.00081683765
rapid O 0 0.0038918229
oral O 0 0.4525891
absorption O 0 0.5520487
and O 0 0.00061124295
early O 0 0.0012008647
onset O 0 0.00354636
of O 0 0.0007892299
action O 0 0.0068784365
in O 0 0.0007281964
the O 0 0.001163889
acute O 0 0.92391145
treatment O 0 0.02466408
of O 0 0.022701576
migraine B-Disease 2 0.9990031
. O 0 0.01096364

This O 0 0.004064004
randomized O 0 0.0027702688
double O 0 0.0014975863
- O 0 0.00181114
blind O 0 0.0026800577
crossover O 0 0.0028980095
outpatient O 0 0.0013584929
study O 0 0.00076157326
assessed O 0 0.00033913588
the O 0 0.00034225037
preference O 0 0.0004891833
for O 0 0.0003417331
1 O 0 0.0005965158
rizatriptan B-Chemical 1 0.99976045
10 O 0 0.00059822015
mg O 0 0.36759254
tablet O 0 0.7316674
to O 0 0.00040160256
2 O 0 0.00055632985
ergotamine B-Chemical 1 0.99985063
1 O 0 0.0006874963
mg O 0 0.45796996
/ O 0 0.001881455
caffeine B-Chemical 1 0.9987073
100 O 0 0.0026451664
mg O 0 0.51207906
tablets O 0 0.7531689
in O 0 0.0003642194
439 O 0 0.0047876043
patients O 0 0.0011378146
treating O 0 0.001937185
a O 0 0.00077571924
single O 0 0.0014993321
migraine B-Disease 2 0.9995395
attack O 0 0.56832296
with O 0 0.0028093152
each O 0 0.0019878082
therapy O 0 0.067742854
. O 0 0.0063923355

Of O 0 0.005240104
patients O 0 0.0041915704
expressing O 0 0.0013663137
a O 0 0.0014497855
preference O 0 0.0015672543
( O 0 0.0012744003
89 O 0 0.0014228914
. O 0 0.0004149772
1 O 0 0.0004834019
% O 0 0.0004911986
) O 0 0.0005501966
, O 0 0.00035622885
more O 0 0.00030246432
than O 0 0.00014987384
twice O 0 0.0002382126
as O 0 0.00017742458
many O 0 0.0002965197
preferred O 0 0.00051812513
rizatriptan B-Chemical 1 0.9998578
to O 0 0.0010566855
ergotamine B-Chemical 1 0.99993455
/ O 0 0.024119627
caffeine B-Chemical 1 0.99946207
( O 0 0.0010829845
69 O 0 0.0006072138
. O 0 0.00017117201
9 O 0 0.00023544137
vs O 0 0.0004282817
. O 0 0.00015438296
30 O 0 0.00021940061
. O 0 0.00017595718
1 O 0 0.00031287374
% O 0 0.0003934518
, O 0 0.00046754477
p O 0 0.00065775675
< O 0 0.0007074582
or O 0 0.0006649645
= O 0 0.0015884897
0 O 0 0.0014973546
. O 0 0.0015415612
001 O 0 0.12542562
) O 0 0.006628607
. O 0 0.005656609

Faster O 0 0.062064897
relief O 0 0.07332018
of O 0 0.0046245437
headache B-Disease 2 0.9970458
was O 0 0.0016176538
the O 0 0.0008373644
most O 0 0.0009983957
important O 0 0.00048701707
reason O 0 0.00046507426
for O 0 0.00034924224
preference O 0 0.0006416698
, O 0 0.00057744386
cited O 0 0.0012077885
by O 0 0.00038227605
67 O 0 0.00070813415
. O 0 0.000177676
3 O 0 0.0001939818
% O 0 0.00021513147
of O 0 0.00024883886
patients O 0 0.00095102494
preferring O 0 0.05555398
rizatriptan B-Chemical 1 0.9998511
and O 0 0.0006001633
54 O 0 0.0008321508
. O 0 0.00021628609
2 O 0 0.00031339886
% O 0 0.0003511901
of O 0 0.00047130042
patients O 0 0.0016276242
who O 0 0.0024543502
preferred O 0 0.002820893
ergotamine B-Chemical 1 0.99962616
/ O 0 0.12129274
caffeine B-Chemical 1 0.997224
. O 0 0.009570499

The O 0 0.0042170496
co O 0 0.06866858
- O 0 0.0039121583
primary O 0 0.0021379795
endpoint O 0 0.0023297612
of O 0 0.001400625
being O 0 0.0019633474
pain B-Disease 0 0.91398966
free O 0 0.0016502764
at O 0 0.00053551956
2 O 0 0.0006394827
h O 0 0.00064722204
was O 0 0.0006388655
also O 0 0.00088968565
in O 0 0.0010771429
favor O 0 0.0031157238
of O 0 0.0075833825
rizatriptan B-Chemical 1 0.99911124
. O 0 0.009926187

Forty O 0 0.011747203
- O 0 0.0034714907
nine O 0 0.0014138428
percent O 0 0.00092927914
of O 0 0.0011093302
patients O 0 0.002147875
were O 0 0.00096286135
pain B-Disease 0 0.87734824
free O 0 0.0012612812
2 O 0 0.0004886479
h O 0 0.00038079495
after O 0 0.00026827632
rizatriptan B-Chemical 1 0.9997609
, O 0 0.00053822855
compared O 0 0.00016410515
with O 0 0.00029068862
24 O 0 0.00026372116
. O 0 0.00014219384
3 O 0 0.00018551385
% O 0 0.00023927241
treated O 0 0.0004057333
with O 0 0.00070096325
ergotamine B-Chemical 1 0.99992037
/ O 0 0.021478692
caffeine B-Chemical 1 0.99949753
( O 0 0.0012184074
p O 0 0.0005905486
< O 0 0.00037703395
or O 0 0.00024823198
= O 0 0.00049387565
0 O 0 0.0003356589
. O 0 0.00022579405
001 O 0 0.10509521
) O 0 0.00077712676
, O 0 0.00080951717
rizatriptan B-Chemical 1 0.99966526
being O 0 0.0010411553
superior O 0 0.0017525892
within O 0 0.00043057755
1 O 0 0.0008910181
h O 0 0.0012002108
of O 0 0.0022836535
treatment O 0 0.0076123043
. O 0 0.005679182

Headache B-Disease 2 0.877077
relief O 0 0.07242692
at O 0 0.0016041036
2 O 0 0.0012483507
h O 0 0.00092813413
was O 0 0.00067440514
75 O 0 0.0008901232
. O 0 0.0003541075
9 O 0 0.00039514856
% O 0 0.00038360854
for O 0 0.00034994294
rizatriptan B-Chemical 1 0.99964523
and O 0 0.00057070015
47 O 0 0.0008106017
. O 0 0.0001981094
3 O 0 0.0002290874
% O 0 0.0002919576
for O 0 0.00031377884
ergotamine B-Chemical 1 0.9998721
/ O 0 0.012134731
caffeine B-Chemical 1 0.99939203
( O 0 0.0011250622
p O 0 0.00056534493
< O 0 0.00036187036
or O 0 0.00023401284
= O 0 0.00045686626
0 O 0 0.00030046306
. O 0 0.00019102705
001 O 0 0.09976958
) O 0 0.0005610121
, O 0 0.0003894128
with O 0 0.00057185336
rizatriptan B-Chemical 1 0.9998124
being O 0 0.0009850591
superior O 0 0.0028359012
to O 0 0.0007407582
ergotamine B-Chemical 1 0.99985766
/ O 0 0.011564214
caffeine B-Chemical 1 0.9980076
within O 0 0.0005965846
30 O 0 0.000906827
min O 0 0.0016727996
of O 0 0.0025267066
dosing O 0 0.06593289
. O 0 0.0055516358

Almost O 0 0.0056595406
36 O 0 0.0026235261
% O 0 0.0016962449
of O 0 0.0013068994
patients O 0 0.0024679983
taking O 0 0.0041371435
rizatriptan B-Chemical 1 0.99973875
were O 0 0.0012968922
pain B-Disease 0 0.92993575
free O 0 0.0010096509
at O 0 0.0002683659
2 O 0 0.00028771904
h O 0 0.00024865576
and O 0 0.00021702773
had O 0 0.00022931227
no O 0 0.00020345878
recurrence O 0 0.19030364
or O 0 0.000214553
need O 0 0.00017589645
for O 0 0.00014876186
additional O 0 0.0001417325
medication O 0 0.019276744
within O 0 0.00011605626
24 O 0 0.00018526583
h O 0 0.00019191692
, O 0 0.0002056651
compared O 0 0.00010105147
to O 0 0.00015811686
20 O 0 0.00023615989
% O 0 0.00021716185
of O 0 0.00026861572
patients O 0 0.001032232
on O 0 0.00036683216
ergotamine B-Chemical 1 0.99989283
/ O 0 0.02407324
caffeine B-Chemical 1 0.9992853
( O 0 0.0017161734
p O 0 0.0010945696
< O 0 0.0008645492
or O 0 0.00071247213
= O 0 0.0016459901
0 O 0 0.0015070761
. O 0 0.0015266932
001 O 0 0.13200638
) O 0 0.0065679443
. O 0 0.0055932812

Rizatriptan B-Chemical 0 0.9981318
was O 0 0.0036595422
also O 0 0.0021832564
superior O 0 0.003915047
to O 0 0.0017754539
ergotamine B-Chemical 1 0.999749
/ O 0 0.016681617
caffeine B-Chemical 1 0.99859565
in O 0 0.0006640719
the O 0 0.00040300065
proportions O 0 0.0003782933
of O 0 0.0005029435
patients O 0 0.0015302481
with O 0 0.0006211157
no O 0 0.0006849248
nausea B-Disease 2 0.9999124
, O 0 0.010136706
vomiting B-Disease 0 0.9998503
, O 0 0.013597267
phonophobia B-Disease 0 0.99994147
or O 0 0.0010008735
photophobia B-Disease 0 0.99969745
and O 0 0.00047136078
for O 0 0.00024054194
patients O 0 0.0010303378
with O 0 0.0003323751
normal O 0 0.00062740844
function O 0 0.00037413268
2 O 0 0.00025678132
h O 0 0.00024457325
after O 0 0.0001817273
drug O 0 0.14568172
intake O 0 0.6483188
( O 0 0.0009534986
p O 0 0.00086886884
< O 0 0.0007779426
or O 0 0.0006769161
= O 0 0.0015918927
0 O 0 0.001477729
. O 0 0.0015070266
001 O 0 0.12859407
) O 0 0.0065140417
. O 0 0.005559842

More O 0 0.013003
patients O 0 0.005624504
were O 0 0.0021355595
( O 0 0.001918883
completely O 0 0.0011778414
, O 0 0.0010267993
very O 0 0.00077895366
or O 0 0.00050692505
somewhat O 0 0.0010503067
) O 0 0.000760492
satisfied O 0 0.00050508836
2 O 0 0.00029292176
h O 0 0.00024913394
after O 0 0.0001434109
treatment O 0 0.0006158307
with O 0 0.00075389683
rizatriptan B-Chemical 1 0.9998845
( O 0 0.0008228288
69 O 0 0.00053451397
. O 0 0.000153035
8 O 0 0.00020699245
% O 0 0.00023104336
) O 0 0.00026394904
than O 0 0.00010640055
at O 0 0.00011177111
2 O 0 0.00016906591
h O 0 0.00017151839
after O 0 0.000113630595
treatment O 0 0.0005911047
with O 0 0.00086265535
ergotamine B-Chemical 1 0.99992347
/ O 0 0.021803439
caffeine B-Chemical 1 0.99942976
( O 0 0.001195569
38 O 0 0.00078247185
. O 0 0.00022509461
6 O 0 0.00026412203
% O 0 0.00040464537
, O 0 0.00047808283
p O 0 0.00066886446
< O 0 0.0007131802
or O 0 0.00066607865
= O 0 0.0015898531
0 O 0 0.0014956119
. O 0 0.0015382292
001 O 0 0.12602529
) O 0 0.006616727
. O 0 0.0056459038

Recurrence O 0 0.36743292
rates O 0 0.0031665526
were O 0 0.0021672575
31 O 0 0.0022619392
. O 0 0.00088598544
4 O 0 0.0007825062
% O 0 0.00087016006
with O 0 0.0011121142
rizatriptan B-Chemical 1 0.99942076
and O 0 0.0011993627
15 O 0 0.00074845366
. O 0 0.00053247646
3 O 0 0.00076321367
% O 0 0.0012731894
with O 0 0.0027560676
ergotamine B-Chemical 1 0.9994074
/ O 0 0.091625296
caffeine B-Chemical 1 0.9965185
. O 0 0.010739027

Both O 0 0.013616991
active O 0 0.012438882
treatments O 0 0.0150643615
were O 0 0.009766028
well O 0 0.011193933
tolerated O 0 0.06485607
. O 0 0.018427826

The O 0 0.0031726372
most O 0 0.0034643584
common O 0 0.0032526213
adverse O 0 0.5427711
events O 0 0.017086118
( O 0 0.0019285843
incidence O 0 0.008282029
> O 0 0.0015928561
or O 0 0.00047040381
= O 0 0.00067990896
5 O 0 0.00027040363
% O 0 0.00027842305
in O 0 0.00018207748
one O 0 0.00018333021
group O 0 0.00038466486
) O 0 0.0005124503
after O 0 0.0002513701
rizatriptan B-Chemical 1 0.9998493
and O 0 0.0015109738
ergotamine B-Chemical 1 0.999938
/ O 0 0.02300987
caffeine B-Chemical 1 0.9995121
, O 0 0.0012046684
respectively O 0 0.0016090698
, O 0 0.000467527
were O 0 0.00045274073
dizziness B-Disease 2 0.99946016
( O 0 0.0006266189
6 O 0 0.00019180679
. O 0 0.00012028825
7 O 0 0.00014868005
and O 0 0.00017856392
5 O 0 0.00016976408
. O 0 0.00011903595
3 O 0 0.00017664708
% O 0 0.00027199692
) O 0 0.0004418011
, O 0 0.0005766213
nausea B-Disease 2 0.999785
( O 0 0.0006791888
4 O 0 0.00022364227
. O 0 0.00012708787
2 O 0 0.00018039433
and O 0 0.00019630147
8 O 0 0.0002051287
. O 0 0.00012914829
5 O 0 0.00018659633
% O 0 0.00027534555
) O 0 0.00042719283
and O 0 0.00050003885
somnolence B-Disease 2 0.99930847
( O 0 0.0007678498
5 O 0 0.00034805053
. O 0 0.00024275744
5 O 0 0.00034962886
and O 0 0.000521182
2 O 0 0.0007405748
. O 0 0.0006752656
3 O 0 0.0012778161
% O 0 0.002422116
) O 0 0.004524422
. O 0 0.004539587

Severe O 0 0.8465436
ocular B-Disease 0 0.63234395
and I-Disease 0 0.0048973705
orbital I-Disease 0 0.089239426
toxicity I-Disease 2 0.98248714
after O 0 0.0018714792
intracarotid O 0 0.9812502
injection O 0 0.011188239
of O 0 0.0039332416
carboplatin B-Chemical 1 0.99690384
for O 0 0.005573772
recurrent O 0 0.94879526
glioblastomas B-Disease 0 0.9945892
. O 0 0.012734225

BACKGROUND O 0 0.9101782
: O 0 0.015239603
Glioblastoma B-Disease 0 0.9896319
is O 0 0.0036582649
a O 0 0.003681983
malignant B-Disease 0 0.99150157
tumor I-Disease 2 0.9651366
that O 0 0.0019050327
occurs O 0 0.0018626207
in O 0 0.0016520952
the O 0 0.002465369
cerebrum O 0 0.47073194
during O 0 0.004337826
adulthood O 0 0.20516084
. O 0 0.0076940665

With O 0 0.0045160907
current O 0 0.0031232447
treatment O 0 0.0029255508
regimens O 0 0.008632898
including O 0 0.0010183054
combined O 0 0.0014330496
surgery O 0 0.003958241
, O 0 0.0009472435
radiation O 0 0.09181044
and O 0 0.0008095214
chemotherapy O 0 0.68525183
, O 0 0.0006288272
the O 0 0.00027774533
average O 0 0.00019216593
life O 0 0.00071413483
expectancy O 0 0.0012786497
of O 0 0.0004973891
the O 0 0.00044351091
patients O 0 0.001363228
is O 0 0.0005835045
limited O 0 0.000704839
to O 0 0.00091500196
approximately O 0 0.0016368079
1 O 0 0.0022627541
year O 0 0.003687965
. O 0 0.0046414007

Therefore O 0 0.0039025927
, O 0 0.0034745587
patients O 0 0.0042211288
with O 0 0.002866586
glioblastoma B-Disease 2 0.9948161
sometimes O 0 0.0069855954
have O 0 0.0017091093
intracarotid O 0 0.9853537
injection O 0 0.0081599215
of O 0 0.0017859692
carcinostatics O 0 0.8453675
added O 0 0.0016848207
to O 0 0.0014000649
the O 0 0.0019113218
treatment O 0 0.0074032103
regimen O 0 0.05610166
. O 0 0.007283359

Generally O 0 0.0058990577
, O 0 0.0049030418
carboplatin B-Chemical 1 0.9925938
is O 0 0.0021198862
said O 0 0.002395436
to O 0 0.00088111986
have O 0 0.0009268726
milder O 0 0.051856615
side O 0 0.024240943
effects O 0 0.0024024027
than O 0 0.0007147947
cisplatin B-Chemical 1 0.99837446
, O 0 0.0015358903
whose O 0 0.0019180158
ocular B-Disease 0 0.6791832
and I-Disease 0 0.0017900962
orbital I-Disease 0 0.25817534
toxicity I-Disease 2 0.9919172
are O 0 0.0029155086
well O 0 0.0028680963
known O 0 0.0065717166
. O 0 0.005983026

However O 0 0.0041658543
, O 0 0.0026980962
we O 0 0.0009939764
experienced O 0 0.0018002514
a O 0 0.0011116078
case O 0 0.00090032147
of O 0 0.0011252573
severe O 0 0.15436918
ocular B-Disease 0 0.7718131
and I-Disease 0 0.0012463548
orbital I-Disease 0 0.14150216
toxicity I-Disease 2 0.9911645
after O 0 0.0005790311
intracarotid O 0 0.9862256
injection O 0 0.007130727
of O 0 0.0017658954
carboplatin B-Chemical 1 0.9984958
, O 0 0.0023759007
which O 0 0.0020897193
is O 0 0.0021611801
infrequently O 0 0.011562028
reported O 0 0.0070813852
. O 0 0.005907892

CASE O 0 0.90695834
: O 0 0.0070050387
A O 0 0.00996213
58 O 0 0.0035340704
- O 0 0.0023333551
year O 0 0.0013183444
- O 0 0.0014517093
old O 0 0.0009459615
man O 0 0.015861508
received O 0 0.00090043765
an O 0 0.0010059698
intracarotid O 0 0.9689419
injection O 0 0.0044910614
of O 0 0.0012089901
carboplatin B-Chemical 1 0.9982516
for O 0 0.0011910672
recurrent O 0 0.8390711
glioblastomas B-Disease 0 0.9967006
in O 0 0.0016392736
his O 0 0.0038682916
left O 0 0.0075700763
temporal O 0 0.11400323
lobe O 0 0.6256479
. O 0 0.006859027

He O 0 0.011235526
complained O 0 0.12207281
of O 0 0.0048344336
pain B-Disease 0 0.9368958
and I-Disease 0 0.0032609615
visual I-Disease 0 0.6976341
disturbance I-Disease 0 0.62878907
in I-Disease 0 0.0012920703
the I-Disease 0 0.0011848666
ipsilateral I-Disease 0 0.00964058
eye I-Disease 0 0.00969065
30 O 0 0.0011233145
h O 0 0.0012757508
after O 0 0.0011342749
the O 0 0.0026014328
injection O 0 0.010909647
. O 0 0.0063481904

Various O 0 0.020210618
ocular O 0 0.62132883
symptoms O 0 0.36070698
and O 0 0.0039745253
findings O 0 0.0054459916
caused O 0 0.0039967066
by O 0 0.005300208
carboplatin B-Chemical 1 0.9977132
toxicity B-Disease 2 0.99449
were O 0 0.008394079
seen O 0 0.008321266
. O 0 0.008855746

RESULTS O 0 0.03291348
: O 0 0.005092213
He O 0 0.0044010086
was O 0 0.0015456887
treated O 0 0.0018335687
with O 0 0.0014073262
intravenous O 0 0.42737123
administration O 0 0.16890067
of O 0 0.0020590022
corticosteroids O 1 0.99839324
and O 0 0.0027077908
glycerin B-Chemical 0 0.9909588
for O 0 0.0009771475
6 O 0 0.0007853471
days O 0 0.0009191451
after O 0 0.00094280235
the O 0 0.0022461507
injection O 0 0.0099559985
. O 0 0.0056741675

Although O 0 0.0039616865
the O 0 0.0029014908
intraocular O 0 0.85359365
pressure O 0 0.20191574
elevation O 0 0.3428147
caused O 0 0.0020106942
by O 0 0.0012551347
secondary O 0 0.0072735394
acute O 0 0.9687043
angle O 0 0.23488878
- O 0 0.0035647473
closure O 0 0.020167828
glaucoma B-Disease 2 0.998998
decreased O 0 0.0072459616
and O 0 0.0012314627
ocular B-Disease 0 0.9905344
pain I-Disease 0 0.99838984
diminished O 0 0.008485531
, O 0 0.0016758472
inexorable O 0 0.5485504
papilledema B-Disease 0 0.9997577
and O 0 0.0043932977
exudative O 0 0.9992111
retinal B-Disease 0 0.9898335
detachment I-Disease 0 0.9856894
continued O 0 0.0028304888
for O 0 0.0015428924
3 O 0 0.0021288535
weeks O 0 0.0032762368
. O 0 0.004386469

Finally O 0 0.0046964306
, O 0 0.003089695
6 O 0 0.0012938982
weeks O 0 0.0010764714
later O 0 0.0010252657
, O 0 0.0014861814
diffuse O 0 0.09465727
chorioretinal B-Disease 0 0.99873334
atrophy I-Disease 2 0.99950314
with O 0 0.011136365
optic B-Disease 0 0.99451894
atrophy I-Disease 2 0.998643
occurred O 0 0.0016622054
and O 0 0.00074189215
the O 0 0.00067480793
vision O 0 0.06622691
in O 0 0.0008083305
his O 0 0.0019974369
left O 0 0.0035845782
eye O 0 0.020135108
was O 0 0.0028249088
lost O 0 0.005331444
. O 0 0.0057551363

CONCLUSION O 0 0.7403884
: O 0 0.004363805
When O 0 0.0015572314
performing O 0 0.0016318968
intracarotid O 0 0.926028
injection O 0 0.0057292087
of O 0 0.0019243191
carboplatin B-Chemical 1 0.99779886
, O 0 0.0014196294
we O 0 0.00039164693
must O 0 0.00045039842
be O 0 0.00062426116
aware O 0 0.0008025671
of O 0 0.0010634196
its O 0 0.002395141
potentially O 0 0.0054950877
blinding O 0 0.06114273
ocular B-Disease 0 0.9918207
toxicity I-Disease 2 0.99722844
. O 0 0.011859729

It O 0 0.0055284468
is O 0 0.0021708515
recommended O 0 0.0016824324
that O 0 0.00091780705
further O 0 0.0009769086
studies O 0 0.0011359499
and O 0 0.00076744554
investigations O 0 0.0013930511
are O 0 0.0005833944
undertaken O 0 0.0004732539
in O 0 0.00043597742
the O 0 0.00050035445
effort O 0 0.0008373277
to O 0 0.00065138
minimize O 0 0.00072418567
such O 0 0.0017824611
severe O 0 0.26489323
side O 0 0.10226329
effects O 0 0.015863754
. O 0 0.0073353616

Visual B-Disease 0 0.97166586
hallucinations I-Disease 2 0.99714714
associated O 0 0.043968692
with O 0 0.046803936
zonisamide B-Chemical 1 0.99705976
. O 0 0.03565664

Zonisamide B-Chemical 0 0.9960646
is O 0 0.0041432343
a O 0 0.002722331
broad O 0 0.0035071112
- O 0 0.0027829169
spectrum O 0 0.0026418236
antiepileptic O 0 0.99752206
drug O 0 0.52919996
used O 0 0.0013804039
to O 0 0.0012671984
treat O 0 0.005512844
various O 0 0.003717125
types O 0 0.0037981889
of O 0 0.0115064345
seizures B-Disease 2 0.998725
. O 0 0.0122113805

Although O 0 0.005153814
visual B-Disease 2 0.7977913
hallucinations I-Disease 2 0.9994265
have O 0 0.002667949
not O 0 0.0011710007
been O 0 0.0010547801
reported O 0 0.0009512478
as O 0 0.00044667456
an O 0 0.0007033227
adverse O 0 0.35277376
effect O 0 0.00053978077
of O 0 0.00048225798
this O 0 0.0003993557
agent O 0 0.045306604
, O 0 0.00037224675
we O 0 0.00010926804
describe O 0 0.00021009751
three O 0 0.00012752245
patients O 0 0.0007333006
who O 0 0.00070523383
experienced O 0 0.0006878653
complex O 0 0.0005692404
visual B-Disease 2 0.91407293
hallucinations I-Disease 2 0.99992895
and O 0 0.0007955874
altered O 0 0.0011652951
mental O 0 0.08138048
status O 0 0.0006766255
after O 0 0.00034666265
zonisamide B-Chemical 1 0.9997956
treatment O 0 0.0028172599
was O 0 0.00071782345
begun O 0 0.0013314633
or O 0 0.0008834279
its O 0 0.0031053086
dosage O 0 0.1885954
increased O 0 0.010277541
. O 0 0.00640984

All O 0 0.0033211457
three O 0 0.0015236381
had O 0 0.0018957946
been O 0 0.0019318276
diagnosed O 0 0.007037926
earlier O 0 0.0016252975
with O 0 0.0024149662
epilepsy B-Disease 2 0.99891293
, O 0 0.0021670763
and O 0 0.0011769219
their O 0 0.0014581208
electroencephalogram O 0 0.9261614
( O 0 0.003042539
EEG O 0 0.9191552
) O 0 0.0034038755
findings O 0 0.004457235
were O 0 0.00346038
abnormal O 0 0.029451575
. O 0 0.0073035387

During O 0 0.0031197637
monitoring O 0 0.0038296864
, O 0 0.0038181052
visual B-Disease 2 0.83439136
hallucinations I-Disease 2 0.9996582
did O 0 0.0015664801
not O 0 0.00070733484
correlate O 0 0.0006787759
with O 0 0.00090182386
EEG O 0 0.8803431
readings O 0 0.0011811514
, O 0 0.00068200903
nor O 0 0.00043218958
did O 0 0.0004197799
video O 0 0.0010481427
recording O 0 0.0010905176
capture O 0 0.0008963549
any O 0 0.0007330993
of O 0 0.0014072565
the O 0 0.0017773677
described O 0 0.002760477
events O 0 0.01762477
. O 0 0.006398614

None O 0 0.009776025
of O 0 0.0040209237
the O 0 0.0028977504
patients O 0 0.005006663
had O 0 0.0030459012
experienced O 0 0.0074844654
visual B-Disease 2 0.92403483
hallucinations I-Disease 2 0.99929476
before O 0 0.0039776256
this O 0 0.005585709
event O 0 0.020707224
. O 0 0.0092622

The O 0 0.0028986698
only O 0 0.0021103506
recent O 0 0.0019309996
change O 0 0.0014927833
in O 0 0.00097501965
their O 0 0.0010447273
treatment O 0 0.0017926729
was O 0 0.00088113715
the O 0 0.0007879313
introduction O 0 0.0010661879
or O 0 0.0010857964
increased O 0 0.0030024496
dosage O 0 0.28428257
of O 0 0.01871101
zonisamide B-Chemical 1 0.9992424
. O 0 0.011760882

With O 0 0.0054932013
either O 0 0.0028218264
discontinuation O 0 0.42541963
or O 0 0.0014773295
decreased O 0 0.0023562373
dosage O 0 0.061507
of O 0 0.0014117453
the O 0 0.0010647152
drug O 0 0.21112087
the O 0 0.0013871236
symptoms O 0 0.2905465
disappeared O 0 0.003821623
and O 0 0.002013587
did O 0 0.0021517405
not O 0 0.0032576013
recur O 0 0.13761358
. O 0 0.00716752

Further O 0 0.0063247844
observations O 0 0.0044096173
and O 0 0.003231288
reports O 0 0.0035923189
will O 0 0.0020593805
help O 0 0.0029500576
clarify O 0 0.0021674887
this O 0 0.004111339
adverse O 0 0.5890652
effect O 0 0.011479518
. O 0 0.010671091

Until O 0 0.005098483
then O 0 0.0028802822
, O 0 0.0028504473
clinicians O 0 0.002768213
need O 0 0.0012008294
to O 0 0.0010499071
be O 0 0.0010338126
aware O 0 0.0010682436
of O 0 0.0011085864
this O 0 0.0011203064
possible O 0 0.0019582168
complication O 0 0.3138985
associated O 0 0.0056885006
with O 0 0.015991595
zonisamide B-Chemical 1 0.9991454
. O 0 0.011994686

Anti O 0 0.5414802
- O 0 0.02507538
epileptic B-Disease 2 0.9962255
drugs O 0 0.9338886
- O 0 0.0117755
induced O 0 0.0077615306
de O 0 0.085636
novo O 0 0.098616876
absence B-Disease 0 0.019979445
seizures I-Disease 2 0.9989254
. O 0 0.02010526

The O 0 0.0026903322
authors O 0 0.0023427578
present O 0 0.0012038826
three O 0 0.0008700035
patients O 0 0.0023657323
with O 0 0.0015628515
de O 0 0.017623354
novo O 0 0.01760255
absence B-Disease 0 0.002343527
epilepsy I-Disease 2 0.9994698
after O 0 0.0013990307
administration O 0 0.2916399
of O 0 0.009875728
carbamazepine B-Chemical 1 0.9997632
and O 0 0.049819384
vigabatrin B-Chemical 0 0.99931395
. O 0 0.011650249

Despite O 0 0.004003549
the O 0 0.0023189003
underlying O 0 0.0043447963
diseases O 0 0.41420153
, O 0 0.0020982907
the O 0 0.0010501407
prognosis O 0 0.50150967
for O 0 0.00084455224
drug O 0 0.5239106
- O 0 0.0017715439
induced O 0 0.0009829552
de O 0 0.028852757
novo O 0 0.020116316
absence B-Disease 0 0.0011093672
seizure I-Disease 2 0.9996779
is O 0 0.0006223117
good O 0 0.0005043138
because O 0 0.0002534846
it O 0 0.00038769265
subsides O 0 0.001735953
rapidly O 0 0.00079000264
after O 0 0.00028228693
discontinuing O 0 0.12681572
the O 0 0.00061514584
use O 0 0.000980872
of O 0 0.0014858751
the O 0 0.0023006129
offending O 0 0.52810985
drugs O 0 0.84228444
. O 0 0.007321382

The O 0 0.0053675557
gamma B-Chemical 1 0.3550282
- I-Chemical 1 0.015673539
aminobutyric I-Chemical 1 0.99728787
acid I-Chemical 1 0.98466206
- O 0 0.004799162
transmitted O 0 0.0017251412
thalamocortical O 0 0.7014286
circuitry O 0 0.02389538
accounts O 0 0.00083684665
for O 0 0.00037715043
a O 0 0.00047960915
major O 0 0.0005596093
part O 0 0.00037647042
of O 0 0.0006000821
the O 0 0.00061642495
underlying O 0 0.0020551516
neurophysiology O 0 0.08050959
of O 0 0.0019996148
the O 0 0.0024651743
absence B-Disease 0 0.007234548
epilepsy I-Disease 2 0.99881387
. O 0 0.0110767875

Because O 0 0.004246576
drug O 0 0.24554804
- O 0 0.0043669012
induced O 0 0.0025798636
de O 0 0.025228672
novo O 0 0.021976728
absence B-Disease 0 0.0021850097
seizure I-Disease 2 0.9994916
is O 0 0.0017476643
rare O 0 0.028301692
, O 0 0.0014697773
pro O 0 0.047990378
- O 0 0.0012277173
absence O 0 0.00041459408
drugs O 0 0.3595454
can O 0 0.00062419573
only O 0 0.00074399664
be O 0 0.0009060946
considered O 0 0.0010096123
a O 0 0.0018789425
promoting O 0 0.0040494846
factor O 0 0.024390675
. O 0 0.006914147

The O 0 0.002918396
underlying O 0 0.0040900214
epileptogenecity O 0 0.016699027
of O 0 0.0017286876
the O 0 0.0010829777
patients O 0 0.0020768265
or O 0 0.0006064441
the O 0 0.0005351132
synergistic O 0 0.0030925209
effects O 0 0.0012372097
of O 0 0.00071864284
the O 0 0.00055797107
accompanying O 0 0.00308868
drugs O 0 0.61001724
is O 0 0.0006536031
required O 0 0.00033611222
to O 0 0.00058420876
trigger O 0 0.0010918916
the O 0 0.0012539829
de O 0 0.034645736
novo O 0 0.05005491
absence B-Disease 0 0.008594196
seizure I-Disease 2 0.9983796
. O 0 0.011017025

The O 0 0.0027960008
possibility O 0 0.0019510485
of O 0 0.0023779585
drug O 0 0.4327722
- O 0 0.0032275398
induced O 0 0.0018763783
aggravation O 0 0.8914324
should O 0 0.00052578124
be O 0 0.0004917954
considered O 0 0.00032974695
whenever O 0 0.0003792578
an O 0 0.0004203445
unexpected O 0 0.0006836886
increase O 0 0.0003945749
in O 0 0.0004452434
seizure B-Disease 2 0.9987093
frequency O 0 0.000830009
and O 0 0.0005623741
/ O 0 0.0010126121
or O 0 0.00030866865
new O 0 0.00083689694
seizure B-Disease 2 0.99842656
types O 0 0.0007773138
appear O 0 0.00065545324
following O 0 0.0006106264
a O 0 0.0008721402
change O 0 0.0011542498
in O 0 0.0015398221
drug O 0 0.3216263
treatment O 0 0.01424609
. O 0 0.006326163

By O 0 0.004588897
understanding O 0 0.0022961558
the O 0 0.001483507
underlying O 0 0.0023077752
mechanism O 0 0.0015223338
of O 0 0.0013380239
absence B-Disease 0 0.0017458767
epilepsy I-Disease 2 0.9997116
, O 0 0.0014533346
we O 0 0.00026106407
can O 0 0.00028975285
avoid O 0 0.00027997012
the O 0 0.00029349118
inappropriate O 0 0.0017673066
use O 0 0.00051299133
of O 0 0.00075706234
anticonvulsants O 0 0.9992525
in O 0 0.00056475203
children O 0 0.0024032735
with O 0 0.0013394208
epilepsy B-Disease 2 0.9993962
and O 0 0.0012869431
prevent O 0 0.0018953119
drug O 0 0.65460074
- O 0 0.0044508004
induced O 0 0.0040066424
absence B-Disease 0 0.009565496
seizures I-Disease 2 0.9994553
. O 0 0.010620005

Prenatal O 0 0.75855535
dexamethasone B-Chemical 0 0.99472624
programs O 0 0.019288898
hypertension B-Disease 2 0.99817777
and O 0 0.016252076
renal B-Disease 2 0.9962147
injury I-Disease 2 0.98991734
in O 0 0.0070365225
the O 0 0.007511299
rat O 0 0.046864633
. O 0 0.011423944

Dexamethasone O 1 0.996249
is O 0 0.0053111822
frequently O 0 0.0046039396
administered O 0 0.004624856
to O 0 0.0018051931
the O 0 0.0018021178
developing O 0 0.005969257
fetus O 0 0.020806314
to O 0 0.002833804
accelerate O 0 0.006561283
pulmonary O 0 0.8989376
development O 0 0.042891238
. O 0 0.01024971

The O 0 0.0025352775
purpose O 0 0.0019426746
of O 0 0.0014653382
the O 0 0.0009714636
present O 0 0.00067339616
study O 0 0.0010787979
was O 0 0.0005811193
to O 0 0.0004345296
determine O 0 0.00024117045
if O 0 0.0003391685
prenatal O 0 0.029853337
dexamethasone B-Chemical 0 0.9989453
programmed O 0 0.41189823
a O 0 0.0010188692
progressive O 0 0.21902841
increase B-Disease 0 0.0007645754
in I-Disease 0 0.00067631673
blood I-Disease 0 0.010870867
pressure I-Disease 0 0.08681531
and O 0 0.002543338
renal B-Disease 2 0.9974113
injury I-Disease 2 0.9935163
in O 0 0.005375762
rats O 0 0.03349353
. O 0 0.0064054835

Pregnant O 0 0.124770775
rats O 0 0.00635029
were O 0 0.0016233906
given O 0 0.0009180204
either O 0 0.0009420225
vehicle O 0 0.0049639265
or O 0 0.00061737833
2 O 0 0.00051966484
daily O 0 0.0011146071
intraperitoneal O 0 0.06830073
injections O 0 0.008368614
of O 0 0.0010669541
dexamethasone B-Chemical 0 0.99919087
( O 0 0.0012180762
0 O 0 0.00041861465
. O 0 0.00016000206
2 O 0 0.00024912087
mg O 0 0.09770159
/ O 0 0.00061146094
kg O 0 0.0018352956
body O 0 0.0010500127
weight O 0 0.0019474882
) O 0 0.0003993109
on O 0 0.00013283304
gestational O 0 0.007360681
days O 0 0.00022351225
11 O 0 0.00024008118
and O 0 0.00020035512
12 O 0 0.00017066827
, O 0 0.0002460545
13 O 0 0.00024304439
and O 0 0.00021727204
14 O 0 0.00027611892
, O 0 0.00027687819
15 O 0 0.00019640836
and O 0 0.00025667314
16 O 0 0.00035386594
, O 0 0.0004212284
17 O 0 0.00053774007
and O 0 0.0004750401
18 O 0 0.0006706648
, O 0 0.00086012913
or O 0 0.0008715172
19 O 0 0.002186606
and O 0 0.002171835
20 O 0 0.0039921226
. O 0 0.004509942

Offspring O 0 0.025800006
of O 0 0.0034969088
rats O 0 0.0071428358
administered O 0 0.007114631
dexamethasone B-Chemical 0 0.9958033
on O 0 0.0006217438
days O 0 0.0005812312
15 O 0 0.00037320008
and O 0 0.0003544647
16 O 0 0.0003612837
gestation O 0 0.0011701215
had O 0 0.00029703128
a O 0 0.0003236984
20 O 0 0.00033591743
% O 0 0.0002840878
reduction B-Disease 2 0.00040411923
in I-Disease 2 0.00024041286
glomerular I-Disease 2 0.43737736
number I-Disease 2 0.0002346769
compared O 0 0.0001421632
with O 0 0.0002444136
control O 0 0.0001831504
at O 0 0.00013736906
6 O 0 0.00014079474
to O 0 0.00014725658
9 O 0 0.00016390234
months O 0 0.00016824622
of O 0 0.00023290257
age O 0 0.0006216362
( O 0 0.0003920771
22 O 0 0.00041082874
527 O 0 0.0030117733
+ O 0 0.00048507997
/ O 0 0.0008412419
- O 0 0.0005296736
509 O 0 0.003954002
versus O 0 0.00025247905
28 O 0 0.0004424942
050 O 0 0.04121163
+ O 0 0.0004998899
/ O 0 0.00095836807
- O 0 0.00066774356
561 O 0 0.01864642
, O 0 0.000510875
P O 0 0.016905384
< O 0 0.00037529008
0 O 0 0.0002938025
. O 0 0.00018011761
05 O 0 0.016099045
) O 0 0.0004685632
, O 0 0.00030380703
which O 0 0.0002897948
was O 0 0.00020459271
comparable O 0 0.0001510775
to O 0 0.00019586118
the O 0 0.00021591439
percent O 0 0.00025665094
reduction O 0 0.00062724453
in O 0 0.00040327891
glomeruli O 0 0.012997371
measured O 0 0.0004354564
at O 0 0.00046241772
3 O 0 0.0007387674
weeks O 0 0.0010925225
of O 0 0.0023455636
age O 0 0.007045951
. O 0 0.005232273

Six O 0 0.0071951672
- O 0 0.0041845487
to O 0 0.0017935928
9 O 0 0.0014414726
- O 0 0.0012842689
month O 0 0.00063520455
old O 0 0.00073983724
rats O 0 0.0016335741
receiving O 0 0.002053942
prenatal O 0 0.036702827
dexamethasone B-Chemical 0 0.9982323
on O 0 0.00030045587
days O 0 0.0003469579
17 O 0 0.00039717354
and O 0 0.00023648437
18 O 0 0.00022764206
of O 0 0.00026108924
gestation O 0 0.0016378041
had O 0 0.00027319972
a O 0 0.00032045433
17 O 0 0.0004308391
% O 0 0.0002852646
reduction O 0 0.0004205173
in O 0 0.00027231371
glomeruli O 0 0.038701534
( O 0 0.000559931
23 O 0 0.00057215104
380 O 0 0.0037978168
+ O 0 0.000547956
/ O 0 0.0010483305
- O 0 0.0007185377
587 O 0 0.025748117
) O 0 0.00052485394
compared O 0 0.00018462921
with O 0 0.00039890895
control O 0 0.00048091525
rats O 0 0.003202917
( O 0 0.0013823754
P O 0 0.023413299
< O 0 0.0015664345
0 O 0 0.0015991712
. O 0 0.0015905533
05 O 0 0.030813007
) O 0 0.006343441
. O 0 0.0056524742

Male O 0 0.022383977
rats O 0 0.0059018745
that O 0 0.0014815227
received O 0 0.0018329237
prenatal O 0 0.029374324
dexamethasone B-Chemical 0 0.99690276
on O 0 0.0005771187
days O 0 0.0005566797
15 O 0 0.00036462984
and O 0 0.00036207572
16 O 0 0.00038219718
, O 0 0.00037111892
17 O 0 0.00037172902
and O 0 0.00025842004
18 O 0 0.0002791931
, O 0 0.00027207212
and O 0 0.00022195642
13 O 0 0.00025192456
and O 0 0.00019560625
14 O 0 0.00021133857
of O 0 0.00024199598
gestation O 0 0.0018065148
had O 0 0.000281865
elevated B-Disease 0 0.0038222207
blood I-Disease 0 0.0042428584
pressures I-Disease 0 0.005737287
at O 0 0.0001588913
6 O 0 0.00014640672
months O 0 0.00018163324
of O 0 0.0002500933
age O 0 0.00068459526
; O 0 0.000469738
the O 0 0.000240026
latter O 0 0.00073405745
group O 0 0.00048301197
did O 0 0.00036953692
not O 0 0.00039423216
have O 0 0.00060802576
a O 0 0.0010169205
reduction B-Disease 2 0.0023487816
in I-Disease 2 0.0020743567
glomerular I-Disease 2 0.78266084
number I-Disease 2 0.0053353948
. O 0 0.006459728

Adult O 0 0.009335517
rats O 0 0.00643192
given O 0 0.001891554
dexamethasone B-Chemical 0 0.9910607
on O 0 0.0008666559
days O 0 0.0008057278
15 O 0 0.00054038054
and O 0 0.000511703
16 O 0 0.0004991792
of O 0 0.0005756499
gestation O 0 0.002743593
had O 0 0.0006664123
more O 0 0.001065149
glomeruli O 0 0.06791748
with O 0 0.0029597734
glomerulosclerosis B-Disease 2 0.999376
than O 0 0.0024863912
control O 0 0.0035417292
rats O 0 0.019495416
. O 0 0.006280706

This O 0 0.004364485
study O 0 0.0027976935
shows O 0 0.0010209238
that O 0 0.001039427
prenatal O 0 0.03083456
dexamethasone B-Chemical 0 0.9980914
in O 0 0.0010535904
rats O 0 0.0037513948
results O 0 0.00051218516
in O 0 0.0004016784
a O 0 0.000494275
reduction B-Disease 2 0.00088744715
in I-Disease 2 0.00044718003
glomerular I-Disease 2 0.73652
number I-Disease 2 0.0006174271
, O 0 0.0018093995
glomerulosclerosis B-Disease 2 0.9997986
, O 0 0.0031735634
and O 0 0.0013531862
hypertension B-Disease 2 0.9994192
when O 0 0.0005804443
administered O 0 0.0018411463
at O 0 0.0004811055
specific O 0 0.00091315305
points O 0 0.0017842401
during O 0 0.0020679713
gestation O 0 0.021348549
. O 0 0.005278134

Hypertension B-Disease 0 0.98640335
was O 0 0.002826364
observed O 0 0.001214373
in O 0 0.00085507
animals O 0 0.00065672194
that O 0 0.0004843049
had O 0 0.0005669133
a O 0 0.0005873728
reduction O 0 0.0009150307
in O 0 0.00040328028
glomeruli O 0 0.031448737
as O 0 0.00026010585
well O 0 0.00021876852
as O 0 0.00019700197
in O 0 0.00020022698
a O 0 0.00025558838
group O 0 0.00028611007
that O 0 0.00017746892
did O 0 0.00019644883
not O 0 0.00017697127
have O 0 0.00022971099
a O 0 0.00029704202
reduction B-Disease 2 0.0006402965
in I-Disease 2 0.00028439186
glomerular I-Disease 2 0.6859563
number I-Disease 2 0.0003225146
, O 0 0.00040168775
suggesting O 0 0.00020879386
that O 0 0.00019123373
a O 0 0.00030466123
reduction B-Disease 2 0.0006597872
in I-Disease 2 0.00032040486
glomerular I-Disease 2 0.6420481
number I-Disease 2 0.00036939306
is O 0 0.00036970468
not O 0 0.00031942094
the O 0 0.00038617145
sole O 0 0.0013863754
cause O 0 0.0018687113
for O 0 0.0007523929
the O 0 0.0012146026
development O 0 0.004919424
of O 0 0.00864149
hypertension B-Disease 2 0.99845004
. O 0 0.009959808

Kidney O 0 0.26878947
function O 0 0.0037421642
and O 0 0.002095828
morphology O 0 0.0027697126
after O 0 0.00067843735
short O 0 0.0009298946
- O 0 0.0011747981
term O 0 0.00076672627
combination O 0 0.0018052747
therapy O 0 0.029846627
with O 0 0.0031985147
cyclosporine B-Chemical 1 0.9998957
A I-Chemical 0 0.7037875
, O 0 0.007194061
tacrolimus B-Chemical 0 0.99956447
and O 0 0.0056634084
sirolimus B-Chemical 1 0.9984485
in O 0 0.0032351695
the O 0 0.0040304707
rat O 0 0.043235052
. O 0 0.007056708

BACKGROUND O 0 0.8876815
: O 0 0.0142458705
Sirolimus B-Chemical 1 0.99356306
( O 0 0.0108385505
SRL B-Chemical 1 0.996876
) O 0 0.005322089
may O 0 0.002253758
supplement O 0 0.037419986
calcineurin O 0 0.9312373
inhibitors O 0 0.19823036
in O 0 0.0031943286
clinical O 0 0.041176308
organ O 0 0.26869306
transplantation O 0 0.5632686
. O 0 0.009898074

These O 0 0.006343127
are O 0 0.00486247
nephrotoxic B-Disease 2 0.99718285
, O 0 0.004750213
but O 0 0.0023765708
SRL B-Chemical 1 0.9977246
seems O 0 0.0013512141
to O 0 0.0006660339
act O 0 0.00091396814
differently O 0 0.00059097854
displaying O 0 0.0008363166
only O 0 0.00063680514
minor O 0 0.0032489097
nephrotoxic B-Disease 2 0.9992188
effects O 0 0.0072791437
, O 0 0.0012018902
although O 0 0.00072644843
this O 0 0.0008141211
question O 0 0.0011558861
is O 0 0.0016068867
still O 0 0.0022838938
open O 0 0.003949301
. O 0 0.0054021347

In O 0 0.002925712
a O 0 0.002113707
number O 0 0.0012836001
of O 0 0.0014411996
treatment O 0 0.0021364153
protocols O 0 0.0014579701
where O 0 0.001060297
SRL B-Chemical 1 0.9981325
was O 0 0.0008501953
combined O 0 0.0011023282
with O 0 0.0008285949
a O 0 0.0009472891
calcineurin O 0 0.9135346
inhibitor O 0 0.1596904
indications O 0 0.0020471886
of O 0 0.0011317973
a O 0 0.0013971194
synergistic O 0 0.06406522
nephrotoxic B-Disease 2 0.99888664
effect O 0 0.0051631858
were O 0 0.0035732873
described O 0 0.004321944
. O 0 0.0060076662

The O 0 0.002517446
aim O 0 0.0018807935
of O 0 0.0014173127
this O 0 0.000989543
study O 0 0.0011804338
was O 0 0.0006049639
to O 0 0.00042941756
examine O 0 0.00026267875
further O 0 0.00045921904
the O 0 0.0004678756
renal O 0 0.9598177
function O 0 0.0011042036
, O 0 0.00056921
including O 0 0.0003410104
morphological O 0 0.0033208905
analysis O 0 0.00048544307
of O 0 0.00039377916
the O 0 0.00032899049
kidneys O 0 0.020735633
of O 0 0.0006364898
male O 0 0.0079535255
Sprague O 0 0.46241876
- O 0 0.0011387147
Dawley O 0 0.2085988
rats O 0 0.0012868291
treated O 0 0.00058871764
with O 0 0.0004817698
either O 0 0.00075708475
cyclosporine B-Chemical 1 0.9999291
A I-Chemical 0 0.70733607
( O 0 0.007519241
CsA B-Chemical 1 0.9997745
) O 0 0.0066588554
, O 0 0.0021940812
tacrolimus B-Chemical 0 0.9998073
( O 0 0.009814617
FK506 B-Chemical 1 0.9996898
) O 0 0.00389621
or O 0 0.00085727876
SRL B-Chemical 1 0.99857545
as O 0 0.00096497126
monotherapies O 0 0.6539978
or O 0 0.0011201095
in O 0 0.0013003226
different O 0 0.0022186325
combinations O 0 0.0046636127
. O 0 0.005943872

METHODS O 0 0.006024136
: O 0 0.0028562502
For O 0 0.0010997421
a O 0 0.0010637064
period O 0 0.0007968681
of O 0 0.0008844546
2 O 0 0.00066468667
weeks O 0 0.00059000764
, O 0 0.00092362665
CsA B-Chemical 1 0.99904925
15 O 0 0.0006405382
mg O 0 0.32057524
/ O 0 0.001199713
kg O 0 0.0040111104
/ O 0 0.0006809809
day O 0 0.00030044504
( O 0 0.0003687434
given O 0 0.00020978865
orally O 0 0.029955506
) O 0 0.0008848689
, O 0 0.0006685583
FK506 B-Chemical 1 0.99938047
3 O 0 0.00039004372
. O 0 0.00017106808
0 O 0 0.0002965316
mg O 0 0.103025176
/ O 0 0.0006710059
kg O 0 0.0024171846
/ O 0 0.00049295987
day O 0 0.00022763098
( O 0 0.00029262085
given O 0 0.00016792488
orally O 0 0.021148346
) O 0 0.00060675683
or O 0 0.0003181269
SRL B-Chemical 1 0.9987251
0 O 0 0.0004454661
. O 0 0.0001477056
4 O 0 0.00019722394
mg O 0 0.09535939
/ O 0 0.0006309494
kg O 0 0.0023557856
/ O 0 0.00046728723
day O 0 0.00021189263
( O 0 0.00026987074
given O 0 0.00014980197
intraperitoneally O 0 0.007660718
) O 0 0.0004280827
was O 0 0.0001924505
administered O 0 0.00047118697
once O 0 0.0001777897
a O 0 0.00018636092
day O 0 0.00016268458
as O 0 0.00013610303
these O 0 0.00028430615
doses O 0 0.009426223
have O 0 0.00031390242
earlier O 0 0.00037755605
been O 0 0.00039526008
found O 0 0.00027247603
to O 0 0.00026351758
achieve O 0 0.0002980829
a O 0 0.0004743584
significant O 0 0.00084942323
immunosuppressive O 0 0.8954286
effect O 0 0.0020923344
in O 0 0.0021993017
Sprague O 0 0.5703808
- O 0 0.0075988253
Dawley O 0 0.38743114
rats O 0 0.012870168
. O 0 0.0066375206

In O 0 0.0031932476
the O 0 0.0022525704
' O 0 0.0023065382
conscious O 0 0.014690699
catheterized O 0 0.006461677
rat O 0 0.0046369266
' O 0 0.0010636131
model O 0 0.0010019247
, O 0 0.00083645084
the O 0 0.0005831912
glomerular O 0 0.6519667
filtration O 0 0.018955527
rate O 0 0.00086526375
( O 0 0.0014835803
GFR O 0 0.9881688
) O 0 0.0012363349
was O 0 0.0004629448
measured O 0 0.00035715481
as O 0 0.00046534682
the O 0 0.0008048556
clearance O 0 0.059806682
of O 0 0.0055365744
Cr O 1 0.99901056
( O 0 0.024715256
EDTA O 0 0.98601425
) O 0 0.012468304
. O 0 0.0069801067

The O 0 0.0028905356
morphological O 0 0.005386864
analysis O 0 0.0021372144
of O 0 0.0014663535
the O 0 0.0010401519
kidneys O 0 0.011769287
included O 0 0.000686209
a O 0 0.000727972
semi O 0 0.0023538452
- O 0 0.0008420171
quantitative O 0 0.0006570043
scoring O 0 0.0008774222
system O 0 0.0005128757
analysing O 0 0.0003523645
the O 0 0.00029904788
degree O 0 0.0004787276
of O 0 0.0006354443
striped O 0 0.023859393
fibrosis B-Disease 2 0.99669373
, O 0 0.0036681462
subcapsular O 0 0.9199926
fibrosis B-Disease 2 0.9955214
and O 0 0.0006462975
the O 0 0.00029149457
number O 0 0.00024678046
of O 0 0.00059484947
basophilic O 0 0.97673017
tubules O 0 0.08803288
, O 0 0.0004945492
plus O 0 0.00025628656
an O 0 0.00027146138
additional O 0 0.00013098659
stereological O 0 0.00192063
analysis O 0 0.00041448916
of O 0 0.00036183727
the O 0 0.00029718023
total O 0 0.00038289427
grade O 0 0.0832171
of O 0 0.0012947373
fibrosis B-Disease 2 0.99097425
in O 0 0.0011073337
the O 0 0.0013377563
cortex O 0 0.3039036
stained O 0 0.0026212963
with O 0 0.004436507
Sirius O 0 0.68864924
Red O 0 0.14814366
. O 0 0.0077519603

RESULTS O 0 0.067456976
: O 0 0.01380243
CsA B-Chemical 1 0.9966054
, O 0 0.011848492
FK506 B-Chemical 1 0.9980282
and O 0 0.008249726
SRL B-Chemical 1 0.99644995
all O 0 0.0034700392
significantly O 0 0.004389449
decreased O 0 0.008107869
the O 0 0.007993665
GFR O 0 0.9807341
. O 0 0.013028998

A O 0 0.013909696
further O 0 0.0035172577
deterioration O 0 0.10996354
was O 0 0.0016212612
seen O 0 0.0010673648
when O 0 0.0007967067
CsA B-Chemical 1 0.9990569
was O 0 0.0008915632
combined O 0 0.0011126689
with O 0 0.0007957458
either O 0 0.0008637987
FK506 B-Chemical 1 0.99960977
or O 0 0.0014173633
SRL B-Chemical 1 0.999498
, O 0 0.0010774605
whereas O 0 0.00036841308
the O 0 0.00034449602
GFR O 0 0.98031783
remained O 0 0.0006330544
unchanged O 0 0.00042313524
in O 0 0.0002308256
the O 0 0.00023330483
group O 0 0.00037811435
treated O 0 0.00069770816
with O 0 0.0008061278
FK506 B-Chemical 1 0.9996811
plus O 0 0.0020428484
SRL B-Chemical 1 0.9993393
when O 0 0.0003291169
compared O 0 0.00023083024
with O 0 0.00047763818
treatment O 0 0.0011841981
with O 0 0.0007717524
any O 0 0.0006781409
of O 0 0.0013113905
the O 0 0.0016983981
single O 0 0.0038278422
substances O 0 0.84715545
. O 0 0.00717641

The O 0 0.007792009
morphological O 0 0.015115146
changes O 0 0.008150418
presented O 0 0.006953738
a O 0 0.0075933323
similar O 0 0.006994525
pattern O 0 0.011619247
. O 0 0.0145172775

The O 0 0.0035203176
semi O 0 0.0067968164
- O 0 0.0030745163
quantitative O 0 0.002098062
scoring O 0 0.002416527
was O 0 0.00093015656
significantly O 0 0.000928257
worst O 0 0.003010893
in O 0 0.0004641303
the O 0 0.0004137107
group O 0 0.0005917622
treated O 0 0.0009586794
with O 0 0.0010861036
CsA B-Chemical 1 0.9997172
plus O 0 0.0040115295
SRL B-Chemical 1 0.99963665
( O 0 0.002712193
P O 0 0.072355
< O 0 0.00045874124
0 O 0 0.00029870312
. O 0 0.00015678549
001 O 0 0.029714264
compared O 0 0.00012575077
with O 0 0.00024304625
controls O 0 0.00041817516
) O 0 0.00039573532
and O 0 0.00020124539
the O 0 0.0001670803
analysis O 0 0.00029856415
of O 0 0.00027072735
the O 0 0.00020753432
total O 0 0.00023764092
grade O 0 0.07406413
of O 0 0.000744771
fibrosis B-Disease 2 0.9919328
also O 0 0.0005626973
showed O 0 0.00026748766
the O 0 0.0001979874
highest O 0 0.00023489649
proportion O 0 0.00015806759
in O 0 0.00016350241
the O 0 0.00016244804
same O 0 0.000116486895
group O 0 0.00029860882
and O 0 0.00027499293
was O 0 0.0002619415
significantly O 0 0.00035456545
different O 0 0.00035343875
from O 0 0.00046597596
controls O 0 0.0011064564
( O 0 0.0012741071
P O 0 0.023512036
< O 0 0.0014430082
0 O 0 0.0014571387
. O 0 0.0014164707
02 O 0 0.01873943
) O 0 0.0061148736
. O 0 0.005428251

The O 0 0.0049422327
FK506 B-Chemical 1 0.99648726
plus O 0 0.004965533
SRL B-Chemical 1 0.9977397
combination O 0 0.007139783
showed O 0 0.0010367029
only O 0 0.00071342976
a O 0 0.0006604676
marginally O 0 0.000939165
higher O 0 0.0004508149
degree O 0 0.00067808764
of O 0 0.0009814581
fibrosis B-Disease 2 0.9889319
as O 0 0.00060491374
compared O 0 0.0003659055
with O 0 0.00075665995
controls O 0 0.0015377393
( O 0 0.0016565006
P O 0 0.043007214
= O 0 0.0021697897
0 O 0 0.0017392542
. O 0 0.001636698
05 O 0 0.034098227
) O 0 0.0063472884
. O 0 0.0056120367

CONCLUSION O 0 0.8290964
: O 0 0.0050590453
This O 0 0.0027769634
rat O 0 0.004437012
study O 0 0.0017549851
demonstrated O 0 0.0010876718
a O 0 0.001125986
synergistic O 0 0.02443874
nephrotoxic B-Disease 2 0.9991893
effect O 0 0.0025691981
of O 0 0.003378394
CsA B-Chemical 1 0.99972767
plus O 0 0.008348181
SRL B-Chemical 1 0.9994312
, O 0 0.0029753298
whereas O 0 0.0017770748
FK506 B-Chemical 1 0.99933165
plus O 0 0.006195403
SRL B-Chemical 1 0.99836475
was O 0 0.0031187406
better O 0 0.004519395
tolerated O 0 0.07094785
. O 0 0.006417288

Evaluation O 0 0.008415365
of O 0 0.0043441346
cardiac O 0 0.34972706
troponin O 0 0.9557476
I O 0 0.011711976
and O 0 0.0018462903
T O 0 0.24957228
levels O 0 0.0008210807
as O 0 0.0005036463
markers O 0 0.0012718242
of O 0 0.0016027633
myocardial B-Disease 0 0.99958354
damage I-Disease 0 0.9922593
in O 0 0.0024834224
doxorubicin B-Chemical 1 0.9996377
- O 0 0.009980648
induced O 0 0.0051221154
cardiomyopathy B-Disease 2 0.9998336
rats O 0 0.035978094
, O 0 0.0007794767
and O 0 0.00046037303
their O 0 0.0004667395
relationship O 0 0.00043168478
with O 0 0.0010277134
echocardiographic O 0 0.14374864
and O 0 0.0026333965
histological O 0 0.365288
findings O 0 0.017081315
. O 0 0.006436645

BACKGROUND O 0 0.8477276
: O 0 0.010044803
Cardiac O 0 0.73547757
troponins O 0 0.9472338
I O 0 0.023436183
( O 0 0.0040290356
cTnI O 0 0.4971676
) O 0 0.0024165795
and O 0 0.0013331579
T O 0 0.44306937
( O 0 0.0020451983
cTnT O 0 0.8382686
) O 0 0.0012047808
have O 0 0.00052203995
been O 0 0.00054887903
shown O 0 0.00031163503
to O 0 0.00035770424
be O 0 0.00041996405
highly O 0 0.0005996513
sensitive O 0 0.0005682533
and O 0 0.0005941797
specific O 0 0.0007614517
markers O 0 0.0024774403
of O 0 0.0042743203
myocardial B-Disease 0 0.9982169
cell I-Disease 0 0.39828604
injury I-Disease 0 0.98828924
. O 0 0.010063982

We O 0 0.0030007714
investigated O 0 0.0020264054
the O 0 0.0014597888
diagnostic O 0 0.0019072726
value O 0 0.0011321304
of O 0 0.0014825424
cTnI O 0 0.4627307
and O 0 0.0012520452
cTnT O 0 0.6832602
for O 0 0.0004917809
the O 0 0.00047006746
diagnosis O 0 0.0053367238
of O 0 0.001253929
myocardial B-Disease 0 0.9995937
damage I-Disease 0 0.981864
in O 0 0.0005862944
a O 0 0.0005231921
rat O 0 0.004779453
model O 0 0.00054949336
of O 0 0.0009863522
doxorubicin B-Chemical 1 0.99957246
( O 0 0.010311283
DOX B-Chemical 1 0.9996014
) O 0 0.006923042
- O 0 0.0014145296
induced O 0 0.0015601969
cardiomyopathy B-Disease 2 0.999838
, O 0 0.0008240486
and O 0 0.00026273832
we O 0 9.893957e-05
examined O 0 0.00013358485
the O 0 0.00015527333
relationship O 0 0.00014428902
between O 0 0.00012859885
serial O 0 0.00084800157
cTnI O 0 0.4825389
and O 0 0.00049983227
cTnT O 0 0.75474346
with O 0 0.00040022001
the O 0 0.00027788573
development O 0 0.0007467466
of O 0 0.0006009859
cardiac B-Disease 0 0.8674876
disorders I-Disease 0 0.94394565
monitored O 0 0.0003695253
by O 0 0.00055870146
echocardiography O 0 0.17041071
and O 0 0.0009202672
histological O 0 0.14918078
examinations O 0 0.0039525903
in O 0 0.0013697376
this O 0 0.0021864376
model O 0 0.004883334
. O 0 0.0054650926

METHODS O 0 0.0070489435
: O 0 0.0038520393
Thirty O 0 0.004781497
- O 0 0.002046137
five O 0 0.0008058199
Wistar O 0 0.057793066
rats O 0 0.0021410158
were O 0 0.00058667513
given O 0 0.00040110442
1 O 0 0.00048050968
. O 0 0.00026010288
5 O 0 0.0003230174
mg O 0 0.09300981
/ O 0 0.0010619512
kg O 0 0.0116214305
DOX B-Chemical 1 0.9983242
, O 0 0.00085419737
i O 0 0.0014392232
. O 0 0.0002488657
v O 0 0.0028507758
. O 0 0.00018212141
, O 0 0.0002672422
weekly O 0 0.00034443723
for O 0 0.00017568744
up O 0 0.00020896057
to O 0 0.00018601191
8 O 0 0.00018430964
weeks O 0 0.00016852542
for O 0 0.00016039952
a O 0 0.00026253174
total O 0 0.00027245318
cumulative O 0 0.0011315456
dose O 0 0.0058912854
of O 0 0.0010594771
12 O 0 0.0010941821
mg O 0 0.3368646
/ O 0 0.0057975026
kg O 0 0.03132637
BW O 0 0.32358927
. O 0 0.005985292

Ten O 0 0.012471311
rats O 0 0.011511626
received O 0 0.0066853617
saline O 0 0.041287348
as O 0 0.004853252
a O 0 0.006240325
control O 0 0.006619267
group O 0 0.012135577
. O 0 0.012782695

cTnI O 0 0.2659572
was O 0 0.003106973
measured O 0 0.001663388
with O 0 0.002283632
Access O 0 0.007818619
( O 0 0.002637075
R O 0 0.66998684
) O 0 0.0021812061
( O 0 0.0011321942
ng O 0 0.0017616086
/ O 0 0.0013774656
ml O 0 0.0021636002
) O 0 0.0006873407
and O 0 0.00035161452
a O 0 0.000385013
research O 0 0.0007198509
immunoassay O 0 0.036283575
( O 0 0.00087497354
pg O 0 0.012395927
/ O 0 0.0014023813
ml O 0 0.0026878293
) O 0 0.0007737734
, O 0 0.0004743709
and O 0 0.00038683027
compared O 0 0.0003027915
with O 0 0.0009927304
cTnT O 0 0.9092987
, O 0 0.003093869
CK O 0 0.9930587
- O 0 0.015722211
MB O 0 0.99485177
mass O 0 0.046132524
and O 0 0.0069157872
CK O 0 0.9825334
. O 0 0.009593601

By O 0 0.00507809
using O 0 0.0024776312
transthoracic O 0 0.039847
echocardiography O 0 0.24650724
, O 0 0.0025681695
anterior O 0 0.0071672355
and O 0 0.0011392898
posterior O 0 0.00774502
wall O 0 0.03060963
thickness O 0 0.12324866
, O 0 0.0014579548
LV O 0 0.99068916
diameters O 0 0.027043255
and O 0 0.0008292572
LV O 0 0.9925713
fractional O 0 0.07951964
shortening O 0 0.062448107
( O 0 0.0010746231
FS O 0 0.21249798
) O 0 0.0006808874
were O 0 0.00024103714
measured O 0 0.00016645409
in O 0 0.000191399
all O 0 0.00020446576
rats O 0 0.000935823
before O 0 0.00021449674
DOX B-Chemical 1 0.99769634
or O 0 0.00038626758
saline O 0 0.094420776
, O 0 0.00043502072
and O 0 0.00026969402
at O 0 0.00016358773
weeks O 0 0.0002516456
6 O 0 0.00020726083
and O 0 0.00029090594
9 O 0 0.00033068127
after O 0 0.0002584954
treatment O 0 0.0010741564
in O 0 0.0008322225
all O 0 0.0013636202
surviving O 0 0.008327044
rats O 0 0.01428689
. O 0 0.0055834716

Histology O 0 0.13985962
was O 0 0.002902731
performed O 0 0.002025799
in O 0 0.002021499
DOX B-Chemical 1 0.99691904
- O 0 0.0031971831
rats O 0 0.0027298774
at O 0 0.00044823374
6 O 0 0.0003792329
and O 0 0.00040387508
9 O 0 0.000347148
weeks O 0 0.00028963876
after O 0 0.00021467454
the O 0 0.00037586706
last O 0 0.00058228703
DOX B-Chemical 1 0.99663806
dose O 0 0.03498654
and O 0 0.0016154959
in O 0 0.0015458042
all O 0 0.0022270267
controls O 0 0.005890639
. O 0 0.0056288317

RESULTS O 0 0.027211122
: O 0 0.0049932078
Eighteen O 0 0.0061637554
of O 0 0.002146464
the O 0 0.0019456334
DOX B-Chemical 1 0.9961212
rats O 0 0.018619107
died O 0 0.022734463
prematurely O 0 0.009179753
of O 0 0.0012732574
general O 0 0.0015644917
toxicity B-Disease 2 0.98106456
during O 0 0.0010192703
the O 0 0.0012471392
9 O 0 0.0015950705
- O 0 0.0023482386
week O 0 0.0020749231
period O 0 0.003705027
. O 0 0.005122064

End O 0 0.043411598
- O 0 0.008712381
diastolic O 0 0.9375447
( O 0 0.004282767
ED O 0 0.20099638
) O 0 0.0021144354
and O 0 0.0009298747
end O 0 0.0005850351
- O 0 0.0015325142
systolic O 0 0.71322465
( O 0 0.0013811738
ES O 0 0.15276514
) O 0 0.0017483416
LV O 0 0.99044025
diameters O 0 0.03216927
/ O 0 0.001755657
BW O 0 0.2495651
significantly O 0 0.0005587307
increased O 0 0.0008308834
, O 0 0.0006201536
whereas O 0 0.0005167392
LV O 0 0.99474066
FS O 0 0.31683657
was O 0 0.0003736791
decreased O 0 0.0005822334
after O 0 0.0001817564
9 O 0 0.00025589517
weeks O 0 0.00023547436
in O 0 0.0002563772
the O 0 0.00047456988
DOX B-Chemical 1 0.9973828
group O 0 0.0014525709
( O 0 0.0012710486
p O 0 0.0013478749
< O 0 0.0013651976
0 O 0 0.0015052438
. O 0 0.0015546608
001 O 0 0.13263817
) O 0 0.006715663
. O 0 0.0057154917

These O 0 0.011520099
parameters O 0 0.011048299
remained O 0 0.010173892
unchanged O 0 0.0103756245
in O 0 0.010213884
controls O 0 0.018108215
. O 0 0.017026043

Histological O 0 0.17029943
evaluation O 0 0.003759028
of O 0 0.002453042
hearts O 0 0.006628096
from O 0 0.0010740049
all O 0 0.0007915855
rats O 0 0.0024049033
given O 0 0.00078315096
DOX B-Chemical 1 0.99653256
revealed O 0 0.001200301
significant O 0 0.0012413957
slight O 0 0.0018324641
degrees O 0 0.0042471234
of O 0 0.0025908104
perivascular O 0 0.7193912
and O 0 0.0068933717
interstitial O 0 0.9860299
fibrosis B-Disease 2 0.99718386
. O 0 0.015842997

In O 0 0.0040208474
7 O 0 0.0025379013
of O 0 0.0023140472
the O 0 0.0019031815
18 O 0 0.0021314644
rats O 0 0.005306119
, O 0 0.003427986
degeneration O 0 0.96475875
and O 0 0.004295393
myocyte O 0 0.9532616
vacuolisation O 0 0.9586149
were O 0 0.0058073783
found O 0 0.0062755025
. O 0 0.0076766512

Only O 0 0.0050709546
five O 0 0.0020670032
of O 0 0.002520789
the O 0 0.001919959
controls O 0 0.002358035
exhibited O 0 0.0018774753
evidence O 0 0.0021287606
of O 0 0.0029339122
very O 0 0.0045580906
slight O 0 0.013830889
perivascular O 0 0.92273736
fibrosis B-Disease 2 0.9916583
. O 0 0.015711967

A O 0 0.016726052
significant O 0 0.0037310517
rise O 0 0.0034001055
in O 0 0.0018574903
cTnT O 0 0.65570325
was O 0 0.0011670653
found O 0 0.0007779696
in O 0 0.00072711497
DOX B-Chemical 1 0.99737096
rats O 0 0.0039676577
after O 0 0.00026094588
cumulative O 0 0.0013023763
doses O 0 0.017099649
of O 0 0.00056672335
7 O 0 0.00031536687
. O 0 0.00015893114
5 O 0 0.00017572983
and O 0 0.00020107202
12 O 0 0.00020070159
mg O 0 0.07533346
/ O 0 0.00066688657
kg O 0 0.0014833981
in O 0 0.00022422946
comparison O 0 0.00026587513
with O 0 0.0004818435
baseline O 0 0.0008941056
( O 0 0.0009938773
p O 0 0.0011927787
< O 0 0.0013004018
0 O 0 0.0014719609
. O 0 0.0015188697
05 O 0 0.0285895
) O 0 0.006201683
. O 0 0.0055548456

cTnT O 0 0.63243484
found O 0 0.002890808
in O 0 0.0015880936
rats O 0 0.0027441445
after O 0 0.0006263759
12 O 0 0.0006546894
mg O 0 0.1353405
/ O 0 0.0013418557
kg O 0 0.0023700038
were O 0 0.00037740738
significantly O 0 0.00041933276
greater O 0 0.0003495084
than O 0 0.000245508
that O 0 0.00030017472
found O 0 0.0003923446
after O 0 0.0003222862
7 O 0 0.00052014005
. O 0 0.00044696164
5 O 0 0.0008503238
mg O 0 0.14473085
/ O 0 0.0051821065
kg O 0 0.05289267
DOX B-Chemical 1 0.9925184
. O 0 0.007869771

Maximal O 0 0.057287946
cTnI O 0 0.5130622
( O 0 0.004598497
pg O 0 0.014681275
/ O 0 0.0034817064
ml O 0 0.004492678
) O 0 0.0016659951
and O 0 0.00093786314
cTnT O 0 0.61797345
levels O 0 0.0005921637
were O 0 0.00043774437
significantly O 0 0.000526161
increased O 0 0.0007879005
in O 0 0.0005600476
DOX B-Chemical 1 0.99874854
rats O 0 0.006829668
compared O 0 0.00025383502
with O 0 0.00048331462
controls O 0 0.0008588383
( O 0 0.0007517035
p O 0 0.0008150141
= O 0 0.0008791043
0 O 0 0.000667233
. O 0 0.0005222355
006 O 0 0.015841972
, O 0 0.0014246105
0 O 0 0.001674621
. O 0 0.0016088485
007 O 0 0.051058393
) O 0 0.0067758234
. O 0 0.0057689073

cTnI O 0 0.47907552
( O 0 0.006390591
ng O 0 0.0063935774
/ O 0 0.0046467837
ml O 0 0.006459886
) O 0 0.0029802094
, O 0 0.002246407
CK O 0 0.98449695
- O 0 0.0065237265
MB O 0 0.9957411
mass O 0 0.0092094615
and O 0 0.0012501559
CK O 0 0.9673318
remained O 0 0.0016568186
unchanged O 0 0.0013682955
in O 0 0.0013308813
DOX B-Chemical 1 0.99738187
rats O 0 0.011798829
compared O 0 0.0013515443
with O 0 0.0032646258
controls O 0 0.0071268124
. O 0 0.0063153277

All O 0 0.00993997
markers O 0 0.011185427
remained O 0 0.010455391
stable O 0 0.01134991
in O 0 0.010690207
controls O 0 0.018660385
. O 0 0.0176113

Analysis O 0 0.0069307312
of O 0 0.0027914043
data O 0 0.0019885283
revealed O 0 0.0013895074
a O 0 0.0010949883
significant O 0 0.0009142969
correlation O 0 0.00046648554
between O 0 0.00038231688
maximal O 0 0.0010643512
cTnT O 0 0.77725637
and O 0 0.0009554388
ED O 0 0.25402972
and O 0 0.00091302604
ES O 0 0.31622607
LV O 0 0.9956786
diameters O 0 0.05441028
/ O 0 0.0025165528
BW O 0 0.37650502
( O 0 0.00068856607
r O 0 0.0005083147
= O 0 0.0005293942
0 O 0 0.0003274447
. O 0 0.00018321033
81 O 0 0.00048672006
and O 0 0.00034312546
0 O 0 0.00044506736
. O 0 0.00028458712
65 O 0 0.00069628074
; O 0 0.00094088877
p O 0 0.0010602908
< O 0 0.0012441794
0 O 0 0.001453181
. O 0 0.0015317394
0001 O 0 0.032340266
) O 0 0.006598318
. O 0 0.0058629285

A O 0 0.012567095
significant O 0 0.0028329066
relationship O 0 0.0013620367
was O 0 0.0011640575
observed O 0 0.00072378997
between O 0 0.0005019581
maximal O 0 0.0011810535
cTnT O 0 0.6141002
and O 0 0.0006932315
the O 0 0.00044599402
extent O 0 0.00034320672
of O 0 0.00078140263
myocardial O 0 0.99734575
morphological O 0 0.043960474
changes O 0 0.0015030038
, O 0 0.0008130528
and O 0 0.00063267356
between O 0 0.0005573661
LV O 0 0.9886929
diameters O 0 0.042637564
/ O 0 0.0044592596
BW O 0 0.2759288
and O 0 0.0027553234
histological O 0 0.2666247
findings O 0 0.014965722
. O 0 0.006962147

CONCLUSIONS O 0 0.72448677
: O 0 0.005702878
Among O 0 0.0045991475
markers O 0 0.0032471793
of O 0 0.0036186238
ischemic B-Disease 0 0.9992637
injury I-Disease 0 0.99458885
after O 0 0.0012389702
DOX B-Chemical 1 0.9988619
in O 0 0.00094792247
rats O 0 0.008485732
, O 0 0.001017708
cTnT O 0 0.7237968
showed O 0 0.00042044395
the O 0 0.00032397776
greatest O 0 0.00071989413
ability O 0 0.00039241326
to O 0 0.00036369197
detect O 0 0.00045099732
myocardial B-Disease 0 0.9991042
damage I-Disease 0 0.94046223
assessed O 0 0.0008256767
by O 0 0.001010529
echocardiographic O 0 0.15844344
detection O 0 0.0020820573
and O 0 0.0026401265
histological O 0 0.3164039
changes O 0 0.00931644
. O 0 0.0062866574

Although O 0 0.003042422
there O 0 0.0014523322
was O 0 0.0013414256
a O 0 0.0011319699
discrepancy O 0 0.0010036586
between O 0 0.0004207366
the O 0 0.0005109506
amount O 0 0.00037796493
of O 0 0.00096934824
cTnI O 0 0.6001283
and O 0 0.0009865245
cTnT O 0 0.83222383
after O 0 0.00044272377
DOX B-Chemical 1 0.9987753
, O 0 0.0007866511
probably O 0 0.0005744981
due O 0 0.00018800257
to O 0 0.00022739888
heterogeneity O 0 0.000493749
in O 0 0.00025548972
cross O 0 0.00059722125
- O 0 0.00061649247
reactivities O 0 0.016455274
of O 0 0.00049023255
mAbs O 0 0.0011890352
to O 0 0.00031617424
various O 0 0.0011706199
cTnI O 0 0.6643041
and O 0 0.0006408011
cTnT O 0 0.8666369
forms O 0 0.0006510914
, O 0 0.00047643203
it O 0 0.0003041771
is O 0 0.00023397671
likely O 0 0.00021164083
that O 0 0.00023665465
cTnT O 0 0.735822
in O 0 0.00026605063
rats O 0 0.00145212
after O 0 0.00020220828
DOX B-Chemical 1 0.9985947
indicates O 0 0.00033454865
cell O 0 0.010256789
damage O 0 0.41378787
determined O 0 0.00024823932
by O 0 0.0002654228
the O 0 0.00021017347
magnitude O 0 0.0002427711
of O 0 0.00051998673
injury O 0 0.84968823
induced O 0 0.0008981554
and O 0 0.00040123676
that O 0 0.00031553255
cTnT O 0 0.79754496
should O 0 0.00018139559
be O 0 0.00021797171
a O 0 0.00021916624
useful O 0 0.00028649523
marker O 0 0.0003145165
for O 0 0.00020229121
the O 0 0.0002385092
prediction O 0 0.0003317777
of O 0 0.00051039
experimentally O 0 0.001151206
induced O 0 0.003055978
cardiotoxicity B-Disease 0 0.9998072
and O 0 0.0020834953
possibly O 0 0.004895623
for O 0 0.0019522859
cardioprotective O 0 0.927012
experiments O 0 0.0051624337
. O 0 0.00665376

Octreotide B-Chemical 0 0.9965287
- O 0 0.01493016
induced O 0 0.009263811
hypoxemia B-Disease 0 0.99424887
and O 0 0.010452136
pulmonary B-Disease 2 0.9938334
hypertension I-Disease 2 0.99939215
in O 0 0.010395563
premature O 0 0.37544265
neonates O 0 0.15565582
. O 0 0.011029386

The O 0 0.0032002665
authors O 0 0.0031697662
report O 0 0.004266624
2 O 0 0.0017129879
cases O 0 0.001994629
of O 0 0.0016996419
premature O 0 0.03425605
neonates O 0 0.020606318
who O 0 0.0041025546
had O 0 0.0029717444
enterocutaneous O 0 0.9780844
fistula B-Disease 0 0.98133206
complicating O 0 0.98194546
necrotizing B-Disease 0 0.9994573
enterocolitis I-Disease 0 0.9987294
. O 0 0.027748963

Pulmonary B-Disease 0 0.96709865
hypertension I-Disease 2 0.9985985
developed O 0 0.0062335124
after O 0 0.0012611353
administration O 0 0.043855164
of O 0 0.0016129615
a O 0 0.0017773642
somatostatin O 0 0.9903266
analogue O 0 0.30476853
, O 0 0.0027804011
octreotide B-Chemical 1 0.99809223
, O 0 0.0018536608
to O 0 0.0009738916
enhance O 0 0.0011102775
resolution O 0 0.010738789
of O 0 0.0033651812
the O 0 0.0047849906
fistula B-Disease 0 0.78301096
. O 0 0.008834202

The O 0 0.002523555
authors O 0 0.0021989108
discuss O 0 0.0013600294
the O 0 0.0010587672
mechanism O 0 0.0011568811
of O 0 0.0009121699
the O 0 0.0006466795
occurrence O 0 0.0012463067
of O 0 0.00072013325
this O 0 0.0006051951
complication O 0 0.13959013
and O 0 0.00051947567
recommend O 0 0.00042306306
caution O 0 0.00070174364
of O 0 0.00059149356
its O 0 0.0011470583
use O 0 0.0008597074
in O 0 0.00072815793
high O 0 0.0017635587
- O 0 0.0032489393
risk O 0 0.06793917
premature O 0 0.26428127
neonates O 0 0.11760103
. O 0 0.0068399995

The O 0 0.003548796
risk O 0 0.010193753
of O 0 0.0034999307
venous B-Disease 0 0.79976803
thromboembolism I-Disease 0 0.9994474
in O 0 0.0024867852
women O 0 0.10095204
prescribed O 0 0.515611
cyproterone B-Chemical 0 0.99993706
acetate I-Chemical 0 0.9977189
in O 0 0.0009273275
combination O 0 0.003968103
with O 0 0.0034610247
ethinyl B-Chemical 0 0.9999001
estradiol I-Chemical 1 0.9997296
: O 0 0.0021902826
a O 0 0.00061673374
nested O 0 0.00093158585
cohort O 0 0.0016478301
analysis O 0 0.0011286852
and O 0 0.0011075636
case O 0 0.0016014872
- O 0 0.002777819
control O 0 0.0022468818
study O 0 0.005600354
. O 0 0.005527933

BACKGROUND O 0 0.923171
: O 0 0.018907303
Cyproterone B-Chemical 0 0.9993168
acetate I-Chemical 0 0.9951302
combined O 0 0.008909796
with O 0 0.008407554
ethinyl B-Chemical 0 0.99984026
estradiol I-Chemical 1 0.9997471
( O 0 0.031818654
CPA B-Chemical 1 0.998616
/ O 0 0.020935658
EE B-Chemical 1 0.97027844
) O 0 0.0015568021
is O 0 0.0004352989
licensed O 0 0.0012075854
in O 0 0.00027365226
the O 0 0.00029736676
UK O 0 0.0027174111
for O 0 0.00020982504
the O 0 0.00023375977
treatment O 0 0.000663134
of O 0 0.0004929077
women O 0 0.022164678
with O 0 0.00091771304
acne B-Disease 2 0.99760383
and O 0 0.001824103
hirsutism B-Disease 0 0.99919444
and O 0 0.000725099
is O 0 0.00039508412
also O 0 0.0003723937
a O 0 0.00040777618
treatment O 0 0.0010155966
option O 0 0.0009474795
for O 0 0.0008789472
polycystic B-Disease 0 0.9980628
ovary I-Disease 0 0.9675308
syndrome I-Disease 0 0.98923326
( O 0 0.029309148
PCOS B-Disease 2 0.99650574
) O 0 0.014772771
. O 0 0.0072229165

Previous O 0 0.0041527143
studies O 0 0.0032437611
have O 0 0.0019070493
demonstrated O 0 0.0014793341
an O 0 0.0014284177
increased O 0 0.0016472898
risk O 0 0.020408126
of O 0 0.0019103268
venous B-Disease 0 0.9445082
thromboembolism I-Disease 0 0.99986017
( O 0 0.032544434
VTE B-Disease 2 0.99951434
) O 0 0.0030984636
associated O 0 0.0010702962
with O 0 0.0013985691
CPA B-Chemical 1 0.99823135
/ O 0 0.00792208
EE B-Chemical 1 0.8555583
compared O 0 0.00033931536
with O 0 0.00059039245
conventional O 0 0.0010618237
combined O 0 0.012045038
oral B-Chemical 1 0.9725002
contraceptives I-Chemical 1 0.9994124
( O 0 0.027520992
COCs O 0 0.9505086
) O 0 0.011065579
. O 0 0.00671476

We O 0 0.003440315
believe O 0 0.0024936846
the O 0 0.0016837545
results O 0 0.0013773233
of O 0 0.0016479273
those O 0 0.0017124538
studies O 0 0.0017796837
may O 0 0.0012417204
have O 0 0.0013783041
been O 0 0.001759069
affected O 0 0.0015694475
by O 0 0.0023886678
residual O 0 0.0044000894
confounding O 0 0.009772758
. O 0 0.008028519

METHODS O 0 0.006367497
: O 0 0.0032746582
Using O 0 0.0019223318
the O 0 0.001374656
General O 0 0.0038513695
Practice O 0 0.0072332774
Research O 0 0.009746435
Database O 0 0.0027549535
we O 0 0.00029089127
conducted O 0 0.00036885485
a O 0 0.0004124705
cohort O 0 0.0008744801
analysis O 0 0.0005724183
and O 0 0.0003968961
case O 0 0.00041565282
- O 0 0.00046606042
control O 0 0.00018705061
study O 0 0.00032791926
nested O 0 0.00035274617
within O 0 0.00012344906
a O 0 0.00023625947
population O 0 0.00033698973
of O 0 0.00034381784
women O 0 0.007038139
aged O 0 0.00047078266
between O 0 0.00010975855
15 O 0 0.0001595225
and O 0 0.00018929965
39 O 0 0.00036049343
years O 0 0.00045207792
with O 0 0.00051219435
acne B-Disease 2 0.996014
, O 0 0.0023822845
hirsutism B-Disease 0 0.99899536
or O 0 0.00085302244
PCOS B-Disease 2 0.9981298
to O 0 0.00040622306
estimate O 0 0.00031080423
the O 0 0.0004958671
risk O 0 0.018799638
of O 0 0.0026814726
VTE B-Disease 2 0.9989838
associated O 0 0.0069885403
with O 0 0.011015893
CPA B-Chemical 1 0.9969662
/ O 0 0.09680481
EE B-Chemical 1 0.96418756
. O 0 0.0086504575

RESULTS O 0 0.02557161
: O 0 0.0040531596
The O 0 0.0015833465
age O 0 0.0026130166
- O 0 0.0017209756
adjusted O 0 0.0011148932
incidence O 0 0.002434706
rate O 0 0.0006628642
ratio O 0 0.00086738076
for O 0 0.00070992607
CPA B-Chemical 1 0.9972318
/ O 0 0.00586424
EE B-Chemical 1 0.8595537
versus O 0 0.0004529633
conventional O 0 0.0007040835
COCs O 0 0.6697965
was O 0 0.0003960742
2 O 0 0.00031741915
. O 0 0.00016892959
20 O 0 0.0003020522
[ O 0 0.0004960644
95 O 0 0.000508508
% O 0 0.00024842258
confidence O 0 0.00060377346
interval O 0 0.0005979115
( O 0 0.0006853793
CI O 0 0.09285124
) O 0 0.000827775
1 O 0 0.0005299001
. O 0 0.00038334494
35 O 0 0.0008219409
- O 0 0.0012673844
3 O 0 0.000984929
. O 0 0.0011160466
58 O 0 0.0037035067
] O 0 0.0063485396
. O 0 0.0049462887

Using O 0 0.0039356505
as O 0 0.0017631968
the O 0 0.001333563
reference O 0 0.0011638086
group O 0 0.0012836349
women O 0 0.0055325483
who O 0 0.0014332511
were O 0 0.00051658857
not O 0 0.00040482116
using O 0 0.0004265383
oral O 0 0.52513456
contraception O 0 0.8765241
, O 0 0.0007044143
had O 0 0.00036088753
no O 0 0.00022674567
recent O 0 0.0004055624
pregnancy O 0 0.14505096
or O 0 0.0004918906
menopausal O 0 0.99917716
symptoms O 0 0.94306827
, O 0 0.00064904866
the O 0 0.00025699663
case O 0 0.00032785488
- O 0 0.00038986356
control O 0 0.00015970423
analysis O 0 0.00032276683
gave O 0 0.00033749064
an O 0 0.00030116655
adjusted O 0 0.0004019812
odds O 0 0.0022452576
ratio O 0 0.0005649385
( O 0 0.0006433553
OR O 0 0.06313041
( O 0 0.0006699475
adj O 0 0.085205734
) O 0 0.0006645271
) O 0 0.00042472853
of O 0 0.00030361878
7 O 0 0.00022935643
. O 0 0.00013979289
44 O 0 0.00035047802
( O 0 0.00029165077
95 O 0 0.0005112281
% O 0 0.00027494732
CI O 0 0.020128617
3 O 0 0.0001884065
. O 0 0.00013493563
67 O 0 0.00043463957
- O 0 0.0003539251
15 O 0 0.0001892316
. O 0 0.00015316304
08 O 0 0.002468569
) O 0 0.00043356657
for O 0 0.00028964068
CPA B-Chemical 1 0.9962819
/ O 0 0.0031618702
EE B-Chemical 1 0.85711014
use O 0 0.00042982958
compared O 0 0.00016458514
with O 0 0.00032929835
an O 0 0.00053066097
OR O 0 0.082842074
( O 0 0.0006879954
adj O 0 0.06482565
) O 0 0.00051258074
of O 0 0.0003448203
2 O 0 0.00029382991
. O 0 0.0001564131
58 O 0 0.00041790158
( O 0 0.00032887165
95 O 0 0.0005769765
% O 0 0.0003228373
CI O 0 0.022948598
1 O 0 0.00026904375
. O 0 0.00016520779
60 O 0 0.00032802773
- O 0 0.00044732096
4 O 0 0.00026396615
. O 0 0.0002208848
18 O 0 0.0004204269
) O 0 0.00064717955
for O 0 0.0004916778
use O 0 0.0011082613
of O 0 0.0019930794
conventional O 0 0.0052139317
COCs O 0 0.8570668
. O 0 0.0069143143

CONCLUSIONS O 0 0.67033833
: O 0 0.0045854896
We O 0 0.0016363702
have O 0 0.0013222634
demonstrated O 0 0.0011152134
an O 0 0.0011409224
increased O 0 0.0014000488
risk O 0 0.027118662
of O 0 0.002145828
VTE B-Disease 2 0.99924785
associated O 0 0.0017373213
with O 0 0.00073800085
the O 0 0.00043665184
use O 0 0.00059608987
of O 0 0.0009927654
CPA B-Chemical 1 0.9984884
/ O 0 0.009922805
EE B-Chemical 1 0.9384704
in O 0 0.00049786206
women O 0 0.01927227
with O 0 0.0010681363
acne B-Disease 2 0.99784946
, O 0 0.004028923
hirsutism B-Disease 0 0.99904364
or O 0 0.001089797
PCOS B-Disease 2 0.9982066
although O 0 0.0006019099
residual O 0 0.0007468715
confounding O 0 0.0012481082
by O 0 0.0010118647
indication O 0 0.0014132997
cannot O 0 0.006448976
be O 0 0.0029552318
excluded O 0 0.005340413
. O 0 0.0058730505

The O 0 0.0031667466
effect O 0 0.002713875
of O 0 0.0024718444
treatment O 0 0.0038014646
with O 0 0.002839099
gum B-Chemical 1 0.93452954
Arabic I-Chemical 1 0.5517472
on O 0 0.0017658653
gentamicin B-Chemical 1 0.99882466
nephrotoxicity B-Disease 0 0.9998266
in O 0 0.0033381633
rats O 0 0.015810896
: O 0 0.0032161833
a O 0 0.0025865051
preliminary O 0 0.005547002
study O 0 0.007335472
. O 0 0.007003991

In O 0 0.002609554
the O 0 0.0016024954
present O 0 0.0009923554
work O 0 0.001182155
we O 0 0.00046367262
assessed O 0 0.0004988501
the O 0 0.00049639144
effect O 0 0.0005825074
of O 0 0.0006483367
treatment O 0 0.0013662947
of O 0 0.000783066
rats O 0 0.005016623
with O 0 0.001005765
gum B-Chemical 1 0.94889057
Arabic I-Chemical 1 0.5274662
on O 0 0.0005668314
acute B-Disease 0 0.9702304
renal I-Disease 0 0.9973393
failure I-Disease 0 0.9158745
induced O 0 0.0052690865
by O 0 0.0037731186
gentamicin B-Chemical 1 0.9984769
( O 0 0.0128459325
GM B-Chemical 0 0.9749307
) O 0 0.070385456
nephrotoxicity B-Disease 0 0.99929905
. O 0 0.012257406

Rats O 0 0.040060952
were O 0 0.0026696979
treated O 0 0.0026395128
with O 0 0.0016104279
the O 0 0.0012180071
vehicle O 0 0.017510992
( O 0 0.0014429194
2 O 0 0.00070957566
mL O 0 0.0023109866
/ O 0 0.0008773879
kg O 0 0.0015258598
of O 0 0.000444499
distilled O 0 0.004948848
water O 0 0.0051538255
and O 0 0.00047174178
5 O 0 0.00032598732
% O 0 0.000369119
w O 0 0.0007906929
/ O 0 0.0010294685
v O 0 0.007882936
cellulose O 0 0.5704398
, O 0 0.00057358004
10 O 0 0.00032015206
days O 0 0.0002794389
) O 0 0.0005302717
, O 0 0.00047333157
gum B-Chemical 1 0.79655164
Arabic I-Chemical 1 0.4147814
( O 0 0.0006289224
2 O 0 0.00032402689
mL O 0 0.0014349245
/ O 0 0.00050360285
kg O 0 0.0010603252
of O 0 0.00027408937
a O 0 0.0002954756
10 O 0 0.00028640483
% O 0 0.00028311738
w O 0 0.0006273737
/ O 0 0.0008108335
v O 0 0.004419255
aqueous O 0 0.26399112
suspension O 0 0.0054910737
of O 0 0.00077295874
gum B-Chemical 1 0.95917237
Arabic I-Chemical 1 0.7074689
powder O 0 0.5708835
, O 0 0.0006819438
orally O 0 0.018717987
for O 0 0.00023010882
10 O 0 0.00026472757
days O 0 0.0002360361
) O 0 0.00042864872
, O 0 0.00031010897
or O 0 0.00025252596
gum B-Chemical 1 0.8161488
Arabic I-Chemical 1 0.41027611
concomitantly O 0 0.025051815
with O 0 0.001080815
GM B-Chemical 0 0.95636815
( O 0 0.0019565606
80mg O 0 0.99587965
/ O 0 0.0020837202
kg O 0 0.0068699857
/ O 0 0.0006271901
day O 0 0.00026866005
intramuscularly O 0 0.008791889
, O 0 0.0003135698
during O 0 0.00016160218
the O 0 0.00020411066
last O 0 0.00019384963
six O 0 0.0002183986
days O 0 0.00038572113
of O 0 0.0006752003
the O 0 0.0008934081
treatment O 0 0.0029998044
period O 0 0.0030709435
) O 0 0.0064087864
. O 0 0.005161552

Nephrotoxicity B-Disease 2 0.9955974
was O 0 0.0029473212
assessed O 0 0.0013441106
by O 0 0.0011148826
measuring O 0 0.0007205907
the O 0 0.0007379178
concentrations O 0 0.002178139
of O 0 0.0012150852
creatinine B-Chemical 1 0.9965575
and O 0 0.0015134137
urea B-Chemical 1 0.9962748
in O 0 0.0005701046
the O 0 0.00047569742
plasma O 0 0.027627088
and O 0 0.0006236721
reduced O 0 0.0034277085
glutathione B-Chemical 0 0.9997336
( O 0 0.023386583
GSH B-Chemical 1 0.99976283
) O 0 0.0027485106
in O 0 0.00043822784
the O 0 0.00054430455
kidney O 0 0.8313821
cortex O 0 0.45271885
, O 0 0.0007627444
and O 0 0.00055153813
by O 0 0.0006108123
light O 0 0.0013638006
microscopic O 0 0.0044051474
examination O 0 0.0027115867
of O 0 0.003214285
kidney O 0 0.8243337
sections O 0 0.010182068
. O 0 0.0066279327

The O 0 0.0025486762
results O 0 0.0017001372
indicated O 0 0.0010946679
that O 0 0.00097285764
concomitant O 0 0.0037382306
treatment O 0 0.0026790355
with O 0 0.0014717283
gum B-Chemical 1 0.94911695
Arabic I-Chemical 1 0.5723617
and O 0 0.0010790917
GM B-Chemical 0 0.8466546
significantly O 0 0.0010028452
increased O 0 0.0017236037
creatinine B-Chemical 1 0.99732345
and O 0 0.0010854779
urea B-Chemical 1 0.99587053
by O 0 0.0005032188
about O 0 0.00033161577
183 O 0 0.0049988492
and O 0 0.00036206227
239 O 0 0.007385445
% O 0 0.0003735956
, O 0 0.00034507384
respectively O 0 0.00062611565
( O 0 0.0003056737
compared O 0 0.00012232066
to O 0 0.00019992347
432 O 0 0.006165265
and O 0 0.00032354472
346 O 0 0.0104312515
% O 0 0.00034496165
, O 0 0.00032084563
respectively O 0 0.00059476955
, O 0 0.000301855
in O 0 0.00019406377
rats O 0 0.0010865302
treated O 0 0.00053730886
with O 0 0.00051056634
cellulose O 0 0.73341
and O 0 0.00083590945
GM B-Chemical 0 0.9493147
) O 0 0.0014504318
, O 0 0.00041781433
and O 0 0.00026261562
decreased O 0 0.0005361824
that O 0 0.00021694702
of O 0 0.0005166654
cortical O 0 0.33781132
GSH B-Chemical 1 0.9997489
by O 0 0.00072427955
21 O 0 0.0006110522
% O 0 0.00034167137
( O 0 0.00026795326
compared O 0 0.00011041801
to O 0 0.00017619424
27 O 0 0.0003815166
% O 0 0.00023245468
in O 0 0.00016484964
the O 0 0.00024507
cellulose O 0 0.39708906
plus O 0 0.0005592585
GM B-Chemical 0 0.8752354
group O 0 0.0009017083
) O 0 0.0008270189
The O 0 0.00034102163
GM B-Chemical 0 0.87806123
- O 0 0.0012898527
induced O 0 0.00078170677
proximal O 0 0.005353941
tubular B-Disease 0 0.9921903
necrosis I-Disease 2 0.9995871
appeared O 0 0.001461272
to O 0 0.00032861964
be O 0 0.00028739308
slightly O 0 0.0002928422
less O 0 0.00030310804
severe O 0 0.036304418
in O 0 0.00028335094
rats O 0 0.0014048886
given O 0 0.00027547157
GM B-Chemical 0 0.6159956
together O 0 0.00046891862
with O 0 0.00084195164
gum B-Chemical 1 0.91998017
Arabic I-Chemical 1 0.3516788
than O 0 0.00048878224
in O 0 0.00065323635
those O 0 0.0012727531
given O 0 0.0013300113
GM B-Chemical 0 0.7744466
and O 0 0.005524249
cellulose O 0 0.81856394
. O 0 0.008210692

It O 0 0.0056126546
could O 0 0.0019575013
be O 0 0.0016842937
inferred O 0 0.001389469
that O 0 0.001098434
gum B-Chemical 1 0.82988256
Arabic I-Chemical 1 0.41031623
treatment O 0 0.0029567482
has O 0 0.0007637994
induced O 0 0.0009030169
a O 0 0.00065295864
modest O 0 0.0012521165
amelioration O 0 0.30908936
of O 0 0.00079030683
some O 0 0.0006433035
of O 0 0.00070045475
the O 0 0.0006687884
histological O 0 0.13181825
and O 0 0.0012100069
biochemical O 0 0.027600726
indices O 0 0.0038647323
of O 0 0.006710153
GM B-Chemical 0 0.9902468
nephrotoxicity B-Disease 0 0.99951684
. O 0 0.015766487

Further O 0 0.004117221
work O 0 0.0027092611
is O 0 0.0014094857
warranted O 0 0.0009955651
on O 0 0.0005086079
the O 0 0.0005677633
effect O 0 0.00062695704
of O 0 0.0006380535
the O 0 0.00047817806
treatments O 0 0.0015922056
on O 0 0.00032847872
renal O 0 0.94913673
functional O 0 0.0009970812
aspects O 0 0.00038997785
in O 0 0.0002842273
models O 0 0.00059778156
of O 0 0.0007945732
chronic B-Disease 2 0.99262047
renal I-Disease 2 0.9984194
failure I-Disease 2 0.9707373
, O 0 0.0014541971
and O 0 0.0006084664
on O 0 0.00035306747
the O 0 0.0006554199
mechanism O 0 0.0015231878
( O 0 0.0019162273
s O 0 0.002342836
) O 0 0.0036237973
involved O 0 0.0038956038
. O 0 0.005520077

Increased O 0 0.0068227397
frequency O 0 0.0029622398
of O 0 0.0029957853
venous B-Disease 0 0.72616076
thromboembolism I-Disease 0 0.9993315
with O 0 0.0022330382
the O 0 0.0009074939
combination O 0 0.0019487418
of O 0 0.001533449
docetaxel B-Chemical 1 0.9986677
and O 0 0.001934263
thalidomide B-Chemical 1 0.99943405
in O 0 0.0009875228
patients O 0 0.00455023
with O 0 0.0019055052
metastatic O 0 0.9898679
androgen O 0 0.9985043
- O 0 0.007828286
independent O 0 0.0030609448
prostate B-Disease 2 0.9963399
cancer I-Disease 2 0.99698204
. O 0 0.013780115

STUDY O 0 0.03419968
OBJECTIVE O 0 0.34404075
: O 0 0.0030947072
To O 0 0.0010150935
evaluate O 0 0.0006192077
the O 0 0.0007205112
frequency O 0 0.0008939505
of O 0 0.0013440158
venous B-Disease 0 0.8879211
thromboembolism I-Disease 0 0.9998337
( O 0 0.024259944
VTE B-Disease 2 0.9994698
) O 0 0.0021102158
in O 0 0.00038224907
patients O 0 0.0012235956
with O 0 0.0005671024
advanced O 0 0.14611642
androgen O 0 0.9990307
- O 0 0.0017089327
independent O 0 0.00042716795
prostate B-Disease 2 0.9984509
cancer I-Disease 2 0.99918574
who O 0 0.011212927
were O 0 0.000505968
treated O 0 0.0009257137
with O 0 0.0009774714
docetaxel B-Chemical 1 0.99801886
alone O 0 0.0012596702
or O 0 0.00081274373
in O 0 0.0010394829
combination O 0 0.0047961385
with O 0 0.008191876
thalidomide B-Chemical 1 0.9981522
. O 0 0.010481591

DESIGN O 0 0.019253198
: O 0 0.0062995423
Retrospective O 0 0.019379465
analysis O 0 0.0041899798
of O 0 0.003708306
a O 0 0.00404008
randomized O 0 0.0060874675
phase O 0 0.010196256
II O 0 0.031643156
trial O 0 0.017503142
. O 0 0.012343802

SETTING O 0 0.036861144
: O 0 0.010592824
National O 0 0.009792231
Institutes O 0 0.0123723475
of O 0 0.0059810104
Health O 0 0.009549219
clinical O 0 0.013730383
research O 0 0.010975074
center O 0 0.012020515
. O 0 0.013155311

PATIENTS O 0 0.014027428
: O 0 0.0047976547
Seventy O 0 0.0078030755
men O 0 0.014105501
, O 0 0.00242559
aged O 0 0.0023587584
50 O 0 0.0016455771
- O 0 0.001375775
80 O 0 0.0011274425
years O 0 0.0013445908
, O 0 0.0010536717
with O 0 0.0012806344
advanced O 0 0.12314318
androgen O 0 0.99697137
- O 0 0.0068450384
independent O 0 0.0036350642
prostate B-Disease 2 0.99546707
cancer I-Disease 2 0.99646664
. O 0 0.015500576

INTERVENTION O 0 0.011609027
: O 0 0.0029717486
Each O 0 0.0009954518
patient O 0 0.0014494066
received O 0 0.0011367752
either O 0 0.0008952573
intravenous O 0 0.5029428
docetaxel B-Chemical 1 0.9982034
30 O 0 0.000895928
mg O 0 0.39934242
/ O 0 0.0013802502
m2 O 0 0.01699936
/ O 0 0.00059393817
week O 0 0.00020226864
for O 0 0.0001619216
3 O 0 0.00015724693
consecutive O 0 0.00020908615
weeks O 0 0.0001842657
, O 0 0.0002246872
followed O 0 0.00013773223
by O 0 0.00020129627
1 O 0 0.00019074004
week O 0 0.00016113887
off O 0 0.0002518799
, O 0 0.00024295843
or O 0 0.00014804176
the O 0 0.00016542895
combination O 0 0.00045437744
of O 0 0.00033378342
continuous O 0 0.00047530327
oral O 0 0.48251203
thalidomide B-Chemical 1 0.9996362
200 O 0 0.009106319
mg O 0 0.32103226
every O 0 0.00027211776
evening O 0 0.001623375
plus O 0 0.000624551
the O 0 0.0008063994
same O 0 0.0012104022
docetaxel B-Chemical 1 0.9955179
regimen O 0 0.1158665
. O 0 0.006525166

This O 0 0.005355503
4 O 0 0.002339636
- O 0 0.0020962937
week O 0 0.0009992041
cycle O 0 0.0019517972
was O 0 0.000669523
repeated O 0 0.00056254526
until O 0 0.0004106555
there O 0 0.00040915576
was O 0 0.0006086047
evidence O 0 0.0008578013
of O 0 0.0015198825
excessive O 0 0.16177952
toxicity B-Disease 2 0.9946516
or O 0 0.0047552045
disease O 0 0.9383244
progression O 0 0.8742553
. O 0 0.009511141

MEASUREMENTS O 0 0.18741278
AND O 0 0.008774612
MAIN O 0 0.29068422
RESULTS O 0 0.018733129
: O 0 0.0025789752
None O 0 0.0025165575
of O 0 0.0010843151
23 O 0 0.0012132846
patients O 0 0.0014597108
who O 0 0.0012905975
received O 0 0.0010257604
docetaxel B-Chemical 1 0.99779224
alone O 0 0.0013183157
developed O 0 0.005710573
VTE B-Disease 2 0.99942917
, O 0 0.0009974113
whereas O 0 0.00036880773
9 O 0 0.00027455387
of O 0 0.00030436015
47 O 0 0.0006322857
patients O 0 0.0010184413
( O 0 0.00045175073
19 O 0 0.00048272204
% O 0 0.0003201099
) O 0 0.0003942066
who O 0 0.00056699326
received O 0 0.0005876757
docetaxel B-Chemical 1 0.9978492
plus O 0 0.0013494543
thalidomide B-Chemical 1 0.9996371
developed O 0 0.05430677
VTE B-Disease 2 0.99948126
( O 0 0.0031118456
p O 0 0.0020083839
= O 0 0.0018989958
0 O 0 0.0015292933
. O 0 0.0014528461
025 O 0 0.1262326
) O 0 0.0061902083
. O 0 0.005242339

CONCLUSION O 0 0.789453
: O 0 0.004488619
The O 0 0.0014632973
addition O 0 0.0010153082
of O 0 0.001797812
thalidomide B-Chemical 1 0.99866676
to O 0 0.002000883
docetaxel B-Chemical 1 0.998161
in O 0 0.00083942583
the O 0 0.00062399666
treatment O 0 0.0017346308
of O 0 0.0018049346
prostate B-Disease 2 0.99819106
cancer I-Disease 2 0.99874425
significantly O 0 0.0036723623
increases O 0 0.0017935367
the O 0 0.0015591512
frequency O 0 0.0030948794
of O 0 0.009176799
VTE B-Disease 2 0.99716574
. O 0 0.010388334

Clinicians O 0 0.010484974
should O 0 0.002037243
be O 0 0.0018941683
aware O 0 0.001626152
of O 0 0.0013685236
this O 0 0.0011285513
potential O 0 0.0018915145
complication O 0 0.1395956
when O 0 0.0012369746
adding O 0 0.00402671
thalidomide B-Chemical 1 0.9984207
to O 0 0.005576664
chemotherapeutic O 0 0.980828
regimens O 0 0.40378562
. O 0 0.009904384

Ticlopidine B-Chemical 0 0.9938221
- O 0 0.06995427
induced O 0 0.13702185
cholestatic B-Disease 0 0.99878377
hepatitis I-Disease 2 0.9980773
. O 0 0.07248457

OBJECTIVE O 0 0.49811396
: O 0 0.0045391
To O 0 0.0015844979
report O 0 0.00293209
2 O 0 0.0012228778
cases O 0 0.001676726
of O 0 0.0020018865
ticlopidine B-Chemical 1 0.99978274
- O 0 0.015069175
induced O 0 0.014521133
cholestatic B-Disease 0 0.9999603
hepatitis I-Disease 2 0.9999393
, O 0 0.0053461404
investigate O 0 0.00035040872
its O 0 0.0009898772
mechanism O 0 0.0007193537
, O 0 0.00045741707
and O 0 0.0002817011
compare O 0 0.0001300544
the O 0 0.00023101277
observed O 0 0.00023400193
main O 0 0.0004948331
characteristics O 0 0.00057844917
with O 0 0.00071290706
those O 0 0.0010225518
of O 0 0.0012668739
the O 0 0.0015680873
published O 0 0.0032024453
cases O 0 0.0076046023
. O 0 0.005999829

CASE O 0 0.921969
SUMMARIES O 0 0.07886974
: O 0 0.0040686154
Two O 0 0.0023355694
patients O 0 0.0031500794
developed O 0 0.002737309
prolonged O 0 0.12848432
cholestatic B-Disease 0 0.9999112
hepatitis I-Disease 2 0.99987304
after O 0 0.0014255267
receiving O 0 0.052646983
ticlopidine B-Chemical 1 0.99980325
following O 0 0.0013597789
percutaneous O 0 0.018186815
coronary O 0 0.7932816
angioplasty O 0 0.94230753
, O 0 0.0008033553
with O 0 0.0005430779
complete O 0 0.0005591372
remission O 0 0.17719197
during O 0 0.00050807395
the O 0 0.00075671717
follow O 0 0.0012179019
- O 0 0.0024868029
up O 0 0.0021541067
period O 0 0.0036526462
. O 0 0.004986642

T O 0 0.5540754
- O 0 0.0062013124
cell O 0 0.0060989605
stimulation O 0 0.0029585117
by O 0 0.0012278475
therapeutic O 0 0.012426699
concentration O 0 0.0041059814
of O 0 0.0017252044
ticlopidine B-Chemical 1 0.99977654
was O 0 0.0010171521
demonstrated O 0 0.0006601473
in O 0 0.00042465155
vitro O 0 0.0009034412
in O 0 0.0004318074
the O 0 0.0005276313
patients O 0 0.0020872173
, O 0 0.0010506551
but O 0 0.00081401865
not O 0 0.0009920179
in O 0 0.0014980998
healthy O 0 0.009327577
controls O 0 0.0057173627
. O 0 0.005364136

DISCUSSION O 0 0.0802709
: O 0 0.013014768
Cholestatic B-Disease 0 0.9993192
hepatitis I-Disease 2 0.9995203
is O 0 0.0031924332
a O 0 0.0016761082
rare O 0 0.011345749
complication O 0 0.24052176
of O 0 0.0011349628
the O 0 0.00086027203
antiplatelet O 0 0.98436546
agent O 0 0.75794214
ticlopidine B-Chemical 1 0.9998983
; O 0 0.003978513
several O 0 0.00065293966
cases O 0 0.0010747367
have O 0 0.000624837
been O 0 0.00079312164
reported O 0 0.0009946992
but O 0 0.000694735
few O 0 0.0007014658
in O 0 0.0011137617
the O 0 0.001997359
English O 0 0.009266866
literature O 0 0.008147801
. O 0 0.0060390322

Our O 0 0.0037106816
patients O 0 0.0053557265
developed O 0 0.0047042295
jaundice B-Disease 2 0.9950132
following O 0 0.0018877651
treatment O 0 0.0032920889
with O 0 0.0017219884
ticlopidine B-Chemical 1 0.9997166
and O 0 0.001063296
showed O 0 0.0005310329
the O 0 0.00040557163
clinical O 0 0.0035560725
and O 0 0.00044025065
laboratory O 0 0.0008259518
characteristics O 0 0.00061126164
of O 0 0.0019835087
cholestatic B-Disease 0 0.99995136
hepatitis I-Disease 2 0.99992144
, O 0 0.008194775
which O 0 0.0014650862
resolved O 0 0.0016549763
after O 0 0.00072325056
discontinuation O 0 0.5748542
of O 0 0.002541824
the O 0 0.003428613
drug O 0 0.52894074
. O 0 0.006964078

Hepatitis B-Disease 0 0.9946983
may O 0 0.003339902
develop O 0 0.0022944338
weeks O 0 0.0011479974
after O 0 0.0006258729
discontinuation O 0 0.26053962
of O 0 0.00086405105
the O 0 0.00059907115
drug O 0 0.17373298
and O 0 0.0005890746
may O 0 0.000400676
run O 0 0.00039756714
a O 0 0.0004111416
prolonged O 0 0.003005909
course O 0 0.0008960309
, O 0 0.00062308897
but O 0 0.00038611036
complete O 0 0.0004857919
remission O 0 0.28334948
was O 0 0.00062475004
observed O 0 0.0005726238
in O 0 0.0008542459
all O 0 0.0013216785
reported O 0 0.0035893843
cases O 0 0.00736676
. O 0 0.0058610863

An O 0 0.005552275
objective O 0 0.003819079
causality O 0 0.0054975455
assessment O 0 0.0014826412
revealed O 0 0.001134647
that O 0 0.0007838775
the O 0 0.00091489905
adverse O 0 0.5666299
drug O 0 0.475687
event O 0 0.0068768053
was O 0 0.000833293
probably O 0 0.0011342096
related O 0 0.0006562109
to O 0 0.00088169303
the O 0 0.0012311601
use O 0 0.0026351705
of O 0 0.0071781045
ticlopidine B-Chemical 1 0.99892694
. O 0 0.011343416

The O 0 0.0048643234
mechanisms O 0 0.005746864
of O 0 0.0047540134
this O 0 0.0058468445
ticlopidine B-Chemical 1 0.999106
- O 0 0.030189376
induced O 0 0.027295625
cholestasis B-Disease 2 0.99932086
are O 0 0.015381523
unclear O 0 0.014909023
. O 0 0.011802221

Immune O 0 0.38057026
mechanisms O 0 0.005583236
may O 0 0.0023109643
be O 0 0.0015881178
involved O 0 0.0010755499
in O 0 0.0008155646
the O 0 0.00082229223
drug O 0 0.18882121
' O 0 0.0013234288
s O 0 0.0019964315
hepatotoxicity B-Disease 2 0.9998128
, O 0 0.0014395274
as O 0 0.00048629942
suggested O 0 0.0006387505
by O 0 0.0006836971
the O 0 0.00087844953
T O 0 0.43896568
- O 0 0.0021171574
cell O 0 0.0047105
stimulation O 0 0.0032037457
study O 0 0.0027549353
reported O 0 0.0038821301
here O 0 0.0039434056
. O 0 0.005819413

CONCLUSIONS O 0 0.92376417
: O 0 0.02893275
Cholestatic B-Disease 0 0.99931574
hepatitis I-Disease 2 0.999443
is O 0 0.004227045
a O 0 0.0024388141
rare O 0 0.0161667
adverse O 0 0.6521307
effect O 0 0.0021334102
of O 0 0.0032860923
ticlopidine B-Chemical 1 0.9995165
that O 0 0.0024826212
may O 0 0.0028428677
be O 0 0.0036176848
immune O 0 0.098169364
mediated O 0 0.007227048
. O 0 0.00813937

Patients O 0 0.009463392
receiving O 0 0.005379815
the O 0 0.001968791
drug O 0 0.10179345
should O 0 0.00095676497
be O 0 0.00091748097
monitored O 0 0.0005368648
with O 0 0.0010395529
liver O 0 0.44708574
function O 0 0.0014032071
tests O 0 0.0018486584
along O 0 0.0011283492
with O 0 0.0015847266
complete O 0 0.0020269349
blood O 0 0.011895671
cell O 0 0.01290523
counts O 0 0.0069695055
. O 0 0.0068727126

This O 0 0.005980347
complication O 0 0.069762915
will O 0 0.001557298
be O 0 0.0012775102
observed O 0 0.00068923045
even O 0 0.00070629787
less O 0 0.00062911306
often O 0 0.00081785023
in O 0 0.0004065531
the O 0 0.00039719493
future O 0 0.00048703747
as O 0 0.000576409
ticlopidine B-Chemical 1 0.999691
is O 0 0.00088277785
being O 0 0.0009094367
replaced O 0 0.0006921204
by O 0 0.0007572883
the O 0 0.0010192464
newer O 0 0.09447048
antiplatelet O 0 0.99135274
agent O 0 0.90351856
clopidogrel B-Chemical 1 0.99849653
. O 0 0.011640931

Epithelial O 0 0.89862317
sodium B-Chemical 0 0.9944945
channel O 0 0.51787245
( O 0 0.0075858515
ENaC O 0 0.96515775
) O 0 0.004152324
subunit O 0 0.007198854
mRNA O 0 0.0022478977
and O 0 0.0009163993
protein O 0 0.001635948
expression O 0 0.0012842787
in O 0 0.0006964327
rats O 0 0.0041112155
with O 0 0.0021192704
puromycin B-Chemical 0 0.990231
aminonucleoside I-Chemical 0 0.9997788
- O 0 0.043900274
induced O 0 0.075426675
nephrotic B-Disease 2 0.9997538
syndrome I-Disease 0 0.9898476
. O 0 0.011378105

In O 0 0.004122854
experimental O 0 0.008003816
nephrotic B-Disease 2 0.9995166
syndrome I-Disease 0 0.98155206
, O 0 0.0070576137
urinary O 0 0.9691683
sodium B-Chemical 0 0.998904
excretion O 0 0.99353105
is O 0 0.0016151945
decreased O 0 0.0019148544
during O 0 0.00069375976
the O 0 0.0008985893
early O 0 0.0022834667
phase O 0 0.003064438
of O 0 0.0029922654
the O 0 0.0043036314
disease O 0 0.7621435
. O 0 0.008867272

The O 0 0.0036928335
molecular O 0 0.009718861
mechanism O 0 0.00413734
( O 0 0.0030963053
s O 0 0.0023822621
) O 0 0.0022693865
leading O 0 0.002294664
to O 0 0.0015077817
salt O 0 0.87023693
retention O 0 0.008617568
has O 0 0.0021931997
not O 0 0.0022574188
been O 0 0.0035334928
completely O 0 0.00462339
elucidated O 0 0.010966143
. O 0 0.0076135863

The O 0 0.0033535091
rate O 0 0.00276177
- O 0 0.003012674
limiting O 0 0.002014781
constituent O 0 0.004748034
of O 0 0.0018795453
collecting O 0 0.006172346
duct O 0 0.88892466
sodium B-Chemical 0 0.99820685
transport O 0 0.07992128
is O 0 0.001547676
the O 0 0.001561356
epithelial O 0 0.45571226
sodium B-Chemical 0 0.9979657
channel O 0 0.64148563
( O 0 0.017517991
ENaC O 0 0.97459066
) O 0 0.017223274
. O 0 0.008274305

We O 0 0.0030421505
examined O 0 0.0017356316
the O 0 0.0015488156
abundance O 0 0.0015737173
of O 0 0.0020570094
ENaC O 0 0.95462763
subunit O 0 0.025122523
mRNAs O 0 0.004214523
and O 0 0.0010919517
proteins O 0 0.0018574797
in O 0 0.0012443927
puromycin B-Chemical 0 0.9870898
aminonucleoside I-Chemical 0 0.99983656
( O 0 0.03206242
PAN B-Chemical 1 0.9985588
) O 0 0.017016722
- O 0 0.0077346633
induced O 0 0.027606508
nephrotic B-Disease 2 0.9996892
syndrome I-Disease 0 0.98787016
. O 0 0.011105132

The O 0 0.0025835447
time O 0 0.0017972112
courses O 0 0.0031526845
of O 0 0.0025911885
urinary O 0 0.93628633
sodium B-Chemical 0 0.9988777
excretion O 0 0.99626356
, O 0 0.005581079
plasma O 0 0.2741335
aldosterone B-Chemical 0 0.9995345
concentration O 0 0.034526702
and O 0 0.001681221
proteinuria B-Disease 2 0.9997677
were O 0 0.0008489285
studied O 0 0.0008443479
in O 0 0.0004429
male O 0 0.0037783594
Sprague O 0 0.33871755
- O 0 0.0011849513
Dawley O 0 0.16501135
rats O 0 0.001343683
treated O 0 0.0006921883
with O 0 0.00053802505
a O 0 0.00059662753
single O 0 0.0007188233
dose O 0 0.008335704
of O 0 0.0017049328
either O 0 0.0028013212
PAN B-Chemical 1 0.9948454
or O 0 0.004902679
vehicle O 0 0.1706984
. O 0 0.0074788886

The O 0 0.0026432362
relative O 0 0.0016314145
amounts O 0 0.0016074375
of O 0 0.002178645
alphaENaC O 0 0.37769103
, O 0 0.0022467661
betaENaC O 0 0.31150058
and O 0 0.0013056544
gammaENaC O 0 0.697484
mRNAs O 0 0.0018841309
were O 0 0.0003689783
determined O 0 0.00023783631
in O 0 0.0002701135
kidneys O 0 0.0061319456
from O 0 0.00026797774
these O 0 0.0003921098
rats O 0 0.0012794646
by O 0 0.00031384436
real O 0 0.000432549
- O 0 0.00050149707
time O 0 0.00023577924
quantitative O 0 0.0006586848
TaqMan O 0 0.031724848
PCR O 0 0.017561492
, O 0 0.0007151656
and O 0 0.0004967033
the O 0 0.00047258858
amounts O 0 0.00066396274
of O 0 0.0012363538
proteins O 0 0.0026550223
by O 0 0.002543256
Western O 0 0.035497263
blot O 0 0.07177459
. O 0 0.008651373

The O 0 0.0033365516
kinetics O 0 0.004214127
of O 0 0.0033518502
urinary O 0 0.90797544
sodium B-Chemical 0 0.9980932
excretion O 0 0.9898224
and O 0 0.0019644708
the O 0 0.0010683083
appearance O 0 0.0031988125
of O 0 0.0021700563
proteinuria B-Disease 2 0.9995092
were O 0 0.0015630813
comparable O 0 0.00094711577
with O 0 0.0018068521
those O 0 0.0029396997
reported O 0 0.0045442022
previously O 0 0.0052572703
. O 0 0.006469068

Sodium B-Chemical 0 0.99463993
retention O 0 0.013636771
occurred O 0 0.0037071998
on O 0 0.0016094437
days O 0 0.0018921492
2 O 0 0.0018017242
, O 0 0.0019254119
3 O 0 0.001366851
and O 0 0.0016676205
6 O 0 0.0017519171
after O 0 0.0024096668
PAN B-Chemical 1 0.98479074
injection O 0 0.045398664
. O 0 0.009067587

A O 0 0.016044134
significant O 0 0.0036889918
up O 0 0.0024117748
- O 0 0.0022903834
regulation O 0 0.00097358366
of O 0 0.0013713
alphaENaC O 0 0.19924048
and O 0 0.0012457252
betaENaC O 0 0.26337358
mRNA O 0 0.0015030022
abundance O 0 0.00054983073
on O 0 0.00025997346
days O 0 0.00039495423
1 O 0 0.0003915241
and O 0 0.0003916307
2 O 0 0.00044704153
preceded O 0 0.00092899054
sodium B-Chemical 0 0.993359
retention O 0 0.0034768987
on O 0 0.00067011284
days O 0 0.001230503
2 O 0 0.0016084893
and O 0 0.0022641723
3 O 0 0.0033003339
. O 0 0.004459967

Conversely O 0 0.006568564
, O 0 0.0037355144
down O 0 0.0027038984
- O 0 0.0023237483
regulation O 0 0.00095216365
of O 0 0.0014305965
alphaENaC O 0 0.34415627
, O 0 0.0016803992
betaENaC O 0 0.30306488
and O 0 0.0011103151
gammaENaC O 0 0.7395445
mRNA O 0 0.0017213745
expression O 0 0.0006770787
on O 0 0.00017291876
day O 0 0.00024859744
3 O 0 0.00019240576
occurred O 0 0.00023785242
in O 0 0.00016086023
the O 0 0.00017197855
presence O 0 0.00021099146
of O 0 0.0003523343
high O 0 0.0009253069
aldosterone B-Chemical 0 0.9996056
concentrations O 0 0.021993259
, O 0 0.00064756826
and O 0 0.00034845274
was O 0 0.00028457493
followed O 0 0.00022452981
by O 0 0.0003513296
a O 0 0.00048561385
return O 0 0.00086854934
of O 0 0.0013301369
sodium B-Chemical 0 0.9976453
excretion O 0 0.97150797
to O 0 0.0021977883
control O 0 0.0025580418
values O 0 0.004177366
. O 0 0.0055813673

The O 0 0.0032358111
amounts O 0 0.0026537182
of O 0 0.0032292092
alphaENaC O 0 0.3411605
, O 0 0.0030978983
betaENaC O 0 0.2924472
and O 0 0.0018910177
gammaENaC O 0 0.63150084
proteins O 0 0.002059842
were O 0 0.0008174201
not O 0 0.000712485
increased O 0 0.0015463857
during O 0 0.0015494189
PAN B-Chemical 1 0.99681
- O 0 0.009797546
induced O 0 0.0095951995
sodium B-Chemical 0 0.99604356
retention O 0 0.1093911
. O 0 0.008861969

In O 0 0.003150316
conclusion O 0 0.0025456399
, O 0 0.003224893
ENaC O 0 0.9024741
mRNA O 0 0.004362728
expression O 0 0.0023802423
, O 0 0.0012833452
especially O 0 0.0015544728
alphaENaC O 0 0.3748508
, O 0 0.00086047297
is O 0 0.0003867871
increased O 0 0.0005649487
in O 0 0.00026056502
the O 0 0.00023995874
very O 0 0.00033592817
early O 0 0.00058627484
phase O 0 0.00060528656
of O 0 0.0003298419
the O 0 0.00023506681
experimental O 0 0.00049483427
model O 0 0.0005566268
of O 0 0.001205631
PAN B-Chemical 1 0.99925345
- O 0 0.008630157
induced O 0 0.010162757
nephrotic B-Disease 2 0.9999616
syndrome I-Disease 0 0.98727554
in O 0 0.0006701435
rats O 0 0.009277897
, O 0 0.0005554961
but O 0 0.00031446674
appears O 0 0.00029307176
to O 0 0.0002780946
escape O 0 0.0013890695
from O 0 0.0004088883
the O 0 0.0004667482
regulation O 0 0.00065571384
by O 0 0.0013101863
aldosterone B-Chemical 0 0.99761766
after O 0 0.0015252865
day O 0 0.0027638238
3 O 0 0.0034607206
. O 0 0.0044571306

Sub O 0 0.38919806
- O 0 0.007653765
chronic O 0 0.7382609
low O 0 0.0039330977
dose O 0 0.12810303
gamma B-Chemical 0 0.7484438
- I-Chemical 0 0.017469956
vinyl I-Chemical 0 0.96198255
GABA I-Chemical 1 0.9997557
( O 0 0.03025645
vigabatrin B-Chemical 0 0.9998641
) O 0 0.009375312
inhibits O 0 0.006529845
cocaine B-Chemical 1 0.9995258
- O 0 0.0046467613
induced O 0 0.0017626036
increases O 0 0.0018575346
in O 0 0.0021436024
nucleus O 0 0.04892148
accumbens O 0 0.99243176
dopamine B-Chemical 1 0.99586546
. O 0 0.008325584

RATIONALE O 0 0.19088551
: O 0 0.011754877
gamma B-Chemical 0 0.33606082
- I-Chemical 0 0.016717993
Vinyl I-Chemical 0 0.93710995
GABA I-Chemical 1 0.9990152
( O 0 0.059427395
GVG B-Chemical 0 0.9994392
) O 0 0.03524379
irreversibly O 0 0.7421246
inhibits O 0 0.091812655
GABA B-Chemical 1 0.99907327
- O 0 0.30449772
transaminase O 0 0.99828076
. O 0 0.018134754

This O 0 0.0067754956
non O 0 0.0065406747
- O 0 0.005061883
receptor O 0 0.048523556
mediated O 0 0.0020378518
inhibition O 0 0.004431152
requires O 0 0.0012426736
de O 0 0.025590042
novo O 0 0.020326452
synthesis O 0 0.0422448
for O 0 0.0014146812
restoration O 0 0.003446638
of O 0 0.0037528456
functional O 0 0.024447994
GABA B-Chemical 1 0.9987363
catabolism O 0 0.9727877
. O 0 0.012031813

OBJECTIVES O 0 0.024755104
: O 0 0.003497856
Given O 0 0.001294503
its O 0 0.0017983236
preclinical O 0 0.00764226
success O 0 0.0017208215
for O 0 0.0007480243
treating O 0 0.012196189
substance B-Disease 0 0.9974541
abuse I-Disease 0 0.9980545
and O 0 0.0009057041
the O 0 0.00042500588
increased O 0 0.00079168734
risk O 0 0.016476125
of O 0 0.0006754182
visual B-Disease 2 0.35235322
field I-Disease 2 0.001285614
defects I-Disease 2 0.002238102
( O 0 0.0012052922
VFD B-Disease 0 0.97852546
) O 0 0.00079234736
associated O 0 0.00038703348
with O 0 0.00032225795
cumulative O 0 0.001485868
lifetime O 0 0.009118354
exposure O 0 0.004528716
, O 0 0.00034791764
we O 0 0.00010696985
explored O 0 0.00020719368
the O 0 0.00019369129
effects O 0 0.0005363482
of O 0 0.00047565272
sub O 0 0.014637881
- O 0 0.0017249935
chronic O 0 0.917785
low O 0 0.0019208156
dose O 0 0.24149399
GVG B-Chemical 0 0.9999168
on O 0 0.0006983435
cocaine B-Chemical 1 0.999757
- O 0 0.0031423413
induced O 0 0.000816942
increases O 0 0.0007192347
in O 0 0.0006425725
nucleus O 0 0.014384464
accumbens O 0 0.99003524
( O 0 0.002245779
NAcc O 0 0.56908804
) O 0 0.0041283774
dopamine B-Chemical 1 0.9976671
( O 0 0.010058768
DA B-Chemical 0 0.99327445
) O 0 0.011275718
. O 0 0.0064196996

METHODS O 0 0.0063110203
: O 0 0.0032202657
Using O 0 0.0018629638
in O 0 0.0011059352
vivo O 0 0.0018127752
microdialysis O 0 0.24209201
, O 0 0.001052563
we O 0 0.00033584796
compared O 0 0.00038554927
acute O 0 0.74668425
exposure O 0 0.015577467
( O 0 0.00097537227
450 O 0 0.0043604877
mg O 0 0.3983638
/ O 0 0.0012474841
kg O 0 0.005084324
) O 0 0.0004780568
to O 0 0.00021129585
an O 0 0.00029870623
identical O 0 0.00018472447
sub O 0 0.003028621
- O 0 0.0010269886
chronic O 0 0.8893868
exposure O 0 0.018894194
( O 0 0.0006660984
150 O 0 0.00083970104
mg O 0 0.17903239
/ O 0 0.0005777863
kg O 0 0.0009589924
per O 0 0.00010054952
day O 0 0.00015800595
for O 0 0.0001501426
3 O 0 0.00018253899
days O 0 0.00023146387
) O 0 0.00043546924
, O 0 0.00033719794
followed O 0 0.00024273312
by O 0 0.00044672098
1 O 0 0.0006161271
- O 0 0.0009042141
or O 0 0.000609309
3 O 0 0.000907614
- O 0 0.0018274706
day O 0 0.0019346349
washout O 0 0.0100133065
. O 0 0.0047568297

Finally O 0 0.004053214
, O 0 0.0024704505
we O 0 0.0008515623
examined O 0 0.0007873714
the O 0 0.00075493497
low O 0 0.00096625014
dose O 0 0.005922051
of O 0 0.0009614432
150 O 0 0.0019116437
mg O 0 0.37048814
/ O 0 0.0014948096
kg O 0 0.004807428
( O 0 0.0005645146
50 O 0 0.00059756765
mg O 0 0.11501945
/ O 0 0.00087668304
kg O 0 0.0014681981
per O 0 0.00022779449
day O 0 0.00043550247
) O 0 0.00075471884
using O 0 0.0005052547
a O 0 0.0009210851
similar O 0 0.001042236
washout O 0 0.006446963
period O 0 0.0040559503
. O 0 0.0052529424

RESULTS O 0 0.05941375
: O 0 0.008225667
Sub O 0 0.2776502
- O 0 0.0058213444
chronic O 0 0.9615303
GVG B-Chemical 0 0.9997086
exposure O 0 0.07196039
inhibited O 0 0.0033855601
the O 0 0.0006473248
effect O 0 0.00071419164
of O 0 0.0010018626
cocaine B-Chemical 1 0.9992531
for O 0 0.000512233
3 O 0 0.00033723607
days O 0 0.00030413535
, O 0 0.00036628213
which O 0 0.00035135722
exceeded O 0 0.0002900386
in O 0 0.00028889993
magnitude O 0 0.00038594438
and O 0 0.0005455979
duration O 0 0.000976243
the O 0 0.0009949001
identical O 0 0.0014892408
acute O 0 0.9332321
dose O 0 0.24056873
. O 0 0.0074828756

CONCLUSIONS O 0 0.8491476
: O 0 0.0090369005
Sub O 0 0.31962857
- O 0 0.004543747
chronic O 0 0.7838125
low O 0 0.0029789556
dose O 0 0.24174492
GVG B-Chemical 0 0.9998292
potentiates O 0 0.43304345
and O 0 0.0010760629
extends O 0 0.0007860385
the O 0 0.00047162417
inhibition O 0 0.0037923797
of O 0 0.0016331987
cocaine B-Chemical 1 0.9997341
- O 0 0.003963607
induced O 0 0.0008883994
increases O 0 0.0007114967
in O 0 0.0006177768
dopamine B-Chemical 1 0.99914
, O 0 0.0008138519
effectively O 0 0.00067758345
reducing O 0 0.00068765716
cumulative O 0 0.003045664
exposures O 0 0.03074903
and O 0 0.0012561686
the O 0 0.0015025509
risk O 0 0.039817665
for O 0 0.0037937744
VFDS O 0 0.46361762
. O 0 0.0069855233

MR O 2 0.75606763
imaging O 0 0.010529305
with O 0 0.0029320423
quantitative O 0 0.0031436833
diffusion O 0 0.008874292
mapping O 0 0.002078191
of O 0 0.0037365826
tacrolimus B-Chemical 0 0.99950314
- O 0 0.016840601
induced O 0 0.00975992
neurotoxicity B-Disease 2 0.99906343
in O 0 0.0037339814
organ O 0 0.28957722
transplant O 0 0.8454337
patients O 0 0.039493296
. O 0 0.0082413815

Our O 0 0.0034127512
objective O 0 0.0035967694
was O 0 0.0014649412
to O 0 0.0010391359
investigate O 0 0.0007568789
brain O 0 0.031475373
MR O 2 0.92288
imaging O 0 0.008145539
findings O 0 0.0015177428
and O 0 0.000511016
the O 0 0.00034637787
utility O 0 0.00041338566
of O 0 0.0005514722
diffusion O 0 0.026203398
- O 0 0.0010478202
weighted O 0 0.0007619638
( O 0 0.00087612815
DW O 0 0.5651793
) O 0 0.0008500893
imaging O 0 0.0019708185
in O 0 0.00036697273
organ O 0 0.01876122
transplant O 0 0.392906
patients O 0 0.0030427924
who O 0 0.0021325499
developed O 0 0.0026426276
neurologic O 0 0.99065536
symptoms O 0 0.6941169
during O 0 0.0032583892
tacrolimus B-Chemical 0 0.99919635
therapy O 0 0.43086365
. O 0 0.008019024

Brain O 0 0.5170473
MR O 2 0.87294805
studies O 0 0.004578065
, O 0 0.002564276
including O 0 0.0016316684
DW O 0 0.42468733
imaging O 0 0.0067746677
, O 0 0.0010909068
were O 0 0.00055824657
prospectively O 0 0.00089543476
performed O 0 0.00041423377
in O 0 0.0004140786
14 O 0 0.00059334753
organ O 0 0.007823392
transplant O 0 0.3002351
patients O 0 0.0042728493
receiving O 0 0.023358937
tacrolimus B-Chemical 0 0.99948347
who O 0 0.032198668
developed O 0 0.02578289
neurologic B-Disease 0 0.9970324
complications I-Disease 0 0.9856716
. O 0 0.009752088

In O 0 0.002578752
each O 0 0.0012262728
patient O 0 0.0022170953
who O 0 0.0023797057
had O 0 0.0012333356
abnormalities O 0 0.022214737
on O 0 0.00048496903
the O 0 0.00058021117
initial O 0 0.00085584633
MR O 2 0.92306143
study O 0 0.0013933781
, O 0 0.000764387
a O 0 0.00057389605
follow O 0 0.0006032012
- O 0 0.0010218838
up O 0 0.00073026144
MR O 2 0.7819769
study O 0 0.0013217164
was O 0 0.0008742856
performed O 0 0.0010552272
1 O 0 0.0016160958
month O 0 0.002206553
later O 0 0.0034704052
. O 0 0.0051174522

Apparent O 0 0.029715063
diffusion O 0 0.023169734
coefficient O 0 0.0069271154
( O 0 0.0036709565
ADC O 0 0.46405166
) O 0 0.0021920302
values O 0 0.0008034008
on O 0 0.0004605684
the O 0 0.0006041805
initial O 0 0.00093293906
MR O 2 0.8709496
study O 0 0.0014202109
were O 0 0.000762364
correlated O 0 0.00074876973
with O 0 0.0014773097
reversibility O 0 0.057669945
of O 0 0.0035070113
the O 0 0.004527871
lesions O 0 0.46460822
. O 0 0.008228774

Of O 0 0.005268413
the O 0 0.0023313775
14 O 0 0.0020478491
patients O 0 0.0028717536
, O 0 0.0015110442
5 O 0 0.00078907114
( O 0 0.0008265332
35 O 0 0.00059960247
. O 0 0.0003028954
7 O 0 0.0003392246
% O 0 0.00041320047
) O 0 0.00048174293
had O 0 0.0003611499
white B-Disease 0 0.0018434427
matter I-Disease 0 0.00259251
abnormalities I-Disease 0 0.2100587
, O 0 0.0007003373
1 O 0 0.00041586204
( O 0 0.00040977309
7 O 0 0.00022325388
. O 0 0.0001484794
1 O 0 0.00024278683
% O 0 0.0002868136
) O 0 0.00040180783
had O 0 0.00044480906
putaminal B-Disease 0 0.99778026
hemorrhage I-Disease 2 0.9994592
, O 0 0.0009575981
and O 0 0.00044095665
8 O 0 0.00036097816
( O 0 0.0004012647
57 O 0 0.0004975299
. O 0 0.00019101686
1 O 0 0.00031567726
% O 0 0.00038049673
) O 0 0.0004977887
had O 0 0.00042868094
normal O 0 0.0010491058
findings O 0 0.0015703922
on O 0 0.0008248876
initial O 0 0.0027836263
MR O 2 0.95220584
images O 0 0.010317679
. O 0 0.0068240385

Among O 0 0.0067733144
the O 0 0.0023252433
5 O 0 0.0015333913
patients O 0 0.002331118
with O 0 0.001339052
white B-Disease 0 0.0038808358
matter I-Disease 0 0.0041833483
abnormalities I-Disease 0 0.1777596
, O 0 0.00093380746
4 O 0 0.0004197527
patients O 0 0.0010943371
( O 0 0.0004894602
80 O 0 0.00047247554
. O 0 0.00017814776
0 O 0 0.0002782431
% O 0 0.00026218657
) O 0 0.00029928377
showed O 0 0.0001765538
higher O 0 0.00020430986
than O 0 0.00015465934
normal O 0 0.0005924067
ADC O 0 0.29658106
values O 0 0.00030138486
on O 0 0.00017518809
initial O 0 0.0004615484
MR O 2 0.92835426
images O 0 0.0010357843
, O 0 0.00052628113
and O 0 0.00035630065
all O 0 0.0002974402
showed O 0 0.00039537766
complete O 0 0.00055164885
resolution O 0 0.0035854941
on O 0 0.00061257445
follow O 0 0.0013761
- O 0 0.0028612453
up O 0 0.0025623147
images O 0 0.0057825977
. O 0 0.0055832737

The O 0 0.0027890706
remaining O 0 0.0021709586
1 O 0 0.0017244878
patient O 0 0.001980313
( O 0 0.0013909743
20 O 0 0.0008658828
. O 0 0.00043175803
0 O 0 0.00055384444
% O 0 0.00050316716
) O 0 0.000531242
showed O 0 0.00030532098
lower O 0 0.00034115254
than O 0 0.00025323336
normal O 0 0.0008812374
ADC O 0 0.28245044
value O 0 0.00056858186
and O 0 0.0005812939
showed O 0 0.00064963504
incomplete O 0 0.0019454142
resolution O 0 0.019876119
with O 0 0.0031779232
cortical B-Disease 0 0.55807084
laminar I-Disease 0 0.3632561
necrosis I-Disease 2 0.99561214
. O 0 0.011297972

Diffusion O 0 0.39253238
- O 0 0.005139694
weighted O 0 0.0027213034
imaging O 0 0.004982634
may O 0 0.001406813
be O 0 0.0010376776
useful O 0 0.0010044652
in O 0 0.0005902366
predicting O 0 0.0006946562
the O 0 0.00061738095
outcomes O 0 0.0012636682
of O 0 0.0009921835
the O 0 0.0010840632
lesions O 0 0.21200319
of O 0 0.006004757
tacrolimus B-Chemical 0 0.9995639
- O 0 0.048232075
induced O 0 0.048246175
neurotoxicity B-Disease 2 0.9985495
. O 0 0.011794997

L B-Chemical 1 0.8529189
- I-Chemical 1 0.014082873
arginine I-Chemical 1 0.8847561
transport O 0 0.023362327
in O 0 0.003168246
humans O 0 0.008648735
with O 0 0.0057116346
cortisol B-Chemical 1 0.98638016
- O 0 0.014990128
induced O 0 0.020984361
hypertension B-Disease 2 0.99750096
. O 0 0.015731039

A O 0 0.033051696
deficient O 0 0.006434909
L B-Chemical 1 0.88472205
- I-Chemical 1 0.01272811
arginine I-Chemical 1 0.9696937
- O 0 0.010391412
nitric B-Chemical 0 0.99761176
oxide I-Chemical 0 0.99681085
system O 0 0.006902217
is O 0 0.0021869203
implicated O 0 0.002704051
in O 0 0.002819608
cortisol B-Chemical 1 0.9886622
- O 0 0.011244852
induced O 0 0.017843548
hypertension B-Disease 2 0.99798524
. O 0 0.01266173

We O 0 0.0037059092
investigate O 0 0.002052163
whether O 0 0.0016135881
abnormalities O 0 0.040060684
in O 0 0.0029111537
L B-Chemical 1 0.87315637
- I-Chemical 1 0.008432834
arginine I-Chemical 1 0.94491845
uptake O 0 0.0385465
contribute O 0 0.003062594
to O 0 0.0029963993
this O 0 0.00487003
deficiency O 0 0.59903014
. O 0 0.010382483

Eight O 0 0.031819623
healthy O 0 0.03285083
men O 0 0.044199083
were O 0 0.01688537
recruited O 0 0.020450033
. O 0 0.023823202

Hydrocortisone B-Chemical 0 0.9989153
acetate I-Chemical 0 0.99546826
( O 0 0.005409537
50 O 0 0.0028195705
mg O 0 0.43001714
) O 0 0.0015917639
was O 0 0.0005412924
given O 0 0.00034019817
orally O 0 0.005082325
every O 0 0.00019228287
6 O 0 0.00018456708
hours O 0 0.00018237095
for O 0 0.00015635316
24 O 0 0.0001920692
hours O 0 0.00017335924
after O 0 0.00012960723
a O 0 0.0002777115
5 O 0 0.00025616807
- O 0 0.0003857553
day O 0 0.00026149055
fixed O 0 0.0004564821
- O 0 0.0011029803
salt O 0 0.8417659
diet O 0 0.15452603
( O 0 0.0018371048
150 O 0 0.0029178439
mmol O 0 0.44275263
/ O 0 0.004789029
d O 0 0.0040603387
) O 0 0.0063581904
. O 0 0.005328398

Crossover O 0 0.054070693
studies O 0 0.010024383
were O 0 0.006763345
performed O 0 0.006580766
2 O 0 0.0077498327
weeks O 0 0.008643479
apart O 0 0.013650928
. O 0 0.015095893

Thirty O 0 0.00751664
milliliters O 0 0.004121408
of O 0 0.0024915698
blood O 0 0.0048443726
was O 0 0.001213014
obtained O 0 0.000874012
for O 0 0.0006951238
isolation O 0 0.0010704838
of O 0 0.001158163
peripheral O 0 0.028602507
blood O 0 0.015738374
mononuclear O 0 0.17997882
cells O 0 0.0019041788
after O 0 0.0007320975
each O 0 0.00090838317
treatment O 0 0.0040438734
period O 0 0.004497998
. O 0 0.0055992124

L B-Chemical 1 0.87281543
- I-Chemical 1 0.010364126
arginine I-Chemical 1 0.8972164
uptake O 0 0.023070483
was O 0 0.0012549136
assessed O 0 0.0007628815
in O 0 0.0007643128
mononuclear O 0 0.12999119
cells O 0 0.0016249586
incubated O 0 0.00050529005
with O 0 0.0010086044
L B-Chemical 1 0.91093814
- I-Chemical 1 0.0038505064
arginine I-Chemical 1 0.95308155
( O 0 0.0008600151
1 O 0 0.0003408846
to O 0 0.0002600426
300 O 0 0.0014460979
micromol O 0 0.28889713
/ O 0 0.0021398133
L O 0 0.3913176
) O 0 0.00080100854
, O 0 0.00038303828
incorporating O 0 0.0003958268
100 O 0 0.0013339097
nmol O 0 0.6611303
/ O 0 0.004564044
L O 0 0.7102248
[ B-Chemical 0 0.008690919
3H I-Chemical 0 0.6566325
] I-Chemical 0 0.0024780722
- I-Chemical 0 0.0009315783
l I-Chemical 0 0.0059963446
- I-Chemical 0 0.0010003315
arginine I-Chemical 0 0.66790015
for O 0 0.00030017187
a O 0 0.00038731034
period O 0 0.0003682767
of O 0 0.00053569063
5 O 0 0.00048093608
minutes O 0 0.0005968915
at O 0 0.00066652824
37 O 0 0.002369174
degrees O 0 0.008840434
C O 0 0.6471499
. O 0 0.008123561

Forearm O 0 0.57915634
[ B-Chemical 0 0.020212881
3H I-Chemical 0 0.60518146
] I-Chemical 0 0.00798608
- I-Chemical 0 0.004396319
L I-Chemical 1 0.7902232
- I-Chemical 1 0.0031413261
arginine I-Chemical 1 0.8435993
extraction O 0 0.0026553175
was O 0 0.0004985378
calculated O 0 0.00027572486
after O 0 0.00024579026
infusion O 0 0.012534139
of O 0 0.0009665024
[ B-Chemical 0 0.00781327
3H I-Chemical 0 0.71109587
] I-Chemical 0 0.0043962123
- I-Chemical 0 0.0019847911
L I-Chemical 1 0.8521388
- I-Chemical 1 0.0019162329
arginine I-Chemical 1 0.84759307
into O 0 0.00026798132
the O 0 0.00040655778
brachial O 0 0.7132927
artery O 0 0.116948105
at O 0 0.0002421054
a O 0 0.00035995085
rate O 0 0.00033975978
of O 0 0.00060931337
100 O 0 0.0017396831
nCi O 0 0.17589955
/ O 0 0.0018230166
min O 0 0.0013736017
for O 0 0.0010425232
80 O 0 0.002781581
minutes O 0 0.003199237
. O 0 0.004458754

Deep O 0 0.027143229
forearm O 0 0.047341824
venous O 0 0.11001764
samples O 0 0.0023370008
were O 0 0.0017290158
collected O 0 0.0013136662
for O 0 0.0014555112
determination O 0 0.004546552
of O 0 0.0050661014
L B-Chemical 1 0.89158785
- I-Chemical 1 0.017220112
arginine I-Chemical 1 0.94813347
extraction O 0 0.048374448
. O 0 0.01157745

Plasma O 0 0.52485067
cortisol B-Chemical 1 0.96081084
concentrations O 0 0.008236164
were O 0 0.0014280357
significantly O 0 0.0011701955
raised O 0 0.0009652886
during O 0 0.00048549534
the O 0 0.00057377794
active O 0 0.0011572074
phase O 0 0.001842797
( O 0 0.0011221718
323 O 0 0.02250117
+ O 0 0.00086827093
/ O 0 0.0012941585
- O 0 0.0007387129
43 O 0 0.0006602486
to O 0 0.00042237918
1082 O 0 0.05930331
+ O 0 0.00082291896
/ O 0 0.0014492038
- O 0 0.0010947391
245 O 0 0.014583188
mmol O 0 0.62595963
/ O 0 0.0037224158
L O 0 0.33736908
, O 0 0.0017842938
P O 0 0.030147525
< O 0 0.0017629687
0 O 0 0.0017397336
. O 0 0.0017103235
05 O 0 0.030378424
) O 0 0.006651665
. O 0 0.0059117135

Systolic O 0 0.874057
blood O 0 0.0163872
pressure O 0 0.0325833
was O 0 0.0031033666
elevated O 0 0.0053933365
by O 0 0.0024712298
an O 0 0.0026603523
average O 0 0.0017564286
of O 0 0.003982196
7 O 0 0.004943485
mm O 0 0.02329266
Hg O 0 0.8916726
. O 0 0.009351013

Neither O 0 0.009159672
L B-Chemical 1 0.8384074
- I-Chemical 1 0.0079294285
arginine I-Chemical 1 0.9071038
transport O 0 0.020400738
into O 0 0.00092352193
mononuclear O 0 0.18890457
cells O 0 0.0024328122
( O 0 0.0010775647
placebo O 0 0.07066832
vs O 0 0.0010740898
active O 0 0.0008084275
, O 0 0.0005442415
26 O 0 0.00053638936
. O 0 0.00019336707
3 O 0 0.00025570637
+ O 0 0.00039667028
/ O 0 0.0007271788
- O 0 0.00044645363
3 O 0 0.00019109229
. O 0 0.00011870146
6 O 0 0.0001340965
vs O 0 0.00033557494
29 O 0 0.00038631726
. O 0 0.00013342664
0 O 0 0.00026165094
+ O 0 0.00031613477
/ O 0 0.00062678504
- O 0 0.00040682917
2 O 0 0.00020873456
. O 0 0.000117355965
1 O 0 0.00019000562
pmol O 0 0.0010759456
/ O 0 0.00041362806
10 O 0 0.00017120727
000 O 0 0.00016980097
cells O 0 0.00021332827
per O 0 8.6544285e-05
5 O 0 0.00012327345
minutes O 0 0.00014815202
, O 0 0.00022094735
respectively O 0 0.00042912256
, O 0 0.0002479772
at O 0 0.00013454043
an O 0 0.0003693209
l B-Chemical 0 0.006874766
- I-Chemical 0 0.0010732285
arginine I-Chemical 0 0.87461025
concentration O 0 0.0022150928
of O 0 0.0005070765
300 O 0 0.0061371
micromol O 0 0.55744857
/ O 0 0.004103659
L O 0 0.5625285
) O 0 0.0009917779
nor O 0 0.00048109677
L B-Chemical 1 0.88562894
- I-Chemical 1 0.0018617599
arginine I-Chemical 1 0.8949073
extraction O 0 0.0022150835
in O 0 0.00027011966
the O 0 0.00028316028
forearm O 0 0.08050409
( O 0 0.00037453236
at O 0 0.00012924144
80 O 0 0.000292716
minutes O 0 0.0002087853
, O 0 0.00029343468
placebo O 0 0.022626637
vs O 0 0.00059189985
active O 0 0.00053504104
, O 0 0.0004194575
1 O 0 0.00033332675
868 O 0 0.011088551
904 O 0 0.019665018
+ O 0 0.00054026354
/ O 0 0.0008886144
- O 0 0.0005560438
434 O 0 0.0015439859
962 O 0 0.010567566
vs O 0 0.00056660856
2 O 0 0.00029319865
013 O 0 0.0070033674
910 O 0 0.0029179577
+ O 0 0.00046473104
/ O 0 0.0007837222
- O 0 0.0005065019
770 O 0 0.008340889
619 O 0 0.012260686
disintegrations O 0 0.0018749947
per O 0 0.0001222943
minute O 0 0.0002231828
) O 0 0.0003611358
was O 0 0.00018862434
affected O 0 0.00019830064
by O 0 0.00033990527
cortisol B-Chemical 1 0.97461617
treatment O 0 0.003810517
; O 0 0.0009912509
ie O 0 0.0010002485
, O 0 0.0005362439
that O 0 0.0004101653
L B-Chemical 1 0.89099735
- I-Chemical 1 0.0030681384
arginine I-Chemical 1 0.9565835
uptake O 0 0.024993395
is O 0 0.00047522446
not O 0 0.0003825101
affected O 0 0.00043844074
by O 0 0.00065225083
short O 0 0.0010124819
- O 0 0.002129445
term O 0 0.0027763904
cortisol B-Chemical 1 0.98146194
treatment O 0 0.021146877
. O 0 0.0067666452

We O 0 0.00326349
conclude O 0 0.0025358445
that O 0 0.0021216394
cortisol B-Chemical 1 0.9738203
- O 0 0.0032963506
induced O 0 0.0014271192
increases B-Disease 0 0.000966345
in I-Disease 0 0.00063486525
blood I-Disease 0 0.0052812705
pressure I-Disease 0 0.028625278
are O 0 0.0005183932
not O 0 0.0003989285
associated O 0 0.00066021987
with O 0 0.00081779715
abnormalities O 0 0.07625038
in O 0 0.0007382606
the O 0 0.0010481158
l B-Chemical 0 0.019058546
- I-Chemical 0 0.0055863825
arginine I-Chemical 0 0.9391539
transport O 0 0.062798716
system O 0 0.00980578
. O 0 0.0070088673

Amount O 0 0.016271567
of O 0 0.0065301573
bleeding B-Disease 0 0.9833661
and O 0 0.005592565
hematoma B-Disease 0 0.99262357
size O 0 0.003006695
in O 0 0.0014843916
the O 0 0.0017841586
collagenase O 0 0.74595726
- O 0 0.0058617136
induced O 0 0.0074127438
intracerebral B-Disease 0 0.9969379
hemorrhage I-Disease 2 0.9988306
rat O 0 0.2793049
model O 0 0.012284314
. O 0 0.008785376

The O 0 0.004528355
aggravated O 0 0.24411505
risk O 0 0.061488345
on O 0 0.0024873116
intracerebral B-Disease 0 0.9960735
hemorrhage I-Disease 2 0.9993624
( O 0 0.035123147
ICH B-Disease 2 0.9993718
) O 0 0.0028391313
with O 0 0.0011190281
drugs O 0 0.40547037
used O 0 0.0008241365
for O 0 0.0009212071
stroke B-Disease 2 0.99352443
patients O 0 0.004794628
should O 0 0.00098238
be O 0 0.0015995222
estimated O 0 0.0020846415
carefully O 0 0.0034281553
. O 0 0.005354756

We O 0 0.0033306167
therefore O 0 0.0026802258
established O 0 0.0021831766
sensitive O 0 0.0015883166
quantification O 0 0.0014899281
methods O 0 0.0013809167
and O 0 0.0011005664
provided O 0 0.0011294564
a O 0 0.0014946836
rat O 0 0.033792403
ICH B-Disease 2 0.9984255
model O 0 0.0022911255
for O 0 0.0014689183
detection O 0 0.0030731761
of O 0 0.008593027
ICH B-Disease 2 0.9982924
deterioration O 0 0.8506268
. O 0 0.010207802

In O 0 0.0067657153
ICH B-Disease 2 0.99651575
intrastriatally O 0 0.98655117
induced O 0 0.0034592275
by O 0 0.0015641892
0 O 0 0.0012416696
. O 0 0.00058492966
014 O 0 0.015797507
- O 0 0.0009376889
unit O 0 0.00047947222
, O 0 0.0005943623
0 O 0 0.0004607906
. O 0 0.0002481158
070 O 0 0.01189029
- O 0 0.0005040231
unit O 0 0.00028061736
, O 0 0.00036798415
and O 0 0.00028390798
0 O 0 0.00030079868
. O 0 0.00014113964
350 O 0 0.00051432283
- O 0 0.00035468495
unit O 0 0.000237706
collagenase O 0 0.35772225
, O 0 0.00036804273
the O 0 0.00018877494
amount O 0 0.00013878282
of O 0 0.00047478205
bleeding B-Disease 0 0.99181175
was O 0 0.00034485396
measured O 0 0.00018250037
using O 0 0.00021066077
a O 0 0.00036041866
hemoglobin O 0 0.6625946
assay O 0 0.00074513693
developed O 0 0.0006330081
in O 0 0.00022726515
the O 0 0.00021199204
present O 0 0.00019172922
study O 0 0.00046960727
and O 0 0.0003640668
was O 0 0.00036024023
compared O 0 0.0002723506
with O 0 0.00065120147
the O 0 0.00083955785
morphologically O 0 0.0037384434
determined O 0 0.0023699033
hematoma B-Disease 0 0.99451315
volume O 0 0.039815232
. O 0 0.006802826

The O 0 0.003325227
blood O 0 0.006523933
amounts O 0 0.0022616026
and O 0 0.0023700667
hematoma B-Disease 0 0.9908965
volumes O 0 0.0036833233
were O 0 0.0008159858
significantly O 0 0.0007768672
correlated O 0 0.0005070618
, O 0 0.00070489384
and O 0 0.0005493805
the O 0 0.0006464349
hematoma B-Disease 0 0.9965084
induced O 0 0.0011717248
by O 0 0.00060975493
0 O 0 0.00060437375
. O 0 0.00030137625
014 O 0 0.013920747
- O 0 0.00073595566
unit O 0 0.00052869733
collagenase O 0 0.25621453
was O 0 0.0008111816
adequate O 0 0.0011547601
to O 0 0.0014179634
detect O 0 0.0025953797
ICH B-Disease 2 0.99798274
deterioration O 0 0.7401339
. O 0 0.008026621

In O 0 0.005702443
ICH B-Disease 2 0.9942095
induction O 0 0.00384269
using O 0 0.001522929
0 O 0 0.0014437111
. O 0 0.0007219654
014 O 0 0.014552542
- O 0 0.0011110699
unit O 0 0.00063015276
collagenase O 0 0.5760177
, O 0 0.0012062495
heparin B-Chemical 1 0.973215
enhanced O 0 0.0012938713
the O 0 0.00077451085
hematoma B-Disease 0 0.99791175
volume O 0 0.0050296355
3 O 0 0.000356907
. O 0 0.00018156797
4 O 0 0.00023056386
- O 0 0.0003669156
fold O 0 0.00035386393
over O 0 0.00011391027
that O 0 0.00018146187
seen O 0 0.00025661738
in O 0 0.00026738158
control O 0 0.0004621322
ICH B-Disease 2 0.9989794
animals O 0 0.00051116996
and O 0 0.00062211993
the O 0 0.0008492772
bleeding B-Disease 0 0.9862096
7 O 0 0.0011844524
. O 0 0.0008599102
6 O 0 0.0013462129
- O 0 0.0033318184
fold O 0 0.0057176608
. O 0 0.004883825

Data O 0 0.0048407996
suggest O 0 0.0018121368
that O 0 0.0013671921
this O 0 0.0012262072
sensitive O 0 0.0015348274
hemoglobin O 0 0.6662803
assay O 0 0.0019304326
is O 0 0.00074270065
useful O 0 0.0008953162
for O 0 0.0006917646
ICH B-Disease 2 0.9992631
detection O 0 0.0010354981
, O 0 0.0006375703
and O 0 0.0003479218
that O 0 0.00022983651
a O 0 0.00031271658
model O 0 0.00040042764
with O 0 0.00039324258
a O 0 0.00042698867
small O 0 0.0008313562
ICH B-Disease 2 0.9995295
induced O 0 0.0009435585
with O 0 0.00052101887
a O 0 0.0004219508
low O 0 0.0006056008
- O 0 0.00078661955
dose O 0 0.01253474
collagenase O 0 0.529034
should O 0 0.00024868135
be O 0 0.00030959435
used O 0 0.00026108723
for O 0 0.00028827315
evaluation O 0 0.000711188
of O 0 0.0010570374
drugs O 0 0.4756683
that O 0 0.0013932827
may O 0 0.0024450354
affect O 0 0.004105511
ICH B-Disease 2 0.9973367
. O 0 0.008432432

Estradiol B-Chemical 0 0.9979964
reduces O 0 0.018329049
seizure B-Disease 2 0.9981675
- O 0 0.01629456
induced O 0 0.007212331
hippocampal B-Disease 0 0.9941257
injury I-Disease 0 0.99328834
in O 0 0.002441615
ovariectomized O 0 0.858267
female O 0 0.00621881
but O 0 0.0015362406
not O 0 0.0016076893
in O 0 0.0022430837
male O 0 0.009548131
rats O 0 0.014761124
. O 0 0.007110008

Estrogens O 0 0.982726
protect O 0 0.027299829
ovariectomized O 0 0.81951386
rats O 0 0.019568067
from O 0 0.0030097023
hippocampal B-Disease 0 0.9895085
injury I-Disease 0 0.9913919
induced O 0 0.006466978
by O 0 0.0050157164
kainic B-Chemical 0 0.99983394
acid I-Chemical 0 0.9927127
- O 0 0.0075239143
induced O 0 0.003217489
status B-Disease 0 0.0121148145
epilepticus I-Disease 0 0.99957186
( O 0 0.014180124
SE B-Disease 0 0.6368402
) O 0 0.010834186
. O 0 0.006878111

We O 0 0.003036351
compared O 0 0.0014651009
the O 0 0.0015168975
effects O 0 0.0026736492
of O 0 0.0039593205
17beta B-Chemical 1 0.9995913
- I-Chemical 1 0.058746964
estradiol I-Chemical 1 0.9996507
in O 0 0.0012640094
adult O 0 0.0016570244
male O 0 0.0026575122
and O 0 0.00076190644
ovariectomized O 0 0.6234109
female O 0 0.0027796766
rats O 0 0.0022494914
subjected O 0 0.0005999214
to O 0 0.0012150863
lithium B-Chemical 1 0.9987478
- O 0 0.040332552
pilocarpine B-Chemical 1 0.9995844
- O 0 0.019516269
induced O 0 0.0105586015
SE B-Disease 0 0.67605084
. O 0 0.0077399975

Rats O 0 0.03251922
received O 0 0.0039158408
subcutaneous O 0 0.041650966
injections O 0 0.017106198
of O 0 0.0049277637
17beta B-Chemical 1 0.99954695
- I-Chemical 1 0.056497
estradiol I-Chemical 1 0.9996445
( O 0 0.0029905972
2 O 0 0.00082598836
microg O 0 0.002093203
/ O 0 0.0016517255
rat O 0 0.005266822
) O 0 0.0010011281
or O 0 0.0005526574
oil O 0 0.49384758
once O 0 0.00083024555
daily O 0 0.0016879917
for O 0 0.0008020939
four O 0 0.0010690815
consecutive O 0 0.0028481227
days O 0 0.0036679653
. O 0 0.0050366274

SE B-Disease 0 0.12337173
was O 0 0.0034079736
induced O 0 0.002704734
20 O 0 0.001788885
h O 0 0.0012691782
following O 0 0.0009845326
the O 0 0.0009325365
second O 0 0.0010937996
injection O 0 0.0030175878
and O 0 0.0016505128
terminated O 0 0.003182154
3 O 0 0.0020388055
h O 0 0.0029943185
later O 0 0.004151859
. O 0 0.0060084467

The O 0 0.0035645948
extent O 0 0.002419904
of O 0 0.0034976897
silver B-Chemical 0 0.90531695
- O 0 0.0063888784
stained O 0 0.004865653
CA3 O 0 0.99315345
and O 0 0.0035077475
CA1 O 0 0.9940156
hippocampal O 0 0.9182948
neurons O 0 0.028082037
was O 0 0.0011171683
evaluated O 0 0.0011414117
2 O 0 0.0014645589
days O 0 0.0017750931
after O 0 0.0023188917
SE B-Disease 0 0.16543853
. O 0 0.006918486

17beta B-Chemical 1 0.99802643
- I-Chemical 1 0.098511174
Estradiol I-Chemical 1 0.9993242
did O 0 0.0026731726
not O 0 0.0011973229
alter O 0 0.0010399014
the O 0 0.000768817
onset O 0 0.002403003
of O 0 0.0009766662
first O 0 0.00087764463
clonus O 0 0.99681914
in O 0 0.0011720808
ovariectomized O 0 0.7912038
rats O 0 0.0069767926
but O 0 0.0012166116
accelerated O 0 0.0038750705
it O 0 0.0025086089
in O 0 0.002653429
males O 0 0.0064284736
. O 0 0.005738098

17beta B-Chemical 1 0.9978103
- I-Chemical 1 0.09475962
Estradiol I-Chemical 1 0.9992311
reduced O 0 0.0042764675
the O 0 0.0024251402
argyrophilic O 0 0.9566423
neurons O 0 0.07550747
in O 0 0.0013505972
the O 0 0.0017937578
CA1 O 0 0.99062777
and O 0 0.0038565174
CA3 O 0 0.9955676
- O 0 0.0063440837
C O 0 0.68841034
sectors O 0 0.01735285
of O 0 0.0057144784
ovariectomized O 0 0.90511096
rats O 0 0.04221676
. O 0 0.008182111

In O 0 0.00628122
males O 0 0.007805575
, O 0 0.008188649
estradiol B-Chemical 1 0.993342
increased O 0 0.0086389
the O 0 0.0051974263
total O 0 0.0067848205
damage O 0 0.5654376
score O 0 0.014659817
. O 0 0.012405978

These O 0 0.004202639
findings O 0 0.0034791832
suggest O 0 0.0012838787
that O 0 0.0010135025
the O 0 0.00092436
effects O 0 0.0017384595
of O 0 0.0017839462
estradiol B-Chemical 1 0.9992544
on O 0 0.00088866137
seizure B-Disease 2 0.9988765
threshold O 0 0.001187069
and O 0 0.0008693392
damage O 0 0.42083862
may O 0 0.0006331471
be O 0 0.0004908078
altered O 0 0.0007461086
by O 0 0.0006195814
sex O 0 0.013074526
- O 0 0.0010480772
related O 0 0.0004690371
differences O 0 0.00053353363
in O 0 0.0009128703
the O 0 0.0017336236
hormonal O 0 0.45808125
environment O 0 0.010442298
. O 0 0.006478275

Pseudoacromegaly B-Disease 0 0.2452399
induced O 0 0.0062823393
by O 0 0.00378483
the O 0 0.003005157
long O 0 0.0039801467
- O 0 0.004822142
term O 0 0.004063961
use O 0 0.0060774153
of O 0 0.013117203
minoxidil B-Chemical 0 0.9984163
. O 0 0.019678414

Acromegaly B-Disease 0 0.9905682
is O 0 0.0043764524
an O 0 0.004061102
endocrine B-Disease 0 0.9892001
disorder I-Disease 0 0.9909004
caused O 0 0.0035623733
by O 0 0.002156955
chronic O 0 0.9723573
excessive O 0 0.34123164
growth O 0 0.097375035
hormone O 0 0.9763346
secretion O 0 0.14918377
from O 0 0.0019401708
the O 0 0.0024861419
anterior O 0 0.12758255
pituitary O 0 0.93221265
gland O 0 0.67845017
. O 0 0.008781976

Significant O 0 0.008431215
disfiguring O 0 0.05085757
changes O 0 0.0030255327
occur O 0 0.0016083103
as O 0 0.0008513165
a O 0 0.00086829363
result O 0 0.00059573975
of O 0 0.0009906457
bone O 0 0.07352858
, O 0 0.0012585483
cartilage O 0 0.052844547
, O 0 0.00073046266
and O 0 0.00048808366
soft O 0 0.008270718
tissue O 0 0.03102597
hypertrophy B-Disease 2 0.99721634
, O 0 0.0008185745
including O 0 0.00039717584
the O 0 0.00039396374
thickening O 0 0.4635847
of O 0 0.00059366145
the O 0 0.00049259776
skin O 0 0.022323886
, O 0 0.0010201173
coarsening O 0 0.63398004
of O 0 0.0013582192
facial O 0 0.29066265
features O 0 0.0069635916
, O 0 0.0023315607
and O 0 0.0032470499
cutis B-Disease 0 0.9736386
verticis I-Disease 0 0.9897149
gyrata I-Disease 0 0.98357004
. O 0 0.011607527

Pseudoacromegaly B-Disease 0 0.2953953
, O 0 0.0035817588
on O 0 0.0011458391
the O 0 0.0011061329
other O 0 0.0010254292
hand O 0 0.0013514991
, O 0 0.001004701
is O 0 0.00050804246
the O 0 0.0003721158
presence O 0 0.00036855132
of O 0 0.000476255
similar O 0 0.0003535432
acromegaloid O 0 0.6040425
features O 0 0.0019859604
in O 0 0.000295725
the O 0 0.00026337287
absence O 0 0.0002020385
of O 0 0.00054871564
elevated O 0 0.010388031
growth O 0 0.021051655
hormone O 0 0.9469825
or O 0 0.0011382316
insulin O 0 0.9806846
- O 0 0.00290281
like O 0 0.0015635245
growth O 0 0.012993005
factor O 0 0.017379116
levels O 0 0.005490449
. O 0 0.0062774895

We O 0 0.0028271796
present O 0 0.0015969601
a O 0 0.0016886082
patient O 0 0.0019984331
with O 0 0.0016045888
pseudoacromegaly B-Disease 0 0.60895145
that O 0 0.00071701466
resulted O 0 0.00062648044
from O 0 0.00051626714
the O 0 0.00045553033
long O 0 0.00071402563
- O 0 0.00081885303
term O 0 0.0005933653
use O 0 0.0007926287
of O 0 0.0014851778
minoxidil B-Chemical 0 0.9996439
at O 0 0.0012087506
an O 0 0.002296583
unusually O 0 0.014517203
high O 0 0.0056513166
dose O 0 0.09678732
. O 0 0.007221631

This O 0 0.0051868185
is O 0 0.0023104125
the O 0 0.0014777221
first O 0 0.0010839315
case O 0 0.0012655184
report O 0 0.0026755598
of O 0 0.0019115856
pseudoacromegaly B-Disease 0 0.7674457
as O 0 0.0012716843
a O 0 0.0017762167
side O 0 0.013835577
effect O 0 0.002731294
of O 0 0.00688088
minoxidil B-Chemical 0 0.99927574
use O 0 0.022166237
. O 0 0.009451392

Combined O 0 0.12825151
androgen O 0 0.99374264
blockade O 0 0.7949638
- O 0 0.0116325645
induced O 0 0.0086469855
anemia B-Disease 0 0.9988763
in O 0 0.0058613657
prostate B-Disease 2 0.9970874
cancer I-Disease 2 0.9978618
patients O 0 0.075705834
without O 0 0.006055406
bone O 0 0.22344652
involvement O 0 0.023456568
. O 0 0.00890576

BACKGROUND O 0 0.6748472
: O 0 0.004194983
To O 0 0.0012870468
determine O 0 0.00063365506
the O 0 0.0008603139
onset O 0 0.0023179518
and O 0 0.00079282204
extent O 0 0.00045351175
of O 0 0.00074684626
combined O 0 0.0026103389
androgen O 0 0.9987154
blockade O 0 0.80875146
( O 0 0.0047733374
CAB O 0 0.48332337
) O 0 0.0028389476
- O 0 0.0015985576
induced O 0 0.002156046
anemia B-Disease 0 0.9994504
in O 0 0.0025828984
prostate B-Disease 2 0.9982899
cancer I-Disease 2 0.99865997
patients O 0 0.063875936
without O 0 0.00422574
bone O 0 0.22378759
involvement O 0 0.021527458
. O 0 0.006862533

PATIENTS O 0 0.015275647
AND O 0 0.0059834262
METHODS O 0 0.0036049697
: O 0 0.0023948264
Forty O 0 0.0040183463
- O 0 0.0015112365
two O 0 0.00063174235
patients O 0 0.0015428065
with O 0 0.0009305262
biopsy O 0 0.007452943
- O 0 0.0017477141
proven O 0 0.011570783
prostatic B-Disease 0 0.9992385
adenocarcinoma I-Disease 0 0.9998234
[ O 0 0.018527145
26 O 0 0.00095236045
with O 0 0.00057638093
stage O 0 0.0025645543
C O 0 0.8727371
( O 0 0.002313313
T3N0M0 O 0 0.9958859
) O 0 0.0010766494
and O 0 0.00041953666
16 O 0 0.0004070666
with O 0 0.0004931234
stage O 0 0.002929955
D1 O 0 0.99259585
( O 0 0.0027100153
T3N1M0 O 0 0.995099
) O 0 0.0021078836
] O 0 0.0015389367
were O 0 0.00066984055
included O 0 0.0008005309
in O 0 0.0011436244
this O 0 0.0020702023
study O 0 0.0051053837
. O 0 0.005389782

All O 0 0.0041227955
patients O 0 0.005110732
received O 0 0.0037568482
CAB O 0 0.28243905
[ O 0 0.018456174
leuprolide B-Chemical 0 0.9992331
acetate I-Chemical 0 0.9986034
( O 0 0.018023776
LHRH B-Chemical 0 0.99896216
- I-Chemical 0 0.007929343
A I-Chemical 0 0.11876318
) O 0 0.001156808
3 O 0 0.00036231158
. O 0 0.0002025898
75 O 0 0.0004850411
mg O 0 0.11663067
, O 0 0.00046781718
intramuscularly O 0 0.011735207
, O 0 0.00029541558
every O 0 0.00010456153
28 O 0 0.00021609936
days O 0 0.00015812335
plus O 0 0.00021998797
250 O 0 0.0007627485
mg O 0 0.5021393
flutamide B-Chemical 0 0.9998211
, O 0 0.0023738737
tid O 0 0.9985424
, O 0 0.0005594987
per O 0 0.00023673884
Os O 0 0.9803829
] O 0 0.0007870893
and O 0 0.00022074417
were O 0 0.00018251325
evaluated O 0 0.0002007678
for O 0 0.00027131804
anemia B-Disease 0 0.9992557
by O 0 0.00043928204
physical O 0 0.005933957
examination O 0 0.00062854553
and O 0 0.00023738029
laboratory O 0 0.00043606074
tests O 0 0.0004320625
at O 0 0.0001370029
baseline O 0 0.00028093942
and O 0 0.00022053275
4 O 0 0.00017141587
subsequent O 0 0.00024397727
intervals O 0 0.000310511
( O 0 0.0003958215
1 O 0 0.00030875162
, O 0 0.0003723085
2 O 0 0.0003250154
, O 0 0.00040308712
3 O 0 0.00031553104
and O 0 0.0004287703
6 O 0 0.00045344414
months O 0 0.00081721606
post O 0 0.0016772097
- O 0 0.0035009207
CAB O 0 0.11184555
) O 0 0.007410397
. O 0 0.0056913546

Hb O 0 0.8902644
, O 0 0.018352898
PSA O 0 0.84413743
and O 0 0.015262862
Testosterone B-Chemical 1 0.9936947
measurements O 0 0.009801669
were O 0 0.009918018
recorded O 0 0.014293793
. O 0 0.014937766

Patients O 0 0.010316597
with O 0 0.0035548543
stage O 0 0.0070190965
D2 O 0 0.9768684
- O 0 0.0032289084
3 O 0 0.0010458526
disease O 0 0.36594167
, O 0 0.0012374489
abnormal O 0 0.013296332
hemoglobin O 0 0.76638204
level O 0 0.0004635864
or O 0 0.00047888304
renal O 0 0.96771973
and O 0 0.0007893487
liver O 0 0.69261384
function O 0 0.00064415263
tests O 0 0.0007626303
that O 0 0.0002467221
were O 0 0.00027008515
higher O 0 0.00027461827
than O 0 0.00020794531
the O 0 0.00032301646
upper O 0 0.0007165594
limits O 0 0.0010399331
were O 0 0.000722556
excluded O 0 0.001193173
from O 0 0.001374212
the O 0 0.0021736512
study O 0 0.0053616324
. O 0 0.0054288926

The O 0 0.004958856
duration O 0 0.0053656674
of O 0 0.004869908
the O 0 0.0042699086
study O 0 0.00595906
was O 0 0.005080784
six O 0 0.005295287
months O 0 0.010026649
. O 0 0.0113254795

RESULTS O 0 0.026003838
: O 0 0.004029958
The O 0 0.0014918097
mean O 0 0.001183862
hemoglobin O 0 0.6126994
( O 0 0.0028836776
Hb O 0 0.91832656
) O 0 0.001537532
levels O 0 0.00052410155
were O 0 0.00040897328
significantly O 0 0.00045720715
declined O 0 0.00064073113
in O 0 0.0002498921
all O 0 0.00022419095
patients O 0 0.00063519244
from O 0 0.00021653
baseline O 0 0.00030330836
of O 0 0.00030073043
14 O 0 0.00031008027
. O 0 0.0001385242
2 O 0 0.00021021553
g O 0 0.00056750636
/ O 0 0.00051435665
dl O 0 0.0017751583
to O 0 0.00020798123
14 O 0 0.00026028644
. O 0 0.00012433284
0 O 0 0.00022397004
g O 0 0.0005336298
/ O 0 0.0005454349
dl O 0 0.0032658358
, O 0 0.00033225596
13 O 0 0.00027618953
. O 0 0.0001236642
5 O 0 0.00016652538
g O 0 0.0005207552
/ O 0 0.0005395275
dl O 0 0.0032979583
, O 0 0.00033364433
13 O 0 0.00027841667
. O 0 0.00012566542
2 O 0 0.00019596914
g O 0 0.0005355812
/ O 0 0.0005001137
dl O 0 0.001896948
and O 0 0.00023864294
12 O 0 0.00017491136
. O 0 0.0001238438
7 O 0 0.00017441208
g O 0 0.0005330426
/ O 0 0.0005381341
dl O 0 0.0018946481
at O 0 0.00018989568
1 O 0 0.00030614645
, O 0 0.00035227113
2 O 0 0.00029747197
, O 0 0.00035701247
3 O 0 0.00026739482
and O 0 0.00034954923
6 O 0 0.00034819703
months O 0 0.00060349243
post O 0 0.0011810834
- O 0 0.0023464966
CAB O 0 0.070772216
, O 0 0.0038824733
respectively O 0 0.007511193
. O 0 0.005466389

Severe O 0 0.75021225
and O 0 0.0043245116
clinically O 0 0.04927219
evident O 0 0.003144191
anemia B-Disease 0 0.9984572
of O 0 0.0040736278
Hb O 0 0.9721604
< O 0 0.0013184644
11 O 0 0.00071056234
g O 0 0.0012750722
/ O 0 0.0009984609
dl O 0 0.0031332837
with O 0 0.00053505076
clinical O 0 0.007371343
symptoms O 0 0.1999912
was O 0 0.00044729174
detected O 0 0.00026291778
in O 0 0.00037587693
6 O 0 0.0004009985
patients O 0 0.0013213274
( O 0 0.0010111409
14 O 0 0.000982372
. O 0 0.000743009
3 O 0 0.0013735009
% O 0 0.0025631897
) O 0 0.0047203805
. O 0 0.0046925624

This O 0 0.014226577
CAB O 0 0.17172998
- O 0 0.012447157
induced O 0 0.0125719495
anemia B-Disease 0 0.9968837
was O 0 0.014976496
normochromic O 0 0.9856318
and O 0 0.020971207
normocytic O 0 0.9858531
. O 0 0.019014163

At O 0 0.0023249588
six O 0 0.0015066728
months O 0 0.0017145216
post O 0 0.0020025994
- O 0 0.0022311118
CAB O 0 0.052058104
, O 0 0.0012430566
patients O 0 0.0018551102
with O 0 0.0010016193
severe O 0 0.39359972
anemia B-Disease 0 0.9995432
had O 0 0.0012277407
a O 0 0.0008208272
Hb O 0 0.87105066
mean O 0 0.00023416664
value O 0 0.0002918171
of O 0 0.00037592454
10 O 0 0.00036721473
. O 0 0.00018429506
2 O 0 0.000292247
+ O 0 0.00040041254
/ O 0 0.00075864507
- O 0 0.0004646159
0 O 0 0.000265716
. O 0 0.00012963814
1 O 0 0.00021459922
g O 0 0.00061739923
/ O 0 0.00068599393
dl O 0 0.011335933
( O 0 0.0007614216
X O 0 0.18108161
+ O 0 0.00073007843
/ O 0 0.0016633238
- O 0 0.0009641934
SE O 0 0.227327
) O 0 0.0006665942
, O 0 0.00030475156
whereas O 0 0.00018746626
the O 0 0.00017357444
other O 0 0.00022774431
patients O 0 0.0010934273
had O 0 0.00045416804
mild O 0 0.7497434
anemia B-Disease 0 0.9997441
with O 0 0.0022458052
Hb O 0 0.9590833
mean O 0 0.00020976084
value O 0 0.00026760984
of O 0 0.00036492632
13 O 0 0.00043897546
. O 0 0.00019954564
2 O 0 0.00033467848
+ O 0 0.00048237754
/ O 0 0.0009390339
- O 0 0.00066059944
0 O 0 0.00044396266
. O 0 0.00027735953
17 O 0 0.00079916656
( O 0 0.0010877869
X O 0 0.085147135
+ O 0 0.00210687
/ O 0 0.004825854
- O 0 0.00518797
SE O 0 0.33672658
) O 0 0.008214175
. O 0 0.0058719926

The O 0 0.0032654975
development O 0 0.0041672573
of O 0 0.0029734476
severe O 0 0.33257043
anemia B-Disease 0 0.99868315
at O 0 0.0010206422
6 O 0 0.0005923521
months O 0 0.0005752953
post O 0 0.0007118966
- O 0 0.0008752646
CAB O 0 0.029283129
was O 0 0.0003868467
predictable O 0 0.0011800594
by O 0 0.00032083003
the O 0 0.00027116368
reduction O 0 0.00056934136
of O 0 0.0005144398
Hb O 0 0.89686733
baseline O 0 0.00045245796
value O 0 0.00024777255
of O 0 0.00030105145
more O 0 0.00034947039
than O 0 0.00017399267
2 O 0 0.00024236544
. O 0 0.00013745186
5 O 0 0.00018565539
g O 0 0.00055010384
/ O 0 0.00053576595
dl O 0 0.0013884843
after O 0 0.00016624885
3 O 0 0.00023290457
months O 0 0.00031985794
of O 0 0.0005599063
CAB O 0 0.07240238
( O 0 0.0011900278
p O 0 0.0013749865
= O 0 0.0016275832
0 O 0 0.0014343822
. O 0 0.0013706458
01 O 0 0.00938662
) O 0 0.005653686
. O 0 0.005215871

The O 0 0.0033319693
development O 0 0.0042623794
of O 0 0.00300184
severe O 0 0.23908764
CAB O 0 0.5113656
- O 0 0.004361123
induced O 0 0.0035853516
anemia B-Disease 0 0.99946755
in O 0 0.002405019
prostate B-Disease 2 0.9986884
cancer I-Disease 2 0.99928015
patients O 0 0.031034866
did O 0 0.00048363762
not O 0 0.00029006074
correlate O 0 0.0003440923
with O 0 0.0005174687
T O 0 0.23862223
baseline O 0 0.0005606173
values O 0 0.00038158082
( O 0 0.00059478654
T O 0 0.1449576
< O 0 0.00038061535
3 O 0 0.0002085384
ng O 0 0.0006352248
/ O 0 0.00062670995
ml O 0 0.0010040188
versus O 0 0.00031579827
T O 0 0.20422103
> O 0 0.000726038
or O 0 0.00022380843
= O 0 0.00039596963
3 O 0 0.00019099718
ng O 0 0.0006285201
/ O 0 0.0006758764
ml O 0 0.0014815707
) O 0 0.00049422483
, O 0 0.00030612896
with O 0 0.00030691593
age O 0 0.0007811234
( O 0 0.0004003933
< O 0 0.0002876549
76 O 0 0.00040026507
yrs O 0 0.0008608252
versus O 0 0.00023598546
> O 0 0.0004924198
or O 0 0.00022330561
= O 0 0.00043402895
76 O 0 0.00051270146
yrs O 0 0.0014503849
) O 0 0.0005100157
, O 0 0.00038491885
and O 0 0.000373451
clinical O 0 0.0031485986
stage O 0 0.0018800874
( O 0 0.0011806621
stage O 0 0.002781012
C O 0 0.6170986
versus O 0 0.0023447801
stage O 0 0.017632764
D1 O 0 0.9862855
) O 0 0.011957651
. O 0 0.006707929

Severe O 0 0.7488041
and O 0 0.004018371
clinically O 0 0.049369942
evident O 0 0.00276693
anemia B-Disease 0 0.99854124
was O 0 0.0013513125
easily O 0 0.0010130792
corrected O 0 0.0005780926
by O 0 0.00054497895
subcutaneous O 0 0.031776894
injections O 0 0.007962537
( O 0 0.00056980434
3 O 0 0.0002227642
times O 0 0.00017058788
/ O 0 0.0004505586
week O 0 0.00021497173
for O 0 0.0002122311
1 O 0 0.0002901747
month O 0 0.0003219076
) O 0 0.0005651413
of O 0 0.0005806512
recombinant O 0 0.0017386609
erythropoietin O 0 0.9950466
( O 0 0.00867649
rHuEPO O 0 0.9931826
- O 0 0.012827746
beta O 0 0.621944
) O 0 0.012393201
. O 0 0.0065779947

CONCLUSION O 0 0.745072
: O 0 0.004356419
Our O 0 0.0018697663
data O 0 0.00158299
suggest O 0 0.001019701
that O 0 0.0012615758
rHuEPO O 0 0.9888631
- O 0 0.0050263987
beta O 0 0.58162767
correctable O 0 0.3986268
CAB O 0 0.6178441
- O 0 0.0029064296
induced O 0 0.0023440756
anemia B-Disease 0 0.9995431
occurs O 0 0.0009328737
in O 0 0.00043605804
14 O 0 0.00046630212
. O 0 0.00020170916
3 O 0 0.00025411742
% O 0 0.00033832903
of O 0 0.0005822343
prostate B-Disease 2 0.9954301
cancer I-Disease 2 0.998114
patients O 0 0.008801736
after O 0 0.00062076503
6 O 0 0.00075785356
months O 0 0.0012321186
of O 0 0.0024061494
therapy O 0 0.03433669
. O 0 0.0058165886

Delirium B-Disease 2 0.9820634
during O 0 0.006454355
clozapine B-Chemical 1 0.99869066
treatment O 0 0.021442333
: O 0 0.0063126
incidence O 0 0.011010664
and O 0 0.004191962
associated O 0 0.0068398695
risk O 0 0.09670958
factors O 0 0.034342784
. O 0 0.011453789

BACKGROUND O 0 0.78118694
: O 0 0.007310279
Incidence O 0 0.05544363
and O 0 0.0027142286
risk O 0 0.011341742
factors O 0 0.0046633435
for O 0 0.0021354272
delirium B-Disease 2 0.9980513
during O 0 0.0027510354
clozapine B-Chemical 1 0.9994431
treatment O 0 0.008472118
require O 0 0.002602361
further O 0 0.0044930656
clarification O 0 0.010315502
. O 0 0.007868294

METHODS O 0 0.006099048
: O 0 0.0030083777
We O 0 0.0013056333
used O 0 0.0010568479
computerized O 0 0.00276567
pharmacy O 0 0.004228095
records O 0 0.0010648054
to O 0 0.00051169423
identify O 0 0.00040323104
all O 0 0.00038924266
adult O 0 0.00097160623
psychiatric B-Disease 2 0.92598027
inpatients O 0 0.03995381
treated O 0 0.001364796
with O 0 0.0012873888
clozapine B-Chemical 1 0.99989426
( O 0 0.002696493
1995 O 0 0.023728875
- O 0 0.0007220332
96 O 0 0.00062362716
) O 0 0.00044929484
, O 0 0.0002951259
reviewed O 0 0.00049111876
their O 0 0.000245326
medical O 0 0.0013649915
records O 0 0.00041333894
to O 0 0.0002131571
score O 0 0.0003119656
incidence O 0 0.0019102386
and O 0 0.0004154672
severity O 0 0.013002413
of O 0 0.0013725935
delirium B-Disease 2 0.9993818
, O 0 0.0009065243
and O 0 0.0004960158
tested O 0 0.00040405677
associations O 0 0.0006833027
with O 0 0.0012339766
potential O 0 0.0027765671
risk O 0 0.06922266
factors O 0 0.026085302
. O 0 0.006547504

RESULTS O 0 0.03005478
: O 0 0.00523339
Subjects O 0 0.0043950374
( O 0 0.0021299557
n O 0 0.0011235398
= O 0 0.0013452395
139 O 0 0.0018483194
) O 0 0.0008794428
were O 0 0.0004302912
72 O 0 0.0005132623
women O 0 0.0017114353
and O 0 0.00042147987
67 O 0 0.000851622
men O 0 0.008759106
, O 0 0.00049498177
aged O 0 0.0006031647
40 O 0 0.0003449597
. O 0 0.00017850891
8 O 0 0.00026893427
+ O 0 0.0003685076
/ O 0 0.00066047924
- O 0 0.00040512477
12 O 0 0.00016668916
. O 0 0.00011693585
1 O 0 0.00017594612
years O 0 0.00032630353
, O 0 0.0002650349
hospitalized O 0 0.010869874
for O 0 0.00018782803
24 O 0 0.00024086898
. O 0 0.00014011437
9 O 0 0.00023706908
+ O 0 0.00032341827
/ O 0 0.0006382007
- O 0 0.00040322507
23 O 0 0.0003228228
. O 0 0.000105031795
3 O 0 0.00012540554
days O 0 0.00014675167
, O 0 0.00021074155
and O 0 0.00019397185
given O 0 0.0002121955
clozapine B-Chemical 1 0.9998523
, O 0 0.0005815172
gradually O 0 0.001095486
increased O 0 0.0005162388
to O 0 0.00020964949
an O 0 0.00025143597
average O 0 0.00011687274
daily O 0 0.0006692946
dose O 0 0.004527886
of O 0 0.00048830145
282 O 0 0.030414483
+ O 0 0.0006076391
/ O 0 0.0011383791
- O 0 0.00060454546
203 O 0 0.0074407686
mg O 0 0.30582207
( O 0 0.00042481636
3 O 0 0.00019674425
. O 0 0.0001273221
45 O 0 0.00022403795
+ O 0 0.00031808112
/ O 0 0.0006303726
- O 0 0.0004155999
2 O 0 0.00021588334
. O 0 0.00012306978
45 O 0 0.0002249873
mg O 0 0.06437735
/ O 0 0.00068659463
kg O 0 0.0021456226
) O 0 0.00044356394
for O 0 0.00023767153
18 O 0 0.00038634674
. O 0 0.0002519899
9 O 0 0.00047284205
+ O 0 0.0007435608
/ O 0 0.0015168395
- O 0 0.0013398112
16 O 0 0.0010689197
. O 0 0.0008445659
4 O 0 0.0014975464
days O 0 0.0026222412
. O 0 0.004045793

Delirium B-Disease 2 0.9840853
was O 0 0.0038375952
diagnosed O 0 0.010175064
in O 0 0.0014791046
14 O 0 0.001387602
( O 0 0.0011300854
10 O 0 0.0006609893
. O 0 0.00034941945
1 O 0 0.00041645812
% O 0 0.00043029364
incidence O 0 0.0013239918
, O 0 0.00048026122
or O 0 0.00028028685
1 O 0 0.00030149493
. O 0 0.00014959913
48 O 0 0.00022287128
cases O 0 0.00042896488
/ O 0 0.0006565759
person O 0 0.00062391703
- O 0 0.0004725467
years O 0 0.00045029732
of O 0 0.0003678032
exposure O 0 0.003463397
) O 0 0.0009531102
; O 0 0.00068458257
71 O 0 0.0007973873
. O 0 0.00021230498
4 O 0 0.00027703578
% O 0 0.0003676297
of O 0 0.0004916544
cases O 0 0.0011839612
were O 0 0.0010938739
moderate O 0 0.006905205
or O 0 0.0028616318
severe O 0 0.2790048
. O 0 0.0066512404

Associated O 0 0.021793181
factors O 0 0.0055990503
were O 0 0.0023478835
co O 0 0.10178099
- O 0 0.0025600086
treatment O 0 0.0018926418
with O 0 0.00093508384
other O 0 0.00076659006
centrally O 0 0.030158242
antimuscarinic O 0 0.99883085
agents O 0 0.38668007
, O 0 0.00085186906
poor O 0 0.001705806
clinical O 0 0.007763846
outcome O 0 0.0017665378
, O 0 0.0005063885
older O 0 0.0011998564
age O 0 0.00067925185
, O 0 0.00032051603
and O 0 0.00022559524
longer O 0 0.00018213617
hospitalization O 0 0.047817025
( O 0 0.00042884366
by O 0 0.000252506
17 O 0 0.00035596947
. O 0 0.00011797261
5 O 0 0.00013387803
days O 0 0.00014837738
, O 0 0.0002103601
increasing O 0 0.00030072185
cost O 0 0.0006268958
) O 0 0.0008074266
; O 0 0.0006143487
sex O 0 0.0043099686
, O 0 0.00041292407
diagnosis O 0 0.0027262694
or O 0 0.00027449577
medical O 0 0.010158921
co O 0 0.34496918
- O 0 0.0021686917
morbidity O 0 0.3683855
, O 0 0.0006046128
and O 0 0.00040119505
daily O 0 0.0044946596
clozapine B-Chemical 1 0.99983895
dose O 0 0.07700934
, O 0 0.0009298203
which O 0 0.0008074967
fell O 0 0.0016857819
with O 0 0.0011638114
age O 0 0.002894794
, O 0 0.0022250991
were O 0 0.002435867
unrelated O 0 0.00814171
. O 0 0.005798715

CONCLUSIONS O 0 0.84744215
: O 0 0.009876111
Delirium B-Disease 2 0.98526925
was O 0 0.0019933651
found O 0 0.0011487544
in O 0 0.0008081606
10 O 0 0.00079701777
% O 0 0.00071485044
of O 0 0.0009914781
clozapine B-Chemical 1 0.9997693
- O 0 0.0029718208
treated O 0 0.0016701499
inpatients O 0 0.027108738
, O 0 0.0007397488
particularly O 0 0.00085767097
in O 0 0.0004804188
older O 0 0.0018176965
patients O 0 0.0016935886
exposed O 0 0.0010221662
to O 0 0.0010383062
other O 0 0.0019853448
central O 0 0.01769893
anticholinergics O 0 0.99728477
. O 0 0.008861696

Delirium B-Disease 2 0.98406523
was O 0 0.0033948
inconsistently O 0 0.0105285
recognized O 0 0.0020750167
clinically O 0 0.024219023
in O 0 0.00080040726
milder O 0 0.033601098
cases O 0 0.0015172391
and O 0 0.00060733507
was O 0 0.00043371416
associated O 0 0.0005509917
with O 0 0.0005136327
increased O 0 0.00081000366
length O 0 0.00052395824
- O 0 0.00079836056
of O 0 0.00059600116
- O 0 0.00082196755
stay O 0 0.0009499725
and O 0 0.0004670911
higher O 0 0.00054116244
costs O 0 0.0016809561
, O 0 0.0012168863
and O 0 0.0013672978
inferior O 0 0.045891885
clinical O 0 0.018134516
outcome O 0 0.010628355
. O 0 0.00585511

Neuroprotective O 0 0.9880036
action O 0 0.047127027
of O 0 0.008201537
MPEP B-Chemical 1 0.9996711
, O 0 0.005433093
a O 0 0.0020521728
selective O 0 0.06304097
mGluR5 O 0 0.9976896
antagonist O 0 0.994467
, O 0 0.0030835602
in O 0 0.0011598825
methamphetamine B-Chemical 1 0.99980897
- O 0 0.0080690365
induced O 0 0.0039671343
dopaminergic O 0 0.99775875
neurotoxicity B-Disease 2 0.99980825
is O 0 0.000832562
associated O 0 0.0007519825
with O 0 0.00055392977
a O 0 0.0005072856
decrease O 0 0.00068090006
in O 0 0.00069056184
dopamine B-Chemical 1 0.99913365
outflow O 0 0.987663
and O 0 0.0016333269
inhibition O 0 0.011658887
of O 0 0.004248224
hyperthermia B-Disease 2 0.9978327
in O 0 0.0051839305
rats O 0 0.04120033
. O 0 0.0064557865

The O 0 0.0025710172
aim O 0 0.0019292257
of O 0 0.0014653556
this O 0 0.0010336511
study O 0 0.0012475175
was O 0 0.000657674
to O 0 0.0004813291
examine O 0 0.00030249893
the O 0 0.00041626208
role O 0 0.00039710713
of O 0 0.0014970817
metabotropic O 0 0.9996531
glutamate B-Chemical 1 0.999713
receptor O 0 0.7112462
5 O 0 0.00093934225
( O 0 0.0012172444
mGluR5 O 0 0.9896818
) O 0 0.0010181061
in O 0 0.00035166228
the O 0 0.00046059687
toxic O 0 0.5503196
action O 0 0.015276671
of O 0 0.0027291127
methamphetamine B-Chemical 1 0.99961686
on O 0 0.0018365242
dopaminergic O 0 0.99078304
neurones O 0 0.7786949
in O 0 0.003373055
rats O 0 0.01635594
. O 0 0.005905417

Methamphetamine B-Chemical 1 0.9979937
( O 0 0.006571897
10 O 0 0.0026431796
mg O 0 0.2564862
/ O 0 0.002823723
kg O 0 0.007570825
sc O 0 0.0700433
) O 0 0.0012593931
, O 0 0.00059963326
administered O 0 0.0007467562
five O 0 0.00019497426
times O 0 0.00021057563
, O 0 0.00036436002
reduced O 0 0.00029933537
the O 0 0.00025874915
levels O 0 0.00031941428
of O 0 0.00073439407
dopamine B-Chemical 1 0.99916327
and O 0 0.0006427017
its O 0 0.0017398007
metabolites O 0 0.80235684
in O 0 0.00058686157
striatal O 0 0.94002926
tissue O 0 0.0047544213
when O 0 0.0002830337
measured O 0 0.0003166672
72 O 0 0.00055874157
h O 0 0.0005565154
after O 0 0.00047552126
the O 0 0.0010221691
last O 0 0.0017339026
injection O 0 0.0088876495
. O 0 0.0050370456

A O 0 0.025132291
selective O 0 0.023814036
antagonist O 0 0.93588954
of O 0 0.00626191
mGluR5 O 0 0.99524814
, O 0 0.0039244913
2 B-Chemical 0 0.0017035794
- I-Chemical 0 0.0026873206
methyl I-Chemical 0 0.9169954
- I-Chemical 0 0.0019144962
6 I-Chemical 0 0.000552933
- I-Chemical 0 0.0010339486
( I-Chemical 0 0.0008600102
phenylethynyl I-Chemical 0 0.67093277
) I-Chemical 0 0.002341325
pyridine I-Chemical 0 0.9963362
( O 0 0.0064310757
MPEP B-Chemical 1 0.99990773
; O 0 0.0028172322
5 O 0 0.000395601
mg O 0 0.24599825
/ O 0 0.0010548529
kg O 0 0.008410985
ip O 0 0.5607622
) O 0 0.00066746905
, O 0 0.0002906914
when O 0 0.00013255833
administered O 0 0.00039462265
five O 0 0.0001099667
times O 0 0.00012015538
immediately O 0 0.00018293383
before O 0 0.0001339922
each O 0 0.00020722329
methamphetamine B-Chemical 1 0.9994624
injection O 0 0.007113712
reversed O 0 0.0019244143
the O 0 0.0006719461
above O 0 0.0007659307
- O 0 0.002361055
mentioned O 0 0.0021469889
methamphetamine B-Chemical 1 0.9986129
effects O 0 0.025376523
. O 0 0.006971301

A O 0 0.023485048
single O 0 0.0061343466
MPEP B-Chemical 1 0.99933344
( O 0 0.005133095
5 O 0 0.0014665135
mg O 0 0.28862464
/ O 0 0.0022954303
kg O 0 0.011027967
ip O 0 0.6204067
) O 0 0.0011591834
injection O 0 0.001491033
reduced O 0 0.0004543523
the O 0 0.00038583475
basal O 0 0.0032484545
extracellular O 0 0.09129001
dopamine B-Chemical 1 0.9992889
level O 0 0.00037500932
in O 0 0.00031722072
the O 0 0.0003969563
striatum O 0 0.615818
, O 0 0.00040502282
as O 0 0.00018467572
well O 0 0.0002074528
as O 0 0.0003193016
dopamine B-Chemical 1 0.9992836
release O 0 0.084935024
stimulated O 0 0.00047278186
either O 0 0.0003530747
by O 0 0.00062538515
methamphetamine B-Chemical 1 0.9997942
( O 0 0.0011048149
10 O 0 0.00045507788
mg O 0 0.23380393
/ O 0 0.0009937093
kg O 0 0.005594425
sc O 0 0.043710865
) O 0 0.00070021884
or O 0 0.00036430583
by O 0 0.00071920495
intrastriatally O 0 0.9816072
administered O 0 0.038121514
veratridine B-Chemical 0 0.99942636
( O 0 0.005412955
100 O 0 0.010032008
microM O 0 0.65728664
) O 0 0.0076210545
. O 0 0.0053910683

Moreover O 0 0.0059599276
, O 0 0.0036355257
it O 0 0.0022131074
transiently O 0 0.005766348
diminished O 0 0.0025338961
the O 0 0.0016414336
methamphetamine B-Chemical 1 0.99950075
( O 0 0.0024040455
10 O 0 0.000932955
mg O 0 0.29813278
/ O 0 0.0016839675
kg O 0 0.009322745
sc O 0 0.09643318
) O 0 0.0014964738
- O 0 0.0011981358
induced O 0 0.001400787
hyperthermia B-Disease 2 0.9975279
and O 0 0.001713682
reduced O 0 0.0020260205
basal O 0 0.0077877147
body O 0 0.016563697
temperature O 0 0.011621091
. O 0 0.006250905

MPEP B-Chemical 1 0.99882513
administered O 0 0.023577115
into O 0 0.0015191936
the O 0 0.0014881542
striatum O 0 0.27836177
at O 0 0.00057633047
high O 0 0.000966705
concentrations O 0 0.0042044055
( O 0 0.0011630246
500 O 0 0.0049032434
microM O 0 0.61180353
) O 0 0.0010507036
increased O 0 0.0011814322
extracellular O 0 0.12510978
dopamine B-Chemical 1 0.9994192
levels O 0 0.00074485823
, O 0 0.0005603245
while O 0 0.00028961748
lower O 0 0.00037633907
concentrations O 0 0.002822508
( O 0 0.0006877109
50 O 0 0.0007632018
- O 0 0.0007971263
100 O 0 0.0013377653
microM O 0 0.28703064
) O 0 0.000961201
were O 0 0.00059042335
devoid O 0 0.0007258778
of O 0 0.0015466117
any O 0 0.0020183069
effect O 0 0.004506702
. O 0 0.0055712643

The O 0 0.0025613399
results O 0 0.001712846
of O 0 0.0016321547
this O 0 0.0011062261
study O 0 0.0012588989
suggest O 0 0.00062729063
that O 0 0.00061193056
the O 0 0.00072724326
blockade O 0 0.124057
of O 0 0.0025427856
mGluR5 O 0 0.9972838
by O 0 0.004870706
MPEP B-Chemical 1 0.99988043
may O 0 0.0025968773
protect O 0 0.0318571
dopaminergic O 0 0.9941024
neurones O 0 0.8886433
against O 0 0.004432168
methamphetamine B-Chemical 1 0.9995461
- O 0 0.023831034
induced O 0 0.017719187
toxicity B-Disease 2 0.9921469
. O 0 0.009567773

Neuroprotection O 0 0.9738177
rendered O 0 0.010500588
by O 0 0.0048550577
MPEP B-Chemical 1 0.9995504
may O 0 0.0025061176
be O 0 0.001168693
associated O 0 0.0009954263
with O 0 0.00076051324
the O 0 0.0005286583
reduction O 0 0.0009683153
of O 0 0.00074715243
the O 0 0.0008884573
methamphetamine B-Chemical 1 0.9998241
- O 0 0.0074953763
induced O 0 0.003712223
dopamine B-Chemical 1 0.99964535
efflux O 0 0.69742334
in O 0 0.00045561636
the O 0 0.0004566542
striatum O 0 0.42648
due O 0 0.00020914215
to O 0 0.0002530017
the O 0 0.00030357452
blockade O 0 0.07977256
of O 0 0.0016087305
extrastriatal O 0 0.99832696
mGluR5 O 0 0.99705565
, O 0 0.0012351985
and O 0 0.00074594654
with O 0 0.0010118826
a O 0 0.0014219107
decrease O 0 0.0024390414
in O 0 0.0037508996
hyperthermia B-Disease 2 0.99548775
. O 0 0.008834661

Protective O 0 0.65396196
efficacy O 0 0.016383337
of O 0 0.0071194936
neuroactive O 0 0.99203753
steroids B-Chemical 0 0.99714667
against O 0 0.02056612
cocaine B-Chemical 1 0.99928826
kindled O 0 0.9981686
- O 0 0.09507182
seizures B-Disease 2 0.99887604
in O 0 0.0065602637
mice O 0 0.0055724056
. O 0 0.008359106

Neuroactive O 0 0.98263943
steroids B-Chemical 0 0.98855597
demonstrate O 0 0.002698992
pharmacological O 0 0.32723755
actions O 0 0.022533046
that O 0 0.0010230254
have O 0 0.00096627814
relevance O 0 0.00082555483
for O 0 0.0007672635
a O 0 0.001228191
host O 0 0.002888276
of O 0 0.0026843587
neurological B-Disease 0 0.9780939
and I-Disease 0 0.00838674
psychiatric I-Disease 2 0.99565613
disorders I-Disease 0 0.98807305
. O 0 0.010968719

They O 0 0.007216115
offer O 0 0.0045654853
protection O 0 0.0063997568
against O 0 0.0026596426
seizures B-Disease 2 0.9992386
in O 0 0.0013333642
a O 0 0.00092515786
range O 0 0.00093612046
of O 0 0.0007055517
models O 0 0.00103637
and O 0 0.00063990365
seem O 0 0.00063153467
to O 0 0.00041510892
inhibit O 0 0.00065149885
certain O 0 0.0010212872
stages O 0 0.0011265675
of O 0 0.0012992331
drug B-Disease 0 0.82309914
dependence I-Disease 0 0.038766105
in O 0 0.002290162
preclinical O 0 0.089285016
assessments O 0 0.006620665
. O 0 0.005878752

The O 0 0.0023427135
present O 0 0.0014241914
study O 0 0.0017731831
was O 0 0.0009594214
designed O 0 0.0008183067
to O 0 0.0005289783
evaluate O 0 0.00031608023
two O 0 0.0003346839
endogenous O 0 0.00070923695
and O 0 0.0004769817
one O 0 0.0003314628
synthetic O 0 0.0020902485
neuroactive O 0 0.99454135
steroid B-Chemical 1 0.9968574
that O 0 0.0005258644
positively O 0 0.00067627965
modulate O 0 0.0004056111
the O 0 0.00055523246
gamma B-Chemical 1 0.6303937
- I-Chemical 1 0.018709084
aminobutyric I-Chemical 1 0.99943024
acid I-Chemical 1 0.99587506
( O 0 0.018593391
GABA B-Chemical 1 0.9998535
( O 0 0.0034977896
A O 0 0.04509846
) O 0 0.0011858327
) O 0 0.0007279015
receptor O 0 0.027437296
against O 0 0.00030123894
the O 0 0.0002646753
increase O 0 0.00028265052
in O 0 0.00024300383
sensitivity O 0 0.0008654851
to O 0 0.00028739063
the O 0 0.00039339895
convulsant O 0 0.99925154
effects O 0 0.002376009
of O 0 0.0012804777
cocaine B-Chemical 1 0.99945515
engendered O 0 0.008429349
by O 0 0.00075770944
repeated O 0 0.0013093762
cocaine B-Chemical 1 0.99936455
administration O 0 0.7271009
( O 0 0.01721581
seizure B-Disease 2 0.998898
kindling O 0 0.9977285
) O 0 0.017627446
. O 0 0.0064815353

Allopregnanolone B-Chemical 0 0.9973423
( O 0 0.022848926
3alpha B-Chemical 0 0.98756623
- I-Chemical 0 0.026870115
hydroxy I-Chemical 0 0.9977945
- I-Chemical 0 0.024764096
5alpha I-Chemical 0 0.99571496
- I-Chemical 0 0.005894937
pregnan I-Chemical 0 0.6112173
- I-Chemical 0 0.0016022766
20 I-Chemical 0 0.0007058508
- I-Chemical 0 0.00073489145
one I-Chemical 0 0.00034978372
) O 0 0.0009948981
, O 0 0.0012490316
pregnanolone B-Chemical 0 0.99983525
( O 0 0.007323
3alpha B-Chemical 0 0.99512464
- I-Chemical 0 0.015205348
hydroxy I-Chemical 0 0.99927324
- I-Chemical 0 0.015752502
5beta I-Chemical 0 0.99593073
- I-Chemical 0 0.00403901
pregnan I-Chemical 0 0.62786436
- I-Chemical 0 0.0010039217
20 I-Chemical 0 0.00041757146
- I-Chemical 0 0.00043459778
one I-Chemical 0 0.00019983314
) O 0 0.0004978663
and O 0 0.0004230558
ganaxolone B-Chemical 0 0.9993055
( O 0 0.0007285011
a O 0 0.0003792994
synthetic O 0 0.001575518
derivative O 0 0.0677381
of O 0 0.004159144
allopregnanolone B-Chemical 0 0.99996495
3alpha B-Chemical 0 0.9990644
- I-Chemical 0 0.059637487
hydroxy I-Chemical 0 0.9995158
- I-Chemical 0 0.027084596
3beta I-Chemical 0 0.9938711
- I-Chemical 0 0.015351078
methyl I-Chemical 0 0.98786306
- I-Chemical 0 0.008700319
5alpha I-Chemical 0 0.99718213
- I-Chemical 0 0.0034308871
pregnan I-Chemical 0 0.5909031
- I-Chemical 0 0.0008701058
20 I-Chemical 0 0.00036325178
- I-Chemical 0 0.0003577443
one I-Chemical 0 0.00015430745
) O 0 0.00030085264
were O 0 0.00014591585
tested O 0 0.00012268852
for O 0 0.00014114867
their O 0 0.00020711485
ability O 0 0.00020721974
to O 0 0.00018576642
suppress O 0 0.00022056531
the O 0 0.00024692755
expression O 0 0.0008803
( O 0 0.00084435026
anticonvulsant O 0 0.9993444
effect O 0 0.0008438564
) O 0 0.00079684565
and O 0 0.00035855419
development O 0 0.0015758218
( O 0 0.00085428986
antiepileptogenic O 0 0.9946371
effect O 0 0.0007901852
) O 0 0.0010132163
of O 0 0.0012095689
cocaine B-Chemical 1 0.99964714
- O 0 0.016273888
kindled O 0 0.9988318
seizures B-Disease 2 0.9997851
in O 0 0.0013764238
male O 0 0.009225321
, O 0 0.0022219464
Swiss O 0 0.029438097
- O 0 0.0047412585
Webster O 0 0.103855886
mice O 0 0.002947467
. O 0 0.0053287237

Kindled O 0 0.9920699
seizures B-Disease 2 0.99851173
were O 0 0.0033661183
induced O 0 0.0023967444
by O 0 0.0014199148
daily O 0 0.0028998908
administration O 0 0.04225474
of O 0 0.0013956359
60 O 0 0.0015962282
mg O 0 0.34232298
/ O 0 0.003572155
kg O 0 0.025494078
cocaine B-Chemical 1 0.9962768
for O 0 0.0022912952
5 O 0 0.002676005
days O 0 0.0038477015
. O 0 0.0053320862

All O 0 0.0038663668
of O 0 0.003035459
these O 0 0.0029716329
positive O 0 0.0031008595
GABA B-Chemical 1 0.9991947
( O 0 0.0061129816
A O 0 0.03648203
) O 0 0.0018880139
modulators O 0 0.010313151
suppressed O 0 0.0010231365
the O 0 0.0005632938
expression O 0 0.0010539001
of O 0 0.0013686937
kindled O 0 0.99891937
seizures B-Disease 2 0.9998677
, O 0 0.0021137292
whereas O 0 0.00072393246
only O 0 0.0011914512
allopregnanolone B-Chemical 0 0.9998604
and O 0 0.003745766
ganaxolone B-Chemical 0 0.99924374
inhibited O 0 0.007518359
the O 0 0.0018344423
development O 0 0.006803316
of O 0 0.008826218
kindling O 0 0.9952291
. O 0 0.00836836

Allopregnanolone B-Chemical 0 0.99648595
and O 0 0.011734189
pregnanolone B-Chemical 0 0.9991423
, O 0 0.0056675454
but O 0 0.0020580785
not O 0 0.0018191403
ganaxolone B-Chemical 0 0.9982162
, O 0 0.002301715
also O 0 0.0013169001
reduced O 0 0.0014760104
cumulative O 0 0.007650879
lethality O 0 0.3249554
associated O 0 0.0063575585
with O 0 0.0125144785
kindling O 0 0.99485177
. O 0 0.010129465

These O 0 0.004348775
findings O 0 0.0036485011
demonstrate O 0 0.0013423106
that O 0 0.0011814513
some O 0 0.0017543822
neuroactive O 0 0.9934362
steroids B-Chemical 0 0.998776
attenuate O 0 0.31286275
convulsant O 0 0.9996593
and O 0 0.0015644178
sensitizing O 0 0.26791653
properties O 0 0.002482065
of O 0 0.001169576
cocaine B-Chemical 1 0.99952614
and O 0 0.0005825215
add O 0 0.0003817782
to O 0 0.00024556657
a O 0 0.00027755185
growing O 0 0.0004149412
literature O 0 0.0005561546
on O 0 0.00014892864
their O 0 0.0002584067
potential O 0 0.00039617257
use O 0 0.0003922859
in O 0 0.00028580145
the O 0 0.00034367116
modulation O 0 0.0008924723
of O 0 0.00081101886
effects O 0 0.0019352252
of O 0 0.0022656375
drugs O 0 0.7885622
of O 0 0.010955649
abuse O 0 0.9888049
. O 0 0.00842833

Effect O 0 0.008940177
of O 0 0.005030139
humoral O 0 0.39949906
modulators O 0 0.07623282
of O 0 0.0067981435
morphine B-Chemical 1 0.9993299
- O 0 0.009632888
induced O 0 0.0026901094
increase B-Disease 0 0.0018168221
in I-Disease 0 0.0020021421
locomotor I-Disease 0 0.3413046
activity I-Disease 0 0.0035004583
of O 0 0.004174621
mice O 0 0.0041152863
. O 0 0.0067821676

The O 0 0.0032678745
effect O 0 0.002846782
of O 0 0.002810562
humoral O 0 0.38159126
modulators O 0 0.043095108
on O 0 0.0010196995
the O 0 0.001667587
morphine B-Chemical 1 0.9994118
- O 0 0.0049438137
induced O 0 0.0014846022
increase B-Disease 0 0.00095850235
in I-Disease 0 0.00096812804
locomotor I-Disease 0 0.27253437
activity I-Disease 0 0.0015029
of O 0 0.0016065141
mice O 0 0.0013499671
was O 0 0.002736204
studied O 0 0.0058535943
. O 0 0.0060678204

The O 0 0.0032035809
subcutaneous O 0 0.017423378
administration O 0 0.041397657
of O 0 0.001983692
10 O 0 0.0015228288
mg O 0 0.29823756
/ O 0 0.0021295117
kg O 0 0.0051515866
of O 0 0.0014872178
morphine B-Chemical 1 0.99954695
- O 0 0.015477156
HC1 O 0 0.9978569
produced O 0 0.0011628907
a O 0 0.001014311
marked O 0 0.001617395
increase B-Disease 0 0.0010097153
in I-Disease 0 0.0013118678
locomotor I-Disease 0 0.32269686
activity I-Disease 0 0.0027312045
in O 0 0.0023794635
mice O 0 0.0030153866
. O 0 0.0054443693

The O 0 0.00678394
morphine B-Chemical 1 0.99719465
- O 0 0.012512038
induced O 0 0.008219748
hyperactivity B-Disease 2 0.99771935
was O 0 0.003943571
potentiated O 0 0.39595783
by O 0 0.0057882234
scopolamine B-Chemical 1 0.9996867
and O 0 0.0069911517
attenuated O 0 0.03168215
by O 0 0.013428003
physostigmine B-Chemical 0 0.9989348
. O 0 0.014284148

In O 0 0.0033675039
contrast O 0 0.0027873246
, O 0 0.002576494
both O 0 0.0018522938
methscopolamine B-Chemical 0 0.9982199
and O 0 0.0034702835
neostigmine B-Chemical 0 0.9996463
, O 0 0.0021962225
which O 0 0.0009088537
do O 0 0.00042654172
not O 0 0.00039336964
penetrate O 0 0.0010536069
the O 0 0.00042766018
blood O 0 0.008402677
- O 0 0.0011305356
brain O 0 0.033948563
barrier O 0 0.0064314688
, O 0 0.0005870904
had O 0 0.0004316385
no O 0 0.00037341946
effect O 0 0.0006336203
on O 0 0.00052313105
the O 0 0.0015142104
hyperactivity B-Disease 2 0.9972088
produced O 0 0.0037574496
by O 0 0.007626062
morphine B-Chemical 1 0.9981212
. O 0 0.010029968

Pretreatment O 0 0.63661
of O 0 0.0035393366
mice O 0 0.0016049662
with O 0 0.0024092083
alpha B-Chemical 0 0.67611253
- I-Chemical 0 0.0062682154
methyltyrosine I-Chemical 0 0.9212312
( O 0 0.0014421137
20 O 0 0.00078304805
mg O 0 0.2538877
/ O 0 0.0012171076
kg O 0 0.003367803
i O 0 0.00096306094
. O 0 0.00022226137
p O 0 0.0004253654
. O 0 0.00018178328
, O 0 0.00029832032
one O 0 0.0001823746
hour O 0 0.0003119602
) O 0 0.0006024224
, O 0 0.00041087827
an O 0 0.00048152832
inhibitor O 0 0.046193875
of O 0 0.0013823444
tyrosine B-Chemical 1 0.9885329
hydroxylase O 0 0.99844044
, O 0 0.0013745545
significantly O 0 0.0007599229
decreased O 0 0.0012578946
the O 0 0.0006246644
activity O 0 0.0012208393
- O 0 0.0014765487
increasing O 0 0.0016943241
effects O 0 0.0045425845
of O 0 0.008319511
morphine B-Chemical 1 0.9983551
. O 0 0.009755497

On O 0 0.0038881756
the O 0 0.0021270614
other O 0 0.0018086917
hand O 0 0.002224314
, O 0 0.0018500948
pretreatment O 0 0.116278
with O 0 0.0015252656
p B-Chemical 0 0.003482617
- I-Chemical 0 0.0016829154
chlorophenylalamine I-Chemical 0 0.06943343
( O 0 0.0010183093
3 O 0 0.00048660245
X O 0 0.06500002
320 O 0 0.017415013
mg O 0 0.38336727
/ O 0 0.0011637631
kg O 0 0.0033820532
i O 0 0.0008718889
. O 0 0.0002055369
p O 0 0.0004078689
. O 0 0.00018345051
, O 0 0.00032899078
24 O 0 0.0002779777
hr O 0 0.00065900607
) O 0 0.000628356
, O 0 0.0005231124
a O 0 0.0007772801
serotonin B-Chemical 1 0.99889046
depletor O 0 0.9993498
, O 0 0.0019389911
caused O 0 0.0010253174
no O 0 0.0006762288
significant O 0 0.0012210372
change O 0 0.0014675675
in O 0 0.0018461294
the O 0 0.004324298
hyperactivity B-Disease 2 0.99549687
. O 0 0.008512414

The O 0 0.0026241376
study O 0 0.0025661807
suggests O 0 0.0011228776
that O 0 0.0009576141
the O 0 0.00096410204
activity O 0 0.001363065
- O 0 0.0011578834
increasing O 0 0.0008215549
effects O 0 0.0013502532
of O 0 0.0012878051
morphine B-Chemical 1 0.9995771
are O 0 0.0009062989
mediated O 0 0.00054684584
by O 0 0.00052650116
the O 0 0.0005320404
release O 0 0.025340248
of O 0 0.001573808
catecholamines B-Chemical 1 0.9986071
from O 0 0.0022293217
adrenergic O 0 0.99614054
neurons O 0 0.09289357
in O 0 0.0019460742
the O 0 0.003119884
brain O 0 0.116731144
. O 0 0.006260767

And O 0 0.008083969
the O 0 0.0022307478
results O 0 0.0015361828
are O 0 0.0012211464
consistent O 0 0.0009376425
with O 0 0.0008731434
the O 0 0.0006569283
hypothesis O 0 0.0009806873
that O 0 0.0007814394
morphine B-Chemical 1 0.99935037
acts O 0 0.0024655447
by O 0 0.0009491551
retarding O 0 0.23262897
the O 0 0.0010662702
release O 0 0.06620617
of O 0 0.0026683663
acetylcholine B-Chemical 1 0.99819773
at O 0 0.0012713427
some O 0 0.0024807174
central O 0 0.012591658
cholinergic O 0 0.9818393
synapses O 0 0.5368547
. O 0 0.0075484985

It O 0 0.005361671
is O 0 0.0020634828
also O 0 0.0014170982
suggested O 0 0.0010528845
from O 0 0.0007197174
collected O 0 0.0004834526
evidence O 0 0.00057652657
that O 0 0.00040419045
the O 0 0.0004640701
activity O 0 0.0007944434
- O 0 0.0006935139
increasing O 0 0.00052116986
effects O 0 0.0010117977
of O 0 0.000905686
morphine B-Chemical 1 0.9996594
in O 0 0.00043883064
mice O 0 0.00020640809
are O 0 0.0002550772
mediated O 0 0.00023355434
by O 0 0.00025005752
mechanisms O 0 0.00047466732
different O 0 0.00025169048
from O 0 0.00026146788
those O 0 0.00039057463
which O 0 0.00039523726
mediate O 0 0.0003478218
the O 0 0.00038504734
activity O 0 0.00077168475
- O 0 0.0008734991
increasing O 0 0.0009085831
effects O 0 0.002192077
of O 0 0.0033531121
morphine B-Chemical 1 0.99894744
in O 0 0.0046272073
rats O 0 0.03479861
. O 0 0.005994088

Effects O 0 0.012505978
of O 0 0.0044202767
uninephrectomy O 0 0.86678237
and O 0 0.0023840475
high O 0 0.0021605326
protein O 0 0.0030925162
feeding O 0 0.004271421
on O 0 0.0012454606
lithium B-Chemical 1 0.9982753
- O 0 0.0064414185
induced O 0 0.00487107
chronic B-Disease 2 0.9943321
renal I-Disease 2 0.9971219
failure I-Disease 2 0.977736
in O 0 0.0068560294
rats O 0 0.04378641
. O 0 0.007744251

Rats O 0 0.10211936
with O 0 0.005917932
lithium B-Chemical 1 0.9970963
- O 0 0.007935351
induced O 0 0.00470993
nephropathy B-Disease 2 0.99962497
were O 0 0.0013168117
subjected O 0 0.00054665306
to O 0 0.0004887179
high O 0 0.0007812696
protein O 0 0.0019186776
( O 0 0.0010901546
HP O 0 0.1685266
) O 0 0.0011769207
feeding O 0 0.0021789155
, O 0 0.0008576501
uninephrectomy O 0 0.96132624
( O 0 0.001467987
NX O 0 0.97069967
) O 0 0.00082203414
or O 0 0.00024513216
a O 0 0.00029503054
combination O 0 0.0006137184
of O 0 0.00042162777
these O 0 0.0005652095
, O 0 0.00050838734
in O 0 0.0002763934
an O 0 0.00042656434
attempt O 0 0.00045335203
to O 0 0.00035471082
induce O 0 0.00060844666
glomerular O 0 0.93003243
hyperfiltration O 0 0.99880815
and O 0 0.0013494246
further O 0 0.0016436831
progression O 0 0.40846676
of O 0 0.0066141267
renal B-Disease 0 0.99434257
failure I-Disease 0 0.9484268
. O 0 0.00939681

Newborn O 0 0.023356587
female O 0 0.008347335
Wistar O 0 0.17149325
rats O 0 0.0050665876
were O 0 0.001313219
fed O 0 0.0019771801
a O 0 0.001535206
lithium B-Chemical 1 0.99823076
- O 0 0.0026404972
containing O 0 0.00079550134
diet O 0 0.06803691
( O 0 0.000881462
50 O 0 0.0007786319
mmol O 0 0.3806909
/ O 0 0.001043195
kg O 0 0.0030179722
) O 0 0.0004142997
for O 0 0.00016910184
8 O 0 0.00017525093
weeks O 0 0.00015166136
and O 0 0.00016379484
then O 0 0.0001480361
randomized O 0 0.0002999293
to O 0 0.0001971211
normal O 0 0.00062000676
diet O 0 0.039271045
, O 0 0.0006212355
HP O 0 0.12580806
diet O 0 0.07965632
( O 0 0.0005876594
40 O 0 0.00038419757
vs O 0 0.00058235135
. O 0 0.00020628533
19 O 0 0.00053789944
% O 0 0.00045309626
) O 0 0.00068735995
, O 0 0.00075298495
NX O 0 0.88482666
or O 0 0.000803827
HP O 0 0.21179758
+ O 0 0.0021192883
NX O 0 0.90797013
for O 0 0.0013093988
another O 0 0.002253723
8 O 0 0.0024670125
weeks O 0 0.0035015228
. O 0 0.004757841

Corresponding O 0 0.022057347
non O 0 0.014853801
- O 0 0.015683247
lithium B-Chemical 1 0.9923638
pretreated O 0 0.14373016
groups O 0 0.00908833
were O 0 0.007891977
generated O 0 0.0086366655
. O 0 0.01337016

When O 0 0.0026744746
comparing O 0 0.0013893248
all O 0 0.00176419
lithium B-Chemical 1 0.9955161
treated O 0 0.0038124523
versus O 0 0.001224136
non O 0 0.0035160098
- O 0 0.0042069377
lithium B-Chemical 1 0.9991621
- O 0 0.003043371
treated O 0 0.0013780881
groups O 0 0.00074626674
, O 0 0.00095796125
lithium B-Chemical 1 0.9989139
caused O 0 0.0010118594
a O 0 0.00056115777
reduction O 0 0.0010284999
in O 0 0.0003589044
glomerular O 0 0.7925619
filtration O 0 0.025265856
rate O 0 0.0005475965
( O 0 0.0010235036
GFR O 0 0.9909446
) O 0 0.0007436177
without O 0 0.00027842596
significant O 0 0.00034892326
changes O 0 0.00040336078
in O 0 0.00022273553
effective O 0 0.00071815704
renal O 0 0.9850424
plasma O 0 0.14825532
flow O 0 0.017917847
( O 0 0.00052216754
as O 0 0.00019321594
determined O 0 0.00019529073
by O 0 0.00028798034
a O 0 0.0003646707
marker O 0 0.00056306645
secreted O 0 0.0008765878
into O 0 0.00032353823
the O 0 0.0005482247
proximal O 0 0.0020497162
tubules O 0 0.033115078
) O 0 0.0031631405
or O 0 0.0027299097
lithium B-Chemical 1 0.99726
clearance O 0 0.57066256
. O 0 0.008341023

Consequently O 0 0.0059166444
, O 0 0.0054447562
lithium B-Chemical 1 0.9953591
pretreatment O 0 0.4254114
caused O 0 0.0025337415
a O 0 0.0015014374
fall O 0 0.0024649478
in O 0 0.0007827332
filtration O 0 0.004125912
fraction O 0 0.0009283954
and O 0 0.001054349
an O 0 0.0014023641
increase O 0 0.0014138488
in O 0 0.0021248318
fractional O 0 0.21391329
Li B-Chemical 1 0.9797926
excretion O 0 0.98475665
. O 0 0.012021947

Lithium B-Chemical 1 0.99642205
also O 0 0.008157148
caused O 0 0.009321599
proteinuria B-Disease 2 0.99891174
and O 0 0.009106259
systolic O 0 0.97853917
hypertension B-Disease 2 0.9985643
in O 0 0.0038037277
absence O 0 0.002993129
of O 0 0.011960219
glomerulosclerosis B-Disease 2 0.9985447
. O 0 0.020097878

HP O 0 0.07053413
failed O 0 0.00380025
to O 0 0.0020950036
accentuante O 0 0.009835566
progression O 0 0.16382216
of O 0 0.0022582696
renal B-Disease 0 0.99213296
failure I-Disease 0 0.79750186
and O 0 0.0010220639
in O 0 0.00047128668
fact O 0 0.0003807634
tended O 0 0.00046140308
to O 0 0.0003759941
increase O 0 0.0005861774
GFR O 0 0.98569214
and O 0 0.00081014633
decrease O 0 0.0011965146
plasma O 0 0.12145781
creatinine B-Chemical 1 0.9959812
levels O 0 0.001944508
in O 0 0.002472862
lithium B-Chemical 1 0.99803275
pretreated O 0 0.36818168
rats O 0 0.06735617
. O 0 0.007254751

NX O 0 0.9026088
caused O 0 0.005530423
an O 0 0.0037889476
additive O 0 0.009054464
deterioration O 0 0.36983502
in O 0 0.0024861547
GFR O 0 0.9895363
which O 0 0.0032152447
, O 0 0.0023612373
however O 0 0.0023691673
, O 0 0.00251613
was O 0 0.0025954451
ameliorated O 0 0.3321856
by O 0 0.0074298745
HP O 0 0.46157038
. O 0 0.010086605

NX O 0 0.9520326
+ O 0 0.0072989245
HP O 0 0.07998396
caused O 0 0.0029955092
a O 0 0.0020671838
further O 0 0.0017960054
rise O 0 0.0024679278
in O 0 0.0014609498
blood O 0 0.008757226
pressure O 0 0.07158515
in O 0 0.0030222924
Li B-Chemical 1 0.8987552
- O 0 0.009244522
pretreated O 0 0.10255175
rats O 0 0.033212073
. O 0 0.008671073

The O 0 0.0028612206
results O 0 0.00200024
indicate O 0 0.0014759043
that O 0 0.0017441887
Li B-Chemical 1 0.87860936
- O 0 0.0040849084
induced O 0 0.004345624
nephropathy B-Disease 2 0.99980456
, O 0 0.0026260153
even O 0 0.0007000364
when O 0 0.00035697603
the O 0 0.00054146064
GFR O 0 0.98742026
is O 0 0.000572971
only O 0 0.0004788098
modestly O 0 0.010588837
reduced O 0 0.0007597021
, O 0 0.0008329262
is O 0 0.0005938324
associated O 0 0.0011305787
with O 0 0.002634683
proteinuria B-Disease 2 0.99956304
and O 0 0.007026908
arterial O 0 0.96950555
systolic O 0 0.9905668
hypertension B-Disease 2 0.9984812
. O 0 0.010099179

In O 0 0.0027432134
this O 0 0.0018172675
model O 0 0.0019054525
of O 0 0.0020321463
chronic B-Disease 2 0.9777746
renal I-Disease 2 0.9966037
failure I-Disease 2 0.94315106
the O 0 0.001100004
decline O 0 0.005928855
in O 0 0.0006551135
GFR O 0 0.99155617
is O 0 0.0005183746
not O 0 0.00032941203
accompanied O 0 0.0008317171
by O 0 0.0003327784
a O 0 0.00031457827
corresponding O 0 0.00021706581
fall O 0 0.0007998763
in O 0 0.00025064804
effective O 0 0.0007929898
renal O 0 0.9854392
plasma O 0 0.14459543
flow O 0 0.015886227
, O 0 0.00057533674
which O 0 0.00044217525
may O 0 0.00031106066
be O 0 0.00029085326
the O 0 0.00026071383
functional O 0 0.00057196076
expression O 0 0.0007048317
of O 0 0.0006994025
the O 0 0.00074831175
formation O 0 0.0029093812
of O 0 0.0023016972
nonfiltrating O 0 0.093714364
atubular O 0 0.35586947
glomeruli O 0 0.38178876
. O 0 0.007488136

The O 0 0.0035727033
fractional O 0 0.027056828
reabsorption O 0 0.907943
of O 0 0.0036181512
tubular O 0 0.7835885
fluid O 0 0.04994559
by O 0 0.0011976822
the O 0 0.0007696948
proximal O 0 0.0017820047
tubules O 0 0.019692149
is O 0 0.0006140024
reduced O 0 0.00061876327
, O 0 0.0006455046
leaving O 0 0.0006849441
the O 0 0.00046234016
distal O 0 0.0010316825
delivery O 0 0.0011349001
unchanged O 0 0.0012634421
. O 0 0.000927867
( O 0 0.0022473468
ABSTRACT O 0 0.014790452
TRUNCATED O 0 0.023711057
AT O 0 0.02496162
250 O 0 0.011366745
WORDS O 0 0.02009429
) O 0 0.021075469

Treatment O 0 0.03203052
of O 0 0.005745183
Crohn B-Disease 0 0.9867324
' I-Disease 0 0.0031211416
s I-Disease 0 0.0026600144
disease I-Disease 0 0.3828049
with O 0 0.0034031868
fusidic B-Chemical 0 0.99872106
acid I-Chemical 0 0.97183675
: O 0 0.0025076151
an O 0 0.0013338793
antibiotic O 0 0.1056822
with O 0 0.0020190629
immunosuppressive O 0 0.95879287
properties O 0 0.0057887803
similar O 0 0.0023579437
to O 0 0.005439234
cyclosporin B-Chemical 0 0.99864036
. O 0 0.012100487

Fusidic O 0 0.9958508
acid O 0 0.9715504
is O 0 0.003428561
an O 0 0.0027219933
antibiotic O 0 0.16912279
with O 0 0.0029614486
T O 0 0.66933393
- O 0 0.0026036124
cell O 0 0.0036864164
specific O 0 0.0010917167
immunosuppressive O 0 0.93181926
effects O 0 0.0031844494
similar O 0 0.001066389
to O 0 0.0015022962
those O 0 0.0031432377
of O 0 0.007518152
cyclosporin B-Chemical 0 0.99879575
. O 0 0.012837399

Because O 0 0.0026505545
of O 0 0.0021469125
the O 0 0.0013358193
need O 0 0.00093430676
for O 0 0.000655917
the O 0 0.0006182822
development O 0 0.0010600141
of O 0 0.00063419435
new O 0 0.00073550834
treatments O 0 0.0017731694
for O 0 0.000593516
Crohn B-Disease 0 0.9961468
' I-Disease 0 0.00068537804
s I-Disease 0 0.00063836685
disease I-Disease 0 0.29568246
, O 0 0.0004451153
a O 0 0.0002700777
pilot O 0 0.00042274152
study O 0 0.0003490445
was O 0 0.00019198553
undertaken O 0 0.00016216651
to O 0 0.00015950488
estimate O 0 0.00015052148
the O 0 0.00025185346
pharmacodynamics O 0 0.66173714
and O 0 0.00044127903
tolerability O 0 0.30840757
of O 0 0.0014715419
fusidic B-Chemical 0 0.99946016
acid I-Chemical 0 0.9701193
treatment O 0 0.007555513
in O 0 0.0007781312
chronic O 0 0.95426124
active O 0 0.0056410525
, O 0 0.002135584
therapy O 0 0.06036931
- O 0 0.0040132483
resistant O 0 0.0057978933
patients O 0 0.01328701
. O 0 0.005553395

Eight O 0 0.024430424
Crohn B-Disease 0 0.9612723
' I-Disease 0 0.008499187
s I-Disease 0 0.00824957
disease I-Disease 0 0.26122937
patients O 0 0.01389932
were O 0 0.007995018
included O 0 0.009664947
. O 0 0.012628885

Fusidic B-Chemical 0 0.99618644
acid I-Chemical 0 0.9726346
was O 0 0.0029509596
administered O 0 0.005152139
orally O 0 0.04319276
in O 0 0.0007596779
a O 0 0.0007172939
dose O 0 0.0047285934
of O 0 0.0007390857
500 O 0 0.0029768746
mg O 0 0.38316733
t O 0 0.0013915666
. O 0 0.00025256642
d O 0 0.00044550328
. O 0 0.00020627135
s O 0 0.00037060346
. O 0 0.00018976827
and O 0 0.0003007565
the O 0 0.00033730888
treatment O 0 0.0009384263
was O 0 0.00060072704
planned O 0 0.0010244483
to O 0 0.0008652329
last O 0 0.001141967
8 O 0 0.0019944336
weeks O 0 0.0030335546
. O 0 0.0043394165

The O 0 0.00462249
disease O 0 0.20533727
activity O 0 0.0038471532
was O 0 0.0021112675
primarily O 0 0.0024441401
measured O 0 0.0013612288
by O 0 0.0017789578
a O 0 0.0021815202
modified O 0 0.003158623
individual O 0 0.0031490226
grading O 0 0.03195403
score O 0 0.008890351
. O 0 0.008680515

Five O 0 0.0059796274
of O 0 0.0031425266
8 O 0 0.0020699964
patients O 0 0.0032599757
( O 0 0.0017220418
63 O 0 0.0016137818
% O 0 0.0009643174
) O 0 0.00091759453
improved O 0 0.00104831
during O 0 0.0006409373
fusidic B-Chemical 0 0.99861765
acid I-Chemical 0 0.9494461
treatment O 0 0.0062205615
: O 0 0.0010005749
3 O 0 0.0003453745
at O 0 0.00022948309
two O 0 0.00029766455
weeks O 0 0.00049809605
and O 0 0.0006693587
2 O 0 0.0008104441
after O 0 0.0007050479
four O 0 0.001350826
weeks O 0 0.0032519132
. O 0 0.004573139

There O 0 0.005289208
were O 0 0.002396202
no O 0 0.0016351475
serious O 0 0.022712724
clinical O 0 0.011446096
side O 0 0.02063311
effects O 0 0.0027433725
, O 0 0.001179101
but O 0 0.00066982675
dose O 0 0.00833786
reduction O 0 0.0012179207
was O 0 0.0005375891
required O 0 0.00033191816
in O 0 0.0005286252
two O 0 0.0006577248
patients O 0 0.0025058398
because O 0 0.0016281675
of O 0 0.0071964716
nausea B-Disease 2 0.99902
. O 0 0.010438434

Biochemically O 0 0.3488807
, O 0 0.0042498056
an O 0 0.002458559
increase O 0 0.0015253265
in O 0 0.0013244052
alkaline O 0 0.2941288
phosphatases O 0 0.4568393
was O 0 0.00091754907
noted O 0 0.0005738487
in O 0 0.00037036254
5 O 0 0.00029090708
of O 0 0.0003655818
8 O 0 0.00032466018
cases O 0 0.00060678343
( O 0 0.00047003585
63 O 0 0.00056836114
% O 0 0.00035469662
) O 0 0.00042554087
, O 0 0.00028886768
and O 0 0.00022351992
the O 0 0.00020070387
greatest O 0 0.00051962154
increases O 0 0.00036120036
were O 0 0.00030863393
seen O 0 0.00029357962
in O 0 0.00028203244
those O 0 0.00052275596
who O 0 0.0010038391
had O 0 0.0006466573
elevated O 0 0.0030170642
levels O 0 0.0010517566
prior O 0 0.0011093856
to O 0 0.0021594206
treatment O 0 0.008330577
. O 0 0.0056542

All O 0 0.0054257335
reversed O 0 0.0062535033
to O 0 0.003035697
pre O 0 0.0071739606
- O 0 0.004079459
treatment O 0 0.0036390543
levels O 0 0.0020860992
after O 0 0.0017467461
cessation O 0 0.010518525
of O 0 0.0059725144
treatment O 0 0.016562572
. O 0 0.009608155

The O 0 0.002502901
results O 0 0.0016563957
of O 0 0.0015563746
this O 0 0.0010422262
pilot O 0 0.0014921451
study O 0 0.0011263583
suggest O 0 0.00059220963
that O 0 0.0008644772
fusidic B-Chemical 0 0.9988225
acid I-Chemical 0 0.95387536
may O 0 0.00074424664
be O 0 0.00042628526
of O 0 0.00043121303
benefit O 0 0.00084347045
in O 0 0.00028865432
selected O 0 0.00038938574
chronic O 0 0.90774226
active O 0 0.008274539
Crohn B-Disease 0 0.998109
' I-Disease 0 0.0008171534
s I-Disease 0 0.0007845348
disease I-Disease 0 0.30312493
patients O 0 0.0020919603
in O 0 0.0006039488
whom O 0 0.002164908
conventional O 0 0.0016283627
treatment O 0 0.0043502646
is O 0 0.0034129978
ineffective O 0 0.07232098
. O 0 0.0066358494

Because O 0 0.002891835
there O 0 0.0015462796
seems O 0 0.0015164432
to O 0 0.0009990013
exist O 0 0.0009205667
a O 0 0.0007718476
scientific O 0 0.0015638153
rationale O 0 0.0010013607
for O 0 0.00039998582
the O 0 0.00040875733
use O 0 0.0005812412
of O 0 0.0009774021
fusidic B-Chemical 0 0.99917114
acid I-Chemical 0 0.93728197
at O 0 0.00032517407
the O 0 0.00036891145
cytokine O 0 0.050434183
level O 0 0.0002886736
in O 0 0.000384931
inflammatory B-Disease 0 0.9278778
bowel I-Disease 0 0.9752516
disease I-Disease 0 0.96105874
, O 0 0.000696756
we O 0 0.00014317861
suggest O 0 0.00019500882
that O 0 0.00022073997
the O 0 0.00026476593
role O 0 0.00025088855
of O 0 0.00054509944
this O 0 0.0005949277
treatment O 0 0.0015854044
should O 0 0.00073690026
be O 0 0.0013533139
further O 0 0.0021756326
investigated O 0 0.0038252464
. O 0 0.0053083817

Changes O 0 0.009903963
in O 0 0.0057131234
depressive B-Disease 2 0.99012125
status O 0 0.005689405
associated O 0 0.004654423
with O 0 0.005751487
topical O 0 0.9810559
beta O 0 0.9397793
- O 0 0.09209019
blockers O 0 0.99276334
. O 0 0.017047523

Depression B-Disease 2 0.9412612
and O 0 0.005483064
sexual B-Disease 0 0.5460564
dysfunction I-Disease 0 0.9798045
have O 0 0.0024197416
been O 0 0.0016985202
related O 0 0.00091022084
to O 0 0.0010507731
side O 0 0.0068896962
effects O 0 0.002642257
of O 0 0.0030789156
topical O 0 0.98679566
beta O 0 0.9437144
- O 0 0.08541313
blockers O 0 0.9944713
. O 0 0.012674368

We O 0 0.0026541245
performed O 0 0.0017110729
a O 0 0.0014296077
preliminary O 0 0.0016530723
study O 0 0.0012871369
in O 0 0.00059178
order O 0 0.00038974299
to O 0 0.00036923308
determine O 0 0.00019013285
any O 0 0.00025182776
difference O 0 0.00020089533
between O 0 0.00017990926
a O 0 0.0003863427
non O 0 0.0009412586
selective O 0 0.025460467
beta O 0 0.7892373
- O 0 0.008841578
blocker O 0 0.9924771
( O 0 0.0063421424
timolol B-Chemical 1 0.99986804
) O 0 0.0023513485
and O 0 0.00049565354
a O 0 0.00057090307
selective O 0 0.02187397
beta O 0 0.73623884
- O 0 0.009279597
blocker O 0 0.9920325
( O 0 0.013724881
betaxolol B-Chemical 0 0.9998541
) O 0 0.0054846066
regarding O 0 0.002008773
CNS O 0 0.8319342
side O 0 0.09425076
effects O 0 0.013317551
. O 0 0.0065780515

Eight O 0 0.015296354
glaucomatous B-Disease 0 0.9948395
patients O 0 0.012983407
chronically O 0 0.057932787
treated O 0 0.0029046957
with O 0 0.002004514
timolol B-Chemical 1 0.9995902
0 O 0 0.0014918674
. O 0 0.00040156642
5 O 0 0.00038773587
% O 0 0.00046447018
/ O 0 0.0008246
12h O 0 0.041042767
, O 0 0.00067370594
suffering O 0 0.4471884
from O 0 0.0008011926
depression B-Disease 0 0.9908023
diagnosed O 0 0.07184284
through O 0 0.00082657096
DMS O 0 0.99356693
- O 0 0.0040168012
III O 0 0.044459246
- O 0 0.0021088386
R O 0 0.5502776
criteria O 0 0.0014457714
, O 0 0.00090571435
were O 0 0.0007107577
included O 0 0.00086914876
in O 0 0.0012349972
the O 0 0.0021619485
study O 0 0.0053814785
. O 0 0.0055824495

During O 0 0.002694369
the O 0 0.0020263793
six O 0 0.0013376754
- O 0 0.0018242013
month O 0 0.00088690105
follow O 0 0.00082973664
up O 0 0.00088527246
, O 0 0.0013022186
depression B-Disease 0 0.9162287
was O 0 0.0007012155
quantified O 0 0.00055170426
through O 0 0.0005500341
the O 0 0.00078510016
Beck O 0 0.12679087
and O 0 0.0013840636
Zung O 0 0.24328603
- O 0 0.0022078634
Conde O 0 0.13860272
scales O 0 0.001475267
every O 0 0.0009585699
two O 0 0.0018251721
months O 0 0.0041900417
. O 0 0.0051483465

In O 0 0.0028428014
a O 0 0.0020593528
double O 0 0.0013600916
blind O 0 0.003802886
cross O 0 0.0017653593
- O 0 0.0011956703
over O 0 0.00032787674
study O 0 0.0006529699
with O 0 0.00046540645
control O 0 0.0003402501
group O 0 0.0005047751
, O 0 0.00042039083
the O 0 0.00026126328
patients O 0 0.00082942407
under O 0 0.0002639989
timolol B-Chemical 1 0.99975723
treatment O 0 0.0032707385
presented O 0 0.00047649452
higher O 0 0.0004770608
depression B-Disease 0 0.9623387
values O 0 0.00030902406
measured O 0 0.00019681256
through O 0 0.00024164276
the O 0 0.00034188738
Beck O 0 0.0762383
and O 0 0.00040747618
the O 0 0.0005087058
Zung O 0 0.2247925
- O 0 0.0010461605
Conde O 0 0.21958978
scales O 0 0.00076409057
( O 0 0.0007673912
p O 0 0.00080299407
< O 0 0.00076871814
0 O 0 0.0007842668
. O 0 0.0006976952
001 O 0 0.055323165
vs O 0 0.0030085563
control O 0 0.0025250292
) O 0 0.00640909
. O 0 0.0056181075

These O 0 0.00422416
results O 0 0.0021625524
suggest O 0 0.0015722781
that O 0 0.0018317194
betaxolol B-Chemical 0 0.99958926
could O 0 0.0013353779
be O 0 0.0009464514
less O 0 0.00072710944
of O 0 0.0009933416
a O 0 0.0016601754
depression B-Disease 0 0.9922609
- O 0 0.0037669956
inducer O 0 0.046364583
than O 0 0.0014943577
timolol B-Chemical 1 0.9993425
in O 0 0.0036723136
predisposed O 0 0.40212703
patients O 0 0.034193873
. O 0 0.007157534

Protection O 0 0.12992142
against O 0 0.0069712577
amphetamine B-Chemical 1 0.9994128
- O 0 0.019115526
induced O 0 0.008925183
neurotoxicity B-Disease 2 0.99933076
toward O 0 0.0068829264
striatal O 0 0.99586135
dopamine B-Chemical 1 0.9993284
neurons O 0 0.123865865
in O 0 0.0009099967
rodents O 0 0.005222345
by O 0 0.0017755656
LY274614 B-Chemical 1 0.9989513
, O 0 0.0030892573
an O 0 0.003982991
excitatory O 0 0.9922294
amino B-Chemical 0 0.98615414
acid I-Chemical 0 0.9936075
antagonist O 0 0.98922193
. O 0 0.01184747

LY274614 B-Chemical 1 0.9958348
, O 0 0.010250682
3SR B-Chemical 0 0.15565638
, I-Chemical 0 0.004272133
4aRS I-Chemical 0 0.01801747
, I-Chemical 0 0.0032661683
6SR I-Chemical 0 0.6576915
, I-Chemical 0 0.0022809226
8aRS I-Chemical 0 0.02127142
- I-Chemical 0 0.0018890603
6 I-Chemical 0 0.0006938487
- I-Chemical 0 0.0013548562
[ I-Chemical 0 0.0020148847
phosphonomethyl I-Chemical 0 0.85781896
] I-Chemical 0 0.0021864187
decahydr I-Chemical 0 0.014175623
oisoquinoline I-Chemical 0 0.031085934
- I-Chemical 0 0.0014033142
3 I-Chemical 0 0.00049106986
- I-Chemical 0 0.0012530205
carboxylic I-Chemical 0 0.99299365
acid I-Chemical 0 0.94259655
, O 0 0.0007591676
has O 0 0.00035931027
been O 0 0.0004010677
described O 0 0.00023107642
as O 0 0.00023160779
a O 0 0.0004098768
potent O 0 0.022841219
antagonist O 0 0.9220296
of O 0 0.0010479814
the O 0 0.0009456969
N B-Chemical 0 0.96515167
- I-Chemical 0 0.010824206
methyl I-Chemical 0 0.98499185
- I-Chemical 0 0.0106258495
D I-Chemical 0 0.8353554
- I-Chemical 0 0.01599509
aspartate I-Chemical 1 0.99933726
( O 0 0.020763138
NMDA B-Chemical 1 0.99970573
) O 0 0.011556765
subtype O 0 0.25687772
of O 0 0.010581476
glutamate B-Chemical 1 0.9981812
receptor O 0 0.789618
. O 0 0.010224576

Here O 0 0.0055005862
its O 0 0.0038313167
ability O 0 0.0018663948
to O 0 0.0013473313
antagonize O 0 0.007971051
the O 0 0.000962677
prolonged O 0 0.009455752
depletion O 0 0.0031981678
of O 0 0.0021164808
dopamine B-Chemical 1 0.99910223
in O 0 0.0009374361
the O 0 0.0009356796
striatum O 0 0.7560053
by O 0 0.0016678252
amphetamine B-Chemical 1 0.9998381
in O 0 0.004746389
iprindole B-Chemical 0 0.9999218
- O 0 0.009721064
treated O 0 0.0043833125
rats O 0 0.010836907
is O 0 0.0031970416
reported O 0 0.006709451
. O 0 0.0058504264

A O 0 0.0129651
single O 0 0.002909875
18 O 0 0.0021558027
. O 0 0.0010330594
4 O 0 0.00095854414
mg O 0 0.12720388
/ O 0 0.0019200704
kg O 0 0.005199007
( O 0 0.0008753388
i O 0 0.0011134486
. O 0 0.00030027088
p O 0 0.0005498685
. O 0 0.00025419588
) O 0 0.0005645752
dose O 0 0.00373893
of O 0 0.0006948887
( O 0 0.0009474845
+ O 0 0.00073615555
/ O 0 0.0018791712
- O 0 0.0012351425
) O 0 0.0012953434
- O 0 0.0025968913
amphetamine B-Chemical 1 0.9999193
hemisulfate O 0 0.9996824
, O 0 0.0009725458
given O 0 0.00022285468
to O 0 0.00027732624
rats O 0 0.0027869828
pretreated O 0 0.029080039
with O 0 0.0018042498
iprindole B-Chemical 0 0.9999609
, O 0 0.0012619531
resulted O 0 0.00043047967
in O 0 0.00037161648
persistent O 0 0.04434545
depletion O 0 0.0029243673
of O 0 0.0018471797
dopamine B-Chemical 1 0.9989857
in O 0 0.0010028081
the O 0 0.001281062
striatum O 0 0.47435832
1 O 0 0.0015570119
week O 0 0.0018073888
later O 0 0.0029255229
. O 0 0.0043586576

This O 0 0.005100781
prolonged O 0 0.008499778
depletion O 0 0.004533148
of O 0 0.0032308795
dopamine B-Chemical 1 0.99822885
in O 0 0.001504435
the O 0 0.0012529882
striatum O 0 0.7049142
was O 0 0.0010238853
antagonized O 0 0.73594046
by O 0 0.002190764
dizocilpine B-Chemical 0 0.9999082
( O 0 0.012018896
MK B-Chemical 0 0.9879232
- I-Chemical 0 0.004444736
801 I-Chemical 0 0.6243352
, O 0 0.00068696926
a O 0 0.0004792022
non O 0 0.0012343944
- O 0 0.0009884655
competitive O 0 0.012447268
antagonist O 0 0.96452457
of O 0 0.0058896774
NMDA B-Chemical 1 0.99991095
receptors O 0 0.7496558
) O 0 0.002647204
or O 0 0.0005395696
by O 0 0.0011135781
LY274614 B-Chemical 1 0.99938977
( O 0 0.001621461
a O 0 0.0011045492
competitive O 0 0.027864551
antagonist O 0 0.97555405
of O 0 0.025404086
NMDA B-Chemical 1 0.9996019
receptors O 0 0.86718315
) O 0 0.024052009
. O 0 0.0073092137

The O 0 0.0033221182
protective O 0 0.0077473284
effect O 0 0.0026829154
of O 0 0.0033048608
LY274614 B-Chemical 1 0.9989089
was O 0 0.0020790813
dose O 0 0.05995608
- O 0 0.0016327563
dependent O 0 0.0006166177
, O 0 0.0006949115
being O 0 0.00058666675
maximum O 0 0.00046280227
at O 0 0.00032564715
10 O 0 0.0005797861
- O 0 0.0008461572
40 O 0 0.0008583777
mgkg O 0 0.7269989
( O 0 0.0014675542
i O 0 0.0023943784
. O 0 0.001038604
p O 0 0.0025266437
. O 0 0.0020523465
) O 0 0.0059471047
. O 0 0.0054315054

A O 0 0.016486714
10 O 0 0.0036295094
mg O 0 0.2314786
/ O 0 0.0033460697
kg O 0 0.0055508376
dose O 0 0.009248279
of O 0 0.0017959368
LY274614 B-Chemical 1 0.9991978
was O 0 0.0009274335
effective O 0 0.0009810751
in O 0 0.00043324352
antagonizing O 0 0.017050141
the O 0 0.00045429252
depletion O 0 0.0017671105
of O 0 0.0012716891
dopamine B-Chemical 1 0.9994123
in O 0 0.00050456723
the O 0 0.00048355883
striatum O 0 0.63148326
, O 0 0.00036493293
when O 0 0.0001352208
given O 0 0.00013444386
as O 0 0.00015112203
long O 0 0.0002476561
as O 0 0.00017535021
8 O 0 0.00021430111
hr O 0 0.00037769135
prior O 0 0.0001701796
to O 0 0.0003833848
amphetamine B-Chemical 1 0.99975663
but O 0 0.0005089309
not O 0 0.00035361724
when O 0 0.00028418965
given O 0 0.0003810078
24 O 0 0.0006757784
hr O 0 0.0014569429
prior O 0 0.0011080598
to O 0 0.0034823087
amphetamine B-Chemical 1 0.99868244
. O 0 0.0082822135

Depletion O 0 0.03089061
of O 0 0.00543992
dopamine B-Chemical 1 0.9966522
in O 0 0.0021474734
the O 0 0.001618962
striatum O 0 0.5781534
was O 0 0.0009025976
also O 0 0.0008717057
antagonized O 0 0.57399887
when O 0 0.00067149376
LY274614 B-Chemical 1 0.9993987
was O 0 0.00050790206
given O 0 0.00022039065
after O 0 0.00016779156
the O 0 0.00026163398
injection O 0 0.0016772976
of O 0 0.0012820343
amphetamine B-Chemical 1 0.9999341
; O 0 0.02151226
LY274614 B-Chemical 1 0.9996562
protected O 0 0.0009905441
when O 0 0.0001948711
given O 0 0.00017605856
up O 0 0.00023028794
to O 0 0.00020599131
4 O 0 0.00019512266
hr O 0 0.0003829395
after O 0 0.00013909402
but O 0 0.00022416252
not O 0 0.00022935316
when O 0 0.00021595291
given O 0 0.0003002849
8 O 0 0.0004889076
or O 0 0.00052067975
24 O 0 0.0009107609
hr O 0 0.0023696774
after O 0 0.002271471
amphetamine B-Chemical 1 0.9984579
. O 0 0.007666077

The O 0 0.0030640243
prolonged O 0 0.007447097
depletion O 0 0.0043277587
of O 0 0.0030927176
dopamine B-Chemical 1 0.99818075
in O 0 0.0013513532
the O 0 0.0010350868
striatum O 0 0.47230464
in O 0 0.00045742598
mice O 0 0.00027978542
, O 0 0.00040942067
given O 0 0.00021034587
multiple O 0 0.00060543866
injections O 0 0.004886992
of O 0 0.0011779728
methamphetamine B-Chemical 1 0.9997855
, O 0 0.0014838255
was O 0 0.00058418093
also O 0 0.0008157849
antagonized O 0 0.7629781
dose O 0 0.16453564
- O 0 0.0062488467
dependently O 0 0.9660171
and O 0 0.0023997172
completely O 0 0.0032748668
by O 0 0.0064441077
LY274614 B-Chemical 1 0.99739397
. O 0 0.008668876

The O 0 0.0028723818
data O 0 0.0024275503
strengthen O 0 0.0019757159
the O 0 0.0011906078
evidence O 0 0.0011466733
that O 0 0.00079264375
the O 0 0.0010101795
neurotoxic B-Disease 0 0.9963386
effect O 0 0.0015802793
of O 0 0.002317416
amphetamine B-Chemical 1 0.9998765
and O 0 0.0013615808
related O 0 0.0005648494
compounds O 0 0.6114582
toward O 0 0.0017826654
nigrostriatal O 0 0.99912745
dopamine B-Chemical 1 0.99965537
neurons O 0 0.19063953
involves O 0 0.0014504408
NMDA B-Chemical 1 0.99989057
receptors O 0 0.4876279
and O 0 0.00083077926
that O 0 0.00065407983
LY274614 B-Chemical 1 0.9996087
is O 0 0.0008847112
an O 0 0.002382746
NMDA B-Chemical 1 0.99988914
receptor O 0 0.7271657
antagonist O 0 0.9879332
with O 0 0.0012656305
long O 0 0.0011394656
- O 0 0.0011682911
lasting O 0 0.0018282492
in O 0 0.00070884277
vivo O 0 0.0018807495
effects O 0 0.0030356466
in O 0 0.0025917138
rats O 0 0.014090581
. O 0 0.005501374

Ketoconazole B-Chemical 0 0.9956352
- O 0 0.051449616
induced O 0 0.04290011
neurologic B-Disease 0 0.9897314
sequelae I-Disease 0 0.97393453
. O 0 0.032150242

A O 0 0.02167948
77 O 0 0.007590901
- O 0 0.0044447784
y O 0 0.0061810357
- O 0 0.0019705324
old O 0 0.0010756036
patient O 0 0.0012131805
developed O 0 0.0016574094
weakness B-Disease 2 0.95461947
of I-Disease 0 0.0017181556
extremities I-Disease 0 0.7398173
, O 0 0.0024776126
legs B-Disease 0 0.78511345
paralysis I-Disease 2 0.99970967
, O 0 0.007009578
dysarthria B-Disease 0 0.99963033
and O 0 0.0019687852
tremor B-Disease 0 0.9994936
1 O 0 0.0004924706
h O 0 0.00029512763
after O 0 0.00016935728
ingestion O 0 0.11881635
of O 0 0.0005159346
200 O 0 0.0020645622
mg O 0 0.6426948
ketoconazole B-Chemical 1 0.99977773
for O 0 0.00060151564
the O 0 0.0005823705
first O 0 0.00058622233
time O 0 0.00084613747
in O 0 0.0014303242
his O 0 0.0044129007
life O 0 0.0083680125
. O 0 0.0056045805

All O 0 0.012535065
complaints O 0 0.071400575
faded O 0 0.019463744
away O 0 0.009397964
within O 0 0.0060922992
24 O 0 0.009256134
h O 0 0.012402718
. O 0 0.014333115

Few O 0 0.0054862085
days O 0 0.0021376975
later O 0 0.0015359649
, O 0 0.0014179345
the O 0 0.0007975674
patient O 0 0.001128114
used O 0 0.00062525016
another O 0 0.00071582396
200 O 0 0.001965724
mg O 0 0.7507934
ketoconazole B-Chemical 1 0.99991035
tablet O 0 0.98706555
, O 0 0.00096237205
and O 0 0.00036950276
within O 0 0.0001554502
an O 0 0.0003091832
hour O 0 0.00025029987
experienced O 0 0.0005009221
a O 0 0.00032379312
similar O 0 0.00025156786
clinical O 0 0.0024690668
picture O 0 0.00095067796
, O 0 0.0007592957
which O 0 0.0008484045
resolved O 0 0.0014962186
again O 0 0.0013576294
spontaneously O 0 0.009425326
within O 0 0.0014527009
hours O 0 0.0036670712
. O 0 0.0047914665

Laboratory O 0 0.017899197
evaluations O 0 0.0067154886
, O 0 0.005516207
including O 0 0.004309109
head O 0 0.026951728
CT O 0 0.30887887
scan O 0 0.012977604
, O 0 0.0076121707
were O 0 0.006534149
normal O 0 0.013631281
. O 0 0.011488567

This O 0 0.0044166166
case O 0 0.0022235434
illustrates O 0 0.001357784
the O 0 0.0010645118
need O 0 0.0008343075
for O 0 0.0006640801
close O 0 0.00076021627
vigilance O 0 0.02900157
in O 0 0.001008334
adverse B-Disease 0 0.8101793
drug I-Disease 0 0.58535606
reactions I-Disease 0 0.063961774
, O 0 0.0022235708
particularly O 0 0.002624949
in O 0 0.0019471693
the O 0 0.003436733
elderly O 0 0.3851259
. O 0 0.007265294

Development O 0 0.02118484
of O 0 0.0063342797
levodopa B-Chemical 1 0.99912316
- O 0 0.012160772
induced O 0 0.0068955454
dyskinesias B-Disease 2 0.99961555
in O 0 0.0026515368
parkinsonian B-Disease 2 0.99960047
monkeys O 0 0.0015273315
may O 0 0.00050390064
depend O 0 0.00042876764
upon O 0 0.00033826625
rate O 0 0.00042183822
of O 0 0.00075028534
symptom O 0 0.06803144
onset O 0 0.0062478073
and O 0 0.0010315438
/ O 0 0.0019489141
or O 0 0.00092751655
duration O 0 0.0022133496
of O 0 0.003971136
symptoms O 0 0.5606813
. O 0 0.006743983

Levodopa B-Chemical 0 0.9983929
- O 0 0.01460872
induced O 0 0.00996817
dyskinesias B-Disease 2 0.9994961
( O 0 0.016702307
LIDs B-Disease 2 0.9984937
) O 0 0.001726667
present O 0 0.00038427504
a O 0 0.0004590921
major O 0 0.0005192153
problem O 0 0.00076442637
for O 0 0.00029688972
the O 0 0.00032808562
long O 0 0.00053079455
- O 0 0.00062524393
term O 0 0.0004735647
management O 0 0.0013702861
of O 0 0.0015491784
Parkinson B-Disease 0 0.9990109
' I-Disease 0 0.0014489664
s I-Disease 0 0.0018640938
disease I-Disease 0 0.6512195
( O 0 0.005669346
PD B-Disease 0 0.9891376
) O 0 0.0070166704
patients O 0 0.012170893
. O 0 0.006159986

Due O 0 0.003936779
to O 0 0.0019613153
the O 0 0.001393609
interdependence O 0 0.0020715315
of O 0 0.0014395686
risk O 0 0.015425813
factors O 0 0.0030347388
in O 0 0.00063994905
clinical O 0 0.0073641385
populations O 0 0.0011551414
, O 0 0.00063997955
it O 0 0.00040738416
is O 0 0.00029011577
difficult O 0 0.0002796116
to O 0 0.00022002804
independently O 0 0.00024523944
examine O 0 0.00020255429
factors O 0 0.00094657
that O 0 0.00041240832
may O 0 0.0005940916
influence O 0 0.0007110094
the O 0 0.0012135995
development O 0 0.0048236707
of O 0 0.008145184
LIDs B-Disease 2 0.9963133
. O 0 0.007925293

Using O 0 0.004326627
macaque O 0 0.0028021073
monkeys O 0 0.0020301251
with O 0 0.0013277738
different O 0 0.0010520162
types O 0 0.0011951408
of O 0 0.002915273
MPTP B-Chemical 0 0.99988174
- O 0 0.012820394
induced O 0 0.0060491823
parkinsonism B-Disease 2 0.99983454
, O 0 0.0010263055
the O 0 0.00029550484
current O 0 0.00049904373
study O 0 0.00040557026
evaluated O 0 0.00022670614
the O 0 0.00020605001
degree O 0 0.0003250207
to O 0 0.00022230166
which O 0 0.00030165797
rate O 0 0.00022522965
of O 0 0.00042853167
symptom O 0 0.14052527
progression O 0 0.42866248
, O 0 0.00085236033
symptom O 0 0.11537317
severity O 0 0.029355174
, O 0 0.0004396484
and O 0 0.00025505165
response O 0 0.00037112032
to O 0 0.00019494524
and O 0 0.00022910225
duration O 0 0.00038893888
of O 0 0.0006725495
levodopa B-Chemical 1 0.9997774
therapy O 0 0.065815024
may O 0 0.00068868545
be O 0 0.00058477727
involved O 0 0.00059924735
in O 0 0.0007202066
the O 0 0.0011260868
development O 0 0.0043778075
of O 0 0.007504654
LIDs B-Disease 2 0.99621934
. O 0 0.0076642935

Monkeys O 0 0.040584855
with O 0 0.0047848085
acute O 0 0.8356544
( O 0 0.003173306
short O 0 0.0015798558
- O 0 0.0019067752
term O 0 0.0014017579
) O 0 0.0039315084
MPTP B-Chemical 0 0.99980766
exposure O 0 0.0277035
, O 0 0.00085781404
rapid O 0 0.0016934678
symptom O 0 0.050964754
onset O 0 0.0024754652
and O 0 0.00029762884
short O 0 0.0002678659
symptom O 0 0.011457891
duration O 0 0.000331392
prior O 0 0.00015240764
to O 0 0.0001943141
initiation O 0 0.00034802253
of O 0 0.00057503406
levodopa B-Chemical 1 0.9998149
therapy O 0 0.13028236
developed O 0 0.01475428
dyskinesia B-Disease 2 0.99991727
between O 0 0.00033361954
11 O 0 0.00049742014
and O 0 0.00038266528
24 O 0 0.00039711257
days O 0 0.00045254314
of O 0 0.0010371391
daily O 0 0.012390167
levodopa B-Chemical 1 0.99914706
administration O 0 0.67474496
. O 0 0.0071391207

In O 0 0.003078813
contrast O 0 0.002449114
, O 0 0.0020995052
monkeys O 0 0.0015505237
with O 0 0.0011139186
long O 0 0.0012632086
- O 0 0.0014774547
term O 0 0.0014846643
MPTP B-Chemical 0 0.99983966
exposure O 0 0.03479189
, O 0 0.0009128399
slow O 0 0.0045480803
symptom O 0 0.15634672
progression O 0 0.33394054
and O 0 0.00053974637
/ O 0 0.00079752714
or O 0 0.00018704936
long O 0 0.0002835631
symptom O 0 0.010169624
duration O 0 0.00028575075
prior O 0 0.00013181215
to O 0 0.0001681678
initiation O 0 0.00030100954
of O 0 0.00047726004
levodopa B-Chemical 1 0.9998233
therapy O 0 0.04734467
were O 0 0.00033906478
more O 0 0.00036891812
resistant O 0 0.00073808205
to O 0 0.0003098353
developing O 0 0.013229691
LIDs B-Disease 2 0.9993112
( O 0 0.00080459984
e O 0 0.00092212786
. O 0 0.00019246225
g O 0 0.00084321783
. O 0 0.00020840025
, O 0 0.00065431674
dyskinesia B-Disease 2 0.9998536
developed O 0 0.0011848345
no O 0 0.00033306214
sooner O 0 0.0011716622
than O 0 0.00029000407
146 O 0 0.0015452631
days O 0 0.00053130253
of O 0 0.0013144215
chronic O 0 0.98708797
levodopa B-Chemical 1 0.9996792
administration O 0 0.87531954
) O 0 0.017600639
. O 0 0.0063241436

All O 0 0.003197075
animals O 0 0.0018723703
were O 0 0.0014237852
similarly O 0 0.0013450364
symptomatic O 0 0.0132635925
at O 0 0.00058809656
the O 0 0.0005672159
start O 0 0.0005158996
of O 0 0.001074469
levodopa B-Chemical 1 0.9995875
treatment O 0 0.0052134795
and O 0 0.0008744977
had O 0 0.00078922836
similar O 0 0.0007033568
therapeutic O 0 0.008324863
responses O 0 0.0030307642
to O 0 0.0019247988
the O 0 0.0032988032
drug O 0 0.4490559
. O 0 0.007425199

These O 0 0.0038659736
data O 0 0.0022898929
suggest O 0 0.0011734945
distinct O 0 0.0012482201
differences O 0 0.00065952376
in O 0 0.00058421073
the O 0 0.0005293054
propensity O 0 0.0015563554
to O 0 0.0005147672
develop O 0 0.0012884934
LIDs B-Disease 2 0.99839574
in O 0 0.000379621
monkeys O 0 0.00041002964
with O 0 0.00026431723
different O 0 0.00022597607
rates O 0 0.00025163553
of O 0 0.00042343023
symptom O 0 0.10255476
progression O 0 0.23540595
or O 0 0.0002872701
symptom O 0 0.023631228
durations O 0 0.00032945847
prior O 0 0.00015429729
to O 0 0.00026859523
levodopa B-Chemical 1 0.999673
and O 0 0.00033157787
demonstrate O 0 0.0001766437
the O 0 0.0002024556
value O 0 0.00023265157
of O 0 0.00031547903
these O 0 0.0004314128
models O 0 0.0006391567
for O 0 0.00039241646
further O 0 0.0006868469
studying O 0 0.0013599007
the O 0 0.0014988197
pathophysiology O 0 0.3563419
of O 0 0.01415596
LIDs B-Disease 2 0.9969023
. O 0 0.008404351

A O 0 0.0244461
diet O 0 0.055311598
promoting O 0 0.0048600365
sugar B-Disease 0 0.5699924
dependency I-Disease 0 0.029720135
causes O 0 0.0049867113
behavioral B-Disease 0 0.07299624
cross I-Disease 0 0.0029125216
- I-Disease 0 0.002612645
sensitization I-Disease 0 0.07794907
to O 0 0.0011995159
a O 0 0.0015456761
low O 0 0.0025123153
dose O 0 0.042748276
of O 0 0.013168299
amphetamine B-Chemical 1 0.99904805
. O 0 0.012731204

Previous O 0 0.003972127
research O 0 0.0032062042
in O 0 0.0013860606
this O 0 0.0010412615
laboratory O 0 0.0015885812
has O 0 0.00081434334
shown O 0 0.00050227466
that O 0 0.00042282155
a O 0 0.0005821968
diet O 0 0.017527219
of O 0 0.0007357754
intermittent O 0 0.11193663
excessive O 0 0.08085701
sugar O 0 0.4821628
consumption O 0 0.14146602
produces O 0 0.0009885733
a O 0 0.0006287181
state O 0 0.00080069643
with O 0 0.0008155494
neurochemical O 0 0.7322642
and O 0 0.0010450666
behavioral O 0 0.021779696
similarities O 0 0.0016346774
to O 0 0.0020062737
drug B-Disease 0 0.8108494
dependency I-Disease 0 0.095421225
. O 0 0.007368155

The O 0 0.0023539066
present O 0 0.00141126
study O 0 0.00169353
examined O 0 0.0008015033
whether O 0 0.0004943419
female O 0 0.0016522714
rats O 0 0.0017639968
on O 0 0.00032346052
various O 0 0.00084750156
regimens O 0 0.008595743
of O 0 0.0007968864
sugar O 0 0.16500804
access O 0 0.000573583
would O 0 0.00029676093
show O 0 0.00031885714
behavioral B-Disease 0 0.013219008
cross I-Disease 0 0.0011067633
- I-Disease 0 0.0012720803
sensitization I-Disease 0 0.058290247
to O 0 0.00072683545
a O 0 0.0010401055
low O 0 0.0018360366
dose O 0 0.037583582
of O 0 0.011328058
amphetamine B-Chemical 1 0.99917954
. O 0 0.0107400995

After O 0 0.0024302294
a O 0 0.0023535877
30 O 0 0.0016165806
- O 0 0.0016256107
min O 0 0.001069596
baseline O 0 0.0006700934
measure O 0 0.00033203018
of O 0 0.0006803727
locomotor O 0 0.22916172
activity O 0 0.0008991859
( O 0 0.0005648723
day O 0 0.0003228918
0 O 0 0.00037466682
) O 0 0.0004242547
, O 0 0.00025912072
animals O 0 0.00016615726
were O 0 0.00017486518
maintained O 0 0.00019637278
on O 0 0.00012508822
a O 0 0.0002915743
cyclic O 0 0.08043771
diet O 0 0.040655565
of O 0 0.0004555058
12 O 0 0.0002626522
- O 0 0.00038822947
h O 0 0.00023540501
deprivation O 0 0.010697118
followed O 0 0.00016937278
by O 0 0.0002302282
12 O 0 0.00019545821
- O 0 0.00031564926
h O 0 0.00019200878
access O 0 0.00018191489
to O 0 0.00016758688
10 O 0 0.00022778036
% O 0 0.0002526946
sucrose B-Chemical 0 0.37157184
solution O 0 0.004297247
and O 0 0.00033418267
chow O 0 0.089393064
pellets O 0 0.014275666
( O 0 0.00039545546
12 O 0 0.00015976212
h O 0 0.0001876723
access O 0 0.0001802073
starting O 0 0.00021138108
4 O 0 0.00017659216
h O 0 0.00019998944
after O 0 0.00013731694
onset O 0 0.00075551786
of O 0 0.0004214308
the O 0 0.0004227029
dark O 0 0.0006625099
period O 0 0.0008085589
) O 0 0.0015132811
for O 0 0.0011525189
21 O 0 0.0026585676
days O 0 0.003056034
. O 0 0.004413877

Locomotor O 0 0.35836238
activity O 0 0.0034151652
was O 0 0.0015232192
measured O 0 0.00083577324
again O 0 0.0009105955
for O 0 0.0006076759
30 O 0 0.00056537247
min O 0 0.0007037206
at O 0 0.000316281
the O 0 0.0003872758
beginning O 0 0.00039601064
of O 0 0.0006670788
days O 0 0.0007195919
1 O 0 0.00081069896
and O 0 0.00096129155
21 O 0 0.0015903512
of O 0 0.0023225318
sugar O 0 0.1470022
access O 0 0.006241306
. O 0 0.0064256205

Beginning O 0 0.010736672
on O 0 0.0023797534
day O 0 0.0024716614
22 O 0 0.0027963093
, O 0 0.002073508
all O 0 0.0013689916
rats O 0 0.0035476629
were O 0 0.0015930035
maintained O 0 0.0019359263
on O 0 0.001892296
ad O 0 0.009585702
libitum O 0 0.06878287
chow O 0 0.19601794
. O 0 0.012558271

Nine O 0 0.007377814
days O 0 0.0022952962
later O 0 0.0017886541
locomotor O 0 0.11641991
activity O 0 0.0014681405
was O 0 0.0007181591
measured O 0 0.0004358148
in O 0 0.0004418799
response O 0 0.00070449116
to O 0 0.00039268142
a O 0 0.00043323234
single O 0 0.00041368956
low O 0 0.00065746973
dose O 0 0.013774686
of O 0 0.0021243726
amphetamine B-Chemical 1 0.9998406
( O 0 0.002245403
0 O 0 0.00093983335
. O 0 0.0005084671
5 O 0 0.0008873871
mg O 0 0.13963266
/ O 0 0.0045005432
kg O 0 0.013773195
) O 0 0.0061843027
. O 0 0.005228586

The O 0 0.0025644589
animals O 0 0.00174508
that O 0 0.0011768076
had O 0 0.0012312551
experienced O 0 0.0022234463
cyclic O 0 0.31009004
sucrose B-Chemical 0 0.9069494
and O 0 0.0012411382
chow O 0 0.17586559
were O 0 0.00076856645
hyperactive B-Disease 0 0.2518659
in O 0 0.00042596337
response O 0 0.0007583946
to O 0 0.000503578
amphetamine B-Chemical 1 0.99981636
compared O 0 0.0002597866
with O 0 0.00032219986
four O 0 0.00016989087
control O 0 0.00022233851
groups O 0 0.00036765911
( O 0 0.00039581698
ad O 0 0.00092592865
libitum O 0 0.007870367
10 O 0 0.00032192384
% O 0 0.00030765327
sucrose B-Chemical 0 0.24202618
and O 0 0.00034056825
chow O 0 0.039162822
followed O 0 0.0002647233
by O 0 0.0005272896
amphetamine B-Chemical 1 0.9998596
injection O 0 0.021329528
, O 0 0.000760334
cyclic O 0 0.18675251
chow O 0 0.16242097
followed O 0 0.00031059154
by O 0 0.00059751846
amphetamine B-Chemical 1 0.9998733
injection O 0 0.020284329
, O 0 0.00063892984
ad O 0 0.0018997415
libitum O 0 0.025034208
chow O 0 0.089335084
with O 0 0.0010673506
amphetamine B-Chemical 1 0.99982566
, O 0 0.0010990986
or O 0 0.00044841497
cyclic O 0 0.11033259
10 O 0 0.00061789574
% O 0 0.0006064027
sucrose B-Chemical 0 0.35161576
and O 0 0.0008309698
chow O 0 0.05653155
with O 0 0.001357263
a O 0 0.0020123166
saline O 0 0.15383327
injection O 0 0.017084045
) O 0 0.008033104
. O 0 0.0058383276

These O 0 0.003742641
results O 0 0.0018265679
suggest O 0 0.00117953
that O 0 0.000976655
a O 0 0.0010905629
diet O 0 0.016514743
comprised O 0 0.00075438304
of O 0 0.00073616434
alternating O 0 0.0059600035
deprivation O 0 0.11266508
and O 0 0.0005905291
access O 0 0.0004438158
to O 0 0.00031886168
a O 0 0.0004512799
sugar O 0 0.13402243
solution O 0 0.012404249
and O 0 0.00046650798
chow O 0 0.12760547
produces O 0 0.0010953868
bingeing O 0 0.99319804
on O 0 0.00025492162
sugar O 0 0.09985992
that O 0 0.00027192195
leads O 0 0.00036034157
to O 0 0.00022181658
a O 0 0.000243834
long O 0 0.00026673335
lasting O 0 0.00074457296
state O 0 0.00037353465
of O 0 0.00033636944
increased O 0 0.00067165954
sensitivity O 0 0.0021208853
to O 0 0.00067566923
amphetamine B-Chemical 1 0.99988425
, O 0 0.001187574
possibly O 0 0.0012926346
due O 0 0.0002905761
to O 0 0.00038809274
a O 0 0.00059209333
lasting O 0 0.0019551308
alteration O 0 0.002137052
in O 0 0.0012616713
the O 0 0.0026543266
dopamine B-Chemical 1 0.9962035
system O 0 0.011093974
. O 0 0.006757181

Reversible O 0 0.95365244
dilated B-Disease 2 0.9869971
cardiomyopathy I-Disease 2 0.9986822
related O 0 0.0123687005
to O 0 0.014193968
amphotericin B-Chemical 1 0.9970481
B I-Chemical 1 0.9178202
therapy O 0 0.40979522
. O 0 0.018676125

We O 0 0.0029658135
describe O 0 0.0022933076
a O 0 0.0019115345
patient O 0 0.002265805
who O 0 0.0028295224
developed O 0 0.0033182949
dilated B-Disease 2 0.9928999
cardiomyopathy I-Disease 2 0.99983394
and O 0 0.0026828987
clinical O 0 0.10690516
congestive O 0 0.99973696
heart B-Disease 0 0.8793437
failure I-Disease 0 0.5684186
after O 0 0.00031153936
2 O 0 0.00034549815
months O 0 0.00031609376
of O 0 0.00043435465
therapy O 0 0.009480692
with O 0 0.0021857657
amphotericin B-Chemical 1 0.99949706
B I-Chemical 1 0.9250587
( O 0 0.013057278
AmB B-Chemical 1 0.9985726
) O 0 0.0060553974
for O 0 0.0033983027
disseminated O 0 0.9857765
coccidioidomycosis B-Disease 0 0.99748516
. O 0 0.011600713

His O 0 0.012503288
echocardiographic O 0 0.09591081
abnormalities O 0 0.07219974
and O 0 0.00332459
heart B-Disease 0 0.33885297
failure I-Disease 0 0.45251003
resolved O 0 0.0045565288
after O 0 0.00212488
posaconazole B-Chemical 0 0.99849343
was O 0 0.0044380357
substituted O 0 0.029410372
for O 0 0.006784326
AmB B-Chemical 1 0.99403703
. O 0 0.011650694

It O 0 0.007216176
is O 0 0.0031026022
important O 0 0.002090342
to O 0 0.0018292695
recognize O 0 0.0018112211
the O 0 0.001769752
rare O 0 0.006809902
and O 0 0.0027503776
potentially O 0 0.008174715
reversible O 0 0.73626506
toxicity B-Disease 2 0.9935555
of O 0 0.05100545
AmB B-Chemical 1 0.9966916
. O 0 0.014067773

NO B-Chemical 0 0.9888727
- O 0 0.012082079
induced O 0 0.008081229
migraine B-Disease 2 0.9992884
attack O 0 0.7816187
: O 0 0.0026032405
strong O 0 0.0011648663
increase O 0 0.0007445985
in O 0 0.0006510389
plasma O 0 0.066080935
calcitonin B-Chemical 1 0.98782057
gene I-Chemical 0 0.0025379052
- I-Chemical 0 0.0012896451
related I-Chemical 0 0.00042835315
peptide I-Chemical 0 0.0056417612
( O 0 0.0017781714
CGRP B-Chemical 1 0.9984895
) O 0 0.0018510635
concentration O 0 0.0018507341
and O 0 0.0006214482
negative O 0 0.0007114028
correlation O 0 0.00080519385
with O 0 0.0028930313
platelet O 0 0.973129
serotonin B-Chemical 1 0.99801135
release O 0 0.61683553
. O 0 0.009211328

The O 0 0.002525243
aim O 0 0.0018843856
of O 0 0.0014065645
the O 0 0.00091736286
present O 0 0.0006246337
study O 0 0.0009786186
was O 0 0.00051674
to O 0 0.00038574412
investigate O 0 0.00027510204
changes O 0 0.00058335025
in O 0 0.00032813812
the O 0 0.0003982913
plasma O 0 0.053533908
calcitonin B-Chemical 1 0.9880348
gene I-Chemical 0 0.0022337546
- I-Chemical 0 0.0010895006
related I-Chemical 0 0.00032624876
peptide I-Chemical 0 0.0064166225
( O 0 0.001640041
CGRP B-Chemical 1 0.99903667
) O 0 0.002080635
concentration O 0 0.0033759002
and O 0 0.0006666209
platelet O 0 0.9466366
serotonin B-Chemical 1 0.999445
( O 0 0.0015178677
5 B-Chemical 0 0.00036399066
- I-Chemical 0 0.0005626008
hydroxytriptamine I-Chemical 0 0.005154026
, O 0 0.00049291993
5 B-Chemical 0 0.0003265092
- I-Chemical 0 0.0007786838
HT I-Chemical 0 0.94743806
) O 0 0.0006660012
content O 0 0.0003584045
during O 0 0.00021806567
the O 0 0.000323492
immediate O 0 0.002533249
headache B-Disease 2 0.9988918
and O 0 0.000713595
the O 0 0.0005986671
delayed O 0 0.0069227237
genuine O 0 0.019951947
migraine B-Disease 2 0.99962854
attack O 0 0.8772256
provoked O 0 0.469848
by O 0 0.017843656
nitroglycerin B-Chemical 1 0.9993186
. O 0 0.011889881

Fifteen O 0 0.014579331
female O 0 0.013374212
migraineurs B-Disease 0 0.987432
( I-Disease 0 0.0047504725
without I-Disease 0 0.0034394388
aura I-Disease 0 0.99887353
) I-Disease 0 0.003565816
and O 0 0.0013852924
eight O 0 0.0011065087
controls O 0 0.0021059278
participated O 0 0.0050422265
in O 0 0.0023253008
the O 0 0.0034339237
study O 0 0.0076497677
. O 0 0.00748955

Sublingual O 0 0.98387814
nitroglycerin B-Chemical 1 0.9988518
( O 0 0.010454557
0 O 0 0.004166387
. O 0 0.002241684
5 O 0 0.0026856228
mg O 0 0.17068766
) O 0 0.006139175
was O 0 0.0049340692
administered O 0 0.013024516
. O 0 0.009112582

Blood O 0 0.021973277
was O 0 0.0022663395
collected O 0 0.0012033301
from O 0 0.001000491
the O 0 0.0008740078
antecubital O 0 0.0029339388
vein O 0 0.005084507
four O 0 0.00035569043
times O 0 0.0003261791
: O 0 0.000550504
60 O 0 0.00035205932
min O 0 0.0003618664
before O 0 0.00014104116
and O 0 0.00022392969
after O 0 0.00015204809
the O 0 0.00032781015
nitroglycerin B-Chemical 1 0.9998056
application O 0 0.0038078248
, O 0 0.00048818765
and O 0 0.00026446997
60 O 0 0.00025661886
and O 0 0.00019239016
120 O 0 0.0002838606
min O 0 0.00024122819
after O 0 9.661753e-05
the O 0 0.00014920438
beginning O 0 0.00016646806
of O 0 0.0003567842
the O 0 0.0005671794
migraine B-Disease 2 0.99974066
attack O 0 0.6095942
( O 0 0.0009136286
mean O 0 0.00036279252
344 O 0 0.009804825
and O 0 0.0006545029
404 O 0 0.0048825527
min O 0 0.0014505341
; O 0 0.0016036495
12 O 0 0.0011616256
subjects O 0 0.0031181849
) O 0 0.0053431266
. O 0 0.004934184

In O 0 0.0031168258
those O 0 0.0026892486
subjects O 0 0.0025534711
who O 0 0.0026622762
had O 0 0.0014110357
no O 0 0.0014706334
migraine B-Disease 2 0.9993819
attack O 0 0.6991326
( O 0 0.0019041579
11 O 0 0.0009197119
subjects O 0 0.0011510294
) O 0 0.0010187218
a O 0 0.0006889527
similar O 0 0.0005770697
time O 0 0.0009157368
schedule O 0 0.0028161742
was O 0 0.002644682
used O 0 0.0039586304
. O 0 0.005921933

Plasma O 0 0.7154564
CGRP B-Chemical 1 0.9948454
concentration O 0 0.019012516
increased O 0 0.0037199922
significantly O 0 0.0025756753
( O 0 0.0020976837
P O 0 0.02927413
< O 0 0.0009625875
0 O 0 0.0006324725
. O 0 0.0003471316
01 O 0 0.0021169926
) O 0 0.00059173093
during O 0 0.0002769811
the O 0 0.00057044096
migraine B-Disease 2 0.9995765
attack O 0 0.39299124
and O 0 0.00064619497
returned O 0 0.00049317814
to O 0 0.00037251585
baseline O 0 0.0005853232
after O 0 0.0003498051
the O 0 0.0006996658
cessation O 0 0.0046542394
of O 0 0.0025596556
the O 0 0.005018318
migraine B-Disease 2 0.9983663
. O 0 0.009503884

In O 0 0.0029641474
addition O 0 0.001736453
, O 0 0.0019498178
both O 0 0.0010810904
change O 0 0.0010025
and O 0 0.0008154394
peak O 0 0.00094305846
, O 0 0.0007505907
showed O 0 0.00045798096
significant O 0 0.00056250504
positive O 0 0.00044606673
correlations O 0 0.0006054337
with O 0 0.0021650668
migraine B-Disease 2 0.9998919
headache B-Disease 0 0.99974567
intensity O 0 0.0021728196
( O 0 0.0027207858
P O 0 0.048507445
< O 0 0.0018703288
0 O 0 0.0017895577
. O 0 0.0017495955
001 O 0 0.13785914
) O 0 0.007209409
. O 0 0.0060906936

However O 0 0.0053348537
, O 0 0.004608986
plasma O 0 0.06657263
CGRP B-Chemical 1 0.9960995
concentrations O 0 0.011734045
failed O 0 0.001663826
to O 0 0.00079112285
change O 0 0.0007525617
during O 0 0.0005188321
immediate O 0 0.00300414
headache B-Disease 2 0.9983785
and O 0 0.0010400035
in O 0 0.00066447764
the O 0 0.00076145027
subjects O 0 0.0017391316
with O 0 0.0020475483
no O 0 0.0035916942
migraine B-Disease 2 0.99883777
attack O 0 0.85588574
. O 0 0.009728342

Basal O 0 0.45806682
CGRP B-Chemical 1 0.9938599
concentration O 0 0.01416589
was O 0 0.0018935592
significantly O 0 0.0014631824
higher O 0 0.0010003767
and O 0 0.0011557731
platelet O 0 0.72375447
5 B-Chemical 0 0.001021257
- I-Chemical 0 0.0016773366
HT I-Chemical 0 0.9304036
content O 0 0.00087983586
tended O 0 0.00057373743
to O 0 0.00040612413
be O 0 0.00044475813
lower O 0 0.00044809427
in O 0 0.0004911722
subjects O 0 0.0012287373
who O 0 0.0022202206
experienced O 0 0.0033044724
a O 0 0.0052765687
migraine B-Disease 2 0.99891436
attack O 0 0.8517432
. O 0 0.009359691

Platelet O 0 0.95183086
serotonin B-Chemical 1 0.99481994
content O 0 0.0046293926
decreased O 0 0.0044396375
significantly O 0 0.0025094168
( O 0 0.0020426754
P O 0 0.030473283
< O 0 0.00092292734
0 O 0 0.00060003577
. O 0 0.00032238825
01 O 0 0.0020531972
) O 0 0.00056689547
after O 0 0.0002603207
nitroglycerin B-Chemical 1 0.9996916
in O 0 0.0004401701
subjects O 0 0.0007327739
with O 0 0.0004838368
no O 0 0.0005052954
migraine B-Disease 2 0.9997563
attack O 0 0.56208664
but O 0 0.0004946457
no O 0 0.00028675402
consistent O 0 0.0003812203
change O 0 0.0004754696
was O 0 0.0004526661
observed O 0 0.00044992534
in O 0 0.0007535298
patients O 0 0.004080484
with O 0 0.0059349556
migraine B-Disease 2 0.9991755
attack O 0 0.88097245
. O 0 0.009025277

In O 0 0.00288024
conclusion O 0 0.0021064177
, O 0 0.0018925717
the O 0 0.0009830325
fact O 0 0.0007829877
that O 0 0.0007954922
plasma O 0 0.08227605
CGRP B-Chemical 1 0.9985191
concentration O 0 0.009088155
correlates O 0 0.000745643
with O 0 0.00052915886
the O 0 0.000338201
timing O 0 0.00038669605
and O 0 0.00045065308
severity O 0 0.008626772
of O 0 0.00082144653
a O 0 0.0022375414
migraine B-Disease 2 0.9999218
headache B-Disease 0 0.9997757
suggests O 0 0.0006603203
a O 0 0.0007268096
direct O 0 0.00065391336
relationship O 0 0.00076274335
between O 0 0.0012688355
CGRP B-Chemical 1 0.9961422
and O 0 0.013223548
migraine B-Disease 2 0.9986588
. O 0 0.010603175

In O 0 0.0035724351
contrast O 0 0.0032325473
, O 0 0.0040376093
serotonin B-Chemical 1 0.9964191
release O 0 0.1543253
from O 0 0.0014441318
platelets O 0 0.19917232
does O 0 0.0007332999
not O 0 0.0006932925
provoke O 0 0.07624992
migraine B-Disease 2 0.9997646
, O 0 0.0017175293
it O 0 0.00061415316
may O 0 0.00041898197
even O 0 0.0004314028
counteract O 0 0.0014012108
the O 0 0.0007854814
headache B-Disease 2 0.998933
and O 0 0.0009555225
the O 0 0.0008602864
concomitant O 0 0.05596942
CGRP B-Chemical 1 0.99858725
release O 0 0.19494903
in O 0 0.0020578827
this O 0 0.0028042477
model O 0 0.0058650943
. O 0 0.0061137024

Hyperbaric O 0 0.9699612
oxygen B-Chemical 1 0.9484759
therapy O 0 0.03433796
for O 0 0.0023922382
control O 0 0.0020290185
of O 0 0.0037563667
intractable O 0 0.98690414
cyclophosphamide B-Chemical 1 0.99932945
- O 0 0.08101577
induced O 0 0.07601644
hemorrhagic B-Disease 2 0.9987607
cystitis I-Disease 0 0.99929464
. O 0 0.026018938

We O 0 0.0036096058
report O 0 0.004813858
a O 0 0.0022770434
case O 0 0.0018315344
of O 0 0.0025492543
intractable O 0 0.98655635
hemorrhagic B-Disease 2 0.99935585
cystitis I-Disease 0 0.9997633
due O 0 0.001783257
to O 0 0.0018279254
cyclophosphamide B-Chemical 1 0.9992429
therapy O 0 0.18320127
for O 0 0.002561236
Wegener B-Disease 0 0.9524942
' I-Disease 0 0.004145531
s I-Disease 0 0.0066015185
granulomatosis I-Disease 0 0.9157219
. O 0 0.00815643

Conservative O 0 0.11139898
treatment O 0 0.006373462
, O 0 0.0028622472
including O 0 0.0017064721
bladder O 0 0.4712221
irrigation O 0 0.026029889
with O 0 0.0014916621
physiological O 0 0.0063067577
saline O 0 0.1298492
and O 0 0.0011460235
instillation O 0 0.09964535
of O 0 0.0046760095
prostaglandin B-Chemical 0 0.99990153
F2 I-Chemical 0 0.9573209
alpha I-Chemical 0 0.92644846
, O 0 0.0030194605
failed O 0 0.0021430268
to O 0 0.0016824692
totally O 0 0.005176304
control O 0 0.0050898553
hemorrhage B-Disease 2 0.99660635
. O 0 0.00950964

We O 0 0.0031159802
then O 0 0.0020572522
used O 0 0.0018545629
hyperbaric O 0 0.76910096
oxygen B-Chemical 1 0.94155717
at O 0 0.0010377557
an O 0 0.0011306938
absolute O 0 0.0009787714
pressure O 0 0.014486631
of O 0 0.0009795266
2 O 0 0.0008230413
atm O 0 0.24873845
, O 0 0.00078088476
5 O 0 0.00040009507
days O 0 0.0004043032
a O 0 0.00053867983
week O 0 0.0006218834
for O 0 0.0007713818
8 O 0 0.0013144617
consecutive O 0 0.002357495
weeks O 0 0.003353501
. O 0 0.0047140624

The O 0 0.004647957
bleeding B-Disease 0 0.92550397
ceased O 0 0.0058396286
completely O 0 0.0019766975
by O 0 0.0012170677
the O 0 0.0008196517
end O 0 0.0005244899
of O 0 0.00090740656
treatment O 0 0.0016770206
and O 0 0.000888432
the O 0 0.00078926334
patient O 0 0.0016268278
remained O 0 0.0019311595
free O 0 0.0032851945
of O 0 0.0058809537
hematuria B-Disease 2 0.9979792
thereafter O 0 0.016550591
. O 0 0.007874724

No O 0 0.009414844
side O 0 0.012999237
effect O 0 0.0039015568
was O 0 0.0027871549
noted O 0 0.0023945998
during O 0 0.0018840089
the O 0 0.0025983956
course O 0 0.0053509963
of O 0 0.0074658147
therapy O 0 0.11408969
. O 0 0.011720505

In O 0 0.003014257
future O 0 0.0022703393
, O 0 0.0019467783
this O 0 0.0010621491
form O 0 0.0010131466
of O 0 0.0010554625
therapy O 0 0.008508921
can O 0 0.00061627687
offer O 0 0.00096557004
a O 0 0.0006244783
safe O 0 0.0015622914
alternative O 0 0.0006118684
in O 0 0.00047934998
the O 0 0.00056788936
treatment O 0 0.0019026551
of O 0 0.0028256183
cyclophosphamide B-Chemical 1 0.99945635
- O 0 0.035189867
induced O 0 0.05077482
hemorrhagic B-Disease 2 0.9991297
cystitis I-Disease 0 0.9994754
. O 0 0.021252831

Acute B-Disease 0 0.99089617
psychosis I-Disease 0 0.9974529
due O 0 0.003971459
to O 0 0.0030206419
treatment O 0 0.0057833623
with O 0 0.0060866047
phenytoin B-Chemical 1 0.9992938
in O 0 0.005423125
a O 0 0.008030031
nonepileptic O 0 0.99080676
patient O 0 0.01688462
. O 0 0.010366112

The O 0 0.0031104113
development O 0 0.0040204995
of O 0 0.0030908585
psychosis B-Disease 0 0.99698216
related O 0 0.001423843
to O 0 0.0012491636
antiepileptic O 0 0.99831295
drug O 0 0.67025197
treatment O 0 0.004633134
is O 0 0.00059175456
usually O 0 0.0008262808
attributed O 0 0.0004482754
to O 0 0.00032098332
the O 0 0.00032903
interaction O 0 0.0004866595
between O 0 0.00029707997
the O 0 0.00079183513
epileptic B-Disease 2 0.9990957
brain O 0 0.23042892
substratum O 0 0.13204508
and O 0 0.0019100169
the O 0 0.0030105705
antiepileptic O 0 0.9975248
drugs O 0 0.9273545
. O 0 0.008189064

The O 0 0.003046201
case O 0 0.002434155
of O 0 0.002255452
a O 0 0.0023334848
nonepileptic O 0 0.9884885
patient O 0 0.0029037043
who O 0 0.003130016
developed O 0 0.003669227
psychosis B-Disease 0 0.99856645
following O 0 0.0039119017
phenytoin B-Chemical 1 0.99975675
treatment O 0 0.015773986
for O 0 0.0025364065
trigeminal B-Disease 0 0.96539205
neuralgia I-Disease 0 0.9991874
is O 0 0.0057572187
described O 0 0.005231521
. O 0 0.006724129

This O 0 0.0044251713
case O 0 0.002195181
suggests O 0 0.0011986181
that O 0 0.001128222
the O 0 0.0017232789
psychotic B-Disease 0 0.99964654
symptoms I-Disease 0 0.94107985
that O 0 0.0007864443
occur O 0 0.0008376585
following O 0 0.0009577217
phenytoin B-Chemical 1 0.99986494
treatment O 0 0.00648055
in O 0 0.00047556637
some O 0 0.000854613
epileptic B-Disease 2 0.9993899
patients O 0 0.0046980176
may O 0 0.00045612673
be O 0 0.0003644842
the O 0 0.00029046286
direct O 0 0.00037763323
result O 0 0.0004553131
of O 0 0.0010825467
medication O 0 0.19678037
, O 0 0.002224191
unrelated O 0 0.0062456145
to O 0 0.004968019
seizures B-Disease 2 0.9987464
. O 0 0.008604054

Risks O 0 0.092117175
of O 0 0.008290822
the O 0 0.006882864
consumption O 0 0.047224797
of O 0 0.011949236
beverages O 0 0.9472479
containing O 0 0.02118095
quinine B-Chemical 1 0.9918828
. O 0 0.023145543

Although O 0 0.0040041935
the O 0 0.0028913154
United O 0 0.0039445786
States O 0 0.0051898677
Food O 0 0.33476546
and O 0 0.0017114856
Drug O 0 0.9300443
Administration O 0 0.48705593
banned O 0 0.011708393
its O 0 0.0013371075
use O 0 0.00072850357
for O 0 0.00050268206
nocturnal B-Disease 0 0.59137976
leg I-Disease 0 0.39842862
cramps I-Disease 0 0.9996581
due O 0 0.00037903225
to O 0 0.00028003257
lack O 0 0.00025231493
of O 0 0.0003723153
safety O 0 0.0015443418
and O 0 0.00040827077
efficacy O 0 0.004824096
, O 0 0.00092568644
quinine B-Chemical 1 0.99874073
is O 0 0.00060902396
widely O 0 0.0009903059
available O 0 0.0005345471
in O 0 0.0006433047
beverages O 0 0.8539322
including O 0 0.0017098987
tonic O 0 0.76173043
water O 0 0.051228028
and O 0 0.004784822
bitter O 0 0.91331863
lemon O 0 0.9762265
. O 0 0.0098969145

Numerous O 0 0.0071884096
anecdotal O 0 0.0103579005
reports O 0 0.002845045
suggest O 0 0.0011793289
that O 0 0.0010051458
products O 0 0.0022692853
containing O 0 0.0012780261
quinine B-Chemical 1 0.9981218
may O 0 0.0011078023
produce O 0 0.0009705866
neurological B-Disease 0 0.99713564
complications I-Disease 0 0.9806522
, O 0 0.0014483987
including O 0 0.00078186364
confusion B-Disease 0 0.74800056
, O 0 0.0008459919
altered O 0 0.001067079
mental O 0 0.11003361
status O 0 0.0014086838
, O 0 0.0017834182
seizures B-Disease 2 0.9997327
, O 0 0.001746082
and O 0 0.0015601947
coma B-Disease 0 0.9988073
, O 0 0.0020678216
particularly O 0 0.0025712592
in O 0 0.0018782011
older O 0 0.010404002
women O 0 0.04315241
. O 0 0.005822443

Psychologists O 0 0.013299943
need O 0 0.0024982411
to O 0 0.0018661666
inquire O 0 0.0034314836
about O 0 0.0013078257
consumption O 0 0.020719245
of O 0 0.0024806005
quinine B-Chemical 1 0.99854314
- O 0 0.004261762
containing O 0 0.0014415879
beverages O 0 0.8347792
as O 0 0.0011151854
part O 0 0.0010594705
of O 0 0.0018713386
an O 0 0.0029070927
evaluation O 0 0.004540948
process O 0 0.0065351464
. O 0 0.006981565

Transient O 0 0.7212998
platypnea B-Disease 0 0.8790099
- I-Disease 0 0.011326391
orthodeoxia I-Disease 0 0.9690234
- I-Disease 0 0.004001716
like I-Disease 0 0.0017005428
syndrome I-Disease 0 0.7303129
induced O 0 0.0022515303
by O 0 0.0024097117
propafenone B-Chemical 0 0.99990594
overdose B-Disease 2 0.9996394
in O 0 0.0012762453
a O 0 0.0012553313
young O 0 0.009030089
woman O 0 0.021653473
with O 0 0.0024339894
Ebstein B-Disease 0 0.6931679
' I-Disease 0 0.0034843446
s I-Disease 0 0.0050689555
anomaly I-Disease 0 0.08644759
. O 0 0.0073401397

In O 0 0.002632455
this O 0 0.001702566
report O 0 0.0024113457
we O 0 0.00064164656
describe O 0 0.0008581905
the O 0 0.0006533184
case O 0 0.00064719125
of O 0 0.0007157506
a O 0 0.0006945311
37 O 0 0.000982305
- O 0 0.00078471494
year O 0 0.0005045184
- O 0 0.0006314748
old O 0 0.00040695217
white O 0 0.0009256927
woman O 0 0.0057969666
with O 0 0.00061773206
Ebstein B-Disease 0 0.65411156
' I-Disease 0 0.0004789775
s I-Disease 0 0.00050999614
anomaly I-Disease 0 0.025227984
, O 0 0.00045046394
who O 0 0.00072951266
developed O 0 0.000580698
a O 0 0.00042148688
rare O 0 0.012497511
syndrome O 0 0.86693716
called O 0 0.0017847922
platypnea B-Disease 0 0.9240285
- I-Disease 0 0.0034584994
orthodeoxia I-Disease 0 0.9760415
, O 0 0.00063876
characterized O 0 0.0007253146
by O 0 0.00041647107
massive O 0 0.027530795
right O 0 0.0030796153
- O 0 0.0008483668
to O 0 0.00039272066
- O 0 0.0007463653
left O 0 0.0011556977
interatrial O 0 0.05723744
shunting O 0 0.38677558
with O 0 0.0014121379
transient O 0 0.10943774
profound O 0 0.24581045
hypoxia B-Disease 2 0.9922017
and O 0 0.0122200865
cyanosis B-Disease 0 0.994507
. O 0 0.008436304

This O 0 0.0058658333
shunt O 0 0.014602928
of O 0 0.0028009282
blood O 0 0.0061018313
via O 0 0.0014828586
a O 0 0.0015608699
patent B-Disease 0 0.06151526
foramen I-Disease 0 0.3813132
ovale I-Disease 0 0.9468088
occurred O 0 0.0010589393
in O 0 0.00044816243
the O 0 0.0003768022
presence O 0 0.0003891291
of O 0 0.00053514715
a O 0 0.0005671246
normal O 0 0.001545682
pulmonary O 0 0.84437823
artery O 0 0.58268714
pressure O 0 0.10530884
, O 0 0.0007780259
and O 0 0.0005419951
was O 0 0.0005552779
probably O 0 0.0010929238
precipitated O 0 0.0031032395
by O 0 0.0020006741
a O 0 0.006860742
propafenone B-Chemical 0 0.9996766
overdose B-Disease 2 0.99876827
. O 0 0.012168187

This O 0 0.0060906303
drug O 0 0.17964093
caused O 0 0.0041696844
biventricular B-Disease 0 0.95560104
dysfunction I-Disease 0 0.99465066
, O 0 0.0021625122
due O 0 0.0005776648
to O 0 0.00054580724
its O 0 0.00097283995
negative O 0 0.00072071364
inotropic O 0 0.98783946
effect O 0 0.0014379991
, O 0 0.001216118
and O 0 0.0013670556
hypotension B-Disease 2 0.9995314
, O 0 0.0014767585
due O 0 0.0005942493
to O 0 0.0009076694
its O 0 0.0027918625
peripheral O 0 0.15237926
vasodilatory O 0 0.98950654
effect O 0 0.009344645
. O 0 0.007071251

These O 0 0.004360953
effects O 0 0.0037887353
gave O 0 0.002593287
rise O 0 0.0021132655
to O 0 0.0010157437
an O 0 0.0010605966
increase O 0 0.00067247264
in O 0 0.00049934484
the O 0 0.00049299037
right O 0 0.0015274456
atrial O 0 0.9237843
pressure O 0 0.05665974
and O 0 0.00043804952
a O 0 0.00036021296
decrease O 0 0.00036495377
in O 0 0.0002199582
the O 0 0.0002255161
left O 0 0.00052972184
one O 0 0.0001804167
with O 0 0.00030392347
a O 0 0.00033146975
consequent O 0 0.0012815843
stretching O 0 0.013058131
of O 0 0.0005888372
the O 0 0.00055455917
foramen O 0 0.320437
ovale O 0 0.8589472
and O 0 0.00049820787
the O 0 0.00039348254
creation O 0 0.0008497487
of O 0 0.00088467624
massive O 0 0.041935485
right O 0 0.004875286
- O 0 0.0022535985
to O 0 0.0015241614
- O 0 0.0036087756
left O 0 0.007544569
shunting O 0 0.6076018
. O 0 0.006848618

In O 0 0.0031169269
our O 0 0.0020406884
case O 0 0.0019791562
this O 0 0.0017265263
interatrial O 0 0.032261748
shunt O 0 0.02743545
was O 0 0.0013921201
very O 0 0.0014344156
accurately O 0 0.0012691075
detected O 0 0.0009981386
at O 0 0.0014293595
bubble O 0 0.016241629
contrast O 0 0.0055098883
echocardiography O 0 0.51469266
. O 0 0.009437145

Noxious O 0 0.96781164
chemical O 0 0.042396575
stimulation O 0 0.0047708983
of O 0 0.0024267246
rat O 0 0.016933288
facial O 0 0.30283776
mucosa O 0 0.482676
increases O 0 0.0016242717
intracranial O 0 0.9158266
blood O 0 0.018210197
flow O 0 0.0051224264
through O 0 0.0004993227
a O 0 0.0007112087
trigemino O 0 0.063287556
- O 0 0.002124579
parasympathetic O 0 0.98898405
reflex O 0 0.92803603
- O 0 0.0017649509
- O 0 0.0007519649
an O 0 0.00046555733
experimental O 0 0.00067496
model O 0 0.00084419094
for O 0 0.00091418327
vascular B-Disease 0 0.9588189
dysfunctions I-Disease 0 0.9923166
in O 0 0.003336869
cluster B-Disease 0 0.01905967
headache I-Disease 2 0.9973908
. O 0 0.008978646

Cluster B-Disease 0 0.8123603
headache I-Disease 2 0.99723816
is O 0 0.004116381
characterized O 0 0.0034793846
by O 0 0.0019286217
typical O 0 0.0029060715
autonomic O 0 0.8747823
dysfunctions O 0 0.8984995
including O 0 0.0030857408
facial O 0 0.36464596
and O 0 0.004847553
intracranial B-Disease 0 0.9904293
vascular I-Disease 0 0.9656532
disturbances I-Disease 0 0.97272
. O 0 0.0104455305

Both O 0 0.0063719065
the O 0 0.0038240894
trigeminal O 0 0.188566
and O 0 0.0026434397
the O 0 0.0021511826
cranial O 0 0.16786085
parasympathetic O 0 0.9684512
systems O 0 0.003377349
may O 0 0.0016037838
be O 0 0.0014723865
involved O 0 0.0014834503
in O 0 0.0017668573
mediating O 0 0.0029812327
these O 0 0.0070962873
dysfunctions O 0 0.9415496
. O 0 0.010529782

An O 0 0.0050128284
experimental O 0 0.0029752052
model O 0 0.0022725381
was O 0 0.0013420256
developed O 0 0.0016555665
in O 0 0.0007695958
the O 0 0.0007021674
rat O 0 0.0026824956
to O 0 0.0005252638
measure O 0 0.00033675175
changes O 0 0.00084574363
in O 0 0.00069059245
lacrimation O 0 0.9975816
and O 0 0.0011410508
intracranial O 0 0.91339284
blood O 0 0.015579807
flow O 0 0.0052455957
following O 0 0.0011253919
noxious O 0 0.735226
chemical O 0 0.049291242
stimulation O 0 0.0047163633
of O 0 0.0039943587
facial O 0 0.60770416
mucosa O 0 0.785247
. O 0 0.008105398

Blood O 0 0.03773791
flow O 0 0.008593298
was O 0 0.0022446571
monitored O 0 0.0011855643
in O 0 0.0013112606
arteries O 0 0.125201
of O 0 0.001389231
the O 0 0.0010750173
exposed O 0 0.0017262716
cranial O 0 0.25383246
dura O 0 0.49520457
mater O 0 0.33390212
and O 0 0.0013536117
the O 0 0.0015086698
parietal O 0 0.5454275
cortex O 0 0.131108
using O 0 0.0022083079
laser O 0 0.0333165
Doppler O 0 0.718901
flowmetry O 0 0.8009616
. O 0 0.010598283

Capsaicin B-Chemical 1 0.99764204
( O 0 0.0077613737
0 O 0 0.0029386266
. O 0 0.0013881477
01 O 0 0.0056709
- O 0 0.0016867835
1 O 0 0.0008395199
mm O 0 0.002164455
) O 0 0.0007705891
applied O 0 0.00043496044
to O 0 0.00044496174
oral O 0 0.0727112
or O 0 0.00056731026
nasal O 0 0.020667512
mucosa O 0 0.411595
induced O 0 0.0010296076
increases B-Disease 0 0.00079004664
in I-Disease 0 0.00069983787
dural I-Disease 0 0.6913182
and I-Disease 0 0.0010962449
cortical I-Disease 0 0.064851016
blood I-Disease 0 0.012807738
flow I-Disease 0 0.010331326
and O 0 0.0034683393
provoked O 0 0.35769042
lacrimation O 0 0.99630296
. O 0 0.009182933

These O 0 0.0052109594
responses O 0 0.0046777227
were O 0 0.0022118231
blocked O 0 0.0031473553
by O 0 0.001848646
systemic O 0 0.6823107
pre O 0 0.020350778
- O 0 0.0032758226
administration O 0 0.14899908
of O 0 0.005902669
hexamethonium B-Chemical 1 0.9999093
chloride I-Chemical 0 0.99952054
( O 0 0.006639778
20 O 0 0.0028425772
mg O 0 0.47865233
/ O 0 0.0071522463
kg O 0 0.021403527
) O 0 0.0075509707
. O 0 0.0060834526

The O 0 0.0036026188
evoked O 0 0.025255192
increases B-Disease 0 0.0023931626
in I-Disease 0 0.0016385145
dural I-Disease 0 0.48974267
blood I-Disease 0 0.009296732
flow I-Disease 0 0.0048552514
were O 0 0.0006880363
also O 0 0.00061278517
abolished O 0 0.0010921005
by O 0 0.00061485945
topical O 0 0.9032993
pre O 0 0.020668741
- O 0 0.0016197637
administration O 0 0.09140013
of O 0 0.0013891702
atropine B-Chemical 0 0.9997831
( O 0 0.0018091351
1 O 0 0.0005018826
mm O 0 0.0028062942
) O 0 0.00052515714
and O 0 0.0003901962
[ O 0 0.0012225045
Lys1 O 0 0.08082724
, O 0 0.00068763224
Pro2 O 0 0.15673095
, O 0 0.00048705188
5 O 0 0.0003037702
, O 0 0.0005287102
Arg3 O 0 0.45380366
, O 0 0.00048156313
4 O 0 0.00030732292
, O 0 0.0005704995
Tyr6 O 0 0.69603384
] O 0 0.0024097883
- O 0 0.0012863494
VIP O 0 0.9723299
( O 0 0.00068568083
0 O 0 0.00037548295
. O 0 0.00017701129
1 O 0 0.00029593398
mm O 0 0.0012814257
) O 0 0.0004835846
, O 0 0.00037992568
a O 0 0.0004664595
vasoactive O 0 0.90949
intestinal O 0 0.62459135
polypeptide O 0 0.51208746
( O 0 0.0043287473
VIP O 0 0.9930743
) O 0 0.0044790003
antagonist O 0 0.9376502
, O 0 0.0018443132
onto O 0 0.001264216
the O 0 0.0017775858
exposed O 0 0.004488702
dura O 0 0.6541538
mater O 0 0.7032968
. O 0 0.0076108743

We O 0 0.0033885331
conclude O 0 0.0025112366
that O 0 0.0018917999
noxious O 0 0.51352155
stimulation O 0 0.003499833
of O 0 0.0019092743
facial O 0 0.32561973
mucosa O 0 0.5327188
increases O 0 0.0018938204
intracranial O 0 0.9380477
blood O 0 0.026403788
flow O 0 0.011362957
and O 0 0.0017978129
lacrimation O 0 0.9967173
via O 0 0.0016458546
a O 0 0.0025077262
trigemino O 0 0.13398553
- O 0 0.01023243
parasympathetic O 0 0.98239905
reflex O 0 0.9049344
. O 0 0.008462607

The O 0 0.0037220127
blood O 0 0.007803703
flow O 0 0.0072429874
responses O 0 0.0035909247
seem O 0 0.0017896328
to O 0 0.0010623216
be O 0 0.0010201369
mediated O 0 0.00087688153
by O 0 0.0009664675
the O 0 0.0010417048
release O 0 0.032249313
of O 0 0.0033089027
acetylcholine B-Chemical 1 0.998317
and O 0 0.005452487
VIP O 0 0.9828037
within O 0 0.0022132127
the O 0 0.0048552784
meninges O 0 0.5929034
. O 0 0.007860123

Similar O 0 0.0047594444
mechanisms O 0 0.005103947
may O 0 0.003012442
be O 0 0.00251443
involved O 0 0.00208306
in O 0 0.0019483968
the O 0 0.002439009
pathogenesis O 0 0.014390245
of O 0 0.0065525114
cluster B-Disease 0 0.02147577
headache I-Disease 2 0.99606293
. O 0 0.014366589

Organophosphate B-Chemical 0 0.9962877
- O 0 0.021237472
induced O 0 0.014590982
convulsions B-Disease 0 0.9979633
and O 0 0.009781645
prevention O 0 0.035020858
of O 0 0.016429773
neuropathological B-Disease 0 0.98999876
damages I-Disease 0 0.9790012
. O 0 0.018933043

Such O 0 0.02836
organophosphorus B-Chemical 0 0.99836594
( O 0 0.022846658
OP B-Chemical 0 0.9949786
) O 0 0.009241648
compounds O 0 0.68517506
as O 0 0.0026620617
diisopropylfluorophosphate B-Chemical 0 0.99946696
( O 0 0.034063585
DFP B-Chemical 0 0.99942267
) O 0 0.010325325
, O 0 0.0027686092
sarin B-Chemical 0 0.9993506
and O 0 0.003012939
soman B-Chemical 0 0.99928445
are O 0 0.0010665911
potent O 0 0.037739657
inhibitors O 0 0.08810291
of O 0 0.001952717
acetylcholinesterases O 0 0.92051876
( O 0 0.0033978762
AChEs O 0 0.78490704
) O 0 0.002247981
and O 0 0.0018937031
butyrylcholinesterases O 0 0.80964226
( O 0 0.005975173
BChEs O 0 0.5024057
) O 0 0.009270798
. O 0 0.006372927

The O 0 0.0048263245
acute O 0 0.87804765
toxicity B-Disease 2 0.9910493
of O 0 0.0048038056
OPs B-Chemical 0 0.96651757
is O 0 0.0011867913
the O 0 0.00063210493
result O 0 0.00047812198
of O 0 0.00066915556
their O 0 0.0007102384
irreversible O 0 0.20723909
binding O 0 0.0008572584
with O 0 0.00089466624
AChEs O 0 0.6316135
in O 0 0.00039242543
the O 0 0.0004199488
central O 0 0.0021473507
nervous O 0 0.7694848
system O 0 0.0018293434
( O 0 0.0014740103
CNS O 0 0.7084102
) O 0 0.0016318255
, O 0 0.0010088793
which O 0 0.0014858765
elevates O 0 0.37813428
acetylcholine B-Chemical 1 0.99892753
( O 0 0.028906263
ACh B-Chemical 1 0.9981019
) O 0 0.008951651
levels O 0 0.0054718377
. O 0 0.0064206426

The O 0 0.003371531
protective O 0 0.008448566
action O 0 0.0078095025
of O 0 0.002550444
subcutaneously O 0 0.015353391
( O 0 0.00230219
SC O 0 0.14219259
) O 0 0.0015905298
administered O 0 0.0025256288
antidotes O 0 0.7519109
or O 0 0.00045085783
their O 0 0.00045514642
combinations O 0 0.0005472816
in O 0 0.0006485184
DFP B-Chemical 0 0.9993735
( O 0 0.0010733963
2 O 0 0.0003701815
. O 0 0.00017576534
0 O 0 0.0003206337
mg O 0 0.09953821
/ O 0 0.000803518
kg O 0 0.00511684
BW O 0 0.29120052
) O 0 0.0010644849
intoxication O 0 0.99648714
was O 0 0.0004575202
studied O 0 0.00056498183
in O 0 0.00034832422
9 O 0 0.00044657174
- O 0 0.0006242567
10 O 0 0.00043947995
- O 0 0.0006393148
weeks O 0 0.0005236137
- O 0 0.0010771162
old O 0 0.001366995
Han O 0 0.57540894
- O 0 0.0040517896
Wistar O 0 0.26453373
male O 0 0.008399901
rats O 0 0.012142011
. O 0 0.0061124396

The O 0 0.003696054
rats O 0 0.007058894
received O 0 0.004392999
AChE O 0 0.9506981
reactivator O 0 0.9805808
pralidoxime B-Chemical 0 0.99928325
- I-Chemical 0 0.00942969
2 I-Chemical 0 0.001455534
- I-Chemical 0 0.0026750965
chloride I-Chemical 0 0.9981828
( O 0 0.003100886
2PAM B-Chemical 1 0.9841601
) O 0 0.0017451888
( O 0 0.0006137948
30 O 0 0.00029093758
. O 0 0.00017814929
0 O 0 0.00033000106
mg O 0 0.08434321
/ O 0 0.0008522284
kg O 0 0.0053433166
BW O 0 0.29502538
) O 0 0.0009302469
, O 0 0.000800822
anticonvulsant O 0 0.9996222
diazepam B-Chemical 1 0.99993706
( O 0 0.0016440378
2 O 0 0.00036807745
. O 0 0.00016441921
0 O 0 0.0003028247
mg O 0 0.097712144
/ O 0 0.0007766685
kg O 0 0.005029404
BW O 0 0.25895593
) O 0 0.0007623
, O 0 0.0005345059
A O 0 0.008303644
( O 0 0.00060229213
1 O 0 0.00041370397
) O 0 0.0007575683
- O 0 0.0009992232
adenosine B-Chemical 1 0.9956514
receptor O 0 0.58455604
agonist O 0 0.9950323
N B-Chemical 0 0.9805525
( I-Chemical 0 0.0014361166
6 I-Chemical 0 0.00036176588
) I-Chemical 0 0.0009409617
- I-Chemical 0 0.0013684755
cyclopentyl I-Chemical 0 0.99711156
adenosine I-Chemical 1 0.998828
( O 0 0.0075144563
CPA B-Chemical 1 0.9989274
) O 0 0.0027439152
( O 0 0.0005945853
2 O 0 0.00028624048
. O 0 0.000151201
0 O 0 0.00029340276
mg O 0 0.09352216
/ O 0 0.00081980514
kg O 0 0.0061519425
BW O 0 0.34749284
) O 0 0.0011801926
, O 0 0.0012971843
NMDA B-Chemical 1 0.9998616
- O 0 0.010319686
receptor O 0 0.565384
antagonist O 0 0.99835855
dizocilpine B-Chemical 0 0.9999771
maleate I-Chemical 0 0.99998176
( O 0 0.04160359
+ O 0 0.004605065
- O 0 0.013697907
MK801 O 1 0.9999641
hydrogen O 0 0.9996934
maleate O 0 0.99997354
) O 0 0.020144321
( O 0 0.0008904914
2 O 0 0.00031843214
. O 0 0.00015290198
0 O 0 0.00028140022
mg O 0 0.09121004
/ O 0 0.00069192454
kg O 0 0.0039020926
BW O 0 0.17872125
) O 0 0.00044200418
or O 0 0.00017170048
their O 0 0.00022334266
combinations O 0 0.00030725411
with O 0 0.00069653796
cholinolytic O 0 0.99948716
drug O 0 0.9428232
atropine B-Chemical 0 0.9999485
sulfate I-Chemical 0 0.99958366
( O 0 0.0025550432
50 O 0 0.000746254
. O 0 0.00017616332
0 O 0 0.00031906943
mg O 0 0.11330459
/ O 0 0.00076975755
kg O 0 0.0039434736
BW O 0 0.13946643
) O 0 0.000472507
immediately O 0 0.00024296097
or O 0 0.00022046527
30 O 0 0.00026455574
min O 0 0.000426655
after O 0 0.00024269844
the O 0 0.0005006221
single O 0 0.0011053575
SC O 0 0.08724458
injection O 0 0.010336456
of O 0 0.00830569
DFP B-Chemical 0 0.9966401
. O 0 0.0092878025

The O 0 0.003075484
control O 0 0.0022443058
rats O 0 0.0055302638
received O 0 0.0040458287
atropine B-Chemical 0 0.9996195
sulfate I-Chemical 0 0.9986181
, O 0 0.0035776868
but O 0 0.0010078998
also O 0 0.0009223006
saline O 0 0.087551616
and O 0 0.00124081
olive O 0 0.79582757
oil O 0 0.89986444
instead O 0 0.0012529505
of O 0 0.0013679881
other O 0 0.0018251193
antidotes O 0 0.95369864
and O 0 0.0074816537
DFP B-Chemical 0 0.99819845
, O 0 0.008797627
respectively O 0 0.013116604
. O 0 0.006758922

All O 0 0.004424047
rats O 0 0.0059173424
were O 0 0.0020770312
terminated O 0 0.0025220143
either O 0 0.0013992331
24 O 0 0.0012049566
h O 0 0.0011122337
or O 0 0.0009322913
3 O 0 0.0009933269
weeks O 0 0.0011957216
after O 0 0.001260816
the O 0 0.0035573028
DFP B-Chemical 0 0.9946688
injection O 0 0.058682904
. O 0 0.008871942

The O 0 0.004175299
rats O 0 0.008225534
treated O 0 0.005075636
with O 0 0.005183545
DFP B-Chemical 0 0.9984421
- O 0 0.024015766
atropine B-Chemical 0 0.99914527
showed O 0 0.003485565
severe O 0 0.4200383
typical O 0 0.013921761
OP B-Chemical 0 0.9969422
- O 0 0.016972812
induced O 0 0.014649896
toxicity B-Disease 2 0.9939646
signs O 0 0.80246633
. O 0 0.0103950575

When O 0 0.006005565
CPA B-Chemical 1 0.98856133
, O 0 0.008690828
diazepam B-Chemical 1 0.99947125
or O 0 0.0027435278
2PAM B-Chemical 1 0.9690626
was O 0 0.0010797463
given O 0 0.000518019
immediately O 0 0.00062061864
after O 0 0.00054387277
DFP B-Chemical 0 0.9992029
- O 0 0.0072008544
atropine B-Chemical 0 0.9996344
, O 0 0.0011110154
these O 0 0.0006972908
treatments O 0 0.0033308356
prevented O 0 0.0033406264
, O 0 0.0007796335
delayed O 0 0.0025089013
or O 0 0.00040405313
shortened O 0 0.0010365957
the O 0 0.0005702988
occurrence O 0 0.0019110182
of O 0 0.0019213705
serious O 0 0.3507199
signs O 0 0.5238636
of O 0 0.018433249
poisoning B-Disease 2 0.99733317
. O 0 0.010486701

Atropine B-Chemical 0 0.99873644
- O 0 0.07868223
MK801 B-Chemical 1 0.9993024
did O 0 0.0042498056
not O 0 0.0022573876
offer O 0 0.0031377622
any O 0 0.0018800622
additional O 0 0.0019829131
protection O 0 0.012616505
against O 0 0.010384805
DFP B-Chemical 0 0.9980039
toxicity B-Disease 2 0.9943456
. O 0 0.01652838

In O 0 0.0036343993
conclusion O 0 0.0030702997
, O 0 0.004297798
CPA B-Chemical 1 0.99393904
, O 0 0.006680208
diazepam B-Chemical 1 0.9997292
and O 0 0.0030996865
2PAM B-Chemical 1 0.9809483
in O 0 0.0007697051
combination O 0 0.0022023795
with O 0 0.001386796
atropine B-Chemical 0 0.9996377
prevented O 0 0.008038885
the O 0 0.00052343187
occurrence O 0 0.0015767952
of O 0 0.00082431117
serious O 0 0.213046
signs O 0 0.29860252
of O 0 0.0024606346
poisoning B-Disease 2 0.99917287
and O 0 0.0010384619
thus O 0 0.0010409501
reduced O 0 0.0009126332
the O 0 0.0012816467
toxicity B-Disease 2 0.99276453
of O 0 0.01240454
DFP B-Chemical 0 0.9985538
in O 0 0.0054351394
rat O 0 0.090721086
. O 0 0.0070730587

A O 0 0.1664337
pyridoxine B-Chemical 1 0.9982047
- O 0 0.016047841
dependent O 0 0.006733697
behavioral B-Disease 0 0.5965256
disorder I-Disease 0 0.98679465
unmasked O 0 0.8440727
by O 0 0.022043055
isoniazid B-Chemical 1 0.99740005
. O 0 0.01885816

A O 0 0.019089075
3 O 0 0.0031340877
- O 0 0.0029188371
year O 0 0.0016373525
- O 0 0.0017340856
old O 0 0.0010759834
girl O 0 0.002475113
had O 0 0.0008716717
behavioral B-Disease 0 0.25809038
deterioration I-Disease 0 0.8253654
, O 0 0.0013268484
with O 0 0.0014566962
hyperkinesis B-Disease 0 0.9987206
, O 0 0.0039329147
irritability B-Disease 2 0.9992975
, O 0 0.001153325
and O 0 0.00071173545
sleeping B-Disease 0 0.46296036
difficulties I-Disease 0 0.025499832
after O 0 0.00043238798
the O 0 0.00076647865
therapeutic O 0 0.018993841
administration O 0 0.25146723
of O 0 0.011281786
isoniazid B-Chemical 1 0.99873775
. O 0 0.009398187

The O 0 0.0037537192
administration O 0 0.02271257
of O 0 0.003135065
pharmacologic O 0 0.33205196
doses O 0 0.18897595
of O 0 0.0099459095
pyridoxine B-Chemical 1 0.99986887
hydrochloride I-Chemical 0 0.9990677
led O 0 0.005473151
to O 0 0.0020578916
a O 0 0.0027062676
disappearance O 0 0.011553716
of O 0 0.006910779
symptoms O 0 0.6846255
. O 0 0.009299815

After O 0 0.0030984299
discontinuing O 0 0.44859123
isoniazid B-Chemical 1 0.9987424
therapy O 0 0.058315504
a O 0 0.0014835381
similar O 0 0.00070507184
pattern O 0 0.00075391267
of O 0 0.0010152637
behavior O 0 0.002267185
was O 0 0.00089065393
noted O 0 0.0009025425
that O 0 0.0008769705
was O 0 0.0014434562
controlled O 0 0.0025663548
by O 0 0.006172001
pyridoxine B-Chemical 1 0.998708
. O 0 0.01199176

A O 0 0.023008328
placebo O 0 0.078320056
had O 0 0.0027934145
no O 0 0.0017859598
effect O 0 0.002362544
, O 0 0.0027646099
but O 0 0.002659893
niacinamide B-Chemical 0 0.9986779
was O 0 0.0031037943
as O 0 0.0023392085
effective O 0 0.0056711826
as O 0 0.0071662962
pyridoxine B-Chemical 1 0.9986455
. O 0 0.014832066

Periodic O 0 0.027896874
withdrawal O 0 0.49259368
of O 0 0.0076663857
pyridoxine B-Chemical 1 0.99913174
was O 0 0.0044397805
associated O 0 0.0038001845
with O 0 0.0034105757
return O 0 0.005032631
of O 0 0.0052983603
the O 0 0.008383921
hyperkinesis B-Disease 0 0.99145496
. O 0 0.012991856

The O 0 0.0035010704
level O 0 0.0024528715
of O 0 0.0037134434
pyridoxal B-Chemical 0 0.9968464
in O 0 0.0023468982
the O 0 0.001626594
blood O 0 0.0054444983
was O 0 0.001314985
normal O 0 0.0019368043
during O 0 0.0010413949
the O 0 0.0015584745
periods O 0 0.0033236407
of O 0 0.006132303
relapse O 0 0.94541556
. O 0 0.010049915

Metabolic O 0 0.37380883
studies O 0 0.0057125497
suggested O 0 0.0033984624
a O 0 0.0030097866
block O 0 0.0036840022
in O 0 0.002408521
the O 0 0.0034396432
kynurenine B-Chemical 0 0.99390936
pathway O 0 0.009592197
of O 0 0.010392654
tryptophan B-Chemical 0 0.9878542
metabolism O 0 0.895485
. O 0 0.013380153

The O 0 0.0027773145
patient O 0 0.003010405
has O 0 0.0016152621
been O 0 0.0012816687
followed O 0 0.00066187023
for O 0 0.00055120344
six O 0 0.00043242818
years O 0 0.0009769492
and O 0 0.0005676515
has O 0 0.0005111107
required O 0 0.00038247177
pharmacologic O 0 0.18318744
doses O 0 0.0922901
of O 0 0.004072493
pyridoxine B-Chemical 1 0.99963903
to O 0 0.002401638
control O 0 0.0023867416
her O 0 0.0059014047
behavior O 0 0.01239919
. O 0 0.0065978616

Recurrent O 0 0.4249987
excitation O 0 0.30024788
in O 0 0.00356439
the O 0 0.0033715488
dentate O 0 0.5047506
gyrus O 0 0.660311
of O 0 0.002181485
a O 0 0.002129043
murine O 0 0.0058000893
model O 0 0.0032081343
of O 0 0.0048718075
temporal B-Disease 2 0.45956865
lobe I-Disease 2 0.96271086
epilepsy I-Disease 2 0.99794847
. O 0 0.014691639

Similar O 0 0.00352185
to O 0 0.002562836
rats O 0 0.0059196097
, O 0 0.0027764312
systemic O 0 0.8431867
pilocarpine B-Chemical 1 0.9997056
injection O 0 0.05281698
causes O 0 0.0052749244
status B-Disease 0 0.004439848
epilepticus I-Disease 0 0.99987006
( O 0 0.0039799144
SE B-Disease 0 0.42293656
) O 0 0.0008668482
and O 0 0.00033818925
the O 0 0.00028188192
eventual O 0 0.0031183537
development O 0 0.0010966456
of O 0 0.00065852574
spontaneous O 0 0.12208739
seizures B-Disease 2 0.99986494
and O 0 0.0017194507
mossy O 0 0.988947
fiber O 0 0.21318965
sprouting O 0 0.930004
in O 0 0.0006590711
C57BL O 0 0.8004552
/ O 0 0.0012550426
6 O 0 0.00022720253
and O 0 0.00028368965
CD1 O 0 0.019629363
mice O 0 0.00020494571
, O 0 0.00034673157
but O 0 0.0002204993
the O 0 0.00021120018
physiological O 0 0.0009500885
correlates O 0 0.0003796467
of O 0 0.0004611632
these O 0 0.0006769893
events O 0 0.003301545
have O 0 0.0007214957
not O 0 0.00078897603
been O 0 0.0012445938
identified O 0 0.0012931942
in O 0 0.0019364873
mice O 0 0.0026257718
. O 0 0.0049549285

Population O 0 0.015546421
responses O 0 0.005189329
in O 0 0.0021549205
granule O 0 0.23968151
cells O 0 0.0024810513
of O 0 0.0013831615
the O 0 0.001203168
dentate O 0 0.58988446
gyrus O 0 0.72749346
were O 0 0.00046599974
examined O 0 0.0003163467
in O 0 0.0003681614
transverse O 0 0.0033878377
slices O 0 0.014592593
of O 0 0.0006386087
the O 0 0.0006062932
ventral O 0 0.00725258
hippocampus O 0 0.30252382
from O 0 0.0011464745
pilocarpine B-Chemical 1 0.99965346
- O 0 0.0036056854
treated O 0 0.002395462
and O 0 0.0018871777
untreated O 0 0.0037377723
mice O 0 0.0029577382
. O 0 0.00533827

In O 0 0.0064145247
Mg B-Chemical 0 0.99613225
( O 0 0.0054447437
2 O 0 0.0021251228
+ O 0 0.0018852699
) O 0 0.0018240944
- O 0 0.0012577706
free O 0 0.0011124203
bathing O 0 0.029404331
medium O 0 0.0041065626
containing O 0 0.0010158579
bicuculline B-Chemical 1 0.9997905
, O 0 0.00091566
conditions O 0 0.0005238853
designed O 0 0.00036763598
to O 0 0.00027238822
increase O 0 0.000387852
excitability O 0 0.85021466
in O 0 0.00028646324
the O 0 0.00029378152
slices O 0 0.031903245
, O 0 0.00043086006
electrical O 0 0.15211762
stimulation O 0 0.00081910007
of O 0 0.00035465622
the O 0 0.0003123313
hilus O 0 0.18139693
resulted O 0 0.00026390905
in O 0 0.00020175109
a O 0 0.00023569178
single O 0 0.00023348977
population O 0 0.00043652664
spike O 0 0.0047338502
in O 0 0.00032168764
granule O 0 0.3154368
cells O 0 0.00072813634
from O 0 0.00024472512
control O 0 0.00022412918
mice O 0 0.0002122481
and O 0 0.0006131971
pilocarpine B-Chemical 1 0.99979013
- O 0 0.002064734
treated O 0 0.0010601111
mice O 0 0.00040998426
that O 0 0.0006215661
did O 0 0.0009859913
not O 0 0.0015559567
experience O 0 0.0071283504
SE B-Disease 0 0.44270238
. O 0 0.006376835

In O 0 0.0041158614
SE B-Disease 0 0.08605866
survivors O 0 0.00837178
, O 0 0.0018624141
similar O 0 0.0007784249
stimulation O 0 0.0014681476
resulted O 0 0.00062014593
in O 0 0.00044997616
a O 0 0.0004877037
population O 0 0.0006235425
spike O 0 0.0027704372
followed O 0 0.00029690613
, O 0 0.00038677902
at O 0 0.00016664928
a O 0 0.00026125807
variable O 0 0.00030125387
latency O 0 0.0023839094
, O 0 0.00040191645
by O 0 0.00027486976
negative O 0 0.0003510197
DC O 0 0.069795065
shifts O 0 0.0009167281
and O 0 0.00034797404
repetitive O 0 0.002579402
afterdischarges O 0 0.99648076
of O 0 0.00053938787
3 O 0 0.00032737077
- O 0 0.00041383415
60 O 0 0.0002615731
s O 0 0.00027438928
duration O 0 0.0003794229
, O 0 0.00045440294
which O 0 0.0005375182
were O 0 0.000583885
blocked O 0 0.0018082408
by O 0 0.0023190458
ionotropic O 0 0.9977664
glutamate B-Chemical 1 0.99913776
receptor O 0 0.9272517
antagonists O 0 0.9908828
. O 0 0.011189515

Focal O 0 0.71774143
glutamate B-Chemical 1 0.99600357
photostimulation O 0 0.2351475
of O 0 0.002773424
the O 0 0.0016697873
granule O 0 0.44623578
cell O 0 0.01041792
layer O 0 0.003781326
at O 0 0.00037632993
sites O 0 0.00044231015
distant O 0 0.0052262656
from O 0 0.00033409792
the O 0 0.0002874849
recording O 0 0.00079373934
pipette O 0 0.025708279
resulted O 0 0.0003234149
in O 0 0.00025538864
population O 0 0.00044841968
responses O 0 0.00062971836
of O 0 0.00041748423
1 O 0 0.00038109566
- O 0 0.00040466353
30 O 0 0.0001865917
s O 0 0.0002396889
duration O 0 0.0003176759
in O 0 0.00030570838
slices O 0 0.01036624
from O 0 0.00061987946
SE B-Disease 0 0.12958321
survivors O 0 0.0055588637
but O 0 0.0010762099
not O 0 0.0013179171
other O 0 0.0022858263
groups O 0 0.004700841
. O 0 0.005496466

These O 0 0.0042354995
data O 0 0.0026328182
support O 0 0.001840998
the O 0 0.00134477
hypothesis O 0 0.0016532037
that O 0 0.0011608851
SE B-Disease 0 0.34004772
- O 0 0.002291835
induced O 0 0.0015807443
mossy O 0 0.97012526
fiber O 0 0.16997728
sprouting O 0 0.907165
and O 0 0.0009217375
synaptic O 0 0.14298895
reorganization O 0 0.012379055
are O 0 0.00035391838
relevant O 0 0.0003285758
characteristics O 0 0.0003466468
of O 0 0.0005635287
seizure B-Disease 2 0.998928
development O 0 0.002254374
in O 0 0.00032998342
these O 0 0.00053865806
murine O 0 0.0054360903
strains O 0 0.0007524197
, O 0 0.0006749134
resembling O 0 0.0013525615
rat O 0 0.0048358147
models O 0 0.0012990783
of O 0 0.0015659939
human O 0 0.0055255378
temporal B-Disease 2 0.49823663
lobe I-Disease 2 0.9658274
epilepsy I-Disease 2 0.998572
. O 0 0.010313721

Urinary B-Disease 0 0.97962254
bladder I-Disease 2 0.98550814
cancer I-Disease 2 0.9961139
in O 0 0.0062416582
Wegener B-Disease 0 0.92854303
' I-Disease 0 0.0031621382
s I-Disease 0 0.0033742029
granulomatosis I-Disease 0 0.8599036
: O 0 0.0035198908
risks O 0 0.008301886
and O 0 0.002394217
relation O 0 0.0023481348
to O 0 0.005375887
cyclophosphamide B-Chemical 1 0.9964024
. O 0 0.012280931

OBJECTIVE O 0 0.44345924
: O 0 0.003901136
To O 0 0.0012257022
assess O 0 0.00063314073
and O 0 0.0008694419
characterise O 0 0.0008393647
the O 0 0.000719303
risk O 0 0.011724008
of O 0 0.001788243
bladder B-Disease 2 0.99460185
cancer I-Disease 2 0.99900407
, O 0 0.0020444812
and O 0 0.0006081411
its O 0 0.0008438022
relation O 0 0.00035214826
to O 0 0.00058193906
cyclophosphamide B-Chemical 1 0.9992343
, O 0 0.0012772694
in O 0 0.0006455658
patients O 0 0.0025384487
with O 0 0.0020432305
Wegener B-Disease 0 0.9244741
' I-Disease 0 0.0032100256
s I-Disease 0 0.005443404
granulomatosis I-Disease 0 0.9099398
. O 0 0.007186398

METHODS O 0 0.006266727
: O 0 0.0030367984
In O 0 0.0012445386
the O 0 0.0009973629
population O 0 0.0012571316
based O 0 0.0010057732
, O 0 0.0009819784
nationwide O 0 0.0013775455
Swedish O 0 0.0022973237
Inpatient O 0 0.03174094
Register O 0 0.0013863253
a O 0 0.000475466
cohort O 0 0.0009402087
of O 0 0.00065035303
1065 O 0 0.12174879
patients O 0 0.0017719503
with O 0 0.001002534
Wegener B-Disease 0 0.89964485
' I-Disease 0 0.0009337536
s I-Disease 0 0.0012662634
granulomatosis I-Disease 0 0.87184733
, O 0 0.001652387
1969 O 0 0.0068243523
- O 0 0.001912501
95 O 0 0.0026145817
, O 0 0.0018134216
was O 0 0.0020540885
identified O 0 0.0033493468
. O 0 0.005314932

Through O 0 0.006707893
linkage O 0 0.0055978983
with O 0 0.002740229
the O 0 0.0020388123
Swedish O 0 0.0063294317
Cancer B-Disease 0 0.8431023
Register O 0 0.0039426456
, O 0 0.001082574
all O 0 0.0005718509
subjects O 0 0.0009296355
in O 0 0.0005206158
this O 0 0.0006402368
cohort O 0 0.0021972114
diagnosed O 0 0.01976389
with O 0 0.0029972726
bladder B-Disease 2 0.9912806
cancer I-Disease 2 0.9967583
were O 0 0.0061326837
identified O 0 0.0056763603
. O 0 0.006920381

Nested O 0 0.021102214
within O 0 0.0016706461
the O 0 0.0015902013
cohort O 0 0.002759191
, O 0 0.0013016043
a O 0 0.00078449066
matched O 0 0.0005826134
case O 0 0.00065357727
- O 0 0.0007122243
control O 0 0.00028894123
study O 0 0.0004715821
was O 0 0.00025091562
performed O 0 0.00021279683
to O 0 0.00020398365
estimate O 0 0.00016838762
the O 0 0.00021336814
association O 0 0.00023529303
between O 0 0.00024480585
cyclophosphamide B-Chemical 1 0.9993728
and O 0 0.001591523
bladder B-Disease 2 0.99428046
cancer I-Disease 2 0.99879444
using O 0 0.0008855997
odds O 0 0.0117747625
ratios O 0 0.0011362673
( O 0 0.0013502943
ORs O 0 0.005873045
) O 0 0.0017274421
as O 0 0.0011805913
relative O 0 0.0020263966
risk O 0 0.0513247
. O 0 0.0066328538

In O 0 0.002772559
the O 0 0.0018653558
cohort O 0 0.002646339
the O 0 0.0011330772
cumulative O 0 0.002748726
risk O 0 0.023454705
of O 0 0.0021590504
bladder B-Disease 2 0.992957
cancer I-Disease 2 0.99869424
after O 0 0.0009812248
Wegener B-Disease 0 0.96378505
' I-Disease 0 0.00076862355
s I-Disease 0 0.00080459326
granulomatosis I-Disease 0 0.86837226
, O 0 0.0004979017
and O 0 0.00026004185
the O 0 0.00018462217
relative O 0 0.00015794644
prevalence O 0 0.00043015095
of O 0 0.0003161043
a O 0 0.00033244194
history O 0 0.005846636
of O 0 0.0008731696
bladder B-Disease 2 0.99209
cancer I-Disease 2 0.9987587
at O 0 0.00031642788
the O 0 0.0002668885
time O 0 0.00023186806
of O 0 0.00044839617
diagnosis O 0 0.006070406
of O 0 0.0011371565
Wegener B-Disease 0 0.94175875
' I-Disease 0 0.0010774337
s I-Disease 0 0.0015269534
granulomatosis I-Disease 0 0.85436964
, O 0 0.0017896328
were O 0 0.00147403
also O 0 0.0022630233
estimated O 0 0.0035998125
. O 0 0.0053349654

RESULTS O 0 0.02335945
: O 0 0.0036552972
The O 0 0.0012737062
median O 0 0.0010563511
cumulative O 0 0.0020950246
doses O 0 0.017428432
of O 0 0.0016940098
cyclophosphamide B-Chemical 1 0.99932706
among O 0 0.0018735916
cases O 0 0.0024976209
( O 0 0.0008868322
n O 0 0.00041597587
= O 0 0.0005921473
11 O 0 0.00037716984
) O 0 0.00045124395
and O 0 0.00029572556
controls O 0 0.00052663015
( O 0 0.00046921126
n O 0 0.0003095262
= O 0 0.0005097721
25 O 0 0.0005026835
) O 0 0.00052237447
were O 0 0.00037337557
113 O 0 0.0014791624
g O 0 0.0012326626
and O 0 0.0008260309
25 O 0 0.0016871545
g O 0 0.003184128
, O 0 0.0030383782
respectively O 0 0.0061765946
. O 0 0.005142208

The O 0 0.0033339965
risk O 0 0.010715063
of O 0 0.0034860042
bladder B-Disease 2 0.9769306
cancer I-Disease 2 0.99623185
doubled O 0 0.0023109172
for O 0 0.00063892367
every O 0 0.00030521853
10 O 0 0.00043564427
g O 0 0.0007961011
increment O 0 0.0005889746
in O 0 0.00045559113
cyclophosphamide B-Chemical 1 0.9994118
( O 0 0.0018236204
OR O 0 0.089959204
= O 0 0.000679667
2 O 0 0.00028257965
. O 0 0.00015538528
0 O 0 0.00024970967
, O 0 0.000257647
95 O 0 0.00046797044
% O 0 0.00023502286
confidence O 0 0.0005825268
interval O 0 0.00058035116
( O 0 0.00066310994
CI O 0 0.090208136
) O 0 0.00076936634
0 O 0 0.00052618334
. O 0 0.00032829397
8 O 0 0.00051004346
to O 0 0.00062823924
4 O 0 0.0009103804
. O 0 0.0010361578
9 O 0 0.0022630878
) O 0 0.0047080303
. O 0 0.004641916

Treatment O 0 0.016673794
duration O 0 0.0027247402
longer O 0 0.0011368463
than O 0 0.0007750069
1 O 0 0.00073241437
year O 0 0.00062728586
was O 0 0.00050544715
associated O 0 0.00063800556
with O 0 0.0006099781
an O 0 0.00071084173
eightfold O 0 0.00583672
increased O 0 0.0015746993
risk O 0 0.087036036
( O 0 0.0015230275
OR O 0 0.079573475
= O 0 0.00079770345
7 O 0 0.0003127172
. O 0 0.00021373283
7 O 0 0.00029130702
, O 0 0.00044823333
95 O 0 0.00094765826
% O 0 0.00065789535
CI O 0 0.021110514
0 O 0 0.00075976946
. O 0 0.0005693126
9 O 0 0.0010085342
to O 0 0.0013869868
69 O 0 0.0038208338
) O 0 0.0054852543
. O 0 0.0051796315

The O 0 0.0028709306
absolute O 0 0.0027134675
risk O 0 0.010938096
for O 0 0.0018230649
bladder B-Disease 2 0.97756606
cancer I-Disease 2 0.99720615
in O 0 0.0010548407
the O 0 0.00061003363
cohort O 0 0.0012875876
reached O 0 0.0006228951
10 O 0 0.00039522027
% O 0 0.00031141524
16 O 0 0.00023679368
years O 0 0.00032358145
after O 0 0.00013577171
diagnosis O 0 0.0013001659
of O 0 0.0005835398
Wegener B-Disease 0 0.9107826
' I-Disease 0 0.0005233804
s I-Disease 0 0.0006274676
granulomatosis I-Disease 0 0.8617083
, O 0 0.00045660566
and O 0 0.00026082297
a O 0 0.00027513716
history O 0 0.0039617396
of O 0 0.00080012134
bladder B-Disease 2 0.994114
cancer I-Disease 2 0.9993284
was O 0 0.0013723634
( O 0 0.0007726622
non O 0 0.0011352868
- O 0 0.0006265524
significantly O 0 0.00039112105
) O 0 0.00039529774
twice O 0 0.00022468934
as O 0 0.00016052561
common O 0 0.00034487044
as O 0 0.00018053612
expected O 0 0.00014263026
at O 0 0.00015892799
the O 0 0.00023602237
time O 0 0.00028931943
of O 0 0.00067411916
diagnosis O 0 0.0081265075
of O 0 0.0023102283
Wegener B-Disease 0 0.9514383
' I-Disease 0 0.0033211869
s I-Disease 0 0.0055687022
granulomatosis I-Disease 0 0.91957384
. O 0 0.007081342

CONCLUSION O 0 0.77950263
: O 0 0.004064154
The O 0 0.0012995369
results O 0 0.0009848526
indicate O 0 0.0007367812
a O 0 0.0010165964
dose O 0 0.017081665
- O 0 0.0011963784
response O 0 0.0006978366
relationship O 0 0.00031188052
between O 0 0.00026860955
cyclophosphamide B-Chemical 1 0.9990783
and O 0 0.0006350692
the O 0 0.0003960665
risk O 0 0.021206971
of O 0 0.0012492446
bladder B-Disease 2 0.99553126
cancer I-Disease 2 0.99929166
, O 0 0.001153691
high O 0 0.00049827364
cumulative O 0 0.0017842214
risks O 0 0.00926325
in O 0 0.00022777493
the O 0 0.00019445513
entire O 0 0.00018037834
cohort O 0 0.00089946133
, O 0 0.00032812537
and O 0 0.00023908795
also O 0 0.00024166811
the O 0 0.00019974721
possibility O 0 0.00022355506
of O 0 0.00044869716
risk O 0 0.014893233
factors O 0 0.002312053
operating O 0 0.0015594289
even O 0 0.00083173416
before O 0 0.00081055687
Wegener B-Disease 0 0.8562941
' I-Disease 0 0.0026808812
s I-Disease 0 0.004830464
granulomatosis I-Disease 0 0.9038257
. O 0 0.0067489264

Differential O 0 0.018618077
modulation O 0 0.0064743236
by O 0 0.003621565
estrogen B-Chemical 1 0.9959824
of O 0 0.0072364314
alpha2 O 0 0.9575404
- O 0 0.014210289
adrenergic O 0 0.9967006
and O 0 0.0038135245
I1 O 0 0.9504274
- O 0 0.0119234
imidazoline B-Chemical 0 0.99918216
receptor O 0 0.7131729
- O 0 0.008240571
mediated O 0 0.0033141326
hypotension B-Disease 2 0.9992493
in O 0 0.0037613197
female O 0 0.02107406
rats O 0 0.020808365
. O 0 0.0067459354

We O 0 0.0031849395
have O 0 0.0024181874
recently O 0 0.0022394122
shown O 0 0.0011266104
that O 0 0.0011107245
estrogen B-Chemical 1 0.99684143
negatively O 0 0.0022519054
modulates O 0 0.0008835243
the O 0 0.0008170891
hypotensive B-Disease 2 0.99751854
effect O 0 0.0013218725
of O 0 0.0021246555
clonidine B-Chemical 1 0.9998832
( O 0 0.0031326013
mixed O 0 0.01048079
alpha2 O 0 0.94464105
- O 0 0.0056276256
/ O 0 0.005664392
I1 O 0 0.8841182
- O 0 0.0022754634
receptor O 0 0.23701741
agonist O 0 0.9773539
) O 0 0.0013928344
in O 0 0.00032252565
female O 0 0.0013199778
rats O 0 0.0013848691
and O 0 0.00041267378
implicates O 0 0.0007921887
the O 0 0.0007251891
cardiovascular O 0 0.96426624
autonomic O 0 0.8562252
control O 0 0.0011199836
in O 0 0.0013274931
this O 0 0.0021575287
interaction O 0 0.0046099573
. O 0 0.005442689

The O 0 0.0024254757
present O 0 0.0014648322
study O 0 0.0017862779
investigated O 0 0.001023587
whether O 0 0.0004811851
this O 0 0.000616192
effect O 0 0.0007820756
of O 0 0.001205771
estrogen B-Chemical 1 0.99825805
involves O 0 0.0013515061
interaction O 0 0.0014322705
with O 0 0.0018870995
alpha2 O 0 0.8722994
- O 0 0.0033906982
and O 0 0.00143809
/ O 0 0.0033888826
or O 0 0.0019978723
I1 O 0 0.78631014
- O 0 0.008952582
receptors O 0 0.22398618
. O 0 0.0075083026

Changes O 0 0.0069287554
evoked O 0 0.02908599
by O 0 0.002087577
a O 0 0.0014671071
single O 0 0.0011787708
intraperitoneal O 0 0.07917437
injection O 0 0.005644659
of O 0 0.0019973114
rilmenidine B-Chemical 0 0.99986994
( O 0 0.0021324302
600 O 0 0.0051342594
microg O 0 0.0020404535
/ O 0 0.0012002421
kg O 0 0.0060596988
) O 0 0.00065635465
or O 0 0.00035870142
alpha B-Chemical 1 0.56521493
- I-Chemical 1 0.0072845006
methyldopa I-Chemical 1 0.9999571
( O 0 0.0020795064
100 O 0 0.0018055558
mg O 0 0.416003
/ O 0 0.001217982
kg O 0 0.0073108813
) O 0 0.00061590376
, O 0 0.00041862344
selective O 0 0.008847811
I1 O 0 0.82632196
- O 0 0.0012034023
and O 0 0.00058072124
alpha2 O 0 0.8502176
- O 0 0.0029876754
receptor O 0 0.25929245
agonists O 0 0.96141917
, O 0 0.000982768
respectively O 0 0.0015044479
, O 0 0.0003714421
in O 0 0.0002136177
blood O 0 0.00288593
pressure O 0 0.02682595
, O 0 0.0004268438
hemodynamic O 0 0.33025235
variability O 0 0.0003639757
, O 0 0.00035754844
and O 0 0.00029224448
locomotor O 0 0.15103406
activity O 0 0.0003450957
were O 0 0.00019650071
assessed O 0 0.00016971746
in O 0 0.00022431902
radiotelemetered O 0 0.04759276
sham O 0 0.00066422945
- O 0 0.0006168819
operated O 0 0.0014125743
and O 0 0.00056778383
ovariectomized O 0 0.84758925
( O 0 0.002052614
Ovx O 0 0.98820275
) O 0 0.0018381692
Sprague O 0 0.3564473
- O 0 0.0011764745
Dawley O 0 0.16292149
female O 0 0.0011477706
rats O 0 0.0013607596
with O 0 0.0005867685
or O 0 0.0005251609
without O 0 0.0008031417
12 O 0 0.00086396746
- O 0 0.0018666028
wk O 0 0.002307045
estrogen B-Chemical 1 0.9933595
replacement O 0 0.073319584
. O 0 0.007997181

Three O 0 0.0039313547
time O 0 0.001878859
domain O 0 0.0017926592
indexes O 0 0.0015750614
of O 0 0.0011237562
hemodynamic O 0 0.29239917
variability O 0 0.00075671397
were O 0 0.0005032507
employed O 0 0.00065872853
: O 0 0.0005638736
the O 0 0.0002474496
standard O 0 0.00020874114
deviation O 0 0.00044388694
of O 0 0.0003304859
mean O 0 0.00023607953
arterial O 0 0.2999072
pressure O 0 0.023821436
as O 0 0.00021590063
a O 0 0.0002378801
measure O 0 0.00011857045
of O 0 0.00027314972
blood O 0 0.0024153248
pressure O 0 0.013271601
variability O 0 0.0002581078
and O 0 0.00021310648
the O 0 0.00016201506
standard O 0 0.00015043882
deviation O 0 0.00039849943
of O 0 0.0003843073
beat O 0 0.020672325
- O 0 0.00073001685
to O 0 0.00030194336
- O 0 0.000567555
beat O 0 0.0043524494
intervals O 0 0.0003681901
( O 0 0.00050078746
SDRR O 0 0.2746238
) O 0 0.000452315
and O 0 0.00022940541
the O 0 0.0002025703
root O 0 0.000675006
mean O 0 0.00014032082
square O 0 0.00042017188
of O 0 0.0002896015
successive O 0 0.00032230554
differences O 0 0.00025211342
in O 0 0.0004423266
R O 0 0.81464887
- O 0 0.0013928317
wave O 0 0.046184104
- O 0 0.0011589504
to O 0 0.00050916575
- O 0 0.00162725
R O 0 0.68395156
- O 0 0.00096633803
wave O 0 0.005550127
intervals O 0 0.00050340133
as O 0 0.00039473153
measures O 0 0.00068358803
of O 0 0.0014425507
heart O 0 0.21293874
rate O 0 0.0026026058
variability O 0 0.004282271
. O 0 0.0055099586

In O 0 0.003631876
sham O 0 0.003928843
- O 0 0.0031614709
operated O 0 0.0037345188
rats O 0 0.006946423
, O 0 0.0026946112
rilmenidine B-Chemical 0 0.9997464
or O 0 0.0018512926
alpha B-Chemical 1 0.8687814
- I-Chemical 1 0.015285088
methyldopa I-Chemical 1 0.9999399
elicited O 0 0.004383121
similar O 0 0.00064482423
hypotension B-Disease 2 0.999592
that O 0 0.00031086168
lasted O 0 0.000305229
at O 0 0.00014284834
least O 0 0.00014134274
5 O 0 0.00017464439
h O 0 0.00020083348
and O 0 0.00021564675
was O 0 0.00023118505
associated O 0 0.00037893688
with O 0 0.00044149
reductions O 0 0.0006583297
in O 0 0.00037265616
standard O 0 0.0004487791
deviation O 0 0.0012239598
of O 0 0.0013851541
mean O 0 0.0018346754
arterial O 0 0.6393965
pressure O 0 0.22267336
. O 0 0.0066630426

SDRR O 0 0.2576743
was O 0 0.006334118
reduced O 0 0.00554918
only O 0 0.0057672663
by O 0 0.008394881
alpha B-Chemical 1 0.7558288
- I-Chemical 1 0.11780804
methyldopa I-Chemical 1 0.99896383
. O 0 0.027740937

Ovx O 0 0.9245912
significantly O 0 0.004314868
enhanced O 0 0.002938202
the O 0 0.0021435102
hypotensive B-Disease 2 0.995275
response O 0 0.0042934422
to O 0 0.0016461491
alpha B-Chemical 1 0.82338905
- I-Chemical 1 0.022473902
methyldopa I-Chemical 1 0.99991477
, O 0 0.0026948866
in O 0 0.00075698923
contrast O 0 0.0008445643
to O 0 0.00080406375
no O 0 0.0009232091
effect O 0 0.001962442
on O 0 0.0029718264
rilmenidine B-Chemical 0 0.9996313
hypotension B-Disease 2 0.99919933
. O 0 0.013985939

The O 0 0.003974593
enhanced O 0 0.005118994
alpha B-Chemical 1 0.7447747
- I-Chemical 1 0.04349262
methyldopa I-Chemical 1 0.9999089
hypotension B-Disease 2 0.9997917
in O 0 0.0042170053
Ovx O 0 0.99190736
rats O 0 0.007923363
was O 0 0.000630296
paralleled O 0 0.0008819002
with O 0 0.00065206573
further O 0 0.0007291933
reduction O 0 0.0013856112
in O 0 0.000878802
SDRR O 0 0.30166963
and O 0 0.0011938688
a B-Disease 0 0.0017214401
reduced I-Disease 0 0.002915118
locomotor I-Disease 0 0.43359837
activity I-Disease 0 0.0071563995
. O 0 0.0063568596

Estrogen O 0 0.9974367
replacement O 0 0.13905215
( O 0 0.025111713
17beta B-Chemical 1 0.9991697
- I-Chemical 1 0.038055982
estradiol I-Chemical 1 0.9994093
subcutaneous O 0 0.35654902
pellet O 0 0.0045242957
, O 0 0.0009988624
14 O 0 0.0005800458
. O 0 0.0002501913
2 O 0 0.00032300694
microg O 0 0.0007586469
/ O 0 0.0006160276
day O 0 0.00027147666
, O 0 0.00030375487
12 O 0 0.00017142357
wk O 0 0.00023790415
) O 0 0.0004057385
of O 0 0.0004379341
Ovx O 0 0.9521116
rats O 0 0.0019306063
restored O 0 0.00040026486
the O 0 0.0003160769
hemodynamic O 0 0.39144608
and O 0 0.0005503627
locomotor O 0 0.25391635
effects O 0 0.0012073497
of O 0 0.0011544642
alpha B-Chemical 1 0.8269887
- I-Chemical 1 0.020655662
methyldopa I-Chemical 1 0.99989355
to O 0 0.002002624
sham O 0 0.0036860453
- O 0 0.0035792375
operated O 0 0.007085745
levels O 0 0.0044958633
. O 0 0.0057828366

These O 0 0.0044462914
findings O 0 0.003881946
suggest O 0 0.0015588974
that O 0 0.0017280712
estrogen B-Chemical 1 0.99792516
downregulates O 0 0.16986224
alpha2 O 0 0.9751887
- O 0 0.005593677
but O 0 0.0007933869
not O 0 0.0007239786
I1 O 0 0.85683596
- O 0 0.0027023545
receptor O 0 0.21703702
- O 0 0.0017785913
mediated O 0 0.00068528816
hypotension B-Disease 2 0.9996455
and O 0 0.00047881473
highlight O 0 0.00028989484
a O 0 0.00031800443
role O 0 0.0001957096
for O 0 0.00024527218
the O 0 0.0003661315
cardiac O 0 0.23094702
autonomic O 0 0.7684069
control O 0 0.000574981
in O 0 0.0008234477
alpha B-Chemical 1 0.7359404
- I-Chemical 1 0.042038906
methyldopa I-Chemical 1 0.9998944
- O 0 0.102513395
estrogen B-Chemical 1 0.9976463
interaction O 0 0.014605715
. O 0 0.00772832

Severe O 0 0.8678205
reversible O 0 0.31380618
left B-Disease 0 0.0110779675
ventricular I-Disease 0 0.9665491
systolic I-Disease 0 0.8796761
and I-Disease 0 0.0037996087
diastolic I-Disease 0 0.9940257
dysfunction I-Disease 0 0.9876551
due O 0 0.0019776837
to O 0 0.002861504
accidental O 0 0.83744234
iatrogenic O 0 0.9804474
epinephrine B-Chemical 0 0.9987208
overdose B-Disease 2 0.99868256
. O 0 0.016002396

Catecholamine B-Chemical 0 0.9943632
- O 0 0.010659338
induced O 0 0.006109694
cardiomyopathy B-Disease 2 0.99894434
due O 0 0.0014995993
to O 0 0.0012490983
chronic O 0 0.8814437
excess O 0 0.002735595
of O 0 0.0013079528
endogenous O 0 0.0036821545
catecholamines B-Chemical 1 0.9987243
has O 0 0.0011270634
been O 0 0.0009865612
recognized O 0 0.0009677759
for O 0 0.00070948777
decades O 0 0.002874337
as O 0 0.0012138837
a O 0 0.0024116095
clinical O 0 0.023701597
phenomenon O 0 0.038847942
. O 0 0.0065411115

In O 0 0.003887205
contrast O 0 0.0032504464
, O 0 0.0030462954
reports O 0 0.0030252363
of O 0 0.0036950833
myocardial B-Disease 0 0.998697
dysfunction I-Disease 0 0.99570495
due O 0 0.0023020108
to O 0 0.003090297
acute O 0 0.98623043
iatrogenic O 0 0.9881214
overdose B-Disease 2 0.9990932
are O 0 0.012329409
rare O 0 0.12277966
. O 0 0.009379479

A O 0 0.017552232
35 O 0 0.004018799
- O 0 0.0030388504
year O 0 0.0016533823
- O 0 0.0017275128
old O 0 0.0010801136
woman O 0 0.0049227998
whose O 0 0.0016331263
cervix O 0 0.73637897
uteri O 0 0.26273403
was O 0 0.00070004206
inadvertently O 0 0.0039135558
injected O 0 0.00041912257
with O 0 0.0004433811
8 O 0 0.00037568685
mg O 0 0.14661492
of O 0 0.00065951847
epinephrine B-Chemical 0 0.99870145
developed O 0 0.0046888585
myocardial B-Disease 0 0.9988795
stunning I-Disease 0 0.94431514
that O 0 0.00038198734
was O 0 0.0003375846
characterized O 0 0.0006280701
by O 0 0.00039884317
severe O 0 0.15328258
hemodynamic O 0 0.781779
compromise O 0 0.0036707455
, O 0 0.0006615237
profound O 0 0.023059579
, O 0 0.00057291635
albeit O 0 0.0011201126
transient O 0 0.038453925
, O 0 0.0006119206
left B-Disease 0 0.0018694744
ventricular I-Disease 0 0.9664809
systolic I-Disease 0 0.8482934
and I-Disease 0 0.000746536
diastolic I-Disease 0 0.9975134
dysfunction I-Disease 0 0.99383
, O 0 0.00083659467
and O 0 0.00045892975
only O 0 0.0004918986
modestly O 0 0.010874909
elevated O 0 0.006949108
biochemical O 0 0.053535793
markers O 0 0.007118489
of O 0 0.016222654
myocardial B-Disease 0 0.9992187
necrosis I-Disease 2 0.99856323
. O 0 0.016827462

Our O 0 0.0032911506
case O 0 0.0023254403
illustrates O 0 0.0014612881
the O 0 0.0012764198
serious O 0 0.018084668
consequences O 0 0.0020657287
of O 0 0.0010610841
medical O 0 0.007566878
errors O 0 0.0016732455
that O 0 0.00049728574
can O 0 0.00046981746
be O 0 0.00052466086
avoided O 0 0.000621964
through O 0 0.0005557611
improved O 0 0.0018207999
medication O 0 0.09486654
labeling O 0 0.0036146508
and O 0 0.0023072765
staff O 0 0.005390659
supervision O 0 0.015858589
. O 0 0.006375047

Cardioprotective O 0 0.9631199
effect O 0 0.0057434374
of O 0 0.0052125193
tincture B-Chemical 0 0.9756634
of I-Chemical 0 0.008567707
Crataegus I-Chemical 0 0.99485105
on O 0 0.0034100376
isoproterenol B-Chemical 1 0.99884486
- O 0 0.025005667
induced O 0 0.019392198
myocardial B-Disease 0 0.9987093
infarction I-Disease 2 0.9995895
in O 0 0.012165522
rats O 0 0.072688594
. O 0 0.008947489

Tincture B-Chemical 0 0.97517836
of I-Chemical 0 0.0091609275
Crataegus I-Chemical 0 0.9902671
( O 0 0.0075547127
TCR B-Chemical 1 0.7112159
) O 0 0.0043587717
, O 0 0.0017227991
an O 0 0.0016337002
alcoholic B-Chemical 0 0.9977368
extract I-Chemical 0 0.044422504
of I-Chemical 0 0.0012602919
the I-Chemical 0 0.0008663491
berries I-Chemical 0 0.42464173
of I-Chemical 0 0.0020420456
hawthorn I-Chemical 0 0.97940767
( O 0 0.0073598586
Crataegus B-Chemical 0 0.9982488
oxycantha I-Chemical 0 0.981006
) O 0 0.0034995833
, O 0 0.0010515181
is O 0 0.00069223024
used O 0 0.0007261041
in O 0 0.0011079003
herbal O 0 0.89232934
and O 0 0.0038713417
homeopathic O 0 0.7077753
medicine O 0 0.18720235
. O 0 0.00826786

The O 0 0.0026269972
present O 0 0.0016435775
study O 0 0.002083153
was O 0 0.0011526452
done O 0 0.00077717967
to O 0 0.00070264674
investigate O 0 0.0004973507
the O 0 0.0006655878
protective O 0 0.0039602118
effect O 0 0.0011567831
of O 0 0.0015253584
TCR B-Chemical 1 0.5889282
on O 0 0.0009017908
experimentally O 0 0.0028405169
induced O 0 0.008112068
myocardial B-Disease 0 0.99894506
infarction I-Disease 2 0.99967825
in O 0 0.010156677
rats O 0 0.070836596
. O 0 0.0074930494

Pretreatment O 0 0.7124984
of O 0 0.0051404745
TCR B-Chemical 1 0.52565056
, O 0 0.0026381952
at O 0 0.00082237966
a O 0 0.00094969926
dose O 0 0.004861716
of O 0 0.0008894496
0 O 0 0.000682496
. O 0 0.00027753462
5 O 0 0.0003081432
mL O 0 0.0012383141
/ O 0 0.00056425243
100 O 0 0.00049052713
g O 0 0.00058143825
bodyweight O 0 0.033681527
per O 0 0.0001301601
day O 0 0.00021018967
, O 0 0.0002750139
orally O 0 0.0038385396
for O 0 0.00017065264
30 O 0 0.00017637914
days O 0 0.00018595517
, O 0 0.00026384564
prevented O 0 0.0005424633
the O 0 0.00022528549
increase O 0 0.00028379026
in O 0 0.00034172673
lipid O 0 0.87494355
peroxidation O 0 0.99987066
and O 0 0.0009228631
activity O 0 0.0006143144
of O 0 0.0004212752
marker O 0 0.00075815764
enzymes O 0 0.070000574
observed O 0 0.0003349836
in O 0 0.0004711095
isoproterenol B-Chemical 1 0.99960786
- O 0 0.0025873808
induced O 0 0.0007799211
rats O 0 0.005155938
( O 0 0.0004419519
85 O 0 0.00050012086
mg O 0 0.21691318
kg O 0 0.00922591
( O 0 0.0005265709
- O 0 0.0004832724
1 O 0 0.00026945502
) O 0 0.00036980587
s O 0 0.00029152984
. O 0 0.00015138656
c O 0 0.00080802356
. O 0 0.00016602928
for O 0 0.0002004283
2 O 0 0.0002676989
days O 0 0.0002593001
at O 0 0.0002344479
an O 0 0.0005691216
interval O 0 0.00093239965
of O 0 0.0011250532
24 O 0 0.0015678023
h O 0 0.0024973608
) O 0 0.005251652
. O 0 0.004821835

TCR B-Chemical 1 0.47858727
prevented O 0 0.011888822
the O 0 0.003839271
isoproterenol B-Chemical 1 0.9986131
- O 0 0.0067182756
induced O 0 0.0017968913
decrease O 0 0.0012550928
in O 0 0.0007934452
antioxidant O 0 0.99549794
enzymes O 0 0.17848194
in O 0 0.00055225834
the O 0 0.0004981369
heart O 0 0.24909092
and O 0 0.00048522287
increased O 0 0.00065453316
the O 0 0.00035994672
rate O 0 0.00044010486
of O 0 0.0011743288
ADP B-Chemical 1 0.9964413
- O 0 0.0027507334
stimulated O 0 0.0012498916
oxygen B-Chemical 1 0.9632483
uptake O 0 0.04908024
and O 0 0.0024330944
respiratory O 0 0.48021525
coupling O 0 0.041738372
ratio O 0 0.008522871
. O 0 0.006784609

TCR B-Chemical 1 0.3181659
protected O 0 0.008017718
against O 0 0.004357772
pathological O 0 0.18746804
changes O 0 0.0055544614
induced O 0 0.0049060523
by O 0 0.0052737887
isoproterenol B-Chemical 1 0.9969896
in O 0 0.007230114
rat O 0 0.12523583
heart O 0 0.72100276
. O 0 0.011552115

The O 0 0.002903989
results O 0 0.0020180976
show O 0 0.001466929
that O 0 0.0012863292
pretreatment O 0 0.08170558
with O 0 0.0020716272
TCR B-Chemical 1 0.59351987
may O 0 0.0011960622
be O 0 0.00080561225
useful O 0 0.000873572
in O 0 0.0005721914
preventing O 0 0.0015812487
the O 0 0.0010323451
damage O 0 0.5054748
induced O 0 0.0029249024
by O 0 0.0028605026
isoproterenol B-Chemical 1 0.998432
in O 0 0.0042044893
rat O 0 0.12841062
heart O 0 0.722488
. O 0 0.00798566

Treatment O 0 0.034073707
of O 0 0.0057359054
tinnitus B-Disease 2 0.9911107
by O 0 0.003850371
intratympanic O 0 0.9946642
instillation O 0 0.3421213
of O 0 0.004892402
lignocaine B-Chemical 1 0.9993387
( O 0 0.009606327
lidocaine B-Chemical 0 0.99907255
) O 0 0.0025442834
2 O 0 0.0008584203
per O 0 0.00057699875
cent O 0 0.0010476307
through O 0 0.0018171698
ventilation O 0 0.03864406
tubes O 0 0.008481621
. O 0 0.0066476744

Idiopathic B-Disease 0 0.9423524
subjective I-Disease 0 0.15613577
tinnitus I-Disease 2 0.9961902
( O 0 0.0107050035
IST B-Disease 0 0.8615209
) O 0 0.0037606033
is O 0 0.001461832
one O 0 0.001073336
of O 0 0.0017592909
the O 0 0.0019771343
most O 0 0.0045240032
obscure O 0 0.03506475
otological O 0 0.74546725
pathologies O 0 0.84878254
. O 0 0.011657636

This O 0 0.004431236
paper O 0 0.0033348016
presents O 0 0.0020817746
the O 0 0.0011367066
results O 0 0.00093163154
of O 0 0.0012662513
treating O 0 0.009078803
IST B-Disease 0 0.8846374
by O 0 0.001369105
intratympanic O 0 0.99697256
instillation O 0 0.32422584
of O 0 0.003433653
lignocaine B-Chemical 1 0.99966145
( O 0 0.006518073
lidocaine B-Chemical 0 0.9995085
) O 0 0.0012992028
2 O 0 0.00032377275
per O 0 0.0001706492
cent O 0 0.0002665328
through O 0 0.00035773547
a O 0 0.0007011029
grommet O 0 0.036028393
, O 0 0.0010283373
for O 0 0.00075851823
five O 0 0.0010695639
weekly O 0 0.003915499
courses O 0 0.009272073
. O 0 0.0060619535

Fifty O 0 0.017418262
- O 0 0.0042622625
two O 0 0.0015545071
patients O 0 0.0036200134
suffering O 0 0.36427203
from O 0 0.0016249709
intractable O 0 0.957475
tinnitus B-Disease 2 0.9976859
entered O 0 0.0017070066
this O 0 0.00067999447
therapeutic O 0 0.010372414
trial O 0 0.0020103038
, O 0 0.000928488
but O 0 0.0006194837
only O 0 0.00069728616
nine O 0 0.001052728
finished O 0 0.0022687044
all O 0 0.0013947183
five O 0 0.0019371785
courses O 0 0.009025746
. O 0 0.0063596885

In O 0 0.0029414434
one O 0 0.0017817841
patient O 0 0.0026202905
, O 0 0.0019159009
the O 0 0.0013615438
tinnitus B-Disease 2 0.99274534
was O 0 0.0010046097
almost O 0 0.0005838428
completely O 0 0.0007145498
abolished O 0 0.001504859
, O 0 0.0007044157
but O 0 0.00037256436
in O 0 0.00027045468
all O 0 0.0002516955
the O 0 0.0002826036
nine O 0 0.00041713993
patients O 0 0.0012948193
the O 0 0.00078880315
decompensated O 0 0.9989581
tinnitus B-Disease 2 0.9979792
changed O 0 0.002196934
to O 0 0.0014021411
a O 0 0.002259197
compensated O 0 0.0058060265
one O 0 0.0039148238
. O 0 0.005817201

We O 0 0.0026546877
suggest O 0 0.0014601389
this O 0 0.0012436149
mode O 0 0.0012925183
of O 0 0.0010991718
treatment O 0 0.001591235
for O 0 0.00058821065
patients O 0 0.0014855631
that O 0 0.00041257855
were O 0 0.00045039717
previously O 0 0.00047120894
treated O 0 0.00084807473
by O 0 0.00065513665
drugs O 0 0.46915957
, O 0 0.0010870704
acupuncture O 0 0.03729791
and O 0 0.0011204653
biofeedback O 0 0.14927521
, O 0 0.0020573013
with O 0 0.0023950464
disappointing O 0 0.014803957
results O 0 0.005022632
. O 0 0.0065327873

Patients O 0 0.0087579135
should O 0 0.00181754
be O 0 0.0017645613
warned O 0 0.004326945
about O 0 0.00097243325
the O 0 0.0008690378
side O 0 0.005045052
effects O 0 0.0016485393
of O 0 0.0017272184
vertigo B-Disease 0 0.9996592
and O 0 0.004898841
vomiting B-Disease 0 0.99972063
, O 0 0.0013901666
which O 0 0.00061653217
subsides O 0 0.0028930423
gradually O 0 0.0009868358
with O 0 0.0003237999
every O 0 0.00013122059
new O 0 0.0003846531
instillation O 0 0.032094855
, O 0 0.00042335028
and O 0 0.00026031723
that O 0 0.0002024946
the O 0 0.00033408904
tinnitus B-Disease 2 0.9960961
may O 0 0.00037415393
not O 0 0.00025924796
disappear O 0 0.0009937368
but O 0 0.00026202915
will O 0 0.00018333948
be O 0 0.00027882468
alleviated O 0 0.016150342
, O 0 0.00044342977
enabling O 0 0.0004464975
them O 0 0.00046721514
to O 0 0.0002570616
cope O 0 0.0008879746
more O 0 0.00044576728
easily O 0 0.0004761113
with O 0 0.0004302721
the O 0 0.00051491364
disease O 0 0.38708892
and O 0 0.0011001597
lead O 0 0.01123428
a O 0 0.0015867347
more O 0 0.0022498856
normal O 0 0.0050783353
life O 0 0.008729178
. O 0 0.0056760325

The O 0 0.00482276
alpha3 O 0 0.64266205
and O 0 0.005309853
beta4 O 0 0.9679345
nicotinic O 0 0.9991242
acetylcholine B-Chemical 1 0.99939287
receptor O 0 0.744565
subunits O 0 0.022039436
are O 0 0.0010228202
necessary O 0 0.0005729139
for O 0 0.0009145867
nicotine B-Chemical 1 0.99759275
- O 0 0.006465122
induced O 0 0.0074685
seizures B-Disease 2 0.99965763
and O 0 0.010813699
hypolocomotion B-Disease 0 0.998796
in O 0 0.0040315706
mice O 0 0.0036695232
. O 0 0.00588658

Binding O 0 0.009154445
of O 0 0.0048257173
nicotine B-Chemical 1 0.99213445
to O 0 0.0048517045
nicotinic O 0 0.9989278
acetylcholine B-Chemical 1 0.99944013
receptors O 0 0.8822502
( O 0 0.011230308
nAChRs O 0 0.9921008
) O 0 0.0017555016
elicits O 0 0.0010438657
a O 0 0.00045058972
series O 0 0.00067850616
of O 0 0.0005564627
dose O 0 0.03300395
- O 0 0.0008449261
dependent O 0 0.0003339467
behaviors O 0 0.0060528265
that O 0 0.00024157736
go O 0 0.00044620963
from O 0 0.0002869616
altered O 0 0.000594695
exploration O 0 0.0013325537
, O 0 0.0008863072
sedation O 0 0.56897354
, O 0 0.0010606438
and O 0 0.0012678921
tremors B-Disease 2 0.99823713
, O 0 0.0024585708
to O 0 0.0026152171
seizures B-Disease 2 0.99935347
and O 0 0.012426127
death B-Disease 2 0.99123466
. O 0 0.008720282

nAChRs O 0 0.9509416
are O 0 0.005912462
pentameric O 0 0.068416886
ion O 0 0.17642239
channels O 0 0.037988164
usually O 0 0.0040204767
composed O 0 0.0029057912
of O 0 0.0036585808
alpha O 0 0.19482331
and O 0 0.0066977823
beta O 0 0.6238077
subunits O 0 0.067593314
. O 0 0.011840142

A O 0 0.015274858
gene O 0 0.003900258
cluster O 0 0.0029841012
comprises O 0 0.0020018856
the O 0 0.0018253243
alpha3 O 0 0.83341926
, O 0 0.003776249
alpha5 O 0 0.97776467
and O 0 0.0022429535
beta4 O 0 0.8769367
subunits O 0 0.017144347
, O 0 0.0018897267
which O 0 0.0017751608
coassemble O 0 0.0218776
to O 0 0.0016810434
form O 0 0.0027617768
functional O 0 0.006288495
receptors O 0 0.24094431
. O 0 0.007989506

We O 0 0.0028419243
examined O 0 0.0015786843
the O 0 0.0013216132
role O 0 0.0008938423
of O 0 0.0012415667
the O 0 0.0011663918
beta4 O 0 0.81245273
subunits O 0 0.018760173
in O 0 0.0012709516
nicotine B-Chemical 1 0.99879223
- O 0 0.0066386657
induced O 0 0.004083442
seizures B-Disease 2 0.9998746
and O 0 0.0041427487
hypolocomotion B-Disease 0 0.99975604
in O 0 0.0008362991
beta4 O 0 0.8610825
homozygous O 0 0.00093164615
null O 0 0.0002993742
( O 0 0.0012302779
beta4 O 0 0.9038624
- O 0 0.0031901319
/ O 0 0.0027243204
- O 0 0.0010765402
) O 0 0.0007732121
and O 0 0.0005989998
alpha3 O 0 0.6895626
heterozygous O 0 0.0015525542
( O 0 0.0018956475
+ O 0 0.0018299469
/ O 0 0.0038506382
- O 0 0.0033336387
) O 0 0.0035570695
mice O 0 0.002547938
. O 0 0.004807459

beta4 O 0 0.88603514
- O 0 0.008723895
/ O 0 0.0050827344
- O 0 0.0021327
mice O 0 0.00060828775
were O 0 0.0005800279
less O 0 0.00049057935
sensitive O 0 0.0004867982
to O 0 0.00032984282
the O 0 0.0003108863
effects O 0 0.0006984886
of O 0 0.0006606146
nicotine B-Chemical 1 0.9972464
both O 0 0.00044707328
at O 0 0.00019942466
low O 0 0.00043916085
doses O 0 0.025386939
, O 0 0.00039841057
measured O 0 0.00016197984
as O 0 0.00016708906
decreased O 0 0.00052932336
exploration O 0 0.0006860864
in O 0 0.00021276479
an O 0 0.0003083954
open O 0 0.00023071581
field O 0 0.00047630924
, O 0 0.000354011
and O 0 0.00025460435
at O 0 0.00016628722
high O 0 0.00044029913
doses O 0 0.016122755
, O 0 0.0005515279
measured O 0 0.00030459207
as O 0 0.0004187488
sensitivity O 0 0.0018099973
to O 0 0.0014218261
nicotine B-Chemical 1 0.9969752
- O 0 0.013583401
induced O 0 0.023361798
seizures B-Disease 2 0.99906284
. O 0 0.00938139

Using O 0 0.0041943053
in O 0 0.0020031102
situ O 0 0.0033244053
hybridization O 0 0.00215625
probes O 0 0.0014299047
for O 0 0.00077763316
the O 0 0.0008856327
alpha3 O 0 0.7718557
and O 0 0.0015593858
alpha5 O 0 0.9861611
subunits O 0 0.014826207
, O 0 0.00069442455
we O 0 0.00017989553
showed O 0 0.00031270643
that O 0 0.00036863692
alpha5 O 0 0.97502905
mRNA O 0 0.0020106437
levels O 0 0.00035648418
are O 0 0.0002944542
unchanged O 0 0.00042938907
, O 0 0.00040301043
whereas O 0 0.00034097696
alpha3 O 0 0.8091019
mRNA O 0 0.0015521832
levels O 0 0.0003006559
are O 0 0.00026137516
selectively O 0 0.00069989555
decreased O 0 0.0006618157
in O 0 0.00021514748
the O 0 0.00026809683
mitral O 0 0.685985
cell O 0 0.006688341
layer O 0 0.0029349457
of O 0 0.00039927743
the O 0 0.00036232296
olfactory O 0 0.060584567
bulb O 0 0.18941276
, O 0 0.00039847795
and O 0 0.0002827462
the O 0 0.000283961
inferior O 0 0.009665126
and O 0 0.00038252288
the O 0 0.0004152615
superior O 0 0.0027762318
colliculus O 0 0.10240417
of O 0 0.0014947589
beta4 O 0 0.8603805
- O 0 0.0060578003
/ O 0 0.006729233
- O 0 0.0052587916
brains O 0 0.008137234
. O 0 0.0052446546

alpha3 O 0 0.8738648
+ O 0 0.006460226
/ O 0 0.0052327476
- O 0 0.0023073568
mice O 0 0.00069078564
were O 0 0.0007250862
partially O 0 0.0008451383
resistant O 0 0.0015580871
to O 0 0.00091401476
nicotine B-Chemical 1 0.9979399
- O 0 0.00420054
induced O 0 0.0028712703
seizures B-Disease 2 0.9996724
when O 0 0.0006383923
compared O 0 0.0004853205
to O 0 0.0007719142
wild O 0 0.0010211179
- O 0 0.0025001362
type O 0 0.0022599099
littermates O 0 0.0019361704
. O 0 0.0049861954

mRNA O 0 0.0066390242
levels O 0 0.0024214883
for O 0 0.0016300365
the O 0 0.0018152981
alpha5 O 0 0.92127854
and O 0 0.001657578
the O 0 0.0012792874
beta4 O 0 0.7181999
subunits O 0 0.0068467143
were O 0 0.0011182816
unchanged O 0 0.0014625763
in O 0 0.0015307466
alpha3 O 0 0.8586178
+ O 0 0.0046511125
/ O 0 0.007807204
- O 0 0.0061712232
brains O 0 0.009284289
. O 0 0.005916745

Together O 0 0.008415377
, O 0 0.0033183375
these O 0 0.0019687682
results O 0 0.001133108
suggest O 0 0.00081144215
that O 0 0.00075619
the O 0 0.0009194758
beta4 O 0 0.6263448
and O 0 0.0010620634
the O 0 0.0008949306
alpha3 O 0 0.8153738
subunits O 0 0.009103449
are O 0 0.0010012499
mediators O 0 0.017161574
of O 0 0.0028231966
nicotine B-Chemical 1 0.998351
- O 0 0.013744479
induced O 0 0.016970921
seizures B-Disease 2 0.9995353
and O 0 0.03214306
hypolocomotion B-Disease 0 0.99836856
. O 0 0.010293682

The O 0 0.0056174225
effects O 0 0.0071590184
of O 0 0.007238158
sevoflurane B-Chemical 1 0.9918031
on O 0 0.007150676
lidocaine B-Chemical 0 0.9976592
- O 0 0.040927026
induced O 0 0.04125236
convulsions B-Disease 0 0.9980406
. O 0 0.019105647

The O 0 0.003669112
influence O 0 0.0028501507
of O 0 0.0039431658
sevoflurane B-Chemical 1 0.9938731
on O 0 0.0030549788
lidocaine B-Chemical 0 0.99879265
- O 0 0.012614812
induced O 0 0.008076289
convulsions B-Disease 0 0.99922955
was O 0 0.00404376
studied O 0 0.00489859
in O 0 0.0044050515
cats O 0 0.02245163
. O 0 0.00800544

The O 0 0.0050293943
convulsive B-Disease 2 0.9975508
threshold O 0 0.0041954294
( O 0 0.002703874
mean O 0 0.0011006314
+ O 0 0.0018098344
/ O 0 0.0026686098
- O 0 0.0018598736
SD O 0 0.014359338
) O 0 0.0011740223
was O 0 0.0005995964
41 O 0 0.0011266544
. O 0 0.00042127763
4 O 0 0.0005880769
+ O 0 0.001011106
/ O 0 0.0019155234
- O 0 0.0016380752
6 O 0 0.0009627187
. O 0 0.001067887
5 O 0 0.0022103293
mg O 0 0.14597376
. O 0 0.005351793

l O 0 0.0116736395
( O 0 0.0053685186
- O 0 0.0034186696
1 O 0 0.0015271361
) O 0 0.0015918517
with O 0 0.0012232045
lidocaine B-Chemical 0 0.99869376
infusion O 0 0.19202879
( O 0 0.0010720658
6 O 0 0.00038684372
mg O 0 0.1478627
. O 0 0.0002756628
kg O 0 0.0036930074
( O 0 0.00060514954
- O 0 0.0005797996
1 O 0 0.0003302267
) O 0 0.00045887596
. O 0 0.00017153213
min O 0 0.00048620856
( O 0 0.00045283983
- O 0 0.0005066299
1 O 0 0.00032150088
) O 0 0.00050926406
) O 0 0.00046211857
, O 0 0.00031192723
increasing O 0 0.00039151104
significantly O 0 0.00044236978
to O 0 0.00035168394
66 O 0 0.00076884346
. O 0 0.0002841688
6 O 0 0.0003888558
+ O 0 0.0007613559
/ O 0 0.0015617338
- O 0 0.0013868131
10 O 0 0.0010832662
. O 0 0.00097310607
9 O 0 0.0023448195
mg O 0 0.16737808
. O 0 0.004975625

l O 0 0.012258677
( O 0 0.005750173
- O 0 0.0036919601
1 O 0 0.0016403369
) O 0 0.0015259089
when O 0 0.0005919704
the O 0 0.00066177215
end O 0 0.0005750054
- O 0 0.0014280647
tidal O 0 0.03205422
concentration O 0 0.0029202641
of O 0 0.0018892473
sevoflurane B-Chemical 1 0.9968142
was O 0 0.0019813764
0 O 0 0.001981905
. O 0 0.0013497395
8 O 0 0.0024736892
% O 0 0.0040465933
. O 0 0.004683205

However O 0 0.0044785966
, O 0 0.0030799753
the O 0 0.0016216539
threshold O 0 0.0016916043
( O 0 0.0016758697
61 O 0 0.0015610721
. O 0 0.0005311711
6 O 0 0.0004964948
+ O 0 0.00071071874
/ O 0 0.0011297992
- O 0 0.000707229
8 O 0 0.0003258307
. O 0 0.00018083747
7 O 0 0.00024545513
mg O 0 0.08464134
. O 0 0.00021655954
l O 0 0.0010310118
( O 0 0.0005774714
- O 0 0.00055581465
1 O 0 0.00030501667
) O 0 0.00043507802
) O 0 0.00033759492
during O 0 0.00014852219
1 O 0 0.00022404606
. O 0 0.00012083317
6 O 0 0.00014548156
% O 0 0.00024142952
sevoflurane B-Chemical 1 0.9813874
was O 0 0.00023996927
not O 0 0.00018511097
significant O 0 0.00027211645
from O 0 0.00020774596
that O 0 0.00019153685
during O 0 0.00021523837
0 O 0 0.00038743683
. O 0 0.00021810767
8 O 0 0.00038427708
% O 0 0.00063628214
sevoflurane B-Chemical 1 0.9859607
, O 0 0.0011924425
indicating O 0 0.0009405119
a O 0 0.0020507474
celling O 0 0.011660536
effect O 0 0.005218017
. O 0 0.005902982

There O 0 0.00636231
was O 0 0.0029086
no O 0 0.0018172052
significant O 0 0.0020815597
difference O 0 0.0012040203
in O 0 0.0014810797
the O 0 0.0022118818
convulsive B-Disease 2 0.9986224
threshold O 0 0.0036762606
between O 0 0.002723103
sevoflurane B-Chemical 1 0.9941248
and O 0 0.013858889
enflurane B-Chemical 1 0.997412
. O 0 0.012923082

The O 0 0.0031641573
rise O 0 0.00344803
in O 0 0.0016647093
blood O 0 0.0048205242
pressure O 0 0.020557594
became O 0 0.0016066205
less O 0 0.0006919292
marked O 0 0.00085766806
when O 0 0.0003044681
higher O 0 0.000405447
concentrations O 0 0.00139448
of O 0 0.0007659464
sevoflurane B-Chemical 1 0.99854386
or O 0 0.0006642801
enflurane B-Chemical 1 0.9996829
were O 0 0.0005177495
administered O 0 0.0013501401
and O 0 0.00029549215
the O 0 0.0002509627
blood O 0 0.003352115
pressure O 0 0.029517608
at O 0 0.0002917762
convulsions B-Disease 0 0.9997011
decreased O 0 0.0024780557
significantly O 0 0.00058950734
in O 0 0.0002828468
1 O 0 0.00030255772
. O 0 0.00014823172
6 O 0 0.00017859676
% O 0 0.00031140068
sevoflurane B-Chemical 1 0.98956454
, O 0 0.00046168084
and O 0 0.00032700205
in O 0 0.0002877262
0 O 0 0.00039970322
. O 0 0.00022333159
8 O 0 0.00036302587
% O 0 0.0004718144
and O 0 0.00055201416
1 O 0 0.0007984572
. O 0 0.000709308
6 O 0 0.0012782727
% O 0 0.003296435
enflurane B-Chemical 1 0.99366295
. O 0 0.006492728

However O 0 0.0043394184
, O 0 0.002883948
there O 0 0.0011631111
was O 0 0.001119919
no O 0 0.0007233956
significant O 0 0.0008939948
difference O 0 0.00047753984
in O 0 0.0005594323
the O 0 0.0007808302
lidocaine B-Chemical 0 0.99864095
concentrations O 0 0.0054898835
measured O 0 0.0005720949
when O 0 0.0005325604
the O 0 0.0009523433
systolic O 0 0.5978648
blood O 0 0.01226712
pressure O 0 0.052810848
became O 0 0.004641163
70 O 0 0.004657519
mmHg O 0 0.018307814
. O 0 0.0053471625

Apamin B-Chemical 0 0.9958669
, O 0 0.006189194
a O 0 0.0030570347
selective O 0 0.022861086
blocker O 0 0.9776889
of O 0 0.007887147
calcium B-Chemical 1 0.9983374
- O 0 0.010956011
dependent O 0 0.0016347348
potassium B-Chemical 0 0.99940646
channels O 0 0.26594105
, O 0 0.0012056746
was O 0 0.0005204505
administered O 0 0.0031095732
intracerebroventricularly O 0 0.9688269
in O 0 0.00035333718
rats O 0 0.0020493378
anesthetized O 0 0.024558233
with O 0 0.00039049907
0 O 0 0.00036908718
. O 0 0.00017333047
8 O 0 0.00026103348
% O 0 0.00035661107
sevoflurane B-Chemical 1 0.95474315
to O 0 0.00033430377
investigate O 0 0.00027632457
the O 0 0.00047981105
mechanism O 0 0.0010213456
of O 0 0.0015160571
the O 0 0.0027188612
anticonvulsive O 0 0.9982287
effects O 0 0.038626265
. O 0 0.007589529

Apamin B-Chemical 0 0.99567395
( O 0 0.0059321625
10 O 0 0.0023183888
ng O 0 0.0032635087
) O 0 0.001674821
had O 0 0.0007848821
a O 0 0.00074138684
tendency O 0 0.0009873253
to O 0 0.00046801902
decrease O 0 0.0006464121
the O 0 0.000631047
convulsive B-Disease 2 0.9996971
threshold O 0 0.0011255206
( O 0 0.00077415287
21 O 0 0.0004925029
. O 0 0.00019063387
6 O 0 0.00022374956
+ O 0 0.000379978
/ O 0 0.0007224596
- O 0 0.0004641703
2 O 0 0.00023343055
. O 0 0.00012683823
2 O 0 0.00017474232
to O 0 0.00016943706
19 O 0 0.0003622349
. O 0 0.00014570313
9 O 0 0.0002472682
+ O 0 0.00034171145
/ O 0 0.000670974
- O 0 0.0004398991
2 O 0 0.00022953954
. O 0 0.00013228622
5 O 0 0.00020008937
mg O 0 0.07001416
. O 0 0.00020316296
l O 0 0.0010131419
( O 0 0.0006353365
- O 0 0.00068745133
1 O 0 0.00044105487
) O 0 0.00070335716
) O 0 0.00068511843
but O 0 0.00043976284
this O 0 0.0005712191
was O 0 0.0008394911
not O 0 0.001192237
statistically O 0 0.0021704896
significant O 0 0.0045195497
. O 0 0.005212942

It O 0 0.006026417
is O 0 0.0024502955
suggested O 0 0.0019179016
that O 0 0.0015262987
sevoflurane B-Chemical 1 0.9946138
reduces O 0 0.0020212866
the O 0 0.0015417271
convulsive B-Disease 2 0.9996182
effect O 0 0.0021442918
of O 0 0.0027902394
lidocaine B-Chemical 0 0.9996866
toxicity B-Disease 2 0.99810934
but O 0 0.0012928705
carries O 0 0.0014747023
some O 0 0.001395398
risk O 0 0.026115367
due O 0 0.0013047253
to O 0 0.0027408141
circulatory O 0 0.9089
depression B-Disease 0 0.9910493
. O 0 0.00859303

Cardiac B-Disease 0 0.9689947
toxicity I-Disease 2 0.99395293
observed O 0 0.0020925712
in O 0 0.0012143035
association O 0 0.0008981113
with O 0 0.0011725789
high O 0 0.0016381859
- O 0 0.0022137035
dose O 0 0.06259083
cyclophosphamide B-Chemical 1 0.99934334
- O 0 0.0040248344
based O 0 0.001714821
chemotherapy O 0 0.72929704
for O 0 0.002758691
metastatic O 0 0.9910806
breast B-Disease 2 0.9963415
cancer I-Disease 2 0.9972735
. O 0 0.01595951

INTRODUCTION O 0 0.18648289
: O 0 0.0096809305
Cyclophosphamide B-Chemical 1 0.99781656
is O 0 0.0029389774
an O 0 0.0027334807
alkylating O 0 0.9914718
agent O 0 0.22429219
given O 0 0.0009866919
frequently O 0 0.0016861502
as O 0 0.0007522362
a O 0 0.001067855
component O 0 0.0013206116
of O 0 0.0019230099
many O 0 0.0030959286
conditioning O 0 0.03712335
regimens O 0 0.10705193
. O 0 0.007529489

In O 0 0.004256739
high O 0 0.0043954276
doses O 0 0.030002309
, O 0 0.0044085663
its O 0 0.0071091424
nonhematological O 0 0.9976997
dose O 0 0.24030422
- O 0 0.006761196
limiting O 0 0.0072267163
toxicity B-Disease 2 0.9932081
is O 0 0.022630855
cardiomyopathy B-Disease 2 0.99869055
. O 0 0.015101182

STUDY O 0 0.031361204
DESIGN O 0 0.009581231
: O 0 0.002792172
We O 0 0.0013893923
combined O 0 0.0024475197
paclitaxel B-Chemical 1 0.9956821
, O 0 0.0039967475
melphalan B-Chemical 1 0.9992772
and O 0 0.001461439
high O 0 0.0014952159
- O 0 0.001650839
dose O 0 0.055078506
cyclophosphamide B-Chemical 1 0.999668
, O 0 0.005509227
thiotepa B-Chemical 0 0.9996575
, O 0 0.0014318641
and O 0 0.00064435985
carboplatin B-Chemical 1 0.9983462
in O 0 0.0003598239
a O 0 0.00033629235
triple O 0 0.0005090776
sequential O 0 0.0008450051
high O 0 0.0007345194
- O 0 0.0008585218
dose O 0 0.0063509224
regimen O 0 0.0045025093
for O 0 0.0005648001
patients O 0 0.0029823964
with O 0 0.0029035264
metastatic O 0 0.9912083
breast B-Disease 2 0.9967841
cancer I-Disease 2 0.99762577
. O 0 0.014278879

Analysis O 0 0.007321153
was O 0 0.0022520726
performed O 0 0.0014581104
on O 0 0.000893764
61 O 0 0.001822293
women O 0 0.0045121782
with O 0 0.001164092
chemotherapy O 0 0.7506307
- O 0 0.0018876302
responsive O 0 0.0014680603
metastatic O 0 0.98229295
breast B-Disease 2 0.99814916
cancer I-Disease 2 0.9992761
receiving O 0 0.05590143
96 O 0 0.0024485458
- O 0 0.00069651764
h O 0 0.00039910903
infusional O 0 0.97949284
cyclophosphamide B-Chemical 1 0.99960345
as O 0 0.0003346111
part O 0 0.00019709385
of O 0 0.00027560658
a O 0 0.00024739886
triple O 0 0.00039512498
sequential O 0 0.0006943325
high O 0 0.00056694617
- O 0 0.0005764856
dose O 0 0.004879007
regimen O 0 0.002474748
to O 0 0.00015670896
assess O 0 7.881533e-05
association O 0 0.00013382724
between O 0 0.00010421631
presence O 0 0.00020228581
of O 0 0.00040650705
peritransplant O 0 0.78470606
congestive B-Disease 0 0.99988306
heart I-Disease 0 0.9651329
failure I-Disease 0 0.95500344
( O 0 0.00812399
CHF B-Disease 2 0.9997733
) O 0 0.0014646567
and O 0 0.0002920094
the O 0 0.00020837264
following O 0 0.00026943523
pretreatment O 0 0.07141867
characteristics O 0 0.0004943753
: O 0 0.00046671144
presence O 0 0.00025425313
of O 0 0.00050850364
electrocardiogram O 0 0.9234364
( O 0 0.0011362612
EKG O 0 0.8600443
) O 0 0.0010264863
abnormalities O 0 0.090049766
, O 0 0.00050099613
age O 0 0.0011247847
, O 0 0.0007380529
hypertension B-Disease 2 0.9994856
, O 0 0.00055100035
prior O 0 0.00021003201
cardiac O 0 0.13564388
history O 0 0.022457471
, O 0 0.0007985035
smoking O 1 0.8333351
, O 0 0.0014946379
diabetes B-Disease 2 0.9978448
mellitus I-Disease 0 0.99924505
, O 0 0.0007577877
prior O 0 0.00025041515
use O 0 0.00047284635
of O 0 0.0009208737
anthracyclines B-Chemical 0 0.99932873
, O 0 0.0017255388
and O 0 0.0011991548
left O 0 0.00420339
- O 0 0.0037024023
sided O 0 0.3954658
chest O 0 0.4666448
irradiation O 0 0.18399188
. O 0 0.007427582

RESULTS O 0 0.024090553
: O 0 0.004341784
Six O 0 0.0027534135
of O 0 0.0018291693
61 O 0 0.0025209468
women O 0 0.0073380135
( O 0 0.0013396912
10 O 0 0.0007597568
% O 0 0.0006948847
) O 0 0.000746083
developed O 0 0.0008485545
clinically O 0 0.029120274
reversible O 0 0.24987921
grade O 0 0.2695405
3 O 0 0.00071288133
CHF B-Disease 2 0.9993399
following O 0 0.0009941747
infusional O 0 0.99558145
cyclophosphamide B-Chemical 1 0.9996501
with O 0 0.0010636846
a O 0 0.00049691286
median O 0 0.0003560506
percent O 0 0.00033720842
decline O 0 0.0011245892
in O 0 0.0006243527
ejection O 0 0.3899554
fraction O 0 0.0015339616
of O 0 0.0027812822
31 O 0 0.0050757253
% O 0 0.0047093243
. O 0 0.004825168

Incidence O 0 0.08607509
of O 0 0.0048293457
transient O 0 0.13737789
cyclophosphamide B-Chemical 1 0.9990589
- O 0 0.008606185
related O 0 0.0016359432
cardiac B-Disease 2 0.9429692
toxicity I-Disease 2 0.99878067
( O 0 0.0025877315
10 O 0 0.0009324579
% O 0 0.00083123223
) O 0 0.0009282668
is O 0 0.00058296666
comparable O 0 0.0005495923
to O 0 0.0009337091
previous O 0 0.0017222924
recorded O 0 0.0035308795
literature O 0 0.008491174
. O 0 0.0062928386

Older O 0 0.043855984
age O 0 0.004439625
was O 0 0.0017522615
significantly O 0 0.0014103047
correlated O 0 0.0008126082
with O 0 0.0010485827
the O 0 0.0011286287
CHF B-Disease 2 0.9993179
development O 0 0.010183596
; O 0 0.001209457
with O 0 0.00043644066
median O 0 0.00031615162
ages O 0 0.00037162128
for O 0 0.000199368
the O 0 0.00022510039
entire O 0 0.00021205918
group O 0 0.00036804084
and O 0 0.000338972
for O 0 0.00033102633
patients O 0 0.0019808477
developing O 0 0.013801452
CHF B-Disease 2 0.9991716
of O 0 0.0017029649
45 O 0 0.001278691
and O 0 0.0013935998
59 O 0 0.003218437
, O 0 0.0031581887
respectively O 0 0.0064953435
. O 0 0.0051963814

No O 0 0.009414101
association O 0 0.004408131
was O 0 0.0044484576
found O 0 0.0041491627
with O 0 0.005389269
other O 0 0.0070389616
pretreatment O 0 0.25015673
characteristics O 0 0.01456604
. O 0 0.013171516

CONCLUSIONS O 0 0.7110224
: O 0 0.004983892
As O 0 0.0012817321
a O 0 0.0013575972
result O 0 0.00090365
of O 0 0.0010847914
these O 0 0.0012536531
findings O 0 0.00217661
, O 0 0.0011421568
oncologists O 0 0.0018714453
should O 0 0.00045332868
carefully O 0 0.0005383342
monitor O 0 0.0007321443
fluid O 0 0.006084981
balance O 0 0.0042762
in O 0 0.0020995273
older O 0 0.008190567
patients O 0 0.010810123
. O 0 0.006441007

Routine O 0 0.014435582
EKG O 0 0.28498712
monitoring O 0 0.004991007
during O 0 0.003343892
infusional O 0 0.98744977
cyclophosphamide B-Chemical 1 0.99824345
did O 0 0.004973135
not O 0 0.0038668865
predict O 0 0.0065051294
CHF B-Disease 2 0.99657476
development O 0 0.053196553
. O 0 0.012167081

Tremor B-Disease 0 0.9534128
side O 0 0.027424805
effects O 0 0.0062787947
of O 0 0.005519378
salbutamol B-Chemical 1 0.998201
, O 0 0.005230099
quantified O 0 0.0025533547
by O 0 0.0027931305
a O 0 0.0037909604
laser O 0 0.024453444
pointer O 0 0.016834153
technique O 0 0.015825327
. O 0 0.010612903

OBJECTIVE O 0 0.50459886
: O 0 0.004771593
To O 0 0.0017630355
study O 0 0.0030033705
tremor B-Disease 0 0.9974045
side O 0 0.042395677
effects O 0 0.0028274388
of O 0 0.0020305214
salbutamol B-Chemical 1 0.99938786
an O 0 0.0019546507
easily O 0 0.0011685097
applicable O 0 0.0006929959
, O 0 0.0007249642
quick O 0 0.0019748784
and O 0 0.0008115855
low O 0 0.0014254681
- O 0 0.002409252
priced O 0 0.030411106
method O 0 0.0031799823
is O 0 0.0028371774
needed O 0 0.0032893426
. O 0 0.005766635

A O 0 0.013594364
new O 0 0.004254831
method O 0 0.0036756718
using O 0 0.0019567693
a O 0 0.0021954316
commercially O 0 0.0052865767
available O 0 0.0021250239
, O 0 0.0025570004
pen O 0 0.0065922914
- O 0 0.0033050426
shaped O 0 0.0038460298
laser O 0 0.01665501
pointer O 0 0.010501214
was O 0 0.005399666
developed O 0 0.011756627
. O 0 0.009573026

Aim O 0 0.048000224
of O 0 0.0028083313
the O 0 0.0016665354
study O 0 0.0018336435
was O 0 0.000972198
to O 0 0.0007011717
determine O 0 0.00038547095
sensitivity O 0 0.0014681511
, O 0 0.00086354197
reproducibility O 0 0.0008793653
, O 0 0.0007597039
reference O 0 0.00056929846
values O 0 0.00059786707
and O 0 0.0007674994
the O 0 0.00088086387
agreement O 0 0.0016549943
with O 0 0.0021677443
a O 0 0.003497
questionnaire O 0 0.0054335254
. O 0 0.006076807

METHODS O 0 0.01419226
: O 0 0.009832781
Tremor B-Disease 0 0.7746548
was O 0 0.003893746
measured O 0 0.0027638264
using O 0 0.0033838572
a O 0 0.0053586154
laser O 0 0.023209633
pointer O 0 0.020819709
technique O 0 0.020608766
. O 0 0.014422561

To O 0 0.0024882534
determine O 0 0.0011355394
sensitivity O 0 0.0023454877
we O 0 0.00079136377
assessed O 0 0.0011386847
tremor B-Disease 0 0.9976719
in O 0 0.0009522402
44 O 0 0.0011901389
patients O 0 0.0016600838
with O 0 0.001225495
obstructive B-Disease 0 0.99828315
lung I-Disease 0 0.7714288
disease I-Disease 0 0.9263585
after O 0 0.00066443277
administration O 0 0.07358778
of O 0 0.0014309536
cumulative O 0 0.008841389
doses O 0 0.15297234
of O 0 0.013056651
salbutamol B-Chemical 1 0.9984446
. O 0 0.0107883215

Subjects O 0 0.005692327
were O 0 0.0019667065
asked O 0 0.0011554242
to O 0 0.0010016805
aim O 0 0.0009142015
at O 0 0.0004960092
the O 0 0.0005503761
centre O 0 0.00068664795
of O 0 0.00075753115
a O 0 0.00074296014
target O 0 0.00068269216
, O 0 0.0008796019
subdivided O 0 0.001037824
in O 0 0.0006162282
concentric O 0 0.07094106
circles O 0 0.0009764299
, O 0 0.0014918844
from O 0 0.0013361559
5 O 0 0.0017362399
m O 0 0.005861436
distance O 0 0.005019597
. O 0 0.0058517884

The O 0 0.0035393806
circle O 0 0.0036377856
in O 0 0.001929493
which O 0 0.0019727582
the O 0 0.001289241
participant O 0 0.0012030716
succeeded O 0 0.0034942362
to O 0 0.0012136387
aim O 0 0.0014397454
was O 0 0.0013815614
recorded O 0 0.002128509
in O 0 0.00245023
millimetres O 0 0.007918103
radius O 0 0.019187422
. O 0 0.0081884395

In O 0 0.0025933709
another O 0 0.0018917486
series O 0 0.0019594438
of O 0 0.001253233
measurements O 0 0.0008481369
, O 0 0.0008561143
reproducibility O 0 0.0007227055
and O 0 0.00048543682
reference O 0 0.0003959644
values O 0 0.00033940093
of O 0 0.00046586385
the O 0 0.0005172037
tremor B-Disease 0 0.9991054
was O 0 0.00043089315
assessed O 0 0.00023232748
in O 0 0.00021709313
65 O 0 0.0003374784
healthy O 0 0.0007842111
subjects O 0 0.00030055674
in O 0 0.0001377799
three O 0 9.857934e-05
sessions O 0 0.00023688107
, O 0 0.00027064295
at O 0 0.0001396763
9 O 0 0.0002093367
a O 0 0.00023806027
. O 0 0.00015711189
m O 0 0.000874211
. O 0 0.00015626238
, O 0 0.00027239602
4 O 0 0.00018104933
p O 0 0.0003049463
. O 0 0.00015487616
m O 0 0.0007717811
. O 0 0.00016220735
and O 0 0.00026790774
9 O 0 0.0002871956
a O 0 0.00034877597
. O 0 0.0002658422
m O 0 0.0013727426
. O 0 0.00037091394
, O 0 0.0008119096
respectively O 0 0.0015165197
, O 0 0.0012901833
1 O 0 0.0012932264
week O 0 0.0017040401
later O 0 0.002916554
. O 0 0.0044436054

Postural O 0 0.9453577
tremor B-Disease 0 0.9967572
was O 0 0.0025406808
measured O 0 0.0010200358
with O 0 0.0010833158
the O 0 0.0007532943
arm O 0 0.0010865404
horizontally O 0 0.0014540656
outstretched O 0 0.012846284
rest O 0 0.0015621352
tremor B-Disease 0 0.998923
with O 0 0.00078937167
the O 0 0.00039586984
arm O 0 0.0005774502
supported O 0 0.0004230846
by O 0 0.00037449703
an O 0 0.0005194351
armrest O 0 0.02333438
and O 0 0.0005217474
finally O 0 0.003588015
tremor B-Disease 0 0.9991924
was O 0 0.00046716185
measured O 0 0.00026216407
after O 0 0.00024402843
holding O 0 0.001132862
a O 0 0.0007298402
2 O 0 0.0008409946
- O 0 0.0014610437
kg O 0 0.0045224577
weight O 0 0.0044197445
until O 0 0.0019908983
exhaustion O 0 0.09192801
. O 0 0.00589773

Inter O 0 0.02799295
- O 0 0.0051898067
observer O 0 0.0041951225
variability O 0 0.0018116118
was O 0 0.0013779654
measured O 0 0.0009948427
in O 0 0.0011152421
a O 0 0.0014676118
series O 0 0.0024556748
of O 0 0.0025476024
10 O 0 0.0032091497
healthy O 0 0.009888581
subjects O 0 0.007764973
. O 0 0.0069633895

Tremor B-Disease 0 0.9037496
was O 0 0.006132812
measured O 0 0.0037219704
simultaneously O 0 0.0046912087
by O 0 0.004526762
two O 0 0.0042980677
independent O 0 0.0057041976
observers O 0 0.015798584
. O 0 0.01353824

RESULTS O 0 0.06451051
: O 0 0.009475186
Salbutamol B-Chemical 0 0.9968892
significantly O 0 0.0039945296
increased O 0 0.0050839456
tremor B-Disease 0 0.9987105
severity O 0 0.102048956
in O 0 0.0013652737
patients O 0 0.0031475078
in O 0 0.0011608585
a O 0 0.0019191112
dose O 0 0.029087216
- O 0 0.004409588
dependent O 0 0.0032871733
way O 0 0.00669684
. O 0 0.0068678157

Within O 0 0.0028572814
healthy O 0 0.005760345
adults O 0 0.0032166294
no O 0 0.0011047485
age O 0 0.0023170335
- O 0 0.0015354069
dependency O 0 0.001549211
could O 0 0.0005456595
be O 0 0.0006351685
found O 0 0.00057495956
( O 0 0.0008035141
b O 0 0.0010536521
= O 0 0.0008313403
0 O 0 0.0004840417
. O 0 0.00028840042
262 O 0 0.0027169613
mm O 0 0.0020898667
/ O 0 0.0010742387
year O 0 0.0008416321
; O 0 0.0015578246
P O 0 0.016831417
= O 0 0.0017669852
0 O 0 0.0013811521
. O 0 0.0011857247
72 O 0 0.0027905235
) O 0 0.0051989276
. O 0 0.005085086

There O 0 0.0052012024
was O 0 0.0022335483
no O 0 0.0012720586
agreement O 0 0.0014413875
between O 0 0.0006379702
the O 0 0.0007842126
questionnaire O 0 0.0010579934
and O 0 0.0013055836
tremor B-Disease 0 0.99890244
severity O 0 0.12685566
( O 0 0.0015440264
r O 0 0.000989721
= O 0 0.0010019009
0 O 0 0.0006577204
. O 0 0.00047036773
093 O 0 0.015248945
; O 0 0.0016142429
P O 0 0.014760935
= O 0 0.0018749482
0 O 0 0.0015030103
. O 0 0.0013302636
53 O 0 0.0043979655
) O 0 0.005760891
. O 0 0.0054100165

Postural O 0 0.944748
tremor B-Disease 0 0.9965479
showed O 0 0.0027233982
no O 0 0.0011883557
significant O 0 0.0011967506
difference O 0 0.0005461372
between O 0 0.00041098995
the O 0 0.00053568755
first O 0 0.0004990931
and O 0 0.0006777792
third O 0 0.0008693326
session O 0 0.001332996
( O 0 0.0018268959
P O 0 0.025782
= O 0 0.0023557623
0 O 0 0.0018521883
. O 0 0.0016827895
07 O 0 0.009188526
) O 0 0.0067281625
. O 0 0.0060089366

Support O 0 0.012698904
of O 0 0.00396072
the O 0 0.0026549513
arm O 0 0.00362763
decreased O 0 0.0071082
tremor B-Disease 0 0.99845254
severity O 0 0.20622674
, O 0 0.0044414923
exhaustion O 0 0.29200506
increased O 0 0.014864328
tremor B-Disease 0 0.9984567
severity O 0 0.3370781
significantly O 0 0.012355171
. O 0 0.00864386

A O 0 0.012218671
good O 0 0.0031181152
agreement O 0 0.0023532207
was O 0 0.001344736
found O 0 0.00091985916
between O 0 0.0004926945
two O 0 0.0005111863
independent O 0 0.00053528685
observers O 0 0.0015465122
( O 0 0.0012103837
interclass O 0 0.0017721358
correlation O 0 0.000835714
coefficient O 0 0.002719249
0 O 0 0.002035428
. O 0 0.0015674969
72 O 0 0.003458131
) O 0 0.0061417236
. O 0 0.005786229

DISCUSSION O 0 0.02498535
: O 0 0.00464137
Quantifying O 0 0.006519882
tremor B-Disease 0 0.9962863
by O 0 0.001834639
using O 0 0.00094038417
an O 0 0.0010593992
inexpensive O 0 0.0074881148
laser O 0 0.0148754595
pointer O 0 0.0036724915
is O 0 0.0007095636
, O 0 0.000640875
with O 0 0.000472328
the O 0 0.0003568381
exception O 0 0.00037012625
of O 0 0.0006140197
children O 0 0.0018907395
( O 0 0.0007546074
< O 0 0.00053373195
12 O 0 0.00034172868
years O 0 0.00084685534
) O 0 0.00089908525
a O 0 0.00080642785
sensitive O 0 0.0011736875
and O 0 0.0016779309
reproducible O 0 0.004612958
method O 0 0.006529502
. O 0 0.0060573835

Safety O 0 0.034783404
and O 0 0.0044386555
adverse O 0 0.3218545
effects O 0 0.00434948
associated O 0 0.0029127044
with O 0 0.0036958964
raloxifene B-Chemical 0 0.9989042
: O 0 0.0044498197
multiple O 0 0.0034859676
outcomes O 0 0.0051543606
of O 0 0.006540829
raloxifene B-Chemical 0 0.9979513
evaluation O 0 0.020141415
. O 0 0.009846779

OBJECTIVE O 0 0.45665374
: O 0 0.004053044
To O 0 0.0012962148
examine O 0 0.0007561208
the O 0 0.00088428485
effect O 0 0.0010607102
of O 0 0.0015827157
raloxifene B-Chemical 0 0.9990621
on O 0 0.00067212956
major O 0 0.0013787767
adverse O 0 0.72077864
events O 0 0.008316707
that O 0 0.00057393056
occur O 0 0.0009372815
with O 0 0.0016861318
postmenopausal O 0 0.99519086
estrogen B-Chemical 1 0.9988355
therapy O 0 0.41184908
or O 0 0.0073859696
tamoxifen B-Chemical 1 0.99609417
. O 0 0.010193031

METHODS O 0 0.006690303
: O 0 0.0033668992
The O 0 0.0015257129
Multiple O 0 0.005085288
Outcomes O 0 0.004305888
of O 0 0.0024287237
Raloxifene B-Chemical 1 0.9994247
Evaluation O 0 0.01300131
, O 0 0.0011131994
a O 0 0.00074691925
multicenter O 0 0.036738835
, O 0 0.0006768213
randomized O 0 0.0008005984
, O 0 0.0005290439
double O 0 0.00038995076
- O 0 0.00075042836
blind O 0 0.0019831578
trial O 0 0.0010677939
, O 0 0.00069694925
enrolled O 0 0.0011007624
7 O 0 0.0005880444
, O 0 0.0010249083
705 O 0 0.015059855
postmenopausal O 0 0.9681778
women O 0 0.082229964
with O 0 0.007899575
osteoporosis B-Disease 2 0.9966119
. O 0 0.010878177

Women O 0 0.01225609
were O 0 0.0021506594
randomly O 0 0.001036195
assigned O 0 0.0013590681
to O 0 0.0015417102
raloxifene B-Chemical 0 0.99777067
60 O 0 0.0022848034
mg O 0 0.4049948
/ O 0 0.0022497785
d O 0 0.0011204233
or O 0 0.00075683766
120 O 0 0.0017389286
mg O 0 0.18756208
/ O 0 0.0032679788
d O 0 0.0025700682
or O 0 0.0028208846
placebo O 0 0.18438096
. O 0 0.006544037

Outcomes O 0 0.010984238
included O 0 0.0041620014
venous B-Disease 0 0.6732129
thromboembolism I-Disease 0 0.99906343
, O 0 0.014021796
cataracts B-Disease 2 0.9968675
, O 0 0.0081207985
gallbladder B-Disease 2 0.9904677
disease I-Disease 2 0.98714244
, O 0 0.0051216003
and O 0 0.004078562
endometrial B-Disease 0 0.9928717
hyperplasia I-Disease 0 0.99731016
or I-Disease 0 0.015528581
cancer I-Disease 2 0.9901612
. O 0 0.013137014

RESULTS O 0 0.022770708
: O 0 0.0036381367
During O 0 0.0012598681
a O 0 0.0011745398
mean O 0 0.00066265324
follow O 0 0.0008796766
- O 0 0.0010931758
up O 0 0.0005228818
of O 0 0.00059191766
3 O 0 0.00040821993
. O 0 0.00023047946
3 O 0 0.00024995476
years O 0 0.0005499143
, O 0 0.00054596446
raloxifene B-Chemical 0 0.9991491
was O 0 0.00041740248
associated O 0 0.00046700565
with O 0 0.00039822294
an O 0 0.00042693206
increased O 0 0.0006800058
risk O 0 0.021255128
for O 0 0.00042955347
venous B-Disease 0 0.876535
thromboembolism I-Disease 0 0.9998816
( O 0 0.0015308834
relative O 0 0.00033243845
risk O 0 0.05631153
[ O 0 0.0040871636
RR O 0 0.62543297
] O 0 0.0011473694
2 O 0 0.0002855811
. O 0 0.00015368927
1 O 0 0.00023994708
; O 0 0.00034344647
95 O 0 0.0004579282
% O 0 0.00023084982
confidence O 0 0.0005988919
interval O 0 0.0006381928
[ O 0 0.0012000169
CI O 0 0.1278908
] O 0 0.001069918
1 O 0 0.00052604993
. O 0 0.00037809883
2 O 0 0.0006974446
- O 0 0.0012256457
3 O 0 0.00092661794
. O 0 0.0010136487
8 O 0 0.0021204837
) O 0 0.004591418
. O 0 0.0045583546

The O 0 0.0029384785
excess O 0 0.0032795735
event O 0 0.003836937
rate O 0 0.0013237447
was O 0 0.0010586012
1 O 0 0.0007858483
. O 0 0.00037219818
8 O 0 0.00035290731
per O 0 0.00021476155
1 O 0 0.00033819088
, O 0 0.00036695984
000 O 0 0.0004025733
woman O 0 0.0033462148
- O 0 0.0006073655
years O 0 0.0006497536
( O 0 0.0004232139
95 O 0 0.0007004785
% O 0 0.0003746856
CI O 0 0.06713741
- O 0 0.0004672082
0 O 0 0.00027686867
. O 0 0.00014111366
5 O 0 0.00019348583
- O 0 0.00031581757
4 O 0 0.00017121607
. O 0 0.00012386992
1 O 0 0.00021183121
) O 0 0.00031850592
, O 0 0.00022590089
and O 0 0.00017751091
the O 0 0.00015289382
number O 0 0.00014957973
needed O 0 0.00013639718
to O 0 0.00020897851
treat O 0 0.0013528577
to O 0 0.0002938148
cause O 0 0.0012022554
1 O 0 0.00034686364
event O 0 0.0010829835
was O 0 0.00031157857
170 O 0 0.0013959722
( O 0 0.00046172205
95 O 0 0.0007988997
% O 0 0.00045203976
CI O 0 0.034849264
100 O 0 0.0009160025
- O 0 0.0009071628
582 O 0 0.0075438526
) O 0 0.00095323694
over O 0 0.00046480392
3 O 0 0.0008768439
. O 0 0.0009208688
3 O 0 0.0017493289
years O 0 0.004516202
. O 0 0.0044314275

Risk O 0 0.03457706
in O 0 0.0026211045
the O 0 0.00227204
raloxifene B-Chemical 0 0.99785537
group O 0 0.0020638518
was O 0 0.0008183588
higher O 0 0.0005567988
than O 0 0.00031849832
in O 0 0.00031870976
the O 0 0.00033841596
placebo O 0 0.034818515
group O 0 0.00039770524
for O 0 0.00021548457
the O 0 0.00022450152
first O 0 0.00020738223
2 O 0 0.000258633
years O 0 0.00046716724
, O 0 0.00030789504
but O 0 0.00021411688
decreased O 0 0.00044256487
to O 0 0.00022805721
about O 0 0.0002156753
the O 0 0.00023074288
same O 0 0.0001839662
rate O 0 0.00037274888
as O 0 0.00041523678
in O 0 0.00059813884
the O 0 0.0010205184
placebo O 0 0.107882604
group O 0 0.0032934693
thereafter O 0 0.005628111
. O 0 0.005225871

Raloxifene B-Chemical 1 0.99748284
did O 0 0.0035525898
not O 0 0.0017269802
increase O 0 0.0014323688
risk O 0 0.016531672
for O 0 0.0014188116
cataracts B-Disease 2 0.9976311
( O 0 0.0033068622
RR O 0 0.5195275
0 O 0 0.0007509749
. O 0 0.0002837321
9 O 0 0.00036313335
; O 0 0.0004942754
95 O 0 0.000648274
% O 0 0.00035857302
CI O 0 0.022629583
0 O 0 0.00030261086
. O 0 0.00016127215
8 O 0 0.0002493359
- O 0 0.00038113783
1 O 0 0.00024128637
. O 0 0.00014675937
1 O 0 0.0002521848
) O 0 0.0004234833
, O 0 0.00043169424
gallbladder B-Disease 2 0.95070755
disease I-Disease 2 0.9776374
( O 0 0.0017218456
RR O 0 0.5425513
1 O 0 0.00037601314
. O 0 0.00016157968
0 O 0 0.00027033247
; O 0 0.00034484
95 O 0 0.000497002
% O 0 0.0002722553
CI O 0 0.021178948
0 O 0 0.00025082874
. O 0 0.00013654669
7 O 0 0.00019859849
- O 0 0.0003409303
1 O 0 0.00021934813
. O 0 0.00013261852
3 O 0 0.00020166743
) O 0 0.00043627055
, O 0 0.00047684435
endometrial B-Disease 0 0.9801844
hyperplasia I-Disease 0 0.9990375
( O 0 0.0030772213
RR O 0 0.6348228
1 O 0 0.00039656064
. O 0 0.00016304347
3 O 0 0.00020338781
; O 0 0.00035310266
95 O 0 0.00050322386
% O 0 0.00027253784
CI O 0 0.021241525
0 O 0 0.00024517794
. O 0 0.00013110504
4 O 0 0.00018802297
- O 0 0.0003212288
5 O 0 0.00017566365
. O 0 0.00012962415
1 O 0 0.00023437546
) O 0 0.00038419157
, O 0 0.00031990826
or O 0 0.0003252581
endometrial B-Disease 2 0.99811184
cancer I-Disease 2 0.99921775
( O 0 0.0039479146
RR O 0 0.6342958
0 O 0 0.0005037469
. O 0 0.00020249153
9 O 0 0.00030752897
; O 0 0.00047453228
95 O 0 0.0007288883
% O 0 0.00046141076
CI O 0 0.020858938
0 O 0 0.0005023307
. O 0 0.00034791068
3 O 0 0.0005863299
- O 0 0.001205213
2 O 0 0.001055362
. O 0 0.0010413289
7 O 0 0.0020188622
) O 0 0.0046236133
. O 0 0.004603232

CONCLUSION O 0 0.93298066
: O 0 0.011666127
Raloxifene B-Chemical 1 0.9984999
was O 0 0.0021758813
associated O 0 0.0016044397
with O 0 0.0011122369
an O 0 0.0010230946
increased O 0 0.0012355497
risk O 0 0.021911029
for O 0 0.0007388688
venous B-Disease 0 0.8775072
thromboembolism I-Disease 0 0.9998394
, O 0 0.0018194052
but O 0 0.0004091078
there O 0 0.00020927501
was O 0 0.00028838473
no O 0 0.00022962948
increased O 0 0.00063964026
risk O 0 0.022713784
for O 0 0.0006921759
cataracts B-Disease 2 0.9986523
, O 0 0.004013803
gallbladder B-Disease 2 0.99525285
disease I-Disease 2 0.9944865
, O 0 0.013188744
endometrial B-Disease 0 0.99701726
hyperplasia I-Disease 0 0.99876934
, O 0 0.010334129
or O 0 0.0046524946
endometrial B-Disease 2 0.9972005
cancer I-Disease 2 0.9970612
. O 0 0.013751902

LEVEL O 0 0.48469543
OF O 0 0.19467925
EVIDENCE O 0 0.5035591
: O 0 0.07338767
I O 0 0.108093105

Optimization O 0 0.052057233
of O 0 0.038202427
levodopa B-Chemical 1 0.99343383
therapy O 0 0.54567426
. O 0 0.03993207

While O 0 0.0034748588
there O 0 0.001529865
is O 0 0.001333554
no O 0 0.00075072236
single O 0 0.000734422
correct O 0 0.00067211705
starting O 0 0.00068812654
dose O 0 0.008244391
for O 0 0.00065014325
levodopa B-Chemical 1 0.9997266
therapy O 0 0.1041754
, O 0 0.00072729524
many O 0 0.00040919165
individuals O 0 0.00048076443
can O 0 0.00023378314
be O 0 0.00023888174
started O 0 0.00029063702
on O 0 0.00012803567
either O 0 0.00020894941
the O 0 0.00022093365
25 O 0 0.00044668032
/ O 0 0.0005055995
100 O 0 0.0004224823
or O 0 0.00016809373
controlled O 0 0.00029858807
- O 0 0.0006050386
release O 0 0.01613634
formula O 0 0.01144258
, O 0 0.00034222752
following O 0 0.00021482505
the O 0 0.0001837709
general O 0 0.00024322799
rule O 0 0.00044861162
not O 0 0.00020266537
to O 0 0.00020783373
attempt O 0 0.00033643038
to O 0 0.00027479685
titrate O 0 0.0074791047
carbidopa B-Chemical 0 0.999928
- O 0 0.008376262
levodopa B-Chemical 1 0.999759
to O 0 0.0004110303
the O 0 0.0002977137
point O 0 0.00030533204
of O 0 0.00054274575
" O 0 0.0007664191
normality O 0 0.010206396
, O 0 0.0010949778
" O 0 0.0010927769
which O 0 0.0013309319
can O 0 0.0013554498
lead O 0 0.014839231
to O 0 0.0044872984
toxicity B-Disease 2 0.9876101
. O 0 0.008545712

The O 0 0.002867797
physician O 0 0.004344395
should O 0 0.0010158877
also O 0 0.0009003026
determine O 0 0.00038089885
the O 0 0.0004948803
proper O 0 0.00052804657
use O 0 0.00060094777
of O 0 0.00057868747
any O 0 0.0004216854
adjunctive O 0 0.04245201
medications O 0 0.67657304
; O 0 0.0011063705
such O 0 0.000406213
combined O 0 0.00096243864
therapy O 0 0.013773707
has O 0 0.0007114842
become O 0 0.0010229195
the O 0 0.00069553463
standard O 0 0.0008955951
approach O 0 0.0021624663
to O 0 0.0024332104
treatment O 0 0.0088434005
. O 0 0.0063320235

Following O 0 0.003236677
the O 0 0.0016956475
initial O 0 0.0012790833
period O 0 0.0009989785
of O 0 0.0011039233
therapy O 0 0.0093395915
, O 0 0.0009486186
emerging O 0 0.00094204675
difficulties O 0 0.0024007622
require O 0 0.00033695583
a O 0 0.00042029627
reassessment O 0 0.002508534
of O 0 0.0005173538
therapeutic O 0 0.009315718
approaches O 0 0.0012759494
, O 0 0.00055300706
such O 0 0.00036426884
as O 0 0.0003605546
dosage O 0 0.03207373
adjustment O 0 0.00094846264
or O 0 0.0006126515
introduction O 0 0.0010216741
of O 0 0.0019618883
a O 0 0.005123649
dopamine B-Chemical 1 0.99797064
agonist O 0 0.9828703
. O 0 0.009034787

Other O 0 0.01012924
possible O 0 0.0038313803
adverse O 0 0.48933795
effects O 0 0.0069752666
- O 0 0.0034164493
- O 0 0.0016249161
such O 0 0.0007552584
as O 0 0.0008477022
gastrointestinal B-Disease 0 0.99723864
disorders I-Disease 0 0.99606776
, O 0 0.01807777
orthostatic B-Disease 2 0.99977523
hypotension I-Disease 2 0.999948
, O 0 0.022749692
levodopa B-Chemical 1 0.99989724
- O 0 0.005889661
induced O 0 0.0024254401
psychosis B-Disease 0 0.9995833
, O 0 0.0021976787
sleep B-Disease 0 0.9499236
disturbances I-Disease 0 0.946298
or O 0 0.00064524787
parasomnias B-Disease 0 0.99643916
, O 0 0.00060792174
or O 0 0.00031962138
drug O 0 0.20060308
interactions O 0 0.001734071
- O 0 0.0011978819
- O 0 0.00074639445
also O 0 0.00045101368
require O 0 0.00040967253
carefully O 0 0.0005923635
monitored O 0 0.00072647503
individual O 0 0.0016677513
treatment O 0 0.00736798
. O 0 0.005393239

Nonpharmacologic O 0 0.04998537
concerns O 0 0.0053086434
can O 0 0.001720023
help O 0 0.0018287592
the O 0 0.0014626879
Parkinson B-Disease 0 0.99721056
' I-Disease 0 0.0012709396
s I-Disease 0 0.0010192649
disease I-Disease 0 0.1790748
patient O 0 0.0008333128
achieve O 0 0.00033852743
and O 0 0.00031705084
maintain O 0 0.00023835392
optimal O 0 0.00023007198
functioning O 0 0.0014127996
, O 0 0.00041893742
including O 0 0.00031618058
daily O 0 0.0011273834
exercise O 0 0.014666645
, O 0 0.00064807205
physical O 0 0.0052263895
therapy O 0 0.013389126
, O 0 0.0009763127
and O 0 0.000887311
involvement O 0 0.0022810118
with O 0 0.0019298603
support O 0 0.002883564
groups O 0 0.0050428705
. O 0 0.0056862896

Long O 0 0.019143522
term O 0 0.0067614517
audiological O 0 0.017097775
evaluation O 0 0.007183415
of O 0 0.008630173
beta B-Disease 0 0.8195303
- I-Disease 0 0.038666394
thalassemic I-Disease 0 0.9862591
patients O 0 0.08717257
. O 0 0.015395778

OBJECTIVE O 0 0.4616092
: O 0 0.0037818037
The O 0 0.0012967341
objective O 0 0.0016524956
of O 0 0.0009562447
this O 0 0.00068400864
study O 0 0.0008971931
was O 0 0.00047207013
to O 0 0.00036001846
identify O 0 0.00031868427
the O 0 0.00034067544
incidence O 0 0.0021027015
and O 0 0.00039654874
to O 0 0.00028240404
monitor O 0 0.00025513218
the O 0 0.00031951384
progression O 0 0.10358273
of O 0 0.00080367766
hearing B-Disease 0 0.80494773
loss I-Disease 0 0.0018069947
in O 0 0.00042404296
children O 0 0.0013348558
and O 0 0.0006224615
young O 0 0.005390534
adults O 0 0.002241924
with O 0 0.0018684551
beta B-Disease 0 0.8254665
- I-Disease 0 0.034775577
thalassemia I-Disease 0 0.9984446
major O 0 0.0223919
. O 0 0.00841003

METHODS O 0 0.006504329
: O 0 0.003229949
One O 0 0.0019951807
hundred O 0 0.001709394
and O 0 0.0011555396
four O 0 0.00075171626
( O 0 0.0011783722
104 O 0 0.0014717045
) O 0 0.0009884471
patients O 0 0.0012132891
aged O 0 0.0009301854
6 O 0 0.00033330574
- O 0 0.00051806297
35 O 0 0.00036974874
years O 0 0.000553845
( O 0 0.00039712279
mean O 0 0.00023543846
17 O 0 0.0005704268
, O 0 0.0005423284
2 O 0 0.00050669536
years O 0 0.001029915
) O 0 0.0011886989
participated O 0 0.0026005544
in O 0 0.0013939854
the O 0 0.0023077673
study O 0 0.0056444854
. O 0 0.005759995

All O 0 0.0037132208
patients O 0 0.0041318666
were O 0 0.0016010138
on O 0 0.00085995696
a O 0 0.001121772
regular O 0 0.0016830203
transfusion O 0 0.11446339
- O 0 0.0022978827
chelation O 0 0.87275183
program O 0 0.00097419706
maintaining O 0 0.0008162138
a O 0 0.0006680313
mean O 0 0.00046410906
hemoglobin O 0 0.4131518
level O 0 0.0006265742
of O 0 0.001114047
9 O 0 0.0011118562
. O 0 0.00076746277
5 O 0 0.0013186383
gr O 0 0.012934444
/ O 0 0.006191306
dl O 0 0.024732593
. O 0 0.0062051695

Subjects O 0 0.0071253814
were O 0 0.0029916323
receiving O 0 0.013878819
desferrioxamine B-Chemical 1 0.9993956
( O 0 0.02745859
DFO B-Chemical 1 0.9994628
) O 0 0.010978614
chelation O 0 0.97100025
treatment O 0 0.0047345688
with O 0 0.00072962954
a O 0 0.00044750882
mean O 0 0.00022444526
daily O 0 0.00086238503
dose O 0 0.0043970323
of O 0 0.00048677996
50 O 0 0.0006926189
- O 0 0.0004963694
60 O 0 0.00034269423
mg O 0 0.13142996
/ O 0 0.0007426476
kg O 0 0.0027242932
, O 0 0.00032441976
5 O 0 0.00019526859
- O 0 0.0002618241
6 O 0 0.00010281543
days O 0 0.000109517554
a O 0 0.0001271183
week O 0 0.00011193944
during O 0 9.018032e-05
the O 0 0.00011570564
first O 0 0.00010502198
six O 0 9.764629e-05
years O 0 0.0002810918
of O 0 0.00020856764
the O 0 0.00019493168
study O 0 0.0004220246
, O 0 0.00032028175
which O 0 0.00031014564
was O 0 0.00022150822
then O 0 0.00019112107
reduced O 0 0.00026843807
to O 0 0.00027060788
40 O 0 0.0004464334
- O 0 0.00054563873
50 O 0 0.00060210214
mg O 0 0.11983355
/ O 0 0.0011089467
kg O 0 0.0020861905
for O 0 0.0004887699
the O 0 0.0007715429
following O 0 0.0013274185
eight O 0 0.0020420193
years O 0 0.0060768593
. O 0 0.0050481143

Patients O 0 0.014319574
were O 0 0.005143845
followed O 0 0.0039214934
for O 0 0.004423764
8 O 0 0.0056538545
- O 0 0.008177473
14 O 0 0.0074920645
years O 0 0.012228499
. O 0 0.010933991

RESULTS O 0 0.026562033
: O 0 0.004569147
Overall O 0 0.0031114966
, O 0 0.0017980104
21 O 0 0.0011523168
out O 0 0.00056161796
of O 0 0.0007648837
104 O 0 0.0013979857
patients O 0 0.0016535894
( O 0 0.00071090437
20 O 0 0.00046132892
. O 0 0.0002299084
2 O 0 0.00030625446
% O 0 0.00033828017
) O 0 0.00038738138
presented O 0 0.00028823025
with O 0 0.0003752475
high O 0 0.00062967493
frequency O 0 0.0014290825
sensorineural B-Disease 2 0.9995869
hearing I-Disease 2 0.9857159
loss I-Disease 2 0.08100363
( O 0 0.014568264
SNHL B-Disease 0 0.99959546
) O 0 0.0046671536
, O 0 0.0017590028
either O 0 0.0016824789
unilateral O 0 0.27040365
or O 0 0.0034598242
bilateral O 0 0.25273997
. O 0 0.006664283

No O 0 0.012060266
ototoxic B-Disease 0 0.98894715
factor O 0 0.0269654
, O 0 0.0031558673
other O 0 0.0018088365
than O 0 0.0015194583
DFO B-Chemical 1 0.9986633
, O 0 0.002470888
was O 0 0.0010936048
present O 0 0.00079960533
in O 0 0.0010270997
any O 0 0.0012190284
of O 0 0.0024461278
the O 0 0.0034072676
patients O 0 0.012664299
. O 0 0.0073290374

Patients O 0 0.012601123
with O 0 0.005072615
SNHL B-Disease 0 0.9979273
presented O 0 0.0023617381
with O 0 0.0014288871
relatively O 0 0.0013188582
lower O 0 0.001006507
serum O 0 0.118326016
ferritin O 0 0.9886673
levels O 0 0.000821542
than O 0 0.00036280032
those O 0 0.0005827844
with O 0 0.0005700388
normal O 0 0.0017088683
hearing O 0 0.747838
, O 0 0.0009750341
however O 0 0.0008857538
, O 0 0.00072777155
no O 0 0.0004825403
statistically O 0 0.00074594934
significant O 0 0.0011256547
difference O 0 0.00097236555
was O 0 0.0021372703
observed O 0 0.0031976742
. O 0 0.005560504

Subjects O 0 0.0124233635
with O 0 0.008348058
SNHL B-Disease 0 0.99615425
were O 0 0.0047091525
submitted O 0 0.00459796
to O 0 0.004511959
DFO B-Chemical 1 0.99681866
reduction O 0 0.011611188
or O 0 0.0058570527
temporary O 0 0.12378163
withdrawal O 0 0.8999347
. O 0 0.013012919

Following O 0 0.0043524336
intervention O 0 0.0033618992
, O 0 0.002351041
7 O 0 0.001076889
out O 0 0.0006693039
of O 0 0.0008829099
21 O 0 0.00089852774
affected O 0 0.0005623743
patients O 0 0.0013403128
recovered O 0 0.0005945841
, O 0 0.0008080802
10 O 0 0.00060829177
remained O 0 0.0008415722
stable O 0 0.0011557307
and O 0 0.0013304624
4 O 0 0.0016075247
demonstrated O 0 0.003394958
aggravation O 0 0.9026596
. O 0 0.007744258

CONCLUSION O 0 0.79496956
: O 0 0.0049822414
The O 0 0.0017858926
findings O 0 0.0025950684
are O 0 0.0013338869
indicative O 0 0.001145719
of O 0 0.002011082
DFO B-Chemical 1 0.998934
' O 0 0.001918086
s O 0 0.0013150463
contributing O 0 0.0011757755
role O 0 0.00065282825
in O 0 0.0008446866
the O 0 0.0011650614
development O 0 0.0035167097
of O 0 0.0047671394
hearing B-Disease 0 0.94903785
impairment I-Disease 0 0.80843884
. O 0 0.00917845

Regular O 0 0.018036593
audiologic O 0 0.054471962
evaluation O 0 0.002939574
is O 0 0.0014444271
imperative O 0 0.0014712673
in O 0 0.0007389793
all O 0 0.0007262559
thalassemic B-Disease 0 0.9457241
patients O 0 0.0029406294
so O 0 0.0004677051
that O 0 0.00033404763
early O 0 0.0008503218
changes O 0 0.00068475615
may O 0 0.00036462722
be O 0 0.00032643703
recognized O 0 0.00042028664
and O 0 0.00035762668
treatment O 0 0.00087388547
may O 0 0.00036313143
be O 0 0.00035432234
judiciously O 0 0.0015715222
adjusted O 0 0.0005632441
in O 0 0.00036992892
order O 0 0.0003557981
to O 0 0.0006000993
prevent O 0 0.0012370871
or O 0 0.0015216266
reverse O 0 0.079436675
hearing B-Disease 0 0.95692843
impairment I-Disease 0 0.80699825
. O 0 0.00778237

Individual O 0 0.0054029212
differences O 0 0.0022058662
in O 0 0.0024068705
renal O 0 0.9774507
ACE O 0 0.99666816
activity O 0 0.0034456619
in O 0 0.0011860025
healthy O 0 0.0046419115
rats O 0 0.0027772645
predict O 0 0.00095639867
susceptibility O 0 0.0047251056
to O 0 0.0022439526
adriamycin B-Chemical 1 0.99901223
- O 0 0.021087239
induced O 0 0.021938093
renal B-Disease 2 0.99731475
damage I-Disease 2 0.9891201
. O 0 0.013250848

BACKGROUND O 0 0.7515352
: O 0 0.005283313
In O 0 0.0021401786
man O 0 0.032427877
, O 0 0.0018906306
differences O 0 0.0008688788
in O 0 0.0012353844
angiotensin B-Chemical 1 0.99914443
- O 0 0.010268413
converting O 0 0.23138927
enzyme O 0 0.40596712
( O 0 0.0036179323
ACE O 0 0.99841
) O 0 0.0023626373
levels O 0 0.0005989125
, O 0 0.0006314583
related O 0 0.00036070606
to O 0 0.0006094211
ACE O 0 0.99799263
( O 0 0.002177159
I O 0 0.0059836647
/ O 0 0.0028666977
D O 0 0.3670595
) O 0 0.0013260064
genotype O 0 0.0016336023
, O 0 0.0011408661
are O 0 0.0009919084
associated O 0 0.001964825
with O 0 0.004301266
renal O 0 0.9918234
prognosis O 0 0.96385366
. O 0 0.00987988

This O 0 0.004148621
raises O 0 0.0014143627
the O 0 0.0013096904
hypothesis O 0 0.0013805189
that O 0 0.0007520592
individual O 0 0.0006883636
differences O 0 0.0006096238
in O 0 0.00092070695
renal O 0 0.99059707
ACE O 0 0.99842936
activity O 0 0.0027150963
are O 0 0.0010368692
involved O 0 0.0010174164
in O 0 0.0013855901
renal O 0 0.9792915
susceptibility O 0 0.036948767
to O 0 0.0047718356
inflicted O 0 0.83217114
damage O 0 0.90675175
. O 0 0.010015641

Therefore O 0 0.0034053477
, O 0 0.002546816
we O 0 0.0009350142
studied O 0 0.0013546357
the O 0 0.0008277226
predictive O 0 0.0013569947
effect O 0 0.0009442684
of O 0 0.0013729596
renal O 0 0.9951422
ACE O 0 0.9988858
activity O 0 0.0019166212
for O 0 0.00046120316
the O 0 0.0004882833
severity O 0 0.016832316
of O 0 0.0016298394
renal B-Disease 2 0.99891746
damage I-Disease 2 0.9842024
induced O 0 0.0024953363
by O 0 0.00075482385
a O 0 0.0007419504
single O 0 0.0008413899
injection O 0 0.003964981
of O 0 0.0030045887
adriamycin B-Chemical 1 0.9985366
in O 0 0.0048975814
rats O 0 0.036545694
. O 0 0.0062650996

METHODS O 0 0.0095831035
: O 0 0.006728599
Renal O 0 0.86733496
ACE O 0 0.9940257
activity O 0 0.0056221266
( O 0 0.003289915
Hip B-Chemical 0 0.3523013
- I-Chemical 0 0.0025841997
His I-Chemical 0 0.008113852
- I-Chemical 0 0.0021459493
Leu I-Chemical 0 0.8869607
cleavage O 0 0.002941162
by O 0 0.00065737637
cortical O 0 0.060454406
homogenates O 0 0.010932448
) O 0 0.0009217423
was O 0 0.0003901915
determined O 0 0.00034123645
by O 0 0.00068958255
renal O 0 0.9500059
biopsy O 0 0.01377309
in O 0 0.001040112
27 O 0 0.002227953
adult O 0 0.0025587282
male O 0 0.007889427
Wistar O 0 0.26472983
rats O 0 0.012154839
. O 0 0.006208246

After O 0 0.002430137
1 O 0 0.001846226
week O 0 0.0011891712
of O 0 0.0014099206
recovery O 0 0.0030390327
, O 0 0.0023609519
proteinuria B-Disease 2 0.99949205
was O 0 0.0013249983
induced O 0 0.0013064338
by O 0 0.0011785458
adriamycin B-Chemical 1 0.9995468
[ O 0 0.007693157
1 O 0 0.0004968456
. O 0 0.00019939974
5 O 0 0.00024897416
mg O 0 0.08839855
/ O 0 0.0007329065
kg O 0 0.0030195983
intravenously O 0 0.0043582562
( O 0 0.00047061665
i O 0 0.0008267802
. O 0 0.00021856294
v O 0 0.002863856
. O 0 0.00022021504
) O 0 0.00046738193
n O 0 0.00026060722
= O 0 0.00043216156
18 O 0 0.00030891475
; O 0 0.0004487928
controls O 0 0.00048299032
, O 0 0.0005592224
saline O 0 0.0358237
i O 0 0.0018167746
. O 0 0.0005352793
v O 0 0.0039112554
. O 0 0.00069784885
n O 0 0.0012313183
= O 0 0.002558049
9 O 0 0.0024921529
] O 0 0.006059644
. O 0 0.004735288

Proteinuria B-Disease 2 0.9914295
was O 0 0.011340202
measured O 0 0.0070148734
every O 0 0.0061300946
2 O 0 0.0095279375
weeks O 0 0.011494454
. O 0 0.01450947

After O 0 0.0033861478
12 O 0 0.0025544937
weeks O 0 0.0023996672
, O 0 0.0027810626
rats O 0 0.0041953535
were O 0 0.0019128988
sacrificed O 0 0.0023409128
and O 0 0.0024377704
their O 0 0.0035576546
kidneys O 0 0.022228448
harvested O 0 0.00659455
. O 0 0.008341953

RESULTS O 0 0.032139666
: O 0 0.0050878637
As O 0 0.0015504145
anticipated O 0 0.0021413045
, O 0 0.0029640517
adriamycin B-Chemical 1 0.9983966
elicited O 0 0.032116286
nephrotic B-Disease 2 0.9998466
range O 0 0.061333578
proteinuria B-Disease 2 0.9997725
, O 0 0.018268196
renal B-Disease 0 0.9975805
interstitial I-Disease 0 0.9571523
damage I-Disease 0 0.9749986
and O 0 0.007437868
mild O 0 0.94402456
focal B-Disease 0 0.9821421
glomerulosclerosis I-Disease 2 0.99958867
. O 0 0.027334075

Baseline O 0 0.021459294
renal O 0 0.9762288
ACE O 0 0.99410546
positively O 0 0.0026493978
correlated O 0 0.00095784856
with O 0 0.00091491966
the O 0 0.0005923414
relative O 0 0.0004559383
rise O 0 0.0011122968
in O 0 0.00074080203
proteinuria B-Disease 2 0.9996772
after O 0 0.0007582357
adriamycin B-Chemical 1 0.9996294
( O 0 0.0018312879
r O 0 0.0006844765
= O 0 0.000573997
0 O 0 0.00030566612
. O 0 0.00015624703
62 O 0 0.0004905768
, O 0 0.0003701522
P O 0 0.00781322
< O 0 0.00035370857
0 O 0 0.00028617936
. O 0 0.00017631188
01 O 0 0.0019176159
) O 0 0.0005253665
, O 0 0.00049335026
renal O 0 0.97282887
interstitial O 0 0.78655976
alpha O 0 0.68852603
- O 0 0.0030934878
smooth O 0 0.13153829
muscle O 0 0.18350407
actin O 0 0.06151397
( O 0 0.0007529189
r O 0 0.00045764452
= O 0 0.00044839573
0 O 0 0.0002591395
. O 0 0.00013718265
49 O 0 0.0003935017
, O 0 0.00033973326
P O 0 0.00777902
< O 0 0.00034385064
0 O 0 0.00028840068
. O 0 0.0001861819
05 O 0 0.01881794
) O 0 0.00056807784
, O 0 0.00047108164
interstitial O 0 0.29575986
macrophage O 0 0.4292722
influx O 0 0.7632022
( O 0 0.0010974298
r O 0 0.00053636864
= O 0 0.0004898902
0 O 0 0.0002680805
. O 0 0.0001363787
56 O 0 0.00032707187
, O 0 0.0003390913
P O 0 0.007504129
< O 0 0.00034463825
0 O 0 0.00028835726
. O 0 0.00018588318
05 O 0 0.017468547
) O 0 0.0005649894
, O 0 0.00046996618
interstitial O 0 0.25910434
collagen O 0 0.43207684
III O 0 0.059434295
( O 0 0.00070379634
r O 0 0.0004787648
= O 0 0.00047364546
0 O 0 0.00027309006
. O 0 0.00014404404
53 O 0 0.00044308158
, O 0 0.00036301618
P O 0 0.008074539
< O 0 0.00035779938
0 O 0 0.00029765774
. O 0 0.00019148769
05 O 0 0.018859042
) O 0 0.00059052685
, O 0 0.00050791225
glomerular O 0 0.7520576
alpha O 0 0.3790797
- O 0 0.001810118
smooth O 0 0.093792595
muscle O 0 0.15579653
actin O 0 0.055889424
( O 0 0.00075249
r O 0 0.0004635241
= O 0 0.00045467378
0 O 0 0.0002618216
. O 0 0.00013748278
74 O 0 0.0004067072
, O 0 0.00034385882
P O 0 0.0072296723
< O 0 0.0003440495
0 O 0 0.00028377998
. O 0 0.00017734239
01 O 0 0.0017362664
) O 0 0.00048363212
and O 0 0.00038937308
glomerular O 0 0.7000124
desmin O 0 0.54368305
( O 0 0.0011339092
r O 0 0.00070835993
= O 0 0.0007112328
0 O 0 0.00044922507
. O 0 0.0002792871
48 O 0 0.0005342838
, O 0 0.0008654468
P O 0 0.008449397
< O 0 0.0014337962
0 O 0 0.001550464
. O 0 0.0015844625
05 O 0 0.027708534
) O 0 0.0063580764
. O 0 0.0056973086

Baseline O 0 0.02559052
renal O 0 0.97999567
ACE O 0 0.99406934
did O 0 0.002630753
not O 0 0.001339135
correlate O 0 0.0012854327
with O 0 0.0018713332
focal B-Disease 0 0.8167049
glomerulosclerosis I-Disease 2 0.9998534
( O 0 0.01198208
r O 0 0.00230322
= O 0 0.0019498011
0 O 0 0.0012354191
. O 0 0.00090141327
22 O 0 0.0024012157
, O 0 0.0036166713
NS O 0 0.49045822
) O 0 0.008461495
. O 0 0.006524594

In O 0 0.0043576644
controls O 0 0.0041522724
, O 0 0.003135052
no O 0 0.0016842305
predictive O 0 0.0027991747
values O 0 0.001971369
for O 0 0.002372361
renal O 0 0.93773407
parameters O 0 0.007921399
were O 0 0.0051474143
observed O 0 0.0058078603
. O 0 0.008843199

CONCLUSION O 0 0.7953152
: O 0 0.004775802
Individual O 0 0.002731368
differences O 0 0.0011597167
in O 0 0.0013522769
renal O 0 0.9761671
ACE O 0 0.9973443
activity O 0 0.0020470445
predict O 0 0.0007392245
the O 0 0.0006882
severity O 0 0.01738445
of O 0 0.0023685882
adriamycin B-Chemical 1 0.99960834
- O 0 0.012122756
induced O 0 0.0060659195
renal B-Disease 2 0.99866116
damage I-Disease 2 0.9814792
in O 0 0.0016996167
this O 0 0.0017715985
outbred O 0 0.005972413
rat O 0 0.019230444
strain O 0 0.0049023204
. O 0 0.006213399

This O 0 0.0044121887
supports O 0 0.0021731092
the O 0 0.0015208928
assumption O 0 0.0016585047
that O 0 0.00089659414
differences O 0 0.00073690695
in O 0 0.0010585765
renal O 0 0.99060833
ACE O 0 0.9984706
activity O 0 0.003415487
predispose O 0 0.011187385
to O 0 0.00078885385
a O 0 0.0008877004
less O 0 0.0009191074
favourable O 0 0.004683485
course O 0 0.00302264
of O 0 0.006261818
renal B-Disease 2 0.9967206
damage I-Disease 2 0.98745257
. O 0 0.012417369

Recurrent O 0 0.8355697
acute O 0 0.9766241
interstitial B-Disease 2 0.987305
nephritis I-Disease 2 0.9990834
induced O 0 0.09470004
by O 0 0.028247165
azithromycin B-Chemical 1 0.9945221
. O 0 0.022088207

A O 0 0.01909538
14 O 0 0.0041564945
- O 0 0.003304526
year O 0 0.0018633762
- O 0 0.0020193576
old O 0 0.001295531
girl O 0 0.0031624956
is O 0 0.0008663507
reported O 0 0.001201651
with O 0 0.0012918899
recurrent O 0 0.5587205
, O 0 0.0046860683
azithromycin B-Chemical 1 0.99896395
- O 0 0.007010475
induced O 0 0.0038057067
, O 0 0.006125381
acute O 0 0.99136955
interstitial B-Disease 2 0.995539
nephritis I-Disease 2 0.99963355
. O 0 0.02547948

The O 0 0.0026438974
second O 0 0.0019847683
episode O 0 0.004871558
was O 0 0.0012927393
more O 0 0.0012930494
severe O 0 0.028917361
than O 0 0.00046450854
the O 0 0.00045209858
first O 0 0.00041839303
; O 0 0.00075761956
and O 0 0.00037974733
although O 0 0.0003222767
both O 0 0.000301872
were O 0 0.00032757147
treated O 0 0.0005879356
with O 0 0.0005074373
intensive O 0 0.0012970569
corticosteroid O 0 0.9986014
therapy O 0 0.2327925
, O 0 0.0036531654
renal O 0 0.9854211
function O 0 0.0042439867
remained O 0 0.0056584114
impaired O 0 0.011038201
. O 0 0.006213591

Although O 0 0.0035694388
most O 0 0.0030864037
cases O 0 0.0026948059
of O 0 0.0019784989
antibiotic O 0 0.2553052
induced O 0 0.005632537
acute O 0 0.9925997
interstitial B-Disease 2 0.9970796
nephritis I-Disease 2 0.99993575
are O 0 0.0061000185
benign O 0 0.94704914
and O 0 0.000916281
self O 0 0.00778536
- O 0 0.0008388978
limited O 0 0.0004121265
, O 0 0.0005127227
some O 0 0.00047748073
patients O 0 0.0011558132
are O 0 0.0005716945
at O 0 0.0005073125
risk O 0 0.008538783
for O 0 0.0016100215
permanent O 0 0.188727
renal B-Disease 2 0.99711764
injury I-Disease 2 0.9936712
. O 0 0.011393526

Spironolactone B-Chemical 0 0.99815375
- O 0 0.013887802
induced O 0 0.007103521
renal B-Disease 0 0.9918778
insufficiency I-Disease 0 0.99713576
and O 0 0.011112865
hyperkalemia B-Disease 2 0.9995468
in O 0 0.0035355284
patients O 0 0.009886686
with O 0 0.005747058
heart B-Disease 0 0.767904
failure I-Disease 0 0.8356283
. O 0 0.010698692

BACKGROUND O 0 0.75030553
: O 0 0.0047815423
A O 0 0.005149187
previous O 0 0.0011014194
randomized O 0 0.001215646
controlled O 0 0.0006905684
trial O 0 0.00094999286
evaluating O 0 0.00038572756
the O 0 0.00042826275
use O 0 0.0005955694
of O 0 0.0009370986
spironolactone B-Chemical 1 0.9998386
in O 0 0.00094901
heart B-Disease 0 0.6659144
failure I-Disease 0 0.6728528
patients O 0 0.0050593526
reported O 0 0.0006979293
a O 0 0.0003800258
low O 0 0.00053082925
risk O 0 0.024196483
of O 0 0.0021558593
hyperkalemia B-Disease 2 0.99989605
( O 0 0.0021186331
2 O 0 0.00060004886
% O 0 0.00059541606
) O 0 0.0007915881
and O 0 0.00087264186
renal B-Disease 0 0.9901751
insufficiency I-Disease 0 0.9975127
( O 0 0.004714933
0 O 0 0.002867797
% O 0 0.0032642935
) O 0 0.0053369743
. O 0 0.004918941

Because O 0 0.002917286
treatments O 0 0.003931783
for O 0 0.0016597408
heart B-Disease 0 0.26066998
failure I-Disease 0 0.35549363
have O 0 0.0010210644
changed O 0 0.00086799497
since O 0 0.00038848384
the O 0 0.00039825676
benefits O 0 0.0006891832
of O 0 0.0009258889
spironolactone B-Chemical 1 0.9998369
were O 0 0.00088336604
reported O 0 0.0009329755
, O 0 0.0005055816
the O 0 0.0003086554
prevalence O 0 0.00068262056
of O 0 0.00054724474
these O 0 0.0008762041
complications O 0 0.3504551
may O 0 0.0008171461
differ O 0 0.000991026
in O 0 0.0010078017
current O 0 0.0027148833
clinical O 0 0.016691646
practice O 0 0.0066679553
. O 0 0.0056831036

We O 0 0.0030676897
therefore O 0 0.0024037254
sought O 0 0.0020417094
to O 0 0.00093931897
determine O 0 0.00044118412
the O 0 0.0006076457
prevalence O 0 0.0011160428
and O 0 0.0006460037
clinical O 0 0.0028516054
associations O 0 0.00063961674
of O 0 0.0013381151
hyperkalemia B-Disease 2 0.9998264
and O 0 0.002898255
renal B-Disease 0 0.9971898
insufficiency I-Disease 0 0.99863845
in O 0 0.0015996995
heart B-Disease 0 0.7359075
failure I-Disease 0 0.7376651
patients O 0 0.013901733
treated O 0 0.0060565514
with O 0 0.011011373
spironolactone B-Chemical 1 0.99923635
. O 0 0.011831978

METHODS O 0 0.0061326055
: O 0 0.0029437838
We O 0 0.0012214745
performed O 0 0.00097151357
a O 0 0.0009784042
case O 0 0.00077118265
control O 0 0.00057174003
study O 0 0.00091005524
of O 0 0.0009530254
heart B-Disease 0 0.4190683
failure I-Disease 0 0.604871
patients O 0 0.0065726475
treated O 0 0.0023390094
with O 0 0.0024701662
spironolactone B-Chemical 1 0.999634
in O 0 0.0020152694
our O 0 0.0021016372
clinical O 0 0.021411503
practice O 0 0.007513108
. O 0 0.00620751

Cases O 0 0.025646966
were O 0 0.002873831
patients O 0 0.0042861276
who O 0 0.004128483
developed O 0 0.006641135
hyperkalemia B-Disease 2 0.99972564
( O 0 0.019736337
K B-Chemical 1 0.99476516
( O 0 0.0029417705
+ O 0 0.0012209481
) O 0 0.0011007976
> O 0 0.00090766075
5 O 0 0.0003103678
. O 0 0.0002127096
0 O 0 0.00043679317
mEq O 0 0.6232675
/ O 0 0.0014330515
L O 0 0.27473918
) O 0 0.0008059016
or O 0 0.0004017234
renal B-Disease 0 0.9925085
insufficiency I-Disease 0 0.9991615
( O 0 0.012737031
Cr B-Chemical 1 0.9997136
> O 0 0.003099439
or O 0 0.0003326404
= O 0 0.0005176535
2 O 0 0.00024577408
. O 0 0.00014347956
5 O 0 0.00021563728
mg O 0 0.10435488
/ O 0 0.0009933354
dL O 0 0.02085889
) O 0 0.00051961537
, O 0 0.00031668047
and O 0 0.0002449422
they O 0 0.0002098929
were O 0 0.00023097971
compared O 0 0.00017090813
to O 0 0.00027760587
2 O 0 0.00033409856
randomly O 0 0.00023342475
selected O 0 0.0005930555
controls O 0 0.0014762199
per O 0 0.0013313816
case O 0 0.0036698196
. O 0 0.0049587805

Clinical O 0 0.04749666
characteristics O 0 0.0036771372
, O 0 0.0031400032
medications O 0 0.25869292
, O 0 0.001956827
and O 0 0.001195831
serum O 0 0.022226447
chemistries O 0 0.04730057
at O 0 0.0005376493
baseline O 0 0.00084876467
and O 0 0.00068708655
follow O 0 0.00077320845
- O 0 0.0012278232
up O 0 0.00077241205
time O 0 0.0008627527
periods O 0 0.0019771848
were O 0 0.0022749105
compared O 0 0.0027144535
. O 0 0.0053674616

RESULTS O 0 0.027194856
: O 0 0.0050429185
Sixty O 0 0.0073308693
- O 0 0.0023014676
seven O 0 0.0010234021
of O 0 0.0013158997
926 O 0 0.21302646
patients O 0 0.0035147164
( O 0 0.001071005
7 O 0 0.0004533743
. O 0 0.00026131436
2 O 0 0.00033353717
% O 0 0.00035749646
) O 0 0.00039069846
required O 0 0.00016723012
discontinuation O 0 0.3912116
of O 0 0.001007655
spironolactone B-Chemical 1 0.99986935
due O 0 0.00055129826
to O 0 0.00094343576
hyperkalemia B-Disease 2 0.99988925
( O 0 0.001680468
n O 0 0.00046991016
= O 0 0.00067548774
33 O 0 0.0006671014
) O 0 0.0006783776
or O 0 0.0005312491
renal B-Disease 0 0.9753184
failure I-Disease 0 0.7560297
( O 0 0.002425415
n O 0 0.0015733945
= O 0 0.0028999872
34 O 0 0.0035560806
) O 0 0.00536163
. O 0 0.0049202507

Patients O 0 0.010708802
who O 0 0.0055141225
developed O 0 0.0053293486
hyperkalemia B-Disease 2 0.9992644
were O 0 0.0018557938
older O 0 0.002860836
and O 0 0.0007242488
more O 0 0.0006618157
likely O 0 0.000395128
to O 0 0.00036129713
have O 0 0.0005752466
diabetes B-Disease 2 0.9932888
, O 0 0.0007308508
had O 0 0.00035981726
higher O 0 0.00031494556
baseline O 0 0.00060687074
serum O 0 0.13633823
potassium B-Chemical 0 0.99919957
levels O 0 0.0005632224
and O 0 0.00036944292
lower O 0 0.00032587326
baseline O 0 0.00079853623
potassium B-Chemical 0 0.9991381
supplement O 0 0.08478172
doses O 0 0.07921703
, O 0 0.00052835775
and O 0 0.00028627104
were O 0 0.0002331203
more O 0 0.00028794355
likely O 0 0.00020618897
to O 0 0.00021560048
be O 0 0.00028183463
treated O 0 0.00058231974
with O 0 0.00072157447
beta O 0 0.6170163
- O 0 0.005204129
blockers O 0 0.995946
than O 0 0.00068848924
controls O 0 0.0016851447
( O 0 0.001537109
n O 0 0.00137935
= O 0 0.0029256172
134 O 0 0.0069632055
) O 0 0.0055541503
. O 0 0.00491864

Patients O 0 0.009784439
who O 0 0.004803564
developed O 0 0.004049833
renal B-Disease 0 0.9820196
insufficiency I-Disease 0 0.9956921
had O 0 0.0014016965
lower O 0 0.00073068956
baseline O 0 0.0007565598
body O 0 0.0018166916
weight O 0 0.0021189807
and O 0 0.00037319364
higher O 0 0.00031833776
baseline O 0 0.00055788824
serum O 0 0.07353003
creatinine B-Chemical 1 0.9960574
, O 0 0.0005533651
required O 0 0.00015020031
higher O 0 0.00026237936
doses O 0 0.0085746385
of O 0 0.0005153806
loop O 0 0.0012234243
diuretics O 0 0.99953234
, O 0 0.0009704026
and O 0 0.00038179435
were O 0 0.00029509718
more O 0 0.000366113
likely O 0 0.00027585105
to O 0 0.0003149096
be O 0 0.00045685994
treated O 0 0.0010813063
with O 0 0.0023697692
thiazide B-Chemical 0 0.99980503
diuretics O 0 0.9993864
than O 0 0.00417729
controls O 0 0.009909155
. O 0 0.0063273213

CONCLUSIONS O 0 0.909666
: O 0 0.016807498
Spironolactone B-Chemical 0 0.9989673
- O 0 0.009457686
induced O 0 0.0053155143
hyperkalemia B-Disease 2 0.9996654
and O 0 0.0042012166
renal B-Disease 0 0.9962004
insufficiency I-Disease 0 0.9980856
are O 0 0.0012249191
more O 0 0.0009102841
common O 0 0.0009281929
in O 0 0.0005242364
our O 0 0.0006034871
clinical O 0 0.004032717
experience O 0 0.0025944025
than O 0 0.001283295
reported O 0 0.0036721008
previously O 0 0.004541707
. O 0 0.0058022956

This O 0 0.0046710535
difference O 0 0.0017582153
is O 0 0.0016382951
explained O 0 0.0012733551
by O 0 0.0012215211
patient O 0 0.0019576843
comorbidities O 0 0.14991933
and O 0 0.0012213326
more O 0 0.0013368959
frequent O 0 0.0029297331
use O 0 0.0019009961
of O 0 0.0033197505
beta O 0 0.72934234
- O 0 0.036527686
blockers O 0 0.9933339
. O 0 0.011847933

Acute O 0 0.98463506
reserpine B-Chemical 1 0.9992238
and O 0 0.015856706
subchronic O 0 0.99922407
haloperidol B-Chemical 1 0.9998865
treatments O 0 0.09764227
change O 0 0.004100554
synaptosomal O 0 0.99156344
brain O 0 0.6315707
glutamate B-Chemical 1 0.9990402
uptake O 0 0.119443044
and O 0 0.0022778756
elicit O 0 0.0035747509
orofacial B-Disease 0 0.99700755
dyskinesia I-Disease 2 0.9998425
in O 0 0.00787354
rats O 0 0.050070398
. O 0 0.007426137

Reserpine B-Chemical 1 0.99889237
- O 0 0.016618595
and O 0 0.0057148742
haloperidol B-Chemical 1 0.9997781
- O 0 0.012759561
induced O 0 0.0055339593
orofacial B-Disease 0 0.9977635
dyskinesia I-Disease 2 0.99995124
are O 0 0.001231725
putative O 0 0.0007639959
animal O 0 0.001017014
models O 0 0.0011837645
of O 0 0.0045067603
tardive B-Disease 0 0.99996924
dyskinesia I-Disease 2 0.99997437
( O 0 0.02761732
TD B-Disease 0 0.99764854
) O 0 0.0016252155
whose O 0 0.0011540706
pathophysiology O 0 0.17076086
has O 0 0.00061624165
been O 0 0.0006580778
related O 0 0.000415253
to O 0 0.00058783765
free O 0 0.0015941452
radical O 0 0.5656109
generation O 0 0.00367219
and O 0 0.004239318
oxidative O 0 0.98361796
stress O 0 0.83226484
. O 0 0.009706749

In O 0 0.0029694962
the O 0 0.0019365455
present O 0 0.0013413777
study O 0 0.0020382397
, O 0 0.0015163205
the O 0 0.0009458858
authors O 0 0.0015112004
induced O 0 0.0033616722
orofacial B-Disease 0 0.9979165
dyskinesia I-Disease 2 0.9999542
by O 0 0.010594338
acute O 0 0.9960271
reserpine B-Chemical 1 0.9998925
and O 0 0.0405432
subchronic O 0 0.9997147
haloperidol B-Chemical 1 0.9999218
administration O 0 0.865957
to O 0 0.0056024813
rats O 0 0.037841734
. O 0 0.006706407

Reserpine B-Chemical 1 0.9985475
injection O 0 0.03699825
( O 0 0.0029150236
one O 0 0.0009849704
dose O 0 0.005039943
of O 0 0.0011559289
1 O 0 0.0008968359
mg O 0 0.28716373
/ O 0 0.0013468337
kg O 0 0.0031754044
s O 0 0.0005326729
. O 0 0.00022489124
c O 0 0.0012643973
. O 0 0.00021347721
) O 0 0.0003551153
every O 0 0.00010163797
other O 0 0.00016213869
day O 0 0.0001752763
for O 0 0.00015040037
3 O 0 0.00015677114
days O 0 0.00016317956
caused O 0 0.00023554894
a O 0 0.00025399606
significant O 0 0.00032866103
increase O 0 0.00029152122
in O 0 0.00037183356
vacuous O 0 0.9714227
chewing O 0 0.94978786
, O 0 0.001214347
tongue O 0 0.085462704
protrusion O 0 0.039160617
and O 0 0.00043019853
duration O 0 0.00062022154
of O 0 0.00084824517
facial O 0 0.33258876
twitching O 0 0.8291689
, O 0 0.0013623193
compared O 0 0.00066835096
to O 0 0.0012119961
the O 0 0.0019610997
control O 0 0.0034759124
. O 0 0.0052898927

Haloperidol B-Chemical 1 0.9994844
administration O 0 0.5779421
( O 0 0.003005607
one O 0 0.00091173546
dose O 0 0.004402906
of O 0 0.00093766744
12 O 0 0.00057559565
mg O 0 0.20369191
/ O 0 0.0010886877
kg O 0 0.0018645854
once O 0 0.00028941382
a O 0 0.0002779006
week O 0 0.0002481532
s O 0 0.0003705543
. O 0 0.00017957727
c O 0 0.0011364071
. O 0 0.00019489601
) O 0 0.00035973973
for O 0 0.00016448992
4 O 0 0.00016695992
weeks O 0 0.00017849224
caused O 0 0.00025517546
an O 0 0.00033299325
increase O 0 0.00029262033
in O 0 0.0003697951
vacuous O 0 0.97094226
chewing O 0 0.9495119
, O 0 0.0011985871
tongue O 0 0.08477504
protrusion O 0 0.038510077
and O 0 0.00040924043
duration O 0 0.00057710026
of O 0 0.0007538379
facial O 0 0.2505611
twitching O 0 0.7013964
observed O 0 0.0006976822
in O 0 0.0008221407
four O 0 0.0010163722
weekly O 0 0.0035719736
evaluations O 0 0.0050332593
. O 0 0.005197059

After O 0 0.0025271368
the O 0 0.002185046
treatments O 0 0.0035899556
and O 0 0.0018508629
behavioral O 0 0.0173462
observation O 0 0.0019148818
, O 0 0.0026237448
glutamate B-Chemical 1 0.998166
uptake O 0 0.045435436
by O 0 0.0013046353
segments O 0 0.0016357282
of O 0 0.0015343869
the O 0 0.0017958755
brain O 0 0.045665637
was O 0 0.0031432437
analyzed O 0 0.0042090835
. O 0 0.006477499

A O 0 0.027663467
decreased O 0 0.009874465
glutamate B-Chemical 1 0.9973062
uptake O 0 0.07425082
was O 0 0.0014285191
observed O 0 0.0007143584
in O 0 0.00060869893
the O 0 0.00065363984
subcortical O 0 0.65012085
parts O 0 0.00068956625
of O 0 0.00059983705
animals O 0 0.00048370723
treated O 0 0.0011055209
with O 0 0.0015106968
reserpine B-Chemical 1 0.99983597
and O 0 0.011056638
haloperidol B-Chemical 1 0.9999039
, O 0 0.0026866407
compared O 0 0.0008807371
to O 0 0.0014285002
the O 0 0.0021891126
control O 0 0.0037543508
. O 0 0.0056169145

Importantly O 0 0.0041247946
, O 0 0.0032599664
a O 0 0.0020370763
decrease O 0 0.0019326516
in O 0 0.0015976052
glutamate B-Chemical 1 0.99818283
uptake O 0 0.04986288
correlates O 0 0.0012503392
negatively O 0 0.0011917839
with O 0 0.0009261046
an O 0 0.0009931107
increase O 0 0.00078240817
in O 0 0.0008119451
the O 0 0.00118338
incidence O 0 0.012591925
of O 0 0.0070802793
orofacial B-Disease 0 0.9947482
diskinesia I-Disease 0 0.99384826
. O 0 0.010733227

These O 0 0.0040163733
results O 0 0.001995442
indicate O 0 0.0012808607
that O 0 0.0011287857
early O 0 0.0021193044
changes O 0 0.0018755
in O 0 0.0012481237
glutamate B-Chemical 1 0.998681
transport O 0 0.041434944
may O 0 0.0008419184
be O 0 0.0005868403
related O 0 0.00037927626
to O 0 0.0004519336
the O 0 0.00054336706
development O 0 0.0015618867
of O 0 0.00184806
vacuous O 0 0.9823276
chewing O 0 0.9543149
movements O 0 0.027838351
in O 0 0.0033921923
rats O 0 0.015527763
. O 0 0.0061117816

Ceftriaxone B-Chemical 0 0.9913818
- O 0 0.013394047
associated O 0 0.010041858
biliary B-Disease 0 0.9909931
pseudolithiasis I-Disease 2 0.996847
in O 0 0.0067340154
paediatric O 0 0.011851418
surgical O 0 0.016002884
patients O 0 0.02319277
. O 0 0.011702237

It O 0 0.0072821663
is O 0 0.00312973
well O 0 0.0021274742
known O 0 0.00290478
that O 0 0.002408929
ceftriaxone B-Chemical 1 0.99735767
leads O 0 0.0042332537
to O 0 0.003499429
pseudolithiasis B-Disease 2 0.99197596
in O 0 0.0041312426
some O 0 0.0060918606
patients O 0 0.016528215
. O 0 0.008630083

Clinical O 0 0.03210228
and O 0 0.0024625454
experimental O 0 0.0020991166
studies O 0 0.0017381053
also O 0 0.0009689683
suggest O 0 0.00059440744
that O 0 0.00059172383
situations O 0 0.0015344045
causing O 0 0.010947789
gallbladder B-Disease 0 0.9949486
dysfunction I-Disease 0 0.99792945
, O 0 0.0014832625
such O 0 0.00052972557
as O 0 0.00045410593
fasting O 0 0.37887064
, O 0 0.00058336364
may O 0 0.00038837886
have O 0 0.00042683503
a O 0 0.0005467872
role O 0 0.00043968466
for O 0 0.00066162954
the O 0 0.0011653278
development O 0 0.0041156868
of O 0 0.006524822
pseudolithiasis B-Disease 2 0.99428236
. O 0 0.00970767

In O 0 0.0026568675
this O 0 0.001769426
study O 0 0.0019083696
, O 0 0.0012187584
we O 0 0.0004618041
prospectively O 0 0.0010746077
evaluated O 0 0.00050762034
the O 0 0.0004632774
incidence O 0 0.002294521
and O 0 0.0004914286
clinical O 0 0.0027162328
importance O 0 0.000360935
of O 0 0.0007259117
pseudolithiasis B-Disease 2 0.996793
in O 0 0.0004078143
paediatric O 0 0.0010012311
surgical O 0 0.0010988243
patients O 0 0.001979049
receiving O 0 0.009973744
ceftriaxone B-Chemical 1 0.99956244
treatment O 0 0.0051937792
, O 0 0.0006404039
who O 0 0.000924785
often O 0 0.00055219035
had O 0 0.00039210494
to O 0 0.00039361164
fast O 0 0.0014430151
in O 0 0.000569152
the O 0 0.00078623096
post O 0 0.0016741856
- O 0 0.0025092592
operative O 0 0.0053171255
period O 0 0.0041943756
. O 0 0.0052103684

Fifty O 0 0.0153995305
children O 0 0.0068791076
who O 0 0.0048435316
were O 0 0.0023069307
given O 0 0.0021199014
ceftriaxone B-Chemical 1 0.9947168
were O 0 0.0024728384
evaluated O 0 0.0022567906
by O 0 0.0030544153
serial O 0 0.00793201
abdominal O 0 0.42434454
sonograms O 0 0.2836462
. O 0 0.010370785

Of O 0 0.009704869
those O 0 0.0061649387
, O 0 0.00515454
13 O 0 0.0041866116
( O 0 0.003959364
26 O 0 0.003994966
% O 0 0.0036002041
) O 0 0.004939258
developed O 0 0.008473697
biliary O 0 0.95168644
pathology O 0 0.41850555
. O 0 0.014257806

Comparison O 0 0.0030093973
of O 0 0.0023578866
the O 0 0.0015775115
patients O 0 0.0026958138
with O 0 0.0012225664
or O 0 0.00076684833
without O 0 0.0010192271
pseudolithiasis B-Disease 2 0.99431735
revealed O 0 0.0008341096
no O 0 0.00037497198
significant O 0 0.00047637805
difference O 0 0.00021821252
with O 0 0.00035590245
respect O 0 0.0003002978
to O 0 0.0003366728
age O 0 0.0009837375
, O 0 0.0005949102
sex O 0 0.003273407
, O 0 0.0005527834
duration O 0 0.000620942
of O 0 0.00072597165
the O 0 0.0008037818
treatment O 0 0.0025534034
and O 0 0.0021990424
starvation O 0 0.07303956
variables O 0 0.007640945
. O 0 0.0060904888

After O 0 0.0029385232
cessation O 0 0.005993108
of O 0 0.00272267
the O 0 0.0020639466
treatment O 0 0.0044649662
, O 0 0.0037529136
pseudolithiasis B-Disease 2 0.99295723
resolved O 0 0.0055093337
spontaneously O 0 0.016795881
within O 0 0.0012667894
a O 0 0.0024735548
short O 0 0.0032403588
period O 0 0.005310774
. O 0 0.0068796743

The O 0 0.0057703154
incidence O 0 0.011626049
of O 0 0.007688157
pseudolithiasis B-Disease 2 0.98778474
is O 0 0.0057067405
not O 0 0.0041606072
affected O 0 0.004770312
by O 0 0.008202293
fasting O 0 0.61532795
. O 0 0.0119143585

Coronary B-Disease 0 0.90993214
aneurysm I-Disease 2 0.9719082
after O 0 0.0037437023
implantation O 0 0.008400798
of O 0 0.004848041
a O 0 0.007203486
paclitaxel B-Chemical 1 0.99370193
- O 0 0.019032428
eluting O 0 0.22222404
stent O 0 0.34348544
. O 0 0.013127985

Formation O 0 0.042898893
of O 0 0.0050687008
coronary B-Disease 0 0.7137567
aneurysm I-Disease 2 0.9780953
is O 0 0.0018766741
a O 0 0.0013406676
rare O 0 0.0063507627
complication O 0 0.1863899
of O 0 0.0013162029
stenting O 0 0.4689411
with O 0 0.0010143067
bare O 0 0.024334984
metal O 0 0.3518853
stents O 0 0.18844205
, O 0 0.0006996915
but O 0 0.00031057437
based O 0 0.00029307287
on O 0 0.00015254489
experimental O 0 0.00046679308
studies O 0 0.0007781857
drug O 0 0.41393578
- O 0 0.0013169271
eluting O 0 0.042770352
stents O 0 0.09290322
may O 0 0.00040140736
induce O 0 0.000405373
toxic O 0 0.62665385
effects O 0 0.0011688732
on O 0 0.00019167495
the O 0 0.0003197863
vessel O 0 0.041536625
wall O 0 0.020623656
with O 0 0.0005102066
incomplete O 0 0.0015210224
stent O 0 0.12037988
apposition O 0 0.014467338
, O 0 0.0010261681
aneurysm B-Disease 2 0.97900987
formation O 0 0.0030391642
and O 0 0.0005091606
with O 0 0.00053330534
the O 0 0.00047601695
potential O 0 0.0009560488
of O 0 0.0016248896
stent O 0 0.43334287
thrombosis B-Disease 2 0.9983937
or O 0 0.005907332
vessel B-Disease 0 0.92667484
rupture I-Disease 0 0.99423957
. O 0 0.01008579

We O 0 0.0031052404
present O 0 0.0018065856
a O 0 0.0020102933
43 O 0 0.0026070084
- O 0 0.001840201
year O 0 0.0010758573
- O 0 0.0012310458
old O 0 0.0008278093
man O 0 0.028426312
who O 0 0.0013981621
developed O 0 0.0010501442
a O 0 0.00081653387
coronary B-Disease 0 0.74340755
aneurysm I-Disease 2 0.98509324
in O 0 0.00052762526
the O 0 0.0004504298
right O 0 0.0015375436
coronary O 0 0.5071095
artery O 0 0.13478695
6 O 0 0.00033872618
months O 0 0.00037943793
after O 0 0.00027849575
receiving O 0 0.0016823498
a O 0 0.0017465184
paclitaxel B-Chemical 1 0.99628735
- O 0 0.008195712
eluting O 0 0.17849338
stent O 0 0.29483646
. O 0 0.00700983

The O 0 0.0035917028
patient O 0 0.004207523
was O 0 0.0026398369
asymptomatic O 0 0.021466784
and O 0 0.0022734066
the O 0 0.0021953043
aneurysm B-Disease 2 0.9478106
was O 0 0.0021143723
detected O 0 0.0013158007
in O 0 0.0018285129
a O 0 0.0028878448
routine O 0 0.0043516317
control O 0 0.005400623
. O 0 0.00772564

Angiography O 0 0.06321485
and O 0 0.003633222
intracoronary O 0 0.74818075
ultrasound O 0 0.026399434
demonstrated O 0 0.0013149764
lack O 0 0.0007992297
of O 0 0.00088157627
contact O 0 0.0010418205
between O 0 0.00039601818
stent O 0 0.025769422
and O 0 0.0006929136
vessel O 0 0.042878285
wall O 0 0.018755712
in O 0 0.0003966355
a O 0 0.00045901095
15 O 0 0.00035875113
- O 0 0.00056607614
mm O 0 0.0010444436
long O 0 0.00036014806
segment O 0 0.00062366197
with O 0 0.0005475996
maximal O 0 0.0012011232
aneurysm B-Disease 2 0.9717138
diameter O 0 0.018306648
of O 0 0.0014890642
6 O 0 0.0011948713
. O 0 0.001189595
0 O 0 0.0028394852
mm O 0 0.008634539
. O 0 0.0045505157

The O 0 0.005012943
patient O 0 0.00594817
was O 0 0.003953045
successfully O 0 0.0054660854
treated O 0 0.0061905575
with O 0 0.0058261184
a O 0 0.008263582
graft O 0 0.10305541
stent O 0 0.29449672
. O 0 0.014463564

Causes O 0 0.13112666
of O 0 0.011731055
acute O 0 0.98552203
thrombotic B-Disease 2 0.9989911
microangiopathy I-Disease 2 0.99963486
in O 0 0.007853585
patients O 0 0.02520011
receiving O 0 0.059507605
kidney O 0 0.9459567
transplantation O 0 0.73683566
. O 0 0.0129496595

OBJECTIVES O 0 0.13325347
: O 0 0.015188486
Thrombotic B-Disease 0 0.9968274
microangiopathy I-Disease 0 0.9995555
is O 0 0.0037394383
a O 0 0.0020249353
well O 0 0.0013269975
- O 0 0.0020915382
known O 0 0.001541923
problem O 0 0.002169441
in O 0 0.0013081739
patients O 0 0.0043689758
following O 0 0.0039417995
renal O 0 0.9865529
transplantation O 0 0.74102265
. O 0 0.009610034

In O 0 0.0062588127
postrenal O 0 0.9717773
transplantation O 0 0.52920127
, O 0 0.013407531
thrombotic B-Disease 2 0.99893445
microangiopathy I-Disease 2 0.9997464
is O 0 0.0041109775
often O 0 0.003339369
a O 0 0.0022311523
reflection O 0 0.004162135
of O 0 0.009715888
hemolytic B-Disease 0 0.9992884
uremic I-Disease 0 0.9992512
syndrome I-Disease 0 0.99247557
. O 0 0.015774755

We O 0 0.0031622145
aimed O 0 0.0024443748
to O 0 0.0014535963
determine O 0 0.0007163068
the O 0 0.0010563729
causes O 0 0.0024000395
of O 0 0.0035196082
thrombotic B-Disease 2 0.99959284
microangiopathy I-Disease 2 0.99990976
in O 0 0.0016062518
a O 0 0.0010011413
population O 0 0.0011184717
of O 0 0.0012529453
renal O 0 0.98527735
transplantation O 0 0.43395397
recipients O 0 0.0061953207
and O 0 0.0016165822
discuss O 0 0.0018696025
the O 0 0.0028969944
literature O 0 0.0091047315
. O 0 0.0064904764

MATERIALS O 0 0.014854611
AND O 0 0.0049993475
METHODS O 0 0.0030867513
: O 0 0.0019273298
We O 0 0.0009356942
investigated O 0 0.0008599061
the O 0 0.0008100041
causes O 0 0.0018767902
of O 0 0.0027365773
thrombotic B-Disease 2 0.9996476
microangiopathy I-Disease 2 0.9999281
during O 0 0.000986634
a O 0 0.00080671604
1 O 0 0.000481501
- O 0 0.0004434847
year O 0 0.0002510094
period O 0 0.00025095697
, O 0 0.00030600931
from O 0 0.00023679572
June O 0 0.00032788145
2003 O 0 0.00051217293
to O 0 0.00022128236
June O 0 0.00033736826
2004 O 0 0.0006199801
, O 0 0.00026864032
at O 0 0.00014242655
the O 0 0.00025096317
King O 0 0.0070579904
Fahad O 0 0.003284815
National O 0 0.0009629466
Guard O 0 0.001623045
Hospital O 0 0.0015890806
in O 0 0.0002499598
Riyadh O 0 0.0011012291
, O 0 0.00043160786
Saudi O 0 0.0020321945
Arabia O 0 0.0019220071
, O 0 0.00035346422
by O 0 0.0002492059
reviewing O 0 0.0006656008
the O 0 0.0002501219
slides O 0 0.0007473339
of O 0 0.00036853147
all O 0 0.00033757268
transplant O 0 0.28054094
biopsies O 0 0.0052724252
( O 0 0.0007791504
n O 0 0.00045106479
= O 0 0.0007310636
25 O 0 0.0007284647
) O 0 0.0007923726
performed O 0 0.0006176438
during O 0 0.00086598465
this O 0 0.0018731804
interval O 0 0.005044136
. O 0 0.004803528

Pre O 0 0.05727453
- O 0 0.0098925885
and O 0 0.005925943
posttransplant O 0 0.15346484
crossmatching O 0 0.010640963
was O 0 0.0049007996
done O 0 0.004620606
when O 0 0.005366194
possible O 0 0.010626316
. O 0 0.012629787

RESULTS O 0 0.039598577
: O 0 0.009857407
Five O 0 0.008602887
cases O 0 0.0082993535
of O 0 0.01229595
thrombotic B-Disease 2 0.9979119
microangiopathy I-Disease 2 0.9992889
were O 0 0.017742971
found O 0 0.012838148
. O 0 0.013178489

Three O 0 0.004123181
of O 0 0.002428867
these O 0 0.0020281612
cases O 0 0.0020303763
were O 0 0.00091672415
from O 0 0.00064246776
the O 0 0.000524222
25 O 0 0.00076065573
transplantations O 0 0.008451067
performed O 0 0.00041205503
at O 0 0.00033415397
King O 0 0.007320682
Fahad O 0 0.0037538407
National O 0 0.0012319331
Guard O 0 0.0020486272
Hospital O 0 0.0021739996
, O 0 0.00036841148
while O 0 0.00022317172
the O 0 0.0002186532
other O 0 0.00026381796
2 O 0 0.00029088542
transplantations O 0 0.01427282
had O 0 0.00033429387
been O 0 0.00035114755
performed O 0 0.00028703874
abroad O 0 0.0013249214
and O 0 0.00043474857
were O 0 0.00041193425
referred O 0 0.0005347076
to O 0 0.00055133086
us O 0 0.0010732531
for O 0 0.000981055
follow O 0 0.0019905667
- O 0 0.004398286
up O 0 0.00421981
. O 0 0.00540762

Three O 0 0.005061477
cases O 0 0.0038881057
were O 0 0.0019215479
related O 0 0.0013316529
to O 0 0.001688715
cyclosporine B-Chemical 1 0.99943215
, O 0 0.0025948242
and O 0 0.0011732036
1 O 0 0.0008593672
case O 0 0.00077337644
was O 0 0.0007897821
secondary O 0 0.0019313691
to O 0 0.0013269925
both O 0 0.0028062551
cyclosporine B-Chemical 1 0.9993849
and O 0 0.03120245
tacrolimus B-Chemical 0 0.9988361
. O 0 0.013127322

The O 0 0.003134599
fifth O 0 0.0040453523
case O 0 0.0020010406
had O 0 0.0016149369
features O 0 0.0034373999
of O 0 0.0035852902
thrombotic B-Disease 2 0.9995136
microangiopathy I-Disease 2 0.999897
related O 0 0.001705138
to O 0 0.0010017597
an O 0 0.0020634837
antiphospholipid B-Disease 0 0.99902153
syndrome I-Disease 0 0.94094867
in O 0 0.0010335256
a O 0 0.0012925299
patient O 0 0.0025888768
with O 0 0.0045584003
systemic B-Disease 0 0.99520016
lupus I-Disease 0 0.9995932
erythematosus I-Disease 0 0.99940765
. O 0 0.030006902

CONCLUSIONS O 0 0.66865164
: O 0 0.0047880565
In O 0 0.0016798027
the O 0 0.0013102121
literature O 0 0.002163067
, O 0 0.0013393455
the O 0 0.00081865414
most O 0 0.0014820822
- O 0 0.0013651067
frequent O 0 0.0024955452
cause O 0 0.0031076756
of O 0 0.0031967089
hemolytic B-Disease 0 0.99983597
uremic I-Disease 0 0.9998529
syndrome I-Disease 0 0.994921
in O 0 0.0007579623
patients O 0 0.0031938276
following O 0 0.00080161553
renal O 0 0.9866578
transplantation O 0 0.43457922
is O 0 0.0012130245
recurrence O 0 0.5770787
of O 0 0.0024178424
the O 0 0.0049253046
hemolytic B-Disease 0 0.9995061
uremic I-Disease 0 0.9994343
syndrome I-Disease 0 0.99352455
. O 0 0.012550841

Other O 0 0.012033264
causes O 0 0.0054579256
include O 0 0.003346604
drug O 0 0.44128123
- O 0 0.0035495425
related O 0 0.0012751785
( O 0 0.0026262763
cyclosporine B-Chemical 1 0.99971455
, O 0 0.012103286
tacrolimus B-Chemical 0 0.999777
) O 0 0.026823359
toxicity B-Disease 2 0.99677557
, O 0 0.0026836654
procoagulant O 0 0.809882
status O 0 0.0023233905
, O 0 0.0015819647
and O 0 0.0014832173
antibody O 0 0.005185175
- O 0 0.0047181635
mediated O 0 0.004559681
rejection O 0 0.9691649
. O 0 0.009235695

We O 0 0.0034695263
found O 0 0.0022202998
that O 0 0.0014769201
the O 0 0.0014575946
most O 0 0.0023931514
- O 0 0.0021977455
frequent O 0 0.003529214
cause O 0 0.004306191
of O 0 0.0041486695
thrombotic B-Disease 2 0.9996749
microangiopathy I-Disease 2 0.9999219
was O 0 0.004355799
drug O 0 0.5751882
related O 0 0.0012185032
, O 0 0.0018535586
secondary O 0 0.0038737252
mainly O 0 0.0048983395
to O 0 0.0056780674
cyclosporine B-Chemical 1 0.9989126
. O 0 0.011660598

In O 0 0.0027856962
the O 0 0.0018269878
current O 0 0.0022716573
study O 0 0.00197584
, O 0 0.001315332
the O 0 0.00075553835
frequency O 0 0.0010297986
of O 0 0.0022934736
thrombotic B-Disease 2 0.9996159
microangiopathy I-Disease 2 0.9999244
was O 0 0.0014055757
similar O 0 0.0004172461
to O 0 0.00038171344
the O 0 0.00035939523
percentage O 0 0.00029629507
reported O 0 0.00078471226
in O 0 0.00056947104
the O 0 0.0008088906
literature O 0 0.0024901526
( O 0 0.0021425793
20 O 0 0.0023224817
% O 0 0.0031783534
) O 0 0.0054576313
. O 0 0.005146748

Comparison O 0 0.0035641121
of O 0 0.0031846717
developmental O 0 0.0070944563
toxicity B-Disease 2 0.98037994
of O 0 0.0023448048
selective O 0 0.019066913
and O 0 0.0013646504
non O 0 0.00325261
- O 0 0.0023891565
selective O 0 0.056402024
cyclooxygenase O 0 0.9996469
- O 0 0.006913397
2 O 0 0.00077259715
inhibitors O 0 0.04643565
in O 0 0.0008203236
CRL O 0 0.93853146
: O 0 0.0017194637
( O 0 0.0012195319
WI O 0 0.019436086
) O 0 0.0019336462
WUBR O 0 0.22395146
Wistar O 0 0.4062705
rats O 0 0.007871959
- O 0 0.0030859401
- O 0 0.004734111
DFU B-Chemical 1 0.999071
and O 0 0.010335555
piroxicam B-Chemical 0 0.9991636
study O 0 0.026570195
. O 0 0.008490516

BACKGROUND O 0 0.92337143
: O 0 0.018660735
Cyclooxygenase O 0 0.99834955
( O 0 0.016042953
COX O 0 0.99842095
) O 0 0.0069993925
inhibitors O 0 0.05757861
are O 0 0.0011312111
one O 0 0.00066227186
of O 0 0.0010013821
the O 0 0.00094796706
most O 0 0.0019011571
often O 0 0.0028002611
ingested O 0 0.16907509
drugs O 0 0.70188236
during O 0 0.0042050485
pregnancy O 0 0.5309851
. O 0 0.008218099

Unlike O 0 0.0044828397
general O 0 0.004343338
toxicity B-Disease 2 0.9648283
data O 0 0.0032340873
, O 0 0.0023168637
their O 0 0.0016374954
prenatal O 0 0.020786561
toxic O 0 0.6887512
effects O 0 0.0038697585
were O 0 0.0016791789
not O 0 0.0016972754
extensively O 0 0.0038485462
studied O 0 0.0044744466
before O 0 0.003835474
. O 0 0.0067607607

The O 0 0.002550449
aim O 0 0.0019145992
of O 0 0.00144124
the O 0 0.0009503003
experiment O 0 0.0006951907
was O 0 0.0006460881
to O 0 0.00046980692
evaluate O 0 0.00030643382
the O 0 0.00045212317
developmental O 0 0.0025309063
toxicity B-Disease 2 0.9844923
of O 0 0.00087827625
the O 0 0.0005298887
non O 0 0.0020738414
- O 0 0.0013311583
selective O 0 0.019713609
( O 0 0.0019642953
piroxicam B-Chemical 0 0.9998385
) O 0 0.002778337
and O 0 0.0005694287
selective O 0 0.023240069
( O 0 0.00214852
DFU B-Chemical 1 0.9997991
; O 0 0.0025024654
5 B-Chemical 0 0.00035720415
, I-Chemical 0 0.0004283272
5 I-Chemical 0 0.00032144145
- I-Chemical 0 0.00081087626
dimethyl I-Chemical 0 0.97788006
- I-Chemical 0 0.001078264
3 I-Chemical 0 0.00034678317
- I-Chemical 0 0.00062296697
( I-Chemical 0 0.00042658037
3 I-Chemical 0 0.000290043
- I-Chemical 0 0.0007264629
fluorophenyl I-Chemical 0 0.90075856
) I-Chemical 0 0.0010555277
- I-Chemical 0 0.0006485416
4 I-Chemical 0 0.00029184768
- I-Chemical 0 0.00054581324
( I-Chemical 0 0.00041208175
4 I-Chemical 0 0.0002970137
- I-Chemical 0 0.0007661175
methylsulphonyl I-Chemical 0 0.8873271
) I-Chemical 0 0.0020680518
phenyl I-Chemical 0 0.98995286
- I-Chemical 0 0.001728802
2 I-Chemical 0 0.00061488675
( I-Chemical 0 0.00092100183
5H I-Chemical 0 0.018842574
) I-Chemical 0 0.0013922931
- I-Chemical 0 0.001552878
furanon I-Chemical 0 0.017446505
) O 0 0.0053894063
COX O 0 0.99823964
- O 0 0.0087432265
2 O 0 0.0040830695
inhibitors O 0 0.10618361
. O 0 0.006895454

METHODS O 0 0.007472567
: O 0 0.0046113054
Drugs O 0 0.45699745
were O 0 0.0015020315
separately O 0 0.00086278154
, O 0 0.0011924618
orally O 0 0.009176292
once O 0 0.0006855897
daily O 0 0.0015713652
dosed O 0 0.0129470015
to O 0 0.00052084064
pregnant O 0 0.007899907
rats O 0 0.0016188108
from O 0 0.00042560737
day O 0 0.00046147537
8 O 0 0.00045785768
to O 0 0.00048731262
21 O 0 0.00097403454
( O 0 0.0012615662
GD1 O 0 0.023699591
= O 0 0.002510458
plug O 0 0.0041591045
day O 0 0.003171534
) O 0 0.006733384
. O 0 0.005738174

Doses O 0 0.38198662
were O 0 0.0025299774
set O 0 0.001498669
at O 0 0.00097399467
0 O 0 0.0011123662
. O 0 0.00054888765
3 O 0 0.00052194734
, O 0 0.00060125825
3 O 0 0.00036098316
. O 0 0.00022786876
0 O 0 0.00031221996
and O 0 0.00027524578
30 O 0 0.00026727552
. O 0 0.0002144442
0mg O 0 0.81476116
/ O 0 0.00094143976
kg O 0 0.0026721149
for O 0 0.00035949695
piroxicam B-Chemical 0 0.99966466
and O 0 0.0007018911
0 O 0 0.0004989611
. O 0 0.00020132716
2 O 0 0.00029513438
, O 0 0.00035912052
2 O 0 0.00029512198
. O 0 0.00019328798
0 O 0 0.00034274143
and O 0 0.00037681585
20 O 0 0.00061190577
. O 0 0.00056289445
0mg O 0 0.82625675
/ O 0 0.0038179564
kg O 0 0.0118717905
for O 0 0.0037655535
DFU B-Chemical 1 0.99762267
. O 0 0.009822109

Fetuses O 0 0.03026045
were O 0 0.005362383
delivered O 0 0.0048672277
on O 0 0.004066187
GD O 0 0.7336913
21 O 0 0.006876635
and O 0 0.0053358357
routinely O 0 0.006523615
examined O 0 0.0073653026
. O 0 0.011593618

Comprehensive O 0 0.02267454
clinical O 0 0.01735584
and O 0 0.008167219
developmental O 0 0.011771162
measurements O 0 0.00712578
were O 0 0.008720217
done O 0 0.010638579
. O 0 0.014807596

The O 0 0.0023131259
pooled O 0 0.0015762444
statistical O 0 0.004138867
analysis O 0 0.0021068507
for O 0 0.0013455278
ventricular B-Disease 0 0.95510554
septal I-Disease 0 0.28629303
( I-Disease 0 0.002412431
VSD I-Disease 0 0.4839815
) I-Disease 0 0.0013767186
and I-Disease 0 0.00064671395
midline I-Disease 0 0.0054560625
( I-Disease 0 0.0009907485
MD I-Disease 0 0.8327041
) I-Disease 0 0.0007847636
defects I-Disease 0 0.00044397154
was O 0 0.00023987681
performed O 0 0.00021605154
for O 0 0.00023708217
rat O 0 0.0034151552
fetuses O 0 0.0043506958
exposed O 0 0.00048888574
to O 0 0.00047094718
piroxicam B-Chemical 0 0.9998023
, O 0 0.001328412
selective O 0 0.011367613
and O 0 0.0005748347
non O 0 0.0020134402
- O 0 0.001560115
selective O 0 0.05073801
COX O 0 0.99957114
- O 0 0.003976526
2 O 0 0.00074154756
inhibitor O 0 0.024687888
based O 0 0.0008469626
on O 0 0.00055425055
present O 0 0.0009365544
and O 0 0.0021301443
historic O 0 0.01278563
data O 0 0.0057948516
. O 0 0.006329684

RESULTS O 0 0.04523266
: O 0 0.0065532937
Maternal O 0 0.09546057
toxicity B-Disease 2 0.9898657
, O 0 0.0042413995
intrauterine B-Disease 0 0.8500284
growth I-Disease 0 0.3434092
retardation I-Disease 0 0.989507
, O 0 0.0014399455
and O 0 0.0006011497
increase B-Disease 0 0.00042209585
of I-Disease 0 0.0005200397
external I-Disease 0 0.00095032476
and I-Disease 0 0.00047735442
skeletal I-Disease 0 0.014860172
variations I-Disease 0 0.0004066698
were O 0 0.00032888167
found O 0 0.0003078534
in O 0 0.00031631053
rats O 0 0.0014394013
treated O 0 0.0008276531
with O 0 0.0007380503
the O 0 0.00079724065
highest O 0 0.0015306168
dose O 0 0.032946073
of O 0 0.009458338
piroxicam B-Chemical 0 0.9990233
. O 0 0.011632429

Decrease O 0 0.024189752
of O 0 0.003936626
fetal O 0 0.057376433
length O 0 0.0016910414
was O 0 0.0011479519
the O 0 0.0008277052
only O 0 0.000833787
signs O 0 0.027863752
of O 0 0.0010713888
the O 0 0.0011217592
DFU B-Chemical 1 0.9996892
developmental O 0 0.07213409
toxicity B-Disease 2 0.9965055
observed O 0 0.00071157276
in O 0 0.0005954587
pups O 0 0.0011372843
exposed O 0 0.0008647289
to O 0 0.0007877414
the O 0 0.001120387
highest O 0 0.0023809692
compound O 0 0.12066781
dose O 0 0.10352121
. O 0 0.007215708

Lack O 0 0.010899324
of O 0 0.006730607
teratogenicity O 0 0.99384177
was O 0 0.0038099904
found O 0 0.0026722993
in O 0 0.0031493714
piroxicam B-Chemical 0 0.9991472
and O 0 0.019224172
DFU B-Chemical 1 0.9992085
- O 0 0.02291103
exposed O 0 0.007323066
groups O 0 0.008519596
. O 0 0.008794774

Prenatal O 0 0.33033696
exposure O 0 0.009746775
to O 0 0.0024952225
non O 0 0.0041435156
- O 0 0.0032014623
selective O 0 0.036851924
COX O 0 0.999186
inhibitors O 0 0.3339705
increases O 0 0.0013400447
the O 0 0.00070764363
risk O 0 0.028889617
of O 0 0.0013506538
VSD O 0 0.6760731
and O 0 0.0010005768
MD O 0 0.8566743
when O 0 0.0002903778
compared O 0 0.0002164173
to O 0 0.000321764
historic O 0 0.0018768329
control O 0 0.0004260988
but O 0 0.00050500367
not O 0 0.00058081123
with O 0 0.001287674
selective O 0 0.088314205
COX O 0 0.9988844
- O 0 0.014154982
2 O 0 0.0043997327
inhibitors O 0 0.13277678
. O 0 0.0069992966

CONCLUSION O 0 0.83724827
: O 0 0.0056034005
Both O 0 0.0030376315
selective O 0 0.0057554636
and O 0 0.0018122195
non O 0 0.003222766
- O 0 0.0027334404
selective O 0 0.050845902
COX O 0 0.9994042
- O 0 0.0052973554
2 O 0 0.00077094196
inhibitors O 0 0.023118993
were O 0 0.0006362724
toxic O 0 0.41170266
for O 0 0.0005324272
rats O 0 0.0028091136
fetuses O 0 0.003259395
when O 0 0.00050816644
administered O 0 0.0018665208
in O 0 0.0009643317
the O 0 0.0014962899
highest O 0 0.0032524492
dose O 0 0.046281483
. O 0 0.0065069287

Unlike O 0 0.010077153
DFU B-Chemical 1 0.99733174
, O 0 0.017416613
piroxicam B-Chemical 0 0.9987477
was O 0 0.005117515
also O 0 0.0038129142
highly O 0 0.0055019376
toxic O 0 0.5606773
to O 0 0.0046794326
the O 0 0.0059981886
dams O 0 0.04881703
. O 0 0.011123351

Prenatal O 0 0.35277447
exposure O 0 0.010882892
to O 0 0.002822245
selective O 0 0.059373073
COX O 0 0.9990576
- O 0 0.0078069675
2 O 0 0.0010864163
inhibitors O 0 0.025509607
does O 0 0.00047173275
not O 0 0.0003581453
increase O 0 0.00036136847
the O 0 0.00037399025
risk O 0 0.014698114
of O 0 0.0009436237
ventricular B-Disease 0 0.985282
septal I-Disease 0 0.20072725
and I-Disease 0 0.0006270623
midline I-Disease 0 0.034105435
defects I-Disease 0 0.0013479474
in O 0 0.00031294234
rat O 0 0.0021198622
when O 0 0.00022907778
compared O 0 0.00022552791
to O 0 0.00041074146
non O 0 0.0013999515
- O 0 0.001574032
selective O 0 0.01045477
drugs O 0 0.5666246
and O 0 0.0026603471
historic O 0 0.01793193
control O 0 0.0042707296
. O 0 0.0057473653

Lone O 0 0.08318133
atrial B-Disease 0 0.9652196
fibrillation I-Disease 0 0.9968713
associated O 0 0.019901048
with O 0 0.022526754
creatine B-Chemical 1 0.99751246
monohydrate O 0 0.99751854
supplementation O 0 0.983657
. O 0 0.025335906

Atrial B-Disease 0 0.9800426
fibrillation I-Disease 0 0.9983317
in O 0 0.0050804396
young O 0 0.010924305
patients O 0 0.0052705305
without O 0 0.0028383269
structural O 0 0.010776308
heart B-Disease 0 0.6664955
disease I-Disease 0 0.81859785
is O 0 0.00816954
rare O 0 0.060215272
. O 0 0.010316121

Therefore O 0 0.0038315295
, O 0 0.0030869585
when O 0 0.0014014957
the O 0 0.0017244952
arrhythmia B-Disease 2 0.9958106
is O 0 0.0012432934
present O 0 0.0006062857
in O 0 0.0005874895
this O 0 0.0006408661
population O 0 0.0012283699
, O 0 0.0012313378
reversible O 0 0.12695155
causes O 0 0.0025206688
must O 0 0.0009111467
be O 0 0.0013274603
identified O 0 0.0015709574
and O 0 0.0030164463
resolved O 0 0.008045573
. O 0 0.006388805

Thyroid B-Disease 0 0.9749273
disorders I-Disease 0 0.9609771
, O 0 0.006936076
illicit O 0 0.98221326
drug O 0 0.5738105
or O 0 0.001993474
stimulant O 0 0.9813269
use O 0 0.0023062748
, O 0 0.0017845833
and O 0 0.0017848168
acute B-Disease 0 0.9909231
alcohol I-Disease 0 0.998814
intoxication I-Disease 0 0.9991436
are O 0 0.0038820363
among O 0 0.0033775077
these O 0 0.0049104756
causes O 0 0.014644368
. O 0 0.007906409

We O 0 0.0031608127
report O 0 0.0040093376
the O 0 0.0015676559
case O 0 0.0013204807
of O 0 0.0012773022
a O 0 0.0011247548
30 O 0 0.00081920106
- O 0 0.0009986555
year O 0 0.0006649369
- O 0 0.0008585066
old O 0 0.00065743143
Caucasian O 0 0.09998832
man O 0 0.04786325
who O 0 0.0011354117
came O 0 0.0006872929
to O 0 0.00040126717
the O 0 0.00045043367
emergency O 0 0.0053487173
department O 0 0.0068727713
in O 0 0.0010402234
atrial B-Disease 0 0.98832405
fibrillation I-Disease 0 0.99937254
with O 0 0.0041306717
rapid O 0 0.028949512
ventricular O 0 0.98308
response O 0 0.012074772
. O 0 0.0065454007

His O 0 0.010333174
medical O 0 0.008776005
history O 0 0.009389604
was O 0 0.0022782148
unremarkable O 0 0.051949408
, O 0 0.0019316782
except O 0 0.0009354001
for O 0 0.0010331795
minor O 0 0.0033844071
fractures B-Disease 2 0.8391892
of O 0 0.0027431648
the O 0 0.0026276333
fingers O 0 0.02191306
and O 0 0.005690368
foot O 0 0.13014512
. O 0 0.008951558

Thyroid O 0 0.86856073
- O 0 0.0076418407
stimulating O 0 0.0063192104
hormone O 0 0.9258375
, O 0 0.0053894804
magnesium B-Chemical 1 0.9982938
, O 0 0.0031485495
and O 0 0.0015043074
potassium B-Chemical 0 0.99833137
levels O 0 0.0008906246
were O 0 0.0004661337
within O 0 0.00021149057
normal O 0 0.00066893344
limits O 0 0.0008592648
, O 0 0.0006434434
urine O 0 0.11767545
drug O 0 0.2140758
screen O 0 0.0006828037
was O 0 0.00052070164
negative O 0 0.00067625
, O 0 0.0011169976
and O 0 0.0014121573
alcohol B-Chemical 0 0.98880965
use O 0 0.0035773607
was O 0 0.00377171
denied O 0 0.027193982
. O 0 0.0067426767

However O 0 0.0041321507
, O 0 0.002701447
when O 0 0.0010899672
the O 0 0.0010088768
patient O 0 0.0013796213
was O 0 0.00075280986
questioned O 0 0.0009867235
about O 0 0.00051427505
use O 0 0.00067714904
of O 0 0.0008762292
herbal O 0 0.93007296
products O 0 0.0045815315
and O 0 0.0011426684
supplements O 0 0.7633964
, O 0 0.0011124954
the O 0 0.0006913369
use O 0 0.0012223178
of O 0 0.0029493931
creatine B-Chemical 1 0.9990823
monohydrate O 0 0.9986092
was O 0 0.0064603267
revealed O 0 0.007279309
. O 0 0.0073125223

The O 0 0.002830813
patient O 0 0.0031366274
was O 0 0.0017543988
admitted O 0 0.003645138
to O 0 0.00096188113
the O 0 0.00080592657
hospital O 0 0.0028467686
, O 0 0.0010517446
anticoagulated O 0 0.014182908
with O 0 0.0006543236
unfractionated O 0 0.13712066
heparin B-Chemical 1 0.9892797
, O 0 0.0009507712
and O 0 0.00043598117
given O 0 0.00031267424
intravenous O 0 0.66923094
diltiazem B-Chemical 1 0.9999082
for O 0 0.00048327746
rate O 0 0.00040424368
control O 0 0.00036883162
and O 0 0.0006323526
intravenous O 0 0.71337986
amiodarone B-Chemical 1 0.9996599
for O 0 0.0010648887
rate O 0 0.0013404491
and O 0 0.0020836212
rhythm O 0 0.04754093
control O 0 0.0038017156
. O 0 0.005427013

When O 0 0.0032415327
discharged O 0 0.009518416
less O 0 0.0016605073
than O 0 0.00078572513
24 O 0 0.00069350854
hours O 0 0.0005329994
later O 0 0.0004988786
, O 0 0.0006060656
he O 0 0.00061829604
was O 0 0.00048250577
receiving O 0 0.00626542
metoprolol B-Chemical 1 0.99991584
and O 0 0.0024917566
aspirin B-Chemical 1 0.99971956
, O 0 0.0012949376
with O 0 0.0005671905
follow O 0 0.00047125344
- O 0 0.0006465193
up O 0 0.00032699676
plans O 0 0.00065256923
for O 0 0.00036890636
echocardiography O 0 0.08975827
and O 0 0.0008681406
nuclear O 0 0.0038771105
imaging O 0 0.0057385713
to O 0 0.0015705269
assess O 0 0.0016839362
perfusion O 0 0.28892264
. O 0 0.0064632543

Exogenous O 0 0.8590261
creatine B-Chemical 1 0.9941367
is O 0 0.005376374
used O 0 0.0030464877
by O 0 0.0028708456
athletes O 0 0.010696443
to O 0 0.0024439702
theoretically O 0 0.00413614
improve O 0 0.0034132379
exercise O 0 0.03944389
performance O 0 0.011813361
. O 0 0.009672363

Vegetarians O 0 0.29704848
may O 0 0.0033488679
also O 0 0.0023163457
take O 0 0.0017130717
creatine B-Chemical 1 0.9932441
to O 0 0.0013898119
replace O 0 0.0011295166
what O 0 0.0010243196
they O 0 0.0005617196
are O 0 0.0005469441
not O 0 0.0004983219
consuming O 0 0.0022039632
from O 0 0.00075737305
meat O 0 0.023260973
, O 0 0.0014532896
fish O 0 0.007855271
, O 0 0.001548857
and O 0 0.00140579
other O 0 0.0019898377
animal O 0 0.00534682
products O 0 0.01142996
. O 0 0.0071080187

Previous O 0 0.0069227605
anecdotal O 0 0.015931915
reports O 0 0.005835425
have O 0 0.0040238635
linked O 0 0.004760854
creatine B-Chemical 1 0.99314815
to O 0 0.0043316544
the O 0 0.0040046843
development O 0 0.009649926
of O 0 0.01283062
arrhythmia B-Disease 2 0.9951414
. O 0 0.0156652

Clinicians O 0 0.0091085015
must O 0 0.0017685468
be O 0 0.001499849
diligent O 0 0.0022324445
when O 0 0.0006877312
interviewing O 0 0.002105562
patients O 0 0.0014941244
about O 0 0.0004806123
their O 0 0.0005529541
drug O 0 0.09715192
therapy O 0 0.010623322
histories O 0 0.001766659
and O 0 0.00047938613
include O 0 0.0005004353
questions O 0 0.00056903454
about O 0 0.00033995887
their O 0 0.00047694347
use O 0 0.00069743424
of O 0 0.0012228191
herbal O 0 0.9257003
products O 0 0.008872663
and O 0 0.004073278
dietary O 0 0.8551536
supplements O 0 0.9386817
. O 0 0.008746496

In O 0 0.0030353987
addition O 0 0.0017966091
, O 0 0.0020929435
it O 0 0.001300133
is O 0 0.0008261765
important O 0 0.0005967991
to O 0 0.0005563964
report O 0 0.002108903
adverse O 0 0.50782174
effects O 0 0.0017048141
associated O 0 0.00076734246
with O 0 0.00062991044
frequently O 0 0.001270251
consumed O 0 0.014920052
supplements O 0 0.7224358
and O 0 0.00079919735
herbal O 0 0.91713506
products O 0 0.002259614
to O 0 0.00056512625
the O 0 0.0007257084
Food O 0 0.59603995
and O 0 0.0013137602
Drug O 0 0.96597713
Administration O 0 0.4884284
and O 0 0.001748751
in O 0 0.0017740544
the O 0 0.0027989408
literature O 0 0.008901915
. O 0 0.0062734713

Seizures B-Disease 0 0.99494416
induced O 0 0.01052709
by O 0 0.006236996
the O 0 0.007205438
cocaine B-Chemical 1 0.997851
metabolite O 0 0.990122
benzoylecgonine B-Chemical 1 0.99934214
in O 0 0.014720604
rats O 0 0.058415484
. O 0 0.012363936

The O 0 0.003095103
half O 0 0.002168252
- O 0 0.0031068674
life O 0 0.0031369599
( O 0 0.0017439239
t1 O 0 0.0018753187
/ O 0 0.0015467788
2 O 0 0.0006289812
) O 0 0.00073059136
of O 0 0.0006611297
cocaine B-Chemical 1 0.9989641
is O 0 0.00050041865
relatively O 0 0.00047595703
short O 0 0.00035596592
, O 0 0.00041477074
but O 0 0.00024036241
some O 0 0.00025286328
of O 0 0.00029749493
the O 0 0.0002454411
consequences O 0 0.0006651739
of O 0 0.00039543514
its O 0 0.00086049456
use O 0 0.00054340856
, O 0 0.0004816878
such O 0 0.00038899522
as O 0 0.0005781488
seizures B-Disease 2 0.9997502
and O 0 0.001909936
strokes B-Disease 0 0.9914833
, O 0 0.001405245
can O 0 0.0007396039
occur O 0 0.001175247
hours O 0 0.0013381559
after O 0 0.00148878
exposure O 0 0.009190332
. O 0 0.005321899

This O 0 0.0049298946
led O 0 0.0031675745
us O 0 0.002402868
to O 0 0.0013235983
hypothesize O 0 0.0014817395
that O 0 0.00087490265
a O 0 0.0012576057
metabolite O 0 0.7143248
of O 0 0.0024002208
cocaine B-Chemical 1 0.9992429
may O 0 0.0012532545
be O 0 0.0008193553
responsible O 0 0.0008120938
for O 0 0.00069815514
some O 0 0.0012201914
of O 0 0.0019447707
those O 0 0.0037038832
delayed O 0 0.044175968
sequelae O 0 0.85560656
. O 0 0.008352286

We O 0 0.003071761
evaluated O 0 0.002032245
the O 0 0.0014874932
potential O 0 0.001643777
of O 0 0.0013947734
the O 0 0.001073478
major O 0 0.0017721419
metabolite O 0 0.81201756
of O 0 0.0043877326
cocaine B-Chemical 1 0.9994949
, O 0 0.027518963
benzoylecgonine B-Chemical 1 0.9998584
( O 0 0.018256728
BE B-Chemical 0 0.9883726
) O 0 0.004663876
, O 0 0.0027489003
to O 0 0.0028279757
cause O 0 0.051043175
seizures B-Disease 2 0.998694
. O 0 0.0109562585

Two O 0 0.004189256
separate O 0 0.0022453878
equimolar O 0 0.06325363
doses O 0 0.0920331
( O 0 0.002287161
0 O 0 0.0010401703
. O 0 0.0004402273
2 O 0 0.00045532917
and O 0 0.00042518746
0 O 0 0.00044049518
. O 0 0.00022562341
4 O 0 0.0002959966
mumol O 0 0.029928332
) O 0 0.0006071618
of O 0 0.00045547474
either O 0 0.00062956056
cocaine B-Chemical 1 0.99910575
or O 0 0.0009163849
BE B-Chemical 0 0.95611036
were O 0 0.0008550855
injected O 0 0.00092633755
ventricularly O 0 0.05691493
in O 0 0.0014807216
unanesthetized O 0 0.22984749
juvenile O 0 0.1373335
rats O 0 0.022574136
. O 0 0.006408611

Treated O 0 0.28174028
rats O 0 0.007077826
were O 0 0.0017361944
then O 0 0.0010794773
evaluated O 0 0.0009385621
for O 0 0.00082015793
incidence O 0 0.0046876026
, O 0 0.0012770601
latency O 0 0.0049172253
, O 0 0.0010296038
and O 0 0.000942858
seizure B-Disease 2 0.9977055
pattern O 0 0.000834242
or O 0 0.0005843107
for O 0 0.0006905921
locomotor O 0 0.22767277
activity O 0 0.001369493
in O 0 0.001083357
animals O 0 0.0017540724
without O 0 0.0053214068
seizures B-Disease 2 0.9986571
. O 0 0.008831868

BE B-Chemical 0 0.9613692
- O 0 0.011621021
Induced O 0 0.42345715
seizures B-Disease 2 0.9990395
occurred O 0 0.0028092205
more O 0 0.0015025437
frequently O 0 0.0013919703
and O 0 0.00068357727
had O 0 0.00059002056
significantly O 0 0.00063539343
longer O 0 0.0003912477
latencies O 0 0.0048709894
than O 0 0.000425106
those O 0 0.00087763247
induced O 0 0.00116546
by O 0 0.0013240497
equimolar O 0 0.12224445
amounts O 0 0.0030883204
of O 0 0.010789514
cocaine B-Chemical 1 0.9978957
. O 0 0.010171113

Whereas O 0 0.008229611
cocaine B-Chemical 1 0.99748284
- O 0 0.0074919225
induced O 0 0.0040180557
seizures B-Disease 2 0.99938774
were O 0 0.0011429116
best O 0 0.000753733
characterized O 0 0.0008947076
as O 0 0.00036809908
brief O 0 0.0006733282
, O 0 0.00066014385
generalized O 0 0.044870067
, O 0 0.00067548093
and O 0 0.00047455516
tonic O 0 0.4988685
and O 0 0.00046001264
resulted O 0 0.0004120358
in O 0 0.00050397724
death B-Disease 2 0.9910159
, O 0 0.0007598237
those O 0 0.00051712705
induced O 0 0.0005313992
by O 0 0.0004950042
BE B-Chemical 0 0.95571494
were O 0 0.00039906678
prolonged O 0 0.006026009
, O 0 0.00046084987
often O 0 0.00048047147
multiple O 0 0.0005679934
and O 0 0.00040647178
mixed O 0 0.0010300351
in O 0 0.00046606932
type O 0 0.0007223178
, O 0 0.0009906084
and O 0 0.0010059883
rarely O 0 0.0022993947
resulted O 0 0.0021738615
in O 0 0.0041949195
death B-Disease 2 0.9869429
. O 0 0.008033275

Electrical O 0 0.48663723
recordings O 0 0.009181071
from O 0 0.0021609683
the O 0 0.0017428966
hippocampus O 0 0.11854657
showed O 0 0.0011599046
a O 0 0.0011991971
rhythmic O 0 0.038670767
progression O 0 0.19352904
in O 0 0.0010854241
EEG O 0 0.8510492
frequency O 0 0.0013032454
and O 0 0.0013002215
voltage O 0 0.025328899
with O 0 0.0026710543
clinical O 0 0.10851562
seizure B-Disease 2 0.99722666
expression O 0 0.020921875
. O 0 0.008253612

BE B-Chemical 0 0.9480166
- O 0 0.007933317
Injected O 0 0.022593983
rats O 0 0.004681602
that O 0 0.0010731907
did O 0 0.00089445495
not O 0 0.00073092774
have O 0 0.0011436428
seizures B-Disease 2 0.9994949
had O 0 0.0011902512
significantly O 0 0.0010675335
more O 0 0.0010916205
locomotor O 0 0.34846565
activity O 0 0.0011539476
than O 0 0.0007357344
cocaine B-Chemical 1 0.9989017
- O 0 0.0027191213
injected O 0 0.0012885106
animals O 0 0.0016413304
without O 0 0.004948195
seizures B-Disease 2 0.99862874
. O 0 0.008391623

The O 0 0.0032479477
finding O 0 0.0036479484
that O 0 0.0023989403
cocaine B-Chemical 1 0.9984028
- O 0 0.006048557
and O 0 0.0020523232
BE B-Chemical 0 0.98503
- O 0 0.0030995451
induced O 0 0.0021928323
seizures B-Disease 2 0.99973696
differ O 0 0.00096329406
in O 0 0.00035752577
several O 0 0.00038372522
respects O 0 0.001074303
suggests O 0 0.00021087058
more O 0 0.0003366436
than O 0 0.00015548046
one O 0 0.00017488068
mechanism O 0 0.00042326818
for O 0 0.0004032122
cocaine B-Chemical 1 0.9995914
- O 0 0.0027970541
induced O 0 0.0019013073
seizures B-Disease 2 0.99977916
and O 0 0.00065212033
emphasizes O 0 0.00075902726
the O 0 0.00043240018
importance O 0 0.00051994086
of O 0 0.0011614537
a O 0 0.0029216309
cocaine B-Chemical 1 0.9990959
metabolite O 0 0.9809507
, O 0 0.01799715
BE B-Chemical 0 0.9810921
. O 0 0.008442034

The O 0 0.0039135963
selective O 0 0.009273217
5 O 0 0.0027034753
- O 0 0.0037404438
HT6 O 0 0.50052446
receptor O 0 0.30752894
antagonist O 0 0.98846763
Ro4368554 B-Chemical 1 0.9083012
restores O 0 0.0019404172
memory O 0 0.28560272
performance O 0 0.001605621
in O 0 0.00074032915
cholinergic O 0 0.9484689
and O 0 0.0011373272
serotonergic O 0 0.9727145
models O 0 0.0018296518
of O 0 0.001998057
memory B-Disease 0 0.88815546
deficiency I-Disease 0 0.93140644
in O 0 0.0029014216
the O 0 0.003855851
rat O 0 0.050342496
. O 0 0.006844572

Antagonists O 0 0.8503349
at O 0 0.0038943787
serotonin B-Chemical 1 0.99188906
type O 0 0.0029605746
6 O 0 0.0014188747
( O 0 0.0015921155
5 B-Chemical 0 0.00092134316
- I-Chemical 0 0.0017426468
HT I-Chemical 0 0.93862796
( O 0 0.0012878587
6 O 0 0.0005231577
) O 0 0.00093021017
) O 0 0.0008841424
receptors O 0 0.012150832
show O 0 0.0004893312
activity O 0 0.0007971734
in O 0 0.0005996467
models O 0 0.0013682682
of O 0 0.0018236708
learning O 0 0.014053238
and O 0 0.0043246592
memory O 0 0.38044482
. O 0 0.007113887

Although O 0 0.0032218348
the O 0 0.002051378
underlying O 0 0.0031552254
mechanism O 0 0.0023640594
( O 0 0.0017682876
s O 0 0.001287669
) O 0 0.0010878671
are O 0 0.0004905281
not O 0 0.00037851342
well O 0 0.00035559793
understood O 0 0.00080875464
, O 0 0.0005337564
these O 0 0.00053025346
effects O 0 0.0009859176
may O 0 0.00053454435
involve O 0 0.0007041529
an O 0 0.00090673333
increase O 0 0.0009409045
in O 0 0.0016769917
acetylcholine B-Chemical 1 0.9985688
( O 0 0.020302389
ACh B-Chemical 1 0.998042
) O 0 0.008593123
levels O 0 0.005381098
. O 0 0.0063435934

The O 0 0.0024697045
present O 0 0.0015048999
study O 0 0.0018767266
sought O 0 0.001577194
to O 0 0.00077651825
characterize O 0 0.00056802144
the O 0 0.0007147466
cognitive O 0 0.5263589
- O 0 0.0011872007
enhancing O 0 0.0006620387
effects O 0 0.0009038049
of O 0 0.00056680414
the O 0 0.00045420916
5 B-Chemical 0 0.0004766926
- I-Chemical 0 0.0011897627
HT I-Chemical 0 0.9716736
( O 0 0.0008267116
6 O 0 0.00032497913
) O 0 0.0008026024
antagonist O 0 0.93040174
Ro4368554 B-Chemical 1 0.88641256
( O 0 0.0010028927
3 B-Chemical 0 0.00041991903
- I-Chemical 0 0.0010338274
benzenesulfonyl I-Chemical 0 0.9906034
- I-Chemical 0 0.0011960468
7 I-Chemical 0 0.0003498464
- I-Chemical 0 0.00060175674
( I-Chemical 0 0.00043416154
4 I-Chemical 0 0.0003045764
- I-Chemical 0 0.000814007
methyl I-Chemical 0 0.9027864
- I-Chemical 0 0.0021876062
piperazin I-Chemical 0 0.91326463
- I-Chemical 0 0.0015498677
1 I-Chemical 0 0.0005529974
- I-Chemical 0 0.0012646351
yl I-Chemical 0 0.7662984
) I-Chemical 0 0.0023386031
1H I-Chemical 0 0.91211295
- I-Chemical 0 0.0013029134
indole I-Chemical 0 0.9277009
) O 0 0.00077241816
in O 0 0.0002205277
a O 0 0.0002939832
rat O 0 0.0019822621
object O 0 0.00079442724
recognition O 0 0.00059820025
task O 0 0.0006645451
employing O 0 0.00043251846
a O 0 0.0006153458
cholinergic O 0 0.98447937
( O 0 0.0032993096
scopolamine B-Chemical 1 0.99993837
pretreatment O 0 0.76055247
) O 0 0.0018706226
and O 0 0.00045122998
a O 0 0.0007229293
serotonergic O 0 0.9941028
- O 0 0.0026870715
( O 0 0.0011169353
tryptophan B-Chemical 0 0.9883907
( O 0 0.002130475
TRP B-Chemical 0 0.99769694
) O 0 0.0018303336
depletion O 0 0.0020876264
) O 0 0.0006420677
deficient O 0 0.000253209
model O 0 0.00043919432
, O 0 0.00037368212
and O 0 0.00024992306
compared O 0 0.00014731877
its O 0 0.00043277582
pattern O 0 0.00029817896
of O 0 0.00048551479
action O 0 0.0036928984
with O 0 0.00070557056
that O 0 0.00059480383
of O 0 0.0013566536
the O 0 0.0023280836
acetylcholinesterase O 0 0.9962012
inhibitor O 0 0.90397733
metrifonate B-Chemical 0 0.9986558
. O 0 0.012638318

Initial O 0 0.0063489005
testing O 0 0.0024467655
in O 0 0.0014751218
a O 0 0.0012873268
time O 0 0.0009344514
- O 0 0.0013133967
dependent O 0 0.0006757302
forgetting O 0 0.17192261
task O 0 0.0012130913
employing O 0 0.0005997093
a O 0 0.00050007197
24 O 0 0.0004004414
- O 0 0.00043598367
h O 0 0.00023525378
delay O 0 0.0004095036
between O 0 0.000110342015
training O 0 0.00023538571
and O 0 0.00021606803
testing O 0 0.00023224596
showed O 0 0.00023560709
that O 0 0.0002717268
metrifonate B-Chemical 0 0.99918944
improved O 0 0.0024208375
object O 0 0.0024477001
recognition O 0 0.0012331317
( O 0 0.00044929291
at O 0 0.0001522409
10 O 0 0.00022531943
and O 0 0.00021050719
30 O 0 0.00023920879
mg O 0 0.09364352
/ O 0 0.0008088313
kg O 0 0.0027557856
, O 0 0.00045609736
p O 0 0.00054140494
. O 0 0.0002885184
o O 0 0.0014584576
. O 0 0.00046709445
) O 0 0.0012163195
, O 0 0.001161546
whereas O 0 0.0014369629
Ro4368554 B-Chemical 1 0.52763045
was O 0 0.0032451367
inactive O 0 0.009872964
. O 0 0.0064122276

Both O 0 0.006895676
, O 0 0.0052343383
Ro4368554 B-Chemical 1 0.43149522
( O 0 0.0026900365
3 O 0 0.0009930785
and O 0 0.00085861003
10 O 0 0.00083490484
mg O 0 0.16915888
/ O 0 0.0015421523
kg O 0 0.004994274
, O 0 0.0007453568
intraperitoneally O 0 0.012687646
( O 0 0.0006724255
i O 0 0.0009784638
. O 0 0.00022872529
p O 0 0.00047239443
. O 0 0.00021852752
) O 0 0.0005633646
) O 0 0.0005228093
and O 0 0.0004288684
metrifonate B-Chemical 0 0.99928457
( O 0 0.0008073532
10 O 0 0.00039344956
mg O 0 0.20634294
/ O 0 0.00083431916
kg O 0 0.0033348368
, O 0 0.00034800457
p O 0 0.00037925257
. O 0 0.00016696882
o O 0 0.000978365
. O 0 0.00019120547
, O 0 0.00037837215
respectively O 0 0.000887771
) O 0 0.00057917216
reversed O 0 0.0017185007
memory B-Disease 0 0.81816995
deficits I-Disease 0 0.96382636
induced O 0 0.0016076221
by O 0 0.001206215
scopolamine B-Chemical 1 0.9999504
and O 0 0.0028696323
TRP B-Chemical 0 0.99866486
depletion O 0 0.011935181
( O 0 0.0007750748
10 O 0 0.0003867156
mg O 0 0.23103598
/ O 0 0.0008676031
kg O 0 0.0036078535
, O 0 0.0003691936
i O 0 0.00069634744
. O 0 0.00017369945
p O 0 0.0003728173
. O 0 0.00016803587
, O 0 0.00031326772
and O 0 0.00029100248
3 O 0 0.00031545165
mg O 0 0.14453812
/ O 0 0.0010974738
kg O 0 0.0033877862
, O 0 0.0006668904
p O 0 0.0008305898
. O 0 0.00050688203
o O 0 0.0023635195
. O 0 0.0009749807
, O 0 0.0023748723
respectively O 0 0.0051541165
) O 0 0.006446111
. O 0 0.005369214

In O 0 0.0030275846
conclusion O 0 0.0023012352
, O 0 0.0022927797
although O 0 0.0015189319
Ro4368554 B-Chemical 1 0.3348206
did O 0 0.00084255997
not O 0 0.0005063154
improve O 0 0.00042028844
a O 0 0.0005031504
time O 0 0.00041985637
- O 0 0.0007648096
related O 0 0.00034875132
retention O 0 0.02211514
deficit O 0 0.6810117
, O 0 0.000769942
it O 0 0.00043078943
reversed O 0 0.0011837882
a O 0 0.00052460434
cholinergic O 0 0.9465808
and O 0 0.00045679894
a O 0 0.00058850914
serotonergic O 0 0.9913878
memory B-Disease 0 0.8990346
deficit I-Disease 0 0.79907435
, O 0 0.00057330454
suggesting O 0 0.00021159061
that O 0 0.00016944337
both O 0 0.00020629358
mechanisms O 0 0.0005425453
may O 0 0.00025303356
be O 0 0.0002298595
involved O 0 0.000201673
in O 0 0.00018675762
the O 0 0.0002148875
facilitation O 0 0.01690754
of O 0 0.0004267561
object O 0 0.0023727473
memory O 0 0.22137561
by O 0 0.000629064
Ro4368554 B-Chemical 1 0.7047997
and O 0 0.00057429034
, O 0 0.0006127684
possibly O 0 0.0011987712
, O 0 0.00061480585
other O 0 0.00053213956
5 B-Chemical 0 0.00065968535
- I-Chemical 0 0.0017762868
HT I-Chemical 0 0.954056
( O 0 0.0019446374
6 O 0 0.0012511743
) O 0 0.0032877764
receptor O 0 0.17572759
antagonists O 0 0.9689775
. O 0 0.008404755

Evaluation O 0 0.00912034
of O 0 0.004331613
the O 0 0.0032671962
anticocaine O 0 0.018994983
monoclonal O 0 0.014874273
antibody O 0 0.009956423
GNC92H2 B-Chemical 1 0.5964016
as O 0 0.00270782
an O 0 0.004180143
immunotherapy O 0 0.16633894
for O 0 0.009703114
cocaine B-Disease 1 0.9992306
overdose I-Disease 2 0.9990251
. O 0 0.02067406

The O 0 0.0041984925
illicit O 0 0.844231
use O 0 0.003468473
of O 0 0.0032167917
cocaine B-Chemical 1 0.99810153
continues O 0 0.0026607292
in O 0 0.0011337963
epidemic O 0 0.0060648816
proportions O 0 0.0010453749
and O 0 0.0011871995
treatment O 0 0.0033232253
for O 0 0.0028728272
cocaine B-Disease 1 0.999622
overdose I-Disease 2 0.99952817
remains O 0 0.015168632
elusive O 0 0.047067612
. O 0 0.009042403

Current O 0 0.031602006
protein O 0 0.0067211804
- O 0 0.0032079509
based O 0 0.0015487942
technology O 0 0.0018747941
offers O 0 0.0012727748
a O 0 0.0008403274
new O 0 0.00095189235
therapeutic O 0 0.006550283
venue O 0 0.0013459316
by O 0 0.00060729607
which O 0 0.00071968115
antibodies O 0 0.0012229639
bind O 0 0.0003527302
the O 0 0.00046806253
drug O 0 0.113821894
in O 0 0.0005307427
the O 0 0.0005965346
blood O 0 0.0049401578
stream O 0 0.003070904
, O 0 0.001626993
inactivating O 0 0.010497889
its O 0 0.0073670913
toxic O 0 0.8736015
effects O 0 0.024420248
. O 0 0.007405092

The O 0 0.003211918
therapeutic O 0 0.006986521
potential O 0 0.00265351
of O 0 0.0020124323
the O 0 0.0015486889
anticocaine O 0 0.022443047
antibody O 0 0.005180482
GNC92H2 B-Chemical 1 0.56915945
was O 0 0.0012130569
examined O 0 0.0008405332
using O 0 0.0010375531
a O 0 0.001773519
model O 0 0.0031571004
of O 0 0.010261166
cocaine B-Disease 1 0.99937516
overdose I-Disease 2 0.99918586
. O 0 0.01793316

Swiss O 0 0.014033911
albino O 0 0.012345568
mice O 0 0.0013494568
prepared O 0 0.0016869748
with O 0 0.0014286361
intrajugular O 0 0.67643887
catheters O 0 0.028162159
were O 0 0.0006177915
tested O 0 0.00039743373
in O 0 0.0003983112
photocell O 0 0.013172303
cages O 0 0.00077655487
after O 0 0.00023841255
administration O 0 0.0147483265
of O 0 0.00052242546
93 O 0 0.0014032044
mg O 0 0.3909186
/ O 0 0.0014650681
kg O 0 0.009919241
( O 0 0.00078577484
LD50 O 0 0.8610969
) O 0 0.0007640677
of O 0 0.0006821306
cocaine B-Chemical 1 0.99925774
and O 0 0.0009808537
GNC92H2 B-Chemical 1 0.7160295
infusions O 0 0.14123048
ranging O 0 0.0015154616
from O 0 0.00057860336
30 O 0 0.0005937441
to O 0 0.00080325495
190 O 0 0.009258106
mg O 0 0.33728698
/ O 0 0.0071552
kg O 0 0.01907418
. O 0 0.0054360023

GNC92H2 B-Chemical 1 0.30974615
was O 0 0.0033286517
delivered O 0 0.0022392843
30 O 0 0.0015802236
min O 0 0.0017758656
before O 0 0.0008256673
, O 0 0.0014649236
concomitantly O 0 0.0042418046
or O 0 0.0011939461
3 O 0 0.0012706473
min O 0 0.0022599373
after O 0 0.00198288
cocaine B-Chemical 1 0.9954358
treatment O 0 0.021810014
. O 0 0.00838343

Significant O 0 0.00810057
blockade O 0 0.09635864
of O 0 0.0049731536
cocaine B-Chemical 1 0.999129
toxicity B-Disease 2 0.9969716
was O 0 0.0014477209
observed O 0 0.00055811653
with O 0 0.00061037356
the O 0 0.00041470476
higher O 0 0.00044140543
dose O 0 0.006628193
of O 0 0.0008772049
GNC92H2 B-Chemical 1 0.79687977
( O 0 0.0009600368
190 O 0 0.0114839
mg O 0 0.39522883
/ O 0 0.0012190591
kg O 0 0.0057958076
) O 0 0.0005525163
, O 0 0.00032352834
where O 0 0.00023804755
premorbid O 0 0.43490458
behaviors O 0 0.009652597
were O 0 0.00028194077
reduced O 0 0.00029346155
up O 0 0.0002704892
to O 0 0.00026255831
40 O 0 0.00042574655
% O 0 0.00044911695
, O 0 0.00068615895
seizures B-Disease 2 0.9993129
up O 0 0.0006214186
to O 0 0.00056091073
77 O 0 0.0015050605
% O 0 0.0009685857
and O 0 0.0013462718
death B-Disease 2 0.94337624
by O 0 0.0026905546
72 O 0 0.0039202753
% O 0 0.0046694847
. O 0 0.0048669577

Importantly O 0 0.008235487
, O 0 0.009244015
GNC92H2 B-Chemical 1 0.6024469
prevented O 0 0.033450782
death B-Disease 2 0.98358613
even O 0 0.006948923
post O 0 0.009493826
- O 0 0.018099472
cocaine B-Chemical 1 0.9961125
injection O 0 0.11425565
. O 0 0.012157227

The O 0 0.0029978794
results O 0 0.0020915081
support O 0 0.0019231618
the O 0 0.0014395206
important O 0 0.0012106397
potential O 0 0.0016658495
of O 0 0.0019865711
GNC92H2 B-Chemical 1 0.50506324
as O 0 0.0013774997
a O 0 0.0019013516
therapeutic O 0 0.017392948
tool O 0 0.0044497247
against O 0 0.008754619
cocaine B-Disease 1 0.99940276
overdose I-Disease 2 0.9992028
. O 0 0.01879541

Electrocardiographic O 0 0.77875394
evidence O 0 0.0069518653
of O 0 0.008341512
myocardial B-Disease 2 0.9970419
injury I-Disease 2 0.9898319
in O 0 0.007887334
psychiatrically O 0 0.9747201
hospitalized O 0 0.9253981
cocaine B-Chemical 1 0.998616
abusers O 0 0.99420774
. O 0 0.016388852

The O 0 0.00434621
electrocardiograms O 0 0.35143518
( O 0 0.0048466423
ECG O 0 0.7562889
) O 0 0.0026434911
of O 0 0.0014929395
99 O 0 0.004053541
cocaine B-Chemical 1 0.9987651
- O 0 0.003593343
abusing O 0 0.64818037
patients O 0 0.0023497606
were O 0 0.0005976785
compared O 0 0.00037463344
with O 0 0.00075112376
the O 0 0.0009235096
ECGs O 0 0.12967783
of O 0 0.0021165141
50 O 0 0.0052908636
schizophrenic B-Disease 2 0.99365133
controls O 0 0.00987028
. O 0 0.0068507744

Eleven O 0 0.0103357285
of O 0 0.0032878858
the O 0 0.0027389901
cocaine B-Chemical 1 0.9985331
abusers O 0 0.99530196
and O 0 0.0014295316
none O 0 0.0009741524
of O 0 0.0007407329
the O 0 0.00050303433
controls O 0 0.00074471347
had O 0 0.0006112634
ECG O 0 0.8067624
evidence O 0 0.0006343029
of O 0 0.000732311
significant O 0 0.0017810771
myocardial B-Disease 2 0.9994956
injury I-Disease 2 0.99590874
defined O 0 0.0012873833
as O 0 0.0011064431
myocardial B-Disease 0 0.9993637
infarction I-Disease 2 0.99990153
, O 0 0.03996903
ischemia B-Disease 2 0.9995121
, O 0 0.0036041872
and O 0 0.002293489
bundle B-Disease 0 0.06523563
branch I-Disease 0 0.014327827
block I-Disease 0 0.012460351
. O 0 0.0068671

Behavioral O 0 0.09803285
effects O 0 0.008871749
of O 0 0.008008288
urotensin B-Chemical 0 0.99255425
- I-Chemical 0 0.016375145
II I-Chemical 0 0.10340153
centrally O 0 0.036033887
administered O 0 0.011241846
in O 0 0.005151489
mice O 0 0.0056690616
. O 0 0.009217793

Urotensin B-Chemical 0 0.96433216
- I-Chemical 0 0.014009697
II I-Chemical 0 0.11253549
( O 0 0.0061839772
U B-Chemical 0 0.73551595
- I-Chemical 0 0.0057348283
II I-Chemical 0 0.07009152
) O 0 0.0030169436
receptors O 0 0.041803263
are O 0 0.00127451
widely O 0 0.0018964333
distributed O 0 0.0014265288
in O 0 0.0012899989
the O 0 0.0019808393
central O 0 0.007991559
nervous O 0 0.78644
system O 0 0.011596892
. O 0 0.008265659

Intracerebroventricular O 0 0.9899018
( O 0 0.0065393513
i O 0 0.0049156863
. O 0 0.0014207304
c O 0 0.004321603
. O 0 0.00092221535
v O 0 0.005154163
. O 0 0.00061618263
) O 0 0.0010683434
injection O 0 0.0017816527
of O 0 0.0011725487
U B-Chemical 0 0.8409358
- I-Chemical 0 0.0034624625
II I-Chemical 0 0.10339628
causes O 0 0.014049478
hypertension B-Disease 2 0.9996213
and O 0 0.004518213
bradycardia B-Disease 0 0.99911016
and O 0 0.0018748753
stimulates O 0 0.0030167114
prolactin O 0 0.99182117
and O 0 0.0056476602
thyrotropin O 0 0.9942684
secretion O 0 0.4756919
. O 0 0.008913975

However O 0 0.0048169433
, O 0 0.0033769913
the O 0 0.0018938747
behavioral O 0 0.0084812
effects O 0 0.0025524038
of O 0 0.0018470815
centrally O 0 0.02635052
administered O 0 0.018107897
U B-Chemical 0 0.78857493
- I-Chemical 0 0.004439799
II I-Chemical 0 0.028335715
have O 0 0.0021152536
received O 0 0.0033939644
little O 0 0.0044065993
attention O 0 0.013497311
. O 0 0.0075146263

In O 0 0.0026800346
the O 0 0.0016893044
present O 0 0.0011134614
study O 0 0.0015963529
, O 0 0.0010416702
we O 0 0.00038245102
tested O 0 0.00043817234
the O 0 0.00047022858
effects O 0 0.0009516295
of O 0 0.0007694961
i O 0 0.0022321544
. O 0 0.0003615335
c O 0 0.0029913592
. O 0 0.00031371156
v O 0 0.0036389471
. O 0 0.00024781108
injections O 0 0.002205671
of O 0 0.0008005988
U B-Chemical 0 0.80186725
- I-Chemical 0 0.0018987528
II I-Chemical 0 0.023554005
on O 0 0.0003261866
behavioral O 0 0.025082318
, O 0 0.001009337
metabolic O 0 0.11379963
, O 0 0.0012007625
and O 0 0.0012560029
endocrine O 0 0.80506974
responses O 0 0.0047534197
in O 0 0.0023819571
mice O 0 0.0029040342
. O 0 0.0052203764

Administration O 0 0.13899237
of O 0 0.0035392763
graded O 0 0.009607393
doses O 0 0.0531161
of O 0 0.0033888395
U B-Chemical 0 0.8896204
- I-Chemical 0 0.0054829344
II I-Chemical 0 0.08985332
( O 0 0.0013940949
1 O 0 0.00067297753
- O 0 0.00070332433
10 O 0 0.0003743207
, O 0 0.00037129215
000 O 0 0.00038707315
ng O 0 0.0008077449
/ O 0 0.0008011304
mouse O 0 0.0005687811
) O 0 0.0007303981
provoked O 0 0.01815312
: O 0 0.00094572443
( O 0 0.00052351237
1 O 0 0.00030832278
) O 0 0.0003947436
a O 0 0.00027615685
dose O 0 0.008517035
- O 0 0.00050502963
dependent O 0 0.00021846045
reduction O 0 0.00049033505
in O 0 0.0001855655
the O 0 0.0001768294
number O 0 0.00017122358
of O 0 0.000329228
head O 0 0.010737202
dips O 0 0.003966782
in O 0 0.0002620014
the O 0 0.0002902458
hole O 0 0.011480615
- O 0 0.0005997141
board O 0 0.00051173544
test O 0 0.00041869766
; O 0 0.00070611114
( O 0 0.0004139397
2 O 0 0.00026540257
) O 0 0.00037011335
a O 0 0.000264925
dose O 0 0.008331003
- O 0 0.0004908475
dependent O 0 0.00021098743
reduction O 0 0.00047730323
in O 0 0.00017806338
the O 0 0.00016864215
number O 0 0.00016128445
of O 0 0.0002998481
entries O 0 0.00056289445
in O 0 0.00019580423
the O 0 0.00020899523
white O 0 0.00077672437
chamber O 0 0.0005081132
in O 0 0.00020390001
the O 0 0.00024557498
black O 0 0.00073350884
- O 0 0.0006069445
and O 0 0.00033939802
- O 0 0.0005260171
white O 0 0.00078453624
compartment O 0 0.00040015898
test O 0 0.00027623028
, O 0 0.00028900156
and O 0 0.00021029374
in O 0 0.00015903196
the O 0 0.00015731576
number O 0 0.00015340229
of O 0 0.00028351144
entries O 0 0.00051825086
in O 0 0.00018165454
the O 0 0.00018653089
central O 0 0.000568178
platform O 0 0.00037428483
and O 0 0.0002359839
open O 0 0.00021309448
arms O 0 0.00052889716
in O 0 0.00019337243
the O 0 0.0002110506
plus O 0 0.0003308856
- O 0 0.0006353814
maze O 0 0.030080061
test O 0 0.0004437118
; O 0 0.0006284569
and O 0 0.00033347553
( O 0 0.00040977876
3 O 0 0.00021937572
) O 0 0.00035739562
a O 0 0.0002599482
dose O 0 0.008144457
- O 0 0.00048012624
dependent O 0 0.00020158381
increase O 0 0.00022447394
in O 0 0.00018363427
the O 0 0.00018828006
duration O 0 0.00036462516
of O 0 0.0004951884
immobility O 0 0.8180369
in O 0 0.00038454586
the O 0 0.00043492124
forced O 0 0.0056929095
- O 0 0.0013544938
swimming O 0 0.027142541
test O 0 0.0010307517
and O 0 0.0013098052
tail O 0 0.0027577823
suspension O 0 0.0101614725
test O 0 0.0051375516
. O 0 0.0060667875

Intracerebroventricular O 0 0.98745394
injection O 0 0.014022035
of O 0 0.004319763
U B-Chemical 0 0.8440121
- I-Chemical 0 0.004904438
II I-Chemical 0 0.03907734
also O 0 0.001039838
caused O 0 0.00089868944
an O 0 0.0008018719
increase O 0 0.000518668
in O 0 0.00044160237
: O 0 0.00072595116
food O 0 0.0066375965
intake O 0 0.3537372
at O 0 0.0002429575
doses O 0 0.0067223716
of O 0 0.00043322987
100 O 0 0.00076004065
and O 0 0.0003013231
1 O 0 0.00027502177
, O 0 0.00027582375
000 O 0 0.0002898675
ng O 0 0.00062209944
/ O 0 0.0005803829
mouse O 0 0.00037584538
, O 0 0.00035467552
water O 0 0.0043326705
intake O 0 0.33734873
at O 0 0.00019354856
doses O 0 0.0075014452
of O 0 0.000436145
100 O 0 0.0011424614
- O 0 0.000478037
10 O 0 0.00024484834
, O 0 0.0002457525
000 O 0 0.0002711316
ng O 0 0.000590434
/ O 0 0.0005682113
mouse O 0 0.0003655318
, O 0 0.00031182167
and O 0 0.00025450968
horizontal O 0 0.00068426714
locomotion O 0 0.027769053
activity O 0 0.00045767767
at O 0 0.00021606
a O 0 0.00043028075
dose O 0 0.0030700662
of O 0 0.00077482895
10 O 0 0.00084779185
, O 0 0.0010472464
000 O 0 0.0014417856
ng O 0 0.0034588235
/ O 0 0.0049044187
mouse O 0 0.0051784255
. O 0 0.005303522

Whatever O 0 0.018100526
was O 0 0.002733139
the O 0 0.0018749313
dose O 0 0.010392433
, O 0 0.0016427673
the O 0 0.0008584383
central O 0 0.0019699307
administration O 0 0.08485599
of O 0 0.0017419021
U B-Chemical 0 0.8866517
- I-Chemical 0 0.0026550775
II I-Chemical 0 0.029828213
had O 0 0.0004607875
no O 0 0.0002778365
effect O 0 0.0003784827
on O 0 0.00021419612
body O 0 0.0024033706
temperature O 0 0.0024452691
, O 0 0.0009925965
nociception O 0 0.983333
, O 0 0.0035869991
apomorphine B-Chemical 1 0.99990463
- O 0 0.004136419
induced O 0 0.0014439118
penile B-Disease 0 0.94115156
erection I-Disease 0 0.97934514
and O 0 0.0007767962
climbing O 0 0.14162512
behavior O 0 0.0029438718
, O 0 0.00084997265
and O 0 0.00083783723
stress O 0 0.24815047
- O 0 0.0031121357
induced O 0 0.0030587094
plasma O 0 0.33430752
corticosterone B-Chemical 1 0.99615544
level O 0 0.0054167574
. O 0 0.006616574

Taken O 0 0.0053865826
together O 0 0.00244723
, O 0 0.002010724
the O 0 0.0009599796
present O 0 0.0006316021
study O 0 0.0009402331
demonstrates O 0 0.00044842417
that O 0 0.00038942136
the O 0 0.00042913193
central O 0 0.0012016315
injection O 0 0.0024270972
of O 0 0.0010556707
U B-Chemical 0 0.85712415
- I-Chemical 0 0.0020170654
II I-Chemical 0 0.025616711
at O 0 0.0002525585
doses O 0 0.010421352
of O 0 0.0005581093
1 O 0 0.00046427632
- O 0 0.00050595694
10 O 0 0.00027816964
, O 0 0.0002903197
000 O 0 0.00033049472
ng O 0 0.000743571
/ O 0 0.0007895578
mouse O 0 0.0005922856
induces O 0 0.0011002551
anxiogenic O 0 0.99797696
- O 0 0.002534974
and O 0 0.0013259603
depressant O 0 0.99882835
- O 0 0.0030842829
like O 0 0.0013892739
effects O 0 0.0034095917
in O 0 0.0025103623
mouse O 0 0.006010024
. O 0 0.005609584

These O 0 0.005083909
data O 0 0.0033579918
suggest O 0 0.0020603843
that O 0 0.0023548368
U B-Chemical 0 0.69044805
- I-Chemical 0 0.0050448924
II I-Chemical 0 0.032149546
may O 0 0.0014284572
be O 0 0.0011708722
involved O 0 0.0010152444
in O 0 0.0010194732
some O 0 0.0015427413
aspects O 0 0.0020091063
of O 0 0.0052416353
psychiatric B-Disease 2 0.99439263
disorders I-Disease 0 0.9867742
. O 0 0.011510336

Learning O 0 0.042938463
of O 0 0.009657981
rats O 0 0.017408535
under O 0 0.008391985
amnesia B-Disease 0 0.99233025
caused O 0 0.017834991
by O 0 0.020484237
pentobarbital B-Chemical 0 0.99439114
. O 0 0.020747397

Dissociated O 0 0.17290293
learning O 0 0.0080218455
of O 0 0.0025088869
rats O 0 0.004190444
in O 0 0.00093978934
the O 0 0.0007220415
normal O 0 0.0011752772
state O 0 0.0008714719
and O 0 0.00054197677
the O 0 0.00043179342
state O 0 0.00074352673
of O 0 0.0010288673
amnesia B-Disease 0 0.9988495
produced O 0 0.0009436004
by O 0 0.0011200027
pentobarbital B-Chemical 0 0.9993692
( O 0 0.00118671
15 O 0 0.00052017084
mg O 0 0.21413766
/ O 0 0.0016675886
kg O 0 0.006449945
, O 0 0.0013514651
ip O 0 0.4543433
) O 0 0.0021476531
was O 0 0.0014426082
carried O 0 0.001767717
out O 0 0.003235488
. O 0 0.0056346823

Rats O 0 0.029851953
were O 0 0.0033639688
trained O 0 0.0031268515
to O 0 0.0020956309
approach O 0 0.0026423212
a O 0 0.0022949118
shelf O 0 0.00544073
where O 0 0.0021956868
they O 0 0.0025358035
received O 0 0.004995624
food O 0 0.02389748
reinforcement O 0 0.030705476
. O 0 0.010400841

In O 0 0.0037823732
Group O 0 0.0077892467
1 O 0 0.0015518205
the O 0 0.0009861497
rats O 0 0.0020399147
were O 0 0.00064655015
trained O 0 0.0007008437
under O 0 0.000350763
the O 0 0.00040601558
influence O 0 0.00042693838
of O 0 0.0008928549
pentobarbital B-Chemical 0 0.99875605
to O 0 0.00055238465
run O 0 0.00051916385
to O 0 0.00039529926
the O 0 0.00039491995
same O 0 0.00035123932
shelf O 0 0.002252786
as O 0 0.00075672445
in O 0 0.0010258342
the O 0 0.0015925037
normal O 0 0.004754067
state O 0 0.0065314225
. O 0 0.006082034

In O 0 0.004298764
Group O 0 0.008416981
2 O 0 0.0018958567
the O 0 0.0013188934
rats O 0 0.0027625335
were O 0 0.0010082484
trained O 0 0.0011928777
to O 0 0.00090077444
approach O 0 0.0013927169
different O 0 0.0013267435
shelves O 0 0.0043487283
in O 0 0.0017377085
different O 0 0.0030276086
drug O 0 0.36693487
states O 0 0.013997939
. O 0 0.008625845

It O 0 0.008239873
was O 0 0.0038527402
shown O 0 0.0026194595
that O 0 0.0028078358
memory B-Disease 0 0.45324656
dissociation I-Disease 0 0.1011997
occurred O 0 0.005278048
in O 0 0.0036895666
both O 0 0.005044885
groups O 0 0.00860207
. O 0 0.009477392

Differences O 0 0.0034998178
in O 0 0.0018878846
the O 0 0.0013894889
parameters O 0 0.0016626123
of O 0 0.0011260519
training O 0 0.0010336014
under O 0 0.0005767756
the O 0 0.0006509079
influence O 0 0.0006995265
of O 0 0.0015498933
pentobarbital B-Chemical 0 0.9984888
between O 0 0.00094591244
Groups O 0 0.011227158
1 O 0 0.0012045766
and O 0 0.0013172006
2 O 0 0.0016833169
were O 0 0.0021640102
revealed O 0 0.0042987717
. O 0 0.0059013176

These O 0 0.00446496
findings O 0 0.003819422
show O 0 0.001462614
that O 0 0.0011131093
the O 0 0.0011847601
brain O 0 0.051897876
- O 0 0.0017824228
dissociated O 0 0.0019190392
state O 0 0.0010085107
induced O 0 0.0009434655
by O 0 0.0008912388
pentobarbital B-Chemical 0 0.9991468
is O 0 0.0006376131
formed O 0 0.00062354543
with O 0 0.0005321367
the O 0 0.00045401743
participation O 0 0.0008561196
of O 0 0.0007761199
the O 0 0.0008064079
mechanisms O 0 0.0019228746
of O 0 0.002196816
information O 0 0.0043323333
perception O 0 0.023731668
. O 0 0.006365962

The O 0 0.0029743777
effects O 0 0.0032430675
of O 0 0.0021305874
short O 0 0.0018721207
- O 0 0.0024019044
term O 0 0.0020591521
raloxifene B-Chemical 0 0.9990928
therapy O 0 0.11660166
on O 0 0.001069514
fibrinolysis O 0 0.98599756
markers O 0 0.012094151
: O 0 0.0071981694
TAFI O 0 0.99532133
, O 0 0.004715759
tPA O 0 0.8578772
, O 0 0.0031421566
and O 0 0.003149729
PAI O 0 0.2526773
- O 0 0.0071830614
1 O 0 0.005626574
. O 0 0.0059491177

BACKGROUND O 0 0.8297353
: O 0 0.007360831
Markers O 0 0.09794676
of O 0 0.004154912
fibrinolysis O 0 0.9857108
, O 0 0.0049330904
thrombin O 0 0.902381
- O 0 0.0052862107
activatable O 0 0.10380437
fibrinolysis O 0 0.9960932
inhibitor O 0 0.6797607
( O 0 0.007935414
TAFI O 0 0.9977825
) O 0 0.0033075053
, O 0 0.0009464004
tissue O 0 0.012017185
- O 0 0.0012001988
type O 0 0.00070481584
plasminogen O 0 0.9803832
activator O 0 0.047439814
( O 0 0.0025326815
tPA O 0 0.91474354
) O 0 0.0015561181
, O 0 0.0006020229
and O 0 0.0005565926
plasminogen O 0 0.9766634
activator O 0 0.04126846
inhibitor O 0 0.43140513
- O 0 0.002634647
1 O 0 0.0005419269
( O 0 0.00061292516
PAI O 0 0.12347247
- O 0 0.0006786537
1 O 0 0.00028873413
) O 0 0.0003345687
levels O 0 0.0001777863
were O 0 0.00018106797
studied O 0 0.00025532636
for O 0 0.00015888433
the O 0 0.00018977224
evaluation O 0 0.00033848328
of O 0 0.0003460683
short O 0 0.00039057556
- O 0 0.0005961336
term O 0 0.00046454635
effects O 0 0.0011673883
of O 0 0.0019025039
raloxifene B-Chemical 0 0.9995142
administration O 0 0.6380429
in O 0 0.003646087
postmenopausal O 0 0.99269
women O 0 0.27417725
. O 0 0.0070983567

METHODS O 0 0.0070373593
: O 0 0.0038485865
Thirty O 0 0.0049148044
- O 0 0.0022985844
nine O 0 0.0014284353
postmenopausal O 0 0.93315446
women O 0 0.038843922
with O 0 0.0021861787
osteopenia B-Disease 0 0.9987204
or O 0 0.0017387957
osteoporosis B-Disease 2 0.9987078
were O 0 0.0009903059
included O 0 0.0006179246
in O 0 0.0005505623
this O 0 0.00073270267
prospective O 0 0.0028228837
, O 0 0.0015782553
controlled O 0 0.0018655157
clinical O 0 0.011235838
study O 0 0.0068033356
. O 0 0.006160423

Twenty O 0 0.009394582
- O 0 0.0037602624
five O 0 0.0013338081
women O 0 0.004936849
were O 0 0.00119437
given O 0 0.0011370579
raloxifene B-Chemical 0 0.99924207
hydrochloride I-Chemical 0 0.9984617
( O 0 0.0021276036
60 O 0 0.0010124145
mg O 0 0.2677636
/ O 0 0.0013799254
day O 0 0.00062531326
) O 0 0.0010250176
plus O 0 0.0009633922
calcium B-Chemical 1 0.9924973
( O 0 0.0023988078
500 O 0 0.0062821936
mg O 0 0.40989894
/ O 0 0.0047264593
day O 0 0.003171644
) O 0 0.00634292
. O 0 0.005371857

Age O 0 0.15330112
- O 0 0.0058581997
matched O 0 0.0025464343
controls O 0 0.003114456
( O 0 0.0025908018
n O 0 0.001623168
= O 0 0.002220225
14 O 0 0.0016356192
) O 0 0.002095477
were O 0 0.0016110918
given O 0 0.0019972592
only O 0 0.0051484937
calcium B-Chemical 1 0.98263943
. O 0 0.011681492

Plasma O 0 0.71576154
TAFI O 0 0.9885527
, O 0 0.008160531
tPA O 0 0.7987754
, O 0 0.0028723052
and O 0 0.0017244024
PAI O 0 0.16420442
- O 0 0.0017954789
1 O 0 0.00068046025
antigen O 0 0.00412122
levels O 0 0.00045157937
were O 0 0.00033660184
measured O 0 0.00022399268
at O 0 0.00019808277
baseline O 0 0.00038575238
and O 0 0.00030733697
after O 0 0.00020018058
3 O 0 0.0002786041
months O 0 0.00036453514
of O 0 0.0005527644
treatment O 0 0.0015001913
by O 0 0.0012694327
commercially O 0 0.008068685
available O 0 0.0034579341
ELISA O 0 0.264391
kits O 0 0.103620395
. O 0 0.008745264

Variations O 0 0.0111952685
of O 0 0.005084232
individuals O 0 0.004556029
were O 0 0.003125591
assessed O 0 0.0027055147
by O 0 0.0037593404
Wilcoxon O 0 0.010333768
' O 0 0.0055835727
s O 0 0.0069896122
test O 0 0.009073091
. O 0 0.011331481

Relationship O 0 0.007975856
between O 0 0.0030552316
those O 0 0.0040738583
markers O 0 0.004811559
and O 0 0.0037840265
demographic O 0 0.0069124936
characteristics O 0 0.004785712
were O 0 0.0052528083
investigated O 0 0.007858698
. O 0 0.010547653

RESULTS O 0 0.023407826
: O 0 0.0038243402
Three O 0 0.002124045
months O 0 0.0013035429
of O 0 0.0016243173
raloxifene B-Chemical 0 0.99875414
treatment O 0 0.005903103
was O 0 0.00075472565
associated O 0 0.0007725437
with O 0 0.0006078985
a O 0 0.00050124543
significant O 0 0.0005294192
decrease O 0 0.00048604084
in O 0 0.0003083886
the O 0 0.0003849691
plasma O 0 0.077187896
TAFI O 0 0.99737144
antigen O 0 0.15477216
concentrations O 0 0.01614353
( O 0 0.00072834635
16 O 0 0.00036690157
% O 0 0.0003015182
change O 0 0.0002947581
, O 0 0.00041883538
P O 0 0.012998504
< O 0 0.00036475188
0 O 0 0.00028600913
. O 0 0.00017105944
01 O 0 0.001843004
) O 0 0.00044107478
, O 0 0.00029966945
and O 0 0.00024319364
a O 0 0.00027921918
significant O 0 0.0003636154
increase O 0 0.00032970667
in O 0 0.00041949135
tPA O 0 0.7820869
antigen O 0 0.06758184
concentrations O 0 0.01083916
( O 0 0.0009039324
25 O 0 0.0008129726
% O 0 0.0005643702
change O 0 0.00063190254
, O 0 0.001067588
P O 0 0.015980432
< O 0 0.0015219606
0 O 0 0.0015827451
. O 0 0.0015861155
05 O 0 0.030081473
) O 0 0.0063452204
. O 0 0.0056612156

A O 0 0.012409518
significant O 0 0.0027609
correlation O 0 0.001265655
was O 0 0.0012118864
found O 0 0.00088084873
between O 0 0.0005143388
baseline O 0 0.0012880911
TAFI O 0 0.9885352
antigen O 0 0.062004067
concentrations O 0 0.004421981
and O 0 0.0005775952
the O 0 0.00039321333
duration O 0 0.00071135676
of O 0 0.0011682581
amenorrhea B-Disease 0 0.99851817
( O 0 0.0019120313
P O 0 0.049034197
< O 0 0.00077539467
0 O 0 0.0006099781
. O 0 0.0004354105
05 O 0 0.016745863
; O 0 0.0012417824
r O 0 0.0011506107
= O 0 0.0015959432
0 O 0 0.0013907811
. O 0 0.0012605583
33 O 0 0.0038236007
) O 0 0.005555225
. O 0 0.0052793375

CONCLUSION O 0 0.7712847
: O 0 0.0042681727
We O 0 0.0014471656
suggest O 0 0.00090580725
that O 0 0.0007855709
the O 0 0.0007585953
increased O 0 0.0012957951
risk O 0 0.018514901
of O 0 0.0015525129
venous B-Disease 0 0.9120956
thromboembolism I-Disease 0 0.9998061
due O 0 0.0007478929
to O 0 0.0008548501
raloxifene B-Chemical 0 0.99959105
treatment O 0 0.0064288797
may O 0 0.0005888461
be O 0 0.0004422022
related O 0 0.00032115198
to O 0 0.00045975603
increased O 0 0.0016322893
tPA O 0 0.8093363
levels O 0 0.0012409567
, O 0 0.0017064754
but O 0 0.0014747676
not O 0 0.0025172387
TAFI O 0 0.9856764
levels O 0 0.0066363704
. O 0 0.0069165933

Valproate B-Chemical 1 0.99491864
- O 0 0.07660275
induced O 0 0.074715994
encephalopathy B-Disease 2 0.9937317
. O 0 0.047918692

Valproate B-Chemical 1 0.9988274
- O 0 0.015440739
induced O 0 0.00840986
encephalopathy B-Disease 2 0.9991042
is O 0 0.002663119
a O 0 0.0019151241
rare O 0 0.021295762
syndrome O 0 0.7710815
that O 0 0.0010805654
may O 0 0.0012758983
manifest O 0 0.009894098
in O 0 0.0014554384
otherwise O 0 0.0040011923
normal O 0 0.011293557
epileptic B-Disease 2 0.9975242
individuals O 0 0.012853652
. O 0 0.007607363

It O 0 0.005779438
may O 0 0.002425851
even O 0 0.0016880295
present O 0 0.0010642239
in O 0 0.0010715205
patients O 0 0.0024286427
who O 0 0.0021483635
have O 0 0.0011569699
tolerated O 0 0.008635241
this O 0 0.0012415566
medicine O 0 0.0074436716
well O 0 0.0015274193
in O 0 0.0019066428
the O 0 0.0029436408
past O 0 0.0083485
. O 0 0.0071418793

It O 0 0.009849084
is O 0 0.004811319
usually O 0 0.0055218753
but O 0 0.0037057314
not O 0 0.0033578689
necessarily O 0 0.00496945
associated O 0 0.007753574
with O 0 0.016651506
hyperammonemia B-Disease 0 0.9979533
. O 0 0.020436924

The O 0 0.004919232
EEG O 0 0.5858729
shows O 0 0.0022827433
characteristic O 0 0.004196854
triphasic O 0 0.7973395
waves O 0 0.044180673
in O 0 0.0021650791
most O 0 0.0034637626
patients O 0 0.005382666
with O 0 0.0038707915
this O 0 0.0054060793
complication O 0 0.50064605
. O 0 0.009996738

A O 0 0.024490407
case O 0 0.007248644
of O 0 0.01071583
valproate B-Chemical 0 0.9990938
- O 0 0.03310673
induced O 0 0.026609616
encephalopathy B-Disease 2 0.9984407
is O 0 0.013474841
presented O 0 0.013991479
. O 0 0.012408525

The O 0 0.0053379415
problems O 0 0.009867912
in O 0 0.0036735996
diagnosing O 0 0.006824449
this O 0 0.0035887773
condition O 0 0.00625193
are O 0 0.0050700065
subsequently O 0 0.00851786
discussed O 0 0.008788168
. O 0 0.010803322

Recurrent O 0 0.8703899
dysphonia B-Disease 0 0.9808415
and O 0 0.06484765
acitretin B-Chemical 0 0.99142075
. O 0 0.050259184

We O 0 0.0034792025
report O 0 0.00440159
the O 0 0.0017933743
case O 0 0.0015568378
of O 0 0.0015779802
a O 0 0.0016495192
woman O 0 0.019477736
complaining O 0 0.18103527
of O 0 0.0029174958
dysphonia B-Disease 0 0.9964264
while O 0 0.0018693623
she O 0 0.0021770925
was O 0 0.002086526
treated O 0 0.0048793317
by O 0 0.0069688847
acitretin B-Chemical 0 0.9977367
. O 0 0.012603645

Her O 0 0.012205454
symptoms O 0 0.09992716
totally O 0 0.0050267656
regressed O 0 0.0061811414
after O 0 0.0014709093
drug O 0 0.284681
withdrawal O 0 0.68019974
and O 0 0.0025728496
reappeared O 0 0.014304895
when O 0 0.0029762774
acitretin B-Chemical 0 0.9979855
was O 0 0.0076490836
reintroduced O 0 0.014130748
. O 0 0.008772286

To O 0 0.0030460781
our O 0 0.0022426632
knowledge O 0 0.0029113158
, O 0 0.0021386435
this O 0 0.0012842035
is O 0 0.0011312767
the O 0 0.0009648982
first O 0 0.0009637347
case O 0 0.0015992824
of O 0 0.0038326457
acitretin B-Chemical 0 0.9990212
- O 0 0.032247316
induced O 0 0.026618106
dysphonia B-Disease 0 0.99582905
. O 0 0.012125936

This O 0 0.005399156
effect O 0 0.0030435708
may O 0 0.0020592962
be O 0 0.0015470897
related O 0 0.00092471193
to O 0 0.00091081514
the O 0 0.00091017055
pharmacological O 0 0.104363814
effect O 0 0.0014985541
of O 0 0.0016559236
this O 0 0.0018447547
drug O 0 0.3045529
on O 0 0.0027716826
mucous O 0 0.86467963
membranes O 0 0.2646336
. O 0 0.009276004

Nitro B-Chemical 0 0.59245443
- I-Chemical 0 0.018468862
L I-Chemical 1 0.8654289
- I-Chemical 1 0.01568678
arginine I-Chemical 1 0.9790886
methyl I-Chemical 0 0.98688823
ester I-Chemical 0 0.97786796
: O 0 0.004876665
a O 0 0.0026032964
potential O 0 0.0038465466
protector O 0 0.10083717
against O 0 0.00981979
gentamicin B-Chemical 1 0.9978746
ototoxicity B-Disease 0 0.99868435
. O 0 0.01829924

The O 0 0.006598011
nitric B-Chemical 0 0.9925316
oxide I-Chemical 0 0.99526995
( O 0 0.03218028
NO B-Chemical 0 0.9965892
) O 0 0.024419153
inhibitor O 0 0.61420983
nitro B-Chemical 0 0.9977436
- I-Chemical 0 0.0447555
L I-Chemical 1 0.9737432
- I-Chemical 1 0.016465435
arginine I-Chemical 1 0.99280167
methyl I-Chemical 0 0.99580175
ester I-Chemical 0 0.9955264
( O 0 0.012041065
L B-Chemical 1 0.9728337
- I-Chemical 1 0.016616832
NAME I-Chemical 1 0.999532
) O 0 0.0021015494
may O 0 0.00043386882
act O 0 0.00056432065
as O 0 0.00025398246
an O 0 0.00046560765
otoprotectant O 0 0.036299296
against O 0 0.00033566676
high B-Disease 0 0.0006900566
- I-Disease 0 0.00067722064
frequency I-Disease 0 0.00046983853
hearing I-Disease 0 0.72032326
loss I-Disease 0 0.0017001679
caused O 0 0.000620015
by O 0 0.00069010496
gentamicin B-Chemical 1 0.99906653
, O 0 0.00059810304
but O 0 0.0002200723
further O 0 0.00023219593
studies O 0 0.00034200738
are O 0 0.0001857528
needed O 0 0.000116584466
to O 0 0.00014717164
confirm O 0 0.00012949988
this O 0 0.0002477619
. O 0 0.00023375172
Aminoglycoside B-Chemical 0 0.9968761
antibiotics O 0 0.5224195
are O 0 0.00035973167
still O 0 0.00027598758
widely O 0 0.0005507486
used O 0 0.00029908918
by O 0 0.00039262974
virtue O 0 0.0011310009
of O 0 0.00075599866
their O 0 0.0009306317
efficacy O 0 0.0036726468
and O 0 0.0017274932
low O 0 0.0032982577
cost O 0 0.006504211
. O 0 0.0057579665

Their O 0 0.080843
ototoxicity B-Disease 0 0.99773765
is O 0 0.0031484193
a O 0 0.0021117185
serious O 0 0.05317153
health O 0 0.0057435823
problem O 0 0.0018630773
and O 0 0.0008049764
, O 0 0.00072415086
as O 0 0.0003677576
their O 0 0.00062311185
ototoxic B-Disease 0 0.99407226
mechanism O 0 0.0010028277
involves O 0 0.00044390006
the O 0 0.00036987793
production O 0 0.0010726522
of O 0 0.0008877085
NO B-Chemical 0 0.9979032
, O 0 0.00066934497
we O 0 0.00014876442
need O 0 0.0001904113
to O 0 0.00017444
assess O 0 0.00010752916
the O 0 0.00020906878
use O 0 0.00035803264
of O 0 0.0006252409
NO B-Chemical 0 0.9970493
inhibitors O 0 0.12634458
for O 0 0.00050167117
the O 0 0.0005588524
prevention O 0 0.004397993
of O 0 0.0022032503
aminoglycoside B-Chemical 0 0.9969663
- O 0 0.0139037585
induced O 0 0.023991058
sensorineural B-Disease 2 0.99934345
hearing I-Disease 2 0.9886933
loss I-Disease 2 0.14666799
. O 0 0.008284285

In O 0 0.0027241001
this O 0 0.001753009
experimental O 0 0.0019444339
study O 0 0.0016876471
we O 0 0.00067327457
used O 0 0.00092103606
30 O 0 0.0009996059
Sprague O 0 0.13845304
- O 0 0.0018745414
Dawley O 0 0.14211707
rats O 0 0.002107627
, O 0 0.0008053005
27 O 0 0.0008311804
of O 0 0.00066296395
which O 0 0.0009505285
had O 0 0.0013449084
gentamicin B-Chemical 1 0.9965649
instilled O 0 0.058611427
into O 0 0.0012499071
the O 0 0.0021345874
middle O 0 0.006376835
ear O 0 0.019992784
. O 0 0.0067453855

The O 0 0.0064573344
otoprotectant O 0 0.20928131
L B-Chemical 1 0.9108791
- I-Chemical 1 0.017929902
NAME I-Chemical 1 0.9966497
was O 0 0.0034213087
administered O 0 0.0077014607
topically O 0 0.70418453
to O 0 0.002726866
12 O 0 0.0023898815
/ O 0 0.0053376225
27 O 0 0.0055555017
animals O 0 0.0046476596
. O 0 0.0068567083

Its O 0 0.05093327
effect O 0 0.0030637793
was O 0 0.001638413
determined O 0 0.00094624277
in O 0 0.0007825732
terms O 0 0.00061247405
of O 0 0.000865597
attenuation O 0 0.0021423101
of O 0 0.0012660976
hearing B-Disease 0 0.83148015
loss I-Disease 0 0.0031921389
, O 0 0.0008948889
measured O 0 0.0004282554
by O 0 0.00063852133
shifts O 0 0.0013797573
in O 0 0.0007543956
the O 0 0.0012098518
auditory O 0 0.11943169
brainstem O 0 0.6655148
response O 0 0.004784222
threshold O 0 0.0052632582
. O 0 0.006068194

L B-Chemical 1 0.90650445
- I-Chemical 1 0.019491145
NAME I-Chemical 1 0.99689806
reduced O 0 0.0065410426
gentamicin B-Chemical 1 0.99830663
- O 0 0.0047332253
induced O 0 0.001941608
hearing B-Disease 0 0.80208164
loss I-Disease 0 0.0022459712
in O 0 0.0004682361
the O 0 0.0004039827
high O 0 0.000713231
- O 0 0.00074676226
frequency O 0 0.00046851046
range O 0 0.00074513874
, O 0 0.0005485548
but O 0 0.0003649947
gave O 0 0.0005586354
no O 0 0.00039555144
protection O 0 0.0017184925
in O 0 0.0006271358
the O 0 0.0008279012
middle O 0 0.0019335487
or O 0 0.0013550279
low O 0 0.0030573166
frequencies O 0 0.0048517133
. O 0 0.0060191383

Safety O 0 0.022401217
profile O 0 0.0031106595
of O 0 0.00229502
a O 0 0.0023044532
nicotine B-Chemical 1 0.9962256
lozenge O 0 0.9680084
compared O 0 0.0006275106
with O 0 0.000689109
that O 0 0.00042329845
of O 0 0.0008632626
nicotine B-Chemical 1 0.9981407
gum O 0 0.8805969
in O 0 0.0005974592
adult O 0 0.0009064327
smokers O 0 0.017091302
with O 0 0.0003937246
underlying O 0 0.001015947
medical O 0 0.0061358674
conditions O 0 0.0006875294
: O 0 0.00059861713
a O 0 0.00036564333
12 O 0 0.00028161114
- O 0 0.00046971493
week O 0 0.00032432386
, O 0 0.0005253169
randomized O 0 0.00087080995
, O 0 0.0009561864
open O 0 0.0011262612
- O 0 0.0025643213
label O 0 0.004790898
study O 0 0.005545976
. O 0 0.005446156

BACKGROUND O 0 0.89083374
: O 0 0.014225068
Nicotine B-Chemical 1 0.99864453
polacrilex O 0 0.99454725
lozenges O 0 0.97152
deliver O 0 0.0017026009
25 O 0 0.0015587274
% O 0 0.00079314236
to O 0 0.00051237294
27 O 0 0.0008684016
% O 0 0.0005701937
more O 0 0.00067409186
nicotine B-Chemical 1 0.98000896
compared O 0 0.0004342859
with O 0 0.00074629026
equivalent O 0 0.001053336
doses O 0 0.033082396
of O 0 0.00446475
nicotine B-Chemical 1 0.9979468
polacrilex O 0 0.996378
gum O 0 0.9705613
. O 0 0.010410584

The O 0 0.0032198697
increased O 0 0.004082507
nicotine B-Chemical 1 0.9898399
exposure O 0 0.011661076
from O 0 0.0012835823
the O 0 0.0010659168
lozenge O 0 0.8182314
has O 0 0.0008948254
raised O 0 0.0009455344
questions O 0 0.0008739321
about O 0 0.00047336626
the O 0 0.0004862308
relative O 0 0.000506071
safety O 0 0.0019583267
of O 0 0.0014991537
the O 0 0.0021762971
lozenge O 0 0.9215798
and O 0 0.006492925
gum O 0 0.8534844
. O 0 0.009899625

OBJECTIVE O 0 0.45978087
: O 0 0.0037548179
The O 0 0.00128497
objective O 0 0.0016337911
of O 0 0.00094153255
this O 0 0.0006691964
study O 0 0.000864016
was O 0 0.00044402998
to O 0 0.00032203348
compare O 0 0.00017039523
the O 0 0.00026781455
safety O 0 0.00079123396
profiles O 0 0.00031142772
of O 0 0.00040583443
the O 0 0.000347365
4 O 0 0.00036180057
- O 0 0.0007443084
mg O 0 0.5067173
nicotine B-Chemical 1 0.9985536
lozenge O 0 0.9756385
and O 0 0.00062288705
4 O 0 0.000394141
- O 0 0.00076120684
mg O 0 0.43319607
nicotine B-Chemical 1 0.99744844
gum O 0 0.77556825
in O 0 0.0006776835
smokers O 0 0.027174234
with O 0 0.00078650605
selected O 0 0.0008861354
label O 0 0.0036885433
- O 0 0.0031065843
restricted O 0 0.002720514
diseases O 0 0.5903764
. O 0 0.007067404

METHODS O 0 0.006247227
: O 0 0.0031827271
This O 0 0.0019555981
was O 0 0.0010562364
a O 0 0.001044591
multicenter O 0 0.017626472
, O 0 0.00094216026
randomized O 0 0.0010207911
, O 0 0.00068473455
open O 0 0.00048254489
- O 0 0.0006781119
label O 0 0.0008229802
study O 0 0.0005232353
in O 0 0.00027716655
adult O 0 0.0005750728
smokers O 0 0.014940199
with O 0 0.00056098157
heart B-Disease 0 0.5247988
disease I-Disease 0 0.84098387
, O 0 0.0020521434
hypertension B-Disease 2 0.99945647
not O 0 0.00050385494
controlled O 0 0.0005126995
by O 0 0.0006164995
medication O 0 0.10990209
, O 0 0.0011157421
and O 0 0.0010966553
/ O 0 0.0030439876
or O 0 0.002310657
diabetes B-Disease 2 0.9956108
mellitus I-Disease 0 0.9975102
. O 0 0.009784274

Patients O 0 0.007817461
were O 0 0.0021003406
randomized O 0 0.0021998712
in O 0 0.0011462598
a O 0 0.0012074807
1 O 0 0.00096463395
: O 0 0.0009943557
1 O 0 0.00052062224
ratio O 0 0.00051276176
to O 0 0.0003848092
receive O 0 0.000520102
the O 0 0.00043974316
4 O 0 0.00050603243
- O 0 0.0010783445
mg O 0 0.5078264
nicotine B-Chemical 1 0.99775285
lozenge O 0 0.9677564
or O 0 0.0011697493
4 O 0 0.0012896071
- O 0 0.0032498846
mg O 0 0.71862483
nicotine B-Chemical 1 0.9952673
gum O 0 0.94522625
. O 0 0.009484055

Safety O 0 0.01834138
assessments O 0 0.0028350733
were O 0 0.0014887332
made O 0 0.0011555848
at O 0 0.0006586005
baseline O 0 0.00089841126
and O 0 0.00069011276
at O 0 0.00043245786
2 O 0 0.0005540831
, O 0 0.0005889791
4 O 0 0.00037412625
, O 0 0.0004578605
6 O 0 0.00027854412
, O 0 0.00037763306
and O 0 0.00032200332
12 O 0 0.00026398076
weeks O 0 0.00032076365
after O 0 0.00027689768
the O 0 0.0005209598
start O 0 0.00076866243
of O 0 0.0017470854
product O 0 0.004540905
use O 0 0.005566859
. O 0 0.005853167

RESULTS O 0 0.021823548
: O 0 0.0040218076
Nine O 0 0.0035436514
hundred O 0 0.0017719839
one O 0 0.0008765979
patients O 0 0.0016148315
were O 0 0.00066550414
randomized O 0 0.0008689934
to O 0 0.0005177741
treatment O 0 0.0012184706
, O 0 0.00077478244
447 O 0 0.008128652
who O 0 0.00090693805
received O 0 0.00054196204
the O 0 0.0004709608
lozenge O 0 0.74396616
and O 0 0.0006382126
454 O 0 0.0014537236
who O 0 0.001256533
received O 0 0.0009009101
the O 0 0.0009869463
gum O 0 0.5807623
( O 0 0.002978395
safety O 0 0.0062804315
population O 0 0.005211402
) O 0 0.007630618
. O 0 0.0058240914

The O 0 0.0050634686
majority O 0 0.004808142
were O 0 0.0046163066
women O 0 0.014373612
( O 0 0.0057037757
52 O 0 0.0056874114
. O 0 0.0033056727
7 O 0 0.0043792296
% O 0 0.006669976
) O 0 0.010408206
. O 0 0.009608773

Patients O 0 0.008995012
' O 0 0.0025885208
mean O 0 0.001157638
age O 0 0.0020846443
was O 0 0.0010117635
53 O 0 0.0013801699
. O 0 0.00046365536
9 O 0 0.00047057157
years O 0 0.00065814296
, O 0 0.00041786133
their O 0 0.00029307793
mean O 0 0.00021056659
weight O 0 0.0012505233
was O 0 0.00036072638
193 O 0 0.0030276969
. O 0 0.0002061143
9 O 0 0.00025980867
pounds O 0 0.00081607763
, O 0 0.0003196872
and O 0 0.00025472406
they O 0 0.00025040965
smoked O 0 0.02451214
a O 0 0.00030959115
mean O 0 0.00019687224
of O 0 0.000423274
25 O 0 0.00066898786
. O 0 0.0002927146
2 O 0 0.00051669247
cigarettes O 0 0.02309743
per O 0 0.00055764196
day O 0 0.0011138316
at O 0 0.001292597
baseline O 0 0.0040518353
. O 0 0.0045629893

Five O 0 0.005616765
hundred O 0 0.0035329757
fifty O 0 0.0033585567
- O 0 0.002313027
three O 0 0.0007573258
patients O 0 0.0021652353
, O 0 0.0011898379
264 O 0 0.0045738686
taking O 0 0.0012154081
the O 0 0.0005766202
lozenge O 0 0.77505136
and O 0 0.0006433078
289 O 0 0.0070639593
taking O 0 0.0008758452
the O 0 0.00038935698
gum O 0 0.44041845
, O 0 0.0006043351
used O 0 0.00026478662
the O 0 0.00023448546
study O 0 0.00042726184
product O 0 0.00055776554
for O 0 0.00027808163
> O 0 0.0006546033
or O 0 0.00022249397
= O 0 0.00034982138
4 O 0 0.00014024241
days O 0 0.0001330843
per O 0 9.764285e-05
week O 0 0.00016554508
during O 0 0.00016098299
the O 0 0.00024843914
first O 0 0.00030388407
2 O 0 0.00048500785
weeks O 0 0.00064450415
( O 0 0.001253191
evaluable O 0 0.007289547
population O 0 0.003508341
) O 0 0.006060574
. O 0 0.005009229

The O 0 0.004635518
nicotine B-Chemical 1 0.9906679
lozenge O 0 0.9667389
and O 0 0.0039582564
nicotine B-Chemical 1 0.9962632
gum O 0 0.8432883
were O 0 0.0013784743
equally O 0 0.0010940895
well O 0 0.0006949175
tolerated O 0 0.011995388
, O 0 0.00096906757
despite O 0 0.0007773086
increased O 0 0.0025500047
nicotine B-Chemical 1 0.99616015
exposure O 0 0.024669629
from O 0 0.0027267504
the O 0 0.0042540054
lozenge O 0 0.94352806
. O 0 0.008145986

The O 0 0.0030979086
incidence O 0 0.005798127
of O 0 0.0026278219
adverse O 0 0.51841
events O 0 0.0064511127
in O 0 0.0007058558
the O 0 0.00052831747
2 O 0 0.00044104076
groups O 0 0.0003902155
was O 0 0.00026535348
similar O 0 0.00017509909
during O 0 0.00015641443
the O 0 0.00019021916
first O 0 0.0001714672
2 O 0 0.00019007936
weeks O 0 0.0001635829
of O 0 0.00023512325
product O 0 0.0005016501
use O 0 0.0003836906
( O 0 0.0003589549
evaluation O 0 0.00037047238
population O 0 0.0005053973
: O 0 0.00045117192
55 O 0 0.00033179572
. O 0 0.00014064873
3 O 0 0.00019106569
% O 0 0.00029054953
lozenge O 0 0.5277133
, O 0 0.0004005622
54 O 0 0.00049911335
. O 0 0.00014740448
7 O 0 0.00019052354
% O 0 0.00027047144
gum O 0 0.20775735
) O 0 0.0006844077
, O 0 0.00030769967
as O 0 0.00015005343
well O 0 0.00014448976
as O 0 0.00013606006
during O 0 0.00012495302
the O 0 0.00016215215
entire O 0 0.00016470383
study O 0 0.00042848405
( O 0 0.00036757987
safety O 0 0.00086023606
population O 0 0.00056355476
: O 0 0.00053673814
63 O 0 0.0005559892
. O 0 0.00019726908
8 O 0 0.00029239664
% O 0 0.00034855175
and O 0 0.00037428897
58 O 0 0.000796624
. O 0 0.0004077053
6 O 0 0.0006161295
% O 0 0.001144578
, O 0 0.0018178679
respectively O 0 0.004186093
) O 0 0.005808295
. O 0 0.005101899

Stratification O 0 0.17263576
of O 0 0.0036278458
patients O 0 0.0046863845
by O 0 0.0017835167
sex O 0 0.008090829
, O 0 0.0014061996
age O 0 0.001542142
, O 0 0.00072070095
extent O 0 0.00031861677
of O 0 0.00049997994
concurrent O 0 0.002748916
smoking O 1 0.7975895
, O 0 0.00068426423
extent O 0 0.0002305553
of O 0 0.0003818341
product O 0 0.0007658814
use O 0 0.0004811532
, O 0 0.0004228006
and O 0 0.000330582
severity O 0 0.0059247077
of O 0 0.0005878371
adverse O 0 0.6509125
events O 0 0.005326553
revealed O 0 0.00043569537
no O 0 0.0003260781
clinically O 0 0.012030634
significant O 0 0.00061358913
differences O 0 0.00039418536
between O 0 0.0004894996
the O 0 0.0014207785
lozenge O 0 0.87874913
and O 0 0.0052021546
gum O 0 0.8329745
. O 0 0.008622059

The O 0 0.0032386126
most O 0 0.0035160831
common O 0 0.0032602744
adverse O 0 0.4518588
events O 0 0.010600453
were O 0 0.0020029806
nausea B-Disease 2 0.99967253
( O 0 0.0020351172
17 O 0 0.00090919365
. O 0 0.00028553672
2 O 0 0.00033158768
% O 0 0.0003198384
and O 0 0.00027405174
16 O 0 0.00031713603
. O 0 0.00017854518
1 O 0 0.00026991422
% O 0 0.00031105295
; O 0 0.00039403266
95 O 0 0.000579801
% O 0 0.0003410711
CI O 0 0.051752467
, O 0 0.00042139553
- O 0 0.00044412373
3 O 0 0.0002018754
. O 0 0.00012978766
7 O 0 0.0001525193
to O 0 0.00015822034
6 O 0 0.00015920537
. O 0 0.0001294252
0 O 0 0.00026393193
) O 0 0.0004196959
, O 0 0.00046767917
hiccups B-Disease 2 0.9961313
( O 0 0.0005497461
10 O 0 0.00026923878
. O 0 0.00012714107
7 O 0 0.00015828462
% O 0 0.00018659669
and O 0 0.00017299448
6 O 0 0.00014745975
. O 0 0.00011486982
6 O 0 0.00014462044
% O 0 0.00023065094
; O 0 0.00031350166
95 O 0 0.00048639145
% O 0 0.00028128648
CI O 0 0.031506516
, O 0 0.00029425102
0 O 0 0.00023911304
. O 0 0.0001184649
5 O 0 0.00014050692
to O 0 0.00015285096
7 O 0 0.00017434587
. O 0 0.00012605594
8 O 0 0.00021226348
) O 0 0.00036721912
, O 0 0.00031987682
and O 0 0.00042561162
headache B-Disease 2 0.9989889
( O 0 0.00064772565
8 O 0 0.00026262112
. O 0 0.00013465504
7 O 0 0.00017071204
% O 0 0.00020635064
and O 0 0.00020076284
9 O 0 0.00022780252
. O 0 0.00014333228
9 O 0 0.00023687677
% O 0 0.00030099374
; O 0 0.00043033305
95 O 0 0.00076227786
% O 0 0.0005824554
Cl O 0 0.99695647
, O 0 0.000945067
- O 0 0.000887109
5 O 0 0.00041543835
. O 0 0.00032155946
0 O 0 0.0005865809
to O 0 0.00063034624
2 O 0 0.0010228539
. O 0 0.000998012
6 O 0 0.0017833554
) O 0 0.004489964
. O 0 0.0045155575

Serious O 0 0.36013854
adverse O 0 0.4794022
events O 0 0.007878942
were O 0 0.0019355327
reported O 0 0.0019585597
in O 0 0.0011393097
11 O 0 0.0012674604
and O 0 0.0010929169
13 O 0 0.0013750219
patients O 0 0.0023028792
in O 0 0.0013290327
the O 0 0.001839391
respective O 0 0.0026511548
groups O 0 0.005995625
. O 0 0.0071342955

Fewer O 0 0.011432028
than O 0 0.0018864889
6 O 0 0.001229811
% O 0 0.0010821538
of O 0 0.00089363544
patients O 0 0.001529508
in O 0 0.0004972981
either O 0 0.00044788097
group O 0 0.00052136113
were O 0 0.0003532769
considered O 0 0.0002981588
by O 0 0.00030321613
the O 0 0.0002877435
investigator O 0 0.0009109982
to O 0 0.00029276818
have O 0 0.00035084356
a O 0 0.00047793152
worsening O 0 0.23554187
of O 0 0.00065361644
their O 0 0.0006250384
overall O 0 0.00090053154
disease O 0 0.45406005
condition O 0 0.0028056672
during O 0 0.0013124776
the O 0 0.0023071659
study O 0 0.005548833
. O 0 0.0053457906

The O 0 0.0029522113
majority O 0 0.002441795
of O 0 0.0024690656
patients O 0 0.0049428823
( O 0 0.0023176996
> O 0 0.0019290359
60 O 0 0.0009830142
% O 0 0.0008603578
) O 0 0.0009083754
experienced O 0 0.0009157018
no O 0 0.00050169183
change O 0 0.00072634284
in O 0 0.0006999265
their O 0 0.0012975476
disease O 0 0.31833732
status O 0 0.0034054806
from O 0 0.0029784315
baseline O 0 0.0061439043
. O 0 0.0058326707

CONCLUSION O 0 0.80266786
: O 0 0.0049358653
The O 0 0.0017775081
4 O 0 0.0014844758
- O 0 0.0021360067
mg O 0 0.45010862
nicotine B-Chemical 1 0.99744
lozenge O 0 0.9786314
and O 0 0.0011551507
4 O 0 0.0006213937
- O 0 0.0009796213
mg O 0 0.4305647
nicotine B-Chemical 1 0.99742645
gum O 0 0.72418785
had O 0 0.0005252333
comparable O 0 0.00026360602
safety O 0 0.00094911264
profiles O 0 0.0003446925
in O 0 0.00030200902
these O 0 0.0005571988
patients O 0 0.0016443086
with O 0 0.00097478984
label O 0 0.0034125762
- O 0 0.0020649403
restricted O 0 0.0014446091
medical O 0 0.01142082
conditions O 0 0.0058317473
. O 0 0.00560935

Pharmacological O 0 0.9424396
modulation O 0 0.008858477
of O 0 0.0051053907
pain B-Disease 0 0.9818755
- O 0 0.0042030383
related O 0 0.0011693923
brain O 0 0.022543492
activity O 0 0.0012196272
during O 0 0.0006199819
normal O 0 0.0015699347
and O 0 0.001176302
central O 0 0.003286486
sensitization O 0 0.1732024
states O 0 0.0052696783
in O 0 0.0034501904
humans O 0 0.015323713
. O 0 0.0065169986

Abnormal O 0 0.014472227
processing O 0 0.0037695856
of O 0 0.0028188545
somatosensory O 0 0.40665612
inputs O 0 0.006979267
in O 0 0.0009008946
the O 0 0.0007789677
central O 0 0.0025499298
nervous O 0 0.7291442
system O 0 0.0017048856
( O 0 0.000899341
central O 0 0.0015021152
sensitization O 0 0.20204248
) O 0 0.0009080812
is O 0 0.0002867116
the O 0 0.00022510685
mechanism O 0 0.0003783177
accounting O 0 0.00059411256
for O 0 0.00025481687
the O 0 0.00031798834
enhanced O 0 0.0008166233
pain B-Disease 0 0.9627907
sensitivity O 0 0.0030776835
in O 0 0.0004576118
the O 0 0.00054581946
skin O 0 0.01761688
surrounding O 0 0.0021227833
tissue B-Disease 0 0.3475958
injury I-Disease 0 0.9941817
( O 0 0.009631909
secondary B-Disease 2 0.36547333
hyperalgesia I-Disease 2 0.999169
) O 0 0.035926472
. O 0 0.0072901407

Secondary B-Disease 0 0.43579513
hyperalgesia I-Disease 2 0.9978168
shares O 0 0.014895334
clinical O 0 0.0129515
characteristics O 0 0.0027744672
with O 0 0.0035726507
neurogenic B-Disease 0 0.9944689
hyperalgesia I-Disease 2 0.9993735
in O 0 0.0037673942
patients O 0 0.018130457
with O 0 0.014119393
neuropathic B-Disease 0 0.9992968
pain I-Disease 0 0.9961086
. O 0 0.015758906

Abnormal O 0 0.022904743
brain O 0 0.025805173
responses O 0 0.0037334242
to O 0 0.0016195324
somatosensory O 0 0.30582425
stimuli O 0 0.0037965889
have O 0 0.0008672192
been O 0 0.00077762647
found O 0 0.00049460627
in O 0 0.0004211443
patients O 0 0.0015474934
with O 0 0.0010472325
hyperalgesia B-Disease 2 0.99913365
as O 0 0.00051656197
well O 0 0.00038623775
as O 0 0.00035392967
in O 0 0.0004067586
normal O 0 0.0010142437
subjects O 0 0.001094958
during O 0 0.0007775553
experimental O 0 0.00264754
central O 0 0.008247518
sensitization O 0 0.38824946
. O 0 0.007038139

The O 0 0.0025298616
aim O 0 0.0018928493
of O 0 0.0014302246
this O 0 0.001001659
study O 0 0.0012001833
was O 0 0.0006205426
to O 0 0.000438204
assess O 0 0.00023494312
the O 0 0.00036453997
effects O 0 0.00087452226
of O 0 0.0010868245
gabapentin B-Chemical 1 0.99981564
, O 0 0.001251601
a O 0 0.00058058015
drug O 0 0.23597293
effective O 0 0.001290424
in O 0 0.00077463215
neuropathic B-Disease 0 0.99988604
pain I-Disease 0 0.99908304
patients O 0 0.021803504
, O 0 0.0006186624
on O 0 0.00021666382
brain O 0 0.012402658
processing O 0 0.0005781419
of O 0 0.00066807965
nociceptive O 0 0.69563925
information O 0 0.00089420436
in O 0 0.00058540236
normal O 0 0.0015437566
and O 0 0.001333566
central O 0 0.00476207
sensitization O 0 0.2731977
states O 0 0.011157358
. O 0 0.0061568515

Using O 0 0.004774039
functional O 0 0.004164579
magnetic O 0 0.041643232
resonance O 0 0.33515003
imaging O 0 0.015201857
( O 0 0.0024343773
fMRI O 0 0.03416867
) O 0 0.0013263342
in O 0 0.00048401745
normal O 0 0.0009148037
volunteers O 0 0.0017125729
, O 0 0.0004891786
we O 0 0.00018969424
studied O 0 0.00053070707
the O 0 0.00054430455
gabapentin B-Chemical 1 0.9998192
- O 0 0.0021188648
induced O 0 0.00065490376
modulation O 0 0.0011426051
of O 0 0.00059857895
brain O 0 0.06252403
activity O 0 0.0005868079
in O 0 0.00027123475
response O 0 0.0005418272
to O 0 0.0003689503
nociceptive O 0 0.70335376
mechanical O 0 0.042885214
stimulation O 0 0.0013123163
of O 0 0.0006505703
normal O 0 0.0018746993
skin O 0 0.031424124
and O 0 0.002156291
capsaicin B-Chemical 0 0.99892837
- O 0 0.010582325
induced O 0 0.007243605
secondary B-Disease 2 0.4814864
hyperalgesia I-Disease 2 0.9989436
. O 0 0.012281654

The O 0 0.0035698
dose O 0 0.01082415
of O 0 0.004105944
gabapentin B-Chemical 1 0.9991097
was O 0 0.0024315952
1 O 0 0.0013912076
, O 0 0.0012469628
800 O 0 0.0029316507
mg O 0 0.15231468
per O 0 0.000794794
os O 0 0.0755894
, O 0 0.001720665
in O 0 0.0012609925
a O 0 0.0021904756
single O 0 0.0037123042
administration O 0 0.21144329
. O 0 0.0074122385

We O 0 0.0035415476
found O 0 0.0023780898
that O 0 0.0017653593
( O 0 0.0022948321
i O 0 0.0031547935
) O 0 0.0027139217
gabapentin B-Chemical 1 0.9994318
reduced O 0 0.001173938
the O 0 0.000634754
activations O 0 0.023796014
in O 0 0.00038279739
the O 0 0.00039178645
bilateral O 0 0.064450726
operculoinsular O 0 0.061024863
cortex O 0 0.230925
, O 0 0.00036219278
independently O 0 0.00020566746
of O 0 0.00028852723
the O 0 0.00022392263
presence O 0 0.00025212805
of O 0 0.00042302656
central O 0 0.0027572552
sensitization O 0 0.4845779
; O 0 0.0021950044
( O 0 0.00060808315
ii O 0 0.0010526137
) O 0 0.00126889
gabapentin B-Chemical 1 0.9997614
reduced O 0 0.0005558107
the O 0 0.0003165929
activation O 0 0.0011299858
in O 0 0.00025082636
the O 0 0.00031943285
brainstem O 0 0.61611855
, O 0 0.00037545484
only O 0 0.00021480086
during O 0 0.00017743609
central O 0 0.0012728282
sensitization O 0 0.3401319
; O 0 0.0016658889
( O 0 0.000577007
iii O 0 0.0015866865
) O 0 0.0014914398
gabapentin B-Chemical 1 0.9997986
suppressed O 0 0.0013287351
stimulus O 0 0.011103521
- O 0 0.0010249789
induced O 0 0.0006804148
deactivations O 0 0.18727037
, O 0 0.00036678565
only O 0 0.0002116822
during O 0 0.00017198725
central O 0 0.0010051837
sensitization O 0 0.17203526
; O 0 0.0006655205
this O 0 0.00024452267
effect O 0 0.00033860913
was O 0 0.00030468675
more O 0 0.0004092508
robust O 0 0.00040218647
than O 0 0.0003265419
the O 0 0.0005943072
effect O 0 0.0011686834
on O 0 0.0012854836
brain O 0 0.102136955
activation O 0 0.01370339
. O 0 0.0061963126

The O 0 0.0034210226
observed O 0 0.0024607528
drug O 0 0.22172454
- O 0 0.0033715006
induced O 0 0.0018007237
effects O 0 0.0020109536
were O 0 0.0009109097
not O 0 0.00071032904
due O 0 0.0005661994
to O 0 0.000767465
changes O 0 0.0013303244
in O 0 0.0010025669
the O 0 0.001449125
baseline O 0 0.0034353535
fMRI O 0 0.043981224
signal O 0 0.005938687
. O 0 0.0070166173

These O 0 0.004396548
findings O 0 0.003773486
indicate O 0 0.0014432514
that O 0 0.0015630858
gabapentin B-Chemical 1 0.9992792
has O 0 0.0014537956
a O 0 0.0010523044
measurable O 0 0.0027922157
antinociceptive O 0 0.99726546
effect O 0 0.0010349433
and O 0 0.0005419848
a O 0 0.00047515376
stronger O 0 0.0006617321
antihyperalgesic O 0 0.998585
effect O 0 0.00085224095
most O 0 0.0008186998
evident O 0 0.00033499574
in O 0 0.00022884856
the O 0 0.0002517824
brain O 0 0.018774636
areas O 0 0.0008856944
undergoing O 0 0.0008365629
deactivation O 0 0.013225883
, O 0 0.0003917857
thus O 0 0.00033009512
supporting O 0 0.00027654888
the O 0 0.00023123778
concept O 0 0.00062774034
that O 0 0.0003829293
gabapentin B-Chemical 1 0.99977547
is O 0 0.00049709954
more O 0 0.0004805514
effective O 0 0.00058447884
in O 0 0.0003540858
modulating O 0 0.00083748414
nociceptive O 0 0.77798027
transmission O 0 0.0026193387
when O 0 0.00071228336
central O 0 0.003424552
sensitization O 0 0.18953235
is O 0 0.0028159823
present O 0 0.0031375892
. O 0 0.0051800464

Investigation O 0 0.01784984
of O 0 0.004913387
mitochondrial O 0 0.16417265
involvement O 0 0.0051074014
in O 0 0.0016076588
the O 0 0.001377978
experimental O 0 0.0023298617
model O 0 0.0028448554
of O 0 0.005132667
epilepsy B-Disease 2 0.99840707
induced O 0 0.01780037
by O 0 0.015827695
pilocarpine B-Chemical 1 0.99873286
. O 0 0.014427917

Mitochondrial B-Disease 0 0.9755779
abnormalities I-Disease 0 0.48926622
have O 0 0.0025716017
been O 0 0.001699713
associated O 0 0.0012794707
with O 0 0.00089963415
several O 0 0.000720917
aspects O 0 0.00063856214
of O 0 0.0011459411
epileptogenesis O 0 0.9979152
, O 0 0.0009121756
such O 0 0.00040593717
as O 0 0.0003194587
energy O 0 0.0028510627
generation O 0 0.00076115824
, O 0 0.00053693564
control O 0 0.00031597025
of O 0 0.0006619419
cell O 0 0.037047762
death B-Disease 2 0.99668026
, O 0 0.003024782
neurotransmitter O 0 0.98447543
synthesis O 0 0.15765117
, O 0 0.0012450011
and O 0 0.0009612665
free O 0 0.0024746305
radical O 0 0.8130751
( O 0 0.005468102
FR O 0 0.6228618
) O 0 0.007218042
production O 0 0.010437385
. O 0 0.007023807

Increased O 0 0.008812974
production O 0 0.0052473075
of O 0 0.0033576952
FRs O 0 0.43400916
may O 0 0.0020119513
cause O 0 0.005528143
mtDNA O 0 0.031905435
damage O 0 0.607536
leading O 0 0.003074484
to O 0 0.0006773572
decreased O 0 0.0013876006
activities O 0 0.001146362
of O 0 0.0011625373
oxidative O 0 0.97117245
phosphorylation O 0 0.10771892
complexes O 0 0.0027758225
containing O 0 0.0016383264
mtDNA O 0 0.023377892
- O 0 0.004156129
encoded O 0 0.0036542364
subunits O 0 0.016061986
. O 0 0.0069555235

In O 0 0.0026902962
this O 0 0.0018035271
study O 0 0.0019942627
, O 0 0.0012772059
we O 0 0.0004673474
investigated O 0 0.0006028636
whether O 0 0.0003042003
increased O 0 0.0007239062
generation O 0 0.0007777543
of O 0 0.00080757093
FR O 0 0.399202
during O 0 0.0003842952
status B-Disease 0 0.0013504686
epilepticus I-Disease 0 0.9998221
would O 0 0.00038259142
be O 0 0.0003160317
sufficient O 0 0.00018943273
to O 0 0.00024934282
provoke O 0 0.009011567
abnormalities O 0 0.12329047
in O 0 0.000311753
mtDNA O 0 0.004668124
and O 0 0.0003128851
in O 0 0.00021085651
the O 0 0.00021928412
expression O 0 0.00049888244
and O 0 0.00031490417
activity O 0 0.0004442709
of O 0 0.00062788307
cytochrome O 0 0.99568933
c O 0 0.13786028
oxidase O 0 0.99741
( O 0 0.0065665385
CCO O 0 0.9780287
) O 0 0.0016514529
, O 0 0.00051191717
complex O 0 0.00044115685
IV O 0 0.028086737
of O 0 0.00043453273
the O 0 0.00039905976
respiratory O 0 0.25435242
chain O 0 0.020049049
, O 0 0.00071045733
in O 0 0.00031619656
the O 0 0.0003950736
chronic O 0 0.82579046
phase O 0 0.0019629588
of O 0 0.00088931277
the O 0 0.0010591863
pilocarpine B-Chemical 1 0.99958473
model O 0 0.0027483357
of O 0 0.0037320964
temporal B-Disease 2 0.5981536
lobe I-Disease 2 0.9726872
epilepsy I-Disease 2 0.9986487
. O 0 0.010426857

DNA O 0 0.013788424
analysis O 0 0.0033024347
revealed O 0 0.0017701994
low O 0 0.001504652
amounts O 0 0.0010128176
of O 0 0.001059431
a O 0 0.0008821048
4 O 0 0.0005298771
. O 0 0.00029356507
8 O 0 0.00034194137
kb O 0 0.0008147653
mtDNA O 0 0.0017541366
deletion O 0 0.0005340195
but O 0 0.0003023712
with O 0 0.00032748218
no O 0 0.00021314977
differences O 0 0.00019065657
in O 0 0.00023765545
frequency O 0 0.00038736884
or O 0 0.00032153862
quantity O 0 0.0004117746
in O 0 0.00046008418
the O 0 0.0005919222
control O 0 0.000813496
and O 0 0.0014643631
experimental O 0 0.0034996017
groups O 0 0.004991583
. O 0 0.005673143

We O 0 0.0031970707
did O 0 0.001985971
not O 0 0.0013080835
find O 0 0.0011932628
abnormalities O 0 0.020181712
in O 0 0.0006847914
the O 0 0.00055474474
expression O 0 0.00085032015
and O 0 0.00046514985
distribution O 0 0.00029849636
of O 0 0.0005310603
an O 0 0.0007298095
mtDNA O 0 0.012181008
- O 0 0.0009288954
encoded O 0 0.00046393144
subunit O 0 0.0029260484
of O 0 0.0011154913
CCO O 0 0.9821395
( O 0 0.0029409328
CCO O 0 0.9756562
- O 0 0.002349088
I O 0 0.0034894878
) O 0 0.0005867769
or O 0 0.00020747894
a O 0 0.00025298144
relative O 0 0.00018185019
decrease O 0 0.00038899208
in O 0 0.00036856328
CCO O 0 0.9435854
- O 0 0.0013135755
I O 0 0.0013049366
when O 0 0.00017703018
compared O 0 0.00016148388
with O 0 0.0003863412
nuclear O 0 0.005094948
- O 0 0.0010312869
encoded O 0 0.00063243724
subunits O 0 0.006063568
( O 0 0.0021268872
CCO O 0 0.95516235
- O 0 0.004590696
IV O 0 0.18224779
and O 0 0.0031182396
SDH O 0 0.9931866
- O 0 0.012739867
fp O 0 0.42780244
) O 0 0.010017674
. O 0 0.0064816824

No O 0 0.013109679
abnormality O 0 0.028552894
in O 0 0.0060412
CCO O 0 0.7268552
activity O 0 0.0070899134
was O 0 0.0048285597
observed O 0 0.004481557
through O 0 0.007278947
histochemistry O 0 0.081011586
. O 0 0.014362146

Although O 0 0.0032673422
evidences O 0 0.004150637
of O 0 0.002876709
mitochondrial B-Disease 0 0.772975
abnormalities I-Disease 0 0.6434249
were O 0 0.0010297245
found O 0 0.0005933506
in O 0 0.00040030034
previously O 0 0.00040829316
published O 0 0.00043042246
studies O 0 0.0005848201
, O 0 0.00038939633
our O 0 0.00021356271
results O 0 0.00023652427
do O 0 0.0002064939
not O 0 0.00018415556
suggest O 0 0.00017244753
that O 0 0.0002072731
the O 0 0.00029381536
FRs O 0 0.33092088
, O 0 0.00037650776
generated O 0 0.00016294974
during O 0 0.00018312808
the O 0 0.0003050981
acute O 0 0.8456227
phase O 0 0.0026663276
, O 0 0.0004767676
determined O 0 0.0002189603
important O 0 0.0003230525
abnormalities O 0 0.08499804
in O 0 0.000385548
mtDNA O 0 0.0076262536
, O 0 0.00057912915
in O 0 0.00034957522
expression O 0 0.0008500828
of O 0 0.0012223423
CCO O 0 0.9676146
- O 0 0.0034736602
I O 0 0.0046422863
, O 0 0.0015803463
and O 0 0.0016270842
in O 0 0.0024355329
CCO O 0 0.86425257
activity O 0 0.008333579
. O 0 0.006850957

Adverse O 0 0.24303262
effect O 0 0.0037488472
of O 0 0.003178878
the O 0 0.0031738654
calcium B-Chemical 1 0.99536765
channel O 0 0.792575
blocker O 0 0.9977653
nitrendipine B-Chemical 1 0.9999143
on O 0 0.00897543
nephrosclerosis B-Disease 0 0.99986506
in O 0 0.0051863757
rats O 0 0.059874877
with O 0 0.019282963
renovascular B-Disease 0 0.9993986
hypertension I-Disease 2 0.9993728
. O 0 0.020303773

The O 0 0.002756808
effect O 0 0.0022826707
of O 0 0.0019224351
a O 0 0.0015673253
6 O 0 0.0008901643
- O 0 0.0010032891
week O 0 0.0004926327
treatment O 0 0.0010601176
with O 0 0.00072730414
the O 0 0.0007908718
calcium B-Chemical 1 0.9981059
channel O 0 0.7160406
blocker O 0 0.9986504
nitrendipine B-Chemical 1 0.99997103
or O 0 0.0020469876
the O 0 0.001432639
angiotensin B-Chemical 1 0.99973625
converting O 0 0.7164317
enzyme O 0 0.69175047
inhibitor O 0 0.7679656
enalapril B-Chemical 1 0.99994075
on O 0 0.00052648433
blood O 0 0.031487573
pressure O 0 0.16749395
, O 0 0.0015959494
albuminuria B-Disease 2 0.999673
, O 0 0.0022771463
renal O 0 0.99439514
hemodynamics O 0 0.987117
, O 0 0.0008417925
and O 0 0.0003502484
morphology O 0 0.0010470479
of O 0 0.0003511559
the O 0 0.00032891272
nonclipped O 0 0.7226729
kidney O 0 0.7685773
was O 0 0.0004391617
studied O 0 0.0005266191
in O 0 0.0003190378
rats O 0 0.0014568514
with O 0 0.0005482221
two O 0 0.00052992004
- O 0 0.0017970359
kidney O 0 0.6314626
, O 0 0.0019191726
one O 0 0.0017004941
clip O 0 0.21041211
renovascular B-Disease 0 0.9994081
hypertension I-Disease 2 0.9994062
. O 0 0.015752546

Six O 0 0.0046505406
weeks O 0 0.0020014008
after O 0 0.0010903785
clipping O 0 0.0035426952
of O 0 0.0014515448
one O 0 0.0011426258
renal O 0 0.9866615
artery O 0 0.75187355
, O 0 0.0033898093
hypertensive B-Disease 2 0.998376
rats O 0 0.020710232
( O 0 0.0011062499
178 O 0 0.0076068337
+ O 0 0.0007234538
/ O 0 0.0011052649
- O 0 0.00061311707
4 O 0 0.00027473614
mm O 0 0.0016804505
Hg O 0 0.8330801
) O 0 0.00035279777
were O 0 0.00014434326
randomly O 0 8.047231e-05
assigned O 0 0.00014807688
to O 0 0.00015309367
three O 0 0.00011914554
groups O 0 0.0003309901
: O 0 0.0005225634
untreated O 0 0.0008651339
hypertensive B-Disease 2 0.99819165
controls O 0 0.0011850965
( O 0 0.00056351366
n O 0 0.0002878787
= O 0 0.00046708086
8 O 0 0.00027448245
) O 0 0.00053515733
, O 0 0.00065767526
enalapril B-Chemical 1 0.9998895
- O 0 0.0023230012
treated O 0 0.0012418783
( O 0 0.0005546945
n O 0 0.00030903702
= O 0 0.00051029905
8 O 0 0.00031268407
) O 0 0.00055482006
, O 0 0.00051369995
or O 0 0.00063312333
nitrendipine B-Chemical 1 0.99988747
- O 0 0.004900804
treated O 0 0.0026021306
( O 0 0.0016401293
n O 0 0.0013322008
= O 0 0.002547806
10 O 0 0.0024437727
) O 0 0.0048462423
. O 0 0.004606591

Sham O 0 0.28803304
- O 0 0.0056561255
operated O 0 0.0047731968
rats O 0 0.004559547
served O 0 0.0021025145
as O 0 0.0013177632
normotensive O 0 0.9464684
controls O 0 0.0021263084
( O 0 0.001610161
128 O 0 0.004134404
+ O 0 0.001349703
/ O 0 0.0020539255
- O 0 0.0014171994
3 O 0 0.00083442556
mm O 0 0.004641626
Hg O 0 0.82530224
, O 0 0.0015881729
n O 0 0.0014720344
= O 0 0.002807434
8 O 0 0.0026161566
) O 0 0.0054014456
. O 0 0.00522781

After O 0 0.0022756073
6 O 0 0.0014872949
weeks O 0 0.0011560341
of O 0 0.001310537
treatment O 0 0.00247675
, O 0 0.0018857089
renal O 0 0.9869055
hemodynamics O 0 0.9893477
( O 0 0.0027369447
glomerular O 0 0.79890925
filtration O 0 0.015236812
rate O 0 0.0006234468
and O 0 0.00083287037
renal O 0 0.97991437
plasma O 0 0.13072139
flow O 0 0.014889176
) O 0 0.0014204787
were O 0 0.00068952085
measured O 0 0.00065870525
in O 0 0.0010633953
the O 0 0.001965189
anesthetized O 0 0.08086635
rats O 0 0.012584475
. O 0 0.005952282

Renal O 0 0.7594151
tissue O 0 0.0120535465
was O 0 0.0029040286
obtained O 0 0.0021179756
for O 0 0.0018341132
determination O 0 0.0046841875
of O 0 0.0042075934
glomerular O 0 0.8252429
size O 0 0.00832478
and O 0 0.00963448
sclerosis O 0 0.9730579
. O 0 0.01279677

Enalapril B-Chemical 0 0.99830127
but O 0 0.011822013
not O 0 0.009398869
nitrendipine B-Chemical 1 0.9989256
reduced O 0 0.013550965
blood O 0 0.08459269
pressure O 0 0.22846285
significantly O 0 0.015250248
. O 0 0.013337492

After O 0 0.0024247353
6 O 0 0.0016095709
weeks O 0 0.001277764
of O 0 0.0015052014
therapy O 0 0.011263461
, O 0 0.0020390123
glomerular O 0 0.66958064
filtration O 0 0.013008252
rate O 0 0.0010162833
was O 0 0.00087583525
not O 0 0.00079197966
different O 0 0.0010748515
among O 0 0.001723165
the O 0 0.0019997663
studied O 0 0.0043258234
groups O 0 0.0061356374
. O 0 0.0070250877

Renal O 0 0.84821224
plasma O 0 0.052868098
flow O 0 0.012131154
increased O 0 0.0037916126
, O 0 0.0027126728
but O 0 0.0019301231
albumin O 0 0.97815996
excretion O 0 0.9838022
and O 0 0.0042770267
glomerulosclerosis B-Disease 2 0.9995363
did O 0 0.0022431754
not O 0 0.001419305
change O 0 0.0019652208
after O 0 0.0022752394
enalapril B-Chemical 1 0.9993074
treatment O 0 0.06801733
. O 0 0.008818413

In O 0 0.003279251
contrast O 0 0.0026925132
, O 0 0.00242281
in O 0 0.0013226381
the O 0 0.0017161611
nitrendipine B-Chemical 1 0.99984646
- O 0 0.007208348
treated O 0 0.0022192062
group O 0 0.0015684047
albuminuria B-Disease 2 0.9994241
increased O 0 0.002054422
from O 0 0.00047029895
12 O 0 0.00029760727
. O 0 0.0001932139
8 O 0 0.00028880217
+ O 0 0.0003912096
/ O 0 0.000719183
- O 0 0.0004398163
2 O 0 0.00021342389
progressively O 0 0.00047180668
to O 0 0.00025295612
163 O 0 0.0036787416
+ O 0 0.00047286862
/ O 0 0.0007913535
- O 0 0.00041191658
55 O 0 0.0002556742
compared O 0 0.00011646224
with O 0 0.00026841194
19 O 0 0.00048115206
. O 0 0.00018264592
2 O 0 0.00031360597
+ O 0 0.00045437508
/ O 0 0.0008793695
- O 0 0.00064468116
9 O 0 0.0004343302
mg O 0 0.09577272
/ O 0 0.001054928
24 O 0 0.00054836215
hr O 0 0.0011254054
in O 0 0.0008655937
the O 0 0.0019839203
hypertensive B-Disease 2 0.9939435
controls O 0 0.009045317
. O 0 0.006270574

Furthermore O 0 0.0062956032
, O 0 0.005313606
glomerulosclerosis B-Disease 2 0.9987054
index O 0 0.0046430817
was O 0 0.0012472752
significantly O 0 0.0010663464
increased O 0 0.001182438
in O 0 0.00061950495
the O 0 0.000922871
nitrendipine B-Chemical 1 0.9999349
- O 0 0.0052669174
treated O 0 0.0011551479
group O 0 0.00047511986
compared O 0 0.00018966335
with O 0 0.00038381302
the O 0 0.0004509363
hypertensive B-Disease 2 0.9983517
controls O 0 0.0013009369
( O 0 0.00059781293
0 O 0 0.00034879174
. O 0 0.00016468813
38 O 0 0.0004922183
+ O 0 0.00042243136
/ O 0 0.0008054471
- O 0 0.0005086013
0 O 0 0.00029777642
. O 0 0.0001497704
1 O 0 0.00022567695
versus O 0 0.00023456795
0 O 0 0.00035161703
. O 0 0.00023481746
13 O 0 0.0005646102
+ O 0 0.0007965671
/ O 0 0.0017272547
- O 0 0.0016386884
0 O 0 0.0014502971
. O 0 0.0013281469
04 O 0 0.023493033
) O 0 0.005827665
. O 0 0.0050753825

In O 0 0.0030603616
addition O 0 0.0018624796
, O 0 0.0025600453
glomerular O 0 0.4962181
size O 0 0.0016617648
was O 0 0.00082694594
higher O 0 0.0006473766
in O 0 0.00056176435
the O 0 0.0008758414
nitrendipine B-Chemical 1 0.99991286
- O 0 0.004716896
treated O 0 0.001385596
group O 0 0.0007365275
( O 0 0.0005986362
14 O 0 0.00038493794
. O 0 0.0001861109
9 O 0 0.00029149317
+ O 0 0.00038740892
/ O 0 0.0007349075
- O 0 0.0004590645
0 O 0 0.00026100487
. O 0 0.00012647832
17 O 0 0.00027947943
10 O 0 0.00023781683
( O 0 0.0003257037
- O 0 0.0003574242
3 O 0 0.00019219487
) O 0 0.000363448
mm2 O 0 0.0013935135
) O 0 0.00038390173
but O 0 0.00018364619
lower O 0 0.00020700133
in O 0 0.00020821356
the O 0 0.00038181184
enalapril B-Chemical 1 0.9999188
- O 0 0.0024550464
treated O 0 0.00095747446
group O 0 0.0005332759
( O 0 0.00045560027
11 O 0 0.00030529857
. O 0 0.00014277505
5 O 0 0.00020183307
+ O 0 0.00032042622
/ O 0 0.00063777994
- O 0 0.00039817323
0 O 0 0.0002265257
. O 0 0.00010611826
15 O 0 0.00014202158
10 O 0 0.00020006343
( O 0 0.00028707267
- O 0 0.00032620557
3 O 0 0.00017962181
) O 0 0.00033963396
mm2 O 0 0.0011939707
) O 0 0.0003262964
compared O 0 0.00011273458
with O 0 0.0002533186
the O 0 0.00032546127
hypertensive B-Disease 2 0.99781346
controls O 0 0.00094651507
( O 0 0.0004734383
12 O 0 0.00020716799
. O 0 0.00015494601
1 O 0 0.0002720099
+ O 0 0.00037184317
/ O 0 0.0007148661
- O 0 0.0004635323
0 O 0 0.00028007157
. O 0 0.00014618214
17 O 0 0.00033710254
10 O 0 0.00030445855
( O 0 0.00044388036
- O 0 0.00054750853
3 O 0 0.0003558931
) O 0 0.00076023117
mm2 O 0 0.0025619026
) O 0 0.0012421125
. O 0 0.00069094304
( O 0 0.0017723239
ABSTRACT O 0 0.009774346
TRUNCATED O 0 0.01715669
AT O 0 0.020715684
250 O 0 0.010667447
WORDS O 0 0.019186553
) O 0 0.02050216

Ketoconazole B-Chemical 0 0.998135
induced O 0 0.023114078
torsades B-Disease 0 0.9991609
de I-Disease 0 0.5657772
pointes I-Disease 0 0.99975234
without O 0 0.003407663
concomitant O 0 0.012121528
use O 0 0.0022700692
of O 0 0.0029450548
QT O 0 0.9905213
interval O 0 0.006037164
- O 0 0.0056171804
prolonging O 0 0.024175832
drug O 0 0.63236916
. O 0 0.00979354

Ketoconazole B-Chemical 0 0.99833506
is O 0 0.0042046267
not O 0 0.001986766
known O 0 0.0019527925
to O 0 0.001195901
be O 0 0.0012790298
proarrhythmic O 0 0.94012535
without O 0 0.0012615878
concomitant O 0 0.005556956
use O 0 0.0015228296
of O 0 0.0022016452
QT O 0 0.99145
interval O 0 0.005134876
- O 0 0.0049133725
prolonging O 0 0.028301824
drugs O 0 0.82224405
. O 0 0.008822789

We O 0 0.0033336952
report O 0 0.00453774
a O 0 0.002270432
woman O 0 0.007854265
with O 0 0.0020353496
coronary B-Disease 0 0.61953247
artery I-Disease 0 0.5142777
disease I-Disease 0 0.7206074
who O 0 0.0031501781
developed O 0 0.0012608136
a O 0 0.0006628913
markedly O 0 0.0021734766
prolonged B-Disease 0 0.056533787
QT I-Disease 0 0.9944824
interval I-Disease 0 0.0024381136
and O 0 0.0010562207
torsades B-Disease 0 0.99977225
de I-Disease 0 0.50965804
pointes I-Disease 0 0.9999558
( O 0 0.023187486
TdP B-Disease 2 0.9997025
) O 0 0.0013853493
after O 0 0.00039323245
taking O 0 0.003394074
ketoconazole B-Chemical 1 0.9996927
for O 0 0.0013863873
treatment O 0 0.005721033
of O 0 0.0050639007
fungal B-Disease 0 0.81310576
infection I-Disease 2 0.96765286
. O 0 0.009693076

Her O 0 0.016395848
QT O 0 0.9192702
interval O 0 0.0058686617
returned O 0 0.0034732362
to O 0 0.002902393
normal O 0 0.004824492
upon O 0 0.0040210076
withdrawal O 0 0.6502972
of O 0 0.020471036
ketoconazole B-Chemical 1 0.998749
. O 0 0.020378575

Genetic O 0 0.01578909
study O 0 0.004095866
did O 0 0.0018651446
not O 0 0.0012257053
find O 0 0.0010587136
any O 0 0.0008379063
mutation O 0 0.0018462833
in O 0 0.0007677415
her O 0 0.0012675835
genes O 0 0.0012600697
that O 0 0.00093089417
encode O 0 0.0022809554
cardiac O 0 0.75717425
IKr O 0 0.9962604
channel O 0 0.3178428
proteins O 0 0.019190745
. O 0 0.00802067

We O 0 0.0033033437
postulate O 0 0.004651119
that O 0 0.0015680977
by O 0 0.0014352691
virtue O 0 0.0025446787
of O 0 0.0012478967
its O 0 0.0015693151
direct O 0 0.0008118787
blocking O 0 0.0028454803
action O 0 0.016259497
on O 0 0.0007377624
IKr O 0 0.9976769
, O 0 0.0037787377
ketoconazole B-Chemical 1 0.9998331
alone O 0 0.0020331154
may O 0 0.001104526
prolong O 0 0.0062631886
QT O 0 0.99165416
interval O 0 0.0037495417
and O 0 0.0030129936
induce O 0 0.0070990897
TdP B-Disease 2 0.99801326
. O 0 0.008481429

This O 0 0.0047617215
calls O 0 0.0031180931
for O 0 0.001674773
attention O 0 0.0036541405
when O 0 0.0012997455
ketoconazole B-Chemical 1 0.99964154
is O 0 0.0015015746
administered O 0 0.0025851326
to O 0 0.00063909875
patients O 0 0.0016024344
with O 0 0.0009318659
risk O 0 0.014222735
factors O 0 0.0029473577
for O 0 0.0011169332
acquired O 0 0.0066766837
long B-Disease 0 0.008830679
QT I-Disease 0 0.9942175
syndrome I-Disease 0 0.97683764
. O 0 0.009541357

Cerebral B-Disease 0 0.9799202
vasculitis I-Disease 2 0.9979954
following O 0 0.0068333275
oral O 0 0.8065013
methylphenidate B-Chemical 1 0.9993241
intake O 0 0.9149792
in O 0 0.002376451
an O 0 0.0028237149
adult O 0 0.0035697846
: O 0 0.003567372
a O 0 0.003210581
case O 0 0.0046229246
report O 0 0.014313222
. O 0 0.008637209

Methylphenidate B-Chemical 0 0.99547523
is O 0 0.009652587
structurally O 0 0.0155609045
and O 0 0.00590179
functionally O 0 0.007286511
similar O 0 0.005313614
to O 0 0.0113620255
amphetamine B-Chemical 1 0.997474
. O 0 0.020309722

Cerebral B-Disease 0 0.98357993
vasculitis I-Disease 2 0.99857104
associated O 0 0.009040258
with O 0 0.00845512
amphetamine B-Disease 1 0.99989045
abuse I-Disease 0 0.99861
is O 0 0.0015653947
well O 0 0.0006411214
documented O 0 0.0012542442
, O 0 0.00070923835
and O 0 0.00047740288
in O 0 0.000412367
rare O 0 0.0073274006
cases O 0 0.010366767
ischaemic B-Disease 0 0.99987674
stroke I-Disease 2 0.9996159
has O 0 0.0017177311
been O 0 0.0012656244
reported O 0 0.0014640411
after O 0 0.0010572806
methylphenidate B-Chemical 1 0.9992487
intake O 0 0.86187947
in O 0 0.0036199735
children O 0 0.011361634
. O 0 0.0060766772

We O 0 0.0031814263
report O 0 0.004044953
the O 0 0.001585088
case O 0 0.0013434117
of O 0 0.0013163653
a O 0 0.0011972043
63 O 0 0.0017673763
- O 0 0.001157918
year O 0 0.0007028017
- O 0 0.000839178
old O 0 0.00053670997
female O 0 0.0010709653
who O 0 0.0009140399
was O 0 0.00040054254
treated O 0 0.00080814864
with O 0 0.0010182492
methylphenidate B-Chemical 1 0.9995234
due O 0 0.0006591109
to O 0 0.0010911726
hyperactivity B-Disease 2 0.9983487
and O 0 0.0017076487
suffered O 0 0.24345665
from O 0 0.0023208119
multiple O 0 0.035466176
ischaemic B-Disease 0 0.99948823
strokes I-Disease 0 0.9973169
. O 0 0.012499643

We O 0 0.0035078346
consider O 0 0.0022833352
drug O 0 0.2798461
- O 0 0.0042851283
induced O 0 0.0035476575
cerebral B-Disease 0 0.9961952
vasculitis I-Disease 2 0.99970716
as O 0 0.001036266
the O 0 0.00062040397
most O 0 0.00088842056
likely O 0 0.00042306748
cause O 0 0.0012642052
of O 0 0.0009474736
recurrent O 0 0.9225837
ischaemic B-Disease 0 0.999928
strokes I-Disease 0 0.9993531
in O 0 0.00062413764
the O 0 0.00033465325
absence O 0 0.00020796912
of O 0 0.00045270173
any O 0 0.0003926185
pathological O 0 0.110494204
findings O 0 0.001564864
during O 0 0.0005231707
the O 0 0.00080389285
diagnostic O 0 0.002154208
work O 0 0.0028041196
- O 0 0.0043312837
up O 0 0.0040673492
. O 0 0.005182672

We O 0 0.0033509328
conclude O 0 0.0026312699
that O 0 0.0023950064
methylphenidate B-Chemical 1 0.9988689
mediated O 0 0.004517909
vasculitis B-Disease 2 0.9989888
should O 0 0.0008842654
be O 0 0.0007269737
considered O 0 0.00047977007
in O 0 0.00042286285
patients O 0 0.0014419298
with O 0 0.0011189615
neurological O 0 0.99572563
symptoms O 0 0.89809406
and O 0 0.0011799977
a O 0 0.0013299886
history O 0 0.021311516
of O 0 0.006069333
methylphenidate B-Chemical 1 0.9990252
therapy O 0 0.38506538
. O 0 0.008434701

This O 0 0.0050055417
potential O 0 0.003747106
side O 0 0.021510532
- O 0 0.0027786354
effect O 0 0.0013941095
, O 0 0.0011668302
though O 0 0.0006841707
very O 0 0.0008302361
rare O 0 0.0053237197
, O 0 0.0007463532
represents O 0 0.0003768205
one O 0 0.00029522157
more O 0 0.00047708992
reason O 0 0.00040245455
to O 0 0.0003964442
be O 0 0.00048714524
very O 0 0.0006624341
restrictive O 0 0.0014946894
in O 0 0.0007707415
the O 0 0.0011166395
use O 0 0.002407229
of O 0 0.0066073816
methylphenidate B-Chemical 1 0.99822074
. O 0 0.009608636

MDMA B-Chemical 0 0.9993554
polydrug O 0 0.99836165
users O 0 0.027982192
show O 0 0.0016229316
process O 0 0.0017375877
- O 0 0.0016105644
specific O 0 0.0008346018
central O 0 0.0022249233
executive O 0 0.1423252
impairments O 0 0.34511688
coupled O 0 0.0012501028
with O 0 0.0011900278
impaired B-Disease 0 0.002493426
social I-Disease 0 0.02369809
and I-Disease 0 0.0023782968
emotional I-Disease 0 0.19536959
judgement I-Disease 0 0.025152842
processes I-Disease 0 0.012776516
. O 0 0.0066388603

In O 0 0.0028452436
recent O 0 0.0024240399
years O 0 0.0028539896
working O 0 0.003608119
memory B-Disease 0 0.6621659
deficits I-Disease 0 0.9019708
have O 0 0.001325574
been O 0 0.0010822193
reported O 0 0.0010602964
in O 0 0.00060881965
users O 0 0.0031820768
of O 0 0.0020449706
MDMA B-Chemical 0 0.9998983
( O 0 0.0025442652
3 B-Chemical 0 0.0008437949
, I-Chemical 0 0.0011349402
4 I-Chemical 0 0.0010843938
- I-Chemical 0 0.004120122
methylenedioxymethamphetamine I-Chemical 0 0.99937755
, O 0 0.023382245
ecstasy B-Chemical 1 0.99853337
) O 0 0.019051854
. O 0 0.00749825

The O 0 0.002434347
current O 0 0.0025425204
study O 0 0.0018608477
aimed O 0 0.0011677487
to O 0 0.00068940484
assess O 0 0.00034612406
the O 0 0.00047069634
impact O 0 0.0004584975
of O 0 0.0010874693
MDMA B-Chemical 0 0.99990034
use O 0 0.0009844876
on O 0 0.0002119108
three O 0 0.00015737908
separate O 0 0.00022015606
central O 0 0.00088778377
executive O 0 0.06471941
processes O 0 0.0016681801
( O 0 0.00045206543
set O 0 0.00021725504
shifting O 0 0.00069997855
, O 0 0.00046239764
inhibition O 0 0.0016099841
and O 0 0.00042280523
memory O 0 0.15828541
updating O 0 0.0029628794
) O 0 0.0007546314
and O 0 0.00034976602
also O 0 0.0003832889
on O 0 0.00026692668
" O 0 0.0008137499
prefrontal O 0 0.35724476
" O 0 0.0007941267
mediated O 0 0.000763037
social O 0 0.011687428
and O 0 0.0017958361
emotional O 0 0.1607584
judgement O 0 0.0212215
processes O 0 0.011502367
. O 0 0.0059720473

Fifteen O 0 0.02383191
polydrug O 0 0.99734396
ecstasy B-Chemical 1 0.9986168
users O 0 0.025134038
and O 0 0.001646577
15 O 0 0.0011528454
polydrug O 0 0.9981213
non O 0 0.0042182873
- O 0 0.0024908325
ecstasy B-Chemical 1 0.99916077
user O 0 0.0009274043
controls O 0 0.0005609995
completed O 0 0.0002968815
a O 0 0.0002926376
general O 0 0.00031540592
drug O 0 0.06350329
use O 0 0.00043266342
questionnaire O 0 0.00041191716
, O 0 0.00037941078
the O 0 0.00030128256
Brixton O 0 0.09896635
Spatial O 0 0.03350616
Anticipation O 0 0.20307453
task O 0 0.0011664896
( O 0 0.00045221887
set O 0 0.000241921
shifting O 0 0.0007880503
) O 0 0.00075513794
, O 0 0.0005696024
Backward O 0 0.13874945
Digit O 0 0.97667617
Span O 0 0.91856146
procedure O 0 0.00071923196
( O 0 0.000682072
memory O 0 0.10302083
updating O 0 0.0030124036
) O 0 0.0010056519
, O 0 0.00053775235
Inhibition O 0 0.0055341492
of O 0 0.0006052387
Return O 0 0.04643883
( O 0 0.00070793444
inhibition O 0 0.003213008
) O 0 0.00081141
, O 0 0.00043724274
an O 0 0.00047457396
emotional O 0 0.07004532
intelligence O 0 0.05491281
scale O 0 0.0007628989
, O 0 0.0005401763
the O 0 0.0004581858
Tromso O 0 0.03825827
Social O 0 0.033039045
Intelligence O 0 0.053318746
Scale O 0 0.30388597
and O 0 0.0009097617
the O 0 0.0013504846
Dysexecutive O 0 0.79168046
Questionnaire O 0 0.025492983
( O 0 0.005603138
DEX O 0 0.9913623
) O 0 0.011422462
. O 0 0.0068629677

Compared O 0 0.004563819
with O 0 0.005459668
MDMA B-Chemical 0 0.99961036
- O 0 0.008722023
free O 0 0.004563388
polydrug O 0 0.99880874
controls O 0 0.0045213047
, O 0 0.0036180443
MDMA B-Chemical 0 0.99993134
polydrug O 0 0.99970514
users O 0 0.031222023
showed O 0 0.00067553757
impairments O 0 0.22598352
in O 0 0.00031658082
set O 0 0.00026934457
shifting O 0 0.0007249411
and O 0 0.0004914768
memory O 0 0.11080572
updating O 0 0.0020978097
, O 0 0.0006674668
and O 0 0.00049724785
also O 0 0.00059699896
in O 0 0.00065340626
social O 0 0.009282281
and O 0 0.0017230354
emotional O 0 0.15283664
judgement O 0 0.02079268
processes O 0 0.011400788
. O 0 0.0059334086

The O 0 0.0035849973
latter O 0 0.004620638
two O 0 0.002131718
deficits O 0 0.11959084
remained O 0 0.0024261833
significant O 0 0.0017997391
after O 0 0.00096794177
controlling O 0 0.0016090567
for O 0 0.0017735527
other O 0 0.0034158032
drug O 0 0.39270613
use O 0 0.009785686
. O 0 0.0086572515

These O 0 0.0043102982
data O 0 0.0027339552
lend O 0 0.0030684187
further O 0 0.0014261607
support O 0 0.0010820687
to O 0 0.00078841654
the O 0 0.0006749105
proposal O 0 0.0017590943
that O 0 0.00062382844
cognitive O 0 0.38841045
processes O 0 0.0021908558
mediated O 0 0.00065153325
by O 0 0.0006843294
the O 0 0.00082208664
prefrontal O 0 0.7668186
cortex O 0 0.21458127
may O 0 0.00075563265
be O 0 0.00082509714
impaired O 0 0.0018266645
by O 0 0.002042756
recreational O 0 0.7462133
ecstasy B-Chemical 1 0.99848974
use O 0 0.011274011
. O 0 0.0073581175

Phase O 0 0.01439193
II O 0 0.009761169
study O 0 0.0031485616
of O 0 0.0023162893
the O 0 0.0023339987
amsacrine B-Chemical 0 0.99861264
analogue O 0 0.6334856
CI B-Chemical 0 0.84327525
- I-Chemical 0 0.0036156832
921 I-Chemical 0 0.15870795
( O 0 0.0021987204
NSC B-Chemical 0 0.97237575
343499 I-Chemical 0 0.7088043
) O 0 0.0019430242
in O 0 0.00087458687
non B-Disease 2 0.0023724139
- I-Disease 2 0.0024041599
small I-Disease 2 0.0025265573
cell I-Disease 2 0.03933684
lung I-Disease 2 0.96872294
cancer I-Disease 2 0.9962715
. O 0 0.013610288

CI B-Chemical 0 0.4140301
- I-Chemical 0 0.00819035
921 I-Chemical 0 0.08163536
( O 0 0.0047415663
NSC B-Chemical 0 0.9591999
343499 I-Chemical 0 0.74360627
; O 0 0.0033310885
9 B-Chemical 0 0.0012801862
- I-Chemical 0 0.0017380127
[ I-Chemical 0 0.0020064588
[ I-Chemical 0 0.001568041
2 I-Chemical 0 0.0007043902
- I-Chemical 0 0.0013318874
methoxy I-Chemical 0 0.98203343
- I-Chemical 0 0.0014703583
4 I-Chemical 0 0.0004903414
- I-Chemical 0 0.00094958436
[ I-Chemical 0 0.0013760258
( I-Chemical 0 0.00081720395
methylsulphonyl I-Chemical 0 0.9128594
) I-Chemical 0 0.0022252263
amino I-Chemical 0 0.7742652
] I-Chemical 0 0.0099540865
phenyl I-Chemical 0 0.9954568
] I-Chemical 0 0.00987301
amino I-Chemical 0 0.7937237
] I-Chemical 0 0.0059047034
- I-Chemical 0 0.0016019891
N I-Chemical 0 0.73175484
, I-Chemical 0 0.0007662789
5 I-Chemical 0 0.00043163766
- I-Chemical 0 0.0010393646
dimethyl I-Chemical 0 0.98091274
- I-Chemical 0 0.0011630999
4 I-Chemical 0 0.0003772583
- I-Chemical 0 0.0007148641
acridinecarboxamide I-Chemical 0 0.059868485
) O 0 0.00082158303
is O 0 0.00041661022
a O 0 0.00065239205
topoisomerase O 0 0.6989547
II O 0 0.043637097
poison O 0 0.12797134
with O 0 0.0014383175
high O 0 0.0021544162
experimental O 0 0.0051782513
antitumour O 0 0.94795734
activity O 0 0.010527401
. O 0 0.0071487464

It O 0 0.0052802796
was O 0 0.0021839289
administered O 0 0.0029413607
by O 0 0.0011636568
15 O 0 0.00072808506
min O 0 0.0009315703
infusion O 0 0.0029738827
to O 0 0.00042303058
16 O 0 0.00044089952
evaluable O 0 0.002926324
patients O 0 0.00092395936
with O 0 0.00048477025
non B-Disease 2 0.0011933503
- I-Disease 2 0.0007562404
small I-Disease 2 0.00051464874
cell I-Disease 2 0.01578513
lung I-Disease 2 0.96709555
cancer I-Disease 2 0.99953103
( O 0 0.018120354
NSCLC B-Disease 2 0.99895775
) O 0 0.0026330384
( O 0 0.0004821773
7 O 0 0.00017865059
with O 0 0.00019358401
no O 0 0.00013310245
prior O 0 0.0001322471
treatment O 0 0.00058382994
, O 0 0.0003208178
9 O 0 0.00020698969
patients O 0 0.0004813546
in O 0 0.00020720353
relapse O 0 0.6708443
following O 0 0.00032538897
surgery O 0 0.0026936273
/ O 0 0.0010476878
radiotherapy O 0 0.54488826
) O 0 0.0006054929
at O 0 0.00015203723
a O 0 0.00028508028
dose O 0 0.007305206
( O 0 0.0005166546
648 O 0 0.031155214
mg O 0 0.30536544
/ O 0 0.0007811893
m2 O 0 0.00596855
divided O 0 0.00014659237
over O 0 0.00010246152
3 O 0 0.0001514937
days O 0 0.00016823804
, O 0 0.0002145579
repeated O 0 0.00018283095
every O 0 0.00014541902
3 O 0 0.00024837285
weeks O 0 0.00035347263
) O 0 0.0006729769
determined O 0 0.0004925395
by O 0 0.0011088559
phase O 0 0.0035380796
I O 0 0.008585485
trial O 0 0.008130044
. O 0 0.0057645463

Patients O 0 0.008441539
had O 0 0.0024191674
a O 0 0.001800674
median O 0 0.0012340577
performance O 0 0.0014718951
status O 0 0.0012783392
of O 0 0.0012755113
1 O 0 0.0011852087
( O 0 0.0013192074
WHO O 0 0.0024787334
) O 0 0.0013827137
, O 0 0.0009912621
and O 0 0.0008696101
median O 0 0.0010701035
age O 0 0.0023815425
of O 0 0.0025475563
61 O 0 0.005702002
years O 0 0.0074953013
. O 0 0.0060566575

The O 0 0.0039582374
histology O 0 0.04757501
comprised O 0 0.0051564593
squamous B-Disease 0 0.99780947
carcinoma I-Disease 2 0.9994105
( O 0 0.00821195
11 O 0 0.0019125375
) O 0 0.0018910537
, O 0 0.0015402165
adenocarcinoma B-Disease 0 0.99829656
( O 0 0.0016895473
1 O 0 0.00063492253
) O 0 0.0007254038
, O 0 0.00046157636
mixed O 0 0.0009268037
histology O 0 0.13684669
( O 0 0.00085198437
2 O 0 0.00046168966
) O 0 0.00068840134
, O 0 0.0005528192
bronchio B-Disease 0 0.019034456
- I-Disease 0 0.0015224402
alveolar I-Disease 0 0.10153768
carcinoma I-Disease 2 0.9993824
( O 0 0.001849945
1 O 0 0.0006087013
) O 0 0.0007048246
and O 0 0.00047772884
large O 0 0.0008737172
cell O 0 0.015853928
undifferentiated B-Disease 0 0.94330156
carcinoma I-Disease 2 0.99939024
( O 0 0.011037619
1 O 0 0.0043737944
) O 0 0.006687451
. O 0 0.0052414644

Neutropenia B-Disease 0 0.9945861
grade O 0 0.10487002
greater O 0 0.0017603104
than O 0 0.0007889625
or O 0 0.0006294741
equal O 0 0.0004919436
to O 0 0.00051914924
3 O 0 0.00040990082
was O 0 0.00036449655
seen O 0 0.00032299277
in O 0 0.00027622475
15 O 0 0.00028649168
patients O 0 0.00087839254
, O 0 0.0006275211
infections B-Disease 2 0.40158737
with O 0 0.0006417279
recovery O 0 0.0013849555
in O 0 0.0004424468
3 O 0 0.00046260204
, O 0 0.0006550131
and O 0 0.00077092735
grand O 0 0.028485805
mal O 0 0.99665904
seizures B-Disease 2 0.9996215
in O 0 0.003187308
1 O 0 0.0036288507
patient O 0 0.006422398
. O 0 0.0055325064

Grade O 0 0.20672765
less O 0 0.002655824
than O 0 0.0011724137
or O 0 0.00094676117
equal O 0 0.0007682487
to O 0 0.00091187184
2 O 0 0.0012668233
nausea B-Disease 2 0.99958485
and O 0 0.0020982947
vomiting B-Disease 0 0.9993236
occurred O 0 0.0011518844
in O 0 0.00045442634
66 O 0 0.0008088436
% O 0 0.00043778488
courses O 0 0.00087863614
and O 0 0.0007895541
phlebitis B-Disease 0 0.9982041
in O 0 0.00073009165
the O 0 0.0008041442
infusion O 0 0.023336176
arm O 0 0.0020953973
in O 0 0.0017050464
37 O 0 0.004012114
% O 0 0.0044984696
. O 0 0.0047510453

1 O 0 0.005059588
patient O 0 0.0049060713
with O 0 0.004549814
squamous B-Disease 0 0.9917748
cell I-Disease 0 0.14493628
carcinoma I-Disease 2 0.99802184
achieved O 0 0.0043268055
a O 0 0.0025296633
partial O 0 0.0037909783
response O 0 0.003681355
lasting O 0 0.0068834345
5 O 0 0.0034228517
months O 0 0.0051960335
. O 0 0.006137787

Further O 0 0.004304629
testing O 0 0.0024583414
in O 0 0.0016344696
this O 0 0.0013736908
and O 0 0.00140728
other O 0 0.0014843046
tumour B-Disease 0 0.57026505
types O 0 0.0015094639
using O 0 0.0010892578
multiple O 0 0.0023582669
daily O 0 0.004495964
schedules O 0 0.006172647
is O 0 0.0038304217
warranted O 0 0.005581175
. O 0 0.0068772966

Pharmacokinetics O 0 0.9699523
of O 0 0.017883135
desipramine B-Chemical 1 0.9996594
HCl I-Chemical 0 0.9979043
when O 0 0.005584947
administered O 0 0.021988627
with O 0 0.017372897
cinacalcet B-Chemical 1 0.9991943
HCl I-Chemical 0 0.9973187
. O 0 0.020664213

OBJECTIVE O 0 0.54467386
: O 0 0.0044555357
In O 0 0.001602388
vitro O 0 0.0019946946
work O 0 0.0015301001
has O 0 0.0009789702
demonstrated O 0 0.001017634
that O 0 0.0009991685
cinacalcet B-Chemical 1 0.9995123
is O 0 0.0012562685
a O 0 0.0009654633
strong O 0 0.0013227201
inhibitor O 0 0.10446111
of O 0 0.0036802148
cytochrome O 0 0.9974573
P450 O 0 0.99919194
isoenzyme O 0 0.99790704
( O 0 0.11696199
CYP O 0 0.99929416
) O 0 0.23501842
2D6 O 0 0.998071
. O 0 0.01700953

The O 0 0.0025095767
purpose O 0 0.0019204032
of O 0 0.0014573148
this O 0 0.0010268968
study O 0 0.0012310579
was O 0 0.0006410998
to O 0 0.00045887814
evaluate O 0 0.00029268142
the O 0 0.00039155062
effect O 0 0.00057012116
of O 0 0.0010121053
cinacalcet B-Chemical 1 0.99972767
on O 0 0.00068548974
CYP2D6 O 0 0.99941254
activity O 0 0.0024871684
, O 0 0.0009922874
using O 0 0.00072556385
desipramine B-Chemical 1 0.9998605
as O 0 0.0006610346
a O 0 0.00078233355
probe O 0 0.0008566382
substrate O 0 0.00329259
, O 0 0.0018267068
in O 0 0.0016920931
healthy O 0 0.010801775
subjects O 0 0.006236275
. O 0 0.005394712

METHODS O 0 0.006244019
: O 0 0.0032652651
Seventeen O 0 0.0051824506
subjects O 0 0.001776997
who O 0 0.0016724635
were O 0 0.00072539446
genotyped O 0 0.0010022675
as O 0 0.00059756683
CYP2D6 O 0 0.9977931
extensive O 0 0.0016274685
metabolizers O 0 0.98915195
were O 0 0.00046496638
enrolled O 0 0.0006458499
in O 0 0.00020916051
this O 0 0.00022566968
randomized O 0 0.00049606105
, O 0 0.00036049946
open O 0 0.00029275674
- O 0 0.00048154642
label O 0 0.0007058642
, O 0 0.00030043843
crossover O 0 0.0012250516
study O 0 0.0003592844
to O 0 0.00019150268
receive O 0 0.00027567966
a O 0 0.00024770928
single O 0 0.00028295684
oral O 0 0.16005346
dose O 0 0.030404277
of O 0 0.0019387087
desipramine B-Chemical 1 0.9999598
( O 0 0.0013229513
50 O 0 0.00076049636
mg O 0 0.30348992
) O 0 0.0003949252
on O 0 9.784706e-05
two O 0 0.00011471801
separate O 0 0.00014439708
occasions O 0 0.00053837773
, O 0 0.00028765816
once O 0 0.00020419576
alone O 0 0.00025647698
and O 0 0.00022328264
once O 0 0.00020556277
after O 0 0.0001354921
multiple O 0 0.00050131837
doses O 0 0.016405463
of O 0 0.0013066081
cinacalcet B-Chemical 1 0.99971765
( O 0 0.0015263393
90 O 0 0.000974912
mg O 0 0.11295571
for O 0 0.00094023586
7 O 0 0.0013441258
days O 0 0.002067293
) O 0 0.004964306
. O 0 0.004615479

Blood O 0 0.022006555
samples O 0 0.003718204
were O 0 0.0029603746
obtained O 0 0.0028623478
predose O 0 0.088149525
and O 0 0.0027814764
up O 0 0.0025200597
to O 0 0.0026536714
72 O 0 0.003908241
h O 0 0.005166295
postdose O 0 0.037886404
. O 0 0.008359889

RESULTS O 0 0.03765443
: O 0 0.010034598
Fourteen O 0 0.0134839155
subjects O 0 0.006324485
completed O 0 0.0051886425
both O 0 0.006047006
treatment O 0 0.013657291
arms O 0 0.021801846
. O 0 0.014884295

Relative O 0 0.005335876
to O 0 0.0038383917
desipramine B-Chemical 1 0.9994722
alone O 0 0.0035452817
, O 0 0.0016927278
mean O 0 0.0006983521
AUC O 0 0.042617615
and O 0 0.0011944114
C O 0 0.8086766
( O 0 0.001715462
max O 0 0.023748565
) O 0 0.0010236839
of O 0 0.00097511534
desipramine B-Chemical 1 0.9999049
increased O 0 0.0024888893
3 O 0 0.00044302875
. O 0 0.00022610732
6 O 0 0.00025712236
- O 0 0.00046396418
and O 0 0.00033612244
1 O 0 0.00038038212
. O 0 0.00025026116
8 O 0 0.00044342407
- O 0 0.00079884485
fold O 0 0.00113702
when O 0 0.0008658977
coadministered O 0 0.89532536
with O 0 0.009241353
cinacalcet B-Chemical 1 0.9988098
. O 0 0.009651885

The O 0 0.003862046
t O 0 0.0060952012
( O 0 0.0031780922
1 O 0 0.0016654283
/ O 0 0.0020893696
2 O 0 0.0009259864
, O 0 0.0009361263
z O 0 0.0035058914
) O 0 0.0010137223
of O 0 0.00096707075
desipramine B-Chemical 1 0.9998802
was O 0 0.00064810045
longer O 0 0.00031343443
when O 0 0.00040787552
desipramine B-Chemical 1 0.99990785
was O 0 0.0011096218
coadministered O 0 0.9617322
with O 0 0.0023989994
cinacalcet B-Chemical 1 0.99980515
( O 0 0.0017295281
21 O 0 0.0007558427
. O 0 0.0003010543
0 O 0 0.0005129522
versus O 0 0.0005313992
43 O 0 0.0013072466
. O 0 0.0007752517
3 O 0 0.001579251
hs O 0 0.033878885
) O 0 0.006245141
. O 0 0.005221082

The O 0 0.005533354
t O 0 0.009159937
( O 0 0.0059128846
max O 0 0.013864756
) O 0 0.0044471
was O 0 0.0023571025
similar O 0 0.0020682015
between O 0 0.0023265956
the O 0 0.004897368
regimens O 0 0.041768417
. O 0 0.011029652

Fewer O 0 0.012498
subjects O 0 0.004026304
reported O 0 0.0029312756
adverse O 0 0.37668377
events O 0 0.0051355017
following O 0 0.00092753384
treatment O 0 0.0021997185
with O 0 0.0016894742
desipramine B-Chemical 1 0.9999083
alone O 0 0.0013088287
than O 0 0.00029160126
when O 0 0.00026302785
receiving O 0 0.012521126
desipramine B-Chemical 1 0.99994457
with O 0 0.0053689945
cinacalcet B-Chemical 1 0.99987864
( O 0 0.0013798611
33 O 0 0.00058247155
versus O 0 0.00024826845
86 O 0 0.0005125029
% O 0 0.00031992135
) O 0 0.00038465954
, O 0 0.00026079966
the O 0 0.00018565469
most O 0 0.00038250463
frequent O 0 0.0009844885
of O 0 0.0004481421
which O 0 0.00081876875
( O 0 0.0015069224
nausea B-Disease 2 0.9998704
and O 0 0.0021949501
headache B-Disease 2 0.9995745
) O 0 0.0013156151
have O 0 0.0003815348
been O 0 0.00042666539
reported O 0 0.00049882825
for O 0 0.00032114002
patients O 0 0.0014689867
treated O 0 0.0011883457
with O 0 0.0012805534
either O 0 0.002945773
desipramine B-Chemical 1 0.99976903
or O 0 0.010461426
cinacalcet B-Chemical 1 0.99901116
. O 0 0.010316977

CONCLUSION O 0 0.79983026
: O 0 0.00569635
This O 0 0.0031491152
study O 0 0.002443575
demonstrates O 0 0.0014597727
that O 0 0.0019375233
cinacalcet B-Chemical 1 0.9987733
is O 0 0.0029734091
a O 0 0.0027515916
strong O 0 0.0041766036
inhibitor O 0 0.18810913
of O 0 0.014640082
CYP2D6 O 0 0.9960939
. O 0 0.015062863

These O 0 0.0039519123
data O 0 0.002363043
suggest O 0 0.0012010804
that O 0 0.0009340401
during O 0 0.000690782
concomitant O 0 0.0037614948
treatment O 0 0.0028669909
with O 0 0.0017264229
cinacalcet B-Chemical 1 0.9997609
, O 0 0.0017197783
dose O 0 0.018708989
adjustment O 0 0.000739079
may O 0 0.00035204485
be O 0 0.00027564995
necessary O 0 0.00017309577
for O 0 0.00024211094
drugs O 0 0.16280594
that O 0 0.00025861867
demonstrate O 0 0.00024654483
a O 0 0.00043708517
narrow O 0 0.0010222859
therapeutic O 0 0.006048815
index O 0 0.0014247476
and O 0 0.0011750516
are O 0 0.0018916738
metabolized O 0 0.8171511
by O 0 0.0061159804
CYP2D6 O 0 0.9962089
. O 0 0.009706908

Case O 0 0.078056544
report O 0 0.029009117
: O 0 0.023543296
acute O 0 0.9560292
unintentional O 0 0.96825635
carbachol B-Chemical 1 0.99674976
intoxication O 0 0.9955531
. O 0 0.033482715

INTRODUCTION O 0 0.14842473
: O 0 0.0100669805
Intoxications O 0 0.8608582
with O 0 0.0061896397
carbachol B-Chemical 1 0.9961649
, O 0 0.005918779
a O 0 0.005063002
muscarinic O 0 0.99656194
cholinergic O 0 0.9936167
receptor O 0 0.7944359
agonist O 0 0.9824791
are O 0 0.009384457
rare O 0 0.08132653
. O 0 0.010219872

We O 0 0.0044788583
report O 0 0.005923085
an O 0 0.0031404616
interesting O 0 0.0017292373
case O 0 0.001975712
investigating O 0 0.0022120294
a O 0 0.0032077804
( O 0 0.004225095
near O 0 0.0049283295
) O 0 0.012172601
fatal O 0 0.98702997
poisoning B-Disease 2 0.9963527
. O 0 0.016204713

METHODS O 0 0.006683544
: O 0 0.003337135
The O 0 0.0015025807
son O 0 0.0034984595
of O 0 0.0013916674
an O 0 0.0013921275
84 O 0 0.0016610419
- O 0 0.0011880135
year O 0 0.00072416634
- O 0 0.0008502076
old O 0 0.00053191185
male O 0 0.000982059
discovered O 0 0.00060253043
a O 0 0.00040484898
newspaper O 0 0.0007323627
report O 0 0.0010989892
stating O 0 0.0010228426
clinical O 0 0.003041371
success O 0 0.0011035947
with O 0 0.00086149474
plant O 0 0.0129349055
extracts O 0 0.008906332
in O 0 0.0026003863
Alzheimer B-Disease 0 0.99888283
' I-Disease 0 0.004468336
s I-Disease 0 0.005682974
disease I-Disease 0 0.59342736
. O 0 0.0075573274

The O 0 0.0028101758
mode O 0 0.0026696902
of O 0 0.0022098506
action O 0 0.0056674806
was O 0 0.0012621165
said O 0 0.0018014738
to O 0 0.0007082296
be O 0 0.0005962674
comparable O 0 0.00034588182
to O 0 0.00039168057
that O 0 0.00034059052
of O 0 0.00056672475
the O 0 0.00054141216
synthetic O 0 0.0021314085
compound O 0 0.07836983
' O 0 0.0014875642
carbamylcholin B-Chemical 0 0.2757628
' O 0 0.0018950539
; O 0 0.0022866705
that O 0 0.0013735376
is O 0 0.0027591242
, O 0 0.006736229
carbachol B-Chemical 1 0.99422705
. O 0 0.009153161

He O 0 0.009768453
bought O 0 0.0087108705
25 O 0 0.003349274
g O 0 0.0035579451
of O 0 0.0022001874
carbachol B-Chemical 1 0.99642086
as O 0 0.001237958
pure O 0 0.0065078572
substance O 0 0.9516839
in O 0 0.0008537703
a O 0 0.00087788136
pharmacy O 0 0.013761049
, O 0 0.0008271273
and O 0 0.00056863745
the O 0 0.0005619362
father O 0 0.002599738
was O 0 0.00092436717
administered O 0 0.0025490567
400 O 0 0.003541406
to O 0 0.0018427742
500 O 0 0.008729728
mg O 0 0.40835428
. O 0 0.0062495545

Carbachol B-Chemical 0 0.99772614
concentrations O 0 0.020892592
in O 0 0.002252606
serum O 0 0.031878844
and O 0 0.001540149
urine O 0 0.06335923
on O 0 0.0005162666
day O 0 0.000616796
1 O 0 0.000518307
and O 0 0.00044015032
2 O 0 0.0003878906
of O 0 0.00048516784
hospital O 0 0.0016763093
admission O 0 0.0059961276
were O 0 0.0006656281
analysed O 0 0.0009075193
by O 0 0.0016174784
HPLC O 0 0.66151917
- O 0 0.004707438
mass O 0 0.0121943
spectrometry O 0 0.10176682
. O 0 0.007850436

RESULTS O 0 0.031187082
: O 0 0.005904346
Minutes O 0 0.14736897
after O 0 0.0014304209
oral O 0 0.09720535
administration O 0 0.10950536
, O 0 0.0015389879
the O 0 0.00084329693
patient O 0 0.0017326204
developed O 0 0.0050340495
nausea B-Disease 2 0.9997459
, O 0 0.009638249
sweating O 0 0.9980375
and O 0 0.0052314294
hypotension B-Disease 2 0.9993506
, O 0 0.0039455225
and O 0 0.0029293504
finally O 0 0.007993384
collapsed O 0 0.012498448
. O 0 0.006868196

Bradycardia B-Disease 2 0.98928577
, O 0 0.020787593
cholinergic O 0 0.96233195
symptoms O 0 0.67455214
and O 0 0.01758347
asystole B-Disease 2 0.99039865
occurred O 0 0.023537874
. O 0 0.016203426

Initial O 0 0.007925428
cardiopulmonary O 0 0.007998174
resuscitation O 0 0.0075909332
and O 0 0.0019041997
immediate O 0 0.0027398353
treatment O 0 0.0032662507
with O 0 0.00297359
adrenaline B-Chemical 1 0.9993742
( O 0 0.011069164
epinephrine B-Chemical 0 0.9984546
) O 0 0.005650705
, O 0 0.0031259777
atropine B-Chemical 0 0.9990527
and O 0 0.0068088504
furosemide B-Chemical 1 0.9993081
was O 0 0.0062066633
successful O 0 0.009550978
. O 0 0.0072856317

On O 0 0.004841622
hospital O 0 0.0067017456
admission O 0 0.013390713
, O 0 0.0026275543
blood O 0 0.0049183457
pressure O 0 0.012744696
of O 0 0.0014406452
the O 0 0.001179293
intubated O 0 0.028828917
, O 0 0.0017864003
bradyarrhythmic O 0 0.43706197
patient O 0 0.0024431727
was O 0 0.0016456711
100 O 0 0.0034794903
/ O 0 0.00471095
65 O 0 0.0047766482
mmHg O 0 0.015764305
. O 0 0.0054832357

Further O 0 0.0061499276
signs O 0 0.046743188
were O 0 0.0038249232
hyperhidrosis B-Disease 0 0.9949255
, O 0 0.008539957
hypersalivation B-Disease 0 0.9993011
, O 0 0.005674671
bronchorrhoea B-Disease 0 0.8408919
, O 0 0.0015406132
and O 0 0.0011208251
severe O 0 0.5079109
miosis B-Disease 0 0.999703
; O 0 0.0027460312
the O 0 0.00079854764
electrocardiographic O 0 0.9108149
finding O 0 0.002140078
was O 0 0.0015302977
atrio B-Disease 0 0.15825187
- I-Disease 0 0.005898954
ventricular I-Disease 0 0.9664877
dissociation I-Disease 0 0.08197192
. O 0 0.0071461303

High O 0 0.021281436
doses O 0 0.039956413
of O 0 0.0048501394
atropine B-Chemical 0 0.9989297
( O 0 0.0032898507
up O 0 0.0010413348
to O 0 0.0007259746
50 O 0 0.001077477
mg O 0 0.07061
per O 0 0.00040015878
24 O 0 0.0005583046
hours O 0 0.00064387
) O 0 0.0013615594
, O 0 0.0017541484
adrenaline B-Chemical 1 0.9983602
and O 0 0.003852645
dopamine B-Chemical 1 0.99669147
were O 0 0.003796731
necessary O 0 0.0037512877
. O 0 0.0060759955

The O 0 0.0073868856
patient O 0 0.009295111
was O 0 0.0070985314
extubated O 0 0.013846708
1 O 0 0.0070531107
week O 0 0.007308176
later O 0 0.0099881
. O 0 0.0130582

However O 0 0.009155639
, O 0 0.008423239
increased O 0 0.010226
dyspnoea B-Disease 0 0.9848658
and O 0 0.014904587
bronchospasm B-Disease 0 0.9968483
necessitated O 0 0.12797129
reintubation O 0 0.8645103
. O 0 0.01581212

Respiratory B-Disease 0 0.9588914
insufficiency I-Disease 0 0.9929675
was O 0 0.004455569
further O 0 0.0036472345
worsened O 0 0.15339589
by O 0 0.004898753
Proteus B-Disease 0 0.98979515
mirabilis I-Disease 0 0.6942092
infection I-Disease 2 0.7622585
and O 0 0.009426623
severe O 0 0.8098302
bronchoconstriction O 0 0.9964142
. O 0 0.016522069

One O 0 0.0043000374
week O 0 0.0020234569
later O 0 0.0016126045
, O 0 0.0015142629
the O 0 0.00087644043
patient O 0 0.0012451434
was O 0 0.0007051692
again O 0 0.00072851504
extubated O 0 0.0017453532
and O 0 0.0005603915
3 O 0 0.0004128985
days O 0 0.0004229703
later O 0 0.0004865125
was O 0 0.00062755187
transferred O 0 0.0008872045
to O 0 0.0011177422
a O 0 0.0022371493
peripheral O 0 0.022596307
ward O 0 0.0059193545
. O 0 0.0063213725

On O 0 0.004198231
the O 0 0.0022419954
next O 0 0.0013167697
day O 0 0.0016282682
he O 0 0.0022679395
died O 0 0.008417394
, O 0 0.0019811124
probably O 0 0.0019155855
as O 0 0.0011449445
a O 0 0.0017041456
result O 0 0.0017974807
of O 0 0.0044306302
heart B-Disease 0 0.75038916
failure I-Disease 0 0.8426137
. O 0 0.010344019

Serum O 0 0.13742088
samples O 0 0.0023757445
from O 0 0.001460182
the O 0 0.000992728
first O 0 0.0006906165
and O 0 0.00070149853
second O 0 0.000529236
days O 0 0.000490443
contained O 0 0.0003787056
3 O 0 0.00040284952
. O 0 0.00026336234
6 O 0 0.00028338013
and O 0 0.00039150234
1 O 0 0.00046612704
. O 0 0.00033505482
9 O 0 0.0006625332
mg O 0 0.125144
/ O 0 0.0028775365
l O 0 0.0069134827
carbachol B-Chemical 1 0.99626714
, O 0 0.006249545
respectively O 0 0.0102135455
. O 0 0.0059509226

The O 0 0.00411904
corresponding O 0 0.0032914632
urine O 0 0.05781636
concentrations O 0 0.007135914
amounted O 0 0.005566828
to O 0 0.0026221066
374 O 0 0.01192912
and O 0 0.0034194556
554 O 0 0.0353267
mg O 0 0.52573997
/ O 0 0.0124068195
l O 0 0.0147438245
. O 0 0.009201238

CONCLUSION O 0 0.82175493
: O 0 0.0045181927
This O 0 0.0022588917
case O 0 0.0012201099
started O 0 0.0012299106
with O 0 0.00095261633
a O 0 0.0008465411
media O 0 0.0018614144
report O 0 0.0017421275
in O 0 0.00041245884
a O 0 0.0004552866
popular O 0 0.0010464436
newspaper O 0 0.0009981709
, O 0 0.0004926414
initiated O 0 0.0004220389
by O 0 0.0003479641
published O 0 0.0004575852
, O 0 0.00050413096
peer O 0 0.0052884105
- O 0 0.0006117623
reviewed O 0 0.00072761206
research O 0 0.00050061947
on O 0 0.00021153492
herbals O 0 0.7640921
, O 0 0.0005266751
and O 0 0.0003178783
involved O 0 0.00030697417
human O 0 0.00084785087
failure O 0 0.27112734
in O 0 0.0003716858
a O 0 0.00046697468
case O 0 0.0005199294
history O 0 0.007861644
, O 0 0.0010067462
medical O 0 0.004734973
examination O 0 0.0022118988
and O 0 0.0018162609
clinical O 0 0.019028101
treatment O 0 0.011021978
. O 0 0.0060046627

For O 0 0.0026134676
the O 0 0.0017966246
first O 0 0.0011563413
time O 0 0.0010401085
, O 0 0.0012101191
an O 0 0.0009186697
analytical O 0 0.0028416729
method O 0 0.0010536691
for O 0 0.00049431756
the O 0 0.0005493666
determination O 0 0.0018344502
of O 0 0.001496302
carbachol B-Chemical 1 0.99850047
in O 0 0.0012959347
plasma O 0 0.061301056
and O 0 0.0017433704
urine O 0 0.2455147
has O 0 0.0027082877
been O 0 0.0044774045
developed O 0 0.008886559
. O 0 0.006750678

The O 0 0.0032257885
analysed O 0 0.0033608978
carbachol B-Chemical 1 0.9947491
concentration O 0 0.0076826657
exceeded O 0 0.0012172352
the O 0 0.00088857964
supposed O 0 0.001572922
serum O 0 0.020176718
level O 0 0.00049203436
resulting O 0 0.0006059062
from O 0 0.0005151307
a O 0 0.0006371044
therapeutic O 0 0.0083014155
dose O 0 0.015134217
by O 0 0.0009774962
a O 0 0.0012443891
factor O 0 0.0039448147
of O 0 0.0023972436
130 O 0 0.006332603
to O 0 0.0032455206
260 O 0 0.018072529
. O 0 0.006032553

Especially O 0 0.010535158
in O 0 0.002450658
old O 0 0.0023195513
patients O 0 0.0032208487
, O 0 0.001646878
intensivists O 0 0.0024146605
should O 0 0.0005622633
consider O 0 0.00071099016
intoxications O 0 0.9977556
( O 0 0.0019634427
with O 0 0.0014472703
cholinergics O 0 0.98607826
) O 0 0.0018282963
as O 0 0.00066005165
a O 0 0.0011190776
cause O 0 0.0034340033
of O 0 0.0037966298
acute B-Disease 0 0.9934366
cardiovascular I-Disease 0 0.99572575
failure I-Disease 0 0.98371017
. O 0 0.010791202

Pharmacological O 0 0.8605213
evidence O 0 0.0042725024
for O 0 0.0022399079
the O 0 0.0019128979
potential O 0 0.0025166462
of O 0 0.0032292001
Daucus O 0 0.52429175
carota O 0 0.6797746
in O 0 0.0021746524
the O 0 0.0021357322
management O 0 0.005927876
of O 0 0.006606662
cognitive B-Disease 0 0.93035734
dysfunctions I-Disease 0 0.9745096
. O 0 0.011733193

The O 0 0.0024026427
present O 0 0.0014630625
study O 0 0.0018075798
was O 0 0.0009897745
aimed O 0 0.00087992346
at O 0 0.00044198835
investigating O 0 0.00053295476
the O 0 0.0005091507
effects O 0 0.001084339
of O 0 0.0011904677
Daucus O 0 0.61935985
carota O 0 0.8112125
seeds O 0 0.01204194
on O 0 0.00044658282
cognitive O 0 0.5684354
functions O 0 0.0011625162
, O 0 0.0006749173
total O 0 0.00052795606
serum O 0 0.15080145
cholesterol B-Chemical 0 0.9947472
levels O 0 0.0011137447
and O 0 0.0013729018
brain O 0 0.20142116
cholinesterase O 0 0.9963505
activity O 0 0.0034787676
in O 0 0.0024328853
mice O 0 0.0029292721
. O 0 0.005224887

The O 0 0.004425507
ethanolic O 0 0.79983693
extract B-Chemical 0 0.029232098
of I-Chemical 0 0.004748356
Daucus I-Chemical 0 0.69668657
carota I-Chemical 0 0.85571724
seeds I-Chemical 0 0.047359116
( O 0 0.0035430216
DCE B-Chemical 1 0.96266735
) O 0 0.001854457
was O 0 0.0005610481
administered O 0 0.0014479774
orally O 0 0.016804105
in O 0 0.00029563252
three O 0 0.00019650014
doses O 0 0.018138219
( O 0 0.0005979126
100 O 0 0.0007189983
, O 0 0.00037160714
200 O 0 0.000643943
, O 0 0.00034487274
400 O 0 0.001131289
mg O 0 0.16493002
/ O 0 0.00076665875
kg O 0 0.0022649944
) O 0 0.00036172348
for O 0 0.00015865768
seven O 0 0.00019898835
successive O 0 0.0002744497
days O 0 0.00028096535
to O 0 0.00028662605
different O 0 0.00041118078
groups O 0 0.0006935082
of O 0 0.0011351466
young O 0 0.005998402
and O 0 0.0019671803
aged O 0 0.004228876
mice O 0 0.0026608733
. O 0 0.005086061

Elevated O 0 0.07563318
plus O 0 0.0034347707
maze O 0 0.027966686
and O 0 0.0020508373
passive O 0 0.0034953489
avoidance O 0 0.0047262604
apparatus O 0 0.002066645
served O 0 0.0015228391
as O 0 0.0008700585
the O 0 0.0011293472
exteroceptive O 0 0.7692412
behavioral O 0 0.03198397
models O 0 0.0027995529
for O 0 0.0020146028
testing O 0 0.0045857118
memory O 0 0.30775404
. O 0 0.008320963

Diazepam B-Chemical 0 0.9991867
- O 0 0.02276218
, O 0 0.00853682
scopolamine B-Chemical 1 0.9996382
- O 0 0.008493286
and O 0 0.0021397155
ageing O 0 0.16102909
- O 0 0.003370839
induced O 0 0.0030789506
amnesia B-Disease 0 0.9979898
served O 0 0.0026597702
as O 0 0.0012845076
the O 0 0.001991823
interoceptive O 0 0.6821928
behavioral O 0 0.098348685
models O 0 0.009545021
. O 0 0.007181827

DCE B-Chemical 1 0.85827726
( O 0 0.0057178717
200 O 0 0.0043757483
, O 0 0.0022498278
400 O 0 0.0036562614
mg O 0 0.27143422
/ O 0 0.0022647725
kg O 0 0.0049023298
, O 0 0.0008653895
p O 0 0.00078444916
. O 0 0.0003513917
o O 0 0.0013697427
. O 0 0.00032861964
) O 0 0.00059991743
showed O 0 0.0003384
significant O 0 0.000503055
improvement O 0 0.00071707374
in O 0 0.0005155293
memory O 0 0.054777354
scores O 0 0.00083586725
of O 0 0.0012986696
young O 0 0.007301302
and O 0 0.0020435203
aged O 0 0.004313608
mice O 0 0.0026766236
. O 0 0.005098391

The O 0 0.0027957866
extent O 0 0.0017195538
of O 0 0.0020414148
memory O 0 0.07521861
improvement O 0 0.002400567
evoked O 0 0.07273052
by O 0 0.0011728007
DCE B-Chemical 1 0.90747863
was O 0 0.0007255621
23 O 0 0.000742998
% O 0 0.0003665109
at O 0 0.00017158904
the O 0 0.00023311518
dose O 0 0.001909696
of O 0 0.00043850322
200 O 0 0.0013525395
mg O 0 0.29721025
/ O 0 0.000858345
kg O 0 0.0019796386
and O 0 0.0002534068
35 O 0 0.00027166362
% O 0 0.00020632232
at O 0 0.00011336857
the O 0 0.0001836199
dose O 0 0.0017001778
of O 0 0.00044651536
400 O 0 0.003073882
mg O 0 0.32272393
/ O 0 0.0011923221
kg O 0 0.0028131865
in O 0 0.000411121
young O 0 0.001758663
mice O 0 0.00045034714
using O 0 0.00087107875
elevated O 0 0.0055390033
plus O 0 0.003826675
maze O 0 0.23548022
. O 0 0.0069488776

Similarly O 0 0.005105892
, O 0 0.003151047
significant O 0 0.0020342509
improvements O 0 0.0015210913
in O 0 0.0010628353
memory O 0 0.034491908
scores O 0 0.0009368754
were O 0 0.0006922651
observed O 0 0.0005450402
using O 0 0.00069310225
passive O 0 0.0026298172
avoidance O 0 0.005471921
apparatus O 0 0.003228994
and O 0 0.0027144763
aged O 0 0.005336149
mice O 0 0.0033479626
. O 0 0.006084436

Furthermore O 0 0.0065263906
, O 0 0.004983499
DCE B-Chemical 1 0.80405444
reversed O 0 0.0063199173
the O 0 0.0022975905
amnesia B-Disease 0 0.99814725
induced O 0 0.0037546288
by O 0 0.002455817
scopolamine B-Chemical 1 0.99989736
( O 0 0.0027230731
0 O 0 0.00064238906
. O 0 0.00023110991
4 O 0 0.0002869241
mg O 0 0.10468737
/ O 0 0.00085351605
kg O 0 0.002921006
, O 0 0.00043246077
i O 0 0.0007805791
. O 0 0.0002068297
p O 0 0.00044842565
. O 0 0.00021974207
) O 0 0.0005830506
and O 0 0.0005972648
diazepam B-Chemical 1 0.9998198
( O 0 0.0013009505
1 O 0 0.0006573159
mg O 0 0.25575122
/ O 0 0.0016402877
kg O 0 0.0048704804
, O 0 0.0010671837
i O 0 0.0020695461
. O 0 0.0009458745
p O 0 0.002363125
. O 0 0.0019420093
) O 0 0.0057159825
. O 0 0.005242672

Daucus B-Chemical 0 0.77825266
carota I-Chemical 0 0.7879645
extract I-Chemical 0 0.20643151
( O 0 0.004135498
200 O 0 0.0034420174
, O 0 0.0016186569
400 O 0 0.003062447
mg O 0 0.29401425
/ O 0 0.001820696
kg O 0 0.004680241
, O 0 0.00069162156
p O 0 0.0006532904
. O 0 0.00028625468
o O 0 0.0012899596
. O 0 0.00028282197
) O 0 0.0005503724
reduced O 0 0.00035748078
significantly O 0 0.00048178612
the O 0 0.0004374545
brain O 0 0.092439815
acetylcholinesterase O 0 0.99571973
activity O 0 0.0015892513
and O 0 0.0011334729
cholesterol B-Chemical 0 0.99364144
levels O 0 0.0011133691
in O 0 0.0010261617
young O 0 0.0062343073
and O 0 0.0019071627
aged O 0 0.0040939157
mice O 0 0.0025711346
. O 0 0.0049541667

The O 0 0.0029033301
extent O 0 0.0017864098
of O 0 0.0020439639
inhibition O 0 0.004082252
of O 0 0.0019862708
brain O 0 0.16760622
cholinesterase O 0 0.9975673
activity O 0 0.0022562398
evoked O 0 0.10707302
by O 0 0.00079155347
DCE B-Chemical 1 0.88410825
at O 0 0.00030729506
the O 0 0.00033294564
dose O 0 0.003826053
of O 0 0.0005515981
400 O 0 0.0035773367
mg O 0 0.35055673
/ O 0 0.0011183247
kg O 0 0.0027042646
was O 0 0.0003533446
22 O 0 0.0005187325
% O 0 0.00041077178
in O 0 0.00035709364
young O 0 0.0017268732
and O 0 0.0007691915
19 O 0 0.0014594065
% O 0 0.0011972863
in O 0 0.0012425048
aged O 0 0.003403581
mice O 0 0.0025094335
. O 0 0.004997141

There O 0 0.0052423314
was O 0 0.0023218521
a O 0 0.0017961918
remarkable O 0 0.0025335792
reduction O 0 0.0018185697
in O 0 0.0007777435
total O 0 0.0008662484
cholesterol B-Chemical 0 0.9847052
level O 0 0.0005310149
as O 0 0.00037443635
well O 0 0.00033859478
, O 0 0.00044097897
to O 0 0.0002549007
the O 0 0.00023970354
extent O 0 0.00019662984
of O 0 0.00037867491
23 O 0 0.0005819247
% O 0 0.0003293197
in O 0 0.00023150358
young O 0 0.0012314544
and O 0 0.00035161586
21 O 0 0.00045189483
% O 0 0.00035339512
in O 0 0.00027789528
aged O 0 0.00066014385
animals O 0 0.00039573797
with O 0 0.00077556836
this O 0 0.001162741
dose O 0 0.014140449
of O 0 0.0055667195
DCE B-Chemical 1 0.96324867
. O 0 0.007985955

Therefore O 0 0.00417849
, O 0 0.004144008
DCE B-Chemical 1 0.67306346
may O 0 0.0018546794
prove O 0 0.0017831296
to O 0 0.0008409226
be O 0 0.0007088478
a O 0 0.00059374014
useful O 0 0.00070209644
remedy O 0 0.0041539213
for O 0 0.00036590587
the O 0 0.00035951068
management O 0 0.0009889351
of O 0 0.0007096987
cognitive B-Disease 0 0.7920186
dysfunctions I-Disease 0 0.8834408
on O 0 0.00023532467
account O 0 0.00033061887
of O 0 0.00034586893
its O 0 0.000709478
multifarious O 0 0.024958808
beneficial O 0 0.003305305
effects O 0 0.0010337795
such O 0 0.00036209056
as O 0 0.00032494843
, O 0 0.0005809566
memory O 0 0.07483192
improving O 0 0.0007445336
property O 0 0.010271398
, O 0 0.0018825148
cholesterol B-Chemical 0 0.99556184
lowering O 0 0.13182189
property O 0 0.02532074
and O 0 0.0041374173
anticholinesterase O 0 0.99740076
activity O 0 0.011592574
. O 0 0.0066287173

Valproic B-Chemical 1 0.99921
acid I-Chemical 1 0.990892
induced O 0 0.051108766
encephalopathy B-Disease 2 0.9995826
- O 0 0.017296318
- O 0 0.0021771693
19 O 0 0.001078363
new O 0 0.00073821994
cases O 0 0.0009721831
in O 0 0.00048675024
Germany O 0 0.0037503506
from O 0 0.00044181163
1994 O 0 0.0027730626
to O 0 0.00043660402
2003 O 0 0.0020817616
- O 0 0.00094203005
- O 0 0.00065278664
a O 0 0.00042199326
side O 0 0.0046719094
effect O 0 0.00058324484
associated O 0 0.00091417535
to O 0 0.001096891
VPA B-Chemical 1 0.9997756
- O 0 0.0040368927
therapy O 0 0.02020888
not O 0 0.0009478863
only O 0 0.0012266361
in O 0 0.0017157267
young O 0 0.013939748
children O 0 0.009176891
. O 0 0.005684634

Valproic B-Chemical 1 0.9992004
acid I-Chemical 1 0.9925178
( O 0 0.037833992
VPA B-Chemical 1 0.99937373
) O 0 0.00626679
is O 0 0.0012755246
a O 0 0.001087521
broad O 0 0.0018069295
- O 0 0.0015768665
spectrum O 0 0.0017717589
antiepileptic O 0 0.99838793
drug O 0 0.6118694
and O 0 0.0015218195
is O 0 0.0013140223
usually O 0 0.002530448
well O 0 0.0021089434
- O 0 0.005966598
tolerated O 0 0.050125312
. O 0 0.0061268825

Rare O 0 0.33263046
serious O 0 0.14657445
complications O 0 0.42169464
may O 0 0.0021063995
occur O 0 0.00147595
in O 0 0.00084315956
some O 0 0.0009858068
patients O 0 0.0027065622
, O 0 0.0012374759
including O 0 0.0016162551
haemorrhagic O 0 0.99950147
pancreatitis B-Disease 0 0.9999366
, O 0 0.018824307
bone B-Disease 0 0.65643924
marrow I-Disease 0 0.95798206
suppression I-Disease 0 0.35084033
, O 0 0.0118086515
VPA B-Chemical 1 0.9998216
- O 0 0.014470562
induced O 0 0.015901614
hepatotoxicity B-Disease 2 0.99988747
and O 0 0.046515603
VPA B-Chemical 1 0.999716
- O 0 0.05514708
induced O 0 0.05456864
encephalopathy B-Disease 2 0.9990307
. O 0 0.012589916

The O 0 0.003428784
typical O 0 0.00388644
signs O 0 0.07370594
of O 0 0.005479747
VPA B-Chemical 1 0.99961203
- O 0 0.015358749
induced O 0 0.006864996
encephalopathy B-Disease 2 0.9997125
are O 0 0.0020127543
impaired B-Disease 0 0.04419835
consciousness I-Disease 0 0.99190545
, O 0 0.0011436385
sometimes O 0 0.00184124
marked O 0 0.0013916475
EEG O 0 0.8871469
background O 0 0.0004856451
slowing O 0 0.047397427
, O 0 0.00094162463
increased O 0 0.0023025703
seizure B-Disease 2 0.99869055
frequency O 0 0.0019399362
, O 0 0.001653606
with O 0 0.0016742502
or O 0 0.002001365
without O 0 0.0065109134
hyperammonemia B-Disease 0 0.9987968
. O 0 0.010161001

There O 0 0.0055097677
is O 0 0.0023716378
still O 0 0.0014588881
no O 0 0.00088975014
proof O 0 0.0014006424
of O 0 0.0011828966
causative O 0 0.008167029
effect O 0 0.0011963778
of O 0 0.0019610038
VPA B-Chemical 1 0.9997553
in O 0 0.0009800224
patients O 0 0.006579797
with O 0 0.0020979804
encephalopathy B-Disease 2 0.9997894
, O 0 0.0015764845
but O 0 0.00048134997
only O 0 0.0004011274
of O 0 0.00056095666
an O 0 0.0006948198
association O 0 0.0005567778
with O 0 0.00105275
an O 0 0.001587206
assumed O 0 0.0020285095
causal O 0 0.0050272616
relation O 0 0.0036749332
. O 0 0.00582487

We O 0 0.0035292578
report O 0 0.0050414586
19 O 0 0.0032275582
patients O 0 0.0039327
with O 0 0.003101234
VPA B-Chemical 1 0.9995741
- O 0 0.007659497
associated O 0 0.0038946988
encephalopathy B-Disease 2 0.9996586
in O 0 0.0011376418
Germany O 0 0.0103702415
from O 0 0.0004328171
the O 0 0.00039705486
years O 0 0.000929454
1994 O 0 0.002172955
to O 0 0.000452785
2003 O 0 0.0012613318
, O 0 0.0005953123
none O 0 0.00065912725
of O 0 0.00087570347
whom O 0 0.002713768
had O 0 0.0014858808
been O 0 0.002269987
published O 0 0.0031729392
previously O 0 0.0046119443
. O 0 0.0058929366

Cerebral B-Disease 0 0.9812354
haemorrhage I-Disease 0 0.9976283
induced O 0 0.008825746
by O 0 0.0046640444
warfarin B-Chemical 1 0.99768686
- O 0 0.0045053805
the O 0 0.001476298
influence O 0 0.0014564103
of O 0 0.0029582838
drug O 0 0.5774363
- O 0 0.009610369
drug O 0 0.4961935
interactions O 0 0.013866465
. O 0 0.008518593

PURPOSE O 0 0.033419177
: O 0 0.0036989262
To O 0 0.0012421191
evaluate O 0 0.0007472175
the O 0 0.00086420454
frequency O 0 0.0011143936
, O 0 0.0012415667
severity O 0 0.011765989
and O 0 0.0009994536
preventability O 0 0.5747441
of O 0 0.0021548376
warfarin B-Chemical 1 0.9996031
- O 0 0.007116131
induced O 0 0.0031830284
cerebral B-Disease 0 0.99809545
haemorrhages I-Disease 0 0.9996886
due O 0 0.00043677984
to O 0 0.0005143493
warfarin B-Chemical 1 0.9993309
and O 0 0.0013752386
warfarin B-Chemical 1 0.99956137
- O 0 0.002504298
drug O 0 0.26695514
interactions O 0 0.0009308588
in O 0 0.00034537746
patients O 0 0.0014023549
living O 0 0.0024244387
in O 0 0.00046925154
the O 0 0.0006080466
county O 0 0.0022387614
of O 0 0.0017728967
Osterg O 0 0.060898043
tland O 0 0.040193614
, O 0 0.0060024606
Sweden O 0 0.014977058
. O 0 0.006192473

METHODS O 0 0.006326424
: O 0 0.0031571079
All O 0 0.0017195408
patients O 0 0.0024677601
with O 0 0.001426916
a O 0 0.001552578
diagnosed O 0 0.06495062
cerebral B-Disease 2 0.9952304
haemorrhage I-Disease 2 0.99950933
at O 0 0.0006633647
three O 0 0.00038537304
hospitals O 0 0.0010145691
during O 0 0.00044415361
the O 0 0.0006420772
period O 0 0.001093778
2000 O 0 0.0032422524
- O 0 0.0026931404
2002 O 0 0.0044698925
were O 0 0.0023836598
identified O 0 0.0037501012
. O 0 0.0058115283

Medical O 0 0.007856989
records O 0 0.003098608
were O 0 0.0015825123
studied O 0 0.0015022125
retrospectively O 0 0.0013815409
to O 0 0.0006788329
evaluate O 0 0.00044179603
whether O 0 0.00045168222
warfarin B-Chemical 1 0.99756014
and O 0 0.0019387067
warfarin B-Chemical 1 0.9991683
- O 0 0.0041255592
drug O 0 0.3139427
interactions O 0 0.0018213815
could O 0 0.00075981865
have O 0 0.0012759555
caused O 0 0.0026001192
the O 0 0.004673014
cerebral B-Disease 2 0.99557793
haemorrhage I-Disease 2 0.9990036
. O 0 0.013738295

The O 0 0.0034838447
proportion O 0 0.0023740802
of O 0 0.002913904
possibly O 0 0.004684701
avoidable O 0 0.011940276
cases O 0 0.0035359988
due O 0 0.0014414473
to O 0 0.0019853448
drug O 0 0.22078699
interactions O 0 0.0056825383
was O 0 0.004155401
estimated O 0 0.0057229106
. O 0 0.007819613

RESULTS O 0 0.02925912
: O 0 0.005323596
Among O 0 0.005166432
593 O 0 0.029897498
patients O 0 0.004099696
with O 0 0.002660666
cerebral B-Disease 2 0.9944876
haemorrhage I-Disease 2 0.99956685
, O 0 0.0029369644
59 O 0 0.0019646625
( O 0 0.00091938773
10 O 0 0.00057514076
% O 0 0.0005771715
) O 0 0.000658785
were O 0 0.0004225709
assessed O 0 0.00045382592
as O 0 0.00062726723
related O 0 0.0009397827
to O 0 0.002202501
warfarin B-Chemical 1 0.99655306
treatment O 0 0.032323398
. O 0 0.0076977634

This O 0 0.0054040183
imply O 0 0.0023991617
an O 0 0.0029256814
incidence O 0 0.0055352827
of O 0 0.0024497292
1 O 0 0.0018411418
. O 0 0.001032505
7 O 0 0.001164783
/ O 0 0.0022621234
100 O 0 0.0023936601
, O 0 0.0020250701
000 O 0 0.0025177882
treatment O 0 0.0049293544
years O 0 0.008155539
. O 0 0.006536425

Of O 0 0.0054705716
the O 0 0.0024311426
59 O 0 0.0029750238
cases O 0 0.002512411
, O 0 0.0017017979
26 O 0 0.0015105932
( O 0 0.0010452305
44 O 0 0.00094178424
% O 0 0.0006393617
) O 0 0.000636796
had O 0 0.00041229057
a O 0 0.00060260505
fatal O 0 0.8946093
outcome O 0 0.002637747
, O 0 0.00052706833
compared O 0 0.00019213624
to O 0 0.00028443523
136 O 0 0.0021578358
( O 0 0.0004555527
25 O 0 0.00046809978
% O 0 0.0003372097
) O 0 0.00039577193
among O 0 0.00029766912
the O 0 0.0003075627
non O 0 0.0011387623
- O 0 0.0016514442
warfarin B-Chemical 1 0.99867684
patients O 0 0.009872562
( O 0 0.0013824102
p O 0 0.0013634115
< O 0 0.0013215628
0 O 0 0.0014036441
. O 0 0.0013728484
01 O 0 0.009395244
) O 0 0.0057207374
. O 0 0.005290528

A O 0 0.06239615
warfarin B-Chemical 1 0.99591136
- O 0 0.0061726444
drug O 0 0.20907824
interaction O 0 0.0016052747
could O 0 0.0006663374
have O 0 0.00069819804
contributed O 0 0.0014754216
to O 0 0.00059373246
the O 0 0.00072482566
haemorrhage B-Disease 0 0.9985826
in O 0 0.0005660945
24 O 0 0.00047926296
( O 0 0.00047006382
41 O 0 0.00061179965
% O 0 0.0003220138
) O 0 0.00033708772
of O 0 0.00027122005
the O 0 0.00030746884
warfarin B-Chemical 1 0.99872154
patients O 0 0.003066411
and O 0 0.00035429615
in O 0 0.00023701866
7 O 0 0.00020019394
of O 0 0.00026977836
these O 0 0.0004306252
( O 0 0.00046257715
12 O 0 0.0002432535
% O 0 0.00035286372
) O 0 0.0004786875
the O 0 0.00042505295
bleeding B-Disease 0 0.98691297
complication O 0 0.35922784
was O 0 0.00083180395
considered O 0 0.00077743974
being O 0 0.0013497163
possible O 0 0.0016188557
to O 0 0.0021569396
avoid O 0 0.0038751734
. O 0 0.005353626

CONCLUSIONS O 0 0.8873727
: O 0 0.01350168
Warfarin B-Chemical 0 0.9974324
- O 0 0.007743927
induced O 0 0.004786705
cerebral B-Disease 0 0.9944383
haemorrhages I-Disease 0 0.9990075
are O 0 0.0016404939
a O 0 0.0010467676
major O 0 0.0011576844
clinical O 0 0.0055250498
problem O 0 0.002194872
with O 0 0.0015599902
a O 0 0.002079966
high O 0 0.004157517
fatality O 0 0.9296682
rate O 0 0.007116646
. O 0 0.007889801

Almost O 0 0.005655673
half O 0 0.0020126845
of O 0 0.0022965502
the O 0 0.0017318098
cases O 0 0.0026391
was O 0 0.0014784517
related O 0 0.0011655405
to O 0 0.0015411503
a O 0 0.0031447082
warfarin B-Chemical 1 0.9973072
- O 0 0.01248993
drug O 0 0.51097405
interaction O 0 0.009809659
. O 0 0.008550448

A O 0 0.013928361
significant O 0 0.0031228203
proportion O 0 0.001598623
of O 0 0.0025549992
warfarin B-Chemical 1 0.998409
- O 0 0.0051491577
related O 0 0.0012239674
cerebral B-Disease 0 0.9951742
haemorrhages I-Disease 0 0.9994228
might O 0 0.00065509725
have O 0 0.0005791026
been O 0 0.00055253366
prevented O 0 0.0008989041
if O 0 0.00021143531
greater O 0 0.00028020245
caution O 0 0.00054396165
had O 0 0.0003710917
been O 0 0.0004268924
taken O 0 0.00027560422
when O 0 0.0003215561
prescribing O 0 0.014246011
drugs O 0 0.3991754
known O 0 0.0014043273
to O 0 0.0010567477
interact O 0 0.0015351577
with O 0 0.0050627766
warfarin B-Chemical 1 0.99670935
. O 0 0.008674993

Antipsychotic O 0 0.99381304
- O 0 0.00744383
like O 0 0.002681367
profile O 0 0.0028185383
of O 0 0.0039270255
thioperamide B-Chemical 0 0.9994759
, O 0 0.004836728
a O 0 0.0025445505
selective O 0 0.054224722
H3 O 0 0.69680333
- O 0 0.00929181
receptor O 0 0.39907166
antagonist O 0 0.97484833
in O 0 0.004839809
mice O 0 0.0046013966
. O 0 0.0072567123

Experimental O 0 0.011260779
and O 0 0.0031520834
clinical O 0 0.005077719
evidence O 0 0.0017127221
points O 0 0.0014730771
to O 0 0.00094258686
a O 0 0.00094762485
role O 0 0.0006400009
of O 0 0.0012127882
central O 0 0.0041647884
histaminergic O 0 0.97614473
system O 0 0.002359022
in O 0 0.0012819085
the O 0 0.0018089932
pathogenesis O 0 0.03319909
of O 0 0.011139097
schizophrenia B-Disease 2 0.9960284
. O 0 0.0110794725

The O 0 0.00241659
present O 0 0.0014816243
study O 0 0.0018615873
was O 0 0.0010287196
designed O 0 0.0009126798
to O 0 0.0006540748
study O 0 0.0008880406
the O 0 0.0005343021
effect O 0 0.0007673813
of O 0 0.0016034982
histamine B-Chemical 1 0.9994272
H O 0 0.9989255
( O 0 0.0031108134
3 O 0 0.00058428565
) O 0 0.0010361915
- O 0 0.0008909853
receptor O 0 0.062227525
ligands O 0 0.105348624
on O 0 0.0005564075
neuroleptic O 0 0.999944
- O 0 0.012207995
induced O 0 0.010502592
catalepsy B-Disease 2 0.99994457
, O 0 0.017174117
apomorphine B-Chemical 1 0.99993086
- O 0 0.004876401
induced O 0 0.0011631964
climbing O 0 0.21628751
behavior O 0 0.005593476
and O 0 0.001699316
amphetamine B-Chemical 1 0.99983096
- O 0 0.0052261655
induced O 0 0.0026126313
locomotor O 0 0.45341414
activities O 0 0.003034518
in O 0 0.002170183
mice O 0 0.0027087538
. O 0 0.004954909

Catalepsy B-Disease 0 0.9958332
was O 0 0.004434363
induced O 0 0.0036373015
by O 0 0.003225284
haloperidol B-Chemical 1 0.9997886
( O 0 0.0034601893
2 O 0 0.0010241766
mg O 0 0.2938676
/ O 0 0.0014682211
kg O 0 0.0033494253
p O 0 0.0006598366
. O 0 0.00027199587
o O 0 0.0012581
. O 0 0.00028735556
) O 0 0.00065393146
, O 0 0.00046526958
while O 0 0.00047054375
apomorphine B-Chemical 1 0.99984634
( O 0 0.0011128018
1 O 0 0.0003448594
. O 0 0.00015089625
5 O 0 0.00020100552
mg O 0 0.074172325
/ O 0 0.00060000864
kg O 0 0.0017280384
s O 0 0.00032618907
. O 0 0.00015669162
c O 0 0.0011646654
. O 0 0.00020699974
) O 0 0.00052533695
and O 0 0.00048581156
amphetamine B-Chemical 1 0.99985373
( O 0 0.0009837095
2 O 0 0.0003729883
mg O 0 0.21282761
/ O 0 0.00075501413
kg O 0 0.0021354803
s O 0 0.00034578104
. O 0 0.00016437186
c O 0 0.0010522963
. O 0 0.00020253129
) O 0 0.00040508542
were O 0 0.00022752683
used O 0 0.00022974226
for O 0 0.00026686257
studying O 0 0.0007958619
climbing O 0 0.064661644
behavior O 0 0.0027047598
and O 0 0.0014527278
locomotor O 0 0.30320016
activities O 0 0.0036190813
, O 0 0.003968323
respectively O 0 0.0078062434
. O 0 0.005423976

( B-Chemical 0 0.012040374
R I-Chemical 0 0.74716216
) I-Chemical 0 0.007312041
- I-Chemical 0 0.0049234335
alpha I-Chemical 0 0.28021574
- I-Chemical 0 0.007568174
methylhistamine I-Chemical 0 0.9965462
( O 0 0.009253125
RAMH B-Chemical 1 0.9990994
) O 0 0.0032137167
( O 0 0.00085495185
5 O 0 0.00036410554
microg O 0 0.00092049426
i O 0 0.0010752232
. O 0 0.00026625468
c O 0 0.0019902154
. O 0 0.00028740158
v O 0 0.004769925
. O 0 0.00028118916
) O 0 0.0007256627
and O 0 0.00069869234
thioperamide B-Chemical 0 0.9998493
( O 0 0.008277871
THP B-Chemical 1 0.99951184
) O 0 0.003014257
( O 0 0.00061637204
15 O 0 0.00030182337
mg O 0 0.14393584
/ O 0 0.00087222835
kg O 0 0.0027139322
i O 0 0.000884302
. O 0 0.00024274144
p O 0 0.00054395804
. O 0 0.00029228235
) O 0 0.0007304243
, O 0 0.0005834545
per O 0 0.00039801004
se O 0 0.0014584131
did O 0 0.0012486612
not O 0 0.0021430892
cause O 0 0.055284113
catalepsy B-Disease 2 0.99913555
. O 0 0.009958918

Administration O 0 0.28996897
of O 0 0.0064840782
THP B-Chemical 1 0.99676824
( O 0 0.0042526904
3 O 0 0.0011943112
. O 0 0.00059637084
75 O 0 0.00094495394
, O 0 0.00067545933
7 O 0 0.0003810167
. O 0 0.00022594762
5 O 0 0.00023344214
and O 0 0.00026007413
15 O 0 0.00026132134
mg O 0 0.07994353
/ O 0 0.00077406294
kg O 0 0.0023696611
i O 0 0.0007824155
. O 0 0.00018463116
p O 0 0.00038334038
. O 0 0.00017254062
) O 0 0.000378526
1 O 0 0.00019859584
h O 0 0.00018132402
prior O 0 0.00013497913
to O 0 0.0002956683
haloperidol B-Chemical 1 0.9999033
resulted O 0 0.00045723727
in O 0 0.00030054097
a O 0 0.0004188422
dose O 0 0.019947117
- O 0 0.0007064302
dependent O 0 0.00029597234
increase O 0 0.00037347345
in O 0 0.0004001468
the O 0 0.0007678461
catalepsy B-Disease 2 0.99976593
times O 0 0.00082326715
( O 0 0.001703234
P O 0 0.033322133
< O 0 0.0015792398
0 O 0 0.0015812245
. O 0 0.0015585879
05 O 0 0.031926785
) O 0 0.006244753
. O 0 0.0055637695

However O 0 0.0051855445
, O 0 0.0041395626
pretreatment O 0 0.112446174
with O 0 0.0038670704
RAMH B-Chemical 1 0.99814594
significantly O 0 0.0026235224
reversed O 0 0.0028438384
such O 0 0.0008078584
an O 0 0.0009554715
effect O 0 0.0008802208
of O 0 0.0016067091
THP B-Chemical 1 0.9990701
( O 0 0.0020796242
15 O 0 0.0007874224
mg O 0 0.26831093
/ O 0 0.0022231394
kg O 0 0.005693803
i O 0 0.0024834587
. O 0 0.0010707765
p O 0 0.002569484
. O 0 0.0021103062
) O 0 0.006073315
. O 0 0.005566466

RAMH B-Chemical 1 0.9900497
per O 0 0.0021733998
se O 0 0.0030750863
showed O 0 0.001329539
significant O 0 0.0013366605
reduction O 0 0.0014597122
in O 0 0.00066423323
locomotor O 0 0.108315304
time O 0 0.0004376578
, O 0 0.0005260367
distance O 0 0.0004610825
traveled O 0 0.0012858614
and O 0 0.00032501633
average O 0 0.00019235107
speed O 0 0.0007138266
but O 0 0.00060197007
THP B-Chemical 1 0.9990094
( O 0 0.0010285175
15 O 0 0.00036841325
mg O 0 0.20234682
/ O 0 0.0009402762
kg O 0 0.0030020073
i O 0 0.0008530449
. O 0 0.00021292004
p O 0 0.00044892836
. O 0 0.00021597782
) O 0 0.0004516502
per O 0 0.00021190435
se O 0 0.0007142359
had O 0 0.00059965276
no O 0 0.00061186927
effect O 0 0.0010779019
on O 0 0.0010062188
these O 0 0.0031512643
parameters O 0 0.007841018
. O 0 0.0061526773

On O 0 0.00969933
amphetamine B-Chemical 1 0.99906176
- O 0 0.014093252
induced O 0 0.008042205
hyperactivity B-Disease 2 0.9987355
, O 0 0.010165309
THP B-Chemical 1 0.9990181
( O 0 0.002258448
3 O 0 0.00052898965
. O 0 0.00025857726
75 O 0 0.00046270745
and O 0 0.00030795674
7 O 0 0.00025307672
. O 0 0.00016347841
5 O 0 0.00022601313
mg O 0 0.06515402
/ O 0 0.0007030479
kg O 0 0.0021587815
i O 0 0.00074929616
. O 0 0.0001827283
p O 0 0.00038856122
. O 0 0.00017646914
) O 0 0.00039695154
reduced O 0 0.00031212982
locomotor O 0 0.06849461
time O 0 0.00025301834
, O 0 0.00037898426
distance O 0 0.00039524402
traveled O 0 0.0012279471
and O 0 0.00039763327
average O 0 0.0003116707
speed O 0 0.0012886922
( O 0 0.0014887401
P O 0 0.024867123
< O 0 0.0016467574
0 O 0 0.001659293
. O 0 0.0016364892
05 O 0 0.032145973
) O 0 0.006466611
. O 0 0.005739286

Pretreatment O 0 0.84410024
with O 0 0.007509109
RAMH B-Chemical 1 0.99703526
( O 0 0.003858344
5 O 0 0.0011708234
microg O 0 0.002163907
i O 0 0.0020078283
. O 0 0.0005094854
c O 0 0.0026390082
. O 0 0.0004243159
v O 0 0.004543872
. O 0 0.00032421507
) O 0 0.0005786822
could O 0 0.00023232173
partially O 0 0.00039457378
reverse O 0 0.0033952582
such O 0 0.00037905178
effects O 0 0.0011587505
of O 0 0.0012907038
THP B-Chemical 1 0.99939704
( O 0 0.0013980238
3 O 0 0.0004012693
. O 0 0.00024828195
75 O 0 0.0007155439
mg O 0 0.12227731
/ O 0 0.0015831272
kg O 0 0.0042429124
i O 0 0.0020835814
. O 0 0.00092696183
p O 0 0.0023111736
. O 0 0.0019171926
) O 0 0.0056642946
. O 0 0.005222085

Climbing O 0 0.31001
behavior O 0 0.009351339
induced O 0 0.004797343
by O 0 0.0043688174
apomorphine B-Chemical 1 0.99922323
was O 0 0.003166897
reduced O 0 0.0023487213
in O 0 0.001897729
animals O 0 0.0023620373
treated O 0 0.0060643614
with O 0 0.01044902
THP B-Chemical 1 0.9950244
. O 0 0.014535019

Such O 0 0.0095635
an O 0 0.0046832287
effect O 0 0.003639912
was O 0 0.0028807768
, O 0 0.003239001
however O 0 0.0031906823
, O 0 0.003160943
reversed O 0 0.0048121936
in O 0 0.002737974
presence O 0 0.004278375
of O 0 0.011734918
RAMH B-Chemical 1 0.99478596
. O 0 0.0143788075

THP B-Chemical 1 0.99314886
exhibited O 0 0.0057646018
an O 0 0.005076077
antipsychotic O 0 0.99811506
- O 0 0.0039002316
like O 0 0.0010361519
profile O 0 0.0012585999
by O 0 0.001108538
potentiating O 0 0.76932395
haloperidol B-Chemical 1 0.9999616
- O 0 0.02816738
induced O 0 0.0135177765
catalepsy B-Disease 2 0.9999291
, O 0 0.0036143577
reducing O 0 0.0066006687
amphetamine B-Chemical 1 0.9999311
- O 0 0.011944194
induced O 0 0.0049456195
hyperactivity B-Disease 2 0.9992654
and O 0 0.001521912
reducing O 0 0.008457047
apomorphine B-Chemical 1 0.9998541
- O 0 0.009900518
induced O 0 0.003558163
climbing O 0 0.23661877
in O 0 0.0026700543
mice O 0 0.0030295905
. O 0 0.0053112125

Such O 0 0.008049036
effects O 0 0.004917811
of O 0 0.0040554707
THP B-Chemical 1 0.99671775
were O 0 0.0025974025
reversed O 0 0.0047002523
by O 0 0.002025716
RAMH B-Chemical 1 0.99794763
indicating O 0 0.0011202702
the O 0 0.0009790784
involvement O 0 0.00284419
of O 0 0.003155536
histamine B-Chemical 1 0.99904484
H O 0 0.99748224
( O 0 0.005593903
3 O 0 0.002279594
) O 0 0.0043703946
- O 0 0.0059146285
receptors O 0 0.11439808
. O 0 0.007327914

Findings O 0 0.0077715665
suggest O 0 0.0021401942
a O 0 0.0021214169
potential O 0 0.0022136737
for O 0 0.0018124931
H O 1 0.9886302
( O 0 0.0025822779
3 O 0 0.0010337131
) O 0 0.0016766118
- O 0 0.0015480135
receptor O 0 0.066573836
antagonists O 0 0.9117187
in O 0 0.0008458763
improving O 0 0.0011394672
the O 0 0.0012149959
refractory O 0 0.35414213
cases O 0 0.00727387
of O 0 0.010563166
schizophrenia B-Disease 2 0.9964251
. O 0 0.010064912

Cauda B-Disease 0 0.93917537
equina I-Disease 0 0.6095262
syndrome I-Disease 0 0.75628626
after O 0 0.0032484173
epidural O 0 0.7071918
steroid B-Chemical 1 0.99105257
injection O 0 0.05158137
: O 0 0.006783252
a O 0 0.004910163
case O 0 0.006297336
report O 0 0.017760813
. O 0 0.010534522

OBJECTIVE O 0 0.540523
: O 0 0.004977327
Conventional O 0 0.0067342385
treatment O 0 0.0028701182
methods O 0 0.0016933153
of O 0 0.0016860146
lumbusacral O 0 0.07549238
radiculopathy B-Disease 0 0.9990011
are O 0 0.0012791625
physical O 0 0.013677134
therapy O 0 0.027928935
, O 0 0.0012494279
epidural O 0 0.7172783
steroid B-Chemical 1 0.99631137
injections O 0 0.07004865
, O 0 0.0016202419
oral O 0 0.41018
medications O 0 0.6763149
, O 0 0.0019526305
and O 0 0.0018472509
spinal O 0 0.12955642
manipulative O 0 0.081780784
therapy O 0 0.099129364
. O 0 0.007015734

Cauda B-Disease 0 0.9486344
equina I-Disease 0 0.7020427
syndrome I-Disease 0 0.8341057
is O 0 0.005045919
a O 0 0.004819811
rare O 0 0.016178438
complication O 0 0.2879483
of O 0 0.010258627
epidural O 0 0.8950608
anesthesia O 0 0.6875734
. O 0 0.013986511

The O 0 0.0029465253
following O 0 0.002230333
case O 0 0.0019019825
is O 0 0.0013785369
a O 0 0.0013014303
report O 0 0.0027888822
of O 0 0.002128501
cauda B-Disease 0 0.82088363
equina I-Disease 0 0.84960514
syndrome I-Disease 0 0.94010484
possibly O 0 0.0036343785
caused O 0 0.0013956844
by O 0 0.0013201815
epidural O 0 0.61694205
injection O 0 0.012397573
of O 0 0.0056241234
triamcinolone B-Chemical 0 0.9995747
and O 0 0.033600677
bupivacaine B-Chemical 1 0.9988361
. O 0 0.01113991

CLINICAL O 0 0.16129969
FEATURES O 0 0.061474178
: O 0 0.004768026
A O 0 0.007911871
50 O 0 0.0025014407
- O 0 0.001813293
year O 0 0.001047912
- O 0 0.001181517
old O 0 0.00076644873
woman O 0 0.003213506
with O 0 0.00064497703
low B-Disease 0 0.00076195
back I-Disease 0 0.0013077004
and I-Disease 0 0.00070218975
right I-Disease 0 0.0017339216
leg I-Disease 0 0.021085594
pain I-Disease 0 0.9288931
was O 0 0.00095000607
scheduled O 0 0.0008564512
for O 0 0.0012422865
epidural O 0 0.75625956
steroid B-Chemical 1 0.99268955
injection O 0 0.102424145
. O 0 0.0075323223

INTERVENTION O 0 0.017480133
AND O 0 0.006414701
OUTCOME O 0 0.035855096
: O 0 0.0033499997
An O 0 0.0025579676
18 O 0 0.0014315615
- O 0 0.0014564138
gauge O 0 0.0014703777
Touhy O 0 0.005143484
needle O 0 0.0015950243
was O 0 0.0005708867
inserted O 0 0.00041607878
until O 0 0.000296598
loss O 0 0.000801831
of O 0 0.00074841944
resistance O 0 0.004323411
occurred O 0 0.001078694
at O 0 0.0006518771
the O 0 0.0013039961
L4 O 0 0.037281513
- O 0 0.003371219
5 O 0 0.0021997748
level O 0 0.002932218
. O 0 0.0051313234

Spread O 0 0.016373778
of O 0 0.0036702307
the O 0 0.0023003784
contrast O 0 0.0028059045
medium O 0 0.005082469
within O 0 0.000914479
the O 0 0.0013311919
epidural O 0 0.28685054
space O 0 0.002374079
was O 0 0.001597876
determined O 0 0.0015785302
by O 0 0.003153603
radiographic O 0 0.07213914
imaging O 0 0.043641318
. O 0 0.009088368

After O 0 0.003172217
verifying O 0 0.0036567838
the O 0 0.0030916992
epidural O 0 0.27844056
space O 0 0.0051705115
, O 0 0.0059807124
bupivacaine B-Chemical 1 0.998555
and O 0 0.016467532
triamcinolone B-Chemical 1 0.99966085
diacetate I-Chemical 1 0.9916521
were O 0 0.008427407
injected O 0 0.008627852
. O 0 0.008944792

After O 0 0.003500776
the O 0 0.0033441714
injection O 0 0.0061377226
, O 0 0.0031118102
there O 0 0.0015805148
was O 0 0.0020934758
a O 0 0.0027749569
reduction O 0 0.005103468
in O 0 0.0052794022
radicular O 0 0.9840211
symptoms O 0 0.8043149
. O 0 0.0118226595

Three O 0 0.0057164137
hours O 0 0.0029882353
later O 0 0.0024153295
, O 0 0.002570571
she O 0 0.002405481
complained O 0 0.09417349
of O 0 0.0037701982
perineal O 0 0.42770413
numbness B-Disease 0 0.9935203
and O 0 0.0047301943
lower B-Disease 0 0.006315424
extremity I-Disease 0 0.5487449
weakness I-Disease 2 0.98664165
. O 0 0.012918879

The O 0 0.003993359
neurologic O 0 0.7644142
evaluation O 0 0.0030400283
revealed O 0 0.0018027371
loss B-Disease 0 0.0028437085
of I-Disease 0 0.0018784219
sensation I-Disease 0 0.78152055
in O 0 0.0009272807
the O 0 0.0008155843
saddle O 0 0.015665274
area O 0 0.0016837767
and O 0 0.0012728627
medial O 0 0.012318068
aspect O 0 0.0014706692
of O 0 0.001988247
her O 0 0.004169005
right O 0 0.008717461
leg O 0 0.049527343
. O 0 0.0077159735

There O 0 0.007918949
was O 0 0.004037138
a O 0 0.0036296851
decrease O 0 0.0033673195
in O 0 0.0026134988
the O 0 0.0030117936
perception O 0 0.009163724
of O 0 0.0072132936
pinprick O 0 0.77020943
test O 0 0.011851284
. O 0 0.011564459

Deep O 0 0.060773563
- O 0 0.010178181
tendon O 0 0.09111947
reflexes O 0 0.79638344
were O 0 0.0034557593
decreased O 0 0.0046424847
especially O 0 0.004063139
in O 0 0.0031171916
the O 0 0.004268727
right O 0 0.011950974
leg O 0 0.050909404
. O 0 0.011437403

She O 0 0.02627302
was O 0 0.01472716
unable O 0 0.0131897135
to O 0 0.018533587
urinate O 0 0.10282906
. O 0 0.027681246

The O 0 0.0037689107
patient O 0 0.004316253
' O 0 0.003186622
s O 0 0.0030514782
symptoms O 0 0.047354292
improved O 0 0.0032122263
slightly O 0 0.0018670983
over O 0 0.0010846086
the O 0 0.0016570315
next O 0 0.0016646
few O 0 0.0028484773
hours O 0 0.005403645
. O 0 0.0072264215

She O 0 0.0070115365
had O 0 0.0031532373
a O 0 0.002563948
gradual O 0 0.0028880136
return O 0 0.0025353027
of O 0 0.0020676896
motor O 0 0.03377016
function O 0 0.0021598153
and O 0 0.0017172545
ability O 0 0.001854705
of O 0 0.0034331551
feeling O 0 0.19318186
Foley O 0 0.17409098
catheter O 0 0.025149727
. O 0 0.008787595

All O 0 0.0044387183
of O 0 0.0035931927
the O 0 0.0028574143
symptoms O 0 0.07793847
were O 0 0.0020539938
completely O 0 0.0019136508
resolved O 0 0.0025458194
over O 0 0.0011688576
the O 0 0.0018056888
next O 0 0.0018734013
8 O 0 0.0034536545
hours O 0 0.0048460853
. O 0 0.0065743527

CONCLUSION O 0 0.8397733
: O 0 0.009965451
Complications O 0 0.040984314
associated O 0 0.0045412076
with O 0 0.0048342347
epidural O 0 0.79574305
steroid B-Chemical 1 0.9914106
injections O 0 0.1613916
are O 0 0.009646603
rare O 0 0.048785128
. O 0 0.012110684

Clinical O 0 0.028950613
examination O 0 0.00458505
and O 0 0.002351852
continued O 0 0.0024447308
vigilance O 0 0.037727404
for O 0 0.0017785041
neurologic B-Disease 0 0.99470985
deterioration I-Disease 0 0.8165592
after O 0 0.0013866256
epidural O 0 0.8474494
steroid B-Chemical 1 0.99472696
injections O 0 0.110091895
is O 0 0.0044235433
important O 0 0.005138187
. O 0 0.006904927

High O 0 0.050500818
- O 0 0.009392235
dose O 0 0.0763985
testosterone B-Chemical 0 0.99490017
is O 0 0.0040066796
associated O 0 0.004263185
with O 0 0.0062023797
atherosclerosis B-Disease 2 0.99745196
in O 0 0.008985038
postmenopausal O 0 0.9892691
women O 0 0.29948097
. O 0 0.0115179615

OBJECTIVES O 0 0.0245932
: O 0 0.0039669476
To O 0 0.0014623208
study O 0 0.0017103708
the O 0 0.0010801043
long O 0 0.0013851448
- O 0 0.0014787122
term O 0 0.0009934712
effects O 0 0.0017114581
of O 0 0.0018747984
androgen O 0 0.99708825
treatment O 0 0.012071338
on O 0 0.0018140164
atherosclerosis B-Disease 2 0.9984028
in O 0 0.0060665575
postmenopausal O 0 0.9919878
women O 0 0.28851217
. O 0 0.008513391

METHODS O 0 0.00623226
: O 0 0.0030919018
In O 0 0.0013022299
a O 0 0.0012530921
population O 0 0.0014971236
- O 0 0.0012226676
based O 0 0.00067291595
study O 0 0.00080494914
in O 0 0.00045872288
513 O 0 0.0072680367
naturally O 0 0.004520723
postmenopausal O 0 0.98169655
women O 0 0.038126122
aged O 0 0.0011677437
54 O 0 0.00076968933
- O 0 0.00048894016
67 O 0 0.00048185018
years O 0 0.00041985835
, O 0 0.00024080148
we O 0 0.00010063163
studied O 0 0.00025660612
the O 0 0.00017608843
association O 0 0.00018511857
between O 0 0.00015752245
self O 0 0.00330232
- O 0 0.00071708433
reported O 0 0.00054445554
intramuscularly O 0 0.033236984
administered O 0 0.0015293215
high O 0 0.00064670085
- O 0 0.0010400682
dose O 0 0.06339482
estrogen B-Chemical 1 0.99955577
- O 0 0.01738819
testosterone B-Chemical 0 0.9994311
therapy O 0 0.27796692
( O 0 0.007962996
estradiol B-Chemical 1 0.99960285
- I-Chemical 0 0.005899391
and I-Chemical 0 0.002143898
testosterone I-Chemical 0 0.9990183
esters I-Chemical 0 0.9883966
) O 0 0.006494208
and O 0 0.0040111276
aortic O 0 0.9429667
atherosclerosis B-Disease 2 0.9978352
. O 0 0.010872042

Aortic O 0 0.8760081
atherosclerosis B-Disease 2 0.9958444
was O 0 0.0035678549
diagnosed O 0 0.014058272
by O 0 0.0014448866
radiographic O 0 0.015654417
detection O 0 0.0011841621
of O 0 0.0012895108
calcified O 0 0.27830622
deposits O 0 0.109191276
in O 0 0.00067082536
the O 0 0.00068627176
abdominal O 0 0.21920495
aorta O 0 0.2084726
, O 0 0.0010096567
which O 0 0.0008360871
have O 0 0.0007763699
been O 0 0.001056389
shown O 0 0.00082553946
to O 0 0.0013665882
reflect O 0 0.0030670192
intima O 0 0.98723364
atherosclerosis B-Disease 2 0.9975471
. O 0 0.011485377

Hormone O 0 0.9467434
therapy O 0 0.05122628
users O 0 0.013383124
were O 0 0.004490829
compared O 0 0.0032642675
with O 0 0.006118462
never O 0 0.0128168035
users O 0 0.025348766
. O 0 0.013431754

RESULTS O 0 0.043977734
: O 0 0.006881848
Intramuscular O 0 0.70124614
hormone O 0 0.76264733
therapy O 0 0.019009868
use O 0 0.0017212359
for O 0 0.0009120804
1 O 0 0.00086437666
year O 0 0.0007880887
or O 0 0.00065072253
longer O 0 0.0006749674
was O 0 0.0011339892
reported O 0 0.0022074203
by O 0 0.0025416403
25 O 0 0.0056379773
women O 0 0.023666224
. O 0 0.006703047

In O 0 0.0026026526
almost O 0 0.001503554
half O 0 0.0009790587
of O 0 0.0012824697
these O 0 0.0015956091
women O 0 0.033410043
severe O 0 0.41544992
atherosclerosis B-Disease 2 0.9991105
of O 0 0.0017993563
the O 0 0.0007111585
aorta O 0 0.13261037
was O 0 0.0004408831
present O 0 0.0002872701
( O 0 0.0004800869
n O 0 0.00027472302
= O 0 0.00043521158
11 O 0 0.00029947667
) O 0 0.00039155886
, O 0 0.00026306347
while O 0 0.00018402463
in O 0 0.00020310582
women O 0 0.0038698206
without O 0 0.00032813288
hormone O 0 0.83065796
use O 0 0.00081979844
severe O 0 0.46122435
atherosclerosis B-Disease 2 0.99955505
of O 0 0.0011203054
the O 0 0.00040694984
aorta O 0 0.11465361
was O 0 0.00024912896
present O 0 0.00014879706
in O 0 0.00016600633
less O 0 0.00020165242
than O 0 0.00013119244
20 O 0 0.00025196152
% O 0 0.0002652268
( O 0 0.0003141455
OR O 0 0.0075520854
3 O 0 0.00021181144
. O 0 0.000140297
1 O 0 0.0002293396
; O 0 0.0003424103
95 O 0 0.0005036653
% O 0 0.00028161195
CI O 0 0.036016922
, O 0 0.0003143849
1 O 0 0.00024036081
. O 0 0.00014055327
1 O 0 0.00023245379
- O 0 0.00032058882
8 O 0 0.00017979197
. O 0 0.00010689031
5 O 0 0.0001402824
, O 0 0.00018700869
adjusted O 0 0.00022267248
for O 0 0.00017316132
age O 0 0.00055159966
, O 0 0.0003553666
years O 0 0.0005252781
since O 0 0.00028929574
menopause O 0 0.66037977
, O 0 0.0011147339
smoking O 1 0.6677503
, O 0 0.0012546302
and O 0 0.0010945096
body O 0 0.0048388015
mass O 0 0.0071419403
index O 0 0.0050774445
) O 0 0.0069561526
. O 0 0.0054687406

The O 0 0.002440585
association O 0 0.0015644246
remained O 0 0.0016646301
after O 0 0.00071823236
additional O 0 0.000608257
adjustment O 0 0.0011581774
for O 0 0.00096708734
diabetes B-Disease 2 0.99399936
, O 0 0.003350509
cholesterol B-Chemical 0 0.9935096
level O 0 0.0009882448
, O 0 0.0015788189
systolic O 0 0.6375735
blood O 0 0.012116972
pressure O 0 0.056092557
, O 0 0.0023639973
or O 0 0.00244104
alcohol B-Chemical 0 0.98688114
use O 0 0.0086329235
. O 0 0.007106279

No O 0 0.0066929017
association O 0 0.0028192592
was O 0 0.0025643907
found O 0 0.0021117006
for O 0 0.0020689347
hormone O 0 0.5794786
use O 0 0.003551208
less O 0 0.0029050508
than O 0 0.0024337103
1 O 0 0.0042273784
year O 0 0.006348203
. O 0 0.0076713976

CONCLUSION O 0 0.74478793
: O 0 0.00387849
Our O 0 0.0015684942
results O 0 0.0010269705
suggest O 0 0.00074823113
that O 0 0.00070401136
high O 0 0.0012721348
- O 0 0.0017073976
dose O 0 0.049579494
testosterone B-Chemical 0 0.9989004
therapy O 0 0.082676776
may O 0 0.00071480015
adversely O 0 0.009830669
affect O 0 0.0005318515
atherosclerosis B-Disease 2 0.9993679
in O 0 0.0008144574
postmenopausal O 0 0.9921245
women O 0 0.03675325
and O 0 0.00040446877
indicate O 0 0.00027516525
that O 0 0.00041887653
androgen O 0 0.9953446
replacement O 0 0.00858572
in O 0 0.0007126663
these O 0 0.001329689
women O 0 0.01711705
may O 0 0.00145133
not O 0 0.0018625691
be O 0 0.0032385804
harmless O 0 0.034721185
. O 0 0.0063335113

Optimising O 0 0.02847062
stroke B-Disease 2 0.9804883
prevention O 0 0.02263188
in O 0 0.0054813228
non O 0 0.0104484875
- O 0 0.01253411
valvular O 0 0.9364795
atrial B-Disease 0 0.99012566
fibrillation I-Disease 0 0.99762326
. O 0 0.021247307

Atrial B-Disease 0 0.9807606
fibrillation I-Disease 0 0.99820495
is O 0 0.0073191915
associated O 0 0.005461343
with O 0 0.004775789
substantial O 0 0.007695428
morbidity O 0 0.46507218
and O 0 0.01050489
mortality O 0 0.44469154
. O 0 0.0132662505

Pooled O 0 0.007641613
data O 0 0.0024664078
from O 0 0.0013303941
trials O 0 0.0013950538
comparing O 0 0.0005785109
antithrombotic O 0 0.91293913
treatment O 0 0.003124997
with O 0 0.0009951472
placebo O 0 0.17411432
have O 0 0.00053280895
shown O 0 0.00031003266
that O 0 0.0003503392
warfarin B-Chemical 1 0.9986236
reduces O 0 0.00071174226
the O 0 0.00044724872
risk O 0 0.026793828
of O 0 0.0012510283
stroke B-Disease 2 0.9977806
by O 0 0.0006620661
62 O 0 0.0012834796
% O 0 0.00042830766
, O 0 0.00038070278
and O 0 0.00034665343
that O 0 0.00042592175
aspirin B-Chemical 1 0.9991762
alone O 0 0.0013217339
reduces O 0 0.0012200443
the O 0 0.001283094
risk O 0 0.038483206
by O 0 0.0027518887
22 O 0 0.0048716087
% O 0 0.00467497
. O 0 0.004728192

Overall O 0 0.0063524125
, O 0 0.003301749
in O 0 0.0015707038
high O 0 0.0020144954
- O 0 0.002302521
risk O 0 0.018631348
patients O 0 0.0053573237
, O 0 0.0016875884
warfarin B-Chemical 1 0.99870884
is O 0 0.00090455794
superior O 0 0.0028240478
to O 0 0.00061884464
aspirin B-Chemical 1 0.9994062
in O 0 0.0007817307
preventing O 0 0.005784734
strokes B-Disease 0 0.99209726
, O 0 0.0010630186
with O 0 0.0006898166
a O 0 0.0006906043
relative O 0 0.0006082298
risk O 0 0.015022945
reduction O 0 0.002891626
of O 0 0.0028077941
36 O 0 0.0038584871
% O 0 0.0046521835
. O 0 0.004790734

Ximelagatran B-Chemical 0 0.99308664
, O 0 0.0052290424
an O 0 0.0029844146
oral O 0 0.16170911
direct O 0 0.0029898952
thrombin O 0 0.9019105
inhibitor O 0 0.73914355
, O 0 0.0017677876
was O 0 0.0006525276
found O 0 0.0004385927
to O 0 0.00036947004
be O 0 0.00037100713
as O 0 0.000261143
efficient O 0 0.0003950826
as O 0 0.00054003217
vitamin B-Chemical 0 0.9997634
K I-Chemical 1 0.999329
antagonist O 0 0.9963378
drugs O 0 0.9146723
in O 0 0.00046580035
the O 0 0.00036824314
prevention O 0 0.00316341
of O 0 0.001026746
embolic B-Disease 0 0.99603695
events I-Disease 0 0.21160828
, O 0 0.00083189475
but O 0 0.0003595777
has O 0 0.00036478927
been O 0 0.0004982478
recently O 0 0.0006449119
withdrawn O 0 0.002470238
because O 0 0.00050724094
of O 0 0.0012884063
abnormal B-Disease 0 0.11540004
liver I-Disease 0 0.85872
function I-Disease 0 0.008558448
tests O 0 0.0121448925
. O 0 0.006539863

The O 0 0.005445319
ACTIVE O 0 0.4857128
- O 0 0.008598638
W O 0 0.6697591
( O 0 0.00575212
Atrial B-Disease 2 0.9898962
Fibrillation I-Disease 2 0.975628
Clopidogrel B-Chemical 0 0.9994993
Trial O 0 0.41190678
with O 0 0.0018409332
Irbesartan B-Chemical 0 0.99948066
for O 0 0.000832681
Prevention O 0 0.019557908
of O 0 0.0010455138
Vascular O 0 0.95112383
Events O 0 0.29219154
) O 0 0.00079979544
study O 0 0.0005110655
has O 0 0.00029066615
demonstrated O 0 0.0003616324
that O 0 0.0003528294
warfarin B-Chemical 1 0.99911314
is O 0 0.00058034505
superior O 0 0.0026396734
to O 0 0.00040753424
platelet O 0 0.7889658
therapy O 0 0.09386523
( O 0 0.0022037881
clopidogrel B-Chemical 1 0.99934393
plus O 0 0.0023564636
aspirin B-Chemical 1 0.9996501
) O 0 0.0034428842
in O 0 0.00088291714
the O 0 0.0012611301
prevention O 0 0.020863364
af O 0 0.5305261
embolic B-Disease 0 0.99422765
events I-Disease 0 0.5449513
. O 0 0.008398435

Idraparinux B-Chemical 0 0.88370794
, O 0 0.006992651
a O 0 0.005048419
Factor O 1 0.9341013
Xa O 1 0.9841643
inhibitor O 0 0.3112487
, O 0 0.0026204262
is O 0 0.0012616658
being O 0 0.0013972769
evaluated O 0 0.0011031854
in O 0 0.0012797633
patients O 0 0.0045169764
with O 0 0.004982596
atrial B-Disease 0 0.9902823
fibrillation I-Disease 0 0.9983681
. O 0 0.013065999

Angiotensin B-Chemical 0 0.9980216
- O 0 0.018289614
converting O 0 0.1603856
enzyme O 0 0.24397942
inhibitors O 0 0.254009
and O 0 0.0044131833
angiotensin B-Chemical 1 0.9995777
II I-Chemical 1 0.71969956
receptor O 0 0.6027877
- O 0 0.003555241
blocking O 0 0.0039210897
drugs O 0 0.5828016
hold O 0 0.001807333
promise O 0 0.0021191733
in O 0 0.0014916209
atrial B-Disease 0 0.98936254
fibrillation I-Disease 0 0.9992005
through O 0 0.0057778326
cardiac B-Disease 0 0.959419
remodelling I-Disease 0 0.82868695
. O 0 0.008756991

Preliminary O 0 0.009555599
studies O 0 0.0038662895
suggest O 0 0.0018982721
that O 0 0.0019860307
statins B-Chemical 1 0.99220467
could O 0 0.0013790505
interfere O 0 0.0014402885
with O 0 0.0013711118
the O 0 0.0012629151
risk O 0 0.014719938
of O 0 0.002880793
recurrence O 0 0.62303233
after O 0 0.002776612
electrical O 0 0.65305316
cardioversion O 0 0.8313538
. O 0 0.00808877

Finally O 0 0.0043942365
, O 0 0.002985676
percutaneous O 0 0.0036313583
methods O 0 0.0015498409
for O 0 0.0008259797
the O 0 0.0007357933
exclusion O 0 0.00077774946
of O 0 0.00093872315
left O 0 0.0022423666
atrial O 0 0.90861243
appendage O 0 0.0084879035
are O 0 0.0006625392
under O 0 0.0004544272
investigation O 0 0.0013703005
in O 0 0.00092357036
high O 0 0.0022488774
- O 0 0.0041791787
risk O 0 0.05414322
patients O 0 0.019339023
. O 0 0.006768106

Anti O 0 0.4151235
- O 0 0.0100558605
oxidant O 0 0.9443201
effects O 0 0.007918155
of O 0 0.005679203
atorvastatin B-Chemical 0 0.99953187
in O 0 0.006328011
dexamethasone B-Chemical 0 0.9988539
- O 0 0.01788507
induced O 0 0.010551574
hypertension B-Disease 2 0.9988588
in O 0 0.004289084
the O 0 0.0049903537
rat O 0 0.04787211
. O 0 0.008147839

1 O 0 0.08232081
. O 0 0.074582

Dexamethasone B-Chemical 1 0.99788266
( O 0 0.027536348
Dex B-Chemical 1 0.99625957
) O 0 0.010173786
- O 0 0.0034746411
induced O 0 0.0029816239
hypertension B-Disease 2 0.99931717
is O 0 0.0013629787
characterized O 0 0.0018710553
by O 0 0.0010024752
endothelial O 0 0.9708562
dysfunction O 0 0.9825295
associated O 0 0.0026917807
with O 0 0.0025309476
nitric B-Chemical 0 0.9994381
oxide I-Chemical 0 0.99925774
( O 0 0.023985086
NO B-Chemical 0 0.99863154
) O 0 0.007998082
deficiency O 0 0.5587476
and O 0 0.0015262709
increased O 0 0.009110912
superoxide B-Chemical 1 0.99898165
( O 0 0.029798456
O2 B-Chemical 0 0.9962088
- I-Chemical 0 0.011527181
) O 0 0.0069086063
production O 0 0.010189867
. O 0 0.007001007

Atorvastatin B-Chemical 0 0.9980584
( O 0 0.012312998
Ato B-Chemical 1 0.8400371
) O 0 0.003526805
possesses O 0 0.0019483418
pleiotropic O 0 0.006145386
properties O 0 0.0015493939
that O 0 0.000502189
have O 0 0.00058403617
been O 0 0.0006196738
reported O 0 0.0006247408
to O 0 0.00034108525
improve O 0 0.0003688981
endothelial O 0 0.7742149
function O 0 0.00071116287
through O 0 0.00032989317
increased O 0 0.00064945326
availability O 0 0.0007063769
of O 0 0.0009488744
NO B-Chemical 0 0.99729294
and O 0 0.0010833849
reduced O 0 0.0017137758
O2 B-Chemical 0 0.99759644
- I-Chemical 0 0.0025652032
production O 0 0.0018582642
in O 0 0.00088472303
various O 0 0.0023051975
forms O 0 0.0030028834
of O 0 0.009305357
hypertension B-Disease 2 0.998408
. O 0 0.010473581

In O 0 0.0026823308
the O 0 0.0016895424
present O 0 0.0011121315
study O 0 0.0015899461
, O 0 0.0010398106
we O 0 0.0003846001
investigated O 0 0.0005236295
whether O 0 0.0002811374
50 O 0 0.0007618607
mg O 0 0.22013272
/ O 0 0.000999906
kg O 0 0.0016713771
per O 0 0.0001695615
day O 0 0.00028064894
, O 0 0.0003736125
p O 0 0.00043187453
. O 0 0.00020251932
o O 0 0.0010612148
. O 0 0.00023962308
, O 0 0.0005370864
Ato B-Chemical 1 0.60476255
could O 0 0.0003005126
prevent O 0 0.0007054762
endothelial O 0 0.9735414
NO B-Chemical 0 0.9991794
synthase O 0 0.99323833
( O 0 0.0076647797
eNOS O 0 0.8993618
) O 0 0.0019140362
downregulation O 0 0.0036656375
and O 0 0.00039867035
the O 0 0.00031061049
increase O 0 0.00040536196
in O 0 0.00055572385
O2 B-Chemical 0 0.9972218
- I-Chemical 0 0.0018194251
in O 0 0.0006105862
Sprague O 0 0.39343262
- O 0 0.0017710422
Dawley O 0 0.31247193
( O 0 0.0010112681
SD O 0 0.01159828
) O 0 0.001301341
rats O 0 0.0024931498
, O 0 0.0013398009
thereby O 0 0.0022160355
reducing O 0 0.0033773475
blood O 0 0.045465127
pressure O 0 0.19055226
. O 0 0.0068429895

2 O 0 0.0815455
. O 0 0.074968144

Male O 0 0.042659644
SD O 0 0.021275477
rats O 0 0.0077455915
( O 0 0.002289882
n O 0 0.0010821328
= O 0 0.001199774
30 O 0 0.00057840673
) O 0 0.00074054365
were O 0 0.00041089652
treated O 0 0.0007330044
with O 0 0.0007776094
Ato B-Chemical 1 0.78509426
( O 0 0.0008055538
50 O 0 0.0007099958
mg O 0 0.1827827
/ O 0 0.0008366326
kg O 0 0.0013352169
per O 0 0.00016450089
day O 0 0.00027760505
in O 0 0.0003347126
drinking O 0 0.25519642
water O 0 0.011022067
) O 0 0.0011825699
or O 0 0.00066059944
tap O 0 0.007427195
water O 0 0.00556451
for O 0 0.0014831793
15 O 0 0.0021246043
days O 0 0.0033215722
. O 0 0.0047906972

Dexamethasone B-Chemical 1 0.9970579
( O 0 0.0058773733
10 O 0 0.002187165
microg O 0 0.003017202
/ O 0 0.0019143313
kg O 0 0.0024495008
per O 0 0.00035583138
day O 0 0.0004867261
, O 0 0.00058089034
s O 0 0.0005454487
. O 0 0.0002625731
c O 0 0.0014794925
. O 0 0.00026576617
) O 0 0.0004982698
or O 0 0.00023795743
saline O 0 0.019645432
was O 0 0.0002575414
started O 0 0.00030403474
after O 0 0.00013711413
4 O 0 0.00017563568
days O 0 0.0001976347
in O 0 0.000256245
Ato B-Chemical 1 0.69034654
- O 0 0.0006528224
treated O 0 0.0005643904
and O 0 0.00037673325
non O 0 0.0011096875
- O 0 0.00079278083
treated O 0 0.0007639854
rats O 0 0.0016305076
and O 0 0.000528656
continued O 0 0.00085149903
for O 0 0.0007239546
11 O 0 0.0014966447
- O 0 0.0022250607
13 O 0 0.0023243807
days O 0 0.0028576427
. O 0 0.0041948017

Systolic O 0 0.89263594
blood O 0 0.019542715
pressure O 0 0.07963454
( O 0 0.0043519745
SBP O 0 0.33817118
) O 0 0.0021949983
was O 0 0.00086872396
measured O 0 0.0005732406
on O 0 0.0004973673
alternate O 0 0.0012166695
days O 0 0.00091934303
using O 0 0.00093421456
the O 0 0.0014012868
tail O 0 0.0032950772
- O 0 0.0045525297
cuff O 0 0.012287995
method O 0 0.008056225
. O 0 0.007283645

Endothelial O 0 0.97628933
function O 0 0.0052196356
was O 0 0.0024604264
assessed O 0 0.0017361706
by O 0 0.0026681211
acetylcholine B-Chemical 1 0.99803084
- O 0 0.007910216
induced O 0 0.0051661576
vasorelaxation O 0 0.99936897
and O 0 0.0092530865
phenylephrine B-Chemical 1 0.9995185
- O 0 0.013746101
induced O 0 0.0071008243
vasoconstriction O 0 0.9978877
in O 0 0.0044555143
aortic O 0 0.77095515
segments O 0 0.0111940745
. O 0 0.0070868325

Vascular O 0 0.8309775
eNOS O 0 0.66400176
mRNA O 0 0.00684902
was O 0 0.0022878163
assessed O 0 0.0015641074
by O 0 0.0018791337
semi O 0 0.0054647457
- O 0 0.0029420266
quantitative O 0 0.0029898067
reverse O 0 0.020766871
transcription O 0 0.007922463
- O 0 0.0058143116
polymerase O 0 0.08688086
chain O 0 0.06749466
reaction O 0 0.107308604
. O 0 0.0100399535

3 O 0 0.07487772
. O 0 0.072802074

In O 0 0.0035884466
rats O 0 0.0062541603
treated O 0 0.0034624194
with O 0 0.0027962958
Dex B-Chemical 1 0.99541426
alone O 0 0.0025870884
, O 0 0.0018031261
SBP O 0 0.47586596
was O 0 0.0006070032
increased O 0 0.0007674705
from O 0 0.0005040361
109 O 0 0.0024422258
+ O 0 0.00072678394
/ O 0 0.0011453317
- O 0 0.0006211592
2 O 0 0.00028637066
to O 0 0.00026223835
133 O 0 0.0019544165
+ O 0 0.00051281485
/ O 0 0.0008881988
- O 0 0.0005441246
2 O 0 0.00028784858
mmHg O 0 0.001331516
on O 0 0.0001536119
Days O 0 0.01137292
4 O 0 0.00024163863
and O 0 0.0003154393
Day O 0 0.0013426661
14 O 0 0.00047720227
, O 0 0.00061274995
respectively O 0 0.0013002396
( O 0 0.0011688677
P O 0 0.014069917
< O 0 0.0014841738
0 O 0 0.0015649245
. O 0 0.0016039746
001 O 0 0.12682796
) O 0 0.0068354146
. O 0 0.0058315503

In O 0 0.004048454
the O 0 0.0036004162
Ato B-Chemical 1 0.7166221
+ O 0 0.004512439
Dex B-Chemical 1 0.99354655
group O 0 0.0024864008
, O 0 0.0017431297
SBP O 0 0.38518408
was O 0 0.00064256485
increased O 0 0.0008014957
from O 0 0.0005361688
113 O 0 0.00361806
+ O 0 0.0007560588
/ O 0 0.0011629742
- O 0 0.00062656886
2 O 0 0.00028255218
to O 0 0.0002510812
119 O 0 0.0015514076
+ O 0 0.0004887571
/ O 0 0.0008520444
- O 0 0.0005110621
2 O 0 0.00026040408
mmHg O 0 0.0012585453
on O 0 0.0001278635
Days O 0 0.011324234
4 O 0 0.00017857517
to O 0 0.00018002783
14 O 0 0.00027609363
, O 0 0.00032102095
respectively O 0 0.00069339824
( O 0 0.00045963292
P O 0 0.01160103
< O 0 0.00035208714
0 O 0 0.000285632
. O 0 0.00017990994
001 O 0 0.10995092
) O 0 0.00053639314
, O 0 0.0003296049
but O 0 0.00021987222
was O 0 0.00021441843
significantly O 0 0.00029358355
lower O 0 0.0002670766
than O 0 0.00021343528
SBP O 0 0.21845436
in O 0 0.00024775506
the O 0 0.00027081155
group O 0 0.00046951484
treated O 0 0.00090194156
with O 0 0.0012003101
Dex B-Chemical 1 0.99752
alone O 0 0.0022141554
( O 0 0.0021631531
P O 0 0.051529203
< O 0 0.001732007
0 O 0 0.001671583
. O 0 0.0016109524
05 O 0 0.03440226
) O 0 0.0063469796
. O 0 0.0056222035

Endothelial O 0 0.9861568
- O 0 0.006461717
dependent O 0 0.0022803433
relaxation O 0 0.10774131
and O 0 0.0020331736
eNOS O 0 0.61170965
mRNA O 0 0.0027217432
expression O 0 0.0012519588
were O 0 0.0005229885
greater O 0 0.00045881514
in O 0 0.00039936765
the O 0 0.00058975123
Dex B-Chemical 1 0.997677
+ O 0 0.0013645191
Ato B-Chemical 1 0.7952901
group O 0 0.0005437176
than O 0 0.00021957685
in O 0 0.00026789805
the O 0 0.0004085937
Dex B-Chemical 1 0.9959894
only O 0 0.0005363513
group O 0 0.00078905164
( O 0 0.0008206442
P O 0 0.024136206
< O 0 0.0005430308
0 O 0 0.00043553405
. O 0 0.00029395378
05 O 0 0.00815454
and O 0 0.00062738446
P O 0 0.011294657
< O 0 0.0009856571
0 O 0 0.00093458814
. O 0 0.00081959344
0001 O 0 0.022160722
, O 0 0.0026802642
respectively O 0 0.0053966986
) O 0 0.0068692304
. O 0 0.005865567

Aortic O 0 0.8334102
superoxide B-Chemical 1 0.9952206
production O 0 0.008754305
was O 0 0.0018887005
lower O 0 0.0012550595
in O 0 0.0009178949
the O 0 0.0011415754
Dex B-Chemical 1 0.9968779
+ O 0 0.001989307
Ato B-Chemical 1 0.77482563
group O 0 0.0007030603
compared O 0 0.00025579467
with O 0 0.0004290982
the O 0 0.00037928185
group O 0 0.00062446314
treated O 0 0.0011415803
with O 0 0.0014297671
Dex B-Chemical 1 0.99751914
alone O 0 0.0024705
( O 0 0.0023138137
P O 0 0.051932164
< O 0 0.0017952917
0 O 0 0.0017077925
. O 0 0.0016339889
0001 O 0 0.042934913
) O 0 0.0067308526
. O 0 0.0058764312

4 O 0 0.07327224
. O 0 0.07212598

Treatment O 0 0.04413035
with O 0 0.0049717054
Ato B-Chemical 1 0.70010674
improved O 0 0.0072666225
endothelial O 0 0.9101205
function O 0 0.0032818157
, O 0 0.001982059
reduced O 0 0.0018335425
superoxide B-Chemical 1 0.9983463
production O 0 0.00869052
and O 0 0.0015341605
reduced O 0 0.0018928688
SBP O 0 0.78543
in O 0 0.0021973043
Dex B-Chemical 1 0.9963948
- O 0 0.0065426705
treated O 0 0.0069930353
SD O 0 0.120460525
rats O 0 0.018898338
. O 0 0.0069405446

Severe O 0 0.9503384
citrate B-Chemical 0 0.98506236
toxicity B-Disease 2 0.991113
complicating O 0 0.7265508
volunteer O 0 0.058085512
apheresis O 0 0.45408484
platelet O 0 0.9607436
donation O 0 0.2284204
. O 0 0.017713152

We O 0 0.004071901
report O 0 0.0054661706
a O 0 0.0026944613
case O 0 0.0021973366
of O 0 0.0027979263
severe O 0 0.3549499
citrate B-Chemical 0 0.99417406
toxicity B-Disease 2 0.9946979
during O 0 0.0022247552
volunteer O 0 0.0064821676
donor O 0 0.0051843636
apheresis O 0 0.1671531
platelet O 0 0.8981099
collection O 0 0.017135413
. O 0 0.009253803

The O 0 0.0032773053
donor O 0 0.003730556
was O 0 0.0020669478
a O 0 0.0018420796
40 O 0 0.0018361905
- O 0 0.0018121429
year O 0 0.0012060635
- O 0 0.001549309
old O 0 0.0011208064
female O 0 0.0021493777
, O 0 0.0012383756
first O 0 0.0009575795
- O 0 0.0020028395
time O 0 0.0015823436
apheresis O 0 0.066927806
platelet O 0 0.83526146
donor O 0 0.014121717
. O 0 0.008287843

Past O 0 0.04811602
medical O 0 0.012529052
history O 0 0.011724638
was O 0 0.0030070909
remarkable O 0 0.0050751367
for O 0 0.0036268614
hypertension B-Disease 2 0.9985044
, O 0 0.026421733
hyperlipidemia B-Disease 0 0.99917907
, O 0 0.013245737
and O 0 0.01004451
depression B-Disease 0 0.98173267
. O 0 0.0116210645

Reported O 0 0.021221675
medications O 0 0.4063444
included O 0 0.009093193
bumetanide B-Chemical 0 0.99881566
, O 0 0.04676171
pravastatin B-Chemical 0 0.9990246
, O 0 0.019910755
and O 0 0.017925091
paroxetine B-Chemical 1 0.9986432
. O 0 0.017935006

Thirty O 0 0.007078154
minutes O 0 0.0022974976
from O 0 0.0014089616
the O 0 0.0010114547
start O 0 0.0007681535
of O 0 0.0009095888
the O 0 0.00070792425
procedure O 0 0.0009013204
, O 0 0.00082250906
the O 0 0.00053455424
donor O 0 0.0010349917
noted O 0 0.0008952126
tingling O 0 0.89960086
around O 0 0.00091422116
the O 0 0.0010474708
mouth O 0 0.031126395
, O 0 0.002101194
hands O 0 0.004222636
, O 0 0.0032374433
and O 0 0.003977108
feet O 0 0.06184873
. O 0 0.0072199763

She O 0 0.007458772
then O 0 0.0031030243
very O 0 0.0031439639
rapidly O 0 0.0042702495
developed O 0 0.0048468565
acute O 0 0.8582472
onset O 0 0.021282364
of O 0 0.004164772
severe O 0 0.428174
facial O 0 0.5503439
and O 0 0.007426548
extremity O 0 0.80928653
tetany B-Disease 0 0.99715
. O 0 0.014904024

Empirical O 0 0.02593738
treatment O 0 0.00591425
with O 0 0.0034456567
intravenous O 0 0.8325105
calcium B-Chemical 1 0.99748945
gluconate I-Chemical 0 0.9958163
was O 0 0.0016784278
initiated O 0 0.0013900661
, O 0 0.0011176047
and O 0 0.00090995594
muscle B-Disease 0 0.38583946
contractions I-Disease 0 0.9779162
slowly O 0 0.005870467
subsided O 0 0.03205999
over O 0 0.0004895579
approximately O 0 0.00093920715
10 O 0 0.0010362674
to O 0 0.0011463326
15 O 0 0.0017018522
minutes O 0 0.002919158
. O 0 0.0043111616

The O 0 0.0033295108
events O 0 0.005184093
are O 0 0.0017711542
consistent O 0 0.0013221042
with O 0 0.0013031561
a O 0 0.0013564818
severe O 0 0.089847304
reaction O 0 0.014943616
to O 0 0.0014631037
calcium B-Chemical 1 0.9974953
chelation O 0 0.9952937
by O 0 0.0068993014
sodium B-Chemical 1 0.9994351
citrate I-Chemical 1 0.99878055
anticoagulant O 0 0.9941263
resulting O 0 0.003919767
in O 0 0.002889265
symptomatic O 0 0.73615766
systemic O 0 0.99093366
hypocalcemia B-Disease 0 0.9991091
. O 0 0.014297139

Upon O 0 0.0049053496
additional O 0 0.0017552928
retrospective O 0 0.008336444
analysis O 0 0.0025297282
, O 0 0.0017900364
it O 0 0.0011844778
was O 0 0.0008708341
noted O 0 0.0008374641
that O 0 0.0009327781
bumetanide B-Chemical 0 0.9996107
is O 0 0.0013673237
a O 0 0.0012612208
loop B-Chemical 0 0.0048787524
diuretic I-Chemical 0 0.999315
that O 0 0.0019293627
may O 0 0.0024471323
cause O 0 0.012712325
significant O 0 0.014969126
hypocalcemia B-Disease 0 0.99838483
. O 0 0.011705017

We O 0 0.0027898746
conclude O 0 0.0018748242
that O 0 0.0011420398
careful O 0 0.0017569578
screening O 0 0.0012286718
for O 0 0.00074074947
medications O 0 0.18730779
and O 0 0.0007562811
underlying O 0 0.0014283245
conditions O 0 0.00092029566
predisposing O 0 0.044701997
to O 0 0.0009639256
hypocalcemia B-Disease 0 0.99962616
is O 0 0.0008486122
recommended O 0 0.00073143706
to O 0 0.0004859908
help O 0 0.0008206169
prevent O 0 0.0011022786
severe O 0 0.13405752
reactions O 0 0.014374435
due O 0 0.001375593
to O 0 0.0031449401
citrate B-Chemical 0 0.99208367
toxicity B-Disease 2 0.99381727
. O 0 0.010388617

Laboratory O 0 0.010595447
measurement O 0 0.0022381244
of O 0 0.0024156247
pre O 0 0.0052637556
- O 0 0.0025543433
procedure O 0 0.0016090744
serum O 0 0.0758547
calcium B-Chemical 1 0.9904812
levels O 0 0.0012044803
in O 0 0.0006868057
selected O 0 0.0006760802
donors O 0 0.0016542508
may O 0 0.00086754933
identify O 0 0.0009321514
cases O 0 0.0024329857
requiring O 0 0.0037234824
heightened O 0 0.067978255
vigilance O 0 0.37310427
. O 0 0.0076175397

The O 0 0.0027209967
case O 0 0.0021147935
also O 0 0.0015048691
illustrates O 0 0.00095613225
the O 0 0.00075427553
importance O 0 0.0006228919
of O 0 0.00077749643
maintaining O 0 0.00088244106
preparedness O 0 0.0017516712
for O 0 0.0005694411
managing O 0 0.0038422225
rare O 0 0.009489944
but O 0 0.0010213912
serious O 0 0.068711825
reactions O 0 0.008837187
in O 0 0.0012613906
volunteer O 0 0.004925324
apheresis O 0 0.0647999
blood O 0 0.034473732
donors O 0 0.012461242
. O 0 0.006692337

Sirolimus B-Chemical 1 0.9879038
- O 0 0.02285055
associated O 0 0.019743111
proteinuria B-Disease 2 0.99779934
and O 0 0.045795586
renal B-Disease 2 0.99458957
dysfunction I-Disease 2 0.99145937
. O 0 0.027052768

Sirolimus B-Chemical 1 0.98838764
is O 0 0.003443743
a O 0 0.0022175258
novel O 0 0.0032209854
immunosuppressant O 0 0.99007297
with O 0 0.002630525
potent O 0 0.11503435
antiproliferative O 0 0.9852899
actions O 0 0.07571723
through O 0 0.0006114307
its O 0 0.0011323391
ability O 0 0.00050707144
to O 0 0.00040962838
inhibit O 0 0.00063552696
the O 0 0.0005496984
raptor O 0 0.04000271
- O 0 0.001264934
containing O 0 0.00066054787
mammalian O 0 0.0014446485
target O 0 0.0010785029
of O 0 0.0025410652
rapamycin B-Chemical 1 0.97165823
protein O 0 0.042923186
kinase O 0 0.5867772
. O 0 0.008933766

Sirolimus B-Chemical 1 0.98524576
represents O 0 0.0030784882
a O 0 0.0021724075
major O 0 0.0019679142
therapeutic O 0 0.007737888
advance O 0 0.0019454594
in O 0 0.0009133339
the O 0 0.0009101241
prevention O 0 0.003732873
of O 0 0.0022839308
acute O 0 0.98383385
renal O 0 0.99733835
allograft O 0 0.995449
rejection O 0 0.99510986
and O 0 0.016552106
chronic O 0 0.9961356
allograft O 0 0.99701935
nephropathy B-Disease 2 0.999655
. O 0 0.026190408

Its O 0 0.04372983
role O 0 0.0024287615
in O 0 0.0018015278
the O 0 0.0015719353
therapy O 0 0.012105682
of O 0 0.0041204295
glomerulonephritis B-Disease 2 0.9997019
, O 0 0.018088879
autoimmunity B-Disease 0 0.99677795
, O 0 0.0050376887
cystic B-Disease 0 0.88667774
renal I-Disease 0 0.9974279
diseases I-Disease 0 0.9810625
and O 0 0.010703165
renal B-Disease 0 0.99876165
cancer I-Disease 2 0.9981312
is O 0 0.0045695766
under O 0 0.0028194792
investigation O 0 0.01013829
. O 0 0.006665786

Because O 0 0.0044388366
sirolimus B-Chemical 1 0.9923483
does O 0 0.0021028286
not O 0 0.0012428197
share O 0 0.0015923701
the O 0 0.0011956418
vasomotor O 0 0.9938712
renal O 0 0.9964263
adverse O 0 0.9355761
effects O 0 0.005020221
exhibited O 0 0.0008678483
by O 0 0.00077870133
calcineurin O 0 0.95792514
inhibitors O 0 0.2898069
, O 0 0.0010054633
it O 0 0.0005492066
has O 0 0.0004662775
been O 0 0.0005988939
designated O 0 0.0005218019
a O 0 0.0007963496
' O 0 0.001139606
non O 0 0.0032872637
- O 0 0.007374135
nephrotoxic B-Disease 2 0.9983754
drug O 0 0.84589595
' O 0 0.009239841
. O 0 0.0068570524

However O 0 0.004244946
, O 0 0.0029937509
clinical O 0 0.0043563945
reports O 0 0.001897554
suggest O 0 0.00085169094
that O 0 0.0007846304
, O 0 0.000958327
under O 0 0.0004592753
some O 0 0.0007659475
circumstances O 0 0.001978592
, O 0 0.001496889
sirolimus B-Chemical 1 0.99865735
is O 0 0.0012098518
associated O 0 0.0017598898
with O 0 0.0038735967
proteinuria B-Disease 2 0.99963987
and O 0 0.018700244
acute B-Disease 0 0.99690825
renal I-Disease 2 0.99884903
dysfunction I-Disease 2 0.9978308
. O 0 0.016147258

A O 0 0.0177445
common O 0 0.005512912
risk O 0 0.023614325
factor O 0 0.008653663
appears O 0 0.001898657
to O 0 0.001306037
be O 0 0.0012242817
presence O 0 0.0011041703
of O 0 0.0018072056
pre O 0 0.008164793
- O 0 0.0041049337
existing O 0 0.0059180725
chronic B-Disease 0 0.993522
renal I-Disease 2 0.99805176
damage I-Disease 2 0.9931526
. O 0 0.016405486

The O 0 0.0032090156
mechanisms O 0 0.0038645214
of O 0 0.0034649824
sirolimus B-Chemical 1 0.9981573
- O 0 0.007038419
associated O 0 0.0038106581
proteinuria B-Disease 2 0.99964225
are O 0 0.0017299338
multifactorial O 0 0.464762
and O 0 0.00084804115
may O 0 0.0005537088
be O 0 0.00043636456
due O 0 0.00025720184
to O 0 0.00034656303
an O 0 0.0005442849
increase O 0 0.0005040995
in O 0 0.0006531858
glomerular O 0 0.8307817
capillary O 0 0.279655
pressure O 0 0.17782049
following O 0 0.0030301115
calcineurin O 0 0.9767339
inhibitor O 0 0.7435162
withdrawal O 0 0.95993125
. O 0 0.008569448

It O 0 0.0056164935
has O 0 0.0023697012
also O 0 0.0018739348
been O 0 0.0015329068
suggested O 0 0.0011724292
that O 0 0.0010019825
sirolimus B-Chemical 1 0.99814844
directly O 0 0.0013734401
causes O 0 0.0030889665
increased O 0 0.0038229397
glomerular O 0 0.97862417
permeability O 0 0.9783232
/ O 0 0.023689637
injury O 0 0.9325298
, O 0 0.0010761567
but O 0 0.00049293524
evidence O 0 0.00057055
for O 0 0.0005064783
this O 0 0.000803239
mechanism O 0 0.0017082097
is O 0 0.0019041273
currently O 0 0.0047507114
inconclusive O 0 0.047799867
. O 0 0.0069136587

The O 0 0.0049160244
acute B-Disease 0 0.9600854
renal I-Disease 2 0.9974316
dysfunction I-Disease 2 0.99719846
associated O 0 0.0066212486
with O 0 0.0033771885
sirolimus B-Chemical 1 0.9992586
( O 0 0.0021138247
such O 0 0.00057175313
as O 0 0.00038521126
in O 0 0.0003673951
delayed O 0 0.0025345904
graft O 0 0.023116963
function O 0 0.00090698904
) O 0 0.0008039512
may O 0 0.0003417113
be O 0 0.0003029382
due O 0 0.00019015225
to O 0 0.00027489802
suppression O 0 0.00081222807
of O 0 0.0006112634
compensatory O 0 0.0077589145
renal O 0 0.9934214
cell O 0 0.10242666
proliferation O 0 0.8493144
and O 0 0.0020967457
survival O 0 0.119951785
/ O 0 0.00609955
repair O 0 0.005967291
processes O 0 0.011929019
. O 0 0.006196251

Although O 0 0.00341315
these O 0 0.0031329812
adverse O 0 0.31742418
effects O 0 0.002815918
occur O 0 0.0011968338
in O 0 0.00062827993
some O 0 0.00069708214
patients O 0 0.001664841
, O 0 0.0005899011
their O 0 0.00040294704
occurrence O 0 0.0008332632
could O 0 0.000250649
be O 0 0.0002652068
minimised O 0 0.00030381253
by O 0 0.00025525113
knowledge O 0 0.00035468108
of O 0 0.0002877454
the O 0 0.00023427157
molecular O 0 0.0053955265
effects O 0 0.00092881656
of O 0 0.00070199074
sirolimus B-Chemical 1 0.99929905
on O 0 0.00025247736
the O 0 0.00038724902
kidney O 0 0.7556707
, O 0 0.0004903579
the O 0 0.00022079845
use O 0 0.00030447944
of O 0 0.00044260625
sirolimus B-Chemical 1 0.9991825
in O 0 0.00029406982
appropriate O 0 0.00023952693
patient O 0 0.0005257061
populations O 0 0.00047586518
, O 0 0.00027799254
close O 0 0.0001581066
monitoring O 0 0.0003316942
of O 0 0.0006227858
proteinuria B-Disease 2 0.99983704
and O 0 0.0013271669
renal O 0 0.99283195
function O 0 0.0014945
, O 0 0.00059067516
use O 0 0.00046773473
of O 0 0.0010841995
angiotensin B-Chemical 1 0.99975735
- O 0 0.009742285
converting O 0 0.22401083
enzyme O 0 0.32547846
inhibitors O 0 0.28570086
or O 0 0.0012615907
angiotensin B-Chemical 1 0.9998375
II I-Chemical 1 0.7417888
receptor O 0 0.7416072
blockers O 0 0.99887246
if O 0 0.002023924
proteinuria B-Disease 2 0.99974376
occurs O 0 0.0026040864
and O 0 0.0022231669
withdrawal O 0 0.65079546
if O 0 0.0019001149
needed O 0 0.0028633901
. O 0 0.0049967957

Further O 0 0.0043885475
long O 0 0.0029098864
- O 0 0.0023650483
term O 0 0.0013166155
analysis O 0 0.0014402679
of O 0 0.0014664221
renal O 0 0.98143023
allograft O 0 0.9577707
studies O 0 0.0023063812
using O 0 0.0007816498
sirolimus B-Chemical 1 0.99861836
as O 0 0.0006920894
de O 0 0.02579239
novo O 0 0.021269854
immunosuppression O 0 0.97168845
along O 0 0.0006115285
with O 0 0.0006032314
clinical O 0 0.004907876
and O 0 0.0004922303
laboratory O 0 0.00086944073
studies O 0 0.0007664801
will O 0 0.0004857613
refine O 0 0.0020398593
these O 0 0.0011844711
issues O 0 0.0024123623
in O 0 0.0016114593
the O 0 0.0024981613
future O 0 0.0044821883
. O 0 0.005972976

Proteinuria B-Disease 2 0.99346775
after O 0 0.005591402
conversion O 0 0.011017088
to O 0 0.005874203
sirolimus B-Chemical 1 0.9944014
in O 0 0.008910546
renal O 0 0.9860826
transplant O 0 0.92321396
recipients O 0 0.083410874
. O 0 0.013817947

Sirolimus B-Chemical 1 0.9909678
( O 0 0.019272804
SRL B-Chemical 1 0.99488693
) O 0 0.008128994
is O 0 0.003130653
a O 0 0.0031688455
new O 0 0.0045430055
, O 0 0.0058190874
potent O 0 0.089801095
immunosuppressive O 0 0.98352355
agent O 0 0.7260408
. O 0 0.014105036

More O 0 0.0155339325
recently O 0 0.0048440346
, O 0 0.004754992
proteinuria B-Disease 2 0.998838
has O 0 0.0022904095
been O 0 0.001552195
reported O 0 0.0012544643
as O 0 0.0005654236
a O 0 0.0006594873
consequence O 0 0.00050578645
of O 0 0.0010998291
sirolimus B-Chemical 1 0.9990238
therapy O 0 0.12552021
, O 0 0.0013701733
although O 0 0.0007711893
the O 0 0.00082945835
mechanism O 0 0.001684434
has O 0 0.0018650319
remained O 0 0.004268956
unclear O 0 0.006563593
. O 0 0.006798514

We O 0 0.0029870009
retrospectively O 0 0.002759367
examined O 0 0.0011997015
the O 0 0.0010602833
records O 0 0.0013498834
of O 0 0.0011526748
25 O 0 0.0017428087
renal O 0 0.9619791
transplant O 0 0.702743
patients O 0 0.006751618
, O 0 0.0011103908
who O 0 0.0015409546
developed O 0 0.0012115937
or O 0 0.00069429225
displayed O 0 0.00095250335
increased O 0 0.0059041074
proteinuria B-Disease 2 0.9994043
after O 0 0.0050819074
SRL B-Chemical 1 0.99752957
conversion O 0 0.11215327
. O 0 0.008382895

The O 0 0.0029300652
patient O 0 0.0034144123
cohort O 0 0.004076717
( O 0 0.0020664325
14 O 0 0.0012854487
men O 0 0.008972238
, O 0 0.0010316893
11 O 0 0.00078683055
women O 0 0.0051770546
) O 0 0.00084649713
was O 0 0.0004003818
treated O 0 0.00072658923
with O 0 0.00078679505
SRL B-Chemical 1 0.9989072
as O 0 0.0005074455
conversion O 0 0.004815357
therapy O 0 0.02497032
, O 0 0.0005952403
due O 0 0.00024312039
to O 0 0.00042786263
chronic B-Disease 0 0.9869511
allograft I-Disease 0 0.99825674
nephropathy I-Disease 2 0.9999713
( O 0 0.04324965
CAN B-Disease 0 0.99861777
) O 0 0.0036398128
( O 0 0.0006212847
n O 0 0.00029022174
= O 0 0.0004409231
15 O 0 0.00024379774
) O 0 0.0006495833
neoplasia B-Disease 0 0.99640286
( O 0 0.00074043823
n O 0 0.00031144972
= O 0 0.00048179386
8 O 0 0.00028026468
) O 0 0.0005824324
; O 0 0.00097236736
Kaposi B-Disease 0 0.9976774
' I-Disease 0 0.00064473273
s I-Disease 0 0.0009093054
sarcoma I-Disease 0 0.99751043
, O 0 0.00078755367
Four O 0 0.0014112076
skin B-Disease 0 0.35790464
cancers I-Disease 2 0.9985631
, O 0 0.001632085
One O 0 0.0016754678
intestinal B-Disease 0 0.9050931
tumors I-Disease 0 0.99362457
, O 0 0.0013590201
One O 0 0.0015467488
renal B-Disease 0 0.99258375
cell I-Disease 0 0.042837452
carsinom I-Disease 0 0.18211672
) O 0 0.0021840692
or O 0 0.0009999565
BK O 0 0.99728274
virus O 0 0.73270696
nephropathy B-Disease 2 0.99983287
( O 0 0.00767614
n O 0 0.0022434967
= O 0 0.0035160715
2 O 0 0.0028817086
) O 0 0.0056141876
. O 0 0.0050637224

SRL B-Chemical 1 0.99111205
was O 0 0.0034435794
started O 0 0.0024509004
at O 0 0.0010336624
a O 0 0.0010729035
mean O 0 0.0006436936
of O 0 0.0011015544
78 O 0 0.002104989
+ O 0 0.0013341721
/ O 0 0.0019440748
- O 0 0.0012790803
42 O 0 0.0010570653
( O 0 0.0008292905
15 O 0 0.0005401025
to O 0 0.0007022711
163 O 0 0.003643178
) O 0 0.0018368835
months O 0 0.0016701198
after O 0 0.0018125138
transplantation O 0 0.088293515
. O 0 0.0062968386

Mean O 0 0.0035373045
follow O 0 0.0030128846
- O 0 0.003203383
up O 0 0.0016312607
on O 0 0.0011642771
SRL B-Chemical 1 0.9956815
therapy O 0 0.0407823
was O 0 0.001283605
20 O 0 0.0012560436
+ O 0 0.0012875501
/ O 0 0.0019659905
- O 0 0.0013515468
12 O 0 0.00068111264
( O 0 0.0010161812
6 O 0 0.0007273326
to O 0 0.0010813928
43 O 0 0.002960128
) O 0 0.0037050378
months O 0 0.0042617014
. O 0 0.0051629213

Proteinuria B-Disease 2 0.99650145
increased O 0 0.0055873445
from O 0 0.00214713
0 O 0 0.0016751782
. O 0 0.0007964627
445 O 0 0.004667729
( O 0 0.0009146363
0 O 0 0.0005287827
to O 0 0.00037424095
1 O 0 0.00039155886
. O 0 0.00021864443
5 O 0 0.00026230584
) O 0 0.00043801466
g O 0 0.0006827094
/ O 0 0.0005268277
d O 0 0.0003024568
before O 0 0.00014491846
conversion O 0 0.0006812957
to O 0 0.00023766837
3 O 0 0.00022678525
. O 0 0.00014797557
2 O 0 0.0002354838
g O 0 0.00068827503
/ O 0 0.0007453489
dL O 0 0.011607812
( O 0 0.00039020658
0 O 0 0.0002787412
. O 0 0.0001437311
2 O 0 0.00020532949
to O 0 0.00020643802
12 O 0 0.00024179004
) O 0 0.0004712786
after O 0 0.0002706543
conversion O 0 0.0019929856
( O 0 0.0013029061
P O 0 0.029105036
= O 0 0.0019171094
0 O 0 0.0016034013
. O 0 0.0015621753
001 O 0 0.14036582
) O 0 0.0066079167
. O 0 0.005604102

Before O 0 0.0057111145
conversion O 0 0.006790459
8 O 0 0.0023877989
( O 0 0.0020657748
32 O 0 0.0017495085
% O 0 0.0012170695
) O 0 0.0012324707
patients O 0 0.001502292
had O 0 0.00087009085
no O 0 0.0010343741
proteinuria B-Disease 2 0.9994481
, O 0 0.0020914008
whereas O 0 0.0010683007
afterwards O 0 0.0019646024
all O 0 0.0013313332
patients O 0 0.006116091
had O 0 0.007009239
proteinuria B-Disease 2 0.9985434
. O 0 0.011586774

In O 0 0.0033749312
28 O 0 0.0029372366
% O 0 0.0019208775
of O 0 0.0016750642
patients O 0 0.005575802
proteinuria B-Disease 2 0.99925154
remained O 0 0.0032388251
unchanged O 0 0.0016573367
, O 0 0.001221364
whereas O 0 0.000777738
it O 0 0.00091681234
increased O 0 0.00142579
in O 0 0.0011261823
68 O 0 0.0026027025
% O 0 0.0020088283
of O 0 0.0030002238
patients O 0 0.010150002
. O 0 0.006400976

In O 0 0.005092741
40 O 0 0.00464078
% O 0 0.003686399
it O 0 0.0029218977
increased O 0 0.0034377328
by O 0 0.0031409303
more O 0 0.004061551
than O 0 0.003223051
100 O 0 0.008791274
% O 0 0.008367775
. O 0 0.008302941

Twenty O 0 0.010119214
- O 0 0.0041471045
eight O 0 0.0016062158
percent O 0 0.0013931692
of O 0 0.0018129416
patients O 0 0.0036104464
showed O 0 0.0019779038
increased O 0 0.0064660283
proteinuria B-Disease 2 0.999158
to O 0 0.0050134873
the O 0 0.007841436
nephrotic B-Disease 2 0.9992656
range O 0 0.030215302
. O 0 0.010315615

Biopsies O 0 0.011648557
performed O 0 0.0023883302
in O 0 0.001554216
five O 0 0.001056065
patients O 0 0.0023235173
revealed O 0 0.0013311646
new O 0 0.0019878582
pathological O 0 0.16959399
changes O 0 0.0033711866
: O 0 0.0035814068
One O 0 0.0077241603
membranoproliferative B-Disease 0 0.99967265
glomerulopathy I-Disease 0 0.99967885
and O 0 0.07326396
interstitial B-Disease 2 0.99448293
nephritis I-Disease 2 0.9995442
. O 0 0.02483119

These O 0 0.011274209
patients O 0 0.012957561
showed O 0 0.007934475
persistently O 0 0.03164922
good O 0 0.012754023
graft O 0 0.05644857
function O 0 0.019334491
. O 0 0.017107697

Serum O 0 0.5482553
creatinine B-Chemical 1 0.9815051
values O 0 0.0024956332
did O 0 0.0013427441
not O 0 0.000887796
change O 0 0.000922897
significantly O 0 0.0010579147
: O 0 0.0011010446
1 O 0 0.0005587307
. O 0 0.00029429534
98 O 0 0.00088363327
+ O 0 0.0005951177
/ O 0 0.0009945313
- O 0 0.0005988352
0 O 0 0.00032811
. O 0 0.00015820359
8 O 0 0.00025337082
mg O 0 0.0954658
/ O 0 0.0008096321
dL O 0 0.00750022
before O 0 0.00019892026
SRL B-Chemical 1 0.9980252
therapy O 0 0.016086979
and O 0 0.00041390065
2 O 0 0.00032014318
. O 0 0.00016702009
53 O 0 0.0005389277
+ O 0 0.00041621682
/ O 0 0.0008065592
- O 0 0.00050463696
1 O 0 0.00026127425
. O 0 0.00014631124
9 O 0 0.0002582067
mg O 0 0.09027929
/ O 0 0.0007936137
dL O 0 0.0042065503
at O 0 0.0001726693
last O 0 0.0002255462
follow O 0 0.00042884448
- O 0 0.0008848996
up O 0 0.00070530263
( O 0 0.0013026386
P O 0 0.02108432
= O 0 0.0020990756
. O 0 0.0012122747
14 O 0 0.00279534
) O 0 0.0051356093
. O 0 0.004894608

Five O 0 0.00909174
grafts O 0 0.009170303
were O 0 0.0031854482
lost O 0 0.00330842
and O 0 0.002838084
the O 0 0.0027785008
patients O 0 0.0062138704
returned O 0 0.004477128
to O 0 0.0055179386
dialysis O 0 0.13023464
. O 0 0.011618124

Five O 0 0.0129831135
patients O 0 0.011775873
displayed O 0 0.0072042714
CAN B-Disease 0 0.97550815
and O 0 0.015290566
Kaposi B-Disease 0 0.9930172
' I-Disease 0 0.015584432
s I-Disease 0 0.02093145
sarcoma I-Disease 0 0.985746
. O 0 0.018507516

Mean O 0 0.0033633357
urinary O 0 0.24012987
protein O 0 0.0037176409
of O 0 0.0018556613
patients O 0 0.0030552768
who O 0 0.0018266201
returned O 0 0.00072143
to O 0 0.00053597364
dialysis O 0 0.023110796
was O 0 0.0005584427
1 O 0 0.00044360204
. O 0 0.0002246056
26 O 0 0.0004645406
( O 0 0.00036525418
0 O 0 0.0002705893
. O 0 0.00013351598
5 O 0 0.00015268024
to O 0 0.00016024086
3 O 0 0.00017660059
. O 0 0.00012660719
5 O 0 0.00017668161
) O 0 0.00031863013
g O 0 0.0005307384
/ O 0 0.00041964828
d O 0 0.000246108
before O 0 0.0001164347
and O 0 0.00021917983
4 O 0 0.00019712167
. O 0 0.0001352631
7 O 0 0.00018759715
( O 0 0.000254734
3 O 0 0.00016015241
to O 0 0.00017639763
12 O 0 0.00020648587
) O 0 0.00043792554
g O 0 0.00076209736
/ O 0 0.0007037527
d O 0 0.00050866493
after O 0 0.00034446758
conversion O 0 0.00250658
( O 0 0.0016450203
P O 0 0.03961473
= O 0 0.0026415973
. O 0 0.0016034066
01 O 0 0.011513455
) O 0 0.0061011673
. O 0 0.0054416

Mean O 0 0.003687846
serum O 0 0.029486746
creatinine B-Chemical 1 0.9624273
level O 0 0.0013807918
before O 0 0.0007500787
conversion O 0 0.0022662596
was O 0 0.000752789
2 O 0 0.00059930846
. O 0 0.00033272573
21 O 0 0.0006157477
mg O 0 0.14780769
/ O 0 0.0012734564
dL O 0 0.00869793
and O 0 0.0004003849
thereafter O 0 0.00056020543
, O 0 0.00048924884
4 O 0 0.0003207722
. O 0 0.0002499512
93 O 0 0.0009781072
mg O 0 0.18539527
/ O 0 0.002360614
dL O 0 0.037545003
( O 0 0.001723462
P O 0 0.024995685
= O 0 0.0026525396
. O 0 0.0017148652
02 O 0 0.024197886
) O 0 0.0067901607
. O 0 0.0058708093

Heavy O 0 0.9117321
proteinuria B-Disease 2 0.99812895
was O 0 0.0037580905
common O 0 0.0026138194
after O 0 0.0009688844
the O 0 0.00110784
use O 0 0.0014745032
of O 0 0.0021969362
SRL B-Chemical 1 0.99715436
as O 0 0.0015916502
rescue O 0 0.0023807476
therapy O 0 0.032702714
for O 0 0.0037755766
renal O 0 0.9892866
transplantation O 0 0.7969007
. O 0 0.010306033

Therefore O 0 0.0040510893
, O 0 0.0035564203
conversion O 0 0.0040365015
should O 0 0.0010527876
be O 0 0.0010702697
considered O 0 0.0007667928
for O 0 0.0006905361
patients O 0 0.0020156344
who O 0 0.0019264742
have O 0 0.0010704369
not O 0 0.0012217723
developed O 0 0.0036529189
advanced O 0 0.3131419
CAN B-Disease 0 0.99443084
and O 0 0.027414223
proteinuria B-Disease 2 0.9988091
. O 0 0.01449827

The O 0 0.0032557144
possibility O 0 0.002338333
of O 0 0.0028475323
de O 0 0.017921118
novo O 0 0.027901584
glomerular O 0 0.8963775
pathology O 0 0.14710832
under O 0 0.0016455975
SRL B-Chemical 1 0.99778026
treatment O 0 0.0038243274
requires O 0 0.0010304525
further O 0 0.0017317027
investigation O 0 0.0038983687
by O 0 0.004005227
renal O 0 0.98347604
biopsy O 0 0.15383469
. O 0 0.009286043

Long O 0 0.023261698
- O 0 0.0043863957
term O 0 0.002256419
follow O 0 0.001797593
- O 0 0.0020303212
up O 0 0.0010085338
of O 0 0.0016080744
ifosfamide B-Chemical 1 0.99944276
renal B-Disease 2 0.9993599
toxicity I-Disease 2 0.9994173
in O 0 0.0011996792
children O 0 0.0032574448
treated O 0 0.0013449788
for O 0 0.0007449555
malignant B-Disease 0 0.99514776
mesenchymal I-Disease 0 0.9921943
tumors I-Disease 0 0.9972777
: O 0 0.0029931974
an O 0 0.001526776
International O 0 0.004385054
Society O 0 0.0034433065
of O 0 0.0022128143
Pediatric O 0 0.0070578344
Oncology O 0 0.06709242
report O 0 0.011906257
. O 0 0.0067629474

The O 0 0.0037234894
renal O 0 0.81617963
function O 0 0.0027449538
of O 0 0.0018154242
74 O 0 0.0021659392
children O 0 0.0022498856
with O 0 0.0014527114
malignant B-Disease 0 0.9914718
mesenchymal I-Disease 0 0.98563147
tumors I-Disease 0 0.9955781
in O 0 0.0005638693
complete O 0 0.00046847184
remission O 0 0.32968622
and O 0 0.00037788477
who O 0 0.0006587122
have O 0 0.000257762
received O 0 0.00033197957
the O 0 0.00022592262
same O 0 0.00020193816
ifosfamide B-Chemical 1 0.99934214
chemotherapy O 0 0.89439476
protocol O 0 0.0018438875
( O 0 0.0006454705
International O 0 0.0015216098
Society O 0 0.0010077097
of O 0 0.00047521043
Pediatric O 0 0.0020156892
Oncology O 0 0.114165775
Malignant B-Disease 0 0.98570037
Mesenchymal I-Disease 0 0.9786557
Tumor I-Disease 0 0.99714726
Study O 0 0.07517981
84 O 0 0.0011491084
[ O 0 0.0011890392
SIOP O 0 0.0061424538
MMT O 0 0.39476526
84 O 0 0.0010086456
] O 0 0.00097235345
) O 0 0.00056605664
were O 0 0.0003287591
studied O 0 0.0005195497
1 O 0 0.00042695506
year O 0 0.00047380422
after O 0 0.00037471592
the O 0 0.0007061215
completion O 0 0.0010649941
of O 0 0.0026910768
treatment O 0 0.009171424
. O 0 0.0062203696

Total O 0 0.004799408
cumulative O 0 0.004825795
doses O 0 0.016795347
were O 0 0.0013643573
36 O 0 0.0010064528
or O 0 0.0005864632
60 O 0 0.0007151418
g O 0 0.0013239817
/ O 0 0.0010920463
m2 O 0 0.0084503135
of O 0 0.0008323582
ifosfamide B-Chemical 1 0.9991566
( O 0 0.00083519606
six O 0 0.00023192953
or O 0 0.00026302808
10 O 0 0.00030675213
cycles O 0 0.0002714676
of O 0 0.0006925542
ifosfamide B-Chemical 1 0.99928015
, I-Chemical 0 0.004305432
vincristine I-Chemical 1 0.9995204
, I-Chemical 0 0.0029074096
and I-Chemical 0 0.0025284893
dactinomycin I-Chemical 0 0.9970092
[ O 0 0.07833309
IVA B-Chemical 0 0.99751925
] O 0 0.035686247
) O 0 0.009994709
. O 0 0.006487289

None O 0 0.016555125
of O 0 0.008200985
them O 0 0.009466386
had O 0 0.0080154585
received O 0 0.01662512
cisplatin B-Chemical 1 0.9937738
chemotherapy O 0 0.9683054
. O 0 0.022981865

Ages O 0 0.011569671
ranged O 0 0.0033982703
from O 0 0.0018661505
4 O 0 0.0012100956
months O 0 0.0010381958
to O 0 0.0008684657
17 O 0 0.0012085544
years O 0 0.0014884964
; O 0 0.0013183746
58 O 0 0.0012900695
patients O 0 0.0017844405
were O 0 0.0011117898
males O 0 0.0020248564
and O 0 0.0021748305
42 O 0 0.004403812
females O 0 0.006147317
. O 0 0.0061689364

The O 0 0.0045355996
most O 0 0.0049972367
common O 0 0.004406646
primary O 0 0.0048392564
tumor B-Disease 2 0.44065645
site O 0 0.0034119857
was O 0 0.0028908974
the O 0 0.0033537769
head O 0 0.024557605
and O 0 0.008083389
neck O 0 0.4001784
. O 0 0.012579286

Renal O 0 0.72746515
function O 0 0.0036353013
was O 0 0.0016893599
investigated O 0 0.0012047738
by O 0 0.0009711758
measuring O 0 0.00074434944
plasma O 0 0.016943578
and O 0 0.0012005892
urinary O 0 0.89515513
electrolytes O 0 0.9961571
, O 0 0.009125154
glucosuria B-Disease 0 0.99970216
, O 0 0.014249633
proteinuria B-Disease 2 0.9998597
, O 0 0.01598659
aminoaciduria B-Disease 0 0.9998399
, O 0 0.0067494055
urinary O 0 0.9736744
pH O 0 0.77729887
, O 0 0.0015279716
osmolarity O 0 0.91004694
, O 0 0.0018213842
creatinine B-Chemical 1 0.9978084
clearance O 0 0.37642884
, O 0 0.0022097006
phosphate B-Chemical 1 0.9946572
tubular O 0 0.9735293
reabsorption O 0 0.99504024
, O 0 0.004369249
beta O 0 0.5557927
2 O 0 0.0022841697
microglobulinuria O 0 0.5113343
, O 0 0.0035255502
and O 0 0.004385471
lysozymuria O 0 0.95659137
. O 0 0.0077864802

Fifty O 0 0.017258435
- O 0 0.0043819626
eight O 0 0.0017007936
patients O 0 0.0035297105
( O 0 0.0018092024
78 O 0 0.0017923896
% O 0 0.00097632804
) O 0 0.0008878666
had O 0 0.0005397291
normal O 0 0.0012830236
renal O 0 0.9424935
tests O 0 0.0025108114
, O 0 0.0008716414
whereas O 0 0.00054846756
16 O 0 0.0006658124
patients O 0 0.0015811695
( O 0 0.0010548367
22 O 0 0.0012093604
% O 0 0.0011801932
) O 0 0.001909635
had O 0 0.0028368724
renal B-Disease 0 0.9937354
abnormalities I-Disease 0 0.93123907
. O 0 0.009057237

Two O 0 0.004006096
subsets O 0 0.0028702533
of O 0 0.0018592674
patients O 0 0.0025346219
were O 0 0.00084419094
identified O 0 0.0005511719
from O 0 0.0004657626
this O 0 0.00041708094
latter O 0 0.0009784863
group O 0 0.00058405375
: O 0 0.0005076235
the O 0 0.00022161873
first O 0 0.00018121272
included O 0 0.00019439954
four O 0 0.00016918813
patients O 0 0.0009303121
( O 0 0.00038453744
5 O 0 0.0001812457
% O 0 0.00018012896
of O 0 0.000181884
the O 0 0.00016410438
total O 0 0.00019413576
population O 0 0.00046366575
) O 0 0.00047792698
who O 0 0.0006011073
developed O 0 0.0005300301
major O 0 0.00066893245
toxicity B-Disease 2 0.992214
resulting O 0 0.00077695755
in O 0 0.0006113471
Fanconi B-Disease 0 0.99658406
' I-Disease 0 0.0007000023
s I-Disease 0 0.00089226465
syndrome I-Disease 0 0.8610245
( O 0 0.0014993051
TDFS B-Disease 0 0.9590635
) O 0 0.0013123626
; O 0 0.0005383085
and O 0 0.00021930294
the O 0 0.00017061002
second O 0 0.00018105019
group O 0 0.00025276467
included O 0 0.00018444638
five O 0 0.00016557839
patients O 0 0.0008157837
with O 0 0.00055063784
elevated O 0 0.0078966925
beta O 0 0.35756677
2 O 0 0.0012435291
microglobulinuria O 0 0.34383893
and O 0 0.001681253
low O 0 0.004328336
phosphate B-Chemical 1 0.99186546
reabsorption O 0 0.98779744
. O 0 0.010339949

The O 0 0.004317268
remaining O 0 0.0035911838
seven O 0 0.0034784474
patients O 0 0.006212513
had O 0 0.0042038783
isolated O 0 0.0059628547
beta O 0 0.3542038
2 O 0 0.010790841
microglobulinuria O 0 0.5935694
. O 0 0.012605373

Severe O 0 0.92994523
toxicity B-Disease 2 0.9871055
was O 0 0.0022062883
correlated O 0 0.0009979578
with O 0 0.00093149487
the O 0 0.0005909407
higher O 0 0.0005231079
cumulative O 0 0.0014405107
dose O 0 0.007830446
of O 0 0.0006226339
60 O 0 0.0005664096
g O 0 0.0011251474
/ O 0 0.0008279458
m2 O 0 0.011562704
of O 0 0.00064619834
ifosfamide B-Chemical 1 0.99940836
, O 0 0.00083966064
a O 0 0.00046499493
younger O 0 0.006665877
age O 0 0.00087675836
( O 0 0.00038927718
less O 0 0.00024323355
than O 0 0.00016395985
2 O 0 0.0002539987
1 O 0 0.00026378955
/ O 0 0.00047827332
2 O 0 0.00025077426
years O 0 0.00045472966
old O 0 0.00041806855
) O 0 0.0005929622
, O 0 0.0004983845
and O 0 0.0004903196
a O 0 0.00073646015
predominance O 0 0.0018483204
of O 0 0.0021895408
vesicoprostatic O 0 0.2119196
tumor B-Disease 2 0.8637067
involvement O 0 0.034889065
. O 0 0.0073708617

This O 0 0.0046057934
low O 0 0.0026396336
percentage O 0 0.0013393965
( O 0 0.0019163148
5 O 0 0.0009234266
% O 0 0.0009397326
) O 0 0.0009490114
of O 0 0.00083259214
TDFS O 0 0.7423644
must O 0 0.00040750767
be O 0 0.00039439436
evaluated O 0 0.00031725824
with O 0 0.00037455594
respect O 0 0.00028348822
to O 0 0.00027630647
the O 0 0.0003011844
efficacy O 0 0.0016229083
of O 0 0.0008767546
ifosfamide B-Chemical 1 0.99929094
in O 0 0.0006845493
the O 0 0.0006419634
treatment O 0 0.0022516265
of O 0 0.0023862454
mesenchymal B-Disease 0 0.96885484
tumors I-Disease 0 0.9894309
in O 0 0.0041395705
children O 0 0.014408146
. O 0 0.006117424

Progressive O 0 0.30749053
myopathy B-Disease 2 0.9918371
with O 0 0.005193811
up O 0 0.0030693554
- O 0 0.0030079016
regulation O 0 0.0013696828
of O 0 0.0020722346
MHC O 0 0.049401183
- O 0 0.004635703
I O 0 0.0058279885
associated O 0 0.0032961627
with O 0 0.0054588546
statin B-Chemical 1 0.9929268
therapy O 0 0.37943792
. O 0 0.010906451

Statins B-Chemical 0 0.99490994
can O 0 0.004811755
cause O 0 0.0079580415
a O 0 0.0047052517
necrotizing O 0 0.99844044
myopathy B-Disease 2 0.99885726
and O 0 0.008330947
hyperCKaemia B-Disease 0 0.93092126
which O 0 0.0024973524
is O 0 0.0014826341
reversible O 0 0.10087224
on O 0 0.0010315606
cessation O 0 0.008186376
of O 0 0.0031680067
the O 0 0.004287937
drug O 0 0.53105104
. O 0 0.008486218

What O 0 0.0137151005
is O 0 0.0024974025
less O 0 0.0016185113
well O 0 0.0010407497
known O 0 0.001366911
is O 0 0.00082432147
a O 0 0.0008381954
phenomenon O 0 0.0041802623
whereby O 0 0.0011365646
statins B-Chemical 1 0.9979387
may O 0 0.0010018225
induce O 0 0.00072852126
a O 0 0.0011835498
myopathy B-Disease 2 0.99854136
, O 0 0.0012936926
which O 0 0.0008029386
persists O 0 0.00079013966
or O 0 0.00052904844
may O 0 0.00068883185
progress O 0 0.0014546404
after O 0 0.00078945997
stopping O 0 0.00804979
the O 0 0.003165594
drug O 0 0.46323225
. O 0 0.006883565

We O 0 0.00558983
investigated O 0 0.0044507557
the O 0 0.004408455
muscle O 0 0.038762037
pathology O 0 0.03737081
in O 0 0.004680176
8 O 0 0.004800244
such O 0 0.005942764
cases O 0 0.013679155
. O 0 0.011428629

All O 0 0.006134855
had O 0 0.005455623
myofibre O 0 0.40846533
necrosis B-Disease 2 0.9884205
but O 0 0.0040397844
only O 0 0.0028240678
3 O 0 0.0024157292
had O 0 0.0031923237
an O 0 0.0065812245
inflammatory O 0 0.8980619
infiltrate O 0 0.92172295
. O 0 0.013170097

In O 0 0.002874013
all O 0 0.0018046182
cases O 0 0.0022975837
there O 0 0.00095010106
was O 0 0.0011298631
diffuse O 0 0.014076275
or O 0 0.0010648938
multifocal O 0 0.9232917
up O 0 0.001188005
- O 0 0.0012001294
regulation O 0 0.00050673954
of O 0 0.0008616655
MHC O 0 0.047352463
- O 0 0.0022473244
I O 0 0.002800264
expression O 0 0.0013265149
even O 0 0.0010321882
in O 0 0.0011611393
non O 0 0.004358705
- O 0 0.006499095
necrotic B-Disease 2 0.8203175
fibres O 0 0.34631476
. O 0 0.007828445

Progressive O 0 0.04860907
improvement O 0 0.0043817475
occurred O 0 0.002319366
in O 0 0.0012311332
7 O 0 0.00086076115
cases O 0 0.0010478317
after O 0 0.00043823582
commencement O 0 0.0011181202
of O 0 0.0013674272
prednisolone B-Chemical 1 0.99949455
and O 0 0.0047159093
methotrexate B-Chemical 1 0.9994863
, O 0 0.0029563408
and O 0 0.0014851295
in O 0 0.0012963387
one O 0 0.0016120541
case O 0 0.0034467229
spontaneously O 0 0.053541236
. O 0 0.006774264

These O 0 0.0042904546
observations O 0 0.0029168841
suggest O 0 0.0015398669
that O 0 0.0016231632
statins B-Chemical 1 0.9948565
may O 0 0.0015004575
initiate O 0 0.00087532884
an O 0 0.0013333432
immune O 0 0.15810871
- O 0 0.0020249633
mediated O 0 0.0008105484
myopathy B-Disease 2 0.99781126
that O 0 0.00050482625
persists O 0 0.0006735242
after O 0 0.00030783462
withdrawal O 0 0.33324784
of O 0 0.0007032081
the O 0 0.000666823
drug O 0 0.2196912
and O 0 0.001220605
responds O 0 0.0027048895
to O 0 0.002238149
immunosuppressive O 0 0.9761589
therapy O 0 0.29844472
. O 0 0.007697734

The O 0 0.002864857
mechanism O 0 0.0026966082
of O 0 0.0021004647
this O 0 0.001957939
myopathy B-Disease 2 0.9962597
is O 0 0.0014906888
uncertain O 0 0.0027388271
but O 0 0.00068943086
may O 0 0.0005022886
involve O 0 0.0005289103
the O 0 0.0003953967
induction O 0 0.0007677108
by O 0 0.00060826045
statins B-Chemical 1 0.9981785
of O 0 0.0014100779
an O 0 0.0022817627
endoplasmic O 0 0.8847336
reticulum O 0 0.9728506
stress O 0 0.47120506
response O 0 0.0015652836
with O 0 0.00054745184
associated O 0 0.00067042717
up O 0 0.0004619732
- O 0 0.00061062496
regulation O 0 0.0002900154
of O 0 0.00055765436
MHC O 0 0.040324174
- O 0 0.0016812866
I O 0 0.0022222577
expression O 0 0.0011010781
and O 0 0.00095334183
antigen O 0 0.02100015
presentation O 0 0.012614022
by O 0 0.0029078214
muscle O 0 0.22527477
fibres O 0 0.24788839
. O 0 0.007046422

Use O 0 0.012375926
of O 0 0.004762531
chromosome O 0 0.008502933
substitution O 0 0.017868562
strains O 0 0.002661625
to O 0 0.0018617599
identify O 0 0.002402988
seizure B-Disease 2 0.9961359
susceptibility O 0 0.023131447
loci O 0 0.0070398184
in O 0 0.004202461
mice O 0 0.0045735426
. O 0 0.0074874633

Seizure B-Disease 2 0.9877616
susceptibility O 0 0.025072275
varies O 0 0.010608387
among O 0 0.008928372
inbred O 0 0.012786221
mouse O 0 0.013726877
strains O 0 0.016026365
. O 0 0.01640978

Chromosome O 0 0.20518863
substitution O 0 0.04429237
strains O 0 0.004086923
( O 0 0.003927684
CSS O 0 0.8825333
) O 0 0.0025666945
, O 0 0.0010572547
in O 0 0.0005033792
which O 0 0.0006145
a O 0 0.000465176
single O 0 0.00043549124
chromosome O 0 0.0016556964
from O 0 0.000301794
one O 0 0.00021839589
inbred O 0 0.0005791332
strain O 0 0.00034639257
( O 0 0.00044336487
donor O 0 0.0005576999
) O 0 0.0005284482
has O 0 0.00026004185
been O 0 0.00031061762
transferred O 0 0.00025148154
onto O 0 0.0001943091
a O 0 0.00023620584
second O 0 0.00022016173
strain O 0 0.00027824764
( O 0 0.0004073329
host O 0 0.000895262
) O 0 0.00042815987
by O 0 0.00019817929
repeated O 0 0.00022043644
backcrossing O 0 0.0007744864
, O 0 0.00039819637
may O 0 0.00025658065
be O 0 0.0002352237
used O 0 0.00018217388
to O 0 0.00018652859
identify O 0 0.00020647344
quantitative O 0 0.0004971301
trait O 0 0.0017677526
loci O 0 0.0014698046
( O 0 0.0010357043
QTLs O 0 0.018247282
) O 0 0.0012218335
that O 0 0.0006887376
contribute O 0 0.0013909587
to O 0 0.0025472438
seizure B-Disease 2 0.9971993
susceptibility O 0 0.098115355
. O 0 0.007560171

QTLs O 0 0.012655669
for O 0 0.0026557848
susceptibility O 0 0.006361734
to O 0 0.0025485645
pilocarpine B-Chemical 1 0.99958605
- O 0 0.00990226
induced O 0 0.004539517
seizures B-Disease 2 0.99975175
, O 0 0.0015209059
a O 0 0.0005920789
model O 0 0.0005952873
of O 0 0.0006965104
temporal B-Disease 2 0.18433246
lobe I-Disease 2 0.8958579
epilepsy I-Disease 2 0.9997503
, O 0 0.0010430291
have O 0 0.00040835657
not O 0 0.00031699945
been O 0 0.0004361957
reported O 0 0.0006059123
, O 0 0.00050087506
and O 0 0.0004940357
CSS O 0 0.7450272
have O 0 0.00045805261
not O 0 0.00039222455
previously O 0 0.00048716264
been O 0 0.0006035592
used O 0 0.00051793136
to O 0 0.0007287438
localize O 0 0.0010780365
seizure B-Disease 2 0.9966748
susceptibility O 0 0.034901995
genes O 0 0.009545901
. O 0 0.0063312976

We O 0 0.0034608734
report O 0 0.0049420586
QTLs O 0 0.0067869388
identified O 0 0.0014375519
using O 0 0.0011782091
a O 0 0.0015556782
B6 O 0 0.11429413
( O 0 0.0016621888
host O 0 0.002763134
) O 0 0.0015516292
x O 0 0.0032163055
A O 0 0.017902037
/ O 0 0.0029774972
J O 0 0.4828083
( O 0 0.0008582788
donor O 0 0.00093864714
) O 0 0.0011040884
CSS O 0 0.60478085
panel O 0 0.00042512605
to O 0 0.0003508227
localize O 0 0.00025119542
genes O 0 0.00060134847
involved O 0 0.00051236653
in O 0 0.0006290807
susceptibility O 0 0.0049076406
to O 0 0.0022104513
pilocarpine B-Chemical 1 0.9996153
- O 0 0.025548968
induced O 0 0.0337771
seizures B-Disease 2 0.99910825
. O 0 0.010036394

Three O 0 0.0047752312
hundred O 0 0.0037328852
fifty O 0 0.0036995679
- O 0 0.0026679994
five O 0 0.0009995525
adult O 0 0.0019276765
male O 0 0.00419982
CSS O 0 0.70132715
mice O 0 0.00071350863
, O 0 0.0010069516
58 O 0 0.001282747
B6 O 0 0.041187327
, O 0 0.0007814695
and O 0 0.00057881593
39 O 0 0.0010889984
A O 0 0.0071335193
/ O 0 0.0018536132
J O 0 0.18537126
were O 0 0.0004909358
tested O 0 0.00041619458
for O 0 0.00059751474
susceptibility O 0 0.004178645
to O 0 0.0023467331
pilocarpine B-Chemical 1 0.9995652
- O 0 0.02553038
induced O 0 0.033519194
seizures B-Disease 2 0.9990527
. O 0 0.010532325

Highest O 0 0.030935558
stage O 0 0.0061084665
reached O 0 0.0032636328
and O 0 0.0021566164
latency O 0 0.003919866
to O 0 0.0013126977
each O 0 0.00086134125
stage O 0 0.002587472
were O 0 0.0015674753
recorded O 0 0.0021057364
for O 0 0.0019844256
all O 0 0.0030360078
mice O 0 0.0040185354
. O 0 0.0071464013

B6 O 0 0.055390082
mice O 0 0.0023495469
were O 0 0.002042411
resistant O 0 0.003006406
to O 0 0.0018906667
seizures B-Disease 2 0.99905103
and O 0 0.0015774125
slower O 0 0.0011721831
to O 0 0.00084516406
reach O 0 0.001231159
stages O 0 0.0015803433
compared O 0 0.000871538
to O 0 0.0017645664
A O 0 0.01902884
/ O 0 0.009253541
J O 0 0.35048127
mice O 0 0.004528301
. O 0 0.007108601

The O 0 0.004731671
CSS O 0 0.5096051
for O 0 0.002761257
Chromosomes O 0 0.17140067
10 O 0 0.0015131559
and O 0 0.0010327712
18 O 0 0.000864665
progressed O 0 0.0019088017
to O 0 0.00062526006
the O 0 0.00062843953
most O 0 0.0013155675
severe O 0 0.075372964
stages O 0 0.0018595444
, O 0 0.0013288922
diverging O 0 0.0030608492
dramatically O 0 0.0020149173
from O 0 0.0017276929
the O 0 0.0025497708
B6 O 0 0.13171783
phenotype O 0 0.00846031
. O 0 0.0068347696

Latencies O 0 0.19271232
to O 0 0.003978799
stages O 0 0.004104961
were O 0 0.0023010527
also O 0 0.002125301
significantly O 0 0.0022159426
shorter O 0 0.0019969617
for O 0 0.002527633
CSS10 O 0 0.070837095
and O 0 0.0057886294
CSS18 O 0 0.06413937
mice O 0 0.0061393925
. O 0 0.009345647

CSS O 0 0.5427592
mapping O 0 0.0049769143
suggests O 0 0.0035839295
seizure B-Disease 2 0.9941552
susceptibility O 0 0.016833374
loci O 0 0.004617946
on O 0 0.0019224132
mouse O 0 0.004774171
Chromosomes O 0 0.3561238
10 O 0 0.0039958023
and O 0 0.0045106728
18 O 0 0.0066763996
. O 0 0.007239766

This O 0 0.0045228307
approach O 0 0.002975281
provides O 0 0.0015274581
a O 0 0.0014261031
framework O 0 0.0013403727
for O 0 0.0007717402
identifying O 0 0.0010578643
potentially O 0 0.0015795362
novel O 0 0.0014082507
homologous O 0 0.00080479344
candidate O 0 0.0011434916
genes O 0 0.0015041513
for O 0 0.001250356
human O 0 0.0048024477
temporal B-Disease 2 0.42218742
lobe I-Disease 2 0.9608411
epilepsy I-Disease 2 0.99832815
. O 0 0.011748375

In O 0 0.0036244392
vitro O 0 0.0038737052
characterization O 0 0.0034133403
of O 0 0.0030478307
parasympathetic O 0 0.9644844
and O 0 0.0027295593
sympathetic O 0 0.8278237
responses O 0 0.004696098
in O 0 0.0019937465
cyclophosphamide B-Chemical 1 0.9992016
- O 0 0.013117765
induced O 0 0.011105302
cystitis B-Disease 0 0.99934953
in O 0 0.004548702
the O 0 0.005035784
rat O 0 0.06211522
. O 0 0.0078835515

In O 0 0.005509846
cyclophosphamide B-Chemical 1 0.9973884
- O 0 0.0093845725
induced O 0 0.006057833
cystitis B-Disease 0 0.99943465
in O 0 0.0015694788
the O 0 0.0010309544
rat O 0 0.01668565
, O 0 0.0014378065
detrusor O 0 0.99078804
function O 0 0.001250353
is O 0 0.00057169696
impaired O 0 0.0009421572
and O 0 0.000509509
the O 0 0.0004698708
expression O 0 0.0009708456
and O 0 0.0008256452
effects O 0 0.0020861132
of O 0 0.0033038445
muscarinic O 0 0.9966575
receptors O 0 0.582494
altered O 0 0.01776163
. O 0 0.007305233

Whether O 0 0.0049912934
or O 0 0.0025013802
not O 0 0.0019171424
the O 0 0.0018893669
neuronal O 0 0.18491392
transmission O 0 0.0046204147
may O 0 0.0016084042
be O 0 0.0014560138
affected O 0 0.0014665764
by O 0 0.0031383336
cystitis B-Disease 0 0.9990767
was O 0 0.0054146596
presently O 0 0.016841061
investigated O 0 0.0069598756
. O 0 0.007896275

Responses O 0 0.008928491
of O 0 0.0034065684
urinary O 0 0.42296848
strip O 0 0.0047175633
preparations O 0 0.0033314244
from O 0 0.0009606004
control O 0 0.00073143153
and O 0 0.0011380082
cyclophosphamide B-Chemical 1 0.9994616
- O 0 0.004680627
pretreated O 0 0.038173053
rats O 0 0.0029206097
to O 0 0.00036852583
electrical O 0 0.15357715
field O 0 0.00074556126
stimulation O 0 0.0009931206
and O 0 0.0003480344
to O 0 0.00031872132
agonists O 0 0.58983004
were O 0 0.0002988871
assessed O 0 0.00020723634
in O 0 0.00021479453
the O 0 0.00022976792
absence O 0 0.00019739439
and O 0 0.00038612602
presence O 0 0.0004748192
of O 0 0.0012874919
muscarinic O 0 0.9976985
, O 0 0.0041788295
adrenergic O 0 0.9957991
and O 0 0.004917291
purinergic O 0 0.9836257
receptor O 0 0.8206432
antagonists O 0 0.9893237
. O 0 0.010608068

Generally O 0 0.0059307376
, O 0 0.005151884
atropine B-Chemical 0 0.99806017
reduced O 0 0.0040605194
contractions O 0 0.93459874
, O 0 0.0018376407
but O 0 0.00069371687
in O 0 0.00042068367
contrast O 0 0.00046422431
to O 0 0.00037306864
controls O 0 0.0006593196
, O 0 0.00048205434
it O 0 0.00033591487
also O 0 0.00030059746
reduced O 0 0.00032431897
responses O 0 0.00061909505
to O 0 0.00024225267
low O 0 0.00042123022
electrical O 0 0.14095478
field O 0 0.0007660387
stimulation O 0 0.0010671166
intensity O 0 0.0004472504
( O 0 0.0008068026
1 O 0 0.0005966273
- O 0 0.0008897146
5 O 0 0.00062808656
Hz O 0 0.06920096
) O 0 0.0015538002
in O 0 0.0013728576
inflamed O 0 0.026563894
preparations O 0 0.011434843
. O 0 0.005966392

In O 0 0.0032731195
both O 0 0.0023421997
types O 0 0.00233752
, O 0 0.0030313435
purinoceptor O 0 0.99348444
desensitization O 0 0.82178485
with O 0 0.0028563996
alpha B-Chemical 0 0.4778621
, I-Chemical 0 0.0031310087
beta I-Chemical 0 0.74340004
- I-Chemical 0 0.0065629273
methylene I-Chemical 0 0.88694304
adenosine I-Chemical 1 0.9987269
- I-Chemical 0 0.0040728836
5 I-Chemical 0 0.00045218304
' I-Chemical 0 0.0005615513
- I-Chemical 0 0.0010158783
triphosphate I-Chemical 0 0.81498826
( O 0 0.0012950333
alpha B-Chemical 0 0.22647865
, I-Chemical 0 0.0015111092
beta I-Chemical 0 0.72201204
- I-Chemical 0 0.010001586
meATP I-Chemical 0 0.99424285
) O 0 0.0011600548
caused O 0 0.00045931136
further O 0 0.00043874574
reductions O 0 0.00061664055
at O 0 0.00027397857
low O 0 0.00067693746
frequencies O 0 0.00092509884
( O 0 0.0014489745
< O 0 0.0015638259
10 O 0 0.0019267254
Hz O 0 0.110521935
) O 0 0.005563339
. O 0 0.0049464693

The O 0 0.005464717
muscarinic O 0 0.9918064
receptor O 0 0.6180803
antagonists O 0 0.99360484
atropine B-Chemical 0 0.99962306
, O 0 0.006083568
4 B-Chemical 0 0.0011962765
- I-Chemical 0 0.0016538296
diphenylacetoxy I-Chemical 0 0.025856074
- I-Chemical 0 0.0028784822
N I-Chemical 0 0.88772446
- I-Chemical 0 0.0034568496
methylpiperidine I-Chemical 0 0.9291417
( O 0 0.0011039991
4 B-Chemical 0 0.0004930426
- I-Chemical 0 0.0011826555
DAMP I-Chemical 0 0.9727691
) O 0 0.0017286324
( O 0 0.0007609762
' O 0 0.0006566801
M O 0 0.4390468
( O 0 0.0007281031
1 O 0 0.000445121
) O 0 0.0007172997
/ O 0 0.001246933
M O 0 0.37140456
( O 0 0.000595356
3 O 0 0.00031920173
) O 0 0.00064031046
/ O 0 0.0011506333
M O 0 0.3652614
( O 0 0.00056703703
5 O 0 0.00029516782
) O 0 0.00055679266
- O 0 0.00051674934
selective O 0 0.0026973945
' O 0 0.00054357224
) O 0 0.00091194833
, O 0 0.0009248556
methoctramine B-Chemical 0 0.99977845
( O 0 0.0014936797
' O 0 0.00074156525
M O 0 0.5629565
( O 0 0.0006738128
2 O 0 0.00037946578
) O 0 0.00062096154
- O 0 0.000523575
selective O 0 0.0026333416
' O 0 0.00048224925
) O 0 0.00069879385
and O 0 0.0006289422
pirenzepine B-Chemical 0 0.9999168
( O 0 0.0020610187
' O 0 0.0008459408
M O 0 0.6296008
( O 0 0.0007393586
1 O 0 0.00040975196
) O 0 0.00063981424
- O 0 0.0005358086
selective O 0 0.0031664155
' O 0 0.0004992428
) O 0 0.0007689954
antagonized O 0 0.33071396
the O 0 0.00035528906
tonic O 0 0.38917252
component O 0 0.00040415407
of O 0 0.0004097264
the O 0 0.0003394632
electrical O 0 0.22083734
field O 0 0.0010816328
stimulation O 0 0.0027608578
- O 0 0.0013433524
evoked O 0 0.10704645
contractile O 0 0.6615506
response O 0 0.0016299419
more O 0 0.0012777695
potently O 0 0.03857887
than O 0 0.00091029104
the O 0 0.0019151014
phasic O 0 0.5651526
component O 0 0.0063455803
. O 0 0.0063476316

4 B-Chemical 0 0.0061655925
- I-Chemical 0 0.007579899
DAMP I-Chemical 0 0.90382963
inhibited O 0 0.0058070174
the O 0 0.0023215052
tonic O 0 0.7322199
contractions O 0 0.89998925
in O 0 0.0015734972
controls O 0 0.0021710775
more O 0 0.0022676466
potently O 0 0.07514852
than O 0 0.0027634085
methoctramine B-Chemical 0 0.9988906
and O 0 0.027924068
pirenzepine B-Chemical 0 0.99924374
. O 0 0.014399196

In O 0 0.0037843785
inflamed O 0 0.012739489
preparations O 0 0.005170781
, O 0 0.0022661025
the O 0 0.0015048325
muscarinic O 0 0.99653023
receptor O 0 0.43762594
antagonism O 0 0.73828864
on O 0 0.00043491728
the O 0 0.00050804386
phasic O 0 0.37382302
component O 0 0.00054133986
of O 0 0.0004908167
the O 0 0.00037080413
electrical O 0 0.2177652
field O 0 0.0010588474
stimulation O 0 0.0027454006
- O 0 0.0010753998
evoked O 0 0.09559577
contraction O 0 0.47588164
was O 0 0.00037017817
decreased O 0 0.0007790123
and O 0 0.0003785399
the O 0 0.0004858118
pirenzepine B-Chemical 0 0.9999032
and O 0 0.0009309651
4 B-Chemical 0 0.0005039237
- I-Chemical 0 0.001242828
DAMP I-Chemical 0 0.9756217
antagonism O 0 0.5514544
on O 0 0.0002657401
the O 0 0.00041324893
tonic O 0 0.39398345
component O 0 0.00064385426
was O 0 0.00049078395
much O 0 0.0003789965
less O 0 0.0006358048
efficient O 0 0.00086399046
than O 0 0.0009272007
in O 0 0.0018735086
controls O 0 0.0053290073
. O 0 0.005227748

In O 0 0.0031591707
contrast O 0 0.0023897635
to O 0 0.0017583483
controls O 0 0.0024183574
, O 0 0.0028153344
methoctramine B-Chemical 0 0.9994437
increased O 0 0.010766274
- O 0 0.0032800275
- O 0 0.00122699
instead O 0 0.00063655875
of O 0 0.0008359855
decreased O 0 0.0029053837
- O 0 0.0020663668
- O 0 0.0013611128
the O 0 0.00087060494
tonic O 0 0.3813477
responses O 0 0.002649869
at O 0 0.0011723908
high O 0 0.0031638516
frequencies O 0 0.004800251
. O 0 0.0060549183

While O 0 0.005382768
contractions O 0 0.6023597
to O 0 0.0032635399
carbachol B-Chemical 1 0.99698085
and O 0 0.003033079
ATP B-Chemical 1 0.9703085
were O 0 0.00089626445
the O 0 0.00048470398
same O 0 0.00027970437
in O 0 0.0004002431
inflamed O 0 0.00894672
and O 0 0.00042512565
in O 0 0.0002674683
control O 0 0.00025701598
strips O 0 0.001326736
when O 0 0.00019393448
related O 0 0.00022035112
to O 0 0.0002733826
a O 0 0.0004063228
reference O 0 0.0006171795
potassium B-Chemical 0 0.9989121
response O 0 0.0051672063
, O 0 0.0026422306
isoprenaline B-Chemical 0 0.99960583
- O 0 0.0041074613
induced O 0 0.0022704622
relaxations O 0 0.9962858
were O 0 0.0012480489
smaller O 0 0.001321415
in O 0 0.0018669191
inflamed O 0 0.06391335
strips O 0 0.028431838
. O 0 0.006329687

Thus O 0 0.0061339834
, O 0 0.005320839
in O 0 0.003895992
cystitis B-Disease 0 0.9978351
substantial O 0 0.004937589
changes O 0 0.0033305981
of O 0 0.002625923
the O 0 0.0027032204
efferent O 0 0.1852255
functional O 0 0.00602902
responses O 0 0.008973553
occur O 0 0.008682513
. O 0 0.008432412

While O 0 0.0069477847
postjunctional O 0 0.9883758
beta O 0 0.86852896
- O 0 0.022656783
adrenoceptor O 0 0.99918216
- O 0 0.010208226
mediated O 0 0.0017716839
relaxations O 0 0.9970919
are O 0 0.00118291
reduced O 0 0.0009804082
, O 0 0.0009987701
effects O 0 0.0015795105
by O 0 0.0012933919
prejunctional O 0 0.99647
inhibitory O 0 0.4430602
muscarinic O 0 0.998428
receptors O 0 0.5556802
may O 0 0.0034418306
be O 0 0.0035641002
increased O 0 0.007828828
. O 0 0.006728704

Direct O 0 0.010174998
inhibition O 0 0.007862262
of O 0 0.004023521
cardiac O 0 0.578759
hyperpolarization O 0 0.9918509
- O 0 0.005602046
activated O 0 0.0030899213
cyclic B-Chemical 0 0.6700219
nucleotide I-Chemical 0 0.32701448
- O 0 0.0045201075
gated O 0 0.0133911995
pacemaker O 0 0.39514008
channels O 0 0.08363641
by O 0 0.008726898
clonidine B-Chemical 1 0.99847823
. O 0 0.011860546

BACKGROUND O 0 0.82470906
: O 0 0.0064312248
Inhibition O 0 0.0086860685
of O 0 0.0024782936
cardiac O 0 0.33138844
sympathetic O 0 0.93136036
tone O 0 0.47120818
represents O 0 0.000789945
an O 0 0.0007173759
important O 0 0.00040338867
strategy O 0 0.00050371134
for O 0 0.00032005835
treatment O 0 0.00095552206
of O 0 0.0008382984
cardiovascular B-Disease 0 0.9887332
disease I-Disease 0 0.9199483
, O 0 0.0013688417
including O 0 0.0010373584
arrhythmia B-Disease 2 0.9991773
, O 0 0.0019571502
coronary B-Disease 0 0.8194167
heart I-Disease 0 0.7608189
disease I-Disease 0 0.82654566
, O 0 0.0021554015
and O 0 0.00214618
chronic O 0 0.9716322
heart B-Disease 0 0.92132473
failure I-Disease 0 0.89388317
. O 0 0.008112364

Activation O 0 0.020249203
of O 0 0.0048977626
presynaptic O 0 0.8197995
alpha2 O 0 0.94054836
- O 0 0.009397596
adrenoceptors O 0 0.9973539
is O 0 0.0011250093
the O 0 0.00057659997
most O 0 0.00081432046
widely O 0 0.0008255867
accepted O 0 0.0009703508
mechanism O 0 0.000521217
of O 0 0.0004632655
action O 0 0.0035198473
of O 0 0.0005186306
the O 0 0.0004585987
antisympathetic O 0 0.86620533
drug O 0 0.8836221
clonidine B-Chemical 1 0.9999224
; O 0 0.0038684465
however O 0 0.00068140903
, O 0 0.00037837902
other O 0 0.00024837238
target O 0 0.00028425036
proteins O 0 0.00057089893
have O 0 0.00035985548
been O 0 0.00046289313
postulated O 0 0.0011322761
to O 0 0.00037925455
contribute O 0 0.0004897402
to O 0 0.00045901118
the O 0 0.0005637382
in O 0 0.00075397734
vivo O 0 0.0023104635
actions O 0 0.036392037
of O 0 0.00880132
clonidine B-Chemical 1 0.99901927
. O 0 0.009642045

METHODS O 0 0.008112206
AND O 0 0.005054381
RESULTS O 0 0.009760564
: O 0 0.0022060208
To O 0 0.00083884853
test O 0 0.0009534958
whether O 0 0.00059676374
clonidine B-Chemical 1 0.99926656
elicits O 0 0.0036940319
pharmacological O 0 0.45516452
effects O 0 0.001725184
independent O 0 0.00036545444
of O 0 0.0012176514
alpha2 O 0 0.922851
- O 0 0.0061430363
adrenoceptors O 0 0.998836
, O 0 0.000627015
we O 0 0.00013548667
have O 0 0.00022091511
generated O 0 0.00015521265
mice O 0 0.00015318567
with O 0 0.00028246787
a O 0 0.0002795892
targeted O 0 0.00020945129
deletion O 0 0.00039118
of O 0 0.0003988251
all O 0 0.0003515257
3 O 0 0.0005043723
alpha2 O 0 0.6706472
- O 0 0.004545024
adrenoceptor O 0 0.99940395
subtypes O 0 0.28337723
( O 0 0.0035735893
alpha2ABC O 0 0.056430414
- O 0 0.004389587
/ O 0 0.006621741
- O 0 0.005772283
) O 0 0.0066923755
. O 0 0.0053518824

Alpha2ABC O 0 0.08711347
- O 0 0.0067753224
/ O 0 0.00473634
- O 0 0.0022182602
mice O 0 0.00067031913
were O 0 0.00067152514
completely O 0 0.0006704456
unresponsive O 0 0.0027102756
to O 0 0.0004952413
the O 0 0.0004996662
analgesic O 0 0.95748967
and O 0 0.0008144644
hypnotic O 0 0.99266595
effects O 0 0.0025176217
of O 0 0.001757883
clonidine B-Chemical 1 0.99989605
; O 0 0.0044686645
however O 0 0.0010859413
, O 0 0.0010486972
clonidine B-Chemical 1 0.9997999
significantly O 0 0.0012290956
lowered O 0 0.012963806
heart O 0 0.3835498
rate O 0 0.00050277193
in O 0 0.0005037025
alpha2ABC O 0 0.025739463
- O 0 0.0015276129
/ O 0 0.0017414163
- O 0 0.0009843132
mice O 0 0.0004199258
by O 0 0.0008097683
up O 0 0.001098234
to O 0 0.0015324301
150 O 0 0.0046315184
bpm O 0 0.016904488
. O 0 0.004684774

Clonidine B-Chemical 1 0.9992373
- O 0 0.013986723
induced O 0 0.0057596625
bradycardia B-Disease 0 0.9974865
in O 0 0.0017778971
conscious O 0 0.121161096
alpha2ABC O 0 0.051319294
- O 0 0.0021067325
/ O 0 0.0017948109
- O 0 0.000795527
mice O 0 0.00024439447
was O 0 0.00032159625
32 O 0 0.00049157446
. O 0 0.0001838177
3 O 0 0.00022239047
% O 0 0.0002869099
( O 0 0.00028881372
10 O 0 0.00023512013
microg O 0 0.0005842979
/ O 0 0.0006164252
kg O 0 0.0022768388
) O 0 0.00042043952
and O 0 0.0002557088
26 O 0 0.00037349586
. O 0 0.00014337274
6 O 0 0.00016881445
% O 0 0.0002528122
( O 0 0.0002805312
100 O 0 0.00045506662
microg O 0 0.00073559344
/ O 0 0.0007520634
kg O 0 0.0024021799
) O 0 0.0005022539
of O 0 0.00040410805
the O 0 0.00041900153
effect O 0 0.00069658307
in O 0 0.00073357386
wild O 0 0.0010369287
- O 0 0.0026286119
type O 0 0.0024561908
mice O 0 0.0028559107
. O 0 0.0052178833

A O 0 0.018451191
similar O 0 0.0033110627
bradycardic O 0 0.9957282
effect O 0 0.002537705
of O 0 0.0025343345
clonidine B-Chemical 1 0.99962556
was O 0 0.0013804446
observed O 0 0.00056042545
in O 0 0.00047905967
isolated O 0 0.0005952173
spontaneously O 0 0.010081264
beating O 0 0.03105541
right O 0 0.0022065707
atria O 0 0.314965
from O 0 0.00068083714
alpha2ABC O 0 0.012939863
- O 0 0.0012066851
knockout O 0 0.00080279587
and O 0 0.0010165249
wild O 0 0.0011477302
- O 0 0.0027764034
type O 0 0.002577273
mice O 0 0.0029881287
. O 0 0.0054387436

Clonidine B-Chemical 1 0.9990144
inhibited O 0 0.00981262
the O 0 0.0020694498
native O 0 0.0023958634
pacemaker O 0 0.104974225
current O 0 0.0028177851
( O 0 0.0017576739
I O 0 0.0033056163
( O 0 0.0010405504
f O 0 0.0012147825
) O 0 0.001050606
) O 0 0.00067088543
in O 0 0.00027606156
isolated O 0 0.00038638906
sinoatrial O 0 0.53710127
node O 0 0.0014201839
pacemaker O 0 0.10579314
cells O 0 0.0008283612
and O 0 0.000359637
the O 0 0.00034282575
I O 0 0.0022948529
( O 0 0.0005738132
f O 0 0.000877439
) O 0 0.00086909323
- O 0 0.00056930777
generating O 0 0.00041715387
hyperpolarization O 0 0.98479927
- O 0 0.0013750336
activated O 0 0.0009766234
cyclic B-Chemical 0 0.6701765
nucleotide I-Chemical 0 0.36743987
- O 0 0.0021425507
gated O 0 0.013567125
( O 0 0.0013759073
HCN O 0 0.9113617
) O 0 0.0013169196
2 O 0 0.0005788281
and O 0 0.00080088567
HCN4 O 0 0.89340574
channels O 0 0.01950006
in O 0 0.0013813678
transfected O 0 0.0040004775
HEK293 O 0 0.7304614
cells O 0 0.011650786
. O 0 0.006782414

As O 0 0.0024528925
a O 0 0.0023186575
consequence O 0 0.0014739457
of O 0 0.0018257432
blocking O 0 0.0050540944
I O 0 0.00926101
( O 0 0.0017575368
f O 0 0.0018983723
) O 0 0.0015996066
, O 0 0.0010833632
clonidine B-Chemical 1 0.9996226
reduced O 0 0.00072615314
the O 0 0.00037329295
slope O 0 0.0015838132
of O 0 0.00048017682
the O 0 0.00043345746
diastolic O 0 0.9726955
depolarization O 0 0.8035965
and O 0 0.0003623114
the O 0 0.00022885598
frequency O 0 0.0003019883
of O 0 0.00040522596
pacemaker O 0 0.12240937
potentials O 0 0.052002385
in O 0 0.00036595337
sinoatrial O 0 0.6696137
node O 0 0.0014164269
cells O 0 0.0008145118
from O 0 0.00040278962
wild O 0 0.00043077485
- O 0 0.0009754787
type O 0 0.00078928855
and O 0 0.001236903
alpha2ABC O 0 0.018588785
- O 0 0.0030304228
knockout O 0 0.0026090525
mice O 0 0.0029442203
. O 0 0.005297609

CONCLUSIONS O 0 0.7342133
: O 0 0.0056865267
Direct O 0 0.004940334
inhibition O 0 0.0042633875
of O 0 0.0020590767
cardiac O 0 0.46656102
HCN O 0 0.9737999
pacemaker O 0 0.6085089
channels O 0 0.049000636
contributes O 0 0.00069469627
to O 0 0.0004994137
the O 0 0.00059117423
bradycardic O 0 0.9990362
effects O 0 0.002176783
of O 0 0.0013484868
clonidine B-Chemical 1 0.9998673
gene O 0 0.0035785232
- O 0 0.0009081128
targeted O 0 0.0002288036
mice O 0 0.00017308752
in O 0 0.00022533488
vivo O 0 0.00065171334
, O 0 0.00041338426
and O 0 0.00033597383
thus O 0 0.0006276814
, O 0 0.0010093545
clonidine B-Chemical 1 0.99981314
- O 0 0.0016366123
like O 0 0.00051467295
drugs O 0 0.2782761
represent O 0 0.00053417863
novel O 0 0.0010869814
structures O 0 0.001393171
for O 0 0.0008612353
future O 0 0.0020369173
HCN O 0 0.94923884
channel O 0 0.3905129
inhibitors O 0 0.5207011
. O 0 0.009051534

Granulomatous B-Disease 0 0.9622694
hepatitis I-Disease 2 0.9977748
due O 0 0.004862357
to O 0 0.0036977404
combination B-Chemical 0 0.0067010694
of I-Chemical 0 0.007512974
amoxicillin I-Chemical 0 0.9963881
and I-Chemical 0 0.023252763
clavulanic I-Chemical 0 0.99769336
acid I-Chemical 0 0.98071474
. O 0 0.016899824

We O 0 0.003296761
report O 0 0.004191288
the O 0 0.0016687479
case O 0 0.0014267184
of O 0 0.0013945583
a O 0 0.0012915178
patient O 0 0.001914202
with O 0 0.0022278354
amoxicillin B-Chemical 0 0.99891806
- I-Chemical 0 0.03326831
clavulanic I-Chemical 0 0.9994561
acid I-Chemical 0 0.99136883
- O 0 0.0107884295
induced O 0 0.0099596
hepatitis B-Disease 2 0.9995486
with O 0 0.013744466
histologic O 0 0.88264346
multiple O 0 0.05356927
granulomas B-Disease 0 0.9760947
. O 0 0.010040399

This O 0 0.0048332848
type O 0 0.0024416603
of O 0 0.0022470732
lesion O 0 0.022211697
broadens O 0 0.005668967
the O 0 0.0009931631
spectrum O 0 0.0013723988
of O 0 0.001635378
liver B-Disease 0 0.9897138
injury I-Disease 0 0.9908353
due O 0 0.0005631273
to O 0 0.00046934347
this O 0 0.0004926983
drug O 0 0.17245848
combination O 0 0.0025725926
, O 0 0.0009874484
mainly O 0 0.0012400681
represented O 0 0.00092168077
by O 0 0.0013869365
a O 0 0.003470247
benign O 0 0.99293655
cholestatic B-Disease 0 0.99987113
syndrome I-Disease 0 0.9964696
. O 0 0.014897593

The O 0 0.0048205084
association O 0 0.0038948965
of O 0 0.006007373
granulomas B-Disease 0 0.81308603
and O 0 0.008641236
eosinophilia B-Disease 2 0.99213976
favor O 0 0.014823199
an O 0 0.012839755
immunoallergic O 0 0.9913032
mechanism O 0 0.025991745
. O 0 0.012745105

As O 0 0.0039433273
penicillin B-Chemical 1 0.99652785
derivatives O 0 0.39036116
and O 0 0.002891725
amoxicillin B-Chemical 0 0.99745005
alone O 0 0.0017584203
are O 0 0.00079512544
known O 0 0.0007842567
to O 0 0.00042139128
induce O 0 0.0003840923
such O 0 0.0003600109
types O 0 0.00043087115
of O 0 0.00063988566
lesions O 0 0.23669027
, O 0 0.0006543357
the O 0 0.00043029798
amoxicillin B-Chemical 0 0.9985934
component O 0 0.0007852487
, O 0 0.0005355725
with O 0 0.00038106332
or O 0 0.00025766913
without O 0 0.00034105367
a O 0 0.00044557676
potentiating O 0 0.08215678
effect O 0 0.00086280087
of O 0 0.0021379497
clavulanic B-Chemical 0 0.9995757
acid I-Chemical 0 0.98105305
, O 0 0.0018103783
might O 0 0.00078680704
have O 0 0.0012371902
a O 0 0.0019871537
major O 0 0.0034656525
role O 0 0.003706059
. O 0 0.006044958

Dobutamine B-Chemical 0 0.9960735
stress O 0 0.47485098
echocardiography O 0 0.56509864
: O 0 0.0030393808
a O 0 0.0012029873
sensitive O 0 0.0009461786
indicator O 0 0.00055055023
of O 0 0.0008393419
diminished O 0 0.002234439
myocardial O 0 0.9976439
function O 0 0.0019157404
in O 0 0.0007522982
asymptomatic O 0 0.41682228
doxorubicin B-Chemical 1 0.9994106
- O 0 0.0039215647
treated O 0 0.001525453
long O 0 0.0011123489
- O 0 0.0014020316
term O 0 0.0013173053
survivors O 0 0.012007769
of O 0 0.0047510453
childhood O 0 0.9636797
cancer B-Disease 2 0.9928813
. O 0 0.01115628

Doxorubicin B-Chemical 1 0.99742645
is O 0 0.0048445123
an O 0 0.003501616
effective O 0 0.004289006
anticancer O 0 0.96990955
chemotherapeutic O 0 0.9874427
agent O 0 0.5182676
known O 0 0.003688967
to O 0 0.002072476
cause O 0 0.018571803
acute O 0 0.9781668
and O 0 0.015691418
chronic O 0 0.99467176
cardiomyopathy B-Disease 2 0.9993444
. O 0 0.019602463

To O 0 0.0028138126
develop O 0 0.0027380872
a O 0 0.0017295124
more O 0 0.0014090079
sensitive O 0 0.0011140379
echocardiographic O 0 0.038324647
screening O 0 0.001003194
test O 0 0.00072967506
for O 0 0.00058906595
cardiac B-Disease 0 0.79358846
damage I-Disease 0 0.90709394
due O 0 0.00045822028
to O 0 0.0005511498
doxorubicin B-Chemical 1 0.99895346
, O 0 0.00072766846
a O 0 0.00034724598
cohort O 0 0.0008034238
study O 0 0.00038801171
was O 0 0.00020059176
performed O 0 0.00019910185
using O 0 0.00026415975
dobutamine B-Chemical 1 0.99932194
infusion O 0 0.08016113
to O 0 0.00034538357
differentiate O 0 0.0015650772
asymptomatic O 0 0.04582468
long O 0 0.00051826594
- O 0 0.00053690677
term O 0 0.00037660287
survivors O 0 0.003598431
of O 0 0.00085975876
childhood O 0 0.9014118
cancer B-Disease 2 0.9959168
treated O 0 0.006317501
with O 0 0.0024475765
doxorubicin B-Chemical 1 0.99866724
from O 0 0.0019401734
healthy O 0 0.012498806
control O 0 0.002106534
subjects O 0 0.0058073206
. O 0 0.0049293446

Echocardiographic O 0 0.29872054
data O 0 0.0028781728
from O 0 0.0013971219
the O 0 0.00094489363
experimental O 0 0.001171636
group O 0 0.0009116104
of O 0 0.00081478077
21 O 0 0.0008352688
patients O 0 0.0013602899
( O 0 0.0005492849
mean O 0 0.0002343929
age O 0 0.00073955563
16 O 0 0.0004546142
+ O 0 0.00051153626
/ O 0 0.0008675601
- O 0 0.00050159486
5 O 0 0.00020667395
years O 0 0.0004184511
) O 0 0.00035907485
treated O 0 0.0003554428
from O 0 0.00022065685
1 O 0 0.0002326611
. O 0 0.000115090304
6 O 0 0.00011872207
to O 0 0.00013646274
14 O 0 0.00019916642
. O 0 0.00010248194
3 O 0 0.00013519837
years O 0 0.0003015631
( O 0 0.00021499101
median O 0 0.00015695047
5 O 0 0.0001440206
. O 0 9.942218e-05
3 O 0 0.00013537743
) O 0 0.00020389631
before O 0 7.7799035e-05
this O 0 0.00013305907
study O 0 0.0002585477
with O 0 0.0002446318
27 O 0 0.00040071533
to O 0 0.00022731413
532 O 0 0.07429757
mg O 0 0.4014326
/ O 0 0.001111961
m2 O 0 0.019563127
of O 0 0.00059281394
doxorubicin B-Chemical 1 0.9991085
( O 0 0.00063316943
mean O 0 0.00019454584
196 O 0 0.0047699134
) O 0 0.00041674054
were O 0 0.00018907632
compared O 0 0.000125999
with O 0 0.0002806714
echocardiographic O 0 0.034361232
data O 0 0.00044583762
from O 0 0.00036467522
12 O 0 0.00033638242
normal O 0 0.00087599206
age O 0 0.0014246466
- O 0 0.001352959
matched O 0 0.0011353052
control O 0 0.0018213384
subjects O 0 0.005342407
. O 0 0.005018947

Graded O 0 0.27313268
dobutamine B-Chemical 1 0.9966074
infusions O 0 0.3203636
of O 0 0.0026556912
0 O 0 0.001546262
. O 0 0.00062598084
5 O 0 0.0005719698
, O 0 0.0006604701
2 O 0 0.00046650931
. O 0 0.00027790247
5 O 0 0.00031460318
, O 0 0.00040130253
5 O 0 0.00028036328
and O 0 0.00034910758
10 O 0 0.00048853306
micrograms O 0 0.032456473
/ O 0 0.0013199124
kg O 0 0.002501316
per O 0 0.0005983818
min O 0 0.0017901029
were O 0 0.0019942836
administered O 0 0.0064231222
. O 0 0.005076093

Echocardiographic O 0 0.365173
Doppler O 0 0.24630679
studies O 0 0.0028049734
were O 0 0.0012562196
performed O 0 0.00089289073
before O 0 0.0006074321
infusion O 0 0.00458599
and O 0 0.0007646019
after O 0 0.0004377056
15 O 0 0.0005627625
min O 0 0.00091917696
of O 0 0.0010355839
infusion O 0 0.008128283
at O 0 0.0011494763
each O 0 0.0015282247
rate O 0 0.0040581888
. O 0 0.0060228165

Dobutamine B-Chemical 0 0.995125
infusion O 0 0.08331564
at O 0 0.0014432609
10 O 0 0.0013879031
micrograms O 0 0.07684703
/ O 0 0.0015822253
kg O 0 0.0021351967
per O 0 0.00028744707
min O 0 0.0005706121
was O 0 0.00032372403
discontinued O 0 0.0022308582
after O 0 0.0001906833
six O 0 0.0002062804
studies O 0 0.00051840825
secondary O 0 0.0009089329
to O 0 0.0004455073
a O 0 0.0006050483
50 O 0 0.00089800986
% O 0 0.00076673983
incidence O 0 0.0021583748
rate O 0 0.0012006343
of O 0 0.0030786435
adverse O 0 0.89384675
symptoms O 0 0.79488236
. O 0 0.0076489896

The O 0 0.0027659722
most O 0 0.0027483357
important O 0 0.0013675744
findings O 0 0.00191797
were O 0 0.0007739205
that O 0 0.00047773888
compared O 0 0.0003084392
with O 0 0.00046169013
values O 0 0.0003751132
in O 0 0.00028671298
control O 0 0.00028893905
subjects O 0 0.0006713005
, O 0 0.00043875142
end O 0 0.00022342124
- O 0 0.0006675021
systolic O 0 0.48312092
left O 0 0.0014136892
ventricular O 0 0.9314403
posterior O 0 0.013220072
wall O 0 0.011471231
dimension O 0 0.00080657046
and O 0 0.00023392607
percent O 0 0.00017779597
of O 0 0.0003070204
left O 0 0.001337966
ventricular O 0 0.95752984
posterior O 0 0.034001663
wall O 0 0.072560206
thickening O 0 0.8231251
in O 0 0.00056307693
doxorubicin B-Chemical 1 0.99948174
- O 0 0.0017044863
treated O 0 0.0007294175
patients O 0 0.001040119
were O 0 0.00021267799
decreased O 0 0.00040883236
at O 0 0.00013420946
baseline O 0 0.00028921655
study O 0 0.00034721798
and O 0 0.00026204888
these O 0 0.0003957368
findings O 0 0.0008922941
were O 0 0.00044047792
more O 0 0.00064192095
clearly O 0 0.00067660003
delineated O 0 0.0023371254
with O 0 0.0032164063
dobutamine B-Chemical 1 0.9981761
stimulation O 0 0.04436944
. O 0 0.0067746905

End O 0 0.034187775
- O 0 0.0064524906
systolic O 0 0.43755877
left O 0 0.0046013314
ventricular O 0 0.9132752
posterior O 0 0.017521176
wall O 0 0.011773869
dimension O 0 0.001394304
at O 0 0.00030387362
baseline O 0 0.00047014427
for O 0 0.00029936992
the O 0 0.00047630767
doxorubicin B-Chemical 1 0.99895656
- O 0 0.0016929454
treated O 0 0.0008397927
group O 0 0.00048501085
was O 0 0.00034925624
11 O 0 0.0004324096
+ O 0 0.00046827583
/ O 0 0.0009190728
- O 0 0.00052106555
1 O 0 0.0002492031
. O 0 0.00012890346
9 O 0 0.00019224179
mm O 0 0.00058457494
versus O 0 0.00016971017
13 O 0 0.00025724547
. O 0 0.00013785441
1 O 0 0.0002486316
+ O 0 0.00034489908
/ O 0 0.00067956053
- O 0 0.000445523
1 O 0 0.00023308716
. O 0 0.00012490967
5 O 0 0.00016454124
mm O 0 0.00053691416
for O 0 0.0001497577
control O 0 0.00022519015
subjects O 0 0.0006038291
( O 0 0.000556996
p O 0 0.0006146477
less O 0 0.0005659547
than O 0 0.0005724347
0 O 0 0.0013358193
. O 0 0.0012777732
01 O 0 0.009411771
) O 0 0.0054661087
. O 0 0.005015588

End O 0 0.03416672
- O 0 0.0065015866
systolic O 0 0.43684474
left O 0 0.0046472508
ventricular O 0 0.91389346
posterior O 0 0.018134287
wall O 0 0.012688763
dimension O 0 0.0015025872
at O 0 0.00033782254
the O 0 0.00039259603
5 O 0 0.00038635117
- O 0 0.0006216478
micrograms O 0 0.06505903
/ O 0 0.0007013969
kg O 0 0.0012966427
per O 0 0.00013648838
min O 0 0.00045441746
dobutamine B-Chemical 1 0.9985648
infusion O 0 0.029886637
for O 0 0.00025740935
the O 0 0.0003949032
doxorubicin B-Chemical 1 0.9992879
- O 0 0.0014970766
treated O 0 0.00069566956
group O 0 0.00037901747
was O 0 0.00026314647
14 O 0 0.00029674708
. O 0 0.00014798979
1 O 0 0.00025651
+ O 0 0.00034293067
/ O 0 0.000668486
- O 0 0.0004115108
2 O 0 0.0002053093
. O 0 0.000111387235
4 O 0 0.00014813508
mm O 0 0.0005425135
versus O 0 0.00016033652
19 O 0 0.00031922242
. O 0 0.00012566686
3 O 0 0.0001896818
+ O 0 0.00031655972
/ O 0 0.00062432094
- O 0 0.00040141848
2 O 0 0.00020270649
. O 0 0.000108724045
6 O 0 0.00012499568
mm O 0 0.00045996005
for O 0 0.00011751465
control O 0 0.00016435758
subjects O 0 0.00043383037
( O 0 0.00035042406
p O 0 0.00034035693
less O 0 0.00027184834
than O 0 0.00022296586
0 O 0 0.00045810716
. O 0 0.0003392597
01 O 0 0.003049909
) O 0 0.0011683729
. O 0 0.00069282716
( O 0 0.001798655
ABSTRACT O 0 0.009826658
TRUNCATED O 0 0.017469637
AT O 0 0.021043388
250 O 0 0.010878716
WORDS O 0 0.019522639
) O 0 0.020833077

Influence O 0 0.024029857
of O 0 0.015523763
smoking B-Chemical 1 0.53264266
on O 0 0.012292047
developing O 0 0.042044416
cochlea O 0 0.24868114
. O 0 0.023311915

Does O 0 0.013387078
smoking B-Chemical 1 0.29357415
during O 0 0.002635459
pregnancy O 0 0.057979412
affect O 0 0.0016523988
the O 0 0.0017273088
amplitudes O 0 0.004793581
of O 0 0.0029879569
transient O 0 0.11050215
evoked O 0 0.57337373
otoacoustic O 0 0.99542326
emissions O 0 0.63766724
in O 0 0.0073300367
newborns O 0 0.057033096
? O 0 0.019115504

OBJECTIVE O 0 0.6410091
: O 0 0.008636311
Maternal O 0 0.038026057
tobacco O 0 0.08472285
smoking B-Chemical 1 0.63576096
has O 0 0.003376882
negative O 0 0.0032004595
effects O 0 0.0058293478
on O 0 0.0036655646
fetal O 0 0.294334
growth O 0 0.04115462
. O 0 0.011197823

The O 0 0.0025731346
influence O 0 0.0017938901
of O 0 0.0020720528
smoking B-Chemical 1 0.3891737
during O 0 0.0010389151
pregnancy O 0 0.092618786
on O 0 0.00050624035
the O 0 0.00061356777
developing O 0 0.0031960981
cochlea O 0 0.049617905
has O 0 0.0004992016
not O 0 0.00037693226
been O 0 0.0004351049
estimated O 0 0.0003565482
, O 0 0.00049625966
although O 0 0.000412878
smoking B-Chemical 1 0.53190434
has O 0 0.00057504175
been O 0 0.00066567026
positively O 0 0.0007858183
associated O 0 0.0011519267
with O 0 0.0018647779
hearing B-Disease 0 0.8200384
loss I-Disease 0 0.0067844354
in O 0 0.0030964112
adults O 0 0.011035214
. O 0 0.0057183816

The O 0 0.0025960957
objective O 0 0.0028590192
of O 0 0.0015466552
this O 0 0.0010440159
study O 0 0.0012502511
was O 0 0.0006469323
to O 0 0.00046358246
determine O 0 0.00024487285
the O 0 0.000389633
effects O 0 0.00082689046
of O 0 0.0007051112
maternal O 0 0.0036240385
smoking B-Chemical 1 0.7096446
on O 0 0.000551154
transient O 0 0.055254567
evoked O 0 0.40662006
otoacoustic O 0 0.9980757
emissions O 0 0.6938156
( O 0 0.003779621
TEOAEs O 0 0.73804975
) O 0 0.0027359438
of O 0 0.0028359012
healthy O 0 0.020518437
neonates O 0 0.03354675
. O 0 0.0066428552

METHODS O 0 0.0061813267
: O 0 0.0030746767
This O 0 0.0018917477
study O 0 0.0014572288
was O 0 0.00082475995
undertaken O 0 0.00063197996
as O 0 0.00049324
part O 0 0.00044603486
of O 0 0.0006884733
neonatal O 0 0.0067998082
screening O 0 0.00095965224
for O 0 0.00068796455
hearing B-Disease 0 0.7944875
impairment I-Disease 0 0.3620444
and O 0 0.0010574649
involved O 0 0.0009881468
both O 0 0.0012592808
ears O 0 0.006647596
of O 0 0.0028846897
200 O 0 0.008251248
newborns O 0 0.021942234
. O 0 0.0062932316

Newborns O 0 0.07114062
whose O 0 0.0039957077
mothers O 0 0.0036178674
reported O 0 0.0024508433
smoking B-Chemical 1 0.43972516
during O 0 0.0010076253
pregnancy O 0 0.23799175
( O 0 0.0012801819
n O 0 0.0005432765
= O 0 0.00069333974
200 O 0 0.00080255565
ears O 0 0.0019368532
) O 0 0.00052537373
were O 0 0.00022741861
compared O 0 0.00013692035
to O 0 0.00019152972
a O 0 0.00024653214
control O 0 0.00020219057
group O 0 0.00032828958
of O 0 0.00042550493
newborns O 0 0.006530909
( O 0 0.00060083525
n O 0 0.00034856886
= O 0 0.00056703
200 O 0 0.00080760673
ears O 0 0.0022023304
) O 0 0.00083913316
, O 0 0.0006470728
whose O 0 0.0009771852
mothers O 0 0.0016099318
were O 0 0.0012631401
non O 0 0.0038920562
- O 0 0.005812151
smokers O 0 0.08231394
. O 0 0.0059180497

Exposure O 0 0.08457667
to O 0 0.0029556437
tobacco O 0 0.025545184
was O 0 0.0016110198
characterized O 0 0.0016930873
as O 0 0.00073226495
low O 0 0.0010905213
( O 0 0.0009427036
< O 0 0.0005699277
5 O 0 0.00031133034
cigarettes O 0 0.020305293
per O 0 0.00019469856
day O 0 0.00030164013
, O 0 0.00037005873
n O 0 0.00026120176
= O 0 0.0004059012
88 O 0 0.0005334286
ears O 0 0.001772323
) O 0 0.0005883956
, O 0 0.00039048138
moderate O 0 0.0028254152
( O 0 0.00043602567
5 O 0 0.0001977842
< O 0 0.00023053047
or O 0 0.0001651111
= O 0 0.00034357797
cigarettes O 0 0.022805547
per O 0 0.00012719916
day O 0 0.00020234617
< O 0 0.00025032662
10 O 0 0.00020837365
, O 0 0.00024138052
n O 0 0.00019703411
= O 0 0.00033650338
76 O 0 0.00040997996
) O 0 0.00035105887
or O 0 0.00019194362
high O 0 0.00043880576
( O 0 0.00053676404
> O 0 0.00063191407
or O 0 0.00027124226
= O 0 0.0005123069
10 O 0 0.0003552186
cigarettes O 0 0.019975396
per O 0 0.00031757535
day O 0 0.00063534046
, O 0 0.001024812
n O 0 0.0011065576
= O 0 0.0023059282
36 O 0 0.002583031
) O 0 0.004843516
. O 0 0.0047092554

RESULTS O 0 0.02722026
: O 0 0.004223344
In O 0 0.0016734448
exposed O 0 0.0017279678
neonates O 0 0.0063752704
, O 0 0.0016133923
TEOAEs O 0 0.3316821
mean O 0 0.00047075868
response O 0 0.000964389
( O 0 0.0006183836
across O 0 0.00021988229
frequency O 0 0.0005104304
) O 0 0.0006478874
and O 0 0.00030793177
mean O 0 0.00021001561
amplitude O 0 0.001568622
at O 0 0.00027884805
4000Hz O 0 0.066740446
was O 0 0.00042050023
significantly O 0 0.0005384633
lower O 0 0.0005195784
than O 0 0.00044882376
in O 0 0.00079396856
non O 0 0.002831719
- O 0 0.0034582743
exposed O 0 0.003658845
neonates O 0 0.033516414
. O 0 0.005996742

Comparisons O 0 0.0051764064
between O 0 0.0027604194
exposed O 0 0.0039273384
newborns O 0 0.008147605
' O 0 0.0038902927
subgroups O 0 0.0047792713
revealed O 0 0.0035528566
no O 0 0.0034846903
significant O 0 0.005939757
differences O 0 0.0057551805
. O 0 0.009502995

However O 0 0.0039347284
, O 0 0.0025758212
by O 0 0.0012773715
comparing O 0 0.00058670633
each O 0 0.0004675446
subgroup O 0 0.0016271052
to O 0 0.00052519975
control O 0 0.00043390173
group O 0 0.00062295207
, O 0 0.000503102
we O 0 0.00019457754
found O 0 0.00031835173
statistically O 0 0.00037063492
significant O 0 0.00045689088
decreases B-Disease 0 0.00058855297
of I-Disease 0 0.00085344946
TEOAEs I-Disease 0 0.6620387
amplitudes I-Disease 0 0.003140735
at O 0 0.0006237392
4000Hz O 0 0.047841914
for O 0 0.00092976436
all O 0 0.0012804216
three O 0 0.0015519726
groups O 0 0.004588875
. O 0 0.0057847146

Mean O 0 0.0040362864
TEOAEs O 0 0.24262637
responses O 0 0.0034321244
of O 0 0.00184913
highly O 0 0.0018247736
exposed O 0 0.0013144754
newborns O 0 0.003495088
were O 0 0.0007492443
also O 0 0.0007354726
significantly O 0 0.0008320671
lower O 0 0.0007130287
in O 0 0.00066513696
comparison O 0 0.0007704525
to O 0 0.0010143408
our O 0 0.0013892369
control O 0 0.0023622003
group O 0 0.0054858266
. O 0 0.006196906

CONCLUSION O 0 0.8226853
: O 0 0.0052872445
In O 0 0.0019892144
utero O 0 0.0079589905
, O 0 0.0019133339
exposure O 0 0.0029101532
to O 0 0.0010277429
tobacco O 0 0.06599508
smoking B-Chemical 1 0.7644364
seems O 0 0.0010553236
to O 0 0.00061931455
have O 0 0.0006908746
a O 0 0.0008327314
small O 0 0.0010646351
impact O 0 0.001019483
on O 0 0.0012530861
outer O 0 0.01701201
hair O 0 0.277745
cells O 0 0.011158657
. O 0 0.0074343416

These O 0 0.004806547
effects O 0 0.0042028045
seem O 0 0.0023063559
to O 0 0.0012639216
be O 0 0.0010450443
equally O 0 0.00091393676
true O 0 0.0006708369
for O 0 0.00053276075
all O 0 0.00056899036
exposed O 0 0.00090367586
newborns O 0 0.0035411099
, O 0 0.0009097551
regardless O 0 0.0004736556
of O 0 0.0011835616
the O 0 0.0013542311
degree O 0 0.0027782419
of O 0 0.004506677
exposure O 0 0.030857397
. O 0 0.0074800104

Further O 0 0.004139659
studies O 0 0.0027751997
are O 0 0.0014515546
needed O 0 0.0007996602
in O 0 0.00067888
order O 0 0.00047119995
to O 0 0.0004679539
establish O 0 0.00042564553
a O 0 0.0004584492
potential O 0 0.00055110827
negative O 0 0.00044984234
effect O 0 0.000561257
of O 0 0.0007311353
maternal O 0 0.003784393
smoking B-Chemical 1 0.6520944
on O 0 0.0006149277
the O 0 0.0010588061
neonate O 0 0.023314524
' O 0 0.0024949908
s O 0 0.0044179484
hearing O 0 0.86784786
acuity O 0 0.9809698
. O 0 0.008903559

Simvastatin B-Chemical 0 0.99863416
- O 0 0.013053168
induced O 0 0.0055877515
bilateral O 0 0.12375106
leg O 0 0.06395784
compartment B-Disease 0 0.042262997
syndrome I-Disease 0 0.9831408
and O 0 0.0069650947
myonecrosis B-Disease 0 0.9977627
associated O 0 0.016214749
with O 0 0.023634812
hypothyroidism B-Disease 0 0.99771154
. O 0 0.014819801

A O 0 0.019990278
54 O 0 0.0060928822
- O 0 0.0036174653
year O 0 0.0019900172
- O 0 0.0022273858
old O 0 0.001600914
hypothyroid B-Disease 2 0.9278232
male O 0 0.0042432086
taking O 0 0.003354768
thyroxine B-Chemical 1 0.9976127
and O 0 0.002327395
simvastatin B-Chemical 1 0.9995977
presented O 0 0.0018256371
with O 0 0.001729383
bilateral O 0 0.2177895
leg O 0 0.08759851
compartment B-Disease 0 0.0674691
syndrome I-Disease 0 0.98898894
and O 0 0.01340306
myonecrosis B-Disease 0 0.99740076
. O 0 0.010661521

Urgent O 0 0.016489226
fasciotomies O 0 0.027521783
were O 0 0.0020508508
performed O 0 0.0013896351
and O 0 0.0012863067
the O 0 0.0009881754
patient O 0 0.001431841
made O 0 0.0009861131
an O 0 0.0011508809
uneventful O 0 0.00296294
recovery O 0 0.0025555305
with O 0 0.0018146657
the O 0 0.0023124823
withdrawal O 0 0.7476782
of O 0 0.015807616
simvastatin B-Chemical 1 0.99874556
. O 0 0.013658377

It O 0 0.0055782115
is O 0 0.0021652768
likely O 0 0.0012905279
that O 0 0.00087268936
this O 0 0.0009561577
complication O 0 0.084030926
will O 0 0.0005731095
be O 0 0.00056644256
seen O 0 0.0004042086
more O 0 0.00047531168
often O 0 0.0005728157
with O 0 0.00040726608
the O 0 0.00031913907
increased O 0 0.0006664587
worldwide O 0 0.0084822755
use O 0 0.00051609584
of O 0 0.00048511074
this O 0 0.0004575468
drug O 0 0.12336785
and O 0 0.00067695737
its O 0 0.0012885678
approval O 0 0.0018431919
for O 0 0.0009603936
all O 0 0.0020956662
arteriopathic B-Disease 0 0.9935562
patients O 0 0.03128384
. O 0 0.006528017

Neuroinflammation B-Disease 0 0.9718608
and O 0 0.005387033
behavioral B-Disease 0 0.27607363
abnormalities I-Disease 0 0.38832724
after O 0 0.0014313803
neonatal O 0 0.07319508
terbutaline B-Chemical 1 0.9992811
treatment O 0 0.014177582
in O 0 0.0019156801
rats O 0 0.007456348
: O 0 0.0033274654
implications O 0 0.003804655
for O 0 0.0040967553
autism B-Disease 0 0.86476195
. O 0 0.009032351

Autism B-Disease 0 0.8223904
is O 0 0.003693081
a O 0 0.0032616328
neurodevelopmental B-Disease 0 0.9735632
disorder I-Disease 0 0.98156655
presenting O 0 0.03086015
before O 0 0.00053609954
3 O 0 0.00047509742
years O 0 0.0006837164
of O 0 0.00050957303
age O 0 0.0010007628
with O 0 0.000750136
deficits B-Disease 0 0.25964043
in I-Disease 0 0.0006562796
communication I-Disease 0 0.0019247064
and I-Disease 0 0.0011014894
social I-Disease 0 0.015434997
skills I-Disease 0 0.005379506
and O 0 0.002544335
repetitive B-Disease 0 0.075785674
behaviors I-Disease 0 0.36332458
. O 0 0.0067557734

In O 0 0.0027654683
addition O 0 0.0014878962
to O 0 0.0013499415
genetic O 0 0.0020232766
influences O 0 0.001153438
, O 0 0.0010064782
recent O 0 0.00074214104
studies O 0 0.00083880546
suggest O 0 0.00044364328
that O 0 0.0005046495
prenatal O 0 0.013763392
drug O 0 0.25210935
or O 0 0.00078522135
chemical O 0 0.027582418
exposures O 0 0.03655041
are O 0 0.00152191
risk O 0 0.02616139
factors O 0 0.008051162
for O 0 0.003886961
autism B-Disease 0 0.9190214
. O 0 0.007627192

Terbutaline B-Chemical 0 0.99606496
, O 0 0.00690807
a O 0 0.0040726434
beta2 O 0 0.93312615
- O 0 0.0121098105
adrenoceptor O 0 0.99930406
agonist O 0 0.9903604
used O 0 0.0013293409
to O 0 0.00095769356
arrest O 0 0.45704803
preterm B-Disease 0 0.9487722
labor I-Disease 0 0.80395144
, O 0 0.0011377394
has O 0 0.00055318925
been O 0 0.00060804427
associated O 0 0.0006667916
with O 0 0.0006739181
increased O 0 0.0011061765
concordance O 0 0.0011544939
for O 0 0.0012375609
autism B-Disease 0 0.80750614
in O 0 0.0024523733
dizygotic O 0 0.03523847
twins O 0 0.047777932
. O 0 0.007336198

We O 0 0.0033721416
studied O 0 0.002873932
the O 0 0.0016883163
effects O 0 0.0024797288
of O 0 0.0024166165
terbutaline B-Chemical 1 0.99934465
on O 0 0.0012636813
microglial O 0 0.8676923
activation O 0 0.0037909748
in O 0 0.0006098057
different O 0 0.0007135855
brain O 0 0.024692457
regions O 0 0.0009793097
and O 0 0.00092530163
behavioral O 0 0.017327068
outcomes O 0 0.0027838408
in O 0 0.0018600816
developing O 0 0.01116203
rats O 0 0.019818798
. O 0 0.0061667883

Newborn O 0 0.01736904
rats O 0 0.0067701964
were O 0 0.0020396186
given O 0 0.0015836617
terbutaline B-Chemical 1 0.9988747
( O 0 0.0026795566
10 O 0 0.0010587582
mg O 0 0.27766693
/ O 0 0.0015712581
kg O 0 0.0048673246
) O 0 0.00068866974
daily O 0 0.0007630621
on O 0 0.0002132701
postnatal O 0 0.0016354946
days O 0 0.00038756078
( O 0 0.0005762911
PN O 0 0.16253547
) O 0 0.0006028463
2 O 0 0.0002525674
to O 0 0.00019922547
5 O 0 0.00019135883
or O 0 0.00019709402
PN O 0 0.047686413
11 O 0 0.000280824
to O 0 0.00018428468
14 O 0 0.00023164265
and O 0 0.000192394
examined O 0 0.00016819571
24 O 0 0.00023091762
h O 0 0.0002442901
after O 0 0.00017231604
the O 0 0.00031553526
last O 0 0.00043301107
dose O 0 0.0041976105
and O 0 0.0013171962
at O 0 0.0014386338
PN O 0 0.20361002
30 O 0 0.003951081
. O 0 0.0047402973

Immunohistochemical O 0 0.0521369
studies O 0 0.0038608392
showed O 0 0.0018578492
that O 0 0.0012756049
administration O 0 0.054677356
of O 0 0.0022234016
terbutaline B-Chemical 1 0.9994855
on O 0 0.00084121106
PN O 0 0.4357347
2 O 0 0.0005459004
to O 0 0.00032310362
5 O 0 0.00024671177
produced O 0 0.00024299802
a O 0 0.00028614173
robust O 0 0.00028578617
increase O 0 0.00031178212
in O 0 0.00035481196
microglial O 0 0.70449835
activation O 0 0.0020429464
on O 0 0.000247326
PN O 0 0.2048814
30 O 0 0.00029655476
in O 0 0.00023902822
the O 0 0.00036174068
cerebral O 0 0.8758912
cortex O 0 0.37952432
, O 0 0.0005671138
as O 0 0.00030328607
well O 0 0.00035819205
as O 0 0.00047389607
in O 0 0.00085998274
cerebellar O 0 0.782064
and O 0 0.002954566
cerebrocortical O 0 0.99332786
white O 0 0.040054012
matter O 0 0.026051931
. O 0 0.006366994

None O 0 0.008519641
of O 0 0.0032662211
these O 0 0.0028225803
effects O 0 0.0031324483
occurred O 0 0.0019305613
in O 0 0.0011841829
animals O 0 0.0012069955
given O 0 0.0015176863
terbutaline B-Chemical 1 0.99851996
on O 0 0.0023815935
PN O 0 0.41175362
11 O 0 0.003798156
to O 0 0.003368997
14 O 0 0.0059107943
. O 0 0.0061220936

In O 0 0.003147439
behavioral O 0 0.009706941
tests O 0 0.0034999861
, O 0 0.0017772508
animals O 0 0.00094142626
treated O 0 0.0014945404
with O 0 0.0013893778
terbutaline B-Chemical 1 0.9994393
on O 0 0.0006785547
PN O 0 0.3967214
2 O 0 0.00047458164
to O 0 0.00028542976
5 O 0 0.00021977938
showed O 0 0.0002048092
consistent O 0 0.00024601183
patterns O 0 0.00026304263
of O 0 0.0005332949
hyper O 0 0.44534326
- O 0 0.0011367715
reactivity O 0 0.0020692958
to O 0 0.0003099582
novelty O 0 0.036175013
and O 0 0.00039982898
aversive O 0 0.20645101
stimuli O 0 0.00148581
when O 0 0.00015459493
assessed O 0 0.00017173063
in O 0 0.00018483934
a O 0 0.0002516053
novel O 0 0.00044487708
open O 0 0.0002869884
field O 0 0.00059175433
, O 0 0.00047082017
as O 0 0.0002823728
well O 0 0.0003374493
as O 0 0.0004154561
in O 0 0.00059589016
the O 0 0.0010285573
acoustic O 0 0.087014705
startle O 0 0.9563701
response O 0 0.0055451766
test O 0 0.0056666723
. O 0 0.0061425674

Our O 0 0.0035744284
findings O 0 0.0037360233
indicate O 0 0.0014967046
that O 0 0.0016477894
beta2 O 0 0.9196319
- O 0 0.011161293
adrenoceptor O 0 0.9995241
overstimulation O 0 0.9967878
during O 0 0.00064433157
an O 0 0.00067761313
early O 0 0.00080017775
critical O 0 0.00036955456
period O 0 0.0003293492
results O 0 0.00031271687
in O 0 0.00036053077
microglial O 0 0.7032325
activation O 0 0.0024675801
associated O 0 0.0007565684
with O 0 0.0008453332
innate O 0 0.23114681
neuroinflammatory O 0 0.9948579
pathways O 0 0.010600103
and O 0 0.00081406446
behavioral B-Disease 0 0.46159464
abnormalities I-Disease 0 0.67778075
, O 0 0.0008638621
similar O 0 0.00046118084
to O 0 0.0006846576
those O 0 0.0013494297
described O 0 0.0014383654
in O 0 0.0029301026
autism B-Disease 0 0.8421795
. O 0 0.0067462483

This O 0 0.0044350326
study O 0 0.002814515
provides O 0 0.0014530075
a O 0 0.0013760306
useful O 0 0.0013569676
animal O 0 0.0015197702
model O 0 0.0011583135
for O 0 0.0007332971
understanding O 0 0.0010016068
the O 0 0.001112015
neuropathological O 0 0.72829914
processes O 0 0.006012868
underlying O 0 0.014595933
autism B-Disease 0 0.97575766
spectrum I-Disease 0 0.020413334
disorders I-Disease 0 0.9642847
. O 0 0.010030053

Upregulation O 0 0.09801519
of O 0 0.004033665
brain O 0 0.038692422
expression O 0 0.0030055027
of O 0 0.0022367407
P O 0 0.18403617
- O 0 0.003025649
glycoprotein O 0 0.4465905
in O 0 0.001441945
MRP2 O 0 0.9994529
- O 0 0.004176671
deficient O 0 0.0009361303
TR O 0 0.9458554
( O 0 0.0018085755
- O 0 0.0012042841
) O 0 0.00076749723
rats O 0 0.0022731328
resembles O 0 0.0009205754
seizure B-Disease 2 0.99925035
- O 0 0.0017415398
induced O 0 0.00068188907
up O 0 0.00045756818
- O 0 0.0005912562
regulation O 0 0.0002793329
of O 0 0.00047024264
this O 0 0.00061514735
drug O 0 0.4935223
efflux O 0 0.65514857
transporter O 0 0.38534275
in O 0 0.0021084812
normal O 0 0.00703621
rats O 0 0.016438799
. O 0 0.0057851584

PURPOSE O 0 0.04008501
: O 0 0.004271235
The O 0 0.001844192
multidrug O 0 0.5973223
resistance O 0 0.017656302
protein O 0 0.003590544
2 O 0 0.0012927626
( O 0 0.0018140353
MRP2 O 0 0.99888605
) O 0 0.0018736931
is O 0 0.00047980415
a O 0 0.0005222706
drug O 0 0.42125624
efflux O 0 0.6007164
transporter O 0 0.26341677
that O 0 0.00030979747
is O 0 0.00026987947
expressed O 0 0.00017518793
predominantly O 0 0.0003371729
at O 0 0.00014647751
the O 0 0.00021413219
apical O 0 0.0006552528
domain O 0 0.00032692257
of O 0 0.00040122107
hepatocytes O 0 0.36623776
but O 0 0.00032007758
seems O 0 0.0002638162
also O 0 0.00022440717
to O 0 0.00018050222
be O 0 0.00018798355
expressed O 0 0.00012585896
at O 0 0.000120242024
the O 0 0.00019130029
apical O 0 0.0006147622
membrane O 0 0.0028512322
of O 0 0.0005411875
brain O 0 0.09157732
capillary O 0 0.2030066
endothelial O 0 0.9267703
cells O 0 0.0013903653
that O 0 0.00034449864
form O 0 0.0005263614
the O 0 0.000580197
blood O 0 0.011599817
- O 0 0.0023492754
brain O 0 0.092212126
barrier O 0 0.04403368
( O 0 0.0069736717
BBB O 0 0.9836907
) O 0 0.010170767
. O 0 0.0061248676

MRP2 O 0 0.9946898
is O 0 0.0037778514
absent O 0 0.0019525768
in O 0 0.0012579005
the O 0 0.0012009551
transport O 0 0.012866969
- O 0 0.0019413882
deficient O 0 0.0009163565
( O 0 0.0016505464
TR O 0 0.89329594
( O 0 0.0017875392
- O 0 0.0013518493
) O 0 0.0009484053
) O 0 0.0007749496
Wistar O 0 0.12670329
rat O 0 0.0022554907
mutant O 0 0.00020530637
, O 0 0.00032858457
so O 0 0.0001956137
that O 0 0.0001700004
this O 0 0.00022807483
rat O 0 0.0022711514
strain O 0 0.00024535405
was O 0 0.00022104576
very O 0 0.0002856794
helpful O 0 0.00042423664
in O 0 0.00017889503
defining O 0 0.00027314867
substrates O 0 0.0008230346
of O 0 0.000659089
MRP2 O 0 0.9993912
by O 0 0.00040656864
comparing O 0 0.0001777287
tissue O 0 0.0046702004
concentrations O 0 0.0018359779
or O 0 0.00023229381
functional O 0 0.000469477
activities O 0 0.00050423766
of O 0 0.00050054153
compounds O 0 0.6148976
in O 0 0.0008139981
MRP2 O 0 0.99959296
- O 0 0.001908869
deficient O 0 0.00046934144
rats O 0 0.002192003
with O 0 0.0006657959
those O 0 0.0009455676
in O 0 0.00084808114
transport O 0 0.012223542
- O 0 0.0030307847
competent O 0 0.0025859661
Wistar O 0 0.28836426
rats O 0 0.011750523
. O 0 0.005833168

By O 0 0.0045318836
using O 0 0.0019104814
this O 0 0.0013940539
strategy O 0 0.001358247
to O 0 0.0008591117
study O 0 0.0010694666
the O 0 0.0006377204
involvement O 0 0.0014615065
of O 0 0.0013229921
MRP2 O 0 0.9992248
in O 0 0.00082119374
brain O 0 0.051190004
access O 0 0.0005603344
of O 0 0.0008501573
antiepileptic O 0 0.9992211
drugs O 0 0.9248702
( O 0 0.002484613
AEDs O 0 0.9794926
) O 0 0.0008386324
, O 0 0.0003572675
we O 0 0.00014423538
recently O 0 0.0004434724
reported O 0 0.00065638876
that O 0 0.00057625846
phenytoin B-Chemical 1 0.9998099
is O 0 0.0009276359
a O 0 0.00094229495
substrate O 0 0.0028733434
for O 0 0.001609276
MRP2 O 0 0.9976903
in O 0 0.003365224
the O 0 0.00581612
BBB O 0 0.98294294
. O 0 0.008381096

However O 0 0.0039456952
, O 0 0.002504752
one O 0 0.0010608279
drawback O 0 0.0015780345
of O 0 0.0010653787
such O 0 0.0007942523
studies O 0 0.0011182949
in O 0 0.00054207235
genetically O 0 0.0016311466
deficient O 0 0.0005169196
rats O 0 0.0020923882
is O 0 0.00037259914
the O 0 0.00028309767
fact O 0 0.00026748766
that O 0 0.0002941562
compensatory O 0 0.0011614127
changes O 0 0.0008191168
with O 0 0.00077001506
upregulation O 0 0.0026344839
of O 0 0.0013821529
other O 0 0.0019900098
transporters O 0 0.2866325
can O 0 0.0029285317
occur O 0 0.005951814
. O 0 0.005927022

This O 0 0.004460466
prompted O 0 0.0026308317
us O 0 0.0020544748
to O 0 0.0011439403
study O 0 0.0013688644
the O 0 0.0008575096
brain O 0 0.017154247
expression O 0 0.0013750899
of O 0 0.001210306
P O 0 0.20410281
- O 0 0.0023668085
glycoprotein O 0 0.5863599
( O 0 0.002501442
Pgp O 0 0.9973231
) O 0 0.0014591506
, O 0 0.0004768551
a O 0 0.00033120313
major O 0 0.0005010618
drug O 0 0.50447446
efflux O 0 0.6169128
transporter O 0 0.26963624
in O 0 0.00031903718
many O 0 0.00040617326
tissues O 0 0.0016110046
, O 0 0.00043253868
including O 0 0.00032964005
the O 0 0.00047209376
BBB O 0 0.98720723
, O 0 0.0007473692
in O 0 0.00045616133
TR O 0 0.910557
( O 0 0.0012194553
- O 0 0.00093083025
) O 0 0.0006240788
rats O 0 0.0010552171
compared O 0 0.00021937174
with O 0 0.00057980785
nonmutant O 0 0.069192275
( O 0 0.0012505964
wild O 0 0.0008102194
- O 0 0.002021219
type O 0 0.0019589104
) O 0 0.0050486657
Wistar O 0 0.33554876
rats O 0 0.012841351
. O 0 0.006033234

METHODS O 0 0.006366493
: O 0 0.003181995
The O 0 0.0013545208
expression O 0 0.001859046
of O 0 0.002066582
MRP2 O 0 0.99837494
and O 0 0.002556502
Pgp O 0 0.99538285
in O 0 0.0008787316
brain O 0 0.036782388
and O 0 0.0007120635
liver O 0 0.5354519
sections O 0 0.0010621055
of O 0 0.0009872839
TR O 0 0.947467
( O 0 0.0015944063
- O 0 0.0010124745
) O 0 0.0005989113
rats O 0 0.0010998076
and O 0 0.00027967425
normal O 0 0.0006994038
Wistar O 0 0.11720762
rats O 0 0.0009676135
was O 0 0.00020936102
determined O 0 0.00015951658
with O 0 0.00029729586
immunohistochemistry O 0 0.006839847
, O 0 0.00044527376
by O 0 0.0002820911
using O 0 0.00023120777
a O 0 0.0003321784
novel O 0 0.000662471
, O 0 0.00049368944
highly O 0 0.00061577576
selective O 0 0.006207361
monoclonal O 0 0.04712569
MRP2 O 0 0.99936193
antibody O 0 0.007048143
and O 0 0.000991469
the O 0 0.0009999169
monoclonal O 0 0.04051109
Pgp O 0 0.99535984
antibody O 0 0.028979622
C219 O 0 0.7050229
, O 0 0.007824917
respectively O 0 0.012017429
. O 0 0.007154492

RESULTS O 0 0.027104162
: O 0 0.0045974385
Immunofluorescence O 0 0.010871719
staining O 0 0.0024583577
with O 0 0.0016182762
the O 0 0.0014978802
MRP2 O 0 0.99842334
antibody O 0 0.005815817
was O 0 0.0007647346
found O 0 0.000472476
to O 0 0.00037767808
label O 0 0.00089831895
a O 0 0.00036553427
high O 0 0.00038763683
number O 0 0.00024487215
of O 0 0.00042980886
microvessels O 0 0.17142761
throughout O 0 0.00023887216
the O 0 0.00030085206
brain O 0 0.016757922
in O 0 0.00028066686
normal O 0 0.00095962256
Wistar O 0 0.19640885
rats O 0 0.0017320316
, O 0 0.00042304976
whereas O 0 0.0002865747
such O 0 0.00034384112
labeling O 0 0.0011802106
was O 0 0.0005368374
absent O 0 0.00066708133
in O 0 0.0010283147
TR O 0 0.8537742
( O 0 0.0034107699
- O 0 0.0042134547
) O 0 0.004854268
rats O 0 0.011061524
. O 0 0.005603645

TR O 0 0.86872417
( O 0 0.007637221
- O 0 0.00431074
) O 0 0.00246768
rats O 0 0.0028406435
exhibited O 0 0.00094741816
a O 0 0.00080409163
significant O 0 0.00084367476
up O 0 0.0006641472
- O 0 0.000839978
regulation O 0 0.00039433647
of O 0 0.00079032034
Pgp O 0 0.99458176
in O 0 0.0006844364
brain O 0 0.09244651
capillary O 0 0.21845546
endothelial O 0 0.9265761
cells O 0 0.0019111725
compared O 0 0.00046584627
with O 0 0.0009832227
wild O 0 0.0011046438
- O 0 0.002746811
type O 0 0.0026618126
controls O 0 0.006261847
. O 0 0.0056551015

No O 0 0.007954278
such O 0 0.003833155
obvious O 0 0.0034514954
upregulation O 0 0.0061333124
of O 0 0.004897326
Pgp O 0 0.9893707
was O 0 0.0036066573
observed O 0 0.00278434
in O 0 0.0043181516
liver O 0 0.6899729
sections O 0 0.013903021
. O 0 0.010040436

A O 0 0.013546159
comparable O 0 0.0021877342
overexpression O 0 0.0035201968
of O 0 0.0027945961
Pgp O 0 0.9915719
in O 0 0.001398238
the O 0 0.0013615658
BBB O 0 0.97478163
was O 0 0.00091290026
obtained O 0 0.0007049256
after O 0 0.00066568993
pilocarpine B-Chemical 1 0.9997105
- O 0 0.0059216022
induced O 0 0.0044053984
seizures B-Disease 2 0.99965715
in O 0 0.0014459905
wild O 0 0.00136704
- O 0 0.003206172
type O 0 0.003214647
Wistar O 0 0.42746657
rats O 0 0.014959398
. O 0 0.006390458

Experiments O 0 0.0067779287
with O 0 0.003354459
systemic O 0 0.5711768
administration O 0 0.16446511
of O 0 0.0020032045
the O 0 0.0015985065
Pgp O 0 0.99679047
substrate O 0 0.056243546
phenobarbital B-Chemical 0 0.99991703
and O 0 0.001644238
the O 0 0.000739426
selective O 0 0.055928838
Pgp O 0 0.998632
inhibitor O 0 0.7110287
tariquidar B-Chemical 0 0.9997588
in O 0 0.0015965765
TR O 0 0.97622865
( O 0 0.0019628147
- O 0 0.001086877
) O 0 0.00061779266
rats O 0 0.0011687052
substantiated O 0 0.0012355526
that O 0 0.00037711623
Pgp O 0 0.9919248
is O 0 0.00042716492
functional O 0 0.0005891838
and O 0 0.0003704413
compensates O 0 0.00038438168
for O 0 0.00037413693
the O 0 0.00051589595
lack O 0 0.00080420426
of O 0 0.0025182036
MRP2 O 0 0.9980379
in O 0 0.003552808
the O 0 0.0060817488
BBB O 0 0.9842153
. O 0 0.008414904

CONCLUSIONS O 0 0.6702149
: O 0 0.0049504163
The O 0 0.0017559219
data O 0 0.001844487
on O 0 0.0011681019
TR O 0 0.7668886
( O 0 0.0026355542
- O 0 0.0017753696
) O 0 0.0010930882
rats O 0 0.0013746342
indicate O 0 0.00035211368
that O 0 0.0004978782
Pgp O 0 0.9905992
plays O 0 0.00083053985
an O 0 0.00070262427
important O 0 0.0004228707
role O 0 0.00034205336
in O 0 0.00042948883
the O 0 0.0005357749
compensation O 0 0.0022174793
of O 0 0.002797751
MRP2 O 0 0.9990134
deficiency O 0 0.8560299
in O 0 0.0040409938
the O 0 0.0067817755
BBB O 0 0.9855466
. O 0 0.0088778185

Because O 0 0.002968412
such O 0 0.002112927
a O 0 0.0018613081
compensatory O 0 0.0027129564
mechanism O 0 0.0015919254
most O 0 0.0013808274
likely O 0 0.0006259424
occurs O 0 0.0005247176
to O 0 0.00044810772
reduce O 0 0.00048547692
injury B-Disease 0 0.65995616
to I-Disease 0 0.00045690002
the I-Disease 0 0.00041055042
brain I-Disease 0 0.026888214
from O 0 0.0004668231
cytotoxic O 0 0.6596697
compounds O 0 0.6610159
, O 0 0.0005399784
the O 0 0.0002337446
present O 0 0.00018029098
data O 0 0.00029723014
substantiate O 0 0.00043692143
the O 0 0.0003290586
concept O 0 0.0008712639
that O 0 0.0006484758
MRP2 O 0 0.99864453
performs O 0 0.0013201041
a O 0 0.0013125081
protective O 0 0.008533935
role O 0 0.0014164275
in O 0 0.0024034532
the O 0 0.005040478
BBB O 0 0.9818397
. O 0 0.008304206

Furthermore O 0 0.0048989435
, O 0 0.00276897
our O 0 0.001317181
data O 0 0.0013534352
suggest O 0 0.00086862047
that O 0 0.0010697946
TR O 0 0.884343
( O 0 0.0023738989
- O 0 0.0015304157
) O 0 0.0009261492
rats O 0 0.0013887852
are O 0 0.00032616325
an O 0 0.00034531043
interesting O 0 0.00018780635
tool O 0 0.00029258628
to O 0 0.00020879565
study O 0 0.00038068934
consequences O 0 0.00058264507
of O 0 0.00037823385
overexpression O 0 0.0012923725
of O 0 0.0009129229
Pgp O 0 0.9974105
in O 0 0.00041648155
the O 0 0.0004752102
BBB O 0 0.97354454
on O 0 0.00019462877
access O 0 0.00029945042
of O 0 0.00039102882
drugs O 0 0.40327388
in O 0 0.000283582
the O 0 0.00029274335
brain O 0 0.028301105
, O 0 0.00037148563
without O 0 0.00024474238
the O 0 0.00021460373
need O 0 0.00021796797
of O 0 0.00042731583
inducing O 0 0.0047684424
seizures B-Disease 2 0.99979633
or O 0 0.00068546616
other O 0 0.001232871
Pgp O 0 0.9971355
- O 0 0.0020280231
enhancing O 0 0.001426033
events O 0 0.0051716594
for O 0 0.0012349674
this O 0 0.0022177957
purpose O 0 0.0040370002
. O 0 0.0047840117

Role O 0 0.016336817
of O 0 0.010830141
xanthine B-Chemical 0 0.99882835
oxidase O 0 0.99309546
in O 0 0.012108117
dexamethasone B-Chemical 0 0.9979867
- O 0 0.030105785
induced O 0 0.018882101
hypertension B-Disease 2 0.99827707
in O 0 0.0097859055
rats O 0 0.046882693
. O 0 0.010234821

1 O 0 0.08232081
. O 0 0.074582

Glucocorticoid O 0 0.9925333
- O 0 0.0127072465
induced O 0 0.00876157
hypertension B-Disease 2 0.99902785
( O 0 0.010225542
GC O 0 0.47720394
- O 0 0.007448993
HT B-Disease 0 0.98399585
) O 0 0.002150145
in O 0 0.00066602405
the O 0 0.0007176118
rat O 0 0.004643904
is O 0 0.00096638134
associated O 0 0.0016371335
with O 0 0.0031620117
nitric B-Chemical 0 0.9983316
oxide I-Chemical 0 0.9976737
- O 0 0.06229295
redox O 0 0.8405488
imbalance O 0 0.46987626
. O 0 0.010889936

2 O 0 0.0815455
. O 0 0.074968144

We O 0 0.003608573
studied O 0 0.0031292397
the O 0 0.0018487584
role O 0 0.0014115833
of O 0 0.003321105
xanthine B-Chemical 0 0.99973875
oxidase O 0 0.9983188
( O 0 0.057003025
XO O 0 0.99964356
) O 0 0.008693503
, O 0 0.0011035978
which O 0 0.0007533338
is O 0 0.0004537145
implicated O 0 0.000521731
in O 0 0.00033547933
the O 0 0.00034363774
production O 0 0.00087875087
of O 0 0.0007565468
reactive O 0 0.49952698
oxygen O 1 0.9902615
species O 0 0.003006436
, O 0 0.0011687813
in O 0 0.0008300279
dexamethasone B-Chemical 0 0.99905676
- O 0 0.0073058167
induced O 0 0.009037247
hypertension B-Disease 2 0.9996358
( O 0 0.032465525
dex B-Chemical 1 0.9975212
- O 0 0.0461399
HT B-Disease 0 0.98895246
) O 0 0.014249372
. O 0 0.006926695

3 O 0 0.07487772
. O 0 0.072802074

Thirty O 0 0.012503033
male O 0 0.010496582
Sprague O 0 0.25867572
- O 0 0.0040967474
Dawley O 0 0.10675918
rats O 0 0.0024542054
were O 0 0.0006538616
divided O 0 0.0003764699
randomly O 0 0.0002360669
into O 0 0.00024650065
four O 0 0.00026104343
treatment O 0 0.00088511605
groups O 0 0.0006868541
: O 0 0.0009797487
saline O 0 0.12015164
, O 0 0.0015125438
dexamethasone B-Chemical 0 0.9990355
( O 0 0.0051304717
dex B-Chemical 1 0.99802715
) O 0 0.0037642336
, O 0 0.0017245952
allopurinol B-Chemical 0 0.9997558
plus O 0 0.0020267575
saline O 0 0.3456812
, O 0 0.0021375257
and O 0 0.0028772284
allopurinol B-Chemical 0 0.9995154
plus O 0 0.024603268
dex B-Chemical 1 0.99475926
. O 0 0.009851465

4 O 0 0.07327224
. O 0 0.07212598

Systolic O 0 0.8773586
blood O 0 0.018278046
pressures O 0 0.018753229
( O 0 0.005261269
SBP O 0 0.31357715
) O 0 0.0032639334
and O 0 0.0018953047
bodyweights O 0 0.013477104
were O 0 0.0017835048
recorded O 0 0.0022036405
each O 0 0.0017427314
alternate O 0 0.005731964
day O 0 0.0065927627
. O 0 0.00808342

Thymus O 0 0.5042343
weight O 0 0.010243254
was O 0 0.0022190476
used O 0 0.0014184045
as O 0 0.0009858476
a O 0 0.001101736
marker O 0 0.0012898355
of O 0 0.0016018038
glucocorticoid O 0 0.9703407
activity O 0 0.0029926456
, O 0 0.0018222914
and O 0 0.0016353026
serum O 0 0.24966916
urate B-Chemical 0 0.99597543
to O 0 0.002998983
assess O 0 0.0027679363
XO O 0 0.997131
inhibition O 0 0.12833208
. O 0 0.010294522

5 O 0 0.074601255
. O 0 0.0729965

Dex B-Chemical 1 0.98928005
increased B-Disease 0 0.040117774
SBP I-Disease 0 0.94586235
( O 0 0.0038922871
110 O 0 0.0043380796
+ O 0 0.0017860942
/ O 0 0.0022620654
- O 0 0.0013845178
2 O 0 0.0007030573
- O 0 0.00093781133
126 O 0 0.0028325387
+ O 0 0.00072519184
/ O 0 0.0011531564
- O 0 0.0007161259
3 O 0 0.00033742728
mmHg O 0 0.0044784076
; O 0 0.00060105976
P O 0 0.0065860897
< O 0 0.00039055213
0 O 0 0.0003196729
. O 0 0.00020638939
001 O 0 0.0702351
) O 0 0.0005275372
and O 0 0.0003206389
decreased B-Disease 0 0.00084055326
thymus I-Disease 0 0.007029986
( I-Disease 0 0.0007860984
P I-Disease 0 0.02030368
< I-Disease 0 0.00049471424
0 I-Disease 0 0.00039771627
. I-Disease 0 0.00026858394
001 I-Disease 0 0.07646376
) I-Disease 0 0.0007576026
and I-Disease 0 0.0005903581
bodyweights I-Disease 0 0.045955397
( O 0 0.0012961853
P O 0 0.018510742
" O 0 0.0013571177
< O 0 0.0015313609
0 O 0 0.0015998458
. O 0 0.0015610838
01 O 0 0.010006571
) O 0 0.0062493677
. O 0 0.0057470305

Allopurinol B-Chemical 0 0.9987821
decreased O 0 0.021667985
serum O 0 0.37044197
urate B-Chemical 0 0.9961683
from O 0 0.0021296549
76 O 0 0.0027573942
+ O 0 0.0014175294
/ O 0 0.0017574806
- O 0 0.00092595414
5 O 0 0.0003392568
to O 0 0.00030757353
30 O 0 0.0003489098
+ O 0 0.0005049622
/ O 0 0.0009081266
- O 0 0.00061488146
3 O 0 0.00032332304
micromol O 0 0.20704755
/ O 0 0.002027809
L O 0 0.39822385
( O 0 0.00078736537
P O 0 0.02084615
< O 0 0.00040931688
0 O 0 0.00030885352
. O 0 0.00018691029
001 O 0 0.0714557
) O 0 0.00045142914
in O 0 0.00021701325
saline O 0 0.015002686
and O 0 0.00029967088
from O 0 0.00027154243
84 O 0 0.0005915189
+ O 0 0.0004513986
/ O 0 0.0008058678
- O 0 0.0004654395
13 O 0 0.00027897969
to O 0 0.00020793284
28 O 0 0.0003929675
+ O 0 0.00041626586
/ O 0 0.00082088815
- O 0 0.0005614841
2 O 0 0.00035563912
micromol O 0 0.21635318
/ O 0 0.0018977207
L O 0 0.32593903
in O 0 0.000667146
dex B-Chemical 1 0.9971181
- O 0 0.0023412772
treated O 0 0.0019358855
( O 0 0.0013269159
P O 0 0.029939633
< O 0 0.0011470108
0 O 0 0.0010641342
. O 0 0.0009305572
01 O 0 0.0063323895
) O 0 0.003450574
groups O 0 0.004237571
. O 0 0.005476978

6 O 0 0.072205186
. O 0 0.07268847

Allopurinol B-Chemical 0 0.99663323
did O 0 0.01319355
not O 0 0.009858105
prevent O 0 0.017995045
dex B-Chemical 1 0.9877707
- O 0 0.084228225
HT B-Disease 0 0.9720171
. O 0 0.023784187

This O 0 0.005077531
, O 0 0.0027232724
together O 0 0.0013501073
with O 0 0.0011416065
our O 0 0.0007111218
previous O 0 0.00076429895
findings O 0 0.0017262028
that O 0 0.0007986596
allopurinol B-Chemical 0 0.9997944
failed O 0 0.0026110292
to O 0 0.0006210846
prevent O 0 0.0012603694
adrenocorticotrophic O 0 0.99870276
hormone O 0 0.9915331
induced O 0 0.01610017
hypertension B-Disease 2 0.9998049
, O 0 0.0016914479
suggests O 0 0.00034751886
that O 0 0.0005224242
XO O 0 0.9995753
activity O 0 0.0013436927
is O 0 0.0004218951
not O 0 0.00031931986
a O 0 0.00040675417
major O 0 0.00055945996
determinant O 0 0.00043813934
of O 0 0.0012148699
GC O 0 0.33923203
- O 0 0.0069513456
HT B-Disease 0 0.97124916
in O 0 0.0023662657
the O 0 0.0034605674
rat O 0 0.03574885
. O 0 0.0067009265

Side O 0 0.30992344
effects O 0 0.0046821474
of O 0 0.0027029223
postoperative O 0 0.0529152
administration O 0 0.13046215
of O 0 0.0027094781
methylprednisolone B-Chemical 1 0.9994221
and O 0 0.004224549
gentamicin B-Chemical 1 0.9978194
into O 0 0.000766227
the O 0 0.0009416649
posterior O 0 0.012551017
sub O 0 0.010222517
- O 0 0.003725041
Tenon O 0 0.49207202
' O 0 0.0032457937
s O 0 0.004115963
space O 0 0.006055509
. O 0 0.0062342538

PURPOSE O 0 0.033252567
: O 0 0.0036335052
To O 0 0.0012084317
assess O 0 0.00063422666
the O 0 0.00085287297
incidence O 0 0.0025732876
of O 0 0.0011491342
postoperative O 0 0.13248956
emetic O 0 0.9951722
side O 0 0.039304603
effects O 0 0.0012911507
after O 0 0.00024340198
the O 0 0.0003341081
administration O 0 0.046381075
of O 0 0.0009178254
methylprednisolone B-Chemical 1 0.9997496
and O 0 0.0022323574
gentamicin B-Chemical 1 0.99893755
into O 0 0.0002732169
the O 0 0.00033429515
posterior O 0 0.008664396
sub O 0 0.006839795
- O 0 0.0012233137
Tenon O 0 0.41286898
' O 0 0.0005160689
s O 0 0.00048815715
space O 0 0.0004608413
at O 0 0.00028184618
the O 0 0.00044071127
end O 0 0.00047654795
of O 0 0.0013607005
routine O 0 0.0031819162
cataract B-Disease 2 0.9743677
surgery O 0 0.06293545
. O 0 0.006860457

SETTING O 0 0.15176643
: O 0 0.06968535
St O 0 0.1026458
. O 0 0.05240843

Luke O 0 0.04907544
' O 0 0.013042666
s O 0 0.013189726
Hospital O 0 0.023983624
, O 0 0.014518772
Gwardamangia O 0 0.078222
, O 0 0.019077875
Malta O 0 0.065269195
. O 0 0.017903663

METHODS O 0 0.007376488
: O 0 0.004271939
A O 0 0.0063463803
double O 0 0.0015971017
- O 0 0.0020066192
blind O 0 0.003010316
double O 0 0.00084904017
- O 0 0.001194557
armed O 0 0.0024810017
prospective O 0 0.0013910579
study O 0 0.0005722869
comprised O 0 0.000363048
40 O 0 0.00038910075
patients O 0 0.00066460174
who O 0 0.0005744048
had O 0 0.00028166972
uneventful O 0 0.0010258274
sutureless O 0 0.011428898
phacoemulsification O 0 0.5726388
under O 0 0.00034898054
sub O 0 0.005371975
- O 0 0.0013147101
Tenon O 0 0.39420745
' O 0 0.00063096674
s O 0 0.00064231467
local O 0 0.0010865063
infiltration O 0 0.2036354
of O 0 0.0012681421
3 O 0 0.0011300413
mL O 0 0.004790579
of O 0 0.002655045
plain O 0 0.14633812
lignocaine B-Chemical 1 0.99659866
. O 0 0.00883583

At O 0 0.002377841
the O 0 0.001781723
end O 0 0.0010234895
of O 0 0.0013363963
the O 0 0.0010070225
procedure O 0 0.0012877819
, O 0 0.0014381859
Group O 0 0.017052708
A O 0 0.011737828
( O 0 0.00087335263
n O 0 0.00043073625
= O 0 0.0005570695
20 O 0 0.00035473364
) O 0 0.00040755936
had O 0 0.0002683173
20 O 0 0.00037242105
mg O 0 0.14308794
/ O 0 0.0007506219
0 O 0 0.0002958285
. O 0 0.00013150345
5 O 0 0.00016702997
mL O 0 0.00063868234
of O 0 0.0003233289
methylprednisolone B-Chemical 1 0.99937767
and O 0 0.00051727646
10 O 0 0.00042614675
mg O 0 0.25571012
/ O 0 0.0007519764
0 O 0 0.0002663034
. O 0 0.000115312105
5 O 0 0.00015245678
mL O 0 0.0006308673
of O 0 0.00031520633
gentamicin B-Chemical 1 0.9961492
injected O 0 0.00027733785
into O 0 0.00013501465
the O 0 0.00020858235
posterior O 0 0.0046749264
sub O 0 0.005230516
- O 0 0.0010025855
Tenon O 0 0.43786165
' O 0 0.00037673357
s O 0 0.00034983107
space O 0 0.0003376432
and O 0 0.000357891
Group O 0 0.017370977
B O 0 0.0753244
( O 0 0.00050319266
n O 0 0.00025039772
= O 0 0.0003648964
20 O 0 0.0002459853
) O 0 0.00029389968
had O 0 0.00018815533
the O 0 0.00017373818
same O 0 0.00013827096
combination O 0 0.0006447926
injected O 0 0.0003615518
into O 0 0.00025058328
the O 0 0.00047173206
anterior O 0 0.0109764505
sub O 0 0.006505259
- O 0 0.0026874535
Tenon O 0 0.4676268
' O 0 0.0025281766
s O 0 0.0033661854
space O 0 0.005127123
. O 0 0.0053845905

Postoperatively O 0 0.040030677
, O 0 0.003675719
all O 0 0.001707909
patients O 0 0.0027290117
were O 0 0.0011658475
assessed O 0 0.0009244331
for O 0 0.0011242754
symptoms O 0 0.17173514
of O 0 0.0050042765
nausea B-Disease 2 0.9997514
, I-Disease 0 0.036649596
vomiting I-Disease 0 0.9992686
, O 0 0.009958407
and O 0 0.009223073
headache B-Disease 2 0.9964754
. O 0 0.010477171

A O 0 0.025774172
chi O 0 0.08350377
- O 0 0.004758954
square O 0 0.0033001679
test O 0 0.0018731065
was O 0 0.001380392
used O 0 0.0011175324
to O 0 0.0010186795
assess O 0 0.000700074
the O 0 0.0013130778
statistical O 0 0.0048196116
significance O 0 0.004299502
of O 0 0.0051390287
results O 0 0.007229347
. O 0 0.009392101

RESULTS O 0 0.024737496
: O 0 0.004673169
Sixty O 0 0.005520168
percent O 0 0.0014815431
in O 0 0.0013461892
Group O 0 0.00671818
A O 0 0.005510408
developed O 0 0.0019455798
postoperative B-Disease 0 0.24013172
emetic I-Disease 0 0.9968671
symptoms I-Disease 0 0.92674375
, O 0 0.0051209903
headache B-Disease 2 0.9991604
, O 0 0.0013435034
or O 0 0.00055859576
both O 0 0.00067698123
; O 0 0.0011614829
1 O 0 0.0006876185
patient O 0 0.0011995889
in O 0 0.0011553416
Group O 0 0.02738905
B O 0 0.08445167
developed O 0 0.008669053
symptoms O 0 0.5805016
. O 0 0.007528171

CONCLUSIONS O 0 0.67334193
: O 0 0.004613348
The O 0 0.0016725702
administration O 0 0.020545144
of O 0 0.00214235
methylprednisolone B-Chemical 1 0.99927086
and O 0 0.0035902506
gentamicin B-Chemical 1 0.9984053
in O 0 0.00073496636
the O 0 0.0005573297
posterior O 0 0.01092263
sub O 0 0.009142715
- O 0 0.0014631824
Tenon O 0 0.47083145
' O 0 0.0004870138
s O 0 0.0004064059
space O 0 0.00034337986
was O 0 0.00023385293
related O 0 0.00017876543
to O 0 0.00021530305
a O 0 0.00028454888
high O 0 0.00042772133
incidence O 0 0.0022235953
of O 0 0.00067927974
side O 0 0.01649413
effects O 0 0.0024936232
including O 0 0.00277388
nausea B-Disease 2 0.99987054
, I-Disease 0 0.029502941
vomiting I-Disease 0 0.9995259
, O 0 0.008040083
and O 0 0.007653185
headache B-Disease 2 0.99721813
. O 0 0.008415914

All O 0 0.010697709
adverse O 0 0.22236927
effects O 0 0.011113641
were O 0 0.0078068567
self O 0 0.020520102
- O 0 0.015522779
limiting O 0 0.01567961
. O 0 0.015195826

Assessment O 0 0.0056352913
of O 0 0.0028886385
a O 0 0.0021361003
new O 0 0.0021844534
non O 0 0.0028698863
- O 0 0.0019684255
invasive O 0 0.003364658
index O 0 0.0012462385
of O 0 0.0010015133
cardiac O 0 0.12728924
performance O 0 0.0012214151
for O 0 0.00059724535
detection O 0 0.0010926719
of O 0 0.0023290894
dobutamine B-Chemical 1 0.99917847
- O 0 0.017855745
induced O 0 0.019652028
myocardial B-Disease 0 0.9983499
ischemia I-Disease 2 0.9989291
. O 0 0.014196594

BACKGROUND O 0 0.8231265
: O 0 0.0074052573
Electrocardiography O 0 0.34412703
has O 0 0.002152156
a O 0 0.0017331028
very O 0 0.0015721297
low O 0 0.0015589604
sensitivity O 0 0.0026785315
in O 0 0.0013500082
detecting O 0 0.0024323747
dobutamine B-Chemical 1 0.99874616
- O 0 0.018716669
induced O 0 0.02055914
myocardial B-Disease 0 0.99803334
ischemia I-Disease 2 0.99876994
. O 0 0.01621598

OBJECTIVES O 0 0.022508265
: O 0 0.0034450626
To O 0 0.0011472293
assess O 0 0.00059987593
the O 0 0.00076538057
added O 0 0.00077080063
diagnostic O 0 0.0009667584
value O 0 0.00052213296
of O 0 0.0005674549
a O 0 0.0005223052
new O 0 0.0006884742
cardiac O 0 0.13844287
performance O 0 0.0009963125
index O 0 0.0010980384
( O 0 0.000882523
dP O 0 0.03959836
/ O 0 0.00096855336
dtejc O 0 0.0059980038
) O 0 0.0005627979
measurement O 0 0.0002435963
, O 0 0.00035448076
based O 0 0.00030321005
on O 0 0.00021297524
brachial O 0 0.7021455
artery O 0 0.24489208
flow O 0 0.006181042
changes O 0 0.0006503369
, O 0 0.00033699005
as O 0 0.00015402463
compared O 0 0.000112958725
to O 0 0.00015319764
standard O 0 0.00016656208
12 O 0 0.0002159247
- O 0 0.0004571135
lead O 0 0.005525108
ECG O 0 0.8891089
, O 0 0.0004251445
for O 0 0.00021762741
detecting O 0 0.00041645652
dobutamine B-Chemical 1 0.999629
- O 0 0.003255179
induced O 0 0.0018131515
myocardial B-Disease 0 0.99940956
ischemia I-Disease 2 0.99984145
, O 0 0.002338946
using O 0 0.0005573834
Tc99m B-Chemical 0 0.99520785
- I-Chemical 0 0.0035551398
Sestamibi I-Chemical 0 0.9970085
single O 0 0.00062651024
- O 0 0.00087727257
photon O 0 0.0639736
emission O 0 0.108663134
computed O 0 0.000669146
tomography O 0 0.03339368
as O 0 0.00027434272
the O 0 0.00028805446
gold O 0 0.020753996
standard O 0 0.00026285308
of O 0 0.00040480494
comparison O 0 0.00031219586
to O 0 0.00031783042
assess O 0 0.00022442621
the O 0 0.0004841044
presence O 0 0.0007513593
or O 0 0.0009697334
absence O 0 0.0013315185
of O 0 0.007178112
ischemia B-Disease 2 0.99818844
. O 0 0.010057503

METHODS O 0 0.006646009
: O 0 0.0031977282
The O 0 0.0013510332
study O 0 0.0016800794
group O 0 0.0013403854
comprised O 0 0.0011298056
40 O 0 0.0012466006
patients O 0 0.0022819333
undergoing O 0 0.0033183661
Sestamibi B-Chemical 0 0.9897613
- O 0 0.0064838263
SPECT O 0 0.9593839
/ O 0 0.016489558
dobutamine B-Chemical 1 0.9981627
stress O 0 0.67001605
test O 0 0.010049973
. O 0 0.008603158

Simultaneous O 0 0.014022482
measurements O 0 0.0031602583
of O 0 0.003672073
ECG O 0 0.8157609
and O 0 0.0036073902
brachial O 0 0.8609113
artery O 0 0.50669837
dP O 0 0.09577637
/ O 0 0.002684646
dtejc O 0 0.003931213
were O 0 0.0010008729
performed O 0 0.0010285184
at O 0 0.0010951385
each O 0 0.001768589
dobutamine B-Chemical 1 0.9949916
level O 0 0.0067428015
. O 0 0.008174097

In O 0 0.0034950401
19 O 0 0.0032397734
of O 0 0.002017455
the O 0 0.0014577056
40 O 0 0.0016334271
patients O 0 0.0028055627
perfusion O 0 0.13002189
defects O 0 0.0020545188
compatible O 0 0.0024916667
with O 0 0.0031409017
ischemia B-Disease 2 0.99833703
were O 0 0.0030834195
detected O 0 0.0022110718
on O 0 0.0036788567
SPECT O 0 0.920566
. O 0 0.010048792

The O 0 0.0031717927
increase O 0 0.0024453297
in O 0 0.0019931735
dP O 0 0.03720952
/ O 0 0.002343923
dtejc O 0 0.0037937367
during O 0 0.0005529488
infusion O 0 0.013932802
of O 0 0.0010130386
dobutamine B-Chemical 1 0.9992741
in O 0 0.0006131372
this O 0 0.00043940893
group O 0 0.0005628639
was O 0 0.0004409638
severely O 0 0.002455671
impaired O 0 0.0008979552
as O 0 0.0003768672
compared O 0 0.00032821577
to O 0 0.0005717193
the O 0 0.00090997416
non O 0 0.003942174
- O 0 0.007912242
ischemic O 0 0.9965397
group O 0 0.009739811
. O 0 0.006763922

dP O 0 0.07148437
/ O 0 0.005580306
dtejc O 0 0.0074097486
outcome O 0 0.0028532369
was O 0 0.0010787958
combined O 0 0.0013678434
with O 0 0.0010395036
the O 0 0.0008644908
ECG O 0 0.82632905
results O 0 0.00081231043
, O 0 0.00089859276
giving O 0 0.00094501337
an O 0 0.0011382462
ECG O 0 0.93402404
- O 0 0.0014595147
enhanced O 0 0.0008754147
value O 0 0.0008097814
, O 0 0.001067854
and O 0 0.0009910936
compared O 0 0.00088461564
to O 0 0.00214002
ECG O 0 0.8448337
alone O 0 0.0070251976
. O 0 0.0069232257

RESULTS O 0 0.025165064
: O 0 0.0038920948
The O 0 0.0014420315
sensitivity O 0 0.0022598903
improved O 0 0.0019693195
dramatically O 0 0.0014203812
from O 0 0.00075804093
16 O 0 0.00069164956
% O 0 0.0005109396
to O 0 0.00033994348
79 O 0 0.0006456209
% O 0 0.00037918263
, O 0 0.00030325138
positive O 0 0.00021331971
predictive O 0 0.00046173454
value O 0 0.0002773992
increased O 0 0.00042715739
from O 0 0.00026422704
60 O 0 0.0003118853
% O 0 0.00023886398
to O 0 0.00017288627
68 O 0 0.00038186408
% O 0 0.00022125093
and O 0 0.0001718966
negative O 0 0.00019305259
predictive O 0 0.00040014312
value O 0 0.00025350586
from O 0 0.00025006515
54 O 0 0.0005271803
% O 0 0.0002884986
to O 0 0.00022608382
78 O 0 0.00059137854
% O 0 0.0003663628
, O 0 0.0003713773
and O 0 0.0003608156
specificity O 0 0.00079708913
decreased O 0 0.0010955659
from O 0 0.00075714535
90 O 0 0.0010963243
% O 0 0.00127475
to O 0 0.0014631329
67 O 0 0.004496271
% O 0 0.0043404736
. O 0 0.0047880476

CONCLUSIONS O 0 0.73239774
: O 0 0.0052983453
If O 0 0.0018630082
ECG O 0 0.5229449
alone O 0 0.0016415664
is O 0 0.0008719641
used O 0 0.00059422245
for O 0 0.00047226655
specificity O 0 0.0011583887
, O 0 0.00065284886
the O 0 0.00037926322
combination O 0 0.0011860935
with O 0 0.0008249155
dP O 0 0.07837875
/ O 0 0.001010593
dtejc O 0 0.0032232013
improved O 0 0.000707933
the O 0 0.00025682396
sensitivity O 0 0.00071028876
of O 0 0.00033905118
the O 0 0.00023907654
test O 0 0.00031132027
and O 0 0.00028609094
could O 0 0.00020063539
be O 0 0.0002484579
a O 0 0.00027592026
cost O 0 0.0005394624
- O 0 0.0005273135
savings O 0 0.0015356957
alternative O 0 0.00027942823
to O 0 0.00025698513
cardiac O 0 0.11147821
imaging O 0 0.004414791
or O 0 0.00030089563
perfusion O 0 0.1257973
studies O 0 0.00060224935
to O 0 0.00033670652
detect O 0 0.00040723773
myocardial B-Disease 0 0.99876785
ischemia I-Disease 2 0.9996922
, O 0 0.0020167008
especially O 0 0.0013364365
in O 0 0.00082028133
patients O 0 0.0025188902
unable O 0 0.0012248752
to O 0 0.002251332
exercise O 0 0.06591712
. O 0 0.005746842

Cocaine B-Chemical 0 0.9980716
- O 0 0.01903817
induced O 0 0.012305283
myocardial B-Disease 0 0.99736977
infarction I-Disease 2 0.99949634
: O 0 0.011841426
clinical O 0 0.0179133
observations O 0 0.004819932
and O 0 0.004796967
pathogenetic O 0 0.12801678
considerations O 0 0.016378371
. O 0 0.010243568

Clinical O 0 0.030722724
and O 0 0.0026266975
experimental O 0 0.00222452
data O 0 0.0015386238
published O 0 0.001117129
to O 0 0.00072529697
date O 0 0.00068314216
suggest O 0 0.00044240837
several O 0 0.0006235068
possible O 0 0.0007118074
mechanisms O 0 0.0012926807
by O 0 0.0008842608
which O 0 0.0019791927
cocaine B-Chemical 1 0.9988933
may O 0 0.0016327344
result O 0 0.0015125918
in O 0 0.0028721741
acute B-Disease 2 0.9949138
myocardial I-Disease 2 0.99914014
infarction I-Disease 2 0.9996692
. O 0 0.023860175

In O 0 0.0029610149
individuals O 0 0.002634559
with O 0 0.002007995
preexisting O 0 0.015114464
, O 0 0.0018826463
high O 0 0.0016253375
- O 0 0.001912215
grade O 0 0.14434065
coronary O 0 0.7894536
arterial O 0 0.87382114
narrowing O 0 0.18020172
, O 0 0.0022710098
acute B-Disease 2 0.9936061
myocardial I-Disease 2 0.99971396
infarction I-Disease 2 0.9999546
may O 0 0.001330361
result O 0 0.00036529003
from O 0 0.0003143037
an O 0 0.00040280688
increase O 0 0.00031840877
in O 0 0.00037946145
myocardial O 0 0.99836904
oxygen B-Chemical 1 0.98884684
demand O 0 0.008885072
associated O 0 0.0014916436
with O 0 0.002399861
cocaine B-Chemical 1 0.9996662
- O 0 0.0032722468
induced O 0 0.0010736459
increase O 0 0.0008028858
in O 0 0.00087541057
rate O 0 0.0015092094
- O 0 0.0038471716
pressure O 0 0.07575742
product O 0 0.008408421
. O 0 0.005976601

In O 0 0.0029339485
other O 0 0.002096967
individuals O 0 0.002075183
with O 0 0.001524337
no O 0 0.0010554745
underlying O 0 0.008232091
atherosclerotic B-Disease 2 0.99895644
obstruction I-Disease 0 0.9953353
, O 0 0.0035577642
coronary B-Disease 0 0.8062872
occlusion I-Disease 0 0.56558204
may O 0 0.0008177103
be O 0 0.0006790302
due O 0 0.00051946804
to O 0 0.0012421954
spasm B-Disease 2 0.9987311
, O 0 0.00526559
thrombus B-Disease 0 0.99212205
, O 0 0.0040369653
or O 0 0.0027843625
both O 0 0.004630373
. O 0 0.0060048876

With O 0 0.005690948
regard O 0 0.0028174235
to O 0 0.0027894527
spasm B-Disease 2 0.99638915
, O 0 0.0023904773
the O 0 0.0009853463
clinical O 0 0.0042415634
findings O 0 0.0017178751
are O 0 0.0006520678
largely O 0 0.0009026819
circumstantial O 0 0.006729361
, O 0 0.00084776036
and O 0 0.0005587994
the O 0 0.0004998337
locus O 0 0.00072490075
of O 0 0.0019964038
cocaine B-Chemical 1 0.99930525
- O 0 0.008575596
induced O 0 0.007175869
vasoconstriction O 0 0.99761367
remains O 0 0.0071188766
speculative O 0 0.06617643
. O 0 0.0076060602

Although O 0 0.0030808572
certain O 0 0.0029066117
clinical O 0 0.0046484736
and O 0 0.0012611485
experimental O 0 0.001325189
findings O 0 0.0015223793
support O 0 0.00069892546
the O 0 0.0005535521
hypothesis O 0 0.00086142984
that O 0 0.0007009536
spasm B-Disease 2 0.9987417
involves O 0 0.0008718157
the O 0 0.0006733304
epicardial O 0 0.36405087
, O 0 0.0010582514
medium O 0 0.0028718247
- O 0 0.0010830495
size O 0 0.0008551645
vessels O 0 0.019569568
, O 0 0.00103757
other O 0 0.00093295594
data O 0 0.0016293601
suggest O 0 0.0024137488
intramural O 0 0.81228966
vasoconstriction O 0 0.99657
. O 0 0.010558124

Diffuse O 0 0.58751464
intramural O 0 0.5198254
vasoconstriction O 0 0.99567324
is O 0 0.0033587406
not O 0 0.001715271
consistent O 0 0.0015518138
with O 0 0.001755388
reports O 0 0.0027532799
of O 0 0.0030185278
segmental O 0 0.034131315
, O 0 0.0065303952
discrete O 0 0.022651853
infarction B-Disease 2 0.99861383
. O 0 0.015265047

Whereas O 0 0.0042230007
certain O 0 0.003282705
in O 0 0.0015211658
vivo O 0 0.0018980885
data O 0 0.0010671589
suggest O 0 0.0006021375
that O 0 0.0005408945
these O 0 0.00083384855
effects O 0 0.0015526548
are O 0 0.0009220659
alpha O 0 0.2162618
- O 0 0.0017807845
mediated O 0 0.00069687923
, O 0 0.0008329763
other O 0 0.0006323689
in O 0 0.0006599365
vitro O 0 0.0015200843
data O 0 0.0013750192
suggest O 0 0.0014719078
the O 0 0.0027905484
opposite O 0 0.0065210257
. O 0 0.0064884173

The O 0 0.003185804
finding O 0 0.003583856
of O 0 0.0035956453
cocaine B-Chemical 1 0.9987644
- O 0 0.007286338
induced O 0 0.0032795768
vasoconstriction O 0 0.99843854
in O 0 0.0008849072
segments O 0 0.0009877562
of O 0 0.00079561124
( O 0 0.00095292414
noninnervated O 0 0.15132973
) O 0 0.0008457368
human O 0 0.0008118892
umbilical O 0 0.037724644
artery O 0 0.12121681
suggests O 0 0.00020523083
that O 0 0.00018944393
the O 0 0.00020335116
presence O 0 0.00023166896
or O 0 0.00018531176
absence O 0 0.00014201402
of O 0 0.00034507367
intact O 0 0.00049123465
innervation O 0 0.14505805
is O 0 0.0002651858
not O 0 0.00019216539
sufficient O 0 0.00015244079
to O 0 0.00018267271
explain O 0 0.00019532145
the O 0 0.0002203192
discrepant O 0 0.0008281205
data O 0 0.0004182788
involving O 0 0.00050801923
the O 0 0.00045089415
possibility O 0 0.0005871226
of O 0 0.0015058337
alpha O 0 0.2912157
- O 0 0.0050530247
mediated O 0 0.0031167888
effects O 0 0.011063392
. O 0 0.006276909

Finally O 0 0.0047190343
, O 0 0.0031046811
the O 0 0.0015768337
contribution O 0 0.0011344196
of O 0 0.0014425473
a O 0 0.0013969976
primary O 0 0.001953284
, O 0 0.0023567136
thrombotic B-Disease 2 0.99540097
effect O 0 0.0023675156
of O 0 0.0035067229
cocaine B-Chemical 1 0.9988877
has O 0 0.002866721
not O 0 0.0025977802
been O 0 0.0041370536
excluded O 0 0.0063125063
. O 0 0.006677791

Proteomic O 0 0.09432393
analysis O 0 0.005157406
of O 0 0.0040416117
striatal O 0 0.9125667
proteins O 0 0.0035244664
in O 0 0.001305537
the O 0 0.001223634
rat O 0 0.0056674806
model O 0 0.0022536393
of O 0 0.003849846
L B-Chemical 1 0.96204036
- I-Chemical 1 0.072116815
DOPA I-Chemical 1 0.9990926
- O 0 0.02908993
induced O 0 0.046943527
dyskinesia B-Disease 2 0.99931514
. O 0 0.0137461275

L B-Chemical 1 0.9377841
- I-Chemical 1 0.04954991
DOPA I-Chemical 1 0.99875677
- O 0 0.013586398
induced O 0 0.011844557
dyskinesia B-Disease 2 0.99985504
( O 0 0.023913203
LID B-Disease 2 0.998171
) O 0 0.0023151482
is O 0 0.0005470914
among O 0 0.00049428677
the O 0 0.00040766812
motor O 0 0.042588323
complications O 0 0.2704185
that O 0 0.0003334278
arise O 0 0.00059461535
in O 0 0.00054722547
Parkinson B-Disease 0 0.9990891
' I-Disease 0 0.000665637
s I-Disease 0 0.0007532774
disease I-Disease 0 0.5955023
( O 0 0.0018565834
PD B-Disease 0 0.99120635
) O 0 0.0010321975
patients O 0 0.0010344363
after O 0 0.0002789475
a O 0 0.00062706193
prolonged O 0 0.0065482357
treatment O 0 0.004268139
with O 0 0.0049973438
L B-Chemical 1 0.9605511
- I-Chemical 1 0.08551125
DOPA I-Chemical 1 0.9979367
. O 0 0.00988748

To O 0 0.0025330933
this O 0 0.0017340446
day O 0 0.0014313285
, O 0 0.0013421584
transcriptome O 0 0.0010946118
analysis O 0 0.0010561504
has O 0 0.0006381952
been O 0 0.0006076388
performed O 0 0.000414766
in O 0 0.00037195501
a O 0 0.00049024017
rat O 0 0.0026207129
model O 0 0.0007022286
of O 0 0.0013204318
LID B-Disease 2 0.9988152
[ O 0 0.019443678
Neurobiol O 0 0.94310236
. O 0 0.00042466048
Dis O 0 0.2564322
. O 0 0.00026703256
, O 0 0.00046605442
17 O 0 0.0005708291
( O 0 0.00055197126
2004 O 0 0.0011940963
) O 0 0.0006737707
, O 0 0.00053805177
219 O 0 0.004509866
] O 0 0.00086412515
but O 0 0.0003569663
information O 0 0.0005304805
regarding O 0 0.00045913324
the O 0 0.00074756396
proteome O 0 0.0026802027
is O 0 0.0017422389
still O 0 0.0022849522
lacking O 0 0.0031176554
. O 0 0.005525024

In O 0 0.0026317365
the O 0 0.001651389
present O 0 0.0010831052
study O 0 0.0015526828
, O 0 0.0010106273
we O 0 0.00037318975
investigated O 0 0.00052441965
the O 0 0.000444791
changes O 0 0.0006810257
occurring O 0 0.00085257436
at O 0 0.00023348734
the O 0 0.00028621292
protein O 0 0.0006617592
level O 0 0.00024230259
in O 0 0.00030795616
striatal O 0 0.7988385
samples O 0 0.00027660583
obtained O 0 0.0002412657
from O 0 0.00023844324
the O 0 0.00027396396
unilaterally O 0 0.03617697
6 B-Chemical 0 0.0002768618
- I-Chemical 0 0.00069756754
hydroxydopamine I-Chemical 0 0.89052707
- O 0 0.0007989111
lesion O 0 0.02713035
rat O 0 0.004121813
model O 0 0.0004466575
of O 0 0.00071866915
PD B-Disease 0 0.9935986
treated O 0 0.0015283324
with O 0 0.00075415766
saline O 0 0.36905605
, O 0 0.0021343282
L B-Chemical 1 0.9554075
- I-Chemical 1 0.011331594
DOPA I-Chemical 1 0.9997595
or O 0 0.00069695583
bromocriptine B-Chemical 1 0.99979573
using O 0 0.00046452114
two O 0 0.00033139138
- O 0 0.0006474318
dimensional O 0 0.00082328997
difference O 0 0.00033490537
gel O 0 0.004918985
electrophoresis O 0 0.049489446
and O 0 0.0011768905
mass O 0 0.0071581337
spectrometry O 0 0.114193425
( O 0 0.0067863506
MS O 2 0.96162766
) O 0 0.011787576
. O 0 0.0069898637

Rats O 0 0.08361398
treated O 0 0.0064987997
with O 0 0.0049710847
L B-Chemical 1 0.9101693
- I-Chemical 1 0.013129763
DOPA I-Chemical 1 0.9988851
were O 0 0.0012792622
allocated O 0 0.0007910565
to O 0 0.00056443154
two O 0 0.00045430832
groups O 0 0.0006949406
based O 0 0.00071921037
on O 0 0.0004801331
the O 0 0.00079010916
presence O 0 0.0011214713
or O 0 0.0013728865
absence O 0 0.0017875017
of O 0 0.007931384
LID B-Disease 2 0.99302834
. O 0 0.009736417

Among O 0 0.006754209
the O 0 0.0024100053
2000 O 0 0.003204318
spots O 0 0.0016276233
compared O 0 0.0005738974
for O 0 0.0005523149
statistical O 0 0.0018987554
difference O 0 0.00043717434
, O 0 0.0006284881
67 O 0 0.0007664272
spots O 0 0.00057016563
were O 0 0.00032410905
significantly O 0 0.00037892605
changed O 0 0.0003881884
in O 0 0.00024943223
abundance O 0 0.00032077893
and O 0 0.00030441818
identified O 0 0.000259693
using O 0 0.00028945215
matrix O 0 0.006808215
- O 0 0.0006656265
assisted O 0 0.000886716
laser O 0 0.019957667
desorption O 0 0.49166283
/ O 0 0.0028597468
ionization O 0 0.11932202
time O 0 0.0004294618
- O 0 0.00072926836
of O 0 0.00053505326
- O 0 0.0008427113
flight O 0 0.0019590447
MS O 2 0.9528887
, O 0 0.00083554396
atmospheric O 0 0.2263274
pressure O 0 0.10660012
matrix O 0 0.017175341
- O 0 0.0008015373
assisted O 0 0.0010064355
laser O 0 0.019583995
desorption O 0 0.48238084
/ O 0 0.0034196153
ionization O 0 0.16634038
and O 0 0.0009406162
HPLC O 0 0.5882794
coupled O 0 0.0011107377
tandem O 0 0.0017589729
MS O 2 0.97660655
( O 0 0.004018337
LC O 0 0.66023785
/ O 0 0.016990518
MS O 2 0.979188
/ O 0 0.036872603
MS O 2 0.9751057
) O 0 0.014177282
. O 0 0.007822056

Out O 0 0.009947829
of O 0 0.0030303923
these O 0 0.0025593392
67 O 0 0.0031390272
proteins O 0 0.0026390208
, O 0 0.00219068
LID B-Disease 2 0.9929704
significantly O 0 0.001096259
changed O 0 0.00072690786
the O 0 0.00042081156
expression O 0 0.00065446884
level O 0 0.0002693759
of O 0 0.0004166017
five O 0 0.0002781102
proteins O 0 0.001094149
: O 0 0.0011469268
alphabeta O 0 0.5330068
- O 0 0.0016383796
crystalin O 0 0.02130685
, O 0 0.001005492
gamma O 0 0.388099
- O 0 0.0035637028
enolase O 0 0.9241309
, O 0 0.0019907565
guanidoacetate O 0 0.88633597
methyltransferase O 0 0.5564619
, O 0 0.0015638586
vinculin O 0 0.20722716
, O 0 0.0014631845
and O 0 0.0013735658
proteasome O 0 0.6244087
alpha O 0 0.47499567
- O 0 0.0066147377
2 O 0 0.003603512
subunit O 0 0.0124597
. O 0 0.0064079156

Complementary O 0 0.007827809
techniques O 0 0.0040649767
such O 0 0.0018152723
as O 0 0.0011762786
western O 0 0.002159582
immunoblotting O 0 0.0013934982
and O 0 0.0009009512
immunohistochemistry O 0 0.0036499316
were O 0 0.0005381559
performed O 0 0.00039415454
to O 0 0.0003501544
investigate O 0 0.00026086305
the O 0 0.0003723422
validity O 0 0.000803469
of O 0 0.0006143521
the O 0 0.0005732684
data O 0 0.000844489
obtained O 0 0.00090329576
using O 0 0.0011023984
the O 0 0.0018155668
proteomic O 0 0.008584925
approach O 0 0.007596136
. O 0 0.0069522737

In O 0 0.0032229426
conclusion O 0 0.002372456
, O 0 0.0021539633
this O 0 0.0012329057
study O 0 0.0014718489
provides O 0 0.0009067645
new O 0 0.0013470555
insights O 0 0.0013474175
into O 0 0.0007625972
the O 0 0.0011567202
protein O 0 0.0030693964
changes O 0 0.0035318648
occurring O 0 0.008024366
in O 0 0.0063072233
LID B-Disease 2 0.9908998
. O 0 0.009822914

Cardiac O 0 0.6594651
Angiography O 0 0.12648317
in O 0 0.0029118417
Renally O 0 0.29131457
Impaired O 0 0.06819945
Patients O 0 0.011296326
( O 0 0.001805432
CARE O 0 0.04959388
) O 0 0.0011493646
study O 0 0.0008213999
: O 0 0.00063382846
a O 0 0.0003846045
randomized O 0 0.0005648074
double O 0 0.00035137462
- O 0 0.0006549384
blind O 0 0.0017348058
trial O 0 0.0007859629
of O 0 0.00053044053
contrast O 0 0.00073363644
- O 0 0.0014133864
induced O 0 0.0022746983
nephropathy B-Disease 2 0.9998005
in O 0 0.0014335273
patients O 0 0.009502731
with O 0 0.0037415563
chronic B-Disease 0 0.99420124
kidney I-Disease 0 0.9906996
disease I-Disease 0 0.98489064
. O 0 0.010559049

BACKGROUND O 0 0.74977773
: O 0 0.004934261
No O 0 0.0025560544
direct O 0 0.0011459668
comparisons O 0 0.0008675551
exist O 0 0.00080162246
of O 0 0.0008242496
the O 0 0.0007457847
renal O 0 0.9699191
tolerability O 0 0.5405013
of O 0 0.00084288995
the O 0 0.0004785148
low O 0 0.0009004596
- O 0 0.0013556534
osmolality O 0 0.7940015
contrast B-Chemical 0 0.0012997448
medium I-Chemical 0 0.028698621
iopamidol B-Chemical 1 0.99577445
with O 0 0.0005766202
that O 0 0.00028110362
of O 0 0.00050164433
the O 0 0.0005822595
iso O 0 0.94406164
- O 0 0.002452062
osmolality O 0 0.8310842
contrast B-Chemical 0 0.0016129038
medium I-Chemical 0 0.03677151
iodixanol B-Chemical 1 0.99364674
in O 0 0.0011632352
high O 0 0.002464187
- O 0 0.004040476
risk O 0 0.06242812
patients O 0 0.019668128
. O 0 0.006077746

METHODS O 0 0.0076999557
AND O 0 0.0047746603
RESULTS O 0 0.009058547
: O 0 0.0019573355
The O 0 0.0007464777
present O 0 0.00056164473
study O 0 0.0009026367
is O 0 0.0005478789
a O 0 0.00060070754
multicenter O 0 0.026780725
, O 0 0.0006151036
randomized O 0 0.00073514116
, O 0 0.0004545083
double O 0 0.00030990358
- O 0 0.0005556239
blind O 0 0.001284623
comparison O 0 0.00023885099
of O 0 0.00049892743
iopamidol B-Chemical 1 0.9953538
and O 0 0.0007463219
iodixanol B-Chemical 1 0.99439573
in O 0 0.00035652576
patients O 0 0.0015960231
with O 0 0.0006132416
chronic B-Disease 0 0.98944306
kidney I-Disease 0 0.9858089
disease I-Disease 0 0.982179
( O 0 0.0012579449
estimated O 0 0.00038610998
glomerular O 0 0.7532311
filtration O 0 0.012620944
rate O 0 0.00036993984
, O 0 0.00040518004
20 O 0 0.00029360314
to O 0 0.00022833963
59 O 0 0.0005857264
mL O 0 0.0016146685
/ O 0 0.0007130511
min O 0 0.00059089484
) O 0 0.00058754516
who O 0 0.000820894
underwent O 0 0.00094282755
cardiac O 0 0.13613637
angiography O 0 0.18560961
or O 0 0.001346168
percutaneous O 0 0.013710289
coronary O 0 0.6286691
interventions O 0 0.0076968274
. O 0 0.0058783563

Serum O 0 0.7025031
creatinine B-Chemical 1 0.9917897
( O 0 0.009811865
SCr O 0 0.9746337
) O 0 0.0025432946
levels O 0 0.00084795395
and O 0 0.0007190717
estimated O 0 0.00064315484
glomerular O 0 0.5620818
filtration O 0 0.008257193
rate O 0 0.00049817417
were O 0 0.00038429318
assessed O 0 0.0002893865
at O 0 0.00024746117
baseline O 0 0.00050970615
and O 0 0.0004570895
2 O 0 0.0004483299
to O 0 0.00042450867
5 O 0 0.00047928962
days O 0 0.0006332165
after O 0 0.0007894814
receiving O 0 0.005802747
medications O 0 0.48557687
. O 0 0.006078539

The O 0 0.0029299632
primary O 0 0.002974959
outcome O 0 0.0032569373
was O 0 0.0014336149
a O 0 0.0014843286
postdose O 0 0.1210092
SCr O 0 0.95633686
increase O 0 0.0009370208
> O 0 0.0013324154
or O 0 0.00047075687
= O 0 0.0007231075
0 O 0 0.00041364424
. O 0 0.00022293332
5 O 0 0.0003160323
mg O 0 0.09472042
/ O 0 0.0012729907
dL O 0 0.015376116
( O 0 0.0006156696
44 O 0 0.0006522764
. O 0 0.00031823944
2 O 0 0.0006368491
micromol O 0 0.13607043
/ O 0 0.0034023842
L O 0 0.21467093
) O 0 0.0028023685
over O 0 0.001521694
baseline O 0 0.0048843673
. O 0 0.0051940675

Secondary O 0 0.01583005
outcomes O 0 0.004310687
were O 0 0.0018629894
a O 0 0.001836881
postdose O 0 0.09823169
SCr O 0 0.9436104
increase O 0 0.0010372808
> O 0 0.0013919305
or O 0 0.00048211066
= O 0 0.0007199304
25 O 0 0.00055777375
% O 0 0.00037292764
, O 0 0.0003281213
a O 0 0.00030696037
postdose O 0 0.01173441
estimated O 0 0.00028911151
glomerular O 0 0.50382996
filtration O 0 0.0067922673
rate O 0 0.00034552845
decrease O 0 0.00046227887
of O 0 0.0005621928
> O 0 0.000997618
or O 0 0.0003193847
= O 0 0.00059069466
25 O 0 0.00051505107
% O 0 0.00039806543
, O 0 0.000415099
and O 0 0.0004005221
the O 0 0.00044782378
mean O 0 0.00053118175
peak O 0 0.001492543
change O 0 0.0021725532
in O 0 0.003590986
SCr O 0 0.97206545
. O 0 0.0068201814

In O 0 0.0034977412
414 O 0 0.009667715
patients O 0 0.0041381516
, O 0 0.0017792432
contrast O 0 0.0011232836
volume O 0 0.0022134315
, O 0 0.00096383423
presence O 0 0.00060358
of O 0 0.0011841992
diabetes B-Disease 2 0.9979672
mellitus I-Disease 0 0.99939656
, O 0 0.001724066
use O 0 0.0007310518
of O 0 0.0011206159
N B-Chemical 0 0.98745537
- I-Chemical 0 0.006065764
acetylcysteine I-Chemical 0 0.999653
, O 0 0.000827486
mean O 0 0.00024698387
baseline O 0 0.0007618248
SCr O 0 0.97284454
, O 0 0.0004839259
and O 0 0.00032848155
estimated O 0 0.00038141786
glomerular O 0 0.5837307
filtration O 0 0.0077865464
rate O 0 0.00058012106
were O 0 0.0005965596
comparable O 0 0.0005578429
in O 0 0.0008895785
the O 0 0.001424262
2 O 0 0.0023758046
groups O 0 0.0039582658
. O 0 0.0050990586

SCr O 0 0.93597203
increases O 0 0.0044570123
> O 0 0.004146031
or O 0 0.0014575745
= O 0 0.0017012019
0 O 0 0.00087179994
. O 0 0.00042949498
5 O 0 0.00047387058
mg O 0 0.10800676
/ O 0 0.0012908168
dL O 0 0.008921602
occurred O 0 0.00043552904
in O 0 0.00027043044
4 O 0 0.00024723267
. O 0 0.00015794058
4 O 0 0.0001974633
% O 0 0.00025745353
( O 0 0.00025829193
9 O 0 0.00017449823
of O 0 0.00023140205
204 O 0 0.001665785
patients O 0 0.00086749817
) O 0 0.0004485582
after O 0 0.00017749482
iopamidol B-Chemical 1 0.97949743
and O 0 0.00035319524
6 O 0 0.00019847638
. O 0 0.0001278111
7 O 0 0.00016581223
% O 0 0.00020930755
( O 0 0.00021081048
14 O 0 0.0001677874
of O 0 0.0002013456
210 O 0 0.0011797565
patients O 0 0.0008425616
) O 0 0.00044271722
after O 0 0.00018729833
iodixanol B-Chemical 1 0.99137306
( O 0 0.0008752616
P O 0 0.04340793
= O 0 0.0004848449
0 O 0 0.00024901092
. O 0 0.0001245797
39 O 0 0.00036577514
) O 0 0.00035641415
, O 0 0.00024561622
whereas O 0 0.0001801446
rates O 0 0.00022472168
of O 0 0.0005051243
SCr O 0 0.9859702
increases O 0 0.0005858121
> O 0 0.0008884041
or O 0 0.00023457469
= O 0 0.00041093508
25 O 0 0.0003268468
% O 0 0.00021680622
were O 0 0.00017481181
9 O 0 0.00019844912
. O 0 0.00012258468
8 O 0 0.00018210267
% O 0 0.00020436636
and O 0 0.00019503933
12 O 0 0.00018562266
. O 0 0.00015950958
4 O 0 0.0002424505
% O 0 0.0003748733
, O 0 0.00049647986
respectively O 0 0.0011151875
( O 0 0.0010468713
P O 0 0.017990362
= O 0 0.0015742301
0 O 0 0.0012618287
. O 0 0.0011019858
44 O 0 0.0033463498
) O 0 0.0050354325
. O 0 0.0048147943

In O 0 0.003411125
patients O 0 0.0050253375
with O 0 0.0034212011
diabetes B-Disease 2 0.9927021
, O 0 0.005175012
SCr O 0 0.98313785
increases O 0 0.0014979935
> O 0 0.0016589881
or O 0 0.000509457
= O 0 0.000735691
0 O 0 0.00039524594
. O 0 0.00019722639
5 O 0 0.00025964796
mg O 0 0.0798109
/ O 0 0.0008505206
dL O 0 0.006280292
were O 0 0.00024357608
5 O 0 0.00019981315
. O 0 0.00013504375
1 O 0 0.00020773805
% O 0 0.00022819554
( O 0 0.00022318025
4 O 0 0.0001313489
of O 0 0.00019893619
78 O 0 0.00045252283
patients O 0 0.00074060867
) O 0 0.00047437314
with O 0 0.00041519187
iopamidol B-Chemical 1 0.99024117
and O 0 0.0004140731
13 O 0 0.00037389842
. O 0 0.00014135784
0 O 0 0.00023108169
% O 0 0.00021150467
( O 0 0.00019864674
12 O 0 0.00011003311
of O 0 0.00018473962
92 O 0 0.0004657555
patients O 0 0.00078454113
) O 0 0.00050660165
with O 0 0.00049340393
iodixanol B-Chemical 1 0.9957145
( O 0 0.00111761
P O 0 0.054861166
= O 0 0.00052220613
0 O 0 0.00026489797
. O 0 0.0001328998
11 O 0 0.00026329383
) O 0 0.00037937931
, O 0 0.00030161394
whereas O 0 0.0003023069
SCr O 0 0.96141064
increases O 0 0.00046022874
> O 0 0.000743693
or O 0 0.00022117942
= O 0 0.00039080816
25 O 0 0.00031419407
% O 0 0.00020752067
were O 0 0.000164118
10 O 0 0.0002013406
. O 0 0.000119595614
3 O 0 0.00016128368
% O 0 0.00020758281
and O 0 0.00020028754
15 O 0 0.00020530146
. O 0 0.00016414271
2 O 0 0.00028880464
% O 0 0.00038832126
, O 0 0.00050643634
respectively O 0 0.0011266598
( O 0 0.0010481068
P O 0 0.01761934
= O 0 0.0015540717
0 O 0 0.0012385255
. O 0 0.0010798197
37 O 0 0.003203744
) O 0 0.0052578766
. O 0 0.0049949754

Mean O 0 0.0034863101
post O 0 0.0039860755
- O 0 0.004217474
SCr O 0 0.87243134
increases O 0 0.0013292467
were O 0 0.00080347474
significantly O 0 0.0007774578
less O 0 0.0006152478
with O 0 0.0008936193
iopamidol B-Chemical 1 0.99522203
( O 0 0.00093732803
all O 0 0.00035360307
patients O 0 0.0013667366
: O 0 0.00059909
0 O 0 0.00034070123
. O 0 0.00016219977
07 O 0 0.0008163362
versus O 0 0.00021096329
0 O 0 0.0002511207
. O 0 0.0001257438
12 O 0 0.00017707743
mg O 0 0.086273916
/ O 0 0.0008504676
dL O 0 0.012149241
, O 0 0.00030744454
6 O 0 0.00015636551
. O 0 0.00010877018
2 O 0 0.00015312519
versus O 0 0.00015145815
10 O 0 0.00019618489
. O 0 0.00011673888
6 O 0 0.00017066272
micromol O 0 0.092640504
/ O 0 0.0013260071
L O 0 0.30634955
, O 0 0.00062755484
P O 0 0.034922197
= O 0 0.00050580385
0 O 0 0.00027413276
. O 0 0.00015462797
03 O 0 0.0041247327
; O 0 0.00043430887
patients O 0 0.0007063322
with O 0 0.00054392545
diabetes B-Disease 2 0.99457437
: O 0 0.0009147379
0 O 0 0.0003433916
. O 0 0.00014729392
07 O 0 0.00078746513
versus O 0 0.00019607831
0 O 0 0.0002426776
. O 0 0.00012774784
16 O 0 0.00026128796
mg O 0 0.10925237
/ O 0 0.0009257575
dL O 0 0.012858589
, O 0 0.00033059588
6 O 0 0.00017279942
. O 0 0.0001248606
2 O 0 0.00018246486
versus O 0 0.00019349802
14 O 0 0.00028997447
. O 0 0.00018614178
1 O 0 0.0003985131
micromol O 0 0.1331828
/ O 0 0.0022730497
L O 0 0.28356782
, O 0 0.0015521331
P O 0 0.04121906
= O 0 0.0019483911
0 O 0 0.0015431687
. O 0 0.0014219317
01 O 0 0.0096157715
) O 0 0.005742468
. O 0 0.0052815746

CONCLUSIONS O 0 0.6658313
: O 0 0.004359469
The O 0 0.0014303827
rate O 0 0.0011642012
of O 0 0.0013483359
contrast O 0 0.001463788
- O 0 0.0020781525
induced O 0 0.0026642366
nephropathy B-Disease 2 0.99983287
, O 0 0.0017829413
defined O 0 0.00045707077
by O 0 0.00035722833
multiple O 0 0.00052653183
end O 0 0.000185908
points O 0 0.00040427755
, O 0 0.00037218645
is O 0 0.00021682668
not O 0 0.00017465271
statistically O 0 0.0001952496
different O 0 0.00017385915
after O 0 0.00012525257
the O 0 0.0002217707
intraarterial O 0 0.47657114
administration O 0 0.11116509
of O 0 0.0010014904
iopamidol B-Chemical 1 0.99749786
or O 0 0.0005513363
iodixanol B-Chemical 1 0.99331784
to O 0 0.00043605268
high O 0 0.00082253554
- O 0 0.0010440776
risk O 0 0.018488428
patients O 0 0.0030974506
, O 0 0.0009002983
with O 0 0.00094741455
or O 0 0.0010888696
without O 0 0.003230098
diabetes B-Disease 2 0.9965281
mellitus I-Disease 0 0.99784863
. O 0 0.010140755

Any O 0 0.006420387
true O 0 0.0024269521
difference O 0 0.0012909226
between O 0 0.0009577647
the O 0 0.0012912835
agents O 0 0.03304399
is O 0 0.0012423593
small O 0 0.0013098227
and O 0 0.0011640264
not O 0 0.0010434407
likely O 0 0.00113357
to O 0 0.0015136012
be O 0 0.0025455398
clinically O 0 0.0408905
significant O 0 0.0071620494
. O 0 0.006934105

A O 0 0.017460587
novel O 0 0.0063633802
compound O 0 0.08658922
, O 0 0.0036582334
maltolyl B-Chemical 1 0.10781566
p I-Chemical 1 0.0032260488
- I-Chemical 1 0.0032854162
coumarate I-Chemical 1 0.9447584
, O 0 0.0020084372
attenuates O 0 0.15795077
cognitive B-Disease 2 0.9894187
deficits I-Disease 2 0.9702997
and O 0 0.00083328306
shows O 0 0.00038168574
neuroprotective O 0 0.8537866
effects O 0 0.001963056
in O 0 0.0006483479
vitro O 0 0.0015389997
and O 0 0.0011123435
in O 0 0.0013493821
vivo O 0 0.0076281982
dementia B-Disease 2 0.99646217
models O 0 0.017206969
. O 0 0.0072996886

To O 0 0.002762264
develop O 0 0.0026776958
a O 0 0.0017203079
novel O 0 0.0020389596
and O 0 0.0011589814
effective O 0 0.0014812005
drug O 0 0.1712897
that O 0 0.0005803605
could O 0 0.00039754232
enhance O 0 0.00043030188
cognitive O 0 0.45729768
function O 0 0.00086478976
and O 0 0.00067535834
neuroprotection O 0 0.94132644
, O 0 0.0006022967
we O 0 0.0001899377
newly O 0 0.0009255819
synthesized O 0 0.0060561066
maltolyl B-Chemical 1 0.14698985
p I-Chemical 1 0.0015609101
- I-Chemical 1 0.0015826984
coumarate I-Chemical 1 0.88627726
by O 0 0.0008133469
the O 0 0.00095682027
esterification O 0 0.98532575
of O 0 0.004784502
maltol B-Chemical 0 0.9993205
and O 0 0.0038572391
p B-Chemical 0 0.006637926
- I-Chemical 0 0.01289841
coumaric I-Chemical 0 0.9949722
acid I-Chemical 0 0.974772
. O 0 0.009871281

In O 0 0.0027047072
the O 0 0.0017087369
present O 0 0.0011309448
study O 0 0.0016322901
, O 0 0.0010806384
we O 0 0.0004068511
investigated O 0 0.0005891996
whether O 0 0.00035055837
maltolyl B-Chemical 1 0.049049053
p I-Chemical 1 0.0013917901
- I-Chemical 1 0.0013993157
coumarate I-Chemical 1 0.86545134
could O 0 0.00033760263
improve O 0 0.00035611392
cognitive B-Disease 0 0.5604349
decline I-Disease 0 0.0060899323
in O 0 0.00069418043
scopolamine B-Chemical 1 0.99994016
- O 0 0.0030591935
injected O 0 0.0004026057
rats O 0 0.0016011236
and O 0 0.00037244504
in O 0 0.00044544577
amyloid B-Chemical 0 0.99375147
beta I-Chemical 0 0.6939426
peptide I-Chemical 0 0.02404088
( I-Chemical 0 0.0013689719
1 I-Chemical 0 0.00084493734
- I-Chemical 0 0.0012593403
42 I-Chemical 0 0.0014476603
) I-Chemical 0 0.0019679046
- O 0 0.0027185108
infused O 0 0.011248692
rats O 0 0.01039104
. O 0 0.0051762913

Maltolyl B-Chemical 0 0.18662733
p I-Chemical 0 0.005918908
- I-Chemical 0 0.004824174
coumarate I-Chemical 0 0.8281539
was O 0 0.0014356797
found O 0 0.000862118
to O 0 0.00073394866
attenuate O 0 0.012098754
cognitive B-Disease 2 0.9764899
deficits I-Disease 2 0.9557525
in O 0 0.00047343987
both O 0 0.00037024042
rat O 0 0.0031054327
models O 0 0.0005405067
using O 0 0.0002432797
passive O 0 0.0010240903
avoidance O 0 0.0020407226
test O 0 0.00038255038
and O 0 0.00031867574
to O 0 0.00027992154
reduce O 0 0.00034572056
apoptotic O 0 0.63899004
cell O 0 0.053806975
death O 2 0.99501675
observed O 0 0.00037811452
in O 0 0.00030560174
the O 0 0.00035231348
hippocampus O 0 0.20977785
of O 0 0.0005047189
the O 0 0.0005594491
amyloid B-Chemical 0 0.9955901
beta I-Chemical 0 0.7432576
peptide I-Chemical 0 0.027017273
( I-Chemical 0 0.0014106156
1 I-Chemical 0 0.00085488026
- I-Chemical 0 0.0012667706
42 I-Chemical 0 0.0014527626
) I-Chemical 0 0.001971192
- O 0 0.002721694
infused O 0 0.011268873
rats O 0 0.0104036005
. O 0 0.0051772706

We O 0 0.0033332047
also O 0 0.002314612
examined O 0 0.0014037738
the O 0 0.001527949
neuroprotective O 0 0.7308746
effects O 0 0.0032767428
of O 0 0.0020226864
maltolyl B-Chemical 1 0.2256662
p I-Chemical 1 0.0031444142
- I-Chemical 1 0.0029972084
coumarate I-Chemical 1 0.8789952
in O 0 0.0012672769
vitro O 0 0.0031440957
using O 0 0.0024882322
SH O 0 0.991595
- O 0 0.04375834
SY5Y O 0 0.9968766
cells O 0 0.025835995
. O 0 0.008837142

Cells O 0 0.014542364
were O 0 0.0030900417
pretreated O 0 0.012346342
with O 0 0.0025015038
maltolyl B-Chemical 1 0.12000893
p I-Chemical 1 0.0030908482
- I-Chemical 1 0.002915248
coumarate I-Chemical 1 0.900821
, O 0 0.0011332592
before O 0 0.00037891304
exposed O 0 0.00069720106
to O 0 0.00070565636
amyloid B-Chemical 0 0.99244714
beta I-Chemical 0 0.714135
peptide I-Chemical 0 0.025825487
( I-Chemical 0 0.0016264669
1 I-Chemical 0 0.0009713336
- I-Chemical 0 0.0013982393
42 I-Chemical 0 0.001577567
) I-Chemical 0 0.0021698063
, O 0 0.003069652
glutamate B-Chemical 1 0.99589765
or O 0 0.0068041948
H2O2 B-Chemical 0 0.99407357
. O 0 0.010190362

We O 0 0.0035362053
found O 0 0.0023717259
that O 0 0.0017857312
maltolyl B-Chemical 1 0.058565114
p I-Chemical 1 0.003148554
- I-Chemical 1 0.0031365154
coumarate I-Chemical 1 0.9102125
significantly O 0 0.0017363961
decreased O 0 0.004769909
apoptotic O 0 0.8184885
cell O 0 0.10482611
death O 2 0.9959841
and O 0 0.0010149387
reduced O 0 0.0009825677
reactive O 0 0.5017094
oxygen O 1 0.98940337
species O 0 0.0037013046
, O 0 0.002132568
cytochrome O 0 0.9934095
c O 0 0.08031033
release O 0 0.20629568
, O 0 0.0027134959
and O 0 0.0026173496
caspase O 0 0.67990017
3 O 0 0.0038233285
activation O 0 0.009946707
. O 0 0.006240703

Taking O 0 0.003906291
these O 0 0.002644418
in O 0 0.0014842439
vitro O 0 0.002008861
and O 0 0.0010623585
in O 0 0.0006550835
vivo O 0 0.0010177178
results O 0 0.0004831172
together O 0 0.00046173547
, O 0 0.00047786292
our O 0 0.00026284484
study O 0 0.00046026552
suggests O 0 0.00021805942
that O 0 0.0002982799
maltolyl B-Chemical 1 0.073679686
p I-Chemical 1 0.0011897332
- I-Chemical 1 0.0012588691
coumarate I-Chemical 1 0.9122193
is O 0 0.0003865084
a O 0 0.0003333719
potentially O 0 0.000683447
effective O 0 0.00046376832
candidate O 0 0.00047592304
against O 0 0.00069144426
Alzheimer B-Disease 0 0.99971896
' I-Disease 0 0.0006893766
s I-Disease 0 0.000586773
disease I-Disease 0 0.2941508
that O 0 0.00028121486
is O 0 0.00031137632
characterized O 0 0.00057128136
by O 0 0.0003907143
wide O 0 0.0017049406
spread O 0 0.011359063
neuronal B-Disease 0 0.97371733
death I-Disease 2 0.9985368
and O 0 0.0017690421
progressive O 0 0.4653202
decline B-Disease 0 0.011516886
of I-Disease 0 0.0036501882
cognitive I-Disease 0 0.8221041
function I-Disease 0 0.008074104
. O 0 0.006089865

Attenuation O 0 0.22729702
of O 0 0.010544587
methamphetamine B-Chemical 1 0.9987369
- O 0 0.018660968
induced O 0 0.012053767
nigrostriatal O 0 0.99763787
dopaminergic O 0 0.9967528
neurotoxicity B-Disease 2 0.99918276
in O 0 0.0035904609
mice O 0 0.0024397518
by O 0 0.0056066886
lipopolysaccharide B-Chemical 0 0.9908449
pretreatment O 0 0.8487542
. O 0 0.012184498

Immunological O 0 0.5487951
activation O 0 0.007955964
has O 0 0.0026656773
been O 0 0.00219971
proposed O 0 0.0019955502
to O 0 0.0012866368
play O 0 0.001619433
a O 0 0.001431432
role O 0 0.0011097875
in O 0 0.0021823593
methamphetamine B-Chemical 1 0.9993455
- O 0 0.012290647
induced O 0 0.009128052
dopaminergic B-Disease 0 0.9920625
terminal I-Disease 0 0.13760048
damage I-Disease 0 0.9430818
. O 0 0.010857498

In O 0 0.0027878124
this O 0 0.0018883196
study O 0 0.0020886678
, O 0 0.0013564132
we O 0 0.00050470675
examined O 0 0.0005326855
the O 0 0.00057130266
roles O 0 0.0006115358
of O 0 0.0011755627
lipopolysaccharide B-Chemical 0 0.9951663
, O 0 0.0017023975
a O 0 0.0009033039
pro O 0 0.066866554
- O 0 0.0019507908
inflammatory O 0 0.7334538
and O 0 0.0010307237
inflammatory O 0 0.86707103
factor O 0 0.029369656
, O 0 0.00086230156
treatment O 0 0.0013443577
in O 0 0.0004507633
modulating O 0 0.00093611376
the O 0 0.0014202968
methamphetamine B-Chemical 1 0.99965644
- O 0 0.0148099195
induced O 0 0.021736123
nigrostriatal O 0 0.998569
dopamine B-Chemical 1 0.9992472
neurotoxicity B-Disease 2 0.9990822
. O 0 0.013016029

Lipopolysaccharide B-Chemical 0 0.9908703
pretreatment O 0 0.3678826
did O 0 0.0024901647
not O 0 0.0013253146
affect O 0 0.0008577106
the O 0 0.00094202743
basal O 0 0.0024319494
body O 0 0.004016759
temperature O 0 0.0031358493
or O 0 0.001498547
methamphetamine B-Chemical 1 0.99945027
- O 0 0.005226674
elicited O 0 0.0035917691
hyperthermia B-Disease 2 0.995587
three O 0 0.0017631843
days O 0 0.0031450265
later O 0 0.004313467
. O 0 0.0058128284

Such O 0 0.012110951
systemic O 0 0.8381566
lipopolysaccharide B-Chemical 0 0.99251384
treatment O 0 0.031117313
mitigated O 0 0.3466031
methamphetamine B-Chemical 1 0.9997547
- O 0 0.019500917
induced O 0 0.005345547
striatal O 0 0.99493223
dopamine B-Chemical 1 0.99928826
and O 0 0.0012248504
3 B-Chemical 0 0.00062084047
, I-Chemical 0 0.00076388306
4 I-Chemical 0 0.0006240262
- I-Chemical 0 0.002347592
dihydroxyphenylacetic I-Chemical 0 0.9996172
acid I-Chemical 0 0.9535389
depletions O 0 0.28558686
in O 0 0.0009328995
a O 0 0.0014921019
dose O 0 0.035035815
- O 0 0.0037390725
dependent O 0 0.0028841095
manner O 0 0.0069634463
. O 0 0.0059783515

As O 0 0.002502475
the O 0 0.0022133137
most O 0 0.0027958439
potent O 0 0.01816168
dose O 0 0.04315754
( O 0 0.0018233913
1 O 0 0.0008941805
mg O 0 0.26927415
/ O 0 0.0015081593
kg O 0 0.005155361
) O 0 0.00070341845
of O 0 0.00058739184
lipopolysaccharide B-Chemical 0 0.98602307
was O 0 0.0005023844
administered O 0 0.0009881459
two O 0 0.0001792461
weeks O 0 0.00023714705
, O 0 0.00024717135
one O 0 0.00012637959
day O 0 0.00015705002
before O 0 0.00010048329
or O 0 0.00013904866
after O 0 0.00012024489
the O 0 0.00028113686
methamphetamine B-Chemical 1 0.99970204
dosing O 0 0.20972867
regimen O 0 0.05218968
, O 0 0.0021081967
methamphetamine B-Chemical 1 0.9998368
- O 0 0.0040407246
induced O 0 0.0022515217
striatal O 0 0.99350125
dopamine B-Chemical 1 0.9993236
and O 0 0.00084895955
3 B-Chemical 0 0.00054222555
, I-Chemical 0 0.0007668351
4 I-Chemical 0 0.0007392964
- I-Chemical 0 0.0032698277
dihydroxyphenylacetic I-Chemical 0 0.9994293
acid I-Chemical 0 0.95632505
depletions O 0 0.40919998
remained O 0 0.005579666
unaltered O 0 0.006580672
. O 0 0.0061512515

Moreover O 0 0.0069255936
, O 0 0.0052985237
systemic O 0 0.84443194
lipopolysaccharide B-Chemical 0 0.99527943
pretreatment O 0 0.7875262
( O 0 0.0030766756
1 O 0 0.0010772927
mg O 0 0.37024027
/ O 0 0.0017644924
kg O 0 0.007235325
) O 0 0.0007995729
attenuated O 0 0.001121817
local O 0 0.0024510694
methamphetamine B-Chemical 1 0.9997981
infusion O 0 0.41115728
- O 0 0.0017626757
produced O 0 0.00066939194
dopamine B-Chemical 1 0.99913615
and O 0 0.00061052246
3 B-Chemical 0 0.00035715377
, I-Chemical 0 0.0004581207
4 I-Chemical 0 0.0003623435
- I-Chemical 0 0.001506021
dihydroxyphenylacetic I-Chemical 0 0.99977237
acid I-Chemical 0 0.9584413
depletions O 0 0.31247744
in O 0 0.00034865408
the O 0 0.00038822115
striatum O 0 0.5945546
, O 0 0.0003620766
indicating O 0 0.0001728624
that O 0 0.00016398676
the O 0 0.00020964068
protective O 0 0.0038555134
effect O 0 0.00047735966
of O 0 0.0008929648
lipopolysaccharide B-Chemical 0 0.99628854
is O 0 0.00057391054
less O 0 0.0003903106
likely O 0 0.00027786611
due O 0 0.00021150064
to O 0 0.00033596196
interrupted O 0 0.00094071886
peripheral O 0 0.0121808825
distribution O 0 0.0007105617
or O 0 0.001296466
metabolism O 0 0.4228025
of O 0 0.011963026
methamphetamine B-Chemical 1 0.99882466
. O 0 0.009967823

We O 0 0.0033205303
concluded O 0 0.0031281451
a O 0 0.0017170109
critical O 0 0.0011953999
time O 0 0.00083517574
window O 0 0.0011760723
for O 0 0.00090061175
systemic O 0 0.8816171
lipopolysaccharide B-Chemical 0 0.9973091
pretreatment O 0 0.65939915
in O 0 0.00097516464
exerting O 0 0.045521095
effective O 0 0.0026292573
protection O 0 0.01713212
against O 0 0.0033973502
methamphetamine B-Chemical 1 0.99972314
- O 0 0.02879896
induced O 0 0.03230461
nigrostriatal O 0 0.99859065
dopamine B-Chemical 1 0.99923825
neurotoxicity B-Disease 2 0.9990652
. O 0 0.014040306

Acute O 0 0.97995824
myocarditis B-Disease 2 0.9968736
associated O 0 0.05509193
with O 0 0.054239985
clozapine B-Chemical 1 0.99701476
. O 0 0.037109654

OBJECTIVE O 0 0.6678774
: O 0 0.006105456
A O 0 0.008965205
case O 0 0.0019187734
of O 0 0.0023595733
acute O 0 0.9772021
myocarditis B-Disease 2 0.99975127
associated O 0 0.005042095
with O 0 0.0010950081
the O 0 0.0005552261
commencement O 0 0.0011204744
of O 0 0.0012110481
clozapine B-Chemical 1 0.999845
is O 0 0.0008372857
described O 0 0.00043086623
, O 0 0.0005345301
highlighting O 0 0.00046623632
the O 0 0.0004866338
onset O 0 0.0029016673
, O 0 0.00092497066
course O 0 0.0012716915
and O 0 0.0012197475
possible O 0 0.0019106186
contributing O 0 0.00399082
factors O 0 0.014032269
. O 0 0.006201795

There O 0 0.0062672887
is O 0 0.002821475
an O 0 0.0023827574
urgent O 0 0.002928952
need O 0 0.0011002551
to O 0 0.00090471446
raise O 0 0.0010007446
awareness O 0 0.0023909642
about O 0 0.00085152173
this O 0 0.0010431539
potentially O 0 0.0042844326
fatal O 0 0.9786695
complication O 0 0.7669047
of O 0 0.01636647
clozapine B-Chemical 1 0.9994153
use O 0 0.018190144
. O 0 0.008765625

RESULTS O 0 0.03510073
: O 0 0.005911635
A O 0 0.008462654
20 O 0 0.0023477003
- O 0 0.0020875847
year O 0 0.0012389583
- O 0 0.0014113615
old O 0 0.00091374264
male O 0 0.001799334
with O 0 0.0011931742
schizophrenia B-Disease 2 0.9970235
developed O 0 0.0026251439
a O 0 0.0013430625
sudden O 0 0.94436073
onset O 0 0.021880843
of O 0 0.003517119
myocarditis B-Disease 2 0.99952435
after O 0 0.001745031
commencement O 0 0.006932503
of O 0 0.010479167
clozapine B-Chemical 1 0.99914885
. O 0 0.010701261

The O 0 0.006563267
patient O 0 0.0077870474
recovered O 0 0.0054099625
with O 0 0.006666104
intensive O 0 0.01028236
medical O 0 0.029435059
support O 0 0.016256599
. O 0 0.016506875

The O 0 0.0042207516
symptoms O 0 0.061383888
occurred O 0 0.0027492035
around O 0 0.0016629986
2 O 0 0.0012814428
weeks O 0 0.0010136304
after O 0 0.0007740968
starting O 0 0.0020760854
clozapine B-Chemical 1 0.9990435
in O 0 0.0026341893
an O 0 0.0038743014
inpatient O 0 0.02080951
setting O 0 0.008820901
. O 0 0.008020449

Possible O 0 0.017748158
contributing O 0 0.0051421355
factors O 0 0.0050136657
may O 0 0.0021856253
have O 0 0.0019507116
been O 0 0.002267583
concomitant O 0 0.017708631
antidepressant B-Chemical 1 0.998033
use O 0 0.0042279507
and O 0 0.0035568161
unaccustomed O 0 0.08973239
physical O 0 0.036957774
activity O 0 0.009061377
. O 0 0.007809864

CONCLUSIONS O 0 0.90135276
: O 0 0.014780004
Myocarditis B-Disease 0 0.99418265
is O 0 0.0027033722
an O 0 0.0021389765
increasingly O 0 0.002578493
recognized O 0 0.0024165506
complication O 0 0.20514171
associated O 0 0.0024104351
with O 0 0.0021299315
the O 0 0.0021016682
use O 0 0.003911502
of O 0 0.009781669
clozapine B-Chemical 1 0.9988764
. O 0 0.01327583

It O 0 0.009290461
can O 0 0.0043344125
be O 0 0.0046388027
fatal O 0 0.68768376
if O 0 0.002484352
not O 0 0.0026946405
recognized O 0 0.0042352215
and O 0 0.004658974
treated O 0 0.009127509
early O 0 0.016618375
. O 0 0.011168448

Considering O 0 0.0033029197
that O 0 0.0026412157
clozapine B-Chemical 1 0.9989531
remains O 0 0.0020927028
the O 0 0.0010402681
gold O 0 0.05460881
standard O 0 0.00061175297
in O 0 0.00051397365
treatment O 0 0.001120625
of O 0 0.00078122417
resistant O 0 0.007319601
psychosis B-Disease 0 0.999398
, O 0 0.0009027541
there O 0 0.00024315935
is O 0 0.00030017816
an O 0 0.00034992886
urgent O 0 0.0006424987
need O 0 0.00020442484
to O 0 0.00019767012
raise O 0 0.00027417927
awareness O 0 0.0011370069
among O 0 0.0003983541
medical O 0 0.002869742
and O 0 0.00043290292
paramedical O 0 0.0025564895
staff O 0 0.0008608809
involved O 0 0.00050147815
in O 0 0.000501538
the O 0 0.00065903366
care O 0 0.0014685034
of O 0 0.0018172484
these O 0 0.003462291
patients O 0 0.0126812635
. O 0 0.0060061715

There O 0 0.0060695284
are O 0 0.0028898031
also O 0 0.002140529
implications O 0 0.002139468
for O 0 0.001356321
recommendations O 0 0.0025341152
and O 0 0.0015930495
regulations O 0 0.0033099344
regarding O 0 0.001408191
the O 0 0.0019758774
use O 0 0.003846892
of O 0 0.009351024
clozapine B-Chemical 1 0.99869686
. O 0 0.013988714

Severe O 0 0.9727798
rhabdomyolysis B-Disease 0 0.999244
and O 0 0.008782881
acute B-Disease 0 0.97824746
renal I-Disease 0 0.9955853
failure I-Disease 0 0.8752937
secondary O 0 0.007876267
to O 0 0.001163557
concomitant O 0 0.006941274
use O 0 0.0016794387
of O 0 0.0033475712
simvastatin B-Chemical 1 0.99966395
, O 0 0.0268133
amiodarone B-Chemical 1 0.99958545
, O 0 0.008498017
and O 0 0.007040132
atazanavir B-Chemical 0 0.9924273
. O 0 0.008772505

OBJECTIVE O 0 0.4978065
: O 0 0.004303088
To O 0 0.0014641435
report O 0 0.0025559668
a O 0 0.0011919348
case O 0 0.00091699144
of O 0 0.0009767956
a O 0 0.00100196
severe O 0 0.080718584
interaction O 0 0.0011229996
between O 0 0.00059868966
simvastatin B-Chemical 1 0.99976987
, O 0 0.00856959
amiodarone B-Chemical 1 0.99984646
, O 0 0.0022083572
and O 0 0.0011147556
atazanavir B-Chemical 0 0.99598026
resulting O 0 0.0015441336
in O 0 0.001948955
rhabdomyolysis B-Disease 0 0.9997906
and O 0 0.010376732
acute B-Disease 0 0.9939751
renal I-Disease 0 0.9969291
failure I-Disease 0 0.97436905
. O 0 0.01078034

BACKGROUND O 0 0.80004424
: O 0 0.006659868
A O 0 0.009718429
72 O 0 0.0024170591
- O 0 0.0020130905
year O 0 0.0011813078
- O 0 0.0013299184
old O 0 0.0008240772
white O 0 0.0015173162
man O 0 0.0318917
with O 0 0.0007411311
underlying O 0 0.0028570204
human B-Disease 0 0.016315559
immunodeficiency I-Disease 0 0.9991653
virus I-Disease 0 0.60471344
, O 0 0.0030059903
atrial B-Disease 0 0.9949173
fibrillation I-Disease 0 0.9998172
, O 0 0.0031071187
coronary B-Disease 0 0.85216385
artery I-Disease 0 0.6629135
disease I-Disease 0 0.8189359
, O 0 0.00085579057
and O 0 0.0006136017
hyperlipidemia B-Disease 0 0.99975795
presented O 0 0.00075814745
with O 0 0.0007408345
generalized O 0 0.2764728
pain B-Disease 0 0.99232614
, O 0 0.0026851427
fatigue B-Disease 2 0.99194485
, O 0 0.0009872603
and O 0 0.00066707627
dark O 0 0.00094469025
orange O 0 0.008942531
urine O 0 0.13937095
for O 0 0.0015984897
3 O 0 0.0022413768
days O 0 0.0033558318
. O 0 0.0046237935

The O 0 0.0028213891
patient O 0 0.0030778823
was O 0 0.0016580052
taking O 0 0.0021993038
80 O 0 0.0020151762
mg O 0 0.59276366
simvastatin B-Chemical 1 0.9994931
at O 0 0.0008260679
bedtime O 0 0.74247366
( O 0 0.000814168
initiated O 0 0.0004871768
27 O 0 0.0005382559
days O 0 0.00027486295
earlier O 0 0.0004079729
) O 0 0.0008041576
; O 0 0.00091930793
amiodarone B-Chemical 1 0.99965954
at O 0 0.00023207419
a O 0 0.00031193998
dose O 0 0.0034486523
of O 0 0.00036856625
400 O 0 0.0019622722
mg O 0 0.15097551
daily O 0 0.00067853724
for O 0 0.00017214131
7 O 0 0.00016059358
days O 0 0.00016000589
, O 0 0.00020639255
then O 0 0.00014995046
200 O 0 0.00049625395
mg O 0 0.100770034
daily O 0 0.0009163163
( O 0 0.00031123773
initiated O 0 0.00025037336
19 O 0 0.00031655066
days O 0 0.00017739636
earlier O 0 0.00028944798
) O 0 0.0005467179
; O 0 0.00044750623
and O 0 0.0002735813
400 O 0 0.001780348
mg O 0 0.42742124
atazanavir B-Chemical 0 0.9936534
daily O 0 0.00329024
( O 0 0.0006129003
initiated O 0 0.0004976068
at O 0 0.0003136855
least O 0 0.00044530627
2 O 0 0.00094316626
years O 0 0.002094586
previously O 0 0.0022626733
) O 0 0.0054013096
. O 0 0.004834479

Laboratory O 0 0.012412592
evaluation O 0 0.0039788657
revealed O 0 0.002675313
66 O 0 0.0035423841
, O 0 0.002494011
680 O 0 0.008972374
U O 0 0.28523993
/ O 0 0.0061482266
L O 0 0.73120725
creatine B-Chemical 1 0.99897826
kinase O 0 0.5985226
, O 0 0.0015995008
93 O 0 0.002166674
mg O 0 0.4629134
/ O 0 0.002318704
dL O 0 0.04336596
blood B-Chemical 1 0.06149013
urea I-Chemical 1 0.9985891
nitrogen I-Chemical 1 0.99590695
, O 0 0.0010890834
4 O 0 0.00037468344
. O 0 0.0002055769
6 O 0 0.0002590264
mg O 0 0.12197531
/ O 0 0.0013494658
dL O 0 0.05173148
creatinine B-Chemical 1 0.9935441
, O 0 0.001377023
1579 O 0 0.1456627
U O 0 0.3547952
/ O 0 0.0070924642
L O 0 0.8510128
aspartate B-Chemical 1 0.9994753
aminotransferase O 0 0.9989742
, O 0 0.0028297915
and O 0 0.0017612927
738 O 0 0.17694421
U O 0 0.43452382
/ O 0 0.017582584
L O 0 0.84372383
alanine B-Chemical 1 0.99263436
aminotransferase O 0 0.9965957
. O 0 0.014021888

Simvastatin B-Chemical 0 0.9988932
, O 0 0.01544643
amiodarone B-Chemical 1 0.999201
, O 0 0.0034381936
and O 0 0.0012390272
the O 0 0.0007720948
patient O 0 0.0012003289
' O 0 0.0007947383
s O 0 0.0008465294
human B-Disease 0 0.0027270243
immunodeficiency I-Disease 0 0.9980393
virus I-Disease 0 0.30284166
medications O 0 0.61876446
were O 0 0.0004219444
all O 0 0.00026963901
temporarily O 0 0.0019429576
discontinued O 0 0.019337714
and O 0 0.00035067755
the O 0 0.0002889448
patient O 0 0.0005958615
was O 0 0.0003706672
given O 0 0.000362639
forced O 0 0.006795195
alkaline O 0 0.61216646
diuresis O 0 0.9981231
and O 0 0.0020771066
started O 0 0.00300663
on O 0 0.002051292
dialysis O 0 0.16008072
. O 0 0.0067159813

Nine O 0 0.0071315304
days O 0 0.0021656062
later O 0 0.001493455
the O 0 0.0012072566
patient O 0 0.0017906885
' O 0 0.0014144887
s O 0 0.0018109824
creatine B-Chemical 1 0.99753714
kinase O 0 0.24868034
had O 0 0.0010893091
dropped O 0 0.0020394644
to O 0 0.00091547857
1695 O 0 0.051302094
U O 0 0.3002698
/ O 0 0.0034977382
L O 0 0.32123023
and O 0 0.001235539
creatinine B-Chemical 1 0.9915412
was O 0 0.0011259383
3 O 0 0.0008795983
. O 0 0.00073069095
3 O 0 0.0013871387
mg O 0 0.20051749
/ O 0 0.0076568327
dL O 0 0.057097625
. O 0 0.005832947

The O 0 0.003094013
patient O 0 0.003455738
was O 0 0.0020112752
discharged O 0 0.009111545
and O 0 0.0013820659
continued O 0 0.0014001487
outpatient O 0 0.0021253717
dialysis O 0 0.020397624
for O 0 0.00085984066
1 O 0 0.00088035036
month O 0 0.0008180579
until O 0 0.0007763285
his O 0 0.0030696213
renal O 0 0.9334079
function O 0 0.0056878375
recovered O 0 0.0054788175
. O 0 0.0070168963

DISCUSSION O 0 0.021802086
: O 0 0.0038896129
The O 0 0.0017032955
risk O 0 0.008743049
of O 0 0.0033531312
rhabdomyolysis B-Disease 0 0.999673
is O 0 0.0018448454
increased O 0 0.0016290504
in O 0 0.0006717449
the O 0 0.00060415117
presence O 0 0.0006936573
of O 0 0.0011855355
concomitant O 0 0.024823034
drugs O 0 0.7941328
that O 0 0.0022534397
inhibit O 0 0.015520507
simvastatin B-Chemical 1 0.999387
metabolism O 0 0.955777
. O 0 0.010424127

Simvastatin B-Chemical 0 0.99562705
is O 0 0.034190778
metabolized O 0 0.9355352
by O 0 0.04086025
CYP3A4 O 0 0.99482155
. O 0 0.039299805

Amiodarone B-Chemical 1 0.99639976
and O 0 0.017693466
atazanavir B-Chemical 0 0.9872388
are O 0 0.011807489
recognized O 0 0.023374278
CYP3A4 O 0 0.9976974
inhibitors O 0 0.7740936
. O 0 0.02187361

CONCLUSIONS O 0 0.7143618
: O 0 0.0063179317
Pharmacokinetic O 0 0.86660427
differences O 0 0.0015435317
in O 0 0.0014582672
statins B-Chemical 1 0.99163073
are O 0 0.0012168544
an O 0 0.0009634987
important O 0 0.0005759411
consideration O 0 0.0005809053
for O 0 0.00044924457
assessing O 0 0.0005214841
the O 0 0.0008191082
risk O 0 0.0078026773
of O 0 0.0021075048
potential O 0 0.004156915
drug O 0 0.5164068
interactions O 0 0.012387541
. O 0 0.007156196

In O 0 0.002913178
patients O 0 0.0035256709
requiring O 0 0.0019903432
the O 0 0.0011463042
concurrent O 0 0.0024923189
use O 0 0.0013146582
of O 0 0.0016056707
statins B-Chemical 1 0.99843603
and O 0 0.0058050794
CYP3A4 O 0 0.999887
inhibitors O 0 0.7563648
, O 0 0.012963226
pravastatin B-Chemical 0 0.9999088
, O 0 0.014826542
fluvastatin B-Chemical 0 0.9999193
, O 0 0.002464547
and O 0 0.0008452108
rosuvastatin B-Chemical 0 0.99980146
carry O 0 0.0004494315
the O 0 0.00028345795
lowest O 0 0.00039292706
risk O 0 0.010834524
of O 0 0.0005753068
drug O 0 0.4698144
interactions O 0 0.0035812706
; O 0 0.0029108217
atorvastatin B-Chemical 0 0.9998344
carries O 0 0.002372923
moderate O 0 0.044346713
risk O 0 0.11564858
, O 0 0.00091320905
whereas O 0 0.00063211273
simvastatin B-Chemical 1 0.999848
and O 0 0.0019749608
lovastatin B-Chemical 1 0.99981827
have O 0 0.00068735186
the O 0 0.00034934928
highest O 0 0.00048135596
risk O 0 0.016056215
and O 0 0.00045057325
should O 0 0.0002580394
be O 0 0.0003841769
avoided O 0 0.0005246261
in O 0 0.00051965204
patients O 0 0.0023356536
taking O 0 0.0042162323
concomitant O 0 0.17135368
CYP3A4 O 0 0.99942124
inhibitors O 0 0.77320796
. O 0 0.009670189

Interaction O 0 0.020494161
between O 0 0.0062967576
warfarin B-Chemical 1 0.99036574
and O 0 0.014035866
levofloxacin B-Chemical 1 0.99491537
: O 0 0.015073697
case O 0 0.009568975
series O 0 0.017348843
. O 0 0.01402636

Warfarin B-Chemical 0 0.994592
is O 0 0.003712526
the O 0 0.0019745897
most O 0 0.002317901
widely O 0 0.0023311016
used O 0 0.0013487346
oral O 0 0.25689384
anticoagulant O 0 0.9588061
and O 0 0.001744868
is O 0 0.0011572682
indicated O 0 0.00088137557
for O 0 0.0012357379
many O 0 0.0026291884
clinical O 0 0.014693731
conditions O 0 0.0075837234
. O 0 0.0071385736

Levofloxacin B-Chemical 0 0.9946485
, O 0 0.0051289313
a O 0 0.0030434448
fluoroquinolone B-Chemical 0 0.99563015
, O 0 0.0022626272
is O 0 0.00080773066
one O 0 0.00043507386
of O 0 0.0005931052
the O 0 0.00045397738
most O 0 0.00078749034
commonly O 0 0.0017762434
prescribed O 0 0.060325395
antibiotics O 0 0.51914585
in O 0 0.00037346347
clinical O 0 0.005381609
practice O 0 0.00059070677
and O 0 0.00035519488
is O 0 0.00031988477
effective O 0 0.00054679875
against O 0 0.00052484544
Gram O 0 0.4665739
- O 0 0.0011859372
positive O 0 0.0006038509
, O 0 0.001159461
Gram O 0 0.3068817
- O 0 0.0016261904
negative O 0 0.0010919991
, O 0 0.0017997315
and O 0 0.0022166504
atypical O 0 0.19650267
bacteria O 0 0.050372723
. O 0 0.0070020705

While O 0 0.0032535286
small O 0 0.0023499597
prospective O 0 0.0035776296
studies O 0 0.0016973338
have O 0 0.0010045422
not O 0 0.0006709689
revealed O 0 0.0006645869
any O 0 0.00046936382
significant O 0 0.000789683
drug O 0 0.3195082
- O 0 0.0013325822
drug O 0 0.18666095
interaction O 0 0.0005945723
between O 0 0.00026083592
warfarin B-Chemical 1 0.9989692
and O 0 0.0012009215
levofloxacin B-Chemical 1 0.9994603
, O 0 0.00061241863
several O 0 0.00031738286
case O 0 0.0002851132
reports O 0 0.00047316396
have O 0 0.00029121424
indicated O 0 0.00024118403
that O 0 0.00041973253
levofloxacin B-Chemical 1 0.9989261
may O 0 0.0006661513
significantly O 0 0.0009009093
potentiate O 0 0.0111348955
the O 0 0.0010575898
anticoagulation O 0 0.77782804
effect O 0 0.0029766934
of O 0 0.008057558
warfarin B-Chemical 1 0.9977291
. O 0 0.009406812

We O 0 0.0034122192
report O 0 0.004477589
3 O 0 0.0015793166
cases O 0 0.0019287108
of O 0 0.0016899317
serious O 0 0.19291809
bleeding B-Disease 0 0.99598604
complications O 0 0.73314327
that O 0 0.000744685
appear O 0 0.00068163144
to O 0 0.00044125586
be O 0 0.0004443736
the O 0 0.00036066287
result O 0 0.00038877537
of O 0 0.0006731248
the O 0 0.00068953657
interaction O 0 0.0012047688
between O 0 0.0011929105
warfarin B-Chemical 1 0.9975407
and O 0 0.010936105
levofloxacin B-Chemical 1 0.99724567
. O 0 0.009382902

Physicians O 0 0.0070841284
should O 0 0.0017002465
be O 0 0.001522065
aware O 0 0.001252913
of O 0 0.0009874625
this O 0 0.00071636273
potential O 0 0.0009416161
interaction O 0 0.00081704906
and O 0 0.0006670839
use O 0 0.0007471057
caution O 0 0.0011077784
when O 0 0.0006287942
prescribing O 0 0.056006264
levofloxacin B-Chemical 1 0.9978934
to O 0 0.0018696949
patients O 0 0.009473534
taking O 0 0.024538832
warfarin B-Chemical 1 0.9967458
. O 0 0.009347536

Mutations O 0 0.016031336
associated O 0 0.003981863
with O 0 0.003919691
lamivudine B-Chemical 1 0.99911803
- O 0 0.0076656416
resistance O 0 0.020078233
in O 0 0.0010928067
therapy O 0 0.09596581
- O 0 0.010708396
na B-Chemical 0 0.9968593
ve O 0 0.81316423
hepatitis B-Disease 2 0.9999417
B I-Disease 2 0.9918629
virus I-Disease 0 0.6022975
( I-Disease 0 0.0052935523
HBV I-Disease 0 0.9956768
) I-Disease 0 0.0018886377
infected I-Disease 0 0.00047722727
patients O 0 0.0011900115
with O 0 0.00042883505
and O 0 0.00040087296
without O 0 0.0005589739
HIV B-Disease 0 0.7227395
co I-Disease 0 0.5501924
- I-Disease 0 0.003944972
infection I-Disease 2 0.2803389
: O 0 0.00071162486
implications O 0 0.0005018258
for O 0 0.0003170333
antiretroviral O 0 0.19852977
therapy O 0 0.024582518
in O 0 0.00080889795
HBV B-Disease 0 0.9912389
and I-Disease 0 0.0021862048
HIV I-Disease 0 0.8454012
co I-Disease 0 0.56904334
- I-Disease 0 0.004264319
infected I-Disease 0 0.0023588403
South O 0 0.008072683
African O 0 0.021164577
patients O 0 0.011905123
. O 0 0.0062406505

This O 0 0.0048670797
was O 0 0.00222258
an O 0 0.0019253175
exploratory O 0 0.003891141
study O 0 0.0016020432
to O 0 0.0008836653
investigate O 0 0.00085053814
lamivudine B-Chemical 1 0.9994691
- O 0 0.012805864
resistant O 0 0.05972032
hepatitis B-Disease 2 0.9999347
B I-Disease 2 0.99072343
virus O 0 0.60482466
( O 0 0.00555675
HBV O 0 0.99555606
) O 0 0.001827648
strains O 0 0.0005666726
in O 0 0.00032808594
selected O 0 0.00057777413
lamivudine B-Chemical 1 0.99974936
- O 0 0.020988388
na B-Chemical 0 0.9974605
ve O 0 0.40037364
HBV O 0 0.99707127
carriers O 0 0.033120837
with O 0 0.00083812466
and O 0 0.00054544717
without O 0 0.0006283707
human B-Disease 0 0.0134867495
immunodeficiency I-Disease 0 0.99914193
virus I-Disease 0 0.6534634
( I-Disease 0 0.0055563813
HIV I-Disease 0 0.8262285
) I-Disease 0 0.0037745761
co I-Disease 0 0.3860242
- I-Disease 0 0.004449182
infection I-Disease 2 0.24938396
in O 0 0.0019303702
South O 0 0.008863393
African O 0 0.02304613
patients O 0 0.012096908
. O 0 0.0061103282

Thirty O 0 0.013220662
- O 0 0.0054476643
five O 0 0.002458428
lamivudine B-Chemical 1 0.9987056
- O 0 0.026025198
na B-Chemical 0 0.9937371
ve O 0 0.41771615
HBV B-Disease 0 0.9979684
infected I-Disease 0 0.006840349
patients O 0 0.0039495425
with O 0 0.00077606074
or O 0 0.00047617807
without O 0 0.00073430757
HIV B-Disease 0 0.71869975
co I-Disease 0 0.5332558
- I-Disease 0 0.0035042893
infection I-Disease 2 0.20291372
were O 0 0.00048181432
studied O 0 0.00068731507
: O 0 0.0006930032
15 O 0 0.00040824505
chronic O 0 0.90944207
HBV B-Disease 0 0.9972288
mono I-Disease 0 0.7212916
- I-Disease 0 0.0020684614
infected I-Disease 0 0.0006225478
patients O 0 0.0015688416
and O 0 0.000699076
20 O 0 0.0012239995
HBV B-Disease 0 0.98713046
- I-Disease 0 0.007001026
HIV I-Disease 0 0.75087637
co I-Disease 0 0.4965909
- I-Disease 0 0.0056904997
infected I-Disease 0 0.0037318212
patients O 0 0.011529808
. O 0 0.0062735546

The O 0 0.003027485
latter O 0 0.003972902
group O 0 0.002146658
was O 0 0.0012954471
further O 0 0.0012778388
sub O 0 0.00404357
- O 0 0.001450661
divided O 0 0.0005087679
into O 0 0.00038694072
13 O 0 0.00076747633
occult O 0 0.20003633
HBV O 0 0.99526477
( O 0 0.0059638214
HBsAg B-Chemical 1 0.9985304
- O 0 0.002164115
negative O 0 0.0007481605
) O 0 0.0010765719
and O 0 0.00066293206
7 O 0 0.0007182672
overt O 0 0.2837761
HBV O 0 0.9941209
( O 0 0.0085881725
HBsAg B-Chemical 1 0.9974269
- O 0 0.0048779207
positive O 0 0.0025626072
) O 0 0.0056112604
patients O 0 0.010624085
. O 0 0.0063139573

HBsAg B-Chemical 1 0.9885566
, O 0 0.008756027
anti O 0 0.017813798
- O 0 0.007964541
HBs O 0 0.9905715
, O 0 0.0036737446
anti O 0 0.013621514
- O 0 0.003957113
HBc O 0 0.9147477
, O 0 0.0015004891
and O 0 0.00087460096
anti O 0 0.0076856473
- O 0 0.002186398
HIV O 0 0.47460082
1 O 0 0.0005809175
/ O 0 0.00074849854
2 O 0 0.00025872447
were O 0 0.00019187004
determined O 0 0.00015652693
as O 0 0.0001751066
part O 0 0.00018522539
of O 0 0.0003196202
routine O 0 0.0004858597
diagnosis O 0 0.0038749143
using O 0 0.00057619147
Axsym O 0 0.3783981
assays O 0 0.0014052336
( O 0 0.0020701746
Abbott O 0 0.68180734
Laboratories O 0 0.1527039
, O 0 0.0023874263
North O 0 0.006177956
Chicago O 0 0.07650233
, O 0 0.0056657083
IL O 0 0.6569728
) O 0 0.010928743
. O 0 0.007572402

Serum O 0 0.13745025
samples O 0 0.0029661919
were O 0 0.002177937
PCR O 0 0.0061302576
amplified O 0 0.0017598422
with O 0 0.002101574
HBV O 0 0.9863625
reverse O 0 0.11854032
transcriptase O 0 0.8009542
( O 0 0.002473971
RT O 0 0.04811166
) O 0 0.0010203399
primers O 0 0.0010334217
, O 0 0.00044505505
followed O 0 0.00020437065
by O 0 0.00024065458
direct O 0 0.00023742193
sequencing O 0 0.00047884646
across O 0 0.00021098464
the O 0 0.0005166378
tyrosine B-Chemical 1 0.9720292
- O 0 0.011903176
methionine B-Chemical 0 0.9987908
- O 0 0.028198987
aspartate B-Chemical 1 0.99967754
- O 0 0.025878854
aspartate B-Chemical 1 0.9995573
( O 0 0.00391575
YMDD O 0 0.9955687
) O 0 0.001393219
motif O 0 0.0007785087
of O 0 0.0003808952
the O 0 0.0003080642
major O 0 0.0005835685
catalytic O 0 0.016106192
region O 0 0.000598166
in O 0 0.00046135575
the O 0 0.000706276
C O 0 0.56995696
domain O 0 0.001447397
of O 0 0.0017898415
the O 0 0.0027321125
HBV O 0 0.9903287
RT O 0 0.39176413
enzyme O 0 0.41150656
. O 0 0.009166621

HBV O 0 0.95556206
viral O 0 0.047112435
load O 0 0.0045061274
was O 0 0.0018721973
performed O 0 0.0014628292
with O 0 0.002107966
Amplicor O 0 0.5215188
HBV O 0 0.9884664
Monitor O 0 0.07225603
test O 0 0.0016492545
v2 O 0 0.0075829085
. O 0 0.0009261972
0 O 0 0.0014537056
( O 0 0.0020113306
Roche O 0 0.06913491
Diagnostics O 0 0.057807792
, O 0 0.004055264
Penzberg O 0 0.2814753
, O 0 0.0057388
Germany O 0 0.020393379
) O 0 0.009752392
. O 0 0.007856439

HBV O 0 0.986666
lamivudine B-Chemical 1 0.9987664
- O 0 0.008446705
resistant O 0 0.0034497213
strains O 0 0.0013670822
were O 0 0.0007431963
detected O 0 0.0004154169
in O 0 0.00044662753
3 O 0 0.00038347434
of O 0 0.0005132075
15 O 0 0.0004746278
mono O 0 0.083230376
- O 0 0.00133994
infected O 0 0.001026526
chronic O 0 0.99675107
hepatitis B-Disease 2 0.99995375
B I-Disease 2 0.99038845
patients O 0 0.017855192
and O 0 0.00069546007
10 O 0 0.00054011226
of O 0 0.00066360115
20 O 0 0.0011964678
HBV B-Disease 0 0.9855429
- I-Disease 0 0.0066676014
HIV I-Disease 0 0.7439542
co I-Disease 0 0.4930519
- I-Disease 0 0.0057160794
infected I-Disease 0 0.003756179
patients O 0 0.0115823075
. O 0 0.006303561

To O 0 0.0024932043
the O 0 0.0016753306
best O 0 0.001427353
of O 0 0.0012623739
our O 0 0.0008506373
knowledge O 0 0.0012487711
, O 0 0.0008307275
this O 0 0.000468325
constitutes O 0 0.0004143878
the O 0 0.00035201383
first O 0 0.00032673278
report O 0 0.0014069222
of O 0 0.0011028737
HBV O 0 0.99794716
lamivudine B-Chemical 1 0.9998493
- O 0 0.00879756
resistant O 0 0.0025614006
strains O 0 0.0007914731
in O 0 0.00056387606
therapy O 0 0.06362224
- O 0 0.007862232
na B-Chemical 0 0.9958339
ve O 0 0.5663534
HBV B-Disease 0 0.99738413
- I-Disease 0 0.026017632
HIV I-Disease 0 0.863604
co I-Disease 0 0.5938161
- I-Disease 0 0.006485417
infected I-Disease 0 0.0039998717
patients O 0 0.012108003
. O 0 0.0065282364

The O 0 0.004788086
HBV O 0 0.92302763
viral O 0 0.043026958
loads O 0 0.004417777
for O 0 0.0015572683
mono O 0 0.24626261
- O 0 0.0023131745
infected O 0 0.00087540137
and O 0 0.00078872265
co O 0 0.15495853
- O 0 0.0011948826
infected O 0 0.00045927856
patients O 0 0.00088771316
ranged O 0 0.0004333544
from O 0 0.00026722156
3 O 0 0.00022617284
. O 0 0.00014254067
32 O 0 0.00033608338
x O 0 0.00061664643
10 O 0 0.00027759766
( O 0 0.00030596496
2 O 0 0.0002238586
) O 0 0.0003026942
to O 0 0.0001727996
3 O 0 0.00017682451
. O 0 0.000121149744
82 O 0 0.0003892558
x O 0 0.0005944765
10 O 0 0.00026902763
( O 0 0.00029847617
7 O 0 0.0001940473
) O 0 0.0003125801
and O 0 0.00021555772
< O 0 0.0002624014
200 O 0 0.00038527517
to O 0 0.00019346573
4 O 0 0.00020174685
. O 0 0.00014659083
40 O 0 0.00029619422
x O 0 0.0007003309
10 O 0 0.00039561893
( O 0 0.00050630595
3 O 0 0.0004152851
) O 0 0.0008289886
copies O 0 0.0008924527
/ O 0 0.002465281
ml O 0 0.004954082
, O 0 0.003257485
respectively O 0 0.0064829355
. O 0 0.0050900676

It O 0 0.0056692893
remains O 0 0.0024003247
to O 0 0.0016017457
be O 0 0.0012998396
seen O 0 0.0008142876
whether O 0 0.0003876912
such O 0 0.00058753433
pre O 0 0.00266404
- O 0 0.0010414406
existing O 0 0.0007351624
antiviral O 0 0.15085292
mutations O 0 0.0036005548
could O 0 0.00026681117
result O 0 0.00024326952
in O 0 0.00023834006
widespread O 0 0.0011483808
emergence O 0 0.0009551416
of O 0 0.00074148143
HBV O 0 0.99414647
resistant O 0 0.0052296775
strains O 0 0.00071245676
when O 0 0.00033828837
lamivudine B-Chemical 1 0.9997609
- O 0 0.0021969927
containing O 0 0.0003412485
highly O 0 0.00059324945
active O 0 0.0010055739
antiretroviral O 0 0.48461962
( O 0 0.0010931841
ARV O 0 0.4848647
) O 0 0.0008739386
treatment O 0 0.001758884
( O 0 0.000779814
HAART O 0 0.8652518
) O 0 0.00066817197
regimens O 0 0.005826911
become O 0 0.00041560386
widely O 0 0.0004758872
applied O 0 0.0002684314
in O 0 0.0002622156
South O 0 0.0016432365
Africa O 0 0.0032077315
, O 0 0.00030608138
as O 0 0.00016103721
this O 0 0.0001969015
is O 0 0.00020247104
likely O 0 0.00017624027
to O 0 0.00017143793
have O 0 0.00021877643
potential O 0 0.00037112637
implications O 0 0.00048943097
in O 0 0.00030250757
the O 0 0.00038062874
management O 0 0.0015877011
of O 0 0.0018890719
HBV B-Disease 0 0.99635714
- I-Disease 0 0.01884677
HIV I-Disease 0 0.8570965
co I-Disease 0 0.600015
- I-Disease 0 0.0062682624
infected I-Disease 0 0.0037665872
patients O 0 0.011924266
. O 0 0.0062044226

Rabbit B-Disease 0 0.28860453
syndrome I-Disease 0 0.94919646
, O 0 0.009174532
antidepressant B-Chemical 1 0.9961825
use O 0 0.0056503084
, O 0 0.004160503
and O 0 0.003835417
cerebral O 0 0.9108606
perfusion O 0 0.8093455
SPECT O 0 0.97251296
scan O 0 0.024917511
findings O 0 0.020116745
. O 0 0.010994396

The O 0 0.004957242
rabbit B-Disease 0 0.026245033
syndrome I-Disease 0 0.919588
is O 0 0.0033816432
an O 0 0.004512088
extrapyramidal O 0 0.9992543
side O 0 0.113756336
effect O 0 0.002795687
associated O 0 0.0034606396
with O 0 0.0062788483
chronic O 0 0.9944508
neuroleptic O 0 0.99974996
therapy O 0 0.76928055
. O 0 0.012428454

Its O 0 0.0639009
occurrence O 0 0.004801955
in O 0 0.0016291816
a O 0 0.0014062062
patient O 0 0.0016378203
being O 0 0.001237457
treated O 0 0.0014785988
with O 0 0.0015095185
imipramine B-Chemical 0 0.9998405
is O 0 0.0009665936
described O 0 0.00044794675
, O 0 0.0004955118
representing O 0 0.00033472278
the O 0 0.00028979202
first O 0 0.00027915504
reported O 0 0.00055807474
case O 0 0.00045568953
of O 0 0.0006919232
this O 0 0.00093573343
syndrome O 0 0.68346256
in O 0 0.0013706334
conjunction O 0 0.0038415615
with O 0 0.0076475064
antidepressants B-Chemical 1 0.99813867
. O 0 0.009560853

Repeated O 0 0.041667853
cerebral O 0 0.82027435
perfusion O 0 0.61199224
SPECT O 0 0.93147844
scans O 0 0.0054903515
revealed O 0 0.0013349558
decreased B-Disease 0 0.0020583938
basal I-Disease 0 0.0040137745
ganglia I-Disease 0 0.09201425
perfusion I-Disease 0 0.14816187
while O 0 0.00044589394
the O 0 0.00038656042
movement B-Disease 0 0.001739168
disorder I-Disease 0 0.73346615
was O 0 0.0004434496
present O 0 0.00028957386
, O 0 0.0004746242
and O 0 0.00036426313
a O 0 0.0004111624
return O 0 0.0005888464
to O 0 0.00039870632
normal O 0 0.0011722416
perfusion O 0 0.09865949
when O 0 0.00074337405
the O 0 0.0014899869
rabbit B-Disease 0 0.074797854
syndrome I-Disease 0 0.9784238
resolved O 0 0.018590864
. O 0 0.00739519

Estrogen O 0 0.9973937
prevents O 0 0.07396331
cholesteryl B-Chemical 0 0.99661
ester I-Chemical 0 0.9918967
accumulation O 0 0.018607954
in O 0 0.0023106413
macrophages O 0 0.010497815
induced O 0 0.0027221823
by O 0 0.0021886774
the O 0 0.0028157171
HIV O 0 0.8215719
protease O 0 0.6303495
inhibitor O 0 0.8713492
ritonavir B-Chemical 0 0.99743974
. O 0 0.014199546

Individuals O 0 0.011457682
with O 0 0.003983297
HIV O 0 0.27107656
can O 0 0.0015275053
now O 0 0.0013770859
live O 0 0.0013983565
long O 0 0.001070287
lives O 0 0.0021661527
with O 0 0.0010234817
drug O 0 0.25083247
therapy O 0 0.021239666
that O 0 0.0007396258
often O 0 0.001538468
includes O 0 0.0012722354
protease O 0 0.12580444
inhibitors O 0 0.12474184
such O 0 0.003279463
as O 0 0.00508831
ritonavir B-Chemical 0 0.9962824
. O 0 0.009316974

Many O 0 0.0071816435
patients O 0 0.0065091313
, O 0 0.003106311
however O 0 0.0022953968
, O 0 0.0016684684
develop O 0 0.0013926777
negative O 0 0.001019112
long O 0 0.0014203009
- O 0 0.0016776018
term O 0 0.0013642851
side O 0 0.012656617
effects O 0 0.0031593766
such O 0 0.002426181
as O 0 0.0035525546
premature B-Disease 0 0.9044756
atherosclerosis I-Disease 2 0.9987206
. O 0 0.015314189

We O 0 0.003150163
have O 0 0.0023699289
previously O 0 0.0017677592
demonstrated O 0 0.0015220237
that O 0 0.0013013707
ritonavir B-Chemical 0 0.9982179
treatment O 0 0.0145234885
increases O 0 0.0044080834
atherosclerotic B-Disease 2 0.9993711
lesion I-Disease 0 0.8715518
formation O 0 0.009083737
in O 0 0.00050627213
male O 0 0.0013989719
mice O 0 0.0002570077
to O 0 0.00035732033
a O 0 0.00048988604
greater O 0 0.00053255894
extent O 0 0.00052516744
than O 0 0.00067821535
in O 0 0.0013345311
female O 0 0.004984374
mice O 0 0.002805579
. O 0 0.005239654

Furthermore O 0 0.006396847
, O 0 0.0043987115
peripheral O 0 0.018448325
blood O 0 0.013498365
monocytes O 0 0.05487711
isolated O 0 0.0016824066
from O 0 0.001659108
ritonavir B-Chemical 0 0.9983132
- O 0 0.0033422315
treated O 0 0.002059007
females O 0 0.001922373
had O 0 0.0018256857
less O 0 0.004039154
cholesteryl B-Chemical 0 0.9963331
ester I-Chemical 0 0.99055684
accumulation O 0 0.08761155
. O 0 0.009902368

In O 0 0.0026662238
the O 0 0.0016793502
present O 0 0.0011053517
study O 0 0.0015862444
, O 0 0.0010432999
we O 0 0.00038837572
have O 0 0.00054329436
investigated O 0 0.00050949975
the O 0 0.00044132333
molecular O 0 0.005561519
mechanisms O 0 0.0012128333
by O 0 0.000530395
which O 0 0.0007188976
female O 0 0.002898175
hormones O 0 0.8054267
influence O 0 0.000983926
cholesterol B-Chemical 0 0.99816257
metabolism O 0 0.67989135
in O 0 0.0006672951
macrophages O 0 0.0052884803
in O 0 0.00052508287
response O 0 0.0010183414
to O 0 0.0007794946
the O 0 0.0013781926
HIV O 0 0.74926925
protease O 0 0.544626
inhibitor O 0 0.8407152
ritonavir B-Chemical 0 0.99779224
. O 0 0.011320108

We O 0 0.003400458
have O 0 0.0025446946
utilized O 0 0.0019881697
the O 0 0.0016041
human O 0 0.0029897215
monocyte O 0 0.33736944
cell O 0 0.018490417
line O 0 0.0037349218
, O 0 0.0030044399
THP O 1 0.998782
- O 0 0.0030915006
1 O 0 0.00079573493
as O 0 0.0005135128
a O 0 0.0007882659
model O 0 0.0010588827
to O 0 0.0010051783
address O 0 0.0010485381
this O 0 0.0022726043
question O 0 0.0042225197
. O 0 0.0057496526

Briefly O 0 0.0043023406
, O 0 0.0029792362
cells O 0 0.0023617158
were O 0 0.0011332851
differentiated O 0 0.002325741
for O 0 0.0005915944
72 O 0 0.00067965954
h O 0 0.00052829634
with O 0 0.0005887197
100 O 0 0.0015408912
nM O 0 0.023160422
PMA O 0 0.8830543
to O 0 0.00036066063
obtain O 0 0.00024810017
a O 0 0.0004587944
macrophage O 0 0.11418566
- O 0 0.0008509661
like O 0 0.00030083596
phenotype O 0 0.0005026035
in O 0 0.00021181144
the O 0 0.00021079478
presence O 0 0.00024425588
or O 0 0.00020503036
absence O 0 0.00017233362
of O 0 0.00054793106
1 O 0 0.0008441009
nM O 0 0.199459
17beta B-Chemical 1 0.99983406
- I-Chemical 1 0.045722045
estradiol I-Chemical 1 0.9998877
( O 0 0.021731332
E2 B-Chemical 0 0.9995173
) O 0 0.004497829
, O 0 0.00089815364
100 O 0 0.002265139
nM O 0 0.0548945
progesterone B-Chemical 1 0.99896514
or O 0 0.0008074313
vehicle O 0 0.03787125
( O 0 0.0013702641
0 O 0 0.0010575821
. O 0 0.0007763966
01 O 0 0.0066703493
% O 0 0.0027094083
ethanol B-Chemical 1 0.9383852
) O 0 0.009093515
. O 0 0.006187593

Cells O 0 0.011647283
were O 0 0.0023589244
then O 0 0.0015489698
treated O 0 0.0019027033
with O 0 0.0012832009
30 O 0 0.0009487225
ng O 0 0.0021625657
/ O 0 0.0020148233
ml O 0 0.005538142
ritonavir B-Chemical 0 0.997552
or O 0 0.0007280643
vehicle O 0 0.009722424
in O 0 0.0004934128
the O 0 0.00049794745
presence O 0 0.00065288687
of O 0 0.001252697
aggregated O 0 0.0033202716
LDL O 0 0.9925787
for O 0 0.0023322816
24 O 0 0.0031203572
h O 0 0.004331603
. O 0 0.005187764

Cell O 0 0.31012833
extracts O 0 0.009055901
were O 0 0.0032889175
harvested O 0 0.0024986283
, O 0 0.0029327716
and O 0 0.0025669143
lipid O 0 0.21401307
or O 0 0.002349725
total O 0 0.0028524215
RNA O 0 0.014502461
was O 0 0.0048412425
isolated O 0 0.007406165
. O 0 0.008524948

E2 B-Chemical 0 0.9902714
decreased O 0 0.010423757
the O 0 0.004109276
accumulation O 0 0.007624185
of O 0 0.007666563
cholesteryl B-Chemical 0 0.9968201
esters I-Chemical 0 0.9911261
in O 0 0.0037109144
macrophages O 0 0.02478648
following O 0 0.006720774
ritonavir B-Chemical 0 0.9967175
treatment O 0 0.059218727
. O 0 0.009718664

Ritonavir B-Chemical 0 0.99544156
increased O 0 0.0051635257
the O 0 0.002104343
expression O 0 0.002413348
of O 0 0.001774365
the O 0 0.001671047
scavenger O 0 0.9881594
receptor O 0 0.5802148
, O 0 0.004351467
CD36 O 0 0.8462073
mRNA O 0 0.003651482
, O 0 0.0014221085
responsible O 0 0.0011607457
for O 0 0.0010703075
the O 0 0.0018546297
uptake O 0 0.024992349
of O 0 0.009714745
LDL O 0 0.9924967
. O 0 0.010956207

Additionally O 0 0.005911433
, O 0 0.004721402
ritonavir B-Chemical 0 0.9958747
treatment O 0 0.00550906
selectively O 0 0.0028516676
increased O 0 0.0012653278
the O 0 0.0005406592
relative O 0 0.00038525512
levels O 0 0.0004905358
of O 0 0.0009257137
PPARgamma O 0 0.9741941
mRNA O 0 0.0028389476
, O 0 0.0006902313
a O 0 0.00050617085
transcription O 0 0.0011841881
factor O 0 0.0022561506
responsible O 0 0.00061846554
for O 0 0.0004777234
the O 0 0.0006579681
regulation O 0 0.0009214056
of O 0 0.002367891
CD36 O 0 0.80304646
mRNA O 0 0.00990004
expression O 0 0.009524869
. O 0 0.00663079

Treatment O 0 0.08799209
with O 0 0.007852362
E2 B-Chemical 0 0.9959912
, O 0 0.004976425
however O 0 0.002913663
, O 0 0.0018805814
failed O 0 0.0014879211
to O 0 0.001003575
prevent O 0 0.0013294239
these O 0 0.0015472083
increases O 0 0.0017219768
at O 0 0.0013405463
the O 0 0.0024067229
mRNA O 0 0.0057745436
level O 0 0.004592028
. O 0 0.0070175286

E2 B-Chemical 0 0.99221647
did O 0 0.005339598
, O 0 0.003877107
however O 0 0.0028756163
, O 0 0.0021537943
significantly O 0 0.0017193796
suppress O 0 0.0016429862
CD36 O 0 0.67302525
protein O 0 0.0037435081
levels O 0 0.001449052
as O 0 0.001222869
measured O 0 0.0014237845
by O 0 0.0027191755
fluorescent O 0 0.010169553
immunocytochemistry O 0 0.07045057
. O 0 0.009139748

This O 0 0.0047469498
data O 0 0.0026516882
suggests O 0 0.0014112397
that O 0 0.0015669545
E2 B-Chemical 0 0.99627423
modifies O 0 0.0043791113
the O 0 0.00092664344
expression O 0 0.0013363251
of O 0 0.0010550045
CD36 O 0 0.65460086
at O 0 0.0003362252
the O 0 0.00031776406
level O 0 0.00024686707
of O 0 0.0004605631
protein O 0 0.0011849942
expression O 0 0.0009655094
in O 0 0.00047076895
monocyte O 0 0.441514
- O 0 0.0010764746
derived O 0 0.0004003274
macrophages O 0 0.003815079
resulting O 0 0.0006008696
in O 0 0.00059569627
reduced O 0 0.0019736653
cholesteryl B-Chemical 0 0.99862766
ester I-Chemical 0 0.99481106
accumulation O 0 0.030342175
following O 0 0.008013115
ritonavir B-Chemical 0 0.99822956
treatment O 0 0.07254073
. O 0 0.0072727343

Acute O 0 0.98332626
hepatitis B-Disease 2 0.9975516
attack O 0 0.7019237
after O 0 0.0086905
exposure O 0 0.024377253
to O 0 0.01563845
telithromycin B-Chemical 1 0.9871796
. O 0 0.020497896

INTRODUCTION O 0 0.18687277
: O 0 0.017704163
Antibiotic O 0 0.7837102
- O 0 0.016856425
associated O 0 0.020254303
hepatotoxicity B-Disease 2 0.9986539
is O 0 0.021160752
rare O 0 0.12218373
. O 0 0.0174037

With O 0 0.0052247033
widespread O 0 0.0048443084
use O 0 0.0023369363
of O 0 0.0020913817
antimicrobial O 0 0.25586233
agents O 0 0.30494803
, O 0 0.0018675225
however O 0 0.0015646272
, O 0 0.0016040382
hepatic B-Disease 0 0.996739
injury I-Disease 0 0.99404657
occurs O 0 0.0011324579
frequently O 0 0.0016721276
, O 0 0.00063090184
and O 0 0.00045980004
among O 0 0.00066384376
adverse B-Disease 0 0.81306714
drug I-Disease 0 0.55467737
reactions I-Disease 0 0.061413705
, O 0 0.0015698852
idiosyncratic O 0 0.38458642
reactions O 0 0.010989482
are O 0 0.0014782194
the O 0 0.0017790147
most O 0 0.005385096
serious O 0 0.2399003
. O 0 0.0067283087

CASE O 0 0.9428207
SUMMARY O 0 0.10345786
: O 0 0.005257884
A O 0 0.008506173
25 O 0 0.0026793925
- O 0 0.0018390119
year O 0 0.0010410344
- O 0 0.0011393066
old O 0 0.0006923981
male O 0 0.0012488151
patient O 0 0.00079119636
, O 0 0.00052404765
with O 0 0.00040317263
a O 0 0.00038352006
height O 0 0.00090777065
of O 0 0.00040554287
175 O 0 0.0023095852
cm O 0 0.000872014
and O 0 0.00025350222
weight O 0 0.0008209586
of O 0 0.0002902184
72 O 0 0.00031121165
kg O 0 0.0011074493
presented O 0 0.00028154915
to O 0 0.00032330083
Marmara O 0 0.23039724
University O 0 0.0029753745
Hospital O 0 0.005438248
Emergency O 0 0.015879543
Department O 0 0.004853459
, O 0 0.00063959573
Istanbul O 0 0.023206541
, O 0 0.0005854878
Turkey O 0 0.008289901
, O 0 0.00042523307
with O 0 0.00034814762
5 O 0 0.00024385354
days O 0 0.00025286834
' O 0 0.0003710377
history O 0 0.0026688485
of O 0 0.0013492563
jaundice B-Disease 2 0.9988187
, O 0 0.011373574
malaise O 0 0.99905664
, O 0 0.018457219
nausea B-Disease 2 0.9996722
, O 0 0.007257914
and O 0 0.00715267
vomiting B-Disease 0 0.9979348
. O 0 0.00897521

He O 0 0.008515262
had O 0 0.0031282639
been O 0 0.0028776529
prescribed O 0 0.07145608
telithromycin B-Chemical 1 0.9962663
400 O 0 0.016549157
mg O 0 0.55839086
/ O 0 0.0025595229
d O 0 0.0013794899
PO O 0 0.6348671
to O 0 0.00077807636
treat O 0 0.0031877928
an O 0 0.0012490003
upper B-Disease 0 0.0022108236
respiratory I-Disease 0 0.42921364
tract I-Disease 0 0.49365413
infection I-Disease 2 0.42056903
7 O 0 0.0020921852
days O 0 0.0022650193
prior O 0 0.0028874741
. O 0 0.0050872113

Admission O 0 0.011613962
laboratory O 0 0.003958925
tests O 0 0.0033239168
were O 0 0.001563601
as O 0 0.0011560302
follows O 0 0.0021321643
: O 0 0.0026629304
alanine B-Chemical 1 0.97685313
aminotransferase O 0 0.9982613
, O 0 0.002312238
67 O 0 0.0026184954
U O 0 0.28371552
/ O 0 0.0030652813
L O 0 0.35574046
( O 0 0.00072015106
reference O 0 0.0003829612
range O 0 0.00061224814
, O 0 0.00050482864
10 O 0 0.0004136131
- O 0 0.00056075753
37 O 0 0.0006550327
U O 0 0.15537201
/ O 0 0.0029895396
L O 0 0.60356605
) O 0 0.0025537505
; O 0 0.0031347116
aspartate B-Chemical 1 0.99937385
aminotransferase O 0 0.99912983
, O 0 0.001577891
98 O 0 0.0023359782
U O 0 0.25986513
/ O 0 0.0027295372
L O 0 0.39406624
( O 0 0.0007280757
10 O 0 0.00043061597
- O 0 0.0005384327
40 O 0 0.00047330765
U O 0 0.10854976
/ O 0 0.0022086094
L O 0 0.48984337
) O 0 0.0016507495
; O 0 0.0013256504
alkaline O 0 0.32617494
phosphatase O 0 0.5957614
, O 0 0.001217488
513 O 0 0.06709123
U O 0 0.39127362
/ O 0 0.003908232
L O 0 0.47211483
( O 0 0.0008086922
0 O 0 0.00050266174
- O 0 0.0006127937
270 O 0 0.00461432
U O 0 0.18684405
/ O 0 0.002589469
L O 0 0.5071723
) O 0 0.0016220154
; O 0 0.001340295
gamma O 0 0.3119157
- O 0 0.0040967083
glutamyltransferase O 0 0.9951982
, O 0 0.0010415134
32 O 0 0.0011740599
U O 0 0.24712469
/ O 0 0.002819628
L O 0 0.42108616
( O 0 0.0007488517
7 O 0 0.0003527006
- O 0 0.00055994117
49 O 0 0.0007244949
U O 0 0.1322821
/ O 0 0.0023114546
L O 0 0.48518673
) O 0 0.0015198073
; O 0 0.00119664
amylase O 0 0.88082314
, O 0 0.00080458564
46 O 0 0.00096529827
U O 0 0.21043845
/ O 0 0.002595844
L O 0 0.41510543
( O 0 0.0007388934
0 O 0 0.00046602864
- O 0 0.0005625727
220 O 0 0.0029387886
U O 0 0.16627914
/ O 0 0.0022163615
L O 0 0.43098712
) O 0 0.0010696173
; O 0 0.0006331764
total O 0 0.00037802872
bilirubin B-Chemical 1 0.9986243
, O 0 0.00066988874
20 O 0 0.00038586088
. O 0 0.00016784195
1 O 0 0.00028645725
mg O 0 0.15490398
/ O 0 0.0010412971
dL O 0 0.02019245
( O 0 0.00037491374
0 O 0 0.00025980198
. O 0 0.00013312037
2 O 0 0.00022603617
- O 0 0.0003423003
1 O 0 0.00020960209
. O 0 0.0001234073
0 O 0 0.0002582348
mg O 0 0.09945783
/ O 0 0.0009499051
dL O 0 0.022899475
) O 0 0.0005650572
; O 0 0.00044645002
direct O 0 0.00033602826
bilirubin B-Chemical 1 0.9985814
, O 0 0.0006360166
14 O 0 0.00036121416
. O 0 0.00015281947
8 O 0 0.00025034542
mg O 0 0.14064392
/ O 0 0.0010422186
dL O 0 0.022881325
( O 0 0.00040061757
0 O 0 0.00030211732
- O 0 0.00034113124
0 O 0 0.00022396578
. O 0 0.00011774021
3 O 0 0.00018838009
mg O 0 0.104563005
/ O 0 0.0009656418
dL O 0 0.02535211
) O 0 0.00060169684
; O 0 0.00049934484
and O 0 0.00035563417
albumin O 0 0.912915
, O 0 0.00051263254
4 O 0 0.0002489176
. O 0 0.00015673123
7 O 0 0.00024005598
mg O 0 0.112758316
/ O 0 0.0010622091
dL O 0 0.01659076
( O 0 0.00045200967
3 O 0 0.00026610898
. O 0 0.00020414434
5 O 0 0.0003121051
- O 0 0.00057724275
5 O 0 0.00038219136
. O 0 0.00037047858
4 O 0 0.00076439726
mg O 0 0.13289873
/ O 0 0.004829243
dL O 0 0.04945572
) O 0 0.006055756
. O 0 0.005040368

No O 0 0.013832937
toxin O 0 0.22770192
, O 0 0.009640015
alcohol B-Chemical 0 0.98320043
, O 0 0.006493011
or O 0 0.0034760197
other O 0 0.0046803914
drugs O 0 0.57263356
were O 0 0.0073703625
reported O 0 0.012353571
. O 0 0.010601194

The O 0 0.0029157954
patient O 0 0.0031757182
had O 0 0.0020191357
suffered O 0 0.024547026
a O 0 0.0014371029
previous O 0 0.0011022215
episode O 0 0.006598586
of O 0 0.0016108082
" O 0 0.0025785766
acute O 0 0.9972144
hepatitis B-Disease 2 0.9998983
of O 0 0.0094363475
unknown O 0 0.017223518
origin O 0 0.005217217
, O 0 0.0014209535
" O 0 0.0011133946
that O 0 0.00078979443
occurred O 0 0.0016881678
after O 0 0.0016808456
telithromycin B-Chemical 1 0.9922747
usage O 0 0.0078487415
. O 0 0.006550131

Both O 0 0.01604531
incidents O 0 0.027055267
occurred O 0 0.010429907
within O 0 0.0064978725
a O 0 0.011690343
year O 0 0.01572107
. O 0 0.017497625

DISCUSSION O 0 0.0323325
: O 0 0.005949693
Telithromycin B-Chemical 0 0.8687374
is O 0 0.001470728
the O 0 0.00088132935
first O 0 0.0006416438
of O 0 0.0008860733
the O 0 0.0008648384
ketolide O 0 0.6387414
antibacterials O 0 0.9428846
to O 0 0.0009142177
receive O 0 0.0013398393
US O 0 0.05389586
Food O 0 0.66363657
and O 0 0.0015396607
Drug O 0 0.955302
Administration O 0 0.45017225
approval O 0 0.0034600645
for O 0 0.0017273303
clinical O 0 0.013038309
use O 0 0.006318539
. O 0 0.006484318

It O 0 0.007228944
has O 0 0.0034173261
been O 0 0.0030836686
associated O 0 0.0028315033
with O 0 0.0027020148
infrequent O 0 0.009813232
and O 0 0.0029971758
usually O 0 0.006269249
reversible O 0 0.63776684
severe O 0 0.8778921
hepatic B-Disease 0 0.99648005
dysfunction I-Disease 0 0.99512756
. O 0 0.017036363

Based O 0 0.0086223595
on O 0 0.0017285871
a O 0 0.0017386649
score O 0 0.0013563377
of O 0 0.0011874258
8 O 0 0.0007730397
on O 0 0.00039490714
the O 0 0.0006525537
Naranjo O 0 0.8982303
adverse B-Disease 0 0.8710333
drug I-Disease 0 0.5214653
reaction I-Disease 0 0.024410227
probability O 0 0.0006500231
scale O 0 0.0010013384
, O 0 0.0008330382
telithromycin B-Chemical 1 0.9978098
was O 0 0.00040751445
the O 0 0.00031118313
probable O 0 0.009858561
cause O 0 0.0033527107
of O 0 0.0020129643
acute O 0 0.9989146
hepatitis B-Disease 2 0.99995923
in O 0 0.001285759
this O 0 0.0005598558
patient O 0 0.0011423016
, O 0 0.00061397196
and O 0 0.0005241413
pathological O 0 0.1472547
findings O 0 0.0027500011
suggested O 0 0.001470455
drug O 0 0.6362829
- O 0 0.007207655
induced O 0 0.01458719
toxic B-Disease 0 0.99568045
hepatitis I-Disease 2 0.99961025
. O 0 0.025404977

Recurrence O 0 0.6266502
of O 0 0.008145825
hepatitis B-Disease 2 0.9991067
attack O 0 0.65167
might O 0 0.0014203523
have O 0 0.0011510316
been O 0 0.0009243865
avoided O 0 0.0006929265
if O 0 0.00031150758
the O 0 0.0003366564
initial O 0 0.0004398203
incident O 0 0.01047579
had O 0 0.0005518605
been O 0 0.00054935005
communicated O 0 0.00059911795
to O 0 0.00032520195
the O 0 0.00036276673
attending O 0 0.0010090527
physician O 0 0.0026981605
who O 0 0.00257203
prescribed O 0 0.097124904
telithromycin B-Chemical 1 0.9949778
the O 0 0.001873843
second O 0 0.00241991
time O 0 0.003539416
. O 0 0.0054297512

CONCLUSION O 0 0.73664916
: O 0 0.0047248947
Here O 0 0.0029049842
we O 0 0.0010191412
report O 0 0.002703529
a O 0 0.0014125387
case O 0 0.0013570089
of O 0 0.0025112135
acute O 0 0.9972916
hepatitis B-Disease 2 0.9998783
probably O 0 0.025211247
associated O 0 0.0031624024
with O 0 0.0021629948
the O 0 0.0021324563
administration O 0 0.24342994
of O 0 0.010518043
telithromycin B-Chemical 1 0.9957378
. O 0 0.009451048

A O 0 0.013537834
study O 0 0.0035193055
on O 0 0.001281103
the O 0 0.0012551347
effect O 0 0.0012487052
of O 0 0.001174843
the O 0 0.0008722981
duration O 0 0.0013053194
of O 0 0.0015387125
subcutaneous O 0 0.18579833
heparin B-Chemical 1 0.98911846
injection O 0 0.025400622
on O 0 0.0021919904
bruising B-Disease 0 0.9889031
and O 0 0.009269047
pain B-Disease 0 0.9825165
. O 0 0.009733595

AIM O 0 0.30817303
: O 0 0.004515278
This O 0 0.0023135277
study O 0 0.0016029411
was O 0 0.0008271702
carried O 0 0.00053580245
out O 0 0.0004325197
to O 0 0.0004097422
determine O 0 0.00021437346
the O 0 0.00032250935
effect O 0 0.00041576513
of O 0 0.0005030881
injection O 0 0.0017187896
duration O 0 0.0006905566
on O 0 0.00033948716
bruising B-Disease 0 0.9820971
and O 0 0.00094023667
pain B-Disease 0 0.9464335
following O 0 0.0005907839
the O 0 0.000491728
administration O 0 0.030806392
of O 0 0.000888979
the O 0 0.00096248026
subcutaneous O 0 0.086424015
injection O 0 0.009432542
of O 0 0.005215849
heparin B-Chemical 1 0.9874067
. O 0 0.008324933

BACKGROUND O 0 0.70844364
: O 0 0.004424256
Although O 0 0.0016174966
different O 0 0.001177423
methods O 0 0.0013305955
to O 0 0.0009482074
prevent O 0 0.0014905445
bruising B-Disease 0 0.9808864
and O 0 0.0014113069
pain B-Disease 0 0.94380033
following O 0 0.0006152267
the O 0 0.00040222178
subcutaneous O 0 0.02920916
injection O 0 0.0018554429
of O 0 0.0005514078
heparin B-Chemical 1 0.9771921
have O 0 0.0005190911
been O 0 0.0004488473
widely O 0 0.00062899553
studied O 0 0.00045667682
and O 0 0.00030507075
described O 0 0.00022748756
, O 0 0.0002993608
the O 0 0.00018735994
effect O 0 0.000257925
of O 0 0.00033444466
injection O 0 0.0011545297
duration O 0 0.00043579028
on O 0 0.00019090943
the O 0 0.00033892872
occurrence O 0 0.0012646333
of O 0 0.0014168086
bruising B-Disease 0 0.9930767
and O 0 0.0027595544
pain B-Disease 0 0.9791141
is O 0 0.0024787937
little O 0 0.00314244
documented O 0 0.0079978965
. O 0 0.0057971813

DESIGN O 0 0.013360521
: O 0 0.0036545943
This O 0 0.0023758453
study O 0 0.0019430427
was O 0 0.001229513
designed O 0 0.0012565916
as O 0 0.0009315823
within O 0 0.0007711583
- O 0 0.0018160682
subject O 0 0.001116296
, O 0 0.0020716842
quasi O 0 0.006930042
- O 0 0.004141938
experimental O 0 0.0050493293
research O 0 0.00861269
. O 0 0.007391586

METHOD O 0 0.031596262
: O 0 0.0037630857
The O 0 0.0013635748
sample O 0 0.0011802383
for O 0 0.0008573168
the O 0 0.00080176006
study O 0 0.0010594033
consisted O 0 0.00070380943
of O 0 0.0009197444
50 O 0 0.0012421788
patients O 0 0.0017296341
to O 0 0.000940041
whom O 0 0.003992602
subcutaneous O 0 0.17403203
heparin B-Chemical 1 0.9848365
was O 0 0.005036285
administered O 0 0.016062671
. O 0 0.0067203026

Heparin B-Chemical 1 0.9832517
was O 0 0.0031168703
injected O 0 0.0015708326
over O 0 0.0007392904
10 O 0 0.0008508093
seconds O 0 0.00069638
on O 0 0.00038217512
the O 0 0.00054958917
right O 0 0.001344681
abdominal O 0 0.03339335
site O 0 0.00070001965
and O 0 0.00065136317
30 O 0 0.0005497568
seconds O 0 0.00065793045
on O 0 0.00052542856
the O 0 0.0011616806
left O 0 0.004121909
abdominal O 0 0.1396319
site O 0 0.0057339706
. O 0 0.0065306714

Injections O 0 0.06962043
areas O 0 0.004320149
were O 0 0.0016143457
assessed O 0 0.0010163835
for O 0 0.0008569664
the O 0 0.0008394695
presence O 0 0.0008916398
of O 0 0.0015007807
bruising B-Disease 0 0.960713
at O 0 0.0007095855
48 O 0 0.000820663
and O 0 0.00075346377
72 O 0 0.00094262854
hours O 0 0.0008820065
after O 0 0.00087516784
each O 0 0.0014634696
injection O 0 0.008788998
. O 0 0.005603587

Dimensions O 0 0.012747829
of O 0 0.003843482
the O 0 0.0029934193
bruising B-Disease 0 0.90520996
on O 0 0.0012762065
the O 0 0.0014659858
heparin B-Chemical 1 0.9272468
applied O 0 0.0016739521
areas O 0 0.0023295505
were O 0 0.0010201891
measured O 0 0.0008522621
using O 0 0.0012553079
transparent O 0 0.004205492
millimetric O 0 0.012089947
measuring O 0 0.0037508942
paper O 0 0.009669303
. O 0 0.008029256

The O 0 0.0036811137
visual O 0 0.058612343
analog O 0 0.027436862
scale O 0 0.0036676757
( O 0 0.0025672673
VAS O 0 0.33450788
) O 0 0.0015161184
was O 0 0.00056421524
used O 0 0.0004205826
to O 0 0.00038711206
measure O 0 0.00032559843
pain B-Disease 0 0.7691706
intensity O 0 0.00049282087
and O 0 0.0005622202
a O 0 0.0006108397
stop O 0 0.0018606564
- O 0 0.0010112686
watch O 0 0.0010347535
was O 0 0.0005144525
used O 0 0.0005232266
to O 0 0.00066590944
time O 0 0.0009470545
the O 0 0.002022445
pain B-Disease 0 0.9093147
period O 0 0.0059825866
. O 0 0.006179561

Data O 0 0.0056896666
were O 0 0.0025350868
analysed O 0 0.0020785471
using O 0 0.0017820912
chi O 0 0.037158806
- O 0 0.0027963372
square O 0 0.0024485874
test O 0 0.0017145256
, O 0 0.002281967
Mann O 0 0.13619784
- O 0 0.0034024038
Whitney O 0 0.33911934
U O 0 0.16754816
, O 0 0.0023524505
Wilcoxon O 0 0.0049949135
signed O 0 0.002711495
ranks O 0 0.0046003615
tests O 0 0.0046887514
and O 0 0.004208152
correlation O 0 0.0047968216
. O 0 0.008163504

RESULTS O 0 0.02334808
: O 0 0.0037739554
The O 0 0.0013210883
percentage O 0 0.00083151547
of O 0 0.0015854395
bruising B-Disease 0 0.9533612
occurrence O 0 0.0035146365
was O 0 0.0008022143
64 O 0 0.0009262215
% O 0 0.00047577155
with O 0 0.00036909615
the O 0 0.0003123507
injection O 0 0.0008619907
of O 0 0.0004006279
10 O 0 0.0003218333
seconds O 0 0.00027829723
duration O 0 0.00037922637
and O 0 0.00039162976
42 O 0 0.0006532764
% O 0 0.0005033121
in O 0 0.0004197635
the O 0 0.0006548461
30 O 0 0.0010006251
- O 0 0.0020112274
second O 0 0.0021503344
injection O 0 0.00908438
. O 0 0.0052213836

It O 0 0.0055112704
was O 0 0.002168799
determined O 0 0.0012458325
that O 0 0.0010296268
the O 0 0.00097235164
size O 0 0.0011518362
of O 0 0.0011875797
the O 0 0.0012330061
bruising B-Disease 0 0.9675504
was O 0 0.0010753385
smaller O 0 0.00087532634
in O 0 0.00083963113
the O 0 0.0010975888
30 O 0 0.001478572
- O 0 0.002722366
second O 0 0.0027258263
injection O 0 0.010792221
. O 0 0.0061131525

Pain B-Disease 2 0.84439695
intensity O 0 0.002850644
and O 0 0.0024995655
pain B-Disease 0 0.7625015
period O 0 0.0011923716
were O 0 0.0007509212
statistically O 0 0.000635288
significantly O 0 0.00058121857
lower O 0 0.0004328237
for O 0 0.0003407274
the O 0 0.00039532
30 O 0 0.0004184814
- O 0 0.0005685084
second O 0 0.00034906404
injection O 0 0.0010234285
than O 0 0.00031818755
for O 0 0.0004550933
the O 0 0.0007630377
10 O 0 0.001280224
- O 0 0.002143342
second O 0 0.0021972512
injection O 0 0.009381833
. O 0 0.00520426

CONCLUSIONS O 0 0.7533875
: O 0 0.0055309217
It O 0 0.0027519842
was O 0 0.0011483514
determined O 0 0.0007025978
that O 0 0.0006355421
injection O 0 0.0015614392
duration O 0 0.000877189
had O 0 0.0006271289
an O 0 0.0007289686
effect O 0 0.0006998019
on O 0 0.00049774774
bruising B-Disease 0 0.9808981
and O 0 0.0014499519
pain B-Disease 0 0.95064795
following O 0 0.0011184376
the O 0 0.0011243612
subcutaneous O 0 0.11429025
administration O 0 0.2099679
of O 0 0.006784159
heparin B-Chemical 1 0.9883763
. O 0 0.009137071

This O 0 0.007332139
study O 0 0.0051409183
should O 0 0.0025531529
be O 0 0.0028551503
repeated O 0 0.002626174
on O 0 0.0024646444
a O 0 0.004324912
larger O 0 0.005111126
sample O 0 0.008292574
. O 0 0.010912981

RELEVANCE O 0 0.11928927
TO O 0 0.2512766
CLINICAL O 0 0.056417912
PRACTICE O 0 0.0028997217
: O 0 0.002070811
When O 0 0.0009835571
administering O 0 0.0041790265
subcutaneous O 0 0.08846674
heparin B-Chemical 1 0.98809016
injections O 0 0.046323407
, O 0 0.0011829631
it O 0 0.00068665744
is O 0 0.0004971632
important O 0 0.0004363733
to O 0 0.00048058093
extend O 0 0.0005434715
the O 0 0.000690171
duration O 0 0.0014772711
of O 0 0.0021547207
the O 0 0.0030337425
injection O 0 0.015773246
. O 0 0.0062562656

Acute B-Disease 0 0.98015505
liver I-Disease 0 0.8827844
failure I-Disease 0 0.7109525
in O 0 0.001908482
two O 0 0.0011473993
patients O 0 0.0025815768
with O 0 0.0014262389
regular O 0 0.0028726852
alcohol B-Chemical 0 0.99437135
consumption O 0 0.46586257
ingesting O 0 0.927607
paracetamol B-Chemical 0 0.99927706
at O 0 0.0033629907
therapeutic O 0 0.11311102
dosage O 0 0.46315303
. O 0 0.009452787

BACKGROUND O 0 0.69923896
: O 0 0.00436254
The O 0 0.0014678987
possible O 0 0.0013724364
role O 0 0.000864588
of O 0 0.0014703737
alcohol B-Chemical 0 0.9899616
in O 0 0.0009095602
the O 0 0.00066521746
development O 0 0.0016443578
of O 0 0.0017668019
hepatotoxicity B-Disease 2 0.999889
associated O 0 0.0028567198
with O 0 0.0011203313
therapeutic O 0 0.045755114
doses O 0 0.11939646
of O 0 0.005067284
paracetamol B-Chemical 0 0.99981254
( O 0 0.03552256
acetaminophen B-Chemical 0 0.99980825
) O 0 0.008514394
is O 0 0.00260874
currently O 0 0.0054548285
debated O 0 0.015947556
. O 0 0.006733655

CASE O 0 0.8041356
REPORT O 0 0.07469213
: O 0 0.0038930785
We O 0 0.0014871972
describe O 0 0.0013200217
2 O 0 0.0010170665
patients O 0 0.0015947616
who O 0 0.0012910746
were O 0 0.00051823724
regular O 0 0.00080035353
consumers O 0 0.0030698562
of O 0 0.00080024643
alcohol B-Chemical 0 0.9931251
and O 0 0.00072508137
who O 0 0.0014191361
developed O 0 0.0011573149
liver B-Disease 0 0.7815344
failure I-Disease 0 0.5309234
within O 0 0.00023042454
3 O 0 0.00028632564
- O 0 0.00036216236
5 O 0 0.0001400914
days O 0 0.00013270669
after O 0 0.0001070426
hospitalization O 0 0.009326986
and O 0 0.00029633797
stopping O 0 0.009403582
alcohol B-Chemical 0 0.9963553
consumption O 0 0.11805129
while O 0 0.00046042923
being O 0 0.00068619166
treated O 0 0.0009270643
with O 0 0.0008744335
4 O 0 0.00096194167
g O 0 0.005885324
paracetamol B-Chemical 0 0.99873096
/ O 0 0.009637061
day O 0 0.004565455
. O 0 0.0051723523

A O 0 0.07621348
paracetamol B-Chemical 0 0.99786586
serum O 0 0.11986941
level O 0 0.001582553
obtained O 0 0.0011911744
in O 0 0.00084285275
one O 0 0.00063776417
of O 0 0.000944885
these O 0 0.00126307
patients O 0 0.0026638766
was O 0 0.001107233
not O 0 0.0011173588
in O 0 0.001398984
the O 0 0.0025092592
toxic O 0 0.6584951
range O 0 0.010805108
. O 0 0.007467179

Possible O 0 0.019844709
risk O 0 0.014918804
factors O 0 0.004307205
for O 0 0.0013659135
the O 0 0.0011866852
development O 0 0.002343264
of O 0 0.0024138754
hepatotoxicity B-Disease 2 0.99981457
in O 0 0.0013610395
patients O 0 0.003931762
treated O 0 0.0015372598
with O 0 0.0011679294
therapeutic O 0 0.030610126
doses O 0 0.11077931
of O 0 0.0066558784
paracetamol B-Chemical 0 0.9992687
are O 0 0.006255311
discussed O 0 0.0060716425
. O 0 0.006956686

CONCLUSION O 0 0.7790035
: O 0 0.0043810634
In O 0 0.001571378
patients O 0 0.0023938117
with O 0 0.00138541
risk O 0 0.014340177
factors O 0 0.00386924
, O 0 0.0011391779
e O 0 0.0013136595
. O 0 0.0003322544
g O 0 0.0009478981
. O 0 0.00022619464
regular O 0 0.00054482406
consumption O 0 0.015528785
of O 0 0.0009417143
alcohol B-Chemical 0 0.99682605
, O 0 0.0018883196
liver B-Disease 0 0.85110533
failure I-Disease 0 0.6001549
is O 0 0.00079824746
possible O 0 0.0008104461
when O 0 0.0007059163
therapeutic O 0 0.020142255
doses O 0 0.09062787
are O 0 0.004315837
ingested O 0 0.22162987
. O 0 0.0066931206

We O 0 0.0029591545
propose O 0 0.002137554
that O 0 0.0014976655
the O 0 0.001693446
paracetamol B-Chemical 0 0.99909866
dose O 0 0.07826144
should O 0 0.00055988354
not O 0 0.00045497747
exceed O 0 0.0004441703
2 O 0 0.00039968337
g O 0 0.00086069235
/ O 0 0.00056412816
day O 0 0.0002380144
in O 0 0.00019274029
such O 0 0.00023889748
patients O 0 0.0007751206
and O 0 0.00029085382
that O 0 0.00022158428
their O 0 0.0003818361
liver O 0 0.48480234
function O 0 0.00061539793
should O 0 0.00025082205
be O 0 0.0003401153
monitored O 0 0.0002489086
closely O 0 0.0005211659
while O 0 0.00061269186
being O 0 0.0014219377
treated O 0 0.0030809187
with O 0 0.006695204
paracetamol B-Chemical 0 0.998728
. O 0 0.009486022

Associations O 0 0.005747112
between O 0 0.0015825921
use O 0 0.0019914242
of O 0 0.0021592623
benzodiazepines B-Chemical 1 0.99855703
or O 0 0.001212332
related O 0 0.00076901924
drugs O 0 0.42920864
and O 0 0.0008394266
health O 0 0.003538634
, O 0 0.0006347894
physical O 0 0.0037565557
abilities O 0 0.0039914516
and O 0 0.000520035
cognitive O 0 0.431756
function O 0 0.0007881161
: O 0 0.0007153265
a O 0 0.00047715628
non O 0 0.0010306569
- O 0 0.0008582575
randomised O 0 0.0010525234
clinical O 0 0.003459114
study O 0 0.001642248
in O 0 0.0014570055
the O 0 0.0028424475
elderly O 0 0.33737677
. O 0 0.0065258155

OBJECTIVE O 0 0.41999316
: O 0 0.0037079505
To O 0 0.0011916653
describe O 0 0.0010959671
associations O 0 0.0008461705
between O 0 0.00046871413
the O 0 0.0005827944
use O 0 0.0007740718
of O 0 0.0010792876
benzodiazepines B-Chemical 1 0.99934965
or O 0 0.00074046606
related O 0 0.0005920728
drugs O 0 0.7617841
( O 0 0.0027270813
BZDs B-Chemical 1 0.99944586
/ O 0 0.0029935432
RDs O 0 0.029411111
) O 0 0.00069132965
and O 0 0.00040424083
health O 0 0.0015170506
, O 0 0.0005342007
functional O 0 0.00071418047
abilities O 0 0.0028996058
and O 0 0.0008893475
cognitive O 0 0.39262602
function O 0 0.0017377232
in O 0 0.0015817704
the O 0 0.0028900015
elderly O 0 0.3851491
. O 0 0.0063473005

METHODS O 0 0.0072305007
: O 0 0.0041820295
A O 0 0.0064962944
non O 0 0.002768932
- O 0 0.0016954021
randomised O 0 0.0012808351
clinical O 0 0.002533731
study O 0 0.0009144952
of O 0 0.00074498105
patients O 0 0.0021189756
aged O 0 0.0014303739
> O 0 0.0009440873
or O 0 0.00037869188
= O 0 0.0006250136
65 O 0 0.00050080416
years O 0 0.00073006033
admitted O 0 0.0019322628
to O 0 0.00070826703
acute O 0 0.73972267
hospital O 0 0.008191613
wards O 0 0.002756129
during O 0 0.0015810077
1 O 0 0.0026845934
month O 0 0.003815666
. O 0 0.004964247

164 O 0 0.011593208
patients O 0 0.0062102852
( O 0 0.0025235715
mean O 0 0.0009946356
age O 0 0.0024312262
+ O 0 0.001540974
/ O 0 0.0019343568
- O 0 0.0010375526
standard O 0 0.00046391977
deviation O 0 0.001343847
[ O 0 0.0017815161
SD O 0 0.013891892
] O 0 0.0011675517
81 O 0 0.00085003814
. O 0 0.0002930986
6 O 0 0.00035061955
+ O 0 0.00061577075
/ O 0 0.0011360077
- O 0 0.0008552081
6 O 0 0.00041580186
. O 0 0.00037843885
8 O 0 0.0006690772
years O 0 0.0015137303
) O 0 0.0020454915
were O 0 0.0022274165
admitted O 0 0.012055432
. O 0 0.0056231874

Of O 0 0.005434794
these O 0 0.0031751432
, O 0 0.0022473691
nearly O 0 0.0013139948
half O 0 0.00088156236
( O 0 0.0012132885
n O 0 0.0006685653
= O 0 0.00087178097
78 O 0 0.0009127811
) O 0 0.00065004406
had O 0 0.00042720506
used O 0 0.0005531602
BZDs B-Chemical 1 0.99899477
/ O 0 0.0016627065
RDs O 0 0.00702254
before O 0 0.00020970983
admission O 0 0.0050183944
, O 0 0.00043979406
and O 0 0.00033023773
the O 0 0.00032177012
remainder O 0 0.00066949235
( O 0 0.0006797807
n O 0 0.0004915082
= O 0 0.00086044095
86 O 0 0.0010879469
) O 0 0.0011733455
were O 0 0.0010372463
non O 0 0.003198241
- O 0 0.0047506476
users O 0 0.011341491
. O 0 0.005683158

Cognitive O 0 0.48765853
ability O 0 0.004150794
was O 0 0.0025733497
assessed O 0 0.0018812957
by O 0 0.002211718
the O 0 0.0023863304
Mini O 0 0.010400341
- O 0 0.0047686687
Mental O 0 0.030119289
State O 0 0.009010737
Examination O 0 0.006605873
( O 0 0.0069104773
MMSE O 0 0.79417044
) O 0 0.010718646
. O 0 0.008151236

Patients O 0 0.010819143
scoring O 0 0.0058730035
> O 0 0.0037503506
or O 0 0.0013655202
= O 0 0.0016076602
20 O 0 0.0009862694
MMSE O 0 0.2755036
sum O 0 0.00044676656
points O 0 0.000556927
were O 0 0.00042733864
interviewed O 0 0.0010490003
( O 0 0.000572129
n O 0 0.00033385656
= O 0 0.00048705397
79 O 0 0.00049928325
) O 0 0.00040169372
and O 0 0.00025315737
questioned O 0 0.00044815557
regarding O 0 0.00030859042
symptoms O 0 0.084634684
and O 0 0.00045524837
functional O 0 0.00073642115
abilities O 0 0.0021080985
during O 0 0.00040027173
the O 0 0.0005650653
week O 0 0.00079516286
prior O 0 0.0009381724
to O 0 0.0020784668
admission O 0 0.03515338
. O 0 0.005366154

Data O 0 0.0056570913
on O 0 0.0018978971
use O 0 0.0023742092
of O 0 0.0028003624
BZDs B-Chemical 1 0.9981027
/ O 0 0.004086065
RDs O 0 0.00902618
before O 0 0.00046390077
admission O 0 0.0049021114
, O 0 0.0007328206
current O 0 0.00096734246
medications O 0 0.18127051
and O 0 0.0008015086
discharge O 0 0.008687748
diagnoses O 0 0.003978194
were O 0 0.00088695856
collected O 0 0.0008886961
from O 0 0.001583676
medical O 0 0.008843848
records O 0 0.0071234256
. O 0 0.0060090562

Health O 0 0.006677073
, O 0 0.0032276928
physical O 0 0.0053787
abilities O 0 0.0054411017
and O 0 0.0013628027
cognitive O 0 0.31204858
function O 0 0.0010767187
were O 0 0.00054707995
compared O 0 0.0003127193
between O 0 0.00036801118
BZD O 0 0.9979114
/ O 0 0.0045239045
RD O 0 0.9432114
users O 0 0.0057812408
and O 0 0.0005587896
non O 0 0.0013810192
- O 0 0.0010264507
users O 0 0.0020957445
, O 0 0.0005804333
and O 0 0.00047467617
adjustments O 0 0.0008039561
were O 0 0.0005943479
made O 0 0.0007896681
for O 0 0.0009977825
confounding O 0 0.0033006787
variables O 0 0.0060152765
. O 0 0.0057229158

The O 0 0.003942037
residual O 0 0.0042457883
serum O 0 0.03453467
concentrations O 0 0.009055786
of O 0 0.006782951
oxazepam B-Chemical 0 0.9997259
, O 0 0.036635455
temazepam B-Chemical 0 0.99974614
and O 0 0.01638049
zopiclone B-Chemical 0 0.9992975
were O 0 0.0066492995
analysed O 0 0.007459337
. O 0 0.008856651

RESULTS O 0 0.026558384
: O 0 0.0043271566
The O 0 0.0016233874
mean O 0 0.0012390097
+ O 0 0.001921729
/ O 0 0.0025514353
- O 0 0.0016194831
SD O 0 0.0046663918
duration O 0 0.00094880746
of O 0 0.0012960878
BZD O 0 0.99860245
/ O 0 0.0068965056
RD O 0 0.9269681
use O 0 0.00092054956
was O 0 0.0005738802
7 O 0 0.00048556086
+ O 0 0.0006859488
/ O 0 0.0011957381
- O 0 0.00083943264
7 O 0 0.00044640788
years O 0 0.00094985345
( O 0 0.00089664495
range O 0 0.0013092988
1 O 0 0.0014993743
- O 0 0.0028172706
31 O 0 0.0038059691
) O 0 0.005360974
. O 0 0.0049874727

Two O 0 0.004848457
or O 0 0.0024906725
three O 0 0.001832977
BZDs B-Chemical 1 0.9965365
/ O 0 0.0043592392
RDs O 0 0.010277479
were O 0 0.0009072186
concomitantly O 0 0.0033132902
taken O 0 0.00061111164
by O 0 0.0007245288
26 O 0 0.001056701
% O 0 0.0007552098
of O 0 0.0009565253
users O 0 0.003947667
( O 0 0.0017987192
n O 0 0.0015304098
= O 0 0.0028893445
20 O 0 0.0030306806
) O 0 0.005654814
. O 0 0.0053057787

Long O 0 0.021577446
- O 0 0.0037997188
term O 0 0.0018778578
use O 0 0.0014965957
of O 0 0.0012147813
these O 0 0.0013777987
drugs O 0 0.498527
was O 0 0.00077895663
associated O 0 0.0007832801
with O 0 0.0006695329
female O 0 0.0020518836
sex O 0 0.00438817
and O 0 0.00037505652
use O 0 0.00036297776
of O 0 0.00035266564
a O 0 0.00031373842
higher O 0 0.00024521817
number O 0 0.00021170381
of O 0 0.00041664217
drugs O 0 0.3919958
with O 0 0.00054064783
effects O 0 0.0009287706
on O 0 0.00023838232
the O 0 0.00048771856
CNS O 0 0.65418464
, O 0 0.000783057
which O 0 0.0006732027
tended O 0 0.00057831383
to O 0 0.0005604391
be O 0 0.0008054967
related O 0 0.0008859134
to O 0 0.0020057952
diagnosed O 0 0.23571284
dementia B-Disease 2 0.995701
. O 0 0.008868769

After O 0 0.0019573504
adjustment O 0 0.0019256308
for O 0 0.001021967
these O 0 0.0011081907
variables O 0 0.0011011076
as O 0 0.00057237037
confounders O 0 0.0013220091
, O 0 0.0007412702
use O 0 0.00063949515
of O 0 0.0010245957
BZDs B-Chemical 1 0.99933726
/ O 0 0.0029529764
RDs O 0 0.016572526
was O 0 0.00037808061
not O 0 0.00032241803
associated O 0 0.00057674473
with O 0 0.0008003532
cognitive O 0 0.41508332
function O 0 0.0011320281
as O 0 0.00076784095
measured O 0 0.000971847
by O 0 0.0020153623
the O 0 0.0038255265
MMSE O 0 0.8653829
. O 0 0.006112126

However O 0 0.004467945
, O 0 0.0031830207
use O 0 0.00222359
of O 0 0.0025846015
BZDs B-Chemical 1 0.99853694
/ O 0 0.004713235
RDs O 0 0.02051577
was O 0 0.00064219564
associated O 0 0.00080219057
with O 0 0.0011713377
dizziness B-Disease 2 0.9994966
, O 0 0.0009169697
inability B-Disease 0 0.00062660425
to I-Disease 0 0.00033397754
sleep I-Disease 0 0.22442439
after O 0 0.00019896125
awaking O 0 0.19648917
at O 0 0.00017727546
night O 0 0.0007646974
and O 0 0.0004074024
tiredness B-Disease 0 0.97553444
in O 0 0.00024739272
the O 0 0.00023485215
mornings O 0 0.028532993
during O 0 0.00014993358
the O 0 0.00015841537
week O 0 0.00015746854
prior O 0 0.00012628116
to O 0 0.0001882167
admission O 0 0.003184092
and O 0 0.00028118084
with O 0 0.00039235677
stronger O 0 0.0010176393
depressive B-Disease 2 0.99968874
symptoms I-Disease 0 0.84493
measured O 0 0.00038158463
at O 0 0.00029123286
the O 0 0.00042600904
beginning O 0 0.0005278683
of O 0 0.0010995782
the O 0 0.0015139017
hospital O 0 0.008137638
stay O 0 0.0097631365
. O 0 0.005828716

Use O 0 0.012211835
of O 0 0.0053848512
BZDs B-Chemical 1 0.9975097
/ O 0 0.0062734354
RDs O 0 0.017113857
tended O 0 0.00095353986
to O 0 0.00058874843
be O 0 0.00054561975
associated O 0 0.00059847167
with O 0 0.0005353546
a O 0 0.00045704877
reduced O 0 0.0004055966
ability O 0 0.00034243852
to O 0 0.000284207
walk O 0 0.0013693012
and O 0 0.0003476173
shorter O 0 0.00032869392
night O 0 0.00119343
- O 0 0.00066892704
time O 0 0.0003812005
sleep O 0 0.062428456
during O 0 0.00041553177
the O 0 0.00057995826
week O 0 0.0008133007
prior O 0 0.000967056
to O 0 0.0021372703
admission O 0 0.032770175
. O 0 0.0055113304

A O 0 0.013112642
higher O 0 0.0025430042
residual O 0 0.0025178767
serum O 0 0.03845119
concentration O 0 0.0047438415
of O 0 0.0024580117
temazepam B-Chemical 0 0.99983597
correlated O 0 0.0010774389
with O 0 0.0009324641
a O 0 0.0007904469
lower O 0 0.00079589523
MMSE O 0 0.59886557
sum O 0 0.0004784457
score O 0 0.0006479664
after O 0 0.0004375429
adjustment O 0 0.0011545137
for O 0 0.0011029238
confounding O 0 0.0035093217
variables O 0 0.0062779235
. O 0 0.0058968184

CONCLUSIONS O 0 0.7706684
: O 0 0.006504926
Long O 0 0.012536233
- O 0 0.0023822521
term O 0 0.0012930027
use O 0 0.0011582727
and O 0 0.00085924723
concomitant O 0 0.0026329318
use O 0 0.0008104267
of O 0 0.00069713296
more O 0 0.0006947956
than O 0 0.00033484533
one O 0 0.0004910278
BZD O 0 0.99823064
/ O 0 0.0039632637
RD O 0 0.88709986
were O 0 0.0005308816
common O 0 0.00079588045
in O 0 0.00058375904
elderly O 0 0.18594997
patients O 0 0.005261985
hospitalised O 0 0.43372735
because O 0 0.0013059052
of O 0 0.004221866
acute O 0 0.98542064
illnesses O 0 0.97922826
. O 0 0.0097658755

Long O 0 0.022453066
- O 0 0.003881054
term O 0 0.0019617148
use O 0 0.0016504908
was O 0 0.0010220123
associated O 0 0.0010759968
with O 0 0.0009922126
daytime O 0 0.028003834
and O 0 0.0007170689
night O 0 0.0018210036
- O 0 0.0007606152
time O 0 0.0003467547
symptoms O 0 0.07919364
indicative O 0 0.00037495303
of O 0 0.0004831469
poorer O 0 0.0015134903
health O 0 0.0021351185
and O 0 0.0004681768
potentially O 0 0.0010641026
caused O 0 0.0006461765
by O 0 0.0006283126
the O 0 0.00076163234
adverse O 0 0.5096152
effects O 0 0.0030563911
of O 0 0.0026258305
these O 0 0.0056208814
drugs O 0 0.8383454
. O 0 0.0073232087

Acute O 0 0.9624981
vocal B-Disease 0 0.41319394
fold I-Disease 0 0.049823422
palsy I-Disease 0 0.99672526
after O 0 0.012148715
acute O 0 0.988801
disulfiram B-Chemical 0 0.9993087
intoxication O 0 0.99714893
. O 0 0.031726826

Acute O 0 0.9794064
peripheral B-Disease 2 0.88158286
neuropathy I-Disease 2 0.99931085
caused O 0 0.006329854
by O 0 0.002353029
a O 0 0.0032873547
disulfiram B-Chemical 0 0.9998461
overdose B-Disease 2 0.9996965
is O 0 0.001654847
very O 0 0.0010641535
rare O 0 0.006359028
and O 0 0.0005997304
there O 0 0.00033837857
is O 0 0.00047711446
no O 0 0.00041150785
report O 0 0.001518485
of O 0 0.001004037
it O 0 0.0012789303
leading O 0 0.0026579543
to O 0 0.002172616
vocal B-Disease 0 0.33194605
fold I-Disease 0 0.053463154
palsy I-Disease 0 0.9982804
. O 0 0.00998911

A O 0 0.019265866
49 O 0 0.0054019326
- O 0 0.0031854894
year O 0 0.0016785708
- O 0 0.0017132228
old O 0 0.0010398399
woman O 0 0.0037884708
was O 0 0.00058096653
transferred O 0 0.0004843823
to O 0 0.000346529
our O 0 0.0003134852
department O 0 0.00074616907
because O 0 0.0003737559
of O 0 0.0011423026
quadriparesis B-Disease 0 0.9996082
, O 0 0.0051178383
lancinating O 0 0.99862385
pain B-Disease 0 0.99509466
, O 0 0.0022213692
sensory B-Disease 0 0.48957145
loss I-Disease 0 0.011819556
, O 0 0.0012079156
and O 0 0.0012931727
paresthesia B-Disease 0 0.9956536
of O 0 0.0021257843
the O 0 0.0021812008
distal O 0 0.0064367517
limbs O 0 0.13146761
. O 0 0.006594043

One O 0 0.0043263533
month O 0 0.0021518942
previously O 0 0.0017182487
, O 0 0.0014669821
she O 0 0.0009609126
had O 0 0.00076234184
taken O 0 0.00048879115
a O 0 0.00052843755
single O 0 0.0004693833
high O 0 0.0006819553
dose O 0 0.010539315
of O 0 0.0015073789
disulfiram B-Chemical 0 0.999856
( O 0 0.0022971795
130 O 0 0.003979474
tablets O 0 0.7331867
of O 0 0.0013518403
ALCOHOL B-Chemical 0 0.92253864
STOP O 0 0.09939707
TAB O 0 0.7462144
, O 0 0.001784495
Shin O 0 0.5539521
- O 0 0.004080537
Poong O 0 0.9923896
Pharm O 0 0.9888571
. O 0 0.00079267466
Co O 0 0.99342126
. O 0 0.00063718756
, O 0 0.0013203193
Ansan O 0 0.64214534
, O 0 0.0015889005
Korea O 0 0.014551831
) O 0 0.001999451
in O 0 0.0014001182
a O 0 0.0031298865
suicide O 0 0.6566673
attempt O 0 0.007721003
. O 0 0.0066951523

She O 0 0.02740145
was O 0 0.015925348
not O 0 0.016544169
an O 0 0.029748352
alcoholic O 0 0.9809965
. O 0 0.038192715

For O 0 0.0025011518
the O 0 0.0016766755
first O 0 0.0010325074
few O 0 0.00076867704
days O 0 0.00079027587
after O 0 0.0005509224
ingestion O 0 0.21554974
, O 0 0.00097449217
she O 0 0.0006642339
was O 0 0.00051414955
in O 0 0.00042398134
a O 0 0.0006230952
confused O 0 0.0027593826
state O 0 0.0008409005
and O 0 0.00066722825
had O 0 0.00093653845
mild O 0 0.2453632
to O 0 0.0016026245
moderate O 0 0.1456138
ataxia B-Disease 2 0.998992
and O 0 0.028424766
giddiness B-Disease 0 0.99850756
. O 0 0.010483223

She O 0 0.0087311715
noticed O 0 0.006798517
hoarseness B-Disease 2 0.9831619
and O 0 0.0030229995
distally O 0 0.0053159557
accentuated O 0 0.012465462
motor O 0 0.06875162
and O 0 0.0014360156
sensory O 0 0.107424036
dysfunction O 0 0.8071509
after O 0 0.00064324687
she O 0 0.0010482655
had O 0 0.0010852411
recovered O 0 0.0011840892
from O 0 0.0017279142
this O 0 0.0027087526
state O 0 0.0064777657
. O 0 0.006260118

A O 0 0.029030763
nerve O 0 0.27981195
conduction O 0 0.1127481
study O 0 0.004899869
was O 0 0.0028129688
consistent O 0 0.002881145
with O 0 0.0045709778
severe O 0 0.42710623
sensorimotor O 0 0.94207925
axonal O 0 0.95623785
polyneuropathy B-Disease 2 0.99802506
. O 0 0.019684495

Laryngeal O 0 0.3644843
electromyography O 0 0.75646716
( O 0 0.011191891
thyroarytenoid O 0 0.100877605
muscle O 0 0.07284013
) O 0 0.007625362
showed O 0 0.004951114
ample O 0 0.014412311
denervation O 0 0.9720132
potentials O 0 0.44727656
. O 0 0.01487458

Laryngoscopy O 0 0.05505183
revealed O 0 0.008297914
asymmetric O 0 0.013794723
vocal O 0 0.086638935
fold O 0 0.013096312
movements O 0 0.016612276
during O 0 0.0085297525
phonation O 0 0.32663748
. O 0 0.015496496

Her O 0 0.011207542
vocal O 0 0.030794656
change O 0 0.0033753638
and O 0 0.0028421404
weakness O 2 0.7653294
began O 0 0.002321226
to O 0 0.001282361
improve O 0 0.0012101185
spontaneously O 0 0.0056902594
about O 0 0.0013988786
3 O 0 0.0014548592
weeks O 0 0.0018004451
after O 0 0.0020082693
transfer O 0 0.0067881886
. O 0 0.0067718416

This O 0 0.0051008877
was O 0 0.0023741245
a O 0 0.0019095924
case O 0 0.0015765256
of O 0 0.0021648728
acute O 0 0.97247225
palsy B-Disease 0 0.99957925
of O 0 0.0025497053
the O 0 0.0011415575
recurrent O 0 0.6258229
laryngeal O 0 0.88996017
nerve O 0 0.80606353
and O 0 0.0009264996
superimposed O 0 0.010183948
severe O 0 0.48218405
acute O 0 0.9890616
sensorimotor O 0 0.9675303
axonal O 0 0.9220701
polyneuropathy B-Disease 2 0.9996834
caused O 0 0.0034784554
by O 0 0.0014629617
high O 0 0.0028453341
- O 0 0.0060452465
dose O 0 0.397883
disulfiram B-Chemical 0 0.99967194
intoxication O 0 0.99827945
. O 0 0.013385844

Encephalopathy B-Disease 0 0.9920053
induced O 0 0.01692258
by O 0 0.0142074255
levetiracetam B-Chemical 1 0.99741757
added O 0 0.016444828
to O 0 0.018589579
valproate B-Chemical 0 0.99776554
. O 0 0.024247361

BACKGROUND O 0 0.7070204
: O 0 0.00547298
We O 0 0.0021486632
report O 0 0.0032449851
on O 0 0.0010764386
the O 0 0.0014099187
manifestation O 0 0.033588253
of O 0 0.0021388298
a O 0 0.0035633654
levetiracetam B-Chemical 1 0.99957806
( O 0 0.01940488
LEV B-Chemical 0 0.9983175
) O 0 0.0111030275
- O 0 0.0078660045
induced O 0 0.01579429
encephalopathy B-Disease 2 0.9984566
. O 0 0.013288855

FINDINGS O 0 0.118154764
: O 0 0.0060646026
A O 0 0.009630832
28 O 0 0.0026406455
- O 0 0.0020545952
year O 0 0.0012035348
- O 0 0.0013952
old O 0 0.0009908703
man O 0 0.078929365
suffering O 0 0.6696635
from O 0 0.0013966962
idiopathic B-Disease 2 0.998747
epilepsy I-Disease 2 0.9998963
with O 0 0.010997175
generalized O 0 0.9641545
seizures B-Disease 2 0.9999496
was O 0 0.0012467187
treated O 0 0.0016586201
with O 0 0.0011882178
LEV B-Chemical 0 0.99929345
( O 0 0.0012081964
3000 O 0 0.0023417214
mg O 0 0.38968822
) O 0 0.0009577897
added O 0 0.0005978819
to O 0 0.00096028426
valproate B-Chemical 0 0.9998167
( O 0 0.016115427
VPA B-Chemical 1 0.9996519
) O 0 0.008329868
( O 0 0.0034603733
2000 O 0 0.008147651
mg O 0 0.5317484
) O 0 0.00817136
. O 0 0.0058930963

Frequency O 0 0.011202914
of O 0 0.004768026
generalized O 0 0.1578341
tonic B-Disease 0 0.92699206
- I-Disease 0 0.028559586
clonic I-Disease 0 0.99969745
seizures I-Disease 2 0.99986446
increased O 0 0.0068234247
from O 0 0.00094863935
one O 0 0.0005407641
per O 0 0.00044378496
6 O 0 0.00053678494
months O 0 0.0007168671
to O 0 0.00078012556
two O 0 0.0010196841
per O 0 0.0015375701
month O 0 0.0039742533
. O 0 0.005370347

Neuropsychological O 0 0.4246857
testing O 0 0.004054234
showed O 0 0.002960528
impaired B-Disease 0 0.0043049394
word I-Disease 0 0.007887028
fluency I-Disease 0 0.9018998
, I-Disease 0 0.0055249133
psychomotor I-Disease 0 0.97824943
speed I-Disease 0 0.006331816
and I-Disease 0 0.00470797
working I-Disease 0 0.012802995
memory I-Disease 0 0.40709963
. O 0 0.010370007

The O 0 0.0047005513
interictal O 0 0.9714976
electroencephalogram O 0 0.95517004
( O 0 0.0045487625
EEG O 0 0.9108329
) O 0 0.00206744
showed O 0 0.0007398573
a O 0 0.00076697365
generalized O 0 0.026551975
slowing O 0 0.025801625
to O 0 0.0005029301
5 O 0 0.00032443277
per O 0 0.00020014109
second O 0 0.0003770023
theta O 0 0.021972483
rhythms O 0 0.004856991
with O 0 0.0008918568
bilateral O 0 0.07584888
generalized O 0 0.07967436
high O 0 0.0033285029
- O 0 0.0052758656
amplitude O 0 0.03730694
discharges O 0 0.78201663
. O 0 0.0073132976

OUTCOME O 0 0.08532783
: O 0 0.004979507
Following O 0 0.0028274592
discontinuation O 0 0.32067156
of O 0 0.003233568
LEV B-Chemical 0 0.99768245
, O 0 0.0033690499
EEG O 0 0.89546186
and O 0 0.0016599643
neuropsychological O 0 0.36021283
findings O 0 0.0029868602
improved O 0 0.0034727543
and O 0 0.0032077744
seizure B-Disease 2 0.99664956
frequency O 0 0.006974094
decreased O 0 0.01691129
. O 0 0.00815665

Norepinephrine B-Chemical 0 0.9971353
signaling O 0 0.009562176
through O 0 0.0034892836
beta O 0 0.53985256
- O 0 0.007542463
adrenergic O 0 0.99497074
receptors O 0 0.29834846
is O 0 0.0012722664
critical O 0 0.001007833
for O 0 0.00087309146
expression O 0 0.002134381
of O 0 0.0038292534
cocaine B-Chemical 1 0.9989151
- O 0 0.015832296
induced O 0 0.012611901
anxiety B-Disease 0 0.9834072
. O 0 0.008849421

BACKGROUND O 0 0.8981885
: O 0 0.014040649
Cocaine B-Chemical 0 0.99844056
is O 0 0.003261527
a O 0 0.0023390695
widely O 0 0.004039773
abused O 0 0.9050596
psychostimulant O 0 0.9971836
that O 0 0.0017288002
has O 0 0.0017677279
both O 0 0.0022400059
rewarding O 0 0.31848824
and O 0 0.004479115
aversive O 0 0.49766457
properties O 0 0.012388043
. O 0 0.007812564

While O 0 0.0036250646
the O 0 0.0021169784
mechanisms O 0 0.0028284732
underlying O 0 0.0051391376
cocaine B-Chemical 1 0.9985495
' O 0 0.0018201241
s O 0 0.0012120198
rewarding O 0 0.101095095
effects O 0 0.0011216807
have O 0 0.00051506486
been O 0 0.0005211326
studied O 0 0.00057504314
extensively O 0 0.00084209006
, O 0 0.0004831824
less O 0 0.00035049842
attention O 0 0.0009896763
has O 0 0.00033382603
been O 0 0.00040640435
paid O 0 0.00065383204
to O 0 0.00029772788
the O 0 0.00037249154
unpleasant O 0 0.16214657
behavioral O 0 0.030070407
states O 0 0.0013830733
induced O 0 0.0012196888
by O 0 0.001603167
cocaine B-Chemical 1 0.99890745
, O 0 0.0027136866
such O 0 0.0022837785
as O 0 0.0034716371
anxiety B-Disease 0 0.9689369
. O 0 0.0070203533

METHODS O 0 0.005934697
: O 0 0.0028403855
In O 0 0.0011437509
this O 0 0.00091498374
study O 0 0.0011763053
, O 0 0.0008075813
we O 0 0.00030809946
evaluated O 0 0.00043941417
the O 0 0.00042183656
performance O 0 0.00082227786
of O 0 0.001266741
dopamine B-Chemical 1 0.99949133
beta O 0 0.9262203
- O 0 0.014193607
hydroxylase O 0 0.997292
knockout O 0 0.0016323497
( O 0 0.0016395522
Dbh O 0 0.19357672
- O 0 0.0012944579
/ O 0 0.0015224932
- O 0 0.0007302906
) O 0 0.00047060385
mice O 0 0.00016818447
, O 0 0.0003312704
which O 0 0.00037236212
lack O 0 0.00049713196
norepinephrine B-Chemical 1 0.999703
( O 0 0.0038237516
NE B-Chemical 0 0.996924
) O 0 0.0015153504
, O 0 0.0004246888
in O 0 0.00021337689
the O 0 0.00023845347
elevated O 0 0.0020200314
plus O 0 0.0004643965
maze O 0 0.15291095
( O 0 0.0011543548
EPM O 0 0.70763123
) O 0 0.000600189
to O 0 0.00023074199
examine O 0 0.00015902953
the O 0 0.00026205336
contribution O 0 0.0003218996
of O 0 0.001011117
noradrenergic O 0 0.9950759
signaling O 0 0.0036867915
to O 0 0.0021514618
cocaine B-Chemical 1 0.99902177
- O 0 0.011057613
induced O 0 0.010062586
anxiety B-Disease 0 0.98311216
. O 0 0.0075642215

RESULTS O 0 0.027531851
: O 0 0.004296368
We O 0 0.001727045
found O 0 0.0013443552
that O 0 0.0012844842
cocaine B-Chemical 1 0.99857616
dose O 0 0.26910615
- O 0 0.0057327165
dependently O 0 0.9793859
increased O 0 0.010473374
anxiety B-Disease 0 0.99530655
- O 0 0.0019487463
like O 0 0.00047225264
behavior O 0 0.0013244861
in O 0 0.00030852505
control O 0 0.00036563532
( O 0 0.000751054
Dbh O 0 0.067844145
+ O 0 0.00068793405
/ O 0 0.0013691089
- O 0 0.00074274745
) O 0 0.0005088921
mice O 0 0.00019175227
, O 0 0.00035724876
as O 0 0.00022619852
measured O 0 0.0002582991
by O 0 0.00044350434
a O 0 0.0006464639
decrease O 0 0.00092140294
in O 0 0.0009158537
open O 0 0.0015473343
arm O 0 0.003710962
exploration O 0 0.0081928065
. O 0 0.0057074875

The O 0 0.0046962476
Dbh O 0 0.09734539
- O 0 0.0047265925
/ O 0 0.0034921914
- O 0 0.0016576075
mice O 0 0.00049840804
had O 0 0.00057498453
normal O 0 0.0008906305
baseline O 0 0.0006373795
performance O 0 0.0007057055
in O 0 0.00040503134
the O 0 0.00053233537
EPM O 0 0.5410094
but O 0 0.0005302939
were O 0 0.00047379176
completely O 0 0.0005927935
resistant O 0 0.0011732526
to O 0 0.0007370726
the O 0 0.001249313
anxiogenic O 0 0.9931171
effects O 0 0.00882774
of O 0 0.01181513
cocaine B-Chemical 1 0.99799395
. O 0 0.009751682

Cocaine B-Chemical 0 0.9986143
- O 0 0.0110469805
induced O 0 0.004764468
anxiety B-Disease 0 0.9632916
was O 0 0.0016238093
also O 0 0.0011569507
attenuated O 0 0.0025367152
in O 0 0.0008791592
Dbh O 0 0.13944656
+ O 0 0.0010878599
/ O 0 0.0015139327
- O 0 0.00066351955
mice O 0 0.00020793383
following O 0 0.00036990244
administration O 0 0.04942148
of O 0 0.0014973419
disulfiram B-Chemical 0 0.9998692
, O 0 0.0030423007
a O 0 0.0024096863
dopamine B-Chemical 1 0.9993482
beta O 0 0.9170729
- O 0 0.033525404
hydroxylase O 0 0.9963819
( O 0 0.01364295
DBH O 0 0.9799882
) O 0 0.011288159
inhibitor O 0 0.2851454
. O 0 0.008234097

In O 0 0.002606944
experiments O 0 0.0017548364
using O 0 0.0014625723
specific O 0 0.0017368814
adrenergic O 0 0.9944991
antagonists O 0 0.98536366
, O 0 0.0016489695
we O 0 0.0003529618
found O 0 0.00044934542
that O 0 0.00037225458
pretreatment O 0 0.089944996
with O 0 0.0007637893
the O 0 0.00067199086
beta O 0 0.72370124
- O 0 0.009452916
adrenergic O 0 0.99884254
receptor O 0 0.84321773
antagonist O 0 0.9986234
propranolol B-Chemical 1 0.9999651
blocked O 0 0.20814389
cocaine B-Chemical 1 0.9998852
- O 0 0.010760455
induced O 0 0.003191829
anxiety B-Disease 0 0.9949319
- O 0 0.0013957208
like O 0 0.00034642412
behavior O 0 0.0014495116
in O 0 0.00033310376
Dbh O 0 0.098259166
+ O 0 0.00058377127
/ O 0 0.0011247457
- O 0 0.0005025762
and O 0 0.0002562741
wild O 0 0.00023327171
- O 0 0.0005221091
type O 0 0.00037033114
C57BL6 O 0 0.02800822
/ O 0 0.0018070396
J O 0 0.33006984
mice O 0 0.0002065396
, O 0 0.000337555
while O 0 0.00022543738
the O 0 0.0003041542
alpha O 0 0.12843934
( O 0 0.00085626444
1 O 0 0.00047850108
) O 0 0.0009985226
antagonist O 0 0.9674058
prazosin B-Chemical 1 0.9999231
and O 0 0.0011250216
the O 0 0.00070816005
alpha O 0 0.2506351
( O 0 0.0014616373
2 O 0 0.00091007777
) O 0 0.002269475
antagonist O 0 0.98160136
yohimbine B-Chemical 1 0.99981874
had O 0 0.004202471
no O 0 0.002922816
effect O 0 0.0055759847
. O 0 0.006160838

CONCLUSIONS O 0 0.65864915
: O 0 0.0047096126
These O 0 0.0022596733
results O 0 0.0012666965
indicate O 0 0.0009577948
that O 0 0.0011585193
noradrenergic O 0 0.9909623
signaling O 0 0.0033605846
via O 0 0.0012345973
beta O 0 0.63413894
- O 0 0.005991276
adrenergic O 0 0.99715155
receptors O 0 0.3137792
is O 0 0.00077712344
required O 0 0.0004057478
for O 0 0.00095067703
cocaine B-Chemical 1 0.9991623
- O 0 0.0053253835
induced O 0 0.0041937623
anxiety B-Disease 0 0.97053045
in O 0 0.0029752841
mice O 0 0.0031758146
. O 0 0.0053765397

Hypothalamic O 0 0.97173023
prolactin O 0 0.9878323
receptor O 0 0.5466169
messenger O 0 0.55782974
ribonucleic B-Chemical 0 0.9950505
acid I-Chemical 0 0.99346864
levels O 0 0.0029102515
, O 0 0.002843603
prolactin O 0 0.991366
signaling O 0 0.0037269546
, O 0 0.0011846038
and O 0 0.0009849685
hyperprolactinemic B-Disease 0 0.9980021
inhibition O 0 0.009343696
of O 0 0.0015333068
pulsatile O 0 0.59662175
luteinizing O 0 0.99470973
hormone O 0 0.9904135
secretion O 0 0.25501743
are O 0 0.0023321838
dependent O 0 0.0025871755
on O 0 0.0036251661
estradiol B-Chemical 1 0.996962
. O 0 0.01038848

Hyperprolactinemia B-Disease 0 0.99108875
can O 0 0.011880407
reduce O 0 0.01058176
fertility O 0 0.05150137
and O 0 0.022323515
libido O 0 0.9623448
. O 0 0.026713384

Although O 0 0.004646462
central O 0 0.007522996
prolactin O 0 0.95977837
actions O 0 0.037144575
are O 0 0.0018890727
thought O 0 0.00184185
to O 0 0.0009714178
contribute O 0 0.0010225548
to O 0 0.0008683796
this O 0 0.00097125734
, O 0 0.0013635955
the O 0 0.0011602278
mechanisms O 0 0.0027860552
are O 0 0.0025325925
poorly O 0 0.0084861545
understood O 0 0.0088125
. O 0 0.006862094

We O 0 0.0028399008
first O 0 0.0016172734
tested O 0 0.0013399055
whether O 0 0.0009872146
chronic O 0 0.95891494
hyperprolactinemia B-Disease 2 0.9997805
inhibited O 0 0.0140248565
two O 0 0.0007363569
neuroendocrine O 0 0.80392057
parameters O 0 0.0014371797
necessary O 0 0.0003470168
for O 0 0.00039677313
female O 0 0.0021360007
fertility O 0 0.0178808
: O 0 0.0014390306
pulsatile O 0 0.26536602
LH O 0 0.9921332
secretion O 0 0.10406648
and O 0 0.0014017646
the O 0 0.0018995308
estrogen B-Chemical 1 0.99829525
- O 0 0.01590698
induced O 0 0.012746826
LH O 0 0.9901247
surge O 0 0.69671285
. O 0 0.009473454

Chronic O 0 0.9918875
hyperprolactinemia B-Disease 2 0.99918896
induced O 0 0.008883851
by O 0 0.0025692594
the O 0 0.0023264405
dopamine B-Chemical 1 0.9991461
antagonist O 0 0.9975624
sulpiride B-Chemical 0 0.9999443
caused O 0 0.0045933574
a O 0 0.000997094
40 O 0 0.0007335382
% O 0 0.00050548767
reduction O 0 0.00090653426
LH O 0 0.9522563
pulse O 0 0.0069170194
frequency O 0 0.0005903702
in O 0 0.00043769393
ovariectomized O 0 0.6907161
rats O 0 0.005388786
, O 0 0.0005429144
but O 0 0.0003090208
only O 0 0.0003015964
in O 0 0.00028212392
the O 0 0.00033707585
presence O 0 0.00048401955
of O 0 0.0011042925
chronic O 0 0.9205373
low O 0 0.0031446293
levels O 0 0.002792404
of O 0 0.009999003
estradiol B-Chemical 1 0.99808156
. O 0 0.010002893

Sulpiride B-Chemical 0 0.99875367
did O 0 0.0034758116
not O 0 0.0015306125
affect O 0 0.0008828322
the O 0 0.00081111235
magnitude O 0 0.0007426218
of O 0 0.0010037759
a O 0 0.0013313249
steroid B-Chemical 1 0.99651504
- O 0 0.005471184
induced O 0 0.0023957868
LH O 0 0.9912151
surge O 0 0.16732307
or O 0 0.0005375258
the O 0 0.00045766067
percentage O 0 0.000365231
of O 0 0.001183658
GnRH O 0 0.95916504
neurons O 0 0.035493415
activated O 0 0.0022489415
during O 0 0.001684276
the O 0 0.003328634
surge O 0 0.26091173
. O 0 0.007231216

Estradiol B-Chemical 0 0.99777716
is O 0 0.003984493
known O 0 0.0024243535
to O 0 0.0011449973
influence O 0 0.00084492523
expression O 0 0.0011861557
of O 0 0.0008113644
the O 0 0.0005418701
long O 0 0.00067780557
form O 0 0.00065530266
of O 0 0.0011729957
prolactin O 0 0.9961289
receptors O 0 0.6266617
( O 0 0.008577327
PRL O 0 0.99914193
- O 0 0.008983722
R O 0 0.82289064
) O 0 0.0012568168
and O 0 0.0006054176
components O 0 0.0007655983
of O 0 0.001522623
prolactin O 0 0.9814393
' O 0 0.002418414
s O 0 0.0028803756
signaling O 0 0.0050148056
pathway O 0 0.00795608
. O 0 0.0064938446

To O 0 0.0026033807
test O 0 0.0022575723
the O 0 0.0015873384
hypothesis O 0 0.0019030165
that O 0 0.0014430165
estrogen B-Chemical 1 0.9980258
increases O 0 0.011808574
PRL O 0 0.9992592
- O 0 0.018779231
R O 0 0.8434267
expression O 0 0.0015386202
and O 0 0.0006036593
sensitivity O 0 0.001589878
to O 0 0.00055394456
prolactin O 0 0.9784349
, O 0 0.0005749933
we O 0 0.00017395435
next O 0 0.00020773428
demonstrated O 0 0.00047936622
that O 0 0.00063047383
estradiol B-Chemical 1 0.9991855
greatly O 0 0.023917424
augments O 0 0.22223139
prolactin O 0 0.9973574
- O 0 0.012912983
induced O 0 0.008548537
STAT5 O 0 0.86546594
activation O 0 0.030331787
. O 0 0.0074351295

Lastly O 0 0.0058537275
, O 0 0.0033044228
we O 0 0.0012823829
measured O 0 0.0017014131
PRL O 0 0.9964575
- O 0 0.007960326
R O 0 0.7034453
and O 0 0.0011313143
suppressor O 0 0.009251662
of O 0 0.0012712458
cytokine O 0 0.29064098
signaling O 0 0.0043805144
( O 0 0.0015249127
SOCS O 0 0.23643294
- O 0 0.0011562504
1 O 0 0.0003982702
and O 0 0.00037609198
- O 0 0.000528251
3 O 0 0.00023689191
and O 0 0.00032990196
CIS O 0 0.4534965
, O 0 0.00045701198
which O 0 0.00034685785
reflect O 0 0.00023069842
the O 0 0.00023828735
level O 0 0.0002450221
of O 0 0.0007081841
prolactin O 0 0.9908279
signaling O 0 0.0030193757
) O 0 0.00151278
mRNAs O 0 0.0014064782
in O 0 0.00064105977
response O 0 0.0016944902
to O 0 0.0023514929
sulpiride B-Chemical 0 0.99973756
and O 0 0.020554516
estradiol B-Chemical 1 0.9981602
. O 0 0.010236696

Sulpiride B-Chemical 0 0.99886924
induced O 0 0.0075392555
only O 0 0.003202366
SOCS O 0 0.27597895
- O 0 0.002969558
1 O 0 0.00096079713
in O 0 0.00058539485
the O 0 0.0006719761
medial O 0 0.041994166
preoptic O 0 0.71660626
area O 0 0.00094602455
, O 0 0.0005948245
where O 0 0.00040803672
GnRH O 0 0.9107724
neurons O 0 0.018517256
are O 0 0.00034863516
regulated O 0 0.00025110441
, O 0 0.00039970243
but O 0 0.00026197193
in O 0 0.00023980436
the O 0 0.00035151868
arcuate O 0 0.47864574
nucleus O 0 0.001808677
and O 0 0.0005923318
choroid O 0 0.90029496
plexus O 0 0.8405208
, O 0 0.002072481
PRL O 0 0.99905294
- O 0 0.006683588
R O 0 0.84440476
, O 0 0.0012150005
SOCS O 0 0.18025042
- O 0 0.0012040702
3 O 0 0.00047851886
, O 0 0.00066998386
and O 0 0.0007872709
CIS O 0 0.5288373
mRNA O 0 0.0021892325
levels O 0 0.0013014512
were O 0 0.0017176565
also O 0 0.002835432
induced O 0 0.006082034
. O 0 0.006161083

Estradiol B-Chemical 0 0.9957943
enhanced O 0 0.009426599
these O 0 0.0065732514
effects O 0 0.0075912094
on O 0 0.0039267982
SOCS O 0 0.22695334
- O 0 0.009807265
3 O 0 0.0054827053
and O 0 0.008421069
CIS O 0 0.71015495
. O 0 0.013409191

Interestingly O 0 0.006129107
, O 0 0.006561656
estradiol B-Chemical 1 0.9968713
also O 0 0.004452842
induced O 0 0.008254386
PRL O 0 0.9984432
- O 0 0.026514815
R O 0 0.89428645
, O 0 0.0029147395
SOCS O 0 0.23135854
- O 0 0.0024970958
3 O 0 0.0010367507
, O 0 0.0014235319
and O 0 0.0017079755
CIS O 0 0.56225246
mRNA O 0 0.0047246525
levels O 0 0.00325926
independently O 0 0.005010201
. O 0 0.006768626

These O 0 0.0046137767
data O 0 0.0029422448
show O 0 0.0016797673
that O 0 0.0015313893
GnRH O 0 0.8116403
pulse O 0 0.010807666
frequency O 0 0.0015962388
is O 0 0.0011394379
inhibited O 0 0.002418957
by O 0 0.001653373
chronic O 0 0.99223244
hyperprolactinemia B-Disease 2 0.9998209
in O 0 0.0025064992
a O 0 0.0036511836
steroid B-Chemical 1 0.9949793
- O 0 0.008820592
dependent O 0 0.0040463516
manner O 0 0.008754081
. O 0 0.0068774526

They O 0 0.00606123
also O 0 0.0022622603
provide O 0 0.0015932089
evidence O 0 0.0015624469
for O 0 0.0014993437
estradiol B-Chemical 1 0.99883777
- O 0 0.0032224462
dependent O 0 0.00079537707
and O 0 0.0008403403
brain O 0 0.03992788
region O 0 0.0008005927
- O 0 0.00079600175
specific O 0 0.0004186035
regulation O 0 0.0004791225
of O 0 0.0013003418
PRL O 0 0.99882454
- O 0 0.007303483
R O 0 0.74147254
expression O 0 0.002061781
and O 0 0.0014346656
signaling O 0 0.0030995598
responses O 0 0.005453232
by O 0 0.004931298
prolactin O 0 0.98531914
. O 0 0.007903057

Clonidine B-Chemical 1 0.9980038
for O 0 0.007970651
attention B-Disease 0 0.017991936
- I-Disease 0 0.01012273
deficit I-Disease 0 0.3234197
/ I-Disease 0 0.044041652
hyperactivity I-Disease 2 0.99729925
disorder I-Disease 0 0.9825685
: O 0 0.024036508
II O 0 0.084366985
. O 0 0.011991398

ECG O 0 0.6664471
changes O 0 0.016048158
and O 0 0.013506152
adverse O 0 0.54022866
events O 0 0.037029482
analysis O 0 0.022165133
. O 0 0.019173482

OBJECTIVE O 0 0.44157615
: O 0 0.0038576422
To O 0 0.0012216363
examine O 0 0.0007025737
the O 0 0.0008241949
safety O 0 0.0019408652
and O 0 0.0008642326
tolerability O 0 0.2058631
of O 0 0.0014695645
clonidine B-Chemical 1 0.9997689
used O 0 0.00078881404
alone O 0 0.00066783145
or O 0 0.0004022062
with O 0 0.0009047712
methylphenidate B-Chemical 1 0.99961865
in O 0 0.00059005065
children O 0 0.0017098319
with O 0 0.00079217745
attention B-Disease 0 0.00545102
- I-Disease 0 0.0022317108
deficit I-Disease 0 0.2909717
/ I-Disease 0 0.026110042
hyperactivity I-Disease 2 0.99909806
disorder I-Disease 0 0.9913094
( O 0 0.0350673
ADHD B-Disease 0 0.9963491
) O 0 0.012342504
. O 0 0.0063529955

METHOD O 0 0.04030642
: O 0 0.004145866
In O 0 0.0015979321
a O 0 0.0014448182
16 O 0 0.0012381042
- O 0 0.0011134465
week O 0 0.00060368405
multicenter O 0 0.015917944
, O 0 0.000712505
double O 0 0.00045401114
- O 0 0.0007653758
blind O 0 0.0019583511
trial O 0 0.0009059397
, O 0 0.00047685712
122 O 0 0.0017868833
children O 0 0.0008544949
with O 0 0.0006237594
ADHD B-Disease 0 0.9965263
were O 0 0.00026640398
randomly O 0 0.00011805399
assigned O 0 0.00024171328
to O 0 0.00036863933
clonidine B-Chemical 1 0.99978215
( O 0 0.0009040315
n O 0 0.00032525344
= O 0 0.00050786673
31 O 0 0.00046292847
) O 0 0.00054474105
, O 0 0.00060134055
methylphenidate B-Chemical 1 0.99959606
( O 0 0.0007290575
n O 0 0.000304561
= O 0 0.0004897689
29 O 0 0.0006010964
) O 0 0.00055307377
, O 0 0.00058574317
clonidine B-Chemical 1 0.99973863
and O 0 0.001461821
methylphenidate B-Chemical 1 0.9997776
( O 0 0.001114736
n O 0 0.00039966812
= O 0 0.00060672994
32 O 0 0.0005981931
) O 0 0.0006479704
, O 0 0.00053867983
or O 0 0.0005050277
placebo O 0 0.08345922
( O 0 0.0013295517
n O 0 0.0011512998
= O 0 0.0022647206
30 O 0 0.0020124526
) O 0 0.0046084695
. O 0 0.004535961

Doses O 0 0.4247626
were O 0 0.0028096961
flexibly O 0 0.0039450848
titrated O 0 0.0030210859
up O 0 0.0010653725
to O 0 0.0007718601
0 O 0 0.00074638234
. O 0 0.00035544386
6 O 0 0.00035906135
mg O 0 0.0587084
/ O 0 0.0007717483
day O 0 0.0003297501
for O 0 0.00035841405
clonidine B-Chemical 1 0.9995364
and O 0 0.00059731735
60 O 0 0.0006037488
mg O 0 0.18977049
/ O 0 0.00087702734
day O 0 0.0003945655
for O 0 0.00053451146
methylphenidate B-Chemical 1 0.9993218
( O 0 0.0012935323
both O 0 0.0007928945
with O 0 0.0013180721
divided O 0 0.0016630428
dosing O 0 0.07788294
) O 0 0.0073607955
. O 0 0.0054448987

Groups O 0 0.011838023
were O 0 0.0022239783
compared O 0 0.0010946586
regarding O 0 0.0012105308
adverse O 0 0.23882009
events O 0 0.004208352
and O 0 0.00091881666
changes O 0 0.000948915
from O 0 0.00053647475
baseline O 0 0.0006932159
to O 0 0.00049686834
week O 0 0.00060619874
16 O 0 0.00083395944
in O 0 0.00089076033
electrocardiograms O 0 0.2167677
and O 0 0.0025446934
vital O 0 0.011675114
signs O 0 0.25901228
. O 0 0.0072662295

RESULTS O 0 0.026385764
: O 0 0.0044218297
There O 0 0.0024672963
were O 0 0.0013161541
more O 0 0.0014012695
incidents O 0 0.006453738
of O 0 0.0015043189
bradycardia B-Disease 0 0.9980665
in O 0 0.00065432297
subjects O 0 0.000950763
treated O 0 0.0008877017
with O 0 0.0008115326
clonidine B-Chemical 1 0.99976784
compared O 0 0.0003020813
with O 0 0.0004264145
those O 0 0.00043651724
not O 0 0.00025778412
treated O 0 0.00067109714
with O 0 0.00086299324
clonidine B-Chemical 1 0.99986374
( O 0 0.001197515
17 O 0 0.00051792
. O 0 0.0001456473
5 O 0 0.00016630118
% O 0 0.00018488996
versus O 0 0.00015403712
3 O 0 0.00016409295
. O 0 0.00011969213
4 O 0 0.00017109825
% O 0 0.00025269843
; O 0 0.0003518942
p O 0 0.00035589904
= O 0 0.0004179249
. O 0 0.00017933293
02 O 0 0.008781271
) O 0 0.00051733095
, O 0 0.0003344469
but O 0 0.00021837113
no O 0 0.00017673604
other O 0 0.00024768565
significant O 0 0.00039112088
group O 0 0.00041625692
differences O 0 0.00029410966
regarding O 0 0.00053770776
electrocardiogram O 0 0.54776305
and O 0 0.0014362042
other O 0 0.002455247
cardiovascular O 0 0.9646369
outcomes O 0 0.021291435
. O 0 0.0062788036

There O 0 0.0058611888
were O 0 0.0026929418
no O 0 0.0017577132
suggestions O 0 0.0025850479
of O 0 0.0020367894
interactions O 0 0.0028192447
between O 0 0.0015749607
clonidine B-Chemical 1 0.99911827
and O 0 0.0069290968
methylphenidate B-Chemical 1 0.9988397
regarding O 0 0.00613916
cardiovascular O 0 0.98021585
outcomes O 0 0.03387169
. O 0 0.009108966

Moderate O 0 0.33207372
or O 0 0.0032266914
severe O 0 0.09642795
adverse O 0 0.611924
events O 0 0.006153718
were O 0 0.0008018654
more O 0 0.0007344301
common O 0 0.00077326293
in O 0 0.00041378188
subjects O 0 0.00077146926
on O 0 0.00036446739
clonidine B-Chemical 1 0.9997055
( O 0 0.0010707994
79 O 0 0.00072760193
. O 0 0.00018257312
4 O 0 0.00019941325
% O 0 0.00022446751
versus O 0 0.00018667466
49 O 0 0.00038889417
. O 0 0.00015167189
2 O 0 0.00023975632
% O 0 0.00030079982
; O 0 0.00040612687
p O 0 0.00040260685
= O 0 0.00046941836
. O 0 0.000198364
0006 O 0 0.006704419
) O 0 0.0005030819
but O 0 0.00025982206
not O 0 0.00025854967
associated O 0 0.00047345922
with O 0 0.0005428885
higher O 0 0.00056934485
rates O 0 0.0007649554
of O 0 0.0014287389
early O 0 0.0045699105
study O 0 0.0065966174
withdrawal O 0 0.8172763
. O 0 0.006823096

Drowsiness B-Disease 0 0.98007137
was O 0 0.003997803
common O 0 0.0036880386
on O 0 0.0020580657
clonidine B-Chemical 1 0.99904436
, O 0 0.0036860867
but O 0 0.0015990409
generally O 0 0.0018884545
resolved O 0 0.0025170336
by O 0 0.0017219422
6 O 0 0.0014622909
to O 0 0.0018444485
8 O 0 0.0027186493
weeks O 0 0.0039859996
. O 0 0.005528709

CONCLUSIONS O 0 0.88515604
: O 0 0.013735616
Clonidine B-Chemical 1 0.9993394
, O 0 0.0038564426
used O 0 0.0014194442
alone O 0 0.00132436
or O 0 0.0009271049
with O 0 0.0018483398
methylphenidate B-Chemical 1 0.9994412
, O 0 0.002022726
appears O 0 0.00096220983
safe O 0 0.0026340631
and O 0 0.0010843627
well O 0 0.0012073173
tolerated O 0 0.026642552
in O 0 0.0035277219
childhood O 0 0.9584806
ADHD B-Disease 0 0.99571747
. O 0 0.0095906565

Physicians O 0 0.011280317
prescribing O 0 0.051835164
clonidine B-Chemical 1 0.9985898
should O 0 0.001380693
monitor O 0 0.0010348827
for O 0 0.0010722256
bradycardia B-Disease 0 0.996609
and O 0 0.0011717493
advise O 0 0.0038473287
patients O 0 0.001754663
about O 0 0.0006207617
the O 0 0.0006953179
high O 0 0.0012939994
likelihood O 0 0.0022469042
of O 0 0.0030319705
initial O 0 0.007314662
drowsiness B-Disease 0 0.99748623
. O 0 0.009503588

Renal B-Disease 0 0.982236
Fanconi I-Disease 2 0.9960068
syndrome I-Disease 2 0.9904274
and O 0 0.006712731
myopathy B-Disease 2 0.99539655
after O 0 0.0023329998
liver O 0 0.88223594
transplantation O 0 0.5527709
: O 0 0.0054190345
drug O 0 0.49318424
- O 0 0.005735362
related O 0 0.0036209768
mitochondrial B-Disease 0 0.7090203
cytopathy I-Disease 0 0.9853212
? O 0 0.03703122

Advances O 0 0.007315999
in O 0 0.002167427
the O 0 0.0014491983
field O 0 0.0016923203
of O 0 0.0013154473
transplantation O 0 0.028821856
provide O 0 0.00075476157
a O 0 0.00062636693
better O 0 0.00057028193
quality O 0 0.00039300908
of O 0 0.0005475099
life O 0 0.0009877486
and O 0 0.00043156976
allow O 0 0.0002956996
more O 0 0.0005095319
favorable O 0 0.0024700195
conditions O 0 0.0007941509
for O 0 0.00065083354
growth O 0 0.0036310114
and O 0 0.0014953882
development O 0 0.0038773592
in O 0 0.0027808626
children O 0 0.009684191
. O 0 0.0059044263

However O 0 0.0046482263
, O 0 0.0031607118
combinations O 0 0.0018699906
of O 0 0.0017524285
different O 0 0.0014834165
therapeutic O 0 0.008577745
regimens O 0 0.010967177
require O 0 0.001289897
consideration O 0 0.0016151529
of O 0 0.0024596634
potential O 0 0.005275095
adverse O 0 0.8370317
reactions O 0 0.10875204
. O 0 0.008915874

We O 0 0.003334109
describe O 0 0.0026491056
a O 0 0.0022751484
15 O 0 0.0016236594
- O 0 0.0020459176
yr O 0 0.0024782065
- O 0 0.0013279256
old O 0 0.00090972235
girl O 0 0.0023445638
who O 0 0.0014621308
had O 0 0.001021131
orthotopic O 0 0.9621704
liver O 0 0.8760733
transplantation O 0 0.2628486
because O 0 0.0010944167
of O 0 0.0023592543
Wilson B-Disease 0 0.42016208
' I-Disease 0 0.003664405
s I-Disease 0 0.0055101626
disease I-Disease 0 0.5428225
. O 0 0.008163952

Tacrolimus B-Chemical 1 0.9967296
, O 0 0.018965287
MMF B-Chemical 0 0.99747854
, O 0 0.007762254
and O 0 0.0049264664
steroids B-Chemical 0 0.989209
were O 0 0.0045862254
given O 0 0.0036786995
as O 0 0.006422867
immunosuppressant O 0 0.9849467
. O 0 0.014505924

Lamivudine B-Chemical 1 0.99632144
was O 0 0.00414336
added O 0 0.002635847
because O 0 0.0015920678
of O 0 0.002626195
de O 0 0.07630016
nova O 0 0.4269984
hepatitis B-Disease 2 0.9998254
B I-Disease 2 0.98270446
infection I-Disease 0 0.8217017
during O 0 0.002228109
her O 0 0.004015521
follow O 0 0.0034461252
- O 0 0.006513492
up O 0 0.005753181
. O 0 0.0070084124

Three O 0 0.005153195
yr O 0 0.0044763396
after O 0 0.0013705846
transplantation O 0 0.0147517435
she O 0 0.0019125466
developed O 0 0.0042446856
renal B-Disease 0 0.9970285
Fanconi I-Disease 2 0.99925
syndrome I-Disease 2 0.9972445
with O 0 0.005685406
severe O 0 0.7733044
metabolic B-Disease 2 0.9913965
acidosis I-Disease 2 0.9998399
, O 0 0.07289822
hypophosphatemia B-Disease 0 0.9997743
, O 0 0.03422472
glycosuria B-Disease 2 0.9990963
, O 0 0.009276384
and O 0 0.009466423
aminoaciduria B-Disease 0 0.99841666
. O 0 0.012175864

Although O 0 0.00552679
tacrolimus B-Chemical 0 0.99775827
was O 0 0.0030990457
suspected O 0 0.017100122
to O 0 0.0011572008
be O 0 0.0009092824
the O 0 0.00065136194
cause O 0 0.0015044083
of O 0 0.0008522552
late O 0 0.0029374447
post O 0 0.0011281334
- O 0 0.0014862147
transplant O 0 0.70866895
renal O 0 0.99763834
acidosis B-Disease 2 0.99970263
and O 0 0.0011828064
was O 0 0.00056153606
replaced O 0 0.00056961924
by O 0 0.00085188536
sirolimus B-Chemical 1 0.99923825
, O 0 0.0069235535
acidosis B-Disease 2 0.99935824
, O 0 0.0026104169
and O 0 0.0019155708
electrolyte O 0 0.91825557
imbalance O 0 0.20843199
got O 0 0.01267376
worse O 0 0.01928917
. O 0 0.0069469004

Proximal O 0 0.20986176
muscle B-Disease 0 0.13321237
weakness I-Disease 2 0.9144902
has O 0 0.0047385427
developed O 0 0.0054575223
during O 0 0.0029139926
her O 0 0.005655949
follow O 0 0.0053609107
- O 0 0.0096643185
up O 0 0.008508856
. O 0 0.010050917

Fanconi B-Disease 2 0.9941514
syndrome I-Disease 2 0.980292
, O 0 0.0039042095
as O 0 0.0013220651
well O 0 0.001003841
as O 0 0.0011404598
myopathy B-Disease 2 0.99751854
, O 0 0.0017332275
is O 0 0.0006037974
well O 0 0.0003864182
recognized O 0 0.00063544395
in O 0 0.00041580832
patients O 0 0.0016495073
with O 0 0.001022583
mitochondrial B-Disease 0 0.8910544
disorders I-Disease 0 0.98021734
and O 0 0.0015321749
caused O 0 0.0017266744
by O 0 0.0017486594
depletion O 0 0.005851886
of O 0 0.0051429775
mtDNA O 0 0.08122619
. O 0 0.007290713

We O 0 0.0027491879
suggest O 0 0.001528072
that O 0 0.0011760192
our O 0 0.0010138593
patient O 0 0.001670277
' O 0 0.0012041939
s O 0 0.0014316208
tubular B-Disease 0 0.93775433
dysfunction I-Disease 0 0.9959572
and O 0 0.0028112046
myopathy B-Disease 2 0.9988111
may O 0 0.0009004055
have O 0 0.00058799004
resulted O 0 0.0005227266
from O 0 0.00067645084
mitochondrial B-Disease 2 0.8970143
dysfunction I-Disease 2 0.99682033
which O 0 0.001960788
is O 0 0.00078604487
triggered O 0 0.0014182093
by O 0 0.001662093
tacrolimus B-Chemical 0 0.99948263
and O 0 0.002923893
augmented O 0 0.0104901595
by O 0 0.007751692
lamivudine B-Chemical 1 0.9984823
. O 0 0.010218242

Higher O 0 0.012697659
optical O 0 0.01706955
density O 0 0.0038244124
of O 0 0.00243169
an O 0 0.0024027308
antigen O 0 0.021317188
assay O 0 0.0029073665
predicts O 0 0.0025139258
thrombosis B-Disease 2 0.99775213
in O 0 0.0017833919
patients O 0 0.0062241326
with O 0 0.003581177
heparin B-Chemical 1 0.99255013
- O 0 0.021257607
induced O 0 0.028377475
thrombocytopenia B-Disease 0 0.9981141
. O 0 0.012171082

OBJECTIVES O 0 0.025867874
: O 0 0.0037762541
To O 0 0.0013141525
correlate O 0 0.0011628773
optical O 0 0.006444835
density O 0 0.0016181073
and O 0 0.00081413315
percent O 0 0.00055820536
inhibition O 0 0.0016948936
of O 0 0.0006988974
a O 0 0.00061646494
two O 0 0.00041309962
- O 0 0.000924968
step O 0 0.0006586148
heparin B-Chemical 1 0.9917156
- O 0 0.0041777384
induced O 0 0.0045489785
thrombocytopenia B-Disease 0 0.9997714
( O 0 0.009327379
HIT B-Disease 2 0.99633837
) O 0 0.0022219412
antigen O 0 0.03535704
assay O 0 0.0013782155
with O 0 0.0011941054
thrombosis B-Disease 2 0.99933285
; O 0 0.0016988104
the O 0 0.00037879584
assay O 0 0.00073005963
utilizes O 0 0.00046692882
reaction O 0 0.0043370044
inhibition O 0 0.002875575
characteristics O 0 0.000890788
of O 0 0.001136379
a O 0 0.0016289225
high O 0 0.0037030037
heparin B-Chemical 1 0.98684454
concentration O 0 0.06997011
. O 0 0.00771632

PATIENTS O 0 0.014599142
AND O 0 0.00562587
METHODS O 0 0.0033374017
: O 0 0.0022009758
Patients O 0 0.0026169792
with O 0 0.0009910837
more O 0 0.000924106
than O 0 0.00045722374
50 O 0 0.0008042565
% O 0 0.00054433
decrease O 0 0.00051458145
in O 0 0.00044800693
platelet O 0 0.62532234
count O 0 0.002756883
or O 0 0.000748968
thrombocytopenia B-Disease 0 0.9995592
( O 0 0.0012422533
< O 0 0.00046373534
150 O 0 0.0005492043
x O 0 0.0007400431
10 O 0 0.00030484222
( O 0 0.0003457001
9 O 0 0.00026885196
) O 0 0.0004647581
/ O 0 0.0008002262
L O 0 0.17507493
) O 0 0.00047242705
after O 0 0.00013787478
exposure O 0 0.0009599005
to O 0 0.00029175341
heparin B-Chemical 1 0.97401977
, O 0 0.0006071948
who O 0 0.00079301425
had O 0 0.00026559416
a O 0 0.0002671054
positive O 0 0.00023386274
two O 0 0.0002263681
- O 0 0.0005162349
step O 0 0.0003314887
antigen O 0 0.016346492
assay O 0 0.0013074334
[ O 0 0.0012821777
optical O 0 0.017558193
density O 0 0.0012800266
( O 0 0.00086118456
OD O 0 0.15600798
) O 0 0.0008823734
> O 0 0.00065696926
0 O 0 0.00026644563
. O 0 0.00012685661
4 O 0 0.00016012767
and O 0 0.00021816342
> O 0 0.00043585815
50 O 0 0.00032404636
inhibition O 0 0.0006796151
with O 0 0.00033506888
high O 0 0.00051955815
concentration O 0 0.0016297556
of O 0 0.0010105671
heparin B-Chemical 1 0.9902908
] O 0 0.003261417
were O 0 0.0008110545
included O 0 0.0008999445
in O 0 0.0012219959
the O 0 0.0021131658
study O 0 0.005274419
. O 0 0.005384105

RESULTS O 0 0.025465397
: O 0 0.0047938135
Forty O 0 0.005335183
of O 0 0.0021472953
94 O 0 0.0027369992
HIT B-Disease 2 0.9127817
patients O 0 0.004261291
had O 0 0.001707404
thrombosis B-Disease 2 0.99750715
at O 0 0.0009315276
diagnosis O 0 0.014730052
; O 0 0.0016839385
54 O 0 0.0014218903
/ O 0 0.0013743415
94 O 0 0.0010423382
had O 0 0.0009680165
isolated O 0 0.0017888662
- O 0 0.0047860914
HIT B-Disease 2 0.9792631
without O 0 0.009553595
thrombosis B-Disease 2 0.99633574
. O 0 0.010891847

Eight O 0 0.0070449803
of O 0 0.002998712
the O 0 0.002028245
isolated O 0 0.0022377775
- O 0 0.0033215561
HIT B-Disease 2 0.96110535
patients O 0 0.0057938294
developed O 0 0.0029347395
thrombosis B-Disease 2 0.99796414
within O 0 0.000367062
the O 0 0.00035717452
next O 0 0.00022155407
30 O 0 0.00030836626
d O 0 0.00047897678
; O 0 0.0005739245
thus O 0 0.00045092963
, O 0 0.00040520533
a O 0 0.00032340747
total O 0 0.00029339382
of O 0 0.00049615605
48 O 0 0.00058590446
patients O 0 0.0014567752
had O 0 0.0014127654
thrombosis B-Disease 2 0.996148
at O 0 0.0015210644
day O 0 0.0026945216
30 O 0 0.00346965
. O 0 0.0044245385

At O 0 0.0027289172
diagnosis O 0 0.0054106065
there O 0 0.0012883513
was O 0 0.0012086907
no O 0 0.0007714509
significant O 0 0.0009619879
difference O 0 0.00052800454
in O 0 0.0006756589
OD O 0 0.048324194
between O 0 0.00062689907
HIT B-Disease 2 0.96606356
patients O 0 0.005164881
with O 0 0.0019611232
thrombosis B-Disease 2 0.99822253
and O 0 0.0018327476
those O 0 0.0020633063
with O 0 0.002341108
isolated O 0 0.0040341327
- O 0 0.011775945
HIT B-Disease 2 0.98155
. O 0 0.008730871

However O 0 0.004685014
, O 0 0.0036859438
OD O 0 0.04266462
was O 0 0.0014082291
significantly O 0 0.0011105097
higher O 0 0.00070638227
in O 0 0.00051426695
all O 0 0.0004633569
patients O 0 0.0015958832
with O 0 0.0011347671
thrombosis B-Disease 2 0.99905676
( O 0 0.001314741
n O 0 0.00041083558
= O 0 0.00051022856
48 O 0 0.00028307445
, O 0 0.00031836657
1 O 0 0.00025423372
. O 0 0.00014977426
34 O 0 0.00037244344
+ O 0 0.00037762025
/ O 0 0.00072252296
- O 0 0.00045458405
0 O 0 0.00026037355
. O 0 0.000127648
89 O 0 0.0004644875
) O 0 0.00037106406
, O 0 0.0002652852
including O 0 0.00023581204
isolated O 0 0.00039784575
- O 0 0.000904614
HIT B-Disease 2 0.96845937
patients O 0 0.0021178308
who O 0 0.0008197782
later O 0 0.00025600227
developed O 0 0.0009698803
thrombosis B-Disease 2 0.9985233
within O 0 0.00018802262
30 O 0 0.00024026274
d O 0 0.0003448976
( O 0 0.00032008364
n O 0 0.0002037935
= O 0 0.00033237538
8 O 0 0.0001923577
, O 0 0.0002453143
1 O 0 0.00020531831
. O 0 0.00012322913
84 O 0 0.00037076848
+ O 0 0.00033607008
/ O 0 0.00066871924
- O 0 0.0004179225
0 O 0 0.0002385615
. O 0 0.000114105416
64 O 0 0.00030754364
) O 0 0.00027325834
as O 0 0.00012339046
compared O 0 0.000108233726
to O 0 0.00018461917
isolated O 0 0.000355653
- O 0 0.0009028745
HIT B-Disease 2 0.9732776
patients O 0 0.0029514492
who O 0 0.0010415253
did O 0 0.00024512023
not O 0 0.00023906058
develop O 0 0.00082367996
thrombosis B-Disease 2 0.9992028
( O 0 0.0009731714
0 O 0 0.00039599475
. O 0 0.0001643902
96 O 0 0.00050005503
+ O 0 0.00040374955
/ O 0 0.00078954134
- O 0 0.0005089638
0 O 0 0.00030819318
. O 0 0.00016556513
75 O 0 0.00048625123
; O 0 0.00061370496
P O 0 0.009700026
= O 0 0.00066131755
0 O 0 0.00046362443
. O 0 0.00033701045
011 O 0 0.014780394
and O 0 0.00087747833
P O 0 0.020730989
= O 0 0.0018532516
0 O 0 0.0015282676
. O 0 0.0014445658
008 O 0 0.012278751
) O 0 0.005830838
. O 0 0.0052869534

The O 0 0.0055495747
Receiver O 0 0.9241191
Operative O 0 0.06574464
Characteristic O 0 0.3524971
Curve O 0 0.8531667
showed O 0 0.0016207033
that O 0 0.0010946139
OD O 0 0.13074277
> O 0 0.0019685708
1 O 0 0.00060046994
. O 0 0.00029159125
27 O 0 0.0005360748
in O 0 0.0002743995
the O 0 0.0003269852
isolated O 0 0.00055786496
- O 0 0.0011741784
HIT B-Disease 2 0.95613486
group O 0 0.00063196424
had O 0 0.00042955534
a O 0 0.00045436271
significantly O 0 0.0005206363
higher O 0 0.00047825213
chance O 0 0.00088128325
of O 0 0.0012001228
developing O 0 0.024541615
thrombosis B-Disease 2 0.9979721
by O 0 0.0030431948
day O 0 0.0033109572
30 O 0 0.0038381966
. O 0 0.0046685627

None O 0 0.010339451
of O 0 0.00427553
these O 0 0.003828893
groups O 0 0.003213335
showed O 0 0.0025233126
significant O 0 0.0031222594
difference O 0 0.0021899869
in O 0 0.003345717
percent O 0 0.0052189664
inhibition O 0 0.018809771
. O 0 0.011029985

Multivariate O 0 0.03386132
analysis O 0 0.004613663
showed O 0 0.0024306905
a O 0 0.0022310717
2 O 0 0.0016610333
. O 0 0.00096666074
8 O 0 0.0011381009
- O 0 0.0015747471
fold O 0 0.0017303686
increased O 0 0.0020001603
risk O 0 0.027323086
of O 0 0.0051727537
thrombosis B-Disease 2 0.9973506
in O 0 0.005494376
females O 0 0.0102561405
. O 0 0.007198278

Similarly O 0 0.00895116
, O 0 0.008529975
thrombotic B-Disease 2 0.98840535
risk O 0 0.10348305
increased O 0 0.006277022
with O 0 0.00473701
age O 0 0.008391865
and O 0 0.0061335936
OD O 0 0.16885597
values O 0 0.008864029
. O 0 0.010408413

CONCLUSION O 0 0.8655965
: O 0 0.0060164887
Higher O 0 0.010761334
OD O 0 0.07899654
is O 0 0.0013567681
associated O 0 0.0011859776
with O 0 0.00091684994
significant O 0 0.0009868841
risk O 0 0.009811517
of O 0 0.00085845793
subsequent O 0 0.0012870671
thrombosis B-Disease 2 0.9989675
in O 0 0.00067760225
patients O 0 0.0026267446
with O 0 0.0007146301
isolated O 0 0.000918387
- O 0 0.00243212
HIT B-Disease 2 0.9872652
; O 0 0.0013705308
percent O 0 0.00055135443
inhibition O 0 0.00281349
, O 0 0.0011825192
however O 0 0.0014263808
, O 0 0.0015981041
was O 0 0.0015364769
not O 0 0.0022311779
predictive O 0 0.0062712547
. O 0 0.005922776

Thalidomide B-Chemical 1 0.9966042
has O 0 0.0034742134
limited O 0 0.0021097502
single O 0 0.00195592
- O 0 0.0025023606
agent O 0 0.047959305
activity O 0 0.0012728536
in O 0 0.0006987
relapsed O 0 0.8992692
or O 0 0.00064012996
refractory O 0 0.50688547
indolent O 0 0.9150158
non B-Disease 0 0.009988813
- I-Disease 0 0.0075756535
Hodgkin I-Disease 0 0.9984806
lymphomas I-Disease 0 0.9973506
: O 0 0.0018742738
a O 0 0.0006877243
phase O 0 0.001376594
II O 0 0.0052307937
trial O 0 0.001493401
of O 0 0.0012512214
the O 0 0.0018875684
Cancer B-Disease 0 0.96122843
and O 0 0.007974769
Leukemia B-Disease 0 0.9979182
Group O 0 0.4855566
B O 0 0.3752669
. O 0 0.008697063

Thalidomide B-Chemical 1 0.9969189
is O 0 0.00444838
an O 0 0.0033309287
immunomodulatory O 0 0.5461916
agent O 0 0.1609742
with O 0 0.0017229983
demonstrated O 0 0.0012650741
activity O 0 0.0012885598
in O 0 0.0008180502
multiple B-Disease 0 0.0032784876
myeloma I-Disease 0 0.9960079
, O 0 0.0046630865
mantle B-Disease 0 0.7285465
cell I-Disease 0 0.15266249
lymphoma I-Disease 0 0.99800867
and O 0 0.031673387
lymphoplasmacytic B-Disease 0 0.9985757
lymphoma I-Disease 0 0.9981888
. O 0 0.017046316

Its O 0 0.09856406
activity O 0 0.004263181
is O 0 0.0021429965
believed O 0 0.0025849654
to O 0 0.0010713857
be O 0 0.00089362945
due O 0 0.000522082
modulation O 0 0.0011973035
of O 0 0.0008950496
the O 0 0.00088748866
tumour B-Disease 0 0.8646484
milieu O 0 0.011889619
, O 0 0.0012044624
including O 0 0.0009330009
downregulation O 0 0.006004529
of O 0 0.0027501734
angiogenesis O 0 0.9799504
and O 0 0.0059792646
inflammatory O 0 0.9601178
cytokines O 0 0.77967954
. O 0 0.008829101

Between O 0 0.008767899
July O 0 0.0039204992
2001 O 0 0.0042627556
and O 0 0.0017160238
April O 0 0.0017241102
2004 O 0 0.0020320034
, O 0 0.0008517969
24 O 0 0.0005282714
patients O 0 0.0010129391
with O 0 0.0007464507
relapsed O 0 0.93616724
/ O 0 0.0025526795
refractory O 0 0.5549241
indolent O 0 0.96493375
lymphomas B-Disease 0 0.99725914
received O 0 0.0043443115
thalidomide B-Chemical 1 0.9996767
200 O 0 0.009504109
mg O 0 0.42698225
daily O 0 0.0012138381
with O 0 0.00036550846
escalation O 0 0.08927878
by O 0 0.0003236703
100 O 0 0.0007792421
mg O 0 0.1438563
daily O 0 0.0006918016
every O 0 0.00012908786
1 O 0 0.0002452612
- O 0 0.00030851623
2 O 0 0.00016740465
weeks O 0 0.0001652872
as O 0 0.00017794744
tolerated O 0 0.002580212
, O 0 0.00040689332
up O 0 0.0003097417
to O 0 0.00032731704
a O 0 0.00051347906
maximum O 0 0.000692248
of O 0 0.0013661576
800 O 0 0.009744631
mg O 0 0.45828846
daily O 0 0.011055893
. O 0 0.005602301

Patients O 0 0.008478008
had O 0 0.00250568
received O 0 0.002252827
a O 0 0.001603857
median O 0 0.0011608895
of O 0 0.0013639422
2 O 0 0.0012226665
( O 0 0.0013064314
range O 0 0.0014181689
, O 0 0.0014107936
1 O 0 0.0012329004
- O 0 0.0017851337
4 O 0 0.0011936903
) O 0 0.0022286186
prior O 0 0.001930994
regimens O 0 0.018321943
. O 0 0.006317663

Of O 0 0.004899916
24 O 0 0.0021629876
evaluable O 0 0.006039932
patients O 0 0.002621345
, O 0 0.0010814201
two O 0 0.00048733983
achieved O 0 0.00068357756
a O 0 0.0005318091
complete O 0 0.0004814239
remission O 0 0.20659123
and O 0 0.000399274
one O 0 0.00023018125
achieved O 0 0.00035577
a O 0 0.00030655827
partial O 0 0.0007020245
remission O 0 0.2962874
for O 0 0.00023449594
an O 0 0.00033692134
overall O 0 0.00027659952
response O 0 0.00038349995
rate O 0 0.00022416102
of O 0 0.0003241279
12 O 0 0.00021881922
. O 0 0.00014475317
5 O 0 0.00018699157
% O 0 0.00024534258
( O 0 0.00026048304
95 O 0 0.00044073773
% O 0 0.00022714036
confidence O 0 0.00055103324
interval O 0 0.0005146338
: O 0 0.0005607081
2 O 0 0.00040241444
. O 0 0.00029552347
6 O 0 0.00042894483
- O 0 0.0009377286
32 O 0 0.0011415053
. O 0 0.00073066656
4 O 0 0.0013270021
% O 0 0.002526692
) O 0 0.004695098
. O 0 0.00469722

Eleven O 0 0.036071613
patients O 0 0.022622017
progressed O 0 0.031411663
during O 0 0.015039463
therapy O 0 0.0798246
. O 0 0.024842836

Grade O 0 0.29593492
3 O 0 0.0034546626
- O 0 0.0031192536
4 O 0 0.0013629202
adverse O 0 0.116454095
effects O 0 0.0022548086
included O 0 0.0015750082
myelosuppression B-Disease 0 0.99947613
, O 0 0.0059236744
fatigue B-Disease 2 0.99612033
, O 0 0.009069982
somnolence B-Disease 2 0.9995826
/ O 0 0.038921308
depressed B-Disease 2 0.98957866
mood I-Disease 0 0.9966968
, O 0 0.016000563
neuropathy B-Disease 0 0.9989881
and O 0 0.014050635
dyspnea B-Disease 0 0.9958056
. O 0 0.009466781

Of O 0 0.009221033
concern O 0 0.008046647
was O 0 0.0037025183
the O 0 0.003355526
occurrence O 0 0.0060714884
of O 0 0.005685238
four O 0 0.007006452
thromboembolic B-Disease 2 0.9967348
events O 0 0.26146385
. O 0 0.014824815

Our O 0 0.0031191262
results O 0 0.0019112126
failed O 0 0.0018158098
to O 0 0.001010207
demonstrate O 0 0.00065952976
an O 0 0.0009057843
important O 0 0.0005686135
response O 0 0.0008142452
rate O 0 0.00044547225
to O 0 0.00039116206
single O 0 0.0005428867
agent O 0 0.1815804
thalidomide B-Chemical 1 0.99965537
in O 0 0.0011081952
indolent O 0 0.9705988
lymphomas B-Disease 0 0.9974037
and O 0 0.0006842483
contrast O 0 0.00041805816
with O 0 0.0003730731
the O 0 0.0002565924
higher O 0 0.00029736478
activity O 0 0.0004169046
level O 0 0.0002527403
reported O 0 0.0005601494
with O 0 0.00049184024
the O 0 0.00046796506
second O 0 0.0006702598
generation O 0 0.0018408332
immunomodulatory O 0 0.7975211
agent O 0 0.59721375
, O 0 0.020517826
lenalidomide B-Chemical 0 0.99828064
. O 0 0.010149728

Sex O 0 0.16069035
differences O 0 0.0031214845
in O 0 0.0035892616
NMDA B-Chemical 1 0.99930024
antagonist O 0 0.9906765
enhancement O 0 0.025954435
of O 0 0.004040406
morphine B-Chemical 1 0.9996952
antihyperalgesia O 0 0.9988022
in O 0 0.0011271676
a O 0 0.0011869288
capsaicin B-Chemical 0 0.9988844
model O 0 0.0012777554
of O 0 0.0010688422
persistent O 0 0.24947633
pain B-Disease 0 0.98811173
: O 0 0.0014380772
comparisons O 0 0.0005289289
to O 0 0.00055802526
two O 0 0.0006690788
models O 0 0.002107286
of O 0 0.004252596
acute B-Disease 0 0.98666847
pain I-Disease 0 0.9914737
. O 0 0.010588212

In O 0 0.0053472994
acute B-Disease 0 0.862094
pain I-Disease 0 0.9780878
models O 0 0.009958872
, O 0 0.005400026
N B-Chemical 0 0.9393339
- I-Chemical 0 0.0121637285
methyl I-Chemical 0 0.9820287
- I-Chemical 0 0.011683474
D I-Chemical 0 0.83802915
- I-Chemical 0 0.014047596
aspartate I-Chemical 1 0.99940467
( O 0 0.016826548
NMDA B-Chemical 1 0.9998559
) O 0 0.007150632
antagonists O 0 0.9233717
enhance O 0 0.00048218327
the O 0 0.0005592539
antinociceptive O 0 0.9968767
effects O 0 0.0025021178
of O 0 0.0014549756
morphine B-Chemical 1 0.99953365
to O 0 0.0006943154
a O 0 0.0006480184
greater O 0 0.00058685575
extent O 0 0.00052728044
in O 0 0.00083547115
males O 0 0.0019177317
than O 0 0.0014745179
females O 0 0.0048126453
. O 0 0.0048945686

The O 0 0.0025256178
purpose O 0 0.0019406084
of O 0 0.0014800032
this O 0 0.0010538644
investigation O 0 0.0016046697
was O 0 0.00068646966
to O 0 0.00048409932
extend O 0 0.00041084463
these O 0 0.00056979863
findings O 0 0.0010223429
to O 0 0.00039322232
a O 0 0.00052006525
persistent O 0 0.07563658
pain B-Disease 0 0.9730208
model O 0 0.0008874387
which O 0 0.0005458946
could O 0 0.00024013266
be O 0 0.0002893073
distinguished O 0 0.00052901165
from O 0 0.0003793473
acute B-Disease 0 0.9342281
pain I-Disease 0 0.98354536
models O 0 0.0010093729
on O 0 0.00016953016
the O 0 0.00021645446
basis O 0 0.0003127193
of O 0 0.00038058122
the O 0 0.00040908268
nociceptive O 0 0.7987249
fibers O 0 0.023773195
activated O 0 0.001050634
, O 0 0.0007891118
neurochemical O 0 0.7567692
substrates O 0 0.0021261082
, O 0 0.0007516497
and O 0 0.0006108534
duration O 0 0.0010477059
of O 0 0.0014820398
the O 0 0.002286031
nociceptive O 0 0.8253578
stimulus O 0 0.025645768
. O 0 0.0064216093

To O 0 0.002876906
this O 0 0.0020607843
end O 0 0.0013070516
, O 0 0.0021556797
persistent O 0 0.110034734
hyperalgesia B-Disease 2 0.9990663
was O 0 0.0014002809
induced O 0 0.0011454921
by O 0 0.0007188897
administration O 0 0.09696632
of O 0 0.0013243222
capsaicin B-Chemical 0 0.99935406
in O 0 0.00053212204
the O 0 0.0003691209
tail O 0 0.00057540747
of O 0 0.0005612503
gonadally O 0 0.027660659
intact O 0 0.0005338386
F344 O 0 0.50293255
rats O 0 0.0028318912
, O 0 0.00038625504
following O 0 0.0002597497
which O 0 0.000331128
the O 0 0.0002328988
tail O 0 0.00041965948
was O 0 0.0002801474
immersed O 0 0.0006055803
in O 0 0.00025511076
a O 0 0.0004381247
mildly O 0 0.094657965
noxious O 0 0.7741261
thermal O 0 0.05937656
stimulus O 0 0.005823086
, O 0 0.0009982012
and O 0 0.0008820354
tail O 0 0.0018676424
- O 0 0.0029067264
withdrawal O 0 0.56787336
latencies O 0 0.03701344
measured O 0 0.0034850067
. O 0 0.0054211295

For O 0 0.0027741678
comparison O 0 0.0020074523
, O 0 0.0019379789
tests O 0 0.001935718
were O 0 0.0009696073
conducted O 0 0.0007881273
in O 0 0.00066614716
two O 0 0.0007032198
acute B-Disease 0 0.89818925
pain I-Disease 0 0.9842743
models O 0 0.002877037
, O 0 0.0011083569
the O 0 0.0007106398
hotplate O 0 0.13298002
and O 0 0.0009968579
warm O 0 0.007112634
water O 0 0.015068629
tail O 0 0.0037020713
- O 0 0.0049817786
withdrawal O 0 0.5598012
procedures O 0 0.0073989923
. O 0 0.006508048

In O 0 0.003609815
males O 0 0.003757241
, O 0 0.0025363727
the O 0 0.0015422879
non O 0 0.003173989
- O 0 0.0030608329
competitive O 0 0.07253457
NMDA B-Chemical 1 0.9998419
antagonist O 0 0.9981706
dextromethorphan B-Chemical 0 0.9999194
enhanced O 0 0.0054646437
the O 0 0.00089528115
antihyperalgesic O 0 0.99886763
effect O 0 0.00085719704
of O 0 0.00056169793
low O 0 0.0005805918
to O 0 0.0003469075
moderate O 0 0.00664958
doses O 0 0.03810201
of O 0 0.0013316954
morphine B-Chemical 1 0.99961615
in O 0 0.0006959275
a O 0 0.0008688664
dose O 0 0.029047042
- O 0 0.0014763689
and O 0 0.0008879623
time O 0 0.0010959139
- O 0 0.0027371135
dependent O 0 0.0024838462
manner O 0 0.0063023428
. O 0 0.005609973

Across O 0 0.0062599336
the O 0 0.0029126531
doses O 0 0.014617977
and O 0 0.0022245622
pretreatment O 0 0.041568927
times O 0 0.0010099063
examined O 0 0.0010531703
, O 0 0.0017144196
enhancement O 0 0.0031832773
was O 0 0.001438403
not O 0 0.0014808078
observed O 0 0.0017281799
in O 0 0.00296977
females O 0 0.0072085797
. O 0 0.006647936

Enhancement O 0 0.03480004
of O 0 0.0067142476
morphine B-Chemical 1 0.9991209
antinociception O 0 0.99956614
by O 0 0.008630606
dextromethorphan B-Chemical 0 0.99978334
was O 0 0.0016804952
seen O 0 0.00067569345
in O 0 0.00040114747
both O 0 0.00037882564
males O 0 0.0005945134
and O 0 0.0003691521
females O 0 0.0005201934
in O 0 0.00027547023
the O 0 0.00039994082
acute B-Disease 0 0.9364824
pain I-Disease 0 0.9891804
models O 0 0.002342274
, O 0 0.00061534194
with O 0 0.00040810945
the O 0 0.0003029382
magnitude O 0 0.00033528358
of O 0 0.00052234007
this O 0 0.000538336
effect O 0 0.00086206786
being O 0 0.0013777816
greater O 0 0.0014907334
in O 0 0.0020992735
males O 0 0.005397333
. O 0 0.0049586305

These O 0 0.0044509526
findings O 0 0.0038427263
demonstrate O 0 0.0015219728
a O 0 0.002054725
sexually O 0 0.039437406
- O 0 0.0026138555
dimorphic O 0 0.004825919
interaction O 0 0.0011493132
between O 0 0.00069176266
NMDA B-Chemical 1 0.99978536
antagonists O 0 0.9936591
and O 0 0.002828121
morphine B-Chemical 1 0.99966216
in O 0 0.0006823493
a O 0 0.0006862695
persistent O 0 0.120520346
pain B-Disease 0 0.97573256
model O 0 0.0008400844
that O 0 0.00034904588
can O 0 0.00034563785
be O 0 0.00042029968
distinguished O 0 0.0007323082
from O 0 0.0005079888
those O 0 0.0008371155
observed O 0 0.0007237448
in O 0 0.001545386
acute B-Disease 0 0.9689621
pain I-Disease 0 0.9908517
models O 0 0.023382677
. O 0 0.007517234

Development O 0 0.019625518
of O 0 0.0058917664
proteinuria B-Disease 2 0.9980453
after O 0 0.0018155117
switch O 0 0.0025645725
to O 0 0.0017295255
sirolimus B-Chemical 1 0.99831235
- O 0 0.0034386052
based O 0 0.0015306495
immunosuppression O 0 0.9501714
in O 0 0.0011856772
long O 0 0.0017335493
- O 0 0.0022058852
term O 0 0.0022641402
cardiac O 0 0.48096493
transplant O 0 0.80540717
patients O 0 0.032746717
. O 0 0.0075544477

Calcineurin O 0 0.9798979
- O 0 0.011060246
inhibitor O 0 0.11437954
therapy O 0 0.03959049
can O 0 0.0023894361
lead O 0 0.015630072
to O 0 0.0030305234
renal B-Disease 2 0.9967236
dysfunction I-Disease 2 0.9951056
in O 0 0.005064002
heart O 0 0.7764852
transplantation O 0 0.60136753
patients O 0 0.028184865
. O 0 0.00869437

The O 0 0.0035926532
novel O 0 0.005477295
immunosuppressive O 0 0.9502361
( O 0 0.005457993
IS O 0 0.22216275
) O 0 0.0031336632
drug O 0 0.40985394
sirolmus B-Chemical 0 0.3313083
( O 0 0.0029927394
Srl B-Chemical 1 0.6908073
) O 0 0.0015578675
lacks O 0 0.0008216324
nephrotoxic B-Disease 2 0.9992106
effects O 0 0.011602634
; O 0 0.0019633418
however O 0 0.0010942806
, O 0 0.0014241175
proteinuria B-Disease 2 0.99969244
associated O 0 0.002662772
with O 0 0.0018914893
Srl B-Chemical 1 0.67339945
has O 0 0.0010287763
been O 0 0.0014519168
reported O 0 0.0022163137
following O 0 0.0031145008
renal O 0 0.98769
transplantation O 0 0.74194276
. O 0 0.008358315

In O 0 0.0047635343
cardiac O 0 0.09300357
transplantation O 0 0.11463835
, O 0 0.0033415505
the O 0 0.0019519912
incidence O 0 0.0076049296
of O 0 0.0047832783
proteinuria B-Disease 2 0.9992473
associated O 0 0.010952199
with O 0 0.007874148
Srl B-Chemical 1 0.7872347
is O 0 0.006229355
unknown O 0 0.016958518
. O 0 0.009356129

In O 0 0.0029892325
this O 0 0.0020872133
study O 0 0.002438581
, O 0 0.0017845399
long O 0 0.0014722694
- O 0 0.0014990317
term O 0 0.0010449075
cardiac O 0 0.17588331
transplant O 0 0.50773096
patients O 0 0.0031986667
were O 0 0.00083404855
switched O 0 0.0018129979
from O 0 0.0015414446
cyclosporine B-Chemical 1 0.99947256
to O 0 0.0037152823
Srl B-Chemical 1 0.8149266
- O 0 0.005746237
based O 0 0.005293992
IS O 0 0.27584425
. O 0 0.0077994736

Concomitant O 0 0.17551413
IS O 0 0.08782321
consisted O 0 0.0058375774
of O 0 0.010661038
mycophenolate B-Chemical 0 0.9993938
mofetil I-Chemical 0 0.99966455
+ O 0 0.072412886
/ O 0 0.046996675
- O 0 0.024609515
steroids B-Chemical 0 0.9911572
. O 0 0.015255797

Proteinuria O 2 0.99681985
increased O 0 0.005246003
significantly O 0 0.0022365758
from O 0 0.001090325
a O 0 0.0008889599
median O 0 0.00062266766
of O 0 0.00070043036
0 O 0 0.0006200316
. O 0 0.0002723423
13 O 0 0.00041840723
g O 0 0.00079985836
/ O 0 0.00061485975
day O 0 0.00030775685
( O 0 0.00038137662
range O 0 0.00041144036
0 O 0 0.00035256258
- O 0 0.00039565744
5 O 0 0.00019238665
. O 0 0.00013110692
7 O 0 0.00018580913
) O 0 0.00033978897
preswitch O 0 0.0075680106
to O 0 0.0002210658
0 O 0 0.00027159345
. O 0 0.00013116657
23 O 0 0.00031847224
g O 0 0.0005554119
/ O 0 0.00047016694
day O 0 0.0002556708
( O 0 0.0003639256
0 O 0 0.0003142842
- O 0 0.00038193035
9 O 0 0.00022654147
. O 0 0.0001388102
88 O 0 0.0004456103
) O 0 0.00035143207
at O 0 0.00016375862
24 O 0 0.00027024435
months O 0 0.00037295683
postswitch O 0 0.0016761394
( O 0 0.00083880586
p O 0 0.0010999418
= O 0 0.0014271648
0 O 0 0.0013309201
. O 0 0.0013404415
0024 O 0 0.028823618
) O 0 0.0059469156
. O 0 0.0051929043

Before O 0 0.004474268
the O 0 0.0024309265
switch O 0 0.0028614155
, O 0 0.002002727
11 O 0 0.00124306
. O 0 0.0005426746
5 O 0 0.0004650377
% O 0 0.00044751415
of O 0 0.00044100417
patients O 0 0.0009946309
had O 0 0.00048193833
high O 0 0.0008461447
- O 0 0.0015266015
grade O 0 0.47316915
proteinuria B-Disease 2 0.99985576
( O 0 0.003001134
> O 0 0.0012058911
1 O 0 0.00030375257
. O 0 0.00014897123
0 O 0 0.00024402284
g O 0 0.0005265052
/ O 0 0.0004635842
day O 0 0.00026052626
) O 0 0.00048137843
; O 0 0.0003952376
this O 0 0.00021062444
increased O 0 0.00042507684
to O 0 0.00031280064
22 O 0 0.0005336369
. O 0 0.00023060432
9 O 0 0.00037019755
% O 0 0.00046709445
postswitch O 0 0.0017266184
( O 0 0.00088939845
p O 0 0.0011613419
= O 0 0.0015081047
0 O 0 0.001404764
. O 0 0.0014089878
006 O 0 0.037953246
) O 0 0.0059163948
. O 0 0.0052924305

ACE B-Chemical 1 0.9938262
inhibitor I-Chemical 1 0.77596927
and O 0 0.010229011
angiotensin B-Chemical 1 0.99867105
- I-Chemical 0 0.033005927
releasing I-Chemical 0 0.25193682
blocker I-Chemical 0 0.9943193
( O 0 0.029393474
ARB B-Chemical 0 0.9989968
) O 0 0.015185969
therapy O 0 0.122469135
reduced O 0 0.012090688
proteinuria B-Disease 2 0.99899274
development O 0 0.118999764
. O 0 0.010984472

Patients O 0 0.011160072
without O 0 0.0039102
proteinuria B-Disease 2 0.9985782
had O 0 0.0026225194
increased O 0 0.003308354
renal O 0 0.9844259
function O 0 0.0023157054
( O 0 0.0009728525
median O 0 0.00044769148
42 O 0 0.0005698011
. O 0 0.0002106666
5 O 0 0.00022950867
vs O 0 0.0004605273
. O 0 0.00016405621
64 O 0 0.00038054932
. O 0 0.00015776025
1 O 0 0.00023907564
, O 0 0.0002833412
p O 0 0.00034999006
= O 0 0.00035677824
0 O 0 0.00022783878
. O 0 0.00012147665
25 O 0 0.00031577237
) O 0 0.0003289306
, O 0 0.00023148194
whereas O 0 0.00018295353
patients O 0 0.0006448897
who O 0 0.00066178694
developed O 0 0.00054466526
high O 0 0.0006061337
- O 0 0.0010416614
grade O 0 0.3629821
proteinuria B-Disease 2 0.9998547
showed O 0 0.0007293149
decreased O 0 0.009371376
renal O 0 0.9891755
function O 0 0.0012523559
at O 0 0.00017405323
the O 0 0.00018365914
end O 0 0.0001227784
of O 0 0.00027705694
follow O 0 0.00031720073
- O 0 0.0005223961
up O 0 0.00026774433
( O 0 0.0003122888
median O 0 0.00021814553
39 O 0 0.00038005447
. O 0 0.00014709882
6 O 0 0.00017841635
vs O 0 0.0004486649
. O 0 0.00019503618
29 O 0 0.00057226315
. O 0 0.00024647266
2 O 0 0.0004396524
, O 0 0.0006585245
p O 0 0.0009927849
= O 0 0.0013109833
0 O 0 0.0011984366
. O 0 0.001136276
125 O 0 0.006904642
) O 0 0.005357919
. O 0 0.004860096

Thus O 0 0.0052617155
, O 0 0.005496065
proteinuria B-Disease 2 0.99830014
may O 0 0.0022511585
develop O 0 0.0017765539
in O 0 0.0008720297
cardiac O 0 0.17059086
transplant O 0 0.47474584
patients O 0 0.002179714
after O 0 0.00031206073
switch O 0 0.00072094105
to O 0 0.0005264159
Srl B-Chemical 1 0.42542195
, O 0 0.00062029395
which O 0 0.0005216012
may O 0 0.0003902581
have O 0 0.0004463483
an O 0 0.0007578029
adverse O 0 0.44274408
effect O 0 0.00094707205
on O 0 0.0006418857
renal O 0 0.96426576
function O 0 0.0024810042
in O 0 0.0017864038
these O 0 0.0037444069
patients O 0 0.013979233
. O 0 0.006241342

Srl B-Chemical 1 0.23856638
should O 0 0.0023303153
be O 0 0.002114893
used O 0 0.0015983554
with O 0 0.0024863558
ACEi B-Chemical 0 0.99902916
/ O 0 0.029552922
ARB B-Chemical 0 0.99910164
therapy O 0 0.12208236
and O 0 0.0013374741
patients O 0 0.0024558639
monitored O 0 0.0006685739
for O 0 0.0013086624
proteinuria B-Disease 2 0.9993668
and O 0 0.0040426073
increased O 0 0.030955343
renal B-Disease 2 0.9976726
dysfunction I-Disease 2 0.99590224
. O 0 0.01354307

Ginsenoside B-Chemical 0 0.99835384
Rg1 I-Chemical 1 0.9987612
restores O 0 0.006965612
the O 0 0.0030801983
impairment B-Disease 0 0.35599566
of I-Disease 0 0.0027648138
learning I-Disease 0 0.029765546
induced O 0 0.003107222
by O 0 0.0029912526
chronic O 0 0.9905228
morphine B-Chemical 1 0.99946266
administration O 0 0.8321072
in O 0 0.0060428614
rats O 0 0.03498154
. O 0 0.007593502

Rg1 B-Chemical 1 0.9956429
, O 0 0.0077848453
as O 0 0.0030231692
a O 0 0.0037686992
ginsenoside B-Chemical 0 0.99735093
extracted O 0 0.003197268
from O 0 0.0029428895
Panax O 0 0.94863546
ginseng O 0 0.9659761
, O 0 0.0042494307
could O 0 0.002038432
ameliorate O 0 0.14231172
spatial O 0 0.079987854
learning B-Disease 0 0.5072683
impairment I-Disease 0 0.94765574
. O 0 0.011078788

Previous O 0 0.004468338
studies O 0 0.003536516
have O 0 0.0021618179
demonstrated O 0 0.0018378088
that O 0 0.0016644177
Rg1 B-Chemical 1 0.998845
might O 0 0.0010781377
be O 0 0.0008169665
a O 0 0.0006687326
useful O 0 0.00086140854
agent O 0 0.021799954
for O 0 0.00045553796
the O 0 0.00050748006
prevention O 0 0.0024192757
and O 0 0.0007104174
treatment O 0 0.0014346718
of O 0 0.0010821733
the O 0 0.0012595232
adverse O 0 0.6747222
effects O 0 0.007831191
of O 0 0.01063865
morphine B-Chemical 1 0.9983359
. O 0 0.010439203

The O 0 0.0025833377
aim O 0 0.0019415324
of O 0 0.0014756928
this O 0 0.0010418801
study O 0 0.0012595862
was O 0 0.0006621936
to O 0 0.0004856303
investigate O 0 0.00033177136
the O 0 0.00042635456
effect O 0 0.00063519605
of O 0 0.0012404579
Rg1 B-Chemical 1 0.99963427
on O 0 0.000581526
learning B-Disease 0 0.18031345
impairment I-Disease 0 0.88758767
by O 0 0.0012536078
chronic O 0 0.9910308
morphine B-Chemical 1 0.9998141
administration O 0 0.56055105
and O 0 0.0008823739
the O 0 0.00064179086
mechanism O 0 0.0011396739
responsible O 0 0.0011816432
for O 0 0.0012492024
this O 0 0.002317469
effect O 0 0.004799998
. O 0 0.0057270257

Male O 0 0.023309514
rats O 0 0.00647502
were O 0 0.0018641
subcutaneously O 0 0.0033492006
injected O 0 0.0010952106
with O 0 0.001433014
morphine B-Chemical 1 0.99920005
( O 0 0.001827294
10 O 0 0.0007134263
mg O 0 0.24496531
/ O 0 0.0011094989
kg O 0 0.003158666
) O 0 0.0004371012
twice O 0 0.000238016
a O 0 0.00021516369
day O 0 0.00017544838
at O 0 0.000113278664
12 O 0 0.000117068725
hour O 0 0.00013276453
intervals O 0 0.000156545
for O 0 0.00013558206
10 O 0 0.00019982626
days O 0 0.0001962094
, O 0 0.00031819486
and O 0 0.00043345994
Rg1 B-Chemical 1 0.9996387
( O 0 0.0007916982
30 O 0 0.000298872
mg O 0 0.19270991
/ O 0 0.0008419092
kg O 0 0.0042466396
) O 0 0.00043468707
was O 0 0.00022344448
intraperitoneally O 0 0.0026848412
injected O 0 0.00021316926
2 O 0 0.00017607702
hours O 0 0.00014826395
after O 0 0.00010137961
the O 0 0.00016859485
second O 0 0.00023813266
injection O 0 0.001001148
of O 0 0.0007719587
morphine B-Chemical 1 0.9991041
once O 0 0.0008905619
a O 0 0.0008665761
day O 0 0.00088435854
for O 0 0.0010281879
10 O 0 0.002002909
days O 0 0.0028053457
. O 0 0.004125394

Spatial O 0 0.029292304
learning O 0 0.013265053
capacity O 0 0.0060464707
was O 0 0.0034016217
assessed O 0 0.0027537749
in O 0 0.0032118997
the O 0 0.00466383
Morris O 0 0.14029376
water O 0 0.070129454
maze O 0 0.3297994
. O 0 0.015755706

The O 0 0.0028092419
results O 0 0.0019910706
showed O 0 0.0016108579
that O 0 0.0012148399
rats O 0 0.004300323
treated O 0 0.0025016563
with O 0 0.003322925
Morphine B-Chemical 1 0.9998405
/ O 0 0.055993102
Rg1 B-Chemical 1 0.9996666
decreased O 0 0.0076057003
escape O 0 0.011350425
latency O 0 0.0071743266
and O 0 0.00051659695
increased O 0 0.00070454733
the O 0 0.00038666138
time O 0 0.00038471274
spent O 0 0.00059415767
in O 0 0.00059831707
platform O 0 0.0014635266
quadrant O 0 0.0064939368
and O 0 0.002139646
entering O 0 0.005100791
frequency O 0 0.005804029
. O 0 0.006436681

By O 0 0.004890341
implantation O 0 0.0047061164
of O 0 0.0021897813
electrodes O 0 0.0080675995
and O 0 0.0012426671
electrophysiological O 0 0.0803968
recording O 0 0.0016491422
in O 0 0.0005764425
vivo O 0 0.0010635782
, O 0 0.00061512383
the O 0 0.00034384243
results O 0 0.00036245768
showed O 0 0.00043253
that O 0 0.00054164056
Rg1 B-Chemical 1 0.9996069
restored O 0 0.0010010136
the O 0 0.00041616862
long O 0 0.00066096726
- O 0 0.00083428813
term O 0 0.00074096303
potentiation O 0 0.93813896
( O 0 0.0030048145
LTP O 0 0.9965417
) O 0 0.0014057168
impaired O 0 0.0012526922
by O 0 0.0008037243
morphine B-Chemical 1 0.9992348
in O 0 0.0007844446
both O 0 0.00083774986
freely O 0 0.0019061546
moving O 0 0.003191377
and O 0 0.0026990382
anaesthetised O 0 0.34773564
rats O 0 0.015747381
. O 0 0.0059310524

The O 0 0.0029950205
electrophysiological O 0 0.044307534
recording O 0 0.0034152707
in O 0 0.0012998347
vitro O 0 0.0018552108
showed O 0 0.0010208728
that O 0 0.0010676627
Rg1 B-Chemical 1 0.9993456
restored O 0 0.0018832291
the O 0 0.0009078356
LTP O 0 0.99466586
in O 0 0.00057010213
slices O 0 0.03238495
from O 0 0.00032466237
the O 0 0.00028927284
rats O 0 0.0016046223
treated O 0 0.0007462049
with O 0 0.0008308126
morphine B-Chemical 1 0.99970716
, O 0 0.0010843825
but O 0 0.0003183648
not O 0 0.00025256668
changed O 0 0.00057653204
LTP O 0 0.9885456
in O 0 0.00028712358
the O 0 0.0002722657
slices O 0 0.01783074
from O 0 0.00026096703
normal O 0 0.0007959442
saline O 0 0.122564465
- O 0 0.00087686564
or O 0 0.00042438044
morphine B-Chemical 1 0.99971133
/ O 0 0.042592265
Rg1 B-Chemical 1 0.99986804
- O 0 0.0041072387
treated O 0 0.0013205461
rats O 0 0.0049406053
; O 0 0.00056432176
this O 0 0.0002408058
restoration O 0 0.00056656223
could O 0 0.00024698646
be O 0 0.00036779285
inhibited O 0 0.001182624
by O 0 0.00090137287
N B-Chemical 0 0.9539961
- I-Chemical 0 0.009699441
methyl I-Chemical 0 0.9833551
- I-Chemical 0 0.010937301
D I-Chemical 0 0.83227247
- I-Chemical 0 0.018848978
aspartate I-Chemical 1 0.99925596
( O 0 0.031866547
NMDA B-Chemical 1 0.9996586
) O 0 0.03723873
receptor O 0 0.7968274
antagonist O 0 0.9959228
MK801 B-Chemical 1 0.99962556
. O 0 0.01774656

We O 0 0.0034720614
conclude O 0 0.0027230848
that O 0 0.0024467865
Rg1 B-Chemical 1 0.9981773
may O 0 0.0017867455
significantly O 0 0.0011729902
improve O 0 0.0006124816
the O 0 0.0005801901
spatial O 0 0.0033198723
learning O 0 0.0049362397
capacity O 0 0.0012020018
impaired O 0 0.0014277126
by O 0 0.00085119286
chonic O 0 0.83040446
morphine B-Chemical 1 0.9996697
administration O 0 0.49431023
and O 0 0.0011792728
restore O 0 0.0010470025
the O 0 0.0019354488
morphine B-Chemical 1 0.9991779
- O 0 0.024076387
inhibited O 0 0.05460354
LTP O 0 0.99162614
. O 0 0.008778054

This O 0 0.017489046
effect O 0 0.014728669
is O 0 0.02008825
NMDA B-Chemical 1 0.99662316
receptor O 0 0.72235334
dependent O 0 0.024875399
. O 0 0.022360036

Synthesis O 0 0.40687707
of O 0 0.00867086
N B-Chemical 0 0.8615499
- I-Chemical 0 0.011270631
pyrimidinyl I-Chemical 0 0.9003739
- I-Chemical 0 0.0055667115
2 I-Chemical 0 0.0024373366
- I-Chemical 0 0.0033600577
phenoxyacetamides I-Chemical 0 0.03128256
as O 0 0.0034286682
adenosine B-Chemical 1 0.9961267
A2A O 0 0.9983632
receptor O 0 0.939231
antagonists O 0 0.9901468
. O 0 0.016090173

A O 0 0.016075782
series O 0 0.0058982945
of O 0 0.00497163
N B-Chemical 0 0.8664226
- I-Chemical 0 0.0084698275
pyrimidinyl I-Chemical 0 0.91890305
- I-Chemical 0 0.00396496
2 I-Chemical 0 0.0015557804
- I-Chemical 0 0.0024298814
phenoxyacetamide I-Chemical 0 0.5750872
adenosine B-Chemical 1 0.99639755
A O 0 0.16016139
( O 0 0.0031944562
2A O 0 0.0035644746
) O 0 0.0042778472
antagonists O 0 0.89050454
is O 0 0.0044744294
described O 0 0.0049463785
. O 0 0.006764761

SAR O 0 0.6132876
studies O 0 0.004665997
led O 0 0.0029439696
to O 0 0.0016507627
compound O 0 0.020550925
14 O 0 0.001223042
with O 0 0.00094478147
excellent O 0 0.002103656
potency O 0 0.2112908
( O 0 0.0028228974
K O 1 0.98971236
( O 0 0.0015943728
i O 0 0.0023548654
) O 0 0.0010730803
= O 0 0.0006583623
0 O 0 0.00035347938
. O 0 0.00018312843
4 O 0 0.00027186133
nM O 0 0.004425114
) O 0 0.0005645146
, O 0 0.00044622537
selectivity O 0 0.010561106
( O 0 0.00074234686
A O 0 0.010737532
( O 0 0.0006067345
1 O 0 0.00039132673
) O 0 0.0006134239
/ O 0 0.0009419427
A O 0 0.008755265
( O 0 0.0005949657
2A O 0 0.00069837837
) O 0 0.0006278259
> O 0 0.0006236644
100 O 0 0.000596658
) O 0 0.0004467757
, O 0 0.00029656128
and O 0 0.0002653358
efficacy O 0 0.0020471262
( O 0 0.0005948932
MED O 0 0.15836708
10 O 0 0.00039474585
mg O 0 0.19934745
/ O 0 0.00078184984
kg O 0 0.0023978082
p O 0 0.0004121658
. O 0 0.00017763246
o O 0 0.00096632884
. O 0 0.00021393527
) O 0 0.00047095102
in O 0 0.00024693814
the O 0 0.0003798581
rat O 0 0.04586304
haloperidol B-Chemical 1 0.99993634
- O 0 0.0063277646
induced O 0 0.004697935
catalepsy B-Disease 2 0.9998171
model O 0 0.002634568
for O 0 0.0018969164
Parkinson B-Disease 0 0.99835145
' I-Disease 0 0.0035119823
s I-Disease 0 0.004915476
disease I-Disease 0 0.5621432
. O 0 0.0070157237

Evidence O 0 0.012291537
for O 0 0.002778477
an O 0 0.0029328957
involvement O 0 0.0037539548
of O 0 0.003027846
D1 O 0 0.98992527
and O 0 0.003779596
D2 O 0 0.99533623
dopamine B-Chemical 1 0.9992047
receptors O 0 0.47314295
in O 0 0.0014579451
mediating O 0 0.0023618964
nicotine B-Chemical 1 0.997883
- O 0 0.012036761
induced O 0 0.010261995
hyperactivity B-Disease 2 0.9977781
in O 0 0.0052840374
rats O 0 0.035783816
. O 0 0.0069598556

Previous O 0 0.0039271447
studies O 0 0.002973972
have O 0 0.0016575765
suggested O 0 0.001193796
that O 0 0.0007013054
repeated O 0 0.0007138508
exposure O 0 0.0020917163
of O 0 0.00084568607
rats O 0 0.0023234133
to O 0 0.00042513417
the O 0 0.00040553455
drug O 0 0.10304108
or O 0 0.00034576014
to O 0 0.00029715963
the O 0 0.00028566006
experimental O 0 0.0006069003
environment O 0 0.00090109074
is O 0 0.00044160662
necessary O 0 0.00033564435
to O 0 0.0005512271
observe O 0 0.0008046753
nicotine B-Chemical 1 0.9963648
- O 0 0.0058896225
induced O 0 0.00507876
locomotor O 0 0.63542503
stimulation O 0 0.014945821
. O 0 0.0061181956

In O 0 0.0026329558
the O 0 0.001636638
present O 0 0.0010472325
study O 0 0.001381785
the O 0 0.00075917377
role O 0 0.0005347515
of O 0 0.00084045395
habituation O 0 0.037696995
to O 0 0.000489337
the O 0 0.00039890455
experimental O 0 0.0007173143
environment O 0 0.00090448814
on O 0 0.00030663604
the O 0 0.00057673897
stimulant O 0 0.9498738
effect O 0 0.0011734146
of O 0 0.0019051897
nicotine B-Chemical 1 0.9967962
in O 0 0.0019610745
rats O 0 0.00882427
was O 0 0.002575364
examined O 0 0.0032809833
. O 0 0.0055314987

In O 0 0.0029539114
addition O 0 0.0017179438
, O 0 0.0019143168
the O 0 0.0010421323
role O 0 0.000769084
of O 0 0.0016791319
dopamine B-Chemical 1 0.99891996
receptors O 0 0.39982465
in O 0 0.00083395065
mediating O 0 0.0011278099
nicotine B-Chemical 1 0.9987853
- O 0 0.0031149893
induced O 0 0.000989815
locomotor O 0 0.39530593
stimulation O 0 0.0011520446
was O 0 0.0002589483
investigated O 0 0.00023804847
by O 0 0.00021776192
examining O 0 0.0001672735
the O 0 0.0002444546
effects O 0 0.0006795873
of O 0 0.0006287942
selective O 0 0.061582904
D1 O 0 0.99628156
and O 0 0.0023772665
D2 O 0 0.99752575
dopamine B-Chemical 1 0.9995727
receptor O 0 0.69927096
antagonists O 0 0.9832381
on O 0 0.0010238581
activity O 0 0.0024576166
induced O 0 0.0036653832
by O 0 0.005574649
nicotine B-Chemical 1 0.99442977
. O 0 0.008783733

Locomotor O 0 0.381344
activity O 0 0.005004507
was O 0 0.0026304452
assessed O 0 0.0019533883
in O 0 0.002149709
male O 0 0.0073984256
Sprague O 0 0.32564893
- O 0 0.0052832277
Dawley O 0 0.170948
rats O 0 0.0053076115
tested O 0 0.0023566878
in O 0 0.0038125287
photocell O 0 0.070773475
cages O 0 0.01439915
. O 0 0.00991579

Nicotine B-Chemical 1 0.99759656
( O 0 0.0067384304
1 O 0 0.0021957597
. O 0 0.0009616736
0 O 0 0.0011103409
mg O 0 0.1411743
/ O 0 0.0017356747
kg O 0 0.0051020663
) O 0 0.00086147914
caused O 0 0.0005000119
a O 0 0.00043368313
significant O 0 0.00048074403
increase B-Disease 0 0.00035635673
in I-Disease 0 0.00034101593
locomotor I-Disease 0 0.24742854
activity I-Disease 0 0.00050218566
in O 0 0.00023480874
rats O 0 0.00097016507
that O 0 0.0001719556
were O 0 0.00020126152
habituated O 0 0.0004375552
to O 0 0.00016037383
the O 0 0.00016886677
test O 0 0.00026459486
environment O 0 0.00059977255
, O 0 0.00037119573
but O 0 0.00022413922
had O 0 0.0002452895
only O 0 0.0002461108
a O 0 0.00030759466
weak O 0 0.0008458843
and O 0 0.0004027489
delayed O 0 0.007830794
stimulant O 0 0.98445475
action O 0 0.014826132
in O 0 0.00043977288
rats O 0 0.0017693024
that O 0 0.00039642176
were O 0 0.0006088843
unfamiliar O 0 0.0028342244
with O 0 0.0012456564
the O 0 0.001506145
test O 0 0.0029066475
environment O 0 0.007338084
. O 0 0.0061363094

The O 0 0.004000692
stimulant O 0 0.8999399
action O 0 0.015915725
of O 0 0.0030119938
nicotine B-Chemical 1 0.9965258
was O 0 0.0017186283
blocked O 0 0.0023598024
by O 0 0.0008156936
the O 0 0.00071168056
central O 0 0.008770984
nicotinic O 0 0.999421
antagonist O 0 0.99817383
mecamylamine B-Chemical 0 0.9999449
but O 0 0.0011790337
not O 0 0.00042239673
by O 0 0.0004109666
the O 0 0.00044809512
peripheral O 0 0.2104577
nicotinic O 0 0.9996131
blocker O 0 0.9988638
hexamethonium B-Chemical 1 0.9999546
, O 0 0.0025363702
indicating O 0 0.00037991098
that O 0 0.00030470305
the O 0 0.0003747356
response O 0 0.00084027456
is O 0 0.0006091403
probably O 0 0.0011786507
mediated O 0 0.0010806008
by O 0 0.001952442
central O 0 0.026242016
nicotinic O 0 0.99743074
receptors O 0 0.69769514
. O 0 0.00848424

Nicotine B-Chemical 1 0.9981536
- O 0 0.013305124
induced O 0 0.007093415
hyperactivity B-Disease 2 0.99771416
was O 0 0.0022126841
blocked O 0 0.0027894499
by O 0 0.0010359896
the O 0 0.0009143706
selective O 0 0.06209746
D1 O 0 0.99766004
antagonist O 0 0.997894
SCH B-Chemical 0 0.99987495
23390 I-Chemical 0 0.9998211
, O 0 0.0022554456
the O 0 0.0007733938
selective O 0 0.068777576
D2 O 0 0.99696845
antagonist O 0 0.9972222
raclopride B-Chemical 0 0.9998479
and O 0 0.003024539
the O 0 0.0026655926
D1 O 0 0.9945432
/ O 0 0.06709212
D2 O 0 0.994875
antagonist O 0 0.99575293
fluphenazine B-Chemical 0 0.99970144
. O 0 0.01674048

Pretreatment O 0 0.77300125
with O 0 0.004852851
the O 0 0.003760923
D2 O 0 0.9889389
agonist O 0 0.9925343
PHNO B-Chemical 0 0.9994893
enhanced O 0 0.02142558
nicotine B-Chemical 1 0.99897504
- O 0 0.015161611
induced O 0 0.007368768
hyperactivity B-Disease 2 0.99923396
, O 0 0.0022234377
whereas O 0 0.0010485067
the O 0 0.001580748
D1 O 0 0.9966467
agonist O 0 0.9972345
SKF B-Chemical 0 0.9998791
38393 I-Chemical 0 0.99991333
had O 0 0.005687749
no O 0 0.0035443555
effect O 0 0.0063723903
. O 0 0.007020625

The O 0 0.0028803535
results O 0 0.001999362
indicate O 0 0.0014485546
that O 0 0.0016563492
acute O 0 0.93479073
nicotine B-Chemical 1 0.99816847
injection O 0 0.048811994
induces O 0 0.002049477
a O 0 0.0013996615
pronounced O 0 0.006691437
hyperactivity B-Disease 2 0.99841344
in O 0 0.0011554996
rats O 0 0.0045595234
habituated O 0 0.0022340594
to O 0 0.0010859346
the O 0 0.0015337813
test O 0 0.0030650382
environment O 0 0.0076811244
. O 0 0.006605175

The O 0 0.0030325775
effect O 0 0.0026421652
appears O 0 0.0017252637
to O 0 0.0012244572
be O 0 0.0010826282
mediated O 0 0.0008371586
by O 0 0.0008663714
central O 0 0.0036976598
nicotine B-Chemical 1 0.99807954
receptors O 0 0.46540838
, O 0 0.0011965175
possibly O 0 0.0016144027
located O 0 0.00046478774
on O 0 0.00029874835
dopaminergic O 0 0.95978236
neurons O 0 0.031209031
, O 0 0.00048809065
and O 0 0.00032098178
also O 0 0.00032500547
requires O 0 0.00024930027
the O 0 0.00040721198
activation O 0 0.0012586155
of O 0 0.00098717
both O 0 0.0016072149
D1 O 0 0.9910392
and O 0 0.00556288
D2 O 0 0.99483347
dopamine B-Chemical 1 0.998444
receptors O 0 0.7281954
. O 0 0.0092068855

Central O 0 0.016502595
retinal B-Disease 0 0.6664378
vein I-Disease 0 0.15045486
occlusion I-Disease 0 0.42088515
associated O 0 0.006770687
with O 0 0.008871975
clomiphene B-Chemical 0 0.99855
- O 0 0.030866278
induced O 0 0.019164473
ovulation O 0 0.94775385
. O 0 0.014416572

OBJECTIVE O 0 0.49239892
: O 0 0.0047151484
To O 0 0.0016673513
report O 0 0.0029165193
a O 0 0.0014363792
case O 0 0.0011583065
of O 0 0.0013487038
central O 0 0.0034428725
retinal B-Disease 0 0.84118843
vein I-Disease 0 0.19958518
occlusion I-Disease 0 0.5214904
associated O 0 0.002609776
with O 0 0.0053471825
clomiphene B-Chemical 0 0.99971026
citrate I-Chemical 0 0.99783045
( O 0 0.0386263
CC B-Chemical 1 0.95959723
) O 0 0.01726629
. O 0 0.008644178

DESIGN O 0 0.0755715
: O 0 0.03664372
Case O 0 0.071590334
study O 0 0.038416665
. O 0 0.036603324

SETTING O 0 0.03936341
: O 0 0.010868591
Ophthalmology O 0 0.01859553
clinic O 0 0.007446321
of O 0 0.007088785
an O 0 0.009244059
academic O 0 0.018895341
hospital O 0 0.030712431
. O 0 0.01570054

PATIENT O 0 0.028302727
( O 0 0.007707669
S O 0 0.39185935
) O 0 0.004717308
: O 0 0.0029047069
A O 0 0.006165055
36 O 0 0.0014529714
- O 0 0.0014014308
year O 0 0.0009137648
- O 0 0.0011636767
old O 0 0.00084420294
woman O 0 0.0038383845
referred O 0 0.0008581799
from O 0 0.0008023179
the O 0 0.0011975184
infertility B-Disease 0 0.9417587
clinic O 0 0.0044969134
for O 0 0.003507536
blurred B-Disease 0 0.96129674
vision I-Disease 0 0.9094686
. O 0 0.00962339

INTERVENTION O 0 0.03374812
( O 0 0.01225112
S O 0 0.3531024
) O 0 0.0095131
: O 0 0.0074375086
Ophthalmic O 0 0.09387636
examination O 0 0.0075272126
after O 0 0.004761152
CC B-Chemical 1 0.77267635
therapy O 0 0.17318797
. O 0 0.014454094

MAIN O 0 0.5323949
OUTCOME O 0 0.22652557
MEASURE O 0 0.065608054
( O 0 0.0068166195
S O 0 0.37476766
) O 0 0.0045788516
: O 0 0.0031052078
Central O 0 0.0047133514
retinal B-Disease 0 0.6377712
vein I-Disease 0 0.117019996
occlusion I-Disease 0 0.35699144
after O 0 0.0018677323
ovulation O 0 0.7264461
induction O 0 0.005873708
with O 0 0.008010736
CC B-Chemical 1 0.9027373
. O 0 0.011175338

RESULT O 0 0.12443505
( O 0 0.00850884
S O 0 0.4519084
) O 0 0.0048384434
: O 0 0.0029022647
A O 0 0.0062075043
36 O 0 0.0014037002
- O 0 0.0013325423
year O 0 0.0008527337
- O 0 0.0010613316
old O 0 0.00076800754
Chinese O 0 0.01485925
woman O 0 0.009046527
developed O 0 0.0014426131
central O 0 0.0027110735
retinal B-Disease 0 0.801444
vein I-Disease 0 0.11222891
occlusion I-Disease 0 0.21972801
after O 0 0.00074038777
eight O 0 0.0012017951
courses O 0 0.0043485053
of O 0 0.005459847
CC B-Chemical 1 0.886223
. O 0 0.00870707

A O 0 0.012833386
search O 0 0.0032682118
of O 0 0.002236667
the O 0 0.0014578007
literature O 0 0.0020485723
on O 0 0.00070744136
the O 0 0.0011711669
thromboembolic B-Disease 2 0.9990896
complications O 0 0.8222462
of O 0 0.0021253573
CC B-Chemical 1 0.8944242
does O 0 0.00052126846
not O 0 0.00036278716
include O 0 0.00045753678
this O 0 0.0004204669
severe O 0 0.09975409
ophthalmic O 0 0.81372213
complication O 0 0.61365503
, O 0 0.0009479481
although O 0 0.00062002364
mild O 0 0.47015235
visual B-Disease 0 0.81774735
disturbance I-Disease 0 0.74027807
after O 0 0.00092306366
CC B-Chemical 1 0.92864424
intake O 0 0.8280779
is O 0 0.002696952
not O 0 0.0032422538
uncommon O 0 0.07574263
. O 0 0.0066771205

CONCLUSION O 0 0.92520344
( O 0 0.009207817
S O 0 0.52931845
) O 0 0.0041003944
: O 0 0.0020844582
This O 0 0.0013514535
is O 0 0.0006980966
the O 0 0.00053210196
first O 0 0.00046340132
reported O 0 0.00079850166
case O 0 0.00061063445
of O 0 0.0008583826
central O 0 0.0029275543
retinal B-Disease 0 0.8391078
vein I-Disease 0 0.16334967
occlusion I-Disease 0 0.36211938
after O 0 0.001138159
treatment O 0 0.0047790855
with O 0 0.0057157357
CC B-Chemical 1 0.89706075
. O 0 0.008615027

Extra O 0 0.020545484
caution O 0 0.0041042482
is O 0 0.0017181082
warranted O 0 0.0012618881
in O 0 0.0009469819
treating O 0 0.006435419
infertility B-Disease 0 0.97891665
patients O 0 0.009095857
with O 0 0.0014043313
CC B-Chemical 1 0.89289963
, O 0 0.0009753207
and O 0 0.00051070366
patients O 0 0.0010975213
should O 0 0.00022974622
be O 0 0.0002954911
well O 0 0.00024376706
informed O 0 0.0009347924
of O 0 0.00051871146
this O 0 0.00054259074
side O 0 0.0044127437
effect O 0 0.00089600566
before O 0 0.0006937135
commencement O 0 0.0026512886
of O 0 0.0034391773
therapy O 0 0.08400245
. O 0 0.0065650633

Acute O 0 0.97371924
bronchodilating O 0 0.99411607
effects O 0 0.012674093
of O 0 0.0076061394
ipratropium B-Chemical 0 0.99955624
bromide I-Chemical 0 0.99871695
and O 0 0.014697688
theophylline B-Chemical 1 0.9992887
in O 0 0.006142332
chronic B-Disease 0 0.9936846
obstructive I-Disease 0 0.9984112
pulmonary I-Disease 0 0.99257654
disease I-Disease 0 0.98117954
. O 0 0.013604712

The O 0 0.0033152986
bronchodilator O 0 0.714189
effects O 0 0.003440701
of O 0 0.0016248039
a O 0 0.0011309594
single O 0 0.00090966286
dose O 0 0.014629707
of O 0 0.0021108587
ipratropium B-Chemical 0 0.99981457
bromide I-Chemical 0 0.999471
aerosol O 0 0.559152
( O 0 0.0014649957
36 O 0 0.0005513001
micrograms O 0 0.14908265
) O 0 0.00059216254
and O 0 0.00027626086
short O 0 0.00032289576
- O 0 0.0006430816
acting O 0 0.006086175
theophylline B-Chemical 1 0.99982554
tablets O 0 0.9885301
( O 0 0.0011765037
dose O 0 0.014166031
titrated O 0 0.001713456
to O 0 0.00022174764
produce O 0 0.00023861951
serum O 0 0.021543756
levels O 0 0.0002592487
of O 0 0.00036462722
10 O 0 0.0003541109
- O 0 0.00039031892
20 O 0 0.000281595
micrograms O 0 0.07949677
/ O 0 0.00085080886
mL O 0 0.0026790674
) O 0 0.0003373012
were O 0 0.00015328414
compared O 0 9.951836e-05
in O 0 0.00014359794
a O 0 0.00021720183
double O 0 0.00022646006
- O 0 0.0005150956
blind O 0 0.0027645335
, O 0 0.00044057477
placebo O 0 0.086311914
- O 0 0.0004064206
controlled O 0 0.0002206135
crossover O 0 0.0011971871
study O 0 0.0004246398
in O 0 0.00025463104
21 O 0 0.00042845623
patients O 0 0.0007966703
with O 0 0.00058031955
stable O 0 0.0011959592
, O 0 0.0020480219
chronic B-Disease 0 0.98611057
obstructive I-Disease 0 0.9985703
pulmonary I-Disease 0 0.9928443
disease I-Disease 0 0.9810131
. O 0 0.010401363

Mean O 0 0.0028284949
peak O 0 0.0026817531
forced O 0 0.0051354193
expiratory O 0 0.2234747
volume O 0 0.0032412675
in O 0 0.0008451749
1 O 0 0.0006348459
second O 0 0.0005174362
( O 0 0.0007502896
FEV1 O 0 0.08058878
) O 0 0.0006323146
increases O 0 0.0002857382
over O 0 0.00013302354
baseline O 0 0.00029104273
and O 0 0.0002114974
the O 0 0.00016714977
proportion O 0 0.00014592726
of O 0 0.00026915694
patients O 0 0.00081939314
attaining O 0 0.002534611
at O 0 0.00014255659
least O 0 0.00013353316
a O 0 0.00023047923
15 O 0 0.00017529019
% O 0 0.00019125687
increase O 0 0.00015967773
in O 0 0.00017106907
the O 0 0.00023833505
FEV1 O 0 0.14764003
( O 0 0.00046544726
responders O 0 0.0012934739
) O 0 0.00040266832
were O 0 0.00021171007
31 O 0 0.00032100655
% O 0 0.00021307253
and O 0 0.00018364373
90 O 0 0.0002442179
% O 0 0.00025998903
, O 0 0.00028817754
respectively O 0 0.0005280978
, O 0 0.00034378277
for O 0 0.0003040037
ipratropium B-Chemical 0 0.9991443
and O 0 0.0007119265
17 O 0 0.000735344
% O 0 0.00045432997
and O 0 0.00042460338
50 O 0 0.00079837034
% O 0 0.0007485171
, O 0 0.0009804011
respectively O 0 0.0020111047
, O 0 0.0021420748
for O 0 0.0030044229
theophylline B-Chemical 1 0.99724305
. O 0 0.00861635

The O 0 0.0025777023
average O 0 0.001541496
FEV1 O 0 0.035657704
increases O 0 0.0013853639
during O 0 0.00069854513
the O 0 0.00070410053
6 O 0 0.00052729214
- O 0 0.000650071
hour O 0 0.00032956808
observation O 0 0.00037718925
period O 0 0.0003731279
were O 0 0.00038974782
18 O 0 0.00047452442
% O 0 0.00051816023
for O 0 0.0005712713
ipratropium B-Chemical 0 0.99792224
and O 0 0.0017568509
8 O 0 0.001546675
% O 0 0.0020008876
for O 0 0.0027563898
theophylline B-Chemical 1 0.9965798
. O 0 0.00862614

The O 0 0.0023913647
mean O 0 0.0013172502
duration O 0 0.0017570875
of O 0 0.001595846
action O 0 0.0046513025
was O 0 0.0009848085
3 O 0 0.0006364623
. O 0 0.00037266666
8 O 0 0.0004074923
hours O 0 0.00041481585
with O 0 0.00077639247
ipratropium B-Chemical 0 0.99851257
and O 0 0.0012816314
2 O 0 0.000922268
. O 0 0.0005616942
4 O 0 0.00081231
hours O 0 0.0013598746
with O 0 0.0038202386
theophylline B-Chemical 1 0.9967632
. O 0 0.008628002

While O 0 0.004625106
side O 0 0.009124482
effects O 0 0.003348007
were O 0 0.0016648362
rare O 0 0.0055131656
, O 0 0.0015121232
those O 0 0.0011277905
experienced O 0 0.0013966317
after O 0 0.0006624079
theophylline B-Chemical 1 0.9988833
use O 0 0.0016027351
did O 0 0.00090606144
involve O 0 0.0012143707
the O 0 0.0015230052
cardiovascular B-Disease 0 0.94425887
and I-Disease 0 0.0048494563
gastrointestinal I-Disease 0 0.97331065
systems I-Disease 0 0.018664079
. O 0 0.007896028

These O 0 0.00431743
results O 0 0.0022505387
show O 0 0.0016434665
that O 0 0.0016771721
ipratropium B-Chemical 0 0.9984314
is O 0 0.0017199279
a O 0 0.0010938623
more O 0 0.0011065808
potent O 0 0.02415481
bronchodilator O 0 0.95801353
than O 0 0.0007692604
oral O 0 0.5946863
theophylline B-Chemical 1 0.99947923
in O 0 0.0014120195
patients O 0 0.005850665
with O 0 0.0033323239
chronic B-Disease 0 0.99165994
airflow I-Disease 0 0.98478794
obstruction I-Disease 0 0.98739934
. O 0 0.010291059

Methamphetamine B-Chemical 1 0.9982779
- O 0 0.016439008
induced O 0 0.010003092
neurotoxicity B-Disease 2 0.99870574
and O 0 0.005222927
microglial O 0 0.88887674
activation O 0 0.006494589
are O 0 0.0016402047
not O 0 0.0013714534
mediated O 0 0.0018407082
by O 0 0.0033795387
fractalkine O 0 0.9766359
receptor O 0 0.5748705
signaling O 0 0.0301933
. O 0 0.009463312

Methamphetamine B-Chemical 1 0.9984213
( O 0 0.038939632
METH B-Chemical 0 0.99923575
) O 0 0.029586865
damages O 0 0.91401124
dopamine B-Chemical 1 0.9992111
( O 0 0.019486548
DA B-Chemical 0 0.998164
) O 0 0.0046271044
nerve O 0 0.5594703
endings O 0 0.40170667
by O 0 0.00056753715
a O 0 0.00045735648
process O 0 0.00042524398
that O 0 0.00027634174
has O 0 0.00035881373
been O 0 0.00045387982
linked O 0 0.0003775202
to O 0 0.00041977272
microglial O 0 0.7496557
activation O 0 0.0028349308
but O 0 0.0003848037
the O 0 0.00033538498
signaling O 0 0.0008074174
pathways O 0 0.0011612008
that O 0 0.00033368444
mediate O 0 0.00046449166
this O 0 0.0005264161
response O 0 0.0010546664
have O 0 0.0009783907
not O 0 0.0012947995
yet O 0 0.0026803736
been O 0 0.0033980736
delineated O 0 0.008223784
. O 0 0.0058425944

Cardona O 0 0.45370886
et O 0 0.078211285
al O 0 0.081891336
. O 0 0.054645985

[ O 0 0.013836451
Nat O 0 0.078171454
. O 0 0.0031209844
Neurosci O 0 0.86186206
. O 0 0.001330335
9 O 0 0.0012440812
( O 0 0.0013138151
2006 O 0 0.0017275754
) O 0 0.0011709047
, O 0 0.0008585892
917 O 0 0.063874274
] O 0 0.0010866062
recently O 0 0.0005204473
identified O 0 0.00034452687
the O 0 0.00044685215
microglial O 0 0.7365283
- O 0 0.00117896
specific O 0 0.00056424405
fractalkine O 0 0.9789235
receptor O 0 0.49078506
( O 0 0.0026259455
CX3CR1 O 0 0.9299526
) O 0 0.0013094092
as O 0 0.0003146134
an O 0 0.0005196723
important O 0 0.0004534305
mediator O 0 0.0038781199
of O 0 0.005405141
MPTP B-Chemical 0 0.9998969
- O 0 0.017114962
induced O 0 0.011048382
neurodegeneration B-Disease 0 0.9981943
of O 0 0.034348216
DA B-Chemical 0 0.9973169
neurons O 0 0.34722072
. O 0 0.0073461393

Because O 0 0.004169819
the O 0 0.0038547353
CNS B-Disease 0 0.9513726
damage I-Disease 0 0.9171743
caused O 0 0.004196017
by O 0 0.0033259334
METH B-Chemical 0 0.99974924
and O 0 0.011982497
MPTP B-Chemical 0 0.9998919
is O 0 0.0012711061
highly O 0 0.0010543369
selective O 0 0.0051813736
for O 0 0.00040319777
the O 0 0.00061563635
DA B-Chemical 0 0.9984438
neuronal O 0 0.6025824
system O 0 0.00090345496
in O 0 0.00029117873
mouse O 0 0.00045811743
models O 0 0.00066062814
of O 0 0.0011424478
neurotoxicity B-Disease 2 0.9997118
, O 0 0.0007475046
we O 0 0.00015746735
hypothesized O 0 0.00034018015
that O 0 0.00024328413
the O 0 0.00037169483
CX3CR1 O 0 0.7758765
plays O 0 0.00082128646
a O 0 0.0006745854
role O 0 0.00048116836
in O 0 0.0011578978
METH B-Chemical 0 0.9997694
- O 0 0.010648723
induced O 0 0.011155201
neurotoxicity B-Disease 2 0.9993771
and O 0 0.00885068
microglial O 0 0.9546048
activation O 0 0.046892386
. O 0 0.007177181

Mice O 0 0.004363047
in O 0 0.0020702062
which O 0 0.0020212173
the O 0 0.0014195443
CX3CR1 O 0 0.6343238
gene O 0 0.0018837326
has O 0 0.0009028793
been O 0 0.0008292675
deleted O 0 0.000741796
and O 0 0.00048976426
replaced O 0 0.00042934596
with O 0 0.00044784386
a O 0 0.0004506415
cDNA O 0 0.000648993
encoding O 0 0.0005955165
enhanced O 0 0.00062483374
green O 0 0.0009025313
fluorescent O 0 0.00301963
protein O 0 0.0030282494
( O 0 0.0009988747
eGFP O 0 0.001409916
) O 0 0.00076066016
were O 0 0.0004072719
treated O 0 0.00091574376
with O 0 0.0013743509
METH B-Chemical 0 0.99951816
and O 0 0.0016019228
examined O 0 0.0013406383
for O 0 0.0029011942
striatal O 0 0.99155784
neurotoxicity B-Disease 2 0.9985587
. O 0 0.010379309

METH B-Chemical 0 0.9981888
depleted O 0 0.009461335
DA B-Chemical 0 0.9962489
, O 0 0.004429465
caused O 0 0.0027161865
microglial O 0 0.88054216
activation O 0 0.008182282
, O 0 0.0010937012
and O 0 0.0005800232
increased O 0 0.0008288646
body O 0 0.0032344412
temperature O 0 0.0016568776
in O 0 0.0003978433
CX3CR1 O 0 0.70639306
knockout O 0 0.0004785173
mice O 0 0.0001929271
to O 0 0.00020978384
the O 0 0.0001845817
same O 0 0.00012261693
extent O 0 0.00016100849
and O 0 0.00022308493
over O 0 0.00012717975
the O 0 0.00019595888
same O 0 0.00015293245
time O 0 0.00027530038
course O 0 0.0007399677
seen O 0 0.00062318187
in O 0 0.00068499666
wild O 0 0.0009655608
- O 0 0.0025193873
type O 0 0.0025159877
controls O 0 0.006043313
. O 0 0.005490907

The O 0 0.0032597138
effects O 0 0.004060674
of O 0 0.003705719
METH B-Chemical 0 0.99923944
in O 0 0.002412826
CX3CR1 O 0 0.86099076
knockout O 0 0.001336509
mice O 0 0.00051398884
were O 0 0.0005596187
not O 0 0.0005261939
gender O 0 0.004443508
- O 0 0.0010481396
dependent O 0 0.00054524053
and O 0 0.00069128117
did O 0 0.00064241426
not O 0 0.000704126
extend O 0 0.0010031854
beyond O 0 0.0018056254
the O 0 0.0033809221
striatum O 0 0.607926
. O 0 0.006308742

Striatal O 0 0.98795253
microglia O 0 0.2423789
expressing O 0 0.002499627
eGFP O 0 0.0036815053
constitutively O 0 0.0019234163
show O 0 0.0011362624
morphological O 0 0.005736879
changes O 0 0.0019613004
after O 0 0.0011514922
METH B-Chemical 0 0.9991652
that O 0 0.0017329645
are O 0 0.0020200068
characteristic O 0 0.0039464883
of O 0 0.00506056
activation O 0 0.016160648
. O 0 0.007881336

This O 0 0.004838725
response O 0 0.0031277165
was O 0 0.0015314333
restricted O 0 0.0010327534
to O 0 0.00091412966
the O 0 0.0009496002
striatum O 0 0.33247748
and O 0 0.00073085603
contrasted O 0 0.001463374
sharply O 0 0.0027166668
with O 0 0.00080521416
unresponsive O 0 0.026926804
eGFP O 0 0.0041581444
- O 0 0.0015124441
microglia O 0 0.10162265
in O 0 0.00045518528
surrounding O 0 0.00087688654
brain O 0 0.025983749
areas O 0 0.0014877993
that O 0 0.0006237119
are O 0 0.00097342505
not O 0 0.0013488194
damaged O 0 0.01324454
by O 0 0.0068831416
METH B-Chemical 0 0.99859923
. O 0 0.00985682

We O 0 0.003304008
conclude O 0 0.0023725291
from O 0 0.0016921131
these O 0 0.0018101076
studies O 0 0.00201808
that O 0 0.0013703802
CX3CR1 O 0 0.79475665
signaling O 0 0.0035486997
does O 0 0.0011958447
not O 0 0.0013162398
modulate O 0 0.0029905916
METH B-Chemical 0 0.99972063
neurotoxicity B-Disease 2 0.9994916
or O 0 0.009669489
microglial O 0 0.9625964
activation O 0 0.054042775
. O 0 0.008600736

Furthermore O 0 0.0058167325
, O 0 0.0036012188
it O 0 0.0021253878
appears O 0 0.0014434747
that O 0 0.0011932879
striatal O 0 0.9523876
- O 0 0.002146614
resident O 0 0.0015436324
microglia O 0 0.14135525
respond O 0 0.0008317652
to O 0 0.00067974307
METH B-Chemical 0 0.99974173
with O 0 0.0011179195
an O 0 0.0008346412
activation O 0 0.0015974272
cascade O 0 0.0018198296
and O 0 0.0004125902
then O 0 0.00030943853
return O 0 0.00052057015
to O 0 0.00033168346
a O 0 0.0004923175
surveying O 0 0.0012778376
state O 0 0.0010619891
without O 0 0.0011113865
undergoing O 0 0.004350653
apoptosis O 0 0.87844586
or O 0 0.0038759043
migration O 0 0.060776513
. O 0 0.0066971225

Nicotine B-Chemical 1 0.9962167
- O 0 0.020104337
induced O 0 0.013120974
nystagmus B-Disease 0 0.99075294
correlates O 0 0.010823869
with O 0 0.012966322
midpontine O 0 0.86288375
activation O 0 0.030055096
. O 0 0.01451195

The O 0 0.005530664
pathomechanism O 0 0.2597311
of O 0 0.0076967464
nicotine B-Chemical 1 0.9952201
- O 0 0.013350003
induced O 0 0.009755603
nystagmus B-Disease 0 0.99716836
( O 0 0.014455091
NIN B-Disease 0 0.97029257
) O 0 0.009688591
is O 0 0.0059920824
unknown O 0 0.015454024
. O 0 0.009903285

The O 0 0.0028963124
aim O 0 0.002229513
of O 0 0.0017517044
this O 0 0.0012987084
study O 0 0.0016233533
was O 0 0.00095668936
to O 0 0.00083141925
delineate O 0 0.0009943414
brain O 0 0.014788437
structures O 0 0.0020885903
that O 0 0.0010043096
are O 0 0.001485566
involved O 0 0.0020293475
in O 0 0.0033234875
NIN B-Disease 0 0.9158724
generation O 0 0.011968642
. O 0 0.0088713

Eight O 0 0.008030789
healthy O 0 0.0070943115
volunteers O 0 0.006221826
inhaled O 0 0.93946177
nicotine B-Chemical 1 0.9964766
in O 0 0.0011908353
darkness O 0 0.0026295045
during O 0 0.00041827242
a O 0 0.00056928786
functional O 0 0.0009088884
magnetic O 0 0.05922638
resonance O 0 0.45664942
imaging O 0 0.013075362
( O 0 0.0011349136
fMRI O 0 0.029401556
) O 0 0.0008220639
experiment O 0 0.0004255232
; O 0 0.0009766021
eye O 0 0.004848255
movements O 0 0.0019312
were O 0 0.0007173909
registered O 0 0.001238286
using O 0 0.0012753097
video O 0 0.0056218007
- O 0 0.0065294956
oculography O 0 0.25927284
. O 0 0.007183218

NIN B-Disease 0 0.6644787
correlated O 0 0.0029650636
with O 0 0.0026547343
blood O 0 0.012028752
oxygen B-Chemical 1 0.92970467
level O 0 0.0015258662
- O 0 0.0020164521
dependent O 0 0.000996332
( O 0 0.0015752157
BOLD O 0 0.24679042
) O 0 0.0012179669
activity O 0 0.0007331426
levels O 0 0.00053330587
in O 0 0.00052323856
a O 0 0.00090280315
midpontine O 0 0.32389617
site O 0 0.0009036151
in O 0 0.0008881018
the O 0 0.0013719491
posterior O 0 0.012512568
basis O 0 0.0048238626
pontis O 0 0.3554074
. O 0 0.006647665

NIN B-Disease 0 0.9238968
- O 0 0.008091996
induced O 0 0.004175
midpontine O 0 0.64459574
activation O 0 0.003695917
may O 0 0.0009677943
correspond O 0 0.000540735
to O 0 0.0005479191
activation O 0 0.0011705982
of O 0 0.0007116697
the O 0 0.00072436547
dorsomedial O 0 0.8587043
pontine O 0 0.9531383
nuclei O 0 0.002557465
and O 0 0.00040688657
the O 0 0.00038226694
nucleus O 0 0.00249405
reticularis O 0 0.87561077
tegmenti O 0 0.038348984
pontis O 0 0.14891951
, O 0 0.00041811256
structures O 0 0.00053380575
known O 0 0.00037330098
to O 0 0.0002529913
participate O 0 0.0002603244
in O 0 0.00024471065
the O 0 0.00029572417
generation O 0 0.0005820029
of O 0 0.0008004248
multidirectional O 0 0.13936888
saccades O 0 0.28247073
and O 0 0.0015913941
smooth O 0 0.09981111
pursuit O 0 0.13781048
eye O 0 0.10667128
movements O 0 0.022471126
. O 0 0.006121891

Acute O 0 0.93094444
effects O 0 0.007364609
of O 0 0.004830089
N B-Chemical 0 0.90150553
- I-Chemical 0 0.00549236
( I-Chemical 0 0.0021162583
2 I-Chemical 0 0.0011252655
- I-Chemical 0 0.0014682378
propylpentanoyl I-Chemical 0 0.010746344
) I-Chemical 0 0.0021448878
urea I-Chemical 1 0.9917173
on O 0 0.0007822568
hippocampal O 0 0.956868
amino B-Chemical 0 0.98013204
acid I-Chemical 0 0.9955102
neurotransmitters O 0 0.98341745
in O 0 0.0029061378
pilocarpine B-Chemical 1 0.9997526
- O 0 0.012938048
induced O 0 0.008468583
seizure B-Disease 2 0.9980489
in O 0 0.0048042843
rats O 0 0.032036338
. O 0 0.006517344

The O 0 0.0023756688
present O 0 0.0014350988
study O 0 0.0017713467
aimed O 0 0.0011871662
to O 0 0.0007424296
investigate O 0 0.0004935728
the O 0 0.0007352505
anticonvulsant O 0 0.99887854
activity O 0 0.0011585829
as O 0 0.00033951778
well O 0 0.00026926553
as O 0 0.00023048166
the O 0 0.00024953045
effects O 0 0.0005394917
on O 0 0.00016228222
the O 0 0.00023868526
level O 0 0.00023105284
of O 0 0.0006994405
hippocampal O 0 0.9677164
amino B-Chemical 0 0.98769337
acid I-Chemical 0 0.9978411
neurotransmitters O 0 0.9946833
( O 0 0.0126930885
glutamate B-Chemical 1 0.9996136
, O 0 0.009153425
aspartate B-Chemical 1 0.9996057
, O 0 0.004660066
glycine B-Chemical 1 0.9981962
and O 0 0.0026997083
GABA B-Chemical 1 0.99982125
) O 0 0.0025486713
of O 0 0.0011395507
N B-Chemical 0 0.9359126
- I-Chemical 0 0.0020882466
( I-Chemical 0 0.0006758564
2 I-Chemical 0 0.00040038355
- I-Chemical 0 0.0006316686
propylpentanoyl I-Chemical 0 0.009616398
) I-Chemical 0 0.0015181893
urea I-Chemical 1 0.99698997
( O 0 0.0018592983
VPU B-Chemical 0 0.9445399
) O 0 0.0009039315
in O 0 0.0002872027
comparison O 0 0.00029006295
to O 0 0.00036140875
its O 0 0.0009867168
parent O 0 0.0010636157
compound O 0 0.18053618
, O 0 0.0072903302
valproic B-Chemical 0 0.9997551
acid I-Chemical 0 0.9935354
( O 0 0.07058997
VPA B-Chemical 1 0.99916935
) O 0 0.02670984
. O 0 0.007658369

VPU B-Chemical 0 0.82356244
was O 0 0.0039412864
more O 0 0.003174573
potent O 0 0.020183997
than O 0 0.0015792204
VPA B-Chemical 1 0.9993711
, O 0 0.0019400137
exhibiting O 0 0.0014060851
the O 0 0.0005161247
median O 0 0.0004917646
effective O 0 0.00085701543
dose O 0 0.030190771
( O 0 0.0012145506
ED O 0 0.2762429
( O 0 0.00070218043
50 O 0 0.00062156876
) O 0 0.0005618192
) O 0 0.00041166553
of O 0 0.00031964088
49 O 0 0.0006750276
mg O 0 0.24095006
/ O 0 0.00088696566
kg O 0 0.002863792
in O 0 0.0002454748
protecting O 0 0.0027495744
rats O 0 0.0034840435
against O 0 0.0006582312
pilocarpine B-Chemical 1 0.9998925
- O 0 0.004767856
induced O 0 0.0019343264
seizure B-Disease 2 0.9992061
whereas O 0 0.0005160961
the O 0 0.00034551398
corresponding O 0 0.00033096387
value O 0 0.00054522126
for O 0 0.00085397076
VPA B-Chemical 1 0.99942493
was O 0 0.0021471474
322 O 0 0.060816254
mg O 0 0.59801877
/ O 0 0.008987128
kg O 0 0.024814995
. O 0 0.00558357

In O 0 0.003028611
vivo O 0 0.0034778025
microdialysis O 0 0.1590889
demonstrated O 0 0.0015124803
that O 0 0.0008160232
an O 0 0.0011283299
intraperitoneal O 0 0.13611074
administration O 0 0.19154525
of O 0 0.002003785
pilocarpine B-Chemical 1 0.9998455
induced O 0 0.0027594797
a O 0 0.0006892859
pronounced O 0 0.0011751534
increment O 0 0.00085270195
of O 0 0.001021293
hippocampal O 0 0.98365134
glutamate B-Chemical 1 0.9996413
and O 0 0.0030003604
aspartate B-Chemical 1 0.9994392
whereas O 0 0.0005539488
no O 0 0.00027539014
significant O 0 0.00043622064
change O 0 0.00039070885
was O 0 0.00034576323
observed O 0 0.00029601637
on O 0 0.00030095273
the O 0 0.0005853159
level O 0 0.0008090645
of O 0 0.0029124354
glycine B-Chemical 1 0.9942754
and O 0 0.018454092
GABA B-Chemical 1 0.99827397
. O 0 0.0105019715

Pretreatment O 0 0.74983877
with O 0 0.0043209465
either O 0 0.0031660348
VPU B-Chemical 0 0.9052225
( O 0 0.0024003338
50 O 0 0.0014128307
and O 0 0.0008271588
100 O 0 0.0014975335
mg O 0 0.28803578
/ O 0 0.0017103103
kg O 0 0.007268466
) O 0 0.0009532683
or O 0 0.0005695859
VPA B-Chemical 1 0.99967885
( O 0 0.0010694116
300 O 0 0.0014655496
and O 0 0.0003843635
600 O 0 0.0025086843
mg O 0 0.3050411
/ O 0 0.0012370698
kg O 0 0.0057917098
) O 0 0.0006726348
completely O 0 0.000498606
abolished O 0 0.003055781
pilocarpine B-Chemical 1 0.99981934
- O 0 0.0056256833
evoked O 0 0.15455765
increases O 0 0.0014542171
in O 0 0.0015259382
extracellular O 0 0.3128459
glutamate B-Chemical 1 0.99862957
and O 0 0.027539369
aspartate B-Chemical 1 0.9976471
. O 0 0.010501055

In O 0 0.0028925997
addition O 0 0.0016838971
, O 0 0.0018989397
a O 0 0.0012132279
statistically O 0 0.00095519755
significant O 0 0.0009103913
reduction O 0 0.0011182746
was O 0 0.00052855397
also O 0 0.00046833899
observed O 0 0.00029027706
on O 0 0.00021140568
the O 0 0.0003113416
level O 0 0.0003141629
of O 0 0.0010785372
GABA B-Chemical 1 0.99974316
and O 0 0.0018749215
glycine B-Chemical 1 0.99716383
but O 0 0.00057662657
less O 0 0.00043722647
than O 0 0.00026434544
a O 0 0.00051262527
drastic O 0 0.0016574016
reduction O 0 0.0018467226
of O 0 0.0029590828
glutamate B-Chemical 1 0.99860567
and O 0 0.012198222
aspartate B-Chemical 1 0.997799
level O 0 0.006649189
. O 0 0.0072788983

Based O 0 0.009176145
on O 0 0.0018366065
the O 0 0.0017684788
finding O 0 0.0022963304
that O 0 0.0014655299
VPU B-Chemical 0 0.92853975
and O 0 0.002819982
VPA B-Chemical 1 0.9996197
could O 0 0.0009061115
protect O 0 0.0023081352
the O 0 0.00049375795
animals O 0 0.00046953207
against O 0 0.00075517566
pilocarpine B-Chemical 1 0.9998838
- O 0 0.007145623
induced O 0 0.002662947
seizure B-Disease 2 0.9994461
it O 0 0.0007316592
is O 0 0.00031209885
suggested O 0 0.00027935952
that O 0 0.00019566593
the O 0 0.00023577317
reduction O 0 0.0006602951
of O 0 0.0006177962
inhibitory O 0 0.1230222
amino B-Chemical 0 0.98315436
acid I-Chemical 0 0.9966066
neurotransmitters O 0 0.9687182
was O 0 0.00050160126
comparatively O 0 0.0011668713
minor O 0 0.0009757827
and O 0 0.0004425807
offset O 0 0.0010465413
by O 0 0.00053679215
a O 0 0.0007105918
pronounced O 0 0.0015971594
reduction O 0 0.0023023416
of O 0 0.0041184886
glutamate B-Chemical 1 0.99839324
and O 0 0.024258213
aspartate B-Chemical 1 0.99758756
. O 0 0.01061955

Therefore O 0 0.0043822643
, O 0 0.004083869
like O 0 0.0032436487
VPA B-Chemical 1 0.9990356
, O 0 0.0027300057
the O 0 0.0009970822
finding O 0 0.001383883
that O 0 0.0007656304
VPU B-Chemical 0 0.9031576
could O 0 0.0005545219
drastically O 0 0.002354516
reduce O 0 0.00084998115
pilocarpine B-Chemical 1 0.99989164
- O 0 0.006190202
induced O 0 0.0010244874
increases O 0 0.0007606572
in O 0 0.00061460666
glutamate B-Chemical 1 0.99945396
and O 0 0.0018778517
aspartate B-Chemical 1 0.9994085
should O 0 0.0002982557
account O 0 0.00036938937
, O 0 0.00030436073
at O 0 0.00012872388
least O 0 0.0001424688
partly O 0 0.00043288225
, O 0 0.0003404699
for O 0 0.00023273232
its O 0 0.0012895738
anticonvulsant O 0 0.9993845
activity O 0 0.0010751904
observed O 0 0.00044006435
in O 0 0.000822013
pilocarpine B-Chemical 1 0.99979335
- O 0 0.0059328605
induced O 0 0.004081104
seizure B-Disease 2 0.9983126
in O 0 0.0019359353
experimental O 0 0.004325477
animals O 0 0.0039418587
. O 0 0.005265196

Some O 0 0.0071973307
other O 0 0.0031406777
mechanism O 0 0.0029843661
than O 0 0.0014804644
those O 0 0.0020528417
being O 0 0.0021496532
reported O 0 0.002350901
herein O 0 0.0028395175
should O 0 0.0015593548
be O 0 0.0025565296
further O 0 0.003656077
investigated O 0 0.0058670626
. O 0 0.007839007

Protective O 0 0.63028795
effect O 0 0.006866902
of O 0 0.0076803244
verapamil B-Chemical 0 0.99906105
on O 0 0.0055910596
gastric B-Disease 0 0.99551564
hemorrhagic I-Disease 2 0.99949396
ulcers B-Disease 0 0.99903834
in O 0 0.012553524
severe O 0 0.8937541
atherosclerotic B-Disease 2 0.995808
rats O 0 0.20009345
. O 0 0.0106199505

Studies O 0 0.011573892
concerning O 0 0.0031702286
with O 0 0.0030755189
pathogenesis O 0 0.015383244
of O 0 0.004311833
gastric B-Disease 0 0.9946485
hemorrhage I-Disease 2 0.99957544
and O 0 0.0067525203
mucosal O 0 0.90140176
ulceration O 0 0.99866664
produced O 0 0.003218535
in O 0 0.0027826976
atherosclerotic B-Disease 2 0.99508286
rats O 0 0.031193659
are O 0 0.0037280757
lacking O 0 0.0038408977
. O 0 0.0062201074

The O 0 0.0025809214
aim O 0 0.0019429522
of O 0 0.0014823906
this O 0 0.0010515362
study O 0 0.0012771367
is O 0 0.00065919483
to O 0 0.00046449545
examine O 0 0.0002839275
the O 0 0.00037389804
role O 0 0.00032607839
of O 0 0.0008227704
gastric O 0 0.9440722
acid O 0 0.9758185
back O 0 0.013974534
- O 0 0.002135082
diffusion O 0 0.0447996
, O 0 0.0013397218
mast O 0 0.898222
cell O 0 0.09753196
histamine B-Chemical 1 0.9995208
release O 0 0.45807302
, O 0 0.002671665
lipid O 0 0.9313287
peroxide O 0 0.99938774
( O 0 0.022258969
LPO O 0 0.9998908
) O 0 0.0031056271
generation O 0 0.000838104
and O 0 0.0005894728
mucosal O 0 0.61790526
microvascular O 0 0.98798686
permeability O 0 0.93742985
in O 0 0.0005814869
modulating O 0 0.0021214052
gastric B-Disease 0 0.9979887
hemorrhage I-Disease 2 0.9998933
and O 0 0.005706473
ulcer B-Disease 2 0.99939847
in O 0 0.0007798296
rats O 0 0.010237628
with O 0 0.0015196684
atherosclerosis B-Disease 2 0.9993156
induced O 0 0.0031950073
by O 0 0.0016307164
coadministration O 0 0.99653995
of O 0 0.016821288
vitamin B-Chemical 0 0.99958974
D2 I-Chemical 0 0.9975574
and O 0 0.020581182
cholesterol B-Chemical 0 0.9944277
. O 0 0.009520625

Additionally O 0 0.00615427
, O 0 0.003939789
the O 0 0.0022628305
protective O 0 0.006816887
effect O 0 0.0025711518
of O 0 0.003706397
verapamil B-Chemical 0 0.9993254
on O 0 0.0020397943
this O 0 0.0032684729
ulcer B-Disease 2 0.9959026
model O 0 0.0068123434
was O 0 0.004844366
evaluated O 0 0.0062484443
. O 0 0.00811236

Male O 0 0.038967248
Wistar O 0 0.15948538
rats O 0 0.005285434
were O 0 0.0013649006
challenged O 0 0.0011709221
intragastrically O 0 0.07766153
once O 0 0.00071350485
daily O 0 0.0011793459
for O 0 0.0003922874
9 O 0 0.00036899655
days O 0 0.0002956748
with O 0 0.00038898893
1 O 0 0.0003637475
. O 0 0.00019644265
0 O 0 0.00032771582
ml O 0 0.0008570374
/ O 0 0.0006870502
kg O 0 0.001747027
of O 0 0.0006681888
corn O 0 0.89123446
oil O 0 0.96632653
containing O 0 0.0032140831
vitamin B-Chemical 0 0.9996191
D2 I-Chemical 0 0.997903
and O 0 0.005523261
cholesterol B-Chemical 0 0.9953561
to O 0 0.0037385535
induce O 0 0.007879502
atherosclerosis B-Disease 2 0.9972562
. O 0 0.010937012

Control O 0 0.028103298
rats O 0 0.025767745
received O 0 0.02039343
corn O 0 0.90798753
oil O 0 0.9370646
only O 0 0.027844578
. O 0 0.02461168

After O 0 0.003418164
gastric O 0 0.29582217
surgery O 0 0.007386266
, O 0 0.0026412157
rat O 0 0.005256519
stomachs O 0 0.0077022403
were O 0 0.00094711664
irrigated O 0 0.0060482956
for O 0 0.0006475229
3 O 0 0.00055557786
h O 0 0.00057700323
with O 0 0.00063475856
either O 0 0.00071586116
simulated O 0 0.0012818164
gastric O 0 0.8987713
juice O 0 0.9920094
or O 0 0.00356576
normal O 0 0.010676257
saline O 0 0.32910225
. O 0 0.0078038215

Gastric O 0 0.789635
acid O 0 0.8675122
back O 0 0.011213303
- O 0 0.004875397
diffusion O 0 0.030801347
, O 0 0.0033259948
mucosal O 0 0.7771297
LPO O 0 0.9996948
generation O 0 0.013014731
, O 0 0.0041389028
histamine B-Chemical 1 0.9987186
concentration O 0 0.038413297
, O 0 0.0022912247
microvascular O 0 0.97685015
permeability O 0 0.9483784
, O 0 0.0026947455
luminal B-Chemical 1 0.596861
hemoglobin O 0 0.92674994
content O 0 0.0021497554
and O 0 0.002528351
ulcer B-Disease 2 0.99726534
areas O 0 0.011620292
were O 0 0.003230875
determined O 0 0.0036626817
. O 0 0.0059196884

Elevated O 0 0.3917277
atherosclerotic B-Disease 2 0.98600554
parameters O 0 0.0059690196
, O 0 0.0022222258
such O 0 0.0011719101
as O 0 0.0009971425
serum O 0 0.13664116
calcium B-Chemical 1 0.9958508
, O 0 0.0017241726
total O 0 0.000935839
cholesterol B-Chemical 0 0.992523
and O 0 0.0009198858
low O 0 0.0011190483
- O 0 0.0014523675
density O 0 0.002220524
lipoprotein O 0 0.9914997
concentration O 0 0.006349629
were O 0 0.0011653985
obtained O 0 0.0014417926
in O 0 0.0025969774
atherosclerotic B-Disease 2 0.9916528
rats O 0 0.05910994
. O 0 0.0069524976

Severe O 0 0.9227726
gastric O 0 0.9581037
ulcers B-Disease 0 0.99759513
accompanied O 0 0.015587458
with O 0 0.0023595595
increased O 0 0.0037190663
ulcerogenic O 0 0.9991134
factors O 0 0.028928341
, O 0 0.0014439614
including O 0 0.0009381951
gastric O 0 0.94877386
acid O 0 0.97353417
back O 0 0.012962489
- O 0 0.002158503
diffusion O 0 0.049868092
, O 0 0.0019622564
histamine B-Chemical 1 0.9991522
release O 0 0.4006389
, O 0 0.00435276
LPO O 0 0.9998084
generation O 0 0.0028107865
and O 0 0.0010727915
luminal B-Chemical 1 0.5511212
hemoglobin O 0 0.9078903
content O 0 0.0012156919
were O 0 0.0008181768
also O 0 0.0009418175
observed O 0 0.00090445747
in O 0 0.0014762649
these O 0 0.0035640225
rats O 0 0.015338016
. O 0 0.006062689

Moreover O 0 0.005696347
, O 0 0.0033238018
a O 0 0.0018535181
positive O 0 0.0012329745
correlation O 0 0.0009356032
of O 0 0.0019746565
histamine B-Chemical 1 0.99722207
to O 0 0.0027265016
gastric B-Disease 0 0.99610835
hemorrhage I-Disease 2 0.999684
and O 0 0.002399003
to O 0 0.0015265617
ulcer B-Disease 2 0.99786466
was O 0 0.0016451213
found O 0 0.0013113841
in O 0 0.0015641953
those O 0 0.0045510414
atherosclerotic B-Disease 2 0.9922072
rats O 0 0.069579735
. O 0 0.007312574

This O 0 0.011321373
hemorrhagic B-Disease 2 0.9938367
ulcer B-Disease 0 0.99596846
and O 0 0.0037197273
various O 0 0.0050676162
ulcerogenic O 0 0.9982967
parameters O 0 0.005628634
were O 0 0.0016711169
dose O 0 0.060895093
- O 0 0.005104664
dependently O 0 0.9765812
ameliorated O 0 0.7007275
by O 0 0.0038191897
daily O 0 0.050787576
intragastric O 0 0.9906916
verapamil B-Chemical 0 0.9991691
. O 0 0.014979337

Atherosclerosis B-Disease 0 0.98153174
could O 0 0.003310027
produce O 0 0.003354389
gastric B-Disease 0 0.9909972
hemorrhagic I-Disease 2 0.999479
ulcer B-Disease 0 0.9991696
via O 0 0.003069379
aggravation O 0 0.9620268
of O 0 0.0035185313
gastric O 0 0.98146534
acid O 0 0.9843316
back O 0 0.017060183
- O 0 0.0024052488
diffusion O 0 0.052428897
, O 0 0.002398591
LPO O 0 0.99979824
generation O 0 0.005862392
, O 0 0.002726228
histamine B-Chemical 1 0.9991209
release O 0 0.23401214
and O 0 0.00124805
microvascular O 0 0.9759665
permeability O 0 0.8756232
that O 0 0.0006825747
could O 0 0.00060435187
be O 0 0.0010242258
ameliorated O 0 0.34700215
by O 0 0.0042662104
verapamil B-Chemical 0 0.9994609
in O 0 0.0058132536
rats O 0 0.04518532
. O 0 0.006623112

Lamivudine B-Chemical 1 0.996181
for O 0 0.0033210178
the O 0 0.0024559395
prevention O 0 0.008245997
of O 0 0.0077837105
hepatitis B-Disease 2 0.99983466
B I-Disease 2 0.9868715
virus O 0 0.5927175
reactivation O 0 0.744298
in O 0 0.003778659
hepatitis B-Chemical 2 0.99983025
- I-Chemical 0 0.0356087
B I-Chemical 0 0.39934188
surface I-Chemical 0 0.013602557
antigen I-Chemical 0 0.15642038
( O 0 0.0036533491
HBSAG B-Chemical 0 0.9766583
) O 0 0.0036618882
seropositive O 0 0.13064288
cancer B-Disease 2 0.9852917
patients O 0 0.020974783
undergoing O 0 0.014309287
cytotoxic O 0 0.92573243
chemotherapy O 0 0.9618128
. O 0 0.00928136

Hepatitis B-Disease 2 0.99788326
B I-Disease 2 0.91324705
virus O 0 0.34072676
( O 0 0.00790774
HBV O 0 0.98631096
) O 0 0.0038358
is O 0 0.0011404906
one O 0 0.0006950301
of O 0 0.0010036096
the O 0 0.0008976989
major O 0 0.00154125
causes O 0 0.0033063719
of O 0 0.0040429076
chronic O 0 0.99476904
liver B-Disease 2 0.99634403
disease I-Disease 2 0.99532133
worldwide O 0 0.6563958
. O 0 0.011034216

Cancer B-Disease 0 0.6717219
patients O 0 0.007908108
who O 0 0.004416355
are O 0 0.0018934151
chronic O 0 0.782081
carriers O 0 0.014042201
of O 0 0.0021350435
HBV O 0 0.9903561
have O 0 0.0010999897
a O 0 0.00079943467
higher O 0 0.00076267566
hepatic B-Disease 0 0.9946333
complication I-Disease 0 0.8887868
rate O 0 0.0006159472
while O 0 0.00046417164
receiving O 0 0.00588016
cytotoxic O 0 0.8544607
chemotherapy O 0 0.9532079
( O 0 0.0022386326
CT O 0 0.46457657
) O 0 0.0009631504
and O 0 0.00045262833
this O 0 0.00044867047
has O 0 0.0006154173
mainly O 0 0.0015474684
been O 0 0.0015516506
attributed O 0 0.0018499637
to O 0 0.0031477818
HBV O 0 0.9892847
reactivation O 0 0.7813456
. O 0 0.009334528

In O 0 0.0028751157
this O 0 0.002033433
study O 0 0.0025929676
, O 0 0.0024165292
cancer B-Disease 2 0.9433349
patients O 0 0.006403764
who O 0 0.0023533267
have O 0 0.00085354166
solid O 0 0.01778442
and O 0 0.0013259944
hematological B-Disease 0 0.9985275
malignancies I-Disease 2 0.9995952
with O 0 0.011530976
chronic O 0 0.9970293
HBV B-Disease 0 0.9996489
infection I-Disease 2 0.9751305
received O 0 0.0018984843
the O 0 0.0004946532
antiviral O 0 0.38265774
agent O 0 0.4295886
lamivudine B-Chemical 1 0.9997484
prior O 0 0.00037059656
and O 0 0.00038037595
during O 0 0.00025692486
CT O 0 0.13069358
compared O 0 0.00020127381
with O 0 0.00038903434
historical O 0 0.00209396
control O 0 0.00045048728
group O 0 0.0008252296
who O 0 0.0016813434
did O 0 0.0009494165
not O 0 0.0014526178
receive O 0 0.004714788
lamivudine B-Chemical 1 0.9977761
. O 0 0.008706353

The O 0 0.0027311149
objectives O 0 0.002622401
were O 0 0.0012766124
to O 0 0.00088414754
assess O 0 0.00045277638
the O 0 0.0006357194
efficacy O 0 0.0020857777
of O 0 0.0012454706
lamivudine B-Chemical 1 0.9994135
in O 0 0.00074959564
reducing O 0 0.00085995207
the O 0 0.0005807755
incidence O 0 0.008361277
of O 0 0.0016589833
HBV O 0 0.99646735
reactivation O 0 0.62743545
, O 0 0.0015005991
and O 0 0.0009585835
diminishing O 0 0.004965283
morbidity O 0 0.47449705
and O 0 0.0025775034
mortality O 0 0.27239907
during O 0 0.003915419
CT O 0 0.5666885
. O 0 0.0073799407

Two O 0 0.009627002
groups O 0 0.00686737
were O 0 0.0053595654
compared O 0 0.004026677
in O 0 0.005566321
this O 0 0.007656413
study O 0 0.014504336
. O 0 0.01459277

The O 0 0.0037113444
prophylactic O 0 0.014383397
lamivudin B-Chemical 0 0.8840173
group O 0 0.0026967674
consisted O 0 0.0014553934
of O 0 0.0016067644
37 O 0 0.002102188
patients O 0 0.003077619
who O 0 0.0033489496
received O 0 0.0032765092
prophylactic O 0 0.200539
lamivudine B-Chemical 1 0.99865484
treatment O 0 0.10975815
. O 0 0.010549831

The O 0 0.0033216637
historical O 0 0.005721272
controls O 0 0.0024511325
consisted O 0 0.0014861355
of O 0 0.0015674015
50 O 0 0.0017445333
consecutive O 0 0.0015369289
patients O 0 0.0027360804
who O 0 0.0030107999
underwent O 0 0.0031026646
CT O 0 0.17804767
without O 0 0.0043240273
prophylactic O 0 0.31913555
lamivudine B-Chemical 1 0.99806374
. O 0 0.013787608

They O 0 0.007931609
were O 0 0.0031273896
followed O 0 0.0020839465
up O 0 0.0021870867
during O 0 0.001629567
and O 0 0.002168355
for O 0 0.001982097
8 O 0 0.0025189524
weeks O 0 0.002973381
after O 0 0.003615338
CT O 0 0.17934845
. O 0 0.010108592

The O 0 0.006654672
outcomes O 0 0.008016209
were O 0 0.0050318814
compared O 0 0.0037511417
for O 0 0.005135916
both O 0 0.007849113
groups O 0 0.012903961
. O 0 0.0144984

Of O 0 0.005048742
our O 0 0.0020803537
control O 0 0.0016633042
group O 0 0.0020810054
( O 0 0.0017901182
n O 0 0.0010126237
= O 0 0.0013034559
50 O 0 0.001110361
) O 0 0.001130444
, O 0 0.00083564623
21 O 0 0.00086205103
patients O 0 0.0016312009
( O 0 0.0011863959
42 O 0 0.00143177
% O 0 0.0013492479
) O 0 0.0020092716
were O 0 0.0021047546
established O 0 0.00835896
hepatitis B-Disease 2 0.99802077
. O 0 0.013304894

Twelve O 0 0.015500046
( O 0 0.0055327374
24 O 0 0.0028723872
% O 0 0.0027150935
) O 0 0.0025995455
of O 0 0.0020072402
them O 0 0.0028057469
were O 0 0.0020983645
evaluated O 0 0.002714852
as O 0 0.0044401726
severe O 0 0.7769673
hepatitis B-Disease 2 0.99844944
. O 0 0.022027347

In O 0 0.0032083339
the O 0 0.002368847
prophylactic O 0 0.02932768
lamivudine B-Chemical 1 0.99892056
group O 0 0.005748984
severe O 0 0.7137168
hepatitis B-Disease 2 0.99976045
were O 0 0.0015123665
observed O 0 0.0005103112
only O 0 0.0004827756
in O 0 0.00037972484
1 O 0 0.00040391026
patient O 0 0.0006485187
( O 0 0.0005058289
2 O 0 0.00031355486
. O 0 0.0001853616
7 O 0 0.00024163334
% O 0 0.0003192267
) O 0 0.0004011161
of O 0 0.00039193232
37 O 0 0.0007354326
patients O 0 0.001497451
( O 0 0.0010279845
p O 0 0.001203636
< O 0 0.0012883402
0 O 0 0.001433118
. O 0 0.0014609067
006 O 0 0.038176876
) O 0 0.0061298977
. O 0 0.005471874

Comparison O 0 0.003128811
of O 0 0.0024478165
the O 0 0.0015618682
mean O 0 0.0011558513
ALT O 0 0.9855282
values O 0 0.0010582091
revealed O 0 0.0008221345
significantly O 0 0.00079935085
higher O 0 0.0005597817
mean O 0 0.00053118274
alanine B-Chemical 1 0.98941845
aminotransferase O 0 0.9993297
( O 0 0.008820667
ALT O 0 0.9985222
) O 0 0.0013322921
values O 0 0.0003259407
in O 0 0.0002248207
the O 0 0.00021307559
control O 0 0.00020807066
group O 0 0.00031657453
than O 0 0.00017165548
the O 0 0.0002730565
prophylactic O 0 0.028030545
lamivudine B-Chemical 1 0.9996443
group O 0 0.0023641156
; O 0 0.0016837005
154 O 0 0.01029515
: O 0 0.00094069325
64 O 0 0.0009930218
( O 0 0.0008370205
p O 0 0.0010080261
< O 0 0.0010880532
0 O 0 0.0011842845
. O 0 0.0011130564
32 O 0 0.0033860803
) O 0 0.005229028
. O 0 0.0050274758

Our O 0 0.0031549286
study O 0 0.0027632616
suggests O 0 0.0011729499
that O 0 0.0010763565
prophylactic O 0 0.033165254
lamivudine B-Chemical 1 0.99935466
significantly O 0 0.0022891087
decreases O 0 0.0011946459
the O 0 0.0006293301
incidence O 0 0.008290296
of O 0 0.0014588756
HBV O 0 0.9962054
reactivation O 0 0.5154103
and O 0 0.0008543199
overall O 0 0.00090658816
morbidity O 0 0.43428275
in O 0 0.00089943304
cancer B-Disease 2 0.98523325
patients O 0 0.005427324
during O 0 0.0007431382
and O 0 0.0012131551
after O 0 0.0013275399
immunosuppressive O 0 0.95770097
therapy O 0 0.22980645
. O 0 0.0072653014

Further O 0 0.004076376
studies O 0 0.0027124663
are O 0 0.0013959873
needed O 0 0.0007461349
to O 0 0.0006712209
determine O 0 0.00034237845
the O 0 0.0005044739
most O 0 0.0008153158
appropriate O 0 0.0005796413
nucleoside B-Chemical 0 0.9479301
or O 0 0.0005905809
nucleotide B-Chemical 0 0.032844763
analogue O 0 0.063989475
for O 0 0.00039847358
antiviral O 0 0.20376949
prophylaxis O 0 0.07732597
during O 0 0.00038664017
CT O 0 0.22618857
and O 0 0.00040456848
the O 0 0.00028546544
optimal O 0 0.00024860597
duration O 0 0.00062622223
of O 0 0.0008529006
administration O 0 0.03891881
after O 0 0.00078561093
completion O 0 0.0014557627
of O 0 0.0039330437
CT O 0 0.4959705
. O 0 0.0068805343

Recovery O 0 0.023973385
of O 0 0.0064975005
tacrolimus B-Chemical 0 0.999022
- O 0 0.010999156
associated O 0 0.0050225295
brachial B-Disease 0 0.994921
neuritis I-Disease 0 0.999666
after O 0 0.000849363
conversion O 0 0.004016091
to O 0 0.0007033769
everolimus B-Chemical 1 0.9981675
in O 0 0.0005529491
a O 0 0.0005984126
pediatric O 0 0.0043719094
renal O 0 0.98692685
transplant O 0 0.820614
recipient O 0 0.010148645
- O 0 0.001710493
- O 0 0.0009490348
case O 0 0.000615397
report O 0 0.0017584747
and O 0 0.0010174217
review O 0 0.0025919394
of O 0 0.002119477
the O 0 0.0028870662
literature O 0 0.009173258
. O 0 0.0061949333

TAC B-Chemical 1 0.935071
has O 0 0.0043958845
been O 0 0.003010353
shown O 0 0.0014287177
to O 0 0.0013008285
be O 0 0.0012442588
a O 0 0.001293169
potent O 0 0.021021442
immunosuppressive O 0 0.96839684
agent O 0 0.22933185
for O 0 0.0015797032
solid O 0 0.050788242
organ O 0 0.1818449
transplantation O 0 0.39374793
in O 0 0.0043033706
pediatrics O 0 0.036055498
. O 0 0.007671819

Neurotoxicity B-Disease 0 0.9915023
is O 0 0.011167311
a O 0 0.009539834
potentially O 0 0.016442075
serious O 0 0.3356443
toxic O 0 0.88588226
effect O 0 0.022129402
. O 0 0.017649118

It O 0 0.008225446
is O 0 0.0039499365
characterized O 0 0.0051162895
by O 0 0.0052499883
encephalopathy B-Disease 2 0.9990264
, O 0 0.02704441
headaches B-Disease 0 0.9988018
, O 0 0.027075017
seizures B-Disease 2 0.99932325
, O 0 0.007943475
or O 0 0.0055692727
neurological B-Disease 0 0.99350303
deficits I-Disease 0 0.9823698
. O 0 0.011071858

Here O 0 0.005856345
, O 0 0.0028735865
we O 0 0.0010310083
describe O 0 0.0013543674
an O 0 0.0013893321
eight O 0 0.0009730684
- O 0 0.001662063
and O 0 0.0009855917
- O 0 0.0012797992
a O 0 0.0007865424
- O 0 0.0009476095
half O 0 0.0004197071
- O 0 0.000981697
yr O 0 0.0016028808
- O 0 0.0008711228
old O 0 0.0007645298
male O 0 0.002578943
renal O 0 0.95640486
transplant O 0 0.6731895
recipient O 0 0.0072029103
with O 0 0.0039545824
right O 0 0.017168581
BN O 0 0.9260375
. O 0 0.008482455

MRI O 0 0.5111712
demonstrated O 0 0.005166608
hyperintense O 0 0.48245472
T2 O 0 0.03617114
signals O 0 0.0020300548
in O 0 0.0011225845
the O 0 0.0011250601
cervical O 0 0.24836023
cord O 0 0.16097559
and O 0 0.0012276353
right O 0 0.0034777082
brachial O 0 0.86160415
plexus O 0 0.6409339
roots O 0 0.0069392463
indicative O 0 0.0008867642
of O 0 0.0013841604
both O 0 0.0023646476
myelitis B-Disease 0 0.9992072
and O 0 0.0047421874
right O 0 0.053576715
brachial B-Disease 0 0.99198806
plexitis I-Disease 0 0.9895392
. O 0 0.009016764

Symptoms O 0 0.13961446
persisted O 0 0.002942344
for O 0 0.0012044035
three O 0 0.0006729127
months O 0 0.0009109661
despite O 0 0.0009128237
TAC B-Chemical 1 0.961207
dose O 0 0.05426623
reduction O 0 0.0025368002
, O 0 0.0011020924
administration O 0 0.061201032
of O 0 0.0012230416
IVIG O 0 0.9914014
and O 0 0.0009976313
four O 0 0.00068076537
doses O 0 0.030589642
of O 0 0.003828697
methylprednisolone B-Chemical 1 0.9991258
pulse O 0 0.30461752
therapy O 0 0.27494735
. O 0 0.008253511

Improvement O 0 0.011934444
and O 0 0.0029793538
eventually O 0 0.0039150133
full O 0 0.0013466263
recovery O 0 0.0022778658
only O 0 0.001011908
occurred O 0 0.0010773605
after O 0 0.00063424534
TAC B-Chemical 1 0.9428837
was O 0 0.0010090629
completely O 0 0.0010370837
discontinued O 0 0.021781651
and O 0 0.0013440184
successfully O 0 0.002621735
replaced O 0 0.002668883
by O 0 0.0050971718
everolimus B-Chemical 1 0.99544734
. O 0 0.009510534

Omitting O 0 0.03890345
fentanyl B-Chemical 1 0.9974577
reduces O 0 0.012556018
nausea B-Disease 2 0.999534
and O 0 0.009757819
vomiting B-Disease 0 0.9991799
, O 0 0.0026565276
without O 0 0.0012968618
increasing O 0 0.002594812
pain B-Disease 0 0.9720777
, O 0 0.002143841
after O 0 0.0011316711
sevoflurane B-Chemical 1 0.99191463
for O 0 0.0020920597
day O 0 0.0034206652
surgery O 0 0.013500467
. O 0 0.0061742477

BACKGROUND O 0 0.7480688
AND O 0 0.008192621
OBJECTIVE O 0 0.33632502
: O 0 0.0025512278
Despite O 0 0.0012619867
advantages O 0 0.0007304703
of O 0 0.0009482182
induction O 0 0.0011207226
and O 0 0.00073339976
maintenance O 0 0.0012011301
of O 0 0.0009825957
anaesthesia O 0 0.15075785
with O 0 0.0015575049
sevoflurane B-Chemical 1 0.998028
, O 0 0.0025243352
postoperative B-Disease 0 0.4789734
nausea I-Disease 2 0.99973685
and I-Disease 0 0.00994803
vomiting I-Disease 0 0.99901557
occurs O 0 0.006768549
frequently O 0 0.012819863
. O 0 0.0065679965

Fentanyl B-Chemical 0 0.9977841
is O 0 0.0037718762
a O 0 0.0022321895
commonly O 0 0.0028958304
used O 0 0.0012452547
supplement O 0 0.005960284
that O 0 0.00080080633
may O 0 0.00082134624
contribute O 0 0.00081049855
to O 0 0.00067146885
this O 0 0.0007613926
, O 0 0.0010749748
although O 0 0.0008666025
it O 0 0.0011806503
may O 0 0.0013335814
also O 0 0.0021116543
improve O 0 0.0035423115
analgesia O 0 0.98238856
. O 0 0.008217727

METHODS O 0 0.0063336436
: O 0 0.0032306768
This O 0 0.0019705927
double O 0 0.0011394898
- O 0 0.0014568092
blind O 0 0.0021195072
study O 0 0.00085725397
examined O 0 0.0003958413
the O 0 0.00044843677
incidence O 0 0.0026625316
and O 0 0.00058897573
severity O 0 0.009634416
of O 0 0.0008353601
postoperative B-Disease 0 0.40152913
nausea I-Disease 2 0.99990225
and I-Disease 0 0.0034499655
vomiting I-Disease 0 0.9997298
and O 0 0.0013764468
pain B-Disease 0 0.9671979
in O 0 0.0003190332
the O 0 0.00023919738
first O 0 0.00020544599
24 O 0 0.00024983828
h O 0 0.00027178123
after O 0 0.00024438396
sevoflurane B-Chemical 1 0.9927361
anaesthesia O 0 0.10397813
in O 0 0.00067016936
216 O 0 0.004428418
adult O 0 0.001382526
day O 0 0.0013532547
surgery O 0 0.005782809
patients O 0 0.007805136
. O 0 0.005120998

Patients O 0 0.0069479686
were O 0 0.001699264
randomly O 0 0.0007823802
allocated O 0 0.0009759068
to O 0 0.00074157165
either O 0 0.0006506974
receive O 0 0.0007618894
or O 0 0.00045139345
not O 0 0.00041931917
receive O 0 0.0005964871
1 O 0 0.00048946927
1 O 0 0.00053004496
fentanyl B-Chemical 1 0.9989454
, O 0 0.0006590758
while O 0 0.00032908306
a O 0 0.0003996245
third O 0 0.000469362
group O 0 0.00066916004
received O 0 0.0012987419
dexamethasone B-Chemical 0 0.9964359
in O 0 0.0013894193
addition O 0 0.0014803517
to O 0 0.003920192
fentanyl B-Chemical 1 0.9977228
. O 0 0.008120038

RESULTS O 0 0.036875714
: O 0 0.005364815
Omission O 0 0.019052994
of O 0 0.002912458
fentanyl B-Chemical 1 0.9985337
did O 0 0.0013739138
not O 0 0.00064337795
reduce O 0 0.00045839045
the O 0 0.00043695647
overall O 0 0.00054509245
incidence O 0 0.0031753469
of O 0 0.0008566333
postoperative B-Disease 0 0.42707962
nausea I-Disease 2 0.9999088
and I-Disease 0 0.0051459055
vomiting I-Disease 0 0.999778
, O 0 0.0012338832
but O 0 0.00032107576
did O 0 0.00022138616
reduce O 0 0.00017919159
the O 0 0.00023917505
incidence O 0 0.0039285836
of O 0 0.0010892309
vomiting B-Disease 0 0.9997166
and O 0 0.00087740377
/ O 0 0.0013820732
or O 0 0.00023621463
moderate O 0 0.0033928421
to O 0 0.0003238169
severe O 0 0.29351908
nausea B-Disease 2 0.99987113
prior O 0 0.00025184912
to O 0 0.00023091103
discharge O 0 0.0040284847
from O 0 0.00022261366
20 O 0 0.00026092379
% O 0 0.00021584936
and O 0 0.00019198423
17 O 0 0.00030994668
% O 0 0.00023921838
with O 0 0.00035894857
fentanyl B-Chemical 1 0.9994375
and O 0 0.0012877531
fentanyl B-Chemical 1 0.99979776
- O 0 0.010750182
dexamethasone B-Chemical 0 0.99924135
, O 0 0.0012361953
respectively O 0 0.0016018135
, O 0 0.0005307296
to O 0 0.00038159665
5 O 0 0.0004338775
% O 0 0.0006520104
( O 0 0.00091495365
P O 0 0.012679417
= O 0 0.0016257493
0 O 0 0.0014088724
. O 0 0.0013653354
013 O 0 0.020968184
) O 0 0.0058768434
. O 0 0.005257622

Antiemetic O 0 0.9312764
requirements O 0 0.0032337722
were O 0 0.001715213
reduced O 0 0.0013632013
from O 0 0.0010261665
24 O 0 0.00089687016
% O 0 0.0008321583
and O 0 0.0007034581
31 O 0 0.0009936199
% O 0 0.0006902303
to O 0 0.00056792947
7 O 0 0.0006676659
% O 0 0.0009690472
( O 0 0.001317796
P O 0 0.011966628
= O 0 0.0021527458
0 O 0 0.0018116357
. O 0 0.0017499035
0012 O 0 0.028385896
) O 0 0.0071293833
. O 0 0.006164144

Dexamethasone B-Chemical 1 0.9960444
had O 0 0.0041606966
no O 0 0.0018596353
significant O 0 0.0019184704
effect O 0 0.0014343822
on O 0 0.0007648618
the O 0 0.0010498306
incidence O 0 0.004415847
or O 0 0.0012687467
severity O 0 0.014072733
of O 0 0.0031871814
postoperative B-Disease 0 0.6861031
nausea I-Disease 2 0.9995622
and I-Disease 0 0.036618423
vomiting I-Disease 0 0.998293
. O 0 0.011935817

Combining O 0 0.004955062
the O 0 0.002165895
two O 0 0.0016075119
fentanyl B-Chemical 1 0.9973169
groups O 0 0.001559466
revealed O 0 0.00082849065
further O 0 0.00066777255
significant O 0 0.0006201004
benefits O 0 0.0006160746
from O 0 0.0003477358
the O 0 0.0003260669
avoidance O 0 0.0017919732
of O 0 0.0007521509
opioids O 0 0.99727255
, O 0 0.00087410276
reducing O 0 0.0007919385
postoperative B-Disease 0 0.38889834
nausea I-Disease 2 0.99991083
and I-Disease 0 0.0030692795
vomiting I-Disease 0 0.9997589
and O 0 0.0019177273
nausea B-Disease 2 0.99987066
prior O 0 0.0002719951
to O 0 0.00024309398
discharge O 0 0.004084955
from O 0 0.00023390778
35 O 0 0.00028131332
% O 0 0.00022189612
and O 0 0.00019361981
33 O 0 0.00034106296
% O 0 0.00021522482
to O 0 0.00016648967
22 O 0 0.00030614994
% O 0 0.00023557158
and O 0 0.00022534133
19 O 0 0.00043765886
% O 0 0.00032988435
( O 0 0.0003967047
P O 0 0.010592625
= O 0 0.00045424447
0 O 0 0.000274728
. O 0 0.00016263741
049 O 0 0.07442789
and O 0 0.00034174073
P O 0 0.02177931
= O 0 0.00050021854
0 O 0 0.00029127367
. O 0 0.00016845025
035 O 0 0.016387876
) O 0 0.00048261855
, O 0 0.00034136235
respectively O 0 0.0006380809
, O 0 0.00035692434
while O 0 0.0003501938
nausea B-Disease 2 0.99978334
in O 0 0.0002733099
the O 0 0.0001953535
first O 0 0.00016202078
24 O 0 0.00019277466
h O 0 0.00019835019
was O 0 0.00018982851
decreased O 0 0.00042634114
from O 0 0.00028217552
42 O 0 0.0005058033
% O 0 0.00036447847
to O 0 0.00032361844
27 O 0 0.0008180107
% O 0 0.00071423076
( O 0 0.0009909855
P O 0 0.013197448
= O 0 0.0017197486
0 O 0 0.0014826426
. O 0 0.0014586673
034 O 0 0.07804725
) O 0 0.0061737616
. O 0 0.005359965

Pain B-Disease 2 0.93013555
severity O 0 0.029819166
and O 0 0.003917558
analgesic O 0 0.9189452
requirements O 0 0.0026152732
were O 0 0.0016839787
unaffected O 0 0.0018352118
by O 0 0.0020132402
the O 0 0.0024026793
omission O 0 0.009702061
of O 0 0.009937981
fentanyl B-Chemical 1 0.9973489
. O 0 0.013505987

Fentanyl B-Chemical 0 0.99751914
did O 0 0.0032568767
reduce O 0 0.0015967458
minor O 0 0.0024613452
intraoperative O 0 0.012554327
movement O 0 0.0029652582
but O 0 0.0008493241
had O 0 0.00074987934
no O 0 0.0007055464
sevoflurane B-Chemical 1 0.9978666
- O 0 0.0020745008
sparing O 0 0.04367401
effect O 0 0.0009121403
and O 0 0.00085542694
increased O 0 0.002798206
respiratory B-Disease 0 0.83222926
depression I-Disease 0 0.99718624
, O 0 0.022755576
hypotension B-Disease 2 0.99935955
and O 0 0.020429036
bradycardia B-Disease 0 0.9974643
. O 0 0.0084645515

CONCLUSION O 0 0.84332734
: O 0 0.005426285
As O 0 0.0017272003
fentanyl B-Chemical 1 0.997556
exacerbated O 0 0.083759435
postoperative B-Disease 0 0.58388114
nausea I-Disease 2 0.9998203
and I-Disease 0 0.0048009986
vomiting I-Disease 0 0.99949515
without O 0 0.00088983454
an O 0 0.00064921944
improvement O 0 0.00074189494
in O 0 0.00036978433
postoperative B-Disease 0 0.5034157
pain I-Disease 0 0.99589264
and O 0 0.0005248309
also O 0 0.0003773653
had O 0 0.0004022921
adverse O 0 0.6430341
cardiorespiratory O 0 0.7466091
effects O 0 0.002137731
, O 0 0.0005028141
it O 0 0.00032560682
appears O 0 0.0002575655
to O 0 0.00022954281
be O 0 0.00027623767
an O 0 0.00036512763
unnecessary O 0 0.00091908197
and O 0 0.00049041637
possibly O 0 0.0013986736
detrimental O 0 0.002804864
supplement O 0 0.019289581
to O 0 0.0013375919
sevoflurane B-Chemical 1 0.99542207
in O 0 0.0018967458
day O 0 0.0028903505
surgery O 0 0.012994216
. O 0 0.0053743008

Valvular B-Disease 0 0.75149673
heart I-Disease 0 0.5360901
disease I-Disease 0 0.710641
in O 0 0.0025438862
patients O 0 0.004908754
with O 0 0.0035595633
Parkinson B-Disease 0 0.99731857
' I-Disease 0 0.0030744136
s I-Disease 0 0.003223094
disease I-Disease 0 0.40977207
treated O 0 0.007811638
with O 0 0.012356288
pergolide B-Chemical 1 0.9988757
. O 0 0.013589019

Course O 0 0.048044454
following O 0 0.021046929
treatment O 0 0.03331982
modifications O 0 0.04645651
. O 0 0.03185477

Valvular B-Disease 0 0.7844721
heart I-Disease 0 0.5140069
abnormalities I-Disease 0 0.19501862
have O 0 0.0020082071
been O 0 0.0015456643
reported O 0 0.0013719668
in O 0 0.0007618005
patients O 0 0.0020841535
with O 0 0.0016590726
Parkinson B-Disease 0 0.998541
' I-Disease 0 0.0014993907
s I-Disease 0 0.0016897458
disease I-Disease 0 0.61561084
( O 0 0.0040928307
PD B-Disease 0 0.9901334
) O 0 0.003940736
treated O 0 0.00463203
with O 0 0.008611403
pergolide B-Chemical 1 0.99901843
. O 0 0.010855588

However O 0 0.0042550517
, O 0 0.002910625
the O 0 0.0015759208
incidence O 0 0.0040701535
and O 0 0.0012765055
severity O 0 0.006760181
of O 0 0.0009464804
these O 0 0.001002809
abnormalities O 0 0.06377038
vary O 0 0.0007521362
from O 0 0.00037663232
study O 0 0.00050877884
to O 0 0.00027993968
study O 0 0.00047542655
and O 0 0.00032263144
their O 0 0.00033988923
course O 0 0.0005741144
after O 0 0.00033022542
drug O 0 0.26187766
withdrawal O 0 0.63583237
has O 0 0.0010447382
not O 0 0.0011084778
been O 0 0.0017532887
systematically O 0 0.0020603077
assessed O 0 0.0031127231
. O 0 0.0051008104

OBJECTIVES O 0 0.023351403
: O 0 0.0035161413
To O 0 0.0011837306
estimate O 0 0.00080089096
the O 0 0.00080866134
frequency O 0 0.0009314673
and O 0 0.00086942205
severity O 0 0.0071793897
of O 0 0.0011673816
valvular B-Disease 0 0.9564896
heart I-Disease 0 0.8046401
abnormality I-Disease 0 0.2538783
and O 0 0.0005350915
its O 0 0.0007586642
possible O 0 0.00048117843
reversibility O 0 0.03776048
after O 0 0.00035539898
drug O 0 0.34977022
withdrawal O 0 0.67992026
in O 0 0.00073697924
a O 0 0.0010749573
case O 0 0.001396302
- O 0 0.0024643687
control O 0 0.002028029
study O 0 0.005155219
. O 0 0.0051667797

METHODS O 0 0.006899586
: O 0 0.0037077141
All O 0 0.002441867
PD B-Disease 0 0.8944316
patients O 0 0.003341733
in O 0 0.0009073461
the O 0 0.00084141066
Amiens O 0 0.022931727
area O 0 0.0011016498
treated O 0 0.0012039623
with O 0 0.0011969204
pergolide B-Chemical 1 0.9997501
were O 0 0.0008868275
invited O 0 0.00075938326
to O 0 0.00049763144
attend O 0 0.0008857394
a O 0 0.0008629436
cardiologic O 0 0.016395742
assessment O 0 0.0016272934
including O 0 0.002372054
transthoracic O 0 0.26725948
echocardiography O 0 0.5468551
. O 0 0.007418072

Thirty O 0 0.031749144
PD B-Disease 0 0.9476066
patients O 0 0.017877745
participated O 0 0.01833554
in O 0 0.007902965
the O 0 0.009408592
study O 0 0.01658182
. O 0 0.01602753

A O 0 0.012186014
second O 0 0.0026289308
echocardiography O 0 0.057757765
was O 0 0.0015722314
performed O 0 0.0011236196
( O 0 0.0011591746
median O 0 0.0006609818
interval O 0 0.00095989316
: O 0 0.0008396263
13 O 0 0.0005950377
months O 0 0.00055256207
) O 0 0.00077915966
after O 0 0.0004878671
pergolide B-Chemical 1 0.99971396
withdrawal O 0 0.9010178
( O 0 0.0018816967
n O 0 0.0011120299
= O 0 0.001867016
10 O 0 0.0016351911
patients O 0 0.0046259053
) O 0 0.00596894
. O 0 0.0051731737

Controls O 0 0.019519987
were O 0 0.0032018973
age O 0 0.004370705
- O 0 0.0028614616
and O 0 0.0015854941
sex O 0 0.006710461
- O 0 0.0018177641
matched O 0 0.0009714151
non O 0 0.0024695084
- O 0 0.0032053478
PD B-Disease 0 0.97992057
patients O 0 0.004224547
referred O 0 0.0016307413
to O 0 0.0014622853
the O 0 0.0021298686
cardiology O 0 0.015449499
department O 0 0.011623666
. O 0 0.0076890117

RESULTS O 0 0.029950429
: O 0 0.0044533703
Compared O 0 0.0017937945
to O 0 0.0013335807
controls O 0 0.0018133726
, O 0 0.0020046742
aortic B-Disease 0 0.92157966
regurgitation I-Disease 0 0.9989072
( O 0 0.0035153762
OR O 0 0.092890024
: O 0 0.0009881777
3 O 0 0.00038329596
. O 0 0.00024025473
1 O 0 0.00034269635
; O 0 0.00048562032
95 O 0 0.00065677083
% O 0 0.0003744528
IC O 0 0.03734958
: O 0 0.0005721374
1 O 0 0.00031044622
. O 0 0.00017165107
1 O 0 0.0002709662
- O 0 0.0003700252
8 O 0 0.00020803892
. O 0 0.00012789716
8 O 0 0.000204511
) O 0 0.00033689593
and O 0 0.00032257513
mitral B-Disease 2 0.96930736
regurgitation I-Disease 2 0.9992867
( O 0 0.001589054
OR O 0 0.079354495
: O 0 0.00055608735
10 O 0 0.000282242
. O 0 0.00014655545
7 O 0 0.00020137765
; O 0 0.00035662315
95 O 0 0.0005413794
% O 0 0.00031325844
IC O 0 0.032796722
: O 0 0.0005099791
2 O 0 0.00028731558
. O 0 0.0001722518
1 O 0 0.00028611007
- O 0 0.0004147741
53 O 0 0.00050254626
) O 0 0.000411549
were O 0 0.00025411643
more O 0 0.00041649904
frequent O 0 0.0014153759
in O 0 0.00077222096
PD B-Disease 0 0.9872847
patients O 0 0.0104581155
( O 0 0.0032208185
tricuspid O 0 0.872731
: O 0 0.007468091
NS O 0 0.74119204
) O 0 0.008415157
. O 0 0.0060625914

The O 0 0.0027376814
number O 0 0.0018389672
of O 0 0.0019375215
affected O 0 0.0015061707
valves O 0 0.03298846
( O 0 0.001653584
n O 0 0.0007614507
= O 0 0.00093355874
2 O 0 0.0004597654
. O 0 0.00026732503
4 O 0 0.0003276371
+ O 0 0.0004883815
/ O 0 0.00086176075
- O 0 0.00054540654
0 O 0 0.00030579756
. O 0 0.00014510943
7 O 0 0.0001858256
) O 0 0.00028491943
and O 0 0.00017781513
the O 0 0.00015910264
sum O 0 0.00017770361
of O 0 0.00046519155
regurgitation O 0 0.9965473
grades O 0 0.08419394
( O 0 0.00065742835
n O 0 0.00027279937
= O 0 0.00039790134
2 O 0 0.00021456998
. O 0 0.00013448797
8 O 0 0.00022142737
+ O 0 0.0003239753
/ O 0 0.000658694
- O 0 0.0004474822
1 O 0 0.00024238299
. O 0 0.00014856838
09 O 0 0.0029665807
) O 0 0.0003656278
were O 0 0.00019927602
higher O 0 0.00025502272
( O 0 0.00038721456
p O 0 0.0004189021
= O 0 0.00042301082
0 O 0 0.00027720595
. O 0 0.0001657049
008 O 0 0.0015998984
and O 0 0.00029311478
p O 0 0.00049945054
= O 0 0.0005394858
0 O 0 0.00039421508
. O 0 0.00027734076
006 O 0 0.013884002
, O 0 0.000722815
respectively O 0 0.0013693874
) O 0 0.0012782818
in O 0 0.0009793885
the O 0 0.0022950647
pergolide B-Chemical 1 0.99908197
group O 0 0.009655086
. O 0 0.0067456733

Severity O 0 0.021507861
of O 0 0.0061304085
regurgitation O 0 0.98202455
was O 0 0.0034827916
not O 0 0.0023351759
correlated O 0 0.0023318923
with O 0 0.0056076106
pergolide B-Chemical 1 0.9989858
cumulative O 0 0.12129892
dose O 0 0.29010838
. O 0 0.012040636

A O 0 0.014579912
restrictive O 0 0.005210221
pattern O 0 0.0020421806
of O 0 0.002450397
valvular B-Disease 0 0.9827963
regurgitation I-Disease 0 0.9987569
, O 0 0.002193258
suggestive O 0 0.0018789362
of O 0 0.00068673305
the O 0 0.0004330148
role O 0 0.00033065007
of O 0 0.0010091778
pergolide B-Chemical 1 0.99988437
, O 0 0.0012662828
was O 0 0.0003892636
observed O 0 0.00024242092
in O 0 0.00026016886
12 O 0 0.00025414454
/ O 0 0.00057885813
30 O 0 0.00027948528
( O 0 0.00037659984
40 O 0 0.0003772894
% O 0 0.00041181
) O 0 0.00058263424
patients O 0 0.00095173233
including O 0 0.0006773581
two O 0 0.000854837
with O 0 0.0025300293
heart B-Disease 0 0.6281548
failure I-Disease 0 0.773592
. O 0 0.007596413

Pergolide B-Chemical 0 0.9978339
was O 0 0.003711967
discontinued O 0 0.024174478
in O 0 0.0011540805
10 O 0 0.0009146698
patients O 0 0.001415266
with O 0 0.0008906492
valvular B-Disease 0 0.8869527
heart I-Disease 0 0.7907587
disease I-Disease 0 0.92531604
, O 0 0.0009079506
resulting O 0 0.0004491576
in O 0 0.00029525475
a O 0 0.00036535447
lower O 0 0.00046447638
regurgitation O 0 0.9962451
grade O 0 0.40305224
( O 0 0.00079612236
p O 0 0.0005441536
= O 0 0.00044977435
0 O 0 0.00026647304
. O 0 0.00014954194
01 O 0 0.0012475413
) O 0 0.00029176645
at O 0 0.00010866289
the O 0 0.00014276199
second O 0 0.00018188261
transthoracic O 0 0.020382203
echocardiography O 0 0.08977119
and O 0 0.00031086258
the O 0 0.00022666808
two O 0 0.00020776855
patients O 0 0.0008886902
with O 0 0.00062234735
heart B-Disease 0 0.36415744
failure I-Disease 0 0.35870042
returned O 0 0.0008170413
to O 0 0.00067148893
nearly O 0 0.0010733196
normal O 0 0.0029838458
clinical O 0 0.013413859
examination O 0 0.008314922
. O 0 0.005694945

This O 0 0.0040579857
study O 0 0.0025089872
supports O 0 0.0013651132
the O 0 0.0009652232
high O 0 0.0010397527
frequency O 0 0.0008819998
of O 0 0.0009553622
restrictive O 0 0.00418818
valve B-Disease 0 0.7920729
regurgitation I-Disease 0 0.99920255
in O 0 0.0013374493
PD B-Disease 0 0.9952866
patients O 0 0.0050248154
treated O 0 0.0011766606
with O 0 0.0009054435
pergolide B-Chemical 1 0.9998869
and O 0 0.0005948307
reveals O 0 0.00043306718
that O 0 0.00022039171
a O 0 0.0002881253
significant O 0 0.00034866424
improvement O 0 0.00046333857
is O 0 0.00025099047
usual O 0 0.00037681835
when O 0 0.00020281883
the O 0 0.00031232505
treatment O 0 0.0010400618
is O 0 0.00056638505
converted O 0 0.0009475744
to O 0 0.0008154612
non O 0 0.0040868223
- O 0 0.012464974
ergot O 0 0.9990778
dopamine B-Chemical 1 0.99899465
agonists O 0 0.9872268
. O 0 0.010103536

Adriamycin B-Chemical 1 0.99778
- O 0 0.012165276
induced O 0 0.005525082
autophagic O 0 0.63532406
cardiomyocyte O 0 0.9865007
death B-Disease 2 0.9956781
plays O 0 0.002397853
a O 0 0.0014417821
pathogenic O 0 0.0034905027
role O 0 0.0006913662
in O 0 0.0008091443
a O 0 0.0012489347
rat O 0 0.0054366733
model O 0 0.0023008173
of O 0 0.003934433
heart B-Disease 0 0.7407991
failure I-Disease 0 0.8259424
. O 0 0.00923338

BACKGROUND O 0 0.6832476
: O 0 0.0049698087
The O 0 0.0018317106
mechanisms O 0 0.0025735043
underlying O 0 0.0037914068
heart B-Disease 0 0.46442822
failure I-Disease 0 0.62531805
induced O 0 0.0029977004
by O 0 0.0023239097
adriamycin B-Chemical 1 0.99882025
are O 0 0.0021546297
very O 0 0.002196813
complicated O 0 0.010519135
and O 0 0.0028515144
still O 0 0.0034472928
unclear O 0 0.006728229
. O 0 0.0073165107

The O 0 0.002519566
aim O 0 0.0018843038
of O 0 0.001422619
this O 0 0.0009982531
study O 0 0.0012027245
was O 0 0.0006223826
to O 0 0.0004509715
investigate O 0 0.0003061313
whether O 0 0.0002603788
autophagy O 0 0.20884085
was O 0 0.00047421397
involved O 0 0.0003625123
in O 0 0.00029644312
the O 0 0.00033677713
progression O 0 0.13945393
of O 0 0.0008524131
heart B-Disease 0 0.67553395
failure I-Disease 0 0.70935607
induced O 0 0.0014789862
by O 0 0.0009486823
adriamycin B-Chemical 1 0.99962413
, O 0 0.0009305684
so O 0 0.0003006089
that O 0 0.00022120979
we O 0 0.00015674303
can O 0 0.0002625771
develop O 0 0.0005181261
a O 0 0.0005219459
novel O 0 0.0010290567
treatment O 0 0.0017104979
strategy O 0 0.001664512
for O 0 0.0019359647
heart B-Disease 0 0.67830616
failure I-Disease 0 0.80085355
. O 0 0.007647646

METHODS O 0 0.007835022
: O 0 0.0044754916
3 B-Chemical 0 0.0022425074
- I-Chemical 0 0.0031767345
methyladenine I-Chemical 0 0.34355208
( O 0 0.0038233425
3MA B-Chemical 1 0.9965802
) O 0 0.0033476695
, O 0 0.0010327357
a O 0 0.0006430905
specific O 0 0.0006004574
inhibitor O 0 0.0577345
on O 0 0.00041816558
autophagy O 0 0.39648595
was O 0 0.00056409376
used O 0 0.0004044771
in O 0 0.00038273295
a O 0 0.00065609795
heart B-Disease 0 0.27287623
failure I-Disease 0 0.37843743
model O 0 0.0013809759
of O 0 0.0016447484
rats O 0 0.008955426
induced O 0 0.0038231632
by O 0 0.0065031513
adriamycin B-Chemical 1 0.9977022
. O 0 0.010598232

Neonatal O 0 0.10850697
cardiomyocytes O 0 0.11097957
were O 0 0.0022163822
isolated O 0 0.0016771418
from O 0 0.0014038701
Sprague O 0 0.25176096
- O 0 0.002154455
Dawley O 0 0.17111056
rat O 0 0.002900379
hearts O 0 0.0026721873
and O 0 0.0003796798
randomly O 0 0.0001763894
divided O 0 0.00024132228
into O 0 0.00020170858
controls O 0 0.0005218663
, O 0 0.00052971655
an O 0 0.0008384119
adriamycin B-Chemical 1 0.99949515
- O 0 0.0025129598
treated O 0 0.0011944432
group O 0 0.0007349832
, O 0 0.0006934177
and O 0 0.00063380337
a O 0 0.0012124879
3MA B-Chemical 1 0.99668103
plus O 0 0.0052779233
adriamycin B-Chemical 1 0.9993075
- O 0 0.015423581
treated O 0 0.007464613
group O 0 0.0065508606
. O 0 0.0061009643

We O 0 0.0030181073
then O 0 0.0018615295
examined O 0 0.0012582935
the O 0 0.001253935
morphology O 0 0.0030403982
, O 0 0.0013146432
expression O 0 0.0012734509
of O 0 0.0012193344
beclin O 0 0.9259691
1 O 0 0.00091348536
gene O 0 0.0009915876
, O 0 0.0009932172
mitochondrial O 0 0.43896967
permeability O 0 0.9370189
transition O 0 0.0827906
( O 0 0.00553078
MPT O 0 0.99930084
) O 0 0.0037506304
, O 0 0.0011427962
and O 0 0.0013535543
Na O 1 0.9991136
+ O 0 0.0036261794
- O 0 0.005265084
K B-Chemical 1 0.9857254
+ O 0 0.0032467025
ATPase O 0 0.23677357
activity O 0 0.0030223327
in O 0 0.0027809488
vivo O 0 0.008037623
. O 0 0.0062537016

We O 0 0.0034086406
also O 0 0.00243605
assessed O 0 0.0016604521
cell O 0 0.0060338457
viability O 0 0.053706672
, O 0 0.0021628898
mitochondrial O 0 0.20636266
membrane O 0 0.011730733
potential O 0 0.001424555
changes O 0 0.001312102
and O 0 0.00089822424
counted O 0 0.00080370746
autophagic O 0 0.18276909
vacuoles O 0 0.008767822
in O 0 0.0022274228
cultured O 0 0.0066304
cardiomyocytes O 0 0.31657174
. O 0 0.007117215

In O 0 0.0028204657
addition O 0 0.0015893135
, O 0 0.001642237
we O 0 0.0006046215
analyzed O 0 0.00069500256
the O 0 0.0006754864
expression O 0 0.001099231
of O 0 0.0010478102
autophagy O 0 0.503313
associated O 0 0.0015320925
gene O 0 0.001617643
, O 0 0.001292781
beclin O 0 0.8915865
1 O 0 0.0007078176
using O 0 0.00048067325
RT O 0 0.018182315
- O 0 0.0010880423
PCR O 0 0.004862766
and O 0 0.00081954116
Western O 0 0.007049822
blotting O 0 0.012633665
in O 0 0.0015333389
an O 0 0.0026013325
animal O 0 0.005016362
model O 0 0.0065077986
. O 0 0.006435233

RESULTS O 0 0.064206034
: O 0 0.010819367
3MA B-Chemical 1 0.97857565
significantly O 0 0.005114535
improved O 0 0.0065393667
cardiac O 0 0.2703412
function O 0 0.0049008923
and O 0 0.0043165525
reduced O 0 0.0073507233
mitochondrial O 0 0.9573941
injury O 0 0.9896437
. O 0 0.015938234

Furthermore O 0 0.0065511833
, O 0 0.00525366
adriamycin B-Chemical 1 0.99720347
induced O 0 0.0035933636
the O 0 0.0013719896
formation O 0 0.0032617098
of O 0 0.001612804
autophagic O 0 0.5317554
vacuoles O 0 0.025605999
, O 0 0.0011577616
and O 0 0.00083080505
3MA B-Chemical 1 0.9972838
strongly O 0 0.0013291403
downregulated O 0 0.0010033164
the O 0 0.0003567162
expression O 0 0.0007605213
of O 0 0.00082064455
beclin O 0 0.9535116
1 O 0 0.00071318296
in O 0 0.00051679
adriamycin B-Chemical 1 0.9995567
- O 0 0.002336315
induced O 0 0.0009085598
failing O 0 0.028777814
heart O 0 0.4500225
and O 0 0.0008095481
inhibited O 0 0.0017490833
the O 0 0.00094194943
formation O 0 0.004265303
of O 0 0.0034450558
autophagic O 0 0.5955061
vacuoles O 0 0.0620048
. O 0 0.006924029

CONCLUSION O 0 0.9311487
: O 0 0.011386233
Autophagic O 0 0.94316226
cardiomyocyte O 0 0.97407067
death B-Disease 2 0.99336445
plays O 0 0.0024390647
an O 0 0.001443463
important O 0 0.00072259805
role O 0 0.0004959291
in O 0 0.0005323196
the O 0 0.0006168284
pathogenesis O 0 0.007967024
of O 0 0.0015122708
heart B-Disease 0 0.6514253
failure I-Disease 0 0.65870446
in O 0 0.0015973053
rats O 0 0.009025656
induced O 0 0.003944466
by O 0 0.006608705
adriamycin B-Chemical 1 0.9975752
. O 0 0.010885562

Mitochondrial O 0 0.9241188
injury O 0 0.80463564
may O 0 0.003053215
be O 0 0.0018166319
involved O 0 0.0011690592
in O 0 0.0008835719
the O 0 0.0009205562
progression O 0 0.10839517
of O 0 0.0017225376
heart B-Disease 0 0.64553136
failure I-Disease 0 0.6907657
caused O 0 0.0024488296
by O 0 0.0026304752
adriamycin B-Chemical 1 0.99879104
via O 0 0.0031148738
the O 0 0.003615273
autophagy O 0 0.70187205
pathway O 0 0.014937098
. O 0 0.008107059

mToR O 0 0.1761506
inhibitors O 0 0.21991703
- O 0 0.009674144
induced O 0 0.008690397
proteinuria B-Disease 2 0.99899465
: O 0 0.0075898194
mechanisms O 0 0.0050418847
, O 0 0.0034658485
significance O 0 0.0044063106
, O 0 0.00450023
and O 0 0.0050505656
management O 0 0.014722719
. O 0 0.009833337

Massive O 0 0.25619215
urinary O 0 0.8306213
protein O 0 0.08784475
excretion O 0 0.9910521
has O 0 0.0020458526
been O 0 0.0013001764
observed O 0 0.00055123854
after O 0 0.00037742592
conversion O 0 0.0019212901
from O 0 0.0005918338
calcineurin O 0 0.8853014
inhibitors O 0 0.11065084
to O 0 0.00049059524
mammalian O 0 0.0010122388
target O 0 0.00041362311
of O 0 0.00082350965
rapamycin B-Chemical 1 0.9830163
( O 0 0.0024754403
mToR O 0 0.16324763
) O 0 0.001432613
inhibitors O 0 0.068477504
, O 0 0.0008372311
especially O 0 0.0014287069
sirolimus B-Chemical 1 0.99920374
, O 0 0.0013353626
in O 0 0.00075945596
renal O 0 0.9848326
transplant O 0 0.81827
recipients O 0 0.020679384
with O 0 0.00481639
chronic B-Disease 0 0.99494135
allograft I-Disease 0 0.99677366
nephropathy I-Disease 2 0.9996741
. O 0 0.021665609

Because O 0 0.005232084
proteinuria B-Disease 2 0.997733
is O 0 0.0026278908
a O 0 0.0014976684
major O 0 0.0012743627
predictive O 0 0.001646537
factor O 0 0.0026324927
of O 0 0.0009174459
poor O 0 0.002655915
transplantation O 0 0.12420393
outcome O 0 0.0020251167
, O 0 0.00063531107
many O 0 0.00046055566
studies O 0 0.00061064464
focused O 0 0.00053495995
on O 0 0.00032378818
this O 0 0.0006777695
adverse O 0 0.41251832
event O 0 0.004093233
during O 0 0.000986665
the O 0 0.0015970956
past O 0 0.004619753
years O 0 0.008061504
. O 0 0.005558376

Whether O 0 0.0077251107
proteinuria B-Disease 2 0.99802667
was O 0 0.0028257025
due O 0 0.0011610743
to O 0 0.0012163763
sirolimus B-Chemical 1 0.9974807
or O 0 0.00086902286
only O 0 0.00061113486
a O 0 0.00053415954
consequence O 0 0.00036608108
of O 0 0.0007144663
calcineurin O 0 0.9453425
inhibitors O 0 0.29132116
withdrawal O 0 0.8250924
remained O 0 0.0009616617
unsolved O 0 0.0020385175
until O 0 0.0001912607
high O 0 0.0004430666
range O 0 0.0012218137
proteinuria B-Disease 2 0.99977905
has O 0 0.00063656236
been O 0 0.00048108623
observed O 0 0.00022555521
during O 0 0.0002747115
sirolimus B-Chemical 1 0.9990133
therapy O 0 0.041758955
in O 0 0.00048239034
islet O 0 0.4786905
transplantation O 0 0.19034477
and O 0 0.0006436068
in O 0 0.0005556227
patients O 0 0.0020984395
who O 0 0.0027197925
received O 0 0.0035413823
sirolimus B-Chemical 1 0.9980217
de O 0 0.32230172
novo O 0 0.1611922
. O 0 0.0077618365

Podocyte O 0 0.949151
injury O 0 0.8313066
and O 0 0.0037118753
focal O 0 0.15438275
segmental O 0 0.13214408
glomerulosclerosis B-Disease 2 0.9996861
have O 0 0.002984528
been O 0 0.0013281918
related O 0 0.0005609345
to O 0 0.00062661356
mToR O 0 0.041633967
inhibition O 0 0.0029476518
in O 0 0.00044610864
some O 0 0.00060293364
patients O 0 0.0018668585
, O 0 0.0007370601
but O 0 0.00049885054
the O 0 0.00054597465
pathways O 0 0.0017353772
underlying O 0 0.0022145135
these O 0 0.0023724965
lesions O 0 0.3031739
remain O 0 0.005014903
hypothetic O 0 0.115953036
. O 0 0.007298869

We O 0 0.0032764454
discuss O 0 0.0022757405
herein O 0 0.0025696761
the O 0 0.0015001469
possible O 0 0.0015532493
mechanisms O 0 0.0020400702
and O 0 0.0012698971
the O 0 0.0011043629
significance O 0 0.0022219096
of O 0 0.0027353882
mToR O 0 0.24864997
blockade O 0 0.66264504
- O 0 0.017633013
induced O 0 0.031563103
proteinuria B-Disease 2 0.9988084
. O 0 0.014969238

Neuropsychiatric O 0 0.76161605
side O 0 0.024077129
effects O 0 0.0073654596
after O 0 0.0032448098
the O 0 0.0044092904
use O 0 0.0071016513
of O 0 0.013697245
mefloquine B-Chemical 1 0.99498785
. O 0 0.019281391

This O 0 0.005484729
study O 0 0.0040690284
describes O 0 0.004546664
neuropsychiatric O 0 0.98497456
side O 0 0.045268882
effects O 0 0.0037663078
in O 0 0.0015696514
patients O 0 0.0035443385
after O 0 0.0013989919
treatment O 0 0.0058357767
with O 0 0.008826669
mefloquine B-Chemical 1 0.9969608
. O 0 0.011667453

Reactions O 0 0.014628903
consisted O 0 0.0029912998
mainly O 0 0.0036169803
of O 0 0.003972532
seizures B-Disease 2 0.99940956
, O 0 0.009401175
acute O 0 0.989949
psychoses B-Disease 0 0.9993352
, O 0 0.017333249
anxiety B-Disease 0 0.99853337
neurosis I-Disease 0 0.9989699
, O 0 0.0019032639
and O 0 0.0009320039
major O 0 0.0014192084
disturbances B-Disease 0 0.41006544
of I-Disease 0 0.0026727337
sleep I-Disease 0 0.6303971
- I-Disease 0 0.00525225
wake I-Disease 0 0.008666107
rhythm I-Disease 0 0.093579955
. O 0 0.00648857

Side O 0 0.36416516
effects O 0 0.0049877353
occurred O 0 0.0022582093
after O 0 0.0009465105
both O 0 0.0010755002
therapeutic O 0 0.0057198694
and O 0 0.0012842285
prophylactic O 0 0.023656748
intake O 0 0.61461115
and O 0 0.0013447842
were O 0 0.0011394575
graded O 0 0.0046837516
from O 0 0.0017373395
moderate O 0 0.00912713
to O 0 0.003984777
severe O 0 0.27425355
. O 0 0.008076533

In O 0 0.003023241
a O 0 0.0024815
risk O 0 0.0071569784
analysis O 0 0.00213634
of O 0 0.0020414237
neuropsychiatric O 0 0.9946897
side O 0 0.07749955
effects O 0 0.0032474683
in O 0 0.0007195295
Germany O 0 0.015405122
, O 0 0.0006084655
it O 0 0.0003995849
is O 0 0.00028444635
estimated O 0 0.0002534817
that O 0 0.0002241388
one O 0 0.0002313019
of O 0 0.00045866036
8 O 0 0.00045022074
, O 0 0.00056763913
000 O 0 0.00087509246
mefloquine B-Chemical 1 0.9978225
users O 0 0.008011759
suffers O 0 0.014270385
from O 0 0.0019905458
such O 0 0.0031581603
reactions O 0 0.03376487
. O 0 0.0064423312

The O 0 0.0027967321
incidence O 0 0.0046272166
calculation O 0 0.0015777723
revealed O 0 0.0011905527
that O 0 0.00071482663
one O 0 0.00052658265
of O 0 0.0007621163
215 O 0 0.004886866
therapeutic O 0 0.010869103
users O 0 0.0036379634
had O 0 0.0005151871
reactions O 0 0.005269033
, O 0 0.0004615801
compared O 0 0.00015709751
with O 0 0.0002622863
one O 0 0.0001771987
of O 0 0.0003203456
13 O 0 0.0003583784
, O 0 0.0002802105
000 O 0 0.00024610985
in O 0 0.00014809905
the O 0 0.00018488572
prophylaxis O 0 0.009173175
group O 0 0.00041288862
, O 0 0.00034856354
making O 0 0.00037010983
the O 0 0.00026246745
risk O 0 0.010405152
of O 0 0.0008457933
neuropsychiatric O 0 0.9966924
reactions O 0 0.02145115
after O 0 0.00036093945
mefloquine B-Chemical 1 0.99909246
treatment O 0 0.0018366388
60 O 0 0.0005726524
times O 0 0.00034667077
higher O 0 0.00067055656
than O 0 0.0007559609
after O 0 0.0013898343
prophylaxis O 0 0.054612447
. O 0 0.0054600155

Therefore O 0 0.0039409115
, O 0 0.0032099003
certain O 0 0.0026331788
limitations O 0 0.0021011883
for O 0 0.0015260194
malaria B-Disease 0 0.59094405
prophylaxis O 0 0.1062097
and O 0 0.0021862607
treatment O 0 0.0050024292
with O 0 0.0050062854
mefloquine B-Chemical 1 0.9979468
are O 0 0.0066815913
recommended O 0 0.008835997
. O 0 0.007672007

Prenatal O 0 0.44166481
protein O 0 0.009894433
deprivation O 0 0.18458006
alters O 0 0.0056266915
dopamine B-Chemical 1 0.9982658
- O 0 0.006270856
mediated O 0 0.0019837804
behaviors O 0 0.032860707
and O 0 0.0027505842
dopaminergic O 0 0.97005725
and O 0 0.0046797767
glutamatergic O 0 0.9891923
receptor O 0 0.42019123
binding O 0 0.010476202
. O 0 0.008445179

Epidemiological O 0 0.035785887
evidence O 0 0.0035488342
indicates O 0 0.001966232
that O 0 0.0016873484
prenatal O 0 0.013503993
nutritional O 0 0.18806121
deprivation O 0 0.15773365
may O 0 0.0020498869
increase O 0 0.001897609
the O 0 0.002535637
risk O 0 0.06139284
of O 0 0.013255917
schizophrenia B-Disease 2 0.9956215
. O 0 0.012486659

The O 0 0.0026128155
goal O 0 0.0025641262
of O 0 0.0016124771
these O 0 0.001461039
studies O 0 0.0014461908
was O 0 0.0007390509
to O 0 0.0005309512
use O 0 0.0005879805
an O 0 0.00053367636
animal O 0 0.0006998192
model O 0 0.0004849889
to O 0 0.00027272815
examine O 0 0.00016927205
the O 0 0.00025244895
effects O 0 0.0006023323
of O 0 0.0005067775
prenatal O 0 0.027362106
protein O 0 0.002368768
deprivation O 0 0.11710121
on O 0 0.0003549258
behaviors O 0 0.015551581
and O 0 0.00080167636
receptor O 0 0.05607259
binding O 0 0.0012713331
with O 0 0.0015308566
relevance O 0 0.0019256776
to O 0 0.003966307
schizophrenia B-Disease 2 0.9949767
. O 0 0.008074769

We O 0 0.0034092597
report O 0 0.00476346
that O 0 0.0019338193
prenatally O 0 0.39884415
protein O 0 0.004661305
deprived O 0 0.010185822
( O 0 0.0031078013
PD O 0 0.9929565
) O 0 0.0021121157
female O 0 0.0022780716
rats O 0 0.0021354202
showed O 0 0.00045596392
an O 0 0.00062007434
increased O 0 0.0011209112
stereotypic O 0 0.77595526
response O 0 0.0014887593
to O 0 0.0008119518
apomorphine B-Chemical 1 0.999824
and O 0 0.0010560101
an O 0 0.001033145
increased O 0 0.0018903642
locomotor O 0 0.44405803
response O 0 0.0025320395
to O 0 0.0025413951
amphetamine B-Chemical 1 0.99950945
in O 0 0.0057241702
adulthood O 0 0.4061575
. O 0 0.0064063305

These O 0 0.009010848
differences O 0 0.0048420304
were O 0 0.0054713786
not O 0 0.0054111276
observed O 0 0.0057598916
during O 0 0.008825696
puberty O 0 0.7219572
. O 0 0.018343981

No O 0 0.007879583
changes O 0 0.00496075
in O 0 0.0038576347
haloperidol B-Chemical 1 0.9996892
- O 0 0.014374637
induced O 0 0.009239964
catalepsy B-Disease 2 0.9997712
or O 0 0.0031632578
MK B-Chemical 0 0.988191
- I-Chemical 0 0.009801025
801 I-Chemical 0 0.7559274
- O 0 0.002632778
induced O 0 0.0019943595
locomotion O 0 0.102325246
were O 0 0.0018687448
seen O 0 0.002464983
following O 0 0.0051623164
PD O 0 0.98196995
. O 0 0.008388827

In O 0 0.0033176737
addition O 0 0.0021525791
, O 0 0.0035974104
PD O 0 0.97720534
female O 0 0.006288317
rats O 0 0.0044772043
showed O 0 0.0009187362
increased O 0 0.0015946082
( O 0 0.0012770206
3 O 0 0.0006805799
) O 0 0.0017327078
H B-Chemical 1 0.9933027
- O 0 0.0036463074
MK B-Chemical 0 0.9613832
- I-Chemical 0 0.0023946268
801 I-Chemical 0 0.42693567
binding O 0 0.0006470235
in O 0 0.00041727477
the O 0 0.0005780965
striatum O 0 0.52974606
and O 0 0.0009520452
hippocampus O 0 0.37865832
, O 0 0.0011256165
but O 0 0.00082227786
not O 0 0.0010089461
in O 0 0.0015122391
the O 0 0.003145574
cortex O 0 0.33580378
. O 0 0.0059664994

PD O 0 0.97523457
female O 0 0.01047762
rats O 0 0.006938
also O 0 0.0017718634
showed O 0 0.0012762465
increased O 0 0.00205684
( O 0 0.0017270917
3 O 0 0.0009290804
) O 0 0.0022346058
H B-Chemical 1 0.99341196
- O 0 0.008511798
haloperidol B-Chemical 1 0.9998708
binding O 0 0.0018430691
and O 0 0.0012443052
decreased O 0 0.009207695
dopamine B-Chemical 1 0.99891865
transporter O 0 0.6447662
binding O 0 0.004308739
in O 0 0.004550056
striatum O 0 0.7569534
. O 0 0.006737665

No O 0 0.005620684
statistically O 0 0.002459923
significant O 0 0.001880396
changes O 0 0.0016310501
in O 0 0.0008830766
behavior O 0 0.0018057844
or O 0 0.00066247606
receptor O 0 0.045153357
binding O 0 0.0008003234
were O 0 0.00048348922
found O 0 0.00041285888
in O 0 0.0004603037
PD O 0 0.97780085
males O 0 0.00072153425
with O 0 0.0003959555
the O 0 0.00029352814
exception O 0 0.00031603198
of O 0 0.00053216633
increased O 0 0.0013012392
( O 0 0.001037231
3 O 0 0.0006483315
) O 0 0.0019592356
H B-Chemical 1 0.99172455
- O 0 0.0056134583
MK B-Chemical 0 0.9576179
- I-Chemical 0 0.0055860723
801 I-Chemical 0 0.5242707
binding O 0 0.0031042178
in O 0 0.0038214398
cortex O 0 0.38720533
. O 0 0.006361922

This O 0 0.0042857244
animal O 0 0.0033660927
model O 0 0.002148115
may O 0 0.0012662308
be O 0 0.0009252011
useful O 0 0.00082986115
to O 0 0.00047817943
explore O 0 0.00037259646
the O 0 0.00039681027
mechanisms O 0 0.0008265765
by O 0 0.00046634767
which O 0 0.0006334021
prenatal O 0 0.03259871
nutritional B-Disease 0 0.8283719
deficiency I-Disease 0 0.943064
enhances O 0 0.0012003947
risk O 0 0.09576427
for O 0 0.0006507446
schizophrenia B-Disease 2 0.9990907
in O 0 0.00043906874
humans O 0 0.0029567175
and O 0 0.00031000286
may O 0 0.00025041206
also O 0 0.00024867518
have O 0 0.0002438447
implications O 0 0.00041644424
for O 0 0.00025971505
developmental O 0 0.0011964643
processes O 0 0.0012283092
leading O 0 0.001047427
to O 0 0.0005062785
differential O 0 0.001454828
sensitivity O 0 0.0025544912
to O 0 0.0015166751
drugs O 0 0.64563054
of O 0 0.008243728
abuse O 0 0.9867879
. O 0 0.008128606

Adverse O 0 0.2440427
effects O 0 0.008786959
of O 0 0.00758499
topical O 0 0.9735652
papaverine B-Chemical 1 0.9982097
on O 0 0.007753291
auditory O 0 0.41497993
nerve O 0 0.7372805
function O 0 0.01623558
. O 0 0.013031782

BACKGROUND O 0 0.9070078
: O 0 0.014206549
Papaverine B-Chemical 0 0.99818087
hydrochloride I-Chemical 0 0.9976484
is O 0 0.0026244486
a O 0 0.0015868887
direct O 0 0.0013287733
- O 0 0.0020418444
acting O 0 0.005318034
vasodilator O 0 0.9959596
used O 0 0.0014181882
to O 0 0.001311744
manage O 0 0.008258169
vasospasm B-Disease 2 0.9992781
during O 0 0.0021030547
various O 0 0.0050750696
neurosurgical O 0 0.03635613
operations O 0 0.014294008
. O 0 0.0073672403

Transient O 0 0.6230607
cranial B-Disease 0 0.60916644
nerve I-Disease 0 0.8107185
dysfunction I-Disease 0 0.96540046
has O 0 0.002824867
been O 0 0.0021240958
described O 0 0.0011933839
in O 0 0.0011400502
a O 0 0.0014169882
few O 0 0.0012714438
cases O 0 0.0035866974
with O 0 0.0055262586
topical O 0 0.9865892
papaverine B-Chemical 1 0.9984888
. O 0 0.016309928

This O 0 0.0042162146
study O 0 0.0026136863
supports O 0 0.0014325347
previous O 0 0.0011775257
reports O 0 0.0015908788
and O 0 0.0010020054
provides O 0 0.0007690265
neurophysiological O 0 0.028090592
evidence O 0 0.0010108646
of O 0 0.0011936164
an O 0 0.0017049423
adverse O 0 0.4902818
effect O 0 0.0018951341
on O 0 0.0012788482
the O 0 0.0029963467
auditory O 0 0.22857416
nerve O 0 0.68420595
. O 0 0.00815248

METHODS O 0 0.0061636264
: O 0 0.002942457
We O 0 0.001237688
conducted O 0 0.0009652094
a O 0 0.00095778523
retrospective O 0 0.003535703
review O 0 0.0014805988
of O 0 0.0007299504
70 O 0 0.0007047612
consecutive O 0 0.00079881935
microvascular O 0 0.6726137
decompression O 0 0.03283013
operations O 0 0.0013126713
and O 0 0.00057337474
studied O 0 0.0007446162
those O 0 0.00079511106
patients O 0 0.0017822938
who O 0 0.0021258937
received O 0 0.0023750598
topical O 0 0.98553663
papaverine B-Chemical 1 0.999376
for O 0 0.022092182
vasospasm B-Disease 2 0.99915767
. O 0 0.012508097

Topical O 0 0.9919199
papaverine B-Chemical 1 0.9984763
was O 0 0.0036477975
used O 0 0.0016491436
as O 0 0.0010000475
a O 0 0.0010265992
direct O 0 0.0008944434
therapeutic O 0 0.007915833
action O 0 0.0069836313
to O 0 0.0011381486
manage O 0 0.007433859
vasospasm B-Disease 2 0.9994869
in O 0 0.0014170172
a O 0 0.0014601167
total O 0 0.0013867444
of O 0 0.0025934125
11 O 0 0.003954415
patients O 0 0.008964783
. O 0 0.00610416

The O 0 0.0030175177
timing O 0 0.0025055218
of O 0 0.0030347607
papaverine B-Chemical 1 0.99813336
application O 0 0.0053359927
and O 0 0.0013219398
ongoing O 0 0.0012570824
operative O 0 0.0027753317
events O 0 0.0038038797
was O 0 0.00084880635
reviewed O 0 0.0016094544
relative O 0 0.0006994624
to O 0 0.0010429493
changes O 0 0.0021000507
in O 0 0.0021002628
neurophysiological O 0 0.15235637
recordings O 0 0.024683831
. O 0 0.00668792

Brainstem O 0 0.8039155
auditory O 0 0.09343786
evoked O 0 0.111220226
potentials O 0 0.14968204
( O 0 0.0038845744
BAEPs O 0 0.76225716
) O 0 0.0018417939
were O 0 0.00075816415
routinely O 0 0.0007652237
used O 0 0.0006621842
to O 0 0.0007416553
monitor O 0 0.000972765
cochlear O 0 0.10580682
nerve O 0 0.29817575
function O 0 0.0022973611
during O 0 0.001786083
these O 0 0.004122196
operations O 0 0.010919622
. O 0 0.0073441295

FINDINGS O 0 0.10826012
: O 0 0.0059243655
A O 0 0.008581719
temporal O 0 0.00656257
relationship O 0 0.0011896312
was O 0 0.0011188687
found O 0 0.0009223932
between O 0 0.0007243786
topical O 0 0.93517524
papaverine B-Chemical 1 0.99949515
and O 0 0.004012951
BAEP O 0 0.9736028
changes O 0 0.0024880827
leading O 0 0.0027609693
to O 0 0.0016088332
complete O 0 0.0023897635
waveform O 0 0.019372428
loss O 0 0.010931731
. O 0 0.007155776

The O 0 0.0028694237
average O 0 0.0017098954
temporal O 0 0.006782495
delay O 0 0.0033230863
between O 0 0.0011874619
papaverine B-Chemical 1 0.9984706
and O 0 0.0016998096
the O 0 0.0010284628
onset O 0 0.0035042225
of O 0 0.001457129
an O 0 0.0021926153
adverse O 0 0.8117035
BAEP O 0 0.96556073
change O 0 0.002273959
was O 0 0.002186217
5 O 0 0.002546083
min O 0 0.005277625
. O 0 0.0052861506

In O 0 0.0033070082
10 O 0 0.0023457375
of O 0 0.0020348926
11 O 0 0.001853503
patients O 0 0.0030133084
, O 0 0.0020872501
BAEP O 0 0.9225688
waves O 0 0.07047237
II O 0 0.038257472
/ O 0 0.0043316153
III O 0 0.031540297
- O 0 0.0020172698
V O 0 0.045030378
completely O 0 0.00077188585
disappeared O 0 0.0011945597
within O 0 0.00042014642
2 O 0 0.0007158478
to O 0 0.0007696446
25 O 0 0.0016814666
min O 0 0.002297771
after O 0 0.0024005393
papaverine B-Chemical 1 0.9958866
. O 0 0.008323931

Eight O 0 0.007458645
of O 0 0.0031755555
these O 0 0.002695521
10 O 0 0.0019077301
patients O 0 0.0025770173
had O 0 0.0012850643
complete O 0 0.0012558581
loss O 0 0.0023860668
of O 0 0.0025468073
BAEP O 0 0.900941
waveforms O 0 0.009652022
within O 0 0.0017391391
10 O 0 0.0035779385
min O 0 0.0062649813
. O 0 0.006122999

One O 0 0.005257075
patient O 0 0.003657507
showed O 0 0.00190073
no O 0 0.0013098295
recovery O 0 0.0024177972
of O 0 0.0015903079
later O 0 0.0013984059
waves O 0 0.011922029
and O 0 0.0017731274
a O 0 0.002231563
delayed O 0 0.019456765
profound O 0 0.45343027
sensorineural B-Disease 2 0.99906904
hearing I-Disease 2 0.9878122
loss I-Disease 2 0.15778166
. O 0 0.010594377

The O 0 0.002842677
average O 0 0.0016042986
recovery O 0 0.0028151267
time O 0 0.0014035677
of O 0 0.002110291
BAEP O 0 0.86719346
waveforms O 0 0.007885185
to O 0 0.0013232643
pre O 0 0.00556743
- O 0 0.0037457445
papaverine B-Chemical 1 0.9983798
baseline O 0 0.0028417527
values O 0 0.0018241814
was O 0 0.0023421429
39 O 0 0.005097162
min O 0 0.0064117354
. O 0 0.0061287642

CONCLUSIONS O 0 0.8335736
: O 0 0.009059668
Topical O 0 0.99276745
papaverine B-Chemical 1 0.99890244
for O 0 0.0017936501
the O 0 0.0011030376
treatment O 0 0.002299574
of O 0 0.0020412647
vasospasm B-Disease 2 0.9997396
was O 0 0.0009979997
associated O 0 0.0008123446
with O 0 0.00056700193
the O 0 0.0003925115
onset O 0 0.0019506046
of O 0 0.00054306944
a O 0 0.0005668722
transient O 0 0.025729038
disturbance O 0 0.12489787
in O 0 0.00049394876
neurophysiological O 0 0.057502866
function O 0 0.00083731604
of O 0 0.0009876678
the O 0 0.0012418777
ascending O 0 0.1359176
auditory O 0 0.32916093
brainstem O 0 0.819206
pathway O 0 0.0096094385
. O 0 0.006572121

The O 0 0.0028611394
complete O 0 0.0022350526
disappearance O 0 0.0042356784
of O 0 0.0023163047
BAEP O 0 0.88868386
waveforms O 0 0.008552519
with O 0 0.0011061934
a O 0 0.000828638
consistent O 0 0.0007087643
temporal O 0 0.005692024
delay O 0 0.0013424755
suggests O 0 0.00042956558
a O 0 0.00068723387
possible O 0 0.00091704517
adverse B-Disease 0 0.40425757
effect I-Disease 0 0.0013354096
on I-Disease 0 0.0008602393
the I-Disease 0 0.0018087056
proximal I-Disease 0 0.0066363513
eighth I-Disease 0 0.08582813
nerve I-Disease 0 0.671184
. O 0 0.008018377

Recommendations O 0 0.009643598
to O 0 0.0041223196
avoid O 0 0.0035264632
potential O 0 0.0052990117
cranial B-Disease 0 0.38840136
nerve I-Disease 0 0.74203813
deficits I-Disease 0 0.85035694
from O 0 0.007148154
papaverine B-Chemical 1 0.997543
are O 0 0.009111781
provided O 0 0.0098222
. O 0 0.0101275435

Simvastatin B-Chemical 0 0.99898225
- I-Chemical 0 0.121614985
ezetimibe I-Chemical 0 0.9988618
- O 0 0.017015237
induced O 0 0.008350273
hepatic B-Disease 0 0.9792203
failure I-Disease 0 0.8729947
necessitating O 0 0.088064395
liver O 0 0.96661437
transplantation O 0 0.7840753
. O 0 0.0131537635

Abstract O 0 0.5474105
Serum O 0 0.75272477
aminotransferase O 0 0.99486876
elevations O 0 0.3039256
are O 0 0.0017050899
a O 0 0.0012198543
commonly O 0 0.0020207257
known O 0 0.0013265092
adverse O 0 0.42706886
effect O 0 0.0009357196
of O 0 0.00097616523
3 O 0 0.00081824267
- O 0 0.0022749137
hydroxy O 0 0.99785465
- O 0 0.002619117
3 O 0 0.00073069165
- O 0 0.00190283
methylglutaryl O 0 0.9685934
coenzyme O 0 0.9995189
A O 0 0.4790548
reductase O 0 0.99768555
inhibitor O 0 0.75219977
( O 0 0.014583318
statin B-Chemical 1 0.9958774
) O 0 0.016993504
therapy O 0 0.1382711
. O 0 0.007872642

However O 0 0.005603111
, O 0 0.0054348917
hepatotoxic B-Disease 0 0.99716896
events O 0 0.014213116
have O 0 0.0014305741
not O 0 0.0008854218
been O 0 0.0009363975
widely O 0 0.0012276834
published O 0 0.0009260693
with O 0 0.001349228
ezetimibe B-Chemical 0 0.99911994
or O 0 0.001131544
the O 0 0.0011754216
combination O 0 0.009867082
agent O 0 0.8393779
simvastatin B-Chemical 1 0.9997732
- I-Chemical 0 0.32966164
ezetimibe I-Chemical 0 0.9991605
. O 0 0.013752161

We O 0 0.0031267654
describe O 0 0.0024246327
a O 0 0.0020133397
70 O 0 0.0019695528
- O 0 0.0018469036
year O 0 0.0011301889
- O 0 0.0013419891
old O 0 0.0009770478
Hispanic O 0 0.23066232
woman O 0 0.0102579305
who O 0 0.0017667253
developed O 0 0.0025496217
fulminant B-Disease 2 0.9996679
hepatic I-Disease 2 0.9969759
failure I-Disease 2 0.9514597
necessitating O 0 0.019141128
liver O 0 0.92217124
transplantation O 0 0.2714749
10 O 0 0.00035634296
weeks O 0 0.00021122294
after O 0 0.00013677175
conversion O 0 0.0008771727
from O 0 0.0003921786
simvastatin B-Chemical 1 0.9996723
40 O 0 0.000968967
mg O 0 0.38763157
/ O 0 0.00090120535
day O 0 0.00034369607
to O 0 0.00048123897
simvastatin B-Chemical 1 0.99955434
10 I-Chemical 0 0.0012260467
mg I-Chemical 0 0.58824956
- I-Chemical 0 0.0033069754
ezetimibe I-Chemical 0 0.99892455
40 I-Chemical 0 0.0031645047
mg I-Chemical 0 0.46174043
/ O 0 0.0057418505
day O 0 0.003941567
. O 0 0.0048504425

The O 0 0.0029894032
patient O 0 0.0033352913
' O 0 0.0022267108
s O 0 0.002002003
lipid O 0 0.13237114
panel O 0 0.0009956568
had O 0 0.0008313974
been O 0 0.0007835388
maintained O 0 0.0006701448
with O 0 0.0010256637
simvastatin B-Chemical 1 0.9994299
for O 0 0.00067478063
18 O 0 0.00059593504
months O 0 0.0004664557
before O 0 0.0002974016
the O 0 0.0005753348
conversion O 0 0.0021611494
without O 0 0.0014491002
evidence O 0 0.0028483612
of O 0 0.010588782
hepatotoxicity B-Disease 2 0.9993637
. O 0 0.013122136

A O 0 0.012813141
routine O 0 0.0034823138
laboratory O 0 0.0036632386
work O 0 0.0028760727
- O 0 0.0023077563
up O 0 0.0011171215
10 O 0 0.0009151462
weeks O 0 0.0007535891
after O 0 0.0006064209
conversion O 0 0.0025434205
revealed O 0 0.001880779
elevated O 0 0.01971902
serum O 0 0.5432107
aminotransferase O 0 0.9959091
levels O 0 0.011670856
. O 0 0.009416653

Simvastatinezetimibe B-Chemical 0 0.19479209
and O 0 0.00512352
escitalopram B-Chemical 0 0.99827003
( O 0 0.0031149774
which O 0 0.0013940166
she O 0 0.0009825939
was O 0 0.0007324736
taking O 0 0.001351774
for O 0 0.00074110995
depression B-Disease 0 0.9794844
) O 0 0.001313807
were O 0 0.0005322942
discontinued O 0 0.017299673
, O 0 0.000680855
and O 0 0.00050735334
other O 0 0.00056841306
potential O 0 0.0011587439
causes O 0 0.003016901
of O 0 0.005477406
hepatotoxicity B-Disease 2 0.9996737
were O 0 0.005728152
excluded O 0 0.00791794
. O 0 0.0065682493

A O 0 0.014327115
repeat O 0 0.004063537
work O 0 0.0031624625
- O 0 0.002304369
up O 0 0.0009879424
revealed O 0 0.0008848348
further O 0 0.0010329728
elevations O 0 0.10023015
in O 0 0.0009478587
aminotransferase O 0 0.9972318
levels O 0 0.001009268
, O 0 0.00084050477
and O 0 0.00061094045
liver O 0 0.4843572
biopsy O 0 0.0047764643
revealed O 0 0.0005674365
evidence O 0 0.0006373653
of O 0 0.0009265525
moderate O 0 0.020868447
- O 0 0.002110768
to O 0 0.0012891558
- O 0 0.0036747048
severe O 0 0.4735061
drug B-Disease 0 0.9837329
toxicity I-Disease 2 0.9970732
. O 0 0.010763228

She O 0 0.012020844
underwent O 0 0.009146565
liver O 0 0.46145692
transplantation O 0 0.11701375
with O 0 0.006079054
an O 0 0.0066609406
uneventful O 0 0.017928725
postoperative O 0 0.112240195
course O 0 0.017878009
. O 0 0.0136822695

Her O 0 0.014015694
aminotransferase O 0 0.98340076
levels O 0 0.0025067327
returned O 0 0.0015556633
to O 0 0.00096128974
normal O 0 0.0013568992
by O 0 0.0007709372
postoperative O 0 0.008874701
day O 0 0.00064422505
23 O 0 0.0008562607
, O 0 0.0005568622
and O 0 0.0004359168
her O 0 0.00069352676
2 O 0 0.00053437543
- O 0 0.0006818342
year O 0 0.0004977591
follow O 0 0.0006117748
- O 0 0.0011279925
up O 0 0.0008121492
showed O 0 0.0011302966
no O 0 0.001907387
adverse O 0 0.637494
events O 0 0.04974394
. O 0 0.006631157

Ezetimibe B-Chemical 0 0.99550384
undergoes O 0 0.005618155
extensive O 0 0.005091222
glucuronidation O 0 0.99729854
by O 0 0.0038919912
uridine B-Chemical 0 0.9946203
diphosphate I-Chemical 0 0.99505097
glucoronosyltransferases O 0 0.64927495
( O 0 0.0039170147
UGT O 0 0.99784446
) O 0 0.00184461
in O 0 0.00039414663
the O 0 0.00039273695
intestine O 0 0.012143582
and O 0 0.0005597966
liver O 0 0.6680589
and O 0 0.00052156474
may O 0 0.00037910746
have O 0 0.00039320881
inhibited O 0 0.0012423835
the O 0 0.00063381635
glucuronidation O 0 0.99931335
of O 0 0.015818985
simvastatin B-Chemical 1 0.99996424
hydroxy I-Chemical 0 0.99977726
acid I-Chemical 0 0.9983962
, O 0 0.002188392
resulting O 0 0.0008658391
in O 0 0.0007157707
increased O 0 0.0051548965
simvastatin B-Chemical 1 0.9996339
exposure O 0 0.0703814
and O 0 0.0039062202
subsequent O 0 0.021051643
hepatotoxicity B-Disease 2 0.9994554
. O 0 0.012130897

To O 0 0.0025943874
our O 0 0.0018390686
knowledge O 0 0.002325906
, O 0 0.001605813
this O 0 0.00088338286
is O 0 0.00069588167
the O 0 0.0005120753
first O 0 0.00042615892
case O 0 0.0005956667
report O 0 0.002163316
of O 0 0.0023063514
simvastatin B-Chemical 1 0.99991095
- I-Chemical 0 0.08389544
ezetimibe I-Chemical 0 0.99987257
- O 0 0.00943128
induced O 0 0.0024557353
liver B-Disease 0 0.9095101
failure I-Disease 0 0.6844164
that O 0 0.0011767475
resulted O 0 0.0016953632
in O 0 0.0026302363
liver O 0 0.88905025
transplantation O 0 0.6678346
. O 0 0.0077250153

We O 0 0.0032929855
postulate O 0 0.004593266
that O 0 0.0015160418
the O 0 0.0012569829
mechanism O 0 0.0014637195
of O 0 0.0012662743
the O 0 0.0011246256
simvastatinezetimibe B-Chemical 0 0.29840368
- O 0 0.003469973
induced O 0 0.004510371
hepatotoxicity B-Disease 2 0.9998964
is O 0 0.0014247565
the O 0 0.0007576748
increased O 0 0.004410036
simvastatin B-Chemical 1 0.99974436
exposure O 0 0.07226982
by O 0 0.0031714325
ezetimibe B-Chemical 0 0.99942315
inhibition O 0 0.07151691
of O 0 0.0116906725
UGT O 0 0.99599165
enzymes O 0 0.6647555
. O 0 0.009970195

Clinicians O 0 0.009841136
should O 0 0.0017649913
be O 0 0.0016267591
aware O 0 0.0014339425
of O 0 0.0013357201
potential O 0 0.003468951
hepatotoxicity B-Disease 2 0.9998661
with O 0 0.029727783
simvastatin B-Chemical 1 0.9999347
- I-Chemical 0 0.06369041
ezetimibe I-Chemical 0 0.99986076
especially O 0 0.0036285522
in O 0 0.0005083079
elderly O 0 0.23260589
patients O 0 0.001585211
and O 0 0.00030859187
should O 0 0.00016069009
carefully O 0 0.0002026837
monitor O 0 0.00028455944
serum O 0 0.07565882
aminotransferase O 0 0.99728966
levels O 0 0.0006134403
when O 0 0.00035816574
starting O 0 0.0007218299
therapy O 0 0.008711458
and O 0 0.001375458
titrating O 0 0.0114408
the O 0 0.003103461
dosage O 0 0.26556063
. O 0 0.006704358

Massive O 0 0.5208695
proteinuria B-Disease 2 0.9984211
and O 0 0.007398159
acute B-Disease 0 0.9676009
renal I-Disease 0 0.99473995
failure I-Disease 0 0.83331096
after O 0 0.0011514655
oral O 0 0.722288
bisphosphonate B-Chemical 0 0.9994474
( O 0 0.015660355
alendronate B-Chemical 0 0.9994197
) O 0 0.004064008
administration O 0 0.095896706
in O 0 0.00069120515
a O 0 0.00093611423
patient O 0 0.0017138524
with O 0 0.002175322
focal B-Disease 0 0.40953326
segmental I-Disease 0 0.56245685
glomerulosclerosis I-Disease 2 0.9993161
. O 0 0.018174581

A O 0 0.01962704
61 O 0 0.006024541
- O 0 0.0035316464
year O 0 0.0019250839
- O 0 0.002074548
old O 0 0.001392596
Japanese O 0 0.016454224
man O 0 0.12931389
with O 0 0.0032115332
nephrotic B-Disease 2 0.99988127
syndrome I-Disease 0 0.9677336
due O 0 0.0006281075
to O 0 0.0006595653
focal B-Disease 0 0.1694282
segmental I-Disease 0 0.1739093
glomerulosclerosis I-Disease 2 0.9998323
was O 0 0.0020503043
initially O 0 0.002365093
responding O 0 0.0040957024
well O 0 0.001225823
to O 0 0.0022436057
steroid B-Chemical 1 0.99144673
therapy O 0 0.28911376
. O 0 0.007835179

The O 0 0.0027989366
amount O 0 0.0015835192
of O 0 0.0020789972
daily O 0 0.004560657
urinary O 0 0.6462839
protein O 0 0.0039578127
decreased O 0 0.0024710686
from O 0 0.0010674685
15 O 0 0.00083380856
. O 0 0.0005811598
6 O 0 0.0006643691
to O 0 0.0008872907
2 O 0 0.0013273092
. O 0 0.001246673
8 O 0 0.0024305775
g O 0 0.006473146
. O 0 0.0052500684

Within O 0 0.002407552
14 O 0 0.001962632
days O 0 0.0012172248
of O 0 0.0012826438
the O 0 0.0011656575
oral O 0 0.44714868
bisphosphonate B-Chemical 0 0.99931157
( O 0 0.025318487
alendronate B-Chemical 0 0.9998017
sodium I-Chemical 0 0.9996731
) O 0 0.010085343
administration O 0 0.20612296
, O 0 0.000581546
the O 0 0.00024726705
amount O 0 0.00015748356
of O 0 0.0003665233
daily O 0 0.0021793512
urinary O 0 0.76053447
protein O 0 0.002174304
increased O 0 0.00093310705
rapidly O 0 0.0011639955
up O 0 0.000381381
to O 0 0.00033051235
12 O 0 0.00031785466
. O 0 0.00027018506
8 O 0 0.00048833084
g O 0 0.0014178447
with O 0 0.00170733
acute B-Disease 0 0.96310365
renal I-Disease 0 0.9948067
failure I-Disease 0 0.95255953
. O 0 0.009661361

After O 0 0.0027929167
discontinuing O 0 0.10253596
the O 0 0.0023304794
oral O 0 0.3889514
alendronate B-Chemical 0 0.9985978
, O 0 0.0019148627
the O 0 0.00067520066
patient O 0 0.00087134284
underwent O 0 0.00067570276
six O 0 0.00030412665
cycles O 0 0.00041180686
of O 0 0.000741761
hemodialysis O 0 0.5038297
and O 0 0.00096482754
four O 0 0.000764558
cycles O 0 0.0014247063
of O 0 0.004143209
LDL O 0 0.9926755
apheresis O 0 0.41415063
. O 0 0.009039659

Urinary O 0 0.87150306
volume O 0 0.008213508
and O 0 0.003102853
serum O 0 0.078671165
creatinine B-Chemical 1 0.9880972
levels O 0 0.001290424
recovered O 0 0.000704558
to O 0 0.000571618
the O 0 0.00051332347
normal O 0 0.0010369858
range O 0 0.0009777388
, O 0 0.00081281917
with O 0 0.0009249816
urinary O 0 0.6517998
protein O 0 0.003836148
disappearing O 0 0.009013931
completely O 0 0.0016478694
within O 0 0.0010998511
40 O 0 0.002747481
days O 0 0.0034135543
. O 0 0.0048138974

This O 0 0.0045830808
report O 0 0.004243791
demonstrates O 0 0.0013590785
that O 0 0.0010140158
not O 0 0.0009061287
only O 0 0.0010043182
intravenous O 0 0.44344583
, O 0 0.0014251589
but O 0 0.0007655111
also O 0 0.0009877834
oral O 0 0.5930853
bisphosphonates B-Chemical 0 0.99939215
can O 0 0.002533226
aggravate O 0 0.95092684
proteinuria B-Disease 2 0.9997466
and O 0 0.021954285
acute B-Disease 0 0.9944179
renal I-Disease 0 0.9968816
failure I-Disease 0 0.9750378
. O 0 0.011543678

Serum O 0 0.5427902
- O 0 0.0077704485
and O 0 0.0039986386
glucocorticoid O 0 0.9542611
- O 0 0.006119074
inducible O 0 0.06735644
kinase O 0 0.31845608
1 O 0 0.0026370836
in O 0 0.00252853
doxorubicin B-Chemical 1 0.9978569
- O 0 0.020632742
induced O 0 0.047919005
nephrotic B-Disease 2 0.9996284
syndrome I-Disease 0 0.98743755
. O 0 0.01338335

Doxorubicin B-Chemical 1 0.9983658
- O 0 0.014666734
induced O 0 0.009021815
nephropathy B-Disease 2 0.99949837
leads O 0 0.0054076724
to O 0 0.0020792393
epithelial O 0 0.5502015
sodium B-Chemical 0 0.99879766
channel O 0 0.6574133
( O 0 0.007248376
ENaC O 0 0.983327
) O 0 0.0041451333
- O 0 0.0018060051
dependent O 0 0.0010481577
volume B-Disease 0 0.02225099
retention I-Disease 0 0.054142214
and O 0 0.005425044
renal O 0 0.99398947
fibrosis B-Disease 2 0.9945062
. O 0 0.013579729

The O 0 0.005219512
aldosterone B-Chemical 0 0.9963521
- O 0 0.006848936
sensitive O 0 0.00266018
serum O 0 0.102577195
- O 0 0.0024618334
and O 0 0.0012055178
glucocorticoid O 0 0.9757295
- O 0 0.0030281157
inducible O 0 0.09428018
kinase O 0 0.6153576
SGK1 O 0 0.97368413
has O 0 0.0008366562
been O 0 0.00064367027
shown O 0 0.00027261893
to O 0 0.0002718901
participate O 0 0.00026088022
in O 0 0.00023071891
the O 0 0.0002672921
stimulation O 0 0.0007806201
of O 0 0.0006797884
ENaC O 0 0.9379141
and O 0 0.0006823289
to O 0 0.00054152875
mediate O 0 0.0009971557
renal O 0 0.9957509
fibrosis B-Disease 2 0.9974106
following O 0 0.012439821
mineralocorticoid O 0 0.99875927
and O 0 0.0076379073
salt O 0 0.9785945
excess O 0 0.034397688
. O 0 0.008251735

The O 0 0.0024957422
present O 0 0.0015338601
study O 0 0.0019032103
was O 0 0.0010219616
performed O 0 0.0007599399
to O 0 0.0006514479
elucidate O 0 0.0004679931
the O 0 0.0005249505
role O 0 0.0004654637
of O 0 0.0010974298
SGK1 O 0 0.86924845
in O 0 0.0008146348
the O 0 0.0008172851
volume B-Disease 0 0.017491734
retention I-Disease 0 0.039006803
and O 0 0.0027633242
fibrosis B-Disease 2 0.9942431
during O 0 0.014890176
nephrotic B-Disease 2 0.99972624
syndrome I-Disease 0 0.9887121
. O 0 0.011279147

To O 0 0.002819994
this O 0 0.0020313014
end O 0 0.0013200477
, O 0 0.002468832
doxorubicin B-Chemical 1 0.997026
( O 0 0.001967268
15 O 0 0.0006498096
mug O 0 0.0011719713
/ O 0 0.0010675335
g O 0 0.0010717915
body O 0 0.0013305828
wt O 0 0.00035109266
) O 0 0.000547044
was O 0 0.00026192423
injected O 0 0.00025397982
intravenously O 0 0.001738572
into O 0 0.00016333477
gene O 0 0.00042942373
- O 0 0.0004302227
targeted O 0 0.00018384488
mice O 0 0.00016727574
lacking O 0 0.00026352156
SGK1 O 0 0.92760926
( O 0 0.0012436268
sgk1 O 0 0.17519145
( O 0 0.0014629972
- O 0 0.0011883425
/ O 0 0.0015834891
- O 0 0.000840309
) O 0 0.00061986496
) O 0 0.00045388998
and O 0 0.00025852254
their O 0 0.00029228206
wild O 0 0.00028152633
- O 0 0.00059479
type O 0 0.00039060402
littermates O 0 0.00022899175
( O 0 0.0008826336
sgk1 O 0 0.055269632
( O 0 0.0019175592
+ O 0 0.0018747367
/ O 0 0.0038457538
+ O 0 0.0030599413
) O 0 0.004840101
) O 0 0.0063483897
. O 0 0.0052423542

Doxorubicin B-Chemical 1 0.99775475
treatment O 0 0.0102913305
resulted O 0 0.0025352053
in O 0 0.0019317699
heavy O 0 0.60977066
proteinuria B-Disease 2 0.9997336
( O 0 0.0065842182
> O 0 0.0020744137
100 O 0 0.001319575
mg O 0 0.25227788
protein O 0 0.0016113174
/ O 0 0.001678392
mg O 0 0.5144592
crea O 0 0.8700916
) O 0 0.00076484313
in O 0 0.00025660195
15 O 0 0.00024233125
/ O 0 0.0004749697
44 O 0 0.00036115057
of O 0 0.00036782367
sgk1 O 0 0.07694363
( O 0 0.0009660228
+ O 0 0.00062027853
/ O 0 0.0010966678
+ O 0 0.00046422012
) O 0 0.0004417424
and O 0 0.00024448303
15 O 0 0.00020793383
/ O 0 0.0004257967
44 O 0 0.00032899706
of O 0 0.0003438873
sgk1 O 0 0.095867194
( O 0 0.001188425
- O 0 0.001072505
/ O 0 0.0014304753
- O 0 0.0007091809
) O 0 0.00046119306
mice O 0 0.00017007692
leading O 0 0.00062592386
to O 0 0.0004314061
severe O 0 0.6186914
nephrotic B-Disease 2 0.9999521
syndrome I-Disease 0 0.98952496
with O 0 0.007599088
ascites B-Disease 0 0.9991197
, O 0 0.012308116
lipidemia B-Disease 0 0.9992136
, O 0 0.0026188465
and O 0 0.0021306735
hypoalbuminemia B-Disease 0 0.99895966
in O 0 0.0023135683
both O 0 0.0029590449
genotypes O 0 0.009213966
. O 0 0.006449984

Plasma O 0 0.6616707
aldosterone B-Chemical 0 0.9969463
levels O 0 0.0032945008
increased O 0 0.0032089516
in O 0 0.0018905101
nephrotic B-Disease 2 0.99968374
mice O 0 0.00069220114
of O 0 0.00076887116
both O 0 0.00049871363
genotypes O 0 0.0010583728
and O 0 0.00048719812
was O 0 0.00035711238
followed O 0 0.00025795776
by O 0 0.00039792643
increased O 0 0.0012584475
SGK1 O 0 0.92130095
protein O 0 0.0030967707
expression O 0 0.0015716627
in O 0 0.0008124886
sgk1 O 0 0.1268603
( O 0 0.002325581
+ O 0 0.0019881206
/ O 0 0.003718591
+ O 0 0.0027208196
) O 0 0.0037419703
mice O 0 0.0026822402
. O 0 0.00502981

Urinary O 0 0.97569066
sodium B-Chemical 0 0.99520516
excretion O 0 0.9788473
reached O 0 0.004397284
signficantly O 0 0.12974487
lower O 0 0.0011200252
values O 0 0.00080648466
in O 0 0.0007128854
sgk1 O 0 0.097742654
( O 0 0.0016748474
+ O 0 0.0010086797
/ O 0 0.0015779022
+ O 0 0.0006712887
) O 0 0.000610714
mice O 0 0.00022512273
( O 0 0.00043666994
15 O 0 0.0002650761
+ O 0 0.0003967047
/ O 0 0.00075263274
- O 0 0.00048288127
5 O 0 0.00023807296
mumol O 0 0.054799307
/ O 0 0.0010631602
mg O 0 0.42785043
crea O 0 0.85405844
) O 0 0.0005875732
than O 0 0.0001633698
in O 0 0.00024736748
sgk1 O 0 0.073110886
( O 0 0.00109116
- O 0 0.0010112879
/ O 0 0.0013564599
- O 0 0.00068540574
) O 0 0.0004566823
mice O 0 0.00017126539
( O 0 0.00035576627
35 O 0 0.00032330822
+ O 0 0.00036290736
/ O 0 0.00070762617
- O 0 0.0004370802
5 O 0 0.00021302947
mumol O 0 0.05524195
/ O 0 0.0009805439
mg O 0 0.42760026
crea O 0 0.8668994
) O 0 0.00055497856
and O 0 0.00022775584
was O 0 0.0001936187
associated O 0 0.00028219787
with O 0 0.0002817218
a O 0 0.0002641137
significantly O 0 0.0002879468
higher O 0 0.00023167492
body O 0 0.0013562222
weight B-Disease 0 0.0024598215
gain I-Disease 0 0.00089212577
in O 0 0.00030259872
sgk1 O 0 0.10522676
( O 0 0.0010380504
+ O 0 0.00061536836
/ O 0 0.0011633749
+ O 0 0.0004427556
) O 0 0.00040287006
compared O 0 0.00013391887
with O 0 0.0003644059
sgk1 O 0 0.12140924
( O 0 0.0013010442
- O 0 0.0011265686
/ O 0 0.0014887005
- O 0 0.0007273975
) O 0 0.00048331963
mice O 0 0.00018441089
( O 0 0.00040375072
+ O 0 0.00031242275
6 O 0 0.00017097205
. O 0 0.00012869074
6 O 0 0.00017297534
+ O 0 0.0003201203
/ O 0 0.0006509579
- O 0 0.0004295408
0 O 0 0.00025500328
. O 0 0.00012714764
7 O 0 0.0001742741
vs O 0 0.00041014142
. O 0 0.0001670064
+ O 0 0.00033251074
4 O 0 0.00024838495
. O 0 0.00020719328
1 O 0 0.00040446242
+ O 0 0.00062874233
/ O 0 0.0012822131
- O 0 0.0010873454
0 O 0 0.0008497847
. O 0 0.0006415769
8 O 0 0.0013083285
g O 0 0.0038677407
) O 0 0.00484506
. O 0 0.0045394762

During O 0 0.0026918664
the O 0 0.0021142524
course O 0 0.0028253975
of O 0 0.004229434
nephrotic B-Disease 2 0.9997987
syndrome I-Disease 0 0.98950887
, O 0 0.004180918
serum O 0 0.32652888
urea B-Chemical 1 0.9976059
concentrations O 0 0.012839037
increased O 0 0.0012150458
significantly O 0 0.0006276643
faster O 0 0.0004315227
in O 0 0.0004171028
sgk1 O 0 0.15376796
( O 0 0.0016102417
- O 0 0.0012762678
/ O 0 0.0015541392
- O 0 0.0007063507
) O 0 0.00042590286
mice O 0 0.0001378548
than O 0 0.0001453389
in O 0 0.0002374618
sgk1 O 0 0.07044403
( O 0 0.0009379868
+ O 0 0.0006061499
/ O 0 0.0011795064
+ O 0 0.0004590164
) O 0 0.00042802928
mice O 0 0.0001506155
leading O 0 0.000614609
to O 0 0.00039630366
uremia B-Disease 0 0.99965465
and O 0 0.0005669597
a O 0 0.00035771227
reduced O 0 0.00029606608
median O 0 0.00029471962
survival O 0 0.015549093
in O 0 0.0003438696
sgk1 O 0 0.14475836
( O 0 0.0013979438
- O 0 0.0011472605
/ O 0 0.0014566642
- O 0 0.0007022718
) O 0 0.0004639224
mice O 0 0.0001756442
( O 0 0.00036217552
29 O 0 0.0004693287
vs O 0 0.00046110252
. O 0 0.00014942762
40 O 0 0.00026462993
days O 0 0.00025235367
in O 0 0.0003512549
sgk1 O 0 0.030237298
( O 0 0.0014136146
+ O 0 0.0013736973
/ O 0 0.0026595122
+ O 0 0.0019417078
) O 0 0.0026677838
mice O 0 0.0018319183
) O 0 0.00591122
. O 0 0.00510278

In O 0 0.003033258
conclusion O 0 0.0023207334
, O 0 0.0023552477
gene O 0 0.0020543789
- O 0 0.0016459235
targeted O 0 0.00063320744
mice O 0 0.00045418902
lacking O 0 0.0005300804
SGK1 O 0 0.84907997
showed O 0 0.00086953136
blunted O 0 0.12382586
volume B-Disease 0 0.04212931
retention I-Disease 0 0.04675896
, O 0 0.0008604978
yet O 0 0.00065355445
were O 0 0.00036751598
not O 0 0.00037478883
protected O 0 0.00079788105
against O 0 0.0009774966
renal O 0 0.9951396
fibrosis B-Disease 2 0.9962607
during O 0 0.002918696
experimental O 0 0.08502946
nephrotic B-Disease 2 0.99974674
syndrome I-Disease 0 0.9890827
. O 0 0.0108955065

Severe O 0 0.9690475
thrombocytopenia B-Disease 0 0.997846
and O 0 0.013310342
haemolytic B-Disease 0 0.99817777
anaemia I-Disease 0 0.99933547
associated O 0 0.012146187
with O 0 0.006421628
ciprofloxacin B-Chemical 1 0.99919945
: O 0 0.0038963363
a O 0 0.0017452727
case O 0 0.001853443
report O 0 0.0057628388
with O 0 0.0051751
fatal O 0 0.9772769
outcome O 0 0.03860118
. O 0 0.008843161

Haematological O 0 0.9791083
adverse O 0 0.7156192
reactions O 0 0.016415108
associated O 0 0.0033048245
with O 0 0.003022965
fatal O 0 0.9440505
outcome O 0 0.0057034544
are O 0 0.0018446846
rare O 0 0.006574107
during O 0 0.0017154252
treatment O 0 0.006425822
with O 0 0.0093687195
ciprofloxacin B-Chemical 1 0.9971541
. O 0 0.011269128

A O 0 0.015772061
30 O 0 0.0030050715
- O 0 0.002592564
year O 0 0.0013714788
old O 0 0.0015221033
Caucasian O 0 0.0878634
man O 0 0.056181606
reported O 0 0.001316379
with O 0 0.0011023481
abdominal B-Disease 0 0.4149091
pain I-Disease 0 0.98346806
and O 0 0.0015230017
jaundice B-Disease 2 0.9982628
after O 0 0.0004041496
3 O 0 0.00040984483
- O 0 0.00050216576
day O 0 0.00029013428
administration O 0 0.013005865
of O 0 0.00066126016
oral O 0 0.5274045
ciprofloxacin B-Chemical 1 0.99934477
for O 0 0.00074015744
a O 0 0.0010921953
suspect O 0 0.004530635
of O 0 0.0029329625
urinary B-Disease 0 0.9614863
tract I-Disease 0 0.85918033
infection I-Disease 2 0.86683637
. O 0 0.009437123

Clinical O 0 0.034930333
evaluations O 0 0.0049588177
suggested O 0 0.0032054943
an O 0 0.003081153
initial O 0 0.002750557
diagnosis O 0 0.010933476
of O 0 0.0057641743
severe O 0 0.80978614
thrombocytopenia B-Disease 0 0.9986779
and O 0 0.04906712
haemolysis B-Disease 0 0.9970969
. O 0 0.017315675

The O 0 0.0040406925
patient O 0 0.004803619
progressively O 0 0.0063889017
developed O 0 0.0077672177
petechiae B-Disease 0 0.98199236
and O 0 0.006461502
purpura B-Disease 0 0.9953027
on O 0 0.002866324
thorax O 0 0.023218129
and O 0 0.0044796322
lower O 0 0.005811517
limbs O 0 0.104736656
. O 0 0.009922323

Despite O 0 0.004628369
pharmacological O 0 0.11026524
and O 0 0.0025132678
supportive O 0 0.004373362
interventions O 0 0.0020822878
, O 0 0.001311217
laboratory O 0 0.0014650611
parameters O 0 0.0015499125
worsened O 0 0.062244575
and O 0 0.0009804879
the O 0 0.00082858076
patient O 0 0.0017856471
died O 0 0.008047924
17 O 0 0.0020107343
hours O 0 0.0015798301
after O 0 0.0017860807
admission O 0 0.023065086
. O 0 0.0059747426

An O 0 0.009258307
accurate O 0 0.006530114
autopsy O 0 0.01656915
revealed O 0 0.004381617
most O 0 0.005887774
organs O 0 0.017873632
with O 0 0.0075090174
diffuse O 0 0.49913213
petechial O 0 0.9881309
haemorrhages B-Disease 0 0.9955819
. O 0 0.018976199

No O 0 0.014810426
signs O 0 0.035787217
of O 0 0.009887224
bone B-Disease 0 0.2553779
marrow I-Disease 0 0.76438576
depression I-Disease 0 0.9869941
were O 0 0.011685594
found O 0 0.011445536
. O 0 0.013248593

No O 0 0.012892838
thrombi B-Disease 2 0.8100216
or O 0 0.004585461
signs O 0 0.0759628
of O 0 0.006130496
microangiopathies B-Disease 0 0.99611974
were O 0 0.004639703
observed O 0 0.003277327
in O 0 0.0050378344
arterial O 0 0.73800504
vessels O 0 0.26020265
. O 0 0.010837876

Blood O 0 0.04210538
and O 0 0.0060144984
urine O 0 0.07818138
cultures O 0 0.0054145134
did O 0 0.0029477107
not O 0 0.0026035716
show O 0 0.0027813269
any O 0 0.0040753055
bacterial O 0 0.024600435
growth O 0 0.03746821
. O 0 0.011780319

This O 0 0.004426497
case O 0 0.0023209036
report O 0 0.0032686996
shows O 0 0.00091990066
that O 0 0.0011861358
ciprofloxacin B-Chemical 1 0.9986312
may O 0 0.0013800806
precipitate O 0 0.0700863
life O 0 0.008481573
- O 0 0.0026975756
threatening O 0 0.31694946
thrombocytopenia B-Disease 0 0.9996866
and O 0 0.0063430886
haemolytic B-Disease 0 0.99963534
anaemia I-Disease 0 0.9998615
, O 0 0.0026996492
even O 0 0.0005212508
in O 0 0.00031201288
the O 0 0.0003133385
early O 0 0.00080261537
phases O 0 0.0011050116
of O 0 0.0007147343
treatment O 0 0.0017685705
and O 0 0.0009106267
without O 0 0.0011531799
apparent O 0 0.0018460222
previous O 0 0.0030795494
exposures O 0 0.09498858
. O 0 0.0065465425

Alpha B-Chemical 0 0.5583195
- I-Chemical 0 0.021003366
lipoic I-Chemical 0 0.9978515
acid I-Chemical 0 0.98202217
prevents O 0 0.02661447
mitochondrial B-Disease 0 0.97282064
damage I-Disease 0 0.9862321
and O 0 0.012485731
neurotoxicity B-Disease 2 0.9989128
in O 0 0.004222249
experimental O 0 0.01639162
chemotherapy O 0 0.98630595
neuropathy B-Disease 0 0.99847573
. O 0 0.015151157

The O 0 0.0028903505
study O 0 0.003110967
investigates O 0 0.0032224627
if O 0 0.001535054
alpha B-Chemical 1 0.30809054
- I-Chemical 1 0.012424107
lipoic I-Chemical 1 0.999508
acid I-Chemical 1 0.9906555
is O 0 0.0019290026
neuroprotective O 0 0.9627175
against O 0 0.0012521477
chemotherapy O 0 0.95099056
induced O 0 0.017159613
neurotoxicity B-Disease 2 0.9998406
, O 0 0.0024729078
if O 0 0.00041698135
mitochondrial B-Disease 0 0.89374727
damage I-Disease 0 0.96542233
plays O 0 0.0010035909
a O 0 0.00047664082
critical O 0 0.000360501
role O 0 0.000248034
in O 0 0.00040642312
toxic B-Disease 0 0.96402234
neurodegenerative I-Disease 0 0.9967423
cascade I-Disease 0 0.07478991
, O 0 0.00079583115
and O 0 0.00038342463
if O 0 0.0002632574
neuroprotective O 0 0.80358195
effects O 0 0.0018889757
of O 0 0.0014985309
alpha B-Chemical 1 0.61952
- I-Chemical 1 0.023874572
lipoic I-Chemical 1 0.9995431
acid I-Chemical 1 0.97876304
depend O 0 0.0025381974
on O 0 0.001966274
mitochondria O 0 0.31470698
protection O 0 0.05404799
. O 0 0.0076484107

We O 0 0.00323535
used O 0 0.0021521745
an O 0 0.0019467238
in O 0 0.0011042147
vitro O 0 0.0015773869
model O 0 0.0011470645
of O 0 0.0011568317
chemotherapy O 0 0.7745043
induced O 0 0.003085233
peripheral B-Disease 2 0.8549357
neuropathy I-Disease 2 0.9998542
that O 0 0.00062513724
closely O 0 0.00051603984
mimic O 0 0.00058925257
the O 0 0.00027116574
in O 0 0.00023767925
vivo O 0 0.0005659612
condition O 0 0.0006655954
by O 0 0.00030767734
exposing O 0 0.0010421744
primary O 0 0.00052912434
cultures O 0 0.000678545
of O 0 0.0005938174
dorsal O 0 0.015496969
root O 0 0.013738327
ganglion O 0 0.9520386
( O 0 0.0012334737
DRG O 0 0.49576035
) O 0 0.0009763192
sensory O 0 0.04268304
neurons O 0 0.0105837025
to O 0 0.00040127579
paclitaxel B-Chemical 1 0.9972639
and O 0 0.0010707052
cisplatin B-Chemical 1 0.99895835
, O 0 0.000814125
two O 0 0.00033891658
widely O 0 0.000881575
used O 0 0.0005458166
and O 0 0.0008342559
highly O 0 0.0017599444
effective O 0 0.0038025246
chemotherapeutic O 0 0.972969
drugs O 0 0.93713015
. O 0 0.008329971

This O 0 0.004062942
approach O 0 0.0025641737
allowed O 0 0.0013713769
investigating O 0 0.0011140831
the O 0 0.0009715173
efficacy O 0 0.0033099141
of O 0 0.0017107356
alpha B-Chemical 1 0.56928074
- I-Chemical 1 0.016230585
lipoic I-Chemical 1 0.9996903
acid I-Chemical 1 0.9898846
in O 0 0.0010340917
preventing O 0 0.010880373
axonal B-Disease 0 0.97243404
damage I-Disease 0 0.98233676
and O 0 0.0018479754
apoptosis O 0 0.9339185
and O 0 0.00049584097
the O 0 0.00029880818
function O 0 0.00044505185
and O 0 0.00036733955
ultrastructural O 0 0.08024354
morphology O 0 0.0022598796
of O 0 0.0005977178
mitochondria O 0 0.062355787
after O 0 0.00030029894
exposure O 0 0.0023098036
to O 0 0.00069290504
toxic O 0 0.7722832
agents O 0 0.31642595
and O 0 0.0027714123
alpha B-Chemical 1 0.62725973
- I-Chemical 1 0.061091185
lipoic I-Chemical 1 0.99889743
acid I-Chemical 1 0.98747456
. O 0 0.010776954

Our O 0 0.0030982282
results O 0 0.0018491986
demonstrate O 0 0.001205162
that O 0 0.0011058942
both O 0 0.0013961424
cisplatin B-Chemical 1 0.9979038
and O 0 0.0027035484
paclitaxel B-Chemical 1 0.99858415
cause O 0 0.021462278
early O 0 0.009644048
mitochondrial B-Disease 0 0.94227755
impairment I-Disease 0 0.9363648
with O 0 0.00100386
loss O 0 0.0014371339
of O 0 0.00068991
membrane O 0 0.007243132
potential O 0 0.0009029637
and O 0 0.00070452713
induction O 0 0.0012348166
of O 0 0.0017364663
autophagic O 0 0.45647788
vacuoles O 0 0.022865014
in O 0 0.0034217022
neurons O 0 0.063716196
. O 0 0.005718986

Alpha B-Chemical 0 0.5403444
- I-Chemical 0 0.015222408
lipoic I-Chemical 0 0.9982685
acid I-Chemical 0 0.97624934
exerts O 0 0.059882764
neuroprotective O 0 0.9771967
effects O 0 0.007532707
against O 0 0.001311348
chemotherapy O 0 0.9366805
induced O 0 0.014492978
neurotoxicity B-Disease 2 0.9997788
in O 0 0.0012162142
sensory O 0 0.33303195
neurons O 0 0.07386549
: O 0 0.0007394696
it O 0 0.00036080077
rescues O 0 0.00072785583
the O 0 0.00046740822
mitochondrial B-Disease 0 0.9230353
toxicity I-Disease 2 0.9993624
and O 0 0.0009136521
induces O 0 0.0006924532
the O 0 0.00032520012
expression O 0 0.00075690734
of O 0 0.00084588194
frataxin O 0 0.9910014
, O 0 0.00094537175
an O 0 0.00063217664
essential O 0 0.0007194585
mitochondrial O 0 0.28602695
protein O 0 0.0035355384
with O 0 0.0014164485
anti O 0 0.023904257
- O 0 0.006125042
oxidant O 0 0.9857115
and O 0 0.004206057
chaperone O 0 0.11414053
properties O 0 0.013608266
. O 0 0.006891615

In O 0 0.0037096909
conclusion O 0 0.0034919854
mitochondrial B-Disease 0 0.8436894
toxicity I-Disease 2 0.9973916
is O 0 0.0022813505
an O 0 0.0016332906
early O 0 0.002054642
common O 0 0.0018102246
event O 0 0.0038989745
both O 0 0.0011884011
in O 0 0.0016210467
paclitaxel B-Chemical 1 0.99696296
and O 0 0.007880515
cisplatin B-Chemical 1 0.9984547
induced O 0 0.15186979
neurotoxicity B-Disease 2 0.9988041
. O 0 0.013379057

Alpha B-Chemical 0 0.5389026
- I-Chemical 0 0.016135627
lipoic I-Chemical 0 0.9982293
acid I-Chemical 0 0.982474
protects O 0 0.088889964
sensory O 0 0.38849455
neurons O 0 0.0533975
through O 0 0.0008701224
its O 0 0.0019000155
anti O 0 0.0106458
- O 0 0.0026710096
oxidant O 0 0.98287576
and O 0 0.0013737829
mitochondrial O 0 0.3056533
regulatory O 0 0.001918014
functions O 0 0.0014642411
, O 0 0.0010711394
possibly O 0 0.0019196996
inducing O 0 0.0023036066
the O 0 0.0014103283
expression O 0 0.0035773453
of O 0 0.00629073
frataxin O 0 0.9872656
. O 0 0.009112255

These O 0 0.0046177404
findings O 0 0.0040432643
suggest O 0 0.0016590117
that O 0 0.0017452267
alpha B-Chemical 1 0.32380927
- I-Chemical 1 0.010199889
lipoic I-Chemical 1 0.9994161
acid I-Chemical 1 0.9757093
might O 0 0.0007079661
reduce O 0 0.00048897724
the O 0 0.00050560664
risk O 0 0.013233097
of O 0 0.00086070335
developing O 0 0.0088987835
peripheral B-Disease 0 0.32873
nerve I-Disease 0 0.89075047
toxicity I-Disease 2 0.99757993
in O 0 0.00057647267
patients O 0 0.0019156984
undergoing O 0 0.0014002823
chemotherapy O 0 0.5237949
and O 0 0.0008224883
encourage O 0 0.0009695362
further O 0 0.0012326968
confirmatory O 0 0.023727989
clinical O 0 0.021974936
trials O 0 0.0074846037
. O 0 0.0055460897

Toxicity B-Disease 0 0.93637407
in O 0 0.0026288617
rhesus O 0 0.0021106014
monkeys O 0 0.0014988469
following O 0 0.0009591444
administration O 0 0.017876271
of O 0 0.0009644038
the O 0 0.00069603923
8 B-Chemical 0 0.00072309474
- I-Chemical 0 0.001094322
aminoquinoline I-Chemical 0 0.6849101
8 B-Chemical 0 0.0007422443
- I-Chemical 0 0.0010836445
[ I-Chemical 0 0.0012099216
( I-Chemical 0 0.0005307149
4 I-Chemical 0 0.00032965923
- I-Chemical 0 0.00072451873
amino I-Chemical 0 0.39519414
- I-Chemical 0 0.0012159662
l I-Chemical 0 0.0026881695
- I-Chemical 0 0.00135005
methylbutyl I-Chemical 0 0.44231755
) I-Chemical 0 0.0017247881
amino I-Chemical 0 0.67862856
] I-Chemical 0 0.003140209
- I-Chemical 0 0.0007990417
5 I-Chemical 0 0.00032995638
- I-Chemical 0 0.0006106264
( I-Chemical 0 0.0005001787
l I-Chemical 0 0.0013538232
- I-Chemical 0 0.001103261
hexyloxy I-Chemical 0 0.51201075
) I-Chemical 0 0.0014583395
- I-Chemical 0 0.0010017835
6 I-Chemical 0 0.00047498217
- I-Chemical 0 0.0013557173
methoxy I-Chemical 0 0.9726045
- I-Chemical 0 0.0019321946
4 I-Chemical 0 0.0009776354
- I-Chemical 0 0.0022426064
methylquinoline I-Chemical 0 0.10348044
( O 0 0.005308463
WR242511 B-Chemical 1 0.98165613
) O 0 0.010276122
. O 0 0.006339258

INTRODUCTION O 0 0.088149056
: O 0 0.006231791
Many O 0 0.0047851945
substances O 0 0.29329902
that O 0 0.0021725926
form O 0 0.0035184612
methemoglobin O 0 0.9977316
( O 0 0.010509629
MHb O 0 0.9840592
) O 0 0.0033903602
effectively O 0 0.0030418108
counter O 0 0.02415257
cyanide O 0 0.9984389
( O 0 0.02227581
CN O 0 0.9765227
) O 0 0.02976027
toxicity B-Disease 2 0.98706263
. O 0 0.011717462

Although O 0 0.0059434767
MHb O 0 0.9401698
formers O 0 0.75138795
are O 0 0.0019205502
generally O 0 0.0014842756
applied O 0 0.0009035557
as O 0 0.00062843354
treatments O 0 0.002004676
for O 0 0.0008861218
CN O 0 0.983226
poisoning B-Disease 2 0.9993136
, O 0 0.0016415367
it O 0 0.00058780564
has O 0 0.0004023546
been O 0 0.00044051133
proposed O 0 0.0004702572
that O 0 0.00027152404
a O 0 0.00039589548
stable O 0 0.0006062565
, O 0 0.00056983426
long O 0 0.0006636441
- O 0 0.001041639
acting O 0 0.005450986
MHb O 0 0.97416997
former O 0 0.005085665
could O 0 0.0006614887
serve O 0 0.0014262979
as O 0 0.0013068888
a O 0 0.0035305289
CN O 0 0.9354341
pretreatment O 0 0.60531574
. O 0 0.008605136

Using O 0 0.004191405
this O 0 0.002289113
rationale O 0 0.0032297724
, O 0 0.0020435872
the O 0 0.001219773
8 B-Chemical 0 0.0012441783
- I-Chemical 0 0.001890314
aminoquinoline I-Chemical 0 0.8799122
WR242511 B-Chemical 1 0.99557436
, O 0 0.0013448303
a O 0 0.0006896164
potent O 0 0.0125174
long O 0 0.00074714096
- O 0 0.0008580785
lasting O 0 0.00348665
MHb O 0 0.96700144
former O 0 0.0034303798
in O 0 0.0002740418
rodents O 0 0.0012627322
and O 0 0.00031960494
beagle O 0 0.013135381
dogs O 0 0.0014674768
, O 0 0.00041677686
was O 0 0.00026400518
studied O 0 0.00037240738
in O 0 0.00023658789
the O 0 0.0002747086
rhesus O 0 0.00046990142
monkey O 0 0.00089004857
for O 0 0.00037607725
advanced O 0 0.013808682
development O 0 0.0019658185
as O 0 0.0009182136
a O 0 0.00177546
potential O 0 0.004339138
CN O 0 0.95328057
pretreatment O 0 0.644376
. O 0 0.008431128

METHODS O 0 0.006155792
: O 0 0.0030024783
In O 0 0.0012331454
this O 0 0.0010396319
study O 0 0.0015669785
, O 0 0.0015779098
WR242511 B-Chemical 1 0.96676296
was O 0 0.00093101483
administered O 0 0.0031385424
intravenously O 0 0.024059739
( O 0 0.0011015208
IV O 0 0.07439617
) O 0 0.00071620644
in O 0 0.0002628937
2 O 0 0.0002720856
female O 0 0.0006009188
and O 0 0.0002461493
4 O 0 0.00019179872
male O 0 0.0005124136
rhesus O 0 0.0002508352
monkeys O 0 0.0002464541
in O 0 0.00016705335
doses O 0 0.003535466
of O 0 0.0003558809
3 O 0 0.0002383364
. O 0 0.00013324355
5 O 0 0.00016188504
and O 0 0.00020727902
/ O 0 0.00045060797
or O 0 0.00017808662
7 O 0 0.00018556285
. O 0 0.00011837321
0 O 0 0.00024102429
mg O 0 0.082239226
/ O 0 0.0006447072
kg O 0 0.0029919313
; O 0 0.0003874442
a O 0 0.00021805319
single O 0 0.0002454692
male O 0 0.00083849893
also O 0 0.00033619377
received O 0 0.0007962677
WR242511 B-Chemical 1 0.9924085
orally O 0 0.240073
( O 0 0.0017673477
PO O 0 0.8893659
) O 0 0.0011161392
at O 0 0.0004099495
7 O 0 0.00059358316
. O 0 0.0005359
0 O 0 0.001373471
mg O 0 0.13565065
/ O 0 0.0057544108
kg O 0 0.015466979
. O 0 0.005104873

Health O 0 0.010828945
status O 0 0.006493497
and O 0 0.006010828
MHb O 0 0.8060376
levels O 0 0.0038346266
were O 0 0.0035492715
monitored O 0 0.003195369
following O 0 0.006096819
exposure O 0 0.019431064
. O 0 0.011565576

RESULTS O 0 0.023447819
: O 0 0.003774881
The O 0 0.001363535
selected O 0 0.0012011565
doses O 0 0.010952838
of O 0 0.0021433185
WR242511 B-Chemical 1 0.99187565
, O 0 0.0015820859
which O 0 0.00091255154
produced O 0 0.0006378553
significant O 0 0.001335238
methemoglobinemia B-Disease 0 0.9994842
in O 0 0.00059425924
beagle O 0 0.03249644
dogs O 0 0.0014809789
in O 0 0.00025163937
earlier O 0 0.000301532
studies O 0 0.00045374638
conducted O 0 0.00029865495
elsewhere O 0 0.000416032
, O 0 0.00038855732
produced O 0 0.00030031815
very O 0 0.0004549131
little O 0 0.0005788027
MHb O 0 0.971731
( O 0 0.00052601635
mean O 0 0.0002409528
< O 0 0.00045094342
2 O 0 0.00037325046
. O 0 0.00028799017
0 O 0 0.00057124486
% O 0 0.0007002482
) O 0 0.0010394946
in O 0 0.0008680898
the O 0 0.0015307595
rhesus O 0 0.0036145274
monkey O 0 0.008182672
. O 0 0.005427988

Furthermore O 0 0.0060318382
, O 0 0.004249564
transient O 0 0.06350231
hemoglobinuria B-Disease 0 0.9982925
was O 0 0.0015518744
noted O 0 0.0007621323
approximately O 0 0.00058065454
60 O 0 0.0004832487
minutes O 0 0.00036050755
postinjection O 0 0.001186007
of O 0 0.000607701
WR242511 B-Chemical 1 0.98148775
( O 0 0.00075936737
3 O 0 0.00028573765
. O 0 0.00015914756
5 O 0 0.00017554928
or O 0 0.00016533353
7 O 0 0.00018815605
. O 0 0.0001280684
0 O 0 0.00025886513
mg O 0 0.07575712
/ O 0 0.0007028462
kg O 0 0.0035084079
) O 0 0.000488534
, O 0 0.00031165197
and O 0 0.00026684324
2 O 0 0.00031296833
lethalities O 0 0.783277
occurred O 0 0.00060280086
( O 0 0.00046226697
one O 0 0.00025030033
IV O 0 0.02535531
and O 0 0.00038125593
one O 0 0.0003607102
PO O 0 0.8222998
) O 0 0.000818766
following O 0 0.00041892883
the O 0 0.00043709684
7 O 0 0.00048454088
. O 0 0.00040344638
0 O 0 0.0009832652
mg O 0 0.11983867
/ O 0 0.003869803
kg O 0 0.013410609
dose O 0 0.0209887
. O 0 0.005683917

Myoglobinuria B-Disease 0 0.9859649
was O 0 0.004016355
also O 0 0.002475949
observed O 0 0.0014338755
following O 0 0.0015063128
the O 0 0.0014519789
7 O 0 0.0013864625
. O 0 0.0010739838
0 O 0 0.0020330825
mg O 0 0.16250737
/ O 0 0.006431091
kg O 0 0.018234454
dose O 0 0.028405497
. O 0 0.007961459

Histopathology O 0 0.15376881
analyses O 0 0.003980572
in O 0 0.001649216
the O 0 0.0011953162
2 O 0 0.0009084191
animals O 0 0.00061244605
that O 0 0.0005260334
died O 0 0.0036324402
revealed O 0 0.0008638992
liver B-Disease 0 0.7100435
and I-Disease 0 0.0013251788
kidney I-Disease 0 0.94950014
toxicity I-Disease 2 0.9973494
, O 0 0.0012127841
with O 0 0.0006787468
greater O 0 0.0006548021
severity O 0 0.010401449
in O 0 0.00072514976
the O 0 0.0010383747
orally O 0 0.09116355
- O 0 0.0035554676
treated O 0 0.0044086836
animal O 0 0.008023518
. O 0 0.006109729

CONCLUSIONS O 0 0.6421812
: O 0 0.0058134682
These O 0 0.0029837776
data O 0 0.0021248076
demonstrate O 0 0.001291623
direct O 0 0.001640689
and O 0 0.0019583905
/ O 0 0.0032955236
or O 0 0.0016244062
indirect O 0 0.0047844816
drug O 0 0.61679256
- O 0 0.010410947
induced O 0 0.013503154
toxicity B-Disease 2 0.990027
. O 0 0.011664115

It O 0 0.0061470433
is O 0 0.0025473624
concluded O 0 0.002749615
that O 0 0.0015403221
WR242511 B-Chemical 1 0.958383
should O 0 0.00075897947
not O 0 0.00064368284
be O 0 0.0006222679
pursued O 0 0.0015611524
as O 0 0.00041817734
a O 0 0.0005957828
pretreatment O 0 0.11114086
for O 0 0.0007298826
CN O 0 0.9873239
poisoning B-Disease 2 0.9993678
unless O 0 0.0013268219
the O 0 0.00051820546
anti O 0 0.009565243
- O 0 0.0017840279
CN O 0 0.808192
characteristics O 0 0.00049169094
of O 0 0.00044600168
this O 0 0.00040570332
compound O 0 0.027482186
can O 0 0.0003860191
be O 0 0.00045036623
successfully O 0 0.0008592386
dissociated O 0 0.0015974758
from O 0 0.0008636453
those O 0 0.0016409107
producing O 0 0.0033115032
undesirable O 0 0.37555984
toxicity B-Disease 2 0.99263847
. O 0 0.00902137

Repetitive O 0 0.060737837
transcranial O 0 0.4062212
magnetic O 0 0.074968904
stimulation O 0 0.006008392
for O 0 0.0030764518
levodopa B-Chemical 1 0.9992248
- O 0 0.010843241
induced O 0 0.008571924
dyskinesias B-Disease 2 0.99937075
in O 0 0.0057423245
Parkinson B-Disease 0 0.99786097
' I-Disease 0 0.0058083716
s I-Disease 0 0.007138874
disease I-Disease 0 0.56497765
. O 0 0.009337827

In O 0 0.003192606
a O 0 0.002807992
placebo O 0 0.099654436
- O 0 0.002255173
controlled O 0 0.0010170441
, O 0 0.000954719
single O 0 0.00069224706
- O 0 0.00085158827
blinded O 0 0.00077298895
, O 0 0.0004819611
crossover O 0 0.0015719142
study O 0 0.0005639604
, O 0 0.00034668233
we O 0 0.00012738461
assessed O 0 0.00018038195
the O 0 0.00021533051
effect O 0 0.0003062977
of O 0 0.000389521
" O 0 0.00040547908
real O 0 0.00036829177
" O 0 0.00039685584
repetitive O 0 0.0012319672
transcranial O 0 0.5114745
magnetic O 0 0.10128347
stimulation O 0 0.0027209618
( O 0 0.00083565345
rTMS O 0 0.867125
) O 0 0.00062630314
versus O 0 0.00026310832
" O 0 0.00033013857
sham O 0 0.0004349339
" O 0 0.0004684886
rTMS O 0 0.8319383
( O 0 0.0006527873
placebo O 0 0.09093534
) O 0 0.0004989692
on O 0 0.00015260732
peak O 0 0.00048083227
dose O 0 0.039266016
dyskinesias B-Disease 2 0.99969983
in O 0 0.00053209683
patients O 0 0.0025531652
with O 0 0.0015108119
Parkinson B-Disease 0 0.99888295
' I-Disease 0 0.0015724831
s I-Disease 0 0.0022087242
disease I-Disease 0 0.6697758
( O 0 0.007847798
PD B-Disease 0 0.9881071
) O 0 0.010557669
. O 0 0.0062709954

Ten O 0 0.007088504
patients O 0 0.0056098234
with O 0 0.0034423068
PD B-Disease 0 0.9784908
and O 0 0.002243246
prominent O 0 0.042507287
dyskinesias B-Disease 2 0.99957114
had O 0 0.0022701619
rTMS O 0 0.95959616
( O 0 0.001159111
1 O 0 0.00046583032
, O 0 0.00042236087
800 O 0 0.0010461285
pulses O 0 0.0026017048
; O 0 0.0006617541
1 O 0 0.00032058882
Hz O 0 0.043785606
rate O 0 0.00024063668
) O 0 0.0003621487
delivered O 0 0.00018462165
over O 0 0.00011665096
the O 0 0.00022553952
motor O 0 0.028574765
cortex O 0 0.07261705
for O 0 0.00016886016
4 O 0 0.0001457451
consecutive O 0 0.00017751733
days O 0 0.00013663096
twice O 0 0.00018382735
, O 0 0.00020161453
once O 0 0.0001512173
real O 0 0.00020886934
stimuli O 0 0.0008055538
and O 0 0.00021269255
once O 0 0.00019647992
sham O 0 0.00030221208
stimulation O 0 0.0004563868
were O 0 0.00020113874
used O 0 0.00020057207
; O 0 0.00033649695
evaluations O 0 0.00024921735
were O 0 0.00016893796
done O 0 0.00013123825
at O 0 0.000115935254
the O 0 0.00016635683
baseline O 0 0.00029029336
and O 0 0.00024127075
1 O 0 0.00021462336
day O 0 0.0001780299
after O 0 0.00012994531
the O 0 0.00020789973
end O 0 0.00019369
of O 0 0.00045505926
each O 0 0.00034769863
of O 0 0.0010457301
the O 0 0.0014235405
treatment O 0 0.005179875
series O 0 0.008173069
. O 0 0.005920727

Direct O 0 0.0066417637
comparison O 0 0.002124935
between O 0 0.001115807
sham O 0 0.001684196
and O 0 0.0011075678
real O 0 0.0012803241
rTMS O 0 0.68429476
effects O 0 0.0018005661
showed O 0 0.0007250067
no O 0 0.00053870765
significant O 0 0.0008250479
difference O 0 0.0005289879
in O 0 0.00089978706
clinician O 0 0.00401184
- O 0 0.0033027425
assessed O 0 0.0035029307
dyskinesia B-Disease 2 0.99945754
severity O 0 0.4012701
. O 0 0.009103841

However O 0 0.004021378
, O 0 0.0026577548
comparison O 0 0.0012813585
with O 0 0.0012046626
the O 0 0.00083037297
baseline O 0 0.00095808215
showed O 0 0.00064086734
small O 0 0.0007876033
but O 0 0.00059892394
significant O 0 0.0008075809
reduction O 0 0.0014009972
in O 0 0.0011246579
dyskinesia B-Disease 2 0.99984324
severity O 0 0.07080491
following O 0 0.0012951887
real O 0 0.002026466
rTMS O 0 0.89174265
but O 0 0.00203753
not O 0 0.0028820632
placebo O 0 0.24418342
. O 0 0.0060863947

The O 0 0.007393395
major O 0 0.008507731
effect O 0 0.008212971
was O 0 0.008345019
on O 0 0.009972732
dystonia B-Disease 2 0.9971209
subscore O 0 0.512855
. O 0 0.02064213

Similarly O 0 0.0047269333
, O 0 0.0028543673
in O 0 0.0013509471
patient O 0 0.00175661
diaries O 0 0.0026206702
, O 0 0.0010856971
although O 0 0.00057678245
both O 0 0.00047997138
treatments O 0 0.001585833
caused O 0 0.0007109958
reduction O 0 0.001211947
in O 0 0.00044210066
subjective O 0 0.037618883
dyskinesia B-Disease 2 0.99990976
scores O 0 0.00043785537
during O 0 0.00017837212
the O 0 0.000186857
days O 0 0.00019150249
of O 0 0.0002675221
intervention O 0 0.00037959352
, O 0 0.0002949436
the O 0 0.00018978273
effect O 0 0.00028589275
was O 0 0.00025233297
sustained O 0 0.0014504173
for O 0 0.00022165317
3 O 0 0.0002156593
days O 0 0.00021085874
after O 0 0.00016300242
the O 0 0.0002972449
intervention O 0 0.00058336474
for O 0 0.0005103207
the O 0 0.00093501515
real O 0 0.0024350062
rTMS O 0 0.85385525
only O 0 0.0047703004
. O 0 0.0057663694

Following O 0 0.0058244914
rTMS O 0 0.6893268
, O 0 0.0033157996
no O 0 0.0014204335
side O 0 0.0059987037
effects O 0 0.0020517774
and O 0 0.0010520072
no O 0 0.00077538664
adverse O 0 0.37595558
effects O 0 0.0019120368
on O 0 0.0006228392
motor O 0 0.05046388
function O 0 0.0018150096
and O 0 0.0024031352
PD B-Disease 0 0.99203295
symptoms O 0 0.5970498
were O 0 0.003899663
noted O 0 0.005149901
. O 0 0.0060058124

The O 0 0.0024568662
results O 0 0.0015999319
suggest O 0 0.0010547569
the O 0 0.00095451204
existence O 0 0.0009568381
of O 0 0.0008681095
residual O 0 0.0009091066
beneficial O 0 0.0025778837
clinical O 0 0.009311494
aftereffects O 0 0.13150017
of O 0 0.00064671825
consecutive O 0 0.0006371536
daily O 0 0.0011020451
applications O 0 0.00081889913
of O 0 0.0006662158
low O 0 0.0010639143
- O 0 0.0014509396
frequency O 0 0.0014745634
rTMS O 0 0.9134787
on O 0 0.0019895763
dyskinesias B-Disease 2 0.99911517
in O 0 0.007457939
PD B-Disease 0 0.98937255
. O 0 0.008395246

The O 0 0.004717568
effects O 0 0.0055572856
may O 0 0.0033445503
be O 0 0.0028300148
further O 0 0.0027336846
exploited O 0 0.0043946705
for O 0 0.0026497028
potential O 0 0.0055363616
therapeutic O 0 0.03471746
uses O 0 0.010967477
. O 0 0.011220199

Intracavernous O 0 0.9828553
epinephrine B-Chemical 0 0.9939791
: O 0 0.0062143095
a O 0 0.0026330473
minimally O 0 0.0038883896
invasive O 0 0.007661501
treatment O 0 0.0048725177
for O 0 0.002970092
priapism B-Disease 0 0.9965005
in O 0 0.0036580698
the O 0 0.0041371854
emergency O 0 0.041475028
department O 0 0.058057025
. O 0 0.010898281

Priapism B-Disease 0 0.98341864
is O 0 0.0041566603
the O 0 0.0024973124
prolonged O 0 0.010240304
erection O 0 0.5479205
of O 0 0.0024351857
the O 0 0.0018433267
penis O 0 0.024889888
in O 0 0.0013851493
the O 0 0.001467427
absence O 0 0.001508272
of O 0 0.0047987024
sexual O 0 0.4047874
arousal O 0 0.85723734
. O 0 0.009692082

A O 0 0.017200697
45 O 0 0.003584789
- O 0 0.0030644203
year O 0 0.0017263471
- O 0 0.0018824601
old O 0 0.0012541845
man O 0 0.038389366
, O 0 0.0010165268
an O 0 0.0008477906
admitted O 0 0.005375415
frequent O 0 0.0066108787
cocaine B-Chemical 1 0.99929345
user O 0 0.0013522923
, O 0 0.00058735796
presented O 0 0.0003835023
to O 0 0.00030681264
the O 0 0.0003632412
Emergency O 0 0.021376304
Department O 0 0.008544318
( O 0 0.0007573221
ED O 0 0.13820025
) O 0 0.00056031434
on O 0 0.00015537847
two O 0 0.00018478492
separate O 0 0.00023631171
occasions O 0 0.00074952364
with O 0 0.000541016
a O 0 0.0007193537
history O 0 0.008337056
of O 0 0.0026899506
priapism B-Disease 0 0.99838924
after O 0 0.0032658672
cocaine B-Chemical 1 0.9981414
use O 0 0.010566191
. O 0 0.007019874

The O 0 0.0030933982
management O 0 0.0042239516
options O 0 0.003205686
in O 0 0.0013723425
the O 0 0.0012311132
ED O 0 0.15464047
, O 0 0.001096543
as O 0 0.00045795087
exemplified O 0 0.00078433513
by O 0 0.00039288244
four O 0 0.00022144445
individual O 0 0.00026802425
case O 0 0.00035497063
reports O 0 0.0006462602
, O 0 0.00041226088
in O 0 0.00021175547
particular O 0 0.0002157864
the O 0 0.00023541487
use O 0 0.0003289134
of O 0 0.0003706457
a O 0 0.00039792887
minimally O 0 0.0009668003
invasive O 0 0.0036215167
method O 0 0.0010752155
of O 0 0.0012132903
intracorporal O 0 0.50391287
epinephrine B-Chemical 0 0.99842876
instillation O 0 0.43274856
, O 0 0.003794268
are O 0 0.0030656618
discussed O 0 0.0042574685
. O 0 0.0056685987

Prophylactic O 0 0.20291345
use O 0 0.005723068
of O 0 0.005677257
lamivudine B-Chemical 1 0.9981238
with O 0 0.0081309285
chronic O 0 0.98586905
immunosuppressive O 0 0.99352574
therapy O 0 0.41759872
for O 0 0.007956701
rheumatologic B-Disease 0 0.9947989
disorders I-Disease 0 0.98892933
. O 0 0.01443219

The O 0 0.0025364307
objective O 0 0.00278541
of O 0 0.0014939301
this O 0 0.0009983977
study O 0 0.0011844876
was O 0 0.0006111294
to O 0 0.00046152246
report O 0 0.0010111283
our O 0 0.00034016944
experience O 0 0.0007004394
concerning O 0 0.00033388648
the O 0 0.00028565322
effectiveness O 0 0.0003505759
of O 0 0.00040551272
the O 0 0.00034234874
prophylactic O 0 0.017672323
administration O 0 0.18911298
of O 0 0.0024881684
lamivudine B-Chemical 1 0.99981993
in O 0 0.008632348
hepatitis B-Chemical 2 0.9999553
B I-Chemical 2 0.9894126
virus I-Chemical 0 0.46158054
surface I-Chemical 0 0.032715466
antigen I-Chemical 0 0.2482372
( O 0 0.00531187
HBs B-Chemical 0 0.99851066
Ag I-Chemical 0 0.91207945
) O 0 0.0021193267
positive O 0 0.0010676738
patients O 0 0.004557636
with O 0 0.0044369274
rheumatologic B-Disease 0 0.99450487
disease I-Disease 0 0.9874127
. O 0 0.010480206

From O 0 0.0059545455
June O 0 0.0037751354
2004 O 0 0.0038387966
to O 0 0.0015523244
October O 0 0.001707569
2006 O 0 0.0020642153
, O 0 0.0011804461
11 O 0 0.0011546897
HBs B-Chemical 0 0.9925022
Ag I-Chemical 0 0.5468706
positive O 0 0.00071937183
patients O 0 0.0023055177
with O 0 0.0011682243
rheumatologic B-Disease 0 0.9968081
diseases I-Disease 0 0.98456466
, O 0 0.0015434802
who O 0 0.0013427901
were O 0 0.00032683526
on O 0 0.00019562322
both O 0 0.00039613977
immunosuppressive O 0 0.8822196
and O 0 0.0009663311
prophylactic O 0 0.12672347
lamivudine B-Chemical 1 0.9995684
therapies O 0 0.20014346
, O 0 0.0023406479
were O 0 0.0016756798
retrospectively O 0 0.003519227
assessed O 0 0.0032341736
. O 0 0.0051992903

Liver O 0 0.92704195
function O 0 0.0059401174
tests O 0 0.008041905
, O 0 0.009132151
hepatitis B-Disease 2 0.9996649
B I-Disease 2 0.9730593
virus O 0 0.46739566
( O 0 0.00529819
HBV O 0 0.99240255
) O 0 0.0029313106
serologic O 0 0.20756258
markers O 0 0.0028189216
, O 0 0.0010336201
and O 0 0.00079691596
HBV O 0 0.98734915
DNA O 0 0.04690527
levels O 0 0.0004736014
of O 0 0.0004936059
the O 0 0.00036397713
patients O 0 0.0009954537
during O 0 0.00028408645
follow O 0 0.0004663219
- O 0 0.0007510461
up O 0 0.00043673406
were O 0 0.00047648745
obtained O 0 0.0006271465
from O 0 0.0009727928
hospital O 0 0.0036216301
file O 0 0.001625822
records O 0 0.0057158605
. O 0 0.0053589754

Eleven O 0 0.01252854
patients O 0 0.005823525
( O 0 0.0023789227
six O 0 0.00092317536
male O 0 0.0026572188
) O 0 0.0013040464
with O 0 0.000672973
median O 0 0.0005218673
age O 0 0.00091455615
47 O 0 0.0008179227
years O 0 0.0007746363
( O 0 0.00048296826
range O 0 0.0005064527
27 O 0 0.00065347756
- O 0 0.0005298059
73 O 0 0.00064077263
) O 0 0.00044966614
, O 0 0.00027599523
median O 0 0.00022919138
disease O 0 0.07684676
duration O 0 0.0004171968
50 O 0 0.00039447486
months O 0 0.00027117608
( O 0 0.0002868475
range O 0 0.00033338458
9 O 0 0.0002568416
- O 0 0.00037137183
178 O 0 0.0016070418
) O 0 0.00033180488
and O 0 0.00018018804
median O 0 0.00017290936
follow O 0 0.00020172184
- O 0 0.00031193878
up O 0 0.00015757758
period O 0 0.00016526732
of O 0 0.00025481664
patients O 0 0.0007726961
13 O 0 0.00032492305
. O 0 0.00013914789
8 O 0 0.00019159183
months O 0 0.00023894323
( O 0 0.0003071679
range O 0 0.00039346397
5 O 0 0.0003104897
- O 0 0.0005722994
27 O 0 0.000692517
) O 0 0.00070350326
were O 0 0.00056027056
enrolled O 0 0.0013918324
in O 0 0.0010360369
this O 0 0.0019477486
study O 0 0.0048755724
. O 0 0.0051761293

Lamivudine B-Chemical 1 0.99698263
therapy O 0 0.05503863
was O 0 0.0024267996
started O 0 0.0022813582
3 O 0 0.0012632369
- O 0 0.0014038406
7 O 0 0.0006064019
days O 0 0.00053361803
prior O 0 0.00048044193
to O 0 0.00087167986
immunosuppressive O 0 0.8513318
therapy O 0 0.039015435
in O 0 0.0022309422
all O 0 0.002958163
patients O 0 0.011342304
. O 0 0.006604866

Baseline O 0 0.011500513
, O 0 0.0039795553
liver O 0 0.28842047
function O 0 0.0019429852
tests O 0 0.002042165
were O 0 0.0008964523
elevated O 0 0.0020722533
in O 0 0.00052302115
two O 0 0.00041925648
patients O 0 0.0017380037
( O 0 0.0007642556
fourth O 0 0.0010075062
patient O 0 0.0011839872
: O 0 0.0014597685
ALT O 0 0.9970318
: O 0 0.0014244614
122 O 0 0.008376999
IU O 0 0.47376502
/ O 0 0.0015064671
l O 0 0.0018162878
, O 0 0.0010104293
AST O 0 0.99743724
: O 0 0.001276767
111 O 0 0.005118868
IU O 0 0.4046991
/ O 0 0.0011131157
l O 0 0.0010341445
, O 0 0.00045571034
tenth O 0 0.0008519958
patient O 0 0.0009382716
: O 0 0.0012244735
ALT O 0 0.9971877
: O 0 0.0013827579
294 O 0 0.02727711
IU O 0 0.4924957
/ O 0 0.0014644057
l O 0 0.001794137
, O 0 0.0010160514
AST O 0 0.99758124
: O 0 0.0014894379
274 O 0 0.05147632
IU O 0 0.48641774
/ O 0 0.0012295124
l O 0 0.0011044603
, O 0 0.00047789942
with O 0 0.00041575625
minimal O 0 0.00053469127
changes O 0 0.00075041334
in O 0 0.0005178267
the O 0 0.0008399748
liver O 0 0.5646477
biopsy O 0 0.015688725
in O 0 0.002012398
both O 0 0.0032968894
) O 0 0.0073593743
. O 0 0.0056769317

Shortly O 0 0.011089267
after O 0 0.0015883476
treatment O 0 0.0023310338
their O 0 0.0011883209
tests O 0 0.0015014281
normalized O 0 0.0005570159
and O 0 0.0006572715
during O 0 0.00040886705
follow O 0 0.00058385474
- O 0 0.0007774875
up O 0 0.0003727169
period O 0 0.00036282587
none O 0 0.000506499
of O 0 0.0005886093
the O 0 0.0006169075
patients O 0 0.0020794037
had O 0 0.0014255173
abnormal B-Disease 0 0.099512525
liver I-Disease 0 0.8542797
function I-Disease 0 0.009150052
tests O 0 0.012831345
. O 0 0.0070645045

In O 0 0.0037501152
four O 0 0.002496197
patients O 0 0.00705613
HBV O 0 0.9694481
DNA O 0 0.047019605
levels O 0 0.0021385124
were O 0 0.0016498971
higher O 0 0.0016064402
than O 0 0.001471689
normal O 0 0.00391203
at O 0 0.00276378
baseline O 0 0.0072004828
. O 0 0.0074581723

Two O 0 0.006552114
of O 0 0.0045573423
these O 0 0.0041871737
normalized O 0 0.0026603064
and O 0 0.0036892723
the O 0 0.0038733245
others O 0 0.008643381
increased O 0 0.009246037
later O 0 0.009359395
. O 0 0.010903289

In O 0 0.0030890417
three O 0 0.0016170794
additional O 0 0.0015559086
patients O 0 0.004415088
, O 0 0.0032573908
HBV O 0 0.97690207
DNA O 0 0.054791115
levels O 0 0.0016753002
were O 0 0.0014276161
increased O 0 0.0022283706
during O 0 0.0016632212
follow O 0 0.0030207124
- O 0 0.0061102845
up O 0 0.005581614
. O 0 0.006886519

None O 0 0.010209049
of O 0 0.004238402
the O 0 0.0030722634
patients O 0 0.0051355576
had O 0 0.0028658176
significant O 0 0.0037526458
clinical O 0 0.0145050185
sings O 0 0.05723211
of O 0 0.0107340375
HBV O 0 0.984202
activation O 0 0.0645385
. O 0 0.013840368

Lamivudine B-Chemical 1 0.99623317
was O 0 0.0045414227
well O 0 0.002699028
tolerated O 0 0.011439097
and O 0 0.0025899468
was O 0 0.002253547
continued O 0 0.003192838
in O 0 0.0027750179
all O 0 0.003958566
patients O 0 0.012960524
. O 0 0.008868702

Prophylactic O 0 0.325687
administration O 0 0.1372737
of O 0 0.0039572227
lamivudine B-Chemical 1 0.9988973
in O 0 0.0015042931
patients O 0 0.0035136384
who O 0 0.0016887626
required O 0 0.00039665287
immunosuppressive O 0 0.9429775
therapy O 0 0.060560636
seems O 0 0.00069240073
to O 0 0.00042362342
be O 0 0.00046727678
safe O 0 0.0017474962
, O 0 0.00063304487
well O 0 0.00045025206
tolerated O 0 0.006671819
and O 0 0.00088373903
effective O 0 0.0016879308
in O 0 0.0016595069
preventing O 0 0.018810235
HBV O 0 0.9934448
reactivation O 0 0.8598395
. O 0 0.009823815

Effect O 0 0.009419991
of O 0 0.0053636753
green B-Chemical 1 0.012181722
tea I-Chemical 1 0.9936069
and O 0 0.010539554
vitamin B-Chemical 1 0.9992428
E I-Chemical 1 0.9938506
combination O 0 0.032543637
in O 0 0.003801138
isoproterenol B-Chemical 1 0.99890447
induced O 0 0.08732264
myocardial B-Disease 0 0.9991079
infarction I-Disease 2 0.9996669
in O 0 0.013349808
rats O 0 0.08306397
. O 0 0.008696022

The O 0 0.002380349
present O 0 0.001448963
study O 0 0.0018000896
was O 0 0.0009827333
aimed O 0 0.0008677189
to O 0 0.0005416248
investigate O 0 0.0003450043
the O 0 0.00040535405
combined O 0 0.0007882828
effects O 0 0.0011876713
of O 0 0.0009169989
green B-Chemical 1 0.009618537
tea I-Chemical 1 0.9987644
and O 0 0.00603753
vitamin B-Chemical 1 0.999821
E I-Chemical 1 0.9967518
on O 0 0.00047889762
heart O 0 0.5432366
weight O 0 0.015933814
, O 0 0.0005670424
body O 0 0.0022962214
weight O 0 0.004891859
, O 0 0.00051631144
serum O 0 0.029055053
marker O 0 0.0008057081
enzymes O 0 0.1024363
, O 0 0.0013444088
lipid O 0 0.92545456
peroxidation O 0 0.9998753
, O 0 0.002249164
endogenous O 0 0.0024201954
antioxidants O 0 0.9982305
and O 0 0.0010338599
membrane O 0 0.020339582
bound O 0 0.0005131102
ATPases O 0 0.77577186
in O 0 0.00091185624
isoproterenol B-Chemical 1 0.9994628
( O 0 0.0067440025
ISO B-Chemical 0 0.9712715
) O 0 0.0037350776
- O 0 0.002544669
induced O 0 0.0045901556
myocardial B-Disease 0 0.9988802
infarction I-Disease 2 0.99967957
in O 0 0.0083233705
rats O 0 0.06120271
. O 0 0.006826263

Adult O 0 0.010994221
male O 0 0.007459005
albino O 0 0.022604391
rats O 0 0.0063448595
, O 0 0.0018973136
treated O 0 0.0017965679
with O 0 0.001472906
ISO B-Chemical 0 0.898
( O 0 0.0013846272
200 O 0 0.0017434907
mg O 0 0.31881583
/ O 0 0.0013053443
kg O 0 0.003917309
, O 0 0.0004729216
s O 0 0.00041753778
. O 0 0.00019191728
c O 0 0.0011681359
. O 0 0.00019828191
) O 0 0.00036064367
for O 0 0.00016296202
2 O 0 0.00018064822
days O 0 0.0001467588
at O 0 0.00010319635
an O 0 0.00020333893
interval O 0 0.00026452699
of O 0 0.00022338633
24 O 0 0.00020843443
h O 0 0.00021200132
caused O 0 0.00026666163
a O 0 0.00031284717
significant O 0 0.00048717076
( O 0 0.0005544754
P O 0 0.020512147
< O 0 0.00037584823
0 O 0 0.00029368798
. O 0 0.00017794574
05 O 0 0.020904245
) O 0 0.0005126956
elevation O 0 0.042889614
of O 0 0.0005272744
heart O 0 0.40299135
weight O 0 0.013301397
, O 0 0.0005739437
serum O 0 0.036738068
marker O 0 0.000812384
enzymes O 0 0.10155111
, O 0 0.0012959315
lipid O 0 0.9205538
peroxidation O 0 0.99987745
and O 0 0.0060911267
Ca B-Chemical 1 0.99953663
+ O 0 0.0012420849
2 O 0 0.0004148269
ATPase O 0 0.056799136
level O 0 0.00019010366
whereas O 0 0.00021665783
there O 0 0.00014925006
was O 0 0.00024244378
a O 0 0.0002997009
significant O 0 0.00047835923
( O 0 0.00054804445
P O 0 0.01858238
< O 0 0.00037402462
0 O 0 0.0002903147
. O 0 0.00017429952
05 O 0 0.013964242
) O 0 0.00040522826
decrease O 0 0.00029906695
in O 0 0.00023560754
body O 0 0.0015245425
weight O 0 0.0037635074
, O 0 0.000565159
endogenous O 0 0.0012744063
antioxidants O 0 0.9982956
, O 0 0.009324172
Na B-Chemical 1 0.99948764
+ O 0 0.0033667088
/ O 0 0.009656417
K B-Chemical 1 0.99063593
+ O 0 0.002344294
ATPase O 0 0.33431494
and O 0 0.0025759963
Mg B-Chemical 0 0.99903286
+ O 0 0.0038429054
2 O 0 0.0029623327
ATPase O 0 0.163976
levels O 0 0.005036467
. O 0 0.006224819

Administration O 0 0.21938643
of O 0 0.00478777
green B-Chemical 1 0.009920379
tea I-Chemical 1 0.9939885
( O 0 0.003996353
100 O 0 0.0032684822
mg O 0 0.44899368
/ O 0 0.002238804
kg O 0 0.0052891225
/ O 0 0.001087146
day O 0 0.00046484845
, O 0 0.0005416764
p O 0 0.0005739248
. O 0 0.00026106034
o O 0 0.0012831936
. O 0 0.00028970145
) O 0 0.0006980314
and O 0 0.00064331363
vitamin B-Chemical 1 0.9996402
E I-Chemical 1 0.99565953
( O 0 0.0013193204
100 O 0 0.0013740152
mg O 0 0.33896834
/ O 0 0.0010090884
kg O 0 0.0035170151
/ O 0 0.0005560502
day O 0 0.0002427359
, O 0 0.00030946068
p O 0 0.0003553456
. O 0 0.00015638907
o O 0 0.00083742343
. O 0 0.00016472567
) O 0 0.00031179967
together O 0 0.00015827193
for O 0 0.00014115256
30 O 0 0.00014709026
consecutive O 0 0.0001884809
days O 0 0.00015952146
and O 0 0.00019249436
challenged O 0 0.0002527946
with O 0 0.00038983778
ISO B-Chemical 0 0.695178
on O 0 0.0001623556
the O 0 0.00021804986
day O 0 0.0002752846
29th O 0 0.0032308549
and O 0 0.0003299633
30th O 0 0.0014166555
, O 0 0.0003669693
showed O 0 0.00025931126
a O 0 0.00034082192
significant O 0 0.00052110426
( O 0 0.00058415695
P O 0 0.019217158
< O 0 0.00038790097
0 O 0 0.00029737613
. O 0 0.00017629306
05 O 0 0.0147930505
) O 0 0.00040887875
decrease O 0 0.00030607177
in O 0 0.00026250948
heart O 0 0.20046824
weight O 0 0.0081711635
, O 0 0.0005368034
serum O 0 0.032761455
marker O 0 0.00081176846
enzymes O 0 0.103954576
, O 0 0.0014165854
lipid O 0 0.93906534
peroxidation O 0 0.9998957
, O 0 0.015682666
Ca B-Chemical 1 0.99949265
+ O 0 0.001218993
2 O 0 0.00042770788
ATPase O 0 0.07101526
and O 0 0.00028447213
a O 0 0.00027363008
significant O 0 0.0003134661
increase O 0 0.00023431024
in O 0 0.00020445525
the O 0 0.00023586623
body O 0 0.0019947998
weight O 0 0.0052490574
, O 0 0.00051538454
endogenous O 0 0.0012117005
antioxidants O 0 0.998637
, O 0 0.009300956
Na B-Chemical 1 0.99963844
+ O 0 0.0032312537
/ O 0 0.009087922
K B-Chemical 1 0.9936845
+ O 0 0.0014749046
ATPase O 0 0.33760804
and O 0 0.0010838137
Mg B-Chemical 0 0.99970907
+ O 0 0.001059259
2 O 0 0.00042216846
ATPase O 0 0.05442861
when O 0 0.00017769904
compared O 0 0.00016640015
with O 0 0.00045140917
ISO B-Chemical 0 0.8176442
treated O 0 0.0010880998
group O 0 0.00068140647
and O 0 0.00068800524
green B-Chemical 1 0.005800271
tea I-Chemical 1 0.9978383
or O 0 0.0038760647
vitamin B-Chemical 1 0.9995802
E I-Chemical 1 0.99400157
alone O 0 0.006305981
treated O 0 0.009001744
groups O 0 0.006776651
. O 0 0.006669269

These O 0 0.004605367
findings O 0 0.0038606448
indicate O 0 0.0014457811
the O 0 0.0014038231
synergistic O 0 0.0053480733
protective O 0 0.013058077
effect O 0 0.0016252819
of O 0 0.0018193827
green B-Chemical 1 0.015321397
tea I-Chemical 1 0.9981987
and O 0 0.0121526355
vitamin B-Chemical 1 0.9996767
E I-Chemical 1 0.9959953
during O 0 0.0025913808
ISO B-Chemical 0 0.97812414
induced O 0 0.026417214
myocardial B-Disease 0 0.99905854
infarction I-Disease 2 0.99967945
in O 0 0.011038399
rats O 0 0.074597605
. O 0 0.007862727

Irreversible O 0 0.8668613
damage O 0 0.34567976
to O 0 0.0036433116
the O 0 0.0030562459
medullary O 0 0.7523387
interstitium O 0 0.12925653
in O 0 0.00234338
experimental O 0 0.0064119846
analgesic O 0 0.9957487
nephropathy B-Disease 2 0.9995561
in O 0 0.014330851
F344 O 0 0.92732817
rats O 0 0.054040864
. O 0 0.009947951

Renal B-Disease 0 0.97662634
papillary I-Disease 0 0.9916066
necrosis I-Disease 2 0.9986701
( O 0 0.031182636
RPN B-Disease 2 0.99173534
) O 0 0.0029130767
and O 0 0.0008804712
a O 0 0.0007109691
decreased O 0 0.0013667062
urinary O 0 0.66516155
concentrating O 0 0.10291898
ability O 0 0.00063128676
developed O 0 0.00073682686
during O 0 0.0002380902
continuous O 0 0.0003872105
long O 0 0.0005424615
- O 0 0.0006285479
term O 0 0.00046631653
treatment O 0 0.0014492479
with O 0 0.0014075809
aspirin B-Chemical 1 0.99956065
and O 0 0.0057455865
paracetamol B-Chemical 0 0.99962544
in O 0 0.0025696626
female O 0 0.026135027
Fischer O 0 0.53073674
344 O 0 0.12803753
rats O 0 0.014907456
. O 0 0.0063786516

Renal O 0 0.7594992
structure O 0 0.0047799065
and O 0 0.0020035917
concentrating O 0 0.012590449
ability O 0 0.0011198076
were O 0 0.00065976736
examined O 0 0.00040257716
after O 0 0.00027691218
a O 0 0.00041254732
recovery O 0 0.0007015507
period O 0 0.00032394877
of O 0 0.0003765246
up O 0 0.00029813036
to O 0 0.00024001021
18 O 0 0.00026173552
weeks O 0 0.00022210038
, O 0 0.00027097188
when O 0 0.00015110703
no O 0 0.0002221582
analgesics O 0 0.9327379
were O 0 0.00032143103
given O 0 0.00021523981
, O 0 0.0003469389
to O 0 0.00022699682
investigate O 0 0.00019914666
whether O 0 0.00021209232
the O 0 0.0005965158
analgesic O 0 0.9757524
- O 0 0.0026383041
induced O 0 0.0020175579
changes O 0 0.003200989
were O 0 0.003253411
reversible O 0 0.35024363
. O 0 0.0065722265

There O 0 0.005230136
was O 0 0.002246031
no O 0 0.0012628284
evidence O 0 0.0013014792
of O 0 0.0012896892
repair O 0 0.001502792
to O 0 0.00077458454
the O 0 0.0007389463
damaged O 0 0.010844218
medullary O 0 0.92720634
interstitial O 0 0.81746626
matrix O 0 0.101271585
, O 0 0.0010558285
or O 0 0.00044059026
proliferation O 0 0.30534473
of O 0 0.00048027709
remaining O 0 0.000378726
undamaged O 0 0.0014893158
type O 0 0.0004958548
1 O 0 0.00052851415
medullary O 0 0.705575
interstitial O 0 0.34215954
cells O 0 0.0011853859
after O 0 0.00027337062
the O 0 0.00042893604
recovery O 0 0.0012690597
period O 0 0.0009775803
following O 0 0.0019148982
analgesic O 0 0.9731435
treatment O 0 0.019076454
. O 0 0.0062491014

The O 0 0.0027849092
recovery O 0 0.003583788
of O 0 0.0023717857
urinary O 0 0.56578755
concentrating O 0 0.10835231
ability O 0 0.0013436077
was O 0 0.00073096715
related O 0 0.0004259603
to O 0 0.00039721787
the O 0 0.00034845705
length O 0 0.0003705939
of O 0 0.0006277433
analgesic O 0 0.9701274
treatment O 0 0.0022625453
and O 0 0.0005382846
the O 0 0.0004022258
extent O 0 0.0003424165
of O 0 0.0006893766
the O 0 0.00077990815
resulting O 0 0.0016868816
inner O 0 0.09193713
medullary O 0 0.93311137
structural O 0 0.10971175
damage O 0 0.8880439
. O 0 0.008903193

During O 0 0.0026519154
the O 0 0.0020476973
early O 0 0.002679469
stages O 0 0.0021343965
of O 0 0.0016776945
analgesic O 0 0.97803646
treatment O 0 0.0057692057
, O 0 0.000981035
the O 0 0.00045894395
changes O 0 0.00069858646
in O 0 0.00040556298
urinary O 0 0.62674534
concentrating O 0 0.11027906
ability O 0 0.0006146324
were O 0 0.00047336152
reversible O 0 0.15907042
, O 0 0.00057809206
but O 0 0.0002837992
after O 0 0.0001804671
prolonged O 0 0.006182531
analgesic O 0 0.9764084
treatment O 0 0.0032829328
, O 0 0.00078913884
maximum O 0 0.0008104306
urinary O 0 0.70713663
concentrating O 0 0.12338166
ability O 0 0.0017511807
failed O 0 0.0025604032
to O 0 0.0025346072
recover O 0 0.005757547
. O 0 0.005721535

This O 0 0.0043178727
study O 0 0.002720294
shows O 0 0.0009822762
that O 0 0.0009567906
prolonged O 0 0.0070968554
analgesic O 0 0.98028105
treatment O 0 0.0053619226
in O 0 0.00085247896
Fischer O 0 0.389566
344 O 0 0.05260935
rats O 0 0.003163876
causes O 0 0.0016015255
progressive O 0 0.2633433
and O 0 0.0009332351
irreversible O 0 0.5319627
damage O 0 0.63041127
to O 0 0.00054328813
the O 0 0.0005409515
interstitial O 0 0.43929216
matrix O 0 0.027871259
and O 0 0.00082999404
type O 0 0.00090759556
1 O 0 0.0011097229
interstitial O 0 0.23503251
cells O 0 0.004148615
leading O 0 0.0060957763
to O 0 0.0047691804
RPN B-Disease 2 0.9826818
. O 0 0.007698072

The O 0 0.0033167843
associated O 0 0.0036555456
urinary O 0 0.54413456
concentrating O 0 0.1344833
defect O 0 0.0021037261
is O 0 0.0013603099
reversible O 0 0.092079565
only O 0 0.0008288377
during O 0 0.0005022429
the O 0 0.0005996804
early O 0 0.0013602036
stages O 0 0.0013325772
of O 0 0.001334467
structural O 0 0.008958773
damage O 0 0.4694346
to O 0 0.0021230318
the O 0 0.0031374416
inner O 0 0.14065008
medulla O 0 0.9073032
. O 0 0.008283744

Testosterone B-Chemical 1 0.99707556
- O 0 0.01072261
dependent O 0 0.004338619
hypertension B-Disease 2 0.99789727
and O 0 0.0034770772
upregulation O 0 0.006506621
of O 0 0.0032916307
intrarenal O 0 0.99103457
angiotensinogen O 0 0.9964533
in O 0 0.0060622697
Dahl O 0 0.98820436
salt B-Chemical 0 0.98117286
- O 0 0.010908042
sensitive O 0 0.006318899
rats O 0 0.020016998
. O 0 0.0083479555

Blood O 0 0.08838896
pressure O 0 0.088598415
( O 0 0.0065840175
BP O 0 0.5671013
) O 0 0.0036366533
is O 0 0.0015575717
more O 0 0.0019012204
salt B-Chemical 0 0.7074226
sensitive O 0 0.0021969709
in O 0 0.0015610497
men O 0 0.018983057
than O 0 0.0015447829
in O 0 0.003009801
premenopausal O 0 0.8957162
women O 0 0.09985015
. O 0 0.0090306

In O 0 0.0059176735
Dahl O 0 0.8936906
salt B-Chemical 0 0.9497285
- O 0 0.005665294
sensitive O 0 0.0024611682
rats O 0 0.009359909
( O 0 0.0026759976
DS O 0 0.8144514
) O 0 0.0022173463
, O 0 0.0010751247
high O 0 0.0012337604
- O 0 0.0021741786
salt B-Chemical 0 0.9467721
( O 0 0.0025953092
HS O 0 0.5969945
) O 0 0.0020331938
diet O 0 0.054943927
increases O 0 0.0014419929
BP O 0 0.6055497
more O 0 0.0014296358
in O 0 0.001117112
males O 0 0.0022780164
than O 0 0.0017194465
females O 0 0.0053369137
. O 0 0.005463359

In O 0 0.0030968057
contrast O 0 0.0023224873
to O 0 0.0016858573
the O 0 0.0016696411
systemic O 0 0.8917328
renin O 0 0.9974203
- O 0 0.022142876
angiotensin B-Chemical 1 0.9993759
system O 0 0.005485837
, O 0 0.0011101601
which O 0 0.0007447646
is O 0 0.00043429458
suppressed O 0 0.00056557776
in O 0 0.00033421768
response O 0 0.00066988624
to O 0 0.00042210633
HS O 0 0.41609874
in O 0 0.00047692185
male O 0 0.0070423465
DS O 0 0.85779685
, O 0 0.0011177033
intrarenal O 0 0.98447925
angiotensinogen O 0 0.99786
expression O 0 0.003980997
is O 0 0.00057393
increased O 0 0.0010333552
, O 0 0.00074233307
and O 0 0.0006782741
intrarenal O 0 0.9191613
levels O 0 0.0011672755
of O 0 0.0029005045
ANG O 0 0.9976857
II O 0 0.092437774
are O 0 0.002502801
not O 0 0.002787176
suppressed O 0 0.006250387
. O 0 0.006313045

In O 0 0.002686241
this O 0 0.0018134485
study O 0 0.002039473
, O 0 0.0013635748
the O 0 0.000751966
hypothesis O 0 0.0009226248
was O 0 0.0005507601
tested O 0 0.00038247617
that O 0 0.00034372378
there O 0 0.00027941223
is O 0 0.00041001473
a O 0 0.00052031956
sexual O 0 0.05516302
dimorphism O 0 0.0050734235
in O 0 0.0005127936
HS O 0 0.6504148
- O 0 0.0012786606
induced O 0 0.0006842763
upregulation O 0 0.0028845652
of O 0 0.0009345199
intrarenal O 0 0.99315673
angiotensinogen O 0 0.9984548
mediated O 0 0.0012084874
by O 0 0.0011683205
testosterone B-Chemical 0 0.99887544
that O 0 0.0005769345
also O 0 0.00076853647
causes O 0 0.0019717652
increases O 0 0.0013505521
in O 0 0.0015143839
BP O 0 0.84985334
and O 0 0.005241968
renal B-Disease 2 0.99696785
injury I-Disease 2 0.9934896
. O 0 0.011015778

On O 0 0.004648184
a O 0 0.0031701291
low O 0 0.0034365244
- O 0 0.0046436004
salt B-Chemical 0 0.9223024
( O 0 0.0038464593
LS O 0 0.090100154
) O 0 0.002366588
diet O 0 0.062262923
, O 0 0.0013859121
male O 0 0.003510012
DS O 0 0.51945925
had O 0 0.0008021651
higher O 0 0.00072055805
levels O 0 0.00085144216
of O 0 0.0019004949
intrarenal O 0 0.9892904
angiotensinogen O 0 0.9960078
mRNA O 0 0.013071824
than O 0 0.0026852982
females O 0 0.0069893473
. O 0 0.0059838463

HS O 0 0.24797377
diet O 0 0.033885416
for O 0 0.0019122061
4 O 0 0.0011649582
wk O 0 0.0010000918
increased O 0 0.0016661849
renal O 0 0.9776883
cortical O 0 0.44873303
angiotensinogen O 0 0.99596417
mRNA O 0 0.004002313
and O 0 0.00080538425
protein O 0 0.0013641565
only O 0 0.0006227405
in O 0 0.00063795474
male O 0 0.0052965907
DS O 0 0.7429923
, O 0 0.0015324879
which O 0 0.0015919139
was O 0 0.0016597179
prevented O 0 0.0056056594
by O 0 0.00501833
castration O 0 0.902345
. O 0 0.008153494

Ovariectomy O 0 0.97157323
of O 0 0.006107358
female O 0 0.011398413
DS O 0 0.62402016
had O 0 0.0023209543
no O 0 0.0014424311
effect O 0 0.0018508636
on O 0 0.0014500623
intrarenal O 0 0.9746466
angiotensinogen O 0 0.9935103
expression O 0 0.007927517
on O 0 0.0026334722
either O 0 0.005385541
diet O 0 0.17971855
. O 0 0.0094126025

Radiotelemetric O 0 0.2261921
BP O 0 0.46159318
was O 0 0.00301963
similar O 0 0.0017425391
between O 0 0.0013814324
males O 0 0.0029329096
and O 0 0.0029274346
castrated O 0 0.24438022
rats O 0 0.010045538
on O 0 0.0037319171
LS O 0 0.108554214
diet O 0 0.19461738
. O 0 0.012331314

HS O 0 0.25325742
diet O 0 0.034713354
for O 0 0.0018975277
4 O 0 0.0011369486
wk O 0 0.0009237569
caused O 0 0.00095054205
a O 0 0.0009052214
progressive O 0 0.09914329
increase O 0 0.0008321385
in O 0 0.0007001197
BP O 0 0.76649594
, O 0 0.0008591252
protein O 0 0.001324104
and O 0 0.00077379926
albumin O 0 0.98887724
excretion O 0 0.9864803
, O 0 0.0014653981
and O 0 0.0010239402
glomerular B-Disease 2 0.99515945
sclerosis I-Disease 2 0.9980977
in O 0 0.0010475887
male O 0 0.015600648
DS O 0 0.8443581
rats O 0 0.0068036607
, O 0 0.0011772864
which O 0 0.0012683938
were O 0 0.0013560072
attenuated O 0 0.0045531695
by O 0 0.0043687597
castration O 0 0.8860537
. O 0 0.0076528783

Testosterone B-Chemical 1 0.9961358
replacement O 0 0.02571106
in O 0 0.0035040362
castrated O 0 0.64356583
DS O 0 0.8796868
rats O 0 0.014820895
increased O 0 0.003694734
BP O 0 0.8915324
, O 0 0.003417958
renal B-Disease 2 0.9980259
injury I-Disease 2 0.9953851
, O 0 0.002092718
and O 0 0.0009786749
upregulation O 0 0.0032242078
of O 0 0.0020731913
renal O 0 0.9955011
angiotensinogen O 0 0.99674004
associated O 0 0.009754735
with O 0 0.007930117
HS O 0 0.8721762
diet O 0 0.46098992
. O 0 0.008906458

Testosterone B-Chemical 1 0.9961792
contributes O 0 0.0036612134
to O 0 0.0018652759
the O 0 0.0013793093
development O 0 0.0025172876
of O 0 0.002341207
hypertension B-Disease 2 0.99937326
and O 0 0.004887205
renal B-Disease 2 0.9989317
injury I-Disease 2 0.9968635
in O 0 0.0012216247
male O 0 0.013811417
DS O 0 0.8321034
rats O 0 0.004348088
on O 0 0.00036739965
HS O 0 0.37682778
diet O 0 0.08197365
possibly O 0 0.001814829
through O 0 0.0005917445
upregulation O 0 0.0021590865
of O 0 0.0011848373
the O 0 0.0016037105
intrarenal O 0 0.9924402
renin O 0 0.99725515
- O 0 0.07037179
angiotensin B-Chemical 1 0.9983146
system O 0 0.027071206
. O 0 0.0085168015

Explicit O 0 0.08749232
episodic O 0 0.8365989
memory O 0 0.25236276
for O 0 0.0022570149
sensory O 0 0.10259695
- O 0 0.0024181344
discriminative O 0 0.010716664
components O 0 0.0012529
of O 0 0.0021563547
capsaicin B-Chemical 0 0.99910516
- O 0 0.007482674
induced O 0 0.0038252086
pain B-Disease 0 0.98453313
: O 0 0.0032318714
immediate O 0 0.0036616623
and O 0 0.0025584726
delayed O 0 0.014080782
ratings O 0 0.009089447
. O 0 0.0064017014

Pain B-Disease 2 0.95685905
memory O 0 0.29036608
is O 0 0.0028831582
thought O 0 0.0023637658
to O 0 0.0011409421
affect O 0 0.0008158506
future O 0 0.001270286
pain B-Disease 0 0.9087747
sensitivity O 0 0.0037315025
and O 0 0.0012681185
thus O 0 0.0015447784
contribute O 0 0.0014175767
to O 0 0.0017057273
clinical O 0 0.039321885
pain B-Disease 0 0.9723528
conditions O 0 0.010463307
. O 0 0.007436292

Systematic O 0 0.0072143697
investigations O 0 0.004739915
of O 0 0.0026489554
the O 0 0.001871408
human O 0 0.002589906
capacity O 0 0.0021663464
to O 0 0.0013214897
remember O 0 0.0037996934
sensory O 0 0.0324187
features O 0 0.0032801942
of O 0 0.0022293227
experimental O 0 0.005474745
pain B-Disease 0 0.9668478
are O 0 0.005911887
sparse O 0 0.011618671
. O 0 0.008095052

In O 0 0.002737408
order O 0 0.001506487
to O 0 0.0012351678
address O 0 0.00073830213
long O 0 0.0011775319
- O 0 0.0013555192
term O 0 0.001128717
pain B-Disease 0 0.9599251
memory O 0 0.39268783
, O 0 0.00083116535
nine O 0 0.00046037656
healthy O 0 0.002097586
male O 0 0.00094677065
volunteers O 0 0.00088071154
received O 0 0.00037497748
intradermal O 0 0.014416374
injections O 0 0.0023981836
of O 0 0.00032613246
three O 0 0.00016486662
doses O 0 0.016055327
of O 0 0.0010560141
capsaicin B-Chemical 0 0.99957377
( O 0 0.0013867471
0 O 0 0.00044131704
. O 0 0.00018655579
05 O 0 0.017892199
, O 0 0.00028927033
1 O 0 0.00019290447
and O 0 0.00017734272
20 O 0 0.00022327837
microg O 0 0.0004917308
, O 0 0.00025018197
separated O 0 0.00020935624
by O 0 0.00020184112
15 O 0 0.00018260846
min O 0 0.00035256945
breaks O 0 0.0028459365
) O 0 0.00045284332
, O 0 0.00022178
each O 0 8.143417e-05
given O 0 0.000101003876
three O 0 8.862914e-05
times O 0 0.00012277218
in O 0 0.00016873993
a O 0 0.00023917071
balanced O 0 0.00046810825
design O 0 0.00067099824
across O 0 0.00019837516
three O 0 0.00024195123
sessions O 0 0.00059003854
at O 0 0.00050357514
one O 0 0.00085569965
week O 0 0.0017186274
intervals O 0 0.0031117867
. O 0 0.004348881

Pain B-Disease 2 0.84990275
rating O 0 0.0055186506
was O 0 0.001603399
performed O 0 0.0010674752
using O 0 0.0008462012
a O 0 0.0009502812
computerized O 0 0.0034912224
visual O 0 0.11990891
analogue O 0 0.06869716
scale O 0 0.0015303618
( O 0 0.0008935359
0 O 0 0.0005729183
- O 0 0.0006000881
100 O 0 0.00068797043
) O 0 0.00050773454
digitized O 0 0.0018014816
at O 0 0.00020297573
1 O 0 0.0003034657
/ O 0 0.0005296524
s O 0 0.00033116492
, O 0 0.0002822673
either O 0 0.00021340638
immediately O 0 0.00025906388
online O 0 0.0003003957
or O 0 0.00025602352
one O 0 0.00027524578
hour O 0 0.00044532242
or O 0 0.00050615973
one O 0 0.000653724
day O 0 0.001200158
after O 0 0.0014364894
injection O 0 0.008515779
. O 0 0.004928541

Subjects O 0 0.012590254
also O 0 0.0064954567
recalled O 0 0.01225668
their O 0 0.0072051813
pains B-Disease 0 0.828362
one O 0 0.006034017
week O 0 0.0075154095
later O 0 0.009668225
. O 0 0.012070296

Capsaicin B-Chemical 1 0.9974833
injection O 0 0.020139785
reliably O 0 0.0033731658
induced O 0 0.0021225119
a O 0 0.0015880655
dose O 0 0.035787787
- O 0 0.0019509419
dependent O 0 0.0009501681
flare O 0 0.94257134
( O 0 0.0015069111
p O 0 0.0009367084
< O 0 0.00063939125
0 O 0 0.00050416123
. O 0 0.00032859208
001 O 0 0.06396776
) O 0 0.0007350441
without O 0 0.00045377988
any O 0 0.0004114227
difference O 0 0.00040693893
within O 0 0.00049521675
or O 0 0.0010265211
across O 0 0.0013502982
sessions O 0 0.004354666
. O 0 0.0052570705

The O 0 0.005201745
strong O 0 0.006565232
burning O 0 0.5522251
pain B-Disease 0 0.9555996
decayed O 0 0.013343831
exponentially O 0 0.0069396365
within O 0 0.0023187392
a O 0 0.004010223
few O 0 0.004058183
minutes O 0 0.007111465
. O 0 0.009046453

Subjects O 0 0.0058227135
were O 0 0.001991087
able O 0 0.0010690347
to O 0 0.0009574006
reliably O 0 0.0011774241
discriminate O 0 0.0010908195
pain B-Disease 0 0.8143878
magnitude O 0 0.00067492377
and O 0 0.00050614047
duration O 0 0.00064804393
across O 0 0.00034784467
capsaicin B-Chemical 0 0.9991418
doses O 0 0.23445131
( O 0 0.0009040758
both O 0 0.00034886372
p O 0 0.00051840284
< O 0 0.00037117003
0 O 0 0.0003002955
. O 0 0.00018189251
001 O 0 0.08939022
) O 0 0.00044919318
, O 0 0.00023713801
regardless O 0 0.00010589769
of O 0 0.00023022645
whether O 0 0.00011231376
first O 0 0.00018496241
- O 0 0.00034099192
time O 0 0.00016709528
ratings O 0 0.00040600376
were O 0 0.00023464738
requested O 0 0.00040758576
immediately O 0 0.00030317335
, O 0 0.00037683433
after O 0 0.0002062167
one O 0 0.0003116356
hour O 0 0.0005345909
or O 0 0.00065446884
after O 0 0.000770272
one O 0 0.0015188191
day O 0 0.0033206092
. O 0 0.0045557353

Pain B-Disease 2 0.865727
recall O 0 0.006001322
after O 0 0.0010871844
one O 0 0.00081222964
week O 0 0.0007649945
was O 0 0.00067886326
similarly O 0 0.0006730648
precise O 0 0.00091351545
( O 0 0.0008448767
magnitude O 0 0.0005652897
: O 0 0.0008667586
p O 0 0.0007165925
< O 0 0.0005817841
0 O 0 0.00049388874
. O 0 0.00032986864
01 O 0 0.0019860382
, O 0 0.0006551665
duration O 0 0.00094752596
: O 0 0.0013437682
p O 0 0.0014209523
< O 0 0.0015340283
0 O 0 0.0017059473
. O 0 0.0017516819
05 O 0 0.027938856
) O 0 0.0068532964
. O 0 0.006102769

Correlation O 0 0.003925099
with O 0 0.002373315
rating O 0 0.0029235457
recall O 0 0.002379202
after O 0 0.0004954481
one O 0 0.0004061344
week O 0 0.00040147817
was O 0 0.0003505614
best O 0 0.00033483387
when O 0 0.000215031
first O 0 0.00025637477
- O 0 0.0004214324
time O 0 0.00019070347
ratings O 0 0.00043348232
were O 0 0.0002263556
requested O 0 0.0003743985
as O 0 0.0001880766
late O 0 0.0007024204
as O 0 0.00017895545
one O 0 0.00015499079
day O 0 0.00020193316
after O 0 0.0001564738
injection O 0 0.0019657577
( O 0 0.00080842053
R O 0 0.653084
( O 0 0.0006002703
2 O 0 0.00033971216
) O 0 0.0004953709
= O 0 0.00039719063
0 O 0 0.000248209
. O 0 0.00013905145
79 O 0 0.00039895592
) O 0 0.0003556103
indicating O 0 0.00019999707
that O 0 0.0002409928
both O 0 0.0003832284
rating O 0 0.0010774569
retrievals O 0 0.000937454
utilized O 0 0.0009970717
similar O 0 0.0014056868
memory O 0 0.14711092
traces O 0 0.011454268
. O 0 0.006295043

These O 0 0.0043509253
results O 0 0.0022117072
indicate O 0 0.0014722791
a O 0 0.0017102667
reliable O 0 0.0019586512
memory O 0 0.034563232
for O 0 0.0010256994
magnitude O 0 0.0010661777
and O 0 0.0012155285
duration O 0 0.0018905542
of O 0 0.0025061187
experimentally O 0 0.004995186
induced O 0 0.009899869
pain B-Disease 0 0.98257947
. O 0 0.010347325

The O 0 0.0026602624
data O 0 0.0021865123
further O 0 0.0015169004
suggest O 0 0.00088822877
that O 0 0.0007701035
the O 0 0.00079085154
consolidation O 0 0.030007847
of O 0 0.0009435379
this O 0 0.0007345438
memory O 0 0.14196594
is O 0 0.00058902183
an O 0 0.00060337887
important O 0 0.00044262057
interim O 0 0.004681663
stage O 0 0.0019024498
, O 0 0.0008572437
and O 0 0.000672357
may O 0 0.0006986937
take O 0 0.00065464544
up O 0 0.0010110253
to O 0 0.0013054902
one O 0 0.0018583527
day O 0 0.0038800805
. O 0 0.005177537

Severe O 0 0.68065524
and O 0 0.0033600319
long O 0 0.0025948156
lasting O 0 0.0100084385
cholestasis B-Disease 2 0.9995214
after O 0 0.0011178012
high O 0 0.0018368793
- O 0 0.0019520099
dose O 0 0.036404815
co B-Chemical 0 0.7405102
- I-Chemical 0 0.003154015
trimoxazole I-Chemical 0 0.44870463
treatment O 0 0.0031959068
for O 0 0.000929481
Pneumocystis B-Disease 0 0.9990821
pneumonia I-Disease 0 0.9997756
in O 0 0.0027739068
HIV B-Disease 2 0.9585781
- I-Disease 2 0.0024829921
infected I-Disease 2 0.0010671462
patients O 0 0.0043021566
- O 0 0.0016024741
- O 0 0.0011840669
a O 0 0.0009179583
report O 0 0.0024207605
of O 0 0.0018460916
two O 0 0.0021932998
cases O 0 0.0074975444
. O 0 0.006068674

Pneumocystis B-Disease 0 0.99386156
pneumonia I-Disease 0 0.99844736
( O 0 0.027403826
PCP B-Disease 0 0.9937382
) O 0 0.0052269376
, O 0 0.00164064
a O 0 0.001057211
common O 0 0.0017874576
opportunistic B-Disease 0 0.506236
infection I-Disease 2 0.5755636
in O 0 0.0011188746
HIV B-Disease 2 0.913592
- I-Disease 2 0.0018493129
infected I-Disease 2 0.00073927524
individuals O 0 0.000766665
, O 0 0.0005752718
is O 0 0.0003721744
generally O 0 0.00056613947
treated O 0 0.0008091261
with O 0 0.00074180594
high O 0 0.0013603105
doses O 0 0.04884227
of O 0 0.0037908957
co B-Chemical 0 0.8656656
- I-Chemical 0 0.02381357
trimoxazole I-Chemical 0 0.7575065
. O 0 0.007840276

However O 0 0.007277741
, O 0 0.0059966883
treatment O 0 0.0060503865
is O 0 0.0035915812
often O 0 0.0046396544
limited O 0 0.004076409
by O 0 0.006093948
adverse O 0 0.71731925
effects O 0 0.022333998
. O 0 0.011950294

Here O 0 0.0058261594
, O 0 0.002873401
we O 0 0.0010423934
report O 0 0.0023613202
two O 0 0.0008499479
cases O 0 0.0015800116
of O 0 0.001391419
severely O 0 0.049320005
immunocompromised O 0 0.98555404
HIV B-Disease 2 0.9678754
- I-Disease 2 0.0024563298
infected I-Disease 2 0.00079317903
patients O 0 0.0018796909
who O 0 0.0014709744
developed O 0 0.0014865213
severe O 0 0.4770005
intrahepatic B-Disease 0 0.99926025
cholestasis I-Disease 2 0.99997985
, O 0 0.007020642
and O 0 0.00055473467
in O 0 0.00027341026
one O 0 0.00022378174
patient O 0 0.00072648993
lesions O 0 0.17333823
mimicking O 0 0.02638247
liver B-Disease 0 0.95862377
abscess I-Disease 0 0.98576933
formation O 0 0.005519962
on O 0 0.00032873245
radiologic O 0 0.0802997
exams O 0 0.007214244
, O 0 0.0008726344
during O 0 0.00064967654
co B-Chemical 0 0.48031422
- I-Chemical 0 0.004085824
trimoxazole I-Chemical 0 0.46263352
treatment O 0 0.0077829664
for O 0 0.004470502
PCP B-Disease 0 0.9880562
. O 0 0.009162659

Whereas O 0 0.00438707
patient O 0 0.0034622762
1 O 0 0.0016977855
showed O 0 0.0012144499
lesions O 0 0.02510467
of O 0 0.0010930898
up O 0 0.0007222473
to O 0 0.000542287
1 O 0 0.00052435865
cm O 0 0.0010190993
readily O 0 0.0004205167
detectable O 0 0.00023125211
on O 0 0.00020810043
magnetic O 0 0.020826241
resonance O 0 0.26275834
imaging O 0 0.0035436566
under O 0 0.00034034578
prolonged O 0 0.014973548
co B-Chemical 0 0.7379141
- I-Chemical 0 0.0031802969
trimoxazole I-Chemical 0 0.46829733
treatment O 0 0.0026922622
, O 0 0.00087193534
therapy O 0 0.006610772
of O 0 0.0010112632
patient O 0 0.0017896319
2 O 0 0.001253504
was O 0 0.0015055734
switched O 0 0.004330912
early O 0 0.0080477195
. O 0 0.0059799016

Bradykinin B-Chemical 0 0.9975641
receptors O 0 0.65216386
antagonists O 0 0.98203456
and O 0 0.0069214227
nitric B-Chemical 0 0.9982394
oxide I-Chemical 0 0.9982703
synthase O 0 0.9919629
inhibitors O 0 0.63661486
in O 0 0.0032092049
vincristine B-Chemical 1 0.99958104
and O 0 0.009854065
streptozotocin B-Chemical 1 0.99981064
induced O 0 0.040744208
hyperalgesia B-Disease 2 0.99948764
in O 0 0.002366349
chemotherapy O 0 0.9434106
and O 0 0.008468178
diabetic B-Disease 2 0.99922013
neuropathy I-Disease 0 0.9996866
rat O 0 0.37788278
model O 0 0.011561439
. O 0 0.0075969486

PURPOSE O 0 0.04436178
: O 0 0.0040985453
The O 0 0.0015068186
influence O 0 0.0012257752
of O 0 0.0015435745
an O 0 0.0019180923
irreversible O 0 0.3343982
inhibitor O 0 0.18377188
of O 0 0.0019356275
constitutive O 0 0.023394907
NO B-Chemical 0 0.9988299
synthase O 0 0.9942526
( O 0 0.016483761
L O 0 0.8745261
- O 0 0.004540565
NOArg O 0 0.8034748
; O 0 0.0011370752
1 O 0 0.00037400608
. O 0 0.00017968757
0 O 0 0.00032456763
mg O 0 0.1009669
/ O 0 0.00084096636
kg O 0 0.0067210123
ip O 0 0.5492452
) O 0 0.000734624
, O 0 0.0003470633
a O 0 0.00027077305
relatively O 0 0.00041202537
selective O 0 0.007228625
inhibitor O 0 0.080369174
of O 0 0.000963697
inducible O 0 0.25702763
NO B-Chemical 0 0.9992939
synthase O 0 0.99521035
( O 0 0.015021505
L O 0 0.87030643
- O 0 0.0032671806
NIL O 0 0.44055954
; O 0 0.0012013682
1 O 0 0.00034435594
. O 0 0.00016034234
0 O 0 0.00029423667
mg O 0 0.098342344
/ O 0 0.00075904466
kg O 0 0.00563305
ip O 0 0.467178
) O 0 0.00054416136
and O 0 0.00024273683
a O 0 0.0002496399
relatively O 0 0.0003414984
specific O 0 0.00034597708
inhibitor O 0 0.06990495
of O 0 0.0012665517
neuronal O 0 0.8693576
NO B-Chemical 0 0.99918693
synthase O 0 0.9899148
( O 0 0.002941344
7 O 0 0.00052314624
- O 0 0.0009902588
NI O 0 0.23888671
; O 0 0.0007316103
0 O 0 0.00032639032
. O 0 0.00015177419
1 O 0 0.00026336082
mg O 0 0.1070393
/ O 0 0.0008077945
kg O 0 0.006753218
ip O 0 0.5483051
) O 0 0.0007514499
, O 0 0.00036862955
on O 0 0.0001898305
antihyperalgesic O 0 0.99764204
action O 0 0.01207235
of O 0 0.0006855488
selective O 0 0.035279542
antagonists O 0 0.9746534
of O 0 0.003419961
B2 O 0 0.9829679
and O 0 0.0021109472
B1 O 0 0.9954183
receptors O 0 0.6261188
: O 0 0.0070723416
D O 0 0.80318445
- O 0 0.005073777
Arg O 0 0.98379886
- O 0 0.0034318115
[ O 0 0.0039296267
Hyp3 O 0 0.962522
, O 0 0.0012027662
Thi5 O 0 0.9604243
, O 0 0.001209176
D O 0 0.54322875
- O 0 0.0014930541
Tic7 O 0 0.038037058
, O 0 0.0012807199
Oic8 O 0 0.9985916
] O 0 0.012833277
bradykinin B-Chemical 1 0.9996592
( O 0 0.0056395414
HOE B-Chemical 0 0.99976486
140 I-Chemical 0 0.040245675
; O 0 0.0008301885
70 O 0 0.0004965705
nmol O 0 0.34366858
/ O 0 0.0011553471
kg O 0 0.00783818
ip O 0 0.4836559
) O 0 0.0006738616
or O 0 0.0003111891
des B-Chemical 0 0.009896709
Arg10 I-Chemical 0 0.9896062
HOE I-Chemical 0 0.9997595
140 I-Chemical 0 0.032343674
( O 0 0.0005806889
70 O 0 0.00046295495
nmol O 0 0.34953773
/ O 0 0.0011520518
kg O 0 0.009811356
ip O 0 0.6027789
) O 0 0.0008011074
respectively O 0 0.0008197981
, O 0 0.00033798974
in O 0 0.00020794432
model O 0 0.00040793812
of O 0 0.0008221552
diabetic B-Disease 2 0.9981659
( I-Disease 0 0.006572582
streptozotocin I-Disease 1 0.9998721
- I-Disease 0 0.0047709728
induced I-Disease 0 0.0012539481
) I-Disease 0 0.0012344527
and I-Disease 0 0.0007442034
toxic I-Disease 0 0.86704445
( I-Disease 0 0.0052492064
vincristine I-Disease 1 0.999603
- I-Disease 0 0.007792347
induced I-Disease 0 0.0037248607
) I-Disease 0 0.0116358185
neuropathy I-Disease 0 0.9988476
was O 0 0.0038421643
investigated O 0 0.0050110547
. O 0 0.005961244

METHODS O 0 0.006225923
: O 0 0.0030904454
The O 0 0.0012885273
changes O 0 0.0015747144
in O 0 0.0010597425
pain B-Disease 0 0.7677688
thresholds O 0 0.0017505984
were O 0 0.0005625967
determined O 0 0.0003686079
using O 0 0.00042976197
mechanical O 0 0.021457406
stimuli O 0 0.009802233
- O 0 0.0014027467
- O 0 0.00072355795
the O 0 0.00033101154
modification O 0 0.0008426311
of O 0 0.0005565584
the O 0 0.0005602533
classic O 0 0.06285997
paw O 0 0.96972984
withdrawal O 0 0.77157855
test O 0 0.001477024
described O 0 0.0013243102
by O 0 0.0025925077
Randall O 0 0.11915066
- O 0 0.011514128
Selitto O 0 0.9457364
. O 0 0.00782822

RESULTS O 0 0.02294996
: O 0 0.0036008665
The O 0 0.0012637536
results O 0 0.0009711458
of O 0 0.0010257653
this O 0 0.00074180454
paper O 0 0.0010282873
confirm O 0 0.0004216621
that O 0 0.0005139707
inhibition O 0 0.0029166203
of O 0 0.0017715786
bradykinin B-Chemical 1 0.9996486
receptors O 0 0.61539364
and O 0 0.0016547912
inducible O 0 0.26683393
NO B-Chemical 0 0.99881774
synthase O 0 0.9853151
but O 0 0.001738145
not O 0 0.0014406842
neuronal O 0 0.8240255
NO B-Chemical 0 0.99807274
synthase O 0 0.98693234
activity O 0 0.014100541
reduces O 0 0.035826452
diabetic B-Disease 2 0.99889946
hyperalgesia I-Disease 0 0.9992173
. O 0 0.017443178

Pretreatment O 0 0.8480685
with O 0 0.0072093136
L O 0 0.69765997
- O 0 0.0066662845
NOArg O 0 0.65880483
and O 0 0.002419186
L O 0 0.6182689
- O 0 0.002846785
NIL O 0 0.17247409
but O 0 0.00078984414
not O 0 0.0005820326
7 O 0 0.0005806504
- O 0 0.001060104
NI O 0 0.13427676
, O 0 0.00072239974
significantly O 0 0.00067577197
increases O 0 0.0009968384
antihyperalgesic O 0 0.9982021
activity O 0 0.002063144
both O 0 0.0016335081
HOE B-Chemical 0 0.9993783
140 I-Chemical 0 0.036063988
and O 0 0.002421083
des B-Chemical 0 0.06834669
Arg10 I-Chemical 0 0.98921376
HOE I-Chemical 0 0.9986076
140 I-Chemical 0 0.15169305
. O 0 0.007894169

It O 0 0.005607933
was O 0 0.002275613
also O 0 0.0016873617
shown O 0 0.0009343334
that O 0 0.00073603314
both O 0 0.0007550638
products O 0 0.001602968
of O 0 0.0011647441
inducible O 0 0.13413717
NO B-Chemical 0 0.99854445
synthase O 0 0.98711723
and O 0 0.0039341254
neuronal O 0 0.91355544
NO B-Chemical 0 0.9989899
synthase O 0 0.9874729
activation O 0 0.012076662
as O 0 0.00057787774
well O 0 0.0005403169
as O 0 0.00074565894
bradykinin B-Chemical 1 0.99909115
are O 0 0.0013155938
involved O 0 0.0012104633
in O 0 0.001837605
hyperalgesia B-Disease 2 0.99823546
produced O 0 0.0045468537
by O 0 0.008652301
vincristine B-Chemical 1 0.99831176
. O 0 0.011202512

Moreover O 0 0.0077954074
, O 0 0.0064035603
L O 0 0.47465453
- O 0 0.0052010124
NOArg O 0 0.46398887
and O 0 0.0016357485
7 O 0 0.0011078144
- O 0 0.0016411968
NI O 0 0.11364886
but O 0 0.0007482996
not O 0 0.0007559924
L O 0 0.4566593
- O 0 0.0018332745
NIL O 0 0.19573493
intensify O 0 0.0073605105
antihyperalgesic O 0 0.9986725
activity O 0 0.0017006933
of O 0 0.0017750992
HOE B-Chemical 0 0.9996196
140 I-Chemical 0 0.025081357
or O 0 0.0008638728
des B-Chemical 0 0.008078257
- I-Chemical 0 0.002414732
Arg10HOE I-Chemical 0 0.018536652
140 I-Chemical 0 0.0048026433
in O 0 0.0029736916
toxic B-Disease 0 0.98904663
neuropathy I-Disease 0 0.99916005
. O 0 0.0128388135

CONCLUSIONS O 0 0.63364
: O 0 0.00449822
Results O 0 0.0023708087
of O 0 0.0015974126
these O 0 0.0014466798
studies O 0 0.0014194037
suggest O 0 0.00076753483
that O 0 0.0009931386
B1 O 0 0.96461964
and O 0 0.0018589958
B2 O 0 0.95422435
receptors O 0 0.20405135
are O 0 0.0007700693
engaged O 0 0.00096973527
in O 0 0.00045381943
transmission O 0 0.0013437433
of O 0 0.0010196471
nociceptive O 0 0.82651216
stimuli O 0 0.0077774227
in O 0 0.000978614
both O 0 0.0017848306
diabetic B-Disease 2 0.99465406
and I-Disease 0 0.00896313
toxic I-Disease 0 0.9947067
neuropathy I-Disease 0 0.9993856
. O 0 0.014142032

In O 0 0.0066584675
streptozotocin B-Chemical 1 0.9984188
- O 0 0.012707522
induced O 0 0.0072189914
hyperalgesia B-Disease 2 0.9989311
, O 0 0.004369965
inducible O 0 0.18526565
NO B-Chemical 0 0.9983095
synthase O 0 0.9829069
participates O 0 0.0034613519
in O 0 0.0010484123
pronociceptive O 0 0.98508495
activity O 0 0.0016436512
of O 0 0.0017088099
bradykinin B-Chemical 1 0.99966264
, O 0 0.0019984313
whereas O 0 0.0006853133
in O 0 0.00081779715
vincristine B-Chemical 1 0.9997055
- O 0 0.009919569
induced O 0 0.0093258545
hyperalgesia B-Disease 2 0.99973565
bradykinin B-Chemical 1 0.99973756
seemed O 0 0.0049773674
to O 0 0.0012718913
activate O 0 0.0019325992
neuronal O 0 0.8323254
NO B-Chemical 0 0.9967533
synthase O 0 0.98341733
pathway O 0 0.03795594
. O 0 0.009576679

Therefore O 0 0.0036413681
, O 0 0.003069023
concomitant O 0 0.0052337777
administration O 0 0.064386286
of O 0 0.0014945283
small O 0 0.0013650812
doses O 0 0.058517266
of O 0 0.002947003
bradykinin B-Chemical 1 0.9997105
receptor O 0 0.8528083
antagonists O 0 0.9958097
and O 0 0.0046034325
NO B-Chemical 0 0.9989889
synthase O 0 0.9899715
inhibitors O 0 0.41114658
can O 0 0.0006479359
be O 0 0.00051962206
effective O 0 0.00073378644
in O 0 0.00050346256
alleviation O 0 0.3230344
of O 0 0.0066073695
neuropathic B-Disease 0 0.99986506
pain I-Disease 0 0.9987864
, O 0 0.0035445895
even O 0 0.0016366132
in O 0 0.0017017752
hospital O 0 0.008899911
care O 0 0.007289447
. O 0 0.0057704444

Confusion B-Disease 0 0.40080333
, O 0 0.004653069
a O 0 0.0024595077
rather O 0 0.0018121456
serious O 0 0.08317462
adverse O 0 0.8948422
drug O 0 0.70767754
reaction O 0 0.09954511
with O 0 0.0055497563
valproic B-Chemical 0 0.9998042
acid I-Chemical 0 0.98599106
: O 0 0.002753995
a O 0 0.0012577634
review O 0 0.0023524023
of O 0 0.0017181932
the O 0 0.0022797792
French O 0 0.035273783
Pharmacovigilance O 0 0.2670058
database O 0 0.007872176
. O 0 0.006738903

INTRODUCTION O 0 0.1388371
: O 0 0.008644366
Confusion B-Disease 0 0.23167992
is O 0 0.0030081172
an O 0 0.0032983487
adverse O 0 0.7223214
drug O 0 0.5352253
reaction O 0 0.05243155
frequently O 0 0.005245697
observed O 0 0.002790819
with O 0 0.01000184
valproic B-Chemical 0 0.99920803
acid I-Chemical 0 0.98430413
. O 0 0.014232048

Some O 0 0.0059148027
case O 0 0.002489557
reports O 0 0.0024174443
are O 0 0.0013413521
published O 0 0.0011294548
in O 0 0.0007095419
the O 0 0.0006365618
literature O 0 0.0011794863
but O 0 0.0005140351
no O 0 0.00033581915
systematic O 0 0.000537523
study O 0 0.0006682636
from O 0 0.00045214407
a O 0 0.0005806299
sample O 0 0.0006461525
of O 0 0.0011795183
patients O 0 0.0034156325
has O 0 0.0021752715
been O 0 0.0038252429
published O 0 0.005638279
. O 0 0.0061376416

We O 0 0.0029122431
performed O 0 0.0019200889
this O 0 0.0015261038
study O 0 0.0017216301
in O 0 0.000907066
order O 0 0.0006485775
to O 0 0.00068044045
describe O 0 0.000797069
the O 0 0.00071959157
main O 0 0.001141782
characteristics O 0 0.0012025561
of O 0 0.0016444892
this O 0 0.002374008
adverse O 0 0.9147638
drug O 0 0.79605305
reaction O 0 0.2317132
. O 0 0.009148405

METHODS O 0 0.006809956
: O 0 0.0035118267
Using O 0 0.002105676
the O 0 0.0015644194
French O 0 0.0063210335
Pharmacovigilance O 0 0.051891617
database O 0 0.001339288
, O 0 0.0008293881
we O 0 0.00032368355
selected O 0 0.00046421902
the O 0 0.0005500446
cases O 0 0.0012365344
of O 0 0.001384004
confusion B-Disease 0 0.6467645
reported O 0 0.002636108
since O 0 0.001486517
1985 O 0 0.027531153
with O 0 0.008181454
valproic B-Chemical 0 0.9993787
acid I-Chemical 0 0.98504466
. O 0 0.011382756

RESULTS O 0 0.029193318
: O 0 0.0055775684
272 O 0 0.008506572
cases O 0 0.0030341605
of O 0 0.002419361
confusion B-Disease 0 0.4077726
were O 0 0.0017288177
reported O 0 0.0023815099
with O 0 0.0033475012
valproic B-Chemical 0 0.9996543
acid I-Chemical 0 0.98519933
: O 0 0.0061835176
153 O 0 0.03488164
women O 0 0.017986
and O 0 0.0034319873
119 O 0 0.015509675
men O 0 0.057293378
. O 0 0.007397858

Confusion B-Disease 0 0.28835696
mostly O 0 0.0043895617
occurred O 0 0.002176143
during O 0 0.0009989538
the O 0 0.00090116804
two O 0 0.00066036684
first O 0 0.00065231894
weeks O 0 0.00087870064
following O 0 0.0014847378
valproic B-Chemical 0 0.9996244
acid I-Chemical 0 0.9745705
exposure O 0 0.038740184
( O 0 0.002512767
39 O 0 0.0024880925
. O 0 0.0011723309
7 O 0 0.0018830372
% O 0 0.003194904
) O 0 0.0056545893
. O 0 0.0054753968

It O 0 0.006240295
was O 0 0.0027398954
" O 0 0.00256493
serious O 0 0.015755564
" O 0 0.0014559042
for O 0 0.0007174019
almost O 0 0.00063862174
2 O 0 0.0006436561
/ O 0 0.00088601426
3 O 0 0.00030076542
of O 0 0.0003611852
the O 0 0.00033688612
patients O 0 0.0012731017
( O 0 0.0005449386
62 O 0 0.00064998027
. O 0 0.00018383225
5 O 0 0.00022152723
% O 0 0.00028291714
) O 0 0.00034200493
and O 0 0.0002380684
its O 0 0.00048412703
outcome O 0 0.0007789136
favourable O 0 0.002709393
in O 0 0.00039497076
most O 0 0.0007643364
of O 0 0.0007509151
the O 0 0.0008294777
cases O 0 0.002454663
( O 0 0.0023712236
82 O 0 0.00424314
% O 0 0.0033915592
) O 0 0.0056033926
. O 0 0.00511989

The O 0 0.0033397784
occurrence O 0 0.0040591042
of O 0 0.002656567
this O 0 0.002492385
ADR O 0 0.9972191
was O 0 0.0016868495
more O 0 0.0014346158
frequent O 0 0.0025582816
in O 0 0.0009049148
patients O 0 0.0024041184
aged O 0 0.0018993574
between O 0 0.00076600874
61 O 0 0.0023559704
and O 0 0.0019971726
80 O 0 0.0040973793
years O 0 0.006887028
. O 0 0.005911058

CONCLUSION O 0 0.8127879
: O 0 0.0048459205
This O 0 0.0025233366
work O 0 0.0017753879
shows O 0 0.0007883445
that O 0 0.0010107398
confusion B-Disease 0 0.51203614
with O 0 0.0034821613
valproic B-Chemical 0 0.999819
acid I-Chemical 0 0.98580337
is O 0 0.0012895052
a O 0 0.0010776287
serious O 0 0.08499492
, O 0 0.001027645
rather O 0 0.000673487
frequent O 0 0.003437339
but O 0 0.0015312859
reversible O 0 0.47158363
adverse O 0 0.96916986
drug O 0 0.85480076
reaction O 0 0.26274222
. O 0 0.008302141

It O 0 0.006089926
occurs O 0 0.0026022135
especially O 0 0.002497799
in O 0 0.0014670582
older O 0 0.0031235002
patients O 0 0.0024017156
and O 0 0.0010146439
during O 0 0.000669717
the O 0 0.0008086961
first O 0 0.00082132133
two O 0 0.0010258469
weeks O 0 0.0018326637
of O 0 0.0035464677
treatment O 0 0.010804083
. O 0 0.007532155

Reversible O 0 0.8778996
inferior B-Disease 0 0.2942285
colliculus I-Disease 0 0.37493664
lesion I-Disease 0 0.108043395
in O 0 0.0023870436
metronidazole B-Chemical 1 0.9985367
- O 0 0.005739801
induced O 0 0.004140638
encephalopathy B-Disease 2 0.9996501
: O 0 0.0041683656
magnetic O 0 0.17023595
resonance O 0 0.48743767
findings O 0 0.0019147614
on O 0 0.0004431473
diffusion O 0 0.017673777
- O 0 0.0014039783
weighted O 0 0.0010419654
and O 0 0.0010993938
fluid O 0 0.015067773
attenuated O 0 0.0057858694
inversion O 0 0.054080453
recovery O 0 0.013874074
imaging O 0 0.052803382
. O 0 0.007534601

OBJECTIVE O 0 0.62902534
: O 0 0.005110072
This O 0 0.0027503385
is O 0 0.0013418791
to O 0 0.0009724041
present O 0 0.000805375
reversible O 0 0.19405171
inferior B-Disease 0 0.32110506
colliculus I-Disease 0 0.46707186
lesions I-Disease 0 0.36606053
in O 0 0.00095861556
metronidazole B-Chemical 1 0.9994295
- O 0 0.0042596566
induced O 0 0.0029320815
encephalopathy B-Disease 2 0.99979895
, O 0 0.001003174
to O 0 0.00031261583
focus O 0 0.00034049278
on O 0 0.00016459206
the O 0 0.000292692
diffusion O 0 0.011480717
- O 0 0.0007521165
weighted O 0 0.0005906333
imaging O 0 0.007845815
( O 0 0.0011976433
DWI O 0 0.975957
) O 0 0.0011521544
and O 0 0.00062842754
fluid O 0 0.009479568
attenuated O 0 0.0031674332
inversion O 0 0.035206877
recovery O 0 0.009450528
( O 0 0.0051876702
FLAIR O 0 0.98598295
) O 0 0.007643714
imaging O 0 0.026883299
. O 0 0.007032473

MATERIALS O 0 0.015874574
AND O 0 0.0053840675
METHODS O 0 0.0033888943
: O 0 0.0022737265
From O 0 0.001615356
November O 0 0.001343797
2005 O 0 0.001417279
to O 0 0.0006818894
September O 0 0.00086213695
2007 O 0 0.0011373595
, O 0 0.00059793115
8 O 0 0.0004005309
patients O 0 0.0009077589
( O 0 0.0004983734
5 O 0 0.00026768562
men O 0 0.0028307654
and O 0 0.00030473093
3 O 0 0.00026792692
women O 0 0.0029908132
) O 0 0.00047366827
were O 0 0.0002706933
diagnosed O 0 0.0030122919
as O 0 0.0002764524
having O 0 0.0008730007
metronidazole B-Chemical 1 0.99947625
- O 0 0.004301818
induced O 0 0.0042923084
encephalopathy B-Disease 2 0.9998023
( O 0 0.0021980738
age O 0 0.0020477918
range O 0 0.0014694743
; O 0 0.0016670044
43 O 0 0.001987483
- O 0 0.0021582916
78 O 0 0.0031625228
years O 0 0.0041634557
) O 0 0.005695631
. O 0 0.0051646847

They O 0 0.006434095
had O 0 0.00264807
been O 0 0.0023197785
taking O 0 0.0042801043
metronidazole B-Chemical 1 0.9978835
( O 0 0.0019966767
total O 0 0.000792941
dosage O 0 0.082452826
, O 0 0.0009499807
45 O 0 0.0005525787
- O 0 0.0005976927
120 O 0 0.0005023478
g O 0 0.00079570524
; O 0 0.00046041692
duration O 0 0.00038158864
, O 0 0.0003479188
30 O 0 0.00021236025
days O 0 0.00021130814
to O 0 0.00023512013
2 O 0 0.00029889224
months O 0 0.00038025377
) O 0 0.000567913
to O 0 0.00042989553
treat O 0 0.0021795512
the O 0 0.0010837576
infection B-Disease 2 0.12471127
in O 0 0.0019402518
various O 0 0.0060554896
organs O 0 0.060850997
. O 0 0.006577459

Initial O 0 0.009776543
brain O 0 0.03268783
magnetic O 0 0.08964379
resonance O 0 0.4239041
imaging O 0 0.020062055
( O 0 0.0028577077
MRI O 0 0.5737062
) O 0 0.0015094107
were O 0 0.0005294613
obtained O 0 0.00040529823
after O 0 0.00026182685
the O 0 0.00040231665
hospitalization O 0 0.04332534
, O 0 0.00069386786
including O 0 0.0006209432
DWI O 0 0.98252434
( O 0 0.00080543675
8 O 0 0.0003666794
/ O 0 0.00063969905
8 O 0 0.00028263137
) O 0 0.0003958804
, O 0 0.0002743754
apparent O 0 0.00030638327
diffusion O 0 0.007507262
coefficient O 0 0.0019142804
( O 0 0.00084203074
ADC O 0 0.62398475
) O 0 0.0008771243
map O 0 0.0004587012
( O 0 0.0005108424
4 O 0 0.00028356176
/ O 0 0.00062707235
8 O 0 0.00031941154
) O 0 0.0005463978
, O 0 0.00057374674
FLAIR O 0 0.9566647
( O 0 0.00062032975
7 O 0 0.0003091278
/ O 0 0.00063687365
8 O 0 0.00032750188
) O 0 0.0005059143
, O 0 0.00041630352
and O 0 0.00045573228
T2 O 0 0.017688585
- O 0 0.0009964026
weighted O 0 0.00089210883
image O 0 0.0015208292
( O 0 0.00164861
8 O 0 0.0014226013
/ O 0 0.0032700046
8 O 0 0.0025815521
) O 0 0.00513993
. O 0 0.004808534

Follow O 0 0.0157403
- O 0 0.004821542
up O 0 0.0022470078
MRIs O 0 0.021701988
were O 0 0.0010934616
performed O 0 0.00079496444
on O 0 0.0005255377
5 O 0 0.0005854308
patients O 0 0.0010894913
from O 0 0.00052168994
third O 0 0.0006440053
to O 0 0.00061597716
14th O 0 0.0042681354
days O 0 0.0007546401
after O 0 0.0006904605
discontinuation O 0 0.52147865
of O 0 0.004887567
metronidazole B-Chemical 1 0.99822944
administration O 0 0.75831884
. O 0 0.008792321

Findings O 0 0.0072177066
of O 0 0.002627247
initial O 0 0.0017465018
and O 0 0.0014058748
follow O 0 0.0011521946
- O 0 0.0013633592
up O 0 0.0006874458
MRIs O 0 0.028442435
were O 0 0.00041424445
retrospectively O 0 0.0005726835
evaluated O 0 0.00033305673
by O 0 0.0003635308
2 O 0 0.00035298822
neuroradiologists O 0 0.0034536186
by O 0 0.00030499164
consensus O 0 0.0002977225
, O 0 0.00030361587
to O 0 0.00017837551
analyze O 0 0.00014005667
the O 0 0.00019234557
presence O 0 0.00023469055
of O 0 0.00037745325
abnormal O 0 0.0064349044
signal O 0 0.00038707408
intensities O 0 0.0002613196
, O 0 0.0004468592
their O 0 0.00035088658
locations O 0 0.0004242397
, O 0 0.0005230757
and O 0 0.000449066
signal O 0 0.0005746646
changes O 0 0.0009167469
on O 0 0.0005312939
follow O 0 0.0012644557
- O 0 0.0027136197
up O 0 0.002459752
images O 0 0.0056181657
. O 0 0.005443231

RESULTS O 0 0.025442926
: O 0 0.0044096215
Initial O 0 0.004696183
MRIs O 0 0.056644537
showed O 0 0.0012760436
abnormal O 0 0.0035190263
high O 0 0.0010821614
signal O 0 0.0007628174
intensities O 0 0.00048179846
on O 0 0.0004755471
DWI O 0 0.95916384
and O 0 0.0012811822
FLAIR O 0 0.9898863
( O 0 0.0010295155
or O 0 0.00043408974
T2 O 0 0.036165956
- O 0 0.0007264342
weighted O 0 0.00047908162
image O 0 0.0006722942
) O 0 0.000602388
at O 0 0.00020099497
the O 0 0.00035279559
dentate O 0 0.23255849
nucleus O 0 0.0015257181
( O 0 0.00045592722
8 O 0 0.000281969
/ O 0 0.0005487825
8 O 0 0.00028105162
) O 0 0.0004559442
, O 0 0.00039797
inferior O 0 0.022417301
colliculus O 0 0.10205204
( O 0 0.0004157969
6 O 0 0.00020664954
/ O 0 0.0005045201
8 O 0 0.0002690261
) O 0 0.00044105426
, O 0 0.0003849827
corpus O 0 0.0036297091
callosum O 0 0.29512873
( O 0 0.0005517274
2 O 0 0.00032410998
/ O 0 0.0006311941
8 O 0 0.0003052063
) O 0 0.0005242937
, O 0 0.00053125975
pons O 0 0.844549
( O 0 0.00049537985
2 O 0 0.00030038712
/ O 0 0.0005828395
8 O 0 0.00029214
) O 0 0.0004980944
, O 0 0.0004951712
medulla O 0 0.6001495
( O 0 0.0005541434
1 O 0 0.0003495212
/ O 0 0.00064111594
8 O 0 0.00032504572
) O 0 0.0005098408
, O 0 0.00042756237
and O 0 0.00048058206
bilateral O 0 0.062986255
cerebral O 0 0.85905856
white O 0 0.0070152455
matter O 0 0.0057735727
( O 0 0.0017833267
1 O 0 0.0015852555
/ O 0 0.0034373344
8 O 0 0.0025782394
) O 0 0.005084218
. O 0 0.004721712

High O 0 0.03087167
- O 0 0.004877653
signal O 0 0.002077473
intensity O 0 0.001474463
lesions O 0 0.056626998
on O 0 0.00086390076
DWI O 0 0.9369701
tended O 0 0.0008513627
to O 0 0.0004570017
show O 0 0.00034122786
low O 0 0.0005205766
signal O 0 0.00044073098
intensity O 0 0.00034949256
on O 0 0.00029918077
ADC O 0 0.49932396
map O 0 0.00071669876
( O 0 0.0006751057
3 O 0 0.00031876867
/ O 0 0.00065677334
4 O 0 0.00025704785
) O 0 0.00042095562
, O 0 0.0002807057
but O 0 0.0001856085
in O 0 0.00015526384
one O 0 0.00015026075
patient O 0 0.00040799117
, O 0 0.0002872411
high O 0 0.00029584146
signal O 0 0.0002605034
intensity O 0 0.00022726558
was O 0 0.00028674034
shown O 0 0.00022212155
at O 0 0.00023678488
bilateral O 0 0.0672502
dentate O 0 0.25654772
nuclei O 0 0.0015165153
on O 0 0.00030007
not O 0 0.0005533714
only O 0 0.0010539141
DWI O 0 0.95338416
but O 0 0.001829846
also O 0 0.003184929
ADC O 0 0.6575947
map O 0 0.0072357226
. O 0 0.0071838535

All O 0 0.0042424756
the O 0 0.0030367638
lesions O 0 0.06526559
in O 0 0.0023321374
dentate O 0 0.3164129
, O 0 0.0022298843
inferior O 0 0.06443078
colliculus O 0 0.2629434
, O 0 0.0015348507
pons O 0 0.84884465
, O 0 0.0007542072
and O 0 0.00048592663
medullas O 0 0.024209064
had O 0 0.00041200334
been O 0 0.000424705
resolved O 0 0.00058015005
completely O 0 0.0003435329
on O 0 0.00017433692
follow O 0 0.0003367254
- O 0 0.00054654165
up O 0 0.0003127485
MRIs O 0 0.057544332
in O 0 0.00024196717
5 O 0 0.0002375082
patients O 0 0.00066981016
, O 0 0.00038358054
but O 0 0.0002752017
in O 0 0.00026730154
1 O 0 0.0003500538
patient O 0 0.00057140907
of O 0 0.0006805423
them O 0 0.0013845571
, O 0 0.0016050196
corpus O 0 0.016928876
callosal B-Disease 0 0.6628343
lesion I-Disease 0 0.4742254
persisted O 0 0.009701255
. O 0 0.0060757473

CONCLUSIONS O 0 0.8371672
: O 0 0.008974879
Reversible O 0 0.8413383
inferior B-Disease 0 0.25309226
colliculus I-Disease 0 0.33550882
lesions I-Disease 0 0.16411701
could O 0 0.000823397
be O 0 0.00069957913
considered O 0 0.000470307
as O 0 0.0003588339
the O 0 0.0004093005
characteristic O 0 0.0009318077
for O 0 0.0007330033
metronidazole B-Chemical 1 0.99935335
- O 0 0.0053134547
induced O 0 0.004604906
encephalopathy B-Disease 2 0.999691
, O 0 0.0016748729
next O 0 0.00058719836
to O 0 0.0010040873
the O 0 0.0017271872
dentate O 0 0.35552394
nucleus O 0 0.0079585835
involvement O 0 0.009711832
. O 0 0.006279188

Clinically O 0 0.1733389
significant O 0 0.0074931984
proteinuria B-Disease 2 0.99785537
following O 0 0.0035355617
the O 0 0.0024018358
administration O 0 0.0877297
of O 0 0.0045895963
sirolimus B-Chemical 1 0.997681
to O 0 0.006233389
renal O 0 0.99126375
transplant O 0 0.93752396
recipients O 0 0.082267605
. O 0 0.010227071

BACKGROUND O 0 0.86166924
: O 0 0.008488529
Sirolimus B-Chemical 1 0.9898114
is O 0 0.0019076148
the O 0 0.0010725183
latest O 0 0.0018908519
immunosuppressive O 0 0.9473969
agent O 0 0.1995765
used O 0 0.00077355077
to O 0 0.000567324
prevent O 0 0.00092062715
rejection O 0 0.9569216
, O 0 0.0010832796
and O 0 0.0005458049
may O 0 0.00045466723
have O 0 0.0005256946
less O 0 0.0010804284
nephrotoxicity B-Disease 0 0.99987054
than O 0 0.001012945
calcineurin O 0 0.98311144
inhibitor O 0 0.67929834
( O 0 0.012760689
CNI O 0 0.99890864
) O 0 0.0077784383
- O 0 0.003967315
based O 0 0.003551601
regimens O 0 0.05319845
. O 0 0.0066239242

To O 0 0.002848999
date O 0 0.002269619
there O 0 0.0012451955
has O 0 0.0013764158
been O 0 0.0012776357
little O 0 0.0009396627
documentation O 0 0.0015689783
of O 0 0.0012747803
clinically O 0 0.056453474
significant O 0 0.0029689681
proteinuria B-Disease 2 0.9994392
linked O 0 0.0020414998
with O 0 0.0018912138
the O 0 0.0017450525
use O 0 0.0031965238
of O 0 0.007203818
sirolimus B-Chemical 1 0.99686015
. O 0 0.01110639

We O 0 0.0037929777
have O 0 0.0029474306
encountered O 0 0.0033085397
several O 0 0.0021474364
patients O 0 0.0039374204
who O 0 0.0036158985
developed O 0 0.0032689825
substantial O 0 0.0052211313
proteinuria B-Disease 2 0.99919194
associated O 0 0.010455707
with O 0 0.010961179
sirolimus B-Chemical 1 0.99755824
use O 0 0.01743572
. O 0 0.009851423

In O 0 0.0025593222
each O 0 0.0012020486
patient O 0 0.0021143672
, O 0 0.0013827222
the O 0 0.0007244735
close O 0 0.00059984735
temporal O 0 0.0026332252
association O 0 0.00041118293
between O 0 0.000260182
the O 0 0.00035308176
commencement O 0 0.0007648042
of O 0 0.00082469423
sirolimus B-Chemical 1 0.9992125
therapy O 0 0.15282977
and O 0 0.0022360631
proteinuria B-Disease 2 0.9998313
implicated O 0 0.008418747
sirolimus B-Chemical 1 0.9993864
as O 0 0.00076540787
the O 0 0.0006940369
most O 0 0.0013409901
likely O 0 0.0010130149
etiology O 0 0.096281424
of O 0 0.0034811238
the O 0 0.0064704716
proteinuria B-Disease 2 0.99885607
. O 0 0.011217068

METHODS O 0 0.005804334
: O 0 0.0027848128
We O 0 0.0011439306
analyzed O 0 0.00084771443
the O 0 0.0007751291
clinical O 0 0.002371295
and O 0 0.0006762958
laboratory O 0 0.0009432727
information O 0 0.0006142512
available O 0 0.00036441183
for O 0 0.00026311786
all O 0 0.00026954315
119 O 0 0.0011435917
patients O 0 0.0008018074
transplanted O 0 0.0020774158
at O 0 0.00019143677
the O 0 0.00029881648
Washington O 0 0.0039931084
Hospital O 0 0.003854858
Center O 0 0.000936186
between O 0 0.00021148653
1999 O 0 0.0019007082
- O 0 0.0006644545
2003 O 0 0.00081459834
for O 0 0.00030716506
whom O 0 0.0025437665
sirolimus B-Chemical 1 0.99849224
was O 0 0.0007911077
a O 0 0.00077915704
component O 0 0.0009712674
of O 0 0.0015528235
their O 0 0.002829385
immunosuppressant O 0 0.9935487
regimen O 0 0.23117316
. O 0 0.0075578312

In O 0 0.0029400352
these O 0 0.00274163
patients O 0 0.0037994552
, O 0 0.0016759749
the O 0 0.00084898504
magnitude O 0 0.0007785863
of O 0 0.0013660183
proteinuria B-Disease 2 0.9995977
was O 0 0.00085347285
assessed O 0 0.00036424212
on O 0 0.00023222646
morning O 0 0.0015008098
urine O 0 0.046767306
samples O 0 0.00033127514
by O 0 0.00032898327
turbidometric O 0 0.0096044885
measurement O 0 0.00026769022
or O 0 0.00024683835
random O 0 0.00048803037
urine O 0 0.20542327
protein O 0 0.0025529596
: O 0 0.0013363818
creatinine B-Chemical 1 0.9933587
ratios O 0 0.000833874
, O 0 0.00063220254
an O 0 0.0005250051
estimate O 0 0.00036650826
of O 0 0.00091809646
grams O 0 0.0044725244
of O 0 0.0036241643
proteinuria B-Disease 2 0.9992329
/ O 0 0.023369066
day O 0 0.0057648635
. O 0 0.005909242

Laboratory O 0 0.012483368
results O 0 0.002728054
were O 0 0.001995831
compared O 0 0.0011248527
between O 0 0.0009404186
prior O 0 0.0011289988
, O 0 0.0018716155
during O 0 0.0013358619
and O 0 0.0024179225
following O 0 0.004483334
sirolimus B-Chemical 1 0.9956216
use O 0 0.013186239
. O 0 0.009541393

RESULTS O 0 0.027477328
: O 0 0.0049623135
Twenty O 0 0.0049494766
- O 0 0.002277296
eight O 0 0.0010053833
patients O 0 0.0023729969
( O 0 0.0012377424
24 O 0 0.00069768255
% O 0 0.00071189215
) O 0 0.0008131183
developed O 0 0.00096067094
increased O 0 0.0017980232
proteinuria B-Disease 2 0.9995278
from O 0 0.0009773498
baseline O 0 0.001027993
during O 0 0.0005987604
their O 0 0.0010991833
post O 0 0.0020733264
- O 0 0.0035081278
transplantation O 0 0.116345786
course O 0 0.00790691
. O 0 0.0064577814

In O 0 0.0032928712
21 O 0 0.0028037424
patients O 0 0.0029931974
an O 0 0.0016170918
alternative O 0 0.0013551428
cause O 0 0.0029068883
of O 0 0.0022729933
proteinuria B-Disease 2 0.9996382
was O 0 0.0013261675
either O 0 0.00071909896
obvious O 0 0.00065024925
or O 0 0.00054422853
insufficient O 0 0.0009737812
data O 0 0.0010824265
was O 0 0.0011138907
available O 0 0.0014264133
to O 0 0.0019555313
be O 0 0.0033390042
conclusive O 0 0.012076275
. O 0 0.0067509403

In O 0 0.0029530635
7 O 0 0.0017010188
of O 0 0.0014273557
the O 0 0.0010152609
28 O 0 0.0011080904
patients O 0 0.0013455413
there O 0 0.0003905067
was O 0 0.000459761
a O 0 0.00045955248
striking O 0 0.00068340654
temporal O 0 0.0037104527
association O 0 0.00031158808
between O 0 0.00020815324
the O 0 0.0003210323
initiation O 0 0.0005690552
of O 0 0.00083674106
sirolimus B-Chemical 1 0.99886584
and O 0 0.0009767277
the O 0 0.00077767746
development O 0 0.0031429706
of O 0 0.006594724
nephrotic B-Disease 2 0.9997975
- O 0 0.03230309
range O 0 0.035537336
proteinuria B-Disease 2 0.9988362
. O 0 0.010986233

Proteinuria B-Disease 2 0.9962655
correlated O 0 0.003230061
most O 0 0.0030295483
strongly O 0 0.0021469053
with O 0 0.0021425122
sirolimus B-Chemical 1 0.9980379
therapy O 0 0.053713225
when O 0 0.00075377757
compared O 0 0.00054070406
to O 0 0.0007508203
other O 0 0.0010362555
demographic O 0 0.0032581124
and O 0 0.002271508
clinical O 0 0.011844757
variables O 0 0.007579171
. O 0 0.0066413735

In O 0 0.0033863587
most O 0 0.0034807501
patients O 0 0.0044079325
, O 0 0.0023964813
discontinuation O 0 0.54205126
of O 0 0.0021895575
sirolimus B-Chemical 1 0.9985977
resulted O 0 0.0013861449
in O 0 0.00080539106
a O 0 0.00092909986
decrease O 0 0.0011434577
, O 0 0.0011955263
but O 0 0.00090318214
not O 0 0.0011594875
resolution O 0 0.016664369
, O 0 0.0037668915
of O 0 0.008500453
proteinuria B-Disease 2 0.9987109
. O 0 0.012051498

CONCLUSIONS O 0 0.8552691
: O 0 0.010163228
Sirolimus B-Chemical 1 0.9914479
induces O 0 0.0036856192
or O 0 0.0018938151
aggravates O 0 0.6739604
pre O 0 0.024209198
- O 0 0.0029915755
existing O 0 0.0027233101
proteinuria B-Disease 2 0.999433
in O 0 0.0013581053
an O 0 0.0015614704
unpredictable O 0 0.009862966
subset O 0 0.0019416525
of O 0 0.0036496194
renal O 0 0.9921445
allograft O 0 0.9866834
recipients O 0 0.11917892
. O 0 0.008694061

Proteinuria B-Disease 2 0.99580896
may O 0 0.00502954
improve O 0 0.0029654922
, O 0 0.0030998837
but O 0 0.0018402787
does O 0 0.0013606545
not O 0 0.0013841676
resolve O 0 0.0018861181
, O 0 0.0026915504
when O 0 0.0024821395
sirolimus B-Chemical 1 0.9958468
is O 0 0.0076891314
withdrawn O 0 0.05402503
. O 0 0.008753224

Components O 0 0.030796705
of O 0 0.009500405
lemon O 0 0.848789
essential O 0 0.010643891
oil O 0 0.9633822
attenuate O 0 0.4102601
dementia B-Disease 2 0.9968591
induced O 0 0.032320432
by O 0 0.02631405
scopolamine B-Chemical 1 0.9990482
. O 0 0.020947818

The O 0 0.004007194
anti O 0 0.01035323
- O 0 0.0064307954
dementia B-Disease 2 0.99414635
effects O 0 0.0038172603
of O 0 0.0017247685
s B-Chemical 0 0.0035970225
- I-Chemical 0 0.002620082
limonene I-Chemical 0 0.99874395
and O 0 0.0011687018
s B-Chemical 0 0.0012274706
- I-Chemical 0 0.0016860603
perillyl I-Chemical 0 0.99915504
alcohol I-Chemical 0 0.9990115
were O 0 0.0005884644
observed O 0 0.00025542692
using O 0 0.00023236712
the O 0 0.00026175624
passive O 0 0.0010848376
avoidance O 0 0.003059691
test O 0 0.00074879464
( O 0 0.0010986803
PA O 0 0.32021835
) O 0 0.000853246
and O 0 0.0004392513
the O 0 0.00041023057
open O 0 0.00055992143
field O 0 0.0013421393
habituation O 0 0.058491617
test O 0 0.002309349
( O 0 0.004598044
OFH O 0 0.6764939
) O 0 0.009039442
. O 0 0.0064148316

These O 0 0.006660777
lemon O 0 0.70283633
essential O 0 0.004122144
oils O 0 0.94103396
showed O 0 0.0016267821
strong O 0 0.0013547052
ability O 0 0.00082124653
to O 0 0.0005873504
improve O 0 0.00062317087
memory B-Disease 0 0.6228028
impaired I-Disease 0 0.022817785
by O 0 0.001697597
scopolamine B-Chemical 1 0.99993765
; O 0 0.006148197
however O 0 0.0010473686
, O 0 0.0006566344
s B-Chemical 0 0.0007112645
- I-Chemical 0 0.0012782229
perillyl I-Chemical 0 0.9993019
alcohol I-Chemical 0 0.9993303
relieved O 0 0.17779234
the O 0 0.00048181682
deficit B-Disease 0 0.09582615
of I-Disease 0 0.00070719764
associative I-Disease 0 0.3037965
memory I-Disease 0 0.38133305
in O 0 0.0005795084
PA O 0 0.4450502
only O 0 0.0004285433
, O 0 0.00046912406
and O 0 0.00033736535
did O 0 0.00028945517
not O 0 0.0002895407
improve O 0 0.00038123594
non O 0 0.0014878219
- O 0 0.0018513898
associative O 0 0.13454376
memory O 0 0.23870517
significantly O 0 0.0034018152
in O 0 0.0039287084
OFH O 0 0.7822777
. O 0 0.0067363535

Analysis O 0 0.008270745
of O 0 0.0041430416
neurotransmitter O 0 0.9219856
concentration O 0 0.0076071112
in O 0 0.0011071634
some O 0 0.0010816412
brain O 0 0.019637212
regions O 0 0.00067708123
on O 0 0.00024599492
the O 0 0.00029226288
test O 0 0.0003490415
day O 0 0.00030931408
showed O 0 0.00032974413
that O 0 0.00039237345
dopamine B-Chemical 1 0.99890125
concentration O 0 0.0045090113
of O 0 0.00056061486
the O 0 0.0004031292
vehicle O 0 0.046403054
/ O 0 0.0076894844
scopolamine B-Chemical 1 0.9999325
group O 0 0.001018859
was O 0 0.00029450105
significantly O 0 0.0003070599
lower O 0 0.00021576193
than O 0 0.00012432788
that O 0 0.0001441757
of O 0 0.0002798068
the O 0 0.00027475916
vehicle O 0 0.02057546
/ O 0 0.0014324042
vehicle O 0 0.013169892
group O 0 0.00047863132
, O 0 0.00036208777
but O 0 0.0002064014
this O 0 0.00022095685
phenomenon O 0 0.0030908906
was O 0 0.0002673699
reversed O 0 0.00074878393
when O 0 0.00022264148
s B-Chemical 0 0.0011372826
- I-Chemical 0 0.0011934504
limonene I-Chemical 0 0.99897695
or O 0 0.0004996158
s B-Chemical 0 0.0009124168
- I-Chemical 0 0.0015841917
perillyl I-Chemical 0 0.9991602
alcohol I-Chemical 0 0.9988225
were O 0 0.000936467
administered O 0 0.0016484516
before O 0 0.00046496236
the O 0 0.0009648349
injection O 0 0.00541237
of O 0 0.0071553863
scopolamine B-Chemical 1 0.99939334
. O 0 0.009873933

Simultaneously O 0 0.012036553
, O 0 0.0033270826
we O 0 0.0011251669
found O 0 0.0011567198
that O 0 0.00081849255
these O 0 0.0011385975
two O 0 0.00085102813
lemon O 0 0.8406556
essential O 0 0.0019016966
oil O 0 0.906246
components O 0 0.0013090643
could O 0 0.00070409616
inhibit O 0 0.0016222841
acetylcholinesterase O 0 0.9940467
activity O 0 0.0018380695
in O 0 0.00094368664
vitro O 0 0.0021389052
using O 0 0.0015199402
the O 0 0.0028699231
Ellman O 0 0.6746148
method O 0 0.009434539
. O 0 0.007538799

Attentional O 0 0.41201323
modulation O 0 0.006940853
of O 0 0.0042428905
perceived O 0 0.008140532
pain B-Disease 0 0.926004
intensity O 0 0.0033180427
in O 0 0.0042450507
capsaicin B-Chemical 0 0.9976828
- O 0 0.016769482
induced O 0 0.011236813
secondary O 2 0.502317
hyperalgesia B-Disease 2 0.9984676
. O 0 0.017421437

Perceived O 0 0.054545335
pain B-Disease 0 0.82319444
intensity O 0 0.008086388
is O 0 0.0075162696
modulated O 0 0.007497845
by O 0 0.01108498
attention O 0 0.026845222
. O 0 0.015864132

However O 0 0.0047386712
, O 0 0.0033644228
it O 0 0.00197273
is O 0 0.0012176434
not O 0 0.0008419328
known O 0 0.000970754
that O 0 0.000553996
how O 0 0.00059632317
pain B-Disease 0 0.8109006
intensity O 0 0.00061804714
ratings O 0 0.0011453081
are O 0 0.0005600351
affected O 0 0.0005331031
by O 0 0.00078870583
attention O 0 0.003268566
in O 0 0.0016223352
capsaicin B-Chemical 0 0.99869883
- O 0 0.01071986
induced O 0 0.0076454002
secondary O 2 0.4886034
hyperalgesia B-Disease 2 0.998896
. O 0 0.012897165

Here O 0 0.004676233
we O 0 0.0014265192
show O 0 0.0013203556
that O 0 0.0011636374
perceived O 0 0.0032342796
pain B-Disease 0 0.9123223
intensity O 0 0.0010115977
in O 0 0.0008697783
secondary O 2 0.07305302
hyperalgesia B-Disease 2 0.9997316
is O 0 0.0010147318
decreased O 0 0.0013721714
when O 0 0.00033448928
attention O 0 0.0015436795
is O 0 0.0004379764
distracted O 0 0.0038353517
away O 0 0.0004931479
from O 0 0.0004389633
the O 0 0.00060611346
painful O 0 0.84471434
pinprick O 0 0.73088235
stimulus O 0 0.0042304024
with O 0 0.0018285835
a O 0 0.0028261447
visual O 0 0.18186574
task O 0 0.009774257
. O 0 0.0060320664

Furthermore O 0 0.0053513716
, O 0 0.0032219542
it O 0 0.0018203598
was O 0 0.0011229716
found O 0 0.00076619093
that O 0 0.00051980827
the O 0 0.00049486733
magnitude O 0 0.0004986519
of O 0 0.0007826769
attentional O 0 0.32393503
modulation O 0 0.0024464594
in O 0 0.00061846554
secondary O 2 0.09245921
hyperalgesia B-Disease 2 0.99978846
is O 0 0.0008287841
very O 0 0.0005789442
similar O 0 0.00029471426
to O 0 0.0003537799
that O 0 0.00040379382
of O 0 0.0013206304
capsaicin B-Chemical 0 0.9990858
- O 0 0.0047805645
untreated O 0 0.0026457263
, O 0 0.0022627886
control O 0 0.0022640894
condition O 0 0.0072707064
. O 0 0.0056589856

Our O 0 0.0038154633
findings O 0 0.004412872
, O 0 0.0022824695
showing O 0 0.0012942497
no O 0 0.0008011895
interaction O 0 0.0010037362
between O 0 0.00055555487
capsaicin B-Chemical 0 0.99823725
treatment O 0 0.0053699296
and O 0 0.0008681488
attentional O 0 0.29698735
modulation O 0 0.0015204743
suggest O 0 0.0004134613
that O 0 0.000652927
capsaicin B-Chemical 0 0.99949276
- O 0 0.0046130614
induced O 0 0.0015821123
secondary O 2 0.14520706
hyperalgesia B-Disease 2 0.9997861
and O 0 0.0013183859
attention O 0 0.0032154357
might O 0 0.0004679271
affect O 0 0.00058415195
mechanical O 0 0.07602894
pain B-Disease 0 0.94396687
through O 0 0.0017964311
independent O 0 0.0020723094
mechanisms O 0 0.008221007
. O 0 0.0057748966

Cardioprotective O 0 0.97236574
effect O 0 0.008017616
of O 0 0.01246686
salvianolic B-Chemical 1 0.99967384
acid I-Chemical 1 0.9961951
A I-Chemical 1 0.6405581
on O 0 0.003092594
isoproterenol B-Chemical 1 0.9988023
- O 0 0.022748291
induced O 0 0.018208267
myocardial B-Disease 0 0.99870193
infarction I-Disease 2 0.9995881
in O 0 0.012040374
rats O 0 0.07227017
. O 0 0.0089189

The O 0 0.0025092019
present O 0 0.0015535718
study O 0 0.0019663488
was O 0 0.0011030445
designed O 0 0.0009757511
to O 0 0.0006697352
evaluate O 0 0.000445009
the O 0 0.0006873705
cardioprotective O 0 0.7666391
potential O 0 0.002095806
of O 0 0.006301662
salvianolic B-Chemical 1 0.9999299
acid I-Chemical 1 0.9984276
A I-Chemical 1 0.6915662
on O 0 0.0014605436
isoproterenol B-Chemical 1 0.999348
- O 0 0.016813071
induced O 0 0.014957206
myocardial B-Disease 0 0.99906474
infarction I-Disease 2 0.9996942
in O 0 0.009926066
rats O 0 0.06974003
. O 0 0.007329496

Hemodynamic O 0 0.6391979
parameters O 0 0.0073043336
and O 0 0.0043130084
lead O 0 0.015115544
II O 0 0.018636681
electrocardiograph O 0 0.32920617
were O 0 0.0027548384
monitored O 0 0.0020645799
and O 0 0.0035477842
recorded O 0 0.005612843
continuously O 0 0.009707564
. O 0 0.009074632

Cardiac O 0 0.48557633
marker O 0 0.006052047
enzymes O 0 0.033709627
and O 0 0.0035493877
antioxidative O 0 0.9791574
parameters O 0 0.004908358
in O 0 0.0019854524
serum O 0 0.050227758
and O 0 0.0030022524
heart O 0 0.3291925
tissues O 0 0.0077291983
were O 0 0.0038744044
measured O 0 0.0045260745
. O 0 0.007229868

Assay O 0 0.12421987
for O 0 0.004543771
mitochondrial O 0 0.19526611
respiratory O 0 0.2941534
function O 0 0.0034934094
and O 0 0.0023431145
histopathological O 0 0.2436906
examination O 0 0.0036176147
of O 0 0.0030637735
heart O 0 0.3791569
tissues O 0 0.0077007757
were O 0 0.0037566393
performed O 0 0.0050177732
. O 0 0.0072452584

Isoproterenol B-Chemical 0 0.99887913
- O 0 0.009055563
treated O 0 0.0034667854
rats O 0 0.0043969285
showed O 0 0.0009622538
significant O 0 0.0009856824
increases O 0 0.0007483014
in O 0 0.0004908665
the O 0 0.0004613217
levels O 0 0.0005440569
of O 0 0.001240598
lactate B-Chemical 0 0.99048924
dehydrogenase O 0 0.99757797
, O 0 0.01972682
aspartate B-Chemical 1 0.99974996
transaminase O 0 0.9999114
, O 0 0.019269092
creatine B-Chemical 1 0.9996038
kinase O 0 0.71064997
and O 0 0.0021969164
malondialdehyde B-Chemical 1 0.99991524
and O 0 0.0012813634
significant O 0 0.0007819892
decreases O 0 0.0006311496
in O 0 0.0003414109
the O 0 0.00037611116
activities O 0 0.0009457199
of O 0 0.0019507217
superoxide B-Chemical 1 0.999619
dismutase O 0 0.99991035
, O 0 0.05097545
catalase O 0 0.9986791
and O 0 0.010955091
glutathione B-Chemical 0 0.9992176
peroxidase O 0 0.9714607
in O 0 0.0033425651
serum O 0 0.25663096
and O 0 0.006046453
heart O 0 0.6472189
. O 0 0.008168305

These O 0 0.0045433636
rats O 0 0.0060758055
also O 0 0.0018718658
showed O 0 0.0012874913
declines O 0 0.0022189813
in O 0 0.0008034709
left O 0 0.0021311538
ventricular O 0 0.9524048
systolic O 0 0.83391297
pressure O 0 0.05440856
, O 0 0.0005006314
maximum O 0 0.0003041142
and O 0 0.00025313176
minimum O 0 0.00017789738
rate O 0 0.00022212641
of O 0 0.00036234746
developed O 0 0.00081484445
left O 0 0.0018844248
ventricular O 0 0.9642735
pressure O 0 0.110068515
, O 0 0.00059757737
and O 0 0.00042996852
elevation O 0 0.097748324
of O 0 0.00065794296
left O 0 0.0025369073
ventricular O 0 0.92812806
end O 0 0.0005553267
- O 0 0.0019463263
diastolic O 0 0.9335283
pressure O 0 0.07187375
and O 0 0.002350199
ST O 0 0.7983849
- O 0 0.0060906075
segment O 0 0.0077772206
. O 0 0.00581295

In O 0 0.003195685
addition O 0 0.0020125734
, O 0 0.002998316
mitochondrial O 0 0.35006475
respiratory B-Disease 0 0.95245886
dysfunction I-Disease 0 0.9962179
characterized O 0 0.005407777
by O 0 0.0009667387
decreased O 0 0.0025878034
respiratory O 0 0.30211127
control O 0 0.0006288652
ratio O 0 0.0010130743
and O 0 0.0011753265
ADP B-Chemical 1 0.9960756
/ O 0 0.012751508
O O 0 0.977009
was O 0 0.0010252992
observed O 0 0.0008047743
in O 0 0.001542183
isoproterenol B-Chemical 1 0.9983931
- O 0 0.008771345
treated O 0 0.0077128457
rats O 0 0.02317498
. O 0 0.0064227087

Administration O 0 0.39273447
of O 0 0.009740491
salvianolic B-Chemical 1 0.9996202
acid I-Chemical 1 0.9945728
A I-Chemical 1 0.2527778
for O 0 0.0010277482
a O 0 0.00082830794
period O 0 0.00057123153
of O 0 0.0006354192
8 O 0 0.00045099904
days O 0 0.0003786778
significantly O 0 0.00059643964
attenuated O 0 0.005329189
isoproterenol B-Chemical 1 0.99957067
- O 0 0.0057791583
induced O 0 0.0022079002
cardiac B-Disease 0 0.96854156
dysfunction I-Disease 0 0.997964
and O 0 0.0052895313
myocardial B-Disease 2 0.99962306
injury I-Disease 2 0.9966016
and O 0 0.0024913705
improved O 0 0.011420907
mitochondrial O 0 0.68288594
respiratory O 0 0.7573863
function O 0 0.012913214
. O 0 0.007064284

The O 0 0.004027338
protective O 0 0.009412976
role O 0 0.002579353
of O 0 0.006317381
salvianolic B-Chemical 1 0.99977916
acid I-Chemical 1 0.9971928
A I-Chemical 1 0.6786781
against O 0 0.0044245636
isoproterenol B-Chemical 1 0.99945074
- O 0 0.016271582
induced O 0 0.0067392765
myocardial B-Disease 0 0.9994103
damage I-Disease 0 0.9815315
was O 0 0.0016689657
further O 0 0.0014952004
confirmed O 0 0.0018646314
by O 0 0.0029568512
histopathological O 0 0.5781902
examination O 0 0.014354709
. O 0 0.007259602

The O 0 0.0026453994
results O 0 0.0017784794
of O 0 0.0016874671
our O 0 0.0011330001
study O 0 0.0015553168
suggest O 0 0.00091150054
that O 0 0.0016863019
salvianolic B-Chemical 1 0.99987924
acid I-Chemical 1 0.99789643
A I-Chemical 1 0.60311955
possessing O 0 0.016070232
antioxidant O 0 0.9976624
activity O 0 0.0022257704
has O 0 0.0006743614
a O 0 0.0006824872
significant O 0 0.0008577196
protective O 0 0.008909725
effect O 0 0.0014316788
against O 0 0.002222985
isoproterenol B-Chemical 1 0.9992569
- O 0 0.029713385
induced O 0 0.037817746
myocardial B-Disease 0 0.9988426
infarction I-Disease 2 0.9995448
. O 0 0.018411359

Long O 0 0.037547566
- O 0 0.007656355
term O 0 0.005974548
glutamate B-Chemical 1 0.9965932
supplementation O 0 0.9485811
failed O 0 0.004762838
to O 0 0.0025022537
protect O 0 0.0065016444
against O 0 0.0040609054
peripheral B-Disease 0 0.9009549
neurotoxicity I-Disease 2 0.99937844
of O 0 0.08665536
paclitaxel B-Chemical 1 0.9966023
. O 0 0.014677246

Toxic O 0 0.97319746
peripheral B-Disease 2 0.8436106
neuropathy I-Disease 2 0.99926466
is O 0 0.0026511094
still O 0 0.0011308345
a O 0 0.0008533867
significant O 0 0.0007895826
limiting O 0 0.0008313016
factor O 0 0.0026135088
for O 0 0.0005272653
chemotherapy O 0 0.7406913
with O 0 0.0019678224
paclitaxel B-Chemical 1 0.9991443
( O 0 0.0042225714
PAC B-Chemical 0 0.97028875
) O 0 0.0021317261
, O 0 0.0006845701
although O 0 0.0005655808
glutamate B-Chemical 1 0.99865144
and O 0 0.0006413363
its O 0 0.001068541
closely O 0 0.0006019176
related O 0 0.000585871
amino B-Chemical 0 0.9349627
acid I-Chemical 0 0.99466264
glutamine B-Chemical 0 0.9979962
were O 0 0.0017323039
claimed O 0 0.005310089
to O 0 0.0021737718
ameliorate O 0 0.54598486
PAC B-Chemical 0 0.99248147
neurotoxicity B-Disease 2 0.9988643
. O 0 0.013362666

This O 0 0.004089578
pilot O 0 0.0031084989
trial O 0 0.002408238
aimed O 0 0.0012701788
to O 0 0.000747848
evaluate O 0 0.00044561413
the O 0 0.0005453504
role O 0 0.0004688462
of O 0 0.0012824176
glutamate B-Chemical 1 0.9992448
supplementation O 0 0.9738887
for O 0 0.0008430567
preventing O 0 0.0087497
PAC B-Chemical 0 0.9879276
- O 0 0.003748071
induced O 0 0.0015808962
peripheral B-Disease 2 0.8041731
neuropathy I-Disease 2 0.9998791
in O 0 0.00049658585
a O 0 0.00042405122
randomized O 0 0.00079051993
, O 0 0.00050634163
placebo O 0 0.11991409
- O 0 0.0005938134
controlled O 0 0.00034155088
, O 0 0.00041318592
double O 0 0.00033788857
- O 0 0.00068499596
blinded O 0 0.0008367055
clinical O 0 0.0038484288
and O 0 0.0012359392
electro O 0 0.08060754
- O 0 0.0033503566
diagnostic O 0 0.0041834614
study O 0 0.0057538874
. O 0 0.0055131945

Forty O 0 0.013548511
- O 0 0.0040808017
three O 0 0.0014317768
ovarian B-Disease 2 0.97598684
cancer I-Disease 2 0.99634856
patients O 0 0.010115146
were O 0 0.0007378201
available O 0 0.00045372383
for O 0 0.00029697974
analysis O 0 0.00046569027
following O 0 0.00028186635
six O 0 0.00017058187
cycles O 0 0.00021280008
of O 0 0.00030110165
the O 0 0.00025257777
same O 0 0.00021327866
PAC B-Chemical 0 0.88344157
- O 0 0.00093845837
containing O 0 0.00031853296
regimen O 0 0.006389247
: O 0 0.0005146588
23 O 0 0.00038724978
had O 0 0.0002520151
been O 0 0.000345952
supplemented O 0 0.0016896396
by O 0 0.0003985809
glutamate B-Chemical 1 0.9986634
all O 0 0.0002657644
along O 0 0.00022758648
the O 0 0.00019470412
treatment O 0 0.00054206065
period O 0 0.00025402513
, O 0 0.00025961729
at O 0 0.00011382698
a O 0 0.00019149848
daily O 0 0.00049499376
dose O 0 0.0017814812
of O 0 0.00023191117
three O 0 0.00010688735
times O 0 0.00015279267
500 O 0 0.0012940278
mg O 0 0.29956853
( O 0 0.0005250561
group O 0 0.0005490363
G O 0 0.27554268
) O 0 0.00081147376
, O 0 0.00040742743
and O 0 0.00030597867
20 O 0 0.00034206934
had O 0 0.00034705008
received O 0 0.0006334377
a O 0 0.0009252844
placebo O 0 0.14148733
( O 0 0.0020535726
group O 0 0.0028093674
P O 0 0.07370688
) O 0 0.0071268827
. O 0 0.0056390683

Patients O 0 0.0091746105
were O 0 0.0026598296
evaluated O 0 0.0021198783
by O 0 0.0023000184
neurological O 0 0.7678245
examinations O 0 0.0056800763
, O 0 0.0019575257
questionnaires O 0 0.0018531325
and O 0 0.0018055281
sensory O 0 0.07297714
- O 0 0.004562701
motor O 0 0.14688973
nerve O 0 0.6179251
conduction O 0 0.3014733
studies O 0 0.010140602
. O 0 0.008080209

There O 0 0.005048421
was O 0 0.0021438356
no O 0 0.001193222
significant O 0 0.0012609427
difference O 0 0.00060592586
in O 0 0.00056783285
the O 0 0.00050170935
frequency O 0 0.00061775977
of O 0 0.00075479836
signs O 0 0.0749564
or O 0 0.00051381503
symptoms O 0 0.15302557
between O 0 0.00020210439
the O 0 0.0002532061
two O 0 0.00021505807
groups O 0 0.00042297636
although O 0 0.0006058248
neurotoxicity B-Disease 2 0.9996026
symptoms O 0 0.5721106
presented O 0 0.0006246
mostly O 0 0.000814298
with O 0 0.0005519147
lower O 0 0.00053563167
scores O 0 0.0006626854
of O 0 0.001195742
severity O 0 0.026945414
in O 0 0.0021346107
group O 0 0.005376282
G O 0 0.4488028
. O 0 0.007137975

However O 0 0.0039834334
, O 0 0.0025517652
this O 0 0.0012157718
difference O 0 0.00070169347
reached O 0 0.0010245845
statistical O 0 0.0022299404
significance O 0 0.001295489
only O 0 0.00068021094
with O 0 0.0007389481
regard O 0 0.00062883616
to O 0 0.0007120828
reported O 0 0.0020140277
pain B-Disease 0 0.98424995
sensation O 0 0.941216
( O 0 0.0031740419
P O 0 0.06590617
= O 0 0.0025141812
0 O 0 0.001907602
. O 0 0.0017635545
011 O 0 0.055031653
) O 0 0.007082616
. O 0 0.005975808

Also O 0 0.00462567
the O 0 0.0019916396
frequency O 0 0.0017988262
of O 0 0.001742048
abnormal O 0 0.0135586355
electro O 0 0.11357716
- O 0 0.0017980565
diagnostic O 0 0.001130646
findings O 0 0.0011534127
showed O 0 0.00043933335
similarity O 0 0.00047294234
between O 0 0.00019798816
the O 0 0.000288437
two O 0 0.00027719935
groups O 0 0.0006025178
( O 0 0.0009054849
G O 0 0.22645721
: O 0 0.0008420328
7 O 0 0.0003507436
/ O 0 0.0006864589
23 O 0 0.00052088476
= O 0 0.00043451862
30 O 0 0.00023711764
. O 0 0.00018416681
4 O 0 0.00027601575
% O 0 0.0004529199
; O 0 0.0007455976
P O 0 0.0074748127
: O 0 0.00090011803
6 O 0 0.0005273721
/ O 0 0.0013165214
20 O 0 0.0010546303
= O 0 0.0016270849
30 O 0 0.0014090427
% O 0 0.0025944195
) O 0 0.004848234
. O 0 0.00490849

This O 0 0.0043857503
pilot O 0 0.003453486
study O 0 0.0023708337
leads O 0 0.0015380445
to O 0 0.00094237213
the O 0 0.00075479184
conclusion O 0 0.00080160215
that O 0 0.00091120304
glutamate B-Chemical 1 0.9988788
supplementation O 0 0.9456618
at O 0 0.00051299226
the O 0 0.0004922499
chosen O 0 0.0005870663
regimen O 0 0.00459491
fails O 0 0.0009213639
to O 0 0.0008389385
protect O 0 0.003269135
against O 0 0.00223643
peripheral B-Disease 0 0.89627934
neurotoxicity I-Disease 2 0.9994978
of O 0 0.043056108
PAC B-Chemical 0 0.9822239
. O 0 0.010281365

Development O 0 0.018809529
of O 0 0.0060215155
ocular B-Disease 0 0.95842654
myasthenia I-Disease 0 0.9977823
during O 0 0.0051161847
pegylated B-Chemical 0 0.9971529
interferon I-Chemical 0 0.9989183
and O 0 0.014188551
ribavirin B-Chemical 1 0.9986077
treatment O 0 0.0547898
for O 0 0.0069774897
chronic B-Disease 2 0.99733317
hepatitis I-Disease 2 0.99976736
C I-Disease 2 0.9961861
. O 0 0.025417974

A O 0 0.019381784
63 O 0 0.0058653825
- O 0 0.0034279062
year O 0 0.0018144613
- O 0 0.0018541673
old O 0 0.0011070325
male O 0 0.001905595
experienced O 0 0.0017406746
sudden O 0 0.9516336
diplopia B-Disease 0 0.99818796
after O 0 0.00039421808
9 O 0 0.00036241952
weeks O 0 0.00026265546
of O 0 0.00039651225
administration O 0 0.04921054
of O 0 0.0013561355
pegylated B-Chemical 0 0.99886274
interferon I-Chemical 0 0.9997527
( I-Chemical 0 0.033661228
IFN I-Chemical 0 0.9993451
) I-Chemical 0 0.011549285
alpha I-Chemical 0 0.44372728
- I-Chemical 0 0.0020789616
2b I-Chemical 0 0.0012892559
and O 0 0.0009948475
ribavirin B-Chemical 1 0.9984102
for O 0 0.0026640766
chronic B-Disease 2 0.9985098
hepatitis I-Disease 2 0.99992704
C I-Disease 2 0.9986731
( O 0 0.15565893
CHC B-Disease 0 0.9934738
) O 0 0.031057345
. O 0 0.008434277

Ophthalmologic O 0 0.6667667
examinations O 0 0.00771539
showed O 0 0.0026983516
ptosis B-Disease 0 0.7546722
on I-Disease 0 0.0010249052
the I-Disease 0 0.0010426554
right I-Disease 0 0.0018961851
upper I-Disease 0 0.001470151
lid I-Disease 0 0.0037755622
and O 0 0.0008470886
restricted B-Disease 0 0.0007019162
right I-Disease 0 0.0017883843
eye I-Disease 0 0.0104413275
movement I-Disease 0 0.0024125944
without O 0 0.0012947817
any O 0 0.0014086404
other O 0 0.003144033
neurological O 0 0.9790394
signs O 0 0.6310552
. O 0 0.008164338

A O 0 0.021368222
brain O 0 0.022528691
imaging O 0 0.009276222
study O 0 0.0038725568
and O 0 0.0026906214
repetitive O 0 0.0065651755
nerve O 0 0.3183244
stimulation O 0 0.00484652
test O 0 0.0030220395
indicated O 0 0.0027966762
no O 0 0.0048630955
abnormality O 0 0.12707955
. O 0 0.010163228

The O 0 0.005626313
acetylcholine B-Chemical 1 0.9946396
receptor O 0 0.36549628
antibody O 0 0.00923088
titer O 0 0.0056286766
and O 0 0.0014461266
response O 0 0.0016667425
to O 0 0.0010433412
acetylcholinesterase O 0 0.993543
inhibitors O 0 0.13989218
were O 0 0.0007138273
negative O 0 0.00062275527
, O 0 0.0006886507
and O 0 0.0004886066
the O 0 0.00043156298
results O 0 0.0005467469
of O 0 0.0011581035
thyroid O 0 0.6582685
function O 0 0.0025141132
tests O 0 0.004244861
were O 0 0.0031127124
normal O 0 0.00806208
. O 0 0.00617502

The O 0 0.0031196335
patient O 0 0.00345777
' O 0 0.0023311768
s O 0 0.0020522205
ophthalmological O 0 0.22240739
symptoms O 0 0.16884872
improved O 0 0.0019548591
rapidly O 0 0.0014655992
3 O 0 0.0004611463
weeks O 0 0.00040579116
after O 0 0.0003226084
discontinuation O 0 0.35637918
of O 0 0.0017294316
pegylated B-Chemical 0 0.9959431
IFN I-Chemical 0 0.9989116
alpha I-Chemical 0 0.8358014
- I-Chemical 0 0.010476904
2b I-Chemical 0 0.005873925
and O 0 0.005888165
ribavirin B-Chemical 1 0.9954265
. O 0 0.009623912

The O 0 0.0040328456
ocular B-Disease 0 0.8881506
myasthenia I-Disease 0 0.9973609
associated O 0 0.004174924
with O 0 0.001772572
combination O 0 0.0033517387
therapy O 0 0.035832312
of O 0 0.0025281457
pegylated B-Chemical 0 0.997561
IFN I-Chemical 0 0.9994992
alpha I-Chemical 0 0.89683694
- I-Chemical 0 0.0051978384
2b I-Chemical 0 0.0013453958
and O 0 0.0006303149
ribavirin B-Chemical 1 0.9987293
for O 0 0.0006807389
CHC B-Disease 0 0.9936231
is O 0 0.00059189537
very O 0 0.0005519507
rarely O 0 0.0009003365
reported O 0 0.0007971336
; O 0 0.0006096584
therefore O 0 0.00034720227
, O 0 0.000264799
we O 0 9.7652344e-05
present O 0 0.00013705112
this O 0 0.00020381606
case O 0 0.00026771525
with O 0 0.00034582108
a O 0 0.0003973076
review O 0 0.0008603307
of O 0 0.0005309777
the O 0 0.00055224303
various O 0 0.0016866841
eye O 0 0.05675766
complications O 0 0.64465916
of O 0 0.007908956
IFN B-Chemical 0 0.99666363
therapy O 0 0.45182368
. O 0 0.00864296

Learning B-Disease 0 0.053058684
and I-Disease 0 0.004866445
memory I-Disease 0 0.66593224
deficits I-Disease 0 0.92249554
in O 0 0.002603293
ecstasy B-Chemical 1 0.99901664
users O 0 0.016984046
and O 0 0.001071403
their O 0 0.00092642225
neural O 0 0.004418095
correlates O 0 0.0009702723
during O 0 0.0007416012
a O 0 0.0014828454
face O 0 0.003463305
- O 0 0.0041847406
learning O 0 0.012738794
task O 0 0.009490212
. O 0 0.0064498503

It O 0 0.0061580734
has O 0 0.0027414567
been O 0 0.002287469
consistently O 0 0.0016355009
shown O 0 0.0011151683
that O 0 0.0013448423
ecstasy B-Chemical 1 0.99856925
users O 0 0.015312478
display O 0 0.0017637752
impairments B-Disease 0 0.2654259
in I-Disease 0 0.0015181026
learning I-Disease 0 0.008069358
and I-Disease 0 0.0032247123
memory I-Disease 0 0.23130932
performance O 0 0.009619564
. O 0 0.0071883267

In O 0 0.0028446552
addition O 0 0.0016705953
, O 0 0.0020110281
working O 0 0.002564537
memory O 0 0.1065504
processing O 0 0.0016982195
in O 0 0.00097429584
ecstasy B-Chemical 1 0.9993774
users O 0 0.019655237
has O 0 0.000605434
been O 0 0.0005493645
shown O 0 0.00025785787
to O 0 0.0002702987
be O 0 0.0002934512
associated O 0 0.00039275817
with O 0 0.00044475094
neural O 0 0.013389635
alterations O 0 0.008343476
in O 0 0.00038896318
hippocampal O 0 0.7777868
and O 0 0.0004994541
/ O 0 0.00091204914
or O 0 0.0002795258
cortical O 0 0.016873516
regions O 0 0.0003994965
as O 0 0.00024493755
measured O 0 0.00027258205
by O 0 0.0004935052
functional O 0 0.0012470578
magnetic O 0 0.10645148
resonance O 0 0.6262087
imaging O 0 0.03349596
( O 0 0.0052495603
fMRI O 0 0.11685762
) O 0 0.008220136
. O 0 0.0062823715

Using O 0 0.0041890056
functional O 0 0.0033095302
imaging O 0 0.0050748945
and O 0 0.001578383
a O 0 0.0013017538
face O 0 0.0020781525
- O 0 0.0014105786
learning O 0 0.0028287906
task O 0 0.0012057578
, O 0 0.00050430704
we O 0 0.00017667336
investigated O 0 0.00031901983
neural O 0 0.0022710098
correlates O 0 0.00035491903
of O 0 0.0003849112
encoding O 0 0.00056894997
and O 0 0.0004009836
recalling O 0 0.012361521
face O 0 0.0013124638
- O 0 0.0006085438
name O 0 0.00033993702
associations O 0 0.00024315565
in O 0 0.00021590349
20 O 0 0.0003345263
recreational O 0 0.052773196
drug O 0 0.16627364
users O 0 0.0023423142
whose O 0 0.0007077789
predominant O 0 0.0010444198
drug O 0 0.2588386
use O 0 0.0013153809
was O 0 0.0016342191
ecstasy B-Chemical 1 0.9985812
and O 0 0.0026454472
20 O 0 0.0031662618
controls O 0 0.0051667113
. O 0 0.0050261053

To O 0 0.0022680548
address O 0 0.0011438477
the O 0 0.0010410642
potential O 0 0.0011350818
confounding O 0 0.0012311401
effects O 0 0.0012950511
of O 0 0.000841626
the O 0 0.00073066517
cannabis B-Chemical 0 0.99829775
use O 0 0.00093124015
of O 0 0.0006532998
the O 0 0.00057999004
ecstasy B-Chemical 1 0.99948657
using O 0 0.0004548203
group O 0 0.00053166144
, O 0 0.00036165313
a O 0 0.00023515712
second O 0 0.00018611888
analysis O 0 0.00032184314
included O 0 0.0002072389
14 O 0 0.00025145564
previously O 0 0.00021684013
tested O 0 0.0002628937
cannabis B-Chemical 0 0.99890506
users O 0 0.020168241
( O 0 0.0010177478
Nestor O 0 0.2236572
, O 0 0.000809506
L O 0 0.34201407
. O 0 0.00029013204
, O 0 0.00060382305
Roberts O 0 0.11525145
, O 0 0.00082269125
G O 0 0.31981334
. O 0 0.0003416971
, O 0 0.00085172214
Garavan O 0 0.9013704
, O 0 0.001186687
H O 1 0.99191684
. O 0 0.0003736791
, O 0 0.0007344587
Hester O 0 0.2168145
, O 0 0.00086132064
R O 0 0.6175522
. O 0 0.00027470783
, O 0 0.00049618824
2008 O 0 0.0011175052
. O 0 0.00020789201
Deficits B-Disease 0 0.08732096
in I-Disease 0 0.0002467007
learning I-Disease 0 0.0021292707
and I-Disease 0 0.0004892631
memory I-Disease 0 0.30612445
: O 0 0.0027588762
parahippocampal O 0 0.9878857
hyperactivity B-Disease 2 0.99924505
and O 0 0.0016083592
frontocortical O 0 0.99677116
hypoactivity O 0 0.9992957
in O 0 0.0010761342
cannabis B-Chemical 0 0.9991372
users O 0 0.022292415
. O 0 0.0007145845
Neuroimage O 0 0.23232475
40 O 0 0.0014286368
, O 0 0.0020763208
1328 O 0 0.036336776
- O 0 0.0053272434
1339 O 0 0.3193789
) O 0 0.007532707
. O 0 0.0059243315

Ecstasy B-Chemical 1 0.99541485
users O 0 0.011510601
performed O 0 0.0021244737
significantly O 0 0.0018979514
worse O 0 0.0024341363
in O 0 0.0010148779
learning O 0 0.003799513
and O 0 0.0013415873
memory O 0 0.05738235
compared O 0 0.0007735939
to O 0 0.0011331615
controls O 0 0.0025077977
and O 0 0.0037480067
cannabis B-Chemical 0 0.9963863
users O 0 0.08592288
. O 0 0.008257689

A O 0 0.012214391
conjunction O 0 0.0032927492
analysis O 0 0.0022642014
of O 0 0.0015048841
the O 0 0.0009777471
encode O 0 0.0009900612
and O 0 0.0007382983
recall O 0 0.0016829546
phases O 0 0.0010782903
of O 0 0.0005997599
the O 0 0.000442037
task O 0 0.0010754317
revealed O 0 0.00088960736
ecstasy B-Chemical 1 0.9996592
- O 0 0.0026419493
specific O 0 0.0008114799
hyperactivity B-Disease 2 0.999138
in O 0 0.0005987435
bilateral O 0 0.20589308
frontal O 0 0.3830598
regions O 0 0.00056456064
, O 0 0.00045926258
left O 0 0.00091375835
temporal O 0 0.010288466
, O 0 0.0006071416
right O 0 0.0016481824
parietal O 0 0.47244263
, O 0 0.0008254773
bilateral O 0 0.044719353
temporal O 0 0.016391758
, O 0 0.0011539558
and O 0 0.0013248659
bilateral O 0 0.22991493
occipital O 0 0.9132407
brain O 0 0.13268885
regions O 0 0.00616238
. O 0 0.0055935574

Ecstasy B-Chemical 1 0.9967489
- O 0 0.009025183
specific O 0 0.003599919
hypoactivity O 0 0.9957639
was O 0 0.0017576888
evident O 0 0.0010960272
in O 0 0.0007373572
the O 0 0.00077277934
right O 0 0.0023102665
dorsal O 0 0.014674201
anterior O 0 0.101978414
cingulated O 0 0.99191463
cortex O 0 0.4902764
( O 0 0.0020389315
ACC O 0 0.7085356
) O 0 0.0020826375
and O 0 0.0015337616
left O 0 0.005486904
posterior O 0 0.1428849
cingulated O 0 0.9882178
cortex O 0 0.5507432
. O 0 0.007204312

In O 0 0.0035084216
both O 0 0.003154188
ecstasy B-Chemical 1 0.9972263
and O 0 0.0036012994
cannabis B-Chemical 0 0.99773836
groups O 0 0.0026209923
brain O 0 0.08746967
activation O 0 0.0025781558
was O 0 0.0005877861
decreased O 0 0.0009798273
in O 0 0.0004125363
the O 0 0.00046076774
right O 0 0.0021025373
medial O 0 0.11426244
frontal O 0 0.7188249
gyrus O 0 0.91934675
, O 0 0.0008665493
left O 0 0.003724243
parahippocampal O 0 0.9734874
gyrus O 0 0.87035495
, O 0 0.0009677929
left O 0 0.0024078349
dorsal O 0 0.034797236
cingulate O 0 0.98182523
gyrus O 0 0.8126261
, O 0 0.0019757533
and O 0 0.0022299953
left O 0 0.008023174
caudate O 0 0.6371162
. O 0 0.00672945

These O 0 0.0050727827
results O 0 0.0031975843
elucidated O 0 0.008534791
ecstasy B-Chemical 1 0.9983367
- O 0 0.004589043
related O 0 0.0012670337
deficits O 0 0.39797375
, O 0 0.0012009569
only O 0 0.0006656148
some O 0 0.0007331671
of O 0 0.0009182492
which O 0 0.001178584
might O 0 0.0008015052
be O 0 0.0012350861
attributed O 0 0.0016941032
to O 0 0.0028240653
cannabis B-Chemical 0 0.9958333
use O 0 0.010400695
. O 0 0.007667652

These O 0 0.008032317
ecstasy B-Chemical 1 0.99680245
- O 0 0.0050074323
specific O 0 0.0016128317
effects O 0 0.0021547505
may O 0 0.0009904385
be O 0 0.00073564495
related O 0 0.00044235654
to O 0 0.000466643
the O 0 0.0005173805
vulnerability O 0 0.018007066
of O 0 0.0011421622
isocortical O 0 0.9679312
and O 0 0.0012633078
allocortical O 0 0.79152983
regions O 0 0.0010433199
to O 0 0.00078996836
the O 0 0.0013482787
neurotoxic B-Disease 0 0.99518114
effects O 0 0.011527095
of O 0 0.014377105
ecstasy B-Chemical 1 0.99838674
. O 0 0.010570599

Disulfiram B-Chemical 0 0.99840933
- O 0 0.011180487
like O 0 0.0038685126
syndrome O 0 0.6632802
after O 0 0.002059158
hydrogen B-Chemical 0 0.99739444
cyanamide I-Chemical 0 0.99944526
professional O 0 0.03952953
skin O 0 0.09057506
exposure O 0 0.011443302
: O 0 0.0022094587
two O 0 0.0011049991
case O 0 0.001925037
reports O 0 0.004089548
in O 0 0.004141879
France O 0 0.06296566
. O 0 0.007451631

Hydrogen B-Chemical 0 0.9912736
cyanamide I-Chemical 0 0.9980313
is O 0 0.0048731067
a O 0 0.0029867978
plant O 0 0.020009141
growth O 0 0.007901667
regulator O 0 0.0010766898
used O 0 0.0010566219
in O 0 0.0010797997
agriculture O 0 0.12233894
to O 0 0.0013728681
induce O 0 0.0017023301
bud O 0 0.012545546
break O 0 0.0051302356
in O 0 0.0032155963
fruit O 0 0.13085997
trees O 0 0.014058239
. O 0 0.008682509

Contact O 0 0.112226404
with O 0 0.003555966
the O 0 0.0021677322
skin O 0 0.008215031
can O 0 0.0011014238
result O 0 0.0007933809
in O 0 0.00070249604
percutaneous O 0 0.0031535518
absorption O 0 0.20284426
of O 0 0.0010080414
the O 0 0.0008249713
substance O 0 0.9485178
that O 0 0.00080367073
inhibits O 0 0.0045936718
aldehyde B-Chemical 0 0.99930596
dehydrogenase O 0 0.99659294
and O 0 0.0015046628
can O 0 0.0007496221
induce O 0 0.0013073351
acetaldehyde B-Chemical 0 0.99949884
syndrome O 0 0.9578586
in O 0 0.0013846963
case O 0 0.0018967676
of O 0 0.0041313428
alcohol B-Chemical 0 0.99361175
use O 0 0.010587538
. O 0 0.0072362707

The O 0 0.002648156
purpose O 0 0.0020600783
of O 0 0.0016086915
this O 0 0.0011789448
report O 0 0.002352925
is O 0 0.0007900215
to O 0 0.0005537357
describe O 0 0.0005830275
two O 0 0.00040522867
cases O 0 0.0009667193
of O 0 0.0008892895
a O 0 0.0016048248
disulfiram B-Chemical 0 0.9998223
- O 0 0.005597132
like O 0 0.0012750427
syndrome O 0 0.7567676
following O 0 0.0014215207
occupational O 0 0.022667868
exposure O 0 0.01941028
to O 0 0.004700895
hydrogen B-Chemical 0 0.9969606
cyanamide I-Chemical 0 0.9987908
. O 0 0.016962092

The O 0 0.0026111507
first O 0 0.0016720925
case O 0 0.0016280116
involved O 0 0.001249118
a O 0 0.001258096
59 O 0 0.0018618461
- O 0 0.0012381048
year O 0 0.0007592953
- O 0 0.0009218332
old O 0 0.0006462131
man O 0 0.031432968
who O 0 0.001309251
used O 0 0.0005486395
Dormex B-Chemical 0 0.58204716
, O 0 0.0007692369
which O 0 0.0007230354
contains O 0 0.00068108644
hydrogen B-Chemical 0 0.99896586
cyanamide I-Chemical 0 0.99981505
, O 0 0.0019700283
without O 0 0.0006044221
protection O 0 0.0019506764
after O 0 0.00027098868
consuming O 0 0.0020757162
a O 0 0.0005229491
large O 0 0.000622326
amount O 0 0.0004671194
of O 0 0.0016110068
alcohol B-Chemical 0 0.99081504
during O 0 0.0022042529
a O 0 0.0042790296
meal O 0 0.070756294
. O 0 0.006524094

In O 0 0.0028641475
less O 0 0.0019745089
than O 0 0.0010440815
1 O 0 0.00090563844
hour O 0 0.00063704734
after O 0 0.000409776
the O 0 0.0005963464
ingestion O 0 0.22962862
of O 0 0.0013701466
alcohol B-Chemical 0 0.99630237
, O 0 0.0012673602
he O 0 0.0010055286
developed O 0 0.0023077037
malaise O 0 0.99836665
with O 0 0.0014458272
flushing B-Disease 0 0.7627477
of I-Disease 0 0.0010714837
the I-Disease 0 0.000892599
face I-Disease 0 0.0028545
, O 0 0.0029744967
tachycardia B-Disease 2 0.9980102
, O 0 0.004972408
and O 0 0.0058258837
dyspnea B-Disease 0 0.9941366
. O 0 0.008428549

Manifestations O 0 0.41995114
regressed O 0 0.019813064
spontaneously O 0 0.01907864
under O 0 0.0046586706
surveillance O 0 0.0080396
in O 0 0.005881766
the O 0 0.0078508
hospital O 0 0.025124883
. O 0 0.015035608

The O 0 0.002926775
second O 0 0.0021631904
case O 0 0.0019268135
occurred O 0 0.0017085057
in O 0 0.0011078919
a O 0 0.0012576903
55 O 0 0.0014991168
- O 0 0.0014841943
year O 0 0.0010849186
- O 0 0.001531536
old O 0 0.0012789717
farmer O 0 0.0057122493
following O 0 0.002030822
cutaneous O 0 0.45900524
contact O 0 0.006059894
with O 0 0.0075094723
Dormex B-Chemical 0 0.82301486
. O 0 0.008706954

Five O 0 0.005524762
hours O 0 0.002135272
after O 0 0.0011756663
exposure O 0 0.0033700047
, O 0 0.001599235
he O 0 0.0015585537
developed O 0 0.0037686902
disulfiram B-Chemical 0 0.9997789
- O 0 0.0062904805
like O 0 0.0011573529
syndrome O 0 0.83891886
with O 0 0.0016841408
flushing B-Disease 0 0.94449663
, O 0 0.0029677518
tachycardia B-Disease 2 0.9991456
, O 0 0.0016781561
and O 0 0.0012141382
arterial B-Disease 0 0.983931
hypotension I-Disease 2 0.9997328
after O 0 0.00085157284
consuming O 0 0.005196763
three O 0 0.0010377083
glasses O 0 0.060942784
of O 0 0.0061744964
wine O 0 0.93484396
. O 0 0.008748034

The O 0 0.0036958945
patient O 0 0.0040359497
recovered O 0 0.0023576173
spontaneously O 0 0.0068775434
in O 0 0.001743041
3 O 0 0.0013602736
hours O 0 0.0012784506
under O 0 0.0011746169
surveillance O 0 0.002915862
in O 0 0.0024392013
the O 0 0.0038636315
hospital O 0 0.015712867
. O 0 0.00890016

These O 0 0.003920052
cases O 0 0.0029633755
confirm O 0 0.001054391
the O 0 0.0010191887
necessity O 0 0.0012258744
of O 0 0.00105802
avoiding O 0 0.0018118325
alcohol B-Chemical 0 0.99581903
consumption O 0 0.17871097
as O 0 0.0005223348
recommended O 0 0.00060857803
in O 0 0.00032589716
the O 0 0.00033775877
instructions O 0 0.0008343075
for O 0 0.0002964558
use O 0 0.00049733534
of O 0 0.00073078705
Dormex B-Chemical 0 0.45675123
and O 0 0.000779336
of O 0 0.001152957
preventing O 0 0.0045659877
cutaneous O 0 0.7081469
contact O 0 0.0041921753
during O 0 0.0025417286
use O 0 0.0056229476
. O 0 0.005823083

Sulpiride B-Chemical 0 0.99651885
- O 0 0.07259673
induced O 0 0.14686497
tardive B-Disease 0 0.9987608
dystonia I-Disease 2 0.99817705
. O 0 0.050590888

Sulpiride B-Chemical 0 0.9986016
is O 0 0.0059184595
a O 0 0.004197264
selective O 0 0.050936762
D2 O 0 0.990217
- O 0 0.009431673
receptor O 0 0.35950655
antagonist O 0 0.98512197
with O 0 0.010345045
antipsychotic O 0 0.99841046
and O 0 0.012116835
antidepressant B-Chemical 1 0.9979207
properties O 0 0.03758303
. O 0 0.009303827

Although O 0 0.0036977155
initially O 0 0.0035080211
thought O 0 0.0026226742
to O 0 0.0013540823
be O 0 0.0011880096
free O 0 0.0015274602
of O 0 0.001985702
extrapyramidal O 0 0.999655
side O 0 0.1823106
effects O 0 0.0130157415
, O 0 0.0069841766
sulpiride B-Chemical 0 0.9999299
- O 0 0.015932037
induced O 0 0.024798492
tardive B-Disease 0 0.99995947
dyskinesia I-Disease 2 0.99995315
and O 0 0.028455114
parkinsonism B-Disease 2 0.99974126
have O 0 0.0035217209
been O 0 0.00388482
reported O 0 0.0058089644
occasionally O 0 0.018543994
. O 0 0.006466724

We O 0 0.0035518187
studied O 0 0.0031311263
a O 0 0.0021998964
37 O 0 0.0025583094
- O 0 0.002016498
year O 0 0.001211581
- O 0 0.0014057604
old O 0 0.00097014377
man O 0 0.02854673
who O 0 0.0016543209
developed O 0 0.001448961
persistent O 0 0.066406704
segmental O 0 0.11881016
dystonia B-Disease 2 0.9997217
within O 0 0.00066753646
2 O 0 0.00082070165
months O 0 0.00082475756
after O 0 0.0007056661
starting O 0 0.0031438381
sulpiride B-Chemical 0 0.9995018
therapy O 0 0.31365377
. O 0 0.008079933

We O 0 0.0038253553
could O 0 0.002158843
not O 0 0.0017225032
find O 0 0.0015030602
any O 0 0.0011760668
previous O 0 0.0014604456
reports O 0 0.0030788572
of O 0 0.006008595
sulpiride B-Chemical 0 0.9997608
- O 0 0.058919072
induced O 0 0.1290693
tardive B-Disease 0 0.9997681
dystonia I-Disease 2 0.99949765
. O 0 0.02259423

Comparative O 0 0.014168862
cognitive O 0 0.3381645
and O 0 0.0026526859
subjective O 0 0.007093221
side O 0 0.009101997
effects O 0 0.0019832973
of O 0 0.0012935841
immediate O 0 0.0044720853
- O 0 0.0029571715
release O 0 0.1656361
oxycodone B-Chemical 1 0.9998067
in O 0 0.0013525615
healthy O 0 0.0135739865
middle O 0 0.0022843229
- O 0 0.0019969046
aged O 0 0.0023156772
and O 0 0.0018976261
older O 0 0.0068708374
adults O 0 0.008655508
. O 0 0.005781238

This O 0 0.00404707
study O 0 0.0024194876
measured O 0 0.0009985408
the O 0 0.0009422021
objective O 0 0.0014201582
and O 0 0.0007777728
subjective O 0 0.0038164186
neurocognitive O 0 0.41039112
effects O 0 0.0010939837
of O 0 0.00054129557
a O 0 0.00043598266
single O 0 0.0003890616
10 O 0 0.0004317187
- O 0 0.0005715882
mg O 0 0.16611902
dose O 0 0.0060864147
of O 0 0.00047107198
immediate O 0 0.0028301536
- O 0 0.0014561093
release O 0 0.11371001
oxycodone B-Chemical 1 0.9999049
in O 0 0.0005721314
healthy O 0 0.011452897
, O 0 0.0005011719
older O 0 0.0018526458
( O 0 0.00044410318
> O 0 0.00048284998
65 O 0 0.00029462943
years O 0 0.00043853297
) O 0 0.00041516713
, O 0 0.0003015849
and O 0 0.00027907998
middle O 0 0.0006458228
- O 0 0.00054943695
aged O 0 0.00057160156
( O 0 0.0002926722
35 O 0 0.00022166225
to O 0 0.00016703698
55 O 0 0.00028650562
years O 0 0.00045244436
) O 0 0.00043885014
adults O 0 0.00060305663
who O 0 0.0006224859
were O 0 0.00032111275
not O 0 0.00042253183
suffering O 0 0.35076466
from O 0 0.0010284779
chronic O 0 0.8764965
or O 0 0.0015291584
significant O 0 0.003078986
daily O 0 0.02038773
pain B-Disease 0 0.9752126
. O 0 0.007418707

Seventy O 0 0.01321445
- O 0 0.0036061604
one O 0 0.0011376532
participants O 0 0.0010424049
completed O 0 0.00074280467
2 O 0 0.000519782
separate O 0 0.00034207906
study O 0 0.00056769676
days O 0 0.0003707759
and O 0 0.00038324267
were O 0 0.0003677527
blind O 0 0.001394148
to O 0 0.00043535154
medication O 0 0.053975437
condition O 0 0.0016666736
( O 0 0.001104604
placebo O 0 0.09282393
, O 0 0.0011861245
10 O 0 0.0012188031
- O 0 0.0027668625
mg O 0 0.77669454
oxycodone B-Chemical 1 0.9992236
) O 0 0.014208078
. O 0 0.0064129876

Plasma O 0 0.6820114
oxycodone B-Chemical 1 0.9991642
concentration O 0 0.019045955
peaked O 0 0.0033513089
between O 0 0.0005929215
60 O 0 0.0007299713
and O 0 0.00050137064
90 O 0 0.00047372832
minutes O 0 0.00044818892
postdose O 0 0.015717579
( O 0 0.0006587012
P O 0 0.008914986
< O 0 0.0004935584
. O 0 0.00023603723
01 O 0 0.0019257941
) O 0 0.00047177167
and O 0 0.00029659178
pupil O 0 0.011708305
size O 0 0.0004435667
, O 0 0.0003507872
an O 0 0.00028145197
indication O 0 0.00020810141
of O 0 0.0002875019
physiological O 0 0.0015837717
effects O 0 0.0006466166
of O 0 0.0003955778
the O 0 0.00033437516
medication O 0 0.11997646
, O 0 0.00047560214
peaked O 0 0.00066953676
at O 0 0.00015145873
approximately O 0 0.00024651052
90 O 0 0.0002564073
to O 0 0.00022438791
120 O 0 0.00046535188
minutes O 0 0.00044693757
postdose O 0 0.01139641
( O 0 0.0011726923
P O 0 0.010682836
< O 0 0.0018245252
. O 0 0.0014982511
01 O 0 0.010166288
) O 0 0.00606998
. O 0 0.005553445

Significant O 0 0.006576524
declines B-Disease 0 0.0041030827
in I-Disease 0 0.0014655397
simple I-Disease 0 0.0020536573
and I-Disease 0 0.0012004732
sustained I-Disease 0 0.0045791366
attention I-Disease 0 0.003329688
, I-Disease 0 0.00093745795
working I-Disease 0 0.0015694675
memory I-Disease 0 0.16386113
, I-Disease 0 0.0007010912
and I-Disease 0 0.00045437744
verbal I-Disease 0 0.06690044
memory I-Disease 0 0.11074275
were O 0 0.0002938235
observed O 0 0.00017164861
at O 0 0.000134343
1 O 0 0.00017627455
hour O 0 0.00016525976
postdose O 0 0.0043151546
compared O 0 9.04322e-05
to O 0 0.00012650774
baseline O 0 0.00021167332
for O 0 0.00014171115
both O 0 0.00019388676
age O 0 0.00048532462
groups O 0 0.00029318494
with O 0 0.00033411547
a O 0 0.00037545935
trend O 0 0.0006076759
toward O 0 0.0004624493
return O 0 0.00074165565
to O 0 0.0005036497
baseline O 0 0.00093733787
by O 0 0.0009749082
5 O 0 0.001167266
hours O 0 0.0020221695
postdose O 0 0.028649284
. O 0 0.004351377

For O 0 0.0024558627
almost O 0 0.001663852
all O 0 0.0013784884
cognitive O 0 0.17281094
measures O 0 0.0010908282
, O 0 0.0008796858
there O 0 0.00034484395
were O 0 0.00041612997
no O 0 0.0003324397
medication O 0 0.033474285
by O 0 0.00046655798
age O 0 0.001205376
- O 0 0.00063081674
interaction O 0 0.00038910372
effects O 0 0.00078179064
, O 0 0.00043122022
which O 0 0.0003560983
indicates O 0 0.00020487617
that O 0 0.00020734148
the O 0 0.0002626469
2 O 0 0.00031473968
age O 0 0.0005864221
groups O 0 0.0004090957
exhibited O 0 0.00046595754
similar O 0 0.0004557599
responses O 0 0.0013421419
to O 0 0.00097240496
the O 0 0.0016760125
medication O 0 0.14376183
challenge O 0 0.006313641
. O 0 0.0056641228

This O 0 0.0040923627
study O 0 0.0025115947
suggests O 0 0.0010319282
that O 0 0.0008543012
for O 0 0.0007882467
healthy O 0 0.0033714143
older O 0 0.0023149531
adults O 0 0.0014393232
who O 0 0.0010475438
are O 0 0.00040662524
not O 0 0.00038739893
suffering O 0 0.39963275
from O 0 0.000660874
chronic B-Disease 0 0.9784057
pain I-Disease 0 0.9954579
, O 0 0.0015334942
neurocognitive O 0 0.69828737
and O 0 0.00045816242
pharmacodynamic O 0 0.8370266
changes O 0 0.00059628364
in O 0 0.00021854628
response O 0 0.00040932588
to O 0 0.00021713617
a O 0 0.00029698596
10 O 0 0.00031639286
- O 0 0.00045462244
mg O 0 0.14271587
dose O 0 0.0050279917
of O 0 0.0004371614
immediate O 0 0.00262353
- O 0 0.0014183214
release O 0 0.108667776
oxycodone B-Chemical 1 0.99987626
are O 0 0.0005502187
similar O 0 0.00028245684
to O 0 0.00034530353
those O 0 0.0005693039
observed O 0 0.0004413541
for O 0 0.0007246534
middle O 0 0.0026333765
- O 0 0.003185471
aged O 0 0.0046554348
adults O 0 0.0069432566
. O 0 0.0050338064

PERSPECTIVE O 0 0.15511987
: O 0 0.0050410903
Study O 0 0.007198949
findings O 0 0.0022494188
indicate O 0 0.00080657046
that O 0 0.0007156354
the O 0 0.0008191676
metabolism O 0 0.23904459
, O 0 0.0012757592
neurocognitive O 0 0.5918265
effects O 0 0.0018429393
, O 0 0.00063448114
and O 0 0.000402805
physical O 0 0.00550079
side O 0 0.008175211
effects O 0 0.0009164739
of O 0 0.0006734962
oral O 0 0.6733837
oxycodone B-Chemical 1 0.99989414
are O 0 0.00066016987
similar O 0 0.0003267892
for O 0 0.0004112545
healthy O 0 0.004066805
middle O 0 0.0015501213
- O 0 0.0015655966
aged O 0 0.0019314958
and O 0 0.0016311776
older O 0 0.0062457975
adults O 0 0.00793257
. O 0 0.0052983803

Therefore O 0 0.0035427895
, O 0 0.002952112
clinicians O 0 0.002637909
should O 0 0.0007796413
not O 0 0.0007019125
avoid O 0 0.0007124446
prescribing O 0 0.018697692
oral O 0 0.35731512
opioids O 0 0.9969399
to O 0 0.00068756175
older O 0 0.0023913193
adults O 0 0.00088543945
based O 0 0.0003237783
on O 0 0.000168129
the O 0 0.0002661384
belief O 0 0.0017785099
that O 0 0.00029802465
older O 0 0.0015070237
adults O 0 0.00083713385
are O 0 0.00029611852
at O 0 0.00020150692
higher O 0 0.00038539586
risk O 0 0.005244414
for O 0 0.00063329824
side O 0 0.011964253
effects O 0 0.002571335
than O 0 0.0014024269
younger O 0 0.023954462
adults O 0 0.009274999
. O 0 0.005388775

The O 0 0.0055751326
glycine B-Chemical 1 0.9903138
transporter O 0 0.6931076
- O 0 0.0054826685
1 O 0 0.0018701394
inhibitor O 0 0.1289689
SSR103800 B-Chemical 0 0.9826743
displays O 0 0.001287387
a O 0 0.00089690764
selective O 0 0.0052632177
and O 0 0.0007703358
specific O 0 0.00096897245
antipsychotic O 0 0.9990386
- O 0 0.0020578757
like O 0 0.0007114642
profile O 0 0.0010365711
in O 0 0.00079708383
normal O 0 0.0020323996
and O 0 0.001657845
transgenic O 0 0.0027102497
mice O 0 0.003019219
. O 0 0.005390207

Schizophrenia B-Disease 0 0.9237127
has O 0 0.0053414926
been O 0 0.0042572077
initially O 0 0.0045926888
associated O 0 0.0044658678
with O 0 0.0058693737
dysfunction O 0 0.9631665
in O 0 0.011963455
dopamine B-Chemical 1 0.9973189
neurotransmission O 0 0.9904446
. O 0 0.015963247

However O 0 0.004432107
, O 0 0.0029948656
the O 0 0.0015223867
observation O 0 0.0014537154
that O 0 0.0011125734
antagonists O 0 0.8535456
of O 0 0.002104386
the O 0 0.0020681284
glutamate B-Chemical 1 0.99950206
N B-Chemical 0 0.9947068
- I-Chemical 0 0.029456444
methyl I-Chemical 0 0.9908857
- I-Chemical 0 0.012689192
D I-Chemical 0 0.86261576
- I-Chemical 0 0.0130111845
aspartate I-Chemical 1 0.99954826
( O 0 0.014433926
NMDA B-Chemical 1 0.99988925
) O 0 0.0068684705
receptor O 0 0.17568786
produce O 0 0.0009882286
schizophrenic B-Disease 2 0.99935883
- O 0 0.0017570531
like O 0 0.0004591667
symptoms O 0 0.27393985
in O 0 0.00030149063
humans O 0 0.0015259163
has O 0 0.00027332272
led O 0 0.00037072005
to O 0 0.00022816184
the O 0 0.00023072968
idea O 0 0.00042907364
of O 0 0.00044249147
a O 0 0.0005861435
dysfunctioning O 0 0.26246414
of O 0 0.00090938
the O 0 0.0010431132
glutamatergic O 0 0.9789508
system O 0 0.002568609
via O 0 0.002080331
its O 0 0.025074512
NMDA B-Chemical 1 0.9992624
receptor O 0 0.7930666
. O 0 0.009979942

As O 0 0.0023767427
a O 0 0.0022770697
result O 0 0.0014846629
, O 0 0.0014922105
there O 0 0.00062373304
is O 0 0.00066094426
a O 0 0.00058556336
growing O 0 0.0007406439
interest O 0 0.0005901038
in O 0 0.000334437
the O 0 0.0003234935
development O 0 0.00074228185
of O 0 0.0005009648
pharmacological O 0 0.41468742
agents O 0 0.1801641
with O 0 0.0006460533
potential O 0 0.0012473998
antipsychotic O 0 0.9991173
properties O 0 0.0014200959
that O 0 0.00023810157
enhance O 0 0.00022511778
the O 0 0.00027208534
activity O 0 0.00043188423
of O 0 0.00047319304
the O 0 0.00055577833
glutamatergic O 0 0.97158766
system O 0 0.0011057103
via O 0 0.00062203134
a O 0 0.00091000093
modulation O 0 0.0020497101
of O 0 0.0023358183
the O 0 0.004923248
NMDA B-Chemical 1 0.9992249
receptor O 0 0.7903674
. O 0 0.010086838

Among O 0 0.008890183
them O 0 0.0050878394
are O 0 0.0034352015
glycine B-Chemical 1 0.9937463
transporter O 0 0.7105254
- O 0 0.00430662
1 O 0 0.0013786774
( O 0 0.0017933256
GlyT1 O 0 0.9965732
) O 0 0.0018084542
inhibitors O 0 0.033032056
such O 0 0.0005877261
as O 0 0.0005708422
SSR103800 B-Chemical 0 0.98624945
, O 0 0.0008708158
which O 0 0.00063981547
indirectly O 0 0.0014222189
enhance O 0 0.0006346012
NMDA B-Chemical 1 0.9998832
receptor O 0 0.45514166
function O 0 0.0011332732
by O 0 0.0004291841
increasing O 0 0.00078376546
the O 0 0.00064023916
glycine B-Chemical 1 0.9976381
( O 0 0.0012092992
a O 0 0.00068614195
co O 0 0.27346644
- O 0 0.0023627228
agonist O 0 0.8571551
for O 0 0.00063972885
the O 0 0.0013550944
NMDA B-Chemical 1 0.99977857
receptor O 0 0.6199934
) O 0 0.0036311923
levels O 0 0.0014953968
in O 0 0.0017501167
the O 0 0.003052971
synapse O 0 0.10752027
. O 0 0.006594306

This O 0 0.0039477577
study O 0 0.002451578
aimed O 0 0.0014913852
at O 0 0.0007057071
investigating O 0 0.00077740307
the O 0 0.0007255901
potential O 0 0.0016233185
antipsychotic O 0 0.99896646
- O 0 0.0020205306
like O 0 0.0005065768
properties O 0 0.0009874963
of O 0 0.00084271695
SSR103800 B-Chemical 0 0.98844784
, O 0 0.00066386204
with O 0 0.00037381682
a O 0 0.00028481268
particular O 0 0.0002067189
focus O 0 0.00028199295
on O 0 0.00014365494
models O 0 0.00051708956
of O 0 0.0009047045
hyperactivity B-Disease 2 0.99935776
, O 0 0.00072789745
involving O 0 0.00041566728
either O 0 0.00033478535
drug O 0 0.22941697
challenge O 0 0.0008126415
( O 0 0.00061048067
ie O 0 0.001144034
, O 0 0.0011066751
amphetamine B-Chemical 1 0.9998779
and O 0 0.001464591
MK B-Chemical 0 0.9856477
- I-Chemical 0 0.0035572755
801 I-Chemical 0 0.6390969
) O 0 0.00069096475
or O 0 0.00022068272
transgenic O 0 0.0003335671
mice O 0 0.00023273783
( O 0 0.0005168723
ie O 0 0.0011022819
, O 0 0.0014626851
NMDA B-Chemical 1 0.9998466
Nr1 O 0 0.885516
( O 0 0.0013570692
neo O 0 0.056147736
- O 0 0.001859456
/ O 0 0.002096163
- O 0 0.0011950759
) O 0 0.0010390384
and O 0 0.00095891417
DAT O 0 0.920363
( O 0 0.0023572103
- O 0 0.0028289466
/ O 0 0.0044061937
- O 0 0.0041681184
) O 0 0.0049715987
) O 0 0.006469727
. O 0 0.0053996732

Results O 0 0.0053005703
showed O 0 0.0029220115
that O 0 0.0024246234
SSR103800 B-Chemical 0 0.96123
( O 0 0.0027252634
10 O 0 0.001243407
- O 0 0.0011641929
30 O 0 0.0005682124
mg O 0 0.12006379
/ O 0 0.0012092383
kg O 0 0.0028815507
p O 0 0.00063907413
. O 0 0.00027062156
o O 0 0.0013581882
. O 0 0.00030437292
) O 0 0.0007894878
blocked O 0 0.0023523285
hyperactivity B-Disease 2 0.99900323
induced O 0 0.0012091169
by O 0 0.0004915798
the O 0 0.00040437793
non O 0 0.0019290026
- O 0 0.0016087143
competitive O 0 0.076887935
NMDA B-Chemical 1 0.99991393
receptor O 0 0.84982145
antagonist O 0 0.9966407
, O 0 0.0055209384
MK B-Chemical 0 0.9886777
- I-Chemical 0 0.0039057452
801 I-Chemical 0 0.54978
and O 0 0.0004914618
partially O 0 0.00058799336
reversed O 0 0.0025096843
spontaneous O 0 0.12604952
hyperactivity B-Disease 2 0.99932027
of O 0 0.013993108
NMDA B-Chemical 1 0.99988425
Nr1 O 0 0.9553463
( O 0 0.003129116
neo O 0 0.092904866
- O 0 0.004002323
/ O 0 0.004779151
- O 0 0.0036521917
) O 0 0.0037700727
mice O 0 0.0026767473
. O 0 0.0050016437

In O 0 0.0035373496
contrast O 0 0.0030924836
, O 0 0.0034536282
SSR103800 B-Chemical 0 0.93440545
failed O 0 0.0021554139
to O 0 0.0010659295
affect O 0 0.0009837558
hyperactivity B-Disease 2 0.9984486
induced O 0 0.0028117625
by O 0 0.0016750098
amphetamine B-Chemical 1 0.99985933
or O 0 0.00074282166
naturally O 0 0.007111624
observed O 0 0.00041760944
in O 0 0.0006275441
dopamine B-Chemical 1 0.9995085
transporter O 0 0.7650151
( O 0 0.0035098668
DAT O 0 0.9770323
( O 0 0.0016615448
- O 0 0.0012901182
/ O 0 0.0016674203
- O 0 0.00089726533
) O 0 0.00066091307
) O 0 0.00048964936
knockout O 0 0.00030272943
mice O 0 0.00022495023
( O 0 0.0004683609
10 O 0 0.00037893257
- O 0 0.00052583544
30 O 0 0.00037152262
mg O 0 0.08341139
/ O 0 0.001404849
kg O 0 0.0036310873
p O 0 0.0013113429
. O 0 0.0008924851
o O 0 0.0041727065
. O 0 0.002143857
) O 0 0.0060682604
. O 0 0.005344239

Importantly O 0 0.004052076
, O 0 0.0031789232
both O 0 0.0018159879
classical O 0 0.0050486177
( O 0 0.0048647225
haloperidol B-Chemical 1 0.99983835
) O 0 0.005275533
and O 0 0.001197903
atypical O 0 0.3071761
( O 0 0.0047759227
olanzapine B-Chemical 1 0.99988794
, O 0 0.006664665
clozapine B-Chemical 1 0.9998803
and O 0 0.0037842006
aripiprazole B-Chemical 0 0.99984777
) O 0 0.007365403
antipsychotics O 0 0.99853206
were O 0 0.0006618144
effective O 0 0.0008556833
in O 0 0.00054363365
all O 0 0.0006567326
these O 0 0.0014391766
models O 0 0.003412696
of O 0 0.007965054
hyperactivity B-Disease 2 0.99671715
. O 0 0.009226777

However O 0 0.004624735
, O 0 0.0031529884
unlike O 0 0.0016068177
these O 0 0.001918451
latter O 0 0.0038344774
, O 0 0.002332135
SSR103800 B-Chemical 0 0.96663564
did O 0 0.00093006133
not O 0 0.0006519699
produce O 0 0.0010436703
catalepsy B-Disease 2 0.99984765
( O 0 0.0017050056
retention O 0 0.0017360242
on O 0 0.00025364466
the O 0 0.00037065148
bar O 0 0.0011461087
test O 0 0.00056518277
) O 0 0.00076199754
up O 0 0.00043382042
to O 0 0.0004700753
30 O 0 0.00067515275
mg O 0 0.14351414
/ O 0 0.002620738
kg O 0 0.0065251295
p O 0 0.002613096
. O 0 0.002012127
o O 0 0.009197066
. O 0 0.0061154123

Together O 0 0.0074867867
these O 0 0.003426027
findings O 0 0.0033695064
show O 0 0.0012880506
that O 0 0.0011001319
the O 0 0.0015423535
GlyT1 O 0 0.997486
inhibitor O 0 0.5098562
, O 0 0.004140931
SSR103800 B-Chemical 0 0.99382097
, O 0 0.0016197028
produces O 0 0.002113361
antipsychotic O 0 0.9994541
- O 0 0.0019313976
like O 0 0.0003972987
effects O 0 0.0010731402
, O 0 0.00043398567
which O 0 0.00033735682
differ O 0 0.00028148846
from O 0 0.00022219401
those O 0 0.00030745097
observed O 0 0.000175669
with O 0 0.00034350756
compounds O 0 0.30543044
primarily O 0 0.00069020916
targeting O 0 0.00025219514
the O 0 0.0003739981
dopaminergic O 0 0.9599053
system O 0 0.00082735665
, O 0 0.00042243718
and O 0 0.0002839697
has O 0 0.00027132503
a O 0 0.00034763152
reduced O 0 0.00045526272
side O 0 0.018538553
- O 0 0.0007681846
effect O 0 0.0004287278
potential O 0 0.0006183341
as O 0 0.0004271643
compared O 0 0.0004335897
with O 0 0.0011217499
these O 0 0.0023248408
latter O 0 0.011677794
drugs O 0 0.8073455
. O 0 0.0071439454

Pyrrolidine B-Chemical 0 0.99528116
dithiocarbamate I-Chemical 0 0.9979442
protects O 0 0.1936694
the O 0 0.007448719
piriform O 0 0.87388414
cortex O 0 0.3276412
in O 0 0.0028785889
the O 0 0.0041796635
pilocarpine B-Chemical 1 0.99880993
status B-Disease 0 0.056956902
epilepticus I-Disease 0 0.99893826
model O 0 0.020135395
. O 0 0.011305325

Pyrrolidine B-Chemical 0 0.99646544
dithiocarbamate I-Chemical 0 0.9988312
( O 0 0.09838662
PDTC B-Chemical 1 0.9995728
) O 0 0.008415635
has O 0 0.001340861
a O 0 0.0010204414
dual O 0 0.0016933605
mechanism O 0 0.0010019314
of O 0 0.00085780467
action O 0 0.006160751
as O 0 0.0005204064
an O 0 0.0010031392
antioxidant O 0 0.9931316
and O 0 0.0010154123
an O 0 0.0010985777
inhibitor O 0 0.056246568
of O 0 0.0011300877
the O 0 0.0010297756
transcription O 0 0.004334143
factor O 0 0.024626212
kappa O 0 0.1410573
- O 0 0.013283628
beta O 0 0.5890641
. O 0 0.008187353

Both O 0 0.005933645
, O 0 0.0037291385
production O 0 0.0032700624
of O 0 0.002244653
reactive O 0 0.32889748
oxygen B-Chemical 1 0.9774894
species O 0 0.002322895
as O 0 0.0006233063
well O 0 0.00047715718
as O 0 0.00044645002
activation O 0 0.001422829
of O 0 0.0010855952
NF O 0 0.95648307
- O 0 0.004136826
kappaB O 0 0.22970338
have O 0 0.00059826375
been O 0 0.0005823006
implicated O 0 0.00055813487
in O 0 0.0004389206
severe O 0 0.30466622
neuronal B-Disease 2 0.96668863
damage I-Disease 2 0.9516001
in O 0 0.00042408888
different O 0 0.0004191821
sub O 0 0.0073953406
- O 0 0.00079091557
regions O 0 0.00039417748
of O 0 0.00043912843
the O 0 0.00047424837
hippocampus O 0 0.20593038
as O 0 0.0004110683
well O 0 0.00047459698
as O 0 0.00059372175
in O 0 0.0009040487
the O 0 0.0015996987
surrounding O 0 0.005465367
cortices O 0 0.8182181
. O 0 0.006026378

The O 0 0.0034623127
effect O 0 0.0032859459
of O 0 0.0041261544
PDTC B-Chemical 1 0.99926466
on O 0 0.0016838722
status B-Disease 0 0.004968918
epilepticus I-Disease 0 0.9997677
- O 0 0.0048153503
associated O 0 0.001281134
cell O 0 0.0072098053
loss O 0 0.0016315024
in O 0 0.00046007626
the O 0 0.00054614164
hippocampus O 0 0.40764692
and O 0 0.00089274225
piriform O 0 0.7460148
cortex O 0 0.13879797
was O 0 0.00043652437
evaluated O 0 0.00045765564
in O 0 0.0005310415
the O 0 0.00085123326
rat O 0 0.009173718
fractionated O 0 0.026302008
pilocarpine B-Chemical 1 0.99905413
model O 0 0.013320365
. O 0 0.007581814

Treatment O 0 0.0325628
with O 0 0.0038239236
150 O 0 0.0049399063
mg O 0 0.4402776
/ O 0 0.0042852443
kg O 0 0.029669564
PDTC B-Chemical 1 0.9993437
before O 0 0.00076163275
and O 0 0.0008164673
following O 0 0.00075126585
status B-Disease 0 0.0016950503
epilepticus I-Disease 0 0.99963915
significantly O 0 0.0015406949
increased O 0 0.0016318511
the O 0 0.001146534
mortality O 0 0.10282059
rate O 0 0.0017538153
to O 0 0.0022319932
100 O 0 0.005888963
% O 0 0.0050598085
. O 0 0.005092418

Administration O 0 0.15872626
of O 0 0.0039176284
50 O 0 0.0040313974
mg O 0 0.48222274
/ O 0 0.0049728896
kg O 0 0.063038535
PDTC B-Chemical 1 0.9996674
( O 0 0.003113266
low O 0 0.0015002261
- O 0 0.0015609026
dose O 0 0.020618383
) O 0 0.00095458893
did O 0 0.00033782865
not O 0 0.00027660688
exert O 0 0.00083511573
major O 0 0.0005098831
effects O 0 0.0007966871
on O 0 0.00022686504
the O 0 0.0003595098
development O 0 0.0009276124
of O 0 0.000698634
a O 0 0.0008921499
status B-Disease 0 0.0023999868
epilepticus I-Disease 0 0.99952817
or O 0 0.0015550555
the O 0 0.0021851074
mortality O 0 0.20451833
rate O 0 0.005242501
. O 0 0.006246869

In O 0 0.0041874247
vehicle O 0 0.0197079
- O 0 0.003921363
treated O 0 0.0027735082
rats O 0 0.0055549853
, O 0 0.0016349948
status B-Disease 0 0.0020840028
epilepticus I-Disease 0 0.99966836
caused O 0 0.0027627754
pronounced O 0 0.011156716
neuronal B-Disease 2 0.96464056
damage I-Disease 2 0.96082073
in O 0 0.0009232668
the O 0 0.0010022513
piriform O 0 0.793649
cortex O 0 0.20703451
comprising O 0 0.0010513088
both O 0 0.001446438
pyramidal O 0 0.8985077
cells O 0 0.004330663
and O 0 0.0042951256
interneurons O 0 0.67829144
. O 0 0.006287146

Low O 0 0.10465082
- O 0 0.0097793685
dose O 0 0.14287126
PDTC B-Chemical 1 0.9992471
treatment O 0 0.01451906
almost O 0 0.0018935214
completely O 0 0.0019766337
protected O 0 0.002405123
from O 0 0.0019417817
lesions O 0 0.14763203
in O 0 0.0026476344
the O 0 0.0045539737
piriform O 0 0.8645065
cortex O 0 0.5166168
. O 0 0.008083053

A O 0 0.01584627
significant O 0 0.0034508086
decrease O 0 0.0023712306
in O 0 0.0014775433
neuronal O 0 0.14327495
density O 0 0.0018534677
of O 0 0.0011678253
the O 0 0.0009942189
hippocampal O 0 0.9125657
hilar O 0 0.9631825
formation O 0 0.0048946217
was O 0 0.0005931273
identified O 0 0.00046013633
in O 0 0.00053478393
vehicle O 0 0.030309413
- O 0 0.002136455
and O 0 0.001778002
PDTC B-Chemical 1 0.9997751
- O 0 0.0076614027
treated O 0 0.0034281828
rats O 0 0.00771823
following O 0 0.0028160063
status B-Disease 0 0.012699657
epilepticus I-Disease 0 0.9988219
. O 0 0.0090327775

In O 0 0.0035907284
conclusion O 0 0.0028378007
, O 0 0.0030448998
the O 0 0.002321722
NF O 0 0.88908124
- O 0 0.008013529
kappaB O 0 0.44922885
inhibitor O 0 0.312529
and O 0 0.0030849485
antioxidant O 0 0.9987552
PDTC B-Chemical 1 0.99989045
protected O 0 0.020158872
the O 0 0.0019200075
piriform O 0 0.9316756
cortex O 0 0.46384752
, O 0 0.00092983845
whereas O 0 0.00059702434
it O 0 0.0007292829
did O 0 0.00067439064
not O 0 0.0008790858
affect O 0 0.0014511205
hilar O 0 0.9590077
neuronal B-Disease 0 0.9510309
loss I-Disease 0 0.14027616
. O 0 0.0077112587

These O 0 0.0042643105
data O 0 0.002654261
might O 0 0.0012570932
indicate O 0 0.00087379804
that O 0 0.0007622085
the O 0 0.0007249573
generation O 0 0.0010556183
of O 0 0.0011404395
reactive O 0 0.4175121
oxygen B-Chemical 1 0.98631257
species O 0 0.0022292326
and O 0 0.0007890847
activation O 0 0.0020227511
of O 0 0.0012177048
NF O 0 0.9657218
- O 0 0.004538793
kappaB O 0 0.24814224
plays O 0 0.0006854737
a O 0 0.000474609
more O 0 0.00045934622
central O 0 0.00083746854
role O 0 0.00027070468
in O 0 0.00050020544
seizure B-Disease 2 0.9993187
- O 0 0.0026071933
associated O 0 0.0016039183
neuronal B-Disease 2 0.9569099
damage I-Disease 2 0.9470874
in O 0 0.0005638965
the O 0 0.00055160123
temporal O 0 0.03935485
cortex O 0 0.161678
as O 0 0.00050488143
compared O 0 0.00049356924
to O 0 0.0010121983
the O 0 0.0021936065
hippocampal O 0 0.912108
hilus O 0 0.6063791
. O 0 0.0066312677

However O 0 0.0041728173
, O 0 0.0027880245
future O 0 0.0015609651
investigations O 0 0.0022574938
are O 0 0.000920525
necessary O 0 0.00051548827
to O 0 0.00050404185
exactly O 0 0.00038277637
analyze O 0 0.00032186153
the O 0 0.0004276039
biochemical O 0 0.008450612
mechanisms O 0 0.0014427415
by O 0 0.0008233719
which O 0 0.0022838395
PDTC B-Chemical 1 0.9997627
exerted O 0 0.02690032
its O 0 0.0040382063
beneficial O 0 0.009457449
effects O 0 0.0039017275
in O 0 0.0018511517
the O 0 0.0034642483
piriform O 0 0.89351135
cortex O 0 0.5537399
. O 0 0.0065853437

Anaesthetists O 0 0.034978215
' O 0 0.005971847
nightmare O 0 0.03412654
: O 0 0.0061254716
masseter B-Disease 0 0.8700834
spasm I-Disease 2 0.99855214
after O 0 0.0015336258
induction O 0 0.0022016093
in O 0 0.0012650898
an O 0 0.002084208
undiagnosed O 0 0.05820743
case O 0 0.0029067872
of O 0 0.0069253575
myotonia B-Disease 0 0.9974631
congenita I-Disease 0 0.6459839
. O 0 0.011839562

We O 0 0.003341182
report O 0 0.0047020772
an O 0 0.0025568302
undiagnosed O 0 0.023171438
case O 0 0.0014851791
of O 0 0.0019978117
myotonia B-Disease 0 0.99876416
congenita I-Disease 0 0.17445856
in O 0 0.0007396297
a O 0 0.00068514975
24 O 0 0.0005267396
- O 0 0.0006014259
year O 0 0.00040694574
- O 0 0.0005195676
old O 0 0.00033265597
previously O 0 0.00029357962
healthy O 0 0.0024986062
primigravida O 0 0.14378405
, O 0 0.00047697214
who O 0 0.00079826155
developed O 0 0.0006978379
life O 0 0.0014976356
threatening O 0 0.13704307
masseter B-Disease 0 0.9749507
spasm I-Disease 2 0.99974674
following O 0 0.00064093084
a O 0 0.0004201446
standard O 0 0.0002988763
dose O 0 0.003751842
of O 0 0.00092571817
intravenous O 0 0.73537207
suxamethonium B-Chemical 1 0.99853957
for O 0 0.0015232002
induction O 0 0.003324876
of O 0 0.0046570813
anaesthesia O 0 0.4841151
. O 0 0.006404273

Neither O 0 0.0043184385
the O 0 0.002237835
patient O 0 0.0024603184
nor O 0 0.0013547834
the O 0 0.001123084
anaesthetist O 0 0.0037527098
was O 0 0.0009127172
aware O 0 0.0009366459
of O 0 0.0008924561
the O 0 0.00080584595
diagnosis O 0 0.0034614345
before O 0 0.0006458917
this O 0 0.0011681063
potentially O 0 0.0040858914
lethal O 0 0.07309562
complication O 0 0.6569587
occurred O 0 0.010496043
. O 0 0.007238141

Twin O 0 0.02160388
preterm O 0 0.22787443
neonates O 0 0.02304419
with O 0 0.0050896136
cardiac B-Disease 2 0.92791605
toxicity I-Disease 2 0.9969695
related O 0 0.0032555363
to O 0 0.0042124484
lopinavir B-Chemical 0 0.996119
/ I-Chemical 0 0.082690075
ritonavir I-Chemical 0 0.9981845
therapy O 0 0.44697562
. O 0 0.010511634

We O 0 0.0033761982
report O 0 0.0047205617
twin O 0 0.008509368
neonates O 0 0.010079414
who O 0 0.0028721413
were O 0 0.0011185415
born O 0 0.0017290751
prematurely O 0 0.0028663324
at O 0 0.0004473263
32 O 0 0.0007451025
weeks O 0 0.00044844614
of O 0 0.0006293227
gestation O 0 0.0026945441
to O 0 0.0006082965
a O 0 0.00093336223
mother O 0 0.0031094884
with O 0 0.0022783112
human B-Disease 0 0.03348447
immunodeficiency I-Disease 0 0.99765503
virus I-Disease 0 0.81580245
infection I-Disease 2 0.8738979
. O 0 0.010319861

One O 0 0.0044900957
of O 0 0.0025750236
the O 0 0.0016906968
twins O 0 0.00428483
developed O 0 0.0020769471
complete O 0 0.0011858585
heart B-Disease 0 0.2484551
block I-Disease 0 0.0019211445
and O 0 0.001316519
dilated B-Disease 2 0.99563736
cardiomyopathy I-Disease 2 0.99990356
related O 0 0.0012122933
to O 0 0.0011191783
lopinavir B-Chemical 0 0.99873036
/ I-Chemical 0 0.019209245
ritonavir I-Chemical 0 0.99966085
therapy O 0 0.13299431
, O 0 0.00077979
a O 0 0.0004750716
boosted O 0 0.0011116422
protease O 0 0.19519894
- O 0 0.0019147176
inhibitor O 0 0.14090562
agent O 0 0.17727038
, O 0 0.00088579266
while O 0 0.00051727
the O 0 0.000611579
other O 0 0.0010310861
twin O 0 0.033067714
developed O 0 0.011466727
mild O 0 0.93720627
bradycardia B-Disease 0 0.9977709
. O 0 0.009167843

We O 0 0.0033195235
recommend O 0 0.0023592007
caution O 0 0.0027440628
in O 0 0.0013458887
the O 0 0.0012018238
use O 0 0.0016008073
of O 0 0.0025555913
lopinavir B-Chemical 0 0.99714524
/ I-Chemical 0 0.026051573
ritonavir I-Chemical 0 0.9987606
in O 0 0.0018018741
the O 0 0.0017604294
immediate O 0 0.005280948
neonatal O 0 0.04153369
period O 0 0.0058862194
. O 0 0.006446765

When O 0 0.0043829195
drugs O 0 0.1840648
disappear O 0 0.005355838
from O 0 0.0018138671
the O 0 0.0014690169
patient O 0 0.002416727
: O 0 0.0021927685
elimination O 0 0.0029720948
of O 0 0.0025773002
intravenous O 0 0.7001632
medication O 0 0.42614862
by O 0 0.006470193
hemodiafiltration O 0 0.86210954
. O 0 0.009894729

Twenty O 0 0.008895664
- O 0 0.0033227056
three O 0 0.0009494287
hours O 0 0.0010139404
after O 0 0.000689351
heart O 0 0.1367056
transplantation O 0 0.15162721
, O 0 0.0012929417
life O 0 0.0023396069
- O 0 0.0013622501
threatening O 0 0.06983729
acute O 0 0.93413585
right B-Disease 0 0.018465007
heart I-Disease 0 0.669331
failure I-Disease 0 0.8027477
was O 0 0.00061504584
diagnosed O 0 0.009729031
in O 0 0.00032558883
a O 0 0.00040889886
patient O 0 0.00061976654
requiring O 0 0.0006946688
continuous O 0 0.00096976024
venovenous O 0 0.074035004
hemodiafiltration O 0 0.842874
( O 0 0.006780138
CVVHDF O 0 0.9375842
) O 0 0.0098583335
. O 0 0.006254641

Increasing O 0 0.009952992
doses O 0 0.047030494
of O 0 0.0049800714
catecholamines B-Chemical 1 0.9973133
, O 0 0.006585584
sedatives O 0 0.9954144
, O 0 0.002212745
and O 0 0.0012301666
muscle O 0 0.06801444
relaxants O 0 0.98583776
administered O 0 0.0048703146
through O 0 0.0008769943
a O 0 0.0012277839
central O 0 0.0030736977
venous O 0 0.33019224
catheter O 0 0.009910221
were O 0 0.0036569939
ineffective O 0 0.037349187
. O 0 0.007258687

However O 0 0.0049831397
, O 0 0.0036347173
a O 0 0.0024619587
bolus O 0 0.03169905
of O 0 0.0029861107
epinephrine B-Chemical 0 0.99573934
injected O 0 0.0018296491
through O 0 0.0011527813
an O 0 0.0015755376
alternative O 0 0.0018093273
catheter O 0 0.009212891
provoked O 0 0.07988412
a O 0 0.008685687
hypertensive B-Disease 2 0.9967051
crisis O 0 0.8829453
. O 0 0.011071314

Thus O 0 0.004772386
, O 0 0.0036729402
interference O 0 0.0034781152
with O 0 0.0020130142
the O 0 0.0015552664
central O 0 0.0035289354
venous O 0 0.32496887
infusion O 0 0.040389866
by O 0 0.0016803225
the O 0 0.0017377563
dialysis O 0 0.06599
catheter O 0 0.013868564
was O 0 0.005049317
suspected O 0 0.07650627
. O 0 0.008446174

The O 0 0.0043583
catheters O 0 0.012506277
were O 0 0.0028423755
changed O 0 0.0029865464
, O 0 0.002770764
and O 0 0.002467592
hemodynamics O 0 0.76958346
stabilized O 0 0.0062609836
at O 0 0.0023863486
lower O 0 0.005409162
catecholamine B-Chemical 0 0.99579805
doses O 0 0.4835334
. O 0 0.012153838

When O 0 0.0029042389
the O 0 0.002014185
effects O 0 0.0025877007
of O 0 0.0021023892
IV O 0 0.1279095
drugs O 0 0.5326583
are O 0 0.0008539536
inadequate O 0 0.0011755163
in O 0 0.00045229538
patients O 0 0.001473947
receiving O 0 0.0048365192
CVVHDF O 0 0.9224191
, O 0 0.0006596624
interference O 0 0.00084705546
with O 0 0.00047271585
adjacent O 0 0.0006393464
catheters O 0 0.012259029
resulting O 0 0.00043428695
in O 0 0.00034251902
elimination O 0 0.001056095
of O 0 0.00063133193
the O 0 0.000675452
drug O 0 0.23870696
by O 0 0.001712554
CVVHDF O 0 0.8851394
should O 0 0.0016171426
be O 0 0.0033083665
suspected O 0 0.0668587
. O 0 0.006347956

Less O 0 0.29337314
frequent O 0 0.026574142
lithium B-Chemical 1 0.9933923
administration O 0 0.42409307
and O 0 0.0077306456
lower O 0 0.0077890516
urine O 0 0.30935055
volume O 0 0.03229655
. O 0 0.014505808

OBJECTIVE O 0 0.5327816
: O 0 0.004098528
This O 0 0.002135343
study O 0 0.0015065265
was O 0 0.00079831376
designed O 0 0.0006861747
to O 0 0.00044558165
determine O 0 0.00021784207
whether O 0 0.00020207299
patients O 0 0.0007500673
maintained O 0 0.000346531
on O 0 0.0001842824
a O 0 0.00034999556
regimen O 0 0.0036289382
of O 0 0.00070583867
lithium B-Chemical 1 0.9989955
on O 0 0.0002682587
a O 0 0.00040914756
once O 0 0.00036537313
- O 0 0.00046282038
per O 0 0.00015049333
- O 0 0.0003246775
day O 0 0.00017172359
schedule O 0 0.0003498776
have O 0 0.00023556306
lower O 0 0.00030331966
urine O 0 0.055082496
volumes O 0 0.0010845362
than O 0 0.0002498454
do O 0 0.00033743435
patients O 0 0.0011521423
receiving O 0 0.0020587828
multiple O 0 0.0021172722
doses O 0 0.029891469
per O 0 0.0017017316
day O 0 0.003776362
. O 0 0.0047445036

METHOD O 0 0.048425373
: O 0 0.004500084
This O 0 0.0025626933
was O 0 0.0013347439
a O 0 0.0011919758
cross O 0 0.0014641602
- O 0 0.0013148561
sectional O 0 0.002176869
study O 0 0.0008596522
of O 0 0.0006613365
85 O 0 0.000913049
patients O 0 0.0012163565
from O 0 0.00056017877
a O 0 0.00093521865
lithium B-Chemical 1 0.9974957
clinic O 0 0.0023092546
who O 0 0.0024661676
received O 0 0.0016931001
different O 0 0.0020881232
dose O 0 0.03419055
schedules O 0 0.016575959
. O 0 0.0070871613

Patients O 0 0.008689772
were O 0 0.0024439264
admitted O 0 0.004286891
to O 0 0.0012190394
the O 0 0.0009413532
hospital O 0 0.0020543612
for O 0 0.0006255293
measurement O 0 0.00059988454
of O 0 0.0012120999
lithium B-Chemical 1 0.9981962
level O 0 0.0010493336
, O 0 0.0018654891
creatinine B-Chemical 1 0.9961976
clearance O 0 0.25788832
, O 0 0.0019354306
urine O 0 0.20569776
volume O 0 0.0050045964
, O 0 0.002125835
and O 0 0.0021487887
maximum O 0 0.0041385726
osmolality O 0 0.8522722
. O 0 0.0074639986

RESULTS O 0 0.028619478
: O 0 0.00553696
Multiple O 0 0.007925252
daily O 0 0.005080972
doses O 0 0.024067366
of O 0 0.0036401763
lithium B-Chemical 1 0.9967879
were O 0 0.0027362
associated O 0 0.0029891701
with O 0 0.0031163031
higher O 0 0.003950053
urine O 0 0.31560388
volumes O 0 0.023287281
. O 0 0.009438679

The O 0 0.0029300582
dosing O 0 0.014336989
schedule O 0 0.003184284
, O 0 0.0016297781
duration O 0 0.0013670002
of O 0 0.0015565124
lithium B-Chemical 1 0.998444
treatment O 0 0.009476704
, O 0 0.001080415
and O 0 0.00059478823
daily O 0 0.001696349
dose O 0 0.013262164
of O 0 0.0012499569
lithium B-Chemical 1 0.99877626
did O 0 0.0007949016
not O 0 0.00057806476
affect O 0 0.00056270027
maximum O 0 0.0014715237
osmolality O 0 0.8378961
or O 0 0.0032618463
creatinine B-Chemical 1 0.99457943
clearance O 0 0.49459076
. O 0 0.008124717

CONCLUSIONS O 0 0.7636274
: O 0 0.006817953
Urine O 0 0.39727065
volume O 0 0.004188631
can O 0 0.0012487081
be O 0 0.0010001737
reduced O 0 0.0008335666
by O 0 0.00078568916
giving O 0 0.0013965572
lithium B-Chemical 1 0.9978072
once O 0 0.00095759484
daily O 0 0.0022670869
and O 0 0.00079155725
/ O 0 0.0013485003
or O 0 0.00054212526
by O 0 0.0007810426
lowering O 0 0.007213089
the O 0 0.0011739301
total O 0 0.0017786844
daily O 0 0.0077000656
dose O 0 0.055391636
. O 0 0.006543404

Lithium B-Chemical 1 0.99788135
- O 0 0.013409588
induced O 0 0.006690698
polyuria B-Disease 2 0.9972415
seems O 0 0.0023412157
to O 0 0.0011661985
be O 0 0.0009964904
related O 0 0.0006862175
to O 0 0.0009611597
extrarenal O 0 0.85268193
as O 0 0.0011098277
well O 0 0.0011330647
as O 0 0.0013951467
to O 0 0.0027177474
renal O 0 0.9762151
effects O 0 0.023565017
. O 0 0.008327969

Antibacterial O 0 0.7395156
medication O 0 0.117050625
use O 0 0.0031801504
during O 0 0.0016174174
pregnancy O 0 0.077404976
and O 0 0.002114514
risk O 0 0.0130475415
of O 0 0.002431012
birth B-Disease 0 0.0067072175
defects I-Disease 0 0.003973483
: O 0 0.0050410284
National O 0 0.010365974
Birth B-Disease 2 0.3354055
Defects I-Disease 2 0.11138314
Prevention O 0 0.12737286
Study O 0 0.107331045
. O 0 0.009743606

OBJECTIVE O 0 0.44241598
: O 0 0.0047993744
To O 0 0.0016546565
estimate O 0 0.0011834094
the O 0 0.0012874097
association O 0 0.0012060388
between O 0 0.0011731096
antibacterial O 0 0.3155705
medications O 0 0.49708763
and O 0 0.0029945865
selected O 0 0.0030928073
birth B-Disease 0 0.011317606
defects I-Disease 0 0.009402324
. O 0 0.008223123

DESIGN O 0 0.01600648
, O 0 0.005049617
SETTING O 0 0.009602321
, O 0 0.0027601568
AND O 0 0.002826612
PARTICIPANTS O 0 0.005296817
: O 0 0.0018090085
Population O 0 0.005384713
- O 0 0.0012574239
based O 0 0.0007146492
, O 0 0.0007325581
multisite O 0 0.0030604415
, O 0 0.0006602766
case O 0 0.00047380736
- O 0 0.0005251524
control O 0 0.00021551663
study O 0 0.00038949784
of O 0 0.00037623505
women O 0 0.008150769
who O 0 0.000771448
had O 0 0.00032535518
pregnancies O 0 0.06255341
affected O 0 0.00027318564
by O 0 0.0002815808
1 O 0 0.00022805501
of O 0 0.00022935665
more O 0 0.00024801126
than O 0 0.00011359905
30 O 0 0.00013443259
eligible O 0 0.00019005073
major O 0 0.00021785453
birth B-Disease 0 0.0006880891
defects I-Disease 0 0.00032752808
identified O 0 0.0001871455
via O 0 0.00020300728
birth B-Disease 0 0.0007682644
defect I-Disease 0 0.00025048462
surveillance O 0 0.00042521668
programs O 0 0.0003112395
in O 0 0.00021136961
10 O 0 0.0002604319
states O 0 0.00047597245
( O 0 0.00034349642
n O 0 0.00020503896
= O 0 0.0003207557
13 O 0 0.00023465834
155 O 0 0.0008633618
) O 0 0.00030448032
and O 0 0.00017757488
control O 0 0.00016469661
women O 0 0.0009161971
randomly O 0 9.769109e-05
selected O 0 0.00019189274
from O 0 0.0002378003
the O 0 0.00026113258
same O 0 0.00024847282
geographical O 0 0.0013560904
regions O 0 0.0011787298
( O 0 0.0014477279
n O 0 0.0013762304
= O 0 0.0031009098
4941 O 0 0.012542652
) O 0 0.005880879
. O 0 0.005073303

MAIN O 0 0.4855424
EXPOSURE O 0 0.08987408
: O 0 0.0043305336
Reported O 0 0.0048547494
maternal O 0 0.0028719297
use O 0 0.0015425289
of O 0 0.0016420792
antibacterials O 0 0.954978
( O 0 0.0015236484
1 O 0 0.000563399
month O 0 0.00041599252
before O 0 0.0002991702
pregnancy O 0 0.018621802
through O 0 0.00051419344
the O 0 0.00053247967
end O 0 0.00047497897
of O 0 0.0011148273
the O 0 0.0013757226
first O 0 0.0022122378
trimester O 0 0.39147526
) O 0 0.00903901
. O 0 0.0064479983

MAIN O 0 0.44804847
OUTCOME O 0 0.14376813
MEASURE O 0 0.025204698
: O 0 0.0036267615
Odds O 0 0.009224743
ratios O 0 0.0015771037
( O 0 0.0014680736
ORs O 0 0.0028346905
) O 0 0.00092021946
measuring O 0 0.00037394263
the O 0 0.00038268862
association O 0 0.00036280032
between O 0 0.0003103284
antibacterial O 0 0.12520534
use O 0 0.00072102516
and O 0 0.00055286504
selected O 0 0.00053403125
birth B-Disease 0 0.0017983887
defects I-Disease 0 0.0011675734
adjusted O 0 0.001368669
for O 0 0.001235941
potential O 0 0.003302992
confounders O 0 0.008436412
. O 0 0.005862131

RESULTS O 0 0.025881859
: O 0 0.0043065837
The O 0 0.001682116
reported O 0 0.0019246497
use O 0 0.001566885
of O 0 0.0017703181
antibacterials O 0 0.9177008
increased O 0 0.0025528504
during O 0 0.0011605003
pregnancy O 0 0.29646543
, O 0 0.0023489636
peaking O 0 0.012394548
during O 0 0.0012593247
the O 0 0.0018971547
third O 0 0.0034635635
month O 0 0.00508279
. O 0 0.006244389

Sulfonamides B-Chemical 0 0.9878939
were O 0 0.0035578979
associated O 0 0.0029858295
with O 0 0.0028911422
anencephaly B-Disease 2 0.97819215
( O 0 0.0024338379
adjusted O 0 0.0018501731
OR O 0 0.117905624
[ O 0 0.0041142795
AOR O 0 0.7637924
] O 0 0.001788958
= O 0 0.0007108123
3 O 0 0.00028373697
. O 0 0.0001846919
4 O 0 0.0002238836
; O 0 0.0003667566
95 O 0 0.00046204473
% O 0 0.0002273464
confidence O 0 0.00055525237
interval O 0 0.00054790836
[ O 0 0.0009842513
CI O 0 0.16851564
] O 0 0.00080782414
, O 0 0.0003840165
1 O 0 0.00027286937
. O 0 0.00015123765
3 O 0 0.00020966068
- O 0 0.00035309728
8 O 0 0.0002056367
. O 0 0.00012949173
8 O 0 0.00021793616
) O 0 0.0003811883
, O 0 0.00035524872
hypoplastic B-Disease 0 0.18802316
left I-Disease 0 0.0016566118
heart I-Disease 0 0.5747287
syndrome I-Disease 0 0.9247281
( O 0 0.0013318836
AOR O 0 0.78821146
= O 0 0.0005953968
3 O 0 0.00021094277
. O 0 0.00013966524
2 O 0 0.00022150167
; O 0 0.00034648555
95 O 0 0.00050736015
% O 0 0.00028723505
CI O 0 0.034529805
, O 0 0.00031825126
1 O 0 0.00024079182
. O 0 0.00013888952
3 O 0 0.00019696685
- O 0 0.00033318598
7 O 0 0.00017532412
. O 0 0.00012034756
6 O 0 0.00015913026
) O 0 0.00033831823
, O 0 0.00030722478
coarctation B-Disease 0 0.40552342
of I-Disease 0 0.00043440433
the I-Disease 0 0.00038948297
aorta I-Disease 0 0.20176302
( O 0 0.0010072778
AOR O 0 0.7268248
= O 0 0.0006053498
2 O 0 0.00025412007
. O 0 0.00014467175
7 O 0 0.00019381246
; O 0 0.00033711828
95 O 0 0.000504328
% O 0 0.00029136118
CI O 0 0.033992466
, O 0 0.0003235617
1 O 0 0.0002449086
. O 0 0.0001418661
3 O 0 0.00020124408
- O 0 0.00033900992
5 O 0 0.00017890817
. O 0 0.00012789802
6 O 0 0.00017464273
) O 0 0.0003858815
, O 0 0.0003731302
choanal B-Disease 0 0.018739669
atresia I-Disease 0 0.84460187
( O 0 0.0012839766
AOR O 0 0.7779453
= O 0 0.00065083074
8 O 0 0.00025054745
. O 0 0.00014348477
0 O 0 0.00025705545
; O 0 0.00034076927
95 O 0 0.0005020473
% O 0 0.00028806794
CI O 0 0.02965543
, O 0 0.0003133131
2 O 0 0.00023402422
. O 0 0.00014331056
7 O 0 0.00020154844
- O 0 0.00033906652
23 O 0 0.00033146658
. O 0 0.00013464913
5 O 0 0.000192039
) O 0 0.00035611968
, O 0 0.00030918024
transverse B-Disease 0 0.006049239
limb I-Disease 0 0.08491445
deficiency I-Disease 0 0.7991809
( O 0 0.0017344846
AOR O 0 0.83276904
= O 0 0.00067303685
2 O 0 0.00026258887
. O 0 0.0001438113
5 O 0 0.00019006614
; O 0 0.00033268606
95 O 0 0.00049993256
% O 0 0.0002894648
CI O 0 0.034616385
, O 0 0.00032427505
1 O 0 0.000246062
. O 0 0.00014272035
0 O 0 0.00026436764
- O 0 0.00033119493
5 O 0 0.00017669794
. O 0 0.00012835336
9 O 0 0.00022229362
) O 0 0.00036443627
, O 0 0.00030423395
and O 0 0.00034452556
diaphragmatic B-Disease 0 0.6176834
hernia I-Disease 0 0.7689544
( O 0 0.0013081895
AOR O 0 0.74440134
= O 0 0.0006787223
2 O 0 0.00029107634
. O 0 0.00017206023
4 O 0 0.00023752428
; O 0 0.00044209854
95 O 0 0.0006871222
% O 0 0.00044597514
CI O 0 0.0305348
, O 0 0.0005692339
1 O 0 0.00050151284
. O 0 0.00037642304
1 O 0 0.0007101819
- O 0 0.0012003141
5 O 0 0.00088158634
. O 0 0.0009580918
4 O 0 0.0018802421
) O 0 0.0045400797
. O 0 0.004514822

Nitrofurantoins B-Chemical 0 0.3843234
were O 0 0.0030633279
associated O 0 0.0027769762
with O 0 0.002808594
anophthalmia B-Disease 0 0.9774203
or O 0 0.0019345069
microphthalmos B-Disease 0 0.9952134
( O 0 0.0033368657
AOR O 0 0.79425675
= O 0 0.00111742
3 O 0 0.00037212577
. O 0 0.00023189724
7 O 0 0.00027958705
; O 0 0.00045383588
95 O 0 0.00062626816
% O 0 0.00036504984
CI O 0 0.035729133
, O 0 0.000381567
1 O 0 0.00028056573
. O 0 0.00016284149
1 O 0 0.00025715178
- O 0 0.00034079025
12 O 0 0.00016685454
. O 0 0.00013349687
2 O 0 0.00023352986
) O 0 0.00040702004
, O 0 0.00036888244
hypoplastic B-Disease 0 0.18874152
left I-Disease 0 0.00165428
heart I-Disease 0 0.56897736
syndrome I-Disease 0 0.9223373
( O 0 0.0013082754
AOR O 0 0.77810055
= O 0 0.00059064117
4 O 0 0.00020905363
. O 0 0.00013844865
2 O 0 0.00022065874
; O 0 0.0003462401
95 O 0 0.0005076845
% O 0 0.0002884436
CI O 0 0.034990814
, O 0 0.00032302106
1 O 0 0.0002474213
. O 0 0.00014636903
9 O 0 0.00024010657
- O 0 0.00035352434
9 O 0 0.0002184092
. O 0 0.00013547724
1 O 0 0.00024466446
) O 0 0.00041354215
, O 0 0.00038748406
atrial B-Disease 0 0.9452935
septal I-Disease 0 0.09227288
defects I-Disease 0 0.0014545711
( O 0 0.0008024597
AOR O 0 0.6990036
= O 0 0.0005923329
1 O 0 0.00025717876
. O 0 0.00014231971
9 O 0 0.00022103479
; O 0 0.0003350293
95 O 0 0.0005019823
% O 0 0.00028732762
CI O 0 0.03561241
, O 0 0.00032266587
1 O 0 0.0002477546
. O 0 0.00014602095
1 O 0 0.00024333513
- O 0 0.0003366346
3 O 0 0.00017581832
. O 0 0.00012545541
4 O 0 0.00018629555
) O 0 0.00035809644
, O 0 0.00029297062
and O 0 0.0003086613
cleft B-Disease 0 0.008566483
lip I-Disease 0 0.015886506
with O 0 0.0006995684
cleft B-Disease 0 0.04501969
palate I-Disease 0 0.06429586
( O 0 0.0011207499
AOR O 0 0.73836684
= O 0 0.0007012034
2 O 0 0.00030583082
. O 0 0.00018418771
1 O 0 0.00030008948
; O 0 0.0004623917
95 O 0 0.00070213596
% O 0 0.0004496803
CI O 0 0.030222928
, O 0 0.0005694713
1 O 0 0.0005002164
. O 0 0.00037509494
2 O 0 0.00070100324
- O 0 0.0012436013
3 O 0 0.0009481622
. O 0 0.0010455118
9 O 0 0.002250579
) O 0 0.0046636146
. O 0 0.0046035247

Other O 0 0.012878105
antibacterial O 0 0.3141894
agents O 0 0.06594179
that O 0 0.0012736134
showed O 0 0.0009867647
associations O 0 0.00090645644
included O 0 0.0009712082
erythromycins B-Chemical 0 0.9895426
( O 0 0.0015228274
2 O 0 0.00060536945
defects O 0 0.0008364552
) O 0 0.0010166542
, O 0 0.0009030363
penicillins B-Chemical 0 0.99678636
( O 0 0.0009156408
1 O 0 0.00040653488
defect O 0 0.00041589758
) O 0 0.0007799805
, O 0 0.0007751213
cephalosporins B-Chemical 1 0.99814296
( O 0 0.0009355244
1 O 0 0.00046600532
defect O 0 0.0005083776
) O 0 0.00092676666
, O 0 0.00082269084
and O 0 0.0011154626
quinolones B-Chemical 0 0.989207
( O 0 0.002517319
1 O 0 0.0019402797
defect O 0 0.0027466803
) O 0 0.0060362997
. O 0 0.0051802387

CONCLUSIONS O 0 0.77128285
: O 0 0.0070638987
Reassuringly O 0 0.017479395
, O 0 0.003900354
penicillins B-Chemical 0 0.9939162
, O 0 0.003571147
erythromycins B-Chemical 0 0.99057454
, O 0 0.0019135715
and O 0 0.0012628481
cephalosporins B-Chemical 1 0.99831414
, O 0 0.0010804079
although O 0 0.00046650597
used O 0 0.0003806226
commonly O 0 0.0011014927
by O 0 0.0005545965
pregnant O 0 0.026844656
women O 0 0.01512199
, O 0 0.0007593742
were O 0 0.0005310484
not O 0 0.00058250077
associated O 0 0.0011616272
with O 0 0.0016003243
many O 0 0.0025980312
birth B-Disease 0 0.0091386
defects I-Disease 0 0.0072125285
. O 0 0.0062721227

Sulfonamides B-Chemical 0 0.98784816
and O 0 0.0048472565
nitrofurantoins B-Chemical 0 0.24575022
were O 0 0.0018326804
associated O 0 0.0016428157
with O 0 0.0012657377
several O 0 0.0012035272
birth B-Disease 0 0.002919323
defects I-Disease 0 0.0016295911
, O 0 0.001284121
indicating O 0 0.0008201614
a O 0 0.0012421416
need O 0 0.0011642321
for O 0 0.0014683476
additional O 0 0.0023124006
scrutiny O 0 0.015534909
. O 0 0.006940248

Differential O 0 0.012740941
impact O 0 0.002629905
of O 0 0.002833013
immune O 0 0.062860176
escape O 0 0.015453109
mutations O 0 0.013537204
G145R O 0 0.5724325
and O 0 0.001393286
P120T O 0 0.0857428
on O 0 0.00040680607
the O 0 0.0005619296
replication O 0 0.0068216925
of O 0 0.0019643363
lamivudine B-Chemical 1 0.999772
- O 0 0.019475719
resistant O 0 0.07248652
hepatitis B-Chemical 2 0.99993575
B I-Chemical 2 0.9848043
virus I-Chemical 0 0.36592907
e I-Chemical 0 0.009168003
antigen I-Chemical 0 0.109865166
- O 0 0.0019846163
positive O 0 0.0009825331
and O 0 0.0015482531
- O 0 0.0026914836
negative O 0 0.002390691
strains O 0 0.0050125625
. O 0 0.0055380394

Immune O 0 0.41197407
escape O 0 0.010636793
variants O 0 0.003751327
of O 0 0.0030182048
the O 0 0.0037568288
hepatitis B-Disease 2 0.99978155
B I-Disease 2 0.98272103
virus O 0 0.54676026
( O 0 0.005598034
HBV O 0 0.9935095
) O 0 0.0017829174
represent O 0 0.00047371542
an O 0 0.0005120614
emerging O 0 0.00070674793
clinical O 0 0.0058765677
challenge O 0 0.00064526295
, O 0 0.00045828102
because O 0 0.00021520532
they O 0 0.0002499898
can O 0 0.00024312921
be O 0 0.00030520573
associated O 0 0.00045675697
with O 0 0.0005884256
vaccine O 0 0.004265743
escape O 0 0.013254178
, O 0 0.0018748135
HBV O 0 0.994128
reactivation O 0 0.5420844
, O 0 0.0017670627
and O 0 0.0014007739
failure O 0 0.31756487
of O 0 0.0029063579
diagnostic O 0 0.0061272103
tests O 0 0.009804844
. O 0 0.006607501

Recent O 0 0.005567688
data O 0 0.002877899
suggest O 0 0.0015001692
a O 0 0.0015504137
preferential O 0 0.0015869787
selection O 0 0.0012355037
of O 0 0.0013633876
immune O 0 0.049167734
escape O 0 0.0053230757
mutants O 0 0.00057052664
in O 0 0.0005795852
distinct O 0 0.00093234994
peripheral O 0 0.02279572
blood O 0 0.0117122345
leukocyte O 0 0.10451227
compartments O 0 0.0022090655
of O 0 0.0024212291
infected O 0 0.003318443
individuals O 0 0.0062255803
. O 0 0.0058810045

We O 0 0.0027933724
therefore O 0 0.0020867407
systematically O 0 0.001230186
analyzed O 0 0.0008495079
the O 0 0.000731174
functional O 0 0.0009562379
impact O 0 0.00048914534
of O 0 0.0006447361
the O 0 0.0005051629
most O 0 0.00094590563
prevalent O 0 0.0030280424
immune O 0 0.064476505
escape O 0 0.0085208975
variants O 0 0.0010772706
, O 0 0.00057752203
the O 0 0.00035663112
sG145R O 0 0.09733736
and O 0 0.00045552428
sP120T O 0 0.01128436
mutants O 0 0.00023337004
, O 0 0.00033845197
on O 0 0.00013684426
the O 0 0.00023481858
viral O 0 0.0126812905
replication O 0 0.009228966
efficacy O 0 0.0043026675
and O 0 0.0003805654
antiviral O 0 0.20378514
drug O 0 0.47471562
susceptibility O 0 0.008083531
of O 0 0.0005606507
common O 0 0.0011174184
treatment O 0 0.003997921
- O 0 0.0008153711
associated O 0 0.0004296272
mutants O 0 0.0002190246
with O 0 0.00046839393
resistance O 0 0.008706852
to O 0 0.00084464
lamivudine B-Chemical 1 0.9996942
( O 0 0.00881503
LAM B-Chemical 0 0.99638087
) O 0 0.0032953292
and O 0 0.0015848919
/ O 0 0.0044778185
or O 0 0.0032283834
HBeAg B-Chemical 1 0.9985078
negativity O 0 0.80073357
. O 0 0.008965716

Replication O 0 0.038347427
- O 0 0.0056779217
competent O 0 0.0028014358
HBV O 0 0.9203792
strains O 0 0.0023696169
with O 0 0.0017995842
sG145R O 0 0.10737601
or O 0 0.00096460537
sP120T O 0 0.01936997
and O 0 0.0012681246
LAM B-Chemical 0 0.99478734
resistance O 0 0.090178795
( O 0 0.002182085
rtM204I O 0 0.92663807
or O 0 0.00071241235
rtL180M O 0 0.98773617
/ O 0 0.0057362644
rtM204V O 0 0.7162789
) O 0 0.00074982963
were O 0 0.0002499867
generated O 0 0.00017460775
on O 0 0.00018958829
an O 0 0.0007956613
HBeAg B-Chemical 1 0.99969506
- O 0 0.0014691043
positive O 0 0.00036381872
and O 0 0.0004393826
an O 0 0.0009870195
HBeAg B-Chemical 1 0.9997056
- O 0 0.00133132
negative O 0 0.00035935256
background O 0 0.00032538123
with O 0 0.0007182713
precore O 0 0.8819379
( O 0 0.0018978367
PC O 0 0.40993524
) O 0 0.0012964506
and O 0 0.00067672133
basal O 0 0.0018630782
core O 0 0.0011233086
promoter O 0 0.0019936422
( O 0 0.003063529
BCP O 0 0.4161177
) O 0 0.0052686133
mutants O 0 0.003366782
. O 0 0.005806671

The O 0 0.0037169873
sG145R O 0 0.047117636
mutation O 0 0.00441345
strongly O 0 0.0020562597
reduced O 0 0.0018426075
HBsAg B-Chemical 1 0.99666214
levels O 0 0.001192597
and O 0 0.0007746684
was O 0 0.00048478873
able O 0 0.00025580125
to O 0 0.00027877896
fully O 0 0.00027629064
restore O 0 0.00025401908
the O 0 0.00028214706
impaired O 0 0.0009018549
replication O 0 0.0076956037
of O 0 0.0012780286
LAM B-Chemical 0 0.99813217
- O 0 0.0034802987
resistant O 0 0.0044739665
HBV O 0 0.9877713
mutants O 0 0.00028594263
to O 0 0.00026200817
the O 0 0.0002426466
levels O 0 0.000278542
of O 0 0.0004290289
wild O 0 0.00037167905
- O 0 0.00090529077
type O 0 0.0007122715
HBV O 0 0.9904503
, O 0 0.0013253278
and O 0 0.0009048614
PC O 0 0.27859405
or O 0 0.00092004664
BCP O 0 0.4068783
mutations O 0 0.0047287005
further O 0 0.0019126966
enhanced O 0 0.0037575513
viral O 0 0.17007846
replication O 0 0.14770669
. O 0 0.007574775

Although O 0 0.003970244
the O 0 0.0027888305
sP120T O 0 0.011977192
substitution O 0 0.025388967
also O 0 0.002004883
impaired O 0 0.00580968
HBsAg B-Chemical 1 0.99816436
secretion O 0 0.28692746
, O 0 0.001623743
it O 0 0.0008358135
did O 0 0.00053512544
not O 0 0.00046372562
enhance O 0 0.00049517327
the O 0 0.0007668326
replication O 0 0.007707078
of O 0 0.0030851394
LAM B-Chemical 0 0.9946865
- O 0 0.0078711705
resistant O 0 0.0069799125
clones O 0 0.006725973
. O 0 0.006560388

However O 0 0.004626268
, O 0 0.003215165
the O 0 0.0017530674
concomitant O 0 0.0044632335
occurrence O 0 0.003503445
of O 0 0.0031719152
HBeAg B-Chemical 1 0.99950516
negativity O 0 0.866132
( O 0 0.0051031774
PC O 0 0.59636253
/ O 0 0.0063464856
BCP O 0 0.6888809
) O 0 0.0019514257
, O 0 0.0008660565
sP120T O 0 0.012877306
, O 0 0.0006920079
and O 0 0.00061431236
LAM B-Chemical 0 0.9898711
resistance O 0 0.016114231
resulted O 0 0.00045603586
in O 0 0.000322905
the O 0 0.0003205191
restoration O 0 0.00073878857
of O 0 0.0006518671
replication O 0 0.005373453
to O 0 0.0005897856
levels O 0 0.0007452431
of O 0 0.0013208744
wild O 0 0.0014843618
- O 0 0.0042841258
type O 0 0.0052197
HBV O 0 0.9844238
. O 0 0.009307353

In O 0 0.0027816484
all O 0 0.0017086699
clones O 0 0.0017712285
with O 0 0.0014409125
combined O 0 0.0020586378
immune O 0 0.07254683
escape O 0 0.014130888
and O 0 0.0014884801
LAM B-Chemical 0 0.99480444
resistance O 0 0.053753432
mutations O 0 0.010629504
, O 0 0.0007933303
the O 0 0.00044499265
nucleotide B-Chemical 0 0.041944504
analogues O 0 0.81576973
adefovir B-Chemical 0 0.99950826
and O 0 0.0020710754
tenofovir B-Chemical 0 0.9984301
remained O 0 0.0017508182
effective O 0 0.001349762
in O 0 0.0007772082
suppressing O 0 0.0032459695
viral O 0 0.102187514
replication O 0 0.04992203
in O 0 0.0030717961
vitro O 0 0.009934148
. O 0 0.006177882

These O 0 0.0043375893
findings O 0 0.0036704752
reveal O 0 0.0018447678
the O 0 0.0011429338
differential O 0 0.0016807177
impact O 0 0.0007580811
of O 0 0.0010663327
immune O 0 0.05824201
escape O 0 0.007344248
variants O 0 0.0009361589
on O 0 0.00026729747
the O 0 0.00037278017
replication O 0 0.003849625
and O 0 0.0004518511
drug O 0 0.2483957
susceptibility O 0 0.005134849
of O 0 0.000589765
complex O 0 0.0007346481
HBV O 0 0.98942494
mutants O 0 0.00032013617
, O 0 0.0003827563
supporting O 0 0.00027543324
the O 0 0.0001981022
need O 0 0.00016928464
of O 0 0.00024140511
close O 0 0.00019733417
surveillance O 0 0.0004228961
and O 0 0.00027908105
treatment O 0 0.0006508174
adjustment O 0 0.00049813924
in O 0 0.00029912914
response O 0 0.00056813547
to O 0 0.00038349922
the O 0 0.0004670902
selection O 0 0.00082670804
of O 0 0.0012987043
distinct O 0 0.0022678776
mutational O 0 0.027878078
patterns O 0 0.004964638
. O 0 0.005920401

Hemolytic B-Disease 0 0.9907176
anemia I-Disease 0 0.9974509
associated O 0 0.012106738
with O 0 0.006833482
the O 0 0.005703284
use O 0 0.008433062
of O 0 0.015343743
omeprazole B-Chemical 1 0.99571735
. O 0 0.022539778

Omeprazole B-Chemical 0 0.9979632
is O 0 0.003495568
the O 0 0.0016403744
first O 0 0.0011086097
drug O 0 0.07419812
designed O 0 0.0011423016
to O 0 0.0007027153
block O 0 0.0010072836
the O 0 0.0005687645
final O 0 0.00097078
step O 0 0.00069161557
in O 0 0.0005870666
the O 0 0.000843489
acid O 0 0.7471566
secretory O 0 0.021391205
process O 0 0.0016964378
within O 0 0.0010391676
the O 0 0.0027097224
parietal O 0 0.65905607
cell O 0 0.025978263
. O 0 0.007222889

It O 0 0.0059291353
has O 0 0.0025949574
been O 0 0.0021255438
shown O 0 0.0010654534
to O 0 0.0009559445
be O 0 0.0008895428
extremely O 0 0.0014974517
effective O 0 0.0010554966
in O 0 0.0005209583
the O 0 0.00050449267
treatment O 0 0.0013267588
of O 0 0.0016274126
peptic B-Disease 0 0.9995192
ulcer I-Disease 2 0.9996321
disease I-Disease 0 0.99490595
, O 0 0.017834868
reflux B-Disease 0 0.9988945
esophagitis I-Disease 0 0.99960166
, O 0 0.00360235
and O 0 0.0015963103
the O 0 0.0021195526
Zollinger B-Disease 0 0.9482032
- I-Disease 0 0.007745936
Ellison I-Disease 0 0.1168257
syndrome I-Disease 0 0.8555582
. O 0 0.008034841

Although O 0 0.003384679
clinical O 0 0.0058781086
experience O 0 0.0034490072
with O 0 0.0023122423
omeprazole B-Chemical 1 0.9986312
is O 0 0.0012939144
still O 0 0.00066937914
limited O 0 0.00059327536
, O 0 0.00061067875
many O 0 0.00044240648
controlled O 0 0.00041630768
studies O 0 0.0006086926
have O 0 0.0004582207
established O 0 0.0007070043
the O 0 0.0004898707
short O 0 0.00070389395
- O 0 0.0011606661
term O 0 0.0010534868
safety O 0 0.0029252071
of O 0 0.0022713395
this O 0 0.0034041503
drug O 0 0.46985942
. O 0 0.007170137

We O 0 0.0031267325
report O 0 0.003875553
the O 0 0.0014579312
first O 0 0.0009774835
case O 0 0.0010042164
of O 0 0.001053354
a O 0 0.0010626966
serious O 0 0.031622536
short O 0 0.00092222105
- O 0 0.001168316
term O 0 0.0008682473
adverse O 0 0.54820913
reaction O 0 0.008138365
with O 0 0.0009465736
the O 0 0.00077252946
use O 0 0.0013451996
of O 0 0.0033848896
omeprazole B-Chemical 1 0.9993517
: O 0 0.21437807
hemolytic B-Disease 2 0.9995561
anemia I-Disease 2 0.9994355
. O 0 0.02275765

The O 0 0.0034074879
patient O 0 0.004233893
developed O 0 0.0050853295
weakness O 2 0.95737326
, O 0 0.005789249
lethargy B-Disease 0 0.99843794
, O 0 0.0023627956
and O 0 0.0013781892
shortness B-Disease 0 0.95781153
of I-Disease 0 0.0014314369
breath I-Disease 0 0.36104795
2 O 0 0.00087322155
days O 0 0.00063033204
after O 0 0.00049705687
starting O 0 0.0013104554
therapy O 0 0.016646344
with O 0 0.0067610773
omeprazole B-Chemical 1 0.9976866
. O 0 0.010247847

Two O 0 0.0035992174
weeks O 0 0.0017894104
after O 0 0.00090080535
the O 0 0.0009260781
initiation O 0 0.0010571128
of O 0 0.0009905169
therapy O 0 0.016193472
, O 0 0.00094322645
her O 0 0.0009347407
hematocrit O 0 0.52916974
had O 0 0.00053891767
decreased O 0 0.0008947008
from O 0 0.00037398346
44 O 0 0.0005795838
. O 0 0.0001844202
1 O 0 0.00024517073
% O 0 0.00022399952
to O 0 0.0001683409
20 O 0 0.00024640805
. O 0 0.00013531496
4 O 0 0.00017891995
% O 0 0.00023482308
, O 0 0.00023945524
and O 0 0.0002144348
she O 0 0.00026911945
had O 0 0.0003015435
a O 0 0.00035775919
positive O 0 0.0003641364
direct O 0 0.00061559567
Coombs O 0 0.63276416
antiglobulin O 0 0.41663125
test O 0 0.0013040816
and O 0 0.001397112
an O 0 0.0023604163
elevated O 0 0.015133392
indirect O 0 0.025397267
bilirubin B-Chemical 1 0.9966703
. O 0 0.011355905

After O 0 0.0028836096
she O 0 0.0032094545
discontinued O 0 0.0153439455
the O 0 0.0028296285
omeprazole B-Chemical 1 0.99810815
, O 0 0.0037723354
her O 0 0.003557113
hemoglobin O 0 0.79516965
and O 0 0.002939426
hematocrit O 0 0.7007144
gradually O 0 0.0066618565
returned O 0 0.0033563692
to O 0 0.0035806426
normal O 0 0.009428342
. O 0 0.007530298

The O 0 0.0030683372
mechanism O 0 0.003032087
by O 0 0.002010058
which O 0 0.0025918125
omeprazole B-Chemical 1 0.99848807
caused O 0 0.0021681879
the O 0 0.0009717645
patient O 0 0.0017041942
' O 0 0.0011659174
s O 0 0.0025226597
hemolytic B-Disease 2 0.99978215
anemia I-Disease 2 0.9998642
is O 0 0.0018825021
uncertain O 0 0.0049298457
, O 0 0.00089424534
but O 0 0.0004963466
physicians O 0 0.000977865
should O 0 0.0003459415
be O 0 0.0005787161
alerted O 0 0.0014951583
to O 0 0.00069552567
this O 0 0.0010195262
possible O 0 0.0022266326
adverse O 0 0.65303195
effect O 0 0.0068267826
. O 0 0.0064348024

Phenylephrine B-Chemical 0 0.997532
but O 0 0.005827878
not O 0 0.0036910602
ephedrine B-Chemical 1 0.9980288
reduces B-Disease 0 0.006688386
frontal I-Disease 0 0.71902186
lobe I-Disease 0 0.6686353
oxygenation I-Disease 0 0.5787753
following O 0 0.0036815458
anesthesia O 0 0.407184
- O 0 0.008168297
induced O 0 0.013766811
hypotension B-Disease 2 0.99806577
. O 0 0.011895591

BACKGROUND O 0 0.83065706
: O 0 0.010186097
Vasopressor O 0 0.89087915
agents O 0 0.096748725
are O 0 0.0027774784
used O 0 0.0020315372
to O 0 0.0020977345
correct O 0 0.0033487391
anesthesia O 0 0.2506603
- O 0 0.009638016
induced O 0 0.015881265
hypotension B-Disease 2 0.9977841
. O 0 0.014214665

We O 0 0.0029776671
describe O 0 0.0022626088
the O 0 0.0016214843
effect O 0 0.0016851913
of O 0 0.0022967106
phenylephrine B-Chemical 1 0.9990957
and O 0 0.0038967342
ephedrine B-Chemical 1 0.99948514
on O 0 0.0010632151
frontal O 0 0.68277675
lobe O 0 0.74878514
oxygenation O 0 0.8043806
( O 0 0.0026551129
S O 0 0.6683805
( O 0 0.0013531921
c O 0 0.008001541
) O 0 0.0025014442
O O 0 0.9643497
( O 0 0.0014490422
2 O 0 0.00082537
) O 0 0.001243053
) O 0 0.0012615805
following O 0 0.001235415
anesthesia O 0 0.16319565
- O 0 0.004700192
induced O 0 0.009487865
hypotension B-Disease 2 0.9983765
. O 0 0.009220576

METHODS O 0 0.0063473005
: O 0 0.0031043226
Following O 0 0.0016922993
induction O 0 0.0015558382
of O 0 0.0013881908
anesthesia O 0 0.119745165
by O 0 0.0014907647
fentanyl B-Chemical 1 0.9993942
( O 0 0.0015942742
0 O 0 0.00056325074
. O 0 0.00021696379
15 O 0 0.0002651231
mg O 0 0.0816863
kg O 0 0.005593409
( O 0 0.0006089322
- O 0 0.0005716251
1 O 0 0.0003306132
) O 0 0.0005001432
) O 0 0.000458309
and O 0 0.0003696606
propofol B-Chemical 1 0.99784577
( O 0 0.0006565971
2 O 0 0.00027540565
. O 0 0.00013661494
0 O 0 0.00025635594
mg O 0 0.083126485
kg O 0 0.0049490873
( O 0 0.00047956707
- O 0 0.00047330337
1 O 0 0.00028224522
) O 0 0.00043696
) O 0 0.00039181949
, O 0 0.00026365076
13 O 0 0.00024883435
patients O 0 0.0005514218
received O 0 0.00058320176
phenylephrine B-Chemical 1 0.9995474
( O 0 0.0007707063
0 O 0 0.0003217235
. O 0 0.00013302467
1 O 0 0.00022530527
mg O 0 0.09232692
iv O 0 0.0017151354
) O 0 0.0004163345
and O 0 0.0002086301
12 O 0 0.00016212046
patients O 0 0.00053144
received O 0 0.00058009475
ephedrine B-Chemical 1 0.999532
( O 0 0.0008567202
10 O 0 0.00046748176
mg O 0 0.20688146
iv O 0 0.002950944
) O 0 0.00075814966
to O 0 0.0004003198
restore O 0 0.0005132295
mean O 0 0.00071110635
arterial O 0 0.50708205
pressure O 0 0.18418683
( O 0 0.005398485
MAP O 0 0.6932204
) O 0 0.009676832
. O 0 0.006408577

Heart O 0 0.04929242
rate O 0 0.0039114836
( O 0 0.004356411
HR O 0 0.15954301
) O 0 0.0034302755
, O 0 0.002225943
MAP O 0 0.54197866
, O 0 0.0025494336
stroke B-Disease 2 0.99458426
volume O 0 0.012531926
( O 0 0.0017295434
SV O 0 0.31217235
) O 0 0.0013772956
, O 0 0.00073812285
cardiac O 0 0.13726096
output O 0 0.0014565616
( O 0 0.0012040065
CO O 1 0.9831087
) O 0 0.0016059842
, O 0 0.0006661583
and O 0 0.00061453786
frontal O 0 0.4025417
lobe O 0 0.6070096
oxygenation O 0 0.71623373
( O 0 0.002096656
S O 0 0.62708217
( O 0 0.0013629865
c O 0 0.008167134
) O 0 0.0029605418
O O 0 0.9576731
( O 0 0.0020607226
2 O 0 0.0013939714
) O 0 0.0022756106
) O 0 0.0025907478
were O 0 0.0023560645
registered O 0 0.0052324915
. O 0 0.0056373407

RESULTS O 0 0.031420924
: O 0 0.004882192
Induction O 0 0.0051700235
of O 0 0.0020099527
anesthesia O 0 0.06059203
was O 0 0.0010213368
followed O 0 0.00058290665
by O 0 0.00065610925
a B-Disease 0 0.0006841867
decrease I-Disease 0 0.0008017164
in I-Disease 0 0.0006679121
MAP I-Disease 0 0.6425731
, I-Disease 0 0.0013949355
HR I-Disease 0 0.27676612
, I-Disease 0 0.0010399176
SV I-Disease 0 0.22847785
, I-Disease 0 0.0007852259
and I-Disease 0 0.0006321535
CO I-Disease 1 0.9677292
concomitant O 0 0.014079378
with O 0 0.0009966015
an O 0 0.0012595514
elevation O 0 0.35769156
in O 0 0.0012213885
S O 0 0.7271339
( O 0 0.002325481
c O 0 0.014346622
) O 0 0.005690972
O O 0 0.95911056
( O 0 0.00482028
2 O 0 0.003857891
) O 0 0.0067369663
. O 0 0.005746434

After O 0 0.002983236
administration O 0 0.0356136
of O 0 0.0041279946
phenylephrine B-Chemical 1 0.998882
, O 0 0.0056453445
MAP O 0 0.70617783
increased O 0 0.003065866
( O 0 0.0015423995
51 O 0 0.0014176354
+ O 0 0.00089630834
/ O 0 0.0012565282
- O 0 0.0006738606
12 O 0 0.0002547724
to O 0 0.00028067865
81 O 0 0.0007450556
+ O 0 0.00056684297
/ O 0 0.0010212658
- O 0 0.0006985238
13 O 0 0.00051958737
mmHg O 0 0.005222085
; O 0 0.00070938637
P O 0 0.007007023
< O 0 0.00053408614
0 O 0 0.00047913528
. O 0 0.00036904513
001 O 0 0.06589274
; O 0 0.0011231761
mean O 0 0.00067727943
+ O 0 0.001761868
/ O 0 0.004065007
- O 0 0.004682118
SD O 0 0.04203209
) O 0 0.0074247206
. O 0 0.005944931

However O 0 0.004703675
, O 0 0.0033461144
a O 0 0.002099794
14 O 0 0.0017051161
% O 0 0.0013459751
( O 0 0.0010297057
from O 0 0.00059797027
70 O 0 0.000819168
+ O 0 0.0008444226
/ O 0 0.0012811407
- O 0 0.00077559095
8 O 0 0.00034914573
% O 0 0.00031374503
to O 0 0.00023858217
60 O 0 0.00039191885
+ O 0 0.00046156603
/ O 0 0.0008563689
- O 0 0.0005600695
7 O 0 0.00025337952
% O 0 0.00031477242
) O 0 0.0004106563
reduction O 0 0.00053505815
in O 0 0.00039286521
S O 0 0.55622405
( O 0 0.00088862417
c O 0 0.008191896
) O 0 0.0019943065
O O 0 0.97765356
( O 0 0.00095423067
2 O 0 0.00044142178
) O 0 0.00066465564
( O 0 0.00049268414
P O 0 0.010410151
< O 0 0.00035898038
0 O 0 0.00028133686
. O 0 0.00016948426
05 O 0 0.009477733
) O 0 0.00035407837
followed O 0 0.00015550536
with O 0 0.00025965882
no O 0 0.00020039525
change O 0 0.00032294195
in O 0 0.0003405585
CO O 1 0.9767578
( O 0 0.0007359412
3 O 0 0.00027564628
. O 0 0.00016814085
7 O 0 0.00023130346
+ O 0 0.0003612644
/ O 0 0.0007176398
- O 0 0.00046975323
1 O 0 0.00024320478
. O 0 0.0001289658
1 O 0 0.00018283547
to O 0 0.00016662339
3 O 0 0.00018935796
. O 0 0.00014308949
4 O 0 0.00022188238
+ O 0 0.00038430432
/ O 0 0.0007637339
- O 0 0.00054951536
0 O 0 0.00036189126
. O 0 0.00020950081
9 O 0 0.00037127954
l O 0 0.0010213902
min O 0 0.0011748166
( O 0 0.0013496238
- O 0 0.001992066
1 O 0 0.0018948312
) O 0 0.0037204942
) O 0 0.0053904923
. O 0 0.0048516816

The O 0 0.00335367
administration O 0 0.03364862
of O 0 0.0033616482
ephedrine B-Chemical 1 0.9985738
led O 0 0.0027112744
to O 0 0.0009420364
a O 0 0.0007982707
similar O 0 0.00048037368
increase O 0 0.0007359234
in O 0 0.0006944193
MAP O 0 0.82596374
( O 0 0.0012004703
53 O 0 0.0012335823
+ O 0 0.0007056489
/ O 0 0.0011127265
- O 0 0.00061688246
9 O 0 0.0002794613
to O 0 0.00023676275
79 O 0 0.0005962472
+ O 0 0.00046827696
/ O 0 0.0008793112
- O 0 0.0005774629
8 O 0 0.00031227866
mmHg O 0 0.0041173017
; O 0 0.00052481337
P O 0 0.006970195
< O 0 0.00035784885
0 O 0 0.00030084632
. O 0 0.00019959414
001 O 0 0.099303134
) O 0 0.0006066065
, O 0 0.0004122116
restored O 0 0.0005373355
CO O 1 0.97370696
( O 0 0.00075545494
3 O 0 0.00028522164
. O 0 0.00017498493
2 O 0 0.0002771153
+ O 0 0.00038095363
/ O 0 0.00073055446
- O 0 0.00046291304
1 O 0 0.00023389886
. O 0 0.00012131575
2 O 0 0.00016709576
to O 0 0.00015715101
5 O 0 0.00017353403
. O 0 0.00012530478
0 O 0 0.0002546376
+ O 0 0.000316781
/ O 0 0.0006421428
- O 0 0.00042960758
1 O 0 0.0002258703
. O 0 0.00012148673
3 O 0 0.0001689534
l O 0 0.00052844844
min O 0 0.0005153438
( O 0 0.0004601203
- O 0 0.00052534445
1 O 0 0.0003515574
) O 0 0.00058076
) O 0 0.0005781587
, O 0 0.0004578963
and O 0 0.0004845116
preserved O 0 0.0018269878
S O 0 0.53827703
( O 0 0.0018786087
c O 0 0.011207479
) O 0 0.005138714
O O 0 0.9564698
( O 0 0.00458498
2 O 0 0.0037088047
) O 0 0.006527452
. O 0 0.0055841208

CONCLUSIONS O 0 0.68510246
: O 0 0.0048122527
The O 0 0.0017222753
utilization O 0 0.0026180497
of O 0 0.0021230127
phenylephrine B-Chemical 1 0.99858934
to O 0 0.0013539753
correct O 0 0.0015978949
hypotension B-Disease 2 0.9995189
induced O 0 0.0020424994
by O 0 0.0007465972
anesthesia O 0 0.13289665
has O 0 0.00041297384
a O 0 0.000376528
negative O 0 0.0003302887
impact O 0 0.00031499186
on O 0 0.00031128852
S O 0 0.60522354
( O 0 0.0010293577
c O 0 0.009261606
) O 0 0.002104376
O O 0 0.97740346
( O 0 0.00093271333
2 O 0 0.00041953786
) O 0 0.00056491216
while O 0 0.0003865862
ephedrine B-Chemical 1 0.99932086
maintains O 0 0.0019903018
frontal O 0 0.64851487
lobe O 0 0.5895491
oxygenation O 0 0.43259043
potentially O 0 0.001930803
related O 0 0.00060738175
to O 0 0.0008354102
an O 0 0.0015702777
increase O 0 0.0019616324
in O 0 0.0036823398
CO O 1 0.973782
. O 0 0.008101003

Prolonged O 0 0.19491296
elevation O 0 0.17564602
of O 0 0.0036265396
plasma O 0 0.088834636
argatroban B-Chemical 1 0.99364215
in O 0 0.0011750165
a O 0 0.0010494132
cardiac O 0 0.1849885
transplant O 0 0.45506138
patient O 0 0.0013850491
with O 0 0.0007456988
a O 0 0.0007597158
suspected O 0 0.015598079
history O 0 0.015466124
of O 0 0.0021980477
heparin B-Chemical 1 0.99481624
- O 0 0.011770208
induced O 0 0.013376013
thrombocytopenia B-Disease 0 0.9990859
with O 0 0.050295588
thrombosis B-Disease 2 0.9977869
. O 0 0.011814835

BACKGROUND O 0 0.83170277
: O 0 0.0070586232
Direct O 0 0.012528853
thrombin O 0 0.7694993
inhibitors O 0 0.54202753
( O 0 0.003045752
DTIs O 0 0.10022493
) O 0 0.0011726046
provide O 0 0.00046015764
an O 0 0.0004903836
alternative O 0 0.00040376282
method O 0 0.0005733215
of O 0 0.0004933999
anticoagulation O 0 0.55281085
for O 0 0.00033712777
patients O 0 0.0012545967
with O 0 0.00039925062
a O 0 0.00039306076
history O 0 0.0074779796
of O 0 0.0009980643
heparin B-Chemical 1 0.99653697
- O 0 0.006584342
induced O 0 0.0060590208
thrombocytopenia B-Disease 0 0.9997887
( O 0 0.010372717
HIT B-Disease 2 0.9963223
) O 0 0.0021262418
or O 0 0.0006165727
HIT B-Disease 2 0.9873383
with O 0 0.0029091586
thrombosis B-Disease 2 0.99938047
( O 0 0.0087812245
HITT B-Disease 2 0.9967451
) O 0 0.0023172603
undergoing O 0 0.002177878
cardiopulmonary O 0 0.011510177
bypass O 0 0.013725087
( O 0 0.0046073785
CPB O 0 0.47097188
) O 0 0.008704992
. O 0 0.006206393

In O 0 0.0029343423
the O 0 0.0019512419
following O 0 0.0016531558
report O 0 0.0033533461
, O 0 0.0015558723
a O 0 0.0010439093
65 O 0 0.0011769665
- O 0 0.000984678
year O 0 0.0006291788
- O 0 0.00077383616
old O 0 0.00054616976
critically B-Disease 0 0.011080276
ill I-Disease 0 0.36133766
patient O 0 0.00093744503
with O 0 0.0004822745
a O 0 0.00046658225
suspected O 0 0.013963074
history O 0 0.013294426
of O 0 0.0013232221
HITT B-Disease 2 0.9974172
was O 0 0.0007792272
administered O 0 0.004944332
argatroban B-Chemical 1 0.99271834
for O 0 0.0007068713
anticoagulation O 0 0.5739063
on O 0 0.0007232611
bypass O 0 0.0052955365
during O 0 0.0019245625
heart O 0 0.54587114
transplantation O 0 0.46182218
. O 0 0.0068010287

The O 0 0.0028299259
patient O 0 0.002937156
required O 0 0.0012132775
massive O 0 0.00708048
transfusion O 0 0.056878734
support O 0 0.0013703377
( O 0 0.0011353479
55 O 0 0.0007014475
units O 0 0.0004634797
of O 0 0.00054622884
red O 0 0.0010447691
blood O 0 0.0039547426
cells O 0 0.00096252153
, O 0 0.00045489008
42 O 0 0.00039648774
units O 0 0.00024280767
of O 0 0.00031730754
fresh O 0 0.0009920847
- O 0 0.0005310451
frozen O 0 0.0008671122
plasma O 0 0.013811807
, O 0 0.00035121338
40 O 0 0.00025642928
units O 0 0.00020546696
of O 0 0.00030697533
cryoprecipitate O 0 0.28608352
, O 0 0.0004058577
40 O 0 0.00027796367
units O 0 0.0002228734
of O 0 0.00034199792
platelets O 0 0.12029384
, O 0 0.00040520838
and O 0 0.0002499765
three O 0 0.00015322627
doses O 0 0.007143012
of O 0 0.00059414294
recombinant O 0 0.0018973895
Factor O 0 0.9780513
VIIa O 0 0.97079957
) O 0 0.001937185
for O 0 0.00076289236
severe O 0 0.112967
intraoperative B-Disease 0 0.061467133
and I-Disease 0 0.003208625
postoperative I-Disease 0 0.49112108
bleeding I-Disease 0 0.9928082
. O 0 0.008486916

STUDY O 0 0.032666836
DESIGN O 0 0.01074191
AND O 0 0.004053006
METHODS O 0 0.0028791183
: O 0 0.0021152839
Plasma O 0 0.021032127
samples O 0 0.0007717804
from O 0 0.0005579455
before O 0 0.00031830743
and O 0 0.00042684417
after O 0 0.00027098897
CPB O 0 0.04309839
were O 0 0.00034108103
analyzed O 0 0.0002787
postoperatively O 0 0.0007962604
for O 0 0.00036408642
argatroban B-Chemical 1 0.99029934
concentration O 0 0.0024968546
using O 0 0.00043081268
a O 0 0.00062793895
modified O 0 0.0010700193
ecarin O 0 0.12711048
clotting O 0 0.2274088
time O 0 0.0015697089
( O 0 0.003803439
ECT O 0 0.97522086
) O 0 0.0071202386
assay O 0 0.008612083
. O 0 0.0069521354

RESULTS O 0 0.027964178
: O 0 0.0041694026
Unexpectedly O 0 0.0035321065
high O 0 0.0017537377
concentrations O 0 0.002892483
of O 0 0.0014924706
argatroban B-Chemical 1 0.9917167
were O 0 0.0007314852
measured O 0 0.00035181607
in O 0 0.00032724935
these O 0 0.00047103807
samples O 0 0.00042933365
( O 0 0.00055200834
range O 0 0.00056979863
, O 0 0.00045519767
0 O 0 0.00037869025
- O 0 0.0004203187
32 O 0 0.0004110985
microg O 0 0.0008785521
/ O 0 0.0009281753
mL O 0 0.0035560792
) O 0 0.000494104
, O 0 0.00028875947
and O 0 0.0002194297
a O 0 0.00025889845
prolonged O 0 0.004930215
plasma O 0 0.050597575
argatroban B-Chemical 1 0.99414164
half O 0 0.00026358943
life O 0 0.0013290655
( O 0 0.0005458112
t O 0 0.00089424365
( O 0 0.00042951334
1 O 0 0.00027823407
/ O 0 0.0005204582
2 O 0 0.0002462434
) O 0 0.0003665081
) O 0 0.00029435454
of O 0 0.00023735946
514 O 0 0.0032606402
minutes O 0 0.00020973624
was O 0 0.00018629715
observed O 0 0.00016797884
( O 0 0.00029660197
published O 0 0.00026886017
elimination O 0 0.0010664094
t O 0 0.0011881839
( O 0 0.00050350063
1 O 0 0.00031898453
/ O 0 0.00059193117
2 O 0 0.0002799792
) O 0 0.00039689348
is O 0 0.0002393256
39 O 0 0.0004913461
- O 0 0.00042581453
51 O 0 0.0004362017
minutes O 0 0.00031336004
[ O 0 0.00065945863
< O 0 0.00038511486
or O 0 0.00030552305
= O 0 0.00068367826
181 O 0 0.0020146086
minutes O 0 0.00064816495
with O 0 0.0015252082
hepatic B-Disease 0 0.99277884
impairment I-Disease 0 0.9634103
] O 0 0.024203982
) O 0 0.008739553
. O 0 0.005870501

CONCLUSIONS O 0 0.6680204
: O 0 0.0044404003
Correlation O 0 0.0023199322
of O 0 0.0019192785
plasma O 0 0.0398945
argatroban B-Chemical 1 0.9939995
concentration O 0 0.0052609523
versus O 0 0.0006165997
the O 0 0.0004398035
patient O 0 0.00075816916
' O 0 0.0004932647
s O 0 0.00051350106
coagulation O 0 0.19854133
variables O 0 0.00055592996
and O 0 0.0003032852
clinical O 0 0.0018027957
course O 0 0.0004266715
suggest O 0 0.00019685722
that O 0 0.00021411016
prolonged O 0 0.0054022353
elevated O 0 0.0038703764
levels O 0 0.0003657176
of O 0 0.0006267922
plasma O 0 0.113628685
argatroban B-Chemical 1 0.9967642
may O 0 0.00052241574
have O 0 0.00046565564
contributed O 0 0.0011448363
to O 0 0.00050457683
the O 0 0.0006069934
patient O 0 0.001447836
' O 0 0.0015221781
s O 0 0.0023289185
extended O 0 0.003953439
coagulopathy B-Disease 2 0.9963229
. O 0 0.00859735

Because O 0 0.0036154618
DTIs O 0 0.017823745
do O 0 0.0015864614
not O 0 0.001058437
have O 0 0.0010288312
reversal O 0 0.0032472347
agents O 0 0.08711287
, O 0 0.0009796371
surgical O 0 0.0012237227
teams O 0 0.0007004755
and O 0 0.00051214494
transfusion O 0 0.030706769
services O 0 0.0008668627
should O 0 0.00021176356
remain O 0 0.000317543
aware O 0 0.00035094697
of O 0 0.00035324524
the O 0 0.00029370614
possibility O 0 0.00031424797
of O 0 0.0006167343
massive O 0 0.03344078
transfusion O 0 0.17989911
events O 0 0.0075221807
during O 0 0.0008843981
anticoagulation O 0 0.6744433
with O 0 0.0027299176
these O 0 0.005024548
agents O 0 0.3709268
. O 0 0.0070769405

This O 0 0.0049183783
is O 0 0.0021493442
the O 0 0.0013544318
first O 0 0.0009859223
report O 0 0.0021540925
to O 0 0.00084604434
measure O 0 0.00060110097
plasma O 0 0.032880176
argatroban B-Chemical 1 0.9949352
concentration O 0 0.0051798727
in O 0 0.00075385044
the O 0 0.0007265644
context O 0 0.00069175573
of O 0 0.0017413865
CPB O 0 0.36190015
and O 0 0.003229346
extended O 0 0.0063182046
coagulopathy B-Disease 2 0.9969933
. O 0 0.010729364

The O 0 0.0027717946
effects O 0 0.0030205832
of O 0 0.001931768
the O 0 0.0014202453
adjunctive O 0 0.12590402
bupropion B-Chemical 0 0.9996543
on O 0 0.0009535671
male O 0 0.015789162
sexual B-Disease 0 0.74047714
dysfunction I-Disease 0 0.99500906
induced O 0 0.002259918
by O 0 0.0007627171
a O 0 0.00086832186
selective B-Chemical 0 0.08949331
serotonin I-Chemical 1 0.9996076
reuptake I-Chemical 0 0.9996383
inhibitor I-Chemical 0 0.6139582
: O 0 0.001668459
a O 0 0.00055392977
double O 0 0.000475699
- O 0 0.0010271354
blind O 0 0.0053294166
placebo O 0 0.14720349
- O 0 0.0013471864
controlled O 0 0.000954617
and O 0 0.0013753715
randomized O 0 0.0031706595
study O 0 0.0050015463
. O 0 0.005172126

OBJECTIVE O 0 0.46035314
: O 0 0.0038338308
To O 0 0.0011803146
determine O 0 0.00057424436
the O 0 0.000763125
safety O 0 0.0017646343
and O 0 0.0007263339
efficacy O 0 0.0021182802
of O 0 0.0008638169
adjunctive O 0 0.24084203
bupropion B-Chemical 0 0.99987686
sustained O 0 0.2792924
- O 0 0.006517165
release O 0 0.14027491
( O 0 0.0015661997
SR O 0 0.78629464
) O 0 0.000953321
on O 0 0.00021406627
male O 0 0.0036509011
sexual B-Disease 0 0.63503045
dysfunction I-Disease 0 0.99695635
( O 0 0.0022236493
SD B-Disease 0 0.05710239
) O 0 0.00073024095
induced O 0 0.00047481377
by O 0 0.00037664236
a O 0 0.00054160133
selective B-Chemical 0 0.06688776
serotonin I-Chemical 1 0.99967027
reuptake I-Chemical 0 0.9997271
inhibitor I-Chemical 0 0.8160926
( O 0 0.013147267
SSRI B-Chemical 0 0.999808
) O 0 0.002867238
, O 0 0.000536701
as O 0 0.00025877755
SD B-Disease 0 0.009981836
is O 0 0.00026028545
a O 0 0.00030537805
common O 0 0.0006364107
side O 0 0.020809932
- O 0 0.00076374266
effect O 0 0.000418715
of O 0 0.0008034433
SSRIs B-Chemical 0 0.9992617
and O 0 0.0005414276
the O 0 0.00040009545
most O 0 0.0008001651
effective O 0 0.0009255352
treatments O 0 0.00228765
have O 0 0.0011186785
yet O 0 0.0018037295
to O 0 0.0015037517
be O 0 0.0023746034
determined O 0 0.00302638
. O 0 0.0053174286

PATIENTS O 0 0.014431783
AND O 0 0.0055344664
METHODS O 0 0.0031533965
: O 0 0.001783089
The O 0 0.0007785057
randomized O 0 0.0010388122
sample O 0 0.00071957125
consisted O 0 0.00069576036
of O 0 0.0010225645
234 O 0 0.02808464
euthymic O 0 0.77161944
men O 0 0.035095718
who O 0 0.0019427062
were O 0 0.0009186758
receiving O 0 0.0026521448
some O 0 0.0018838564
type O 0 0.0028037599
of O 0 0.008469666
SSRI B-Chemical 0 0.99777573
. O 0 0.010653888

The O 0 0.0030918268
men O 0 0.007910274
were O 0 0.0014189753
randomly O 0 0.00068538095
assigned O 0 0.00096251647
to O 0 0.0011990269
bupropion B-Chemical 0 0.9995615
SR O 0 0.93627685
( O 0 0.0015179529
150 O 0 0.0012113295
mg O 0 0.10008193
twice O 0 0.00047706012
daily O 0 0.0010983961
, O 0 0.00055891846
117 O 0 0.0016517995
) O 0 0.0005969338
or O 0 0.0003302947
placebo O 0 0.051729534
( O 0 0.00058868283
twice O 0 0.00052285835
daily O 0 0.0014014494
, O 0 0.0010299066
117 O 0 0.0027743897
) O 0 0.0014808238
for O 0 0.0010616289
12 O 0 0.0016572815
weeks O 0 0.0029816225
. O 0 0.0043427525

Efficacy O 0 0.040592685
was O 0 0.0026401656
evaluated O 0 0.0017492255
using O 0 0.0013310905
the O 0 0.0014038059
Clinical O 0 0.070096456
Global O 0 0.012127068
Impression O 0 0.03842933
- O 0 0.002386955
Sexual O 0 0.2657578
Function O 0 0.06470085
( O 0 0.0014162719
CGI O 0 0.17900024
- O 0 0.0014563563
SF O 0 0.08338408
; O 0 0.00079316733
the O 0 0.0002868686
primary O 0 0.00047052404
outcome O 0 0.00082274305
measure O 0 0.00023499687
) O 0 0.00062283984
, O 0 0.00039192598
the O 0 0.00029631288
International O 0 0.0013910698
Index O 0 0.0017784127
of O 0 0.0005942975
Erectile O 0 0.3203102
Function O 0 0.036845032
( O 0 0.00086904404
IIEF O 0 0.12164649
) O 0 0.0008299078
, O 0 0.0005964987
Arizona O 0 0.015650067
Sexual O 0 0.20407645
Experience O 0 0.2018694
Scale O 0 0.7494215
( O 0 0.0012715644
ASEX O 0 0.93315756
) O 0 0.00090412365
, O 0 0.00055052555
and O 0 0.0006110726
Erectile B-Disease 0 0.7271452
Dysfunction I-Disease 0 0.7334012
Inventory O 0 0.030312667
of O 0 0.0008291865
Treatment O 0 0.13679345
Satisfaction O 0 0.022595659
( O 0 0.0016594713
EDITS O 0 0.25626364
) O 0 0.0017604579
( O 0 0.0014194557
secondary O 0 0.0027295332
outcome O 0 0.0041006044
measures O 0 0.0035354374
) O 0 0.007487729
. O 0 0.0058776205

Participants O 0 0.007900755
were O 0 0.004767564
followed O 0 0.0039624735
biweekly O 0 0.00960126
during O 0 0.0051540555
study O 0 0.00945652
period O 0 0.010896437
. O 0 0.013561434

RESULTS O 0 0.020020768
: O 0 0.0032922048
After O 0 0.0010084809
12 O 0 0.0007529843
weeks O 0 0.00065807655
of O 0 0.0007831779
treatment O 0 0.0014405517
, O 0 0.00076139474
the O 0 0.00040911365
mean O 0 0.00033048465
( O 0 0.00061019405
sd O 0 0.001123007
) O 0 0.00054842647
scores O 0 0.00031252138
for O 0 0.0003182343
CGI O 0 0.12619476
- O 0 0.0008835432
SF O 0 0.0381663
were O 0 0.00031186952
significantly O 0 0.00037959707
lower O 0 0.0003360723
, O 0 0.00043218094
i O 0 0.00085879257
. O 0 0.00018052339
e O 0 0.00053555897
. O 0 0.00014193753
better O 0 0.00027357033
, O 0 0.00029016112
in O 0 0.00019568496
patients O 0 0.000829877
on O 0 0.00023815584
bupropion B-Chemical 0 0.9998418
SR O 0 0.9092232
, O 0 0.000605243
at O 0 0.00018438521
2 O 0 0.00024687508
. O 0 0.00013274972
4 O 0 0.00018102549
( O 0 0.00026379433
1 O 0 0.00019735657
. O 0 0.00011711517
2 O 0 0.0001960886
) O 0 0.00031038845
, O 0 0.00021538681
than O 0 0.00011009953
in O 0 0.00014484402
the O 0 0.00019501144
placebo O 0 0.040010985
group O 0 0.0003821755
, O 0 0.0003308856
at O 0 0.00016567313
3 O 0 0.00022895004
. O 0 0.00016669203
9 O 0 0.00028500665
( O 0 0.00038027155
1 O 0 0.00032388017
. O 0 0.00023467578
1 O 0 0.00046567296
) O 0 0.0008892162
( O 0 0.0009934816
P O 0 0.013996063
= O 0 0.0016678956
0 O 0 0.001431419
. O 0 0.001368899
01 O 0 0.009245727
) O 0 0.0056375526
. O 0 0.005220106

Men O 0 0.070817955
who O 0 0.0049815346
received O 0 0.0034886622
bupropion B-Chemical 0 0.99886715
had O 0 0.0017758327
a O 0 0.0010779579
significant O 0 0.0009000813
increase O 0 0.0005499917
in O 0 0.0004023464
the O 0 0.00037023157
total O 0 0.0004273517
IIEF O 0 0.05658429
score O 0 0.00054434186
( O 0 0.0005128823
54 O 0 0.0005640349
. O 0 0.00017296264
4 O 0 0.00020447296
% O 0 0.0002540188
vs O 0 0.00040541435
1 O 0 0.00024448935
. O 0 0.00015159599
2 O 0 0.0002467499
% O 0 0.0003271935
; O 0 0.0005065263
P O 0 0.009120375
= O 0 0.00051139
0 O 0 0.00032531546
. O 0 0.00020298484
003 O 0 0.011743062
) O 0 0.0005748399
, O 0 0.0003969173
and O 0 0.00032907052
in O 0 0.0002932442
the O 0 0.00034300706
five O 0 0.00035807426
different O 0 0.00075388135
domains O 0 0.0012309296
of O 0 0.0022681518
the O 0 0.0037152995
IIEF O 0 0.258295
. O 0 0.006398854

Total O 0 0.0073972135
ASEX O 0 0.6726177
scores O 0 0.002011461
were O 0 0.001245154
significantly O 0 0.0011759425
lower O 0 0.0009037791
, O 0 0.0010201805
i O 0 0.0014682917
. O 0 0.00036910566
e O 0 0.00083228055
. O 0 0.00023426734
better O 0 0.00039229132
, O 0 0.00040334562
among O 0 0.0003794511
men O 0 0.011803811
who O 0 0.00083487463
received O 0 0.0006907544
bupropion B-Chemical 0 0.99975985
than O 0 0.00032108556
placebo O 0 0.12051526
, O 0 0.00036853077
at O 0 0.0001501147
15 O 0 0.00018817758
. O 0 0.00012473992
5 O 0 0.00017539435
( O 0 0.0002484586
4 O 0 0.00016339598
. O 0 0.00012009409
3 O 0 0.00017657921
) O 0 0.00032213356
vs O 0 0.00041432655
21 O 0 0.0003053978
. O 0 0.0001544074
5 O 0 0.00022625978
( O 0 0.00034606896
4 O 0 0.00025732396
. O 0 0.00022787943
7 O 0 0.00039234984
) O 0 0.0008777726
( O 0 0.0010264051
P O 0 0.0138973
= O 0 0.001779129
0 O 0 0.0015612378
. O 0 0.0015508935
002 O 0 0.0728916
) O 0 0.0062574577
. O 0 0.005421654

The O 0 0.0039158165
EDITS O 0 0.038187858
scores O 0 0.0018908934
were O 0 0.0013045574
67 O 0 0.0018330241
. O 0 0.0006254423
4 O 0 0.0005807647
( O 0 0.00066591037
10 O 0 0.00044041855
. O 0 0.00024677505
2 O 0 0.00032115902
) O 0 0.00042046112
for O 0 0.00022334394
the O 0 0.00036968602
bupropion B-Chemical 0 0.9995931
and O 0 0.00055419095
36 O 0 0.00042497637
. O 0 0.00018344841
3 O 0 0.00023499619
( O 0 0.00032847057
11 O 0 0.00027532768
. O 0 0.00014929047
7 O 0 0.00020709135
) O 0 0.0003351507
for O 0 0.00020316218
the O 0 0.0003431627
placebo O 0 0.054691654
group O 0 0.0010078182
( O 0 0.0013578526
P O 0 0.03137347
= O 0 0.0019237137
0 O 0 0.0016047797
. O 0 0.0015632758
001 O 0 0.1411014
) O 0 0.006603755
. O 0 0.005598089

The O 0 0.0053946665
ASEX O 0 0.6352586
score O 0 0.0034733946
and O 0 0.0028396794
CGI O 0 0.12380369
- O 0 0.0034205692
SF O 0 0.03296584
score O 0 0.001556388
were O 0 0.0011599092
correlated O 0 0.0012184068
( O 0 0.002360359
P O 0 0.030108843
= O 0 0.00301161
0 O 0 0.0023212677
. O 0 0.0021170017
003 O 0 0.037156627
) O 0 0.007840309
. O 0 0.0066905622

In O 0 0.0026568624
linear O 0 0.0031001195
regression O 0 0.0048104348
analyses O 0 0.0024321063
the O 0 0.0015059147
CGI O 0 0.16402327
- O 0 0.0021574628
SF O 0 0.039755084
score O 0 0.00078228815
was O 0 0.00047079683
not O 0 0.00034684828
affected O 0 0.0003390502
significantly O 0 0.0004877174
by O 0 0.00037998127
the O 0 0.00034093633
duration O 0 0.0006445214
of O 0 0.0008342404
SD B-Disease 0 0.029968813
, O 0 0.0009313222
type O 0 0.0009075899
of O 0 0.0022267425
SSRI B-Chemical 0 0.99888486
used O 0 0.0026312722
and O 0 0.0037109074
age O 0 0.010196478
. O 0 0.006303973

CONCLUSIONS O 0 0.88616264
: O 0 0.013907297
Bupropion B-Chemical 0 0.99791676
is O 0 0.0030687512
an O 0 0.0024240124
effective O 0 0.00259913
treatment O 0 0.003523353
for O 0 0.0019946347
male O 0 0.009008868
SD B-Disease 0 0.045421634
induced O 0 0.006105046
by O 0 0.009152015
SSRIs B-Chemical 0 0.9956197
. O 0 0.011633536

These O 0 0.004738316
results O 0 0.002517077
provide O 0 0.0021814487
empirical O 0 0.0032125043
support O 0 0.0019086439
for O 0 0.001439888
conducting O 0 0.001999184
a O 0 0.0020980213
further O 0 0.0025240688
study O 0 0.0045829765
of O 0 0.008952231
bupropion B-Chemical 0 0.99812394
. O 0 0.0141161205

Prevention O 0 0.016906938
of O 0 0.0055875485
seizures B-Disease 2 0.9986172
and O 0 0.0032180364
reorganization O 0 0.016504074
of O 0 0.0020251956
hippocampal O 0 0.7952958
functions O 0 0.0016468021
by O 0 0.0008564056
transplantation O 0 0.06874757
of O 0 0.0010986149
bone O 0 0.07278215
marrow O 0 0.23462747
cells O 0 0.001669428
in O 0 0.0006698019
the O 0 0.0009508378
acute O 0 0.8157784
phase O 0 0.004962646
of O 0 0.0037058196
experimental O 0 0.027738096
epilepsy B-Disease 2 0.99809176
. O 0 0.0105994325

In O 0 0.0027828193
this O 0 0.0018819637
study O 0 0.0020782643
, O 0 0.0013493719
we O 0 0.00050655263
investigated O 0 0.00066521205
the O 0 0.00057496235
therapeutic O 0 0.0035948355
potential O 0 0.0009571946
of O 0 0.00097373576
bone O 0 0.099256076
marrow O 0 0.49836782
mononuclear O 0 0.52021813
cells O 0 0.0028935927
( O 0 0.0010510605
BMCs O 0 0.12027746
) O 0 0.0007369955
in O 0 0.00032037005
a O 0 0.00046975774
model O 0 0.00073612394
of O 0 0.0015636769
epilepsy B-Disease 2 0.99918884
induced O 0 0.0050469437
by O 0 0.0045621595
pilocarpine B-Chemical 1 0.99940777
in O 0 0.005201814
rats O 0 0.037713896
. O 0 0.0063957106

BMCs O 0 0.06130257
obtained O 0 0.0026181268
from O 0 0.0018387055
green O 0 0.0023414076
fluorescent O 0 0.003889044
protein O 0 0.0037211042
( O 0 0.0017997005
GFP O 0 0.0027129345
) O 0 0.0011050907
transgenic O 0 0.0005791923
mice O 0 0.00030680446
or O 0 0.0003599004
rats O 0 0.0014226468
were O 0 0.00043135445
transplanted O 0 0.0031735061
intravenously O 0 0.0026864146
after O 0 0.00033620096
induction O 0 0.0008965318
of O 0 0.0012792929
status B-Disease 0 0.006373667
epilepticus I-Disease 0 0.9995957
( O 0 0.011048075
SE B-Disease 0 0.61995363
) O 0 0.009662648
. O 0 0.006172156

Spontaneous B-Disease 0 0.18403898
recurrent I-Disease 0 0.80240774
seizures I-Disease 2 0.9993187
( O 0 0.016238643
SRS B-Disease 0 0.77213967
) O 0 0.0031640925
were O 0 0.0012273763
monitored O 0 0.00086752826
using O 0 0.001333229
Racine O 0 0.013003815
' O 0 0.0024220229
s O 0 0.0041976753
seizure B-Disease 2 0.99462974
severity O 0 0.13222414
scale O 0 0.011465262
. O 0 0.008352105

All O 0 0.0034111477
of O 0 0.0025793235
the O 0 0.0017387707
rats O 0 0.0037206002
in O 0 0.0010233159
the O 0 0.0009495183
saline O 0 0.13901329
- O 0 0.0018779446
treated O 0 0.0021402347
epileptic B-Disease 2 0.99902475
control O 0 0.0005529818
group O 0 0.000719643
developed O 0 0.0016723393
SRS B-Disease 0 0.75542825
, O 0 0.0005838864
whereas O 0 0.00029163546
none O 0 0.0003740715
of O 0 0.0004128835
the O 0 0.00044704237
BMC O 0 0.85547936
- O 0 0.0014048645
treated O 0 0.0018449366
epileptic B-Disease 2 0.9994294
animals O 0 0.00043219863
had O 0 0.0006812574
seizures B-Disease 2 0.99978405
in O 0 0.00032787267
the O 0 0.00023404341
short O 0 0.00025137988
term O 0 0.00038710487
( O 0 0.00041547176
15 O 0 0.00020784524
days O 0 0.00022098298
after O 0 0.00021140507
transplantation O 0 0.035271004
) O 0 0.00096512487
, O 0 0.00068994414
regardless O 0 0.00045814583
of O 0 0.0014686147
the O 0 0.0023618864
BMC O 0 0.64256185
source O 0 0.005724129
. O 0 0.0067102257

Over O 0 0.0048068934
the O 0 0.002372641
long O 0 0.002400712
- O 0 0.0022674548
term O 0 0.0015749667
chronic O 0 0.8335421
phase O 0 0.0040642717
( O 0 0.0010430703
120 O 0 0.00064163556
days O 0 0.0003173033
after O 0 0.0002226164
transplantation O 0 0.03891607
) O 0 0.00074856344
, O 0 0.0003994554
only O 0 0.00027735505
25 O 0 0.00045603412
% O 0 0.00029625636
of O 0 0.0004086403
BMC O 0 0.7420144
- O 0 0.0011240259
treated O 0 0.0015401066
epileptic B-Disease 2 0.99939096
animals O 0 0.00045945327
had O 0 0.00085520244
seizures B-Disease 2 0.999851
, O 0 0.0009268718
but O 0 0.00030771963
with O 0 0.0003314909
a O 0 0.0003120557
lower O 0 0.0002765605
frequency O 0 0.00036982473
and O 0 0.00038290798
duration O 0 0.000596455
compared O 0 0.00035477645
to O 0 0.0006987782
the O 0 0.0014780146
epileptic B-Disease 2 0.9975668
control O 0 0.002986843
group O 0 0.0058253836
. O 0 0.0057326835

The O 0 0.0032306795
density O 0 0.003747914
of O 0 0.0031163932
hippocampal O 0 0.76797086
neurons O 0 0.02832654
in O 0 0.0009968755
the O 0 0.0008245795
brains O 0 0.0015801108
of O 0 0.0009259145
animals O 0 0.00085029984
treated O 0 0.0017887402
with O 0 0.001999067
BMCs O 0 0.18433513
was O 0 0.002639636
markedly O 0 0.0093633225
preserved O 0 0.010919206
. O 0 0.0071645593

At O 0 0.004239316
hippocampal O 0 0.691365
Schaeffer O 0 0.2988945
collateral O 0 0.3185634
- O 0 0.009471566
CA1 O 0 0.98963964
synapses O 0 0.28817
, O 0 0.0014170225
long O 0 0.0010443281
- O 0 0.0011158665
term O 0 0.0008754168
potentiation O 0 0.7080261
was O 0 0.00073254196
preserved O 0 0.0013334283
in O 0 0.0007777373
BMC O 0 0.7341549
- O 0 0.0020657699
transplanted O 0 0.009805881
rats O 0 0.0034250435
compared O 0 0.00096966274
to O 0 0.00261856
epileptic B-Disease 2 0.99698013
controls O 0 0.011095514
. O 0 0.0069380766

The O 0 0.0035560434
donor O 0 0.0045897095
- O 0 0.0035199646
derived O 0 0.0017700485
GFP O 0 0.0047456003
( O 0 0.0022243327
+ O 0 0.0014386496
) O 0 0.0012643695
cells O 0 0.0010812114
were O 0 0.00058503787
rarely O 0 0.0009426892
found O 0 0.0005713832
in O 0 0.0005610024
the O 0 0.00076578103
brains O 0 0.0022381407
of O 0 0.0023472202
transplanted O 0 0.18145368
epileptic B-Disease 2 0.99816626
rats O 0 0.08402513
. O 0 0.007568067

In O 0 0.0029449682
conclusion O 0 0.0022117642
, O 0 0.0021563156
treatment O 0 0.0023688604
with O 0 0.0015221867
BMCs O 0 0.11994514
can O 0 0.0006461011
prevent O 0 0.0007065894
the O 0 0.00050424074
development O 0 0.0012663067
of O 0 0.0011825913
chronic O 0 0.9934669
seizures B-Disease 2 0.99991155
, O 0 0.0028455372
reduce O 0 0.00068405137
neuronal B-Disease 0 0.90670735
loss I-Disease 0 0.020224852
, O 0 0.00071596185
and O 0 0.0004361666
influence O 0 0.00040526767
the O 0 0.0005674455
reorganization O 0 0.007629791
of O 0 0.0014250475
the O 0 0.002008509
hippocampal O 0 0.93114054
neuronal O 0 0.68901813
network O 0 0.009633137
. O 0 0.006416908

Normalizing O 0 0.0118647255
effects O 0 0.0068391315
of O 0 0.006388078
modafinil B-Chemical 1 0.9983687
on O 0 0.0037555618
sleep O 0 0.5280948
in O 0 0.005758026
chronic O 0 0.9858531
cocaine B-Chemical 1 0.9983374
users O 0 0.23696767
. O 0 0.012501002

OBJECTIVE O 0 0.44763076
: O 0 0.0037071647
The O 0 0.0012678419
purpose O 0 0.0010985604
of O 0 0.0009048364
the O 0 0.0006298997
present O 0 0.00045109043
study O 0 0.00077568035
was O 0 0.0004126425
to O 0 0.00030740263
determine O 0 0.00016766647
the O 0 0.0002818994
effect O 0 0.00041100307
of O 0 0.0005775498
morning O 0 0.0077949944
- O 0 0.0012423216
dosed O 0 0.09624056
modafinil B-Chemical 1 0.99966466
on O 0 0.0004743675
sleep O 0 0.35004523
and O 0 0.0010316265
daytime B-Disease 0 0.57148886
sleepiness I-Disease 0 0.99591833
in O 0 0.002199164
chronic O 0 0.98930687
cocaine B-Chemical 1 0.99901617
users O 0 0.15924577
. O 0 0.0071993205

METHOD O 0 0.050638426
: O 0 0.005093807
Twenty O 0 0.007166122
cocaine B-Chemical 1 0.99735767
- O 0 0.0026662846
dependent O 0 0.0007761643
participants O 0 0.0006173265
were O 0 0.00038357198
randomly O 0 0.00020012086
assigned O 0 0.00031992287
to O 0 0.00034462576
receive O 0 0.00079864886
modafinil B-Chemical 1 0.99969184
, O 0 0.0010673449
400 O 0 0.0051777377
mg O 0 0.53247005
( O 0 0.0009887326
N O 0 0.670964
= O 0 0.00071932963
10 O 0 0.00033438217
) O 0 0.00044470496
, O 0 0.00030935244
or O 0 0.00023614865
placebo O 0 0.112274036
( O 0 0.00070147176
N O 0 0.6186484
= O 0 0.0005774262
10 O 0 0.00025584464
) O 0 0.00027860623
every O 0 9.3713985e-05
morning O 0 0.0005010049
at O 0 0.00012660598
7 O 0 0.00017731584
: O 0 0.00025955093
30 O 0 0.00015686176
a O 0 0.00021013578
. O 0 0.0001439802
m O 0 0.0006524653
. O 0 0.00013224273
for O 0 0.0001610862
16 O 0 0.00024114129
days O 0 0.00021718007
in O 0 0.00023680001
an O 0 0.00047766004
inpatient O 0 0.003152524
, O 0 0.00083032943
double O 0 0.00074545294
- O 0 0.0017772964
blind O 0 0.004792478
randomized O 0 0.0034899914
trial O 0 0.006662074
. O 0 0.005232159

Participants O 0 0.0039606704
underwent O 0 0.003067124
polysomnographic O 0 0.08499745
sleep O 0 0.13726722
recordings O 0 0.0033010882
on O 0 0.0005397602
days O 0 0.00060900825
1 O 0 0.00050807296
to O 0 0.00039215002
3 O 0 0.00035903015
, O 0 0.00042713783
7 O 0 0.0002592828
to O 0 0.00024896322
9 O 0 0.0002916402
, O 0 0.00031322858
and O 0 0.00026451537
14 O 0 0.00028818467
to O 0 0.00022692476
16 O 0 0.0003274126
( O 0 0.00034843016
first O 0 0.00023071999
, O 0 0.0004005393
second O 0 0.00036053712
, O 0 0.0005564876
and O 0 0.0005223321
third O 0 0.00077646825
weeks O 0 0.0010117168
of O 0 0.0023950804
abstinence O 0 0.8451085
) O 0 0.008444501
. O 0 0.0056726024

The O 0 0.003914526
Multiple O 0 0.012678384
Sleep O 0 0.21677712
Latency O 0 0.1361778
Test O 0 0.013329173
was O 0 0.0009764969
performed O 0 0.0006921171
at O 0 0.00049900135
11 O 0 0.00070224033
: O 0 0.0006869419
30 O 0 0.000362025
a O 0 0.00042327584
. O 0 0.00027829324
m O 0 0.0012051745
. O 0 0.0002526582
, O 0 0.00042527786
2 O 0 0.00033536818
: O 0 0.00049311004
00 O 0 0.002823662
p O 0 0.000453731
. O 0 0.00020492774
m O 0 0.0009770208
. O 0 0.00019615571
, O 0 0.00032973185
and O 0 0.0002823066
4 O 0 0.00024959305
: O 0 0.00036970046
30 O 0 0.00022183267
p O 0 0.0003651532
. O 0 0.00020739547
m O 0 0.0009113794
. O 0 0.00022650477
on O 0 0.00023582306
days O 0 0.00048114956
2 O 0 0.0006609572
, O 0 0.0009676836
8 O 0 0.0010024508
, O 0 0.0015822772
and O 0 0.0020933882
15 O 0 0.003050138
. O 0 0.0042485516

For O 0 0.0024297892
comparison O 0 0.0016905022
of O 0 0.0019335193
sleep O 0 0.16014755
architecture O 0 0.0025864793
variables O 0 0.0013240547
, O 0 0.00079222576
12 O 0 0.0003589205
healthy O 0 0.00093315064
comparison O 0 0.00024292972
participants O 0 0.0002909742
underwent O 0 0.00038984962
a O 0 0.00029424933
single O 0 0.00029728
night O 0 0.00069392874
of O 0 0.00040807595
experimental O 0 0.00069807627
polysomnography O 0 0.0027585167
that O 0 0.00039699808
followed O 0 0.00048536673
1 O 0 0.00084406073
night O 0 0.002078197
of O 0 0.0021152555
accommodation O 0 0.03236516
polysomnography O 0 0.033060316
. O 0 0.005875245

RESULTS O 0 0.03279818
: O 0 0.0058197
Progressive O 0 0.05715755
abstinence O 0 0.6551364
from O 0 0.0024705396
cocaine B-Chemical 1 0.997886
was O 0 0.0015616117
associated O 0 0.0014432383
with O 0 0.0014019895
worsening O 0 0.35857883
of O 0 0.0015533793
all O 0 0.0011769958
measured O 0 0.0014612094
polysomnographic O 0 0.33923188
sleep O 0 0.4287301
outcomes O 0 0.010926732
. O 0 0.0067559434

Compared O 0 0.0034342597
with O 0 0.0028858148
placebo O 0 0.14462386
, O 0 0.00319091
modafinil B-Chemical 1 0.999252
decreased O 0 0.0050912923
nighttime O 0 0.120483644
sleep O 0 0.4274868
latency O 0 0.0048158714
and O 0 0.0006341819
increased O 0 0.0009967558
slow O 0 0.0046971766
- O 0 0.0014829654
wave O 0 0.026120562
sleep O 0 0.26813605
time O 0 0.0008618222
in O 0 0.0015198388
cocaine B-Chemical 1 0.99847347
- O 0 0.0047659767
dependent O 0 0.0027279332
participants O 0 0.0048900163
. O 0 0.0055138795

The O 0 0.002695588
effect O 0 0.0023773387
of O 0 0.0026421254
modafinil B-Chemical 1 0.99920183
interacted O 0 0.0020372123
with O 0 0.0010683677
the O 0 0.00068029686
abstinence O 0 0.5124916
week O 0 0.00046796777
and O 0 0.00040139953
was O 0 0.00030530524
associated O 0 0.00037748835
with O 0 0.0003224328
longer O 0 0.00019155802
total O 0 0.00027752513
sleep O 0 0.066636264
time O 0 0.00025698318
and O 0 0.00035243807
shorter O 0 0.00047152757
REM O 0 0.98693943
sleep O 0 0.339541
latency O 0 0.0028507607
in O 0 0.0005020361
the O 0 0.0006133299
third O 0 0.0010522206
week O 0 0.0013987642
of O 0 0.0034985659
abstinence O 0 0.8423422
. O 0 0.0064755375

Comparison O 0 0.0033752997
of O 0 0.0029016247
slow O 0 0.00627961
- O 0 0.0029759575
wave O 0 0.018990345
sleep O 0 0.21935388
time O 0 0.0007216019
, O 0 0.0007503948
total O 0 0.00047669304
sleep O 0 0.092792645
time O 0 0.0003815184
, O 0 0.00052018574
and O 0 0.00042912582
sleep O 0 0.20986664
latency O 0 0.0047179796
in O 0 0.00047093013
cocaine B-Chemical 1 0.99949884
- O 0 0.0011133193
dependent O 0 0.00028662907
and O 0 0.00031874256
healthy O 0 0.0014067534
participants O 0 0.00024971776
revealed O 0 0.00025652148
a O 0 0.00031027902
normalizing O 0 0.000619758
effect O 0 0.0005904943
of O 0 0.0015183476
modafinil B-Chemical 1 0.99972636
in O 0 0.0029452886
cocaine B-Chemical 1 0.99922144
- O 0 0.005834382
dependent O 0 0.0025827752
participants O 0 0.0046268185
. O 0 0.0051060254

Modafinil B-Chemical 0 0.9981036
was O 0 0.0032360463
associated O 0 0.002183562
with O 0 0.0015046714
increased O 0 0.0019267502
daytime O 0 0.09172382
sleep O 0 0.43372473
latency O 0 0.0068069515
, O 0 0.00071061315
as O 0 0.0003127595
measured O 0 0.0002715652
by O 0 0.00037678657
the O 0 0.00041270803
Multiple O 0 0.018921642
Sleep O 0 0.47649303
Latency O 0 0.26613003
Test O 0 0.029015949
, O 0 0.000609142
and O 0 0.00044363143
a O 0 0.0004837432
nearly O 0 0.00052852597
significant O 0 0.0008320655
decrease O 0 0.0010971479
in O 0 0.0012939045
subjective O 0 0.023000162
daytime B-Disease 0 0.7239309
sleepiness I-Disease 0 0.99210256
. O 0 0.00719309

CONCLUSIONS O 0 0.795387
: O 0 0.007589845
Morning O 0 0.17790522
- O 0 0.0039368523
dosed O 0 0.0814809
modafinil B-Chemical 1 0.99929976
promotes O 0 0.0018115626
nocturnal O 0 0.5613048
sleep O 0 0.61005867
, O 0 0.0012624364
normalizes O 0 0.14115593
sleep O 0 0.5232035
architecture O 0 0.0028829551
, O 0 0.00082918967
and O 0 0.0006353547
decreases O 0 0.0013451339
daytime B-Disease 0 0.59607154
sleepiness I-Disease 0 0.99621874
in O 0 0.00254269
abstinent O 0 0.986634
cocaine B-Chemical 1 0.9984124
users O 0 0.08853713
. O 0 0.0069424175

These O 0 0.006167221
effects O 0 0.0054940134
may O 0 0.0030068946
be O 0 0.0024004148
relevant O 0 0.0021500906
in O 0 0.001732858
the O 0 0.002050197
treatment O 0 0.0053688106
of O 0 0.007915802
cocaine B-Chemical 1 0.99746406
dependence O 0 0.09108062
. O 0 0.012203022

Safety O 0 0.020796336
of O 0 0.0048261317
transesophageal O 0 0.29853693
echocardiography O 0 0.24824664
in O 0 0.0028877927
adults O 0 0.00497203
: O 0 0.0031101953
study O 0 0.002745527
in O 0 0.0022235585
a O 0 0.0036988822
multidisciplinary O 0 0.011271998
hospital O 0 0.021883134
. O 0 0.010034102

BACKGROUND O 0 0.77939105
: O 0 0.0063302983
TEE O 0 0.13134882
is O 0 0.0019630876
a O 0 0.0015772809
semi O 0 0.0038291935
- O 0 0.001704316
invasive O 0 0.0031915847
tool O 0 0.0009674715
broadly O 0 0.00063977926
used O 0 0.00044794742
and O 0 0.00049995596
its O 0 0.0009252521
utilization O 0 0.0012317431
associated O 0 0.00088396587
to O 0 0.0008046036
sedatives O 0 0.9961045
drugs O 0 0.6891686
might O 0 0.00071846205
to O 0 0.00077960675
affect O 0 0.0007922371
the O 0 0.0014711047
procedure O 0 0.0032305354
safety O 0 0.010211493
. O 0 0.005927958

OBJECTIVE O 0 0.48168957
: O 0 0.0039536776
to O 0 0.0014994665
analyze O 0 0.00086438376
aspects O 0 0.00091130286
of O 0 0.0010656249
TEE O 0 0.18163444
safety O 0 0.0024705648
associated O 0 0.0008041943
to O 0 0.00045062343
the O 0 0.00040362834
use O 0 0.00057672715
of O 0 0.0008744989
Midazolan B-Chemical 0 0.9245487
( O 0 0.0013953947
MZ B-Chemical 1 0.39099494
) O 0 0.0015585078
and O 0 0.0011570421
Flumazenil B-Chemical 1 0.99991715
( O 0 0.0027373428
FL B-Chemical 0 0.58530027
) O 0 0.0007798735
and O 0 0.0003292324
the O 0 0.0002645401
influence O 0 0.00028041942
of O 0 0.00049035775
the O 0 0.0004923201
clinical O 0 0.0032481286
variables O 0 0.0012672419
on O 0 0.00074447825
the O 0 0.0016069006
event O 0 0.0073115947
rate O 0 0.0044460404
. O 0 0.005950017

METHOD O 0 0.031068869
: O 0 0.0044351164
prospective O 0 0.004438952
study O 0 0.0023102632
with O 0 0.0016704553
137 O 0 0.003733953
patients O 0 0.0022186653
that O 0 0.000870192
underwent O 0 0.001777728
TEE O 0 0.18164328
with O 0 0.002116424
MZ B-Chemical 1 0.18383227
associated O 0 0.0031606175
to O 0 0.0030318089
moderate O 0 0.053767946
sedation O 0 0.82662046
. O 0 0.00836548

We O 0 0.002995717
analyzed O 0 0.0018930959
the O 0 0.0015509858
following O 0 0.0014588505
events O 0 0.0042728106
: O 0 0.0018946049
complications O 0 0.14445242
related O 0 0.000624151
with O 0 0.0007532692
the O 0 0.00069556775
topical O 0 0.89575505
anesthesia O 0 0.42512408
, O 0 0.0012429499
with O 0 0.0011223664
MZ B-Chemical 1 0.16104485
use O 0 0.0014970539
and O 0 0.0014700678
with O 0 0.0021365616
the O 0 0.0027110658
procedure O 0 0.005546865
. O 0 0.0061264187

Uni O 0 0.8872803
- O 0 0.0046348516
and O 0 0.0016748705
multivariate O 0 0.0037533913
analyses O 0 0.0015642414
were O 0 0.0007618005
used O 0 0.0005392714
to O 0 0.00042605834
test O 0 0.00045825128
the O 0 0.00034072172
influence O 0 0.00030927078
of O 0 0.00044686516
the O 0 0.00036115886
clinical O 0 0.003855336
variables O 0 0.0009465069
: O 0 0.00075101026
age O 0 0.0010256534
, O 0 0.00057852035
sex O 0 0.010279292
, O 0 0.001094471
stroke B-Disease 2 0.9978503
, O 0 0.0044076876
myocardiopathy B-Disease 0 0.99979
( O 0 0.0050372793
MP B-Disease 0 0.9492667
) O 0 0.0012575333
, O 0 0.00040392275
duration O 0 0.00037726478
of O 0 0.0003720169
the O 0 0.00032933473
test O 0 0.000574269
, O 0 0.0010716273
mitral B-Disease 2 0.98855025
regurgitation I-Disease 2 0.9991671
( O 0 0.006575967
MR B-Disease 2 0.9752618
) O 0 0.0026381775
and O 0 0.0016227352
the O 0 0.002329484
MZ B-Chemical 1 0.35073814
dose O 0 0.0959421
. O 0 0.007550395

RESULTS O 0 0.02508691
: O 0 0.0047808657
All O 0 0.002523105
patients O 0 0.003954806
( O 0 0.0023225767
65 O 0 0.0019041889
+ O 0 0.0016090163
/ O 0 0.0022143521
- O 0 0.0015166944
16 O 0 0.0009909457
yrs O 0 0.0029186737
; O 0 0.0013235222
58 O 0 0.0013917158
% O 0 0.001151924
males O 0 0.0017050835
) O 0 0.002413596
finished O 0 0.0037226425
the O 0 0.0029880304
examination O 0 0.008234236
. O 0 0.0070035793

The O 0 0.0027515758
mean O 0 0.0016857489
doses O 0 0.009037772
of O 0 0.0022942196
MZ B-Chemical 1 0.22439197
and O 0 0.0017731728
FL B-Chemical 0 0.3207258
were O 0 0.00081774505
4 O 0 0.0005279656
. O 0 0.0003174782
3 O 0 0.0003807964
+ O 0 0.0005588314
/ O 0 0.0009707827
- O 0 0.0006303176
1 O 0 0.00031631082
. O 0 0.00017199463
9 O 0 0.0002695059
mg O 0 0.043940537
and O 0 0.00033427568
0 O 0 0.00036694077
. O 0 0.00020237028
28 O 0 0.00047496497
+ O 0 0.0005761401
/ O 0 0.0011577223
- O 0 0.000923778
0 O 0 0.0006825162
. O 0 0.00048530984
2 O 0 0.0011032152
mg O 0 0.13697726
, O 0 0.003182086
respectively O 0 0.0062354654
. O 0 0.004920558

The O 0 0.0024584047
duration O 0 0.0023191057
of O 0 0.0017277036
the O 0 0.001104907
examination O 0 0.0015457445
and O 0 0.00080403074
the O 0 0.0005350811
mean O 0 0.0004049875
ejection O 0 0.3801332
fraction O 0 0.00084441906
( O 0 0.0011186423
EF O 0 0.50983423
) O 0 0.0008424585
were O 0 0.00034847285
16 O 0 0.000366246
. O 0 0.00019803912
4 O 0 0.00026999143
+ O 0 0.00042555932
/ O 0 0.0007700906
- O 0 0.00049964315
6 O 0 0.00020403633
. O 0 0.00015128871
1 O 0 0.00022390726
minutes O 0 0.00023881342
and O 0 0.00033147226
60 O 0 0.00056253106
+ O 0 0.0007995509
/ O 0 0.0016762047
- O 0 0.0015541317
9 O 0 0.0012035485
% O 0 0.0016936363
, O 0 0.0025935115
respectively O 0 0.0056763934
. O 0 0.0049285125

Mild O 0 0.9856758
hypoxia B-Disease 2 0.98771125
( O 0 0.00868539
SO2 O 0 0.9850537
< O 0 0.002097175
90 O 0 0.0011404358
% O 0 0.00093292666
) O 0 0.0008572775
was O 0 0.0004226037
the O 0 0.00036898025
most O 0 0.0006435322
common O 0 0.00076149486
event O 0 0.0028911834
( O 0 0.0006677916
11 O 0 0.00042913278
patients O 0 0.0012072035
) O 0 0.0006998505
; O 0 0.0005099628
3 O 0 0.00021626074
patients O 0 0.0007239667
( O 0 0.00037455792
2 O 0 0.00024000242
% O 0 0.00025790362
) O 0 0.00031168526
presented O 0 0.00025897796
transient O 0 0.022409609
hypoxia B-Disease 2 0.961004
due O 0 0.00023366013
to O 0 0.00027025357
upper O 0 0.0006650507
airway B-Disease 0 0.13142593
obstruction I-Disease 0 0.8217904
by O 0 0.00037846647
probe O 0 0.00030052237
introduction O 0 0.0003391019
and O 0 0.00034974952
8 O 0 0.0003266512
( O 0 0.00036914082
5 O 0 0.00022490197
. O 0 0.00016692774
8 O 0 0.00028063232
% O 0 0.00037754577
) O 0 0.0005286623
due O 0 0.00032887352
to O 0 0.00076276046
hypoxia B-Disease 2 0.9269983
caused O 0 0.0026057875
by O 0 0.0031921205
MZ B-Chemical 1 0.4595634
use O 0 0.0074390434
. O 0 0.0066462983

Transient O 0 0.8960123
hypotension B-Disease 2 0.9985189
( O 0 0.014623035
SAP O 0 0.84191525
< O 0 0.00380721
90mmHg O 0 0.2414514
) O 0 0.0020673256
occurred O 0 0.0011918519
in O 0 0.0008641469
1 O 0 0.0010114844
patient O 0 0.0016717927
( O 0 0.0016565936
0 O 0 0.0014624058
. O 0 0.0011118705
7 O 0 0.0018585101
% O 0 0.0032359266
) O 0 0.005775308
. O 0 0.0056823757

The O 0 0.002619159
multivariate O 0 0.0058164783
analysis O 0 0.0027565132
showed O 0 0.0016045603
that O 0 0.0013910944
severe O 0 0.2706599
MR B-Disease 2 0.9883513
, O 0 0.004126721
MP B-Disease 0 0.9495341
( O 0 0.0024710523
EF O 0 0.53736657
< O 0 0.00075067935
45 O 0 0.00041852606
% O 0 0.00041233128
) O 0 0.00044807125
and O 0 0.00027994424
high O 0 0.00042823784
doses O 0 0.010546318
of O 0 0.0007985797
MZ B-Chemical 1 0.52756065
( O 0 0.001238877
> O 0 0.0018170669
5mg O 0 0.9765951
) O 0 0.0009018308
were O 0 0.00037606384
associated O 0 0.00059378083
with O 0 0.00078066904
events O 0 0.0059131146
( O 0 0.0012814195
p O 0 0.0013585315
< O 0 0.0013825365
0 O 0 0.0015216141
. O 0 0.0015690222
001 O 0 0.13111538
) O 0 0.0067668245
. O 0 0.005760855

The O 0 0.0039225216
EF O 0 0.20572884
was O 0 0.0021393267
40 O 0 0.0017419943
% O 0 0.0012551969
, O 0 0.00092941016
in O 0 0.00050676684
the O 0 0.00047503237
group O 0 0.00066151074
with O 0 0.0007782487
MP B-Disease 0 0.74505454
and O 0 0.0006984227
44 O 0 0.00077756896
% O 0 0.00037448612
in O 0 0.00021309529
the O 0 0.00023527643
group O 0 0.0003872311
with O 0 0.00051362836
severe O 0 0.23096858
MR B-Disease 2 0.9792739
and O 0 0.00060580403
it O 0 0.00044620963
can O 0 0.00027726803
be O 0 0.00031816083
a O 0 0.00037680147
factor O 0 0.0016976674
associated O 0 0.00070167176
with O 0 0.00077922613
clinical O 0 0.009460197
events O 0 0.0051574255
in O 0 0.00094286294
the O 0 0.0012500808
last O 0 0.0018039029
group O 0 0.0045131333
. O 0 0.005190161

CONCLUSION O 0 0.8040787
: O 0 0.008105153
TEE O 0 0.10229776
with O 0 0.004145405
sedation O 0 0.35341722
presents O 0 0.0038864699
a O 0 0.0028503335
low O 0 0.0033662524
rate O 0 0.0036360954
of O 0 0.006990347
events O 0 0.0336722
. O 0 0.010658634

There O 0 0.0061587133
were O 0 0.0029132525
no O 0 0.0021149255
severe O 0 0.029361939
events O 0 0.005351925
and O 0 0.0016076245
there O 0 0.00094283285
was O 0 0.0012062662
no O 0 0.0010766172
need O 0 0.0013094597
to O 0 0.0017790807
interrupt O 0 0.004022956
the O 0 0.0038738267
examinations O 0 0.013791694
. O 0 0.008197378

Effect O 0 0.0072047417
of O 0 0.0033965446
direct O 0 0.0027402784
intracoronary O 0 0.89901054
administration O 0 0.27166256
of O 0 0.0036909832
methylergonovine B-Chemical 0 0.9986206
in O 0 0.0018229383
patients O 0 0.00414622
with O 0 0.0019587465
and O 0 0.0022857755
without O 0 0.003755282
variant B-Disease 2 0.12801072
angina I-Disease 2 0.99912137
. O 0 0.014336349

The O 0 0.0028070693
effects O 0 0.003156041
of O 0 0.002300526
intracoronary O 0 0.9076012
administration O 0 0.258703
of O 0 0.0023808763
methylergonovine B-Chemical 0 0.99905807
were O 0 0.0009037093
studied O 0 0.00076960423
in O 0 0.00036303626
21 O 0 0.0004755471
patients O 0 0.00081721606
with O 0 0.0005065386
variant B-Disease 2 0.016136875
angina I-Disease 2 0.9998776
and O 0 0.00080815406
22 O 0 0.0006393857
patients O 0 0.0009813763
with O 0 0.00047819765
atypical O 0 0.16199632
chest B-Disease 0 0.50854874
pain I-Disease 0 0.9752975
and O 0 0.0006407339
in O 0 0.00045093868
others O 0 0.0016506974
without O 0 0.001701286
angina B-Disease 0 0.999762
pectoris I-Disease 0 0.9997737
( O 0 0.005196911
control O 0 0.0019580473
group O 0 0.0038573563
) O 0 0.0066860644
. O 0 0.0053155795

Methylergonovine B-Chemical 0 0.78645515
was O 0 0.0032219621
administered O 0 0.0038555355
continuously O 0 0.0018973821
at O 0 0.000784127
a O 0 0.00093625434
rate O 0 0.0007784458
of O 0 0.0011113039
10 O 0 0.0012630473
micrograms O 0 0.108230546
/ O 0 0.0025335706
min O 0 0.0017917227
up O 0 0.0013809628
to O 0 0.0018796846
50 O 0 0.0047856807
micrograms O 0 0.18128185
. O 0 0.006589235

In O 0 0.0029044016
all O 0 0.0019359757
patients O 0 0.003435192
with O 0 0.0021674477
variant B-Disease 2 0.036505736
angina I-Disease 2 0.9997706
, O 0 0.013646749
coronary B-Disease 2 0.9941351
spasm I-Disease 2 0.9997557
was O 0 0.0012483912
provoked O 0 0.017663997
at O 0 0.0002782967
a O 0 0.0003358132
mean O 0 0.00021175285
dose O 0 0.0023311225
of O 0 0.000539983
28 O 0 0.0007146151
+ O 0 0.00064592285
/ O 0 0.0011594815
- O 0 0.00078173215
13 O 0 0.0006357805
micrograms O 0 0.082788974
( O 0 0.0008601155
mean O 0 0.000594387
+ O 0 0.0015792443
/ O 0 0.0037711062
- O 0 0.0043038265
SD O 0 0.044244982
) O 0 0.006867598
. O 0 0.0055102147

In O 0 0.0038569954
the O 0 0.0027290352
control O 0 0.0022173706
group O 0 0.002922491
neither O 0 0.0039036237
ischemic O 0 0.9971143
ST O 0 0.92247534
change O 0 0.0038279078
nor O 0 0.0035997615
localized O 0 0.008187434
spasm B-Disease 2 0.99675626
occurred O 0 0.019042114
. O 0 0.010099678

The O 0 0.0035779215
basal O 0 0.005593393
tone O 0 0.092028834
of O 0 0.002245094
the O 0 0.0014777065
right O 0 0.00322546
coronary O 0 0.59536356
artery O 0 0.27493644
was O 0 0.0008822855
significantly O 0 0.0008300446
lower O 0 0.0006399253
than O 0 0.00046270058
that O 0 0.0006109803
of O 0 0.001281056
the O 0 0.0017284637
left O 0 0.007861774
coronary O 0 0.8214665
artery O 0 0.6470889
. O 0 0.008020992

The O 0 0.0027970567
percentage O 0 0.001556811
of O 0 0.0026439854
vasoconstriction O 0 0.9943356
of O 0 0.0022156255
the O 0 0.001242041
right O 0 0.003141904
coronary O 0 0.6625381
artery O 0 0.303199
was O 0 0.00073033525
significantly O 0 0.00069571397
higher O 0 0.0005376867
than O 0 0.00040731038
that O 0 0.0005513586
of O 0 0.0011807014
the O 0 0.0016110076
left O 0 0.0075936522
coronary O 0 0.8205409
artery O 0 0.6448649
. O 0 0.0077381735

These O 0 0.004174165
results O 0 0.0021447039
suggest O 0 0.0015649786
that O 0 0.0019021707
spasm B-Disease 2 0.9979722
provocation O 0 0.7523724
tests O 0 0.004450976
, O 0 0.0010973461
which O 0 0.0007338913
use O 0 0.0005940933
an O 0 0.0006376893
intracoronary O 0 0.8514459
injection O 0 0.0029408576
of O 0 0.00044157752
a O 0 0.00033763194
relatively O 0 0.00037459133
low O 0 0.00043003447
dose O 0 0.010952999
of O 0 0.0009263667
methylergonovine B-Chemical 0 0.99957293
, O 0 0.00078167557
have O 0 0.00031273894
a O 0 0.0002964366
high O 0 0.0003833563
sensitivity O 0 0.0011210052
in O 0 0.00032656715
variant B-Disease 2 0.020433469
angina I-Disease 2 0.9999076
and O 0 0.0008445937
the O 0 0.0004759965
vasoreactivity O 0 0.99383116
of O 0 0.0005907971
the O 0 0.00038682474
right O 0 0.0018846277
coronary O 0 0.6802444
artery O 0 0.28122374
may O 0 0.00042441094
be O 0 0.00033452982
greater O 0 0.00031911352
than O 0 0.0002543981
that O 0 0.00037294082
of O 0 0.00084428996
the O 0 0.0011414369
other O 0 0.002499091
coronary O 0 0.87883365
arteries O 0 0.8590188
. O 0 0.0071008448

Oral O 0 0.86768997
manifestations O 0 0.6265398
of O 0 0.008078203
" O 0 0.009625998
meth B-Disease 2 0.9945221
mouth I-Disease 2 0.68349093
" O 0 0.0074087414
: O 0 0.0066247247
a O 0 0.00534244
case O 0 0.006983274
report O 0 0.018771138
. O 0 0.011648766

AIM O 0 0.24802145
: O 0 0.004114741
The O 0 0.0014047353
aim O 0 0.00120385
of O 0 0.0010019357
the O 0 0.0007298774
documentation O 0 0.0011215959
of O 0 0.00070027553
this O 0 0.0005219827
clinical O 0 0.0035387336
case O 0 0.00053759216
is O 0 0.0003822294
to O 0 0.00030563786
make O 0 0.00036717995
clinicians O 0 0.0007377674
aware O 0 0.00048139636
of O 0 0.0005907853
" O 0 0.0010443203
meth B-Disease 2 0.9985832
mouth I-Disease 2 0.52502286
" O 0 0.0007720944
and O 0 0.0004759403
the O 0 0.00044634214
medical O 0 0.0041353665
risks O 0 0.009890646
associated O 0 0.0014470698
with O 0 0.0016302958
this O 0 0.0021335953
serious O 0 0.19080213
condition O 0 0.012270994
. O 0 0.00624845

BACKGROUND O 0 0.9096511
: O 0 0.013452492
Methamphetamine B-Chemical 1 0.99856746
is O 0 0.0025386186
a O 0 0.0016454785
very O 0 0.001832021
addictive O 0 0.95913106
, O 0 0.001365297
powerful O 0 0.0037780902
stimulant O 0 0.9645162
that O 0 0.0005024662
increases O 0 0.0007141549
wakefulness O 0 0.8232016
and O 0 0.0004747703
physical O 0 0.006383643
activity O 0 0.00051149726
and O 0 0.0003070087
can O 0 0.00021378885
produce O 0 0.00023094735
other O 0 0.0002890195
effects O 0 0.0007262909
such O 0 0.0004293351
as O 0 0.0005571497
cardiac B-Disease 0 0.96675414
dysrhythmias I-Disease 0 0.99989474
, O 0 0.026491588
hypertension B-Disease 2 0.9996954
, O 0 0.026485136
hallucinations B-Disease 2 0.99965465
, O 0 0.0044866847
and O 0 0.004075503
violent B-Disease 0 0.9795051
behavior I-Disease 0 0.12833211
. O 0 0.0067696935

Dental O 0 0.013068323
patients O 0 0.008994877
abusing O 0 0.85498524
methamphetamine B-Chemical 1 0.99891746
can O 0 0.0016029098
present O 0 0.0007990375
with O 0 0.0010470434
poor O 0 0.0031851244
oral O 0 0.3378117
hygiene O 0 0.031890552
, O 0 0.0030070923
xerostomia B-Disease 0 0.998607
, O 0 0.0020619154
rampant O 0 0.065593936
caries B-Disease 0 0.9859672
( O 0 0.002184123
" O 0 0.0018232212
meth B-Disease 2 0.99808156
mouth I-Disease 2 0.6426094
" O 0 0.0022201503
) O 0 0.0022581492
, O 0 0.0017630241
and O 0 0.0020211095
excessive O 0 0.054182794
tooth B-Disease 0 0.076441154
wear I-Disease 0 0.15686816
. O 0 0.0079335235

Oral O 0 0.67892706
rehabilitation O 0 0.015918711
of O 0 0.0063113556
patients O 0 0.010787065
using O 0 0.006628601
methamphetamine B-Chemical 1 0.9970873
can O 0 0.007946268
be O 0 0.008291583
challenging O 0 0.0137024885
. O 0 0.012046768

CASE O 0 0.9306664
DESCRIPTION O 0 0.37877104
: O 0 0.0056751817
A O 0 0.0081734555
30 O 0 0.0017370087
- O 0 0.0017839787
year O 0 0.0010946307
- O 0 0.0012914053
old O 0 0.0009295075
Caucasian O 0 0.063351095
woman O 0 0.0051272106
presented O 0 0.00069849915
with O 0 0.00084028015
dental O 0 0.0033984673
pain B-Disease 0 0.97087526
, O 0 0.0015499243
bad B-Disease 0 0.09410079
breath I-Disease 0 0.827511
, O 0 0.0016748769
and O 0 0.0012671629
self O 0 0.007067077
- O 0 0.0031347508
reported O 0 0.0034538975
poor O 0 0.010489986
esthetics O 0 0.20154585
. O 0 0.007076717

A O 0 0.011455014
comprehensive O 0 0.0030917784
examination O 0 0.00274691
including O 0 0.0014064908
her O 0 0.001715623
medical O 0 0.0053289845
history O 0 0.013982417
, O 0 0.0015131243
panoramic O 0 0.050507765
radiograph O 0 0.06445005
, O 0 0.000852146
and O 0 0.00050861225
intraoral O 0 0.0019172664
examination O 0 0.00085501216
revealed O 0 0.0005763551
19 O 0 0.0012003445
carious B-Disease 0 0.30005276
lesions I-Disease 0 0.66061854
, O 0 0.000894184
which O 0 0.0006761924
is O 0 0.0004690677
not O 0 0.0004449937
very O 0 0.00074199814
common O 0 0.0012314275
for O 0 0.0010358302
a O 0 0.0023155448
healthy O 0 0.01266133
adult O 0 0.00639949
. O 0 0.005394006

She O 0 0.006153053
reported O 0 0.003151301
her O 0 0.00241949
use O 0 0.0017592482
of O 0 0.0018558998
methamphetamine B-Chemical 1 0.9988753
for O 0 0.000862141
five O 0 0.00045685473
years O 0 0.00095081277
and O 0 0.00047382896
had O 0 0.00044376234
not O 0 0.00038260946
experienced O 0 0.0007762834
any O 0 0.0004037482
major O 0 0.00089190144
carious B-Disease 0 0.28201908
episodes I-Disease 0 0.36875814
before O 0 0.00053482945
she O 0 0.0010521966
started O 0 0.0016677583
using O 0 0.0015265326
the O 0 0.003009529
drug O 0 0.37626737
. O 0 0.007134914

SUMMARY O 0 0.0552476
: O 0 0.0039677555
The O 0 0.0015000341
patient O 0 0.0018940279
' O 0 0.0013210172
s O 0 0.0011055503
medical O 0 0.0023693792
and O 0 0.0006958333
dental O 0 0.0010959932
histories O 0 0.0011600307
along O 0 0.0004331923
with O 0 0.00049886294
radiographic O 0 0.017290037
and O 0 0.00046339005
clinical O 0 0.0052234107
findings O 0 0.0014190963
lead O 0 0.006096574
to O 0 0.0003177462
a O 0 0.00039345067
diagnosis O 0 0.0039312695
of O 0 0.00060990226
" O 0 0.0009963177
meth B-Disease 2 0.9989611
mouth I-Disease 2 0.59708124
. O 0 0.00024665767
" O 0 0.00029450248
Although O 0 0.0001706839
three O 0 9.746925e-05
different O 0 0.00020124693
dental O 0 0.0006172745
treatment O 0 0.00083244464
modalities O 0 0.0064889207
( O 0 0.00043828532
either O 0 0.0002078827
conventional O 0 0.00033937098
or O 0 0.00024121944
implant O 0 0.0062463246
- O 0 0.00057840924
supported O 0 0.00035007743
) O 0 0.00046500753
have O 0 0.00025052522
been O 0 0.00028819704
offered O 0 0.0003393681
to O 0 0.00021364559
the O 0 0.0002255335
patient O 0 0.00047724138
since O 0 0.0002530625
August O 0 0.0005143501
2007 O 0 0.00071844936
, O 0 0.00039755975
the O 0 0.00033139516
patient O 0 0.0007871531
has O 0 0.00067663647
yet O 0 0.0011448223
to O 0 0.00089269085
initiate O 0 0.0013199754
any O 0 0.0020878096
treatment O 0 0.008114862
. O 0 0.0058657164

CLINICAL O 0 0.14284253
SIGNIFICANCE O 0 0.05829193
: O 0 0.0034305556
This O 0 0.0020549567
clinical O 0 0.003404814
case O 0 0.0010872906
showing O 0 0.0010716256
oral O 0 0.29244134
manifestations O 0 0.78586173
of O 0 0.0026906966
meth B-Disease 2 0.99911433
mouth I-Disease 2 0.6607341
was O 0 0.0006447785
presented O 0 0.00049257005
to O 0 0.00037774627
help O 0 0.0005689942
dental O 0 0.0010021725
practitioners O 0 0.00084408035
recognize O 0 0.00048151202
and O 0 0.0005851017
manage O 0 0.0014852675
patients O 0 0.0025343974
who O 0 0.0025878523
may O 0 0.0016832959
be O 0 0.0033819086
abusing O 0 0.968228
methamphetamines B-Chemical 0 0.9987747
. O 0 0.01057226

Dental O 0 0.011322829
practitioners O 0 0.0042969263
also O 0 0.001816503
may O 0 0.0012143134
be O 0 0.00092521036
skeptical O 0 0.0017079519
about O 0 0.00051963143
the O 0 0.0004420332
reliability O 0 0.00049831235
of O 0 0.0005394234
appointment O 0 0.0012394676
keeping O 0 0.0005766431
by O 0 0.00045472232
these O 0 0.00063908723
patients O 0 0.0018501846
, O 0 0.00063584297
as O 0 0.00035760895
they O 0 0.0004403237
frequently O 0 0.0010056668
miss O 0 0.0019530925
their O 0 0.0010788676
appointments O 0 0.00420231
without O 0 0.0018330853
reasonable O 0 0.002825755
justification O 0 0.008240345
. O 0 0.0058820997

Antituberculosis B-Chemical 0 0.97801197
therapy O 0 0.14658964
- O 0 0.006414324
induced O 0 0.00416643
acute B-Disease 2 0.98195803
liver I-Disease 2 0.9781406
failure I-Disease 2 0.953946
: O 0 0.002825634
magnitude O 0 0.0009974218
, O 0 0.0011410172
profile O 0 0.0012911605
, O 0 0.0015720116
prognosis O 0 0.5125692
, O 0 0.0017745518
and O 0 0.0014417911
predictors O 0 0.0018406432
of O 0 0.0036754536
outcome O 0 0.011023734
. O 0 0.0066922936

Antituberculosis B-Chemical 0 0.97375184
therapy O 0 0.12350548
( O 0 0.006709012
ATT O 0 0.675108
) O 0 0.004424753
- O 0 0.0024216683
associated O 0 0.0020252015
acute B-Disease 2 0.981584
liver I-Disease 2 0.9829517
failure I-Disease 2 0.97772425
( O 0 0.0074101156
ATT O 0 0.8757318
- O 0 0.007438238
ALF B-Disease 2 0.9989697
) O 0 0.0026695847
is O 0 0.0006981283
the O 0 0.000739654
commonest O 0 0.2012629
drug O 0 0.7399257
- O 0 0.0053209756
induced O 0 0.006033334
ALF B-Disease 2 0.9977718
in O 0 0.004999575
South O 0 0.03076175
Asia O 0 0.12484151
. O 0 0.007156972

Prospective O 0 0.059747063
studies O 0 0.011422801
on O 0 0.0075775706
ATT O 0 0.6178788
- O 0 0.024755955
ALF B-Disease 2 0.9882902
are O 0 0.0145422
lacking O 0 0.011718523
. O 0 0.015730485

The O 0 0.002505592
current O 0 0.0026287741
study O 0 0.002003259
prospectively O 0 0.0019479905
evaluated O 0 0.0008957863
the O 0 0.00074436114
magnitude O 0 0.0007603072
, O 0 0.00092471414
clinical O 0 0.0030218083
course O 0 0.001300502
, O 0 0.0010216604
outcome O 0 0.0016249808
, O 0 0.00096726883
and O 0 0.0008784889
prognostic O 0 0.0047914023
factors O 0 0.0046790773
in O 0 0.0028067743
ATT O 0 0.80805475
- O 0 0.026453897
ALF B-Disease 2 0.9949168
. O 0 0.011384624

From O 0 0.005693776
January O 0 0.0032741274
1986 O 0 0.005686182
to O 0 0.0016437427
January O 0 0.001556582
2009 O 0 0.002426294
, O 0 0.0012093298
1223 O 0 0.010077301
consecutive O 0 0.0012397256
ALF B-Disease 2 0.9967655
patients O 0 0.00376808
were O 0 0.00059563096
evaluated O 0 0.00058724626
: O 0 0.0010369897
ATT O 0 0.24647011
alone O 0 0.000669966
was O 0 0.00046142485
the O 0 0.00043250463
cause O 0 0.0013192847
in O 0 0.0005075417
70 O 0 0.0008051992
( O 0 0.0008528665
5 O 0 0.0005925688
. O 0 0.00054043386
7 O 0 0.00093439437
% O 0 0.0016381487
) O 0 0.0030377484
patients O 0 0.006533506
. O 0 0.0052803215

Another O 0 0.007548605
15 O 0 0.0032371418
( O 0 0.0031416398
1 O 0 0.001790229
. O 0 0.0010663759
2 O 0 0.0012165316
% O 0 0.0013738946
) O 0 0.0016489193
had O 0 0.0015220895
ATT O 0 0.2530379
and O 0 0.0029571196
simultaneous O 0 0.062263835
hepatitis B-Disease 2 0.99948335
virus I-Disease 0 0.9036303
infection I-Disease 2 0.9628029
. O 0 0.013969641

In O 0 0.0038720914
44 O 0 0.004074688
( O 0 0.0027124302
62 O 0 0.0024840154
. O 0 0.00088801555
8 O 0 0.0008827741
% O 0 0.00091674423
) O 0 0.0010445779
patients O 0 0.0015433863
, O 0 0.0010464406
ATT O 0 0.22032516
was O 0 0.0008002883
prescribed O 0 0.014124464
empirically O 0 0.0019692536
without O 0 0.001165479
definitive O 0 0.0025645653
evidence O 0 0.0026120974
of O 0 0.0054291235
tuberculosis B-Disease 2 0.8722598
. O 0 0.009325115

ATT O 0 0.63611364
- O 0 0.009895401
ALF B-Disease 2 0.99363035
patients O 0 0.008272657
were O 0 0.0017448664
younger O 0 0.00984179
( O 0 0.0013482415
32 O 0 0.0010907827
. O 0 0.00043247972
87 O 0 0.0011677941
[ O 0 0.0013760476
+ O 0 0.0007314998
/ O 0 0.0011188543
- O 0 0.0006599193
15 O 0 0.00028401738
. O 0 0.00019210657
8 O 0 0.00029641233
] O 0 0.00057714235
years O 0 0.0005914642
) O 0 0.0005618059
, O 0 0.0004345385
and O 0 0.0004121006
49 O 0 0.00080441096
( O 0 0.0006130417
70 O 0 0.0006415151
% O 0 0.00073619623
) O 0 0.0010413725
of O 0 0.0012188216
them O 0 0.0025954177
were O 0 0.0029384703
women O 0 0.022710465
. O 0 0.0059946016

Most O 0 0.008672125
had O 0 0.003914584
hyperacute O 0 0.909226
presentation O 0 0.028039368
; O 0 0.003187305
the O 0 0.0011753757
median O 0 0.0016794074
icterus B-Disease 0 0.9985304
encephalopathy B-Disease 2 0.9996244
interval O 0 0.0038233027
was O 0 0.0008739603
4 O 0 0.0006277053
. O 0 0.00044796386
5 O 0 0.00061630807
( O 0 0.0009959671
0 O 0 0.0010988938
- O 0 0.0016933952
30 O 0 0.0014286382
) O 0 0.0029197647
days O 0 0.0032996957
. O 0 0.0047893384

The O 0 0.0031775874
median O 0 0.0023475597
duration O 0 0.0025965576
of O 0 0.0027119038
ATT O 0 0.2761404
before O 0 0.0016760493
ALF B-Disease 2 0.9953348
was O 0 0.0022579224
30 O 0 0.0016660588
( O 0 0.0021069762
7 O 0 0.0016195162
- O 0 0.0028915105
350 O 0 0.004347201
) O 0 0.004498867
days O 0 0.0044624005
. O 0 0.006045834

At O 0 0.0031276927
presentation O 0 0.007669303
, O 0 0.0037782714
advanced O 0 0.14818366
encephalopathy B-Disease 2 0.9993563
and O 0 0.004600724
cerebral B-Disease 0 0.98466265
edema I-Disease 0 0.99901414
were O 0 0.0009756822
present O 0 0.00043186033
in O 0 0.00044611396
51 O 0 0.0008958845
( O 0 0.000595851
76 O 0 0.00073112664
% O 0 0.00047152553
) O 0 0.0005517211
and O 0 0.000418964
29 O 0 0.00089454185
( O 0 0.000633193
41 O 0 0.00088741793
. O 0 0.0003605976
4 O 0 0.000548091
% O 0 0.00091902073
) O 0 0.0015494677
patients O 0 0.0032022747
, O 0 0.0033648866
respectively O 0 0.006877538
. O 0 0.0053427313

Gastrointestinal B-Disease 0 0.9183035
bleed I-Disease 0 0.84153014
, O 0 0.0096901
seizures B-Disease 2 0.99928206
, O 0 0.0065867384
infection B-Disease 2 0.39932603
, O 0 0.0017133988
and O 0 0.0011364359
acute B-Disease 0 0.9418572
renal I-Disease 0 0.99654007
failure I-Disease 0 0.8375536
were O 0 0.0006808822
documented O 0 0.00084814656
in O 0 0.00031263015
seven O 0 0.00035696736
( O 0 0.00047885653
10 O 0 0.00032317755
% O 0 0.0003236305
) O 0 0.0003960812
, O 0 0.0002781341
five O 0 0.00017150464
( O 0 0.0003638068
7 O 0 0.00021486988
. O 0 0.00014712618
1 O 0 0.0002399027
% O 0 0.00028330233
) O 0 0.0003803854
, O 0 0.00031264566
26 O 0 0.0003917842
( O 0 0.00032290377
37 O 0 0.00037302246
. O 0 0.00017353041
1 O 0 0.00028404014
% O 0 0.00034176125
) O 0 0.0004599162
, O 0 0.00037997472
and O 0 0.0003618149
seven O 0 0.0004638375
( O 0 0.0007656661
10 O 0 0.00069962116
% O 0 0.00093082804
) O 0 0.0015351351
patients O 0 0.0031805206
, O 0 0.0032818879
respectively O 0 0.006762592
. O 0 0.005206567

Compared O 0 0.005503294
with O 0 0.007959258
hepatitis B-Disease 2 0.9995504
E I-Disease 0 0.9964516
virus O 0 0.56929773
( O 0 0.0059542805
HEV O 0 0.8845368
) O 0 0.0023771892
and O 0 0.0009346744
non O 0 0.002046128
- O 0 0.0017701724
A O 0 0.014300822
non O 0 0.0026733554
- O 0 0.003031803
E O 0 0.9418411
- O 0 0.0021727495
induced O 0 0.0019506083
ALF B-Disease 2 0.9993449
, O 0 0.004039961
ATT O 0 0.86494046
- O 0 0.0037229501
ALF B-Disease 2 0.9990464
patients O 0 0.0047145863
had O 0 0.0003724374
nearly O 0 0.0003090574
similar O 0 0.00022428331
presentations O 0 0.001579746
except O 0 0.00026431927
for O 0 0.00033291703
older O 0 0.0014625435
age O 0 0.0010943959
and O 0 0.00072133006
less O 0 0.001105434
elevation O 0 0.18370119
of O 0 0.0041709193
liver O 0 0.92587763
enzymes O 0 0.45088094
. O 0 0.008097424

The O 0 0.0033761633
mortality O 0 0.025428062
rate O 0 0.0018832056
among O 0 0.0017291452
patients O 0 0.0030326769
with O 0 0.0018451806
ATT O 0 0.77427226
- O 0 0.0047444203
ALF B-Disease 2 0.9983829
was O 0 0.00094398524
high O 0 0.00096725684
( O 0 0.00078603625
67 O 0 0.00085837196
. O 0 0.00024342288
1 O 0 0.00032347842
% O 0 0.00033079545
, O 0 0.00032064258
n O 0 0.00025169263
= O 0 0.00042463533
47 O 0 0.0005309555
) O 0 0.00045766108
, O 0 0.00032120926
and O 0 0.00026566384
only O 0 0.000293555
23 O 0 0.0005615489
( O 0 0.00043682466
32 O 0 0.00049434096
. O 0 0.0002203083
9 O 0 0.00036090778
% O 0 0.0004615737
) O 0 0.0006741902
patients O 0 0.0011233564
recovered O 0 0.000774313
with O 0 0.0017621608
medical O 0 0.018143713
treatment O 0 0.011401665
. O 0 0.006127786

In O 0 0.002485373
multivariate O 0 0.0050747595
analysis O 0 0.002390598
, O 0 0.0014238178
three O 0 0.0005313615
factors O 0 0.0014534731
independently O 0 0.000635567
predicted O 0 0.00065470935
mortality O 0 0.17859839
: O 0 0.001940809
serum O 0 0.25900602
bilirubin B-Chemical 1 0.9993523
( O 0 0.0021045494
> O 0 0.0011231579
or O 0 0.00030804717
= O 0 0.0004909945
10 O 0 0.00026527757
. O 0 0.00015050797
8 O 0 0.00025410042
mg O 0 0.11278561
/ O 0 0.0010742135
dL O 0 0.025130227
) O 0 0.00059882546
, O 0 0.00042817704
prothrombin O 0 0.5804009
time O 0 0.00036084963
( O 0 0.00067599036
PT O 0 0.03461794
) O 0 0.0009094727
prolongation O 0 0.106736325
( O 0 0.0007036458
> O 0 0.00071370485
or O 0 0.00026702264
= O 0 0.0004884876
26 O 0 0.000407782
seconds O 0 0.00036897938
) O 0 0.0005927504
, O 0 0.0005425127
and O 0 0.00065539737
grade O 0 0.11261909
III O 0 0.033816215
/ O 0 0.006731018
IV O 0 0.46614048
encephalopathy B-Disease 2 0.99899596
at O 0 0.0036036957
presentation O 0 0.045662973
. O 0 0.007351266

CONCLUSION O 0 0.8901715
: O 0 0.009429334
ATT O 0 0.54819
- O 0 0.006543275
ALF B-Disease 2 0.9945891
constituted O 0 0.0034329642
5 O 0 0.0010675519
. O 0 0.00055289455
7 O 0 0.0005333603
% O 0 0.0005783207
of O 0 0.00077129214
ALF B-Disease 2 0.9954882
at O 0 0.00051779853
our O 0 0.00052931096
center O 0 0.00074663316
and O 0 0.0008474078
had O 0 0.0010957291
a O 0 0.001637952
high O 0 0.0031591437
mortality O 0 0.1710613
rate O 0 0.005934973
. O 0 0.0070658755

Because O 0 0.0032675737
the O 0 0.002494845
mortality O 0 0.033086702
rate O 0 0.001602282
is O 0 0.0011869665
so O 0 0.00087861775
high O 0 0.0011586944
, O 0 0.00103773
determining O 0 0.0006187022
which O 0 0.0011207088
factors O 0 0.002264699
are O 0 0.0011859315
predictors O 0 0.0013690137
is O 0 0.0018287314
less O 0 0.002611727
important O 0 0.003984879
. O 0 0.0060559115

A O 0 0.012526456
high O 0 0.0032053646
proportion O 0 0.001665387
of O 0 0.0019649756
patients O 0 0.0032546946
had O 0 0.0016720956
consumed O 0 0.012434736
ATT O 0 0.47333756
empirically O 0 0.00484638
, O 0 0.0021048046
which O 0 0.0019839148
could O 0 0.001467502
have O 0 0.0027382306
been O 0 0.005252151
prevented O 0 0.014657813
. O 0 0.008597036

Design O 0 0.076106556
and O 0 0.0031306944
analysis O 0 0.0025423756
of O 0 0.001855414
the O 0 0.0014652064
HYPREN O 0 0.14509255
- O 0 0.0020848033
trial O 0 0.0018488236
: O 0 0.0010752109
safety O 0 0.0018080581
of O 0 0.0012043908
enalapril B-Chemical 1 0.99987197
and O 0 0.0035869805
prazosin B-Chemical 1 0.999902
in O 0 0.00068641733
the O 0 0.00042021708
initial O 0 0.0004976158
treatment O 0 0.001255753
phase O 0 0.0013006501
of O 0 0.0010839816
patients O 0 0.005216599
with O 0 0.0043635154
congestive B-Disease 0 0.9993204
heart I-Disease 0 0.96160907
failure I-Disease 0 0.92748934
. O 0 0.008850307

Since O 0 0.0029596637
the O 0 0.0021889647
introduction O 0 0.0020383252
of O 0 0.002970295
angiotensin B-Chemical 1 0.9988991
converting I-Chemical 0 0.68512076
enzyme I-Chemical 0 0.6485239
( I-Chemical 0 0.0067956257
ACE I-Chemical 0 0.9984353
) I-Chemical 0 0.0035178526
inhibitors I-Chemical 0 0.04407907
into O 0 0.00027534057
the O 0 0.00029531674
adjunctive O 0 0.011219977
treatment O 0 0.0010824652
of O 0 0.000514885
patients O 0 0.0023410455
with O 0 0.0009645573
congestive B-Disease 0 0.99979323
heart I-Disease 0 0.9129643
failure I-Disease 0 0.83128387
, O 0 0.00077924575
cases O 0 0.0008785144
of O 0 0.00071319897
severe O 0 0.6042616
hypotension B-Disease 2 0.9998479
, O 0 0.0010699241
especially O 0 0.000543233
on O 0 0.00016601598
the O 0 0.00023069227
first O 0 0.0002219628
day O 0 0.00032044214
of O 0 0.00056353974
treatment O 0 0.0017418457
, O 0 0.0012035919
have O 0 0.0013002445
occasionally O 0 0.005999767
been O 0 0.0036502504
reported O 0 0.006475746
. O 0 0.005673735

To O 0 0.0024597335
assess O 0 0.0011642759
the O 0 0.0013813133
safety O 0 0.0027714241
of O 0 0.0015405893
the O 0 0.0015695924
ACE B-Chemical 1 0.99879885
inhibitor I-Chemical 1 0.9286964
enalapril B-Chemical 0 0.9999045
a O 0 0.003093851
multicenter O 0 0.2222104
, O 0 0.00079522084
randomized O 0 0.0011759979
, O 0 0.0010328213
prazosin B-Chemical 1 0.99990153
- O 0 0.0014840636
controlled O 0 0.00034081138
trial O 0 0.0006227075
was O 0 0.00022222959
designed O 0 0.00023336493
that O 0 0.0001610478
compared O 0 0.00013358932
the O 0 0.00022533209
incidence O 0 0.002188492
and O 0 0.00045097346
severity O 0 0.012247619
of O 0 0.0010035353
symptomatic O 0 0.58815587
hypotension B-Disease 2 0.9996039
on O 0 0.0005418667
the O 0 0.0007017359
first O 0 0.00075759465
day O 0 0.0012789042
of O 0 0.002614926
treatment O 0 0.009067415
. O 0 0.005798594

Trial O 0 0.061026134
medication O 0 0.070041224
was O 0 0.0030075412
2 O 0 0.0021514825
. O 0 0.0012956958
5 O 0 0.0015705469
mg O 0 0.43092546
enalapril B-Chemical 1 0.9993113
or O 0 0.0030699626
0 O 0 0.0031832324
. O 0 0.0022361642
5 O 0 0.0047142776
prazosin B-Chemical 1 0.9979377
. O 0 0.01104944

Subjects O 0 0.008006663
were O 0 0.0036654705
1210 O 0 0.15038826
inpatients O 0 0.009004369
with O 0 0.0021703462
New O 0 0.0036642796
York O 0 0.0073881727
Heart O 0 0.04867317
Association O 0 0.0027709657
( O 0 0.0023812049
NYHA O 0 0.5062096
) O 0 0.0028124282
functional O 0 0.002677591
class O 0 0.004736488
II O 0 0.021342874
and O 0 0.005769643
III O 0 0.04213011
. O 0 0.008426206

Patients O 0 0.0099288225
who O 0 0.004725574
received O 0 0.0035217493
enalapril B-Chemical 1 0.9994653
experienced O 0 0.008401497
clinically O 0 0.07203656
and O 0 0.0008905224
statistically O 0 0.0006677745
significantly O 0 0.0006423098
less O 0 0.0006402031
symptomatic O 0 0.35538027
hypotension B-Disease 2 0.99975365
( O 0 0.001375031
5 O 0 0.00033374457
. O 0 0.0001806327
2 O 0 0.00025737204
% O 0 0.00029008175
) O 0 0.00033187954
than O 0 0.0001478771
the O 0 0.00024043486
patients O 0 0.000905635
who O 0 0.0012388227
received O 0 0.0016526508
prazosin B-Chemical 1 0.9998085
( O 0 0.0023394013
12 O 0 0.0009224377
. O 0 0.0008330711
9 O 0 0.0016407968
% O 0 0.0026094073
) O 0 0.0047640544
. O 0 0.004683167

All O 0 0.031133803
patients O 0 0.041127004
recovered O 0 0.03369852
. O 0 0.038806394

It O 0 0.005427064
was O 0 0.0022183887
concluded O 0 0.0022848004
that O 0 0.0010761269
treatment O 0 0.0023918266
with O 0 0.0019502986
enalapril B-Chemical 1 0.99982005
was O 0 0.0012327124
well O 0 0.00054238865
tolerated O 0 0.01433065
and O 0 0.0005325635
it O 0 0.0004968103
is O 0 0.00040141656
, O 0 0.00047254443
therefore O 0 0.0004917022
, O 0 0.0004913789
unreasonable O 0 0.0018628921
to O 0 0.00028611033
restrict O 0 0.00031276903
the O 0 0.0003529347
initiation O 0 0.0006494218
of O 0 0.000849796
treatment O 0 0.0033364086
with O 0 0.004127677
enalapril B-Chemical 1 0.99962175
to O 0 0.005570377
inpatients O 0 0.18980208
. O 0 0.006654709

Central B-Disease 0 0.014194727
nervous I-Disease 0 0.5185963
system I-Disease 0 0.0052799606
complications I-Disease 0 0.19905551
during O 0 0.0015872265
treatment O 0 0.0037443924
of O 0 0.0042998167
acute B-Disease 2 0.99683785
lymphoblastic I-Disease 2 0.99977714
leukemia I-Disease 2 0.99975353
in O 0 0.0043327115
a O 0 0.0031408807
single O 0 0.0032796827
pediatric O 0 0.013591116
institution O 0 0.010691003
. O 0 0.0074319635

Central B-Disease 0 0.015133763
nervous I-Disease 0 0.6302637
system I-Disease 0 0.0061178417
( I-Disease 0 0.004216265
CNS I-Disease 0 0.6139859
) I-Disease 0 0.0029434897
complications I-Disease 0 0.17180787
during O 0 0.0006997188
treatment O 0 0.0019363399
of O 0 0.0018643829
childhood O 0 0.969075
acute B-Disease 2 0.998869
lymphoblastic I-Disease 2 0.9999156
leukemia I-Disease 2 0.9999286
( O 0 0.15474038
ALL B-Disease 0 0.99852043
) O 0 0.0038336886
remain O 0 0.001447743
a O 0 0.0016284233
challenging O 0 0.0031706474
clinical O 0 0.019434642
problem O 0 0.010244713
. O 0 0.006601544

Outcome O 0 0.009543426
improvement O 0 0.0032835354
with O 0 0.0019304336
more O 0 0.001624906
intensive O 0 0.001893714
chemotherapy O 0 0.5593959
has O 0 0.0011948398
significantly O 0 0.0012263907
increased O 0 0.001439637
the O 0 0.0010292816
incidence O 0 0.007479367
and O 0 0.0018714934
severity O 0 0.03191392
of O 0 0.0049757753
adverse O 0 0.9024451
events O 0 0.108983845
. O 0 0.0076680407

This O 0 0.004133534
study O 0 0.0025836278
analyzed O 0 0.0013157378
the O 0 0.001185264
incidence O 0 0.0040809433
of O 0 0.001942719
neurological B-Disease 0 0.9962625
complications I-Disease 0 0.97418267
during O 0 0.0010816122
ALL B-Disease 0 0.9977946
treatment O 0 0.0041752434
in O 0 0.00041299214
a O 0 0.000414359
single O 0 0.00039694321
pediatric O 0 0.0016393565
institution O 0 0.0008680794
, O 0 0.0005574285
focusing O 0 0.0007881348
on O 0 0.00036539993
clinical O 0 0.0049813217
, O 0 0.0013025984
radiological O 0 0.03618887
, O 0 0.0020185607
and O 0 0.002238967
electrophysiological O 0 0.26259303
findings O 0 0.011220121
. O 0 0.006234118

Exclusion O 0 0.10413893
criteria O 0 0.004978749
included O 0 0.002817173
CNS O 0 0.8148564
leukemic B-Disease 0 0.99637717
infiltration I-Disease 0 0.8008308
at O 0 0.00093130977
diagnosis O 0 0.015439884
, O 0 0.0012439928
therapy O 0 0.027816089
- O 0 0.0013794483
related O 0 0.00057803193
peripheral B-Disease 2 0.69140464
neuropathy I-Disease 2 0.9998524
, O 0 0.0024715648
late O 0 0.011784004
- O 0 0.0020940837
onset O 0 0.04062713
encephalopathy B-Disease 2 0.9996928
, O 0 0.0017292737
or O 0 0.0007941312
long O 0 0.0015037488
- O 0 0.00236228
term O 0 0.0030352096
neurocognitive B-Disease 0 0.95441246
defects I-Disease 0 0.033095725
. O 0 0.0068047144

During O 0 0.002884831
a O 0 0.0026606887
9 O 0 0.001824473
- O 0 0.0015262592
year O 0 0.0007828966
period O 0 0.00061752106
, O 0 0.0005912477
we O 0 0.0002406805
retrospectively O 0 0.00057265564
collected O 0 0.00031193878
27 O 0 0.0008001644
neurological O 0 0.8157585
events O 0 0.008798815
( O 0 0.0006848566
11 O 0 0.0004074502
% O 0 0.00034138287
) O 0 0.00036976283
in O 0 0.00018181815
as O 0 0.00017973248
many O 0 0.00031472647
patients O 0 0.00097288366
, O 0 0.00042329865
from O 0 0.00032557797
253 O 0 0.0048216474
children O 0 0.00096829596
enrolled O 0 0.0009728007
in O 0 0.00053277897
the O 0 0.00105555
ALL B-Disease 0 0.99299836
front O 0 0.006027675
- O 0 0.0041164826
line O 0 0.0045561567
protocol O 0 0.006708653
. O 0 0.0059975972

CNS O 0 0.64326346
complications O 0 0.36563274
included O 0 0.0028759402
posterior O 0 0.0248927
reversible O 0 0.7042797
leukoencephalopathy B-Disease 2 0.99953556
syndrome O 0 0.9881719
( O 0 0.0023414697
n O 0 0.0006847359
= O 0 0.00084899965
10 O 0 0.00048414827
) O 0 0.0007266197
, O 0 0.00070544047
stroke B-Disease 2 0.99315053
( O 0 0.00076380494
n O 0 0.00032783172
= O 0 0.00047417305
5 O 0 0.00023643745
) O 0 0.00043658758
, O 0 0.00039683218
temporal B-Disease 2 0.045449734
lobe I-Disease 2 0.791432
epilepsy I-Disease 2 0.99974877
( O 0 0.0010917083
n O 0 0.00032383573
= O 0 0.0004636116
2 O 0 0.00025404134
) O 0 0.00039788635
, O 0 0.0002866389
high O 0 0.0004028249
- O 0 0.00067517586
dose O 0 0.03796255
methotrexate B-Chemical 1 0.9998259
toxicity B-Disease 2 0.99906737
( O 0 0.0016805911
n O 0 0.00034268916
= O 0 0.00048553242
2 O 0 0.0002570481
) O 0 0.000433547
, O 0 0.00037714772
syndrome O 0 0.43918478
of O 0 0.00055923447
inappropriate B-Disease 0 0.04271637
antidiuretic I-Disease 0 0.99878746
hormone I-Disease 0 0.9901196
secretion I-Disease 0 0.31282216
( O 0 0.0010506209
n O 0 0.00038651118
= O 0 0.0005871869
1 O 0 0.00033621126
) O 0 0.00050275587
, O 0 0.0003838291
and O 0 0.00036259557
other O 0 0.00051955413
unclassified O 0 0.040026736
events O 0 0.012597836
( O 0 0.0017332588
n O 0 0.0013554939
= O 0 0.0025780173
7 O 0 0.0021160399
) O 0 0.0047616204
. O 0 0.0045436136

In O 0 0.0033449568
conclusion O 0 0.0026739417
, O 0 0.0032520122
CNS O 0 0.5344917
complications O 0 0.3895781
are O 0 0.0012651501
frequent O 0 0.0028684768
events O 0 0.0038413191
during O 0 0.00070453354
ALL B-Disease 0 0.99619424
therapy O 0 0.06345708
, O 0 0.0008854964
and O 0 0.00048045543
require O 0 0.00035616057
rapid O 0 0.0012702969
detection O 0 0.0007746588
and O 0 0.0008066937
prompt O 0 0.0042302916
treatment O 0 0.002695457
to O 0 0.0015420106
limit O 0 0.0042128786
permanent O 0 0.116741076
damage O 0 0.8099641
. O 0 0.00857485

Cocaine B-Chemical 0 0.9981919
causes O 0 0.013504061
memory B-Disease 0 0.26261914
and I-Disease 0 0.002248123
learning I-Disease 0 0.011771201
impairments I-Disease 0 0.35619724
in O 0 0.00090918544
rats O 0 0.00392493
: O 0 0.0010450324
involvement O 0 0.0011308361
of O 0 0.00075568573
nuclear O 0 0.0074632214
factor O 0 0.016607579
kappa O 0 0.08877166
B O 0 0.26372704
and O 0 0.0016223782
oxidative O 0 0.97931916
stress O 0 0.6384127
, O 0 0.0027641314
and O 0 0.0021078286
prevention O 0 0.020938937
by O 0 0.008369278
topiramate B-Chemical 0 0.99918586
. O 0 0.009999093

Different O 0 0.008535219
mechanisms O 0 0.0041528484
have O 0 0.0020955896
been O 0 0.0016609855
suggested O 0 0.0012559658
for O 0 0.0011969649
cocaine B-Chemical 1 0.9993235
toxicity B-Disease 2 0.9974819
including O 0 0.0012547588
an O 0 0.00091424165
increase O 0 0.0005272643
in O 0 0.00049709267
oxidative O 0 0.96122164
stress O 0 0.4286936
but O 0 0.00047449954
the O 0 0.00028163588
association O 0 0.00026295462
between O 0 0.00022701803
oxidative O 0 0.8680304
status O 0 0.000940471
in O 0 0.00037690962
the O 0 0.00044627345
brain O 0 0.046457205
and O 0 0.0011639788
cocaine B-Chemical 1 0.9992924
induced O 0 0.0038584596
- O 0 0.0030313204
behaviour O 0 0.003979948
is O 0 0.0019034675
poorly O 0 0.0075172554
understood O 0 0.007189872
. O 0 0.005519059

Nuclear O 0 0.312473
factor O 0 0.019472154
kappa O 0 0.083753325
B O 0 0.3530056
( O 0 0.00474176
NFkappaB O 0 0.78200495
) O 0 0.0023687445
is O 0 0.0007344287
a O 0 0.0006247533
sensor O 0 0.00067283446
of O 0 0.00089039636
oxidative O 0 0.96794844
stress O 0 0.5147709
and O 0 0.00091653457
participates O 0 0.0008273164
in O 0 0.0004932066
memory O 0 0.1936893
formation O 0 0.0021049788
that O 0 0.0003722574
could O 0 0.00035110005
be O 0 0.00048428006
involved O 0 0.000566431
in O 0 0.0008941116
drug O 0 0.93009263
toxicity B-Disease 2 0.9980634
and O 0 0.0070177475
addiction O 0 0.975453
mechanisms O 0 0.019676153
. O 0 0.00655788

Therefore O 0 0.0055481857
NFkappaB O 0 0.5358585
activity O 0 0.00453391
, O 0 0.0037211215
oxidative O 0 0.9596847
stress O 0 0.6872625
, O 0 0.004992099
neuronal O 0 0.81905496
nitric B-Chemical 0 0.9992488
oxide I-Chemical 0 0.99909735
synthase O 0 0.9952003
( O 0 0.011934264
nNOS O 0 0.82232726
) O 0 0.0017263257
activity O 0 0.0006915517
, O 0 0.00048153775
spatial O 0 0.0021715392
learning O 0 0.0035430894
and O 0 0.0004136561
memory O 0 0.07819832
as O 0 0.0002161519
well O 0 0.00017993858
as O 0 0.0001633005
the O 0 0.00018968398
effect O 0 0.00031004392
of O 0 0.000739383
topiramate B-Chemical 0 0.9999229
, O 0 0.0008385057
a O 0 0.00035125724
previously O 0 0.00027979346
proposed O 0 0.00043398922
therapy O 0 0.011881353
for O 0 0.00053064054
cocaine B-Disease 1 0.99987876
addiction I-Disease 0 0.99812704
, O 0 0.0008284434
were O 0 0.0002964437
evaluated O 0 0.0002689691
in O 0 0.00025688473
an O 0 0.00042326073
experimental O 0 0.0006823052
model O 0 0.00094820553
of O 0 0.0021208387
cocaine B-Chemical 1 0.9990771
administration O 0 0.5264028
in O 0 0.003735012
rats O 0 0.02410935
. O 0 0.0058322614

NFkappaB O 0 0.5870298
activity O 0 0.0041124853
was O 0 0.0018859179
decreased O 0 0.0023086371
in O 0 0.0010336225
the O 0 0.001066294
frontal O 0 0.31901705
cortex O 0 0.24628805
of O 0 0.0013160431
cocaine B-Chemical 1 0.99938345
treated O 0 0.004435127
rats O 0 0.008435059
, O 0 0.00059707975
as O 0 0.00027365042
well O 0 0.0003011522
as O 0 0.0004913454
GSH B-Chemical 1 0.9996487
concentration O 0 0.022421438
and O 0 0.0015604002
glutathione B-Chemical 0 0.9995517
peroxidase O 0 0.9676601
activity O 0 0.0016758027
in O 0 0.00046725568
the O 0 0.0005675277
hippocampus O 0 0.4520834
, O 0 0.0008150879
whereas O 0 0.0006486038
nNOS O 0 0.31352684
activity O 0 0.001117395
in O 0 0.0008138651
the O 0 0.0013678604
hippocampus O 0 0.3575796
was O 0 0.0027490857
increased O 0 0.0065986556
. O 0 0.0059700347

Memory O 0 0.32748184
retrieval O 0 0.0055286665
of O 0 0.002506239
experiences O 0 0.0036044815
acquired O 0 0.0028750682
prior O 0 0.0007376053
to O 0 0.0010139245
cocaine B-Chemical 1 0.9989716
administration O 0 0.33326808
was O 0 0.00080045004
impaired O 0 0.0011860941
and O 0 0.0005981914
negatively O 0 0.0008234257
correlated O 0 0.0005958016
with O 0 0.0013244527
NFkappaB O 0 0.6974796
activity O 0 0.0021464701
in O 0 0.0015995383
the O 0 0.0029304316
frontal O 0 0.6602194
cortex O 0 0.5230894
. O 0 0.006604346

In O 0 0.0029642629
contrast O 0 0.0023252433
, O 0 0.002012335
learning O 0 0.0031372793
of O 0 0.0011632878
new O 0 0.0012472158
tasks O 0 0.0023411848
was O 0 0.00061309285
enhanced O 0 0.0006768184
and O 0 0.00049820147
correlated O 0 0.00036614665
with O 0 0.00050457567
the O 0 0.00041365094
increase O 0 0.0005021098
of O 0 0.00097457384
nNOS O 0 0.49950325
activity O 0 0.0012700955
and O 0 0.000943639
the O 0 0.0010446194
decrease O 0 0.0022584994
of O 0 0.0063258186
glutathione B-Chemical 0 0.99776983
peroxidase O 0 0.97859573
. O 0 0.012891685

These O 0 0.0038985892
results O 0 0.0019466522
provide O 0 0.0015381221
evidence O 0 0.0013025606
for O 0 0.0008462053
a O 0 0.00088920054
possible O 0 0.0008051751
mechanistic O 0 0.0018578528
role O 0 0.0005479389
of O 0 0.0012266214
oxidative O 0 0.968304
and O 0 0.002738464
nitrosative O 0 0.99865353
stress O 0 0.7707025
and O 0 0.0025654275
NFkappaB O 0 0.8014933
in O 0 0.0010888469
the O 0 0.0012710522
alterations O 0 0.014597016
induced O 0 0.0044174935
by O 0 0.0072741252
cocaine B-Chemical 1 0.9975356
. O 0 0.009712007

Topiramate B-Chemical 0 0.99838054
prevented O 0 0.013862832
all O 0 0.003167355
the O 0 0.0026990764
alterations O 0 0.0076145194
observed O 0 0.002137845
, O 0 0.0032068107
showing O 0 0.0032649718
novel O 0 0.008436312
neuroprotective O 0 0.94605297
properties O 0 0.02380529
. O 0 0.0108011635

Efficacy O 0 0.04778896
and O 0 0.0030329952
safety O 0 0.0043848925
of O 0 0.002610027
asenapine B-Chemical 1 0.99906725
in O 0 0.0012873011
a O 0 0.0012695682
placebo O 0 0.27394986
- O 0 0.0017281857
and O 0 0.0011078994
haloperidol B-Chemical 1 0.9998995
- O 0 0.0018152705
controlled O 0 0.0005725637
trial O 0 0.0010657766
in O 0 0.00052818586
patients O 0 0.0021143942
with O 0 0.0019202387
acute O 0 0.9762053
exacerbation O 0 0.9908331
of O 0 0.058008093
schizophrenia B-Disease 2 0.99769396
. O 0 0.010669455

Asenapine B-Chemical 0 0.9944916
is O 0 0.0037084646
approved O 0 0.0053482153
by O 0 0.0016282721
the O 0 0.0013635427
Food O 0 0.49515465
and O 0 0.0015126934
Drugs O 0 0.9393517
Administration O 0 0.4911146
in O 0 0.0005979454
adults O 0 0.0013398316
for O 0 0.0004221773
acute O 0 0.8357955
treatment O 0 0.0038962378
of O 0 0.0015866176
schizophrenia B-Disease 2 0.9989612
or O 0 0.00051922543
of O 0 0.0013295035
manic B-Disease 0 0.999617
or O 0 0.00046248344
mixed O 0 0.0021821058
episodes O 0 0.21424
associated O 0 0.0012765896
with O 0 0.0021821866
bipolar B-Disease 2 0.9988399
I I-Disease 0 0.2657021
disorder I-Disease 0 0.9692202
with O 0 0.0019450003
or O 0 0.0015638691
without O 0 0.004346049
psychotic B-Disease 0 0.99860954
features O 0 0.053506274
. O 0 0.0070927297

In O 0 0.003146603
a O 0 0.0024249912
double O 0 0.0017637248
- O 0 0.002276573
blind O 0 0.0034113117
6 O 0 0.00072866125
- O 0 0.00079690875
week O 0 0.0003977151
trial O 0 0.00082655693
, O 0 0.00053520733
458 O 0 0.0025827852
patients O 0 0.0011059531
with O 0 0.0006484177
acute O 0 0.958033
schizophrenia B-Disease 2 0.9990727
were O 0 0.000359473
randomly O 0 0.000116768926
assigned O 0 0.00019198826
to O 0 0.00018339227
fixed O 0 0.00029206145
- O 0 0.00048117366
dose O 0 0.004856892
treatment O 0 0.0010241449
with O 0 0.0006487357
asenapine B-Chemical 1 0.9997029
at O 0 0.00020821356
5 O 0 0.00022437956
mg O 0 0.070964985
twice O 0 0.00028487976
daily O 0 0.0011720055
( O 0 0.0006683108
BID O 0 0.9830746
) O 0 0.0010702444
, O 0 0.00061824394
asenapine B-Chemical 1 0.9995196
at O 0 0.00021684571
10 O 0 0.00037117657
mg O 0 0.38224557
BID O 0 0.98683375
, O 0 0.000741348
placebo O 0 0.13876571
, O 0 0.00051722245
or O 0 0.0004145721
haloperidol B-Chemical 1 0.9998834
at O 0 0.0003729266
4 O 0 0.00050788437
mg O 0 0.50213385
BID O 0 0.9823308
( O 0 0.0010665648
to O 0 0.0006282527
verify O 0 0.0005667239
assay O 0 0.002719257
sensitivity O 0 0.0069897277
) O 0 0.008088247
. O 0 0.005960769

With O 0 0.0045626382
last O 0 0.0017183453
observations O 0 0.0019485108
carried O 0 0.0011856637
forward O 0 0.00506521
( O 0 0.0022521021
LOCF O 0 0.725637
) O 0 0.001450224
, O 0 0.00062561675
mean O 0 0.00030533146
Positive O 0 0.0019405716
and O 0 0.00052800804
Negative O 0 0.028079486
Syndrome O 0 0.8489576
Scale O 0 0.3362263
total O 0 0.0002701356
score O 0 0.00031121165
reductions O 0 0.0003554155
from O 0 0.00018757496
baseline O 0 0.00026796272
to O 0 0.00017254028
endpoint O 0 0.00046583163
were O 0 0.00018527906
significantly O 0 0.00024319506
greater O 0 0.00023401887
with O 0 0.00047599198
asenapine B-Chemical 1 0.9996395
at O 0 0.00023187778
5 O 0 0.00029913
mg O 0 0.44075385
BID O 0 0.99149656
( O 0 0.0008563012
- O 0 0.0005265917
16 O 0 0.0002665744
. O 0 0.00013637246
2 O 0 0.00022883591
) O 0 0.00040253703
and O 0 0.00042417517
haloperidol B-Chemical 1 0.9999356
( O 0 0.0013154936
- O 0 0.00056419626
15 O 0 0.00018956499
. O 0 0.00011531739
4 O 0 0.00016011439
) O 0 0.00028111273
than O 0 0.0001378263
placebo O 0 0.05247325
( O 0 0.00046399757
- O 0 0.00041281918
10 O 0 0.0002316387
. O 0 0.00012432088
7 O 0 0.00017971054
; O 0 0.00031706225
both O 0 0.00021514359
P O 0 0.011232522
< O 0 0.00032451074
0 O 0 0.00026135647
. O 0 0.00015983128
05 O 0 0.015890976
) O 0 0.0004382914
; O 0 0.00033181946
using O 0 0.00014423704
mixed O 0 0.00038823707
model O 0 0.00027690246
for O 0 0.00015940817
repeated O 0 0.00021804737
measures O 0 0.00033781028
( O 0 0.00059473637
MMRM O 0 0.6849753
) O 0 0.00069399225
, O 0 0.0003046441
changes O 0 0.00028287532
at O 0 0.000108592256
day O 0 0.00015790683
42 O 0 0.00024571622
were O 0 0.00014629426
significantly O 0 0.0002033781
greater O 0 0.00020725293
with O 0 0.0004214073
asenapine B-Chemical 1 0.99960023
at O 0 0.00019800704
5 O 0 0.00019854431
and O 0 0.00021078433
10 O 0 0.00028763595
mg O 0 0.3217212
BID O 0 0.9887504
( O 0 0.00077462627
- O 0 0.00050131005
21 O 0 0.00029428804
. O 0 0.00011764651
3 O 0 0.00015519028
and O 0 0.00022108371
- O 0 0.0003750503
19 O 0 0.00034781365
. O 0 0.00012211961
4 O 0 0.00016934889
, O 0 0.0002654294
respectively O 0 0.0006170495
) O 0 0.0005081158
and O 0 0.00050137064
haloperidol B-Chemical 1 0.9999423
( O 0 0.0014991523
- O 0 0.00062628515
20 O 0 0.00029469767
. O 0 0.00013726378
0 O 0 0.00024769604
) O 0 0.0003220052
than O 0 0.00016627168
placebo O 0 0.048998326
( O 0 0.0005677268
- O 0 0.0005620295
14 O 0 0.00037902052
. O 0 0.00021975442
6 O 0 0.00031122466
; O 0 0.0006638656
all O 0 0.0005444219
P O 0 0.010536838
< O 0 0.0013953581
0 O 0 0.0014997179
. O 0 0.0015275452
05 O 0 0.028732233
) O 0 0.0061888415
. O 0 0.00554595

On O 0 0.0041838293
the O 0 0.0025098321
Positive O 0 0.0056658206
and O 0 0.0020008006
Negative O 0 0.0295627
Syndrome O 0 0.8141954
Scale O 0 0.40496057
positive O 0 0.0007273025
subscale O 0 0.0019188045
, O 0 0.0005771382
all O 0 0.00029458586
treatments O 0 0.0009146938
were O 0 0.00033270128
superior O 0 0.00091000233
to O 0 0.00028904318
placebo O 0 0.053496853
with O 0 0.00052221585
LOCF O 0 0.7049584
and O 0 0.0005660953
MMRM O 0 0.8455023
; O 0 0.0018599285
asenapine B-Chemical 1 0.9995264
at O 0 0.00023388372
5 O 0 0.0002737243
mg O 0 0.27740324
BID O 0 0.97311324
was O 0 0.00031791342
superior O 0 0.0008594462
to O 0 0.0002164334
placebo O 0 0.022989545
on O 0 0.00012596462
the O 0 0.000182251
negative O 0 0.00025874446
subscale O 0 0.0009315898
with O 0 0.00047492396
MMRM O 0 0.53778154
and O 0 0.00040795736
on O 0 0.00022253704
the O 0 0.00038212354
general O 0 0.0007690526
psychopathology O 0 0.7594539
subscale O 0 0.003923483
with O 0 0.0022562945
LOCF O 0 0.7271499
and O 0 0.0045544747
MMRM O 0 0.7786938
. O 0 0.0069438606

Treatment O 0 0.0917049
- O 0 0.005285727
related O 0 0.0019974122
adverse O 0 0.45363742
events O 0 0.016239624
( O 0 0.00242103
AEs O 0 0.8031881
) O 0 0.0011351125
occurred O 0 0.0005596888
in O 0 0.00034622801
44 O 0 0.0005769963
% O 0 0.0003570608
and O 0 0.0002946345
52 O 0 0.0004976177
% O 0 0.00034515728
, O 0 0.00033167045
57 O 0 0.0004676101
% O 0 0.0003019641
, O 0 0.00028267343
and O 0 0.0002472543
41 O 0 0.00048731797
% O 0 0.00024235298
of O 0 0.00026310032
the O 0 0.00033692326
asenapine B-Chemical 1 0.9994271
at O 0 0.00024011411
5 O 0 0.00024920283
and O 0 0.00028072545
10 O 0 0.00040924572
mg O 0 0.3716929
BID O 0 0.99084723
, O 0 0.0026121172
haloperidol B-Chemical 1 0.9998865
, O 0 0.0016767667
and O 0 0.0012198369
placebo O 0 0.1549634
groups O 0 0.0023136816
, O 0 0.0035227067
respectively O 0 0.0071779895
. O 0 0.0052100993

Extrapyramidal B-Disease 0 0.99713683
symptoms I-Disease 0 0.87393624
reported O 0 0.0038941347
as O 0 0.0015351374
AEs O 0 0.6368635
occurred O 0 0.0010232974
in O 0 0.00050889625
15 O 0 0.00040454202
% O 0 0.00040840154
and O 0 0.0003365812
18 O 0 0.00036864865
% O 0 0.00035389527
, O 0 0.0003446218
34 O 0 0.00040213755
% O 0 0.00030894543
, O 0 0.00028977628
and O 0 0.00024428195
10 O 0 0.00025079626
% O 0 0.00022154034
of O 0 0.00024980016
the O 0 0.00032551773
asenapine B-Chemical 1 0.9993963
at O 0 0.00023855217
5 O 0 0.000248725
and O 0 0.00028078488
10 O 0 0.000409775
mg O 0 0.37078694
BID O 0 0.9908297
, O 0 0.0026130565
haloperidol B-Chemical 1 0.9998863
, O 0 0.0016785284
and O 0 0.0012210197
placebo O 0 0.1549651
groups O 0 0.0023153927
, O 0 0.0035248064
respectively O 0 0.007180671
. O 0 0.005212487

Across O 0 0.0058555626
all O 0 0.0024367003
groups O 0 0.0024181758
, O 0 0.0019146858
no O 0 0.0009470766
more O 0 0.0011648373
than O 0 0.00063187967
5 O 0 0.0006515978
% O 0 0.0007172183
of O 0 0.00081510463
patients O 0 0.0020482363
had O 0 0.0014763519
clinically O 0 0.033915035
significant O 0 0.0034438462
weight O 0 0.014167283
change O 0 0.006006798
. O 0 0.006594915

Post O 0 0.0125237685
hoc O 0 0.00952683
analyses O 0 0.0025514557
indicated O 0 0.0010506755
that O 0 0.00090140855
efficacy O 0 0.0026448104
was O 0 0.0007310887
similar O 0 0.000509775
with O 0 0.00113774
asenapine B-Chemical 1 0.99961275
and O 0 0.002893788
haloperidol B-Chemical 1 0.9999291
; O 0 0.0022437389
greater O 0 0.00053875026
contrasts O 0 0.0009376218
were O 0 0.00057064055
seen O 0 0.00066588755
in O 0 0.0009210799
AEs O 0 0.7795939
, O 0 0.0024277868
especially O 0 0.010025726
extrapyramidal B-Disease 2 0.9995962
symptoms I-Disease 2 0.9825701
. O 0 0.009046192

Salvage O 0 0.08679245
therapy O 0 0.02197124
with O 0 0.004209399
nelarabine B-Chemical 0 0.9740514
, O 0 0.0051574497
etoposide B-Chemical 1 0.99808395
, O 0 0.0024420843
and O 0 0.0014654294
cyclophosphamide B-Chemical 1 0.99918836
in O 0 0.0016014363
relapsed O 0 0.98067516
/ O 0 0.005251585
refractory O 0 0.53255254
paediatric O 0 0.019678276
T B-Disease 0 0.81316197
- I-Disease 0 0.007994206
cell I-Disease 0 0.21222359
lymphoblastic I-Disease 0 0.9995993
leukaemia I-Disease 0 0.99961996
and I-Disease 0 0.12977901
lymphoma I-Disease 0 0.99647224
. O 0 0.013538783

A O 0 0.013604202
combination O 0 0.0045319004
of O 0 0.0023784293
5 O 0 0.00128053
d O 0 0.0012818004
of O 0 0.0013255303
nelarabine B-Chemical 0 0.9591646
( O 0 0.0021326067
AraG B-Chemical 1 0.69589335
) O 0 0.0011226862
with O 0 0.0005361023
5 O 0 0.0003390486
d O 0 0.000464864
of O 0 0.0007062306
etoposide B-Chemical 1 0.99909127
( O 0 0.0032029098
VP B-Chemical 0 0.9606152
) O 0 0.0012674333
and O 0 0.00062357134
cyclophosphamide B-Chemical 1 0.99963164
( O 0 0.0030565944
CPM B-Chemical 0 0.9912881
) O 0 0.0010346511
and O 0 0.00033654523
prophylactic O 0 0.015768273
intrathecal O 0 0.9456816
chemotherapy O 0 0.87028784
was O 0 0.00038963856
used O 0 0.00022564967
as O 0 0.00018630711
salvage O 0 0.008567783
therapy O 0 0.0065554236
in O 0 0.00025750557
seven O 0 0.00029165385
children O 0 0.0008307813
with O 0 0.0005623078
refractory O 0 0.31063715
or O 0 0.001082542
relapsed O 0 0.9908572
T B-Disease 0 0.8577906
- I-Disease 0 0.007965303
cell I-Disease 0 0.13077427
leukaemia I-Disease 0 0.99924076
or I-Disease 0 0.015936865
lymphoma I-Disease 0 0.99561584
. O 0 0.010843518

The O 0 0.0031914986
most O 0 0.003372033
common O 0 0.0028473267
side O 0 0.008388358
effects O 0 0.002329853
attributable O 0 0.0009245379
to O 0 0.0007241975
the O 0 0.0007556951
AraG B-Chemical 1 0.4536221
included O 0 0.0008766843
Grade O 0 0.37016216
2 O 0 0.000630351
and O 0 0.0005700926
3 O 0 0.00058053556
sensory O 0 0.012276311
and O 0 0.0013757986
motor O 0 0.7842575
neuropathy B-Disease 0 0.9995003
and O 0 0.007306522
musculoskeletal B-Disease 0 0.9480922
pain I-Disease 0 0.989442
. O 0 0.009296274

Haematological B-Disease 0 0.99417526
toxicity I-Disease 2 0.9949986
was O 0 0.0022695917
greater O 0 0.0011562125
for O 0 0.00071461755
the O 0 0.0006429014
combination O 0 0.0014239609
than O 0 0.0005118796
AraG B-Chemical 1 0.50292534
alone O 0 0.00082432886
, O 0 0.0006153367
although O 0 0.0003269282
median O 0 0.00029077288
time O 0 0.00025786672
to O 0 0.0003902676
neutrophil O 0 0.09279747
and O 0 0.0007554891
platelet O 0 0.69048697
recovery O 0 0.0027074066
was O 0 0.0007129615
consistent O 0 0.00083979627
with O 0 0.0013678069
other O 0 0.002114065
salvage O 0 0.10918009
therapies O 0 0.12817577
. O 0 0.007120552

All O 0 0.0034377428
patients O 0 0.0038397524
had O 0 0.0015847152
some O 0 0.0012885543
response O 0 0.0012969854
to O 0 0.00064634497
the O 0 0.0005107372
combined O 0 0.00089955394
therapy O 0 0.0070872684
and O 0 0.00046286642
five O 0 0.00022982554
of O 0 0.00039561326
the O 0 0.00030152625
seven O 0 0.00031557737
went O 0 0.0006285659
into O 0 0.00019037192
complete O 0 0.00031920781
remission O 0 0.11213654
after O 0 0.00021221288
one O 0 0.0002640628
or O 0 0.00032215536
two O 0 0.0003866662
courses O 0 0.0016016169
of O 0 0.0019516236
AraG B-Chemical 1 0.85842437
/ O 0 0.019447198
VP B-Chemical 0 0.9638058
/ O 0 0.033566814
CPM B-Chemical 0 0.9813033
. O 0 0.009067055

Our O 0 0.0032448927
experience O 0 0.003402769
supports O 0 0.0016158404
the O 0 0.0011821667
safety O 0 0.002254025
of O 0 0.0011113357
giving O 0 0.0015023205
AraG B-Chemical 1 0.4749134
as O 0 0.0005874142
salvage O 0 0.021214003
therapy O 0 0.016638163
in O 0 0.00054616405
synchrony O 0 0.008227421
with O 0 0.0011743138
etoposide B-Chemical 1 0.9988955
and O 0 0.0023699845
cyclophosphamide B-Chemical 1 0.99961084
, O 0 0.0027485655
although O 0 0.0016666196
neurological B-Disease 0 0.99765044
toxicity I-Disease 2 0.9983677
must O 0 0.0015549236
be O 0 0.0019229017
closely O 0 0.0024803658
monitored O 0 0.00271545
. O 0 0.004982568

Effect O 0 0.008803604
of O 0 0.005399123
adriamycin B-Chemical 1 0.9963403
combined O 0 0.0057631778
with O 0 0.0027479199
whole O 0 0.0024552846
body O 0 0.021265106
hyperthermia B-Disease 2 0.9964405
on O 0 0.002476068
tumor B-Disease 2 0.69039047
and O 0 0.0043181186
normal O 0 0.008727591
tissues O 0 0.01502813
. O 0 0.00807511

Thermal O 0 0.25722975
enhancement O 0 0.0096845245
of O 0 0.005557001
Adriamycin B-Chemical 1 0.999129
- O 0 0.006414401
mediated O 0 0.0015586556
antitumor O 0 0.8109381
activity O 0 0.0014592444
and O 0 0.00073943124
normal O 0 0.001524033
tissue O 0 0.023098052
toxicities B-Disease 2 0.9982798
by O 0 0.00072098366
whole O 0 0.0006949386
body O 0 0.0086616315
hyperthermia B-Disease 2 0.9973017
were O 0 0.00087651814
compared O 0 0.00052143174
using O 0 0.0008975377
a O 0 0.0021790075
F344 O 0 0.5358334
rat O 0 0.022338975
model O 0 0.007179465
. O 0 0.00691645

Antitumor O 0 0.8859863
activity O 0 0.0070802416
was O 0 0.0038334976
studied O 0 0.0041872314
using O 0 0.0031406793
a O 0 0.005113899
tumor B-Disease 2 0.6220247
growth O 0 0.027982475
delay O 0 0.017200956
assay O 0 0.01625637
. O 0 0.012068654

Acute O 0 0.93767107
normal O 0 0.008638879
tissue O 0 0.056430615
toxicities B-Disease 2 0.99734205
( O 0 0.0036078806
i O 0 0.0029094708
. O 0 0.00065466546
e O 0 0.0014830246
. O 0 0.0005012509
, O 0 0.0012184161
leukopenia B-Disease 0 0.999506
and O 0 0.0023430858
thrombocytopenia B-Disease 0 0.99961025
) O 0 0.002119828
and O 0 0.00047831575
late O 0 0.0016574543
normal O 0 0.0013643566
tissue O 0 0.035344757
toxicities B-Disease 2 0.9991829
( O 0 0.0012689341
i O 0 0.0015078728
. O 0 0.00021782088
e O 0 0.0007259968
. O 0 0.00020858833
, O 0 0.00048840337
myocardial B-Disease 0 0.99595296
and I-Disease 0 0.0010556439
kidney I-Disease 0 0.99164784
injury I-Disease 0 0.9949635
) O 0 0.0014687545
were O 0 0.0003281313
evaluated O 0 0.00032063585
by O 0 0.0004107667
functional O 0 0.000848837
/ O 0 0.0012885316
physiological O 0 0.0021844576
assays O 0 0.0012541966
and O 0 0.0014061541
by O 0 0.0021028984
morphological O 0 0.014266752
techniques O 0 0.009088485
. O 0 0.0063437955

Whole O 0 0.013092794
body O 0 0.012539359
hyperthermia B-Disease 2 0.99372417
( O 0 0.0032079415
120 O 0 0.0017246405
min O 0 0.0012207942
at O 0 0.0005016118
41 O 0 0.0010772906
. O 0 0.0003775319
5 O 0 0.00042210994
degrees O 0 0.0020324218
C O 0 0.64139533
) O 0 0.0014915349
enhanced O 0 0.0010040978
both O 0 0.0012338414
Adriamycin B-Chemical 1 0.9996
- O 0 0.0038905793
mediated O 0 0.001223947
antitumor O 0 0.84207803
activity O 0 0.0025539033
and O 0 0.002461925
toxic O 0 0.8731253
side O 0 0.1680657
effects O 0 0.019320415
. O 0 0.0070542796

The O 0 0.0042155404
thermal O 0 0.014028185
enhancement O 0 0.006146249
ratio O 0 0.0027889204
calculated O 0 0.0016370502
for O 0 0.002090393
antitumor O 0 0.6111056
activity O 0 0.0040433896
was O 0 0.0030471755
1 O 0 0.0033722764
. O 0 0.0027696006
6 O 0 0.0042334483
. O 0 0.006032805

Thermal O 0 0.18363073
enhancement O 0 0.0064780232
ratios O 0 0.0021879745
estimated O 0 0.00132936
for O 0 0.0010824905
" O 0 0.0016229292
acute O 0 0.80327547
" O 0 0.0016835011
hematological O 0 0.950317
changes O 0 0.0013140405
were O 0 0.00049622037
1 O 0 0.00039467006
. O 0 0.00018787103
3 O 0 0.00021366659
, O 0 0.0002684273
whereas O 0 0.00019908685
those O 0 0.00027288782
estimated O 0 0.00021763777
for O 0 0.00023072264
" O 0 0.00042309347
late O 0 0.0015529254
" O 0 0.0006401961
damage O 0 0.37405834
( O 0 0.000597034
based O 0 0.00033359602
on O 0 0.00019032383
morphological O 0 0.005769432
cardiac B-Disease 0 0.28950828
and I-Disease 0 0.0010070072
renal I-Disease 0 0.99859744
lesions I-Disease 0 0.93355775
) O 0 0.0014746898
varied O 0 0.000696089
between O 0 0.00030240775
2 O 0 0.0005324635
. O 0 0.0003704085
4 O 0 0.00055973046
and O 0 0.00087503315
4 O 0 0.0011609338
. O 0 0.0013267915
3 O 0 0.0026891157
. O 0 0.003966011

Thus O 0 0.004176695
, O 0 0.003006855
while O 0 0.001518435
whole O 0 0.0015183851
body O 0 0.009023149
hyperthermia B-Disease 2 0.9978131
enhances O 0 0.0073248106
Adriamycin B-Chemical 1 0.99974865
- O 0 0.006713497
mediated O 0 0.0008508462
antitumor O 0 0.85580945
effect O 0 0.0010796203
, O 0 0.0006983365
normal O 0 0.0013511967
tissue O 0 0.029194139
toxicity B-Disease 2 0.9956863
is O 0 0.0004988107
also O 0 0.00039386423
increased O 0 0.000689599
, O 0 0.00041665608
and O 0 0.00026684857
the O 0 0.00022283301
potential O 0 0.00041871404
therapeutic O 0 0.004277404
gain O 0 0.0010680436
of O 0 0.0006110907
the O 0 0.00058505597
combined O 0 0.0016268768
modality O 0 0.018752072
treatment O 0 0.008056143
is O 0 0.0041962704
eroded O 0 0.050982237
. O 0 0.006706985

Permeability O 0 0.58819187
, O 0 0.005080201
ultrastructural O 0 0.049291205
changes O 0 0.0026664117
, O 0 0.0015326731
and O 0 0.00085213134
distribution O 0 0.00052819186
of O 0 0.0008070067
novel O 0 0.0013922163
proteins O 0 0.0013982474
in O 0 0.0007045124
the O 0 0.00093697046
glomerular O 0 0.80664504
barrier O 0 0.026355691
in O 0 0.0018375735
early O 0 0.021079488
puromycin B-Chemical 0 0.9939604
aminonucleoside I-Chemical 0 0.99972147
nephrosis B-Disease 2 0.9993286
. O 0 0.019656729

BACKGROUND O 0 0.841985
/ O 0 0.012346609
AIMS O 0 0.11167351
: O 0 0.004154429
It O 0 0.0025183868
is O 0 0.001240757
still O 0 0.0010425587
unclear O 0 0.0011886655
what O 0 0.0015935228
happens O 0 0.0014347455
in O 0 0.0011525934
the O 0 0.0017389611
glomerulus O 0 0.15044762
when O 0 0.004181813
proteinuria B-Disease 2 0.99862695
starts O 0 0.02821862
. O 0 0.009684703

Using O 0 0.009517698
puromycin B-Chemical 0 0.97470933
aminonucleoside I-Chemical 0 0.9996561
nephrosis B-Disease 2 0.99969816
( O 0 0.058915235
PAN O 1 0.998423
) O 0 0.004997867
rats O 0 0.00551538
, O 0 0.00068121526
we O 0 0.00022252518
studied O 0 0.00052373175
early O 0 0.00087099295
ultrastructural O 0 0.121782355
and O 0 0.00068221794
permeability O 0 0.6674606
changes O 0 0.00080231676
in O 0 0.00023668015
relation O 0 0.00017716357
to O 0 0.00020068511
the O 0 0.00021079379
expression O 0 0.00044326452
of O 0 0.00040018515
the O 0 0.00042145312
podocyte O 0 0.93224406
- O 0 0.0016222902
associated O 0 0.0006980397
molecules O 0 0.0026535036
nephrin O 0 0.9702542
, O 0 0.0011926208
a O 0 0.00067721255
- O 0 0.001310172
actinin O 0 0.52841586
, O 0 0.0009630755
dendrin O 0 0.12529959
, O 0 0.000548878
and O 0 0.00038832313
plekhh2 O 0 0.015876524
, O 0 0.00040111152
the O 0 0.00022336993
last O 0 0.00019111887
two O 0 0.00021660105
of O 0 0.0004604029
which O 0 0.00065930386
were O 0 0.0005829228
only O 0 0.0007859137
recently O 0 0.0016464218
discovered O 0 0.003234613
in O 0 0.0031153357
podocytes O 0 0.5955324
. O 0 0.007198223

METHODS O 0 0.008426729
: O 0 0.0045193504
Using O 0 0.0030557604
immune O 0 0.0118504
stainings O 0 0.0066732313
, O 0 0.0022555937
semiquantitative O 0 0.003331475
measurement O 0 0.0012343281
was O 0 0.0013132353
performed O 0 0.0013824437
under O 0 0.0015402884
the O 0 0.0030236407
electron O 0 0.037862483
microscope O 0 0.011346721
. O 0 0.008953055

Permeability O 0 0.36134735
was O 0 0.0050842534
assessed O 0 0.003352725
using O 0 0.0035382845
isolated O 0 0.0054125753
kidney O 0 0.6939381
perfusion O 0 0.57807165
with O 0 0.012754034
tracers O 0 0.12238023
. O 0 0.013743981

Possible O 0 0.03155252
effects O 0 0.0138384225
of O 0 0.013597663
ACE O 0 0.9867242
inhibition O 0 0.051464528
were O 0 0.011879842
tested O 0 0.012119302
. O 0 0.016676156

RESULTS O 0 0.026720043
: O 0 0.0050838795
By O 0 0.0030153363
day O 0 0.0018231657
2 O 0 0.0015229274
, O 0 0.0014332011
some O 0 0.0012189489
patchy O 0 0.004687639
foot O 0 0.027793434
process O 0 0.0023660248
effacement O 0 0.29996905
, O 0 0.002513134
but O 0 0.0019083604
no O 0 0.0029428743
proteinuria B-Disease 2 0.99886084
, O 0 0.009839877
appeared O 0 0.008228588
. O 0 0.0073184296

The O 0 0.0034797648
amount O 0 0.0021748813
of O 0 0.0035177493
nephrin O 0 0.8193757
was O 0 0.0025183498
reduced O 0 0.002032923
in O 0 0.001582825
both O 0 0.0019444117
diseased O 0 0.008053953
and O 0 0.0035571284
normal O 0 0.00786465
areas O 0 0.0125083625
. O 0 0.008250842

The O 0 0.003385364
other O 0 0.0027760311
proteins O 0 0.0031288634
showed O 0 0.0016882383
few O 0 0.0012845173
changes O 0 0.0021458003
, O 0 0.0018664108
which O 0 0.0017095284
were O 0 0.0014364299
limited O 0 0.0018498906
to O 0 0.0026728306
diseased O 0 0.013796721
areas O 0 0.012565257
. O 0 0.008205478

By O 0 0.005205962
day O 0 0.0026884314
4 O 0 0.0017942897
, O 0 0.0018195699
foot O 0 0.006778963
process O 0 0.001564858
effacement O 0 0.083055206
was O 0 0.0008282255
complete O 0 0.00074292393
and O 0 0.0011487396
proteinuria B-Disease 2 0.9994698
appeared O 0 0.0014045358
in O 0 0.0006440796
parallel O 0 0.0009974227
with O 0 0.0013109085
signs O 0 0.0719453
of O 0 0.0024758407
size O 0 0.004542229
barrier O 0 0.075511955
damage O 0 0.8029439
. O 0 0.0089909155

Nephrin O 0 0.16591512
decreased O 0 0.0049096346
further O 0 0.0026108776
, O 0 0.0021327855
while O 0 0.0013110802
dendrin O 0 0.049382877
and O 0 0.0014295751
plekhh2 O 0 0.021118479
also O 0 0.0012389938
decreased O 0 0.0022112674
but O 0 0.0013084112
a O 0 0.0019362818
- O 0 0.0038540654
actinin O 0 0.43929428
remained O 0 0.006603333
unchanged O 0 0.007593092
. O 0 0.007329267

ACE O 0 0.9783262
inhibition O 0 0.025737574
had O 0 0.008459683
no O 0 0.00677789
significant O 0 0.0103952475
protective O 0 0.033495825
effect O 0 0.018563548
. O 0 0.017871825

CONCLUSIONS O 0 0.83515596
: O 0 0.009876563
PAN O 1 0.98864913
glomeruli O 0 0.12353468
already O 0 0.0019159327
showed O 0 0.0013098777
significant O 0 0.0015918987
pathology O 0 0.013553309
by O 0 0.0011727705
day O 0 0.0010927541
4 O 0 0.00096632657
, O 0 0.0013297049
despite O 0 0.0014774441
relatively O 0 0.0044733863
mild O 0 0.9171223
proteinuria B-Disease 2 0.998884
. O 0 0.0139912935

This O 0 0.005559444
was O 0 0.0026981642
preceded O 0 0.002755313
by O 0 0.0020181667
altered O 0 0.0032988489
nephrin O 0 0.9014626
expression O 0 0.00404737
, O 0 0.0018074868
supporting O 0 0.0014250781
its O 0 0.0023714334
pivotal O 0 0.002767831
role O 0 0.0018829403
in O 0 0.003621379
podocyte O 0 0.9341962
morphology O 0 0.06400143
. O 0 0.009051662

The O 0 0.0029757852
novel O 0 0.003882217
proteins O 0 0.0036130028
dendrin O 0 0.062289387
and O 0 0.001726943
plekhh2 O 0 0.017205808
were O 0 0.0009012011
both O 0 0.0006928913
reduced O 0 0.0008231986
, O 0 0.0008583753
suggesting O 0 0.00052109483
roles O 0 0.00064931385
in O 0 0.0008916189
PAN O 1 0.99676716
, O 0 0.0017037927
whereas O 0 0.0010468328
a O 0 0.0016660739
- O 0 0.0034254144
actinin O 0 0.43182445
was O 0 0.0037229764
unchanged O 0 0.0061786384
. O 0 0.0064438786

A O 0 0.014923247
novel O 0 0.005448577
, O 0 0.0031695087
multiple O 0 0.003001502
symptom O 0 0.028157918
model O 0 0.0023836736
of O 0 0.0034463361
obsessive B-Disease 0 0.9972211
- I-Disease 0 0.029959887
compulsive I-Disease 0 0.99817896
- I-Disease 0 0.0050214785
like I-Disease 0 0.0024822175
behaviors I-Disease 0 0.021703528
in O 0 0.00305398
animals O 0 0.0044458737
. O 0 0.0061885538

BACKGROUND O 0 0.703137
: O 0 0.0048042233
Current O 0 0.009621349
animal O 0 0.0028722943
models O 0 0.002391045
of O 0 0.002791723
obsessive B-Disease 0 0.99753344
- I-Disease 0 0.02403419
compulsive I-Disease 0 0.9992176
disorder I-Disease 0 0.9913094
( O 0 0.013907478
OCD B-Disease 2 0.9995066
) O 0 0.0018481215
typically O 0 0.000965679
involve O 0 0.0008365633
acute O 0 0.93235075
, O 0 0.0015629735
drug O 0 0.5397286
- O 0 0.0013676682
induced O 0 0.00084073347
symptom O 0 0.1067609
provocation O 0 0.35947955
or O 0 0.00047430847
a O 0 0.00062412245
genetic O 0 0.0013934883
association O 0 0.00096672395
with O 0 0.0035261982
stereotypies O 0 0.9982722
or O 0 0.0060416493
anxiety B-Disease 0 0.9841292
. O 0 0.0075729857

None O 0 0.0093058795
of O 0 0.0037180434
these O 0 0.0032096896
current O 0 0.0034789643
models O 0 0.0033767312
demonstrate O 0 0.002263356
multiple O 0 0.011469467
OCD B-Disease 2 0.99775463
- O 0 0.012358744
like O 0 0.007392363
behaviors O 0 0.09460853
. O 0 0.010124543

METHODS O 0 0.0072337054
: O 0 0.00418587
Neonatal O 0 0.024109332
rats O 0 0.0040236856
were O 0 0.0011356194
treated O 0 0.00147785
with O 0 0.0010841013
the O 0 0.0012084709
tricyclic O 0 0.99948525
antidepressant B-Chemical 1 0.9997775
clomipramine B-Chemical 0 0.99994504
or O 0 0.000952582
vehicle O 0 0.016914325
between O 0 0.00023486179
days O 0 0.0003350082
9 O 0 0.00030491082
and O 0 0.0002917047
16 O 0 0.00034003198
twice O 0 0.00040330522
daily O 0 0.001087419
and O 0 0.00085646106
behaviorally O 0 0.024014337
tested O 0 0.0013014016
in O 0 0.0026586016
adulthood O 0 0.1502737
. O 0 0.0056420635

RESULTS O 0 0.07014043
: O 0 0.009218363
Clomipramine B-Chemical 0 0.998985
exposure O 0 0.012846175
in O 0 0.0012296758
immature O 0 0.0030325945
rats O 0 0.0024554664
produced O 0 0.0005981572
significant O 0 0.0006909523
behavioral O 0 0.0106260395
and O 0 0.00045175827
biochemical O 0 0.012362463
changes O 0 0.0006168948
that O 0 0.00025774282
include O 0 0.00045619736
enhanced O 0 0.0010065506
anxiety B-Disease 0 0.9888158
( O 0 0.00094538665
elevated O 0 0.0032739893
plus O 0 0.00040574954
maze O 0 0.06412911
and O 0 0.0005094866
marble O 0 0.019088076
burying O 0 0.1705034
) O 0 0.0012973858
, O 0 0.0005956165
behavioral B-Disease 0 0.29250845
inflexibility I-Disease 0 0.85648173
( O 0 0.0013061477
perseveration O 0 0.95928186
in O 0 0.00024490742
the O 0 0.00023042981
spontaneous O 0 0.0069911615
alternation O 0 0.012810892
task O 0 0.0007648315
and O 0 0.00028741526
impaired O 0 0.000655837
reversal O 0 0.00304655
learning O 0 0.010922775
) O 0 0.0008493407
, O 0 0.0004320394
working O 0 0.0014106701
memory B-Disease 2 0.80729735
impairment I-Disease 2 0.9092795
( O 0 0.0008895086
e O 0 0.0009890373
. O 0 0.00020927082
g O 0 0.0008405893
. O 0 0.00021030213
, O 0 0.00044454198
win O 0 0.0015162174
- O 0 0.0007171851
shift O 0 0.00086062006
paradigm O 0 0.0016142896
) O 0 0.0016687209
, O 0 0.0017445424
hoarding B-Disease 0 0.8308083
, O 0 0.0026767359
and O 0 0.003957666
corticostriatal B-Disease 0 0.9947464
dysfunction I-Disease 0 0.9926292
. O 0 0.009229959

Dopamine B-Chemical 1 0.99713624
D2 O 0 0.9886895
receptors O 0 0.28078634
were O 0 0.0022297322
elevated O 0 0.0047086985
in O 0 0.0010466439
the O 0 0.0011232332
striatum O 0 0.65665174
, O 0 0.001215257
whereas O 0 0.00090021425
serotonin B-Chemical 1 0.99829787
2C O 0 0.0022983886
, O 0 0.00081732316
but O 0 0.000477117
not O 0 0.00058415584
serotonin B-Chemical 1 0.99809426
1A O 0 0.0018387063
, O 0 0.0009434394
receptors O 0 0.041299768
were O 0 0.0007832757
elevated O 0 0.0029958081
in O 0 0.0010285479
the O 0 0.0017505833
orbital O 0 0.17497067
frontal O 0 0.75808924
cortex O 0 0.5575495
. O 0 0.0065522976

CONCLUSIONS O 0 0.72609466
: O 0 0.00510403
This O 0 0.0026192202
is O 0 0.0012249051
the O 0 0.0008161993
first O 0 0.0006050219
demonstration O 0 0.0009851402
of O 0 0.0008706195
multiple O 0 0.0016587566
symptoms O 0 0.24964173
consistent O 0 0.0009775329
with O 0 0.0013110868
an O 0 0.0033855187
OCD B-Disease 2 0.9990657
- O 0 0.003323754
like O 0 0.0016081738
profile O 0 0.0025826502
in O 0 0.0024943303
animals O 0 0.0039400286
. O 0 0.0056326655

Moreover O 0 0.005751929
, O 0 0.0034792821
these O 0 0.0025920207
behaviors O 0 0.009158465
are O 0 0.0013692301
accompanied O 0 0.0019696683
by O 0 0.0009539215
biochemical O 0 0.013752044
changes O 0 0.0013542861
in O 0 0.0007324719
brain O 0 0.021042842
regions O 0 0.0010230229
previously O 0 0.0008514252
identified O 0 0.0009026914
as O 0 0.001173389
relevant O 0 0.0025985567
to O 0 0.004770335
OCD B-Disease 2 0.9960306
. O 0 0.008640962

This O 0 0.004298955
novel O 0 0.0034021256
model O 0 0.002360745
of O 0 0.0025963897
OCD B-Disease 2 0.99805754
demonstrates O 0 0.0009125211
that O 0 0.00062436936
drug O 0 0.19319196
exposure O 0 0.0034509166
during O 0 0.00030978658
a O 0 0.00037375232
sensitive O 0 0.00034620264
period O 0 0.0002804633
can O 0 0.0002325145
program O 0 0.00043672076
disease O 0 0.58629704
- O 0 0.0009013506
like O 0 0.00032121598
systems O 0 0.00067311066
permanently O 0 0.0029039322
, O 0 0.00040333543
which O 0 0.00031980453
could O 0 0.00016231256
have O 0 0.00020981906
implications O 0 0.00033779803
for O 0 0.00019459889
current O 0 0.0004540546
and O 0 0.0003103302
future O 0 0.00033407088
therapeutic O 0 0.002894169
strategies O 0 0.0007270347
for O 0 0.0004845887
this O 0 0.00075240934
and O 0 0.0013121575
other O 0 0.0029843606
psychiatric B-Disease 2 0.9951108
disorders I-Disease 0 0.98762995
. O 0 0.0090273535

Elevation O 0 0.40104654
of O 0 0.007814315
ADAM10 O 0 0.9844875
, O 0 0.008472496
ADAM17 O 0 0.9834812
, O 0 0.006255821
MMP O 0 0.98544127
- O 0 0.0032661015
2 O 0 0.0009436021
and O 0 0.001015463
MMP O 0 0.961118
- O 0 0.0014981348
9 O 0 0.00049732084
expression O 0 0.0006637581
with O 0 0.0006537075
media O 0 0.008167574
degeneration O 0 0.9917311
features O 0 0.04360551
CaCl2 B-Chemical 0 0.9985557
- O 0 0.002677148
induced O 0 0.0015899537
thoracic B-Disease 0 0.24568026
aortic I-Disease 0 0.895245
aneurysm I-Disease 2 0.9949656
in O 0 0.0018850177
a O 0 0.0028007391
rat O 0 0.017779332
model O 0 0.0062595955
. O 0 0.0062310086

PURPOSE O 0 0.044290315
: O 0 0.0039975834
This O 0 0.002251841
study O 0 0.0016423896
was O 0 0.00090328243
designed O 0 0.00081108033
to O 0 0.0005743278
establish O 0 0.0005183465
a O 0 0.0006247179
rat O 0 0.002627578
model O 0 0.00074333017
of O 0 0.0008680297
thoracic B-Disease 0 0.1775869
aortic I-Disease 0 0.9146415
aneurysm I-Disease 2 0.99837875
( O 0 0.006419928
TAA B-Disease 0 0.9920575
) O 0 0.0029050247
by O 0 0.0010612265
calcium B-Chemical 1 0.9988809
chloride I-Chemical 0 0.9996718
( O 0 0.023410875
CaCl B-Chemical 0 0.99945563
( I-Chemical 0 0.0013406797
2 I-Chemical 0 0.0004888722
) I-Chemical 0 0.0007686492
) O 0 0.0007247681
- O 0 0.0005936482
induced O 0 0.00062506925
arterial B-Disease 0 0.9593468
injury I-Disease 0 0.98075
and O 0 0.0003993958
to O 0 0.00020082678
explore O 0 0.00015170501
the O 0 0.00016975372
potential O 0 0.0003044176
role O 0 0.00017879358
of O 0 0.00042007215
a O 0 0.0006810448
disintegrin O 0 0.95082164
and O 0 0.0014498932
metalloproteinase O 0 0.9921829
( O 0 0.0052778577
ADAM O 0 0.98288786
) O 0 0.0023101994
, O 0 0.0009377916
matrix O 0 0.049184307
metalloproteinases O 0 0.9975222
( O 0 0.0043890118
MMPs O 0 0.98837346
) O 0 0.0012002494
and O 0 0.00049783214
their O 0 0.00057648093
endogenous O 0 0.001452326
inhibitors O 0 0.18223749
( O 0 0.0039998046
TIMPs O 0 0.9854012
) O 0 0.0045747547
in O 0 0.0030089684
TAA B-Disease 0 0.9753954
formation O 0 0.046697438
. O 0 0.0076408684

METHODS O 0 0.008449183
: O 0 0.0050786133
Thoracic O 0 0.010502447
aorta O 0 0.0359906
of O 0 0.0023186512
male O 0 0.0067703184
Sprague O 0 0.3647457
- O 0 0.0025837878
Dawley O 0 0.18458495
rats O 0 0.002355567
was O 0 0.0006490091
exposed O 0 0.00070481555
to O 0 0.0005676289
0 O 0 0.0007816125
. O 0 0.00053953804
5M O 0 0.2846578
CaCl B-Chemical 0 0.99787545
( I-Chemical 0 0.0014073403
2 I-Chemical 0 0.000793841
) I-Chemical 0 0.0010755295
or O 0 0.0007352434
normal O 0 0.0024525018
saline O 0 0.15792978
( O 0 0.0056236987
NaCl B-Chemical 1 0.97801584
) O 0 0.0094621135
. O 0 0.006482487

After O 0 0.0026945572
12weeks O 0 0.008849906
, O 0 0.0020474324
animals O 0 0.0010154848
were O 0 0.00087577675
euthanized O 0 0.0013894764
, O 0 0.0010889319
and O 0 0.0011764632
CaCl B-Chemical 0 0.9981889
( I-Chemical 0 0.00142326
2 I-Chemical 0 0.0006410427
) I-Chemical 0 0.00094500615
- O 0 0.0007844024
treated O 0 0.0010046154
, O 0 0.0012011175
CaCl B-Chemical 0 0.9989404
( I-Chemical 0 0.0009428908
2 I-Chemical 0 0.0004247412
) I-Chemical 0 0.00065316405
- O 0 0.0005125068
untreated O 0 0.00050476665
( O 0 0.00039630572
n O 0 0.00023670858
= O 0 0.00037065998
12 O 0 0.00018693169
) O 0 0.00040646904
and O 0 0.0003863392
NaCl B-Chemical 1 0.9873165
- O 0 0.0008041108
treated O 0 0.000825951
aortic O 0 0.35399172
segments O 0 0.00089901034
( O 0 0.00052156
n O 0 0.000300315
= O 0 0.00045411978
12 O 0 0.00023412779
) O 0 0.000435539
were O 0 0.0003028804
collected O 0 0.00033889138
for O 0 0.0005681764
histological O 0 0.051017962
and O 0 0.002046645
molecular O 0 0.018853635
assessments O 0 0.006126168
. O 0 0.005772789

MMP O 0 0.9688112
- O 0 0.014117781
TIMP O 0 0.89020675
and O 0 0.0040968014
ADAM O 0 0.8981032
mRNAs O 0 0.0038510256
were O 0 0.0012262553
semi O 0 0.003273611
- O 0 0.0014328765
quantitatively O 0 0.0008846847
analyzed O 0 0.00064305955
and O 0 0.0009115279
protein O 0 0.0019106453
expressions O 0 0.0022938193
were O 0 0.0014408262
determined O 0 0.0015928905
by O 0 0.0034613537
immunohistochemistry O 0 0.03414336
. O 0 0.0077632903

RESULTS O 0 0.023605436
: O 0 0.003928843
Despite O 0 0.0020110367
similar O 0 0.0011047655
external O 0 0.0021581035
diameters O 0 0.011230045
among O 0 0.002249224
CaCl B-Chemical 0 0.99815506
( I-Chemical 0 0.001919706
2 I-Chemical 0 0.00078810484
) I-Chemical 0 0.0010700852
- O 0 0.00081516785
treated O 0 0.00082955393
, O 0 0.0006700969
non O 0 0.0017764245
- O 0 0.0031540287
CaCl B-Chemical 0 0.9990484
( I-Chemical 0 0.0009756822
2 I-Chemical 0 0.00042677374
) I-Chemical 0 0.0006582183
- O 0 0.0005215249
treated O 0 0.00057438674
and O 0 0.00051803037
NaCl B-Chemical 1 0.9938478
- O 0 0.0008795781
treated O 0 0.0006627078
segments O 0 0.0005749566
, O 0 0.00043932415
aneurymal O 0 0.0078027206
alteration O 0 0.0022220374
( O 0 0.00053232367
n O 0 0.00026652694
= O 0 0.00039056793
6 O 0 0.00016236487
, O 0 0.00024936852
50 O 0 0.00034038958
% O 0 0.00027768235
) O 0 0.00037953432
, O 0 0.0003224583
media O 0 0.0016875
degeneration O 0 0.95506346
with O 0 0.00046965672
regional O 0 0.0010478212
disruption O 0 0.00069886114
, O 0 0.0004565678
fragmentation O 0 0.007692349
of O 0 0.00049720093
elastic O 0 0.064007126
fiber O 0 0.060672197
, O 0 0.00060917775
and O 0 0.00035652865
increased O 0 0.0009839616
collagen O 0 0.2927802
deposition O 0 0.05746708
( O 0 0.0007748152
n O 0 0.00030622934
= O 0 0.0004203167
12 O 0 0.00018427377
, O 0 0.00029002977
100 O 0 0.000512863
% O 0 0.00032918158
) O 0 0.00040628752
were O 0 0.00028390365
demonstrated O 0 0.00047082268
in O 0 0.00074284227
CaCl B-Chemical 0 0.9978587
( I-Chemical 0 0.0015870475
2 I-Chemical 0 0.001157392
) I-Chemical 0 0.002051954
- O 0 0.0025172876
treated O 0 0.0036407108
segments O 0 0.0057845553
. O 0 0.00538584

MMP O 0 0.9611663
- O 0 0.009009544
2 O 0 0.0033631758
, O 0 0.0037161151
MMP O 0 0.9469228
- O 0 0.0033282512
9 O 0 0.0012456238
, O 0 0.0014725245
ADAM O 0 0.8875011
- O 0 0.0013725641
10 O 0 0.00057807
and O 0 0.0006275737
ADAM O 0 0.8940533
- O 0 0.0010028817
17 O 0 0.0005728626
mRNA O 0 0.000574303
levels O 0 0.00027975108
were O 0 0.00028912697
increased O 0 0.00064507965
in O 0 0.00055225886
CaCl B-Chemical 0 0.9991731
( I-Chemical 0 0.00090460014
2 I-Chemical 0 0.00038884638
) I-Chemical 0 0.0005936147
- O 0 0.00044852315
treated O 0 0.0004544519
segments O 0 0.0004697145
( O 0 0.0003430268
all O 0 0.000187837
p O 0 0.00035650638
< O 0 0.00028912144
0 O 0 0.00025017676
. O 0 0.00015413246
01 O 0 0.0017180935
) O 0 0.00040467412
, O 0 0.0002743885
with O 0 0.00026446595
trends O 0 0.00045825
of O 0 0.00052745105
elevation O 0 0.3623435
in O 0 0.0008385517
CaCl B-Chemical 0 0.9993043
( I-Chemical 0 0.0010218702
2 I-Chemical 0 0.00043965134
) I-Chemical 0 0.00066862674
- O 0 0.0005327333
untreated O 0 0.0005167171
segments O 0 0.00060552685
, O 0 0.00052060734
as O 0 0.0003588394
compared O 0 0.00041478855
with O 0 0.0014951363
NaCl B-Chemical 1 0.98726976
- O 0 0.0039998027
treated O 0 0.004692402
segments O 0 0.006528629
. O 0 0.005585233

Immunohistochemistry O 0 0.100735016
displayed O 0 0.0026291697
significantly O 0 0.002323348
increased O 0 0.0022710843
expressions O 0 0.003092853
of O 0 0.0026257397
MMP O 0 0.99037033
- O 0 0.00403466
2 O 0 0.0010026877
, O 0 0.0013044123
MMP O 0 0.96739143
- O 0 0.0017382717
9 O 0 0.00059260544
, O 0 0.0007940832
ADAM O 0 0.8882684
- O 0 0.000902147
10 O 0 0.00040288275
and O 0 0.00047297144
ADAM O 0 0.8936762
- O 0 0.00089618337
17 O 0 0.00053914916
( O 0 0.00035557756
all O 0 0.00020738677
p O 0 0.000389811
< O 0 0.00033446756
0 O 0 0.00029768643
. O 0 0.00019283035
01 O 0 0.0017891958
) O 0 0.0005274253
in O 0 0.00036694936
intima O 0 0.73846793
and O 0 0.00062950025
media O 0 0.0025786944
for O 0 0.00094153255
CaCl B-Chemical 0 0.99832875
( I-Chemical 0 0.0018212664
2 I-Chemical 0 0.0012349326
) I-Chemical 0 0.0021426354
- O 0 0.0025923743
treated O 0 0.0037187326
segments O 0 0.005873866
. O 0 0.0054563447

TIMP O 0 0.85828316
mRNA O 0 0.0075040367
and O 0 0.003081352
tissue O 0 0.006256864
levels O 0 0.0016784988
did O 0 0.0012376409
not O 0 0.0010199444
differ O 0 0.0014126045
obviously O 0 0.0033707763
among O 0 0.0018408177
the O 0 0.0017744952
three O 0 0.0020390123
aortic O 0 0.41879267
segments O 0 0.0104424255
. O 0 0.007932701

CONCLUSION O 0 0.80138665
: O 0 0.004804321
This O 0 0.0025473745
study O 0 0.001938371
establishes O 0 0.0018259038
a O 0 0.0015808195
TAA B-Disease 0 0.9224234
model O 0 0.0019194202
by O 0 0.0014768793
periarterial O 0 0.98207206
CaCl B-Chemical 0 0.99933714
( I-Chemical 0 0.0016690453
2 I-Chemical 0 0.000509784
) I-Chemical 0 0.0005852596
exposure O 0 0.0011254438
in O 0 0.0002769917
rats O 0 0.0015064405
, O 0 0.00035766113
and O 0 0.0002482843
demonstrates O 0 0.00019108936
a O 0 0.00029123094
significant O 0 0.0004374386
elevation O 0 0.09248334
of O 0 0.0005452088
expression O 0 0.0011192199
of O 0 0.0013778328
MMP O 0 0.9927886
- O 0 0.0026150655
2 O 0 0.00058867555
, O 0 0.000892034
MMP O 0 0.9661854
- O 0 0.0013979318
9 O 0 0.0005321456
, O 0 0.0007666002
ADAM10 O 0 0.9368369
and O 0 0.0010689023
ADAM17 O 0 0.9112327
in O 0 0.0008062964
the O 0 0.0010243424
pathogenesis O 0 0.01775506
of O 0 0.0042218384
vascular O 0 0.87778234
remodeling O 0 0.32546434
. O 0 0.007633571

Suxamethonium B-Chemical 1 0.97779137
induced O 0 0.0081296675
prolonged O 0 0.07193596
apnea B-Disease 2 0.9926714
in O 0 0.0033034538
a O 0 0.0032403034
patient O 0 0.0052282983
receiving O 0 0.02207528
electroconvulsive O 0 0.9928818
therapy O 0 0.3740139
. O 0 0.01307229

Suxamethonium B-Chemical 1 0.98133594
causes O 0 0.008862421
prolonged O 0 0.07045429
apnea B-Disease 2 0.99530375
in O 0 0.0019700301
patients O 0 0.0036455537
in O 0 0.0011909237
whom O 0 0.0074436152
pseudocholinesterase O 0 0.9946295
enzyme O 0 0.2547769
gets O 0 0.0053240075
deactivated O 0 0.09226187
by O 0 0.0051865894
organophosphorus B-Chemical 0 0.99949527
( I-Chemical 0 0.04381359
OP I-Chemical 0 0.99557495
) I-Chemical 0 0.028115502
poisons I-Chemical 0 0.8544899
. O 0 0.010811286

Here O 0 0.005829486
, O 0 0.0028474499
we O 0 0.0009892384
present O 0 0.0009073728
a O 0 0.0010537604
similar O 0 0.00071581954
incident O 0 0.0075101233
in O 0 0.0007628709
a O 0 0.0009605382
severely O 0 0.008580539
depressed B-Disease 2 0.41818848
patient O 0 0.0015481005
who O 0 0.00207157
received O 0 0.0018938
electroconvulsive O 0 0.9959181
therapy O 0 0.25331444
( O 0 0.009783506
ECT O 0 0.9863513
) O 0 0.012061732
. O 0 0.0069385036

Prolonged O 0 0.33080164
apnea B-Disease 2 0.9893266
in O 0 0.002218121
our O 0 0.0012580899
case O 0 0.0012292584
ensued O 0 0.0058432226
because O 0 0.0006640997
the O 0 0.00065352017
information O 0 0.0009787165
about O 0 0.00085522723
suicidal O 0 0.9816595
attempt O 0 0.001454175
by O 0 0.0012983413
OP B-Chemical 0 0.9980154
compound I-Chemical 0 0.4840596
was O 0 0.0013606378
concealed O 0 0.004815304
from O 0 0.0014364504
the O 0 0.0019942664
treating O 0 0.009181349
team O 0 0.006796006
. O 0 0.006913044

Curcumin B-Chemical 0 0.9981933
ameliorates O 0 0.98571604
cognitive B-Disease 0 0.9804827
dysfunction I-Disease 0 0.98701155
and O 0 0.0065598907
oxidative O 0 0.98813707
damage O 0 0.917637
in O 0 0.005378871
phenobarbitone B-Chemical 0 0.99967253
and O 0 0.033361893
carbamazepine B-Chemical 1 0.9997179
administered O 0 0.17446616
rats O 0 0.06505643
. O 0 0.008471097

The O 0 0.0051848013
antiepileptic O 0 0.9946181
drugs O 0 0.90300745
, O 0 0.00838035
phenobarbitone B-Chemical 0 0.9996685
and O 0 0.008723058
carbamazepine B-Chemical 1 0.9998398
are O 0 0.0016967567
well O 0 0.00081564806
known O 0 0.0012118389
to O 0 0.000950446
cause O 0 0.004856855
cognitive B-Disease 0 0.8016396
impairment I-Disease 0 0.49779812
on O 0 0.0022399612
chronic O 0 0.9542989
use O 0 0.011372346
. O 0 0.007676358

The O 0 0.0029948785
increase O 0 0.002176985
in O 0 0.0015411371
free O 0 0.0021639564
radical O 0 0.38863236
generation O 0 0.0020802745
has O 0 0.0010124289
been O 0 0.0009264527
implicated O 0 0.00074500416
as O 0 0.0004147656
one O 0 0.00033734943
of O 0 0.00052982004
the O 0 0.00044630916
important O 0 0.0004992263
mechanisms O 0 0.0012043838
of O 0 0.0014507557
cognitive B-Disease 0 0.83344805
impairment I-Disease 0 0.6669778
by O 0 0.005632137
antiepileptic O 0 0.99821967
drugs O 0 0.94991994
. O 0 0.008465956

Curcumin B-Chemical 0 0.997375
has O 0 0.0074533946
shown O 0 0.004438786
antioxidant O 0 0.98982364
, O 0 0.0067243194
anti O 0 0.023652025
- O 0 0.007483945
inflammatory O 0 0.7680979
and O 0 0.00531648
neuro O 0 0.75488734
- O 0 0.01006534
protective O 0 0.041769736
properties O 0 0.015463604
. O 0 0.009385738

Therefore O 0 0.0032622404
, O 0 0.0024479143
the O 0 0.0011763748
present O 0 0.00077022234
study O 0 0.0011028774
was O 0 0.0005919219
carried O 0 0.00039947388
out O 0 0.00033671674
to O 0 0.00034184274
investigate O 0 0.00024352732
the O 0 0.00032312152
effect O 0 0.0004833625
of O 0 0.00088199135
chronic O 0 0.98968047
curcumin B-Chemical 1 0.99979776
administration O 0 0.8330281
on O 0 0.000860534
phenobarbitone B-Chemical 0 0.9999342
- O 0 0.013504438
and O 0 0.0021712359
carbamazepine B-Chemical 1 0.999936
- O 0 0.0049996125
induced O 0 0.0019153612
cognitive B-Disease 0 0.8658407
impairment I-Disease 0 0.59673315
and O 0 0.0023554582
oxidative O 0 0.98360205
stress O 0 0.6868453
in O 0 0.004430721
rats O 0 0.029301157
. O 0 0.006077182

Pharmacokinetic O 0 0.9210704
interactions O 0 0.007963968
of O 0 0.0060270373
curcumin B-Chemical 1 0.99680126
with O 0 0.016380092
phenobarbitone B-Chemical 0 0.9995696
and O 0 0.02974026
carbamazepine B-Chemical 1 0.9996045
were O 0 0.0068589267
also O 0 0.0064080125
studied O 0 0.01022683
. O 0 0.0093590235

Vehicle O 0 0.62693554
/ O 0 0.00986331
drugs O 0 0.27939135
were O 0 0.0028464196
administered O 0 0.004459992
daily O 0 0.004329473
for O 0 0.002188892
21days O 0 0.123879395
to O 0 0.0037260002
male O 0 0.015002946
Wistar O 0 0.38645217
rats O 0 0.020170711
. O 0 0.0096424185

Passive O 0 0.026258701
avoidance O 0 0.008894113
paradigm O 0 0.004618479
and O 0 0.0022847133
elevated O 0 0.0041788253
plus O 0 0.0017115126
maze O 0 0.02873098
test O 0 0.0016154774
were O 0 0.0013286542
used O 0 0.001317794
to O 0 0.0016154851
assess O 0 0.0017147844
cognitive O 0 0.36656716
function O 0 0.008952726
. O 0 0.008291496

At O 0 0.0023362392
the O 0 0.0017418076
end O 0 0.0009967311
of O 0 0.0013528082
study O 0 0.0015539107
period O 0 0.0011053097
, O 0 0.0015361514
serum O 0 0.1861638
phenobarbitone B-Chemical 0 0.9998128
and O 0 0.008013286
carbamazepine B-Chemical 1 0.99990416
, O 0 0.0025632507
whole O 0 0.0013815191
brain O 0 0.3096368
malondialdehyde B-Chemical 1 0.9998196
and O 0 0.0035181872
reduced O 0 0.010629032
glutathione B-Chemical 0 0.9987134
levels O 0 0.0042948867
were O 0 0.0036638791
estimated O 0 0.0048250076
. O 0 0.0064814645

The O 0 0.0034738153
administration O 0 0.044925883
of O 0 0.0040106513
phenobarbitone B-Chemical 0 0.9995921
and O 0 0.007157202
carbamazepine B-Chemical 1 0.99983644
for O 0 0.0013902697
21days O 0 0.36563146
caused O 0 0.0009735781
a O 0 0.000659137
significant O 0 0.0007804832
impairment B-Disease 0 0.23698054
of I-Disease 0 0.0007911183
learning I-Disease 0 0.018778505
and I-Disease 0 0.0007787588
memory I-Disease 0 0.115959026
as O 0 0.0005380941
well O 0 0.0005915848
as O 0 0.00075328996
an O 0 0.0017865772
increased O 0 0.005520038
oxidative O 0 0.98423994
stress O 0 0.8439467
. O 0 0.009612679

Concomitant O 0 0.42756885
curcumin B-Chemical 1 0.9971706
administration O 0 0.5036614
prevented O 0 0.008392182
the O 0 0.0017434012
cognitive B-Disease 0 0.7714017
impairment I-Disease 0 0.4435998
and O 0 0.0010596041
decreased O 0 0.0016707692
the O 0 0.00075972127
increased O 0 0.0024195854
oxidative O 0 0.9800613
stress O 0 0.6299922
induced O 0 0.0038217306
by O 0 0.0023863032
these O 0 0.0070144823
antiepileptic O 0 0.99805886
drugs O 0 0.9531997
. O 0 0.009095195

Curcumin B-Chemical 0 0.99831945
co O 0 0.7239458
- O 0 0.008595329
administration O 0 0.1232098
did O 0 0.0013256749
not O 0 0.0008436216
cause O 0 0.0017252218
any O 0 0.00053011905
significant O 0 0.00077326584
alteration O 0 0.0013382629
in O 0 0.0004676453
the O 0 0.0005332903
serum O 0 0.044423923
concentrations O 0 0.0031370462
of O 0 0.0011449651
both O 0 0.0016365026
phenobarbitone B-Chemical 0 0.9996829
as O 0 0.0019793946
well O 0 0.002372336
as O 0 0.004834954
carbamazepine B-Chemical 1 0.99932873
. O 0 0.009905002

These O 0 0.0041051838
results O 0 0.0020913908
show O 0 0.0014662
that O 0 0.0014169982
curcumin B-Chemical 1 0.9975121
has O 0 0.0014633877
beneficial O 0 0.0046050763
effect O 0 0.00094023667
in O 0 0.0005165541
mitigating O 0 0.005215656
the O 0 0.0005348544
deterioration B-Disease 0 0.18506517
of I-Disease 0 0.00087788136
cognitive I-Disease 0 0.7355177
functions I-Disease 0 0.001268429
and O 0 0.0007270406
oxidative O 0 0.98224235
damage O 0 0.81124777
in O 0 0.00054074265
rats O 0 0.0051729456
treated O 0 0.0011482211
with O 0 0.0012783738
phenobarbitone B-Chemical 0 0.9998882
and O 0 0.0052605327
carbamazepine B-Chemical 1 0.99990594
without O 0 0.0016133699
significantly O 0 0.0016041549
altering O 0 0.002541215
their O 0 0.0025711039
serum O 0 0.23102677
concentrations O 0 0.034277163
. O 0 0.0065210196

The O 0 0.002938864
findings O 0 0.0034434325
suggest O 0 0.0014452359
that O 0 0.0015259527
curcumin B-Chemical 1 0.99765944
can O 0 0.001203479
be O 0 0.00079231366
considered O 0 0.0004705422
as O 0 0.0003225616
a O 0 0.00040159762
potential O 0 0.0005352642
safe O 0 0.0015575903
and O 0 0.0004509348
effective O 0 0.0008097741
adjuvant O 0 0.24870048
to O 0 0.0008681001
phenobarbitone B-Chemical 0 0.99989235
and O 0 0.004601637
carbamazepine B-Chemical 1 0.99993587
therapy O 0 0.13286762
in O 0 0.00074565754
preventing O 0 0.0044472776
cognitive B-Disease 0 0.87549645
impairment I-Disease 0 0.52437913
associated O 0 0.0026014897
with O 0 0.0028899133
these O 0 0.005802364
drugs O 0 0.8433896
. O 0 0.007316161

Can O 0 0.07997453
angiogenesis O 0 0.82109654
be O 0 0.003810924
a O 0 0.002510716
target O 0 0.0019886487
of O 0 0.0025061844
treatment O 0 0.005049864
for O 0 0.0039845533
ribavirin B-Chemical 1 0.9976521
associated O 0 0.28823513
hemolytic B-Disease 2 0.9994778
anemia I-Disease 2 0.99934846
? O 0 0.27777526

BACKGROUND O 0 0.8274576
/ O 0 0.010067603
AIMS O 0 0.09538011
: O 0 0.0033136064
Recently O 0 0.0039094924
ribavirin B-Chemical 1 0.99703467
has O 0 0.0014609165
been O 0 0.0011147509
found O 0 0.00060723204
to O 0 0.00052313955
inhibit O 0 0.0009773858
angiogenesis O 0 0.9236616
and O 0 0.0006107451
a O 0 0.00044871744
number O 0 0.0003062606
of O 0 0.00072896684
angiogenesis O 0 0.9652825
inhibitors O 0 0.14529924
such O 0 0.0006412972
as O 0 0.00064662896
sunitinib B-Chemical 0 0.99938357
and O 0 0.0019942978
sorafenib B-Chemical 1 0.9993875
have O 0 0.0013336488
been O 0 0.0013472628
found O 0 0.0010742812
to O 0 0.0016224433
cause O 0 0.03404774
acute O 0 0.9924623
hemolysis B-Disease 0 0.99823254
. O 0 0.013033835

We O 0 0.0028969378
aimed O 0 0.0021678559
to O 0 0.0012467157
investigate O 0 0.00070025516
whether O 0 0.00045075407
there O 0 0.00043830037
is O 0 0.0005429824
a O 0 0.0005260382
relation O 0 0.0003529734
between O 0 0.00031617665
hemoglobin O 0 0.7970023
, O 0 0.0013855802
haptoglobin O 0 0.972484
and O 0 0.0011437637
angiogenesis O 0 0.9554586
soluble O 0 0.013344709
markers O 0 0.0019784
which O 0 0.0007685126
are O 0 0.0005088542
modifiable O 0 0.018446174
and O 0 0.0006034117
can O 0 0.00049012987
help O 0 0.00086882
in O 0 0.0008189452
developing O 0 0.004232498
strategies O 0 0.0038627947
against O 0 0.0064569246
anemia B-Disease 0 0.9981179
. O 0 0.011152839

METHODS O 0 0.00739095
: O 0 0.0040997854
Fourteen O 0 0.006694388
patients O 0 0.0037103572
chronically B-Disease 0 0.021354632
infected I-Disease 0 0.0019404256
with I-Disease 0 0.0041359
hepatitis I-Disease 2 0.99985325
C I-Disease 0 0.9971969
virus I-Disease 0 0.356517
were O 0 0.0014498788
treated O 0 0.0024014453
by O 0 0.002050929
pegylated B-Chemical 0 0.99749655
interferon I-Chemical 0 0.99922884
alpha I-Chemical 0 0.86455166
2a I-Chemical 0 0.020615788
and O 0 0.009396708
ribavirin B-Chemical 1 0.9961935
. O 0 0.011102768

Serum O 0 0.59349054
hemoglobin O 0 0.8762451
, O 0 0.0064212843
haptoglobin O 0 0.9452779
and O 0 0.0029242712
angiogenesis O 0 0.9139402
markers O 0 0.0034382718
of O 0 0.0019058761
vascular O 0 0.86739284
endothelial O 0 0.98359203
growth O 0 0.045576856
factor O 0 0.01576065
and O 0 0.0010853488
angiopoetin O 0 0.22248404
- O 0 0.0013515622
2 O 0 0.000536633
were O 0 0.0004642095
investigated O 0 0.0005947418
before O 0 0.00058366195
and O 0 0.0013535524
after O 0 0.0016583358
therapy O 0 0.028113
. O 0 0.0060004094

RESULTS O 0 0.026178958
: O 0 0.0042974246
We O 0 0.0016953899
observed O 0 0.0010911402
a O 0 0.0012162408
significant O 0 0.0012414379
decrease O 0 0.001211062
in O 0 0.0009956623
haptoglobin O 0 0.8858164
levels O 0 0.0010531252
at O 0 0.00056968495
the O 0 0.00069527753
end O 0 0.00061746716
of O 0 0.0014184687
the O 0 0.0017877612
treatment O 0 0.005434935
period O 0 0.005356425
. O 0 0.006254031

Hemoglobin O 0 0.9783554
levels O 0 0.0075013875
also O 0 0.005977468
decreased O 0 0.008626009
but O 0 0.006696383
insignificantly O 0 0.21733898
by O 0 0.009864534
treatment O 0 0.022744391
. O 0 0.014022204

In O 0 0.0028867135
contrast O 0 0.0021580523
with O 0 0.0017537227
the O 0 0.0012598765
literature O 0 0.002375611
, O 0 0.0014212392
serum O 0 0.023921195
levels O 0 0.00075456774
of O 0 0.0011295386
angiogenesis O 0 0.94325244
factors O 0 0.004998673
did O 0 0.0005814972
not O 0 0.0004564917
change O 0 0.0006424075
significantly O 0 0.0009895355
by O 0 0.0015542515
pegylated B-Chemical 0 0.99712294
interferon I-Chemical 0 0.99905354
and O 0 0.031358577
ribavirin B-Chemical 1 0.9984848
therapy O 0 0.6118218
. O 0 0.009812129

We O 0 0.0037051945
found O 0 0.002349374
no O 0 0.0014903955
correlation O 0 0.0012374759
of O 0 0.0023945896
angiogenesis O 0 0.9074659
soluble O 0 0.018212657
markers O 0 0.0050566406
with O 0 0.0032517384
either O 0 0.0038068115
hemoglobin O 0 0.9170279
or O 0 0.0076420656
haptoglobin O 0 0.97843516
. O 0 0.012480821

CONCLUSION O 0 0.8315401
: O 0 0.004676408
This O 0 0.002351438
is O 0 0.0010676759
the O 0 0.0006962863
first O 0 0.0005115082
study O 0 0.00077237585
in O 0 0.00039256611
the O 0 0.00036203847
literature O 0 0.00071033614
investigating O 0 0.0003936176
a O 0 0.00041534385
link O 0 0.00037598872
between O 0 0.00026335832
angiogenesis O 0 0.89350533
soluble O 0 0.012227935
markers O 0 0.003027527
and O 0 0.0011258218
ribavirin B-Chemical 1 0.99939024
induced O 0 0.01542629
anemia B-Disease 0 0.99976486
in O 0 0.0010184622
patients O 0 0.013022292
with O 0 0.0062442645
hepatitis B-Disease 2 0.99993575
C I-Disease 0 0.99699473
and O 0 0.0013985351
we O 0 0.00045534695
could O 0 0.0006188084
not O 0 0.0009013248
find O 0 0.0013406095
any O 0 0.0018845431
relation O 0 0.0030308578
. O 0 0.005262824

Future O 0 0.004368216
research O 0 0.0028597275
with O 0 0.0015951404
larger O 0 0.0010133311
number O 0 0.00074653036
of O 0 0.0009562488
patients O 0 0.0018228282
is O 0 0.000554606
needed O 0 0.00031121346
to O 0 0.00035383052
find O 0 0.0003623331
out O 0 0.00030979363
modifiable O 0 0.0073706903
factors O 0 0.0013422008
that O 0 0.00039522687
will O 0 0.00035408916
improve O 0 0.0004800198
the O 0 0.0007649806
safety O 0 0.003245749
of O 0 0.003775268
ribavirin B-Chemical 1 0.99728525
therapy O 0 0.40426967
. O 0 0.008759299

Reduction O 0 0.012616237
in O 0 0.0034350273
injection O 0 0.0082953945
pain B-Disease 0 0.9086901
using O 0 0.002515775
buffered O 0 0.58992356
lidocaine B-Chemical 0 0.9981548
as O 0 0.0017055025
a O 0 0.0018125111
local O 0 0.003301065
anesthetic O 0 0.33544827
before O 0 0.0024373366
cardiac O 0 0.39376438
catheterization O 0 0.27677065
. O 0 0.008028983

Previous O 0 0.004214697
reports O 0 0.0034776619
have O 0 0.0019798006
suggested O 0 0.00162831
that O 0 0.0012908727
pain B-Disease 0 0.9052148
associated O 0 0.0015879718
with O 0 0.00096597994
the O 0 0.00065845676
injection O 0 0.002498731
of O 0 0.0012585595
lidocaine B-Chemical 0 0.9992273
is O 0 0.00094555784
related O 0 0.0005545372
to O 0 0.00068849354
the O 0 0.0010130763
acidic O 0 0.10304951
pH O 0 0.18461859
of O 0 0.0028693979
the O 0 0.0036246134
solution O 0 0.041175567
. O 0 0.0073000994

To O 0 0.0022996299
determine O 0 0.0009941155
if O 0 0.0008587184
the O 0 0.0007904236
addition O 0 0.0005459626
of O 0 0.0008120837
a O 0 0.0008105538
buffering O 0 0.07034553
solution O 0 0.009907742
to O 0 0.00043612916
adjust O 0 0.00036154987
the O 0 0.00043515576
pH O 0 0.09778458
of O 0 0.00067881023
lidocaine B-Chemical 0 0.99921536
into O 0 0.0002534781
the O 0 0.00025892508
physiologic O 0 0.004970827
range O 0 0.00048224395
would O 0 0.00020162607
reduce O 0 0.00026647863
pain B-Disease 0 0.88375765
during O 0 0.00025141463
injection O 0 0.0014569181
, O 0 0.00029502742
we O 0 0.00010659087
performed O 0 0.00018712516
a O 0 0.00027072502
blinded O 0 0.00049602106
randomized O 0 0.00062738894
study O 0 0.000717473
in O 0 0.0006205509
patients O 0 0.0024312101
undergoing O 0 0.0038861097
cardiac O 0 0.4713404
catheterization O 0 0.33845976
. O 0 0.006305694

Twenty O 0 0.0070071556
patients O 0 0.0041053086
were O 0 0.0014586713
asked O 0 0.0008515092
to O 0 0.0007181027
quantify O 0 0.0004986259
the O 0 0.00060002715
severity O 0 0.0055086003
of O 0 0.0010697916
pain B-Disease 0 0.9314075
after O 0 0.0003444587
receiving O 0 0.001641819
standard O 0 0.00044412733
lidocaine B-Chemical 0 0.99890673
in O 0 0.000457353
one O 0 0.00034909433
femoral O 0 0.011675957
area O 0 0.00088394445
and O 0 0.0007870556
buffered O 0 0.5505316
lidocaine B-Chemical 0 0.9986646
in O 0 0.0012020756
the O 0 0.0013732859
opposite O 0 0.0030852347
femoral O 0 0.08581673
area O 0 0.008355173
. O 0 0.006244951

The O 0 0.0027711736
mean O 0 0.0018922924
pain B-Disease 0 0.63587123
score O 0 0.0017972405
for O 0 0.0010856454
buffered O 0 0.4997534
lidocaine B-Chemical 0 0.99911505
was O 0 0.00091275666
significantly O 0 0.000625465
lower O 0 0.00036399424
than O 0 0.00019319549
the O 0 0.00020485486
mean O 0 0.0001564319
score O 0 0.00026688038
for O 0 0.00020305393
standard O 0 0.00032097718
lidocaine B-Chemical 0 0.9992654
( O 0 0.0008725184
2 O 0 0.00033799553
. O 0 0.00017123403
7 O 0 0.0002319844
+ O 0 0.00036075182
/ O 0 0.0007186887
- O 0 0.00046850377
1 O 0 0.00024106931
. O 0 0.000129562
9 O 0 0.00019203882
vs O 0 0.00036678635
. O 0 0.00013455686
3 O 0 0.00018581162
. O 0 0.00014896144
8 O 0 0.00026220907
+ O 0 0.00040752435
/ O 0 0.00082594313
- O 0 0.00062692724
2 O 0 0.0003851527
. O 0 0.00027097034
2 O 0 0.00050278654
, O 0 0.000853216
P O 0 0.013200435
= O 0 0.0016345544
0 O 0 0.0014188387
. O 0 0.0013806458
03 O 0 0.014065465
) O 0 0.0058421954
. O 0 0.0052858545

The O 0 0.0037174022
pH O 0 0.046999536
adjustment O 0 0.002151321
of O 0 0.0015072986
standard O 0 0.0011444576
lidocaine B-Chemical 0 0.9980546
can O 0 0.0009337954
be O 0 0.00064665696
accomplished O 0 0.00074207626
easily O 0 0.0005811006
in O 0 0.0002852766
the O 0 0.0002947404
catheterization O 0 0.00877399
laboratory O 0 0.00057216256
before O 0 0.00017806285
injection O 0 0.0008422153
and O 0 0.00028586248
results O 0 0.0002619342
in O 0 0.00025555186
a O 0 0.0003607033
reduction O 0 0.00062846835
of O 0 0.00056263723
the O 0 0.0006695135
pain B-Disease 0 0.9424085
occurring O 0 0.0027537802
during O 0 0.00080685865
the O 0 0.001419718
infiltration O 0 0.4719097
of O 0 0.004643421
tissues O 0 0.021395393
. O 0 0.0062122364

Effect O 0 0.01108715
of O 0 0.007371071
L B-Chemical 0 0.6557657
- I-Chemical 0 0.010408708
alpha I-Chemical 0 0.44711882
- I-Chemical 0 0.019594528
glyceryl I-Chemical 0 0.99862206
- I-Chemical 0 0.019407388
phosphorylcholine I-Chemical 0 0.7748975
on O 0 0.0032167474
amnesia B-Disease 0 0.9973748
caused O 0 0.010856161
by O 0 0.016440786
scopolamine B-Chemical 1 0.99925226
. O 0 0.015705153

The O 0 0.0024257519
present O 0 0.0014801414
study O 0 0.0018339221
was O 0 0.0009848742
carried O 0 0.00064321863
out O 0 0.00052532344
to O 0 0.000520153
test O 0 0.0005876619
the O 0 0.00049164245
effects O 0 0.0011222429
of O 0 0.001266261
L B-Chemical 0 0.77782255
- I-Chemical 0 0.0042058867
alpha I-Chemical 0 0.43596938
- I-Chemical 0 0.0062754457
glycerylphosphorylcholine I-Chemical 0 0.98244494
( O 0 0.0030743056
L B-Chemical 0 0.71046394
- I-Chemical 0 0.0028406559
alpha I-Chemical 0 0.303518
- I-Chemical 0 0.0037216628
GFC I-Chemical 0 0.90203005
) O 0 0.0015869047
on O 0 0.0005324729
memory B-Disease 2 0.7378168
impairment I-Disease 2 0.8828241
induced O 0 0.004214397
by O 0 0.0053573293
scopolamine B-Chemical 1 0.999688
in O 0 0.007869243
man O 0 0.61830145
. O 0 0.007563126

Thirty O 0 0.01222847
- O 0 0.0047399285
two O 0 0.0018930717
healthy O 0 0.004700663
young O 0 0.004361931
volunteers O 0 0.002948483
were O 0 0.0010252061
randomly O 0 0.00066505646
allocated O 0 0.0012355385
to O 0 0.0013940629
four O 0 0.0016056439
different O 0 0.0033265324
groups O 0 0.0066581075
. O 0 0.007824932

They O 0 0.0058682975
were O 0 0.0020117844
given O 0 0.0011424909
a O 0 0.0011315543
ten O 0 0.00068896054
day O 0 0.00080166495
pretreatment O 0 0.043774396
with O 0 0.0010597849
either O 0 0.0010643207
L B-Chemical 0 0.69621164
- I-Chemical 0 0.003091499
alpha I-Chemical 0 0.31535915
- I-Chemical 0 0.0027141876
GFC I-Chemical 0 0.8381134
or O 0 0.00053171307
placebo O 0 0.19059883
, O 0 0.00060392
p O 0 0.0005560905
. O 0 0.00021719458
o O 0 0.0011162976
. O 0 0.00021892981
, O 0 0.0003591183
and O 0 0.00027727307
on O 0 0.00017576467
the O 0 0.00030970655
eleventh O 0 0.002338778
day O 0 0.00048530498
either O 0 0.00082707364
scopolamine B-Chemical 1 0.9997924
or O 0 0.0014803882
placebo O 0 0.36657906
, O 0 0.002403346
i O 0 0.004947819
. O 0 0.0022185897
m O 0 0.010904601
. O 0 0.005490641

Before O 0 0.0049493476
and O 0 0.0030103906
0 O 0 0.0021600556
. O 0 0.0010197968
5 O 0 0.0008876543
, O 0 0.0009951552
1 O 0 0.00068922085
, O 0 0.0006950774
2 O 0 0.0004847435
, O 0 0.00050653477
3 O 0 0.0003162345
, O 0 0.00037671725
and O 0 0.00029478112
6 O 0 0.00020600918
h O 0 0.00023877679
after O 0 0.0001611163
injection O 0 0.0006812437
the O 0 0.00032350552
subjects O 0 0.0006737951
were O 0 0.0005032006
given O 0 0.0005775044
attention O 0 0.0025806993
and O 0 0.0021001578
mnemonic O 0 0.09013068
tests O 0 0.008962376
. O 0 0.0062488737

The O 0 0.002734699
findings O 0 0.0030618142
of O 0 0.001697896
this O 0 0.0010953231
study O 0 0.0012183249
indicate O 0 0.0005587432
that O 0 0.00054116215
the O 0 0.00063724647
drug O 0 0.18617675
is O 0 0.00068734394
able O 0 0.00037308125
to O 0 0.0005072361
antagonize O 0 0.017585902
impairment B-Disease 0 0.23193967
of I-Disease 0 0.0013002711
attention I-Disease 0 0.0051803393
and I-Disease 0 0.0016549248
memory I-Disease 0 0.30939382
induced O 0 0.005367172
by O 0 0.009575634
scopolamine B-Chemical 1 0.9994235
. O 0 0.0111165345

Safety O 0 0.06512061
of O 0 0.021239677
capecitabine B-Chemical 1 0.9885434
: O 0 0.025424145
a O 0 0.018005818
review O 0 0.031154636
. O 0 0.02089332

IMPORTANCE O 0 0.12080405
OF O 0 0.027482042
THE O 0 0.02024852
FIELD O 0 0.3632697
: O 0 0.004326103
Fluoropyrimidines B-Chemical 0 0.9043514
, O 0 0.0017524775
in O 0 0.0007252548
particular O 0 0.00065396575
5 B-Chemical 0 0.0006877712
- I-Chemical 0 0.0013889148
fluorouracil I-Chemical 0 0.9981224
( O 0 0.0012197061
5 B-Chemical 0 0.0004627707
- I-Chemical 0 0.00078771176
FU I-Chemical 0 0.5644631
) O 0 0.0007464479
, O 0 0.00036211885
have O 0 0.00025775365
been O 0 0.00027842834
the O 0 0.0001990842
mainstay O 0 0.0024857183
of O 0 0.00045386096
treatment O 0 0.0010181691
for O 0 0.00025055557
several O 0 0.0004223466
solid O 0 0.036878858
tumors B-Disease 0 0.8993878
, O 0 0.0007310946
including O 0 0.00057390507
colorectal B-Disease 0 0.97416216
, I-Disease 0 0.0015841873
breast I-Disease 0 0.8823779
and I-Disease 0 0.00087240245
head I-Disease 0 0.030116225
and I-Disease 0 0.0011085428
neck I-Disease 0 0.56936264
cancers I-Disease 2 0.99222386
, O 0 0.0022903897
for O 0 0.0013625777
> O 0 0.0034950352
40 O 0 0.0027656408
years O 0 0.005359416
. O 0 0.004777514

AREAS O 0 0.03975224
COVERED O 0 0.06331135
IN O 0 0.14676017
THIS O 0 0.23647258
REVIEW O 0 0.07574411
: O 0 0.0022284724
This O 0 0.0013810009
article O 0 0.0012379168
reviews O 0 0.0013646367
the O 0 0.00069698214
pharmacology O 0 0.071299694
and O 0 0.00081437366
efficacy O 0 0.0026824672
of O 0 0.0013795233
capecitabine B-Chemical 1 0.998276
with O 0 0.0015965566
a O 0 0.0013074146
special O 0 0.0017755392
emphasis O 0 0.003090572
on O 0 0.0014513293
its O 0 0.0055966983
safety O 0 0.014535565
. O 0 0.006687765

WHAT O 0 0.12054544
THE O 0 0.023489516
READER O 0 0.33953914
WILL O 0 0.1081545
GAIN O 0 0.083799675
: O 0 0.0023319721
The O 0 0.0008753688
reader O 0 0.0017418723
will O 0 0.0004927011
gain O 0 0.0009755613
better O 0 0.00057597517
insight O 0 0.0005142993
into O 0 0.00023937853
the O 0 0.0003021697
safety O 0 0.0010690961
of O 0 0.0006546098
capecitabine B-Chemical 1 0.9986035
in O 0 0.00041226324
special O 0 0.0005674712
populations O 0 0.000575135
such O 0 0.00033886504
as O 0 0.00031268198
patients O 0 0.0012214123
with O 0 0.00072472525
advanced O 0 0.049911063
age O 0 0.0037904868
, O 0 0.0021847738
renal B-Disease 0 0.97912997
and I-Disease 0 0.004795379
kidney I-Disease 0 0.95560485
disease I-Disease 0 0.9310305
. O 0 0.008976864

We O 0 0.0040424797
also O 0 0.0028947815
explore O 0 0.001992299
different O 0 0.0023421028
dosing O 0 0.01647625
and O 0 0.003048129
schedules O 0 0.007341492
of O 0 0.00852855
capecitabine B-Chemical 1 0.9967614
administration O 0 0.79613304
. O 0 0.013212976

TAKE O 0 0.17107356
HOME O 0 0.27320904
MESSAGE O 0 0.24177442
: O 0 0.0062970775
Capecitabine B-Chemical 0 0.996633
is O 0 0.0016760946
an O 0 0.0014978866
oral O 0 0.27395326
prodrug O 0 0.9203659
of O 0 0.0012683141
5 B-Chemical 0 0.00065128837
- I-Chemical 0 0.00092152937
FU I-Chemical 0 0.4125157
and O 0 0.00040879514
was O 0 0.000301386
developed O 0 0.000455023
to O 0 0.00023412064
fulfill O 0 0.00036405865
the O 0 0.00022520858
need O 0 0.00020823283
for O 0 0.00019748815
a O 0 0.00030446405
more O 0 0.0003702524
convenient O 0 0.00067394803
therapy O 0 0.0031754856
and O 0 0.00049109396
provide O 0 0.00049875147
an O 0 0.0008277557
improved O 0 0.0018588594
safety O 0 0.0045835967
/ O 0 0.004367376
efficacy O 0 0.0081935385
profile O 0 0.006179104
. O 0 0.005870181

It O 0 0.005234249
has O 0 0.0021478932
shown O 0 0.0012029364
promising O 0 0.002101365
results O 0 0.0009138035
alone O 0 0.0009716049
or O 0 0.000557287
in O 0 0.00044995517
combination O 0 0.001122677
with O 0 0.00065078516
other O 0 0.0006563297
chemotherapeutic O 0 0.9500348
agents O 0 0.3679822
in O 0 0.00079432945
colorectal B-Disease 0 0.9844216
, I-Disease 0 0.0026077204
breast I-Disease 0 0.95020604
, I-Disease 0 0.0022368003
pancreaticobiliary I-Disease 0 0.9786952
, I-Disease 0 0.002230889
gastric I-Disease 0 0.9132502
, I-Disease 0 0.0024316667
renal I-Disease 0 0.9854226
cell I-Disease 0 0.023245402
and I-Disease 0 0.0018572534
head I-Disease 0 0.048032623
and I-Disease 0 0.0037589336
neck I-Disease 0 0.7457661
cancers I-Disease 2 0.9900295
. O 0 0.01024307

The O 0 0.0032663452
most O 0 0.003558824
commonly O 0 0.0039351997
reported O 0 0.002803952
toxic O 0 0.55795294
effects O 0 0.003437723
of O 0 0.0024898648
capecitabine B-Chemical 1 0.99896634
are O 0 0.004483923
diarrhea B-Disease 2 0.9992392
, O 0 0.018356126
nausea B-Disease 2 0.99988735
, O 0 0.022923393
vomiting B-Disease 0 0.9997029
, O 0 0.011684856
stomatitis B-Disease 2 0.9984479
and O 0 0.0025321625
hand B-Disease 2 0.004234924
- I-Disease 2 0.006240014
foot I-Disease 2 0.22194049
syndrome I-Disease 2 0.9140845
. O 0 0.007897684

Capecitabine B-Chemical 0 0.9938415
has O 0 0.003278531
a O 0 0.002103459
well O 0 0.0012596018
- O 0 0.0016209218
established O 0 0.0010681855
safety O 0 0.0017684737
profile O 0 0.000819045
and O 0 0.00056051096
can O 0 0.00038352807
be O 0 0.00038483046
given O 0 0.00027415212
safely O 0 0.0014398153
to O 0 0.000402151
patients O 0 0.00122979
with O 0 0.0008186432
advanced O 0 0.044119064
age O 0 0.0038363684
, O 0 0.0023693226
hepatic B-Disease 0 0.9523295
and I-Disease 0 0.0059391772
renal I-Disease 0 0.9934683
dysfunctions I-Disease 0 0.9855966
. O 0 0.010024363

Levodopa B-Chemical 0 0.9983121
- O 0 0.011735427
induced O 0 0.0064357477
dyskinesias B-Disease 2 0.99908745
in O 0 0.0017215655
patients O 0 0.0039188555
with O 0 0.0020612432
Parkinson B-Disease 0 0.9985788
' I-Disease 0 0.0014135998
s I-Disease 0 0.0013640188
disease I-Disease 0 0.3637101
: O 0 0.0016338114
filling O 0 0.003803695
the O 0 0.0010612331
bench O 0 0.0114374785
- O 0 0.0025623816
to O 0 0.0018025864
- O 0 0.0038827832
bedside O 0 0.008506114
gap O 0 0.0074922987
. O 0 0.0068395296

Levodopa B-Chemical 0 0.99728966
is O 0 0.004257016
the O 0 0.0022383055
most O 0 0.0025714443
effective O 0 0.0024553789
drug O 0 0.12338602
for O 0 0.0012317479
the O 0 0.0013191835
treatment O 0 0.0034414348
of O 0 0.004512238
Parkinson B-Disease 0 0.9977557
' I-Disease 0 0.0056424863
s I-Disease 0 0.0070918333
disease I-Disease 0 0.5908691
. O 0 0.009199556

However O 0 0.004490077
, O 0 0.0030672273
the O 0 0.001609001
long O 0 0.0017844685
- O 0 0.0016943853
term O 0 0.00100713
use O 0 0.0009879989
of O 0 0.0010412848
this O 0 0.0012126801
dopamine B-Chemical 1 0.998638
precursor O 0 0.060962006
is O 0 0.0010840141
complicated O 0 0.0066483514
by O 0 0.0012675389
highly O 0 0.0029062193
disabling O 0 0.91232586
fluctuations O 0 0.014219665
and O 0 0.009214576
dyskinesias B-Disease 2 0.9986284
. O 0 0.009266108

Although O 0 0.0031950865
preclinical O 0 0.009360916
and O 0 0.0018323646
clinical O 0 0.0045007463
findings O 0 0.0019349442
suggest O 0 0.0006741426
pulsatile O 0 0.054534465
stimulation O 0 0.002250819
of O 0 0.0013406319
striatal O 0 0.98840535
postsynaptic O 0 0.98214805
receptors O 0 0.185555
as O 0 0.0003911699
a O 0 0.00041663484
key O 0 0.00042231905
mechanism O 0 0.0007488293
underlying O 0 0.008809144
levodopa B-Chemical 1 0.99984705
- O 0 0.009013148
induced O 0 0.0069425846
dyskinesias B-Disease 2 0.999741
, O 0 0.0018442554
their O 0 0.0013245044
pathogenesis O 0 0.022364
is O 0 0.0021271158
still O 0 0.0026069703
unclear O 0 0.005533441
. O 0 0.006049732

In O 0 0.0026998802
recent O 0 0.0022663816
years O 0 0.0024872771
, O 0 0.0013647146
evidence O 0 0.00084610435
from O 0 0.00060442527
animal O 0 0.0010058047
models O 0 0.001028355
of O 0 0.0012252266
Parkinson B-Disease 0 0.9990539
' I-Disease 0 0.00081193045
s I-Disease 0 0.000676018
disease I-Disease 0 0.24082267
has O 0 0.00035976217
provided O 0 0.00032528755
important O 0 0.0002497316
information O 0 0.0003421724
to O 0 0.00020067155
understand O 0 0.00015204042
the O 0 0.00019496105
effect O 0 0.00028064707
of O 0 0.00036322334
specific O 0 0.00041891364
receptor O 0 0.07792013
and O 0 0.00056703645
post O 0 0.00077164575
- O 0 0.00093625387
receptor O 0 0.029625239
molecular O 0 0.011219375
mechanisms O 0 0.0014429118
underlying O 0 0.0019430214
the O 0 0.0010535191
development O 0 0.0044455547
of O 0 0.008157606
dyskinetic B-Disease 0 0.9992268
movements I-Disease 0 0.43511212
. O 0 0.0073348754

Recent O 0 0.005405964
preclinical O 0 0.013125544
and O 0 0.0020666274
clinical O 0 0.0041216505
data O 0 0.0011494616
from O 0 0.00069313
promising O 0 0.0013709466
lines O 0 0.0017056398
of O 0 0.00063897454
research O 0 0.00076845294
focus O 0 0.00046111265
on O 0 0.00019963355
the O 0 0.00026914026
differential O 0 0.000649984
role O 0 0.00024796987
of O 0 0.0005733529
presynaptic O 0 0.5336921
versus O 0 0.0005903288
postsynaptic O 0 0.9272186
mechanisms O 0 0.003387603
, O 0 0.00148299
dopamine B-Chemical 1 0.9994293
receptor O 0 0.4356343
subtypes O 0 0.17123866
, O 0 0.0019537385
ionotropic O 0 0.9981912
and O 0 0.0037653667
metabotropic O 0 0.99979717
glutamate B-Chemical 1 0.99978596
receptors O 0 0.6792157
, O 0 0.0011310149
and O 0 0.00050785247
non O 0 0.001933256
- O 0 0.0020223581
dopaminergic O 0 0.97675574
neurotransmitter O 0 0.95578724
systems O 0 0.0012045623
in O 0 0.00044250453
the O 0 0.000604809
pathophysiology O 0 0.1799065
of O 0 0.0050193304
levodopa B-Chemical 1 0.99966717
- O 0 0.031710085
induced O 0 0.038719337
dyskinesias B-Disease 2 0.9989963
. O 0 0.009334031

Effects O 0 0.01724011
of O 0 0.007483694
pallidal O 0 0.9919818
neurotensin B-Chemical 0 0.99753475
on O 0 0.004233384
haloperidol B-Chemical 1 0.99981755
- O 0 0.032544706
induced O 0 0.03550227
parkinsonian B-Disease 2 0.99987185
catalepsy I-Disease 0 0.99991
: O 0 0.016320143
behavioral O 0 0.0931811
and O 0 0.0035255922
electrophysiological O 0 0.30115658
studies O 0 0.008705968
. O 0 0.007225311

OBJECTIVE O 0 0.6292511
: O 0 0.008199512
The O 0 0.004459019
globus O 0 0.98203385
pallidus O 0 0.98985684
plays O 0 0.0032768939
a O 0 0.0024670546
critical O 0 0.002315809
role O 0 0.002119396
in O 0 0.003170331
movement O 0 0.009309507
regulation O 0 0.006842452
. O 0 0.008647619

Previous O 0 0.004142221
studies O 0 0.003183037
have O 0 0.0018089811
indicated O 0 0.001073109
that O 0 0.001064561
the O 0 0.0016185641
globus O 0 0.99354196
pallidus O 0 0.9965462
receives O 0 0.0020667019
neurotensinergic O 0 0.14702038
innervation O 0 0.14508834
from O 0 0.00050244236
the O 0 0.0005393282
striatum O 0 0.4702141
, O 0 0.0006056406
and O 0 0.0004956829
systemic O 0 0.6473576
administration O 0 0.1518386
of O 0 0.0010993027
a O 0 0.0016485993
neurotensin B-Chemical 0 0.998295
analog O 0 0.07369692
could O 0 0.0012104852
produce O 0 0.0025402794
antiparkinsonian O 0 0.9958759
effects O 0 0.021195028
. O 0 0.006764293

The O 0 0.0026270472
present O 0 0.0016211662
study O 0 0.0020133015
aimed O 0 0.0013892587
to O 0 0.0009044373
investigate O 0 0.0006064914
the O 0 0.00078460545
effects O 0 0.0017612057
of O 0 0.0023676844
pallidal O 0 0.9971047
neurotensin B-Chemical 0 0.9988405
on O 0 0.0027802743
haloperidol B-Chemical 1 0.9998652
- O 0 0.038615305
induced O 0 0.048944138
parkinsonian B-Disease 2 0.99960417
symptoms I-Disease 0 0.985024
. O 0 0.010372306

METHODS O 0 0.007709766
: O 0 0.004180437
Behavioral O 0 0.012289453
experiments O 0 0.0016292003
and O 0 0.0017466763
electrophysiological O 0 0.050732683
recordings O 0 0.0043852483
were O 0 0.0013235366
performed O 0 0.0013161529
in O 0 0.0015463503
the O 0 0.002101768
present O 0 0.0028402035
study O 0 0.0077246428
. O 0 0.007828738

RESULTS O 0 0.035454452
: O 0 0.00634611
Bilateral O 0 0.048817605
infusions O 0 0.06529714
of O 0 0.0033993025
neurotensin B-Chemical 0 0.9960478
into O 0 0.0014080812
the O 0 0.0022048128
globus O 0 0.9959953
pallidus O 0 0.99809307
reversed O 0 0.09095838
haloperidol B-Chemical 1 0.99989796
- O 0 0.032418948
induced O 0 0.050618056
parkinsonian B-Disease 2 0.9998534
catalepsy I-Disease 0 0.99984443
in O 0 0.0095231235
rats O 0 0.060276944
. O 0 0.007314932

Electrophysiological O 0 0.6712902
recordings O 0 0.009054172
showed O 0 0.0020582585
that O 0 0.0013814522
microinjection O 0 0.011840856
of O 0 0.0024242634
neurotensin B-Chemical 0 0.9977975
induced O 0 0.0036079423
excitation O 0 0.53878695
of O 0 0.0026834384
pallidal O 0 0.9952146
neurons O 0 0.036304466
in O 0 0.0006800211
the O 0 0.0007188044
presence O 0 0.0010603009
of O 0 0.0029821696
systemic O 0 0.99041754
haloperidol B-Chemical 1 0.9998293
administration O 0 0.9227691
. O 0 0.009912893

The O 0 0.005399512
neurotensin B-Chemical 0 0.991219
type I-Chemical 0 0.00503554
- I-Chemical 0 0.004570713
1 I-Chemical 0 0.002095216
receptor I-Chemical 0 0.21671242
antagonist I-Chemical 0 0.99430203
SR48692 B-Chemical 0 0.99972373
blocked O 0 0.009341092
both O 0 0.00089818577
the O 0 0.00074127875
behavioral O 0 0.015817678
and O 0 0.00088121224
the O 0 0.00091212563
electrophysiological O 0 0.17798084
effects O 0 0.0038407044
induced O 0 0.0043541654
by O 0 0.006702666
neurotensin B-Chemical 0 0.99511456
. O 0 0.009584199

CONCLUSION O 0 0.87681866
: O 0 0.00805449
Activation O 0 0.014367276
of O 0 0.0042386074
pallidal O 0 0.9934489
neurotensin B-Chemical 0 0.99819356
receptors O 0 0.39652637
may O 0 0.0019244782
be O 0 0.0013996796
involved O 0 0.0013435435
in O 0 0.0019943947
neurotensin B-Chemical 0 0.9973515
- O 0 0.008110254
induced O 0 0.008044454
antiparkinsonian O 0 0.99619293
effects O 0 0.031185122
. O 0 0.008394739

Carmofur B-Chemical 0 0.95599383
- O 0 0.025029676
induced O 0 0.020623825
organic B-Disease 0 0.9623296
mental I-Disease 0 0.8054851
disorders I-Disease 0 0.9581981
. O 0 0.02615445

Organic B-Disease 0 0.9601961
mental I-Disease 0 0.3974965
disorder I-Disease 0 0.9201002
was O 0 0.0020192703
observed O 0 0.0009346838
in O 0 0.00075761165
a O 0 0.0008802614
29 O 0 0.0014978204
- O 0 0.00093038165
year O 0 0.00059335487
- O 0 0.0007243186
old O 0 0.0004607862
female O 0 0.00078278244
in O 0 0.0002662054
the O 0 0.00029008868
prognostic O 0 0.001430476
period O 0 0.00040868446
after O 0 0.00027955882
the O 0 0.00052565895
onset O 0 0.0034175417
of O 0 0.0027131783
carmofur B-Chemical 0 0.9984792
- O 0 0.022362208
induced O 0 0.03491923
leukoencephalopathy B-Disease 2 0.99855226
. O 0 0.01152621

Symptoms O 0 0.21686246
such O 0 0.0031975538
as O 0 0.0024964786
euphoria O 0 0.99403185
, O 0 0.0030227008
emotional O 0 0.19962738
lability O 0 0.42374364
and O 0 0.000987765
puerile O 0 0.011014922
attitude O 0 0.0028287016
noted O 0 0.00044252185
in O 0 0.00028331613
the O 0 0.0002778664
patient O 0 0.00054795336
were O 0 0.0003485132
diagnosed O 0 0.0054448033
as O 0 0.00038525806
organic B-Disease 0 0.97320044
personality I-Disease 0 0.9851879
syndrome I-Disease 0 0.9587545
according O 0 0.00044377166
to O 0 0.0003119376
the O 0 0.00032707502
criteria O 0 0.00070815027
defined O 0 0.0004964108
in O 0 0.0006123825
the O 0 0.0011135961
DSM O 0 0.108684435
- O 0 0.0044999477
III O 0 0.04723787
- O 0 0.009874786
R O 0 0.70376426
. O 0 0.007639162

It O 0 0.010075694
is O 0 0.004917888
referred O 0 0.004447822
to O 0 0.003965504
as O 0 0.004125798
a O 0 0.0081439335
frontal B-Disease 0 0.7809225
lobe I-Disease 0 0.8682181
syndrome I-Disease 0 0.95674324
. O 0 0.016155427

Brain O 0 0.42031923
CT O 0 0.20781219
revealed O 0 0.0029948426
a O 0 0.0023999151
periventricular O 0 0.30212203
low O 0 0.0014784109
density O 0 0.0015699265
area O 0 0.0012032521
in O 0 0.0005842416
the O 0 0.0006457286
frontal O 0 0.15333208
white O 0 0.0020051417
matter O 0 0.0018043923
and O 0 0.0005347561
moderate O 0 0.007841765
dilatation O 0 0.8078677
of O 0 0.0008458799
the O 0 0.00067296857
lateral O 0 0.010894973
ventricles O 0 0.064536
especially O 0 0.001119413
at O 0 0.0007040234
the O 0 0.0015404087
bilateral O 0 0.14999825
anterior O 0 0.11216055
horns O 0 0.15433902
. O 0 0.0064632604

Consequently O 0 0.0064031626
, O 0 0.006456901
carmofur B-Chemical 0 0.9960538
- O 0 0.008425071
induced O 0 0.0066552144
leukoencephalopathy B-Disease 2 0.99915195
may O 0 0.002719063
uncommonly O 0 0.36850142
result O 0 0.0010999764
in O 0 0.0012637092
organic B-Disease 0 0.9834177
personality I-Disease 0 0.9890687
syndrome I-Disease 0 0.9626946
in O 0 0.0018212375
the O 0 0.0020398372
residual O 0 0.004101692
state O 0 0.007712178
. O 0 0.0066664205

It O 0 0.008238506
may O 0 0.0039548962
be O 0 0.0031312956
attributed O 0 0.0025093667
to O 0 0.0020393673
the O 0 0.0022283643
structural B-Disease 0 0.007791432
damage I-Disease 0 0.33546218
to I-Disease 0 0.003910967
the I-Disease 0 0.005588907
frontal I-Disease 0 0.65787953
lobe I-Disease 0 0.675723
. O 0 0.010647447

Butyrylcholinesterase O 0 0.37640482
gene O 0 0.004604982
mutations O 0 0.005034596
in O 0 0.0016865651
patients O 0 0.0032056142
with O 0 0.0019093787
prolonged O 0 0.042828746
apnea B-Disease 2 0.9955858
after O 0 0.002112442
succinylcholine B-Chemical 1 0.99681693
for O 0 0.004273397
electroconvulsive O 0 0.99496716
therapy O 0 0.35894412
. O 0 0.010204314

BACKGROUND O 0 0.7297003
: O 0 0.0051490357
patients O 0 0.004088449
undergoing O 0 0.00324203
electroconvulsive O 0 0.99149126
therapy O 0 0.13871022
( O 0 0.0034183234
ECT O 0 0.98068327
) O 0 0.0021345965
often O 0 0.0014260752
receive O 0 0.0014527085
succinylcholine B-Chemical 1 0.9966041
as O 0 0.0009895454
part O 0 0.0009180982
of O 0 0.0016582324
the O 0 0.0022871501
anesthetic O 0 0.45594376
procedure O 0 0.0072224825
. O 0 0.0066521633

The O 0 0.0025295862
duration O 0 0.0024865274
of O 0 0.002058252
action O 0 0.0052997675
may O 0 0.0011249472
be O 0 0.0008116976
prolonged O 0 0.0030983184
in O 0 0.00051966636
patients O 0 0.0012827872
with O 0 0.00053820363
genetic O 0 0.001096904
variants O 0 0.0007061723
of O 0 0.00060799276
the O 0 0.00059720327
butyrylcholinesterase O 0 0.9859747
enzyme O 0 0.37772486
( O 0 0.0026311334
BChE O 0 0.99264103
) O 0 0.0012800039
, O 0 0.0004947055
the O 0 0.0003075454
most O 0 0.0005978115
common O 0 0.00072713924
being O 0 0.0008445028
the O 0 0.00085865956
K O 1 0.9815137
- O 0 0.0023353538
and O 0 0.0012669124
the O 0 0.001665456
A O 0 0.021289572
- O 0 0.004957731
variants O 0 0.0061625782
. O 0 0.006006846

The O 0 0.0025598004
aim O 0 0.0019243775
of O 0 0.0014625672
the O 0 0.001015632
study O 0 0.0012260941
was O 0 0.00062761415
to O 0 0.0004325847
assess O 0 0.00022530506
the O 0 0.00033136798
clinical O 0 0.0015760498
significance O 0 0.0006843226
of O 0 0.00047822724
genetic O 0 0.0011530492
variants O 0 0.0008167093
in O 0 0.0004684591
butyrylcholinesterase O 0 0.96681654
gene O 0 0.0019599884
( O 0 0.0014866824
BCHE O 0 0.9840418
) O 0 0.0010860892
in O 0 0.00029330823
patients O 0 0.0009465827
with O 0 0.00041537118
a O 0 0.00046630148
suspected O 0 0.008716854
prolonged O 0 0.004109248
duration O 0 0.0008699126
of O 0 0.0010196306
action O 0 0.008951863
of O 0 0.0031572029
succinylcholine B-Chemical 1 0.99781847
after O 0 0.0039824345
ECT O 0 0.98593163
. O 0 0.00747169

METHODS O 0 0.006478502
: O 0 0.0031846217
a O 0 0.0016311923
total O 0 0.0010894113
of O 0 0.0012473856
13 O 0 0.0011687175
patients O 0 0.0015786609
were O 0 0.00066657335
referred O 0 0.00070737937
to O 0 0.00061090104
the O 0 0.0007788412
Danish O 0 0.0048812623
Cholinesterase O 0 0.9927926
Research O 0 0.058553178
Unit O 0 0.009069558
after O 0 0.0011390097
ECT O 0 0.90485156
during O 0 0.0021549948
38 O 0 0.005213672
months O 0 0.004895565
. O 0 0.0056268997

We O 0 0.0033096608
determined O 0 0.001978531
the O 0 0.0021410354
BChE O 0 0.91215444
activity O 0 0.001955747
and O 0 0.0010516715
the O 0 0.0008598521
BCHE O 0 0.9201423
genotype O 0 0.0020613747
using O 0 0.0004904262
molecular O 0 0.006119866
genetic O 0 0.0013843375
methods O 0 0.00064575934
, O 0 0.0004710962
the O 0 0.00026858342
duration O 0 0.0004980388
of O 0 0.0007890042
apnea B-Disease 2 0.9976373
, O 0 0.00060008065
time O 0 0.00026645782
to O 0 0.0002848689
sufficient O 0 0.0002750349
spontaneous O 0 0.0035382628
ventilation O 0 0.022416892
and O 0 0.0007296976
whether O 0 0.00048944756
neuromuscular O 0 0.28162345
monitoring O 0 0.0026560363
was O 0 0.0024535297
used O 0 0.003425672
. O 0 0.0050731846

The O 0 0.0032538413
duration O 0 0.0036008887
of O 0 0.004087848
apnea B-Disease 2 0.99027246
was O 0 0.0022763591
compared O 0 0.0011069572
with O 0 0.001710098
published O 0 0.0020422428
data O 0 0.0023674166
on O 0 0.0019733084
normal O 0 0.006633102
subjects O 0 0.0094479835
. O 0 0.008094325

RESULTS O 0 0.026437286
: O 0 0.0043146103
in O 0 0.0017494088
11 O 0 0.0016097442
patients O 0 0.002302451
, O 0 0.0012626371
mutations O 0 0.0018381525
were O 0 0.0006653205
found O 0 0.00054361805
in O 0 0.00048687807
the O 0 0.00068265933
BCHE O 0 0.95299244
gene O 0 0.0018304837
, O 0 0.0012325834
the O 0 0.0010427317
K O 1 0.9827776
- O 0 0.0024302085
variant O 0 0.001975007
being O 0 0.001990768
the O 0 0.0018679873
most O 0 0.004839079
frequent O 0 0.014824531
. O 0 0.006632876

The O 0 0.0027411852
duration O 0 0.0029514632
of O 0 0.0032678451
apnea B-Disease 2 0.9928671
was O 0 0.0017735444
5 O 0 0.0009510574
- O 0 0.001008961
15 O 0 0.00043140916
min O 0 0.0005801233
compared O 0 0.00026590863
with O 0 0.0005331478
3 O 0 0.00053366995
- O 0 0.00085408636
5 O 0 0.0004663459
. O 0 0.0003820693
3 O 0 0.00059060793
min O 0 0.0011650714
from O 0 0.0011989069
the O 0 0.0021286418
literature O 0 0.0070027313
. O 0 0.0057462538

Severe O 0 0.9208074
distress O 0 0.75863653
was O 0 0.0036562576
noted O 0 0.002453748
in O 0 0.0017784728
the O 0 0.0018700004
recovery O 0 0.0042786067
phase O 0 0.004620615
in O 0 0.0029841263
two O 0 0.0038882701
patients O 0 0.01382834
. O 0 0.009298914

Neuromuscular O 0 0.13167049
monitoring O 0 0.009181932
was O 0 0.006225285
used O 0 0.0057433094
in O 0 0.006034847
two O 0 0.007573746
patients O 0 0.021321125
. O 0 0.015747083

CONCLUSION O 0 0.7657079
: O 0 0.0040900796
eleven O 0 0.0020703704
of O 0 0.001546664
13 O 0 0.0012593032
patients O 0 0.0015689573
with O 0 0.00071659073
a O 0 0.0005717989
prolonged O 0 0.0020889132
duration O 0 0.0006523031
of O 0 0.0005737555
action O 0 0.0048800535
of O 0 0.0008876019
succinylcholine B-Chemical 1 0.99916935
had O 0 0.00083844666
mutations O 0 0.0063995537
in O 0 0.0005244296
BCHE O 0 0.98685974
, O 0 0.00067314174
indicating O 0 0.00024670284
that O 0 0.00021395118
this O 0 0.0002565171
is O 0 0.0002645671
the O 0 0.0002467221
possible O 0 0.00036409494
reason O 0 0.00041167808
for O 0 0.00041547473
a O 0 0.0008243945
prolonged O 0 0.005516207
period O 0 0.0019472131
of O 0 0.005193944
apnea B-Disease 2 0.9942952
. O 0 0.007889245

We O 0 0.005042377
recommend O 0 0.0042486982
objective O 0 0.006297307
neuromuscular O 0 0.23588307
monitoring O 0 0.005344515
during O 0 0.0032901808
the O 0 0.0046236087
first O 0 0.0071396246
ECT O 0 0.96227145
. O 0 0.013815223

Perhexiline B-Chemical 0 0.9950513
maleate I-Chemical 0 0.9982558
and O 0 0.08323645
peripheral B-Disease 2 0.950888
neuropathy I-Disease 2 0.9965216
. O 0 0.043177534

Peripheral B-Disease 2 0.9674805
neuropathy I-Disease 2 0.9987527
has O 0 0.0036078223
been O 0 0.0020790522
noted O 0 0.0010887578
as O 0 0.0006640592
a O 0 0.0008676634
complication O 0 0.095306605
of O 0 0.0009670984
therapy O 0 0.0418551
with O 0 0.0037913006
perhexiline B-Chemical 1 0.99996877
maleate I-Chemical 1 0.9999776
, O 0 0.005100017
a O 0 0.0007227785
drug O 0 0.26182362
widely O 0 0.0010802284
used O 0 0.00032739603
in O 0 0.00032447727
France O 0 0.018840075
( O 0 0.00041326764
and O 0 0.0002517764
in O 0 0.0002078581
clinical O 0 0.0017836526
trials O 0 0.00054058066
in O 0 0.00026091357
the O 0 0.0003430087
United O 0 0.0008653664
States O 0 0.0014866487
) O 0 0.0005739888
for O 0 0.00032899893
the O 0 0.00054127333
prophylactic O 0 0.0096801305
treatment O 0 0.005076433
of O 0 0.011939506
angina B-Disease 0 0.9995522
pectoris I-Disease 0 0.9994004
. O 0 0.016000932

In O 0 0.0028616525
24 O 0 0.0019122752
patients O 0 0.002508819
with O 0 0.0013230311
this O 0 0.0011244873
complication O 0 0.1411061
, O 0 0.0011371251
the O 0 0.00058198406
marked O 0 0.0011420454
slowing O 0 0.017988708
of O 0 0.0010137404
motor O 0 0.15976393
nerve O 0 0.5791655
conduction O 0 0.16132067
velocity O 0 0.00287601
and O 0 0.000626851
the O 0 0.00061763736
electromyographic O 0 0.29703924
changes O 0 0.0013254022
imply O 0 0.0008527807
mainly O 0 0.003165809
a O 0 0.005637617
demyelinating B-Disease 0 0.99792635
disorder I-Disease 0 0.9934453
. O 0 0.011337258

Improvement O 0 0.023088155
was O 0 0.007151844
noted O 0 0.0061721997
with O 0 0.007118883
cessation O 0 0.020572763
of O 0 0.013217946
therapy O 0 0.12821785
. O 0 0.017693093

In O 0 0.0030542416
a O 0 0.0022148981
few O 0 0.0012792185
cases O 0 0.0019614347
the O 0 0.0010557858
presence O 0 0.0009783006
of O 0 0.0012939329
active O 0 0.0026441112
denervation O 0 0.97692126
signified O 0 0.03092679
a O 0 0.0015022546
poor O 0 0.006423335
prognosis O 0 0.73058474
, O 0 0.0021633466
with O 0 0.0019672315
only O 0 0.0023766942
slight O 0 0.0060537937
improvement O 0 0.0080421185
. O 0 0.006741489

The O 0 0.0030660306
underlying O 0 0.004100632
mechanism O 0 0.0028651496
causing O 0 0.0047380347
the O 0 0.0020834415
neuropathy B-Disease 0 0.9991511
is O 0 0.0012917485
not O 0 0.0006639596
yet O 0 0.0008048851
fully O 0 0.00044671862
known O 0 0.00063127774
, O 0 0.000521872
although O 0 0.00033397565
some O 0 0.00038483634
evidence O 0 0.00043798794
indicates O 0 0.00035111897
that O 0 0.00041576376
it O 0 0.0006864788
may O 0 0.0007490438
be O 0 0.000986885
a O 0 0.0016795202
lipid O 0 0.52168757
storage O 0 0.016339147
process O 0 0.006894161
. O 0 0.006471269

A O 0 0.022244278
phase O 0 0.008726059
I O 0 0.009111248
study O 0 0.0044904007
of O 0 0.0039054076
4 B-Chemical 0 0.0032442051
' I-Chemical 0 0.004461434
- I-Chemical 0 0.006185825
0 I-Chemical 0 0.0054089846
- I-Chemical 0 0.009136888
tetrahydropyranyladriamycin I-Chemical 0 0.3449605
. O 0 0.010578146

Clinical O 0 0.17124832
pharmacology O 0 0.38049433
and O 0 0.03359476
pharmacokinetics O 0 0.9276632
. O 0 0.034734238

A O 0 0.01923169
Phase O 0 0.01054026
I O 0 0.005305623
study O 0 0.0022455778
of O 0 0.001852293
intravenous O 0 0.57909966
( O 0 0.0027882021
IV O 0 0.114990816
) O 0 0.0015407798
bolus O 0 0.040913798
4 B-Chemical 0 0.00052194216
' I-Chemical 0 0.00061377627
- I-Chemical 0 0.0007553001
0 I-Chemical 0 0.00050030585
- I-Chemical 0 0.00070365483
tetrahydropyranyladriamycin I-Chemical 0 0.29929245
( O 0 0.0011022168
Pirarubicin B-Chemical 0 0.9941127
) O 0 0.00075656123
was O 0 0.0002742211
done O 0 0.00020500337
in O 0 0.0002396816
55 O 0 0.00041278117
patients O 0 0.0007072867
in O 0 0.0003458295
good O 0 0.0006487144
performance O 0 0.0010527441
status O 0 0.001597158
with O 0 0.002681048
refractory O 0 0.7676748
tumors B-Disease 0 0.9574665
. O 0 0.0083623165

Twenty O 0 0.008643892
- O 0 0.0032508934
six O 0 0.0010013789
had O 0 0.0010351165
minimal O 0 0.00095037447
prior O 0 0.0005874685
therapy O 0 0.008598576
( O 0 0.00096603465
good O 0 0.00077393086
risk O 0 0.020840436
) O 0 0.0011115909
, O 0 0.00050921016
23 O 0 0.00044542813
had O 0 0.0002535552
extensive O 0 0.00036025312
prior O 0 0.0002254043
therapy O 0 0.008654899
( O 0 0.00061050477
poor O 0 0.0016785987
risk O 0 0.032568928
) O 0 0.0010402274
, O 0 0.0004860242
and O 0 0.00036014823
six O 0 0.00029668427
had O 0 0.0008060229
renal B-Disease 0 0.9646948
and I-Disease 0 0.0019647137
/ I-Disease 0 0.005136947
or I-Disease 0 0.0029017956
hepatic I-Disease 0 0.9949386
dysfunction I-Disease 0 0.9947167
. O 0 0.010609669

A O 0 0.01216957
total O 0 0.0026389505
of O 0 0.0025121805
167 O 0 0.0038480577
courses O 0 0.0025675565
at O 0 0.00091012754
doses O 0 0.006111843
of O 0 0.0012777895
15 O 0 0.0008431074
to O 0 0.00082771387
70 O 0 0.0015217221
mg O 0 0.19796237
/ O 0 0.0043172366
m2 O 0 0.023589678
were O 0 0.0035453811
evaluable O 0 0.022359619
. O 0 0.0066395556

Maximum O 0 0.0134907095
tolerated O 0 0.017174276
dose O 0 0.014459277
in O 0 0.0013606001
good O 0 0.0016138193
- O 0 0.0016544893
risk O 0 0.009031889
patients O 0 0.0020298762
was O 0 0.0005541602
70 O 0 0.00069116626
mg O 0 0.25116593
/ O 0 0.0014509865
m2 O 0 0.021321412
, O 0 0.00057062996
and O 0 0.00041776235
in O 0 0.00039049145
poor O 0 0.0018091894
- O 0 0.001247444
risk O 0 0.014675613
patients O 0 0.003376673
, O 0 0.0015361403
60 O 0 0.0019283273
mg O 0 0.3194114
/ O 0 0.0072403275
m2 O 0 0.061383117
. O 0 0.0057816524

The O 0 0.005441742
dose O 0 0.021350404
- O 0 0.0063357567
limiting O 0 0.0049176454
toxic O 0 0.61583406
effect O 0 0.0052317167
was O 0 0.0051416354
transient O 0 0.31003278
noncumulative O 0 0.98494685
granulocytopenia B-Disease 0 0.9983376
. O 0 0.017843956

Granulocyte O 0 0.47339642
nadir O 0 0.015643751
was O 0 0.002733494
on O 0 0.0014324165
day O 0 0.0018508873
14 O 0 0.0021230006
( O 0 0.0022047185
range O 0 0.0025112915
, O 0 0.0027404167
4 O 0 0.002358342
- O 0 0.004524195
22 O 0 0.0055501224
) O 0 0.0078009716
. O 0 0.0069735628

Less O 0 0.20465632
frequent O 0 0.011011712
toxic O 0 0.62753195
effects O 0 0.0064954166
included O 0 0.0032732796
thrombocytopenia B-Disease 0 0.9990858
, O 0 0.016934954
anemia B-Disease 0 0.9994072
, O 0 0.02673489
nausea B-Disease 2 0.99980074
, O 0 0.011266116
mild O 0 0.9460384
alopecia B-Disease 0 0.99947494
, O 0 0.027470833
phlebitis B-Disease 0 0.9988794
, O 0 0.009683651
and O 0 0.010522947
mucositis B-Disease 2 0.99856466
. O 0 0.011036151

Myelosuppression B-Disease 0 0.9924481
was O 0 0.006669746
more O 0 0.0058084712
in O 0 0.0044475435
patients O 0 0.010726633
with O 0 0.011954632
hepatic B-Disease 0 0.99093
dysfunction I-Disease 0 0.9912383
. O 0 0.021619365

Pharmacokinetic O 0 0.8770246
analyses O 0 0.00423031
in O 0 0.0017309783
21 O 0 0.0016855603
patients O 0 0.0021979702
revealed O 0 0.0014809655
Pirarubicin B-Chemical 0 0.99482167
plasma O 0 0.1778377
T O 0 0.580927
1 O 0 0.0008330508
/ O 0 0.001146517
2 O 0 0.0005030461
alpha O 0 0.07275881
( O 0 0.000960507
+ O 0 0.0007082523
/ O 0 0.0014454458
- O 0 0.0009253822
SE O 0 0.1442979
) O 0 0.00057686627
of O 0 0.0003707542
2 O 0 0.00031504108
. O 0 0.0001650563
5 O 0 0.00022260241
+ O 0 0.00034552402
/ O 0 0.00066765957
- O 0 0.00041644898
0 O 0 0.0002350921
. O 0 0.00010939169
85 O 0 0.00025536574
minutes O 0 0.00020485683
, O 0 0.00035763317
T O 0 0.16400418
beta O 0 0.17760363
1 O 0 0.00040093716
/ O 0 0.0005541164
2 O 0 0.00019910242
of O 0 0.00024126247
25 O 0 0.00038602704
. O 0 0.00013954529
6 O 0 0.00017622397
+ O 0 0.00031258186
/ O 0 0.0006097566
- O 0 0.00038344893
6 O 0 0.00015194403
. O 0 0.00010677377
5 O 0 0.00013618078
minutes O 0 0.00017176043
, O 0 0.0002611913
and O 0 0.0003043314
T O 0 0.10777642
1 O 0 0.00036637296
/ O 0 0.000617013
2 O 0 0.000306091
gamma O 0 0.016370423
of O 0 0.00052674464
23 O 0 0.00075414724
. O 0 0.00028183678
6 O 0 0.00038357126
+ O 0 0.0007517024
/ O 0 0.001553409
- O 0 0.001355337
7 O 0 0.0008633461
. O 0 0.0008212203
6 O 0 0.0013631578
hours O 0 0.0026034797
. O 0 0.00396586

The O 0 0.002906164
area O 0 0.0027602934
under O 0 0.0012327231
the O 0 0.0012311953
curve O 0 0.0021473935
was O 0 0.001223747
537 O 0 0.03522661
+ O 0 0.0013233841
/ O 0 0.0017085137
- O 0 0.0010035872
149 O 0 0.003073318
ng O 0 0.0012999534
/ O 0 0.00093993224
ml O 0 0.0012463727
x O 0 0.0008454206
hours O 0 0.00027393678
, O 0 0.00030711055
volume O 0 0.0005280161
of O 0 0.000324468
distribution O 0 0.0002877004
( O 0 0.00070381415
Vd O 0 0.17264484
) O 0 0.00093635375
3504 O 0 0.10034602
+ O 0 0.00061603525
/ O 0 0.001067176
- O 0 0.0006366953
644 O 0 0.014150378
l O 0 0.0010816018
/ O 0 0.00087926263
m2 O 0 0.016628541
, O 0 0.0003557903
and O 0 0.00025281194
total O 0 0.00029112128
clearance O 0 0.058649044
( O 0 0.0010092859
ClT O 0 0.84239346
) O 0 0.00078142906
was O 0 0.00039516325
204 O 0 0.0025959157
+ O 0 0.0005628048
39 O 0 0.0007362467
. O 0 0.000323071
3 O 0 0.00051711104
l O 0 0.0016044131
/ O 0 0.0021303643
hour O 0 0.0017290217
/ O 0 0.0054808753
m2 O 0 0.04398119
. O 0 0.005534758

Adriamycinol B-Chemical 0 0.70741254
, O 0 0.00737786
doxorubicin B-Chemical 1 0.9967836
, O 0 0.0049678185
adriamycinone B-Chemical 0 0.72362447
, O 0 0.0017156114
and O 0 0.00091332383
tetrahydropyranyladriamycinol B-Chemical 0 0.042983916
were O 0 0.0005791426
the O 0 0.0004916558
metabolites O 0 0.49386993
detected O 0 0.0002969806
in O 0 0.00033714413
plasma O 0 0.010959676
and O 0 0.00033751834
the O 0 0.00024206706
amount O 0 0.000174833
of O 0 0.00057503383
doxorubicin B-Chemical 1 0.99898845
was O 0 0.00049700995
less O 0 0.00034804785
than O 0 0.00019053009
or O 0 0.00023497849
equal O 0 0.00026744968
to O 0 0.000418726
10 O 0 0.00059356756
% O 0 0.00066606374
of O 0 0.00090417877
the O 0 0.0013221281
total O 0 0.0027596084
metabolites O 0 0.723949
. O 0 0.006695077

Urinary O 0 0.9497612
excretion O 0 0.9312347
of O 0 0.0055054766
Pirarubicin B-Chemical 0 0.9897827
in O 0 0.0013431387
the O 0 0.0008200673
first O 0 0.00058537367
24 O 0 0.0005792641
hours O 0 0.0005029442
was O 0 0.00050653645
less O 0 0.0005770101
than O 0 0.00047107734
or O 0 0.0007034071
equal O 0 0.0009617034
to O 0 0.0018075076
10 O 0 0.003074993
% O 0 0.00451473
. O 0 0.0049559036

Activity O 0 0.029968023
was O 0 0.004509673
noted O 0 0.0036168706
in O 0 0.0035136365
mesothelioma B-Disease 0 0.9622805
, O 0 0.009248619
leiomyosarcoma B-Disease 0 0.9940806
, O 0 0.0059167594
and O 0 0.0045175576
basal B-Disease 0 0.023013283
cell I-Disease 0 0.13515197
carcinoma I-Disease 2 0.9963983
. O 0 0.01670949

The O 0 0.0028701262
recommended O 0 0.0024796638
starting O 0 0.0018746512
dose O 0 0.006402526
for O 0 0.001185945
Phase O 0 0.0063525722
II O 0 0.0051136855
trials O 0 0.0013897675
is O 0 0.0007561507
60 O 0 0.0009973809
mg O 0 0.19648021
/ O 0 0.0024641366
m2 O 0 0.035069685
IV O 0 0.051583003
bolus O 0 0.032218225
every O 0 0.0011886655
3 O 0 0.0020677252
weeks O 0 0.0033245867
. O 0 0.0046846676

Ocular B-Disease 0 0.8156813
and I-Disease 0 0.009324612
auditory I-Disease 0 0.25132427
toxicity I-Disease 2 0.98568416
in O 0 0.007690867
hemodialyzed O 0 0.99321944
patients O 0 0.08685776
receiving O 0 0.2899796
desferrioxamine B-Chemical 1 0.99818075
. O 0 0.022947371

During O 0 0.002784532
an O 0 0.0027242517
18 O 0 0.0018295473
- O 0 0.0014460399
month O 0 0.0006525898
period O 0 0.0005428811
of O 0 0.00062950025
study O 0 0.0009113794
41 O 0 0.0015196993
hemodialyzed O 0 0.9941168
patients O 0 0.007454897
receiving O 0 0.03534014
desferrioxamine B-Chemical 1 0.99985325
( O 0 0.002349318
10 O 0 0.00056127255
- O 0 0.0005440289
40 O 0 0.00038428605
mg O 0 0.13841079
/ O 0 0.0008078949
kg O 0 0.003675721
BW O 0 0.1253129
/ O 0 0.0005589166
3 O 0 0.00016005852
times O 0 0.00012150527
weekly O 0 0.0003878172
) O 0 0.0003633782
for O 0 0.00017290823
the O 0 0.00020761923
first O 0 0.0002047135
time O 0 0.00025848212
were O 0 0.00036327567
monitored O 0 0.00033091594
for O 0 0.0005723979
detection O 0 0.0014420904
of O 0 0.0032854162
audiovisual B-Disease 0 0.6462172
toxicity I-Disease 2 0.99595696
. O 0 0.01030722

6 O 0 0.0044521694
patients O 0 0.0056351875
presented O 0 0.0035548813
clinical O 0 0.009721992
symptoms O 0 0.15841933
of O 0 0.0051789465
visual B-Disease 0 0.22710618
or I-Disease 0 0.00633494
auditory I-Disease 0 0.46462467
toxicity I-Disease 2 0.9865607
. O 0 0.013942232

Moreover O 0 0.006193213
, O 0 0.003812215
detailed O 0 0.0023619507
ophthalmologic O 0 0.068196304
and O 0 0.0020693552
audiologic O 0 0.048166472
studies O 0 0.002506572
disclosed O 0 0.005013787
abnormalities O 0 0.064113595
in O 0 0.0016627847
7 O 0 0.0017547689
more O 0 0.0030003977
asymptomatic O 0 0.10143244
patients O 0 0.014254155
. O 0 0.007557645

Visual B-Disease 0 0.975809
toxicity I-Disease 2 0.99448615
was O 0 0.0028072936
of O 0 0.002217278
retinal O 0 0.74513525
origin O 0 0.0029625176
and O 0 0.0009303321
was O 0 0.0006456917
characterized O 0 0.0009596806
by O 0 0.00060789107
a O 0 0.0008253782
tritan O 0 0.9744645
- O 0 0.0018447732
type O 0 0.0007315821
dyschromatopsy B-Disease 0 0.38272932
, O 0 0.0007601891
sometimes O 0 0.0012889133
associated O 0 0.00062724185
with O 0 0.00058620836
a B-Disease 0 0.00061389914
loss I-Disease 0 0.0012007835
of I-Disease 0 0.0012213244
visual I-Disease 0 0.4146038
acuity I-Disease 0 0.9888632
and O 0 0.0050305706
pigmentary B-Disease 0 0.9964084
retinal I-Disease 0 0.98748815
deposits I-Disease 0 0.8765736
. O 0 0.009859706

Auditory B-Disease 0 0.9386836
toxicity I-Disease 2 0.99416345
was O 0 0.0028992335
characterized O 0 0.0025921639
by O 0 0.0012963951
a O 0 0.0012000615
mid O 0 0.002437151
- O 0 0.001258471
to O 0 0.00053510274
high O 0 0.0008739445
- O 0 0.001054986
frequency O 0 0.00095231243
neurosensorial B-Disease 0 0.9932112
hearing I-Disease 0 0.90683997
loss I-Disease 0 0.005255919
and O 0 0.0008081734
the O 0 0.0007476246
lesion O 0 0.030114165
was O 0 0.0010285156
of O 0 0.0016369404
the O 0 0.0022909476
cochlear O 0 0.20338324
type O 0 0.0058006947
. O 0 0.0065370686

Desferrioxamine B-Chemical 0 0.99788815
withdrawal O 0 0.84052587
resulted O 0 0.002379846
in O 0 0.0011574698
a O 0 0.0009212818
complete O 0 0.00064314716
recovery O 0 0.0011497193
of O 0 0.0007318893
visual O 0 0.08480272
function O 0 0.0007265464
in O 0 0.0003475745
1 O 0 0.00031563602
patient O 0 0.0004062657
and O 0 0.00026038275
partial O 0 0.0005176294
recovery O 0 0.00076272327
in O 0 0.00024883673
3 O 0 0.00023539737
, O 0 0.0002802337
and O 0 0.00022037573
a O 0 0.00023684134
complete O 0 0.00022568385
reversal O 0 0.0009533246
of O 0 0.0005574814
hearing B-Disease 0 0.6745004
loss I-Disease 0 0.0014671708
in O 0 0.00043664753
3 O 0 0.0004473907
patients O 0 0.0011850953
and O 0 0.0007839485
partial O 0 0.0020561744
recovery O 0 0.0035098884
in O 0 0.002279302
3 O 0 0.0035044658
. O 0 0.0045232177

This O 0 0.007466091
toxicity B-Disease 2 0.95946
appeared O 0 0.0025293424
in O 0 0.0011516026
patients O 0 0.002138015
receiving O 0 0.0021859175
the O 0 0.0006163459
higher O 0 0.0006329287
doses O 0 0.023623953
of O 0 0.0017987449
desferrioxamine B-Chemical 1 0.99974924
or O 0 0.0008732761
coincided O 0 0.0013841426
with O 0 0.00075597817
the O 0 0.0005984623
normalization O 0 0.0012721942
of O 0 0.0020572452
ferritin O 0 0.99208915
or O 0 0.0032856818
aluminium B-Chemical 0 0.9920562
serum O 0 0.51367044
levels O 0 0.007783253
. O 0 0.0075532263

The O 0 0.0031589095
data O 0 0.0026904498
indicate O 0 0.0015596843
that O 0 0.0016753393
audiovisual B-Disease 0 0.21336679
toxicity I-Disease 2 0.9968369
is O 0 0.0017766333
not O 0 0.0010237314
an O 0 0.0014206398
infrequent O 0 0.013497483
complication O 0 0.4040199
in O 0 0.0023533998
hemodialyzed O 0 0.99644524
patients O 0 0.06693819
receiving O 0 0.26225543
desferrioxamine B-Chemical 1 0.99891067
. O 0 0.014716488

Periodical O 0 0.0073278546
audiovisual O 0 0.008082464
monitoring O 0 0.002477134
should O 0 0.0009962043
be O 0 0.00094505167
performed O 0 0.0006983688
on O 0 0.00057004695
hemodialyzed O 0 0.98951334
patients O 0 0.003866257
receiving O 0 0.0029892088
the O 0 0.00059640774
drug O 0 0.1507462
in O 0 0.00046634502
order O 0 0.00032453545
to O 0 0.00042539506
detect O 0 0.0004757031
adverse O 0 0.36520436
effects O 0 0.002230123
as O 0 0.0011520183
early O 0 0.0034396807
as O 0 0.0023952925
possible O 0 0.0051179035
. O 0 0.0059484574

Serial O 0 0.056477834
epilepsy B-Disease 2 0.995689
caused O 0 0.0071716686
by O 0 0.005880748
levodopa B-Chemical 1 0.9995951
/ I-Chemical 0 0.14143138
carbidopa I-Chemical 0 0.9998141
administration O 0 0.55272835
in O 0 0.0019699642
two O 0 0.0017297148
patients O 0 0.005583297
on O 0 0.0032335527
hemodialysis O 0 0.8527488
. O 0 0.009639231

Two O 0 0.0040674964
patients O 0 0.0038640173
with O 0 0.0016590148
similar O 0 0.0009181297
clinical O 0 0.0034959519
features O 0 0.002045471
are O 0 0.0006602508
presented O 0 0.00066070777
: O 0 0.0007258312
both O 0 0.0003762155
patients O 0 0.0011548662
had O 0 0.00061366864
chronic B-Disease 2 0.9857291
renal I-Disease 2 0.9982168
failure I-Disease 2 0.9663921
, O 0 0.0009872087
on O 0 0.0002144481
hemodialysis O 0 0.57361424
for O 0 0.0002476776
many O 0 0.00032230155
years O 0 0.0005450584
but O 0 0.00021626754
recently O 0 0.00030418002
begun O 0 0.00040398096
on O 0 0.00013344952
a O 0 0.00026752846
high O 0 0.0004479559
- O 0 0.0006162572
flux O 0 0.007529176
dialyzer O 0 0.3172135
; O 0 0.0007749755
both O 0 0.00024169692
had O 0 0.00030067598
been O 0 0.0003718766
receiving O 0 0.0023726567
a O 0 0.0010388503
carbidopa B-Chemical 0 0.9999554
/ I-Chemical 0 0.028936796
levodopa I-Chemical 1 0.9999212
preparation O 0 0.010512834
; O 0 0.00096800353
and O 0 0.00028802096
both O 0 0.0002331074
had O 0 0.00028207738
the O 0 0.00028340716
onset O 0 0.002994739
of O 0 0.0015184612
hallucinosis B-Disease 0 0.9998523
and O 0 0.0023716195
recurrent O 0 0.9455102
seizures B-Disease 2 0.99984264
, O 0 0.0024866208
which O 0 0.0015430761
were O 0 0.001479954
refractory O 0 0.36781734
to O 0 0.0048911907
anticonvulsants O 0 0.99732924
. O 0 0.008150596

The O 0 0.0025906218
first O 0 0.0017016229
patient O 0 0.0024566664
died O 0 0.00554413
without O 0 0.0012048119
a O 0 0.0011635366
diagnosis O 0 0.0078720795
; O 0 0.001209758
the O 0 0.00043953088
second O 0 0.00043628638
patient O 0 0.0007594487
had O 0 0.00053288304
a O 0 0.00060396607
dramatic O 0 0.0010712653
recovery O 0 0.001530831
following O 0 0.0009016906
the O 0 0.0012117773
administration O 0 0.15407825
of O 0 0.008838996
vitamin B-Chemical 0 0.9986753
B6 I-Chemical 0 0.9131062
. O 0 0.009842935

Neither O 0 0.004627053
patient O 0 0.0036180909
was O 0 0.0018174025
considered O 0 0.0012459779
to O 0 0.0010220065
have O 0 0.0010881874
a O 0 0.0014654337
renal O 0 0.94318104
state O 0 0.002326235
sufficiently O 0 0.0021205128
severe O 0 0.07135203
enough O 0 0.0015190794
to O 0 0.0014776345
explain O 0 0.0019839846
their O 0 0.0037268805
presentation O 0 0.02174764
. O 0 0.007668741

Randomized O 0 0.022708254
, O 0 0.005827938
double O 0 0.0034717266
- O 0 0.0048162877
blind O 0 0.0075405436
trial O 0 0.005729356
of O 0 0.0071001956
mazindol B-Chemical 1 0.9988275
in O 0 0.014419181
Duchenne B-Disease 0 0.99424595
dystrophy I-Disease 0 0.99426126
. O 0 0.019304281

There O 0 0.0059869834
is O 0 0.0026769903
evidence O 0 0.0021640582
that O 0 0.0015823436
growth O 0 0.0075428057
hormone O 0 0.81433976
may O 0 0.0015490385
be O 0 0.0010690794
related O 0 0.00069250143
to O 0 0.0008289941
the O 0 0.0010991269
progression O 0 0.15942526
of O 0 0.003771201
weakness B-Disease 2 0.986032
in O 0 0.00736798
Duchenne B-Disease 0 0.9959394
dystrophy I-Disease 0 0.9956247
. O 0 0.013282096

We O 0 0.0029977357
conducted O 0 0.0020372043
a O 0 0.0017480968
12 O 0 0.0010818853
- O 0 0.0011824279
month O 0 0.0005924866
controlled O 0 0.00060149207
trial O 0 0.0011649582
of O 0 0.0012385349
mazindol B-Chemical 1 0.99973506
, O 0 0.0014133004
a O 0 0.0007383075
putative O 0 0.0009414218
growth O 0 0.012833857
hormone O 0 0.9607533
secretion O 0 0.24051079
inhibitor O 0 0.27940097
, O 0 0.0017159911
in O 0 0.0010240356
83 O 0 0.0027781427
boys O 0 0.00849531
with O 0 0.004728668
Duchenne B-Disease 0 0.99445903
dystrophy I-Disease 0 0.99494994
. O 0 0.011719334

Muscle O 0 0.37276584
strength O 0 0.009041095
, O 0 0.004515169
contractures O 0 0.9793546
, O 0 0.0021971695
functional O 0 0.0014605708
ability O 0 0.0007405981
and O 0 0.0006825691
pulmonary O 0 0.48520118
function O 0 0.0007744672
were O 0 0.0003499832
tested O 0 0.00023304632
at O 0 0.00018792387
baseline O 0 0.000403835
, O 0 0.000346439
and O 0 0.00025415976
6 O 0 0.00016777891
and O 0 0.00018837667
12 O 0 0.00014440464
months O 0 0.00018505697
after O 0 0.00012803689
treatment O 0 0.0006380307
with O 0 0.00091290544
mazindol B-Chemical 1 0.9997656
( O 0 0.001389626
3 O 0 0.0006874105
mg O 0 0.25810748
/ O 0 0.0021502643
d O 0 0.0016327726
) O 0 0.0023284492
or O 0 0.0021807523
placebo O 0 0.18174775
. O 0 0.0054610693

The O 0 0.0026254985
study O 0 0.0026153638
was O 0 0.0013925994
designed O 0 0.0011801257
to O 0 0.0007989141
have O 0 0.0007175892
a O 0 0.0006726143
power O 0 0.0018938023
of O 0 0.0006588534
greater O 0 0.00048629573
than O 0 0.00027358442
0 O 0 0.00035948172
. O 0 0.00015253908
90 O 0 0.00021586953
to O 0 0.00016911313
detect O 0 0.00015239834
a O 0 0.00028412763
slowing O 0 0.0055424897
to O 0 0.0002710538
25 O 0 0.0004411728
% O 0 0.00024124038
of O 0 0.000230797
the O 0 0.00019763246
expected O 0 0.00014320374
rate O 0 0.00024654035
of O 0 0.00049430673
progression O 0 0.18565217
of O 0 0.0012487362
weakness B-Disease 2 0.9710783
at O 0 0.0006578781
P O 0 0.035081595
less O 0 0.0009915588
than O 0 0.00089940993
0 O 0 0.0020585388
. O 0 0.002038172
05 O 0 0.039926045
. O 0 0.005169658

Mazindol B-Chemical 0 0.99228245
did O 0 0.004394184
not O 0 0.0025463933
benefit O 0 0.00359846
strength O 0 0.003975167
at O 0 0.0015090283
any O 0 0.0016853516
point O 0 0.0021139465
in O 0 0.0026498411
the O 0 0.0040510506
study O 0 0.008831234
. O 0 0.008736886

Side O 0 0.4297267
effects O 0 0.005407674
attributable O 0 0.0021626574
to O 0 0.0020347908
mazindol B-Chemical 1 0.99938023
included O 0 0.001756952
decreased B-Disease 0 0.04147429
appetite I-Disease 0 0.9980028
( O 0 0.001703294
36 O 0 0.0007090887
% O 0 0.0005837944
) O 0 0.0006774775
, O 0 0.00054288434
dry B-Disease 2 0.077667974
mouth I-Disease 2 0.33277264
( O 0 0.0007447308
10 O 0 0.000381361
% O 0 0.00035657556
) O 0 0.00043706724
, O 0 0.0003311728
behavioral O 0 0.0053224596
change O 0 0.00038483267
( O 0 0.00042747802
22 O 0 0.00041533555
% O 0 0.00032592175
) O 0 0.00042563883
, O 0 0.00034187158
and O 0 0.000415609
gastrointestinal B-Disease 0 0.9948258
symptoms I-Disease 0 0.9482468
( O 0 0.0009978565
18 O 0 0.0004478206
% O 0 0.00044166678
) O 0 0.00071134797
; O 0 0.0011608829
mazindol B-Chemical 1 0.9996815
dosage O 0 0.1746846
was O 0 0.00068724767
reduced O 0 0.000775398
in O 0 0.0008212649
43 O 0 0.002030553
% O 0 0.0016352362
of O 0 0.0025408233
patients O 0 0.009216217
. O 0 0.005690799

The O 0 0.003011146
effect O 0 0.0027777175
of O 0 0.0033824262
mazindol B-Chemical 1 0.99935144
on O 0 0.0016035883
GH O 0 0.98051786
secretion O 0 0.096379004
was O 0 0.00071926526
estimated O 0 0.00048162814
indirectly O 0 0.00090340636
by O 0 0.00037567844
comparing O 0 0.00021282848
the O 0 0.0004414698
postabsorptive O 0 0.8425094
IGF O 0 0.9951514
- O 0 0.0016962754
I O 0 0.0014674782
levels O 0 0.00029031193
obtained O 0 0.00026251096
following O 0 0.00030070118
3 O 0 0.0002593194
, O 0 0.00031556713
6 O 0 0.00018686146
, O 0 0.0002741265
9 O 0 0.00021927012
, O 0 0.00023904852
and O 0 0.00020073414
12 O 0 0.00016042798
months O 0 0.00022456277
in O 0 0.00021652193
the O 0 0.00041963905
mazindol B-Chemical 1 0.99960333
treated O 0 0.0014887565
to O 0 0.0006387079
those O 0 0.0010219344
in O 0 0.0008777154
the O 0 0.0015612177
placebo O 0 0.16660835
groups O 0 0.0050341743
. O 0 0.00551412

Although O 0 0.0060466942
mazindol B-Chemical 1 0.99876237
- O 0 0.004934812
treated O 0 0.0022202337
patients O 0 0.0021195766
gained O 0 0.0013609559
less O 0 0.0006657416
weight O 0 0.002383104
and O 0 0.00051525777
height O 0 0.0014495674
than O 0 0.00031678856
placebo O 0 0.1052292
- O 0 0.00080613664
treated O 0 0.00074399984
patients O 0 0.0015512909
, O 0 0.0005215793
no O 0 0.000301601
significant O 0 0.00056194665
effect O 0 0.00070419087
on O 0 0.00067843345
IGF O 0 0.9878554
- O 0 0.0038205397
I O 0 0.004901576
levels O 0 0.0019086873
was O 0 0.002630549
observed O 0 0.0034393014
. O 0 0.0056815357

Mazindol B-Chemical 0 0.99365234
doses O 0 0.07996812
not O 0 0.0034839336
slow O 0 0.0067132586
the O 0 0.0031436353
progression O 0 0.20101406
of O 0 0.0068135783
weakness B-Disease 2 0.98315746
in O 0 0.010986633
Duchenne B-Disease 0 0.9945433
dystrophy I-Disease 0 0.9946156
. O 0 0.017636862

Facilitation O 0 0.0743022
of O 0 0.0040263697
memory O 0 0.11415558
retrieval O 0 0.004421253
by O 0 0.0015597171
pre O 0 0.00414919
- O 0 0.0016586817
test O 0 0.001111969
morphine B-Chemical 1 0.9989178
and O 0 0.00095030846
its O 0 0.0011463905
state O 0 0.00078967185
dependency O 0 0.0011747287
in O 0 0.00038008124
the O 0 0.00038869295
step O 0 0.00055873464
- O 0 0.0007733448
through O 0 0.0003917474
type O 0 0.0005979722
passive O 0 0.0021044263
avoidance O 0 0.0048317323
learning O 0 0.00611498
test O 0 0.0020454037
in O 0 0.0022737745
mice O 0 0.0029838686
. O 0 0.005492485

Amnesia B-Disease 0 0.86293876
produced O 0 0.004243841
by O 0 0.003894005
scopolamine B-Chemical 1 0.9996524
and O 0 0.0052604848
cycloheximide B-Chemical 1 0.99650997
were O 0 0.0013016738
reversed O 0 0.002647861
by O 0 0.0008860826
morphine B-Chemical 1 0.99927133
given O 0 0.00040594957
30 O 0 0.0002978088
min O 0 0.0003333083
before O 0 0.00011511489
the O 0 0.00016780659
test O 0 0.00026694374
trial O 0 0.0006959964
( O 0 0.0004466403
pre O 0 0.001388331
- O 0 0.000567479
test O 0 0.00038272183
) O 0 0.0005754547
, O 0 0.0003575694
and O 0 0.00029295945
pre O 0 0.0015102064
- O 0 0.0005706501
test O 0 0.00044314977
morphine B-Chemical 1 0.9992255
also O 0 0.0004941788
facilitated O 0 0.00050065195
the O 0 0.0003533306
memory O 0 0.09972945
retrieval O 0 0.0013334499
in O 0 0.00032518336
the O 0 0.00035148667
animals O 0 0.00048373514
administered O 0 0.0048970445
naloxone B-Chemical 1 0.9994622
during O 0 0.0010794258
the O 0 0.0014325966
training O 0 0.0031591903
trial O 0 0.0074721416
. O 0 0.0052414937

Similarly O 0 0.005597492
, O 0 0.0037766292
pre O 0 0.005773786
- O 0 0.00301713
test O 0 0.0022468818
scopolamine B-Chemical 1 0.9996834
partially O 0 0.0028678784
reversed O 0 0.0062023117
the O 0 0.0015755196
scopolamine B-Chemical 1 0.99992406
- O 0 0.014832144
induced O 0 0.00606604
amnesia B-Disease 0 0.9995478
, O 0 0.0013150935
but O 0 0.00039904244
not O 0 0.00031224109
significantly O 0 0.0005652854
; O 0 0.0006931527
and O 0 0.00038479985
pre O 0 0.002265505
- O 0 0.0008240549
test O 0 0.0006783634
cycloheximide B-Chemical 1 0.9887326
failed O 0 0.0012668064
to O 0 0.00082262146
reverse O 0 0.01986155
the O 0 0.0021414491
cycloheximide B-Chemical 1 0.9964927
- O 0 0.018334666
induced O 0 0.025155794
amnesia B-Disease 0 0.99747807
. O 0 0.009318492

These O 0 0.0038167739
results O 0 0.0018640618
suggest O 0 0.0012026642
that O 0 0.0009853828
the O 0 0.0009442128
facilitation O 0 0.01826474
of O 0 0.0012514543
memory O 0 0.18869714
retrieval O 0 0.0026819776
by O 0 0.0007109542
pre O 0 0.0034557756
- O 0 0.0010028878
test O 0 0.00072764605
morphine B-Chemical 1 0.9991442
might O 0 0.0004550306
be O 0 0.00039233718
the O 0 0.0002880561
direct O 0 0.00037561043
action O 0 0.0027556624
of O 0 0.0011158462
morphine B-Chemical 1 0.99926764
rather O 0 0.00091091753
than O 0 0.00064543914
a O 0 0.0012571005
state O 0 0.0021921583
dependent O 0 0.00237096
effect O 0 0.0051976554
. O 0 0.005942438

Naloxone B-Chemical 0 0.99802655
reverses O 0 0.35750648
the O 0 0.010926722
antihypertensive O 0 0.98034793
effect O 0 0.014229668
of O 0 0.024152882
clonidine B-Chemical 1 0.9977241
. O 0 0.02539614

In O 0 0.0040756036
unanesthetized O 0 0.087203115
, O 0 0.0033855555
spontaneously O 0 0.032065127
hypertensive B-Disease 2 0.9962296
rats O 0 0.008296925
the O 0 0.00077734125
decrease O 0 0.00081492786
in O 0 0.00048946997
blood O 0 0.0034558054
pressure O 0 0.025443869
and O 0 0.00056675146
heart O 0 0.15238447
rate O 0 0.0003575401
produced O 0 0.00036847263
by O 0 0.0004679976
intravenous O 0 0.7609246
clonidine B-Chemical 1 0.9998683
, O 0 0.0008915281
5 O 0 0.0002386814
to O 0 0.00019146873
20 O 0 0.00030353628
micrograms O 0 0.06451884
/ O 0 0.00077562383
kg O 0 0.003619425
, O 0 0.00036470234
was O 0 0.00026922082
inhibited O 0 0.0006292043
or O 0 0.0003066714
reversed O 0 0.0012488789
by O 0 0.0006148562
nalozone B-Chemical 0 0.5028991
, O 0 0.0009000615
0 O 0 0.0006242891
. O 0 0.00032785145
2 O 0 0.0005274699
to O 0 0.00065311923
2 O 0 0.0012904461
mg O 0 0.18621762
/ O 0 0.0059565185
kg O 0 0.016078468
. O 0 0.005076813

The O 0 0.004381029
hypotensive B-Disease 2 0.9772325
effect O 0 0.0031677883
of O 0 0.0023423142
100 O 0 0.003831797
mg O 0 0.5247015
/ O 0 0.003651248
kg O 0 0.025025181
alpha B-Chemical 1 0.6459945
- I-Chemical 1 0.0109130945
methyldopa I-Chemical 1 0.99984896
was O 0 0.002273082
also O 0 0.0018616413
partially O 0 0.0025980375
reversed O 0 0.008369049
by O 0 0.008007912
naloxone B-Chemical 1 0.9988312
. O 0 0.012043427

Naloxone B-Chemical 0 0.998577
alone O 0 0.007347812
did O 0 0.0031053764
not O 0 0.0020831213
affect O 0 0.0016475759
either O 0 0.0023255853
blood O 0 0.011017025
pressure O 0 0.06074578
or O 0 0.00425797
heart O 0 0.33830318
rate O 0 0.007963155
. O 0 0.00919594

In O 0 0.0038472046
brain O 0 0.023625627
membranes O 0 0.017372806
from O 0 0.0019439416
spontaneously O 0 0.057467833
hypertensive B-Disease 2 0.9979328
rats O 0 0.09511762
clonidine B-Chemical 1 0.9997477
, O 0 0.002266415
10 O 0 0.0008407587
( O 0 0.00079819927
- O 0 0.0006839034
8 O 0 0.00034487652
) O 0 0.00044084442
to O 0 0.00025488684
10 O 0 0.00035890302
( O 0 0.00046376587
- O 0 0.0004980289
5 O 0 0.00027065017
) O 0 0.0005809441
M O 0 0.20256232
, O 0 0.0003719741
did O 0 0.00020924606
not O 0 0.0001881324
influence O 0 0.00025648187
stereoselective O 0 0.75942373
binding O 0 0.00054969423
of O 0 0.00092662673
[ B-Chemical 0 0.00897108
3H I-Chemical 0 0.72679687
] I-Chemical 0 0.0040832865
- I-Chemical 0 0.0021484902
naloxone I-Chemical 1 0.9998462
( O 0 0.0013678551
8 O 0 0.00044618876
nM O 0 0.012915207
) O 0 0.00057859754
, O 0 0.00039018833
and O 0 0.00046527758
naloxone B-Chemical 1 0.9998259
, O 0 0.0009374178
10 O 0 0.0004453793
( O 0 0.00046507138
- O 0 0.00044383315
8 O 0 0.0002341751
) O 0 0.00032243587
to O 0 0.00019271934
10 O 0 0.00028921795
( O 0 0.00038410275
- O 0 0.0004293138
4 O 0 0.00024235896
) O 0 0.00055765786
M O 0 0.20991395
, O 0 0.00036423304
did O 0 0.00021656592
not O 0 0.00021874142
influence O 0 0.00040650452
clonidine B-Chemical 1 0.9998355
- O 0 0.0030240675
suppressible O 0 0.19434485
binding O 0 0.00076652574
of O 0 0.0012543483
[ B-Chemical 0 0.009614591
3H I-Chemical 0 0.65495604
] I-Chemical 0 0.0044767917
- I-Chemical 0 0.003160428
dihydroergocryptine I-Chemical 0 0.9959512
( O 0 0.003242476
1 O 0 0.0026986662
nM O 0 0.02729846
) O 0 0.0062263007
. O 0 0.0051794867

These O 0 0.0045281393
findings O 0 0.0038422735
indicate O 0 0.0014153058
that O 0 0.0012108947
in O 0 0.0011518209
spontaneously O 0 0.03467727
hypertensive B-Disease 2 0.9972886
rats O 0 0.0066971667
the O 0 0.00065348507
effects O 0 0.0011471605
of O 0 0.0009258183
central O 0 0.0039989506
alpha O 0 0.37829986
- O 0 0.006542499
adrenoceptor O 0 0.99915886
stimulation O 0 0.011010892
involve O 0 0.0021693993
activation O 0 0.006355823
of O 0 0.006730833
opiate O 0 0.99819547
receptors O 0 0.76156336
. O 0 0.009571642

As O 0 0.0038506945
naloxone B-Chemical 1 0.9985348
and O 0 0.005654892
clonidine B-Chemical 1 0.9993574
do O 0 0.001533926
not O 0 0.0007788575
appear O 0 0.0006755795
to O 0 0.00042605243
interact O 0 0.00034525615
with O 0 0.0004365395
the O 0 0.00031681333
same O 0 0.00022509653
receptor O 0 0.03862097
site O 0 0.00047083627
, O 0 0.0004277933
the O 0 0.0002301514
observed O 0 0.00019910563
functional O 0 0.0005572171
antagonism O 0 0.32737747
suggests O 0 0.00022952969
the O 0 0.00030038884
release O 0 0.01817449
of O 0 0.000471679
an O 0 0.0005582721
endogenous O 0 0.0017164665
opiate O 0 0.9994617
by O 0 0.0019325847
clonidine B-Chemical 1 0.99989665
or O 0 0.0010375131
alpha B-Chemical 1 0.89343435
- I-Chemical 1 0.012760545
methyldopa I-Chemical 1 0.999956
and O 0 0.0007230709
the O 0 0.00031443496
possible O 0 0.0003430252
role O 0 0.00023420392
of O 0 0.000518712
the O 0 0.00063050096
opiate O 0 0.99827147
in O 0 0.00073955214
the O 0 0.0007635447
central O 0 0.002010967
control O 0 0.0012888703
of O 0 0.003493476
sympathetic O 0 0.9298131
tone O 0 0.69737643
. O 0 0.0077745747

Neurotoxicity B-Disease 0 0.9944353
of O 0 0.010117524
halogenated B-Chemical 0 0.990466
hydroxyquinolines I-Chemical 0 0.9784606
: O 0 0.0051534097
clinical O 0 0.007291141
analysis O 0 0.0030152905
of O 0 0.0030648133
cases O 0 0.0056743664
reported O 0 0.006194557
outside O 0 0.00562532
Japan O 0 0.086075135
. O 0 0.0094593605

An O 0 0.0058845095
analysis O 0 0.0034377526
is O 0 0.0018125069
presented O 0 0.001450626
of O 0 0.0014654155
220 O 0 0.0039274544
cases O 0 0.0016920519
of O 0 0.0012901298
possible O 0 0.001863517
neurotoxic B-Disease 0 0.9970499
reactions O 0 0.044516683
to O 0 0.001967562
halogenated B-Chemical 0 0.9958455
hydroxyquinolines I-Chemical 0 0.9853048
reported O 0 0.0048776
from O 0 0.002773928
outside O 0 0.0037278275
Japan O 0 0.07422754
. O 0 0.0069972025

In O 0 0.0026915479
80 O 0 0.002594592
cases O 0 0.0021120051
insufficient O 0 0.0014266627
information O 0 0.0012228168
was O 0 0.0006921362
available O 0 0.0005364075
for O 0 0.0003946232
adequate O 0 0.00062744063
comment O 0 0.002442334
and O 0 0.0005459095
in O 0 0.00040822657
29 O 0 0.0007498569
a O 0 0.00039586888
relationship O 0 0.0002993211
to O 0 0.00041619458
the O 0 0.000590063
administration O 0 0.06331719
of O 0 0.0030078657
clioquinol B-Chemical 0 0.99925715
could O 0 0.002475638
be O 0 0.0033789754
excluded O 0 0.005830409
. O 0 0.0061531817

Of O 0 0.005515118
the O 0 0.002433824
remainder O 0 0.0026069141
, O 0 0.0019489578
a O 0 0.001230728
relationship O 0 0.0008141183
to O 0 0.0011746438
clioquinol B-Chemical 0 0.9990428
was O 0 0.0012867643
considered O 0 0.0008732944
probable O 0 0.004263448
in O 0 0.0008399652
42 O 0 0.001416968
and O 0 0.0010912811
possible O 0 0.0015682224
in O 0 0.0018833401
69 O 0 0.004596464
cases O 0 0.0069748005
. O 0 0.006304869

In O 0 0.0025488918
six O 0 0.0013336226
of O 0 0.0016333829
the O 0 0.0012158307
probable O 0 0.0049043815
cases O 0 0.0019257811
the O 0 0.0010715664
neurological B-Disease 0 0.99447745
disturbance I-Disease 0 0.7964893
consisted O 0 0.00069790037
of O 0 0.0007754486
an O 0 0.001227378
acute O 0 0.97014105
reversible O 0 0.90840286
encephalopathy B-Disease 2 0.99987197
usually O 0 0.004480687
related O 0 0.00034654982
to O 0 0.00031448263
the O 0 0.00034424744
ingestion O 0 0.27900866
of O 0 0.0005653166
a O 0 0.00051015965
high O 0 0.00071852875
dose O 0 0.012105682
of O 0 0.0017701775
clioquinol B-Chemical 0 0.9992341
over O 0 0.0009827428
a O 0 0.001886295
short O 0 0.0023985417
period O 0 0.004073419
. O 0 0.0052827885

The O 0 0.003568055
most O 0 0.0039261454
common O 0 0.0037335944
manifestation O 0 0.082403995
, O 0 0.0021376314
observed O 0 0.0009341105
in O 0 0.00085942034
15 O 0 0.0007754627
further O 0 0.0010033892
cases O 0 0.0020781574
, O 0 0.002023238
was O 0 0.0020315796
isolated O 0 0.004506474
optic B-Disease 0 0.97795755
atrophy I-Disease 2 0.99498606
. O 0 0.011453567

This O 0 0.0049297777
was O 0 0.0023408693
most O 0 0.0023726206
frequently O 0 0.0020441855
found O 0 0.0009830798
in O 0 0.0007571958
children O 0 0.001657725
, O 0 0.0008053312
many O 0 0.00059602084
of O 0 0.00071962044
whom O 0 0.001925488
had O 0 0.00080820604
received O 0 0.0020228531
clioquinol B-Chemical 0 0.9993818
as O 0 0.0015352528
treatment O 0 0.006850862
for O 0 0.0033989567
acrodermatitis B-Disease 0 0.99407035
enteropathica I-Disease 0 0.99548584
. O 0 0.012804314

In O 0 0.0029709067
the O 0 0.0019591828
remaining O 0 0.0016599502
cases O 0 0.0025181535
, O 0 0.0016043795
a O 0 0.0011087275
combination O 0 0.0022696026
of O 0 0.0031749394
myelopathy B-Disease 0 0.9996731
, O 0 0.004602202
visual B-Disease 0 0.88061285
disturbance I-Disease 0 0.85589397
, O 0 0.0016097197
and O 0 0.0012488217
peripheral B-Disease 2 0.70702845
neuropathy I-Disease 2 0.99966455
was O 0 0.0017906451
the O 0 0.001507188
most O 0 0.0035194142
common O 0 0.0062352796
manifestation O 0 0.3803218
. O 0 0.007399374

Isolated O 0 0.096368216
myelopathy B-Disease 0 0.99710053
or O 0 0.0062383492
peripheral B-Disease 2 0.81928784
neuropathy I-Disease 2 0.9993861
, O 0 0.0043987823
or O 0 0.0015855236
these O 0 0.00249365
manifestations O 0 0.58913636
occurring O 0 0.0056500784
together O 0 0.002734427
, O 0 0.0039696535
were O 0 0.0039984756
infrequent O 0 0.023748675
. O 0 0.007922621

The O 0 0.0032781246
onset O 0 0.005351722
of O 0 0.0025038419
all O 0 0.0018872953
manifestations O 0 0.6207828
( O 0 0.0024029273
except O 0 0.0012078948
toxic O 0 0.9517806
encephalopathy B-Disease 2 0.99974424
) O 0 0.007151167
was O 0 0.0012261091
usually O 0 0.003227282
subacute O 0 0.9925867
, O 0 0.0024273817
with O 0 0.0019968874
subsequent O 0 0.0029462143
partial O 0 0.007520173
recovery O 0 0.0140352575
. O 0 0.006972559

Older O 0 0.04408162
subjects O 0 0.008219841
tended O 0 0.005312986
to O 0 0.0045078793
display O 0 0.00532742
more O 0 0.008256517
side O 0 0.03587281
effects O 0 0.020413678
. O 0 0.014295398

The O 0 0.003265681
full O 0 0.002913729
syndrome O 0 0.45937055
of O 0 0.00410066
subacute O 0 0.99619234
myelo B-Disease 0 0.8983881
- I-Disease 0 0.021761859
optic I-Disease 0 0.9974184
neuropathy I-Disease 0 0.99981683
was O 0 0.0012279359
more O 0 0.00083017594
frequent O 0 0.0023083242
in O 0 0.00047451293
women O 0 0.011846448
, O 0 0.00057890586
but O 0 0.00035272614
they O 0 0.0003059457
tended O 0 0.00037364755
to O 0 0.00033358365
have O 0 0.00045374702
taken O 0 0.00043223886
greater O 0 0.00070531346
quantities O 0 0.001486696
of O 0 0.0021333485
the O 0 0.003246195
drug O 0 0.48517674
. O 0 0.007105475

Prazosin B-Chemical 0 0.9969406
- O 0 0.050754756
induced O 0 0.033239026
stress B-Disease 2 0.9498023
incontinence I-Disease 2 0.98942155
. O 0 0.039699692

A O 0 0.014692013
case O 0 0.0031920203
of O 0 0.0028118384
genuine O 0 0.005743612
stress B-Disease 2 0.84688365
incontinence I-Disease 2 0.9970368
due O 0 0.0017556777
to O 0 0.0020531437
prazosin B-Chemical 1 0.9997613
, O 0 0.0028564252
a O 0 0.0015317949
common O 0 0.0030186495
antihypertensive O 0 0.99381727
drug O 0 0.7396369
, O 0 0.0046443315
is O 0 0.0036939073
presented O 0 0.005913428
. O 0 0.006542785

Prazosin B-Chemical 0 0.9988883
exerts O 0 0.03721769
its O 0 0.00790206
antihypertensive O 0 0.9905156
effects O 0 0.006506128
through O 0 0.0017421973
vasodilatation O 0 0.9983564
caused O 0 0.0022164055
by O 0 0.0012318915
selective O 0 0.017387565
blockade O 0 0.2921223
of O 0 0.0037774332
postsynaptic O 0 0.98816574
alpha O 0 0.6829751
- O 0 0.0086890785
1 O 0 0.004239612
adrenergic O 0 0.99087876
receptors O 0 0.515617
. O 0 0.008440381

As O 0 0.0029917676
an O 0 0.0041165077
alpha O 0 0.24669567
- O 0 0.0069638677
blocker O 0 0.9712189
, O 0 0.0024529966
it O 0 0.0011560137
also O 0 0.00087294506
exerts O 0 0.0025709816
a O 0 0.0009722363
significant O 0 0.0012943272
relaxant O 0 0.97352433
effect O 0 0.0013318253
on O 0 0.00073663174
the O 0 0.0016262957
bladder O 0 0.8390903
neck O 0 0.60937107
and O 0 0.007237367
urethra O 0 0.42073828
. O 0 0.008203907

The O 0 0.0028015238
patient O 0 0.0030277574
' O 0 0.0019167416
s O 0 0.0014938312
clinical O 0 0.00266495
course O 0 0.0012468664
is O 0 0.0006412455
described O 0 0.00040915457
and O 0 0.00043238737
correlated O 0 0.00031470758
with O 0 0.00042054072
initial O 0 0.00047176064
urodynamic O 0 0.20034978
studies O 0 0.0008941925
while O 0 0.0005027923
on O 0 0.0004966292
prazosin B-Chemical 1 0.99975127
and O 0 0.0012785717
subsequent O 0 0.0013732434
studies O 0 0.0021989078
while O 0 0.0021959832
taking O 0 0.03027821
verapamil B-Chemical 0 0.9989042
. O 0 0.010729067

Her O 0 0.0214139
incontinence B-Disease 2 0.92740715
resolved O 0 0.011310959
with O 0 0.0062751095
the O 0 0.0053960634
change O 0 0.00678646
of O 0 0.010780375
medication O 0 0.38383415
. O 0 0.015207356

The O 0 0.002890702
restoration O 0 0.0031580403
of O 0 0.0022376669
continence O 0 0.027329467
was O 0 0.0013432454
accompanied O 0 0.0019054109
by O 0 0.0008456015
a O 0 0.00072905194
substantial O 0 0.0008451081
rise O 0 0.0009288431
in O 0 0.00041652445
maximum O 0 0.00059815426
urethral O 0 0.068186544
pressure O 0 0.04144831
, O 0 0.00078256836
maximum O 0 0.0006971206
urethral O 0 0.059530865
closure O 0 0.005002546
pressure O 0 0.042328686
, O 0 0.0015519304
and O 0 0.0014804263
functional O 0 0.0032682365
urethral O 0 0.1284598
length O 0 0.0053899894
. O 0 0.0064609

Patients O 0 0.009029904
who O 0 0.0038817246
present O 0 0.0013602866
with O 0 0.0019339151
stress B-Disease 2 0.7628875
incontinence I-Disease 2 0.99776757
while O 0 0.0015325989
taking O 0 0.009114881
prazosin B-Chemical 1 0.9998691
should O 0 0.0004922919
change O 0 0.00048384746
their O 0 0.00045856638
antihypertensive O 0 0.9806708
medication O 0 0.08056612
before O 0 0.00016668442
considering O 0 0.00023051354
surgery O 0 0.0013677821
, O 0 0.00036075388
because O 0 0.0002046214
their O 0 0.00043951639
incontinence B-Disease 2 0.97212034
may O 0 0.00052318664
resolve O 0 0.00051948807
spontaneously O 0 0.006589094
with O 0 0.00082691846
a O 0 0.001023314
change O 0 0.0012881059
in O 0 0.0016922277
drug O 0 0.40273032
therapy O 0 0.1252332
. O 0 0.006845531

Myocardial B-Disease 0 0.98539346
infarction I-Disease 2 0.9986964
following O 0 0.014435229
sublingual O 0 0.9792894
administration O 0 0.65619403
of O 0 0.07567143
isosorbide B-Chemical 0 0.9997706
dinitrate I-Chemical 0 0.9996884
. O 0 0.05555188

A O 0 0.019301612
78 O 0 0.006313186
- O 0 0.0035190212
year O 0 0.0018741391
- O 0 0.0019327244
old O 0 0.001119235
with O 0 0.0010201833
healed O 0 0.014117242
septal O 0 0.22748856
necrosis B-Disease 2 0.9968375
suffered O 0 0.5080334
a O 0 0.0018066353
recurrent O 0 0.8622035
myocardial B-Disease 0 0.9995639
infarction I-Disease 2 0.999908
of O 0 0.0030506575
the O 0 0.0007315316
anterior O 0 0.025893394
wall O 0 0.013780127
following O 0 0.00052753574
the O 0 0.0005583051
administration O 0 0.085246824
of O 0 0.006081738
isosorbide B-Chemical 0 0.99996436
dinitrate I-Chemical 0 0.99995255
5 O 0 0.016109396
mg O 0 0.9504818
sublingually O 0 0.99374443
. O 0 0.008832903

After O 0 0.0022370387
detailing O 0 0.0027727236
the O 0 0.0014068519
course O 0 0.0016346368
of O 0 0.0013467745
events O 0 0.003406
, O 0 0.00083193707
we O 0 0.00026789602
discuss O 0 0.00036925805
the O 0 0.00036402498
role O 0 0.00030660973
of O 0 0.0007050235
paradoxical O 0 0.4181216
coronary O 2 0.99636406
spasm B-Disease 2 0.9998801
and O 0 0.012801523
hypotension B-Disease 2 0.9998752
- O 0 0.0065200026
mediated O 0 0.0008866015
myocardial B-Disease 0 0.9993105
ischemia I-Disease 2 0.9997962
occurring O 0 0.010064733
downstream O 0 0.00072971813
to O 0 0.0003648995
significant O 0 0.0007905915
coronary B-Disease 0 0.8552022
arterial I-Disease 0 0.91730285
stenosis I-Disease 0 0.9973098
in O 0 0.00075757765
the O 0 0.000856666
pathophysiology O 0 0.19152856
of O 0 0.004182467
acute B-Disease 0 0.994038
coronary I-Disease 0 0.9908512
insufficiency I-Disease 0 0.9976931
. O 0 0.012071918

Comparison O 0 0.003420701
of O 0 0.0027907076
the O 0 0.0021134163
respiratory O 0 0.10128183
effects O 0 0.0028098337
of O 0 0.0016668217
i O 0 0.0033172367
. O 0 0.00070158613
v O 0 0.004521951
. O 0 0.00051719183
infusions O 0 0.035570055
of O 0 0.0015830857
morphine B-Chemical 1 0.99907184
and O 0 0.0020704602
regional O 0 0.008105426
analgesia O 0 0.99090695
by O 0 0.0048314496
extradural O 0 0.9516828
block O 0 0.012755104
. O 0 0.007431857

The O 0 0.002973706
incidence O 0 0.0053346693
of O 0 0.002410786
postoperative O 0 0.11828181
respiratory O 0 0.767578
apnoea B-Disease 0 0.99823135
was O 0 0.00092163647
compared O 0 0.0002855103
between O 0 0.00018804432
five O 0 0.00020375445
patients O 0 0.0007968354
receiving O 0 0.0011357135
a O 0 0.00035231785
continuous O 0 0.00038726823
i O 0 0.0012498819
. O 0 0.00022712737
v O 0 0.0030480449
. O 0 0.00018108111
infusion O 0 0.007826316
of O 0 0.0006292807
morphine B-Chemical 1 0.99966896
( O 0 0.0006526458
mean O 0 0.00016971632
73 O 0 0.0005058193
. O 0 0.0001290375
6 O 0 0.000155616
mg O 0 0.077477634
) O 0 0.00033068538
and O 0 0.00016055316
five O 0 0.00011090087
patients O 0 0.0005224352
receiving O 0 0.00079899444
a O 0 0.00025024734
continuous O 0 0.00033225946
extradural O 0 0.74573493
infusion O 0 0.021783654
of O 0 0.0004002206
0 O 0 0.00034046147
. O 0 0.00013880133
25 O 0 0.000365953
% O 0 0.00035584072
bupivacaine B-Chemical 1 0.99927336
( O 0 0.00043615123
mean O 0 0.00018184257
192 O 0 0.004235322
mg O 0 0.22657391
) O 0 0.0005651674
in O 0 0.00024329317
the O 0 0.0002918864
24 O 0 0.0003957404
- O 0 0.0005782265
h O 0 0.0004475835
period O 0 0.0005717885
following O 0 0.0009873328
upper O 0 0.0028393487
abdominal O 0 0.21166533
surgery O 0 0.02176308
. O 0 0.005824599

Monitoring O 0 0.007096391
consisted O 0 0.0023773036
of O 0 0.0024817877
airflow O 0 0.3096044
detection O 0 0.0019824726
by O 0 0.001272784
a O 0 0.0013261699
carbon B-Chemical 0 0.77617836
dioxide I-Chemical 0 0.98747885
analyser O 0 0.15672499
, O 0 0.0016022308
chest O 0 0.17446591
wall O 0 0.024399657
movement O 0 0.0014635595
detected O 0 0.00028330775
by O 0 0.00043834504
pneumatic O 0 0.021475691
capsules O 0 0.0516354
, O 0 0.0006814804
and O 0 0.00046220663
continuous O 0 0.000644354
electrocardiograph O 0 0.2339549
recorded O 0 0.0009988953
with O 0 0.0011963858
a O 0 0.0019705775
Holter O 0 0.76071596
ambulatory O 0 0.007019841
monitor O 0 0.004022793
. O 0 0.005639657

Both O 0 0.009010614
obstructive B-Disease 0 0.98904455
( I-Disease 0 0.005473696
P I-Disease 0 0.023952678
less I-Disease 0 0.0012533714
than I-Disease 0 0.0006560667
0 I-Disease 0 0.00083602377
. I-Disease 0 0.00047596951
05 I-Disease 0 0.017975979
) I-Disease 0 0.0008470635
and I-Disease 0 0.0005371389
central I-Disease 0 0.0027013416
apnoea I-Disease 0 0.99808335
( O 0 0.0011899365
P O 0 0.01802014
less O 0 0.0003701755
than O 0 0.0002251502
0 O 0 0.0003813419
. O 0 0.00023095658
05 O 0 0.013541573
) O 0 0.0005177653
occurred O 0 0.00038389774
more O 0 0.00044681403
frequently O 0 0.00069748744
in O 0 0.000449831
patients O 0 0.0016600151
who O 0 0.001932634
had O 0 0.0014842545
a O 0 0.0035843805
morphine B-Chemical 1 0.99841654
infusion O 0 0.506727
. O 0 0.0074267974

There O 0 0.0051672407
was O 0 0.0023029638
also O 0 0.0016597226
a O 0 0.001314018
higher O 0 0.0010393377
incidence O 0 0.00438838
of O 0 0.002058626
tachyarrhythmias B-Disease 0 0.9995933
( O 0 0.003266296
P O 0 0.044360384
less O 0 0.00048806414
than O 0 0.00026800894
0 O 0 0.0004251706
. O 0 0.0002454692
05 O 0 0.019441739
) O 0 0.00056400103
and O 0 0.00039618238
ventricular B-Disease 0 0.949084
ectopic I-Disease 0 0.012571126
beats I-Disease 0 0.7744675
( O 0 0.0009197973
P O 0 0.015341524
less O 0 0.00037577053
than O 0 0.00026134125
0 O 0 0.00049811456
. O 0 0.00035424225
05 O 0 0.0136207575
) O 0 0.0009739138
in O 0 0.00069724955
the O 0 0.0014889841
morphine B-Chemical 1 0.9982765
infusion O 0 0.2921379
group O 0 0.007429023
. O 0 0.0063004615

Effects O 0 0.014728947
of O 0 0.0058601135
aminophylline B-Chemical 1 0.99843484
on O 0 0.0019052142
the O 0 0.0015708444
threshold O 0 0.0015800761
for O 0 0.0013759858
initiating O 0 0.005515647
ventricular B-Disease 0 0.9910164
fibrillation I-Disease 0 0.9990227
during O 0 0.0056432756
respiratory B-Disease 0 0.7846558
failure I-Disease 0 0.8990937
. O 0 0.010582159

Cardiac B-Disease 0 0.9706579
arrhythmias I-Disease 2 0.9983979
have O 0 0.005599
frequently O 0 0.004973125
been O 0 0.0028853526
reported O 0 0.002840249
in O 0 0.0019080988
association O 0 0.002335356
with O 0 0.005476936
respiratory B-Disease 0 0.65309674
failure I-Disease 0 0.89205486
. O 0 0.012825645

The O 0 0.002810372
possible O 0 0.0023933058
additive O 0 0.0035927796
role O 0 0.0011044744
of O 0 0.0014990703
pharmacologic O 0 0.38004014
agents O 0 0.3030659
in O 0 0.0011213089
precipitating O 0 0.7680424
cardiac B-Disease 0 0.96344346
disturbances I-Disease 0 0.97118485
in O 0 0.00071626576
patients O 0 0.0025488967
with O 0 0.001054384
respiratory B-Disease 0 0.43468347
failure I-Disease 0 0.67176694
has O 0 0.001433399
only O 0 0.0016312816
recently O 0 0.0029711935
been O 0 0.0037502293
emphasized O 0 0.005592033
. O 0 0.006093552

The O 0 0.0030179336
effects O 0 0.0036544707
of O 0 0.003122152
aminophylline B-Chemical 1 0.99922025
on O 0 0.0011873251
the O 0 0.0013003288
ventricular B-Disease 0 0.9870183
fibrillation I-Disease 0 0.9995478
threshold O 0 0.0011899122
during O 0 0.00045062753
normal O 0 0.0020457143
acid O 0 0.8797739
- O 0 0.0010600201
base O 0 0.00072345935
conditions O 0 0.00052017433
and O 0 0.0003914497
during O 0 0.00034407736
respiratory B-Disease 0 0.19921118
failure I-Disease 0 0.46263808
were O 0 0.00078121165
studied O 0 0.0011137234
in O 0 0.0009704405
anesthetized O 0 0.036659185
open O 0 0.002073561
chest O 0 0.20114435
dogs O 0 0.014138097
. O 0 0.0058770804

The O 0 0.0039400924
ventricular B-Disease 0 0.92751795
fibrillation I-Disease 0 0.99824286
threshold O 0 0.0022938615
was O 0 0.0009726065
measured O 0 0.0005148953
by O 0 0.0005754297
passing O 0 0.0010612045
a O 0 0.00052360323
gated O 0 0.0014923696
train O 0 0.0008162346
of O 0 0.00042045873
12 O 0 0.00022549632
constant O 0 0.0002571633
current O 0 0.00045024385
pulses O 0 0.0017360565
through O 0 0.00031028286
the O 0 0.0004051348
ventricular O 0 0.936746
myocardium O 0 0.35676435
during O 0 0.00037167163
the O 0 0.0004779771
vulnerable O 0 0.0016242532
period O 0 0.00074089586
of O 0 0.001240465
the O 0 0.0018675367
cardiac O 0 0.41134527
cycle O 0 0.031313144
. O 0 0.006305703

During O 0 0.0026875709
the O 0 0.0022454264
infusion O 0 0.015361166
of O 0 0.0029898693
aminophylline B-Chemical 1 0.9995571
, O 0 0.0029143807
the O 0 0.0010756355
ventricular B-Disease 0 0.9867051
fibrillation I-Disease 0 0.9996019
threshold O 0 0.0010243997
was O 0 0.00042235467
reduced O 0 0.00036183192
by O 0 0.00029579917
30 O 0 0.00021200052
to O 0 0.00016961619
40 O 0 0.00021178577
percent O 0 0.00014159594
of O 0 0.0002287482
the O 0 0.00020616576
control O 0 0.00021848336
when O 0 0.00022631479
pH O 0 0.049267948
and O 0 0.0002948289
partial O 0 0.0006297304
pressures O 0 0.0032133104
of O 0 0.0007426392
oxygen B-Chemical 1 0.98177445
( O 0 0.0028011468
PO2 B-Chemical 0 0.99820054
) O 0 0.0013327351
and O 0 0.00065958034
carbon B-Chemical 0 0.79226905
dioxide I-Chemical 0 0.9863202
( O 0 0.002235632
CO2 B-Chemical 0 0.6591802
) O 0 0.0014769475
were O 0 0.0007634967
kept O 0 0.0008503922
within O 0 0.0009019373
normal O 0 0.003906942
limits O 0 0.007188852
. O 0 0.0060031232

When O 0 0.004118853
respiratory B-Disease 0 0.17057085
failure I-Disease 0 0.39949888
was O 0 0.0019362615
produced O 0 0.0015536817
by O 0 0.0020169877
hypoventilation B-Disease 0 0.9981426
( O 0 0.00322257
pH O 0 0.1776488
7 O 0 0.0005621304
. O 0 0.00032569314
05 O 0 0.006008392
to O 0 0.0003343528
7 O 0 0.00030450267
. O 0 0.0002031614
25 O 0 0.00049366354
; O 0 0.00055725564
PC02 O 0 0.028674815
70 O 0 0.0003491773
to O 0 0.00025623012
100 O 0 0.0007064813
mm O 0 0.0023402327
Hg O 0 0.87596947
: O 0 0.00059732964
P02 O 0 0.019595014
20 O 0 0.000284006
to O 0 0.00020820482
40 O 0 0.00035098175
mm O 0 0.001816702
Hg O 0 0.89280534
) O 0 0.00055853237
, O 0 0.0003554311
infusion O 0 0.0074320375
of O 0 0.00060994114
aminophylline B-Chemical 1 0.99983287
resulted O 0 0.0005871738
in O 0 0.00030084286
an O 0 0.00037571965
even O 0 0.00025653836
greater O 0 0.00026875126
decrease O 0 0.00041756983
in O 0 0.0003780698
ventricular B-Disease 0 0.98201156
fibrillation I-Disease 0 0.9995559
threshold O 0 0.0007163723
to O 0 0.00044154594
60 O 0 0.0005545708
percent O 0 0.00047197813
of O 0 0.0009287139
the O 0 0.0012338973
control O 0 0.0019549634
level O 0 0.0032004002
. O 0 0.005344574

These O 0 0.0033923488
experiments O 0 0.0016807945
suggest O 0 0.001142246
that O 0 0.0009306698
although O 0 0.0008336361
many O 0 0.00081804895
factors O 0 0.0018358993
may O 0 0.0006086787
contribute O 0 0.0005217484
to O 0 0.00036505194
the O 0 0.00034396208
increased O 0 0.00077659445
incidence O 0 0.008847941
of O 0 0.0015463318
ventricular B-Disease 0 0.99907446
arrhythmias I-Disease 2 0.9999175
in O 0 0.0012923453
respiratory B-Disease 0 0.6951469
failure I-Disease 0 0.83566356
, O 0 0.0012292431
pharmacologic O 0 0.5204664
agents O 0 0.35511065
, O 0 0.001384712
particularly O 0 0.0049624424
aminophylline B-Chemical 1 0.9997466
, O 0 0.0020757506
may O 0 0.0011199629
play O 0 0.0016949986
a O 0 0.0020968704
significant O 0 0.0032425295
role O 0 0.0034080078
. O 0 0.005817838

Pentoxifylline B-Chemical 0 0.997827
( O 0 0.02618069
Trental B-Chemical 0 0.99792767
) O 0 0.005861147
does O 0 0.0012952547
not O 0 0.0010632691
inhibit O 0 0.002164494
dipyridamole B-Chemical 0 0.9995419
- O 0 0.00663281
induced O 0 0.00256473
coronary O 0 0.9316912
hyperemia B-Disease 2 0.99880016
: O 0 0.0018446171
implications O 0 0.0012320252
for O 0 0.0010463315
dipyridamole B-Chemical 0 0.99945
- O 0 0.02077752
thallium B-Chemical 1 0.9975291
- O 0 0.011717193
201 O 0 0.13704431
myocardial O 0 0.99474794
imaging O 0 0.135261
. O 0 0.008124762

Dipyridamole B-Chemical 0 0.9979309
- O 0 0.01835366
thallium B-Chemical 1 0.993729
- O 0 0.005058316
201 O 0 0.007721931
imaging O 0 0.0042132586
is O 0 0.0008367993
often O 0 0.0009313448
performed O 0 0.0005450771
in O 0 0.0005208788
patients O 0 0.0012626977
unable O 0 0.0004734967
to O 0 0.0005991066
exercise O 0 0.005911141
because O 0 0.0008639526
of O 0 0.0022183256
peripheral B-Disease 0 0.32373747
vascular I-Disease 0 0.9223432
disease I-Disease 0 0.9666322
. O 0 0.0095089795

Many O 0 0.0054832515
of O 0 0.0029379756
these O 0 0.002650739
patients O 0 0.0038391578
are O 0 0.0016602852
taking O 0 0.005815767
pentoxifylline B-Chemical 1 0.999521
( O 0 0.021153582
Trental B-Chemical 0 0.9992698
) O 0 0.005046024
, O 0 0.0015051321
a O 0 0.0016073288
methylxanthine B-Chemical 0 0.99940133
derivative O 0 0.22651671
which O 0 0.0021955655
may O 0 0.0016349785
improve O 0 0.0022095228
intermittent B-Disease 0 0.45356008
claudication I-Disease 0 0.98953724
. O 0 0.00935856

Whether O 0 0.008179858
pentoxifylline B-Chemical 1 0.9984113
inhibits O 0 0.033052694
dipyridamole B-Chemical 0 0.9994879
- O 0 0.015050409
induced O 0 0.0035612818
coronary O 0 0.92877877
hyperemia B-Disease 2 0.99886453
like O 0 0.0011034092
other O 0 0.00097641407
methylxanthines B-Chemical 0 0.99949074
such O 0 0.0009634051
as O 0 0.0006642614
theophylline B-Chemical 1 0.9996044
and O 0 0.00071757653
should O 0 0.00027795677
be O 0 0.00034328166
stopped O 0 0.0007041529
prior O 0 0.00031581725
to O 0 0.00071172864
dipyridamole B-Chemical 0 0.9995129
- O 0 0.011954224
thallium B-Chemical 1 0.9977876
- O 0 0.0051831836
201 O 0 0.024170643
imaging O 0 0.01093626
is O 0 0.0033987015
unknown O 0 0.010552266
. O 0 0.0066129146

Therefore O 0 0.0035214117
, O 0 0.0026921108
we O 0 0.0010217013
studied O 0 0.00164702
the O 0 0.0012291844
hyperemic O 0 0.7830054
response O 0 0.0017306166
to O 0 0.0008586702
dipyridamole B-Chemical 0 0.9993525
in O 0 0.0006371007
seven O 0 0.00047902888
open O 0 0.0005054332
- O 0 0.0008730348
chest O 0 0.0780675
anesthetized O 0 0.038665626
dogs O 0 0.00085903273
after O 0 0.00016938522
pretreatment O 0 0.046531275
with O 0 0.00047502315
either O 0 0.00057707634
pentoxifylline B-Chemical 1 0.9997789
( O 0 0.001505307
0 O 0 0.00044839765
, O 0 0.0003350229
7 O 0 0.00019535555
. O 0 0.00012020363
5 O 0 0.00015669386
, O 0 0.00020580812
or O 0 0.00015141687
15 O 0 0.00020015294
mg O 0 0.0867085
/ O 0 0.0006878272
kg O 0 0.0025106391
i O 0 0.0008237223
. O 0 0.00021991773
v O 0 0.00278731
. O 0 0.00023962492
) O 0 0.0005773842
or O 0 0.00041330527
theophylline B-Chemical 1 0.9994086
( O 0 0.0011657608
3 O 0 0.00054810115
mg O 0 0.23724508
/ O 0 0.0017998248
kg O 0 0.0052623763
i O 0 0.002329484
. O 0 0.0010679624
v O 0 0.0072738663
. O 0 0.0021841836
) O 0 0.0060451636
. O 0 0.005305153

Baseline O 0 0.016349988
circumflex O 0 0.26387686
coronary O 0 0.30932245
blood O 0 0.011696305
flows O 0 0.012302044
did O 0 0.0018420735
not O 0 0.001488441
differ O 0 0.0020362178
significantly O 0 0.00285791
among O 0 0.0036896437
treatment O 0 0.00840935
groups O 0 0.0085833995
. O 0 0.0089181075

Dipyridamole B-Chemical 0 0.9971951
significantly O 0 0.004662531
increased O 0 0.00346875
coronary O 0 0.4511229
blood O 0 0.010475134
flow O 0 0.0036806136
before O 0 0.00040549648
and O 0 0.0004909494
after O 0 0.0002711691
7 O 0 0.00032790174
. O 0 0.00019725892
5 O 0 0.0002154447
or O 0 0.00020332924
15 O 0 0.00025335
mm O 0 0.0010458998
/ O 0 0.0006236798
kg O 0 0.0018874508
i O 0 0.0009128846
. O 0 0.0002920386
v O 0 0.0033571017
. O 0 0.00044693757
pentoxifylline B-Chemical 1 0.99935037
( O 0 0.0014730485
p O 0 0.0010346195
less O 0 0.000767778
than O 0 0.00071031926
0 O 0 0.0016101556
. O 0 0.001553835
002 O 0 0.09790749
) O 0 0.006341923
. O 0 0.0053929426

Neither O 0 0.0048210756
dose O 0 0.014900042
of O 0 0.0035205767
pentoxifylline B-Chemical 1 0.9991105
significantly O 0 0.0037688566
decreased O 0 0.004025926
the O 0 0.0015218216
dipyridamole B-Chemical 0 0.9997074
- O 0 0.010184996
induced O 0 0.0035435609
hyperemia B-Disease 2 0.9990119
, O 0 0.0009422349
while O 0 0.00034082256
peak O 0 0.00058824086
coronary O 0 0.4013304
blood O 0 0.007952085
flow O 0 0.003537051
was O 0 0.00032920262
significantly O 0 0.00038792595
lower O 0 0.00035329725
after O 0 0.00034762608
theophylline B-Chemical 1 0.9993869
( O 0 0.0012724814
p O 0 0.00089651125
less O 0 0.0006677573
than O 0 0.0006181788
0 O 0 0.0013973755
. O 0 0.0013025507
01 O 0 0.009645178
) O 0 0.0055038184
. O 0 0.005031246

We O 0 0.0035178664
conclude O 0 0.0026397097
that O 0 0.0019871746
pentoxyifylline B-Chemical 0 0.05727172
does O 0 0.0015442728
not O 0 0.0013745793
inhibit O 0 0.0030001337
dipyridamole B-Chemical 0 0.9994407
- O 0 0.009082646
induced O 0 0.003974204
coronary O 0 0.9375518
hyperemia B-Disease 2 0.99770856
even O 0 0.0024138337
at O 0 0.0016033136
high O 0 0.0046363175
doses O 0 0.10528481
. O 0 0.007444792

Cause O 0 0.107263684
of O 0 0.0061586457
death B-Disease 2 0.9603734
among O 0 0.0030786213
patients O 0 0.0047429753
with O 0 0.0028867163
Parkinson B-Disease 0 0.9981452
' I-Disease 0 0.0019737554
s I-Disease 0 0.0018501935
disease I-Disease 0 0.40524206
: O 0 0.002037628
a O 0 0.0014036648
rare O 0 0.009543584
mortality O 0 0.15924409
due O 0 0.0020635026
to O 0 0.0047576944
cerebral B-Disease 2 0.99421954
haemorrhage I-Disease 2 0.9987747
. O 0 0.014119911

Causes O 0 0.10121715
of O 0 0.0063311593
death B-Disease 2 0.9788254
, O 0 0.0029878689
with O 0 0.0014512911
special O 0 0.0013899708
reference O 0 0.0009810298
to O 0 0.0010587617
cerebral B-Disease 2 0.99456704
haemorrhage I-Disease 2 0.9997105
, O 0 0.0015744817
among O 0 0.0005905652
240 O 0 0.001435174
patients O 0 0.00086353824
with O 0 0.0004401321
pathologically O 0 0.31645393
verified O 0 0.0006335479
Parkinson B-Disease 0 0.9992355
' I-Disease 0 0.0005568192
s I-Disease 0 0.0005088897
disease I-Disease 0 0.1637276
were O 0 0.00030329562
investigated O 0 0.00029312595
using O 0 0.0002633249
the O 0 0.00036461296
Annuals O 0 0.017449971
of O 0 0.0006462445
the O 0 0.0007907091
Pathological O 0 0.9165021
Autopsy O 0 0.9372143
Cases O 0 0.2449152
in O 0 0.0013605794
Japan O 0 0.028936876
from O 0 0.0019699342
1981 O 0 0.007955132
to O 0 0.0034878496
1985 O 0 0.01971346
. O 0 0.006238577

The O 0 0.0035777758
leading O 0 0.0048336647
causes O 0 0.0041932445
of O 0 0.0035523453
death B-Disease 2 0.99076676
were O 0 0.0034078115
pneumonia B-Disease 0 0.99849844
and O 0 0.0065396456
bronchitis B-Disease 0 0.9994307
( O 0 0.0028552413
44 O 0 0.0010979024
. O 0 0.0002898562
1 O 0 0.00038385676
% O 0 0.0004200219
) O 0 0.0005854769
, O 0 0.0005907485
malignant O 0 0.9578751
neoplasms B-Disease 0 0.99608827
( O 0 0.001144603
11 O 0 0.00042954163
. O 0 0.00016743371
6 O 0 0.00018477064
% O 0 0.00027821737
) O 0 0.0003957706
, O 0 0.0003821713
heart B-Disease 0 0.23134582
diseases I-Disease 0 0.54369915
( O 0 0.00070892484
4 O 0 0.00025912517
. O 0 0.0001612703
1 O 0 0.00026478205
% O 0 0.00032043664
) O 0 0.00049757364
, O 0 0.00056562707
cerebral B-Disease 0 0.95254886
infarction I-Disease 2 0.9998665
( O 0 0.0015334097
3 O 0 0.00035900171
. O 0 0.00021102403
7 O 0 0.00028728598
% O 0 0.0004191765
) O 0 0.0006642472
and O 0 0.0008158183
septicaemia B-Disease 0 0.9961455
( O 0 0.0017384993
3 O 0 0.0009312881
. O 0 0.0007999823
3 O 0 0.0014164714
% O 0 0.0025937017
) O 0 0.0047357823
. O 0 0.004684772

Cerebral B-Disease 0 0.9804129
haemorrhage I-Disease 0 0.9976312
was O 0 0.0034335991
the O 0 0.0018160916
11th O 0 0.0059078024
most O 0 0.0018481552
frequent O 0 0.0033768178
cause O 0 0.0029813005
of O 0 0.0017109155
death B-Disease 2 0.9932295
, O 0 0.0010501747
accounting O 0 0.0010910566
for O 0 0.00031329697
only O 0 0.00034074235
0 O 0 0.0003542578
. O 0 0.0001509649
8 O 0 0.0001977676
% O 0 0.00020511677
of O 0 0.00026820425
deaths B-Disease 0 0.11678016
among O 0 0.00034690285
the O 0 0.0002559337
patients O 0 0.0013622681
, O 0 0.00039057276
whereas O 0 0.00025271627
it O 0 0.00028501882
was O 0 0.00024037823
the O 0 0.0002454275
5th O 0 0.0011206255
most O 0 0.0005592579
common O 0 0.0007120388
cause O 0 0.0019689137
of O 0 0.0013341428
death B-Disease 2 0.9907358
among O 0 0.0011879609
the O 0 0.0009256983
Japanese O 0 0.025224082
general O 0 0.0014909548
population O 0 0.0028717155
in O 0 0.0030177888
1985 O 0 0.024055464
. O 0 0.0055226665

The O 0 0.0029659604
low O 0 0.0029722783
incidence O 0 0.007102223
of O 0 0.0035195982
cerebral B-Disease 2 0.99522346
haemorrhage I-Disease 2 0.99955183
as O 0 0.0013116428
a O 0 0.0010700016
cause O 0 0.0026173647
of O 0 0.0013694225
death B-Disease 2 0.9913874
in O 0 0.0005565226
patients O 0 0.0027866857
with O 0 0.0011011579
Parkinson B-Disease 0 0.99936265
' I-Disease 0 0.0006208905
s I-Disease 0 0.000570256
disease I-Disease 0 0.2662514
may O 0 0.00032819196
reflect O 0 0.000261524
the O 0 0.00032690665
hypotensive B-Disease 2 0.9963231
effect O 0 0.00068200217
of O 0 0.0011630688
levodopa B-Chemical 1 0.99984336
and O 0 0.00095593266
a O 0 0.0009052355
hypotensive B-Disease 2 0.99788684
mechanism O 0 0.001091776
due O 0 0.00033852796
to O 0 0.0005011827
reduced O 0 0.0012349054
noradrenaline B-Chemical 1 0.99924207
levels O 0 0.0014813654
in O 0 0.0015337128
the O 0 0.0034780356
parkinsonian B-Disease 2 0.9990175
brain O 0 0.5181979
. O 0 0.0072277933

Possible O 0 0.053148933
intramuscular O 0 0.77386975
midazolam B-Chemical 1 0.99846953
- O 0 0.0212278
associated O 0 0.012042841
cardiorespiratory B-Disease 0 0.9788507
arrest I-Disease 0 0.9568561
and O 0 0.018190518
death B-Disease 2 0.98474574
. O 0 0.016189225

Midazolam B-Chemical 0 0.99873775
hydrochloride I-Chemical 0 0.99599385
is O 0 0.0056631886
commonly O 0 0.0061406987
used O 0 0.0028269405
for O 0 0.0026427007
dental O 0 0.0063436083
or O 0 0.0041120867
endoscopic O 0 0.01775451
procedures O 0 0.011284859
. O 0 0.010587588

Although O 0 0.0032364738
generally O 0 0.0024415255
consisted O 0 0.0014898762
safe O 0 0.002926121
when O 0 0.0008271895
given O 0 0.0007742628
intramuscularly O 0 0.037669547
, O 0 0.001420746
intravenous O 0 0.4839686
administration O 0 0.18236561
is O 0 0.0009828514
known O 0 0.0011965267
to O 0 0.0009932296
cause O 0 0.005806472
respiratory B-Disease 0 0.53813034
and I-Disease 0 0.008066905
cardiovascular I-Disease 0 0.99716187
depression I-Disease 0 0.99712735
. O 0 0.010505515

This O 0 0.0045955232
report O 0 0.004324405
describes O 0 0.0023127396
the O 0 0.0011733996
first O 0 0.0008375359
published O 0 0.0010172884
case O 0 0.00092713133
of O 0 0.0014348705
cardiorespiratory B-Disease 0 0.97109705
arrest I-Disease 0 0.9047862
and O 0 0.002266125
death B-Disease 2 0.9904128
associated O 0 0.0023885767
with O 0 0.0023646443
intramuscular O 0 0.7137755
administration O 0 0.47899985
of O 0 0.016699802
midazolam B-Chemical 1 0.9988105
. O 0 0.010436582

Information O 0 0.008170538
regarding O 0 0.003890742
midazolam B-Chemical 1 0.9970778
use O 0 0.0040434506
is O 0 0.0021713595
reviewed O 0 0.003276067
to O 0 0.001652878
provide O 0 0.0019572629
recommendation O 0 0.00511015
for O 0 0.0028442305
safe O 0 0.016213447
administration O 0 0.3131633
. O 0 0.010003998

Myasthenia B-Disease 0 0.97657996
gravis I-Disease 0 0.99336493
presenting O 0 0.20354459
as O 0 0.008978961
weakness O 2 0.96005034
after O 0 0.00939527
magnesium B-Chemical 1 0.9948919
administration O 0 0.8378783
. O 0 0.018218616

We O 0 0.0031855165
studied O 0 0.0027082309
a O 0 0.0017541876
patient O 0 0.0017917218
with O 0 0.001064776
no O 0 0.0005807959
prior O 0 0.0004651831
history O 0 0.0031681196
of O 0 0.0012065191
neuromuscular B-Disease 0 0.9744689
disease I-Disease 0 0.97923124
who O 0 0.005827057
became O 0 0.0017120097
virtually O 0 0.001369928
quadriplegic B-Disease 0 0.9829896
after O 0 0.0009906437
parenteral O 0 0.9591077
magnesium B-Chemical 1 0.9990387
administration O 0 0.8005309
for O 0 0.008215589
preeclampsia B-Disease 0 0.9981993
. O 0 0.011238847

The O 0 0.0045596557
serum O 0 0.08463775
magnesium B-Chemical 1 0.9952146
concentration O 0 0.016505064
was O 0 0.0019939535
3 O 0 0.0012180355
. O 0 0.0007853534
0 O 0 0.0013119314
mEq O 0 0.71194047
/ O 0 0.0033325374
L O 0 0.22142927
, O 0 0.0016862699
which O 0 0.0016221496
is O 0 0.0015408085
usually O 0 0.0032145677
well O 0 0.0030784078
tolerated O 0 0.051061563
. O 0 0.0068161255

The O 0 0.006059965
magnesium B-Chemical 1 0.98568255
was O 0 0.0042877626
stopped O 0 0.005108191
and O 0 0.002606338
she O 0 0.002489544
recovered O 0 0.0020116696
over O 0 0.0017399364
a O 0 0.0033475235
few O 0 0.0035741162
days O 0 0.006344519
. O 0 0.00839039

While O 0 0.0038566731
she O 0 0.002756293
was O 0 0.0019438678
weak O 0 0.0031735364
, O 0 0.0018769992
2 O 0 0.0011416125
- O 0 0.0014184605
Hz O 0 0.08084705
repetitive O 0 0.0013964401
stimulation O 0 0.0009517953
revealed O 0 0.00044251993
a O 0 0.0004446628
decrement O 0 0.0034740185
without O 0 0.00039691487
significant O 0 0.0005356488
facilitation O 0 0.018216059
at O 0 0.0002497623
rapid O 0 0.00089378486
rates O 0 0.00041560942
or O 0 0.00037419653
after O 0 0.00036757198
exercise O 0 0.015749598
, O 0 0.0015156197
suggesting O 0 0.0018062658
postsynaptic B-Disease 0 0.98552716
neuromuscular I-Disease 0 0.989542
blockade I-Disease 0 0.9778568
. O 0 0.009607583

After O 0 0.0025228062
her O 0 0.0030460812
strength O 0 0.0035619233
returned O 0 0.0018288428
, O 0 0.0015838925
repetitive O 0 0.0024225623
stimulation O 0 0.0019955216
was O 0 0.00082023925
normal O 0 0.0014255978
, O 0 0.00093806064
but O 0 0.0006182792
single O 0 0.00082159514
fiber O 0 0.020996928
EMG O 0 0.65084946
revealed O 0 0.0017257375
increased O 0 0.0033977795
jitter O 0 0.13238376
and O 0 0.0046685673
blocking O 0 0.01555286
. O 0 0.008293183

Her O 0 0.03363104
acetylcholine B-Chemical 1 0.9916768
receptor O 0 0.377858
antibody O 0 0.015677217
level O 0 0.0059520733
was O 0 0.0076671587
markedly O 0 0.021032961
elevated O 0 0.047631953
. O 0 0.016168915

Although O 0 0.005634958
paralysis B-Disease 2 0.990515
after O 0 0.0020855
magnesium B-Chemical 1 0.99738437
administration O 0 0.40991813
has O 0 0.0011889118
been O 0 0.0008749686
described O 0 0.00042260773
in O 0 0.00037796368
patients O 0 0.0010299442
with O 0 0.00052727084
known O 0 0.0010353187
myasthenia B-Disease 0 0.99888664
gravis I-Disease 0 0.99930525
, O 0 0.0019461807
it O 0 0.00053733424
has O 0 0.00034612647
not O 0 0.0002955071
previously O 0 0.00035607742
been O 0 0.00040912264
reported O 0 0.00048390674
to O 0 0.00030834574
be O 0 0.00034318873
the O 0 0.0003073754
initial O 0 0.00047472958
or O 0 0.000529284
only O 0 0.00092453
manifestation O 0 0.058717523
of O 0 0.0025146024
the O 0 0.003641548
disease O 0 0.7866645
. O 0 0.007642329

Patients O 0 0.010287834
who O 0 0.0045021907
are O 0 0.0018577963
unusually O 0 0.0037693223
sensitive O 0 0.0013426321
to O 0 0.00082468556
the O 0 0.00078457996
neuromuscular O 0 0.40095395
effects O 0 0.0022265129
of O 0 0.0014340647
magnesium B-Chemical 1 0.9987196
should O 0 0.0005918799
be O 0 0.0006476275
suspected O 0 0.0072533675
of O 0 0.0007556861
having O 0 0.0009243729
an O 0 0.0011818289
underlying O 0 0.0041797645
disorder B-Disease 0 0.86762923
of I-Disease 0 0.004973729
neuromuscular I-Disease 0 0.90157527
transmission I-Disease 0 0.038174108
. O 0 0.0072386414

No O 0 0.008333658
enhancement O 0 0.0077295494
by O 0 0.0042243605
phenobarbital B-Chemical 0 0.9994972
of O 0 0.004282261
the O 0 0.0025412946
hepatocarcinogenicity O 0 0.996188
of O 0 0.0034036005
a O 0 0.0039692833
choline B-Chemical 1 0.9972812
- O 0 0.00470696
devoid O 0 0.001886689
diet O 0 0.051599067
in O 0 0.002593339
the O 0 0.003933309
rat O 0 0.027890243
. O 0 0.007836327

An O 0 0.004694873
experiment O 0 0.0017076145
was O 0 0.0013327898
performed O 0 0.00094995764
to O 0 0.00077987387
test O 0 0.00077967026
whether O 0 0.00038256808
inclusion O 0 0.00058662076
of O 0 0.0013158293
phenobarbital B-Chemical 0 0.99989355
in O 0 0.0013362501
a O 0 0.00206635
choline B-Chemical 1 0.9984451
- O 0 0.002261523
devoid O 0 0.000648111
diet O 0 0.032044206
would O 0 0.0005910275
increase O 0 0.0008466891
the O 0 0.0014531285
hepatocarcinogenicity O 0 0.9941433
of O 0 0.0040372033
the O 0 0.00443968
diet O 0 0.2390133
. O 0 0.0076224324

Groups O 0 0.012960891
of O 0 0.0033260742
5 O 0 0.0018957702
- O 0 0.0017434799
week O 0 0.0008351325
old O 0 0.0010391101
male O 0 0.0024789046
Fischer O 0 0.22302617
- O 0 0.0012499819
344 O 0 0.010823843
rats O 0 0.0013644579
were O 0 0.00035700123
fed O 0 0.00059099786
for O 0 0.00030406666
7 O 0 0.00034395946
- O 0 0.00048279864
25 O 0 0.00041328123
months O 0 0.00036156125
semipurified O 0 0.26976636
choline B-Chemical 1 0.99823725
- O 0 0.0014006116
devoid O 0 0.00042276533
or O 0 0.0005804434
choline B-Chemical 1 0.99823904
- O 0 0.0022137929
supplemented O 0 0.004633438
diets O 0 0.04855443
, O 0 0.0007812752
containing O 0 0.00054497266
or O 0 0.000559335
not O 0 0.0007780553
0 O 0 0.0012652591
. O 0 0.0010886245
06 O 0 0.014766956
% O 0 0.005528698
phenobarbital B-Chemical 0 0.9988011
. O 0 0.009250069

No O 0 0.010228355
hepatic O 0 0.9471027
preneoplastic O 0 0.98574394
nodules O 0 0.6084842
or O 0 0.0029905958
hepatocellular B-Disease 0 0.9997117
carcinomas I-Disease 0 0.99884665
developed O 0 0.011404771
in O 0 0.00080699055
rats O 0 0.0034960813
fed O 0 0.0011288029
the O 0 0.0005713565
plain O 0 0.087347046
choline B-Chemical 1 0.9987338
- O 0 0.0031259626
supplemented O 0 0.006102303
diet O 0 0.06140625
, O 0 0.00055759837
while O 0 0.0003028934
one O 0 0.00031475408
preneoplastic O 0 0.9722645
nodule O 0 0.3672376
and O 0 0.000675081
one O 0 0.0006584778
hepatocellular B-Disease 2 0.9998981
carcinoma I-Disease 2 0.99986446
developed O 0 0.0139534725
in O 0 0.0005778331
two O 0 0.0004381955
rats O 0 0.0021291757
fed O 0 0.001184913
the O 0 0.00077175465
same O 0 0.0009136373
diet O 0 0.0802635
containing O 0 0.006920879
phenobarbital B-Chemical 0 0.9993455
. O 0 0.011278775

The O 0 0.003367454
incidence O 0 0.00671448
of O 0 0.0033048652
preneoplastic O 0 0.97061825
nodules O 0 0.42787337
and O 0 0.001653233
of O 0 0.0025137533
hepatocellular B-Disease 0 0.9998093
carcinomas I-Disease 0 0.9990716
was O 0 0.0014556324
10 O 0 0.0006169178
% O 0 0.0004073249
and O 0 0.000303993
37 O 0 0.00048724972
% O 0 0.00036286912
, O 0 0.00036410673
respectively O 0 0.0006458376
, O 0 0.00034691824
in O 0 0.00022352248
rats O 0 0.0010689344
fed O 0 0.000583735
the O 0 0.00035125506
plain O 0 0.061473183
choline B-Chemical 1 0.9986784
- O 0 0.001411471
devoid O 0 0.00035429362
diet O 0 0.04835499
, O 0 0.00048596482
and O 0 0.00032180327
17 O 0 0.00042647836
% O 0 0.0002720752
and O 0 0.00023148637
30 O 0 0.00023308162
% O 0 0.0002899623
, O 0 0.00030795851
in O 0 0.00025510395
rats O 0 0.0012016406
fed O 0 0.0009675495
the O 0 0.0009672007
phenobarbital B-Chemical 0 0.9998877
- O 0 0.007915346
containing O 0 0.0026953148
choline B-Chemical 1 0.9968534
- O 0 0.006631255
devoid O 0 0.0036000109
diet O 0 0.16201054
. O 0 0.006912389

The O 0 0.0033751589
results O 0 0.002673184
evinced O 0 0.010914268
no O 0 0.00168163
enhancement O 0 0.0034099435
of O 0 0.001871367
the O 0 0.0018284806
hepatocarcinogenicity O 0 0.9953063
of O 0 0.003072728
the O 0 0.0029245743
choline B-Chemical 1 0.99706584
- O 0 0.006300085
devoid O 0 0.0027979556
diet O 0 0.19963016
by O 0 0.010698612
phenobarbital B-Chemical 0 0.999298
. O 0 0.014084322

Sporadic O 0 0.71478933
neoplastic O 0 0.76371807
lesions O 0 0.1991054
were O 0 0.0017280962
observed O 0 0.0008830526
in O 0 0.00075226097
organs O 0 0.0031349685
other O 0 0.00061811315
than O 0 0.00036154938
the O 0 0.00047892984
liver O 0 0.33912593
of O 0 0.0007133033
some O 0 0.00058813853
of O 0 0.00061939104
the O 0 0.00051728176
animals O 0 0.0005789136
, O 0 0.00081960123
irrespective O 0 0.0005877135
of O 0 0.0015609643
the O 0 0.0022584242
diet O 0 0.1197916
fed O 0 0.010363558
. O 0 0.006612954

On O 0 0.004114876
two O 0 0.0022147633
paradoxical O 0 0.051086366
side O 0 0.035683963
- O 0 0.0025977236
effects O 0 0.00193891
of O 0 0.0017646963
prednisolone B-Chemical 1 0.99948394
in O 0 0.0013485126
rats O 0 0.008700783
, O 0 0.001265824
ribosomal O 0 0.015253134
RNA O 0 0.050947506
biosyntheses O 0 0.7853888
, O 0 0.0016921656
and O 0 0.0012270883
a O 0 0.0016067077
mechanism O 0 0.0026123594
of O 0 0.0040926095
action O 0 0.03750274
. O 0 0.007144781

Liver B-Disease 0 0.9875707
enlargement I-Disease 0 0.7073959
and O 0 0.0046654795
muscle B-Disease 0 0.38266817
wastage I-Disease 0 0.3312098
occurred O 0 0.0024562203
in O 0 0.0014077659
Wistar O 0 0.1637666
rats O 0 0.0031413021
following O 0 0.0011876938
the O 0 0.0014350257
subcutaneous O 0 0.08166897
administration O 0 0.23986588
of O 0 0.012021173
prednisolone B-Chemical 1 0.9984328
. O 0 0.0133692045

In O 0 0.003170705
the O 0 0.0023928313
liver O 0 0.23927088
both O 0 0.0014147977
the O 0 0.00094625354
content O 0 0.0010104197
of O 0 0.0010107085
RNA O 0 0.0104884375
and O 0 0.0006797418
the O 0 0.00051656226
biosynthesis O 0 0.05768232
of O 0 0.000743576
ribosomal O 0 0.020184526
RNA O 0 0.021800518
increased O 0 0.000924494
while O 0 0.00033792303
both O 0 0.00030179057
the O 0 0.0003171318
RNA O 0 0.0042865304
content O 0 0.00054738094
and O 0 0.0005611048
ribosomal O 0 0.013854745
RNA O 0 0.03494308
biosynthesis O 0 0.15215363
were O 0 0.0008109018
reduced O 0 0.0009854785
in O 0 0.0010809087
the O 0 0.0018502214
gastrocnemius O 0 0.08027878
muscle O 0 0.16326854
. O 0 0.006517696

It O 0 0.0056814933
is O 0 0.0022313613
suggested O 0 0.0016155698
that O 0 0.0010356999
the O 0 0.001025845
drug O 0 0.16532691
acted O 0 0.0053152046
in O 0 0.00068048853
a O 0 0.0007060849
selective O 0 0.004825834
and O 0 0.00067791867
tissue O 0 0.010384657
- O 0 0.0008489584
specific O 0 0.00037349248
manner O 0 0.0005576493
to O 0 0.00028230742
enhance O 0 0.0003079867
ribosomal O 0 0.009349682
RNA O 0 0.027602987
synthesis O 0 0.04847869
in O 0 0.00048874685
the O 0 0.0006109954
liver O 0 0.68822217
and O 0 0.0011858799
depress O 0 0.12089865
such O 0 0.0015349047
synthesis O 0 0.05704761
in O 0 0.0019918804
the O 0 0.003223676
muscle O 0 0.17564635
. O 0 0.0067834654

This O 0 0.0050232513
view O 0 0.00366979
supports O 0 0.0018538613
the O 0 0.0014599069
contention O 0 0.0029873345
that O 0 0.0010208329
the O 0 0.0011980936
liver O 0 0.5093322
and O 0 0.0015965148
muscle O 0 0.031964447
are O 0 0.001125371
independent O 0 0.0008975463
sites O 0 0.0018181741
of O 0 0.0048502954
prednisolone B-Chemical 1 0.9986577
action O 0 0.26869807
. O 0 0.0095885275

Differential O 0 0.018257892
effects O 0 0.0067806193
of O 0 0.0056210756
gamma B-Chemical 0 0.8649329
- I-Chemical 0 0.039271977
hexachlorocyclohexane I-Chemical 0 0.9989254
( O 0 0.025572473
lindane B-Chemical 1 0.99902964
) O 0 0.008149873
on O 0 0.0021424273
pharmacologically O 0 0.96836334
- O 0 0.013393259
induced O 0 0.02396126
seizures B-Disease 2 0.9987212
. O 0 0.012765905

Gamma B-Chemical 0 0.79669964
- I-Chemical 0 0.019288756
hexachlorocyclohexane I-Chemical 0 0.9978764
( O 0 0.010154745
gamma B-Chemical 1 0.8253739
- I-Chemical 1 0.010390756
HCH I-Chemical 1 0.9967158
) O 0 0.003709737
, O 0 0.0009903125
the O 0 0.00051539263
active O 0 0.0010714825
ingredient O 0 0.38855156
of O 0 0.0008007079
the O 0 0.0006377277
insecticide O 0 0.9686867
lindane B-Chemical 1 0.99980825
, O 0 0.0021247207
has O 0 0.000497901
been O 0 0.00047959955
shown O 0 0.00022625417
to O 0 0.00026277918
decrease O 0 0.0006313616
seizure B-Disease 2 0.9987531
threshold O 0 0.00064186216
to O 0 0.0005334784
pentylenetrazol O 0 0.98104215
( O 0 0.00555494
PTZ B-Chemical 1 0.9999529
) O 0 0.001575821
3 O 0 0.00023810405
h O 0 0.00021315912
after O 0 0.00012269811
exposure O 0 0.00091994327
to O 0 0.0003434992
gamma B-Chemical 1 0.6810798
- I-Chemical 1 0.00343845
HCH I-Chemical 1 0.99755824
and O 0 0.00065467664
conversely O 0 0.015323815
increase O 0 0.00040116138
threshold O 0 0.0005302247
to O 0 0.0008306606
PTZ B-Chemical 1 0.99996054
- O 0 0.0054143644
induced O 0 0.0022974242
seizures B-Disease 2 0.9998024
24 O 0 0.00045972358
h O 0 0.00030075278
after O 0 0.00017798002
exposure O 0 0.0012682556
to O 0 0.00056720263
gamma B-Chemical 1 0.70756584
- I-Chemical 1 0.007644177
HCH I-Chemical 1 0.99720395
( O 0 0.004081271
Vohland O 0 0.26209822
et O 0 0.0049567386
al O 0 0.005928396
. O 0 0.0022079865
1981 O 0 0.013500486
) O 0 0.0076892707
. O 0 0.0061308555

In O 0 0.0027837802
this O 0 0.0019057019
study O 0 0.0021897855
, O 0 0.0015338048
the O 0 0.00091488904
severity O 0 0.0052715926
of O 0 0.000987232
response O 0 0.0011723953
to O 0 0.00057887495
other O 0 0.00092048594
seizure B-Disease 2 0.9993586
- O 0 0.0030026021
inducing O 0 0.002127472
agents O 0 0.12824391
was O 0 0.00035283345
tested O 0 0.00021779264
in O 0 0.00021669855
mice O 0 0.00016312183
1 O 0 0.00022956973
and O 0 0.00020785216
24 O 0 0.00019636922
h O 0 0.00019841222
after O 0 0.00014749519
intraperitoneal O 0 0.021520888
administration O 0 0.028941832
of O 0 0.00073047995
80 O 0 0.0015114091
mg O 0 0.4034125
/ O 0 0.003865166
kg O 0 0.033123482
gamma B-Chemical 1 0.6738175
- I-Chemical 1 0.018306674
HCH I-Chemical 1 0.9890463
. O 0 0.009257284

One O 0 0.004215372
hour O 0 0.0019139743
after O 0 0.001037395
the O 0 0.0011860862
administration O 0 0.03499879
of O 0 0.001993021
gamma B-Chemical 1 0.84020597
- I-Chemical 1 0.008677397
HCH I-Chemical 1 0.99740654
, O 0 0.001339931
the O 0 0.0004954896
activity O 0 0.00070102507
of O 0 0.0010721647
seizure B-Disease 2 0.99948454
- O 0 0.0031143555
inducing O 0 0.002331961
agents O 0 0.16502605
was O 0 0.0003812274
increased O 0 0.00063747057
, O 0 0.00032762147
regardless O 0 0.00012739192
of O 0 0.00029289463
their O 0 0.00030243056
mechanism O 0 0.00048735956
, O 0 0.00037664684
while O 0 0.0002437257
24 O 0 0.00027062697
h O 0 0.00030027234
after O 0 0.0002690017
gamma B-Chemical 1 0.42275786
- I-Chemical 1 0.0030221476
HCH I-Chemical 1 0.99288356
a O 0 0.0014886806
differential O 0 0.0030468728
response O 0 0.0031199772
was O 0 0.0026449335
observed O 0 0.0033643078
. O 0 0.005467081

Seizure B-Disease 2 0.9922267
activity O 0 0.0057025133
due O 0 0.0021846595
to O 0 0.0030114874
PTZ B-Chemical 1 0.9997861
and O 0 0.014173658
picrotoxin B-Chemical 0 0.999882
( O 0 0.02245057
PTX B-Chemical 0 0.9984665
) O 0 0.0028540578
was O 0 0.00054786535
significantly O 0 0.0006306391
decreased O 0 0.0016405781
; O 0 0.0011065528
however O 0 0.00076762005
, O 0 0.0009124751
seizure B-Disease 2 0.998858
activity O 0 0.0009170007
due O 0 0.00026813112
to O 0 0.00036380315
3 B-Chemical 0 0.0004482109
- I-Chemical 0 0.0014610515
mercaptopropionic I-Chemical 0 0.99565387
acid I-Chemical 0 0.976665
( O 0 0.006466666
MPA B-Chemical 0 0.9995708
) O 0 0.007118095
, O 0 0.0029816462
bicuculline B-Chemical 1 0.9998809
( O 0 0.006287843
BCC B-Chemical 0 0.9985671
) O 0 0.0038783888
, O 0 0.001062688
methyl B-Chemical 0 0.8598988
6 I-Chemical 0 0.00035005758
, I-Chemical 0 0.00046864426
7 I-Chemical 0 0.00034484165
- I-Chemical 0 0.0008362603
dimethoxy I-Chemical 0 0.96728855
- I-Chemical 0 0.0012506179
4 I-Chemical 0 0.00044091803
- I-Chemical 0 0.0013197019
ethyl I-Chemical 0 0.9944917
- I-Chemical 0 0.0033565846
B I-Chemical 0 0.29498774
- I-Chemical 0 0.0029656123
carboline I-Chemical 0 0.9929836
- I-Chemical 0 0.0018828228
3 I-Chemical 0 0.00048628644
- I-Chemical 0 0.0012787794
carboxylate I-Chemical 0 0.9536608
( O 0 0.0050812014
DMCM B-Chemical 0 0.99992144
) O 0 0.0033924258
, O 0 0.00088002865
or O 0 0.00073402777
strychnine B-Chemical 0 0.9997527
( O 0 0.0032315892
STR B-Chemical 0 0.9247796
) O 0 0.0018598612
was O 0 0.00079472014
not O 0 0.00083637954
different O 0 0.0013310708
from O 0 0.0021590036
control O 0 0.0035798245
. O 0 0.005379557

In O 0 0.0040746247
vitro O 0 0.0054123956
, O 0 0.004482574
gamma B-Chemical 1 0.67207575
- I-Chemical 1 0.010529658
HCH I-Chemical 1 0.99684465
, O 0 0.0143177435
pentylenetetrazol B-Chemical 0 0.9999075
and O 0 0.0091696745
picrotoxin B-Chemical 0 0.9998932
were O 0 0.0011556575
shown O 0 0.00042621858
to O 0 0.00046599953
inhibit O 0 0.0013877202
3H B-Chemical 1 0.93367606
- I-Chemical 1 0.0035378404
TBOB I-Chemical 1 0.99197024
binding O 0 0.0005811044
in O 0 0.000287988
mouse O 0 0.00043953944
whole O 0 0.00038261476
brain O 0 0.029039942
, O 0 0.0005011114
with O 0 0.00049457845
IC50 O 0 0.4860873
values O 0 0.00033030918
of O 0 0.00042879357
4 O 0 0.0003234599
. O 0 0.0002058517
6 O 0 0.00025480424
, O 0 0.00044611818
404 O 0 0.0019655097
and O 0 0.00054540706
9 O 0 0.0006490607
. O 0 0.00051881315
4 O 0 0.0010759255
microM O 0 0.1914631
, O 0 0.0032519612
respectively O 0 0.0065428466
. O 0 0.005029927

MPA B-Chemical 0 0.9943909
, O 0 0.016509987
BCC B-Chemical 0 0.99251634
, O 0 0.016890636
DMCM B-Chemical 0 0.9997135
, O 0 0.004006132
and O 0 0.0015905057
STR B-Chemical 0 0.76745313
showed O 0 0.0009804411
no O 0 0.0006204382
inhibition O 0 0.0042205034
of O 0 0.002189396
3H B-Chemical 1 0.96508485
- I-Chemical 1 0.00968383
TBOB I-Chemical 1 0.99650574
( O 0 0.0019186328
t B-Chemical 0 0.004037522
- I-Chemical 0 0.0031874143
butyl I-Chemical 0 0.99589694
bicyclo I-Chemical 0 0.9931045
- I-Chemical 0 0.004371345
orthobenzoate I-Chemical 0 0.46314225
) O 0 0.0014371119
binding O 0 0.0008757727
at O 0 0.00066052953
concentrations O 0 0.0029456918
of O 0 0.002612174
100 O 0 0.007564232
micron O 0 0.1438079
. O 0 0.0060010296

The O 0 0.0030195666
pharmacological O 0 0.06839057
challenge O 0 0.002355482
data O 0 0.0014517106
suggest O 0 0.0008017183
that O 0 0.0007850867
tolerance O 0 0.04321881
may O 0 0.0008294552
occur O 0 0.0008142181
to O 0 0.00075198326
seizure B-Disease 2 0.9988416
activity O 0 0.0017183837
induced O 0 0.0013440722
by O 0 0.001546725
PTZ B-Chemical 1 0.9999484
and O 0 0.0022026992
PTX B-Chemical 0 0.99792236
24 O 0 0.00050498947
h O 0 0.00034320424
after O 0 0.0002248833
gamma B-Chemical 1 0.5531735
- I-Chemical 1 0.0029851214
HCH I-Chemical 1 0.9971934
, O 0 0.00072121184
since O 0 0.00023535159
the O 0 0.00027383544
response O 0 0.00050743774
to O 0 0.00030229797
only O 0 0.00036421957
these O 0 0.00063546794
two O 0 0.00073210587
seizure B-Disease 2 0.99876875
- O 0 0.0042997305
inducing O 0 0.0060343
agents O 0 0.29108015
is O 0 0.0036296593
decreased O 0 0.010899043
. O 0 0.006159335

The O 0 0.0028010656
in O 0 0.0018557266
vitro O 0 0.0022166735
data O 0 0.0012681434
suggest O 0 0.0006870591
that O 0 0.00057642994
the O 0 0.0005363812
site O 0 0.00053004955
responsible O 0 0.0005308818
for O 0 0.0003478256
the O 0 0.00037443402
decrease O 0 0.00058255787
in O 0 0.0005026574
seizure B-Disease 2 0.9986431
activity O 0 0.0008321321
24 O 0 0.00035455145
h O 0 0.00031565258
after O 0 0.00024141962
gamma B-Chemical 1 0.48674393
- I-Chemical 1 0.0028967548
HCH I-Chemical 1 0.995992
may O 0 0.0008567043
be O 0 0.00076393085
the O 0 0.0011093039
GABA B-Chemical 1 0.9996068
- O 0 0.008543055
A O 0 0.067497574
receptor O 0 0.298172
- O 0 0.0061064805
linked O 0 0.004715482
chloride O 0 0.9967757
channel O 0 0.5564278
. O 0 0.009839124

Tolerance O 0 0.21921878
and O 0 0.005096916
antiviral O 0 0.07367417
effect O 0 0.0034752472
of O 0 0.004318662
ribavirin B-Chemical 1 0.9966079
in O 0 0.0037396513
patients O 0 0.012900244
with O 0 0.008572889
Argentine B-Disease 0 0.839046
hemorrhagic I-Disease 2 0.99831957
fever I-Disease 0 0.99778074
. O 0 0.017921733

Tolerance O 0 0.22378089
and O 0 0.0035334188
antiviral O 0 0.07314946
effect O 0 0.0019940673
of O 0 0.0021019182
ribavirin B-Chemical 1 0.9981117
was O 0 0.0013071719
studied O 0 0.0011179168
in O 0 0.00052284915
6 O 0 0.00040301506
patients O 0 0.0011843105
with O 0 0.0010174292
Argentine B-Disease 0 0.49890995
hemorrhagic I-Disease 2 0.9995604
fever I-Disease 0 0.9997166
( O 0 0.022930007
AHF B-Disease 0 0.9992756
) O 0 0.0019765706
of O 0 0.000858101
more O 0 0.00092997495
than O 0 0.0005552383
8 O 0 0.000872348
days O 0 0.0011223825
of O 0 0.0024432868
evolution O 0 0.006008141
. O 0 0.0055474173

Administration O 0 0.25411984
of O 0 0.0055787405
ribavirin B-Chemical 1 0.9956149
resulted O 0 0.0026530318
in O 0 0.001444885
a O 0 0.0014968229
neutralization O 0 0.016408017
of O 0 0.0022035274
viremia B-Disease 0 0.92982256
and O 0 0.0015785791
a O 0 0.0015583875
drop O 0 0.0029691688
of O 0 0.002833699
endogenous O 0 0.010763406
interferon O 0 0.99540615
titers O 0 0.12632245
. O 0 0.010349766

The O 0 0.006384251
average O 0 0.0044443817
time O 0 0.005942801
of O 0 0.011405965
death B-Disease 2 0.9709462
was O 0 0.014831648
delayed O 0 0.050022744
. O 0 0.017522957

A O 0 0.056707483
reversible O 0 0.56824917
anemia B-Disease 0 0.9961469
was O 0 0.006260824
the O 0 0.0043626805
only O 0 0.005331871
adverse O 0 0.57249266
effect O 0 0.009096146
observed O 0 0.008270862
. O 0 0.01146797

From O 0 0.0041178707
these O 0 0.0025978656
results O 0 0.001597409
, O 0 0.0014891663
we O 0 0.00054373
conclude O 0 0.0008197751
that O 0 0.0007895289
ribavirin B-Chemical 1 0.9980599
has O 0 0.0009545115
an O 0 0.00096517184
antiviral O 0 0.1818164
effect O 0 0.00072566024
in O 0 0.00040493018
advanced O 0 0.039326504
cases O 0 0.0018678468
of O 0 0.0017795998
AHF B-Disease 0 0.99950147
, O 0 0.0013334214
and O 0 0.00056969904
that O 0 0.00058631285
anemia B-Disease 0 0.9994949
, O 0 0.0010660545
the O 0 0.00043663
only O 0 0.0005065992
secondary O 0 0.0018368731
reaction O 0 0.0076288767
observed O 0 0.0008377989
, O 0 0.0014572074
can O 0 0.001168478
be O 0 0.0018633193
easily O 0 0.0034489215
managed O 0 0.0069162888
. O 0 0.0057721594

The O 0 0.0031796005
possible O 0 0.002824291
beneficial O 0 0.0043071727
effect O 0 0.0021704938
of O 0 0.0026003479
ribavirin B-Chemical 1 0.9967272
during O 0 0.0013505546
the O 0 0.0011980737
initial O 0 0.0014602828
days O 0 0.0018372952
of O 0 0.004157659
AHF B-Disease 0 0.9965268
is O 0 0.0062745204
discussed O 0 0.006761103
. O 0 0.007906163

Is O 0 0.030652959
the O 0 0.011715055
treatment O 0 0.018385896
of O 0 0.021686887
scabies B-Disease 0 0.95295256
hazardous O 0 0.7190533
? O 0 0.05384595

Treatment O 0 0.041491237
for O 0 0.0033505124
scabies B-Disease 0 0.80399376
is O 0 0.0019488167
usually O 0 0.0019287383
initiated O 0 0.0012568784
by O 0 0.0008690013
general O 0 0.00090133597
practitioners O 0 0.0018552992
; O 0 0.0012460983
most O 0 0.000989246
consider O 0 0.0007224868
lindane B-Chemical 1 0.99942386
( O 0 0.008134201
gamma B-Chemical 0 0.95811456
benzene I-Chemical 0 0.99957913
hexachloride I-Chemical 0 0.99966204
) O 0 0.008715264
the O 0 0.001778494
treatment O 0 0.004483161
of O 0 0.0042711236
choice O 0 0.0072248895
. O 0 0.0070392624

Lindane B-Chemical 0 0.99639016
is O 0 0.0038215255
also O 0 0.0020965282
widely O 0 0.002219567
used O 0 0.0009986858
as O 0 0.000707134
an O 0 0.0010398529
agricultural O 0 0.074348435
and O 0 0.0009619307
industrial O 0 0.18940844
pesticide O 0 0.94483584
, O 0 0.0011118529
and O 0 0.00051553437
as O 0 0.00032680196
a O 0 0.00043020508
result O 0 0.00035036844
the O 0 0.00048534016
toxic O 0 0.4278758
profile O 0 0.0010521704
of O 0 0.0010628343
this O 0 0.0012944629
insecticide O 0 0.80647665
is O 0 0.0024656886
well O 0 0.0027680984
understood O 0 0.00756406
. O 0 0.0058114016

Evidence O 0 0.015989756
is O 0 0.0033049406
accumulating O 0 0.0043078475
that O 0 0.002290089
lindane B-Chemical 1 0.99831855
can O 0 0.0018792606
be O 0 0.0015016597
toxic B-Disease 0 0.4725889
to I-Disease 0 0.00088907644
the I-Disease 0 0.0008025434
central I-Disease 0 0.0029575904
nervous I-Disease 0 0.69544363
system I-Disease 0 0.0016518688
and O 0 0.0010168977
may O 0 0.0010539673
be O 0 0.0013072173
associated O 0 0.002728054
with O 0 0.012404533
aplastic B-Disease 0 0.9993839
anaemia I-Disease 0 0.9990496
. O 0 0.020076517

Preparations O 0 0.044705033
containing O 0 0.00458332
lindane B-Chemical 1 0.9965699
continue O 0 0.0031817832
to O 0 0.0014001649
be O 0 0.0011408074
sold O 0 0.0022671495
over O 0 0.00044703
the O 0 0.0006156699
counter O 0 0.0016958597
and O 0 0.0007951383
may O 0 0.00069519994
represent O 0 0.00072789943
a O 0 0.0011106256
hazard O 0 0.05042512
to O 0 0.0015338202
poorly O 0 0.0054889545
informed O 0 0.009153307
patients O 0 0.012532563
. O 0 0.006636923

This O 0 0.0043228655
literature O 0 0.0032829894
review O 0 0.0027962509
suggests O 0 0.000834213
that O 0 0.0006784318
general O 0 0.0007825945
practitioners O 0 0.0011874982
should O 0 0.00038216493
prescribe O 0 0.009344251
scabicides O 0 0.6357359
with O 0 0.00061372574
increased O 0 0.00070518977
caution O 0 0.0007276973
for O 0 0.00029576162
certain O 0 0.00074409414
at O 0 0.00031686405
- O 0 0.00082907436
risk O 0 0.008744107
groups O 0 0.0006705239
, O 0 0.00064302393
and O 0 0.0005268212
give O 0 0.0006281847
adequate O 0 0.0010896262
warnings O 0 0.018227024
regarding O 0 0.0017433803
potential O 0 0.006196648
toxicity B-Disease 2 0.98780245
. O 0 0.008153094

Mouse O 0 0.024835398
strain O 0 0.004412784
- O 0 0.0042316797
dependent O 0 0.0020835632
effect O 0 0.002321798
of O 0 0.0035464042
amantadine B-Chemical 1 0.99792695
on O 0 0.0027918345
motility O 0 0.41528454
and O 0 0.006197594
brain O 0 0.49907705
biogenic O 0 0.9905317
amines B-Chemical 0 0.9926722
. O 0 0.014695831

The O 0 0.0030580028
effect O 0 0.0028273219
of O 0 0.003520239
amantadine B-Chemical 1 0.9993444
hydrochloride I-Chemical 0 0.9991923
, O 0 0.003729863
injected O 0 0.0010025817
i O 0 0.0018082614
. O 0 0.00033442423
p O 0 0.00053842703
. O 0 0.00019869054
in O 0 0.00020936302
6 O 0 0.00017174766
increments O 0 0.00043345976
of O 0 0.00029641317
100 O 0 0.00072866294
mg O 0 0.1906817
/ O 0 0.0006171459
kg O 0 0.0010412536
each O 0 8.964463e-05
over O 0 9.58054e-05
30 O 0 0.00016442797
hr O 0 0.0003731103
, O 0 0.00024183707
on O 0 0.00012451936
mouse O 0 0.00039522897
motility O 0 0.043513432
and O 0 0.00030795822
whole O 0 0.0003320188
brain O 0 0.011820354
content O 0 0.00039444043
of O 0 0.0004452434
selected O 0 0.0005253354
biogenic O 0 0.9907636
amines B-Chemical 0 0.9974062
and O 0 0.00077405147
major O 0 0.0010601202
metabolites O 0 0.7387909
was O 0 0.0007154106
studied O 0 0.00095712696
in O 0 0.0007033304
4 O 0 0.0008306808
strains O 0 0.0014025779
of O 0 0.0024260608
mice O 0 0.0027886636
. O 0 0.005114801

These O 0 0.0056946
were O 0 0.0033305997
the O 0 0.0028597084
albino O 0 0.038995825
Sprague O 0 0.39818993
- O 0 0.004559839
Dawley O 0 0.3239726
ICR O 0 0.019961454
and O 0 0.0016679933
BALB O 0 0.17325518
/ O 0 0.004022509
C O 0 0.666747
, O 0 0.0013347155
the O 0 0.0007740186
black O 0 0.0018138024
C57BL O 0 0.59638435
/ O 0 0.0019185524
6 O 0 0.0005474827
and O 0 0.000673853
the O 0 0.0008682332
brown O 0 0.004881186
CDF O 0 0.43058905
- O 0 0.0050599286
I O 0 0.0077488977
mouse O 0 0.004831047
strains O 0 0.0065037184
. O 0 0.0070383786

Amantadine B-Chemical 0 0.9959273
treatment O 0 0.012396476
produced O 0 0.005044277
a O 0 0.005025721
biphasic O 0 0.067605875
effect O 0 0.005618619
on O 0 0.004216845
mouse O 0 0.011811579
motility O 0 0.4304408
. O 0 0.013990813

The O 0 0.002840202
initial O 0 0.0024023878
dose O 0 0.012208604
of O 0 0.0032131607
amantadine B-Chemical 1 0.9991503
depressed B-Disease 2 0.9465834
locomotor O 0 0.73531216
activity O 0 0.0012051637
in O 0 0.00044102038
all O 0 0.00037057974
mouse O 0 0.0006048232
strains O 0 0.0005771489
studied O 0 0.0006880138
with O 0 0.00068196934
the O 0 0.0007752052
BALB O 0 0.2036585
/ O 0 0.0035249267
C O 0 0.48763853
mice O 0 0.00083737
being O 0 0.0017901233
the O 0 0.00175089
most O 0 0.004268074
sensitive O 0 0.0052604876
. O 0 0.0060076686

Subsequent O 0 0.008749717
amantadine B-Chemical 1 0.99577785
treatments O 0 0.009153749
produced O 0 0.0017952917
enhancement O 0 0.0036330342
of O 0 0.001446447
motility O 0 0.14526811
from O 0 0.00060721213
corresponding O 0 0.00037495227
control O 0 0.00034343355
in O 0 0.00031351447
all O 0 0.00030990416
mouse O 0 0.000549799
strains O 0 0.0005528587
with O 0 0.00060717977
the O 0 0.00069106946
BALB O 0 0.18013072
/ O 0 0.0031093203
C O 0 0.4570243
mice O 0 0.0007308111
being O 0 0.0015106838
the O 0 0.001375107
least O 0 0.0017461093
sensitive O 0 0.0046717986
. O 0 0.0056803934

The O 0 0.0034309223
locomotor O 0 0.14167903
activity O 0 0.0023286883
was O 0 0.0011031296
decreased O 0 0.0013589076
from O 0 0.0005966096
corresponding O 0 0.00041088654
controls O 0 0.0006138412
in O 0 0.00031446974
all O 0 0.0002818314
strains O 0 0.00044546888
studied O 0 0.0005352311
, O 0 0.00040502247
except O 0 0.00020253439
for O 0 0.00022637242
the O 0 0.000300988
ICR O 0 0.010969531
mice O 0 0.0002207006
, O 0 0.00035327976
during O 0 0.00019201904
an O 0 0.00038306258
overnight O 0 0.00047120175
drug O 0 0.16950144
- O 0 0.00091747084
free O 0 0.00074703066
period O 0 0.0005816552
following O 0 0.00076102477
the O 0 0.0011240036
fourth O 0 0.0070040314
amantadine B-Chemical 1 0.9977603
treatment O 0 0.040078092
. O 0 0.0072068567

Readministration O 0 0.6488075
of O 0 0.005200102
amantadine B-Chemical 1 0.99788034
, O 0 0.0026856738
after O 0 0.0006930391
a O 0 0.0010070705
drug O 0 0.29538286
- O 0 0.0012607458
free O 0 0.0007269003
overnight O 0 0.00046269334
period O 0 0.00038753136
, O 0 0.0004577477
increased O 0 0.0006531597
motility O 0 0.070213534
from O 0 0.00029655168
respective O 0 0.00023764887
saline O 0 0.029815907
control O 0 0.0002374439
in O 0 0.0002056806
all O 0 0.00019991357
strains O 0 0.00033141603
with O 0 0.00033706366
exception O 0 0.00030875666
of O 0 0.0005168836
the O 0 0.0006037158
BALB O 0 0.22695701
/ O 0 0.0030047598
C O 0 0.51690704
mice O 0 0.00058739295
where O 0 0.00091484026
suppression B-Disease 0 0.004733037
of I-Disease 0 0.0035707718
motility I-Disease 0 0.64900786
occurred O 0 0.009976786
. O 0 0.0067145876

Treatment O 0 0.057279576
with O 0 0.0047079455
amantadine B-Chemical 1 0.9974727
did O 0 0.0019023599
not O 0 0.0009353114
alter O 0 0.00090346613
whole O 0 0.00092827604
brain O 0 0.12972207
dopamine B-Chemical 1 0.99889827
levels O 0 0.00079372263
but O 0 0.00045340523
decreased O 0 0.0007689486
the O 0 0.0003279552
amounts O 0 0.00035730464
of O 0 0.0005399807
3 B-Chemical 0 0.00042142704
, I-Chemical 0 0.00057604455
4 I-Chemical 0 0.00047786045
- I-Chemical 0 0.0019170911
dihydroxyphenylacetic I-Chemical 0 0.9996741
acid I-Chemical 0 0.89677304
in O 0 0.0005904115
the O 0 0.0006945603
BALB O 0 0.19028601
/ O 0 0.0030498784
C O 0 0.4392792
mice O 0 0.00067615655
compared O 0 0.0007465417
to O 0 0.0015868141
saline O 0 0.07402571
control O 0 0.0041894033
. O 0 0.0057564634

Conversely O 0 0.007528909
, O 0 0.005126428
brain O 0 0.14070159
normetanephrine B-Chemical 0 0.9990362
concentration O 0 0.016989244
was O 0 0.0012736188
increased O 0 0.0014080731
from O 0 0.0008924063
saline O 0 0.044283185
control O 0 0.00087683724
by O 0 0.0014147836
amantadine B-Chemical 1 0.998285
in O 0 0.0017220408
the O 0 0.002199873
BALB O 0 0.2999346
/ O 0 0.011252983
C O 0 0.6382498
mice O 0 0.0048023653
. O 0 0.0072344174

The O 0 0.0025983602
results O 0 0.0017637786
suggest O 0 0.0012520732
a O 0 0.0014767934
strain O 0 0.0011570802
- O 0 0.0013370513
dependent O 0 0.0005916627
effect O 0 0.0007260709
of O 0 0.0010867375
amantadine B-Chemical 1 0.9992841
on O 0 0.0005249465
motility O 0 0.1943769
and O 0 0.00050761236
indicate O 0 0.00029444465
a O 0 0.00044326027
differential O 0 0.00092643994
response O 0 0.0008179734
to O 0 0.00048803267
the O 0 0.000671744
acute O 0 0.80752295
and O 0 0.0013122051
multiple O 0 0.0030995938
dose O 0 0.057305023
regimens O 0 0.06791305
used O 0 0.004649316
. O 0 0.0058202515

The O 0 0.004667574
BALB O 0 0.12501414
/ O 0 0.006497054
C O 0 0.5326709
mouse O 0 0.0022123074
was O 0 0.0009901535
the O 0 0.00068661
most O 0 0.0009484162
sensitive O 0 0.00067495677
strain O 0 0.00045651975
and O 0 0.00044511445
could O 0 0.0002851716
serve O 0 0.00047513068
as O 0 0.00026550583
the O 0 0.00029091124
strain O 0 0.00030786573
of O 0 0.00043537584
choice O 0 0.0005281294
for O 0 0.0003948185
evaluating O 0 0.0005205066
the O 0 0.00093316665
side O 0 0.014893876
effects O 0 0.0049673286
of O 0 0.008375764
amantadine B-Chemical 1 0.9979184
. O 0 0.009968877

The O 0 0.0031281586
biochemical O 0 0.008441893
results O 0 0.0019927218
of O 0 0.002510773
brain O 0 0.14774403
biogenic O 0 0.99294704
amines B-Chemical 0 0.996903
of O 0 0.0037423025
BALB O 0 0.561437
/ O 0 0.0050002676
C O 0 0.72314036
mouse O 0 0.00088509324
strain O 0 0.00036870842
suggest O 0 0.00026192196
a O 0 0.00041403755
probable O 0 0.0053979526
decrease O 0 0.00056569447
of O 0 0.00090524764
catecholamine B-Chemical 0 0.9994522
turnover O 0 0.0087620085
rate O 0 0.00044791767
and O 0 0.00047154643
/ O 0 0.0011193841
or O 0 0.0003135115
metabolism O 0 0.31646383
by O 0 0.0008202665
monoamine O 0 0.99978393
oxidase O 0 0.99644345
and O 0 0.00085344946
a O 0 0.00046965873
resulting O 0 0.00039891104
increase O 0 0.00040612667
in O 0 0.0004725597
O O 0 0.9892021
- O 0 0.001659236
methylation O 0 0.024060728
of O 0 0.0009866382
norepinephrine B-Chemical 1 0.9996414
which O 0 0.0008039343
may O 0 0.00034374732
account O 0 0.00032391414
for O 0 0.00024818446
a O 0 0.00052116264
behavioral B-Disease 0 0.48376334
depression I-Disease 0 0.99787676
caused O 0 0.0014518138
by O 0 0.0013745936
amantadine B-Chemical 1 0.999042
in O 0 0.0012888679
the O 0 0.0017034017
BALB O 0 0.31687006
/ O 0 0.010138256
C O 0 0.6440323
mice O 0 0.0040186094
. O 0 0.006239757

Chloroacetaldehyde B-Chemical 0 0.95331806
and O 0 0.004455172
its O 0 0.004076138
contribution O 0 0.001917063
to O 0 0.0024027699
urotoxicity O 0 0.9968208
during O 0 0.0020993792
treatment O 0 0.006159078
with O 0 0.0060564335
cyclophosphamide B-Chemical 1 0.99857545
or O 0 0.0149852345
ifosfamide B-Chemical 1 0.9978194
. O 0 0.014034156

An O 0 0.016405817
experimental O 0 0.0126141645
study O 0 0.013657453
/ O 0 0.01772429
short O 0 0.0143026095
communication O 0 0.029981997
. O 0 0.020889526

Based O 0 0.008980912
on O 0 0.0018754401
clinical O 0 0.005343945
data O 0 0.0020510461
, O 0 0.001659108
indicating O 0 0.00087073486
that O 0 0.0010254233
chloroacetaldehyde B-Chemical 0 0.9987457
( O 0 0.007898543
CAA B-Chemical 0 0.9946121
) O 0 0.0020832007
is O 0 0.00046629144
an O 0 0.0005083298
important O 0 0.00040260208
metabolite O 0 0.6934678
of O 0 0.0011315786
oxazaphosphorine O 0 0.9976922
cytostatics O 0 0.9978363
, O 0 0.0010682766
an O 0 0.0004085293
experimental O 0 0.00045192603
study O 0 0.00043360522
was O 0 0.00021102905
carried O 0 0.00015937306
out O 0 0.00016354265
in O 0 0.00018796581
order O 0 0.00015498901
to O 0 0.00019965124
elucidate O 0 0.00018733992
the O 0 0.00028151504
role O 0 0.00031818575
of O 0 0.0009894749
CAA B-Chemical 0 0.97525626
in O 0 0.00090788567
the O 0 0.0011022205
development O 0 0.004687185
of O 0 0.010986394
hemorrhagic B-Disease 2 0.99901664
cystitis I-Disease 0 0.99945205
. O 0 0.020091372

The O 0 0.0032498352
data O 0 0.0027816298
demonstrate O 0 0.001637988
that O 0 0.0018299869
CAA B-Chemical 0 0.9055118
after O 0 0.0010996117
i O 0 0.0030692972
. O 0 0.0008651418
v O 0 0.0055263788
. O 0 0.0007414302
administration O 0 0.028846074
does O 0 0.0009691059
not O 0 0.0011483567
contribute O 0 0.0019481565
to O 0 0.003309016
bladder B-Disease 0 0.98463154
damage I-Disease 0 0.9814385
. O 0 0.011260476

When O 0 0.00371199
instilled O 0 0.01071258
directly O 0 0.0020065333
into O 0 0.0009950754
the O 0 0.0012365516
bladder O 0 0.6155797
, O 0 0.0030529916
CAA B-Chemical 0 0.9879242
exerts O 0 0.045754556
urotoxic O 0 0.9978702
effects O 0 0.014132941
, O 0 0.0014031269
it O 0 0.0008356566
is O 0 0.0006909726
, O 0 0.000865305
however O 0 0.0010040968
, O 0 0.0010585241
susceptible O 0 0.0014204016
to O 0 0.0014460938
detoxification O 0 0.71412665
with O 0 0.011885271
mesna B-Chemical 1 0.9978179
. O 0 0.010733592

Source O 0 0.08182231
of O 0 0.0073061283
pain B-Disease 0 0.91643584
and O 0 0.0053489306
primitive O 0 0.057641003
dysfunction O 0 0.95317477
in O 0 0.0064526317
migraine B-Disease 2 0.99880207
: O 0 0.0090656765
an O 0 0.0051612826
identical O 0 0.0037781387
site O 0 0.008095136
? O 0 0.016404903

Twenty O 0 0.00863663
common O 0 0.005688031
migraine B-Disease 2 0.99795246
patients O 0 0.0069051203
received O 0 0.0017321208
a O 0 0.001033338
one O 0 0.0006808838
sided O 0 0.2654886
frontotemporal O 0 0.981601
application O 0 0.003010066
of O 0 0.0018060481
nitroglycerin B-Chemical 1 0.99988496
( O 0 0.0018843476
10 O 0 0.0005235104
patients O 0 0.0012453592
) O 0 0.00062661234
or O 0 0.00032913135
placebo O 0 0.18310848
ointment O 0 0.99013877
( O 0 0.0009520266
10 O 0 0.0005400358
patients O 0 0.0012985602
) O 0 0.0009429444
in O 0 0.00058546994
a O 0 0.0010180174
double O 0 0.0013432303
blind O 0 0.00841761
study O 0 0.005868378
. O 0 0.005632345

Early O 0 0.058144417
onset O 0 0.06426764
migraine B-Disease 2 0.99897075
attacks O 0 0.9420016
were O 0 0.0019262267
induced O 0 0.0017510717
by O 0 0.0014474026
nitroglycerin B-Chemical 1 0.9996921
in O 0 0.0007924093
seven O 0 0.0005012624
out O 0 0.00031875347
of O 0 0.0005112999
10 O 0 0.0004889319
patients O 0 0.0009059021
versus O 0 0.00044252817
no O 0 0.00044963416
patient O 0 0.0011005962
in O 0 0.00089752575
the O 0 0.0015904928
placebo O 0 0.15525684
group O 0 0.0055778143
. O 0 0.0056755105

Subsequently O 0 0.0062196534
20 O 0 0.004279783
migraine B-Disease 2 0.9978789
patients O 0 0.010238812
, O 0 0.0018562
who O 0 0.0019350778
developed O 0 0.0013034343
an O 0 0.0008723987
early O 0 0.0013401698
onset O 0 0.009070573
attack O 0 0.32223207
with O 0 0.0022224498
frontotemporal O 0 0.99822515
nitroglycerin B-Chemical 1 0.9999211
, O 0 0.0015593391
received O 0 0.00068337854
the O 0 0.0004031317
drug O 0 0.13788402
in O 0 0.0003941245
a O 0 0.0004676754
second O 0 0.00043704914
induction O 0 0.00080425607
test O 0 0.0008143115
at O 0 0.0007295304
other O 0 0.0017565306
body O 0 0.010183039
areas O 0 0.009508724
. O 0 0.0059376033

No O 0 0.018634332
early O 0 0.018735634
onset O 0 0.09627869
migraine B-Disease 2 0.99568534
was O 0 0.019232137
observed O 0 0.015032163
. O 0 0.01899701

Thus O 0 0.0045408923
the O 0 0.0039194957
migraine B-Disease 2 0.998681
- O 0 0.0054313894
inducing O 0 0.0026947188
effect O 0 0.0012666568
of O 0 0.0017950577
nitroglycerin B-Chemical 1 0.9998355
seems O 0 0.0011675439
to O 0 0.00040927707
depend O 0 0.0003621094
on O 0 0.00018515388
direct O 0 0.0002878387
stimulation O 0 0.0006531117
of O 0 0.0003722645
the O 0 0.00030524476
habitual O 0 0.056845393
site O 0 0.00034911776
of O 0 0.0006480714
pain B-Disease 0 0.97285175
, O 0 0.0005868227
suggesting O 0 0.0002378311
that O 0 0.00020934448
the O 0 0.000325827
frontotemporal O 0 0.9752789
region O 0 0.00044082932
is O 0 0.00028569112
of O 0 0.0003614134
crucial O 0 0.00033560343
importance O 0 0.00037869855
in O 0 0.00043895113
the O 0 0.00060401816
development O 0 0.0018595355
of O 0 0.0020761103
a O 0 0.0059841266
migraine B-Disease 2 0.9991493
crisis O 0 0.92707485
. O 0 0.009097008

This O 0 0.007112445
is O 0 0.0035547446
not O 0 0.0024783975
consistent O 0 0.0024655587
with O 0 0.002951949
a O 0 0.004089227
CNS O 0 0.6186085
origin O 0 0.009978105
of O 0 0.0129558155
migraine B-Disease 2 0.99858403
attack O 0 0.9128455
. O 0 0.0150633

Hypersensitivity B-Disease 0 0.9555403
to O 0 0.0061496133
carbamazepine B-Chemical 1 0.99942374
presenting O 0 0.128802
with O 0 0.0030713158
a O 0 0.002926435
leukemoid B-Disease 0 0.96831256
reaction I-Disease 0 0.06678421
, O 0 0.0056056674
eosinophilia B-Disease 2 0.99716467
, O 0 0.00840354
erythroderma B-Disease 0 0.99290717
, O 0 0.0047420887
and O 0 0.004834062
renal B-Disease 0 0.98981935
failure I-Disease 0 0.91806805
. O 0 0.010630863

We O 0 0.0032958272
report O 0 0.004411349
a O 0 0.0020638267
patient O 0 0.0022589413
in O 0 0.0012076015
whom O 0 0.004578469
hypersensitivity B-Disease 2 0.7174285
to O 0 0.0013670146
carbamazepine B-Chemical 1 0.99985516
presented O 0 0.0014207019
with O 0 0.0011338677
generalized O 0 0.32456
erythroderma B-Disease 0 0.99656504
, O 0 0.0016281488
a O 0 0.0010344023
severe O 0 0.37419683
leukemoid B-Disease 0 0.99056154
reaction I-Disease 0 0.09478445
, O 0 0.0050158477
eosinophilia B-Disease 2 0.9983689
, O 0 0.014748354
hyponatremia B-Disease 2 0.99952877
, O 0 0.0049934727
and O 0 0.0042722425
renal B-Disease 0 0.99134797
failure I-Disease 0 0.91719085
. O 0 0.009212511

This O 0 0.0061892583
is O 0 0.0029548416
the O 0 0.0020458836
first O 0 0.0016617054
report O 0 0.0037238274
of O 0 0.002365435
such O 0 0.002421942
an O 0 0.0037235266
unusual O 0 0.013530047
reaction O 0 0.035511576
to O 0 0.01044832
carbamazepine B-Chemical 1 0.99909437
. O 0 0.015449236

Fluoxetine B-Chemical 1 0.9984124
- O 0 0.023261003
induced O 0 0.017801221
akathisia B-Disease 0 0.99912554
: O 0 0.011192576
clinical O 0 0.016338665
and O 0 0.0061193146
theoretical O 0 0.019562436
implications O 0 0.014386873
. O 0 0.011643476

Five O 0 0.0067642448
patients O 0 0.0059207156
receiving O 0 0.011767952
fluoxetine B-Chemical 1 0.99926275
for O 0 0.0015983855
the O 0 0.0011824899
treatment O 0 0.0026702767
of O 0 0.003460311
obsessive B-Disease 0 0.9989563
compulsive I-Disease 0 0.9993051
disorder I-Disease 0 0.99043417
or O 0 0.002688526
major B-Disease 2 0.03833517
depression I-Disease 2 0.9973611
developed O 0 0.20163517
akathisia B-Disease 0 0.9993549
. O 0 0.0115765985

The O 0 0.0035619435
typical O 0 0.0055257287
fluoxetine B-Chemical 1 0.9993849
- O 0 0.0059594917
induced O 0 0.0022847543
symptoms O 0 0.30953273
of O 0 0.001909
restlessness O 0 0.9974075
, O 0 0.0010102045
constant O 0 0.00063409423
pacing O 0 0.41433507
, O 0 0.0008605828
purposeless O 0 0.9326354
movements O 0 0.0020800924
of O 0 0.00041965125
the O 0 0.0003256084
feet O 0 0.013177714
and O 0 0.00047555956
legs O 0 0.024898056
, O 0 0.0005083813
and O 0 0.00038258976
marked O 0 0.0011350174
anxiety B-Disease 0 0.9168536
were O 0 0.00042123246
indistinguishable O 0 0.00030707192
from O 0 0.0004920283
those O 0 0.0009753974
of O 0 0.002595165
neuroleptic O 0 0.999803
- O 0 0.029699175
induced O 0 0.045986492
akathisia B-Disease 0 0.99943453
. O 0 0.009670176

Three O 0 0.0049057873
patients O 0 0.0049216114
who O 0 0.0035635973
had O 0 0.0018432776
experienced O 0 0.006588626
neuroleptic O 0 0.9998354
- O 0 0.010805887
induced O 0 0.004711406
akathisia B-Disease 0 0.9998572
in O 0 0.0006235039
the O 0 0.0003907169
past O 0 0.0007242737
reported O 0 0.0005934146
that O 0 0.00028108188
the O 0 0.00038990294
symptoms O 0 0.2517917
of O 0 0.0022054003
fluoxetine B-Chemical 1 0.99991703
- O 0 0.007583691
induced O 0 0.005341244
akathisia B-Disease 0 0.99985194
were O 0 0.0010284106
identical O 0 0.00068028935
, O 0 0.0015241316
although O 0 0.0016357244
somewhat O 0 0.0049391077
milder O 0 0.16966158
. O 0 0.0068566077

Akathisia B-Disease 0 0.9960525
appeared O 0 0.0040669637
to O 0 0.0018206277
be O 0 0.001339711
a O 0 0.0010515372
common O 0 0.0013371914
side O 0 0.007428858
effect O 0 0.00092879706
of O 0 0.0014602127
fluoxetine B-Chemical 1 0.9998592
and O 0 0.0009701776
generally O 0 0.00078585243
responded O 0 0.0008618609
well O 0 0.0002567921
to O 0 0.00028233
treatment O 0 0.0008328441
with O 0 0.0005105211
the O 0 0.00055451324
beta O 0 0.61338943
- O 0 0.00839081
adrenergic O 0 0.99866486
antagonist O 0 0.9978555
propranolol B-Chemical 1 0.9999099
, O 0 0.0069462387
dose O 0 0.090648934
reduction O 0 0.0047831694
, O 0 0.0026047705
or O 0 0.0022108443
both O 0 0.00404223
. O 0 0.0054220785

The O 0 0.0028123292
authors O 0 0.0026397237
suggest O 0 0.0015913245
that O 0 0.00209116
fluoxetine B-Chemical 1 0.9996942
- O 0 0.010093534
induced O 0 0.006181168
akathisia B-Disease 0 0.99986637
may O 0 0.0011894327
be O 0 0.0006130329
caused O 0 0.0006013993
by O 0 0.00055456895
serotonergically O 0 0.5270505
mediated O 0 0.00051886303
inhibition O 0 0.0058761244
of O 0 0.0013672638
dopaminergic O 0 0.9955664
neurotransmission O 0 0.99276406
and O 0 0.00044629004
that O 0 0.00023614956
the O 0 0.0003067489
pathophysiology O 0 0.19998896
of O 0 0.0030401046
fluoxetine B-Chemical 1 0.99994576
- O 0 0.010440069
induced O 0 0.0079627475
akathisia B-Disease 0 0.9999409
and O 0 0.0065293843
tricyclic O 0 0.99979705
antidepressant B-Chemical 1 0.9997534
- O 0 0.0076193814
induced O 0 0.0021769137
" O 0 0.002679638
jitteriness O 0 0.9972875
" O 0 0.0022088534
may O 0 0.0017967904
be O 0 0.0023163336
identical O 0 0.002596302
. O 0 0.0050804326

Effect O 0 0.009142675
of O 0 0.005053401
converting O 0 0.07725448
enzyme O 0 0.11906171
inhibition O 0 0.007324123
on O 0 0.0012860389
the O 0 0.0015988242
course O 0 0.0032664866
of O 0 0.0057197097
adriamycin B-Chemical 1 0.998803
- O 0 0.052527737
induced O 0 0.064473785
nephropathy B-Disease 2 0.9991708
. O 0 0.01890268

The O 0 0.003053282
effect O 0 0.0026243038
of O 0 0.00233874
the O 0 0.0019158999
converting O 0 0.1123963
enzyme O 0 0.3690427
inhibitor O 0 0.56379455
( O 0 0.008208506
CEI O 0 0.99675447
) O 0 0.009830292
enalapril B-Chemical 1 0.9997999
was O 0 0.0011336628
assessed O 0 0.0006465495
in O 0 0.00080068345
Munich O 0 0.021020269
- O 0 0.0021788524
Wistar O 0 0.18915112
rats O 0 0.00365433
with O 0 0.0022832137
established O 0 0.013503503
adriamycin B-Chemical 1 0.9990557
nephrosis B-Disease 2 0.99917346
. O 0 0.017415725

Rats O 0 0.030776797
were O 0 0.0022526786
given O 0 0.0011886434
a O 0 0.001194334
single O 0 0.0009862648
dose O 0 0.0070331823
of O 0 0.0014360872
adriamycin B-Chemical 1 0.99902487
and O 0 0.0008721369
one O 0 0.00032472613
month O 0 0.00032219436
later O 0 0.00025892188
divided O 0 0.0001960581
into O 0 0.00014571284
four O 0 0.00016150097
groups O 0 0.00030689925
matched O 0 0.00033432862
for O 0 0.00051594543
albuminuria B-Disease 2 0.9992663
, O 0 0.001625426
blood O 0 0.0137437815
pressure O 0 0.06417032
, O 0 0.0015559152
and O 0 0.0017340231
plasma O 0 0.14480917
albumin O 0 0.9811608
concentration O 0 0.04171675
. O 0 0.0071895593

Groups O 0 0.0155181885
1 O 0 0.003006792
and O 0 0.0020296006
3 O 0 0.0013017786
remained O 0 0.0015090203
untreated O 0 0.0016151867
while O 0 0.0011441648
groups O 0 0.0015293042
2 O 0 0.0014726381
and O 0 0.0017408443
4 O 0 0.0022039518
received O 0 0.006521056
enalapril B-Chemical 1 0.9985852
. O 0 0.011867008

Groups O 0 0.018328087
1 O 0 0.0044223424
and O 0 0.0032603878
2 O 0 0.0026089102
underwent O 0 0.003215445
micropuncture O 0 0.011273314
studies O 0 0.0042603905
after O 0 0.0028132412
10 O 0 0.0048218947
days O 0 0.006150881
. O 0 0.008256478

These O 0 0.004290436
short O 0 0.002806019
- O 0 0.0026734993
term O 0 0.0014981577
studies O 0 0.0016067475
showed O 0 0.0010230084
that O 0 0.0010498351
enalapril B-Chemical 1 0.9997528
reduced O 0 0.0025068352
arterial O 0 0.8053372
blood O 0 0.032466825
pressure O 0 0.117151715
( O 0 0.0009544152
101 O 0 0.0046492964
+ O 0 0.0006316463
/ O 0 0.0010179111
- O 0 0.0005628204
2 O 0 0.00027087296
vs O 0 0.0004984855
. O 0 0.00016963785
124 O 0 0.0013017152
+ O 0 0.0004362279
/ O 0 0.00079751806
- O 0 0.000489761
3 O 0 0.0002382242
mm O 0 0.0016890125
Hg O 0 0.83683276
, O 0 0.00030441702
group O 0 0.00027728706
2 O 0 0.0002230392
vs O 0 0.00042932938
. O 0 0.00014006923
1 O 0 0.000222126
, O 0 0.00028140718
P O 0 0.0048432057
less O 0 0.00022033244
than O 0 0.00014908718
0 O 0 0.00027560396
. O 0 0.00016723506
05 O 0 0.019101625
) O 0 0.00045660656
and O 0 0.00033059303
glomerular O 0 0.6740129
capillary O 0 0.14310534
pressure O 0 0.12243661
( O 0 0.0006887935
54 O 0 0.00082368904
+ O 0 0.00047637057
/ O 0 0.0008824499
- O 0 0.00050191785
1 O 0 0.000250929
vs O 0 0.0004519381
. O 0 0.00015002167
61 O 0 0.0004821973
+ O 0 0.00038775214
/ O 0 0.00075843075
- O 0 0.0004998311
2 O 0 0.00028874155
mm O 0 0.002038142
Hg O 0 0.8822303
, O 0 0.00038537948
P O 0 0.0068574487
less O 0 0.00023460556
than O 0 0.00015338942
0 O 0 0.00027545585
. O 0 0.00016539328
05 O 0 0.015095659
) O 0 0.0004041327
without O 0 0.00027754204
reducing O 0 0.00085042586
albuminuria B-Disease 2 0.9996934
( O 0 0.0021211507
617 O 0 0.07764825
+ O 0 0.00067802006
/ O 0 0.0010987818
- O 0 0.0005111863
50 O 0 0.0003910029
vs O 0 0.0005131378
. O 0 0.00017240134
570 O 0 0.003840281
+ O 0 0.00045012883
/ O 0 0.00080856774
- O 0 0.00049772393
47 O 0 0.0006184449
mg O 0 0.1786082
/ O 0 0.00067085354
day O 0 0.00028221565
) O 0 0.00047332884
or O 0 0.00028816104
GFR O 0 0.9840163
( O 0 0.00065421377
1 O 0 0.00033999895
. O 0 0.00020168109
03 O 0 0.006889863
+ O 0 0.00046960413
/ O 0 0.00084527954
- O 0 0.00051800493
0 O 0 0.00030814527
. O 0 0.00017149335
04 O 0 0.0043105334
vs O 0 0.00056799233
. O 0 0.00018988065
1 O 0 0.00030631464
. O 0 0.0002332904
04 O 0 0.009249537
+ O 0 0.0006632812
/ O 0 0.001202875
- O 0 0.0008615924
0 O 0 0.000595029
. O 0 0.00039354968
11 O 0 0.0008783515
ml O 0 0.0027433215
/ O 0 0.00313832
min O 0 0.0036035518
) O 0 0.0053614276
. O 0 0.004882168

Groups O 0 0.012250227
3 O 0 0.002015415
and O 0 0.0014416827
4 O 0 0.0008318146
were O 0 0.00063810527
studied O 0 0.0006868935
at O 0 0.00032040055
four O 0 0.00028158943
and O 0 0.00036576728
at O 0 0.00020796912
six O 0 0.00018751544
months O 0 0.00028160415
to O 0 0.00020916009
assess O 0 0.00013647406
the O 0 0.000259267
effect O 0 0.00045556552
of O 0 0.0010405157
enalapril B-Chemical 1 0.9998505
on O 0 0.0008341415
progression O 0 0.5398091
of O 0 0.006788909
renal B-Disease 2 0.9988405
injury I-Disease 2 0.9973653
in O 0 0.03068851
adriamycin B-Chemical 1 0.9994609
nephrosis B-Disease 2 0.99938524
. O 0 0.018354228

Chronic O 0 0.98950094
enalapril B-Chemical 1 0.99932396
treatment O 0 0.021636888
reduced O 0 0.0034786437
blood O 0 0.014485707
pressure O 0 0.055106502
without O 0 0.002489942
reducing O 0 0.005346866
albuminuria B-Disease 2 0.99826825
in O 0 0.004512493
group O 0 0.0060995216
4 O 0 0.0055347867
. O 0 0.00664638

Untreated O 0 0.2016237
group O 0 0.0035796135
3 O 0 0.0016106556
rats O 0 0.0029400203
exhibited O 0 0.0010821245
a O 0 0.0010388053
progressive O 0 0.12249886
reduction O 0 0.0023497327
in O 0 0.0008621377
GFR O 0 0.9934029
( O 0 0.0011204829
0 O 0 0.0005113145
. O 0 0.00021994123
35 O 0 0.00039305104
+ O 0 0.00044576285
/ O 0 0.0008047448
- O 0 0.00051312236
0 O 0 0.0003015173
. O 0 0.00016179492
08 O 0 0.0019885474
ml O 0 0.00086273556
/ O 0 0.0005100783
min O 0 0.00032525344
at O 0 0.00013131122
4 O 0 0.00016807177
months O 0 0.00022560704
, O 0 0.00027897197
0 O 0 0.00027045803
. O 0 0.00015904107
27 O 0 0.00047548133
+ O 0 0.00044304505
/ O 0 0.0008544355
- O 0 0.0006014938
0 O 0 0.00039695363
. O 0 0.00024671978
07 O 0 0.0015260114
ml O 0 0.001504644
/ O 0 0.0012265611
min O 0 0.0010225986
at O 0 0.00065863965
6 O 0 0.0011092689
months O 0 0.002209465
) O 0 0.004754963
. O 0 0.0046560797

Enalapril B-Chemical 0 0.9992391
treatment O 0 0.028853519
blunted O 0 0.17278756
but O 0 0.0017324259
did O 0 0.00094488414
not O 0 0.00065523596
prevent O 0 0.00083902245
reduction O 0 0.0012914642
in O 0 0.00062474736
GFR O 0 0.9835084
in O 0 0.00048144517
group O 0 0.0005784784
4 O 0 0.00034833714
( O 0 0.00041839303
0 O 0 0.00030421917
. O 0 0.00015669192
86 O 0 0.00047149134
+ O 0 0.00039764046
/ O 0 0.00073081354
- O 0 0.00044498802
0 O 0 0.00024621078
. O 0 0.00011424912
15 O 0 0.00015087827
ml O 0 0.00054752774
/ O 0 0.00039548226
min O 0 0.00027064088
at O 0 0.000111412715
4 O 0 0.00014518389
months O 0 0.00019566967
, O 0 0.00023986652
0 O 0 0.0002278592
. O 0 0.00012564912
69 O 0 0.00036192563
+ O 0 0.00033927575
/ O 0 0.0006619453
- O 0 0.00041829955
0 O 0 0.00024059997
. O 0 0.00011651466
13 O 0 0.00022808091
ml O 0 0.0006285719
/ O 0 0.00042936724
min O 0 0.0002897904
at O 0 0.00011980129
6 O 0 0.00014211467
months O 0 0.00021293158
, O 0 0.00026857806
both O 0 0.00025828354
P O 0 0.0068317344
less O 0 0.00034618477
than O 0 0.00026438705
0 O 0 0.0005263401
. O 0 0.0003907907
05 O 0 0.010753915
vs O 0 0.0014345715
. O 0 0.000729097
group O 0 0.0017776849
3 O 0 0.0023079454
) O 0 0.005234785
. O 0 0.0048821107

Reduction O 0 0.013543381
in O 0 0.0032934346
GFR O 0 0.9592379
was O 0 0.0018431919
associated O 0 0.0014905977
with O 0 0.0010866595
the O 0 0.00078158575
development O 0 0.001779262
of O 0 0.0016236099
glomerular B-Disease 2 0.99553996
sclerosis I-Disease 2 0.9977471
in O 0 0.0008419473
both O 0 0.00063366775
treated O 0 0.00118745
and O 0 0.0007438587
untreated O 0 0.0014922248
rats O 0 0.004619481
. O 0 0.0009318411
( O 0 0.002237174
ABSTRACT O 0 0.014747023
TRUNCATED O 0 0.023628246
AT O 0 0.024870263
250 O 0 0.011342924
WORDS O 0 0.020093257
) O 0 0.021059982

Clotiazepam B-Chemical 0 0.905755
- O 0 0.039847437
induced O 0 0.04556487
acute O 0 0.98874235
hepatitis B-Disease 2 0.9979773
. O 0 0.06334156

We O 0 0.003154507
report O 0 0.003999382
the O 0 0.001556966
case O 0 0.0013102075
of O 0 0.0012626564
a O 0 0.0011299268
patient O 0 0.0016267031
who O 0 0.002594443
developed O 0 0.004519003
acute O 0 0.99787056
hepatitis B-Disease 2 0.9999356
with O 0 0.015731653
extensive B-Disease 0 0.06574863
hepatocellular I-Disease 0 0.9999403
necrosis I-Disease 2 0.99983454
, O 0 0.00474257
7 O 0 0.0003739175
months O 0 0.00028701933
after O 0 0.0001485569
the O 0 0.00025493835
onset O 0 0.001238668
of O 0 0.00069504173
administration O 0 0.124456435
of O 0 0.0034756204
clotiazepam B-Chemical 0 0.99961
, O 0 0.004297119
a O 0 0.0044993195
thienodiazepine B-Chemical 0 0.9911981
derivative O 0 0.3946934
. O 0 0.007840125

Clotiazepam B-Chemical 0 0.81149065
withdrawal O 0 0.5657061
was O 0 0.0076113385
followed O 0 0.005781866
by O 0 0.008386892
prompt O 0 0.025409583
recovery O 0 0.028177315
. O 0 0.016615657

The O 0 0.0031904078
administration O 0 0.022878826
of O 0 0.0024162175
several O 0 0.0024272485
benzodiazepines B-Chemical 1 0.99906355
, O 0 0.0026593248
chemically O 0 0.070325635
related O 0 0.0006790056
to O 0 0.0008864761
clotiazepam B-Chemical 0 0.9996563
, O 0 0.0011343721
did O 0 0.00041114513
not O 0 0.0003119067
interfere O 0 0.0004276008
with O 0 0.00054631685
recovery O 0 0.0014135143
and O 0 0.00062317384
did O 0 0.00056547165
not O 0 0.0006157312
induce O 0 0.0009429959
any O 0 0.0015505865
relapse O 0 0.93868864
of O 0 0.025285752
hepatitis B-Disease 2 0.99903166
. O 0 0.015752127

This O 0 0.0045832195
observation O 0 0.0024482568
shows O 0 0.0012238182
that O 0 0.0016370167
clotiazepam B-Chemical 0 0.9992151
can O 0 0.001597596
induce O 0 0.0019269593
acute O 0 0.99781716
hepatitis B-Disease 2 0.999925
and O 0 0.0028976584
suggests O 0 0.0005080057
that O 0 0.00041344532
there O 0 0.00033213373
is O 0 0.0005098082
no O 0 0.0004979081
cross O 0 0.0023103887
hepatotoxicity B-Disease 2 0.9997961
between O 0 0.0018872541
clotiazepam B-Chemical 0 0.9994073
and O 0 0.004061025
several O 0 0.008142685
benzodiazepines B-Chemical 1 0.998103
. O 0 0.009080403

5 B-Chemical 0 0.007043323
- I-Chemical 0 0.008890637
azacytidine I-Chemical 0 0.9826984
potentiates O 0 0.17320424
initiation B-Disease 0 0.0054232795
induced I-Disease 0 0.004761089
by I-Disease 0 0.0044198046
carcinogens I-Disease 0 0.9628143
in O 0 0.0062028794
rat O 0 0.13020256
liver O 0 0.9058211
. O 0 0.012190343

To O 0 0.00244482
test O 0 0.002038888
the O 0 0.0013805025
validity O 0 0.0018769045
of O 0 0.0010567972
the O 0 0.0007338137
hypothesis O 0 0.0009512971
that O 0 0.00058459135
hypomethylation O 0 0.2802574
of O 0 0.0010681825
DNA O 0 0.041135356
plays O 0 0.00072452286
an O 0 0.00058727735
important O 0 0.00031513182
role O 0 0.00022552919
in O 0 0.00024763038
the O 0 0.00025192645
initiation B-Disease 0 0.00043997166
of I-Disease 0 0.0006130073
carcinogenic I-Disease 0 0.99276805
process I-Disease 0 0.001089812
, O 0 0.0007187441
5 B-Chemical 0 0.00036763423
- I-Chemical 0 0.0009018763
azacytidine I-Chemical 0 0.9923288
( O 0 0.0008485298
5 B-Chemical 0 0.00033989004
- I-Chemical 0 0.0007900253
AzC I-Chemical 0 0.8330952
) O 0 0.0007480975
( O 0 0.00038780837
10 O 0 0.00028692
mg O 0 0.14301918
/ O 0 0.0007899944
kg O 0 0.0049496605
) O 0 0.0005080555
, O 0 0.00031443854
an O 0 0.00034946422
inhibitor O 0 0.02527781
of O 0 0.00059742614
DNA O 0 0.05091215
methylation O 0 0.053126454
, O 0 0.0004761054
was O 0 0.00022114084
given O 0 0.00013883298
to O 0 0.0001844195
rats O 0 0.00073059625
during O 0 0.00013978982
the O 0 0.00018878575
phase O 0 0.00049772183
of O 0 0.00037360485
repair O 0 0.00088587485
synthesis O 0 0.035161115
induced O 0 0.00060634955
by O 0 0.0003320055
the O 0 0.00026078595
three O 0 0.00020939995
carcinogens O 0 0.96969855
, O 0 0.002217513
benzo B-Chemical 0 0.99823403
[ I-Chemical 0 0.0057703434
a I-Chemical 0 0.00069027924
] I-Chemical 0 0.0018645994
- I-Chemical 0 0.00091605366
pyrene I-Chemical 0 0.8926082
( O 0 0.0006472878
200 O 0 0.0011419822
mg O 0 0.2834732
/ O 0 0.0011046134
kg O 0 0.0075373934
) O 0 0.00077856553
, O 0 0.00070642546
N B-Chemical 0 0.84537196
- I-Chemical 0 0.0032873705
methyl I-Chemical 0 0.9712399
- I-Chemical 0 0.004613904
N I-Chemical 0 0.92653805
- I-Chemical 0 0.00317149
nitrosourea I-Chemical 0 0.99834836
( O 0 0.00082281703
60 O 0 0.0004672672
mg O 0 0.2234334
/ O 0 0.0009251154
kg O 0 0.004136686
) O 0 0.00049505435
and O 0 0.0003034284
1 B-Chemical 0 0.0003262494
, I-Chemical 0 0.00039002526
2 I-Chemical 0 0.0003678854
- I-Chemical 0 0.0007746842
dimethylhydrazine I-Chemical 0 0.99149865
( O 0 0.0009632509
1 B-Chemical 0 0.0004912567
, I-Chemical 0 0.00056283356
2 I-Chemical 0 0.0005561668
- I-Chemical 0 0.0012805972
DMH I-Chemical 0 0.97982234
) O 0 0.001642668
( O 0 0.0011930838
100 O 0 0.002222322
mg O 0 0.27551782
/ O 0 0.0050309366
kg O 0 0.015589449
) O 0 0.0062253
. O 0 0.005203924

The O 0 0.0031731108
initiated O 0 0.003186327
hepatocytes O 0 0.12840346
in O 0 0.0013594091
the O 0 0.0011267624
liver O 0 0.44027004
were O 0 0.0008063994
assayed O 0 0.0004937843
as O 0 0.00045711675
the O 0 0.0006561765
gamma O 0 0.43316436
- O 0 0.008892713
glutamyltransferase O 0 0.9975594
( O 0 0.002980599
gamma O 0 0.5005378
- O 0 0.003341471
GT O 0 0.8336662
) O 0 0.00083022896
positive O 0 0.0002654028
foci O 0 0.00038832164
formed O 0 0.0003667112
following O 0 0.00028447536
a O 0 0.00031971277
2 O 0 0.00026426106
- O 0 0.00028408508
week O 0 0.00014382982
selection O 0 0.0002163484
regimen O 0 0.0011632247
consisting O 0 0.00024340059
of O 0 0.00041453852
dietary O 0 0.35468587
0 O 0 0.0005262779
. O 0 0.00024138005
02 O 0 0.009062982
% O 0 0.0004437926
2 B-Chemical 0 0.00042149212
- I-Chemical 0 0.0008143023
acetylaminofluorene I-Chemical 0 0.819264
coupled O 0 0.0009853574
with O 0 0.001152476
a O 0 0.0019401431
necrogenic O 0 0.98151165
dose O 0 0.21258344
of O 0 0.029144524
CCl4 B-Chemical 0 0.99921155
. O 0 0.0125728315

The O 0 0.002450797
results O 0 0.0016343878
obtained O 0 0.0012189037
indicate O 0 0.00077893026
that O 0 0.000678298
with O 0 0.0007632305
all O 0 0.0004953732
three O 0 0.0003667678
carcinogens O 0 0.9209123
, O 0 0.0011470944
administration O 0 0.07867544
of O 0 0.00076483324
5 B-Chemical 0 0.0004771934
- I-Chemical 0 0.0008652333
AzC I-Chemical 0 0.6721683
during O 0 0.00021846878
repair O 0 0.00065492006
synthesis O 0 0.019609844
increased O 0 0.00065486477
the O 0 0.00029159957
incidence O 0 0.004169439
of O 0 0.00047669146
initiated O 0 0.0007314298
hepatocytes O 0 0.44992262
, O 0 0.0004732456
for O 0 0.00021262119
example O 0 0.0002734181
10 O 0 0.00032020424
- O 0 0.00036765472
20 O 0 0.00022966848
foci O 0 0.0003071539
/ O 0 0.00064386503
cm2 O 0 0.0013755956
in O 0 0.00022010399
5 B-Chemical 0 0.0002626464
- I-Chemical 0 0.00058880856
AzC I-Chemical 0 0.73407054
and O 0 0.0004792648
carcinogen O 0 0.9918143
- O 0 0.0012916101
treated O 0 0.00075181416
rats O 0 0.0014363355
compared O 0 0.00015840765
with O 0 0.0003449022
3 O 0 0.0003078678
- O 0 0.0004885692
5 O 0 0.00023998001
foci O 0 0.00043653074
/ O 0 0.00095573097
cm2 O 0 0.0018340163
in O 0 0.00051288126
rats O 0 0.0023972255
treated O 0 0.0019529195
with O 0 0.0030073666
carcinogen O 0 0.98356515
only O 0 0.0065811835
. O 0 0.0065179435

Administration O 0 0.31557044
of O 0 0.005987755
[ B-Chemical 0 0.0125183035
3H I-Chemical 0 0.58914095
] I-Chemical 0 0.004816365
- I-Chemical 0 0.001880515
5 I-Chemical 0 0.00071757345
- I-Chemical 0 0.0009759304
azadeoxycytidine I-Chemical 0 0.035671063
during O 0 0.00034127827
the O 0 0.0003954225
repair O 0 0.00091363344
synthesis O 0 0.02806482
induced O 0 0.00082320924
by O 0 0.0005180872
1 B-Chemical 0 0.00046171324
, I-Chemical 0 0.0004547362
2 I-Chemical 0 0.0003545916
- I-Chemical 0 0.0005928636
DMH I-Chemical 0 0.9379901
further O 0 0.0003213278
showed O 0 0.00024351201
that O 0 0.00020701908
0 O 0 0.00031017815
. O 0 0.00016235883
019 O 0 0.014375793
mol O 0 0.049925175
% O 0 0.00035685353
of O 0 0.00042236588
cytosine B-Chemical 0 0.906367
residues O 0 0.018082898
in O 0 0.00034027084
DNA O 0 0.01463271
were O 0 0.00035011835
substituted O 0 0.003698784
by O 0 0.00031925595
the O 0 0.00031987834
analogue O 0 0.03533517
, O 0 0.00048568513
indicating O 0 0.0002714741
that O 0 0.0003075357
incorporation O 0 0.0012893509
of O 0 0.0007798731
5 B-Chemical 0 0.00076564495
- I-Chemical 0 0.0017839599
AzC I-Chemical 0 0.6836705
occurs O 0 0.0013561021
during O 0 0.0014873105
repair O 0 0.0061249807
synthesis O 0 0.13809758
. O 0 0.006837166

In O 0 0.002949487
the O 0 0.0018752792
absence O 0 0.0011014104
of O 0 0.0015901537
the O 0 0.0014378566
carcinogen O 0 0.9826247
, O 0 0.0020213614
5 B-Chemical 0 0.0007835512
- I-Chemical 0 0.0011398792
AzC I-Chemical 0 0.48292348
given O 0 0.0002530285
after O 0 0.00017680886
a O 0 0.00026871896
two O 0 0.00018029269
thirds O 0 0.00042666905
partial O 0 0.0008513441
hepatectomy O 0 0.9427169
, O 0 0.0005235713
when O 0 0.00020531754
its O 0 0.0006507378
incorporation O 0 0.0011620369
should O 0 0.00021148774
be O 0 0.00030070235
maximum O 0 0.0003673378
, O 0 0.00047639577
failed O 0 0.0005284892
to O 0 0.00042747616
induce O 0 0.0006166759
any O 0 0.00087143254
gamma O 0 0.29182982
- O 0 0.0059829014
GT O 0 0.7326285
positive O 0 0.0034514284
foci O 0 0.007518995
. O 0 0.0065106847

The O 0 0.0029337509
results O 0 0.002036931
suggest O 0 0.0015076589
that O 0 0.0015190606
hypomethylation O 0 0.1617651
of O 0 0.0020048097
DNA O 0 0.016600002
per O 0 0.00079811714
se O 0 0.0019783052
may O 0 0.0011877979
not O 0 0.0011426007
be O 0 0.0014163514
sufficient O 0 0.0013690033
for O 0 0.002333417
initiation O 0 0.0065165726
. O 0 0.006590124

Perhaps O 0 0.0051773842
two O 0 0.0018781411
events O 0 0.0037194393
might O 0 0.001016431
be O 0 0.0008876421
necessary O 0 0.0004954025
for O 0 0.0005156116
initiation O 0 0.0008647124
, O 0 0.00067273836
the O 0 0.0003850108
first O 0 0.00035079272
caused O 0 0.0005866925
by O 0 0.0005586042
the O 0 0.00064085546
carcinogen O 0 0.96842504
and O 0 0.00095971854
a O 0 0.00094806345
second O 0 0.0009790064
involving O 0 0.0021031678
hypomethylation O 0 0.48834804
of O 0 0.0058179293
DNA O 0 0.17401543
. O 0 0.007530074

Antihypertensive O 0 0.9894504
drugs O 0 0.8750042
and O 0 0.018751794
depression B-Disease 0 0.9763218
: O 0 0.019404072
a O 0 0.015208747
reappraisal O 0 0.30304796
. O 0 0.019120978

Eighty O 0 0.012946356
- O 0 0.004202677
nine O 0 0.0018711676
new O 0 0.0021592295
referral O 0 0.006069065
hypertensive B-Disease 2 0.9958395
out O 0 0.0010630413
- O 0 0.0013626544
patients O 0 0.0013330564
and O 0 0.0005144827
46 O 0 0.00061585096
new O 0 0.0005390253
referral O 0 0.0016131335
non O 0 0.0017713913
- O 0 0.0020130253
hypertensive B-Disease 2 0.99838805
chronically O 0 0.096514806
physically O 0 0.004207046
ill O 0 0.098074935
out O 0 0.0003170118
- O 0 0.00057781383
patients O 0 0.0007017336
completed O 0 0.00030119842
a O 0 0.0004387357
mood O 0 0.7334061
rating O 0 0.0010911303
scale O 0 0.00060344243
at O 0 0.00030899548
regular O 0 0.0008392183
intervals O 0 0.00080136163
for O 0 0.00092715875
one O 0 0.0016241712
year O 0 0.0039949263
. O 0 0.0050135995

The O 0 0.002634003
results O 0 0.0018238565
showed O 0 0.0014304209
a O 0 0.0012501624
high O 0 0.0012587671
prevalence O 0 0.0017764801
of O 0 0.0015392702
depression B-Disease 0 0.97545743
in O 0 0.0006699251
both O 0 0.0005200172
groups O 0 0.0005852771
of O 0 0.0006932182
patients O 0 0.0022581792
, O 0 0.0008419649
with O 0 0.0007707044
no O 0 0.00070940907
preponderance O 0 0.003945386
in O 0 0.001436884
the O 0 0.0029093302
hypertensive B-Disease 2 0.9954631
group O 0 0.00904107
. O 0 0.0071600694

Hypertensive B-Disease 0 0.9942888
patients O 0 0.010504821
with O 0 0.0036791645
psychiatric B-Disease 2 0.88519835
histories O 0 0.0046333564
had O 0 0.00129777
a O 0 0.0010745167
higher O 0 0.000909741
prevalence O 0 0.0018996982
of O 0 0.0021020174
depression B-Disease 0 0.9680126
than O 0 0.0013158201
the O 0 0.0018885317
comparison O 0 0.002803119
patients O 0 0.010613239
. O 0 0.006805804

This O 0 0.0046741012
was O 0 0.0021591082
accounted O 0 0.0017370591
for O 0 0.0010882699
by O 0 0.0010865481
a O 0 0.000990978
significant O 0 0.0009656933
number O 0 0.00067735976
of O 0 0.0014146204
depressions B-Disease 0 0.97617435
occurring O 0 0.0075168326
in O 0 0.0017936075
methyl B-Chemical 0 0.9949162
dopa I-Chemical 0 0.99945885
treated O 0 0.011717723
patients O 0 0.014079146
with O 0 0.005472025
psychiatric B-Disease 2 0.98106235
histories O 0 0.057885002
. O 0 0.00810036

Chronic B-Disease 0 0.9841548
active I-Disease 0 0.06685328
hepatitis I-Disease 2 0.9984378
associated O 0 0.03277787
with O 0 0.0547841
diclofenac B-Chemical 1 0.99961
sodium I-Chemical 0 0.997922
therapy O 0 0.8088814
. O 0 0.021182874

Diclofenac B-Chemical 0 0.9992594
sodium I-Chemical 0 0.99795085
( O 0 0.042915735
Voltarol B-Chemical 0 0.99790585
, O 0 0.010817352
Geigy O 0 0.9958255
Pharmaceuticals O 0 0.91914237
) O 0 0.002427444
is O 0 0.0009023461
a O 0 0.0010021003
non O 0 0.002428594
- O 0 0.0030662606
steroidal O 0 0.99183214
anti O 0 0.06486804
- O 0 0.009285315
inflammatory O 0 0.9105046
derivative O 0 0.4151943
of O 0 0.02388645
phenylacetic B-Chemical 1 0.99872524
acid I-Chemical 1 0.9914021
. O 0 0.012618853

Although O 0 0.0035462538
generally O 0 0.0029129675
well O 0 0.0017518437
- O 0 0.0026330585
tolerated O 0 0.014088747
, O 0 0.0014556788
asymptomatic O 0 0.05968099
abnormalities B-Disease 0 0.07598329
of I-Disease 0 0.0010480419
liver I-Disease 0 0.7432246
function I-Disease 0 0.0009906074
have O 0 0.0005668676
been O 0 0.0005751175
recorded O 0 0.00056061166
and O 0 0.0005415546
, O 0 0.00066686876
less O 0 0.0006258359
commonly O 0 0.002240595
, O 0 0.0019264779
severe O 0 0.6623614
hepatitis B-Disease 2 0.99957865
induced O 0 0.043491855
by O 0 0.028862024
diclofenac B-Chemical 1 0.9994686
. O 0 0.01368122

The O 0 0.0028951738
patient O 0 0.0032421798
described O 0 0.0016638583
developed O 0 0.003243988
chronic B-Disease 0 0.95999676
active I-Disease 0 0.018923668
hepatitis I-Disease 2 0.999691
after O 0 0.00066792365
six O 0 0.00039042576
months O 0 0.0005797397
therapy O 0 0.010351036
with O 0 0.0018633957
diclofenac B-Chemical 1 0.999962
sodium I-Chemical 0 0.9996424
which O 0 0.0020825197
progressed O 0 0.008573472
despite O 0 0.0004324703
the O 0 0.00042460338
withdrawal O 0 0.40302902
of O 0 0.00066002837
the O 0 0.0005984146
drug O 0 0.2885578
, O 0 0.0010988944
a O 0 0.0009771708
finding O 0 0.0016027016
not O 0 0.0014354473
previously O 0 0.0026103707
reported O 0 0.0061688665
. O 0 0.005607286

Arterial O 0 0.951968
hypertension B-Disease 2 0.9953112
as O 0 0.0057712733
a O 0 0.0057648197
complication O 0 0.17467473
of O 0 0.007558711
prolonged O 0 0.32424676
ketoconazole B-Chemical 1 0.99911886
treatment O 0 0.18498442
. O 0 0.016110666

Two O 0 0.0041175582
of O 0 0.002752539
14 O 0 0.002110658
patients O 0 0.0029420627
with O 0 0.002139005
Cushing B-Disease 0 0.99718434
' I-Disease 0 0.0017397336
s I-Disease 0 0.0015048733
syndrome I-Disease 0 0.4997593
treated O 0 0.0012432697
on O 0 0.00036879646
a O 0 0.00063282164
long O 0 0.0008118505
- O 0 0.0009654252
term O 0 0.000756608
basis O 0 0.0011980193
with O 0 0.0028245607
ketoconazole B-Chemical 1 0.99967754
developed O 0 0.05707407
sustained O 0 0.57710683
hypertension B-Disease 2 0.9986904
. O 0 0.012022136

In O 0 0.0028069399
both O 0 0.001897806
cases O 0 0.0024221682
normal O 0 0.002418088
plasma O 0 0.019369604
and O 0 0.0012911101
urinary O 0 0.7146135
free O 0 0.0032465067
cortisol B-Chemical 1 0.9829334
levels O 0 0.00065877306
had O 0 0.0005154727
been O 0 0.00047475632
achieved O 0 0.00048677527
following O 0 0.0006270482
ketoconazole B-Chemical 1 0.99989533
therapy O 0 0.12770204
, O 0 0.00072103756
yet O 0 0.000436167
continuous O 0 0.00030796553
blood O 0 0.0028754452
pressure O 0 0.016850758
monitoring O 0 0.0005748815
demonstrated O 0 0.00071522524
hypertension B-Disease 2 0.99955493
31 O 0 0.0013512424
( O 0 0.0004946174
patient O 0 0.00054318766
1 O 0 0.00035145468
) O 0 0.0004494133
and O 0 0.00030890002
52 O 0 0.0005333402
weeks O 0 0.00041530668
( O 0 0.0006782089
patient O 0 0.0010413725
2 O 0 0.0010260624
) O 0 0.001748493
after O 0 0.0012880412
treatment O 0 0.0059562162
. O 0 0.0051582376

In O 0 0.0038020404
patient O 0 0.0041589583
1 O 0 0.002468833
, O 0 0.00234909
plasma O 0 0.007722486
levels O 0 0.0016049577
of O 0 0.0032005704
deoxycorticosterone B-Chemical 0 0.9996166
and O 0 0.004258754
11 B-Chemical 0 0.0037501012
- I-Chemical 0 0.005591455
deoxycortisol I-Chemical 0 0.97201407
were O 0 0.004868958
elevated O 0 0.0221822
. O 0 0.008161373

In O 0 0.0031246883
patient O 0 0.003239781
2 O 0 0.0017305581
, O 0 0.0014030935
in O 0 0.0006860658
addition O 0 0.0004687202
to O 0 0.00051766285
an O 0 0.0006525658
increase O 0 0.00047616512
in O 0 0.00042885327
both O 0 0.00071302976
deoxycorticosterone B-Chemical 0 0.9998808
and O 0 0.0014143634
11 B-Chemical 0 0.0010328025
- I-Chemical 0 0.0013604085
deoxycortisol I-Chemical 0 0.9812418
levels O 0 0.00056734734
, O 0 0.0007584695
plasma O 0 0.07836215
aldosterone B-Chemical 0 0.99936396
values O 0 0.0005555771
were O 0 0.00041850915
raised O 0 0.00062263897
, O 0 0.00063000957
with O 0 0.00064309634
a O 0 0.0008808567
concomitant O 0 0.0064600212
suppression O 0 0.005166981
of O 0 0.004427783
renin O 0 0.9898601
levels O 0 0.0074150036
. O 0 0.006888562

Our O 0 0.003434617
findings O 0 0.00352343
show O 0 0.0013418881
that O 0 0.0010038724
long O 0 0.0013221125
- O 0 0.0013074226
term O 0 0.0007824819
treatment O 0 0.0013501426
with O 0 0.0007156906
high O 0 0.0008989927
doses O 0 0.046806343
of O 0 0.0024834094
ketoconazole B-Chemical 1 0.9998981
may O 0 0.0014693533
induce O 0 0.0010367266
enzyme O 0 0.18911815
blockade O 0 0.45809078
leading O 0 0.009120284
to O 0 0.002612502
mineralocorticoid O 0 0.99864024
- O 0 0.017251061
related O 0 0.0052310075
hypertension B-Disease 2 0.9982426
. O 0 0.009671003

Effects O 0 0.013052246
of O 0 0.0039896676
an O 0 0.0037171694
inhibitor O 0 0.1212908
of O 0 0.0050426065
angiotensin B-Chemical 1 0.99931324
converting O 0 0.7973891
enzyme O 0 0.7588032
( O 0 0.01840822
Captopril B-Chemical 1 0.99982697
) O 0 0.0034036634
on O 0 0.0005192841
pulmonary B-Disease 0 0.7289605
and I-Disease 0 0.0017088017
renal I-Disease 0 0.99563736
insufficiency I-Disease 0 0.9979481
due O 0 0.0011572201
to O 0 0.0017384761
intravascular B-Disease 0 0.97665524
coagulation I-Disease 0 0.98093224
in O 0 0.0030448067
the O 0 0.00388992
rat O 0 0.03978511
. O 0 0.006967226

Induction O 0 0.013960816
of O 0 0.0052061914
intravascular B-Disease 0 0.95931554
coagulation I-Disease 0 0.9774285
and O 0 0.0025558625
inhibition O 0 0.006377549
of O 0 0.0017976767
fibrinolysis O 0 0.9838875
by O 0 0.0010444825
injection O 0 0.00429227
of O 0 0.0010412367
thrombin O 0 0.844915
and O 0 0.0017250403
tranexamic B-Chemical 0 0.99921834
acid I-Chemical 0 0.99375916
( O 0 0.006435242
AMCA B-Chemical 0 0.9870367
) O 0 0.0013717073
in O 0 0.0002940149
the O 0 0.0002990553
rat O 0 0.0028213756
gives O 0 0.0003676791
rise O 0 0.00061462424
to O 0 0.00037000596
pulmonary B-Disease 0 0.696968
and I-Disease 0 0.0010655096
renal I-Disease 0 0.99628747
insufficiency I-Disease 0 0.99874413
resembling O 0 0.008168502
that O 0 0.0006243328
occurring O 0 0.0021856877
after O 0 0.0007527217
trauma B-Disease 0 0.8009008
or O 0 0.0024251428
sepsis B-Disease 2 0.9958138
in O 0 0.0055964435
man O 0 0.5166816
. O 0 0.0070828605

Injection O 0 0.2630873
of O 0 0.00836374
Captopril B-Chemical 1 0.99930084
( O 0 0.0056031514
1 O 0 0.0017859022
mg O 0 0.36548284
/ O 0 0.0024859041
kg O 0 0.009915973
) O 0 0.0012585064
, O 0 0.0007144364
an O 0 0.0007327355
inhibitor O 0 0.059066482
of O 0 0.0020235155
angiotensin B-Chemical 1 0.99966633
converting O 0 0.72264004
enzyme O 0 0.6663789
( O 0 0.005931449
ACE O 0 0.9988381
) O 0 0.0028502727
, O 0 0.0006666387
reduced O 0 0.00049744366
both O 0 0.0005678277
pulmonary B-Disease 0 0.7422513
and I-Disease 0 0.0018368302
renal I-Disease 0 0.99585944
insufficiency I-Disease 0 0.99762934
in O 0 0.0019596827
this O 0 0.0023299805
rat O 0 0.023924312
model O 0 0.006485872
. O 0 0.006236372

The O 0 0.003533115
lung O 0 0.032081738
weights O 0 0.0027836359
were O 0 0.0014769933
lower O 0 0.0012490425
and O 0 0.0014232777
PaO2 O 0 0.7927341
was O 0 0.00093403563
improved O 0 0.0015309462
in O 0 0.0007697898
rats O 0 0.0022963383
given O 0 0.0007696736
this O 0 0.0014321451
enzyme O 0 0.08106571
- O 0 0.005750014
blocking O 0 0.013935712
agent O 0 0.39468935
. O 0 0.00882835

The O 0 0.00338433
contents O 0 0.005530353
of O 0 0.0031542329
albumin O 0 0.88695264
in O 0 0.0013882839
the O 0 0.0009819594
lungs O 0 0.0026286219
were O 0 0.0006622277
not O 0 0.0005108015
changed O 0 0.0007702198
, O 0 0.00075316586
indicating O 0 0.00050601165
that O 0 0.000809914
Captopril B-Chemical 1 0.9996674
did O 0 0.0009790974
not O 0 0.0007332572
influence O 0 0.0009036835
the O 0 0.0016787843
extravasation O 0 0.6617329
of O 0 0.005095929
protein O 0 0.015450671
. O 0 0.007175863

Renal B-Disease 0 0.9808523
damage I-Disease 0 0.800877
as O 0 0.0023246894
reflected O 0 0.0016132955
by O 0 0.001352018
an O 0 0.0013688001
increase O 0 0.0009660228
in O 0 0.00093646976
serum O 0 0.12322118
urea B-Chemical 1 0.9947436
and O 0 0.0015391257
in O 0 0.0012506418
kidney O 0 0.7354796
weight O 0 0.02378979
was O 0 0.0024451632
prevented O 0 0.009510413
by O 0 0.009902031
Captopril B-Chemical 1 0.9989083
. O 0 0.012433266

The O 0 0.0027601228
amount O 0 0.001566638
of O 0 0.0022057581
fibrin O 0 0.08009454
in O 0 0.001121693
the O 0 0.0008850519
kidneys O 0 0.01656881
was O 0 0.0006509132
also O 0 0.0005678526
considerably O 0 0.00069591583
lower O 0 0.0004916787
than O 0 0.00032971235
in O 0 0.0004251599
animals O 0 0.00055218063
which O 0 0.001088682
received O 0 0.0020270045
thrombin O 0 0.718178
and O 0 0.005052823
AMCA B-Chemical 0 0.9749078
alone O 0 0.010640211
. O 0 0.0080861

It O 0 0.0056185736
is O 0 0.0021975855
suggested O 0 0.0015796677
that O 0 0.0009980482
the O 0 0.0009284458
effects O 0 0.0017716527
of O 0 0.002019846
Captopril B-Chemical 1 0.99975425
on O 0 0.0005674947
the O 0 0.0005784563
lungs O 0 0.003236691
may O 0 0.00045707557
be O 0 0.00035622425
attributable O 0 0.0002690686
to O 0 0.0002614791
a O 0 0.0003906938
vasodilatory O 0 0.97238535
effect O 0 0.0005188546
due O 0 0.00020164972
to O 0 0.00023895531
a O 0 0.00030437612
reduction O 0 0.000544281
in O 0 0.00021429274
the O 0 0.00022995619
circulating O 0 0.0020863977
level O 0 0.00023518338
of O 0 0.0006554564
Angiotension B-Chemical 0 0.9283032
II I-Chemical 0 0.07376674
and O 0 0.00047934265
an O 0 0.00054291537
increase O 0 0.0004549972
in O 0 0.00066502066
prostacyclin B-Chemical 0 0.99973637
( O 0 0.0022885227
secondary O 0 0.0026677456
to O 0 0.00083794823
an O 0 0.0013970893
increase O 0 0.0016042221
in O 0 0.0031842194
bradykinin B-Chemical 1 0.9982091
) O 0 0.022044666
. O 0 0.007162123

Captopril B-Chemical 1 0.9982936
may O 0 0.004621841
, O 0 0.0026660287
by O 0 0.001267732
the O 0 0.00079653977
same O 0 0.00046839708
mechanism O 0 0.0009831791
, O 0 0.00072996155
reduce O 0 0.00038368278
the O 0 0.00038482313
increase O 0 0.00041628745
in O 0 0.00040474994
glomerular O 0 0.77296114
filtration O 0 0.020907884
that O 0 0.00034006423
is O 0 0.00033139074
known O 0 0.00039501954
to O 0 0.00022854283
occur O 0 0.00027122317
after O 0 0.00013517773
an O 0 0.00031386712
injection O 0 0.0010643319
of O 0 0.00045967623
thrombin O 0 0.74905145
, O 0 0.000537513
thereby O 0 0.0005901918
diminishing O 0 0.0014047514
the O 0 0.0003071217
aggregation O 0 0.0204326
of O 0 0.00063847547
fibrin O 0 0.3233433
monomers O 0 0.004183257
in O 0 0.0002777819
the O 0 0.0002933781
glomeruli O 0 0.061529826
, O 0 0.000402101
with O 0 0.00029326518
the O 0 0.00021044536
result O 0 0.00020045297
that O 0 0.00020641675
less O 0 0.00034527163
fibrin O 0 0.06677798
will O 0 0.0002687246
be O 0 0.00038816195
deposited O 0 0.0009220941
and O 0 0.0005013317
thus O 0 0.0008637135
less O 0 0.0011987739
kidney B-Disease 0 0.97265834
damage I-Disease 0 0.93554384
will O 0 0.0019994131
be O 0 0.002852614
produced O 0 0.004248557
. O 0 0.0056910883

Stroke B-Disease 0 0.9440027
associated O 0 0.022895731
with O 0 0.025940266
cocaine B-Chemical 1 0.9911165
use O 0 0.03782835
. O 0 0.026444245

We O 0 0.0028341138
describe O 0 0.002107678
eight O 0 0.0014184428
patients O 0 0.0027424023
in O 0 0.0011498464
whom O 0 0.004829937
cocaine B-Chemical 1 0.9985605
use O 0 0.0016757165
was O 0 0.0007913724
related O 0 0.00056457357
to O 0 0.00084170216
stroke B-Disease 2 0.98824966
and O 0 0.0011705165
review O 0 0.0023951875
39 O 0 0.0017987826
cases O 0 0.0020115077
from O 0 0.0017319921
the O 0 0.0027019302
literature O 0 0.008523137
. O 0 0.0063062226

Among O 0 0.006615267
these O 0 0.0030242042
47 O 0 0.0030426453
patients O 0 0.002619893
the O 0 0.0009930942
mean O 0 0.00075272744
( O 0 0.0014408735
+ O 0 0.0011514401
/ O 0 0.0018583843
- O 0 0.0012250323
SD O 0 0.0127269495
) O 0 0.0007425496
age O 0 0.0007365015
was O 0 0.0003437498
32 O 0 0.00053168146
. O 0 0.00021088567
5 O 0 0.0002785558
+ O 0 0.0004261451
/ O 0 0.00076376554
- O 0 0.0004966475
12 O 0 0.00022032109
. O 0 0.00017154586
1 O 0 0.00028450356
years O 0 0.0005731237
; O 0 0.0005994864
76 O 0 0.0007443009
% O 0 0.00058007846
( O 0 0.00069808325
34 O 0 0.00095172826
/ O 0 0.0015669245
45 O 0 0.001187782
) O 0 0.0021924367
were O 0 0.0024502696
men O 0 0.02404714
. O 0 0.0057264986

Stroke B-Disease 0 0.9354197
followed O 0 0.004586787
cocaine B-Chemical 1 0.9959259
use O 0 0.004146835
by O 0 0.0026704355
inhalation O 0 0.47494355
, O 0 0.0033888714
intranasal O 0 0.1318958
, O 0 0.0034660513
intravenous O 0 0.5405076
, O 0 0.0038175427
and O 0 0.0038472158
intramuscular O 0 0.5106416
routes O 0 0.05983091
. O 0 0.008537257

Intracranial B-Disease 0 0.97323555
aneurysms I-Disease 2 0.990254
or O 0 0.003837214
arteriovenous B-Disease 0 0.88051736
malformations I-Disease 0 0.9613059
were O 0 0.0011875241
present O 0 0.00058059895
in O 0 0.0005256485
17 O 0 0.0006619172
of O 0 0.0005177695
32 O 0 0.0007344909
patients O 0 0.0010944636
studied O 0 0.00084617216
angiographically O 0 0.9118407
or O 0 0.00049754535
at O 0 0.00041295434
autopsy O 0 0.08664372
; O 0 0.0035735704
cerebral B-Disease 0 0.99596244
vasculitis I-Disease 2 0.99963653
was O 0 0.0016064958
present O 0 0.0009571826
in O 0 0.0013683711
two O 0 0.0019935546
patients O 0 0.008817449
. O 0 0.0057187015

Cerebral B-Disease 0 0.9833038
infarction I-Disease 2 0.99918336
occurred O 0 0.004898414
in O 0 0.0016358107
10 O 0 0.0013153676
patients O 0 0.0023182079
( O 0 0.00119751
22 O 0 0.0010162639
% O 0 0.0007927178
) O 0 0.0010055262
, O 0 0.0009786056
intracerebral B-Disease 0 0.99299663
hemorrhage I-Disease 2 0.999183
in O 0 0.000720135
22 O 0 0.0009483642
( O 0 0.00063847273
49 O 0 0.0007623669
% O 0 0.0005318951
) O 0 0.0007163484
, O 0 0.0006555388
and O 0 0.0009426811
subarachnoid B-Disease 0 0.9977463
hemorrhage I-Disease 2 0.99899405
in O 0 0.0015127772
13 O 0 0.0020347221
( O 0 0.0021838662
29 O 0 0.0036634004
% O 0 0.0032399427
) O 0 0.005515014
. O 0 0.0051648435

These O 0 0.0042931195
data O 0 0.0026663353
indicate O 0 0.0014221666
that O 0 0.0013444946
( O 0 0.0016792845
1 O 0 0.0009055177
) O 0 0.00090676354
the O 0 0.0004230556
apparent O 0 0.0005803127
incidence O 0 0.0032416128
of O 0 0.0010787772
stroke B-Disease 2 0.99699163
related O 0 0.0004918754
to O 0 0.0005368415
cocaine B-Chemical 1 0.99943465
use O 0 0.0008942976
is O 0 0.00039479538
increasing O 0 0.00090558967
; O 0 0.0012901151
( O 0 0.0005561586
2 O 0 0.00036176102
) O 0 0.0009274026
cocaine B-Chemical 1 0.9994599
- O 0 0.0014180904
associated O 0 0.0010409023
stroke B-Disease 2 0.9973687
occurs O 0 0.00046477446
primarily O 0 0.00072466035
in O 0 0.00028603344
young O 0 0.0067693377
adults O 0 0.0020716055
; O 0 0.00074238866
( O 0 0.0004002511
3 O 0 0.00023610317
) O 0 0.0005505203
stroke B-Disease 2 0.98072916
may O 0 0.0002586335
follow O 0 0.00020828562
any O 0 0.0001838319
route O 0 0.0010449109
of O 0 0.0006861453
cocaine B-Chemical 1 0.999699
administration O 0 0.61900896
; O 0 0.0025870588
( O 0 0.0005405191
4 O 0 0.00025785097
) O 0 0.0005917523
stroke B-Disease 2 0.98640776
after O 0 0.00023846052
cocaine B-Chemical 1 0.999405
use O 0 0.00057845796
is O 0 0.00029132064
frequently O 0 0.00060587557
associated O 0 0.0005180249
with O 0 0.0008989508
intracranial B-Disease 0 0.9979358
aneurysms I-Disease 2 0.99928564
and O 0 0.002073349
arteriovenous B-Disease 0 0.98434806
malformations I-Disease 0 0.9974112
; O 0 0.0026023162
and O 0 0.00048483195
( O 0 0.0005175284
5 O 0 0.00025756378
) O 0 0.00045106033
in O 0 0.00032265086
cocaine B-Chemical 1 0.9994142
- O 0 0.0016025358
associated O 0 0.0013169703
stroke B-Disease 2 0.99759513
, O 0 0.00072975707
the O 0 0.0003511442
frequency O 0 0.00058938994
of O 0 0.0014147762
intracranial B-Disease 0 0.99794286
hemorrhage I-Disease 2 0.9996697
exceeds O 0 0.0015709096
that O 0 0.0015969208
of O 0 0.006150791
cerebral B-Disease 0 0.9932808
infarction I-Disease 2 0.999387
. O 0 0.013569206

A O 0 0.016439723
randomized O 0 0.005852873
comparison O 0 0.0036568723
of O 0 0.0067952243
labetalol B-Chemical 1 0.9995096
and O 0 0.030395925
nitroprusside B-Chemical 1 0.99947673
for O 0 0.012016268
induced O 0 0.07366073
hypotension B-Disease 2 0.9982576
. O 0 0.01820561

In O 0 0.0029032556
a O 0 0.0022483016
randomized O 0 0.0025282355
study O 0 0.002680228
, O 0 0.0033032354
labetalol B-Chemical 1 0.9998635
- O 0 0.014750412
induced O 0 0.0070690503
hypotension B-Disease 2 0.99976605
and O 0 0.011625304
nitroprusside B-Chemical 1 0.9999547
- O 0 0.018542208
induced O 0 0.004406064
hypotension B-Disease 2 0.99975914
were O 0 0.0004987869
compared O 0 0.00018410782
in O 0 0.0002175245
20 O 0 0.00031792253
patients O 0 0.0007685866
( O 0 0.00039122827
10 O 0 0.0002610337
in O 0 0.00019957758
each O 0 0.00017940973
group O 0 0.0005527112
) O 0 0.00079685973
scheduled O 0 0.0005453804
for O 0 0.0007260463
major O 0 0.0020824177
orthopedic O 0 0.01315759
procedures O 0 0.0058509284
. O 0 0.005648531

Each O 0 0.0021942328
patient O 0 0.002691649
was O 0 0.0013138545
subjected O 0 0.00079692696
to O 0 0.00072059967
an O 0 0.00075884
identical O 0 0.0004121442
anesthetic O 0 0.16867934
protocol O 0 0.00096234493
and O 0 0.00048285828
similar O 0 0.0003629153
drug O 0 0.28275862
- O 0 0.0010937529
induced O 0 0.00061391346
reductions B-Disease 0 0.0006600642
in I-Disease 0 0.00029931281
mean I-Disease 0 0.00030278688
arterial I-Disease 0 0.3578546
blood I-Disease 0 0.013897254
pressure I-Disease 0 0.102736026
( O 0 0.0015617196
BP O 0 0.6577833
) O 0 0.001593862
( O 0 0.0011283945
50 O 0 0.0012602073
to O 0 0.0011576794
55 O 0 0.00268926
mmHg O 0 0.011605672
) O 0 0.005472341
. O 0 0.005093899

Nitroprusside O 0 0.997262
infusion O 0 0.16172084
was O 0 0.0021184275
associated O 0 0.0016537666
with O 0 0.0011939303
a O 0 0.0009769395
significant O 0 0.0010567942
( O 0 0.0008365748
p O 0 0.00060245115
less O 0 0.0003844938
than O 0 0.00024593162
0 O 0 0.00039994734
. O 0 0.0002293173
05 O 0 0.017902238
) O 0 0.00047941212
increase B-Disease 0 0.0002617647
in I-Disease 0 0.0002745811
heart I-Disease 0 0.10758211
rate I-Disease 0 0.0003266942
and I-Disease 0 0.0004008529
cardiac I-Disease 0 0.19817597
output I-Disease 0 0.0013623193
; O 0 0.0013581353
rebound O 0 0.5888073
hypertension B-Disease 2 0.99959546
was O 0 0.00059862365
observed O 0 0.00032235504
in O 0 0.0003424263
three O 0 0.00031473156
patients O 0 0.0016001605
after O 0 0.0008894119
discontinuation O 0 0.7746847
of O 0 0.012596354
nitroprusside B-Chemical 1 0.99946004
. O 0 0.012118251

Labetalol B-Chemical 0 0.99832195
administration O 0 0.38288316
was O 0 0.003621016
not O 0 0.0023618697
associated O 0 0.0029054538
with O 0 0.0028073217
any O 0 0.0024816156
of O 0 0.004315858
these O 0 0.007173784
findings O 0 0.017095033
. O 0 0.010388222

Arterial O 0 0.9299279
PO2 B-Chemical 0 0.9781311
decreased O 0 0.021932246
in O 0 0.011431646
both O 0 0.012821601
groups O 0 0.018275863
. O 0 0.019753778

It O 0 0.009857993
was O 0 0.0050102463
concluded O 0 0.0063641556
that O 0 0.0053321314
labetalol B-Chemical 1 0.9989323
offers O 0 0.010899361
advantages O 0 0.006373872
over O 0 0.008529277
nitroprusside B-Chemical 1 0.99823594
. O 0 0.021773767

Sodium B-Chemical 0 0.9916889
status O 0 0.012291226
influences O 0 0.010357212
chronic O 0 0.9849975
amphotericin B-Chemical 1 0.99887747
B I-Chemical 1 0.98589873
nephrotoxicity B-Disease 0 0.99945575
in O 0 0.019824287
rats O 0 0.0897616
. O 0 0.013818328

The O 0 0.0047484906
nephrotoxic B-Disease 2 0.9933854
potential O 0 0.004611454
of O 0 0.004718096
amphotericin B-Chemical 1 0.99928635
B I-Chemical 1 0.891808
( O 0 0.0022708068
5 O 0 0.0006980773
mg O 0 0.21371116
/ O 0 0.0010489898
kg O 0 0.0015365852
per O 0 0.00016530075
day O 0 0.0002495076
intraperitoneally O 0 0.0016450686
for O 0 0.00020221793
3 O 0 0.00019619835
weeks O 0 0.00022551631
) O 0 0.00036925785
has O 0 0.00023148659
been O 0 0.00031587025
investigated O 0 0.0003259286
in O 0 0.0003949896
salt O 0 0.9466884
- O 0 0.001587813
depleted O 0 0.00051296834
, O 0 0.00077204814
normal O 0 0.001833909
- O 0 0.0018365993
salt O 0 0.89694357
, O 0 0.0018247057
and O 0 0.0017773523
salt O 0 0.94406706
- O 0 0.0060202996
loaded O 0 0.0047775116
rats O 0 0.015593196
. O 0 0.0061514033

In O 0 0.005000434
salt O 0 0.83641523
- O 0 0.0051905694
depleted O 0 0.001970054
rats O 0 0.0088938065
, O 0 0.0032194806
amphotericin B-Chemical 1 0.99919146
B I-Chemical 1 0.79250985
decreased O 0 0.010780992
creatinine B-Chemical 1 0.9977034
clearance O 0 0.21594867
linearly O 0 0.0021562625
with O 0 0.0007232271
time O 0 0.0005013814
, O 0 0.0007290832
with O 0 0.0006741272
an O 0 0.0008945806
85 O 0 0.0012368732
% O 0 0.0009967146
reduction O 0 0.0015814715
by O 0 0.0016171902
week O 0 0.0024559957
3 O 0 0.003459466
. O 0 0.0046527428

In O 0 0.0032192406
contrast O 0 0.0026244298
, O 0 0.002326195
in O 0 0.0012233848
normal O 0 0.002546083
- O 0 0.002319791
salt O 0 0.9098843
rats O 0 0.032543406
creatinine B-Chemical 1 0.9974038
clearance O 0 0.24190313
was O 0 0.0005879996
decreased O 0 0.0009904593
but O 0 0.0003425956
to O 0 0.00026363038
a O 0 0.0003166874
lesser O 0 0.0008911407
extent O 0 0.00017218513
at O 0 0.00013480676
week O 0 0.00019557528
2 O 0 0.00020846883
and O 0 0.00021046864
3 O 0 0.00019047887
, O 0 0.000254386
and O 0 0.00023378246
in O 0 0.00026612903
salt O 0 0.92403054
- O 0 0.0010840792
loaded O 0 0.0005062396
rats O 0 0.005226565
creatinine B-Chemical 1 0.9966365
clearance O 0 0.109800465
did O 0 0.00029637275
not O 0 0.0002078034
change O 0 0.00024504264
for O 0 0.00018785222
2 O 0 0.00023370559
weeks O 0 0.00022539291
and O 0 0.00028765845
was O 0 0.00034214824
decreased O 0 0.00083237566
by O 0 0.00070253154
43 O 0 0.0014658746
% O 0 0.0010416185
at O 0 0.0008155116
week O 0 0.0018501043
3 O 0 0.002930313
. O 0 0.0041613765

All O 0 0.0040201214
rats O 0 0.0059738397
in O 0 0.0018382943
the O 0 0.0018235545
sodium B-Chemical 0 0.99453676
- O 0 0.002687754
depleted O 0 0.0007354347
group O 0 0.000763854
had O 0 0.0005952998
histopathological O 0 0.2414153
evidence O 0 0.00062419486
of O 0 0.00068488537
patchy O 0 0.022242785
tubular O 0 0.8602225
cytoplasmic O 0 0.010158791
degeneration O 0 0.99495333
in O 0 0.0005537257
tubules O 0 0.02502013
that O 0 0.00029987842
was O 0 0.0003114081
not O 0 0.00026025565
observed O 0 0.00024211875
in O 0 0.00030337917
any O 0 0.00037150935
normal O 0 0.0015456127
- O 0 0.0018445951
salt O 0 0.88042885
or O 0 0.0017988905
salt O 0 0.96557105
- O 0 0.0072164224
loaded O 0 0.0052819354
rat O 0 0.03824297
. O 0 0.0066146594

Concentrations O 0 0.26395607
of O 0 0.007145062
amphotericin B-Chemical 1 0.9984818
B I-Chemical 1 0.73814493
in O 0 0.001685692
plasma O 0 0.021914126
were O 0 0.0007909389
not O 0 0.00051653787
significantly O 0 0.0005934329
different O 0 0.0004708184
among O 0 0.0005435373
the O 0 0.00039437777
three O 0 0.00029345817
groups O 0 0.00060660066
at O 0 0.00041613413
any O 0 0.00058080535
time O 0 0.00080801704
during O 0 0.0011677186
the O 0 0.002317622
study O 0 0.0057070055
. O 0 0.0058039357

However O 0 0.004210523
, O 0 0.002755124
at O 0 0.0010837162
the O 0 0.0009421827
end O 0 0.00058290834
of O 0 0.0008697949
3 O 0 0.00058704766
weeks O 0 0.0006235318
, O 0 0.001121081
amphotericin B-Chemical 1 0.9992391
B I-Chemical 1 0.602918
levels O 0 0.00057541433
in O 0 0.0003285636
the O 0 0.0003230328
kidneys O 0 0.018832399
and O 0 0.00044888028
liver O 0 0.6150618
were O 0 0.0003500564
significantly O 0 0.00036913482
higher O 0 0.00029887655
in O 0 0.00032875847
salt O 0 0.95534813
- O 0 0.0011816488
depleted O 0 0.00029910487
and O 0 0.00035799763
normal O 0 0.001451394
- O 0 0.0009968755
salt O 0 0.90286404
rats O 0 0.004636581
than O 0 0.00018528367
those O 0 0.00037727447
in O 0 0.00029445672
salt O 0 0.94813323
- O 0 0.0012016852
loaded O 0 0.0004817927
rats O 0 0.002226141
, O 0 0.00038258865
with O 0 0.00037463612
plasma O 0 0.030863483
/ O 0 0.0013443909
kidney O 0 0.5198719
ratios O 0 0.0004159943
of O 0 0.00040751733
21 O 0 0.0004506228
, O 0 0.00032629078
14 O 0 0.00027884965
, O 0 0.0002691007
and O 0 0.0002365757
8 O 0 0.00024125513
in O 0 0.0002540723
salt O 0 0.889154
- O 0 0.0010509943
depleted O 0 0.00039209303
, O 0 0.0005999391
normal O 0 0.001483211
- O 0 0.0014237155
salt O 0 0.90137404
, O 0 0.0012613198
and O 0 0.0011205935
salt O 0 0.9453272
- O 0 0.0033342345
loaded O 0 0.0023007724
rats O 0 0.007813094
, O 0 0.0039643515
respectively O 0 0.007820224
. O 0 0.0055256924

In O 0 0.0030466195
conclusion O 0 0.0023275034
, O 0 0.0023062474
reductions O 0 0.0018960806
in O 0 0.0012054559
creatinine B-Chemical 1 0.99269015
clearance O 0 0.24795277
and O 0 0.0018995136
renal O 0 0.997276
amphotericin B-Chemical 1 0.9997832
B I-Chemical 1 0.9311109
accumulation O 0 0.010119134
after O 0 0.00053532876
chronic O 0 0.99196154
amphotericin B-Chemical 1 0.9998473
B I-Chemical 1 0.9460946
administration O 0 0.4412326
were O 0 0.0005699956
enhanced O 0 0.0007158475
by O 0 0.0006890081
salt O 0 0.94358677
depletion O 0 0.005790735
and O 0 0.0010476639
attenuated O 0 0.0047453344
by O 0 0.001986782
sodium B-Chemical 0 0.9964713
loading O 0 0.010872098
in O 0 0.0036686675
rats O 0 0.02136953
. O 0 0.00612326

Flestolol B-Chemical 1 0.91197044
: O 0 0.0070738825
an O 0 0.0041668853
ultra O 0 0.044570353
- O 0 0.0043059373
short O 0 0.002534612
- O 0 0.003965885
acting O 0 0.010194167
beta O 0 0.6712088
- O 0 0.017458148
adrenergic O 0 0.9923545
blocking O 0 0.0909145
agent O 0 0.62660867
. O 0 0.011666611

Flestolol B-Chemical 1 0.9570159
( O 0 0.009554448
ACC B-Chemical 0 0.8318067
- I-Chemical 0 0.0053467085
9089 I-Chemical 0 0.051044263
) O 0 0.0021996975
is O 0 0.0008956707
a O 0 0.0009893195
nonselective O 0 0.8563814
, O 0 0.0013660385
competitive O 0 0.009483796
, O 0 0.0010345506
ultra O 0 0.08129756
- O 0 0.001134392
short O 0 0.00056508585
- O 0 0.0009742944
acting O 0 0.0044810656
beta O 0 0.6453774
- O 0 0.0048956648
adrenergic O 0 0.9963905
blocking O 0 0.0166373
agent O 0 0.278523
, O 0 0.001423447
without O 0 0.0010922472
any O 0 0.0012614856
intrinsic O 0 0.0062671313
sympathomimetic O 0 0.99657226
activity O 0 0.011830639
. O 0 0.0068421443

Flestolol B-Chemical 1 0.9256614
is O 0 0.004481772
metabolized O 0 0.78230983
by O 0 0.002349613
plasma O 0 0.069430225
esterases O 0 0.87096494
and O 0 0.0012757508
has O 0 0.0008052438
an O 0 0.0009222552
elimination O 0 0.0017370335
half O 0 0.00056698296
- O 0 0.0011387803
life O 0 0.0012419772
of O 0 0.00093207497
approximately O 0 0.0011222723
6 O 0 0.00093495374
. O 0 0.0009441723
5 O 0 0.0016370448
minutes O 0 0.0028141134
. O 0 0.0042036567

This O 0 0.00584604
agent O 0 0.03497041
was O 0 0.001909947
well O 0 0.0011932157
tolerated O 0 0.007236555
in O 0 0.0008844968
healthy O 0 0.002993028
volunteers O 0 0.0019552854
at O 0 0.00047494957
doses O 0 0.005764705
up O 0 0.0007641176
to O 0 0.00076787395
100 O 0 0.0021676838
micrograms O 0 0.15132226
/ O 0 0.0040992633
kg O 0 0.011275627
/ O 0 0.0056874487
min O 0 0.005940636
. O 0 0.0054243286

In O 0 0.0030197103
long O 0 0.0027227208
- O 0 0.0023995144
term O 0 0.0014520538
infusion O 0 0.018834293
studies O 0 0.0017769716
, O 0 0.0013216472
flestolol B-Chemical 1 0.96513456
was O 0 0.0006288763
well O 0 0.00037045736
tolerated O 0 0.004763654
at O 0 0.00023235669
the O 0 0.0003139874
effective O 0 0.0009218762
beta O 0 0.46751818
- O 0 0.0014066362
blocking O 0 0.0022036226
dose O 0 0.03712333
( O 0 0.0007077428
5 O 0 0.00033921795
micrograms O 0 0.074821524
/ O 0 0.0010274012
kg O 0 0.0034133468
/ O 0 0.00098067
min O 0 0.00079832855
) O 0 0.0007856928
for O 0 0.0005161316
up O 0 0.0008667471
to O 0 0.0011476536
seven O 0 0.0020214194
days O 0 0.0035079245
. O 0 0.004876929

Flestolol B-Chemical 1 0.8867709
blood O 0 0.015409778
concentrations O 0 0.0053895363
increased O 0 0.0019708981
linearly O 0 0.0020520322
with O 0 0.00096874445
increasing O 0 0.0011051195
dose O 0 0.013276429
and O 0 0.000561623
good O 0 0.00050623354
correlation O 0 0.0002697568
exists O 0 0.00035898105
between O 0 0.00027323668
blood O 0 0.002789438
concentrations O 0 0.0021653706
of O 0 0.0013757056
flestolol B-Chemical 1 0.9889631
and O 0 0.0028880797
beta O 0 0.7631705
- O 0 0.026824668
adrenergic O 0 0.994783
blockade O 0 0.8273833
. O 0 0.009245126

Flestolol B-Chemical 1 0.82110506
produced O 0 0.004654781
a O 0 0.0038677887
dose O 0 0.03173348
- O 0 0.004052463
dependent O 0 0.0020661654
attenuation O 0 0.0059379525
of O 0 0.006049007
isoproterenol B-Chemical 1 0.9984794
- O 0 0.03436756
induced O 0 0.025950871
tachycardia B-Disease 2 0.99701786
. O 0 0.013385133

Electrophysiologic O 0 0.8902463
and O 0 0.0044050263
hemodynamic O 0 0.30257288
effects O 0 0.0037321153
of O 0 0.0024905591
flestolol B-Chemical 1 0.97274643
are O 0 0.0015754851
similar O 0 0.00091058767
to O 0 0.0010901671
those O 0 0.0017112927
of O 0 0.0023454833
other O 0 0.0041458025
beta O 0 0.82816225
blockers O 0 0.99519193
. O 0 0.0146949105

In O 0 0.0029352617
contrast O 0 0.0022706937
with O 0 0.0020135774
other O 0 0.002027809
beta O 0 0.7073758
blockers O 0 0.9983753
, O 0 0.00980277
flestolol B-Chemical 1 0.99680233
- O 0 0.0028409366
induced O 0 0.00089619355
effects O 0 0.0016215878
reverse O 0 0.017970037
rapidly O 0 0.002095785
( O 0 0.0004701085
within O 0 0.00013347829
30 O 0 0.00019576744
minutes O 0 0.00022474698
) O 0 0.00036796345
following O 0 0.00030141303
discontinuation O 0 0.21159168
because O 0 0.00033086297
of O 0 0.0006683251
its O 0 0.0013164938
short O 0 0.00112941
half O 0 0.0013742612
- O 0 0.004291039
life O 0 0.00768444
. O 0 0.0053958027

Flestolol B-Chemical 1 0.83643687
effectively O 0 0.006608107
reduced O 0 0.004263752
heart O 0 0.18823278
rate O 0 0.00286597
in O 0 0.0026723957
patients O 0 0.007843277
with O 0 0.009448779
supraventricular B-Disease 0 0.99848974
tachyarrhythmia I-Disease 0 0.9985067
. O 0 0.019794436

In O 0 0.0034406662
patients O 0 0.004824025
with O 0 0.0030309863
unstable B-Disease 0 0.43662614
angina I-Disease 0 0.99970776
, O 0 0.007285262
flestolol B-Chemical 1 0.992242
infusion O 0 0.13950342
was O 0 0.0008252261
found O 0 0.00056117837
to O 0 0.00052001
be O 0 0.0006219826
safe O 0 0.0017497927
and O 0 0.000894978
effective O 0 0.0015519097
in O 0 0.0013861358
controlling O 0 0.0032742925
chest B-Disease 0 0.65112406
pain I-Disease 0 0.9831792
. O 0 0.008976761

It O 0 0.006137839
is O 0 0.0025431905
concluded O 0 0.002704464
that O 0 0.001470812
flestolol B-Chemical 1 0.9651811
is O 0 0.0014112955
a O 0 0.0011674212
potent O 0 0.025602205
, O 0 0.0010566537
well O 0 0.00059515564
- O 0 0.0012433567
tolerated O 0 0.013602487
, O 0 0.00088087766
ultra O 0 0.06013401
- O 0 0.0012504559
short O 0 0.00076948875
- O 0 0.0015078656
acting O 0 0.0064061033
beta O 0 0.65164894
- O 0 0.01280118
adrenergic O 0 0.9940871
blocking O 0 0.07125129
agent O 0 0.6021872
. O 0 0.008487285

Use O 0 0.012246558
of O 0 0.005069434
flestolol B-Chemical 1 0.9266642
in O 0 0.0024976686
the O 0 0.0018249612
critical O 0 0.0019245151
care O 0 0.002855533
setting O 0 0.002683127
is O 0 0.0023961267
currently O 0 0.0043352586
undergoing O 0 0.007194932
investigation O 0 0.011443147
. O 0 0.008570489

Immunohistochemical O 0 0.068639934
, O 0 0.0050354013
electron O 0 0.01452402
microscopic O 0 0.007436615
and O 0 0.0018519696
morphometric O 0 0.007446145
studies O 0 0.0021972929
of O 0 0.0026897846
estrogen B-Chemical 1 0.9984712
- O 0 0.008161018
induced O 0 0.003752222
rat O 0 0.12899366
prolactinomas B-Disease 0 0.99767774
after O 0 0.0040223366
bromocriptine B-Chemical 1 0.999126
treatment O 0 0.08411819
. O 0 0.009648746

To O 0 0.0025108235
clarify O 0 0.0014477139
the O 0 0.0013788128
effects O 0 0.0021614518
of O 0 0.0021947047
bromocriptine B-Chemical 1 0.9995994
on O 0 0.0013450081
prolactinoma B-Disease 2 0.9991916
cells O 0 0.0040748892
in O 0 0.00054266525
vivo O 0 0.0010442666
, O 0 0.00056719215
immunohistochemical O 0 0.010102058
, O 0 0.0005996241
ultrastructural O 0 0.04152588
and O 0 0.00036795522
morphometrical O 0 0.040230032
analyses O 0 0.0006036311
were O 0 0.00029509916
applied O 0 0.00031376895
to O 0 0.00042198424
estrogen B-Chemical 1 0.99917173
- O 0 0.0026375717
induced O 0 0.0010968047
rat O 0 0.060552176
prolactinoma B-Disease 2 0.9994991
cells O 0 0.0020868897
1 O 0 0.00032108556
h O 0 0.00023825713
and O 0 0.00020494395
6 O 0 0.00014450052
h O 0 0.0001761988
after O 0 0.00012171319
injection O 0 0.0007309755
of O 0 0.0006661357
bromocriptine B-Chemical 1 0.99977225
( O 0 0.0013655098
3 O 0 0.00058424077
mg O 0 0.2408649
/ O 0 0.0017391563
kg O 0 0.0039884956
of O 0 0.0014803001
body O 0 0.0077392394
weight O 0 0.015898647
) O 0 0.0070542167
. O 0 0.0054576155

One O 0 0.006944449
h O 0 0.0038281642
after O 0 0.0022705866
treatment O 0 0.0054940064
, O 0 0.0050977087
serum O 0 0.16273029
prolactin O 0 0.9823356
levels O 0 0.0064840354
decreased O 0 0.0141291525
markedly O 0 0.03362569
. O 0 0.012084156

Electron O 0 0.075890005
microscopy O 0 0.0050336486
disclosed O 0 0.0051525375
many O 0 0.0023251902
secretory O 0 0.021617128
granules O 0 0.03133609
, O 0 0.0016301554
slightly O 0 0.0010912233
distorted O 0 0.005875958
rough O 0 0.0077531226
endoplasmic O 0 0.82351595
reticulum O 0 0.952296
, O 0 0.0014675424
and O 0 0.00079813914
partially O 0 0.0011832544
dilated O 0 0.8582947
Golgi O 0 0.045649923
cisternae O 0 0.066013835
in O 0 0.0016500044
the O 0 0.0030246957
prolactinoma B-Disease 2 0.9971706
cells O 0 0.016340343
. O 0 0.0073190774

Morphometric O 0 0.18990484
analysis O 0 0.003725705
revealed O 0 0.0018960959
that O 0 0.0010922212
the O 0 0.0009647842
volume O 0 0.001977838
density O 0 0.0014177954
of O 0 0.0011673855
secretory O 0 0.025024788
granules O 0 0.02743741
increased O 0 0.0016982647
, O 0 0.0009130599
while O 0 0.00050763506
the O 0 0.00054872053
volume O 0 0.0017957918
density O 0 0.0015799821
of O 0 0.0017968998
cytoplasmic O 0 0.004657711
microtubules O 0 0.21482855
decreased O 0 0.01767444
. O 0 0.0072576054

These O 0 0.0042204307
findings O 0 0.0036279438
suggest O 0 0.0013716591
that O 0 0.0012222287
lowered O 0 0.0072290087
serum O 0 0.19534305
prolactin O 0 0.9889704
levels O 0 0.00093042996
in O 0 0.00047960048
the O 0 0.00040004644
early O 0 0.0008947581
phase O 0 0.001155653
of O 0 0.001018336
bromocriptine B-Chemical 1 0.99984086
treatment O 0 0.009590977
may O 0 0.00048610524
result O 0 0.00030565707
from O 0 0.00033196306
an O 0 0.0005063279
impaired O 0 0.0012505228
secretion O 0 0.03427022
of O 0 0.0010812005
prolactin O 0 0.9856022
due O 0 0.00044935333
to O 0 0.00056479155
decreasing O 0 0.0011754037
numbers O 0 0.00097412686
of O 0 0.0021291573
cytoplasmic O 0 0.0065077553
microtubules O 0 0.2879547
. O 0 0.007042646

At O 0 0.0027296296
6 O 0 0.0018063638
h O 0 0.001502287
after O 0 0.0008857028
injection O 0 0.003002378
, O 0 0.0017295335
serum O 0 0.06866354
prolactin O 0 0.97342455
levels O 0 0.0011037266
were O 0 0.0008483494
still O 0 0.0008174384
considerably O 0 0.0013400632
lower O 0 0.0013282265
than O 0 0.0013021159
in O 0 0.002421165
controls O 0 0.006389504
. O 0 0.0062261918

The O 0 0.0044479654
prolactinoma B-Disease 2 0.99203426
cells O 0 0.0040472355
at O 0 0.00095565594
this O 0 0.00079004175
time O 0 0.0006143405
were O 0 0.000641435
well O 0 0.00057644525
granulated O 0 0.056038816
, O 0 0.0010889584
with O 0 0.0010382008
vesiculated O 0 0.29525363
rough O 0 0.010314446
endoplasmic O 0 0.82567453
reticulum O 0 0.9386733
and O 0 0.002578421
markedly O 0 0.025633987
dilated O 0 0.9622861
Golgi O 0 0.18729728
cisternae O 0 0.25791177
. O 0 0.007828105

Electron O 0 0.066813365
microscopical O 0 0.015476852
immunohistochemistry O 0 0.009978863
revealed O 0 0.0018010957
positive O 0 0.0012588517
reaction O 0 0.004275193
products O 0 0.0022274698
noted O 0 0.0007243124
on O 0 0.0003520952
the O 0 0.0005471467
secretory O 0 0.014820608
granules O 0 0.03755581
, O 0 0.0013460604
Golgi O 0 0.021195352
cisternae O 0 0.061300505
, O 0 0.0009138902
and O 0 0.0008416553
endoplasmic O 0 0.60848
reticulum O 0 0.8288038
of O 0 0.0014483966
the O 0 0.0012191869
untreated O 0 0.003740842
rat O 0 0.12423714
prolactinoma B-Disease 2 0.9979665
cells O 0 0.02152914
. O 0 0.0073909145

However O 0 0.0045212605
, O 0 0.0032224723
only O 0 0.0019126295
secretory O 0 0.009168491
granules O 0 0.009998399
showed O 0 0.0009944547
the O 0 0.0006943677
positive O 0 0.0006817133
reaction O 0 0.0034040792
products O 0 0.0019112761
for O 0 0.0007146975
prolactin O 0 0.96430624
6 O 0 0.0005136156
h O 0 0.0005578801
after O 0 0.0004897831
bromocriptine B-Chemical 1 0.99926037
treatment O 0 0.0048616235
of O 0 0.0025900146
the O 0 0.0036181186
adenoma B-Disease 0 0.99627364
cells O 0 0.026910668
. O 0 0.0078829685

An O 0 0.005554332
increase O 0 0.0021253424
in O 0 0.0013253896
the O 0 0.0010427674
volume O 0 0.0019999137
density O 0 0.0014074442
of O 0 0.001101247
secretory O 0 0.022160407
granules O 0 0.022044845
and O 0 0.0006311617
a O 0 0.00048372478
decrease O 0 0.00045783696
in O 0 0.0002598842
the O 0 0.00025371645
volume O 0 0.0007925932
densities O 0 0.00041818988
of O 0 0.00047301038
rough O 0 0.0057796817
endoplasmic O 0 0.80619806
reticulum O 0 0.9375337
and O 0 0.0006097628
microtubules O 0 0.039282102
was O 0 0.00027161906
determined O 0 0.00016476779
by O 0 0.00022647865
morphometric O 0 0.0052486816
analysis O 0 0.0006571152
, O 0 0.00042144285
suggesting O 0 0.0002507733
that O 0 0.000341722
bromocriptine B-Chemical 1 0.9998455
inhibits O 0 0.0036023655
protein O 0 0.004925186
synthesis O 0 0.052040834
as O 0 0.00030695717
well O 0 0.00028363743
as O 0 0.0002959518
bringing O 0 0.00086710975
about O 0 0.00048389036
a O 0 0.0008839672
disturbance O 0 0.07320376
of O 0 0.0019574657
the O 0 0.003074921
prolactin O 0 0.9912412
secretion O 0 0.36614594
. O 0 0.0077427253

Sulfasalazine B-Chemical 0 0.99308985
- O 0 0.068717115
induced O 0 0.10922388
lupus B-Disease 0 0.9967615
erythematosus I-Disease 0 0.9962309
. O 0 0.050561648

Pneumonitis B-Disease 0 0.98977685
, O 0 0.006133215
bilateral O 0 0.10805199
pleural B-Disease 0 0.5913208
effusions I-Disease 0 0.93651664
, O 0 0.0019876948
echocardiographic O 0 0.08435553
evidence O 0 0.00083052955
of O 0 0.0008833774
cardiac B-Disease 0 0.39529783
tamponade I-Disease 0 0.9339081
, O 0 0.00081379374
and O 0 0.00039059418
positive O 0 0.00035307117
autoantibodies O 0 0.1125442
developed O 0 0.0011311119
in O 0 0.00032540105
a O 0 0.000411661
43 O 0 0.00077248184
- O 0 0.00053114555
year O 0 0.00037019118
- O 0 0.000520623
old O 0 0.0004011341
man O 0 0.036078103
, O 0 0.00047357078
who O 0 0.0007664684
was O 0 0.0003247648
receiving O 0 0.0012210105
long O 0 0.0006975915
- O 0 0.0010191246
term O 0 0.0013091273
sulfasalazine B-Chemical 1 0.99971443
therapy O 0 0.23863508
for O 0 0.0042166132
chronic O 0 0.9971481
ulcerative B-Disease 0 0.9998116
colitis I-Disease 0 0.99967444
. O 0 0.038682397

After O 0 0.0023996867
cessation O 0 0.0049201893
of O 0 0.0021471116
the O 0 0.0017975937
sulfasalazine B-Chemical 1 0.99931073
and O 0 0.0012955668
completion O 0 0.0005458156
of O 0 0.0006484931
a O 0 0.00052698795
six O 0 0.00030083684
- O 0 0.0005371292
week O 0 0.00025750778
course O 0 0.00046910794
of O 0 0.000597106
corticosteroids O 1 0.9983529
, O 0 0.0008466682
these O 0 0.0005821233
problems O 0 0.0039557037
resolved O 0 0.00070597825
over O 0 0.00021847564
a O 0 0.00042789138
period O 0 0.00046298734
of O 0 0.00070440496
four O 0 0.0006723486
to O 0 0.0011719224
six O 0 0.001575458
months O 0 0.00389938
. O 0 0.0046680444

It O 0 0.0056474856
is O 0 0.0022249944
suggested O 0 0.0016134208
that O 0 0.0010309961
the O 0 0.000986714
patient O 0 0.0017656719
had O 0 0.0018417009
sulfasalazine B-Chemical 1 0.99981374
- O 0 0.013918495
induced O 0 0.0062420666
lupus B-Disease 0 0.99932766
, O 0 0.0023438805
which O 0 0.0011205311
manifested O 0 0.029420283
with O 0 0.0020522303
serositis B-Disease 0 0.9996209
and O 0 0.0021051355
pulmonary O 0 0.95593697
parenchymal O 0 0.95161664
involvement O 0 0.0067454046
in O 0 0.0007120998
the O 0 0.00075082394
absence O 0 0.0007906853
of O 0 0.0027264718
joint O 0 0.22627686
symptoms O 0 0.7869507
. O 0 0.007209549

Physicians O 0 0.00858391
who O 0 0.0050048097
use O 0 0.0034404094
sulfasalazine B-Chemical 1 0.9989506
to O 0 0.0017977128
treat O 0 0.007724054
patients O 0 0.0036948079
with O 0 0.0014773807
inflammatory B-Disease 0 0.9508564
bowel I-Disease 0 0.97744566
disease I-Disease 0 0.9434931
should O 0 0.0005428194
be O 0 0.0005383603
aware O 0 0.00057525013
of O 0 0.000643988
the O 0 0.0007060546
signs O 0 0.12752324
of O 0 0.0052783685
sulfasalazine B-Chemical 1 0.9998067
- O 0 0.05726719
induced O 0 0.068770915
lupus B-Disease 0 0.99936944
syndrome I-Disease 0 0.99542266
. O 0 0.013204436

Chronic O 0 0.99062
carbamazepine B-Chemical 1 0.9995365
treatment O 0 0.01819114
in O 0 0.0017066362
the O 0 0.0013197527
rat O 0 0.009123541
: O 0 0.0018177934
efficacy O 0 0.005401031
, O 0 0.0018162505
toxicity B-Disease 2 0.98905563
, O 0 0.0013070947
and O 0 0.0007705935
effect O 0 0.00086278113
on O 0 0.00062610616
plasma O 0 0.02464547
and O 0 0.00225545
tissue O 0 0.08157833
folate B-Chemical 0 0.99617505
concentrations O 0 0.09778698
. O 0 0.008276211

Folate B-Chemical 1 0.99758697
depletion O 0 0.011400622
has O 0 0.0028993285
often O 0 0.0030321477
been O 0 0.0018499716
a O 0 0.0015106027
problem O 0 0.0024338379
in O 0 0.0015389639
chronic O 0 0.9762815
antiepileptic O 0 0.99905866
drug O 0 0.9346252
( O 0 0.011499289
AED O 0 0.95776874
) O 0 0.009363283
therapy O 0 0.076866515
. O 0 0.00799334

Carbamazepine B-Chemical 1 0.9992723
( O 0 0.049002234
CBZ B-Chemical 0 0.999616
) O 0 0.008808665
, O 0 0.002180819
a O 0 0.0013225246
commonly O 0 0.0023403408
used O 0 0.001228831
AED O 0 0.8373104
, O 0 0.0015915608
has O 0 0.0010759374
been O 0 0.0013906347
implicated O 0 0.0016370923
in O 0 0.0015079697
some O 0 0.00269756
clinical O 0 0.015058265
studies O 0 0.008353124
. O 0 0.007115427

A O 0 0.017888438
rat O 0 0.008823169
model O 0 0.0027493194
was O 0 0.0014963676
developed O 0 0.0016517641
to O 0 0.00080715516
examine O 0 0.00047781126
the O 0 0.00063958473
effects O 0 0.0014148698
of O 0 0.0017473615
chronic O 0 0.9942036
CBZ B-Chemical 0 0.99992836
treatment O 0 0.040580392
on O 0 0.0014623124
folate B-Chemical 0 0.9974802
concentrations O 0 0.022709828
in O 0 0.0025597333
the O 0 0.0037660222
rat O 0 0.037605647
. O 0 0.0072067846

In O 0 0.002739748
the O 0 0.0017669615
course O 0 0.0019561844
of O 0 0.001573946
developing O 0 0.0030205732
this O 0 0.0008829184
model O 0 0.001129614
, O 0 0.0008861611
a O 0 0.00065324444
common O 0 0.0010714143
vehicle O 0 0.0382022
, O 0 0.0017262741
propylene B-Chemical 0 0.9979662
glycol I-Chemical 0 0.98151714
, O 0 0.0009558434
by O 0 0.00041765644
itself O 0 0.0005885238
in O 0 0.00027148676
high O 0 0.00051784154
doses O 0 0.035080303
, O 0 0.0005657821
was O 0 0.00031172475
found O 0 0.0002694784
to O 0 0.00027566202
exhibit O 0 0.00047333556
protective O 0 0.006030035
properties O 0 0.0015884406
against O 0 0.0008393459
induced O 0 0.0057797586
seizures B-Disease 2 0.99969184
and O 0 0.0031370495
inhibited O 0 0.010009214
weight B-Disease 0 0.051223975
gain I-Disease 0 0.013698257
. O 0 0.0063071162

Seizures B-Disease 0 0.99679166
induced O 0 0.007474441
by O 0 0.0043776873
hexafluorodiethyl B-Chemical 0 0.9891678
ether I-Chemical 0 0.99475753
( O 0 0.0052790246
HFDE B-Chemical 0 0.6365939
) O 0 0.0017480004
were O 0 0.0005835788
also O 0 0.000525882
found O 0 0.00039575325
to O 0 0.00035470809
be O 0 0.00036559696
a O 0 0.00034911177
more O 0 0.00038259028
sensitive O 0 0.00034866706
measure O 0 0.00019237603
of O 0 0.00051707576
protection O 0 0.005010037
by O 0 0.001581497
CBZ B-Chemical 0 0.99991417
than O 0 0.0014195368
seizures B-Disease 2 0.9997303
induced O 0 0.0033862763
by O 0 0.0018422785
maximal O 0 0.009707762
electroshock O 0 0.9994184
( O 0 0.02926363
MES O 0 0.99069524
) O 0 0.013772794
. O 0 0.007049538

Oral O 0 0.8273254
administration O 0 0.22542186
of O 0 0.005879892
CBZ B-Chemical 0 0.99972063
as O 0 0.0017294514
an O 0 0.0016347707
aqueous O 0 0.36548236
suspension O 0 0.005332051
every O 0 0.00030536583
8 O 0 0.00034177757
h O 0 0.0002837237
at O 0 0.00016740544
a O 0 0.00029073653
dose O 0 0.0021541836
of O 0 0.00046271586
250 O 0 0.0010734183
mg O 0 0.2544656
/ O 0 0.00089244253
kg O 0 0.0024539114
was O 0 0.00024302446
continuously O 0 0.0004117111
protective O 0 0.0042116945
against O 0 0.0005374367
HFDE B-Chemical 0 0.7966671
- O 0 0.0019193033
induced O 0 0.0017494021
seizures B-Disease 2 0.9998325
and O 0 0.00064878643
was O 0 0.0003717088
minimally O 0 0.0013775718
toxic O 0 0.54233015
as O 0 0.00030963038
measured O 0 0.00026943703
by O 0 0.00042221395
weight B-Disease 0 0.002089832
gain I-Disease 0 0.0011007147
over O 0 0.00040494566
8 O 0 0.00076031295
weeks O 0 0.0010153102
of O 0 0.002224448
treatment O 0 0.007557438
. O 0 0.0055929474

The O 0 0.0052904
CBZ B-Chemical 0 0.99899226
levels O 0 0.002759136
measured O 0 0.0011888065
in O 0 0.0010506465
plasma O 0 0.011597295
and O 0 0.0010042278
brain O 0 0.013069314
of O 0 0.00078677887
these O 0 0.000829044
animals O 0 0.00062868814
, O 0 0.00083006953
however O 0 0.0008936815
, O 0 0.0008313693
were O 0 0.00063943333
below O 0 0.00059457147
those O 0 0.0013503579
normally O 0 0.0017522641
considered O 0 0.002581476
protective O 0 0.019812675
. O 0 0.006925193

This O 0 0.005331009
treatment O 0 0.0048535075
with O 0 0.0037541701
CBZ B-Chemical 0 0.99964905
had O 0 0.0019852219
no O 0 0.0008023925
apparent O 0 0.0010620166
adverse O 0 0.5126223
effect O 0 0.00092378864
on O 0 0.00042049744
folate B-Chemical 0 0.99828535
concentrations O 0 0.010351016
in O 0 0.0004078349
the O 0 0.00038670676
rat O 0 0.0077757374
, O 0 0.00053181825
and O 0 0.00037090565
, O 0 0.00041423022
indeed O 0 0.00033656706
, O 0 0.00039708425
the O 0 0.00033819088
folate B-Chemical 0 0.9982943
concentration O 0 0.0053955014
increased O 0 0.0009371825
in O 0 0.0003464294
liver O 0 0.4741677
after O 0 0.00017841431
6 O 0 0.00016204287
weeks O 0 0.00017357658
of O 0 0.0002724251
treatment O 0 0.0007130111
and O 0 0.00041755472
in O 0 0.00041433805
plasma O 0 0.007887405
at O 0 0.000453973
8 O 0 0.0007464037
weeks O 0 0.0009720794
of O 0 0.00212449
treatment O 0 0.0073032863
. O 0 0.0053843963

Dipyridamole B-Chemical 0 0.9941508
- O 0 0.04928432
induced O 0 0.04510267
myocardial B-Disease 0 0.9927411
ischemia I-Disease 2 0.99614394
. O 0 0.04060647

Angina B-Disease 0 0.98877865
and O 0 0.0071112905
ischemic O 0 0.9958806
electrocardiographic O 0 0.96493316
changes O 0 0.0026612266
occurred O 0 0.0011817924
after O 0 0.0005038328
administration O 0 0.03043685
of O 0 0.0011951533
oral O 0 0.5762567
dipyridamole B-Chemical 0 0.99952054
in O 0 0.0009557775
four O 0 0.0006585271
patients O 0 0.0028368658
awaiting O 0 0.017026123
urgent O 0 0.015291801
myocardial O 0 0.9966543
revascularization O 0 0.8063159
procedures O 0 0.009534163
. O 0 0.0066906447

To O 0 0.0024572148
our O 0 0.0017199196
knowledge O 0 0.0021624395
, O 0 0.0014774377
this O 0 0.000813962
has O 0 0.00069936644
not O 0 0.0005513918
previously O 0 0.00057605724
been O 0 0.0005800942
reported O 0 0.0006111457
as O 0 0.00029669926
a O 0 0.00042006333
side O 0 0.0039151735
effect O 0 0.00040795383
of O 0 0.0004927555
preoperative O 0 0.116097435
dipyridamole B-Chemical 0 0.9998048
therapy O 0 0.24698235
, O 0 0.0013779456
although O 0 0.00084587303
dipyridamole B-Chemical 0 0.9998155
- O 0 0.005457833
induced O 0 0.0026015316
myocardial B-Disease 0 0.9994992
ischemia I-Disease 2 0.99984133
has O 0 0.0010923768
been O 0 0.0006421431
demonstrated O 0 0.0003991602
to O 0 0.00030603644
occur O 0 0.0004196665
in O 0 0.00032197236
animals O 0 0.0004025547
and O 0 0.00066286296
humans O 0 0.0027460388
with O 0 0.002080041
coronary B-Disease 0 0.8557808
artery I-Disease 0 0.7892773
disease I-Disease 0 0.881011
. O 0 0.007876781

Epicardial O 0 0.25519812
coronary O 0 0.40324545
collateral O 0 0.09455289
vessels O 0 0.027383873
were O 0 0.0010814669
demonstrated O 0 0.00079002115
in O 0 0.00049543654
all O 0 0.0003941961
four O 0 0.00034566913
patients O 0 0.0015948481
; O 0 0.0009220558
a O 0 0.0006071878
coronary O 0 0.3850981
" O 0 0.00088885234
steal O 0 0.1947323
" O 0 0.0007136916
phenomenon O 0 0.0027939007
may O 0 0.0004349034
be O 0 0.00040225184
the O 0 0.00036241816
mechanism O 0 0.0006916063
of O 0 0.0009071965
the O 0 0.0014972904
dipyridamole B-Chemical 0 0.99947554
- O 0 0.01657893
induced O 0 0.016346468
ischemia B-Disease 2 0.9987503
observed O 0 0.0068431585
. O 0 0.0073371697

Inhibition O 0 0.022521688
of O 0 0.007773328
sympathoadrenal O 0 0.9149906
activity O 0 0.006719609
by O 0 0.005406341
atrial O 0 0.97529024
natriuretic O 0 0.9887871
factor O 0 0.056101263
in O 0 0.007379962
dogs O 0 0.02190673
. O 0 0.010927619

In O 0 0.0027781138
six O 0 0.0016496928
conscious O 0 0.012245219
, O 0 0.0017356565
trained O 0 0.001355521
dogs O 0 0.0021024062
, O 0 0.0008902453
maintained O 0 0.0005599783
on O 0 0.00030513533
a O 0 0.00054047577
normal O 0 0.0014463003
sodium B-Chemical 0 0.99685365
intake O 0 0.73838186
of O 0 0.0007464073
2 O 0 0.00041474207
to O 0 0.00029813036
4 O 0 0.00033354387
mEq O 0 0.6378589
/ O 0 0.00079070986
kg O 0 0.002422409
/ O 0 0.0005369922
day O 0 0.00025038648
, O 0 0.00036829335
sympathetic O 0 0.4857056
activity O 0 0.00039069826
was O 0 0.00020785216
assessed O 0 0.00015953316
as O 0 0.0001678842
the O 0 0.00023442888
release O 0 0.009485122
rate O 0 0.00030749117
of O 0 0.00080766296
norepinephrine B-Chemical 1 0.99968493
and O 0 0.0010358514
epinephrine B-Chemical 0 0.99863845
during O 0 0.00029018964
15 O 0 0.00028658126
- O 0 0.00038015717
minute O 0 0.00024400356
i O 0 0.00074576517
. O 0 0.0002228579
v O 0 0.0020120698
. O 0 0.00024838423
infusions O 0 0.019656567
of O 0 0.0007892434
human O 0 0.002678875
alpha O 0 0.36453304
- O 0 0.01108577
atrial O 0 0.99051636
natriuretic O 0 0.9935464
factor O 0 0.14415982
. O 0 0.0077916686

Mean O 0 0.0039524254
arterial O 0 0.23703869
pressure O 0 0.050154876
( O 0 0.002169084
as O 0 0.0007789989
a O 0 0.00073666044
percentage O 0 0.0003785051
of O 0 0.0006861619
control O 0 0.00061039394
+ O 0 0.0009287866
/ O 0 0.0014682839
- O 0 0.00074106787
SEM O 0 0.0011839236
) O 0 0.00043980076
during O 0 0.00015835345
randomized O 0 0.00043017388
infusions O 0 0.020522257
of O 0 0.0004177082
0 O 0 0.00039683122
. O 0 0.00018541339
03 O 0 0.0049170246
, O 0 0.00032897983
0 O 0 0.00027081542
. O 0 0.00013494297
1 O 0 0.00021110577
, O 0 0.00024464953
0 O 0 0.00022107674
. O 0 0.000113563314
3 O 0 0.00015423332
, O 0 0.00021500926
or O 0 0.00015854684
1 O 0 0.00020831126
. O 0 0.000115948416
0 O 0 0.0002263299
microgram O 0 0.04637257
/ O 0 0.0006566303
kg O 0 0.0025409637
/ O 0 0.000534912
min O 0 0.0003631072
was O 0 0.00021982715
99 O 0 0.0006586588
+ O 0 0.00040408992
/ O 0 0.0007980227
- O 0 0.0005059475
1 O 0 0.00026543599
, O 0 0.00030415392
95 O 0 0.0006906317
+ O 0 0.00036306877
/ O 0 0.0007249282
- O 0 0.00047538322
1 O 0 0.0002509881
( O 0 0.00026479067
p O 0 0.00024635546
less O 0 0.00018795524
than O 0 0.00014085247
0 O 0 0.00027005578
. O 0 0.0001712618
05 O 0 0.017468467
) O 0 0.00048524688
, O 0 0.00034778102
93 O 0 0.0006797379
+ O 0 0.000440074
/ O 0 0.00085848325
- O 0 0.0005207336
1 O 0 0.00026406633
( O 0 0.00027276817
p O 0 0.0002492594
less O 0 0.00018704703
than O 0 0.00013749013
0 O 0 0.00025737006
. O 0 0.0001563436
01 O 0 0.0018589142
) O 0 0.00042767078
, O 0 0.0002960333
or O 0 0.00020796
79 O 0 0.000568623
+ O 0 0.0004220371
/ O 0 0.0007997204
- O 0 0.00046192936
6 O 0 0.00017746772
% O 0 0.00024033767
( O 0 0.00023825486
p O 0 0.00023615181
less O 0 0.00018394533
than O 0 0.0001372902
0 O 0 0.00026332942
. O 0 0.00016649807
001 O 0 0.13002281
) O 0 0.00053660077
, O 0 0.00035698354
respectively O 0 0.0006775186
, O 0 0.00033190614
but O 0 0.00022277227
no O 0 0.00023308628
tachycardia B-Disease 2 0.998451
and O 0 0.00040013817
no O 0 0.00023276715
augmentation O 0 0.005120837
of O 0 0.00044361196
the O 0 0.0005073553
norepinephrine B-Chemical 1 0.9996997
release O 0 0.104407586
rate O 0 0.00046553422
( O 0 0.00046582593
up O 0 0.00022864921
to O 0 0.00020158822
0 O 0 0.00025565253
. O 0 0.00011906592
3 O 0 0.00017265975
microgram O 0 0.05555657
/ O 0 0.0006991849
kg O 0 0.0030700893
/ O 0 0.0005915053
min O 0 0.00042975703
) O 0 0.00034876246
were O 0 0.00019484154
observed O 0 0.00018446398
, O 0 0.00033609092
which O 0 0.00036066287
is O 0 0.00028205558
in O 0 0.0002504624
contrast O 0 0.00037287292
to O 0 0.0004135577
comparable O 0 0.00065019523
hypotension B-Disease 2 0.9994167
induced O 0 0.0039527593
by O 0 0.0048444066
hydralazine B-Chemical 0 0.99978274
or O 0 0.025142865
nitroglycerin B-Chemical 1 0.999423
. O 0 0.011875303

The O 0 0.0036274923
release O 0 0.011590787
rate O 0 0.0020442915
of O 0 0.0027287782
epinephrine B-Chemical 0 0.99737155
( O 0 0.002420499
control O 0 0.00078928744
, O 0 0.00088067504
6 O 0 0.00041031174
. O 0 0.00027879598
7 O 0 0.00034500906
+ O 0 0.0004946678
/ O 0 0.0008662703
- O 0 0.0005373763
0 O 0 0.00029478507
. O 0 0.00013603478
6 O 0 0.00015548342
ng O 0 0.000501695
/ O 0 0.000556228
kg O 0 0.0022862765
/ O 0 0.0005544381
min O 0 0.0003960146
) O 0 0.00030137593
declined O 0 0.0003051039
immediately O 0 0.00016496285
during O 0 0.0001367081
infusions O 0 0.022900477
of O 0 0.00048712757
atrial O 0 0.9787789
natriuretic O 0 0.9940211
factor O 0 0.010548268
to O 0 0.00026283055
a O 0 0.00025093163
minimum O 0 0.00016764809
of O 0 0.0003281704
49 O 0 0.00072475494
+ O 0 0.0004530114
/ O 0 0.00085409445
- O 0 0.00043301145
5 O 0 0.00016953
% O 0 0.00017515836
of O 0 0.00019130412
control O 0 0.00019620902
( O 0 0.0003086257
p O 0 0.0002728358
less O 0 0.00019697662
than O 0 0.00013935886
0 O 0 0.00026012765
. O 0 0.00015600884
001 O 0 0.08000312
) O 0 0.0003606653
during O 0 0.0001466599
0 O 0 0.0002447013
. O 0 0.000121987636
1 O 0 0.00021223695
microgram O 0 0.05592246
/ O 0 0.00067848136
kg O 0 0.0026010706
/ O 0 0.0005231198
min O 0 0.00033844306
and O 0 0.00020693168
to O 0 0.0002127879
63 O 0 0.000560652
+ O 0 0.00041979871
/ O 0 0.0008051636
- O 0 0.00046787717
5 O 0 0.00020169377
% O 0 0.00024371965
( O 0 0.0002450321
0 O 0 0.0001957137
. O 0 9.7617056e-05
1 O 0 0.00013288014
greater O 0 0.0001306991
than O 0 0.000101256934
p O 0 0.00021395016
greater O 0 0.00017486016
than O 0 0.00014216456
0 O 0 0.00026691498
. O 0 0.00016172811
05 O 0 0.014946581
) O 0 0.00039133345
or O 0 0.00020286255
95 O 0 0.000772405
+ O 0 0.00039310782
/ O 0 0.0007518972
- O 0 0.000477824
13 O 0 0.00031531724
% O 0 0.0002741252
( O 0 0.00026385722
not O 0 0.000179567
significant O 0 0.00033164897
) O 0 0.00041128212
during O 0 0.00018691456
0 O 0 0.00031704237
. O 0 0.00016366995
3 O 0 0.00022115369
or O 0 0.00024989687
1 O 0 0.0003857362
. O 0 0.00028882525
0 O 0 0.0006849653
microgram O 0 0.06367628
/ O 0 0.002900509
kg O 0 0.0086268615
/ O 0 0.0046707876
min O 0 0.0050455504
. O 0 0.00470056

Steady O 0 0.3548249
state O 0 0.005500049
arterial O 0 0.46333775
plasma O 0 0.045425553
concentrations O 0 0.004716321
of O 0 0.0018150305
atrial O 0 0.977459
natriuretic O 0 0.9945661
factor O 0 0.022123102
were O 0 0.0007543668
39 O 0 0.0011428783
+ O 0 0.0007312705
/ O 0 0.0011461682
- O 0 0.000647775
10 O 0 0.0003587576
pg O 0 0.0037689698
/ O 0 0.00086983386
ml O 0 0.0016139338
( O 0 0.00039972813
n O 0 0.00022490174
= O 0 0.0003357172
6 O 0 0.0001483539
) O 0 0.0002511638
during O 0 0.00012636368
infusions O 0 0.01069512
of O 0 0.00035762292
saline O 0 0.06812934
and O 0 0.0004207615
284 O 0 0.009680004
+ O 0 0.00050508906
/ O 0 0.0008606936
- O 0 0.00045358308
24 O 0 0.0002472086
pg O 0 0.0033175554
/ O 0 0.00076004094
ml O 0 0.0014855921
( O 0 0.00036160555
n O 0 0.00021411647
= O 0 0.0003382108
6 O 0 0.00016192933
) O 0 0.00032635892
and O 0 0.00027856507
1520 O 0 0.011734659
+ O 0 0.0004457023
/ O 0 0.00081592327
- O 0 0.0004994698
300 O 0 0.001066294
pg O 0 0.0058435737
/ O 0 0.00084546936
ml O 0 0.0015915578
( O 0 0.00037081793
n O 0 0.00021700827
= O 0 0.0003492173
9 O 0 0.00020317768
) O 0 0.00027125468
during O 0 0.00013125013
0 O 0 0.00023891065
. O 0 0.00013424492
03 O 0 0.0017706958
and O 0 0.00022524381
0 O 0 0.00025692338
. O 0 0.00013231851
1 O 0 0.00023345393
microgram O 0 0.051490087
/ O 0 0.00075245695
kg O 0 0.0024634781
/ O 0 0.0006437246
min O 0 0.0005013407
infusions O 0 0.009855945
of O 0 0.00055972085
the O 0 0.0006296179
factor O 0 0.0046191695
. O 0 0.0009113377
( O 0 0.0021923506
ABSTRACT O 0 0.016160263
TRUNCATED O 0 0.024876246
AT O 0 0.025557304
250 O 0 0.011027567
WORDS O 0 0.019495567
) O 0 0.020410454

Inhibition O 0 0.016242163
of O 0 0.004702662
immunoreactive O 0 0.0803997
corticotropin O 0 0.9986835
- O 0 0.009638604
releasing O 0 0.04258343
factor O 0 0.017760364
secretion O 0 0.047478914
into O 0 0.0007490876
the O 0 0.0010654224
hypophysial O 0 0.5071604
- O 0 0.0027154991
portal O 0 0.10147138
circulation O 0 0.014692813
by O 0 0.0021901194
delayed O 0 0.025707496
glucocorticoid O 0 0.9732029
feedback O 0 0.015973348
. O 0 0.007875872

Nitroprusside B-Chemical 0 0.997948
- O 0 0.0150387995
induced O 0 0.008921264
hypotension B-Disease 2 0.99935895
evokes O 0 0.6883076
ACTH O 0 0.99954575
secretion O 0 0.3705753
which O 0 0.0017490891
is O 0 0.00067212567
primarily O 0 0.00090617285
mediated O 0 0.0005113008
by O 0 0.0005145045
enhanced O 0 0.00083634915
secretion O 0 0.04200322
of O 0 0.0010876101
immunoreactive O 0 0.14718774
corticotropin O 0 0.9997434
- O 0 0.007865044
releasing O 0 0.061866496
factor O 0 0.033281855
( O 0 0.002562278
irCRF O 0 0.7958372
) O 0 0.0014206917
into O 0 0.00056887674
the O 0 0.001189892
hypophysial O 0 0.49662563
- O 0 0.0052363323
portal O 0 0.22674993
circulation O 0 0.06533693
. O 0 0.006766251

Portal O 0 0.45529032
plasma O 0 0.03900616
concentrations O 0 0.006552456
of O 0 0.0026509808
neither O 0 0.0028458252
arginine B-Chemical 0 0.9323555
vasopressin I-Chemical 1 0.99828136
nor O 0 0.003671473
oxytocin B-Chemical 1 0.9953891
are O 0 0.0020061305
significantly O 0 0.002028531
altered O 0 0.0026653921
in O 0 0.0021081143
this O 0 0.0032845463
paradigm O 0 0.009668527
. O 0 0.0070893154

Application O 0 0.010252674
of O 0 0.0030415386
a O 0 0.0021565885
delayed O 0 0.0040073385
feedback O 0 0.0020275156
signal O 0 0.001180042
, O 0 0.0009862216
in O 0 0.00046752766
the O 0 0.00041431273
form O 0 0.00047892708
of O 0 0.0005591756
a O 0 0.0005754198
2 O 0 0.0004883999
- O 0 0.00060898997
h O 0 0.00042113065
systemic O 0 0.76441383
corticosterone B-Chemical 1 0.9991943
infusion O 0 0.19845429
in O 0 0.0005609008
urethane B-Chemical 0 0.9837625
- O 0 0.0012064977
anesthetized O 0 0.048005696
rats O 0 0.0013077614
with O 0 0.00033220463
pharmacological O 0 0.3024184
blockade O 0 0.24314842
of O 0 0.0012238853
glucocorticoid O 0 0.99415016
synthesis O 0 0.31058332
, O 0 0.0007613378
is O 0 0.00027196293
without O 0 0.0002492677
effect O 0 0.0002847049
on O 0 0.00014402292
the O 0 0.00025250332
resting O 0 0.0012587886
secretion O 0 0.023988903
of O 0 0.0010560433
arginine B-Chemical 0 0.9580025
vasopressin I-Chemical 1 0.9992131
and O 0 0.0020861945
oxytocin B-Chemical 1 0.9959602
at O 0 0.00064262823
any O 0 0.0011161461
corticosterone B-Chemical 1 0.9958835
feedback O 0 0.004814103
dose O 0 0.046303205
tested O 0 0.0041450625
. O 0 0.006011993

Resting O 0 0.18735357
irCRF O 0 0.57451665
levels O 0 0.0022003746
are O 0 0.0013732655
suppressed O 0 0.0012681565
only O 0 0.00074191974
at O 0 0.00042716815
the O 0 0.00050325494
highest O 0 0.000827538
corticosterone B-Chemical 1 0.99751353
infusion O 0 0.09105489
rate O 0 0.00063309073
, O 0 0.00068367075
which O 0 0.0005894118
resulted O 0 0.000483521
in O 0 0.000605845
systemic O 0 0.8916135
corticosterone B-Chemical 1 0.99844944
levels O 0 0.0012660031
of O 0 0.0016953794
40 O 0 0.0025258535
micrograms O 0 0.319998
/ O 0 0.008100298
dl O 0 0.04771658
. O 0 0.005786723

Suppression O 0 0.018036019
of O 0 0.0058969078
irCRF O 0 0.850518
secretion O 0 0.08845173
in O 0 0.0015779772
response O 0 0.0023035796
to O 0 0.0017729669
nitroprusside B-Chemical 1 0.9998981
- O 0 0.018062618
induced O 0 0.006120231
hypotension B-Disease 2 0.99976057
is O 0 0.00084027334
observed O 0 0.0003435077
and O 0 0.00039309898
occurs O 0 0.00034604798
at O 0 0.00023384267
a O 0 0.0005027796
plasma O 0 0.045367364
corticosterone B-Chemical 1 0.9970469
level O 0 0.00052070164
between O 0 0.00041651612
8 O 0 0.00080236193
- O 0 0.0013309263
12 O 0 0.0010363385
micrograms O 0 0.099020965
/ O 0 0.005989947
dl O 0 0.030471992
. O 0 0.005482817

These O 0 0.0038151972
studies O 0 0.002664007
provide O 0 0.0014818587
further O 0 0.0012110117
evidence O 0 0.0009783912
for O 0 0.0006409443
a O 0 0.0007021216
strong O 0 0.0007538763
central O 0 0.0011735428
component O 0 0.0006060323
of O 0 0.0006111638
the O 0 0.0004702324
delayed O 0 0.0022475028
feedback O 0 0.0009353804
process O 0 0.00073027716
which O 0 0.0008652518
is O 0 0.0007047175
mediated O 0 0.0008218109
by O 0 0.0012469236
modulation O 0 0.003816259
of O 0 0.0052776574
irCRF O 0 0.9505228
release O 0 0.31802192
. O 0 0.008063956

Noradrenergic O 0 0.952154
involvement O 0 0.014640606
in O 0 0.007609556
catalepsy B-Disease 2 0.99880743
induced O 0 0.0101191625
by O 0 0.0062619844
delta B-Chemical 0 0.20363967
9 I-Chemical 0 0.00833629
- I-Chemical 0 0.018716894
tetrahydrocannabinol I-Chemical 0 0.99700063
. O 0 0.014742827

In O 0 0.0027151455
order O 0 0.0014842728
to O 0 0.0011996175
elucidate O 0 0.00076757796
the O 0 0.00074236246
role O 0 0.00054607453
of O 0 0.0008502076
the O 0 0.0008020152
catecholaminergic O 0 0.94245964
system O 0 0.0012494035
in O 0 0.0004668728
the O 0 0.00053490314
cataleptogenic O 0 0.9984419
effect O 0 0.0008410091
of O 0 0.00096258515
delta B-Chemical 0 0.21460614
9 I-Chemical 0 0.000891932
- I-Chemical 0 0.0026405999
tetrahydrocannabinol I-Chemical 0 0.9998215
( O 0 0.007769629
THC B-Chemical 0 0.999899
) O 0 0.0026236621
, O 0 0.0004370433
the O 0 0.00021710884
effect O 0 0.00029697406
of O 0 0.00041273315
pretreatment O 0 0.16828436
with O 0 0.0006928519
6 B-Chemical 0 0.0003654043
- I-Chemical 0 0.00093285454
hydroxydopamine I-Chemical 0 0.9018071
( O 0 0.00061728776
6 B-Chemical 0 0.00027766672
- I-Chemical 0 0.0007599645
OHDA I-Chemical 0 0.9593176
) O 0 0.00064685673
or O 0 0.00025559863
with O 0 0.000741082
desipramine B-Chemical 1 0.99991846
and O 0 0.000760948
6 B-Chemical 0 0.0004017952
- I-Chemical 0 0.00094838545
OHDA I-Chemical 0 0.9290851
and O 0 0.0005037608
lesions O 0 0.05238044
of O 0 0.00061038317
the O 0 0.00055249414
locus O 0 0.0009494965
coeruleus O 0 0.8652098
were O 0 0.0011547331
investigated O 0 0.0015509917
in O 0 0.0023510016
rats O 0 0.0115193175
. O 0 0.0054597743

The O 0 0.004315553
cataleptogenic O 0 0.99219126
effect O 0 0.0033979118
of O 0 0.0035530427
THC B-Chemical 0 0.9996191
was O 0 0.0018593436
significantly O 0 0.0011535684
reduced O 0 0.00074401405
in O 0 0.0004907463
rats O 0 0.0025197074
treated O 0 0.00090237655
with O 0 0.0005933752
6 B-Chemical 0 0.00038712574
- I-Chemical 0 0.0008906942
OHDA I-Chemical 0 0.9407258
and O 0 0.00036056456
in O 0 0.00024571738
rats O 0 0.0011945388
with O 0 0.00037376868
lesions O 0 0.06502699
of O 0 0.0004102396
the O 0 0.00029789968
locus O 0 0.00046527115
coeruleus O 0 0.93130225
but O 0 0.00029752954
not O 0 0.00022351097
in O 0 0.00022363589
rats O 0 0.0014807027
treated O 0 0.00075403694
with O 0 0.0011119711
desipramine B-Chemical 1 0.9999248
and O 0 0.0010121226
6 B-Chemical 0 0.0005533664
- I-Chemical 0 0.0014754441
OHDA I-Chemical 0 0.9480425
, O 0 0.0008503275
as O 0 0.0005235823
compared O 0 0.00056277856
with O 0 0.0014953065
control O 0 0.002359029
rats O 0 0.011899066
. O 0 0.005509326

On O 0 0.0039113853
the O 0 0.0021680705
contrary O 0 0.002575117
, O 0 0.002001358
the O 0 0.0013240377
cataleptogenic O 0 0.997449
effect O 0 0.0017587978
of O 0 0.00253076
haloperidol B-Chemical 1 0.99993277
was O 0 0.001145552
significantly O 0 0.0007359718
reduced O 0 0.0004954266
in O 0 0.00034410995
rats O 0 0.0027401468
treated O 0 0.0009937632
with O 0 0.001235315
desipramine B-Chemical 1 0.9999417
and O 0 0.00096399087
6 B-Chemical 0 0.00039590304
- I-Chemical 0 0.0009892402
OHDA I-Chemical 0 0.954794
but O 0 0.00028864114
not O 0 0.0002215416
in O 0 0.0002213636
rats O 0 0.0012752454
treated O 0 0.00057893846
with O 0 0.00046898142
6 B-Chemical 0 0.00035782397
- I-Chemical 0 0.0009102407
OHDA I-Chemical 0 0.91252226
or O 0 0.0003616797
in O 0 0.00039784028
rats O 0 0.0017720996
with O 0 0.00090849656
lesions O 0 0.088417456
of O 0 0.0016876165
the O 0 0.0019577716
locus O 0 0.004283243
coeruleus O 0 0.96241385
. O 0 0.006611602

These O 0 0.004046186
results O 0 0.0020477928
indicate O 0 0.0013960301
that O 0 0.00154291
noradrenergic O 0 0.9902624
neurons O 0 0.039527714
have O 0 0.00088406657
an O 0 0.0008050596
important O 0 0.00047529148
role O 0 0.0003471308
in O 0 0.00039662793
the O 0 0.0004790111
manifestation O 0 0.119588956
of O 0 0.00266202
catalepsy B-Disease 2 0.99991405
induced O 0 0.0059431167
by O 0 0.0024573058
THC B-Chemical 0 0.9998913
, O 0 0.002451275
whereas O 0 0.0009947687
dopaminergic O 0 0.9777789
neurons O 0 0.029789431
are O 0 0.00067460956
important O 0 0.0007957288
in O 0 0.0017147852
catalepsy B-Disease 2 0.99963474
induced O 0 0.011355991
by O 0 0.014291818
haloperidol B-Chemical 1 0.99957377
. O 0 0.010781993

Reversibility O 0 0.54294956
of O 0 0.008366117
captopril B-Chemical 1 0.99917275
- O 0 0.011373247
induced O 0 0.0043789176
renal B-Disease 0 0.99367404
insufficiency I-Disease 0 0.9969861
after O 0 0.00093225035
prolonged O 0 0.012030809
use O 0 0.0013129145
in O 0 0.0008845945
an O 0 0.0014908797
unusual O 0 0.005969178
case O 0 0.0025913797
of O 0 0.010581377
renovascular B-Disease 0 0.99946994
hypertension I-Disease 2 0.999453
. O 0 0.019244045

We O 0 0.003279711
report O 0 0.004364729
a O 0 0.0019721086
case O 0 0.0015021302
of O 0 0.0018271921
severe O 0 0.40781277
hypertension B-Disease 2 0.99940264
with O 0 0.0022635898
an O 0 0.0014040058
occluded O 0 0.017034119
renal O 0 0.9908742
artery O 0 0.47855866
to O 0 0.0005401856
a O 0 0.0006169816
solitary O 0 0.03236344
kidney O 0 0.73534995
, O 0 0.00084450154
who O 0 0.0012736649
developed O 0 0.0013070225
sudden B-Disease 0 0.95054466
deterioration I-Disease 0 0.38989168
of I-Disease 0 0.0016906568
renal I-Disease 0 0.9884205
function I-Disease 0 0.0022350173
following O 0 0.0017337673
treatment O 0 0.007461131
with O 0 0.009802816
captopril B-Chemical 1 0.9988165
. O 0 0.010659351

His O 0 0.013736349
renal O 0 0.90427655
function O 0 0.0028996856
remained O 0 0.0019900403
impaired O 0 0.0018337694
but O 0 0.0007181379
stable O 0 0.00072171947
during O 0 0.00035875538
2 O 0 0.00042199728
years O 0 0.0006478074
' O 0 0.00040868093
treatment O 0 0.00087107875
with O 0 0.00082287664
captopril B-Chemical 1 0.9997212
but O 0 0.0006241772
returned O 0 0.0004584855
to O 0 0.00035677824
pre O 0 0.0021647979
- O 0 0.00084867293
treatment O 0 0.00092872634
levels O 0 0.0005142922
soon O 0 0.000737105
after O 0 0.00050101447
cessation O 0 0.0041985447
of O 0 0.0020423874
the O 0 0.0030684376
drug O 0 0.46899265
. O 0 0.0067540803

This O 0 0.0049720947
indicates O 0 0.0022447468
reversibility O 0 0.066161126
in O 0 0.0024383455
captopril B-Chemical 1 0.9995209
- O 0 0.0067672986
induced O 0 0.0023533124
renal B-Disease 0 0.9925053
failure I-Disease 0 0.7442573
even O 0 0.00065491133
after O 0 0.0002462958
its O 0 0.00067964656
prolonged O 0 0.0046495125
use O 0 0.00048841385
and O 0 0.0003523242
suggests O 0 0.00023088064
that O 0 0.000285525
no O 0 0.00040816513
organic O 0 0.9196551
damage O 0 0.72228384
occurs O 0 0.001135891
to O 0 0.0010644585
glomerular O 0 0.9374416
arterioles O 0 0.9257899
following O 0 0.0042885626
chronic O 0 0.99146444
ACE O 0 0.99785584
inhibition O 0 0.24886715
. O 0 0.009034181

HMG O 0 0.94137263
CoA O 1 0.9831818
reductase O 0 0.9779838
inhibitors O 0 0.77151966
. O 0 0.049939584

Current O 0 0.103845656
clinical O 0 0.07139541
experience O 0 0.06038949
. O 0 0.044364307

Lovastatin B-Chemical 1 0.99830663
and O 0 0.009133496
simvastatin B-Chemical 1 0.99891245
are O 0 0.0023982408
the O 0 0.0011605446
2 O 0 0.0008566239
best O 0 0.000823452
- O 0 0.001005824
known O 0 0.0006468662
members O 0 0.00044792198
of O 0 0.0005439555
the O 0 0.00047556797
class O 0 0.0012007824
of O 0 0.0015569645
hypolipidaemic O 0 0.998451
agents O 0 0.5485032
known O 0 0.0043409844
as O 0 0.0027562655
HMG O 0 0.98973936
CoA O 1 0.9985268
reductase O 0 0.9962369
inhibitors O 0 0.80496246
. O 0 0.012208086

Clinical O 0 0.05051361
experience O 0 0.0054036365
with O 0 0.0032521621
lovastatin B-Chemical 1 0.9985672
includes O 0 0.001437565
over O 0 0.0005404578
5000 O 0 0.0017359473
patients O 0 0.0015199373
, O 0 0.00061167986
700 O 0 0.00096175243
of O 0 0.00045001775
whom O 0 0.0011387022
have O 0 0.00037693154
been O 0 0.00039508042
treated O 0 0.0004858861
for O 0 0.0002308333
2 O 0 0.00025585003
years O 0 0.00038886158
or O 0 0.00017650852
more O 0 0.00030341308
, O 0 0.00029546686
and O 0 0.00023513762
experience O 0 0.0006237227
with O 0 0.0005526195
simvastatin B-Chemical 1 0.99974185
includes O 0 0.00040123105
over O 0 0.00017101638
3500 O 0 0.0013026828
patients O 0 0.0008666331
, O 0 0.00035756375
of O 0 0.00037064534
whom O 0 0.0011871533
350 O 0 0.00082643837
have O 0 0.00042986093
been O 0 0.00058709853
treated O 0 0.0008702811
for O 0 0.000621755
18 O 0 0.0010588302
months O 0 0.0013173191
or O 0 0.0016816492
more O 0 0.0041492023
. O 0 0.0049243607

Lovastatin B-Chemical 1 0.99766785
has O 0 0.006789623
been O 0 0.005021884
marketed O 0 0.065342136
in O 0 0.002458938
the O 0 0.0023912464
United O 0 0.0038536515
States O 0 0.004461907
for O 0 0.0017940436
over O 0 0.0019286796
6 O 0 0.003161555
months O 0 0.005490714
. O 0 0.0068539553

Both O 0 0.005056766
agents O 0 0.022157814
show O 0 0.0014409559
substantial O 0 0.0016891026
clinical O 0 0.006755444
efficacy O 0 0.0064630276
, O 0 0.0010108723
with O 0 0.0006813451
reductions O 0 0.00077932
in O 0 0.00036633085
total O 0 0.00047415702
cholesterol B-Chemical 0 0.98028916
of O 0 0.00057012687
over O 0 0.00022172337
30 O 0 0.00031913177
% O 0 0.000365539
and O 0 0.00038359684
in O 0 0.00060188817
LDL O 0 0.99683964
- O 0 0.0037986992
cholesterol B-Chemical 0 0.9876803
of O 0 0.0013546938
40 O 0 0.0013422582
% O 0 0.0012208651
in O 0 0.0012213226
clinical O 0 0.0073905787
studies O 0 0.006156326
. O 0 0.0057897214

Modest O 0 0.43418467
increases O 0 0.005651635
in O 0 0.0047638263
HDL O 0 0.9937955
- O 0 0.010040992
cholesterol B-Chemical 0 0.9833266
levels O 0 0.0018442123
of O 0 0.0017578118
about O 0 0.0013970267
10 O 0 0.0017085357
% O 0 0.0018927644
are O 0 0.0019990888
also O 0 0.0033141028
reported O 0 0.0071744625
. O 0 0.007052496

Clinical O 0 0.06618934
tolerability O 0 0.21163656
of O 0 0.002379948
both O 0 0.0014872397
agents O 0 0.06385984
has O 0 0.0010318441
been O 0 0.00087196863
good O 0 0.0007919186
, O 0 0.0006382287
with O 0 0.00046481102
fewer O 0 0.0004036466
than O 0 0.0002470375
3 O 0 0.00027418975
% O 0 0.00030133774
of O 0 0.00033978606
patients O 0 0.00095759035
withdrawn O 0 0.0019772386
from O 0 0.0004600532
treatment O 0 0.0010871511
because O 0 0.0005835059
of O 0 0.0015070459
clinical O 0 0.041664742
adverse O 0 0.8575634
experiences O 0 0.041069914
. O 0 0.0063798274

Ophthalmological O 0 0.13438515
examinations O 0 0.005321907
in O 0 0.0014207141
over O 0 0.00073687814
1100 O 0 0.002685936
patients O 0 0.0017778532
treated O 0 0.0010668839
with O 0 0.00062299304
one O 0 0.00034810347
or O 0 0.0003266409
the O 0 0.0003259124
other O 0 0.00040361698
agent O 0 0.03041882
have O 0 0.00040358098
revealed O 0 0.0003757313
no O 0 0.00024251382
evidence O 0 0.00034023434
of O 0 0.0004077785
significant O 0 0.00047624114
short O 0 0.00039811517
term O 0 0.00065442274
( O 0 0.0007809459
up O 0 0.0005470896
to O 0 0.0006174663
2 O 0 0.00091347756
years O 0 0.0020857223
) O 0 0.003032909
cataractogenic O 0 0.7181925
potential O 0 0.007735732
. O 0 0.006517881

One O 0 0.0050097923
to O 0 0.002404735
2 O 0 0.0017059458
% O 0 0.0012964548
of O 0 0.0010823188
patients O 0 0.0020177613
have O 0 0.0009921853
elevations O 0 0.081523
of O 0 0.0014198986
serum O 0 0.27596733
transaminases O 0 0.9985397
to O 0 0.00071243814
greater O 0 0.00054419664
than O 0 0.0003313282
3 O 0 0.00037769033
times O 0 0.00035453722
the O 0 0.00065388466
upper O 0 0.0016028434
limit O 0 0.0024247838
of O 0 0.0035950847
normal O 0 0.009585023
. O 0 0.0064326692

These O 0 0.0076908055
episodes O 0 0.059631027
are O 0 0.004571843
asymptomatic O 0 0.04164462
and O 0 0.004040521
reversible O 0 0.11819678
when O 0 0.0032436766
therapy O 0 0.037715
is O 0 0.0075679524
discontinued O 0 0.20836948
. O 0 0.010899422

Minor O 0 0.25688857
elevations O 0 0.11219811
of O 0 0.0064523467
creatine B-Chemical 1 0.9971295
kinase O 0 0.49304315
levels O 0 0.0024839586
are O 0 0.0017961663
reported O 0 0.0020395536
in O 0 0.0012638968
about O 0 0.0013994323
5 O 0 0.0016231339
% O 0 0.0022975837
of O 0 0.0034697289
patients O 0 0.010770098
. O 0 0.007429663

Myopathy B-Disease 0 0.98837644
, O 0 0.0047646193
associated O 0 0.0024528354
in O 0 0.0011922949
some O 0 0.001188558
cases O 0 0.0019316346
with O 0 0.002138154
myoglobinuria B-Disease 0 0.99979264
, O 0 0.0017998907
and O 0 0.00059553585
in O 0 0.00035183452
2 O 0 0.0003229709
cases O 0 0.00051743275
with O 0 0.0004325288
transient O 0 0.05055391
renal B-Disease 0 0.99489033
failure I-Disease 0 0.87513006
, O 0 0.0010131786
has O 0 0.00039878517
been O 0 0.00045988438
rarely O 0 0.000715334
reported O 0 0.0007103375
with O 0 0.0009359501
lovastatin B-Chemical 1 0.99979526
, O 0 0.0013644852
especially O 0 0.0008165564
in O 0 0.00038368863
patients O 0 0.0020751979
concomitantly O 0 0.018775914
treated O 0 0.0023894815
with O 0 0.003485843
cyclosporin B-Chemical 0 0.99978083
, O 0 0.057514742
gemfibrozil B-Chemical 0 0.99972695
or O 0 0.03200004
niacin B-Chemical 0 0.9993414
. O 0 0.013164043

Lovastatin B-Chemical 1 0.99837756
and O 0 0.009697901
simvastatin B-Chemical 1 0.9990183
are O 0 0.0025558467
both O 0 0.0012729566
effective O 0 0.0016127955
and O 0 0.0009846378
well O 0 0.0007647411
- O 0 0.00148311
tolerated O 0 0.0136558395
agents O 0 0.064162254
for O 0 0.0007708476
lowering O 0 0.035565034
elevated O 0 0.009605251
levels O 0 0.0018471157
of O 0 0.0042302157
serum O 0 0.6447577
cholesterol B-Chemical 0 0.9936149
. O 0 0.009783834

As O 0 0.0020710398
wider O 0 0.0023195124
use O 0 0.0015982306
confirms O 0 0.0009849323
their O 0 0.0009805065
safety O 0 0.0019890922
profile O 0 0.0010415174
, O 0 0.0007688514
they O 0 0.00039938322
will O 0 0.00029405783
gain O 0 0.00077570364
increasing O 0 0.0005783758
importance O 0 0.00042146962
in O 0 0.00041126885
the O 0 0.00049393636
therapeutic O 0 0.005880768
approach O 0 0.0015046139
to O 0 0.0015802581
hypercholesterolaemia B-Disease 0 0.99880743
and O 0 0.0036162827
its O 0 0.00775557
consequences O 0 0.014853186
. O 0 0.006691304

Hepatic O 0 0.8969656
reactions O 0 0.020557959
associated O 0 0.007822681
with O 0 0.009423573
ketoconazole B-Chemical 1 0.9988391
in O 0 0.0077807643
the O 0 0.007731136
United O 0 0.014737059
Kingdom O 0 0.026221002
. O 0 0.011116592

Ketoconazole B-Chemical 0 0.996923
was O 0 0.0077686734
introduced O 0 0.004610062
in O 0 0.0042973347
the O 0 0.005158027
United O 0 0.009501941
Kingdom O 0 0.015250869
in O 0 0.0075251823
1981 O 0 0.026746854
. O 0 0.012424989

By O 0 0.0060658962
November O 0 0.0037163002
1984 O 0 0.0052493014
the O 0 0.0014882057
Committee O 0 0.002896081
on O 0 0.00068290846
Safety O 0 0.009598218
of O 0 0.0011504529
Medicines O 0 0.05834948
had O 0 0.00060639
received O 0 0.0006872509
82 O 0 0.00096358266
reports O 0 0.000722988
of O 0 0.0006895498
possible O 0 0.0013523753
hepatotoxicity B-Disease 2 0.99985313
associated O 0 0.0027016373
with O 0 0.0013136343
the O 0 0.0011101391
drug O 0 0.3551256
, O 0 0.0021558683
including O 0 0.0020245546
five O 0 0.0026432413
deaths B-Disease 0 0.52220106
. O 0 0.0069330544

An O 0 0.005062388
analysis O 0 0.0027721715
of O 0 0.0018007734
the O 0 0.0011386859
75 O 0 0.0013499573
cases O 0 0.001122763
that O 0 0.00047433286
had O 0 0.00053609564
been O 0 0.00052387576
adequately O 0 0.00049517496
followed O 0 0.00024929125
up O 0 0.00029757575
suggested O 0 0.00031592447
that O 0 0.00025474327
16 O 0 0.00036149938
, O 0 0.00034750032
including O 0 0.00028100933
three O 0 0.00023037929
deaths B-Disease 0 0.19721597
, O 0 0.0006090602
were O 0 0.00039713964
probably O 0 0.00067336764
related O 0 0.0004400505
to O 0 0.000678247
treatment O 0 0.0020898103
with O 0 0.0021134426
the O 0 0.003129424
drug O 0 0.4891337
. O 0 0.006846082

Of O 0 0.0051204874
the O 0 0.0022016566
remainder O 0 0.002295283
, O 0 0.001681461
48 O 0 0.0009471014
were O 0 0.0006780457
possibly O 0 0.0011322264
related O 0 0.00045801376
to O 0 0.00048402415
treatment O 0 0.001148542
, O 0 0.0005966281
five O 0 0.00028473994
were O 0 0.0004130024
unlikely O 0 0.00044240121
to O 0 0.0004823773
be O 0 0.000629221
so O 0 0.0006802272
, O 0 0.0011151002
and O 0 0.001128417
six O 0 0.0012605871
were O 0 0.0029794346
unclassifiable O 0 0.3459764
. O 0 0.0072484454

The O 0 0.00249991
mean O 0 0.0014377525
age O 0 0.0023107731
of O 0 0.0014828756
patients O 0 0.002282156
in O 0 0.0007351842
the O 0 0.0006290553
16 O 0 0.00069017266
probable O 0 0.002670696
cases O 0 0.0011395547
was O 0 0.0005870823
57 O 0 0.0009562575
. O 0 0.0003431804
9 O 0 0.00050550397
, O 0 0.0006876558
with O 0 0.0012710764
hepatotoxicity B-Disease 2 0.9997063
being O 0 0.0028380137
more O 0 0.0020763306
common O 0 0.003144493
in O 0 0.0031459539
women O 0 0.048943534
. O 0 0.0062551303

The O 0 0.0027364553
average O 0 0.0015039846
duration O 0 0.002168379
of O 0 0.0019468415
treatment O 0 0.0025969357
before O 0 0.0009411237
the O 0 0.0013319008
onset O 0 0.005514091
of O 0 0.003960972
jaundice B-Disease 2 0.99633515
was O 0 0.005107966
61 O 0 0.0077590393
days O 0 0.0055248667
. O 0 0.0067494824

None O 0 0.007858037
of O 0 0.0029077162
these O 0 0.002308556
well O 0 0.0013053691
validated O 0 0.0013742757
cases O 0 0.0018713758
occurred O 0 0.0012287034
within O 0 0.0005690604
the O 0 0.00082465186
first O 0 0.0008902276
10 O 0 0.0012946416
days O 0 0.0014470442
after O 0 0.0016971081
treatment O 0 0.0072286217
. O 0 0.0063677263

The O 0 0.0029153537
results O 0 0.0021176331
of O 0 0.0024614576
serum O 0 0.061336923
liver O 0 0.69102395
function O 0 0.0019956545
tests O 0 0.002738767
suggested O 0 0.0021775342
hepatocellular B-Disease 0 0.9997749
injury I-Disease 0 0.9971264
in O 0 0.0012701027
10 O 0 0.0009116138
( O 0 0.0007942917
63 O 0 0.00095110235
% O 0 0.0006650437
) O 0 0.0008767525
; O 0 0.0008458609
the O 0 0.0005510106
rest O 0 0.0011991669
showed O 0 0.0011597655
a O 0 0.0020918886
mixed O 0 0.005596396
pattern O 0 0.0052984054
. O 0 0.006489893

In O 0 0.0034374031
contrast O 0 0.0027351412
, O 0 0.002307021
the O 0 0.0012344996
results O 0 0.0010371282
of O 0 0.0013705186
histological O 0 0.089147985
examination O 0 0.0021075709
of O 0 0.0013782929
the O 0 0.0013575042
liver O 0 0.6345239
often O 0 0.0030896333
showed O 0 0.0020162698
evidence O 0 0.0037402287
of O 0 0.012187593
cholestasis B-Disease 2 0.99925953
. O 0 0.017354852

The O 0 0.0033383013
characteristics O 0 0.0026251052
of O 0 0.0022907604
the O 0 0.0017343707
48 O 0 0.0016851544
patients O 0 0.002681923
in O 0 0.0013038061
the O 0 0.0014733283
possible O 0 0.002253837
cases O 0 0.0044311285
were O 0 0.0037590011
similar O 0 0.004612181
. O 0 0.0074427733

Allergic O 0 0.96155965
manifestations O 0 0.67079765
such O 0 0.0070108925
as O 0 0.0068753096
rash B-Disease 2 0.9931403
and O 0 0.013349135
eosinophilia B-Disease 2 0.9917143
were O 0 0.012437687
rare O 0 0.06507796
. O 0 0.013357824

Hepatitis B-Disease 0 0.99559504
was O 0 0.0038733517
usually O 0 0.0035332157
reversible O 0 0.081772566
when O 0 0.00092030707
treatment O 0 0.0018428515
was O 0 0.00073591707
stopped O 0 0.0014753795
, O 0 0.00069202343
with O 0 0.00047711947
the O 0 0.00033507336
results O 0 0.0003388166
of O 0 0.0005986066
liver O 0 0.6304137
function O 0 0.000758167
tests O 0 0.001055647
returning O 0 0.0008781148
to O 0 0.00035183402
normal O 0 0.0006841182
after O 0 0.00025946184
an O 0 0.0005437979
average O 0 0.00036433747
of O 0 0.0009994269
3 O 0 0.0010788738
. O 0 0.0010001604
1 O 0 0.0020103382
months O 0 0.0032350696
. O 0 0.004151721

In O 0 0.002631709
two O 0 0.0014847688
of O 0 0.0016441708
the O 0 0.0011194977
three O 0 0.000732182
deaths B-Disease 0 0.16187069
probably O 0 0.0015723745
associated O 0 0.0011886582
with O 0 0.0016163143
ketoconazole B-Chemical 1 0.99987864
treatment O 0 0.010093069
the O 0 0.000586764
drug O 0 0.28022724
had O 0 0.0005395455
been O 0 0.0004497135
continued O 0 0.00043832313
after O 0 0.00020589623
the O 0 0.00035223822
onset O 0 0.0022934636
of O 0 0.0013510254
jaundice B-Disease 2 0.99809676
and O 0 0.002048163
other O 0 0.0025139137
symptoms O 0 0.7145566
of O 0 0.025811607
hepatitis B-Disease 2 0.99905807
. O 0 0.015252488

Clinical O 0 0.031625405
and O 0 0.0026548414
biochemical O 0 0.006904302
monitoring O 0 0.0016166439
at O 0 0.0006267874
regular O 0 0.000916615
intervals O 0 0.00057960564
for O 0 0.00040004114
evidence O 0 0.0006162152
of O 0 0.001270171
hepatitis B-Disease 2 0.9997286
is O 0 0.001161557
advised O 0 0.0030698837
during O 0 0.000310937
long O 0 0.00049259444
term O 0 0.0005880027
treatment O 0 0.0019162528
with O 0 0.0019622582
ketoconazole B-Chemical 1 0.9997764
to O 0 0.0015136573
prevent O 0 0.0021542974
possible O 0 0.0032112736
serious O 0 0.7135228
hepatic B-Disease 0 0.99700445
injury I-Disease 0 0.9944912
. O 0 0.0119581055

Glyburide B-Chemical 0 0.99107283
- O 0 0.070517436
induced O 0 0.07730542
hepatitis B-Disease 2 0.99380314
. O 0 0.05353911

Drug O 0 0.9595246
- O 0 0.010144306
induced O 0 0.008292767
hepatotoxicity B-Disease 2 0.9996062
, O 0 0.0043358123
although O 0 0.0015477438
common O 0 0.0020292106
, O 0 0.0015797316
has O 0 0.0011591116
been O 0 0.0015320474
reported O 0 0.0020042362
only O 0 0.0019439305
infrequently O 0 0.009877029
with O 0 0.0072398824
sulfonylureas B-Chemical 0 0.9965959
. O 0 0.010959391

For O 0 0.0047435
glyburide B-Chemical 0 0.996732
, O 0 0.00414607
a O 0 0.002013171
second O 0 0.0015423374
- O 0 0.0022118052
generation O 0 0.0022268773
sulfonylurea B-Chemical 0 0.9984862
, O 0 0.0020032949
only O 0 0.00094349874
two O 0 0.0007731849
brief O 0 0.0017154047
reports O 0 0.0032100957
of O 0 0.0069264034
hepatotoxicity B-Disease 2 0.9994105
exist O 0 0.018412095
. O 0 0.009326551

Two O 0 0.004906378
patients O 0 0.0050935824
with O 0 0.0026077798
type B-Disease 0 0.0024863477
II I-Disease 0 0.04782843
diabetes I-Disease 2 0.9964819
mellitus I-Disease 0 0.99890745
developed O 0 0.016470037
an O 0 0.00580015
acute B-Disease 0 0.9984397
hepatitis I-Disease 2 0.99993813
- I-Disease 0 0.038378827
like I-Disease 0 0.0017483208
syndrome I-Disease 0 0.7709691
soon O 0 0.0012441262
after O 0 0.00064120826
initiation O 0 0.0017846767
of O 0 0.00396081
glyburide B-Chemical 0 0.9988424
therapy O 0 0.3903778
. O 0 0.008347233

There O 0 0.0055705034
was O 0 0.0024645398
no O 0 0.0015233452
serologic O 0 0.027432049
evidence O 0 0.0016727273
of O 0 0.0019349535
viral B-Disease 0 0.43649474
infection I-Disease 2 0.8954433
, O 0 0.00154165
and O 0 0.0007208047
a O 0 0.0007416893
liver O 0 0.48276672
biopsy O 0 0.004668904
sample O 0 0.00051979563
showed O 0 0.0004886612
a O 0 0.00065095857
histologic O 0 0.16061981
pattern O 0 0.0008025338
consistent O 0 0.0009776196
with O 0 0.001907879
drug B-Disease 0 0.6424772
- I-Disease 0 0.010343898
induced I-Disease 0 0.027494935
hepatitis I-Disease 2 0.99891067
. O 0 0.014987121

Both O 0 0.0045067477
patients O 0 0.0038437995
recovered O 0 0.0013885438
quickly O 0 0.0017170502
after O 0 0.00063829136
stopping O 0 0.010006671
glyburide B-Chemical 0 0.99927956
therapy O 0 0.06216884
and O 0 0.0007589217
have O 0 0.0005331889
remained O 0 0.0006603795
well O 0 0.00036540395
for O 0 0.00038168867
a O 0 0.00059110386
follow O 0 0.0006551878
- O 0 0.0011016295
up O 0 0.0007285321
period O 0 0.0009827961
of O 0 0.0018366212
1 O 0 0.0025976223
year O 0 0.0040793833
. O 0 0.005047758

Glyburide B-Chemical 0 0.99544686
can O 0 0.005195299
produce O 0 0.0040729083
an O 0 0.006886946
acute B-Disease 0 0.99551755
hepatitis I-Disease 2 0.999757
- I-Disease 0 0.048981592
like I-Disease 0 0.005182888
illness I-Disease 0 0.8920661
in O 0 0.004025474
some O 0 0.0061264564
persons O 0 0.016396804
. O 0 0.008579652

Intracranial O 0 0.65846133
pressure O 0 0.0501055
increases O 0 0.0076848175
during O 0 0.0074987113
alfentanil B-Chemical 0 0.99675745
- O 0 0.025512986
induced O 0 0.02085387
rigidity B-Disease 2 0.97021824
. O 0 0.017845921

Intracranial O 0 0.7525514
pressure O 0 0.14438269
( O 0 0.0072639016
ICP O 0 0.9153045
) O 0 0.00398906
was O 0 0.0015512465
measured O 0 0.0011784548
during O 0 0.0017758809
alfentanil B-Chemical 0 0.998519
- O 0 0.0079758065
induced O 0 0.006215835
rigidity B-Disease 2 0.9648941
in O 0 0.005685222
rats O 0 0.02647778
. O 0 0.008171183

Ten O 0 0.008350248
rats O 0 0.0076483497
had O 0 0.0031717056
arterial O 0 0.34305948
, O 0 0.0029641264
central O 0 0.004202589
venous O 0 0.5106385
( O 0 0.0036414186
CVP O 0 0.9810626
) O 0 0.0027443916
, O 0 0.0016225623
and O 0 0.0017798318
subdural O 0 0.9866812
cannulae O 0 0.029529968
inserted O 0 0.0020032572
under O 0 0.0026309243
halothane B-Chemical 1 0.99460655
anesthesia O 0 0.6862461
. O 0 0.008845085

The O 0 0.0027949521
animals O 0 0.0019924624
were O 0 0.0016682079
mechanically O 0 0.006149922
ventilated O 0 0.0067786635
to O 0 0.0009093514
achieve O 0 0.000851469
normocarbia O 0 0.1488016
( O 0 0.0017364903
PCO2 O 0 0.93688166
= O 0 0.0014183882
42 O 0 0.0010176257
+ O 0 0.0008552448
/ O 0 0.0014327788
- O 0 0.0010381998
1 O 0 0.0006563388
mmHg O 0 0.0034716337
, O 0 0.0007398884
mean O 0 0.0006319574
+ O 0 0.0016860578
/ O 0 0.0040034847
- O 0 0.0049615623
SE O 0 0.28695637
) O 0 0.00849564
. O 0 0.006194364

Following O 0 0.0049881143
instrumentation O 0 0.011858255
, O 0 0.0041385726
halothane B-Chemical 1 0.99446183
was O 0 0.0020699995
discontinued O 0 0.0459447
and O 0 0.0018293774
alfentanil B-Chemical 0 0.99931574
( O 0 0.0023605565
125 O 0 0.00948281
mu O 0 0.07394182
/ O 0 0.0019885418
kg O 0 0.0065544615
) O 0 0.001124179
administered O 0 0.0015617945
iv O 0 0.0022942184
during O 0 0.0008438211
emergence O 0 0.0027901465
from O 0 0.0030095866
halothane B-Chemical 1 0.9961243
anesthesia O 0 0.71454716
. O 0 0.0075410786

In O 0 0.0028427271
the O 0 0.0018104323
five O 0 0.0011663052
rats O 0 0.0031306588
that O 0 0.0010118359
developed O 0 0.0022551517
somatic B-Disease 0 0.06642217
rigidity I-Disease 2 0.9965205
, O 0 0.0034719885
ICP O 0 0.98110723
and O 0 0.0011427024
CVP O 0 0.9871237
increased O 0 0.0010895961
significantly O 0 0.0005546663
above O 0 0.00025335557
baseline O 0 0.00064064044
( O 0 0.0006893097
delta O 0 0.060550746
ICP O 0 0.9595788
7 O 0 0.00038082566
. O 0 0.00019310579
5 O 0 0.00025064757
+ O 0 0.00038696543
/ O 0 0.0007614676
- O 0 0.00051518396
1 O 0 0.00027580585
. O 0 0.00015702879
0 O 0 0.00030311898
mmHg O 0 0.0019161272
, O 0 0.00041197255
delta O 0 0.023367494
CVP O 0 0.9610657
5 O 0 0.00041348892
. O 0 0.0002658759
9 O 0 0.00045404703
+ O 0 0.0006873675
/ O 0 0.001408331
- O 0 0.0012323204
1 O 0 0.00090445665
. O 0 0.0007648709
3 O 0 0.0015205975
mmHg O 0 0.009126888
) O 0 0.0047173663
. O 0 0.0045509264

These O 0 0.005406774
variables O 0 0.00405306
returned O 0 0.0028156058
to O 0 0.002152828
baseline O 0 0.0026227515
when O 0 0.0021645806
rigidity B-Disease 2 0.82176024
was O 0 0.003988181
abolished O 0 0.008237053
with O 0 0.010541682
metocurine B-Chemical 0 0.99368614
. O 0 0.013838071

In O 0 0.0030935896
five O 0 0.0018260924
rats O 0 0.0042329035
that O 0 0.0013586204
did O 0 0.0012048061
not O 0 0.0010034656
become O 0 0.0015864455
rigid O 0 0.002817997
, O 0 0.0022128609
ICP O 0 0.9310004
and O 0 0.0023105203
CVP O 0 0.96718496
did O 0 0.0015470277
not O 0 0.0014953447
change O 0 0.0025462054
following O 0 0.00530449
alfentanil B-Chemical 0 0.99673307
. O 0 0.009994996

These O 0 0.0041907206
observations O 0 0.0028158645
suggest O 0 0.0014617683
that O 0 0.0014736439
rigidity B-Disease 2 0.83886886
should O 0 0.0008182942
be O 0 0.0008313088
prevented O 0 0.0016203645
when O 0 0.0006204178
alfentanil B-Chemical 0 0.9995059
, O 0 0.0013156214
and O 0 0.0006104684
, O 0 0.00060572376
presumably O 0 0.0010245957
, O 0 0.00056162145
other O 0 0.0005395427
opiates O 0 0.9987907
, O 0 0.0007840232
are O 0 0.00036969077
used O 0 0.00029792462
in O 0 0.00029883863
the O 0 0.00042247708
anesthetic O 0 0.17642276
management O 0 0.0022237613
of O 0 0.0015256997
patients O 0 0.0064363764
with O 0 0.004480717
ICP O 0 0.982443
problems O 0 0.10419423
. O 0 0.0071733356

Verapamil B-Chemical 1 0.9988876
withdrawal O 0 0.858349
as O 0 0.0023051535
a O 0 0.0018512681
possible O 0 0.0016132456
cause O 0 0.0035291454
of O 0 0.0028520662
myocardial B-Disease 0 0.9990533
infarction I-Disease 2 0.99983966
in O 0 0.0023430646
a O 0 0.0028361196
hypertensive B-Disease 2 0.9982779
woman O 0 0.07718571
with O 0 0.001999652
a O 0 0.002437086
normal O 0 0.0069191484
coronary O 0 0.8370552
angiogram O 0 0.834708
. O 0 0.008562616

Verapamil B-Chemical 1 0.99810284
is O 0 0.006423454
an O 0 0.004515208
effective O 0 0.0043501444
and O 0 0.0033585983
relatively O 0 0.0047413683
- O 0 0.0069881636
safe O 0 0.023942342
antihypertensive O 0 0.9892413
drug O 0 0.8434847
. O 0 0.013751398

Serious O 0 0.36856502
adverse O 0 0.48748732
effects O 0 0.004335176
are O 0 0.0016770827
uncommon O 0 0.009001068
and O 0 0.00096337206
mainly O 0 0.0011865376
have O 0 0.0006805832
been O 0 0.00062383886
related O 0 0.00033923125
to O 0 0.00037063155
the O 0 0.00047220895
depression B-Disease 0 0.95523673
of O 0 0.0008569077
cardiac O 0 0.55253947
contractility O 0 0.9648452
and O 0 0.00073761726
conduction O 0 0.20471911
, O 0 0.00055854354
especially O 0 0.00047407567
when O 0 0.00022765162
the O 0 0.00036388377
drug O 0 0.124173775
is O 0 0.00062794314
combined O 0 0.0013967236
with O 0 0.0019515557
beta O 0 0.6146101
- O 0 0.0072010797
blocking O 0 0.01801092
agents O 0 0.507859
. O 0 0.0073719085

We O 0 0.0033362424
report O 0 0.00453357
a O 0 0.0020683736
case O 0 0.0015912486
in O 0 0.0011686722
which O 0 0.0021933247
myocardial B-Disease 0 0.99847704
infarction I-Disease 2 0.99982363
coincided O 0 0.007445958
with O 0 0.0009384969
the O 0 0.00048032906
introduction O 0 0.00052702334
of O 0 0.000978322
captopril B-Chemical 1 0.9997489
and O 0 0.000929718
the O 0 0.0005756623
withdrawal O 0 0.6604504
of O 0 0.0017830906
verapamil B-Chemical 0 0.99982125
in O 0 0.00087031646
a O 0 0.00092326856
previously O 0 0.0010541452
asymptomatic O 0 0.1621964
woman O 0 0.07224083
with O 0 0.00487499
severe O 0 0.8591461
hypertension B-Disease 2 0.99872154
. O 0 0.011554696

Possible O 0 0.016689423
mechanisms O 0 0.0045176665
that O 0 0.0018165843
involve O 0 0.0021439733
a O 0 0.0025715553
verapamil B-Chemical 0 0.9996463
- O 0 0.0045904634
related O 0 0.00068073696
increase O 0 0.00066309917
in O 0 0.0006139696
platelet O 0 0.7004764
and O 0 0.0009006492
/ O 0 0.0015988225
or O 0 0.0005420106
vascular O 0 0.5827506
alpha O 0 0.3059884
2 O 0 0.0012259502
- O 0 0.002457336
adrenoreceptor O 0 0.9987766
affinity O 0 0.012548974
for O 0 0.0022151067
catecholamines B-Chemical 1 0.9967361
are O 0 0.0045498554
discussed O 0 0.0051343087
. O 0 0.0062584803

Haemolytic B-Disease 0 0.9547351
- I-Disease 0 0.023408512
uraemic I-Disease 0 0.9918577
syndrome I-Disease 0 0.84808326
after O 0 0.005099252
treatment O 0 0.013282608
with O 0 0.016249295
metronidazole B-Chemical 1 0.994235
. O 0 0.02058992

This O 0 0.004357954
paper O 0 0.003226578
describes O 0 0.0021933268
the O 0 0.0012314991
clinical O 0 0.0032404575
features O 0 0.0018931301
of O 0 0.0008654745
six O 0 0.000493884
children O 0 0.0014993692
who O 0 0.0015124931
developed O 0 0.0013411351
the O 0 0.0010888412
haemolytic B-Disease 0 0.9957955
- I-Disease 0 0.016694093
uraemic I-Disease 0 0.9986947
syndrome I-Disease 0 0.926558
after O 0 0.0013307489
treatment O 0 0.0066932095
with O 0 0.008293936
metronidazole B-Chemical 1 0.99717015
. O 0 0.010033708

These O 0 0.0045925444
children O 0 0.0044053323
were O 0 0.001843004
older O 0 0.0028535337
and O 0 0.0010841583
were O 0 0.00076399156
more O 0 0.0007791359
likely O 0 0.00048355514
to O 0 0.00041523756
have O 0 0.0004462273
undergone O 0 0.00057907804
recent O 0 0.0007911398
bowel O 0 0.5683207
surgery O 0 0.0041749063
than O 0 0.0004659438
are O 0 0.00066129677
other O 0 0.00085019984
children O 0 0.0023260145
with O 0 0.0019156901
this O 0 0.0026650208
condition O 0 0.007815072
. O 0 0.00611589

While O 0 0.0037343006
the O 0 0.0022167491
involvement O 0 0.0031049661
of O 0 0.0022794476
metronidazole B-Chemical 1 0.9977714
in O 0 0.0011568273
the O 0 0.000849015
aetiology O 0 0.103505805
of O 0 0.0011425399
the O 0 0.0010669366
haemolytic B-Disease 0 0.9977187
- I-Disease 0 0.01706711
uraemic I-Disease 0 0.9993963
syndrome I-Disease 0 0.9637965
is O 0 0.00053576624
not O 0 0.00030243516
established O 0 0.0005171423
firmly O 0 0.0008392135
, O 0 0.00037524177
the O 0 0.00022450068
action O 0 0.0014454754
of O 0 0.00033307643
this O 0 0.00029280197
drug O 0 0.17252824
in O 0 0.00029844177
sensitizing O 0 0.12642634
tissues O 0 0.0036626903
to O 0 0.00041738915
oxidation O 0 0.9369633
injury O 0 0.89444757
and O 0 0.00041611964
the O 0 0.0002467866
reported O 0 0.0003974381
evidence O 0 0.00030443937
of O 0 0.0005161894
oxidation O 0 0.8777898
changes O 0 0.0009213212
in O 0 0.0002980667
the O 0 0.00044894317
haemolytic B-Disease 0 0.99725264
- I-Disease 0 0.008213321
uraemic I-Disease 0 0.99935406
syndrome I-Disease 0 0.90826035
suggest O 0 0.00029403454
a O 0 0.00035073337
possible O 0 0.00030799728
link O 0 0.00030345094
between O 0 0.00023850986
metronidazole B-Chemical 1 0.99893254
treatment O 0 0.0025349325
and O 0 0.0005377083
some O 0 0.0005778202
cases O 0 0.001094167
of O 0 0.0011058863
the O 0 0.0017830813
haemolytic B-Disease 0 0.9959286
- I-Disease 0 0.0643675
uraemic I-Disease 0 0.9982101
syndrome I-Disease 0 0.9814995
. O 0 0.009499154

Adverse O 0 0.35449824
cardiac O 0 0.116510004
effects O 0 0.0036142734
during O 0 0.0012754214
induction O 0 0.0022178476
chemotherapy O 0 0.6573657
treatment O 0 0.0046516247
with O 0 0.0021911426
cis B-Chemical 0 0.1038749
- I-Chemical 0 0.00562476
platin I-Chemical 0 0.988892
and O 0 0.0033674783
5 B-Chemical 0 0.0031970735
- I-Chemical 0 0.0084481435
fluorouracil I-Chemical 0 0.9932706
. O 0 0.009224743

Survival O 0 0.043741386
for O 0 0.002602097
patients O 0 0.003981081
with O 0 0.0021007864
advanced O 0 0.034697972
head B-Disease 0 0.032954432
and I-Disease 0 0.0020762715
neck I-Disease 0 0.6111332
carcinoma I-Disease 2 0.9990081
and O 0 0.005461367
esophageal B-Disease 0 0.99707925
carcinoma I-Disease 2 0.9996526
is O 0 0.0023140556
poor O 0 0.004930854
with O 0 0.0018399978
radiotherapy O 0 0.7027634
and O 0 0.0027345612
/ O 0 0.005163575
or O 0 0.0029318363
surgery O 0 0.015123098
. O 0 0.006331652

Obviously O 0 0.010516248
, O 0 0.0058688284
there O 0 0.0028868043
is O 0 0.0033163447
a O 0 0.003563105
need O 0 0.0032430862
for O 0 0.0038757608
effective O 0 0.010922806
chemotherapy O 0 0.8419099
. O 0 0.014453733

In O 0 0.002874662
the O 0 0.0018759988
present O 0 0.0013158545
study O 0 0.00218335
, O 0 0.0019373868
cis B-Chemical 0 0.040434837
- I-Chemical 0 0.0030946175
platin I-Chemical 0 0.9921886
( O 0 0.0014250502
80 O 0 0.0010545122
- O 0 0.00078526104
120 O 0 0.0007034752
mg O 0 0.18758065
/ O 0 0.0011833503
m2BSA O 0 0.006749172
) O 0 0.00065284607
and O 0 0.0003654926
5 B-Chemical 0 0.00032681256
- I-Chemical 0 0.0006147135
FU I-Chemical 0 0.46419048
( O 0 0.00048311005
1000 O 0 0.00068736944
mg O 0 0.22873221
/ O 0 0.0008145351
m2BSA O 0 0.002748504
daily O 0 0.0006400719
as O 0 0.00017018124
a O 0 0.00022139397
continuous O 0 0.00025700548
infusion O 0 0.0054472783
during O 0 0.00018269851
5 O 0 0.00020182805
days O 0 0.00022534735
) O 0 0.0003738612
were O 0 0.00022557047
given O 0 0.000208854
to O 0 0.00035337507
76 O 0 0.0008748811
patients O 0 0.0012451552
before O 0 0.00071633654
radiotherapy O 0 0.3256151
and O 0 0.0033174262
surgery O 0 0.017352361
. O 0 0.005626081

The O 0 0.0026976406
aim O 0 0.00205105
of O 0 0.0015844302
the O 0 0.0011271638
study O 0 0.0013888844
was O 0 0.0007467762
to O 0 0.0005620932
clarify O 0 0.0004114843
the O 0 0.000549002
incidence O 0 0.0031291412
and O 0 0.00087882165
severity O 0 0.012593804
of O 0 0.0015249099
adverse O 0 0.81398356
cardiac O 0 0.507191
effects O 0 0.00369793
to O 0 0.0017512984
this O 0 0.002612855
treatment O 0 0.009313505
. O 0 0.0062042135

Before O 0 0.004435978
treatment O 0 0.0038149322
all O 0 0.0016185151
patients O 0 0.0027700395
had O 0 0.0012479603
a O 0 0.001263495
cardiac O 0 0.0811163
evaluation O 0 0.0014517563
and O 0 0.00091859786
during O 0 0.0006946112
treatment O 0 0.002175642
serial O 0 0.003672994
ECG O 0 0.8628711
recordings O 0 0.009930912
were O 0 0.003012766
performed O 0 0.0042556375
. O 0 0.0063731414

In O 0 0.003348077
the O 0 0.0024369725
pre O 0 0.0052108583
- O 0 0.0027937058
treatment O 0 0.0022511638
evaluation O 0 0.0016768425
, O 0 0.0013470375
signs O 0 0.03274053
of O 0 0.0014152102
cardiovascular B-Disease 0 0.980843
disease I-Disease 0 0.81413865
were O 0 0.00095277344
found O 0 0.00070182123
in O 0 0.0006979619
33 O 0 0.0015906026
patients O 0 0.002845318
( O 0 0.0023070648
43 O 0 0.0036700077
% O 0 0.0035213947
) O 0 0.0058430233
. O 0 0.0054083774

During O 0 0.0034665193
treatment O 0 0.005265885
, O 0 0.0035738696
adverse O 0 0.41913965
cardiac O 0 0.24431881
effects O 0 0.002777576
were O 0 0.001062161
observed O 0 0.00076460483
in O 0 0.00091521436
14 O 0 0.0014224389
patients O 0 0.0031127096
( O 0 0.0025459402
18 O 0 0.002601174
% O 0 0.0036356119
) O 0 0.006229334
. O 0 0.0058899405

The O 0 0.0025743549
mean O 0 0.0014835832
age O 0 0.0023334203
of O 0 0.00143228
these O 0 0.0014644419
patients O 0 0.0023575178
was O 0 0.0007855285
the O 0 0.00057541236
same O 0 0.000396707
as O 0 0.000529714
for O 0 0.0005899249
the O 0 0.00078767946
entire O 0 0.0009663417
group O 0 0.002053862
, O 0 0.0028962714
64 O 0 0.0046086926
years O 0 0.006835961
. O 0 0.005744734

The O 0 0.0032729127
incidence O 0 0.007010175
of O 0 0.0039908527
cardiotoxicity B-Disease 0 0.9994986
was O 0 0.0017867949
not O 0 0.0007602123
higher O 0 0.0006080353
in O 0 0.00046700964
patients O 0 0.0012307098
with O 0 0.0006390814
signs O 0 0.0583286
of O 0 0.0010216477
cardiovascular B-Disease 0 0.9871853
disease I-Disease 0 0.83486325
than O 0 0.00038277308
in O 0 0.00038301293
those O 0 0.00058592577
without O 0 0.0005379536
in O 0 0.0005687204
the O 0 0.00085559493
pre O 0 0.0051004183
- O 0 0.0031239635
treatment O 0 0.005026968
evaluation O 0 0.0064701713
. O 0 0.005958122

The O 0 0.0035889647
most O 0 0.003861228
common O 0 0.0034308722
signs O 0 0.05743402
of O 0 0.0042858385
cardiotoxicity B-Disease 0 0.9996389
were O 0 0.0034508447
chest B-Disease 0 0.6488835
pain I-Disease 0 0.99095696
, O 0 0.0043763528
ST O 0 0.8854755
- O 0 0.004140963
T O 0 0.2906977
wave O 0 0.037981734
changes O 0 0.0035390176
and O 0 0.004122606
atrial B-Disease 0 0.9887433
fibrillation I-Disease 0 0.99825877
. O 0 0.011915358

This O 0 0.005470214
was O 0 0.0026514374
followed O 0 0.001790582
by O 0 0.0024025857
ventricular B-Disease 0 0.967681
fibrillation I-Disease 0 0.9989016
in O 0 0.0018961906
one O 0 0.0012500004
patient O 0 0.0028647603
and O 0 0.0034163892
sudden B-Disease 0 0.99496645
death I-Disease 2 0.99658644
in O 0 0.0059495745
another O 0 0.008419947
. O 0 0.0077488353

It O 0 0.00567582
is O 0 0.0022827955
concluded O 0 0.002250941
that O 0 0.0010642684
patients O 0 0.0021299152
on O 0 0.0005717106
5 B-Chemical 0 0.000690247
- I-Chemical 0 0.0010481817
FU I-Chemical 0 0.3854931
treatment O 0 0.0011008483
should O 0 0.00023919466
be O 0 0.00026654775
under O 0 0.00015837926
close O 0 0.00021044316
supervision O 0 0.00086463
and O 0 0.00029352587
that O 0 0.00021022116
the O 0 0.00025648405
treatment O 0 0.00070952025
should O 0 0.00024474564
be O 0 0.00039800207
discontinued O 0 0.011770986
if O 0 0.00049843563
chest B-Disease 0 0.31614977
pain I-Disease 0 0.9762566
or O 0 0.0023194123
tachyarrhythmia B-Disease 0 0.9980708
is O 0 0.0040253387
observed O 0 0.003707989
. O 0 0.0054792226

Death B-Disease 0 0.66131765
from O 0 0.010854196
chemotherapy O 0 0.6062635
in O 0 0.010528633
gestational B-Disease 0 0.47734135
trophoblastic I-Disease 0 0.97663945
disease I-Disease 0 0.93737644
. O 0 0.023883464

Multiple O 0 0.023731226
cytotoxic O 0 0.64801615
drug O 0 0.5590817
administration O 0 0.23932162
is O 0 0.0013083408
the O 0 0.00076345744
generally O 0 0.00096280547
accepted O 0 0.0014291361
treatment O 0 0.0012607301
of O 0 0.00083443674
patients O 0 0.0021164848
with O 0 0.0008879432
a O 0 0.0009864216
high O 0 0.0015900165
- O 0 0.00253998
risk O 0 0.029417632
stage O 0 0.007461071
of O 0 0.009367817
choriocarcinoma B-Disease 0 0.997063
. O 0 0.010888252

Based O 0 0.00831725
on O 0 0.0016310161
this O 0 0.0014876532
principle O 0 0.0020049834
a O 0 0.0013304385
27 O 0 0.0016920931
- O 0 0.0010859863
year O 0 0.0005922325
old O 0 0.0006728602
woman O 0 0.005423125
, O 0 0.0005896569
classified O 0 0.00044500388
as O 0 0.0002533981
being O 0 0.000422311
in O 0 0.00024281439
the O 0 0.00026211535
high O 0 0.000557873
- O 0 0.00078281196
risk O 0 0.012980365
group O 0 0.0007147329
( O 0 0.0007278818
Goldstein O 0 0.164337
and O 0 0.0005815599
Berkowitz O 0 0.39350015
score O 0 0.00062057516
: O 0 0.00077211397
11 O 0 0.0005772438
) O 0 0.0007575524
, O 0 0.0006136142
was O 0 0.0005525895
treated O 0 0.0012123118
with O 0 0.0015374486
multiple O 0 0.005499563
cytotoxic O 0 0.88997144
drugs O 0 0.91817516
. O 0 0.008191187

The O 0 0.0030502004
multiple O 0 0.0037724483
drug O 0 0.13751961
schema O 0 0.007986899
consisted O 0 0.001568973
of O 0 0.002068848
: O 0 0.0039291093
Etoposide B-Chemical 0 0.99888366
16 O 0 0.0015793166
. O 0 0.0006420559
213 O 0 0.013683299
, O 0 0.0020106141
Methotrexate B-Chemical 0 0.9991916
, O 0 0.00798333
Cyclophosphamide B-Chemical 1 0.9996151
, O 0 0.0073127574
Actomycin B-Chemical 0 0.9412234
- I-Chemical 0 0.009391831
D I-Chemical 0 0.8016342
, O 0 0.005172739
and O 0 0.007559566
Cisplatin B-Chemical 1 0.99795
. O 0 0.009733627

On O 0 0.0035147148
the O 0 0.0017824406
first O 0 0.0011160409
day O 0 0.0010422162
of O 0 0.0010650387
the O 0 0.00081329374
schedule O 0 0.0016320631
, O 0 0.0010545097
moderate O 0 0.0031482424
high O 0 0.0011718766
doses O 0 0.04758487
of O 0 0.0038507148
Methotrexate B-Chemical 0 0.999549
, O 0 0.020919299
Etoposide B-Chemical 0 0.9994337
and O 0 0.009812962
Cyclophosphamide B-Chemical 1 0.9992042
were O 0 0.0054838858
administered O 0 0.017735038
. O 0 0.006386517

Within O 0 0.002327924
8 O 0 0.0016149222
hours O 0 0.0009830189
after O 0 0.0005496756
initiation O 0 0.0007928126
of O 0 0.00073976716
therapy O 0 0.005174889
the O 0 0.00051845174
patient O 0 0.0009460341
died O 0 0.006675018
with O 0 0.0005421059
a O 0 0.0004822166
clinical O 0 0.004427827
picture O 0 0.0009153369
resembling O 0 0.0019188665
massive O 0 0.09899973
pulmonary B-Disease 0 0.9949768
obstruction I-Disease 0 0.99149466
due O 0 0.00047210994
to O 0 0.00050440687
choriocarcinomic O 0 0.010880239
tissue O 0 0.009199073
plugs O 0 0.003405571
, O 0 0.0011075004
probably O 0 0.0014130373
originating O 0 0.0019208468
from O 0 0.0018332885
the O 0 0.003043258
uterus O 0 0.19075221
. O 0 0.006490643

Formation O 0 0.026504874
of O 0 0.0032731844
these O 0 0.0026763934
plugs O 0 0.003837079
was O 0 0.0012923805
probably O 0 0.0013717741
due O 0 0.00055557076
to O 0 0.0005973621
extensive O 0 0.0012419802
tumor B-Disease 2 0.85122234
necrosis B-Disease 0 0.99620974
at O 0 0.0003771004
the O 0 0.00031529617
level O 0 0.00022299541
of O 0 0.00036645535
the O 0 0.00031548025
walls O 0 0.010077217
of O 0 0.0004059571
the O 0 0.00029610103
major O 0 0.0005854375
uterine O 0 0.6157473
veins O 0 0.4687901
, O 0 0.0005662523
which O 0 0.00039135604
resulted O 0 0.00025264567
in O 0 0.00020832995
an O 0 0.00030113323
open O 0 0.00023153934
exchange O 0 0.0005055727
of O 0 0.00050086767
tumor B-Disease 2 0.6434227
plugs O 0 0.0023637465
to O 0 0.00028759456
the O 0 0.00032700392
vascular O 0 0.5339045
spaces O 0 0.0042696125
; O 0 0.00080396794
decrease O 0 0.00041337442
in O 0 0.000311695
tumor B-Disease 2 0.49126792
tissue O 0 0.009961274
coherence O 0 0.047368065
secondary O 0 0.0015423388
to O 0 0.00040255298
chemotherapy O 0 0.5129554
may O 0 0.00042609248
have O 0 0.00040491472
further O 0 0.0005334472
contributed O 0 0.0012878217
to O 0 0.00067947106
the O 0 0.00093555794
formation O 0 0.0041025216
of O 0 0.004208979
tumor B-Disease 2 0.94203067
emboli O 0 0.98472416
. O 0 0.009022966

In O 0 0.0027605193
view O 0 0.0027504824
of O 0 0.0015526303
the O 0 0.0009365397
close O 0 0.0006370595
time O 0 0.00047771249
association O 0 0.00042029686
between O 0 0.00027477593
the O 0 0.0003398735
start O 0 0.00030872723
of O 0 0.0005427773
chemotherapy O 0 0.59952563
and O 0 0.00057576515
the O 0 0.00048704818
acute O 0 0.8845618
onset O 0 0.015699098
of O 0 0.0010217826
massive O 0 0.22095488
embolism B-Disease 0 0.9991555
other O 0 0.0007201778
explanations O 0 0.000626727
, O 0 0.0005541806
such O 0 0.00041275483
as O 0 0.00047450452
spontaneous O 0 0.066736974
necrosis B-Disease 2 0.9964972
, O 0 0.0016527087
must O 0 0.0006870414
be O 0 0.0010274622
considered O 0 0.0011721234
less O 0 0.0019968154
likely O 0 0.0030139845
. O 0 0.004565127

Patients O 0 0.009021226
with O 0 0.00294046
large O 0 0.002905465
pelvic B-Disease 0 0.68789196
tumor I-Disease 2 0.9395837
loads O 0 0.004476197
are O 0 0.0010766264
, O 0 0.00088877324
according O 0 0.00045648034
to O 0 0.00039512047
existing O 0 0.0006435071
classifications O 0 0.00093849417
, O 0 0.00059051445
at O 0 0.00029390334
high O 0 0.0007071535
risk O 0 0.0074415086
to O 0 0.00075688894
die O 0 0.0019509539
and O 0 0.0010246342
to O 0 0.0012030108
develop O 0 0.0031266122
drug O 0 0.46164393
resistance O 0 0.07443778
. O 0 0.0070577543

Notwithstanding O 0 0.005841051
these O 0 0.002673057
facts O 0 0.0044065095
our O 0 0.0010708133
findings O 0 0.0015455524
suggest O 0 0.00054969714
that O 0 0.00047042404
these O 0 0.0006962224
patients O 0 0.0014060511
might O 0 0.00032214305
benefit O 0 0.0007579915
from O 0 0.00031430757
relatively O 0 0.0005350768
mild O 0 0.17507206
initial O 0 0.0004953267
treatment O 0 0.0016132402
, O 0 0.00051326596
especially O 0 0.00047670372
true O 0 0.00033234974
for O 0 0.0003300923
patients O 0 0.0012754154
not O 0 0.0005469163
previously O 0 0.00078633934
exposed O 0 0.0011659802
to O 0 0.0013416837
this O 0 0.0025965797
drug O 0 0.3747157
. O 0 0.0062920214

Close O 0 0.012970856
observation O 0 0.0025024668
of O 0 0.0018813021
the O 0 0.0012114132
response O 0 0.0014677926
status O 0 0.0011118005
both O 0 0.00070079224
clinically O 0 0.026341587
and O 0 0.00070309546
with O 0 0.0009519966
beta O 0 0.6197652
- O 0 0.003636455
hCG O 0 0.9027035
values O 0 0.000402406
may O 0 0.00027619844
indicate O 0 0.00017830309
whether O 0 0.00012896137
and O 0 0.00024530376
when O 0 0.00018083712
more O 0 0.0004278773
agressive O 0 0.25468814
combination O 0 0.0032384468
chemotherapy O 0 0.7487795
should O 0 0.00045885274
be O 0 0.00065392774
started O 0 0.0011359341
. O 0 0.0007560358
( O 0 0.001918326
ABSTRACT O 0 0.012489199
TRUNCATED O 0 0.02085456
AT O 0 0.023034066
250 O 0 0.010777412
WORDS O 0 0.019252181
) O 0 0.020287035

Pulmonary O 0 0.45901835
shunt O 0 0.06757278
and O 0 0.005516126
cardiovascular O 0 0.8744616
responses O 0 0.0067219064
to O 0 0.0032949129
CPAP O 0 0.8647241
during O 0 0.0056397584
nitroprusside B-Chemical 1 0.9995696
- O 0 0.057901543
induced O 0 0.046574794
hypotension B-Disease 2 0.9982926
. O 0 0.015004991

The O 0 0.002681173
effects O 0 0.00279674
of O 0 0.0016963645
continuous O 0 0.0013983417
positive O 0 0.0012084024
airway O 0 0.10624368
pressure O 0 0.20799503
( O 0 0.0020631806
CPAP O 0 0.8637476
) O 0 0.0011741974
on O 0 0.00032122518
cardiovascular O 0 0.8380445
dynamics O 0 0.001000246
and O 0 0.00062565994
pulmonary O 0 0.79723555
shunt O 0 0.2645282
( O 0 0.0013093957
QS O 0 0.16958226
/ O 0 0.00262976
QT O 0 0.9918609
) O 0 0.0006800016
were O 0 0.00023702747
investigated O 0 0.00023335313
in O 0 0.00018856484
12 O 0 0.00016661163
dogs O 0 0.00045104677
before O 0 0.00013304639
and O 0 0.00027227477
during O 0 0.00033520052
sodium B-Chemical 1 0.99947375
nitroprusside I-Chemical 1 0.99997115
infusion O 0 0.34374633
that O 0 0.00044131305
decreased O 0 0.0010439563
mean O 0 0.0004119641
arterial O 0 0.40284094
blood O 0 0.010452442
pressure O 0 0.03813735
40 O 0 0.0012627129
- O 0 0.0015351038
50 O 0 0.0015608951
per O 0 0.0011858457
cent O 0 0.0027434232
. O 0 0.004488747

Before O 0 0.00915285
nitroprusside B-Chemical 1 0.9992399
infusion O 0 0.38091293
, O 0 0.0031914709
5 O 0 0.0012802824
cm O 0 0.0036200462
H2O B-Chemical 1 0.9271209
CPAP O 0 0.8615547
significantly O 0 0.0013523772
, O 0 0.00094889523
P O 0 0.015048629
less O 0 0.00046119394
than O 0 0.00028351822
. O 0 0.00028034006
05 O 0 0.022933457
, O 0 0.00046509603
decreased O 0 0.0008635921
arterial O 0 0.46357805
blood O 0 0.013000637
pressure O 0 0.063091785
, O 0 0.000520387
but O 0 0.00026802605
did O 0 0.0002185421
not O 0 0.00020189291
significantly O 0 0.00034407145
alter O 0 0.00040017025
heart O 0 0.19132833
rate O 0 0.00043935305
, O 0 0.0006292132
cardiac O 0 0.1444673
output O 0 0.0011707837
, O 0 0.0010171594
systemic O 0 0.81599647
vascular O 0 0.83718574
resistance O 0 0.053244323
, O 0 0.0021513512
or O 0 0.0018274082
QS O 0 0.2277536
/ O 0 0.018727867
QT O 0 0.9859621
. O 0 0.007620348

Ten O 0 0.0092382785
cm O 0 0.010294614
H2O B-Chemical 1 0.90677506
CPAP O 0 0.8208885
before O 0 0.0017021877
nitroprusside B-Chemical 1 0.9997068
infusion O 0 0.19204538
produced O 0 0.0009301299
a O 0 0.0006641589
further O 0 0.00057216553
decrease B-Disease 0 0.00061814726
in I-Disease 0 0.00044700108
arterial I-Disease 0 0.4204405
blood I-Disease 0 0.009527268
pressure I-Disease 0 0.032971185
and O 0 0.00043197622
significantly O 0 0.0005095998
increased O 0 0.00087494066
heart O 0 0.22060663
rate O 0 0.00053334096
and O 0 0.0006570939
decreased B-Disease 0 0.002911846
cardiac I-Disease 0 0.29771614
output I-Disease 0 0.0040787603
and O 0 0.0026788763
QS O 0 0.2878785
/ O 0 0.02228324
QT O 0 0.9863029
. O 0 0.008025364

Nitroprusside B-Chemical 0 0.9970477
caused O 0 0.0051693297
significant O 0 0.002799743
decreases B-Disease 0 0.0020179919
in I-Disease 0 0.0012239646
arterial I-Disease 0 0.4317179
blood I-Disease 0 0.012903656
pressure I-Disease 0 0.047551945
and O 0 0.00086069846
systemic O 0 0.80404615
vascular O 0 0.8110533
resistance O 0 0.029343633
and O 0 0.00053401163
increases O 0 0.00050600606
in O 0 0.00039470056
heart O 0 0.22016695
rate O 0 0.0004740725
, O 0 0.00058137364
but O 0 0.00037330046
did O 0 0.00035755406
not O 0 0.00039969597
change O 0 0.0007370365
cardiac O 0 0.103619516
output O 0 0.0022286612
or O 0 0.0018750794
QS O 0 0.22310933
/ O 0 0.019013168
QT O 0 0.9857529
. O 0 0.007899013

Five O 0 0.009423774
cm O 0 0.011732431
H2O B-Chemical 1 0.9237302
CPAP O 0 0.863315
during O 0 0.0026100678
nitroprusside B-Chemical 1 0.9996253
did O 0 0.0017319326
not O 0 0.00084435265
further O 0 0.0008885047
alter O 0 0.0008597505
any O 0 0.0006712206
of O 0 0.0011067705
the O 0 0.00114926
above O 0 0.0013057335
- O 0 0.0032328072
mentioned O 0 0.0022819485
variables O 0 0.00623793
. O 0 0.0063305055

However O 0 0.0053087818
, O 0 0.004064401
10 O 0 0.0026798486
cm O 0 0.0057193656
H2O B-Chemical 1 0.89852595
CPAP O 0 0.8147207
decreased O 0 0.0043965694
arterial O 0 0.5552147
blood O 0 0.016696371
pressure O 0 0.060917884
, O 0 0.0019942722
cardiac O 0 0.1291875
output O 0 0.0028902076
, O 0 0.0025260635
and O 0 0.0029376617
QS O 0 0.18362622
/ O 0 0.018798532
QT O 0 0.98298925
. O 0 0.009791561

These O 0 0.0043701623
data O 0 0.002753458
indicate O 0 0.0015400699
that O 0 0.001818529
nitroprusside B-Chemical 1 0.9996996
infusion O 0 0.25389257
rates O 0 0.001008554
that O 0 0.00051984173
decrease O 0 0.00063498
mean O 0 0.0003749598
arterial O 0 0.3417301
blood O 0 0.007873584
pressure O 0 0.027940251
by O 0 0.00045213118
40 O 0 0.00050877937
- O 0 0.00046949805
50 O 0 0.0003391873
per O 0 0.0001483515
cent O 0 0.00023539894
do O 0 0.00028457274
not O 0 0.00037320436
change O 0 0.00070946617
cardiac O 0 0.08004532
output O 0 0.0021927652
or O 0 0.0018948538
QS O 0 0.21267027
/ O 0 0.018607367
QT O 0 0.9855043
. O 0 0.00802907

During O 0 0.004596097
nitroprusside B-Chemical 1 0.999209
infusion O 0 0.19289231
low O 0 0.0022067775
levels O 0 0.0010919876
of O 0 0.0013544816
CPAP O 0 0.8371272
do O 0 0.0006474902
not O 0 0.00046862685
markedly O 0 0.0017435339
alter O 0 0.0007288591
cardiovascular O 0 0.9601837
dynamics O 0 0.0015682606
, O 0 0.00058615586
but O 0 0.0002720638
high O 0 0.00036666085
levels O 0 0.00029919588
of O 0 0.0005847034
CPAP O 0 0.9233831
( O 0 0.00072836725
10 O 0 0.00040271436
cm O 0 0.0016661467
H2O B-Chemical 1 0.9115519
) O 0 0.00072182954
, O 0 0.0003707365
while O 0 0.0002558549
decreasing O 0 0.0007531995
QS O 0 0.17810076
/ O 0 0.003506748
QT O 0 0.9922361
, O 0 0.00069215597
produce O 0 0.00041694913
marked O 0 0.0009503003
decreases B-Disease 0 0.0008773875
in I-Disease 0 0.0008004164
arterial I-Disease 0 0.5193622
blood I-Disease 0 0.019940246
pressure I-Disease 0 0.072130874
and I-Disease 0 0.00263495
cardiac I-Disease 0 0.3468141
output I-Disease 0 0.008885651
. O 0 0.0061624055

Systolic O 0 0.8695244
pressure O 0 0.029117983
variation O 0 0.0021935208
is O 0 0.0014948515
greater O 0 0.0012370817
during O 0 0.0011958515
hemorrhage B-Disease 2 0.9971644
than O 0 0.0010866796
during O 0 0.0015587311
sodium B-Chemical 1 0.99927825
nitroprusside I-Chemical 1 0.9999409
- O 0 0.058721814
induced O 0 0.018563055
hypotension B-Disease 2 0.999298
in O 0 0.004270113
ventilated O 0 0.13173291
dogs O 0 0.01864277
. O 0 0.0068336762

The O 0 0.0039512278
systolic O 0 0.30039206
pressure O 0 0.03153891
variation O 0 0.002046752
( O 0 0.0024127718
SPV O 0 0.7147889
) O 0 0.0019070057
, O 0 0.000868599
which O 0 0.0006491866
is O 0 0.00037965702
the O 0 0.00027786402
difference O 0 0.00018732903
between O 0 0.00014809285
the O 0 0.00022275209
maximal O 0 0.00035848585
and O 0 0.0002761284
minimal O 0 0.0003085701
values O 0 0.00024322195
of O 0 0.0003422791
the O 0 0.00035038384
systolic O 0 0.64455086
blood O 0 0.010574599
pressure O 0 0.07697527
( O 0 0.00078958296
SBP O 0 0.41232067
) O 0 0.00045950976
after O 0 0.00013653353
one O 0 0.00017675373
positive O 0 0.00030877933
- O 0 0.00068245246
pressure O 0 0.020497618
breath O 0 0.19380918
, O 0 0.0007240918
was O 0 0.00046302445
studied O 0 0.00071012095
in O 0 0.00062421913
ventilated O 0 0.008018292
dogs O 0 0.0029639644
subjected O 0 0.0015730239
to O 0 0.004038961
hypotension B-Disease 2 0.99789715
. O 0 0.008341578

Mean O 0 0.0039053296
arterial O 0 0.19109458
pressure O 0 0.027077781
was O 0 0.0015971663
decreased O 0 0.00175107
to O 0 0.0008670643
50 O 0 0.0012226473
mm O 0 0.0030062518
Hg O 0 0.7089203
for O 0 0.00034563025
30 O 0 0.00030290667
minutes O 0 0.0002940757
either O 0 0.0003400887
by O 0 0.00066273875
hemorrhage B-Disease 2 0.9992368
( O 0 0.00424522
HEM B-Disease 0 0.9980751
, O 0 0.000880266
n O 0 0.00037848344
= O 0 0.0005142199
7 O 0 0.00023565383
) O 0 0.00035258176
or O 0 0.00018375758
by O 0 0.00024639728
continuous O 0 0.00039481418
infusion O 0 0.023926416
of O 0 0.0019768802
sodium B-Chemical 1 0.99961
nitroprusside I-Chemical 1 0.9999616
( O 0 0.018080212
SNP B-Chemical 1 0.65429425
, O 0 0.0025698987
n O 0 0.0017653744
= O 0 0.0030467773
7 O 0 0.0023671552
) O 0 0.005156887
. O 0 0.004862745

During O 0 0.005451017
HEM B-Disease 0 0.99034226
- O 0 0.006891935
induced O 0 0.0043404857
hypotension B-Disease 2 0.9990854
the O 0 0.0015531842
cardiac O 0 0.28568953
output O 0 0.0014501964
was O 0 0.0005568749
significantly O 0 0.00056441105
lower O 0 0.00044579746
and O 0 0.00056724
systemic O 0 0.7787255
vascular O 0 0.786905
resistance O 0 0.0188656
higher O 0 0.00054907496
compared O 0 0.00032661538
with O 0 0.00067456363
that O 0 0.0006670147
in O 0 0.0010064648
the O 0 0.0017912493
SNP B-Chemical 1 0.2722351
group O 0 0.0074512316
. O 0 0.0065880865

The O 0 0.004233422
systemic O 0 0.43191713
, O 0 0.003899456
central O 0 0.004722556
venous O 0 0.45088923
, O 0 0.0026457289
pulmonary O 0 0.75243264
capillary O 0 0.20814249
wedge O 0 0.35332143
pressures O 0 0.015591043
, O 0 0.0010597744
and O 0 0.0007872217
heart O 0 0.1456463
rates O 0 0.0007935772
, O 0 0.0008937657
were O 0 0.00063984114
similar O 0 0.00062368275
in O 0 0.00093173
the O 0 0.0014073356
two O 0 0.0020636322
groups O 0 0.004963144
. O 0 0.006147198

Analysis O 0 0.008215216
of O 0 0.0035813656
the O 0 0.0026324347
respiratory O 0 0.1238311
changes O 0 0.0025199759
in O 0 0.0011424603
the O 0 0.0011847363
arterial O 0 0.3782337
pressure O 0 0.04677506
waveform O 0 0.011062083
enabled O 0 0.0019778023
differentiation O 0 0.02219504
between O 0 0.001048754
the O 0 0.0018305305
two O 0 0.002506926
groups O 0 0.0057319202
. O 0 0.0069304584

The O 0 0.00444854
SPV O 0 0.4276883
during O 0 0.0028230154
hypotension B-Disease 2 0.9981963
was O 0 0.0018929266
15 O 0 0.00095463794
. O 0 0.0005383375
7 O 0 0.0005738036
+ O 0 0.00074197305
/ O 0 0.0011656177
- O 0 0.0007168995
6 O 0 0.0002713049
. O 0 0.0001903556
7 O 0 0.00025423325
mm O 0 0.001275458
Hg O 0 0.74164253
in O 0 0.00025255512
the O 0 0.00035598257
HEM B-Disease 0 0.9940461
group O 0 0.000644342
, O 0 0.00040690188
compared O 0 0.00016048367
with O 0 0.00033085537
9 O 0 0.00030977477
. O 0 0.00017265335
1 O 0 0.00029337368
+ O 0 0.00039309188
/ O 0 0.0007583336
- O 0 0.0004863411
2 O 0 0.0002531834
. O 0 0.0001473577
0 O 0 0.00028695117
mm O 0 0.0011980941
Hg O 0 0.66592693
in O 0 0.0002338139
the O 0 0.0003148096
SNP B-Chemical 1 0.0945452
group O 0 0.0009760161
( O 0 0.001032444
P O 0 0.013679823
less O 0 0.0007565363
than O 0 0.00067336054
0 O 0 0.001492867
. O 0 0.0014108226
02 O 0 0.022149298
) O 0 0.006125843
. O 0 0.005367034

The O 0 0.0035955939
delta O 0 0.025501227
down O 0 0.0027294112
, O 0 0.0019477921
which O 0 0.0013173544
is O 0 0.0007205468
the O 0 0.00048188807
measure O 0 0.0002938983
of O 0 0.000538931
decrease O 0 0.0006082043
of O 0 0.0006855501
SBP O 0 0.37078854
after O 0 0.00023136479
a O 0 0.000392801
mechanical O 0 0.020219304
breath O 0 0.28112537
, O 0 0.0006039108
was O 0 0.00030770258
20 O 0 0.00032559226
. O 0 0.00016129245
3 O 0 0.00022403005
+ O 0 0.00035514022
/ O 0 0.0006651899
- O 0 0.0004210002
8 O 0 0.00020311784
. O 0 0.000111072106
4 O 0 0.00014060609
and O 0 0.0001780503
10 O 0 0.00021786678
. O 0 0.00013058152
1 O 0 0.00023765906
+ O 0 0.00032976267
/ O 0 0.0006445905
- O 0 0.00041124903
3 O 0 0.00018782626
. O 0 0.00012646313
8 O 0 0.00020957034
mm O 0 0.0011227477
Hg O 0 0.73996204
in O 0 0.00021338565
the O 0 0.00032690231
HEM B-Disease 0 0.994165
and O 0 0.0005601419
SNP B-Chemical 1 0.2796727
groups O 0 0.00072519743
, O 0 0.0006545347
respectively O 0 0.0012090161
, O 0 0.00058484945
during O 0 0.0005294873
hypotension B-Disease 2 0.9995802
( O 0 0.0017661914
P O 0 0.029260615
less O 0 0.00076513045
than O 0 0.00065388874
0 O 0 0.0014444578
. O 0 0.001357087
02 O 0 0.02170586
) O 0 0.0059584253
. O 0 0.005239769

It O 0 0.005815461
is O 0 0.002344798
concluded O 0 0.0023243146
that O 0 0.0010434745
increases O 0 0.0011083933
in O 0 0.00077064487
the O 0 0.0008043204
SPV O 0 0.6483854
and O 0 0.00075671467
the O 0 0.0005786593
delta O 0 0.03181052
down O 0 0.00070180785
are O 0 0.00045148857
characteristic O 0 0.0007506036
of O 0 0.0006558157
a O 0 0.0008901174
hypotensive B-Disease 2 0.9969029
state O 0 0.0013197372
due O 0 0.00045747092
to O 0 0.0006219305
a O 0 0.00097198033
predominant O 0 0.0019404625
decrease O 0 0.002598497
in O 0 0.0033703086
preload O 0 0.927375
. O 0 0.007159609

They O 0 0.008161619
are O 0 0.0032860797
thus O 0 0.0029759223
more O 0 0.0023173378
important O 0 0.0016021926
during O 0 0.0014245413
absolute O 0 0.003252935
hypovolemia B-Disease 0 0.9959602
than O 0 0.002587126
during O 0 0.0037307418
deliberate O 0 0.43564737
hypotension B-Disease 2 0.9981528
. O 0 0.013041814

Ventricular B-Disease 0 0.9844765
tachyarrhythmias I-Disease 0 0.99824333
during O 0 0.003514069
cesarean O 0 0.02858942
section O 0 0.0020672667
after O 0 0.0017412008
ritodrine B-Chemical 0 0.99724716
therapy O 0 0.13983104
: O 0 0.005939921
interaction O 0 0.0047093984
with O 0 0.008232635
anesthetics O 0 0.98532087
. O 0 0.011784215

This O 0 0.0041329064
case O 0 0.0020466093
illustrates O 0 0.0012387648
that O 0 0.0009234226
patients O 0 0.0023011041
receiving O 0 0.006537886
ritodrine B-Chemical 0 0.9990287
for O 0 0.0012026196
preterm B-Disease 0 0.93237376
labor I-Disease 0 0.6920922
may O 0 0.0007708696
risk O 0 0.021772932
interactions O 0 0.0008475912
between O 0 0.00018353241
the O 0 0.0002595284
residual O 0 0.00052605115
betamimetic O 0 0.8342143
effects O 0 0.0015732327
of O 0 0.0010602186
ritodrine B-Chemical 0 0.999342
and O 0 0.00084549835
the O 0 0.0006003189
effects O 0 0.001516587
of O 0 0.0017784737
anesthetics O 0 0.9862639
during O 0 0.0022209594
cesarean O 0 0.1295458
section O 0 0.0046177274
. O 0 0.005831796

Such O 0 0.008018017
interactions O 0 0.004333065
may O 0 0.00211273
result O 0 0.0014639259
in O 0 0.0014479347
serious O 0 0.14780721
cardiovascular B-Disease 0 0.9958515
complications I-Disease 0 0.9528313
even O 0 0.0012823762
after O 0 0.0006070142
cessation O 0 0.003994334
of O 0 0.0015353975
an O 0 0.0024430698
infusion O 0 0.073664896
of O 0 0.007832879
ritodrine B-Chemical 0 0.9975769
. O 0 0.010768494

Preoperative O 0 0.034599517
assessment O 0 0.0041269143
should O 0 0.002127638
focus O 0 0.0027218573
on O 0 0.0019891048
cardiovascular O 0 0.82949126
status O 0 0.005558608
and O 0 0.0050792177
serum O 0 0.39747608
potassium B-Chemical 0 0.99542636
level O 0 0.011038668
. O 0 0.01138667

Delaying O 0 0.016753081
induction O 0 0.006997109
of O 0 0.005820525
anesthesia O 0 0.08560755
should O 0 0.00328098
be O 0 0.0040510427
considered O 0 0.003985326
whenever O 0 0.006502815
possible O 0 0.009457784
. O 0 0.011044303

Careful O 0 0.011113537
fluid O 0 0.013854661
administration O 0 0.060117867
and O 0 0.0023010538
cautious O 0 0.0040900563
use O 0 0.001763881
of O 0 0.001891268
titrated O 0 0.0060598506
doses O 0 0.060325556
of O 0 0.006261788
ephedrine B-Chemical 1 0.99847513
are O 0 0.008629423
advised O 0 0.030005915
. O 0 0.008658009

After O 0 0.0024052488
delivery O 0 0.0027552655
of O 0 0.0019047472
the O 0 0.0013784736
infant O 0 0.0050982316
, O 0 0.0011650049
there O 0 0.00043949843
should O 0 0.0003606282
be O 0 0.0004134597
no O 0 0.00026959841
contraindication O 0 0.0006209408
to O 0 0.00029077174
the O 0 0.00028432813
use O 0 0.00039834916
of O 0 0.00048643295
an O 0 0.00081660075
alpha O 0 0.29837674
- O 0 0.0038284843
adrenergic O 0 0.99756867
vasopressor O 0 0.9965274
such O 0 0.0009515107
as O 0 0.00085609633
phenylephrine B-Chemical 1 0.9992378
to O 0 0.0012386504
treat O 0 0.051596865
hypotensive B-Disease 2 0.99795675
patients O 0 0.042453464
with O 0 0.011389981
tachycardia B-Disease 2 0.99755305
. O 0 0.009243479

Verapamil B-Chemical 1 0.9966216
- O 0 0.07252206
induced O 0 0.1076882
carbamazepine B-Chemical 1 0.9988953
neurotoxicity B-Disease 2 0.99724555
. O 0 0.043961477

A O 0 0.042907853
report O 0 0.024972852
of O 0 0.016999615
two O 0 0.016292304
cases O 0 0.031510707
. O 0 0.027262004

Two O 0 0.0047275145
patients O 0 0.004903297
with O 0 0.0025605322
signs O 0 0.078479126
of O 0 0.0043348595
carbamazepine B-Chemical 1 0.9999045
neurotoxicity B-Disease 2 0.99970156
after O 0 0.00072405004
combined O 0 0.0015836617
treatment O 0 0.0027499222
with O 0 0.0014078584
verapamil B-Chemical 0 0.99978
showed O 0 0.00079588575
complete O 0 0.00055705913
recovery O 0 0.0012138473
after O 0 0.0004418837
discontinuation O 0 0.53016466
of O 0 0.0016035013
the O 0 0.0023337353
calcium B-Chemical 1 0.9953915
entry O 0 0.06682949
blocker O 0 0.98777103
. O 0 0.010684551

Use O 0 0.011684092
of O 0 0.0047507924
verapamil B-Chemical 0 0.99904364
in O 0 0.0021420645
combination O 0 0.004300956
with O 0 0.0025008423
carbamazepine B-Chemical 1 0.99985003
should O 0 0.0006246528
either O 0 0.000515346
be O 0 0.0004154803
avoided O 0 0.0004092611
or O 0 0.00027762406
prescribed O 0 0.01175512
only O 0 0.00027171153
with O 0 0.00028647034
appropriate O 0 0.00022001062
adjustment O 0 0.00039062716
of O 0 0.00040193176
the O 0 0.0005283739
carbamazepine B-Chemical 1 0.999928
dose O 0 0.14776056
( O 0 0.0008723089
usually O 0 0.0007444311
reduction O 0 0.00078741414
of O 0 0.00067726424
the O 0 0.0010124713
carbamazepine B-Chemical 1 0.9998522
dose O 0 0.09344507
by O 0 0.0016173274
one O 0 0.0014563092
half O 0 0.0021153975
) O 0 0.0061374465
. O 0 0.0051574255

Paracetamol B-Chemical 0 0.9982419
- O 0 0.015595787
associated O 0 0.009532403
coma B-Disease 0 0.9972837
, O 0 0.012102062
metabolic B-Disease 2 0.96740216
acidosis I-Disease 2 0.9994436
, O 0 0.022885563
renal B-Disease 0 0.9909739
and I-Disease 0 0.011187512
hepatic I-Disease 0 0.98717356
failure I-Disease 0 0.93428797
. O 0 0.013052343

A O 0 0.016671278
case O 0 0.0037609697
of O 0 0.004278718
metabolic B-Disease 2 0.9271136
acidosis I-Disease 2 0.9995634
, O 0 0.014572571
acute B-Disease 0 0.98670805
renal I-Disease 0 0.9970795
failure I-Disease 0 0.91887385
and I-Disease 0 0.0031061324
hepatic I-Disease 0 0.9887665
failure I-Disease 0 0.8823187
following O 0 0.008174237
paracetamol B-Chemical 0 0.9995746
ingestion O 0 0.9584965
is O 0 0.0055114324
presented O 0 0.006929638
. O 0 0.0067811073

The O 0 0.007366384
diagnostic O 0 0.009747315
difficulty O 0 0.013846995
at O 0 0.0059692604
presentation O 0 0.01788079
is O 0 0.01043871
highlighted O 0 0.0121135935
. O 0 0.015336316

Continuous O 0 0.013294739
arteriovenous O 0 0.6817198
haemofiltration O 0 0.9058948
proved O 0 0.0069427886
a O 0 0.0023765585
valuable O 0 0.0021953043
means O 0 0.0016653149
of O 0 0.0021570146
maintaining O 0 0.003320712
fluid O 0 0.029987305
and O 0 0.005998152
electrolyte O 0 0.92681026
balance O 0 0.05033193
. O 0 0.010915453

The O 0 0.025611278
patient O 0 0.03517772
recovered O 0 0.033284772
. O 0 0.038890127

Sexual B-Disease 0 0.8449826
dysfunction I-Disease 0 0.9646053
among O 0 0.016387824
patients O 0 0.026699034
with O 0 0.02512181
arthritis B-Disease 0 0.98872685
. O 0 0.030597292

The O 0 0.0027474079
relationship O 0 0.0018577043
of O 0 0.0028946784
arthritis B-Disease 0 0.9956103
and O 0 0.0034174153
sexual B-Disease 0 0.7611672
dysfunction I-Disease 0 0.99213237
was O 0 0.0009596508
investigated O 0 0.0006350486
among O 0 0.0006443681
169 O 0 0.003973691
patients O 0 0.0019557546
with O 0 0.0013615022
rheumatoid B-Disease 2 0.99921787
arthritis I-Disease 2 0.9998179
, O 0 0.02170789
osteoarthritis B-Disease 0 0.9975898
and O 0 0.0031033754
spondyloarthropathy B-Disease 0 0.9988182
, O 0 0.0011423077
130 O 0 0.0014102631
of O 0 0.0005850928
whom O 0 0.0016272222
were O 0 0.000664039
pair O 0 0.0009407861
- O 0 0.00171597
matched O 0 0.0013895287
to O 0 0.002094586
controls O 0 0.005457393
. O 0 0.0054170745

Assessments O 0 0.005784791
of O 0 0.0033818025
marital O 0 0.20475513
happiness O 0 0.13271333
and O 0 0.0025839896
depressed B-Disease 2 0.93583584
mood I-Disease 0 0.99027646
were O 0 0.0009605926
also O 0 0.0006695345
made O 0 0.00057495054
using O 0 0.00051312137
the O 0 0.000796426
CES O 0 0.7485021
- O 0 0.002414208
D O 0 0.1745806
and O 0 0.0010333543
the O 0 0.001228879
Azrin O 0 0.36192703
Marital O 0 0.93978614
Happiness O 0 0.6539026
Scale O 0 0.79449373
( O 0 0.0059390785
AMHS O 0 0.10980258
) O 0 0.008887066
. O 0 0.006873253

Sexual B-Disease 0 0.7492214
dysfunctions I-Disease 0 0.92852646
were O 0 0.0024855162
found O 0 0.001337766
to O 0 0.0009461048
be O 0 0.00082165864
common O 0 0.0009622854
among O 0 0.0007540965
patients O 0 0.0014764573
and O 0 0.0005843625
controls O 0 0.0007820287
, O 0 0.00056094653
the O 0 0.0003519749
majority O 0 0.0004712516
in O 0 0.00040173854
both O 0 0.0005124503
groups O 0 0.00079783995
reporting O 0 0.0015601864
one O 0 0.0009733341
or O 0 0.00161758
more O 0 0.0044153105
dysfunctions O 0 0.8898208
. O 0 0.0073265196

Impotence B-Disease 2 0.880941
was O 0 0.002808008
more O 0 0.0020243502
common O 0 0.0017743498
among O 0 0.0012041917
male O 0 0.0022545746
patients O 0 0.0016185975
than O 0 0.00038061882
controls O 0 0.0006588067
and O 0 0.00047979868
was O 0 0.00040849907
found O 0 0.0003558538
to O 0 0.0003565358
be O 0 0.00042930213
associated O 0 0.0006525963
with O 0 0.0009394317
co O 0 0.29144773
- O 0 0.0029507237
morbidity O 0 0.25016764
and O 0 0.00123362
the O 0 0.0012962063
taking O 0 0.0043833023
of O 0 0.0068940404
methotrexate B-Chemical 1 0.9981488
. O 0 0.010895393

Depressed B-Disease 0 0.98589295
mood I-Disease 0 0.9803467
was O 0 0.002491456
more O 0 0.0017407675
common O 0 0.0015568511
among O 0 0.0010792202
patients O 0 0.0018925401
and O 0 0.00077040953
was O 0 0.0006040253
associated O 0 0.0007954934
with O 0 0.0008316629
certain O 0 0.0018115556
sexual O 0 0.09074792
difficulties O 0 0.013888881
, O 0 0.0017380766
but O 0 0.001325425
not O 0 0.001804918
with O 0 0.004895667
impotence B-Disease 0 0.9850854
. O 0 0.008601829

Marital O 0 0.7774208
unhappiness O 0 0.8101834
, O 0 0.0033284032
as O 0 0.0012340789
indicated O 0 0.00088781
by O 0 0.001163694
AMHS O 0 0.034758672
scores O 0 0.00080788153
, O 0 0.00074282486
was O 0 0.0004272814
not O 0 0.00035225434
associated O 0 0.00062439713
with O 0 0.0010407032
arthritis B-Disease 0 0.9986578
but O 0 0.0008277817
was O 0 0.0005150462
associated O 0 0.00075567345
with O 0 0.0011412627
sexual B-Disease 0 0.77754927
dysfunction I-Disease 0 0.9960162
, O 0 0.0029934875
sexual O 0 0.19203317
dissatisfaction O 0 0.12747796
and O 0 0.0023128067
being O 0 0.004172795
female O 0 0.011208113
. O 0 0.0055884435

Does O 0 0.050008327
paracetamol B-Chemical 0 0.9971372
cause O 0 0.21015917
urothelial B-Disease 0 0.9957339
cancer I-Disease 2 0.9962173
or O 0 0.035457104
renal B-Disease 2 0.9958027
papillary I-Disease 2 0.99555427
necrosis I-Disease 2 0.9977756
? O 0 0.21398361

The O 0 0.0035230669
risk O 0 0.010604055
of O 0 0.003204644
developing O 0 0.022580428
renal B-Disease 2 0.99669135
papillary I-Disease 2 0.99797875
necrosis I-Disease 2 0.99956137
or O 0 0.0036174909
cancer B-Disease 2 0.99389607
of I-Disease 0 0.0016638094
the I-Disease 0 0.0008608711
renal I-Disease 0 0.99298394
pelvis I-Disease 0 0.65528363
, I-Disease 0 0.001246961
ureter I-Disease 0 0.13694689
or I-Disease 0 0.00040463096
bladder I-Disease 0 0.614545
associated O 0 0.0007804225
with O 0 0.0005728553
consumption O 0 0.050641432
of O 0 0.0005882053
either O 0 0.0007306283
phenacetin B-Chemical 1 0.9999229
or O 0 0.0011206315
paracetamol B-Chemical 0 0.9998104
was O 0 0.0004963197
calculated O 0 0.00023163647
from O 0 0.00029038833
data O 0 0.0004209671
acquired O 0 0.0012402411
by O 0 0.00052783854
questionnaire O 0 0.00071089657
from O 0 0.0007557786
381 O 0 0.005435825
cases O 0 0.0022383907
and O 0 0.002410557
808 O 0 0.089194134
controls O 0 0.006794371
. O 0 0.005830473

The O 0 0.0035567568
risk O 0 0.012297271
of O 0 0.0039947475
renal B-Disease 2 0.995082
papillary I-Disease 2 0.9972893
necrosis I-Disease 2 0.9994147
was O 0 0.0021184224
increased O 0 0.0014495046
nearly O 0 0.0007103582
20 O 0 0.00071554154
- O 0 0.00072780304
fold O 0 0.0006637074
by O 0 0.00036140185
consumption O 0 0.030663384
of O 0 0.0011493624
phenacetin B-Chemical 1 0.9999267
, O 0 0.0013956171
which O 0 0.00055892376
also O 0 0.00034457858
increased O 0 0.0005234857
the O 0 0.0003201813
risk O 0 0.016377695
for O 0 0.000452387
cancer B-Disease 2 0.9773751
of I-Disease 0 0.00092760136
the I-Disease 0 0.00073168176
renal I-Disease 0 0.9905854
pelvis I-Disease 0 0.57119536
and I-Disease 0 0.0015195915
bladder I-Disease 0 0.7886043
but O 0 0.0013123875
not O 0 0.0013796476
for O 0 0.00230887
ureteric B-Disease 0 0.95902234
cancer I-Disease 2 0.9959139
. O 0 0.012108033

By O 0 0.0049277176
contrast O 0 0.0026285881
, O 0 0.0019362652
we O 0 0.0006747716
were O 0 0.0007502314
unable O 0 0.00049418357
to O 0 0.00045752194
substantiate O 0 0.0007062023
an O 0 0.00066008465
increased O 0 0.0009575361
risk O 0 0.03199949
from O 0 0.00086156116
paracetamol B-Chemical 0 0.9997776
consumption O 0 0.34565896
for O 0 0.00075947953
renal B-Disease 2 0.9984463
papillary I-Disease 2 0.9989518
necrosis I-Disease 2 0.9997533
or O 0 0.000721918
any O 0 0.00030035197
of O 0 0.00043118215
these O 0 0.0008344388
cancers B-Disease 2 0.98516464
although O 0 0.00044197385
there O 0 0.00021325467
was O 0 0.0003091935
a O 0 0.0003733316
suggestion O 0 0.0014403261
of O 0 0.000580693
an O 0 0.00074557343
association O 0 0.00067147455
with O 0 0.001853825
cancer B-Disease 2 0.97777814
of I-Disease 0 0.0042903605
the I-Disease 0 0.0045328275
ureter I-Disease 0 0.45883107
. O 0 0.0077263014

Dapsone B-Chemical 0 0.99594915
- O 0 0.010343361
associated O 0 0.005575887
Heinz O 0 0.6588301
body O 0 0.1691092
hemolytic B-Disease 2 0.99958616
anemia I-Disease 2 0.9996357
in O 0 0.0032827144
a O 0 0.0030486623
Cambodian O 0 0.14200659
woman O 0 0.059015002
with O 0 0.0054337624
hemoglobin O 0 0.9716385
E O 0 0.9586483
trait O 0 0.09857994
. O 0 0.010983393

A O 0 0.024274029
Cambodian O 0 0.04181427
woman O 0 0.018190911
with O 0 0.0034184451
hemoglobin O 0 0.9071635
E O 0 0.95142555
trait O 0 0.039351914
( O 0 0.0034230195
AE O 0 0.8823669
) O 0 0.0018453641
and O 0 0.0008347434
leprosy B-Disease 0 0.93904454
developed O 0 0.0021705085
a O 0 0.0009498142
Heinz O 0 0.7104754
body O 0 0.102599
hemolytic B-Disease 2 0.99988866
anemia I-Disease 2 0.9999051
while O 0 0.0012438785
taking O 0 0.0024145988
a O 0 0.00052713894
dose O 0 0.01433158
of O 0 0.0011928027
dapsone B-Chemical 1 0.99965894
( O 0 0.0013947097
50 O 0 0.00097261806
mg O 0 0.30619803
/ O 0 0.0010511009
day O 0 0.00046062985
) O 0 0.00071734993
not O 0 0.00046928885
usually O 0 0.0011778545
associated O 0 0.0016215389
with O 0 0.0029923492
clinical O 0 0.20344846
hemolysis B-Disease 0 0.9969495
. O 0 0.00961607

Her O 0 0.009532456
red O 0 0.005764557
blood O 0 0.008649932
cells O 0 0.0040546446
( O 0 0.0023434903
RBCs O 0 0.032988567
) O 0 0.0014552529
had O 0 0.00069502374
increased O 0 0.0010324985
incubated O 0 0.0006094716
Heinz O 0 0.3570485
body O 0 0.0074889837
formation O 0 0.0033883806
, O 0 0.00093759154
decreased O 0 0.0018686266
reduced O 0 0.005445686
glutathione B-Chemical 0 0.99959344
( O 0 0.040649608
GSH B-Chemical 1 0.9995484
) O 0 0.0077009723
, O 0 0.0022642878
and O 0 0.0022084243
decreased O 0 0.016844455
GSH B-Chemical 1 0.99793506
stability O 0 0.022021962
. O 0 0.008868991

The O 0 0.005648027
pentose B-Chemical 0 0.9357312
phosphate I-Chemical 1 0.9892096
shunt O 0 0.23237711
activity O 0 0.0028510913
of O 0 0.0019299411
the O 0 0.0018868282
dapsone B-Chemical 1 0.99920756
- O 0 0.0059539895
exposed O 0 0.0021274197
AE O 0 0.85454893
RBCs O 0 0.08637377
was O 0 0.0010945289
increased O 0 0.0016918144
compared O 0 0.0010194664
to O 0 0.0019827292
normal O 0 0.00650394
RBCs O 0 0.09517439
. O 0 0.006870903

Although O 0 0.0037507496
the O 0 0.002745407
AE O 0 0.5141958
RBCs O 0 0.036917653
from O 0 0.0010954468
an O 0 0.00095645385
individual O 0 0.00055844244
not O 0 0.00057306857
taking O 0 0.0021884972
dapsone B-Chemical 1 0.99918264
had O 0 0.0009339663
increased O 0 0.0013109085
incubated O 0 0.0005779256
Heinz O 0 0.43845093
body O 0 0.007772199
formation O 0 0.0033556658
, O 0 0.0010773168
the O 0 0.0010699435
GSH B-Chemical 1 0.99906164
content O 0 0.0030878477
and O 0 0.0036064035
GSH B-Chemical 1 0.9987777
stability O 0 0.0068943175
were O 0 0.0039542657
normal O 0 0.009333747
. O 0 0.0065796967

The O 0 0.005473247
pentose B-Chemical 0 0.9334014
phosphate I-Chemical 1 0.9890744
shunt O 0 0.21343158
activity O 0 0.0025706613
of O 0 0.0016078486
the O 0 0.0011864568
non O 0 0.0033762788
- O 0 0.0048514786
dapsone B-Chemical 1 0.9993622
- O 0 0.004690151
exposed O 0 0.0017132724
AE O 0 0.8484625
RBCs O 0 0.07989672
was O 0 0.0009610769
decreased O 0 0.0018139819
compared O 0 0.0009146711
to O 0 0.0018149915
normal O 0 0.0061077713
RBCs O 0 0.091505185
. O 0 0.006540981

Thus O 0 0.0049434267
, O 0 0.004534351
AE O 0 0.60024554
RBCs O 0 0.055657342
appear O 0 0.0014009144
to O 0 0.0007704598
have O 0 0.00071459875
an O 0 0.00080337207
increased O 0 0.0009574481
sensitivity O 0 0.0019512139
to O 0 0.0006442803
oxidant O 0 0.9906
stress O 0 0.5075993
both O 0 0.0006064013
in O 0 0.00036274563
vitro O 0 0.0008438026
and O 0 0.00038146498
in O 0 0.00029580254
vivo O 0 0.0008562759
, O 0 0.00052393373
since O 0 0.00034604387
dapsone B-Chemical 1 0.9994174
does O 0 0.0005234839
not O 0 0.00058403064
cause O 0 0.040694624
hemolytic B-Disease 2 0.9998896
anemia I-Disease 2 0.9998734
at O 0 0.0008578888
this O 0 0.0009576214
dose O 0 0.023573631
in O 0 0.0014316733
hematologically O 0 0.76999533
normal O 0 0.006424629
individuals O 0 0.006247884
. O 0 0.005509708

Given O 0 0.0032857785
the O 0 0.0028294257
influx O 0 0.14012706
of O 0 0.0030622492
Southeast O 0 0.053773552
Asians O 0 0.39506117
into O 0 0.0005948273
the O 0 0.00068602007
United O 0 0.0013771993
States O 0 0.0024239316
, O 0 0.0007530668
oxidant O 0 0.97464776
medications O 0 0.6564016
should O 0 0.00029044817
be O 0 0.00030294512
used O 0 0.00022094819
with O 0 0.00030995082
caution O 0 0.00066151423
, O 0 0.00040878635
especially O 0 0.00041365906
if O 0 0.00018484164
an O 0 0.0004597104
infection B-Disease 2 0.124126785
is O 0 0.00029942076
present O 0 0.00020092636
, O 0 0.0003317018
in O 0 0.00019894265
individuals O 0 0.00035756835
of O 0 0.00040770508
ethnic O 0 0.006955313
backgrounds O 0 0.0005201907
that O 0 0.00034759904
have O 0 0.0005345341
an O 0 0.00087989535
increased O 0 0.0016821487
prevalence O 0 0.0037819922
of O 0 0.0051657874
hemoglobin O 0 0.9836447
E O 0 0.9702148
. O 0 0.009484908

Severe O 0 0.809807
complications O 0 0.37665227
of O 0 0.003993581
antianginal O 0 0.9972466
drug O 0 0.7239241
therapy O 0 0.055442154
in O 0 0.0007654911
a O 0 0.0006800664
patient O 0 0.00082903093
identified O 0 0.00039588226
as O 0 0.0003364028
a O 0 0.0005026334
poor O 0 0.0019239179
metabolizer O 0 0.9730505
of O 0 0.0032111378
metoprolol B-Chemical 1 0.9999199
, O 0 0.022917885
propafenone B-Chemical 0 0.99986124
, O 0 0.025622102
diltiazem B-Chemical 1 0.99977344
, O 0 0.008367391
and O 0 0.0068121464
sparteine B-Chemical 1 0.99626726
. O 0 0.00958774

A O 0 0.019736785
47 O 0 0.0060445853
- O 0 0.0034059805
year O 0 0.0018011257
- O 0 0.001816503
old O 0 0.0010916812
patient O 0 0.0014372255
suffering O 0 0.3114308
from O 0 0.001071323
coronary B-Disease 0 0.67030877
artery I-Disease 0 0.51994294
disease I-Disease 0 0.68529654
was O 0 0.0009904465
admitted O 0 0.0044383733
to O 0 0.000761123
the O 0 0.0010643024
CCU O 0 0.12148933
in O 0 0.0023125561
shock B-Disease 0 0.98736215
with O 0 0.008838817
III O 0 0.120121315
. O 0 0.007987583

AV B-Disease 0 0.72812706
block I-Disease 0 0.019828076
, O 0 0.00857864
severe O 0 0.5065822
hypotension B-Disease 2 0.99875045
, O 0 0.006990973
and O 0 0.0042565814
impairment B-Disease 0 0.28673565
of I-Disease 0 0.007703509
ventricular I-Disease 0 0.9794351
function I-Disease 0 0.014531912
. O 0 0.010043943

One O 0 0.0037687675
week O 0 0.0016416352
prior O 0 0.0010005992
to O 0 0.0010063627
admission O 0 0.0041900203
a O 0 0.0008713685
therapy O 0 0.0045873965
with O 0 0.0006531989
standard O 0 0.00043387047
doses O 0 0.020649156
of O 0 0.0017065379
metoprolol B-Chemical 1 0.999938
( O 0 0.0020685832
100 O 0 0.0017032243
mg O 0 0.364175
t O 0 0.0012053325
. O 0 0.00021262749
i O 0 0.000710386
. O 0 0.00018068303
d O 0 0.0003425858
. O 0 0.00015313805
and O 0 0.00023312496
then O 0 0.00023472279
100 O 0 0.0007112998
mg O 0 0.16036208
b O 0 0.00094089995
. O 0 0.0003075732
i O 0 0.001078675
. O 0 0.00037590915
d O 0 0.00085571397
. O 0 0.0005817686
) O 0 0.0015202139
had O 0 0.00158222
been O 0 0.0029622116
initiated O 0 0.0052225627
. O 0 0.0056984485

Two O 0 0.0041806637
days O 0 0.0022361767
before O 0 0.0013660807
admission O 0 0.027613308
diltiazem B-Chemical 1 0.9996526
( O 0 0.0029494094
60 O 0 0.0013791892
mg O 0 0.24402757
b O 0 0.0017275031
. O 0 0.00052661635
i O 0 0.0014362247
. O 0 0.00048156476
d O 0 0.0009416487
. O 0 0.0005879118
) O 0 0.0014032084
was O 0 0.0012086222
prescribed O 0 0.013648623
in O 0 0.002319463
addition O 0 0.0032051208
. O 0 0.0057426095

Analyses O 0 0.005577238
of O 0 0.0027552303
a O 0 0.0019792863
blood O 0 0.0037352908
sample O 0 0.0010557335
revealed O 0 0.0009490877
unusually O 0 0.003520229
high O 0 0.0011921029
plasma O 0 0.033659376
concentrations O 0 0.004704412
of O 0 0.0018292398
metoprolol B-Chemical 1 0.99992967
( O 0 0.0014546681
greater O 0 0.00043760898
than O 0 0.00026409808
3000 O 0 0.0010534534
ng O 0 0.0012718805
/ O 0 0.0012382244
ml O 0 0.002433825
) O 0 0.001068937
and O 0 0.0011070236
diltiazem B-Chemical 1 0.99977714
( O 0 0.0034638084
526 O 0 0.06673094
ng O 0 0.0055156443
/ O 0 0.0055301036
ml O 0 0.010845148
) O 0 0.0069054337
. O 0 0.0055100787

The O 0 0.0035206222
patient O 0 0.003685061
recovered O 0 0.0019759913
within O 0 0.001203693
1 O 0 0.0014746225
week O 0 0.0013325588
following O 0 0.0019156984
discontinuation O 0 0.51324505
of O 0 0.0064084674
antianginal O 0 0.9960841
therapy O 0 0.40357012
. O 0 0.011540154

Three O 0 0.0039576828
months O 0 0.0019750465
later O 0 0.001249081
the O 0 0.0009747875
patient O 0 0.0013742113
was O 0 0.0007500859
exposed O 0 0.00071064354
to O 0 0.00045285275
a O 0 0.00047847256
single O 0 0.00047682395
dose O 0 0.010955846
of O 0 0.0017608897
metoprolol B-Chemical 1 0.9999517
, O 0 0.016527075
diltiazem B-Chemical 1 0.9999559
, O 0 0.012390073
propafenone B-Chemical 0 0.99993694
( O 0 0.0010553015
since O 0 0.00020006075
he O 0 0.00032503708
had O 0 0.00023770462
received O 0 0.00031292293
this O 0 0.0002456972
drug O 0 0.098903015
in O 0 0.0002395797
the O 0 0.00023773883
past O 0 0.0007076638
) O 0 0.00071520585
, O 0 0.00039365664
and O 0 0.00039648448
sparteine B-Chemical 1 0.99913317
( O 0 0.00062475214
as O 0 0.00020596065
a O 0 0.0002659877
probe O 0 0.00025426428
for O 0 0.00026401854
the O 0 0.0005131894
debrisoquine B-Chemical 0 0.9996221
/ O 0 0.010175821
sparteine B-Chemical 1 0.99890554
type O 0 0.0012640294
polymorphism O 0 0.017902367
of O 0 0.0034710022
oxidative O 0 0.9916733
drug O 0 0.9510708
metabolism O 0 0.91509026
) O 0 0.016318247
. O 0 0.006707617

It O 0 0.005472396
was O 0 0.0022013055
found O 0 0.0014085451
that O 0 0.0009431042
he O 0 0.0012551311
was O 0 0.0007750423
a O 0 0.00072224933
poor O 0 0.0017979284
metabolizer O 0 0.91837376
of O 0 0.0007118067
all O 0 0.00038985573
four O 0 0.00033325652
drugs O 0 0.3732259
, O 0 0.0006546292
indicating O 0 0.00032284777
that O 0 0.0003259525
their O 0 0.000586915
metabolism O 0 0.13508007
is O 0 0.00068156363
under O 0 0.00051036273
the O 0 0.0008347283
same O 0 0.0009370878
genetic O 0 0.0043258746
control O 0 0.004081013
. O 0 0.0057392134

Therefore O 0 0.0034649645
, O 0 0.0029030666
patients O 0 0.0030099482
belonging O 0 0.0011575514
to O 0 0.0008270721
the O 0 0.000740423
poor O 0 0.0026252687
- O 0 0.0015000341
metabolizer O 0 0.95185906
phenotype O 0 0.0011376905
of O 0 0.000989392
sparteine B-Chemical 1 0.9994618
/ O 0 0.018707892
debrisoquine B-Chemical 0 0.9997595
polymorphism O 0 0.055294536
in O 0 0.0005379492
drug O 0 0.56618375
metabolism O 0 0.58372086
, O 0 0.0006006039
which O 0 0.00040411574
constitutes O 0 0.00025596566
6 O 0 0.00018056246
. O 0 0.0001152367
4 O 0 0.00014081434
% O 0 0.00015926064
of O 0 0.0001744979
the O 0 0.00018359034
German O 0 0.0007091248
population O 0 0.00042291486
, O 0 0.00032554317
may O 0 0.00024087563
experience O 0 0.00088984723
adverse B-Disease 0 0.7992684
drug I-Disease 0 0.44968987
reactions I-Disease 0 0.021316947
when O 0 0.00023012112
treated O 0 0.0005604498
with O 0 0.00038379527
standard O 0 0.00034050577
doses O 0 0.007866242
of O 0 0.00078512746
one O 0 0.000641909
of O 0 0.0014081212
these O 0 0.003015702
drugs O 0 0.7300228
alone O 0 0.00774347
. O 0 0.00645386

Moreover O 0 0.005641951
, O 0 0.0033838542
the O 0 0.0019333224
coadministration O 0 0.95458406
of O 0 0.0017051713
these O 0 0.0014517026
frequently O 0 0.0017439655
used O 0 0.0008122184
drugs O 0 0.42069405
is O 0 0.0006613796
expected O 0 0.00032104267
to O 0 0.00045856848
be O 0 0.00057068653
especially O 0 0.0009522879
harmful O 0 0.028962897
in O 0 0.000855718
this O 0 0.0011529388
subgroup O 0 0.0048858505
of O 0 0.0036663031
patients O 0 0.016279278
. O 0 0.0063781594

Clinical O 0 0.05237198
experiences O 0 0.008386174
in O 0 0.0028762387
an O 0 0.002941145
open O 0 0.0022468313
and O 0 0.0024059697
a O 0 0.002776583
double O 0 0.0030475566
- O 0 0.006629371
blind O 0 0.015074143
trial O 0 0.013078292
. O 0 0.009580094

A O 0 0.010548029
total O 0 0.0021063215
of O 0 0.0019039396
sixty O 0 0.0024918255
patients O 0 0.0026101638
were O 0 0.0009940455
trated O 0 0.030182285
with O 0 0.0014526752
bromperidol B-Chemical 0 0.99974686
first O 0 0.00059725484
in O 0 0.00038307442
open O 0 0.00036213093
conditions O 0 0.0005457495
( O 0 0.0004794935
20 O 0 0.00034692534
patients O 0 0.0009178988
) O 0 0.0005353768
, O 0 0.0003055184
then O 0 0.00017944102
on O 0 0.00012581218
a O 0 0.00023761013
double O 0 0.00021887681
blind O 0 0.0013954963
basis O 0 0.0004927039
( O 0 0.0005305852
40 O 0 0.0004765127
patients O 0 0.0012401136
) O 0 0.0010592137
with O 0 0.0014590909
haloperidol B-Chemical 1 0.9997713
as O 0 0.0015473901
the O 0 0.0020241942
reference O 0 0.0043385616
substance O 0 0.953278
. O 0 0.0077190376

The O 0 0.0026040296
open O 0 0.0018533097
study O 0 0.0017776517
lasted O 0 0.0011701171
for O 0 0.0007329506
four O 0 0.0005609543
weeks O 0 0.00077658147
; O 0 0.0010582585
the O 0 0.0005748708
drug O 0 0.10296524
was O 0 0.00083942193
administrated O 0 0.024519587
in O 0 0.00068022776
the O 0 0.0007538932
form O 0 0.0011806666
of O 0 0.0019899
1 O 0 0.003170343
mg O 0 0.6964835
tablets O 0 0.9109737
. O 0 0.007655355

The O 0 0.0029144026
daily O 0 0.004731424
dose O 0 0.017638119
( O 0 0.002004387
initial O 0 0.0011139814
dose O 0 0.018165054
: O 0 0.0014155356
1 O 0 0.0006776287
mg O 0 0.22681583
; O 0 0.0006763982
mean O 0 0.00020433072
dose O 0 0.0017012521
at O 0 0.00018305458
the O 0 0.00020533556
end O 0 0.00014523292
of O 0 0.00030407187
the O 0 0.00028526515
trial O 0 0.00086938316
: O 0 0.00054351887
4 O 0 0.00026185208
. O 0 0.00018284489
47 O 0 0.0006527475
mg O 0 0.15364878
) O 0 0.000728369
was O 0 0.0004099671
always O 0 0.0005644438
administered O 0 0.0013843409
in O 0 0.00077740493
one O 0 0.0010745116
single O 0 0.0026482665
dose O 0 0.03924532
. O 0 0.0059480546

Nineteen O 0 0.018122109
patients O 0 0.005103732
finished O 0 0.0031706113
the O 0 0.0014133594
trial O 0 0.0022294607
, O 0 0.0012700597
and O 0 0.0008178612
in O 0 0.0005798687
18 O 0 0.0006226623
cases O 0 0.0008408829
the O 0 0.00054666295
therapeutic O 0 0.004271805
result O 0 0.00075346377
was O 0 0.00089352904
considered O 0 0.00094445125
very O 0 0.0016007815
good O 0 0.0023272885
to O 0 0.0026404494
good O 0 0.005777022
. O 0 0.0061363787

These O 0 0.009339208
results O 0 0.005955567
were O 0 0.005781998
confirmed O 0 0.0062751845
by O 0 0.007895674
statistical O 0 0.021557856
analysis O 0 0.019220915
. O 0 0.017994236

Nine O 0 0.00975183
patients O 0 0.0057801176
exhibited O 0 0.0027655617
mild O 0 0.14660212
to O 0 0.0018377815
moderate O 0 0.050872765
extrapyramidal B-Disease 0 0.9997023
concomitant I-Disease 0 0.21353811
symptoms I-Disease 0 0.91280574
; O 0 0.0026870193
no O 0 0.000838318
other O 0 0.0012747863
side O 0 0.015069387
effects O 0 0.00417468
were O 0 0.0030513168
observed O 0 0.003788764
. O 0 0.006095285

The O 0 0.0025219254
results O 0 0.0016572926
of O 0 0.0015397744
detailed O 0 0.0010881657
laboratory O 0 0.0014362822
tests O 0 0.0014214924
and O 0 0.00071732595
evaluations O 0 0.0007416794
of O 0 0.0006294133
various O 0 0.0009102581
quantitative O 0 0.0009300949
and O 0 0.000597277
qualitative O 0 0.0014380942
tolerability O 0 0.188879
parameters O 0 0.0013703012
were O 0 0.00073781057
not O 0 0.0007822165
indicative O 0 0.0012142406
of O 0 0.0029379574
toxic O 0 0.81223947
effects O 0 0.02070704
. O 0 0.0074302433

In O 0 0.002782401
the O 0 0.0017743211
double O 0 0.0013735815
blind O 0 0.004019751
study O 0 0.00197412
with O 0 0.0020563323
haloperidol B-Chemical 1 0.99985576
, O 0 0.002028497
both O 0 0.0007349937
substances O 0 0.63191783
were O 0 0.0005470969
found O 0 0.0003611618
to O 0 0.000308699
be O 0 0.00032974756
highly O 0 0.00044632086
effective O 0 0.00048466792
in O 0 0.00027457823
the O 0 0.0003107281
treatment O 0 0.0011190281
of O 0 0.0015941877
psychotic B-Disease 0 0.9997092
syndromes I-Disease 0 0.89081985
belonging I-Disease 0 0.0010715812
predominantly I-Disease 0 0.00148737
to I-Disease 0 0.0012307485
the I-Disease 0 0.0024285468
schizophrenia I-Disease 2 0.99570674
group I-Disease 0 0.008534161
. O 0 0.006417893

Certain O 0 0.02343038
clues O 0 0.0046893302
, O 0 0.0027401743
including O 0 0.0014938241
the O 0 0.0011900237
onset O 0 0.0031767345
of O 0 0.0014798689
action O 0 0.010918655
, O 0 0.0013749457
seem O 0 0.000949288
to O 0 0.00063286023
be O 0 0.00071281707
indicative O 0 0.0007109511
of O 0 0.0011647097
the O 0 0.0014070971
superiority O 0 0.0059204376
of O 0 0.0096522495
bromperidol B-Chemical 0 0.9991898
. O 0 0.012010795

No O 0 0.00610831
differences O 0 0.002098781
were O 0 0.0019539178
observed O 0 0.0013908162
with O 0 0.0017135538
respect O 0 0.0014608206
to O 0 0.00171814
side O 0 0.009531485
effects O 0 0.0042635086
and O 0 0.0034767601
general O 0 0.0056854542
tolerability O 0 0.5590126
. O 0 0.009129493

Prolonged O 0 0.6680682
cholestasis B-Disease 2 0.99826896
after O 0 0.01630348
troleandomycin B-Chemical 0 0.99924576
- O 0 0.09157331
induced O 0 0.07063578
acute O 0 0.99543154
hepatitis B-Disease 2 0.9991892
. O 0 0.050837524

We O 0 0.0032811577
report O 0 0.0041745733
the O 0 0.0016550596
case O 0 0.0014111276
of O 0 0.0013730786
a O 0 0.0012404668
patient O 0 0.0016672931
in O 0 0.0009825139
whom O 0 0.019452458
troleandomycin B-Chemical 0 0.9998653
- O 0 0.015296483
induced O 0 0.008690774
hepatitis B-Disease 2 0.99967563
was O 0 0.002225239
followed O 0 0.0012989244
by O 0 0.0025224723
prolonged O 0 0.34975162
anicteric O 0 0.9988625
cholestasis B-Disease 2 0.99961996
. O 0 0.02850846

Jaundice B-Disease 0 0.9792981
occurred O 0 0.004055443
after O 0 0.0016331155
administration O 0 0.039501347
of O 0 0.0031572161
troleandomycin B-Chemical 0 0.9996032
for O 0 0.0016453326
7 O 0 0.0010687337
days O 0 0.00097404566
and O 0 0.001248977
was O 0 0.0016161859
associated O 0 0.0035156817
with O 0 0.008205462
hypereosinophilia B-Disease 0 0.9959293
. O 0 0.011868853

Jaundice B-Disease 0 0.9771598
disappeared O 0 0.005020388
within O 0 0.0011542641
3 O 0 0.00095659733
months O 0 0.0008273862
but O 0 0.00061300903
was O 0 0.0005040692
followed O 0 0.0003935291
by O 0 0.0006029595
prolonged O 0 0.0350817
anicteric O 0 0.99948823
cholestasis B-Disease 2 0.99993515
marked O 0 0.047517963
by O 0 0.0027627146
pruritus B-Disease 2 0.99950826
and O 0 0.0011139346
high O 0 0.0011086261
levels O 0 0.0008805353
of O 0 0.0018529905
alkaline O 0 0.66807383
phosphatase O 0 0.7658801
and O 0 0.005156046
gammaglutamyltransferase O 0 0.7842411
activities O 0 0.012082459
. O 0 0.007153869

Finally O 0 0.0056635425
, O 0 0.0054184482
pruritus B-Disease 2 0.99583095
disappeared O 0 0.0039507076
within O 0 0.00077921123
19 O 0 0.0012821167
months O 0 0.0007588634
, O 0 0.0007388804
and O 0 0.00064085727
liver O 0 0.28316298
tests O 0 0.0012928993
returned O 0 0.00059404434
to O 0 0.0004652609
normal O 0 0.0009826145
27 O 0 0.00094886083
months O 0 0.00066070026
after O 0 0.00051239494
the O 0 0.0011635077
onset O 0 0.008304279
of O 0 0.009511625
hepatitis B-Disease 2 0.99868304
. O 0 0.014725984

This O 0 0.0053138607
observation O 0 0.0029285538
demonstrates O 0 0.0018779911
that O 0 0.001897992
prolonged O 0 0.06087007
cholestasis B-Disease 2 0.99956363
can O 0 0.0038491366
follow O 0 0.00567133
troleandomycin B-Chemical 0 0.99970055
- O 0 0.05673722
induced O 0 0.053494547
acute O 0 0.99730253
hepatitis B-Disease 2 0.9995473
. O 0 0.041528784

Serial O 0 0.015065268
studies O 0 0.0061814026
of O 0 0.006268471
auditory B-Disease 0 0.79895324
neurotoxicity I-Disease 2 0.998926
in O 0 0.005444852
patients O 0 0.02129119
receiving O 0 0.13828279
deferoxamine B-Chemical 1 0.99870384
therapy O 0 0.6373681
. O 0 0.015048763

Visual B-Disease 0 0.67580485
and I-Disease 0 0.005511563
auditory I-Disease 0 0.76692843
neurotoxicity I-Disease 2 0.999403
was O 0 0.0020694912
previously O 0 0.0010564926
documented O 0 0.0011370617
in O 0 0.00047877096
42 O 0 0.0006300485
of O 0 0.00047378725
89 O 0 0.0009087928
patients O 0 0.0010189901
with O 0 0.0006098752
transfusion O 0 0.14167005
- O 0 0.0011818031
dependent O 0 0.00067630544
anemia B-Disease 0 0.99939275
who O 0 0.005170968
were O 0 0.0006721475
receiving O 0 0.011216176
iron B-Chemical 1 0.9985531
chelation O 0 0.9921818
therapy O 0 0.16306663
with O 0 0.003369902
daily O 0 0.031783026
subcutaneous O 0 0.7508267
deferoxamine B-Chemical 1 0.998825
. O 0 0.011352404

Twenty O 0 0.009015656
- O 0 0.0034693745
two O 0 0.0012175819
patients O 0 0.0022382895
in O 0 0.0007734844
the O 0 0.0006148853
affected O 0 0.00052467285
group O 0 0.00064134126
had O 0 0.000535375
abnormal B-Disease 0 0.007838541
audiograms I-Disease 0 0.3967986
with I-Disease 0 0.0008605233
deficits I-Disease 0 0.47472754
mostly I-Disease 0 0.00080109335
in I-Disease 0 0.00024784813
the I-Disease 0 0.00020974784
high I-Disease 0 0.0003104471
frequency I-Disease 0 0.0002968863
range I-Disease 0 0.00040528856
of I-Disease 0 0.00033492997
4 I-Disease 0 0.0002377377
, I-Disease 0 0.00027171025
000 I-Disease 0 0.00024740357
to I-Disease 0 0.00017610069
8 I-Disease 0 0.00021054491
, I-Disease 0 0.000255902
000 I-Disease 0 0.0003160751
Hz I-Disease 0 0.027739318
and O 0 0.00026469753
in O 0 0.00024876132
the O 0 0.00036531733
hearing O 0 0.2731863
threshold O 0 0.0006420344
levels O 0 0.00064836274
of O 0 0.00107348
30 O 0 0.0010886135
to O 0 0.0014393512
100 O 0 0.004628567
decibels O 0 0.0260648
. O 0 0.005142367

When O 0 0.004646512
deferoxamine B-Chemical 1 0.9976513
therapy O 0 0.06896561
was O 0 0.0017099376
discontinued O 0 0.019405643
and O 0 0.0008141172
serial O 0 0.0010293195
studies O 0 0.00073629065
were O 0 0.00039297962
performed O 0 0.0003629336
, O 0 0.0005067729
audiograms O 0 0.09205542
in O 0 0.000293029
seven O 0 0.00027759606
cases O 0 0.0005635566
reverted O 0 0.0012639741
to O 0 0.00026047806
normal O 0 0.00054546585
or O 0 0.00020477363
near O 0 0.0002720934
normal O 0 0.00040520992
within O 0 0.00010911145
two O 0 0.0001359999
to O 0 0.00016789958
three O 0 0.00012459158
weeks O 0 0.0002551312
, O 0 0.00033281965
and O 0 0.0002884997
nine O 0 0.00035994197
of O 0 0.0005546047
13 O 0 0.0007981924
patients O 0 0.0017589629
with O 0 0.0017274636
symptoms O 0 0.42453596
became O 0 0.00986937
asymptomatic O 0 0.34221318
. O 0 0.006496835

Audiograms O 0 0.053640775
from O 0 0.0025079397
15 O 0 0.0015083165
patients O 0 0.0022362715
remained O 0 0.0014739934
abnormal O 0 0.0037509957
and O 0 0.0009314496
four O 0 0.0006199899
patients O 0 0.0018966041
required O 0 0.00077097805
hearing O 0 0.4987197
aids O 0 0.004033665
because O 0 0.0016680936
of O 0 0.0041558333
permanent B-Disease 0 0.4997585
disability I-Disease 0 0.9630181
. O 0 0.009709017

Since O 0 0.0026793287
18 O 0 0.0019709019
of O 0 0.0015173228
the O 0 0.0010657432
22 O 0 0.0012494046
patients O 0 0.0014793468
were O 0 0.000587553
initially O 0 0.00095866574
receiving O 0 0.007626441
deferoxamine B-Chemical 1 0.9997322
doses O 0 0.22373968
in O 0 0.00046040726
excess O 0 0.00076745177
of O 0 0.0004518808
the O 0 0.00030526507
commonly O 0 0.0010471077
recommended O 0 0.0004445229
50 O 0 0.00057294534
mg O 0 0.2450199
/ O 0 0.0007006447
kg O 0 0.0015315054
per O 0 0.00012586472
dose O 0 0.0032030514
, O 0 0.00033706753
therapy O 0 0.0036059888
was O 0 0.00024100015
restarted O 0 0.0025120382
with O 0 0.00031863773
lower O 0 0.00030537543
doses O 0 0.020288419
, O 0 0.00040876845
usually O 0 0.0004887643
50 O 0 0.00049768697
mg O 0 0.22227564
/ O 0 0.0006188567
kg O 0 0.0013264769
per O 0 0.00010890906
dose O 0 0.0015480409
or O 0 0.00016010829
less O 0 0.00019045961
depending O 0 0.00024927934
on O 0 0.00011206289
the O 0 0.00017715107
degree O 0 0.00033327017
of O 0 0.00052119175
auditory B-Disease 0 0.59363574
abnormality I-Disease 0 0.5389296
, O 0 0.0005547786
and O 0 0.00031056904
with O 0 0.0003351488
the O 0 0.0002607099
exception O 0 0.00028419343
of O 0 0.0004353122
two O 0 0.0003648962
cases O 0 0.0010545354
no O 0 0.00070016936
further O 0 0.0017647628
toxicity B-Disease 2 0.9859227
was O 0 0.0034818253
demonstrated O 0 0.0052002203
. O 0 0.005696717

Auditory O 0 0.3776481
deterioration O 0 0.14540786
and O 0 0.0021397541
improvement O 0 0.0020147227
, O 0 0.0011880242
demonstrated O 0 0.0007085756
serially O 0 0.00080309657
in O 0 0.00033030036
individual O 0 0.00031291458
patients O 0 0.001076253
receiving O 0 0.0015789339
and O 0 0.0003940785
not O 0 0.00033854664
receiving O 0 0.009513782
deferoxamine B-Chemical 1 0.9998288
, O 0 0.001531003
respectively O 0 0.0016527111
, O 0 0.0003761266
provided O 0 0.0002651198
convincing O 0 0.0008250818
evidence O 0 0.00033897988
for O 0 0.00026734004
a O 0 0.00048738354
cause O 0 0.0027795446
- O 0 0.0010302406
and O 0 0.00052640354
- O 0 0.00077136635
effect O 0 0.00052464136
relation O 0 0.0005055619
between O 0 0.00084819715
deferoxamine B-Chemical 1 0.9994399
administration O 0 0.7882196
and O 0 0.020388952
ototoxicity B-Disease 0 0.9987306
. O 0 0.01034838

Based O 0 0.008940304
on O 0 0.0018538039
these O 0 0.00228208
data O 0 0.001952968
, O 0 0.0015846837
a O 0 0.0010188295
plan O 0 0.0013093794
of O 0 0.0009602215
management O 0 0.0018863252
was O 0 0.00075697945
developed O 0 0.0011052861
that O 0 0.0005593331
allows O 0 0.00074672705
effective O 0 0.0015423681
yet O 0 0.002003647
safe O 0 0.00734349
administration O 0 0.25949368
of O 0 0.014903962
deferoxamine B-Chemical 1 0.9988207
. O 0 0.013461853

A O 0 0.017782057
dose O 0 0.012676325
of O 0 0.003374729
50 O 0 0.0037214858
mg O 0 0.38018975
/ O 0 0.0037996033
kg O 0 0.006236919
is O 0 0.001280291
recommended O 0 0.0015241083
in O 0 0.0013278269
those O 0 0.0024481006
without O 0 0.0035258199
audiogram O 0 0.6622651
abnormalities O 0 0.4880737
. O 0 0.00943113

With O 0 0.007984908
mild O 0 0.5062531
toxicity B-Disease 2 0.99122417
, O 0 0.0029475675
a O 0 0.0013319711
reduction O 0 0.0013370055
to O 0 0.00057407387
30 O 0 0.00042363105
or O 0 0.0003198622
40 O 0 0.00049876305
mg O 0 0.13694257
/ O 0 0.0008225615
kg O 0 0.0015485192
per O 0 0.0001619542
dose O 0 0.00181833
should O 0 0.00017110184
result O 0 0.00020728615
in O 0 0.00022545803
a O 0 0.00031849497
reversal O 0 0.0010751392
of O 0 0.00048226354
the O 0 0.00043948417
abnormal O 0 0.0050311293
results O 0 0.0005979913
to O 0 0.0006958642
normal O 0 0.0015701312
within O 0 0.0007508422
four O 0 0.0014631065
weeks O 0 0.0034219655
. O 0 0.004598894

Moderate O 0 0.43741897
abnormalities O 0 0.0451512
require O 0 0.0020169895
a O 0 0.0019110386
reduction O 0 0.0023216046
of O 0 0.0023182984
deferoxamine B-Chemical 1 0.99923825
to O 0 0.0016495679
25 O 0 0.002280927
mg O 0 0.39045364
/ O 0 0.0023330974
kg O 0 0.0037440988
per O 0 0.00072770566
dose O 0 0.0050624693
with O 0 0.00242309
careful O 0 0.0054113176
monitoring O 0 0.007226172
. O 0 0.0067199203

In O 0 0.0030760218
those O 0 0.0026294596
with O 0 0.0020990036
symptoms O 0 0.10699957
of O 0 0.0019472853
hearing B-Disease 0 0.7980728
loss I-Disease 0 0.0033702028
, O 0 0.0009626448
the O 0 0.00048896886
drug O 0 0.12517314
should O 0 0.00027562815
be O 0 0.00029306783
stopped O 0 0.0005068884
for O 0 0.00018543389
four O 0 0.00015624285
weeks O 0 0.0002462014
, O 0 0.00028921242
and O 0 0.00021611956
when O 0 0.00014558982
the O 0 0.00022459662
audiogram O 0 0.21043485
is O 0 0.00028806244
stable O 0 0.0003786523
or O 0 0.00022358086
improved O 0 0.000807499
, O 0 0.00044657366
therapy O 0 0.0047333287
should O 0 0.00021259402
be O 0 0.00030226828
restarted O 0 0.0015789038
at O 0 0.00023908338
10 O 0 0.00037668404
to O 0 0.0003774538
25 O 0 0.0009939669
mg O 0 0.13847438
/ O 0 0.0024116347
kg O 0 0.0053875125
per O 0 0.0015621276
dose O 0 0.01536286
. O 0 0.005460616

Serial O 0 0.011495647
audiograms O 0 0.090412594
should O 0 0.0013596098
be O 0 0.0010597
performed O 0 0.0006329027
every O 0 0.0003310775
six O 0 0.00030900197
months O 0 0.0004295117
in O 0 0.0003061917
those O 0 0.00042265048
without O 0 0.00036305076
problems O 0 0.0022202134
and O 0 0.00036719692
more O 0 0.00041573544
frequently O 0 0.00057757896
in O 0 0.0002673699
young O 0 0.0021449262
patients O 0 0.000988871
with O 0 0.00045481898
normal O 0 0.0012934265
serum O 0 0.123623975
ferritin O 0 0.9842993
values O 0 0.00075784995
and O 0 0.0007788568
in O 0 0.00079350645
those O 0 0.0016714829
with O 0 0.003076373
auditory B-Disease 0 0.8024442
dysfunction I-Disease 0 0.99132955
. O 0 0.008864393

Lidocaine B-Chemical 0 0.99395967
- O 0 0.041886296
induced O 0 0.032321565
cardiac B-Disease 0 0.96076894
asystole I-Disease 2 0.9942557
. O 0 0.03273995

Intravenous O 0 0.8942506
administration O 0 0.09947645
of O 0 0.0023122467
a O 0 0.00144585
single O 0 0.0010731037
50 O 0 0.0014747684
- O 0 0.001294908
mg O 0 0.22034904
bolus O 0 0.051552895
of O 0 0.001000481
lidocaine B-Chemical 0 0.9992841
in O 0 0.00052656885
a O 0 0.0005143118
67 O 0 0.0010206258
- O 0 0.00057206873
year O 0 0.00038992212
- O 0 0.00053681945
old O 0 0.00039557065
man O 0 0.0226049
resulted O 0 0.00033724622
in O 0 0.00034336024
profound O 0 0.029589826
depression B-Disease 0 0.97567856
of O 0 0.0006726992
the O 0 0.0004659027
activity O 0 0.0006672295
of O 0 0.00072500604
the O 0 0.0008925143
sinoatrial O 0 0.70790225
and O 0 0.0021081504
atrioventricular O 0 0.8576509
nodal O 0 0.3772453
pacemakers O 0 0.3606
. O 0 0.0066492213

The O 0 0.0026943276
patient O 0 0.0028305342
had O 0 0.001529575
no O 0 0.00092377845
apparent O 0 0.0010510691
associated O 0 0.0010455915
conditions O 0 0.00096573564
which O 0 0.00082569406
might O 0 0.00040219873
have O 0 0.0005597347
predisposed O 0 0.05373909
him O 0 0.0018483326
to O 0 0.00036405795
the O 0 0.00034645072
development O 0 0.0010409034
of O 0 0.0010825028
bradyarrhythmias B-Disease 0 0.99956745
; O 0 0.00207724
and O 0 0.000519346
, O 0 0.0005465684
thus O 0 0.00055695634
, O 0 0.00048908865
this O 0 0.00037143112
probably O 0 0.0007418543
represented O 0 0.0006357487
a O 0 0.0010273111
true O 0 0.0015034934
idiosyncrasy O 0 0.531193
to O 0 0.0050336914
lidocaine B-Chemical 0 0.99748504
. O 0 0.008608309

Flurbiprofen B-Chemical 0 0.9944634
in O 0 0.0075507527
the O 0 0.00589094
treatment O 0 0.010569707
of O 0 0.0121340575
juvenile B-Disease 0 0.87952584
rheumatoid I-Disease 2 0.9963128
arthritis I-Disease 2 0.9981633
. O 0 0.039977636

Thirty O 0 0.010497894
- O 0 0.0037748518
four O 0 0.0013000082
patients O 0 0.002949135
with O 0 0.0019512381
juvenile B-Disease 0 0.49022546
rheumatoid I-Disease 2 0.99892575
arthritis I-Disease 2 0.99977165
, O 0 0.006443894
who O 0 0.0027277272
were O 0 0.00047979248
treated O 0 0.00080506265
with O 0 0.0007964908
flurbiprofen B-Chemical 0 0.9998217
at O 0 0.00030612486
a O 0 0.0003481252
maximum O 0 0.00031690695
dose O 0 0.0037409342
of O 0 0.0004136129
4 O 0 0.0003078405
mg O 0 0.23350471
/ O 0 0.0008332461
kg O 0 0.0030944028
/ O 0 0.0004905679
day O 0 0.00020777172
, O 0 0.00024728023
had O 0 0.0002085756
statistically O 0 0.00023625472
significant O 0 0.00029230438
decreases O 0 0.0003511581
from O 0 0.0002684744
baseline O 0 0.00043511592
in O 0 0.00031627796
6 O 0 0.0004020722
arthritis B-Disease 0 0.98851556
indices O 0 0.001198814
after O 0 0.00044479166
12 O 0 0.0006206083
weeks O 0 0.00096012955
of O 0 0.0021193307
treatment O 0 0.007227527
. O 0 0.0054017534

Improvements O 0 0.0052771573
were O 0 0.002409433
seen O 0 0.0015984928
in O 0 0.0010249877
the O 0 0.0008287122
number O 0 0.00070041226
of O 0 0.0011183843
tender B-Disease 0 0.16281396
joints I-Disease 0 0.30253944
, O 0 0.0010253105
the O 0 0.0004952721
severity O 0 0.010932356
of O 0 0.0010968101
swelling B-Disease 0 0.9857632
and O 0 0.0012573866
tenderness B-Disease 0 0.9849732
, O 0 0.00055893476
the O 0 0.00022422796
time O 0 0.00018981223
of O 0 0.00033155762
walk O 0 0.0017358514
50 O 0 0.0005455946
feet O 0 0.0058645266
, O 0 0.00036809276
the O 0 0.0002240995
duration O 0 0.00040507998
of O 0 0.0005274173
morning B-Disease 0 0.027604628
stiffness I-Disease 0 0.7723463
and O 0 0.0008419737
the O 0 0.0008022575
circumference O 0 0.0349105
of O 0 0.0015648565
the O 0 0.0019809296
left O 0 0.0073677017
knee O 0 0.2955322
. O 0 0.007070219

The O 0 0.0030459214
most O 0 0.0031893465
frequently O 0 0.002497885
observed O 0 0.0010886624
side O 0 0.0051107947
effect O 0 0.0010893112
was O 0 0.0008235501
fecal B-Disease 0 0.1707408
occult I-Disease 0 0.3732736
blood I-Disease 0 0.06829603
( O 0 0.0009817311
25 O 0 0.00065497804
% O 0 0.0003519707
of O 0 0.00037669804
patients O 0 0.0016752443
) O 0 0.0008691612
; O 0 0.0006217121
however O 0 0.00043625289
, O 0 0.00034584122
there O 0 0.00016837027
was O 0 0.0002504271
no O 0 0.00020460384
other O 0 0.00029326964
evidence O 0 0.00048340028
of O 0 0.0009967017
gastrointestinal B-Disease 0 0.9833382
( I-Disease 0 0.0047980743
GI I-Disease 0 0.90794533
) I-Disease 0 0.006432517
bleeding I-Disease 0 0.99089605
in O 0 0.002135646
these O 0 0.0040530325
patients O 0 0.014216174
. O 0 0.0063055204

One O 0 0.0054600774
patient O 0 0.0039987345
was O 0 0.0022709053
prematurely O 0 0.0058901524
discontinued O 0 0.014954142
from O 0 0.0012613276
the O 0 0.0010959525
study O 0 0.0017914496
for O 0 0.0015840017
severe O 0 0.42479962
headache B-Disease 2 0.99814904
and O 0 0.007999769
abdominal B-Disease 0 0.8383519
pain I-Disease 0 0.9847477
. O 0 0.010977205

Most O 0 0.011874525
side O 0 0.014207256
effects O 0 0.005580725
were O 0 0.0033525354
mild O 0 0.13957098
and O 0 0.003189912
related O 0 0.0024154074
to O 0 0.0032713667
the O 0 0.0053228177
GI O 0 0.82850415
tract O 0 0.5410428
. O 0 0.013729945

Hyperkalemia B-Disease 0 0.9918869
associated O 0 0.02661247
with O 0 0.032764647
sulindac B-Chemical 1 0.9982911
therapy O 0 0.737583
. O 0 0.031241732

Hyperkalemia B-Disease 0 0.9959726
has O 0 0.0039860792
recently O 0 0.0030198453
been O 0 0.0019321414
recognized O 0 0.0016290987
as O 0 0.0009388819
a O 0 0.001340655
complication O 0 0.20917393
of O 0 0.0036900786
nonsteroidal O 0 0.9998399
antiinflammatory O 0 0.9990508
agents O 0 0.9329382
( O 0 0.041670147
NSAID O 0 0.9997515
) O 0 0.009783193
such O 0 0.0035016346
as O 0 0.0055500935
indomethacin B-Chemical 1 0.9984987
. O 0 0.012156741

Several O 0 0.004662433
recent O 0 0.0026890428
studies O 0 0.0023973258
have O 0 0.0015475693
stressed O 0 0.0022836288
the O 0 0.0012729671
renal O 0 0.963863
sparing O 0 0.1840802
features O 0 0.006990367
of O 0 0.0026505648
sulindac B-Chemical 1 0.99990916
, O 0 0.0022892274
owing O 0 0.00093957596
to O 0 0.00053142436
its O 0 0.0009811216
lack O 0 0.0006296413
of O 0 0.0011187242
interference O 0 0.0035196387
with O 0 0.0051476974
renal O 0 0.9967083
prostacyclin B-Chemical 0 0.99953544
synthesis O 0 0.8981179
. O 0 0.012395063

We O 0 0.002926011
describe O 0 0.0022619555
4 O 0 0.0014444578
patients O 0 0.0022583832
in O 0 0.0009941771
whom O 0 0.0052062087
hyperkalemia B-Disease 2 0.9996145
ranging O 0 0.004662491
from O 0 0.0006133029
6 O 0 0.00035900722
. O 0 0.00022411872
1 O 0 0.00027699035
to O 0 0.00023923801
6 O 0 0.00022575747
. O 0 0.00018656041
9 O 0 0.0003461142
mEq O 0 0.45200706
/ O 0 0.00079563126
l O 0 0.00078950217
developed O 0 0.0005981233
within O 0 0.00022627466
3 O 0 0.00034774325
to O 0 0.00040457404
8 O 0 0.00056356314
days O 0 0.0008018093
of O 0 0.0027558
sulindac B-Chemical 1 0.9996037
administration O 0 0.8324349
. O 0 0.008640578

In O 0 0.0030505396
all O 0 0.0019380159
of O 0 0.002126794
them O 0 0.0025725816
normal O 0 0.0031775348
serum O 0 0.15936674
potassium B-Chemical 0 0.99789304
levels O 0 0.0015254907
reached O 0 0.00127556
within O 0 0.00048753634
2 O 0 0.00071157474
to O 0 0.0006563294
4 O 0 0.0007370645
days O 0 0.0010230385
of O 0 0.0024458834
stopping O 0 0.15897958
sulindac B-Chemical 1 0.9993338
. O 0 0.013556723

As O 0 0.0022170045
no O 0 0.0016265752
other O 0 0.0016756671
medications O 0 0.21838014
known O 0 0.0016095801
to O 0 0.0007978
effect O 0 0.0010799401
serum O 0 0.19635314
potassium B-Chemical 0 0.99903464
had O 0 0.001133988
been O 0 0.00065048505
given O 0 0.00030025002
concomitantly O 0 0.00843234
, O 0 0.0004531053
this O 0 0.00024296976
course O 0 0.0004299195
of O 0 0.00042890458
events O 0 0.0035481772
is O 0 0.00034301536
suggestive O 0 0.0010296886
of O 0 0.0005087461
a O 0 0.0006097194
cause O 0 0.003859682
- O 0 0.0011444669
and O 0 0.0005707782
- O 0 0.0008398983
effect O 0 0.00059636857
relationship O 0 0.0006331112
between O 0 0.0011867576
sulindac B-Chemical 1 0.9997272
and O 0 0.047045574
hyperkalemia B-Disease 2 0.9994487
. O 0 0.012322711

These O 0 0.0040361793
observations O 0 0.0026028212
indicate O 0 0.0012037577
that O 0 0.0009764095
initial O 0 0.0010853093
hopes O 0 0.003786808
that O 0 0.0011467792
sulindac B-Chemical 1 0.99984646
may O 0 0.0013057209
not O 0 0.00060054264
be O 0 0.0005067753
associated O 0 0.00059564033
with O 0 0.000589803
the O 0 0.0005703945
adverse O 0 0.76642376
renal O 0 0.98901623
effects O 0 0.0034922576
of O 0 0.0014376644
other O 0 0.002533578
NSAID O 0 0.9997316
are O 0 0.0027679023
probably O 0 0.0037168234
not O 0 0.0030750716
justified O 0 0.012493758
. O 0 0.0061386474

Drug O 0 0.93914306
- O 0 0.019439565
induced O 0 0.0154627105
arterial O 0 0.93677014
spasm B-Disease 2 0.99641126
relieved O 0 0.609404
by O 0 0.023466187
lidocaine B-Chemical 0 0.9951382
. O 0 0.022468472

Case O 0 0.18628418
report O 0 0.097534604
. O 0 0.06525026

Following O 0 0.0043454813
major O 0 0.0037926065
intracranial O 0 0.62837726
surgery O 0 0.005858108
in O 0 0.0012158816
a O 0 0.001151806
35 O 0 0.001143182
- O 0 0.0011387
year O 0 0.000784472
- O 0 0.0010742054
old O 0 0.00087887986
man O 0 0.0840873
, O 0 0.0017945442
sodium B-Chemical 0 0.9988142
pentothal I-Chemical 0 0.9986237
was O 0 0.0015097377
intravenously O 0 0.016152456
infused O 0 0.007843448
to O 0 0.0014492645
minimize O 0 0.00255729
cerebral B-Disease 0 0.9940965
ischaemia I-Disease 0 0.99927145
. O 0 0.013345877

Intense O 0 0.06419914
vasospasm B-Disease 2 0.997661
with O 0 0.00689626
threatened O 0 0.045971915
gangrene B-Disease 0 0.9903854
arose O 0 0.0032612076
in O 0 0.001617885
the O 0 0.0015201669
arm O 0 0.0024811209
used O 0 0.0018524687
for O 0 0.0022222428
the O 0 0.004158654
infusion O 0 0.093786106
. O 0 0.008708791

Since O 0 0.002915862
the O 0 0.00225174
cranial O 0 0.02357246
condition O 0 0.0021055127
precluded O 0 0.0015885191
use O 0 0.0009799164
of O 0 0.0008002212
more O 0 0.00073134265
usual O 0 0.0007880507
methods O 0 0.0008109899
, O 0 0.00097032025
lidocaine B-Chemical 0 0.9988695
was O 0 0.00057300465
given O 0 0.00033398837
intra O 0 0.0053428705
- O 0 0.0009779786
arterially O 0 0.04665585
, O 0 0.00056034327
with O 0 0.00052508566
careful O 0 0.0015501243
cardiovascular O 0 0.91562396
monitoring O 0 0.0021048046
, O 0 0.0015605148
to O 0 0.0013630345
counteract O 0 0.005896092
the O 0 0.006141552
vasospasm B-Disease 2 0.99877006
. O 0 0.010236922

The O 0 0.0119519895
treatment O 0 0.017145116
was O 0 0.013443886
rapidly O 0 0.022303678
successful O 0 0.024852611
. O 0 0.022549791

Regional O 0 0.0067326156
localization O 0 0.0032643683
of O 0 0.0028055683
the O 0 0.0024248403
antagonism O 0 0.5282683
of O 0 0.008390548
amphetamine B-Chemical 1 0.9997516
- O 0 0.029028894
induced O 0 0.013604469
hyperactivity B-Disease 2 0.9984554
by O 0 0.010094592
intracerebral O 0 0.9966259
calcitonin B-Chemical 1 0.9940394
injections O 0 0.3451795
. O 0 0.009506869

Calcitonin B-Chemical 0 0.9737848
receptors O 0 0.17851123
are O 0 0.0027867227
found O 0 0.0015946386
in O 0 0.0011083384
the O 0 0.001124315
brain O 0 0.02668855
, O 0 0.0015274296
and O 0 0.0013254504
intracerebral O 0 0.98597413
infusions O 0 0.30206472
of O 0 0.002742487
calcitonin B-Chemical 1 0.98137903
can O 0 0.0019635754
produce O 0 0.0024933028
behavioral O 0 0.07193473
effects O 0 0.011372046
. O 0 0.0070198914

Among O 0 0.0067841723
these O 0 0.0032036023
behavioral O 0 0.013940324
effects O 0 0.002885225
are O 0 0.001228081
decreases O 0 0.0013029557
in O 0 0.0009054797
food O 0 0.013020152
intake O 0 0.53907484
and O 0 0.0013070672
decreases O 0 0.0019443986
in O 0 0.0023293553
amphetamine B-Chemical 1 0.9996574
- O 0 0.011840885
induced O 0 0.006791868
locomotor O 0 0.6556098
activity O 0 0.008432304
. O 0 0.0068275556

In O 0 0.002255555
previous O 0 0.001455295
experiments O 0 0.0010727476
we O 0 0.00063556095
found O 0 0.00072900706
that O 0 0.00053400017
decreases O 0 0.0008119525
in O 0 0.0005506683
food O 0 0.010823011
intake O 0 0.4904684
were O 0 0.00050815626
induced O 0 0.0005711515
by O 0 0.00041642797
local O 0 0.0009114983
administration O 0 0.07074469
of O 0 0.00096861616
calcitonin B-Chemical 1 0.9746694
into O 0 0.00040925626
several O 0 0.0007631265
hypothalamic O 0 0.54829824
sites O 0 0.00078071636
and O 0 0.0009329222
into O 0 0.0008271048
the O 0 0.0018738894
nucleus O 0 0.014613596
accumbens O 0 0.96038985
. O 0 0.00592062

In O 0 0.002768965
the O 0 0.0017587317
present O 0 0.0011638126
experiment O 0 0.0012479584
calcitonin B-Chemical 1 0.9154697
decreased O 0 0.0047652437
locomotor O 0 0.4583539
activity O 0 0.0011253329
when O 0 0.0004332154
locally O 0 0.005823534
injected O 0 0.00053585914
into O 0 0.0002861136
the O 0 0.000362133
same O 0 0.0003108247
sites O 0 0.00064897747
where O 0 0.000808733
it O 0 0.0014809408
decreases O 0 0.003160362
food O 0 0.06584943
intake O 0 0.77596956
. O 0 0.007511253

The O 0 0.003163438
areas O 0 0.004126233
where O 0 0.0021414002
calcitonin B-Chemical 1 0.9190463
is O 0 0.0015544426
most O 0 0.0015052732
effective O 0 0.0012095654
in O 0 0.00054661476
decreasing O 0 0.0011503932
locomotor O 0 0.40547112
activity O 0 0.0007798664
are O 0 0.00038296834
located O 0 0.00032179776
in O 0 0.00025660073
the O 0 0.0003364838
hypothalamus O 0 0.18760845
and O 0 0.00046443366
nucleus O 0 0.00450308
accumbens O 0 0.9615933
, O 0 0.00034298463
suggesting O 0 0.00017654824
that O 0 0.00015692877
these O 0 0.00029673125
areas O 0 0.00061298447
are O 0 0.00023907472
the O 0 0.00020189116
major O 0 0.00033281487
sites O 0 0.00029075347
of O 0 0.00044886314
action O 0 0.0048327106
of O 0 0.001109733
calcitonin B-Chemical 1 0.9896716
in O 0 0.0012605955
inhibiting O 0 0.043582425
amphetamine B-Chemical 1 0.99983275
- O 0 0.017635439
induced O 0 0.0070330016
locomotor O 0 0.69447076
activity O 0 0.0075217006
. O 0 0.0059633576

The O 0 0.003862193
hematologic O 0 0.76845527
effects O 0 0.0038803276
of O 0 0.002615875
cefonicid B-Chemical 0 0.99372286
and O 0 0.0026756716
cefazedone B-Chemical 1 0.99645436
in O 0 0.000972885
the O 0 0.00077214855
dog O 0 0.0020513984
: O 0 0.0011253317
a O 0 0.00073663663
potential O 0 0.0010698853
model O 0 0.0014907838
of O 0 0.0033105966
cephalosporin B-Chemical 0 0.9986003
hematotoxicity B-Disease 0 0.99941325
in O 0 0.011043527
man O 0 0.66077965
. O 0 0.00872507

Cephalosporin B-Chemical 0 0.9823533
antibiotics O 0 0.6994474
cause O 0 0.007205929
a O 0 0.0020829528
variety O 0 0.0039510136
of O 0 0.0024710242
hematologic B-Disease 0 0.9971687
disturbances I-Disease 0 0.9740814
in O 0 0.0013077696
man O 0 0.18906382
, O 0 0.0010793529
the O 0 0.00069016154
pathogeneses O 0 0.08650239
and O 0 0.0010400831
hematopathology O 0 0.003097281
of O 0 0.0014667936
which O 0 0.00204107
remain O 0 0.0024522648
poorly O 0 0.008284398
characterized O 0 0.008738232
. O 0 0.006727704

There O 0 0.0055067562
is O 0 0.0024082817
a O 0 0.0017823388
need O 0 0.0011300193
for O 0 0.00084075745
a O 0 0.00097395846
well O 0 0.0007284168
- O 0 0.0010764874
defined O 0 0.00052765897
animal O 0 0.0010304782
model O 0 0.00091455004
in O 0 0.0006704671
which O 0 0.0011604528
these O 0 0.001859169
blood B-Disease 0 0.34151244
dyscrasias I-Disease 0 0.9975553
can O 0 0.0030728213
be O 0 0.0037265208
studied O 0 0.006474562
. O 0 0.006452338

In O 0 0.0032219407
four O 0 0.0022663085
subacute O 0 0.98582757
toxicity B-Disease 2 0.993226
studies O 0 0.0037524942
, O 0 0.0014070595
the O 0 0.0007148866
intravenous O 0 0.37575746
administration O 0 0.13602613
of O 0 0.0012875134
cefonicid B-Chemical 0 0.9973642
or O 0 0.0007759919
cefazedone B-Chemical 1 0.99803144
to O 0 0.00049817294
beagle O 0 0.03664759
dogs O 0 0.0019567916
caused O 0 0.0005099132
a O 0 0.00050639134
dose O 0 0.026326748
- O 0 0.0007999608
dependent O 0 0.00034026385
incidence O 0 0.0079827905
of O 0 0.0021164312
anemia B-Disease 0 0.9997578
, O 0 0.011535292
neutropenia B-Disease 2 0.9995041
, O 0 0.0019376607
and O 0 0.0012096697
thrombocytopenia B-Disease 0 0.9991491
after O 0 0.0005508074
1 O 0 0.00084851804
- O 0 0.0010977539
3 O 0 0.00067600224
months O 0 0.00107281
of O 0 0.0020383971
treatment O 0 0.006807438
. O 0 0.005313591

A O 0 0.053056993
nonregenerative O 0 0.8860366
anemia B-Disease 0 0.9978563
was O 0 0.0024537633
the O 0 0.0012090494
most O 0 0.0014458472
compromising O 0 0.0017708153
of O 0 0.0010182415
the O 0 0.00097195624
cytopenias B-Disease 0 0.9990871
and O 0 0.0008941345
occurred O 0 0.0006225247
in O 0 0.0002885355
approximately O 0 0.00033784442
50 O 0 0.00042075667
% O 0 0.0002511425
of O 0 0.00025907526
dogs O 0 0.0008303531
receiving O 0 0.0014927277
400 O 0 0.002329976
- O 0 0.00062678143
500 O 0 0.0012893374
mg O 0 0.18303153
/ O 0 0.0010733114
kg O 0 0.006254641
cefonicid B-Chemical 0 0.9724583
or O 0 0.0007147827
540 O 0 0.01343077
- O 0 0.0018818885
840 O 0 0.023283845
mg O 0 0.42580715
/ O 0 0.006771729
kg O 0 0.065787144
cefazedone B-Chemical 1 0.98873514
. O 0 0.0076925675

All O 0 0.0037034012
three O 0 0.002094541
cytopenias B-Disease 0 0.9944969
were O 0 0.0017707439
completely O 0 0.0012939809
reversible O 0 0.057111282
following O 0 0.0007502539
cessation O 0 0.00360875
of O 0 0.00073035195
treatment O 0 0.0020366528
; O 0 0.00071455154
the O 0 0.00022719041
time O 0 0.00018316456
required O 0 0.00012959389
for O 0 0.00018407956
recovery O 0 0.0005943853
of O 0 0.00038297038
the O 0 0.00040067124
erythron O 0 0.955983
( O 0 0.00060567295
approximately O 0 0.0003058929
1 O 0 0.00021820024
month O 0 0.00020444064
) O 0 0.00032008547
was O 0 0.00016164148
considerably O 0 0.00023245423
longer O 0 0.00013064442
than O 0 0.00012566963
that O 0 0.00016391312
of O 0 0.0003425843
the O 0 0.00039157752
granulocytes O 0 0.19880529
and O 0 0.0007421807
platelets O 0 0.20388761
( O 0 0.0008576697
hours O 0 0.0005547059
to O 0 0.0006005644
a O 0 0.0009890961
few O 0 0.001096554
days O 0 0.0023001605
) O 0 0.005454353
. O 0 0.0048900726

Upon O 0 0.006805991
rechallenge O 0 0.24583381
with O 0 0.0027265586
either O 0 0.0021486734
cephalosporin B-Chemical 0 0.9967114
, O 0 0.0022299252
the O 0 0.0011841236
hematologic B-Disease 0 0.997813
syndrome I-Disease 0 0.9911199
was O 0 0.0007804962
reproduced O 0 0.0010551095
in O 0 0.000329099
most O 0 0.00057454413
dogs O 0 0.0011999466
tested O 0 0.00033836017
; O 0 0.0012219067
cefonicid B-Chemical 0 0.99556375
( O 0 0.0008032126
but O 0 0.00031936704
not O 0 0.0003890596
cefazedone B-Chemical 1 0.99859005
) O 0 0.0021371862
- O 0 0.00066121673
treated O 0 0.0004953782
dogs O 0 0.00092988886
showed O 0 0.00022973111
a O 0 0.00025878247
substantially O 0 0.00030006884
reduced O 0 0.00028548553
induction O 0 0.00045496252
period O 0 0.00033597287
( O 0 0.00041002413
15 O 0 0.00022518585
+ O 0 0.00033752396
/ O 0 0.0006528604
- O 0 0.00035921007
5 O 0 0.00014351608
days O 0 0.00015468104
) O 0 0.0002429487
compared O 0 8.827151e-05
to O 0 0.00013024837
that O 0 0.00012913204
of O 0 0.00023422291
the O 0 0.00020487285
first O 0 0.00020716265
exposure O 0 0.001002088
to O 0 0.00031131966
the O 0 0.00041638772
drug O 0 0.24243075
( O 0 0.0010929113
61 O 0 0.0014407266
+ O 0 0.0011083015
/ O 0 0.002093399
- O 0 0.0017634798
24 O 0 0.001347789
days O 0 0.0019671416
) O 0 0.0048210574
. O 0 0.0045039565

This O 0 0.004470616
observation O 0 0.0024389904
, O 0 0.001858472
along O 0 0.0010343072
with O 0 0.0009377872
the O 0 0.0006312928
rapid O 0 0.0012929116
rate O 0 0.0005046786
of O 0 0.0006572558
decline O 0 0.0021041618
in O 0 0.00040172396
red O 0 0.00097564835
cell O 0 0.0027385706
mass O 0 0.0018764632
parameters O 0 0.0006104841
of O 0 0.0003829202
affected O 0 0.00030414667
dogs O 0 0.0014758846
, O 0 0.00037928965
suggests O 0 0.00017959115
that O 0 0.00023142014
a O 0 0.0005599066
hemolytic B-Disease 0 0.99914336
component O 0 0.0008222946
complicated O 0 0.01163255
the O 0 0.00042011138
red O 0 0.0012987889
cell O 0 0.004892332
production O 0 0.0013475637
problem O 0 0.0010908808
and O 0 0.00046472886
that O 0 0.00037283293
multiple O 0 0.0010947364
toxicologic O 0 0.18988596
mechanisms O 0 0.0023296212
contributed O 0 0.0035530932
to O 0 0.0021996326
the O 0 0.004788486
cytopenia B-Disease 0 0.9978258
. O 0 0.010093158

We O 0 0.0028183856
conclude O 0 0.0019510702
that O 0 0.0012169087
the O 0 0.0010948428
administration O 0 0.025306493
of O 0 0.001025518
high O 0 0.0010468096
doses O 0 0.029812617
of O 0 0.0013270588
cefonicid B-Chemical 0 0.9973591
or O 0 0.0008923362
cefazedone B-Chemical 1 0.99820113
to O 0 0.0005377211
dogs O 0 0.0025094752
can O 0 0.0003515864
induce O 0 0.00059052743
hematotoxicity B-Disease 0 0.99970955
similar O 0 0.0003534772
to O 0 0.000317447
the O 0 0.00044210532
cephalosporin B-Chemical 0 0.9990864
- O 0 0.0023726814
induced O 0 0.0010506476
blood B-Disease 0 0.31857967
dyscrasias I-Disease 0 0.9992219
described O 0 0.00039872853
in O 0 0.0003114114
man O 0 0.054233596
and O 0 0.00032170906
thus O 0 0.0003815919
provides O 0 0.00023026839
a O 0 0.00031526765
useful O 0 0.0004163734
model O 0 0.0004527485
for O 0 0.00036410659
studying O 0 0.00088307116
the O 0 0.00077749125
mechanisms O 0 0.0019669686
of O 0 0.0022949665
these O 0 0.0052703028
disorders O 0 0.86217195
. O 0 0.007787917

Cerebral O 0 0.5333688
blood O 0 0.013289066
flow O 0 0.009465887
and O 0 0.00270357
metabolism O 0 0.17656396
during O 0 0.0015563352
isoflurane B-Chemical 1 0.9960963
- O 0 0.0043666256
induced O 0 0.0031364171
hypotension B-Disease 2 0.9994079
in O 0 0.0011061949
patients O 0 0.0023005852
subjected O 0 0.00074563443
to O 0 0.0011086008
surgery O 0 0.0055488776
for O 0 0.003119574
cerebral B-Disease 0 0.9919842
aneurysms I-Disease 2 0.9957307
. O 0 0.010905331

Cerebral O 0 0.51459396
blood O 0 0.011947592
flow O 0 0.008325366
and O 0 0.0023017523
cerebral O 0 0.7035077
metabolic O 0 0.13724783
rate O 0 0.0008708349
for O 0 0.0006738889
oxygen B-Chemical 1 0.8775096
were O 0 0.00063410663
measured O 0 0.00036799538
during O 0 0.00044838354
isoflurane B-Chemical 1 0.9967064
- O 0 0.002136766
induced O 0 0.0017333983
hypotension B-Disease 2 0.9996517
in O 0 0.0004947159
10 O 0 0.0004206287
patients O 0 0.000706416
subjected O 0 0.00027886932
to O 0 0.0004395839
craniotomy O 0 0.0344998
for O 0 0.00062497455
clipping O 0 0.0051557375
of O 0 0.0020869372
a O 0 0.004944796
cerebral B-Disease 0 0.99333304
aneurysm I-Disease 2 0.99573165
. O 0 0.010870303

Flow O 0 0.3272093
and O 0 0.0042497437
metabolism O 0 0.1027859
were O 0 0.0015643166
measured O 0 0.0008857406
5 O 0 0.0008324375
- O 0 0.0009528052
13 O 0 0.00052913843
days O 0 0.000347291
after O 0 0.00024601744
the O 0 0.0005687851
subarachnoid B-Disease 0 0.999236
haemorrhage I-Disease 0 0.99974006
by O 0 0.00082735665
a O 0 0.00051128154
modification O 0 0.00090794015
of O 0 0.00039937033
the O 0 0.0003147598
classical O 0 0.002081542
Kety O 0 0.54773676
- O 0 0.0010615683
Schmidt O 0 0.027932674
technique O 0 0.0007391354
using O 0 0.00034925624
xenon B-Chemical 0 0.8758306
- O 0 0.0012290615
133 O 0 0.003380244
i O 0 0.0010841892
. O 0 0.00021813036
v O 0 0.0029379225
. O 0 0.0002025058
Anaesthesia O 0 0.1756041
was O 0 0.00022107527
maintained O 0 0.00022639593
with O 0 0.0002738133
an O 0 0.00038120724
inspired O 0 0.004980351
isoflurane B-Chemical 1 0.9961188
concentration O 0 0.0034181315
of O 0 0.00049269263
0 O 0 0.00037824016
. O 0 0.00014429768
75 O 0 0.00035672536
% O 0 0.0002590844
( O 0 0.00025920421
plus O 0 0.00021981625
67 O 0 0.00056392717
% O 0 0.00036634394
nitrous B-Chemical 0 0.9766212
oxide I-Chemical 0 0.9967989
in O 0 0.00078727317
oxygen B-Chemical 1 0.9864271
) O 0 0.001649106
, O 0 0.00043874347
during O 0 0.00020910487
which O 0 0.00051081757
CBF O 0 0.7184886
and O 0 0.00054659677
CMRO2 O 0 0.983335
were O 0 0.00034973738
34 O 0 0.00045029284
. O 0 0.00016567
3 O 0 0.00022587481
+ O 0 0.00035926228
/ O 0 0.00068709697
- O 0 0.0004359197
2 O 0 0.00022268754
. O 0 0.00012536907
1 O 0 0.00019993224
ml O 0 0.0006457966
/ O 0 0.00043320467
100 O 0 0.00041728592
g O 0 0.0005496819
min O 0 0.00039799087
- O 0 0.0003403398
1 O 0 0.00019348087
and O 0 0.00019728056
2 O 0 0.00021027327
. O 0 0.00012965556
32 O 0 0.0003645157
+ O 0 0.00034598814
/ O 0 0.00067407644
- O 0 0.0004147093
0 O 0 0.00023601834
. O 0 0.00011328471
16 O 0 0.0002016328
ml O 0 0.0006259857
/ O 0 0.00044128596
100 O 0 0.00043029408
g O 0 0.00056827307
min O 0 0.00041047466
- O 0 0.00035448142
1 O 0 0.00020677882
at O 0 0.00016274433
PaCO2 O 0 0.6977257
4 O 0 0.00023341365
. O 0 0.00016159586
1 O 0 0.0002841604
+ O 0 0.0003965667
/ O 0 0.0007705076
- O 0 0.00054422807
0 O 0 0.00035887465
. O 0 0.00021239101
1 O 0 0.00042209605
kPa O 0 0.009835692
( O 0 0.000665039
mean O 0 0.00051666243
+ O 0 0.0013979797
/ O 0 0.0032105378
- O 0 0.0035528499
SEM O 0 0.00812401
) O 0 0.0066063735
. O 0 0.0054652556

Controlled O 0 0.013744098
hypotension B-Disease 2 0.9962076
to O 0 0.002774705
an O 0 0.002039507
average O 0 0.00096715183
MAP O 0 0.23726396
of O 0 0.0014451038
50 O 0 0.0016303516
- O 0 0.0011556366
55 O 0 0.0007658792
mm O 0 0.002640281
Hg B-Chemical 0 0.8443857
was O 0 0.00036320413
induced O 0 0.00042274516
by O 0 0.00030867365
increasing O 0 0.0004550792
the O 0 0.0003178816
dose O 0 0.008873931
of O 0 0.00075517455
isoflurane B-Chemical 1 0.99746525
, O 0 0.0006186226
and O 0 0.00030003226
maintained O 0 0.00026501974
at O 0 0.00016045952
an O 0 0.00034954408
inspired O 0 0.0016677179
concentration O 0 0.0013290718
of O 0 0.00057557144
2 O 0 0.00051146577
. O 0 0.00030464554
2 O 0 0.0005391512
+ O 0 0.00084273063
/ O 0 0.0017196889
- O 0 0.0015019737
0 O 0 0.001223904
. O 0 0.0009777566
2 O 0 0.0020568979
% O 0 0.0034606298
. O 0 0.0040571406

This O 0 0.0047933813
resulted O 0 0.0022773317
in O 0 0.0014751714
a O 0 0.0013648908
significant O 0 0.0013076875
decrease O 0 0.0012201901
in O 0 0.0009874273
CMRO2 O 0 0.9886764
( O 0 0.001166133
to O 0 0.0005063812
1 O 0 0.00048478317
. O 0 0.00025845008
73 O 0 0.00078635686
+ O 0 0.00055804127
/ O 0 0.0009458578
- O 0 0.00057932694
0 O 0 0.00032565184
. O 0 0.00016109263
16 O 0 0.00027702446
ml O 0 0.00080653466
/ O 0 0.00061689864
100 O 0 0.00062360254
g O 0 0.00087462476
min O 0 0.0007266498
- O 0 0.0007902063
1 O 0 0.00060463103
) O 0 0.0010182025
, O 0 0.0010243346
while O 0 0.0012491995
CBF O 0 0.57593054
was O 0 0.002728323
unchanged O 0 0.0051913382
. O 0 0.0058456855

After O 0 0.002775329
the O 0 0.0024516247
clipping O 0 0.005602543
of O 0 0.0023523811
the O 0 0.0021111965
aneurysm B-Disease 2 0.9514358
the O 0 0.002200022
isoflurane B-Chemical 1 0.99476045
concentration O 0 0.009401463
was O 0 0.0013685498
reduced O 0 0.0014157196
to O 0 0.0014875685
0 O 0 0.0020849828
. O 0 0.0015654541
75 O 0 0.0041006496
% O 0 0.004751241
. O 0 0.005322646

There O 0 0.0056311404
was O 0 0.002568739
a O 0 0.0020525323
significant O 0 0.0018440848
increase O 0 0.0013102333
in O 0 0.0012593188
CBF O 0 0.76099825
, O 0 0.0015958702
although O 0 0.0010946795
CMRO2 O 0 0.98023707
was O 0 0.0008756967
unchanged O 0 0.001038311
, O 0 0.0010188688
compared O 0 0.00057412015
with O 0 0.0014755474
pre O 0 0.009463423
- O 0 0.007053952
hypotensive B-Disease 2 0.99304354
values O 0 0.0067907292
. O 0 0.0071948506

These O 0 0.0057565775
changes O 0 0.004127715
might O 0 0.002044855
offer O 0 0.0032281196
protection O 0 0.004838769
to O 0 0.0019303564
brain O 0 0.025509287
tissue O 0 0.006221764
during O 0 0.0014871589
periods O 0 0.0030295947
of O 0 0.004551678
induced O 0 0.01913455
hypotension B-Disease 2 0.9983108
. O 0 0.013141927

Triazolam B-Chemical 0 0.9979049
- O 0 0.008103159
induced O 0 0.0033912945
brief O 0 0.0032100286
episodes O 0 0.07744709
of O 0 0.0032802254
secondary O 0 0.01878898
mania B-Disease 0 0.99767834
in O 0 0.0039038835
a O 0 0.0058252537
depressed B-Disease 2 0.6743965
patient O 0 0.013068515
. O 0 0.008947777

Large O 0 0.011460555
doses O 0 0.03020189
of O 0 0.005382675
triazolam B-Chemical 0 0.9995777
repeatedly O 0 0.004244341
induced O 0 0.0021085015
brief O 0 0.0021301706
episodes O 0 0.14506091
of O 0 0.0034349095
mania B-Disease 0 0.99832445
in O 0 0.0024346448
a O 0 0.0039892932
depressed B-Disease 2 0.84194106
elderly O 0 0.72728986
woman O 0 0.20962764
. O 0 0.008740173

Features O 0 0.033629976
of O 0 0.008040776
organic B-Disease 0 0.95042384
mental I-Disease 0 0.6903179
disorder I-Disease 0 0.98612
( O 0 0.019413173
delirium B-Disease 2 0.99750036
) O 0 0.007709806
were O 0 0.0035115501
not O 0 0.0038216289
present O 0 0.0050654956
. O 0 0.008397001

Manic B-Disease 0 0.9674164
excitement O 0 0.10760607
was O 0 0.0036558218
coincident O 0 0.0038195346
with O 0 0.0025272835
the O 0 0.002087255
duration O 0 0.0032100696
of O 0 0.0041835485
action O 0 0.026577955
of O 0 0.019107966
triazolam B-Chemical 0 0.99917716
. O 0 0.016205207

The O 0 0.0031946949
possible O 0 0.0026563343
contribution O 0 0.0016722867
of O 0 0.0020959654
the O 0 0.0020375252
triazolo B-Chemical 0 0.9825538
group O 0 0.002297902
to O 0 0.0013798657
changes O 0 0.0021792152
in O 0 0.0018617973
affective O 0 0.6939592
status O 0 0.004625477
is O 0 0.004025859
discussed O 0 0.0054953825
. O 0 0.0071421326

The O 0 0.0036108957
correlation O 0 0.0025224318
between O 0 0.0025287743
neurotoxic B-Disease 0 0.99420905
esterase O 0 0.9196967
inhibition O 0 0.05599038
and O 0 0.006406907
mipafox B-Chemical 0 0.99897325
- O 0 0.018803876
induced O 0 0.021562707
neuropathic B-Disease 0 0.9995407
damage I-Disease 0 0.9900913
in O 0 0.008507417
rats O 0 0.049380098
. O 0 0.008507304

The O 0 0.0028975643
correlation O 0 0.0019409319
between O 0 0.001920822
neuropathic B-Disease 0 0.9991937
damage I-Disease 0 0.9738704
and O 0 0.0025638177
inhibition O 0 0.011935496
of O 0 0.0029901904
neurotoxic B-Disease 0 0.9991007
esterase O 0 0.9670951
or O 0 0.0019515342
neuropathy B-Disease 0 0.9996846
target O 0 0.0015152914
enzyme O 0 0.34628692
( O 0 0.002587983
NTE O 0 0.9880778
) O 0 0.0010283842
was O 0 0.00029697237
examined O 0 0.00022046588
in O 0 0.0002807394
rats O 0 0.0021231035
acutely O 0 0.047057923
exposed O 0 0.00065930135
to O 0 0.0006695989
Mipafox B-Chemical 0 0.9992999
( O 0 0.0025182671
N B-Chemical 0 0.8677962
, I-Chemical 0 0.0017722194
N I-Chemical 0 0.7907727
' I-Chemical 0 0.0014822684
- I-Chemical 0 0.0020480733
diisopropylphosphorodiamidofluoridate I-Chemical 0 0.018889463
) O 0 0.0027780018
, O 0 0.0025625569
a O 0 0.005052497
neurotoxic B-Disease 0 0.9975604
organophosphate B-Chemical 0 0.9992323
. O 0 0.013931819

Brain O 0 0.32219377
and O 0 0.005185586
spinal O 0 0.093240164
cord O 0 0.2296321
NTE O 0 0.95887077
activities O 0 0.00221962
were O 0 0.0008292304
measured O 0 0.00052693015
in O 0 0.0006432983
Long O 0 0.017822454
- O 0 0.0014931201
Evans O 0 0.24559988
male O 0 0.0022172322
rats O 0 0.0018514654
1 O 0 0.00039339368
hr O 0 0.0006401153
post O 0 0.00046092478
- O 0 0.00053234067
exposure O 0 0.00086841325
to O 0 0.00028691208
various O 0 0.00073566707
dosages O 0 0.1934885
of O 0 0.0021206362
Mipafox B-Chemical 0 0.99948066
( O 0 0.0030055372
ip O 0 0.78180164
, O 0 0.0011689457
1 O 0 0.00082327187
- O 0 0.0011682247
15 O 0 0.0008770077
mg O 0 0.15590551
/ O 0 0.0044374396
kg O 0 0.01385726
) O 0 0.0060154167
. O 0 0.0050858683

These O 0 0.004421836
data O 0 0.0028071618
were O 0 0.0016714829
correlated O 0 0.0011233933
with O 0 0.001408749
histologically O 0 0.09588522
scored O 0 0.002162891
cervical O 0 0.5588574
cord B-Disease 0 0.8545064
damage I-Disease 0 0.8965506
in O 0 0.0005486542
a O 0 0.00042932446
separate O 0 0.00026013088
group O 0 0.0004204585
of O 0 0.00045526662
similarly O 0 0.00055839506
dosed O 0 0.016767053
rats O 0 0.0017228354
sampled O 0 0.00045365532
14 O 0 0.00076143467
- O 0 0.0010157388
21 O 0 0.00091572065
days O 0 0.000935384
post O 0 0.0020867744
- O 0 0.0038794947
exposure O 0 0.009386025
. O 0 0.0056140493

Those O 0 0.010510419
dosages O 0 0.18689485
( O 0 0.0026863536
greater O 0 0.001107761
than O 0 0.0005872754
or O 0 0.00050616096
equal O 0 0.0004177104
to O 0 0.00047582618
10 O 0 0.0005820323
mg O 0 0.23284662
/ O 0 0.00127619
kg O 0 0.0057923184
) O 0 0.0005913106
that O 0 0.00024303558
inhibited O 0 0.00066146353
mean O 0 0.00029601637
NTE O 0 0.9582252
activity O 0 0.0006446022
in O 0 0.00027177477
the O 0 0.0003078851
spinal O 0 0.04883384
cord O 0 0.040383108
greater O 0 0.00024175546
than O 0 0.00012897773
or O 0 0.00013925075
equal O 0 0.00014015286
to O 0 0.00018641603
73 O 0 0.0004847783
% O 0 0.00022749537
and O 0 0.00019769256
brain O 0 0.0043417057
greater O 0 0.00019728563
than O 0 0.00011526978
or O 0 0.00012850939
equal O 0 0.00013080337
to O 0 0.00017456146
67 O 0 0.0004246809
% O 0 0.00019370808
of O 0 0.0001888277
control O 0 0.00016177764
values O 0 0.00020741741
produced O 0 0.00028996394
severe O 0 0.09597143
( O 0 0.00045493347
greater O 0 0.00023759698
than O 0 0.00014661656
or O 0 0.00017563214
equal O 0 0.00019337113
to O 0 0.0002917275
3 O 0 0.00035671346
) O 0 0.0007817071
cervical O 0 0.17738245
cord O 0 0.124585964
pathology O 0 0.022769975
in O 0 0.0007185665
85 O 0 0.0013851356
% O 0 0.0011297077
of O 0 0.0015809196
the O 0 0.0025331923
rats O 0 0.011395556
. O 0 0.005749617

In O 0 0.0031945533
contrast O 0 0.0026171731
, O 0 0.0025093094
dosages O 0 0.13491729
of O 0 0.0030278163
Mipafox B-Chemical 0 0.9988952
( O 0 0.0016891332
less O 0 0.00056171935
than O 0 0.00025966624
or O 0 0.00025036666
equal O 0 0.00023082428
to O 0 0.00029428524
5 O 0 0.0003114859
mg O 0 0.18957202
/ O 0 0.000994342
kg O 0 0.0056507704
) O 0 0.00053391315
which O 0 0.00037283133
inhibited O 0 0.0006488275
mean O 0 0.0002765004
NTE O 0 0.9633097
activity O 0 0.0006991636
in O 0 0.0003258276
spinal O 0 0.062189028
cord O 0 0.050796326
less O 0 0.00024511694
than O 0 0.00012085356
or O 0 0.0001333376
equal O 0 0.00013691252
to O 0 0.00018607931
61 O 0 0.000429789
% O 0 0.0002268032
and O 0 0.00020266497
brain O 0 0.0052966163
less O 0 0.00021079318
than O 0 0.00011551053
or O 0 0.00013294975
equal O 0 0.00013813283
to O 0 0.00018616344
60 O 0 0.00026610692
% O 0 0.00022241149
produced O 0 0.00019206956
this O 0 0.0002321417
degree O 0 0.00044970663
of O 0 0.00079751574
cord B-Disease 0 0.7397464
damage I-Disease 0 0.8792976
in O 0 0.0007157731
only O 0 0.0007818301
9 O 0 0.0008714027
% O 0 0.0009811545
of O 0 0.001331171
the O 0 0.001957098
animals O 0 0.0033053427
. O 0 0.005013442

These O 0 0.0041329083
data O 0 0.0024995983
indicate O 0 0.0012499683
that O 0 0.0010146174
a O 0 0.0010337156
critical O 0 0.00081897434
percentage O 0 0.00047786025
of O 0 0.001184992
NTE O 0 0.98186
inhibition O 0 0.010701151
in O 0 0.00065532024
brain O 0 0.045287285
and O 0 0.00070696353
spinal O 0 0.07222546
cord O 0 0.04373128
sampled O 0 0.00030203897
shortly O 0 0.0006955568
after O 0 0.0003312897
Mipafox B-Chemical 0 0.99844044
exposure O 0 0.0053780056
can O 0 0.0005451026
predict O 0 0.0010421268
neuropathic B-Disease 0 0.9997321
damage I-Disease 0 0.9762931
in O 0 0.0015294533
rats O 0 0.0050548087
several O 0 0.0018676657
weeks O 0 0.0023645058
later O 0 0.0034353011
. O 0 0.0049091005

Allergic B-Disease 0 0.9681948
reaction I-Disease 0 0.07847159
to O 0 0.009539163
5 B-Chemical 0 0.008614204
- I-Chemical 0 0.016763203
fluorouracil I-Chemical 0 0.9894121
infusion O 0 0.43924764
. O 0 0.017851563

An O 0 0.012991843
allergic B-Disease 2 0.99388325
reaction I-Disease 2 0.1438354
consisting O 0 0.002417803
of O 0 0.0042003947
angioneurotic B-Disease 0 0.99960464
edema I-Disease 0 0.9997327
secondary O 0 0.02264438
to O 0 0.00066777255
continuous O 0 0.0006970489
infusion O 0 0.041561138
5 B-Chemical 0 0.00048628508
- I-Chemical 0 0.0008760059
fluorouracil I-Chemical 0 0.99760675
occurred O 0 0.00058443437
in O 0 0.0002528881
a O 0 0.0003045976
patient O 0 0.0005224501
with O 0 0.00053770107
recurrent O 0 0.682805
carcinoma B-Disease 2 0.99939716
of I-Disease 0 0.0014449642
the I-Disease 0 0.0006687347
oral I-Disease 0 0.52670676
cavity I-Disease 0 0.018264124
, O 0 0.0031862871
cirrhosis B-Disease 2 0.99985576
, O 0 0.0029064794
and O 0 0.0019300019
cisplatin B-Chemical 1 0.99895537
- O 0 0.005199555
induced O 0 0.0030256535
impaired B-Disease 0 0.03584966
renal I-Disease 0 0.99087733
function I-Disease 0 0.02720513
. O 0 0.007432495

This O 0 0.006851936
reaction O 0 0.007825628
occurred O 0 0.0030362168
during O 0 0.0016616667
the O 0 0.0018899911
sixth O 0 0.0051730336
and O 0 0.0023622517
seventh O 0 0.006470355
courses O 0 0.0059794113
of O 0 0.0067109824
infusional O 0 0.9906018
chemotherapy O 0 0.9644881
. O 0 0.012996711

Oral O 0 0.9650543
diphenhydramine B-Chemical 0 0.9995258
and O 0 0.009192791
prednisone B-Chemical 1 0.99823284
were O 0 0.002797139
ineffective O 0 0.017941315
in O 0 0.0014163115
preventing O 0 0.002886549
the O 0 0.0019313415
recurrence O 0 0.5366502
of O 0 0.004224868
the O 0 0.0059209736
allergic B-Disease 2 0.99675024
reaction I-Disease 2 0.74585277
. O 0 0.011830294

Discontinuance O 0 0.26080653
of O 0 0.0036967637
effective O 0 0.0037644587
chemotherapy O 0 0.5061956
in O 0 0.0013053108
this O 0 0.00097422954
patient O 0 0.0013852793
during O 0 0.00071639445
partial O 0 0.0023778128
remission O 0 0.47463012
resulted O 0 0.0018070267
in O 0 0.0026684362
fatal O 0 0.9872032
disease O 0 0.9636847
progression O 0 0.8970066
. O 0 0.01005532

Myasthenia B-Disease 0 0.9800654
gravis I-Disease 0 0.9946531
caused O 0 0.011021729
by O 0 0.007378101
penicillamine B-Chemical 1 0.9989767
and O 0 0.0128580015
chloroquine B-Chemical 1 0.99634236
therapy O 0 0.42890885
for O 0 0.011464467
rheumatoid B-Disease 2 0.997029
arthritis I-Disease 2 0.99829644
. O 0 0.027494803

We O 0 0.0030914403
have O 0 0.0022360722
described O 0 0.0013463657
a O 0 0.0013177076
unique O 0 0.0013427882
patient O 0 0.001510668
who O 0 0.0016987247
had O 0 0.0008596718
reversible O 0 0.10814608
and O 0 0.00093848706
dose O 0 0.030227317
- O 0 0.0012876543
related O 0 0.0006205503
myasthenia B-Disease 0 0.99814343
gravis I-Disease 0 0.99869066
after O 0 0.001439779
penicillamine B-Chemical 1 0.9997378
and O 0 0.006615856
chloroquine B-Chemical 1 0.99814165
therapy O 0 0.35041818
for O 0 0.00668519
rheumatoid B-Disease 2 0.99819297
arthritis I-Disease 2 0.9988564
. O 0 0.019988585

Although O 0 0.0065378086
acetylcholine B-Chemical 1 0.9943786
receptor O 0 0.27664903
antibodies O 0 0.0057809344
were O 0 0.001456201
not O 0 0.00094371906
detectable O 0 0.0007067291
, O 0 0.00089291023
the O 0 0.00055045605
time O 0 0.000553943
course O 0 0.0012210988
was O 0 0.0009516638
consistent O 0 0.0012244409
with O 0 0.0021345578
an O 0 0.004514627
autoimmune O 0 0.98198366
process O 0 0.012236895
. O 0 0.008270154

On O 0 0.003940631
the O 0 0.0021888753
mechanisms O 0 0.0025219063
of O 0 0.0016922978
the O 0 0.0012189419
development O 0 0.0021090335
of O 0 0.0014515837
tolerance O 0 0.04148716
to O 0 0.0010131616
the O 0 0.0011466328
muscular B-Disease 0 0.50737816
rigidity I-Disease 2 0.9646135
produced O 0 0.0025578504
by O 0 0.003926841
morphine B-Chemical 1 0.99851817
in O 0 0.005766793
rats O 0 0.034120128
. O 0 0.0072425962

The O 0 0.0035489525
development O 0 0.0043504173
of O 0 0.0028434787
tolerance O 0 0.025924431
to O 0 0.0016513058
the O 0 0.0015854775
muscular B-Disease 0 0.43808118
rigidity I-Disease 2 0.9585056
produced O 0 0.0023026
by O 0 0.0028431856
morphine B-Chemical 1 0.9988023
was O 0 0.0033014838
studied O 0 0.0041612815
in O 0 0.0038225015
rats O 0 0.01684981
. O 0 0.007316075

Saline O 0 0.98568416
- O 0 0.0067390027
pretreated O 0 0.012386782
controls O 0 0.0017410864
given O 0 0.0007123084
a O 0 0.00078462256
test O 0 0.0007844562
dose O 0 0.0076335575
of O 0 0.0014735976
morphine B-Chemical 1 0.99955076
( O 0 0.0017022092
20 O 0 0.00071281707
mg O 0 0.28492486
/ O 0 0.0011379962
kg O 0 0.003410861
i O 0 0.0009322472
. O 0 0.00022514505
p O 0 0.00046294302
. O 0 0.00021921286
) O 0 0.000485086
showed O 0 0.000315243
a O 0 0.00048540233
pronounced O 0 0.0014207588
rigidity B-Disease 2 0.8582815
recorded O 0 0.001074985
as O 0 0.0008399636
tonic O 0 0.46174547
activity O 0 0.0020589102
in O 0 0.0017862958
the O 0 0.0033553247
electromyogram O 0 0.79661345
. O 0 0.0072136633

Rats O 0 0.03892821
treated O 0 0.0035989713
for O 0 0.0014319875
11 O 0 0.0012406731
days O 0 0.0008192436
with O 0 0.0010912893
morphine B-Chemical 1 0.9986953
and O 0 0.0010133457
withdrawn O 0 0.0035641002
for O 0 0.00038358054
36 O 0 0.0004826774
- O 0 0.00046419707
40 O 0 0.00026892324
h O 0 0.00020388406
showed O 0 0.00017115341
differences O 0 0.00013954382
in O 0 0.00016634668
the O 0 0.00019508769
development O 0 0.00055187027
of O 0 0.00042301446
tolerance O 0 0.078057766
: O 0 0.0004884993
about O 0 0.00016034555
half O 0 0.00011946534
of O 0 0.00022275953
the O 0 0.0001824447
animals O 0 0.000187011
showed O 0 0.00022457176
a O 0 0.00034784735
rigidity B-Disease 2 0.75813806
after O 0 0.00014594912
the O 0 0.00018178902
test O 0 0.0002658179
dose O 0 0.005523735
of O 0 0.0006794419
morphine B-Chemical 1 0.99964535
that O 0 0.000362901
was O 0 0.00029085437
not O 0 0.0002171776
significantly O 0 0.0003172062
less O 0 0.00026094588
than O 0 0.00016631038
in O 0 0.00022580978
the O 0 0.00029301055
controls O 0 0.0006451209
and O 0 0.0006636549
were O 0 0.0011560197
akinetic B-Disease 2 0.98974156
( O 0 0.0027897207
A O 0 0.015809732
group O 0 0.0039730496
) O 0 0.0068885027
. O 0 0.0054464736

The O 0 0.0027689885
other O 0 0.0021872907
rats O 0 0.004018077
showed O 0 0.0012162251
a O 0 0.001031971
strong O 0 0.0010122779
decrease O 0 0.0008916223
in O 0 0.00053263357
the O 0 0.000600093
rigidity B-Disease 2 0.85981333
and O 0 0.0006070524
the O 0 0.00040770564
occurrence O 0 0.0012966396
of O 0 0.0009784815
stereotyped O 0 0.8752608
( O 0 0.0021805149
S O 0 0.7330969
) O 0 0.0015005448
licking O 0 0.45502436
and O 0 0.0005240344
/ O 0 0.0010704935
or O 0 0.0003424331
gnawing O 0 0.76106006
in O 0 0.0002735873
presence O 0 0.00031591332
of O 0 0.00075192016
akinetic B-Disease 2 0.9962121
or O 0 0.0008010452
hyperkinetic B-Disease 0 0.99951136
( O 0 0.004783396
K O 1 0.9940574
) O 0 0.0019094398
behaviour O 0 0.0036052354
( O 0 0.00097623095
AS O 0 0.34095797
/ O 0 0.0042160302
KS O 0 0.92971885
group O 0 0.0013259489
) O 0 0.0014380737
, O 0 0.0009939764
suggesting O 0 0.0009269171
signs O 0 0.09967244
of O 0 0.0045872964
dopaminergic O 0 0.9845383
activation O 0 0.027652783
. O 0 0.006802098

The O 0 0.004639978
rigidity B-Disease 2 0.69913775
was O 0 0.0027484295
considerably O 0 0.002531405
decreased O 0 0.0026794255
in O 0 0.0012538604
both O 0 0.001209096
groups O 0 0.0014196688
after O 0 0.00095159863
20 O 0 0.0017752657
days O 0 0.0020036232
' O 0 0.0036723607
treatment O 0 0.008751011
. O 0 0.0073195724

In O 0 0.0027522235
a O 0 0.0019807778
further O 0 0.0014836631
series O 0 0.001701913
of O 0 0.0012032228
experiments O 0 0.0010507806
, O 0 0.0024859668
haloperidol B-Chemical 1 0.999876
( O 0 0.002028887
0 O 0 0.0006278097
. O 0 0.00024250134
2 O 0 0.0003414138
mg O 0 0.11005093
/ O 0 0.0008129544
kg O 0 0.002432877
i O 0 0.00077883236
. O 0 0.00018072197
p O 0 0.0003740899
. O 0 0.0001643308
) O 0 0.0003612014
was O 0 0.00019278111
used O 0 0.00017320838
in O 0 0.00016190464
order O 0 0.00013759152
to O 0 0.00018946812
block O 0 0.00043081917
the O 0 0.0003373126
dopaminergic O 0 0.9475396
activation O 0 0.0012727822
and O 0 0.0002727214
to O 0 0.00018953969
estimate O 0 0.00015098606
the O 0 0.00019401658
real O 0 0.0002934302
degree O 0 0.00040663572
of O 0 0.0004670517
the O 0 0.00046090523
tolerance O 0 0.029982943
to O 0 0.000637587
the O 0 0.0009238176
rigidity B-Disease 2 0.90476894
without O 0 0.0019550992
any O 0 0.0024853684
dopaminergic O 0 0.96171397
interference O 0 0.015360552
. O 0 0.006647866

Haloperidol B-Chemical 1 0.99861336
enhanced O 0 0.013817823
the O 0 0.008635561
rigidity B-Disease 2 0.9029747
in O 0 0.007092243
the O 0 0.0078920545
A O 0 0.03200347
group O 0 0.014698267
. O 0 0.014091793

However O 0 0.004655561
, O 0 0.0032014945
the O 0 0.0016557595
level O 0 0.0011774702
in O 0 0.0011036792
the O 0 0.0012425819
AS O 0 0.31704807
/ O 0 0.0052222903
KS O 0 0.89342934
group O 0 0.0012798967
remained O 0 0.0011758496
considerably O 0 0.0011724225
lower O 0 0.0009503175
than O 0 0.00079360243
in O 0 0.0012943952
the O 0 0.002261906
A O 0 0.016445933
group O 0 0.0066388925
. O 0 0.0068525043

The O 0 0.0026895236
results O 0 0.0018570379
suggest O 0 0.0013721334
that O 0 0.0014956126
rigidity B-Disease 2 0.9140602
, O 0 0.001851395
which O 0 0.0011230349
is O 0 0.00060197787
assumed O 0 0.0005610476
to O 0 0.00039936346
be O 0 0.00038588332
due O 0 0.00022237119
to O 0 0.0002810527
an O 0 0.00044232703
action O 0 0.0028301198
of O 0 0.0008641725
morphine B-Chemical 1 0.9996495
in O 0 0.0006057681
the O 0 0.0005966901
striatum O 0 0.73070675
, O 0 0.0005655106
can O 0 0.0002903421
be O 0 0.000405213
antagonized O 0 0.32656828
by O 0 0.00047870044
another O 0 0.0005600626
process O 0 0.00068586547
leading O 0 0.0016131904
to O 0 0.0010846974
dopaminergic O 0 0.9630073
activation O 0 0.004750891
in O 0 0.0018636376
the O 0 0.0034503296
striatum O 0 0.69100225
. O 0 0.005902008

Nevertheless O 0 0.0061846636
, O 0 0.004634583
there O 0 0.0021942516
occurs O 0 0.0025291895
some O 0 0.002802639
real O 0 0.0035132458
tolerance O 0 0.034390204
to O 0 0.003978374
this O 0 0.0050178827
effect O 0 0.008752808
. O 0 0.009931527

The O 0 0.003021675
rapid O 0 0.004462453
alternations O 0 0.010080927
of O 0 0.0026548833
rigidity B-Disease 2 0.91120523
and O 0 0.0014094871
the O 0 0.0008529706
signs O 0 0.07603801
of O 0 0.001499108
dopaminergic O 0 0.9847622
activation O 0 0.0029190858
observed O 0 0.00031619417
in O 0 0.00026014302
the O 0 0.00023898382
animals O 0 0.00023729204
of O 0 0.00037857672
the O 0 0.00041731776
AS O 0 0.4419755
/ O 0 0.0047452897
KS O 0 0.936729
group O 0 0.000620768
might O 0 0.00026152475
be O 0 0.00029243372
due O 0 0.00018269694
to O 0 0.00026010635
rapid O 0 0.00091202644
shifts O 0 0.0008621106
in O 0 0.0003614415
the O 0 0.00045122072
predominance O 0 0.0014086699
of O 0 0.0013620178
various O 0 0.009803872
DA O 0 0.9972494
- O 0 0.010767345
innervated O 0 0.16413955
structures O 0 0.0096344985
. O 0 0.0061223027

A O 0 0.024882225
case O 0 0.0076555074
of O 0 0.009056611
massive O 0 0.3275817
rhabdomyolysis B-Disease 0 0.9990601
following O 0 0.11076867
molindone B-Chemical 0 0.9994789
administration O 0 0.93123823
. O 0 0.01942726

Rhabdomyolysis B-Disease 0 0.99627006
is O 0 0.004694567
a O 0 0.003203529
potentially O 0 0.0050370307
lethal O 0 0.05462562
syndrome O 0 0.84691256
that O 0 0.00252049
psychiatric B-Disease 2 0.9719876
patients O 0 0.015796345
seem O 0 0.0040956577
predisposed O 0 0.086943775
to O 0 0.004272776
develop O 0 0.008877948
. O 0 0.007867635

The O 0 0.0035559456
clinical O 0 0.008099249
signs O 0 0.05305087
and O 0 0.0026098385
symptoms O 0 0.21199991
, O 0 0.0017120318
typical O 0 0.0013525538
laboratory O 0 0.0018721635
features O 0 0.0026912584
, O 0 0.0014796251
and O 0 0.0014750079
complications O 0 0.43424326
of O 0 0.0070790127
rhabdomyolysis B-Disease 0 0.9995358
are O 0 0.0073738275
presented O 0 0.008081998
. O 0 0.0073084217

The O 0 0.002880437
case O 0 0.002313556
of O 0 0.002202743
a O 0 0.0024786263
schizophrenic B-Disease 2 0.995939
patient O 0 0.0030337307
is O 0 0.0009880282
reported O 0 0.0010195092
to O 0 0.000577617
illustrate O 0 0.0007399603
massive O 0 0.12681662
rhabdomyolysis B-Disease 0 0.9998247
and O 0 0.0019930692
subsequent O 0 0.002822725
acute B-Disease 0 0.9891481
renal I-Disease 0 0.99750656
failure I-Disease 0 0.9684483
following O 0 0.046004888
molindone B-Chemical 0 0.9998197
administration O 0 0.8943589
. O 0 0.009640583

Physicians O 0 0.01391171
who O 0 0.010609354
prescribe O 0 0.115116365
molindone B-Chemical 0 0.9993082
should O 0 0.0036975227
be O 0 0.0035644763
aware O 0 0.0038221858
of O 0 0.0046946565
this O 0 0.0060702306
reaction O 0 0.030115042
. O 0 0.011569148

Compression B-Disease 0 0.7370027
neuropathy I-Disease 0 0.99557894
of I-Disease 0 0.0060152793
the I-Disease 0 0.003523522
radial I-Disease 0 0.014626799
nerve I-Disease 0 0.40053424
due O 0 0.0025250656
to O 0 0.0045388173
pentazocine B-Chemical 1 0.999622
- O 0 0.031023154
induced O 0 0.017283637
fibrous B-Disease 0 0.9771209
myopathy I-Disease 2 0.9978988
. O 0 0.01877318

Fibrous B-Disease 0 0.8111057
myopathy I-Disease 2 0.9963857
is O 0 0.0039859884
a O 0 0.0024759844
common O 0 0.0026935902
, O 0 0.0019499997
well O 0 0.0011900805
- O 0 0.0020581363
known O 0 0.0016474074
side O 0 0.006734539
effect O 0 0.0016731436
of O 0 0.0025197268
repeated O 0 0.0057529164
pentazocine B-Chemical 1 0.99954295
injection O 0 0.23612425
. O 0 0.009420996

However O 0 0.0060193012
, O 0 0.005685414
compression B-Disease 0 0.693053
neuropathy I-Disease 0 0.99916184
due O 0 0.0017962586
to O 0 0.0014611989
fibrotic O 0 0.54495025
muscle O 0 0.14842759
affected O 0 0.0011963978
by O 0 0.0020189176
pentazocine B-Chemical 1 0.9999058
- O 0 0.013742205
induced O 0 0.0050505223
myopathy B-Disease 2 0.99826705
has O 0 0.0020317421
not O 0 0.0017106166
previously O 0 0.0024315463
been O 0 0.00396177
reported O 0 0.006949937
. O 0 0.0061928793

In O 0 0.0032429534
a O 0 0.0026444797
37 O 0 0.00293949
- O 0 0.0022520788
year O 0 0.0013169653
- O 0 0.0014670896
old O 0 0.00094051904
woman O 0 0.005261815
with O 0 0.0009886939
documented O 0 0.0056028375
pentazocine B-Chemical 1 0.99993217
- O 0 0.010263883
induced O 0 0.0024360034
fibrous B-Disease 0 0.93774027
myopathy I-Disease 2 0.99964
of O 0 0.0034872403
triceps O 0 0.9798197
and O 0 0.00065347477
deltoid O 0 0.47653466
muscles O 0 0.013965661
bilaterally O 0 0.01878073
and O 0 0.0002363942
a O 0 0.00021959169
three O 0 0.00012167606
- O 0 0.00029896692
week O 0 0.00016529161
history O 0 0.0012772942
of O 0 0.000352338
right O 0 0.0010056166
wrist O 0 0.09563602
drop O 0 0.0011792695
, O 0 0.00044022486
electrodiagnostic O 0 0.23853424
examination O 0 0.0006902233
showed O 0 0.0002868716
a O 0 0.00037374397
severe O 0 0.052187763
but O 0 0.00030299393
partial O 0 0.0007610723
lesion O 0 0.02140995
of O 0 0.00039820813
the O 0 0.0003077771
right O 0 0.0009838345
radial O 0 0.0048079425
nerve O 0 0.27135766
distal O 0 0.00066886767
to O 0 0.00028212043
the O 0 0.0002964493
branches O 0 0.0008721593
to O 0 0.00036972616
the O 0 0.0005273774
triceps O 0 0.8480738
, O 0 0.00084926066
in O 0 0.00053324335
addition O 0 0.0005811653
to O 0 0.0011665674
the O 0 0.0024484908
fibrous B-Disease 0 0.9324965
myopathy I-Disease 2 0.998131
. O 0 0.011943584

Surgery O 0 0.011553748
revealed O 0 0.0031769383
the O 0 0.0021977718
right O 0 0.003438277
radial O 0 0.007218695
nerve O 0 0.25778314
to O 0 0.0012813677
be O 0 0.0011363352
severely O 0 0.0033406706
compressed O 0 0.0022592053
by O 0 0.00088924414
the O 0 0.00089255086
densely O 0 0.0029239848
fibrotic O 0 0.5211134
lateral O 0 0.029911589
head O 0 0.023666224
of O 0 0.0035840129
the O 0 0.004903083
triceps O 0 0.94481415
. O 0 0.008088822

Decompression O 0 0.08223095
and O 0 0.0053366376
neurolysis O 0 0.09292999
were O 0 0.0026157307
performed O 0 0.0020484535
with O 0 0.0024150617
good O 0 0.0029852933
subsequent O 0 0.0034697372
recovery O 0 0.0072739944
of O 0 0.0067864144
function O 0 0.011161862
. O 0 0.01044421

Recurrent O 0 0.67685544
reversible O 0 0.6606434
acute B-Disease 0 0.97696006
renal I-Disease 0 0.9898789
failure I-Disease 0 0.9495448
from O 0 0.029967567
amphotericin B-Chemical 0 0.9932287
. O 0 0.025873693

A O 0 0.018505149
patient O 0 0.0056921593
with O 0 0.005419242
cryptogenic O 0 0.9986539
cirrhosis B-Disease 2 0.99977905
and O 0 0.015449244
disseminated O 0 0.99154097
sporotrichosis B-Disease 0 0.9985311
developed O 0 0.023965811
acute B-Disease 0 0.9885988
renal I-Disease 0 0.9975783
failure I-Disease 0 0.8223957
immediately O 0 0.00076362473
following O 0 0.00056998344
the O 0 0.0005642091
administration O 0 0.07379874
of O 0 0.002561905
amphotericin B-Chemical 1 0.99933076
B I-Chemical 1 0.608413
on O 0 0.0010060664
four O 0 0.0013082847
separate O 0 0.00229892
occasions O 0 0.008992281
. O 0 0.0059289555

The O 0 0.0032518683
abruptness O 0 0.010192853
of O 0 0.002376655
the O 0 0.0018320819
renal B-Disease 0 0.97345394
failure I-Disease 0 0.64558184
and O 0 0.0012189215
its O 0 0.0015223592
reversibility O 0 0.041996945
within O 0 0.00027972253
days O 0 0.0003552938
suggests O 0 0.00024416065
that O 0 0.00027835296
there O 0 0.00027021088
was O 0 0.00045636462
a O 0 0.0006152842
functional O 0 0.0010469112
component O 0 0.0011529691
to O 0 0.0014034824
the O 0 0.0030354937
renal B-Disease 2 0.9964683
dysfunction I-Disease 2 0.9949845
. O 0 0.011663686

We O 0 0.0032438505
propose O 0 0.0025460878
that O 0 0.0023266554
amphotericin B-Chemical 0 0.996872
, O 0 0.0023700553
in O 0 0.0007943711
the O 0 0.00059911824
setting O 0 0.00075864146
of O 0 0.00067955593
reduced O 0 0.0006838711
effective O 0 0.0012753803
arterial O 0 0.64540076
volume O 0 0.004910478
, O 0 0.00075509865
may O 0 0.00045841341
activate O 0 0.00048010613
tubuloglomerular O 0 0.76095706
feedback O 0 0.0017398156
, O 0 0.0010959082
thereby O 0 0.0015505769
contributing O 0 0.0019381774
to O 0 0.002130417
acute B-Disease 0 0.9842539
renal I-Disease 0 0.99584705
failure I-Disease 0 0.96525216
. O 0 0.010418545

Cerebral B-Disease 0 0.9802412
infarction I-Disease 2 0.99860317
with O 0 0.008912329
a O 0 0.005555744
single O 0 0.005422266
oral O 0 0.38320488
dose O 0 0.15686224
of O 0 0.027635647
phenylpropanolamine B-Chemical 0 0.9989477
. O 0 0.022099745

Phenylpropanolamine B-Chemical 1 0.99641114
( O 0 0.0148745105
PPA B-Chemical 1 0.9928463
) O 0 0.0050323275
, O 0 0.0018668196
a O 0 0.0011923068
synthetic O 0 0.0031538398
sympathomimetic O 0 0.9977308
that O 0 0.00083216856
is O 0 0.00066221
structurally O 0 0.0034193208
similar O 0 0.00037644853
to O 0 0.00062564795
amphetamine B-Chemical 1 0.9998448
, O 0 0.0011691973
is O 0 0.0003995291
available O 0 0.00030595012
over O 0 0.0001846345
the O 0 0.00033576135
counter O 0 0.0014019294
in O 0 0.00067678385
anorectics O 0 0.95818514
, O 0 0.0014025003
nasal O 0 0.016900623
congestants O 0 0.014927707
, O 0 0.0020119825
and O 0 0.002179713
cold O 0 0.03425637
preparations O 0 0.0155767575
. O 0 0.0067617917

Its O 0 0.055262007
prolonged O 0 0.0102368845
use O 0 0.0030288037
or O 0 0.0018384098
overuse O 0 0.6057841
has O 0 0.0015248741
been O 0 0.0013704598
associated O 0 0.0015169688
with O 0 0.00263026
seizures B-Disease 2 0.9997559
, O 0 0.011350472
intracerebral B-Disease 0 0.99847406
hemorrhage I-Disease 2 0.99961424
, O 0 0.018820597
neuropsychiatric B-Disease 0 0.99929094
symptoms I-Disease 0 0.9816616
, O 0 0.00432366
and O 0 0.0047776294
nonhemorrhagic O 0 0.998324
cerebral B-Disease 0 0.9956261
infarction I-Disease 2 0.9994221
. O 0 0.014977403

We O 0 0.003281448
report O 0 0.004173281
the O 0 0.0016485653
case O 0 0.0014072218
of O 0 0.001388961
a O 0 0.0013327172
young O 0 0.0058737136
woman O 0 0.017860562
who O 0 0.0028534508
suffered O 0 0.13442034
a O 0 0.0019313599
cerebral B-Disease 0 0.98401904
infarction I-Disease 2 0.9997372
after O 0 0.0008103666
taking O 0 0.0021016162
a O 0 0.0010906825
single O 0 0.0014734734
oral O 0 0.34136766
dose O 0 0.09330806
of O 0 0.0111238165
PPA B-Chemical 1 0.993097
. O 0 0.009345082

Remission O 0 0.90585953
induction O 0 0.008066638
of O 0 0.00842692
meningeal B-Disease 0 0.9967135
leukemia I-Disease 0 0.9993729
with O 0 0.008966342
high O 0 0.0067846505
- O 0 0.008166516
dose O 0 0.14353938
intravenous O 0 0.9656078
methotrexate B-Chemical 1 0.99809486
. O 0 0.017012065

Twenty O 0 0.009464958
children O 0 0.006578893
with O 0 0.004614086
acute B-Disease 2 0.99264234
lymphoblastic I-Disease 2 0.99971646
leukemia I-Disease 2 0.9998247
who O 0 0.10751615
developed O 0 0.020010313
meningeal B-Disease 0 0.9986791
disease I-Disease 0 0.98875684
were O 0 0.00084812875
treated O 0 0.0009951561
with O 0 0.000485482
a O 0 0.00042366155
high O 0 0.00061562494
- O 0 0.0007668936
dose O 0 0.014544762
intravenous O 0 0.7349459
methotrexate B-Chemical 1 0.9997445
regimen O 0 0.044671692
that O 0 0.00026738335
was O 0 0.00023914561
designed O 0 0.00023421041
to O 0 0.00017586778
achieve O 0 0.00018143056
and O 0 0.00024034774
maintain O 0 0.00028018374
CSF O 0 0.5440084
methotrexate B-Chemical 1 0.99965525
concentrations O 0 0.013787459
of O 0 0.00075079245
10 O 0 0.00057343463
( O 0 0.0005823075
- O 0 0.0005600303
5 O 0 0.0002861832
) O 0 0.00057597354
mol O 0 0.061827924
/ O 0 0.0016573643
L O 0 0.12419251
without O 0 0.00053753454
the O 0 0.00050211296
need O 0 0.0005832221
for O 0 0.00085276767
concomitant O 0 0.022104712
intrathecal O 0 0.9760867
dosing O 0 0.46381846
. O 0 0.0069586234

The O 0 0.004008724
methotrexate B-Chemical 1 0.99627066
was O 0 0.0025614018
administered O 0 0.0032567577
as O 0 0.00076028035
a O 0 0.0007658657
loading O 0 0.0011395378
dose O 0 0.007116285
of O 0 0.00070582115
6 O 0 0.00035894036
, O 0 0.00041805656
000 O 0 0.00042912463
mg O 0 0.13442597
/ O 0 0.0007432851
m2 O 0 0.005762634
for O 0 0.00017275693
a O 0 0.00020790291
period O 0 0.00017749838
of O 0 0.0002228959
one O 0 0.00014704959
hour O 0 0.00019106496
followed O 0 0.00016279273
by O 0 0.00024221597
an O 0 0.0003747552
infusion O 0 0.008031118
of O 0 0.00046886117
1 O 0 0.00043412036
, O 0 0.00047391665
200 O 0 0.0011215701
mg O 0 0.21132609
/ O 0 0.0016350992
m2 O 0 0.01726383
/ O 0 0.0016368974
h O 0 0.0010202811
for O 0 0.0011051105
23 O 0 0.003015828
hours O 0 0.0032066065
. O 0 0.0044993367

Leucovorin B-Chemical 0 0.99595284
rescue O 0 0.003868439
was O 0 0.0015839218
initiated O 0 0.0011775038
12 O 0 0.00054853887
hours O 0 0.00042207312
after O 0 0.0002359686
the O 0 0.0002756255
end O 0 0.00018935288
of O 0 0.00035565707
the O 0 0.0003117628
infusion O 0 0.011038342
with O 0 0.00038767565
a O 0 0.0003324014
loading O 0 0.00060374505
dose O 0 0.006302531
of O 0 0.00044099893
200 O 0 0.0015659312
mg O 0 0.34838817
/ O 0 0.00085509854
m2 O 0 0.009237036
followed O 0 0.00015474303
by O 0 0.00019895821
12 O 0 0.0001782803
mg O 0 0.114545606
/ O 0 0.0005310891
m2 O 0 0.0035924928
every O 0 7.221342e-05
three O 0 6.733414e-05
hours O 0 0.000114966024
for O 0 9.853422e-05
six O 0 0.00010181501
doses O 0 0.0032434377
and O 0 0.00019772687
then O 0 0.00013285292
every O 0 7.199079e-05
six O 0 8.554996e-05
hours O 0 0.00013496986
until O 0 9.863069e-05
the O 0 0.00018952866
plasma O 0 0.025739796
methotrexate B-Chemical 1 0.9994597
level O 0 0.00034655991
decreased O 0 0.00094773236
to O 0 0.00030465075
less O 0 0.00035502613
than O 0 0.00025820374
1 O 0 0.0005214699
X O 0 0.044385724
10 O 0 0.00072041806
( O 0 0.00096772506
- O 0 0.0012651399
7 O 0 0.0009389983
) O 0 0.0022494188
mol O 0 0.12779617
/ O 0 0.010964954
L O 0 0.42169726
. O 0 0.0070645344

The O 0 0.0025414745
mean O 0 0.0015049049
steady O 0 0.0022207312
- O 0 0.0022454232
state O 0 0.0016045918
plasma O 0 0.016274072
and O 0 0.0012567489
CSF O 0 0.6475307
methotrexate B-Chemical 1 0.99949884
concentrations O 0 0.017553695
achieved O 0 0.0008897404
were O 0 0.00048493827
1 O 0 0.00042240095
. O 0 0.00022579772
1 O 0 0.0003749189
X O 0 0.03198812
10 O 0 0.00042609227
( O 0 0.00049650756
- O 0 0.000502172
3 O 0 0.00027031443
) O 0 0.000546189
mol O 0 0.06374432
/ O 0 0.001604879
L O 0 0.19405167
and O 0 0.0004389164
3 O 0 0.00031705684
. O 0 0.00020862711
6 O 0 0.00028962744
X O 0 0.019188495
10 O 0 0.00053783617
( O 0 0.0007087829
- O 0 0.00086107827
5 O 0 0.0005740082
) O 0 0.0013299912
mol O 0 0.088938296
/ O 0 0.005790043
L O 0 0.3496173
, O 0 0.0047592144
respectively O 0 0.008472643
. O 0 0.0057895295

All O 0 0.0034284336
20 O 0 0.002439154
patients O 0 0.0028528133
responded O 0 0.0019884668
to O 0 0.000892349
this O 0 0.00078213157
regimen O 0 0.004640295
, O 0 0.0009638586
16 O 0 0.00066234125
/ O 0 0.00092948234
20 O 0 0.000503184
( O 0 0.00047112993
80 O 0 0.0005134203
% O 0 0.00040028684
) O 0 0.00044408752
achieved O 0 0.00036516713
a O 0 0.0003762279
complete O 0 0.0004540531
remission O 0 0.2607217
, O 0 0.0007421304
and O 0 0.0006109751
20 O 0 0.00076427526
% O 0 0.0007943084
obtained O 0 0.0008566822
a O 0 0.0017980994
partial O 0 0.00605557
remission O 0 0.6569045
. O 0 0.0066142087

The O 0 0.003648867
most O 0 0.004193551
common O 0 0.004728122
toxicities B-Disease 2 0.9948271
encountered O 0 0.0048348308
were O 0 0.0017084277
transient O 0 0.06353044
serum O 0 0.5267129
transaminase O 0 0.9995913
and O 0 0.007751817
bilirubin B-Chemical 1 0.99897826
elevations O 0 0.8337125
, O 0 0.010760699
neutropenia B-Disease 2 0.9981346
, O 0 0.007861986
and O 0 0.009645824
mucositis B-Disease 2 0.9984524
. O 0 0.011349204

One O 0 0.007163508
patient O 0 0.005618888
had O 0 0.0042690244
focal O 0 0.19248551
seizures B-Disease 2 0.9990252
and O 0 0.009403889
transient B-Disease 0 0.88466334
hemiparesis I-Disease 0 0.9991234
but O 0 0.006515017
recovered O 0 0.0052452
completely O 0 0.008322718
. O 0 0.0087787425

High O 0 0.04089306
- O 0 0.005877474
dose O 0 0.029587304
intravenous O 0 0.8063763
methotrexate B-Chemical 1 0.99925727
is O 0 0.0017756737
an O 0 0.0011440421
effective O 0 0.0010949742
treatment O 0 0.0013090076
for O 0 0.00044884623
the O 0 0.00048443675
induction O 0 0.00085862644
of O 0 0.0010318938
remission O 0 0.6261658
after O 0 0.0009672254
meningeal O 0 0.993845
relapse O 0 0.9891515
in O 0 0.007060334
acute B-Disease 2 0.9973999
lymphoblastic I-Disease 2 0.99964297
leukemia I-Disease 2 0.9995221
. O 0 0.039540134

Interaction O 0 0.029788896
of O 0 0.018411072
cyclosporin B-Chemical 1 0.99815947
A I-Chemical 1 0.53065515
with O 0 0.022443771
antineoplastic O 0 0.9812454
agents O 0 0.8168883
. O 0 0.023269994

A O 0 0.017422752
synergistic O 0 0.009267335
effect O 0 0.002978361
of O 0 0.0033512898
etoposide B-Chemical 1 0.99802774
and O 0 0.006030523
cyclosporin B-Chemical 1 0.99985456
A I-Chemical 1 0.5246913
was O 0 0.0010679252
observed O 0 0.0005395701
in O 0 0.00052214717
a O 0 0.0007218234
patient O 0 0.0013491992
with O 0 0.0017719183
acute B-Disease 0 0.98023784
T I-Disease 0 0.9451438
- I-Disease 0 0.055336107
lymphocytic I-Disease 0 0.99906987
leukemia I-Disease 0 0.9995017
in O 0 0.02538712
relapse O 0 0.9861268
. O 0 0.009953865

The O 0 0.0034805604
concomitant O 0 0.007575169
administration O 0 0.1054621
of O 0 0.0039470973
etoposide B-Chemical 1 0.9982315
and O 0 0.0059856786
cyclosporin B-Chemical 1 0.99984324
A I-Chemical 1 0.43228933
resulted O 0 0.0011769969
in O 0 0.0008056997
eradication O 0 0.020046415
of O 0 0.0015774611
hitherto O 0 0.0944581
refractory O 0 0.91069555
leukemic B-Disease 0 0.9980854
infiltration I-Disease 0 0.95037365
of O 0 0.0118502
bone O 0 0.51782537
marrow O 0 0.70910424
. O 0 0.008685275

Severe O 0 0.80464375
side O 0 0.024017556
effects O 0 0.0035799248
in O 0 0.0012058108
terms O 0 0.0008483228
of O 0 0.0013158406
mental O 0 0.2017795
confusion B-Disease 0 0.7700926
and O 0 0.0013680414
progressive O 0 0.7798226
hyperbilirubinemia B-Disease 0 0.9997749
, O 0 0.0019687535
however O 0 0.0009085322
, O 0 0.00046981455
point O 0 0.0002654441
to O 0 0.0002664944
an O 0 0.00041040426
enhancement O 0 0.0009937712
not O 0 0.0002708337
only O 0 0.00029971547
of O 0 0.0005684456
antineoplastic O 0 0.9640061
effects O 0 0.0029710296
but O 0 0.0006729547
also O 0 0.00082953466
of O 0 0.0017998291
toxicity B-Disease 2 0.9908953
in O 0 0.0021737886
normal O 0 0.007031563
tissues O 0 0.0135316895
. O 0 0.0057392763

This O 0 0.0042172377
report O 0 0.0037568803
demonstrates O 0 0.0011685889
for O 0 0.00084128405
the O 0 0.00068581285
first O 0 0.00047718882
time O 0 0.000430283
that O 0 0.00039098444
the O 0 0.0004807358
pharmacodynamic O 0 0.70093256
properties O 0 0.0015262259
of O 0 0.0014972264
cyclosporin B-Chemical 1 0.9999131
A I-Chemical 1 0.4430045
may O 0 0.0006883787
not O 0 0.000427555
be O 0 0.0004247969
confined O 0 0.00047414665
strictly O 0 0.00055614824
to O 0 0.00047099835
suppression O 0 0.001423168
of O 0 0.0012450952
normal O 0 0.0054243826
T O 0 0.56885993
- O 0 0.0049371906
cell O 0 0.012955676
functions O 0 0.0077686105
. O 0 0.0060336106

Incidence O 0 0.10574809
of O 0 0.0064557777
neoplasms B-Disease 0 0.9625828
in O 0 0.002915592
patients O 0 0.0066007213
with O 0 0.0044008335
rheumatoid B-Disease 2 0.9977449
arthritis I-Disease 2 0.99917346
exposed O 0 0.0059768446
to O 0 0.0022747058
different O 0 0.0028940164
treatment O 0 0.00994773
regimens O 0 0.108471006
. O 0 0.00878722

Immunosuppressive O 0 0.985913
drugs O 0 0.7012314
have O 0 0.0028243233
been O 0 0.0017600467
used O 0 0.00092457235
during O 0 0.0005706142
the O 0 0.00057144964
last O 0 0.0004542072
30 O 0 0.0004953414
years O 0 0.0007988156
in O 0 0.00047112207
treatment O 0 0.0011970253
of O 0 0.0012325611
patients O 0 0.004542898
with O 0 0.0037613804
severe O 0 0.8476853
rheumatoid B-Disease 2 0.9983595
arthritis I-Disease 2 0.9988919
. O 0 0.021530507

The O 0 0.0036066875
drugs O 0 0.21435507
commonly O 0 0.004773752
used O 0 0.0017362292
are O 0 0.001774931
cyclophosphamide B-Chemical 1 0.9988438
and O 0 0.004606816
chlorambucil B-Chemical 0 0.9996642
( O 0 0.01165651
alkylating B-Chemical 0 0.9978619
agents I-Chemical 0 0.7568558
) O 0 0.0060763876
, O 0 0.0023358162
azathioprine B-Chemical 1 0.9997904
( O 0 0.008217345
purine B-Chemical 0 0.99686396
analogue O 0 0.42835194
) O 0 0.0027298373
, O 0 0.0012966724
and O 0 0.0017591418
methotrexate B-Chemical 1 0.9994332
( O 0 0.032480974
folic B-Chemical 0 0.99922585
acid I-Chemical 0 0.9902388
analogue O 0 0.6447004
) O 0 0.015729098
. O 0 0.007326034

There O 0 0.005281677
is O 0 0.002230246
evidence O 0 0.0016356885
that O 0 0.0009775208
all O 0 0.00079667004
four O 0 0.0006868833
immunosuppressive O 0 0.9438048
drugs O 0 0.8093811
can O 0 0.0008411915
reduce O 0 0.000881208
synovitis B-Disease 0 0.99659365
, O 0 0.0015575917
but O 0 0.00073483255
disease O 0 0.4847809
activity O 0 0.0009792071
almost O 0 0.00055774825
always O 0 0.00093970704
recurs O 0 0.08913364
after O 0 0.0009538698
therapy O 0 0.021718632
is O 0 0.0032118398
stopped O 0 0.010560548
. O 0 0.0058019296

Since O 0 0.0037153207
adverse O 0 0.2919375
reactions O 0 0.008355201
are O 0 0.0015212363
frequent O 0 0.0029660873
, O 0 0.0010037448
less O 0 0.00054937234
than O 0 0.0002913281
50 O 0 0.00046164682
percent O 0 0.00025287556
of O 0 0.00040390468
patients O 0 0.0010068153
are O 0 0.00035442502
able O 0 0.00021670538
to O 0 0.0002752634
continue O 0 0.00040103807
a O 0 0.00040200702
particular O 0 0.00044325902
drug O 0 0.080202766
for O 0 0.00069893943
more O 0 0.0012700828
than O 0 0.0009362221
one O 0 0.0016723154
year O 0 0.0041248654
. O 0 0.0050724656

Since O 0 0.0027934865
it O 0 0.0020919822
takes O 0 0.0009628884
three O 0 0.0006234234
to O 0 0.0007149503
12 O 0 0.00048121373
months O 0 0.0004602309
to O 0 0.00034018306
achieve O 0 0.00032275697
maximal O 0 0.0004989091
effects O 0 0.00084705907
, O 0 0.0005467049
those O 0 0.00051918166
patients O 0 0.0011515785
who O 0 0.0008983771
are O 0 0.00033812478
unable O 0 0.0002511731
to O 0 0.00030348942
continue O 0 0.00047142236
the O 0 0.00047075015
drug O 0 0.07925391
receive O 0 0.0011302744
little O 0 0.0012430418
benefit O 0 0.0030956005
from O 0 0.0025770918
it O 0 0.0048049255
. O 0 0.0053382963

Patients O 0 0.010749508
treated O 0 0.004214641
with O 0 0.0028612998
alkylating B-Chemical 0 0.99095726
agents I-Chemical 0 0.3561146
have O 0 0.0013541597
an O 0 0.001116229
increased O 0 0.0013062684
risk O 0 0.023328047
of O 0 0.0009637622
development O 0 0.0026695326
of O 0 0.0021007622
acute B-Disease 0 0.9980825
nonlymphocytic I-Disease 0 0.9999032
leukemia I-Disease 0 0.9999399
, O 0 0.009290238
and O 0 0.00078158686
both O 0 0.0005919853
alkylating B-Chemical 0 0.9970311
agents I-Chemical 0 0.4917121
and O 0 0.0015015625
azathioprine B-Chemical 1 0.9998272
are O 0 0.000776421
associated O 0 0.0007150811
with O 0 0.0005516457
the O 0 0.00045056935
development O 0 0.0012503654
of O 0 0.0010265568
non B-Disease 0 0.0038911595
- I-Disease 0 0.0052669547
Hodgkin I-Disease 0 0.99160165
' I-Disease 0 0.004016183
s I-Disease 0 0.006822149
lymphoma I-Disease 0 0.98844075
. O 0 0.008437286

Cyclophosphamide B-Chemical 1 0.9963761
therapy O 0 0.06458728
increases O 0 0.004683556
the O 0 0.0035660854
risk O 0 0.031087596
of O 0 0.0078737475
carcinoma B-Disease 2 0.99576426
of I-Disease 0 0.010638434
the I-Disease 0 0.009841986
bladder I-Disease 0 0.9194248
. O 0 0.014541892

There O 0 0.0050447076
have O 0 0.0025416233
been O 0 0.0018724521
several O 0 0.0013117215
long O 0 0.0013800437
- O 0 0.0012571333
term O 0 0.00071511447
studies O 0 0.0008543187
of O 0 0.0007644956
patients O 0 0.002882414
with O 0 0.0016523334
rheumatoid B-Disease 2 0.99915886
arthritis I-Disease 2 0.9997801
treated O 0 0.021051273
with O 0 0.00283684
azathioprine B-Chemical 1 0.9998553
and O 0 0.0028530296
cyclophosphamide B-Chemical 1 0.99968123
and O 0 0.00080920896
the O 0 0.0004179593
incidence O 0 0.0035832245
of O 0 0.00060698093
most O 0 0.0008663606
of O 0 0.00072016305
the O 0 0.00075893546
common O 0 0.0029681849
cancers B-Disease 2 0.9856976
is O 0 0.0026423966
not O 0 0.0026912868
increased O 0 0.0074949935
. O 0 0.0061517176

Data O 0 0.005210596
on O 0 0.001638197
the O 0 0.0014867022
possible O 0 0.0014825637
increased O 0 0.0019416644
risk O 0 0.02769076
of O 0 0.00280554
malignancy B-Disease 2 0.99847656
in O 0 0.0026723715
rheumatoid B-Disease 2 0.99923265
arthritis I-Disease 2 0.999736
are O 0 0.0012599181
still O 0 0.00042252237
being O 0 0.00044020743
collected O 0 0.00021545273
, O 0 0.00029455413
and O 0 0.00020050172
until O 0 0.000115432464
further O 0 0.00022233368
information O 0 0.00032466237
is O 0 0.00023222735
available O 0 0.00023787013
, O 0 0.00028391666
the O 0 0.0001849818
use O 0 0.0002823109
of O 0 0.0004309796
immunosuppressive O 0 0.9813369
drugs O 0 0.91280293
, O 0 0.0011852785
particularly O 0 0.0024205558
alkylating B-Chemical 0 0.99787676
agents I-Chemical 0 0.5110392
, O 0 0.00071669463
in O 0 0.00023236888
the O 0 0.0002331721
treatment O 0 0.0010020231
of O 0 0.0011340962
rheumatoid B-Disease 2 0.99942493
arthritis I-Disease 2 0.999793
should O 0 0.00045996884
be O 0 0.0003746359
reserved O 0 0.0006891299
for O 0 0.0002628872
patients O 0 0.0011404858
with O 0 0.00064945826
severe O 0 0.18002392
progressive O 0 0.582184
disease O 0 0.8257021
or O 0 0.0014599625
life O 0 0.007488045
- O 0 0.0052014394
threatening O 0 0.21602885
complications O 0 0.7993344
. O 0 0.006747398

Warfarin B-Chemical 0 0.9945372
- O 0 0.015733412
induced O 0 0.009572764
iliopsoas O 0 0.76880765
hemorrhage B-Disease 2 0.99592495
with O 0 0.008392037
subsequent O 0 0.010203573
femoral B-Disease 0 0.6611967
nerve I-Disease 0 0.9712207
palsy I-Disease 0 0.99802846
. O 0 0.021187382

We O 0 0.0027831262
present O 0 0.0015157495
the O 0 0.0013244237
case O 0 0.0011765754
of O 0 0.0011752303
a O 0 0.0010834582
28 O 0 0.0011788392
- O 0 0.001024587
year O 0 0.0006510553
- O 0 0.00080381124
old O 0 0.0005552124
man O 0 0.025972936
on O 0 0.00030398488
chronic O 0 0.9420184
warfarin B-Chemical 1 0.99957913
therapy O 0 0.13892548
who O 0 0.0037053914
sustained O 0 0.008217894
a O 0 0.00049208786
minor O 0 0.0015004805
muscle B-Disease 0 0.460634
tear I-Disease 0 0.73962027
and O 0 0.0005779452
developed O 0 0.0010045657
increasing O 0 0.0013410929
pain B-Disease 0 0.9617784
and O 0 0.0009694402
a O 0 0.0013061769
flexure O 0 0.70580894
contracture B-Disease 0 0.9906819
of O 0 0.0028237244
the O 0 0.0026945933
right O 0 0.010952323
hip O 0 0.5877305
. O 0 0.007940924

Surgical O 0 0.010083983
exploration O 0 0.0057910667
revealed O 0 0.0029359118
an O 0 0.0033432103
iliopsoas O 0 0.53112316
hematoma B-Disease 0 0.9949758
and O 0 0.0024069473
femoral O 0 0.13872845
nerve B-Disease 0 0.9607158
entrapment I-Disease 0 0.95015717
, O 0 0.0014371496
resulting O 0 0.0008315563
in O 0 0.0006445125
a O 0 0.001014584
femoral B-Disease 0 0.17201181
nerve I-Disease 0 0.888561
palsy I-Disease 0 0.9995857
and O 0 0.0017509366
partial B-Disease 0 0.0030436388
loss I-Disease 0 0.0034399896
of I-Disease 0 0.003573255
quadriceps I-Disease 0 0.7586102
functions I-Disease 0 0.009631469
. O 0 0.006841823

Anticoagulant O 0 0.9092316
- O 0 0.007547555
induced O 0 0.0040279836
femoral B-Disease 0 0.19797578
nerve I-Disease 0 0.9042084
palsy I-Disease 0 0.9995197
represents O 0 0.0012818566
the O 0 0.00070785277
most O 0 0.000962683
common O 0 0.0008667429
form O 0 0.0006169718
of O 0 0.0011323473
warfarin B-Chemical 1 0.99951255
- O 0 0.004915406
induced O 0 0.0020504233
peripheral B-Disease 2 0.8931393
neuropathy I-Disease 2 0.9999248
; O 0 0.005001122
it O 0 0.0004563098
is O 0 0.00029707825
characterized O 0 0.0005868221
by O 0 0.0003992801
severe O 0 0.23991925
pain B-Disease 0 0.97271144
in O 0 0.0003111398
the O 0 0.0002646758
inguinal O 0 0.0012971386
region O 0 0.00028743336
, O 0 0.000278246
varying O 0 0.00039005338
degrees O 0 0.0012027496
of O 0 0.0005433679
motor B-Disease 0 0.058856525
and I-Disease 0 0.00062094885
sensory I-Disease 0 0.106922135
impairment I-Disease 0 0.28552845
, O 0 0.00095825666
and O 0 0.0009569916
flexure O 0 0.66409725
contracture B-Disease 0 0.989907
of O 0 0.002430146
the O 0 0.0021751258
involved O 0 0.0037324545
extremity O 0 0.332394
. O 0 0.0074521876

Pneumonitis O 0 0.98460877
with O 0 0.006855627
pleural B-Disease 0 0.27200297
and I-Disease 0 0.0046699787
pericardial I-Disease 0 0.38539824
effusion I-Disease 0 0.9165306
and O 0 0.008414446
neuropathy B-Disease 0 0.9985159
during O 0 0.008907721
amiodarone B-Chemical 1 0.9990287
therapy O 0 0.5387218
. O 0 0.012438983

A O 0 0.014521284
patient O 0 0.004033993
with O 0 0.002605468
sinuatrial B-Disease 0 0.23151885
disease I-Disease 0 0.8307951
and O 0 0.0014041363
implanted O 0 0.00387903
pacemaker O 0 0.118263476
was O 0 0.0006132798
treated O 0 0.00094243593
with O 0 0.00096233725
amiodarone B-Chemical 1 0.9998035
( O 0 0.0010979527
maximum O 0 0.00043109382
dose O 0 0.008079903
1000 O 0 0.0011451211
mg O 0 0.3090249
, O 0 0.00043303994
maintenance O 0 0.00064097584
dose O 0 0.007590828
800 O 0 0.0033420634
mg O 0 0.23886444
daily O 0 0.0013654291
) O 0 0.0005433961
for O 0 0.00024886592
10 O 0 0.00035539575
months O 0 0.0004006575
, O 0 0.0005134203
for O 0 0.00045883175
control O 0 0.00090451405
of O 0 0.003486504
supraventricular B-Disease 0 0.9991068
tachyarrhythmias I-Disease 0 0.9993782
. O 0 0.012598306

He O 0 0.013973674
developed O 0 0.011400133
pneumonitis B-Disease 0 0.9975944
, O 0 0.0067439666
pleural B-Disease 0 0.38984448
and I-Disease 0 0.0028954807
pericardial I-Disease 0 0.4005476
effusions I-Disease 0 0.9392421
, O 0 0.0027166773
and O 0 0.0016907477
a O 0 0.0020619328
predominantly O 0 0.0037971905
proximal B-Disease 0 0.025576487
motor I-Disease 0 0.9532262
neuropathy I-Disease 0 0.9991233
. O 0 0.014607171

Immediate O 0 0.01650323
but O 0 0.003350901
gradual O 0 0.0032916418
improvement O 0 0.0027091068
followed O 0 0.0016100691
withdrawal O 0 0.41003218
of O 0 0.0041969176
amiodarone B-Chemical 1 0.99931467
and O 0 0.0048135454
treatment O 0 0.013645521
with O 0 0.013789074
prednisolone B-Chemical 1 0.9982716
. O 0 0.014882576

Review O 0 0.008561985
of O 0 0.0024621238
this O 0 0.0014763873
and O 0 0.001239179
previously O 0 0.0009449531
reported O 0 0.0010211014
cases O 0 0.0010269423
indicates O 0 0.00039028696
the O 0 0.00036206245
need O 0 0.00031169446
for O 0 0.0002848689
early O 0 0.00089815666
diagnosis O 0 0.010647397
of O 0 0.0020309477
amiodarone B-Chemical 1 0.99993217
pneumonitis B-Disease 0 0.99987173
, O 0 0.0037553192
immediate O 0 0.005494741
withdrawal O 0 0.7702214
of O 0 0.00173471
amiodarone B-Chemical 1 0.9998783
, O 0 0.0011790482
and O 0 0.00048397106
prompt O 0 0.003219199
but O 0 0.0004752333
continued O 0 0.0010018512
steroid B-Chemical 1 0.9869332
therapy O 0 0.02884076
to O 0 0.0010421432
ensure O 0 0.0007473065
full O 0 0.0020766696
recovery O 0 0.008240726
. O 0 0.0055061243

Amiodarone B-Chemical 1 0.9949203
- O 0 0.03821778
induced O 0 0.026437664
sinoatrial B-Disease 0 0.8635521
block I-Disease 0 0.036286343
. O 0 0.024697868

We O 0 0.0034567907
observed O 0 0.0021771498
sinoatrial B-Disease 0 0.42280957
block I-Disease 0 0.0025006402
due O 0 0.0009232201
to O 0 0.0010990275
chronic O 0 0.9682363
amiodarone B-Chemical 1 0.99985397
administration O 0 0.6582283
in O 0 0.0006771752
a O 0 0.0006196248
5 O 0 0.0003993353
- O 0 0.0005477604
year O 0 0.00039952624
- O 0 0.00056108076
old O 0 0.0004164196
boy O 0 0.0017365342
with O 0 0.0006173506
primary B-Disease 0 0.016589405
cardiomyopathy I-Disease 2 0.9998965
, O 0 0.011338685
Wolff B-Disease 0 0.9563445
- I-Disease 0 0.015916292
Parkinson I-Disease 0 0.999263
- I-Disease 0 0.0052813115
White I-Disease 0 0.13259418
syndrome I-Disease 0 0.84605116
and O 0 0.0058682673
supraventricular B-Disease 0 0.99910766
tachycardia I-Disease 2 0.9989121
. O 0 0.012395441

Reduction O 0 0.010774174
in O 0 0.0023897805
the O 0 0.0018004905
dosage O 0 0.053846657
of O 0 0.002719764
amiodarone B-Chemical 1 0.9995433
resulted O 0 0.0014456298
in O 0 0.0006863218
the O 0 0.00055853557
disappearance O 0 0.0022266877
of O 0 0.0007670307
the O 0 0.00068262283
sinoatrial B-Disease 0 0.68982255
block I-Disease 0 0.0013233197
and O 0 0.0008101858
the O 0 0.0008116988
persistence O 0 0.002297199
of O 0 0.0030447475
asymptomatic O 0 0.65398765
sinus B-Disease 2 0.96302253
bradycardia I-Disease 2 0.99854386
. O 0 0.00961252

Desipramine B-Chemical 0 0.9989594
- O 0 0.014391147
induced O 0 0.007750379
delirium B-Disease 2 0.9971234
at O 0 0.0022667418
" O 0 0.0033654163
subtherapeutic O 0 0.96900934
" O 0 0.0036003392
concentrations O 0 0.0072412463
: O 0 0.004124971
a O 0 0.0034722146
case O 0 0.0048237094
report O 0 0.014947071
. O 0 0.008691153

An O 0 0.0072806766
elderly O 0 0.08111306
patient O 0 0.0032172564
treated O 0 0.0023508428
with O 0 0.0013659599
low O 0 0.0016117785
dose O 0 0.147319
Desipramine B-Chemical 0 0.9998696
developed O 0 0.0069119963
a O 0 0.0017456365
delirium B-Disease 2 0.9990758
while O 0 0.00071513496
her O 0 0.0010809606
plasma O 0 0.016951162
level O 0 0.0004865002
was O 0 0.0006326558
in O 0 0.00064742815
the O 0 0.0010005264
" O 0 0.0023430074
subtherapeutic O 0 0.95883405
" O 0 0.0046136174
range O 0 0.0067126453
. O 0 0.0059726047

Delirium B-Disease 2 0.9869423
, O 0 0.0052955467
which O 0 0.002876846
may O 0 0.0016704996
be O 0 0.0013232972
induced O 0 0.0014525226
by O 0 0.00143013
tricyclic O 0 0.999019
drug O 0 0.66618836
therapy O 0 0.051635332
in O 0 0.00062645297
the O 0 0.0006467436
elderly O 0 0.25412118
, O 0 0.0008350043
can O 0 0.0004492154
be O 0 0.00055447593
caused O 0 0.0008183461
by O 0 0.0012380983
tricyclics O 0 0.997775
with O 0 0.0027101003
low O 0 0.0074131824
anticholinergic O 0 0.9985501
potency O 0 0.68691987
. O 0 0.008614534

Therapeutic O 0 0.065626934
ranges O 0 0.0039015699
for O 0 0.0021771353
antidepressants B-Chemical 1 0.997389
that O 0 0.0012713489
have O 0 0.0010263688
been O 0 0.00083787204
derived O 0 0.0005355265
from O 0 0.00048698063
general O 0 0.00054895936
adult O 0 0.0007826262
population O 0 0.00074348925
studies O 0 0.00083605526
may O 0 0.0006090405
not O 0 0.00062574405
be O 0 0.0007961239
appropriate O 0 0.0009244626
for O 0 0.0014368696
the O 0 0.0031445366
elderly O 0 0.35361257
. O 0 0.007004913

Further O 0 0.0040748217
studies O 0 0.0027495173
of O 0 0.0019832898
specifically O 0 0.001643612
elderly O 0 0.12701401
patients O 0 0.0027500088
are O 0 0.0007378478
now O 0 0.0006514433
required O 0 0.0002928567
to O 0 0.00040644887
establish O 0 0.00046125444
safer O 0 0.0014803206
and O 0 0.0006555194
more O 0 0.00082875753
appropriate O 0 0.00077740493
guidelines O 0 0.001654806
for O 0 0.001718293
drug O 0 0.38761845
therapy O 0 0.12316524
. O 0 0.0075040157

Indomethacin B-Chemical 0 0.9983119
- O 0 0.02263114
induced O 0 0.013371425
renal B-Disease 0 0.99085706
insufficiency I-Disease 0 0.99558383
: O 0 0.025259558
recurrence O 0 0.765277
on O 0 0.00785836
rechallenge O 0 0.8069724
. O 0 0.014316377

We O 0 0.003298441
have O 0 0.002504037
reported O 0 0.0023537346
a O 0 0.0015496608
case O 0 0.0012820263
of O 0 0.0018472562
acute O 0 0.9815833
oliguric O 0 0.99972814
renal B-Disease 0 0.998654
failure I-Disease 0 0.9652335
with O 0 0.009877528
hyperkalemia B-Disease 2 0.9998832
in O 0 0.0008425419
a O 0 0.0007120818
patient O 0 0.001280629
with O 0 0.0019579483
cirrhosis B-Disease 2 0.99987316
, O 0 0.011363348
ascites B-Disease 0 0.99847776
, O 0 0.0036315292
and O 0 0.0036687178
cor B-Disease 0 0.9991461
pulmonale I-Disease 0 0.9998534
after O 0 0.0075685256
indomethacin B-Chemical 1 0.99940336
therapy O 0 0.5907359
. O 0 0.009119173

Prompt O 0 0.054333597
restoration O 0 0.0045738705
of O 0 0.0030146097
renal O 0 0.9491538
function O 0 0.0022205673
followed O 0 0.00094709866
drug O 0 0.42741233
withdrawal O 0 0.8365099
, O 0 0.0012251704
while O 0 0.0006181143
re O 0 0.017968563
- O 0 0.0009425571
exposure O 0 0.0013727935
to O 0 0.0003530735
a O 0 0.00041397184
single O 0 0.00046918215
dose O 0 0.009457079
of O 0 0.0016331691
indomethacin B-Chemical 1 0.9996735
caused O 0 0.007552314
recurrence O 0 0.9295331
of O 0 0.012537533
acute O 0 0.9942714
reversible O 0 0.9862483
oliguria B-Disease 0 0.99908257
. O 0 0.013491998

Our O 0 0.0031272706
case O 0 0.0021393327
supports O 0 0.0014931728
the O 0 0.0011357935
hypothesis O 0 0.0013263924
that O 0 0.0007875702
endogenous O 0 0.0024947005
renal O 0 0.9958949
prostaglandins B-Chemical 1 0.99948645
play O 0 0.0029962154
a O 0 0.00083234947
role O 0 0.00035687943
in O 0 0.0003489697
the O 0 0.0003458323
maintenance O 0 0.0008559578
of O 0 0.0008674328
renal O 0 0.98098534
blood O 0 0.0303306
flow O 0 0.007503682
when O 0 0.0006491226
circulating O 0 0.010015267
plasma O 0 0.06362892
volume O 0 0.007436298
is O 0 0.0031823397
diminished O 0 0.007903852
. O 0 0.0061403704

Since O 0 0.0056159445
nonsteroidal O 0 0.9987239
anti O 0 0.121186614
- O 0 0.008531567
inflammatory O 0 0.8117636
agents O 0 0.28436798
interfere O 0 0.0012158707
with O 0 0.0007979764
this O 0 0.0005109418
compensatory O 0 0.0014815812
mechanism O 0 0.00078131777
and O 0 0.00052395824
may O 0 0.0005427535
cause O 0 0.006086388
acute B-Disease 0 0.9826569
renal I-Disease 0 0.99832886
failure I-Disease 0 0.93392044
, O 0 0.0012271735
they O 0 0.00041875397
should O 0 0.00028750548
be O 0 0.0004512399
used O 0 0.00046007187
with O 0 0.00085026096
caution O 0 0.0017731305
in O 0 0.0014162947
such O 0 0.0027932662
patients O 0 0.01190463
. O 0 0.0060149375

Patterns O 0 0.02683712
of O 0 0.017174985
hepatic B-Disease 0 0.9855036
injury I-Disease 0 0.9831956
induced O 0 0.031894557
by O 0 0.02917513
methyldopa B-Chemical 0 0.9984339
. O 0 0.030209195

Twelve O 0 0.012026679
patients O 0 0.006746478
with O 0 0.0041950806
liver B-Disease 2 0.9587958
disease I-Disease 2 0.9460504
related O 0 0.0022804053
to O 0 0.002686733
methyldopa B-Chemical 0 0.99957055
were O 0 0.0030561527
seen O 0 0.0022982005
between O 0 0.0019133795
1967 O 0 0.009532047
and O 0 0.0054833298
1977 O 0 0.027218502
. O 0 0.008227317

Illness O 0 0.13221228
occurred O 0 0.003187269
within O 0 0.001259041
1 O 0 0.0015498167
- O 0 0.0017160976
- O 0 0.0010312181
9 O 0 0.00041817018
weeks O 0 0.00029209213
of O 0 0.00034164757
commencement O 0 0.0005475293
of O 0 0.00044349823
therapy O 0 0.0071112257
in O 0 0.00032116147
9 O 0 0.00030296593
patients O 0 0.0006804467
, O 0 0.00028249508
the O 0 0.00016771654
remaining O 0 0.000190987
3 O 0 0.00017374381
patients O 0 0.00041777786
having O 0 0.00023864841
received O 0 0.00029337785
the O 0 0.00023417264
drug O 0 0.05715433
for O 0 0.00025639532
13 O 0 0.00035935495
months O 0 0.00030439615
, O 0 0.00033396037
15 O 0 0.0002369032
months O 0 0.00032863097
and O 0 0.00041102327
7 O 0 0.00049175374
years O 0 0.0010851191
before O 0 0.0008473965
experiencing O 0 0.02511225
symptoms O 0 0.4511109
. O 0 0.006122715

Jaundice B-Disease 0 0.98421186
with O 0 0.0056492426
tender O 0 0.104743965
hepatomegaly B-Disease 2 0.9966563
, O 0 0.0027838382
usually O 0 0.0017811201
preceded O 0 0.0013193939
by O 0 0.0009834226
symptoms O 0 0.26497775
of O 0 0.0022137046
malaise O 0 0.9992944
, O 0 0.008519394
anorexia B-Disease 0 0.99953866
, O 0 0.0069300937
nausea B-Disease 2 0.9998896
and O 0 0.0032134694
vomiting B-Disease 0 0.9997141
, O 0 0.0009760481
and O 0 0.00039838091
associated O 0 0.0005142839
with O 0 0.0005416819
upper O 0 0.0013303751
abdominal B-Disease 0 0.5000196
pain I-Disease 0 0.9822134
, O 0 0.0010118391
was O 0 0.0005468615
an O 0 0.000806228
invariable O 0 0.008592002
finding O 0 0.0018956801
in O 0 0.0014086303
all O 0 0.002212808
patients O 0 0.009512736
. O 0 0.0056197965

Biochemical O 0 0.57512593
liver O 0 0.67279106
function O 0 0.003501904
tests O 0 0.0036819095
indicated O 0 0.0018436498
hepatocellular O 0 0.9996997
necrosis B-Disease 2 0.9993185
and O 0 0.002242055
correlated O 0 0.00066253066
with O 0 0.0007840165
histopathological O 0 0.45141435
evidence O 0 0.0007799378
of O 0 0.0013237143
hepatic B-Disease 0 0.9984376
injury I-Disease 0 0.99671483
, O 0 0.0011102585
the O 0 0.00031845615
spectrum O 0 0.0004941704
of O 0 0.00045350505
which O 0 0.00053408137
ranged O 0 0.0006507951
from O 0 0.00061529066
fatty B-Disease 0 0.9969739
change I-Disease 0 0.0030283923
and O 0 0.001321982
focal O 0 0.6007552
hepatocellular O 0 0.99986756
necrosis B-Disease 2 0.9994728
to O 0 0.01242856
massive B-Disease 0 0.79066896
hepatic I-Disease 0 0.9960522
necrosis I-Disease 2 0.99715555
. O 0 0.01408725

Most O 0 0.008895495
patients O 0 0.005988533
showed O 0 0.0025318805
moderate O 0 0.0072732368
to O 0 0.0024368614
severe O 0 0.579065
acute B-Disease 0 0.9979163
hepatitis I-Disease 2 0.99987304
or O 0 0.015860671
chronic B-Disease 0 0.9963923
active I-Disease 0 0.23249722
hepatitis I-Disease 2 0.99970156
with O 0 0.0663052
associated O 0 0.17617948
cholestasis B-Disease 2 0.9994617
. O 0 0.022835271

The O 0 0.0034631733
drug O 0 0.074020684
was O 0 0.0022170215
withdrawn O 0 0.0040429975
on O 0 0.00082073576
presentation O 0 0.0028109069
to O 0 0.00086222973
hospital O 0 0.0023098015
in O 0 0.0007040832
11 O 0 0.0008607497
patients O 0 0.001581193
, O 0 0.0009506996
with O 0 0.00096735766
rapid O 0 0.0026739747
clinical O 0 0.008221652
improvement O 0 0.003415227
in O 0 0.0028756857
9 O 0 0.004642053
. O 0 0.005128807

One O 0 0.0050174138
patient O 0 0.0038891102
died O 0 0.008612233
, O 0 0.0018585498
having O 0 0.0011983402
presented O 0 0.0009996812
in O 0 0.00081370544
hepatic B-Disease 0 0.94503725
failure I-Disease 0 0.7468771
, O 0 0.0011286654
and O 0 0.00053664506
another O 0 0.00053955877
, O 0 0.0005008013
who O 0 0.0007232067
had O 0 0.00034487635
been O 0 0.00043554048
taking O 0 0.0017131573
methyldopa B-Chemical 0 0.999871
for O 0 0.00042443324
7 O 0 0.00028755562
years O 0 0.00048310662
, O 0 0.00028077417
showed O 0 0.00020788427
slower O 0 0.00031281915
clinical O 0 0.0018214259
and O 0 0.00040839688
biochemical O 0 0.009966072
resolution O 0 0.004787393
over O 0 0.00035310723
a O 0 0.0007335599
period O 0 0.0008978328
of O 0 0.0016041481
several O 0 0.0027181285
months O 0 0.0044036172
. O 0 0.004901343

The O 0 0.0026271434
remaining O 0 0.0019928266
patient O 0 0.002316349
in O 0 0.0011174084
the O 0 0.0009524938
series O 0 0.0019459245
developed O 0 0.00592402
fulminant B-Disease 0 0.9997931
hepatitis I-Disease 2 0.99992204
when O 0 0.0012383081
the O 0 0.0008186939
drug O 0 0.35603958
was O 0 0.0006857645
accidentally O 0 0.0080927005
recommenced O 0 0.028466836
1 O 0 0.00043937046
year O 0 0.00036012832
after O 0 0.0002192398
a O 0 0.0004215717
prior O 0 0.0003956759
episode O 0 0.005298604
of O 0 0.0035826492
methyldopa B-Chemical 0 0.9998
- O 0 0.047846843
induced O 0 0.05834775
hepatitis B-Disease 2 0.99902046
. O 0 0.016122747

In O 0 0.0028115576
this O 0 0.0019173403
latter O 0 0.0029226048
patient O 0 0.002194732
, O 0 0.0013609708
and O 0 0.0008246613
in O 0 0.0005601003
2 O 0 0.00053099747
others O 0 0.0009233209
, O 0 0.00046433983
the O 0 0.00028066928
causal O 0 0.0006758029
relationship O 0 0.00027374618
between O 0 0.00028587502
methyldopa B-Chemical 0 0.9998926
and O 0 0.0021544418
hepatic B-Disease 0 0.99868935
dysfunction I-Disease 0 0.9980154
was O 0 0.00075012306
proved O 0 0.001498615
with O 0 0.00041900852
the O 0 0.00038190014
recurrence O 0 0.5333763
of O 0 0.0018205242
hepatitis B-Disease 2 0.9997646
within O 0 0.0004352306
2 O 0 0.00049824757
weeks O 0 0.00043527607
of O 0 0.0007727804
re O 0 0.015193292
- O 0 0.0017774996
exposure O 0 0.0030238777
to O 0 0.001617081
the O 0 0.002835373
drug O 0 0.3859443
. O 0 0.0067374352

Suxamethonium B-Chemical 1 0.96903604
infusion O 0 0.09645861
rate O 0 0.010109462
and O 0 0.011650129
observed O 0 0.014520963
fasciculations B-Disease 0 0.99354136
. O 0 0.026215453

A O 0 0.05736462
dose O 0 0.07806568
- O 0 0.025216164
response O 0 0.021337358
study O 0 0.025158968
. O 0 0.023200205

Suxamethonium B-Chemical 1 0.9953583
chloride I-Chemical 0 0.9981065
( O 0 0.044701513
Sch B-Chemical 0 0.9993175
) O 0 0.0048751887
was O 0 0.0011711875
administered O 0 0.0026823122
i O 0 0.0020287482
. O 0 0.00044269295
v O 0 0.0029657767
. O 0 0.00025545296
to O 0 0.00027106827
36 O 0 0.0003206432
adult O 0 0.00037143854
males O 0 0.0003319963
at O 0 0.00014093603
six O 0 0.00015618448
rates O 0 0.0003088744
: O 0 0.0005079222
0 O 0 0.00033788278
. O 0 0.00017658998
25 O 0 0.00047821473
mg O 0 0.07350025
s O 0 0.0006213813
- O 0 0.00068007584
1 O 0 0.00043093873
to O 0 0.00046397457
20 O 0 0.00095642876
mg O 0 0.11438205
s O 0 0.002398518
- O 0 0.0036811398
1 O 0 0.003717729
. O 0 0.0044232956

The O 0 0.0030244598
infusion O 0 0.012120102
was O 0 0.001781115
discontinued O 0 0.010110024
either O 0 0.0009013772
when O 0 0.00050766364
there O 0 0.00040518097
was O 0 0.00051806343
no O 0 0.00043967587
muscular O 0 0.09903038
response O 0 0.0011197884
to O 0 0.0006959504
tetanic B-Disease 0 0.9934242
stimulation O 0 0.001947898
of O 0 0.0007587041
the O 0 0.0007193866
ulnar O 0 0.28704932
nerve O 0 0.3717742
or O 0 0.0007886555
when O 0 0.0010409778
Sch B-Chemical 0 0.99911934
120 O 0 0.004174292
mg O 0 0.401416
was O 0 0.0027469897
exceeded O 0 0.0038783283
. O 0 0.0054261116

Six O 0 0.005288431
additional O 0 0.0019502428
patients O 0 0.0035038595
received O 0 0.002150016
a O 0 0.0017936272
30 O 0 0.001508229
- O 0 0.0024892879
mg O 0 0.23857056
i O 0 0.0038684017
. O 0 0.0013839264
v O 0 0.007005642
. O 0 0.0020862233
bolus O 0 0.09395979
dose O 0 0.060163043
. O 0 0.0080386875

Fasciculations B-Disease 0 0.5989113
in O 0 0.0021915578
six O 0 0.0011386804
areas O 0 0.0019098142
of O 0 0.0011466068
the O 0 0.0008282582
body O 0 0.0021434368
were O 0 0.0006485695
scored O 0 0.0007593713
from O 0 0.0005175605
0 O 0 0.00055293407
to O 0 0.00041430249
3 O 0 0.00043364058
and O 0 0.00057282817
summated O 0 0.0023582913
as O 0 0.0007756903
a O 0 0.0014825481
total O 0 0.0024182966
fasciculation B-Disease 0 0.95589024
score O 0 0.007212
. O 0 0.0064256145

The O 0 0.002879054
times O 0 0.0017578714
to O 0 0.0018177959
first O 0 0.0017222778
fasciculation B-Disease 0 0.9490131
, O 0 0.0032559684
twitch B-Disease 0 0.9711944
suppression O 0 0.0054200348
and O 0 0.001577371
tetanus B-Disease 0 0.8806291
suppression O 0 0.003429043
were O 0 0.00091706926
inversely O 0 0.001219388
related O 0 0.0008465487
to O 0 0.0012219866
the O 0 0.0019167416
infusion O 0 0.04418121
rates O 0 0.0053909253
. O 0 0.0065313396

Fasciculations B-Disease 0 0.6231392
in O 0 0.0023577486
the O 0 0.0014408194
six O 0 0.0009098224
areas O 0 0.0017979343
and O 0 0.00094193994
the O 0 0.00072106096
total O 0 0.0008673618
fasciculation B-Disease 0 0.9010871
score O 0 0.0010147392
were O 0 0.0006314182
related O 0 0.0005093415
directly O 0 0.0007121893
to O 0 0.00077556795
the O 0 0.0010224993
rate O 0 0.0016434485
of O 0 0.0038895337
infusion O 0 0.14775868
. O 0 0.0070071956

Total O 0 0.0072187595
fasciculation B-Disease 0 0.8240198
scores O 0 0.0021963888
in O 0 0.0011237742
the O 0 0.0008752271
30 O 0 0.0007846985
- O 0 0.0010883921
mg O 0 0.16328962
bolus O 0 0.035879232
group O 0 0.0005995907
and O 0 0.00039803132
the O 0 0.0003319963
5 O 0 0.00033870808
- O 0 0.00059529324
mg O 0 0.16139553
s O 0 0.0005330729
- O 0 0.00048554144
1 O 0 0.0002487155
and O 0 0.00024803067
20 O 0 0.0003547147
- O 0 0.0005485509
mg O 0 0.119911216
s O 0 0.00058704533
- O 0 0.0006288002
1 O 0 0.0004249253
infusion O 0 0.0032053723
groups O 0 0.0007036253
were O 0 0.00077871134
not O 0 0.0010774164
significantly O 0 0.0023091536
different O 0 0.0037512183
. O 0 0.0055058366

Treatment O 0 0.092529975
of O 0 0.025916375
psoriasis B-Disease 2 0.98574907
with O 0 0.08218162
azathioprine B-Chemical 1 0.9963348
. O 0 0.04140402

Azathioprine B-Chemical 0 0.9969566
treatment O 0 0.011226337
benefited O 0 0.024576489
19 O 0 0.0042240233
( O 0 0.0023236335
66 O 0 0.0021411974
% O 0 0.0013047265
) O 0 0.0012278493
out O 0 0.00062950293
of O 0 0.0011193148
29 O 0 0.002357106
patients O 0 0.004219529
suffering O 0 0.6551745
from O 0 0.004609423
severe O 0 0.7661169
psoriasis B-Disease 2 0.99584705
. O 0 0.012555953

Haematological O 0 0.9708929
complications O 0 0.33488762
were O 0 0.0026930263
not O 0 0.0017928061
troublesome O 0 0.02456841
and O 0 0.0014750465
results O 0 0.001120727
of O 0 0.0016943566
biochemical O 0 0.05084102
liver O 0 0.7623798
function O 0 0.003674818
tests O 0 0.00562535
remained O 0 0.0061458433
normal O 0 0.011116461
. O 0 0.007833548

Minimal O 0 0.1802681
cholestasis B-Disease 2 0.99887425
was O 0 0.0041278168
seen O 0 0.0019208238
in O 0 0.0011251867
two O 0 0.00087580434
cases O 0 0.0018995997
and O 0 0.0015571987
portal O 0 0.25023907
fibrosis B-Disease 2 0.9880862
of O 0 0.0030544256
a O 0 0.0027753476
reversible O 0 0.2451613
degree O 0 0.0040517356
in O 0 0.0032959718
eight O 0 0.0049301544
. O 0 0.0067574275

Liver O 0 0.89104325
biopsies O 0 0.006730652
should O 0 0.0013270602
be O 0 0.0011001187
undertaken O 0 0.0006731709
at O 0 0.00042138467
regular O 0 0.0007319495
intervals O 0 0.0005435212
if O 0 0.00041725865
azathioprine B-Chemical 1 0.9994848
therapy O 0 0.06481686
is O 0 0.00054808834
continued O 0 0.0005772142
so O 0 0.00033770484
that O 0 0.00033794623
structural O 0 0.006447039
liver B-Disease 2 0.9873439
damage I-Disease 2 0.9589793
may O 0 0.0008600905
be O 0 0.0005753612
detected O 0 0.00034024892
at O 0 0.00043942005
an O 0 0.0011002519
early O 0 0.0024804354
and O 0 0.0025486227
reversible O 0 0.3579918
stage O 0 0.015055649
. O 0 0.006812376

Angiosarcoma B-Disease 0 0.5878284
of I-Disease 0 0.01125675
the I-Disease 0 0.010242412
liver I-Disease 0 0.70982426
associated O 0 0.018565437
with O 0 0.02855505
diethylstilbestrol B-Chemical 1 0.99619496
. O 0 0.029352754

Angiosarcoma B-Disease 0 0.5339037
of I-Disease 0 0.003669736
the I-Disease 0 0.002359712
liver I-Disease 0 0.49998146
occurred O 0 0.0018347149
in O 0 0.00085415266
a O 0 0.0008734209
76 O 0 0.0013706079
- O 0 0.00090248836
year O 0 0.00056733214
- O 0 0.00070306833
old O 0 0.00049380265
man O 0 0.025779078
who O 0 0.000900629
had O 0 0.00038451783
been O 0 0.0004138971
treated O 0 0.00054710085
for O 0 0.000273954
a O 0 0.00041703533
well O 0 0.0003745606
- O 0 0.00096710655
differentiated O 0 0.010414268
adenocarcinoma B-Disease 0 0.99824035
of I-Disease 0 0.0012759645
the I-Disease 0 0.001077385
liver I-Disease 0 0.82917553
with O 0 0.004898735
diethylstilbestrol B-Chemical 1 0.99923944
for O 0 0.0027986732
13 O 0 0.004506523
years O 0 0.0071261497
. O 0 0.005330499

Angiosarcoma B-Disease 0 0.61053365
was O 0 0.005131681
also O 0 0.003788865
present O 0 0.0027481576
within O 0 0.0028848215
pulmonary O 0 0.6358662
and O 0 0.011277573
renal O 0 0.98739016
arteries O 0 0.93630666
. O 0 0.015020976

The O 0 0.003446618
possibility O 0 0.0024292066
that O 0 0.0019097257
the O 0 0.0022300656
intraarterial B-Disease 0 0.9212164
lesions I-Disease 0 0.63526875
might O 0 0.0014531236
represent O 0 0.0014204604
independent O 0 0.001354744
primary O 0 0.0043826676
tumors B-Disease 0 0.83699805
is O 0 0.0053490014
considered O 0 0.0057757073
. O 0 0.007167711

Galanthamine B-Chemical 0 0.9955842
hydrobromide I-Chemical 0 0.9982817
, O 0 0.0049906024
a O 0 0.0018395032
longer O 0 0.0009639831
acting O 0 0.0055128857
anticholinesterase O 0 0.9986162
drug O 0 0.7694553
, O 0 0.001396389
in O 0 0.0005154609
the O 0 0.00046857653
treatment O 0 0.0010302553
of O 0 0.0007253232
the O 0 0.000652455
central O 0 0.0019301414
effects O 0 0.002656443
of O 0 0.005961877
scopolamine B-Chemical 1 0.99981314
( O 0 0.076599374
Hyoscine B-Chemical 0 0.9974806
) O 0 0.015484156
. O 0 0.0070056957

Galanthamine B-Chemical 0 0.9958034
hydrobromide I-Chemical 0 0.99843985
, O 0 0.0064803804
an O 0 0.0033955714
anticholinesterase O 0 0.9977368
drug O 0 0.60906214
capable O 0 0.0016693788
of O 0 0.0012385536
penetrating O 0 0.4850017
the O 0 0.00077346014
blood O 0 0.020530809
- O 0 0.00141038
brain O 0 0.043747418
barrier O 0 0.008325209
, O 0 0.000516659
was O 0 0.00028707375
used O 0 0.00023868526
in O 0 0.00022645746
a O 0 0.00031962778
patient O 0 0.0005121322
demonstrating O 0 0.00038493134
central O 0 0.0011689026
effects O 0 0.0015741206
of O 0 0.0034139692
scopolamine B-Chemical 1 0.99987257
( O 0 0.07722278
hyoscine B-Chemical 0 0.9997807
) O 0 0.1839621
overdosage B-Disease 0 0.99868673
. O 0 0.011023184

It O 0 0.0058501605
is O 0 0.0022824425
longer O 0 0.0013258001
acting O 0 0.0035476713
than O 0 0.0013746507
physostigmine B-Chemical 0 0.999468
and O 0 0.0017408122
is O 0 0.0009051191
used O 0 0.0006572517
in O 0 0.0006404399
anaesthesia O 0 0.04043126
to O 0 0.0007903841
reverse O 0 0.0057360576
the O 0 0.0010601981
non O 0 0.0033635485
- O 0 0.004270113
depolarizing O 0 0.84766823
neuromuscular O 0 0.8165791
block O 0 0.012856
. O 0 0.0071303216

However O 0 0.0052147675
, O 0 0.0037810726
studies O 0 0.002858844
into O 0 0.0013296517
the O 0 0.0015129504
dose O 0 0.0062072347
necessary O 0 0.0013766177
to O 0 0.0021828099
combating O 0 0.17996664
scopolamine B-Chemical 1 0.99979883
intoxication O 0 0.99847513
are O 0 0.009155377
indicated O 0 0.006213497
. O 0 0.008413821

Comparison O 0 0.003075133
of O 0 0.002408711
the O 0 0.0016397872
subjective O 0 0.004532602
effects O 0 0.0021474927
and O 0 0.0011619073
plasma O 0 0.023938326
concentrations O 0 0.003353646
following O 0 0.00084516045
oral O 0 0.20439382
and O 0 0.0009200243
i O 0 0.002155024
. O 0 0.00049458264
m O 0 0.0022508758
. O 0 0.000554579
administration O 0 0.036349796
of O 0 0.0033382198
flunitrazepam B-Chemical 0 0.9994748
in O 0 0.004288273
volunteers O 0 0.03127923
. O 0 0.0060934424

Flunitrazepam B-Chemical 0 0.9975496
0 O 0 0.0042409445
. O 0 0.0014123907
5 O 0 0.0010652894
, O 0 0.0010991383
1 O 0 0.00068683183
. O 0 0.00035545402
0 O 0 0.00042805212
or O 0 0.000293202
2 O 0 0.00032844863
. O 0 0.00018537947
0 O 0 0.00030209828
mg O 0 0.040834405
was O 0 0.00023781887
given O 0 0.00016558912
by O 0 0.00025674244
the O 0 0.00027955722
oral O 0 0.092070386
or O 0 0.00036190316
i O 0 0.0013654042
. O 0 0.00025274805
m O 0 0.0012441332
. O 0 0.00020911921
routes O 0 0.0011070004
to O 0 0.00032025552
groups O 0 0.00046047138
of O 0 0.0006678145
volunteers O 0 0.0026052028
and O 0 0.0010713112
its O 0 0.0025644128
effects O 0 0.004101376
compared O 0 0.0027267297
. O 0 0.0049834754

Plasma O 0 0.2379912
concentrations O 0 0.006048847
of O 0 0.0022204288
the O 0 0.0014296882
drug O 0 0.11889148
were O 0 0.0009890966
estimated O 0 0.0007520169
by O 0 0.0008635452
gas O 0 0.08287476
- O 0 0.0016270826
liquid O 0 0.003122054
chromatography O 0 0.02010529
, O 0 0.0009734918
in O 0 0.00056735706
a O 0 0.0007513096
smaller O 0 0.0007844716
number O 0 0.0009824166
of O 0 0.0020241356
the O 0 0.0028106796
subjects O 0 0.0072058705
. O 0 0.006215876

The O 0 0.0028719353
most O 0 0.002846245
striking O 0 0.0022599287
effect O 0 0.0015083654
was O 0 0.0011353873
sedation O 0 0.3802513
which O 0 0.0010608768
increased O 0 0.000980075
with O 0 0.0006738658
the O 0 0.0005134066
dose O 0 0.013768907
, O 0 0.0007155364
2 O 0 0.00045601194
mg O 0 0.10717383
producing O 0 0.00067187974
deep O 0 0.0025253634
sleep O 0 0.16147111
although O 0 0.00055716006
the O 0 0.0006003177
subjects O 0 0.0013278767
could O 0 0.0009105955
still O 0 0.0016978119
be O 0 0.0030644073
aroused O 0 0.019316865
. O 0 0.0061186943

The O 0 0.0029558954
effects O 0 0.0033238758
of O 0 0.002326049
i O 0 0.0035808503
. O 0 0.0009598803
m O 0 0.002861852
. O 0 0.0005198899
administration O 0 0.015356873
were O 0 0.0005020029
apparent O 0 0.0005215314
earlier O 0 0.00051990733
and O 0 0.00052120216
sometimes O 0 0.0010650717
lasted O 0 0.0005776709
longer O 0 0.00041877833
than O 0 0.0005099791
those O 0 0.001316744
following O 0 0.002034633
oral O 0 0.4453846
administration O 0 0.45274636
. O 0 0.0071359337

Dizziness B-Disease 0 0.9846764
was O 0 0.0037218607
less O 0 0.002443008
marked O 0 0.0029919522
than O 0 0.0015329008
sedation O 0 0.3911049
, O 0 0.0025881156
but O 0 0.0017287633
increased O 0 0.0029418487
with O 0 0.0035093566
the O 0 0.0046503907
dose O 0 0.0713972
. O 0 0.009098616

There O 0 0.006692096
was O 0 0.0038190065
pain B-Disease 0 0.77433455
on O 0 0.0015398837
i O 0 0.0033157489
. O 0 0.00095632573
m O 0 0.0027274496
. O 0 0.0005844259
injection O 0 0.0017771289
of O 0 0.0014820482
flunitrazepam B-Chemical 0 0.99968505
significantly O 0 0.0018861549
more O 0 0.001409189
often O 0 0.0017627781
than O 0 0.0010102036
with O 0 0.0028318095
isotonic O 0 0.7047703
saline O 0 0.4975381
. O 0 0.0077895313

Plasma O 0 0.26227584
concentrations O 0 0.0070662196
varied O 0 0.0030589143
with O 0 0.0022026298
dose O 0 0.011922176
and O 0 0.0016532511
route O 0 0.0035154016
and O 0 0.0012707448
corresponded O 0 0.0010731897
qualitatively O 0 0.001765498
with O 0 0.0019119113
the O 0 0.0024090963
subjective O 0 0.012712112
effects O 0 0.0103581315
. O 0 0.007365456

The O 0 0.0034029793
drug O 0 0.0697732
was O 0 0.0019862482
still O 0 0.0012351974
present O 0 0.0007837745
in O 0 0.0007616237
measurable O 0 0.0013462686
quantities O 0 0.0010722893
after O 0 0.0004794368
24 O 0 0.00066795363
h O 0 0.00072944624
even O 0 0.0008574111
with O 0 0.0013623111
the O 0 0.00180487
smallest O 0 0.0038389512
dose O 0 0.045583528
. O 0 0.007235736

Possible O 0 0.23516949
teratogenicity O 0 0.982873
of O 0 0.0853947
sulphasalazine B-Chemical 1 0.9947068
. O 0 0.053176515

Three O 0 0.00520646
infants O 0 0.0058636763
, O 0 0.0025207384
born O 0 0.0021900274
of O 0 0.0011361452
two O 0 0.00068111066
mothers O 0 0.0014963341
with O 0 0.0011350331
inflammatory B-Disease 0 0.9173137
bowel I-Disease 0 0.9721848
disease I-Disease 0 0.95805544
who O 0 0.005007271
received O 0 0.0008417431
treatment O 0 0.0017428186
with O 0 0.0011592242
sulphasalazine B-Chemical 1 0.9997744
throughout O 0 0.00067224645
pregnancy O 0 0.29957017
, O 0 0.00090051745
were O 0 0.0005774251
found O 0 0.0005988662
to O 0 0.0007543593
have O 0 0.0013487904
major O 0 0.0037006398
congenital B-Disease 0 0.83866173
anomalies I-Disease 0 0.8220134
. O 0 0.008470901

In O 0 0.003118057
the O 0 0.0022514886
singleton O 0 0.0059764646
pregnancy O 0 0.12683499
, O 0 0.0020667936
the O 0 0.0010877458
mother O 0 0.0042007095
had O 0 0.0030185392
ulcerative B-Disease 0 0.9998363
colitis I-Disease 0 0.99990475
, O 0 0.006085812
and O 0 0.00079844915
the O 0 0.00052187225
infant O 0 0.0065784506
, O 0 0.00064182945
a O 0 0.00049946125
male O 0 0.0015900611
, O 0 0.0005331557
had O 0 0.0005257066
coarctation B-Disease 0 0.6373032
of I-Disease 0 0.00092165964
the I-Disease 0 0.0008531831
aorta I-Disease 0 0.11722447
and O 0 0.0013995171
a O 0 0.0024189397
ventricular B-Disease 0 0.98399645
septal I-Disease 0 0.2797479
defect I-Disease 0 0.0071399217
. O 0 0.006233515

In O 0 0.0042260657
the O 0 0.0033484208
twin O 0 0.012329327
pregnancy O 0 0.16064951
, O 0 0.0039529167
the O 0 0.0024818173
mother O 0 0.006949864
had O 0 0.005268191
Crohn B-Disease 0 0.9884454
' I-Disease 0 0.007625092
s I-Disease 0 0.009432341
disease I-Disease 0 0.5635819
. O 0 0.011921249

The O 0 0.0028848257
first O 0 0.0019957228
twin O 0 0.007959818
, O 0 0.0023294918
a O 0 0.0015370739
female O 0 0.002870383
, O 0 0.0011967004
had O 0 0.00079849135
a O 0 0.0008856639
left O 0 0.0019323474
Potter B-Disease 0 0.039475348
- I-Disease 0 0.001422726
type I-Disease 0 0.001014253
IIa I-Disease 0 0.61163175
polycystic I-Disease 0 0.99741226
kidney I-Disease 0 0.92582685
and O 0 0.001961207
a O 0 0.0020675932
rudimentary B-Disease 0 0.006958617
left I-Disease 0 0.011420789
uterine I-Disease 0 0.8479637
cornu I-Disease 0 0.8168994
. O 0 0.008171983

The O 0 0.0028719762
second O 0 0.0022248535
twin O 0 0.008254819
, O 0 0.0022518164
a O 0 0.001441568
male O 0 0.0027382981
, O 0 0.0010305723
had O 0 0.0006363332
some O 0 0.000640147
features O 0 0.00131032
of O 0 0.0008391955
Potter B-Disease 0 0.038061794
' I-Disease 0 0.00080031535
s I-Disease 0 0.0009394954
facies I-Disease 0 0.5303487
, O 0 0.0013283592
hypoplastic B-Disease 0 0.8884859
lungs I-Disease 0 0.05153195
, O 0 0.00094916
absent B-Disease 0 0.00066673465
kidneys I-Disease 0 0.018594895
and I-Disease 0 0.0012199404
ureters I-Disease 0 0.19419135
, O 0 0.0025233065
and O 0 0.0034816703
talipes B-Disease 0 0.9821685
equinovarus I-Disease 0 0.9944878
. O 0 0.012770051

Despite O 0 0.004871623
reports O 0 0.0038847076
to O 0 0.0021578246
the O 0 0.0017786132
contrary O 0 0.002494896
, O 0 0.0021909717
it O 0 0.0016617838
is O 0 0.0014080247
suggested O 0 0.0018230728
that O 0 0.0025674002
sulphasalazine B-Chemical 1 0.9990522
may O 0 0.006753531
be O 0 0.009160313
teratogenic O 0 0.9922586
. O 0 0.011511046

Thrombotic B-Disease 0 0.9949726
microangiopathy I-Disease 0 0.99904746
and O 0 0.016310692
renal B-Disease 0 0.9889647
failure I-Disease 0 0.8473086
associated O 0 0.009837215
with O 0 0.011258141
antineoplastic O 0 0.9880475
chemotherapy O 0 0.975205
. O 0 0.016788796

Five O 0 0.0071664318
patients O 0 0.006522255
with O 0 0.0045189466
carcinoma B-Disease 2 0.9975942
developed O 0 0.0785551
thrombotic B-Disease 2 0.999592
microangiopathy I-Disease 2 0.9999199
( O 0 0.011971433
characterized O 0 0.0028800808
by O 0 0.0013137332
renal B-Disease 0 0.99681264
insufficiency I-Disease 0 0.9992555
, O 0 0.033158436
microangiopathic B-Disease 0 0.99984884
hemolytic I-Disease 2 0.9999585
anemia I-Disease 2 0.9999627
, O 0 0.011029927
and O 0 0.0010001804
usually O 0 0.0060123946
thrombocytopenia B-Disease 0 0.9996037
) O 0 0.0015347309
after O 0 0.00025914444
treatment O 0 0.0013220079
with O 0 0.0013249278
cisplatin B-Chemical 1 0.9990778
, O 0 0.004836763
bleomycin B-Chemical 0 0.9972631
, O 0 0.0028147148
and O 0 0.0020067112
a O 0 0.004667683
vinca B-Chemical 0 0.99780685
alkaloid I-Chemical 0 0.99656713
. O 0 0.011691339

One O 0 0.005774114
patient O 0 0.004688086
had O 0 0.004224834
thrombotic B-Disease 2 0.99797875
thrombocytopenic I-Disease 0 0.99948955
purpura I-Disease 0 0.9994678
, O 0 0.005240455
three O 0 0.0007268992
the O 0 0.0015206134
hemolytic B-Disease 0 0.9994635
- I-Disease 0 0.0361633
uremic I-Disease 0 0.99964714
syndrome I-Disease 0 0.9790492
, O 0 0.0011920672
and O 0 0.00053512293
one O 0 0.00034739234
an O 0 0.0006194218
apparent O 0 0.0008707552
forme O 0 0.6842531
fruste O 0 0.9190182
of O 0 0.0018012405
one O 0 0.001302199
of O 0 0.0026833902
these O 0 0.0057945815
disorders O 0 0.8580485
. O 0 0.008361083

Histologic O 0 0.23701334
examination O 0 0.0045321155
of O 0 0.0024934167
the O 0 0.0018761166
renal O 0 0.94882625
tissue O 0 0.0148860635
showed O 0 0.0010252148
evidence O 0 0.0010296961
of O 0 0.0015315479
intravascular B-Disease 0 0.98217094
coagulation I-Disease 0 0.9902766
, O 0 0.0016433382
primarily O 0 0.0012582827
affecting O 0 0.001051721
the O 0 0.00071144564
small O 0 0.0014653848
arteries O 0 0.6283169
, O 0 0.0027570701
arterioles O 0 0.7099252
, O 0 0.003221893
and O 0 0.0036727479
glomeruli O 0 0.12870856
. O 0 0.0066362764

Because O 0 0.0026064224
each O 0 0.0012581754
patient O 0 0.0024348695
was O 0 0.0016753498
tumor B-Disease 2 0.5347068
- O 0 0.0019330942
free O 0 0.0010806663
or O 0 0.00047086726
had O 0 0.0004789161
only O 0 0.00041167476
a O 0 0.0004493619
small O 0 0.0005780714
tumor B-Disease 2 0.3179796
at O 0 0.00025860238
the O 0 0.00030816084
onset O 0 0.0015089042
of O 0 0.0005285626
this O 0 0.0006098208
syndrome O 0 0.8391299
, O 0 0.0011465548
the O 0 0.0012080272
thrombotic B-Disease 2 0.9996699
microangiopathy I-Disease 2 0.99991167
may O 0 0.0024349957
have O 0 0.0016004132
been O 0 0.0020952797
induced O 0 0.0030061288
by O 0 0.0043012863
chemotherapy O 0 0.8732777
. O 0 0.007506416

Diagnosis O 0 0.05198772
of O 0 0.0032910127
this O 0 0.0020890436
potentially O 0 0.0047332593
fatal O 0 0.96569353
complication O 0 0.5688462
may O 0 0.0011738528
be O 0 0.00074266415
delayed O 0 0.0021901985
or O 0 0.00041307442
missed O 0 0.0008834456
if O 0 0.00034232702
renal O 0 0.9644346
tissue O 0 0.014943491
or O 0 0.00034437713
the O 0 0.00032677266
peripheral O 0 0.017636688
blood O 0 0.0049509867
smear O 0 0.0016874911
is O 0 0.0002660917
not O 0 0.00019978265
examined O 0 0.00019158196
, O 0 0.00033580905
because O 0 0.00024370104
renal B-Disease 0 0.9809825
failure I-Disease 0 0.70810854
may O 0 0.0005621615
be O 0 0.00042317557
ascribed O 0 0.0008538833
to O 0 0.0005791658
cisplatin B-Chemical 1 0.9996008
nephrotoxicity B-Disease 0 0.9999517
and O 0 0.0025210837
the O 0 0.0014511185
anemia B-Disease 0 0.9996499
and O 0 0.0054354435
thrombocytopenia B-Disease 0 0.9995234
to O 0 0.001672758
drug O 0 0.70915
- O 0 0.0043274257
induced O 0 0.0038308254
bone B-Disease 0 0.49602026
marrow I-Disease 0 0.9237619
suppression I-Disease 0 0.3259722
. O 0 0.007821741

International O 0 0.021882044
mexiletine B-Chemical 0 0.99766517
and O 0 0.008770436
placebo O 0 0.52142763
antiarrhythmic O 0 0.9911049
coronary O 0 0.9087114
trial O 0 0.021294033
: O 0 0.014121359
I O 0 0.023355141
. O 0 0.011946314

Report O 0 0.03994335
on O 0 0.011727355
arrhythmia B-Disease 2 0.9821231
and O 0 0.015668267
other O 0 0.015042107
findings O 0 0.029273221
. O 0 0.020460334

Impact O 0 0.06812681
Research O 0 0.11760812
Group O 0 0.10891515
. O 0 0.04691305

The O 0 0.0033864907
antiarrhythmic O 0 0.9166968
effects O 0 0.0034573034
of O 0 0.0016687582
the O 0 0.0011021165
sustained O 0 0.012422579
release O 0 0.049232177
form O 0 0.0010041302
of O 0 0.0018283197
mexiletine B-Chemical 0 0.9998939
( O 0 0.009882538
Mexitil B-Chemical 0 0.9561275
- I-Chemical 0 0.0023584466
Perlongets I-Chemical 0 0.4231898
) O 0 0.0006481054
were O 0 0.00024494968
evaluated O 0 0.00023686956
in O 0 0.00021947698
a O 0 0.00029977207
double O 0 0.000292398
- O 0 0.0006077413
blind O 0 0.0023285642
placebo O 0 0.06053754
trial O 0 0.0009510647
in O 0 0.0004501456
630 O 0 0.008735877
patients O 0 0.0016940839
with O 0 0.0011495277
recent O 0 0.0022181862
documented O 0 0.020601554
myocardial B-Disease 0 0.9983575
infarction I-Disease 2 0.9994578
. O 0 0.016035188

The O 0 0.002649137
primary O 0 0.002540677
response O 0 0.0020323193
variable O 0 0.001191655
was O 0 0.00083673705
based O 0 0.0007347657
on O 0 0.0003727695
central O 0 0.0011051997
reading O 0 0.0010711082
of O 0 0.0004488375
24 O 0 0.00030334425
hour O 0 0.00024723922
ambulatory O 0 0.00093347346
electrocardiographic O 0 0.7769094
recordings O 0 0.0029621485
and O 0 0.00027454077
was O 0 0.000200048
defined O 0 0.00016818673
as O 0 0.00014123874
the O 0 0.00017153604
occurrence O 0 0.0004915361
of O 0 0.00029887856
30 O 0 0.00020077106
or O 0 0.00014918475
more O 0 0.00023536685
single O 0 0.00024471135
premature O 0 0.0319808
ventricular O 0 0.951303
complexes O 0 0.0006293173
in O 0 0.00017729725
any O 0 0.00013162501
two O 0 0.00010977477
consecutive O 0 0.00020241372
30 O 0 0.00013069488
minute O 0 0.00013579529
blocks O 0 0.00020148559
or O 0 0.00014172765
one O 0 0.00013159025
or O 0 0.00014984641
more O 0 0.00023491398
runs O 0 0.00033092475
of O 0 0.00028179752
two O 0 0.00019002646
or O 0 0.00023692782
more O 0 0.00045233764
premature O 0 0.036439057
ventricular O 0 0.94348127
complexes O 0 0.00092649256
in O 0 0.00040653895
the O 0 0.00044529437
entire O 0 0.00052739144
24 O 0 0.00085361366
hour O 0 0.0014297966
electrocardiographic O 0 0.778399
recording O 0 0.00876473
. O 0 0.005444023

Large O 0 0.00822009
differences O 0 0.0020768864
, O 0 0.0021951862
regarded O 0 0.0018390572
as O 0 0.00083268026
statistically O 0 0.0008677309
significant O 0 0.00087542715
, O 0 0.0007033008
between O 0 0.0002827349
the O 0 0.0005138558
mexiletine B-Chemical 0 0.999744
and O 0 0.0009196943
placebo O 0 0.15511937
groups O 0 0.0004494514
were O 0 0.000284249
noted O 0 0.00024671483
in O 0 0.00018290819
that O 0 0.00015566498
end O 0 0.00012234972
point O 0 0.00018424321
at O 0 0.00014744287
months O 0 0.00026637042
1 O 0 0.00023997908
and O 0 0.0002534307
4 O 0 0.00024772764
, O 0 0.00034808303
but O 0 0.00028054675
only O 0 0.0003537354
trends O 0 0.0007271053
were O 0 0.0006074008
observed O 0 0.00065129675
at O 0 0.0008817847
month O 0 0.002070752
12 O 0 0.002803344
. O 0 0.004149206

These O 0 0.0037809822
differences O 0 0.001584762
were O 0 0.0013590279
observed O 0 0.0008632317
even O 0 0.0008803805
though O 0 0.00073923956
the O 0 0.00068659463
serum O 0 0.11909004
mexiletine B-Chemical 0 0.99979275
levels O 0 0.0008039648
obtained O 0 0.00040501647
in O 0 0.00026243416
this O 0 0.0002485339
study O 0 0.000397533
were O 0 0.00022938901
generally O 0 0.0003220482
lower O 0 0.00023999212
than O 0 0.00015896722
those O 0 0.00030002595
observed O 0 0.00018669032
in O 0 0.0002192212
studies O 0 0.00042578127
that O 0 0.0002617425
have O 0 0.0004025301
used O 0 0.0004218585
the O 0 0.0005182897
regular O 0 0.0012124799
form O 0 0.0012692447
of O 0 0.002149568
the O 0 0.003267999
drug O 0 0.49338222
. O 0 0.0071214964

There O 0 0.005412734
were O 0 0.0026076632
more O 0 0.0027161152
deaths B-Disease 0 0.12521803
in O 0 0.0012176271
the O 0 0.0012359368
mexiletine B-Chemical 0 0.99961084
group O 0 0.0025223931
( O 0 0.0011102939
7 O 0 0.00041910438
. O 0 0.00022996472
6 O 0 0.00023254156
% O 0 0.00031405568
) O 0 0.00035235056
than O 0 0.00014508552
in O 0 0.0001855103
the O 0 0.00024731114
placebo O 0 0.044693824
group O 0 0.00051933015
( O 0 0.00047841374
4 O 0 0.00026028097
. O 0 0.00018481487
8 O 0 0.00029650357
% O 0 0.0004008334
) O 0 0.0005970349
; O 0 0.0006152982
the O 0 0.00039546302
difference O 0 0.0004305979
was O 0 0.00084509724
not O 0 0.001251033
statistically O 0 0.0022887115
significant O 0 0.0047391206
. O 0 0.00546803

The O 0 0.004698147
incidence O 0 0.008578442
of O 0 0.0048333765
coronary O 0 0.4600032
events O 0 0.011334521
was O 0 0.0028066558
similar O 0 0.0022809913
in O 0 0.003042735
both O 0 0.004635303
groups O 0 0.008302858
. O 0 0.00945862

Previously O 0 0.00841757
recognized O 0 0.004122347
side O 0 0.012621246
effects O 0 0.0037115542
, O 0 0.002116926
particularly O 0 0.003367792
tremor B-Disease 0 0.99905473
and O 0 0.0023291449
gastrointestinal B-Disease 0 0.99672467
problems I-Disease 0 0.3257879
, O 0 0.0009518021
were O 0 0.0004196623
more O 0 0.0004928293
frequent O 0 0.0012554431
in O 0 0.00039745006
the O 0 0.0006137409
mexiletine B-Chemical 0 0.999681
group O 0 0.0013666617
than O 0 0.0005954746
in O 0 0.00088658254
the O 0 0.0015801003
placebo O 0 0.17149846
group O 0 0.0055608465
. O 0 0.0056365337

Changes O 0 0.0072986963
in O 0 0.0033053975
heart O 0 0.08983011
size O 0 0.00254041
during O 0 0.0013323202
long O 0 0.0021613962
- O 0 0.0028002292
term O 0 0.0029683711
timolol B-Chemical 1 0.9991327
treatment O 0 0.027836407
after O 0 0.0052381926
myocardial B-Disease 0 0.9978235
infarction I-Disease 2 0.9992861
. O 0 0.01937431

The O 0 0.0027718341
effect O 0 0.0023002285
of O 0 0.0019638706
long O 0 0.001989756
- O 0 0.001976387
term O 0 0.0014521526
timolol B-Chemical 1 0.9995826
treatment O 0 0.008078249
on O 0 0.00050977134
heart O 0 0.30757037
size O 0 0.0008137325
after O 0 0.00041236388
myocardial B-Disease 0 0.99899465
infarction I-Disease 2 0.9998946
was O 0 0.000985566
evaluated O 0 0.0005404135
by O 0 0.00067485194
X O 0 0.37505198
- O 0 0.0011724578
ray O 0 0.029898722
in O 0 0.0003163823
a O 0 0.00034980444
double O 0 0.0003012228
- O 0 0.000568256
blind O 0 0.0014551474
study O 0 0.00052503456
including O 0 0.00044477446
241 O 0 0.0058914875
patients O 0 0.0020289382
( O 0 0.0011842195
placebo O 0 0.103117295
126 O 0 0.010136749
, O 0 0.0030633076
timolol B-Chemical 1 0.99893147
115 O 0 0.068262994
) O 0 0.00785619
. O 0 0.0055918023

The O 0 0.0061436477
follow O 0 0.005919483
- O 0 0.006910563
up O 0 0.004353198
period O 0 0.0044173026
was O 0 0.0050858706
12 O 0 0.005490256
months O 0 0.008612908
. O 0 0.010427078

The O 0 0.0045339656
timolol B-Chemical 1 0.9984921
- O 0 0.005840301
treated O 0 0.002568514
patients O 0 0.0026389833
showed O 0 0.0007745627
a O 0 0.0006948085
small O 0 0.00067961804
but O 0 0.00045985793
significant O 0 0.0005344016
increase O 0 0.0003974144
in O 0 0.0003844416
heart O 0 0.16429709
size O 0 0.0005111607
from O 0 0.0003086257
baseline O 0 0.00043921696
in O 0 0.00027783302
contrast O 0 0.000391075
to O 0 0.0004034373
a O 0 0.0006148668
decrease O 0 0.00087545015
in O 0 0.0008746509
the O 0 0.0015550413
placebo O 0 0.1808495
group O 0 0.0054714433
. O 0 0.005524165

These O 0 0.0045741904
differences O 0 0.002053512
may O 0 0.0019944562
be O 0 0.0016823978
caused O 0 0.0017328144
by O 0 0.0020235868
timolol B-Chemical 1 0.99967456
- O 0 0.009396038
induced O 0 0.0036093176
bradycardia B-Disease 0 0.9988433
and O 0 0.0011378829
a O 0 0.0009184981
compensatory O 0 0.001994375
increase O 0 0.0009223963
in O 0 0.0010144498
end O 0 0.0012233695
- O 0 0.0047995863
diastolic O 0 0.9323301
volume O 0 0.015882509
. O 0 0.0063912035

The O 0 0.004719935
timolol B-Chemical 1 0.99846894
- O 0 0.0055249403
related O 0 0.0012328358
increase O 0 0.0010105585
in O 0 0.00084247487
heart O 0 0.1874714
size O 0 0.0009619747
was O 0 0.0005411689
observed O 0 0.00037057075
only O 0 0.00047240706
in O 0 0.00047506002
patients O 0 0.0014636612
with O 0 0.0009554729
normal O 0 0.002120188
and O 0 0.0018725519
borderline O 0 0.36591765
heart O 0 0.58173925
size O 0 0.008152303
. O 0 0.006712718

In O 0 0.0037397505
patients O 0 0.005566162
with O 0 0.0038555833
cardiomegaly B-Disease 0 0.9969008
, O 0 0.0027690202
the O 0 0.001134325
increase O 0 0.0010498726
in O 0 0.0010390384
heart O 0 0.19053572
size O 0 0.0016013104
was O 0 0.0011642666
similar O 0 0.0011019942
in O 0 0.0016940968
both O 0 0.0028939822
groups O 0 0.0056653693
. O 0 0.006729294

After O 0 0.003954684
re O 0 0.026637059
- O 0 0.009224637
infarction B-Disease 2 0.9989874
, O 0 0.004149712
heart O 0 0.3254213
size O 0 0.001311468
increased O 0 0.0011667274
in O 0 0.00056270504
the O 0 0.000575636
placebo O 0 0.057868566
group O 0 0.00081133883
and O 0 0.0006804304
remained O 0 0.0010631618
unchanged O 0 0.0012456445
in O 0 0.0012987271
the O 0 0.0027392698
timolol B-Chemical 1 0.99884254
group O 0 0.011412168
. O 0 0.007411372

Vitamin B-Chemical 0 0.99707747
D3 I-Chemical 0 0.99513596
toxicity B-Disease 2 0.98699796
in O 0 0.022339206
dairy O 0 0.35731816
cows O 0 0.106473856
. O 0 0.027356306

Large O 0 0.011791493
parenteral O 0 0.6138496
doses O 0 0.11188017
of O 0 0.00625596
vitamin B-Chemical 1 0.9993662
D3 I-Chemical 1 0.9992699
( O 0 0.0029181128
15 O 0 0.00064694
to O 0 0.00048177142
17 O 0 0.0006617993
. O 0 0.00025760112
5 O 0 0.00028429265
x O 0 0.00075418927
10 O 0 0.00036538896
( O 0 0.00040283968
6 O 0 0.00024859578
) O 0 0.0006500327
IU O 0 0.59830105
vitamin B-Chemical 1 0.9997104
D3 I-Chemical 1 0.9996551
) O 0 0.0017023578
were O 0 0.0003259385
associated O 0 0.00045000768
with O 0 0.0005537241
prolonged O 0 0.11482988
hypercalcemia B-Disease 2 0.9999411
, O 0 0.027089283
hyperphosphatemia B-Disease 0 0.9999572
, O 0 0.001883522
and O 0 0.000406982
large O 0 0.00040786192
increases O 0 0.0004471289
of O 0 0.0012319272
vitamin B-Chemical 1 0.99982446
D3 I-Chemical 1 0.9996939
and O 0 0.0009304548
its O 0 0.0021603066
metabolites O 0 0.74588555
in O 0 0.00040353023
the O 0 0.0004137545
blood O 0 0.005486347
plasma O 0 0.01859723
of O 0 0.0011118868
nonlactating O 0 0.34671158
nonpregnant O 0 0.17892799
and O 0 0.0021213435
pregnant O 0 0.061512507
Jersey O 0 0.054915257
cows O 0 0.0218323
. O 0 0.006745693

Calcium B-Chemical 0 0.9931912
concentrations O 0 0.01295964
1 O 0 0.0019070149
day O 0 0.0011373623
postpartum O 0 0.0035696335
were O 0 0.00069090875
higher O 0 0.0005551129
in O 0 0.00046568803
cows O 0 0.0027094907
treated O 0 0.0012104594
with O 0 0.0013623259
vitamin B-Chemical 1 0.99968755
D3 I-Chemical 1 0.9994968
about O 0 0.00062604557
32 O 0 0.0006668624
days O 0 0.00034523738
prepartum O 0 0.045512762
( O 0 0.0005125355
8 O 0 0.0002687705
. O 0 0.0001500317
8 O 0 0.00024160591
mg O 0 0.076718956
/ O 0 0.00065237866
100 O 0 0.0005907847
ml O 0 0.001055393
) O 0 0.0004007662
than O 0 0.00014868983
in O 0 0.00019699163
control O 0 0.00026850868
cows O 0 0.0022903027
( O 0 0.0006534237
5 O 0 0.000399587
. O 0 0.00032927856
5 O 0 0.0006002188
mg O 0 0.08162421
/ O 0 0.0026312722
100 O 0 0.0032646307
ml O 0 0.0069611673
) O 0 0.0058037443
. O 0 0.0049877875

None O 0 0.0076997913
of O 0 0.0028678514
the O 0 0.00186326
cows O 0 0.005972475
treated O 0 0.0028800766
with O 0 0.0027443655
vitamin B-Chemical 1 0.9995085
D3 I-Chemical 1 0.9994167
showed O 0 0.0018001169
signs O 0 0.22813554
of O 0 0.002010965
milk B-Disease 2 0.92006654
fever I-Disease 2 0.99952364
during O 0 0.000511645
the O 0 0.00043804283
peripartal O 0 0.093457595
period O 0 0.0005645816
; O 0 0.00073154934
however O 0 0.00048429915
, O 0 0.0004009882
22 O 0 0.00039042838
% O 0 0.00024655706
of O 0 0.00024509872
the O 0 0.00022500857
control O 0 0.0002561815
cows O 0 0.0018757205
developed O 0 0.0009194091
clinical O 0 0.008561187
signs O 0 0.11880639
of O 0 0.002197026
milk B-Disease 2 0.89620656
fever I-Disease 2 0.99882704
during O 0 0.0021051294
this O 0 0.0027307197
period O 0 0.004486093
. O 0 0.0054603466

Signs O 0 0.773215
of O 0 0.009014783
vitamin B-Chemical 1 0.99888605
D3 I-Chemical 1 0.9992143
toxicity B-Disease 2 0.9969572
were O 0 0.0016434164
not O 0 0.0007503655
observed O 0 0.00048230024
in O 0 0.00049575797
nonlactating O 0 0.13261835
nonpregnant O 0 0.13522986
cows O 0 0.009533271
; O 0 0.0010634034
however O 0 0.00066450174
, O 0 0.0005620798
pregnant O 0 0.0062644323
cows O 0 0.0031187972
commonly O 0 0.0014887373
developed O 0 0.0014189192
severe O 0 0.16729428
signs O 0 0.25357947
of O 0 0.0042247293
vitamin B-Chemical 1 0.99979144
D3 I-Chemical 1 0.9997068
toxicity B-Disease 2 0.99761486
and O 0 0.0017880303
10 O 0 0.0012881412
of O 0 0.0016426499
17 O 0 0.0031183138
cows O 0 0.013371323
died O 0 0.04413204
. O 0 0.006600474

There O 0 0.008534859
was O 0 0.0048344037
widespread O 0 0.0117003685
metastatic O 0 0.9626289
calcification O 2 0.98788995
in O 0 0.0044150967
the O 0 0.0041267723
cows O 0 0.015148383
that O 0 0.0064406893
died O 0 0.062140048
. O 0 0.012273651

Because O 0 0.0030347104
of O 0 0.0026379116
the O 0 0.001913824
extreme O 0 0.0053452025
toxicity B-Disease 2 0.9906465
of O 0 0.0067392387
vitamin B-Chemical 1 0.9996908
D3 I-Chemical 1 0.99954337
in O 0 0.001228209
pregnant O 0 0.049747363
Jersey O 0 0.013252094
cows O 0 0.0027434207
and O 0 0.0003960527
the O 0 0.00027828765
low O 0 0.00040338136
margin O 0 0.0009138013
of O 0 0.00039159076
safety O 0 0.0013896313
between O 0 0.00019158745
doses O 0 0.02041954
of O 0 0.0015304739
vitamin B-Chemical 1 0.99983144
D3 I-Chemical 1 0.9997029
that O 0 0.0006486418
prevent O 0 0.0013636538
milk B-Disease 2 0.9281812
fever I-Disease 2 0.9997156
and O 0 0.0012356126
doses O 0 0.076494075
that O 0 0.0003887235
induce O 0 0.0006458917
milk B-Disease 2 0.90273947
fever I-Disease 2 0.99970067
, O 0 0.0010683454
we O 0 0.00019672641
concluded O 0 0.0008466383
that O 0 0.00053660234
vitamin B-Chemical 1 0.9997502
D3 I-Chemical 1 0.9996269
cannot O 0 0.03032803
be O 0 0.0005283572
used O 0 0.0003633924
practically O 0 0.00085131533
to O 0 0.0005061528
prevent O 0 0.001181463
milk B-Disease 2 0.8132047
fever I-Disease 2 0.999025
when O 0 0.0010517928
injected O 0 0.0013261309
several O 0 0.0019296088
weeks O 0 0.003013873
prepartum O 0 0.14216407
. O 0 0.0060500484

Diseases B-Disease 0 0.02540917
of I-Disease 0 0.0071198745
peripheral I-Disease 0 0.047359224
nerves I-Disease 0 0.16452149
as O 0 0.0038066145
seen O 0 0.0038646515
in O 0 0.0038856505
the O 0 0.0058809123
Nigerian O 0 0.07957981
African O 0 0.04255072
. O 0 0.011927699

The O 0 0.0031727054
anatomical O 0 0.00455175
and O 0 0.0023785944
aetiological O 0 0.073127344
diagnoses O 0 0.006816571
of O 0 0.0016686829
peripheral B-Disease 0 0.15269807
nerve I-Disease 0 0.73904324
disease I-Disease 0 0.83433205
excluding O 0 0.0016309656
its O 0 0.0015302001
primary O 0 0.0013525041
benign O 0 0.88427186
and O 0 0.0014402953
malignant O 0 0.98848826
disorders O 0 0.91428363
, O 0 0.0014413601
as O 0 0.000672837
seen O 0 0.0008940102
in O 0 0.001105018
358 O 0 0.019787462
Nigerians O 0 0.15924644
are O 0 0.002974297
presented O 0 0.0049978057
. O 0 0.0057693147

There O 0 0.006493448
is O 0 0.003050741
a O 0 0.0025658084
male O 0 0.0043260474
preponderance O 0 0.004531696
and O 0 0.0016751711
the O 0 0.0013451332
peak O 0 0.0021346512
incidence O 0 0.0066593355
is O 0 0.0020555973
in O 0 0.001935893
the O 0 0.002787029
fourth O 0 0.008107312
decade O 0 0.018718163
. O 0 0.0088691255

Sensori B-Disease 0 0.030429756
- I-Disease 0 0.011807271
motor I-Disease 0 0.71844244
neuropathy I-Disease 0 0.99868745
was O 0 0.0044350117
the O 0 0.0032153702
commonest O 0 0.13045867
presentation O 0 0.028832437
( O 0 0.006020819
50 O 0 0.006162876
% O 0 0.006087643
) O 0 0.009022872
. O 0 0.007949945

Guillain B-Disease 0 0.99218655
- I-Disease 0 0.015891902
Barr I-Disease 0 0.8235769
syndrome I-Disease 0 0.7376308
was O 0 0.001742476
the O 0 0.0012612513
commonest O 0 0.09700036
identifiable O 0 0.021385672
cause O 0 0.0055076075
( O 0 0.0010978647
15 O 0 0.00043277314
. O 0 0.00025470782
6 O 0 0.0002714829
% O 0 0.00039034904
) O 0 0.0004937165
, O 0 0.00038084705
accounting O 0 0.0005540145
for O 0 0.00030872575
half O 0 0.00033294057
of O 0 0.0007422638
the O 0 0.0009252178
cases O 0 0.0028916849
with O 0 0.004808091
motor B-Disease 0 0.95652497
neuropathy I-Disease 0 0.9991742
. O 0 0.011685573

Peripheral B-Disease 2 0.9654245
neuropathy I-Disease 2 0.9984908
due O 0 0.0026619975
to O 0 0.0019489354
nutritional B-Disease 0 0.6209384
deficiency I-Disease 0 0.9107275
of O 0 0.005211743
thiamine B-Chemical 0 0.9995383
and O 0 0.004130985
riboflavin B-Chemical 0 0.9994388
was O 0 0.0011330416
common O 0 0.0014296733
( O 0 0.00081269955
10 O 0 0.00044002867
. O 0 0.000221504
1 O 0 0.00032326693
% O 0 0.00035615158
) O 0 0.0004281111
and O 0 0.00030922887
presented O 0 0.00042346676
mainly O 0 0.00083625555
as O 0 0.0006306625
sensory O 0 0.041981168
and O 0 0.0017227787
sensori B-Disease 0 0.16981593
- I-Disease 0 0.011309366
motor I-Disease 0 0.9359294
neuropathy I-Disease 0 0.99907696
. O 0 0.010835474

Diabetes B-Disease 0 0.9849557
mellitus I-Disease 0 0.9951439
was O 0 0.0069625457
the O 0 0.0045943824
major O 0 0.0064246985
cause O 0 0.013133057
of O 0 0.014822323
autonomic B-Disease 0 0.9919504
neuropathy I-Disease 0 0.99855334
. O 0 0.023650752

Isoniazid B-Chemical 0 0.99611807
was O 0 0.0050837616
the O 0 0.0031789138
most O 0 0.004242792
frequent O 0 0.0077616675
agent O 0 0.11024049
in O 0 0.0039583636
drug O 0 0.65058196
- O 0 0.014136315
induced O 0 0.02530082
neuropathy B-Disease 0 0.99772626
. O 0 0.015110873

Migraine B-Disease 0 0.9955753
( O 0 0.0058679413
20 O 0 0.0025396068
% O 0 0.0018667129
) O 0 0.0015872916
was O 0 0.00074920786
not O 0 0.00059942016
an O 0 0.00090999797
uncommon O 0 0.011949241
cause O 0 0.0027583565
of O 0 0.0016178156
cranial B-Disease 0 0.9697168
neuropathy I-Disease 0 0.9998872
although O 0 0.002848793
malignancies B-Disease 2 0.99814093
arising O 0 0.0016698136
from O 0 0.0004467408
the O 0 0.00041737343
reticuloendothelial O 0 0.8402681
system O 0 0.00073226256
or O 0 0.00026045626
related O 0 0.00023013605
structures O 0 0.0005522896
of O 0 0.0003918826
the O 0 0.0003739867
head O 0 0.008200985
and O 0 0.0006684812
neck O 0 0.09509038
were O 0 0.0007688427
more O 0 0.0011443654
frequent O 0 0.003966533
( O 0 0.0023337386
26 O 0 0.0030463526
% O 0 0.0031485136
) O 0 0.0053730295
. O 0 0.005033899

In O 0 0.003756354
26 O 0 0.0035543055
. O 0 0.0014361003
5 O 0 0.001122268
% O 0 0.0010199414
of O 0 0.00087055116
all O 0 0.0006860305
the O 0 0.0007542324
cases O 0 0.0015695319
, O 0 0.0012168532
the O 0 0.0009915194
aetiology O 0 0.0779051
of O 0 0.0025793726
the O 0 0.0038125594
neuropathy B-Disease 0 0.9986902
was O 0 0.0070826723
undetermined O 0 0.23670444
. O 0 0.009200607

Heredofamilial O 0 0.58327985
and O 0 0.013012869
connective B-Disease 0 0.16342278
tissue I-Disease 0 0.061667006
disorders I-Disease 0 0.86915106
were O 0 0.015256972
rare O 0 0.051279172
. O 0 0.01845346

Some O 0 0.0059696785
of O 0 0.0028879533
the O 0 0.0018413881
factors O 0 0.002793638
related O 0 0.0009761388
to O 0 0.0008537572
the O 0 0.00078803714
clinical O 0 0.0037692953
presentation O 0 0.0045758667
and O 0 0.0012788153
pathogenesis O 0 0.010027341
of O 0 0.0020442447
the O 0 0.0026836514
neuropathies B-Disease 0 0.9979724
are O 0 0.004177971
briefly O 0 0.0058341282
discussed O 0 0.0055712643
. O 0 0.0070108366

Reduction O 0 0.03755855
in O 0 0.017333671
caffeine B-Chemical 1 0.99298495
toxicity B-Disease 2 0.98991454
by O 0 0.06526509
acetaminophen B-Chemical 0 0.9978605
. O 0 0.035905153

A O 0 0.014546662
patient O 0 0.004336839
who O 0 0.004123324
allegedly O 0 0.010215051
consumed O 0 0.006612626
100 O 0 0.0026400879
tablets O 0 0.5900197
of O 0 0.0010613848
an O 0 0.00087710965
over O 0 0.00037610525
- O 0 0.0009120212
the O 0 0.00048064115
- O 0 0.00089405023
counter O 0 0.0025950044
analgesic O 0 0.9884228
containing O 0 0.0019965465
sodium B-Chemical 0 0.9996915
acetylsalicylate I-Chemical 0 0.99997044
, O 0 0.026580503
caffeine B-Chemical 1 0.9996643
, O 0 0.002095793
and O 0 0.00093342946
acetaminophen B-Chemical 0 0.99989414
displayed O 0 0.0005035141
no O 0 0.00029981261
significant O 0 0.00061360636
CNS O 0 0.50809896
stimulation O 0 0.00090951304
despite O 0 0.00028202147
the O 0 0.00026584195
presence O 0 0.00031487446
of O 0 0.00054369454
175 O 0 0.0074693346
micrograms O 0 0.1583612
of O 0 0.0014097715
caffeine B-Chemical 1 0.99802655
per O 0 0.0012964037
mL O 0 0.011770037
of O 0 0.0036753262
serum O 0 0.18978372
. O 0 0.006439335

Because O 0 0.004664257
salicylates O 0 0.99658513
have O 0 0.0032582546
been O 0 0.0020541847
reported O 0 0.0015490567
to O 0 0.0007755188
augment O 0 0.00089880347
the O 0 0.00059605576
stimulatory O 0 0.011188663
effects O 0 0.0017527377
of O 0 0.0012003463
caffeine B-Chemical 1 0.9991129
on O 0 0.0004050985
the O 0 0.0005702879
CNS O 0 0.7368173
, O 0 0.00064175454
attention O 0 0.001156164
was O 0 0.00024279981
focused O 0 0.00026031325
on O 0 0.00013011269
the O 0 0.00019173216
possibility O 0 0.0001970155
that O 0 0.00019264218
the O 0 0.00024040048
presence O 0 0.00033494591
of O 0 0.0010593892
acetaminophen B-Chemical 0 0.99990904
( O 0 0.0020410314
52 O 0 0.0013496327
micrograms O 0 0.25345212
/ O 0 0.0019856251
mL O 0 0.0051743547
) O 0 0.0009484617
reduced O 0 0.00079646875
the O 0 0.0013045177
CNS O 0 0.87531817
toxicity B-Disease 2 0.99358314
of O 0 0.020826317
caffeine B-Chemical 1 0.99770725
. O 0 0.010498994

Studies O 0 0.019769866
in O 0 0.00449158
DBA O 0 0.86409587
/ O 0 0.007900008
2J O 0 0.3123397
mice O 0 0.00079773506
showed O 0 0.0007836931
that O 0 0.00065671786
: O 0 0.0011307045
1 O 0 0.00063237495
) O 0 0.0008436072
pretreatment O 0 0.0744455
with O 0 0.0014236992
acetaminophen B-Chemical 0 0.99990237
( O 0 0.002013729
100 O 0 0.0017029631
mg O 0 0.39822733
/ O 0 0.0010775683
kg O 0 0.004726164
) O 0 0.00040662487
increased O 0 0.00032389068
the O 0 0.00018629414
interval O 0 0.00032647932
between O 0 0.00011084336
the O 0 0.00021018327
administration O 0 0.033523474
of O 0 0.0007813062
caffeine B-Chemical 1 0.9994535
( O 0 0.0010019785
300 O 0 0.0012830037
to O 0 0.0002317275
450 O 0 0.0020449786
mg O 0 0.25888896
/ O 0 0.0008903307
kg O 0 0.0044825524
IP O 0 0.016296742
) O 0 0.0005196505
and O 0 0.00024073901
the O 0 0.00021908726
onset O 0 0.00175415
of O 0 0.0007641915
fatal O 0 0.994048
convulsions B-Disease 0 0.9998921
by O 0 0.0007704716
a O 0 0.00046110846
factor O 0 0.0026089028
of O 0 0.00037284306
about O 0 0.00023410613
two O 0 0.00021259605
; O 0 0.00052672176
and O 0 0.0002840076
2 O 0 0.00030116137
) O 0 0.00048155716
pretreatment O 0 0.07058239
with O 0 0.0010596275
acetaminophen B-Chemical 0 0.9999232
( O 0 0.0014223183
75 O 0 0.0008657962
mg O 0 0.3205175
/ O 0 0.00095910474
kg O 0 0.004497731
) O 0 0.00039568456
reduced O 0 0.00023678533
the O 0 0.00023283284
incidence O 0 0.0032546192
of O 0 0.0011687407
audiogenic O 0 0.99984145
seizures B-Disease 2 0.99989796
produced O 0 0.00075417385
in O 0 0.0003150435
the O 0 0.00027223272
presence O 0 0.00033465293
of O 0 0.0008187235
caffeine B-Chemical 1 0.99926645
( O 0 0.001088147
12 O 0 0.0003362505
. O 0 0.00022798525
5 O 0 0.00030055328
to O 0 0.00039342215
75 O 0 0.001134175
mg O 0 0.15340242
/ O 0 0.0034881313
kg O 0 0.013697117
IP O 0 0.042513747
) O 0 0.0077273115
. O 0 0.005776863

The O 0 0.0029189454
frequency O 0 0.002572747
of O 0 0.0024675028
sound O 0 0.008787112
- O 0 0.0030669428
induced O 0 0.0024686228
seizures B-Disease 2 0.9994098
after O 0 0.00058288337
12 O 0 0.0004416558
. O 0 0.00025020633
5 O 0 0.00025400452
or O 0 0.0002380462
25 O 0 0.0005650834
mg O 0 0.14792019
/ O 0 0.0011092469
kg O 0 0.008522151
caffeine B-Chemical 1 0.9976078
was O 0 0.00060092914
reduced O 0 0.0005861491
from O 0 0.00059039687
50 O 0 0.0009928604
to O 0 0.000780169
5 O 0 0.0010685174
% O 0 0.0018932456
by O 0 0.0036568986
acetaminophen B-Chemical 0 0.99860734
. O 0 0.009453572

In O 0 0.003065204
the O 0 0.0020106034
absence O 0 0.0012770505
of O 0 0.0025093188
caffeine B-Chemical 1 0.99846894
, O 0 0.012665504
acetaminophen B-Chemical 0 0.99983406
( O 0 0.0026403202
up O 0 0.0006139129
to O 0 0.00044578407
300 O 0 0.0019327813
mg O 0 0.31863865
/ O 0 0.0012639198
kg O 0 0.0056612017
) O 0 0.0005489484
did O 0 0.00023336068
not O 0 0.00021162588
modify O 0 0.00037183324
the O 0 0.0004476603
seizures B-Disease 2 0.9997844
induced O 0 0.0013356463
by O 0 0.00048397106
maximal O 0 0.0012951097
electroshock O 0 0.99978
and O 0 0.0006606914
did O 0 0.00031604193
not O 0 0.00023455766
alter O 0 0.00031991678
the O 0 0.00037795177
convulsant O 0 0.999432
dose O 0 0.04217259
of O 0 0.0007602814
pentylenetetrezol B-Chemical 0 0.13583085
in O 0 0.00034872643
mice O 0 0.0002498988
( O 0 0.0004539112
tests O 0 0.00061761023
performed O 0 0.00040562887
by O 0 0.0006502666
the O 0 0.001157321
Anticonvulsant O 0 0.99910396
Screening O 0 0.0388394
Project O 0 0.06303048
of O 0 0.005213296
NINCDS O 0 0.7974599
) O 0 0.010728672
. O 0 0.006841816

Acetaminophen B-Chemical 0 0.99901605
( O 0 0.0061514783
up O 0 0.0020420204
to O 0 0.0013810245
150 O 0 0.0023610236
micrograms O 0 0.16507162
/ O 0 0.0026311735
mL O 0 0.0053141257
) O 0 0.0009573396
did O 0 0.0003997973
not O 0 0.00037621587
retard O 0 0.052911285
the O 0 0.00053234503
incorporation O 0 0.0015551605
of O 0 0.00081470073
radioactive O 0 0.04338879
adenosine B-Chemical 1 0.9968143
into O 0 0.0009807933
ATP B-Chemical 1 0.97825223
in O 0 0.001317951
slices O 0 0.0690425
of O 0 0.0029152425
rat O 0 0.11836482
cerebral O 0 0.98080564
cortex O 0 0.76600426
. O 0 0.0072981054

Thus O 0 0.0039958847
the O 0 0.0024919393
mechanism O 0 0.0027578503
by O 0 0.0020531376
which O 0 0.0034503476
acetaminophen B-Chemical 0 0.9996549
antagonizes O 0 0.113085866
the O 0 0.0016529969
actions O 0 0.032603234
of O 0 0.00287226
caffeine B-Chemical 1 0.9982699
in O 0 0.0023883802
the O 0 0.0028753357
CNS O 0 0.7564839
remains O 0 0.0053480044
unknown O 0 0.017305374
. O 0 0.008045087

A O 0 0.015071234
double O 0 0.0029234304
- O 0 0.0030328755
blind O 0 0.0036102042
study O 0 0.0014723612
of O 0 0.0010062136
the O 0 0.0007464372
efficacy O 0 0.002473104
and O 0 0.00080029893
safety O 0 0.0029518744
of O 0 0.0026641719
dothiepin B-Chemical 0 0.9999621
hydrochloride I-Chemical 0 0.99926394
in O 0 0.0011551644
the O 0 0.00094222225
treatment O 0 0.0024977517
of O 0 0.0024241873
major O 0 0.009408943
depressive B-Disease 2 0.9984497
disorder I-Disease 0 0.98215806
. O 0 0.009745616

In O 0 0.003216562
a O 0 0.0025227007
6 O 0 0.0014611809
- O 0 0.0014958625
week O 0 0.0007041586
double O 0 0.0006837085
- O 0 0.0010311818
blind O 0 0.0018049834
parallel O 0 0.0006425131
treatment O 0 0.0013159298
study O 0 0.0012170891
, O 0 0.0014792708
dothiepin B-Chemical 0 0.9999318
and O 0 0.0023806978
amitriptyline B-Chemical 0 0.9999304
were O 0 0.0006106101
compared O 0 0.00024652577
to O 0 0.00037067587
placebo O 0 0.04034462
in O 0 0.00044001904
the O 0 0.0005667674
treatment O 0 0.0016910493
of O 0 0.001866178
33 O 0 0.0049115364
depressed B-Disease 2 0.6546599
outpatients O 0 0.09071349
. O 0 0.006288919

Dothiepin B-Chemical 0 0.9940906
and O 0 0.006435193
amitriptyline B-Chemical 0 0.999566
were O 0 0.002067748
equally O 0 0.0014023669
effective O 0 0.0013496418
in O 0 0.0007018035
alleviating O 0 0.03407524
the O 0 0.00088735286
symptoms O 0 0.378333
of O 0 0.003523311
depressive B-Disease 2 0.99977106
illness I-Disease 0 0.99678206
, O 0 0.0015942028
and O 0 0.0007171828
both O 0 0.0006460875
were O 0 0.00079059124
significantly O 0 0.0013808653
superior O 0 0.004374534
to O 0 0.002678261
placebo O 0 0.25393447
. O 0 0.0058968132

The O 0 0.002760279
overall O 0 0.0023542375
incidence O 0 0.0044847643
of O 0 0.0018233707
side O 0 0.011171392
effects O 0 0.0018704374
and O 0 0.0007518313
the O 0 0.000490108
frequency O 0 0.00061822624
and O 0 0.0005884369
severity O 0 0.010386883
of O 0 0.0010364112
blurred B-Disease 0 0.9623305
vision I-Disease 0 0.8967165
, O 0 0.0014319489
dry B-Disease 2 0.310391
mouth I-Disease 2 0.52718455
, O 0 0.0009287073
and O 0 0.000783266
drowsiness O 0 0.9991918
were O 0 0.00057662325
significantly O 0 0.0006686723
less O 0 0.0007232209
with O 0 0.0020031007
dothiepin B-Chemical 0 0.99980897
than O 0 0.0020098984
with O 0 0.0109605435
amitriptyline B-Chemical 0 0.9995234
. O 0 0.009915192

Dothiepin B-Chemical 0 0.9868329
also O 0 0.00793447
produced O 0 0.006001445
fewer O 0 0.0071439184
CNS O 0 0.63668215
and O 0 0.01068006
cardiovascular O 0 0.9626914
effects O 0 0.034270942
. O 0 0.0143408235

There O 0 0.008451347
were O 0 0.0043938523
no O 0 0.0035000094
clinically O 0 0.014084595
important O 0 0.0036565948
changes O 0 0.0052247434
in O 0 0.0041485694
laboratory O 0 0.009478328
parameters O 0 0.013547447
. O 0 0.01125553

Dothiepin B-Chemical 0 0.9928349
thus O 0 0.0046564844
was O 0 0.0018964361
found O 0 0.0011763962
to O 0 0.0009131142
be O 0 0.0008272479
an O 0 0.00087580184
effective O 0 0.0015198955
antidepressant B-Chemical 1 0.9991279
drug O 0 0.63840604
associated O 0 0.0012904425
with O 0 0.0007012371
fewer O 0 0.0006059024
side O 0 0.011837486
effects O 0 0.0017026842
than O 0 0.00061535573
amitriptyline B-Chemical 0 0.9998541
in O 0 0.0008808148
the O 0 0.000926304
treatment O 0 0.003160975
of O 0 0.0036522886
depressed B-Disease 2 0.8557535
outpatients O 0 0.164371
. O 0 0.0066599636

Behavioral O 0 0.085254975
effects O 0 0.006350417
of O 0 0.0052784486
diazepam B-Chemical 1 0.9994312
and O 0 0.0076309647
propranolol B-Chemical 1 0.9994924
in O 0 0.0028733434
patients O 0 0.008657186
with O 0 0.0057294234
panic B-Disease 0 0.9982849
disorder I-Disease 0 0.9855693
and O 0 0.029027848
agoraphobia B-Disease 2 0.9987325
. O 0 0.013512685

The O 0 0.0028088705
effects O 0 0.003193049
of O 0 0.0022686904
oral O 0 0.22274837
doses O 0 0.10341426
of O 0 0.0035775104
diazepam B-Chemical 1 0.9998603
( O 0 0.0020393827
single O 0 0.0005929979
dose O 0 0.007526322
of O 0 0.00055713614
10 O 0 0.00045468827
mg O 0 0.14689842
and O 0 0.00029581776
a O 0 0.00025414405
median O 0 0.00021754173
dose O 0 0.0015903672
of O 0 0.00032065116
30 O 0 0.0002671273
mg O 0 0.13430706
/ O 0 0.0004981018
day O 0 0.00017703963
for O 0 0.00014835289
2 O 0 0.00018826318
weeks O 0 0.00019747307
) O 0 0.00037298456
and O 0 0.0003360481
propranolol B-Chemical 1 0.99983406
( O 0 0.00061106123
single O 0 0.0002620049
dose O 0 0.0038712074
of O 0 0.00031337223
80 O 0 0.0005161938
mg O 0 0.1661678
and O 0 0.00023547796
a O 0 0.00021041489
median O 0 0.0001850665
dose O 0 0.0015234846
of O 0 0.00030830957
240 O 0 0.001953931
mg O 0 0.21844523
/ O 0 0.0005025316
day O 0 0.0001660676
for O 0 0.00013602921
2 O 0 0.00016731625
weeks O 0 0.00016339129
) O 0 0.00024830725
on O 0 9.804067e-05
psychological O 0 0.0049606543
performance O 0 0.00032957093
of O 0 0.00029865807
patients O 0 0.0013191409
with O 0 0.0008295718
panic B-Disease 0 0.9994822
disorders I-Disease 0 0.90444607
and O 0 0.0018055558
agoraphobia B-Disease 2 0.9998356
were O 0 0.0004603476
investigated O 0 0.00036435341
in O 0 0.00028614225
a O 0 0.00040443256
double O 0 0.00042103874
- O 0 0.00095009466
blind O 0 0.0026396557
, O 0 0.0009148742
randomized O 0 0.001361748
and O 0 0.0015148844
crossover O 0 0.008370696
design O 0 0.010073459
. O 0 0.0060225595

Both O 0 0.0062836995
drugs O 0 0.26301336
impaired B-Disease 0 0.004074427
immediate I-Disease 0 0.0033581802
free I-Disease 0 0.0023044017
recall I-Disease 0 0.003543404
but O 0 0.0010094835
the O 0 0.0008145029
decrease O 0 0.0011440837
was O 0 0.0009886638
greater O 0 0.0012929584
for O 0 0.0022727877
diazepam B-Chemical 1 0.99940014
than O 0 0.0069163707
propranolol B-Chemical 1 0.9989242
. O 0 0.012383208

Delayed B-Disease 0 0.115594566
free I-Disease 0 0.005590408
recall I-Disease 0 0.0065904893
was I-Disease 0 0.0021852893
also I-Disease 0 0.0018678968
impaired I-Disease 0 0.002613694
but O 0 0.0014452753
the O 0 0.0013310297
two O 0 0.0015880081
drugs O 0 0.3402207
did O 0 0.0028963275
not O 0 0.0033585664
differ O 0 0.0064134127
. O 0 0.007886334

Patients O 0 0.009892804
tapped O 0 0.006810356
faster O 0 0.0022794344
after O 0 0.0015991521
propranolol B-Chemical 1 0.9991916
than O 0 0.0020947573
diazepam B-Chemical 1 0.99962986
and O 0 0.0018102074
they O 0 0.00096282095
were O 0 0.0009523986
more O 0 0.0015238307
sedated O 0 0.098853946
after O 0 0.0018257874
diazepam B-Chemical 1 0.9992944
than O 0 0.00611383
propranolol B-Chemical 1 0.9988165
. O 0 0.011706347

After O 0 0.0022570773
2 O 0 0.0017097456
weeks O 0 0.0011180881
of O 0 0.0011925901
treatment O 0 0.001937259
, O 0 0.0010836321
patients O 0 0.0014708961
tested O 0 0.00048039705
5 O 0 0.0004635332
- O 0 0.0005893998
8 O 0 0.00026356478
h O 0 0.00022828717
after O 0 0.00012926952
the O 0 0.00019182489
last O 0 0.0002012811
dose O 0 0.0023075962
of O 0 0.0005869061
medication O 0 0.06780064
did O 0 0.00049178844
not O 0 0.00045957175
show O 0 0.00053506705
any O 0 0.0008669957
decrement O 0 0.0076275417
of O 0 0.0031836017
performance O 0 0.007156227
. O 0 0.0057968018

These O 0 0.0054351594
results O 0 0.0030131927
are O 0 0.0024827584
similar O 0 0.0016589612
to O 0 0.0018460021
those O 0 0.0024176927
previously O 0 0.0021735115
found O 0 0.0023737382
in O 0 0.0030405095
healthy O 0 0.013159112
subjects O 0 0.009632989
. O 0 0.008221944

Accumulation O 0 0.0216226
of O 0 0.0061511523
drugs O 0 0.4049631
was O 0 0.0035171811
not O 0 0.002556893
reflected O 0 0.0026457035
in O 0 0.0032389038
prolonged O 0 0.04276925
behavioral B-Disease 0 0.70883656
impairment I-Disease 0 0.94035417
. O 0 0.0129624335

Comparison O 0 0.003771126
of O 0 0.0033461237
i O 0 0.0046922932
. O 0 0.0015056459
v O 0 0.00819714
. O 0 0.0011411514
glycopyrrolate B-Chemical 1 0.9997025
and O 0 0.0026785145
atropine B-Chemical 0 0.999501
in O 0 0.0008219323
the O 0 0.00059080555
prevention O 0 0.0037170388
of O 0 0.0015984344
bradycardia B-Disease 0 0.9991917
and O 0 0.0017332407
arrhythmias B-Disease 2 0.9994288
following O 0 0.0009414595
repeated O 0 0.00089210033
doses O 0 0.036598902
of O 0 0.0032498934
suxamethonium B-Chemical 1 0.9979956
in O 0 0.0040979516
children O 0 0.014054817
. O 0 0.006172475

The O 0 0.00265745
effectiveness O 0 0.0022310365
of O 0 0.002073927
administration O 0 0.061085057
of O 0 0.002516088
glycopyrrolate B-Chemical 1 0.99978095
5 O 0 0.00097620767
and O 0 0.00060185883
10 O 0 0.00052953383
micrograms O 0 0.076163255
kg O 0 0.0074219243
- O 0 0.00064510736
1 O 0 0.00030166688
and O 0 0.0003445876
atropine B-Chemical 0 0.99911183
10 O 0 0.00038025016
and O 0 0.00025193393
20 O 0 0.0003095619
micrograms O 0 0.06012997
kg O 0 0.0058634174
- O 0 0.0004897887
1 O 0 0.00024434322
i O 0 0.00057728926
. O 0 0.00015843802
v O 0 0.0013655422
. O 0 0.00011742145
immediately O 0 0.00014621516
before O 0 9.532042e-05
the O 0 0.00015913967
induction O 0 0.00032478743
of O 0 0.00039085658
anaesthesia O 0 0.14830515
, O 0 0.0004400499
to O 0 0.0002709688
prevent O 0 0.0006400147
arrhythmia B-Disease 2 0.99911636
and O 0 0.0009982184
bradycardia B-Disease 0 0.9988242
following O 0 0.0004217994
repeated O 0 0.00041298094
doses O 0 0.018756574
of O 0 0.0013274641
suxamethonium B-Chemical 1 0.9987476
in O 0 0.0012969235
children O 0 0.0043327482
, O 0 0.0023262217
was O 0 0.0024368
studied O 0 0.0052072974
. O 0 0.0054789474

A O 0 0.01252339
control O 0 0.0022124767
group O 0 0.0020391918
was O 0 0.0011925776
included O 0 0.00081014185
for O 0 0.0006425967
comparison O 0 0.0006325684
with O 0 0.0008062595
the O 0 0.0007192612
lower O 0 0.00093788817
dose O 0 0.0076315096
range O 0 0.0024630865
of O 0 0.0043119374
glycopyrrolate B-Chemical 1 0.999597
and O 0 0.025393527
atropine B-Chemical 0 0.9984333
. O 0 0.011994297

A O 0 0.013730977
frequency O 0 0.0033292957
of O 0 0.0033646212
bradycardia B-Disease 0 0.9956844
of O 0 0.0021293215
50 O 0 0.0016989196
% O 0 0.0008367115
was O 0 0.00047955016
noted O 0 0.0004082842
in O 0 0.00030130325
the O 0 0.0002939689
control O 0 0.0002930399
group O 0 0.000491668
, O 0 0.0004546222
but O 0 0.00027906508
this O 0 0.000261145
was O 0 0.0002708996
not O 0 0.00025081963
significantly O 0 0.00037911072
different O 0 0.00036584487
from O 0 0.00043128643
the O 0 0.00050552783
frequency O 0 0.000928952
with O 0 0.0014215031
the O 0 0.0018765696
active O 0 0.006631462
drugs O 0 0.7954176
. O 0 0.0073255002

Bradycardia B-Disease 2 0.9941955
( O 0 0.004323107
defined O 0 0.0014644822
as O 0 0.00095285417
a O 0 0.00098681
decrease O 0 0.0009383074
in O 0 0.0006369535
heart O 0 0.11856262
rate O 0 0.000481258
to O 0 0.00035924657
less O 0 0.00035222783
than O 0 0.00021015503
50 O 0 0.0004749672
beat O 0 0.0036656882
min O 0 0.000747231
- O 0 0.00058953435
1 O 0 0.00032542838
) O 0 0.00042945033
was O 0 0.00024343027
prevented O 0 0.0005670176
when O 0 0.00020035016
the O 0 0.00026769275
larger O 0 0.00035782004
dose O 0 0.003517149
of O 0 0.0008073051
either O 0 0.0009161431
active O 0 0.0025983565
drug O 0 0.3606607
was O 0 0.0030527015
used O 0 0.0038778437
. O 0 0.0054220962

It O 0 0.0056356313
is O 0 0.0022457498
recommended O 0 0.0018319312
that O 0 0.001074537
either O 0 0.001390129
glycopyrrolate B-Chemical 1 0.9996768
10 O 0 0.0016262439
micrograms O 0 0.2619305
kg O 0 0.01617277
- O 0 0.0008996157
1 O 0 0.0003782775
or O 0 0.0003266786
atropine B-Chemical 0 0.99909854
20 O 0 0.000674123
micrograms O 0 0.1648396
kg O 0 0.010545407
- O 0 0.00059726706
1 O 0 0.00027994928
i O 0 0.00064658065
. O 0 0.00017852066
v O 0 0.0016904555
. O 0 0.00013984488
should O 0 0.00011897127
immediately O 0 0.00019331378
precede O 0 0.00091525743
induction O 0 0.0004570028
of O 0 0.0004723098
anaesthesia O 0 0.1640241
, O 0 0.00048098786
in O 0 0.00027313302
children O 0 0.0008274994
, O 0 0.00038826224
if O 0 0.00019798061
the O 0 0.00030146964
repeated O 0 0.0005436995
administration O 0 0.058999028
of O 0 0.0028077038
suxamethonium B-Chemical 1 0.99815303
is O 0 0.004178121
anticipated O 0 0.005651906
. O 0 0.0055492013

Veno B-Disease 0 0.16160345
- I-Disease 0 0.011647553
occlusive I-Disease 0 0.98017716
liver I-Disease 2 0.9846598
disease I-Disease 2 0.9653947
after O 0 0.0031369273
dacarbazine B-Chemical 0 0.99794203
therapy O 0 0.40514272
( O 0 0.01761801
DTIC B-Chemical 0 0.9986767
) O 0 0.012216403
for O 0 0.006503441
melanoma B-Disease 0 0.9891935
. O 0 0.012133559

A O 0 0.0141114695
case O 0 0.0030799021
of O 0 0.0028980677
veno B-Disease 0 0.1309626
- I-Disease 0 0.004430412
occlusive I-Disease 0 0.9853116
disease I-Disease 0 0.7104802
of I-Disease 0 0.0015137524
the I-Disease 0 0.0009777845
liver I-Disease 0 0.74345344
with O 0 0.0017667405
fatal O 0 0.9665404
outcome O 0 0.0043971157
after O 0 0.00065141876
dacarbazine B-Chemical 0 0.9991177
( O 0 0.009145891
DTIC B-Chemical 0 0.9995597
) O 0 0.0040640114
therapy O 0 0.037038952
for O 0 0.0020838887
melanoma B-Disease 0 0.99444747
is O 0 0.00496266
reported O 0 0.008887209
. O 0 0.0063305986

There O 0 0.007355088
was O 0 0.0038133434
a O 0 0.0042396444
fulminant O 0 0.995025
clinical O 0 0.021430379
course O 0 0.0037994317
from O 0 0.0020412588
start O 0 0.0019717612
of O 0 0.003867715
symptoms O 0 0.40944207
until O 0 0.005897428
death B-Disease 2 0.9808833
. O 0 0.011559827

At O 0 0.0038888038
autopsy O 0 0.013220695
the O 0 0.0034636674
liver O 0 0.45822117
was O 0 0.00291664
enlarged O 0 0.008474265
and O 0 0.0026323951
firm O 0 0.012191756
with O 0 0.0038903204
signs O 0 0.15104267
of O 0 0.009056685
venous B-Disease 0 0.9795328
congestion I-Disease 0 0.99015397
. O 0 0.014116958

Small O 0 0.028663892
- O 0 0.007489054
and O 0 0.004044532
medium O 0 0.0074597145
- O 0 0.0045471066
sized O 0 0.003769833
hepatic O 0 0.9106097
veins O 0 0.37923387
were O 0 0.0042253914
blocked O 0 0.008579355
by O 0 0.009705296
thrombosis B-Disease 2 0.9941976
. O 0 0.014856662

Eosinophilic O 0 0.76547873
infiltrations O 0 0.6417193
were O 0 0.008487434
found O 0 0.006849059
around O 0 0.0076550795
the O 0 0.010315479
vessels O 0 0.081863455
. O 0 0.017042361

Published O 0 0.021561481
cases O 0 0.00606558
from O 0 0.002978738
the O 0 0.002516081
literature O 0 0.0041235476
are O 0 0.0026869818
reviewed O 0 0.004951765
and O 0 0.0033967819
pertinent O 0 0.0048503927
features O 0 0.009858193
discussed O 0 0.00784232
. O 0 0.009693305

Maternal O 0 0.1478663
lithium B-Chemical 1 0.99364716
and O 0 0.005377965
neonatal O 0 0.059662618
Ebstein B-Disease 0 0.6822894
' I-Disease 0 0.002629142
s I-Disease 0 0.0024724854
anomaly I-Disease 0 0.023603216
: O 0 0.0023452234
evaluation O 0 0.0020760247
with O 0 0.002296181
cross O 0 0.0042493423
- O 0 0.006135178
sectional O 0 0.018115744
echocardiography O 0 0.42468753
. O 0 0.009766752

Cross O 0 0.027843894
- O 0 0.005002213
sectional O 0 0.006436855
echocardiography O 0 0.067045875
was O 0 0.0015201286
used O 0 0.0009820008
to O 0 0.0007818871
evaluate O 0 0.0005462536
two O 0 0.0007401274
neonates O 0 0.004437884
whose O 0 0.0023656522
mothers O 0 0.00482815
ingested O 0 0.37932116
lithium B-Chemical 1 0.9972536
during O 0 0.0062485687
pregnancy O 0 0.6497284
. O 0 0.009722615

In O 0 0.003971983
one O 0 0.0027222456
infant O 0 0.00802533
, O 0 0.003930996
Ebstein B-Disease 0 0.36611417
' I-Disease 0 0.0023250289
s I-Disease 0 0.0021917839
anomaly I-Disease 0 0.01012891
of O 0 0.002043632
the O 0 0.002402645
tricuspid O 0 0.7374086
valve O 0 0.16564734
was O 0 0.00480124
identified O 0 0.005753522
. O 0 0.007833598

In O 0 0.0030918797
the O 0 0.0021053024
other O 0 0.0018569193
infant O 0 0.004686291
cross O 0 0.0021844245
- O 0 0.0018193636
sectional O 0 0.0034381805
echocardiography O 0 0.099102125
provided O 0 0.0009725328
reassurance O 0 0.0044813403
that O 0 0.00058049
the O 0 0.00068715075
infant O 0 0.0032530446
did O 0 0.0008099445
not O 0 0.00089312636
have O 0 0.0017068394
Ebstein B-Disease 0 0.56587666
' I-Disease 0 0.0034076548
s I-Disease 0 0.0050550313
anomaly I-Disease 0 0.085487686
. O 0 0.007389155

Cross O 0 0.025727483
- O 0 0.0043050298
sectional O 0 0.0053006196
echocardiographic O 0 0.0394313
screening O 0 0.0016607415
of O 0 0.0012728093
newborns O 0 0.005410738
exposed O 0 0.0010496211
to O 0 0.0007268542
lithium B-Chemical 1 0.99768126
during O 0 0.0005265832
gestation O 0 0.0041952776
can O 0 0.0002997692
provide O 0 0.00030418698
highly O 0 0.00047521
accurate O 0 0.0005333808
, O 0 0.0004176142
noninvasive O 0 0.0028554597
assessment O 0 0.00040812444
of O 0 0.00044373295
the O 0 0.00036394535
presence O 0 0.00042978488
or O 0 0.00042084893
absence O 0 0.00044523983
of O 0 0.0021160117
lithium B-Chemical 1 0.99900264
- O 0 0.0125162685
induced O 0 0.01050836
cardiac B-Disease 0 0.98454386
malformations I-Disease 0 0.9962057
. O 0 0.0100978725

Effects O 0 0.011172203
of O 0 0.0035686623
training O 0 0.0027897563
on O 0 0.0013885775
the O 0 0.0015009806
extent O 0 0.0012409058
of O 0 0.002145983
experimental O 0 0.0073822336
myocardial B-Disease 0 0.99832577
infarction I-Disease 2 0.99958724
in O 0 0.009774239
aging O 0 0.6069436
rats O 0 0.06599414
. O 0 0.009270037

The O 0 0.0027734663
effects O 0 0.00302971
of O 0 0.0020136596
exercise O 0 0.00944504
on O 0 0.00076250423
the O 0 0.0009014604
severity O 0 0.014973942
of O 0 0.0022259208
isoproterenol B-Chemical 1 0.9995359
- O 0 0.009767397
induced O 0 0.0042276233
myocardial B-Disease 0 0.9994821
infarction I-Disease 2 0.99991596
were O 0 0.0012358066
studied O 0 0.00089648686
in O 0 0.00037166558
female O 0 0.0016122506
albino O 0 0.008936485
rats O 0 0.0012272437
of O 0 0.00046986653
20 O 0 0.00050994457
, O 0 0.0004935069
40 O 0 0.00049015373
, O 0 0.0005088426
60 O 0 0.0005326371
and O 0 0.0005818124
80 O 0 0.0011246873
weeks O 0 0.001167037
of O 0 0.002488471
age O 0 0.0073316055
. O 0 0.0055326167

The O 0 0.0033173882
rats O 0 0.0052898675
were O 0 0.0018061213
trained O 0 0.0018599082
to O 0 0.0013086941
swim O 0 0.019137332
for O 0 0.0009919008
a O 0 0.0010715796
specific O 0 0.000932597
duration O 0 0.0014980864
and O 0 0.0013426911
for O 0 0.0012680314
a O 0 0.0021924472
particular O 0 0.0026259855
period O 0 0.0052189766
. O 0 0.0065371958

The O 0 0.005835032
occurrence O 0 0.008221213
of O 0 0.00777232
infarcts B-Disease 0 0.9903156
were O 0 0.00553103
confirmed O 0 0.0052895416
by O 0 0.006736657
histological O 0 0.22601056
methods O 0 0.014466999
. O 0 0.012790466

Elevations O 0 0.37042093
in O 0 0.0035308509
the O 0 0.0029686335
serum O 0 0.22273257
GOT O 0 0.9983613
and O 0 0.0037671064
GPT O 0 0.9935607
were O 0 0.0010521444
maximum O 0 0.0007849321
in O 0 0.00055321376
the O 0 0.00060733047
sedentary O 0 0.004096852
- O 0 0.0012414532
isoproterenols B-Chemical 0 0.018138167
and O 0 0.0007430132
minimum O 0 0.0006255335
in O 0 0.0008425725
the O 0 0.0013776931
exercise O 0 0.043589406
- O 0 0.005499663
controls O 0 0.0066160695
. O 0 0.006002597

These O 0 0.0050893775
changes O 0 0.0036928041
in O 0 0.0019171615
the O 0 0.0018116988
serum O 0 0.09757278
transaminases O 0 0.9970341
were O 0 0.0015816408
associated O 0 0.0014603516
with O 0 0.0012391992
corresponding O 0 0.0010531854
depletions O 0 0.0806892
in O 0 0.0015004734
the O 0 0.0024530385
cardiac O 0 0.86723536
GOT O 0 0.9985222
and O 0 0.022413917
GPT O 0 0.99251974
. O 0 0.011171087

However O 0 0.0048431824
, O 0 0.0035490452
age O 0 0.0033126744
was O 0 0.001504548
seen O 0 0.0010809642
to O 0 0.00085892517
interfere O 0 0.0009783229
with O 0 0.0009829815
the O 0 0.0008206067
responses O 0 0.0017120022
exhibited O 0 0.001083582
by O 0 0.0011574742
the O 0 0.0013631339
young O 0 0.0068239677
and O 0 0.002576891
old O 0 0.004518643
rats O 0 0.012538744
. O 0 0.0065864483

Studies O 0 0.017331252
dealing O 0 0.008056804
with O 0 0.0067923474
myocardial B-Disease 0 0.99639374
infarction I-Disease 2 0.9993395
are O 0 0.0043408275
more O 0 0.0030547625
informative O 0 0.0033220553
when O 0 0.002143288
dealt O 0 0.007285577
with O 0 0.005900772
age O 0 0.014169555
. O 0 0.009432779

Effect O 0 0.014213817
of O 0 0.010090963
polyethylene B-Chemical 1 0.93025625
glycol I-Chemical 1 0.9815337
400 I-Chemical 1 0.08507072
on O 0 0.005713709
adriamycin B-Chemical 1 0.99770856
toxicity B-Disease 2 0.9925512
in O 0 0.009415515
mice O 0 0.007625016
. O 0 0.010903021

The O 0 0.002906399
effect O 0 0.0024204243
of O 0 0.0020310883
a O 0 0.001708644
widely O 0 0.0022418906
used O 0 0.0013669983
organic O 0 0.9036654
solvent O 0 0.74671066
, O 0 0.0038301009
polyethylene B-Chemical 1 0.97400665
glycol I-Chemical 1 0.9949844
400 I-Chemical 1 0.109471895
( O 0 0.0016585095
PEG B-Chemical 0 0.61340404
400 I-Chemical 0 0.005472331
) O 0 0.0008740832
, O 0 0.0004304426
on O 0 0.00018350579
the O 0 0.0003291684
toxic O 0 0.4855871
action O 0 0.007817627
of O 0 0.00066117104
an O 0 0.0010135748
acute O 0 0.9231879
or O 0 0.00071728363
chronic O 0 0.96514654
treatment O 0 0.014445171
with O 0 0.004651139
adriamycin B-Chemical 1 0.99970466
( O 0 0.024456367
ADR B-Chemical 0 0.99932444
) O 0 0.003434358
was O 0 0.001218429
evaluated O 0 0.0014581499
in O 0 0.0020401808
mice O 0 0.0027329312
. O 0 0.0051178695

PEG B-Chemical 0 0.44221902
400 I-Chemical 0 0.010087776
impressively O 0 0.033361018
decreased O 0 0.003852341
both O 0 0.0018987156
acute O 0 0.8539353
high O 0 0.002903732
- O 0 0.0023811655
dose O 0 0.019283092
and O 0 0.0012714415
chronic O 0 0.9212274
low O 0 0.0033429894
- O 0 0.004157965
dose O 0 0.10993494
- O 0 0.015626961
ADR B-Chemical 0 0.9986028
- O 0 0.010058008
associated O 0 0.0075554885
lethality O 0 0.5039978
. O 0 0.0079327915

Light O 0 0.039763
microscopic O 0 0.0104952045
analysis O 0 0.0038773038
showed O 0 0.002200648
a O 0 0.0021623396
significant O 0 0.002445546
protection O 0 0.007201894
against O 0 0.0039424845
ADR B-Chemical 0 0.99861014
- O 0 0.011203147
induced O 0 0.006226265
cardiac B-Disease 0 0.8209389
morphological I-Disease 0 0.15515645
alterations I-Disease 0 0.21080449
. O 0 0.009197096

Such O 0 0.00868606
treatment O 0 0.005358829
did O 0 0.0022594314
not O 0 0.0016110811
diminish O 0 0.002448173
the O 0 0.0023526766
ADR B-Chemical 0 0.99859065
antitumor O 0 0.9728818
activity O 0 0.005672051
in O 0 0.0035273028
L1210 B-Disease 0 0.99933666
leukemia I-Disease 0 0.99972063
and O 0 0.010958114
in O 0 0.0065070493
Ehrlich B-Disease 0 0.9954997
ascites I-Disease 0 0.9978108
tumor I-Disease 2 0.98639166
. O 0 0.014069605

Sublingual O 0 0.96120137
absorption O 0 0.33214945
of O 0 0.005700072
the O 0 0.004665922
quaternary B-Chemical 0 0.8960805
ammonium I-Chemical 0 0.99718696
antiarrhythmic O 0 0.99675435
agent O 0 0.7893405
, O 0 0.015089669
UM B-Chemical 0 0.9293034
- I-Chemical 0 0.019608492
272 I-Chemical 0 0.12999652
. O 0 0.010267129

UM B-Chemical 0 0.71461123
- I-Chemical 0 0.009619931
272 I-Chemical 0 0.042637214
( O 0 0.0045677633
N B-Chemical 0 0.70210046
, I-Chemical 0 0.0035335398
N I-Chemical 0 0.84301823
- I-Chemical 0 0.0035185886
dimethylpropranolol I-Chemical 0 0.23255387
) O 0 0.0018530559
, O 0 0.00084336364
a O 0 0.00070160616
quaternary O 0 0.38344002
antiarrhythmic O 0 0.9964485
agent O 0 0.31581113
, O 0 0.0009512233
was O 0 0.0005081601
administered O 0 0.0026756513
sublingually O 0 0.9893957
to O 0 0.0007006023
dogs O 0 0.0035372002
with O 0 0.0023871083
ouabain B-Chemical 1 0.9993777
- O 0 0.012803441
induced O 0 0.01090813
ventricular B-Disease 0 0.9968346
tachycardias I-Disease 0 0.99672735
. O 0 0.009794499

Both O 0 0.008246556
anti O 0 0.012954927
- O 0 0.0073674293
arrhythmic O 0 0.9771648
efficacy O 0 0.016754504
and O 0 0.0031491423
bioavailability O 0 0.949811
were O 0 0.002421062
compared O 0 0.0016418978
to O 0 0.0032576816
oral O 0 0.4460354
drug O 0 0.70915425
. O 0 0.010751724

Sublingual O 0 0.9785745
UM B-Chemical 0 0.86671716
- I-Chemical 0 0.009033434
272 I-Chemical 0 0.028508699
converted O 0 0.0054524154
ventricular B-Disease 2 0.9937995
tachycardia I-Disease 2 0.9988637
to O 0 0.0030754693
sinus O 0 0.08927881
rhythm O 0 0.023337295
in O 0 0.0018204073
all O 0 0.002234624
5 O 0 0.0031507772
dogs O 0 0.009308363
. O 0 0.006705505

The O 0 0.002659942
area O 0 0.0025116927
under O 0 0.0011058379
the O 0 0.0011473169
plasma O 0 0.009443611
concentration O 0 0.0019658492
time O 0 0.000501015
curve O 0 0.0009019175
at O 0 0.00026814747
90 O 0 0.00037575833
min O 0 0.00046325292
was O 0 0.0002621758
4 O 0 0.0002270308
- O 0 0.00029603444
12 O 0 0.000116276475
times O 0 9.371685e-05
greater O 0 0.00015362361
than O 0 0.0001149154
for O 0 0.00016971324
oral O 0 0.10932878
drug O 0 0.34902823
, O 0 0.00043932477
suggesting O 0 0.00019436561
the O 0 0.00018409359
existence O 0 0.00027584107
of O 0 0.00035351253
an O 0 0.0005928693
absorption O 0 0.46471098
- O 0 0.0007453656
limiting O 0 0.00039614088
process O 0 0.0003558222
in O 0 0.00023269148
the O 0 0.00029092704
intestine O 0 0.012532197
, O 0 0.00047066758
and O 0 0.0003341712
providing O 0 0.0004388543
an O 0 0.00053361524
alternate O 0 0.0008270185
form O 0 0.0007411664
of O 0 0.0012878481
administration O 0 0.14542429
for O 0 0.0023837301
quaternary O 0 0.73635876
drugs O 0 0.90048444
. O 0 0.007868925

Early O 0 0.10042835
adjuvant O 0 0.6905006
adriamycin B-Chemical 1 0.995178
in O 0 0.016527062
superficial O 0 0.5885543
bladder B-Disease 0 0.9754768
carcinoma I-Disease 2 0.9945379
. O 0 0.03213188

A O 0 0.015628178
multicenter O 0 0.023741566
study O 0 0.0029123486
was O 0 0.0014255308
performed O 0 0.0011072257
in O 0 0.0009796559
110 O 0 0.002276729
patients O 0 0.0021250541
with O 0 0.0014702043
superficial O 0 0.070860915
transitional O 0 0.2382412
cell O 0 0.10500796
carcinoma B-Disease 2 0.9978363
of I-Disease 0 0.0074156844
the I-Disease 0 0.0066290754
bladder I-Disease 0 0.9180931
. O 0 0.010422021

Adriamycin B-Chemical 1 0.9969055
( O 0 0.00603824
50 O 0 0.0034908575
mg O 0 0.31537417
/ O 0 0.0026599043
50 O 0 0.001397398
ml O 0 0.0023803704
) O 0 0.0009791262
was O 0 0.0004544235
administered O 0 0.0010568595
intravesically O 0 0.064982586
within O 0 0.00021848774
24 O 0 0.000287817
h O 0 0.00026463444
after O 0 0.00018510231
transurethral O 0 0.008739727
resection O 0 0.006592407
of O 0 0.0010987354
TA O 0 0.74202025
- O 0 0.003199501
T1 O 0 0.07058565
( O 0 0.0029440676
O O 0 0.97500473
- O 0 0.0059000305
A O 0 0.047389653
) O 0 0.008190721
bladder B-Disease 0 0.98442566
tumors I-Disease 0 0.9876722
. O 0 0.010298244

Instillation O 0 0.51819235
was O 0 0.002226232
repeated O 0 0.0012928154
twice O 0 0.0010896765
during O 0 0.00058980804
the O 0 0.0005519123
first O 0 0.00041682873
week O 0 0.0004580823
, O 0 0.00051955815
then O 0 0.00030741957
weekly O 0 0.0005448688
during O 0 0.000266245
the O 0 0.00032948106
first O 0 0.00033133643
month O 0 0.00050702173
and O 0 0.000664232
afterwards O 0 0.0013125595
monthly O 0 0.0013280388
for O 0 0.0013622546
1 O 0 0.0025270944
year O 0 0.0040547503
. O 0 0.0050844927

The O 0 0.0033585108
tolerance O 0 0.014634829
was O 0 0.001811547
evaluated O 0 0.0012515252
in O 0 0.0009026909
these O 0 0.0011393358
110 O 0 0.0022360343
patients O 0 0.0019434514
, O 0 0.0009325151
and O 0 0.0007038973
29 O 0 0.0012093091
patients O 0 0.0014201257
presented O 0 0.0009553823
with O 0 0.0014124997
local O 0 0.003831779
side O 0 0.0595815
- O 0 0.0068049137
effects O 0 0.009382356
. O 0 0.006590402

In O 0 0.0030171217
24 O 0 0.001921078
of O 0 0.0016910463
these O 0 0.0018314011
patients O 0 0.0039821207
chemical O 0 0.18086083
cystitis B-Disease 0 0.99958795
was O 0 0.0021361127
severe O 0 0.11518101
enough O 0 0.00086924894
for O 0 0.000597785
them O 0 0.0011492826
to O 0 0.0007922175
drop O 0 0.0018249245
out O 0 0.0010051774
of O 0 0.002130266
the O 0 0.0028977948
study O 0 0.00663116
. O 0 0.006422611

No O 0 0.018503007
systemic O 0 0.69476926
side O 0 0.1012117
- O 0 0.013270403
effects O 0 0.011345437
were O 0 0.008706806
observed O 0 0.009555959
. O 0 0.013850941

Recurrence O 0 0.45649436
was O 0 0.0028836434
studied O 0 0.0022390531
in O 0 0.0011187531
82 O 0 0.0017583618
evaluable O 0 0.0045475513
patients O 0 0.0013353499
after O 0 0.00032079362
1 O 0 0.00036955948
year O 0 0.00032163886
of O 0 0.00038106987
follow O 0 0.00040362639
- O 0 0.0005720246
up O 0 0.00027499004
and O 0 0.0002700522
in O 0 0.00021814804
72 O 0 0.00030559534
patients O 0 0.0005292378
followed O 0 0.00021577057
for O 0 0.00028837513
2 O 0 0.00045590417
- O 0 0.0006630433
3 O 0 0.00039567813
years O 0 0.0008848263
( O 0 0.0007957689
mean O 0 0.0006679622
32 O 0 0.0019819434
months O 0 0.00242752
) O 0 0.0050602932
. O 0 0.004810563

Of O 0 0.005634728
the O 0 0.0025124466
82 O 0 0.0033991958
patients O 0 0.0030448358
studied O 0 0.001657976
after O 0 0.0007400298
1 O 0 0.0009126776
year O 0 0.0009290387
, O 0 0.0010920719
23 O 0 0.0012095245
had O 0 0.0009437654
primary O 0 0.0017187938
and O 0 0.002117332
59 O 0 0.005549738
recurrent O 0 0.58236283
disease O 0 0.8545627
. O 0 0.009837173

Of O 0 0.005112463
the O 0 0.0022178823
82 O 0 0.0030732565
evaluable O 0 0.0076281624
patients O 0 0.0028192217
, O 0 0.0011751954
50 O 0 0.00091361115
did O 0 0.00043725895
not O 0 0.0003242472
show O 0 0.00028072787
any O 0 0.00032617507
recurrence O 0 0.16614436
after O 0 0.0002486714
1 O 0 0.00033501748
year O 0 0.0003565074
( O 0 0.00042586203
61 O 0 0.0005466421
% O 0 0.00035136356
) O 0 0.000426255
, O 0 0.00030568856
while O 0 0.00022382573
32 O 0 0.00040078376
presented O 0 0.00031178808
with O 0 0.00040693543
one O 0 0.0003501087
or O 0 0.0005038218
more O 0 0.0011848068
recurrences O 0 0.23017627
( O 0 0.0024913999
39 O 0 0.0035250997
% O 0 0.003243425
) O 0 0.0054186773
. O 0 0.005008526

Of O 0 0.0062310486
these O 0 0.004161979
recurrences O 0 0.10923427
, O 0 0.0028925887
27 O 0 0.0024028106
were O 0 0.0014017911
T1 O 0 0.016014947
tumors B-Disease 0 0.4893956
while O 0 0.0010680407
five O 0 0.00080973207
progressed O 0 0.0040608128
to O 0 0.0014545212
more O 0 0.002455587
highly O 0 0.0041577006
invasive O 0 0.038241044
lesions O 0 0.5579859
. O 0 0.009126931

In O 0 0.0028656935
patients O 0 0.0033965106
that O 0 0.0011963118
were O 0 0.001008187
free O 0 0.0012055788
of O 0 0.0010507981
recurrence O 0 0.26307306
during O 0 0.00043871359
the O 0 0.00039114774
first O 0 0.00030275225
year O 0 0.00043957614
, O 0 0.00044959717
80 O 0 0.00050856627
% O 0 0.00035690906
remained O 0 0.0005531391
tumor B-Disease 2 0.48041436
- O 0 0.00080048165
free O 0 0.00053399685
during O 0 0.00024565458
the O 0 0.0003431488
2 O 0 0.00044394468
- O 0 0.0006020616
to O 0 0.0003679617
3 O 0 0.00045310383
- O 0 0.0007923243
year O 0 0.00071335403
follow O 0 0.0010096653
- O 0 0.002160806
up O 0 0.0019687347
period O 0 0.0034247653
. O 0 0.0047940775

Of O 0 0.0049121575
the O 0 0.0021698312
patients O 0 0.0034133221
developing O 0 0.0030880123
one O 0 0.000771215
or O 0 0.00063935074
more O 0 0.0008360126
recurrences O 0 0.05605592
during O 0 0.0003331933
the O 0 0.0003270295
first O 0 0.00027315153
year O 0 0.0004175848
, O 0 0.00043569368
only O 0 0.0003136601
50 O 0 0.00048909936
% O 0 0.00033284916
presented O 0 0.00031562042
with O 0 0.00044284892
further O 0 0.0006898357
recurrence O 0 0.24580051
once O 0 0.001067374
the O 0 0.0013055762
instillations O 0 0.12092815
were O 0 0.0032238078
stopped O 0 0.010155455
. O 0 0.006068421

The O 0 0.003024562
beneficial O 0 0.004674715
effect O 0 0.0022767077
of O 0 0.0028515183
Adriamycin B-Chemical 1 0.99923646
appears O 0 0.0015051902
obvious O 0 0.000791527
and O 0 0.00062840804
might O 0 0.00037579218
be O 0 0.00040283738
related O 0 0.00026405274
to O 0 0.0003018386
the O 0 0.0003480311
drug O 0 0.14108205
itself O 0 0.0009662373
, O 0 0.0005621401
the O 0 0.00034249763
early O 0 0.00078810216
and O 0 0.0005040961
repeated O 0 0.00064798805
instillations O 0 0.079154134
after O 0 0.0010101743
TUR O 0 0.7041065
, O 0 0.0028515619
or O 0 0.002397652
both O 0 0.0042679445
. O 0 0.00567473

D B-Chemical 0 0.8936625
- I-Chemical 0 0.053364024
penicillamine I-Chemical 1 0.9984511
- O 0 0.062361196
induced O 0 0.04334723
angiopathy B-Disease 0 0.99797946
in O 0 0.01773056
rats O 0 0.06791589
. O 0 0.015723178

The O 0 0.0029682624
effect O 0 0.0025193167
of O 0 0.0022144872
high O 0 0.0026523352
dose O 0 0.12861612
D B-Chemical 0 0.95665026
- I-Chemical 0 0.014002244
penicillamine I-Chemical 1 0.9997886
treatment O 0 0.020117646
on O 0 0.0007636812
aortic O 0 0.7445474
permeability O 0 0.853882
to O 0 0.0012682441
albumin O 0 0.9580398
and O 0 0.0010689293
on O 0 0.0006023055
the O 0 0.0011194759
ultrastructure O 0 0.01783841
of O 0 0.0030113966
the O 0 0.0040959455
vessel O 0 0.16662133
. O 0 0.0075290296

Male O 0 0.07858609
Sprague O 0 0.33619815
- O 0 0.006027509
Dawley O 0 0.17101038
rats O 0 0.0041557425
were O 0 0.0012489121
treated O 0 0.0018909249
with O 0 0.0019719875
D B-Chemical 0 0.9209499
- I-Chemical 0 0.016274575
penicillamine I-Chemical 1 0.99986386
( O 0 0.01944052
D B-Chemical 1 0.9383249
- I-Chemical 1 0.0024971697
pen I-Chemical 1 0.024760913
) O 0 0.0011777204
500 O 0 0.0021426121
mg O 0 0.25996843
/ O 0 0.0014930824
kg O 0 0.003263062
/ O 0 0.0010654132
day O 0 0.00057124154
for O 0 0.0006044639
10 O 0 0.0010244244
or O 0 0.0011627211
42 O 0 0.0028838287
days O 0 0.0031775485
. O 0 0.0046401676

Pair O 0 0.1496158
fed O 0 0.02012538
rats O 0 0.023086151
served O 0 0.016068349
as O 0 0.012832192
controls O 0 0.022071505
. O 0 0.020818634

Changes O 0 0.006935386
in O 0 0.0030675817
aortic O 0 0.12942366
morphology O 0 0.0042705713
were O 0 0.0012804875
examined O 0 0.00089500303
by O 0 0.0011442344
light O 0 0.00244127
- O 0 0.0019754563
and O 0 0.0012865933
transmission O 0 0.0035251984
- O 0 0.0029065316
electron O 0 0.027829297
microscopy O 0 0.0047318954
( O 0 0.0053821495
TEM O 0 0.05965934
) O 0 0.009861427
. O 0 0.007099876

In O 0 0.0030364126
addition O 0 0.0018064944
, O 0 0.0021861368
the O 0 0.0014729166
endothelial O 0 0.89095855
permeability O 0 0.8198953
and O 0 0.0011985227
the O 0 0.00071758684
penetration O 0 0.007174928
through O 0 0.0004664388
the O 0 0.0005033773
aortic O 0 0.36760795
wall O 0 0.026954394
of O 0 0.00082805625
albumin O 0 0.9571795
were O 0 0.000404858
studied O 0 0.00042030468
10 O 0 0.00025542715
minutes O 0 0.00020535178
, O 0 0.000232335
24 O 0 0.00016809325
and O 0 0.00016328803
48 O 0 0.00017367591
hours O 0 0.00015225817
after O 0 0.000121477584
i O 0 0.0006012245
. O 0 0.00018933303
v O 0 0.0018175254
. O 0 0.00018550198
injection O 0 0.0007642632
of O 0 0.00047504145
human O 0 0.0013445831
serum O 0 0.20866601
131I O 0 0.97700286
- O 0 0.008433417
albumin O 0 0.98807794
( O 0 0.005052267
131I O 0 0.96164984
- O 0 0.012609605
HSA O 0 0.9049063
) O 0 0.011054625
. O 0 0.0067398264

TEM O 0 0.021674464
revealed O 0 0.0034322287
extensive O 0 0.0036727358
elastolysis O 0 0.6623286
in O 0 0.0015300813
the O 0 0.0012961549
arterial O 0 0.5743838
wall O 0 0.052701164
of O 0 0.0022018766
D B-Chemical 1 0.92588836
- I-Chemical 1 0.0029346251
pen I-Chemical 1 0.044808865
- O 0 0.001301013
treated O 0 0.001089196
rats O 0 0.0027065338
, O 0 0.0006792117
consistent O 0 0.00054136774
with O 0 0.00077145465
an O 0 0.0011913809
inhibitory O 0 0.0135474205
effect O 0 0.0018707134
on O 0 0.0015566213
crosslink O 0 0.038367756
formation O 0 0.03059264
. O 0 0.007642796

In O 0 0.0025209587
experimental O 0 0.0023541744
animals O 0 0.0013963047
excess O 0 0.0020108577
deposition O 0 0.009217697
of O 0 0.0015788835
collagen O 0 0.25899053
and O 0 0.0012169651
glycoaminoglycans O 0 0.21442327
was O 0 0.00056967005
observed O 0 0.0003152974
in O 0 0.0003094548
the O 0 0.00037161878
subendothelial O 0 0.0412513
and O 0 0.0005652913
medial O 0 0.027331287
layer O 0 0.0018903482
of O 0 0.00042970566
the O 0 0.00040532375
aortic O 0 0.48025557
wall O 0 0.044948343
, O 0 0.0005669144
together O 0 0.00035162224
with O 0 0.0005518014
prominent O 0 0.0056458446
basal O 0 0.0046434696
membrane O 0 0.030288298
substance O 0 0.95560527
around O 0 0.0018606917
aortic O 0 0.6673885
smooth O 0 0.26142755
muscle O 0 0.26513004
cells O 0 0.010277352
. O 0 0.006220904

The O 0 0.0041875695
aorta O 0 0.08032195
/ O 0 0.0055381395
serum O 0 0.056766726
- O 0 0.0022439396
ratio O 0 0.0010477882
and O 0 0.00070119277
the O 0 0.0005364535
radioactive O 0 0.0041075842
build O 0 0.0012834949
- O 0 0.00079255196
up O 0 0.00032263115
24 O 0 0.00025219636
and O 0 0.00021593705
48 O 0 0.00020117423
hours O 0 0.00015795142
after O 0 0.00011444322
injection O 0 0.0006133508
of O 0 0.00044153334
131I O 0 0.9553442
- O 0 0.002221009
HSA O 0 0.83205533
was O 0 0.0003208805
reduced O 0 0.00028844088
in O 0 0.00020180206
animals O 0 0.00022077408
treated O 0 0.0005893035
with O 0 0.0006502777
D B-Chemical 1 0.86026573
- I-Chemical 1 0.0009278331
pen I-Chemical 1 0.006054514
for O 0 0.00020043462
42 O 0 0.00035146478
days O 0 0.0002060076
, O 0 0.0002554496
indicating O 0 0.00016421331
an O 0 0.00028981137
impeded O 0 0.0004990855
transmural O 0 0.80968314
transport O 0 0.00859431
of O 0 0.0005891782
tracer O 0 0.027104726
which O 0 0.0005987415
may O 0 0.00039504177
be O 0 0.00038685498
caused O 0 0.0004934187
by O 0 0.0005123123
a O 0 0.0007242065
steric O 0 0.0365981
exclusion O 0 0.0010394225
effect O 0 0.0014549937
of O 0 0.0027346886
abundant O 0 0.0070093423
hyaluronate B-Chemical 0 0.99635196
. O 0 0.010587928

The O 0 0.0039948807
endothelial O 0 0.6855909
ultrastructure O 0 0.06382477
was O 0 0.0018527224
unaffected O 0 0.0015900395
by O 0 0.0016811787
D B-Chemical 1 0.84397835
- I-Chemical 1 0.0023851774
pen I-Chemical 1 0.02012885
, O 0 0.0007812868
and O 0 0.0004369379
no O 0 0.00027023096
differences O 0 0.00024296445
in O 0 0.00035912244
aortic O 0 0.46110627
131I O 0 0.9731887
- O 0 0.0030362555
HSA O 0 0.8650807
radioactivity O 0 0.03652776
or O 0 0.00041062298
aorta O 0 0.18487455
/ O 0 0.0018160612
serum O 0 0.07746383
- O 0 0.00056017877
ratio O 0 0.00028406936
were O 0 0.00017587682
recorded O 0 0.00019080425
between O 0 9.01596e-05
experimental O 0 0.00027126478
and O 0 0.00020236199
control O 0 0.00015990078
groups O 0 0.00021644331
10 O 0 0.00017217643
minutes O 0 0.00013359111
after O 0 9.7204356e-05
tracer O 0 0.0026646547
injection O 0 0.0011009843
, O 0 0.00029318075
indicating O 0 0.00016456694
that O 0 0.0001723599
the O 0 0.00026209583
permeability O 0 0.4216786
of O 0 0.00057173404
the O 0 0.0005030533
endothelial O 0 0.9214258
barrier O 0 0.020464258
to O 0 0.00067897135
albumin O 0 0.961337
remained O 0 0.0014725105
unaffected O 0 0.0012484137
by O 0 0.001971436
D B-Chemical 1 0.8577649
- I-Chemical 1 0.0063469037
pen I-Chemical 1 0.06165727
treatment O 0 0.012545867
. O 0 0.0065753097

These O 0 0.0038132165
observations O 0 0.002483833
support O 0 0.0015481211
the O 0 0.0010526798
hypothesis O 0 0.0011544757
that O 0 0.0006332162
treatment O 0 0.0014032673
with O 0 0.00075464294
high O 0 0.00092414295
doses O 0 0.05021734
of O 0 0.0019090207
D B-Chemical 1 0.947693
- I-Chemical 1 0.0022464006
pen I-Chemical 1 0.02387018
may O 0 0.00044641728
induce O 0 0.0003918994
a O 0 0.0005697444
fibroproliferative O 0 0.814715
response O 0 0.0016950292
in O 0 0.00041488584
rat O 0 0.015676728
aorta O 0 0.19718747
, O 0 0.0005837356
possibly O 0 0.00092761207
by O 0 0.00035492194
an O 0 0.0004993294
inhibitory O 0 0.007175493
effect O 0 0.0004923004
on O 0 0.00025562153
the O 0 0.00045559133
cross O 0 0.0010819337
- O 0 0.0012771143
linking O 0 0.0012354179
of O 0 0.0020615985
collagen O 0 0.25920376
and O 0 0.005500589
elastin O 0 0.7192497
. O 0 0.008009932

Effect O 0 0.008773194
of O 0 0.0055115265
aspirin B-Chemical 1 0.9980082
on O 0 0.0028162086
N B-Chemical 0 0.9270992
- I-Chemical 0 0.005637205
[ I-Chemical 0 0.0030009781
4 I-Chemical 0 0.00083602255
- I-Chemical 0 0.0012148016
( I-Chemical 0 0.00081027456
5 I-Chemical 0 0.0005026088
- I-Chemical 0 0.0010357813
nitro I-Chemical 0 0.98194855
- I-Chemical 0 0.0015995108
2 I-Chemical 0 0.0006210284
- I-Chemical 0 0.0011521555
furyl I-Chemical 0 0.9223746
) I-Chemical 0 0.0016912541
- I-Chemical 0 0.0009807514
2 I-Chemical 0 0.00052326516
- I-Chemical 0 0.0012369314
thiazolyl I-Chemical 0 0.9793211
] I-Chemical 0 0.006981072
- I-Chemical 0 0.0017173805
formamide I-Chemical 0 0.8348344
- O 0 0.0012666674
induced O 0 0.0009230487
epithelial O 0 0.26295266
proliferation O 0 0.6639698
in O 0 0.0005302586
the O 0 0.000682418
urinary O 0 0.8700521
bladder O 0 0.92598814
and O 0 0.003307766
forestomach O 0 0.9832903
of O 0 0.0040904838
the O 0 0.004116905
rat O 0 0.05808582
. O 0 0.0068329317

The O 0 0.0042243768
co O 0 0.09805027
- O 0 0.0049795993
administration O 0 0.073363826
of O 0 0.0029468727
aspirin B-Chemical 1 0.9993149
with O 0 0.009071547
N B-Chemical 0 0.97161925
- I-Chemical 0 0.0052039716
[ I-Chemical 0 0.0023336264
4 I-Chemical 0 0.000552908
- I-Chemical 0 0.0008733443
( I-Chemical 0 0.0005987201
5 I-Chemical 0 0.00038636572
- I-Chemical 0 0.00084597373
nitro I-Chemical 0 0.9817988
- I-Chemical 0 0.0013977234
2 I-Chemical 0 0.0005457402
- I-Chemical 0 0.0010532241
furyl I-Chemical 0 0.92262256
) I-Chemical 0 0.0015946781
- I-Chemical 0 0.0009241227
2 I-Chemical 0 0.00048787292
- I-Chemical 0 0.0011763031
thiazolyl I-Chemical 0 0.9795034
] I-Chemical 0 0.006609839
- I-Chemical 0 0.0016106794
formamide I-Chemical 0 0.8588042
( O 0 0.0016927633
FANFT B-Chemical 1 0.99946254
) O 0 0.0012652327
to O 0 0.00029895178
rats O 0 0.0014347594
resulted O 0 0.0002711011
in O 0 0.0002367113
a O 0 0.00031158095
reduced O 0 0.0003834321
incidence O 0 0.006808447
of O 0 0.0017098521
FANFT B-Chemical 1 0.99966633
- O 0 0.006054313
induced O 0 0.002857769
bladder B-Disease 0 0.9947707
carcinomas I-Disease 0 0.9986172
but O 0 0.0013445535
a O 0 0.0012441723
concomitant O 0 0.013507028
induction O 0 0.003928604
of O 0 0.009077592
forestomach B-Disease 0 0.99728036
tumors I-Disease 0 0.9932921
. O 0 0.0110059865

An O 0 0.0056581427
autoradiographic O 0 0.008494837
study O 0 0.0027008448
was O 0 0.0013134117
performed O 0 0.0010068748
on O 0 0.0007204592
male O 0 0.004115607
F O 0 0.16778322
- O 0 0.0016540405
344 O 0 0.021728048
rats O 0 0.002013286
fed O 0 0.0010142747
diet O 0 0.03063531
containing O 0 0.0006500633
FANFT B-Chemical 1 0.99877995
at O 0 0.0003221415
a O 0 0.00036457862
level O 0 0.00021882234
of O 0 0.0003828005
0 O 0 0.00037575368
. O 0 0.00016039402
2 O 0 0.00022505685
% O 0 0.000237791
and O 0 0.00023070986
/ O 0 0.0005385379
or O 0 0.0002490672
aspirin B-Chemical 1 0.9992499
at O 0 0.00021890142
a O 0 0.00027297426
level O 0 0.00016663354
of O 0 0.00030678284
0 O 0 0.00030198658
. O 0 0.00012334046
5 O 0 0.00014429165
% O 0 0.00015319866
to O 0 0.00010980576
evaluate O 0 9.315524e-05
the O 0 0.00016267449
effect O 0 0.00028575375
of O 0 0.0005735319
aspirin B-Chemical 1 0.9995946
on O 0 0.00032434924
the O 0 0.0004299943
increased O 0 0.0014141027
cell O 0 0.029497515
proliferation O 0 0.78311026
induced O 0 0.0020680747
by O 0 0.0017749665
FANFT B-Chemical 1 0.9989109
in O 0 0.001620938
the O 0 0.0023198086
forestomach O 0 0.9837617
and O 0 0.0069903275
bladder O 0 0.9315898
. O 0 0.008737298

FANFT B-Chemical 1 0.9960496
- O 0 0.010456892
induced O 0 0.0040104897
cell O 0 0.01860525
proliferation O 0 0.5758668
in O 0 0.0009955956
the O 0 0.0008526585
bladder O 0 0.62672323
was O 0 0.00082128803
significantly O 0 0.000813741
suppressed O 0 0.0009503781
by O 0 0.001031311
aspirin B-Chemical 1 0.999683
co O 0 0.81770694
- O 0 0.0035680516
administration O 0 0.06423263
after O 0 0.00032905076
4 O 0 0.00039369284
weeks O 0 0.00045694946
but O 0 0.0005220897
not O 0 0.00066214125
after O 0 0.00075136713
12 O 0 0.0014571969
weeks O 0 0.0027158791
. O 0 0.0040396773

In O 0 0.0037230845
the O 0 0.0031802317
forestomach O 0 0.91655606
, O 0 0.0028719162
and O 0 0.0014300157
also O 0 0.001082226
in O 0 0.0007371665
the O 0 0.0008640445
liver O 0 0.7851749
, O 0 0.0024679007
aspirin B-Chemical 1 0.99941385
did O 0 0.00090180925
not O 0 0.00053798046
affect O 0 0.00046681333
the O 0 0.0010103114
FANFT B-Chemical 1 0.9990821
- O 0 0.0037624384
induced O 0 0.0017682457
increase O 0 0.0014920186
in O 0 0.0018568946
labeling O 0 0.006790961
index O 0 0.008368824
. O 0 0.00629617

The O 0 0.00245319
present O 0 0.0014626738
results O 0 0.0012533248
are O 0 0.0010242943
consistent O 0 0.00079674204
with O 0 0.0007675323
the O 0 0.00063277915
carcinogenicity O 0 0.96402353
experiment O 0 0.00046329998
suggesting O 0 0.00036108264
that O 0 0.00026847847
different O 0 0.00033725362
mechanisms O 0 0.00078560977
are O 0 0.0003711727
involved O 0 0.00038089667
in O 0 0.00052408304
FANFT B-Chemical 1 0.9996333
carcinogenesis B-Disease 2 0.9988004
in O 0 0.0006096666
the O 0 0.0004813849
bladder O 0 0.7912448
and O 0 0.0010426888
forestomach O 0 0.99053395
, O 0 0.0008363484
and O 0 0.00039192874
that O 0 0.00035596473
aspirin B-Chemical 1 0.99957937
' O 0 0.00070498756
s O 0 0.00047515193
effect O 0 0.00036786438
on O 0 0.00024848845
FANFT B-Chemical 1 0.9991555
in O 0 0.0004803858
the O 0 0.00052539
forestomach O 0 0.9780807
is O 0 0.0005197067
not O 0 0.00033621478
due O 0 0.00024934305
to O 0 0.00037858338
an O 0 0.00081331155
irritant O 0 0.9621414
effect O 0 0.0012778102
associated O 0 0.0016706373
with O 0 0.0020986602
increased O 0 0.006415331
cell O 0 0.11072467
proliferation O 0 0.90344995
. O 0 0.0076532033

Also O 0 0.006464041
, O 0 0.0034347756
there O 0 0.0014062076
appears O 0 0.0014435009
to O 0 0.0011013341
be O 0 0.001030652
an O 0 0.0010736672
adaptation O 0 0.001658467
by O 0 0.00088138855
the O 0 0.00085132144
rats O 0 0.0026918678
to O 0 0.0010556257
the O 0 0.0016776737
chronic O 0 0.95414066
ingestion O 0 0.9421514
of O 0 0.029973734
aspirin B-Chemical 1 0.9985519
. O 0 0.013943898

A O 0 0.027911672
case O 0 0.009785479
of O 0 0.018698322
tardive B-Disease 0 0.999403
dyskinesia I-Disease 2 0.99948406
caused O 0 0.055987004
by O 0 0.03168572
metoclopramide B-Chemical 1 0.99852246
. O 0 0.023495367

Abnormal B-Disease 0 0.08721029
involuntary I-Disease 0 0.92214215
movements I-Disease 0 0.088269554
appeared O 0 0.0022530581
in O 0 0.0010738045
the O 0 0.0010301003
mouth O 0 0.033343844
, O 0 0.0014540429
tongue O 0 0.05496629
, O 0 0.0010807095
neck O 0 0.088184714
and O 0 0.0006956977
abdomen O 0 0.018432805
of O 0 0.0005533997
a O 0 0.00049697445
64 O 0 0.0007407946
- O 0 0.0005274583
year O 0 0.00035264748
- O 0 0.00045182006
old O 0 0.00029084412
male O 0 0.0005753145
patient O 0 0.00032799618
after O 0 0.0001334513
he O 0 0.00033637873
took O 0 0.00037384106
metoclopramide B-Chemical 1 0.99981254
for O 0 0.00057806476
gastrointestinal B-Disease 0 0.9983065
disorder I-Disease 0 0.99523336
in O 0 0.00040893545
a O 0 0.00038032804
regimen O 0 0.002708102
of O 0 0.0003698011
30 O 0 0.0002951509
mg O 0 0.04936164
per O 0 0.00017226643
day O 0 0.00028151396
for O 0 0.00028794547
a O 0 0.00051690213
total O 0 0.00059864647
of O 0 0.0012021797
about O 0 0.0015537449
260 O 0 0.008819025
days O 0 0.003572642
. O 0 0.0047018635

The O 0 0.006413379
symptoms O 0 0.104746155
exacerbated O 0 0.01459782
to O 0 0.0039690863
a O 0 0.004045356
maximum O 0 0.004162487
in O 0 0.0042447224
a O 0 0.006559326
month O 0 0.008844382
. O 0 0.010449414

When O 0 0.0037030003
the O 0 0.0035070342
metoclopramide B-Chemical 1 0.99910456
administration O 0 0.42230272
was O 0 0.0019801287
discontinued O 0 0.061288606
, O 0 0.0015209609
the O 0 0.00094963406
abnormal B-Disease 0 0.058967732
movements I-Disease 0 0.02248773
gradually O 0 0.003083462
improved O 0 0.002603069
to O 0 0.0014781449
a O 0 0.0022377882
considerable O 0 0.0036396629
extent O 0 0.0037935616
. O 0 0.006184295

Attention O 0 0.05488516
to O 0 0.0026343323
the O 0 0.0017475712
possible O 0 0.001662033
induction O 0 0.0017908104
of O 0 0.0016855362
specific O 0 0.003215425
tardive B-Disease 0 0.99992263
dyskinesia I-Disease 2 0.9999261
is O 0 0.0018983813
called O 0 0.0012478973
for O 0 0.00066337886
in O 0 0.00071814406
the O 0 0.00088266976
use O 0 0.0015077638
of O 0 0.0023322173
this O 0 0.0036155994
drug O 0 0.47758028
. O 0 0.007641211

Intra O 0 0.18139295
- O 0 0.009569111
arterial O 0 0.7188482
BCNU B-Chemical 1 0.9985391
chemotherapy O 0 0.8869326
for O 0 0.0019448376
treatment O 0 0.0040345276
of O 0 0.0037084173
malignant B-Disease 0 0.9965591
gliomas I-Disease 0 0.99827504
of O 0 0.004978307
the O 0 0.0033825224
central O 0 0.014888539
nervous O 0 0.86656344
system O 0 0.012684665
. O 0 0.008518976

Because O 0 0.0029903
of O 0 0.002532306
the O 0 0.0017476968
rapid O 0 0.003882337
systemic O 0 0.79101807
clearance O 0 0.28397283
of O 0 0.0041608703
BCNU B-Chemical 1 0.99964297
( O 0 0.0033408261
1 B-Chemical 0 0.00082087994
, I-Chemical 0 0.0007286456
3 I-Chemical 0 0.00049088453
- I-Chemical 0 0.0010743181
bis I-Chemical 0 0.7484266
- I-Chemical 0 0.0013735795
( I-Chemical 0 0.0006730013
2 I-Chemical 0 0.000455143
- I-Chemical 0 0.00089099084
chloroethyl I-Chemical 0 0.9832671
) I-Chemical 0 0.0019195572
- I-Chemical 0 0.00095641776
1 I-Chemical 0 0.00045143216
- I-Chemical 0 0.0008906492
nitrosourea I-Chemical 0 0.99752694
) O 0 0.001367846
, O 0 0.00052011583
intra O 0 0.0070454204
- O 0 0.00083321723
arterial O 0 0.4130158
administration O 0 0.05001502
should O 0 0.00015970971
provide O 0 0.00019635858
a O 0 0.0002379096
substantial O 0 0.00032410998
advantage O 0 0.00024429196
over O 0 0.00018850424
intravenous O 0 0.23420197
administration O 0 0.062144045
for O 0 0.0005555289
the O 0 0.0008298707
treatment O 0 0.003703419
of O 0 0.006390285
malignant B-Disease 0 0.9970914
gliomas I-Disease 0 0.9981608
. O 0 0.012246299

Thirty O 0 0.009931031
- O 0 0.0035075543
six O 0 0.0011444166
patients O 0 0.0023336755
were O 0 0.0009883181
treated O 0 0.0014318269
with O 0 0.0012869101
BCNU B-Chemical 1 0.99902916
every O 0 0.0004133139
6 O 0 0.0003065688
to O 0 0.00025940445
8 O 0 0.00024150021
weeks O 0 0.00022363565
, O 0 0.0002695881
either O 0 0.00020175858
by O 0 0.00024748946
transfemoral O 0 0.0023467308
catheterization O 0 0.012799481
of O 0 0.00035285598
the O 0 0.0002767433
internal O 0 0.0004958797
carotid O 0 0.67922825
or O 0 0.00037551267
vertebral O 0 0.31752366
artery O 0 0.16013788
or O 0 0.00022594524
through O 0 0.00019171042
a O 0 0.00024085012
fully O 0 0.000221894
implantable O 0 0.029687153
intracarotid O 0 0.977452
drug O 0 0.3498161
delivery O 0 0.00085352827
system O 0 0.0005895408
, O 0 0.00034689624
beginning O 0 0.00019900184
with O 0 0.00032117128
a O 0 0.00037899366
dose O 0 0.0033796208
of O 0 0.00063673925
200 O 0 0.0022873492
mg O 0 0.35758108
/ O 0 0.0023408418
sq O 0 0.01983775
m O 0 0.00460303
body O 0 0.0059901793
surface O 0 0.0069994717
area O 0 0.0070448075
. O 0 0.0058594523

Twelve O 0 0.011140147
patients O 0 0.0060875253
with O 0 0.003562614
Grade O 0 0.52859753
III O 0 0.019344108
or O 0 0.0016247868
IV O 0 0.23190537
astrocytomas B-Disease 0 0.99642026
were O 0 0.0010551739
treated O 0 0.0010603429
after O 0 0.0003739922
partial O 0 0.001139859
resection O 0 0.00484386
of O 0 0.000992522
the O 0 0.0010785798
tumor B-Disease 2 0.4257008
without O 0 0.0017622377
prior O 0 0.0018370767
radiation O 0 0.3086293
therapy O 0 0.18822545
. O 0 0.0077904747

After O 0 0.002083417
two O 0 0.0014216466
to O 0 0.0012022908
seven O 0 0.00090997765
cycles O 0 0.00074884004
of O 0 0.0010021061
chemotherapy O 0 0.54189384
, O 0 0.0009524884
nine O 0 0.00056127197
patients O 0 0.001277192
showed O 0 0.0004285968
a O 0 0.0004790608
decrease O 0 0.000568967
in O 0 0.00044509795
tumor B-Disease 2 0.4523522
size O 0 0.0007808499
and O 0 0.00064690236
surrounding O 0 0.0016988355
edema B-Disease 0 0.9984268
on O 0 0.0006301945
contrast O 0 0.0012664148
- O 0 0.002104486
enhanced O 0 0.002130799
computerized O 0 0.018755633
tomography O 0 0.23372321
scans O 0 0.022674128
. O 0 0.007290309

In O 0 0.002754278
the O 0 0.0017880558
nine O 0 0.0015468001
responders O 0 0.0028499826
, O 0 0.0010576367
median O 0 0.00055221934
duration O 0 0.0006642434
of O 0 0.0006987206
chemotherapy O 0 0.49552774
response O 0 0.0009057204
from O 0 0.00034156258
the O 0 0.00025105555
time O 0 0.00021697702
of O 0 0.0003558494
operation O 0 0.0005836135
was O 0 0.00032559657
25 O 0 0.00046553224
weeks O 0 0.0003184789
( O 0 0.00042294676
range O 0 0.00047720634
12 O 0 0.00031295398
to O 0 0.00040782132
more O 0 0.0007692193
than O 0 0.0006883279
91 O 0 0.0024538343
weeks O 0 0.0022565103
) O 0 0.0052055414
. O 0 0.004834051

The O 0 0.002394635
median O 0 0.0016334141
duration O 0 0.0016738494
of O 0 0.0014949627
survival O 0 0.013241812
in O 0 0.0006944961
the O 0 0.00052232237
12 O 0 0.00038080913
patients O 0 0.00085232215
was O 0 0.0003453218
54 O 0 0.0005403285
weeks O 0 0.0002953505
( O 0 0.0003477946
range O 0 0.00035398203
21 O 0 0.0002895606
to O 0 0.00018474703
more O 0 0.00027355237
than O 0 0.00016261898
156 O 0 0.0008200461
weeks O 0 0.00029489805
) O 0 0.0005064626
, O 0 0.00037046283
with O 0 0.0003798695
an O 0 0.0005390638
18 O 0 0.0005375133
- O 0 0.0007071333
month O 0 0.0005982743
survival O 0 0.005373131
rate O 0 0.001146517
of O 0 0.0023371386
42 O 0 0.004651225
% O 0 0.0046615615
. O 0 0.0047916523

Twenty O 0 0.009303269
- O 0 0.0036870732
four O 0 0.0013005524
patients O 0 0.0028190368
with O 0 0.001834012
recurrent O 0 0.47613052
Grade O 0 0.8301076
I O 0 0.00604309
to O 0 0.0010292705
IV O 0 0.2747076
astrocytomas B-Disease 0 0.9980398
, O 0 0.0011022614
whose O 0 0.00091399514
resection O 0 0.0076464275
and O 0 0.00046194586
irradiation O 0 0.015000016
therapy O 0 0.014840102
had O 0 0.00046885558
failed O 0 0.00057913025
, O 0 0.0004163069
received O 0 0.00037612926
two O 0 0.00023050058
to O 0 0.000299887
eight O 0 0.0003501387
courses O 0 0.0012451931
of O 0 0.0012654051
intra O 0 0.03014111
- O 0 0.0065185917
arterial O 0 0.94093347
BCNU B-Chemical 1 0.9988815
therapy O 0 0.42447916
. O 0 0.008645273

Seventeen O 0 0.011681906
of O 0 0.0027581626
these O 0 0.0021630279
had O 0 0.0014298176
a O 0 0.0011881817
response O 0 0.0012383709
or O 0 0.00056271476
were O 0 0.00048062715
stable O 0 0.00056973845
for O 0 0.00033345958
a O 0 0.0004037107
median O 0 0.00032734577
of O 0 0.0004065764
20 O 0 0.00043194572
weeks O 0 0.00038672445
( O 0 0.00051135244
range O 0 0.00057523366
6 O 0 0.0003584267
to O 0 0.00045529418
more O 0 0.00084296113
than O 0 0.00074786507
66 O 0 0.0024197302
weeks O 0 0.002360606
) O 0 0.0054263305
. O 0 0.005032908

The O 0 0.0036396352
catheterization O 0 0.011635116
procedure O 0 0.0028562907
is O 0 0.001951058
safe O 0 0.0041466337
, O 0 0.0019771578
with O 0 0.0014405285
no O 0 0.0011338497
immediate O 0 0.003332612
complication O 0 0.19203942
in O 0 0.0022248535
111 O 0 0.011623633
infusions O 0 0.21441309
of O 0 0.011634622
BCNU B-Chemical 1 0.9975649
. O 0 0.01296322

A O 0 0.018080082
delayed O 0 0.0095323
complication O 0 0.11914709
in O 0 0.0016206338
nine O 0 0.0014457811
patients O 0 0.002669124
has O 0 0.0011571551
been O 0 0.0014360346
unilateral O 0 0.12147491
loss B-Disease 0 0.003298419
of I-Disease 0 0.0019465616
vision I-Disease 0 0.3984878
secondary O 0 0.0056652967
to O 0 0.002417839
a O 0 0.0053707976
retinal B-Disease 0 0.98003983
vasculitis I-Disease 2 0.9978782
. O 0 0.013490919

The O 0 0.0030599032
frequency O 0 0.002748052
of O 0 0.0027935782
visual B-Disease 2 0.43422344
loss I-Disease 2 0.008450069
decreased O 0 0.0024848413
after O 0 0.00072889315
the O 0 0.0009683024
concentration O 0 0.0026065225
of O 0 0.0017382145
the O 0 0.0021913878
ethanol B-Chemical 1 0.99033034
diluent O 0 0.31854725
was O 0 0.00553137
lowered O 0 0.029348735
. O 0 0.008174174

Provocation O 0 0.5858013
of O 0 0.012568533
postural O 0 0.98593104
hypotension B-Disease 2 0.9991924
by O 0 0.026981907
nitroglycerin B-Chemical 1 0.99930716
in O 0 0.023472983
diabetic B-Disease 2 0.99712247
autonomic I-Disease 0 0.9959632
neuropathy I-Disease 0 0.9990613
? O 0 0.11622413

The O 0 0.0029594642
effect O 0 0.0026518463
of O 0 0.003052336
nitroglycerin B-Chemical 1 0.999403
on O 0 0.0013894963
heart O 0 0.32884282
rate O 0 0.00090407155
and O 0 0.00086463784
systolic O 0 0.58756465
blood O 0 0.0070233024
pressure O 0 0.023153447
was O 0 0.00034725756
compared O 0 0.00017309314
in O 0 0.00021275788
5 O 0 0.0002012178
normal O 0 0.00040889613
subjects O 0 0.00046416325
, O 0 0.00036334127
12 O 0 0.00027064036
diabetic B-Disease 2 0.9500599
subjects O 0 0.0008911662
without O 0 0.00076345087
autonomic B-Disease 0 0.9951426
neuropathy I-Disease 0 0.99982184
, O 0 0.0016003486
and O 0 0.00084788713
5 O 0 0.0008646267
diabetic B-Disease 2 0.978092
subjects O 0 0.0033172683
with O 0 0.0046999133
autonomic B-Disease 0 0.9940606
neuropathy I-Disease 0 0.99915195
. O 0 0.010920674

The O 0 0.002523459
magnitude O 0 0.0017458592
and O 0 0.0012708511
time O 0 0.00078446633
course O 0 0.0011044239
of O 0 0.00085852534
the O 0 0.0005800461
increase O 0 0.0005486641
in O 0 0.00048092168
heart O 0 0.17159493
rate O 0 0.0004141953
and O 0 0.000376742
the O 0 0.00029050407
decrease O 0 0.00043111396
in O 0 0.00031425516
systolic O 0 0.5573055
blood O 0 0.005139521
pressure O 0 0.020848637
after O 0 0.00023271189
nitroglycerin B-Chemical 1 0.99982774
were O 0 0.00034207228
similar O 0 0.0001756809
in O 0 0.00017520665
the O 0 0.00019106423
normal O 0 0.0005443382
and O 0 0.0003766497
diabetic B-Disease 2 0.9890865
subjects O 0 0.0011453098
without O 0 0.0006632654
autonomic B-Disease 0 0.9969559
neuropathy I-Disease 0 0.99991643
, O 0 0.0012095545
whereas O 0 0.000315717
a O 0 0.00031006814
lesser O 0 0.0013004154
increase O 0 0.0002729115
in O 0 0.00025539353
heart O 0 0.16886076
rate O 0 0.0002624149
and O 0 0.0002638902
a O 0 0.00026272982
greater O 0 0.00025115567
decrease O 0 0.00037556348
in O 0 0.00031663154
systolic O 0 0.5525754
blood O 0 0.005478994
pressure O 0 0.022441514
occurred O 0 0.0006380867
in O 0 0.00047471464
the O 0 0.0008080698
diabetic B-Disease 2 0.98802036
subjects O 0 0.004173398
with O 0 0.005464066
autonomic B-Disease 0 0.9946649
neuropathy I-Disease 0 0.9991955
. O 0 0.011247499

It O 0 0.005671379
is O 0 0.0022399111
therefore O 0 0.001793388
suggested O 0 0.0011963368
that O 0 0.0007846432
caution O 0 0.0013078868
should O 0 0.0004949715
be O 0 0.00063331943
exercised O 0 0.002979556
when O 0 0.0004720184
prescribing O 0 0.039588314
vasodilator O 0 0.99796176
drugs O 0 0.89320445
in O 0 0.0013174709
diabetic B-Disease 2 0.9963529
patients O 0 0.010227319
, O 0 0.0014621719
particularly O 0 0.0019953982
those O 0 0.0022873855
with O 0 0.0048117093
autonomic B-Disease 0 0.99428
neuropathy I-Disease 0 0.999169
. O 0 0.011691487

Blood O 0 0.049540985
pressure O 0 0.025530681
response O 0 0.004272445
to O 0 0.0025484168
chronic O 0 0.7986995
low O 0 0.004125144
- O 0 0.0045957547
dose O 0 0.08224758
intrarenal O 0 0.992763
noradrenaline B-Chemical 1 0.9993093
infusion O 0 0.41841075
in O 0 0.004160252
conscious O 0 0.19450176
rats O 0 0.022220448
. O 0 0.007575205

Sodium B-Chemical 0 0.99837434
chloride I-Chemical 0 0.9980065
solution O 0 0.24280398
( O 0 0.003935207
0 O 0 0.0016155296
. O 0 0.00068494043
9 O 0 0.00071490294
% O 0 0.0007108109
) O 0 0.0007978118
or O 0 0.00050804246
noradrenaline B-Chemical 1 0.9989625
in O 0 0.00048222163
doses O 0 0.01432997
of O 0 0.0005399786
4 O 0 0.0003078264
, O 0 0.00030749847
12 O 0 0.0001628589
and O 0 0.00019852274
36 O 0 0.00026571448
micrograms O 0 0.032500893
h O 0 0.00033374073
- O 0 0.000409867
1 O 0 0.00023074551
kg O 0 0.0017615652
- O 0 0.00034299283
1 O 0 0.00017319796
was O 0 0.0001471976
infused O 0 0.0005802399
for O 0 0.00011384359
five O 0 0.000104868675
consecutive O 0 0.0002314122
days O 0 0.00020649981
, O 0 0.00028428453
either O 0 0.0002757086
intrarenally O 0 0.8100048
( O 0 0.0004972919
by O 0 0.0002716538
a O 0 0.00030495386
new O 0 0.00044220034
technique O 0 0.000906779
) O 0 0.000709949
or O 0 0.000371548
intravenously O 0 0.002692047
into O 0 0.0004100304
rats O 0 0.0019264695
with O 0 0.0012215985
one O 0 0.0016353653
kidney O 0 0.574107
removed O 0 0.0047889906
. O 0 0.005830887

Intrarenal O 0 0.95373636
infusion O 0 0.12813576
of O 0 0.0064279167
noradrenaline B-Chemical 1 0.99888974
caused O 0 0.012471005
hypertension B-Disease 2 0.9991792
at O 0 0.00141134
doses O 0 0.056959134
which O 0 0.0016361014
did O 0 0.0009431285
not O 0 0.0008520436
do O 0 0.0009462057
so O 0 0.0012458717
when O 0 0.0016085475
infused O 0 0.016922383
intravenously O 0 0.037507247
. O 0 0.0064684614

Intrarenal O 0 0.8979752
compared O 0 0.0020847935
with O 0 0.002239927
intravenous O 0 0.39136407
infusion O 0 0.09844805
of O 0 0.0027752249
noradrenaline B-Chemical 1 0.9994722
caused O 0 0.0019819434
higher O 0 0.0010028692
plasma O 0 0.21573971
noradrenaline B-Chemical 1 0.99970347
concentrations O 0 0.014535483
and O 0 0.0005102788
a O 0 0.000418423
shift O 0 0.0006483173
of O 0 0.0004647359
the O 0 0.00046753229
plasma O 0 0.1775417
noradrenaline B-Chemical 1 0.99973303
concentration O 0 0.024168992
- O 0 0.0014545696
blood O 0 0.005697065
pressure O 0 0.022912353
effect O 0 0.0006586258
curve O 0 0.0013606442
towards O 0 0.001007179
lower O 0 0.0017282178
plasma O 0 0.28475744
noradrenaline B-Chemical 1 0.9984756
levels O 0 0.007489646
. O 0 0.0067112586

These O 0 0.0040504104
results O 0 0.002058254
suggest O 0 0.0014675256
that O 0 0.0016730129
hypertension B-Disease 2 0.9983273
after O 0 0.0012217804
chronic O 0 0.9786213
intrarenal O 0 0.9977209
noradrenaline B-Chemical 1 0.9998216
infusion O 0 0.37185502
is O 0 0.000564022
produced O 0 0.0003790449
by O 0 0.0003242899
relatively O 0 0.00042139634
higher O 0 0.0003181536
levels O 0 0.0003348725
of O 0 0.0006135906
circulating O 0 0.041259848
noradrenaline B-Chemical 1 0.99960977
and O 0 0.0008177029
by O 0 0.0006483563
triggering O 0 0.0017409291
of O 0 0.0010717482
an O 0 0.0014738643
additional O 0 0.0013670516
intrarenal O 0 0.9862277
pressor O 0 0.9936726
mechanism O 0 0.014533967
. O 0 0.0071225343

Characterization O 0 0.011311984
of O 0 0.008366865
estrogen B-Chemical 1 0.99553347
- O 0 0.01615993
induced O 0 0.009846709
adenohypophyseal B-Disease 0 0.9909567
tumors I-Disease 0 0.984932
in O 0 0.0044271275
the O 0 0.005232789
Fischer O 0 0.5137664
344 O 0 0.16489324
rat O 0 0.036111202
. O 0 0.010553616

Pituitary B-Disease 0 0.94981766
tumors I-Disease 0 0.9618294
were O 0 0.0030640052
induced O 0 0.0025842793
in O 0 0.0014690763
F344 O 0 0.5197982
female O 0 0.0040031704
rats O 0 0.003741654
by O 0 0.0009734724
chronic O 0 0.9003927
treatment O 0 0.009984089
with O 0 0.003876888
diethylstilbestrol B-Chemical 1 0.9998202
( O 0 0.012159748
DES B-Chemical 0 0.99824476
, O 0 0.0014290586
8 O 0 0.0006550767
- O 0 0.0008277825
10 O 0 0.0006062793
mg O 0 0.12949096
) O 0 0.0012757065
implanted O 0 0.0026325465
subcutaneously O 0 0.003233949
in O 0 0.0017251724
silastic O 0 0.11370437
capsules O 0 0.15797287
. O 0 0.0067484183

Over O 0 0.0047941953
a O 0 0.002635602
range O 0 0.0023520016
of O 0 0.0018107082
1 O 0 0.0013414563
- O 0 0.0012435598
150 O 0 0.0009513248
days O 0 0.0004454243
of O 0 0.00070740294
DES B-Chemical 0 0.99477744
treatment O 0 0.0030324992
, O 0 0.0006036729
pairs O 0 0.00029808033
of O 0 0.000414386
control O 0 0.00035520876
and O 0 0.00065625366
DES B-Chemical 0 0.99817204
- O 0 0.0014061636
treated O 0 0.0007927744
rats O 0 0.0014414748
were O 0 0.00028090377
sacrificed O 0 0.0003628781
, O 0 0.0003667206
and O 0 0.000310878
their O 0 0.0004119388
pituitaries O 0 0.021240076
dissociated O 0 0.0017305531
enzymatically O 0 0.016157942
into O 0 0.00064414955
single O 0 0.0014803036
- O 0 0.0032268951
cell O 0 0.0094828475
preparations O 0 0.013287709
. O 0 0.0061415895

The O 0 0.0029323644
cell O 0 0.0049510575
populations O 0 0.00209036
were O 0 0.0009771502
examined O 0 0.0005844106
regarding O 0 0.00051362783
total O 0 0.000529524
cell O 0 0.0022071756
recovery O 0 0.0012691516
correlated O 0 0.00039775553
with O 0 0.000647107
gland O 0 0.32066646
weight O 0 0.016971905
, O 0 0.0009318898
intracellular O 0 0.024202306
prolactin O 0 0.99735343
( O 0 0.003850653
PRL O 0 0.99897826
) O 0 0.0011911074
content O 0 0.0004466769
and O 0 0.00033586926
subsequent O 0 0.0004558633
release O 0 0.021299632
in O 0 0.00027180067
primary O 0 0.00053150306
culture O 0 0.0014808802
, O 0 0.00047830777
immunocytochemical O 0 0.04015488
PRL O 0 0.99896073
staining O 0 0.0012788578
, O 0 0.0005406548
density O 0 0.0006409608
and O 0 0.00037371885
/ O 0 0.0006967862
or O 0 0.00019795322
size O 0 0.00032539765
alterations O 0 0.0024751201
via O 0 0.00024286393
separation O 0 0.00068301405
on O 0 0.00021205634
Ficoll O 0 0.69481295
- O 0 0.0011771057
Hypaque O 0 0.97835994
and O 0 0.00033345196
by O 0 0.00026104244
unit O 0 0.000266243
gravity O 0 0.011124735
sedimentation O 0 0.009655551
, O 0 0.00056574465
and O 0 0.0003906759
cell O 0 0.0026653742
cycle O 0 0.002242036
analysis O 0 0.0008008933
, O 0 0.00065243803
after O 0 0.00040525707
acriflavine B-Chemical 0 0.9872979
DNA O 0 0.065847516
staining O 0 0.0020121338
, O 0 0.0017350303
by O 0 0.0016863373
laser O 0 0.02140096
flow O 0 0.017092086
cytometry O 0 0.007877955
. O 0 0.0073563308

Total O 0 0.0059350007
cell O 0 0.007009187
yields O 0 0.0035378134
from O 0 0.0022147729
DES B-Chemical 0 0.99544466
- O 0 0.0032221612
treated O 0 0.0016908628
pituitaries O 0 0.040769596
increased O 0 0.00095410063
from O 0 0.00046400444
1 O 0 0.00038174522
. O 0 0.00016560493
3 O 0 0.00015542057
times O 0 0.000115974064
control O 0 0.0001578132
yields O 0 0.00032613217
at O 0 0.0001486748
8 O 0 0.00018925506
days O 0 0.0001706388
of O 0 0.0002672898
treatment O 0 0.0006084345
to O 0 0.00030993958
58 O 0 0.00060948293
. O 0 0.00022004315
9 O 0 0.00030508646
times O 0 0.0002557632
control O 0 0.00047333087
values O 0 0.0008062918
by O 0 0.0013904909
day O 0 0.0023741696
150 O 0 0.00599144
. O 0 0.004494423

Intracellular O 0 0.15726264
PRL O 0 0.98989224
content O 0 0.0035024881
ranged O 0 0.0021332195
from O 0 0.0011599797
1 O 0 0.00088503375
. O 0 0.0004258657
9 O 0 0.00042022474
to O 0 0.00032893594
9 O 0 0.00032747688
. O 0 0.00016708778
4 O 0 0.00016421269
times O 0 0.00012839315
control O 0 0.00018925345
levels O 0 0.00028550404
, O 0 0.00045524578
and O 0 0.0005193542
PRL O 0 0.99878615
release O 0 0.07533522
in O 0 0.00032440678
vitro O 0 0.00078763335
was O 0 0.00027478536
significantly O 0 0.0003331228
and O 0 0.00025784803
consistently O 0 0.0002598456
higher O 0 0.00024745762
than O 0 0.00018034068
controls O 0 0.00044880688
, O 0 0.00037761306
after O 0 0.0001930953
at O 0 0.00024085563
least O 0 0.0003363829
8 O 0 0.0006380426
days O 0 0.00089531916
of O 0 0.0025660095
DES B-Chemical 0 0.9919807
exposure O 0 0.049377438
. O 0 0.0068483097

Beyond O 0 0.008933428
8 O 0 0.0024877232
days O 0 0.0016504995
of O 0 0.0021554253
DES B-Chemical 0 0.99173135
exposure O 0 0.018482823
, O 0 0.0016464187
the O 0 0.0009972241
immunochemically O 0 0.71635175
PRL O 0 0.99878377
- O 0 0.0017666497
positive O 0 0.00044971588
proportion O 0 0.0003319302
of O 0 0.000549198
cells O 0 0.0009280435
increased O 0 0.00076807296
to O 0 0.0004521755
over O 0 0.0003321144
50 O 0 0.0009202693
% O 0 0.0007608768
of O 0 0.00095571554
the O 0 0.001270928
total O 0 0.0022134348
population O 0 0.0055922824
. O 0 0.0056518763

Increased O 0 0.0077284887
density O 0 0.00429577
and O 0 0.002454773
/ O 0 0.0027791748
or O 0 0.0009688802
size O 0 0.0011674322
and O 0 0.0011376722
PRL O 0 0.9952815
content O 0 0.0010209418
were O 0 0.00048592596
indicated O 0 0.00028898835
for O 0 0.00029801697
the O 0 0.0003282818
majority O 0 0.00042905012
of O 0 0.00060825073
the O 0 0.00074338465
PRL O 0 0.99797124
cell O 0 0.012332428
population O 0 0.0012962414
in O 0 0.00063662394
both O 0 0.00079466344
types O 0 0.0012310336
of O 0 0.0022147028
separation O 0 0.006273989
protocols O 0 0.0064474884
. O 0 0.0062412387

All O 0 0.004731128
these O 0 0.0040073274
effects O 0 0.0044349246
of O 0 0.004099628
DES B-Chemical 0 0.98930174
were O 0 0.0027525758
more O 0 0.0027415506
pronounced O 0 0.0038355356
among O 0 0.0031514692
previously O 0 0.0043796827
ovariectomized O 0 0.67647856
animals O 0 0.007239011
. O 0 0.00867606

The O 0 0.002719058
data O 0 0.0022200549
extend O 0 0.0013693435
the O 0 0.0010750004
findings O 0 0.0016156104
of O 0 0.0009785541
other O 0 0.00076948915
investigators O 0 0.0010473132
, O 0 0.00071075675
further O 0 0.000535193
establishing O 0 0.00078174524
the O 0 0.00074909045
DES B-Chemical 0 0.9981018
- O 0 0.002356626
induced O 0 0.0011776189
tumor B-Disease 2 0.5800826
as O 0 0.0004132111
a O 0 0.0005000558
model O 0 0.00059166073
for O 0 0.00047259583
study O 0 0.0011905414
of O 0 0.001980289
PRL O 0 0.9964288
cellular O 0 0.035364274
control O 0 0.0034472714
mechanisms O 0 0.009803427
. O 0 0.006398804

Age O 0 0.14481932
and O 0 0.017822454
renal O 0 0.96150434
clearance O 0 0.44586858
of O 0 0.0425552
cimetidine B-Chemical 1 0.9976566
. O 0 0.039163075

In O 0 0.0031366646
35 O 0 0.0026384008
patients O 0 0.0033385595
( O 0 0.0016777217
ages O 0 0.0011615354
20 O 0 0.0007398087
to O 0 0.0005158077
86 O 0 0.0009139699
yr O 0 0.0013514528
) O 0 0.00078758295
receiving O 0 0.0032142545
cimetidine B-Chemical 1 0.99986887
therapeutically O 0 0.5309183
two O 0 0.00039833458
serum O 0 0.033647537
samples O 0 0.00033310376
and O 0 0.0003085948
all O 0 0.00024743826
urine O 0 0.058599852
formed O 0 0.00041305556
in O 0 0.00021686865
the O 0 0.00020875844
interim O 0 0.0012841099
were O 0 0.00022146241
collected O 0 0.00016039264
for O 0 0.00018443832
analysis O 0 0.00046748825
of O 0 0.0008345366
cimetidine B-Chemical 1 0.9998772
by O 0 0.0011327681
high O 0 0.0015817696
- O 0 0.0017282317
pressure O 0 0.03728
liquid O 0 0.0047006137
chromatography O 0 0.027453396
and O 0 0.0022503275
for O 0 0.0032724303
creatinine B-Chemical 1 0.9891255
. O 0 0.00815095

Cimetidine B-Chemical 0 0.9957242
clearance O 0 0.44986004
decreased O 0 0.026938576
with O 0 0.02045119
age O 0 0.035431903
. O 0 0.023362678

The O 0 0.003182113
extrapolated O 0 0.0033933693
6 O 0 0.001626951
- O 0 0.001938206
hr O 0 0.0018597798
serum O 0 0.017966479
concentration O 0 0.0026004615
of O 0 0.001418597
cimetidine B-Chemical 1 0.99980325
per O 0 0.0005515156
unit O 0 0.00065323286
dose O 0 0.015179201
, O 0 0.0007158646
after O 0 0.0003490765
intravenous O 0 0.7430226
cimetidine B-Chemical 1 0.99988353
, O 0 0.0021141816
increased O 0 0.0017074576
with O 0 0.0013465334
age O 0 0.0026844097
of O 0 0.0021377984
the O 0 0.002831743
patients O 0 0.011965923
. O 0 0.0061754477

The O 0 0.0031847123
ratio O 0 0.003067248
of O 0 0.0035852988
cimetidine B-Chemical 1 0.9995845
clearance O 0 0.50557256
to O 0 0.0020976518
creatinine B-Chemical 1 0.9969146
clearance O 0 0.48725978
( O 0 0.0027677035
Rc O 0 0.74178374
) O 0 0.0009134398
averaged O 0 0.00033560247
4 O 0 0.00033019518
. O 0 0.0002234626
8 O 0 0.00033952342
+ O 0 0.00048300278
/ O 0 0.00091246335
- O 0 0.0006471863
2 O 0 0.0003626694
. O 0 0.00022974666
0 O 0 0.0004262607
, O 0 0.0005038684
indicating O 0 0.00048568237
net O 0 0.0015785709
tubular O 0 0.6794729
secretion O 0 0.23922192
for O 0 0.0064029293
cimetidine B-Chemical 1 0.9993461
. O 0 0.012765273

Rc O 0 0.4884682
seemed O 0 0.0036997928
to O 0 0.0016151506
be O 0 0.0011167215
independent O 0 0.00060131133
of O 0 0.0009366031
age O 0 0.0014917509
and O 0 0.0006636758
decreased O 0 0.0010824049
with O 0 0.00066884316
increasing O 0 0.0010526727
serum O 0 0.118979886
concentration O 0 0.005570953
of O 0 0.0020219395
cimetidine B-Chemical 1 0.999915
, O 0 0.0021460536
suggesting O 0 0.00059149996
that O 0 0.00059408176
secretion O 0 0.043650456
of O 0 0.003228776
cimetidine B-Chemical 1 0.9998004
is O 0 0.0035726065
a O 0 0.0038964842
saturable O 0 0.5624592
process O 0 0.008208544
. O 0 0.0069399197

There O 0 0.0050254213
was O 0 0.002180852
only O 0 0.0014482932
one O 0 0.00093434006
case O 0 0.00108191
of O 0 0.0016845906
dementia B-Disease 2 0.9976361
possibly O 0 0.0048406
due O 0 0.0005392716
to O 0 0.00081050233
cimetidine B-Chemical 1 0.99989355
( O 0 0.001757567
with O 0 0.0005544255
a O 0 0.00045963816
drug O 0 0.10914351
level O 0 0.0002570893
of O 0 0.00042523548
1 O 0 0.0003419453
. O 0 0.0001562831
9 O 0 0.00023818287
microgram O 0 0.07048396
/ O 0 0.00067306514
ml O 0 0.0008100692
6 O 0 0.00014218122
hr O 0 0.0002824027
after O 0 9.817483e-05
a O 0 0.0002213539
dose O 0 0.0049276142
) O 0 0.00043630006
in O 0 0.00016463852
a O 0 0.00021090012
group O 0 0.00023796833
of O 0 0.00026832038
13 O 0 0.0003093946
patients O 0 0.0006155757
without O 0 0.00032554162
liver B-Disease 0 0.557142
or I-Disease 0 0.00040919828
kidney I-Disease 0 0.8563499
disease I-Disease 0 0.8209408
who O 0 0.0046883286
had O 0 0.0011138646
cimetidine B-Chemical 1 0.9998665
levels O 0 0.0010287792
above O 0 0.0005660375
1 O 0 0.0008269165
. O 0 0.0005778235
25 O 0 0.0018000914
microgram O 0 0.16202495
/ O 0 0.0061715855
ml O 0 0.011800576
. O 0 0.005194821

Thus O 0 0.0060446346
, O 0 0.00519558
high O 0 0.005629229
cimetidine B-Chemical 1 0.99906856
levels O 0 0.00461427
alone O 0 0.0036486345
do O 0 0.0025170865
not O 0 0.0027378092
always O 0 0.0044938973
induce O 0 0.008251048
dementia B-Disease 2 0.99345917
. O 0 0.01312757

Further O 0 0.006083539
observations O 0 0.003966827
on O 0 0.0020051284
the O 0 0.0025094051
electrophysiologic O 0 0.3184799
effects O 0 0.0058332733
of O 0 0.0060974406
oral O 0 0.8961385
amiodarone B-Chemical 1 0.9991615
therapy O 0 0.6380388
. O 0 0.013972833

A O 0 0.014970153
case O 0 0.0029048447
is O 0 0.0017331714
presented O 0 0.0013696058
of O 0 0.0013876819
a O 0 0.0013731589
reversible O 0 0.20228887
intra B-Disease 0 0.03103464
- I-Disease 0 0.0021694782
Hisian I-Disease 0 0.20789616
block I-Disease 0 0.0009333045
occurring O 0 0.0012939114
under O 0 0.00047114585
amiodarone B-Chemical 1 0.99976057
treatment O 0 0.0069478373
for O 0 0.0007445382
atrial B-Disease 0 0.9980861
tachycardia I-Disease 2 0.99966717
in O 0 0.00079771597
a O 0 0.0007969786
patient O 0 0.0012079168
without O 0 0.0010953742
clear O 0 0.002064511
intraventricular B-Disease 0 0.98790437
conduction I-Disease 0 0.73645395
abnormalities I-Disease 0 0.75719
. O 0 0.0075509637

His O 0 0.010480948
bundle O 0 0.00970344
recordings O 0 0.0065005757
showed O 0 0.0016842338
an O 0 0.0021761968
atrial B-Disease 0 0.9942521
tachycardia I-Disease 2 0.99945575
with O 0 0.0021951934
intermittent O 0 0.18322976
exit O 0 0.0053162733
block O 0 0.0009884028
and O 0 0.00052978663
greatly O 0 0.0013417827
prolonged O 0 0.015477774
BH O 0 0.2680224
and O 0 0.00074288546
HV O 0 0.08755157
intervals O 0 0.00064898306
( O 0 0.0006967899
40 O 0 0.0006252385
and O 0 0.0006911422
100 O 0 0.0018443228
msec O 0 0.0400858
, O 0 0.002576675
respectively O 0 0.005197155
) O 0 0.0064754616
. O 0 0.005459805

Thirty O 0 0.007842072
days O 0 0.0025500315
after O 0 0.0016992689
amiodarone B-Chemical 1 0.9990012
discontinuation O 0 0.935747
, O 0 0.0021200196
His O 0 0.004192143
bundle O 0 0.0070379893
electrograms O 0 0.23414499
showed O 0 0.000973667
atrial B-Disease 0 0.94944394
flutter I-Disease 0 0.9706147
without O 0 0.0012590284
intra O 0 0.018609919
- O 0 0.0026124674
Hisian O 0 0.20567349
or O 0 0.0014057008
infra O 0 0.014779061
- O 0 0.0054463376
Hisian O 0 0.3066746
delay O 0 0.011070527
. O 0 0.006818276

Amiodarone B-Chemical 1 0.99780077
should O 0 0.0023474924
be O 0 0.0016855218
used O 0 0.0009939555
with O 0 0.00092635833
caution O 0 0.0011815819
during O 0 0.00048486295
long O 0 0.0008520818
- O 0 0.0009296257
term O 0 0.0006715847
oral O 0 0.17108986
therapy O 0 0.022498082
in O 0 0.0005815271
patients O 0 0.0017457852
with O 0 0.000797787
or O 0 0.00069184107
without O 0 0.0011336991
clear O 0 0.0020640737
intraventricular O 0 0.9708811
conduction O 0 0.5222604
defects O 0 0.010044471
. O 0 0.0066288807

Development O 0 0.018305851
of O 0 0.005257113
clear B-Disease 0 0.0051551405
cell I-Disease 0 0.035781723
adenocarcinoma I-Disease 0 0.9974962
in O 0 0.006513165
DES B-Chemical 0 0.995795
- O 0 0.0075264964
exposed O 0 0.0036248218
offspring O 0 0.006867123
under O 0 0.003431066
observation O 0 0.0074343695
. O 0 0.008545576

Two O 0 0.004412872
cases O 0 0.0035570895
of O 0 0.0022979842
clear B-Disease 0 0.002257305
cell I-Disease 0 0.016678588
adenocarcinoma I-Disease 0 0.99821436
of I-Disease 0 0.0019914582
the I-Disease 0 0.0009818568
vagina I-Disease 0 0.023143865
detected O 0 0.00038166885
at O 0 0.0003255978
follow O 0 0.0005184186
- O 0 0.00079663843
up O 0 0.0004296284
in O 0 0.00042686475
young O 0 0.0032292395
women O 0 0.006639587
exposed O 0 0.0009183769
in O 0 0.00085188536
utero O 0 0.02131252
to O 0 0.0025622046
diethylstilbestrol B-Chemical 1 0.99892944
are O 0 0.0058001583
reported O 0 0.009605152
. O 0 0.0068147182

One O 0 0.005253257
patient O 0 0.0039018842
, O 0 0.00257248
aged O 0 0.0023967924
23 O 0 0.0015014225
, O 0 0.00092666195
had O 0 0.0006075554
been O 0 0.00055924593
followed O 0 0.0003118493
for O 0 0.0003138545
2 O 0 0.00034909748
years O 0 0.0005386224
before O 0 0.00025330993
carcinoma B-Disease 2 0.9980848
was O 0 0.00065696484
diagnosed O 0 0.027116297
; O 0 0.000651524
the O 0 0.00023052585
second O 0 0.00025276808
patient O 0 0.00055706204
, O 0 0.00041629001
aged O 0 0.00057581736
22 O 0 0.00037801542
, O 0 0.00030779385
had O 0 0.000285049
been O 0 0.00035537287
seen O 0 0.0002683086
on O 0 0.00018272323
a O 0 0.00035732504
regular O 0 0.0005831804
basis O 0 0.0005901015
for O 0 0.00053113716
5 O 0 0.00074927433
years O 0 0.0016870092
, O 0 0.0017594402
8 O 0 0.0019534382
months O 0 0.0032731164
. O 0 0.004253316

In O 0 0.0030679698
both O 0 0.0020841912
instances O 0 0.0015906873
, O 0 0.0018794208
suspicion O 0 0.016550459
of O 0 0.0011548359
the O 0 0.0007521667
presence O 0 0.0007598305
of O 0 0.0014755059
carcinoma B-Disease 2 0.9987299
was O 0 0.0011363184
aroused O 0 0.008829581
by O 0 0.0006265458
the O 0 0.00055721105
palpation O 0 0.024563424
of O 0 0.0008277813
a O 0 0.00090905244
small O 0 0.0013217918
nodule O 0 0.09547581
in O 0 0.0016052747
the O 0 0.0025670887
vaginal O 0 0.17103224
fornix O 0 0.65416646
. O 0 0.0074497056

Hysterosalpingography O 0 0.01238403
was O 0 0.0022580826
performed O 0 0.0014030226
on O 0 0.0008102726
both O 0 0.00094305887
patients O 0 0.0020611088
and O 0 0.0009091122
, O 0 0.0008529693
in O 0 0.00045833254
1 O 0 0.00046259322
instance O 0 0.00044188916
, O 0 0.0005144165
an O 0 0.0005195002
abnormal O 0 0.009985715
x O 0 0.0046483893
- O 0 0.0008851974
ray O 0 0.024517806
film O 0 0.0063408534
was O 0 0.00035087386
reflected O 0 0.00028095732
by O 0 0.00032113452
the O 0 0.00030155302
gross O 0 0.0011967968
appearance O 0 0.0012879622
of O 0 0.0006093763
the O 0 0.00064064196
uterine O 0 0.41579014
cavity O 0 0.0038285495
found O 0 0.0009500631
in O 0 0.0009700745
the O 0 0.0014374398
surgical O 0 0.005351821
specimen O 0 0.0062404633
. O 0 0.005907142

Neurologic O 0 0.9048128
effects O 0 0.0061403704
of O 0 0.0038867025
subarachnoid O 0 0.9937749
administration O 0 0.26442987
of O 0 0.0022097742
2 B-Chemical 0 0.0016121953
- I-Chemical 0 0.0032022202
chloroprocaine I-Chemical 0 0.9988293
- I-Chemical 0 0.007300459
CE I-Chemical 0 0.97386235
, O 0 0.0029469314
bupivacaine B-Chemical 1 0.9995017
, O 0 0.0016668926
and O 0 0.0009964616
low O 0 0.0016711623
pH O 0 0.12816332
normal O 0 0.0034230049
saline O 0 0.09333551
in O 0 0.0031320327
dogs O 0 0.011872656
. O 0 0.0063321698

The O 0 0.002530655
purpose O 0 0.0019392311
of O 0 0.0014756802
this O 0 0.0010432946
study O 0 0.0012536752
was O 0 0.0006605976
to O 0 0.00048237087
evaluate O 0 0.00032222137
the O 0 0.00052907434
neurologic O 0 0.9313655
consequences O 0 0.0019713317
of O 0 0.0008087885
deliberate O 0 0.10651634
subarachnoid O 0 0.9975956
injection O 0 0.0046249214
of O 0 0.00054309116
large O 0 0.00056626357
volumes O 0 0.0013065165
of O 0 0.0007604931
2 B-Chemical 0 0.00089668034
- I-Chemical 0 0.0023700914
chloroprocaine I-Chemical 0 0.99843055
- I-Chemical 0 0.0050185737
CE I-Chemical 0 0.8903235
in O 0 0.0017149525
experimental O 0 0.003844837
animals O 0 0.0040005897
. O 0 0.005533595

The O 0 0.0027591335
possible O 0 0.0022615595
role O 0 0.0012732508
of O 0 0.0016284016
low O 0 0.0019858305
pH O 0 0.12332211
as O 0 0.00067783217
well O 0 0.0005063894
as O 0 0.00043069824
total O 0 0.0004839215
volume O 0 0.0012314018
as O 0 0.00047856176
potential O 0 0.0009787756
factors O 0 0.0026136218
in O 0 0.0013624517
causing O 0 0.038083035
neurotoxicity B-Disease 2 0.9989606
was O 0 0.004855737
evaluated O 0 0.005326495
. O 0 0.0064943302

The O 0 0.0027929659
65 O 0 0.0025900698
dogs O 0 0.0027277789
in O 0 0.00095747627
the O 0 0.0007484686
study O 0 0.0009849628
received O 0 0.0008825676
injections O 0 0.0034297144
in O 0 0.00049957767
the O 0 0.0005836466
subarachnoid O 0 0.9942772
space O 0 0.0008239621
as O 0 0.00034920298
follows O 0 0.0007205471
: O 0 0.0005335224
6 O 0 0.00019289473
to O 0 0.00019793172
8 O 0 0.00023629077
ml O 0 0.0007324105
of O 0 0.0005689654
bupivacaine B-Chemical 1 0.99972266
( O 0 0.0020036225
N O 0 0.8042769
= O 0 0.0007856061
15 O 0 0.0002766053
) O 0 0.00047790963
, O 0 0.00038121466
2 B-Chemical 0 0.00036441215
- I-Chemical 0 0.0009410223
chloroprocaine I-Chemical 0 0.999019
- I-Chemical 0 0.003371318
CE I-Chemical 0 0.9750572
( O 0 0.001340644
N O 0 0.7461791
= O 0 0.00073746406
20 O 0 0.00037468201
) O 0 0.0004727382
, O 0 0.00033380694
low O 0 0.00045210225
pH O 0 0.08029913
normal O 0 0.000922559
saline O 0 0.11955743
( O 0 0.00086465635
pH O 0 0.082499124
3 O 0 0.00029138505
. O 0 0.00018719994
0 O 0 0.00035965967
) O 0 0.00057170674
( O 0 0.0005842717
N O 0 0.40203974
= O 0 0.00074240746
20 O 0 0.00046769125
) O 0 0.00063977623
, O 0 0.0005064667
or O 0 0.0004187202
normal O 0 0.0014473122
saline O 0 0.11675666
( O 0 0.0026026426
N O 0 0.645016
= O 0 0.0039732433
10 O 0 0.0030343325
) O 0 0.0055333045
. O 0 0.005021891

Of O 0 0.004915565
the O 0 0.0020324907
20 O 0 0.0016129668
animals O 0 0.0009803902
that O 0 0.0007659022
received O 0 0.0014662362
subarachnoid O 0 0.9910971
injection O 0 0.005352174
of O 0 0.0011313899
2 B-Chemical 0 0.0009939957
- I-Chemical 0 0.0021282693
chloroprocaine I-Chemical 0 0.99884003
- I-Chemical 0 0.0034975568
CE I-Chemical 0 0.90444314
seven O 0 0.000806989
( O 0 0.00096490973
35 O 0 0.0008180606
% O 0 0.0008683069
) O 0 0.0012939348
developed O 0 0.0022625993
hind O 0 0.07155087
- O 0 0.005618011
limb O 0 0.44288284
paralysis B-Disease 2 0.9958326
. O 0 0.009027916

None O 0 0.0072622476
of O 0 0.0026078941
the O 0 0.0015212022
animals O 0 0.001112035
that O 0 0.0008593057
received O 0 0.0018303109
bupivacaine B-Chemical 1 0.9994149
, O 0 0.0017779378
normal O 0 0.0017589804
saline O 0 0.0982245
, O 0 0.0007279977
or O 0 0.00036075784
normal O 0 0.00086010445
saline O 0 0.039758116
titrated O 0 0.001713084
to O 0 0.00048188557
a O 0 0.0007715512
pH O 0 0.065007836
3 O 0 0.0005494564
. O 0 0.00040480628
0 O 0 0.0008098705
developed O 0 0.001819026
hind O 0 0.048564635
- O 0 0.004939942
limb O 0 0.40079764
paralysis B-Disease 2 0.99576855
. O 0 0.008629447

Of O 0 0.005415615
the O 0 0.0023643263
15 O 0 0.0017109993
spinal O 0 0.010271908
cords O 0 0.0048864465
of O 0 0.00096764026
the O 0 0.0006003321
animals O 0 0.00048710947
that O 0 0.00040184997
received O 0 0.0007629548
2 B-Chemical 0 0.00072713237
- I-Chemical 0 0.0017022436
chloroprocaine I-Chemical 0 0.9989795
- I-Chemical 0 0.0043410994
CE I-Chemical 0 0.9555399
, O 0 0.0009189941
13 O 0 0.00067550864
showed O 0 0.00071209774
subpial B-Disease 0 0.97251296
necrosis I-Disease 2 0.99904484
; O 0 0.0036421746
the O 0 0.00092204835
nerve O 0 0.47509634
roots O 0 0.018260641
and O 0 0.002455121
subarachnoid O 0 0.9963097
vessels O 0 0.18550359
were O 0 0.0033800676
normal O 0 0.007995193
. O 0 0.0058600246

The O 0 0.003712002
spinal O 0 0.018818086
cords O 0 0.007997235
of O 0 0.001637252
the O 0 0.0009548455
animals O 0 0.0007301608
that O 0 0.0005909081
received O 0 0.0014275741
bupivacaine B-Chemical 1 0.999529
, O 0 0.0015669112
low O 0 0.0011819112
pH O 0 0.1956126
normal O 0 0.0015480313
saline O 0 0.16631651
( O 0 0.001162621
pH O 0 0.091835976
3 O 0 0.0003670039
. O 0 0.00022972892
0 O 0 0.00040990394
) O 0 0.00055298256
, O 0 0.00043692833
or O 0 0.00034104846
normal O 0 0.0010148683
saline O 0 0.029048158
did O 0 0.0007923356
not O 0 0.000931068
show O 0 0.0014032966
abnormal O 0 0.02355824
findings O 0 0.012190591
. O 0 0.0065322923

Procainamide B-Chemical 0 0.99455667
- O 0 0.029857935
induced O 0 0.02259783
polymorphous O 0 0.97741246
ventricular B-Disease 2 0.9945633
tachycardia I-Disease 2 0.997451
. O 0 0.03291083

Seven O 0 0.012296119
cases O 0 0.0070095747
of O 0 0.0068849735
procainamide B-Chemical 1 0.99854714
- O 0 0.013644019
induced O 0 0.007828568
polymorphous O 0 0.98806715
ventricular B-Disease 2 0.99773383
tachycardia I-Disease 2 0.9989901
are O 0 0.010786258
presented O 0 0.010214443
. O 0 0.00923484

In O 0 0.002879209
four O 0 0.0017299834
patients O 0 0.004090301
, O 0 0.002600735
polymorphous O 0 0.93650264
ventricular B-Disease 2 0.9982108
tachycardia I-Disease 2 0.99961984
appeared O 0 0.0015170166
after O 0 0.0003686722
intravenous O 0 0.29817507
administration O 0 0.06726645
of O 0 0.00059346604
200 O 0 0.0009920407
to O 0 0.000316865
400 O 0 0.0015509584
mg O 0 0.15844393
of O 0 0.00080495793
procainamide B-Chemical 1 0.99940574
for O 0 0.00060663774
the O 0 0.0006869752
treatment O 0 0.0021068729
of O 0 0.0022787047
sustained O 0 0.22862093
ventricular B-Disease 2 0.9976394
tachycardia I-Disease 2 0.99901986
. O 0 0.010980085

In O 0 0.0026904754
the O 0 0.0016904024
remaining O 0 0.0012851408
three O 0 0.00080684177
patients O 0 0.002834595
, O 0 0.0018726074
procainamide B-Chemical 1 0.99924004
was O 0 0.0011190376
administered O 0 0.0027287079
orally O 0 0.02652672
for O 0 0.00047881954
treatment O 0 0.0014031054
of O 0 0.0012950659
chronic O 0 0.9745608
premature B-Disease 0 0.7766506
ventricular I-Disease 0 0.9961688
contractions I-Disease 0 0.9896269
or O 0 0.0040341825
atrial B-Disease 0 0.98919404
flutter I-Disease 0 0.987005
. O 0 0.007847924

These O 0 0.0060659396
patients O 0 0.0070841624
had O 0 0.004094855
Q B-Disease 0 0.4580947
- I-Disease 0 0.006084958
T I-Disease 0 0.36866254
prolongation I-Disease 0 0.18777905
and O 0 0.0027781639
recurrent O 0 0.8323205
syncope B-Disease 0 0.99937516
due O 0 0.0023665065
to O 0 0.0036094685
polymorphous O 0 0.98877877
ventricular B-Disease 2 0.9976799
tachycardia I-Disease 2 0.9988674
. O 0 0.015123397

In O 0 0.002845042
four O 0 0.0017003532
patients O 0 0.0036757644
, O 0 0.0020050234
the O 0 0.0014328436
arrhythmia B-Disease 2 0.996881
was O 0 0.0012084807
rapidly O 0 0.002062766
diagnosed O 0 0.014250264
and O 0 0.000737073
treated O 0 0.0010648237
with O 0 0.0008005171
disappearance O 0 0.002917641
of O 0 0.0011503185
further O 0 0.0015578935
episodes O 0 0.15166332
of O 0 0.0034530342
the O 0 0.0054903966
arrhythmia B-Disease 2 0.9965664
. O 0 0.009371862

In O 0 0.003372603
two O 0 0.0022272025
patients O 0 0.004489953
, O 0 0.0026418602
the O 0 0.002065241
arrhythmia B-Disease 2 0.99689376
degenerated O 0 0.05205768
into O 0 0.001261911
irreversible O 0 0.48949564
ventricular B-Disease 0 0.9943546
fibrillation I-Disease 0 0.99929667
and O 0 0.003648971
both O 0 0.0031455066
patients O 0 0.013695267
died O 0 0.08464171
. O 0 0.007593286

In O 0 0.0031627093
the O 0 0.002239786
seventh O 0 0.0045679975
patient O 0 0.0025314423
, O 0 0.0015604256
a O 0 0.001061768
permanent O 0 0.0075235586
ventricular O 0 0.94118047
pacemaker O 0 0.22893201
was O 0 0.00060248503
inserted O 0 0.00038583236
and O 0 0.0004130325
, O 0 0.00045075748
despite O 0 0.00035735028
continuation O 0 0.0030232437
of O 0 0.0011544977
procainamide B-Chemical 1 0.9996927
therapy O 0 0.21759377
, O 0 0.0033618654
polymorphous O 0 0.9915804
ventricular B-Disease 2 0.9988411
tachycardia I-Disease 2 0.9995066
did O 0 0.003543961
not O 0 0.0034595774
reoccur O 0 0.06586059
. O 0 0.006089476

These O 0 0.0040998417
seven O 0 0.0022270067
cases O 0 0.0025880996
demonstrate O 0 0.0011744094
that O 0 0.0013653022
procainamide B-Chemical 1 0.99887794
can O 0 0.0011658353
produce O 0 0.00087966403
an O 0 0.0011613043
acquired O 0 0.004001538
prolonged B-Disease 0 0.055836763
Q I-Disease 0 0.8020062
- I-Disease 0 0.007670424
T I-Disease 0 0.70878845
syndrome I-Disease 0 0.91035825
with O 0 0.005814598
polymorphous O 0 0.99310666
ventricular B-Disease 2 0.99821043
tachycardia I-Disease 2 0.99905604
. O 0 0.013703133

Phenobarbitone B-Chemical 0 0.99855727
- O 0 0.009770081
induced O 0 0.0038447164
enlargement B-Disease 0 0.09264724
of I-Disease 0 0.0018855922
the I-Disease 0 0.001367357
liver I-Disease 0 0.5926578
in O 0 0.00097488496
the O 0 0.0008962208
rat O 0 0.006175989
: O 0 0.001361977
its O 0 0.0013283201
relationship O 0 0.0008022441
to O 0 0.0015899236
carbon B-Chemical 0 0.95827895
tetrachloride I-Chemical 0 0.99969816
- O 0 0.084097706
induced O 0 0.078069516
cirrhosis B-Disease 2 0.9992537
. O 0 0.016519066

The O 0 0.0031645978
yield O 0 0.0035677126
of O 0 0.0029887226
severe O 0 0.3733193
cirrhosis B-Disease 2 0.99961406
of I-Disease 0 0.0034211413
the I-Disease 0 0.0014331915
liver I-Disease 0 0.8660925
( O 0 0.0012460592
defined O 0 0.00045116807
as O 0 0.00033173052
a O 0 0.0004855535
shrunken O 0 0.026367445
finely O 0 0.01226332
nodular O 0 0.96986985
liver O 0 0.91966003
with O 0 0.0020598727
micronodular O 0 0.9990507
histology O 0 0.73235756
, O 0 0.0019455318
ascites B-Disease 0 0.99670744
greater O 0 0.00044875234
than O 0 0.0001872251
30 O 0 0.00022781793
ml O 0 0.001010006
, O 0 0.0003793744
plasma O 0 0.01804766
albumin O 0 0.91764957
less O 0 0.00032892308
than O 0 0.00016200253
2 O 0 0.00022302178
. O 0 0.000125754
2 O 0 0.00020370938
g O 0 0.0006102584
/ O 0 0.0006384921
dl O 0 0.008523496
, O 0 0.00066476146
splenomegaly B-Disease 0 0.9964155
2 O 0 0.00043442668
- O 0 0.0003913331
3 O 0 0.00013499534
times O 0 0.00010464172
normal O 0 0.00039714001
, O 0 0.00029210935
and O 0 0.00030683284
testicular O 0 0.8688526
atrophy B-Disease 2 0.9980617
approximately O 0 0.00041668784
half O 0 0.00016347342
normal O 0 0.0005560759
weight O 0 0.0026379293
) O 0 0.00036938742
after O 0 0.00011189513
12 O 0 0.00015222175
doses O 0 0.002511128
of O 0 0.0004635937
carbon B-Chemical 0 0.9308398
tetrachloride I-Chemical 0 0.99992514
given O 0 0.000665765
intragastrically O 0 0.67288154
in O 0 0.0004006491
the O 0 0.00055311096
phenobarbitone B-Chemical 0 0.999918
- O 0 0.0028475295
primed O 0 0.0006879229
rat O 0 0.0062735784
was O 0 0.00025913576
increased O 0 0.00040187332
from O 0 0.00023838186
25 O 0 0.0003832341
% O 0 0.00021407891
to O 0 0.00015230493
56 O 0 0.00027447115
% O 0 0.00019813319
by O 0 0.0001641842
giving O 0 0.00026165193
the O 0 0.00018325575
initial O 0 0.00025600157
" O 0 0.0003250182
calibrating O 0 0.0004931775
" O 0 0.00040258426
dose O 0 0.0040014433
of O 0 0.0006624536
carbon B-Chemical 0 0.939853
tetrachloride I-Chemical 0 0.99989223
at O 0 0.00047815318
the O 0 0.0004300349
peak O 0 0.0006533434
of O 0 0.00075078884
the O 0 0.0011492136
phenobarbitone B-Chemical 0 0.9998275
- O 0 0.007354687
induced O 0 0.0029826998
enlargement B-Disease 0 0.35812572
of I-Disease 0 0.003383931
the I-Disease 0 0.004452339
liver I-Disease 0 0.8839577
. O 0 0.008127364

At O 0 0.0024896504
this O 0 0.0019472463
point O 0 0.0015195612
it O 0 0.0014801146
was O 0 0.0010448208
assumed O 0 0.0010238942
that O 0 0.00074595533
the O 0 0.0011511002
cytochrome O 0 0.99435693
P450 O 0 0.99907136
/ O 0 0.13258022
CCl4 B-Chemical 0 0.99985385
toxic O 0 0.9715236
state O 0 0.0033581578
was O 0 0.0012662754
both O 0 0.001307081
maximal O 0 0.002456254
and O 0 0.0029744497
stable O 0 0.0060998765
. O 0 0.0062844884

The O 0 0.00272566
optimal O 0 0.0018188582
rat O 0 0.0052140127
size O 0 0.0017315387
to O 0 0.0010680528
begin O 0 0.001639191
phenobarbitone B-Chemical 0 0.9996131
was O 0 0.0009897071
determined O 0 0.00041048016
as O 0 0.0003508374
100 O 0 0.0008426551
g O 0 0.001008934
, O 0 0.00037212152
and O 0 0.0002481603
this O 0 0.00021094197
size O 0 0.00028112266
as O 0 0.0001745901
a O 0 0.0002450277
group O 0 0.0002696339
had O 0 0.00022291548
a O 0 0.00021457407
mean O 0 0.00012695864
maximum O 0 0.00022071155
relative O 0 0.00020978264
liver O 0 0.46794283
weight O 0 0.005492329
increase O 0 0.00036018767
47 O 0 0.000708206
% O 0 0.0003055283
greater O 0 0.0002474673
than O 0 0.0002104859
normal O 0 0.00073590444
rats O 0 0.0013683523
of O 0 0.0008158304
the O 0 0.00091948494
same O 0 0.0010742516
body O 0 0.009108122
weight O 0 0.019163487
. O 0 0.005762404

The O 0 0.0026667248
optimal O 0 0.0015934136
time O 0 0.0013765482
for O 0 0.0011273964
the O 0 0.0010454666
initial O 0 0.0011778442
dose O 0 0.008668065
of O 0 0.0022148718
carbon B-Chemical 0 0.95528024
tetrachloride I-Chemical 0 0.9997174
was O 0 0.0025584262
after O 0 0.0011457283
14 O 0 0.0019502931
days O 0 0.0020827337
on O 0 0.0031038946
phenobarbitone B-Chemical 0 0.99824
. O 0 0.011201054

Triamterene B-Chemical 0 0.9898301
nephrolithiasis B-Disease 2 0.9968051
complicating O 0 0.9383361
dyazide B-Chemical 0 0.926188
therapy O 0 0.4471863
. O 0 0.032457996

A O 0 0.017579362
case O 0 0.003753778
of O 0 0.005418323
triamterene B-Chemical 0 0.9998754
nephrolithiasis B-Disease 2 0.99976104
is O 0 0.0037991737
reported O 0 0.0020184817
in O 0 0.0007248665
a O 0 0.00084122876
man O 0 0.028130308
after O 0 0.00038890383
4 O 0 0.00048628065
years O 0 0.0010509443
of O 0 0.0017738248
hydrochlorothiazide B-Chemical 0 0.99991477
- I-Chemical 0 0.11022591
triamterene I-Chemical 0 0.9999294
therapy O 0 0.5740123
for O 0 0.009599813
hypertension B-Disease 2 0.99845433
. O 0 0.0113508515

The O 0 0.004151557
stone O 0 0.07227003
passed O 0 0.0037863585
spontaneously O 0 0.009886593
and O 0 0.0019215936
was O 0 0.0012923884
found O 0 0.000992973
to O 0 0.0009279188
contain O 0 0.0010020211
a O 0 0.0026781696
triamterene B-Chemical 0 0.99988997
metabolite O 0 0.9901779
admixed O 0 0.47922692
with O 0 0.036507264
uric B-Chemical 0 0.99938
acid I-Chemical 0 0.99307805
salts I-Chemical 0 0.99460125
. O 0 0.015115458

Factors O 0 0.15289667
affecting O 0 0.016239677
triamterene B-Chemical 0 0.99978393
nephrolithiasis B-Disease 2 0.9995116
are O 0 0.0041674864
discussed O 0 0.0019202278
and O 0 0.0017823693
2 O 0 0.0015510973
previously O 0 0.001626189
reported O 0 0.002800834
cases O 0 0.0045307777
are O 0 0.004406455
reviewed O 0 0.011755056
. O 0 0.0080989385

Busulfan B-Chemical 0 0.98843956
- O 0 0.047502592
induced O 0 0.059712444
hemorrhagic B-Disease 2 0.99488115
cystitis I-Disease 0 0.99759126
. O 0 0.047756575

A O 0 0.018598523
case O 0 0.0047493814
of O 0 0.0046690055
a O 0 0.006312677
busulfan B-Chemical 1 0.9980432
- O 0 0.021806922
induced O 0 0.027691312
hemorrhage B-Disease 2 0.9990398
cystitis I-Disease 0 0.9994289
is O 0 0.022056451
reported O 0 0.019916903
. O 0 0.010508747

Spontaneous O 0 0.036563445
resolution O 0 0.019231534
occurred O 0 0.0064160386
following O 0 0.005152691
cessation O 0 0.013558859
of O 0 0.007855524
the O 0 0.00955922
drug O 0 0.52237386
. O 0 0.016119573

The O 0 0.0030077237
similarity O 0 0.0026225334
between O 0 0.0011156715
the O 0 0.0013387002
histologic O 0 0.13161463
appearances O 0 0.008023097
of O 0 0.002529299
busulfan B-Chemical 1 0.9996462
cystitis B-Disease 0 0.999833
and O 0 0.0023318788
both O 0 0.00086999434
radiation O 0 0.3355509
and O 0 0.002090221
cyclophosphamide B-Chemical 1 0.99970526
- O 0 0.010645894
induced O 0 0.0062658694
cystitis B-Disease 0 0.9997559
is O 0 0.0014864992
discussed O 0 0.00092266663
and O 0 0.0011247607
the O 0 0.0013610063
world O 0 0.0050498033
literature O 0 0.007218497
reviewed O 0 0.011356285
. O 0 0.0064720265

In O 0 0.0030013293
view O 0 0.0031148263
of O 0 0.001892777
the O 0 0.0012980977
known O 0 0.0015091952
tendency O 0 0.0016761074
of O 0 0.0014354016
busulfan B-Chemical 1 0.9991831
to O 0 0.0010163235
induce O 0 0.0008024017
cellular O 0 0.026892843
atypia O 0 0.9538835
and O 0 0.0019748432
carcinoma B-Disease 2 0.9992768
in O 0 0.00056858
other O 0 0.00046056858
sites O 0 0.00042959017
, O 0 0.0005173926
periodic O 0 0.0063971044
urinary O 0 0.7768038
cytology O 0 0.02169726
is O 0 0.0005580505
suggested O 0 0.00054934196
in O 0 0.0004918902
patients O 0 0.001497908
on O 0 0.00054385746
long O 0 0.0016407423
- O 0 0.002731011
term O 0 0.0033120366
therapy O 0 0.06365895
. O 0 0.006603517

Variant O 0 0.6325401
ventricular B-Disease 2 0.9885113
tachycardia I-Disease 2 0.9970306
in O 0 0.069603324
desipramine B-Chemical 1 0.9990834
toxicity B-Disease 2 0.9914281
. O 0 0.030081103

We O 0 0.004284976
report O 0 0.005771503
a O 0 0.0029206013
case O 0 0.0023961447
of O 0 0.0029003199
variant O 0 0.0070794914
ventricular B-Disease 2 0.99651414
tachycardia I-Disease 2 0.99925035
induced O 0 0.031847503
by O 0 0.025954578
desipramine B-Chemical 1 0.99970406
toxicity B-Disease 2 0.9956204
. O 0 0.015716348

Unusual O 0 0.068330616
features O 0 0.0054153837
of O 0 0.002599422
the O 0 0.002110681
arrhythmia B-Disease 2 0.9962942
are O 0 0.001349813
repetitive O 0 0.0026011209
group O 0 0.0010591521
beating O 0 0.027218213
, O 0 0.0009020778
progressive O 0 0.12444124
shortening O 0 0.0220401
of O 0 0.00085130724
the O 0 0.00082265906
R O 0 0.9218138
- O 0 0.0029422138
R O 0 0.667475
interval O 0 0.00089518656
, O 0 0.00047554163
progressive O 0 0.07144202
widening O 0 0.0027542305
of O 0 0.00043621418
the O 0 0.00035762583
QRS O 0 0.9306223
complex O 0 0.00046363528
with O 0 0.0004820971
eventual O 0 0.009429469
failure O 0 0.44264972
of O 0 0.001178086
intraventricular O 0 0.9866019
conduction O 0 0.4585039
, O 0 0.0008631969
and O 0 0.00055323774
changes O 0 0.00083042437
in O 0 0.00057297543
direction O 0 0.0013284897
of O 0 0.0015894043
the O 0 0.002446662
QRS O 0 0.96766347
axis O 0 0.04134496
. O 0 0.007159975

Recognition O 0 0.018097378
of O 0 0.00411825
variant O 0 0.00604423
ventricular B-Disease 2 0.99546754
tachycardia I-Disease 2 0.99930346
is O 0 0.0018754087
important O 0 0.00086498726
because O 0 0.0006391655
therapy O 0 0.0061601494
differs O 0 0.000932302
from O 0 0.00092253165
that O 0 0.000962709
of O 0 0.0024997387
classic O 0 0.38714105
ventricular B-Disease 2 0.9973737
tachycardia I-Disease 2 0.99890554
. O 0 0.013243918

Rebound O 0 0.9358793
hypertensive B-Disease 2 0.99157286
after O 0 0.009022573
sodium B-Chemical 1 0.99741334
nitroprusside I-Chemical 1 0.9997143
prevented O 0 0.24494646
by O 0 0.016014565
saralasin B-Chemical 1 0.99812394
in O 0 0.011702779
rats O 0 0.047480162
. O 0 0.012147227

The O 0 0.0029649932
role O 0 0.0018575856
of O 0 0.0023107193
the O 0 0.0022171799
renin O 0 0.99215937
- O 0 0.00912174
- O 0 0.0039078533
angiotensin B-Chemical 1 0.9988444
system O 0 0.0021385336
in O 0 0.0005115063
the O 0 0.00040979264
maintenance O 0 0.0008339022
of O 0 0.0006234273
blood O 0 0.006025386
pressure O 0 0.029830625
during O 0 0.00048593222
halothane B-Chemical 1 0.99882036
anesthesia O 0 0.5959951
and O 0 0.0022794984
sodium B-Chemical 1 0.9996166
nitroprusside I-Chemical 1 0.9999665
( O 0 0.020686261
SNP B-Chemical 1 0.79687065
) O 0 0.005911668
- O 0 0.003240776
induced O 0 0.0048594694
hypotension B-Disease 2 0.9990687
was O 0 0.0041233785
evaluated O 0 0.0047824048
. O 0 0.0060541756

Control O 0 0.009405638
rats O 0 0.0070151757
received O 0 0.0037331227
halothane B-Chemical 1 0.9964882
anesthesia O 0 0.5782323
( O 0 0.0022875678
1 O 0 0.000984421
MAC O 0 0.21369655
) O 0 0.00094608177
for O 0 0.0003116968
one O 0 0.00025150433
hour O 0 0.00032485987
, O 0 0.00037874407
followed O 0 0.0002169768
by O 0 0.0003470932
SNP B-Chemical 1 0.16227588
infusion O 0 0.05064311
, O 0 0.00052363065
40 O 0 0.00042921602
microgram O 0 0.14723994
/ O 0 0.00096828776
kg O 0 0.003674467
/ O 0 0.00063153467
min O 0 0.000414817
, O 0 0.00026633413
for O 0 0.00017487034
30 O 0 0.00022652591
min O 0 0.00039347916
, O 0 0.0003309317
followed O 0 0.00024217949
by O 0 0.00041697617
a O 0 0.0006396073
30 O 0 0.0007078551
- O 0 0.0013634942
min O 0 0.001740267
recovery O 0 0.0033619262
period O 0 0.0035900527
. O 0 0.004855109

A O 0 0.011767264
second O 0 0.0021978018
group O 0 0.0018758873
of O 0 0.0015105954
rats O 0 0.003459752
was O 0 0.0007901961
treated O 0 0.00096464774
identically O 0 0.0006507334
and O 0 0.0006040513
, O 0 0.0005827281
in O 0 0.0002967765
addition O 0 0.00024721614
, O 0 0.00041390184
received O 0 0.00042391403
an O 0 0.0004926703
infusion O 0 0.023335263
of O 0 0.001173418
saralasin B-Chemical 1 0.99977535
( O 0 0.0014770578
a O 0 0.0006502929
competitive O 0 0.012318045
inhibitor O 0 0.1651013
of O 0 0.0037519187
angiotensin B-Chemical 1 0.99973637
II I-Chemical 1 0.4980175
) O 0 0.0024224608
throughout O 0 0.00083591347
the O 0 0.0012912558
experimental O 0 0.0032446247
period O 0 0.0044429684
. O 0 0.0055378927

In O 0 0.0026840193
each O 0 0.0012770843
group O 0 0.0020030246
, O 0 0.0018816342
SNP B-Chemical 1 0.12228812
infusion O 0 0.04772053
resulted O 0 0.0008346956
in O 0 0.0005221268
an O 0 0.00059783057
initial O 0 0.0004730007
decrease O 0 0.00057439186
in O 0 0.0003836718
blood O 0 0.0028945946
pressure O 0 0.013761916
from O 0 0.00042300537
86 O 0 0.0008653722
torr O 0 0.036735903
and O 0 0.0005352655
83 O 0 0.0012610735
torr O 0 0.06578832
, O 0 0.0010813732
respectively O 0 0.0017904593
, O 0 0.0014774841
to O 0 0.001559129
48 O 0 0.003071977
torr O 0 0.103978924
. O 0 0.005230819

During O 0 0.0026516102
the O 0 0.0022578505
SNP B-Chemical 1 0.072452374
infusion O 0 0.025942039
the O 0 0.00097387406
control O 0 0.0006248847
animals O 0 0.00054087106
demonstrated O 0 0.0005778849
a O 0 0.0006219545
progressive O 0 0.09481217
increase B-Disease 0 0.000570618
in I-Disease 0 0.0004210811
blood I-Disease 0 0.0044111162
pressure I-Disease 0 0.020001763
to O 0 0.0003966491
61 O 0 0.00092696975
torr O 0 0.09007892
, O 0 0.000531304
whereas O 0 0.00041762812
the O 0 0.0006818322
saralasin B-Chemical 1 0.99948287
- O 0 0.0024610981
treated O 0 0.0016081394
animals O 0 0.0010371864
showed O 0 0.0015203354
no O 0 0.002153709
change O 0 0.004438246
. O 0 0.005435283

Following O 0 0.0046246382
discontinuation O 0 0.3731652
of O 0 0.0030860165
SNP B-Chemical 1 0.29072753
, O 0 0.0022302258
blood O 0 0.0060632806
pressure O 0 0.023121804
in O 0 0.00054431567
the O 0 0.0004101545
control O 0 0.00034670235
animals O 0 0.0003742233
rebounded O 0 0.0052774125
to O 0 0.00036724014
94 O 0 0.00065422506
torr O 0 0.05990293
, O 0 0.00043748537
as O 0 0.00023773203
compared O 0 0.00020993233
with O 0 0.00047882067
78 O 0 0.0012118777
torr O 0 0.055192277
in O 0 0.00070844666
the O 0 0.0014419504
saralasin B-Chemical 1 0.99903893
- O 0 0.007223833
treated O 0 0.0069683935
rats O 0 0.020156344
. O 0 0.0062954603

This O 0 0.0042533753
study O 0 0.0026690986
indicates O 0 0.0011803107
that O 0 0.0009037231
with O 0 0.0010789334
stable O 0 0.0016282449
halothane B-Chemical 1 0.99825245
anesthesia O 0 0.4931203
, O 0 0.0008615448
the O 0 0.00035957413
partial O 0 0.0007046712
recovery O 0 0.00087649224
of O 0 0.0004936779
blood O 0 0.0050116605
pressure O 0 0.021868605
during O 0 0.00028549967
SNP B-Chemical 1 0.20371366
infusion O 0 0.038582664
and O 0 0.00041256403
the O 0 0.00033331022
post O 0 0.0006133316
- O 0 0.00085913227
SNP B-Chemical 1 0.16595927
rebound O 0 0.2567726
of O 0 0.00090597075
blood O 0 0.012868259
pressure O 0 0.042615715
can O 0 0.0007528731
be O 0 0.0010101234
completely O 0 0.001520289
blocked O 0 0.004358314
by O 0 0.005865914
saralasin B-Chemical 1 0.99807394
. O 0 0.009826259

This O 0 0.0043566176
demonstrates O 0 0.0017862609
the O 0 0.0015094845
participation O 0 0.0019467266
of O 0 0.0015134492
the O 0 0.00152172
renin O 0 0.99433786
- O 0 0.008488573
- O 0 0.003774076
angiotensin B-Chemical 1 0.9990144
system O 0 0.0024231605
in O 0 0.0007187733
antagonizing O 0 0.016431507
the O 0 0.00081911334
combined O 0 0.002890081
hypotensive B-Disease 2 0.9973175
effects O 0 0.0077758622
of O 0 0.005427535
halothane B-Chemical 1 0.9978421
and O 0 0.008784812
SNP B-Chemical 1 0.7264919
. O 0 0.009137693

Clinical O 0 0.5381145
nephrotoxicity B-Disease 0 0.99768555
of O 0 0.04015456
tobramycin B-Chemical 1 0.99405885
and O 0 0.04115127
gentamicin B-Chemical 1 0.99020725
. O 0 0.026466513

A O 0 0.08070097
prospective O 0 0.06032988
study O 0 0.047874134
. O 0 0.044369884

Nearly O 0 0.008310959
3 O 0 0.0029889997
. O 0 0.0016762335
2 O 0 0.0015522054
million O 0 0.002135514
people O 0 0.0021766939
in O 0 0.0010537314
this O 0 0.0012167883
country O 0 0.0028446037
receive O 0 0.0036767984
aminoglycoside B-Chemical 0 0.9885767
antibiotics O 0 0.88993543
annually O 0 0.047812015
. O 0 0.008697937

Gentamicin B-Chemical 0 0.9977552
sulfate I-Chemical 0 0.994575
and O 0 0.009831926
tobramycin B-Chemical 1 0.99898344
sulfate I-Chemical 0 0.99727684
continue O 0 0.0029653683
to O 0 0.0012110006
demonstrate O 0 0.0012881462
ototoxicity B-Disease 0 0.9994332
and O 0 0.006117506
nephrotoxicity B-Disease 0 0.99981254
in O 0 0.0016984523
both O 0 0.0014340543
animal O 0 0.0029895054
and O 0 0.0025738457
clinical O 0 0.018959504
studies O 0 0.008143544
. O 0 0.0067643314

In O 0 0.0027058597
this O 0 0.0018343839
study O 0 0.0020806766
, O 0 0.0014654266
62 O 0 0.0015297804
patients O 0 0.0014190306
with O 0 0.0006254889
confirmed O 0 0.00050837087
initial O 0 0.00050876406
normal O 0 0.0014314558
renal O 0 0.9686891
function O 0 0.0009298349
and O 0 0.00045022718
treated O 0 0.00067713874
with O 0 0.00040702915
2 O 0 0.0002874816
to O 0 0.00021919174
5 O 0 0.00023791323
mg O 0 0.11655152
/ O 0 0.00069924415
kg O 0 0.0023327044
/ O 0 0.0004708432
day O 0 0.00021677335
of O 0 0.0005127821
gentamicin B-Chemical 1 0.9995441
sulfate I-Chemical 0 0.9989706
or O 0 0.0011441115
tobramycin B-Chemical 1 0.99980503
sulfate I-Chemical 0 0.9990914
for O 0 0.00037413463
a O 0 0.00029551555
minimum O 0 0.00014849457
of O 0 0.00021540753
seven O 0 0.0001678959
days O 0 0.00016030841
were O 0 0.00014310326
followed O 0 0.000110624256
up O 0 0.00015038044
prospectively O 0 0.0003429245
for O 0 0.00013555516
the O 0 0.00018181537
development O 0 0.00057222904
of O 0 0.0005808898
aminoglycoside B-Chemical 0 0.996795
- O 0 0.0015127028
related O 0 0.00033196088
renal B-Disease 0 0.9900213
failure I-Disease 0 0.78324485
, O 0 0.00062040956
defined O 0 0.00026101907
as O 0 0.00019231641
at O 0 0.00015887675
least O 0 0.00018981566
a O 0 0.00040278118
one O 0 0.00039026872
- O 0 0.00091819366
third O 0 0.0008509516
reduction O 0 0.0019279381
in O 0 0.001972296
renal O 0 0.9753979
function O 0 0.00956978
. O 0 0.006646377

In O 0 0.0035540385
these O 0 0.0032969303
62 O 0 0.003987463
patients O 0 0.0039343773
, O 0 0.0019599986
no O 0 0.0010275029
other O 0 0.0012557355
causes O 0 0.0026775147
for O 0 0.0018296716
renal B-Disease 0 0.9884715
failure I-Disease 0 0.7920289
could O 0 0.0030464716
be O 0 0.0040454865
identified O 0 0.0049820878
. O 0 0.0070042564

Five O 0 0.0061483076
of O 0 0.003292308
33 O 0 0.003450174
( O 0 0.0020537847
15 O 0 0.0009438738
% O 0 0.0009436026
) O 0 0.0008819695
of O 0 0.00064714503
the O 0 0.0007340592
tobramycin B-Chemical 1 0.9985915
- O 0 0.0017728802
treated O 0 0.00093979435
patients O 0 0.0012949394
and O 0 0.00037830448
16 O 0 0.00033393712
of O 0 0.00037289958
29 O 0 0.00078101136
( O 0 0.00041581152
55 O 0 0.00036628213
. O 0 0.00017272927
2 O 0 0.00026703154
% O 0 0.00032150335
) O 0 0.00040302888
of O 0 0.00040314265
the O 0 0.00062222214
gentamicin B-Chemical 1 0.9977582
- O 0 0.0020100693
treated O 0 0.0018275046
patients O 0 0.0045688823
had O 0 0.0033674524
renal B-Disease 0 0.99169147
failure I-Disease 0 0.9288427
. O 0 0.009047502

Thus O 0 0.0049192975
, O 0 0.0048600184
gentamicin B-Chemical 1 0.9918841
was O 0 0.0019453799
associated O 0 0.0017321324
with O 0 0.001727646
renal B-Disease 0 0.98454076
failure I-Disease 0 0.6560144
more O 0 0.0012717247
than O 0 0.00043621066
three O 0 0.00035191685
times O 0 0.0005038297
as O 0 0.0007766578
often O 0 0.0019668085
as O 0 0.0017635972
was O 0 0.0043821996
tobramycin B-Chemical 1 0.99365556
. O 0 0.00883984

Metabolic O 0 0.6381015
involvement O 0 0.03487402
in O 0 0.02689615
adriamycin B-Chemical 1 0.99559116
cardiotoxicity B-Disease 0 0.997962
. O 0 0.049064003

The O 0 0.0045632557
cardiotoxic B-Disease 2 0.99155605
effects O 0 0.0057720207
of O 0 0.0033449933
adriamycin B-Chemical 1 0.99869543
were O 0 0.0018254971
studied O 0 0.0016317781
in O 0 0.0008808127
mammalian O 0 0.0029758164
myocardial O 0 0.99608696
cells O 0 0.0031054206
in O 0 0.0010456832
culture O 0 0.0024795542
as O 0 0.0011985343
a O 0 0.0022757372
model O 0 0.0039344295
system O 0 0.0074066874
. O 0 0.0067499876

Adriamycin B-Chemical 1 0.99709225
inhibited O 0 0.015832296
cell O 0 0.01628574
growth O 0 0.009317113
and O 0 0.0018852036
the O 0 0.0015085959
rhythmic O 0 0.060326204
contractions O 0 0.82861227
characteristic O 0 0.0038698122
of O 0 0.0038500128
myocardial O 0 0.99601066
cells O 0 0.009674427
in O 0 0.0043017054
culture O 0 0.013151982
. O 0 0.0073375837

A O 0 0.012848631
possible O 0 0.002984487
involvement O 0 0.0031788233
of O 0 0.0018262592
energy O 0 0.011334275
metabolism O 0 0.31984603
was O 0 0.000915101
suggested O 0 0.00073102495
previously O 0 0.0006328753
, O 0 0.0006074474
and O 0 0.0003904103
in O 0 0.00027002027
this O 0 0.000281124
study O 0 0.0004900224
the O 0 0.0003698384
adenylate O 0 0.7436387
energy O 0 0.011008487
charge O 0 0.016691424
and O 0 0.0008538398
phosphorylcreatine B-Chemical 0 0.97459126
mole O 0 0.20646201
fraction O 0 0.00062786153
were O 0 0.00051269314
determined O 0 0.00044175287
in O 0 0.00067796133
the O 0 0.0014170172
adriamycin B-Chemical 1 0.9987876
- O 0 0.009022666
treated O 0 0.006752386
cells O 0 0.009099024
. O 0 0.00615452

The O 0 0.004273038
adenylate O 0 0.571731
energy O 0 0.013762506
charge O 0 0.013162321
was O 0 0.0016946273
found O 0 0.0010828985
to O 0 0.0008815238
be O 0 0.00086630456
significantly O 0 0.0009643386
decreased O 0 0.0016905874
, O 0 0.0011237678
while O 0 0.0007520442
the O 0 0.000990675
phophorylcreatine B-Chemical 0 0.101406954
mole O 0 0.20085196
fraction O 0 0.0028105672
was O 0 0.0035349187
unchanged O 0 0.006397377
. O 0 0.006893456

Such O 0 0.014063712
disparity O 0 0.009102719
suggests O 0 0.0052140923
an O 0 0.008379066
inhibition O 0 0.019600326
of O 0 0.023125982
creatine B-Chemical 1 0.9970392
phosphokinase O 0 0.997497
. O 0 0.033521112

The O 0 0.002948661
addition O 0 0.0018653361
of O 0 0.002570275
1 O 0 0.0023633903
mM O 0 0.31457123
adenosine B-Chemical 1 0.9908791
to O 0 0.0010852008
the O 0 0.0009363837
myocardial O 0 0.99751943
cell O 0 0.03047998
cultures O 0 0.0017111851
markedly O 0 0.0032838692
increases O 0 0.0007266987
the O 0 0.00068491674
ATP B-Chemical 1 0.9829759
concentration O 0 0.0056872605
through O 0 0.0005327557
a O 0 0.0007198952
pathway O 0 0.0013172639
reportedly O 0 0.020248095
leading O 0 0.0022932712
to O 0 0.001190334
a O 0 0.0021288453
compartmentalized O 0 0.021629933
ATP B-Chemical 1 0.97194666
pool O 0 0.0078932885
. O 0 0.007292156

In O 0 0.0036487787
the O 0 0.0032806995
adriamycin B-Chemical 1 0.9977512
- O 0 0.005302599
treated O 0 0.0024718824
cells O 0 0.0020225255
, O 0 0.0008780725
the O 0 0.00042115315
addition O 0 0.00031004066
of O 0 0.00075828226
adenosine B-Chemical 1 0.9950525
increased O 0 0.0023067028
the O 0 0.00064995856
adenylate O 0 0.9376147
charge O 0 0.036550436
and O 0 0.00063831144
, O 0 0.00054275274
concomitant O 0 0.0030204656
with O 0 0.00042947754
this O 0 0.00032820168
inrcease O 0 0.009665359
, O 0 0.00042664446
the O 0 0.0002439433
cells O 0 0.00057964
' O 0 0.00031217263
functional O 0 0.0004770478
integrity O 0 0.00056777487
, O 0 0.0003290021
in O 0 0.00017400527
terms O 0 0.00016087007
of O 0 0.00026442006
percentage O 0 0.00016628626
of O 0 0.00043513998
beating O 0 0.01647903
cells O 0 0.000937994
and O 0 0.0005342387
rate O 0 0.00061448687
of O 0 0.0014367348
contractions O 0 0.88150984
, O 0 0.0028276662
was O 0 0.0025167034
maintained O 0 0.0040550698
. O 0 0.0051694545

Age O 0 0.1792069
- O 0 0.006402938
dependent O 0 0.0027158079
sensitivity O 0 0.0039924756
of O 0 0.002614028
the O 0 0.0023242924
rat O 0 0.010460968
to O 0 0.0036025997
neurotoxic B-Disease 0 0.99368346
effects O 0 0.017199336
of O 0 0.016403802
streptomycin B-Chemical 1 0.9964406
. O 0 0.0125593245

Streptomycin B-Chemical 0 0.9912253
sulfate O 0 0.98950326
( O 0 0.0051845405
300 O 0 0.0061720125
mg O 0 0.4044309
/ O 0 0.0024564387
kg O 0 0.0042987037
s O 0 0.0009022786
. O 0 0.00037968234
c O 0 0.0017244993
. O 0 0.00033720618
) O 0 0.0005935726
was O 0 0.00029078865
injected O 0 0.00025476754
for O 0 0.00021375605
various O 0 0.00051648717
periods O 0 0.00054234
into O 0 0.00030903643
preweanling O 0 0.5867107
rats O 0 0.0019460873
and O 0 0.0005796377
for O 0 0.0005282774
3 O 0 0.00068826426
weeks O 0 0.00095815305
into O 0 0.0012207294
weanling O 0 0.12596305
rats O 0 0.012147044
. O 0 0.0059179263

Beginning O 0 0.008430514
at O 0 0.001835528
8 O 0 0.0013920135
days O 0 0.0009635565
of O 0 0.0010677532
age O 0 0.0017442934
, O 0 0.0010127492
body O 0 0.001967372
movement O 0 0.0015213882
and O 0 0.00075085403
hearing O 0 0.38102925
were O 0 0.000516611
examined O 0 0.00035335287
for O 0 0.00039937792
6 O 0 0.00041010446
and O 0 0.00053539657
up O 0 0.0006338713
to O 0 0.0007693545
17 O 0 0.001542029
weeks O 0 0.0015656062
, O 0 0.0030425435
respectively O 0 0.006351633
. O 0 0.0053063775

Abnormal B-Disease 0 0.11845542
movements I-Disease 0 0.02786848
and O 0 0.0032621624
deafness B-Disease 0 0.99326247
occurred O 0 0.002078189
only O 0 0.0009207539
in O 0 0.00059202424
rats O 0 0.0020324297
treated O 0 0.00073254335
during O 0 0.00026062364
the O 0 0.00030772432
preweaning O 0 0.036431998
period O 0 0.00040130215
; O 0 0.00044894402
within O 0 0.00010736922
this O 0 0.00015933735
period O 0 0.00017758606
the O 0 0.00016441969
greatest O 0 0.00040700255
sensitivities O 0 0.0005217056
for O 0 0.00020025123
these O 0 0.00040827098
abnormalities O 0 0.062469553
occurred O 0 0.00039646216
from O 0 0.00024019979
2 O 0 0.00022058217
to O 0 0.00018573826
11 O 0 0.00028455103
- O 0 0.0003228
17 O 0 0.00024828242
and O 0 0.00016664532
5 O 0 0.00013094985
to O 0 0.00012226969
11 O 0 0.00016050202
days O 0 0.00012825683
of O 0 0.00021224869
age O 0 0.0006012958
, O 0 0.00034245744
respectively O 0 0.0006583795
, O 0 0.00028110578
indicating O 0 0.00016333073
that O 0 0.00016842198
the O 0 0.0002381597
cochlea O 0 0.019746853
is O 0 0.00026567548
more O 0 0.00032323858
sensitive O 0 0.00034703698
to O 0 0.00037300165
streptomycin B-Chemical 1 0.99887055
than O 0 0.00023846644
the O 0 0.00030177357
site O 0 0.0004615423
( O 0 0.0007983852
vestibular O 0 0.580567
or O 0 0.0005466093
central O 0 0.0018393464
) O 0 0.0014491472
responsible O 0 0.0012424168
for O 0 0.0015718275
the O 0 0.00434621
dyskinesias B-Disease 2 0.99839044
. O 0 0.008166527

Late O 0 0.2526684
, O 0 0.030747088
late O 0 0.09834855
doxorubicin B-Chemical 1 0.99400204
cardiotoxicity B-Disease 0 0.9976319
. O 0 0.05266126

Cardiac B-Disease 0 0.9721094
toxicity I-Disease 2 0.9942411
is O 0 0.0030443857
a O 0 0.0018945517
major O 0 0.0019912794
complication O 0 0.12997052
which O 0 0.0015478567
limits O 0 0.0017028514
the O 0 0.000890306
use O 0 0.0013122795
of O 0 0.0022622827
adriamycin B-Chemical 1 0.998425
as O 0 0.0027370604
a O 0 0.0049844002
chemotherapeutic O 0 0.97498816
agent O 0 0.6641395
. O 0 0.009825429

Cardiomyopathy B-Disease 0 0.9799539
is O 0 0.003039119
frequent O 0 0.0034578259
when O 0 0.00084805617
the O 0 0.0007395616
total O 0 0.00065597857
dose O 0 0.0048899604
exceeds O 0 0.0005447133
600 O 0 0.004541858
mg O 0 0.4310768
/ O 0 0.0015411886
m2 O 0 0.015930146
and O 0 0.00041497327
occurs O 0 0.0003390321
within O 0 0.00018689726
one O 0 0.00025413145
to O 0 0.00032978342
six O 0 0.00032549078
months O 0 0.0006480371
after O 0 0.00057113246
cessation O 0 0.004679983
of O 0 0.0032580567
therapy O 0 0.069242135
. O 0 0.006480084

A O 0 0.01598152
patient O 0 0.0042301114
is O 0 0.0020167897
reported O 0 0.0019848144
who O 0 0.0024081601
developed O 0 0.0022532803
progressive O 0 0.5341688
cardiomyopathy B-Disease 2 0.9996357
two O 0 0.00078651647
and O 0 0.0006892238
one O 0 0.00040184692
- O 0 0.00058960903
half O 0 0.00020968348
years O 0 0.00047623998
after O 0 0.00018361851
receiving O 0 0.0011435722
580 O 0 0.012852025
mg O 0 0.38788098
/ O 0 0.0016470326
m2 O 0 0.019890554
which O 0 0.0008832987
apparently O 0 0.0021199882
represents O 0 0.00112526
late O 0 0.006950154
, O 0 0.0041619255
late O 0 0.101186246
cardiotoxicity B-Disease 0 0.9992065
. O 0 0.011640688

Attenuation O 0 0.12246427
of O 0 0.005014356
the O 0 0.0041438206
lithium B-Chemical 1 0.9975533
- O 0 0.010787217
induced O 0 0.0066760955
diabetes B-Disease 2 0.9973603
- I-Disease 0 0.034765527
insipidus I-Disease 0 0.99905545
- I-Disease 0 0.006127434
like I-Disease 0 0.0023888669
syndrome I-Disease 0 0.87295526
by O 0 0.0049170507
amiloride B-Chemical 1 0.99848443
in O 0 0.0063319514
rats O 0 0.039435096
. O 0 0.007773181

The O 0 0.0032058016
effect O 0 0.003006313
of O 0 0.0036927827
amiloride B-Chemical 1 0.99873596
on O 0 0.00210174
lithium B-Chemical 1 0.999079
- O 0 0.010454148
induced O 0 0.0050856196
polydipsia B-Disease 2 0.9997789
and O 0 0.0037762867
polyuria B-Disease 2 0.99926776
and O 0 0.0007526479
on O 0 0.00026553014
the O 0 0.00047346982
lithium B-Chemical 1 0.9990119
concentration O 0 0.007834548
in O 0 0.0003640288
the O 0 0.00036675276
plasma O 0 0.038789175
, O 0 0.00068898586
brain O 0 0.05328635
, O 0 0.0007570321
kidney O 0 0.7522931
, O 0 0.0008202533
thyroid O 0 0.66856873
and O 0 0.0005247869
red O 0 0.001077422
blood O 0 0.004571125
cells O 0 0.00082258857
was O 0 0.0003784537
investigated O 0 0.0004540635
in O 0 0.00052990735
rats O 0 0.003103632
, O 0 0.0014237927
chronically O 0 0.036645
treated O 0 0.0043718214
with O 0 0.0069863433
LiCl B-Chemical 1 0.9932702
. O 0 0.008108517

Amiloride B-Chemical 0 0.9975223
reduced O 0 0.0040576374
the O 0 0.0021715073
drinking O 0 0.38530436
and O 0 0.0017690193
urine O 0 0.139079
volume O 0 0.002655704
of O 0 0.0010534758
rats O 0 0.0034365794
in O 0 0.0005509366
an O 0 0.0009840422
acute O 0 0.8897418
( O 0 0.0009999346
6 O 0 0.00029976407
or O 0 0.00025815997
12 O 0 0.00026059235
h O 0 0.00039427934
) O 0 0.00061995565
and O 0 0.0005144341
a O 0 0.0009810391
subacute O 0 0.9870566
( O 0 0.0018526395
3 O 0 0.0010376578
days O 0 0.0013964841
) O 0 0.0028669417
experiment O 0 0.0027276503
. O 0 0.0049539497

6 O 0 0.0028171756
h O 0 0.0019112924
after O 0 0.0009262974
the O 0 0.0010963974
administration O 0 0.037506357
of O 0 0.002232777
amiloride B-Chemical 1 0.99945575
, O 0 0.002030899
a O 0 0.00078184763
reduction O 0 0.0010751904
was O 0 0.0004265529
observed O 0 0.00028564915
in O 0 0.0003157426
the O 0 0.00043753057
lithium B-Chemical 1 0.99823284
content O 0 0.0008608674
of O 0 0.0007944389
the O 0 0.00080969493
renal O 0 0.99478817
medulla O 0 0.9505372
but O 0 0.00081333256
not O 0 0.0006527847
in O 0 0.000704461
the O 0 0.0010182308
other O 0 0.0018799657
organs O 0 0.022480391
studied O 0 0.0067723547
. O 0 0.0060292315

At O 0 0.002931351
12 O 0 0.0020800054
h O 0 0.001956625
, O 0 0.0017538345
all O 0 0.001034217
the O 0 0.0010853765
tissues O 0 0.002392531
showed O 0 0.0012555837
a O 0 0.0016381183
slight O 0 0.0029833294
increase O 0 0.0023502053
in O 0 0.0038725422
lithium B-Chemical 1 0.9958682
levels O 0 0.010364273
. O 0 0.009225713

After O 0 0.0022501252
3 O 0 0.0015373286
days O 0 0.0010813464
of O 0 0.0011150981
combined O 0 0.0015715177
treatment O 0 0.0025284593
, O 0 0.0011548321
a O 0 0.0008001164
marked O 0 0.001581994
elevation O 0 0.19693974
in O 0 0.0006455551
plasma O 0 0.029633766
and O 0 0.0008145331
tissue O 0 0.028571047
lithium B-Chemical 1 0.99882954
levels O 0 0.0013151078
accompanied O 0 0.0031851667
a O 0 0.0015140582
reduction O 0 0.0028918898
in O 0 0.0022592936
water O 0 0.06805856
intake O 0 0.8088453
. O 0 0.0076598306

In O 0 0.002719133
all O 0 0.0016338846
the O 0 0.0012845014
experiments O 0 0.0010970639
, O 0 0.0012678371
the O 0 0.00074194657
attenuation O 0 0.0018047256
of O 0 0.0010200378
the O 0 0.001050772
lithium B-Chemical 1 0.99933535
- O 0 0.007149278
induced O 0 0.0042027286
diabetes B-Disease 2 0.9988581
- I-Disease 0 0.02057912
insipidus I-Disease 0 0.9996532
- I-Disease 0 0.003378176
like I-Disease 0 0.0006455554
syndrome I-Disease 0 0.882118
by O 0 0.00094575144
amiloride B-Chemical 1 0.99971443
was O 0 0.0006384507
accompanied O 0 0.0014574919
by O 0 0.00033128524
a O 0 0.00031621495
reduction O 0 0.0004941445
of O 0 0.0003118972
the O 0 0.00022846527
ratio O 0 0.00034297744
between O 0 0.00014614951
the O 0 0.0003270401
lithium B-Chemical 1 0.9991122
concentration O 0 0.0070237247
in O 0 0.00032610918
the O 0 0.00040656843
renal O 0 0.99219644
medulla O 0 0.9393794
and O 0 0.0004605036
its O 0 0.0007578947
levels O 0 0.0003313415
in O 0 0.0002766333
the O 0 0.0003285627
blood O 0 0.0030234538
and O 0 0.0005553354
an O 0 0.0009323126
elevation O 0 0.14991388
in O 0 0.0009726835
the O 0 0.001597853
plasma O 0 0.24724968
potassium B-Chemical 0 0.99715143
level O 0 0.006344045
. O 0 0.007094752

It O 0 0.006348883
is O 0 0.0026673235
concluded O 0 0.0030014135
that O 0 0.0017984152
acute O 0 0.9690412
amiloride B-Chemical 1 0.9996178
administration O 0 0.77872354
to O 0 0.0019777683
lithium B-Chemical 1 0.9994367
- O 0 0.0036595266
treated O 0 0.0015007005
patients O 0 0.0049426667
suffering O 0 0.7782687
from O 0 0.0011757519
polydipsia B-Disease 2 0.99983454
and O 0 0.0019959754
polyuria B-Disease 2 0.9993211
might O 0 0.00038047676
relieve O 0 0.024957107
these O 0 0.0006433133
patients O 0 0.0026896463
but O 0 0.00041836055
prolonged O 0 0.054596566
amiloride B-Chemical 1 0.99978894
supplementation O 0 0.978296
would O 0 0.00050528697
result O 0 0.00045814607
in O 0 0.0005703239
elevated O 0 0.023615828
lithium B-Chemical 1 0.99871445
levels O 0 0.0016812161
and O 0 0.0017270057
might O 0 0.0016593529
be O 0 0.0032516208
hazardous O 0 0.16478808
. O 0 0.006592182

Cardiovascular B-Disease 0 0.9816773
complications I-Disease 0 0.8760349
associated O 0 0.008524358
with O 0 0.008529181
terbutaline B-Chemical 1 0.9981939
treatment O 0 0.042636845
for O 0 0.008833158
preterm B-Disease 0 0.9518503
labor I-Disease 0 0.90127265
. O 0 0.016498983

Severe O 0 0.93082297
cardiovascular B-Disease 0 0.990973
complications I-Disease 0 0.9180792
occurred O 0 0.0028244092
in O 0 0.0011189481
eight O 0 0.0008271344
of O 0 0.0012016783
160 O 0 0.0038547814
patients O 0 0.0027376343
treated O 0 0.002451284
with O 0 0.0033795133
terbutaline B-Chemical 1 0.99896157
for O 0 0.006613034
preterm B-Disease 0 0.97198975
labor I-Disease 0 0.9178143
. O 0 0.01099282

Associated O 0 0.066119395
corticosteroid O 0 0.9903837
therapy O 0 0.06877037
and O 0 0.004125812
twin O 0 0.021407742
gestations O 0 0.03841778
appear O 0 0.0035296015
to O 0 0.0030485461
be O 0 0.004323764
predisposing O 0 0.045390602
factors O 0 0.021868024
. O 0 0.010797935

Potential O 0 0.024922494
mechanisms O 0 0.0092940405
of O 0 0.0068858545
the O 0 0.006671809
pathophysiology O 0 0.13403028
are O 0 0.008746562
briefly O 0 0.012011441
discussed O 0 0.011714305
. O 0 0.014036084

Toxic B-Disease 0 0.9934729
hepatitis I-Disease 2 0.99939466
induced O 0 0.0134839285
by O 0 0.0033404185
antithyroid O 0 0.97944117
drugs O 0 0.88518846
: O 0 0.0018346859
four O 0 0.0004832119
cases O 0 0.0010297062
including O 0 0.00058585923
one O 0 0.00045859563
with O 0 0.00080157485
cross O 0 0.001478261
- O 0 0.0017413169
reactivity O 0 0.0036186823
between O 0 0.001410511
carbimazole B-Chemical 0 0.9973501
and O 0 0.009644849
benzylthiouracil B-Chemical 0 0.9819219
. O 0 0.009327608

OBJECTIVE O 0 0.5275019
: O 0 0.0044426266
This O 0 0.0023625854
study O 0 0.001694813
was O 0 0.0009245679
conducted O 0 0.0007021507
to O 0 0.0005851695
assess O 0 0.0003427475
the O 0 0.0005650188
occurrence O 0 0.0014673215
of O 0 0.0015147944
hepatic B-Disease 0 0.9904669
adverse I-Disease 0 0.9208137
effects I-Disease 0 0.017996164
encountered O 0 0.0064263735
with O 0 0.005048265
antithyroid O 0 0.98982847
drugs O 0 0.94759625
. O 0 0.009699588

METHODS O 0 0.0064309877
: O 0 0.0034449613
Retrospective O 0 0.015638994
review O 0 0.0025405004
of O 0 0.001257007
medical O 0 0.0030500381
records O 0 0.0011677913
of O 0 0.00085704966
236 O 0 0.003490549
patients O 0 0.0018258872
with O 0 0.0010708907
hyperthyroidism B-Disease 0 0.99951863
admitted O 0 0.035651665
in O 0 0.00041236935
our O 0 0.00036040635
department O 0 0.0012776696
( O 0 0.00077047234
in O 0 0.00044913878
- O 0 0.00079687004
or O 0 0.00040748707
out O 0 0.00048376166
- O 0 0.0012574669
patients O 0 0.0023118798
) O 0 0.00191991
from O 0 0.0016185889
1986 O 0 0.009927871
to O 0 0.003185158
1992 O 0 0.018057719
. O 0 0.005953744

RESULTS O 0 0.026343694
: O 0 0.0046843654
Four O 0 0.003371848
patients O 0 0.0037600978
( O 0 0.0019482196
1 O 0 0.0009879594
. O 0 0.00050995866
7 O 0 0.00050078146
% O 0 0.00056203
) O 0 0.0006018436
were O 0 0.00034209737
identified O 0 0.00035965125
with O 0 0.00084145274
toxic B-Disease 0 0.99266064
hepatitis I-Disease 2 0.9999236
which O 0 0.004761407
could O 0 0.0005132334
reasonably O 0 0.001122546
be O 0 0.000575744
attributed O 0 0.00057957356
to O 0 0.0005597657
the O 0 0.000750776
use O 0 0.0014960107
of O 0 0.0031718654
antithyroid O 0 0.9864158
agent O 0 0.6352195
. O 0 0.008865823

Two O 0 0.0064251344
patients O 0 0.007006134
had O 0 0.0039742007
a O 0 0.007151983
cholestatic B-Disease 0 0.9997174
hepatitis I-Disease 2 0.99967825
induced O 0 0.054490045
by O 0 0.010563499
carbimazole B-Chemical 0 0.99865735
( O 0 0.03276019
N B-Chemical 0 0.9773433
omercazole I-Chemical 0 0.43323958
) O 0 0.01757
. O 0 0.009880882

Two O 0 0.0062396885
others O 0 0.005895136
had O 0 0.002992014
a O 0 0.0030961358
mixed O 0 0.006863157
( O 0 0.008147825
cholestatic B-Disease 0 0.9994843
and O 0 0.01012717
cytolytic O 0 0.94596195
) O 0 0.06385067
hepatitis B-Disease 2 0.9991192
following O 0 0.05419819
carbimazole B-Chemical 0 0.99722666
. O 0 0.016008973

One O 0 0.004565672
of O 0 0.0026091086
the O 0 0.0016559046
latter O 0 0.0023282885
two O 0 0.00089267467
patients O 0 0.0019230904
further O 0 0.0009934737
experienced O 0 0.0016601472
a O 0 0.0013467098
cytolytic O 0 0.9021318
hepatitis B-Disease 2 0.9997589
which O 0 0.0035792189
appeared O 0 0.0012239196
after O 0 0.0006480563
Benzylthiouracil B-Chemical 0 0.43442774
( O 0 0.0021337892
Basd B-Chemical 0 0.27913502
ne I-Chemical 0 0.6723158
) O 0 0.0034086471
had O 0 0.0025973704
replaced O 0 0.005181018
carbimazole B-Chemical 0 0.9958139
. O 0 0.010146643

Biological O 0 0.046022344
features O 0 0.006696909
of O 0 0.0044786073
hepatitis B-Disease 2 0.9990952
disappeared O 0 0.0077856844
in O 0 0.000984907
all O 0 0.0006085702
cases O 0 0.0009366224
after O 0 0.00031232834
cessation O 0 0.0019395032
of O 0 0.0006020645
the O 0 0.0005530695
incriminated O 0 0.106188074
drug O 0 0.5012594
, O 0 0.0011361333
while O 0 0.00079809205
biliary O 0 0.94602
, O 0 0.0017332804
viral O 0 0.024620622
and O 0 0.0014713864
immunological O 0 0.0510654
searches O 0 0.0029947343
were O 0 0.0025393565
negative O 0 0.004293354
. O 0 0.0058917664

Only O 0 0.005616904
2 O 0 0.0026927947
patients O 0 0.0029987337
of O 0 0.0016613889
our O 0 0.0012665257
retrospective O 0 0.007310172
study O 0 0.002308032
experienced O 0 0.003085776
a O 0 0.0029033828
mild O 0 0.3905234
or O 0 0.0047543673
severe O 0 0.7813931
neutropenia B-Disease 2 0.99702805
. O 0 0.013181424

CONCLUSION O 0 0.94033116
: O 0 0.014609368
Toxic B-Disease 0 0.99478936
hepatitis I-Disease 2 0.99961096
is O 0 0.0028515467
a O 0 0.0013756524
potential O 0 0.0014832611
adverse O 0 0.5145476
effect O 0 0.00090525195
of O 0 0.00094470236
antithyroid O 0 0.9796714
drugs O 0 0.83221465
which O 0 0.0010641398
warrants O 0 0.0010105852
, O 0 0.0004839028
as O 0 0.0002344432
for O 0 0.00030452793
haematological O 0 0.9784546
disturbances O 0 0.7712983
, O 0 0.000666445
a O 0 0.00041627118
pre O 0 0.002039639
- O 0 0.00062575744
therapeutic O 0 0.0036936551
determination O 0 0.0012852215
and O 0 0.0004090068
a O 0 0.00043547465
careful O 0 0.0008259903
follow O 0 0.0006089769
- O 0 0.0010411558
up O 0 0.00068809174
of O 0 0.0011400448
relevant O 0 0.0018338742
biological O 0 0.004738188
markers O 0 0.008800554
. O 0 0.0064039696

Moreover O 0 0.00891987
, O 0 0.008645239
hepatotoxicity B-Disease 2 0.99911636
may O 0 0.0032713371
not O 0 0.0016879322
be O 0 0.0013953714
restricted O 0 0.0010373718
to O 0 0.0011270914
one O 0 0.0011916091
class O 0 0.0034487578
of O 0 0.0050466666
antithyroid O 0 0.98427
agents O 0 0.71125644
. O 0 0.011257213

Interactive O 0 0.025669001
effects O 0 0.0049640303
of O 0 0.0029299825
variations O 0 0.0023187064
in O 0 0.0021884216
[ O 0 0.009158538
Na B-Chemical 1 0.99793845
] O 0 0.0066547217
o O 0 0.0052575716
and O 0 0.001936645
[ O 0 0.0089529455
Ca B-Chemical 1 0.9975885
] O 0 0.005350361
o O 0 0.00389247
on O 0 0.0011500781
rat O 0 0.021333804
atrial O 0 0.96086115
spontaneous O 0 0.090338185
frequency O 0 0.008006516
. O 0 0.007741151

The O 0 0.0027740067
effects O 0 0.0029680268
of O 0 0.0018675099
varying O 0 0.0022902775
the O 0 0.0014542914
extracellular O 0 0.03368708
concentrations O 0 0.008143441
of O 0 0.002998889
Na B-Chemical 1 0.9992415
and O 0 0.0060505355
Ca B-Chemical 1 0.9993376
( O 0 0.0077913664
[ O 0 0.014934228
Na B-Chemical 1 0.9992022
] O 0 0.004862205
o O 0 0.003843862
and O 0 0.0008778011
[ O 0 0.00696903
Ca B-Chemical 1 0.99900264
] O 0 0.003985093
o O 0 0.0033087062
) O 0 0.0006612797
on O 0 0.00017213935
both O 0 0.00028077792
, O 0 0.00036494024
the O 0 0.0002490477
spontaneous O 0 0.0048843953
beating O 0 0.01501857
and O 0 0.00033971542
the O 0 0.0002649576
negative O 0 0.00039751196
chronotropic O 0 0.9631261
action O 0 0.014235355
of O 0 0.0017580847
verapamil B-Chemical 0 0.9998424
, O 0 0.0016320358
were O 0 0.00067248126
studied O 0 0.00094710465
in O 0 0.00073700066
the O 0 0.0011007446
isolated O 0 0.0023360627
rat O 0 0.033680443
atria O 0 0.55140656
. O 0 0.006483968

Basal O 0 0.092519686
frequency O 0 0.0044427635
( O 0 0.003795045
BF O 0 0.08128168
) O 0 0.002117351
evaluated O 0 0.00090235076
by O 0 0.0008625543
surface O 0 0.0023433496
electrogram O 0 0.67351955
was O 0 0.0008901419
223 O 0 0.018454317
+ O 0 0.0008996602
/ O 0 0.0012179438
- O 0 0.00065464235
4 O 0 0.00028705268
beats O 0 0.08916563
/ O 0 0.00079464103
min O 0 0.0004959457
. O 0 0.00016872142
in O 0 0.00021677562
control O 0 0.00034516238
Krebs O 0 0.89832354
- O 0 0.0012887524
Ringer O 0 0.6179517
containing O 0 0.0005885288
137 O 0 0.010678211
mM O 0 0.38150442
Na B-Chemical 1 0.99810386
and O 0 0.0010295524
1 O 0 0.00089303707
. O 0 0.00059617194
35 O 0 0.0016043221
mM O 0 0.31714535
Ca B-Chemical 1 0.9961358
( O 0 0.007982932
N O 0 0.8186417
) O 0 0.01112183
. O 0 0.007014498

It O 0 0.006026209
decreased O 0 0.004110234
by O 0 0.0023233504
16 O 0 0.002070688
+ O 0 0.0018735226
/ O 0 0.0023820638
- O 0 0.001359999
3 O 0 0.000537884
% O 0 0.00057026953
by O 0 0.00052820146
lowering O 0 0.028221171
[ O 0 0.008706346
Na B-Chemical 1 0.9990803
] O 0 0.003329207
o O 0 0.0020269367
to O 0 0.0004706705
78 O 0 0.0016829824
mM O 0 0.21792555
( O 0 0.000861496
LNa O 0 0.73017484
) O 0 0.00079455733
, O 0 0.0004770478
23 O 0 0.00060113217
+ O 0 0.00047233637
/ O 0 0.0008670965
- O 0 0.00051337096
2 O 0 0.00025226583
% O 0 0.00024805267
by O 0 0.00023007856
lowering O 0 0.005859891
simultaneously O 0 0.0007531777
[ O 0 0.0068016956
Na B-Chemical 1 0.9992836
] O 0 0.002757806
o O 0 0.0016959663
to O 0 0.00037304038
78 O 0 0.0013400894
mM O 0 0.13793823
and O 0 0.0005860827
[ O 0 0.0039946376
Ca B-Chemical 1 0.9988223
] O 0 0.0023299118
o O 0 0.0015304215
to O 0 0.00033496218
0 O 0 0.00041752306
. O 0 0.00022528657
675 O 0 0.013382337
mM O 0 0.1743257
( O 0 0.0007616909
LNa O 0 0.757377
+ O 0 0.00082640216
LCa O 0 0.98808485
) O 0 0.0008713047
and O 0 0.00039171643
31 O 0 0.0006314926
+ O 0 0.0004803224
/ O 0 0.00089163426
- O 0 0.00050792575
5 O 0 0.00021791561
% O 0 0.00025793805
by O 0 0.00027438274
lowering O 0 0.024644718
[ O 0 0.007014199
Na B-Chemical 1 0.9992797
] O 0 0.0026909115
o O 0 0.0016526992
to O 0 0.00036416922
78 O 0 0.0011752022
mM O 0 0.075620115
plus O 0 0.00039541005
increasing O 0 0.001190072
[ O 0 0.009088193
Ca B-Chemical 1 0.9988985
] O 0 0.0030985756
o O 0 0.0019115637
to O 0 0.00050643727
3 O 0 0.0005101043
. O 0 0.00040911717
6 O 0 0.00067569857
mM O 0 0.07059913
( O 0 0.0021827186
LNa O 0 0.7003041
+ O 0 0.004795201
HCa O 0 0.97825706
) O 0 0.009008982
. O 0 0.006248989

At O 0 0.0035928392
normal O 0 0.006435828
[ O 0 0.01090283
Na B-Chemical 1 0.9966864
] O 0 0.0069870646
o O 0 0.005066467
, O 0 0.0014675277
decrease O 0 0.0011637909
( O 0 0.0010290763
0 O 0 0.00064710365
. O 0 0.00034194675
675 O 0 0.010564655
mM O 0 0.12605135
) O 0 0.0006797308
or O 0 0.0002819733
increase O 0 0.00037229928
( O 0 0.0005084901
3 O 0 0.00027040413
. O 0 0.00018314045
6 O 0 0.0002539854
mM O 0 0.047903292
) O 0 0.0005225515
of O 0 0.00055542646
[ O 0 0.0047542593
Ca B-Chemical 1 0.999042
] O 0 0.0027901067
o O 0 0.0016956733
did O 0 0.00026976035
not O 0 0.00022794263
modify O 0 0.0004395191
BF O 0 0.18517837
; O 0 0.0006223942
a O 0 0.00027576849
reduction O 0 0.0004030062
of O 0 0.00027210842
ten O 0 0.00017795846
times O 0 0.0001941891
( O 0 0.00039710916
0 O 0 0.00029818923
. O 0 0.0001606904
135 O 0 0.0011340431
mM O 0 0.031106068
of O 0 0.00039515572
normal O 0 0.0016781313
[ O 0 0.004806061
Ca B-Chemical 1 0.99891293
] O 0 0.002581136
o O 0 0.0017263931
was O 0 0.00037823457
effective O 0 0.000555553
to O 0 0.0003904239
reduce O 0 0.0005003955
BF O 0 0.08513465
by O 0 0.0008814805
40 O 0 0.0013092277
+ O 0 0.0016517965
/ O 0 0.00338277
- O 0 0.0032279172
13 O 0 0.0032747204
% O 0 0.0041358573
. O 0 0.004555599

All O 0 0.007859517
negative O 0 0.007036803
chronotropic O 0 0.8697313
effects O 0 0.0122471675
were O 0 0.008387522
BF O 0 0.2365858
- O 0 0.015142982
dependent O 0 0.011414985
. O 0 0.0141330995

Dose O 0 0.48411962
- O 0 0.007610777
dependent O 0 0.0038272317
bradycardia B-Disease 0 0.9962781
induced O 0 0.0047134715
by O 0 0.0033073572
verapamil B-Chemical 0 0.9995938
was O 0 0.0036545072
potentiated O 0 0.3693596
by O 0 0.0034485923
LNa O 0 0.9320951
, O 0 0.0056703254
LCa O 0 0.9857954
, O 0 0.005948841
and O 0 0.006895565
HCa O 0 0.97704744
. O 0 0.009116824

Independent O 0 0.012579155
but O 0 0.0027174782
not O 0 0.0015585589
additive O 0 0.003313808
effects O 0 0.0026682431
of O 0 0.0027032823
Na B-Chemical 1 0.99901724
and O 0 0.003677352
Ca B-Chemical 1 0.9988966
are O 0 0.00089745654
shown O 0 0.0003707487
by O 0 0.00037773006
decreases O 0 0.00048891647
in O 0 0.00027769743
the O 0 0.00026754403
values O 0 0.00032043233
of O 0 0.00067341956
[ O 0 0.0074164597
verapamil B-Chemical 0 0.999864
] O 0 0.004726576
o O 0 0.0015757071
needed O 0 0.00019015533
to O 0 0.00022945246
reduce O 0 0.0002573836
BF O 0 0.08425965
by O 0 0.00034406045
30 O 0 0.0002993765
% O 0 0.00038177546
( O 0 0.0005758001
IC30 O 0 0.99831164
) O 0 0.00067082373
with O 0 0.00030486664
the O 0 0.00021711442
following O 0 0.00024692662
order O 0 0.00018042805
of O 0 0.00044012224
inhibitory O 0 0.03994397
potency O 0 0.34567615
: O 0 0.0032757027
LNa O 0 0.9384914
> O 0 0.0048036645
LCa O 0 0.99381244
> O 0 0.0056164325
HCa O 0 0.99103945
> O 0 0.0029016412
N O 0 0.610408
, O 0 0.0011658497
resulting O 0 0.0013709213
LNa O 0 0.8630751
+ O 0 0.0027677352
HCa O 0 0.965153
similar O 0 0.0019142167
to O 0 0.0037468032
LNa O 0 0.733114
. O 0 0.006727665

The O 0 0.005378317
[ O 0 0.011880939
verapamil B-Chemical 0 0.9990545
] O 0 0.010339227
o O 0 0.0047810865
that O 0 0.0010816039
arrested O 0 0.015969332
atrial O 0 0.9704094
beating O 0 0.21337803
( O 0 0.0020090023
AC O 0 0.7236097
) O 0 0.0014002555
was O 0 0.00045406912
also O 0 0.00049190706
potentiated O 0 0.056398384
with O 0 0.0005938086
the O 0 0.00042952073
order O 0 0.0004271655
LNa O 0 0.8287357
= O 0 0.0016919313
LNa O 0 0.7844191
+ O 0 0.0014714894
LCa O 0 0.99128294
= O 0 0.0029039541
LNa O 0 0.8088855
+ O 0 0.0022189463
HCa O 0 0.98921555
= O 0 0.0048604314
LCa O 0 0.9873053
> O 0 0.012937044
HCa O 0 0.9831004
= O 0 0.009109211
N O 0 0.6113247
. O 0 0.00805627

The O 0 0.0026782867
results O 0 0.0018044449
indicate O 0 0.0012292981
that O 0 0.0011949718
rat O 0 0.008152075
atrial O 0 0.93252945
spontaneous O 0 0.041439857
beating O 0 0.055532504
is O 0 0.00069751474
more O 0 0.00068175554
dependent O 0 0.00050600513
on O 0 0.00042980397
[ O 0 0.005922175
Na B-Chemical 1 0.99916196
] O 0 0.0035438132
o O 0 0.0020884254
than O 0 0.0002932037
on O 0 0.00031367742
[ O 0 0.0035552497
Ca B-Chemical 1 0.9987595
] O 0 0.0025078312
o O 0 0.0016372132
in O 0 0.00031972924
a O 0 0.0003996163
range O 0 0.0006042364
of O 0 0.0006834698
+ O 0 0.0009543906
/ O 0 0.0016399979
- O 0 0.001037957
50 O 0 0.000919365
% O 0 0.00074061466
of O 0 0.0009769906
their O 0 0.0015890502
normal O 0 0.0045293584
concentration O 0 0.011199195
. O 0 0.006045634

Also O 0 0.0053059957
the O 0 0.0024827656
enhancement O 0 0.004213759
of O 0 0.0028464508
verapamil B-Chemical 0 0.99949384
effects O 0 0.008320263
on O 0 0.00079892634
atrial O 0 0.9527652
beating O 0 0.07561918
was O 0 0.0006765704
more O 0 0.00070327136
pronounced O 0 0.0010379634
at O 0 0.00044806546
LNa O 0 0.44021562
than O 0 0.0004919434
at O 0 0.00072881574
LCa O 0 0.9649122
. O 0 0.001190216
( O 0 0.0025549834
ABSTRACT O 0 0.014792272
TRUNCATED O 0 0.023124643
AT O 0 0.024433555
250 O 0 0.011885489
WORDS O 0 0.020954205
) O 0 0.022078976

Pseudo O 0 0.6584687
- O 0 0.019689793
allergic B-Disease 0 0.9926846
reactions I-Disease 0 0.24443305
to O 0 0.006210871
corticosteroids B-Chemical 1 0.99600464
: O 0 0.011762202
diagnosis O 0 0.026216295
and O 0 0.0070136846
alternatives O 0 0.013195177
. O 0 0.010366068

Two O 0 0.005423933
patients O 0 0.005727794
treated O 0 0.0038845616
with O 0 0.0031132025
parenteral O 0 0.9478546
paramethasone B-Chemical 1 0.9991653
( O 0 0.008672253
Triniol O 0 0.08786182
) O 0 0.0030387493
and O 0 0.002343848
dexamethasone B-Chemical 0 0.99764925
( O 0 0.005563355
Sedionbel O 0 0.05313373
) O 0 0.0044879313
are O 0 0.0034322499
described O 0 0.0045158956
. O 0 0.006687413

A O 0 0.010202317
few O 0 0.0017763915
minutes O 0 0.0015029343
after O 0 0.00083436084
administration O 0 0.010386442
of O 0 0.0011370308
the O 0 0.00088722224
drugs O 0 0.4901464
, O 0 0.0010454701
they O 0 0.0005431375
presented O 0 0.0010673205
urticaria B-Disease 2 0.9994892
( O 0 0.0019677212
patients O 0 0.0022881276
1 O 0 0.0005516112
and O 0 0.00053276424
2 O 0 0.0006277188
) O 0 0.0010910358
and O 0 0.0012712796
conjunctivitis B-Disease 0 0.99705064
( O 0 0.0032256641
patient O 0 0.0038038143
1 O 0 0.0033573185
) O 0 0.0058570867
. O 0 0.0049929423

The O 0 0.0024619575
purpose O 0 0.001868359
of O 0 0.001376041
our O 0 0.00092426623
study O 0 0.0012392404
was O 0 0.00064883096
to O 0 0.00046411855
determine O 0 0.00024239456
the O 0 0.0003940383
cause O 0 0.0010071013
of O 0 0.00054142275
the O 0 0.00041440417
patients O 0 0.001643501
' O 0 0.0005114543
reactions O 0 0.003914892
, O 0 0.00044285183
the O 0 0.0002578827
immunological O 0 0.013685822
mechanisms O 0 0.0007589021
involved O 0 0.0002992912
and O 0 0.00029292316
whether O 0 0.00013864764
these O 0 0.00038701855
patients O 0 0.0011068005
would O 0 0.00031026395
be O 0 0.0003948789
able O 0 0.000285014
to O 0 0.00047694985
tolerate O 0 0.0017143813
any O 0 0.00097265834
kind O 0 0.0029383053
of O 0 0.00509321
corticoid O 0 0.99158525
. O 0 0.009096149

Clinical O 0 0.04197381
examinations O 0 0.006802214
and O 0 0.0029217615
skin O 0 0.013539508
, O 0 0.0024096235
oral O 0 0.09711358
and O 0 0.0014671986
parenteral O 0 0.55429643
challenges O 0 0.0019420376
with O 0 0.0011882144
different O 0 0.0014158653
corticosteroids B-Chemical 1 0.9969206
and O 0 0.0031278413
ELISA O 0 0.15078501
tests O 0 0.005153395
were O 0 0.003396304
performed O 0 0.0047433088
. O 0 0.0068991585

In O 0 0.0029404855
the O 0 0.0019368283
two O 0 0.0013930273
patients O 0 0.0031707124
, O 0 0.0017824236
skin O 0 0.008003975
and O 0 0.001147489
ELISA O 0 0.048561458
tests O 0 0.0019204646
with O 0 0.001275362
paramethasone B-Chemical 1 0.9988763
were O 0 0.00081029773
negative O 0 0.0006212255
, O 0 0.00064273877
as O 0 0.0003473953
was O 0 0.00041443718
the O 0 0.00044327803
prick O 0 0.0034017214
test O 0 0.00074565894
with O 0 0.0009477581
each O 0 0.0007548713
of O 0 0.002497248
its O 0 0.0089040585
excipients O 0 0.9806302
. O 0 0.009061859

A O 0 0.016135946
single O 0 0.0035126647
- O 0 0.0034315274
blind O 0 0.0049076313
parenteral O 0 0.5236249
challenge O 0 0.0016516203
with O 0 0.0011009298
Triniol O 0 0.014462293
was O 0 0.0004903325
positive O 0 0.00038304177
in O 0 0.00032056923
both O 0 0.00032370797
patients O 0 0.00078248413
after O 0 0.00018291918
the O 0 0.00028254112
administration O 0 0.02130612
of O 0 0.000503673
1 O 0 0.0004108307
ml O 0 0.000982329
of O 0 0.0004354628
the O 0 0.00047774383
drug O 0 0.16845642
, O 0 0.0009959205
and O 0 0.0008241597
negative O 0 0.0011474512
with O 0 0.002316993
its O 0 0.008713176
excipients O 0 0.9820379
. O 0 0.008154219

We O 0 0.003166244
also O 0 0.002174606
carried O 0 0.0013433874
out O 0 0.001174042
oral O 0 0.047683854
and O 0 0.001417576
parenteral O 0 0.54206836
challenges O 0 0.0018659027
with O 0 0.0010767084
other O 0 0.0011512976
corticosteroids B-Chemical 1 0.99766266
and O 0 0.0018020157
found O 0 0.00150989
intolerance O 0 0.83724916
to O 0 0.0016679028
some O 0 0.0024350546
of O 0 0.0039062018
them O 0 0.008060485
. O 0 0.0066127167

These O 0 0.005618342
results O 0 0.0031520834
suggest O 0 0.0025572071
that O 0 0.0033297052
paramethasone B-Chemical 1 0.99690515
caused O 0 0.010990026
pseudoallergic O 0 0.98375005
reactions O 0 0.060615186
in O 0 0.0037095097
our O 0 0.0044313953
patients O 0 0.014838597
. O 0 0.008854584

Corticosteroids O 0 0.96266896
different O 0 0.0035952728
from O 0 0.0028888665
paramethasone B-Chemical 1 0.997349
also O 0 0.0024170764
produced O 0 0.0017529982
hypersensitivity B-Disease 2 0.8011476
reactions O 0 0.016978672
in O 0 0.0006649756
these O 0 0.00097069435
patients O 0 0.0035585433
; O 0 0.0013321615
however O 0 0.0009259559
, O 0 0.00082146644
a O 0 0.000716361
few O 0 0.00062824134
of O 0 0.0014130379
them O 0 0.002906352
were O 0 0.0031125192
tolerated O 0 0.03533738
. O 0 0.006275883

The O 0 0.004227748
basic O 0 0.004769149
mechanisms O 0 0.004294606
of O 0 0.0032865545
those O 0 0.0035707995
reactions O 0 0.0075918916
are O 0 0.002857303
not O 0 0.0027518715
yet O 0 0.0045064306
fully O 0 0.0043819477
understood O 0 0.009698882
. O 0 0.008580442

To O 0 0.002807326
our O 0 0.002023962
knowledge O 0 0.002584331
, O 0 0.0018308113
this O 0 0.0010481396
is O 0 0.00086675695
the O 0 0.00068473717
first O 0 0.0006269021
report O 0 0.0018737031
of O 0 0.0012270438
a O 0 0.0016537681
pseudo O 0 0.038195737
- O 0 0.0068681897
allergy B-Disease 0 0.9748823
caused O 0 0.007390551
by O 0 0.00995527
paramethasone B-Chemical 1 0.99722594
. O 0 0.012314854

Study O 0 0.01360479
of O 0 0.0034973074
the O 0 0.0022469
role O 0 0.0017080876
of O 0 0.003956061
vitamin B-Chemical 0 0.9993892
B12 I-Chemical 0 0.99975055
and O 0 0.03686296
folinic B-Chemical 0 0.9998505
acid I-Chemical 0 0.9973315
supplementation O 0 0.9884465
in O 0 0.002883786
preventing O 0 0.040746074
hematologic O 0 0.99840987
toxicity B-Disease 2 0.998454
of O 0 0.05667101
zidovudine B-Chemical 1 0.9927205
. O 0 0.0113024255

A O 0 0.0135591375
prospective O 0 0.0061822846
, O 0 0.0021550995
randomized O 0 0.001676055
study O 0 0.0012699269
was O 0 0.000667931
conducted O 0 0.0005066381
to O 0 0.00042126878
evaluate O 0 0.00028453936
the O 0 0.0004003072
role O 0 0.00039543325
of O 0 0.0015196603
vitamin B-Chemical 0 0.99978095
B12 I-Chemical 0 0.9999083
and O 0 0.020117283
folinic B-Chemical 0 0.9999356
acid I-Chemical 0 0.9983729
supplementation O 0 0.98932683
in O 0 0.0011715607
preventing O 0 0.013074341
zidovudine B-Chemical 1 0.99712926
( O 0 0.016634388
ZDV B-Chemical 0 0.9992459
) O 0 0.0063573807
- O 0 0.0032374444
induced O 0 0.0035346989
bone B-Disease 0 0.45732874
marrow I-Disease 0 0.9187184
suppression I-Disease 0 0.3208879
. O 0 0.008049851

Seventy O 0 0.017335387
- O 0 0.004815163
five O 0 0.0017307334
human B-Disease 0 0.0069393516
immunodeficiency I-Disease 0 0.99675494
virus I-Disease 0 0.58273244
( I-Disease 0 0.005302046
HIV I-Disease 0 0.7937101
) I-Disease 0 0.0029208323
- I-Disease 0 0.0011413883
infected I-Disease 0 0.00053696975
patients O 0 0.001382091
with O 0 0.0007191014
CD4 O 0 0.28671536
+ O 0 0.00072638015
cell O 0 0.0025319573
counts O 0 0.00038792577
< O 0 0.00036355542
500 O 0 0.0007565633
/ O 0 0.00049962767
mm3 O 0 0.00084284233
were O 0 0.00016252892
randomized O 0 0.00027106417
to O 0 0.0001677119
receive O 0 0.00029046508
either O 0 0.00037131764
ZDV B-Chemical 0 0.99904495
( O 0 0.0006734
500 O 0 0.0019171342
mg O 0 0.26653334
daily O 0 0.0017859259
) O 0 0.0005690213
alone O 0 0.00038330271
( O 0 0.00041483404
group O 0 0.00039035783
I O 0 0.0014217603
, O 0 0.00037491173
n O 0 0.00024195609
= O 0 0.00038260926
38 O 0 0.00040368777
) O 0 0.00034355224
or O 0 0.00016758098
in O 0 0.00019153811
combination O 0 0.00089408003
with O 0 0.0012803924
folinic B-Chemical 0 0.9999323
acid I-Chemical 0 0.99717134
( O 0 0.001351517
15 O 0 0.00031680003
mg O 0 0.19009513
daily O 0 0.0015603558
) O 0 0.00062520837
and O 0 0.00043094796
intramascular O 0 0.68848085
vitamin B-Chemical 0 0.9998179
B12 I-Chemical 0 0.99990594
( O 0 0.0017396673
1000 O 0 0.0013585944
micrograms O 0 0.11759378
monthly O 0 0.00078256766
) O 0 0.001070333
( O 0 0.0007969931
group O 0 0.0009321429
II O 0 0.005578539
, O 0 0.001462401
n O 0 0.0013939291
= O 0 0.0027396427
37 O 0 0.003630373
) O 0 0.0057164137
. O 0 0.0052289036

Finally O 0 0.0040974244
, O 0 0.002671504
15 O 0 0.0012295194
patients O 0 0.0017462838
were O 0 0.0007275021
excluded O 0 0.00072285393
from O 0 0.0004872263
the O 0 0.00045636247
study O 0 0.0008960206
( O 0 0.00083494146
noncompliance O 0 0.24235973
14 O 0 0.0007313406
, O 0 0.0008588293
death B-Disease 2 0.9777646
1 O 0 0.0006453524
) O 0 0.00075630134
; O 0 0.0005338231
thus O 0 0.00037958988
, O 0 0.00032981925
60 O 0 0.0003022504
patients O 0 0.00071673695
( O 0 0.00039116712
31 O 0 0.00037002255
in O 0 0.00020899961
group O 0 0.00039849943
I O 0 0.0010616265
and O 0 0.00040406684
29 O 0 0.0007583787
in O 0 0.00037426595
group O 0 0.00079374155
II O 0 0.005067123
) O 0 0.0013559884
were O 0 0.00092672335
eligible O 0 0.0016540296
for O 0 0.001749169
analysis O 0 0.005334626
. O 0 0.005819446

No O 0 0.008086678
significant O 0 0.004370581
differences O 0 0.002362934
between O 0 0.002038373
groups O 0 0.0033604824
were O 0 0.0034342252
found O 0 0.0039016695
at O 0 0.0044328137
enrollment O 0 0.015597463
. O 0 0.010905156

During O 0 0.0028466985
the O 0 0.00240077
study O 0 0.0033159505
, O 0 0.0037979505
vitamin B-Chemical 0 0.99913293
B12 I-Chemical 0 0.9997224
and O 0 0.004761148
folate B-Chemical 0 0.9981394
levels O 0 0.0010396279
were O 0 0.0005493294
significantly O 0 0.0005350915
higher O 0 0.00037529418
in O 0 0.0003154008
group O 0 0.0005554408
II O 0 0.007724058
patients O 0 0.0028093006
; O 0 0.00076419476
however O 0 0.00046913145
, O 0 0.0003418698
no O 0 0.00017830955
differences O 0 0.00017775412
in O 0 0.00027898687
hemoglobin O 0 0.78211784
, O 0 0.00074971357
hematocrit O 0 0.6742766
, O 0 0.0004819703
mean O 0 0.00025300749
corpuscular O 0 0.9915815
volume O 0 0.005351613
, O 0 0.00064480456
and O 0 0.00044078229
white O 0 0.0025724948
- O 0 0.00081678835
cell O 0 0.004355133
, O 0 0.00065002334
neutrophil O 0 0.148678
and O 0 0.00052294135
platelet O 0 0.6557158
counts O 0 0.00040338928
were O 0 0.00027277338
observed O 0 0.00019552736
between O 0 0.00016200147
groups O 0 0.00036408397
at O 0 0.00025986444
3 O 0 0.00039920473
, O 0 0.00059264334
6 O 0 0.0004567341
, O 0 0.00078686286
9 O 0 0.00082443294
and O 0 0.0011090218
12 O 0 0.0014976691
months O 0 0.002986585
. O 0 0.0040014996

Severe O 0 0.9605171
hematologic O 0 0.99628973
toxicity B-Disease 2 0.9981896
( O 0 0.008442481
neutrophil O 0 0.30444843
count O 0 0.0032855177
< O 0 0.0010834056
1000 O 0 0.0012248193
/ O 0 0.0012105036
mm3 O 0 0.0022731407
and O 0 0.00051165035
/ O 0 0.000912469
or O 0 0.00037228724
hemoglobin O 0 0.5889109
< O 0 0.00054553186
8 O 0 0.0003079209
g O 0 0.00080367114
/ O 0 0.0007622474
dl O 0 0.005639627
) O 0 0.0005299387
occurred O 0 0.00032828428
in O 0 0.00022284662
4 O 0 0.0002239946
patients O 0 0.0005513647
assigned O 0 0.00027868807
to O 0 0.0003357231
group O 0 0.000645624
I O 0 0.0016703462
and O 0 0.0007101947
7 O 0 0.0006893454
assigned O 0 0.0008575987
to O 0 0.0014380737
group O 0 0.0035711979
II O 0 0.022711003
. O 0 0.0062315897

There O 0 0.0061137695
was O 0 0.0027747669
no O 0 0.0017142072
correlation O 0 0.0014742545
between O 0 0.0018165358
vitamin B-Chemical 0 0.99880815
B12 I-Chemical 0 0.99952614
or O 0 0.005132246
folate B-Chemical 0 0.9965082
levels O 0 0.003412474
and O 0 0.0034052539
development O 0 0.0086843185
of O 0 0.0134925
myelosuppression B-Disease 0 0.9983706
. O 0 0.013875779

Vitamin B-Chemical 0 0.99904364
B12 I-Chemical 0 0.99920374
and O 0 0.026612425
folinic B-Chemical 0 0.99970067
acid I-Chemical 0 0.9960498
supplementation O 0 0.983814
of O 0 0.008509227
ZDV B-Chemical 0 0.9993319
therapy O 0 0.12920727
does O 0 0.00060389814
not O 0 0.00041132251
seem O 0 0.00048963825
useful O 0 0.00047826624
in O 0 0.00028733473
preventing O 0 0.00087531045
or O 0 0.00036965302
reducing O 0 0.0016569353
ZDV B-Chemical 0 0.99964
- O 0 0.0041491548
induced O 0 0.003035416
myelotoxicity B-Disease 0 0.99983454
in O 0 0.00039962298
the O 0 0.00026673437
overall O 0 0.0003351973
treated O 0 0.0006678527
population O 0 0.000638101
, O 0 0.00039046965
although O 0 0.00024988592
a O 0 0.00030741343
beneficial O 0 0.0011049575
effect O 0 0.00045788535
in O 0 0.00036277922
certain O 0 0.0009269883
subgroups O 0 0.0013987495
of O 0 0.0011932543
patients O 0 0.004747403
cannot O 0 0.008157321
be O 0 0.0028850778
excluded O 0 0.005161302
. O 0 0.0056189043

Safety O 0 0.05233564
and O 0 0.010907106
side O 0 0.033072844
- O 0 0.012997591
effects O 0 0.0138573395
of O 0 0.022555439
alprazolam B-Chemical 1 0.99827933
. O 0 0.025078464

Controlled O 0 0.018155264
study O 0 0.012296593
in O 0 0.012352378
agoraphobia B-Disease 2 0.9961457
with O 0 0.042876717
panic B-Disease 0 0.9948066
disorder I-Disease 0 0.97261673
. O 0 0.025817072

BACKGROUND O 0 0.6950519
: O 0 0.0047937473
The O 0 0.0017418823
widespread O 0 0.0031020893
use O 0 0.0018420052
of O 0 0.0022433996
benzodiazepines B-Chemical 1 0.9987872
has O 0 0.0017506225
led O 0 0.0016449866
to O 0 0.0009883972
increasing O 0 0.0016825573
recognition O 0 0.002668256
of O 0 0.0024290332
their O 0 0.0032683115
unwanted O 0 0.08309599
effects O 0 0.01531888
. O 0 0.0080602

The O 0 0.003001499
efficacy O 0 0.0055189175
of O 0 0.0034546196
alprazolam B-Chemical 1 0.99962246
and O 0 0.0025804574
placebo O 0 0.31130844
in O 0 0.0013278661
panic B-Disease 0 0.99905485
disorder I-Disease 0 0.9749448
with O 0 0.007494511
agoraphobia B-Disease 2 0.9998524
, O 0 0.0014794072
and O 0 0.0005271683
the O 0 0.0004226124
side O 0 0.01616962
- O 0 0.000779814
effect O 0 0.000434789
and O 0 0.00046566848
adverse O 0 0.38385627
effect O 0 0.0006003652
profiles O 0 0.00052792905
of O 0 0.0008149528
both O 0 0.00100675
drug O 0 0.23983027
groups O 0 0.0022093703
were O 0 0.00236607
measured O 0 0.0030530307
. O 0 0.005160419

METHOD O 0 0.04133751
: O 0 0.004701189
In O 0 0.002051289
London O 0 0.006075495
and O 0 0.0015991841
Toronto O 0 0.0071703745
154 O 0 0.0045319777
patients O 0 0.0019321386
who O 0 0.001681698
met O 0 0.0013192967
DSM O 0 0.06701904
- O 0 0.0012548752
III O 0 0.003859809
criteria O 0 0.00092912646
for O 0 0.000654216
panic B-Disease 0 0.9988427
disorder I-Disease 0 0.95052785
with O 0 0.004033585
agoraphobia B-Disease 2 0.9996953
were O 0 0.0011856355
randomised O 0 0.002262192
to O 0 0.0019294396
alprazolam B-Chemical 1 0.9995326
or O 0 0.0042420207
placebo O 0 0.46872342
. O 0 0.0064329496

Subjects O 0 0.007132063
in O 0 0.002480103
each O 0 0.0014947461
drug O 0 0.05160447
group O 0 0.0025870798
also O 0 0.0020181346
received O 0 0.0025744974
either O 0 0.0026138406
exposure O 0 0.008637197
or O 0 0.0051000216
relaxation O 0 0.3622244
. O 0 0.010236941

Treatment O 0 0.027384654
was O 0 0.0026943882
from O 0 0.0016554316
weeks O 0 0.0013120907
0 O 0 0.0011359395
to O 0 0.00079537026
8 O 0 0.0007375916
and O 0 0.0007122898
was O 0 0.0006865685
then O 0 0.0007249763
tapered O 0 0.0036206446
from O 0 0.0011676091
weeks O 0 0.0015386172
8 O 0 0.0018490383
to O 0 0.002436976
16 O 0 0.004739531
. O 0 0.0054620947

RESULTS O 0 0.039658487
: O 0 0.00907797
Mean O 0 0.005653048
alprazolam B-Chemical 1 0.9980697
dose O 0 0.06961194
was O 0 0.0055489377
5 O 0 0.005428647
mg O 0 0.30994263
daily O 0 0.01889588
. O 0 0.01148277

Compared O 0 0.003142476
with O 0 0.0025020821
placebo O 0 0.06735612
subjects O 0 0.0028490967
, O 0 0.0023082471
alprazolam B-Chemical 1 0.9997149
patients O 0 0.0075874203
developed O 0 0.0015703457
more O 0 0.0009936005
adverse O 0 0.64515644
reactions O 0 0.020980977
( O 0 0.0008207387
21 O 0 0.0005167543
% O 0 0.00038700268
v O 0 0.001687365
. O 0 0.00018900729
0 O 0 0.00029584483
% O 0 0.0002869241
) O 0 0.00037527346
of O 0 0.00047079456
depression B-Disease 0 0.9860584
, O 0 0.0014870102
enuresis B-Disease 0 0.99705935
, O 0 0.0012841608
disinhibition O 0 0.98155814
and O 0 0.00084989646
aggression B-Disease 2 0.9899541
; O 0 0.0010358854
and O 0 0.00032490105
more O 0 0.00045863824
side O 0 0.013958559
- O 0 0.0006999439
effects O 0 0.0007889438
, O 0 0.0005002474
particularly O 0 0.0010253114
sedation O 0 0.7547124
, O 0 0.0017478024
irritability B-Disease 2 0.9992355
, O 0 0.0014410189
impaired B-Disease 0 0.020094318
memory I-Disease 0 0.77366996
, O 0 0.0019188401
weight B-Disease 0 0.012551739
loss I-Disease 0 0.005496852
and O 0 0.005872213
ataxia B-Disease 2 0.9978855
. O 0 0.00877132

Side O 0 0.65521854
- O 0 0.006157803
effects O 0 0.0036486797
tended O 0 0.0017792069
to O 0 0.0011898669
diminish O 0 0.0015615151
during O 0 0.00089492294
treatment O 0 0.0023171029
but O 0 0.0012438169
remained O 0 0.0018114141
significant O 0 0.0019903525
at O 0 0.0015172065
week O 0 0.0030065833
8 O 0 0.004488647
. O 0 0.0054601515

Despite O 0 0.006395392
this O 0 0.0040589096
, O 0 0.0042067417
the O 0 0.0029020496
drop O 0 0.005698624
- O 0 0.004622848
out O 0 0.0024565635
rate O 0 0.003483646
was O 0 0.005016797
low O 0 0.009263947
. O 0 0.010377065

CONCLUSIONS O 0 0.8851573
: O 0 0.013522921
Alprazolam B-Chemical 0 0.9992872
caused O 0 0.0046200505
side O 0 0.058086
- O 0 0.002277285
effects O 0 0.0016748919
and O 0 0.0009251366
adverse O 0 0.47761816
effects O 0 0.0015261852
during O 0 0.00043933082
treatment O 0 0.0013722328
but O 0 0.0005898721
many O 0 0.00077870284
patients O 0 0.0019639006
were O 0 0.0010312117
willing O 0 0.0017994761
to O 0 0.0015088976
accept O 0 0.0032728752
these O 0 0.005409228
. O 0 0.0063149515

Crescentic O 0 0.9708947
fibrillary O 0 0.9538968
glomerulonephritis B-Disease 2 0.998616
associated O 0 0.008915141
with O 0 0.0053883456
intermittent O 0 0.6244547
rifampin B-Chemical 1 0.99920577
therapy O 0 0.3549453
for O 0 0.007829945
pulmonary B-Disease 0 0.99025774
tuberculosis I-Disease 2 0.9875766
. O 0 0.016317526

This O 0 0.0043068165
case O 0 0.0022167135
study O 0 0.0021193025
reveals O 0 0.0015075571
an O 0 0.0013709775
unusual O 0 0.0032924097
finding O 0 0.0012806593
of O 0 0.0009740652
rapidly O 0 0.003334
proliferative O 0 0.7961109
crescentic O 0 0.9990835
glomerulonephritis B-Disease 2 0.9999039
in O 0 0.0010378438
a O 0 0.00063262956
patient O 0 0.00085989706
treated O 0 0.0009094909
with O 0 0.00093142997
rifampin B-Chemical 1 0.99975306
who O 0 0.0036932179
had O 0 0.00051344116
no O 0 0.00037516115
other O 0 0.0005772155
identifiable O 0 0.0054374468
causes O 0 0.0020983308
for O 0 0.0011245576
developing O 0 0.0077070165
this O 0 0.0035572078
disease O 0 0.7745748
. O 0 0.0072383913

This O 0 0.0044475566
patient O 0 0.0030436837
underwent O 0 0.0022392047
a O 0 0.0014796806
10 O 0 0.0011526643
- O 0 0.001035659
month O 0 0.000540769
regimen O 0 0.0026372168
of O 0 0.0010934346
rifampin B-Chemical 1 0.99971443
and O 0 0.0021463546
isoniazid B-Chemical 1 0.9997656
for O 0 0.00092448335
pulmonary B-Disease 0 0.99488246
tuberculosis I-Disease 2 0.98891884
and O 0 0.0008523006
was O 0 0.00038778322
discovered O 0 0.00053862645
to O 0 0.00025538547
have O 0 0.0003265086
developed O 0 0.00079608144
signs O 0 0.061771005
of O 0 0.0008207759
severe O 0 0.3684903
renal B-Disease 0 0.9939499
failure I-Disease 0 0.6158755
five O 0 0.0005182222
weeks O 0 0.0006881652
after O 0 0.0005258614
completion O 0 0.0010306285
of O 0 0.0027385547
therapy O 0 0.05303361
. O 0 0.0061801868

Renal O 0 0.75285834
biopsy O 0 0.011630313
revealed O 0 0.004118524
severe O 0 0.438981
glomerulonephritis B-Disease 2 0.99939144
with O 0 0.0069320956
crescents O 0 0.94645107
, O 0 0.0029577268
electron O 0 0.069356754
dense O 0 0.005016248
fibrillar O 0 0.4732487
deposits O 0 0.27178228
and O 0 0.0031569358
moderate O 0 0.18366642
lymphocytic O 0 0.99819547
interstitial O 0 0.9826156
infiltrate O 0 0.9791539
. O 0 0.012601918

Other O 0 0.011700776
possible O 0 0.004284586
causes O 0 0.0047313618
of O 0 0.0033633246
rapidly O 0 0.0072089653
progressive O 0 0.77439904
glomerulonephritis B-Disease 2 0.99937326
were O 0 0.004262582
investigated O 0 0.0033617094
and O 0 0.004280994
ruled O 0 0.009553206
out O 0 0.00583755
. O 0 0.008763802

This O 0 0.0049835886
report O 0 0.0049391454
documents O 0 0.0031642336
the O 0 0.0013973522
unusual O 0 0.0035110794
occurrence O 0 0.002201116
of O 0 0.0013425275
rapidly O 0 0.004210265
progressive O 0 0.7931376
glomerulonephritis B-Disease 2 0.9998324
with O 0 0.008885907
crescents O 0 0.97445947
and O 0 0.0027484584
fibrillar O 0 0.8755533
glomerulonephritis B-Disease 2 0.9997633
in O 0 0.0015470999
a O 0 0.0015414642
patient O 0 0.0026751268
treated O 0 0.0042447885
with O 0 0.008143953
rifampin B-Chemical 1 0.99853575
. O 0 0.009746058

Acute O 0 0.9756203
confusion B-Disease 0 0.71410495
induced O 0 0.004422798
by O 0 0.0021160417
a O 0 0.0017113236
high O 0 0.0019635754
- O 0 0.00225217
dose O 0 0.0110328
infusion O 0 0.030226033
of O 0 0.0018226512
5 B-Chemical 0 0.0016535555
- I-Chemical 0 0.0042577754
fluorouracil I-Chemical 0 0.9969271
and O 0 0.016924862
folinic B-Chemical 0 0.9994985
acid I-Chemical 0 0.991621
. O 0 0.013316562

A O 0 0.019246027
61 O 0 0.0057016457
- O 0 0.003266701
year O 0 0.0017274718
- O 0 0.0017983159
old O 0 0.001127493
man O 0 0.025894664
was O 0 0.0006441299
treated O 0 0.0008633005
with O 0 0.0006013222
combination O 0 0.001895117
chemotherapy O 0 0.80687237
incorporating O 0 0.002658478
cisplatinum B-Chemical 0 0.9997521
, O 0 0.008043244
etoposide B-Chemical 1 0.9994093
, O 0 0.0012300876
high O 0 0.0008964715
- O 0 0.0009120869
dose O 0 0.010547771
5 B-Chemical 0 0.000389434
- I-Chemical 0 0.00087556447
fluorouracil I-Chemical 0 0.998459
( O 0 0.00072948873
2 O 0 0.00033020935
, O 0 0.00035709192
250 O 0 0.00067031593
mg O 0 0.13683687
/ O 0 0.00093014183
m2 O 0 0.014202804
/ O 0 0.0007274241
24 O 0 0.0003091287
hours O 0 0.0003501854
) O 0 0.00074874324
and O 0 0.00095201394
folinic B-Chemical 0 0.9997272
acid I-Chemical 0 0.98338634
for O 0 0.0016071612
an O 0 0.0047534895
inoperable O 0 0.990824
gastric B-Disease 0 0.99696165
adenocarcinoma I-Disease 0 0.99905246
. O 0 0.01798546

He O 0 0.010475331
developed O 0 0.006702416
acute O 0 0.9031461
neurologic O 0 0.9924825
symptoms O 0 0.6617017
of O 0 0.002786858
mental O 0 0.45209265
confusion B-Disease 0 0.90761924
, O 0 0.0035065976
disorientation B-Disease 0 0.9987752
and O 0 0.0021198655
irritability B-Disease 2 0.99934596
, O 0 0.0008711744
and O 0 0.0003774371
then O 0 0.00028347145
lapsed O 0 0.005239798
into O 0 0.00018334351
a O 0 0.00034198584
deep O 0 0.0029967497
coma B-Disease 0 0.9989889
, O 0 0.0005028814
lasting O 0 0.00080845994
for O 0 0.00016651077
approximately O 0 0.00022038161
40 O 0 0.00020826182
hours O 0 0.00014339367
during O 0 0.00011131556
the O 0 0.00016160835
first O 0 0.00019065403
dose O 0 0.0043259305
( O 0 0.0004391433
day O 0 0.0002985408
2 O 0 0.0003536423
) O 0 0.00052705803
of O 0 0.0005320629
5 B-Chemical 0 0.0006404118
- I-Chemical 0 0.0018576
fluorouracil I-Chemical 0 0.9973833
and O 0 0.0071258363
folinic B-Chemical 0 0.9996971
acid I-Chemical 0 0.9943158
infusion O 0 0.67488027
. O 0 0.008141807

This O 0 0.0058491426
complication O 0 0.06529043
reappeared O 0 0.006011255
on O 0 0.00095132575
day O 0 0.0009488726
25 O 0 0.0010086587
during O 0 0.0004067584
the O 0 0.00043418407
second O 0 0.00046389856
dose O 0 0.0041401098
of O 0 0.0008058739
5 B-Chemical 0 0.0006397408
- I-Chemical 0 0.0014590258
fluorouracil I-Chemical 0 0.99843687
and O 0 0.0028246292
folinic B-Chemical 0 0.9998944
acid I-Chemical 0 0.9956911
, O 0 0.0016449225
which O 0 0.0009377782
were O 0 0.00065807963
then O 0 0.00066664733
the O 0 0.00097174867
only O 0 0.0018879026
drugs O 0 0.426771
given O 0 0.0039396207
. O 0 0.0059503126

Because O 0 0.006507469
folinic B-Chemical 0 0.99909437
acid I-Chemical 0 0.98601913
was O 0 0.0022410422
unlikely O 0 0.0011352153
to O 0 0.00077088206
be O 0 0.000687682
associated O 0 0.00073528226
with O 0 0.00065624743
this O 0 0.0005590138
condition O 0 0.0018285477
, O 0 0.0016029702
neurotoxicity B-Disease 2 0.9993807
due O 0 0.00046992657
to O 0 0.00049357914
high O 0 0.00096257747
- O 0 0.0013482454
dose O 0 0.011125783
5 B-Chemical 0 0.00094494136
- I-Chemical 0 0.0023352648
fluorouracil I-Chemical 0 0.9959357
was O 0 0.002617808
highly O 0 0.0053113885
suspected O 0 0.097460136
. O 0 0.006531104

The O 0 0.0036869
pathogenesis O 0 0.009057651
of O 0 0.0030110031
5 B-Chemical 0 0.0020688255
- I-Chemical 0 0.0038713985
fluorouracil I-Chemical 0 0.99876523
neurotoxicity B-Disease 2 0.9995766
may O 0 0.001521491
be O 0 0.0007202736
due O 0 0.00035238065
to O 0 0.00044190953
a O 0 0.00071691663
Krebs O 0 0.9198587
cycle O 0 0.0071735526
blockade O 0 0.32014942
by O 0 0.0021547517
fluoroacetate B-Chemical 0 0.9997191
and O 0 0.0113116
fluorocitrate B-Chemical 0 0.9998714
, O 0 0.02529912
thiamine B-Chemical 0 0.9996383
deficiency O 0 0.9320433
, O 0 0.0045599085
or O 0 0.0029340673
dihydrouracil B-Chemical 0 0.9937715
dehydrogenase O 0 0.995031
deficiency O 0 0.9567577
. O 0 0.011532893

High O 0 0.037925497
- O 0 0.0065285703
dose O 0 0.017289463
5 B-Chemical 0 0.00227842
- I-Chemical 0 0.0037251578
fluorouracil I-Chemical 0 0.99766916
/ O 0 0.032151576
folinic B-Chemical 0 0.99982435
acid I-Chemical 0 0.99539727
infusion O 0 0.30341795
therapy O 0 0.045733415
has O 0 0.00084114016
recently O 0 0.0010446328
become O 0 0.0010702014
a O 0 0.00091998617
popular O 0 0.0025031012
regimen O 0 0.0083507225
for O 0 0.0019640052
various O 0 0.009954063
cancers B-Disease 2 0.98506886
. O 0 0.009593926

It O 0 0.006103454
is O 0 0.0024326679
necessary O 0 0.0013545176
that O 0 0.001188126
both O 0 0.0012716509
oncologists O 0 0.0031922602
and O 0 0.0014806448
neurologists O 0 0.0041069696
be O 0 0.0011398026
fully O 0 0.000991488
aware O 0 0.0014294636
of O 0 0.0019472159
this O 0 0.002749312
unusual O 0 0.028791439
complication O 0 0.65172756
. O 0 0.009322164

Effect O 0 0.00887596
of O 0 0.0048801424
switching O 0 0.008501771
carbamazepine B-Chemical 1 0.9995229
to O 0 0.0073026987
oxcarbazepine B-Chemical 0 0.9997514
on O 0 0.0020204287
the O 0 0.0024421087
plasma O 0 0.039537568
levels O 0 0.0039453693
of O 0 0.009765387
neuroleptics O 0 0.9968257
. O 0 0.012599925

A O 0 0.08210929
case O 0 0.04106954
report O 0 0.06590444
. O 0 0.04666739

Carbamazepine B-Chemical 1 0.99901617
was O 0 0.0038412262
switched O 0 0.0036509894
to O 0 0.0014459807
its O 0 0.0022741507
10 O 0 0.0014817753
- O 0 0.002332497
keto O 0 0.9960647
analogue O 0 0.6291264
oxcarbazepine B-Chemical 0 0.9999404
among O 0 0.0011862128
six O 0 0.0003442135
difficult O 0 0.00058812404
- O 0 0.0007786983
to O 0 0.00040827427
- O 0 0.00089329196
treat O 0 0.011928165
schizophrenic B-Disease 2 0.9987832
or O 0 0.00096700614
organic B-Disease 0 0.99800557
psychotic I-Disease 0 0.9998896
patients O 0 0.031566072
using O 0 0.0011293822
concomitantly O 0 0.34894332
haloperidol B-Chemical 1 0.9999126
, O 0 0.043165322
chlorpromazine B-Chemical 1 0.99960274
or O 0 0.019047156
clozapine B-Chemical 1 0.99933535
. O 0 0.011022565

This O 0 0.0046545267
change O 0 0.0023196428
resulted O 0 0.0014614952
within O 0 0.0007702473
2 O 0 0.0009700606
- O 0 0.0009724114
4 O 0 0.00037631128
weeks O 0 0.00032903915
in O 0 0.0002754734
the O 0 0.00030937427
50 O 0 0.0006088835
- O 0 0.00055852573
200 O 0 0.00064905453
% O 0 0.00029099776
increase O 0 0.00021950524
in O 0 0.00022034043
the O 0 0.00027801664
plasma O 0 0.0070336354
levels O 0 0.00037807538
of O 0 0.000583878
these O 0 0.0011980428
neuroleptics O 0 0.9989291
and O 0 0.0011746063
the O 0 0.0010846824
appearance O 0 0.006591189
of O 0 0.009254293
extrapyramidal B-Disease 2 0.9996884
symptoms I-Disease 2 0.9866642
. O 0 0.009580995

None O 0 0.007955919
of O 0 0.0030204859
the O 0 0.001972087
patients O 0 0.0032012432
showed O 0 0.0012929116
any O 0 0.0010180125
clinical O 0 0.005196628
deteriotation O 0 0.017309137
during O 0 0.00086935377
the O 0 0.001092524
following O 0 0.0015310877
3 O 0 0.0017608763
- O 0 0.0030697903
6 O 0 0.0021672165
months O 0 0.003915709
. O 0 0.0050226413

The O 0 0.002466902
results O 0 0.001640361
of O 0 0.0015498084
this O 0 0.0010222729
case O 0 0.00089922233
report O 0 0.0016149592
support O 0 0.0006563665
the O 0 0.00049923896
idea O 0 0.00074529136
that O 0 0.00037429307
in O 0 0.00036735673
contrast O 0 0.0005478695
with O 0 0.0017920629
carbamazepine B-Chemical 1 0.9999671
oxcarbazepine B-Chemical 0 0.9999778
does O 0 0.00075837073
not O 0 0.000394802
induce O 0 0.00038750807
the O 0 0.00048073372
hepatic O 0 0.9757051
microsomal O 0 0.9934376
enzyme O 0 0.2477764
systems O 0 0.0018175702
regulating O 0 0.00061402
the O 0 0.00091459195
inactivation O 0 0.0035608234
of O 0 0.0051985974
antipsychotic O 0 0.998437
drugs O 0 0.9559558
. O 0 0.008551758

Time O 0 0.017704718
course O 0 0.006991489
of O 0 0.006935064
lipid O 0 0.90413773
peroxidation O 0 0.9988914
in O 0 0.013724818
puromycin B-Chemical 0 0.9920975
aminonucleoside I-Chemical 0 0.9995165
- O 0 0.087400615
induced O 0 0.08110464
nephropathy B-Disease 2 0.99905723
. O 0 0.021393673

Reactive O 0 0.9744421
oxygen B-Chemical 1 0.93733215
species O 0 0.004822407
have O 0 0.0021594039
been O 0 0.0017094802
implicated O 0 0.0013336176
in O 0 0.0008184863
the O 0 0.00081774854
pathogenesis O 0 0.014180835
of O 0 0.0022127577
acute O 0 0.99255097
puromycin B-Chemical 0 0.9977235
aminonucleoside I-Chemical 0 0.9999281
( O 0 0.040279526
PAN B-Chemical 1 0.9992631
) O 0 0.011703252
- O 0 0.0025723185
induced O 0 0.003804241
nephropathy B-Disease 2 0.99985325
, O 0 0.0035184564
with O 0 0.0024751632
antioxidants O 0 0.99664706
significantly O 0 0.0040143332
reducing O 0 0.0051060426
the O 0 0.0077523454
proteinuria B-Disease 2 0.9989197
. O 0 0.011836294

The O 0 0.0035218936
temporal O 0 0.007641659
relationship O 0 0.0018053701
between O 0 0.0014473853
lipid O 0 0.6804702
peroxidation O 0 0.9992393
in O 0 0.0019943519
the O 0 0.0016129783
kidney O 0 0.8073932
and O 0 0.0032163528
proteinuria B-Disease 2 0.9994209
was O 0 0.0020995801
examined O 0 0.0013578933
in O 0 0.0018267897
this O 0 0.0029049101
study O 0 0.0065866197
. O 0 0.0065229596

Rats O 0 0.039879076
were O 0 0.002637809
treated O 0 0.0025906072
with O 0 0.0015413263
a O 0 0.0012570412
single O 0 0.0012082021
IV O 0 0.062870495
injection O 0 0.004003404
of O 0 0.0016981862
puromycin B-Chemical 0 0.98795474
aminonucleoside I-Chemical 0 0.9998772
, O 0 0.005552947
( O 0 0.002473529
PAN B-Chemical 1 0.99805343
, O 0 0.0009388318
7 O 0 0.00031872798
. O 0 0.00016361501
5 O 0 0.00021434118
mg O 0 0.08320173
/ O 0 0.00063985423
kg O 0 0.002266882
) O 0 0.00033897263
and O 0 0.0001779415
24 O 0 0.00015355098
hour O 0 0.0001524373
urine O 0 0.011709718
samples O 0 0.00018768857
were O 0 0.00017166564
obtained O 0 0.00015495547
prior O 0 0.00012531242
to O 0 0.00017348424
sacrifice O 0 0.00051003497
on O 0 0.000120760604
days O 0 0.00021060776
3 O 0 0.00020229006
, O 0 0.00027445858
5 O 0 0.00019433298
, O 0 0.00026551948
7 O 0 0.00019691183
, O 0 0.00026914076
10 O 0 0.00025267337
, O 0 0.00030337804
17 O 0 0.00038588993
, O 0 0.0003593423
27 O 0 0.0005404253
, O 0 0.00046052577
41 O 0 0.00092929765
( O 0 0.00079998875
N O 0 0.4165482
= O 0 0.0011262548
5 O 0 0.0005744012
- O 0 0.00100027
10 O 0 0.00079965795
per O 0 0.00079976773
group O 0 0.0025781435
) O 0 0.005351237
. O 0 0.004869566

The O 0 0.005138399
kidneys O 0 0.01336811
were O 0 0.0034663293
removed O 0 0.0030310077
, O 0 0.0038943342
flushed O 0 0.0057306862
with O 0 0.0047743707
ice O 0 0.03217209
cold O 0 0.17457429
TRIS O 0 0.98728323
buffer O 0 0.22687098
. O 0 0.015124277

Kidney O 0 0.49748704
cortices O 0 0.37845114
from O 0 0.0031862538
each O 0 0.00175712
animal O 0 0.0038711776
were O 0 0.0028833752
used O 0 0.0031006045
to O 0 0.004207605
prepare O 0 0.008455591
homogenates O 0 0.023659905
. O 0 0.012115454

Tissue O 0 0.49250132
lipid O 0 0.860738
peroxidation O 0 0.99882096
was O 0 0.0026516796
measured O 0 0.00097181636
in O 0 0.00076918525
whole O 0 0.0008100805
homogenates O 0 0.002761052
as O 0 0.0005099224
well O 0 0.00045522154
as O 0 0.0004622419
in O 0 0.0006083504
lipid O 0 0.39100263
extracts O 0 0.004234699
from O 0 0.0012090672
homogenates O 0 0.016670713
as O 0 0.0026648485
thiobarbituric B-Chemical 0 0.99909043
acid I-Chemical 0 0.9950112
reactive O 0 0.9538608
substances O 0 0.98040307
. O 0 0.011819992

Proteinuria B-Disease 2 0.99634534
was O 0 0.003903594
evident O 0 0.0020605116
at O 0 0.0010522727
day O 0 0.001167534
5 O 0 0.0009430405
, O 0 0.0010782604
peaked O 0 0.0014888132
at O 0 0.0005479596
day O 0 0.0007947921
7 O 0 0.000790465
and O 0 0.0010035598
persisted O 0 0.001849468
to O 0 0.0018073124
day O 0 0.0030954944
27 O 0 0.007045748
. O 0 0.0056725857

Lipid O 0 0.9888515
peroxidation O 0 0.9983827
in O 0 0.003585827
homogenates O 0 0.008584848
was O 0 0.0012546045
maximal O 0 0.0010962883
at O 0 0.0005054486
day O 0 0.0006025619
3 O 0 0.0004956737
and O 0 0.00054628926
declined O 0 0.0010336782
rapidly O 0 0.0012549219
to O 0 0.0007116626
control O 0 0.0008560654
levels O 0 0.0013074377
by O 0 0.0019957998
day O 0 0.0030878505
17 O 0 0.0060696816
. O 0 0.0052493038

This O 0 0.0049426337
study O 0 0.00320614
supports O 0 0.0019112235
the O 0 0.001515471
role O 0 0.0011959004
of O 0 0.0024188443
lipid O 0 0.90511084
peroxidation O 0 0.99947256
in O 0 0.0025858777
mediating O 0 0.0025242812
the O 0 0.0041414876
proteinuric B-Disease 0 0.99961406
injury I-Disease 0 0.9969784
in O 0 0.043146793
PAN B-Chemical 1 0.9984158
nephropathy B-Disease 2 0.9994923
. O 0 0.024860445

Composition O 0 0.018895552
of O 0 0.0059266393
gall B-Disease 0 0.47611684
bladder I-Disease 0 0.91240346
stones I-Disease 0 0.96552557
associated O 0 0.0053588315
with O 0 0.0046587037
octreotide B-Chemical 1 0.9976307
: O 0 0.006248432
response O 0 0.0042248946
to O 0 0.0038749122
oral O 0 0.88419217
ursodeoxycholic B-Chemical 0 0.999226
acid I-Chemical 0 0.9867035
. O 0 0.014863517

Octreotide B-Chemical 0 0.996594
, O 0 0.0053686635
an O 0 0.0026799187
effective O 0 0.0024346285
treatment O 0 0.0029662664
for O 0 0.0014981903
acromegaly B-Disease 0 0.99560636
, O 0 0.0023147538
induces O 0 0.0021426731
gall B-Disease 0 0.765154
bladder I-Disease 0 0.9712256
stones I-Disease 0 0.9832872
in O 0 0.0015678477
13 O 0 0.0018219635
- O 0 0.0019037032
60 O 0 0.0015122555
% O 0 0.0017472816
of O 0 0.002749682
patients O 0 0.008988147
. O 0 0.0063038603

Because O 0 0.0029552968
knowledge O 0 0.0027952192
of O 0 0.0022671549
stone O 0 0.18593524
composition O 0 0.0034392246
is O 0 0.00091797666
essential O 0 0.00071004045
for O 0 0.00041764588
studies O 0 0.00066472153
of O 0 0.0005549412
their O 0 0.0006074066
pathogenesis O 0 0.021646058
, O 0 0.0007728482
treatment O 0 0.0016238288
, O 0 0.0005356396
and O 0 0.00037092454
prevention O 0 0.0023661281
, O 0 0.0004120841
this O 0 0.00022918876
was O 0 0.00021996847
investigated O 0 0.0002358107
by O 0 0.00023783722
direct O 0 0.0002523592
and O 0 0.0002974768
indirect O 0 0.00060740806
methods O 0 0.00048609573
in O 0 0.00038278697
14 O 0 0.000753574
octreotide B-Chemical 1 0.9974815
treated O 0 0.008347959
acromegalic B-Disease 0 0.9974648
patients O 0 0.020843677
with O 0 0.006572588
gall B-Disease 0 0.9682815
stones I-Disease 0 0.9914704
. O 0 0.0120641

Chemical O 0 0.7031819
analysis O 0 0.005045402
of O 0 0.003781692
gall B-Disease 0 0.71391165
stones I-Disease 0 0.9626139
retrieved O 0 0.0014443046
at O 0 0.000759516
cholecystectomy O 0 0.060645048
from O 0 0.00058829726
two O 0 0.00042269402
patients O 0 0.001398047
, O 0 0.0006495719
showed O 0 0.00042015305
that O 0 0.0003572018
they O 0 0.00040550652
contained O 0 0.00043294748
71 O 0 0.001455959
% O 0 0.00077731075
and O 0 0.00081181794
87 O 0 0.002138142
% O 0 0.0021649254
cholesterol B-Chemical 0 0.9580806
by O 0 0.004227156
weight O 0 0.023016619
. O 0 0.006596511

In O 0 0.0027110016
the O 0 0.0017150121
remaining O 0 0.001338066
12 O 0 0.0009565176
patients O 0 0.0018850599
, O 0 0.0010259388
localised O 0 0.0014198187
computed O 0 0.0008752003
tomography O 0 0.019951282
of O 0 0.00067632034
the O 0 0.0005312632
gall O 0 0.20565891
bladder O 0 0.7464466
showed O 0 0.0005016293
that O 0 0.0002654013
eight O 0 0.00024374803
had O 0 0.0004019174
stones O 0 0.6297703
with O 0 0.00048328328
maximum O 0 0.0003974667
attenuation O 0 0.0011400285
scores O 0 0.00033287742
of O 0 0.00040485972
< O 0 0.00042908
100 O 0 0.0005937769
Hounsfield O 0 0.0054513765
units O 0 0.00035146376
( O 0 0.00038279628
values O 0 0.0002671749
of O 0 0.00044852463
< O 0 0.00062397524
100 O 0 0.0011291449
HU O 0 0.40849423
predict O 0 0.0012233759
cholesterol B-Chemical 0 0.99274194
rich O 0 0.02060347
, O 0 0.004798274
dissolvable O 0 0.9230767
stones O 0 0.9608496
) O 0 0.015804337
. O 0 0.00768324

Gall O 0 0.32531247
bladder O 0 0.7396952
bile O 0 0.8743744
was O 0 0.0029945637
obtained O 0 0.0018981819
by O 0 0.0017890316
ultrasound O 0 0.0076067005
guided O 0 0.0021714899
, O 0 0.0023005907
fine O 0 0.005009804
needle O 0 0.0047687343
puncture O 0 0.0072132736
from O 0 0.002368571
six O 0 0.0027681065
patients O 0 0.010354593
. O 0 0.00760008

All O 0 0.0032423553
six O 0 0.0016921397
patients O 0 0.0034214288
had O 0 0.0020811278
supersaturated O 0 0.9556217
bile O 0 0.9650872
( O 0 0.0020020544
mean O 0 0.0005830048
( O 0 0.0009394273
SEM O 0 0.0021025676
) O 0 0.0013775593
cholesterol B-Chemical 0 0.98138267
saturation O 0 0.008865059
index O 0 0.0007052879
of O 0 0.00052471034
1 O 0 0.00040828265
. O 0 0.00019734113
19 O 0 0.0004744509
( O 0 0.00035542215
0 O 0 0.0002877728
. O 0 0.00016993767
08 O 0 0.0031748463
) O 0 0.000485203
( O 0 0.0003322341
range O 0 0.00037154
1 O 0 0.0002761666
. O 0 0.00017516539
01 O 0 0.0021082568
- O 0 0.00041998923
1 O 0 0.00023307737
. O 0 0.00013187174
53 O 0 0.00042179256
) O 0 0.00039823606
) O 0 0.00033409282
and O 0 0.00019220165
all O 0 0.00016075077
had O 0 0.00024362674
abnormally O 0 0.004099688
rapid O 0 0.006727914
cholesterol B-Chemical 0 0.99836296
microcrystal O 0 0.9792063
nucleation O 0 0.30527064
times O 0 0.00032588598
( O 0 0.0004831649
< O 0 0.00028536175
4 O 0 0.00015653334
days O 0 0.00018664903
( O 0 0.00027260074
range O 0 0.00034220694
1 O 0 0.0002878845
- O 0 0.00040526362
4 O 0 0.00022591594
) O 0 0.0004420216
) O 0 0.0004301581
, O 0 0.000310498
whilst O 0 0.0004096858
in O 0 0.00023731965
four O 0 0.00024244263
, O 0 0.0005302384
the O 0 0.00053432066
bile O 0 0.8057942
contained O 0 0.0012801413
cholesterol B-Chemical 0 0.9960758
microcrystals O 0 0.90370923
immediately O 0 0.0022548307
after O 0 0.001672806
sampling O 0 0.003861153
. O 0 0.00533901

Of O 0 0.004966338
the O 0 0.0020776019
12 O 0 0.0013200331
patients O 0 0.0021923794
considered O 0 0.00095292873
for O 0 0.0008936303
oral O 0 0.56207126
ursodeoxycholic B-Chemical 0 0.9998264
acid I-Chemical 0 0.9962568
( O 0 0.02740923
UDCA B-Chemical 0 0.99994206
) O 0 0.00706423
treatment O 0 0.0030442176
, O 0 0.0005640416
two O 0 0.00023760469
had O 0 0.0003700061
a O 0 0.00046466658
blocked O 0 0.0014890301
cystic O 0 0.461445
duct O 0 0.7553182
and O 0 0.0006300261
were O 0 0.00039995858
not O 0 0.00033155698
started O 0 0.0006332986
on O 0 0.0004671372
UDCA B-Chemical 0 0.99982977
while O 0 0.0009373522
one O 0 0.0006759749
was O 0 0.0008924553
lost O 0 0.0013853704
to O 0 0.0014639915
follow O 0 0.0024212627
up O 0 0.0041738516
. O 0 0.0054139555

After O 0 0.0020378733
one O 0 0.0013778638
year O 0 0.0013263127
of O 0 0.0012829119
treatment O 0 0.0018945334
, O 0 0.00084901345
five O 0 0.00032917436
of O 0 0.00048861356
the O 0 0.0003379116
remaining O 0 0.00032795395
nine O 0 0.00037952367
patients O 0 0.0009623377
showed O 0 0.000323262
either O 0 0.0003285257
partial O 0 0.0010345672
( O 0 0.0005466302
n O 0 0.00029102858
= O 0 0.00043627055
3 O 0 0.00021255249
) O 0 0.00034259591
or O 0 0.00018080641
complete O 0 0.00026591573
( O 0 0.00038822816
n O 0 0.0002702853
= O 0 0.00047212437
2 O 0 0.00033007277
) O 0 0.00070539553
gall B-Disease 0 0.5520511
stone I-Disease 0 0.94191325
dissolution O 0 0.86347884
, O 0 0.0011605257
suggesting O 0 0.000603638
that O 0 0.0006762358
their O 0 0.0014719946
stones O 0 0.7952767
were O 0 0.004435378
cholesterol B-Chemical 0 0.99146783
rich O 0 0.05606441
. O 0 0.007898005

This O 0 0.0049123005
corresponds O 0 0.0020019342
, O 0 0.002125999
by O 0 0.001484598
actuarial O 0 0.22819586
( O 0 0.001678089
life O 0 0.0015936792
table O 0 0.00066686724
) O 0 0.0009083897
analysis O 0 0.0007386298
, O 0 0.00056544435
to O 0 0.0003505759
a O 0 0.0004539125
combined O 0 0.0011026873
gall B-Disease 0 0.82909375
stone I-Disease 0 0.9629065
dissolution O 0 0.811551
rate O 0 0.0006892232
of O 0 0.00082563976
58 O 0 0.0012355184
. O 0 0.0004142492
3 O 0 0.0005697751
( O 0 0.0008756174
15 O 0 0.0007086837
. O 0 0.0007509155
9 O 0 0.0015612199
% O 0 0.0025902425
) O 0 0.004822943
. O 0 0.004825708

In O 0 0.0032312477
conclusion O 0 0.0025947813
, O 0 0.0032579142
octreotide B-Chemical 1 0.9958145
induced O 0 0.006410357
gall B-Disease 0 0.9347153
stones I-Disease 0 0.9920459
are O 0 0.0012132555
generally O 0 0.00094779924
small O 0 0.0006939026
, O 0 0.0006111413
multiple O 0 0.0008229221
, O 0 0.0006509157
and O 0 0.0006142248
cholesterol B-Chemical 0 0.9936479
rich O 0 0.005417886
although O 0 0.00043830537
, O 0 0.00042213828
in O 0 0.00023053268
common O 0 0.0004740104
with O 0 0.0004673305
spontaneous O 0 0.038898576
gall B-Disease 0 0.9636514
stone I-Disease 0 0.98825735
disease I-Disease 0 0.97553307
, O 0 0.00093290256
at O 0 0.00021805525
presentation O 0 0.0018904741
some O 0 0.00039139314
patients O 0 0.00097278535
will O 0 0.00023889748
have O 0 0.000375515
a O 0 0.0005712914
blocked O 0 0.0018651107
cystic O 0 0.50574565
duct O 0 0.77861947
and O 0 0.0016990223
some O 0 0.002740534
gall B-Disease 0 0.9322476
stones I-Disease 0 0.99291235
containing O 0 0.016299328
calcium B-Chemical 1 0.9939154
. O 0 0.011038794

Erythema B-Disease 0 0.98953044
multiforme I-Disease 0 0.99662244
and O 0 0.031107234
hypersensitivity B-Disease 2 0.9926885
myocarditis I-Disease 0 0.9994342
caused O 0 0.065619506
by O 0 0.024860486
ampicillin B-Chemical 1 0.99179685
. O 0 0.017805073

OBJECTIVE O 0 0.49615848
: O 0 0.0052997456
To O 0 0.0019675302
report O 0 0.003571415
a O 0 0.0019330685
case O 0 0.0018765472
of O 0 0.0036216232
erythema B-Disease 0 0.9981937
multiforme I-Disease 0 0.9990214
and O 0 0.026373688
hypersensitivity B-Disease 2 0.9974246
myocarditis I-Disease 0 0.99981767
caused O 0 0.057515636
by O 0 0.020221518
ampicillin B-Chemical 1 0.9951001
. O 0 0.010783132

CASE O 0 0.9439671
SUMMARY O 0 0.10642891
: O 0 0.0057454016
A O 0 0.009097696
13 O 0 0.0024895177
- O 0 0.0020832543
year O 0 0.0012576956
- O 0 0.0014664736
old O 0 0.0009786388
boy O 0 0.0024786722
was O 0 0.0007171599
treated O 0 0.0013078221
with O 0 0.0015677462
ampicillin B-Chemical 1 0.99627715
and O 0 0.0025871485
gentamicin B-Chemical 1 0.9964663
because O 0 0.001835272
of O 0 0.004720582
suspected O 0 0.55911285
septicemia B-Disease 0 0.9967518
. O 0 0.012001679

Medications O 0 0.83597046
were O 0 0.0041247946
discontinued O 0 0.027209098
when O 0 0.0028204313
erythema B-Disease 0 0.99628013
multiforme I-Disease 0 0.99816173
and O 0 0.007564443
congestive B-Disease 0 0.9994562
heart I-Disease 0 0.95541537
failure I-Disease 0 0.8970064
caused O 0 0.007604955
by O 0 0.010060913
myocarditis B-Disease 2 0.9991379
occurred O 0 0.040996432
. O 0 0.009861737

The O 0 0.0047363425
patient O 0 0.0056856186
was O 0 0.0037548519
treated O 0 0.0053831968
with O 0 0.0063950373
methylprednisolone B-Chemical 1 0.9973502
and O 0 0.00981992
gradually O 0 0.021175185
improved O 0 0.021732012
. O 0 0.012597813

Macrophage O 0 0.8959706
- O 0 0.011501825
migration O 0 0.017978868
inhibition O 0 0.014913416
( O 0 0.0054736803
MIF O 0 0.73791754
) O 0 0.004561168
test O 0 0.002919866
with O 0 0.0048981956
ampicillin B-Chemical 1 0.98993343
was O 0 0.006180679
positive O 0 0.0073478017
. O 0 0.009395772

DISCUSSION O 0 0.021645097
: O 0 0.003884484
After O 0 0.0014831765
most O 0 0.0029896076
infections B-Disease 2 0.7304191
causing O 0 0.06526222
erythema B-Disease 0 0.99895346
multiforme I-Disease 0 0.99937856
and O 0 0.009459021
myocarditis B-Disease 2 0.99978715
were O 0 0.0016365539
ruled O 0 0.002732606
out O 0 0.00056417985
, O 0 0.0009498639
a O 0 0.0010222074
drug B-Disease 0 0.4032676
- I-Disease 0 0.003326978
induced I-Disease 0 0.0045550372
allergic I-Disease 2 0.9982494
reaction I-Disease 2 0.5952648
was O 0 0.006592082
suspected O 0 0.20216689
. O 0 0.007352804

Positive O 0 0.016443083
MIF O 0 0.3967513
test O 0 0.0036484268
for O 0 0.0025863724
ampicillin B-Chemical 1 0.9892259
showed O 0 0.0021855973
sensitization O 0 0.09994471
of O 0 0.0019192868
the O 0 0.0014273727
patient O 0 0.0026167077
' O 0 0.0023746102
s O 0 0.0032245251
lymphocytes O 0 0.10866831
to O 0 0.0056095575
ampicillin B-Chemical 1 0.98950326
. O 0 0.009301182

CONCLUSIONS O 0 0.91998094
: O 0 0.022230776
Hypersensitivity B-Disease 0 0.9952538
myocarditis I-Disease 2 0.9995216
is O 0 0.004203088
a O 0 0.0026205024
rare O 0 0.008765181
and O 0 0.002478466
dangerous O 0 0.056267884
manifestation O 0 0.21602757
of O 0 0.0061938236
allergy B-Disease 0 0.9850668
to O 0 0.010157051
penicillins B-Chemical 0 0.9924744
. O 0 0.011613782

Clomipramine B-Chemical 0 0.99884194
- O 0 0.011652117
induced O 0 0.0058031487
sleep B-Disease 0 0.9074309
disturbance I-Disease 0 0.67305136
does O 0 0.0017680966
not O 0 0.0014589727
impair O 0 0.0020214347
its O 0 0.006748575
prolactin O 0 0.99059594
- O 0 0.01046474
releasing O 0 0.09044167
action O 0 0.06730833
. O 0 0.009341525

The O 0 0.0023745697
present O 0 0.0014421158
study O 0 0.0017768693
was O 0 0.00094216026
undertaken O 0 0.00065917784
to O 0 0.00051980204
examine O 0 0.000317497
the O 0 0.00040455707
role O 0 0.0003444858
of O 0 0.0008542597
sleep B-Disease 0 0.9369441
disturbance I-Disease 0 0.8405841
, O 0 0.0010238137
induced O 0 0.000862782
by O 0 0.0009370856
clomipramine B-Chemical 0 0.99994123
administration O 0 0.51024747
, O 0 0.00067593006
on O 0 0.00017943214
the O 0 0.00028878346
secretory O 0 0.0056227925
rate O 0 0.00039955348
of O 0 0.0010356072
prolactin O 0 0.9967193
( O 0 0.00413086
PRL O 0 0.99858725
) O 0 0.00142383
in O 0 0.00046570823
addition O 0 0.0004163708
to O 0 0.00066327426
the O 0 0.00092592376
direct O 0 0.001793861
drug O 0 0.29832196
effect O 0 0.0063751494
. O 0 0.0063584857

Two O 0 0.0037562274
groups O 0 0.0021848816
of O 0 0.0016779891
supine O 0 0.0032404375
subjects O 0 0.0013653393
were O 0 0.0006569576
studied O 0 0.00073959434
under O 0 0.00041102874
placebo O 0 0.10066768
- O 0 0.0007823317
controlled O 0 0.00036941963
conditions O 0 0.00048350834
, O 0 0.00037128045
one O 0 0.00017627153
during O 0 0.00016794553
the O 0 0.00023866637
night O 0 0.00088415976
, O 0 0.00039274877
when O 0 0.00022439325
sleeping O 0 0.096100055
( O 0 0.00054000696
n O 0 0.00028309526
= O 0 0.00042716594
7 O 0 0.00021102786
) O 0 0.00033023898
and O 0 0.00021771746
the O 0 0.00021243923
other O 0 0.0002853805
at O 0 0.00027603417
daytime O 0 0.012721224
, O 0 0.0006638147
when O 0 0.0004675158
awake O 0 0.006925681
( O 0 0.001280671
n O 0 0.0012004896
= O 0 0.0023538892
6 O 0 0.0018799996
) O 0 0.0046693156
. O 0 0.004591045

Each O 0 0.002175463
subject O 0 0.0016867613
received O 0 0.0017870195
a O 0 0.001329134
single O 0 0.0010897481
50 O 0 0.0015559183
mg O 0 0.22113174
dose O 0 0.01506234
of O 0 0.0020517597
clomipramine B-Chemical 0 0.9997887
given O 0 0.0011803382
orally O 0 0.053481165
2 O 0 0.0011986323
hours O 0 0.0011319407
before O 0 0.0011381919
blood O 0 0.0073708547
collection O 0 0.0066675735
. O 0 0.005965891

Plasma O 0 0.6191506
PRL O 0 0.9922247
concentrations O 0 0.008424776
were O 0 0.0014828333
analysed O 0 0.0010301169
at O 0 0.00059589784
10 O 0 0.00066891906
min O 0 0.0007469608
intervals O 0 0.00048304768
and O 0 0.0005290411
underlying O 0 0.0012788938
secretory O 0 0.004439595
rates O 0 0.0009014
calculated O 0 0.0008015752
by O 0 0.0014409249
a O 0 0.0023392965
deconvolution O 0 0.008431654
procedure O 0 0.0063308533
. O 0 0.0066394643

For O 0 0.0024752636
both O 0 0.0017227606
experiments O 0 0.001280196
the O 0 0.0012476519
drug O 0 0.20786692
intake O 0 0.6155506
led O 0 0.0013600844
to O 0 0.0006219832
significant O 0 0.0007776783
increases O 0 0.0007302294
in O 0 0.00074965495
PRL O 0 0.99879944
secretion O 0 0.1841443
, O 0 0.0008647668
acting O 0 0.0021077702
preferentially O 0 0.0005229999
on O 0 0.00024937253
tonic O 0 0.61530113
secretion O 0 0.036376815
as O 0 0.00029033466
pulse O 0 0.0042776056
amplitude O 0 0.0038303924
and O 0 0.00038185614
frequency O 0 0.0004466724
did O 0 0.00035204252
not O 0 0.0003423114
differ O 0 0.0005563015
significantly O 0 0.00082266645
from O 0 0.0008277932
corresponding O 0 0.0010296657
control O 0 0.0018541531
values O 0 0.0035370034
. O 0 0.005110019

During O 0 0.0028904506
the O 0 0.0025052999
night O 0 0.0076649166
clomipramine B-Chemical 0 0.9996044
ingestion O 0 0.8259469
altered O 0 0.0022475661
the O 0 0.00075088255
complete O 0 0.00073875545
sleep O 0 0.23285435
architecture O 0 0.0017574003
in O 0 0.00042203406
that O 0 0.00035620457
it O 0 0.00053572
suppressed O 0 0.0010855338
REM O 0 0.9949615
sleep O 0 0.4502487
and O 0 0.0006294271
the O 0 0.0005928707
sleep O 0 0.1318692
cycles O 0 0.0007822575
and O 0 0.0011727343
induced O 0 0.0024526205
increased O 0 0.007360573
wakefulness O 0 0.9229274
. O 0 0.0067265565

As O 0 0.0021000525
the O 0 0.0016950753
relative O 0 0.0011536562
increase O 0 0.0012280154
in O 0 0.0012752927
PRL O 0 0.9973265
secretion O 0 0.08350366
expressed O 0 0.0004958086
as O 0 0.00035085896
a O 0 0.00035839222
percentage O 0 0.00016998874
of O 0 0.00032426824
the O 0 0.00023408048
mean O 0 0.00016896032
did O 0 0.00021189223
not O 0 0.00018503843
significantly O 0 0.00027286078
differ O 0 0.0002479077
between O 0 0.0001238163
the O 0 0.00019533822
night O 0 0.0005782661
and O 0 0.00021850482
day O 0 0.00018897036
time O 0 0.00017597279
studies O 0 0.00048462662
( O 0 0.0004443702
46 O 0 0.0005149556
+ O 0 0.00042598182
/ O 0 0.0008052434
- O 0 0.0004850511
19 O 0 0.0004079807
% O 0 0.0002493029
vs O 0 0.00040512768
34 O 0 0.00038398796
+ O 0 0.0003737527
/ O 0 0.00072859804
- O 0 0.00046068957
10 O 0 0.00026639964
% O 0 0.00027633962
) O 0 0.00036655477
, O 0 0.0002706378
it O 0 0.00022817965
can O 0 0.00017531811
be O 0 0.0002184044
concluded O 0 0.00036497883
that O 0 0.00018427907
the O 0 0.00024275812
observed O 0 0.0003162665
sleep B-Disease 0 0.84828043
disturbance I-Disease 0 0.57638985
did O 0 0.00043721896
not O 0 0.0003582636
interfere O 0 0.0005351655
with O 0 0.0007537391
the O 0 0.0009232509
drug O 0 0.25242743
action O 0 0.012354751
per O 0 0.0019912508
se O 0 0.0076554124
. O 0 0.0058458024

The O 0 0.0029272162
presence O 0 0.0023380972
of O 0 0.002980137
REM O 0 0.99126786
sleep O 0 0.62802297
was O 0 0.0010995573
shown O 0 0.0004985102
not O 0 0.00040663494
to O 0 0.00036727727
be O 0 0.00035612407
a O 0 0.0003169949
determining O 0 0.00024363138
factor O 0 0.0014525424
either O 0 0.0003136978
for O 0 0.00027366818
secretory O 0 0.0068264306
pulse O 0 0.006528781
amplitude O 0 0.0048965267
and O 0 0.0003426637
frequency O 0 0.00042044613
, O 0 0.00040099912
as O 0 0.00021015143
, O 0 0.00030669302
for O 0 0.00018302086
both O 0 0.00024018052
, O 0 0.00030206775
mean O 0 0.00017833183
nocturnal O 0 0.03696036
values O 0 0.00028431727
were O 0 0.0002929874
similar O 0 0.00027748547
with O 0 0.0005746608
and O 0 0.0007687086
without O 0 0.0012340541
prior O 0 0.0022542558
clomipramine B-Chemical 0 0.9996061
ingestion O 0 0.95863694
. O 0 0.008386237

Survey O 0 0.012517696
of O 0 0.007151485
complications O 0 0.17388189
of O 0 0.009420043
indocyanine B-Chemical 0 0.98505974
green I-Chemical 0 0.02383029
angiography O 0 0.5657737
in O 0 0.01171326
Japan O 0 0.13427934
. O 0 0.014224992

PURPOSE O 0 0.039347205
: O 0 0.004943464
We O 0 0.002035958
evaluated O 0 0.0016365413
the O 0 0.0015412478
safety O 0 0.0033807727
of O 0 0.0025841799
indocyanine B-Chemical 0 0.9849439
green I-Chemical 0 0.004727465
for O 0 0.0021404547
use O 0 0.003680731
in O 0 0.0043278965
fundus O 0 0.77884185
angiography O 0 0.6137279
. O 0 0.010429062

METHODS O 0 0.0062415306
: O 0 0.0030703216
We O 0 0.0013298949
sent O 0 0.0012488753
a O 0 0.00095023226
questionnaire O 0 0.00086740963
concerning O 0 0.00073782424
complications O 0 0.112815164
of O 0 0.0011808162
indocyanine B-Chemical 0 0.99389267
green I-Chemical 0 0.0019244911
to O 0 0.0005124554
32 O 0 0.000763029
institutions O 0 0.0010778455
in O 0 0.0003603969
Japan O 0 0.018836243
, O 0 0.00039485178
which O 0 0.00031114515
were O 0 0.00019893942
selected O 0 0.0001719423
on O 0 0.00012244015
the O 0 0.00018243704
basis O 0 0.00027562972
of O 0 0.00031983413
the O 0 0.00028520075
client O 0 0.000660438
list O 0 0.00031604225
from O 0 0.00034559565
the O 0 0.00047220106
Topcon O 0 0.11281016
Company O 0 0.22040804
, O 0 0.00086103927
which O 0 0.0009853035
manufactures O 0 0.0106857
the O 0 0.0017173837
indocyanine B-Chemical 0 0.9906476
green I-Chemical 0 0.015682157
fundus O 0 0.86600024
camera O 0 0.030232253
. O 0 0.008246613

RESULTS O 0 0.029904552
: O 0 0.004923083
Ophthalmologists O 0 0.0076487106
at O 0 0.001013982
15 O 0 0.00087201357
institutions O 0 0.0015212796
responded O 0 0.0013312713
, O 0 0.00076817913
reporting O 0 0.00085879583
a O 0 0.00046778886
total O 0 0.00035443957
of O 0 0.00052472256
3 O 0 0.00040917253
, O 0 0.00055217405
774 O 0 0.005247738
indocyanine B-Chemical 0 0.98203075
green I-Chemical 0 0.0015172621
angiograms O 0 0.18030773
performed O 0 0.00042122477
on O 0 0.00028771904
2 O 0 0.0004944444
, O 0 0.0006228369
820 O 0 0.0024861312
patients O 0 0.0013908381
between O 0 0.0005942267
June O 0 0.0016157281
1984 O 0 0.004898846
and O 0 0.0023296524
September O 0 0.0045784777
1992 O 0 0.012906002
. O 0 0.0057109795

Before O 0 0.006397522
angiography O 0 0.108954266
, O 0 0.0034314082
intradermal O 0 0.01622529
or O 0 0.0015244002
intravenous O 0 0.4927266
indocyanine B-Chemical 0 0.99372685
green I-Chemical 0 0.002874561
testing O 0 0.001165474
, O 0 0.0010262957
or O 0 0.000554909
both O 0 0.00060882117
was O 0 0.000632415
performed O 0 0.00067489897
at O 0 0.0006971466
13 O 0 0.0014503067
of O 0 0.001959591
15 O 0 0.002576114
institutions O 0 0.007882077
. O 0 0.005761377

For O 0 0.0026885092
three O 0 0.0015688611
patients O 0 0.003590203
, O 0 0.0018992317
the O 0 0.0011105038
decision O 0 0.0020926849
was O 0 0.0008390096
made O 0 0.00075405603
not O 0 0.00063505594
to O 0 0.0006870349
proceed O 0 0.0013679301
with O 0 0.0013537484
angiography O 0 0.07871418
after O 0 0.0010348354
positive O 0 0.0020890695
preangiographic O 0 0.037008833
testing O 0 0.0060357735
. O 0 0.0068851532

The O 0 0.0033647076
dosage O 0 0.027439192
of O 0 0.0033602526
indocyanine B-Chemical 0 0.98439676
green I-Chemical 0 0.0035321366
used O 0 0.00117922
for O 0 0.000899881
angiography O 0 0.075817905
varied O 0 0.0012110785
from O 0 0.0007129499
25 O 0 0.0009676976
to O 0 0.00061347545
75 O 0 0.0013667359
mg O 0 0.15752113
, O 0 0.0014935895
depending O 0 0.0016893133
upon O 0 0.0016091816
the O 0 0.0027681866
institution O 0 0.007847739
. O 0 0.006662298

There O 0 0.0050802296
were O 0 0.0023281854
13 O 0 0.0019457095
cases O 0 0.0019494976
of O 0 0.0016419876
adverse O 0 0.56874365
reactions O 0 0.022605667
( O 0 0.0012682894
0 O 0 0.0006082965
. O 0 0.00026117067
34 O 0 0.0004917547
% O 0 0.00039235002
) O 0 0.00044341516
, O 0 0.00028230256
ten O 0 0.00016430634
of O 0 0.00030935835
which O 0 0.00041396337
were O 0 0.00034807326
mild O 0 0.1549566
reactions O 0 0.0061966125
such O 0 0.0004744683
as O 0 0.0006507257
nausea B-Disease 2 0.9998965
, O 0 0.0067398543
exanthema B-Disease 0 0.99886215
, O 0 0.003189675
urtication B-Disease 0 0.9691714
, O 0 0.001868743
itchiness B-Disease 0 0.9888172
, O 0 0.0006966189
and O 0 0.0004890733
urgency O 0 0.07493401
to O 0 0.00060892844
defecate O 0 0.044691168
, O 0 0.0008767613
and O 0 0.0007840669
did O 0 0.0008451447
not O 0 0.0011133548
require O 0 0.00175352
treatment O 0 0.007963035
. O 0 0.0058474927

Also O 0 0.004645531
recorded O 0 0.002416828
were O 0 0.001407656
one O 0 0.000900584
case O 0 0.0010127637
of O 0 0.0013581287
pain B-Disease 0 0.88493735
of O 0 0.0012977639
the O 0 0.0008768991
vein O 0 0.0424699
, O 0 0.0009054935
which O 0 0.00071001943
required O 0 0.0003693573
treatment O 0 0.001536629
, O 0 0.0010963943
and O 0 0.00095697015
two O 0 0.0010359026
cases O 0 0.0037496665
of O 0 0.007987719
hypotension B-Disease 2 0.9984653
. O 0 0.01010875

The O 0 0.0059770206
two O 0 0.005521907
hypotensive B-Disease 2 0.98020923
patients O 0 0.01286058
required O 0 0.0042162607
treatment O 0 0.011783438
for O 0 0.01033813
shock B-Disease 0 0.9814989
. O 0 0.01926998

CONCLUSIONS O 0 0.7334654
: O 0 0.005561208
A O 0 0.0064129876
comparison O 0 0.0011970961
of O 0 0.0011712377
frequency O 0 0.0010822451
of O 0 0.001255699
adverse O 0 0.624786
reactions O 0 0.013219829
to O 0 0.00070451136
indocyanine B-Chemical 0 0.99369264
green I-Chemical 0 0.0017272021
with O 0 0.0005771121
the O 0 0.000347055
previously O 0 0.00036695233
reported O 0 0.00046188646
frequency O 0 0.00035209756
of O 0 0.00040871135
such O 0 0.00038345772
reactions O 0 0.007946342
to O 0 0.0005252148
fluorescein B-Chemical 0 0.95467466
sodium I-Chemical 0 0.9991621
indicated O 0 0.00045148554
that O 0 0.00048687877
indocyanine B-Chemical 0 0.9951929
green I-Chemical 0 0.0022865683
is O 0 0.0006080841
a O 0 0.00065294123
safe O 0 0.0023103007
as O 0 0.0007484622
fluorescein B-Chemical 0 0.30570835
for O 0 0.0012152207
use O 0 0.0025338335
in O 0 0.0032432217
angiography O 0 0.40579557
. O 0 0.0068088016

Angioedema B-Disease 0 0.9908564
following O 0 0.00886255
the O 0 0.007498541
intravenous O 0 0.6322234
administration O 0 0.48293242
of O 0 0.03323686
metoprolol B-Chemical 1 0.99883384
. O 0 0.026129358

A O 0 0.016605042
72 O 0 0.0039173793
- O 0 0.003005247
year O 0 0.0016542863
- O 0 0.0017318933
old O 0 0.0010801089
woman O 0 0.004378186
was O 0 0.00070476317
admitted O 0 0.0022709137
to O 0 0.0004709916
the O 0 0.00045191048
hospital O 0 0.0017165892
with O 0 0.00072049914
" O 0 0.0007931632
flash O 0 0.008312343
" O 0 0.0013408758
pulmonary B-Disease 0 0.943789
edema I-Disease 0 0.99929714
, O 0 0.0020932348
preceded O 0 0.0017022978
by O 0 0.0015392049
chest B-Disease 0 0.504831
pain I-Disease 0 0.9781707
, O 0 0.003947371
requiring O 0 0.0055380557
intubation O 0 0.10265087
. O 0 0.0061299144

Her O 0 0.008160319
medical O 0 0.007935696
history O 0 0.00847147
included O 0 0.0021646712
coronary B-Disease 0 0.4834392
artery I-Disease 0 0.40897173
disease I-Disease 0 0.5943942
with O 0 0.001798315
previous O 0 0.002126188
myocardial B-Disease 0 0.9985305
infarctions I-Disease 0 0.9988977
, O 0 0.022377
hypertension B-Disease 2 0.9992908
, O 0 0.00631657
and O 0 0.0057073254
diabetes B-Disease 2 0.99617934
mellitus I-Disease 0 0.99743325
. O 0 0.012041918

A O 0 0.022522418
history O 0 0.017385079
of O 0 0.009064557
angioedema B-Disease 2 0.998021
secondary O 0 0.03715508
to O 0 0.0077092843
lisinopril B-Chemical 0 0.9991093
therapy O 0 0.33788547
was O 0 0.009006092
elicited O 0 0.013383616
. O 0 0.01102335

Current O 0 0.04303199
medications O 0 0.3515158
did O 0 0.0028369748
not O 0 0.0019664632
include O 0 0.0034198198
angiotensin B-Chemical 1 0.99867356
- O 0 0.013000027
converting O 0 0.21685278
enzyme O 0 0.29263002
inhibitors O 0 0.27274635
or O 0 0.0041315285
beta O 0 0.7961055
- O 0 0.045776002
blockers O 0 0.9931652
. O 0 0.013075486

She O 0 0.009954946
had O 0 0.0048604426
no O 0 0.0036204243
previous O 0 0.004990039
beta O 0 0.37498322
- O 0 0.011394545
blocking O 0 0.017643893
drug O 0 0.71763414
exposure O 0 0.08392378
. O 0 0.013794943

During O 0 0.0024848732
the O 0 0.0017705836
first O 0 0.0011327286
day O 0 0.0011185718
of O 0 0.001378591
hospitalization O 0 0.08999305
( O 0 0.0014623285
while O 0 0.0007769583
intubated O 0 0.036795232
) O 0 0.0014356921
, O 0 0.0010331386
intravenous O 0 0.724424
metoprolol B-Chemical 1 0.99988186
was O 0 0.0012897274
given O 0 0.00076498825
, O 0 0.0013968579
resulting O 0 0.001661427
in O 0 0.0026635802
severe O 0 0.7592003
angioedema B-Disease 2 0.99892527
. O 0 0.012600435

The O 0 0.0063465666
angioedema B-Disease 2 0.99546427
resolved O 0 0.006730941
after O 0 0.0019530172
therapy O 0 0.012770755
with O 0 0.003992303
intravenous O 0 0.88387746
steroids B-Chemical 0 0.997391
and O 0 0.06787699
diphenhydramine B-Chemical 0 0.99975103
hydrochloride O 0 0.99726
. O 0 0.017303547

Effect O 0 0.015491694
of O 0 0.010487547
coniine B-Chemical 1 0.93495804
on O 0 0.0057544843
the O 0 0.007443023
developing O 0 0.025937084
chick O 0 0.17563765
embryo O 0 0.034522984
. O 0 0.01669995

Coniine B-Chemical 0 0.89470786
, O 0 0.0066913227
an O 0 0.004876044
alkaloid O 0 0.97893685
from O 0 0.0046117124
Conium O 0 0.99791485
maculatum O 0 0.8766808
( O 0 0.0045375056
poison O 0 0.35478094
hemlock O 0 0.96424586
) O 0 0.0040460215
, O 0 0.0015433553
has O 0 0.0010623712
been O 0 0.0013226011
shown O 0 0.0009367834
to O 0 0.001415899
be O 0 0.0027771797
teratogenic O 0 0.9907911
in O 0 0.0052988133
livestock O 0 0.19782415
. O 0 0.0087287165

The O 0 0.0045184577
major O 0 0.0058824457
teratogenic O 0 0.99052984
outcome O 0 0.010787874
is O 0 0.003569308
arthrogryposis B-Disease 0 0.9328818
, O 0 0.003697196
presumably O 0 0.0041675204
due O 0 0.002008878
to O 0 0.004193808
nicotinic O 0 0.99659157
receptor O 0 0.78452003
blockade O 0 0.85298645
. O 0 0.012784284

However O 0 0.0053966986
, O 0 0.0047363983
coniine B-Chemical 1 0.9346584
has O 0 0.0021367772
failed O 0 0.0018474356
to O 0 0.0010580856
produce O 0 0.00114494
arthrogryposis B-Disease 0 0.8728709
in O 0 0.0009268179
rats O 0 0.0030728856
or O 0 0.00058512826
mice O 0 0.00045312912
and O 0 0.000783823
is O 0 0.00086735474
only O 0 0.0011930828
weakly O 0 0.0039394223
teratogenic O 0 0.99336654
in O 0 0.004212986
rabbits O 0 0.015650155
. O 0 0.006682005

The O 0 0.0025677592
purpose O 0 0.0019717878
of O 0 0.0015068895
this O 0 0.0010712694
study O 0 0.0012868426
was O 0 0.00068329356
to O 0 0.0005004453
evaluate O 0 0.00032752403
and O 0 0.00046206257
compare O 0 0.00024447372
the O 0 0.00043228682
effects O 0 0.0010840497
of O 0 0.001334216
coniine B-Chemical 1 0.9909169
and O 0 0.002578097
nicotine B-Chemical 1 0.9961593
in O 0 0.0020750207
the O 0 0.0026310834
developing O 0 0.025896698
chick O 0 0.16312382
. O 0 0.007237312

Concentrations O 0 0.2252541
of O 0 0.00546036
coniine B-Chemical 1 0.9799304
and O 0 0.004396129
nicotine B-Chemical 1 0.99735886
sulfate O 0 0.9955419
were O 0 0.0016689863
0 O 0 0.0010857364
. O 0 0.0004940147
015 O 0 0.09353296
% O 0 0.00059517834
, O 0 0.0004962708
0 O 0 0.00041293606
. O 0 0.0002390223
03 O 0 0.0028696272
% O 0 0.00039342104
, O 0 0.00036761654
0 O 0 0.00032693066
. O 0 0.00019263061
075 O 0 0.005424964
% O 0 0.0003203456
, O 0 0.00029748757
0 O 0 0.00025794373
. O 0 0.00013197515
15 O 0 0.00017259031
% O 0 0.00023060586
, O 0 0.0002457436
0 O 0 0.0002305098
. O 0 0.0001239389
75 O 0 0.00030934095
% O 0 0.0002455895
, O 0 0.0002620614
1 O 0 0.00021990848
. O 0 0.00013050582
5 O 0 0.0001732315
% O 0 0.00022946602
, O 0 0.00024744417
3 O 0 0.0001883977
% O 0 0.00024807744
, O 0 0.00025521562
and O 0 0.00023744865
6 O 0 0.00019752904
% O 0 0.00026942109
and O 0 0.00027095742
1 O 0 0.00033607922
% O 0 0.00038741023
, O 0 0.00042939218
5 O 0 0.000356433
% O 0 0.0005220575
, O 0 0.00065341056
and O 0 0.0007824462
10 O 0 0.0011845574
% O 0 0.0016913095
, O 0 0.0026294584
respectively O 0 0.005756621
. O 0 0.005004901

Both O 0 0.008297808
compounds O 0 0.2884042
caused O 0 0.0057279
deformations B-Disease 0 0.42857218
and O 0 0.0038225784
lethality O 0 0.15412253
in O 0 0.0023365226
a O 0 0.0032490692
dose O 0 0.050000023
- O 0 0.0065942127
dependent O 0 0.004798807
manner O 0 0.010144834
. O 0 0.00851652

All O 0 0.004258621
concentrations O 0 0.005780033
of O 0 0.0036832164
nicotine B-Chemical 1 0.9969217
sulfate O 0 0.9960521
caused O 0 0.0037727796
some O 0 0.0018783004
lethality O 0 0.22242773
but O 0 0.00080937333
a O 0 0.00063920364
no O 0 0.0004024116
effect O 0 0.00058485975
level O 0 0.0004789319
for O 0 0.0008060476
coniine B-Chemical 1 0.9904288
lethality O 0 0.35460228
was O 0 0.0016924363
0 O 0 0.0018379461
. O 0 0.0012889695
75 O 0 0.0035536976
% O 0 0.00409183
. O 0 0.0046376423

The O 0 0.004044123
deformations B-Disease 0 0.12319398
caused O 0 0.0031637242
by O 0 0.0019941148
both O 0 0.0017906245
coniine B-Chemical 1 0.98548955
and O 0 0.0028437127
nicotine B-Chemical 1 0.9983265
sulfate O 0 0.9967362
were O 0 0.0015897349
excessive B-Disease 0 0.05267253
flexion I-Disease 0 0.6378827
or I-Disease 0 0.0008902115
extension I-Disease 0 0.0013764513
of I-Disease 0 0.001319671
one I-Disease 0 0.0012055264
or I-Disease 0 0.0018436935
more I-Disease 0 0.0043024775
toes I-Disease 0 0.071762905
. O 0 0.006870272

No O 0 0.007006014
histopathological O 0 0.19271924
alterations O 0 0.007471672
or O 0 0.0011914037
differences O 0 0.0007183652
in O 0 0.00074021495
bone O 0 0.021631088
formation O 0 0.0020833227
were O 0 0.00053324533
seen O 0 0.00039754531
in O 0 0.00029886657
the O 0 0.00032940134
limbs O 0 0.010117992
or O 0 0.00031370678
toes O 0 0.007013416
of O 0 0.00041126198
any O 0 0.00027336227
chicks O 0 0.001219827
from O 0 0.00026996387
any O 0 0.0002497723
group O 0 0.0005042071
; O 0 0.00068562594
however O 0 0.00054792716
, O 0 0.0005431954
extensive O 0 0.0010550241
cranial B-Disease 0 0.9019872
hemorrhage I-Disease 2 0.99968266
occurred O 0 0.0017307748
in O 0 0.0006985851
all O 0 0.0011021432
nicotine B-Chemical 1 0.9980945
sulfate O 0 0.99669707
- O 0 0.011845991
treated O 0 0.008120468
chicks O 0 0.02187943
. O 0 0.0062395916

There O 0 0.00559412
was O 0 0.0025618891
a O 0 0.0020917032
statistically O 0 0.0016848359
significant O 0 0.0017696688
( O 0 0.0017621036
P O 0 0.015757885
< O 0 0.00096304354
or O 0 0.00055120396
= O 0 0.0008465318
0 O 0 0.00050349365
. O 0 0.0002892105
01 O 0 0.0020766982
) O 0 0.000561966
decrease O 0 0.00041157648
in O 0 0.00032252504
movement O 0 0.0011330185
in O 0 0.0005323031
coniine B-Chemical 1 0.9852991
and O 0 0.001590529
nicotine B-Chemical 1 0.99877816
sulfate O 0 0.9971106
treated O 0 0.0060508684
chicks O 0 0.0061599123
as O 0 0.0011248501
determined O 0 0.001517414
by O 0 0.0033605304
ultrasound O 0 0.08841896
. O 0 0.0070349965

Control O 0 0.008520314
chicks O 0 0.0059548276
were O 0 0.0018180065
in O 0 0.001205317
motion O 0 0.004238147
an O 0 0.0010178555
average O 0 0.00042529672
of O 0 0.00073770894
33 O 0 0.0009796494
. O 0 0.00030727105
67 O 0 0.0006696924
% O 0 0.00033658874
of O 0 0.00030734605
the O 0 0.00025877828
time O 0 0.00027364187
, O 0 0.00047411182
while O 0 0.00040069755
coniine B-Chemical 1 0.988957
- O 0 0.0011042892
treated O 0 0.000674526
chicks O 0 0.001332303
were O 0 0.00023631216
only O 0 0.00022394612
moving O 0 0.00061284046
8 O 0 0.0002507183
. O 0 0.00012829377
95 O 0 0.00041807708
% O 0 0.00018599065
of O 0 0.00021094277
a O 0 0.00026999015
5 O 0 0.00022943057
- O 0 0.00035255522
min O 0 0.0003296033
interval O 0 0.0003575316
, O 0 0.00029979204
and O 0 0.00026663445
no O 0 0.00025128358
movement O 0 0.00089713593
was O 0 0.0004647665
observed O 0 0.00049022667
for O 0 0.0010454381
nicotine B-Chemical 1 0.99733126
sulfate O 0 0.99530256
treated O 0 0.027093712
chicks O 0 0.046034478
. O 0 0.006860226

In O 0 0.002898015
summary O 0 0.0017419618
, O 0 0.00216667
the O 0 0.001375644
chick O 0 0.010946627
embryo O 0 0.002442063
provides O 0 0.0007008263
a O 0 0.00070890185
reliable O 0 0.0007725217
and O 0 0.000574214
simple O 0 0.0009976523
experimental O 0 0.0010486216
animal O 0 0.0016776521
model O 0 0.0017448248
of O 0 0.003153119
coniine B-Chemical 1 0.9928498
- O 0 0.012152395
induced O 0 0.011363953
arthrogryposis B-Disease 0 0.98057944
. O 0 0.009857379

Data O 0 0.005367918
from O 0 0.0022597753
this O 0 0.0015927826
model O 0 0.0016591413
support O 0 0.0013119264
a O 0 0.001305394
mechanism O 0 0.001689109
involving O 0 0.002347314
nicotinic O 0 0.9983908
receptor O 0 0.5608491
blockade O 0 0.52409387
with O 0 0.0027352283
subsequent O 0 0.0032006528
decreased O 0 0.010592924
fetal O 0 0.5000887
movement O 0 0.025761342
. O 0 0.007665806

Immediate O 0 0.20427631
allergic B-Disease 0 0.9841828
reactions I-Disease 0 0.38981953
to O 0 0.028594771
amoxicillin B-Chemical 0 0.98646927
. O 0 0.031080432

A O 0 0.0131256245
large O 0 0.0033512944
group O 0 0.0025139637
of O 0 0.0021246567
patients O 0 0.0038635542
with O 0 0.0023638513
suspected O 0 0.20808059
allergic B-Disease 0 0.998589
reactions I-Disease 0 0.48587972
to O 0 0.0026527983
beta B-Chemical 0 0.9259488
- I-Chemical 0 0.015196568
lactam I-Chemical 0 0.993665
antibiotics O 0 0.8744455
was O 0 0.004520177
evaluated O 0 0.0053172065
. O 0 0.0067903018

A O 0 0.011179476
detailed O 0 0.002643686
clinical O 0 0.00538599
history O 0 0.007873577
, O 0 0.0016794499
together O 0 0.00090571697
with O 0 0.0010591208
skin O 0 0.011049815
tests O 0 0.0023240955
, O 0 0.0013531947
RAST O 0 0.6536408
( O 0 0.0009829234
radioallergosorbent O 0 0.0051052887
test O 0 0.00070926535
) O 0 0.000824008
, O 0 0.00042559052
and O 0 0.00028175834
controlled O 0 0.00027487683
challenge O 0 0.00036678146
tests O 0 0.00074365747
, O 0 0.00038270373
was O 0 0.0002313994
used O 0 0.00018589807
to O 0 0.00017882767
establish O 0 0.00019525443
whether O 0 0.00013773078
patients O 0 0.0022563387
allergic B-Disease 0 0.9967153
to O 0 0.0009491976
beta B-Chemical 0 0.94463074
- I-Chemical 0 0.0067574913
lactam I-Chemical 0 0.9968629
antibiotics O 0 0.8114685
had O 0 0.0006170718
selective O 0 0.014137552
immediate O 0 0.0076838
allergic B-Disease 0 0.99801266
responses O 0 0.0071591
to O 0 0.00070891296
amoxicillin B-Chemical 0 0.99936336
( O 0 0.0026461491
AX B-Chemical 1 0.9819903
) O 0 0.0010568168
or O 0 0.00036199353
were O 0 0.00046146088
cross O 0 0.0009770917
- O 0 0.0013582374
reacting O 0 0.010914525
with O 0 0.002150069
other O 0 0.0042825886
penicillin B-Chemical 1 0.99834585
derivatives O 0 0.72065043
. O 0 0.008014886

Skin O 0 0.052634075
tests O 0 0.004796075
were O 0 0.0020537036
performed O 0 0.001635447
with O 0 0.0021905934
benzylpenicilloyl B-Chemical 0 0.39387703
- I-Chemical 0 0.004916444
poly I-Chemical 0 0.27019563
- I-Chemical 0 0.006440147
L I-Chemical 0 0.7446812
- I-Chemical 0 0.004610644
lysine I-Chemical 0 0.5589469
( O 0 0.0037355283
BPO B-Chemical 0 0.99916303
- I-Chemical 0 0.013231275
PLL I-Chemical 0 0.97350085
) O 0 0.0027596138
, O 0 0.001308574
benzylpenicilloate B-Chemical 0 0.94870937
, O 0 0.0025755751
benzylpenicillin B-Chemical 0 0.99794966
( O 0 0.00498752
PG B-Chemical 0 0.99709415
) O 0 0.0045819995
, O 0 0.0027711526
ampicillin B-Chemical 1 0.9973591
( O 0 0.0056584813
AMP B-Chemical 1 0.9955319
) O 0 0.0061294297
, O 0 0.003990348
and O 0 0.0051838127
AX B-Chemical 1 0.95601434
. O 0 0.00869414

RAST O 0 0.52656627
for O 0 0.01127842
BPO B-Chemical 0 0.9924736
- I-Chemical 0 0.0269071
PLL I-Chemical 0 0.9157589
and O 0 0.010610385
AX B-Chemical 1 0.97688234
- O 0 0.019368902
PLL O 0 0.66616195
was O 0 0.008643433
done O 0 0.009037037
. O 0 0.012200646

When O 0 0.0032483153
both O 0 0.0024401208
skin O 0 0.00682905
test O 0 0.0019453771
and O 0 0.001736921
RAST O 0 0.43142202
for O 0 0.0012931555
BPO B-Chemical 0 0.9941803
were O 0 0.00095706544
negative O 0 0.0007220412
, O 0 0.000750264
single O 0 0.0006017401
- O 0 0.0009252808
blind O 0 0.0034898638
, O 0 0.0006677369
placebo O 0 0.09556546
- O 0 0.000573051
controlled O 0 0.00028799567
challenge O 0 0.00036403298
tests O 0 0.00058511517
were O 0 0.0003010015
done O 0 0.00024829165
to O 0 0.00031124247
ensure O 0 0.00025442624
tolerance O 0 0.015417877
of O 0 0.001899426
PG B-Chemical 0 0.9926987
or O 0 0.0021241938
sensitivity O 0 0.007629845
to O 0 0.0050176918
AX B-Chemical 1 0.9707065
. O 0 0.008803982

A O 0 0.013159577
total O 0 0.0030199487
of O 0 0.0031045026
177 O 0 0.008329183
patients O 0 0.004079539
were O 0 0.0018680023
diagnosed O 0 0.012419421
as O 0 0.0022486271
allergic B-Disease 0 0.991662
to O 0 0.0046266033
beta B-Chemical 0 0.9324679
- I-Chemical 0 0.03500201
lactam I-Chemical 0 0.99193937
antibiotics O 0 0.95039237
. O 0 0.0113272555

We O 0 0.003190288
selected O 0 0.0021156755
the O 0 0.0018539769
54 O 0 0.002704001
( O 0 0.001645903
30 O 0 0.00085194537
. O 0 0.00053636456
5 O 0 0.00055411825
% O 0 0.0006723473
) O 0 0.00078285707
cases O 0 0.0008550174
of O 0 0.0009013557
immediate O 0 0.004062572
AX B-Chemical 1 0.9878864
allergy B-Disease 0 0.98498046
with O 0 0.0029663017
good O 0 0.0035635955
tolerance O 0 0.14640686
of O 0 0.01053653
PG B-Chemical 0 0.9913216
. O 0 0.011247969

Anaphylaxis B-Disease 0 0.94860405
was O 0 0.0032268984
seen O 0 0.0017809363
in O 0 0.0011495934
37 O 0 0.001592076
patients O 0 0.0023370974
( O 0 0.0012064489
69 O 0 0.0011225359
% O 0 0.0007634123
) O 0 0.0008110799
, O 0 0.00054216484
the O 0 0.00037837576
other O 0 0.0004990299
17 O 0 0.0008701555
( O 0 0.0007506432
31 O 0 0.00083168555
% O 0 0.00070068374
) O 0 0.0010416916
having O 0 0.0015860754
urticaria B-Disease 2 0.9987212
and O 0 0.0038173543
/ O 0 0.009754031
or O 0 0.00530441
angioedema B-Disease 2 0.9984383
. O 0 0.01087856

All O 0 0.003490413
the O 0 0.0022017448
patients O 0 0.0032014346
were O 0 0.0014091186
skin O 0 0.004437267
test O 0 0.0011053145
negative O 0 0.00092936016
to O 0 0.0010605525
BPO B-Chemical 0 0.99590164
; O 0 0.0019597101
49 O 0 0.0009471691
of O 0 0.0005947038
51 O 0 0.0009426002
( O 0 0.000583169
96 O 0 0.00065407576
% O 0 0.00040903155
) O 0 0.00044467297
were O 0 0.00025228987
also O 0 0.0002980724
negative O 0 0.00035799984
to O 0 0.00047798138
MDM B-Disease 0 0.27452406
, O 0 0.00070252956
and O 0 0.0005191957
44 O 0 0.0007792807
of O 0 0.0007329865
46 O 0 0.0013526356
( O 0 0.0012389903
96 O 0 0.0018922456
% O 0 0.001708958
) O 0 0.002872181
to O 0 0.0036261673
PG B-Chemical 0 0.9803862
. O 0 0.0086656865

Skin O 0 0.068657435
tests O 0 0.0073400713
with O 0 0.0048797317
AX B-Chemical 1 0.8208338
were O 0 0.0027354455
positive O 0 0.0021473137
in O 0 0.002115314
34 O 0 0.003437099
( O 0 0.0033006554
63 O 0 0.0044752965
% O 0 0.003989945
) O 0 0.0060220915
patients O 0 0.011000288
. O 0 0.008441842

RAST O 0 0.34497717
was O 0 0.0033253168
positive O 0 0.0020775998
for O 0 0.0018332911
AX B-Chemical 1 0.825684
in O 0 0.001375025
22 O 0 0.0015901754
patients O 0 0.002338017
( O 0 0.0012254786
41 O 0 0.0014184564
% O 0 0.00082278886
) O 0 0.0009033212
and O 0 0.00065006607
to O 0 0.00085080724
BPO B-Chemical 0 0.9900059
in O 0 0.0010929675
just O 0 0.0011263163
5 O 0 0.0012287562
( O 0 0.0019715875
9 O 0 0.0020556787
% O 0 0.003133288
) O 0 0.005529055
. O 0 0.0053598224

None O 0 0.009692142
of O 0 0.003935151
the O 0 0.0027635505
sera O 0 0.005087436
with O 0 0.0028585298
negative O 0 0.003083632
RAST O 0 0.50918627
for O 0 0.0035095515
AX B-Chemical 1 0.91268593
were O 0 0.004120562
positive O 0 0.0046944646
to O 0 0.008363547
BPO B-Chemical 0 0.9844972
. O 0 0.015502958

Challenge O 0 0.011554471
tests O 0 0.004746069
with O 0 0.002928892
AX B-Chemical 1 0.80632454
were O 0 0.0013261468
performed O 0 0.00086582673
in O 0 0.0006837577
23 O 0 0.0009740851
subjects O 0 0.0009863263
( O 0 0.0007166571
43 O 0 0.000761349
% O 0 0.00046987057
) O 0 0.00045043838
to O 0 0.00022777711
establish O 0 0.00023927538
the O 0 0.00026897065
diagnosis O 0 0.0022097784
of O 0 0.00056935084
immediate O 0 0.007574918
allergic B-Disease 2 0.99934477
reaction I-Disease 2 0.3664406
to O 0 0.0008424986
AX B-Chemical 1 0.987278
, O 0 0.0006622475
and O 0 0.0003325605
in O 0 0.00023766428
15 O 0 0.00023151549
cases O 0 0.000521925
( O 0 0.00044570313
28 O 0 0.00042001007
% O 0 0.00037661006
) O 0 0.00047098869
both O 0 0.00035542215
skin O 0 0.0031307915
test O 0 0.00076891226
and O 0 0.0011339784
RAST O 0 0.45329058
for O 0 0.0019291266
AX B-Chemical 1 0.9314493
were O 0 0.0035702426
negative O 0 0.005158145
. O 0 0.0066401497

PG B-Chemical 0 0.9652875
was O 0 0.007875472
well O 0 0.0054693087
tolerated O 0 0.017710183
by O 0 0.005807981
all O 0 0.0057524303
54 O 0 0.0121173095
patients O 0 0.017640423
. O 0 0.012466272

We O 0 0.0031558766
describe O 0 0.0024089871
the O 0 0.0017209173
largest O 0 0.0018396423
group O 0 0.0018218523
of O 0 0.0024093643
AX B-Chemical 1 0.9860297
- O 0 0.008659908
allergic B-Disease 0 0.99537057
patients O 0 0.017132916
who O 0 0.004037261
have O 0 0.0018814454
tolerated O 0 0.13046438
PG B-Chemical 0 0.99318624
reported O 0 0.0062183654
so O 0 0.003887548
far O 0 0.005594682
. O 0 0.006886379

Diagnosis O 0 0.04649719
of O 0 0.0035625868
these O 0 0.0030057817
patients O 0 0.0040201256
can O 0 0.0013157292
be O 0 0.001158568
achieved O 0 0.0011630412
only O 0 0.00092367333
if O 0 0.0007367423
specific O 0 0.0015455723
AX B-Chemical 1 0.96525604
- O 0 0.0038279674
related O 0 0.0018442079
reagents O 0 0.038179398
are O 0 0.004272705
employed O 0 0.007324453
. O 0 0.0073327855

Further O 0 0.00423227
studies O 0 0.0028356977
are O 0 0.0014673196
necessary O 0 0.00079129444
to O 0 0.00070482894
determine O 0 0.00035647364
the O 0 0.00051171007
exact O 0 0.0009769055
extent O 0 0.00041504385
of O 0 0.00062863895
this O 0 0.00055875414
problem O 0 0.0011242303
and O 0 0.0006217133
to O 0 0.0005367753
improve O 0 0.0005906887
the O 0 0.00086354325
efficacy O 0 0.0032213894
of O 0 0.0024606124
diagnostic O 0 0.005346866
methods O 0 0.0063292636
. O 0 0.0065523074

Reversal O 0 0.22564667
by O 0 0.0048955814
phenylephrine B-Chemical 1 0.9967694
of O 0 0.002918102
the O 0 0.0014362752
beneficial O 0 0.003333692
effects O 0 0.0022480343
of O 0 0.0019088227
intravenous O 0 0.9192949
nitroglycerin B-Chemical 1 0.9997961
in O 0 0.002492455
patients O 0 0.014952843
with O 0 0.006934184
acute B-Disease 2 0.99585897
myocardial I-Disease 2 0.99916255
infarction I-Disease 2 0.9996593
. O 0 0.024932962

Nitroglycerin B-Chemical 0 0.99819833
has O 0 0.004426728
been O 0 0.0026821971
shown O 0 0.0011748597
to O 0 0.0010577263
reduce O 0 0.0010986349
ST O 0 0.82197773
- O 0 0.0023878214
segment O 0 0.0018829367
elevation O 0 0.21321395
during O 0 0.00077929295
acute B-Disease 2 0.99455947
myocardial I-Disease 2 0.99971944
infarction I-Disease 2 0.9999567
, O 0 0.0055173947
an O 0 0.0009265274
effect O 0 0.00071239297
potentiated O 0 0.10667512
in O 0 0.00041800074
the O 0 0.0004203395
dog O 0 0.0014041562
by O 0 0.00069132505
agents O 0 0.07098029
that O 0 0.001096938
reverse O 0 0.24587287
nitroglycerin B-Chemical 1 0.9997986
- O 0 0.045555543
induced O 0 0.042400166
hypotension B-Disease 2 0.99893683
. O 0 0.0099187065

Our O 0 0.0036191605
study O 0 0.0032739735
was O 0 0.0017627773
designed O 0 0.001523441
to O 0 0.0010509032
determine O 0 0.00057839596
the O 0 0.00092304253
effects O 0 0.001831328
of O 0 0.0019454695
combined O 0 0.0100791
nitroglycerin B-Chemical 1 0.99961734
and O 0 0.02700336
phenylephrine B-Chemical 1 0.9987332
therapy O 0 0.54496187
. O 0 0.010709468

Ten O 0 0.0073283785
patients O 0 0.005702229
with O 0 0.003293773
acute O 0 0.90905905
transmural O 0 0.98487407
myocardial B-Disease 0 0.9989767
infarctions I-Disease 0 0.9988096
received O 0 0.00752935
intravenous O 0 0.9400685
nitroglycerin B-Chemical 1 0.999913
, O 0 0.0015603149
sufficient O 0 0.00030675123
to O 0 0.00026543497
reduce O 0 0.00022663675
mean O 0 0.00023002327
arterial O 0 0.28093976
pressure O 0 0.027831864
from O 0 0.0003656902
107 O 0 0.001083993
+ O 0 0.0005092113
/ O 0 0.0008474587
- O 0 0.00045658782
6 O 0 0.00016877614
to O 0 0.00019120968
85 O 0 0.00046044745
+ O 0 0.00042647286
/ O 0 0.00080732856
- O 0 0.0005333659
6 O 0 0.0002521711
mm O 0 0.0019949898
Hg O 0 0.88098675
( O 0 0.0005447
P O 0 0.0052591106
less O 0 0.0003586089
than O 0 0.00027915213
0 O 0 0.00056768645
. O 0 0.00044716342
001 O 0 0.08100745
) O 0 0.0014289791
, O 0 0.0012309859
for O 0 0.0011406769
60 O 0 0.0024264473
minutes O 0 0.0032217966
. O 0 0.004562428

Left O 0 0.08251717
ventricular O 0 0.89052343
filling O 0 0.01630344
pressure O 0 0.034734275
decreased O 0 0.0025633336
from O 0 0.0011257518
19 O 0 0.0016694805
+ O 0 0.0011372702
/ O 0 0.0015959372
- O 0 0.00093009276
2 O 0 0.00042659725
to O 0 0.00037084182
11 O 0 0.0005586538
+ O 0 0.00064039417
/ O 0 0.0011491412
- O 0 0.0008198684
2 O 0 0.0005318966
mm O 0 0.0033115756
Hg O 0 0.88732064
( O 0 0.0009332783
P O 0 0.0063794823
less O 0 0.00075285695
than O 0 0.0007035368
0 O 0 0.0015942802
. O 0 0.0016002283
001 O 0 0.14786565
) O 0 0.006870181
. O 0 0.005788437

SigmaST O 0 0.15557402
, O 0 0.0036563931
the O 0 0.0016427202
sum O 0 0.0013158196
of O 0 0.0019973998
ST O 0 0.8023672
- O 0 0.002531429
segment O 0 0.0018060851
elevations O 0 0.0794083
in O 0 0.00060045876
16 O 0 0.00073505874
precordial O 0 0.9353446
leads O 0 0.0009049601
, O 0 0.0007388389
decreased O 0 0.0013588972
( O 0 0.000867541
P O 0 0.013662874
less O 0 0.00046919426
than O 0 0.00034163488
0 O 0 0.0006592812
. O 0 0.0004988536
02 O 0 0.009467273
) O 0 0.0018833929
with O 0 0.0026796022
intravenous O 0 0.90123975
nitroglycerin B-Chemical 1 0.99918514
. O 0 0.011101176

Subsequent O 0 0.005536257
addition O 0 0.0019971735
of O 0 0.0030372518
phenylephrine B-Chemical 1 0.9986388
infusion O 0 0.2829825
, O 0 0.0015755871
sufficient O 0 0.00056681497
to O 0 0.00062721793
re O 0 0.014992494
- O 0 0.0010476878
elevate O 0 0.002123744
mean O 0 0.00034295765
arterial O 0 0.3052805
pressure O 0 0.026740957
to O 0 0.00040352024
106 O 0 0.0007489338
+ O 0 0.00055383134
/ O 0 0.00093537336
- O 0 0.0005518347
4 O 0 0.00026559416
mm O 0 0.001985439
Hg O 0 0.8960214
( O 0 0.00043834274
P O 0 0.00558962
less O 0 0.00023319964
than O 0 0.00015081326
0 O 0 0.00026629044
. O 0 0.00015768746
001 O 0 0.0649796
) O 0 0.00034816848
for O 0 0.00015016364
30 O 0 0.00016686918
minutes O 0 0.00018485592
, O 0 0.00024400612
increased O 0 0.00037353786
left O 0 0.0009841623
ventricular O 0 0.9151642
filling O 0 0.008480627
pressure O 0 0.028253824
to O 0 0.00031671365
17 O 0 0.0005750569
+ O 0 0.00046335557
/ O 0 0.00088253943
- O 0 0.0005356672
2 O 0 0.00030424178
mm O 0 0.0023166048
Hg O 0 0.9078232
( O 0 0.0004363972
P O 0 0.005966969
less O 0 0.00024011388
than O 0 0.00016043196
0 O 0 0.00029128758
. O 0 0.00017967218
05 O 0 0.015291958
) O 0 0.00044556317
and O 0 0.00027982733
also O 0 0.00034681454
significantly O 0 0.0005427525
increased O 0 0.0014500223
sigmaST O 0 0.5100406
( O 0 0.0012422457
P O 0 0.01954509
less O 0 0.00078527856
than O 0 0.0006964068
0 O 0 0.0015664981
. O 0 0.001504995
05 O 0 0.03862686
) O 0 0.006098574
. O 0 0.0053810803

Our O 0 0.0030909555
results O 0 0.0018420551
suggest O 0 0.0012085579
that O 0 0.0009816068
addition O 0 0.0007696167
of O 0 0.0016849249
phenylephrine B-Chemical 1 0.99925655
to O 0 0.002126701
nitroglycerin B-Chemical 1 0.9998474
is O 0 0.0010932402
not O 0 0.00053124275
beneficial O 0 0.0018117349
in O 0 0.00044759078
the O 0 0.00048541254
treatment O 0 0.0013570096
of O 0 0.0012259065
patients O 0 0.0072679576
with O 0 0.0054635303
acute B-Disease 2 0.9962663
myocardial I-Disease 2 0.999265
infarction I-Disease 2 0.99970156
. O 0 0.024030551

Acetazolamide B-Chemical 0 0.99839884
- O 0 0.018122032
induced O 0 0.010841313
nephrolithiasis B-Disease 2 0.99882954
: O 0 0.006709164
implications O 0 0.0034663805
for O 0 0.002106619
treatment O 0 0.0056160837
of O 0 0.0071463203
neuromuscular B-Disease 0 0.98477256
disorders I-Disease 0 0.9851216
. O 0 0.013701767

Carbonic O 0 0.9862477
anhydrase O 0 0.98640114
inhibitors O 0 0.53244674
can O 0 0.022971597
cause O 0 0.18826461
nephrolithiasis B-Disease 2 0.9960424
. O 0 0.041985895

We O 0 0.0034373344
studied O 0 0.0029660803
20 O 0 0.0020598096
patients O 0 0.002891384
receiving O 0 0.0033191356
long O 0 0.0018385935
- O 0 0.0021769062
term O 0 0.0022206001
carbonic O 0 0.99780613
anhydrase O 0 0.9986077
inhibitor O 0 0.56353474
treatment O 0 0.010820454
for O 0 0.002239196
periodic O 0 0.14682846
paralysis B-Disease 2 0.99787104
and O 0 0.017287122
myotonia B-Disease 0 0.9968189
. O 0 0.011469277

Three O 0 0.007877079
patients O 0 0.008142385
on O 0 0.003781469
acetazolamide B-Chemical 0 0.99718165
( O 0 0.00676173
15 O 0 0.00299919
% O 0 0.00365783
) O 0 0.0051825293
developed O 0 0.010541891
renal B-Disease 0 0.99340844
calculi I-Disease 0 0.9934471
. O 0 0.020111255

Extracorporeal O 0 0.014889498
lithotripsy O 0 0.037323095
successfully O 0 0.0036298335
removed O 0 0.0016705872
a O 0 0.0021172664
renal B-Disease 0 0.9956593
calculus I-Disease 0 0.9833051
in O 0 0.0009624184
one O 0 0.00051654055
patient O 0 0.0008979064
and O 0 0.0005705669
surgery O 0 0.001491756
removed O 0 0.0005068168
a O 0 0.00089673465
staghorn O 0 0.8825945
calculus B-Disease 0 0.8740784
in O 0 0.0011819673
another O 0 0.0015413169
, O 0 0.0018475254
permitting O 0 0.0034667724
continued O 0 0.0041950643
treatment O 0 0.009967833
. O 0 0.0064019854

Renal O 0 0.71621877
function O 0 0.009542087
remained O 0 0.008088706
normal O 0 0.009157998
in O 0 0.0062726336
all O 0 0.0077001853
patients O 0 0.020540033
. O 0 0.014529692

Nephrolithiasis B-Disease 0 0.984239
is O 0 0.004914459
a O 0 0.0039470526
complication O 0 0.16035593
of O 0 0.0049618776
acetazolamide B-Chemical 0 0.99874854
but O 0 0.0033503375
does O 0 0.0019489233
not O 0 0.0020649878
preclude O 0 0.0039379927
its O 0 0.0074276347
use O 0 0.00852219
. O 0 0.008536514

Effects O 0 0.021677943
of O 0 0.009904964
calcium B-Chemical 1 0.9910172
channel O 0 0.67768365
blockers O 0 0.9955101
on O 0 0.008220712
bupivacaine B-Chemical 1 0.9989813
- O 0 0.048700646
induced O 0 0.026800068
toxicity B-Disease 2 0.98958886
. O 0 0.015452057

The O 0 0.0025951464
purpose O 0 0.0019974979
of O 0 0.0015319596
this O 0 0.0010945168
study O 0 0.001326194
was O 0 0.0007136535
to O 0 0.0005353313
investigate O 0 0.00037600272
the O 0 0.00048943213
influence O 0 0.0005849883
of O 0 0.0015602993
calcium B-Chemical 1 0.99779737
channel O 0 0.6738012
blockers O 0 0.99840254
on O 0 0.0028788187
bupivacaine B-Chemical 1 0.9996457
- O 0 0.02627574
induced O 0 0.017061606
acute O 0 0.9923929
toxicity B-Disease 2 0.9959168
. O 0 0.012366755

For O 0 0.0023367652
each O 0 0.0011363779
of O 0 0.0015429894
the O 0 0.0010428539
three O 0 0.00064917793
tested O 0 0.0011070648
calcium B-Chemical 1 0.99648595
channel O 0 0.70455253
blockers O 0 0.9992028
( O 0 0.04392525
diltiazem B-Chemical 1 0.9999461
, O 0 0.019017568
verapamil B-Chemical 0 0.99989367
and O 0 0.0054573617
bepridil B-Chemical 1 0.99989474
) O 0 0.002120651
6 O 0 0.00022185869
groups O 0 0.00022939075
of O 0 0.00024855972
mice O 0 0.00014449583
were O 0 0.00020228524
treated O 0 0.0003605204
by O 0 0.00021301325
two O 0 0.00015781622
different O 0 0.0002733915
doses O 0 0.02547068
, O 0 0.0005503635
i O 0 0.0010527882
. O 0 0.00018046229
e O 0 0.0005454713
. O 0 0.00014325754
2 O 0 0.0001867733
and O 0 0.00019207214
10 O 0 0.00025055296
mg O 0 0.10211244
/ O 0 0.0006747423
kg O 0 0.0029918887
/ O 0 0.00061054603
i O 0 0.00066789956
. O 0 0.00015071993
p O 0 0.0003218815
. O 0 0.00013355316
, O 0 0.00022992637
or O 0 0.00014210303
an O 0 0.00021420328
equal O 0 0.00013924783
volume O 0 0.00052603194
of O 0 0.0002923816
saline O 0 0.034120925
for O 0 0.00018480304
the O 0 0.00019197508
control O 0 0.00019616843
group O 0 0.00037514308
( O 0 0.00036765946
n O 0 0.00021380722
= O 0 0.000338011
20 O 0 0.00024400519
) O 0 0.0003468585
; O 0 0.0002791987
15 O 0 0.00011869897
minutes O 0 0.00012521961
later O 0 0.00013517671
, O 0 0.00018760144
all O 0 0.0001207834
the O 0 0.00013918953
animals O 0 0.0001537146
were O 0 0.00017701449
injected O 0 0.00018130949
with O 0 0.00023871302
a O 0 0.00026503793
single O 0 0.00029646966
50 O 0 0.0006216588
mg O 0 0.21762462
/ O 0 0.0012076729
kg O 0 0.0043779095
/ O 0 0.0011211727
i O 0 0.001257843
. O 0 0.00045004566
p O 0 0.0010534574
. O 0 0.0007468673
dose O 0 0.008024715
of O 0 0.0058442284
bupivacaine B-Chemical 1 0.9982803
. O 0 0.008896126

The O 0 0.0048490623
convulsant O 0 0.9955147
activity O 0 0.004120359
, O 0 0.0019467367
the O 0 0.0008892561
time O 0 0.0006805877
of O 0 0.0009575457
latency O 0 0.003183632
to O 0 0.0007891261
convulse O 0 0.30134922
and O 0 0.00076198846
the O 0 0.00068510533
mortality O 0 0.044828173
rate O 0 0.00083869515
were O 0 0.000870498
assessed O 0 0.00089803647
in O 0 0.0012959013
each O 0 0.001520211
group O 0 0.0049612564
. O 0 0.005835967

The O 0 0.0034410392
local O 0 0.004979847
anesthetic O 0 0.52941287
- O 0 0.0041751405
induced O 0 0.0023349605
mortality O 0 0.13978976
was O 0 0.0011362437
significantly O 0 0.0011347379
increased O 0 0.0013457694
by O 0 0.00094468525
the O 0 0.00086022215
three O 0 0.0008006095
different O 0 0.0025960589
calcium B-Chemical 1 0.994665
channel O 0 0.7628148
blockers O 0 0.9956792
. O 0 0.015021069

The O 0 0.004389537
convulsant O 0 0.99567235
activity O 0 0.0037639935
of O 0 0.0029520176
bupivacaine B-Chemical 1 0.9993339
was O 0 0.0014458762
not O 0 0.0006723916
significantly O 0 0.000811488
modified O 0 0.0010595316
but O 0 0.0008098397
calcium B-Chemical 1 0.99747294
channel O 0 0.45254168
blockers O 0 0.9983662
decreased O 0 0.0045526247
the O 0 0.0003459573
time O 0 0.0002539072
of O 0 0.0004155997
latency O 0 0.002633095
to O 0 0.00033174414
obtain O 0 0.00040426696
bupivacaine B-Chemical 1 0.9997321
- O 0 0.0034988052
induced O 0 0.0030086911
convulsions B-Disease 0 0.9998087
; O 0 0.0020756847
this O 0 0.00051522563
effect O 0 0.0007226985
was O 0 0.00075813767
less O 0 0.0011113908
pronounced O 0 0.0032599277
with O 0 0.0060298173
bepridil B-Chemical 1 0.9988206
. O 0 0.009491459

Epidural O 0 0.793785
blood O 0 0.02555844
flow O 0 0.020558972
during O 0 0.007973039
prostaglandin B-Chemical 1 0.99926525
E1 I-Chemical 1 0.99365026
or O 0 0.020539157
trimethaphan B-Chemical 0 0.9986737
induced O 0 0.27997735
hypotension B-Disease 2 0.9983936
. O 0 0.021915972

To O 0 0.0027172195
evaluate O 0 0.0015146054
the O 0 0.0016802001
effect O 0 0.0020691415
of O 0 0.004627341
prostaglandin B-Chemical 1 0.99986374
E1 I-Chemical 1 0.9988298
( O 0 0.10554557
PGE1 B-Chemical 1 0.9999052
) O 0 0.019148642
or O 0 0.0014088576
trimethaphan B-Chemical 0 0.9997508
( O 0 0.013619566
TMP B-Chemical 0 0.9994454
) O 0 0.004641905
induced O 0 0.0025352414
hypotension B-Disease 2 0.9997054
on O 0 0.0003927274
epidural O 0 0.6457739
blood O 0 0.018585484
flow O 0 0.013683402
( O 0 0.0008811161
EBF O 0 0.32519025
) O 0 0.000597429
during O 0 0.00021833697
spinal O 0 0.022391928
surgery O 0 0.0021568318
, O 0 0.00047257144
EBF O 0 0.13343138
was O 0 0.00023250963
measured O 0 0.00015039292
using O 0 0.00017477667
the O 0 0.00022484598
heat O 0 0.004397156
clearance O 0 0.04150648
method O 0 0.00066632126
in O 0 0.0002861581
30 O 0 0.0002942392
patients O 0 0.000768413
who O 0 0.00091075565
underwent O 0 0.0010021003
postero O 0 0.092648044
- O 0 0.0014251805
lateral O 0 0.0055381684
interbody O 0 0.099371284
fusion O 0 0.0021688938
under O 0 0.0020325603
isoflurane B-Chemical 1 0.98989505
anaesthesia O 0 0.5548083
. O 0 0.0071165925

An O 0 0.0053085783
initial O 0 0.0024145849
dose O 0 0.0074925846
of O 0 0.0018184078
0 O 0 0.0012894701
. O 0 0.0005457795
1 O 0 0.0006234652
microgram O 0 0.080086686
. O 0 0.00038177453
kg O 0 0.0038336904
- O 0 0.0007228294
1 O 0 0.00034868735
. O 0 0.00019221594
min O 0 0.00048847083
- O 0 0.00045997146
1 O 0 0.00028065083
of O 0 0.0005665233
PGE1 B-Chemical 1 0.9998791
( O 0 0.0010101104
15 O 0 0.00028388525
patients O 0 0.0009967311
) O 0 0.0005271198
, O 0 0.00029773443
or O 0 0.0001821631
10 O 0 0.0002650541
micrograms O 0 0.049518168
. O 0 0.00016027981
kg O 0 0.0027618005
- O 0 0.00041774602
1 O 0 0.0002205212
. O 0 0.00012504635
min O 0 0.0003524611
- O 0 0.00033320984
1 O 0 0.00020227501
of O 0 0.00036569525
TMP B-Chemical 0 0.99891996
( O 0 0.0005987062
15 O 0 0.00021291252
patients O 0 0.0007418352
) O 0 0.00039870632
was O 0 0.00019678495
administered O 0 0.00061306066
intravenously O 0 0.0015546919
after O 0 0.00012172828
the O 0 0.00022613275
dural O 0 0.5620911
opening O 0 0.0033915364
and O 0 0.00026819145
the O 0 0.00021913614
dose O 0 0.0050048963
was O 0 0.00024476432
adjusted O 0 0.0003045999
to O 0 0.00019459426
maintain O 0 0.00019704764
the O 0 0.00023797173
mean O 0 0.00027408596
arterial O 0 0.29308692
blood O 0 0.012063618
pressure O 0 0.09204084
( O 0 0.0016666553
MAP O 0 0.44954845
) O 0 0.0017646166
at O 0 0.00082627806
about O 0 0.0014926553
60 O 0 0.0033232602
mmHg O 0 0.013762506
. O 0 0.004720233

The O 0 0.0053019146
hypotensive B-Disease 2 0.98648316
drug O 0 0.45839617
was O 0 0.0029123775
discontinued O 0 0.015819978
at O 0 0.0012264105
the O 0 0.0013445511
completion O 0 0.0013892587
of O 0 0.0023388825
the O 0 0.0028270748
operative O 0 0.00973059
procedure O 0 0.00841527
. O 0 0.008676502

After O 0 0.0033246614
starting O 0 0.0051038098
PGE1 B-Chemical 1 0.9992611
or O 0 0.0050924276
TMP B-Chemical 0 0.99851185
, O 0 0.005020357
MAP O 0 0.61123496
and O 0 0.0010721281
rate O 0 0.0007304086
pressure O 0 0.034515038
product O 0 0.0021648123
( O 0 0.0012381715
RPP O 0 0.89170504
) O 0 0.0008951609
decreased O 0 0.00072794355
significantly O 0 0.00041356497
compared O 0 0.00017785736
with O 0 0.0003770742
preinfusion O 0 0.18449132
values O 0 0.0004367266
( O 0 0.00060348824
P O 0 0.018443057
< O 0 0.00038638135
0 O 0 0.00029531337
. O 0 0.00017494138
01 O 0 0.001821823
) O 0 0.00044146684
, O 0 0.0002963948
and O 0 0.00023262693
the O 0 0.00021880626
degree O 0 0.0004251072
of O 0 0.00084743166
hypotension B-Disease 2 0.99966276
due O 0 0.0004450058
to O 0 0.0007249376
PGE1 B-Chemical 1 0.9998385
remained O 0 0.0013086032
constant O 0 0.00062443764
until O 0 0.0003810586
60 O 0 0.00075470546
min O 0 0.0010844904
after O 0 0.0008240151
its O 0 0.0040245648
discontinuation O 0 0.77271384
. O 0 0.0061540534

Heart O 0 0.051121693
rate O 0 0.005184676
( O 0 0.0059295627
HR O 0 0.10872497
) O 0 0.0042216377
did O 0 0.0020449376
not O 0 0.001920037
change O 0 0.0025470052
in O 0 0.0026906189
either O 0 0.0042238547
group O 0 0.008229308
. O 0 0.008833892

EBFF O 0 0.09771986
did O 0 0.0029447048
not O 0 0.0016988484
change O 0 0.0015758196
during O 0 0.0013060953
PGE1 B-Chemical 1 0.99969494
infusion O 0 0.2770216
whereas O 0 0.000958832
in O 0 0.0005580003
the O 0 0.0006786669
TMP B-Chemical 0 0.99881077
group O 0 0.0014763001
, O 0 0.0008748757
EBF O 0 0.28745145
decreased O 0 0.00095800695
significantly O 0 0.00042435678
at O 0 0.00016980778
30 O 0 0.00019198387
and O 0 0.00018863208
60 O 0 0.00021914535
min O 0 0.00024284888
after O 0 9.8297074e-05
the O 0 0.00015302113
start O 0 0.0001852443
of O 0 0.00053231657
TMP B-Chemical 0 0.9992537
( O 0 0.0012698529
preinfusion O 0 0.35255507
: O 0 0.0005868624
45 O 0 0.0002820561
. O 0 0.00015534635
9 O 0 0.0002523012
+ O 0 0.00034181424
/ O 0 0.0006563772
- O 0 0.0004249397
13 O 0 0.00027504275
. O 0 0.0001288118
9 O 0 0.00020516296
ml O 0 0.0007512562
/ O 0 0.0006339312
100g O 0 0.08288288
/ O 0 0.0006248725
min O 0 0.00037784586
. O 0 0.00012254914
30 O 0 0.00016455376
min O 0 0.00030950023
: O 0 0.0003123024
32 O 0 0.00033852586
. O 0 0.00014426331
3 O 0 0.0002111112
+ O 0 0.0003482535
/ O 0 0.00067527243
- O 0 0.00044266318
9 O 0 0.00022515922
. O 0 0.00012455451
9 O 0 0.0001965172
ml O 0 0.0006405935
/ O 0 0.00046507496
100 O 0 0.00047094855
g O 0 0.0006658114
/ O 0 0.0005703948
min O 0 0.00048257344
( O 0 0.00039922624
P O 0 0.0073122284
< O 0 0.00033431972
0 O 0 0.00027692434
. O 0 0.00017431648
05 O 0 0.011087741
) O 0 0.0004167308
. O 0 0.0001421472
60 O 0 0.00024726326
min O 0 0.00036562694
: O 0 0.0003615511
30 O 0 0.00024246552
+ O 0 0.00037411664
/ O 0 0.00070288917
- O 0 0.00047352468
7 O 0 0.00021770917
. O 0 0.00014402869
5 O 0 0.0002008218
ml O 0 0.0007269217
/ O 0 0.0005944626
100 O 0 0.0006332543
g O 0 0.0009271278
/ O 0 0.0009194994
min O 0 0.0008745922
( O 0 0.00089967815
P O 0 0.00873246
< O 0 0.0011511495
0 O 0 0.0012005778
. O 0 0.0011691304
05 O 0 0.02615942
) O 0 0.004739879
) O 0 0.006517545
. O 0 0.005785625

These O 0 0.0046009663
results O 0 0.0024457148
suggest O 0 0.0018787705
that O 0 0.0024545125
PGE1 B-Chemical 1 0.9995074
may O 0 0.002397075
be O 0 0.001279743
preferable O 0 0.001160061
to O 0 0.0011321423
TMP B-Chemical 0 0.99768543
for O 0 0.0015157684
hypotensive B-Disease 2 0.9978503
anaesthesia O 0 0.47944725
in O 0 0.0013292762
spinal O 0 0.08313823
surgery O 0 0.007198206
because O 0 0.0022523883
TMP B-Chemical 0 0.99643207
decreased O 0 0.049385943
EBF O 0 0.81082684
. O 0 0.00911608

Dup B-Chemical 0 0.9272934
753 I-Chemical 0 0.6062827
prevents O 0 0.006803625
the O 0 0.003721378
development O 0 0.006765911
of O 0 0.0074297474
puromycin B-Chemical 0 0.98921776
aminonucleoside I-Chemical 0 0.99948466
- O 0 0.08293088
induced O 0 0.070073366
nephrosis B-Disease 2 0.9984003
. O 0 0.018417105

The O 0 0.003558919
appearance O 0 0.0061223027
of O 0 0.005287339
nephrotic B-Disease 2 0.9996648
syndromes I-Disease 0 0.93303996
such O 0 0.0020853658
as O 0 0.0017807048
proteinuria B-Disease 2 0.9997857
, O 0 0.020102367
hypoalbuminemia B-Disease 0 0.9997769
, O 0 0.012011102
hypercholesterolemia B-Disease 0 0.999801
and O 0 0.0010553448
increase O 0 0.0005137363
in O 0 0.000401655
blood B-Chemical 0 0.07664709
nitrogen I-Chemical 0 0.9714137
urea I-Chemical 1 0.9994209
, O 0 0.0012906626
induced O 0 0.0006778716
in O 0 0.0002965633
rats O 0 0.0018534351
by O 0 0.00030910803
injection O 0 0.0019580508
of O 0 0.00081357016
puromycin B-Chemical 0 0.9856399
aminonucleoside I-Chemical 0 0.99991715
was O 0 0.00087713636
markedly O 0 0.008000194
inhibited O 0 0.0025509656
by O 0 0.00051363494
oral O 0 0.4673599
administration O 0 0.30664334
of O 0 0.0022283122
Dup B-Chemical 0 0.99699366
753 I-Chemical 0 0.9727998
( O 0 0.0046513863
losartan B-Chemical 1 0.99983466
) O 0 0.003046285
, O 0 0.0005330574
a O 0 0.0004131471
novel O 0 0.0020430358
angiotensin B-Chemical 1 0.9998047
II I-Chemical 1 0.61749256
receptor O 0 0.62433445
antagonist O 0 0.9900317
, O 0 0.00089437317
at O 0 0.00023576127
a O 0 0.00039852335
dose O 0 0.0039140186
of O 0 0.0005769718
1 O 0 0.00050444383
or O 0 0.0004226565
2 O 0 0.00072604726
mg O 0 0.16418204
/ O 0 0.0023843697
kg O 0 0.0048061362
per O 0 0.0013038669
day O 0 0.0031753154
. O 0 0.0044420166

The O 0 0.0026915832
results O 0 0.0018131265
suggest O 0 0.001264864
a O 0 0.0014094556
possible O 0 0.0012681367
involvement O 0 0.0020435154
of O 0 0.0012978505
the O 0 0.0013130902
renin O 0 0.9955187
- O 0 0.009788404
angiotensin B-Chemical 1 0.9991721
system O 0 0.0024466168
in O 0 0.00070035
the O 0 0.0007280736
development O 0 0.002156723
of O 0 0.0029259513
puromycin B-Chemical 0 0.99239373
aminonucleoside I-Chemical 0 0.999729
- O 0 0.054365475
induced O 0 0.057508603
nephrosis B-Disease 2 0.998914
. O 0 0.013011828

Neuroplasticity O 0 0.2492289
of O 0 0.005484133
the O 0 0.0037211324
adult O 0 0.005076604
primate O 0 0.0072223525
auditory O 0 0.09852636
cortex O 0 0.25845003
following O 0 0.005503642
cochlear O 0 0.421969
hearing B-Disease 0 0.88667583
loss I-Disease 0 0.024982248
. O 0 0.011609283

Tonotopic O 0 0.13622008
organization O 0 0.00508512
is O 0 0.0021121625
an O 0 0.0018228447
essential O 0 0.0014018888
feature O 0 0.0015819294
of O 0 0.0011892505
the O 0 0.0009595924
primary O 0 0.0017837689
auditory O 0 0.083527595
area O 0 0.0031106493
( O 0 0.0030746418
A1 O 0 0.38515237
) O 0 0.0037959556
of O 0 0.0038012424
primate O 0 0.013817354
cortex O 0 0.43911198
. O 0 0.0075302618

In O 0 0.004447529
A1 O 0 0.0878915
of O 0 0.0027351126
macaque O 0 0.0021881934
monkeys O 0 0.0017782223
, O 0 0.0012461352
low O 0 0.000999345
frequencies O 0 0.0008940289
are O 0 0.00082727155
represented O 0 0.00087018206
rostrolaterally O 0 0.006747379
and O 0 0.0010501117
high O 0 0.0015255458
frequencies O 0 0.0017855878
are O 0 0.0024355296
represented O 0 0.0037397346
caudomedially O 0 0.032813404
. O 0 0.0068832324

The O 0 0.0026206207
purpose O 0 0.0020230243
of O 0 0.0015590102
this O 0 0.0011219619
study O 0 0.0013736337
was O 0 0.0007446652
to O 0 0.00055432774
determine O 0 0.0003043828
if O 0 0.00038105808
changes O 0 0.0008038255
occur O 0 0.0007082286
in O 0 0.0005721688
this O 0 0.00083680835
tonotopic O 0 0.19172099
organization O 0 0.0025925424
following O 0 0.0024048574
cochlear O 0 0.43268034
hearing B-Disease 0 0.8823432
loss I-Disease 0 0.019304927
. O 0 0.0073968633

Under O 0 0.010312188
anesthesia O 0 0.11281798
, O 0 0.0029413495
the O 0 0.0014406986
superior O 0 0.0038928625
temporal O 0 0.04052987
gyrus O 0 0.6733768
of O 0 0.000884573
adult O 0 0.0009583543
macaque O 0 0.0005980719
monkeys O 0 0.0005512079
was O 0 0.00037181567
exposed O 0 0.00048865395
, O 0 0.00048084074
and O 0 0.00037848848
the O 0 0.00039528287
tonotopic O 0 0.14376278
organization O 0 0.0009948205
of O 0 0.0008934664
A1 O 0 0.29828414
was O 0 0.0007020162
mapped O 0 0.0006591926
using O 0 0.0007736997
conventional O 0 0.0019824025
microelectrode O 0 0.037685692
recording O 0 0.005872611
techniques O 0 0.008470665
. O 0 0.006477661

Following O 0 0.004584891
recovery O 0 0.005066796
, O 0 0.0026358825
the O 0 0.0014139323
monkeys O 0 0.001614342
were O 0 0.0010739398
selectively O 0 0.0021061942
deafened O 0 0.023694506
for O 0 0.00089179387
high O 0 0.0014648386
frequencies O 0 0.0017174679
using O 0 0.0024468666
kanamycin B-Chemical 1 0.97008944
and O 0 0.01069624
furosemide B-Chemical 1 0.9986045
. O 0 0.01331363

The O 0 0.0028164955
actual O 0 0.0019616138
frequencies O 0 0.0020029217
deafened O 0 0.025146969
were O 0 0.0012357668
determined O 0 0.0008132856
by O 0 0.0009510254
the O 0 0.0008769717
loss O 0 0.001858757
of O 0 0.0018819834
tone O 0 0.55413073
- O 0 0.0040528267
burst O 0 0.016481478
elicited O 0 0.005397492
auditory O 0 0.37602055
brainstem O 0 0.85340667
responses O 0 0.014621261
. O 0 0.007283435

Three O 0 0.010726395
months O 0 0.006960248
after O 0 0.005274174
deafening O 0 0.1338145
, O 0 0.012739358
A1 O 0 0.32534146
was O 0 0.011194291
remapped O 0 0.018025188
. O 0 0.0151619045

Postmortem O 0 0.7179754
cytoarchitectural O 0 0.2697569
features O 0 0.007943891
identifying O 0 0.004692798
A1 O 0 0.22120994
were O 0 0.0026270195
correlated O 0 0.0021468522
with O 0 0.0032790455
the O 0 0.004248858
electrophysiologic O 0 0.6246836
data O 0 0.010785839
. O 0 0.010499954

The O 0 0.0026932773
results O 0 0.0017992561
indicate O 0 0.0011893648
that O 0 0.0010303668
the O 0 0.0010178777
deprived O 0 0.0023927505
area O 0 0.0014088154
of O 0 0.0014119388
A1 O 0 0.3608607
undergoes O 0 0.0013054089
extensive O 0 0.0013961537
reorganization O 0 0.013603415
and O 0 0.0010680585
becomes O 0 0.001321885
responsive O 0 0.0015546608
to O 0 0.0014497102
intact O 0 0.0030254263
cochlear O 0 0.15991679
frequencies O 0 0.006079502
. O 0 0.006837422

The O 0 0.00311395
region O 0 0.0025272847
of O 0 0.0024015561
cortex O 0 0.07108771
that O 0 0.00093288795
represents O 0 0.0007453446
the O 0 0.0006464321
low O 0 0.00085946464
frequencies O 0 0.00080498174
was O 0 0.00071986736
not O 0 0.0006892189
obviously O 0 0.002163876
affected O 0 0.0009929508
by O 0 0.0014856303
the O 0 0.0022338885
cochlear O 0 0.47080228
hearing B-Disease 0 0.90953624
loss I-Disease 0 0.023642803
. O 0 0.007819384

Sodium B-Chemical 0 0.9978077
bicarbonate I-Chemical 0 0.99724823
alleviates O 0 0.8879551
penile B-Disease 0 0.9868367
pain I-Disease 0 0.99517584
induced O 0 0.008387029
by O 0 0.0047579855
intracavernous O 0 0.9903132
injections O 0 0.065359086
for O 0 0.006112799
erectile B-Disease 0 0.9957657
dysfunction I-Disease 0 0.9837943
. O 0 0.013865187

In O 0 0.0030873192
an O 0 0.0025024295
attempt O 0 0.0018596257
to O 0 0.0010189471
determine O 0 0.0004986766
whether O 0 0.0005203248
penile B-Disease 0 0.7527933
pain I-Disease 0 0.9940409
associated O 0 0.0013211683
with O 0 0.00070956687
intracorporeal O 0 0.005781773
injections O 0 0.0070329024
could O 0 0.0002830205
be O 0 0.00027827494
due O 0 0.00016128075
to O 0 0.0002103896
the O 0 0.00025529688
acidity O 0 0.763522
of O 0 0.00052479515
the O 0 0.00033521716
medication O 0 0.08430814
, O 0 0.00030031614
we O 0 8.7757704e-05
performed O 0 0.0001396253
a O 0 0.00017675897
randomized O 0 0.00027951697
study O 0 0.00023898769
comparing O 0 0.00010221384
the O 0 0.00020038495
incidence O 0 0.0021939008
of O 0 0.00063714146
penile B-Disease 0 0.9393252
pain I-Disease 0 0.99602205
following O 0 0.0005066284
intracorporeal O 0 0.0057938676
injections O 0 0.0049685165
with O 0 0.00038440165
or O 0 0.00025017007
without O 0 0.00031602508
the O 0 0.000303147
addition O 0 0.00032033582
of O 0 0.0012517006
sodium B-Chemical 0 0.9982284
bicarbonate I-Chemical 0 0.99787104
to O 0 0.0018002952
the O 0 0.0020778133
intracorporeal O 0 0.046095762
medications O 0 0.7410912
. O 0 0.0070036566

A O 0 0.01057043
total O 0 0.0021008574
of O 0 0.0018666346
38 O 0 0.0018505113
consecutive O 0 0.0011684586
patients O 0 0.0016853847
who O 0 0.0012381278
presented O 0 0.0005381959
to O 0 0.00036991955
our O 0 0.00031784285
clinic O 0 0.00061392284
with O 0 0.0006022298
impotence B-Disease 0 0.97009516
received O 0 0.00080777874
0 O 0 0.00044865397
. O 0 0.000169428
2 O 0 0.00022775192
ml O 0 0.0006302504
. O 0 0.000121330435
of O 0 0.0002194523
a O 0 0.0002439889
combination O 0 0.0005394444
of O 0 0.00040038393
3 O 0 0.00031314735
drugs O 0 0.3398705
: O 0 0.000597793
6 O 0 0.00022987548
mg O 0 0.18386835
. O 0 0.00024738305
papaverine B-Chemical 1 0.9995111
, O 0 0.00066887884
100 O 0 0.001142111
micrograms O 0 0.18613459
. O 0 0.00027156778
phentolamine B-Chemical 0 0.9998049
and O 0 0.00054451526
10 O 0 0.00047928962
micrograms O 0 0.2421891
. O 0 0.00040216497
prostaglandin B-Chemical 1 0.99992657
E1 I-Chemical 1 0.997724
with O 0 0.002994007
( O 0 0.0018844043
pH O 0 0.21007073
7 O 0 0.00032844677
. O 0 0.00021233999
05 O 0 0.021676846
) O 0 0.00045164095
or O 0 0.00022095366
without O 0 0.00037002272
( O 0 0.0006241427
pH O 0 0.055626754
4 O 0 0.0002604329
. O 0 0.00016580084
17 O 0 0.00037267857
) O 0 0.00037332607
the O 0 0.000220571
addition O 0 0.00024292576
of O 0 0.0009414918
sodium B-Chemical 0 0.9986305
bicarbonate I-Chemical 0 0.9989555
( O 0 0.0029157843
0 O 0 0.001382621
. O 0 0.0009414891
03 O 0 0.03873955
mEq O 0 0.75397545
. O 0 0.0023533425
) O 0 0.006055826
. O 0 0.0052870936

Of O 0 0.0052775447
the O 0 0.0023600748
19 O 0 0.002721847
patients O 0 0.003065633
without O 0 0.0018546396
sodium B-Chemical 0 0.99704546
bicarbonate I-Chemical 0 0.9983595
added O 0 0.0013935746
to O 0 0.00060518127
the O 0 0.0005252438
medication O 0 0.06644272
11 O 0 0.0006366464
( O 0 0.00050275563
58 O 0 0.00055787666
% O 0 0.00037693838
) O 0 0.00049131195
complained O 0 0.061961446
of O 0 0.0006741352
penile B-Disease 0 0.9292447
pain I-Disease 0 0.99613816
due O 0 0.00029808146
to O 0 0.00027067188
the O 0 0.00027792336
medication O 0 0.06885574
, O 0 0.00038730516
while O 0 0.00020998037
only O 0 0.00022576781
1 O 0 0.00021922539
of O 0 0.0002539585
the O 0 0.0002554174
19 O 0 0.00060461636
men O 0 0.011880815
( O 0 0.00049534586
5 O 0 0.00029602033
% O 0 0.000405282
) O 0 0.00057529256
who O 0 0.0009823927
received O 0 0.0013589432
sodium B-Chemical 0 0.99736613
bicarbonate I-Chemical 0 0.99841475
complained O 0 0.8928076
of O 0 0.01283427
penile B-Disease 0 0.9881131
pain I-Disease 0 0.99468
. O 0 0.010901247

From O 0 0.0040275515
these O 0 0.002463389
data O 0 0.0016864416
we O 0 0.00072715874
conclude O 0 0.00094696245
that O 0 0.00070694607
the O 0 0.0008658546
penile B-Disease 0 0.85578525
pain I-Disease 0 0.9941625
following O 0 0.00084488874
intracorporeal O 0 0.0070060603
injections O 0 0.008355692
is O 0 0.00039830152
most O 0 0.0005075812
likely O 0 0.00024153104
due O 0 0.00016186743
to O 0 0.00021782253
the O 0 0.00027471987
acidity O 0 0.7769345
of O 0 0.00061354524
the O 0 0.00043717434
medication O 0 0.15049392
, O 0 0.0005790998
which O 0 0.00046685807
can O 0 0.0002924856
be O 0 0.00035264512
overcome O 0 0.00044189065
by O 0 0.00062461075
elevating O 0 0.059087075
the O 0 0.0011866406
pH O 0 0.1144431
to O 0 0.0012576203
a O 0 0.0021164226
neutral O 0 0.006076698
level O 0 0.0038535178
. O 0 0.0059811687

The O 0 0.0033992878
use O 0 0.003441306
and O 0 0.0031481513
toxicity B-Disease 2 0.9804867
of O 0 0.0066224155
didanosine B-Chemical 1 0.99949396
( O 0 0.020175627
ddI B-Chemical 0 0.99565214
) O 0 0.0024751
in O 0 0.0008254989
HIV B-Disease 0 0.52504194
antibody I-Disease 0 0.004249578
- I-Disease 0 0.0014073825
positive I-Disease 0 0.0007264058
individuals O 0 0.0015048791
intolerant O 0 0.018988619
to O 0 0.0023800794
zidovudine B-Chemical 1 0.9890448
( O 0 0.021471027
AZT B-Chemical 1 0.9949523
) O 0 0.043009274

One O 0 0.004576698
hundred O 0 0.0032731718
and O 0 0.002101622
fifty O 0 0.0026014561
- O 0 0.0019914252
one O 0 0.00075466454
patients O 0 0.0019914233
intolerant O 0 0.010547472
to O 0 0.000918142
zidovudine B-Chemical 1 0.98817456
( O 0 0.003880862
AZT B-Chemical 1 0.9986022
) O 0 0.002405837
received O 0 0.0021965662
didanosine B-Chemical 1 0.9996699
( O 0 0.006167168
ddI B-Chemical 0 0.99276465
) O 0 0.0008228871
to O 0 0.00027283427
a O 0 0.00031848557
maximum O 0 0.00035405013
dose O 0 0.0028148994
of O 0 0.0005568492
12 O 0 0.00041310082
. O 0 0.0003402653
5 O 0 0.0006112686
mg O 0 0.112653576
/ O 0 0.0028923384
kg O 0 0.007993589
/ O 0 0.0043479865
day O 0 0.0036429914
. O 0 0.004782429

Patient O 0 0.009571334
response O 0 0.0034670427
was O 0 0.0016542753
assessed O 0 0.0010900295
using O 0 0.0010161365
changes O 0 0.0015221039
in O 0 0.0010421601
CD4 O 0 0.19313227
+ O 0 0.0016055882
lymphocyte O 0 0.33447415
subset O 0 0.0011394608
count O 0 0.0024646819
, O 0 0.0013754284
HIV O 0 0.6164691
p24 O 0 0.43705872
antigen O 0 0.07561125
, O 0 0.0015246602
weight O 0 0.0052475045
, O 0 0.001309419
and O 0 0.0011990091
quality O 0 0.0015294388
of O 0 0.0034916336
life O 0 0.009992331
. O 0 0.006282367

Seventy O 0 0.0119487075
patients O 0 0.005925342
developed O 0 0.0037428362
major O 0 0.003180069
opportunistic B-Disease 0 0.5012971
infections I-Disease 2 0.87123394
whilst O 0 0.003263124
on O 0 0.00074789993
therapy O 0 0.025419196
; O 0 0.0017202834
this O 0 0.0007549447
was O 0 0.0008308352
the O 0 0.0009927233
first O 0 0.0017302122
AIDS B-Disease 2 0.9902649
diagnosis O 0 0.043281943
in O 0 0.003968218
17 O 0 0.007817893
. O 0 0.00608904

Only O 0 0.0055860723
minor O 0 0.0046349484
changes O 0 0.0030648545
in O 0 0.001780309
CD4 O 0 0.17771165
+ O 0 0.0019022324
lymphocyte O 0 0.25151548
subset O 0 0.0009624428
count O 0 0.0012084346
were O 0 0.00045417648
observed O 0 0.00034836988
in O 0 0.00053047517
AIDS B-Disease 2 0.9944882
patients O 0 0.0054728966
, O 0 0.0005885516
although O 0 0.0003217002
a O 0 0.00034844162
more O 0 0.00040459374
significant O 0 0.00045601328
rise O 0 0.00067381124
occurred O 0 0.0005626048
in O 0 0.0004226678
those O 0 0.0007414518
with O 0 0.0008700274
earlier O 0 0.0013529183
stages O 0 0.002799936
of O 0 0.004525024
disease O 0 0.80863786
. O 0 0.007722245

Of O 0 0.0052561136
those O 0 0.002624829
positive O 0 0.0014891203
for O 0 0.0012588726
p24 O 0 0.082047716
antigen O 0 0.011812514
at O 0 0.0005069811
the O 0 0.00045183516
commencement O 0 0.0007040731
of O 0 0.00048924
the O 0 0.00035889377
study O 0 0.0005845541
67 O 0 0.0007140709
% O 0 0.0003316907
showed O 0 0.00023315809
a O 0 0.00028156498
positive O 0 0.00026670485
response O 0 0.00059342576
, O 0 0.00040900565
and O 0 0.00028207764
this O 0 0.00025405342
was O 0 0.00027195385
most O 0 0.00045730214
likely O 0 0.00027752356
in O 0 0.00027929503
those O 0 0.0005436339
with O 0 0.0007643225
CD4 O 0 0.24552777
+ O 0 0.0014004849
lymphocyte O 0 0.29072285
subset O 0 0.0012912306
counts O 0 0.0012907032
above O 0 0.0012507805
100 O 0 0.004762058
mm3 O 0 0.013612138
. O 0 0.0047469004

A O 0 0.016950894
positive O 0 0.0041308245
weight O 0 0.008522231
response O 0 0.004278458
was O 0 0.002661058
seen O 0 0.002411533
in O 0 0.0022893352
16 O 0 0.0031051817
% O 0 0.003526378
of O 0 0.004895992
patients O 0 0.013869659
. O 0 0.0094970185

Most O 0 0.0077223913
patients O 0 0.004871923
showed O 0 0.0018793609
improvement O 0 0.002023365
in O 0 0.001023082
individual O 0 0.000889395
parameters O 0 0.0016419291
and O 0 0.0011511183
global O 0 0.0015848458
score O 0 0.001416369
of O 0 0.0018228567
quality O 0 0.0021797358
of O 0 0.004575213
life O 0 0.012439069
. O 0 0.007471994

Adverse O 0 0.36891007
reactions O 0 0.016020223
possibly O 0 0.009433483
attributable O 0 0.0050756233
to O 0 0.006952392
didanosine B-Chemical 1 0.99563795
were O 0 0.010124426
common O 0 0.0154218
. O 0 0.013005264

The O 0 0.0033444453
most O 0 0.003667787
common O 0 0.0033787666
side O 0 0.024395945
- O 0 0.0026985519
effect O 0 0.0014918821
was O 0 0.0015638542
diarrhoea B-Disease 0 0.99819666
, O 0 0.0016849572
which O 0 0.001041316
resulted O 0 0.0007152147
in O 0 0.00069258554
cessation O 0 0.004377994
of O 0 0.0015669231
therapy O 0 0.022599548
in O 0 0.0021588719
19 O 0 0.0047106543
individuals O 0 0.005516327
. O 0 0.0056794537

Peripheral B-Disease 2 0.95998245
neuropathy I-Disease 2 0.997693
occurred O 0 0.007115012
in O 0 0.0032003482
12 O 0 0.0025677106
patients O 0 0.0062386305
and O 0 0.0063335886
pancreatitis B-Disease 0 0.9986228
in O 0 0.008094622
six O 0 0.0073073185
. O 0 0.010065046

Thirteen O 0 0.016591685
patients O 0 0.008627897
developed O 0 0.0060579726
a O 0 0.00443079
raised O 0 0.0058238623
serum O 0 0.13146378
amylase O 0 0.93277
without O 0 0.011387618
abdominal B-Disease 0 0.8002467
pain I-Disease 0 0.9796769
. O 0 0.016624682

Seven O 0 0.008966401
patients O 0 0.005911652
developed O 0 0.004549535
glucose B-Disease 1 0.935449
tolerance I-Disease 0 0.105097786
curves I-Disease 0 0.0022458632
characteristic O 0 0.0016921115
of O 0 0.0014689594
diabetes B-Disease 2 0.9946378
but O 0 0.00077175535
these O 0 0.0007425432
were O 0 0.0005890771
mild O 0 0.24596357
, O 0 0.00067874807
did O 0 0.00034227697
not O 0 0.0002872671
require O 0 0.0003020879
treatment O 0 0.001010958
and O 0 0.000632358
returned O 0 0.0007246365
to O 0 0.0007570948
normal O 0 0.0020274597
on O 0 0.001459694
ceasing O 0 0.2769372
didanosine B-Chemical 1 0.997607
. O 0 0.009027123

Immunohistochemical O 0 0.05234224
studies O 0 0.004738462
with O 0 0.0029896519
antibodies O 0 0.0040299813
to O 0 0.0020521875
neurofilament O 0 0.6381067
proteins O 0 0.0040689707
on O 0 0.0013841438
axonal B-Disease 0 0.8589184
damage I-Disease 0 0.91288275
in O 0 0.0018275098
experimental O 0 0.0037392299
focal O 0 0.20411935
lesions O 0 0.50845313
in O 0 0.0051473095
rat O 0 0.055404045
. O 0 0.008059436

Immunohistochemistry O 0 0.09476173
with O 0 0.0039122566
monoclonal O 0 0.008783657
antibodies O 0 0.0047773616
against O 0 0.0021584078
neurofilament O 0 0.88802034
( O 0 0.004945587
NF O 0 0.900695
) O 0 0.0020395943
proteins O 0 0.0010615779
of O 0 0.00066827034
middle O 0 0.0008285006
and O 0 0.00039516023
high O 0 0.00050928566
molecular O 0 0.007538727
weight O 0 0.0068425657
class O 0 0.0018419974
, O 0 0.0014401142
NF O 0 0.9420182
- O 0 0.0042468105
M O 0 0.6272718
and O 0 0.00096254173
NF O 0 0.9559385
- O 0 0.0063612554
H O 1 0.99527705
, O 0 0.00080741086
was O 0 0.00035745726
used O 0 0.00028579927
to O 0 0.00033389733
study O 0 0.0009979759
axonal B-Disease 0 0.8017292
injury I-Disease 0 0.980791
in O 0 0.00078384945
the O 0 0.0009429829
borderzone O 0 0.97573733
of O 0 0.0021181402
focal O 0 0.24083464
lesions O 0 0.52677304
in O 0 0.0037936768
rats O 0 0.022385972
. O 0 0.006122575

Focal O 0 0.5776902
injury B-Disease 0 0.72612137
in I-Disease 0 0.002617864
the I-Disease 0 0.0019532945
cortex I-Disease 0 0.10419105
was O 0 0.0010503877
produced O 0 0.00087034464
by O 0 0.0008966172
infusion O 0 0.020938916
of O 0 0.0014690331
lactate B-Chemical 0 0.9164901
at O 0 0.0009622786
acid O 0 0.8938244
pH O 0 0.27124816
or O 0 0.0009551903
by O 0 0.0014082836
stab O 0 0.18503343
caused O 0 0.0024673585
by O 0 0.002862006
needle O 0 0.008554901
insertion O 0 0.0060190097
. O 0 0.006379822

Infarcts B-Disease 0 0.90441275
in I-Disease 0 0.007508279
substantia I-Disease 0 0.98959523
nigra I-Disease 0 0.987703
pars I-Disease 0 0.85790104
reticulata I-Disease 0 0.94962466
were O 0 0.0021114412
evoked O 0 0.037772194
by O 0 0.0021179756
prolonged O 0 0.09946852
pilocarpine B-Chemical 1 0.99949825
- O 0 0.015100217
induced O 0 0.0074720355
status B-Disease 0 0.02845393
epilepticus I-Disease 0 0.99880314
. O 0 0.011730253

Immunohistochemical O 0 0.053430792
staining O 0 0.0048769307
for O 0 0.0025633615
NFs O 0 0.07279989
showed O 0 0.001893779
characteristic O 0 0.0027563951
terminal O 0 0.0050999103
clubs O 0 0.0043275226
of O 0 0.0021519077
axons O 0 0.017748415
in O 0 0.0016398949
the O 0 0.0026063046
borderzone O 0 0.9729168
of O 0 0.007693626
lesions O 0 0.57925653
. O 0 0.009405247

Differences O 0 0.0035172813
in O 0 0.0019276078
the O 0 0.0014758327
labelling O 0 0.0024301473
pattern O 0 0.0010412406
occurred O 0 0.00096729555
with O 0 0.0007759565
different O 0 0.0006653135
antibodies O 0 0.0015761934
which O 0 0.00086970296
apparently O 0 0.0015648045
depended O 0 0.00086922693
on O 0 0.0004067925
molecular O 0 0.00691399
weight O 0 0.0056998506
class O 0 0.002090712
of O 0 0.0021486864
NFs O 0 0.2867925
and O 0 0.0031504359
phosphorylation O 0 0.061097637
state O 0 0.009404218
. O 0 0.0069647324

These O 0 0.0046328064
immunohistochemical O 0 0.009276866
changes O 0 0.0029764555
of O 0 0.0023204267
NFs O 0 0.11983197
can O 0 0.0010394914
serve O 0 0.0012290406
as O 0 0.0006432269
a O 0 0.00080681284
marker O 0 0.0010807866
for O 0 0.0009409277
axonal B-Disease 0 0.8541672
damage I-Disease 0 0.91654843
in O 0 0.0011959836
various O 0 0.0027518072
experimental O 0 0.0067529874
traumatic B-Disease 0 0.99374795
or O 0 0.008874072
ischemic O 0 0.99900466
lesions O 0 0.9788411
. O 0 0.0108490875

Pharmacokinetic O 0 0.89027864
and O 0 0.004293919
clinical O 0 0.007030951
studies O 0 0.0031318245
in O 0 0.001914202
patients O 0 0.004897047
with O 0 0.005115881
cimetidine B-Chemical 1 0.9995751
- O 0 0.022557942
associated O 0 0.010281817
mental O 0 0.6088021
confusion B-Disease 0 0.91477853
. O 0 0.011216773

15 O 0 0.0047807526
cases O 0 0.0056417533
of O 0 0.0062903436
cimetidine B-Chemical 1 0.99934286
- O 0 0.013702734
associated O 0 0.0061592003
mental O 0 0.35823527
confusion B-Disease 0 0.76858336
have O 0 0.005553621
been O 0 0.007428566
reported O 0 0.010935227
. O 0 0.009276871

In O 0 0.0027645705
order O 0 0.0015534224
that O 0 0.0012317513
this O 0 0.0013435999
syndrome O 0 0.42616186
might O 0 0.0007350735
be O 0 0.000678139
investigated O 0 0.00055902585
changes O 0 0.0008126786
in O 0 0.00047958858
mental O 0 0.069829464
status O 0 0.0013029508
( O 0 0.0012121657
M O 0 0.5504804
. O 0 0.00033797557
S O 0 0.43145025
. O 0 0.0002381472
) O 0 0.00043834528
were O 0 0.00019763886
correlated O 0 0.00018270407
with O 0 0.0003408346
serum O 0 0.04540876
concentrations O 0 0.0031433874
and O 0 0.0004958506
renal O 0 0.9800086
and O 0 0.00070713804
hepatic O 0 0.95497245
function O 0 0.00067452044
in O 0 0.0002470121
36 O 0 0.0002886568
patients O 0 0.0006690937
, O 0 0.0002873879
30 O 0 0.00018642191
patients O 0 0.00048954715
had O 0 0.00028407073
no O 0 0.0003174858
M O 0 0.4504464
. O 0 0.0003174991
S O 0 0.3343967
. O 0 0.0002438061
change O 0 0.0003947201
on O 0 0.00034541794
cimetidine B-Chemical 1 0.99976605
and O 0 0.001039621
6 O 0 0.0005858933
had O 0 0.0008624709
moderate O 0 0.005613088
to O 0 0.0020019629
severe O 0 0.20121714
changes O 0 0.00847244
. O 0 0.005958004

These O 0 0.0043621236
6 O 0 0.0019693484
patients O 0 0.002788812
had O 0 0.001349818
both O 0 0.0013083738
renal B-Disease 0 0.9698454
and I-Disease 0 0.0024668316
liver I-Disease 0 0.9937516
dysfunction I-Disease 0 0.9979473
( O 0 0.0031283111
P O 0 0.047400318
less O 0 0.0004340101
than O 0 0.00023650828
0 O 0 0.00037978098
. O 0 0.00021681428
05 O 0 0.023792977
) O 0 0.0005309858
, O 0 0.00031539658
as O 0 0.00017913537
well O 0 0.00020831841
as O 0 0.00034292333
cimetidine B-Chemical 1 0.9999089
trough O 0 0.55016434
- O 0 0.0012372808
concentrations O 0 0.001394816
of O 0 0.00038173984
more O 0 0.0004022183
than O 0 0.0001905012
1 O 0 0.00027558557
. O 0 0.00015996437
25 O 0 0.0004620423
microgram O 0 0.09658178
/ O 0 0.0012467501
ml O 0 0.0024435392
( O 0 0.00082352146
P O 0 0.008488597
less O 0 0.00069298333
than O 0 0.0006492937
0 O 0 0.0014933996
. O 0 0.0014616685
05 O 0 0.03632425
) O 0 0.006008389
. O 0 0.005325414

The O 0 0.0038355356
severity O 0 0.011566161
of O 0 0.004072593
M O 0 0.6475505
. O 0 0.0016191038
S O 0 0.3935149
. O 0 0.0007211644
changes O 0 0.001036189
increased O 0 0.0011006729
as O 0 0.00069692335
trough O 0 0.100649305
- O 0 0.0016779994
concentrations O 0 0.0028370516
rose O 0 0.006367473
, O 0 0.0012997393
5 O 0 0.0009121004
patients O 0 0.0025586647
had O 0 0.002755981
lumbar O 0 0.72489524
puncture O 0 0.04959011
. O 0 0.0065262695

The O 0 0.004450906
cerebrospinal O 0 0.7474562
fluid O 0 0.04523678
: O 0 0.0033972855
serum O 0 0.026782703
ratio O 0 0.0014408571
of O 0 0.0017664571
cimetidine B-Chemical 1 0.9998356
concentrations O 0 0.0372633
was O 0 0.0007556377
0 O 0 0.00053191057
. O 0 0.00020775014
24 O 0 0.00027824895
: O 0 0.00037059336
1 O 0 0.00022539678
and O 0 0.00021131238
indicates O 0 0.00018853859
that O 0 0.00029655138
cimetidine B-Chemical 1 0.9998653
passes O 0 0.007940864
the O 0 0.0004618653
blood O 0 0.019838836
- O 0 0.00112514
brain O 0 0.05278533
barrier O 0 0.01222741
; O 0 0.0006304667
it O 0 0.00024734606
also O 0 0.00021524393
raises O 0 0.00012242136
the O 0 0.00019327397
possibility O 0 0.0002325043
that O 0 0.0003317261
M O 0 0.59169954
. O 0 0.00030944328
S O 0 0.42730036
. O 0 0.00021329327
changes O 0 0.00044020364
are O 0 0.00026980462
due O 0 0.00019580516
to O 0 0.00032931342
blockade O 0 0.097854644
of O 0 0.002285846
histamine B-Chemical 1 0.9994536
H2 O 0 0.9975395
- O 0 0.009593016
receptors O 0 0.14069274
in O 0 0.0012065207
the O 0 0.0016335492
central O 0 0.008515538
nervous O 0 0.83077675
system O 0 0.009625376
. O 0 0.0066370186

Patients O 0 0.008626519
likely O 0 0.0020866573
to O 0 0.001430803
have O 0 0.0012534154
both O 0 0.0010448486
raised O 0 0.0015565894
trough O 0 0.099466756
- O 0 0.0018206007
concentrations O 0 0.0025166662
and O 0 0.00090839755
mental O 0 0.13834918
confusion B-Disease 0 0.6021578
are O 0 0.00075275183
those O 0 0.00083022343
with O 0 0.0008379466
both O 0 0.0011079647
severe O 0 0.3925545
renal B-Disease 0 0.993587
and I-Disease 0 0.013453692
hepatic I-Disease 0 0.99692637
dysfunction I-Disease 0 0.9957956
. O 0 0.012272052

They O 0 0.0073312726
should O 0 0.0021709856
be O 0 0.0020931044
closely O 0 0.0016032485
observed O 0 0.001081828
and O 0 0.0013028155
should O 0 0.0008811548
be O 0 0.0012085928
given O 0 0.0010568863
reduced O 0 0.0023312978
doses O 0 0.07809594
of O 0 0.015438281
cimetidine B-Chemical 1 0.99923396
. O 0 0.016619079

Prospective O 0 0.035095356
study O 0 0.003231363
of O 0 0.0019511164
the O 0 0.0012910647
long O 0 0.0014829292
- O 0 0.0014156933
term O 0 0.0008533623
effects O 0 0.0013805367
of O 0 0.0013396707
somatostatin O 0 0.9942747
analog O 0 0.2343108
( O 0 0.0028016623
octreotide B-Chemical 1 0.99890494
) O 0 0.0019908093
on O 0 0.00041313982
gallbladder O 0 0.6404591
function O 0 0.0015385448
and O 0 0.0017973379
gallstone B-Disease 0 0.9987685
formation O 0 0.02239323
in O 0 0.0024106004
Chinese O 0 0.4799834
acromegalic B-Disease 0 0.9960913
patients O 0 0.054425552
. O 0 0.0076211956

This O 0 0.0042675473
article O 0 0.0030307267
reports O 0 0.0021592972
the O 0 0.0011773995
changes O 0 0.0013835859
in O 0 0.00079946854
gallbladder O 0 0.3962269
function O 0 0.00093987223
examined O 0 0.0004143955
by O 0 0.0004992654
ultrasonography O 0 0.11301483
in O 0 0.00035377906
20 O 0 0.0004173625
Chinese O 0 0.015950056
patients O 0 0.0011772985
with O 0 0.00046977
active O 0 0.0015981125
acromegaly B-Disease 0 0.99729747
treated O 0 0.0015575339
with O 0 0.0005913737
sc O 0 0.10531284
injection O 0 0.0020319954
of O 0 0.00039715556
the O 0 0.0003683411
somatostatin O 0 0.98942393
analog O 0 0.121100456
octreotide B-Chemical 1 0.99929154
in O 0 0.000445016
dosages O 0 0.22017598
of O 0 0.0006247733
300 O 0 0.0050862534
- O 0 0.0005844382
1500 O 0 0.001428609
micrograms O 0 0.07053365
/ O 0 0.0004958915
day O 0 0.00018118542
for O 0 0.000149592
a O 0 0.00021436671
mean O 0 0.00015063157
of O 0 0.00033986298
24 O 0 0.0003720208
. O 0 0.0002549408
2 O 0 0.00048759935
+ O 0 0.00078274374
/ O 0 0.0015997499
- O 0 0.0014068694
13 O 0 0.0012327355
. O 0 0.0008990099
9 O 0 0.0017932582
months O 0 0.0029741472
. O 0 0.0039838604

During O 0 0.0029152979
treatment O 0 0.0041126725
with O 0 0.0028695576
octreotide B-Chemical 1 0.9958015
, O 0 0.00253624
17 O 0 0.001516813
patients O 0 0.0019128798
developed O 0 0.0016858379
sludge O 0 0.32996634
, O 0 0.0012692761
10 O 0 0.00076963205
had O 0 0.0010129329
gallstones B-Disease 0 0.9981363
, O 0 0.0016855218
and O 0 0.001107921
1 O 0 0.0012615114
developed O 0 0.004623324
acute B-Disease 0 0.9960704
cholecystitis I-Disease 0 0.9996767
requiring O 0 0.05002591
surgery O 0 0.13765295
. O 0 0.007801197

In O 0 0.0028958716
all O 0 0.0017887342
of O 0 0.0018662802
7 O 0 0.0012104242
patients O 0 0.0019190622
examined O 0 0.0008126701
acutely O 0 0.063352816
, O 0 0.0016789407
gallbladder O 0 0.85617155
contractility O 0 0.97074014
was O 0 0.001027826
inhibited O 0 0.0014530509
after O 0 0.000469015
a O 0 0.0008916393
single O 0 0.0011758287
100 O 0 0.0032526166
- O 0 0.0037329774
micrograms O 0 0.25292468
injection O 0 0.015277117
. O 0 0.0056766625

In O 0 0.0033154467
8 O 0 0.0022046722
patients O 0 0.0025817167
followed O 0 0.0010230088
for O 0 0.0009271304
24 O 0 0.0009719122
weeks O 0 0.0010133653
, O 0 0.0017135482
gallbladder O 0 0.6760813
contractility O 0 0.95818937
remained O 0 0.006574705
depressed B-Disease 2 0.6481886
throughout O 0 0.003439975
therapy O 0 0.063851304
. O 0 0.007733566

After O 0 0.0027921638
withdrawal O 0 0.18161379
of O 0 0.002973907
octreotide B-Chemical 1 0.9957533
in O 0 0.00136542
10 O 0 0.0009820828
patients O 0 0.0016691157
without O 0 0.0010208524
gallstones B-Disease 0 0.99845004
, O 0 0.0011575503
8 O 0 0.00046694375
patients O 0 0.0007887347
assessed O 0 0.0002973248
had O 0 0.00043380342
return O 0 0.0007397911
of O 0 0.0007766459
normal O 0 0.002662152
gallbladder O 0 0.8589879
contractility O 0 0.9449886
within O 0 0.0014817548
1 O 0 0.0027412393
month O 0 0.0037349358
. O 0 0.004749737

In O 0 0.0028629862
8 O 0 0.0017313937
of O 0 0.0013665505
the O 0 0.00091036083
remaining O 0 0.00079125096
10 O 0 0.0007577849
patients O 0 0.0013600145
who O 0 0.0013881146
developed O 0 0.0017592291
gallstones B-Disease 0 0.99855953
during O 0 0.0005249302
treatment O 0 0.0029943243
, O 0 0.0009336607
gallbladder O 0 0.83277726
contractility O 0 0.94118184
normalized O 0 0.00027062904
in O 0 0.00025697975
5 O 0 0.00022003517
patients O 0 0.0006831136
( O 0 0.00029555784
3 O 0 0.0001442153
of O 0 0.00021252675
whom O 0 0.0007066338
has O 0 0.00022527776
disappearance O 0 0.0014720408
of O 0 0.0003642961
their O 0 0.00040190932
stones O 0 0.635695
within O 0 0.00016593275
3 O 0 0.0002039461
weeks O 0 0.00022942401
) O 0 0.00039638908
, O 0 0.00027228228
and O 0 0.00023754966
remained O 0 0.00051818695
depressed B-Disease 2 0.2743102
in O 0 0.0002867622
3 O 0 0.00028233728
( O 0 0.00035797185
2 O 0 0.0002438847
of O 0 0.00035097706
whom O 0 0.0011496614
had O 0 0.0006976712
stones O 0 0.48647627
present O 0 0.00075831584
at O 0 0.00084425014
6 O 0 0.0012783324
months O 0 0.0024294504
) O 0 0.004958557
. O 0 0.0046448316

Our O 0 0.0030594496
results O 0 0.0018152705
suggest O 0 0.0011944865
that O 0 0.0009861425
the O 0 0.0009162946
suppression O 0 0.0018488255
of O 0 0.0014010771
gallbladder O 0 0.91465825
contractility O 0 0.98046577
is O 0 0.0007960063
the O 0 0.0004558635
cause O 0 0.0011935653
of O 0 0.00048657853
the O 0 0.00032916336
successive O 0 0.0004650255
formation O 0 0.0016183826
of O 0 0.00096445985
bile O 0 0.9736656
sludge O 0 0.89129263
, O 0 0.006424994
gallstones B-Disease 0 0.99942774
, O 0 0.0022783806
and O 0 0.0016046965
cholecystitis B-Disease 0 0.99963796
during O 0 0.0012536019
octreotide B-Chemical 1 0.99885166
therapy O 0 0.14795439
in O 0 0.0023406737
Chinese O 0 0.5182429
acromegalic B-Disease 0 0.99637574
patients O 0 0.054625344
. O 0 0.0072644004

It O 0 0.005688582
is O 0 0.0022445826
therefore O 0 0.0017932088
very O 0 0.0013420403
important O 0 0.0008122858
to O 0 0.0006480844
follow O 0 0.0005892113
the O 0 0.000515758
changes O 0 0.00077630335
of O 0 0.0007909219
gallbladder O 0 0.6119586
function O 0 0.00094056025
during O 0 0.0004291205
long O 0 0.00084644073
- O 0 0.0011218442
term O 0 0.0011953459
octreotide B-Chemical 1 0.9977851
therapy O 0 0.12769283
of O 0 0.008251895
acromegalic B-Disease 0 0.9967691
patients O 0 0.06354823
. O 0 0.0075251213

Increase O 0 0.028997779
of O 0 0.018509433
Parkinson B-Disease 0 0.9966163
disability I-Disease 0 0.9667391
after O 0 0.01331115
fluoxetine B-Chemical 1 0.99861443
medication O 0 0.8599128
. O 0 0.018816942

Depression B-Disease 2 0.9033376
is O 0 0.004582996
a O 0 0.0033160232
major O 0 0.0033378112
clinical O 0 0.008122488
feature O 0 0.0048938557
of O 0 0.006423661
Parkinson B-Disease 0 0.99639964
' I-Disease 0 0.007862771
s I-Disease 0 0.009382874
disease I-Disease 0 0.57468104
. O 0 0.011643135

We O 0 0.0031430917
report O 0 0.0040476355
the O 0 0.0015751852
increased O 0 0.001686042
amount O 0 0.00074955
of O 0 0.0014085826
motor B-Disease 2 0.54105777
disability I-Disease 2 0.8818186
in O 0 0.000563373
four O 0 0.0003418636
patients O 0 0.0014332333
with O 0 0.0009390541
idiopathic B-Disease 0 0.99332136
Parkinson I-Disease 0 0.9995097
' I-Disease 0 0.0012030315
s I-Disease 0 0.0010355362
disease I-Disease 0 0.20349866
after O 0 0.000535442
exposure O 0 0.0026908668
to O 0 0.0012811047
the O 0 0.0028905661
antidepressant B-Chemical 1 0.99895453
fluoxetine B-Chemical 0 0.99947685
. O 0 0.011633059

The O 0 0.002812384
possibility O 0 0.0019041444
of O 0 0.0020154908
a O 0 0.0018721172
clinically O 0 0.03899286
relevant O 0 0.0025133016
dopamine B-Chemical 1 0.9987349
- O 0 0.002903808
antagonistic O 0 0.0053499937
capacity O 0 0.0014004816
of O 0 0.0017279373
fluoxetine B-Chemical 1 0.99984396
in O 0 0.0020739667
Parkinson B-Disease 0 0.99911445
' I-Disease 0 0.0014017965
s I-Disease 0 0.0015120765
disease I-Disease 0 0.3298658
patients O 0 0.0040651658
must O 0 0.0014572726
be O 0 0.0025678019
considered O 0 0.0034907346
. O 0 0.005144963

Sinus B-Disease 0 0.7798091
arrest I-Disease 0 0.5030397
associated O 0 0.0073836795
with O 0 0.0059121503
continuous O 0 0.007816144
- O 0 0.014976896
infusion O 0 0.53510046
cimetidine B-Chemical 1 0.99851567
. O 0 0.023434956

The O 0 0.003185945
administration O 0 0.018128429
of O 0 0.002503163
intermittent O 0 0.10092025
intravenous O 0 0.70576096
infusions O 0 0.39777467
of O 0 0.004174684
cimetidine B-Chemical 1 0.9998323
is O 0 0.0024664912
infrequently O 0 0.008116536
associated O 0 0.001687843
with O 0 0.001641621
the O 0 0.0017269768
development O 0 0.0056987
of O 0 0.008390691
bradyarrhythmias B-Disease 0 0.99762756
. O 0 0.0101390695

A O 0 0.017478453
40 O 0 0.004132013
- O 0 0.0031538596
year O 0 0.0017319623
- O 0 0.001858518
old O 0 0.0012387336
man O 0 0.049632818
with O 0 0.0017543506
leukemia B-Disease 0 0.999288
and O 0 0.0009802085
no O 0 0.0004092962
history O 0 0.00451979
of O 0 0.0006940256
cardiac B-Disease 0 0.44207233
disease I-Disease 0 0.79565483
developed O 0 0.0032813917
recurrent O 0 0.4963052
, O 0 0.0005789589
brief O 0 0.0005253044
episodes O 0 0.060636617
of O 0 0.000522027
apparent O 0 0.0008020439
sinus B-Disease 0 0.5969408
arrest I-Disease 0 0.65831953
while O 0 0.00040994267
receiving O 0 0.0019773894
continuous O 0 0.0007793813
- O 0 0.0017255404
infusion O 0 0.16853634
cimetidine B-Chemical 1 0.9997644
50 O 0 0.008798757
mg O 0 0.66805536
/ O 0 0.0063595073
hour O 0 0.004080083
. O 0 0.0049827374

The O 0 0.0045655
arrhythmias B-Disease 2 0.99556583
were O 0 0.0025359432
temporally O 0 0.004249548
related O 0 0.0011161291
to O 0 0.0014302896
cimetidine B-Chemical 1 0.9997732
administration O 0 0.60772604
, O 0 0.00150632
disappeared O 0 0.0016490843
after O 0 0.0005357136
dechallenge O 0 0.9884878
, O 0 0.0012156814
and O 0 0.0007727245
did O 0 0.0006976669
not O 0 0.0008849612
recur O 0 0.049195375
during O 0 0.0024745292
ranitidine B-Chemical 1 0.999233
treatment O 0 0.060827773
. O 0 0.008182231

This O 0 0.0052240663
is O 0 0.002352078
the O 0 0.0015399511
first O 0 0.0011691794
reported O 0 0.0016784086
case O 0 0.0012742783
of O 0 0.0018890674
sinus B-Disease 0 0.588678
arrest I-Disease 0 0.7276587
associated O 0 0.0021302598
with O 0 0.0019413927
continuous O 0 0.0029164776
- O 0 0.0072033163
infusion O 0 0.49396962
cimetidine B-Chemical 1 0.9992173
. O 0 0.013025

Phase O 0 0.018412532
II O 0 0.013774672
trial O 0 0.0062475144
of O 0 0.0054023885
vinorelbine B-Chemical 1 0.9944207
in O 0 0.006514705
metastatic O 0 0.9859148
squamous B-Disease 0 0.99606436
cell I-Disease 0 0.6409954
esophageal I-Disease 0 0.9953359
carcinoma I-Disease 2 0.99849653
. O 0 0.027424805

European O 0 0.009505492
Organization O 0 0.0060309945
for O 0 0.0031848336
Research O 0 0.01218073
and O 0 0.0038745883
Treatment O 0 0.056118656
of O 0 0.0076274155
Cancer B-Disease 0 0.98155
Gastrointestinal O 0 0.97159785
Treat O 0 0.9440368
Cancer B-Disease 0 0.97710013
Cooperative O 0 0.5493645
Group O 0 0.12454126
. O 0 0.011532552

PURPOSE O 0 0.034438703
: O 0 0.0037550607
To O 0 0.0012631341
evaluate O 0 0.00076164404
the O 0 0.00086954713
response O 0 0.0011755638
rate O 0 0.0007499626
and O 0 0.00090244366
toxic O 0 0.58517206
effects O 0 0.0025904248
of O 0 0.0020036707
vinorelbine B-Chemical 1 0.9993205
( O 0 0.006382464
VNB B-Chemical 1 0.99596643
) O 0 0.0015831807
administered O 0 0.0014476905
as O 0 0.00033066864
a O 0 0.0004980144
single O 0 0.00066292105
agent O 0 0.059747268
in O 0 0.0013914038
metastatic O 0 0.9876794
squamous B-Disease 0 0.9980793
cell I-Disease 0 0.63151157
esophageal I-Disease 0 0.9974221
carcinoma I-Disease 2 0.99915874
. O 0 0.019909125

PATIENTS O 0 0.015056681
AND O 0 0.0058810734
METHODS O 0 0.0035042225
: O 0 0.0022828314
Forty O 0 0.0036272886
- O 0 0.0013282214
six O 0 0.0004895826
eligible O 0 0.00081284676
patients O 0 0.0012137386
with O 0 0.00067876396
measurable O 0 0.0013724981
lesions O 0 0.07347491
were O 0 0.00053997966
included O 0 0.00044009418
and O 0 0.0005254606
were O 0 0.000540206
stratified O 0 0.0010119206
according O 0 0.0009872349
to O 0 0.0014396769
previous O 0 0.0033655614
chemotherapy O 0 0.7531303
. O 0 0.0075552277

Thirty O 0 0.008220732
patients O 0 0.004427207
without O 0 0.0016952147
prior O 0 0.0011067262
chemotherapy O 0 0.35614482
and O 0 0.0012999268
16 O 0 0.0010800373
pretreated O 0 0.0125470115
with O 0 0.0016123051
cisplatin B-Chemical 1 0.99870205
- O 0 0.0026039332
based O 0 0.0011046764
chemotherapy O 0 0.5621741
were O 0 0.0012056327
assessable O 0 0.010229779
for O 0 0.0017000854
toxicity B-Disease 2 0.9831372
and O 0 0.0046491595
response O 0 0.009064828
. O 0 0.0067591565

VNB B-Chemical 1 0.9484871
was O 0 0.0032405932
administered O 0 0.003647033
weekly O 0 0.0021389155
as O 0 0.000947735
a O 0 0.0010925375
25 O 0 0.0015301518
- O 0 0.0014993179
mg O 0 0.26234135
/ O 0 0.0017444477
m2 O 0 0.01165361
short O 0 0.00081003556
intravenous O 0 0.39350548
( O 0 0.00166607
i O 0 0.0026000338
. O 0 0.0009844351
v O 0 0.0067121363
. O 0 0.0016509237
) O 0 0.0047141165
infusion O 0 0.05410328
. O 0 0.006204608

RESULTS O 0 0.02272052
: O 0 0.0040030438
Six O 0 0.002454042
of O 0 0.0015195988
30 O 0 0.0010616747
patients O 0 0.0019803594
( O 0 0.001037089
20 O 0 0.00067141344
% O 0 0.0005718787
) O 0 0.0005364336
without O 0 0.00029948752
prior O 0 0.00024350295
chemotherapy O 0 0.24077974
achieved O 0 0.0005202522
a O 0 0.0003967257
partial O 0 0.0008485746
response O 0 0.0010703008
( O 0 0.0009382009
PR O 0 0.7055307
) O 0 0.0010458948
( O 0 0.00049928395
95 O 0 0.00069255685
% O 0 0.00030573783
confidence O 0 0.0007656771
interval O 0 0.0007949273
[ O 0 0.001497483
CI O 0 0.14822736
] O 0 0.0014088026
, O 0 0.0008685981
8 O 0 0.0007415002
% O 0 0.00094132137
to O 0 0.0010627502
39 O 0 0.0029232774
% O 0 0.0031580445
) O 0 0.005538888
. O 0 0.0053002504

The O 0 0.0028429646
median O 0 0.0020228915
duration O 0 0.0021043299
of O 0 0.0018544499
response O 0 0.002113878
was O 0 0.0012652737
21 O 0 0.0013715232
weeks O 0 0.0010765668
( O 0 0.0014467184
range O 0 0.0017414843
, O 0 0.0018885046
17 O 0 0.0022889825
to O 0 0.002115515
28 O 0 0.004445198
) O 0 0.006935547
. O 0 0.0062558716

One O 0 0.004676706
of O 0 0.002825613
16 O 0 0.002146129
patients O 0 0.0031822263
( O 0 0.0015566671
6 O 0 0.00064158364
% O 0 0.0006939489
) O 0 0.0006580383
with O 0 0.00040474915
prior O 0 0.00029334793
chemotherapy O 0 0.27833778
had O 0 0.00046648819
a O 0 0.0004063104
complete O 0 0.0003521254
response O 0 0.0007601782
( O 0 0.00067674706
CR O 0 0.14108443
) O 0 0.00056856696
of O 0 0.00036278646
31 O 0 0.00043443497
weeks O 0 0.0002515297
' O 0 0.00031592988
duration O 0 0.0005054443
( O 0 0.0005820692
95 O 0 0.0010417008
% O 0 0.0006273803
CI O 0 0.03943385
, O 0 0.00076711253
0 O 0 0.00076560926
% O 0 0.00083867315
to O 0 0.0009174376
30 O 0 0.0014936015
% O 0 0.002727219
) O 0 0.0050485865
. O 0 0.0050209216

The O 0 0.0030080131
overall O 0 0.0024836867
response O 0 0.0024684845
rate O 0 0.0015835742
( O 0 0.001837764
World O 0 0.002217183
Health O 0 0.0018393638
Organization O 0 0.0016706461
[ O 0 0.0016047676
WHO O 0 0.0020429727
] O 0 0.0011295376
criteria O 0 0.0008637106
) O 0 0.0007100597
was O 0 0.00035737513
15 O 0 0.00031359316
% O 0 0.00041683269
( O 0 0.00050296244
CR O 0 0.052062225
, O 0 0.0005554652
2 O 0 0.00039869169
% O 0 0.00046627683
; O 0 0.00069280074
PR O 0 0.21699099
13 O 0 0.00061642844
% O 0 0.0005349997
; O 0 0.0006707055
95 O 0 0.0010024699
% O 0 0.0006698683
CI O 0 0.028410183
, O 0 0.00081818464
6 O 0 0.00060610543
% O 0 0.00093980646
to O 0 0.0010989237
29 O 0 0.0032425248
% O 0 0.0032172245
) O 0 0.0056376113
. O 0 0.0053908327

The O 0 0.0035079578
median O 0 0.0029843054
dose O 0 0.014654646
- O 0 0.0035594297
intensity O 0 0.00175145
( O 0 0.0028122088
DI O 0 0.29629132
) O 0 0.0025413514
was O 0 0.0013118876
20 O 0 0.0018889621
mg O 0 0.25875485
/ O 0 0.0056012548
m2 O 0 0.037612244
/ O 0 0.0072551835
wk O 0 0.0055955313
. O 0 0.0064808847

VNB B-Chemical 1 0.9551146
was O 0 0.0036881473
well O 0 0.002084085
tolerated O 0 0.007526222
and O 0 0.0015412861
zero O 0 0.000994666
instances O 0 0.0011038608
of O 0 0.0020445134
WHO O 0 0.0067916075
grade O 0 0.16515668
4 O 0 0.003965115
nonhematologic O 0 0.997267
toxicity B-Disease 2 0.9913345
occurred O 0 0.014252039
. O 0 0.00817931

At O 0 0.0023677745
least O 0 0.0015301547
one O 0 0.0013674586
episode O 0 0.0039045657
of O 0 0.0017934053
grade O 0 0.06298595
3 O 0 0.0009849642
or O 0 0.0007874667
4 O 0 0.0010394146
granulocytopenia B-Disease 0 0.9983852
was O 0 0.001188134
seen O 0 0.0010035315
in O 0 0.0010297947
59 O 0 0.0024327752
% O 0 0.0019352445
of O 0 0.0029650102
patients O 0 0.009860805
. O 0 0.00649494

A O 0 0.021517301
grade O 0 0.046791222
2 O 0 0.0025386806
or O 0 0.0014940461
3 O 0 0.0012690139
infection B-Disease 2 0.029517988
occurred O 0 0.0011698572
in O 0 0.00070493034
16 O 0 0.0007945369
% O 0 0.0007077428
of O 0 0.0008263678
patients O 0 0.0023672576
, O 0 0.0014885219
but O 0 0.0012580989
no O 0 0.0017635847
toxic O 0 0.8139764
deaths B-Disease 0 0.7928264
occurred O 0 0.011793448
. O 0 0.007406939

Other O 0 0.012627053
side O 0 0.012616649
effects O 0 0.0039863535
were O 0 0.0019981842
rare O 0 0.006992618
, O 0 0.0020952376
and O 0 0.0017407608
peripheral B-Disease 0 0.6671812
neurotoxicity I-Disease 2 0.99966645
has O 0 0.0021528443
been O 0 0.0018074783
minor O 0 0.0030811443
( O 0 0.0021280516
26 O 0 0.0022950277
% O 0 0.002176726
grade O 0 0.039504513
1 O 0 0.0039249146
) O 0 0.006720745
. O 0 0.0058113798

CONCLUSION O 0 0.784641
: O 0 0.005328385
These O 0 0.002698299
data O 0 0.0019363933
indicate O 0 0.0012144602
that O 0 0.0014840891
VNB B-Chemical 1 0.96847034
is O 0 0.0015428732
an O 0 0.0016136135
active O 0 0.0024803542
agent O 0 0.102166675
in O 0 0.0023271467
metastatic O 0 0.98567295
esophageal B-Disease 0 0.9928421
squamous I-Disease 0 0.99847907
cell I-Disease 0 0.8171623
carcinoma I-Disease 2 0.9984347
. O 0 0.018029064

Given O 0 0.0029676668
its O 0 0.0034733287
excellent O 0 0.0033445754
tolerance O 0 0.025369463
profile O 0 0.0018088417
and O 0 0.0011992644
low O 0 0.0017383057
toxicity B-Disease 2 0.98733914
, O 0 0.0013094853
further O 0 0.00080551807
evaluation O 0 0.0011047955
of O 0 0.0014856289
VNB B-Chemical 1 0.9826105
in O 0 0.0013071925
combination O 0 0.0045772544
therapy O 0 0.04949364
is O 0 0.0036702885
warranted O 0 0.0052265255
. O 0 0.006178421

Evaluation O 0 0.013171851
of O 0 0.0078447275
adverse O 0 0.45414376
reactions O 0 0.018516071
of O 0 0.008179728
aponidine B-Chemical 0 0.4052479
hydrochloride I-Chemical 0 0.99638474
ophthalmic O 0 0.9704892
solution O 0 0.29648975
. O 0 0.015585761

We O 0 0.0030725321
prospectively O 0 0.003367531
evaluated O 0 0.0016168407
the O 0 0.0014273442
adverse O 0 0.32280624
reactions O 0 0.007832362
of O 0 0.0016274615
apraclonidine B-Chemical 0 0.9996555
in O 0 0.0007638613
20 O 0 0.00057075423
normal O 0 0.000719905
volunteers O 0 0.0012037726
by O 0 0.00040407144
instilling O 0 0.0051198946
a O 0 0.00045682877
single O 0 0.00043711188
drop O 0 0.0009678869
of O 0 0.00076473056
1 O 0 0.0008648216
% O 0 0.0012267178
apraclonidine B-Chemical 0 0.99882
in O 0 0.0014718481
their O 0 0.002300747
right O 0 0.007489405
eyes O 0 0.09220973
. O 0 0.006129049

Examinations O 0 0.013629705
, O 0 0.0038478367
including O 0 0.002094542
blood O 0 0.0061687054
pressure O 0 0.032565083
, O 0 0.0015206134
pulse O 0 0.0035864061
rate O 0 0.00084592024
, O 0 0.0011207799
conjunctiva O 0 0.38291746
and O 0 0.0008834288
cornea O 0 0.24566007
, O 0 0.0011463484
intraocular O 0 0.95044816
pressure O 0 0.22792734
( O 0 0.0015266867
IOP O 0 0.9931624
) O 0 0.0011273201
, O 0 0.00052628666
pupil O 0 0.032355934
diameter O 0 0.011798523
, O 0 0.00051914086
basal O 0 0.001581863
tear O 0 0.19877371
secretion O 0 0.033412527
and O 0 0.00041891084
margin O 0 0.001849145
reflex O 0 0.4301319
distance O 0 0.00035044944
of O 0 0.0003323231
both O 0 0.00026791875
upper O 0 0.00048610545
and O 0 0.0002857933
lower O 0 0.00031861433
eyelids O 0 0.06621761
, O 0 0.00034275206
were O 0 0.00018911273
performed O 0 0.00016638856
prior O 0 0.0001510104
to O 0 0.00023204942
entry O 0 0.0005216902
and O 0 0.0003198091
at O 0 0.00022678354
1 O 0 0.00038124976
, O 0 0.0004434336
3 O 0 0.00034159777
, O 0 0.0004963727
5 O 0 0.00040117648
and O 0 0.0005668952
7 O 0 0.00069516094
hours O 0 0.0010306627
after O 0 0.0014247259
instillation O 0 0.045156844
. O 0 0.0053930194

The O 0 0.004276604
ocular B-Disease 0 0.8907103
hypotensive I-Disease 2 0.9977591
effects O 0 0.006588049
were O 0 0.0011868083
statistically O 0 0.00086485373
significant O 0 0.0008258223
for O 0 0.00067529106
apraclonidine B-Chemical 0 0.99974495
- O 0 0.0024362807
treated O 0 0.0010278759
eyes O 0 0.014757837
throughout O 0 0.0001980516
the O 0 0.00022436587
study O 0 0.00039864267
and O 0 0.00026448208
also O 0 0.00027634145
statistically O 0 0.00026469704
significant O 0 0.00030558367
for O 0 0.00022736375
contralateral O 0 0.0028888541
eyes O 0 0.007912635
from O 0 0.00025422065
three O 0 0.00016882298
hours O 0 0.0003273086
after O 0 0.00031932836
topical O 0 0.74178267
administration O 0 0.14642943
of O 0 0.0023668509
1 O 0 0.0028681841
% O 0 0.0048988764
apraclonidine B-Chemical 0 0.9980071
. O 0 0.007455596

Decreases B-Disease 0 0.026274312
in I-Disease 0 0.004340543
systolic I-Disease 0 0.3851966
blood I-Disease 0 0.010903896
pressure I-Disease 0 0.02594729
were O 0 0.0019723638
statistically O 0 0.0019610792
, O 0 0.0022307055
but O 0 0.0018473864
not O 0 0.0023300692
clinically O 0 0.038682804
, O 0 0.0059923944
significant O 0 0.0077502546
. O 0 0.007933647

No O 0 0.0067334734
significant O 0 0.0035959033
changes O 0 0.0030266347
in O 0 0.0019716271
diastolic O 0 0.84360135
blood O 0 0.01130709
pressure O 0 0.038824767
, O 0 0.0015887038
pulse O 0 0.0034856028
rate O 0 0.0011426274
and O 0 0.0015886311
basal O 0 0.005484396
tear O 0 0.39449278
secretion O 0 0.10139916
were O 0 0.004583355
noted O 0 0.0062055164
. O 0 0.0072092484

Conjunctival B-Disease 0 0.9457597
blanching I-Disease 0 0.9616582
and O 0 0.018474475
mydriasis B-Disease 0 0.9952496
were O 0 0.012322636
commonly O 0 0.020135913
found O 0 0.01341208
. O 0 0.015447204

Upper O 0 0.060834784
lid O 0 0.03888751
retraction O 0 0.10556099
was O 0 0.014797972
frequently O 0 0.02059493
noted O 0 0.018953402
. O 0 0.020668171

While O 0 0.0038262627
the O 0 0.002342916
elevations O 0 0.020172236
of O 0 0.0017204963
the O 0 0.0010895105
upper O 0 0.001524726
lid O 0 0.004375036
margin O 0 0.0020184969
in O 0 0.00045162588
most O 0 0.00066320226
subjects O 0 0.00062061363
were O 0 0.00029423696
not O 0 0.00024093557
more O 0 0.0003342126
than O 0 0.00018310083
2 O 0 0.00026752488
mm O 0 0.00096524996
and O 0 0.00022736483
did O 0 0.00020273455
not O 0 0.00020347121
cause O 0 0.00075585424
noticeable O 0 0.0009883209
change O 0 0.0003316401
in O 0 0.00023482373
appearance O 0 0.0011548564
, O 0 0.00032999663
one O 0 0.00016598353
subject O 0 0.00021388305
suffered O 0 0.028408512
from O 0 0.0003959806
mechanical O 0 0.07552014
entropion B-Disease 0 0.98206145
and O 0 0.00069460657
marked O 0 0.0022650138
corneal B-Disease 0 0.9697492
abrasion I-Disease 0 0.88403255
3 O 0 0.0005989929
hours O 0 0.0005218951
after O 0 0.00045799057
instillation O 0 0.012365824
of O 0 0.001972165
the O 0 0.0028658025
medication O 0 0.30191925
. O 0 0.0059763743

This O 0 0.0068552145
may O 0 0.0036001343
well O 0 0.0024874476
be O 0 0.0026424595
a O 0 0.0026013264
particularly O 0 0.0037385006
notable O 0 0.0068327826
finding O 0 0.005429464
in O 0 0.004793758
Asian O 0 0.1415857
people O 0 0.01759298
. O 0 0.010021383

Thiopentone B-Chemical 0 0.99118537
pretreatment O 0 0.28617522
for O 0 0.006194686
propofol B-Chemical 1 0.99454284
injection O 0 0.1031293
pain B-Disease 0 0.9732835
in O 0 0.005726537
ambulatory O 0 0.016497772
patients O 0 0.018697212
. O 0 0.010463397

This O 0 0.0059837867
study O 0 0.004384066
investigated O 0 0.0035401308
propofol B-Chemical 1 0.99351996
injection O 0 0.052182145
pain B-Disease 0 0.9655029
in O 0 0.0028275936
patients O 0 0.0063310363
undergoing O 0 0.006358703
ambulatory O 0 0.016347839
anaesthesia O 0 0.33420902
. O 0 0.009018787

In O 0 0.0028874082
a O 0 0.002238608
randomized O 0 0.0024150743
, O 0 0.0016108112
double O 0 0.0009773277
- O 0 0.0013875477
blind O 0 0.002571949
trial O 0 0.001272633
, O 0 0.0006154478
90 O 0 0.00046343755
women O 0 0.0016136027
were O 0 0.00028732378
allocated O 0 0.00027245266
to O 0 0.00024194893
receive O 0 0.00032635487
one O 0 0.00020311784
of O 0 0.00033484792
three O 0 0.00021234687
treatments O 0 0.00093105383
prior O 0 0.00036604787
to O 0 0.00056189584
induction O 0 0.0011910849
of O 0 0.001827289
anaesthesia O 0 0.2865976
with O 0 0.0068307575
propofol B-Chemical 1 0.9955688
. O 0 0.008217058

Patients O 0 0.010779577
in O 0 0.0030330846
Group O 0 0.014553828
C O 0 0.37062398
received O 0 0.002015551
2 O 0 0.0011018314
ml O 0 0.0021249752
normal O 0 0.0014313312
saline O 0 0.07071592
, O 0 0.0012138706
Group O 0 0.024779543
L O 0 0.2836877
, O 0 0.00076257903
2 O 0 0.0004488381
ml O 0 0.0015186882
, O 0 0.0006800586
lidocaine B-Chemical 0 0.9987018
2 O 0 0.0005185441
% O 0 0.00040659774
( O 0 0.0003606497
40 O 0 0.00036598963
mg O 0 0.12077622
) O 0 0.0006283383
and O 0 0.0004406541
Group O 0 0.015378014
T O 0 0.20182404
, O 0 0.00064484915
2 O 0 0.00048247824
ml O 0 0.0029294896
thiopentone B-Chemical 0 0.99923813
2 O 0 0.0007567555
. O 0 0.00041080898
5 O 0 0.00058121525
% O 0 0.0009251513
( O 0 0.0013403234
50 O 0 0.0025341576
mg O 0 0.22504432
) O 0 0.006507891
. O 0 0.0052395654

Venous O 0 0.073877394
discomfort O 0 0.20185494
was O 0 0.0019915341
assessed O 0 0.0010835732
with O 0 0.0011834049
a O 0 0.0011498115
visual O 0 0.093168
analogue O 0 0.0683803
scale O 0 0.0018046056
( O 0 0.0012591195
VAS O 0 0.3693774
) O 0 0.000886814
5 O 0 0.0003184671
- O 0 0.00038685204
15 O 0 0.00016971437
sec O 0 0.0001920315
after O 0 0.00010947674
commencing O 0 0.0008665761
propofol B-Chemical 1 0.9970644
administration O 0 0.096925095
using O 0 0.00027383727
an O 0 0.00044962091
infusion O 0 0.027374255
pump O 0 0.071639165
( O 0 0.0005333758
rate O 0 0.0003030306
1000 O 0 0.00089448434
micrograms O 0 0.11306956
. O 0 0.00033708033
kg O 0 0.0039085443
- O 0 0.0009502495
1 O 0 0.00065046735
. O 0 0.0005351706
min O 0 0.0016339757
- O 0 0.002430004
1 O 0 0.002520882
) O 0 0.0049614892
. O 0 0.004634786

Loss B-Disease 0 0.019910613
of I-Disease 0 0.008533229
consciousness I-Disease 0 0.77728504
occurred O 0 0.0065842867
in O 0 0.004313934
60 O 0 0.005576196
- O 0 0.006970456
90 O 0 0.006391294
sec O 0 0.008974858
. O 0 0.009713136

Visual O 0 0.69078434
analogue O 0 0.08480813
scores O 0 0.00288582
( O 0 0.0021919124
mean O 0 0.0009245264
+ O 0 0.0015358903
/ O 0 0.0023066916
- O 0 0.0014780922
SD O 0 0.012972998
) O 0 0.0007367556
during O 0 0.00025025496
induction O 0 0.0005002465
were O 0 0.00031176218
lower O 0 0.00032885908
in O 0 0.000352014
Groups O 0 0.020243151
L O 0 0.37292007
( O 0 0.0006382877
3 O 0 0.0002696601
. O 0 0.00016697869
3 O 0 0.00023071891
+ O 0 0.00036829791
/ O 0 0.0007045241
- O 0 0.00045891645
2 O 0 0.00023815992
. O 0 0.00013576524
5 O 0 0.00018924063
) O 0 0.0003456652
and O 0 0.0003018251
T O 0 0.18021682
( O 0 0.0004526771
4 O 0 0.00021856044
. O 0 0.0001464419
1 O 0 0.00025255198
+ O 0 0.00034247458
/ O 0 0.00066956895
- O 0 0.00043397534
2 O 0 0.00022527175
. O 0 0.00012849407
7 O 0 0.00017696907
) O 0 0.00029165274
than O 0 0.000134017
in O 0 0.00023884462
Group O 0 0.015095664
C O 0 0.63993543
( O 0 0.00064698095
5 O 0 0.0002767409
. O 0 0.00017652298
6 O 0 0.00023190254
+ O 0 0.00043063544
/ O 0 0.0008667041
- O 0 0.0006497818
2 O 0 0.00039551692
. O 0 0.0002775045
3 O 0 0.00047156436
) O 0 0.0010993205
; O 0 0.0015173013
P O 0 0.016916579
= O 0 0.0021866984
0 O 0 0.0019448209
. O 0 0.0019356349
0031 O 0 0.016831417
. O 0 0.0053954828

The O 0 0.003193474
incidence O 0 0.005620252
of O 0 0.0027172482
venous O 0 0.42407823
discomfort O 0 0.5148844
was O 0 0.0012067235
lower O 0 0.0008547577
in O 0 0.0007638547
Group O 0 0.026473003
L O 0 0.3523454
( O 0 0.0009530018
76 O 0 0.000867337
. O 0 0.00025998338
6 O 0 0.00027127124
% O 0 0.0004070561
; O 0 0.0005844663
P O 0 0.0063370173
< O 0 0.00042019552
0 O 0 0.00033904682
. O 0 0.00021353258
05 O 0 0.011126514
) O 0 0.0004766994
than O 0 0.00019540304
in O 0 0.00032126252
Group O 0 0.017289655
C O 0 0.6665518
( O 0 0.000830312
100 O 0 0.00095885806
% O 0 0.00047859456
) O 0 0.0005341241
but O 0 0.00030619785
not O 0 0.00032379344
different O 0 0.000502397
from O 0 0.0008681882
Group O 0 0.029018577
T O 0 0.24906453
( O 0 0.0023040124
90 O 0 0.002236378
% O 0 0.0030542356
) O 0 0.005303505
. O 0 0.0050438032

The O 0 0.0034931635
VAS O 0 0.061306044
scores O 0 0.0016977376
for O 0 0.0010253526
recall O 0 0.002429396
of O 0 0.0013913115
pain B-Disease 0 0.9188427
in O 0 0.0006272263
the O 0 0.00043665536
recovery O 0 0.000907046
room O 0 0.00025494324
were O 0 0.00027909674
correlated O 0 0.00024335533
with O 0 0.00037577053
the O 0 0.00037077325
VAS O 0 0.15293242
scores O 0 0.0003572791
during O 0 0.0002557149
induction O 0 0.00072777644
( O 0 0.00064844213
r O 0 0.0005926557
= O 0 0.00069702836
0 O 0 0.00049295917
. O 0 0.00035302658
7045 O 0 0.0056608533
; O 0 0.0014573697
P O 0 0.012720492
< O 0 0.0015018692
0 O 0 0.0015639047
. O 0 0.0015779105
0001 O 0 0.035276834
) O 0 0.006659988
. O 0 0.005890387

Recovery O 0 0.013350561
room O 0 0.0020741876
discharge O 0 0.0049455655
times O 0 0.001077125
were O 0 0.0010960245
similar O 0 0.00088285573
: O 0 0.0018112367
C O 0 0.516723
( O 0 0.0012916882
75 O 0 0.0009866848
. O 0 0.00035299966
9 O 0 0.0004599787
+ O 0 0.0005546268
/ O 0 0.0009375888
- O 0 0.00060944405
19 O 0 0.000492135
. O 0 0.00016887064
4 O 0 0.00021410607
min O 0 0.00045062063
) O 0 0.0005462536
; O 0 0.0006359439
L O 0 0.086358435
73 O 0 0.00077142747
. O 0 0.0001921564
6 O 0 0.00022080414
+ O 0 0.0003756081
/ O 0 0.00071076135
- O 0 0.0004738977
21 O 0 0.00032162474
. O 0 0.00014166035
6 O 0 0.00017704266
min O 0 0.00043222462
) O 0 0.0005749829
; O 0 0.0007371795
T O 0 0.1345991
( O 0 0.00061917945
77 O 0 0.0008357032
. O 0 0.00026786816
1 O 0 0.0004675383
+ O 0 0.00068257016
/ O 0 0.0013234597
- O 0 0.0011025833
18 O 0 0.0008318201
. O 0 0.000659355
9 O 0 0.0013586706
min O 0 0.0028322388
) O 0 0.0047823316
. O 0 0.0046181963

Assessing O 0 0.0070769475
their O 0 0.0034448137
overall O 0 0.002881722
satisfaction O 0 0.00626728
, O 0 0.0026269148
89 O 0 0.0029831873
. O 0 0.0010921712
7 O 0 0.0011583146
% O 0 0.0013641436
would O 0 0.0011590763
choose O 0 0.0029108522
propofol B-Chemical 1 0.9919214
anaesthesia O 0 0.4469302
again O 0 0.008490597
. O 0 0.00797926

We O 0 0.0030489883
conclude O 0 0.0022715663
that O 0 0.0017977084
lidocaine B-Chemical 0 0.9972633
reduces O 0 0.0019325173
the O 0 0.0010243992
incidence O 0 0.006213031
and O 0 0.0009055536
severity O 0 0.015264617
of O 0 0.0013444691
propofol B-Chemical 1 0.99897385
injection O 0 0.049684145
pain B-Disease 0 0.9782558
in O 0 0.0005786996
ambulatory O 0 0.0026337246
patients O 0 0.002251754
whereas O 0 0.0011001843
thiopentone B-Chemical 0 0.9993297
only O 0 0.0016930067
reduces O 0 0.0027368406
its O 0 0.008553804
severity O 0 0.15102531
. O 0 0.0068972306

Persistent O 0 0.73702705
paralysis B-Disease 2 0.99036026
after O 0 0.0024528434
prolonged O 0 0.007685243
use O 0 0.0026133556
of O 0 0.0030352906
atracurium B-Chemical 0 0.9948165
in O 0 0.0023283304
the O 0 0.0021205046
absence O 0 0.0021904723
of O 0 0.008015981
corticosteroids O 1 0.9955083
. O 0 0.013956419

Neuromuscular O 0 0.25077268
blocking O 0 0.010642043
agents O 0 0.24509753
( O 0 0.0050603896
NMBAs O 0 0.9716731
) O 0 0.002883704
are O 0 0.0010540145
often O 0 0.0013067909
used O 0 0.00080696243
for O 0 0.0008479405
patients O 0 0.0026641933
requiring O 0 0.002740229
prolonged O 0 0.028912133
mechanical O 0 0.18736972
ventilation O 0 0.33641207
. O 0 0.008929827

Reports O 0 0.012010563
of O 0 0.00412085
persistent O 0 0.10510769
paralysis B-Disease 2 0.9955754
after O 0 0.000977953
the O 0 0.0009095298
discontinuance O 0 0.40556213
of O 0 0.000929562
these O 0 0.001000047
drugs O 0 0.5095288
have O 0 0.00065976963
most O 0 0.0009178346
often O 0 0.00089315453
involved O 0 0.00057349744
aminosteroid O 0 0.96390444
- O 0 0.001350592
based O 0 0.00058243156
NMBAs O 0 0.9499679
such O 0 0.00049602624
as O 0 0.0005140664
vecuronium B-Chemical 0 0.9972584
bromide I-Chemical 0 0.9977882
, O 0 0.0012357186
especially O 0 0.0008785274
when O 0 0.00044050437
used O 0 0.0006749745
in O 0 0.00093030813
conjunction O 0 0.0027300513
with O 0 0.0054307175
corticosteroids O 1 0.996252
. O 0 0.009693597

Atracurium B-Chemical 0 0.9948683
besylate I-Chemical 0 0.9994618
, O 0 0.005379047
a O 0 0.0018400818
short O 0 0.0014260169
- O 0 0.0019209536
acting O 0 0.007734392
benzylisoquinolinium B-Chemical 0 0.996436
NMBA O 0 0.99837226
that O 0 0.00074720045
is O 0 0.00047598084
eliminated O 0 0.00047299147
independently O 0 0.00033697093
of O 0 0.0006550614
renal O 0 0.9854328
or O 0 0.0006121222
hepatic O 0 0.97524965
function O 0 0.0013279703
, O 0 0.00057882094
has O 0 0.00032592207
also O 0 0.00038421794
been O 0 0.0004213698
associated O 0 0.00054809725
with O 0 0.0007796914
persistent O 0 0.3320852
paralysis B-Disease 2 0.9992731
, O 0 0.0014017599
but O 0 0.000627163
only O 0 0.0006644292
when O 0 0.0006707991
used O 0 0.0013650565
with O 0 0.004291214
corticosteroids O 1 0.99581146
. O 0 0.009011018

We O 0 0.0032730228
report O 0 0.0043218513
a O 0 0.0019707484
case O 0 0.0015194041
of O 0 0.001994019
atracurium B-Chemical 0 0.99781966
- O 0 0.0034439263
related O 0 0.0009127942
paralysis B-Disease 2 0.9976641
persisting O 0 0.016808359
for O 0 0.00038876923
approximately O 0 0.00044017783
50 O 0 0.000489223
hours O 0 0.00028899685
in O 0 0.00026373673
a O 0 0.00041690876
patient O 0 0.0007921118
who O 0 0.0012984327
was O 0 0.0007105701
not O 0 0.00091866445
treated O 0 0.0026821564
with O 0 0.0051600444
corticosteroids O 1 0.9961898
. O 0 0.009662512

A O 0 0.021662451
phase O 0 0.006980084
I O 0 0.008172388
/ O 0 0.004175658
II O 0 0.0059739975
study O 0 0.0017512933
of O 0 0.0015952201
paclitaxel B-Chemical 1 0.9969703
plus O 0 0.002252876
cisplatin B-Chemical 1 0.9988391
as O 0 0.0007313329
first O 0 0.00056389376
- O 0 0.0009426141
line O 0 0.0008379342
therapy O 0 0.005952745
for O 0 0.00063241593
head B-Disease 0 0.019219996
and I-Disease 0 0.0016434768
neck I-Disease 0 0.6120026
cancers I-Disease 2 0.9919872
: O 0 0.0058187675
preliminary O 0 0.005862131
results O 0 0.00498279
. O 0 0.0065560667

Improved O 0 0.0104149375
outcomes O 0 0.0046023102
among O 0 0.0023838014
patients O 0 0.0032427902
with O 0 0.0017372501
head B-Disease 0 0.010560842
and I-Disease 0 0.0016481425
neck I-Disease 0 0.21239161
carcinomas I-Disease 0 0.9529542
require O 0 0.0010193547
investigations O 0 0.002276172
of O 0 0.0014692288
new O 0 0.0024860117
drugs O 0 0.5029364
for O 0 0.0024361403
induction O 0 0.0066581774
therapy O 0 0.11576513
. O 0 0.008052898

Preliminary O 0 0.008865488
results O 0 0.0025123237
of O 0 0.0024448144
an O 0 0.0025318817
Eastern O 0 0.029707551
Cooperative O 0 0.06935377
Oncology O 0 0.031346243
Group O 0 0.006169887
study O 0 0.000854403
of O 0 0.00067760545
single O 0 0.0008138969
- O 0 0.0017394894
agent O 0 0.2577206
paclitaxel B-Chemical 1 0.9991912
( O 0 0.013224571
Taxol B-Chemical 1 0.9997907
; O 0 0.007037799
Bristol O 0 0.11875732
- O 0 0.0017055527
Myers O 0 0.2673125
Squibb O 0 0.9597059
Company O 0 0.6211162
, O 0 0.00095634675
Princeton O 0 0.33469036
, O 0 0.00094429596
NJ O 0 0.2467844
) O 0 0.00076518144
reported O 0 0.00045462156
a O 0 0.00030632046
37 O 0 0.0004141291
% O 0 0.00025659485
response O 0 0.0002910802
rate O 0 0.00020659555
in O 0 0.00020712551
patients O 0 0.00080741046
with O 0 0.00038927383
head B-Disease 0 0.014356449
and I-Disease 0 0.000554169
neck I-Disease 0 0.50394344
cancer I-Disease 2 0.99598604
, O 0 0.0010564532
and O 0 0.00041731057
the O 0 0.0004278498
paclitaxel B-Chemical 1 0.9987419
/ O 0 0.009728424
cisplatin B-Chemical 1 0.99920386
combination O 0 0.0046046083
has O 0 0.00039398912
been O 0 0.0003697015
used O 0 0.0002207789
successfully O 0 0.00047603194
and O 0 0.00030530756
has O 0 0.00030798258
significantly O 0 0.00045202594
improved O 0 0.00083556026
median O 0 0.0004920599
response O 0 0.00086950086
duration O 0 0.0013564075
in O 0 0.0017314752
ovarian B-Disease 2 0.9948055
cancer I-Disease 2 0.9975809
patients O 0 0.1866683
. O 0 0.007991373

We O 0 0.003513635
initiated O 0 0.0029017816
a O 0 0.0022629816
phase O 0 0.0032838865
I O 0 0.0050461753
/ O 0 0.002579289
II O 0 0.004493847
trial O 0 0.0012079662
to O 0 0.00042156244
determine O 0 0.00020859829
the O 0 0.00033745816
response O 0 0.0006870578
and O 0 0.00059832534
toxicity B-Disease 2 0.9850922
of O 0 0.0010193415
escalating O 0 0.84152454
paclitaxel B-Chemical 1 0.9993637
doses O 0 0.1844666
combined O 0 0.0016701928
with O 0 0.0005395372
fixed O 0 0.00057352014
- O 0 0.0010574794
dose O 0 0.045907967
cisplatin B-Chemical 1 0.99936193
with O 0 0.0019722353
granulocyte O 0 0.93470967
colony O 0 0.098472394
- O 0 0.0013311025
stimulating O 0 0.001076212
factor O 0 0.0026306289
support O 0 0.00034446595
in O 0 0.0002864245
patients O 0 0.0010765869
with O 0 0.0005200496
untreated O 0 0.0010574997
locally O 0 0.030181434
advanced O 0 0.23907791
inoperable O 0 0.98166084
head B-Disease 0 0.27726215
and I-Disease 0 0.0059988536
neck I-Disease 0 0.9033248
carcinoma I-Disease 2 0.99771285
. O 0 0.012226731

To O 0 0.003075212
date O 0 0.0026953649
, O 0 0.0023968571
23 O 0 0.0021011722
men O 0 0.006084439
with O 0 0.0010225597
a O 0 0.0007968085
median O 0 0.0006011199
age O 0 0.0009593675
of O 0 0.00063942146
50 O 0 0.00080263376
years O 0 0.00082858274
and O 0 0.00050603895
good O 0 0.0007109991
performance O 0 0.0010344115
status O 0 0.001283045
have O 0 0.0013728385
entered O 0 0.0026402073
the O 0 0.0027769199
trial O 0 0.008216888
. O 0 0.0063406606

Primary O 0 0.020107612
tumor B-Disease 2 0.3486642
sites O 0 0.0025392843
were O 0 0.0019875178
oropharynx O 0 0.30351725
, O 0 0.0014865373
10 O 0 0.00086872233
patients O 0 0.0019482678
; O 0 0.0015066069
hypopharynx O 0 0.7089388
, O 0 0.0007403652
four O 0 0.0003550104
; O 0 0.0009882711
larynx O 0 0.28436187
, O 0 0.000600395
two O 0 0.00030129435
; O 0 0.0007829582
oral O 0 0.12348781
cavity O 0 0.0022357982
, O 0 0.0004525099
three O 0 0.0001928493
; O 0 0.0005708046
unknown O 0 0.0007524226
primary O 0 0.00062110124
, O 0 0.00052565645
two O 0 0.00031833322
; O 0 0.0007530395
and O 0 0.00052197423
nasal O 0 0.0069437856
cavity O 0 0.002594047
and O 0 0.0011691148
parotid O 0 0.40628883
gland O 0 0.32104212
, O 0 0.002460205
one O 0 0.0018472195
each O 0 0.0024356744
. O 0 0.0051973057

Of O 0 0.005398181
20 O 0 0.0027898028
patients O 0 0.0035235405
evaluable O 0 0.0078077912
for O 0 0.0014718833
toxicity B-Disease 2 0.9748263
, O 0 0.0015036258
four O 0 0.0006084173
had O 0 0.00096090714
stage O 0 0.0024235405
III O 0 0.007388536
and O 0 0.0012783951
16 O 0 0.0014661582
had O 0 0.001850197
stage O 0 0.006743476
IV O 0 0.29434744
disease O 0 0.8105324
. O 0 0.009593244

Treatment O 0 0.037534323
, O 0 0.0029490674
given O 0 0.0010488059
every O 0 0.00058082864
21 O 0 0.00074870477
days O 0 0.000434823
for O 0 0.00032348768
a O 0 0.0003722106
maximum O 0 0.0003300929
of O 0 0.00034902123
three O 0 0.00017626783
cycles O 0 0.00027599945
, O 0 0.00034627307
consisted O 0 0.0002532964
of O 0 0.0004947664
paclitaxel B-Chemical 1 0.99750286
by O 0 0.0005203739
3 O 0 0.0003131587
- O 0 0.00036464861
hour O 0 0.00019133513
infusion O 0 0.0027307186
followed O 0 0.0001423356
the O 0 0.0001539672
next O 0 0.00011192597
day O 0 0.0001940932
by O 0 0.00022402129
a O 0 0.0002784745
fixed O 0 0.00035745726
dose O 0 0.005432294
of O 0 0.0012549972
cisplatin B-Chemical 1 0.99867105
( O 0 0.0021901836
75 O 0 0.0025040826
mg O 0 0.42337677
/ O 0 0.0059003686
m2 O 0 0.07266489
) O 0 0.006843942
. O 0 0.0052634524

The O 0 0.0030521771
dose O 0 0.008155647
levels O 0 0.0017157805
incorporate O 0 0.0013606494
escalating O 0 0.54294795
paclitaxel B-Chemical 1 0.9983896
doses O 0 0.29861227
, O 0 0.0013515223
and O 0 0.00072269817
intrapatient O 0 0.05217587
escalations O 0 0.42686442
within O 0 0.0002791556
a O 0 0.00046833986
given O 0 0.00036164484
dose O 0 0.0037280365
level O 0 0.00059366174
are O 0 0.00095690443
permitted O 0 0.0021063257
if O 0 0.0017731288
toxicity B-Disease 2 0.97709686
permits O 0 0.0085702045
. O 0 0.0068811304

At O 0 0.0023013349
the O 0 0.0017000878
time O 0 0.0012112049
of O 0 0.0013703887
this O 0 0.0010543343
writing O 0 0.008944859
, O 0 0.001265634
dose O 0 0.0060186386
level O 0 0.0005068252
4 O 0 0.00048797435
( O 0 0.00060180493
260 O 0 0.0018476873
, O 0 0.0005024596
270 O 0 0.0020040139
, O 0 0.00042481598
and O 0 0.0003490805
280 O 0 0.007215289
mg O 0 0.34640384
/ O 0 0.0013743731
m2 O 0 0.030926002
) O 0 0.00062293484
is O 0 0.00028667826
being O 0 0.00039875004
evaluated O 0 0.00035928612
; O 0 0.0005907619
three O 0 0.0002454191
patients O 0 0.0011172196
from O 0 0.0006450431
this O 0 0.00087597576
level O 0 0.0011690425
are O 0 0.002661534
evaluable O 0 0.033985987
. O 0 0.005407726

With O 0 0.007633789
paclitaxel B-Chemical 1 0.98937756
doses O 0 0.07284386
of O 0 0.0023147913
200 O 0 0.004227832
mg O 0 0.5348661
/ O 0 0.0024456051
m2 O 0 0.024805661
and O 0 0.0006124577
higher O 0 0.0005694998
, O 0 0.00083658914
granulocyte O 0 0.68675476
colony O 0 0.042300053
- O 0 0.0012787306
stimulating O 0 0.0012106571
factor O 0 0.003799587
5 O 0 0.0004115327
micrograms O 0 0.1289215
/ O 0 0.0011179721
kg O 0 0.00397164
/ O 0 0.00081312517
d O 0 0.00050316454
is O 0 0.00038796532
given O 0 0.00037283203
( O 0 0.0007714219
days O 0 0.0006730442
4 O 0 0.00080388784
through O 0 0.0011710452
12 O 0 0.0018985177
) O 0 0.0047061336
. O 0 0.0045732283

Of O 0 0.005143367
18 O 0 0.0024296818
patients O 0 0.002949286
evaluable O 0 0.0054478305
for O 0 0.00088394736
response O 0 0.0013867115
, O 0 0.0009796559
seven O 0 0.0006497796
( O 0 0.00082049915
39 O 0 0.0008416284
% O 0 0.00052507914
) O 0 0.000530134
achieved O 0 0.00039683408
a O 0 0.00035929948
complete O 0 0.00033539362
response O 0 0.0005796918
and O 0 0.0004519495
six O 0 0.00037863594
( O 0 0.00082979666
33 O 0 0.0010646643
% O 0 0.0008725783
) O 0 0.0011898199
achieved O 0 0.0012901764
a O 0 0.0018846089
partial O 0 0.004854191
response O 0 0.006876632
. O 0 0.0062312474

Three O 0 0.007040285
patients O 0 0.006667968
had O 0 0.0032796874
no O 0 0.002460644
change O 0 0.0031064958
and O 0 0.0038817397
disease O 0 0.44598138
progressed O 0 0.031454332
in O 0 0.0057037678
two O 0 0.006916714
. O 0 0.009880397

The O 0 0.007414698
overall O 0 0.0072404547
response O 0 0.00850233
rate O 0 0.007096247
is O 0 0.008607129
72 O 0 0.0111016
% O 0 0.013198852
. O 0 0.013005443

Eleven O 0 0.014706645
responding O 0 0.008270612
patients O 0 0.0058511617
had O 0 0.002865323
subsequent O 0 0.0033190772
surgery O 0 0.009005219
/ O 0 0.0077088103
radiotherapy O 0 0.5662525
or O 0 0.006133786
radical O 0 0.86261
radiotherapy O 0 0.9432734
. O 0 0.014831154

Two O 0 0.0056355237
pathologic O 0 0.033404715
complete O 0 0.0024450668
responses O 0 0.002889728
were O 0 0.0013375487
observed O 0 0.00093996763
in O 0 0.00101813
patients O 0 0.0026068226
who O 0 0.0026113405
had O 0 0.0016424785
achieved O 0 0.0025932156
clinical O 0 0.00967774
complete O 0 0.004352973
responses O 0 0.010237531
. O 0 0.0073960866

Alopecia B-Disease 0 0.9896026
, O 0 0.009219321
paresthesias B-Disease 0 0.9964144
, O 0 0.004232301
and O 0 0.0028432352
arthralgias B-Disease 0 0.9979603
/ O 0 0.033277944
myalgias B-Disease 0 0.9995315
have O 0 0.0010958376
occurred O 0 0.0008808684
frequently O 0 0.0011724986
, O 0 0.0005699967
but O 0 0.00032360552
with O 0 0.00036612502
one O 0 0.00025996828
exception O 0 0.0003751141
( O 0 0.000549408
a O 0 0.0004925968
grade O 0 0.08378314
3 O 0 0.0008520749
myalgia B-Disease 2 0.9994893
) O 0 0.0014831426
they O 0 0.0005617654
have O 0 0.00080739014
been O 0 0.0014446492
grade O 0 0.067193165
1 O 0 0.0020490384
or O 0 0.0021227098
2 O 0 0.0038067468
. O 0 0.004565487

No O 0 0.012508858
dose O 0 0.033779435
- O 0 0.0091018975
limiting O 0 0.009237812
hematologic O 0 0.9944489
toxicity B-Disease 2 0.9962412
has O 0 0.009960381
been O 0 0.010420708
seen O 0 0.009743808
. O 0 0.010801749

Paclitaxel B-Chemical 0 0.9970758
/ O 0 0.025675103
cisplatin B-Chemical 1 0.99670666
is O 0 0.0020802508
an O 0 0.0014273789
effective O 0 0.0013094123
first O 0 0.00065590884
- O 0 0.001007717
line O 0 0.0008170378
regimen O 0 0.003291382
for O 0 0.0005391296
locoregionally O 0 0.97295636
advanced O 0 0.16375627
head B-Disease 0 0.0725184
and I-Disease 0 0.0013431937
neck I-Disease 0 0.53801525
cancer I-Disease 2 0.98974824
and O 0 0.0016945291
continued O 0 0.0021767777
study O 0 0.0026613467
is O 0 0.0026074601
warranted O 0 0.0043144934
. O 0 0.0056217154

Results O 0 0.0049492535
thus O 0 0.0031094237
far O 0 0.001658012
suggest O 0 0.0011407585
no O 0 0.0011169418
dose O 0 0.018199291
- O 0 0.0018941837
response O 0 0.0012630149
effect O 0 0.000998555
for O 0 0.0009877075
paclitaxel B-Chemical 1 0.9967937
doses O 0 0.1092478
above O 0 0.0013751959
200 O 0 0.0062836963
mg O 0 0.54338926
/ O 0 0.009539248
m2 O 0 0.07981563
. O 0 0.0064770714

Improvement O 0 0.018582212
of O 0 0.008090649
levodopa B-Chemical 1 0.9988355
- O 0 0.016561864
induced O 0 0.012804273
dyskinesia B-Disease 2 0.99971837
by O 0 0.01036797
propranolol B-Chemical 1 0.99960476
in O 0 0.008677348
Parkinson B-Disease 0 0.9980564
' I-Disease 0 0.0063586724
s I-Disease 0 0.0075813658
disease I-Disease 0 0.58096725
. O 0 0.0096317865

Seven O 0 0.00926543
patients O 0 0.006846386
suffering O 0 0.43209425
from O 0 0.003025629
Parkinson B-Disease 0 0.9977398
' I-Disease 0 0.001974183
s I-Disease 0 0.0017593898
disease I-Disease 0 0.6200887
( O 0 0.0030188374
PD B-Disease 0 0.9928542
) O 0 0.0015396007
with O 0 0.0007638165
severely O 0 0.024611946
disabling O 0 0.9870286
dyskinesia B-Disease 2 0.9999436
received O 0 0.0024490326
low O 0 0.0013983671
- O 0 0.0015750524
dose O 0 0.061486974
propranolol B-Chemical 1 0.9998338
as O 0 0.000595738
an O 0 0.0007554546
adjunct O 0 0.0011168631
to O 0 0.0005639164
the O 0 0.0006913089
currently O 0 0.0016222394
used O 0 0.0014934657
medical O 0 0.016053451
treatment O 0 0.011269362
. O 0 0.0062614083

There O 0 0.005739461
was O 0 0.0026179277
a O 0 0.0020774268
significant O 0 0.001824765
40 O 0 0.001518206
% O 0 0.0011446396
improvement O 0 0.0011680729
in O 0 0.00079473684
the O 0 0.0012814079
dyskinesia B-Disease 2 0.99965143
score O 0 0.0017330287
without O 0 0.0013489414
increase O 0 0.001675707
of O 0 0.006027823
parkinsonian B-Disease 2 0.9993444
motor B-Disease 0 0.97167116
disability I-Disease 0 0.98112065
. O 0 0.009597552

Ballistic O 0 0.1641664
and O 0 0.009698689
choreic O 0 0.99783057
dyskinesia B-Disease 2 0.9996309
were O 0 0.0055257366
markedly O 0 0.01872015
ameliorated O 0 0.65832424
, O 0 0.0062310994
whereas O 0 0.006056936
dystonia B-Disease 2 0.999065
was O 0 0.007712992
not O 0 0.007312135
. O 0 0.008483178

This O 0 0.0041185473
study O 0 0.0025600134
suggests O 0 0.0010690952
that O 0 0.00094439
administration O 0 0.0243682
of O 0 0.0010780088
low O 0 0.0011543267
doses O 0 0.046733327
of O 0 0.0019220957
beta O 0 0.8192473
- O 0 0.008979707
blockers O 0 0.99726355
may O 0 0.0011099951
improve O 0 0.0010295553
levodopa B-Chemical 1 0.99976677
- O 0 0.004111333
induced O 0 0.0018432953
ballistic O 0 0.11317749
and O 0 0.004814601
choreic O 0 0.99944264
dyskinesia B-Disease 2 0.9998165
in O 0 0.016809113
PD B-Disease 0 0.99225396
. O 0 0.009053888

Habitual O 0 0.2324772
use O 0 0.004414829
of O 0 0.0040891943
acetaminophen B-Chemical 0 0.9992768
as O 0 0.002037315
a O 0 0.0018019757
risk O 0 0.02539708
factor O 0 0.0078014326
for O 0 0.001386611
chronic B-Disease 2 0.9917679
renal I-Disease 2 0.9975152
failure I-Disease 2 0.9738783
: O 0 0.004576933
a O 0 0.0021773498
comparison O 0 0.0022988261
with O 0 0.007689157
phenacetin B-Chemical 1 0.99903023
. O 0 0.013164086

Six O 0 0.00500701
epidemiologic O 0 0.005723665
studies O 0 0.0024678926
in O 0 0.0012254594
the O 0 0.0010983623
United O 0 0.0017354863
States O 0 0.002030414
and O 0 0.0006320592
Europe O 0 0.0024185632
indicate O 0 0.00029602766
that O 0 0.00032312213
habitual O 0 0.04062311
use O 0 0.00056976365
of O 0 0.00095053937
phenacetin B-Chemical 1 0.99991417
is O 0 0.0007960841
associated O 0 0.0006637833
with O 0 0.0004410286
the O 0 0.0002967884
development O 0 0.0009294655
of O 0 0.0007382677
chronic B-Disease 2 0.99301356
renal I-Disease 2 0.99855953
failure I-Disease 2 0.96194637
and O 0 0.0007740452
end B-Disease 0 0.0002738514
- I-Disease 0 0.00085087126
stage I-Disease 0 0.0028475649
renal I-Disease 0 0.99893445
disease I-Disease 0 0.9966534
( O 0 0.01938143
ESRD B-Disease 2 0.9997656
) O 0 0.0026353972
, O 0 0.0005170393
with O 0 0.00037984978
a O 0 0.0003735471
relative O 0 0.00030065878
risk O 0 0.0058721877
in O 0 0.0004919622
the O 0 0.00058025797
range O 0 0.0011766718
of O 0 0.0013855867
4 O 0 0.0014669569
to O 0 0.0021148156
19 O 0 0.0055295373
. O 0 0.0046367776

As O 0 0.002349774
a O 0 0.0021465374
result O 0 0.0012989931
of O 0 0.0013811864
these O 0 0.0013795018
and O 0 0.0010311301
other O 0 0.00088169344
studies O 0 0.0016086978
, O 0 0.001906621
phenacetin B-Chemical 1 0.99977833
has O 0 0.0013031306
now O 0 0.0011753041
been O 0 0.0009788498
withdrawn O 0 0.0030037805
from O 0 0.0008109949
the O 0 0.000997199
market O 0 0.003223189
in O 0 0.0018215176
most O 0 0.0049023484
countries O 0 0.012711172
. O 0 0.0065784557

However O 0 0.003825303
, O 0 0.002385787
three O 0 0.000866283
case O 0 0.0010325783
control O 0 0.00073126145
studies O 0 0.0011251196
, O 0 0.0007793999
one O 0 0.00035622646
each O 0 0.00025381084
in O 0 0.0004207274
North O 0 0.001446235
Carolina O 0 0.0039791637
, O 0 0.00053899724
northern O 0 0.001548946
Maryland O 0 0.011687616
, O 0 0.0004636083
and O 0 0.00038796218
West O 0 0.002144912
Berlin O 0 0.0036409323
, O 0 0.00054983096
Germany O 0 0.0050876727
, O 0 0.00033290117
showed O 0 0.00021894318
that O 0 0.00020387025
habitual O 0 0.04035079
use O 0 0.00041486564
of O 0 0.0007663494
acetaminophen B-Chemical 0 0.9999161
is O 0 0.0006522577
also O 0 0.0004141528
associated O 0 0.0005524057
with O 0 0.00082078885
chronic B-Disease 2 0.9934749
renal I-Disease 2 0.99872714
failure I-Disease 2 0.98239523
and O 0 0.0061138067
ESRD B-Disease 2 0.9997688
, O 0 0.0011015439
with O 0 0.0005083648
a O 0 0.00042251754
relative O 0 0.00031640916
risk O 0 0.0069668265
in O 0 0.0004953185
the O 0 0.0005805192
range O 0 0.001183043
of O 0 0.0013989772
2 O 0 0.0016707485
to O 0 0.0019937637
4 O 0 0.003106163
. O 0 0.0043007843

These O 0 0.004134744
studies O 0 0.0029828842
suggest O 0 0.0014277834
that O 0 0.0012759051
both O 0 0.0017321743
phenacetin B-Chemical 1 0.99974555
and O 0 0.005914348
acetaminophen B-Chemical 0 0.9998466
may O 0 0.0014123506
contribute O 0 0.0007094658
to O 0 0.00041830156
the O 0 0.0004007486
burden O 0 0.0012746546
of O 0 0.0014176421
ESRD B-Disease 2 0.99964404
, O 0 0.0010005059
with O 0 0.0004950063
the O 0 0.00035172582
risk O 0 0.00838479
of O 0 0.0005113174
the O 0 0.0003783157
latter O 0 0.0011148938
being O 0 0.000686734
somewhat O 0 0.0008852054
less O 0 0.00058018405
than O 0 0.00045464924
that O 0 0.00074107567
of O 0 0.0018429629
the O 0 0.002851226
former O 0 0.026604695
. O 0 0.006364985

This O 0 0.004591719
apparent O 0 0.002474468
difference O 0 0.0012258376
in O 0 0.0012741915
risk O 0 0.007734754
may O 0 0.0011206965
not O 0 0.00077949604
be O 0 0.0007125043
due O 0 0.000431763
to O 0 0.00053130556
differences O 0 0.00049738935
in O 0 0.000922555
nephrotoxic B-Disease 2 0.99756324
potential O 0 0.0025872802
of O 0 0.0024849751
the O 0 0.0030376462
drugs O 0 0.7535139
themselves O 0 0.013457749
. O 0 0.007026771

A O 0 0.012875398
lower O 0 0.0023913053
relative O 0 0.0014611718
risk O 0 0.008161932
would O 0 0.0009233477
be O 0 0.0007687847
expected O 0 0.00038623775
for O 0 0.000575292
acetaminophen B-Chemical 0 0.99972373
if O 0 0.0004613815
the O 0 0.0004234964
risk O 0 0.0109793395
of O 0 0.0005744001
both O 0 0.00043523085
drugs O 0 0.44636357
in O 0 0.00032063035
combination O 0 0.001004477
with O 0 0.00048347906
other O 0 0.0005189237
analgesics O 0 0.98677075
was O 0 0.00045630828
higher O 0 0.00038133116
than O 0 0.00029055038
the O 0 0.00052982935
risk O 0 0.008704379
of O 0 0.0016503234
either O 0 0.0022711037
agent O 0 0.18528223
alone O 0 0.007191214
. O 0 0.006357293

Thus O 0 0.0049452204
, O 0 0.005069393
acetaminophen B-Chemical 0 0.99916315
has O 0 0.0023699764
been O 0 0.0014516333
used O 0 0.00074390805
both O 0 0.00057363656
as O 0 0.0004227645
a O 0 0.0005089527
single O 0 0.0005143243
agent O 0 0.03330625
and O 0 0.0004952111
in O 0 0.0003278952
combination O 0 0.0009699658
with O 0 0.000602821
other O 0 0.0007373126
analgesics O 0 0.99452305
, O 0 0.0013546769
whereas O 0 0.0011583053
phenacetin B-Chemical 1 0.99979466
was O 0 0.001480119
available O 0 0.0012668148
only O 0 0.0015598135
in O 0 0.0020640953
combinations O 0 0.004491786
. O 0 0.0058453586

The O 0 0.0027209297
possibility O 0 0.001839355
that O 0 0.0014290715
habitual O 0 0.030687563
use O 0 0.0016293625
of O 0 0.0019251838
acetaminophen B-Chemical 0 0.99974865
alone O 0 0.002129435
increases O 0 0.0009829656
the O 0 0.00066806056
risk O 0 0.033685215
of O 0 0.002582602
ESRD B-Disease 2 0.9995448
has O 0 0.0010254086
not O 0 0.00066449604
been O 0 0.00078085216
clearly O 0 0.00064367667
demonstrated O 0 0.001082341
, O 0 0.0015959616
but O 0 0.0015632154
cannot O 0 0.0069002914
be O 0 0.004030326
dismissed O 0 0.029504327
. O 0 0.0068038027

Acetaminophen B-Chemical 0 0.9962603
- O 0 0.077701986
induced O 0 0.06721839
hypotension B-Disease 2 0.9934121
. O 0 0.043496102

Through O 0 0.0059292195
30 O 0 0.00225498
years O 0 0.0022665272
of O 0 0.0015222011
widespread O 0 0.0029948398
use O 0 0.0018147201
, O 0 0.002283444
acetaminophen B-Chemical 0 0.9997234
has O 0 0.0015266429
been O 0 0.0010798811
shown O 0 0.0005009154
to O 0 0.0005347038
be O 0 0.0006114501
a O 0 0.0007408194
remarkably O 0 0.00258635
safe O 0 0.005315461
medication O 0 0.12228838
in O 0 0.0021579333
therapeutic O 0 0.06397483
dosages O 0 0.57408065
. O 0 0.007994384

The O 0 0.004212433
potential O 0 0.0046607386
for O 0 0.003922812
acetaminophen B-Chemical 0 0.9987658
to O 0 0.004445365
produce O 0 0.005082173
cardiovascular B-Disease 0 0.995869
toxicities I-Disease 2 0.998792
is O 0 0.0069460017
very O 0 0.0068115694
low O 0 0.009255037
. O 0 0.009014463

However O 0 0.0056591462
, O 0 0.005672094
acetaminophen B-Chemical 0 0.9990515
has O 0 0.0027736588
been O 0 0.0017705313
demonstrated O 0 0.001110605
to O 0 0.0008302424
produce O 0 0.00094859774
symptoms O 0 0.23867019
of O 0 0.0025299028
anaphylaxis B-Disease 2 0.9984517
, O 0 0.0033840584
including O 0 0.0030768495
hypotension B-Disease 2 0.99940026
, O 0 0.0032435346
in O 0 0.0018875486
sensitive O 0 0.0032495477
individuals O 0 0.0061440933
. O 0 0.005994264

This O 0 0.004493789
article O 0 0.003252864
describes O 0 0.002313226
two O 0 0.0012745737
critically B-Disease 0 0.018488493
ill I-Disease 0 0.43222547
patients O 0 0.0037697859
in O 0 0.00079969066
whom O 0 0.0025591515
transient O 0 0.03242903
episodes O 0 0.23376499
of O 0 0.0028247274
hypotension B-Disease 2 0.99956053
reproducibly O 0 0.022212602
developed O 0 0.0026601485
after O 0 0.0011547167
administration O 0 0.18810773
of O 0 0.012581489
acetaminophen B-Chemical 0 0.999323
. O 0 0.01216954

Other O 0 0.022083774
symptoms O 0 0.21749505
of O 0 0.010478565
allergic B-Disease 0 0.9944496
reactions I-Disease 0 0.2881774
were O 0 0.00541336
not O 0 0.00504612
clinically O 0 0.054965027
detectable O 0 0.0074745785
. O 0 0.010103216

The O 0 0.006765309
hypotensive B-Disease 2 0.98437726
episodes O 0 0.26655108
were O 0 0.0045606787
severe O 0 0.05041471
enough O 0 0.003488468
to O 0 0.0032592693
require O 0 0.0046327407
vasopressor O 0 0.98476505
administration O 0 0.67170775
. O 0 0.013200938

The O 0 0.0028398037
reports O 0 0.002818659
illustrate O 0 0.0015920261
the O 0 0.0012408219
need O 0 0.0009752528
for O 0 0.00079790794
clinicians O 0 0.0016001763
to O 0 0.0007889385
consider O 0 0.0008909853
acetaminophen B-Chemical 0 0.9996214
in O 0 0.001539891
patients O 0 0.0059931045
with O 0 0.0036920493
hypotension B-Disease 2 0.99906
of O 0 0.00601972
unknown O 0 0.023456255
origin O 0 0.017969068
. O 0 0.007687676

Reduction O 0 0.014652724
of O 0 0.006573989
heparan B-Chemical 0 0.99142116
sulphate I-Chemical 0 0.99768615
- O 0 0.009114062
associated O 0 0.0027616865
anionic O 0 0.3598337
sites O 0 0.001101989
in O 0 0.00069672975
the O 0 0.0007854855
glomerular O 0 0.84838253
basement O 0 0.33206478
membrane O 0 0.020738913
of O 0 0.001603926
rats O 0 0.013126482
with O 0 0.004178413
streptozotocin B-Chemical 1 0.99964774
- O 0 0.03272606
induced O 0 0.04524318
diabetic B-Disease 2 0.9990206
nephropathy I-Disease 0 0.9997149
. O 0 0.02489243

Heparan B-Chemical 0 0.98556685
sulphate I-Chemical 0 0.9948325
- O 0 0.007862731
associated O 0 0.003090866
anionic O 0 0.26530638
sites O 0 0.0012310323
in O 0 0.00072568626
the O 0 0.0007294758
glomerular O 0 0.8233476
basement O 0 0.29656175
membrane O 0 0.016600072
were O 0 0.00051381206
studied O 0 0.0005684212
in O 0 0.0003015648
rats O 0 0.0010918654
8 O 0 0.00023491263
months O 0 0.00020739844
after O 0 0.00011896367
induction O 0 0.00035078067
of O 0 0.0005441479
diabetes B-Disease 2 0.99567586
by O 0 0.001127898
streptozotocin B-Chemical 1 0.9998505
and O 0 0.0008072486
in O 0 0.00038710615
age O 0 0.0017237121
- O 0 0.0009879068
adn O 0 0.16318424
sex O 0 0.017032491
- O 0 0.00066182297
matched O 0 0.00031785647
control O 0 0.00036609464
rats O 0 0.0016671638
, O 0 0.0007530926
employing O 0 0.0009559468
the O 0 0.0012716278
cationic O 0 0.17793322
dye O 0 0.06451997
cuprolinic B-Chemical 0 0.70936966
blue I-Chemical 0 0.044628955
. O 0 0.008662274

Morphometric O 0 0.17917056
analysis O 0 0.004663014
at O 0 0.0018725271
the O 0 0.0018435287
ultrastructural O 0 0.014943323
level O 0 0.0013690817
was O 0 0.0013761995
performed O 0 0.0013833609
using O 0 0.0016361995
a O 0 0.0028283359
computerized O 0 0.010077811
image O 0 0.008448139
processor O 0 0.03337731
. O 0 0.010503859

The O 0 0.005095566
heparan B-Chemical 0 0.9712442
sulphate I-Chemical 0 0.9930139
specificity O 0 0.00573391
of O 0 0.0020003475
the O 0 0.0013507348
cuprolinic B-Chemical 0 0.34960267
blue I-Chemical 0 0.0053293807
staining O 0 0.0012864015
was O 0 0.00064561446
demonstrated O 0 0.00066181953
by O 0 0.0008279797
glycosaminoglycan B-Chemical 0 0.9944841
- O 0 0.003692053
degrading O 0 0.053779855
enzymes O 0 0.14137875
, O 0 0.00065703655
showing O 0 0.00037153237
that O 0 0.00026601006
pretreatment O 0 0.05733494
of O 0 0.00046344218
the O 0 0.00031727488
sections O 0 0.00064669806
with O 0 0.0006394275
heparitinase O 0 0.9530901
abolished O 0 0.002128874
all O 0 0.0004999854
staining O 0 0.0010315399
, O 0 0.00097295025
whereas O 0 0.0010020274
chondroitinase O 0 0.89288175
ABC O 0 0.14461525
had O 0 0.0025203954
no O 0 0.0027105822
effect O 0 0.005451477
. O 0 0.0063676666

The O 0 0.0029891303
majority O 0 0.0025182925
of O 0 0.002668837
anionic O 0 0.19313058
sites O 0 0.0018601198
( O 0 0.0016308234
74 O 0 0.001427056
% O 0 0.000771495
in O 0 0.0005509353
diabetic B-Disease 2 0.9687589
and O 0 0.0006651582
81 O 0 0.000928872
% O 0 0.00039707325
in O 0 0.00023129706
control O 0 0.00026795862
rats O 0 0.0014350121
) O 0 0.00056719757
were O 0 0.0002881514
found O 0 0.0002748299
within O 0 0.00019679396
the O 0 0.00043728584
lamina O 0 0.0029759041
rara O 0 0.29522958
externa O 0 0.9404178
of O 0 0.0023601255
the O 0 0.0025767193
glomerular O 0 0.95713305
basement O 0 0.723215
membrane O 0 0.18289284
. O 0 0.00866528

A O 0 0.0154463295
minority O 0 0.005754511
of O 0 0.0028823717
anionic O 0 0.14005855
sites O 0 0.0013719648
were O 0 0.0008843889
scattered O 0 0.0014717185
throughout O 0 0.0004641418
the O 0 0.00056314876
lamina O 0 0.0022436695
densa O 0 0.12591353
and O 0 0.00083654094
lamina O 0 0.005770152
rara O 0 0.37379554
interna O 0 0.6763327
, O 0 0.00068584556
and O 0 0.00035112782
were O 0 0.00026121474
significantly O 0 0.0002960353
smaller O 0 0.00022484276
than O 0 0.00015901678
those O 0 0.00030822813
in O 0 0.0002108579
the O 0 0.00027583947
lamina O 0 0.00256667
rara O 0 0.3018383
externa O 0 0.94286674
of O 0 0.0008101102
the O 0 0.00053856696
glomerular O 0 0.93288743
basement O 0 0.49983197
membrane O 0 0.048662417
( O 0 0.0008462266
p O 0 0.0005527262
< O 0 0.00037904055
0 O 0 0.00030455692
. O 0 0.00018727439
001 O 0 0.035750642
and O 0 0.00032042683
p O 0 0.00046380697
< O 0 0.00039252386
0 O 0 0.00034572024
. O 0 0.00022970374
01 O 0 0.0015239088
for O 0 0.00044222246
diabetic B-Disease 2 0.9643408
and O 0 0.00096553145
control O 0 0.0010334306
rats O 0 0.0052330773
, O 0 0.002840954
respectively O 0 0.0059590572
) O 0 0.0068070544
. O 0 0.005488095

Diabetic B-Disease 0 0.99601305
rats O 0 0.0165047
progressively O 0 0.0060985098
developed O 0 0.005505706
albuminuria B-Disease 2 0.998437
reaching O 0 0.0049265972
40 O 0 0.0012080455
. O 0 0.00043471338
3 O 0 0.0004274971
( O 0 0.0005278733
32 O 0 0.00054187136
. O 0 0.00022544061
2 O 0 0.00032687766
- O 0 0.00045393605
62 O 0 0.00051326916
. O 0 0.00016426641
0 O 0 0.00028560043
) O 0 0.00041775696
mg O 0 0.0871334
/ O 0 0.00051111216
24 O 0 0.00017838538
h O 0 0.00015467248
after O 0 9.001725e-05
8 O 0 0.00013750298
months O 0 0.00014471645
in O 0 0.00011530474
contrast O 0 0.00016665357
to O 0 0.0001527513
the O 0 0.00016031545
control O 0 0.00017383414
animals O 0 0.00022932517
( O 0 0.00034360713
0 O 0 0.0002551312
. O 0 0.00012700645
8 O 0 0.00020165493
( O 0 0.00026089267
0 O 0 0.00022747564
. O 0 0.00012880491
2 O 0 0.00022952378
- O 0 0.00035312233
0 O 0 0.0002536386
. O 0 0.00014608863
9 O 0 0.00026189227
) O 0 0.00049557135
mg O 0 0.08560964
/ O 0 0.000828059
24 O 0 0.0003945312
h O 0 0.0004926313
, O 0 0.0007157521
p O 0 0.0010395359
< O 0 0.0012061036
0 O 0 0.001416487
. O 0 0.0014951299
002 O 0 0.068671405
) O 0 0.006231167
. O 0 0.00542374

At O 0 0.002307563
the O 0 0.0016996444
same O 0 0.00093866943
time O 0 0.0010589241
, O 0 0.0012378471
the O 0 0.0006981388
number O 0 0.00062072306
of O 0 0.0014067038
heparan B-Chemical 0 0.99551326
sulphate I-Chemical 0 0.9990559
anionic O 0 0.8375139
sites O 0 0.00082578807
and O 0 0.0005099959
the O 0 0.00033725618
total O 0 0.00037423617
anionic O 0 0.20248309
site O 0 0.00050517305
surface O 0 0.0022244726
( O 0 0.0004873626
number O 0 0.00021927744
of O 0 0.000432702
anionic O 0 0.22752811
sites O 0 0.00040337484
x O 0 0.0012850986
mean O 0 0.00020959551
anionic O 0 0.13616623
site O 0 0.00041646132
surface O 0 0.002278149
) O 0 0.00065880135
in O 0 0.00023292856
the O 0 0.00027983563
lamina O 0 0.0026589707
rara O 0 0.30058077
externa O 0 0.9424358
of O 0 0.00076331163
the O 0 0.00048591438
glomerular O 0 0.9224521
basement O 0 0.4125727
membrane O 0 0.023102513
was O 0 0.00038400642
reduced O 0 0.0003606392
by O 0 0.0003572885
19 O 0 0.0006347077
% O 0 0.00036538023
( O 0 0.00034545714
p O 0 0.00035358436
< O 0 0.00030732117
0 O 0 0.00027515265
. O 0 0.00018050704
021 O 0 0.018362163
) O 0 0.00049781834
and O 0 0.00032045922
by O 0 0.00038096125
26 O 0 0.0006600224
% O 0 0.00052094937
( O 0 0.000576913
p O 0 0.0006989221
< O 0 0.0007387491
0 O 0 0.000786921
. O 0 0.0007199606
02 O 0 0.010316268
) O 0 0.0029249804
, O 0 0.0034176635
respectively O 0 0.0068441243
. O 0 0.005604129

Number O 0 0.006934499
and O 0 0.0026566237
total O 0 0.0018635021
anionic O 0 0.09851356
site O 0 0.0014163075
surface O 0 0.0022731598
in O 0 0.0006247328
the O 0 0.00047966605
remaining O 0 0.00045257786
part O 0 0.00035253505
of O 0 0.0005567383
the O 0 0.00058165076
glomerular O 0 0.8848315
basement O 0 0.46251118
membrane O 0 0.056145657
( O 0 0.001430015
lamina O 0 0.003489151
densa O 0 0.14603792
and O 0 0.000995075
lamina O 0 0.007974071
rara O 0 0.43330646
interna O 0 0.7428627
) O 0 0.0022874887
were O 0 0.0012266373
not O 0 0.0014998848
significantly O 0 0.0030746975
changed O 0 0.005528274
. O 0 0.006155952

We O 0 0.003270948
conclude O 0 0.002419484
that O 0 0.0017391812
in O 0 0.0020846266
streptozotocin B-Chemical 1 0.99954826
- O 0 0.021937948
diabetic B-Disease 2 0.99618185
rats O 0 0.01428611
with O 0 0.0008367127
an O 0 0.00078381813
increased O 0 0.0015780464
urinary O 0 0.9512536
albumin O 0 0.99779606
excretion O 0 0.99429613
, O 0 0.0013601842
a O 0 0.0005923299
reduced O 0 0.0009310955
heparan B-Chemical 0 0.9967145
sulphate I-Chemical 0 0.99922943
charge O 0 0.1680422
barrier O 0 0.054760028
/ O 0 0.0021958672
density O 0 0.0008875461
is O 0 0.0003868592
found O 0 0.00031779858
at O 0 0.00024031477
the O 0 0.00044709098
lamina O 0 0.00330665
rara O 0 0.3220706
externa O 0 0.94521934
of O 0 0.0023328788
the O 0 0.0025393602
glomerular O 0 0.9578605
basement O 0 0.7248484
membrane O 0 0.1832314
. O 0 0.008562487

Mediation O 0 0.33413658
of O 0 0.006056316
enhanced O 0 0.0060227653
reflex O 0 0.8990999
vagal O 0 0.9914619
bradycardia B-Disease 0 0.9986601
by O 0 0.00669351
L B-Chemical 1 0.95670295
- I-Chemical 1 0.017693011
dopa I-Chemical 1 0.9987871
via O 0 0.003205584
central O 0 0.019981226
dopamine B-Chemical 1 0.99739516
formation O 0 0.021222565
in O 0 0.0046526403
dogs O 0 0.016297586
. O 0 0.007859874

L B-Chemical 0 0.8943612
- I-Chemical 0 0.019444542
Dopa I-Chemical 0 0.9964678
( O 0 0.0037739016
5 O 0 0.0013775461
mg O 0 0.20363624
/ O 0 0.00207525
kg O 0 0.0045332173
i O 0 0.0016245221
. O 0 0.00042464284
v O 0 0.0035282853
. O 0 0.0003291778
) O 0 0.00061053556
decreased O 0 0.00070121017
blood O 0 0.0036790895
pressure O 0 0.026839947
and O 0 0.0004978008
heart O 0 0.17835045
rate O 0 0.00037239582
after O 0 0.0002916455
extracerebral O 0 0.9614671
decarboxylase O 0 0.99459016
inhibition O 0 0.019761221
with O 0 0.0015779659
MK B-Chemical 0 0.9852747
- I-Chemical 0 0.0040303757
486 I-Chemical 0 0.5234425
( O 0 0.0006826235
25 O 0 0.000672199
mg O 0 0.20292051
/ O 0 0.0010375289
kg O 0 0.0033288684
i O 0 0.0011203644
. O 0 0.0003545303
v O 0 0.0031747613
. O 0 0.0004718857
) O 0 0.001206384
in O 0 0.0010753087
anesthetize O 0 0.2892264
MAO B-Chemical 0 0.9994572
- O 0 0.010961023
inhibited O 0 0.010097386
dogs O 0 0.023069486
. O 0 0.0069813663

In O 0 0.0034030958
addition O 0 0.002187764
, O 0 0.0033361379
reflex O 0 0.8366749
bradycardia B-Disease 0 0.99827063
caused O 0 0.0025205405
by O 0 0.0011947328
injected O 0 0.0012015165
norepinephrine B-Chemical 1 0.9993199
was O 0 0.00080988556
significantly O 0 0.0007697833
enhanced O 0 0.00092915114
by O 0 0.001151734
L B-Chemical 1 0.96161634
- I-Chemical 1 0.015348296
dopa I-Chemical 1 0.9997315
, O 0 0.0041470984
DL B-Chemical 0 0.8449696
- I-Chemical 0 0.0022019509
Threo I-Chemical 0 0.09795184
- I-Chemical 0 0.0011428064
dihydroxyphenylserine I-Chemical 0 0.6804368
had O 0 0.00042211133
no O 0 0.0002736306
effect O 0 0.0004024233
on O 0 0.0002656375
blood O 0 0.004720799
pressure O 0 0.045531597
, O 0 0.0010779317
heart O 0 0.15003033
rate O 0 0.000920975
or O 0 0.0012314921
reflex O 0 0.6451878
responses O 0 0.0057343123
to O 0 0.004715186
norepinephrine B-Chemical 1 0.99720675
. O 0 0.008438374

FLA B-Chemical 0 0.7056511
- I-Chemical 0 0.0072794785
63 I-Chemical 0 0.004455553
, O 0 0.0027165688
a O 0 0.0025496944
dopamine B-Chemical 1 0.9983399
- O 0 0.010602154
beta O 0 0.73391545
- O 0 0.008693902
oxidase O 0 0.9929188
inhibitor O 0 0.4969135
, O 0 0.0012610339
did O 0 0.00042947472
not O 0 0.00030497246
have O 0 0.0003308913
any O 0 0.0002725142
effect O 0 0.0004056395
on O 0 0.00025464222
the O 0 0.00069078564
hypotension B-Disease 2 0.99970907
, O 0 0.0040857694
bradycardia B-Disease 0 0.99910384
or O 0 0.0009117524
reflex O 0 0.85341
- O 0 0.0015397216
enhancing O 0 0.0012537326
effect O 0 0.001673815
of O 0 0.0042729788
L B-Chemical 1 0.958783
- I-Chemical 1 0.06931986
dopa I-Chemical 1 0.9977836
. O 0 0.010514174

Pimozide B-Chemical 0 0.99827445
did O 0 0.0037682282
not O 0 0.0017398671
affect O 0 0.0010678474
the O 0 0.0011412232
actions O 0 0.013370852
of O 0 0.0025739437
L B-Chemical 1 0.95729876
- I-Chemical 1 0.011373327
dopa I-Chemical 1 0.9993388
on O 0 0.00061374996
blood O 0 0.008775023
pressure O 0 0.04217601
and O 0 0.00083237444
heart O 0 0.1892709
rate O 0 0.00069505355
but O 0 0.00070028845
completely O 0 0.00095456163
blocked O 0 0.001938131
the O 0 0.0015202544
enhancement O 0 0.0066940687
of O 0 0.0065997466
reflexes O 0 0.9711528
. O 0 0.007958508

Removal O 0 0.015460889
of O 0 0.0039050959
the O 0 0.0029392482
carotid O 0 0.76191336
sinuses O 0 0.26483294
caused O 0 0.0019329193
an O 0 0.0016718298
elevation O 0 0.18814135
blood O 0 0.013300245
pressure O 0 0.048728686
and O 0 0.000883119
heart O 0 0.1761539
rate O 0 0.00063482934
and O 0 0.00070357375
abolished O 0 0.0013120376
the O 0 0.00077689945
negative O 0 0.0013959231
chronotropic O 0 0.9656217
effect O 0 0.004014581
of O 0 0.0106605645
norepinephrine B-Chemical 1 0.99798214
. O 0 0.010146591

However O 0 0.006840113
, O 0 0.0072019966
L B-Chemical 1 0.85301834
- I-Chemical 1 0.0112093175
dopa I-Chemical 1 0.9985689
restored O 0 0.0032770247
the O 0 0.0018208016
bradycardia B-Disease 0 0.99843436
caused O 0 0.0023547434
by O 0 0.0016355165
norepinephrine B-Chemical 1 0.9992149
in O 0 0.00077864045
addition O 0 0.00048522244
to O 0 0.0006609152
decreasing O 0 0.0015424091
blood O 0 0.012800651
pressure O 0 0.06948755
and O 0 0.0028836587
heart O 0 0.3552011
rate O 0 0.0052588363
. O 0 0.006349319

5 B-Chemical 0 0.005018966
- I-Chemical 0 0.0051736766
HTP I-Chemical 0 0.09670787
( O 0 0.0027334702
5 O 0 0.0012377694
mg O 0 0.15174335
/ O 0 0.0020474663
kg O 0 0.004355294
i O 0 0.0016742575
. O 0 0.00045730782
v O 0 0.0034287418
. O 0 0.00036847245
) O 0 0.000690223
decreased O 0 0.0008070712
blood O 0 0.00360442
pressure O 0 0.024166994
and O 0 0.0006693737
heart O 0 0.14171258
rate O 0 0.0006065215
and O 0 0.0007612011
decreased O 0 0.0018717999
the O 0 0.0017330883
reflex O 0 0.9453363
bradycardia B-Disease 0 0.99819475
to O 0 0.008095484
norepinephrine B-Chemical 1 0.9977258
. O 0 0.009194338

It O 0 0.0074833957
is O 0 0.003386127
concluded O 0 0.004086779
that O 0 0.0027600361
L B-Chemical 1 0.88618445
- I-Chemical 1 0.013326646
dopa I-Chemical 1 0.9988722
enhances O 0 0.005347104
reflex O 0 0.9741222
bradycardia B-Disease 0 0.9985703
through O 0 0.0023163336
central O 0 0.008649778
alpha O 0 0.38204283
- O 0 0.010068667
receptor O 0 0.25497213
stimulation O 0 0.02338678
. O 0 0.008107388

Furthermore O 0 0.005466676
, O 0 0.003278106
the O 0 0.0017214621
effects O 0 0.002412133
are O 0 0.001277969
mediated O 0 0.0011055393
through O 0 0.0011726761
dopamine B-Chemical 1 0.99764436
rather O 0 0.0010775585
than O 0 0.00084428996
norepinephrine B-Chemical 1 0.99871683
and O 0 0.0011666173
do O 0 0.000760067
not O 0 0.00078705297
require O 0 0.0009830968
the O 0 0.0021819957
carotid O 0 0.84992373
sinus O 0 0.3986844
baroreceptors O 0 0.84076244
. O 0 0.007227397

Microangiopathic B-Disease 0 0.9857816
hemolytic I-Disease 2 0.99875665
anemia I-Disease 2 0.99936014
complicating O 0 0.98383164
FK506 B-Chemical 1 0.99908936
( O 0 0.19770175
tacrolimus B-Chemical 0 0.99881077
) O 0 0.049194876
therapy O 0 0.20445938
. O 0 0.014075607

We O 0 0.003560879
describe O 0 0.0028958912
3 O 0 0.0021168543
episodes O 0 0.036740597
of O 0 0.004636115
microangiopathic B-Disease 0 0.99944514
hemolytic I-Disease 2 0.999892
anemia I-Disease 2 0.9999335
( O 0 0.17163764
MAHA B-Disease 2 0.99923134
) O 0 0.003245837
in O 0 0.0006566522
2 O 0 0.00065627025
solid O 0 0.0046645934
organ O 0 0.026151171
recipients O 0 0.0043233107
under O 0 0.0013314582
FK506 B-Chemical 1 0.9992016
( O 0 0.023582328
tacrolimus B-Chemical 0 0.99932003
) O 0 0.02117438
therapy O 0 0.14709488
. O 0 0.007628426

In O 0 0.0030241692
both O 0 0.0021278083
cases O 0 0.0029924605
, O 0 0.0021522914
discontinuation O 0 0.5426321
of O 0 0.0020752659
FK506 B-Chemical 1 0.99938476
and O 0 0.0013781762
treatment O 0 0.0024441762
with O 0 0.0008055285
plasma O 0 0.03726599
exchange O 0 0.0012073767
, O 0 0.00053466915
fresh O 0 0.0007893427
frozen O 0 0.0011512503
plasma O 0 0.018239671
replacement O 0 0.007417443
, O 0 0.0014483036
corticosteroids B-Chemical 1 0.99893755
, O 0 0.005905605
aspirin B-Chemical 1 0.99965394
, O 0 0.0025250232
and O 0 0.0016541508
dipyridamole B-Chemical 0 0.9992644
led O 0 0.003060513
to O 0 0.002065955
resolution O 0 0.06262514
of O 0 0.01322266
MAHA B-Disease 2 0.9961356
. O 0 0.010256039

In O 0 0.0039033454
one O 0 0.0025588884
patient O 0 0.0038216251
, O 0 0.0031789595
reintroduction O 0 0.0056634466
of O 0 0.00415884
FK506 B-Chemical 1 0.99813277
led O 0 0.0051846737
to O 0 0.0029388168
rapid O 0 0.011711091
recurrence O 0 0.8423749
of O 0 0.025809353
MAHA B-Disease 2 0.9953056
. O 0 0.014655623

FK506 B-Chemical 1 0.99714416
- O 0 0.015057374
associated O 0 0.007878108
MAHA B-Disease 2 0.9962954
is O 0 0.002417566
probably O 0 0.0025176806
rare O 0 0.0073836166
but O 0 0.0012330995
physicians O 0 0.0019591267
must O 0 0.0007556281
be O 0 0.0010324321
aware O 0 0.0013594402
of O 0 0.0019058316
this O 0 0.0029001017
severe O 0 0.39116323
complication O 0 0.7448057
. O 0 0.009140379

In O 0 0.0026699773
our O 0 0.0017080925
experience O 0 0.0025386512
and O 0 0.0013630519
according O 0 0.0008977255
to O 0 0.00072039507
the O 0 0.0006883266
literature O 0 0.001780026
, O 0 0.0014380984
FK506 B-Chemical 1 0.9992169
does O 0 0.0006699563
not O 0 0.00044364817
seem O 0 0.00050677435
to O 0 0.0003437295
cross O 0 0.0007704804
- O 0 0.00086360855
react O 0 0.0015666425
with O 0 0.0014111041
cyclosporin B-Chemical 1 0.9999143
A I-Chemical 1 0.7339548
( O 0 0.007900367
CyA B-Chemical 0 0.9997495
) O 0 0.0033011746
, O 0 0.0008455568
an O 0 0.0008642367
immuno O 0 0.23205416
- O 0 0.0020392083
suppressive O 0 0.019151555
drug O 0 0.38892394
already O 0 0.001723735
known O 0 0.0026064557
to O 0 0.0025890649
induce O 0 0.0067353104
MAHA B-Disease 2 0.9954065
. O 0 0.009395957

Effect O 0 0.009248108
of O 0 0.0049180193
some O 0 0.0048308214
anticancer O 0 0.9217255
drugs O 0 0.74918723
and O 0 0.004016749
combined O 0 0.007164969
chemotherapy O 0 0.8873213
on O 0 0.0061368905
renal B-Disease 2 0.99641657
toxicity I-Disease 2 0.9968202
. O 0 0.018633356

The O 0 0.0048253722
nephrotoxic B-Disease 2 0.994951
action O 0 0.027910851
of O 0 0.0032171784
anticancer O 0 0.9741391
drugs O 0 0.84197634
such O 0 0.0014231394
as O 0 0.0011124462
nitrogranulogen B-Chemical 0 0.9955069
( O 0 0.005710173
NG B-Chemical 0 0.95270807
) O 0 0.0031683382
, O 0 0.0017121352
methotrexate B-Chemical 1 0.99965274
( O 0 0.011102254
MTX B-Chemical 1 0.99972886
) O 0 0.003081456
, O 0 0.00070782437
5 B-Chemical 0 0.00039041793
- I-Chemical 0 0.00088900654
fluorouracil I-Chemical 0 0.9984107
( O 0 0.0008549983
5 B-Chemical 0 0.00034945845
- I-Chemical 0 0.000655097
FU I-Chemical 0 0.55674666
) O 0 0.0007381949
and O 0 0.00050372264
cyclophosphamide B-Chemical 1 0.9996113
( O 0 0.0038114474
CY B-Chemical 1 0.9992023
) O 0 0.0018622768
administered O 0 0.0016627815
alone O 0 0.00037606384
or O 0 0.00024178265
in O 0 0.00027397284
combination O 0 0.0029482602
[ O 0 0.010196597
MTX B-Chemical 1 0.9996687
+ O 0 0.0011754911
5 B-Chemical 0 0.00044517088
- I-Chemical 0 0.0009423627
FU I-Chemical 0 0.70650226
+ O 0 0.0013125814
CY B-Chemical 1 0.9987606
( O 0 0.0026734762
CMF O 0 0.96444404
) O 0 0.0016458529
] O 0 0.0011784048
was O 0 0.00046012952
evaluated O 0 0.00054207776
in O 0 0.0006713648
experiments O 0 0.0010414103
on O 0 0.0016514325
Wistar O 0 0.28763276
rats O 0 0.013174565
. O 0 0.0062848907

After O 0 0.002813541
drug O 0 0.15478458
administration O 0 0.19931516
, O 0 0.003243604
creatinine B-Chemical 1 0.9917359
concentrations O 0 0.0073184716
in O 0 0.0006682582
the O 0 0.0005646446
plasma O 0 0.011835791
and O 0 0.0005276683
in O 0 0.00034888985
the O 0 0.00037353113
urine O 0 0.053617224
of O 0 0.00057902787
the O 0 0.0004535031
rats O 0 0.0018044818
were O 0 0.00046665166
determined O 0 0.00044129416
, O 0 0.0008344332
as O 0 0.0006463055
well O 0 0.0010268658
as O 0 0.0020477695
creatinine B-Chemical 1 0.9927942
clearance O 0 0.41830564
. O 0 0.0076896413

Histopathologic O 0 0.5798948
evaluation O 0 0.008298294
of O 0 0.0061851474
the O 0 0.0055032317
kidneys O 0 0.026926005
was O 0 0.0062519624
also O 0 0.007383652
performed O 0 0.009386243
. O 0 0.012666727

After O 0 0.0038785678
MTX B-Chemical 1 0.99668556
administration O 0 0.22940378
a O 0 0.0019574752
significant O 0 0.0015110327
increase O 0 0.0010191002
( O 0 0.0011547767
p O 0 0.0009491832
= O 0 0.00080220326
0 O 0 0.0004476249
. O 0 0.00023709054
0228 O 0 0.0017678383
) O 0 0.00052662013
in O 0 0.00023817968
the O 0 0.00029837005
plasma O 0 0.029720219
creatinine B-Chemical 1 0.9961514
concentration O 0 0.004787502
and O 0 0.0004315531
a O 0 0.0004069116
significant O 0 0.0005361376
( O 0 0.0005161886
p O 0 0.0005180768
= O 0 0.0005059429
0 O 0 0.0003332359
. O 0 0.00020946327
0001 O 0 0.020760905
) O 0 0.00055782637
decrease O 0 0.00047653247
in O 0 0.000522183
creatinine B-Chemical 1 0.9937828
clearance O 0 0.120881304
was O 0 0.0010610841
noted O 0 0.0010823621
compared O 0 0.0009230003
to O 0 0.0019836635
controls O 0 0.0053723874
. O 0 0.0053435704

After O 0 0.0025855298
the O 0 0.002387366
administration O 0 0.03221455
of O 0 0.0028668914
NG B-Chemical 0 0.8467103
, O 0 0.0022484474
5 B-Chemical 0 0.0009582352
- I-Chemical 0 0.0013465771
FU I-Chemical 0 0.44906104
and O 0 0.0008379203
CY B-Chemical 1 0.9971993
neither O 0 0.0007442622
a O 0 0.00048559677
statistically O 0 0.0003927016
significant O 0 0.00041472452
increase O 0 0.0003342875
in O 0 0.0003757845
creatinine B-Chemical 1 0.9957367
concentration O 0 0.004590137
nor O 0 0.0003620978
an O 0 0.00044715957
increase O 0 0.0003422288
in O 0 0.00038956804
creatinine B-Chemical 1 0.99677485
clearance O 0 0.14092651
was O 0 0.00045164506
observed O 0 0.00028751776
compared O 0 0.0002498971
to O 0 0.00041880843
the O 0 0.0006081898
group O 0 0.0013225353
receiving O 0 0.0052203485
no O 0 0.0031918809
cytostatics O 0 0.9840301
. O 0 0.008465576

Following O 0 0.0054041566
polytherapy O 0 0.9860627
according O 0 0.002030675
to O 0 0.0012564816
the O 0 0.0011926015
CMF O 0 0.9538625
regimen O 0 0.09110036
, O 0 0.0011035878
a O 0 0.0006314655
statistically O 0 0.0005218066
significant O 0 0.00057496916
decrease O 0 0.00065704505
( O 0 0.0006529522
p O 0 0.00060225965
= O 0 0.0005449305
0 O 0 0.0003260924
. O 0 0.00018192444
0343 O 0 0.0023627768
) O 0 0.00049836934
in O 0 0.00029386414
creatinine B-Chemical 1 0.99226564
clearance O 0 0.11144158
was O 0 0.00044969955
found O 0 0.000380634
, O 0 0.0005254276
but O 0 0.00046690702
creatinine B-Chemical 1 0.9937163
concentration O 0 0.0037611732
did O 0 0.0005145501
not O 0 0.0004816635
increase O 0 0.0006794859
significantly O 0 0.0012043173
compared O 0 0.0009265185
to O 0 0.001981928
controls O 0 0.0054734703
. O 0 0.005227793

CY B-Chemical 1 0.992251
caused O 0 0.022039164
hemorrhagic B-Disease 2 0.9982591
cystitis I-Disease 0 0.99955994
in O 0 0.002345396
40 O 0 0.0014685764
% O 0 0.0008194497
of O 0 0.0007301897
rats O 0 0.0029561087
, O 0 0.0007539802
but O 0 0.000441539
it O 0 0.00043783372
did O 0 0.00033151303
not O 0 0.00032129255
cause O 0 0.00095860776
this O 0 0.0004891849
complication O 0 0.10011838
when O 0 0.00041158433
combined O 0 0.0011840368
with O 0 0.0012809113
5 B-Chemical 0 0.0013140312
- I-Chemical 0 0.0031578706
FU I-Chemical 0 0.67776513
and O 0 0.006553726
MTX B-Chemical 1 0.9974542
. O 0 0.009009506

Histologic O 0 0.36171177
changes O 0 0.0038933689
were O 0 0.0017818374
found O 0 0.0012004016
in O 0 0.00090485014
rat O 0 0.0037478395
kidneys O 0 0.012471363
after O 0 0.000463683
administration O 0 0.060988918
of O 0 0.0019072191
MTX B-Chemical 1 0.9997024
, O 0 0.004650675
CY B-Chemical 1 0.9990626
and O 0 0.0016849675
NG B-Chemical 0 0.930632
, O 0 0.0007141174
while O 0 0.00028243338
no O 0 0.00020113184
such O 0 0.00024393399
change O 0 0.00031536113
was O 0 0.0002432941
observed O 0 0.00017908617
after O 0 0.00016085195
5 B-Chemical 0 0.00027042194
- I-Chemical 0 0.0005240039
FU I-Chemical 0 0.30591577
and O 0 0.0003959423
joint O 0 0.020292683
administration O 0 0.15465838
of O 0 0.0021746722
MTX B-Chemical 1 0.9996848
+ O 0 0.0018658923
5 B-Chemical 0 0.00074930006
- I-Chemical 0 0.0016478199
FU I-Chemical 0 0.67864
+ O 0 0.002388986
CY B-Chemical 1 0.9948002
compared O 0 0.0013921169
to O 0 0.0023698558
controls O 0 0.0059410576
. O 0 0.0055421693

Our O 0 0.003733357
studies O 0 0.0033775931
indicate O 0 0.0017992295
that O 0 0.0023828323
nephrotoxicity B-Disease 0 0.99960774
of O 0 0.016142162
MTX B-Chemical 1 0.99956244
+ O 0 0.003850971
5 B-Chemical 0 0.0010654401
- I-Chemical 0 0.0017432593
FU I-Chemical 0 0.6920256
+ O 0 0.0016907911
CY B-Chemical 1 0.9974565
administered O 0 0.00834739
jointly O 0 0.00770648
is O 0 0.0010540653
lower O 0 0.0011488993
than O 0 0.0011557257
in O 0 0.002649801
monotherapy O 0 0.72921413
. O 0 0.0067601297

The O 0 0.0053938944
interpeduncular O 0 0.6308433
nucleus O 0 0.005597368
regulates O 0 0.0016595473
nicotine B-Chemical 1 0.9843699
' O 0 0.0027875751
s O 0 0.002216587
effects O 0 0.0024762175
on O 0 0.0013459731
free O 0 0.0042013084
- O 0 0.0053796847
field O 0 0.006457402
activity O 0 0.008183953
. O 0 0.007894998

Partial O 0 0.016412783
lesions O 0 0.05529294
were O 0 0.0026873704
made O 0 0.0023359172
with O 0 0.0035089564
kainic B-Chemical 0 0.999608
acid I-Chemical 0 0.9690569
in O 0 0.001516166
the O 0 0.0014020542
interpeduncular O 0 0.86032486
nucleus O 0 0.0022439181
of O 0 0.0011555057
the O 0 0.0013090421
ventral O 0 0.0087249745
midbrain O 0 0.51511824
of O 0 0.002939907
the O 0 0.0037909462
rat O 0 0.028073471
. O 0 0.0074375016

Compared O 0 0.0034145808
with O 0 0.0025987541
sham O 0 0.002891098
- O 0 0.0022815305
operated O 0 0.0025147852
controls O 0 0.0015037202
, O 0 0.0012414473
lesions O 0 0.09034941
significantly O 0 0.0011264022
( O 0 0.0008292933
p O 0 0.0006284089
< O 0 0.00044775673
0 O 0 0.00033695405
. O 0 0.00017695152
25 O 0 0.00043101452
) O 0 0.00045840794
blunted O 0 0.0072781765
the O 0 0.00028259773
early O 0 0.0008737214
( O 0 0.00048755077
< O 0 0.00030417333
60 O 0 0.00026005675
min O 0 0.0004020774
) O 0 0.0004103651
free O 0 0.00051075424
- O 0 0.0005641448
field O 0 0.0008292118
locomotor B-Disease 0 0.947235
hypoactivity I-Disease 0 0.9996793
caused O 0 0.0012162676
by O 0 0.0008164564
nicotine B-Chemical 1 0.9987658
( O 0 0.00096693664
0 O 0 0.00033661711
. O 0 0.00013000665
5 O 0 0.0001823327
mg O 0 0.07939183
kg O 0 0.0048042256
( O 0 0.00046931076
- O 0 0.0004684183
1 O 0 0.00027816035
) O 0 0.00041737262
, O 0 0.00031418118
i O 0 0.00070699956
. O 0 0.00018487162
m O 0 0.0012520266
. O 0 0.0001819796
) O 0 0.00042673477
, O 0 0.00027707723
enhanced O 0 0.00028784364
the O 0 0.00022102302
later O 0 0.00026886887
( O 0 0.00038588812
60 O 0 0.00032897262
- O 0 0.00039204853
120 O 0 0.0004013944
min O 0 0.0005267426
) O 0 0.0008059001
nicotine B-Chemical 1 0.9956825
- O 0 0.0020160645
induced O 0 0.0023090316
hyperactivity B-Disease 2 0.99887615
, O 0 0.001575095
and O 0 0.0011350478
raised O 0 0.0021054687
spontaneous O 0 0.061353154
nocturnal O 0 0.5276477
activity O 0 0.007025128
. O 0 0.0060105654

Lesions O 0 0.1743207
reduced O 0 0.002773995
the O 0 0.0015599807
extent O 0 0.0009652089
of O 0 0.0012141365
immunohistological O 0 0.049092207
staining O 0 0.001974274
for O 0 0.001282157
choline B-Chemical 1 0.99846256
acetyltransferase O 0 0.9945082
in O 0 0.0008666488
the O 0 0.0007884835
interpeduncular O 0 0.91986865
nucleus O 0 0.0022704124
( O 0 0.00056942605
p O 0 0.0004848403
< O 0 0.00039085175
0 O 0 0.00033985602
. O 0 0.0002277404
025 O 0 0.065303326
) O 0 0.00066168484
, O 0 0.0004432387
but O 0 0.00031694048
not O 0 0.00034799546
for O 0 0.0005368484
tyrosine B-Chemical 1 0.9338089
hydroxylase O 0 0.9938412
in O 0 0.0011718386
the O 0 0.0013536053
surrounding O 0 0.00452214
catecholaminergic O 0 0.9868716
A10 O 0 0.9198522
region O 0 0.007845296
. O 0 0.0067323796

We O 0 0.0032464138
conclude O 0 0.0023835034
that O 0 0.0016814923
the O 0 0.0019229475
interpeduncular O 0 0.8476428
nucleus O 0 0.0042723115
mediates O 0 0.0015048118
nicotinic O 0 0.9987727
depression B-Disease 0 0.9950185
of O 0 0.002074266
locomotor O 0 0.5844965
activity O 0 0.0011205557
and O 0 0.00077259785
dampens O 0 0.009182451
nicotinic O 0 0.99901354
arousal O 0 0.90835994
mechanisms O 0 0.0029026845
located O 0 0.0012585667
elsewhere O 0 0.0016134023
in O 0 0.0016158327
the O 0 0.002926896
brain O 0 0.0971911
. O 0 0.0063372394

Lithium B-Chemical 1 0.99765956
- O 0 0.0082867695
associated O 0 0.0035079608
cognitive B-Disease 0 0.41008818
and I-Disease 0 0.0016258452
functional I-Disease 0 0.002064044
deficits I-Disease 0 0.3442777
reduced O 0 0.0010325813
by O 0 0.000823888
a O 0 0.0008901512
switch O 0 0.0014554412
to O 0 0.0016098223
divalproex B-Chemical 0 0.9996755
sodium I-Chemical 0 0.99815696
: O 0 0.0056187357
a O 0 0.0028763672
case O 0 0.00355163
series O 0 0.008298678
. O 0 0.006779065

BACKGROUND O 0 0.89583397
: O 0 0.011092365
Lithium B-Chemical 1 0.9978668
remains O 0 0.0026879879
a O 0 0.0016063909
first O 0 0.0010065242
- O 0 0.0014817732
line O 0 0.0011576788
treatment O 0 0.001382359
for O 0 0.0006294322
the O 0 0.00088841555
acute O 0 0.8147656
and O 0 0.0015071996
maintenance O 0 0.0034021547
treatment O 0 0.0056583523
of O 0 0.006245315
bipolar B-Disease 2 0.9927046
disorder I-Disease 0 0.97913444
. O 0 0.009975572

Although O 0 0.003106906
much O 0 0.0016521857
has O 0 0.0014696709
been O 0 0.0013586921
written O 0 0.0014510715
about O 0 0.00061246555
the O 0 0.00052808266
management O 0 0.0010673307
of O 0 0.0006203321
the O 0 0.0004264999
more O 0 0.00056010584
common O 0 0.0008296734
adverse O 0 0.56161326
effects O 0 0.0018978121
of O 0 0.0012111836
lithium B-Chemical 1 0.99943966
, O 0 0.0010125408
such O 0 0.00042473176
as O 0 0.00045774138
polyuria B-Disease 2 0.9992149
and O 0 0.0014217062
tremor B-Disease 0 0.99963355
, O 0 0.0009085503
more O 0 0.00055361725
subtle O 0 0.0027728728
lithium B-Chemical 1 0.9991841
side O 0 0.040211465
effects O 0 0.0012768478
such O 0 0.000393138
as O 0 0.00042577865
cognitive B-Disease 2 0.96701396
deficits I-Disease 2 0.96005917
, O 0 0.00084732345
loss B-Disease 0 0.001733916
of I-Disease 0 0.0009067429
creativity I-Disease 0 0.36664966
, O 0 0.0011897604
and O 0 0.0010845147
functional B-Disease 0 0.007397263
impairments I-Disease 0 0.8480574
remain O 0 0.004486953
understudied O 0 0.05639243
. O 0 0.0062291455

This O 0 0.004284286
report O 0 0.00378588
summarizes O 0 0.0015079775
our O 0 0.0010386786
experience O 0 0.0017991901
in O 0 0.0008244722
switching O 0 0.0017361334
bipolar B-Disease 2 0.95607036
patients O 0 0.005850743
from O 0 0.0010857198
lithium B-Chemical 1 0.9987386
to O 0 0.002169763
divalproex B-Chemical 0 0.999816
sodium I-Chemical 0 0.998428
to O 0 0.0013634188
alleviate O 0 0.00971309
such O 0 0.0019545525
cognitive B-Disease 0 0.7049888
and I-Disease 0 0.0032934505
functional I-Disease 0 0.0320744
impairments I-Disease 0 0.93207544
. O 0 0.0076336153

METHOD O 0 0.08048484
: O 0 0.016644275
Open O 0 0.016144425
, O 0 0.010322276
case O 0 0.009230959
series O 0 0.015772136
design O 0 0.028639255
. O 0 0.01986386

RESULTS O 0 0.022883099
: O 0 0.0038153785
We O 0 0.001499023
report O 0 0.0022885012
seven O 0 0.0009856937
cases O 0 0.0014931514
where O 0 0.0007883117
substitution O 0 0.017228028
of O 0 0.0015630554
lithium B-Chemical 1 0.9991652
, O 0 0.0012939194
either O 0 0.00045492675
fully O 0 0.0003510788
or O 0 0.00026953412
partially O 0 0.0004631381
, O 0 0.00052651594
with O 0 0.0009537512
divalproex B-Chemical 0 0.99988925
sodium I-Chemical 0 0.9992205
was O 0 0.0006730109
extremely O 0 0.0017488225
helpful O 0 0.0006718487
in O 0 0.00022931861
reducing O 0 0.0003932823
the O 0 0.00036729145
cognitive B-Disease 0 0.5738881
, I-Disease 0 0.00069705455
motivational I-Disease 0 0.04407544
, I-Disease 0 0.00052155677
or I-Disease 0 0.0003378575
creative I-Disease 0 0.022369698
deficits I-Disease 0 0.49199605
attributed O 0 0.0008508291
to O 0 0.0009603579
lithium B-Chemical 1 0.99770576
in O 0 0.0015337769
our O 0 0.0023322352
bipolar B-Disease 2 0.9782827
patients O 0 0.029705282
. O 0 0.0066981344

CONCLUSION O 0 0.77273935
: O 0 0.0042909454
In O 0 0.0014285233
this O 0 0.0010538609
preliminary O 0 0.0017674
report O 0 0.00413592
, O 0 0.0026929716
divalproex B-Chemical 0 0.99974614
sodium I-Chemical 0 0.9987381
was O 0 0.0010548886
a O 0 0.000646581
superior O 0 0.0015140423
alternative O 0 0.0004884169
to O 0 0.0005180936
lithium B-Chemical 1 0.998749
in O 0 0.0007631806
bipolar B-Disease 2 0.97816133
patients O 0 0.007449198
experiencing O 0 0.12473905
cognitive B-Disease 2 0.9873704
deficits I-Disease 2 0.9716804
, O 0 0.0011967111
loss B-Disease 0 0.0023626934
of I-Disease 0 0.0014036434
creativity I-Disease 0 0.40611634
, O 0 0.002202263
and O 0 0.0022753866
functional B-Disease 0 0.01861025
impairments I-Disease 0 0.9121701
. O 0 0.006990715

Effect O 0 0.010836733
of O 0 0.007471201
nifedipine B-Chemical 1 0.99886787
on O 0 0.0036996892
renal O 0 0.977785
function O 0 0.00465359
in O 0 0.0028688041
liver O 0 0.8184938
transplant O 0 0.80955493
recipients O 0 0.051329743
receiving O 0 0.15334901
tacrolimus B-Chemical 0 0.9982834
. O 0 0.01463912

The O 0 0.0031523262
effect O 0 0.0029034007
of O 0 0.003446472
nifedipine B-Chemical 1 0.9994106
on O 0 0.0016828023
renal O 0 0.98223925
function O 0 0.0020819718
in O 0 0.00088319567
liver O 0 0.7313298
transplant O 0 0.6323982
recipients O 0 0.0058106524
who O 0 0.0014394801
were O 0 0.00052793865
receiving O 0 0.0042650523
tacrolimus B-Chemical 0 0.99948174
was O 0 0.0008994245
evaluated O 0 0.0007380904
between O 0 0.0006129929
January O 0 0.0014675062
1992 O 0 0.0046663536
and O 0 0.0022653413
January O 0 0.003938255
1996 O 0 0.0107069025
. O 0 0.0056395363

Two O 0 0.003885925
groups O 0 0.0023108218
of O 0 0.0018854217
patients O 0 0.0032766962
receiving O 0 0.008952424
tacrolimus B-Chemical 0 0.9994295
were O 0 0.0008813084
compared O 0 0.00027703075
over O 0 0.00018998841
a O 0 0.00030621883
period O 0 0.0002701629
of O 0 0.00035711288
1 O 0 0.0002919824
year O 0 0.0002841696
, O 0 0.0002928634
one O 0 0.0001650826
group O 0 0.0003209163
comprising O 0 0.000423343
hypertensive B-Disease 2 0.99783343
patients O 0 0.0030784619
who O 0 0.0012260018
were O 0 0.00037027203
receiving O 0 0.0076281982
nifedipine B-Chemical 1 0.9998673
, O 0 0.0010722568
and O 0 0.00046699293
the O 0 0.00038486032
other O 0 0.00053524616
comprising O 0 0.0011122968
nonhypertensive O 0 0.9942707
patients O 0 0.0053413888
not O 0 0.0021573317
receiving O 0 0.08817336
nifedipine B-Chemical 1 0.99923885
. O 0 0.010865285

The O 0 0.003456032
time O 0 0.0025619515
from O 0 0.0025584847
transplant O 0 0.07803952
to O 0 0.0021109611
baseline O 0 0.0023939915
was O 0 0.0018331251
similar O 0 0.0016986623
in O 0 0.0024328968
all O 0 0.003688328
patients O 0 0.012278051
. O 0 0.008685831

Nifedipine B-Chemical 0 0.9983485
significantly O 0 0.00480345
improved O 0 0.0050905556
kidney O 0 0.6607692
function O 0 0.0017404907
as O 0 0.00066871283
indicated O 0 0.0004919263
by O 0 0.0006060627
a O 0 0.0006302426
significant O 0 0.0007701358
lowering O 0 0.010309589
of O 0 0.0011862189
serum O 0 0.22108747
creatinine B-Chemical 1 0.9951519
levels O 0 0.0011984182
at O 0 0.00073262793
6 O 0 0.00091163215
and O 0 0.0013603034
12 O 0 0.0017324769
months O 0 0.0033313974
. O 0 0.004352035

The O 0 0.0027502936
observed O 0 0.0015939327
positive O 0 0.001337957
impact O 0 0.0011308753
of O 0 0.0019570244
nifedipine B-Chemical 1 0.99965155
on O 0 0.00080832123
reducing O 0 0.0013972131
the O 0 0.0013277344
nephrotoxicity B-Disease 0 0.9998982
associated O 0 0.005100433
with O 0 0.0025679988
tacrolimus B-Chemical 0 0.9998184
in O 0 0.00093107065
liver O 0 0.9000609
transplant O 0 0.7629005
recipients O 0 0.005591826
should O 0 0.00022370688
be O 0 0.00027178074
an O 0 0.00032173915
important O 0 0.00027357502
factor O 0 0.0015682754
in O 0 0.00030699495
selecting O 0 0.00039286076
an O 0 0.00076081086
agent O 0 0.044862118
to O 0 0.0008938117
treat O 0 0.049071476
hypertension B-Disease 2 0.99912435
in O 0 0.0023090877
this O 0 0.0028204098
population O 0 0.006306848
. O 0 0.005659125

Alpha O 0 0.18255723
and O 0 0.00846348
beta O 0 0.6253845
coma B-Disease 0 0.99664104
in O 0 0.0062393313
drug O 0 0.8695771
intoxication O 0 0.99769753
uncomplicated O 0 0.94826883
by O 0 0.020573301
cerebral B-Disease 0 0.9940916
hypoxia I-Disease 2 0.9948244
. O 0 0.017227473

Four O 0 0.006148929
patients O 0 0.0054060663
who O 0 0.0038673184
were O 0 0.0017690378
rendered O 0 0.0036475114
comatose B-Disease 0 0.9105163
or O 0 0.0017070571
stuporous B-Disease 0 0.9961695
by O 0 0.0016985186
drug O 0 0.7612536
intoxication O 0 0.99878556
, O 0 0.0021027245
but O 0 0.0008901427
who O 0 0.0017655643
were O 0 0.00091774925
not O 0 0.0013102283
hypoxic O 0 0.84223664
, O 0 0.0033915802
are O 0 0.003044484
described O 0 0.0039507602
. O 0 0.0058275703

Three O 0 0.004541142
patients O 0 0.0040377765
received O 0 0.0021147514
high O 0 0.0018695741
doses O 0 0.023248194
of O 0 0.0025826155
chlormethiazole B-Chemical 0 0.99980885
for O 0 0.0024282176
alcohol B-Chemical 0 0.99849546
withdrawal B-Disease 0 0.99600995
symptoms I-Disease 0 0.96012837
, O 0 0.001389497
and O 0 0.00073747314
one O 0 0.00057186343
took O 0 0.0010061604
a O 0 0.0023188763
suicidal O 0 0.99615794
overdose B-Disease 2 0.9989845
of O 0 0.07806605
nitrazepam B-Chemical 0 0.9997285
. O 0 0.012894257

The O 0 0.003148705
patient O 0 0.004024125
with O 0 0.0045164786
nitrazepam B-Chemical 0 0.99989235
overdose B-Disease 2 0.99939716
and O 0 0.0017083627
two O 0 0.00055665954
of O 0 0.0007695059
those O 0 0.00087844953
with O 0 0.0012144343
chlormethiazole B-Chemical 0 0.9999242
intoxication O 0 0.9993831
conformed O 0 0.002963027
to O 0 0.00036488005
the O 0 0.00030028576
criteria O 0 0.00059974473
of O 0 0.00050176773
' O 0 0.00070762954
alpha O 0 0.35978922
coma B-Disease 0 0.9994978
' O 0 0.001024855
, O 0 0.0006208807
showing O 0 0.00047753894
non O 0 0.0014934132
- O 0 0.0011715919
reactive O 0 0.16573238
generalized O 0 0.11157969
or O 0 0.00081277505
frontally O 0 0.46435043
predominant O 0 0.0022287027
alpha O 0 0.16162577
activity O 0 0.0025235573
in O 0 0.0020391305
the O 0 0.0038887835
EEG O 0 0.93677974
. O 0 0.0070400154

The O 0 0.0030381414
fourth O 0 0.0037458867
patient O 0 0.002884092
who O 0 0.002918854
was O 0 0.0013370042
unconscious O 0 0.04908156
after O 0 0.0009640717
chlormethiazole B-Chemical 0 0.9997936
administration O 0 0.6483985
exhibite O 0 0.474177
generalized O 0 0.25124145
non O 0 0.006136711
- O 0 0.0026309795
reactive O 0 0.17915407
activity O 0 0.001627917
in O 0 0.0010126126
the O 0 0.0014201365
slow O 0 0.009681072
beta O 0 0.46037975
range O 0 0.010980275
. O 0 0.006980865

All O 0 0.0037276433
four O 0 0.0019071874
recovered O 0 0.0018312713
completely O 0 0.001995193
without O 0 0.0022558772
neurological B-Disease 0 0.99086785
sequelae I-Disease 0 0.9448977
following O 0 0.0019881506
the O 0 0.0017038195
withdrawal O 0 0.49801263
of O 0 0.0030310005
the O 0 0.0036691327
offending O 0 0.5179253
agents O 0 0.46515772
. O 0 0.008946999

The O 0 0.0028309785
similarities O 0 0.0023695051
between O 0 0.0010051918
the O 0 0.0010914307
effects O 0 0.0016384607
of O 0 0.001288804
structural O 0 0.0050162408
lesions O 0 0.17803201
and O 0 0.0011988641
pharmacological O 0 0.6872747
depression B-Disease 0 0.9903295
of O 0 0.0015288288
the O 0 0.0012204923
brain O 0 0.13052353
stem O 0 0.21710521
reticular O 0 0.7549006
formation O 0 0.010043272
are O 0 0.0036684948
discussed O 0 0.0048362217
. O 0 0.006294887

It O 0 0.0058376025
is O 0 0.0023263409
suggested O 0 0.0017107656
that O 0 0.0011085232
in O 0 0.0009309402
both O 0 0.00089283334
situations O 0 0.0017645796
disturbed O 0 0.011378764
reticulo O 0 0.59012526
- O 0 0.003176576
thalamic O 0 0.73106825
interactions O 0 0.0012626967
are O 0 0.0006298679
important O 0 0.0005817117
in O 0 0.0006934835
the O 0 0.0010814
pathogenesis O 0 0.016399994
of O 0 0.0055388645
alpha O 0 0.81431544
coma B-Disease 0 0.997908
. O 0 0.011850004

It O 0 0.0056496663
is O 0 0.0022461186
concluded O 0 0.0021374726
that O 0 0.00092415564
when O 0 0.00063927093
this O 0 0.00075612
electroencephalographic O 0 0.8495708
and O 0 0.0008187863
behavioural O 0 0.013376308
picture O 0 0.0010208203
is O 0 0.00045072226
seen O 0 0.00037962585
in O 0 0.0003709663
drug O 0 0.5037373
intoxication O 0 0.9990231
, O 0 0.0009533328
in O 0 0.000305293
the O 0 0.0002687538
absence O 0 0.00021052305
of O 0 0.00055639056
significant O 0 0.0013376799
hypoxaemia B-Disease 0 0.99794215
, O 0 0.0012193868
a O 0 0.0009432642
favourable O 0 0.00662377
outcome O 0 0.0030470525
may O 0 0.0019083841
be O 0 0.002643176
anticipated O 0 0.0045234235
. O 0 0.0053985054

Magnetic O 0 0.74394345
resonance O 0 0.3432459
volumetry O 0 0.050118368
of O 0 0.004298949
the O 0 0.0034342061
cerebellum O 0 0.10736799
in O 0 0.003904725
epileptic B-Disease 2 0.9971523
patients O 0 0.025635643
after O 0 0.0060193576
phenytoin B-Chemical 1 0.99929154
overdosages B-Disease 0 0.989962
. O 0 0.014305677

The O 0 0.0025562793
aim O 0 0.00191532
of O 0 0.0014500499
this O 0 0.0010185922
study O 0 0.0012187376
was O 0 0.00063481205
to O 0 0.00045416932
evaluate O 0 0.000287091
the O 0 0.00037127247
relationship O 0 0.0003610909
between O 0 0.00041915552
phenytoin B-Chemical 1 0.99983287
medication O 0 0.5786284
and O 0 0.0018660626
cerebellar B-Disease 0 0.99659365
atrophy I-Disease 2 0.9992878
in O 0 0.0009702505
patients O 0 0.0035409366
who O 0 0.002330963
had O 0 0.0014539217
experienced O 0 0.0052288566
clinical O 0 0.15826371
intoxication O 0 0.99614656
. O 0 0.009075041

Five O 0 0.006271789
females O 0 0.0034823818
and O 0 0.001930226
6 O 0 0.0010859692
males O 0 0.0014289246
, O 0 0.0010987939
21 O 0 0.00092979945
- O 0 0.0008011028
59 O 0 0.00067486515
years O 0 0.00056582934
of O 0 0.0004190778
age O 0 0.0008186553
, O 0 0.0004281503
were O 0 0.00026294135
examined O 0 0.00021814575
with O 0 0.0003804479
a O 0 0.00043523766
1 O 0 0.00038669014
. O 0 0.00021266093
5 O 0 0.00030603935
- O 0 0.0006205666
T O 0 0.061311547
whole O 0 0.0005250111
- O 0 0.0007810747
body O 0 0.00143688
system O 0 0.0007872956
using O 0 0.00058255706
a O 0 0.0011008495
circular O 0 0.0034508856
polarized O 0 0.00859706
head O 0 0.07994744
coil O 0 0.017783606
. O 0 0.007482794

Conventional O 0 0.01729562
spin O 0 0.025854332
echo O 0 0.026902545
images O 0 0.0048307967
were O 0 0.0027119555
acquired O 0 0.0049142656
in O 0 0.0023271202
the O 0 0.0028626497
sagittal O 0 0.019999305
and O 0 0.0050009936
transverse O 0 0.02122111
orientation O 0 0.011780057
. O 0 0.010439957

In O 0 0.0028762496
addition O 0 0.0016288466
, O 0 0.0016882255
we O 0 0.00063000503
performed O 0 0.00078252814
a O 0 0.0008890649
high O 0 0.0011604683
- O 0 0.0013867115
resolution O 0 0.0076050987
3D O 0 0.007636093
gradient O 0 0.0026879301
echo O 0 0.06421779
, O 0 0.0012513864
T1 O 0 0.020590879
- O 0 0.0010330672
weighted O 0 0.0007283255
sequences O 0 0.0007105092
at O 0 0.00051356864
a O 0 0.0011014852
1 O 0 0.001460175
- O 0 0.002740504
mm O 0 0.008187523
slice O 0 0.10229919
thickness O 0 0.12162183
. O 0 0.006441312

The O 0 0.003690054
images O 0 0.0039964444
were O 0 0.002244151
subsequently O 0 0.0025262882
processed O 0 0.0017525243
to O 0 0.0014905098
obtain O 0 0.0014114347
volumetric O 0 0.0056889965
data O 0 0.002961339
for O 0 0.0029362412
the O 0 0.005438692
cerebellum O 0 0.18811296
. O 0 0.009473641

Cerebellar O 0 0.8583414
volume O 0 0.00527912
for O 0 0.0015491165
the O 0 0.001155257
patient O 0 0.0014455538
group O 0 0.00096950156
ranged O 0 0.00085645536
between O 0 0.0003905203
67 O 0 0.0010125326
. O 0 0.000349612
66 O 0 0.0007329656
and O 0 0.000506236
131 O 0 0.0017167068
. O 0 0.00041213477
08 O 0 0.0036850364
ml O 0 0.0018385166
( O 0 0.00085391465
mean O 0 0.0005567173
108 O 0 0.0019342657
. O 0 0.00093877234
9 O 0 0.0018384806
ml O 0 0.0061543128
) O 0 0.0060870955
. O 0 0.0053914646

In O 0 0.0028130475
addition O 0 0.0016761561
3D O 0 0.00561357
gradient O 0 0.0031869204
echo O 0 0.01496968
data O 0 0.0010923337
sets O 0 0.0006890555
from O 0 0.0005759845
10 O 0 0.00056479825
healthy O 0 0.0015619604
male O 0 0.0010568051
and O 0 0.00040942343
10 O 0 0.00040831606
healthy O 0 0.0013842401
female O 0 0.0009856392
age O 0 0.0008799104
- O 0 0.0006104675
matched O 0 0.00038115325
volunteers O 0 0.0013034845
were O 0 0.00053623825
used O 0 0.00062503957
to O 0 0.0009209429
compare O 0 0.0010962004
cerebellar O 0 0.64583504
volumes O 0 0.013180059
. O 0 0.0064565334

Using O 0 0.0035715352
linear O 0 0.0031668246
regression O 0 0.004126988
we O 0 0.00084099825
found O 0 0.0008504657
that O 0 0.00056373794
no O 0 0.00044390917
correlation O 0 0.00037933502
exists O 0 0.00050710485
between O 0 0.00044653562
seizure B-Disease 2 0.9978333
duration O 0 0.0023050297
, O 0 0.001432088
elevation O 0 0.29641396
of O 0 0.0037032024
phenytoin B-Chemical 1 0.9998354
serum O 0 0.47043285
levels O 0 0.0025005012
and O 0 0.0036677318
cerebellar O 0 0.90872353
volume O 0 0.025755107
. O 0 0.006718437

However O 0 0.0037460453
, O 0 0.0024385797
multiple O 0 0.0019067697
regression O 0 0.003654957
for O 0 0.00086867186
the O 0 0.0007391798
daily O 0 0.0020272147
dosage O 0 0.08413672
, O 0 0.00087612646
duration O 0 0.0008337791
of O 0 0.0012504767
phenytoin B-Chemical 1 0.9998542
treatment O 0 0.009665185
and O 0 0.0011085833
cerebellar O 0 0.8135272
volume O 0 0.0023543302
revealed O 0 0.000830481
a O 0 0.0009193229
correlation O 0 0.0007632109
of O 0 0.0019229567
these O 0 0.0036136224
parameters O 0 0.008521442
. O 0 0.0064741396

We O 0 0.0034276799
conclude O 0 0.0027886585
that O 0 0.0028688086
phenytoin B-Chemical 1 0.9997384
overdosage B-Disease 0 0.99957544
does O 0 0.0015372584
not O 0 0.00073625974
necessarily O 0 0.0007956628
result O 0 0.0005120697
in O 0 0.000704776
cerebellar B-Disease 0 0.99569917
atrophy I-Disease 2 0.999526
and O 0 0.0010405951
it O 0 0.0005546353
is O 0 0.00034500673
unlikely O 0 0.0003285899
that O 0 0.00039723373
phenytoin B-Chemical 1 0.99989474
medication O 0 0.37672535
was O 0 0.0004445746
the O 0 0.00033100427
only O 0 0.00043870203
cause O 0 0.0018941307
of O 0 0.0018760087
cerebellar B-Disease 0 0.996756
atrophy I-Disease 2 0.99908566
in O 0 0.0015661684
the O 0 0.0015877193
remaining O 0 0.002597274
patients O 0 0.011086617
. O 0 0.005644322

Quantitative O 0 0.011357238
morphometric O 0 0.009614421
studies O 0 0.0032753744
of O 0 0.0022780667
the O 0 0.0017398671
cerebellum O 0 0.015494365
provide O 0 0.0012139503
valuable O 0 0.0014872496
insights O 0 0.0014436808
into O 0 0.00088431215
the O 0 0.001525782
pathogenesis O 0 0.018468967
of O 0 0.0080522355
cerebellar B-Disease 0 0.99212587
disorders I-Disease 0 0.98587984
. O 0 0.012011498

Late O 0 0.07367332
recovery O 0 0.00715709
of O 0 0.0045325453
renal O 0 0.94874996
function O 0 0.0038479941
in O 0 0.0019465449
a O 0 0.002460927
woman O 0 0.017996663
with O 0 0.003855748
the O 0 0.00690845
hemolytic B-Disease 0 0.99907994
uremic I-Disease 0 0.9991229
syndrome I-Disease 0 0.9917664
. O 0 0.017121397

A O 0 0.017054677
case O 0 0.00356237
is O 0 0.0023396069
reported O 0 0.002358736
of O 0 0.0021825803
the O 0 0.0029771053
hemolytic B-Disease 0 0.99954516
uremic I-Disease 0 0.9997261
syndrome I-Disease 0 0.9976731
( O 0 0.06462889
HUS B-Disease 2 0.999731
) O 0 0.004604584
in O 0 0.0011708935
a O 0 0.0018250238
woman O 0 0.0356642
taking O 0 0.013566162
oral B-Chemical 1 0.95720047
contraceptives I-Chemical 1 0.9971993
. O 0 0.012627944

She O 0 0.006497097
was O 0 0.0026739798
treated O 0 0.0029507673
with O 0 0.002291677
heparin B-Chemical 1 0.982927
, O 0 0.0041001653
dipyridamole B-Chemical 0 0.9994018
and O 0 0.0022294235
hemodialysis O 0 0.9340968
; O 0 0.0014860986
and O 0 0.0004016412
after O 0 0.00018388378
more O 0 0.0003095613
than O 0 0.00014042026
three O 0 0.000117784795
months O 0 0.00026106756
, O 0 0.00028982686
her O 0 0.0004300267
urinary O 0 0.43628383
output O 0 0.00076540676
rose O 0 0.0032212285
above O 0 0.00022233957
500 O 0 0.0012370587
ml O 0 0.0014716974
; O 0 0.00042443484
and O 0 0.00020459115
six O 0 0.00013754312
months O 0 0.00023281178
after O 0 0.00014447545
the O 0 0.0002790957
onset O 0 0.001787598
of O 0 0.0012842959
anuria B-Disease 2 0.9985079
, O 0 0.0024157339
dialysis O 0 0.152949
treatment O 0 0.0059650005
was O 0 0.003173532
stopped O 0 0.010480414
. O 0 0.0058374777

This O 0 0.004341193
case O 0 0.0022077279
emphasizes O 0 0.0021980363
the O 0 0.0012282412
possibility O 0 0.0010727777
that O 0 0.0014190949
HUS B-Disease 2 0.99960357
in O 0 0.0011664928
adults O 0 0.0027057633
is O 0 0.0005248697
not O 0 0.00042097652
invariably O 0 0.008213023
irreversible O 0 0.2511748
and O 0 0.0005697732
that O 0 0.00035653973
, O 0 0.00049891626
despite O 0 0.00042760593
prolonged O 0 0.04271116
oliguria B-Disease 0 0.9995534
, O 0 0.0014241209
recovery O 0 0.0023292135
of O 0 0.0015753185
renal O 0 0.9837466
function O 0 0.0029785845
can O 0 0.0019167764
be O 0 0.0027229423
obtained O 0 0.003922796
. O 0 0.005595484

Therefore O 0 0.0036249496
, O 0 0.0029471095
in O 0 0.0014559929
adult O 0 0.0018465677
patients O 0 0.0023417582
affected O 0 0.0009865264
by O 0 0.0016556964
HUS B-Disease 2 0.99972254
, O 0 0.0019258801
dialysis O 0 0.07001688
should O 0 0.00031646254
not O 0 0.00032852474
be O 0 0.00037877544
discontinued O 0 0.024217118
prematurely O 0 0.017705746
; O 0 0.000967502
moreover O 0 0.0065103215
, O 0 0.0005950944
bilateral O 0 0.05376562
nephrectomy O 0 0.7372416
, O 0 0.0005152124
for O 0 0.0002543746
treatment O 0 0.0008852299
of O 0 0.0007852524
severe O 0 0.6189209
hypertension B-Disease 2 0.9997726
and O 0 0.015046345
microangiopathic B-Disease 0 0.99984276
hemolytic I-Disease 2 0.99994195
anemia I-Disease 2 0.9999274
, O 0 0.006808331
should O 0 0.000847964
be O 0 0.0011506923
performed O 0 0.0013629365
with O 0 0.0030744518
caution O 0 0.007440153
. O 0 0.006046665

Morphological O 0 0.07891641
features O 0 0.007464754
of O 0 0.004989934
encephalopathy B-Disease 2 0.9984964
after O 0 0.0021129982
chronic O 0 0.9430751
administration O 0 0.33487952
of O 0 0.0026814165
the O 0 0.0027280175
antiepileptic O 0 0.9985826
drug O 0 0.97324884
valproate B-Chemical 0 0.9995944
to O 0 0.007904397
rats O 0 0.05188955
. O 0 0.008028993

A O 0 0.01873491
transmission O 0 0.008663421
electron O 0 0.019555165
microscopic O 0 0.010910438
study O 0 0.0043035788
of O 0 0.0039906325
capillaries O 0 0.070087925
in O 0 0.0039212867
the O 0 0.0061797183
cerebellar O 0 0.9460915
cortex O 0 0.6712864
. O 0 0.011207316

Long O 0 0.023878358
- O 0 0.0044691693
term O 0 0.0025464238
intragastric O 0 0.62855005
application O 0 0.0034946215
of O 0 0.0016369972
the O 0 0.0014492879
antiepileptic O 0 0.99882346
drug O 0 0.9547153
sodium B-Chemical 0 0.9995436
valproate I-Chemical 0 0.99993896
( O 0 0.009417891
Vupral O 1 0.46138445
" O 0 0.0014087906
Polfa O 0 0.9869616
" O 0 0.0009741719
) O 0 0.0007694096
at O 0 0.00026057297
the O 0 0.0003739824
effective O 0 0.0008184658
dose O 0 0.0059294864
of O 0 0.0013127177
200 O 0 0.004772372
mg O 0 0.4788717
/ O 0 0.005928674
kg O 0 0.016706428
b O 0 0.007462692
. O 0 0.005907724

w O 0 0.007381402
. O 0 0.0019153374
once O 0 0.0015192905
daily O 0 0.0023095072
to O 0 0.0010104206
rats O 0 0.002240479
for O 0 0.0006556214
1 O 0 0.0006798344
, O 0 0.00064243155
3 O 0 0.00037884858
, O 0 0.00044497676
6 O 0 0.00025420848
, O 0 0.0003365048
9 O 0 0.00024121141
and O 0 0.00022094883
12 O 0 0.00017905905
months O 0 0.00026123293
revealed O 0 0.0004504974
neurological B-Disease 0 0.99370766
disorders I-Disease 0 0.9792047
indicating O 0 0.0013903143
cerebellum B-Disease 0 0.9209302
damage I-Disease 0 0.97354525
( O 0 0.004889789
" O 0 0.0071872794
valproate B-Chemical 0 0.99980205
encephalopathy B-Disease 2 0.99958223
" O 0 0.01864935
) O 0 0.012239995
. O 0 0.006696465

The O 0 0.0027477187
first O 0 0.001863817
ultrastructural O 0 0.021599274
changes O 0 0.0019866612
in O 0 0.00092776143
structural O 0 0.002136028
elements O 0 0.001137099
of O 0 0.00076687353
the O 0 0.0006337095
blood O 0 0.014346264
- O 0 0.001742646
brain O 0 0.0806271
- O 0 0.0015481027
barrier O 0 0.014475036
( O 0 0.0015218151
BBB O 0 0.9858947
) O 0 0.0010158075
in O 0 0.00034042736
the O 0 0.00045597128
cerebellar O 0 0.8297638
cortex O 0 0.18292038
were O 0 0.00041196746
detectable O 0 0.00031776953
after O 0 0.0003116879
3 O 0 0.00050462905
months O 0 0.00073692173
of O 0 0.0011914922
the O 0 0.0017537843
experiment O 0 0.0028773819
. O 0 0.005159599

They O 0 0.006781865
became O 0 0.0037817368
more O 0 0.0024035617
severe O 0 0.023611935
in O 0 0.000908057
the O 0 0.00063315796
later O 0 0.0004967594
months O 0 0.00045329914
of O 0 0.00043237724
the O 0 0.00032830308
experiment O 0 0.000308046
, O 0 0.00046791512
and O 0 0.0003397585
were O 0 0.00030744364
most O 0 0.0005306231
severe O 0 0.017837366
after O 0 0.00018854756
12 O 0 0.00020818895
months O 0 0.00027931156
, O 0 0.00032587574
located O 0 0.0002808055
mainly O 0 0.000538059
in O 0 0.00035525483
the O 0 0.0004944234
molecular O 0 0.007097564
layer O 0 0.0048187543
of O 0 0.002109649
the O 0 0.0033220141
cerebellar O 0 0.96372974
cortex O 0 0.704633
. O 0 0.0069711525

Lesions O 0 0.16965324
of O 0 0.0064684977
the O 0 0.0050981133
capillary O 0 0.055795927
included O 0 0.0069311964
necrosis B-Disease 2 0.9850558
of O 0 0.015649928
endothelial O 0 0.9687715
cells O 0 0.03196517
. O 0 0.013740504

Organelles O 0 0.046892542
of O 0 0.0032095602
these O 0 0.0025787815
cells O 0 0.0028420486
, O 0 0.0014374049
in O 0 0.000646498
particular O 0 0.00055442576
the O 0 0.0006370033
mitochondria O 0 0.09713655
( O 0 0.00083628955
increased O 0 0.0006367611
number O 0 0.00032970356
and O 0 0.00040537916
size O 0 0.00052373647
, O 0 0.00049485336
distinct O 0 0.0005860916
degeneration O 0 0.95106477
of O 0 0.00069005194
their O 0 0.00065163546
matrix O 0 0.011809654
and O 0 0.0009850769
cristae O 0 0.47888187
) O 0 0.0017869837
and O 0 0.0011746292
Golgi O 0 0.00930879
apparatus O 0 0.0028141926
were O 0 0.0024880334
altered O 0 0.0057614646
. O 0 0.005763576

Reduced O 0 0.008501751
size O 0 0.0031162747
of O 0 0.002527084
capillary O 0 0.04660059
lumen O 0 0.004498717
and O 0 0.0014423514
occlusion O 0 0.19370897
were O 0 0.0008446037
caused O 0 0.0009035364
by O 0 0.00082087563
swollen O 0 0.01769737
endothelial O 0 0.90714115
cells O 0 0.0026065104
which O 0 0.001329634
had O 0 0.0014403927
luminal B-Chemical 1 0.4496388
protrusions O 0 0.1475388
and O 0 0.003521271
swollen O 0 0.09813767
microvilli O 0 0.43499258
. O 0 0.007931418

Pressure O 0 0.17251413
on O 0 0.0033341898
the O 0 0.0034890599
vessel O 0 0.026552329
wall O 0 0.01953081
was O 0 0.0027118884
produced O 0 0.002751644
by O 0 0.0036294593
enlarged O 0 0.05034937
perivascular O 0 0.8443541
astrocytic O 0 0.9756114
processes O 0 0.049418863
. O 0 0.011290171

Fragments O 0 0.019349052
of O 0 0.0049453666
necrotic B-Disease 2 0.68546426
endothelial O 0 0.9202806
cells O 0 0.0037206039
were O 0 0.00100011
in O 0 0.0006307909
the O 0 0.0006579276
vascular O 0 0.29725364
lumens O 0 0.012581405
and O 0 0.0006374566
in O 0 0.00041052714
these O 0 0.0005741084
there O 0 0.00037006434
was O 0 0.00068641244
loosening O 0 0.09824948
and O 0 0.0012044108
breaking O 0 0.009070792
of O 0 0.0023416216
tight O 0 0.006850668
cellular O 0 0.03265096
junctions O 0 0.013181323
. O 0 0.006672419

Damage O 0 0.11806059
to O 0 0.0062313443
the O 0 0.0058221095
vascular O 0 0.5162952
basement O 0 0.28239784
lamina O 0 0.017732302
was O 0 0.0064530717
also O 0 0.0074646166
observed O 0 0.008106967
. O 0 0.011853965

Damage O 0 0.11886045
to O 0 0.0032233053
the O 0 0.0023593095
capillary O 0 0.02557468
was O 0 0.0018280961
accompanied O 0 0.002788055
by O 0 0.001385724
marked O 0 0.0028110675
damage O 0 0.4104741
to O 0 0.0014424709
neuroglial O 0 0.8518049
cells O 0 0.0026911176
, O 0 0.0013388237
mainly O 0 0.0016771754
to O 0 0.0013930638
perivascular O 0 0.35969433
processes O 0 0.0076672095
of O 0 0.006295431
astrocytes O 0 0.6853475
. O 0 0.0077253045

The O 0 0.004459696
proliferation O 0 0.23950395
of O 0 0.0042148395
astrocytes O 0 0.6129592
( O 0 0.0038876254
Bergmann O 0 0.48479718
' O 0 0.0013639481
s O 0 0.0010772179
in O 0 0.0006281389
particular O 0 0.000740089
) O 0 0.0014279676
and O 0 0.0010461175
occasionally O 0 0.0030634182
of O 0 0.002584165
oligodendrocytes O 0 0.5309588
was O 0 0.0038587677
found O 0 0.0048765843
. O 0 0.006262067

Alterations O 0 0.01180123
in O 0 0.002343651
the O 0 0.0017078111
structural O 0 0.003240208
elements O 0 0.0017920025
of O 0 0.0012610488
the O 0 0.0012288672
BBB O 0 0.9832575
coexisted O 0 0.03677416
with O 0 0.0011584228
marked O 0 0.002088032
lesions O 0 0.1467902
of O 0 0.001034418
neurons O 0 0.018957855
of O 0 0.0008600951
the O 0 0.0009004758
cerebellum O 0 0.21897724
( O 0 0.002111829
Purkinje O 0 0.82481885
cells O 0 0.0026344687
are O 0 0.0021925578
earliest O 0 0.006240614
) O 0 0.0072519146
. O 0 0.005686149

In O 0 0.0034073452
electron O 0 0.010005159
micrographs O 0 0.0024600637
both O 0 0.0018309463
luminal B-Chemical 1 0.1824347
and O 0 0.0019412235
antiluminal O 0 0.11245285
sides O 0 0.0027698039
of O 0 0.0013022126
the O 0 0.0013544286
BBB O 0 0.97077346
of O 0 0.0018407615
the O 0 0.0018721091
cerebellar O 0 0.9419116
cortex O 0 0.45150635
had O 0 0.0027638872
similar O 0 0.0031872368
lesions O 0 0.32029012
. O 0 0.0076841665

The O 0 0.0029961215
possible O 0 0.00248065
influence O 0 0.0016725989
of O 0 0.0020387736
the O 0 0.0021026756
hepatic B-Disease 2 0.99537295
damage I-Disease 2 0.9831687
, O 0 0.004060107
mainly O 0 0.010007786
hyperammonemia B-Disease 0 0.99971503
, O 0 0.0021155323
upon O 0 0.00074469927
the O 0 0.00088028365
development O 0 0.0030401738
of O 0 0.0066779465
valproate B-Chemical 0 0.9998357
encephalopathy B-Disease 2 0.9996172
is O 0 0.010649787
discussed O 0 0.007267923
. O 0 0.007553622

Fatal O 0 0.91107005
intracranial B-Disease 0 0.98764485
bleeding I-Disease 0 0.9940842
associated O 0 0.010096165
with O 0 0.006705905
prehospital O 0 0.05473002
use O 0 0.008874878
of O 0 0.014203618
epinephrine B-Chemical 0 0.99218714
. O 0 0.017613115

We O 0 0.0028304157
present O 0 0.0015651621
a O 0 0.0015655139
case O 0 0.0011728951
of O 0 0.0011732577
paramedic O 0 0.0036658638
misjudgment O 0 0.061743315
in O 0 0.0005955765
the O 0 0.000491222
execution O 0 0.0034976534
of O 0 0.00057769794
a O 0 0.00048317108
protocol O 0 0.00057957607
for O 0 0.00028733857
the O 0 0.0003464897
treatment O 0 0.0011418278
of O 0 0.001332603
allergic B-Disease 2 0.9991192
reaction I-Disease 2 0.29953957
in O 0 0.00072556693
a O 0 0.0008170179
case O 0 0.0009143436
of O 0 0.0021160739
pulmonary B-Disease 0 0.98115623
edema I-Disease 0 0.99908483
with O 0 0.060154606
wheezing B-Disease 0 0.9956987
. O 0 0.009863711

The O 0 0.004139221
sudden O 0 0.653929
onset O 0 0.010795865
of O 0 0.003861056
respiratory B-Disease 0 0.9600921
distress I-Disease 0 0.99405503
, O 0 0.006291559
rash B-Disease 2 0.9983115
, O 0 0.0013120964
and O 0 0.0005439762
a O 0 0.00046652113
history O 0 0.0025885724
of O 0 0.00051869324
a O 0 0.00045992847
new O 0 0.00059973105
medicine O 0 0.0044555017
led O 0 0.0006115813
the O 0 0.00036231332
two O 0 0.0003269098
paramedics O 0 0.0009189497
on O 0 0.00036983137
the O 0 0.0007096322
scene O 0 0.0031108696
to O 0 0.0014448836
administer O 0 0.007536933
subcutaneous O 0 0.39423192
epinephrine B-Chemical 0 0.9951342
. O 0 0.008192574

Subsequently O 0 0.012789242
, O 0 0.01021005
acute O 0 0.9267556
cardiac B-Disease 2 0.9680162
arrest I-Disease 2 0.9555894
and O 0 0.013479912
fatal O 0 0.9931197
subarachnoid B-Disease 0 0.9981026
hemorrhage I-Disease 2 0.99826777
occurred O 0 0.046999287
. O 0 0.013079529

Epinephrine B-Chemical 1 0.9960406
has O 0 0.003958027
a O 0 0.0025421735
proven O 0 0.004068423
role O 0 0.0010235235
in O 0 0.0011254783
cardiac B-Disease 2 0.82847834
arrest I-Disease 2 0.8246339
in O 0 0.00076952355
prehospital O 0 0.03279659
care O 0 0.001509136
; O 0 0.0008833732
however O 0 0.0005387936
, O 0 0.00041563736
use O 0 0.0003567277
by O 0 0.0003020548
paramedics O 0 0.00066529884
in O 0 0.00028095944
patients O 0 0.0011299489
with O 0 0.00068347895
suspected O 0 0.18401617
allergic B-Disease 2 0.9993119
reaction I-Disease 2 0.4591942
and O 0 0.001996443
severe O 0 0.70203155
hypertension B-Disease 2 0.99948573
should O 0 0.0010528739
be O 0 0.0013826755
viewed O 0 0.0019113692
with O 0 0.003074113
caution O 0 0.007270631
. O 0 0.0058615585

Role O 0 0.009570231
of O 0 0.0042961556
activation O 0 0.005582148
of O 0 0.004401667
bradykinin B-Chemical 1 0.999241
B2 O 0 0.9919504
receptors O 0 0.40728757
in O 0 0.0012073601
disruption O 0 0.0014099878
of O 0 0.0011655105
the O 0 0.0010574452
blood O 0 0.017328922
- O 0 0.0029187582
brain O 0 0.066664
barrier O 0 0.018637555
during O 0 0.0031544801
acute O 0 0.9892203
hypertension B-Disease 2 0.9988009
. O 0 0.013247551

Cellular O 0 0.08668456
mechanisms O 0 0.004810864
which O 0 0.0026830074
account O 0 0.0016177956
for O 0 0.0009967758
disruption O 0 0.0014940887
the O 0 0.0010615056
blood O 0 0.011765805
- O 0 0.0023358604
brain O 0 0.043033402
barrier O 0 0.010218406
during O 0 0.0014623179
acute O 0 0.98524517
hypertension B-Disease 2 0.99925
are O 0 0.0044900915
not O 0 0.0035366877
clear O 0 0.005521064
. O 0 0.0063626445

The O 0 0.0025838763
goal O 0 0.0025208895
of O 0 0.0015677939
this O 0 0.0010529758
study O 0 0.0012501111
was O 0 0.000643093
to O 0 0.000455872
determine O 0 0.00023591146
the O 0 0.00036167985
role O 0 0.00031692692
of O 0 0.0007531744
synthesis O 0 0.08935808
/ O 0 0.0037512379
release O 0 0.05078563
of O 0 0.0015121195
bradykinin B-Chemical 1 0.99963677
to O 0 0.0008282677
activate O 0 0.00076356146
B2 O 0 0.9492713
receptors O 0 0.16317916
in O 0 0.00045929517
disruption O 0 0.0006966076
of O 0 0.0006368858
the O 0 0.000633685
blood O 0 0.0155016035
- O 0 0.0021249389
brain O 0 0.06309604
barrier O 0 0.016616998
during O 0 0.0025564688
acute O 0 0.98990977
hypertension B-Disease 2 0.99892753
. O 0 0.011839038

Permeability O 0 0.36385685
of O 0 0.0037416522
the O 0 0.002289004
blood O 0 0.011267602
- O 0 0.0028088947
brain O 0 0.028242087
barrier O 0 0.0058220676
was O 0 0.00067445746
quantitated O 0 0.0009306161
by O 0 0.00058072346
clearance O 0 0.033685744
of O 0 0.00076321483
fluorescent O 0 0.005753636
- O 0 0.001190462
labeled O 0 0.00057506206
dextran B-Chemical 1 0.9100785
before O 0 0.00024384006
and O 0 0.00038980765
during O 0 0.00038630326
phenylephrine B-Chemical 1 0.9997019
- O 0 0.0038195997
induced O 0 0.0021689113
acute O 0 0.9921795
hypertension B-Disease 2 0.9998442
in O 0 0.00080093415
rats O 0 0.007143743
treated O 0 0.00092593126
with O 0 0.00063841545
vehicle O 0 0.030821567
and O 0 0.0013388416
Hoe B-Chemical 0 0.99883157
- I-Chemical 0 0.002455955
140 I-Chemical 0 0.0028358097
( O 0 0.001066133
0 O 0 0.0009897904
. O 0 0.00078069145
1 O 0 0.0019917286
microM O 0 0.27028632
) O 0 0.006203849
. O 0 0.005100005

Phenylephrine B-Chemical 0 0.99792707
infusion O 0 0.22310823
increased O 0 0.005735139
arterial O 0 0.7249388
pressure O 0 0.17339537
, O 0 0.002522387
arteriolar O 0 0.9889858
diameter O 0 0.02481195
and O 0 0.00095015
clearance O 0 0.02843204
of O 0 0.0010559215
fluorescent O 0 0.0056071854
dextran B-Chemical 1 0.96123075
by O 0 0.001140314
a O 0 0.0010411723
similar O 0 0.0007583058
magnitude O 0 0.0011744134
in O 0 0.001566316
both O 0 0.002662905
groups O 0 0.005235342
. O 0 0.0061246417

These O 0 0.004205789
findings O 0 0.003492968
suggest O 0 0.0012881542
that O 0 0.0010296312
disruption O 0 0.0013251258
of O 0 0.0011036462
the O 0 0.00085601275
blood O 0 0.015615066
- O 0 0.0017215465
brain O 0 0.043017067
barrier O 0 0.008350738
during O 0 0.0005269899
acute O 0 0.98134995
hypertension B-Disease 2 0.9997689
is O 0 0.0008393535
not O 0 0.0003772849
related O 0 0.00028445447
to O 0 0.00035051396
the O 0 0.0004800066
synthesis O 0 0.04043624
/ O 0 0.0028966814
release O 0 0.04241087
of O 0 0.0026619115
bradykinin B-Chemical 1 0.99907756
to O 0 0.002895525
activate O 0 0.004172374
B2 O 0 0.96538204
receptors O 0 0.5492124
. O 0 0.008936324

Risk O 0 0.048042446
factors O 0 0.014125867
of O 0 0.01361135
sensorineural B-Disease 2 0.99705195
hearing I-Disease 2 0.976539
loss I-Disease 2 0.059398998
in O 0 0.01080368
preterm O 0 0.92052156
infants O 0 0.21849243
. O 0 0.016157284

Among O 0 0.00997106
547 O 0 0.02719973
preterm O 0 0.61819816
infants O 0 0.015490545
of O 0 0.0018451879
< O 0 0.0013303206
or O 0 0.00067326654
= O 0 0.00085404736
34 O 0 0.00055530947
weeks O 0 0.00037302583
gestation O 0 0.0015440147
born O 0 0.00070294674
between O 0 0.00023150227
1987 O 0 0.0026073619
and O 0 0.00044519082
1991 O 0 0.0012684374
, O 0 0.0004882488
8 O 0 0.0003364721
children O 0 0.0007649146
( O 0 0.0004882314
1 O 0 0.00033125238
. O 0 0.0002012546
46 O 0 0.0004931547
% O 0 0.00042810128
) O 0 0.0006059195
developed O 0 0.00095880916
severe O 0 0.08500083
progressive O 0 0.375671
and O 0 0.002979341
bilateral O 0 0.8184168
sensorineural B-Disease 2 0.9992811
hearing I-Disease 2 0.9874835
loss I-Disease 2 0.12999691
. O 0 0.008340651

Perinatal O 0 0.0931424
risk O 0 0.01715238
factors O 0 0.004005146
of O 0 0.0018133526
infants O 0 0.0036523875
with O 0 0.0013524264
hearing B-Disease 0 0.68747133
loss I-Disease 0 0.0019114837
were O 0 0.00048610012
compared O 0 0.00023294453
with O 0 0.00037937894
those O 0 0.00040711975
of O 0 0.0003495797
two O 0 0.00021741087
control O 0 0.0002472774
groups O 0 0.00033314375
matched O 0 0.0003010908
for O 0 0.00032653598
gestation O 0 0.0025137316
and O 0 0.0006210198
birth O 0 0.0021184909
weight O 0 0.0038361752
and O 0 0.0013902202
for O 0 0.001881113
perinatal O 0 0.34615573
complications O 0 0.8017947
. O 0 0.007846974

Our O 0 0.0036066843
observations O 0 0.0030351963
demonstrated O 0 0.0019185005
an O 0 0.0016898023
association O 0 0.0010660792
of O 0 0.0017841246
hearing B-Disease 0 0.69688904
loss I-Disease 0 0.0032296202
with O 0 0.0015560959
a O 0 0.0015075267
higher O 0 0.001583749
incidence O 0 0.009179618
of O 0 0.00486113
perinatal O 0 0.62510717
complications O 0 0.89245135
. O 0 0.009896989

Ototoxicity B-Disease 0 0.9956234
appeared O 0 0.003962496
closely O 0 0.0018210862
related O 0 0.00092374015
to O 0 0.00079762866
a O 0 0.0008155038
prolonged O 0 0.0046016853
administration O 0 0.065097585
and O 0 0.0006640567
higher O 0 0.0004923996
total O 0 0.00050557347
dose O 0 0.0108251255
of O 0 0.001806614
ototoxic B-Disease 0 0.99823844
drugs O 0 0.92402494
, O 0 0.0028274618
particularly O 0 0.006397407
aminoglycosides B-Chemical 1 0.9931109
and O 0 0.012336247
furosemide B-Chemical 1 0.99904233
. O 0 0.010680599

Finally O 0 0.0040553706
, O 0 0.0024848778
we O 0 0.0008704308
strongly O 0 0.0011879496
recommend O 0 0.0007964051
to O 0 0.00061824516
prospectively O 0 0.0011163172
and O 0 0.00048094848
regularly O 0 0.00053419155
perform O 0 0.00034265572
audiologic O 0 0.020369593
assessment O 0 0.0004683497
in O 0 0.00034167038
sick O 0 0.0032398382
preterm O 0 0.23504665
children O 0 0.001446235
as O 0 0.0003690821
hearing B-Disease 0 0.6443967
loss I-Disease 0 0.0014253698
is O 0 0.0003941532
of O 0 0.00051903125
delayed O 0 0.0043727
onset O 0 0.0051104696
and O 0 0.00068738195
in O 0 0.0006419365
most O 0 0.0015384291
cases O 0 0.0030331442
bilateral O 0 0.16610874
and O 0 0.0039878967
severe O 0 0.3827388
. O 0 0.006787028

Seizure B-Disease 2 0.9821294
resulting O 0 0.014447528
from O 0 0.012256818
a O 0 0.022798747
venlafaxine B-Chemical 0 0.9979042
overdose B-Disease 2 0.99642295
. O 0 0.032441914

OBJECTIVE O 0 0.49525574
: O 0 0.008583325
To O 0 0.0037954778
report O 0 0.0071339887
a O 0 0.004894833
case O 0 0.0058208127
of O 0 0.014243854
venlafaxine B-Chemical 0 0.9989095
overdose B-Disease 2 0.9978436
. O 0 0.024170777

CASE O 0 0.9423647
SUMMARY O 0 0.10087203
: O 0 0.0053649372
A O 0 0.008079704
40 O 0 0.0022668808
- O 0 0.0019190226
year O 0 0.0011402589
- O 0 0.0013109589
old O 0 0.00087778934
woman O 0 0.0042292858
with O 0 0.00094575324
major B-Disease 2 0.0046401164
depression I-Disease 2 0.9967456
took O 0 0.0012305785
an O 0 0.0021003145
overdose B-Disease 2 0.9991818
of O 0 0.005459008
venlafaxine B-Chemical 0 0.9996278
in O 0 0.0017783999
an O 0 0.0026334003
apparent O 0 0.003857679
suicide O 0 0.7985954
attempt O 0 0.008243915
. O 0 0.006781396

After O 0 0.0027586084
the O 0 0.0026151452
ingestion O 0 0.121187516
of O 0 0.0026073137
26 O 0 0.003610844
venlafaxine B-Chemical 0 0.99918145
50 O 0 0.0033774823
- O 0 0.0023366471
mg O 0 0.52301973
tablets O 0 0.8319661
, O 0 0.0012190429
the O 0 0.00074124016
patient O 0 0.0015189261
experienced O 0 0.0022715533
a O 0 0.0023009665
witnessed O 0 0.03725254
generalized O 0 0.6071775
seizure B-Disease 2 0.9970613
. O 0 0.010943782

She O 0 0.006542568
was O 0 0.0028149248
admitted O 0 0.004869219
to O 0 0.0013889663
the O 0 0.0010795327
medical O 0 0.00344502
intensive O 0 0.0015108335
care O 0 0.0014848156
unit O 0 0.00091759104
, O 0 0.0015506839
venlafaxine B-Chemical 0 0.9994704
was O 0 0.0010995425
discontinued O 0 0.044761684
, O 0 0.0011013256
and O 0 0.00084514875
no O 0 0.0008308977
further O 0 0.0017775833
sequelae O 0 0.44368958
were O 0 0.0034048026
seen O 0 0.004758399
. O 0 0.00589356

DISCUSSION O 0 0.018340275
: O 0 0.0033032824
To O 0 0.0011844338
our O 0 0.0009793683
knowledge O 0 0.0014332476
, O 0 0.0010582258
this O 0 0.0006196853
is O 0 0.0005274631
the O 0 0.00041875537
first O 0 0.0003834897
reported O 0 0.0007383642
case O 0 0.00063379016
of O 0 0.0016890542
venlafaxine B-Chemical 0 0.9998404
overdose B-Disease 2 0.9995553
that O 0 0.0012498297
resulted O 0 0.0013195492
in O 0 0.0014699354
a O 0 0.0032096487
generalized O 0 0.54495513
seizure B-Disease 2 0.9973028
. O 0 0.009866132

Based O 0 0.00956541
on O 0 0.0020885733
nonoverdose O 0 0.04677738
pharmacokinetics O 0 0.8728952
and O 0 0.0019061837
pharmacodynamics O 0 0.83498394
of O 0 0.002043745
venlafaxine B-Chemical 0 0.9996056
and O 0 0.0009194954
the O 0 0.00049496
potential O 0 0.0007730077
risks O 0 0.0051589133
of O 0 0.0008086077
available O 0 0.00072439236
interventions O 0 0.0011473474
, O 0 0.0010219626
no O 0 0.0007937601
emergent O 0 0.0036481249
therapy O 0 0.02650641
was O 0 0.0036041166
instituted O 0 0.01457079
. O 0 0.0063090026

CONCLUSIONS O 0 0.76096797
: O 0 0.005989299
The O 0 0.0027904648
venlafaxine B-Chemical 0 0.9992207
overdose B-Disease 2 0.9990096
in O 0 0.0012390303
our O 0 0.0006889973
patient O 0 0.0010708469
resulted O 0 0.00056338584
in O 0 0.00044287063
a O 0 0.00051259785
single O 0 0.0005335627
episode O 0 0.0038744304
of O 0 0.0011709684
generalized O 0 0.36516103
seizure B-Disease 2 0.9988142
but O 0 0.0018382034
elicited O 0 0.0024171935
no O 0 0.0018675711
further O 0 0.0041329004
sequelae O 0 0.7543589
. O 0 0.007364975

Combined O 0 0.020468203
effects O 0 0.0060705496
of O 0 0.0042973286
prolonged O 0 0.26260024
prostaglandin B-Chemical 1 0.9998247
E1 I-Chemical 1 0.9981839
- O 0 0.038233396
induced O 0 0.013933137
hypotension B-Disease 2 0.9994942
and O 0 0.004937514
haemodilution B-Disease 2 0.98029387
on O 0 0.0020383338
human O 0 0.009115916
hepatic O 0 0.9722201
function O 0 0.013587318
. O 0 0.008761255

Combined O 0 0.019560864
effects O 0 0.0055169445
of O 0 0.0037744506
prolonged O 0 0.24959211
prostaglandin B-Chemical 1 0.99986124
E1 I-Chemical 1 0.9987872
( O 0 0.13299856
PGE1 B-Chemical 1 0.99990356
) O 0 0.040459026
- O 0 0.003708218
induced O 0 0.0029452147
hypotension B-Disease 2 0.9996947
and O 0 0.0016745412
haemodilution B-Disease 2 0.97517186
on O 0 0.00047154506
hepatic O 0 0.92907304
function O 0 0.0010162721
were O 0 0.0005725809
studied O 0 0.0007747403
in O 0 0.0005792044
30 O 0 0.0007551217
patients O 0 0.0021880069
undergoing O 0 0.0036238988
hip O 0 0.39426002
surgery O 0 0.037651528
. O 0 0.006481651

The O 0 0.0025818995
patients O 0 0.0031508564
were O 0 0.001131517
randomly O 0 0.00053107645
allocated O 0 0.00068411295
to O 0 0.00050880865
one O 0 0.00035597084
of O 0 0.00048777988
three O 0 0.00026908095
groups O 0 0.0005957831
; O 0 0.00074648554
those O 0 0.00045500544
in O 0 0.00029396274
group O 0 0.00054825866
A O 0 0.009346243
( O 0 0.0005317995
n O 0 0.00027633275
= O 0 0.0003999357
10 O 0 0.00023384557
) O 0 0.00028329476
were O 0 0.00015242131
subjected O 0 0.0001323054
to O 0 0.00019118925
controlled O 0 0.0004149491
hypotension B-Disease 2 0.9996049
alone O 0 0.0008389617
, O 0 0.0004908822
those O 0 0.00038811163
in O 0 0.00023421465
group O 0 0.0004946478
B O 0 0.08992195
( O 0 0.00051672297
n O 0 0.00025496096
= O 0 0.00038668644
10 O 0 0.00023530157
) O 0 0.00031967866
to O 0 0.00021126603
haemodilution B-Disease 2 0.8055807
alone O 0 0.00042554637
and O 0 0.0003316673
those O 0 0.00041713755
in O 0 0.0002754227
group O 0 0.0006600935
C O 0 0.7380675
( O 0 0.0008063349
n O 0 0.0004082883
= O 0 0.0006261978
10 O 0 0.0004159806
) O 0 0.00059752417
to O 0 0.00043455802
both O 0 0.00074130803
controlled O 0 0.0020111469
hypotension B-Disease 2 0.99885774
and O 0 0.0069552567
haemodilution B-Disease 2 0.9849582
. O 0 0.007881769

Haemodilution B-Disease 0 0.96922404
in O 0 0.0033580095
groups O 0 0.0030007213
B O 0 0.06610837
and O 0 0.001955478
C O 0 0.5863472
was O 0 0.00096175657
produced O 0 0.00070086843
by O 0 0.00063105096
withdrawing O 0 0.027952118
approximately O 0 0.00060536223
1000 O 0 0.000926218
mL O 0 0.0016793476
of O 0 0.00039365888
blood O 0 0.0022686655
and O 0 0.0003303139
replacing O 0 0.0005024392
it O 0 0.00030382673
with O 0 0.00028313004
the O 0 0.00020294593
same O 0 0.00013280517
amount O 0 0.00016890945
of O 0 0.00057385804
dextran B-Chemical 1 0.9734238
solution O 0 0.03610863
, O 0 0.00075067364
and O 0 0.0005141261
final O 0 0.0010811744
haematocrit O 0 0.5950426
values O 0 0.00080581754
were O 0 0.0009406759
21 O 0 0.0014747943
or O 0 0.0013918144
22 O 0 0.0034796523
% O 0 0.0040543415
. O 0 0.0045306785

Controlled O 0 0.01420681
hypotension B-Disease 2 0.99660206
in O 0 0.0030221145
groups O 0 0.002661005
A O 0 0.01181625
and O 0 0.0018680069
C O 0 0.6438033
was O 0 0.0012155898
induced O 0 0.0014663312
with O 0 0.002112774
PGE1 B-Chemical 1 0.9997875
to O 0 0.00093813834
maintain O 0 0.0005699331
mean O 0 0.0004999288
arterial O 0 0.3092085
blood O 0 0.007222687
pressure O 0 0.01891406
at O 0 0.0006389194
55 O 0 0.0013789866
mmHg O 0 0.0041190046
for O 0 0.0012063795
180 O 0 0.0044546183
min O 0 0.005013316
. O 0 0.005025945

Measurements O 0 0.0064596906
included O 0 0.0035152866
arterial O 0 0.53370786
ketone O 0 0.98752105
body O 0 0.013976342
ratio O 0 0.002795541
( O 0 0.0030433782
AKBR O 0 0.9895019
, O 0 0.0032364295
aceto B-Chemical 0 0.9697328
- I-Chemical 0 0.009933285
acetate I-Chemical 0 0.99637175
/ O 0 0.0052588214
3 B-Chemical 0 0.0010498465
- I-Chemical 0 0.00254261
hydroxybutyrate I-Chemical 0 0.9987649
) O 0 0.0025470376
and O 0 0.0014013562
clinical O 0 0.023308992
hepatic O 0 0.9481458
function O 0 0.0060964064
parameters O 0 0.010447872
. O 0 0.0067571523

AKBR O 0 0.9225051
and O 0 0.0038157986
biological O 0 0.0047692386
hepatic O 0 0.8269346
function O 0 0.0021032188
tests O 0 0.0021084794
showed O 0 0.00087247934
no O 0 0.00059722323
change O 0 0.0006850753
throughout O 0 0.00044230235
the O 0 0.0005486395
time O 0 0.0006317595
course O 0 0.001531587
in O 0 0.0013101295
groups O 0 0.0026183035
A O 0 0.016438412
and O 0 0.005410709
B O 0 0.17479868
. O 0 0.0083645005

In O 0 0.0038162556
group O 0 0.0041238745
C O 0 0.59265596
, O 0 0.0037167366
AKBR O 0 0.96681154
showed O 0 0.0011427945
a O 0 0.0008435926
significant O 0 0.00075483567
decrease O 0 0.0006005349
at O 0 0.0002956111
120 O 0 0.00063557725
min O 0 0.0006928338
( O 0 0.0005406667
- O 0 0.0004912459
40 O 0 0.00033736133
% O 0 0.00029896264
) O 0 0.0003301949
and O 0 0.00020291515
at O 0 0.00014134328
180 O 0 0.000556854
min O 0 0.00047825807
( O 0 0.00040131056
- O 0 0.00040539715
49 O 0 0.00040639428
% O 0 0.0002527242
) O 0 0.00026055457
after O 0 9.70309e-05
the O 0 0.00014683956
start O 0 0.00016826323
of O 0 0.00045876944
hypotension B-Disease 2 0.99962604
and O 0 0.00040110902
at O 0 0.00017108685
60 O 0 0.00030186508
min O 0 0.000449909
( O 0 0.00038012146
- O 0 0.00039441485
32 O 0 0.00036996926
% O 0 0.0002617323
) O 0 0.00028578565
after O 0 0.00012002426
recovery O 0 0.0005287651
of O 0 0.00052627636
normotension O 0 0.9731949
, O 0 0.001081976
and O 0 0.0016670837
SGOT O 0 0.9998349
, O 0 0.017914424
SGPT O 0 0.9999174
, O 0 0.0071280333
LDH O 0 0.99801636
and O 0 0.00096713885
total O 0 0.0009831117
bilirubin B-Chemical 1 0.99790275
showed O 0 0.001296957
significant O 0 0.0017140174
increases O 0 0.0019268465
after O 0 0.0018044561
operation O 0 0.006562558
. O 0 0.0055917865

The O 0 0.0025075388
results O 0 0.0016588144
suggest O 0 0.0011104495
that O 0 0.0009139481
a O 0 0.00095578836
prolonged O 0 0.0033787198
combination O 0 0.0015983634
of O 0 0.00082011806
more O 0 0.00070652977
than O 0 0.00029967888
120 O 0 0.00062078366
min O 0 0.0006754571
of O 0 0.0009980643
PGE1 B-Chemical 1 0.9998932
- O 0 0.0071609104
induced O 0 0.0039581396
hypotension B-Disease 2 0.9997397
and O 0 0.0013451884
moderate O 0 0.04789688
haemodilution B-Disease 2 0.9773901
would O 0 0.00093949627
cause O 0 0.0071028215
impairment B-Disease 0 0.4632774
of I-Disease 0 0.0052287052
hepatic I-Disease 0 0.9844052
function I-Disease 0 0.013757898
. O 0 0.007244544

Cardiovascular B-Disease 0 0.98049325
alterations I-Disease 0 0.10369461
in O 0 0.004315438
rat O 0 0.013451243
fetuses O 0 0.013390412
exposed O 0 0.004885285
to O 0 0.005751629
calcium B-Chemical 1 0.9915073
channel O 0 0.7871411
blockers O 0 0.99402964
. O 0 0.021185933

Preclinical O 0 0.5362002
toxicologic O 0 0.22860013
investigation O 0 0.004080147
suggested O 0 0.0016230752
that O 0 0.0009880525
a O 0 0.0011938978
new O 0 0.0020755483
calcium B-Chemical 1 0.996953
channel O 0 0.59185255
blocker O 0 0.9951415
, O 0 0.004674542
Ro B-Chemical 0 0.973371
40 I-Chemical 0 0.0013001366
- I-Chemical 0 0.001085391
5967 I-Chemical 0 0.0028503607
, O 0 0.0006059149
induced O 0 0.0009454353
cardiovascular B-Disease 0 0.9958819
alterations I-Disease 0 0.21699433
in O 0 0.0006222875
rat O 0 0.009835407
fetuses O 0 0.005385627
exposed O 0 0.00082585844
to O 0 0.00075365935
this O 0 0.0012346868
agent O 0 0.058241226
during O 0 0.0029565897
organogenesis O 0 0.43528152
. O 0 0.006561221

The O 0 0.0023937135
present O 0 0.0014638103
study O 0 0.0018347367
was O 0 0.0010064418
designed O 0 0.000875846
to O 0 0.00058685686
investigate O 0 0.00038717114
the O 0 0.0004938393
hypothesis O 0 0.00086730055
that O 0 0.00074184826
calcium B-Chemical 1 0.9976636
channel O 0 0.579984
blockers O 0 0.99851185
in O 0 0.0009816347
general O 0 0.0010181217
induce O 0 0.0013789335
cardiovascular B-Disease 0 0.998083
malformations I-Disease 0 0.99810094
indicating O 0 0.0013371749
a O 0 0.0019227583
pharmacologic O 0 0.33768073
class O 0 0.008684529
effect O 0 0.0068688276
. O 0 0.00647976

We O 0 0.003521912
studied O 0 0.003195644
three O 0 0.0016980821
calcium B-Chemical 1 0.9900591
channel O 0 0.3843738
blockers O 0 0.9963038
of O 0 0.0025595508
different O 0 0.0013805013
structure O 0 0.0037020084
, O 0 0.0030429924
nifedipine B-Chemical 1 0.9998442
, O 0 0.016130002
diltiazem B-Chemical 1 0.9999068
, O 0 0.0038376409
and O 0 0.0020624246
verapamil B-Chemical 0 0.9996979
, O 0 0.002212844
along O 0 0.0012494333
with O 0 0.0017155427
the O 0 0.0020569302
new O 0 0.005286281
agent O 0 0.22973308
. O 0 0.007649265

Pregnant O 0 0.12507288
rats O 0 0.0065336786
were O 0 0.0017669725
administered O 0 0.002381751
one O 0 0.0007368999
of O 0 0.0010176097
these O 0 0.0016686273
calcium B-Chemical 1 0.99714833
channel O 0 0.47800756
blockers O 0 0.9977235
during O 0 0.0005255059
the O 0 0.00037390698
period O 0 0.00036835903
of O 0 0.00051889225
cardiac O 0 0.28185785
morphogenesis O 0 0.0047239396
and O 0 0.0003719956
the O 0 0.00029167082
offspring O 0 0.00087278365
examined O 0 0.000275738
on O 0 0.00023792504
day O 0 0.00043985175
20 O 0 0.00060547265
of O 0 0.0009293292
gestation O 0 0.0073274625
for O 0 0.002317319
cardiovascular B-Disease 0 0.99489564
malformations I-Disease 0 0.9956891
. O 0 0.009652933

A O 0 0.0142308455
low O 0 0.0035241132
incidence O 0 0.0075273085
of O 0 0.003399186
cardiovascular B-Disease 0 0.9967243
malformations I-Disease 0 0.99767214
was O 0 0.0011639766
observed O 0 0.00043133367
after O 0 0.00026040606
exposure O 0 0.0011284037
to O 0 0.0002783291
each O 0 0.00014960299
of O 0 0.0003509309
the O 0 0.00030784166
four O 0 0.00034156
calcium B-Chemical 1 0.9975816
channel O 0 0.5021569
blockers O 0 0.99890316
, O 0 0.0016323475
but O 0 0.00042170894
this O 0 0.00037941188
incidence O 0 0.0037463547
was O 0 0.00048746573
statistically O 0 0.0005405355
significant O 0 0.00075647753
only O 0 0.0008949708
for O 0 0.0017192387
verapamil B-Chemical 0 0.9994318
and O 0 0.030542111
nifedipine B-Chemical 1 0.99934715
. O 0 0.0127810575

All O 0 0.0033815198
four O 0 0.001814113
agents O 0 0.020744309
were O 0 0.0014821477
associated O 0 0.0015359583
with O 0 0.0015116667
aortic O 0 0.54206383
arch O 0 0.4428602
branching O 0 0.04731158
variants O 0 0.001448776
, O 0 0.00084731134
although O 0 0.0004964723
significantly O 0 0.0006383717
increased O 0 0.00089613034
only O 0 0.0007054331
for O 0 0.00087129755
Ro B-Chemical 0 0.8995542
40 I-Chemical 0 0.0021915443
- I-Chemical 0 0.0029679323
5967 I-Chemical 0 0.009019087
and O 0 0.0048907776
verapamil B-Chemical 0 0.99842405
. O 0 0.009978887

The O 0 0.0057034297
site O 0 0.004962584
of O 0 0.005364667
common O 0 0.0074749715
side O 0 0.02795046
effects O 0 0.013465102
of O 0 0.021159431
sumatriptan B-Chemical 1 0.9983694
. O 0 0.020895792

Atypical B-Disease 0 0.8748085
sensations I-Disease 0 0.81733936
following O 0 0.0025975937
the O 0 0.0015848067
use O 0 0.0016257368
of O 0 0.0018228003
subcutaneous O 0 0.27575022
sumatriptan B-Chemical 1 0.9996394
are O 0 0.0021601666
common O 0 0.002530194
, O 0 0.0021217363
but O 0 0.0016456742
of O 0 0.0028938102
uncertain O 0 0.008930313
origin O 0 0.01320356
. O 0 0.007793151

They O 0 0.007346321
are O 0 0.0027201183
almost O 0 0.0018232161
always O 0 0.0021766927
benign O 0 0.6343384
, O 0 0.0021738708
but O 0 0.0010719473
can O 0 0.0007714939
be O 0 0.00091540493
mistaken O 0 0.0057904935
for O 0 0.0007607305
a O 0 0.0013859345
serious O 0 0.13086738
adverse O 0 0.7791699
event O 0 0.012006502
by O 0 0.00257219
the O 0 0.0031690956
patient O 0 0.007971578
. O 0 0.0066140764

Two O 0 0.0048310766
patients O 0 0.004599248
are O 0 0.001938551
presented O 0 0.0016613282
with O 0 0.001891329
tingling B-Disease 0 0.9201327
or I-Disease 0 0.0015183938
burning I-Disease 0 0.59005594
sensations I-Disease 0 0.5743077
limited O 0 0.0011614813
to O 0 0.0009839053
areas O 0 0.0021740845
of O 0 0.0019450058
heat O 0 0.032835245
exposure O 0 0.032051113
or O 0 0.006829671
sunburn B-Disease 0 0.99295926
. O 0 0.011338808

In O 0 0.0035164643
these O 0 0.0033045246
individuals O 0 0.0031939887
, O 0 0.0027436635
side O 0 0.007818219
effects O 0 0.0026802693
are O 0 0.001406245
most O 0 0.0018374335
likely O 0 0.0011018923
generated O 0 0.001140865
superficially O 0 0.0063073253
in O 0 0.0023272885
the O 0 0.0038939144
skin O 0 0.055066876
. O 0 0.008187539

Macula O 0 0.89819175
toxicity B-Disease 2 0.9681864
after O 0 0.02100268
intravitreal O 0 0.99024945
amikacin B-Chemical 1 0.99438006
. O 0 0.037245106

BACKGROUND O 0 0.7362569
: O 0 0.005302182
Although O 0 0.0024756733
intravitreal O 0 0.98993427
aminoglycosides B-Chemical 1 0.99084294
have O 0 0.0016783485
substantially O 0 0.0014218376
improved O 0 0.0027776659
visual O 0 0.38728422
prognosis O 0 0.8723601
in O 0 0.0019858794
endophthalmitis B-Disease 0 0.99919826
, O 0 0.01864541
macular O 0 0.9997229
infarction B-Disease 2 0.99980766
may O 0 0.0028702207
impair O 0 0.002121155
full O 0 0.0025935066
visual O 0 0.25118387
recovery O 0 0.01662851
. O 0 0.00691514

METHODS O 0 0.006222985
: O 0 0.003035322
We O 0 0.0012629933
present O 0 0.00083345507
a O 0 0.0009899125
case O 0 0.0008492744
of O 0 0.0010903691
presumed O 0 0.023067843
amikacin B-Chemical 1 0.9995627
retinal B-Disease 0 0.9978447
toxicity I-Disease 2 0.9991879
following O 0 0.0013443193
treatment O 0 0.0030565565
with O 0 0.0015054209
amikacin B-Chemical 1 0.99928075
and O 0 0.0016790543
vancomycin B-Chemical 1 0.99755186
for O 0 0.0014708799
alpha O 0 0.55262566
- O 0 0.03801104
haemolytic O 0 0.9974826
streptococcal B-Disease 0 0.9983175
endophthalmitis I-Disease 0 0.9992737
. O 0 0.01704693

RESULTS O 0 0.042420037
: O 0 0.0078068124
Endophthalmitis B-Disease 0 0.9651101
resolved O 0 0.0037403442
with O 0 0.001878531
improvement O 0 0.0020840594
in O 0 0.0013092776
visual O 0 0.1324219
acuity O 0 0.945535
to O 0 0.0014123893
6 O 0 0.0010411106
/ O 0 0.0020050271
24 O 0 0.0011535523
at O 0 0.0010217183
three O 0 0.0015713712
months O 0 0.0043638865
. O 0 0.0055176406

Fundus O 0 0.92295057
fluorescein B-Chemical 0 0.67508274
angiography O 0 0.36895245
confirmed O 0 0.011056695
macular O 0 0.9967462
capillary O 0 0.60272586
closure O 0 0.08062297
and O 0 0.018052528
telangiectasis B-Disease 0 0.98770344
. O 0 0.01966846

CONCLUSIONS O 0 0.7018001
: O 0 0.0064329803
Currently O 0 0.004286052
accepted O 0 0.004985325
intravitreal O 0 0.9896054
antibiotic O 0 0.47221595
regimens O 0 0.09534936
may O 0 0.0030181557
cause O 0 0.028191552
retinal B-Disease 0 0.99480635
toxicity I-Disease 2 0.9984231
and O 0 0.074838
macular O 0 0.99932206
ischaemia B-Disease 0 0.9991416
. O 0 0.019758373

Treatment O 0 0.027222581
strategies O 0 0.007068462
aimed O 0 0.005226092
at O 0 0.003492108
avoiding O 0 0.009605406
retinal B-Disease 0 0.9852513
toxicity I-Disease 2 0.99493545
are O 0 0.012824189
discussed O 0 0.011369434
. O 0 0.012217924

The O 0 0.0044097006
role O 0 0.0031956697
of O 0 0.0049908888
nicotine B-Chemical 1 0.9893119
in O 0 0.00550146
smoking O 1 0.86522007
- O 0 0.009124951
related O 0 0.00529742
cardiovascular B-Disease 0 0.9767021
disease I-Disease 0 0.92190295
. O 0 0.013464031

Nicotine B-Chemical 1 0.9966876
activates O 0 0.0062901583
the O 0 0.0036478098
sympathetic O 0 0.88235176
nervous O 0 0.82704073
system O 0 0.0030338492
and O 0 0.0014434891
in O 0 0.00097142195
this O 0 0.0010028937
way O 0 0.0014554224
could O 0 0.001117674
contribute O 0 0.0020390705
to O 0 0.0032767504
cardiovascular B-Disease 0 0.9800925
disease I-Disease 0 0.92946714
. O 0 0.010325974

Animal O 0 0.011779387
studies O 0 0.003203319
and O 0 0.001755495
mechanistic O 0 0.0027160905
studies O 0 0.0014094495
indicate O 0 0.00065684586
that O 0 0.0007417281
nicotine B-Chemical 1 0.9945549
could O 0 0.00062035344
play O 0 0.0007429573
a O 0 0.0005235054
role O 0 0.00030228758
in O 0 0.00037964399
accelerating O 0 0.007916713
atherosclerosis B-Disease 2 0.99953127
, O 0 0.0014104766
but O 0 0.00038248874
evidence O 0 0.00041478578
among O 0 0.00047153968
humans O 0 0.0016668075
is O 0 0.00036721
too O 0 0.00040760532
inadequate O 0 0.00081243634
to O 0 0.0004909959
be O 0 0.0006110712
definitive O 0 0.0012293684
about O 0 0.00089904445
such O 0 0.0016239686
an O 0 0.0033346587
effect O 0 0.004943593
. O 0 0.005853173

Almost O 0 0.0066512562
certainly O 0 0.004019734
, O 0 0.0031761262
nicotine B-Chemical 1 0.98754984
via O 0 0.0014632082
its O 0 0.0021088829
hemodynamic O 0 0.55245113
effects O 0 0.0022970561
contributes O 0 0.000643877
to O 0 0.000610329
acute O 0 0.95191467
cardiovascular O 0 0.9936708
events O 0 0.037401598
, O 0 0.00054055644
although O 0 0.00022676945
current O 0 0.0003628117
evidence O 0 0.00024534235
suggests O 0 0.00014326068
that O 0 0.00015708807
the O 0 0.0001873012
effects O 0 0.0005552526
of O 0 0.0005476956
nicotine B-Chemical 1 0.99779594
are O 0 0.0003657936
much O 0 0.00016369119
less O 0 0.00021380394
important O 0 0.00018847137
than O 0 0.00014466594
are O 0 0.00021312293
the O 0 0.00024471182
prothrombotic O 0 0.5264195
effects O 0 0.0011772661
of O 0 0.0008640819
cigarette O 0 0.88155043
smoking O 1 0.83874404
or O 0 0.00077702425
the O 0 0.0008823739
effects O 0 0.0024558897
of O 0 0.0037795065
carbon B-Chemical 0 0.9559735
monoxide I-Chemical 0 0.9970772
. O 0 0.012406023

Nicotine B-Chemical 1 0.99515826
does O 0 0.0066768485
not O 0 0.0043892204
appear O 0 0.004377026
to O 0 0.0039638192
enhance O 0 0.0056207054
thrombosis B-Disease 2 0.99312913
among O 0 0.014389847
humans O 0 0.040879894
. O 0 0.013105906

Clinical O 0 0.029304722
studies O 0 0.0033927083
of O 0 0.0024019785
pipe O 0 0.038427696
smokers O 0 0.04025465
and O 0 0.0012066622
people O 0 0.0017426627
using O 0 0.00073363463
transdermal O 0 0.99237716
nicotine B-Chemical 1 0.9974367
support O 0 0.0007999155
the O 0 0.00044094573
idea O 0 0.0006612955
that O 0 0.00038167104
toxins O 0 0.17607161
other O 0 0.00054701924
than O 0 0.0003942089
nicotine B-Chemical 1 0.99499846
are O 0 0.00062275527
the O 0 0.00048026882
most O 0 0.00094482885
important O 0 0.00071378954
causes O 0 0.0025972233
of O 0 0.0034729752
acute O 0 0.98870695
cardiovascular O 0 0.9941544
events O 0 0.29401538
. O 0 0.007523957

Finally O 0 0.004356552
, O 0 0.0028746827
the O 0 0.001525989
dose O 0 0.0066712215
response O 0 0.0017408668
for O 0 0.00090180064
cardiovascular O 0 0.93717843
events O 0 0.013247128
of O 0 0.0013971737
nicotine B-Chemical 1 0.99812526
appears O 0 0.00071128964
to O 0 0.0003689834
be O 0 0.00037412695
flat O 0 0.0017326467
, O 0 0.00041691176
suggesting O 0 0.00023204567
that O 0 0.0002161554
if O 0 0.0002345919
nicotine B-Chemical 1 0.9958925
is O 0 0.0004719671
involved O 0 0.0003959738
, O 0 0.00059902295
adverse O 0 0.5013799
effects O 0 0.001205475
might O 0 0.0002878908
be O 0 0.00036143186
seen O 0 0.0003403537
with O 0 0.00051318546
relatively O 0 0.0008961457
low O 0 0.0014416799
- O 0 0.0022661726
level O 0 0.001698931
cigarette O 0 0.81856424
exposures O 0 0.20204529
. O 0 0.006879381

Iatrogenically O 0 0.71993613
induced O 0 0.0060120616
intractable O 0 0.914119
atrioventricular B-Disease 0 0.97579706
reentrant I-Disease 0 0.98994946
tachycardia I-Disease 2 0.9990952
after O 0 0.0013682466
verapamil B-Chemical 0 0.9996606
and O 0 0.0012357933
catheter O 0 0.0034824577
ablation O 0 0.0016382744
in O 0 0.00042045198
a O 0 0.0005091895
patient O 0 0.00086892105
with O 0 0.0010438882
Wolff B-Disease 0 0.83318496
- I-Disease 0 0.007847563
Parkinson I-Disease 0 0.99916756
- I-Disease 0 0.004366638
White I-Disease 0 0.113346405
syndrome I-Disease 0 0.8307012
and O 0 0.0039937873
idiopathic B-Disease 0 0.9967795
dilated I-Disease 2 0.9976792
cardiomyopathy I-Disease 2 0.9997104
. O 0 0.022812594

In O 0 0.003383095
a O 0 0.0028208415
patient O 0 0.0034387393
with O 0 0.0039576995
WPW B-Disease 0 0.99936837
syndrome I-Disease 0 0.99274135
and O 0 0.0041971826
idiopathic B-Disease 0 0.9971942
dilated I-Disease 2 0.99865
cardiomyopathy I-Disease 2 0.99993265
, O 0 0.020777646
intractable O 0 0.99055254
atrioventricular B-Disease 0 0.99419576
reentrant I-Disease 0 0.99614835
tachycardia I-Disease 2 0.9995498
( O 0 0.016404677
AVRT B-Disease 0 0.9975069
) O 0 0.0047603995
was O 0 0.0031979568
iatrogenically O 0 0.5522258
induced O 0 0.008867256
. O 0 0.0074109575

QRS O 0 0.8337219
without O 0 0.005030607
preexcitation O 0 0.9902734
, O 0 0.0031186831
caused O 0 0.0016608749
by O 0 0.0011487813
junctional O 0 0.01091367
escape O 0 0.006820423
beats O 0 0.3995462
after O 0 0.00058478065
verapamil B-Chemical 0 0.9996691
or O 0 0.0006602533
unidirectional O 0 0.0028277023
antegrade O 0 0.04440909
block O 0 0.0008282361
of O 0 0.0006345961
accessory O 0 0.0013749707
pathway O 0 0.0008625075
after O 0 0.00038443223
catheter O 0 0.0025235347
ablation O 0 0.0026687954
, O 0 0.0016391423
established O 0 0.0027141126
frequent O 0 0.03423309
AVRT B-Disease 0 0.9963496
attack O 0 0.68852156
. O 0 0.008409947

Epidemic O 0 0.21185902
of O 0 0.006323305
liver B-Disease 2 0.9681027
disease I-Disease 2 0.9586584
caused O 0 0.004210099
by O 0 0.0026333241
hydrochlorofluorocarbons B-Chemical 0 0.7842195
used O 0 0.0019344285
as O 0 0.0018333643
ozone B-Chemical 0 0.9672523
- O 0 0.006992423
sparing O 0 0.15018047
substitutes O 0 0.021854948
of O 0 0.008061107
chlorofluorocarbons B-Chemical 0 0.9060189
. O 0 0.010588527

BACKGROUND O 0 0.83378106
: O 0 0.008579457
Hydrochlorofluorocarbons B-Chemical 0 0.4242043
( O 0 0.0045119254
HCFCs B-Chemical 0 0.71295047
) O 0 0.002428213
are O 0 0.00094025285
used O 0 0.0007226847
increasingly O 0 0.001233156
in O 0 0.00068572327
industry O 0 0.0046198755
as O 0 0.00068644586
substitutes O 0 0.0030729293
for O 0 0.0010759189
ozone B-Chemical 0 0.9723475
- O 0 0.005583793
depleting O 0 0.046453957
chlorofluorocarbons B-Chemical 0 0.95101386
( O 0 0.0100270035
CFCs B-Chemical 0 0.8578633
) O 0 0.0109959105
. O 0 0.0068951473

Limited O 0 0.03011029
studies O 0 0.004743439
in O 0 0.0023253008
animals O 0 0.0018175244
indicate O 0 0.0016302218
potential O 0 0.004694875
hepatotoxicity B-Disease 2 0.9993375
of O 0 0.0050712475
some O 0 0.004061194
of O 0 0.0049846717
these O 0 0.008820904
compounds O 0 0.7699815
. O 0 0.011301695

We O 0 0.0032149083
investigated O 0 0.002273339
an O 0 0.002268851
epidemic O 0 0.0065268483
of O 0 0.0020363727
liver B-Disease 2 0.97819114
disease I-Disease 2 0.96468914
in O 0 0.00080529973
nine O 0 0.00069888873
industrial O 0 0.062563084
workers O 0 0.0012456522
who O 0 0.0009841331
had O 0 0.000335614
had O 0 0.00030849333
repeated O 0 0.00034945508
accidental O 0 0.27572665
exposure O 0 0.0032758897
to O 0 0.00029795818
a O 0 0.00033529382
mixture O 0 0.001027041
of O 0 0.0005077718
1 B-Chemical 0 0.00043764114
, I-Chemical 0 0.00046332402
1 I-Chemical 0 0.00040386236
- I-Chemical 0 0.00075697765
dichloro I-Chemical 0 0.92347693
- I-Chemical 0 0.00085214275
2 I-Chemical 0 0.00031874166
, I-Chemical 0 0.0003418789
2 I-Chemical 0 0.0002668315
, I-Chemical 0 0.00033278693
2 I-Chemical 0 0.0003042267
- I-Chemical 0 0.0005398444
trifluoroethane I-Chemical 0 0.02550466
( O 0 0.00087790686
HCFC B-Chemical 0 0.99162966
123 I-Chemical 0 0.082034744
) O 0 0.0008511827
and O 0 0.00044423933
1 B-Chemical 0 0.00052336045
- I-Chemical 0 0.0010196203
chloro I-Chemical 0 0.9817254
- I-Chemical 0 0.0011706639
1 I-Chemical 0 0.0004516567
, I-Chemical 0 0.00047475361
2 I-Chemical 0 0.00039250846
, I-Chemical 0 0.00050545076
2 I-Chemical 0 0.0004771911
, I-Chemical 0 0.0006937809
2 I-Chemical 0 0.00079088536
- I-Chemical 0 0.0017868731
tetrafluoroethane I-Chemical 0 0.4804825
( O 0 0.004616121
HCFC B-Chemical 0 0.9876637
124 I-Chemical 0 0.12413916
) O 0 0.008944457
. O 0 0.006322595

All O 0 0.005965685
nine O 0 0.0046530827
exposed O 0 0.0045481944
workers O 0 0.0052667195
were O 0 0.0035030707
affected O 0 0.0034896333
to O 0 0.00463635
various O 0 0.010650732
degrees O 0 0.02766594
. O 0 0.014136775

Both O 0 0.006246265
compounds O 0 0.2711161
are O 0 0.0028959243
metabolised O 0 0.768953
in O 0 0.0010657714
the O 0 0.00069927255
same O 0 0.00042045116
way O 0 0.0008126244
as O 0 0.00056783523
1 B-Chemical 0 0.00084462145
- I-Chemical 0 0.0016826966
bromo I-Chemical 0 0.98978955
- I-Chemical 0 0.0019097149
1 I-Chemical 0 0.0006744671
- I-Chemical 0 0.0011577787
chloro I-Chemical 0 0.98425347
- I-Chemical 0 0.0011258229
2 I-Chemical 0 0.00037942763
, I-Chemical 0 0.00038963225
2 I-Chemical 0 0.0002941531
, I-Chemical 0 0.0003584809
2 I-Chemical 0 0.00031952266
- I-Chemical 0 0.0005521988
trifluoroethane I-Chemical 0 0.024328526
( O 0 0.00083948905
halothane B-Chemical 1 0.99870133
) O 0 0.0010875501
to O 0 0.00034072416
form O 0 0.00054705434
reactive O 0 0.35916683
trifluoroacetyl B-Chemical 0 0.9899003
halide O 0 0.9497227
intermediates O 0 0.16002245
, O 0 0.0010031321
which O 0 0.0007519986
have O 0 0.00065512105
been O 0 0.0009101836
implicated O 0 0.0011733806
in O 0 0.001224803
the O 0 0.0027715943
hepatotoxicity B-Disease 2 0.99956447
of O 0 0.042304985
halothane B-Chemical 1 0.9975151
. O 0 0.011361774

We O 0 0.0038227723
aimed O 0 0.0030500786
to O 0 0.0019959325
test O 0 0.0020479818
whether O 0 0.0012819982
HCFCs B-Chemical 0 0.47066903
123 I-Chemical 0 0.008013855
and I-Chemical 0 0.0016856679
124 I-Chemical 0 0.00418317
can O 0 0.0012231552
result O 0 0.00147493
in O 0 0.0024450584
serious O 0 0.3821776
liver B-Disease 2 0.98875964
disease I-Disease 2 0.9853195
. O 0 0.012901125

METHODS O 0 0.0065614604
: O 0 0.0031735545
For O 0 0.0012531189
one O 0 0.0010238601
severely O 0 0.0028780494
affected O 0 0.0008817107
worker O 0 0.0021396605
liver O 0 0.54675657
biopsy O 0 0.0058716172
and O 0 0.0007305796
immunohistochemical O 0 0.008063136
stainings O 0 0.004316071
for O 0 0.00056515716
the O 0 0.0006168316
presence O 0 0.0008038906
of O 0 0.0017036833
trifluoroacetyl B-Chemical 0 0.9569063
protein O 0 0.011488334
adducts O 0 0.5603763
were O 0 0.0041865
done O 0 0.004436641
. O 0 0.006432456

The O 0 0.003026344
serum O 0 0.009218529
of O 0 0.0018428189
six O 0 0.0008486579
affected O 0 0.00083993556
workers O 0 0.001209676
and O 0 0.0005912244
five O 0 0.00031528235
controls O 0 0.0005843884
was O 0 0.00034207874
tested O 0 0.00026620744
for O 0 0.00031834719
autoantibodies O 0 0.07758138
that O 0 0.00041662194
react O 0 0.0018352083
with O 0 0.0007523284
human O 0 0.002731768
liver O 0 0.9553294
cytochrome O 0 0.9983467
- O 0 0.03859051
P450 O 0 0.9994036
2E1 O 0 0.9998785
( O 0 0.045245618
P450 O 0 0.9993862
2E1 O 0 0.99984086
) O 0 0.0145872915
and O 0 0.0017084016
P58 O 0 0.5235687
protein O 0 0.008948672
disulphide O 0 0.9776678
isomerase O 0 0.9905263
isoform O 0 0.063017264
( O 0 0.00975067
P58 O 0 0.5945712
) O 0 0.011214064
. O 0 0.0072541465

FINDINGS O 0 0.07756173
: O 0 0.004578254
The O 0 0.0019205576
liver O 0 0.23649275
biopsy O 0 0.005481227
sample O 0 0.0013478157
showed O 0 0.0017811627
hepatocellular O 0 0.9997825
necrosis B-Disease 2 0.9995154
which O 0 0.0071239644
was O 0 0.00085408636
prominent O 0 0.0077662882
in O 0 0.00059673755
perivenular O 0 0.9858722
zone O 0 0.0033534833
three O 0 0.00019142126
and O 0 0.0003226865
extended O 0 0.0003487638
focally O 0 0.07284904
from O 0 0.0004852252
portal O 0 0.06623047
tracts O 0 0.0017210935
to O 0 0.000535538
portal O 0 0.09320046
tracts O 0 0.0034372462
and O 0 0.0014306662
centrilobular O 0 0.9948015
areas O 0 0.015352462
( O 0 0.0038025356
bridging O 0 0.061175566
necrosis B-Disease 2 0.99483716
) O 0 0.021419542
. O 0 0.0070041693

Trifluoroacetyl B-Chemical 0 0.820993
- O 0 0.011520018
adducted O 0 0.019079516
proteins O 0 0.00661048
were O 0 0.003931719
detected O 0 0.0031500629
in O 0 0.0049576326
surviving O 0 0.021259738
hepatocytes O 0 0.56827635
. O 0 0.014504283

Autoantibodies O 0 0.38490412
against O 0 0.0064565884
P450 O 0 0.9963833
2E1 O 0 0.9993513
or O 0 0.0048889536
P58 O 0 0.6910517
, O 0 0.00209395
previously O 0 0.00104703
associated O 0 0.0012845882
with O 0 0.0019025356
halothane B-Disease 1 0.9994617
hepatitis I-Disease 2 0.99986434
, O 0 0.00399559
were O 0 0.0007566116
detected O 0 0.00040395802
in O 0 0.00054627436
the O 0 0.0007368971
serum O 0 0.015600276
of O 0 0.0015792917
five O 0 0.0014128614
affected O 0 0.0027336704
workers O 0 0.008238662
. O 0 0.0065063257

INTERPRETATION O 0 0.08336016
: O 0 0.004550918
Repeated O 0 0.009287483
exposure O 0 0.0041251243
of O 0 0.0017109538
human O 0 0.002210366
beings O 0 0.0124219945
to O 0 0.0010265089
HCFCs B-Chemical 0 0.75713444
123 I-Chemical 0 0.008192403
and I-Chemical 0 0.0006510979
124 I-Chemical 0 0.0020669175
can O 0 0.00034964268
result O 0 0.0003565686
in O 0 0.00047213404
serious O 0 0.16199878
liver B-Disease 0 0.99126446
injury I-Disease 0 0.99150676
in O 0 0.0007068938
a O 0 0.00066884764
large O 0 0.0007394535
proportion O 0 0.0006109101
of O 0 0.001284453
the O 0 0.0016459187
exposed O 0 0.0032216788
population O 0 0.00617838
. O 0 0.0058531617

Although O 0 0.003277008
the O 0 0.0020554145
exact O 0 0.0030366122
mechanism O 0 0.0022075684
of O 0 0.0026741095
hepatotoxicity B-Disease 2 0.9997259
of O 0 0.0025789556
these O 0 0.0018267427
agents O 0 0.20294262
is O 0 0.00070700794
not O 0 0.00046262448
known O 0 0.00068800396
, O 0 0.0005225139
the O 0 0.00031672514
results O 0 0.00035444903
suggest O 0 0.00039493275
that O 0 0.0006544209
trifluoroacetyl B-Chemical 0 0.9562726
- O 0 0.0028737492
altered O 0 0.0029318333
liver O 0 0.8096972
proteins O 0 0.0058168704
are O 0 0.003355967
involved O 0 0.0046950597
. O 0 0.006081591

In O 0 0.0030530915
view O 0 0.0031285807
of O 0 0.0018773421
the O 0 0.0012828674
potentially O 0 0.0020465564
widespread O 0 0.0024231432
use O 0 0.0010638306
of O 0 0.0009740522
these O 0 0.0013208479
compounds O 0 0.5639648
, O 0 0.0011547882
there O 0 0.00046546658
is O 0 0.0006767458
an O 0 0.00091842684
urgent O 0 0.0017462748
need O 0 0.0008399167
to O 0 0.0011368617
develop O 0 0.0027067068
safer O 0 0.007850732
alternatives O 0 0.007697344
. O 0 0.0063133207

Bile B-Disease 0 0.9828468
duct I-Disease 0 0.87487924
hamartoma I-Disease 0 0.9765029
occurring O 0 0.0065799956
in O 0 0.0017680327
association O 0 0.0013370106
with O 0 0.0018052266
long O 0 0.0024123117
- O 0 0.0030264105
term O 0 0.002700814
treatment O 0 0.007353014
with O 0 0.010332091
danazol B-Chemical 1 0.9970325
. O 0 0.014566265

We O 0 0.0035351757
report O 0 0.004762926
a O 0 0.0022323404
case O 0 0.0017892605
of O 0 0.0024247377
bile B-Disease 0 0.963458
duct I-Disease 0 0.9495366
hamartoma I-Disease 0 0.9942127
which O 0 0.0020013284
developed O 0 0.0015041957
in O 0 0.0005187026
a O 0 0.0005944363
patient O 0 0.0009200677
who O 0 0.0012211511
had O 0 0.00064750714
been O 0 0.00076389255
on O 0 0.00048521944
long O 0 0.0014233413
- O 0 0.0024659375
term O 0 0.0035622246
danazol B-Chemical 1 0.99787986
treatment O 0 0.062025763
. O 0 0.008669339

Such O 0 0.0073824604
patients O 0 0.004795481
should O 0 0.001348678
be O 0 0.0012482699
under O 0 0.000690376
close O 0 0.00075642567
follow O 0 0.0009216317
- O 0 0.0013485368
up O 0 0.0007526141
, O 0 0.0008758544
preferably O 0 0.0011946071
with O 0 0.0010268658
periodic O 0 0.0046619726
ultrasound O 0 0.017132891
examination O 0 0.0032664433
of O 0 0.0032043974
the O 0 0.00467553
liver O 0 0.8340169
. O 0 0.009090736

If O 0 0.0026764402
the O 0 0.0020205756
patient O 0 0.0026084771
develops O 0 0.00490854
a O 0 0.0019386957
liver B-Disease 0 0.9360254
mass I-Disease 0 0.045367137
, O 0 0.0010002685
because O 0 0.0003743218
of O 0 0.00058921805
non O 0 0.001247201
- O 0 0.0007360647
specific O 0 0.0003534674
clinical O 0 0.0033581532
features O 0 0.0013998927
and O 0 0.00046076952
imaging O 0 0.0039120116
appearances O 0 0.004638754
, O 0 0.00061494176
biopsy O 0 0.002154029
may O 0 0.00043990955
be O 0 0.0004129416
the O 0 0.00036950543
only O 0 0.00049842615
way O 0 0.0007645481
to O 0 0.00072530523
achieve O 0 0.0009957422
a O 0 0.0019206592
definitive O 0 0.005096118
diagnosis O 0 0.031728413
. O 0 0.0068545756

Endocrine O 0 0.592282
screening O 0 0.0049972837
in O 0 0.002519078
1 O 0 0.0020935156
, O 0 0.0021846043
022 O 0 0.24461818
men O 0 0.025179256
with O 0 0.0020680826
erectile B-Disease 0 0.9973809
dysfunction I-Disease 0 0.9737626
: O 0 0.0024680616
clinical O 0 0.005509326
significance O 0 0.0019834756
and O 0 0.0015232096
cost O 0 0.0030065433
- O 0 0.0039159097
effective O 0 0.0045336606
strategy O 0 0.0068744277
. O 0 0.0070155575

PURPOSE O 0 0.041963503
: O 0 0.004088336
We O 0 0.0016819198
reviewed O 0 0.0023490328
the O 0 0.0010013054
results O 0 0.0008592681
of O 0 0.0013214074
serum O 0 0.22976288
testosterone B-Chemical 0 0.99881786
and O 0 0.0019893195
prolactin O 0 0.99082774
determination O 0 0.0056229047
in O 0 0.00048622733
1 O 0 0.00046110165
, O 0 0.00049732754
022 O 0 0.19892257
patients O 0 0.0008402385
referred O 0 0.00029349845
because O 0 0.00018447032
of O 0 0.00053769385
erectile B-Disease 0 0.9988387
dysfunction I-Disease 0 0.96560895
and O 0 0.0004348311
compared O 0 0.00015169909
the O 0 0.00018428871
data O 0 0.00026056802
with O 0 0.00031194685
history O 0 0.007350449
, O 0 0.00035916897
results O 0 0.00020314088
of O 0 0.00030795118
physical O 0 0.004743225
examination O 0 0.0008261899
, O 0 0.0003436633
other O 0 0.00025944383
etiological O 0 0.08012453
investigations O 0 0.0014118812
and O 0 0.00028976722
effects O 0 0.00059226836
of O 0 0.00045238438
endocrine O 0 0.89628917
therapy O 0 0.022466509
to O 0 0.0003170348
refine O 0 0.0012840054
the O 0 0.00023453486
rules O 0 0.00050928904
of O 0 0.00040101094
cost O 0 0.0008403691
- O 0 0.000753574
effective O 0 0.0006979436
endocrine O 0 0.7763059
screening O 0 0.00081345264
and O 0 0.0005065034
to O 0 0.00045526226
pinpoint O 0 0.0009739028
actual O 0 0.0007470605
responsibility O 0 0.0033855587
for O 0 0.0017661661
hormonal O 0 0.7031328
abnormalities O 0 0.5031611
. O 0 0.0068874652

MATERIALS O 0 0.027390307
AND O 0 0.010397598
METHODS O 0 0.008246789
: O 0 0.008212838
Testosterone B-Chemical 1 0.9937494
and O 0 0.0066468655
prolactin O 0 0.9463805
were O 0 0.004955789
determined O 0 0.0044006538
by O 0 0.008290266
radioimmunoassay O 0 0.48423517
. O 0 0.0142379105

Every O 0 0.0038669512
patient O 0 0.003094984
was O 0 0.0015827941
screened O 0 0.0014149217
for O 0 0.0011364158
testosterone B-Chemical 0 0.9951416
and O 0 0.0012982781
451 O 0 0.007874064
were O 0 0.00049600686
screened O 0 0.0005135015
for O 0 0.00041306167
prolactin O 0 0.9245051
on O 0 0.00024272758
the O 0 0.00028421023
basis O 0 0.00038671005
of O 0 0.00044662668
low B-Disease 0 0.0010443894
sexual I-Disease 0 0.12783861
desire I-Disease 0 0.06416649
, O 0 0.001755495
gynecomastia B-Disease 0 0.99848574
or O 0 0.0010130415
testosterone B-Chemical 0 0.99828607
less O 0 0.0009173969
than O 0 0.00053386326
4 O 0 0.0008104352
ng O 0 0.0025143994
. O 0 0.0012794702
/ O 0 0.0047582043
ml O 0 0.010000695
. O 0 0.0051160147

Determination O 0 0.013537064
was O 0 0.0040125963
repeated O 0 0.0032705208
in O 0 0.002973381
case O 0 0.0033634033
of O 0 0.004542313
abnormal O 0 0.016696945
first O 0 0.005609999
results O 0 0.008623074
. O 0 0.011112075

Prolactin O 0 0.9859292
results O 0 0.0027103955
were O 0 0.0015665817
compared O 0 0.0007498304
with O 0 0.0009253641
those O 0 0.0008591437
of O 0 0.00070204167
a O 0 0.0005881744
previous O 0 0.0005212601
personal O 0 0.0021344149
cohort O 0 0.0014243651
of O 0 0.00071332307
1 O 0 0.00061661913
, O 0 0.00065456313
340 O 0 0.0038143487
patients O 0 0.0015593665
with O 0 0.0014186731
erectile B-Disease 0 0.997741
dysfunction I-Disease 0 0.96539783
and O 0 0.0025553615
systematic O 0 0.00479223
prolactin O 0 0.9858424
determination O 0 0.033493053
. O 0 0.00768954

Main O 0 0.019885357
clinical O 0 0.00729274
criteria O 0 0.0026481042
tested O 0 0.0010943947
regarding O 0 0.00092019525
efficiency O 0 0.0011064352
in O 0 0.0009086564
hormone O 0 0.6956846
determination O 0 0.0033437838
were O 0 0.00093555165
low B-Disease 0 0.0017856488
sexual I-Disease 0 0.08338682
desire I-Disease 0 0.02553309
, O 0 0.002044489
small O 0 0.0024422153
testes O 0 0.011839947
and O 0 0.0061138477
gynecomastia B-Disease 0 0.99464744
. O 0 0.0101171555

Endocrine O 0 0.6558522
therapy O 0 0.019288724
consisted O 0 0.0026365973
of O 0 0.0035366437
testosterone B-Chemical 0 0.998279
heptylate I-Chemical 0 0.7613781
or O 0 0.0016673369
human O 0 0.004564222
chorionic O 0 0.991833
gonadotropin O 0 0.9977858
for O 0 0.0045963344
hypogonadism B-Disease 0 0.99915886
and O 0 0.015210248
bromocriptine B-Chemical 1 0.9994702
for O 0 0.021209337
hyperprolactinemia B-Disease 2 0.9991503
. O 0 0.014695774

RESULTS O 0 0.06291428
: O 0 0.008406174
Testosterone B-Chemical 1 0.9964168
was O 0 0.0020460268
less O 0 0.0012070591
than O 0 0.00064103224
3 O 0 0.0006314652
ng O 0 0.0014106567
. O 0 0.00043462924
/ O 0 0.0010402333
ml O 0 0.0014257854
. O 0 0.00027678945
in O 0 0.0003129877
107 O 0 0.0008218713
patients O 0 0.0009890774
but O 0 0.00045600085
normal O 0 0.00092198077
in O 0 0.0005687488
40 O 0 0.0009474421
% O 0 0.0009980188
at O 0 0.00085512665
repeat O 0 0.0030039889
determination O 0 0.009460558
. O 0 0.0060365684

The O 0 0.0027557188
prevalence O 0 0.003057587
of O 0 0.0019363151
repeatedly O 0 0.0021250844
low O 0 0.0022091812
testosterone B-Chemical 0 0.99705637
increased O 0 0.0028196184
with O 0 0.0012403015
age O 0 0.0022626314
( O 0 0.0008473069
4 O 0 0.0003641376
% O 0 0.00035158172
before O 0 0.00018677008
age O 0 0.00058900326
50 O 0 0.0005335301
years O 0 0.00066641194
and O 0 0.0004928596
9 O 0 0.0005693023
% O 0 0.0006683481
50 O 0 0.00097405916
years O 0 0.0015443343
or O 0 0.0014450528
older O 0 0.0061985566
) O 0 0.006507632
. O 0 0.0055777295

Two O 0 0.014738962
pituitary B-Disease 0 0.937218
tumors I-Disease 0 0.9478904
were O 0 0.0078450525
discovered O 0 0.010238889
after O 0 0.006974471
testosterone B-Chemical 0 0.9887298
determination O 0 0.0657982
. O 0 0.01743447

Most O 0 0.006483519
of O 0 0.002697465
the O 0 0.0016389505
other O 0 0.0014229151
low O 0 0.0021000279
testosterone B-Chemical 0 0.9972006
levels O 0 0.0012904179
seemed O 0 0.0010288713
to O 0 0.00045926432
result O 0 0.00040746844
from O 0 0.0005881246
nonorganic O 0 0.99740356
hypothalamic B-Disease 0 0.9963941
dysfunction I-Disease 0 0.9957676
because O 0 0.00040854557
of O 0 0.0006299362
normal O 0 0.0026186898
serum O 0 0.28549442
luteinizing O 0 0.9883554
hormone O 0 0.97928864
and O 0 0.0011165491
prolactin O 0 0.99024135
and O 0 0.00042162713
to O 0 0.0002513183
have O 0 0.00025743782
only O 0 0.00023630698
a O 0 0.00025947945
small O 0 0.00029059552
role O 0 0.00019844154
in O 0 0.0003784582
erectile B-Disease 0 0.99883467
dysfunction I-Disease 0 0.98292303
( O 0 0.0009904841
definite O 0 0.01482942
improvement O 0 0.00057816145
in O 0 0.00021099388
only O 0 0.00022417214
16 O 0 0.00023850235
of O 0 0.00028259936
44 O 0 0.00054262107
[ O 0 0.00059492426
36 O 0 0.00027805642
% O 0 0.00027643843
] O 0 0.00040719894
after O 0 0.00015474184
androgen O 0 0.99285805
therapy O 0 0.024055094
, O 0 0.00048923
normal O 0 0.0006618614
morning O 0 0.0014459256
or O 0 0.000292675
nocturnal O 0 0.20843963
erections O 0 0.88379294
in O 0 0.0003256807
30 O 0 0.00032282004
% O 0 0.000376187
and O 0 0.00042192586
definite O 0 0.011283917
vasculogenic O 0 0.8956618
contributions O 0 0.0017785201
in O 0 0.0015594512
42 O 0 0.0033948193
% O 0 0.0033768546
) O 0 0.0055918735
. O 0 0.0050922944

Determining O 0 0.010170147
testosterone B-Chemical 0 0.99078757
only O 0 0.002433596
in O 0 0.0012133006
cases O 0 0.0015373982
of O 0 0.0010062439
low B-Disease 0 0.0014734882
sexual I-Disease 0 0.0712827
desire I-Disease 0 0.016058777
or O 0 0.0004700188
abnormal O 0 0.0052132914
physical O 0 0.0050744247
examination O 0 0.0007884011
would O 0 0.00023504415
have O 0 0.00028085907
missed O 0 0.00057384244
40 O 0 0.00035492005
% O 0 0.0002427033
of O 0 0.00023455275
the O 0 0.000216644
cases O 0 0.0005222873
with O 0 0.00040986098
low O 0 0.00087173976
testosterone B-Chemical 0 0.99882334
, O 0 0.00074657524
including O 0 0.0004298867
37 O 0 0.00066089514
% O 0 0.0004288723
of O 0 0.00048680356
those O 0 0.00078143866
subsequently O 0 0.0012683783
improved O 0 0.0027040406
by O 0 0.0029899292
androgen O 0 0.99540234
therapy O 0 0.2948296
. O 0 0.007758638

Prolactin O 0 0.9829943
exceeded O 0 0.0034419699
20 O 0 0.0026087025
ng O 0 0.003587724
. O 0 0.0010631315
/ O 0 0.00192317
ml O 0 0.002337661
. O 0 0.0004987931
in O 0 0.0004923262
5 O 0 0.00050492084
men O 0 0.0036189782
and O 0 0.0006334909
was O 0 0.00063243276
normal O 0 0.00125936
in O 0 0.0008284461
2 O 0 0.0011157293
at O 0 0.0010357212
repeat O 0 0.0034224454
determination O 0 0.01028399
. O 0 0.006477274

Only O 0 0.024158506
1 O 0 0.02080577
prolactinoma B-Disease 2 0.98234737
was O 0 0.022110969
discovered O 0 0.032090634
. O 0 0.024982302

These O 0 0.0042069554
data O 0 0.002645716
are O 0 0.0015660289
lower O 0 0.0010766346
than O 0 0.0006010784
those O 0 0.0007267624
we O 0 0.00030338875
found O 0 0.00038068625
during O 0 0.0002595257
the O 0 0.0002945238
last O 0 0.00025064946
2 O 0 0.00032467162
decades O 0 0.0010215782
( O 0 0.00049393985
overall O 0 0.00040401562
prolactin O 0 0.9271011
greater O 0 0.00031889853
than O 0 0.00017671681
20 O 0 0.0003060385
ng O 0 0.0007219204
. O 0 0.00018550198
/ O 0 0.00058552535
ml O 0 0.0009837919
. O 0 0.0001510055
in O 0 0.00018982778
1 O 0 0.00023643611
. O 0 0.00013274567
86 O 0 0.00035375595
% O 0 0.00023508626
of O 0 0.00028263
1 O 0 0.00033134338
, O 0 0.00042107143
821 O 0 0.00783792
patients O 0 0.0015963052
, O 0 0.00096213963
prolactinomas B-Disease 0 0.9970221
in O 0 0.0006741375
7 O 0 0.00066082395
, O 0 0.00091233815
0 O 0 0.00097641966
. O 0 0.0007714678
38 O 0 0.0024795495
% O 0 0.0027392244
) O 0 0.0049580866
. O 0 0.004846334

Bromocriptine B-Chemical 0 0.99708587
was O 0 0.004413097
definitely O 0 0.007825028
effective O 0 0.0026755799
in O 0 0.0013180143
cases O 0 0.0022557548
with O 0 0.0019159409
prolactin O 0 0.9558706
greater O 0 0.001466385
than O 0 0.0009869058
35 O 0 0.0018359771
ng O 0 0.0038733338
. O 0 0.0019758458
/ O 0 0.0064754183
ml O 0 0.012586109
. O 0 0.006607469

( O 0 0.005171999
8 O 0 0.0019732097
of O 0 0.0015106343
12 O 0 0.0008254081
compared O 0 0.00047998328
to O 0 0.0005428091
only O 0 0.000525389
9 O 0 0.00045740005
of O 0 0.00048673816
22 O 0 0.0006280659
cases O 0 0.0007583502
with O 0 0.00071568653
prolactin O 0 0.94520324
between O 0 0.0003327124
20 O 0 0.00056545244
and O 0 0.0005394136
35 O 0 0.00078841345
ng O 0 0.0017157446
. O 0 0.0007822411
/ O 0 0.002711994
ml O 0 0.005121236
. O 0 0.0020820987
) O 0 0.0057969587
. O 0 0.005200512

Testosterone B-Chemical 1 0.9961487
was O 0 0.003465845
low O 0 0.002268864
in O 0 0.0011953115
less O 0 0.0010010387
than O 0 0.0005704551
50 O 0 0.0009307008
% O 0 0.00061815995
of O 0 0.0006042081
cases O 0 0.0011461906
with O 0 0.0010984172
prolactin O 0 0.9562731
greater O 0 0.00096466794
than O 0 0.0006854724
35 O 0 0.0013835935
ng O 0 0.0030991915
. O 0 0.0015813571
/ O 0 0.005542369
ml O 0 0.0112281805
. O 0 0.0057857106

CONCLUSIONS O 0 0.739685
: O 0 0.0057712295
Low O 0 0.013399448
prevalences O 0 0.004763559
and O 0 0.001491028
effects O 0 0.001782579
of O 0 0.0012709383
low O 0 0.0019493018
testosterone B-Chemical 0 0.9978808
and O 0 0.0014514867
high O 0 0.001998809
prolactin O 0 0.9894656
in O 0 0.0017654399
erectile B-Disease 0 0.9980494
dysfunction I-Disease 0 0.9741683
cannot O 0 0.016998643
justify O 0 0.0031137988
their O 0 0.0024273032
routine O 0 0.004108955
determination O 0 0.012585128
. O 0 0.0072336737

However O 0 0.004554842
, O 0 0.003315339
cost O 0 0.0029883236
- O 0 0.0021809018
effective O 0 0.0013754561
screening O 0 0.001047914
strategies O 0 0.0009789637
recommended O 0 0.0007378894
so O 0 0.00043502095
far O 0 0.00040186397
missed O 0 0.00074275525
40 O 0 0.00046461393
to O 0 0.00030379224
50 O 0 0.0004945007
% O 0 0.00033057886
of O 0 0.0003526699
cases O 0 0.0007042277
improved O 0 0.0010961709
with O 0 0.0010440805
endocrine O 0 0.9046309
therapy O 0 0.06971936
and O 0 0.002327964
the O 0 0.0034605942
pituitary B-Disease 0 0.9907197
tumors I-Disease 0 0.98906696
. O 0 0.009559851

We O 0 0.0031581766
now O 0 0.0025171177
advocate O 0 0.0027363978
that O 0 0.0010137588
before O 0 0.0006310218
age O 0 0.001417792
50 O 0 0.0010502267
years O 0 0.0014154507
testosterone B-Chemical 0 0.9956637
be O 0 0.00057833566
determined O 0 0.00027579218
only O 0 0.0003132841
in O 0 0.00025275745
cases O 0 0.0005189172
of O 0 0.00039384674
low B-Disease 0 0.00082722027
sexual I-Disease 0 0.06947103
desire I-Disease 0 0.016301109
and O 0 0.00040402674
abnormal O 0 0.006826825
physical O 0 0.0062667537
examination O 0 0.00089079526
but O 0 0.00030682932
that O 0 0.00024500996
it O 0 0.00036411852
be O 0 0.00032468152
measured O 0 0.00025717705
in O 0 0.00037831496
all O 0 0.00056761294
men O 0 0.015959952
older O 0 0.0026528232
than O 0 0.0010784228
50 O 0 0.0031139217
years O 0 0.0054175677
. O 0 0.004710199

Prolactin O 0 0.9866736
should O 0 0.0023075389
be O 0 0.0016975307
determined O 0 0.0008736323
only O 0 0.0008532737
in O 0 0.00063517544
cases O 0 0.0010362827
of O 0 0.0007795714
low B-Disease 0 0.0013968532
sexual I-Disease 0 0.1267479
desire I-Disease 0 0.06461431
, O 0 0.0019195644
gynecomastia B-Disease 0 0.9982095
and O 0 0.0011412725
/ O 0 0.0020801832
or O 0 0.0006889602
testosterone B-Chemical 0 0.9970163
less O 0 0.00088306266
than O 0 0.00054576487
4 O 0 0.000837777
ng O 0 0.0025771728
. O 0 0.0013345769
/ O 0 0.004903679
ml O 0 0.010224446
. O 0 0.005265728

Extrapyramidal O 0 0.9926559
side O 0 0.051282685
effects O 0 0.006089724
with O 0 0.00478447
risperidone B-Chemical 0 0.9996182
and O 0 0.007760804
haloperidol B-Chemical 1 0.99978286
at O 0 0.0018200229
comparable O 0 0.0021679858
D2 O 0 0.9779193
receptor O 0 0.29215103
occupancy O 0 0.011092635
levels O 0 0.007527804
. O 0 0.008191613

Risperidone B-Chemical 1 0.9985875
is O 0 0.004562494
an O 0 0.0038552615
antipsychotic O 0 0.9971162
drug O 0 0.534552
with O 0 0.0017483516
high O 0 0.0016977878
affinity O 0 0.0036785332
at O 0 0.0012900506
dopamine B-Chemical 1 0.99877185
D2 O 0 0.99329835
and O 0 0.0042771427
serotonin B-Chemical 1 0.99721694
5 I-Chemical 0 0.0034620776
- I-Chemical 0 0.007498996
HT2 I-Chemical 0 0.9306723
receptors O 0 0.45116812
. O 0 0.009516525

Previous O 0 0.004081246
clinical O 0 0.0061106784
studies O 0 0.0024234946
have O 0 0.0014484698
proposed O 0 0.0016318534
that O 0 0.0011847132
risperidone B-Chemical 0 0.9996834
' O 0 0.0012457549
s O 0 0.00077958143
pharmacologic O 0 0.083314136
profile O 0 0.00069848495
may O 0 0.00035235946
produce O 0 0.00027712746
improved O 0 0.000735909
efficacy O 0 0.0018534008
for O 0 0.00029021647
negative O 0 0.0008466367
psychotic B-Disease 0 0.99989367
symptoms I-Disease 0 0.94827354
and O 0 0.000523245
decreased O 0 0.001068128
propensity O 0 0.0033313292
for O 0 0.00047294007
extrapyramidal O 0 0.99983215
side O 0 0.079857446
effects O 0 0.0034895206
; O 0 0.0009446997
features O 0 0.0012336816
shared O 0 0.0006124107
by O 0 0.00057087716
so O 0 0.00069315505
- O 0 0.0014262341
called O 0 0.0013921798
' O 0 0.0019509381
atypical O 0 0.20747821
' O 0 0.007569156
neuroleptics O 0 0.9971455
. O 0 0.008308217

To O 0 0.0023821318
determine O 0 0.001052899
if O 0 0.001005322
routine O 0 0.0018419507
risperidone B-Chemical 0 0.99955946
treatment O 0 0.005935735
is O 0 0.0007539809
associated O 0 0.00074817555
with O 0 0.0005687017
a O 0 0.00045452575
unique O 0 0.0005076412
degree O 0 0.0005489034
of O 0 0.0008338026
D2 O 0 0.9899927
receptor O 0 0.20039016
occupancy O 0 0.0016031084
and O 0 0.00034706295
pattern O 0 0.00026343518
of O 0 0.00035391754
clinical O 0 0.0067093684
effects O 0 0.0011153813
, O 0 0.00040150154
we O 0 0.00014989384
used O 0 0.0003521966
[ O 0 0.0020173842
123I O 0 0.96651244
] O 0 0.0060352464
IBZM O 0 0.998793
SPECT O 0 0.94261736
to O 0 0.00033833776
determine O 0 0.00017760656
D2 O 0 0.92388815
occupancy O 0 0.00081505714
in O 0 0.00024100106
subjects O 0 0.00046570846
treated O 0 0.0004282315
with O 0 0.0002918928
routine O 0 0.00037819144
clinical O 0 0.0060440577
doses O 0 0.03798441
of O 0 0.0017932394
risperidone B-Chemical 0 0.999918
( O 0 0.0013088059
n O 0 0.00042963578
= O 0 0.0006104588
12 O 0 0.00031695832
) O 0 0.0007310462
or O 0 0.00076450943
haloperidol B-Chemical 1 0.9997936
( O 0 0.0023785287
n O 0 0.0014887601
= O 0 0.0026580426
7 O 0 0.0021501817
) O 0 0.0048001693
. O 0 0.004593615

Both O 0 0.009279101
risperidone B-Chemical 0 0.9989808
and O 0 0.0070749843
haloperidol B-Chemical 1 0.99974734
produced O 0 0.0041446416
D2 O 0 0.9853076
occupancy O 0 0.002527715
levels O 0 0.00072495383
between O 0 0.00034943843
approximately O 0 0.00058800826
60 O 0 0.0006239417
and O 0 0.0005615591
90 O 0 0.0007203161
% O 0 0.0007801856
at O 0 0.0006138818
standard O 0 0.001291583
clinical O 0 0.010205171
doses O 0 0.08211869
. O 0 0.007196431

There O 0 0.0057934364
was O 0 0.0025659562
no O 0 0.0015373733
significant O 0 0.0017021884
difference O 0 0.00090830104
between O 0 0.0007963424
occupancy O 0 0.0019445672
levels O 0 0.0014566205
obtained O 0 0.0019386607
with O 0 0.005578611
haloperidol B-Chemical 1 0.9996457
or O 0 0.020033816
risperidone B-Chemical 0 0.99917895
. O 0 0.013123246

Drug B-Disease 0 0.9600274
- I-Disease 0 0.00810648
induced I-Disease 0 0.0058076754
parkinsonism I-Disease 2 0.9993135
was O 0 0.0016977822
observed O 0 0.00067201804
in O 0 0.0005401699
subjects O 0 0.00094497507
treated O 0 0.0010750622
with O 0 0.0012853863
risperidone B-Chemical 0 0.99987054
( O 0 0.001450079
42 O 0 0.0008177941
% O 0 0.00048270935
) O 0 0.0005991026
and O 0 0.0005803068
haloperidol B-Chemical 1 0.9999095
( O 0 0.0012073001
29 O 0 0.0009818733
% O 0 0.0004275501
) O 0 0.00047858251
and O 0 0.00032580897
was O 0 0.00033370068
observed O 0 0.00031136477
at O 0 0.00036631286
occupancy O 0 0.0011653912
levels O 0 0.0010792816
above O 0 0.0012602565
60 O 0 0.0029484534
% O 0 0.0040369234
. O 0 0.004458009

Based O 0 0.008706168
on O 0 0.0017290447
these O 0 0.002163516
observations O 0 0.0021622446
, O 0 0.001632562
it O 0 0.0010257995
is O 0 0.00069666136
concluded O 0 0.0009982986
that O 0 0.0004783226
5 O 0 0.000527745
- O 0 0.0010172932
HT2 O 0 0.8629946
blockade O 0 0.22080043
obtained O 0 0.00057796977
with O 0 0.0011767098
risperidone B-Chemical 0 0.999894
at O 0 0.00044976067
D2 O 0 0.97280574
occupancy O 0 0.000918334
rates O 0 0.0003039119
of O 0 0.00037048262
60 O 0 0.00037809578
% O 0 0.00027385712
and O 0 0.00021694392
above O 0 0.00016683928
does O 0 0.00021449408
not O 0 0.00024761359
appear O 0 0.0003371401
to O 0 0.0003228308
protect O 0 0.0010364822
against O 0 0.0005403864
the O 0 0.0007793315
risk O 0 0.031903803
for O 0 0.0023755492
extrapyramidal O 0 0.99944717
side O 0 0.29494518
effects O 0 0.025847493
. O 0 0.006895431

Treatment O 0 0.024833921
of O 0 0.0032209621
previously O 0 0.0021935438
treated O 0 0.003913855
metastatic O 0 0.9810814
breast B-Disease 2 0.99727374
cancer I-Disease 2 0.99898213
by O 0 0.0048021306
mitoxantrone B-Chemical 1 0.99928135
and O 0 0.0010554846
48 O 0 0.0005502266
- O 0 0.00044143022
hour O 0 0.0002039819
continuous O 0 0.00026878633
infusion O 0 0.006337942
of O 0 0.0003810637
high O 0 0.0006373819
- O 0 0.0007793813
dose O 0 0.008926347
5 B-Chemical 0 0.00035665598
- I-Chemical 0 0.0006514384
FU I-Chemical 0 0.5014007
and O 0 0.00070550677
leucovorin B-Chemical 0 0.99965477
( O 0 0.0022274028
MFL B-Chemical 0 0.95670384
) O 0 0.0012734794
: O 0 0.00060221745
low O 0 0.00048359012
palliative O 0 0.001214664
benefit O 0 0.0012269445
and O 0 0.0007303398
high O 0 0.0013539146
treatment O 0 0.0044231275
- O 0 0.003986643
related O 0 0.0032596875
toxicity B-Disease 2 0.98709667
. O 0 0.0076411837

For O 0 0.003252864
previously O 0 0.0027835658
treated O 0 0.003933333
advanced O 0 0.16921444
breast B-Disease 2 0.9949944
cancer I-Disease 2 0.99815035
, O 0 0.0036139607
there O 0 0.00088405097
is O 0 0.0010002776
no O 0 0.0007704863
standard O 0 0.0009935435
second O 0 0.001784495
- O 0 0.0038929307
line O 0 0.005463904
therapy O 0 0.056417648
. O 0 0.007935753

Combination O 0 0.43229592
chemotherapy O 0 0.7731017
with O 0 0.0053649675
mitoxantrone B-Chemical 1 0.9981658
, O 0 0.0030964173
high O 0 0.0019456206
- O 0 0.0018544171
dose O 0 0.01412495
5 B-Chemical 0 0.00073554966
- I-Chemical 0 0.0013971465
fluorouracil I-Chemical 0 0.99827003
( O 0 0.0011596406
5 B-Chemical 0 0.00045304664
- I-Chemical 0 0.0007955123
FU I-Chemical 0 0.5507387
) O 0 0.00084311294
and O 0 0.0005953429
leucovorin B-Chemical 0 0.99957556
( O 0 0.0017761277
MFL B-Chemical 0 0.9843284
regimen I-Chemical 0 0.121182546
) O 0 0.0009623619
had O 0 0.00043976994
been O 0 0.0005140604
reported O 0 0.0006299207
as O 0 0.00038298898
an O 0 0.0007302044
effective O 0 0.0010919435
and O 0 0.0011027956
well O 0 0.0014819234
tolerated O 0 0.047001928
regimen O 0 0.046670508
. O 0 0.005825806

From O 0 0.0054243444
October O 0 0.00340897
1993 O 0 0.0048773037
to O 0 0.0014215688
November O 0 0.0015606127
1995 O 0 0.0032292907
, O 0 0.00081349135
we O 0 0.00030954747
treated O 0 0.00075264246
13 O 0 0.0005472443
patients O 0 0.00092105963
with O 0 0.000488998
previously O 0 0.00054627773
chemotherapy O 0 0.77748704
- O 0 0.0014233997
treated O 0 0.0019602757
metastatic O 0 0.98791015
breast B-Disease 2 0.9987054
cancer I-Disease 2 0.99950063
by O 0 0.0047009196
mitoxantrone B-Chemical 1 0.9996158
, O 0 0.0010922155
12 O 0 0.00029485452
mg O 0 0.28760096
/ O 0 0.0009442743
m2 O 0 0.017983396
, O 0 0.00027229683
on O 0 0.00010179093
day O 0 0.0001689254
1 O 0 0.00016737593
and O 0 0.00015027309
continuous O 0 0.00020648802
infusion O 0 0.0050245365
of O 0 0.00035600952
5 B-Chemical 0 0.00029868286
- I-Chemical 0 0.00056256726
FU I-Chemical 0 0.45085484
, O 0 0.00042123586
3000 O 0 0.0010683937
mg O 0 0.24756254
/ O 0 0.0009485056
m2 O 0 0.018158255
, O 0 0.000345921
together O 0 0.00025635032
with O 0 0.0005884918
leucovorin B-Chemical 0 0.9995591
, O 0 0.000903115
300 O 0 0.0036163807
mg O 0 0.37335798
/ O 0 0.0012312937
m2 O 0 0.014619455
, O 0 0.0004565852
for O 0 0.00029157515
48 O 0 0.00043929188
h O 0 0.000495509
from O 0 0.0005799366
day O 0 0.0009378078
1 O 0 0.0013754606
to O 0 0.0018162522
2 O 0 0.003401062
. O 0 0.0042963265

Each O 0 0.0037395537
course O 0 0.004879597
of O 0 0.0046428484
chemotherapy O 0 0.44055012
was O 0 0.0035620232
given O 0 0.0026001167
every O 0 0.0024897747
4 O 0 0.0039379126
weeks O 0 0.005909393
. O 0 0.007936575

Most O 0 0.0069875377
of O 0 0.0030031563
these O 0 0.0026126113
patients O 0 0.0034151396
had O 0 0.0014344616
more O 0 0.0014035205
than O 0 0.0007388765
two O 0 0.00093572406
metastatic O 0 0.7333933
sites O 0 0.0018884185
, O 0 0.0024519102
with O 0 0.0033987355
lung O 0 0.76367325
metastasis O 0 0.9972574
predominant O 0 0.038719554
. O 0 0.009530008

Seven O 0 0.017744383
patients O 0 0.011944194
had O 0 0.0071866764
been O 0 0.008316525
treated O 0 0.012511639
with O 0 0.018244369
anthracycline B-Chemical 1 0.9935368
. O 0 0.025873853

Seven O 0 0.009348587
patients O 0 0.0053831125
had O 0 0.0024022416
previously O 0 0.0019498123
received O 0 0.0024424281
radiotherapy O 0 0.3362408
and O 0 0.0022618137
seven O 0 0.0019191571
had O 0 0.0026376157
received O 0 0.0057265097
hormone O 0 0.92806625
therapy O 0 0.22868118
. O 0 0.011318565

Median O 0 0.00389501
number O 0 0.001718082
of O 0 0.0016738789
courses O 0 0.0024212052
of O 0 0.0017174343
MFL B-Chemical 0 0.95396256
regimen I-Chemical 0 0.054720577
given O 0 0.00054941693
was O 0 0.00046023456
six O 0 0.0002664324
and O 0 0.00037266256
the O 0 0.00030124583
median O 0 0.00033985617
cumulative O 0 0.0010637803
dose O 0 0.009050763
of O 0 0.001278378
mitoxantrone B-Chemical 1 0.99868935
was O 0 0.001189915
68 O 0 0.0017571787
. O 0 0.0006882046
35 O 0 0.0016844718
mg O 0 0.23121268
/ O 0 0.0068869274
m2 O 0 0.056204673
. O 0 0.005832826

One O 0 0.0046501504
patient O 0 0.0031022043
had O 0 0.0016489383
complete O 0 0.0012601124
response O 0 0.0015804418
, O 0 0.0010370244
seven O 0 0.0005906108
had O 0 0.00063156115
stable O 0 0.0010837787
disease O 0 0.47218758
, O 0 0.0009849821
none O 0 0.0007608834
had O 0 0.0006266876
partial O 0 0.001274563
response O 0 0.0012101049
and O 0 0.0009649217
five O 0 0.00091467856
had O 0 0.0025278495
progressive O 0 0.6024272
disease O 0 0.900441
. O 0 0.00904095

The O 0 0.0043924577
overall O 0 0.003981455
objective O 0 0.0049652997
response O 0 0.0038659812
rate O 0 0.0029294228
was O 0 0.0032440296
7 O 0 0.0031936807
. O 0 0.00281555
6 O 0 0.003913268
% O 0 0.0068048565
. O 0 0.0075646434

The O 0 0.00488389
median O 0 0.004018911
follow O 0 0.003998812
- O 0 0.004995283
up O 0 0.0032420196
period O 0 0.0034741573
was O 0 0.0042583058
14 O 0 0.0060081333
months O 0 0.007663542
. O 0 0.00914684

Median O 0 0.020686036
survival O 0 0.037270106
was O 0 0.014797568
16 O 0 0.016782666
months O 0 0.018520396
. O 0 0.02072629

Median O 0 0.012223356
progression O 0 0.17731865
- O 0 0.009961456
free O 0 0.008451523
survival O 0 0.03254035
was O 0 0.0066483896
5 O 0 0.0063999956
months O 0 0.009015294
. O 0 0.010482996

A O 0 0.015711516
complete O 0 0.00409189
responder O 0 0.01391434
had O 0 0.004162849
relapse O 0 0.8965679
- O 0 0.0054395637
free O 0 0.0043146983
survival O 0 0.024255099
up O 0 0.0031284809
to O 0 0.0032908372
17 O 0 0.0058496166
months O 0 0.006355061
. O 0 0.007352324

Major O 0 0.080868386
toxicities B-Disease 2 0.9865187
were O 0 0.02755534
cardiotoxicity B-Disease 0 0.99760866
and O 0 0.077404566
leukopenia B-Disease 0 0.9959728
. O 0 0.031039095

Eight O 0 0.007541935
patients O 0 0.0046485197
were O 0 0.001828794
dead O 0 0.0024401858
in O 0 0.00092914107
the O 0 0.00074116787
last O 0 0.000574029
follow O 0 0.0008001473
- O 0 0.0011654422
up O 0 0.00064820424
; O 0 0.0008262383
two O 0 0.0003740756
of O 0 0.0007311283
them O 0 0.0013432417
died O 0 0.007553061
of O 0 0.0017692558
treatment O 0 0.00713663
- O 0 0.005175066
related O 0 0.0039215344
toxicity B-Disease 2 0.9874544
. O 0 0.008546391

The O 0 0.004176485
MFL B-Chemical 0 0.7797123
regimen I-Chemical 0 0.029873231
achieves O 0 0.0023466817
little O 0 0.0015719936
palliative O 0 0.00337496
benefit O 0 0.0028282488
and O 0 0.0014516561
induces O 0 0.002213138
severe O 0 0.45035365
toxicity B-Disease 2 0.9930936
at O 0 0.0013242944
a O 0 0.0020894452
fairly O 0 0.00426571
high O 0 0.004261586
rate O 0 0.0052436874
. O 0 0.0069420165

Administration O 0 0.13256659
of O 0 0.0029670408
this O 0 0.0017715778
regimen O 0 0.0069022826
to O 0 0.0015533852
breast B-Disease 2 0.99032974
cancer I-Disease 2 0.998276
patients O 0 0.025952123
who O 0 0.002789815
have O 0 0.0006519544
been O 0 0.0006436059
treated O 0 0.00084083807
by O 0 0.00058086304
chemotherapy O 0 0.57072604
and O 0 0.0006924222
those O 0 0.0008054974
with O 0 0.0008349024
impaired B-Disease 0 0.0035988751
heart I-Disease 0 0.3118235
function I-Disease 0 0.002309563
requires O 0 0.001518128
careful O 0 0.0056730947
attention O 0 0.012304888
. O 0 0.0058890777

Ticlopidine B-Chemical 0 0.9976821
- O 0 0.017234918
induced O 0 0.015039796
aplastic B-Disease 2 0.99947673
anemia I-Disease 2 0.99967194
: O 0 0.0068907533
report O 0 0.0036130166
of O 0 0.0012659089
three O 0 0.00073484797
Chinese O 0 0.026347956
patients O 0 0.0032151071
and O 0 0.0017050859
review O 0 0.0037431102
of O 0 0.0028919918
the O 0 0.0037139037
literature O 0 0.010884761
. O 0 0.007423217

In O 0 0.0028007885
this O 0 0.0019131309
study O 0 0.0021518366
, O 0 0.0014667362
three O 0 0.00065820164
Chinese O 0 0.017626388
patients O 0 0.0033774227
with O 0 0.0021519256
ticlopidine B-Chemical 1 0.9998247
- O 0 0.014172993
induced O 0 0.011238471
aplastic B-Disease 2 0.9998754
anemia I-Disease 2 0.9998946
were O 0 0.0015991667
reported O 0 0.0010959201
and O 0 0.0005364867
another O 0 0.00058991654
13 O 0 0.00065553945
patients O 0 0.0011664135
in O 0 0.0006043478
the O 0 0.0009241033
English O 0 0.0039501204
literature O 0 0.0030544943
were O 0 0.002648864
reviewed O 0 0.008088935
. O 0 0.0060520293

We O 0 0.0032692822
attempted O 0 0.0029886046
to O 0 0.0015543938
find O 0 0.0012471147
underlying O 0 0.0019758681
similarities O 0 0.0011813944
, O 0 0.0008872661
evaluate O 0 0.0003886459
the O 0 0.0005814783
risk O 0 0.009886519
factors O 0 0.0029883347
, O 0 0.0009433171
and O 0 0.00062593166
identify O 0 0.0005533849
appropriate O 0 0.00073869637
treatment O 0 0.0021741446
for O 0 0.0015633613
this O 0 0.0033404354
complication O 0 0.4637348
. O 0 0.007296427

All O 0 0.003580765
but O 0 0.0020711788
one O 0 0.00110365
of O 0 0.0012641058
the O 0 0.000926304
patients O 0 0.0016735387
were O 0 0.0005825823
over O 0 0.00031473546
60 O 0 0.0005412058
years O 0 0.000735916
old O 0 0.00055968453
, O 0 0.0005275493
and O 0 0.00043179918
the O 0 0.0004230761
6 O 0 0.00042079377
who O 0 0.0011413877
died O 0 0.003291535
were O 0 0.00086729316
all O 0 0.0010531181
older O 0 0.003601924
than O 0 0.0018461708
65 O 0 0.005034508
. O 0 0.0049931314

Therefore O 0 0.004589396
, O 0 0.003967701
old O 0 0.0028064675
age O 0 0.0031976115
may O 0 0.0017580354
be O 0 0.0016091465
a O 0 0.0017927941
risk O 0 0.013263206
factor O 0 0.0069132242
for O 0 0.00233356
developing O 0 0.00963297
this O 0 0.0056399084
complication O 0 0.5663631
. O 0 0.0097447

Agranulocytosis B-Disease 0 0.9969722
occurred O 0 0.004738593
3 O 0 0.0018586215
- O 0 0.0016308718
20 O 0 0.0007734668
weeks O 0 0.0005102096
after O 0 0.00031778254
initiation O 0 0.0006491591
of O 0 0.0009766592
ticlopidine B-Chemical 1 0.99973315
, O 0 0.0011909107
so O 0 0.00049358053
frequent O 0 0.0016127126
examination O 0 0.001055741
of O 0 0.00083915045
white O 0 0.002974809
cell O 0 0.0042980327
count O 0 0.0022417384
during O 0 0.00097633316
treatment O 0 0.0038121953
is O 0 0.0030009525
recommended O 0 0.0055203415
. O 0 0.005572897

There O 0 0.005723893
seemed O 0 0.0032480345
to O 0 0.0016913457
be O 0 0.0012686743
no O 0 0.0006690631
direct O 0 0.00065053336
correlation O 0 0.0004517025
between O 0 0.0003583326
the O 0 0.0005206669
dose O 0 0.0038418777
or O 0 0.0004969448
duration O 0 0.0008175767
used O 0 0.00059665286
and O 0 0.0007706691
the O 0 0.00093932525
severity O 0 0.013320629
of O 0 0.003383645
bone B-Disease 0 0.5016861
marrow I-Disease 0 0.92833614
suppression I-Disease 0 0.33937955
. O 0 0.008643107

Treatment O 0 0.06256755
for O 0 0.005112291
ticlopidine B-Chemical 1 0.9992269
- O 0 0.018779857
induced O 0 0.016363107
aplastic B-Disease 2 0.9997216
anemia I-Disease 2 0.9998092
with O 0 0.01317474
colony O 0 0.11265936
- O 0 0.0029574751
stimulating O 0 0.0024157637
factors O 0 0.0033904908
seemed O 0 0.001727916
to O 0 0.0012424423
have O 0 0.0018780268
little O 0 0.0031469287
effect O 0 0.005694816
. O 0 0.006717848

The O 0 0.002568752
fact O 0 0.0016691134
that O 0 0.0012047773
5 O 0 0.00087795255
of O 0 0.00084819674
the O 0 0.0006258284
6 O 0 0.00045080372
patients O 0 0.0010162712
who O 0 0.00096104253
received O 0 0.00068267813
concurrent O 0 0.0077078114
calcium B-Chemical 1 0.99837494
channel O 0 0.5985594
blockers O 0 0.99901175
died O 0 0.23558436
, O 0 0.0008789837
should O 0 0.00027092904
alert O 0 0.0009290786
clinicians O 0 0.000707222
to O 0 0.0003122834
be O 0 0.00035575745
more O 0 0.00046108494
cautious O 0 0.0011489891
when O 0 0.00038651028
using O 0 0.0005990403
these O 0 0.0012997654
two O 0 0.0016145026
drugs O 0 0.4565717
simultaneously O 0 0.006376494
. O 0 0.006422611

Upregulation O 0 0.07394617
of O 0 0.003373661
the O 0 0.002024707
expression O 0 0.0025585308
of O 0 0.0023707633
vasopressin B-Chemical 1 0.9969772
gene O 0 0.002731047
in O 0 0.0009759853
the O 0 0.00111458
paraventricular O 0 0.9650555
and O 0 0.0014515657
supraoptic O 0 0.97167337
nuclei O 0 0.0027973999
of O 0 0.0010615835
the O 0 0.001392983
lithium B-Chemical 1 0.9985886
- O 0 0.008461495
induced O 0 0.0104814675
diabetes B-Disease 2 0.99780256
insipidus I-Disease 0 0.9989177
rat O 0 0.39092913
. O 0 0.009298352

The O 0 0.0034770933
expression O 0 0.0040353383
of O 0 0.0037627905
arginine B-Chemical 0 0.94280285
vasopressin I-Chemical 1 0.9987049
( O 0 0.020855218
AVP B-Chemical 1 0.9987244
) O 0 0.0030885863
gene O 0 0.0011920609
in O 0 0.00064038875
the O 0 0.00086528435
paraventricular O 0 0.9813353
( O 0 0.0020582206
PVN O 0 0.93974656
) O 0 0.001232176
and O 0 0.00073130615
supraoptic O 0 0.97609884
nuclei O 0 0.0055338363
( O 0 0.00086682965
SON O 0 0.6504481
) O 0 0.00064257556
was O 0 0.00026092946
investigated O 0 0.00028023878
in O 0 0.00027260362
rats O 0 0.0019097978
with O 0 0.00089230173
lithium B-Chemical 1 0.9994085
( O 0 0.0046891924
Li B-Chemical 1 0.9644375
) O 0 0.002738942
- O 0 0.0012974971
induced O 0 0.0014174667
polyuria B-Disease 2 0.99874806
, O 0 0.0010311952
using O 0 0.0005485737
in O 0 0.0006520768
situ O 0 0.0026739645
hybridization O 0 0.0031565393
histochemistry O 0 0.081132896
and O 0 0.0051556155
radioimmunoassay O 0 0.65716624
. O 0 0.0075267567

The O 0 0.0036913499
male O 0 0.0066063423
Wistar O 0 0.12274525
rats O 0 0.0048867087
consuming O 0 0.004641916
a O 0 0.0014406668
diet O 0 0.021380164
that O 0 0.0008160531
contained O 0 0.0008927776
LiCl B-Chemical 1 0.9951131
( O 0 0.0014502421
60 O 0 0.0009611831
mmol O 0 0.3589547
/ O 0 0.0017765808
kg O 0 0.004049087
) O 0 0.0009783623
for O 0 0.00054191245
4 O 0 0.000709596
weeks O 0 0.0010706807
developed O 0 0.0030649025
marked O 0 0.009322793
polyuria B-Disease 2 0.99545586
. O 0 0.008700126

The O 0 0.0052947956
Li B-Chemical 1 0.7133182
- O 0 0.0048236614
treated O 0 0.0030095435
rats O 0 0.0039041836
produced O 0 0.0012107787
a O 0 0.001110962
large O 0 0.0011697833
volume O 0 0.0023159788
of O 0 0.0017091271
hypotonic O 0 0.7490301
urine O 0 0.39915845
with O 0 0.0032337643
low O 0 0.005226246
ionic O 0 0.63740975
concentrations O 0 0.054993134
. O 0 0.009043368

Plasma O 0 0.6285242
sodium B-Chemical 0 0.99174964
concentrations O 0 0.015035143
were O 0 0.0017505025
found O 0 0.0010730859
to O 0 0.0008296176
be O 0 0.00076730776
slightly O 0 0.0007461313
increased O 0 0.0010267877
in O 0 0.0006378955
the O 0 0.0008807124
Li B-Chemical 1 0.90699154
- O 0 0.0020450884
treated O 0 0.001575932
rats O 0 0.0028785123
compared O 0 0.00062344025
with O 0 0.0014384593
those O 0 0.0023771115
in O 0 0.0024250376
controls O 0 0.006334814
. O 0 0.005947363

Plasma O 0 0.3193126
concentration O 0 0.008423204
of O 0 0.0041312245
AVP B-Chemical 1 0.9963863
and O 0 0.0021012842
transcripts O 0 0.0018107925
of O 0 0.001911781
AVP B-Chemical 1 0.99844235
gene O 0 0.0019056185
in O 0 0.00065837393
the O 0 0.0007483053
PVN O 0 0.9117938
and O 0 0.00081666344
SON O 0 0.6561506
were O 0 0.00046436352
significantly O 0 0.00054201495
increased O 0 0.00076924387
in O 0 0.0005047076
the O 0 0.0007872806
Li B-Chemical 1 0.9021018
- O 0 0.0022053143
treated O 0 0.0019608224
rats O 0 0.0039129355
compared O 0 0.0010587667
with O 0 0.0028247691
controls O 0 0.006504858
. O 0 0.005854485

These O 0 0.0040269587
results O 0 0.0020384185
suggest O 0 0.0014312745
that O 0 0.001503051
dehydration B-Disease 2 0.9586598
and O 0 0.0016554553
/ O 0 0.0019037549
or O 0 0.00051326986
the O 0 0.0004697915
activation O 0 0.0010613707
of O 0 0.0006749707
visceral O 0 0.2554416
afferent O 0 0.46790308
inputs O 0 0.009006743
may O 0 0.0003768453
contribute O 0 0.0003322766
to O 0 0.00025761733
the O 0 0.00029769837
elevation O 0 0.13744122
of O 0 0.0008216097
plasma O 0 0.21814877
AVP B-Chemical 1 0.99933213
and O 0 0.00054895313
the O 0 0.00035585836
upregulation O 0 0.002407168
of O 0 0.0010576416
AVP B-Chemical 1 0.9992704
gene O 0 0.0012208609
expression O 0 0.001045745
in O 0 0.0003712237
the O 0 0.0004938024
PVN O 0 0.8651574
and O 0 0.00050910894
the O 0 0.0005402242
SON O 0 0.5469453
of O 0 0.00091620453
the O 0 0.0011559239
Li B-Chemical 1 0.932842
- O 0 0.004788607
induced O 0 0.007632839
diabetes B-Disease 2 0.9978375
insipidus I-Disease 0 0.99895966
rat O 0 0.37904164
. O 0 0.00875248

Antinociceptive O 0 0.99119216
and O 0 0.008067882
antiamnesic O 0 0.96956897
properties O 0 0.0062253056
of O 0 0.0036826252
the O 0 0.0037330585
presynaptic O 0 0.82768077
cholinergic O 0 0.9881024
amplifier O 0 0.40933797
PG B-Chemical 0 0.9931124
- I-Chemical 0 0.020117588
9 I-Chemical 0 0.009342928
. O 0 0.008784143

The O 0 0.0040845745
antinociceptive O 0 0.9791967
effect O 0 0.0027962043
of O 0 0.0021074242
3 B-Chemical 0 0.0014197355
alpha I-Chemical 0 0.16824788
- I-Chemical 0 0.0028438843
tropyl I-Chemical 0 0.2376214
2 I-Chemical 0 0.0010059922
- I-Chemical 0 0.001238093
( I-Chemical 0 0.00076153036
p I-Chemical 0 0.00083797146
- I-Chemical 0 0.0011290788
bromophenyl I-Chemical 0 0.8122035
) I-Chemical 0 0.0037452762
propionate I-Chemical 0 0.99932194
[ O 0 0.012800222
( O 0 0.0010911636
+ O 0 0.00074980006
/ O 0 0.0017052273
- O 0 0.0011311313
) O 0 0.0011151375
- O 0 0.001463958
PG B-Chemical 0 0.9963909
- I-Chemical 0 0.0015313515
9 I-Chemical 0 0.00042651535
] O 0 0.0007543147
( O 0 0.0003478543
10 O 0 0.00025404376
- O 0 0.00031381595
40 O 0 0.0002588365
mg O 0 0.08257802
kg O 0 0.0039160918
- O 0 0.00042481738
1 O 0 0.0002144732
s O 0 0.0002567623
. O 0 0.00013489806
c O 0 0.00097373204
. O 0 0.00018049224
; O 0 0.00039583546
30 O 0 0.00020363345
- O 0 0.00030526423
60 O 0 0.00025326648
mg O 0 0.077470005
kg O 0 0.00390686
- O 0 0.00044442993
1 O 0 0.00022520946
p O 0 0.0003052616
. O 0 0.0001475613
o O 0 0.00081924873
. O 0 0.00018688639
; O 0 0.00043071015
10 O 0 0.00026106782
- O 0 0.0003235802
30 O 0 0.00019286403
mg O 0 0.07088172
kg O 0 0.0038655864
- O 0 0.00046155456
1 O 0 0.00024445273
i O 0 0.0005926179
. O 0 0.00017694561
v O 0 0.0023421408
. O 0 0.00018922583
; O 0 0.00042874351
10 O 0 0.00025992832
- O 0 0.0003264389
30 O 0 0.00019470617
micrograms O 0 0.036676932
/ O 0 0.00060829066
mouse O 0 0.000378934
i O 0 0.0008466706
. O 0 0.0001849416
c O 0 0.0018417202
. O 0 0.00020263618
v O 0 0.0038059673
. O 0 0.00017756541
) O 0 0.00036272348
was O 0 0.00017279877
examined O 0 0.0001428084
in O 0 0.0001713817
mice O 0 0.00015108573
, O 0 0.0003138061
rats O 0 0.0010182492
and O 0 0.00027920824
guinea O 0 0.008921776
pigs O 0 0.00050330395
by O 0 0.0002513171
use O 0 0.00029814857
of O 0 0.00033710155
the O 0 0.00031775347
hot O 0 0.0017723519
- O 0 0.0010045484
plate O 0 0.0014263509
, O 0 0.0008192675
abdominal O 0 0.27857116
- O 0 0.0020271528
constriction O 0 0.77562845
, O 0 0.0011180169
tail O 0 0.0014152842
- O 0 0.0017974766
flick O 0 0.12577696
and O 0 0.0019757813
paw O 0 0.92367136
- O 0 0.0054372717
pressure O 0 0.079716116
tests O 0 0.008869607
. O 0 0.0063427854

( O 0 0.009542133
+ O 0 0.0055439197
/ O 0 0.006335186
- O 0 0.0044933944
) O 0 0.003737783
- O 0 0.003908496
PG B-Chemical 0 0.99321306
- I-Chemical 0 0.003735081
9 I-Chemical 0 0.001467945
antinociception O 0 0.9988188
peaked O 0 0.002708893
15 O 0 0.0005848207
min O 0 0.0007887964
after O 0 0.00042847055
injection O 0 0.0018337466
and O 0 0.0012068127
then O 0 0.0015639935
slowly O 0 0.0064412756
diminished O 0 0.007975184
. O 0 0.006559406

The O 0 0.0053007836
antinociception O 0 0.99655414
produced O 0 0.0037065747
by O 0 0.002727809
( O 0 0.002906242
+ O 0 0.0019921456
/ O 0 0.0032038584
- O 0 0.002156638
) O 0 0.0019115218
- O 0 0.0022017132
PG B-Chemical 0 0.9957936
- I-Chemical 0 0.0017832689
9 I-Chemical 0 0.00044445854
was O 0 0.00032433408
prevented O 0 0.00082801084
by O 0 0.00040307845
the O 0 0.0004445831
unselective O 0 0.86199886
muscarinic O 0 0.9994295
antagonist O 0 0.9982389
atropine B-Chemical 0 0.9998969
, O 0 0.0033971274
the O 0 0.000728068
M1 O 0 0.7190337
- O 0 0.0018952623
selective O 0 0.036876462
antagonists O 0 0.99501723
pirenzepine B-Chemical 0 0.9999646
and O 0 0.010023057
dicyclomine B-Chemical 0 0.9999378
and O 0 0.0017391383
the O 0 0.00130546
acetylcholine B-Chemical 1 0.999739
depletor O 0 0.9998636
hemicholinium B-Chemical 0 0.9999089
- I-Chemical 0 0.008198372
3 I-Chemical 0 0.00037187716
, O 0 0.00036597304
but O 0 0.0002155643
not O 0 0.0001994585
by O 0 0.0002682477
the O 0 0.0003937681
opioid O 0 0.99874425
antagonist O 0 0.9974734
naloxone B-Chemical 1 0.999944
, O 0 0.0031747208
the O 0 0.00076697476
gamma B-Chemical 0 0.736308
- I-Chemical 0 0.025229922
aminobutyric I-Chemical 0 0.9995278
acidB I-Chemical 0 0.99531436
antagonist O 0 0.99426633
3 B-Chemical 0 0.0009920889
- I-Chemical 0 0.0022723987
aminopropyl I-Chemical 0 0.89050126
- I-Chemical 0 0.007037343
diethoxy I-Chemical 0 0.99531627
- I-Chemical 0 0.009845612
methyl I-Chemical 0 0.98562557
- I-Chemical 0 0.008839279
phosphinic I-Chemical 0 0.9974705
acid I-Chemical 0 0.97038966
, O 0 0.0011746561
the O 0 0.0006094208
H3 O 0 0.69591326
agonist O 0 0.9934227
R B-Chemical 0 0.9814983
- I-Chemical 0 0.004293032
( I-Chemical 0 0.0011170129
alpha I-Chemical 0 0.25593808
) I-Chemical 0 0.0027229048
- I-Chemical 0 0.0019331456
methylhistamine I-Chemical 0 0.99620014
, O 0 0.0009801114
the O 0 0.0005917636
D2 O 0 0.9949538
antagonist O 0 0.9965035
quinpirole B-Chemical 0 0.99991846
, O 0 0.0013868257
the O 0 0.00038084216
5 B-Chemical 0 0.00034003035
- I-Chemical 0 0.0006116609
hydroxytryptamine4 I-Chemical 0 0.016011454
antagonist O 0 0.9577956
2 B-Chemical 0 0.0008744318
- I-Chemical 0 0.0019333048
methoxy I-Chemical 0 0.9927078
- I-Chemical 0 0.0014046156
4 I-Chemical 0 0.00037113522
- I-Chemical 0 0.0008064063
amino I-Chemical 0 0.42766985
- I-Chemical 0 0.0009466174
5 I-Chemical 0 0.00034097632
- I-Chemical 0 0.0007635061
chlorobenzoic I-Chemical 0 0.76948225
acid I-Chemical 0 0.89941347
2 I-Chemical 0 0.0007195169
- I-Chemical 0 0.0011896244
( I-Chemical 0 0.0009188544
diethylamino I-Chemical 0 0.96401167
) I-Chemical 0 0.005184875
ethyl I-Chemical 0 0.99821234
ester I-Chemical 0 0.99452704
hydrochloride O 0 0.99910825
, O 0 0.0011338574
the O 0 0.0003864926
5 B-Chemical 0 0.00035532255
- I-Chemical 0 0.0006394588
hydroxytryptamin1A I-Chemical 0 0.016029539
antagonist O 0 0.9425544
1 B-Chemical 0 0.0007330945
- I-Chemical 0 0.0009187353
( I-Chemical 0 0.000518957
2 I-Chemical 0 0.0003847824
- I-Chemical 0 0.00082261715
methoxyphenyl I-Chemical 0 0.8190132
) I-Chemical 0 0.001101588
- I-Chemical 0 0.0006822222
4 I-Chemical 0 0.0003091493
- I-Chemical 0 0.0006097651
[ I-Chemical 0 0.0007294528
4 I-Chemical 0 0.0002994881
- I-Chemical 0 0.00058679533
( I-Chemical 0 0.000492982
2 I-Chemical 0 0.00044907842
- I-Chemical 0 0.0010541667
phthalimido I-Chemical 0 0.93345374
) I-Chemical 0 0.003886863
butyl I-Chemical 0 0.9952743
] I-Chemical 0 0.027809853
piperazine I-Chemical 0 0.99930906
hydrobromide O 0 0.99912053
and O 0 0.0032505072
the O 0 0.0037521897
polyamines O 0 0.99622667
depletor O 0 0.99917173
reserpine B-Chemical 1 0.99959046
. O 0 0.02234649

Based O 0 0.0089775855
on O 0 0.0018423322
these O 0 0.0023145645
data O 0 0.0020329936
, O 0 0.001739895
it O 0 0.0011006471
can O 0 0.00069538754
be O 0 0.00073397026
postulated O 0 0.0017149991
that O 0 0.00064517895
( O 0 0.0011932015
+ O 0 0.000999884
/ O 0 0.0022171882
- O 0 0.0014817788
) O 0 0.0014002621
- O 0 0.0017659216
PG B-Chemical 0 0.9957371
- I-Chemical 0 0.0014578799
9 I-Chemical 0 0.000426983
exerted O 0 0.0011097466
an O 0 0.00082427077
antinociceptive O 0 0.9955171
effect O 0 0.0008776999
mediated O 0 0.00064840965
by O 0 0.00077938836
a O 0 0.0011224658
central O 0 0.004388083
potentiation O 0 0.838847
of O 0 0.0055445614
cholinergic O 0 0.98383784
transmission O 0 0.034171045
. O 0 0.007115598

( O 0 0.009060374
+ O 0 0.005175429
/ O 0 0.00587941
- O 0 0.00406549
) O 0 0.0033082785
- O 0 0.0033395803
PG B-Chemical 0 0.9934691
- I-Chemical 0 0.002632798
9 I-Chemical 0 0.0007575117
( O 0 0.0006664132
10 O 0 0.0004390974
- O 0 0.0005046646
40 O 0 0.00038791448
mg O 0 0.10264174
kg O 0 0.0051557133
- O 0 0.0005758837
1 O 0 0.0002823276
i O 0 0.000610434
. O 0 0.00016775845
p O 0 0.00036425373
. O 0 0.00016788772
) O 0 0.00038187555
was O 0 0.00020805161
able O 0 0.00014901115
to O 0 0.00023027213
prevent O 0 0.0006348287
amnesia B-Disease 0 0.99919647
induced O 0 0.0016013196
by O 0 0.0013033876
scopolamine B-Chemical 1 0.99994934
( O 0 0.0019895034
1 O 0 0.0004460298
mg O 0 0.30024132
kg O 0 0.009409459
- O 0 0.00051427016
1 O 0 0.00024605918
i O 0 0.00056223816
. O 0 0.00015158615
p O 0 0.00034793786
. O 0 0.00016831266
) O 0 0.0004648263
and O 0 0.0004616356
dicyclomine B-Chemical 0 0.99984884
( O 0 0.0009291786
2 O 0 0.00037192536
mg O 0 0.22454087
kg O 0 0.007366592
- O 0 0.000564172
1 O 0 0.00029376076
i O 0 0.0006556301
. O 0 0.0002037558
p O 0 0.0004638521
. O 0 0.0002465479
) O 0 0.00057917496
in O 0 0.00036172365
the O 0 0.0005364198
mouse O 0 0.001238746
passive O 0 0.0042590457
- O 0 0.0034632096
avoidance O 0 0.008768302
test O 0 0.005151757
. O 0 0.0059364694

Affinity O 0 0.031544507
profiles O 0 0.0033029704
of O 0 0.0034563127
( O 0 0.0036030605
+ O 0 0.0024615687
/ O 0 0.0036121274
- O 0 0.0024630106
) O 0 0.0021046435
- O 0 0.002276294
PG B-Chemical 0 0.9946956
- I-Chemical 0 0.0016618021
9 I-Chemical 0 0.00046381002
for O 0 0.00038397606
muscarinic O 0 0.99688184
receptor O 0 0.28130323
subtypes O 0 0.06625103
, O 0 0.00055258896
determined O 0 0.00022353204
by O 0 0.0002923328
functional O 0 0.000552519
studies O 0 0.00073987286
( O 0 0.0006105644
rabbit O 0 0.0022080988
vas O 0 0.8643779
deferens O 0 0.54847664
for O 0 0.00044834425
M1 O 0 0.3934704
, O 0 0.0007018452
guinea O 0 0.023282574
pig O 0 0.002101652
atrium O 0 0.27692407
for O 0 0.0003949668
M2 O 0 0.24506289
, O 0 0.0006710059
guinea O 0 0.019744553
pig O 0 0.0021059867
ileum O 0 0.5442068
for O 0 0.000438204
M3 O 0 0.9171893
and O 0 0.00052855397
immature O 0 0.0031056271
guinea O 0 0.026020326
pig O 0 0.0017365342
uterus O 0 0.04347449
for O 0 0.00033114915
putative O 0 0.00097399845
M4 O 0 0.9887149
) O 0 0.0013812823
, O 0 0.00046975972
have O 0 0.000327138
shown O 0 0.0002706481
an O 0 0.00072601513
M4 O 0 0.9853446
/ O 0 0.0037090003
M1 O 0 0.37848812
selectivity O 0 0.014211405
ratio O 0 0.00044176175
of O 0 0.0003843214
10 O 0 0.00031360384
. O 0 0.00013190847
2 O 0 0.00016917071
that O 0 0.000128388
might O 0 0.00013896264
be O 0 0.00019697963
responsible O 0 0.00023818738
for O 0 0.00021510296
the O 0 0.00040247542
antinociception O 0 0.9996006
and O 0 0.0005688586
the O 0 0.00040957137
anti O 0 0.013304175
- O 0 0.0047477884
amnesic B-Disease 0 0.9995839
effect O 0 0.0008903421
induced O 0 0.0009728896
by O 0 0.00067148864
( O 0 0.0010367937
+ O 0 0.0007719231
/ O 0 0.001979501
- O 0 0.0012445765
) O 0 0.0012257016
- O 0 0.0016489398
PG B-Chemical 0 0.99496955
- I-Chemical 0 0.0013693749
9 I-Chemical 0 0.0004770924
through O 0 0.00039789264
an O 0 0.00077536074
increase O 0 0.00093632384
in O 0 0.0018528281
acetylcholine B-Chemical 1 0.99758565
extracellular O 0 0.25489885
levels O 0 0.007188273
. O 0 0.006757592

In O 0 0.0035652237
the O 0 0.002963908
antinociceptive O 0 0.989479
and O 0 0.003051861
antiamnesic O 0 0.9891889
dose O 0 0.09042832
range O 0 0.00293949
, O 0 0.0016086755
( O 0 0.0013182164
+ O 0 0.0010246105
/ O 0 0.0020760775
- O 0 0.0014337499
) O 0 0.0013591017
- O 0 0.0016703503
PG B-Chemical 0 0.99591786
- I-Chemical 0 0.0013196039
9 I-Chemical 0 0.00033514304
did O 0 0.00021958165
not O 0 0.00020145121
impair O 0 0.00025946333
mouse O 0 0.00040602157
performance O 0 0.000490429
evaluated O 0 0.00037595505
by O 0 0.00048517177
the O 0 0.00061137433
rota O 0 0.023075059
- O 0 0.0018733223
rod O 0 0.0065452983
test O 0 0.0017577643
and O 0 0.002793189
Animex O 0 0.14704129
apparatus O 0 0.00893142
. O 0 0.0069838073

The O 0 0.0036138317
effect O 0 0.0030954843
of O 0 0.0027935354
different O 0 0.0026598054
anaesthetic O 0 0.25981733
agents O 0 0.21023072
in O 0 0.0032377294
hearing B-Disease 0 0.7686679
loss I-Disease 0 0.00808817
following O 0 0.005550106
spinal O 0 0.33681005
anaesthesia O 0 0.46954113
. O 0 0.009468158

The O 0 0.0056663877
cause O 0 0.008185846
of O 0 0.00584276
hearing B-Disease 0 0.6571084
loss I-Disease 0 0.008007739
after O 0 0.0033654752
spinal O 0 0.15319888
anaesthesia O 0 0.29762194
is O 0 0.0074778455
unknown O 0 0.017443957
. O 0 0.010934228

Up O 0 0.018196277
until O 0 0.0021046347
now O 0 0.0022985921
, O 0 0.001750725
the O 0 0.00095965725
only O 0 0.0008958298
factor O 0 0.0027822265
studied O 0 0.0010848318
has O 0 0.0006292915
been O 0 0.0006072025
the O 0 0.00038591417
effect O 0 0.0004758101
of O 0 0.0005368187
the O 0 0.00047063705
diameter O 0 0.0041356003
of O 0 0.0006365406
the O 0 0.00062372803
spinal O 0 0.039467003
needle O 0 0.0018608157
on O 0 0.0005101092
post O 0 0.0014984801
- O 0 0.002537431
operative O 0 0.02732635
sensorineural B-Disease 2 0.99882036
hearing I-Disease 2 0.9801695
loss I-Disease 2 0.09397116
. O 0 0.008557363

The O 0 0.0026000387
aim O 0 0.0019559248
of O 0 0.001489445
this O 0 0.0010528113
study O 0 0.0012689884
was O 0 0.00067735615
to O 0 0.00051581906
describe O 0 0.0005990606
this O 0 0.00060893485
hearing B-Disease 0 0.49788487
loss I-Disease 0 0.0013943285
and O 0 0.0005147756
to O 0 0.00035850567
investigate O 0 0.0002717828
other O 0 0.00046901766
factors O 0 0.001369739
influencing O 0 0.00061265565
the O 0 0.00092035264
degree O 0 0.001981463
of O 0 0.003806074
hearing B-Disease 0 0.8978893
loss I-Disease 0 0.025324844
. O 0 0.007380783

Two O 0 0.0039921757
groups O 0 0.0023355267
of O 0 0.0017915248
22 O 0 0.0015485496
similar O 0 0.00070559885
patients O 0 0.0015296756
were O 0 0.0006408044
studied O 0 0.0008424251
: O 0 0.000723487
one O 0 0.00029913228
group O 0 0.0004586343
received O 0 0.0005388519
6 O 0 0.00036736374
mL O 0 0.0049324404
prilocaine B-Chemical 1 0.9995461
2 O 0 0.000568999
% O 0 0.00045374938
; O 0 0.00046285827
and O 0 0.00028116125
the O 0 0.00027702865
other O 0 0.0003821879
received O 0 0.00072587846
3 O 0 0.00070730987
mL O 0 0.010264246
bupivacaine B-Chemical 1 0.99859256
0 O 0 0.0019137545
. O 0 0.0011420147
5 O 0 0.0019187242
% O 0 0.003478614
. O 0 0.004120639

Patients O 0 0.009630132
given O 0 0.0027080828
prilocaine B-Chemical 1 0.99818027
were O 0 0.0018281162
more O 0 0.0012617188
likely O 0 0.0006618377
to O 0 0.0005577403
develop O 0 0.0010288219
hearing B-Disease 0 0.63388145
loss I-Disease 0 0.002279582
( O 0 0.0007209899
10 O 0 0.000336969
out O 0 0.00018729012
of O 0 0.00035100468
22 O 0 0.0005209808
) O 0 0.00044840088
than O 0 0.0001691575
those O 0 0.00035122372
given O 0 0.00031891887
bupivacaine B-Chemical 1 0.9995128
( O 0 0.00077726896
4 O 0 0.0002883545
out O 0 0.00022853323
of O 0 0.00052224967
22 O 0 0.0009812649
) O 0 0.0012178741
( O 0 0.0012163381
P O 0 0.014570112
< O 0 0.0015259628
0 O 0 0.0015913545
. O 0 0.0016042
05 O 0 0.02920071
) O 0 0.0063966285
. O 0 0.005714576

The O 0 0.0029092056
average O 0 0.0018406239
hearing B-Disease 0 0.26552802
loss I-Disease 0 0.0029876444
for O 0 0.0012255581
speech O 0 0.036436167
frequencies O 0 0.0011834321
was O 0 0.0008459734
about O 0 0.00068304094
10 O 0 0.00085169374
dB O 0 0.0017538628
after O 0 0.0006719442
prilocaine B-Chemical 1 0.99851364
and O 0 0.0017879265
15 O 0 0.0016072859
dB O 0 0.004305745
after O 0 0.0025259193
bupivacaine B-Chemical 1 0.996198
. O 0 0.008432918

None O 0 0.012259115
of O 0 0.0055184886
the O 0 0.0044698357
patients O 0 0.009261054
complained O 0 0.22415869
of O 0 0.008494837
subjective O 0 0.06689402
hearing B-Disease 0 0.8967568
loss I-Disease 0 0.030968603
. O 0 0.013918482

Long O 0 0.024892084
- O 0 0.005761358
term O 0 0.0032260488
follow O 0 0.0027188072
- O 0 0.0031882417
up O 0 0.0017612735
of O 0 0.0020362758
the O 0 0.0020898688
patients O 0 0.0052507254
was O 0 0.0031703974
not O 0 0.0039135595
possible O 0 0.0071630124
. O 0 0.00847179

A O 0 0.027040599
transient O 0 0.0772883
neurological B-Disease 0 0.9901557
deficit I-Disease 0 0.7334589
following O 0 0.0025924188
intrathecal O 0 0.91091967
injection O 0 0.007921317
of O 0 0.0015451148
1 O 0 0.0012134151
% O 0 0.0013783689
hyperbaric O 0 0.9007486
bupivacaine B-Chemical 1 0.9991134
for O 0 0.0032602192
unilateral O 0 0.663117
spinal O 0 0.46265694
anaesthesia O 0 0.4973724
. O 0 0.0077509806

We O 0 0.0029246327
describe O 0 0.002228411
a O 0 0.001770582
case O 0 0.0013595691
of O 0 0.001525787
transient O 0 0.08135745
neurological B-Disease 0 0.9965487
deficit I-Disease 0 0.8078405
that O 0 0.0006196225
occurred O 0 0.0006518538
after O 0 0.00028542048
unilateral O 0 0.13949546
spinal O 0 0.07798116
anaesthesia O 0 0.10010931
with O 0 0.00044299033
8 O 0 0.00032669763
mg O 0 0.07867635
of O 0 0.0003823056
1 O 0 0.0003308276
% O 0 0.00035047467
hyperbaric O 0 0.82102346
bupivacaine B-Chemical 1 0.9996636
slowly O 0 0.005656021
injected O 0 0.00043156173
through O 0 0.0003547458
a O 0 0.0005646581
25 O 0 0.00096509035
- O 0 0.0010363997
gauge O 0 0.0014178838
pencil O 0 0.013696587
- O 0 0.002784981
point O 0 0.0022684617
spinal O 0 0.110227354
needle O 0 0.013312979
. O 0 0.0061127464

The O 0 0.0030145568
surgery O 0 0.0047529507
and O 0 0.0021081483
anaesthesia O 0 0.03140988
were O 0 0.0011262402
uneventful O 0 0.0024201572
, O 0 0.0010135653
but O 0 0.0005188501
3 O 0 0.0003231745
days O 0 0.00026957731
after O 0 0.00017933463
surgery O 0 0.0008791093
, O 0 0.00036446872
the O 0 0.00023477201
patient O 0 0.0004884713
reported O 0 0.00044161943
an O 0 0.00036734884
area O 0 0.0004531114
of O 0 0.00048202337
hypoaesthesia O 0 0.90623933
over O 0 0.00025430304
L3 O 0 0.021808768
- O 0 0.00092943624
L4 O 0 0.02639436
dermatomes O 0 0.19385022
of O 0 0.00034895822
the O 0 0.00026603186
leg O 0 0.0037583103
which O 0 0.0004086097
had O 0 0.00033518515
been O 0 0.00038885267
operated O 0 0.0010060271
on O 0 0.00023109757
( O 0 0.0005047421
loss B-Disease 0 0.00070402276
of I-Disease 0 0.000753364
pinprick I-Disease 0 0.8601557
sensation I-Disease 0 0.8350582
) O 0 0.0016297797
without O 0 0.0009921228
reduction O 0 0.0021916768
in O 0 0.0018667058
muscular O 0 0.36733606
strength O 0 0.015997712
. O 0 0.006392935

Sensation O 0 0.13532877
in O 0 0.0031547544
this O 0 0.002265391
area O 0 0.0025524122
returned O 0 0.0017688265
to O 0 0.0014456951
normal O 0 0.0022503661
over O 0 0.0011239178
the O 0 0.0018699799
following O 0 0.0027986905
2 O 0 0.003846123
weeks O 0 0.0051405425
. O 0 0.0066922423

Prospective O 0 0.057029914
multicentre O 0 0.01320241
studies O 0 0.002435334
with O 0 0.0014508097
a O 0 0.0010608813
large O 0 0.00094462396
population O 0 0.001017303
and O 0 0.0006032193
a O 0 0.0005153821
long O 0 0.0005147508
follow O 0 0.00047490402
- O 0 0.00066254084
up O 0 0.00030594133
should O 0 0.0001857781
be O 0 0.0002486112
performed O 0 0.0002218572
in O 0 0.00022473518
order O 0 0.00019244537
to O 0 0.0002508644
evaluate O 0 0.00022152638
the O 0 0.00044278623
incidence O 0 0.0025695919
of O 0 0.0012169052
this O 0 0.0015006278
unusual O 0 0.017409246
side O 0 0.06537965
effect O 0 0.0071378537
. O 0 0.0067216456

However O 0 0.0038785234
, O 0 0.0024342753
we O 0 0.0008289223
suggest O 0 0.0007872161
that O 0 0.0007056496
a O 0 0.0007988589
low O 0 0.00093484146
solution O 0 0.008117197
concentration O 0 0.0020878848
should O 0 0.00029417247
be O 0 0.0003206261
preferred O 0 0.00029527335
for O 0 0.00029140618
unilateral O 0 0.12463519
spinal O 0 0.07388426
anaesthesia O 0 0.09350749
with O 0 0.00038708997
a O 0 0.00037785037
hyperbaric O 0 0.87185574
anaesthetic O 0 0.5313945
solution O 0 0.033537716
( O 0 0.0005188969
if O 0 0.00018010303
pencil O 0 0.009688471
- O 0 0.000512293
point O 0 0.00021952136
needle O 0 0.00066128577
and O 0 0.00023858697
slow O 0 0.0010165782
injection O 0 0.0010441173
rate O 0 0.00023699267
are O 0 0.00025335606
employed O 0 0.0004435906
) O 0 0.00052324793
, O 0 0.00027816728
in O 0 0.00015177665
order O 0 0.00011586342
to O 0 0.00014067489
minimize O 0 0.00012298085
the O 0 0.00019964726
risk O 0 0.005117146
of O 0 0.00037994434
a O 0 0.00034096884
localized O 0 0.00031348373
high O 0 0.00040610108
peak O 0 0.00056992064
anaesthetic O 0 0.21245852
concentration O 0 0.004033753
, O 0 0.00070738577
which O 0 0.00066130434
might O 0 0.00048063957
lead O 0 0.004492537
to O 0 0.0009671089
a O 0 0.0019588794
transient O 0 0.24879913
neurological B-Disease 0 0.9957431
deficit I-Disease 0 0.946855
. O 0 0.008448663

Transient B-Disease 0 0.7792163
neurologic I-Disease 0 0.98366284
symptoms I-Disease 0 0.6148925
after O 0 0.0017394911
spinal O 0 0.078071855
anesthesia O 0 0.18265381
: O 0 0.001659274
a O 0 0.0008634926
lower O 0 0.00081697
incidence O 0 0.0041577322
with O 0 0.002283232
prilocaine B-Chemical 1 0.99952376
and O 0 0.005093633
bupivacaine B-Chemical 1 0.9991825
than O 0 0.0025840679
with O 0 0.0076630274
lidocaine B-Chemical 0 0.9972574
. O 0 0.010007295

BACKGROUND O 0 0.68786013
: O 0 0.0047079725
Recent O 0 0.0031285894
evidence O 0 0.0017354534
suggests O 0 0.001003373
that O 0 0.0010502398
transient B-Disease 0 0.10590853
neurologic I-Disease 0 0.9953844
symptoms I-Disease 0 0.9346102
( O 0 0.0036892092
TNSs B-Disease 0 0.88955307
) O 0 0.0012822932
frequently O 0 0.000984696
follow O 0 0.0008185269
lidocaine B-Chemical 0 0.99885833
spinal O 0 0.28801423
anesthesia O 0 0.20263635
but O 0 0.0011068163
are O 0 0.0014181336
infrequent O 0 0.012083474
with O 0 0.0069661406
bupivacaine B-Chemical 1 0.9982703
. O 0 0.009411304

However O 0 0.004218736
, O 0 0.002885561
identification O 0 0.0020434065
of O 0 0.0015283709
a O 0 0.0012206441
short O 0 0.0010665667
- O 0 0.0013458681
acting O 0 0.0018381306
local O 0 0.0014819602
anesthetic O 0 0.31946835
to O 0 0.0005664876
substitute O 0 0.00062077155
for O 0 0.0004969171
lidocaine B-Chemical 0 0.9980428
for O 0 0.00052528933
brief O 0 0.000825766
surgical O 0 0.001559968
procedures O 0 0.001329639
remains O 0 0.00134607
an O 0 0.0021544192
important O 0 0.0025081376
goal O 0 0.006389955
. O 0 0.005722653

Prilocaine B-Chemical 0 0.982577
is O 0 0.0041753426
an O 0 0.0033901006
amide O 0 0.25634325
local O 0 0.003350465
anesthetic O 0 0.34868953
with O 0 0.001480883
a O 0 0.0010390126
duration O 0 0.0011924886
of O 0 0.0012524227
action O 0 0.004246151
similar O 0 0.000996526
to O 0 0.0013891343
that O 0 0.0018867609
of O 0 0.0062803063
lidocaine B-Chemical 0 0.997071
. O 0 0.010517666

Accordingly O 0 0.0042858818
, O 0 0.0027114383
the O 0 0.0013377819
present O 0 0.00092854904
, O 0 0.0011927135
prospective O 0 0.0020738908
double O 0 0.0006780531
- O 0 0.0010390448
blind O 0 0.0022113707
study O 0 0.0008207326
compares O 0 0.00061729894
prilocaine B-Chemical 1 0.99967647
with O 0 0.0020761113
lidocaine B-Chemical 0 0.99957997
and O 0 0.0017831585
bupivacaine B-Chemical 1 0.9997008
with O 0 0.00074644823
respect O 0 0.00034984975
to O 0 0.00031611032
duration O 0 0.0005624139
of O 0 0.00070052047
action O 0 0.0037991577
and O 0 0.0009975168
relative O 0 0.0011104282
risk O 0 0.040130425
of O 0 0.0072518606
TNSs B-Disease 0 0.9541907
. O 0 0.0071319826

METHODS O 0 0.0062256106
: O 0 0.0031535868
Ninety O 0 0.004031524
patients O 0 0.0025648812
classified O 0 0.0012380882
as O 0 0.0007374517
American O 0 0.0020514051
Society O 0 0.0014293845
of O 0 0.0006521689
Anesthesiologists O 0 0.0027889232
physical O 0 0.003498343
status O 0 0.00079230574
I O 0 0.0015498588
or O 0 0.00034959987
II O 0 0.0029761558
who O 0 0.0006631359
were O 0 0.000218697
scheduled O 0 0.00016328631
for O 0 0.00014517862
short O 0 0.00021226348
gynecologic O 0 0.005933859
procedures O 0 0.00038890014
under O 0 0.00020039831
spinal O 0 0.021250376
anesthesia O 0 0.030828333
were O 0 0.00017441425
randomly O 0 8.4779174e-05
allocated O 0 0.0001702994
to O 0 0.00016631988
receive O 0 0.0002683843
2 O 0 0.00022111491
. O 0 0.000121912046
5 O 0 0.00015964638
ml O 0 0.00053518184
2 O 0 0.000217953
% O 0 0.00028786503
lidocaine B-Chemical 0 0.99706644
in O 0 0.00026077926
7 O 0 0.00021907203
. O 0 0.00013269822
5 O 0 0.00018489048
% O 0 0.000280219
glucose B-Chemical 1 0.50106907
, O 0 0.0003922629
2 O 0 0.00028866148
% O 0 0.00038900765
prilocaine B-Chemical 1 0.9993981
in O 0 0.00030141044
7 O 0 0.0002431487
. O 0 0.00014666074
5 O 0 0.000204994
% O 0 0.00031526494
glucose B-Chemical 1 0.47699973
, O 0 0.0004148605
or O 0 0.0002612466
0 O 0 0.00036802382
. O 0 0.00020608008
5 O 0 0.00031841698
% O 0 0.00061328476
bupivacaine B-Chemical 1 0.9978409
in O 0 0.00078216585
7 O 0 0.00083047897
. O 0 0.0007368381
5 O 0 0.0013595147
% O 0 0.002847302
glucose B-Chemical 1 0.5730498
. O 0 0.0056840144

All O 0 0.0051606414
solutions O 0 0.008197143
were O 0 0.0027478784
provided O 0 0.0024482845
in O 0 0.0019312614
blinded O 0 0.0033299427
vials O 0 0.004465106
by O 0 0.0029655204
the O 0 0.0036329252
hospital O 0 0.014277276
pharmacy O 0 0.06299675
. O 0 0.010882327

Details O 0 0.0044816188
of O 0 0.0035761239
spinal O 0 0.03930048
puncture O 0 0.009089563
, O 0 0.0017372825
extension O 0 0.0012688809
and O 0 0.000796987
regression O 0 0.0031924755
of O 0 0.0011697096
spinal O 0 0.06532045
block O 0 0.0013899468
, O 0 0.0008043254
and O 0 0.00052452163
the O 0 0.00043141897
times O 0 0.00039484916
to O 0 0.0006374557
reach O 0 0.0012173754
discharge O 0 0.0074573252
criteria O 0 0.003332837
were O 0 0.0029037222
noted O 0 0.004668279
. O 0 0.0059351553

In O 0 0.0028765036
the O 0 0.0019548684
evening O 0 0.0037037213
of O 0 0.0016753146
postoperative O 0 0.013777788
day O 0 0.0010096697
1 O 0 0.00072863617
, O 0 0.000628654
patients O 0 0.0008726927
were O 0 0.00033754727
evaluated O 0 0.00033110272
for O 0 0.00036299246
TNSs B-Disease 0 0.58887345
by O 0 0.00040359487
a O 0 0.0004053902
physician O 0 0.0011478034
unaware O 0 0.00072372693
of O 0 0.00045709082
the O 0 0.00041124705
drug O 0 0.17651281
administered O 0 0.0020021982
and O 0 0.00055019057
the O 0 0.0004998904
details O 0 0.00045344242
of O 0 0.0011546011
the O 0 0.0017597466
anesthetic O 0 0.41108096
procedure O 0 0.006177607
. O 0 0.0058127022

RESULTS O 0 0.024341749
: O 0 0.0042466535
Nine O 0 0.0037725468
of O 0 0.0015572549
30 O 0 0.001030594
patients O 0 0.0018515184
receiving O 0 0.004175735
lidocaine B-Chemical 0 0.9989856
experienced O 0 0.01034404
TNSs B-Disease 0 0.9149554
, O 0 0.0007720076
1 O 0 0.0003427728
of O 0 0.00033003694
30 O 0 0.00027255606
patients O 0 0.0008210932
receiving O 0 0.006360502
prilocaine B-Chemical 1 0.99982846
( O 0 0.00175976
P O 0 0.06886168
= O 0 0.0006105748
0 O 0 0.0003178889
. O 0 0.00017918048
03 O 0 0.0032708084
) O 0 0.00042118723
had O 0 0.00028809294
them O 0 0.00052373926
, O 0 0.00042338038
and O 0 0.00033910206
none O 0 0.0004723854
of O 0 0.0005657134
30 O 0 0.0005934411
patients O 0 0.0020433236
receiving O 0 0.016344015
bupivacaine B-Chemical 1 0.9990644
had O 0 0.009498518
TNSs B-Disease 0 0.95218414
. O 0 0.007038979

Times O 0 0.0074983565
to O 0 0.00245742
ambulate O 0 0.006298885
and O 0 0.0013936855
to O 0 0.0009340392
void O 0 0.0015420376
were O 0 0.0006289833
similar O 0 0.000424429
after O 0 0.00041101288
lidocaine B-Chemical 0 0.9987336
and O 0 0.0017244432
prilocaine B-Chemical 1 0.9998017
( O 0 0.0012632747
150 O 0 0.0008224251
vs O 0 0.00056513265
. O 0 0.0001541936
165 O 0 0.0007194449
min O 0 0.00034021
and O 0 0.00022995048
238 O 0 0.0010602757
vs O 0 0.00050253567
. O 0 0.0001542536
253 O 0 0.0022409228
min O 0 0.0004389652
, O 0 0.00033198524
respectively O 0 0.0006313003
) O 0 0.00042378998
but O 0 0.00021775982
prolonged O 0 0.0017184714
after O 0 0.00027521193
bupivacaine B-Chemical 1 0.999637
( O 0 0.00079731434
200 O 0 0.00087392126
and O 0 0.00039078508
299 O 0 0.017054237
min O 0 0.0008170973
, O 0 0.00069926924
respectively O 0 0.0015031699
; O 0 0.0015099748
P O 0 0.01643694
< O 0 0.0015026174
0 O 0 0.0015629298
. O 0 0.0015712156
05 O 0 0.029333357
) O 0 0.006301241
. O 0 0.0056334296

CONCLUSIONS O 0 0.83343804
: O 0 0.008632396
Prilocaine B-Chemical 0 0.97987354
may O 0 0.001992847
be O 0 0.0011818266
preferable O 0 0.0009555739
to O 0 0.00078024296
lidocaine B-Chemical 0 0.997493
for O 0 0.0005028455
short O 0 0.00041228233
surgical O 0 0.00083856133
procedures O 0 0.00054474256
because O 0 0.00027505666
it O 0 0.0003714114
has O 0 0.00030941528
a O 0 0.00034603744
similar O 0 0.0002375868
duration O 0 0.00050552713
of O 0 0.00064755866
action O 0 0.004243974
but O 0 0.0007571021
a O 0 0.0010385633
lower O 0 0.0014136825
incidence O 0 0.012058396
of O 0 0.006649082
TNSs B-Disease 0 0.94696254
. O 0 0.007386599

Suxamethonium B-Chemical 1 0.9875317
- O 0 0.010850655
induced O 0 0.00635212
cardiac B-Disease 2 0.89391136
arrest I-Disease 2 0.890635
and O 0 0.004674425
death B-Disease 2 0.9784626
following O 0 0.002739059
5 O 0 0.0019563064
days O 0 0.0022517485
of O 0 0.0044247243
immobilization O 0 0.062156253
. O 0 0.0093263425

The O 0 0.0025074338
present O 0 0.0015740658
report O 0 0.003100951
describes O 0 0.001879878
a O 0 0.0011878122
case O 0 0.0009687882
of O 0 0.0013057087
cardiac B-Disease 2 0.8978897
arrest I-Disease 2 0.8675945
and O 0 0.00089079014
subsequent O 0 0.0012487692
death B-Disease 2 0.98963636
as O 0 0.0004198436
a O 0 0.0004272167
result O 0 0.0002951425
of O 0 0.00071626954
hyperkalaemia B-Disease 0 0.9994855
following O 0 0.0005748045
the O 0 0.00035001087
use O 0 0.00047334327
of O 0 0.0007448224
suxamethonium B-Chemical 1 0.99881184
in O 0 0.00064680836
a O 0 0.0008174872
23 O 0 0.0013062702
- O 0 0.0012626281
year O 0 0.0012123152
- O 0 0.0022671816
old O 0 0.0026915413
Malawian O 0 0.043881163
woman O 0 0.050055724
. O 0 0.006465361

Five O 0 0.0052728234
days O 0 0.002033609
after O 0 0.0010260288
the O 0 0.001099067
onset O 0 0.0025402843
of O 0 0.0012061582
the O 0 0.0010212385
symptoms O 0 0.2492102
of O 0 0.0023489422
meningitis B-Disease 2 0.9976157
, O 0 0.0013967041
the O 0 0.0006486517
patient O 0 0.0012782441
aspirated O 0 0.0024773723
stomach O 0 0.23033026
contents O 0 0.0043374244
and O 0 0.0016738893
needed O 0 0.0016216933
endotracheal O 0 0.012544579
intubation O 0 0.087940745
. O 0 0.0063794195

Forty O 0 0.010491571
seconds O 0 0.0036036612
after O 0 0.001791854
injection O 0 0.004538025
of O 0 0.0038370555
suxamethonium B-Chemical 1 0.9976398
, O 0 0.01228358
bradycardia B-Disease 0 0.9977197
and O 0 0.0071223928
cardiac B-Disease 2 0.95893675
arrest I-Disease 2 0.9511589
occurred O 0 0.014192547
. O 0 0.009019883

Attempts O 0 0.014957094
to O 0 0.0069275578
resuscitate O 0 0.016846605
the O 0 0.0051723146
patient O 0 0.0074412064
were O 0 0.0061837933
not O 0 0.0072102826
successful O 0 0.013875982
. O 0 0.013861889

The O 0 0.0039272625
serum O 0 0.014029142
level O 0 0.0021693388
of O 0 0.0032737725
potassium B-Chemical 0 0.99647397
was O 0 0.0022315239
observed O 0 0.001102116
to O 0 0.0011462785
be O 0 0.001246876
8 O 0 0.0011325615
. O 0 0.0008892756
4 O 0 0.0016351029
mequiv O 0 0.7400182
L O 0 0.4108385
- O 0 0.0076385876
1 O 0 0.005782968
. O 0 0.0061220704

Apart O 0 0.0068686446
from O 0 0.002286542
the O 0 0.0015570578
reduction O 0 0.0018538658
in O 0 0.0008095622
the O 0 0.00066905865
patient O 0 0.0010399399
' O 0 0.00065983814
s O 0 0.00055467075
level O 0 0.00028796823
of O 0 0.0005856083
consciousness O 0 0.7341878
, O 0 0.00056081556
there O 0 0.00020251758
were O 0 0.00027251238
no O 0 0.00023036588
signs O 0 0.022362003
of O 0 0.00058108335
motor O 0 0.17492115
neurone O 0 0.8609847
damage O 0 0.5664336
or O 0 0.00030690365
of O 0 0.00035754862
any O 0 0.00021138995
of O 0 0.00031406106
the O 0 0.00025378328
other O 0 0.00031300352
known O 0 0.0005744575
predisposing O 0 0.020900676
conditions O 0 0.0008301332
for O 0 0.00068039255
hyperkalaemia B-Disease 0 0.999154
following O 0 0.0013860435
the O 0 0.001429699
administration O 0 0.1844934
of O 0 0.007918754
suxamethonium B-Chemical 1 0.9975304
. O 0 0.00868732

It O 0 0.0063184714
is O 0 0.0026775787
postulated O 0 0.0036368107
that O 0 0.0014260779
her O 0 0.0030423165
death B-Disease 2 0.98154175
was O 0 0.0014610549
caused O 0 0.0014185488
by O 0 0.0013297746
hypersensitivity B-Disease 2 0.7961422
to O 0 0.0013297835
suxamethonium B-Chemical 1 0.99898916
, O 0 0.0017011864
associated O 0 0.0012678733
with O 0 0.0012566108
her O 0 0.0020693925
5 O 0 0.0014357802
- O 0 0.0025918912
day O 0 0.0026263515
immobilization O 0 0.02938525
. O 0 0.0064897174

Acute O 0 0.9878642
hepatitis B-Disease 2 0.99882394
, O 0 0.09723215
autoimmune B-Disease 2 0.9978806
hemolytic I-Disease 2 0.9997267
anemia I-Disease 2 0.99975854
, O 0 0.024749229
and O 0 0.005482227
erythroblastocytopenia B-Disease 0 0.2439466
induced O 0 0.008469719
by O 0 0.011289234
ceftriaxone B-Chemical 1 0.9968566
. O 0 0.013524322

An O 0 0.008283972
80 O 0 0.005882376
- O 0 0.0047965758
yr O 0 0.0050551323
- O 0 0.0029188732
old O 0 0.002229881
man O 0 0.073007174
developed O 0 0.007832271
acute O 0 0.9961999
hepatitis B-Disease 2 0.9997576
shortly O 0 0.045187462
after O 0 0.0028322414
ingesting O 0 0.8679707
oral O 0 0.9472942
ceftriaxone B-Chemical 1 0.9980453
. O 0 0.012552554

Although O 0 0.003863595
the O 0 0.0029109295
transaminases O 0 0.9913585
gradually O 0 0.004241964
returned O 0 0.0011623811
to O 0 0.0006402401
baseline O 0 0.0006660837
after O 0 0.0003130238
withholding O 0 0.0054679625
the O 0 0.00067024986
beta B-Chemical 0 0.82148755
lactam I-Chemical 0 0.9974994
antibiotic O 0 0.64520913
, O 0 0.00083299715
there O 0 0.00022202986
was O 0 0.00028867967
a O 0 0.00029535475
gradual O 0 0.00053345587
increase O 0 0.0003236058
in O 0 0.00033824067
serum O 0 0.16152173
bilirubin B-Chemical 1 0.9992279
and O 0 0.0006453749
a O 0 0.00048382574
decrease O 0 0.0005520115
in O 0 0.0004434363
hemoglobin O 0 0.82898134
concentration O 0 0.0050529046
caused O 0 0.0011272813
by O 0 0.0011723243
an O 0 0.004838719
autoimmune B-Disease 2 0.99895716
hemolytic I-Disease 2 0.9998667
anemia I-Disease 2 0.99983406
and O 0 0.07312616
erythroblastocytopenia B-Disease 0 0.7569873
. O 0 0.00908159

These O 0 0.011679566
responded O 0 0.012470772
to O 0 0.009504862
systemic O 0 0.8920804
steroids B-Chemical 0 0.99229807
and O 0 0.025491113
immunoglobulins O 0 0.84168446
. O 0 0.022016706

Despite O 0 0.003788962
the O 0 0.002023599
widespread O 0 0.0031841767
use O 0 0.0015356716
of O 0 0.0012086688
these O 0 0.001282019
agents O 0 0.057991527
this O 0 0.0007686719
triad O 0 0.02198861
of O 0 0.0008858951
side O 0 0.01822051
effects O 0 0.0015554826
has O 0 0.0005233493
not O 0 0.00044514754
previously O 0 0.0005484662
been O 0 0.0006742069
reported O 0 0.0008845629
in O 0 0.00065630086
connection O 0 0.0015093251
with O 0 0.0025403402
beta B-Chemical 0 0.9133884
lactam I-Chemical 0 0.9951794
antibiotics O 0 0.96479666
. O 0 0.009560785

Thyroxine B-Chemical 0 0.99232095
abuse O 0 0.9808872
: O 0 0.008940685
an O 0 0.0048994925
unusual O 0 0.008806953
case O 0 0.0042133387
of O 0 0.007395061
thyrotoxicosis B-Disease 0 0.99583083
in O 0 0.011314105
pregnancy O 0 0.7114725
. O 0 0.014029175

Eating B-Disease 0 0.51144505
disorders I-Disease 0 0.76108277
and O 0 0.0031474063
the O 0 0.0018754749
associated O 0 0.0022632084
behavioural O 0 0.017886173
problems O 0 0.01338147
and O 0 0.002491592
drug B-Disease 2 0.9434473
abuse I-Disease 2 0.99587977
are O 0 0.0045065484
uncommon O 0 0.06999552
in O 0 0.0048522432
pregnancy O 0 0.51316977
. O 0 0.008969368

When O 0 0.0031763283
they O 0 0.0020778312
do O 0 0.0014808781
occur O 0 0.0013165652
they O 0 0.00086931227
are O 0 0.00076116226
often O 0 0.0010028937
unrecognized O 0 0.0016826919
because O 0 0.00040532643
of O 0 0.0007090305
denial O 0 0.08424234
but O 0 0.00048815855
when O 0 0.0002736507
significant O 0 0.0005092584
may O 0 0.000431649
pose O 0 0.0009300768
a O 0 0.00067065685
risk O 0 0.008106622
to O 0 0.000629659
both O 0 0.0007221003
the O 0 0.0009483172
mother O 0 0.0038022215
and O 0 0.0023962373
her O 0 0.0058802767
fetus O 0 0.07339239
. O 0 0.0067719123

This O 0 0.004208528
case O 0 0.0020920157
illustrates O 0 0.0012723894
a O 0 0.0011047475
number O 0 0.00071193837
of O 0 0.00094075385
problems O 0 0.003779984
that O 0 0.0005020885
may O 0 0.0005162794
be O 0 0.0004595347
encountered O 0 0.00077983824
in O 0 0.00037508958
women O 0 0.0078971535
with O 0 0.0007341911
eating B-Disease 0 0.8935233
disorders I-Disease 0 0.94727457
in O 0 0.0005643917
pregnancy O 0 0.2383955
, O 0 0.00064395997
including O 0 0.00045982483
prolonged O 0 0.006918932
and O 0 0.0009603785
recurrent O 0 0.67874
metabolic O 0 0.9401905
disturbances O 0 0.9858905
and O 0 0.011959667
diuretic O 0 0.9992687
abuse O 0 0.9943111
. O 0 0.010567437

In O 0 0.0026812851
particular O 0 0.001726722
it O 0 0.0015694265
illustrates O 0 0.0009840638
the O 0 0.0009354327
derangements O 0 0.71557343
of O 0 0.00147149
thyroid O 0 0.8282831
function O 0 0.0013875628
seen O 0 0.0005289375
in O 0 0.0003769628
pregnant O 0 0.018601991
women O 0 0.012768483
with O 0 0.0007291193
eating B-Disease 0 0.8840855
disorders I-Disease 0 0.9329042
and O 0 0.0005655624
reminds O 0 0.0068611098
us O 0 0.00047789098
that O 0 0.00022496867
when O 0 0.00019345355
a O 0 0.00036263224
cause O 0 0.0011824889
for O 0 0.00046307387
thyrotoxicosis B-Disease 0 0.99903476
remains O 0 0.0011661907
obscure O 0 0.033480026
, O 0 0.0026530167
thyroxine B-Chemical 1 0.99901605
abuse O 0 0.99083674
should O 0 0.0009227285
be O 0 0.0012367425
considered O 0 0.0013328107
and O 0 0.0022894996
explored O 0 0.003977209
. O 0 0.0053279

Repeated O 0 0.25450927
trimipramine B-Chemical 0 0.9993413
induces O 0 0.042277258
dopamine B-Chemical 1 0.99865156
D2 O 0 0.9952915
/ O 0 0.05550664
D3 O 0 0.9967788
and O 0 0.005278256
alpha1 O 0 0.9642669
- O 0 0.017382618
adrenergic O 0 0.9921199
up O 0 0.00559351
- O 0 0.0075838487
regulation O 0 0.00573248
. O 0 0.007452047

Trimipramine B-Chemical 0 0.99459535
( O 0 0.009335718
TRI B-Chemical 1 0.93005246
) O 0 0.0043510413
, O 0 0.0016676417
which O 0 0.0010858255
shows O 0 0.00044725358
a O 0 0.000722805
clinical O 0 0.016136626
antidepressant B-Chemical 1 0.9992938
activity O 0 0.002130801
, O 0 0.0007870931
is O 0 0.00042034173
chemically O 0 0.034016248
related O 0 0.0003252432
to O 0 0.0005181079
imipramine B-Chemical 0 0.99989533
but O 0 0.0005769908
does O 0 0.00028928608
not O 0 0.00027164185
inhibit O 0 0.00048040482
the O 0 0.00047914992
reuptake O 0 0.99872416
of O 0 0.0025275347
noradrenaline B-Chemical 1 0.9997459
and O 0 0.00085757626
5 B-Chemical 0 0.0004812789
- I-Chemical 0 0.0010449846
hydroxytryptamine I-Chemical 0 0.96398145
, O 0 0.0006221807
nor O 0 0.00038496067
does O 0 0.00036635023
it O 0 0.00057966175
induce O 0 0.00084156706
beta O 0 0.5272315
- O 0 0.007832251
adrenergic O 0 0.9938047
down O 0 0.0046942555
- O 0 0.0056445203
regulation O 0 0.0040638843
. O 0 0.0053893323

The O 0 0.0050903023
mechanism O 0 0.0053386353
of O 0 0.0051258346
its O 0 0.0102934195
antidepressant B-Chemical 1 0.9964085
activity O 0 0.009387157
is O 0 0.005994377
still O 0 0.0066141514
unknown O 0 0.017979538
. O 0 0.011561647

The O 0 0.002560391
aim O 0 0.001917039
of O 0 0.0014378786
the O 0 0.000944795
present O 0 0.000650243
study O 0 0.0010351096
was O 0 0.0005567545
to O 0 0.00042487666
find O 0 0.00039002526
out O 0 0.00027901563
whether O 0 0.000214924
TRI B-Chemical 1 0.6618121
given O 0 0.00029329758
repeatedly O 0 0.00058396405
was O 0 0.00031275
able O 0 0.0001854491
to O 0 0.00022923073
induce O 0 0.0002670369
adaptive O 0 0.0006125389
changes O 0 0.0005249049
in O 0 0.00027170609
the O 0 0.00038950937
dopaminergic O 0 0.9550549
and O 0 0.0008450083
alpha1 O 0 0.95258355
- O 0 0.0043961564
adrenergic O 0 0.99559116
systems O 0 0.002085475
, O 0 0.0007359876
demonstrated O 0 0.0005735753
by O 0 0.0006283203
us O 0 0.0010822981
previously O 0 0.0011192275
for O 0 0.0014828255
various O 0 0.010689088
antidepressants B-Chemical 1 0.9979861
. O 0 0.008884252

TRI B-Chemical 1 0.7496389
was O 0 0.003685077
given O 0 0.0018390451
to O 0 0.0017895917
male O 0 0.0044338787
Wistar O 0 0.17327054
rats O 0 0.0040191556
and O 0 0.0012962635
male O 0 0.004006876
Albino O 0 0.20781416
Swiss O 0 0.004439538
mice O 0 0.00067367696
perorally O 0 0.11940847
twice O 0 0.0014786974
daily O 0 0.00291397
for O 0 0.0016794476
14 O 0 0.0031112423
days O 0 0.0038338797
. O 0 0.005383431

In O 0 0.0034053314
the O 0 0.0026750267
acute O 0 0.5451245
experiment O 0 0.0020198172
TRI B-Chemical 1 0.93862134
( O 0 0.002087533
given O 0 0.0006795294
i O 0 0.0017960806
. O 0 0.00042777005
p O 0 0.0007497639
. O 0 0.0003225435
) O 0 0.0006335739
does O 0 0.000282291
not O 0 0.00032126467
antagonize O 0 0.010539522
the O 0 0.0007569823
reserpine B-Chemical 1 0.9999163
hypothermia B-Disease 2 0.9993831
in O 0 0.00062039687
mice O 0 0.00028324398
and O 0 0.00040165367
does O 0 0.00031162016
not O 0 0.00037137198
potentiate O 0 0.004688164
the O 0 0.00064876233
5 B-Chemical 0 0.0008049104
- I-Chemical 0 0.0022348864
hydroxytryptophan I-Chemical 0 0.9813595
head O 0 0.577613
twitches O 0 0.99165064
in O 0 0.00393677
rats O 0 0.020428384
. O 0 0.0059504877

TRI B-Chemical 1 0.67013997
given O 0 0.0025370847
repeatedly O 0 0.0026559022
to O 0 0.001500522
rats O 0 0.0036542034
increases O 0 0.0012902423
the O 0 0.0012618545
locomotor O 0 0.9684219
hyperactivity B-Disease 2 0.99961793
induced O 0 0.0039152103
by O 0 0.0011110854
d B-Chemical 0 0.0060286685
- I-Chemical 0 0.007873756
amphetamine I-Chemical 1 0.9999347
, O 0 0.0114947045
quinpirole B-Chemical 0 0.99985147
and O 0 0.0015413594
( O 0 0.0012769664
+ O 0 0.00082980574
) O 0 0.0010402784
- O 0 0.000887426
7 O 0 0.00047887184
- O 0 0.0013437803
hydroxy O 0 0.9971186
- O 0 0.0028123893
dipropyloaminotetralin O 0 0.04873617
( O 0 0.0037356701
dopamine B-Chemical 1 0.99900776
D2 O 0 0.9932092
and O 0 0.005580211
D3 O 0 0.99627775
effects O 0 0.018657362
) O 0 0.010686164
. O 0 0.006523454

The O 0 0.006721753
stereotypies O 0 0.9937808
induced O 0 0.006304804
by O 0 0.0035755136
d B-Chemical 0 0.007354733
- I-Chemical 0 0.010375762
amphetamine I-Chemical 1 0.9996712
or O 0 0.006071654
apomorphine B-Chemical 1 0.9995604
are O 0 0.004157335
not O 0 0.0034156148
potentiated O 0 0.28042674
by O 0 0.008848693
TRI B-Chemical 1 0.9692392
. O 0 0.011463495

It O 0 0.005442738
increases O 0 0.0024630844
the O 0 0.001764258
behaviour O 0 0.0033641288
stimulation O 0 0.0029462255
evoked O 0 0.10656581
by O 0 0.0017326574
phenylephrine B-Chemical 1 0.9994758
( O 0 0.0020551905
given O 0 0.00051607867
intraventricularly O 0 0.89794457
) O 0 0.0009260151
in O 0 0.00029054898
rats O 0 0.001399475
, O 0 0.00032780017
evaluated O 0 0.0002169032
in O 0 0.00017645082
the O 0 0.00017545826
open O 0 0.00018776179
field O 0 0.00033123657
test O 0 0.00025069818
as O 0 0.00017191758
well O 0 0.00018112737
as O 0 0.00019761133
the O 0 0.000321344
aggressiveness B-Disease 2 0.9302384
evoked O 0 0.24657227
by O 0 0.0009037671
clonidine B-Chemical 1 0.99983525
in O 0 0.00042447998
mice O 0 0.00023066856
, O 0 0.0003655163
both O 0 0.00024733614
these O 0 0.00041413173
effects O 0 0.0008932268
being O 0 0.0007560812
mediated O 0 0.0006232003
by O 0 0.0009566757
an O 0 0.0024275628
alpha1 O 0 0.95474833
- O 0 0.03168359
adrenergic O 0 0.9952803
receptor O 0 0.6964162
. O 0 0.008834135

It O 0 0.005936695
may O 0 0.002570604
be O 0 0.0019041526
concluded O 0 0.0019874375
that O 0 0.0009907556
, O 0 0.0012454228
like O 0 0.0008550757
other O 0 0.0012448404
tricyclic O 0 0.9994955
antidepressants B-Chemical 1 0.99970573
studied O 0 0.0035115501
previously O 0 0.00075919373
, O 0 0.0007510508
TRI B-Chemical 1 0.8501898
given O 0 0.00027020674
repeatedly O 0 0.0005186249
increases O 0 0.00036770993
the O 0 0.0002898537
responsiveness O 0 0.00089116796
of O 0 0.00071652484
brain O 0 0.3745797
dopamine B-Chemical 1 0.9996947
D2 O 0 0.997269
and O 0 0.0021727174
D3 O 0 0.9992329
( O 0 0.0014959665
locomotor O 0 0.3778164
activity O 0 0.00062140316
but O 0 0.00034975255
not O 0 0.0004721055
stereotypy O 0 0.998963
) O 0 0.0010669429
as O 0 0.0002986578
well O 0 0.00035573746
as O 0 0.0005813432
alpha1 O 0 0.91339445
- O 0 0.00809574
adrenergic O 0 0.9957885
receptors O 0 0.30932006
to O 0 0.0024829046
their O 0 0.0044005825
agonists O 0 0.9008742
. O 0 0.007173396

A O 0 0.014075474
question O 0 0.0025495552
arises O 0 0.0020870445
whether O 0 0.00088873634
the O 0 0.0013838263
reuptake O 0 0.9970675
inhibition O 0 0.01255785
is O 0 0.00070242805
of O 0 0.0006145721
any O 0 0.0003499832
importance O 0 0.0003237234
to O 0 0.0003118722
the O 0 0.00030531516
adaptive O 0 0.0007101541
changes O 0 0.000618614
induced O 0 0.00053272006
by O 0 0.00040297318
repeated O 0 0.0006256036
antidepressants B-Chemical 1 0.9995024
, O 0 0.0009989301
suggested O 0 0.000582088
to O 0 0.00051375566
be O 0 0.000642559
responsible O 0 0.00085517677
for O 0 0.0010087
the O 0 0.0023860263
antidepressant B-Chemical 1 0.99749506
activity O 0 0.0107273
. O 0 0.006833747

Pethidine B-Chemical 0 0.9966192
- O 0 0.0095565645
associated O 0 0.005198099
seizure B-Disease 2 0.99573404
in O 0 0.0020538317
a O 0 0.0019472936
healthy O 0 0.007043059
adolescent O 0 0.03416782
receiving O 0 0.022100033
pethidine B-Chemical 1 0.99930036
for O 0 0.0038387163
postoperative B-Disease 0 0.86286485
pain I-Disease 0 0.9925734
control O 0 0.008349166
. O 0 0.008241452

A O 0 0.021065254
healthy O 0 0.009107009
17 O 0 0.0032813963
- O 0 0.0022267266
year O 0 0.0012166786
- O 0 0.0012630449
old O 0 0.000714612
male O 0 0.001061983
received O 0 0.000492135
standard O 0 0.0003297856
intermittent O 0 0.02570272
doses O 0 0.032556526
of O 0 0.0014110879
pethidine B-Chemical 1 0.99981433
via O 0 0.00066478143
a O 0 0.0005819225
patient O 0 0.0010228343
- O 0 0.00077658147
controlled O 0 0.00057865377
analgesia O 0 0.986326
( O 0 0.0013998975
PCA O 0 0.8029339
) O 0 0.0014374193
pump O 0 0.023864586
for O 0 0.00070173386
management O 0 0.0025926656
of O 0 0.0026404017
postoperative B-Disease 0 0.8268254
pain I-Disease 0 0.99347645
control O 0 0.0066449447
. O 0 0.006717807

Twenty O 0 0.010680086
- O 0 0.0044127163
three O 0 0.001461073
h O 0 0.0018682051
postoperatively O 0 0.0028034186
he O 0 0.0021124342
developed O 0 0.002450989
a O 0 0.0019632373
brief O 0 0.0030018415
self O 0 0.009520363
- O 0 0.0063898014
limited O 0 0.0069889603
seizure B-Disease 2 0.9942021
. O 0 0.011646471

Both O 0 0.0067546563
plasma O 0 0.0831502
pethidine B-Chemical 1 0.9990834
and O 0 0.004964984
norpethidine B-Chemical 0 0.99631786
were O 0 0.0015640196
elevated O 0 0.003319036
in O 0 0.0006461039
the O 0 0.00056834077
range O 0 0.0009451579
associated O 0 0.00091812713
with O 0 0.001047649
clinical O 0 0.016260672
manifestations O 0 0.6171454
of O 0 0.002747068
central O 0 0.014456112
nervous O 0 0.88129663
system O 0 0.010253019
excitation O 0 0.5750542
. O 0 0.008442951

No O 0 0.010117051
other O 0 0.005776458
risk O 0 0.017312746
factors O 0 0.009867381
for O 0 0.005800024
CNS O 0 0.89366925
toxicity B-Disease 2 0.9867578
were O 0 0.008938943
identified O 0 0.008994893
. O 0 0.011183345

This O 0 0.0044842535
method O 0 0.0030868116
allowed O 0 0.0017256957
frequent O 0 0.0033155254
self O 0 0.005473836
- O 0 0.0019947118
dosing O 0 0.020696213
of O 0 0.0013577058
pethidine B-Chemical 1 0.99952567
at O 0 0.00046505895
short O 0 0.0004588416
time O 0 0.00038521583
intervals O 0 0.0005420338
and O 0 0.0006395366
rapid O 0 0.0020277875
accumulation O 0 0.0031915107
of O 0 0.004757656
pethidine B-Chemical 1 0.99945027
and O 0 0.018022742
norpethidine B-Chemical 0 0.9958805
. O 0 0.009967159

The O 0 0.003206053
routine O 0 0.0030167114
use O 0 0.0026809112
of O 0 0.0032383483
pethidine B-Chemical 1 0.9990759
via O 0 0.0027433007
PCA O 0 0.7241007
even O 0 0.0014695415
for O 0 0.0009195025
a O 0 0.0012315494
brief O 0 0.002008821
postoperative O 0 0.116312884
analgesia O 0 0.9799698
should O 0 0.0024637312
be O 0 0.004060921
reconsidered O 0 0.008184921
. O 0 0.0070175943

An O 0 0.010911284
unusual O 0 0.013883988
toxic O 0 0.5551468
reaction O 0 0.014041903
to O 0 0.0037201722
axillary O 0 0.068306416
block O 0 0.006192415
by O 0 0.0065691485
mepivacaine B-Chemical 0 0.99787116
with O 0 0.033885937
adrenaline B-Chemical 1 0.99710554
. O 0 0.015846968

An O 0 0.0062981723
increase B-Disease 0 0.0025512385
in I-Disease 0 0.0018073338
blood I-Disease 0 0.006294153
pressure I-Disease 0 0.047536768
, O 0 0.0017127009
accompanied O 0 0.0021177994
by O 0 0.0012029399
atrial B-Disease 0 0.989012
fibrillation I-Disease 0 0.9997334
, O 0 0.006114201
agitation B-Disease 2 0.98671186
, O 0 0.0012501559
incomprehensible B-Disease 0 0.044579644
shouts I-Disease 0 0.07515419
and O 0 0.00047245098
loss B-Disease 0 0.0013107824
of I-Disease 0 0.00069302024
consciousness I-Disease 0 0.9574797
, O 0 0.0006405473
was O 0 0.0002834855
observed O 0 0.00019403917
in O 0 0.00022626
an O 0 0.00047076895
elderly O 0 0.2128894
, O 0 0.00066760933
ASA O 1 0.9438788
classification O 0 0.0010238902
group O 0 0.00059365865
II O 0 0.010074158
, O 0 0.00055815245
cardiovascularly O 0 0.54064834
medicated O 0 0.77073693
male O 0 0.0025239885
, O 0 0.0003149702
12 O 0 0.00014459508
min O 0 0.0002196386
after O 0 8.733285e-05
performance O 0 0.00023885466
of O 0 0.0002764208
axillary O 0 0.029265312
block O 0 0.0005803107
with O 0 0.00064671703
mepivacaine B-Chemical 0 0.9996388
850 O 0 0.02723675
mg O 0 0.51423556
containing O 0 0.00060654926
adrenaline B-Chemical 1 0.999335
0 O 0 0.00054801046
. O 0 0.00021194274
225 O 0 0.001954917
mg O 0 0.11412482
, O 0 0.0005519876
for O 0 0.00041190145
correction O 0 0.0018734095
of O 0 0.001978085
Dupuytren B-Disease 0 0.99108255
' I-Disease 0 0.0037902833
s I-Disease 0 0.006112179
contracture I-Disease 0 0.984823
. O 0 0.008320853

After O 0 0.0028499516
intravenous O 0 0.2134597
administration O 0 0.13488752
of O 0 0.0044283
labetalol B-Chemical 1 0.9998807
, O 0 0.019864447
metoprolol B-Chemical 1 0.99989855
and O 0 0.003835964
midazolam B-Chemical 1 0.99966204
the O 0 0.00078142755
patient O 0 0.001058436
' O 0 0.00056613266
s O 0 0.00055031356
condition O 0 0.0007485832
improved O 0 0.0010640054
, O 0 0.00073926355
and O 0 0.0006235639
15 O 0 0.0006130455
min O 0 0.0011261073
later O 0 0.001086629
he O 0 0.002620024
woke O 0 0.006165841
up O 0 0.004426377
. O 0 0.005709972

The O 0 0.0032588344
block O 0 0.0034645558
was O 0 0.0018823203
successful O 0 0.0019667712
and O 0 0.0014583123
surgery O 0 0.0029047662
was O 0 0.0010323526
conducted O 0 0.0009017049
as O 0 0.000866586
scheduled O 0 0.0011547083
despite O 0 0.0019651926
persisting O 0 0.07563948
atrial B-Disease 0 0.9905025
fibrillation I-Disease 0 0.9983236
. O 0 0.013460301

Postoperatively O 0 0.044292394
, O 0 0.0054286676
the O 0 0.0030330701
patient O 0 0.004352382
refused O 0 0.008019652
DC O 0 0.10196953
cardioversion O 0 0.5047892
and O 0 0.0039670607
was O 0 0.0041281222
treated O 0 0.009796144
medically O 0 0.541965
. O 0 0.011158425

Both O 0 0.004326196
the O 0 0.002134249
temporal O 0 0.005024508
relationship O 0 0.00096513133
of O 0 0.0011724884
events O 0 0.002848679
and O 0 0.00072407705
the O 0 0.00048266473
response O 0 0.00071627053
to O 0 0.00036643303
treatment O 0 0.0007706985
suggest O 0 0.00026263416
that O 0 0.00026128
a O 0 0.00036352105
rapid O 0 0.0015772083
systemic O 0 0.83090013
absorption O 0 0.6750216
of O 0 0.0019922554
mepivacaine B-Chemical 0 0.99980277
with O 0 0.0032041825
adrenaline B-Chemical 1 0.9997317
and O 0 0.00072484853
/ O 0 0.0009800796
or O 0 0.00019572489
interaction O 0 0.0002633219
of O 0 0.00029043265
these O 0 0.00044157752
drugs O 0 0.36726803
with O 0 0.00043334428
the O 0 0.0002908222
patient O 0 0.0006123468
' O 0 0.00044581256
s O 0 0.00062151626
cardiovascular O 0 0.8801353
medications O 0 0.36239862
were O 0 0.0006455102
responsible O 0 0.0007863345
for O 0 0.00083533296
the O 0 0.0016937273
perioperative O 0 0.34925193
complications O 0 0.78576714
. O 0 0.007054069

Drug O 0 0.9522505
- O 0 0.008928545
associated O 0 0.00546657
acute O 0 0.92480886
- O 0 0.0058806753
onset O 0 0.014353912
vanishing B-Disease 0 0.25384405
bile I-Disease 0 0.98326784
duct I-Disease 0 0.9493392
and O 0 0.003866143
Stevens B-Disease 0 0.31883472
- I-Disease 0 0.0052969735
Johnson I-Disease 0 0.23726346
syndromes I-Disease 0 0.5214674
in O 0 0.002795743
a O 0 0.0046992553
child O 0 0.009793994
. O 0 0.0075240456

Acute O 0 0.96368325
vanishing B-Disease 0 0.33731827
bile I-Disease 0 0.9799819
duct I-Disease 0 0.9713055
syndrome O 0 0.9440539
is O 0 0.0016660936
a O 0 0.0011793089
rare O 0 0.0056131603
but O 0 0.00070683146
established O 0 0.00094522355
cause O 0 0.0019497955
of O 0 0.0010895899
progressive O 0 0.82282805
cholestasis B-Disease 2 0.99993944
in O 0 0.0016712632
adults O 0 0.0077210907
, O 0 0.00063712505
is O 0 0.00035714032
most O 0 0.0005865856
often O 0 0.00074743794
drug O 0 0.16985658
or O 0 0.0005561782
toxin O 0 0.17460382
related O 0 0.00060791394
, O 0 0.0009772582
and O 0 0.00090060104
is O 0 0.0011239466
of O 0 0.0021744631
unknown O 0 0.010668613
pathogenesis O 0 0.14706062
. O 0 0.0075625754

It O 0 0.01048403
has O 0 0.0053896746
not O 0 0.004583453
been O 0 0.0055160965
reported O 0 0.006572136
previously O 0 0.006095548
in O 0 0.0072358013
children O 0 0.01859549
. O 0 0.01302364

Stevens B-Disease 0 0.14945884
- I-Disease 0 0.008050278
Johnson I-Disease 0 0.16617061
syndrome I-Disease 0 0.64838
is O 0 0.0015418439
a O 0 0.0011656709
well O 0 0.0007996656
- O 0 0.0013179686
recognized O 0 0.00097057875
immune O 0 0.058780883
complex O 0 0.001064125
- O 0 0.0013114766
mediated O 0 0.0005815754
hypersensitivity B-Disease 2 0.7638325
reaction O 0 0.010605695
that O 0 0.00028176425
affects O 0 0.00020282075
all O 0 0.000238897
age O 0 0.00070831843
groups O 0 0.00039353428
, O 0 0.00042012878
is O 0 0.00031608145
drug O 0 0.16076699
or O 0 0.0004243169
infection B-Disease 2 0.23102047
induced O 0 0.0010099818
, O 0 0.00064195297
and O 0 0.00045711917
has O 0 0.00055344286
classic O 0 0.071964934
systemic O 0 0.91752607
, O 0 0.0032111884
mucosal O 0 0.5670729
, O 0 0.0027674194
and O 0 0.0028564662
dermatologic O 0 0.840412
manifestations O 0 0.9291851
. O 0 0.0077585317

A O 0 0.016931525
previously O 0 0.003230431
healthy O 0 0.005766843
child O 0 0.0028253747
who O 0 0.0029845582
developed O 0 0.0029934917
acute O 0 0.92187923
, O 0 0.0024336837
severe O 0 0.19357544
, O 0 0.0011381286
rapidly O 0 0.001894292
progressive O 0 0.3207857
vanishing B-Disease 0 0.37625468
bile I-Disease 0 0.9920391
duct I-Disease 0 0.9823798
syndrome I-Disease 0 0.94858986
shortly O 0 0.0021946214
after O 0 0.00036621332
Stevens B-Disease 0 0.15413167
- I-Disease 0 0.0015528301
Johnson I-Disease 0 0.22824992
syndrome I-Disease 0 0.73521274
is O 0 0.0005031152
described O 0 0.00040491764
; O 0 0.0007316323
this O 0 0.00042367607
was O 0 0.0005799002
temporally O 0 0.002650557
associated O 0 0.0020515586
with O 0 0.0050837616
ibuprofen B-Chemical 0 0.9991524
use O 0 0.014086463
. O 0 0.0075763944

Despite O 0 0.0052905004
therapy O 0 0.015976932
with O 0 0.0050853076
ursodeoxycholic B-Chemical 0 0.9994259
acid I-Chemical 0 0.9892725
, O 0 0.0077792085
prednisone B-Chemical 1 0.9992182
, O 0 0.0020021093
and O 0 0.00082671706
then O 0 0.0007666613
tacrolimus B-Chemical 0 0.9996259
, O 0 0.001817366
her O 0 0.006057054
cholestatic B-Disease 0 0.99996185
disease I-Disease 0 0.99681795
was O 0 0.0020800042
unrelenting O 0 0.7429791
, O 0 0.0013839304
with O 0 0.0018499399
cirrhosis B-Disease 2 0.9997807
shown O 0 0.0009534636
by O 0 0.000997714
biopsy O 0 0.004414837
6 O 0 0.00090789
months O 0 0.0013546228
after O 0 0.0014071647
presentation O 0 0.009884997
. O 0 0.0054402347

This O 0 0.005115595
case O 0 0.0029069711
documents O 0 0.0046812333
acute O 0 0.8720161
drug O 0 0.73911756
- O 0 0.0029877708
related O 0 0.0008229759
vanishing B-Disease 0 0.12008429
bile I-Disease 0 0.98297554
duct I-Disease 0 0.9760243
syndrome I-Disease 0 0.94346076
in O 0 0.0005144878
the O 0 0.00037692793
pediatric O 0 0.0016072752
age O 0 0.00078066456
group O 0 0.00037523892
and O 0 0.00027873137
suggests O 0 0.00019278954
shared O 0 0.00044542472
immune O 0 0.023745667
mechanisms O 0 0.00088737364
in O 0 0.0002892538
the O 0 0.00033736037
pathogenesis O 0 0.0065494734
of O 0 0.0007387332
both O 0 0.00083741697
Stevens B-Disease 0 0.233632
- I-Disease 0 0.002830023
Johnson I-Disease 0 0.290822
syndrome I-Disease 0 0.77716225
and O 0 0.002224011
vanishing B-Disease 0 0.40200275
bile I-Disease 0 0.99024546
duct I-Disease 0 0.98779595
syndrome I-Disease 0 0.98326313
. O 0 0.010505138

High O 0 0.022360167
incidence O 0 0.011165253
of O 0 0.004592111
primary B-Disease 0 0.009315828
pulmonary I-Disease 2 0.9930112
hypertension I-Disease 2 0.999617
associated O 0 0.022986203
with O 0 0.013879852
appetite B-Chemical 1 0.99677247
suppressants I-Chemical 1 0.99739206
in O 0 0.010588482
Belgium O 0 0.17989473
. O 0 0.010057808

Primary B-Disease 0 0.10398752
pulmonary I-Disease 2 0.9884006
hypertension I-Disease 2 0.999469
is O 0 0.0033762401
a O 0 0.0018274646
rare O 0 0.00788181
, O 0 0.0014316038
progressive O 0 0.12948641
and O 0 0.0012062368
incurable O 0 0.7712269
disease O 0 0.8904978
, O 0 0.0012984495
which O 0 0.00078617106
has O 0 0.0005359266
been O 0 0.0006578932
associated O 0 0.00078411883
with O 0 0.0009000452
the O 0 0.0010828752
intake O 0 0.63051957
of O 0 0.00553496
appetite B-Chemical 0 0.9972705
suppressant I-Chemical 0 0.99730647
drugs O 0 0.9742587
. O 0 0.010315517

The O 0 0.0024395194
importance O 0 0.0016204511
of O 0 0.0015044035
this O 0 0.0009972526
association O 0 0.00073622854
was O 0 0.0006957939
evaluated O 0 0.0006181141
in O 0 0.00056633755
Belgium O 0 0.0056115
while O 0 0.00041938934
this O 0 0.0004011669
country O 0 0.0007938486
still O 0 0.00041530826
had O 0 0.00046324538
no O 0 0.0004137162
restriction O 0 0.001475447
on O 0 0.0005178146
the O 0 0.001080165
prescription O 0 0.046623748
of O 0 0.0066250665
appetite B-Chemical 1 0.99637336
suppressants I-Chemical 1 0.9971295
. O 0 0.011360531

Thirty O 0 0.0103060575
- O 0 0.0036620449
five O 0 0.0012221449
patients O 0 0.0025765381
with O 0 0.0014213583
primary B-Disease 0 0.0031558224
pulmonary I-Disease 2 0.99372476
hypertension I-Disease 2 0.99983335
and O 0 0.001379689
85 O 0 0.0008583144
matched O 0 0.00035684067
controls O 0 0.0004920614
were O 0 0.00032899395
recruited O 0 0.0003284089
over O 0 0.0002480127
32 O 0 0.0007398217
months O 0 0.0007267801
( O 0 0.0011707803
1992 O 0 0.0048541874
- O 0 0.002443317
1994 O 0 0.0073498497
) O 0 0.003308801
in O 0 0.0030041714
Belgium O 0 0.03672779
. O 0 0.006385954

Exposure O 0 0.14730944
to O 0 0.0055557075
appetite B-Chemical 0 0.9921726
- I-Chemical 0 0.009778573
suppressants I-Chemical 0 0.99518883
was O 0 0.0016412608
assessed O 0 0.0008242893
on O 0 0.0005553553
the O 0 0.0007201816
basis O 0 0.001035006
of O 0 0.0013224945
hospital O 0 0.0038925034
records O 0 0.002669454
and O 0 0.002327315
standardized O 0 0.0036092354
interview O 0 0.0065367403
. O 0 0.006612616

Twenty O 0 0.008469179
- O 0 0.0031475588
three O 0 0.0008926155
of O 0 0.001219949
the O 0 0.000906742
patients O 0 0.001803291
had O 0 0.00078783295
previously O 0 0.00073076197
taken O 0 0.00069331296
appetite B-Chemical 1 0.9972474
suppressants I-Chemical 1 0.9991866
, O 0 0.0016762047
mainly O 0 0.00226127
fenfluramines B-Chemical 0 0.9937761
, O 0 0.0006553427
as O 0 0.00021608926
compared O 0 0.00014712282
with O 0 0.00026746574
only O 0 0.0002454114
5 O 0 0.00019532946
of O 0 0.00026467835
the O 0 0.00026051953
controls O 0 0.0005548884
( O 0 0.00048788873
66 O 0 0.00056716084
versus O 0 0.00034295587
6 O 0 0.00034546488
% O 0 0.0005503073
, O 0 0.00068760174
p O 0 0.0010223107
< O 0 0.0011944984
0 O 0 0.0013943943
. O 0 0.0014638159
0001 O 0 0.033364456
) O 0 0.0063721603
. O 0 0.0056625037

Five O 0 0.007205144
patients O 0 0.0058166496
died O 0 0.0065119094
before O 0 0.0012147889
the O 0 0.001342916
interview O 0 0.0018025837
, O 0 0.0015629074
all O 0 0.0010456718
of O 0 0.001681787
them O 0 0.0028246103
had O 0 0.0028867824
taken O 0 0.0043132296
appetite B-Chemical 1 0.99291795
suppressants I-Chemical 1 0.9958371
. O 0 0.013848714

In O 0 0.0032476548
8 O 0 0.0021743502
patients O 0 0.0027470603
the O 0 0.0012750656
diagnosis O 0 0.0039695036
of O 0 0.0014886934
primary B-Disease 0 0.004440506
pulmonary I-Disease 2 0.99600166
hypertension I-Disease 2 0.9998592
was O 0 0.002031291
uncertain O 0 0.0031715517
, O 0 0.0011049344
5 O 0 0.00059056096
of O 0 0.00087959575
them O 0 0.001629461
had O 0 0.001823803
taken O 0 0.002947467
appetite B-Chemical 1 0.9935998
suppressants I-Chemical 1 0.9962639
. O 0 0.011013702

The O 0 0.0030358543
patients O 0 0.004481874
who O 0 0.0032873827
had O 0 0.0015361139
been O 0 0.0014090944
exposed O 0 0.0012650387
to O 0 0.0011262461
appetite B-Chemical 1 0.9967654
suppressants I-Chemical 1 0.9987639
tended O 0 0.0010391789
to O 0 0.00044591862
be O 0 0.00036705253
on O 0 0.00017269187
average O 0 0.00018378106
more O 0 0.00046859687
severely O 0 0.004619435
ill O 0 0.0985637
, O 0 0.00053783134
and O 0 0.00031919143
to O 0 0.0002502466
have O 0 0.00028409157
a O 0 0.00031174437
shorter O 0 0.00026295136
median O 0 0.0003427751
delay O 0 0.0008368363
between O 0 0.00036470202
onset O 0 0.0029409244
of O 0 0.0019184758
symptoms O 0 0.44856685
and O 0 0.00394385
diagnosis O 0 0.06352564
. O 0 0.0065420787

A O 0 0.01585533
policy O 0 0.005321152
of O 0 0.0025506464
unrestricted O 0 0.0039818804
prescription O 0 0.039257187
of O 0 0.0031377338
appetite B-Chemical 1 0.9974017
suppressants I-Chemical 1 0.9986784
may O 0 0.0018371091
lead O 0 0.01202572
to O 0 0.00076316315
a O 0 0.0008504888
high O 0 0.0011909204
incidence O 0 0.005259712
of O 0 0.0019447302
associated O 0 0.0038045265
primary B-Disease 0 0.033198398
pulmonary I-Disease 2 0.99617994
hypertension I-Disease 2 0.99956304
. O 0 0.01841718

Intake O 0 0.6896351
of O 0 0.0104314
appetite B-Chemical 1 0.99202335
suppressants I-Chemical 1 0.99545574
may O 0 0.0046989406
accelerate O 0 0.004416883
the O 0 0.0034135524
progression O 0 0.2063053
of O 0 0.0063174977
the O 0 0.0075256564
disease O 0 0.79464334
. O 0 0.012900026

Inappropriate O 0 0.03273188
use O 0 0.0063591045
of O 0 0.0074081593
carbamazepine B-Chemical 1 0.9993899
and O 0 0.01434586
vigabatrin B-Chemical 0 0.9993062
in O 0 0.005487653
typical O 0 0.008796005
absence B-Disease 0 0.013849274
seizures I-Disease 2 0.9989827
. O 0 0.017385429

Carbamazepine B-Chemical 1 0.99876285
and O 0 0.0151864095
vigabatrin B-Chemical 0 0.9989489
are O 0 0.007374344
contraindicated O 0 0.21945712
in O 0 0.0044052545
typical O 0 0.008150781
absence B-Disease 0 0.013474358
seizures I-Disease 2 0.99880517
. O 0 0.018706368

Of O 0 0.0047981013
18 O 0 0.0021296071
consecutive O 0 0.001676947
referrals O 0 0.0026530281
of O 0 0.001166729
children O 0 0.001766484
with O 0 0.00083855895
resistant O 0 0.0013800542
typical O 0 0.0009512953
absences O 0 0.27454385
only O 0 0.0005390135
, O 0 0.0004805615
eight O 0 0.00025550995
were O 0 0.0003211339
erroneously O 0 0.003445614
treated O 0 0.00090849353
with O 0 0.001072178
carbamazepine B-Chemical 1 0.9998939
either O 0 0.0008414421
as O 0 0.0006010964
monotherapy O 0 0.5744019
or O 0 0.0007327807
as O 0 0.000808382
an O 0 0.0016698993
add O 0 0.002232947
- O 0 0.0040279417
on O 0 0.0027407787
. O 0 0.005345342

Vigabatrin B-Chemical 1 0.9972403
was O 0 0.005240432
also O 0 0.0033162218
used O 0 0.0024340104
in O 0 0.0020965224
the O 0 0.0023474053
treatment O 0 0.004934339
of O 0 0.0047296435
two O 0 0.005064223
children O 0 0.015691876
. O 0 0.010337954

Frequency O 0 0.009093777
of O 0 0.0034230326
absences O 0 0.17541665
increased O 0 0.002397724
in O 0 0.0009141162
four O 0 0.00058177667
children O 0 0.0016269254
treated O 0 0.001298042
with O 0 0.001290498
carbamazepine B-Chemical 1 0.99985516
and O 0 0.0008538381
two O 0 0.00036569632
of O 0 0.000594293
these O 0 0.0009220783
developed O 0 0.008741661
myoclonic B-Disease 2 0.9998872
jerks I-Disease 2 0.9995363
, O 0 0.0025720226
which O 0 0.0013972996
resolved O 0 0.0020295968
on O 0 0.0010832548
withdrawal O 0 0.74573445
of O 0 0.015433693
carbamazepine B-Chemical 1 0.9994904
. O 0 0.010855645

Absences O 0 0.23657496
were O 0 0.0038198775
aggravated O 0 0.123066686
in O 0 0.0019069893
both O 0 0.0015488451
cases O 0 0.0027056718
where O 0 0.002006012
vigabatrin B-Chemical 0 0.999485
was O 0 0.0020879663
added O 0 0.0016714956
on O 0 0.0011631155
to O 0 0.0022040512
concurrent O 0 0.009127466
treatment O 0 0.015004806
. O 0 0.008241342

Optimal O 0 0.0072226804
control O 0 0.0022064457
of O 0 0.0021672288
the O 0 0.001618053
absences O 0 0.16375905
was O 0 0.0012969935
achieved O 0 0.0014709701
with O 0 0.0021599445
sodium B-Chemical 0 0.99886334
valproate I-Chemical 0 0.9999093
, O 0 0.03759545
lamotrigine B-Chemical 0 0.9998807
, O 0 0.0039390093
or O 0 0.0018573216
ethosuximide B-Chemical 0 0.9996953
alone O 0 0.0030224102
or O 0 0.0020175674
in O 0 0.0027328283
combination O 0 0.010340325
. O 0 0.0067804907

Choreoathetoid B-Disease 0 0.47684088
movements I-Disease 0 0.026193684
associated O 0 0.0064991903
with O 0 0.0054387175
rapid O 0 0.010103374
adjustment O 0 0.008932994
to O 0 0.010320431
methadone B-Chemical 1 0.98879737
. O 0 0.017468901

Choreatiform B-Disease 0 0.23007636
hyperkinesias I-Disease 0 0.9898106
are O 0 0.0032552485
known O 0 0.0024322197
to O 0 0.0013759113
be O 0 0.0013257609
occasional O 0 0.0059097465
movement B-Disease 0 0.022790829
abnormalities I-Disease 0 0.5604396
during O 0 0.0017105506
intoxications O 0 0.9980635
with O 0 0.011454421
cocaine B-Chemical 1 0.99887246
but O 0 0.0046337387
not O 0 0.0058904486
opiates O 0 0.99535
. O 0 0.009759781

This O 0 0.004949606
is O 0 0.002211421
a O 0 0.0016601857
case O 0 0.0013119665
report O 0 0.0025217922
of O 0 0.0018046028
euphoria O 0 0.9978319
and O 0 0.003057164
choreoathetoid B-Disease 0 0.99967396
movements I-Disease 0 0.13317752
both O 0 0.00061926
transiently O 0 0.009373692
induced O 0 0.00065653113
by O 0 0.00036554117
rapid O 0 0.001035739
adjustment O 0 0.0004984114
to O 0 0.0002679864
the O 0 0.00030146618
selective O 0 0.011067812
mu O 0 0.3207527
- O 0 0.0040040663
opioid O 0 0.998648
receptor O 0 0.6758084
agonist O 0 0.99480826
methadone B-Chemical 1 0.9991722
in O 0 0.0007659347
an O 0 0.0010372022
inpatient O 0 0.012446018
previously O 0 0.0019213267
abusing O 0 0.86939615
heroine B-Chemical 0 0.47917196
and O 0 0.009028139
cocaine B-Chemical 1 0.9975109
. O 0 0.009217666

In O 0 0.008312995
addition O 0 0.006342698
, O 0 0.010091811
minor O 0 0.016852293
EEG O 0 0.94307727
abnormalities O 0 0.40788475
occurred O 0 0.020982353
. O 0 0.016463133

Possible O 0 0.03743481
underlying O 0 0.020868635
neurobiological O 0 0.18764259
phenomena O 0 0.037987
are O 0 0.01502852
discussed O 0 0.016678626
. O 0 0.019239469

Adverse O 0 0.2764139
effects O 0 0.013593398
of O 0 0.011086298
the O 0 0.012590247
atypical O 0 0.59500855
antipsychotics O 0 0.9925154
. O 0 0.026694756

Collaborative O 0 0.07120541
Working O 0 0.053494904
Group O 0 0.033199478
on O 0 0.010000542
Clinical O 0 0.17672303
Trial O 0 0.17754428
Evaluations O 0 0.033726566
. O 0 0.02038769

Adverse O 0 0.2947582
effects O 0 0.0102892965
of O 0 0.009289619
antipsychotics O 0 0.9930615
often O 0 0.014638906
lead O 0 0.044786707
to O 0 0.010252819
noncompliance O 0 0.6836227
. O 0 0.0149085

Thus O 0 0.003913541
, O 0 0.0028436924
clinicians O 0 0.0023930736
should O 0 0.0006944665
address O 0 0.00050157355
patients O 0 0.0013295339
' O 0 0.00067919237
concerns O 0 0.0010182104
about O 0 0.00044563788
adverse O 0 0.29531416
effects O 0 0.0010400504
and O 0 0.0003915467
attempt O 0 0.00040432904
to O 0 0.0002463174
choose O 0 0.00035771666
medications O 0 0.108461864
that O 0 0.0002236717
will O 0 0.00016694462
improve O 0 0.00019310635
their O 0 0.00029907038
patients O 0 0.00082477793
' O 0 0.00038739893
quality O 0 0.0003178874
of O 0 0.0005780515
life O 0 0.0012737461
as O 0 0.0005849431
well O 0 0.00079591194
as O 0 0.0011713537
overall O 0 0.0027597055
health O 0 0.012453764
. O 0 0.0056288657

The O 0 0.00337763
side O 0 0.0075888317
effect O 0 0.0020577004
profiles O 0 0.0013564753
of O 0 0.0014781202
the O 0 0.0012639144
atypical O 0 0.2726496
antipsychotics O 0 0.99842143
are O 0 0.0012092929
more O 0 0.0009955079
advantageous O 0 0.00090493896
than O 0 0.00055606314
those O 0 0.0011382429
of O 0 0.0015222998
the O 0 0.0020916455
conventional O 0 0.007125506
neuroleptics O 0 0.99679023
. O 0 0.009484396

Conventional O 0 0.016622256
agents O 0 0.06858009
are O 0 0.0023008503
associated O 0 0.0019363943
with O 0 0.0015589464
unwanted O 0 0.023975683
central O 0 0.005557001
nervous O 0 0.7901815
system O 0 0.0016380996
effects O 0 0.0019527597
, O 0 0.0009924745
including O 0 0.0012934536
extrapyramidal B-Disease 2 0.9999292
symptoms I-Disease 2 0.99306536
( O 0 0.012900347
EPS B-Disease 2 0.9989304
) O 0 0.006636949
, O 0 0.0050652055
tardive B-Disease 0 0.9999659
dyskinesia I-Disease 2 0.9999703
, O 0 0.0038746307
sedation O 0 0.8043388
, O 0 0.0004540103
and O 0 0.00024368294
possible O 0 0.0002893186
impairment O 0 0.07827737
of O 0 0.000363343
some O 0 0.00041333915
cognitive O 0 0.46169043
measures O 0 0.00035060133
, O 0 0.00033087053
as O 0 0.00015743297
well O 0 0.00016819827
as O 0 0.00020319395
cardiac O 0 0.1652254
effects O 0 0.0028075299
, O 0 0.00212961
orthostatic B-Disease 2 0.9997477
hypotension I-Disease 2 0.9999428
, O 0 0.004436822
hepatic O 0 0.98240674
changes O 0 0.0028686011
, O 0 0.0014156912
anticholinergic O 0 0.9994281
side O 0 0.08079672
effects O 0 0.004818379
, O 0 0.001917959
sexual B-Disease 0 0.7503495
dysfunction I-Disease 0 0.9942021
, O 0 0.002774235
and O 0 0.002280352
weight B-Disease 0 0.01682653
gain I-Disease 0 0.009627585
. O 0 0.0057140775

The O 0 0.0033146131
newer O 0 0.015509189
atypical O 0 0.090962164
agents O 0 0.104965106
have O 0 0.0014772766
a O 0 0.0010901045
lower O 0 0.0008738429
risk O 0 0.01969503
of O 0 0.0021497675
EPS B-Disease 2 0.99834275
, O 0 0.0014648177
but O 0 0.0004510762
are O 0 0.00032509252
associated O 0 0.00039694968
in O 0 0.00022597432
varying O 0 0.0004936466
degrees O 0 0.0020745222
with O 0 0.0006224428
sedation O 0 0.7329038
, O 0 0.0008300142
cardiovascular O 0 0.9554789
effects O 0 0.0036731127
, O 0 0.0009565841
anticholinergic O 0 0.99943215
effects O 0 0.0035156356
, O 0 0.0005631622
weight B-Disease 0 0.005303014
gain I-Disease 0 0.001748509
, O 0 0.0007212149
sexual B-Disease 0 0.6189992
dysfunction I-Disease 0 0.99600273
, O 0 0.0015665651
hepatic O 0 0.9738583
effects O 0 0.004982761
, O 0 0.0008402565
lowered O 0 0.019219013
seizure B-Disease 2 0.9991873
threshold O 0 0.0010050405
( O 0 0.0009180011
primarily O 0 0.002555775
clozapine B-Chemical 1 0.9998658
) O 0 0.00443954
, O 0 0.0013855874
and O 0 0.002097129
agranulocytosis B-Disease 0 0.99973685
( O 0 0.026331497
clozapine B-Chemical 1 0.99957067
only O 0 0.0063678287
) O 0 0.009859176
. O 0 0.0058972347

Since O 0 0.0027358658
the O 0 0.0020791325
incidence O 0 0.004708455
and O 0 0.0015632035
severity O 0 0.006693786
of O 0 0.0010933033
specific O 0 0.00085574243
adverse O 0 0.5500278
effects O 0 0.0016186353
differ O 0 0.0005653622
among O 0 0.00045248927
the O 0 0.00031734325
various O 0 0.0010179776
atypicals O 0 0.9692236
, O 0 0.0005200635
the O 0 0.00024477785
clinician O 0 0.0007201462
should O 0 0.00012276375
carefully O 0 0.00013890328
consider O 0 0.00013679013
which O 0 0.0003147607
side O 0 0.004502905
effects O 0 0.00071716914
are O 0 0.00026396615
most O 0 0.00039823473
likely O 0 0.00019444793
to O 0 0.00019004675
lead O 0 0.0019410547
to O 0 0.0001950942
the O 0 0.00018212767
individual O 0 0.00019793889
' O 0 0.00030771462
s O 0 0.00036856238
dissatisfaction O 0 0.011694834
and O 0 0.00037929762
noncompliance O 0 0.10556515
before O 0 0.0002398103
choosing O 0 0.000554198
an O 0 0.0010683516
antipsychotic O 0 0.9966619
for O 0 0.0010339868
a O 0 0.0017108837
particular O 0 0.0020959836
patient O 0 0.0063700923
. O 0 0.0053507118

A O 0 0.014799834
randomized O 0 0.004421616
, O 0 0.0030064918
placebo O 0 0.11477464
- O 0 0.0019021843
controlled O 0 0.0009095135
dose O 0 0.013675822
- O 0 0.0010728402
comparison O 0 0.00041971813
trial O 0 0.0009979749
of O 0 0.0010930971
haloperidol B-Chemical 1 0.99989474
for O 0 0.0014861482
psychosis B-Disease 0 0.9992569
and O 0 0.0018920547
disruptive B-Disease 0 0.5233033
behaviors I-Disease 0 0.41038105
in O 0 0.0025670216
Alzheimer B-Disease 0 0.99889946
' I-Disease 0 0.0040517473
s I-Disease 0 0.005267089
disease I-Disease 0 0.56466126
. O 0 0.0072062635

OBJECTIVE O 0 0.4904796
: O 0 0.0038178328
The O 0 0.0012846946
goal O 0 0.0014296385
of O 0 0.0009623931
this O 0 0.00068190374
study O 0 0.00087722327
was O 0 0.00045036213
to O 0 0.00032626308
compare O 0 0.00017260053
the O 0 0.00028384035
efficacy O 0 0.0013695067
and O 0 0.00041237054
side O 0 0.005602566
effects O 0 0.00072965136
of O 0 0.0003900853
two O 0 0.00023483785
doses O 0 0.026444215
of O 0 0.001364438
haloperidol B-Chemical 1 0.99995613
and O 0 0.0009930852
placebo O 0 0.2152536
in O 0 0.00024710962
the O 0 0.00023925283
treatment O 0 0.0008378201
of O 0 0.0008529839
psychosis B-Disease 0 0.99937195
and O 0 0.0010414877
disruptive B-Disease 0 0.40933394
behaviors I-Disease 0 0.1980488
in O 0 0.0006392807
patients O 0 0.003203519
with O 0 0.002749134
Alzheimer B-Disease 0 0.9990308
' I-Disease 0 0.003708056
s I-Disease 0 0.004910156
disease I-Disease 0 0.5766748
. O 0 0.006739995

METHOD O 0 0.041727502
: O 0 0.0041587017
In O 0 0.0016029563
a O 0 0.0014319896
6 O 0 0.0008920259
- O 0 0.001000961
week O 0 0.00049411476
random O 0 0.0007630974
- O 0 0.0009572101
assignment O 0 0.0008718461
, O 0 0.0005852359
double O 0 0.00040084907
- O 0 0.0007736514
blind O 0 0.0034646478
, O 0 0.00059720303
placebo O 0 0.11600486
- O 0 0.0005554945
controlled O 0 0.00029817328
trial O 0 0.0008680674
( O 0 0.0004784439
phase O 0 0.0009982298
A O 0 0.019803895
) O 0 0.0011648884
, O 0 0.0010275202
haloperidol B-Chemical 1 0.9999294
, O 0 0.0010462571
2 O 0 0.0004032322
- O 0 0.0004609437
3 O 0 0.00021577571
mg O 0 0.11246121
/ O 0 0.00052616
day O 0 0.00021629414
( O 0 0.00025673752
standard O 0 0.00016661608
dose O 0 0.0065512736
) O 0 0.0006890768
, O 0 0.00042416342
and O 0 0.00053054217
haloperidol B-Chemical 1 0.9999343
, O 0 0.000859124
0 O 0 0.0003729705
. O 0 0.00014389731
50 O 0 0.00036179347
- O 0 0.00034148231
0 O 0 0.00021373466
. O 0 0.00010774604
75 O 0 0.00031236382
mg O 0 0.068491936
/ O 0 0.0005090662
day O 0 0.00022961963
( O 0 0.00029819118
low O 0 0.0003346839
dose O 0 0.008557829
) O 0 0.0006867396
, O 0 0.00037364665
were O 0 0.00025389777
compared O 0 0.0001889644
in O 0 0.00032885405
71 O 0 0.0012243364
outpatients O 0 0.0071027474
with O 0 0.002297103
Alzheimer B-Disease 0 0.99879336
' I-Disease 0 0.0037163463
s I-Disease 0 0.0049704737
disease I-Disease 0 0.5565715
. O 0 0.006989795

For O 0 0.0026769445
the O 0 0.0019250024
subsequent O 0 0.0018451561
6 O 0 0.0011067827
- O 0 0.0011750261
week O 0 0.0005460214
double O 0 0.0005435596
- O 0 0.00087461347
blind O 0 0.0020439685
crossover O 0 0.0036551096
phase O 0 0.0015744983
( O 0 0.0007875687
phase O 0 0.0013988514
B O 0 0.14027014
) O 0 0.0009822447
, O 0 0.00044373167
patients O 0 0.0008804405
taking O 0 0.00066829997
standard O 0 0.00026123738
- O 0 0.0005019026
or O 0 0.00020584818
low O 0 0.00047208092
- O 0 0.00077167444
dose O 0 0.040282737
haloperidol B-Chemical 1 0.9999434
were O 0 0.0004162706
switched O 0 0.00080081896
to O 0 0.00025606964
placebo O 0 0.087925866
, O 0 0.00032763084
and O 0 0.00022969893
patients O 0 0.00072432344
taking O 0 0.0006791273
placebo O 0 0.03765542
were O 0 0.00019798212
randomly O 0 0.000110279005
assigned O 0 0.00023393989
to O 0 0.00028524827
standard O 0 0.00039855673
- O 0 0.0009477075
or O 0 0.00064816466
low O 0 0.0017773167
- O 0 0.004527179
dose O 0 0.27211052
haloperidol B-Chemical 1 0.9995136
. O 0 0.009521127

RESULTS O 0 0.02204542
: O 0 0.003609959
For O 0 0.0012522402
the O 0 0.0010313307
60 O 0 0.0010713183
patients O 0 0.0015579448
who O 0 0.0013158032
completed O 0 0.00063289405
phase O 0 0.0013302432
A O 0 0.009391113
, O 0 0.0006801131
standard O 0 0.0004113994
- O 0 0.00095029705
dose O 0 0.04541812
haloperidol B-Chemical 1 0.9999356
was O 0 0.0007627502
efficacious O 0 0.022092836
and O 0 0.00037148778
superior O 0 0.0012251531
to O 0 0.00022488632
both O 0 0.00024123049
low O 0 0.0005151456
- O 0 0.00084298966
dose O 0 0.045305327
haloperidol B-Chemical 1 0.99994254
and O 0 0.000688721
placebo O 0 0.105544925
for O 0 0.00023403026
scores O 0 0.00028507158
on O 0 0.00018295232
the O 0 0.00038685242
Brief O 0 0.019659214
Psychiatric O 0 0.27717617
Rating O 0 0.19359499
Scale O 0 0.7927446
psychosis B-Disease 0 0.9984548
factor O 0 0.012844217
and O 0 0.0018297918
on O 0 0.0019261717
psychomotor B-Disease 0 0.9926259
agitation I-Disease 2 0.98635036
. O 0 0.008214835

Response O 0 0.019517513
rates O 0 0.0022554598
according O 0 0.0013126289
to O 0 0.0008469776
three O 0 0.00044820982
sets O 0 0.00054946187
of O 0 0.00066939986
criteria O 0 0.00086709316
were O 0 0.00039676295
greater O 0 0.0003521254
with O 0 0.0003877819
the O 0 0.00028963518
standard O 0 0.00029317517
dose O 0 0.009268494
( O 0 0.00060353905
55 O 0 0.00045815605
% O 0 0.00036181833
- O 0 0.00039080964
60 O 0 0.00028065
% O 0 0.0002648707
) O 0 0.00029622304
than O 0 0.00012022036
the O 0 0.00017328172
low O 0 0.00035859094
dose O 0 0.009362446
( O 0 0.0005600415
25 O 0 0.00053656916
% O 0 0.0003737304
- O 0 0.00043727123
35 O 0 0.0003426137
% O 0 0.0003537939
) O 0 0.00048054542
and O 0 0.0004419228
placebo O 0 0.058334157
( O 0 0.0009396968
25 O 0 0.0011488752
% O 0 0.0010926
- O 0 0.001653965
30 O 0 0.0014306701
% O 0 0.0025570684
) O 0 0.0047426284
. O 0 0.0047179195

The O 0 0.0029831566
advantage O 0 0.0021187197
of O 0 0.0019408523
standard O 0 0.0013771632
dose O 0 0.0057167145
over O 0 0.00090846454
low O 0 0.0018041682
dose O 0 0.01145158
was O 0 0.0018585745
replicated O 0 0.0019289732
in O 0 0.0029535885
phase O 0 0.01031197
B O 0 0.2083529
. O 0 0.009731738

In O 0 0.0039441213
phase O 0 0.005507639
A O 0 0.02510363
, O 0 0.005018404
extrapyramidal B-Disease 0 0.9996644
signs I-Disease 0 0.83517927
tended O 0 0.001170888
to O 0 0.0005241288
be O 0 0.0004186697
greater O 0 0.00032201348
with O 0 0.00034856936
the O 0 0.00024653308
standard O 0 0.00022767897
dose O 0 0.0035346143
than O 0 0.00018441827
in O 0 0.00019018035
the O 0 0.00019251842
other O 0 0.00021635067
two O 0 0.00017988027
conditions O 0 0.0003943246
, O 0 0.00034687837
primarily O 0 0.00038679264
because O 0 0.00018787138
of O 0 0.00036136416
a O 0 0.00043596473
subgroup O 0 0.002696576
( O 0 0.0006216695
20 O 0 0.0004970803
% O 0 0.0005265054
) O 0 0.000733172
who O 0 0.0011936266
developed O 0 0.001528128
moderate O 0 0.00730087
to O 0 0.0023702246
severe O 0 0.37432808
signs O 0 0.4920644
. O 0 0.0072404374

Low O 0 0.0898117
- O 0 0.007338212
dose O 0 0.10192331
haloperidol B-Chemical 1 0.9996884
did O 0 0.0018671982
not O 0 0.000861196
differ O 0 0.0008799398
from O 0 0.0007424523
placebo O 0 0.034870535
on O 0 0.00041441622
any O 0 0.00048565507
measure O 0 0.00044182493
of O 0 0.0011958976
efficacy O 0 0.004866344
or O 0 0.002251736
side O 0 0.042983416
effects O 0 0.012308401
. O 0 0.0070575736

CONCLUSIONS O 0 0.6556473
: O 0 0.0041380255
The O 0 0.0013237194
results O 0 0.0009856543
indicated O 0 0.00068733346
a O 0 0.00083816826
favorable O 0 0.0033242835
therapeutic O 0 0.007760917
profile O 0 0.001071861
for O 0 0.0007522448
haloperidol B-Chemical 1 0.99990106
in O 0 0.00071638863
doses O 0 0.03718788
of O 0 0.00076210755
2 O 0 0.00054487266
- O 0 0.0006230281
3 O 0 0.00029528068
mg O 0 0.13226874
/ O 0 0.000698986
day O 0 0.00030141935
, O 0 0.0003802942
although O 0 0.00030172121
a O 0 0.0004503467
subgroup O 0 0.0018239261
developed O 0 0.0015046535
moderate O 0 0.010875591
to O 0 0.002125499
severe O 0 0.83837605
extrapyramidal B-Disease 0 0.9996995
signs I-Disease 0 0.97573787
. O 0 0.009853368

A O 0 0.013467997
starting O 0 0.0033693193
dose O 0 0.009316071
of O 0 0.0024138407
1 O 0 0.0017983185
mg O 0 0.25587964
/ O 0 0.0020459108
day O 0 0.00082422403
with O 0 0.0009437846
gradual O 0 0.0017497936
, O 0 0.0015219267
upward O 0 0.006952701
dose O 0 0.02868997
titration O 0 0.017778192
is O 0 0.0039882944
recommended O 0 0.006651507
. O 0 0.0065599903

The O 0 0.002773516
narrow O 0 0.0037196176
therapeutic O 0 0.0068451944
window O 0 0.0020349931
observed O 0 0.0010275851
with O 0 0.0018708755
haloperidol B-Chemical 1 0.99984074
may O 0 0.0011727136
also O 0 0.0006634987
apply O 0 0.00042096287
to O 0 0.00040232338
other O 0 0.0005980315
neuroleptics O 0 0.9989919
used O 0 0.0007048048
in O 0 0.00080129795
Alzheimer B-Disease 0 0.99939954
' I-Disease 0 0.00095950544
s I-Disease 0 0.0009894506
disease I-Disease 0 0.34361652
patients O 0 0.0043706615
with O 0 0.0026801007
psychosis B-Disease 0 0.9984322
and O 0 0.004923772
disruptive B-Disease 0 0.67376775
behaviors I-Disease 0 0.5567232
. O 0 0.007247166

Effects O 0 0.020840686
of O 0 0.008978961
acetylsalicylic B-Chemical 0 0.99954385
acid I-Chemical 0 0.9949875
, O 0 0.0179713
dipyridamole B-Chemical 0 0.99938047
, O 0 0.0050014732
and O 0 0.0025434059
hydrocortisone B-Chemical 1 0.99889225
on O 0 0.0018605448
epinephrine B-Chemical 0 0.99867517
- O 0 0.010715891
induced O 0 0.010120575
myocardial B-Disease 2 0.99911684
injury I-Disease 2 0.9946674
in O 0 0.0062358617
dogs O 0 0.029966777
. O 0 0.007163304

A O 0 0.012740473
reproducible O 0 0.0041700797
model O 0 0.002381887
for O 0 0.0013069903
producing O 0 0.0021502054
diffuse O 0 0.22611938
myocardial B-Disease 2 0.99949217
injury I-Disease 2 0.99813986
( O 0 0.014249722
epinephrine B-Chemical 0 0.99907446
infusion O 0 0.27658823
) O 0 0.0011534909
has O 0 0.0003657371
been O 0 0.00039145976
developed O 0 0.00050039357
to O 0 0.00024717322
study O 0 0.00043234762
the O 0 0.0002843913
cardioprotective O 0 0.77666175
effects O 0 0.0012764418
of O 0 0.00066024764
agents O 0 0.10833186
or O 0 0.0004197299
maneuvers O 0 0.01338378
which O 0 0.000646959
might O 0 0.0003537452
alter O 0 0.000572294
the O 0 0.0006723368
evolution O 0 0.0018537766
of O 0 0.0039725965
acute O 2 0.9963237
myocardial B-Disease 2 0.9992937
infarction I-Disease 2 0.99971515
. O 0 0.024623118

Infusions O 0 0.74749017
of O 0 0.005287781
epinephrine B-Chemical 0 0.99581194
( O 0 0.0028115325
4 O 0 0.00078098464
mug O 0 0.0009188561
per O 0 0.0002666286
kilogram O 0 0.0010058528
per O 0 0.0002002961
minute O 0 0.00026523788
for O 0 0.00021589012
6 O 0 0.00019288332
hours O 0 0.00023904144
) O 0 0.00041982636
increased O 0 0.00058899936
radiocalcium B-Chemical 0 0.991437
uptakes O 0 0.28641626
into O 0 0.00021619107
intact O 0 0.0003937178
myocardium O 0 0.21992016
and O 0 0.00024323122
each O 0 9.632261e-05
of O 0 0.00022474161
its O 0 0.0004234062
subcellular O 0 0.00043805497
components O 0 0.0002919913
with O 0 0.00031556594
the O 0 0.00025392266
mitochondrial O 0 0.10080694
fraction O 0 0.00028586984
showing O 0 0.00028727198
the O 0 0.00021690484
most O 0 0.0004036472
consistent O 0 0.00024133471
changes O 0 0.00034402995
when O 0 0.00012793827
compared O 0 0.00011809338
to O 0 0.00020410038
saline O 0 0.07746201
- O 0 0.00058083807
infused O 0 0.0020759946
control O 0 0.00018126005
animals O 0 0.00022479864
( O 0 0.00033395912
4 O 0 0.00019710588
, O 0 0.00030049228
957 O 0 0.009299173
vs O 0 0.0005201275
. O 0 0.0001546775
827 O 0 0.0022716573
counts O 0 0.00019609195
per O 0 0.00012314574
minute O 0 0.00020945248
per O 0 0.00018367874
gram O 0 0.0010507321
of O 0 0.0007949735
dried O 0 0.0034218275
tissue O 0 0.006509072
or O 0 0.001668597
fraction O 0 0.003076332
) O 0 0.007027796
. O 0 0.0054423814

Myocardial O 0 0.80838233
concentrations O 0 0.010326826
of O 0 0.003615402
calcium B-Chemical 1 0.9909889
also O 0 0.0020180976
increased O 0 0.00191496
significantly O 0 0.0013593297
( O 0 0.0009309806
12 O 0 0.00036592368
. O 0 0.00023127612
0 O 0 0.0003350989
vs O 0 0.0005145116
. O 0 0.00017475316
5 O 0 0.0002056067
. O 0 0.00014708703
0 O 0 0.00028251874
mg O 0 0.03598164
. O 0 0.0001709489
per O 0 0.00017529739
100 O 0 0.0007630858
Gm O 0 0.16801494
. O 0 0.00035105838
of O 0 0.0008810237
fat O 0 0.66834736
- O 0 0.0023612708
free O 0 0.002762029
dry O 0 0.041043315
weight O 0 0.03214364
) O 0 0.00830758
. O 0 0.0059861606

Infusions O 0 0.81775415
of O 0 0.0069866246
calcium B-Chemical 1 0.99464476
chloride I-Chemical 0 0.99758184
sufficient O 0 0.0016600119
to O 0 0.0010678265
raise O 0 0.001173341
serum O 0 0.16001303
calcium B-Chemical 1 0.9964484
concentrations O 0 0.023436418
2 O 0 0.0010021873
mEq O 0 0.803111
. O 0 0.0002725501
per O 0 0.00022435156
liter O 0 0.0022855762
failed O 0 0.0006769084
to O 0 0.00054313487
increase O 0 0.0010638549
calcium B-Chemical 1 0.99549544
influx O 0 0.6491784
into O 0 0.0015712903
the O 0 0.0032132464
myocardial O 0 0.9956642
cell O 0 0.1332862
. O 0 0.008168216

Mitochondrial O 0 0.93049896
radiocalcium B-Chemical 0 0.98832685
uptakes O 0 0.38689542
were O 0 0.0018844338
significantly O 0 0.0014835098
decreased O 0 0.0017222924
in O 0 0.00069627876
animals O 0 0.0006953331
pretreated O 0 0.031868238
with O 0 0.0023289209
acetylsalicylic B-Chemical 0 0.9999311
acid I-Chemical 0 0.99773824
or O 0 0.0015448984
dipyridamole B-Chemical 0 0.9997658
or O 0 0.0006409627
when O 0 0.00040307114
hydrocortisone B-Chemical 1 0.99940455
was O 0 0.00053636765
added O 0 0.0003620483
to O 0 0.0002744633
the O 0 0.00037855937
epinephrine B-Chemical 0 0.9985233
infusion O 0 0.13359253
( O 0 0.000676425
2 O 0 0.00032995007
, O 0 0.00037816502
682 O 0 0.0048271827
, O 0 0.00037742557
2 O 0 0.00027980388
, O 0 0.00035818625
803 O 0 0.019395785
, O 0 0.0003546865
and O 0 0.0002699654
3 O 0 0.00022594979
, O 0 0.000299142
424 O 0 0.0015039063
counts O 0 0.00020995732
per O 0 0.00012823641
minute O 0 0.00021491498
per O 0 0.00018752813
gram O 0 0.0010651504
of O 0 0.00080151093
dried O 0 0.0031497022
fraction O 0 0.0015148888
, O 0 0.0028490517
respectively O 0 0.00603559
) O 0 0.006724555
. O 0 0.0053429217

Myocardial O 0 0.9327111
calcium B-Chemical 1 0.9901202
concentrations O 0 0.015097048
also O 0 0.0018439823
were O 0 0.0011234028
decreased O 0 0.0019359576
( O 0 0.0011671225
11 O 0 0.0006867733
. O 0 0.00030598388
2 O 0 0.00037371137
, O 0 0.00040911013
8 O 0 0.00028234185
. O 0 0.00016236272
3 O 0 0.0001986909
, O 0 0.00026546835
and O 0 0.00023258082
8 O 0 0.00022182187
. O 0 0.00012817467
9 O 0 0.00020829398
mg O 0 0.047650866
. O 0 0.000120260265
per O 0 0.0001116895
100 O 0 0.0005067565
Gm O 0 0.20882338
. O 0 0.00015803576
of O 0 0.00035472045
fat O 0 0.7054211
- O 0 0.00072000455
free O 0 0.0005298544
dry O 0 0.012405271
weight O 0 0.0078022745
, O 0 0.0004931535
respectively O 0 0.0009155737
) O 0 0.00042125853
in O 0 0.00016853669
the O 0 0.00016947003
three O 0 0.00012929148
treatment O 0 0.0006430194
groups O 0 0.0004425786
, O 0 0.00047478138
being O 0 0.00052754884
significantly O 0 0.0005866298
decreased O 0 0.0011422274
only O 0 0.0007712554
in O 0 0.00085167564
the O 0 0.0012111692
last O 0 0.0016985735
two O 0 0.0029885191
. O 0 0.005072922

Evidence O 0 0.012591735
of O 0 0.004211399
microscopic O 0 0.015327737
damage O 0 0.33132666
was O 0 0.0020912664
graded O 0 0.0056559783
as O 0 0.0011634829
less O 0 0.0014368404
severe O 0 0.033024732
in O 0 0.0012869206
the O 0 0.0014216533
three O 0 0.0014465053
treatment O 0 0.006103075
groups O 0 0.0068165325
. O 0 0.00745192

Acetylsalicylic B-Chemical 0 0.99871945
acid I-Chemical 0 0.98882383
, O 0 0.012049452
dipyridamole B-Chemical 0 0.9990036
, O 0 0.004433525
and O 0 0.0021161002
hydrocortisone B-Chemical 1 0.998461
all O 0 0.0010776869
appear O 0 0.0008790449
to O 0 0.00059348915
have O 0 0.0008251647
cardioprotective O 0 0.8041526
effects O 0 0.0023591893
when O 0 0.0007937492
tested O 0 0.0010472573
in O 0 0.0015923808
this O 0 0.0026688115
model O 0 0.0059833867
. O 0 0.006485372

Clinical O 0 0.038731277
and O 0 0.0036510637
histopathologic O 0 0.09810997
examination O 0 0.003220604
of O 0 0.002398228
renal O 0 0.98185986
allografts O 0 0.57660323
treated O 0 0.0041044373
with O 0 0.0030843213
tacrolimus B-Chemical 0 0.9997094
( O 0 0.015246273
FK506 B-Chemical 1 0.9993893
) O 0 0.0029073583
for O 0 0.0008650671
at O 0 0.0007960272
least O 0 0.0010944512
one O 0 0.0020037435
year O 0 0.004699726
. O 0 0.0057221726

BACKGROUND O 0 0.7161285
: O 0 0.004938428
We O 0 0.0019208603
clinically O 0 0.007873212
and O 0 0.0014859699
pathologically O 0 0.19362082
analyzed O 0 0.0011416553
renal O 0 0.9748443
allografts O 0 0.38232872
from O 0 0.00072897854
1 O 0 0.00055301416
9 O 0 0.0004749672
renal O 0 0.9082976
transplant O 0 0.54082376
patients O 0 0.0036697045
treated O 0 0.001421608
with O 0 0.0016336783
tacrolimus B-Chemical 0 0.9997801
( O 0 0.011454603
FK506 B-Chemical 1 0.9995016
) O 0 0.0026631623
for O 0 0.0008220584
more O 0 0.0014428413
than O 0 0.0010976039
1 O 0 0.002251845
year O 0 0.0037519096
. O 0 0.0047898563

METHODS O 0 0.007366132
: O 0 0.0040432895
Twenty O 0 0.004413475
- O 0 0.0021819915
six O 0 0.000962324
renal O 0 0.9003654
allograft O 0 0.8649897
biopsy O 0 0.00794169
specimens O 0 0.0010312299
from O 0 0.00057195337
1 O 0 0.0005230458
9 O 0 0.0004916434
renal O 0 0.84646904
transplant O 0 0.38418752
patients O 0 0.0022623958
who O 0 0.0012928599
underwent O 0 0.0010042178
transplantations O 0 0.027388705
between O 0 0.0006252969
1991 O 0 0.0027523127
and O 0 0.0016467384
1993 O 0 0.0072820904
were O 0 0.0024630937
evaluated O 0 0.003996653
. O 0 0.005963002

Thirteen O 0 0.009406216
biopsies O 0 0.0044231717
were O 0 0.0014369073
performed O 0 0.0009829637
from O 0 0.0008081471
stable O 0 0.0010617981
functioning O 0 0.0033339362
renal O 0 0.9595872
allografts O 0 0.31508756
with O 0 0.00091811485
informed O 0 0.0035507064
consent O 0 0.001545189
( O 0 0.00062593614
nonepisode O 0 0.00384609
biopsy O 0 0.0032788243
) O 0 0.0005858065
and O 0 0.0002688566
the O 0 0.00021495554
other O 0 0.00024728378
13 O 0 0.00030820255
were O 0 0.00020974965
from O 0 0.00024527684
dysfunctional O 0 0.006120794
renal O 0 0.97458005
allografts O 0 0.35065746
with O 0 0.0006662818
a O 0 0.0005698639
clinical O 0 0.0028701345
indication O 0 0.0006052107
for O 0 0.00067408034
biopsy O 0 0.006927272
( O 0 0.0023228219
episode O 0 0.01661205
biopsy O 0 0.02571609
) O 0 0.008439041
. O 0 0.0059331497

RESULTS O 0 0.024134548
: O 0 0.0040867054
The O 0 0.0015754775
main O 0 0.00205125
pathologic O 0 0.11433921
diagnoses O 0 0.014873337
( O 0 0.0014558674
some O 0 0.00079349236
overlap O 0 0.00062559766
) O 0 0.0010244728
were O 0 0.00063342985
acute O 0 0.8958746
rejection O 0 0.9924557
( O 0 0.0044021583
AR O 0 0.8684306
; O 0 0.0015574776
n O 0 0.0003962408
= O 0 0.00055112067
4 O 0 0.0002647601
) O 0 0.0004976065
, O 0 0.00046986944
chronic O 0 0.88138366
rejection O 0 0.9900774
( O 0 0.0024370572
CR O 0 0.46396706
; O 0 0.0008965207
n O 0 0.0003079362
= O 0 0.0004671748
5 O 0 0.00023859949
) O 0 0.00047085783
, O 0 0.00046040615
AR O 0 0.5053253
+ O 0 0.0008051823
CR O 0 0.26274514
( O 0 0.0005527528
n O 0 0.0002826322
= O 0 0.0004380742
4 O 0 0.00023162678
) O 0 0.00046750624
, O 0 0.00047190348
recurrent O 0 0.54661375
IgA B-Disease 0 0.9983866
nephropathy I-Disease 2 0.9999684
( O 0 0.0053069843
n O 0 0.0004462345
= O 0 0.00053902296
5 O 0 0.00022165569
) O 0 0.00037581366
, O 0 0.00026739508
normal O 0 0.00046679776
findings O 0 0.0008745785
( O 0 0.0004145905
n O 0 0.00024401426
= O 0 0.00040643645
2 O 0 0.00024579564
) O 0 0.0004016596
, O 0 0.00029975292
minimal O 0 0.00037481438
- O 0 0.00058505294
type O 0 0.00049967814
chronic O 0 0.9860541
FK506 B-Chemical 1 0.9999219
nephropathy B-Disease 2 0.99996376
( O 0 0.007936833
n O 0 0.00053940277
= O 0 0.00068335974
9 O 0 0.00033800345
) O 0 0.0005221713
, O 0 0.0004179251
and O 0 0.00046850933
mild O 0 0.3165168
- O 0 0.0017203802
type O 0 0.0017688063
FK506 B-Chemical 1 0.99973506
nephropathy B-Disease 2 0.99987507
( O 0 0.008978091
n O 0 0.0021329557
= O 0 0.0033982075
11 O 0 0.0031549016
) O 0 0.005383452
. O 0 0.00488554

Of O 0 0.0056517394
the O 0 0.002639267
nonepisode O 0 0.0076850103
biopsies O 0 0.004458134
, O 0 0.0017278754
7 O 0 0.0007742573
and O 0 0.0006440851
4 O 0 0.0004632856
biopsies O 0 0.0011494545
showed O 0 0.00050023285
minimal O 0 0.00078451453
- O 0 0.0009983353
type O 0 0.00063289166
and O 0 0.00086294976
mild O 0 0.4493583
- O 0 0.002463663
type O 0 0.0020708544
chronic O 0 0.9944832
FK506 B-Chemical 1 0.9997687
nephropathy B-Disease 2 0.99982136
, O 0 0.05213699
respectively O 0 0.032903954
. O 0 0.0071810344

Chronic O 0 0.99016666
FK506 B-Chemical 1 0.9990748
nephropathy B-Disease 2 0.9995571
consisted O 0 0.0033558097
of O 0 0.002225999
rough O 0 0.004321765
and O 0 0.0016465338
foamy O 0 0.5722845
tubular O 0 0.9281829
vacuolization O 0 0.95367086
( O 0 0.0016967753
5 O 0 0.00046473838
biopsies O 0 0.0020048916
) O 0 0.0009803838
, O 0 0.0007910943
arteriolopathy O 0 0.9965443
( O 0 0.00080554845
angiodegeneration O 0 0.0048042005
of O 0 0.0004876444
the O 0 0.0004910263
arteriolar O 0 0.99554473
wall O 0 0.10918126
; O 0 0.0009638692
20 O 0 0.00038792816
biopsies O 0 0.0015325871
) O 0 0.00067595136
, O 0 0.00044753015
focal B-Disease 0 0.061480694
segmental I-Disease 0 0.09011934
glomerulosclerosis I-Disease 2 0.99989545
( O 0 0.0026371214
4 O 0 0.00035299527
biopsies O 0 0.0017303668
) O 0 0.000579395
and O 0 0.00031690457
the O 0 0.00032970827
striped O 0 0.0016108856
form O 0 0.00064669125
of O 0 0.001453116
interstitial B-Disease 0 0.9758614
fibrosis I-Disease 2 0.9987184
( O 0 0.008330026
11 O 0 0.003259317
biopsies O 0 0.011428165
) O 0 0.0073493393
. O 0 0.005397779

The O 0 0.0036408855
serum O 0 0.041709874
creatinine B-Chemical 1 0.97835577
levels O 0 0.0017691118
of O 0 0.0014704255
patients O 0 0.0026315753
in O 0 0.00069784455
the O 0 0.00073394726
mild O 0 0.42973807
- O 0 0.001761111
type O 0 0.00090068136
chronic O 0 0.98868
FK506 B-Chemical 1 0.99990594
nephropathy B-Disease 2 0.999954
group O 0 0.0073231324
, O 0 0.00077223126
which O 0 0.0004268737
included O 0 0.0002384112
7 O 0 0.00019808898
episode O 0 0.0013008119
biopsies O 0 0.0013217754
, O 0 0.00032194747
were O 0 0.00019262382
statistically O 0 0.00019672546
higher O 0 0.00018164518
than O 0 0.00013418526
those O 0 0.00026742287
in O 0 0.00018439874
the O 0 0.00021879982
minimum O 0 0.00026959737
- O 0 0.000679048
type O 0 0.0006324656
chronic O 0 0.9867656
FK506 B-Chemical 1 0.9998574
- O 0 0.09180972
nephropathy B-Disease 2 0.9998766
group O 0 0.007304496
( O 0 0.002603299
P O 0 0.05794281
< O 0 0.0017061903
0 O 0 0.0016390246
. O 0 0.0016096431
001 O 0 0.14202927
) O 0 0.0067850393
. O 0 0.005747837

CONCLUSIONS O 0 0.6903326
: O 0 0.0046858503
This O 0 0.0024246753
study O 0 0.0017558794
demonstrates O 0 0.0008964975
that O 0 0.0010236766
chronic O 0 0.9740511
FK506 B-Chemical 1 0.9998229
nephropathy B-Disease 2 0.99992
consists O 0 0.0023481986
primarily O 0 0.0020691426
of O 0 0.0016822624
arteriolopathy O 0 0.9989506
manifesting O 0 0.6914304
as O 0 0.0005537751
insudative O 0 0.38693345
hyalinosis O 0 0.84110785
of O 0 0.00085229124
the O 0 0.000578982
arteriolar O 0 0.99725074
wall O 0 0.11954146
, O 0 0.00059578597
and O 0 0.00030106236
suggests O 0 0.0001918302
that O 0 0.0002797308
mild O 0 0.42450398
- O 0 0.001256916
type O 0 0.000686862
chronic O 0 0.99154824
FK506 B-Chemical 1 0.99992657
nephropathy B-Disease 2 0.9999585
is O 0 0.0019640808
a O 0 0.0007213442
condition O 0 0.00124817
which O 0 0.0006844514
may O 0 0.0005735595
lead O 0 0.005445741
to O 0 0.0008532209
deterioration O 0 0.21341771
of O 0 0.0035785441
renal O 0 0.99429554
allograft O 0 0.9869783
function O 0 0.017148122
. O 0 0.007454777

Different O 0 0.01330912
lobular O 0 0.95319045
distributions O 0 0.0027802002
of O 0 0.0026279644
altered O 0 0.0034222645
hepatocyte O 0 0.8123345
tight O 0 0.005021016
junctions O 0 0.0029829012
in O 0 0.0011043419
rat O 0 0.005114442
models O 0 0.0023077752
of O 0 0.0031528058
intrahepatic B-Disease 0 0.9761269
and I-Disease 0 0.018560886
extrahepatic I-Disease 0 0.9984242
cholestasis I-Disease 2 0.99973196
. O 0 0.039345402

Hepatocyte O 0 0.9499095
tight O 0 0.009264844
junctions O 0 0.0070821964
( O 0 0.003744412
TJs O 0 0.29964107
) O 0 0.002143388
, O 0 0.0009602783
the O 0 0.00052414305
only O 0 0.00057144696
intercellular O 0 0.008169294
barrier O 0 0.004285296
between O 0 0.00026920464
the O 0 0.000397346
sinusoidal O 0 0.046983343
and O 0 0.0006236854
the O 0 0.00064273784
canalicular O 0 0.90530443
spaces O 0 0.0033528479
, O 0 0.00099813
play O 0 0.00094127876
a O 0 0.00096095743
key O 0 0.0011940912
role O 0 0.0012309871
in O 0 0.0026485175
bile O 0 0.92821467
formation O 0 0.047704905
. O 0 0.008027852

Although O 0 0.0052189403
hepatocyte O 0 0.7438581
TJs O 0 0.4377294
are O 0 0.0020976278
impaired O 0 0.0027183509
in O 0 0.0015453383
cholestasis B-Disease 2 0.99973065
, O 0 0.002036422
attempts O 0 0.0011630434
to O 0 0.00040203388
localize O 0 0.00023447875
the O 0 0.00029778123
precise O 0 0.0005017976
site O 0 0.00044248224
of O 0 0.0008616138
hepatocyte O 0 0.96622914
TJ O 0 0.99712116
damage O 0 0.8470526
by O 0 0.001195708
freeze O 0 0.025969546
- O 0 0.0024823225
fracture O 0 0.7723071
electron O 0 0.046207156
microscopy O 0 0.0019094804
have O 0 0.0014139256
produced O 0 0.0019032103
limited O 0 0.0030536056
information O 0 0.0062690973
. O 0 0.006153059

Recently O 0 0.009306763
, O 0 0.004642659
several O 0 0.0037200504
TJ O 0 0.97724277
- O 0 0.00444473
associated O 0 0.0021715888
proteins O 0 0.0026422958
like O 0 0.0019942874
ZO O 0 0.96129245
- O 0 0.002919873
1 O 0 0.0011039407
and O 0 0.0011769353
7H6 O 0 0.1623648
have O 0 0.0016244318
been O 0 0.0020356248
identified O 0 0.0019787087
and O 0 0.0035641275
characterized O 0 0.008452766
. O 0 0.0073595066

Immunolocalization O 0 0.017766772
of O 0 0.0077802795
7H6 O 0 0.29608598
appears O 0 0.0046071443
to O 0 0.0033051714
closely O 0 0.0034579341
correlate O 0 0.0039021075
with O 0 0.0076512913
paracellular O 0 0.7532139
permeability O 0 0.94686645
. O 0 0.016222212

We O 0 0.0034433766
used O 0 0.0025161398
rat O 0 0.0056423848
models O 0 0.0027756856
of O 0 0.0030379244
intrahepatic B-Disease 0 0.9972205
cholestasis I-Disease 2 0.99993587
by O 0 0.065302655
ethinyl B-Chemical 0 0.9999219
estradiol I-Chemical 1 0.9998222
( O 0 0.017466297
EE B-Chemical 1 0.9770015
) O 0 0.0019447651
treatment O 0 0.002087237
and O 0 0.0012589984
extrahepatic B-Disease 0 0.99935454
cholestasis I-Disease 2 0.9999701
by O 0 0.018526627
bile O 0 0.99552226
duct O 0 0.9597192
ligation O 0 0.06201613
( O 0 0.0034356685
BDL O 0 0.99690044
) O 0 0.0013141336
to O 0 0.0004544049
precisely O 0 0.0005256084
determine O 0 0.00033511713
the O 0 0.0008337799
site O 0 0.0016338496
of O 0 0.0047912705
TJ O 0 0.988953
damage O 0 0.92608565
. O 0 0.010083184

Alterations O 0 0.015366135
in O 0 0.0033635371
hepatocyte O 0 0.7011688
TJs O 0 0.30409294
were O 0 0.0013046135
assessed O 0 0.00077323505
by O 0 0.00081168883
double O 0 0.00075207313
- O 0 0.0012882113
immunolabeling O 0 0.0031305691
for O 0 0.00078929233
7H6 O 0 0.40233344
and O 0 0.0017653469
ZO O 0 0.943282
- O 0 0.0020312374
1 O 0 0.00084339257
using O 0 0.0006896227
a O 0 0.00120224
confocal O 0 0.0031384842
laser O 0 0.015408356
scanning O 0 0.0066458457
microscope O 0 0.008529474
. O 0 0.007198244

In O 0 0.003238945
control O 0 0.0021935906
rats O 0 0.004893712
, O 0 0.0020218964
immunostaining O 0 0.0020619505
for O 0 0.0012154069
7H6 O 0 0.38331768
and O 0 0.002301727
ZO O 0 0.9607614
- O 0 0.0024014085
1 O 0 0.00079844496
colocalized O 0 0.00059324206
to O 0 0.0007060017
outline O 0 0.001762248
bile O 0 0.88710815
canaliculi O 0 0.45982906
in O 0 0.0018064358
a O 0 0.002539946
continuous O 0 0.0038968245
fashion O 0 0.01327508
. O 0 0.006875636

In O 0 0.0038359873
contrast O 0 0.0033727572
, O 0 0.003805228
7H6 O 0 0.32207423
and O 0 0.0033818525
ZO O 0 0.95113355
- O 0 0.002982504
1 O 0 0.0009779301
immunostaining O 0 0.0012352502
was O 0 0.00071714143
more O 0 0.00094403507
discontinuous O 0 0.0024478713
, O 0 0.0015047744
outlining O 0 0.002785158
the O 0 0.0022358533
bile O 0 0.93641627
canaliculi O 0 0.7282788
after O 0 0.005755548
BDL O 0 0.9906538
. O 0 0.010744585

Immunostaining O 0 0.014480767
for O 0 0.0036223598
7H6 O 0 0.33001426
, O 0 0.0036321383
not O 0 0.0020753283
ZO O 0 0.9364473
- O 0 0.0028190503
1 O 0 0.00087475975
, O 0 0.00071034906
decreased O 0 0.00087527744
and O 0 0.0004934168
predominantly O 0 0.00059271645
appeared O 0 0.00044697296
as O 0 0.00026559088
discrete O 0 0.0005495399
signals O 0 0.00053175597
in O 0 0.00040357964
the O 0 0.00055957725
submembranous O 0 0.14166763
cytoplasm O 0 0.0021036924
of O 0 0.002618727
periportal O 0 0.9820764
hepatocytes O 0 0.80669135
after O 0 0.0047228434
BDL O 0 0.99267066
. O 0 0.009089626

After O 0 0.0032806713
EE B-Chemical 1 0.55208564
treatment O 0 0.0048044445
, O 0 0.002070817
changes O 0 0.0014325421
in O 0 0.00071117404
immunostaining O 0 0.0012728462
for O 0 0.00072726334
7H6 O 0 0.4278737
and O 0 0.0014910387
ZO O 0 0.96617717
- O 0 0.00154968
1 O 0 0.00041464862
were O 0 0.00026738335
similar O 0 0.00020304715
to O 0 0.0002651724
those O 0 0.00043600242
seen O 0 0.0003546674
in O 0 0.00042056158
periportal O 0 0.932739
hepatocytes O 0 0.5313883
after O 0 0.00055271934
BDL O 0 0.9971949
, O 0 0.0010932131
but O 0 0.0005522699
distributed O 0 0.0006867907
more O 0 0.0009768571
diffusely O 0 0.003320038
throughout O 0 0.0013753138
the O 0 0.0032277682
lobule O 0 0.8826676
. O 0 0.0066580456

This O 0 0.0044362494
study O 0 0.00283368
is O 0 0.0013817172
the O 0 0.00089609786
first O 0 0.000623429
to O 0 0.0005745047
demonstrate O 0 0.00043085963
that O 0 0.0005123189
impairment O 0 0.14214875
of O 0 0.0012598801
hepatocyte O 0 0.9643993
TJs O 0 0.7645583
occurs O 0 0.0007231182
heterogenously O 0 0.023152083
in O 0 0.00035078303
the O 0 0.0004322732
liver O 0 0.8555435
lobule O 0 0.95924926
after O 0 0.00035964575
BDL O 0 0.9958259
and O 0 0.000496203
suggests O 0 0.0002626875
that O 0 0.0003921442
BDL O 0 0.99586594
and O 0 0.0008787044
EE B-Chemical 1 0.89078206
treatments O 0 0.0022508749
produce O 0 0.0005064421
different O 0 0.0007418056
lobular O 0 0.9893623
distributions O 0 0.0012972911
of O 0 0.0023542887
increased O 0 0.011140194
paracellular O 0 0.8780234
permeability O 0 0.96664923
. O 0 0.00963503

Memory O 0 0.49925107
facilitation O 0 0.056752525
and O 0 0.003076651
stimulation O 0 0.003335629
of O 0 0.002006564
endogenous O 0 0.0033274144
nerve O 0 0.6320498
growth O 0 0.020520478
factor O 0 0.018831128
synthesis O 0 0.101448566
by O 0 0.002283093
the O 0 0.0035322725
acetylcholine B-Chemical 1 0.9988304
releaser O 0 0.9977744
PG B-Chemical 0 0.9972687
- I-Chemical 0 0.031702686
9 I-Chemical 0 0.007716314
. O 0 0.0069682184

The O 0 0.0034799965
effects O 0 0.0044285464
of O 0 0.004257117
PG B-Chemical 0 0.99380153
- I-Chemical 0 0.0066831326
9 I-Chemical 0 0.0017775266
( O 0 0.00207143
3alpha B-Chemical 0 0.9564921
- I-Chemical 0 0.0027531148
tropyl I-Chemical 0 0.23381655
2 I-Chemical 0 0.0008567349
- I-Chemical 0 0.0010835706
( I-Chemical 0 0.0006812091
p I-Chemical 0 0.00077138323
- I-Chemical 0 0.0010531542
bromophenyl I-Chemical 0 0.8027311
) I-Chemical 0 0.0031336423
propionate I-Chemical 0 0.99919754
) O 0 0.0027719224
, O 0 0.00074252026
the O 0 0.0006236602
acetylcholine B-Chemical 1 0.99936193
releaser O 0 0.9972861
, O 0 0.0010703802
on O 0 0.00029953325
memory O 0 0.1282589
processes O 0 0.0021541324
and O 0 0.0008431177
nerve O 0 0.5747298
growth O 0 0.016995337
factor O 0 0.029064963
( O 0 0.004793461
NGF O 1 0.9978745
) O 0 0.0054542567
synthesis O 0 0.05775347
were O 0 0.00293347
evaluated O 0 0.0042592497
. O 0 0.0059502055

In O 0 0.0030912068
the O 0 0.002172341
mouse O 0 0.0024891226
passive O 0 0.004371668
- O 0 0.0024965068
avoidance O 0 0.003914783
test O 0 0.001511805
, O 0 0.0020756284
PG B-Chemical 0 0.9953512
- I-Chemical 0 0.0025935525
9 I-Chemical 0 0.00067842053
( O 0 0.0006048304
10 O 0 0.00040415485
- O 0 0.00047007305
30 O 0 0.00026874972
mg O 0 0.08361554
/ O 0 0.00077451154
kg O 0 0.0026753866
, O 0 0.0003911119
i O 0 0.0007072233
. O 0 0.00017513466
p O 0 0.00037370154
. O 0 0.0001670669
) O 0 0.00039764083
, O 0 0.00027004653
administered O 0 0.00047039124
20 O 0 0.00020316352
min O 0 0.00021607423
before O 0 8.0618396e-05
the O 0 0.00012514167
training O 0 0.00021536523
session O 0 0.000338679
, O 0 0.00042080562
prevented O 0 0.0032146804
amnesia B-Disease 0 0.9993037
induced O 0 0.00095510465
by O 0 0.00035497706
both O 0 0.00026327246
the O 0 0.00025306176
non O 0 0.0008530656
selective O 0 0.025536934
antimuscarinic O 0 0.99944633
drug O 0 0.9471349
scopolamine B-Chemical 1 0.99995804
and O 0 0.0015567865
the O 0 0.0008074463
M1 O 0 0.7070975
- O 0 0.0023161883
selective O 0 0.05254767
antagonist O 0 0.9938267
S B-Chemical 0 0.95740014
- I-Chemical 0 0.0064439005
( I-Chemical 0 0.0021322942
- I-Chemical 0 0.002574392
) I-Chemical 0 0.0028650572
- I-Chemical 0 0.0041196174
ET I-Chemical 0 0.7788447
- I-Chemical 0 0.007548666
126 I-Chemical 0 0.021586234
. O 0 0.005698716

In O 0 0.0027614196
the O 0 0.001713204
same O 0 0.00097489427
experimental O 0 0.0018903787
conditions O 0 0.0020329035
, O 0 0.0025441658
PG B-Chemical 0 0.9949891
- I-Chemical 0 0.0029386992
9 I-Chemical 0 0.00075938826
( O 0 0.0006547571
5 O 0 0.0003332219
- O 0 0.00043328133
20 O 0 0.00028294144
microg O 0 0.00049641676
per O 0 0.00015695392
mouse O 0 0.00041535927
, O 0 0.000410771
i O 0 0.00085228146
. O 0 0.00021297789
c O 0 0.0018961157
. O 0 0.00023267197
v O 0 0.0041248654
. O 0 0.00020890738
) O 0 0.00043861676
was O 0 0.00022100424
also O 0 0.00024742575
able O 0 0.00016410532
to O 0 0.00024440285
prevent O 0 0.0005392722
antimuscarine O 0 0.38272414
- O 0 0.0015622549
induced O 0 0.001854706
amnesia B-Disease 0 0.9992287
, O 0 0.0009381907
demonstrating O 0 0.00054054224
a O 0 0.0007433033
central O 0 0.0016529416
localization O 0 0.0011994552
of O 0 0.0019435864
the O 0 0.002588356
activity O 0 0.0056486693
. O 0 0.0055955793

At O 0 0.0024930774
the O 0 0.002018959
highest O 0 0.0018729441
effective O 0 0.002581665
doses O 0 0.08791952
, O 0 0.0037587977
PG B-Chemical 0 0.9964066
- I-Chemical 0 0.0028958034
9 I-Chemical 0 0.0006035293
did O 0 0.00034413033
not O 0 0.00026929192
produce O 0 0.00027782295
any O 0 0.00028696872
collateral O 0 0.053681117
symptoms O 0 0.16806018
as O 0 0.00024767383
revealed O 0 0.00031517565
by O 0 0.00029145172
the O 0 0.00029489136
Irwin O 0 0.08775293
test O 0 0.0004164609
, O 0 0.00041081916
and O 0 0.00029870452
it O 0 0.00030115765
did O 0 0.00022391065
not O 0 0.00020909612
modify O 0 0.00038565733
spontaneous O 0 0.013884641
motility O 0 0.1264573
and O 0 0.0004646761
inspection O 0 0.00089742744
activity O 0 0.00069999194
, O 0 0.00056659017
as O 0 0.00035660798
revealed O 0 0.0006310332
by O 0 0.00081743806
the O 0 0.0011378813
hole O 0 0.02027406
- O 0 0.003515119
board O 0 0.0043015215
test O 0 0.004731321
. O 0 0.0058148964

PG B-Chemical 0 0.9851606
- I-Chemical 0 0.0072531644
9 I-Chemical 0 0.0020908655
was O 0 0.0011869146
also O 0 0.0009304012
able O 0 0.000516835
to O 0 0.0005197114
increase O 0 0.00049324636
the O 0 0.0004442588
amount O 0 0.00034243736
of O 0 0.001095463
NGF O 1 0.9986405
secreted O 0 0.002954305
in O 0 0.00058895897
vitro O 0 0.001426535
by O 0 0.0008809852
astrocytes O 0 0.28038126
in O 0 0.00083115866
a O 0 0.0014156003
dose O 0 0.031582408
- O 0 0.00366631
dependent O 0 0.0028657615
manner O 0 0.006900295
. O 0 0.005938158

The O 0 0.0038621197
maximal O 0 0.004898275
NGF O 1 0.9923235
contents O 0 0.009151324
obtained O 0 0.0020104425
by O 0 0.0023148388
PG B-Chemical 0 0.9939079
- I-Chemical 0 0.0030478248
9 I-Chemical 0 0.00088875793
were O 0 0.0006467436
17 O 0 0.0009142956
. O 0 0.00044805268
6 O 0 0.00055818324
- O 0 0.0010850322
fold O 0 0.0013245763
of O 0 0.0012647591
the O 0 0.0015315964
control O 0 0.0023332238
value O 0 0.004341092
. O 0 0.0059905774

During O 0 0.0036546425
culture O 0 0.005455732
, O 0 0.002771244
no O 0 0.0013845908
morphological O 0 0.004382694
changes O 0 0.0017428742
were O 0 0.0010348615
found O 0 0.00092027895
at O 0 0.0007834638
effective O 0 0.0020954073
concentrations O 0 0.0061272928
of O 0 0.0057808054
PG B-Chemical 0 0.99354607
- I-Chemical 0 0.015111825
9 I-Chemical 0 0.0070839473
. O 0 0.0067589707

The O 0 0.002578958
current O 0 0.0027471625
work O 0 0.001970313
indicates O 0 0.0009755103
the O 0 0.00088549516
ability O 0 0.0009266068
of O 0 0.0015666106
PG B-Chemical 0 0.99661666
- I-Chemical 0 0.0026792395
9 I-Chemical 0 0.0005508751
to O 0 0.00034400864
induce O 0 0.00036035324
beneficial O 0 0.0013376768
effects O 0 0.0009372325
on O 0 0.00030153632
cognitive O 0 0.45646125
processes O 0 0.0019138596
and O 0 0.0006017918
stimulate O 0 0.0005608407
activity O 0 0.001074404
of O 0 0.0021624083
NGF O 1 0.99837315
synthesis O 0 0.32503226
in O 0 0.0037334103
astroglial O 0 0.98084223
cells O 0 0.016311137
. O 0 0.0068475413

Therefore O 0 0.0049519716
, O 0 0.005845182
PG B-Chemical 0 0.9865459
- I-Chemical 0 0.004156072
9 I-Chemical 0 0.0011991464
could O 0 0.0005758824
represent O 0 0.0005668055
a O 0 0.0005874676
potential O 0 0.0007639872
useful O 0 0.0008893348
drug O 0 0.090274535
able O 0 0.00042050405
to O 0 0.0004567948
improve O 0 0.0004883126
the O 0 0.0006517724
function O 0 0.0012008185
of O 0 0.0018594859
impaired O 0 0.0069007953
cognitive O 0 0.7713501
processes O 0 0.022109546
. O 0 0.0068994886

Mechanisms O 0 0.13904674
of O 0 0.013813586
FK B-Chemical 1 0.9950919
506 I-Chemical 1 0.9839289
- O 0 0.018341456
induced O 0 0.012993548
hypertension B-Disease 2 0.9975311
in O 0 0.007428894
the O 0 0.008022878
rat O 0 0.04686953
. O 0 0.012082762

- O 0 0.02406566
Tacrolimus B-Chemical 1 0.9976736
( O 0 0.017288864
FK B-Chemical 1 0.99676347
506 I-Chemical 1 0.9816714
) O 0 0.0058873333
is O 0 0.002045757
a O 0 0.0021759712
powerful O 0 0.005447019
, O 0 0.0035347792
widely O 0 0.005566073
used O 0 0.0058502355
immunosuppressant O 0 0.9857722
. O 0 0.012787826

The O 0 0.004117789
clinical O 0 0.0075135035
utility O 0 0.0034991794
of O 0 0.0045154565
FK B-Chemical 1 0.9966305
506 I-Chemical 1 0.97214115
is O 0 0.0032542306
complicated O 0 0.01270047
by O 0 0.0031295249
substantial O 0 0.009563626
hypertension B-Disease 2 0.998669
and O 0 0.057486247
nephrotoxicity B-Disease 0 0.99929225
. O 0 0.01775205

To O 0 0.002720875
clarify O 0 0.0015978332
the O 0 0.0015752182
mechanisms O 0 0.0024648963
of O 0 0.0027377033
FK B-Chemical 1 0.99867094
506 I-Chemical 1 0.9939885
- O 0 0.008616395
induced O 0 0.0037668701
hypertension B-Disease 2 0.9995728
, O 0 0.0011411916
we O 0 0.00023064348
studied O 0 0.00052957085
the O 0 0.00039488194
chronic O 0 0.8453512
effects O 0 0.0030404357
of O 0 0.0016944404
FK B-Chemical 1 0.99949634
506 I-Chemical 1 0.9814897
on O 0 0.00030748209
the O 0 0.0004147589
synthesis O 0 0.040116876
of O 0 0.0014802319
endothelin O 0 0.9995264
- O 0 0.005881662
1 O 0 0.00061872735
( O 0 0.00073064497
ET O 0 0.77941775
- O 0 0.0009015009
1 O 0 0.0003383008
) O 0 0.00042193997
, O 0 0.00025570393
the O 0 0.00017738942
expression O 0 0.00037276113
of O 0 0.0003694681
mRNA O 0 0.00081557117
of O 0 0.00066466077
ET O 0 0.9296505
- O 0 0.0013599136
1 O 0 0.00037920705
and O 0 0.0004749885
endothelin O 0 0.9991673
- O 0 0.0034694325
converting O 0 0.15083186
enzyme O 0 0.29103318
- O 0 0.0017037772
1 O 0 0.0004864302
( O 0 0.00062093366
ECE O 0 0.8585066
- O 0 0.001055992
1 O 0 0.0004060821
) O 0 0.00054515264
, O 0 0.00037497288
the O 0 0.00035874092
endothelial O 0 0.92688525
nitric B-Chemical 0 0.9994998
oxide I-Chemical 0 0.9993374
synthase O 0 0.99560463
( O 0 0.01003874
eNOS O 0 0.9015395
) O 0 0.00182294
activity O 0 0.00065880764
, O 0 0.0004195305
and O 0 0.00027678054
the O 0 0.00023727711
expression O 0 0.0004821651
of O 0 0.00045463504
mRNA O 0 0.0009408542
of O 0 0.0007192954
eNOS O 0 0.76655555
and O 0 0.0012940057
C O 0 0.9190893
- O 0 0.0020443557
type O 0 0.00097419706
natriuretic O 0 0.99131155
peptide O 0 0.03096809
( O 0 0.0026560375
CNP O 0 0.8090805
) O 0 0.002802523
in O 0 0.0016044558
rat O 0 0.016101876
blood O 0 0.033988416
vessels O 0 0.13615339
. O 0 0.00672447

In O 0 0.0030197992
addition O 0 0.0017563122
, O 0 0.0019401828
the O 0 0.0010547849
effect O 0 0.0010491387
of O 0 0.0010355124
the O 0 0.0008135084
specific O 0 0.0011639224
endothelin O 0 0.9985385
type O 0 0.0030344115
A O 0 0.13002488
receptor O 0 0.5687642
antagonist O 0 0.9960807
FR B-Chemical 1 0.99401903
139317 I-Chemical 1 0.99953365
on O 0 0.0014738693
FK B-Chemical 1 0.9993812
506 I-Chemical 1 0.9954051
- O 0 0.00982478
induced O 0 0.0057780384
hypertension B-Disease 2 0.99927217
in O 0 0.0023897928
rats O 0 0.011936408
was O 0 0.0030574184
studied O 0 0.0060479008
. O 0 0.006042683

FK B-Chemical 1 0.98137605
506 I-Chemical 1 0.9398932
, O 0 0.03270792
5 O 0 0.02170483
mg O 0 0.4717658
. O 0 0.02706163

kg O 0 0.08957719
- O 0 0.051186062
1 O 0 0.037511762
. O 0 0.036501057

d O 0 0.006020516
- O 0 0.0038195418
1 O 0 0.0014128594
given O 0 0.0007313726
for O 0 0.00064743275
4 O 0 0.0005387764
weeks O 0 0.00052046945
, O 0 0.00063936313
elevated O 0 0.0014945298
blood O 0 0.0033762883
pressure O 0 0.019319385
from O 0 0.0004740124
102 O 0 0.0024657384
+ O 0 0.0006191464
/ O 0 0.0009773216
- O 0 0.00054132775
13 O 0 0.00031410597
to O 0 0.00023409967
152 O 0 0.001458943
+ O 0 0.0004588939
/ O 0 0.0008086023
- O 0 0.00046456963
15 O 0 0.00021983973
mm O 0 0.0013238555
Hg O 0 0.7746525
and O 0 0.00023659487
increased O 0 0.00039324164
the O 0 0.0002742632
synthesis O 0 0.01663755
of O 0 0.0007762412
ET O 0 0.9297225
- O 0 0.0011114628
1 O 0 0.00028454888
and O 0 0.00022218002
the O 0 0.00019765431
levels O 0 0.0002551796
of O 0 0.000555079
ET O 0 0.89055127
- O 0 0.0011501389
1 O 0 0.00037444045
mRNA O 0 0.00054692617
in O 0 0.00025919237
the O 0 0.0003886242
mesenteric O 0 0.40269735
artery O 0 0.24107596
( O 0 0.00088615355
240 O 0 0.0016265458
% O 0 0.0006505436
and O 0 0.00070422067
230 O 0 0.003237865
% O 0 0.0015027197
, O 0 0.002115025
respectively O 0 0.00460817
) O 0 0.006149258
. O 0 0.00531643

Little O 0 0.02130257
change O 0 0.0035255435
was O 0 0.0021583685
observed O 0 0.0013634501
in O 0 0.0012502803
the O 0 0.0012635218
expression O 0 0.0021672992
of O 0 0.0025873194
ECE O 0 0.9245002
- O 0 0.004788493
1 O 0 0.0023368562
mRNA O 0 0.0038705617
and O 0 0.003972715
CNP O 0 0.7655819
mRNA O 0 0.015115365
. O 0 0.008534077

FK B-Chemical 1 0.9925122
506 I-Chemical 1 0.9478028
decreased O 0 0.012888985
eNOS O 0 0.71027946
activity O 0 0.0024165327
and O 0 0.0011322093
the O 0 0.000742251
levels O 0 0.00071222737
of O 0 0.0011425095
eNOS O 0 0.6869236
mRNA O 0 0.0022800276
in O 0 0.00058590417
the O 0 0.00065429864
aorta O 0 0.0963451
( O 0 0.0009870209
48 O 0 0.0006460813
% O 0 0.00066903984
and O 0 0.0007172946
55 O 0 0.0012841277
% O 0 0.0014784208
, O 0 0.0021898379
respectively O 0 0.0047895657
) O 0 0.00643798
. O 0 0.0055543743

The O 0 0.0037672406
administration O 0 0.0361009
of O 0 0.0041615088
FR B-Chemical 1 0.93153244
139317 I-Chemical 1 0.99867564
( O 0 0.0033078005
10 O 0 0.0012104438
mg O 0 0.26178527
. O 0 0.0005252298
kg O 0 0.00452252
- O 0 0.0009720423
1 O 0 0.0004909379
. O 0 0.00029428804
d O 0 0.00066816306
- O 0 0.0009023803
1 O 0 0.0006320375
) O 0 0.001113766
prevented O 0 0.0044354727
FK B-Chemical 1 0.99894506
506 I-Chemical 1 0.9924597
- O 0 0.009775306
induced O 0 0.008696499
hypertension B-Disease 2 0.9989318
in O 0 0.0053651556
rats O 0 0.034951966
. O 0 0.006573899

These O 0 0.004332857
results O 0 0.0022295765
indicate O 0 0.0015704975
that O 0 0.0018394706
FK B-Chemical 1 0.9971726
506 I-Chemical 1 0.9683879
may O 0 0.001416367
increase O 0 0.00084788876
blood O 0 0.006480801
pressure O 0 0.027584719
not O 0 0.00044630552
only O 0 0.0004119641
by O 0 0.0004468628
increasing O 0 0.001117196
ET O 0 0.9179491
- O 0 0.0016090093
1 O 0 0.0005077914
production O 0 0.00085683336
but O 0 0.00044975276
also O 0 0.0005657312
by O 0 0.0007245433
decreasing O 0 0.0028398728
NO B-Chemical 0 0.9963683
synthesis O 0 0.23003028
in O 0 0.0025821626
the O 0 0.003959127
vasculature O 0 0.5354037
. O 0 0.0073437234

